<SEC-DOCUMENT>0001367644-24-000033.txt : 20240308
<SEC-HEADER>0001367644-24-000033.hdr.sgml : 20240308
<ACCEPTANCE-DATETIME>20240308162144
ACCESSION NUMBER:		0001367644-24-000033
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		183
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240308
DATE AS OF CHANGE:		20240308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emergent BioSolutions Inc.
		CENTRAL INDEX KEY:			0001367644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				141902018
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33137
		FILM NUMBER:		24734685

	BUSINESS ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-631-3200

	MAIL ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ebs-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ebs="http://emergentbiosolutions.com/20231231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ebs-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-32">0001367644</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-33">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-672">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-673">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-706">http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-707">http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1164">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1165">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1168">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1169">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1172">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1173">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ebs-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="category"><xbrli:measure>ebs:category</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>ebs:product</xbrli:measure></xbrli:unit><xbrli:unit id="category2"><xbrli:measure>ebs:Category</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ebs:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>ebs:plan</xbrli:measure></xbrli:unit><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:A2023EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>ebs:employee</xbrli:measure></xbrli:unit><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BioservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BioservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:EbangaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">ebs:MCMProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingIn2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfter2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:UntilMarch312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFREURIBOROrCDORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFREURIBOROrCDORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfterMarch312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFREURIBOROrCDORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfterMarch312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfterMarch312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfterMarch312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ForbearanceAgreementAndAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ForbearanceAgreementAndAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-29</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFRSONIAAndEurocurrencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-28</xbrli:startDate><xbrli:endDate>2024-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFRSONIAAndEurocurrencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ForbearanceAgreementAndAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-29</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ForbearanceAgreementAndAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-29</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:A2023EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:A2023EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-28</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceSharesAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceSharesAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceSharesAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceSharesAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>ebs:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ebs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ebs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-18</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-11</xbrli:startDate><xbrli:endDate>2022-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:NARCANMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:NARCANMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:NARCANMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherCommercialProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherCommercialProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherCommercialProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AnthraxMCMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AnthraxMCMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AnthraxMCMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:SmallpoxMCMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:SmallpoxMCMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:SmallpoxMCMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:ReservationOfManufacturingCapacityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:AcceleratedExpansionOfFillFinishCapacityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7b0776f670624692b261a662f247fc47_1"></div><div style="min-height:15.75pt;width:100%"><div style="margin-bottom:15pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"><tr><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:513.25pt"/><td style="width:1.0pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"><tr><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:513.25pt"/><td style="width:1.0pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from    to        </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission file number: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-33137</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:center"><img src="ebs-20231231_g1.jpg" alt="emergent logo gray + carmine  r.jpg" style="height:20px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"/></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">EMERGENT BIOSOLUTIONS INC.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.740%"><tr><td style="width:1.0%"/><td style="width:44.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">14-1902018</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.343%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.021%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">300 Professional Drive</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Gaithersburg,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">MD</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">20879</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(City)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">240</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">631-3200</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"/><td style="width:39.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">EBS</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated filer", "smaller reporting company" and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Accelerated filer</ix:nonNumeric> &#9746; Non-accelerated filer &#9744; Smaller reporting company <ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric> Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric> No &#9744;</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric> No &#9746;</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2023 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-29">380.7</ix:nonFraction>&#160;million based on the price at which the registrant's common stock was last sold on that date as reported on the New York Stock Exchange.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;28, 2024, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">52,203,433</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant's definitive proxy statement for its 2024 annual meeting of stockholders which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the end of the registrant's fiscal year ended December&#160;31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K. With the exception of the portions of the registrant's definitive proxy statement for its 2024 annual meeting of stockholders that are expressly incorporated by reference into this Annual Report on Form 10-K, such proxy statement shall not be deemed filed as part of this Annual Report on Form 10-K.</span></div></ix:nonNumeric><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:15pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EMERGENT BIOSOLUTIONS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report on Form 10-K</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Ended December&#160;31, 2023</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:11.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.006%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_13">PART I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_1099511629765">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Business</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_1099511629765">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_1099511629785">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Risk Factors</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_1099511629785">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_22">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_2203">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_2203">Cyber Security</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_22">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_25">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_28">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_31">58</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_34">PART II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_37">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_37">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_40">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_40">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_43">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_43">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_43">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_58">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_58">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_58">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_61">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_61">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_61">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_145">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_145">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_145">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_148">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_148">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_148">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_151">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_151">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_151">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_154">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_154">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_154">139</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_157">PART III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_160">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_160">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_160">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_163">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_163">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_163">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_166">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_166">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_166">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_169">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_169">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_169">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_172">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_172">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_172">139</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_175">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_178">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_178">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_178">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_184">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_184">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_184">147</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_181">Exhibit Index</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_181">141</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_187">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_187">148</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K and the documents we incorporate by reference include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future", "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target", "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. These forward-looking statements are based on our current intentions, beliefs, assumptions and expectations regarding future events based on information that is currently available.  You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. You are, therefore, cautioned not to place undue reliance on any forward-looking statement contained herein. Any forward-looking statement speaks only as of the date on which such statement is made and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of U.S. Government ("USG") funding for contracts related to procurement of our medical countermeasures ("MCM"), including CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed) and ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Smallpox (Vaccinia) Vaccine, Live) among others, as well as contracts related to development of medical countermeasures; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of government funding for our other commercialized products, including Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ansuvimab-zykl), BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)) and RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Reactive Skin Decontamination Lotion Kit);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to meet our commitments to quality and compliance in all of our manufacturing operations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to negotiate additional USG procurement or follow-on contracts for our MCM products that have expired or will be expiring;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the commercial availability and acceptance of over-the-counter NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of a generic and competitive marketplace on NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray and future NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray sales;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to provide bioservices for the development and/or manufacture of product and/or product candidates of our customers at required levels and on required timelines;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to negotiate further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing under our existing Bioservices contracts;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to collect reimbursement for raw materials and payment of service fees from our Bioservices customers;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the results of pending stockholder litigation and government investigations and their potential impact on our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to comply with the operating and financial covenants required by our revolving credit facility (the "Revolving Credit Facility") and our term loan facility (the "Term Loan Facility" and, together with the Revolving Credit Facility, the "Senior Secured Credit Facilities") under a senior secured credit agreement, dated October 15, 2018, between the Company and multiple lending institutions, as amended from time to time, as well as our 3.875% Senior Unsecured Notes due 2028 ("Senior Unsecured Notes");</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to remediate a material weakness in our internal control over financial reporting and to prepare accurate financial statements in a timely manner;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to resolve the going concern qualification in our consolidated financial statements and otherwise successfully manage our liquidity in order to continue as a going concern;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the procurement of our product candidates by USG entities under regulatory authorities that permit government procurement of certain medical products prior to United States Food and Drug Administration (&#8220;FDA&#8221;) marketing authorization, and corresponding procurement by government entities outside of the United States;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to realize the expected benefits of the sale of our travel health business to Bavarian Nordic; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of the organizational changes we announced in January 2023 and August 2023;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the success of our commercialization, marketing and manufacturing capabilities and strategy; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of cybersecurity incidents, including the risks from the unauthorized access, interruption, failure or compromise of our information systems or those of our business partners, collaborators or other third parties; and</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the accuracy of our estimates regarding future revenues, expenses, capital requirements and needs for additional financing.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. When evaluating our forward-looking statements, you should consider this cautionary statement along with the risk factors identified in the sections entitled &#8220;Risk Factor Summary,&#8221; &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K and the risk factors identified in our other periodic reports filed with the SEC when evaluating our forward-looking statements. New factors emerge from time to time, and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Emergent BioSolutions Inc. and its consolidated subsidiaries.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADENAMES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BaciThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i7b0776f670624692b261a662f247fc47_1099511629765"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;BUSINESS</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats ("PHTs"). Our solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. The types of PHTs we are currently addressing are focused on the following four categories:</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">chemical, biological, radiological, nuclear and explosives ("CBRNE"); </span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">emerging infectious diseases ("EID"); </span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">public health crises (such as the opioid crisis); and </span></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">acute, emergency and community care. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues are derived from a combination of the sale and procurement of our product/product candidate portfolio (described below), the provision of our bioservices to external customers, and non-dilutive contract and grant funding for research and development ("R&amp;D") projects from various third-party sources.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR OPERATING SEGMENTS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting process. The revised reporting structure reflects the internal reporting and review process used by our Chief Operating Decision Maker, for making decisions and assessing performance, and is consistent with how we currently manage the business. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We now manage our business with a focus on three reportable segments:</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">our Commercial Products Segment consisting of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other commercial products which were sold as part of our travel health business in the second quarter of 2023; </span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">our MCM Products Segment consisting of Anthrax&#8212;MCM products, Smallpox&#8212;MCM products and Other Products (as discussed below)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services Segment consisting of our Bioservices portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a centralized R&amp;D organization and an enterprise-wide governance approach to managing our portfolio of R&amp;D projects.</span></div><div style="margin-bottom:5pt;padding-left:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Products Segment</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and international markets, our Commercial business primarily focuses on sales of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray. NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray is sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, we completed the sale of our products segment's travel health business, including rights to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed typhoid vaccine; Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#8217;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California.  In connection with the divestiture, the Company entered into a Transition Services Agreement (&#8220;TSA&#8221;) with Bavarian Nordic to help support its ongoing operations. Under the TSA, the Company provides certain transition services to Bavarian Nordic, including information technology, finance and enterprise resource planning, research and development, human resources, employee benefits and other limited services.  Services pursuant to the TSA remain ongoing.  For additional information, refer to Note 3, "Divestiture."</span></div><div style="margin-bottom:9pt;padding-left:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MCM Products Segment</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Government - MCM business focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers, with an emphasis on the United States ("U.S.") Government ("USG"), which is our largest customer. We also sell MCM products and procured product candidates to domestic and international non-government organizations and to governments outside of the U.S.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services Segment</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur portfolio of Bioservices consists of three distinct but interrelated service pillars: development services (process and analytical development); drug substance manufacturing; and drug product manufacturing (fill/finish). These services, which we collectively refer to as a &#8220;molecule-to-market&#8221; offering, employ diverse technology platforms across a network of development and manufacturing sites operated by us. These Bioservices support all phases of the drug development life cycle, from pre-clinical development programs through commercial manufacturing of approved pharmaceutical products. The customer base for Bioservices is primarily innovators in the biotechnology and pharmaceutical segments.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR STRATEGY</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to execute the three-year strategic plan (2023-2025) adopted by management to strengthen the Company&#8217;s financial position and adapt to new strategic priorities. We expected this strategy would refocus the business and increase the Company&#8217;s ability to make more aggressive investments for future growth.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Specifically, throughout 2023 the Company has taken significant steps to strengthen our financial position and de-risk the business.  We have executed the travel health divestiture, implemented actions intended to save over $160 million of annualized operating expense, and announced a strategic shift to de-emphasize our CDMO business as a source of growth. At the same time, we have achieved a number of positive milestones in our core products business, including the receipt of approximately $250 million of USG orders for ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (discussed more fully below), VIGIV CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the FDA approvals of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over-the-counter, new long-term contracts for RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Ebanga&#8482; and the growth of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRIMARY PRODUCTS AND PRODUCT CANDIDATES</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government - MCM Products</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portfolio of our Government - MCM business consists of the following products:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.873%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#19415e;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">GOVERNMENT - MCM PRODUCTS</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Product</span></div></td><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Indication(s)</span></div></td><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Regulatory Approvals, Licensures or Clearances</span></div></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, (Smallpox (Vaccinia) Vaccine, Live)</span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaccine for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.</span></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, Australia, Singapore, Canada</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANTHRASIL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[Anthrax Immune Globulin Intravenous (human)]</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, Canada</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)]</span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients.</span></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, Canada, Ukraine, Singapore</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Anthrax Vaccine Adsorbed)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaccine for active immunization for the prevention of disease caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bacillus anthracis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in persons 18 through 65 years of age. BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is approved for:</span></div><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Pre-exposure prophylaxis of disease in persons at high risk of exposure.</span></div><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Post-exposure prophylaxis of disease following suspected or confirmed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bacillus anthracis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> exposure, when administered in conjunction with recommended antibacterial drugs.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, Canada, France (where it is known as BaciThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), Germany, Italy, the Netherlands, Poland, Singapore and UK</span></div></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Anthrax Vaccine Adsorbed Adjuvanted)</span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously known as AV7909, approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.</span></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ebanga&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ansuvimab-zykl)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for injection</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of infection caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zaire ebolavirus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zaire ebolavirus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> infection. </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Raxibacumab injection</span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of adult and pediatric patients with inhalational anthrax due to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bacillus anthracis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.</span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Reactive Skin Decontamination Lotion Kit)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intended to remove or neutralize chemical warfare agents and T-2 Toxin from the skin. </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States (510k), Australia, Canada, European Union and Israel</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(brincidofovir), (tablet and oral suspension)</span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, Canada</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Auto-injector atropine sulfate, obidoxime chloride auto-injector</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicated for the emergency treatment of known or suspected exposure to nerve agents or toxic organophosphates in adults &gt; 18 years of age.</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium*</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIGIV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[Vaccinia Immune Globulin Intravenous (Human)]</span></div></td><td colspan="3" style="background-color:#f5fafe;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of complications due to vaccinia vaccination, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.96pt">Eczema vaccinatum</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.96pt">Progressive vaccinia;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.96pt">Severe generalized vaccinia;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.96pt">Vaccinia infections in individuals who have skin conditions; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.96pt">Aberrant infections induced by vaccinia virus (except in cases of isolated keratitis).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIGIV is not indicated for postvaccinial encephalitis.</span></div></td><td colspan="3" style="background-color:#f5fafe;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, Canada</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">*TROBIGARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> is not approved by the FDA. It is only approved by the Belgian Health Authority but has been procured by various government entities for emergency preparedness purposes. </span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Description of MCM Products</span></div><div style="text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACAM2000</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Smallpox (Vaccinia) Vaccine, Live).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine is a smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection and comprises the largest percentage of the current USG stockpile in the Strategic National Stockpile ("SNS") designated for use in a bioterrorism emergency. On December 5, 2023, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine received a Notice of Compliance from Health Canada for its Extraordinary Use New Drug Submission (EUNDS) for the indication of active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. On October 27, 2023, Emergent submitted a supplemental Biological License Application (sBLA) to the US FDA seeking approval for the expansion of the indication for ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to include immunization against mpox virus. ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine is currently stockpiled both in the U.S. and internationally. Smallpox is a highly contagious disease caused by the Variola virus. According to the Centers for Disease Control and Prevention ("CDC"), smallpox is a devastating disease, with a mortality rate as high as 30%. The vaccine stimulates a person's immune system to develop antibodies and cells in the blood and elsewhere that can then help the body fight off a smallpox infection if exposure to smallpox occurs. On September 3, 2019, we announced the award by the USG of a contract valued at up to approximately $2 billion over 10 years for the continued supply of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine into the SNS, assuming all contract options are exercised. This multiple-year contract is intended to support the replacement of the smallpox vaccine stockpile and included a one-year base period of performance in 2019 valued at approximately $170.0 million, and nine option years. The number of doses under the base period were delivered by year end 2019. On May 28, 2020, we announced the exercise by the U.S. Department of Health and Human Services ("HHS") of the first contract option, valued at $176.0 million, to procure doses of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine. The number of doses under the first contract option were delivered by year end 2020. On July 13, 2021, we announced the exercise by HHS of the second contract option, valued at $182.2 million, to procure doses of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine. We completed the delivery of all ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> doses in 2022. The USG chose to not exercise its option year in 2022. On May 26, 2023, the Company, through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response (&#8220;ASPR&#8221;), an agency of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), exercising and funding the third of nine annual contract term extension options (the &#8220;Third Option Exercise&#8221;) for Emergent to supply ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the SNS. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Third Option Exercise is valued at approximately $120 million and was made under a bilateral modification of Emergent&#8217;s existing 10-year contract awarded by ASPR on August 30, 2019. The period of performance under the Third Option Exercise required Emergent to deliver doses of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into the SNS by June 30, 2023 and the Company achieved delivery in this period.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANTHRASIL</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ANTHRASIL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Immune Globulin Intravenous (human)) is the only polyclonal antibody therapeutic licensed by the FDA for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs. We currently have two contracts with HHS for Anthrasil Anthrax IGIV: 1) a development and procurement contract which has been extended to expire in September 2024 for possible additional scope, and 2) a multiple award, indefinite delivery/indefinite quantity contract for the collection of anti-anthrax plasma, as well as the manufacture of such plasma into bulk drug substance and finished drug product; such contract covered extended plasma storage, and the options for manufacturing and delivery of finished product into the SNS to be exercised by HHS through September 2023. We anticipate that the direct disposition of the plasma and close out activities will be completed before July 31, 2025. In addition to domestic USG sales, Anthrasil solution has been sold to several foreign governments, including the Canadian government. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAT</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) &#8211; (Equine)].</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antitoxin is the only equine plasma antitoxin licensed by the FDA and Health Canada for the treatment of all seven botulinum neurotoxin serotypes. BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antitoxin is licensed by the FDA for the treatment of symptomatic botulism following suspected or documented exposure to botulinum neurotoxin serotypes A, B, C, D, E, F or G in adults and pediatric patients. It is also licensed in Canada pursuant to Health Canada&#8217;s Extraordinary Use New Drugs regulations. BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antitoxin is the only heptavalent botulism antitoxin available in the U.S. and Canada for treating naturally occurring botulism in adults or pediatric patients. Botulinum toxin is a nerve toxin produced by the bacterium Clostridium botulinum that causes botulism, a serious paralytic illness. On May 8, 2020, we announced the finalization of a previously announced contract with HHS, valued at up to $550.0 million, if all options under the contract are exercised. The contract has two deliverables. The first deliverable, negotiated in September 2019 and valued at up to approximately $90.0 million, is to supply annual doses of BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antitoxin into the SNS for 10 years by converting existing bulk drug substance into final drug product. This deliverable also includes options for additional doses valued at up to approximately $94.0 million over 10 years. The second deliverable, valued at up to approximately $366.0 million, is for the production of additional doses of bulk drug substance over 10 years to maintain the plasma collection and production capability for botulism response planning. In addition to domestic government sales, BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antitoxin continues to be sold internationally, with deliveries to 15 foreign governments in 2023.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioThrax</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Anthrax Vaccine Adsorbed).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine is the only vaccine licensed by the FDA for pre-exposure prophylaxis of anthrax disease in persons at high risk of exposure. BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine is also approved by the FDA for post-exposure prophylaxis administration in combination with antimicrobial therapy in the event of suspected or confirmed exposure to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bacillus anthracis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Anthrax is a potentially fatal disease caused by the spore-forming bacterium, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bacillus anthracis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Inhalational anthrax is the most lethal form of anthrax. In the U.S., BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine is administered in a pre-exposure prophylaxis setting by intramuscular </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injection as a three-dose primary series over a six-month period. Per the U.S. label, booster doses are administered six and 12 months after completion of the primary series and at 12-month intervals thereafter. BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine is administered in a post-exposure prophylaxis setting as three subcutaneous injections two weeks apart in conjunction with recommended antibacterial drugs following suspected or confirmed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bacillus anthracis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> exposure. When we report the revenue associated with &#8220;anthrax vaccines,&#8221; it reflects the combined revenue from the procurement and sale of BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine as well as CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine (formerly known as AV7909, described below).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we signed a follow-on contract with the CDC for the supply of up to approximately 29.4 million doses of BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine for delivery into the SNS, over a five-year period ending in September 2021. On September 29, 2021, we were granted a no-cost contract extension, which extended the date through which the USG procured BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine to March 31, 2022. On June 16, 2022, the contract's period of performance was extended to June 30, 2022. All deliveries under this contract were completed in August 2022.   On January 11, 2024, the Company announced that it has secured an indefinite-delivery, indefinite-quantity ("IDIQ") procurement contract with a maximum value up to $235.8 million to supply BioThrax&#174; vaccine for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. The new contract with the U.S. Department of Defense ("DoD") and led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, is comprised of a five-year base agreement ending on September 30, 2028, and an additional five-year option that would extend the contract to September 30, 2033.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CYFENDUS</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax Vaccine Adsorbed, Adjuvanted)</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (known as AV7909 prior to FDA approval in July 2023). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vaccine was approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.  In 2021, AV7909 was granted orphan drug designation by the FDA. Studies have shown that CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> elicits a stronger immune response using fewer doses than BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine, which is expected to allow patients to reach a protective level of immunity more rapidly. CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to provide protection with a two-dose regimen (versus the BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> three-dose regimen) for post-exposure prophylaxis of anthrax disease, when administered in combination with the recommended antibacterial drugs. In September 2016, we signed a combination development and procurement contract with Biomedical Advanced Research and Development Authority ("BARDA"), which included a five-year base period of performance to develop CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for post-exposure prophylaxis of anthrax disease and to deliver to the SNS an initial two million doses, subsequently modified to three million doses in March 2017. The contract also includes procurement options for the delivery of an additional 7.5 million to 50.0 million doses of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into the SNS and options for an additional clinical study and post marketing commitments. In 2019, we initiated and completed enrollment of a Phase 3 study; the 3,850 subject trial evaluating safety, immunogenicity and lot consistency was completed in 2020. In collaboration with us, the CDC filed with the FDA a pre-EUA submission package related to CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following this submission, BARDA began procuring CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> , exercising its first contract option in July 2019 (valued at approximately $261.0 million) to procure doses to be delivered to the SNS through June of 2020, its second contract option in July 2020 (valued at $258.0 million) to procure additional doses of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  for delivery into the SNS over 12 months, in September 2021 funding another contract option (valued at approximately $399.0 million) to deliver doses of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the SNS over 18 months. Two contract modifications (each valued at $75 million) were executed with BARDA in 2023; the first modification was filled during 2023 and the second modification expires in March 2024.  In April 2022, we completed our submission of a Biologics License Application ("BLA") for CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the FDA and received BLA approval in July 2023. When we report the revenue associated with &#8220;anthrax vaccines,&#8221; it reflects the combined revenue from the procurement and sale of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (described above).</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ebanga</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ansuvimab-zykl), for injection.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ansuvimab-zykl) is a monoclonal antibody with antiviral activity provided through a single IV infusion (over 60 minutes) for the treatment of Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus. On July 1, 2022, we entered into an asset purchase agreement and a license agreement with Ridgeback Biotherapeutics (&#8220;Ridgeback&#8221;) to expand the availability of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ansuvimab-zykl). This included a license to the Ebanga&#8482; trademark and to certain patent rights related to Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ansuvimab-zykl). We will be responsible for manufacturing, selling and distributing Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ansuvimab-zykl) in the U.S. and Canada and Ridgeback will serve as the global access partner.  In July 2023, the Company announced it was awarded a 10-year contract by BARDA, valued at up to a maximum of $704 million, for advanced development, manufacturing scale-up, and procurement of Ebanga&#8482;.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raxibacumab injection.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our raxibacumab product is the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax due to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bacillus anthracis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our raxibacumab product is indicated for the treatment of adult and pediatric patients with inhalational anthrax in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or appropriate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSDL</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Reactive Skin Decontamination Lotion Kit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kit is cleared by the FDA and is intended to remove or neutralize chemical warfare agents from the skin, including tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin. RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kit has also been cleared as a medical device by Health Canada, has a current European Conformity ("CE") mark under European Directives, and is licensed by the Israel Ministry of Health and by Australia's Therapeutic Goods Administration. To date, the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principal customers for RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kits have been agencies of the USG, including the DoD and the National Guard. Our current contract with the DoD awarded in December 2022 is a five-year contract including a base year period and four single year option periods, valued at up to $379.6&#160;million to supply RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kits for use by all branches of the U.S. military. We also sold RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kits to ten foreign countries outside the U.S. in 2023. In November 2022, three lots of our RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kits was recalled due to leakage, which could cause the product not to perform as effectively as intended. There have been no reports of injuries or death related to this recall of which we are aware. We identified and remediated the cause leading to the November 2022 recall, as well as completed all required actions, notices and report submissions related to the recalled batch. We are currently awaiting formal closure of the recall from FDA.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TEMBEXA</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(brincidofovir) tablets and oral suspension. TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first oral antiviral approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates. On September 26, 2022, we acquired exclusive worldwide rights to brincidofovir from Chimerix Inc. for the treatment of any human smallpox disease or any other disease caused by any orthopox virus. Following the acquisition, the 10-year contract with BARDA, valued at up to $680.0&#160;million, to supply up to 1.7 million tablet and suspension formulations of TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was novated to the Company. On December 11, 2023, Emergent received a Notice of Compliance from Health Canada for its Extraordinary Use New Drug Submission (EUNDS) for indication of the treatment of human smallpox disease in adults and pediatric patients, including newborn infants. The Company has 2 patent families relating to the TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product including but not limited to, those listed in the Orange Book: 8,962,829, 9,303,051, 9,371,344, 10,112,909, and 10,487,061.  The latest expiring United States composition of matter patents expires in 2034. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROBIGARD</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> atropine sulfate, obidoxime chloride auto-injector.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TROBIGARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> auto-injector was approved by the Federal Agency for Medicines and Health Products of the Belgium Health Authority on February 18, 2021. TROBIGARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">auto-injector is not currently approved or cleared by the FDA. TROBIGARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">auto-injector is only distributed to authorized government buyers for use outside the U.S. In Belgium, the TROBIGARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">auto-injector is indicated for the emergency treatment of known or suspected exposure to nerve agents or toxic organophosphates in adults (&gt; 18 years of age). In February 2019, Emergent was awarded a 10-year contract, valued at up to approximately $100.0 million, by the U.S. Department of State, to procure our TROBIGARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, training auto-injectors and RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kits for emergency use outside of the U.S. The contract consists of a five-year base period of performance with five one-year option periods.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIGIV CNJ-016</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Vaccinia Immune Globulin Intravenous (Human)).</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIGIV is the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from replicating virus smallpox vaccination. The principal customer for VIGIV is the USG, specifically HHS. In June 2019, we announced a contract award by HHS valued at approximately $535.0&#160;million over 10 years for the continued supply of VIGIV into the SNS for smallpox preparedness. VIGIV has also been procured by a limited number of foreign governments.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current Commercial portfolio consists of the following products:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.040%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#19415e;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">COMMERCIAL PRODUCTS</span></td></tr><tr><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Indication(s)</span></td><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;Regulatory Approvals</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(naloxone HCI) Nasal Spray</span></div></td><td colspan="3" style="background-color:#f5fafe;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.</span></div></td><td colspan="3" style="background-color:#f5fafe;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, Canada</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Description of Commercial Products</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, a product we obtained in connection with our acquisition of Adapt Pharma Inc. in 2018, is an intranasal formulation of naloxone approved by the FDA and Health Canada for the emergency treatment of known or suspected opioid overdose as demonstrated by respiratory and/or central nervous system depression. We have rights to formulations of naloxone used in NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray from Indivior PLC (f/k/a Opiant Pharmaceuticals Inc.). The primary customers for NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray are state health departments, local law enforcement agencies, community-based organizations, substance abuse centers, federal agencies, and consumers. We completed two important product life cycle improvements in 2020. First, we launched the Generation II NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray device, which has a claim for enhanced temperature excursions and storage below 25&#176;C. Second, we gained FDA approval for an extension of the shelf life of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray from 24 months to 36 months. On January 18, 2024, the Company announced that the FDA has acknowledged the shelf-life extension of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray from 36 months to 48 months based on the company&#8217;s four-year stability data. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we filed our supplemental New Drug Application (&#8220;sNDA&#8221;) for NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, as an over-the-counter ("OTC") emergency treatment for known or suspected opioid overdose. The FDA accepted the application and also granted Priority Review.  On February 15, 2023, the U.S. Food and Drug Administration (FDA) Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee unanimously voted in favor (a total of 19 votes) that the benefit-risk profile of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray was supportive of its use as a nonprescription opioid overdose reversal agent.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray was approved as an OTC medication on March 29, 2023. It was the first 4 mg naloxone nasal spray available OTC in the U.S. The new OTC product was shipped out to retailers and e-commerce providers nationwide in August of 2023. Emergent is prepared to supply all segments and customers of the business with OTC product.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Candidates</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below highlights our current portfolio of product candidates:</span></div><div style="margin-bottom:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.039%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;PRODUCT CANDIDATES </span></td></tr><tr><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Product Candidate</span></td><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Target Indication</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CGRD-001 (Pralidoxime chloride/atropine auto-injector)</span></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBS-LASV (rVSV-vectored vaccine for Lassa fever)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active immunization to prevent Lassa fever.</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBS-MARV (rVSV-vectored vaccine for Marburg virus disease)</span></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active immunization to prevent Marburg virus disease.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBS-SUDV (rVSV-vectored vaccine for Sudan virus disease)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active immunization to prevent Sudan virus disease.</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pan-Ebola mAbs</span></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of ebola virus disease caused by infection in patients with confirmed Sudan virus.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIAN (stabilized isoamyl nitrite)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidote for initial treatment of certain or suspected acute cyanide poisoning. </span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UniFlu (Universal influenza vaccine)</span></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intended to induce broad and supra-seasonal immunity against influenza A and B viruses.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WEVEE-VLP</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To prevent disease caused by Western, Eastern, and Venezuelan equine encephalitis virus infections.</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Description of Product Candidates</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CGRD-001. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CGRD-001 auto-injector is being developed for treatment of poisoning by organophosphorus nerve agents, as well as organophosphorus compounds for use by military personnel. CGRD-001 is being developed as an auto-injector for delivery of 600 mg of pralidoxime and 2 mg of atropine for intramuscular injection following nerve agent exposure. The product is being designed for injection by non-medical personnel, including self-injection or buddy aid by service members. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EBS-LASV.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This vaccine candidate is a recombinant, vesicular stomatitis virus vectored, monovalent vaccine encoding the surface glycoprotein precursor gene of Lassa virus. The development program is partnered with the Coalition for Epidemic Preparedness Innovations ("CEPI"). We have completed our Phase 1 clinical trial and are currently analyzing the data.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EBS-MARV. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">his vaccine candidate is a recombinant, vesicular stomatitis virus vectored, monovalent vaccine encoding the surface glycoprotein precursor gene of Marburg virus. The development program is partnered with Auro Vaccines and is currently in IND-enabling stage. NIAID is funding Auro Vaccines program with contract options through Phase 1 development. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EBS-SUDV. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This vaccine candidate is a recombinant, vesicular stomatitis virus vectored, monovalent vaccine encoding the surface glycoprotein precursor gene of Sudan virus. The development program is partnered with Auro Vaccines and is currently in IND-enabling stage. NIAID is funding Auro Vaccines program with contract options through Phase 1 development. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pan-Ebola mAbs. I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BT-T02 is a cocktail comprised of two chimeric mAbs, FVM04 and CA45. The mAb cocktail candidate targets two highly conserved and non-overlapping epitopes on the glycoprotein of Sudan ebolavirus (SUDV) and other ebolaviruses. The preclinical program is in partnership with Integrated Biotherapeutics with a BARDA funded non-human primate study in progress. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIAN. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing SIAN (stabilized Isoamyl nitrate) as an antidote for initial treatment of acute poisoning of cyanide that is judged to be serious or life threatening. The USG consistently identifies cyanide ("CN") as a high-priority threat, most recently in the Public Health Emergency Medical Countermeasure Enterprise 2022 Strategy and Implementation Plan. Historically, CN has been used as a chemical warfare agent and could be an agent for a terrorist attack. CN also represents a threat from accidental poisoning, such as industrial accidents or exposure during building fires. The SIAN program is funded by BARDA and is focused on the development of a single-use intranasal spray device that can be rapidly deployed and easily dispensed so that it will deliver SIAN following a cyanide incident or in a mass exposure setting. We have completed our Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics, and are currently analyzing the data. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UniFlu.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a universal influenza vaccine candidate based on a nanoparticle technology involving a cross-reactive hemagglutinin (HA) antigen for active immunization against influenza virus A and B. The nanoparticle technology was developed by and licensed from the NIAID Vaccine Research Center. Using this technology, we are seeking to develop a universal influenza </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vaccine designed to confer protection against numerous strains and subtypes of influenza virus. We have completed our Phase 1 clinical trial to assess safety, tolerability, and immunogenicity and are currently analyzing the data.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WEVEE-VLP. WEVEE VLP vaccine is a recombinant VLP vaccine. The development program is in partnership with NIAID Vaccine Research Center (VRC), who has already completed a Phase 1 clinical trial of the trivalent vaccine, in addition to a monovalent Phase 1 clinical study of the VEEV VLP component only. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioservices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Bioservices are based on our established development and manufacturing infrastructure, technology platforms and expertise, as well as continuing capital expenditure projects to expand our capabilities and increase capacity. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug product. Collectively, this portfolio of services provides &#8220;molecule-to-market&#8221; solutions to clients engaged in all stages of drug development and commercialization. These services are provided to innovator biopharmaceutical companies and non-governmental organizations ("NGOs").</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have 8 development and manufacturing sites located in the U.S. and Canada. These sites allow us to meet our internal manufacturing needs as well as performing services for our external customers. Six of these sites currently provide bioservices to customers.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our Winnipeg and Gaithersburg sites house our development services expertise;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our Lansing and Winnipeg sites house our drug substance expertise; and </span></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our Camden, Winnipeg, Rockville and Hattiesburg sites house our drug product and packaging expertise.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have over 55 active Bioservices customers.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing and Sales</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have dedicated sales channels for each of our products and service offerings.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government - MCM Products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partner with stakeholders in the USG and domestic NGOs to support procurement of our MCM products and procured product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also partner with foreign governments and international NGOs to support procurement of MCM products and procured product candidates internationally.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our specialized team has expertise and experience in the public and private sector, dealing with counter terrorism, CBRNE preparedness and public health. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists the registered trademarks for our MCM products:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Trademark</span></td><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Country of Origin</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia, Brazil, Canada, EU, Hong Kong, Israel, Singapore, United Kingdom, U.S.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia, Canada, Egypt, EU, Israel, Lebanon, Republic of Korea, Qatar, Saudi Arabia, Singapore, Turkey, United Kingdom, United Arab Emirates, U.S. </span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div><img src="ebs-20231231_g2.jpg" alt="ANTHRASIL Logo.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:67px"/></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div><img src="ebs-20231231_g3.jpg" alt="ANTHRASIL Logo _ Multicolor Lines .jpg" style="height:51px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU, UK</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada, China, EU, Japan, Mexico, Republic of Korea, United Kingdom, U.S.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia, Brazil, Canada, EU, India, Malaysia, Saudi Arabia, Singapore, United Kingdom, U.S.</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;  </span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia, EU, United Kingdom, U.S.</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina, Australia, Brazil, Canada, Chile, China, EU, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Norway, Russia, Singapore, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, U.S. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Commercial Products.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. market, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray is sold directly to state and local governments and used by first responders, including: police, firefighters and emergency medical teams. In addition, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray is sold to consumers online and through retailers nationwide. In 2022, we submitted a supplemental New Drug Application (sNDA) requesting that FDA switch NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray (4mg) from a prescription drug to an over-the-counter medicine. On February 15, 2023, the U.S. Food and Drug Administration (FDA) Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee unanimously voted in favor (a total of 19 votes) that the benefit-risk profile of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray was supportive of its use as a nonprescription opioid overdose reversal agent. NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray was approved as an OTC medication on March 29, 2023.  It was the first 4 mg naloxone nasal spray available OTC in the U.S.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Canadian market, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray is sold directly to federal, provincial and local governments and agencies for use by first responders, public health and harm reduction agencies, and indigenous communities. In addition, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray is sold to businesses and consumers online and through pharmacies nationwide. On November 24, 2023, we submitted a Medical Device Establishment License (MDEL) Application to Health Canada that would permit Emergent to distribute Narcan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray (4mg) in kitted-format with other medical devices as well as in standard approved packaging to comply with provincial legislative requirements. The performance standard to issue a decision is 120 calendar days from submission. On December 22, 2023, the Health Canada MDEL Review Committee granted Emergent BioSolutions Canada Inc. the MDEL, enabling the direct sale of kitted NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray across Canada.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists the registered trademarks for NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray: </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Trademark</span></td><td colspan="3" style="background-color:#19415e;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Country of Registration</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benelux, Canada, Denmark, Estonia, EU, Finland, Germany, Ireland, Italy, Norway, Spain, Sweden, United Kingdom, U.S.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div><img src="ebs-20231231_g4.jpg" alt="Written.jpg" style="height:35px;margin-bottom:5pt;vertical-align:text-bottom;width:105px"/></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU, Norway, United Kingdom, U.S.</span></td></tr><tr><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div><img src="ebs-20231231_g5.jpg" alt="Gray Asterisk1.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"/></div></td><td colspan="3" style="background-color:#f5fafe;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada, U.S.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div><img src="ebs-20231231_g6.jpg" alt="Red asterisk.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"/></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada, U.S.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div><img src="ebs-20231231_g7.jpg" alt="Gray Asterisk 2.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"/></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bioservices.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our bioservices to the global pharmaceutical and biotechnology industry, governments and NGOs. We also provided bioservices to the USG, which ended in 2021. Our bioservices are supported by a dedicated group of professionals qualified to represent the full breadth of our service offerings.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our products and any product or product candidate that we acquire or successfully develop and commercialize are likely to compete with current products and product candidates that are in development for the same indications. The competition for our products and product candidates includes the following:</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.96pt">ACAM2000</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine, which is licensed by the FDA and recently licensed by Health Canada, remains the primary smallpox vaccine stockpiled by the USG and offers key features for public health mass vaccination programs that are critical, including a single dose vaccination schedule and multi-dose vial presentation. ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine faces competition from JYNNEOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vaccine, which is licensed by the FDA for the prevention of smallpox and mpox disease in adults 18 years of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">age and older determined to be at high risk for smallpox or mpox infection. JYNNEOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine is also approved in Canada and in the EU under the trade names IMVAMUNE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IMVANEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. </span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.97pt">CYFENDUS</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and BioThrax</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccines are currently procured, primarily by the USG, for prevention of anthrax disease. BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vaccines are currently the only two anthrax vaccine approved by the FDA for prevention of anthrax disease, and CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are the only anthrax vaccines procured by the USG for the SNS to date. We face potential future competition for the supply of anthrax vaccines if the USG chooses to procure alternative products or product candidates. GC Pharma, Blue Willow Biologics/Porton Biopharma, and Greffex are each currently developing anthrax vaccine product candidates, which are in various stages of clinical development. Of these product candidates, GC Pharma and Blue Willow Biologics have completed Phase 1 trials.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.55pt">BAT</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our botulinum antitoxin immune globulin product is the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism for all seven botulinum neurotoxin serotypes. Direct competition is currently limited.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.96pt">CNJ-016</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our VIGIV product is the only therapeutic licensed by the FDA and Health Canada to address adverse events from smallpox vaccination with replicating virus smallpox vaccines. While direct competition in terms of the treatment of smallpox vaccination side effects is limited, SIGA has obtained EU approval for TPOXX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tecovirimat), an oral therapy, for the treatment of complications following vaccination against smallpox. TPOXX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently procured by the USG for the SNS.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.96pt">Ebanga</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansuvimab-zykl).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A monoclonal antibody therapeutic approved by the FDA in December 2020 for the treatment of infection caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zaire Ebolavirus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in adult and pediatric patients, including neonates born to RT-PCR+ mother for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zaire Ebolavirus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infection. Ebanga faces competition from another monoclonal antibody, Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (atoltivimab, maftivimab and odesivimab-ebgn), which was approved by the FDA in October 2020 with the same indication. Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently procured by the USG for the SNS</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.14pt">NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray is the first FDA-approved intranasal naloxone spray for the emergency reversal of opioid overdoses. Teva Pharmaceuticals Industries Ltd. and its Canadian affiliate (collectively, "Teva") have generic versions of an intranasal naloxone spray based on NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray approved by the FDA and Health Canada. Teva launched its generic naloxone nasal spray in the U.S. In 2021, Padagis Pharmaceuticals also has a generic version of an intranasal naloxone spray based on NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray approved by the FDA. Padagis launched its generic naloxone nasal spray. NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray also faces branded competition: Kloxxado</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) nasal spray 8mg, a branded product developed by Hikma Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc.'s naloxone injection product, Teleflex Medical Inc.'s Intranasal Mucosal Atomization Device and Zimhi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone), a branded injectable product developed by Adamis and RiVive&#8482; a 3mg naloxone nasal spray formulation intended for use in opioid overdose reversal by Harm Reduction Therapeutics. On May 22, 2023, FDA granted approval of Opvee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nalmefene) Nasal Spray to Opiant Pharmaceuticals Inc, (now a wholly owned subsidiary of Indivior PLC), which was released in the market during fourth quarter of 2023. Teva Pharmaceutical Industries Ltd. also received a notice of compliance (NOC) from Health Canada on January 2, 2024. NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray may face additional generic and branded competition in the future.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.55pt">Raxibacumab and Anthrasil</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">[Anthrax Immune Globulin Intravenous (human)].</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our raxibacumab product is the first FDA-licensed fully human anthrax monoclonal antibody therapeutic and Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [Anthrax Immune Globulin Intravenous (Human)] is the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs. Elusys Therapeutics, Inc. has obtained FDA licensure for Anthim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (obiltoxaximab) injection, a chimeric (or partially human) antibody indicated for the treatment and prophylaxis of inhalational anthrax. Obiltoxaximab is also approved in Canada and the EU.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.55pt">RSDL</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the U.S., the RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Kit is cleared by the FDA to remove or neutralize chemical warfare agents and T-2 toxin from the skin. Internationally, various Ministries of Defense have procured Fullers Earth, Dutch Powder and French Powder as a preparedness countermeasure for the decontamination of liquid chemical weapons from the skin.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.97pt">TEMBEXA</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (brincidofovir).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first oral antiviral approved by the FDA, in June 2021, for all age groups for the treatment of smallpox. In December 2023, TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received approval by Health Canada. TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> faces competition from TPOXX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tecovirimat), an oral therapy for the treatment of smallpox disease that was approved by the FDA in July 2018 and is currently procured by the USG for the SNS. TPOXX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved in Canada and the EU. In the EU, TPOXX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is indicated for the treatment of smallpox, mpox and cowpox, as well as the treatment of complications following vaccination against smallpox.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.96pt">Trobigard</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> atropine sulfate, obidoxime chloride auto-injector. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., Meridian Medical Technologies has been the primary supplier of nerve-agent antidote auto-injectors. The USG has funded the development of a number of nerve agent antidote auto-injectors including development programs at Aktiv Pharma Group, Kaleo and others. Outside of the U.S. there are a number of suppliers of these devices though few with approvals from national or regional regulatory authorities.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bioservices</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete for bioservices with several biopharmaceutical product R&amp;D organizations, contract manufacturers of biopharmaceutical products, other bioservices organizations, and university research laboratories. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies with which we compete to provide bioservices include, among others: Lonza Group Ltd., Catalent, Inc., Thermo Fisher Scientific, Curia Global, Inc., Resilience, Grand River Aseptic Manufacturing, Berkshire Sterile Manufacturing, Jubilant HollisterSteirVetter Pharma, and FUJIFILM Diosynth Biotechnologies. We also compete with in-house research, development and support service departments of other biopharmaceutical companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING OPERATIONS</span></div><div style="text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Network: </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent relies on an internal and external network of manufacturers and other third parties to produce its commercial and clinical supply of products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following products are manufactured internally: ACAM2000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Anthrasil</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VIGIV CNJ-016</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RSDL</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, EBANGA&#8482;, TEMBEXA, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and BioThrax</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are produced externally in whole or in part by contract manufacturers.  However, we perform the majority of the work internally to produce </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and BioThrax</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, materials for production of NARCAN</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, such as the naloxone active pharmaceutical ingredient and other excipients, along with the vial, stopper and device are produced around the world by other third parties and delivered to the primary manufacturer and released to manufacturing following appropriate testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplies and Raw Materials: </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We place purchase orders for quantities of raw material and supplies in advance of their use in manufacturing in quantities believed to be sufficient to meet upcoming demand requirements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once received into our facilities or our contract manufacturer&#8217;s facility, these materials are subject to rigorous testing to ensure they are appropriate for use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Alhydrogel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant 2%, used to manufacture CYFENDUS</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BioThrax</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccines, from a single-source supplier for which we currently have no alternative source of supply. However, we maintain stored supplies of this adjuvant in quantities we believed to be sufficient to meet our expected manufacturing needs. We also utilize single-source suppliers for other raw materials in our manufacturing processes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we utilize single source suppliers for all components of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on single source suppliers for our plasma collection to support the VIGIV CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BAT</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> programs. We work closely with our suppliers for these specialty programs and operate under long-term agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect intellectual property related to our assets, including patent rights, trademark rights, trade secrets and proprietary confidential information, through defense and enforcement of existing rights and pursuit of protection on new and arising innovations. The duration of and the type of protection for patent rights depends upon many factors including the type of patent, the scope of its coverage, the availability of regulatory-related extensions or administrative term adjustments, the availability of legal remedies in a particular country, and the validity and enforceability of the patents. We are a party to various license agreements, including those under which we license patents, patent applications, trademarks, know-how, and other intellectual property rights. It is our policy to ethically consider the enforcement and defense of our intellectual property rights, and to respect the valid and enforceable intellectual property rights of others.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGULATION</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulations in the U.S. and other countries have a significant impact on our product development, manufacturing and marketing activities.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Contracting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our status as a USG contractor means that we are subject to various statutes and regulations, including:</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the Federal Acquisition Regulation ("FAR") and agency-specific regulations supplemental to FAR, which comprehensively regulate the award, formation, administration and performance of government contracts;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the Defense Federal Acquisition Regulations ("DFARs") and agency-specific regulations supplemental to DFARs, which comprehensively regulate the award, formation, administration and performance of DoD government contracts;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the Department of State Acquisition Regulation which regulates the relationship between a Department of State organization and a contractor or potential contractor;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, the False Claims Act and the Foreign Corrupt Practices Act;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">export and import control laws and regulations, including but not limited to the Export Administration Regulations and International Traffic in Arms Regulations; and</span></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USG agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. Our role and status as a large government supplier to HHS, particularly BARDA increases the likelihood of Congressional review and oversight. The legal framework we are subject to as a government contractor imposes stricter penalties than those normally applicable to commercial contracts, such as criminal and civil liability and suspension and debarment from future government contracting. In addition, pursuant to various laws, our government contracts can be subject to unilateral termination or modification by the government for convenience, detailed auditing and accounting systems requirements, statutorily controlled pricing, sourcing and subcontracting restrictions and statutorily mandated processes for adjudicating contract disputes. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Project BioShield Act of 2004.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Project BioShield Act of 2004 (Project BioShield) was enacted to augment market incentives for companies pursuing the development of MCMs of which the government is the only significant market. Project BioShield provided $5.6 billion over 10 years to develop, purchase, and stockpile MCMs for use in a public health emergency against CBRNE agents.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Pandemic and All Hazards Preparedness Act of 2006 and Reauthorization Acts.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pandemic and All Hazards Preparedness Act of 2006 established the role of ASPR within HHS and provided statutory authorities for a number of programs, including the creation of BARDA to support the development and procurement of MCMs to respond to CBRNE. The Pandemic All Hazards Preparedness Reauthorization Act of 2013 ("PAHPRA") continued BARDA&#8217;s role and reauthorized Project BioShield funding through fiscal year 2018 and provided BARDA with additional appropriations to support advanced research and development. The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 reauthorized Project BioShield&#8217;s special reserve fund and authorized 10-year funding for product development. BARDA has used the incentives under Project BioShield and subsequent reauthorizations of it to build a robust pipeline of MCMs for multiple CBRNE agents. It has also procured and stockpiled many of our related products for potential use in the event of a PHT emergency, including BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VIGIV and raxibacumab products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funding for BARDA is provided by annual appropriations by Congress. Congress appropriates annual funding for procurement of MCMs for the SNS (currently managed by ASPR) and for the NIAID to conduct biodefense research. This appropriation funding supplements amounts available under Project BioShield.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergency Use Authorization</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 564 of the Federal Food, Drug, and Cosmetics Act ("FDCA") authorizes FDA to issue an Emergency Use Authorization ("EUA") to permit the introduction into interstate commerce of unapproved MCMs, or approved MCMs for unapproved uses, in the context of certain potential or actual public health emergencies. Several actions are required to trigger FDA&#8217;s authority to issue EUAs. First, there must be a determination by certain federal officials that a particular threat or emergency exists. This can be (1) a determination by the Secretary of HHS that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of United States citizens living abroad, and that involves CBRN agents, or a disease or condition that may be attributable to CBRN agents; (2) a determination by the Secretary of Homeland Security (&#8220;DHS&#8221;) that there is a domestic emergency, or a significant potential for a domestic emergency, involving a heightened risk of attack with a CBRN agent; (3) a determination by the Secretary of Defense that there is a military emergency, or a significant potential for a military emergency, involving a heightened risk to United States military forces from an attack with a CBRN agent or an agent that may cause, or is otherwise associated with, an imminently life-threatening and specific risk to United States military forces; or (4) the identification of a material threat pursuant to section 319F&#8211;2 of the Public Health Service Act (&#8220;PHSA&#8221;) sufficient to affect national security or the health and security of United States citizens living abroad. Based on one of these determinations, the Secretary of HHS may make a declaration (the EUA Declaration) that circumstances exist justifying EUAs for MCMs to respond to the threat or emergency at issue. Once the relevant determination and EUA declaration are issued, FDA has the authority to issue EUAs for the use of specific medical products based on criteria established by statute, including that the product at issue may be effective in diagnosing, treating, or preventing a serious or life-threatening disease or condition related to the threat or emergency and that there are no adequate, approved, and available alternatives to the product for diagnosing, preventing, or treating the disease or condition. EUAs are subject to additional conditions and restrictions, are product-specific, and terminate when the EUA is revoked or the EUA declaration is terminated because the Secretary of HHS has determined that the circumstances that led to the emergency determination have ceased or because the authorized use has been approved.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under PAHPRA, the USG may purchase certain MCMs for the SNS prior to FDA approval, licensure or authorization, under certain circumstances. BARDA is currently procuring AV7909, a product candidate that has not been approved or authorized by the FDA under these authorities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public Readiness and Emergency Preparedness Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Public Readiness and Emergency Preparedness Act ("PREP Act") creates liability immunity for manufacturers of MCMs when the Secretary of HHS issues a declaration related to a specific disease, condition or public health threat. A PREP Act declaration is intended to provide liability immunity from claims under federal or state law for loss caused by, arising out of, relating to, or resulting from the administration or use of a covered MCM. The only statutory exception to this immunity is for actions or failures to act that constitute willful misconduct. The Secretary of HHS has issued PREP Act declarations covering MCMs for smallpox, mpox, and other orthopox; anthrax; and botulinum toxin. These declarations could apply to BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, raxibacumab, Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and VIGIV products, as covered MCMs. The declarations for anthrax and botulism expire on December 31, 2027. The declaration for smallpox, mpox, and other orthopox expires on December 31, 2032. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Support Anti-Terrorism by Fostering Effective Technology Act of 2002. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (&#8220;SAFETY Act&#8221;) was enacted to create certain liability limitations for Qualified Anti-Terrorism Technologies (&#8220;QATTs&#8221;) for claims arising out of, related to, or resulting from an act of terrorism. DHS administers the SAFETY Act program, which provides two potential categories of liability protections &#8211; designation and certification. If DHS deems an MCM a &#8220;Designated Technology,&#8221; then the company&#8217;s liability is limited to the amount of liability insurance that DHS determines the company must maintain. To receive &#8220;certification,&#8221; a QATT must first be &#8220;designated&#8221; and also be shown to perform as intended, conform to the manufacturer&#8217;s specifications, and be safe for use as intended. Certification allows the company to assert the Government Contractor defense for claims arising from acts of terrorism. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DHS granted SAFETY Act designation and certification for BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2006 and has continued to renew those determinations. Any future renewals of the SAFETY Act designation and certification for BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products may not provide adequate protection from all claims made against us.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Development for Therapeutics and Vaccines</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Clinical Testing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We generally perform pre-clinical safety and efficacy testing on our product candidates before we initiate clinical trials.</span></div><div style="text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Animal Rule.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Conducting controlled human clinical trials to determine efficacy of MCMs against dangerous pathogens may sometimes be unethical or unfeasible. In such circumstances, products may be approved under the FDA&#8217;s &#8220;Animal Rule.&#8221; According to the FDA, this regulatory pathway can only be pursued if conducting human efficacy studies would be unethical and field trials to study the product&#8217;s effectiveness, after an accidental or deliberate exposure, are not feasible. Under the &#8220;Animal Rule,&#8221; under some circumstances, approval of product candidates can be based on efficacy data from animal studies. In assessing the sufficiency of animal data, the FDA may take into account other available data, including human data. These approvals generally are associated with a requirement for post-approval trials that would be conducted in the event of an act of bioterrorism, a pandemic, or other natural exposure to the pathogen at issue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigational New Drug Application.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Before clinical testing may begin, the results of pre-clinical testing and other available clinical data and manufacturing information must be submitted to the FDA as part of an Investigational New Drug application ("IND"). The data must provide an adequate basis for evaluating both the safety and the scientific rationale for the initial clinical studies. The FDA may impose a full or partial clinical hold on the effectiveness of an IND pending receipt of additional information.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical trials involve administration of a product candidate to healthy human volunteers or patients under the supervision of a qualified physician under a regulatory agency approved protocol for the country in which the human trial is to be conducted. Human clinical trials typically are conducted in the following three sequential phases.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Phase 1 involves introduction of the drug into healthy human subjects to assess safety, metabolism, pharmacokinetics, pharmacological actions, side effects and early evidence of effectiveness.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Phase 2 involves studies to assess the efficacy of the drug in specific, targeted indications, explore tolerance, optimal dosage, and safety.</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Phase 3 trials must assess clinical efficacy and safety in a larger number of healthy subjects or patients, are intended to permit the FDA to evaluate the overall benefit-risk relationship of the product, and provide adequate information for drug labeling. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in certain circumstances Phase 4 studies may be conducted following marketing approval in order to provide additional data related to drug use. The FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that a clinical trial is not being conducted in accordance with the FDA requirements or presents an unacceptable risk to the clinical trial subjects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Good Clinical Practice.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All phases of clinical studies must be conducted in conformance with the FDA&#8217;s bioresearch monitoring regulations and Good Clinical Practices ("GCP") which are ethical and scientific quality standards for conducting clinical trials.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing Approval &#8211; Biologics, Drugs and Vaccines</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biologics License Application/New Drug Application</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For large molecule products, such as vaccines, products derived from blood and blood components, and antibodies, all data obtained from a development program, including research and product development, manufacturing, pre-clinical and clinical trials, labeling and related information are submitted in a BLA to the FDA and in similar regulatory filings with the corresponding agencies in other countries for review and approval. For small molecule drugs, this information is submitted in an NDA filing. The submission of an application, either a BLA or an NDA, is not a guarantee that the FDA will find the application complete and accept it for filing. The FDA may issue a refuse to file, or RTF, letter to the applicant and request additional information, in which case the application must be resubmitted. Most applications are subject to a substantial application fee and each approved product will be assessed an annual fee. Under the FDCA, the FDA has the authority to grant waivers of certain user fees.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In reviewing a BLA or NDA, the FDA may grant approval, request more information or data, or decline to approve the application if, among other potential deficiencies, the FDA determines that the application does not provide substantial evidence of effectiveness, the drug is not safe for use under the conditions of use in the proposed labeling, or there are deficiencies in manufacturing quality. If the FDA decides not to approve an application, it will issue a complete response letter, or CRL. During the FDA's review of the application, the FDA will also typically inspect one or more clinical sites to ensure compliance with GCPs as well as the facility or facilities at which the candidate is manufactured to ensure compliance with current good manufacturing practices ("CGMPs").</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The receipt of regulatory approval may take many years, and typically involves the expenditure of substantial financial resources. The FDA may also impose conditions upon approval or significantly limit the indications approved for a given product and/or require, as a condition of approval, enhanced labeling, packaging, post-approval clinical trials, expedited reporting of certain adverse events, pre-approval of promotional materials or restrictions on consumer advertising, which could negatively impact the commercial success of a product.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abbreviated New Drug Applications and Section 505(b)(2) New Drug Applications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most drug products obtain FDA marketing approval under a full NDA for innovator products, or an abbreviated new drug application ("ANDA") for generic products. The Hatch-Waxman amendments to the FDCA established a statutory procedure for submission and FDA review and approval of ANDAs for generic versions of branded drugs previously approved by the FDA (reference listed drugs, or RLDs). Because the safety and efficacy of RLDs have already been established by the brand company (sometimes referred to as the innovator), the FDA does not require ANDA applicants to independently demonstrate safety and efficacy of generic products. However, a generic manufacturer is required to demonstrate that its product contains the same active ingredient as, and is bioequivalent to, the RLD, among other requirements. For a systemically absorbed drug, bioequivalence generally is established when there is an absence of a significant difference in the rate and extent of absorption of the generic product and the RLD.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third alternative for approval of a drug product is commonly referred to as a Section 505(b)(2) NDA, which enables the applicant to rely, in part, on the FDA&#8217;s findings of safety and efficacy of an existing product in support of its application. Section 505(b)(2) NDAs often provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant might rely upon the FDA&#8217;s findings with respect to certain pre-clinical or clinical studies conducted for an approved product. The FDA may also require companies to perform additional studies or submit other information to support the change from the approved product. The FDA may then approve the new product candidate for certain indications for which the referenced product has been approved, as well as for any new indication sought by the applicant.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to submit to the FDA information about certain patents of the applicant or that are held by third parties whose claims cover the applicant&#8217;s product. Upon approval of an NDA, each of the patents for which the applicant has submitted information in connection with the NDA is then published in the Orange Book. Any subsequent applicant who files an ANDA or a 505(b)(2) NDA must make one of the following certifications to the FDA concerning each patent for which the RLD sponsor was required to submit information in connection with the RLD: (1) the patent information has not been submitted to the FDA; (2) the patent has expired; (3) the date on which the patent will expire; or (4) the patent is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. Alternatively, the ANDA or 505(b)(2) NDA applicant may submit a statement that there are no relevant patents or that a method-of-use patent does not claim a proposed indication or other condition of use for which the applicant is seeking approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the RLD&#8217;s NDA holder or patent owner initiates patent litigation to enforce an Orange Book-listed patent within 45 days after receiving notice of a paragraph IV certification, the FDA generally is prohibited from approving the application until 30 months from the date of receipt of the paragraph IV notice, although this stay may terminate earlier depending upon the resolution of the litigation, if the court issues an order terminating the stay, or if the patent owner or exclusive patent licensee consents to approval of the application before the expiration of the stay. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the RLD has expired. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilar Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a biological product is licensed for marketing by FDA through the approval of a BLA under section 351(a) of the PHSA, the product may be entitled to exclusivity barring FDA from accepting or approving an application under section 351(k) of the PHSA for a competing product for certain periods of time. The Biologics Price Competition and Innovation Act of 2009 (the "BPCIA") added Section 351(k) of the PHSA, which provides an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may approve a biosimilar product if it finds that the product is highly similar to the reference product notwithstanding minor differences in clinically inactive components and there are no clinically meaningful differences between the proposed biosimilar product and the reference product in terms of safety, purity, and potency.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the FDA to approve an interchangeable biosimilar product, it must conclude that the product is biosimilar to the reference product, can be expected to produce the same clinical result as the reference product in any given patient, and&#8212;for a product that is administered more than once to an individual&#8212;alternating or switching between the proposed interchangeable product and the reference product would not create an increased risk in terms of safety or diminished efficacy compared to using the reference product only.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA will not accept a biosimilar application until four years after the date of first licensure of a biological product licensed under section 351(a) of the PHSA, and FDA will not approve a biosimilar application until 12 years after such date of first licensure. This type of exclusivity is known as reference product exclusivity. The approval of a supplemental BLA or certain subsequent BLAs does not give rise to a new date of first licensure, and, consequently, does not yield an additional period of reference product exclusivity. from the date of first licensure of a biological product approved under section 351(a), Moreover, reference product exclusivity does not affect the timing of FDA&#8217;s acceptance or approval of a competing sponsor&#8217;s section 351(a) BLA containing the sponsor&#8217;s own pre-clinical data and data from adequate and well&#8209;controlled clinical trials to demonstrate the safety, purity, and potency of its product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been recent legislative proposals to reduce the duration of the 12-year reference product exclusivity period, but none has been enacted to date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, many states have enacted laws that address pharmacy practices involving biosimilar products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Requirements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Any drug, biologic or medical device product for which we receive FDA marketing authorization will be subject to continuing regulation by the FDA, including, among other things, record keeping requirements, reporting of adverse events, providing FDA with updated safety and efficacy information, product sampling and distribution requirements (for drugs and biologics), restrictions on advertising and promotion, and FDA inspections. Adverse events that are reported after marketing approval can result in additional limitations being placed on the product&#8217;s distribution or use and, potentially, withdrawal or suspension of the product from the market. The FDA may also require post-approval clinical trials and/or safety labeling changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities involved in the manufacture and distribution of approved products are required to be registered with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA for compliance with CGMP and other laws. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company that is found to have improperly promoted unapproved or off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drugs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the Orphan Drug Act, an applicant can request the FDA to designate a product as an &#8220;orphan drug" in the U.S. if the drug is intended to treat a rare disease or condition. A disease or condition is considered rare if it affects fewer than 200,000 people in the U.S. or there is no reasonable expectation that the cost of developing the drug and making it available in the United States will be recovered from sales in the United States. A manufacturer must request orphan drug designation prior to submitting a BLA or NDA. Products designated as orphan drugs may be eligible for special grant funding for R&amp;D, FDA assistance with the review of clinical trial protocols, potential tax credits for research, an exemption from the application fee for marketing applications and a seven-year period of orphan drug exclusivity after marketing approval. A grant of an orphan designation is not a guarantee that a product will be approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug exclusivity (afforded to the first applicant to receive approval for an orphan designated drug for a particular rare disease or condition) generally prevents FDA approval of another sponsor&#8217;s application for the same drug for the same indication. Orphan drug exclusivity will not bar approval of the same drug marketed by a different manufacturer under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand, grants consent to the FDA&#8217;s approval of the subsequent product or the subsequent product is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the U.S. Court of Appeals for the Eleventh Circuit held in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Catalyst Pharmaceuticals, Inc. v. Becerra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the FDA had erred by limiting the scope of orphan drug exclusivity for FIRDAPSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amifampridine) to the product&#8217;s approved indication, an action that the FDA took in accordance with its regulations interpreting the Orphan Drug Act. The court held that under the Orphan Drug Act, FIRDAPSE&#8217;s orphan drug exclusivity instead protected the rare disease or condition that received orphan drug designation. Following this court decision in the Catalyst case, the FDA announced in January 2023 that it would continue to apply the FDA&#8217;s regulations limiting the scope of orphan drug exclusivity to a product&#8217;s approved uses or indications. As a result of the FDA&#8217;s announcement, the scope of orphan drug exclusivity and other issues relating to the FDA&#8217;s implementation of the Orphan Drug Act with respect to previously approved and future products may be the subject of further litigation or legislation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccine and Therapeutic Product Lot Protocol.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Because the manufacturing process for biological products is complex, the FDA requires for many biologics, including most vaccines and immune globulin products, that each product lot undergo thorough testing for purity, potency, identity and sterility. FDA may request samples of any lot and, when deemed necessary for the safety, purity, and potency of the product, FDA may prohibit us from distributing a lot until FDA releases the lot. Several of our vaccines are subject to lot release protocols by the FDA and other regulatory agencies.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing Approval &#8211; Devices</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Devices may be marketed as stand-alone devices or as constituent parts of a Combination Product, such as a device for delivery of a drug product. Unless an exemption applies, each medical device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, approval of a premarket approval application (&#8220;PMA&#8221;) or issuance of a de novo classification order. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices are classified into one of three classes&#8212;Class I, Class II or Class III&#8212;depending on the degree of risk and the level of control necessary to assure the safety and effectiveness of each medical device. Medical devices deemed to pose lower risks are generally placed in either Class I or II. While most Class I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required to submit to the FDA a pre-market notification. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining life-supporting or many implantable devices, or devices that have been found not substantially equivalent to a legally marketed Class I or Class II predicate device, are placed in Class III, requiring approval of a PMA.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;) regulations that govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of study review and approval, informed consent, recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. All clinical device studies, including non-significant risk studies, must be approved by, and conducted under the oversight of, an Institutional Review Board (&#8220;IRB&#8221;). The IRB is responsible for the initial and continuing review of the study and may pose additional requirements for the conduct of the study.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both before and after a medical device is commercially distributed, manufacturers and marketers of the device have ongoing responsibilities under FDA regulations, including, for example, establishment registration and device listing; compliance with the requirements of the Quality System Regulation (&#8220;QSR&#8221;); compliance with requirements regarding the labeling and marketing of devices; medical device reporting regulations; correction and removal reporting regulations; compliance with requirements for Unique Device Identification (&#8220;UDI&#8221;); and post-market surveillance activities and requirements. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Device manufacturers are subject to periodic and unannounced inspection by the FDA. The FDA reviews design and manufacturing practices, record keeping, reports of adverse events, labeling and other information to ensure compliance with the QSR and other applicable requirements, and to identify potential problems with manufacturing processes and marketed medical devices.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A combination product is a product comprised of two or more regulated components (e.g., a drug and device) that are combined into a single product, co-packaged, or sold separately but intended for co-administration, as evidenced by the labeling for the products (cross-labeling). Like their constituent parts&#8212;e.g., drugs and devices&#8212;combination products are highly regulated and subject to a broad range of pre- and post-market requirements including premarket review, CGMPs and/or QSRs, adverse event reporting, periodic reports, labeling and advertising and promotion requirements and restrictions, market withdrawal and recall. Combination products are typically reviewed through a marketing submission that corresponds to the constituent part which provides the primary mode of action (&#8220;PMOA&#8221;) for the combination product. For example, if the PMOA of a device-biologic combination product is attributable to the biologic, the agency center that reviews biologics would have the primary jurisdiction for the review.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also regulates the export of medical devices from the U.S., and medical devices that are not authorized to be legally marketed in the U.S. are subject to FDA export requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Requirements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA's statutory provisions and regulations require that drugs be manufactured in FDA-registered facilities and in accordance with CGMPs. The CGMP regulations include requirements relating to organization and personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned and salvaged products. The manufacturing processes for devices must likewise be performed in compliance with the applicable portions of the QSR, which covers the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. Manufacturers and other entities involved in the manufacture and distribution of cleared, approved, or otherwise authorized products are required to register their establishments with the FDA, and in some instances state agencies, and they are subject to periodic unannounced inspections by the FDA for compliance with CGMPs and/or QSRs and other requirements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA uses a "risk-based approach" to inspections, whereby the agency prioritizes medical product surveillance inspections deemed high risk based on a variety of specific criteria, such as facility type, compliance history, and inherent risks of product manufactured at the facility. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved drug product are strictly regulated and often require prior FDA approval before being implemented. Likewise, FDA&#8217;s regulations require clearance of a new 510(k) premarket notification for modifications to 510(k) cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in the intended use of the device, and approval of a PMA supplement for certain modifications to PMA-approved devices that affect the safety or effectiveness of the device. The FDA's regulations also require, among other things, the investigation and correction of any deviations from CGMP or failures to follow the QSR and the maintenance of applicable documentation by the sponsor and any third-party manufacturers involved in producing the approved, cleared, or otherwise authorized product.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation Outside of the U.S.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we maintain a commercial presence in the U.S. and Canada as well as certain other countries. Each foreign country has its own regulatory requirements for medicines and medical devices.  In the EU, medicinal products are authorized following a process that is similarly demanding as the process required in the U.S. Drug products may be authorized in one of two ways, either through the mutual recognition/decentralized procedure, which provides for the mutual recognition procedure of national approval decisions by the competent authorities of the EU Member States or through the centralized procedure, which provides for the grant of a single marketing authorization that is valid for all EU member states. Before a medical device can be placed on the market in the EU compliance with the requirements of the Medical Devices Regulation (EU) 2017/745 must be demonstrated in order to affix the CE Mark to the product. The method of assessing conformity varies depending on the class of the product, but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a notified body. We are also subject to many of the same continuing post-approval requirements in the EU as we are in the U.S. (e.g., good manufacturing practices).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2021, the UK is no longer part of the EU following &#8220;Brexit&#8221;. All existing EU law in force on December 31, 2020 has been retained in UK law, subject to certain revisions that have become necessary as a result of Brexit. Thus, at least initially, the UK and the EU laws were aligned. Northern Ireland continues to be subject to EU rules governing medicines and medical devices under the Northern Ireland Protocol. However, EU laws that took effect after January 1, 2021, including the EU Medical Devices Regulation, are not effective in Great Britain, comprising England, Scotland and Wales, and the national laws applicable in Great Britain may further diverge from EU law in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potential Sanctions</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all FDA-regulated products, if the FDA finds that a manufacturer has failed to comply with applicable laws and regulations, or that a product is ineffective or poses an unreasonable health risk, it can institute or seek a wide variety of enforcement actions and remedies, including but not limited to:</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">restrictions on products, manufacturers or manufacturing processes;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">restrictions on distribution or use of a product;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">warning letters or untitled letters;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">withdrawal of the products from the market;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">refusal to approve pending applications or supplements to approved applications that are submitted;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">recall of products;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">refusal to permit the import or export of our products;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">product seizure; and</span></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health regulatory authorities in other countries have similar rules and regulations although the specifics vary from jurisdiction to jurisdiction.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fraud, Abuse and Anti-Corruption Laws</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and most other jurisdictions have detailed requirements that apply to government and private health care programs, and a broad range of fraud and abuse laws, transparency laws, and other laws. Relevant U.S. federal and state healthcare laws and regulations include:</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">The federal Anti-Kickback Statute;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">The False Claims Act;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">The federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health ("HITECH") Act;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">The price reporting requirements under the Medicaid Drug Rebate Program and the Veterans Health Care Act of 1992;</span></div><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">The federal Physician Payment Sunshine Act, being implemented as the Open Payments Program; and</span></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Analogous and similar state laws and regulations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are also subject to compliance with the Foreign Corrupt Practices Act ("FCPA") which prohibits corporations and individuals from corruptly paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party or party official, or political candidate, directly or indirectly, in an attempt to influence a person working in an official capacity or otherwise obtain an improper advantage. We also may be impacted under the FCPA by the activities of our distributors, collaborators, contract research organizations, vendors, consultants, agents, or other business partners. As a public company, the FCPA also requires us to make and keep books and records that accurately and fairly reflect all of our transactions and to devise and maintain an adequate system of internal accounting controls. Our operations are also subject to compliance with the U.K. Bribery Act, which applies to bribery activities both in the public and private sector, Canada&#8217;s Corruption of Foreign Public Officials Act and similar laws in other countries. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these laws and regulations could subject us to criminal or civil penalties.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulations Governing Reimbursement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing practices of U.S. pharmaceutical manufacturers are also subject to federal and state healthcare laws related to government funded healthcare programs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., certain of our products are reimbursed under federal and state health care programs such as Medicaid, Medicare, Tricare, and or state pharmaceutical assistance programs. Many foreign countries have similar laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various U.S. federal health care laws apply when we or customers submit claims for items or services that are reimbursed under federally funded health care programs, including federal and state anti-kickback laws, false claims laws, and anti-self-referral laws, which may apply to federal and state-funded health care programs and private third-party payers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these laws and regulations could subject us to criminal or civil penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, drug pricing is an active area for regulatory reform at the federal and state levels, and significant changes to current drug pricing and reimbursement structures in the U.S. continue to be considered and enacted. For example, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), was signed into law on August 16, 2022. As written, the IRA will, among other provisions, give HHS the ability and authority to directly negotiate with manufacturers the price that Medicare will pay for certain single-source drugs that account for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">high Medicare spending. The IRA will also require manufacturers of certain Part B and Part D drugs to issue to HHS rebates based on certain calculations and triggers (i.e., when drug prices increase and outpace the rate of inflation). The Centers for Medicare &amp; Medicaid Services is in the process of implementing a Medicare Drug Price Negotiation Program, and this program may affect future Medicare reimbursement for certain of our products.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Data Privacy Laws</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of states in the U.S. have passed or introduced bills, which, if passed, impose operational privacy requirements on U.S. companies similar to the requirements reflected in the General Data Protection Regulation ("GDPR") in the EU ("State Consumer Privacy Laws"). As of December 31, 2023, State Consumer Privacy Laws were effective in five U.S. states. Three more State Consumer Privacy Laws become effective in 2024. For example, the California Consumer Privacy Act of 2018 ("CCPA"), which came into effect on January 1, 2020, requires covered companies that process personal information on California residents to make new disclosures to consumers about their data collection, use and sharing practices, allows consumers to opt out of certain data sharing with third parties and provides a new private right of action for data breaches. Additionally, the Federal Trade Commission and many state attorney generals are interpreting federal and state consumer protection laws to impose standards for the online collection, use, dissemination and security of data. The compliance and other burdens imposed by the EU's GDPR, CCPA and similar privacy laws and regulations may be substantial as they are subject to differing interpretations and implementation among jurisdictions. The restrictions imposed by such laws may require us to modify our data handling practices and impose additional compliance costs and burdens.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Industry Regulation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents used in connection with our product development, are or may be applicable to our activities.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value our employees and the contributions each of them makes to achieving our mission to protect and enhance life. We strive to create an environment that is professionally and personally rewarding by offering challenging work and projects for individual and team contribution, and opportunities for professional and personal development. Ongoing investments in employee engagement and leadership development remain essential to building the capabilities needed to realize our business strategy. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, our number of employees declined by approximately 900 due to organizational restructurings announced in January and August 2023 and the sale of our travel health business to Bavarian Nordic in May. As of December 31, 2023, we had approximately 1,600 employees. </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health and Wellness</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our company, we are deeply committed to the health and wellbeing of our employees. We provide a comprehensive range of benefits and resources to support their physical, mental, and financial wellness. This includes access to mindfulness tools, online therapy apps, fitness apps, and programs focused on financial literacy and wellbeing. Additionally, our safety programs comply with regional requirements and are designed to ensure a safe and comfortable work environment, incorporating measures such as ergonomics, COVID-19 prevention protocols, and a strong culture of safety in our day-to-day operations. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hiring and Talent Management </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus on building leaders at every level with the requisite scientific, technical and professional skills to develop and deliver products and services that protect life. We have consistent talent processes and systems across the company including performance management, training and development and succession planning. We recognize the need for ongoing skill enhancement and support continued learning through on-the-job assignments, leadership and technical training programs, tuition assistance professional memberships and professional conference attendance. We continue to use the Gallup Q12 instrument to measure employee engagement and inclusion and administer &#8220;pulse surveys&#8221; throughout the year to gather feedback on matters of interest and importance to our employees and our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards plan consists of comprehensive benefits and salaries, bonuses, and for employees in eligible roles, equity awards. We focus on results and behavior because we value how we do things as much as getting them done. This approach is core to our pay-for-performance philosophy. We continue to provide employees access to country-specific salary range information so that they may have greater visibility to their current compensation levels and more context as they explore developing their careers within our company.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diversity, Equity and Inclusion Commitment </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diversity, equity and inclusion ("DEI") is integral to how we operate and our success. We are committed to attracting, developing, and retaining the best talent reflecting a diversity of ideas, backgrounds, and perspectives. DEI fuels our business growth, drives innovation in the products and services we develop, in the way we solve problems, and how we serve the needs of a global and diverse patient, customer and partner base. We demonstrate respect for the individual by providing fair and equal treatment to all our employees and identifying ways to recognize their various needs and interests. Our three inaugural Emergent Resource Groups ("ERGs") for black, women and veteran employees continue to open pathways of communication, help to expand learning opportunities, and offer avenues to give back to communities. In 2023, the ERGs brought guest speakers and learning opportunities on important topics such as imposter syndrome, maintaining mental fitness and challenges faced by women in the workplace. Another important initiative has been implementing and planning to expand the SkillBridge internship program and other efforts that support veterans' successful transition into the private sector. While aligned by constituency, our ERGs are open to all employees and are another way we will look to catalyze a sense of belonging and connection to the organization.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENVIRONMENTAL, SOCIAL AND GOVERNANCE</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission to protect and enhance life has motivated us to explore our impact at a broader scale &#8212; environmental, social and governance ("ESG") stewardship, corporate responsibility, and ethics. Our approach to these issues is the foundation of good governance and strengthens accountability in all aspects of our business activities and relationships. Since 2020, Emergent has annually reported on ESG matters under the responsibility of the Vice President, Assistant Treasurer reporting into the Chief Financial Officer ("CFO"), with oversight from the Nominating and Corporate Governance Committee. In 2023, we created a dedicated role within our organization to manage this work full time, reinforcing our commitment to ESG progress at Emergent. In addition to creating and publishing Emergent&#8217;s annual ESG report, this new role will work with core stakeholders across the organization to evolve and implement a multiyear ESG strategy that supports our mission. Our Nominating and Corporate Governance Committee will continue to oversee ESG efforts, with executive sponsorship from the CFO and Executive Vice President of External Affairs and General Counsel.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is influenced by the Task Force on Climate-Related Disclosures framework ("TCFD") as well as the Sustainability Accounting Standards Board&#8217;s standards focused on the healthcare, biotechnology, and pharmaceutical industries. The SASB standards provide guidelines on key sustainability issues that directly impact the operational performance and financial condition of our company. Our most recent ESG Report can be found at: www.emergentbiosolutions.com/wp-content/uploads/2023/10/EBSI_2022_ESG_Report. The information contained in the ESG report is not a part of, or incorporated by reference into, this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strengthening our culture and the quality of products and services we offer is an ongoing endeavor. Open and transparent communication with employees, customers, government officials, and community partners is vital to our success.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESG Priority Issues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since conducting our first materiality assessment in 2020, Emergent and the world have changed significantly. To ensure our priority issues support business needs and meet stakeholder expectations, we conducted a materiality refresh in 2023 with input from internal and external stakeholders. Our updated priority issues are:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Top Priorities</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Talent Attraction, Engagement &amp; Development</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Ethics &amp; Compliance </span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Product Quality &amp; Patient Safety</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Sustainable Innovation</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Product Affordability &amp; Accessibility</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Responsible Supply Chain</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Relative Priorities</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Carbon Emissions</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Climate Policy and Risk Management</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Clinical Trial Practices</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Diversity, Equity and Inclusion</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Employee Health and Safety</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Energy Use and Efficiency</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Environmental Policy and Management</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ESG Oversight</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Supplier Product Quality, Reliability and Compliance</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Waste Management</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sustainability and Environmental Management</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that our operations have an impact on our local and global communities from the waste we generate, the energy we source, and the water we discharge. Environmental sustainability is a central consideration when improving and innovating our operational infrastructure across our enterprise and we must do our part to reverse the impacts of climate change which threaten environmental and human health. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate ESG risks and opportunities related to climate change through the framework that the Task Force on Climate-Related Financial Disclosures ("TCFD") recommends: (i) governance, (ii) strategy, and (iii) risk management. As we further develop our environmental sustainability strategies, we intend to collect data on our Scope 1 and Scope 2 greenhouse gas ("GHG") emissions associated with our material operations. Doing so will enable Emergent to establish an energy baseline and prioritize future footprint reductions. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these efforts will also allow us to make informed decisions on setting targets and creating an accompanying strategy and road map for meeting our goals. Emergent will determine the relevance of disclosure related to the quantifiable financial impact to our company under various global warming scenarios in line with TCFD recommendations.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Committee Oversight</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary oversight of ESG issues is delegated to the Nominating and Corporate Governance Committee of the Company's board of directors. ESG executive sponsors provide regular updates on ESG initiatives and progress at both the committee and full board meetings.  Each director serves on at least one committee. The composition of the committees, biographies of our directors, and other relevant corporate governance information are available on the investor section of our website under &#8220;Governance.&#8221; In addition, we also provide detailed corporate governance information, disclosures, and data in our annual proxy statement.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVAILABLE INFORMATION</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the New York Stock Exchange under the ticker symbol &#8220;EBS.&#8221; Our principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland 20879. Our telephone number is (240) 631-3200, and our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.emergentbiosolutions.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make available, free of charge on our website, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the "Exchange Act") as soon as reasonably practicable after we electronically file those reports with, or furnish them to, the SEC.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. In addition, we intend to make available on our website all disclosures that are required to be posted by applicable law, the rules of the SEC or the New York Stock Exchange listing standards regarding any amendment to, or waiver of, our code of business conduct and ethics. We have included our website address as an inactive textual reference only. The information contained on, or that can be accessed through, our website is not a part of, or incorporated by reference into, this Annual Report on Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_1099511629785"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risk factors and other information included in this Annual Report on Form 10-K should be carefully considered. The occurrence of any of the following risks or of unknown risks and uncertainties may adversely affect our business, operating results and financial condition. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of government contracting risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Reduced demand for and/or funding for procurement of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccines or ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and discontinuation of funding of our other USG procurement and development contracts.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Inability to secure follow-on product procurement contracts with the USG upon the expiration of any of our existing procurement contracts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of manufacturing risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our inability to maintain quality and manufacturing compliance at our manufacturing facilities for our products and for product candidates for our Bioservices customers.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Disruption at, damage to or destruction of our development and/or manufacturing facilities may impede our ability to manufacture our products, as well as deliver our bioservices.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses expose us to significant potential liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of product development and commercialization risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain. </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">We may fail to capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of regulatory and compliance risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Failure to comply with complex laws and regulations pertaining to government contracts and resources required for responding to related government inquiries.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Conditions associated with approvals and ongoing regulation of products may limit how and the extent to which we manufacture and market them.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Failure to comply with various health care laws could result in substantial penalties.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Failure to comply with obligations under USG pricing programs may require reimbursement for underpayments and the payment of substantial penalties, sanctions and fines.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">The extent to which we may be able to lawfully offer to sell and sell unapproved products in many jurisdictions may be unclear or ambiguous and such activities may subject us to regulatory enforcement actions. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of competitive and political risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Development and commercialization of pharmaceutical products are subject to evolving private and public sector competition.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.97pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray is currently subject to generic and branded competition in the U.S. and may be subject to branded and generic competition in Canada. In addition, the success of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, including in over-the-counter form, is subject to commercial availability of the product and our ability to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Biologic products may be affected by the approval and entry of follow-on biologics, or biosimilars in the United States and other jurisdictions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to our intellectual property that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Challenges in obtaining or maintaining intellectual property rights and defense or enforcement of such rights.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Potential discrepancies or challenges with respect to licenses, including our failure to comply with obligations under such licenses.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Potential loss or misappropriation of proprietary information, know-how, and trade secrets which carries the risk of reducing the value of our technology and products.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Entry of competing generic drugs upon patent and/or regulatory expires or with patents no longer in force.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to reliance on third parties that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">The loss of sole-source suppliers or an increase in the price of inventory.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">If other parties do not perform as contractually required or as expected, we may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of legal and reputational risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Unfavorable results of legal proceedings and government investigations could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our work on PHTs has exposed us to criticism and may expose us to further criticism, from the media, government personnel and others, which could further harm our reputation, negatively affect our share price, operations and our ability to attract and retain talent.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Cybersecurity incidents involving us, our business partners, collaborators or other third parties could harm our ability to operate our business effectively in light of our heightened risk profile. </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">We could face product liability exposure associated with the use of our medical products. There can be no assurance that the SAFETY Act, Public Readiness and Emergency Preparedness Act (the "PREP Act"), or other liability protections will be sufficient to limit or avoid product liability, and defending such cases requires significant resources.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of financial risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our ability to maintain sufficient cash flow from our operations to pay our substantial debt, both now and in the future.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our ability to obtain additional funding and be able to raise capital when needed, including in order to be able to continue as a going concern.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our ability to comply with the covenants under our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Credit Facility, Term Loan Facility, Senior Unsecured Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any other debt agreements to which we may be a party.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our ability to remediate a material weakness in our internal control over financial reporting and to prepare accurate financial statements in a timely manner.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to our strategic acquisitions, divestitures and collaborations that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">We may not be successful in identifying, structuring or acquiring businesses and products to drive our growth.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our failure to successfully integrate acquired businesses and/or assets into our operations and our ability to realize the benefits of such acquisitions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our failure to realize the full benefits from the sale of our travel health business to Bavarian Nordic.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks associated with our common stock, including, but not limited to:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Our business or our share price could be negatively affected as a result of the actions of stockholders.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">The price of our common stock has been and remains subject to extreme volatility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors below contain more detailed descriptions of the risks identified above, as well as additional risks that may materially harm our business, financial condition or results of cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT CONTRACTING RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently derive a substantial portion of our revenue from USG procurement of the CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> vaccine and the TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, oral antiviral and have historically derived a substantial portion of our revenue from USG procurement of the ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> vaccine and of BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. If the USG&#8217;s demand for and/or funding for procurement of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and/or TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> are substantially reduced, our business, financial condition, operating results and cash flows would be materially harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive a substantial portion of our current and expected future revenues from USG procurement of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As with any approved product, there is a risk that we may encounter challenges causing delays or an inability to deliver CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which may have a material effect on our ability to generate and recognize revenue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The success of our business and our future operating results are significantly dependent on anticipated funding for the procurement of our anthrax vaccines and the terms of such procurement by the USG, including the price per dose, the number of doses and the timing of deliveries. We have no certainty that funding will be made available for the procurement of our anthrax vaccines. If priorities for the Strategic National Stockpile (&#8220;SNS&#8221;) change generally, or as a result of the conclusion of the USG&#8217;s audit of the SNS, or with respect to the level of procurement of our anthrax vaccines, funding to procure future doses of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccines may be delayed, limited or not available, BARDA may never complete the anticipated full transition to stockpiling CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in support of anthrax preparedness, and our future business, financial condition, operating results and cash flows could be materially harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past we have derived a substantial portion of our revenues from sales of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine to the USG. If priorities for the SNS change with respect to ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine or the USG decides not to exercise additional options under our ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contract, our future business, financial condition, operating results and cash flows could be materially harmed. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our USG procurement and development contracts require ongoing funding decisions by the USG. Any reduction or discontinuation of funding of any of these contracts could cause our business, financial condition, operating results and cash flows to suffer materially.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USG is the principal customer for our MCMs and the primary source of funds for the development of most of our product candidates in our development pipeline. We anticipate that the USG will also be a principal customer for any MCMs that we successfully develop from within our existing product development pipeline, as well as those we acquire in the future. Additionally, a significant portion of our revenue comes from USG development contracts and grants. Over its lifetime, a USG procurement or development program, such as for CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our development and procurement contract with BARDA, may be implemented through the award of many different individual contracts and subcontracts. The funding for such government programs is subject to Congressional appropriations, generally made on a fiscal year basis, even for programs designed to continue for several years. These appropriations can be subject to a number of uncertainties, including political considerations, changes in priorities due to global pandemics, the results of elections and stringent budgetary constraints.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our government-funded development contracts typically give the USG the right, exercisable in its sole discretion, to extend these contracts for successive option periods following a base period of performance. The value of the services to be performed during these option periods may constitute the majority of the total value of the underlying contract. On July 31, 2023, we were awarded a 10-year contract by BARDA for the advanced development, manufacturing scale-up, and procurement of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ansuvimab-zykl) treatment for Ebola. The contract consists of a base period of performance with two option periods valued at approximately $121 million, and option periods for procurement of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over five years valued at up to $583 million. If all option periods are exercised, the total contract value will be valued at up to approximately $704 million. If levels of government expenditures and authorizations for public health countermeasure preparedness decrease or shift to programs in areas where we do not offer products or are not developing product candidates, or if the USG otherwise declines to exercise its options under this contract or our other existing contracts, our revenues would suffer, as well as our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There can be no assurance that we will be able to secure follow-on product procurement contracts with the USG upon the expiration of any of our existing procurement contracts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue is substantially dependent upon product procurement contracts with the USG and foreign governments for our MCMs and other commercialized products. Upon the expiration of a procurement contract, we may not be able to negotiate a follow-on procurement contract for the particular product on similar terms. We intend to negotiate follow-on procurement contracts for most of our MCMs and other commercialized products upon the expiration of a related procurement contract, but there can be no assurance that we will be successful obtaining any follow-on contracts. Even if we are successful in negotiating a follow-on procurement contract, it may be for a lower product volume, over a shorter period of performance or be on less favorable pricing or other terms. An inability to secure follow-on procurement contracts for our approved products or product candidates could materially and adversely affect our revenues, and our business, financial condition, operating results and cash flows could be harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The government contracting process is typically a competitive bidding process and involves unique risks and requirements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business involves government contracts and grants, which may be awarded through competitive bidding. Competitive bidding for government contracts presents many risks and requirements, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the possibility that we may be ineligible to respond to a request for proposal;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the commitment of substantial time and attention of management and key employees to the preparation of bids and proposals;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the need to accurately estimate the resources and cost structure that will be required to perform any contract that we might be awarded;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the submission by third parties of protests to our responses to requests for proposal that could result in delays or withdrawals of those requests for proposal; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">in the event our competitors protest or challenge contract or grant awards made to us through competitive bidding, the potential that we may incur expenses or delays, and that any such protest or challenge could result in the resubmission of bids based on modified specifications, or in the termination, reduction or modification of the awarded contract.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USG may choose not to award us future contracts for either the development of our new product candidates or for the procurement of our existing MCM and other commercialized products and may instead award such contracts to our competitors. If we are unable to secure particular contracts, we may not be able to operate in the market for products that are provided under those contracts. Additionally, if we are unable to consistently win new contract awards over an extended period, or if we fail to anticipate all of the costs or resources that we will be required to secure and, if applicable, perform under such contract awards, our growth strategy and our business, financial condition and operating results and cash flows could be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The amounts we are paid under our fixed price government procurement contracts are based on estimates we have made of the time, resources and expenses required for us to perform under those contracts. If our actual costs exceed our estimates, we may not be able to earn an adequate return or may incur a loss under these contracts, which could harm our operating results and materially reduce our net income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current procurement contracts with the U.S. Department of Health &amp; Human Services (&#8220;HHS&#8221;) and the U.S. Department of Defense (&#8220;DoD&#8221;) are generally fixed price contracts. We expect that any future procurement contracts we successfully secure with the USG would likely also be fixed price contracts. Under a fixed price contract, we are required to deliver our products at a fixed price regardless of the actual costs we incur. Estimating costs that are related to performance in accordance with contract specifications is difficult, particularly where the period of performance is over several years, and when factoring in higher levels of inflation. Our failure to anticipate technical problems, estimate costs accurately or control costs during performance of a fixed price contract could reduce the profitability of such a contract or cause a loss, which could harm our operating results and materially reduce our net income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unfavorable provisions in government contracts, some of which may be customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not typically found in commercial contracts, including provisions that allow the USG to:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">terminate existing contracts, in whole or in part, for any reason;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">unilaterally reduce or modify contracts or subcontracts;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">decline, in whole or in part, to exercise an option to purchase product under a procurement contract or to fund additional development under a development contract;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">decline to renew a procurement contract;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">claim certain rights to facilities or to products, including intellectual property, developed under the contract;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">require repayment of contract funds spent on construction of facilities in the event of contract default;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">take actions that result in a longer development timeline than expected;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">direct the course of a development program in a manner not chosen by the government contractor;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">suspend or debar the contractor from doing business with the government or a specific government agency;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">pursue civil or criminal remedies under acts such as the False Claims Act and False Statements Act; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">control or prohibit the export of products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, government contracts contain provisions permitting unilateral termination or modification, in whole or in part, at the USG&#8217;s convenience. Under general principles of government contracting law, if the USG terminates a contract for convenience, the government contractor may recover only its incurred or committed costs, settlement expenses and profit on work completed prior to the termination. If the USG terminates a contract for default, the government contractor is entitled to recover costs incurred and associated profits on accepted items only and may be liable for excess costs incurred by the government in procuring undelivered items from another source. All of our development and procurement contracts with the USG are terminable at their convenience with these potential consequences.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our USG contracts grant the USG the right to use technologies developed by us under the government contract or the right to share data related to our technologies, for or on behalf of the USG. Under our USG contracts, we may not be able to limit third parties, including our competitors, from accessing certain of these technology or data rights, including intellectual property, in providing products and services to the USG.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An inability to maintain manufacturing compliance at our manufacturing facilities, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts periodic inspections of our manufacturing facilities for compliance with CGMP requirements. The Company's failure to maintain compliance with CGMP requirements at our manufacturing facilities has hindered and could continue to hinder our ability to continue manufacturing for our own products and for Bioservices customers, which could adversely affect our business, financial condition, operating results and cash flows. For example, in February 2022, the FDA inspected Emergent&#8217;s Camden facility located in Baltimore, Maryland and issued a Form FDA 483. In August 2022, the FDA issued a warning letter to Emergent related to the February 2022 inspection. The warning letter included issues pertaining to equipment cleaning and maintenance; aseptic sterilization technique and procedures; and quality systems. In July and August of 2023, the FDA inspected the Camden facility, and in October 2023, the FDA determined that the inspection classification of the Camden facility was "voluntary action indicated" or VAI. A VAI classification indicates that, although investigators found and documented objectionable conditions during the inspection, the FDA would not take or recommend any administrative or regulatory action. Furthermore, the FDA concluded that the Camden facility inspection was "closed" under 21 CFR 20.64(d)(3) and issued to the Company a "Warning Letter close-out letter". In August 2023, the FDA inspected Emergent's Canton facility located in Canton, Massachusetts and issued a Form FDA 483. The Canton facility inspection was classified as VAI. In December 2023, the FDA inspected Emergent's Lansing facility located in Lansing, Michigan and issued a Form FDA 483. At this point, the Lansing facility inspection has not been classified and we are not aware of  specific timing regarding the classification decision. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to remedy any remaining objectionable conditions at Emergent's manufacturing facilities, or any additional failures to maintain compliance with CGMP requirements at any of our manufacturing facilities, could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disruption at, damage to or destruction of, our manufacturing facilities could impede our ability to manufacture anthrax vaccines, our ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> vaccine or our other products or product candidates, as well as impact the delivery of bioservices, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any interruptions in our manufacturing operations could result in our inability to produce products and product candidates for delivery to satisfy the demands of our customers in a timely manner, which would reduce our revenues and materially harm our business, financial condition, operating results and cash flows. A number of factors could cause interruptions, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">equipment malfunctions or failures;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">technology malfunctions;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">cyber-attacks;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">work stoppages or slowdowns;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">civil unrest and protests, including by animal rights activists;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">injunctions;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">damage to or destruction of our manufacturing equipment, or of one or more of our facilities; </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">findings and recommendations of health authorities or qualified persons in connection with facility inspections;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">ongoing supply chain interruptions; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">product contamination or tampering.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors listed above could cause disruptions at any of our manufacturing facilities. We do not have any redundant manufacturing facilities for any of our products. Accordingly, any damage to, or disruption or destruction of one or more of our facilities could impede our ability to manufacture our products, and our product candidates and our ability to provide manufacturing and development services for external customers, result in losses and delays, including delays in the performance of our contractual obligations or delays in our clinical trials, any of which could be costly to us and materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providers of MCMs could be subject to an increased risk of terrorist activities. The USG has designated our Lansing, Michigan facility as requiring additional security. Although we continually evaluate and update security measures, there can be no assurance that any additional security measures would protect these facilities from terrorist efforts determined to disrupt our manufacturing activities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Problems may arise during the production of our products and product candidates, as well as those we produce for our Bioservices customers, due to the complexity of the processes involved in their development, manufacturing and shipment or other factors. Significant delays in product manufacturing or development and our ability to ramp up production to meet the needs of our customers could cause delays in recognizing revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our products and product candidates are biologics. Manufacturing biologics, especially in large quantities, is complex. The products must be made consistently and in compliance with a clearly-defined manufacturing process. Problems during manufacturing may arise for a variety of reasons, including problems with raw materials, equipment malfunction and failure to follow specific protocols and procedures. Slight deviations anywhere in the manufacturing process, including obtaining materials, maintaining master seed or cell banks and preventing genetic drift, seed or cell growth, fermentation, contamination including from particulates among other things, filtration, filling, labeling, packaging, storage and shipping, potency and stability issues and other quality control testing, may result in lot failures or manufacturing shut-downs, delays in the release of lots, product recalls, spoilage or regulatory action. Such deviations may require us to revise manufacturing processes or change manufacturers. Additionally, as our equipment ages, it will need to be replaced, which has the potential to result in similar consequences. Success rates can also vary dramatically at different stages of the manufacturing process, which can reduce yields and increase costs. From time to time, we may experience deviations in the manufacturing process that may take significant time and resources to resolve and, if unresolved, may affect manufacturing output and could cause us to fail to satisfy customer orders or contractual commitments, lead to a termination of one or more of our contracts, lead to delays in our clinical trials, result in litigation, or other restrictions on the marketing or manufacturing of a product, any of which could be costly to us, damage our reputation and negatively impact our business. Regulatory action, including the issuance of Form FDA 483s and warning letters can also have an impact.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if changes are made to the manufacturing process, we may be required to provide the FDA with pre-clinical and clinical data showing the comparable identity, strength, quality, purity or potency of any impacted products before and after the changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are contractually required to ship our biologic products at a prescribed temperature range and variations from that temperature range could result in loss of product and could significantly and adversely impact our revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not be able to ramp up our manufacturing processes to meet the rapidly changing demand or specifications of our customers on the desired timeframe, if at all. Our inability to ramp up manufacturing to meet the demand or specifications of our customers or the inability to timely obtain regulatory authorization to produce the products or product candidates of our customers could also harm our business, financial condition, operating results and cash flows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products and product candidates procured by the USG and other customers require us to perform tests for and meet certain potency and lot release standards prescribed by the FDA and other agencies, which may not be met on a timely basis or at all.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to sell any products and product candidates that fail to satisfy certain testing specifications. For example, we must provide the FDA with the results of certain tests, including potency tests, before certain lots are released for sale. Potency testing of each applicable lot is performed against qualified control lots that we maintain. We continually monitor the status of such reference lots for FDA compliance and periodically produce and qualify a new reference lot to replace the existing reference lot. If we are unable to satisfy USG requirements for the release of our products or product candidates, our ability to supply such products and product candidates to authorized buyers would be impaired until such time as we become able to meet such requirements, which could materially harm our future business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses, require us to comply with regulatory requirements and expose us to significant potential liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve the use of hazardous materials, including chemicals, bacteria and viruses, and may produce dangerous waste products. Accordingly, we, along with the third parties that conduct clinical trials and manufacture our products and product candidates on our behalf, are subject to federal, state, local and foreign laws and regulations that govern the use, manufacture, distribution, storage, handling, exposure, disposal and recordkeeping with respect to these materials. Under the Federal Select Agent Program, pursuant to the Public Health Security and Bioterrorism Preparedness and Response Act, we are required to register with and be inspected by the Centers for Disease Control and Prevention (the "CDC") and the Animal and Plant Health Inspection Service if we have in our possession, or if we use or transfer, select biological agents or toxins that could pose a threat to public health and safety, to animal or plant health or to animal or plant products. This legislation requires stringent safeguards and security measures for these select agents and toxins, including controlled access and the screening of entities and personnel and establishes a comprehensive national database of registered entities. We are also subject to a variety of environmental and occupational health and safety laws. Compliance with current or future laws and regulations in this area can require significant costs and we could be subject to substantial fines and penalties in the event of noncompliance. In addition, the risk of contamination or injury from these materials cannot be completely eliminated. In such event, we could be held liable for substantial civil damages or costs associated with the cleanup of hazardous materials. From time to time, we have been involved in remediation activities and may be so involved in the future. Any related cost or liability might not be fully covered by insurance, could exceed our resources and could have a material adverse effect on our business, financial condition, operating results and cash flows. In addition to complying with environmental and occupational health and safety laws, we must comply with special regulations relating to biosafety administered by the CDC, HHS, U.S. Department of Agriculture and the DoD, as well as regulatory authorities in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCT DEVELOPMENT AND COMMERCIALIZATION RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The product candidates that we work on for our Bioservices customers may not be safe or effective and even if they are, we may be unable to manufacture sufficient quantities to meet demand.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide bioservices for the development and/or manufacture of various product candidates. There can be no assurance that these product candidates will be safe or effective or that they will be authorized for emergency use or approved by the FDA or any other health regulatory authority. Even if product candidates are found to be safe and/or effective and receive authorization or approval by a health regulatory authority or we receive authorization to produce drug substance or drug product at our facilities, the manufacturing processes for our Bioservices programs are complex. There can be no assurance that we will be able to produce sufficient clinical or commercial quantities of any product candidate in a timely basis or at all. Difficulties manufacturing COVID-19 product candidates for certain Bioservices customers and the November 2021 termination of the termination of the Center for Innovation in Advanced Development and Manufacturing agreement with BARDA for COVID-19 vaccine development and manufacturing caused us to suffer considerable reputational and financial damage and resulted in the instigation of stockholder litigation and government investigations described elsewhere in this Annual Report. Further, our announcement in the third quarter of 2023 that we are de-emphasizing focus on our Bioservices business may raise concerns regarding our ability to fulfill manufacturing commitments to our Bioservices customers. Any future failure to satisfy manufacturing commitments could adversely affect our reputation, subject us to potential legal liability and harm our business, financial condition, operating results and cash fl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ou</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">r growth depends on our success in developing and commercializing our product candidates. If we are unable to commercialize these product candidates or experience significant delays or unanticipated costs in doing so, our business would be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested significant efforts and financial resources in the development of our vaccines, therapeutics and medical device product candidates and the acquisition of additional product candidates. In addition to our product sales, our ability to generate revenue is dependent on a number of factors, including the success of our development programs, the USG's interest in providing development funding for or procuring certain of our product candidates, and the commercial viability of our acquired or developed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates. The commercial success of our product candidates can depend on many factors, including accomplishing the following in an economical manner:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">successful development, formulation and CGMP or Quality System Regulation ("QSR") scale-up of manufacturing that meets FDA and/or foreign regulatory requirements;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">successful program partnering;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">successful completion of clinical or non-clinical development;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">receipt of marketing approvals, clearances, or other authorizations from the FDA and equivalent foreign regulatory authorities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">establishment of commercial manufacturing processes and product supply arrangements;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">training of a commercial sales force for the product;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">successful registration and maintenance of relevant patent and/or other proprietary protection;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">competitive pricing and market access; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">acceptance of the product by potential government and other customers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, the success of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, including in over-the-counter form, is subject to commercial availability of the product and our ability to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain. We must invest substantial amounts of time and financial resources in these trials, which may not yield viable products. Failure to obtain regulatory approval for product candidates, particularly in the United States, could materially and adversely affect our financial resources, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval or other authorization of our product candidates, we and our collaborative partners, where applicable, must conduct pre-clinical studies and clinical trials to establish proof of concept and demonstrate the safety and efficacy of our product candidates. Pre-clinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success in pre-clinical testing and early clinical trials does not ensure that later clinical trials will be successful, and interim results of such trials do not necessarily predict final results. An unexpected result in one or more of our clinical trials can occur at any stage of testing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience unforeseen events or issues during, or as a result of, pre-clinical testing, clinical trials or animal efficacy studies. These issues and events, which could delay or prevent our ability to receive regulatory approval for a product candidate, include, among others:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">our inability to manufacture sufficient quantities for use in trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the unavailability or variability in the number and types of subjects for each study;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">safety issues or inconclusive or incomplete testing, trial or study results;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">drug immunogenicity;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">lack of efficacy of product candidates during trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">government or regulatory restrictions or delays; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">greater than anticipated costs of trials</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical and clinical testing for certain of our MCM product candidates may face additional difficulties and uncertainties because they cannot ethically or feasibly be tested in human subjects. In the U.S. we expect to rely on the Animal Rule to obtain regulatory approval for some of our MCM product candidates. The Animal Rule permits, for certain limited diseases and circumstances, the use of animal efficacy studies, together with human clinical safety and immunogenicity trials, to support an application for marketing approval. For a product approved under the Animal Rule, certain additional post-marketing requirements apply. For example, to the extent feasible and ethical, applicants must conduct post-marketing clinical studies, such as field studies in the event of an outbreak or act of bioterrorism, to assess the drug's safety and effectiveness. It is possible that results from the animal efficacy studies used to support approval under the Animal Rule may not be predictive of the actual efficacy of our product candidates in humans.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Public Health Service Act (the "PHSA") and the Federal Food, Drug, and Cosmetic Act (the "FDCA"), the Secretary of HHS can contract to purchase MCMs for the SNS prior to FDA approval, clearance, or other authorization of certain MCM product candidates. If the USG does not provide funding for and procure our MCM product candidates, they generally will have to be approved by the FDA through traditional regulatory mechanisms prior to sale and distribution in the United States. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our product development strategy and, as a result, may modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay or halt the development of various product candidates. We may change or refocus our existing product development, commercialization and manufacturing activities based on government funding decisions and other factors. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates or choose candidates for which government development funds are not available. Our decisions to allocate our R&amp;D, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources from better business opportunities. Similarly, our decisions to delay or terminate product development programs could also cause us to miss valuable opportunities.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGULATORY AND COMPLIANCE RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There are a number of complex laws and regulations that pertain to government contracts and compliance with those laws and regulations require significant time and cost, which could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a manufacturer and supplier of MCMs and other approved products to the USG addressing PHTs, we must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. These laws and regulations govern how we transact business with our government clients and, in some instances, impose additional costs and related obligations on our operations. For a detailed description of the most significant regulations that affect our government contracting business, see the prior discussion under &#8220;Regulation - Government Contracting.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to government investigations of compliance with government acquisition regulations. USG agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. Even though we take significant precautions to identify, prevent and deter fraud, misconduct and non-compliance, we face the risk that our personnel or outside partners may engage in misconduct, fraud or improper activities. If we are audited or investigated and such audit or investigation were to uncover improper or illegal activities, we could be subject to civil and criminal fines and penalties, administrative sanctions, including suspension or debarment from government contracting, and suffer significant reputational harm. The loss of our status as an eligible government contractor or significant fines or penalties associated with contract non-compliance or resulting from investigations could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our long-term success depends, in part, upon our ability to develop, receive regulatory approval for and commercialize product candidates we develop or acquire and, if we are not successful, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with them are subject to extensive FDA regulation and oversight. This includes, but is not limited to, laws and regulations governing product development, product labeling, product testing, manufacturing, storage, product distribution, record keeping, and advertising and promotion. In limited circumstances, governments may have the authority to procure products that have not obtained regulatory approval to stockpile for emergency preparedness and to respond to public health emergencies. In other circumstances, failure to obtain regulatory approval for a product candidate will prevent us from selling and commercializing the product candidate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, to obtain authorization from the FDA to market and sell any of our future drug, biologic, or vaccine products, we will be required to submit a New Drug Application (an &#8220;NDA&#8221;) or Biologics License Application (a &#8220;BLA&#8221;) to the FDA. Under the FDCA, the PHSA, and the FDA&#8217;s implementation of those statutes, a company must support an NDA or BLA with substantial evidence that the product candidate is effective and evidence that the product is safe. Ordinarily, the FDA requires data from adequate and well-controlled clinical trials, including Phase 3 trials conducted in patients with the disease or condition being targeted, to demonstrate that a drug meets the statutory standards for approval. Once an NDA or BLA is submitted, the FDA has substantial discretion and may refuse to accept our application or may decide that our data are insufficient to support approval and require additional pre-clinical, clinical or other studies. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed, or to conditions of approval, or contain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Likewise, the data in our device submissions may be insufficient to support approval, de novo classification or clearance where required, and we may not be able to demonstrate to the satisfaction of the FDA that our devices are safe or effective for their intended uses or, for a 510(k) device, that they are substantially equivalent to the predicate. Even if we are granted 510(k) clearances, de novo authorizations, or premarket approval application ("PMA") approvals, they may include significant limitations on the indications for use for the device.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can market a new medical device, or an existing medical device for a new use, or make significant modifications to an existing product, we must first receive either clearance under Section 510(k) of the FDCA, de novo authorization, or approval of a PMA from the FDA, unless an exemption applies. These marketing submissions must also be supported by appropriate data, including in many cases clinical data. Likewise, changes to our combination products, including changes to the device constituent part, may also require a new submission to, and approval from, the FDA.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, our MCM product candidates may be eligible for approval under the FDA's &#8220;Animal Rule,&#8221; under which findings from adequate and well controlled animal efficacy studies may serve as the basis of an approval when it is not feasible or ethical to conduct efficacy trials in humans. We cannot guarantee that the FDA will permit us to proceed with approval or licensure of any of our MCM product candidates under the Animal Rule. Even if we are able to proceed under the Animal Rule, product development can take a considerable amount of time, and the FDA may decide that our data are insufficient to support approval and require additional pre-clinical, clinical or other studies, refuse to approve our products, or place restrictions on our ability to commercialize those products. Furthermore, products approved under the Animal Rule are subject to certain additional post-marketing requirements. We cannot guarantee that we will be able to meet this regulatory requirement even if one or more of our product candidates are approved under the Animal Rule.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining these regulatory approvals is expensive, often takes many years if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidate involved. Changes in the regulatory approval process may cause delays in the approval or other marketing authorization, or rejection of an application. There is a high rate of failure inherent in the medical product development process, and product candidates that appear promising at early stages of development may fail for a number of reasons, and positive results from pre-clinical studies may not be predictive of similar results in human clinical trials. Similarly, promising results from earlier clinical trials of a product candidate may not be replicated in later clinical trials.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure to successfully develop future product candidates may materially adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unapproved and investigational stage products are also subject to the FDA's laws and regulations governing advertising and promotion, which prohibit the promotion of both unapproved products and unapproved uses of approved products. There is some risk that the FDA could conclude that our communications relating to unapproved products or unapproved uses of approved products constitute the promotion of an unapproved product or product use in violation of FDA laws and regulations.&#160;There is also a risk that a regulatory authority in another country could take a similar position under that country's laws and regulations and conclude that we have violated the laws and regulations related to product development, approval, or promotion in that country.&#160;If the FDA or any foreign regulatory authority determines that any of our communications constitute pre-approval promotion or promotion of an off-label use, the FDA could request that we modify our promotional materials, issue an untitled letter or warning letter, or subject us to regulatory or enforcement actions, including injunction, seizure, civil fine or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Even if we or our collaborators obtain marketing approvals for our product candidates, the conditions of approvals and ongoing regulation of our products may limit how we manufacture, market and sell our products, which could materially impair our ability to generate revenue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once marketing authorization has been granted, we and our business partners will remain subject to ongoing regulatory oversight of our medical products, including with respect to labeling; safety surveillance and reporting; registration and listing requirements; CGMP and QSR requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents; advertising and promotional activities; requirements regarding the distribution of samples to physicians and related recordkeeping; and medical device design, development and manufacturing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other agencies, including the U.S. Department of Justice (&#8220;DOJ&#8221;) and the HHS Office of Inspector General (&#8220;OIG&#8221;), closely regulate and monitor the marketing and promotion of medical products to ensure that they are marketed in a manner consistent with the FDA-approved label. For drug products, we must promote the product in a manner consistent with the full prescribing information or, for 510(k) cleared devices, consistent with the cleared indication. The FDA, DOJ, and OIG impose stringent restrictions on manufacturers&#8217; communications regarding unapproved/uncleared products and unapproved/uncleared uses of approved/cleared products. If we market unapproved/uncleared products or market our approved/cleared products for unapproved/uncleared indications, we may be subject to enforcement action. Violations of the FDCA and other statutes, including the False Claims </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are subject to post-marketing requirements (&#8220;PMRs&#8221;), which we are required to conduct, and post marketing commitments, which we have agreed to conduct. The FDA has the authority to take action against sponsors who fail to meet the obligations of a PMR, including civil monetary penalties and/or misbranding charges.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, discovery of previously unknown adverse events or other problems with our products, manufacturing partners or manufacturing processes, or failure to comply with regulatory requirements, may result in various penalties and sanctions. For all FDA-regulated products, if the FDA finds that a manufacturer has failed to comply with applicable laws and regulations, or that a product is ineffective or poses an unreasonable health risk, it can institute or seek a wide variety of enforcement actions and other remedies, including but not limited to:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">restrictions on distribution or use of a product;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">warning letters or untitled letters;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">refusal to approve pending applications or supplements to approved applications that are submitted;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">delay in or refusal to approve, clear or authorize pending PMA applications, 510(k) premarket submissions, or de novo authorization requests;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">fines, restitution or disgorgement of profits or revenues; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">refusal to permit the import or export of our products;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">product seizure; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and our collaborators are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market and sell any products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we or our collaborators obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU and other legal and regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions. Non-compliance with similar requirements in other foreign jurisdictions can also result in enforcement actions and significant penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and may affect the prices we, or our collaborators, may obtain.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there has been recent heightened federal governmental scrutiny over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and has been proposed and enacted </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), was signed into law on August 16, 2022. While the IRA is still subject to rulemaking (with more information to come via guidance documents from the responsible federal agencies), the IRA, as written, will, among other changes, give HHS the ability and authority to directly negotiate with manufacturers the price that Medicare will pay for certain high-priced drugs. The IRA will also require manufacturers of certain Part B and Part D drugs to issue to HHS rebates based on certain calculations and triggers (i.e., when drug prices increase and outpace the rate of inflation). At this time, we cannot predict the implications the IRA provisions will have on our business. These types of laws may have a significant impact on our ability to set a product price we believe is fair and may adversely affect our ability to generate revenue and achieve or maintain profitability.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program (&#8220;SIP&#8221;), to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation. At least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada, and at least three states (Colorado, Florida, and New Mexico) have submitted SIPs to the FDA for review and approval.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, and wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. A growing number of state attorneys general are filing legal challenges, including antitrust challenges, related to drug pricing and reimbursement against various supply chain entities, such as pharmacy benefit managers, and such litigation may also involve drug manufacturers in the future. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with foreign, federal, state and local health care laws, including fraud and abuse laws, health information privacy and security laws, and antitrust laws, we could face substantial&#160;penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, certain of our products are reimbursed under federal and state health care programs such as Medicaid, Medicare, Tricare, and/or state pharmaceutical assistance programs. Many foreign countries have similar laws. Federal and state laws designed to prevent fraud and abuse under these programs prohibit pharmaceutical companies from offering valuable items or services to customers or potential customers to induce them to buy, prescribe, or recommend our product (the so-called &#8220;anti-kickback&#8221; laws). Exceptions are provided for discounts and certain other arrangements if specified requirements are met. Other federal and state laws, and similar foreign laws, not only prohibit us from submitting any false information to government reimbursement programs but also prohibit us, our employees, or any third party acting on our behalf from doing anything to cause, assist, or encourage our customers to submit false claims for payment to these programs. We are also subject to various federal, state and foreign antitrust and competition laws that prohibit certain activities that may have an impact against potential competitors. Violations of the various fraud and abuse and antitrust laws may result in severe penalties against the responsible employees and us, including jail sentences, large fines, and the exclusion of our products from reimbursement under federal and state programs. Some of the laws that may affect our ability to operate include:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay remuneration, directly or indirectly, overtly or covertly, to induce, or in return for, either the referral of an individual, or the purchase, lease, prescribing or recommendation of an item, good, facility or service reimbursable by a federally funded health care program, such as the Medicare or Medicaid program. The term &#8220;remuneration&#8221; has been interpreted broadly and may constrain our marketing practices, educational programs, pricing policies and relationships with health care providers or other entities, among other activities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims for payment by a federal health care program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability, including mandatory treble damages and significant per-claim penalties.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statement, in connection with the delivery of, or payment for, health care benefits, items or services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">HIPAA, as amended by HITECH, and their respective implementing regulations mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common health care transactions, as well as standards relating to the privacy, security and transmission of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA's security standards directly applicable to &#8220;business associates,&#8221; or independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the Physician Payments Sunshine Act and its implementing regulations require certain manufacturers of drugs, biologics, medical devices and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program  to report certain payments and transfers of value made to U.S. physicians, prescribers and teaching hospitals, as well as ownership or investment interests held by physicians, and their immediate family members; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; state, local and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, obtain pharmaceutical agent licensure, and/or otherwise restrict payments that may be made to health care providers and entities; and state, local and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to health care providers or entities, or marketing expenditures.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under the federal Anti-Kickback Statute, it is possible that some of our business activities could be subject to challenges under one or more of such laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or otherwise, we may be subject to penalties, including civil and criminal penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from federal health care programs and the curtailment or restructuring of our operations. Any such penalties could adversely affect our financial results. We continue to improve our corporate compliance program designed to ensure that our development, marketing, and sales of existing and future products and product candidates are in compliance with all applicable laws and regulations, but we cannot guarantee that this program will protect us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties comply with health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from government funded health care programs, such as Medicare and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid, and the curtailment or restructuring of our operations. If a third party fails to comply with applicable laws and regulations while acting on our behalf, we may also be subject to criminal, civil, and administrative penalties, including those listed above.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States government, state governments and private payors regularly investigate the pricing and competitive practices of pharmaceutical companies and biotechnology companies, and many file actions alleging that inaccurate reporting of prices has improperly inflated reimbursement rates. We may also be subject to investigations related to our pricing practices. Regardless of merit or eventual outcome, these types of investigations and related litigation can result in:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">diversion of management time and attention;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">significant legal fees and payment of damages or penalties;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">limitations on our ability to continue certain operations;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">decreased product demand; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">injury to our reputation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, an adverse outcome, or the imposition of penalties or sanctions for failing to comply with applicable fraud and abuse and antitrust laws, could adversely affect us and may have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with our obligations under U.S. governmental pricing programs, we could&#160;be required to reimburse government programs for underpayments and could pay penalties, sanctions and fines.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of regulations and coverage expansion by various governmental agencies relating to the Medicaid rebate program will continue to increase our costs and the complexity of compliance and will be time-consuming. Because we participate in the Medicaid rebate program, we are required to report average sales price ("ASP"), information to CMS for certain categories of drugs that are paid for under Part B of the Medicare program. Future statutory or regulatory changes or CMS binding guidance could affect the ASP calculations for our products and the resulting Medicare payment rate and could negatively impact our results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs, involve complex calculations and are often subject to interpretation by us, governmental or regulatory agencies and the courts. The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current AMP and &#8220;best price&#8221; for the quarter. If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision. Such restatements and recalculations would increase our costs for complying with the laws and regulations governing the Medicaid rebate program. Price recalculations also may affect the &#8220;ceiling price&#8221; at which we are required to offer our products to certain covered entities, such as safety-net providers, under the 340B/Public Health Service ("PHS") drug pricing program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we are found to have made a misrepresentation in the reporting of ASP, we are subject to civil monetary penalties for each such price misrepresentation and for each day in which such price misrepresentation was applied. If we are found to have knowingly submitted false AMP or &#8220;best price&#8221; information to the government, we may be liable for civil monetary penalties per item of false information. Any refusal of a request for information or knowing provision of false information in connection with an AMP survey verification would also subject us to civil monetary penalties. In addition, our failure to submit monthly/quarterly AMP or &#8220;best price&#8221; information on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure could also be grounds for CMS to terminate our Medicaid drug rebate agreement, under which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot ensure that our submissions will not be found by CMS to be incomplete or incorrect.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for our products to be reimbursed by the primary federal governmental programs, we must report certain pricing data to the USG. Compliance with reporting and other requirements of these federal programs is a pre-condition to: (i)&#160;the availability of federal funds to pay for our products under Medicaid and Medicare Part B; and (ii)&#160;procurement of our products by the Department of Veterans Affairs ("DVA"), and by covered entities under the 340B/PHS program. The pricing data reported are used as the basis for establishing Federal Supply Schedule ("FSS"), and 340B/PHS program contract pricing and payment and rebate rates under the Medicare Part B and Medicaid programs, respectively. Pharmaceutical companies have been prosecuted under federal and state false claims laws for submitting inaccurate and/or incomplete pricing information to the government that resulted in increased payments made by these programs. Although we maintain and follow strict procedures to ensure the maximum possible integrity for our federal pricing calculations, the process for making the required calculations is complex, involves some subjective judgments and the risk of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">errors always exists, which creates the potential for exposure under the false claims laws. If we become subject to investigations or other inquiries concerning our compliance with price reporting laws and regulations, and our methodologies for calculating federal prices are found to include flaws or to have been incorrectly applied, we could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible to have our products paid for or reimbursed with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we also must participate in the DVA FSS pricing program. To participate, we are required to enter into an&#160;FSS contract with the DVA, under which we must make our innovator &#8220;covered drugs&#8221; available to all federal purchasers. In addition, for the &#8220;Big Four&#8221; federal agencies&#8212;the DVA, the DoD, the PHS (including the Indian Health Service), and the Coast Guard&#8212;we must make covered drugs available at pricing that is capped at the statutory federal ceiling price ("FCP").  The FCP is calculated using the formula set forth in Section&#160;603 of the Veterans Health Care Act of 1992 (the "VHCA") and based on a weighted average wholesale price known as the Non-Federal Average Manufacturer Price ("Non-FAMP"), which manufacturers are required to report on a quarterly and annual basis to the DVA. Under the VHCA, knowingly providing false information in connection with a Non-FAMP filing can subject us to significant penalties for each item of false information. If we overcharge the government in connection with our FSS contract or Tricare program agreements, whether due to a misstated FCP or otherwise, we are required to disclose the error and refund the difference to the government. The failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government&#160;investigation or enforcement action, can be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">From time to time, we sell unapproved MCMs to government entities under certain circumstances. While this is permissible in some cases, the extent to which we may be able to lawfully offer to sell and sell unapproved products in many jurisdictions may be unclear or ambiguous. Such sales could subject us to regulatory enforcement action, product liability and reputational risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain and narrow circumstances, MCMs may be procured by government entities prior to approval by the FDA or other regulatory authorities, a practice which we follow in connection with certain MCMs, including TROBIGARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (and CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, prior to its approval by the FDA) in the United States. In the United States, the Secretary of HHS has the authority to contract to purchase MCMs for the SNS prior to FDA approval of the relevant MCM in specified circumstances. The FDA also has the authority to permit the emergency use of medical products that have not yet been approved by the FDA under an EUA. An EUA terminates when the EUA is revoked or the emergency declaration underlying the EUA terminates. An EUA is not a long-term alternative to obtaining FDA approval, licensure, clearance, or other marketing authorization for a product. An EUA has not been granted for TROBIGARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Absent an applicable exception, our MCM product candidates generally will have to be approved, licensed, or cleared by the FDA or other regulatory authorities in the relevant country through traditional pathways before we can sell those products to governments. Additionally, the laws in certain jurisdictions regarding the ability of government entities to purchase unapproved product candidates can be ambiguous, and the permissibility of exporting unapproved products from the United States and importing them to foreign countries may be unclear in some instances. Nevertheless, government bodies, such as U.S. federal entities other than HHS, state and local governments within the United States, and foreign governments have sought and may further seek to procure our MCM product candidates that are not yet approved. In this situation, we would expect to assess the permissibility and liability implications of supplying our product candidates to such entities on a case-by-case basis, which presents certain challenges, both in the case of U.S. and foreign governments, and particularly under emergency conditions. In addition, agencies or branches of one country&#8217;s government may take different positions regarding the permissibility of such sales than another country&#8217;s government or even other agencies or branches of the same government. If local enforcement authorities disagree with our conclusion that such activities are permissible, they may take enforcement action against us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale of unapproved products also could give rise to product liability claims for which we may not be able to obtain adequate indemnification or insurance coverage. For example, despite liability protections applicable to claims arising under U.S. law and resulting from the use of certain unlicensed or unauthorized MCMs, such as a declaration issued under the PREP Act, plaintiffs still may bring lawsuits alleging, among other things, that their claims are not barred under the PREP Act.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a user of one or more of our products experiences an adverse event, we may be subject to additional reputational risk if the product has not been approved by the FDA or the corresponding regulatory authority of another country, particularly because we will not have approved labeling regarding the safety or efficacy of those products. In addition, legislatures and other governmental bodies that have oversight responsibility for procuring agencies may raise concerns after the fact, even if procurement was permissible at the time, which could result in negative publicity, reputational risk and harm to our business prospects.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that our communications with governments about our unapproved/uncleared products, such as in the procurement context, could be considered promotion of an unapproved/uncleared product or unapproved/uncleared use of an approved </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product. Therefore, there is a risk that we could be subject to enforcement actions if found to be in violation of such laws or regulations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Even after regulatory approval is received, if we fail to comply with regulatory requirements, or if we experience unanticipated problems with our approved products, they could be subject to restrictions, penalties or withdrawal from the market.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any vaccine, therapeutic product or medical device for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to the continual requirements of and review by the FDA and other regulatory bodies. Our approved products are subject to these requirements and ongoing review. For drugs and vaccines, these requirements include submissions of safety and other post-marketing information and reports, plasma donor testing, registration requirements, CGMP, requirements relating to potency and stability, quality control, quality assurance, restrictions on advertising and promotion, import and export restrictions and recordkeeping requirements. Requirements for medical devices are similar and include QSR compliance, establishment registration and device listing; record keeping; restrictions on advertising and promotion; post-market surveillance, and restrictions on import and export. In addition, various state laws require that companies that manufacture and/or distribute drug products within the state obtain and maintain a manufacturer or distributor license, as appropriate. Some states have similar requirements for devices. Because of the breadth of these laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government regulators enforce CGMP, QSR, and other requirements through periodic unannounced inspections of manufacturing facilities. The FDA is authorized to inspect domestic and foreign manufacturing facilities without prior notice at reasonable times and in a reasonable manner. Health Canada may conduct similar inspections of our domestic and foreign facilities where products offered and sold in Canada are produced, or related formulation and filling operations are conducted. The FDA, Health Canada, and other foreign regulatory agencies conduct periodic inspections of our facilities. Following several of these inspections, regulatory authorities have issued inspectional observations, some of which were significant, but all of which are being, or have been, addressed through corrective actions. If, in connection with any future inspection, regulatory authorities find that we are not in substantial compliance with all applicable requirements, or if they are not satisfied with the corrective actions we take, our regulators may undertake enforcement action against us, which may include:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">warning letters, untitled letters, and other communications;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">product seizure or withdrawal of the product from the market;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">restrictions on the marketing or manufacturing of a product;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">suspension or withdrawal of regulatory approvals or refusal to approve pending applications or other marketing submissions, or supplements to approved applications;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">fines or disgorgement of profits or revenue; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar action may be taken against us should we fail to comply with regulatory requirements, or later discover previously unknown problems with our products or manufacturing processes. For instance, our products are tested regularly to determine if they satisfy potency and stability requirements for their required shelf lives. Failure to meet potency, stability or other specification requirements could result in delays in distributions, recalls or other consequences. In November 2022, three lots of our RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kits was recalled due to leakage (the "November 2022 Recall"), which could cause the product not to perform as effectively as intended. We identified and remediated the cause leading to the November 2022 Recall, as well as completed all required actions, notices and report submissions related to the recalled batch. We are currently awaiting formal closure of the November 2022 Recall from the FDA, Center for Devices and Radiological Health. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approval, clearance, or other marketing authorization of a product is granted, the approval, clearance, or marketing authorization may be subject to limitations on the indicated uses for which the product may be marketed or sold or to the conditions of approval. Regulatory approval or other authorization may also contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. If we experience any of these post-approval events, our business, financial condition, operating results and cash flows could be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, companies may not promote unapproved products or unapproved uses of approved products (i.e., &#8220;off-label&#8221; uses or uses that are not described in the product&#8217;s approved labeling and/or that differ from the uses approved or cleared by the applicable regulatory agencies). A company that is found to have improperly promoted an unapproved/uncleared product or an unapproved/uncleared use of an approved/cleared product may be subject to significant liability, including civil and administrative remedies (such as entering into corporate integrity agreements with the USG), as well as criminal sanctions. If our employees or agents engage in marketing of an unapproved/uncleared product or the unapproved/uncleared use of an approved/cleared product, we could be subject </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to civil or criminal investigations and monetary and injunctive penalties, which could adversely impact our ability to conduct business in certain markets, negatively affect our business, financial condition, operating results and cash flows, and damage our reputation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure to obtain or maintain regulatory approval in international jurisdictions could prevent us from marketing our products abroad and could limit the growth of our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently sell certain of our products outside the United States and intend to expand the countries in which we sell our products and have received market authorization under the mutual recognition procedure to sell BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in France, Italy, the Netherlands, Poland, and the United Kingdom. To market or sell our products in foreign jurisdictions under normal circumstances, we generally need to obtain separate regulatory approvals and comply with numerous and varying requirements or use alternative &#8220;emergency use&#8221; or other exemptions from general approval and import requirements. Approval by the FDA in the United States or the mutual recognition procedure in the European member states does not ensure approval by all foreign regulatory authorities. The approval procedures in foreign jurisdictions can vary widely and can involve additional clinical trials and data review beyond that required by the FDA or under the mutual recognition procedure. There is also a risk that a regulatory authority in another country could conclude that we have violated the rules and regulations related to product development, approval or promotion in that country. Therefore, there is a risk that we could be subject to a foreign enforcement action if found to be in violation of such laws and regulations. We and our collaborators may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and we may be unable to successfully commercialize our products in desired jurisdictions internationally if no alternate procurement pathway is identified for authorized government customers in a particular jurisdiction. We have limited experience in preparing, filing and prosecuting the applications necessary to gain foreign regulatory approvals and expect to rely on third-party contract research organizations and consultants to assist us in this process. Our reliance on third parties can introduce additional uncertainty into the process.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency (the "MHRA"), became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland continues to be subject to European Union rules under the Northern Ireland Protocol. The MHRA relies on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended) (the "HMR"), as the basis for regulating medicines. The HMR has incorporated into the domestic law of the body of European Union law instruments governing medicinal products that pre-existed prior to the United Kingdom's withdrawal from the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain products outside of the United States, require us to develop and implement costly compliance programs, and if violated, can lead to financial and other impacts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our commercialization activities outside of the United States, we are subject to an increased risk of violating, and must dedicate additional resources towards avoiding inadvertently conducting activities in a manner that violates, the U.S. Foreign Corrupt Practices Act (the "FCPA"), the U.K. Bribery Act, Canada's Corruption of Foreign Public Officials Act, and other similar foreign anti-bribery laws that prohibit corporations and individuals from corruptly paying, offering to pay, or authorizing the payment of anything of value, directly or indirectly, to any foreign government official, government staff member, political party or party official, or political candidate in an attempt to influence a person working in an official capacity or otherwise obtain an improper advantage. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the Company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Some anti-bribery laws also apply to private sector bribery. Compliance with the FCPA and other anti-bribery laws is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals and other parts of the health system are operated by the government, and doctors, hospital employees, and other health care providers are considered foreign officials. Certain payments to hospital employees and other health care professionals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including the United States, also have various lobbying laws and regulations governing the conduct of individuals and companies who interact with government officials. These laws and regulations typically include certain restrictions and disclosure obligations. If we, our employees, or third parties acting on our behalf do not comply with these laws and regulations, we may be subject to civil and criminal penalties. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including the United States, restrict the export or import of products to or from certain countries through, for example, bans, sanction programs, and boycotts. Such restrictions may preclude us from supplying products in certain countries, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could limit our growth potential. Furthermore, if we, or third parties acting on our behalf, do not comply with these restrictions, we may be subject to civil and criminal penalties. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we continue to expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties, suspension or debarment from government contracting, and other sanctions, and can cause reputational harm. The SEC also may bring enforcement actions against issuers for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITIVE AND POLITICAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development and commercialization of pharmaceutical products, including for PHT preparedness, are routinely subject to evolving private and public sector competition. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new biopharmaceutical and medical technology products is highly competitive and subject to rapid technological advances. We will continue to face future competition from other companies and governments, universities and other non-profit research organizations in respect to our products, any products that we acquire, our current product candidates and any products we may seek to develop or commercialize in the future. The market for products can be subject to development of safer, more effective, more convenient or less costly products. The market for current products can also depend on what resources can be devoted to marketing or selling products, or how companies are positioned to adapt more quickly to new technologies, respond to scientific advances or patient preferences and needs, initiate or withstand substantial price competition and/or procure third-party licensing and collaborative arrangements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of companies with products or product candidates addressing PHT preparedness that are competing with us for both USG procurement and development resources. Factors to consider include competitors' financial, technical, marketing and selling resources as well as potential leverage that their intellectual property estates may offer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in demand for our products or reduction or loss of development funding for our products or product candidates in favor of a competing product could lead to a loss of market share for our products and cause reduced revenues, margins and levels of profitability for us, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our biologic products may face risks of competition from biosimilar manufacturers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biological products and product candidates, which we refer to as &#8220;Biologic Products,&#8221; can be affected by the approval and entry of &#8220;biosimilars&#8221; in the United States and other jurisdictions. Biosimilar products are licensed through an abbreviated pathway based on a showing that they are &#8220;highly similar&#8221; to a previously licensed product (known as the reference product) notwithstanding minor differences in clinically inactive components, and there are no clinically meaningful differences from the reference product in terms of safety, purity, and potency. Biologic Products in our current pipeline include CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If a biosimilar version of one of our Biologic Products were approved, it could have a material adverse effect on the sales and gross profits of the affected Biologic Product and could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray is currently subject to generic and branded competition and may be subject to additional generic and branded competition in the future. If demand for over-the-counter NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nasal Spray outpaces current estimations, there could be supply challenges to meet demand.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray was approved as an over-the-counter (&#8220;OTC&#8221;) medication on March 29, 2023. The new OTC product was shipped out to retailers and e-commerce providers nationwide in August of 2023. Emergent is prepared to supply all segments/customers of the business with OTC product. If demand for NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray increases beyond our current estimates, there could be supply interruptions. Should this occur, Emergent has contingency plans to continue to provide product to those at the highest need and increase production to meet the new demand.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray currently faces generic competition. In 2016, Teva Pharmaceuticals Industries Limited and Teva Pharmaceuticals USA (collectively, &#8220;Teva&#8221;) filed an Abbreviated New Drug Application (an &#8220;ANDA&#8221;) seeking regulatory approval to market a generic version of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray. In patent litigation related to Teva&#8217;s ANDA filing, a trial court decided in favor of Teva, and this decision was subsequently affirmed by the Court of Appeals for the Federal Circuit. The FDA approved Teva's ANDA on April 19, 2019. On December 22, 2021, Teva commenced the launch of its generic naloxone nasal spray. As part of state settlements, including in Florida, Texas, Rhode Island, and West Virginia, Teva has agreed to supply Medication- Assisted Treatment </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;MAT&#8221;) and generic opioid overdose reversal agents, like naloxone, to states at no cost in lieu of additional monetary compensation. The terms of these product donation agreements stretch 10 to 15 years. NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray also faces generic competition from Padagis LLC (&#8220;Padagis&#8221;). Prior to Padagis' separation from Perrigo UK FINCO Limited Partnership (&#8220;Perrigo&#8221;) in 2021, Perrigo filed its own ANDA for generic naloxone nasal spray in 2018. Emergent settled with Perrigo on February 12, 2020 providing for a license effective upon the Teva litigation decision. In June 2022, the FDA approved the ANDA and Padagis launched its prescription generic naloxone nasal spray.  On July 18, 2023 the FDA approved an Rx-to-OTC switch of Padagis' product. In March 2023, Amneal Pharmaceuticals, Inc. (&#8220;Amneal&#8221;) announced that the FDA had accepted for review Amneal&#8217;s ANDA for generic naloxone nasal spray. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of generic versions of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray at prices lower than our branded product or provided at no cost by Teva, Padagis and Amneal (pending approval) have the potential to erode our sales and could impact our product revenue related to NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray also faces branded competition from RiViveTM (naloxene HCl nasal spray 3mg), a branded product developed by Harm Reduction Therapeutics; Kloxxado&#8482; (naloxone HCl nasal spray 8mg), a branded product developed by Hikma Pharmaceuticals, Inc.; Amphastar Pharmaceuticals, Inc.'s naloxone injection product; Teleflex Medical Inc.'s Intranasal Mucosal Atomization Device and Zimhi&#8482; (naloxone), a branded injectable product developed by Adamis Pharmaceuticals Corporation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray may also face additional generic and branded competition in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Political or social factors may delay or impair our ability to market and sell our products and may require us to spend significant management time and financial resources to address these issues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products developed to counter the potential impact of PHTs are subject to changing political and social environments. The political responses and social awareness of the risks of these threats on military personnel or civilians and the level of emphasis placed on such risks by the USG may vary over time. If the threat of terrorism were to decline, then the public perception of the risk on public health and safety may be reduced. This perception, as well as political or social pressures (including as a result of negative publicity we have received based on our longstanding ties to the USG), could delay or cause resistance to bringing our products in development to market or limit pricing or purchases of our products, any of which could negatively affect our revenues and our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, substantial delays or cancellations of purchases could result from protests or challenges from third parties. Lawsuits brought against us by third parties or activists, even if not successful, could require us to spend significant management time and financial resources defending the related litigation and could potentially damage the public's perception of us and our products. Any publicity campaigns or other negative publicity may adversely affect the degree of market acceptance of our MCMs and thereby limit the demand for our products, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to obtain orphan drug exclusivity for product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or foreign regulatory authorities from approving other competing products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication for that time period. The applicable period is seven years in the United States. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for the FDA to grant orphan drug designation to one of our products, the agency must find, among other requirements, that the product is being or will be investigated for a condition or disease with a patient population of fewer than 200,000 individuals in the United States, or, for a vaccine, diagnostic drug, or preventive drug, it will be administered to fewer than 200,000 persons per year in the United States. Alternatively, the FDA may determine that there is no reasonable expectation that the costs of research and development of the drug can be recovered from sales of the drug in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug designation does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same indication. In addition, even after a product receives orphan drug exclusivity, the FDA can subsequently approve the same product for the same indication if the FDA or such authorities conclude that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care; if the FDA determines that the holder of orphan drug exclusivity cannot ensure the availability of sufficient quantities of the product to meet the needs of patients with the rare disease or condition; or if the holder of orphan drug exclusivity consents to the approval of such subsequent product. Additionally, the FDA may revoke orphan drug designation if the FDA determines that the request for designation contained an untrue statement of material fact, omitted </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material information, or the FDA subsequently finds that the drug in fact had not been eligible for orphan drug designation at the time of submission of the request for designation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face similar risks in the EU and other foreign jurisdictions that have comparable regulations concerning orphan drug exclusivity.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Protection of our intellectual property rights is an important tool for sustaining our business and the failure to do so could impact our financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect intellectual property rights related to our Company's assets, including patent rights, trademark rights, trade secrets, know-how and proprietary confidential information, through defense and enforcement of existing rights and pursuit of protection on new and arising innovations. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining, maintaining and enforcing our intellectual property rights in the United States and other countries remains a critical component of the development and commercialization of our Company's assets. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the risks associated with procurement, maintenance and enforcement of intellectual property rights include changes in patent laws or administrative patent office rules, evolving criteria and eligibility of obtaining patent protection on particular subject matter, the validity and enforceability of our intellectual property rights, the potential scope of coverage of our intellectual property rights, and/or the availability or strength of legal remedies in a particular country to defend and enforce intellectual property rights.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks include associated costs, such as costs of patent prosecution and maintenance and costs associated with post-grant challenges. For example, such costs include </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review proceedings in the United States and oppositions in Europe, as well as costs associated with litigating and enforcing patent and trademark rights. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional risks include limitations on our extent or ability to procure, maintain or defend intellectual property rights associated with in-licensed or acquired intellectual property, where, for example, other parties (e.g., licensors) may have the first right to maintain or defend intellectual property rights in which we have an interest, or may pursue strategies that are divergent to the interest of our Company.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third-party claims of alleged patent infringement could delay, stop or affect the development and commercialization of our products and product candidates. Such challenges, while ongoing, could be costly, requiring and utilizing company resources. Such challenges, if successful, may impact marketing or launch of products, or require ongoing license and/or royalty fees associated with potential settlement agreements. These challenges may have the potential to materially harm our business, financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of license agreements and expect to enter into additional license agreements in the future. Such license agreements or collaboration arrangements can be subject to challenges if interests or expectations under such license agreements diverge. Such challenges may be costly, risk time and resources, and could delay or impact development, commercialization or launch of our products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential loss of proprietary information and know-how generally carries the risk of reducing the value of our technology and products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented proprietary technology, processes, and know-how, particularly as to our proprietary manufacturing processes. These types of proprietary confidential information, know-how, and trade secrets can be difficult to protect, and potential loss or misappropriation of this information generally carries the risk of reducing the value of our technology and products. We seek to protect this confidential information, in part, through agreements with our employees, consultants, and third parties, as well as through internal policies and audits, although these may not always be successful in protecting our proprietary confidential information, know-how, and trade secrets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are approved as drug products under the provisions of the FDCA, which may render it susceptible to potential competition from generic manufacturers via the Hatch-Waxman Act and ANDA process. Other of our products may be susceptible to challenges by entry of biosimilars through the route established under the Biologics Price Competition and Innovation Action of 2009. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to vigorously enforce our intellectual property rights, there can be no assurance that we will prevail in our enforcement or defense of our patent rights. Our existing patents could be invalidated, found unenforceable, or found not to cover a generic form of our product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO RELIANCE ON OTHER PARTIES </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The loss of any of our non-exclusive, sole-source or single source suppliers, a shortage of related supplies or an increase in the price of inventory supplied to us could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase certain supplies used in our manufacturing processes from non-exclusive, or single sources due to quality considerations, costs or constraints resulting from regulatory requirements. We depend on certain single-source suppliers for key materials and services necessary to manufacture the majority of our products and certain product candidates. For example, we rely on a single-source supplier to provide us with Alhydrogel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in sufficient quantities to meet our needs to manufacture CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccines and the specialty plasma in our hyperimmune specialty plasma products and certain ingredients for the ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine. We also rely on single-source suppliers for the materials necessary to produce NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(naloxone HCl) Nasal Spray, such as the naloxone active pharmaceutical ingredient and other excipients, along with the vial, stopper and device. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where a particular single-source supply relationship is terminated, we may not be able to establish additional or replacement suppliers for certain components or materials quickly. This is largely due to the FDA approval system, which mandates validation of materials prior to use in our products and product candidates, and the complex nature of manufacturing processes. In addition, we may lose a sole-source supplier due to, among other things, the acquisition of a supplier by a competitor (which may cause the supplier to stop selling its products to us) or the bankruptcy of such a supplier, which may cause the supplier to cease operations. Any reduction or interruption by a sole-source supplier of the supply of materials or key components used in the manufacturing of our products or product candidates, a reduction in quality or an increase in the price of those materials or components could adversely affect us. If we are unable to locate or establish alternative suppliers, our ability to manufacture our products and product candidates could be adversely affected and could harm our revenues, cause us to fail to satisfy contractual commitments, lead to a termination of one or more of our contracts or lead to delays in our clinical trials, any of which could be costly to us and otherwise materially harm our business, financial condition, operating results and cash flows. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend on third parties to conduct many of our clinical and non-clinical trials. If these third parties do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates and, as a result, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on third parties, such as independent clinical investigators, contract research organizations and other third-party service providers, to conduct the clinical and non-clinical trials of our product candidates and expect to continue to do so. We rely heavily on these third parties for successful execution of our clinical and non-clinical trials, but do not exercise day-to-day control over their activities. Our reliance on these service providers does not relieve us of our regulatory responsibilities, including ensuring that our trials are conducted in accordance with good clinical practice regulations and the plan and protocols contained in the relevant regulatory application. In addition, these organizations may not complete these activities on our anticipated or desired timeframe. We also may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a contract research organization or other third party may lead us to seek to terminate the relationship and use an alternative service provider, which may prove difficult, costly and result in a delay of our trials. Any delay in or inability to complete our trials could delay or prevent the development, approval and commercialization of our product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, government entities and non-governmental organizations ("NGOs") conduct studies of our product candidates, and we may seek to rely on these studies in applying for marketing approval for certain of our product candidates. These government entities and NGOs have no obligation or commitment to us to conduct or complete any of these studies or clinical trials and may choose to discontinue these development efforts at any time. Furthermore, government entities depend on annual Congressional appropriations to fund their development efforts, which may not be approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain any necessary third-party services on acceptable terms or if these service providers do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for our product candidates may be delayed or prevented.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL AND REPUTATIONAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings or government investigations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various claims, legal proceedings and government investigations that have not yet been fully resolved, including stockholder derivative and putative class action lawsuits, and new matters may arise in the future. In addition, agreements entered into by us sometimes include indemnification provisions which can subject us to costs and damages in the event of a claim against an indemnified third party. The number of claims, legal proceedings and government investigations involving us, and the alleged magnitude of such claims, proceedings and government investigations, has generally increased over time and may continue to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase. Certain of these actions include, and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other actions adverse to us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, multiple purported class action lawsuits have been filed against us and certain of our current and former senior officers in the United States District Court for the District of Maryland seeking unspecified damages on behalf of a putative class of persons who purchased or otherwise acquired shares of our common stock during various date ranges. The complaints, allege, among other things, that we made materially false and misleading statements regarding our procedures and quality controls relating to vaccine production, in violation of federal securities laws. As another example, multiple stockholder derivative lawsuits were filed in The Court of Chancery of the State of Delaware and the United States District Court for the District of Maryland on behalf of the Company against certain current and former officers and directors for breach of fiduciary duties, waste of corporate assets, unjust enrichment and insider trading, each allegation related to the Company&#8217;s capabilities to manufacture COVID-19 vaccine bulk drug substance. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of merit, litigation can be both time-consuming and disruptive to our operations and cause significant expense and diversion of management&#8217;s attention. The outcome of litigation or government investigations is also inherently uncertain. If one or more legal matters were resolved against us or an indemnified third party in a reporting period for amounts above management&#8217;s expectations, our financial condition and operating results for that reporting period could be materially adversely affected. Further, such an outcome could result in significant compensatory, punitive or trebled monetary damages, disgorgement of revenue or profits, remedial corporate measures or injunctive relief against us and could require us to change our business practices or limit our ability to offer certain products and services, all of which could materially adversely affect our financial condition and operating results. While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely significantly on information technology systems and any cyber security incidents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, unauthorized access or other failure, inadequacy, interruption or security lapse of that technology could harm our ability to operate our business effectively or result in data leakage of proprietary or confidential business or employee information.</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. We previously contracted with the USG and pharmaceutical companies for the development and manufacture of a significant quantity of COVID-19 vaccines, which raised our security profile and heightened potential risks that malicious actors may seek to disrupt our systems or misappropriate our information. The size and complexity of our computer systems and those of many of our business partners, collaborators and other third parties make them potentially vulnerable to interruption, invasion, computer viruses, destruction, unauthorized or malicious intrusion and additional related disruptions, which may result in the impairment of production and key business processes. Our systems and information are also potentially vulnerable to cyber security incidents through user error, phishing scams, or malfeasance, as well as cyber security incidents involving our employees, business partners, collaborators or other third parties, any of which may expose sensitive data to unauthorized persons. Our systems and those of our business partners and collaborators have in the past been, and in the future likely will be subject to computer viruses, malicious codes, unauthorized access and other cyber security incidents. We are not aware of any significant impact on our operations or financial results from such incidents although, as of the date of this report, we are assessing the potential impact of a cyber security incident involving misuse of authorized access by a business partner of which we became aware in October 2023.</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No system of protection is adequate to protect against all such threats, even if they are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deemed to be industry standard, and there can be no assurance that we will be able to repel any such attacks. Cyber security incidents could lead to the loss of trade secrets or other intellectual property or the public exposure of personal information, including sensitive personal information, of our employees, clinical trial patients, customers and others. Responding to any such threats may also be expensive and time-consuming. Any such unauthorized access to our information, whether through an incident involving our information technology systems or those of our business partners, collaborators or other third parties, could disrupt our business operations, result in the loss of assets, and have a material adverse effect on our reputation, business, financial condition, or results of operations. While the Company has experienced non-material cyber incidents involving third-party vendors, the Company&#8217;s continued use of third parties in its business yields the potential for material cyber security incidents that may harm business operations. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant business disruption or a breach in security resulting in misappropriation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">theft or sabotage with respect to proprietary or confidential business or employee information could result in significant financial losses, legal, business or reputational harm to us, compromise our business prospects and our commitments to the USG or other customers, any of which could materially and adversely affect our business, financial condition and operating results.</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e face</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> product liability exposure, which could cause us to incur substantial liabilities and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the sale of our products, any other products that we successfully acquire or develop and the testing of our product candidates in clinical trials.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One measure of protection against such lawsuits is coverage under the PREP Act, which was signed into law in December 2005. The PREP Act creates liability protection for manufacturers of biodefense countermeasures when the Secretary of HHS issues a declaration for their manufacture, administration or use. A PREP Act declaration is meant to provide liability protection from all claims under federal or state law for loss arising out of the administration or use of a covered countermeasure under a government contract. The Secretary of HHS has issued PREP Act declarations covering countermeasures for smallpox, mpox, and other orthopox; anthrax; and botulinum toxin. These declarations apply to certain of our products, namely BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, raxibacumab, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and VIGIV products, as covered countermeasures.</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers are not entitled to protection under the PREP Act in cases of willful misconduct or for cases brought in non-U.S. tribunals or under non-U.S. law. We cannot predict whether the Secretary of HHS will renew the declarations when they expire, whether Congress will fund the relevant PREP Act compensation programs, or whether the necessary prerequisites for immunity would be triggered with respect to our products or product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain of our products, namely BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are under the SAFETY Act, which provides certain product liability limitations for qualifying anti-terrorism technologies for claims arising from or related to an act of terrorism. Although BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are designated and certified under the SAFETY Act, the law may not provide adequate protection from claims made against us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against future claims that our products or product candidates caused injuries and if we are not entitled to indemnity by the USG, or the USG does not honor its obligations to us under the PREP Act or SAFETY Act, or if the liability protections under the PREP Act and SAFETY Act are not adequate to cover all claims, we may incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">decreased demand or withdrawal of a product;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">injury to our reputation;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">costs to defend the related litigation;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">loss of revenue; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">an inability to commercialize products that we may develop.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. Further product liability insurance may be difficult and expensive to obtain. We may not be able to maintain insurance coverage at a reasonable cost and we may not be able to obtain insurance coverage that will be adequate to satisfy all potential liabilities. For example, we may not have sufficient insurance against potential liabilities associated with a possible large-scale deployment of BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine as a countermeasure to a bioterrorism threat. We rely on PREP Act protection for BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, raxibacumab, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and VIGIV products, and SAFETY Act protection for BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products in addition to our insurance coverage to help mitigate our product liability exposure for these products. Additionally, potential product liability claims related to our commercial products, including NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(naloxone HCl) Nasal Spray</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, may be made by patients, health care providers or others who sell or consume these products. Such claims may be made even with respect to those products that possess regulatory approval for commercial sale. Claims or losses in excess of our product liability insurance coverage could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have incurred significant indebtedness in connection with our acquisitions and servicing our debt requires a significant amount of cash. We may not have sufficient cash flow from our operations to pay our substantial debt.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments of the principal of, to pay interest on or to further refinance, our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing can have significant adverse consequences for our business, including:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">requiring us to dedicate a substantial portion of cash flows from operations to payment on our debt, which would reduce available funds for other corporate initiatives;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">increasing the amount of interest that we have to pay on debt with variable interest rates, if market rates of interest increase, to the extent we are unable to offset such risk through our hedging instruments;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">subjecting us, as under our Senior Secured Credit Facilities and the indenture governing the Senior Unsecured Notes, to restrictive covenants that reduce our ability to take certain corporate actions, acquire companies, products or technology, or obtain further debt financing; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">requiring us to pledge our assets as collateral, which could limit our ability to obtain additional debt financing; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">limiting our flexibility in planning for, or reacting to, general adverse economic and industry conditions; and </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">placing us at a competitive disadvantage compared to our competitors that have less debt, better debt servicing options or stronger debt servicing capacity.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient funds or be able to obtain additional financing to pay the amounts due under our indebtedness. In addition, failure to comply with the covenants under our Senior Secured Credit Facilities and other debt agreements, including the maintenance of a specified consolidated net leverage ratio, debt service coverage ratio, consolidated EBITDA level, minimum liquidity level and required liquidity raise under our Senior Secured Credit Facilities, and the additional terms and conditions imposed by the Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement, dated February 29, 2024 (the "Forbearance Agreement and Amendment") could result in an event of default under those agreements. An event of default could result in the acceleration of amounts due under a particular debt agreement and a cross default and acceleration under other debt agreements, and we may not have sufficient funds to pay or be able to obtain additional financing to make any accelerated payments. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current indebtedness restricts and any additional debt financing may restrict the operation of our business and limit the cash available for investment in our&#160;business operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities include the Term Loan Facility, which had an outstanding principal balance of $198.2 million as of December 31, 2023 and the ability to borrow up to $300.0&#160;million under our Revolving Credit Facility under which we had $219.2 million of outstanding borrowings as of December 31, 2023. On August 7, 2020, we completed an offering of $450.0&#160;million aggregate principal amount of Senior Unsecured Notes. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing can have significant adverse consequences for our business, including:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the level, timing and cost of product sales and bioservices;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the payment obligations under our indebtedness;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the scope, progress, results and costs of our development activities;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the extent to which we repurchase common stock under any future share repurchase program; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the costs of commercialization activities, including product marketing, sales and distribution.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Senior Secured Credit Facilities and our Senior Unsecured Notes each contain cross-default provisions whereby a default under one agreement would likely result in cross defaults under agreements covering other indebtedness. The occurrence of a default under any of these arrangements would permit the holders of the notes or the lenders under our Senior Secured Credit Facilities to declare all amounts outstanding under those borrowing arrangements to be immediately due and payable, and there is no assurance that we would have sufficient funds to satisfy any such accelerated obligations. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our hedging programs have been, and any hedging program we initiate in the future will be, subject to counterparty default risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we manage our interest rate risk in part by entering into interest rate swaps with a number of counterparties to swap a portion of our indebtedness that is based on variable interest rates to a fixed rate. As a result, when we are party to such interest rate swaps, we are subject to the risk that the counterparty to one or more of these contracts defaults on its performance under the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract. During an economic downturn, the counterparty's financial condition may deteriorate rapidly and with little notice and we may be unable to take action to protect our exposure. In the event of a counterparty default, we could incur losses, which may harm our business and financial condition. In the event that one or more of our counterparties becomes insolvent or files for bankruptcy, our ability to eventually recover any losses suffered as a result of that counterparty's default may be limited by the liquidity of the counterparty. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We require significant additional funding to be able to continue as a going concern and we may be unable to raise capital when needed or on acceptable terms, which would harm our ability to grow our business, and our results of operations and financial condition. In addition, any capital we raise may result in dilution to our current stockholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had unrestricted cash and cash equivalents of $111.7 million and remaining capacity under our Revolving Credit Facility of $80.3 million. Also as of December 31, 2023, there was $219.2 million outstanding on our Revolving Credit Facility and $198.2 million on our Term Loan Facility that mature in May 2025. We are not in compliance with certain provisions of the Senior Credit Facilities, most notably that we comply with the minimum consolidated EBITDA covenant and that our financial statements not contain a "going concern" qualification. In addition, it is unlikely that we will be able to comply with the requirement in the Credit Agreement Amendment (as define below) that we raise not less than $75.0&#160;million through the issuance of equity and/or unsecured indebtedness by April 30, 2024. As a result, the Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements included in this Annual Report on Form 10-K were issued. On February 29, 2024, the requisite lenders under the Senior Credit Facilities agreed to enter into the Forbearance Agreement and Amendment to, among other things, (a) provide that the Administrative Agent and the Lenders forbear from exercising all rights and remedies under the Existing Credit Agreement and the other related loan documents arising from the occurrence and continuation of certain specified events of default during a forbearance period (the &#8220;Forbearance Period&#8221;) between the forbearance effective date until the earlier to occur of (x) 5:00 p.m. on April 30, 2024 and (y) the occurrence of any event of default (other than the specified events of default) or default under the Forbearance Agreement and Amendment and notice by the Administrative Agent to the Company of the termination of the Forbearance Period and (b) provide consent by the required revolving credit lenders to make further loans to the Company or other extensions of credit to the credit parties during the Forbearance Period, notwithstanding the occurrence of the specified events of default, subject to certain conditions set forth in the Forbearance Agreement and Amendment, including a limit on Revolving Credit Facility indebtedness of $270 million. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to or forbearance arrangements under the Credit Agreement. We will need to obtain substantial additional funding in connection with our continuing operations, which cannot be assured.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements. In August 2021, we filed a shelf registration statement, which immediately became effective under SEC rules. As a result of the delayed filing of certain of our periodic reports with the SEC, we are not currently eligible to register the offer and sale of our securities using the shelf registration statement and we will not become eligible until we have timely filed certain periodic reports required under the Securities Exchange Act of 1934 for 12 consecutive calendar months. There can be no assurance that we will be eligible to file a shelf registration statement or to have such a shelf registration statement become effective after such period, which may inhibit our ability to access the capital markets to raise funds.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds by issuing equity securities, including through our ATM Program, our stockholders may experience dilution. Debt financing, if available, may involve agreements that include covenants, like those contained in our Senior Secured Credit Facilities and the indenture governing the Senior Unsecured Notes, limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us. </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Senior Secured Credit Facilities as well as the indenture governing the Senior Unsecured Notes restrict our ability to incur additional indebtedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions may make it difficult to obtain financing on attractive terms, or at all. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not maintain profitability in future periods or on a consistent basis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our profitability has been substantially dependent on product sales, which historically have fluctuated significantly from quarter to quarter, and we expect that they will continue to fluctuate significantly based primarily on the timing of our fulfillment of orders from the USG. We may not be able to achieve consistent profitability on a quarterly basis or sustain or increase profitability on an annual basis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment charges to our intangible assets or property, plant and equipment could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, we are required to assess the value of our intangible assets and goodwill annually, or more frequently whenever events or changes in circumstances indicate potential impairment, such as changing market conditions or any changes in key assumptions. If the testing performed indicates that an asset may not be recoverable, we are required to record a non-cash impairment charge for the difference between the carrying value of the asset and its implied fair value in the period the determination is made. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also periodically monitor the remaining net book values of our property, plant and equipment, or whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. For example, we performed recoverability tests on certain asset groups within the Bioservices reporting unit during the three months ended June 30, 2023, and allocated and recognized a non-cash impairment charge of $306.7&#160;million during the three months ended June 30, 2023 related to certain Bioservices long-lived assets. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we annually perform a goodwill impairment evaluation, during the fourth quarter, or sooner if triggering events are identified. During the three months ended September&#160;30, 2023 as a result of continued market volatility, including significant declines in our market capitalization and revised financial outlook, we determined that a triggering event had occurred that required an evaluation of our goodwill for potential impairment. As a result of the quantitative assessments, we determined that our goodwill, which related to the MCM reporting unit within the Products segment, was fully impaired and recorded a $218.2&#160;million non-cash goodwill impairment charge during the three months ended September&#160;30, 2023. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant amount of intangible assets and property, plant and equipment on our balance sheet. The impairment tests require us to make an estimate of the fair value of our reporting units. An impairment could be recorded as a result of changes in assumptions, estimates or circumstances, some of which are beyond our control. Since a number of factors may influence determinations of fair value, we are unable to predict whether impairments of intangible assets and property, plant and equipment will occur in the future, and we can provide no assurance that continued conditions will not result in future impairments of these assets. The future occurrence of a potential indicator of impairment could include matters such as (i) a decrease in expected net earnings, (ii) adverse equity market conditions, (iii) a decline in current market multiples, (iv) a decline in our common stock price, (v) a significant adverse change in legal factors or the general business climate, and (vi) an adverse action or assessment by a regulator. Any such impairment would result in us recognizing a non-cash charge in our Consolidated Balance Sheets, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accuracy of our financial reporting depends on the effectiveness of our internal control over financial reporting. We have identified material weaknesses in our internal control over financial reporting and have restated prior period financial statements that resulted from one of these material weaknesses, which may raise questions regarding the accuracy and reliability of our financial statements and our ability to report accurately in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. During the process of preparing the financial statements as of and for the year ended December 31, 2022, we determined that we had a material weakness related to our inventory accounting. Subsequently, in connection with the preparation of the financial statements as of and for the periods ended September 30, 2023, we determined that we had a material weakness related to the calculation and review of the Company&#8217;s net state deferred tax liability and that this material weakness had existed as of December 31, 2022 and resulted in a material misstatement to our consolidated financial statements for the period ended December 31, 2022. Due to the existence of these material weaknesses, our management concluded that as of December 31, 2022 our internal control over financial reporting was not effective and we were required to restate the financial statements included in our Original Form 10-K and filing Amendment No. 1 to the Original Form 10-K for the fiscal year ended December 31, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that we remediated our internal weakness with respect to inventory accounting as of March 31, 2023 and we are taking steps to remediate the material weakness related to the calculation and review of the Company&#8217;s net state deferred tax liability. In addition, we have restated our financial statements for the fiscal year ended December 31, 2022 to correct the errors that were identified as a result of the material weakness regarding our calculation and review of the Company&#8217;s net state deferred tax liability, and corrected other unrelated errors that were either unrecorded or addressed as out-of-period adjustments in previously filed financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements that were not material, individually or in the aggregate, to those financial statements. However, we cannot provide any assurance that the measures we have taken to date and we intend to implement will be sufficient to remediate the material weakness regarding state deferred taxes that we have identified, or to avoid additional material weaknesses from occurring in the future. The material weaknesses in our internal control over financial reporting and the restatement of our prior financial statements may raise significant questions regarding the accuracy and reliability of our filed financial statements and our ability to report in an accurate and timely manner in the future. These material weaknesses and resulting errors in our financial statements, or those that may occur in the future, could have an adverse effect on our ability to meet our reporting obligations, which could cause our investors to lose confidence in our publicly reported information, cause the market price of our stock to decline, harm our reputation, business and financial results, and expose us to stockholder litigation and sanctions or investigations by the SEC or other regulatory authorities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The expansion of our international operations increases our risk of exposure to credit losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our business activities with foreign governments in certain countries that have experienced deterioration in credit and economic conditions or otherwise, our exposure to uncollectible accounts will rise. Global economic conditions and liquidity issues in certain countries have resulted and may continue to result in delays in the collection of accounts receivable and may result in credit losses. Future governmental actions and customer specific actions may require us to re-evaluate the collectability of our accounts receivable and we may potentially incur credit losses that materially impact our operating results.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO STRATEGIC ACQUISITIONS, DIVESTITURES AND COLLABORATIONS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be successful in identifying, structuring or acquiring businesses and products to drive our growth.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in identifying, effectively evaluating, structuring, acquiring or in-licensing, and developing and commercializing additional products on favorable terms, or at all. Competition for attractive product opportunities is intense and may require us to devote substantial resources, both managerial and financial, to an acquisition opportunity. A number of more established companies are also pursuing strategies to acquire or in-license products in the biopharmaceutical field. These companies may have a competitive advantage over us due to their size, cash resources, cost of capital, effective tax rate and greater clinical development and commercialization capabilities. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition efforts can consume significant management attention and require substantial expenditures, which could detract from our other programs. In addition, we may devote significant resources to potential acquisitions that are never completed. Even if we are successful in acquiring a company or product, it may not result in a successfully developed or commercialized product or, even if an acquired product is commercialized, competing products or technologies could render a product noncompetitive, uneconomical or obsolete. Moreover, the cost of acquiring other companies or in-licensing products could be substantial, and in order to acquire companies or new products, we may need to incur substantial debt or issue dilutive securities. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in our efforts to identify and acquire other companies, products, or in-license and develop additional products, or if we acquire or in-license unproductive assets, it could have a material adverse effect on the growth of our business, and we could be compelled to record significant impairment charges to write-down the carrying value of our acquired intangible assets, which could materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our failure to successfully integrate acquired businesses and/or assets into our operations could adversely affect our ability to realize the benefits of such acquisitions and, therefore, to grow our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to integrate any acquired business successfully or operate any acquired business profitably. In addition, cost synergies, if achieved at all, may be less than we expect, or may take greater time to achieve than we anticipate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issues that could delay or prevent successful integration or cost synergies of an acquired business or products include, among others:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">retaining existing customers and attracting new customers;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">retaining key employees;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">diversion of management attention and resources;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">conforming internal controls, policies and procedures, business cultures and compensation programs;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">consolidating corporate and administrative infrastructures;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">successfully executing technology transfers and obtaining required regulatory approvals;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">consolidating sales and marketing operations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">identifying and eliminating redundant and underperforming operations and assets;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">assumption of known and unknown liabilities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">coordinating geographically dispersed organizations; </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">managing tax costs or inefficiencies associated with integrating operations; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">risks associated with intellectual property rights related to an acquisition or collaboration, including but not limited to, license rights, freedom-to-operate, litigation, and loss of proprietary confidential information, know-how, and trade secrets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully integrate pending and future acquisitions with our existing businesses, or operate any acquired business profitably, we may not obtain the advantages that the acquisitions were intended to create, which may materially adversely affect the growth of our business, financial condition, operating results and cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not realize the expected benefits of the sale of our travel health business to Bavarian Nordic.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, pursuant to the Purchase and Sale Agreement, we completed the previously announced sale to Bavarian Nordic of our travel health business, including rights to Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as our development-stage chikungunya vaccine candidate CHIKV VLP, our manufacturing site in Bern, Switzerland and certain of our development facilities in San Diego, California for a cash purchase price of $270.2&#160;million, subject to certain customary adjustments. In addition, we may receive milestone payments of up to $80.0&#160;million related to the development of CHIKV VLP and receipt of marketing approval and authorization in the U.S. and Europe, and sales-based milestone payments of up to $30.0&#160;million based on aggregate net sales of Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in calendar year 2026. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to realize in full the expected benefits of the transaction. If we are unable to or do not realize the expected strategic, economic, or other benefits of the transaction, it could adversely affect our business and financial position.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business or our share price could be negatively affected as a result of the actions of stockholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, some stockholders have placed increasing pressure on publicly traded companies in our industry and others to effect changes to corporate governance practices, executive compensation practices, social and environmental practices and to undertake certain corporate actions. This may be true even if they only hold a minority of shares. In addition, many institutional investors are increasingly focused on environmental, social, and corporate governance ("ESG") factors. These investors may be seeking enhanced ESG disclosures or to implement policies adverse to our business. There can be no assurances that stockholders will not publicly advocate for us to make corporate governance changes or engage in certain corporate actions. Responding to challenges from stockholders, such as proxy contests, media campaigns or other public or private means, could be costly and time consuming and could have an adverse effect on our reputation and divert the attention and resources of management and our board of directors, which could have an adverse effect on our business and operational results. Any such stockholder actions or requests, or the mere public presence of stockholders with a reputation for taking such actions among our investor base, could also cause the market price of our common stock to experience periods of significant volatility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and by-laws and under Delaware law may discourage acquisition proposals, delay a change in control or prevent transactions that stockholders may consider favorable.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and by-laws may discourage, delay or prevent a merger, acquisition or other changes in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions include:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the classification of our directors;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">limitations on changing the size of our board of directors;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">limitations on the removal of directors;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">limitations on filling vacancies on the board of directors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">advance notice requirements for stockholder nominations of candidates for election to the board of directors and other proposals to be voted on at meetings of stockholders;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the inability of stockholders to act by written consent;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the inability of stockholders to call special meetings; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the ability of our board of directors to designate the terms of and issue a new series of preferred stock without stockholder approval.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative vote of a majority of our board of directors or the holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal the above provisions of our certificate of incorporation or by-laws. The affirmative vote of either a majority of the directors present at a meeting of our board of directors or holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal our by-laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to Section 203 of the Delaware General Corporation Law ("Section 203"). In general and subject to certain exceptions, Section 203 prohibits a publicly-held corporation from engaging in a business combination with an interested stockholder, generally a person which, together with its affiliates, owns or within the last three years has owned 15% or more of the corporation's voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, Section 203 may discourage, delay or prevent a change in control of us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our board of directors may adopt a new stockholder rights plan without stockholder approval, which could prevent a change in control of us in instances in which some stockholders may believe a change in control is in their best interests.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors may adopt a stockholder rights plan without stockholder approval, which may have anti-takeover effects, potentially preventing a change in control of us in instances in which some stockholders may believe a change in control is in their best interests. This could cause substantial dilution to a person or group that attempts to acquire us on terms that our board of directors does not believe are in our best interests or those of our stockholders and may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price is volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been, and is likely to continue to be, volatile. The market price of our common stock could fluctuate significantly for many reasons, including in response to the risks described in this &#8220;Risk Factors&#8221; section, or for reasons unrelated to our operations, such as reports by industry analysts, investor perceptions or negative announcements by our customers, competitors or suppliers regarding their own performance, as we</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ll as industry conditions and general financial, economic and political instability. From November 15, 2006, when our common stock first began trading on the New York Stock Exchange, through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our common stock has traded as high as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$137.61</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share and as low as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.81</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be influenced by many factors, including, among others:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">contracts, decisions and procurement policies by the USG affecting our anthrax vaccines and our other products and product candidates;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">results of clinical and non-clinical trials of our product candidates;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">announcements of acquisitions, financings or other transactions by us;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">litigation or legal proceedings;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">public concern as to the safety of our products;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">termination or delay of a development program;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">variations in our product revenue and profitability; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because we currently do not pay dividends, investors will benefit from an investment in our common stock only if it appreciates in value.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not pay dividends on our common stock. Our Senior Secured Credit Facilities and the indenture governing our Senior Unsecured Notes limit and any future debt agreements that we enter into may limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders based on current expectations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future sales </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of our common stock or other securities convertible into common stock, or the perception that such sales or issuances could occur, could result in dilution of our stockholders and could cause our share price to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> decline.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors is authorized, without stockholder approval, to cause us to issue additional shares of our common stock or to raise capital through the issuance of preferred shares or the sale of debt securities that are convertible into common stock, options, warrants and other rights, on terms and for consideration as our board of directors in its sole discretion may determine. In addition, under the Credit Agreement Amendment, we are required to increase our liquidity by April 30, 2024 by raising at least $75&#160;million of equity or unsecured indebtedness. We also require substantial additional funding to be able to continue as a going concern and we may seek to achieve such funding through future sales of our common stock or other securities convertible into our common stock. Sales of substantial amounts of our common stock or the issuance of preferred shares, convertible debt, options, restricted stock units, performance stock units, warrants and other rights, or the perception that such sales or issuances could occur could cause the market price of our common stock to decrease significantly. As of December 31, 2023, we had 52,167,256 shares of common stock issued and outstanding. We cannot predict the effect, if any, of future sales of our common stock or any preferred shares, convertible debt securities, options, restricted stock units, performance stock units, warrants or other rights or the availability of our common stock for future sales on the value of our common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISK FACTORS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our success is dependent on our continued ability to attract, motivate and retain key personnel, and any failure to attract or retain key personnel may negatively affect our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific nature of our business, our ability to develop products and to compete with our current and future competitors largely depends upon our ability to attract, retain and motivate highly qualified managerial and key scientific and technical personnel (including quality and manufacturing personnel). If we are unable to retain the services of one or more of the principal members of senior management or other key employees, our ability to implement our business strategy could be materially harmed. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, there may be changes in our senior management team resulting from the hiring or departure of executives. For example, we hired a new Chief Executive Officer in February 2024. Our new Chief Executive Officer will be critical to executing on and achieving our vision, strategic direction, and business objectives. If we are unable to successfully transition leadership to our new Chief Executive Officer, our business, results of operations and financial conditions could be adversely affected.  In addition, w</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e face intense competition for qualified employees from biopharmaceutical companies, research organizations and academic institutions. Attracting, retaining or replacing these personnel on acceptable terms may be difficult and time-consuming given the high demand in our industry for similar personnel. We believe part of being able to attract, motivate and retain personnel is our ability to offer a competitive compensation package, including equity incentive awards. If we cannot offer a competitive compensation package to attract and retain the qualified personnel necessary for the continued development of our business, we may not be able to maintain our operations or grow our business.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7b0776f670624692b261a662f247fc47_2203"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C. CYBERSECURITY</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CYBERSECURITY</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity program is aligned and integrated into the overall company risk management process through its Enterprise Risk Management Program ("ERM"). At Emergent, ERM is a centralized process that prioritizes, and groups the top risks to our organization into 12 categories, one of which is Cybersecurity. We conduct an Enterprise Risk Assessment ("ERA") annually to proactively identify, assess, respond, monitor, and report risks to our enterprise. Identified risks are assessed and we accordingly will either accept the risk or take action to reduce or avoid the risk. Mitigations against risks are developed, as necessary, and all risks are monitored, reviewed quarterly, and reported to executive leadership and the Board of Directors. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ERM program and ERA process is described in the company&#8217;s Enterprise Risk Management Policy which was released this year. The program includes enterprise level risks grouped in 12 risk categories. Cybersecurity is included as a standing risk category. The ERM program does not itself independently review cybersecurity policies and practices. In first quarter 2024, ERM, in collaboration with Emergent&#8217;s Policy and Training Center of Excellence, provided training on Emergent&#8217;s Enterprise Risk Management Policy to all employees who are at the vice president level and above. We are currently working on an all-employee awareness communication to further educate the full employee population about the ERM program, policy and intranet page. Timing for this communication is expected in first half of 2024. Annually, an ERM training will be provided to all participants in advance of the Company's annual ERA. Full retraining on the ERM policy will occur every three years. The Company leverages the Committee of Sponsoring Organizations&#8217;("COSO") guidelines as the foundation for our ERM program and leverage external expertise. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company proactively reviews threats landscape, impacts to the company, and address any gaps where necessary. Also, we maintain security operations metrics, incident response plan and conduct tabletop exercises. The Company engages outside consultants to review both its Cybersecurity posture, and maturity, and perform for a cyber assessments of</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s manufacturing/operational technology environments.  The Company has a process in place to oversee and identify material risks from cybersecurity threats associated with its use of any third-party service provider, na</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mely its Third-Party Risk Management Assessment Process. We utilize the NIST framework when assessing third parties. The framework covers 23 categories. When applicable, we may request if the third party vendor is SOC1/2, GDPRS, certified.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Information Security Officer (&#8220;CISO&#8221;) is responsible for assessing and managing the Cybersecurity risks with comprehensive oversight of information security functions with an emphasis on strategic leadership, governance, risk management and technical proficiency.  Moreover, the Company&#8217;s CISO provides cyber security updates to the entire board of directors and the board's Quality Compliance Management Risk Committee (the "Committee"). The purpose of the Committee is to assist the Board in fulfilling its oversight responsibilities relating to the Company&#8217;s compliance with laws, regulations, and industry standards that, if breached, may cause significant business, regulatory, or reputational damage to the Company, including oversight of the Company's:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Compliance with good (&#8220;x&#8221; = manufacturing, clinical, laboratory, pharmacovigilance, storage, distribution etc.) (GxP) and medical device Quality Systems Regulations (QSR);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Healthcare compliance, anti-corruption, privacy and data security landscape, medical product safety, supply chain, employee health and safety, political expenditures and lobbying activities, and government contracting;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Enterprise Risk Management program;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Cyber and information security risks.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee is the primary oversight body to monitor the Company&#8217;s cybersecurity and related information technology risks and receives periodic updates from Company management (including, the Chief Information Officer and the CISO) on the Company&#8217;s policies, processes, procedures, and any significant developments related to the identification, mitigation, and remediation of cybersecurity risks.  The Chair or Vice-Chair of the Committee meet as necessary with the Chief Information Officer and the CISO to engage in a more detailed review of the Company&#8217;s cybersecurity and information security activities. The Committee charter also requires that the Committee ensure that Company management provides an annual cyber and information security update to the full Board. Current Committee members are: Zsolt Harsanyi, Ph.D., Sujata Dayal and Kathryn C. Zoon, Ph.D., all of whom are independent directors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's CISO is a Certified Information Systems Security Professional (CISSP) and Certified Information Security Manager (CISM), and is certified in Risk and Information Systems Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CRISC).  The CISO reports to the Quality Compliance Management Risk Committee twice per year and also reports to the Board twice per year. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not incurred material cybersecurity incidents over the past three years The Company is not aware that any risks from cybersecurity threats, including because of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect the company. The Company proactively reviews threats landscape, impacts to the company, and address any gaps where necessary. Also, we maintain security operations metrics, incident response plan and conduct tabletop exercises. In addition, the Company has: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Managed Security Service Provider (MSSP) that maintains 24 hours per day, 7 days per week, monitoring of the Company's environment;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Formed partnership with Cybersecurity Infrastructure Security Agency (CISA), to monitor the Company's external traffic and external facing web environment;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Performed an internal red campaign;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Been audited by internal and external auditors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and lease approximately 1.4 million square feet of building space for development and manufacturing, laboratories, fill/finish facility services, offices and warehouse space for the conduct of our businesses at 16 locations in North America and Europe. Properties that have been leased expire on various dates between 2024 and 2034. Principal locations include:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Location</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Use</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Approximate </span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">square feet</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Owned/leased</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Operating Segment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lansing, Michigan </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing operations, office and laboratory space. </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products &amp; Services</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Winnipeg, Manitoba, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing operations, office and laboratory space. </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,000 (Owned); 15,800 (Leased)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned/Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products &amp; Services</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gaithersburg, Maryland </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory space, office space and rental real estate.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,000 (Owned);<br/>11,547 (Leased)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned/Leased</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products &amp; Services</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canton, Massachusetts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing operations and warehouse space.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,508 (Owned); 27,000 (Leased)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned/Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products &amp; Services</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baltimore, Maryland (Bayview)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing facilities, office and laboratory space.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products &amp; Services</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elkridge, Maryland</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warehouse space.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,182</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products &amp; Services</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baltimore, Maryland (Camden)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing facilities, office and laboratory space. </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,900 (Owned); 41,000 (Leased)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned/Leased</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products &amp; Services</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rockville, Maryland</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing facilities, office and warehouse space.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,295</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products &amp; Services</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,012</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each property is considered to be in good condition, adequate for its purpose, and suitably utilized according to the individual nature and requirements of the relevant operations. Our policy is to improve and replace property as considered appropriate to meet the needs of the individual operations.</span></div><div id="i7b0776f670624692b261a662f247fc47_28"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;LEGAL PROCEEDINGS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 8 of Part II, &#8220;Financial Statements and Supplemental Data &#8212; Notes to Consolidated Financial Statements" &#8212; Note 19, "Litigation."</span></div><div id="i7b0776f670624692b261a662f247fc47_31"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div id="i7b0776f670624692b261a662f247fc47_34"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Market Information and Holders</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the New York Stock Exchange under the symbol "EBS".</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;28, 2024, the closing price per share of our common stock on the New York Stock Exchange was $3.20 and we had 19 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dividend Policy</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our common stock since becoming a publicly traded company in November 2006. We currently have no plans to pay dividends.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining information required by Item 5 is hereby incorporated by reference from our Definitive Proxy Statement relating to our 2024 Annual Meeting of the Stockholders, to be filed with the SEC within 120 days following the end of our fiscal year.</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Performance Graph</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph provides a comparison of five year cumulative total stockholder returns of Emergent BioSolutions Inc.'s common stock, the Standard &amp; Poor&#8217;s ("S&amp;P") 500 Stock Index, the Russell 2000 Index, the S&amp;P SmallCap 600 Index, the S&amp;P Pharmaceuticals Index and the S&amp;P Biotechnology Index. The annual changes for the five-year period shown on the graph are based on the assumptions that $100 had been invested in Emergent BioSolutions Inc.'s common stock and each index on December 31, 2018, all fiscal years end December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and all dividends were reinvested. </span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20231231_g8.jpg" alt="1517" style="height:336px;margin-bottom:5pt;vertical-align:text-bottom;width:710px"/></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="18" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Performance</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company / Index</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergent BioSolutions Inc.</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.01&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.15&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.33&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.92&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell 2000</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P SmallCap 600</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P Pharmaceuticals</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P Biotechnology</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="i7b0776f670624692b261a662f247fc47_40"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. [RESERVED]</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amounts and uncertainties of cash flows from operations and from outside resources, so as to allow investors to better view our company from management&#8217;s perspective. You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K (the "Annual Report"). Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and financing, includes forward-looking statements that involve risks and uncertainties. You should carefully review the "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" sections of this Annual Report  for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div id="i7b0776f670624692b261a662f247fc47_549755815746"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS OVERVIEW</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (&#8220;PHTs&#8221;). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services ("CDMO") portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently focused on the following four PHT categories: chemical, biological, radiological, nuclear and explosives (&#8220;CBRNE&#8221;); emerging infectious diseases (&#8220;EID&#8221;); public health crises; and acute, emergency and community care. We have a product portfolio of 12 products that contribute a substantial portion of our revenue and are sold to government and commercial customers. Additionally, we have a development pipeline consisting of a diversified mix of both pre-clinical and clinical stage product candidates. Finally, we have a fully integrated portfolio of CDMO services which cover development services, drug substance manufacturing and drug product manufacturing and packaging. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures (&#8220;MCM&#8221;) Products, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Smallpox - MCM products and Emergent Bioservices (CDMO) services ("Bioservices").  In the fourth quarter of 2023, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting process. The revised reporting structure reflects the internal reporting and review process used by our Chief Operating Decision Maker, for making decisions and assessing performance, and is consistent with how we currently manage the business. We now manage our business with a focus on three reportable segments: (1) a Commercial Products segment consisting of our NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Other Commercial Products; (2) a MCM Products segment consisting of the Anthrax - MCM, Smallpox - MCM and Other Products and (3) a Services segment consisting of our Bioservices offerings.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Products Segment:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our Commercial product revenue comes from the following products:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA (including in over-the-counter form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.</span></div><div style="margin-bottom:5pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Commercial Products (Sold to Bavarian Nordic as part of our travel health business in Mar 2023)</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the first vaccine approved by the FDA for the prevention of cholera, which we sold to Bavarian Nordic as part of our travel health business; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), a live attenuated vaccine for oral administration for the prevention of typhoid fever, which we sold to Bavarian Nordic as part of our travel health business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MCM Products Segment:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our MCM product revenue comes from the following products and procured product candidates:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax - MCM Products</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the United States Food and Drug Administration (&#8220;FDA&#8221;) for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax vaccine adsorbed (AVA), adjuvanted), previously known as AV7909, which was recently approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is procured by certain authorized government buyers for their use; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Smallpox - MCM Products</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Ebanga&#8482; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#8482;;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services Segment:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bioservices - contract development and manufacturing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services revenue consists of distinct but interrelated Bioservices: drug substance manufacturing; drug product manufacturing (also referred to as &#8220;fill/finish&#8221; services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations. These services, which we refer to as &#8220;molecule-to-market&#8221; offerings, employ diverse technology platforms (mammalian, microbial, viral and plasma) across a network of eight geographically distinct development and manufacturing sites operated by us for our internal products and pipeline candidates and third-party Bioservices. We service both clinical-stage and commercial-stage projects for a variety of third-party customers, including government agencies, innovative pharmaceutical companies, and non-government organizations. In August 2023, we initiated an organizational restructuring plan (the &#8220;August 2023 Plan&#8221;) which included actions to reduce investment in and de-emphasize focus on our Bioservices business.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Strategic Activities</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">January 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company initiated an organizational restructuring plan (the &#8220;January 2023 Plan&#8221;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. As part of the January 2023 Plan, the Company reduced its workforce by approximately 125 employees. The Company incurred approximately $9.3&#160;million in charges in connection with the January 2023 Plan during the year ended December 31, 2023. These charges consist primarily of charges related to employee transition, severance payments and employee benefits. All activities related to the January 2023 Plan were substantially completed during the first quarter of 2023.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Travel Health Business to Bavarian Nordic</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, pursuant to the Purchase and Sale Agreement (the "Purchase and Sale Agreement"), by and between the Company, through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc., and Bavarian Nordic, the Company completed the previously announced sale of the Company's travel health business, including rights to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed typhoid vaccine; Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#8217;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, Bavarian Nordic paid a cash purchase price of $270.2&#160;million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing. Bavarian Nordic may also be required to pay milestone payments of up to $80.0&#160;million related to the development of CHIKV VLP and receipt of marketing approval and authorization in the U.S. and Europe, and earn-out payments of up to $30.0&#160;million based on aggregate net sales of Vaxchora and Vivotif in calendar year 2026.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the divestiture, the Company recognized a pre-tax gain of $74.2&#160;million during year ended December 31, 2023, net of transaction costs of $4.0&#160;million, which was recorded within "Gain on sale of business" on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FDA Approval of CYFENDUS</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2023, the FDA approved CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. In December 2018, CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine was the subject of a pre-emergency use authorization package submitted to the FDA. The following year, the USG began procuring this product for national preparedness efforts.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ebanga</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Procurement Contract</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2023, the Company was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority ("BARDA") for advanced development, manufacturing scale-up, and procurement of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment for Ebola. The contract consists of a base period of performance with two option periods valued at approximately $121.0&#160;million, and five option periods for procurement of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over five years valued at up to $583.0&#160;million. If all option periods are exercised, the total contract value will be valued at up to approximately $704.0&#160;million. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent is responsible for the manufacturing, sale, and distribution of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and Canada pursuant to a collaboration agreement with Ridgeback, the developer of the treatment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent paid Ridgeback $6.3&#160;million in contingent consideration as a result of the award of the BARDA contract in the third quarter of 2023. In addition, the Company could owe up to $50.4&#160;million in contingent consideration to Ridgeback if activities under the awarded contract have not ceased by June 1, 2026. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company initiated the August 2023 Plan intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its Bioservices business for future growth. As part of the August 2023 Plan, the Company reduced its workforce by approximately 400 employees. The Company incurred approximately $20.0&#160;million in charges in connection with the August 2023 Plan during the year ended December 31, 2023. These charges consist primarily of charges related to severance payments, transition services, and employee benefits. All activities related to the August 2023 Plan were substantially completed during the third quarter of 2023. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Launch of NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Naloxone HCl Nasal Spray 4 mg Over-The-Counter ("NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> OTC")</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2023, the Company launched NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC, which was approved by the FDA as an over-the-counter emergency treatment of opioid overdose, broadening our customer base and sales channels to retail pharmacies and digital commerce websites. The Company's Nasal Naloxone products are now sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Triggering Events</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Long-Live Asset Impairment Testing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its long-lived assets that are held and used for recoverability whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, due to deterioration in performance and resulting downward revisions to our internal Bioservices forecast made during the second quarter, including future expected cash flows, the Company determined there were sufficient indicators of impairment on certain asset groups within the Bioservices reporting unit to require an impairment analysis. As a result, the Company performed recoverability tests on certain asset groups within the Bioservices reporting unit and concluded that the impacted asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset groups are written down only to the extent that their carrying value is higher than their respective fair value. The Company, with the assistance of a third-party valuation firm, applied valuation methods to estimate the fair values for each of the assets within the different asset classes. For the intangible assets, an option pricing model was applied to estimate the assets' fair value. An orderly liquidation value was applied to estimate the fair value of the personal property assets and market and cost based approaches were applied to estimate the fair value of the real property assets, each representing Level 3 non-recurring fair value measurements. Based on this analysis, the Company allocated and recognized a non-cash impairment charge of $306.7 million during the year ended December 31, 2023.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill Impairment Testing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs its goodwill impairment evaluation annually, during the fourth quarter, or sooner if triggering events are identified. During the third quarter of 2023, the Company observed continued market volatility including significant declines in its market capitalization and revised its financial outlook during the third quarter, which was identified as a triggering event. As a result of the quantitative assessments performed in connection with the preparation of the financial statements as of and for the quarter ended September 30, 2023, the Company recorded a $218.2 million non-cash goodwill impairment charge for the MCM reporting unit within the Products segment, which is included in "Goodwill impairment" on the Condensed Consolidated Statement of Operations for the year ended December 31, 2023. The MCM reporting unit and Products segment had no remaining goodwill as of December 31, 2023. The goodwill impairment charge resulted from a reduction in the estimated fair value of the MCM reporting unit due to changes in the risk profile of the Company as well as revisions to the long-term operating plan that reflected lower expectations for growth and profitability than previous expectations. The Company used a quantitative assessment, utilizing an income-based (discounted cash flows) approach, Level 3 non-recurring fair value measurement, for our goodwill impairment testing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate Commercial Product revenues through sale of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, which is sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. In addition we previously generated Commercial product revenues through sale of the Company's travel health products, which we sold to Bavarian Nordic in May 2023.We generate MCM Product revenues from the sale of our marketed products and procured product candidates. The USG is the largest purchaser of our Government - MCM products and primarily purchases our products for the SNS, a national repository of medical countermeasures including critical antibiotics, vaccines, chemical antidotes, antitoxins, and other critical medical supplies. The USG primarily purchases our products under long-term, firm fixed-price procurement contracts, generally with annual options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also generate revenue for our Services segment through our Bioservices portfolio, which is based on our established development and manufacturing infrastructure, technology platforms and expertise. Our services include a fully integrated molecule-to-market bioservices business offering across development </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services, drug substance and drug product for small to large pharmaceutical and biotechnology industry and government agencies/non-governmental organizations. From time to time, clients require suite reservations at our various manufacturing sites, which may be considered leases depending on the facts and circumstances.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received contracts and grant funding from the USG and other non-governmental organizations to perform R&amp;D activities, particularly related to programs addressing certain CBRNE threats and EIDs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue, operating results and profitability vary quarterly based on the timing of production and deliveries, the timing of manufacturing services performed and the nature of our business, which involves providing large scale bundles of products and services as needs arise. We expect continued variability in our quarterly financial results.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cost of Product Sales and Services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and MCM Products</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The primary expenses that we incur to deliver NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MCM and other commercial products consist of fixed and variable costs. We determine the cost of product sales for products sold during a reporting period based on the average manufacturing cost per unit in the period those units were manufactured. Fixed manufacturing costs include facilities, utilities and amortization of intangible assets. Variable manufacturing costs primarily consist of costs for materials and personnel-related expenses for direct and indirect manufacturing support staff, contract manufacturing operations, sales-based royalties, shipping and logistics. In addition to the fixed and variable manufacturing costs described above, the cost of product sales depends on utilization of available manufacturing capacity. For our commercial sales, other associated expenses include sales-based royalties, shipping, and logistics.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The primary expenses that we incur to deliver our Bioservices offerings consist of fixed and variable costs, including personnel, equipment, and facilities costs. Our manufacturing process includes the production of bulk material and performing drug product work for containment and distribution of biological products. For drug product customers, we receive work in process inventory to be prepared for distribution. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses ("R&amp;D")</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense R&amp;D costs as incurred. Our R&amp;D expenses consist primarily of:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">personnel-related expenses;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of our clinical trials and obtaining and evaluating data from our clinical trials and non-clinical studies;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">costs of Bioservices for our clinical trial material; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">costs of materials intended for use and used in clinical trials and R&amp;D.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many cases, we seek funding for development activities from external sources and third parties, such as governments and non-governmental organizations, or through collaborative partnerships. We expect our R&amp;D spending will be dependent upon such factors as the results from our clinical trials, the availability of reimbursement of R&amp;D spending, the number of product candidates under development, the size, structure and duration of any clinical programs that we may initiate, the costs associated with manufacturing and development of our product candidates on a large-scale basis for later stage clinical trials, and our ability to use or rely on data generated by government agencies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel-related costs and professional fees in support of our executives, sales and marketing, business development, government affairs, finance, accounting, information technology, legal, human resource functions and other corporate functions. Other costs include facility costs not otherwise included in cost of product sales and Bioservices or R&amp;D expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty in income taxes is accounted for using a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize in our financial statements the impact of a tax position if that position is more likely than not of being sustained on audit, based on the technical merits of the position.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the assumptions and estimates related to the provision for income taxes are critical to the Company&#8217;s results of operations. For the year ended December 31, 2023, income tax expense totaled $29.3 million. For every 1% change in the 2023 effective rate, income tax expense would have changed by approximately $7.3 million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OECD ("Organization for Economic Co-operation and Development") has proposed a global minimum tax of 15% of reported profits (Pillar 2) that has been agreed upon in principle by over 140 countries. During 2023, many countries took steps to incorporate Pillar 2 model rule concepts into their domestic laws. On December 18, 2023, Ireland enacted laws related to this minimum tax, effective January 1, 2024.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pillar Two rules, a company would be required to determine a combined effective tax rate for all entities located in a jurisdiction. If the jurisdictional effective tax rate determined under the Pillar Two is less than 15%; a top-up tax will be due to bring the jurisdictional effective tax rate up to 15%. We continue to evaluate the potential impacts of proposed and enacted legislative changes on our business in future periods in Ireland and elsewhere.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our uncertain tax positions and income tax expense, refer to Note 15, "Income taxes" to our consolidated financial statements included in this report. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_549755815767"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated and Segment Operating Results:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except %)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commercial Product sales, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Commercial Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Commercial Product sales, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MCM Product sales, net:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anthrax MCM</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smallpox MCM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Products</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total MCM product sales, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(132.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Services:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bioservices - Services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bioservices - Leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Services revenues</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Commercial product sales</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of MCM product sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Bioservices</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,775.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,287.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">488.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(726.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(556.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(731.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(512.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(760.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(548.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:3pt"><td colspan="24" style="padding:0 1pt"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM - Not meaningful</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2023 Compared with Year Ended December 31, 2022</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues and gross margin</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total segment revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,023.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,076.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Commercial Product sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">210.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">160.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of MCM Product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">305.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">264.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Bioservices</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">189.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">268.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cost of sales or services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">705.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">693.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total segment gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">317.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">383.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total segment gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> We define total segment revenues, which is a non-GAAP financial measure, as our total revenues, less contracts and grants revenue, which is also equal to the sum of the revenues of our operating segments. We define total segment gross margin, which is a non-GAAP financial measure, as total segment revenues less our aggregate cost of sales or services. We define total segment gross margin %, which is a non-GAAP financial measure, as total segment gross margin as a percentage of total segment revenues.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues decreased $68.2 million, or 6%, to $1.0 billion in 2023. The decrease was due to a decrease in MCM Products revenue of $132.4 million, Bioservices revenue of $31.4 million and Contracts and Grants revenue of $15.1 million, offset by an increase in Commercial Products revenue of $110.7 million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total segment gross margin decreased $65.4 million, or 17%, to $317.6 million in 2023. Total segment gross margin percentage decreased 5 percentage points to 31%. The decrease was primarily due to a decrease in the MCM Products segment gross margin of $173.7 million, partially offset by increases in the Commercial Products segment gross margin and Bioservices segment gross margin of $60.7 million and $47.6 million, respectively. Total segment gross margin and gross margin percentage excludes contracts and grants revenues because the related costs are R&amp;D expenses. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Segment Results" for an expanded discussion of revenues and gross profit.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unallocated corporate operating expenses</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill Impairment</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment increased $211.5&#160;million to $218.2&#160;million in 2023. During the third quarter of 2023, the Company recognized a $218.2&#160;million impairment charge to goodwill in the MCM reporting unit, reducing the goodwill balance of the reporting unit and segment to zero as of December&#160;31, 2023. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impairment of long-lived assets</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recorded a non-cash impairment charge of $306.7&#160;million related to certain asset groups within our Bioservices reporting unit. The asset groups were written down only to the extent their carrying value was higher than their respective fair values. The Company, with the assistance of a third-party valuation firm, applied valuation methods to estimate the fair values for each of the assets within the different asset classes to determine the amount of the impairment.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Expenses</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased $76.9&#160;million, or 41%, to $111.4&#160;million in 2023. The decrease was primarily due to the sale of our development program for CHIKV VLP to Bavarian Nordic and reduction in related overhead costs driven by the headcount reductions, which were significant contributors to prior period R&amp;D expense, partially offset by write-offs related to program terminations during the period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $28.9&#160;million, or 9%, to $368.4&#160;million in 2023. The increase was primarily due to higher professional services fees related to general corporate initiatives, including organizational transformation consulting fees and legal remediation services fees as well as an increase in marketing expenses related to the launch of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC. The increase was partially offset by decreases in compensation and other employee costs related to the restructuring initiatives during 2023. Selling, general and administrative costs as a percentage of total revenue increased 5 percentage points to 35% for the year ended December 31, 2023. The increase was due to an increase in selling, general and administrative expenses coupled with a decrease in revenues during the period.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets increased $5.7&#160;million, or 10%, to $65.6&#160;million in 2023. The increase was primarily due to amortization expense for intangible assets related to TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which were acquired during the second half of 2022. The increase was partially offset by a decrease in amortization expense resulting from the intangibles sold as part of our travel health business to Bavarian Nordic.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased $50.6&#160;million, or 136%, to $87.9&#160;million in 2023. The increase was primarily due to higher interest costs related to our syndicated borrowings and debt service costs attributable to the negotiation of the Fourth Amendment to Amended and Restated Credit Agreement, Waiver and First Amendment to Amended and Restated Collateral Agreement (the &#8220;Credit Agreement Amendment"), partially offset by reduced interest expense related to the termination of our interest rate swap hedging agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on sale of business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of business was $74.2&#160;million for the year ended December 31, 2023, which was attributable to the sale of our travel health business to Bavarian Nordic on May 15, 2023. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other, net</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net decreased $20.6&#160;million, or 176%, to an income of $8.9&#160;million in 2023. The decrease in expense was primarily attributable to a write-off of a tax indemnity receivable in the prior period that did not reoccur in the current period,  favorable foreign exchange revaluations, higher interest income from rising interest rates during the year, income from the Transition Services Agreement with Bavarian Nordic and a gain on extinguishment of debt.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit of $7.4&#160;million for the year ended December&#160;31, 2022 decreased $36.7&#160;million to a provision of $29.3&#160;million for the year ended December 31, 2023. The effective tax rate was (4)% for the year ended December 31, 2023 as compared to 3% in 2022. The effective annual tax rate decreased largely due to an increase in nondeductible expenses, specifically the impact of a valuation allowance charge in the U.S., state and foreign jurisdictions, goodwill impairment charge, GILTI, and other permanent items. This is partially offset by tax credits and favorable rates in foreign jurisdictions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEGMENT RESULTS</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMERCIAL PRODUCTS</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Commercial Products</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">497.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">386.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">210.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">160.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">287.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">226.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">287.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">226.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues. </span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Segment adjusted gross margin, which is a non-GAAP financial measure, is calculated as gross margin plus restructuring costs and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. Segment adjusted gross margin %, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin % for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2023 Compared with Year Ended December 31, 2022</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales increased $113.8 million, or 30%, to $487.5 million in 2023. The increase was primarily driven by higher sales of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC and branded NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to U.S. public interest channels and Canadian retail, partially offset by the cessation of authorized generic NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales related to the termination of the Company's relationship with Sandoz and a reduction in commercial retail sales in the U.S.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Commercial Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Commercial Products sales decreased $3.1 million, or 24%, to $9.8 million. The decrease was driven by lower sales of Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by higher sales of Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the second quarter of 2023, we sold Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Bavarian Nordic as part of our travel health business.</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Commercial product sales increased $50.0 million, or 31%, to $210.3 million in 2023. The increase was primarily driven by higher sales of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC and higher branded NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products gross margin increased $60.7 million, or 27%, to $287.0 million in 2023. Commercial Products gross margin percentage decreased 1 percentage point to 58% in 2023. The decrease was largely due to a decrease in the per unit selling price in response to increased competition for generic NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by a decrease in royalty expense. Commercial Products Segment Adjusted Gross Margin is consistent with gross margin.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MCM PRODUCTS</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">MCM Products</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">447.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">579.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">305.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">264.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">141.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">315.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Add back:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Inventory step-up provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">51.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">151.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">369.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues. </span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Segment adjusted gross margin, which is a non-GAAP financial measure, is calculated as gross margin plus restructuring costs and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. Segment adjusted gross margin %, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin % for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">NM - Not meaningful</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2023 Compared with Year Ended December 31, 2022</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anthrax MCM </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax MCM sales decreased $102.5 million, or 35%, to $187.6 million in 2023. The decrease reflects the impact of timing of sales related to CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BioThrax, partially offset by an increase in Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options, the timing and amount of USG purchases, the availability of governmental funding and timing of Company delivery of orders that follow. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Smallpox MCM</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smallpox MCM sales decreased $67.0 million, or 29%, to $167.4 million in 2023. The decrease was primarily due to lower sales of TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by an increase related the exercise and full delivery in the current period of a $120&#160;million option by the USG to purchase ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fluctuations in revenues result from the timing of the exercise of annual purchase options in existing procurement contracts, the timing of USG purchases, the availability of governmental funding and timing of Company delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Product Sales </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Product sales increased $37.1 million, or 67%, to $92.2 million in 2023. The increase was primarily due to higher BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales, partially offset by lower RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales due to timing. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of MCM Product sales increased $41.3 million, or 16%, to $305.6 million in 2023. The increase was primarily due to higher sales of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and AIG, partially offset by lower sales of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, coupled with higher allocations to MCM Product COGS at our Bayview facility, shutdown costs and inventory write-offs. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products gross margin decreased $173.7 million, or 55%, to $141.6 million in 2023. MCM Products gross margin percentage decreased 22 percentage points to 32% in 2023. The decrease was largely due to lower sales volumes and higher shutdown related costs and inventory write-offs, coupled with an unfavorable product revenue mix which was weighted more heavily to lower margin products compared with the prior year. The 2023 MCM Product Segment Adjusted Gross Margin excludes the impact of restructuring costs of $5.6&#160;million, non-cash items related to the changes in the fair value of contingent consideration of $0.2 million and the inventory step-up provision of $3.9&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SERVICES</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Services</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">78.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">109.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">189.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">268.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(111.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(158.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(141)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add back:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(102.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(158.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(131)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues. </span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">((2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Segment adjusted gross margin, which is a non-GAAP financial measure, is calculated as gross margin plus restructuring costs and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. Segment adjusted gross margin %, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin % for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">NM - Not meaningful</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2023 Compared with Year Ended December 31, 2022</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioservices revenue decreased $32.2&#160;million, or 31%, to $72.8&#160;million in 2023. The decrease was driven by reduced production activities at the Company's Winnipeg and Camden facilities. The decreases were partially offset by an increase in production at our Canton facility for a Bioservices customer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioservices lease revenue increased $0.8&#160;million, or 16%, to $5.7&#160;million in 2023. The increase was related to a Bioservices customer at our Canton facility.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Services and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Services decreased $79.0&#160;million, or 29%, to $189.5&#160;million in 2023. The decrease was primarily due to reduced production activities related to the halt in manufacturing under the Janssen Agreement coupled with higher allocations to MCM Product cost of sales at our Bayview facility and lower production activities at our Winnipeg facility, partially offset by increased costs at our Camden facility for additional investments in quality enhancement and improvement initiatives and increased costs associated with production activities at our Canton facility for a Bioservices customer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross margin increased $47.6&#160;million, or 30%, to $(111.0)&#160;million in 2023. Services gross margin percentage increased 3 percentage points to (141)% in 2023. The increase was primarily driven by one-time costs and reserves related to the Janssen </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement in the prior year. The 2023 Services Segment Adjusted Gross Margin excludes the impact of restructuring costs of $8.4&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER REVENUE</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2023 Compared with Year Ended December 31, 2022</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts and Grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract and grants revenue decreased $15.1&#160;million, or 36%, to $26.3&#160;million in 2023. The decrease was primarily attributable to one-time indirect rate adjustments in the prior period, the conclusion of COVID-19 related studies in the fourth quarter of 2022, and decreases in development activities associated with various externally funded research and development projects. These decreases were partially offset by increases in revenue on the BARDA contract for the procurement of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was awarded in the current period, and TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_2179"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2022 Compared with Year Ended December 31, 2021</span></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated and Segment Operating Results:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except %)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commercial Product sales, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Commercial Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Commercial Product sales, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MCM Product sales, net:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anthrax MCM</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smallpox MCM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Products</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total MCM product sales, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Services:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bioservices - Services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bioservices - Leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Services revenues</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(505.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,773.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(656.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Commercial product sales</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of MCM product sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Bioservices</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,287.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,432.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(511.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(522.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(431.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:3pt"><td colspan="24" style="padding:0 1pt"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM - Not meaningful</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2022 Compared with Year Ended December 31, 2021</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues and gross margin</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">134.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total segment revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,076.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,639.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Commercial Product sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">160.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">187.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of MCM Product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">264.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">195.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Bioservices</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">268.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">365.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cost of sales or services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">693.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">748.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total segment gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">383.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">891.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total segment gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> We define total segment revenues, which is a non-GAAP financial measure, as our total revenues, less contracts and grants revenue, which is also equal to the sum of the revenues of our operating segments. We define total segment gross margin, which is a non-GAAP financial measure, as total segment revenues less our aggregate cost of sales or services. We define total segment gross margin %, which is a non-GAAP financial measure, as total segment gross margin as a percentage of total segment revenues.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues decreased $656.1 million, or 37%, to $1.1 billion in 2022. The decrease was primarily due to a decrease in Bioservices revenue of $505.6 million, coupled with decreases in Contracts and grants revenue of $92.8 million, Commercial Products revenue of $51.4 million and MCM Products revenue of $6.3 million. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total segment gross margin decreased $508.3 million, or 57%, to $383.0 million in 2022. Total segment gross margin percentage decreased 19 percentage points to 36%. The decrease was primarily due to a decrease in the Bioservices segment gross margin of $408.6 million, coupled with decreases in MCM Products segment gross margin and Commercial Products segment gross margin of $75.2 million and $24.5 million, respectively. Total segment gross margin percentage excludes contracts and grants revenues because the related costs are R&amp;D expenses. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Segment Results" for an expanded discussion of revenues and gross profit.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unallocated corporate operating expenses</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Expenses</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased $46.9&#160;million, or 20%, to $188.3&#160;million in 2022. The decrease was primarily due to the non-cash write-off in 2021 of $38.0&#160;million of the contract asset associated with the completion of the BARDA COVID-19 Development Public Private Partnership (as defined below), coupled with a decrease in spending for the Company's COVID-19 therapeutic product candidates along with a number of other developmental activities, partially offset by an increase in costs associated with the Company's Phase 3 study of our chikungunya virus-like particle vaccine candidate and pre-launch inventory related to CGRD-001.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased $9.2&#160;million, or 3%, to $339.5&#160;million in 2022. The decrease was primarily  due to lower professional services and marketing expenses partially offset by increased employee costs, primarily due to increased travel costs. Selling, general and administrative costs as a percentage of total revenue increased 11 percentage points  to 30% for the year ended December 31, 2022. The increase was due to a decrease in revenues during the period, partially offset by a decrease in selling, general and administrative expenses during the period.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill Impairment</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment decreased $35.0&#160;million to $6.7&#160;million in 2022. The decrease was due to a smaller non-cash impairment charge taken in 2022 as compared with 2021. In 2022, as part of its annual goodwill impairment testing, the Company recognized a $6.7&#160;million impairment charge to goodwill in the Bioservices reporting unit, reducing the goodwill balance to zero as of December&#160;31, 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is the risk of future impairments in our reporting units as any further deterioration in their performance compared to forecast, changes in order volumes or delivery schedules for major customers, as well as any changes in economic forecasts and expected recovery in the biopharmaceutical industry, may require the Company to complete additional impairment tests in future quarters and could result in the reporting unit&#8217;s fair value falling below carrying value in subsequent quarters. In the event the Company experiences factors that it believes indicate a decline in fair value, including negative changes to long-term growth rates or if discount rates increase, we may be required to record impairments of goodwill and other identified intangible assets. Further, if the composition of the Company&#8217;s reporting unit&#8217;s assets and liabilities were to change and result in an increase in the reporting unit&#8217;s carrying value, it could lead to additional impairment testing and further impairment losses.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets increased $1.4&#160;million, or 2%, to $59.9&#160;million in 2022. Apart from the addition of the intangibles related to the Company's acquisition of the worldwide rights to TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2022, the composition of intangible assets amortized was largely consistent with 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased $2.8&#160;million, or 8%, to $37.3&#160;million in 2022. The increase was primarily due to higher interest costs related to our syndicated borrowings, partially offset by a decrease in interest expense related to our interest rate swap hedging agreements. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other, net</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net increased $8.0&#160;million to an expense of $11.7&#160;million in 2022. The increase was primarily due to a write-off of a tax indemnity receivable, which was offset in income tax provision, and unrealized foreign currency losses recorded related to the remeasurement of certain intercompany balances. The increases in expense were partially offset by an increase in interest income due to higher interest rates in 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax provision</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision decreased $91.1&#160;million to an income tax benefit of $7.4&#160;million for the year ended December 31, 2022. The decrease was largely due to the decline in income before income taxes. The effective tax rate was 3% for the year ended December 31, 2022 as compared to 28% in 2021. The effective annual tax rate decreased largely due to the impact of a valuation allowance charge in the U.S., state and foreign jurisdictions, a charge due the Company&#8217;s indefinite reinvestment assertion, GILTI, and other permanent items. This is partially offset by tax credits, favorable rates in foreign jurisdictions, and the release of an indemnified unrecognized tax benefit. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEGMENT RESULTS</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMERCIAL PRODUCTS</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Commercial Products</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">386.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">438.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">160.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">187.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">226.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">250.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">226.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">250.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues. </span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Segment adjusted gross margin, which is a non-GAAP financial measure, is calculated as gross margin plus restructuring costs and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. Segment adjusted gross margin %, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin % for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2022 Compared with Year Ended December 31, 2021</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales decreased $60.7 million, or 14%, to $373.7 million in 2022. The decrease was primarily driven by a reduction in commercial retail sales and a decrease in the price per unit following the launch of a generic version of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray 4mg in December 2021, partially offset by an increase in U.S. public interest and Canadian sales.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Commercial Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Commercial Products sales increased $9.3 million to $12.9 million in 2022. The increase was primarily driven by higher sales of Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2022.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Commercial product sales decreased $26.9 million, or 14%, to $160.3 million in 2022. The decrease was primarily driven by a decrease in royalties paid for NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales due to the royalty settlement in 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products gross margin decreased $24.5 million, or 10%, to $226.3 million in 2022. Commercial Products gross margin percentage increased 2 percentage points to 59% in 2022. The increase was largely due to a decrease in royalties paid for NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales due to the royalty settlement in 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MCM PRODUCTS</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">MCM Products</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">579.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">585.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">264.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">195.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">315.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">390.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Add back:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Inventory step-up provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">51.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">369.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">393.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues. </span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Segment adjusted gross margin, which is a non-GAAP financial measure, is calculated as gross margin plus restructuring costs and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. Segment adjusted gross margin %, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin % for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">NM - Not meaningful</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2022 Compared with Year Ended December 31, 2021</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anthrax MCM </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax MCM sales increased $27.5 million, or 10%, to $290.1 million in 2022. The increase was primarily due to an increase in the number of doses sold as a result of the timing of deliveries to the USG in 2022 as compared with 2021, as well as an increase in sales to non-USG customers at a higher price per unit in 2022. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options and the USG purchases and Company delivery of orders that follow. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Smallpox MCM</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smallpox MCM sales decreased $32.3 million, or 12%, to $234.4 million in 2022. The decrease was primarily due to lower sales of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales following the 2022 acquisition of worldwide rights for TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fluctuations in revenues result from the timing of the exercise of annual purchase options in existing procurement contracts, the timing of USG purchases, the availability of governmental funding and timing of Company delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Product Sales </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Product sales decreased $1.5 million, or 3%, to $55.1 million in 2022. The decrease was primarily due to lower BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales, partially offset by higher RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of MCM Product sales increased $68.9 million, or 35%, to $264.3 million in 2022. The increase was primarily due to cost of sales for TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following our 2022 acquisition of the worldwide rights for TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Excluding the acquisition related product costs, cost of MCM product sales increased $8.7&#160;million, primarily due to inventory write-offs, primarily related to CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and higher costs due to under-utilized capacity at our facilities. These increases were partially offset by decreases in ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales which were due to a reduced number of units sold to the USG and decreased expenses at our Bern facility due to higher facility utilization versus prior year.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products gross margin decreased $75.2&#160;million, or 19%, to $315.3&#160;million in 2022. MCM Products gross margin percentage decreased 13 percentage points to 54% in 2022. The decrease was largely due to lower sales volumes and higher shutdown related costs and inventory write-offs, coupled with an unfavorable product revenue mix which was weighted more heavily to lower </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">margin products compared with the prior year. The 2022 MCM Product Segment Adjusted Gross Margin excludes the impact of non-cash items related to the changes in the fair value of contingent consideration of $2.6&#160;million and the inventory step-up provision of $51.4&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SERVICES</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Services</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">109.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">615.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">268.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">365.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(158.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">250.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(158.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">250.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Segment adjusted gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:700;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Gross margin is calculated as revenues less cost of services. Gross margin % is calculated as gross margin divided by revenues. </span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Segment adjusted gross margin, which is a non-GAAP financial measure, is calculated as gross margin plus restructuring costs and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. Segment adjusted gross margin %, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin % for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">NM - Not meaningful</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2022 Compared with Year Ended December 31, 2021</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioservices revenue decreased $205.3&#160;million, or 66%, to $105.0&#160;million in 2022. The decrease was primarily due to $170.9&#160;million less of combined revenue related to reduced production activities at the Company's Bayview facility as a result of a halt in manufacturing under the Janssen contract in first quarter of 2022 and the cessation of manufacturing activities under the AstraZeneca contract which occurred in 2021. Additionally, the decrease also reflects reduced production at the Camden facility. The decreases were slightly offset by an increase in manufacturing activities at the Company's Winnipeg facility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioservices lease revenue decreased $300.3&#160;million, or 98%, to $4.9&#160;million in 2022. The decrease was primarily due to a reduction of $243.1&#160;million associated with the completion of our COVID-19 development public-private partnership with BARDA in November 2021 and reduced lease revenues under the Janssen contract of $58.1&#160;million.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Services and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services decreased $97.0&#160;million, or 27%, to $268.5&#160;million in 2022. The decrease was primarily due to reduced production activities across our Bioservices network, as well as a $41.5&#160;million inventory write-off related to the Bayview facility in the second quarter of 2021, partially offset by increased costs at our Camden facility for additional investments in quality enhancement and improvement initiatives.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services gross margin decreased $408.6&#160;million to $(158.6)&#160;million in 2022. Services gross margin percentage decreased 185 percentage points to (144)% in 2022. The decrease was primarily driven by reduced production activities across our Bioservices network including the completion of the Company's arrangement with BARDA in November 2021, the halt in manufacturing under the Janssen and AstraZeneca contracts and the decrease in margins at the Company's Camden facility due to additional investments in quality enhancement and improvement initiatives, including an increase in professional services costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER REVENUE</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2022 Compared with Year Ended December 31, 2021</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts and Grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract and grants revenue decreased $92.8&#160;million, or 69%, to $41.4&#160;million in 2022. The decrease was primarily due to BARDA's completion of the CIADM agreement in November 2021 as well as decreases in development activities associated with various other externally funded research and development projects, most notably the Company's COVID-HIG therapeutic product candidate, as well as decreases in development activities for CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Decreases were partially offset by revenue increases relating to indirect rate adjustments during the period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except percentages)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Change %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">111.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Borrowings:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Debt, current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">413.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">446.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">860.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Working capital:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">679.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">651.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total working capital</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">NM - Not Meaningful</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Principal Sources of Capital Resources</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operating and capital expenditures through existing cash and cash equivalents, cash from operations, development contracts and grant funding and borrowings under our senior revolving credit facility ("Revolving Credit Facility"),our senior term loan facility ("Term Loan Facility" and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"), and other lines of credit we have established from time to time. We also obtain financing from the sale of our common stock upon exercise of stock options and participation in an at-the market equity offering program that we entered into on May 18, 2023 (the "ATM Program"). As of December&#160;31, 2023, we had unrestricted cash and cash equivalents of $111.7&#160;million and remaining capacity under our Revolving Credit Facility of $80.3&#160;million.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Going Concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared on the going concern basis of accounting, which assumes the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $219.2&#160;million outstanding on our Revolving Credit Facility and $198.2&#160;million on our Term Loan Facility that mature in May 2025. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The evaluation considered the potential mitigating effects of management&#8217;s plans that have not been fully implemented. Management has evaluated the mitigating effects of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern. Managements's plans include (A) amending the Senior Secured Credit Facilities, and (B) improving operating performance, reducing working capital and the potential sale of assets to pay down the Senior Secured Credit Facilities before they become due. As neither plan is in the complete control of Management, neither is probable of occurring. In this regard, management may not be able to find a buyer for the assets it is willing to divest and may not be able to close on any asset sales for which management is able to reach an agreement with a buyer, and as a result the Company may be unable to meet its obligations as they become due. In addition, any asset sales that are completed could have potential negative impacts on the Company's future operating cash flows and profitability.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt Covenants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities mature in May 2025 which provide for (1) revolving credit commitments, (2) a term loan, and (3) the issuance of commercial letters of credit. As of December 31, 2023, we had $417.4&#160;million outstanding under the Senior Secured Credit Facilities. Under the Senior Secured Credit Facilities, the Company is subject to a monthly minimum consolidated EBITDA covenant through February 29, 2024, and is also required to raise at least $75.0&#160;million through the issuance of equity and/or unsecured indebtedness by April 30, 2024. Beginning with the quarter ended March 31, 2024, the Company is subject to a minimum </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated debt service coverage ratio and a maximum consolidated leverage ratio covenant. As of December 31, 2023, the Company was not in compliance with the minimum consolidated EBITDA covenant under the Senior Secured Credit Facilities and did not expect to be able to raise the remaining of the $75.0&#160;million through the issuance of equity under the at-the-market equity offering program (the "ATM Program") that we entered into on May 18, 2023, by April 30, 2024, as required by the requisite lenders. In addition, the Company is required to deliver audited annual financial statements without a &#8220;going concern&#8221; explanatory paragraph with respect to its financial statements for the year ended December 31, 2023, within 90-days of year end, while the financial statements included in this Annual Report contain an explanatory paragraph related to Going Concern. On February 29, 2024, the requisite lenders agreed to enter into the Forbearance Agreement, which includes a limited waiver of any defaults or events of default that result from (a) any violation of the financial covenants set forth in the Senior Secured Credit Facilities with respect to the fiscal quarter ending December 31, 2023 and the fiscal quarter ending March 31, 2024 and (b) the going concern explanatory paragraph contained in the audited financial statements for the fiscal year ended December 31, 2023. This forbearance period will expire on the earlier to occur of (i) any other event of default and (ii) April&#160;30, 2024. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Senior Secured Credit Facilities. The Senior Secured Credit Facilities and the Company&#8217;s other debt facilities are described in more detail in Note 10, &#8220;Debt&#8221; in the Notes to Consolidated Financial Statements in Part II, Item 8. of this Annual Report.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, acceleration of the repayment of the Senior Secured Credit Facilities would result in a cross-default of the Company&#8217;s obligations under the 3.875% Senior Unsecured Notes due in 2028. If the Company would be unable to obtain additional waivers or forbearance of such covenants or defaults, to successfully renegotiate the terms of the Senior Secured Credit Facilities, or to cure the potential covenant breach or default, and the lenders enforced one or more of their rights upon default and/or the default resulted in a cross-default under the 3.875% Senior Unsecured Notes due in 2028, the Company would be unable to meet its obligations under those agreements and could be forced into insolvency proceedings.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the facts and circumstances described above, there can be no assurance that the Forbearance Period will continue to remain in place, and that the Company would be able to comply with covenants in the future. As a result, the Company continues to evaluate a number of factors related to its ability to continue as a going concern, including its ability to comply with the terms and operating and financial covenants required by the Senior Secured Credit Facilities, its ability to satisfy the capital raise requirement, other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, and disruptions or volatility caused by factors such as regional conflicts, inflation, and supply chain disruptions. The Company has engaged legal and financial advisors to assist with a comprehensive review of alternatives to enhance its capital structure, which may include taking steps to cure any potential defaults or seeking forbearance, waivers, further cost reductions, asset sales or other alternatives to avoid an event of default.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $111.7 million of cash on hand at December 31, 2023. On January 9, 2023, the Company announced the January 2023 Plan, intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. The January 2023 Plan included a reduction of the Company&#8217;s current workforce by approximately 125 employees. Additionally, on August 8, 2023, the Company announced the August 2023 Plan, intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its Bioservices business for future growth. The August 2023 Plan included a reduction of the Company's current workforce by approximately 400 employees. These actions, in combination with other cost reduction initiatives, are expected to result in annualized savings of over $160&#160;million when fully implemented.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">At-the-Market Equity Offering Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, from time to time, sell up to $150.0&#160;million aggregate gross sales price of shares of our common stock through Evercore Group L.L.C. and RBC Capital Markets, LLC, as sales agents, under the ATM Program that we entered into on May 18, 2023. Between the adoption of the ATM Program and December 31, 2023, we sold 1.1 million shares of our common stock under the ATM Program for gross proceeds of $9.1&#160;million, representing an average price of $8.22 per share. As of December 31, 2023, $140.9&#160;million aggregate gross sales price of shares of our common stock remains available for issuance under the ATM Program. We intend to use proceeds obtained from the sale of shares under the ATM Program for general corporate purposes. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(535.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities increased $172.2&#160;million in 2023. The increase in net cash used in operating activities was primarily due to negative working capital changes of $68.2&#160;million, driven by lower cash collections on accounts receivable, and an increase in cash payments for accrued compensation and income taxes, partially offset by lower cash payments for inventories, prepaid expenses and other assets, accrued expenses and other liabilities, and accounts payable.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities increased $593.6&#160;million in 2023. The increase in net cash provided by investing activities was primarily due to the proceeds received from the sale of the travel health business during the second quarter of 2023 of $270.2 million, a decrease in payments for the acquisition of businesses of $243.7 million and a decrease of $64.2 million in capital expenditures, partially offset by an increase in milestone payments of $6.3 million for prior asset acquisitions.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities increased $1.0&#160;billion in 2023. The increase in cash used in financing activities was primarily due to increased principal payments on our Revolving Credit Facility and Term Loan Facility of $398.8&#160;million and $130.8 million, respectively, coupled with a reduction in proceeds of $578.0 million under our Revolving Credit Facility, partially offset by a decrease in purchases of treasury stock of $82.1 million in the current year and an increase of $8.4 million in proceeds from the sale of stock under our ATM program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:4.5pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has $868.4&#160;million of fixed and variable rate debt with varying maturities, with $418.4&#160;million payable within 12 months (see Note 10, "Debt" in the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K).</span></div><div style="margin-bottom:7pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Uncertainties and Trends Affecting Funding Requirements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to fund our short-term and long-term anticipated operating expenses, capital expenditures and debt service requirements from the following sources:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">existing cash and cash equivalents;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">net proceeds from the sale of our products and bioservices;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">development contracts and grant funding; </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">proceeds from the sale of our common stock through the ATM Program; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">our Senior Secured Credit Facilities and any replacement or other lines of credit we may establish from time to time.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous risks and uncertainties associated with product sales and with the development and commercialization of our product candidates. We may seek additional external financing to provide additional financial flexibility. Our future capital requirements will depend on many factors, including (but not limited to):</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the level, timing and cost of product sales and bioservices;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the payment obligations under our indebtedness;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the scope, progress, results and costs of our development activities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">the costs of commercialization activities, including product marketing, sales and distribution.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans, collaboration and licensing arrangements, cost reductions, assets sales or a combination of these options. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds by issuing equity securities, including through the ATM Program, our stockholders may experience dilution. Public or bank debt financing, if available, may involve agreements that include covenants, like those contained in our 3.875% Senior Unsecured Notes due 2028 (the &#8220;Senior Unsecured Notes&#8221;) and the Senior Secured Credit Facilities, which could limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities, buying back shares or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions, including market volatility and adverse impacts on financial markets, may make it more difficult to obtain financing on attractive terms, or at all. Any new debt funding, if available, may be on terms less favorable to us than our Senior Secured Credit Facilities or the Senior Unsecured Notes. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Unused Credit Capacity</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available room under the Revolving Credit Facility as of December&#160;31, 2023 and December&#160;31, 2022 was:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Capacity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding Letters of Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding Indebtedness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unused Capacity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contractual Obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has contractual obligations related to lease arrangements and purchase commitments. The lease arrangements are for certain equipment and facilities. As of December&#160;31, 2023, the Company had fixed lease payment obligations of $20.4 million, with $4.3 million due within 12 months. The Company has non-cancelable purchase commitments of $526.9 million, with an estimated $117.0 million being due within 12 months. </span></div><div id="i7b0776f670624692b261a662f247fc47_55"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements and related disclosures are prepared in accordance with US GAAP, which requires management to make estimates, judgments and assumptions that affect the amounts reported. Note 2, &#8220;Summary of significant accounting policies&#8221; of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K describes the accounting policies and methods used in the preparation of the Company&#8217;s consolidated financial statements. Management considers an accounting policy to be critical if it is important to reporting our financial condition and results of operations, and if it requires significant judgment and estimates on the part of management in its application. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes the Company&#8217;s critical accounting policies and estimates are those related to revenue recognition, contingent consideration, and income taxes. </span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's product sales are recognized at a point-in-time generally upon delivery to the customer, depending on the performance obligation which the Company is delivering. The Company's Bioservices arrangements are generally recognized on a percentage of completion basis utilizing a cost-to-cost method. Revenues are recognized as a percentage of the work completed during the period in an amount that reflects the percentage of the consideration which the Company expects to receive in exchange for the product or services.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with multiple performance obligations, the Company allocates the contract price to each performance obligation on a relative standalone selling price basis using the Company&#8217;s best estimate of the standalone selling price of each distinct product or service in the contract. Certain contracts may include lease components which are recognized under Accounting Standards Codification ("ASC") 842. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price based on the best available information. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCM product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with customers. The Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Estimates of variable consideration includes allowances for returns, specialty distributor fees, wholesaler fees, prompt payment discounts, government rebates, chargebacks and rebates under managed care plans. Revenues from sales of MCM products is recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. Provisions for variable consideration revenues from sales of products are recorded at the net sales price. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC customer contracts are fixed price contracts. For that majority of the Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC contract, the Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for these NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC arrangements are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration includes allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC may also be sold on consignment through third-party online retailers where revenues are recognized point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as selling general &amp; administrative expenses and cost of commercial product sales, respectively, in the Consolidated Statement of Operations. Revenues from NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC, including inventory levels within the distribution channel and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenues, refer to Note 13, "Revenue recognition" in the Notes to Consolidated Financial Statements in Part II, Item 8. of this Form 10-K. </span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company's acquisitions accounted for as business combinations, the Company records contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones at fair value, as applicable. The fair value model used to calculate these obligations is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales and achievement of the milestones. The inputs the Company uses for determining the fair value of the contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones are Level 3 fair value measurements. The Company re-evaluates the fair value of contingent consideration on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales and/or the achievement of development and regulatory milestones.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based royalties, sales-based milestones and development and regulatory milestones. We assess whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date. For additional information on the Company's contingent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration, refer to Note 8, "Fair value measurements" in the Notes to Consolidated Financial Statements in Part II, Item 8. of this Form 10-K. </span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and R&amp;D tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax expense, deferred tax assets and liabilities and liabilities for unrecognized tax benefits reflect management&#8217;s best assessment of estimated current and future taxes to be paid. As tax laws are complex and subject to different interpretations, significant management judgement is required in (1) calculating the Company's income tax expense, deferred tax assets and deferred tax liabilities, (2) determining any valuation allowance recorded against deferred tax assets and (3) evaluating the amount of unrecognized tax benefits, as well as the interest and penalties related to such uncertain tax positions. The Company's estimates and assumptions may differ from tax benefits ultimately realized. For additional information on the Company's income taxes, refer to Note 15, "Income taxes" in the Notes to Consolidated Financial Statements in Part II, Item 8. of this Form 10-K.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill and long-lived assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our goodwill for impairment annually as of the first day of the fourth quarter and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. We assess our goodwill for impairment at the reporting unit level.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the evaluation of goodwill for potential impairment, we exercise judgment to:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Perform a qualitative assessment to determine whether it is &#8220;more likely than not&#8221; that the fair value of a reporting unit is less than it&#8217;s carrying value. Factors we consider when making the determination include assessing macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and other relevant reporting unit specific events;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Decide whether to bypass the qualitative assessment and perform a quantitative assessment. Factors we consider when making this determination include changes in the Company or general economic conditions since the previous quantitative assessment was performed, the amount by which the fair value exceeded the carrying value at that time and the period of time that has passed since such quantitative assessment; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Perform a quantitative assessment by comparing the estimated fair value of the reporting unit with the carrying amount of that reporting unit. We estimate fair value using a combination of an income approach (based on discounted cash flows) and market approach, using appropriate weighting factors.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flows employed in the income approach are based on our most recent forecasts, budgets and business plans, as well as various growth rate assumptions for years beyond the current business plan period, discounted using an estimated weighted average cost of capital, which reflects an assessment of the risk inherent in the future revenue streams and cash flows. In the market approach, we utilize market multiples derived from comparable guideline companies and comparable market transactions to the extent available. These valuations are based on estimates and assumptions, including projected future cash flows, determination of appropriate comparable guideline companies and the determination of whether a premium or discount should be applied to such comparable guideline companies.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of evaluating the potential impairment of goodwill requires significant judgment and estimates. In 2023, due to triggering events in the respective quarters, we performed interim impairment tests during the second and third quarter for the MCM reporting unit. The results of the test performed during the second quarter, which yielded no impairment of goodwill. The results of the test performed during the third quarter indicated that for our MCM reporting unit, an impairment existed. As a result, the Company recorded a $218.2&#160;million non-cash goodwill impairment charge for the MCM reporting unit within the Products segment, reducing the goodwill balance to zero across all reporting units.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets such as finite lived intangible assets and property, plant and equipment are not required to be tested for impairment annually, instead they are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans or changes in anticipated future cash flows. If an impairment indicator is present, we evaluate recoverability of assets to be held and used by a comparison of the carrying value of the assets with future undiscounted net </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash flows expected to be generated by the assets. We group assets at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset group, we estimate the fair value of the asset group to determine whether an impairment loss should be recognized. Impairment would then be measured as the excess of the asset&#8217;s carrying value over its fair value. Fair value is typically determined by discounting the future cash flows associated with that asset. Significant judgments used for long-lived asset impairment assessments include identifying the appropriate asset groupings and primary assets within those groupings, determining whether events or circumstances indicate that the carrying amount of the asset may not be recoverable, determining the future cash flows for the assets involved and assumptions applied in determining fair value, which include, reasonable discount rates, growth rates, market risk premiums and other assumptions about the economic environment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, due to deterioration in performance and resulting downward revisions to our internal Bioservices forecast made during the second quarter, including future expected cash flows, the Company determined there were sufficient indicators of impairment on certain asset groups within the Bioservices reporting unit to require an impairment analysis. As a result, the Company performed recoverability tests on certain asset groups within the Bioservices reporting unit and concluded that the impacted asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values. Based on this analysis, the Company recorded a non-cash impairment charge of $306.7&#160;million during 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant New Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, &#8220;Summary of significant accounting policies&#8221; in the Notes to Consolidated Financial Statements in Part II, Item 8. of this Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of additional risks arising from our operations, see &#8220;Item&#160;1A&#8212;Business&#8212;Risk Factors&#8221; in this&#160;2023&#160;Annual Report.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Risks</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have interest rate and foreign currency market risk. Because of the short-term maturities of our cash and cash equivalents, we believe that an increase in market rates would likely not have a significant impact on the realized value of our investments.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have debt with a mix of fixed and variable rates of interest. We terminated our interest rate swaps in June 2023, and we are satisfied with the current fix-float mix of the Company's debt portfolio. Floating rate debt carries interest based generally on the eurocurrency rate, as defined in our senior secured credit agreement, as amended by the Credit Agreement Amendment, plus an applicable margin. Increases in interest rates could result in an increase in interest payments for our floating rate debt. See&#160;Note 10, "Debt" in the Notes to Consolidated Financial Statements in Part II, Item 8. of this Form 10-K. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may use derivative instruments to manage our interest rate risk and market risk exposure.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assessed our exposure to changes in interest rates by analyzing the sensitivity to our operating results assuming various changes in market interest rates. A hypothetical increase of one percentage point in the eurocurrency rate as of December&#160;31, 2023 would increase our interest expense by approximately $4.2 million annually.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to foreign currency exchange rate fluctuations worldwide and primarily with respect to the Euro, Canadian dollar, Swiss franc and British pound. We manage our foreign currency exchange rate risk primarily by either entering into foreign currency hedging transactions or incurring operating expenses in the local currency in the countries in which we operate, to the extent practicable. We currently do not hedge all of our foreign currency exchange exposure and the movement of foreign currency exchange rates could have an adverse or positive impact on our results of operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to Consolidated Financial Statements</span></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_1900">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_1900">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_64">Consolidated Balance Sheets for the years ended </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_64">December 31, 2023</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_64"> and </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_64">December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_64">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Statements of Operations for the years ended December 31, 2023, December 31, 2022 and December 31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_549755815963">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_70">Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2023, December 31, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_70">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_73">Consolidated Statements of Cash Flows for the years ended December 31, 2023, December 31, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_73">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_76">Consolidated Statements of </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_76">Changes in </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_76">S</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_76">tock</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_76">holders&#8217; Equity for the years ended December 31, 2023, December 31, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_76">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b0776f670624692b261a662f247fc47_79">96</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_1900"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Emergent BioSolutions Inc.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Emergent BioSolutions Inc. and subsidiaries (the Company) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes and financial statement schedule listed in the Index at Item 15 (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March&#160;8, 2024 expressed an unqualified  opinion thereon.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's Ability to Continue as a Going Concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to its Senior Secured Credit Facilities and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition - Allowance for product returns</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 2 and 13 to the consolidated financial statements, the Company recognized revenues of $487.5&#160;million for the year ended December&#160;31, 2023 related to the sale of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. For these product sales, revenue is recognized at a point in time, net of estimates of allowances, including allowances for product returns.  </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s measurement of allowances for returns of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales involved significant auditor judgment because the calculation involves subjective assumptions and estimates made by management, including historical return activity used to forecast expected returns and estimates of inventory levels within the distribution channel.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s process to measure the allowance for returns on NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales. For example, we tested controls over management&#8217;s review of the assumptions used in the calculation of the product returns allowance. We also tested management&#8217;s controls over the completeness and accuracy of the data used in the underlying calculations.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the calculation of the product returns allowance, our audit procedures included the following procedures, amongst others. We independently estimated the allowance for product returns using the Company&#8217;s historical data and compared the result to the Company&#8217;s estimated returns allowance, inspected contracts and related modifications with the Company&#8217;s customers to evaluate the Company&#8217;s standard returns policy, performed revenue cutoff testing to assess whether there were relevant factors at period end not considered in the Company&#8217;s analysis of product returns, and examined credit memos issued after year end for relevant factors or trends not consistent with the Company&#8217;s analysis of product returns. We also tested the Company's retrospective review of the accuracy of the allowance for returns on product revenue and compared the results of the retrospective review to the current year assumptions. </span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-36">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2004.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-37">Tysons, Virginia</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;8, 2024 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except per share data)</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-38">111.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-39">642.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-40">191.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-41">159.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-42">328.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-43">350.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-44">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-45">57.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="f-46">679.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-47">1,210.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-48">382.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-49">817.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-50">566.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-51">728.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-53">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-54">194.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-55">191.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-56">1,823.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-57">3,166.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-58">112.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-59">103.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-60">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-61">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-62">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-63">87.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Debt, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="f-64">413.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="f-65">957.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-66">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-67">45.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-68">651.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-69">1,228.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-70">446.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-71">448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-72">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-73">59.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-74">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-75">41.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-76">1,173.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-77">1,778.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-78"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-79">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-81">15.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-85">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-88"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-89">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-91">200.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-92">57.8</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-93">55.7</ix:nonFraction> shares issued; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-94">52.2</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-95">50.1</ix:nonFraction> shares outstanding, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-96">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-97">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-98">5.6</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-99">5.6</ix:nonFraction> common shares, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="f-100">227.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="f-101">227.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-102">904.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-103">873.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-104">5.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-105">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-106">21.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-107">738.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-108">649.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-109">1,387.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-110">1,823.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-111">3,166.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_549755815963"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except per share data)</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:47.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-112">497.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-113">386.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-114">438.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-115">447.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-116">579.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-117">585.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total Product sales, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-118">944.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-119">966.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-120">1,023.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Bioservices:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-121">72.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-122">105.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-123">310.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-124">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-125">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-126">305.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total Bioservices revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-127">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-128">109.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-129">615.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-130">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-131">41.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-132">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-133">1,049.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-134">1,117.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-135">1,773.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of Commercial Product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-136">210.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-137">160.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-138">187.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-139">305.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-140">264.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-141">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of Bioservices</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-142">189.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-143">268.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-144">365.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-145">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-146">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-147">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-148">306.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-151">111.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-152">188.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-153">235.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-154">368.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-155">339.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-156">348.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-157">65.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-158">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-159">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-160">1,775.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-161">1,287.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-162">1,432.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-163">726.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-164">170.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-165">341.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-166">87.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-167">37.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-168">34.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Gain on sale of business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-169">74.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-172">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-173">11.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-174">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-175">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-176">49.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-177">38.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-178">731.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-179">219.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-180">303.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-181">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-182">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-183">83.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-184">760.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-185">211.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-186">219.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Net income (loss) per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-187">14.85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-188">4.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-189">4.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-190">14.85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-191">4.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-192">4.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-193">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-194">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-195">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-196">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-197">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-198">54.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:47.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-199">760.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-200">211.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-201">219.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-202">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-203">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-204">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Unrealized gains (losses) on hedging activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-205">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-206">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-207">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses (gains) on hedging activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-208">8.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-209">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-210">5.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Reclassification adjustment for gains on pension benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" scale="6" id="f-211">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" scale="6" id="f-212">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" scale="6" id="f-213">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-214">8.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-215">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-216">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Comprehensive income (loss), net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-217">769.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-218">192.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-219">228.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_73"></div><hr style="page-break-after:always"/><div style="min-height:15.75pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.726%"><tr><td style="width:1.0%"/><td style="width:62.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-220">760.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-221">211.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-222">219.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-223">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-224">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-225">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-226">125.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-227">143.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-228">123.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent obligations, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-229">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-230">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-231">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-232">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-233">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-234">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-235">8.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-236">28.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-237">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of travel health business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-238">74.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-241">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-242">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-243">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-244">306.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write off of contract asset and liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnContractTermination" format="ixt:fixed-zero" scale="6" id="f-247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GainLossOnContractTermination" format="ixt:fixed-zero" scale="6" id="f-248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GainLossOnContractTermination" scale="6" id="f-249">17.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-250">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-251">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-252">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;text-indent:17.99pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-253">21.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-254">118.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-255">16.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-256">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-257">57.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-258">66.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-259">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-260">19.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-261">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-262">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-263">14.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-264">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-265">55.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-266">66.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-267">9.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term incentive plan accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual" scale="6" id="f-268">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual" format="ixt:fixed-zero" scale="6" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual" format="ixt:fixed-zero" scale="6" id="f-270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="f-271">10.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="f-272">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="f-273">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes receivable and payable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="f-274">16.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="f-275">28.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="f-276">31.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-277">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-278">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-279">31.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-280">206.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-281">34.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-282">320.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-283">51.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-284">115.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-285">224.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty settlement payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-287">21.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payment from prior asset acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" scale="6" id="f-289">6.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" format="ixt:fixed-zero" scale="6" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" format="ixt:fixed-zero" scale="6" id="f-291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:fixed-zero" scale="6" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="6" id="f-293">243.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:fixed-zero" scale="6" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of travel health business, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="f-295">270.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-298">212.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-299">381.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-300">224.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-302">82.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-303">106.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payments on convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="f-304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="f-306">10.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="f-307">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="f-308">598.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payments on revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="f-310">398.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="6" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="6" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payments on term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="f-313">164.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="f-314">33.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="f-315">25.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from stock-based compensation activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-316">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-317">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-318">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid for stock-based compensation activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-319">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-320">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-321">13.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from at-the-market sale of stock, net of commissions and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-322">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="f-327">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by (used in) financing activities:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-328">535.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-329">481.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-330">141.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-331">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-332">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-333">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-334">530.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-335">66.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-336">45.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-337">642.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-338">576.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-339">621.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-340">111.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-341">642.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-342">576.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-343">68.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-344">33.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-345">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-346">52.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-347">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-348">71.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment unpaid at period end</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-349">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-350">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-351">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock unpaid at period end</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:NoncashPurchasesOfTreasuryStock" format="ixt:fixed-zero" scale="6" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="ebs:NoncashPurchasesOfTreasuryStock" format="ixt:fixed-zero" scale="6" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="ebs:NoncashPurchasesOfTreasuryStock" scale="6" id="f-354">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on extinguishment of debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-355">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:6.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Changes in Stockholders' Equity</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except per share data)</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.791%"><tr><td style="width:1.0%"/><td style="width:21.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.242%"/><td style="width:0.1%"/></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-358"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-359"><ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-360">0.001</ix:nonFraction></ix:nonFraction></ix:nonFraction> Par Value</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">&#160;Common Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Treasury Stock</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-361">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-362">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-363">784.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-364">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-365">39.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-366">25.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-367">730.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-368">1,450.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-369">219.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-370">219.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-371">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-372">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Share-based compensation activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-373">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-374">44.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-375">44.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-376">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="f-377">112.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="f-378">112.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-379">55.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-380">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-381">829.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-382">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-383">152.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-384">16.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-385">950.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-386">1,611.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-387">211.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-388">211.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-389">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-390">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Share-based compensation activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-391">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-392">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-393">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-394">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="f-395">75.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="f-396">75.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-397">55.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-398">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-399">873.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-400">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-401">227.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-402">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-403">738.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-404">1,387.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-405">760.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-406">760.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-407">8.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-408">8.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Share-based compensation activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-409">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-410">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-411">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">At-the-market sale of stock, net of commissions and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-412">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-413">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-414">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-415">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-416">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-417">904.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-418">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-419">227.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-420">5.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-421">21.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-422">649.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollar and share amounts in tables expressed in millions, except per share data) </span></div><div id="i7b0776f670624692b261a662f247fc47_1099511629708"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-423" continuedAt="f-423-1" escape="true">Nature of the business and organization </ix:nonNumeric></span></div><ix:continuation id="f-423-1" continuedAt="f-423-2"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats ("PHTs"). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following <ix:nonFraction unitRef="category" contextRef="c-1" decimals="INF" name="ebs:NumberOfCategoriesOfPublicHealthThreats" format="ixt-sec:numwordsen" scale="0" id="f-424">four</ix:nonFraction> PHT categories: chemical, biological, radiological, nuclear and explosives ("CBRNE"); emerging infectious diseases ("EID"); emerging health crises; and acute, emergency and community care. The Company has a product portfolio of <ix:nonFraction unitRef="product" contextRef="c-1" decimals="INF" name="ebs:NumberOfRevenueGeneratingProducts" id="f-425">12</ix:nonFraction> products (vaccines, therapeutics, and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following <ix:nonFraction unitRef="category2" contextRef="c-1" decimals="INF" name="ebs:NumberOfProductAndServiceCategories" format="ixt-sec:numwordsen" id="f-426">four</ix:nonFraction> product and service categories: Anthrax - Medical Countermeasures (&#8220;MCM") Products, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial product, Smallpox - MCM products and Emergent Bioservices (CDMO) ("Bioservices").</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Beginning in the fourth quarter of 2023, the Company manages our business with a focus on <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-427">three</ix:nonFraction> operating segments: (1) a Commercial Products segment consisting of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray and other commercial products which were sold as part of our travel health business in the second quarter of 2023 (see Note 3, "Divestiture" for more information on the sale of the travel health business); (2) a MCM Products segment consisting of our Anthrax - MCM,  Smallpox - MCM and Other Products, described below and (3) a Services segment consisting of our Bioservices offerings (See Note 18, "Segment information</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" for more information on our reportable segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Products Segment:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA (including in over-the-counter form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Travel Health Business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;15, 2023, the Company completed the sale of its Commercial Products segment's travel health business, including rights to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed typhoid vaccine; Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#8217;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California. For additional information, refer to Note 3, "Divestiture".</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MCM Products Segment</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.14pt">Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the United States Food and Drug Administration (&#8220;FDA&#8221;) and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax vaccine adsorbed (AVA), adjuvanted), previously known as AV7909, which was recently approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bacillus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">anthracis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is procured by certain authorized government buyers for their use; and</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-423-2"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Smallpox - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Ebanga&#8482; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#8482;;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services Segment:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bioservices - CDMO</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations. These services, which we refer to as "molecule-to-market" offerings, employ diverse technology platforms (mammalian, microbial, viral and plasma) across a network of nine geographically distinct development and manufacturing sites operated by us for our internal products and pipeline candidates and third-party Bioservices. We service both clinical-stage and commercial-stage projects for a variety of third-party customers, including government agencies, innovative pharmaceutical companies, and non-government organizations. In August 2023, the Company initiated an organizational restructuring plan (the &#8220;August 2023 Plan&#8221;) which included actions to reduce investment in and de-emphasize focus on its Bioservices business.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-428" continuedAt="f-428-1" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="f-428-1" continuedAt="f-428-2"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation and consolidation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-429" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements are prepared in conformity with U.S. generally accepted accounting principles ("GAAP"). The accompanying consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Reclassifications of certain prior period amounts have been made to conform to the current period presentation.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared on the going concern basis of accounting, which assumes the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-430">219.2</ix:nonFraction>&#160;million outstanding on our senior revolving credit facility ("Revolving Credit Facility") and $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-431">198.2</ix:nonFraction>&#160;million on our senior term loan facility ("Term Loan Facility"</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that mature in May 2025. As of December 31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-432">111.7</ix:nonFraction> million in cash and cash equivalents. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The evaluation considered the potential mitigating effects of management&#8217;s plans that have not been fully implemented. Management has evaluated the mitigating effects of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern. Management's plans include (A) amending the Senior Secured Credit Facilities, and (B)  improving operating performance, reducing working capital and the potential of the sale of assets to pay down the Senior Secured Credit Facilities before they become due. As neither plan is in the complete control of Management, neither is probable of occurring. In this regard, management may not be able to find a buyer for the assets it is willing to divest and may not be able to close on any asset sale for which management is able to reach an agreement with a buyer, and as a result the Company may be unable to meet its obligations as they become due. In addition, any asset sales that are completed could have potential negative impacts on the Company's future operating cash flows and profitability.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt Covenants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities mature in May 2025, which provide for (1) revolving credit commitments, (2) a term loan, and (3) the issuance of commercial letters of credit. As of December 31, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-433">417.4</ix:nonFraction>&#160;million outstanding under the Senior Secured Credit Facilities. Under the Senior Secured Credit Facilities, the Company is subject to a monthly minimum consolidated EBITDA covenant through February 29, 2024, and is also required to raise at least $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="ebs:DebtInstrumentCovenantConsiderationThreshold" format="ixt:num-dot-decimal" scale="6" id="f-434">75.0</ix:nonFraction>&#160;million through the issuance of equity and/or unsecured indebtedness by April 30, 2024. Beginning with the quarter ended March 31, 2024, the Company is subject to a minimum consolidated debt service coverage ratio and a maximum consolidated leverage ratio covenant. As of December 31, 2023, the Company was not in compliance with the minimum consolidated EBITDA covenant under the Senior Secured Credit Facilities and did not expect to be able to raise the remaining of the $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="ebs:DebtInstrumentCovenantConsiderationThreshold" format="ixt:num-dot-decimal" scale="6" id="f-435">75.0</ix:nonFraction>&#160;million through the issuance of equity under the at-the-market equity offering program (the "ATM Program") that we entered into on May 18, 2023, by April&#160;30, 2024, as required by the requisite lenders. In addition, the Company is required to deliver audited annual financial statements without a &#8220;going concern&#8221; explanatory paragraph with respect to its financial statements for the year ended December 31, 2023, within 90-days of year end, while the financial statements included in this Annual Report contain an explanatory paragraph related to Going Concern. On February&#160;29, 2024, the requisite lenders agreed to enter into a &#8239;Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement (the &#8220;Forbearance Agreement and Amendment&#8221;), which includes a limited waiver of any defaults or events of default that result from (a) any violation of the financial covenants set forth in the Senior Secured Credit Facilities with respect to the fiscal quarter ending December 31, 2023 and the fiscal quarter ending March&#160;31, 2024 and (b) the going concern explanatory paragraph contained in the audited financial statements for the fiscal year ended December 31, 2023. This forbearance period will expire on the earlier to occur of (i) any other event of default and (ii) April&#160;30, 2024. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Senior Secured Credit Facilities. The Senior Secured Credit Facilities and the Company&#8217;s other debt facilities are described in more detail below in Note 10, &#8220;Debt&#8221;.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, acceleration of the repayment of the Senior Secured Credit Facilities would result in a cross-default of the Company&#8217;s obligations under the <ix:nonFraction unitRef="number" contextRef="c-70" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-436">3.875</ix:nonFraction>% Senior Unsecured Notes due in 2028. If the Company would be unable to obtain additional waivers or forbearance of such covenants or defaults, to successfully renegotiate the terms of the Senior Secured Credit Facilities, or to cure the potential covenant breach or default, and the lenders enforced one or more of their rights upon default and/or the default resulted in a cross-default under the <ix:nonFraction unitRef="number" contextRef="c-70" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-437">3.875</ix:nonFraction>% Senior Unsecured Notes due in 2028, the Company would be unable to meet its obligations under those agreements and could be forced into insolvency proceedings.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-428-2" continuedAt="f-428-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the facts and circumstances described above, there can be no assurance that the Forbearance Period will continue to remain in place, and that the Company would be able to comply with covenants in the future. As a result, the Company continues to evaluate a number of factors related to its ability to continue as a going concern, including its ability to comply with the terms and operating and financial covenants required by the Senior Secured Credit Facilities, its ability to satisfy the capital raise requirement, other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, and disruptions or volatility caused by factors such as regional conflicts, inflation, and supply chain disruptions. The Company has engaged legal and financial advisors to assist with a comprehensive review of alternatives to enhance its capital structure, which may include taking steps to cure any potential defaults or seeking forbearance, waivers, further cost reductions, asset sales or other alternatives to avoid an event of default.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-438" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make estimates, judgments and assumptions that affect reported amounts and disclosures in the consolidated financial statements and accompanying notes. Due to the inherent uncertainty involved in making those estimates, judgements and assumptions, actual results could differ from those estimates. Our most significant estimates relate to revenue recognitions and the assessment of the recoverability of goodwill, definite lived intangible assets and other long-lived assets. Other estimates include allowances for expected credit losses, inventory, depreciation and amortization, business combinations, contingent consideration, share-based compensation, income taxes, and other contingencies. Management continually re-evaluates its estimates, judgments and assumptions and basis its estimates on historical trends, projections, current experience and other assumptions that it believes are reasonable. These estimates are sometimes complex, sensitive to changes in assumptions and require fair value determinations using Level 3 fair value measurements.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-439" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Also, the Company maintains cash balances with financial institutions in excess of insured limits.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value measurements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-440" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs for identical assets or liabilities such as quoted prices in active markets;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs other than quoted prices in active markets that are either directly or indirectly observable; and</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#8217;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant customers and accounts receivable</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MajorCustomersPolicyPolicyTextBlock" id="f-441" continuedAt="f-441-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billed accounts receivable are stated at invoice amounts and consist of amounts due from the USG, commercial and Bioservices customers, as well as amounts due under reimbursement contracts with other government entities and non-government organizations. The Company's branded and generic opioid overdose reversal product, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, is sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-428-3" continuedAt="f-428-4"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-441-1">We maintain an allowance for expected credit losses, which represents the estimated aggregate amount of credit risk arising from the inability or unwillingness of specific customers to pay our fees or disputes that may affect our ability to fully collect our billed accounts receivable. We estimate the current-period provision for expected credit losses on a specific identification basis and we consider factors such as the age of the receivables balance, knowledge of the specific customers' circumstances and historical collection experience for similar customers. Amounts determined to be uncollectible are charged or written-off against the reserve. Accounts receivable, net of the allowance for expected credit losses, represents the amount we expect to collect. Our actual experience may vary from our estimates. At each reporting date, we adjust the allowance for expected credit losses to reflect our current estimate. Unbilled accounts receivable relates to various service contracts for which work has been performed and the Company has a right to bill but invoicing has not yet occurred. Contract assets include revenues recognized in advance of billings and the Company does not have a right to invoice the customer under the terms of the contract. The Company has receivables from contracts containing lease components. At each reporting period, the Company assesses whether it is probable that the Company will collect all future lease payments. The Company considers payment history and current credit status when assessing collectability. The Company does not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration Risk</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-442" escape="true"><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Customers</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has long-term contracts with the USG that expire at various times from 2024 through 2036. The Company has derived a significant portion of its revenue from sales of our Government - MCM products under contracts with the USG. The Company's current USG contracts do not necessarily increase the likelihood that it will secure future comparable contracts with the USG. The Company expects that a significant portion of the business will continue to be under government contracts that present a number of risks that are not typically present in the commercial contracting process. USG contracts for ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Anthrax Vaccines and other medical countermeasures products are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of its medical countermeasures products, including ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Anthrax Vaccines to customers in addition to the USG, which would harm their growth opportunities. The Company's commercial product sales, largely NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, are sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. Refer to Note 13, "Revenue recognition" for more information regarding significant customers. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company seeks to expand its customer base and to renew its agreements with its customers prior to expiration of a contract, a delay in securing a renewal or a failure to secure a renewal or securing a renewal on less favorable terms may have a material adverse effect on the Company&#8217;s financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable do not represent a significant concentration of credit risk. The USG accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="0" id="f-443">38</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-444">43</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-445">51</ix:nonFraction>% of total revenues for 2023, 2022 and 2021, respectively. The Company&#8217;s accounts receivable as of December&#160;31, 2023 and 2022, consist primarily of amounts due from the USG or other large multi-national highly reputable customers for product sales, Bioservices or from government agencies under government grants.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financial Institutions</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are maintained with several financial institutions. The Company has deposits held with banks that exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and, therefore, bear minimal credit risk.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lender Counterparties</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is lender counterparty risk associated with the Company's revolving credit facility and derivatives instruments. There is risk that the Company&#8217;s revolving credit facility investors and derivative counterparties will not be available to fund as obligated. If funding under the revolving credit facility is unavailable, the Company may have to acquire a replacement credit facility from different counterparties at a higher cost or may be unable to find a suitable replacement. The Company seeks to manage risks from its revolving credit facility and derivative instruments by contracting with experienced large financial institutions and monitoring the credit quality of its lenders. As of December&#160;31, 2023, the Company does not anticipate nonperformance by any of its counterparties.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-428-4" continuedAt="f-428-5"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories, net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-446" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value with cost being determined using a standard cost method, which approximates actual cost. Actual cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. The Company records inventory acquired in business combinations utilizing the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to short-dated, contaminated or expired inventory. Inventory reserves for write-downs are relieved when the inventory is disposed of through scrap or sale.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pre-launch inventory</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the Company's Commercial Products and MCM Products segments costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and the Company believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, the Company considers a number of specific facts and circumstances, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a Bioservices contract as Bioservices pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, plant and equipment, net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-447" continuedAt="f-447-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost less accumulated depreciation and impairments. subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes internal-use software when both (a) the software is internally developed, acquired, or modified solely to meet the entity&#8217;s internal needs and (b) during the software&#8217;s development or modification, no substantive plan either exists or is being developed to market the software externally. Capitalization of qualifying internal-use software costs begins when the preliminary project stage is completed, management with the relevant authority, implicitly or explicitly, authorizes and commits to the funding of the software project, and it is probable that the project will be completed and the software will be used to perform the function intended.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-448" continuedAt="f-448-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally depreciates or amortizes the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.388%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-74" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-449">31</ix:nonNumeric>-<ix:nonNumeric contextRef="c-75" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-450">39</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-76" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-451">10</ix:nonNumeric>-<ix:nonNumeric contextRef="c-77" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-452">39</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-78" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-453">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-79" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-454">15</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-80" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-455">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-81" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-456">7</ix:nonNumeric> years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of the asset life or lease term</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the property, plant and equipment acquired in a business combination utilizing either the cost approach or the sales comparison approach. The cost approach is determined by establishing replacement cost of the asset and </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-428-5" continuedAt="f-428-6"><ix:continuation id="f-447-1"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach determines an asset is equal to the market price of an asset of comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.</span></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income taxes</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-457" continuedAt="f-457-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and research and development ("R&amp;D") tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax effects of transactions reported in different periods for financial reporting and income tax return purposes are recognized under the asset and liability method of accounting for income taxes. This method gives consideration to the future tax consequences of the deferred income tax items and immediately recognizes changes in income tax laws in the year of enactment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. The Company considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if the Company determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, the Company will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to income taxes in the period in which the determination is made. Likewise, if the Company determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, the Company will establish a valuation allowance against deferred tax assets, with an offsetting increase to income taxes, in the period in which the determination is made.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under sections 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a "loss corporation", as defined therein, there are annual limitations on the amount of net operating losses and deductions that are available. The Company has recognized the portion of net operating losses and R&amp;D tax credits acquired that will not be limited and are more likely than not to be realized.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because tax laws are complex and subject to different interpretations, significant judgment is required. As a result, the Company makes certain estimates and assumptions, in (1)&#160;calculating the Company's income tax expense, deferred tax assets and deferred tax liabilities, (2)&#160;determining any valuation allowance recorded against deferred tax assets and (3)&#160;evaluating the amount of unrecognized tax benefits, as well as the interest and penalties related to such uncertain tax positions. The Company's estimates and assumptions may differ from tax benefits ultimately realized.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Impairment Analysis</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="f-458" continuedAt="f-458-1" escape="true"><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill and Indefinite-lived Intangible Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized but is reviewed for impairment. Goodwill is allocated to the Company's reporting units, which are components of our business for which discrete cash flow information is available one level below its operating segment. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and at interim if an event or other circumstance indicates that we may not recover the carrying value of the asset. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative goodwill impairment test is performed using a one-step process. The process is to compare the fair value of a reporting unit with its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not impaired. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the reporting unit is impaired and an impairment loss is recognized in an amount equal to that excess up to the total amount of goodwill included in the reporting unit. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company has material indefinite lived intangible assets associated with in-process research and development ("IPR&amp;D"), a qualitative assessment is performed. If the qualitative assessment indicates that it is not more likely than not that the fair value of the indefinite lived intangible asset exceeds its carrying amount, the Company compares the estimated fair value of the intangible with its carrying value. If the carrying value of the intangible asset exceeds its fair value, an impairment loss is recognized </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-428-6" continuedAt="f-428-7"><ix:continuation id="f-458-1"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in an amount equal to that excess. Determining fair value requires the exercise of judgment about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows (see Note 7, "Intangible assets and goodwill"). </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Long-lived Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, they are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when the disposal of such assets is likely or there is an adverse change in the market involving the business employing the related assets. If an impairment analysis is required, the impairment test employed is based on whether the Company&#8217;s intent is to hold the asset for continued use or to hold the asset for sale. If the intent is to hold the asset for continued use, the impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. If the carrying value of the asset exceeds the undiscounted cash flows, the asset would not be deemed to be recoverable. Impairment would then be measured as the excess of the asset&#8217;s carrying value over its fair value. Fair value is typically determined by discounting the future cash flows associated with that asset. If the intent is to hold the asset for sale and certain other criteria are met, the impairment test involves comparing the asset&#8217;s carrying value to its fair value less costs to sell. To the extent the carrying value is greater than the asset&#8217;s fair value less costs to sell, an impairment loss is recognized in an amount equal to the difference. Significant judgments used for long-lived asset impairment assessments include identifying the appropriate asset groupings and primary assets within those groupings, determining whether events or circumstances indicate that the carrying amount of the asset may not be recoverable, determining the future cash flows for the assets involved and assumptions applied in determining fair value, which include, reasonable discount rates, growth rates, market risk premiums and other assumptions about the economic environment.</span></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><ix:nonNumeric contextRef="c-1" name="ebs:ContingentConsiderationObligationsPolicyTextBlock" id="f-459" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company's acquisitions accounted for as business combinations, the Company records contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones at fair value. The fair value model used to calculate these obligations is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales and achievement of the milestones. The inputs the Company uses for determining the fair value of the contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales and/or the achievement of development and regulatory milestones. Any future increase or decrease in the fair value of the contingent consideration associated with sales-based royalties and sales-based milestones along with development and regulatory milestones are based on an assessment of the likelihood that the underlying net sales or milestones will be achieved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The associated payments which will become due and payable for sales-based royalties and milestones result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of contingent consideration associated with sales-based royalties and sales-based milestones will result in a reduction in cost of product sales. The changes in fair value for potential future sales-based royalties associated with product candidates in development will result in a charge to cost of product sales in the period in which the increase is determined. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based royalties, sales-based milestones and development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date.</span></div></ix:nonNumeric><div style="margin-bottom:7pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-460" continuedAt="f-460-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for corporate offices, R&amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases with future minimum lease payments in excess of 12 months and total lease payments greater than $0.4&#160;million are included in right-of-use ("ROU") assets and liabilities. The Company has elected to record expense on a cash basis for leases with minimum lease payments of 12 months or less and/or total lease payments less $0.4&#160;million. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-428-7" continuedAt="f-428-8"><ix:continuation id="f-460-1"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately.</span></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-461" continuedAt="f-461-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services by analyzing the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Multiple performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the products or services promised in a contract and identifies a performance obligation for each promise to transfer to the customer a product or service that is distinct, including evaluating whether the contract includes a customer option for additional goods or services which could represent a material right. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. Contracts sometimes include more than one product, a lease, or options for customers to purchase additional products or services in the future for free or at a discount, which gives rise to separate performance obligations. For contracts with multiple performance obligations, the Company allocates the contract price to each performance obligation on a relative standalone selling price basis using the Company&#8217;s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts&#8217; inception. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Transaction price and variable consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the performance obligations in the contract have been identified, the Company estimates the transaction price of the contract. The estimate includes amounts that are fixed as well as those that can vary based on expected outcomes of the activities or contractual terms. The Company's variable consideration includes net profit received from sales of the Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, certain products sold on a net basis, cost-plus-fee contract terms and consideration transferred under its development contracts as consideration received can vary based on developmental progression of the product candidate. When a contract's transaction price includes variable consideration, the Company evaluates the variable consideration to determine whether the estimate needs to be constrained; therefore, the Company includes the variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration estimates are updated at each reporting date. There were no significant constraints or material changes to the Company's variable consideration estimates as of or during the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product sales</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our product sales, we recognize revenue at a point in time when the Company&#8217;s performance obligations have been satisfied and control of the products transfer to the customer. To indicate the transfer of control the Company will have a present right to payment, legal title must have passed to the customer, and the customer must have the significant risks and rewards of ownership. This point in time depends on several factors, including delivery, transfer of legal title, transition of risk and rewards of the product to the customer and the Company's right to payment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contracts for the sale of the Company's Government - MCM products include certain acceptance criteria before title passes to the customer. The primary customer for the Company's Government - MCM products and the primary source of funding for the development of its MCM product candidate portfolio is the USG. The USG contracts for the sale of the Company's Government - MCM products are normally multi-year contracts with annual options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCM product revenue is recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. Provisions for variable consideration revenues from sales of MCM products are recorded at the net sales price. Calculating certain of these provisions involves estimates and judgments and the Company determines their expected value based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs&#8217; regulations and guidelines that would impact the amount of the actual rebates, the Company's expectations regarding future utilization rates for these programs and channel inventory data. These provisions reflect the Company's best estimate of the amount of consideration to which the Company is </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-461-1" continuedAt="f-461-2"><ix:continuation id="f-428-8" continuedAt="f-428-9"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entitled based on the terms of the contract. The Company reassesses the Company's provisions for variable consideration at each reporting date.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over-the-counter ("OTC") customer contracts are fixed price contracts. For that majority of the Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC contract, the Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for these NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC arrangements are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration includes allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC may also be sold on consignment through third-party online retailers where revenues are recognized point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as selling general &amp; administrative expenses and cost of commercial product sales, respectively, in the Consolidated Statement of Operations. Revenues from NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC, including inventory levels within the distribution channel and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bioservices</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs it's Bioservices offerings for third parties. Under these contracts, activities can include drug substance and drug product manufacturing services for injectable and other sterile products, and development services such as pharmaceutical product process development, process design, technology transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging, stability studies, and suite-reservations. These contracts vary in duration, activities, and number of performance obligations. Performance obligations identified under these arrangements may include drug substance and/or drug product manufacturing, technology transfer activities, and suite-reservations. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug substance, drug product manufacturing, development services and technology transfer performance obligations are recognized as revenue over-time because the Company&#8217;s performance does not create an asset with an alternative use and the Company has an enforceable right to payment for performance completed as work is performed. In drug product arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (API), that is used in the manufacturing process; in drug substance arrangements, the customer provides certain seed material that is used in the manufacturing process. The transaction price generally contains both a fixed and variable component. The fixed component is stated in the agreement as a fixed price per unit with no contractual provision for a refund or price concession and the variable component generally results from pass-through costs that are billed at cost-plus over the life of the contract. The Company uses an input method to measure progress toward the satisfaction of the related performance obligations based on costs incurred as a percentage of total costs to complete which the Company believes best depicts the transfer of control of goods or services promised to its customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suite reservations are classified as leases when the customer directs the use of the identified suite and obtains substantially all the economic benefits from the manufacturing capacity. If a customer reserves more than one suite, the allocation of contract value is based on relative selling price which varies due to size, location, capacity, production capability for drug product or drug substance, and the time of planned use. The associated revenue is recognized on a straight-line basis over the period of performance. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling price basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Bioservices customer contracts generally include provisions entitling the Company to a termination penalty when the contract is terminated prior to the contract&#8217;s nominal end date. The termination penalties in the customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated duration of the contract. The Company accounts for a contract cancellation as a contract modification. The determination of the contract termination penalty is based on the terms stated in the related customer agreement. As of the modification date, the Company updates its estimate of the transaction price, subject to constraints, and recognizes the amount over the remaining performance period or measure of progress under the arrangement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts that contain lease components, the Company assesses the collectability of the lease payments. If the collectability of the lease payments is probable, the Company recognizes lease income over the term of the lease on a straight-line basis. If collectability is not deemed probable at any time during the term of the lease, the Company&#8217;s lease income is limited to the lesser of (i) the lease payments that have been collected from the lessee, or the straight-line recognition of the contract value. If the collectability assessment changes to probable after the Company has determined collectability is not deemed probable, any difference between the lease income that would have been recognized if collectability had always been assessed as probable and the lease income recognized to date is recognized as a current-period adjustment to lease income. Changes to the collectability of operating leases are recorded as adjustments to lease income in the Consolidated Statements of Operations in the period that they occur.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-428-9" continuedAt="f-428-10"><ix:continuation id="f-461-2" continuedAt="f-461-3"><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contracts and grants</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-461-3">The Company generates contract and grant revenue primarily from cost-plus-fee contracts associated with development of certain product candidates. Revenues from reimbursable contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company uses this input method to measure progress as the customer has access to the development research under these projects and benefits incrementally as R&amp;D activities occur. When applicable, the Company considers fixed fees under cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract, the cost-to-cost measure of progress. The Company analyzes costs for contracts and reimbursable grants to ensure reporting of revenues gross versus net is appropriate. The USG contracts for the development of the Company's MCM product candidates are normally multi-year contracts.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-462" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses R&amp;D costs as incurred. The Company's R&amp;D expenses consist primarily of:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">personnel-related expenses;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of the Company's clinical trials and obtaining and evaluating data from the Company's clinical trials and non-clinical studies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of Bioservices for clinical trial material; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of materials intended for use and used in clinical trials and R&amp;D.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive income (loss)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-463" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is comprised of net income (loss) and other changes in equity that are excluded from net income (loss). The Company includes translation gains and losses incurred when converting its subsidiaries' financial statements from their functional currency to the U.S. dollar in accumulated other comprehensive income (loss) as well as gains and losses on its pension benefit obligation and derivative instruments.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Translation and remeasurement of foreign currencies</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-464" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income (loss) and are recorded in accumulated other comprehensive income (loss), a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are remeasured at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are remeasured at current rates of exchange as of the balance sheet date. Income and expense items are remeasured at the average foreign currency rates for the period. Remeasurement adjustments of these subsidiaries are included in "Other income (expense), net" in our Consolidated Statements of Operations.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) per common share</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-465" escape="true">Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive.</ix:nonNumeric> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury stock</span></div><ix:nonNumeric contextRef="c-1" name="ebs:TreasuryStockPolicyTextBlock" id="f-466" continuedAt="f-466-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When stock is acquired for purposes other than formal or constructive retirement, the purchase price of the acquired stock is recorded in a separate treasury stock account, which is separately reported as a reduction of equity.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When stock is retired or purchased for formal or constructive retirement, the purchase price is initially recorded as a reduction to the par value of the shares repurchased, with any excess purchase price over par value recorded as a reduction to additional paid-in capital related to the series of shares repurchased and any remainder excess purchase price recorded as a reduction to retained earnings. If the purchase price exceeds the amounts allocated to par value and additional paid-in capital related to the series of shares repurchased and retained earnings, the remainder is allocated to additional paid-in capital related to other series of shares.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the cost of treasury stock that is either sold or reissued, the Company uses the last in, first out method. If the proceeds from the re-issuance of treasury stock are greater than the cost, the excess is recorded as additional paid-in capital. If the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-428-10" continuedAt="f-428-11"><ix:continuation id="f-466-1"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from re-issuance of treasury stock are less than the cost, the excess cost first reduces any additional paid-in capital arising from previous treasury stock transactions for that class of stock, and any additional excess is recorded as a reduction of retained earnings.</span></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for share-based compensation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-467" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="plan" contextRef="c-4" decimals="INF" name="ebs:NumberOfShareBasedEmployeeCompensationPlans" format="ixt-sec:numwordsen" id="f-468">two</ix:nonFraction> share-based employee compensation plans, the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "Emergent Plan") and the Emergent BioSolutions, Inc. Inducement Plan (the "Inducement Plan") under which the Company may grant various types of equity awards including stock options, restricted stock units and performance stock units. For all of our share-based awards, the Company recognizes forfeitures and compensation costs when they occur. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2023, the Company's Board of Directors adopted and approved the Emergent BioSolutions, Inc. Inducement Plan, pursuant to which the Company may from time to time make equity grants to individuals not previously an employee or director of the Company or any of its subsidiaries (or following a bona fide period of interruption of employment) as a material inducement to their employment by the Company. The Inducement Plan was adopted by the board of directors without stockholder approval pursuant to New York Stock Exchange Listing Rule 303A.08. The board of directors reserved <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="f-469">5.0</ix:nonFraction> million shares of the Company's common stock for issuance under the Inducement Plan. The terms and conditions of the Inducement Plan are substantially similar to the Company's stockholder-approved Emergent Plan as discussed below.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plan is determined by the compensation committee of the Company's board of directors, which administers the Emergent Plan. Each equity award granted under the Emergent Plan vests as specified in the relevant agreement with the award recipient and no option can be exercised after <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-470">seven years</ix:nonNumeric> from the date of grant. The Company records the estimated fair value of awards in expense on a straight-line basis over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), the Company estimates and recognizes expense based on the period from the grant date to the date the employee becomes retirement eligible.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of restricted stock units using the closing market price of the Company's common stock on the day prior to the date of grant. The Company's performance stock units settle in the Company's stock. The fair value is determined on the date of the grant using the number of shares expected to be earned and the ending market value of the stock on the day prior to the grant date. The number of shares expected to vest is adjusted each reporting period by assessing the probability that the performance criteria will be met and the associated targeted payout level that is forecasted will be achieved. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below is a discussion of the Company's methodology for developing each of the assumptions used:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Expected dividend yield &#8212; the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Expected volatility &#8212; a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. The Company analyzed its own historical volatility to estimate expected volatility over the same period as the expected average life of the options.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Risk-free interest rate &#8212; the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Expected average life of options &#8212; the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of option exercise behavior subsequent to vesting of options.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pension plans</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy" id="f-471" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically maintained a defined benefit plan for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The Company's defined benefit plan was included in the sale of the travel health business on May 15, 2023. See Note 3, "Divestiture" for more information. The plan was valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increase, and pension adjustments. The Company reviewed its actuarial assumptions on an annual basis and made modifications to the assumptions based on current rates and trends. Actuarial gains and losses were deferred in accumulated other comprehensive income (loss), net of tax and were amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return were amortized to net periodic benefit cost over the estimated remaining life as a component of selling, general and administrative expenses in the Consolidated Statements of Operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-428-11"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative instruments and hedging activities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-472" continuedAt="f-472-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. From time to time, the Company enters into interest rate swaps to manage exposures that arise from the Company's payments of variable interest rate debt under its senior secured credit agreements. The objective and strategy with respect to these interest rate swaps is to protect the Company against adverse fluctuations in interest rates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, the Company terminated its designated interest rate swap transactions with a total notional value of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-473">350.0</ix:nonFraction>&#160;million. Hedge accounting was also discontinued at that time. As of December 31, 2023, all accumulated other comprehensive income associated with the terminated interest rate swaps was amortized to earnings over the remaining term of the interest rate swaps prior to termination.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy. See Note 9, "Derivative instruments and hedging activities" for further details on the interest rate swaps. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-474" escape="true"><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards board ("FASB") issued Accounting Standards Update ("ASU") 2023-07 ("ASU 2023-07"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which improves reportable segment disclosure requirements, on an annual and interim basis, primarily through enhanced disclosures about significant segment expenses. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker ("CODM"). The ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The amendments in the ASU are effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires a public business entity ("PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on it consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i7b0776f670624692b261a662f247fc47_1099511629538"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-475" continuedAt="f-475-1" escape="true">Divestiture </ix:nonNumeric></span></div><ix:continuation id="f-475-1" continuedAt="f-475-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, pursuant to the Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;), by and between the Company, through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc., and Bavarian Nordic (&#8220;Bavarian Nordic&#8221;), the Company completed the previously announced sale of the Company&#8217;s travel health business, including rights to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed typhoid vaccine; Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#8217;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, Bavarian Nordic paid a cash purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-476">270.2</ix:nonFraction>&#160;million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing. Bavarian Nordic may also be required to pay </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-475-2"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-477">80.0</ix:nonFraction>&#160;million related to the development of CHIKV VLP and receipt of marketing approval and authorization in the U.S. and Europe, and earn-out payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-478">30.0</ix:nonFraction>&#160;million based on aggregate net sales of Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in calendar year 2026.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the divestiture, during the year ended December 31, 2023, the Company recognized a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-479">74.2</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:DispositionOfBusinessTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-480">4.0</ix:nonFraction>&#160;million recorded within "Gain on sale of business" on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the disposal of the travel health business does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on our operations and financial results. No adjustments were made to prior period results as a result of the disposal. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture, the Company entered into a Transition Services Agreement (&#8220;TSA&#8221;) with Bavarian Nordic to help support its ongoing operations. Under the TSA, the Company provides certain transition services to Bavarian Nordic, including information technology, finance and enterprise resource planning, research and development, human resources, employee benefits and other limited services. Income from performing services under the TSA was recorded within "Other, net" on the Consolidated Statements of Operations and was $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-481">3.2</ix:nonFraction>&#160;million for the year ended December 31, 2023.</span></div></ix:continuation><div id="i7b0776f670624692b261a662f247fc47_1099511629727"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-482" continuedAt="f-482-1" escape="true">Long-lived asset impairment and restructuring charges</ix:nonNumeric></span></div><ix:continuation id="f-482-1" continuedAt="f-482-2"><div style="margin-bottom:7pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Impairment of long-lived assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its long-lived assets that are held and used for recoverability whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, due to deterioration in performance and resulting downward revisions to our internal Bioservices forecast made during the second quarter, including future expected cash flows, the Company determined there were sufficient indicators of impairment on certain asset groups within the Bioservices reporting unit to require an impairment analysis. As a result, the Company performed recoverability tests on certain asset groups within the Bioservices reporting unit and concluded that the impacted asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset groups are written down only to the extent that their carrying value is higher than their respective fair value. The Company, with the assistance of a third-party valuation firm, applied valuation methods to estimate the fair values for each of the assets within the different asset classes. An orderly liquidation value was applied to estimate the fair value of the personal property assets and market and cost based approaches were applied to estimate the fair value of the real property assets. All of the valuation approaches applied represented Level 3 non-recurring fair value measurements. Based on this analysis, the Company allocated and recognized a non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-483">306.7</ix:nonFraction>&#160;million during the year ended December 31, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" id="f-484" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the total impairment charge by asset class for the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-485">81.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-486">117.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-487">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-488">107.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total impairment of long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-489">306.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">January 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company initiated an organizational restructuring plan (the &#8220;January 2023 Plan&#8221;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. As part of the January 2023 Plan, the Company reduced its workforce by approximately <ix:nonFraction unitRef="employee" contextRef="c-92" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-490">125</ix:nonFraction> employees. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-491">9.3</ix:nonFraction>&#160;million in charges during the year ended December 31, 2023. These charges consist primarily of charges related to employee transition, severance payments and employee benefits. All activities related to the January 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-482-2"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">August 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company initiated the August 2023 Plan intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its Bioservices business for future growth. As part of the August 2023 Plan, the Company reduced its workforce by approximately <ix:nonFraction unitRef="employee" contextRef="c-94" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-492">400</ix:nonFraction> employees. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-493">20.0</ix:nonFraction>&#160;million in charges in connection with the August 2023 Plan during the year ended December 31, 2023. These charges consist primarily of charges related to severance payments, transition services, and employee benefits. All activities related to the August 2023 Plan were substantially completed during the third quarter of 2023. Restructuring costs are recognized as an operating expense within the Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-494" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs associated with the Company&#8217;s segments as well as unallocated corporate and research and development ("R&amp;D") charges for the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.427%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Commercial Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-496">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-497">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total restructuring costs by segment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-498">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-499">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-500">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-501">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs, by function, for the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.150%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Employee transition</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-502">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Severance payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-503">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-504">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-505">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-506" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of and changes in the Company's restructuring accrual for the January 2023 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-511">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-512">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-513">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-514">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-515">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-516">7.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-517">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-518">7.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-520">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-522">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of and changes in the Company's restructuring accrual for the August 2023 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-527">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-528">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-529">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-530">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-531">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-532">13.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-533">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-534">14.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-536">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-537">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-538">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-539" continuedAt="f-539-1" escape="true">Inventories, net</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-540" escape="true"><ix:continuation id="f-539-1" continuedAt="f-539-2"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="f-541">128.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="f-542">142.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-543">113.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-544">116.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-545">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-546">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-547">328.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-548">350.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-539-2">Inventories, net is stated at the lower of cost or net realizable value.</ix:continuation> </span></div><div id="i7b0776f670624692b261a662f247fc47_94"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-549" continuedAt="f-549-1" escape="true">Property, plant and equipment, net </ix:nonNumeric></span></div><ix:continuation id="f-549-1"><ix:continuation id="f-448-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consists of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023 </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Land and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-550">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-551">54.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-552">229.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-553">327.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-554">433.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-555">567.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-556">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-557">65.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-558">36.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-559">185.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-560">794.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-561">1,201.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-562">411.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-563">383.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-564">382.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-565">817.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> During the year ended December 31, 2023, the Company recorded a non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-566">306.7</ix:nonFraction> million related to certain Bioservices long-lived assets. See Note 4, "Long-lived asset impairment and restructuring charges" for more details regarding the impairment charge.</span></div></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, construction-in-progress primarily included costs incurred to advance the Company's MCM Product capabilities. For the year ended December&#160;31, 2022, construction-in-progress primarily included costs incurred related to construction to advance the Company's Bioservices capabilities. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense associated with property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-567">59.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-568">83.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-569">62.2</ix:nonFraction> million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. During the year ended December&#160;31, 2022, the Company recorded accelerated depreciation of $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-570">12.7</ix:nonFraction>&#160;million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement (the "Janssen Agreement") with Janssen Pharmaceuticals, Inc. ("Janssen"). For additional information related to the termination of the Janssen Agreement, refer to Note 13 "Revenue recognition".</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_1099511629746"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-571" continuedAt="f-571-1" escape="true">Intangible assets and goodwill </ix:nonNumeric></span></div><ix:continuation id="f-571-1" continuedAt="f-571-2"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-572" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. Components of the Company&#8217;s intangible assets, excluding goodwill, consists of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:19.345%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Weighted Average Useful Life in Years</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-138" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-573">13.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-574">855.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-575">288.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-576">566.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-577">982.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-578">253.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-579">728.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-140" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-580">0.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-581">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-582">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="f-583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-584">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-585">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="f-586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%">Bioservices</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-142" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-587">0.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-588">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-589">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="f-590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-591">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-592">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="f-593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-594">13.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-595">889.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-596">322.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-597">566.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-598">1,016.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-599">287.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-600">728.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company sold $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" scale="6" id="f-601">102.9</ix:nonFraction> million of intangible assets, net as part of the sale of its travel health business to Bavarian Nordic. See Note 3, "Divestiture" for more information on the sale of the travel health business. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2023, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="f-602">6.3</ix:nonFraction> million intangible asset addition related to the contingent consideration payment to Ridgeback for the award of a <ix:nonNumeric contextRef="c-146" name="ebs:RevenueFromContractWithCustomerTermOfContract" format="ixt-sec:duryear" id="f-603">10</ix:nonNumeric>-year contract by the Biomedical Advanced Research and Development Authority for advanced development, manufacturing scale-up, and procurement of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment for Ebola. The related intangible asset was acquired through an asset acquisition that was completed in 2022. </span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="f-604" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company's intangible assets was recorded as follows: </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-605">65.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-606">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-607">58.5</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-608" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates our future amortization expense for our intangible assets as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">&#160;As of<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-609">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-610">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-611">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-612">60.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-613">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="f-614">260.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total remaining amortization</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-615">566.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-571-2" continuedAt="f-571-3"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-616" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the changes in the carrying amount of goodwill by reportable segment:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Commercial Products </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">MCM Products </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Services </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-618">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-619">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-620">224.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-623">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-624">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-626">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-628">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-630">218.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-632">218.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Amounts for the Company's Commercial Products segment include gross carrying values of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="f-637"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="f-638"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="f-639">41.7</ix:nonFraction></ix:nonFraction></ix:nonFraction> million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-640"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-641"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-642">41.7</ix:nonFraction></ix:nonFraction></ix:nonFraction> million as of December&#160;31, 2023, 2022 and 2021.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts for the Company's MCM Products segment include gross carrying values of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="f-643"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="f-644"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="f-645">218.2</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-646">218.2</ix:nonFraction>&#160;million as of December&#160;31, 2023.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts for the Company's Services segment include gross carrying values of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="f-647"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="f-648"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="f-649">6.7</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million as of December&#160;31, 2023, 2022, and 2021, and accumulated impairment losses of $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-650"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-651">6.7</ix:nonFraction></ix:nonFraction>&#160;million as of December&#160;31, 2023 and 2022.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-571-3">The Company performs its goodwill impairment evaluation annually, during the fourth quarter, or sooner if triggering events are identified. During the third quarter of 2023, the Company observed continued market volatility including significant declines in its market capitalization and revised its financial outlook during the third quarter of 2023, which was identified as a triggering event. As a result of the quantitative assessments performed in connection with the preparation of the financial statements as of and for the quarter ended September&#160;30, 2023, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-652">218.2</ix:nonFraction>&#160;million non-cash goodwill impairment charge for the MCM Products reporting unit, which is included in "Goodwill impairment" on the Consolidated Statement of Operations for the year ended December 31, 2023. The MCM Products reporting unit and segment had <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-653">no</ix:nonFraction> remaining goodwill as of December 31, 2023. The goodwill impairment charge resulted from a reduction in the estimated fair value of the MCM reporting unit due to changes in the risk profile of the Company as well as revisions to the long-term operating plan that reflected lower expectations for growth and profitability than previous expectations. The Company used a quantitative assessment, utilizing an income-based (discounted cash flows) approach, Level 3 non-recurring fair value measurement, for its goodwill impairment testing.</ix:continuation> </span></div><div id="i7b0776f670624692b261a662f247fc47_100"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-654" continuedAt="f-654-1" escape="true">Fair value measurements </ix:nonNumeric></span></div><ix:continuation id="f-654-1" continuedAt="f-654-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-655" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-656">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-657">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-660">320.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-661">320.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-662">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-668">170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-670">170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-672"><span style="-sec-ix-hidden:f-673">Derivative instruments</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-678">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-680">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-682">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-683">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-686">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-687">320.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-688">179.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-689">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-690">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="f-692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-693">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-694">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="f-695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="f-696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-697">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-698">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-701">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-702">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-705">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingent consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s products are classified in the Company's <span style="-sec-ix-hidden:f-706"><span style="-sec-ix-hidden:f-707">Consolidated Statement of Operations</span></span> as cost of product sales. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s product candidates are recorded in R&amp;D expense for regulatory and development milestones.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-654-2" continuedAt="f-654-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-708" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the beginning and ending balance of the contingent consideration liabilities measured at fair value during the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-709">59.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-710">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="f-711">23.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-712">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-713">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="f-714">33.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-715">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-716">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="f-717">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-718">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the current portion of the contingent consideration liability was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-719">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-720">3.4</ix:nonFraction>&#160;million, respectively, and was included in "Other current liabilities" on the Consolidated Balance Sheets. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-current portion of the contingent consideration liability is included in "Other liabilities" on the Consolidated Balance Sheets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-721" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"/><td style="width:18.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.768%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.349%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Contingent Consideration Liability</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Fair Value as of December 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Range</span></td><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Royalty based</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-722">5.6</ix:nonFraction> million</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-186" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-723">9.5</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-187" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-724">0.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-188" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-725">75.0</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2023 - 2028</span></td><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Non-Variable Rate Debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the fair value of the Company's <ix:nonFraction unitRef="number" contextRef="c-189" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-726"><ix:nonFraction unitRef="number" contextRef="c-190" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-727">3.875</ix:nonFraction></ix:nonFraction>% Senior Unsecured Notes was $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-728">184.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-729">225.1</ix:nonFraction> million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, "Debt").</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Non-recurring fair value measurements</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-654-3">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. As of December&#160;31, 2023 and December&#160;31, 2022, other than those liabilities mentioned above and those assets outlined in Note 7 "Intangible assets and goodwill", there were no material assets or liabilities measured at fair value on a non-recurring basis.</ix:continuation> </span></div><div id="i7b0776f670624692b261a662f247fc47_103"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-730" continuedAt="f-730-1" escape="true">Derivative instruments and hedging activities</ix:nonNumeric></span></div><ix:continuation id="f-730-1" continuedAt="f-730-2"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risk management objective of using derivatives</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. From time to time, the Company enters into interest rate swap transactions to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements. The objective and strategy with respect to these interest rate swaps is to protect the Company against adverse fluctuations in interest rates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, the Company terminated its designated interest rate swap transactions with a total notional value of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-731">350.0</ix:nonFraction>&#160;million. Hedge accounting was also discontinued at that time. As of December 31, 2023, there was no remaining accumulated other comprehensive income associated with the terminated interest rate swaps.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-730-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-732" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the Consolidated Balance Sheets: </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"/><td style="width:40.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.994%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Fair Value of Asset Derivatives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-734">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to their termination, t<ix:continuation id="f-472-1">he valuation of the interest rate swaps was determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflected the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps were determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) were based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporated credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</ix:continuation></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-735" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gains or losses reclassified from "Accumulated other comprehensive income (loss), net" into "Interest expense" on the Consolidated Statement of Operations during the years ended December 31, 2023 and 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"/><td style="width:43.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.731%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-736">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-737">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7b0776f670624692b261a662f247fc47_106"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-738" continuedAt="f-738-1" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="f-738-1" continuedAt="f-738-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-739" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below present the components of the Company's debt:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Senior secured credit agreement - Term loan due 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-740">198.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-741">362.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Senior secured credit agreement - Revolver loan due 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-742">219.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-743">598.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-744">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-745">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-746">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-747">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-748">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-749">868.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-750">1,413.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-751">413.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-752">957.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="f-753">8.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="f-754">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Non-current portion of debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-755">446.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-756">448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023 and 2022, the Company reclassified the debt issuance costs associated with the revolver loan to a contra account to directly offset the loan balance in "Other current liabilities" on the Company's Consolidated Balance Sheets. As of December 31, 2023 and 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="f-757">5.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="f-758">1.3</ix:nonFraction>&#160;million of debt issuance costs associated with the revolver loan, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-738-2" continuedAt="f-738-3"><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-759">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company completed its offering of $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-760">450.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-70" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-761">3.875</ix:nonFraction>% Senior unsecured Notes due 2028 (the "2028 Notes")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related indenture, plus accrued and unpaid interest. As of August 15, 2023, the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="c-199" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-762">100</ix:nonFraction>% of the principal amount of the 2028 Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest as set forth in the related indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of <ix:nonFraction unitRef="number" contextRef="c-200" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-763">101</ix:nonFraction>% of the principal amount of such 2028 Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, the Company entered into the Fourth Amendment to Amended and Restated Credit Agreement, Waiver and First Amendment to Amended and Restated Collateral Agreement (the "Credit Agreement Amendment"). The Credit Agreement Amendment amended the existing Amended and Restated Credit Agreement to, among other things, (a) extend the maturity date of the Senior Secured Credit Facilities from October 13, 2023 to May 15, 2025, (b) reduce the available commitments under the Revolving Credit Facility from $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-764">600.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-765">300.0</ix:nonFraction>&#160;million, (c) remove the Company's ability to incur incremental loans and (d) amend certain mandatory prepayment triggers, affirmative covenants, negative covenants and events of default thereunder. In connection with the Credit Agreement Amendment, the Company used the approximately $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-766">270.2</ix:nonFraction>&#160;million of proceeds from the sale of its travel health business to Bavarian Nordic, which closed on May 15, 2023, together with approximately $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="f-767">217.2</ix:nonFraction>&#160;million of cash on hand, to repay approximately $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-768">144.4</ix:nonFraction>&#160;million in outstanding principal amount of loans under the Term Loan Facility and $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-769">342.8</ix:nonFraction>&#160;million outstanding principal amount of loans under the Revolving Credit Facility. The Credit Agreement Amendment also requires that the Company make quarterly principal payments on the Term Loan Facility of approximately $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="f-770">3.9</ix:nonFraction>&#160;million, which commenced on June 30, 2023 and will extend through March 31, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement Amendment also (i) amended the consolidated debt service coverage ratio financial covenant to require the minimum level to be <ix:nonFraction unitRef="number" contextRef="c-207" decimals="INF" name="ebs:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="f-771">2.25</ix:nonFraction> to 1.00 for the fiscal quarters ending March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and then <ix:nonFraction unitRef="number" contextRef="c-208" decimals="INF" name="ebs:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="f-772">2.50</ix:nonFraction> to 1.00 for each fiscal quarter ending thereafter, (ii) amended the consolidated leverage ratio to require the maximum level to be <ix:nonFraction unitRef="number" contextRef="c-209" decimals="INF" name="ebs:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="f-773">4.50</ix:nonFraction> to 1.00 for the fiscal quarter ending March 31, 2024 and each fiscal quarter ending thereafter, (iii) added minimum Consolidated EBITDA requirements and maximum capital expenditure requirements for each of the months ending April 30, 2023 through February 29, 2024 and a minimum liquidity requirement as of the end of each calendar month and (iv) requires the Company to increase its liquidity by April 30, 2024 by raising at least $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="ebs:DebtInstrumentCovenantConsiderationThreshold" format="ixt:num-dot-decimal" scale="6" id="f-774">75.0</ix:nonFraction>&#160;million of equity or unsecured indebtedness. See Note 2, "Summary of significant accounting policies" for additional information related to the Company's compliance with the debt covenants described above.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Credit Agreement Amendment replaced the interest rate benchmark such that borrowings under the Revolving Credit Facility and the outstanding principal amount of the Term Loan Facility shall bear interest at a rate per annum equal to (a) a rate based on SOFR, EURIBOR or CDOR plus a margin of <ix:nonFraction unitRef="number" contextRef="c-210" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-775">6.00</ix:nonFraction>% until March 31, 2024 and thereafter, a margin ranging from <ix:nonFraction unitRef="number" contextRef="c-211" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-776">2.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-212" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-777">4.00</ix:nonFraction>% depending on the Company&#8217;s consolidated leverage ratio, or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="c-213" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-778">0.50</ix:nonFraction>%, and a SOFR rate for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="c-214" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-779">1.00</ix:nonFraction>%) plus a margin of <ix:nonFraction unitRef="number" contextRef="c-215" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-780">5.00</ix:nonFraction>% until March 31, 2024 and thereafter, a margin ranging from <ix:nonFraction unitRef="number" contextRef="c-216" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-781">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-217" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-782">3.00</ix:nonFraction>% depending on the Company&#8217;s consolidated leverage ratio. In addition, the commitment fee the Company is required to pay in respect of the annual daily unused commitments under the Revolving Credit Facility shall be <ix:nonFraction unitRef="number" contextRef="c-218" decimals="4" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-783">0.15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-219" decimals="4" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-784">0.40</ix:nonFraction>% per annum, depending on the Company&#8217;s consolidated leverage ratio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Credit Agreement Amendment, the Company and the other guarantors also agreed to provide a lien over certain assets as additional collateral for the benefit of the lenders, including owned real property, equity interests of foreign subsidiaries and certain deposit accounts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 29, 2024, the Company entered into the Forbearance Agreement and Amendment to, among other things, (a) provide that the Administrative Agent and the Lenders forbear from exercising all rights and remedies under the Senior Secured Credit Facilities and the other related loan documents arising from the occurrence and continuation of certain specified events of default during the Forbearance Period and (b) provide consent by the required revolving credit lenders to make further loans to the Company or other extensions of credit to the credit parties during the Forbearance Period, notwithstanding the occurrence of the specified events of default, subject to certain conditions set forth in the Forbearance Agreement and Amendment, including a limit on Revolving Credit Facility indebtedness of $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-785">270</ix:nonFraction>&#160;million. The Forbearance Agreement and Amendment also amends, among other things, (x)(A) the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-738-3"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest rate benchmark to provide that borrowings shall bear interest at a rate per annum equal to <ix:nonFraction unitRef="number" contextRef="c-221" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-786">5.00</ix:nonFraction>% with respect to Base Rate Loans, (B) the interest rate benchmark from <ix:nonFraction unitRef="number" contextRef="c-222" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-787">6.00</ix:nonFraction>% per annum to <ix:nonFraction unitRef="number" contextRef="c-223" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-788">6.50</ix:nonFraction>% per annum with respect to SOFR Loans, Daily Simple SONIA Loans and Eurocurrency Rate Loans, and (C) <ix:nonFraction unitRef="number" contextRef="c-224" decimals="4" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-789">0.40</ix:nonFraction>% with respect to Commitment Fees, (y) the mandatory prepayment threshold amount for unrestricted cash and cash equivalents from $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="INF" name="ebs:DebtInstrumentMandatoryPrepaymentThreshold" format="ixt:num-dot-decimal" scale="0" id="f-790">125,000,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="INF" name="ebs:DebtInstrumentMandatoryPrepaymentThreshold" format="ixt:num-dot-decimal" scale="0" id="f-791">100,000,000</ix:nonFraction>, and (z) the mandatory principal prepayment amount from <ix:nonFraction unitRef="number" contextRef="c-225" decimals="INF" name="ebs:DebtInstrumentMandatoryPrincipalPrepaymentPercentage" scale="-2" id="f-792">75</ix:nonFraction>% of all milestone payments received by the Company and its subsidiaries from certain project milestone payments to <ix:nonFraction unitRef="number" contextRef="c-220" decimals="INF" name="ebs:DebtInstrumentMandatoryPrincipalPrepaymentPercentage" scale="-2" id="f-793">100</ix:nonFraction>%. Under the Forbearance Agreement and Amendment, the Company and the other guarantors have also agreed to cause Emergent BioSolutions Canada Inc. to (i) become a guarantor under the Senior Secured Credit Facilities and (ii) grant a security lien in all collateral owned by Emergent BioSolutions Canada Inc. (subject to the exclusions and exceptions specified in the Collateral Agreement) to the Administrative Agent. In addition, in connection with the entry into the Forbearance Agreement and Amendment, the Company paid a forbearance fee of approximately $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-794">1.2</ix:nonFraction>&#160;million. Refer to Note 2, "Summary of significant accounting policies" for further discussion of the Forbearance Agreement and Amendment. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt Maturity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-795" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future debt payments of long-term indebtedness are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">As of <br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="f-796">418.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="6" id="f-797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="6" id="f-798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="6" id="f-799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="f-800">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:fixed-zero" scale="6" id="f-801">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-802">868.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7b0776f670624692b261a662f247fc47_4947802327108"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-803" continuedAt="f-803-1" escape="true">Share-based compensation and stockholders' equity</ix:nonNumeric></span></div><ix:continuation id="f-803-1" continuedAt="f-803-2"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="plan" contextRef="c-4" decimals="INF" name="ebs:NumberOfShareBasedEmployeeCompensationPlans" format="ixt-sec:numwordsen" scale="0" id="f-804">two</ix:nonFraction> share-based employee compensation plans, the Emergent Plan and the Inducement Plan, which include stock options and performance and restricted stock units.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-226" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-805">29.1</ix:nonFraction> million shares of common stock were authorized for issuance under the Emergent Plan, of which a total of approximately <ix:nonFraction unitRef="shares" contextRef="c-226" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-806">5.9</ix:nonFraction> million shares of common stock remain available for future awards to be made to plan participants. As of December 31, 2023, an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-227" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="f-807">5.0</ix:nonFraction> million shares of common stock were authorized for issuance under the Inducement Plan and <ix:nonFraction unitRef="shares" contextRef="c-228" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="6" id="f-808">no</ix:nonFraction> shares had been issued under the Inducement Plan. The exercise price of each option must be not less than <ix:nonFraction unitRef="number" contextRef="c-226" decimals="INF" name="ebs:ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum" scale="-2" id="f-809">100</ix:nonFraction>% of the fair market value of the shares underlying such option on the date of grant. Options granted under the Emergent Plan and the Inducement Plan have a contractual life of <ix:nonNumeric contextRef="c-229" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-810">seven years</ix:nonNumeric>. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-811" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-812">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-813">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-232" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-814">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-815">63</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-816">69</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-817">54</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-818">62</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-232" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-819">47</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-232" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-820">48</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-821">4.00</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-822">4.46</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-823">1.54</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-824">4.31</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-232" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-825">0.43</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-232" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-826">0.94</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected average life of options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-230" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-827">4.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-828">4.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-232" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-829">4.5</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-803-2" continuedAt="f-803-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-830" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option award activity under the Emergent Plan:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Aggregate </span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-233" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="f-831">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-233" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-832">51.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-234" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="f-833">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-234" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-834">9.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-234" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-234" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-234" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="f-837">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-234" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-838">42.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-235" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="f-839">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-235" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-840">34.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-234" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-841">5.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="6" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-235" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="f-843">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-235" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-844">56.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-234" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-845">3.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="6" id="f-846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-847">no</ix:nonFraction> cash received from option exercises for the year ended December&#160;31, 2023. Cash received from option exercises for the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-848">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-849">10.4</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of options granted during the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-850">5.35</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-851">17.85</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-852">35.16</ix:nonFraction> per share, respectively. The intrinsic value of stock options exercised is the amount by which the market value of our common stock on the exercise date exceeds the exercise price. There was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="6" id="f-853">no</ix:nonFraction> intrinsic value of options exercised during the year ended December&#160;31, 2023. The total intrinsic value of options exercised during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-854">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-855">15.7</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-856">4.4</ix:nonFraction> million of unrecognized compensation cost related to stock options.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Performance stock units and restricted stock units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-857" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of performance stock unit and restricted stock unit award activity under the Emergent Plan:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Aggregate<br/>&#160;Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-236" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-858">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-236" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-859">42.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="f-860">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-237" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-861">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-237" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-862">8.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-237" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="f-863">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-237" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-864">46.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-237" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="f-865">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-237" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-866">26.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-867">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-238" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-868">16.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="f-869">6.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Performance stock units granted and forfeited during the year ended December&#160;31, 2023 are included at the target payout percentage, or <ix:nonFraction unitRef="number" contextRef="c-239" decimals="2" name="ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" scale="-2" id="f-870">100</ix:nonFraction>%, of shares granted.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock unit awards released during the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="f-871">31.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="f-872">30.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="f-873">26.9</ix:nonFraction> million, respectively. As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-874">22.6</ix:nonFraction> million of unrecognized compensation cost related to unvested restricted stock units. That cost is expected to be recognized straight-line over a weighted average period of <ix:nonNumeric contextRef="c-240" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-875"><ix:nonNumeric contextRef="c-244" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-876">1.8</ix:nonNumeric></ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units represent common stock potentially issuable in the future, subject to achievement of performance conditions. Our current outstanding performance stock units vest based on certain financial metrics over the applicable performance period. The vesting and payout range for our performance stock units is typically between <ix:nonFraction unitRef="number" contextRef="c-245" decimals="2" name="ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" scale="-2" id="f-877">50</ix:nonFraction>% and up to <ix:nonFraction unitRef="number" contextRef="c-246" decimals="2" name="ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" scale="-2" id="f-878">200</ix:nonFraction>% of the target number of shares granted at the end of a <ix:nonNumeric contextRef="c-244" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-879">three-year</ix:nonNumeric> performance period. The total fair value of performance unit awards released during the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="f-880">2.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="f-881">2.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="f-882">3.8</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-883">2.2</ix:nonFraction> million of unrecognized compensation cost related to unvested performance stock units. That cost is expected to be recognized straight-line over a weighted average period of <ix:nonNumeric contextRef="c-240" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-884"><ix:nonNumeric contextRef="c-244" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-885">1.8</ix:nonNumeric></ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-803-3" continuedAt="f-803-4"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Share-based compensation expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-886" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of Commercial Product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-887">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-888">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-889">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-890">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-891">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-892">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of Bioservices</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-893">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-894">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-895">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-896">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-897">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-898">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-899">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-900">30.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-901">29.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-902">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-903">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-904">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders' equity</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Preferred stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-905">15.0</ix:nonFraction> million shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-906">0.001</ix:nonFraction> par value per share ("Preferred Stock"). Any Preferred Stock issued may have dividend rights, voting rights, conversion privileges, redemption characteristics, and sinking fund requirements as approved by the Company's board of directors.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Common stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has one class of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-907">0.001</ix:nonFraction> par value per share common stock ("Common Stock"), authorized and outstanding. The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-908">200.0</ix:nonFraction> million shares of Common Stock. Holders of Common Stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-1" decimals="INF" name="ebs:CommonStockNumberOfVotesPerCommonShare" format="ixt-sec:numwordsen" scale="0" id="f-909">one</ix:nonFraction> vote for each share of Common Stock held on all matters, except as may be provided by law.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">At-the-Market Equity Offering Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="ebs:SaleOfStockAggregateOfferingAmountMaximum" format="ixt:num-dot-decimal" scale="6" id="f-910">150.0</ix:nonFraction>&#160;million aggregate gross sales price of shares of our common stock through Evercore Group L.L.C. and RBC Capital Markets, LLC, as sales agents, under an ATM Program that we entered into on May 18, 2023. Between the entry into the ATM Program and December&#160;31, 2023, we sold <ix:nonFraction unitRef="shares" contextRef="c-266" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-911">1.1</ix:nonFraction> million shares of our common stock under the ATM Program for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="ebs:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="f-912">9.1</ix:nonFraction>&#160;million, representing an average share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-265" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-913">8.22</ix:nonFraction> per share. As of December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="ebs:SaleOfStockAmountRemainingAvailableForSaleOfShares" format="ixt:num-dot-decimal" scale="6" id="f-914">140.9</ix:nonFraction>&#160;million aggregate gross sales price of shares of our common stock remains available for issuance under the ATM Program. We intend to use proceeds obtained from the sale of shares under the ATM Program for general corporate purposes.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 Share Repurchase Program</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2021, the Company announced that its Board of Directors authorized a stock repurchase program of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-915">250.0</ix:nonFraction>&#160;million of Common Stock (the "2021 Share Repurchase Program"), of which $<ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-916">187.9</ix:nonFraction>&#160;million was utilized to purchase approximately <ix:nonFraction unitRef="shares" contextRef="c-268" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="f-917">4.4</ix:nonFraction>&#160;million. The 2021 Share Repurchase Program expired on November 11, 2022. During the year ended December&#160;31, 2022, the Company utilized $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-918">75.5</ix:nonFraction>&#160;million to purchase approximately <ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="f-919">1.8</ix:nonFraction>&#160;million shares. The 2021 Share Repurchase Program did not obligate the Company to acquire any specific number of shares. Repurchased shares are available for use in connection with the Company's stock plans and for other corporate purposes.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-803-4"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accumulated other comprehensive income (loss), net of tax</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-920" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.598%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Defined Benefit Pension Plan</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-921">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-922">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-923">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-924">16.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-925">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-926">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-927">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-928">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-929">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-930">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-932">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-933">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-934">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-935">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-936">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-937">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-938">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-939">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-940">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-941">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-942">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-943">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-944">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-945">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-946">8.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-948">12.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-949">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-950">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-951">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-952">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-953">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-955">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-956">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock" id="f-957" escape="true"><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present the tax effects related to each component of other comprehensive income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2023</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Tax Benefit (Expense)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Defined benefit pension plan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-958">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-959">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-960">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-961">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-962">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-963">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-964">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-965">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-966">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-967">8.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-968">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-969">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-970">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-971">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-972">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-973">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-974">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-975">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-976">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-977">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-978">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-979">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-980">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-981">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-982">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-983">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-984">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-985">11.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-986">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-987">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-988">23.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-989">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-990">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="f-991">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="f-992">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-993">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-994" continuedAt="f-994-1" escape="true">Net income (loss) per common share</ix:nonNumeric></span></div><ix:continuation id="f-994-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share adjusts basic loss per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units and performance stock units. Diluted net income (loss) per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plans that were excluded from diluted net income (loss) per common share because their effect would have been antidilutive. <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt-sec:numwordsen" id="f-995"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt-sec:numwordsen" id="f-996">No</ix:nonFraction></ix:nonFraction> adjustment for the potential dilutive effect of dilutive securities is reported for the years ended December&#160;31, 2023 and 2022 as the effect would have been anti-dilutive due to the Company's net loss.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-997" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net income (loss) per common share:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-998">760.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-999">211.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1000">219.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Weighted-average number of shares-basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1001">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1002">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1003">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Dilutive effect of employee incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-1004">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-1005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1006">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Weighted-average number of shares-diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1007">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1008">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1009">54.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income (loss) per common share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1010">14.85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1011">4.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1012">4.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income (loss) per common share - diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1013">14.85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="f-1014">4.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1015">4.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1016" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the share-based awards that are not considered in the diluted net income (loss) per common share calculation generally because the exercise price of the awards was greater than the average per share closing price during the year ending December&#160;31, 2023, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price. </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Anti-dilutive stock awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1017">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1018">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1019">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_1099511629806"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-1020" continuedAt="f-1020-1" escape="true">Revenue recognition </ix:nonNumeric></span></div><ix:continuation id="f-1020-1" continuedAt="f-1020-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="f-1021"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-1022">three</ix:nonFraction></ix:nonFraction> business segments (see Note 18, "Segment information"). <ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-1023" continuedAt="f-1023-1" escape="true">The Company's revenues disaggregated by the major sources were as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1023-1"><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:19.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.093%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.833%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="51" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:20pt"><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1024">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1025">496.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1026">497.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1027">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1028">385.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1029">386.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1030">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1031">435.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1032">438.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1033">373.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1034">73.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1035">447.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1036">444.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1037">135.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1038">579.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1039">527.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1040">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1041">585.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%">Bioservices:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1042">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1043">72.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1044">72.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1045">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1046">105.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1047">105.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1049">310.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1050">310.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="6" id="f-1051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-1052">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-1053">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="6" id="f-1054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-1055">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-1056">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-1057">243.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-1058">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="f-1059">305.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total Bioservices</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1061">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1062">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1063">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1064">109.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1065">109.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1066">243.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1067">372.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1068">615.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1069">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1070">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1071">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1072">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1073">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1074">41.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1075">130.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1076">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1077">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1078">394.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1079">654.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1080">1,049.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1081">482.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1082">634.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1083">1,117.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1084">903.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1085">870.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1086">1,773.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-1087" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company's product sales from NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Other commercial products, Anthrax MCM, Smallpox MCM and Other products as a percentage of total product sales were as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">% of product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Products:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-329" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1088">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-330" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1089">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1090">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other Commercial products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-332" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1091">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-333" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1092">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-334" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-1093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Anthrax MCM</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-335" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1094">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-336" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1095">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-337" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1096">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Smallpox MCM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-338" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1097">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-339" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1098">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-340" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1099">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-341" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1100">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-342" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1101">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-343" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1102">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023 and 2021, aside from sales to the USG, there were no sales to an individual customer in excess of 10% of total revenues. For the year ended December 31, 2022, there were two customers in excess of 10% of total revenues. The USG accounted for <ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1103">43</ix:nonFraction>% of total revenues and the second customer's revenue accounted for <ix:nonFraction unitRef="number" contextRef="c-344" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1104">10</ix:nonFraction>% and was primarily attributable to the MCM Products segment. For the years ended December&#160;31, 2023, 2022, and 2021, the Company&#8217;s revenues from customers within the United States comprised <ix:nonFraction unitRef="number" contextRef="c-345" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1105">58</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-346" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1106">79</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-347" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1107">92</ix:nonFraction>%, respectively, of total revenues. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, the Company, through its wholly owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Janssen Agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the Company provided to Janssen a notice (the &#8220;Notice&#8221;) of material breach of the Janssen Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Janssen Agreement and (ii) to confirm Janssen&#8217;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Janssen Agreement and instead, wind-down the Janssen Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#8220;Janssen Notice&#8221;) of the Janssen Agreement for asserted material breaches of the Janssen Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company&#8217;s breaches were not curable and that, therefore, termination of the Janssen Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-1020-2" continuedAt="f-1020-3"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Janssen Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process through arbitration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023 there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Agreement. As of December&#160;31, 2023, the Company has no billed or unbilled net accounts receivable related to the Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2022, because the arbitration process is expected to extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from "Inventories, net" and from "Prepaid expenses and other current assets" to "Other assets", resulting in $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="f-1108">152.7</ix:nonFraction> million in long-term assets related to the Janssen Agreement on the Consolidated Balance Sheet as of December 31, 2022. The long-term asset balance within "Other Assets" related to the Janssen Agreement as of December 31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-1109">158.8</ix:nonFraction> million. These assets include termination penalties, certain inventory related items and raw materials inventory representing materials purchased for the Janssen Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of the inventory as of December 31, 2023, concluding that because the Janssen Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. As of December 31, 2023, all non-cancelable orders have been received by Janssen and are included in the long-term asset balance within "Other Assets". </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">BARDA Centers of Innovation and Advanced Development and Manufacturing Agreement ("CIADM")</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company announced the issuance of a task order under its existing CIADM agreement with BARDA for COVID-19 vaccine development and manufacturing (the "BARDA COVID-19 Development Public Private Partnership"). The BARDA COVID-19 Development Public Private Partnership is considered a lease and is accounted for under ASC 842. The initial task order had a contract value of up to $<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-1110">628.2</ix:nonFraction>&#160;million and included the reservation of manufacturing capacity and accelerated expansion of fill/finish capacity valued at $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-1111">542.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-1112">85.5</ix:nonFraction>&#160;million, respectively. Subsequently, the task order was expanded to include incremental capital activities which increased the value to $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-1113">650.8</ix:nonFraction>&#160;million. On November 1, 2021, the Company and BARDA mutually agreed to the completion of the Company's CIADM contract and associated task orders, including the BARDA COVID-19 Development Public Private Partnership. The Company did <ix:nonFraction unitRef="usd" contextRef="c-354" decimals="INF" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="0" id="f-1114"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="INF" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="0" id="f-1115">not</ix:nonFraction></ix:nonFraction> recognize lease revenues under this arrangement during the years ended December 31, 2023 and December 31, 2022. Revenue associated with the base arrangement was $<ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1116">71.3</ix:nonFraction>&#160;million during the year ended December 31, 2021 and is reflected as a component of contracts and grants revenue on the Consolidated Statements of Operations. Revenue associated with the BARDA COVID-19 Development Public-Private Partnership was $<ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-1117">243.1</ix:nonFraction>&#160;million during the year ended December 31, 2021 and is recorded as Bioservices "Leases" on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bioservices Operating Leases</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain multi-year Bioservices arrangements with non-USG customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates <ix:nonNumeric contextRef="c-358" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1118">5.0</ix:nonNumeric> years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components. During the year ended December 31, 2023, the Company's non-USG lease revenues were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-1119">5.7</ix:nonFraction>&#160;million, which is included within Bioservices "Leases" on the Consolidated Statement of Operations. Excluding future amounts related to the Agreement as discussed above, the Company estimates future operating lease revenues to be $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1120">0.8</ix:nonFraction>&#160;million in 2024, $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="6" id="f-1121">0.9</ix:nonFraction>&#160;million in 2025, $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" format="ixt:num-dot-decimal" scale="6" id="f-1122">0.9</ix:nonFraction>&#160;million in 2026, $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" format="ixt:num-dot-decimal" scale="6" id="f-1123">0.9</ix:nonFraction>&#160;million in 2027, $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" format="ixt:num-dot-decimal" scale="6" id="f-1124">0.9</ix:nonFraction>&#160;million in 2028 and <ix:nonFraction unitRef="usd" contextRef="c-359" decimals="INF" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter" format="ixt:fixed-zero" scale="6" id="f-1125">no</ix:nonFraction> lease revenue in 2029 and beyond</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction price allocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has future contract value on unsatisfied performance obligations of approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-1126">379.5</ix:nonFraction> million associated with all arrangements entered into by the Company. The Company expects to recognize $<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-1127">372.3</ix:nonFraction> million of unsatisfied performance obligations within the next <ix:nonNumeric contextRef="c-360" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="f-1128">24</ix:nonNumeric> months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> associat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-1020-3" continuedAt="f-1020-4"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of December&#160;31, 2023 and December&#160;31, 2022, the Compan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1129">21.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1130">34.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within "Accounts receivable, net" on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. <ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-1131" continuedAt="f-1131-1" escape="true">The following table presents the roll forward of the contract liabilities:</ix:nonNumeric></span></div><ix:continuation id="f-1131-1"><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">&#160;Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1132">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1133">29.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-1134">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the current portion of contract liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1135">27.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1136">26.4</ix:nonFraction>&#160;million, respectively, and was included in "Other current liabilities" on the Consolidated Balance Sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Expected Credit Losses</span></div><ix:nonNumeric contextRef="c-1" name="ebs:ScheduleOfAccountsReceivableNetTableTextBlock" id="f-1137" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of "Accounts receivable, net" as presented on the Consolidated Balance Sheets:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Billed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="f-1138">141.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="f-1139">102.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="f-1140">51.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="f-1141">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Allowance for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="f-1142">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="f-1143">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1144">191.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1145">159.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1020-4">The Company's provisions for expected credit losses for the year's ended years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="6" id="f-1146">2.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="6" id="f-1147">0.3</ix:nonFraction> million, and $(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-1148">0.1</ix:nonFraction>) million, respectively.</ix:continuation> </span></div><div id="i7b0776f670624692b261a662f247fc47_124"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1149" continuedAt="f-1149-1" escape="true">Leases </ix:nonNumeric></span></div><ix:continuation id="f-1149-1" continuedAt="f-1149-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, R&amp;D facilities and manufacturing facilities, which may include renewal or termination options. The Company determines if an arrangement is a lease at inception. Operating leases are included in ROU assets and liabilities. The Company's leases have remaining lease terms of less than <ix:nonNumeric contextRef="c-361" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-1150">one year</ix:nonNumeric> to approximately <ix:nonNumeric contextRef="c-362" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1151">10</ix:nonNumeric> years. Most leases included one or more options to renew, with renewal terms that can extend the lease term up to <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1152">five years</ix:nonNumeric>.  For a discussion of lessor activities, refer to Note 13, "Revenue recognition".</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1153" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-1154">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-1155">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-1156">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1157">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1158">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1159">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total operating lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1160">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1161">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1162">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-1149-2"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of "Cost of Commercial Product sales", "Cost of MCM Product sales", "Cost of Bioservices", "R&amp;D" expense and "Selling, general and administrative" expense on the Company's Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><ix:nonNumeric contextRef="c-1" name="ebs:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-1163" escape="true"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline">Leases</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Classification</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1164"><span style="-sec-ix-hidden:f-1165">Other assets</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-1166">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-1167">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1168"><span style="-sec-ix-hidden:f-1169">Other current liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-1170">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-1171">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1172"><span style="-sec-ix-hidden:f-1173">Other liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-1174">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-1175">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1176">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1177">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1178">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1179">5.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1180">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1181">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1182" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity analysis below summarizes future undiscounted cash flows for our operating leases as of December&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">As of<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-1183">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-1184">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-1185">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-1186">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-1187">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="f-1188">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="f-1189">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-1190">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1191">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7b0776f670624692b261a662f247fc47_127"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1192" continuedAt="f-1192-1" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="f-1192-1" continuedAt="f-1192-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-457-1">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company reassessed the valuation allowance and considered negative evidence, including its significant losses in the current year and the substantial doubt about the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued, positive evidence, scheduled reversal of deferred tax liabilities, available taxes in carryback periods, tax planning strategies and projected future taxable income. After assessing both the negative and positive evidence, the Company concluded that it should record an additional valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1193">192.7</ix:nonFraction>&#160;million on its global net operating losses, credits and other deferred tax assets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global intangible low-tax income (&#8220;GILTI&#8221;) provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. The Company is subject to incremental U.S. tax on GILTI income. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-1192-2" continuedAt="f-1192-3"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not provided any deferred tax impacts of GILTI in its consolidated financial statements for the years ended December&#160;31, 2023, 2022 and 2021. BEAT provisions do not have material impact on the consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, the Company has evaluated its historical indefinite reinvestment assertion in connection with the Company&#8217;s going concern uncertainty. The Company recognized a deferred withholding tax liability for the undistributed earnings of the Company&#8217;s international subsidiaries available cash and net working capital in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:DeferredTaxLiabilitiesForeignWithholdingTax" format="ixt:num-dot-decimal" scale="6" id="f-1194">5.5</ix:nonFraction> million. All other international subsidiaries&#8217; outside basis differences are indefinitely reinvested.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1195" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of income taxes attributable to operations consist of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1196">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1197">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1198">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1199">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1200">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1201">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1202">36.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1203">33.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1204">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1205">36.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1206">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1207">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1208">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1209">37.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1210">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-1211">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-1212">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-1213">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1214">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1215">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1216">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1217">7.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1218">33.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1219">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1220">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1221">7.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1222">83.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-1192-3" continuedAt="f-1192-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1223" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net deferred tax liability consists of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal losses carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="f-1224">58.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="f-1225">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State losses carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="f-1226">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="f-1227">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="f-1228">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="f-1229">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1230">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1231">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign losses carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="f-1232">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="f-1233">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="6" id="f-1234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="f-1235">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1236">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1237">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="f-1238">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ebs:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="f-1239">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRC 263A capitalized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" scale="6" id="f-1240">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ebs:DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" scale="6" id="f-1241">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="6" id="f-1242">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ebs:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="6" id="f-1243">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRC 163(j) Interest Limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="6" id="f-1244">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="6" id="f-1245">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="f-1246">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="f-1247">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:DeferredTaxAssetsIntangibleAssets" scale="6" id="f-1248">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ebs:DeferredTaxAssetsIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="f-1250">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="f-1251">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1252">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1253">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-1254">269.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-1255">130.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1256">257.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1257">65.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="f-1258">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="f-1259">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1260">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1261">63.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="f-1262">40.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="f-1263">46.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="f-1264">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="f-1265">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Withholding Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:DeferredTaxLiabilitiesForeignWithholdingTax" scale="6" id="f-1266">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ebs:DeferredTaxLiabilitiesForeignWithholdingTax" scale="6" id="f-1267">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="f-1268">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="f-1269">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1270">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1271">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-1272">58.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-1273">125.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="f-1274">47.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="f-1275">59.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1276">279.3</ix:nonFraction> million in U.S. federal net operating loss ("NOL") carryforwards, $<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="ebs:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1277">36.0</ix:nonFraction>&#160;million of NOL&#8217;s which will expire in varying amounts in 2031 through 2035 and $<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="ebs:OperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1278">243.3</ix:nonFraction>&#160;million which will carryforward indefinitely, although, limited to eighty percent of taxable income annually. The Company has U.S. federal tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1279">16.9</ix:nonFraction> million which will expire in 2027 through 2042. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had post-apportionment NOLs totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1280">667.6</ix:nonFraction> million that will begin to expire in 2028. The Company has state R&amp;D tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1281">5.0</ix:nonFraction> million which will expire in 2027 through 2038. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deductibility of such US federal and state net operating losses and credits may be limited. Under Section 382/383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and corresponding provisions of state law, if a corporation undergoes an "ownership change," which generally occurs if the percentage of the corporation's stock owned by 5% stockholders increases by more than 50% over a three-year period, the corporation's ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. Certain of the net operating loss carryforwards and the credit carryforwards are subject to an annual limitation pursuant to Internal Revenue Code Section 382 and 383 as a result of historical acquisitions. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control, which may further limit our carryforwards. If we determine that an ownership change has occurred and our ability to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-1192-4" continuedAt="f-1192-5"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use our historical NOL and credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately $<ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1282">55.7</ix:nonFraction> million in net operating losses from foreign jurisdictions as of December&#160;31, 2023, which will carryforward indefinitely.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1283">192.7</ix:nonFraction>&#160;million due to the Company&#8217;s generation of significant losses in 2023. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1284" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes differ from the amount of taxes determined by applying the U.S. federal statutory rate to income before taxes as a result of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1285">805.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1286">442.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1287">100.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1288">73.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1289">224.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1290">203.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Earnings (losses) before taxes on income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossAttributableToParent" scale="6" id="f-1291">731.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeLossAttributableToParent" scale="6" id="f-1292">218.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeLossAttributableToParent" scale="6" id="f-1293">303.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Federal tax at statutory rates</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1294">153.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1295">46.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1296">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1297">52.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1298">13.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1299">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="f-1300">8.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="f-1301">7.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="f-1302">18.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-1303">193.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-1304">37.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-1305">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="f-1306">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="f-1307">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="f-1308">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1309">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1310">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1311">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill Impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="f-1312">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="f-1313">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="f-1314">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Adjustment of prior year taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="6" id="f-1315">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="6" id="f-1316">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="6" id="f-1317">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:EffectiveIncomeTaxRateReconciliationTransactionCosts" format="ixt:fixed-zero" scale="6" id="f-1318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="ebs:EffectiveIncomeTaxRateReconciliationTransactionCosts" format="ixt:fixed-zero" scale="6" id="f-1319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="ebs:EffectiveIncomeTaxRateReconciliationTransactionCosts" scale="6" id="f-1320">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Compensation limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" scale="6" id="f-1321">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="ebs:EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" scale="6" id="f-1322">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="ebs:EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" scale="6" id="f-1323">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Unrecognized tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="f-1324">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="f-1325">9.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="f-1326">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">GILTI, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" scale="6" id="f-1327">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" scale="6" id="f-1328">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" scale="6" id="f-1329">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Foreign withholding tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" scale="6" id="f-1330">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" scale="6" id="f-1331">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" format="ixt:fixed-zero" scale="6" id="f-1332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ebs:EffectiveIncomeTaxRateReconciliationPermanentDifference" scale="6" id="f-1333">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="ebs:EffectiveIncomeTaxRateReconciliationPermanentDifference" scale="6" id="f-1334">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="ebs:EffectiveIncomeTaxRateReconciliationPermanentDifference" scale="6" id="f-1335">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1336">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1337">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1338">83.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual tax rate for the years ended December&#160;31, 2023, 2022, and 2021 was (<ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1339">4</ix:nonFraction>)%, <ix:nonFraction unitRef="number" contextRef="c-27" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1340">3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-28" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1341">28</ix:nonFraction>%, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual tax rate of (<ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1342">4</ix:nonFraction>)% in 2023 is lower than the statutory rate primarily due to the impact of a valuation allowance charge in the U.S., state and certain Foreign Jurisdictions, goodwill impairment, GILTI, and other permanent items. This is partially offset by tax credits and favorable rates in foreign jurisdictions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual tax rate of <ix:nonFraction unitRef="number" contextRef="c-27" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1343">3</ix:nonFraction>% in 2022 is lower than the statutory rate primarily due to the impact of a valuation allowance charge in the U.S., state and certain Foreign Jurisdictions, a charge due the Company&#8217;s indefinite reinvestment assertion, goodwill impairment, GILTI, and other permanent items. This is partially offset by tax credits, favorable rates in foreign jurisdictions, and the release of an indemnified unrecognized tax benefit.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual tax rate of <ix:nonFraction unitRef="number" contextRef="c-28" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1344">28</ix:nonFraction>% in 2021 is higher than the statutory rate primarily due to the impact of goodwill impairment, state taxes, GILTI and other non-deductible items. This is partially offset by stock option deduction benefits, tax credits, and favorable rates in foreign jurisdictions. The jurisdictional mix of profit has changed from the prior year largely due to lower U.S. Bioservices margins, the termination of the CIADM arrangement in the U.S. and an increase in sales of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which a portion of the profit is attributable to a foreign subsidiary.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized tax benefits recorded at December&#160;31, 2023 and 2022 of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:UnrecognizedTaxBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1345">6.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ebs:UnrecognizedTaxBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1346">6.8</ix:nonFraction> million, respectively, is classified primarily as a non-current liability on the Consolidated Balance Sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-1192-5" continuedAt="f-1192-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1347" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the gross unrecognized tax benefits activity for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1348">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1349">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1350">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions for prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1351">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1352">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1353">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions for current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1354">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1355">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1356">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="f-1357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="f-1358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="f-1359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1360">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1361">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="f-1362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1363">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1364">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1365">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross unrecognized tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1366">6.6</ix:nonFraction> million, includes the release of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="6" id="f-1367">0.7</ix:nonFraction> million of liability that related to the 2019 R&amp;D and other reserves due to a lapse of the statute of limitations during the year.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes interest and potential penalties related to unrecognized tax benefits in income tax expense. As of December&#160;31, 2023 and 2022, the total amount of interest and penalties accrued was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-1368"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-1369">1.6</ix:nonFraction></ix:nonFraction>&#160;million, respectively, in each of the years. The Company recognized interest and penalty expense (benefit) in 2023, 2022 and 2021 of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-1370">0.2</ix:nonFraction> million, $(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="f-1371">2.1</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-1372">1.1</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate a significant change within the next twelve months for unrecognized tax benefits and when resolved, all of these liabilities would impact the effective tax rate. However, the Company maintains a full valuation allowance as of December&#160;31, 2023 and the recognition of any unrecognized tax benefits would be offset with a change in the valuation allowance and therefore there would be no income statement impact.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's federal and state income tax returns for the tax years 2020 and onwards remain open to examination. The Company's tax returns for Canada remain open to examination for the tax years 2015 through 2022. The Company's Irish tax returns remain open to examination for the tax years 2017 through 2022.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1192-6">As of December&#160;31, 2023, the Company&#8217;s 2018 and 2020 Canadian Scientific Research and Experimental Development Claims are subject to proceedings with the Tax Court of Canada and the Company's 2021 Canadian Scientific Research and Experimental Development Claim is under audit. The Company's 2016 and 2017 Canadian income tax returns for the Adapt entities are under audit. The Company&#8217;s Irish group is under Level 1 Compliance Intervention review for 2021. In addition, the Company&#8217;s 2019 through 2022 Michigan state income tax returns are under audit.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1373" continuedAt="f-1373-1" escape="true">Defined benefit and 401(k) savings plan</ix:nonNumeric></span></div><ix:continuation id="f-1373-1" continuedAt="f-1373-2"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Define benefit pension plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically sponsored a defined benefit pension plan covering eligible employees in Switzerland (the "Swiss Plan"), which was sold as part of our travel health business to Bavarian Nordic, as described further in Note 3, "Divestiture". Under the Swiss Plan, the Company and certain of its employees with annual earnings in excess of government determined amounts were required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. The Swiss Plan's assets were comprised of an insurance contract that had a fair value consistent with its contract value based on the practicability exception using Level 3 inputs. The entire liability was listed as non-current because plan assets were greater than the expected benefit payments over the next year. The Company recognized pension expense related to the Swiss Plan of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PensionExpense" format="ixt:num-dot-decimal" scale="6" id="f-1374">0.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PensionExpense" format="ixt:num-dot-decimal" scale="6" id="f-1375">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:PensionExpense" format="ixt:num-dot-decimal" scale="6" id="f-1376">2.0</ix:nonFraction> million, reflected as a component of selling, general and administrative expenses, for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" id="f-1377" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The funded status of the Swiss Plan for the years ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in Plan Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1378">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1379">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="f-1380">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net benefits received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-1381">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-1382">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="f-1383">5.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="f-1384">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Fair value of plan assets, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1385">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in Benefit Obligation:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="f-1386">46.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1387">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest Cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1388">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="f-1389">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1390">10.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net benefits received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1391">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="f-1392">5.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="f-1393">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Projected benefit obligation, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="f-1394">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Funded status, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-1395">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accumulated benefit obligation, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="f-1396">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-1373-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="f-1397" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic pension cost incurred during the years ended December&#160;31, 2023, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023 </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1398">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1399">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1400">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1401">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1402">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:fixed-zero" scale="6" id="f-1403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-1404">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-1405">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-1406">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="f-1407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-1408">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-1409">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="f-1410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-1411">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-1412">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-1413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="f-1414">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-1415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1416">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1417">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1418">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">The Swiss Plan was sold as part of our travel health business to Bavarian Nordic, as described further in Note 3, "Divestiture".</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="f-1419" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used to calculate the projected benefit obligations were as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.788%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-1420">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Expected rate of return</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-1421">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Rate of future compensation increases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-1422">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall expected long-term rate of return on assets assumption considers historical returns, as well as expected future returns based on the fact that investment returns are insured, and the legal minimum interest crediting rate as applicable.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="f-1423" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents gains (losses) recognized in accumulated other comprehensive income (loss) before income tax related to the Company&#8217;s defined benefit pension plans:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.483%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:19.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net actuarial gain</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-1424">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Prior service cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-1425">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total recognized in other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-1426">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no future benefits expected to be paid as of December&#160;31, 2023.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">401(k) savings plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code (the "401(k) Plan"). The 401(k) Plan covers substantially all U.S. employees. Under the 401(k) Plan, employees may make elective salary deferrals. During the years ended December&#160;31, 2023, 2022 and 2021, the Company made matching contributions of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-1427">8.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-1428">8.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-1429">8.9</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i7b0776f670624692b261a662f247fc47_133"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock" id="f-1430" continuedAt="f-1430-1" escape="true">Purchase commitments </ix:nonNumeric></span></div><ix:continuation id="f-1430-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with vendors for raw materials and other goods or services. Purchase commitments are agreements to purchase raw materials and services that are enforceable, legally binding, and specify terms that (1) include fixed or minimum quantities to be purchased, (2) include fixed, minimum or variable price provisions and (3) are longer than one year. Purchase commitments exclude agreements that are cancellable without penalty.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-1431">526.9</ix:nonFraction> million of purchase commitments associated with raw materials and Bioservices that will be purchased in the next <ix:nonNumeric contextRef="c-1" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:durwordsen" id="f-1432">five years</ix:nonNumeric>, of which the Company estimates that approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1433">117.0</ix:nonFraction> million will be purchased within the next year. For the years ended December&#160;31, 2023, 2022, and 2021, the Company purchased $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1434">107.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1435">199.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1436">110.7</ix:nonFraction> million, respectively, of materials and services under these commitments.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_549755815707"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 18.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1437" continuedAt="f-1437-1" escape="true">Segment information</ix:nonNumeric></span></div><ix:continuation id="f-1437-1" continuedAt="f-1437-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting process. The revised reporting structure reflects the internal reporting and review process used by our CODM for making decisions and assessing performance and is consistent with how we currently manage the business. We now manage our business with a focus on <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="f-1438">three</ix:nonFraction> reportable segments. Our Commercial Products segment, which includes NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products and other commercial products which were sold as part of our travel health business in the second quarter of 2023 (see Note 3, "Divestiture" for more information on the sale of the travel health business), our MCM Products segment, which includes the Anthrax - MCM products, Smallpox - MCM products and Other Products, and our Services segment consisting of our Bioservices offerings. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of these reportable segments based on revenue and segment adjusted gross margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. We define segment adjusted gross margin, as segment gross margin excluding the impact of restructuring costs and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. We define total segment adjusted gross margin, which is a non-GAAP financial measure, as total segment gross margin, excluding the impact of restructuring costs, inventory step-up provision and the fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-1439" continuedAt="f-1439-1" escape="true"><ix:continuation id="f-1437-2" continuedAt="f-1437-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment cost of sales or services, segment gross margin, segment gross margin % and total segment adjusted gross margin for each of our reportable segments for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1440">497.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1441">386.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1442">438.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1443">447.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1444">579.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1445">585.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1446">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1447">109.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1448">615.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1449">1,023.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1450">1,076.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1451">1,639.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1452">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1453">41.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1454">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1455">1,049.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1456">1,117.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1457">1,773.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost of sales or services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1458">210.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1459">160.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1460">187.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1461">305.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1462">264.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1463">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1464">189.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1465">268.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1466">365.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total cost of sales or services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1467">705.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1468">693.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1469">748.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1470">287.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1471">226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1472">250.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1473">141.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1474">315.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1475">390.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="f-1476">111.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="f-1477">158.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1478">250.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total segment gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1479">317.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1480">383.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-1481">891.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross margin %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-156" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1482">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-150" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1483">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-378" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1484">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-157" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1485">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1486">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-379" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1487">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-158" decimals="2" sign="-" name="ebs:GrossProfitPercentage" scale="-2" id="f-1488">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" sign="-" name="ebs:GrossProfitPercentage" scale="-2" id="f-1489">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-380" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1490">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1491">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1492">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="2" name="ebs:GrossProfitPercentage" scale="-2" id="f-1493">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment adjusted gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1494">287.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1495">226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1496">250.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1497">151.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1498">369.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1499">393.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" sign="-" name="ebs:AdjustedGrossMargin" scale="6" id="f-1500">102.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" sign="-" name="ebs:AdjustedGrossMargin" scale="6" id="f-1501">158.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1502">250.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total segment adjusted gross margin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1503">335.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1504">437.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1505">894.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Services revenue, Services gross margin and Services segment adjusted gross margin for the year ended December&#160;31, 2021 includes the impact of $<ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-1506">243.1</ix:nonFraction> million of Bioservices leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Segment revenues less total cost of sales or services.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><ix:continuation id="f-1437-3"><ix:continuation id="f-1439-1"><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the Company's total segment adjusted gross margin to the Consolidated Statement of Operations:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total segment adjusted gross margin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1507">335.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1508">437.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1509">894.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1510">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1511">41.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1512">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1513">14.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-1514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-1515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment inventory step-up provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" sign="-" name="ebs:InventoryStepUp" scale="6" id="f-1516">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-5" sign="-" name="ebs:InventoryStepUp" scale="6" id="f-1517">51.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-5" name="ebs:InventoryStepUp" format="ixt:fixed-zero" scale="6" id="f-1518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1519">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1520">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1521">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-1522">306.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-1523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-1524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1525">111.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1526">188.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1527">235.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1528">368.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1529">339.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1530">348.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-1531">218.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-1532">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-1533">41.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1534">65.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1535">59.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1536">58.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1537">87.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1538">37.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1539">34.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-1540">74.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-1541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-1542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1543">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1544">11.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1545">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1546">731.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1547">219.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1548">303.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1549" escape="true"><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each segment:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Depreciation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1550">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1551">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1552">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1553">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1554">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1555">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1556">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1557">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1558">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1559">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1560">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1561">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1562">59.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1563">83.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1564">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1565" escape="true"><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes revenues by country. Revenues have been attributed based on the location of the customer:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1566">607.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1567">886.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1568">1,623.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1569">224.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1570">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1571">66.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1572">217.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1573">82.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1574">83.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1575">1,049.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1576">1,117.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1577">1,773.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="f-1578" escape="true"><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table included long-lived assets, net by country. Long-lived assets, net includes right-of-use assets and property, plant &amp; equipment, net, excluding software, net:</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Long-lived assets, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1579">352.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1580">696.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:fixed-zero" scale="6" id="f-1581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1582">88.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1583">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1584">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1585">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1586">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total long-lived assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1587">392.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1588">826.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-1589" continuedAt="f-1589-1" escape="true">Litigation</ix:nonNumeric></span></div><ix:continuation id="f-1589-1"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#8211; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The lead plaintiffs in the consolidated matter (the "Lead Plaintiffs") are Nova Scotia Health Employees&#8217; Pension Plan and The City of Fort Lauderdale Police &amp; Firefighters&#8217; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiffs filed an opposition to that motion on July 19, 2022. A hearing on the motion to dismiss was conducted on April 19, 2023 and an order was entered on September 1, 2023, granting in part and denying in part the motion to dismiss. The defendant's answer to the complaint was filed on October 30, 2023. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Lincolnshire Police Pension Fund (&#8220;Lincolnshire&#8221;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022, the Court approved the parties' joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp; Police Officers Pension Fund, respectively, in the Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#8217; filed a motion to dismiss the complaint. Ruling on this motion is stayed pursuant to a March 29, 2022 order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities. The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#8217; motion to dismiss, and on November 2, 2023, the Court approved the parties' joint stipulation to extend the stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above actions, the Company has received inquiries and subpoenas to produce documents related to these matters from the Department of Justice, the SEC, the Maryland Attorney General&#8217;s Office, and the New York Attorney General&#8217;s Office. The Company produced or is producing documents as required in response and will continue to cooperate with these government inquiries. The Company also received inquiries and subpoenas from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis and Senator Murray of the Committee on Health, Education, Labor and Pensions. The Company produced documents and provided testimony and briefings as requested in response to these inquiries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_145"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:7pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7b0776f670624692b261a662f247fc47_148"></div><div style="margin-bottom:7pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:7pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our interim chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2023. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2023, our interim chief executive officer and chief financial officer concluded that, as of such date, that the disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:7pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our system of internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2023. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013 Framework). As a result of this assessment, our management concluded that, as of December&#160;31, 2023, our internal control over financial reporting was effective based on those criteria.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young LLP, the independent registered public accounting firm that has audited our consolidated financial statements included herein, has issued an attestation report on the effectiveness of our internal control over financial reporting as of December&#160;31, 2023, a copy of which is included in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:7pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September 30, 2023, a material weakness was identified related to the design of our controls associated with the review of the calculation of our state deferred tax assets and liabilities and the operating effectiveness of the controls associated with the review of the valuation allowance calculation and included in Amendment No. 1 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To remediate the material weakness and as part of our commitment to strengthening our internal control over financial reporting, we enhanced and revised the design of existing controls and procedures to properly assess the state income taxes issue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended December 31, 2023, we successfully completed the testing necessary to conclude that the material weakness has been remediated.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Except those described above, there has been no change in the Company's internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) that occurred during the quarter ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Emergent BioSolutions Inc.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Emergent BioSolutions Inc. and subsidiaries&#8217; internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Emergent BioSolutions Inc. and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of  December 31, 2023, based on the COSO criteria.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and financial statement schedule listed in the Index at Item 15 and our report dated March&#160;8, 2024, expressed an unqualified opinion thereon that included an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.                                                                                                                  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tysons, Virginia</span></div><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;8, 2024</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. OTHER INFORMATION</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2023, none of the Company's directors or Section 16 reporting officers <ix:nonNumeric contextRef="c-401" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1590"><ix:nonNumeric contextRef="c-401" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1591">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-401" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1592"><ix:nonNumeric contextRef="c-401" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1593">terminated</ix:nonNumeric></ix:nonNumeric> any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).</span></div><div id="i7b0776f670624692b261a662f247fc47_154"></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7b0776f670624692b261a662f247fc47_157"></div><div style="margin-bottom:9pt;margin-top:7pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i7b0776f670624692b261a662f247fc47_160"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of business conduct and ethics that applies to our directors, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions), as well as our other employees. A copy of our code of business conduct and ethics is available on our website at www.emergentbiosolutions.com. We intend to post on our website all disclosures that are required by applicable law, the rules of the SEC or the New York Stock Exchange concerning any amendment to, or waiver of, our code of business conduct and ethics. The reference to our website is intended to be an inactive textual reference only. Neither the information on nor that can be accessed through our website are incorporated by reference in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining information required by Item 10 is hereby incorporated by reference from our Definitive Proxy Statement relating to our 2024 Annual Meeting of Stockholders, to be filed with the U.S. Securities and Exchange Commission ("SEC") within 120 days following the end of our fiscal year.</span></div><div id="i7b0776f670624692b261a662f247fc47_163"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 11 is hereby incorporated by reference from our Definitive Proxy Statement relating to our 2024 annual meeting of stockholders, to be filed with the SEC within 120 days following the end of our fiscal year.</span></div><div id="i7b0776f670624692b261a662f247fc47_166"></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 12 is hereby incorporated by reference from our Definitive Proxy Statement relating to our 2024 Annual Meeting of Stockholders, to be filed with the SEC within 120 days following the end of our fiscal year.</span></div><div id="i7b0776f670624692b261a662f247fc47_169"></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 13 is hereby incorporated by reference from our Definitive Proxy Statement relating to our 2024 Annual Meeting of Stockholders, to be filed with the SEC within 120 days following the end of our fiscal year.</span></div><div id="i7b0776f670624692b261a662f247fc47_172"></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 14 is hereby incorporated by reference from our Definitive Proxy Statement relating to our 2024 Annual Meeting of Stockholders, to be filed with the SEC within 120 days following the end of our fiscal year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_175"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i7b0776f670624692b261a662f247fc47_178"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial statements and supplementary data are filed as a part of this Annual Report on Form 10-K in Part II, Item 8.</span></div><div style="margin-bottom:4pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-1594">42</ix:nonNumeric>)</span></div><div style="margin-bottom:4pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Consolidated Balance Sheets at December&#160;31, 2023 and 2022 </span></div><div style="margin-bottom:4pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Consolidated Statements of Operations for the years ended December&#160;31, 2023, 2022 and 2021 </span></div><div style="margin-bottom:4pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Consolidated Statements of Comprehensive Income (Loss) for the years ended December&#160;31, 2023, 2022 and 2021 </span></div><div style="margin-bottom:4pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2023, 2022 and 2021 </span></div><div style="margin-bottom:4pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Consolidated Statement of Changes in Stockholders' Equity for the years ended December&#160;31, 2023, 2022 and 2021 </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statement Schedules</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule II - Valuation and Qualifying Accounts for the years ended December&#160;31, 2023, 2022 and 2021 has been filed as part of this annual report on Form 10-K. All other financial statement schedules are omitted because they are not applicable or the required information is included in the financial statements or notes thereto.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits hereto and such listing is incorporated herein by reference.</span></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="f-1595" escape="true"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-style:italic;font-weight:400;line-height:100%">(in millions)&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Beginning Balance</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Charged to Costs and Expenses</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Deductions</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Ending Balance</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1596">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-1597">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-1598">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1599">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1600">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-1601">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-1602">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1603">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1604">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-1605">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-1606">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1607">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All documents referenced below were filed pursuant to the Securities Exchange Act of 1934 by the Company, (File No. 001-33137), unless otherwise indicated.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Number</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-left:1pt solid #ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td></tr><tr><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764416000074/ex3.htm">Third Restated Certificate of Incorporation of the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 3 to the Company's Quarterly Report on Form 10-Q filed on August 5, 2016).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764412000042/exhibit3.htm">Amended and Restated By-laws of the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 3 to the Company's Current Report on Form 8-K filed on August 16, 2012).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000095013306004496/w20323a3exv4w1.htm">Specimen Common Stock Certificate </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 4.1 to Amendment No. 3 to the Company's Registration Statement on Form S-1 filed on October 20, 2006) (Registration No. 333-136622).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000095013306004169/w20323a1exv4w3.htm">Registration Rights Agreement, dated as of September 22, 2006, among the Company and the stockholders listed on Schedule 1 thereto</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 4.3 to Amendment No. 1 to the Company's Registration Statement on Form S-1 filed on September 25, 2006) (Registration No. 333-136622).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/registrationrightstermin.htm">Agreement to Terminate Class A Stockholders Registration Rights Agreement, dated December 9, 2021 by and among Emergent BioSolutions Inc., Intervac, L.L.C. and BioVac, L.L.C.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K filed on February 25, 2022).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764414000007/exhibit4-1.htm">Indenture, dated as of January 29, 2014, between the Company and Wells Fargo Bank, National Association, including the form of 2.875% Convertible Senior Notes due 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on January 29, 2014).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000110465920092005/tm2026914d1_ex4-1.htm">Indenture, dated as of August 7, 2020, by and among the Company, certain subsidiaries of the Company and U.S. Bank National Association, as trustee. (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, filed on August 7, 2020.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000110465920092005/tm2026914d1_ex4-1.htm">Form of 3.875% Senior Unsecured Note due 2028 (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, filed on August 7, 2020.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 4.2 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit46-descriptionofs.htm">Description of the Company's Securities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 4.6 to the Company's Annual Report on Form 10-K filed on February 19, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000110465918062153/a18-36350_2ex10.htm">Amended and Restated Credit Agreement, dated October 15, 2018, by and among Emergent BioSolutions Inc., the lenders party thereto from time to time, and Wells Fargo Bank, National Association, as the Administrative Agent</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10 to the Company's Current Report on Form 8-K, filed on October 15, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764419000038/ebs-201906030xex102.htm">First Amendment to Amended and Restated Credit Agreement, dated June 27, 2019</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (incorporated by reference to Exhibit 10.2 to the Company's Annual Report on Form 10-K filed on February 19, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000110465920092005/tm2026914d1_ex10-2.htm">Second Amendment to Amended and Restated Credit Agreement, dated August 7, 2020 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K, filed on August 7, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000046/consentlimitedwaiverandt.htm">Consent, Limited Waiver, and Third Amendment to the Amended and Restated Credit Agreement, dated February 14, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.4 to the Company's Annual Report on Form 10-K, filed on March 1, 2023). </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000119312523147301/d499270dex101.htm">Fourth Amendment to Amended and Restated Credit Agreement, Waiver and First Amendment to Amended and Restated Collateral Agreement, dated May 15, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed on May 18, 2023). </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fifthamendmenttoamendeda.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fifthamendmenttoamendeda.htm">ifth Amendment to Amended and Restated Credit Agreement, dated July 14, 2023</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764424000026/emergent-forbearanceagre.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764424000026/emergent-forbearanceagre.htm">or</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764424000026/emergent-forbearanceagre.htm">bearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement, dated February 29, 2024</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed March 6, 2024)</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000095013306004611/w20323a5exv10w3.htm">Emergent BioSolutions Inc. 2006 Stock Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.3 to Amendment No. 5 to the Company's Registration Statement on Form S-1 filed on October 30, 2006) (Registration No. 001-33137).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764409000055/ex10.htm">Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on August 7, 2009).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000119312512153604/d288376ddef14a.htm">Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(incorporated by reference to Appendix A to the Company's definitive proxy statement on Schedule 14A filed on April 6, 2012).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000119312514133581/d703513ddef14a.htm">Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">corporated by reference to Appendix A to the Company's definitive proxy statement on Schedule 14A filed on April 7, 2014).</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Number</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-left:1pt solid #ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764416000074/ex10_2.htm">Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on August 5, 2016).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000046/ebsstockincentiveplan-ja.htm">Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan Approved by the Compensation Committee of the Board of Directors of Emergent BioSolutions Inc. on January 4, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.10 to the Company's Annual Report on Form 10-K filed on March 1, 2023). </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000027/exhibit99.htm">Emergent BioSolutions Inc. Stock Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 99 to Registration Statement on Form S-8, filed on May 30, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000119312523160848/d401818dex44.htm">Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-8, filed on June 5, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000119312523160848/d401818dex45.htm">Emergent BioSolutions Inc. Amended Employee Stock Purchase Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-8, filed on June 5, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000119312523147301/d499270dex102.htm">Equity Distribution Agreement, dated May 17, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the 8-K filed on May 18, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000155/ebs-brginterimmanagement.htm">Consulting Agreement, dated as of July 7, 2023 and effective as of July 7, 2023, by and between Emergent BioSolutions Inc. and Haywood Miller</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.10 to the Company's Quarterly Report on Form 10-Q filed on August 8, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/finalpapaexecutiveemploy.htm">Executive Agreement, dated February 19, 2024 between Emergent BioSolutions Inc. and Joseph Papa</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10 to the Company's Current Report on Form 8-K filed on February 21, 2024). </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000142/formofletteragreement726.htm">Form of Letter Agreement, dated July 26, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 99.1 to the 8-K filed on July 27, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764419000016/exhibit10-10.htm">Form of Director Nonstatutory Stock Option Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764419000016/exhibit10-11.htm">Form of Director Restricted Stock Unit Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit1013-globalrsu_aw.htm">Global Form of Restricted Stock Unit Award Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.13 to the Company's Annual Report on Form 10-K filed on February 19, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001367644/000136764420000010/ebs-20191231exhibit1011.htm">Global Form of Non-Qualified Stock Option Agreement </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764419000012/exhibit_10.htm">Form of 2019-2021 Performance-Based Stock Unit Award Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10 to the Company&#8217;s Current Report on Form 8-K filed on February 12, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764420000006/ex102020-2022psuagreement.htm">Form of 2020-2022 Performance-Based Stock Unit Award Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10 to the Company&#8217;s Current Report on Form 8-K filed on February 18, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000020/a2021-2023psuagreementedga.htm">Form of 2021-2023 Performance-Based Stock Unit Award Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 99 to the Company&#8217;s Current Report on Form 8-K filed on February 16, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000009/exhibit10formof2022-2024.htm">Form of 2022-2024 Performance-Based Stock Unit Award Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10 to Current Report on Form 8-K filed on February 22, 2022).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000075/exc_compmins2-9x23v1x202.htm">Form of 2023-2025 Performance Based Stock Unit Award Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10 to Current Report on Form 8-K filed on March 23, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000208/emergentbiosolutionsincind.htm">Emergent BioSolutions Inc. Inducement Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference from Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed on December 11, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764413000004/exhibit10.htm">Form of Indemnity Agreement for Directors and Senior Officers</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10 to the Company's Current Report on Form 8-K filed on January 18, 2013).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764410000008/ex10_7.htm">Annual Bonus Plan for Executive Officers </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.7 to the Company's Annual Report on Form 10-K filed on March 5, 2010).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764411000068/ex10-1.htm">Amended and Restated Senior Management Severance Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on December 22, 2011).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764415000033/ex_10.htm">Second Amended and Restated Senior Management Severance Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10 to the Company's Current Report on Form 8-K filed on July 16, 2015).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764417000014/exhibit10-24.htm">Solicitation/Contract/Order for Commercial Items (the CDC BioThrax Procurement Contract), effective December 8, 2016, from the Centers for Disease Control and Prevention to Emergent Biodefense Operations Lansing LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.24 to the Company&#8217;s Annual Report on Form 10-K, filed on February 28, 2017).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000014/exhibit10-22.htm">Modification No. 1, effective January 27, 2017, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.22 to the Company's Annual Report on Form 10-K filed on February 23, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000014/exhibit10-23.htm">Modification No. 2, effective February 23, 2017, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.23 to the Company's Annual Report on Form 10-K filed on February 23, 2018).</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Number</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-left:1pt solid #ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000014/exhibit10-24.htm">Modification No. 3, effective March 22, 2017, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.24 to the Company's Annual Report on Form 10-K filed on February 23, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000014/exhibit10-25.htm">Modification No. 4, effective April 5, 2017, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.25 to the Company's Annual Report on Form 10-K filed on February 23, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764417000048/exhibit10_2.htm">Modification No. 5, effective September 8, 2017, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on November 3, 2017).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000014/exhibit10-27.htm">Modification No. 6, effective September 21, 2017, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.27 the Company&#8217;s Annual Report on Form 10-K filed on February 23, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000023/exhibit10_1.htm">Modification No. 7, effective February 26, 2018, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000023/exhibit10_2.htm">Modification No. 8, effective March 6, 2018, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000033/exhibit10_2.htm">Modification No. 9, effective June 6, 2018, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on August 3, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000033/exhibit10_3.htm">Modification No. 10, effective June 18, 2018, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on August 3, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000033/exhitbit10_4.htm">Modification No. 11, effective June 20, 2018, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on August 3, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000033/exhibit10_5.htm">Modification No. 12, effective June 21, 2018, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on August 3, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764418000044/exhibit10_2.htm">Modification No. 13, effective September 21, 2018 to the CDC BioThrax Procurement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on November 2, 2018).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764419000016/exhibit10-45.htm">Modification No. 14, effective October 1, 2018, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.45 the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764419000016/exhibit10-46.htm">Modification No. 15, effective December 7, 2018, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.46 the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764419000016/exhibit10-47.htm">Modification No. 16, effective January 14, 2019, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.47 the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764419000038/ebs-20190630xex101.htm">Modification No. 17, effective June 13, 2019, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on August 2, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000010/ebs20191231exhibit1039.htm">Modification No. 18, effective September 11, 2019, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.39 the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000010/ebs20191231exhibit1040.htm">Modification No. 19, effective January 6, 2020, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.40 the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000010/ebs20191231exhibit1041.htm">Modification No. 20, effective January 7, 2020, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.41 the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit1045-mod21to200x2.htm">Modification No. 21, effective January 7, 2020, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.45 the Company&#8217;s Annual Report on Form 10-K filed on February 19, 2021)</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit1046-mod22to200x2.htm">Modification No. 22 to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.46 the Company&#8217;s Annual Report on Form 10-K filed on February 19, 2021)</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit1047-mod23to200x2.htm">Modification No. 23, effective September 30, 2020, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.47 the Company&#8217;s Annual Report on Form 10-K filed on February 19, 2021)</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000137/emergentbiosolutions200-.htm">Modification No. 24, effective February 2, 2021, to the CDC BioThrax Procurement Contract</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000137/emergentbiosolutions27a1.htm">Modification No. 25, effective September 29, 2021, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutions200-.htm">Modification No. 26, effective November 1, 2021, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.48 the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2022).  </span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000070/biothraxcontractmod27edg.htm">Modification No. 27, effective March 31, 2022, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on April 29, 2022).</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Number</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-left:1pt solid #ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000119/a200-2017x92634xmod28exe.htm">Modification No. 28, effective April 14, 2022, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on August 2, 2022).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000119/a200-2017x92634xmod29exe.htm">Modification No. 29, effective June 16, 2022, to the CDC BioThrax Procurement Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on August 2, 2022). </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764416000082/exhibit10_2.htm">Award/Contract (the BARDA AV7909 Contract), effective September 30, 2016, from the BioMedical Advanced Research and Development Authority to Emergent Product Development Gaithersburg Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on November 9, 2016).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764417000022/exhibit10_2.htm">Modification No. 1, effective March 16, 2017, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2021) </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764418000044/exhibit10_3.htm">Modification No. 2, effective August 29, 2018, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764419000053/bardassleditsv4.htm">Modification No. 3, effective July 30, 2019, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on November 9, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000047/a101-bardaav7909mod4.htm">Modification No. 4, effective March 3, 2020, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 1, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000047/a102-bardaav7909mod5.htm">Modification No. 5, effective April 10, 2020, to the BARDA AV7909 Contract </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 1, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a103-hhsmod6.htm">Modification No. 6, effective July 13, 2020, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionshso1.htm">Modification No. 7, effective December 2, 2020, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionshb12.htm">Modification No. 8, effective March 22, 2021, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsh621.htm">Modification No. 9, effective April 21, 2021, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsh396.htm">Modification No. 10, effective June 10, 2021 to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000137/emergentbiosolutionshhso.htm">Modification No. 11, effective September 30, 2021, to the BARDA AV7909 Contract </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutionsha65.htm">Modification No. 12, effective December 2, 2021, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.61 to the Company's Annual Report on Form 10-K filed on February 25, 2022).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000155/modificationno13effectiv.htm">Modification No. 13, effective March 30, 2023, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on August 9, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000155/modificationno14effectiv.htm">Modification No. 14, effective March 30, 2023, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on August 9, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"># &#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="modificationno15effectiv.htm">Modification No. 15, effective October 6, 2023, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"># &#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="modificationno16effectiv.htm">Modification No. 16, effective November 21, 2023, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764419000016/exhibit10-51.htm">License Agreement, dated as of December 15, 2014, by and between Opiant Pharmaceuticals, Inc. (formerly known as Lightlake Therapeutics Inc.) and Adapt Pharma Operations Limited.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.51 the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1367644/000136764419000016/exhibit10-52.htm">Amendment No. 1 to License Agreement, dated as of December 13, 2016, by and between Opiant Pharmaceuticals, Inc. and Adapt Pharma Operations Limited.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.52 the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764419000023/ebs-20190331xex10.htm">Amendment No. 2 to License Agreement, dated December 15, 2014, by and between Opiant Pharmaceuticals, Inc. and Adapt Pharma Operations Limited, effective March 18, 2019 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.1 the Company&#8217;s Quarterly Report on Form 10-Q filed on May 8, 2019).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000010/ebs20191231exhibit1048.htm">Award/Contract, effective August 30, 2019 (ACAM2000 Contract), from the Assistant Secretary, U.S. Department of Health and Human Services (ASPR/OPM) to Emergent Product Development Gaithersburg Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (incorporated by reference to Exhibit 10.48 the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000124/a105-mod1acam2000.htm">Modification No. 1, effective, May 28, 2020 to the ACAM2000 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on July 31, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit1060-mod2to5a5011.htm">Modification No. 2, effective, October 28, 2020 to the ACAM2000 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.60 the Company&#8217;s Annual Report on Form 10-K filed on February 19, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutions75a5.htm">Modification No. 3, effective, April 1</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutions75a5.htm">, 2021</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutions75a5.htm"> to the ACAM2000 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Number</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-left:1pt solid #ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutions70f0.htm">Modification No. 4, effective, July 13, 2021 to the ACAM2000 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.69 to the Company's Annual Report on Form 10-K filed on February 25, 2022).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutions77ea.htm">Modification No. 5, effective, September 29, 2021 to the ACAM2000 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.70 to the Company's Annual Report on Form 10-K filed on February 25, 2022).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutions75a5.htm">Modification No. 6, effective, November 1, 2021 to the ACAM2000 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.71 to the Company's Annual Report on Form 10-K filed on February 25, 2022).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"># </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="modificationno7effective.htm">Modification No. 7, effective October 6, 2022, to the ACAM2000 Contract.</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"># &#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="modificationno8effective.htm">Modification No. 8, effective November 21, 2022, to the ACAM2000 Contract.</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000155/modificationno9effective.htm">Modification No. 9, effective May 24, 2023, to the ACAM2000 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q filed on August 9, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000155/modificationno10effectiv.htm">Modification No. 10, effective May 26, 2023, to the ACAM2000 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed on August 9, 2023).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000124/a101-bardaadm2012agree.htm">Award/Contract, effective June 15, 2012 (BARDA ADM Contract), from the BioMedical Advance Research and Development Authority to Emergent Manufacturing Operations Baltimore LLC. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on July 31, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsh657.htm">Order for Supplies and Services Between Emergent Manufacturing Operations Baltimore LLC and the BioMedical Advance Research and Development Authority, dated April 2, 2020, under the BARDA ADM Contract (Task Order 75A50120F33006)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.8 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionshhso.htm">Modification No. 1, effective April 12, 2021, to Task Order 75A50120F33006</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  (incorporated by reference to Exhibit 10.9 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/ebshhso100201200004i_75a.htm">Modification No. 3, effective</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/ebshhso100201200004i_75a.htm"> October 1, 2021,</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/ebshhso100201200004i_75a.htm"> to Task Order 75A50120F33006</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.75 to the Company's Annual Report on Form 10-K filed on February 25, 2022).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutionshhso.htm">Modification No. 4, effective </a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutionshhso.htm">November 1, 2021,</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutionshhso.htm"> to Task Order 75A50120F33006</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.76 to the Company's Annual Report on Form 10-K filed on February 25, 2022).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000124/a104-bardaadmorder.htm">Order for Supplies and Services Between Emergent Manufacturing Operations Baltimore LLC and the BioMedical Advance Research and Development Authority, dated May 24, 2020, under the BARDA ADM Contract (Task Order 75A50120F33007) </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000124/a104-bardaadmorder.htm"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.4 to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">filed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 31, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a109-dpas.htm">Modification No. 1, effective August 24, 2020, to Task Order 75A50120F33007</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.9 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit1064-mod2to75a501.htm">Modification No. 2, effective September 18, 2020, to Task Order 75A50120F33007</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.64 to the Company's Annual Report on Form 10-K filed on February 19, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit1065-mod3to75a501.htm">Modification No. 3, effective October 7, 2020, to Task Order 75A50120F33007</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.65 to the Company's Annual Report on Form 10-K filed on February 19, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000073/emergentbiosolutionshhso.htm">Modification No. 4, effective January 29, 2021, to Task Order 75A50120F33007</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on April 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000073/emergentbiosolutionshf1c.htm">Modification No. 5, effective February 22, 2021, to Task Order 75A50120F33007</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on April 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000073/emergentbiosolutionsmod6.htm">Modification No. 6, effective March 24, 2021, to Task Order 75A50120F33007</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on April 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionshb43.htm">Modification No. 7, effective May 24, 2021, to Task Order 75A50120F33007</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.10 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutionsmodp.htm">Modification No. 8, effective November 1, 2021, to Task Order 75A50120F33007</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.85 to the Company's Annual Report on Form 10-K filed on February 25, 2022).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a1010-hhso.htm">Order for Supplies and Services Between Emergent Manufacturing Operations Baltimore LLC and the BioMedical Advance Research and Development Authority, dated August 6, 2020, under the BARDA ADM Contract (Task Order 75A50120F33008).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.10 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a1011-admdpas.htm">Modification No. 1, effective August 24, 2020, to Task Order 75A50120F33008</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.11 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit1068-mod2to75a501.htm">Modification No. 2, effective November 17, 2020, to Task Order 75A50120F33008.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.68 the Company&#8217;s Annual Report on Form 10-K filed on February 19, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000124/a102-mod19bardaadm.htm">Modification No. 19, effective, May 25, 2020, to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on July 31, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000124/a103-mod20bardaadm.htm">Modification No. 20, effective, May 26, 2020, to the BARDA ADM Contract </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on July 31, 2020).</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Number</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-left:1pt solid #ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a104-mod21.htm">Modification No. 21, effective June 12, 2020 to the BARDA ADM Contract </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a105-mod22.htm">Modification No. 22, effective June 12, 2020 to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a106-mod23.htm">Modification No. 23, effective July 22, 2020 to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a107-mod24.htm">Modification No. 24, effective August 28, 2020 to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a108-mod25.htm">Modification No. 25, effective September 23, 2020 to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.8 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/exhibit1078-mod26to2012a.htm">Modification No. 26, effective November 2, 2020 to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (incorporated by reference to Exhibit 10.77 the Company&#8217;s Annual Report on Form 10-K filed on February 19, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsmod0.htm">Modification No. 27, effective May 6, 2021, to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsmd98.htm">Modification No. 28, effective May 27, 2021, to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001367644/000136764421000137/emergentbiosolutionsadm-.htm">Modification No. 30, effective September 30, 2021, to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2021).</span></div></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutionsadm-.htm">Modification No. 31, effective October 20, 2021, to the BARDA ADM Contract</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.100 to the Company's Annual Report on Form 10-K filed on February 25, 2022). </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/emergentbiosolutionsaa47.htm">Modification No. 32, effective November 1, 2021, to the BARDA ADM Contract.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.101 to the Company's Annual Report on Form 10-K filed on February 25, 2022).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a1012-azmaster.htm">Master Services Agreement, dated July 24, 2020, by and between Emergent Manufacturing Operations Baltimore, LLC and AstraZeneca Pharmaceuticals LP.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (AZ MSA) (incorporated by reference to Exhibit 10.12 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a1013-azproductschedule.htm">Manufacturing Product Schedule, dated July 26, 2020 to AZ MSA</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.13 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a1014-azminixmsa.htm">Work Order to Manufacturing Services Agreement, dated June 10, 2020, between Emergent Manufacturing Operations Baltimore, LLC and AstraZeneca Pharmaceuticals LP</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (included as part of AZ MSA) (incorporated by reference to Exhibit 10.14 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a1015-azmsaamend.htm">Amendment No. 1, effective September 30, 2020, to AZ MSA</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.15 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.210&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000073/emergentbiosolutionsa7d5.htm">Amendment No. 2, effective October 30, 2020, to AZ MSA</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on April 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000073/emergentbiosolutionsa35c.htm">Amendment No. 3, effective November 25, 2020, to AZ MSA</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q filed on April 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000073/emergentbiosolutionsazms.htm">Amendment No. 4, effective January 21, 2021, to AZ MSA</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed on April 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsazch.htm">Change Order No. 1 to Work Order #5997-01, effective July 31, 2020, to AZ MSA</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.11 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsad3e.htm">Change Order No. 2 to Work Order #5997-01, effective August 04, 2020, to AZ MSA </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.12 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsaz_c.htm">Change Order No. 4 to Work Order #5997-01, effective November 17, 2020, to AZ MSA </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.13 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsaa7f.htm">Change Order No. 5 to Work Order #5997-01, effective September 16, 2020, to AZ MSA </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.14 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsa41c.htm">Change Order No. 6 to Work Order #5997-01, effective October 13, 2020, to AZ MSA </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.15 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsastr.htm">Change Order No. 10 to Work Order #5997-01, effective March 10, 2021, to AZ MSA </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.16 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000115/emergentbiosolutionsae53.htm">Change Order No. 13 to Work Order #5997-01, effective April 23, 2021, to AZ MSA </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(incorporated by reference to Exhibit 10.17 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764420000163/a1016-janssenagreement.htm">Manufacturing Services Agreement, dated July 2, 2020, by and between Emergent Manufacturing Operations Baltimore, LLC and Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (JNJ MSA) (incorporated by reference to Exhibit 10.16 to the Company's Quarterly Report on Form 10-Q filed on November 6, 2020).</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Number</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-left:1pt solid #ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764421000073/emergentbiosolutionsjans.htm">Amendment No. 1, effective February 25, 2021, to JNJ MSA</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on April 30, 2021).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000075/exhibit2-projecteaglexas.htm">Asset Purchase Agreement, dated May 15, 2022, by and among Emergent BioSolutions Inc., the Sellers identified therein, Chimerix, Inc.,</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 2 to the Company's Current Report on Form 8-K, filed on May 16, 2022).</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764423000046/purchaseandsaleagreement.htm">Purchase and Sale Agreement dated February 15, 2023 by and between Emergent BioSolutions Inc., through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc. and Bavarian Nordic</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (incorporated by reference to Exhibit 10.204 to the Company's Annual Report on Form 10-K filed on March 1, 2023). </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="emergentbiosolutionscomp.htm">Emergent BioSolutions Compensation Recovery Policy, effective October 26, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="subsidiariesofthecompany.htm">Subsidiaries of the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23-consentofindepen.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a311-papacert123123.htm">Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a312-lindhalcert123123.htm">Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a321-papacert123123.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a322-lindhalcert123123.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information related to the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income (Loss), (iv) the Consolidated Statements of Cash Flows, (v) the Consolidated Statement of Changes in Stockholders' Equity; (vi) the related Notes to Consolidated Financial Statements; and (vii) the Cover Page.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment granted by the SEC as to certain portions. Confidential materials omitted and filed separately with the SEC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement filed herewith in response to Item 15(a) of Form 10-K.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b0776f670624692b261a662f247fc47_184"></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.666%"><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div></div><div style="display:inline-block;max-width:6.666%;min-width:5.666%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.668%"></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><div id="i7b0776f670624692b261a662f247fc47_187"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:11pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EMERGENT BIOSOLUTIONS INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/RICHARD S. LINDAHL</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard S. Lindahl</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer and Treasurer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 8, 2024</span></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"/><td style="width:22.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Signature</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Title</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Date</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Joseph C. Papa</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Richard S. Lindahl</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard S. Lindahl</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer and Treasurer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Zsolt Harsanyi, Ph.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zsolt Harsanyi, Ph.D.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Kathryn Zoon, Ph.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn Zoon, Ph.D.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Ronald B. Richard</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ronald B. Richard</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Louis W. Sullivan, M.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louis W. Sullivan, M.D.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Don DeGolyer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Don DeGolyer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Neal Fowler</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neal Fowler</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Marvin White</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marvin White</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Sujata Dayal</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sujata Dayal</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Keith Katkin</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Keith Katkin</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>fifthamendmenttoamendeda.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>fifthamendmenttoamendeda</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- fifthamendmenttoamendeda001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="fifthamendmenttoamendeda001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">EXECUTION VERSION  175106645_4  FIFTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT  FIFTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this  &#8220;Amendment&#8221;), dated as of July 14, 2023, among EMERGENT BIOSOLUTIONS INC., a Delaware  corporation (the &#8220;Borrower&#8221;) and WELLS FARGO BANK, NATIONAL ASSOCIATION, as  administrative agent (the &#8220;Administrative Agent&#8221;). Unless otherwise indicated, all capitalized terms used  herein and not otherwise defined herein shall have the respective meanings provided such terms in the  Credit Agreement referred to below.  W I T N E S S E T H:  WHEREAS, the Borrower, the lenders party thereto from time to time (the &#8220;Lenders&#8221;) and the  Administrative Agent have entered into that certain Amended and Restated Credit Agreement, dated as of  October 15, 2018 (as amended by the First Amendment to Amended and Restated Credit Agreement dated  as of June 27, 2019, as further amended by the Second Amendment to Amended and Restated Credit  Agreement dated as of August 7, 2020, as further amended by the Consent, Limited Waiver, Third  Amendment to Amended and Restated Credit Agreement dated as of February 14, 2023,  and as further  amended by the Fourth Amendment to Amended and Restated Credit Agreement, Waiver and First  Amendment to Amended and Restated Collateral Agreement dated as of May 15, 2023, and as may further  be amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof,  including as amended by this Amendment, the &#8220;Credit Agreement&#8221;);  WHEREAS, pursuant to Section 12.2 of the Credit Agreement, the Administrative Agent and the  Borrower are permitted to amend any provision of the Loan Documents (and such amendment shall become  effective without any further action or consent of any other party to any Loan Document) if the  Administrative Agent and the Borrower shall have jointly identified an obvious error or any error,  ambiguity, defect or inconsistency or omission of a technical or immaterial nature in any such provisions;  WHEREAS, the Borrower and the Administrative Agent have jointly identified an obvious error  resulting from an omission of a technical nature in the Credit Agreement; and  WHEREAS, the parties hereto have agreed to the amendments to the Credit Agreement set forth in  Section 1 hereof.  NOW, THEREFORE, in consideration of the foregoing and for other good and valuable  consideration set forth herein, the parties hereto agree that the Credit Agreement is amended as follows:   SECTION 1. Amendment to Credit Agreement.  Subject to and in accordance with the terms  and conditions set forth herein, the parties hereto agree that the Credit Agreement is amended as follows:  (a) The definition of &#8220;Applicable Margin&#8221; in Section 1.1 of the Credit Agreement is hereby  amended by amending and restating the introductory paragraph thereof in its entirety to read as follows:  &#8220;Applicable Margin&#8221; means (a) from the Fourth Amendment Effective Date through the later of  March 31, 2024 and the first Calculation Date occurring after December 31, 2023, (i) 5.00% per  annum with respect to Base Rate Loans, (ii) 6.00% per annum with respect to SOFR Loans, Daily  Simple SONIA Loans and Eurocurrency Rate Loans, and (iii) 0.40% with respect to Commitment  Fees, and (b) thereafter, the corresponding percentages per annum as set forth below based on the  Consolidated Leverage Ratio calculated as of the last day of the most recently ended fiscal quarter  of the Borrower preceding the applicable Calculation Date:&#8221;   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- fifthamendmenttoamendeda002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="fifthamendmenttoamendeda002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">2  175106645_4  (b) The definition of &#8220;Applicable Margin&#8221; in Section 1.1 of the Credit Agreement is hereby  further amended by amending and restating the headers in the pricing grid set forth therein to read as  follows:  Pricing  Level  Consolidated Leverage  Ratio  Commitment  Fee  Eurocurrency Rate,  Adjusted Term  SOFR or Adjusted  Daily Simple  SONIA +  Base  Rate +        SECTION 2. Conditions of Effectiveness of Amendment.  This Amendment, and the  amendments set forth in Section 1 above, shall become effective on the date (such date, the &#8220;Amendment  Effective Date&#8221;) when the Administrative Agent shall have received this Amendment, duly executed by a  Responsible Officer of the Borrower and the Administrative Agent.  SECTION 3. Reference to and Effect on the Credit Agreement and the Loan Documents.    Except as expressly provided herein, the Credit Agreement and the other Loan Documents shall remain  unmodified and in full force and effect.  This Amendment shall not be deemed (a) to be a waiver of, or  consent to, or a modification or amendment of, any other term or condition of the Credit Agreement or any  other Loan Document other than as expressly set forth herein, (b) to prejudice any right or rights which the  Administrative Agent or the Lenders may now have or may have in the future under or in connection with  the Credit Agreement or the other Loan Documents or any of the instruments or agreements referred to  therein, as the same may be amended, restated, supplemented or modified from time to time, or (c) to be a  commitment or any other undertaking or expression of any willingness to engage in any further discussion  with the Borrower, any of its Subsidiaries or any other Person with respect to any other waiver, amendment,  modification or any other change to the Credit Agreement or the Loan Documents or any rights or remedies  arising in favor of the Lenders or the Administrative Agent, or any of them, under or with respect to any  such documents.  References in the Credit Agreement to &#8220;this Agreement&#8221; (and indirect references such as  &#8220;hereunder&#8221;, &#8220;hereby&#8221;, &#8220;herein&#8221;, &#8220;hereof&#8221; or other words of like import) and in any Loan Document to the  &#8220;Credit Agreement&#8221; shall be deemed to be references to the Credit Agreement as modified hereby.    SECTION 4. Costs and Expenses. The Borrower hereby reconfirms its obligations pursuant to  Section 12.3(a) of the Credit Agreement to pay and reimburse the Administrative Agent in accordance with  the terms thereof.  SECTION 5. Governing Law. THIS AMENDMENT SHALL BE GOVERNED BY, AND  CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.  SECTION 6. Counterparts. This Amendment may be executed in any number of counterparts  and by the different parties hereto on separate counterparts, each of which counterparts when executed and  delivered shall be an original, but all of which shall together constitute one and the same instrument.  Delivery by facsimile or electronic transmission of an executed counterpart of a signature page to this  Amendment shall be effective as delivery of an original executed counterpart of this Amendment.  SECTION 7. Entire Agreement.  This Amendment is the entire agreement, and supersedes any  prior agreements and contemporaneous oral agreements, of the parties concerning its subject matter.  This  Amendment is a Loan Document and is subject to the terms and conditions of the Credit Agreement.  SECTION 8. Successors and Assigns.  This Amendment shall be binding on and inure to the  benefit of the parties hereto and their successors and permitted assigns.  [The remainder of this page is intentionally left blank.] </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- fifthamendmenttoamendeda003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="fifthamendmenttoamendeda003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">IN WITNESS WHEREOF, the parties hereto have caused their duly authorized officers to execute  and deliver this Amendment as of the date first above written.  ~:RwOO~MC., $ Borrowcr  Name: Richard S. Lindahl  Title: Executive Vice President, Chief Financial  Officer and Treasurer  f.mergent BioSolutions Inc.  fifth Amendment to Amended and Restated Credit Agreement  Signature Page  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- fifthamendmenttoamendeda004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="fifthamendmenttoamendeda004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.80
<SEQUENCE>3
<FILENAME>modificationno15effectiv.htm
<DESCRIPTION>EX-10.80
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>modificationno15effectiv</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- modificationno15effectiv001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or  confidential. Double asterisks denote omissions.  AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT  2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE  P00015 See Block 16C  6. ISSUED BY CODE AS PR-BARDA  AS PR-BARDA  200 Independence Ave., s.w. Room 640-G  Washington DC 20201  8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)  E  E  3  G  MERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. MERGENT PRODUCT DEVELOPMENT GAITHE  00 PROFESSIONAL DR# 100  AITHERSBURG MD 208793419  CODE 1365869 FACILITY CODE  1 1. CONTRACT ID CODE  4. REQUISITION/PURCHASE REQ. NO. 7. ADMINISTERED BY (If other than Item 6)  AS PR-BARDA  200 Independence Ave.,  Room 638-G  Washington DC 20201  &pound;L  9A. AMENDMENT OF SOLICITATION NO.  98. DATED (SEE ITEM 11)  I PAGE OF PAGES  1 I 2  1 5. PROJECT NO. (If applicable)  s.w. CODE IASPR-BARDA  X  10A. MODIFICATION OF CONTRACT/ORDER NO.  HHSO100201600030C  108. DATED (SEE ITEM 13)  09/30/2016  11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS  &#9633;The above numbered solicilation is amended as set forth in Item 14. The hour and date specified for receipt of Offers Dis extended. Dis not extended.  Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing  Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By  separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE  RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR  OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided  each letter or electronic communication makes reference to the solicitation and this amendment. and is received prior to the opening hour and date specified.  12. ACCOUNTING AND APPROPRIATION DATA (If required)  See Schedule  13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.  CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT  ORDER NO. IN ITEM 10A.  B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office,  appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  X FAR Part 43.103(a) - Bilateral Modifications  D. OTHER (Specify type of modification and authority)  E. IMPORTANT: Contractor Dis not Iii] is required to sign this document and return ______ 1 __ copies to the issuing office.  14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)  Tax ID Number: [**]  UEI: [* *]  The purpose of this modification is to modify ARTICLE C.l. STATEMENT OF WORK, ARTICLE G.3.  KEY PERSONNEL, ARTICLE F.3 DELIVERABLES, and SECTION J- LIST OF ATTACHMENTS  All other terms and conditions remain unchanged.  OTA: N  Period of Performance: 09/30/2016 to 08/31/2025  Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect .  15A. NAME AND TITLE OF SIGNER (Type or print)  Kelly Warfield  158. CONTRACTOR/OFFEROR  )f-,fJ;:)? Electronically signed by: Kelly Warfield  Reason: I approve this document  Date: Oct 6, 2023 12:50 EDT  (Signature of person authorized to sign)  Previous edition unusable  SVP, S&amp;D  15C. DATE SIGNED  Oct6,2023  &#65533;-&gt;&#65533;?I E AND TIT\ EJF CONTRACTING fJ,='r5r&#65533;ff&#65533;l)',Pgf&#65533;ned by Yifan yJ&#65533;af\AtfGang - Yanq-5 -----&#65533;---------1S UNITED STATES OF AMERICA  (Signature of ContraCVnu t:tficer)  Date: 20}&#65533;&#65533;1'tt:o6'GNED  13:06:03 04'00'  STANDARD FORM 30 (REV. 11/2016)  Prescribed by GSA FAR (48 CFR) 53.243  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">HHSO100201600030C P00015 Page 2 of 2  The purpose of this modification is to modify ARTICLE C.1. STATEMENT OF WORK, ARTICLE G.3. KEY  PERSONNEL, ARTICLE F.3 DELIVERABLES, and SECTION J- LIST OF ATTACHMENTS  ARTICLE C.1.   STATEMETN OF WORK is hereby modified as follows:  Independently and not as an agent of the Government, the Contractor shall furnish all necessary services,  qualified personnel, material, equipment, and facilities not otherwise provided by the Government as needed  to perform the Statement of Work dated September 30, 2023, set forth in SECTION J List of Attachments,  attached hereto and incorporated into this Prime Contract.  ARTICLE G.3.   KEY PERSONNEL is hereby modified as follows:  The key personnel specified in this contract are considered to be essential to work performance. At least 30  days prior to diverting any of the specified individuals to other programs or contracts (or as soon as possible, if  an individual must be replaced, for example, as a result of leaving the employ of the Contractor), the  Contractor shall notify the Contracting Officer and shall submit comprehensive justification for the diversion or  replacement request (including proposed substitutions for key personnel) to permit evaluation by the  Government of the impact on performance under this contract. The Contractor shall not divert or otherwise  replace any key personnel without the written consent of the Contracting Officer. The Government may modify  the contract to add or delete key personnel at the request of the Contractor or Government.  The following individuals are considered to be essential to the work being performed hereunder:  Name Position Principal Investigator  Manufacturing Operations Lead  Regulatory Affairs Lead Clinical Development Lead  ARTICLE F.3 Deliverables &#150; Item No. 14 Earned Value Management Requirements is updated as follows:  Item No. Description Addresses Deliverable Schedule 14 Earned Value  Management  Requirements   CO: (1) electronic  copy   COR: (1) electronic  copy   As detailed in Section F.2 Reporting  Requirements, subpart -F. No Longer Required  from the period starting 10/01/2023 onward.   SECTION J &#150; LIST OF ATTACHMENTS is modified as follows:  1. Statement of Work, dated Sep 30, 2023, 10 pages All other terms and conditions of this contract remain unchanged.  End of Modification #15  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">September 30, 2023 Page 1  ATTACHMENT 1: STATEMENT OF WORK  NEXT GENERATION ANTHRAX VACCINE  RFP 16-100-SOL-0015  AV7909 Anthrax Vaccine  1.0 Contractual Statement of Work  Preamble to the Statement of Work  Independently and not as an agent of the Government, the Contractor shall be required to furnish all the  necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the  Government, as needed to perform the Statement of Work submitted in response to RFP 16-100-SOL-  00015. 1.1 Scope The scope of work for this contract includes AV7909 development activities through licensure that fall into  the following areas: program management, nonclinical, clinical, regulatory, and chemistry, manufacturing,  and controls (CMC). The scope of work also includes activities to support post-marketing requirements.  1.2 Objective  The objective of this Statement of Work (SOW) is to conduct all necessary activities to advance the  development of AV7909 through Biologics License Application (BLA) submission and approval and post-  marketing requirements. Activities to meet the objective of this SOW fall in the following eight (8) contract  line item number (CLIN):  CLIN 0001 &#150; Approval of Emergency Use Authorization (EUA), licensure, approval, and clearance of  product through the FDA (Base)  CLIN 0001A &#150; Conduct of a Phase 2 clinical potency study or other studies required by the FDA for the establishment  of a potency specification (Option)  CLIN 0012 &#150; Include doxycycline arm in the conduct of the Phase 2 clinical drug-drug interaction study and qualify a  redundant contract filler (Base)  CLIN 0002 &#150; Initial purchase, storage, and delivery of product (Base)  CLIN 0004 - Surge Capacity &#150; Additional procurement of product (EUA) (Option) &#150;  to   CLIN 0006 &#150; Surge Capacity &#150; Additional procurement of product (EUA) (Option) &#150;  to  doses  CLIN 0010 &#150; Surge Capacity - Additional procurement of product (EUA) (Option) &#150; 1  or more doses  CLIN 0011 &#150; Surge Capacity - Additional procurement of product (EUA and Licensed) (Option) &#150; up to  doses  1.3 CLIN 0001 - Approval of Emergency Use Authorization (EUA), licensure, approval, and  clearance of product through the FDA (Base)  This section identifies representative tasks and sub-tasks for CLIN 0001 with associated WBS code for each  task or subtask.   Program Management  Emergent shall provide program management activities. The activities shall include but are not limited to:  Identification of and management to, distinct stages of the product development pathway that are  gates for Go/No Go decisions for advancing to the next stage of the Integrated Product  Development Plan.  Establishment of and tracking of milestones and timelines for the initiation conduct, and completion  of product development activities for each stage with a budget (in direct costs) linked to each stage.  Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">September 30, 2023 Page 2  scientific merit and technical feasibility of proceeding to the next stage of product development.  Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and  dedicated effort to perform the work.  Directing and overseeing subcontractors and consultants to assure successful performance of  planned activities within the cost and schedule constraints of the contract.  Conducting performance measurement that shall include establishing an initial plan; defining  measurable parameters; defining how these parameters relate to cost and schedule impacts; their  approach in providing a detailed schedule that generates a critical path for the project; and a  description of the cost-accounting system used or intended to be used based on budget estimates to  monitor all costs related to the contract award for both Emergent and subcontractors on a real time  basis.  Manage contract activities in accordance with Earned Value Management. In this regard, Emergent  shall:  o Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly indicates the critical path to support product approval. The Integrated Master Project Plan shall outline key, critical path milestones, with &#147;Go/No-Go&#148; decision criteria and a contract Work Breakdown Structure (due within 90 days of contract award with updates as requested by the Contracting Officer&#146;s Representative (COR). o Submit an updated Integrated Master Schedule in an approved format. o Use principles of Earned Value Management System (EVMS) in the management of this contract. o Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award. Develop and maintain a risk management plan.  Participate in regular meetings to coordinate and oversee the contracting effort.   Non-Clinical Toxicology  Emergent shall conduct safety and toxicology of AV7909 using animal models following Good Laboratory  Practice guidelines (GLP: as defined in the U.S. Code of Federal Regulations, 21CFR Part 58), as  appropriate. The activities shall include but are not limited to:        Non-Clinical Efficacy  Emergent shall conduct efficacy, pharmacokinetics/pharmacodynamics, bioavailability, solubility,  formulation, dose, route and schedule of the medical countermeasure using both in vitro and animal models  following Good Laboratory Practice guidelines (GLP: as defined in the U.S. Code of Federal Regulations,  21 CFR Part 58), as appropriate. The activities shall include but are not limited to:   Clinical Evaluation  Emergent shall design and conduct Phase 2 and Phase 3 clinical studies in accordance with all Federal  regulations and Good Clinical Practice (GCP) guidelines. The activities shall include but are not limited to:   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">September 30, 2023 Page 3   Regulatory Activities  Emergent shall conduct all required regulatory activities to support submission of BLA licensure for  AV7909. The activities shall include but are not limited to:   Chemistry and Manufacturing Controls (CMC)  Emergent shall complete the manufacturing activities necessary to support BLA submission. The activities  shall include but are not limited to:   Phase 4 post-marketing requirement is modified as follows:  1.4 CLIN 0001A - Conduct of a Phase 2 clinical  study or other studies required by the FDA  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">September 30, 2023 Page 4  for the establishment of a potency specification (Option)  This section identifies representative tasks and sub-tasks for CLIN 0001A with associated WBS code for  each task or subtask.   Program Management  Emergent shall provide program management activities. The activities shall include but are not limited to:  Identification of and management to, distinct stages of the product development pathway that are  gates for Go/No Go decisions for advancing to the next stage of the Integrated Product  Development Plan.  Establishment of and tracking of milestones and timelines for the initiation conduct, and completion  of product development activities for each stage with a budget (in direct costs) linked to each stage.  Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess  the scientific merit and technical feasibility of proceeding to the next stage of product development.  Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and  dedicated effort to perform the work.  Directing and overseeing subcontractors and consultants to assure successful performance of  planned activities within the cost and schedule constraints of the contract.  Conducting performance measurement that shall include establishing an initial plan; defining  measurable parameters; defining how these parameters relate to cost and schedule impacts; their  approach in providing a detailed schedule that generates a critical path for the project; and a  description of the cost-accounting system used or intended to be used based on budget estimates to  monitor all costs related to the contract award for both Emergent and subcontractors on a real time  basis.  Manage contract activities in accordance with Earned Value Management. In this regard, Emergent  shall:  o Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly indicates the critical path to support product approval. The Integrated Master Project Plan shall outline key, critical path milestones, with &#147;Go/ No Go&#148; decision criteria and a contract Work Breakdown Structure (due within 90 days of contract award with updates as requested by the Contracting Officer&#146;s Representative (COR). o Submit an updated Integrated Master Schedule in an approved format. o Use principles of Earned Value Management System (EVMS) in the management of this contract. o Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award. Develop and maintain a risk management plan.  Participate in regular meetings to coordinate and oversee the contracting effort.   Clinical Evaluation  Emergent shall design and conduct a Phase 2 clinical study in accordance with all Federal regulations and  Good Clinical Practice (GCP) guidelines unless other studies are required by the FDA for the establishment  of potency specification. The activities shall include, but are not limited to:    Chemistry and Manufacturing Controls (CMC)  Emergent shall complete the manufacturing activities necessary to support  Study. The activities  below are specific to conducting a Phase 2  study. If the FDA requires an alternate strategy for  establishment of potency specification, the activities below may no longer be applicable.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">September 30, 2023 Page 5  Upon new guidance from the FDA, Emergent will update the SOW accordingly.   CPG 7909 Manufacturing   Manufacture of AV7909 for AVA.214 clinical trial  WBS   Stability Studies  1.5 CLIN 0012 &#150; Include doxycycline arm in the conduct of the Phase 2 clinical drug-drug interaction  study and qualify a redundant contract filler (Base)  This section identifies representative activities of CLIN 0012 associated with CLIN0001 subtask  - AVA.210 Phase 2  and task  Chemistry and Manufacturing Controls: 1.6 CLIN 0002 - Initial purchase, storage, and delivery of product (Base)  Under the Base Period funding Emergent shall manufacture, fill, and deliver [**] doses procured in fiscal  year 2019 as an initial procurement to the Strategic National Stockpile (SNS). Emergent is approved to use  management reserve funding for shipping costs associated with these deliveries.  1.7 CLIN 0003 - Phase 4 post marketing requirements (Option)  Reclassified to CLIN 0001. See under CLIN 0001 for details.  1.8 CLIN 0004 through 11 - Surge Capacity &#150; Additional procurement of product (Option)   Emergent shall deliver up to [**] dose regimens (equivalent to [**]doses of AV7909). This option may be  triggered after EUA pre-authorization approval by FDA, which is currently linked to release of PPQ lots,  and deliveries will start within  after trigger.  Under CLIN 0004, Emergent shall manufacture, fill, and deliver [**]doses procured in fiscal year 2019 as  an initial procurement to the Strategic National Stockpile (SNS). .  Under CLIN 0006 Emergent shall manufacture, fill, and deliver [**] doses procured from August 1,  2020 through July 31, 2021, as an additional procurement to the SNS.  For CLINs 0004 and 0006, BARDA may accept  if such doses are delivered along with the  appropriate number of additional doses (&#147;Additional Doses&#148;).  Additional Doses shall be calculated as  % of the number of delivered  For CLIN 0011, BARDA agrees to accept  at a discounted price.  These anthrax vaccine doses will have  prices depending on the Vaccine doses delivered  will be charged a dose price of  per dose. Vaccines delivered with a  but  will be charged a unit  dose price of  per dose. BARDA will not accept any vaccine .  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">September 30, 2023 Page 6  For delivery to the SNS, Emergent shall comply with the relevant associated activities and deliverables as  outlined in the Quality Agreement (attached) as signed by Emergent, BARDA, and the SNS. Emergent shall  provide appropriate documentation to BARDA for quality assurance of the final drug product delivered to  the SNS and invoice appropriately.  1.9 Reporting Requirements and Deliverables Reports  As part of the work to be performed under this contract, Emergent will prepare and deliver the following  reports throughout the period of performance.  Monthly Technical Progress Reports  On the fifteenth (15) day of each month for the previous calendar month, Emergent will submit to the  COR and the CO a Technical Progress Report covering the previous calendar month. The first reporting  period consists of the first full month of performance plus any fractional part of the initial month.  Thereafter, the reporting period will consist of each calendar month. The frequency of Technical Progress  Reporting will be determined by the CO and COR during negotiations of the contract. The format and  type of Technical Progress Report and Executive Summary will be provided by the COR. The Technical  Progress Reports will summarize progress for the reporting period, such as: management and  administrative updates, technical progress, issues, proposed work, manufacturing and supply chain  management, and a summary of invoices. A Technical Progress Report will not be required for the period  when the same month Annual Progress Reports or a Final Report are due. Emergent will submit one copy  of the Technical Progress Report electronically via e-mail to the CO and COR.  Annual Progress Reports  On the thirtieth (30th) calendar day following the last day of each reporting period, Emergent will submit  to the COR and the CO an Annual Progress Report. The first reporting period consists of the first full year  of performance plus any fractional part of the initial year. Thereafter, the reporting period shall consist of  each calendar year. Annual Progress Reports will summarize progress for the reporting period, such as:  management and administrative updates, technical progress, issues, proposed work, manufacturing and  supply chain management, and a summary of invoices. An Annual Progress Report will not be required  for the period when the Final Technical Progress Report is due.  Draft Final Report and Final Report  Emergent will submit the Draft Final Progress Report forty-five (45) calendar days prior to the expiration  date of the contract and the Final Progress Report on or before the expiration date of the contract. These  reports will include a summation of the work performed and results obtained for execution of various  studies or technical work packages during the entire contract period of performance. This report will be in  sufficient detail to describe comprehensively the results achieved. An electronic copy of the Draft Final  Report and Final Report will be submitted to the COR and CO.  FDA Regulatory Agency Correspondence, Meeting Summaries, and Submissions  With regard to interactions with the FDA, Emergent shall:  Forward the initial draft minutes to BARDA within five business days of any formal meeting  with the FDA or other regulatory agency, and forward the final minutes when available.  Forward the initial draft minutes to BARDA within five business days of any informal meeting  with the FDA or other regulatory agency, and forward the final minutes when available and if  applicable.  Forward the dates and times of any meeting with the FDA and other regulatory agencies  to BARDA as soon as the meeting times are known and make arrangements for  appropriate BARDA staff to attend the meetings.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">September 30, 2023 Page 7  Provide BARDA the opportunity to review and comment upon any documents to be submitted to  the FDA or other regulatory agency. Emergent will provide BARDA with five (5) business days  in which to review and provide comments prior to Emergent&#146;s submission to the FDA.  Emergent will notify the COR and CO within 24 hours of all FDA arrivals to conduct site visits/audits by  any regulatory agency and provide the USG with an exact copy (non-redacted) of the FDA Form 483 and  the Establishment Inspection Report (EIR). Emergent will provide the COR and CO copies of the plan  for addressing areas of non-conformance to FDA regulations for Good Laboratory Practice (GLP)  guidelines as identified in the audit report, status updates during the plan's execution, and a copy of all  final responses to the FDA. Emergent will also provide redacted copies of any FDA audits received from  subcontractors that occur as a result of this contract or for this product. Emergent will make arrangements  with the COR for the appropriate BARDA representative(s) to be present during the final debrief by the  regulatory inspector.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">September 30, 2023 Page 8  Key Deliverables  A summary of Key Deliverables for this contract follow  No. Deliverable Description Due Date 01 Monthly Progress Report Shall include a description of the activities during the reporting period and the activities planned for the ensuing reporting period. The first reporting period consists of the first full month of performance plus any fractional part of the initial month. Thereafter, the reporting period shall consist of each calendar month. Due on or before the 15th day of eachmonth following the endof each reporting period. Monthly progress reports are not required in the same month Annual Progress reports or a Final Report aredue. 02 Annual Progress Report Shall include a summation of the activities during the reporting period, and the activities planned for the ensuing reporting period. The first reporting period consists of the first full year of performance plus any fractional part of the initial year. Thereafter, the reporting period shall consist of each calendar year. Due on or before the 30th calendar day following the end of each reporting period. 03 Draft Final Progress Report To include a summation of the work performed and results obtained for execution of various studies or technical work packages during entire contract period of performance. Shall be in sufficient detail to describe comprehensively the results achieved. Due 45 Calendar days prior to the expiration date of the contract. 04 Final Progress Report To include a summation of the work performed and results obtained for execution of various studies or technical work packages during entire contract period of performance. Shall be in sufficient detail to describe comprehensively the results achieved. Due on/before the expiration date of the contract. 05 FDA/Regulatory Agency Correspondence and Meeting Minutes The Contractor shall forward initial draft minutes and final draft minutes of any formal or informal meeting with the FDA or other regulatory agency. The contractor shall forward the dates and times of any meeting with the FDA and other regulatory agencies as soon as the meeting times are known and make arrangements for appropriate BARDA staff to attend the meetings. The Contractor shall provide BARDA the opportunity to review and comment upon any documents to be submitted to the FDA or other regulatory agency. The Contractor shall forward SOPs upon request from the COR. The contractor shall notify the COR and CO within 24 hours of all FDA arrivals to conduct site visits/audits by any regulatory agency, and provide copies of any associated reports, documentation, or communication. Due within 5 business days of each meeting for Contractor&#146;s minutes, upon receipt of minutes from FDA/ regulatory agency, and upon request from the COR or Co COR. 06 Integrated Master Project Plan (Critical Path Milestones, Work Breakdown Structure, Risk Mitigation Plan/ Matrix) The contractor shall provide an Integrated Master Plan (including tabular and Gantt forms) to BARDA that clearly indicates the critical path to annual deliverables (key, critical path milestones, with &#147;Go/No Go&#148; decision criteria) and Work Breakdown Structure (WBS) elements that shall be discernable and consistent. The contractor shall develop and maintain a risk management plan that highlights potential problems and/or issues that may arise during the life of the contract, their impact on cost, schedule and performance, and appropriate remediation plans. Due within 90 days of contract award. Updates are due as requested by the COR or Co COR. 07 Technology Packages Technology packages developed under the contract that includes complete protocols must be submitted at the request of the BARDA COR. Due upon request from the COR or Co COR. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">September 30, 2023 Page 9  No. Deliverable Description Due Date 08 Experimental Protocols The Contractor shall submit to the COR all study/experiment/test plans, designs, and protocols prior to execution for BARDA approval or upon request by the COR or Co COR when required. Due upon request from the COR or Co COR. 09 Annual/Final Invention Report All reports and documentation required by FAR Clause 52.227 11, Patent Rights Ownership by the Contractor, including, but not limited to, the invention disclosure report, the confirmatory license, and the Government support certification. If no invention is disclosed or no activity has occurred on a previously disclosed invention during the applicable reporting period, a negative report shall be submitted to the CO. Annual Invention Report Due on or before the 30th calendar day after the completion of each reporting period. Final Invention Report due on or before the expiration of the contract. 10 Publications Any manuscript or scientific meeting abstract containing data generated under this contract must be submitted to COR for review prior to submission. Due within 30 calendar days for manuscripts prior to publication and 15 calendar days for abstracts. 11 Press Releases The Contractor agrees to accurately and factually represent the work conducted under this contract in all press releases. The Contractor shall ensure the CO has received and approved an advanced copy of any press release not less than five (5) business days prior to the issuance of any potential press release. Reports/Notices due for approval to the CO not less than five (5) business days prior to the issuance of any potential press release. 12 Security Report The contractor shall report to the government any activity or incident that is in violation of established security standards or indicates the loss or theft of government products Due within 24 hours after occurrence of an activity or incident. 13 Earned Value Management System Requirements Subject to the requirements under FAR 52.234 4 Earned Value Management System, the Contract shall use principles of Earned Value Management System (EVMS) in the management of this contract (include this plan as part of the monthly, annual, and final reports). The Contractor shall also submit a Performance Measurement Baseline Review plan electronically via email to the CO and COR for a PMBR to occur within 90 days of contract award, and an Integrated Master Schedule electronically via email as outlined in a format agreed upon by BARDA to the COR and CO. The Offeror shall deliver an Earned Value Contract Performance Report on a monthly basis. As detailed in Section F.3.2 Subpart  F. [**] </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno15effectiv012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno15effectiv012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">M il es to n e   #   W B S   #   M il e s to n e  D e li v e ra b le s  S u m m a ry  ( D e ta il s   a s  s p e c if ie d  i n  t h e  D el iv e ra b le s)   Q u a n ti ty   E s ti m a te d   C o m p le ti o n   D a te   C L IN  0 00 1  &amp;      C L IN  0 01 2  1      1  E le ct ro ni c  C op y  to   C on tr ac t O ff ic er   R ep re se nt at iv e  (C O R );   1  E le ct ro ni c  C op y  to   C on tr ac ti ng  O ff ic er   (C O )  12 /1 9/ 20 17   2        S ee  A bo ve   1/ 18 /2 01 8  3        S ee  A bo ve   5/ 24 /2 01 8  4      S ee  A bo ve   11 /6 /2 01 8  5        S ee  A bo ve   11 /8 /2 01 8  8    S ee  A bo ve   3/ 21 /2 02 1  9    S ee  A bo ve   8/ 18 /2 02 0  10     S ee  A bo ve   12 /3 1/ 20 21   11     S ee  A bo ve   5/ 12 /2 02 1  12         S ee  A bo ve   12 /1 5/ 20 21   C L IN  0 00 2  16   -  S ee  A bo ve   10 /2 4/ 20 19   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.81
<SEQUENCE>4
<FILENAME>modificationno16effectiv.htm
<DESCRIPTION>EX-10.81
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>modificationno16effectiv</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1365;"><!-- modificationno16effectiv001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT  2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE  P00016 See Block 16C  6. ISSUED BY CODE AS PR-BARDA  AS PR-BARDA  200 Independence Ave., s.w. Room 640-G  Washington DC 20201  8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)  MERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. MERGENT PRODUCT DEVELOPMENT GAITHE  00 PROFESSIONAL DR# 100  1 1. CONTRACT ID CODE  4. REQUISITION/PURCHASE REQ. NO.  ASP322481  7. ADMINISTERED BY (If other than Item 6)  AS PR-BARDA  200 Independence Ave.,  Room 638-G  Washington DC 20201  &pound;L  9A. AMENDMENT OF SOLICITATION NO.  98. DATED (SEE ITEM 11)  I PAGE OF PAGES  1 I 4  1 5. PROJECT NO. (If applicable)  s.w. CODE IASPR-BARDA  E  E  3  G AITHERSBURG MD 208793419  X  10A. MODIFICATION OF CONTRACT/ORDER NO.  HHSO100201600030C  108. DATED (SEE ITEM 13)  CODE 1365869 FACILITY CODE 09/30/2016  11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS  &#9633; The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers Dis extended, Dis not extended.  Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended . by one of the following methods: (a) By completing  Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By  separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE  RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR  OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided  each letter or electronic communication makes reference to the solicitation and this amendment. and is received prior to the opening hour and date specified.  12. ACCOUNTING AND APPROPRIATION DATA(lf required) Net Increase: [**] 2024.Q990100.26088  13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.  CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT  ORDER NO. IN ITEM 10A  X  B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office,  appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  FAR Part 43.103(a) - Bilateral Modifications  D. OTHER (Specify type of modification and authority)  E. IMPORTANT: Contractor Dis not Iii] is required to sign this document and return ______ 1 __ copies to the issuing office.  14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)  Tax ID Number: [**] UEI: [**]  The purpose of this modification is to exercise CLIN 0011b and update ARTICLEs B.3. OPTION  PRICES, B.5 ADVANCE UNDERSTANDINGS, C.l. STATEMENT OF WORK, and SECTION J- LIST OF  ATTACHMENTS.  Funds Obligated Prior to this Modification: [**]  Funds Obligated with Mod #16:  Total Funds Obligated to Date:  [**] [**]  All other terms and conditions remain unchanged.  Continued  Except as provided herein, all tenns and conditions of the document referenced in Item 9 A or 1 0A, as heretofore changed, remains unchanged and in full force and effect .  15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)  Paul Williams  (Signature of person authorized to sign)  Previous edition unusable  SVP, Products Business Jona than Gonzalez  15C. DATE SIGNED 168. UNITED STATES OF AMERICA  (Signature of Contracting Officer)  16C. DATE SIGNED  STANDARD FORM 30 (REV. 11/2016)  Prescribed by GSA FAR (48 CFR) 53.243  Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as  private or confidential.  Double asterisks denote omissions. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">HHS0100201600030C P00016 Page 3 of 4  The purpose of this modification is to modify ARTICLES B.3 OPTION PRICES, B.5. ADVANCE UNDERSTANDINGS,  ARTICLE C.l. STATEMENT OF WORK, and SECTION J- LIST OF ATTACHMENTS  ARTICLE B.3. OPTION PRICES- CUN 0011B is added as follows:  CUN Period of Supplies/ Doses* Price per Dose Total Not to Exceed  Performance Services Cost  0011B Nov 21, 2023 Additional [**] [**] $74,999,936.10  (Option through Mar Surge  Quantity) 31, 2024 Capacity  (Funded)  (Licensure)  *Under CUN 0011B a total of 2.8 million doses are expected to be procured at the unit prices stated above. There is no anticipated supply of material between [**] from date of manufacture under  CLIN00llB; this product would only be provided at the request of the USG at a price of $18.00 per  dose.  ARTICLE B.S. ADVANCE UNDERSTANDINGS - is modified as follows:  o. CUN 0011B &#8226; For CUN 0011B receiving doses will be less than or equal to [**] from the date of manufacture. The following table is provided to note doses to be delivered under CUN 0011B. Product Price per Quantity for Delivery  Dose (USO)  Base Doses [**] 2,822,730 doses  Dating  [**] </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">ATTACHMENT l; STATEMENT OF WORK  NEXT GENERATION ANTHRAX VACCINE  RFP 16-100-SOL-0015  A V7909 Anthrax Vaccine  LD Contractual Statement of Work  Preamble to the Statement of Work  Independently and not as an agent of the Government, the Contractor shall be required to furnish all the  necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the  Government, as needed to perform the Statement of Work submitted in response to RFP 16-100-SOL- 00015.  l.l&#65533;  The scope of work for this contract includes A V7909 development activities through licensure that fall into  the following areas: program management, nonclinical, clinical, regulatory, and chemistry, manufacturing,  and controls (CMC). The scope of work also includes activities to support post-marketing requirements.  Ll Qhiectiye  The objective of this Statement of Work (SOW) is to conduct all necessary activities to advance the  development of A V7909 through Biologics License Application (BLA) submission and approval and post&shy; marketing requirements. Activities to meet the objective of this SOW fall in the following nine (9) contract  line item number (CUN):  &#8226; CLIN 0001 -Approval of Emergency Use Authorization (EUA), licensure, approval, and clearance of product through the FDA (Base) &#8226; CLIN 000 IA -Conduct of a Phase 2 clinical [**] study or other studies required by the FDA [**] (Option) &#8226; CLIN 0012 -Include doxycycline arm in the conduct of the Phase 2 clinical drug-drug interaction study and qualify a redundant contract filler (Base) &#8226; CLIN 0002 -Initial purchase, storage, and delivery of product (Base) &#8226; CLIN 0003 -Phase 4 post marketing requirements (Option) &#8226; CLIN 0004 - Surge Capacity-Additional procurement of product (EUA) (Option)-[**] to [**] &#8226; CLIN 0006 -Surge Capacity -Additional procurement of product (EUA) (Option)-[**] to [**] &#8226; CLIN 0010-Surge Capacity - Additional procurement of product (EUA) (Option)-[**] or more doses &#8226; CLIN 0011 -Surge Capacity - Additional procurement of product (EUA and Licensed) (Option)-up to [**] doses &#8226; CLIN 001 lB-Surge Capacity- Additional procurement of product (Licensed) (Option)-[**] doses 02 2023  Aor-Jun  November 02, 2023  AV7909 Target Delivery Schedule (CLIN 0011)  I 03 2023 I 04 2023  I I Oct Jul-Seo  [**] doses  Cvfendus Target Delivery Schedule (CLIN 001 lB)  Q4 2023 -Q 1 2024  Nov- Mar  [**] doses  Page 1  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">L.J CLIN 0001 - Approval of Emergency Use Authorization fEUA}, Jicensure. approval. and  clearance of product through the FDA mase}  This section identifies representative tasks and sub-tasks for CUN 0001 with associated WBS code for each  task or subtask.  [**] Program Management Emergent shall provide program management activities. The activities shall include but are not limited to:  &#8226; Identification of and management to, distinct stages of the product development pathway that are gates for Go/No Go decisions for advancing to the next stage of the Integrated Product Development Plan. &#8226; Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of product development activities for each stage with a budget (in direct costs)linked to each stage. &#8226; Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the scientific merit and technical feasibility of proceeding to the next stage of product development. &#8226; Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated effort to perform the work. &#8226; Directing and overseeing subcontractors and consultants to assure successful performance of planned activities within the cost and schedule constraints of the contract. &#8226; Conducting performance measurement that shall include establishing an initial plan; defining measurable parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a detailed schedule that generates a critical path for the project; and a description of the cost-accounting system used or intended to be used based on budget estimates to monitor all costs related to the contract award for both Emergent and subcontractors on a real time basis. &#8226; Manage contract activities in accordance with Earned Value Management. In this regard, Emergent shall: o Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly indicates the critical path to support product approval. The Integrated Master Project Plan shall outline key, critical path milestones, with &quot;Go/No-Go&quot; decision criteria and a contract Work Breakdown Structure ( due within 90 days of contract award with updates as requested by the Contracting Officer's Representative(COR). o Submit an updated Integrated Master Schedule in an approved format. o Use principles of Earned Value Management System (EVMS) in the management of this contract. o Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award. &#8226; Develop and maintain a risk management plan. &#8226; Participate in regular meetings to coordinate and oversee the contracting effort. [**] Non-Clinical Toxicology Emergent shall conduct safety and toxicology of A V7909 using animal models following Good Laboratory  Practice guidelines (GLP: as defined in the U.S. Code of Federal Regulations, 21CFR Part 58), as  appropriate. The activities shall include but are not limited to:  &#8226; [**] &#8226; [**] [**]Non-Clinical Efficacy Emergent shall conduct efficacy, pharmacokinetics/pharmacodynamics, bioavailability, solubility,  fgppulatjog dose route agd schedule 0{the medjcal countermeasure usjpg both io xilrn and apjmal models  November 02, 2023 Page 2  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">following Good Laboratory Practice guidelines (GLP: as defined in the U.S. Code of Federal Regulations,  21 CFR Part 58), as appropriate. The activities shall include but are not limited to:  &#8226; [**] [**] [**] Clinical Evaluation Emergent shall design and conduct Phase 2 and Phase 3 clinical studies in accordance with all Federal  regulations and Good Clinical Practice (GCP) guidelines. The activities shall include but are not limited to:  &#8226; [**] [**] [**] Regulatory Activities Emergent shall conduct all required regulatory activities to support submission ofBLA licensure for  AV7909. The activities shall include but are not limited to:  &#8226; [**] [**] - Chemistry and Manufacturing Controls fCMC} Emergent shall complete the manufacturing activities necessary to support BLA submission. The activities  shall include but are not limited to:  o [**] [**] - Phase 4 post-marketing requirement:  Development of Post-Marketing Requirement (PMR) Program per FDA Request  Phase 4 Retrospective Observational Study Protocol, ICF, Assent, Mock CRFs &amp; CRF Completion  Guidelines of AV7909 ([**])  &#8226; [**] November 02, 2023 Page 3  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">1d CLIN 0001 A - Conduct of a Phase 2 clinical potency study or other studies required by the FDA  for the establishment of a [**] specification CQption} This section identifies representative tasks and sub-tasks for CUN 0001A with associated WBS code for  each task or subtask.  [**] Program Management Emergent shall provide program management activities. The activities shall include but are not limited to:  &#8226; Identification of and management to, distinct stages of the product development pathway that are gates for Go/No Go decisions for advancing to the next stage of the Integrated Product Development Plan. &#8226; Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of product development activities for each stage with a budget (in direct costs)linked to each stage. &#8226; Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the scientific merit and technical feasibility of proceeding to the next stage of product development. &#8226; Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated effort to perform the work. &#8226; Directing and overseeing subcontractors and consultants to assure successful performance of planned activities within the cost and schedule constraints of the contract. November 02, 2023 Page4  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">&#8226; Conducting performance measurement that shall include establishing an initial plan; defining measurable parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a detailed schedule that generates a critical path for the project; and a description of the cost-accounting system used or intended to be used based on budget estimates to monitor all costs related to the contract award for both Emergent and subcontractors on a real time basis. &#8226; Manage contract activities in accordance with Earned Value Management. In this regard, Emergent shall: o Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly indicates the critical path to support product approval. The Integrated Master Project Plan shall outline key, critical path milestones, with &quot;Go/ No Go&quot; decision criteria and a contract Work Breakdown Structure ( due within 90 days of contract award with updates as requested by the Contracting Officer's Representative(COR). o Submit an updated Integrated Master Schedule in an approved format. o Use principles of Earned Value Management System (EVMS) in the management of this contract. o Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award. &#8226; Develop and maintain a risk management plan. &#8226; Participate in regular meetings to coordinate and oversee the contracting effort. [**] Clinical Evaluation Emergent shall design and conduct a Phase 2 clinical study in accordance with all Federal regulations and  Good Clinical Practice (GCP) guidelines unless other studies are required by the FDA [**]. The activities  shall include, but are not limited to:  &#8226; [**] - AV A.214 Phase 2 [**] Study [**] - Chemistry and Manufacturing Controls fCMC} Emergent shall complete the manufacturing activities necessary to support AVA.214 Phase 2 [**] Spec  Study. The activities below are specific to conducting a Phase 2 [**] clinical study. If the FDA requires an  alternate strategy for [**], the activities below may no longer be applicable. Upon new guidance from the  FDA, Emergent will update the SOW accordingly.  &#8226; [**] 1,!i CLIN 0012 - Include doxycycline arm in the conduct of the Phase 2 clinical drug-drug interaction  study and qualify a redundant contract filler rnase}  This section identifies representative activities of CLIN 0012 associated with CLIN000l subtask [**]  - AV A.210 Phase 2 [**] and [**] Chemistry and Manufacturing Controls: &#8226; [**] U CLIN 0002 - Initial purchase, storage, and delivery of product rnase}  Under the Base Period funding Emergent shall manufacture, fill, and deliver [**] doses procured in fiscal  year 2019 as an initial procurement to the Strategic National Stockpile (SNS). Emergent is approved to  use management reserve funding for shipping costs associated with these deliveries.  November 02, 2023 Page 5  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">lJ CLIN 0003 - Phase 4 post marketing requirements fOption}  [**]  Program Management  Emergent shall provide program management activities. The activities shall include but are not limited to:  &#8226; Identification of and management to, distinct stages of the product development pathway that are gates for Go/No Go decisions for advancing to the next stage of the Integrated Product Development Plan. &#8226; Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of product development activities for each stage with a budget ( in direct costs) linked to each stage. &#8226; Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the scientific merit and technical feasibility of proceeding to the next stage of product development. &#8226; Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated effort to perform the work. &#8226; Directing and overseeing subcontractors and consultants to assure successful performance of planned activities within the cost and schedule constraints of the contract. &#8226; Conducting performance measurement that shall include establishing an initial plan; defining measurable parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a detailed schedule that generates a critical path for the project; and a description of the cost-accounting system used or intended to be used based on budget estimates to monitor all costs related to the contract award for both Emergent and subcontractors on a real time basis. &#8226; Manage contract activities in accordance with Earned Value Management. In this regard, Emergent shall: o Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly indicates the critical path to support product approval. The Integrated Master Project Plan shall outline key, critical path milestones, with &quot;Go/No Go&quot; decision criteria and a contract Work Breakdown Structure ( due within 90 days of contract award with updates as requested by the Contracting Officer's Representative(COR). o Submit an updated Integrated Master Schedule in an approved format. o Use principles of Earned Value Management System (EVMS) in the management of this contract. o Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award. &#8226; Develop and maintain a risk management plan. &#8226; Participate in regular meetings to coordinate and oversee the contracting effort. [**] lrB CLIN 0004 through 11 - Surge Capacity - Additional procurement 0( product fOption}  Emergent shall deliver up to [**] ( equivalent to [**] doses of A V7909). This option may be triggered  after EUA pre-authorization approval by FDA, which is currently linked to release  November 02, 2023 Page 6  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">of PPQ lots, and deliveries will start within [**] after trigger.  Under CLIN 0004, Emergent shall manufacture, fill, and deliver [**] doses procured in fiscal year 2019  as an initial procurement to the Strategic National Stockpile (SNS). [**] Under CLIN 0006 Emergent shall manufacture, fill, and deliver [**] doses procured from August 1, 2020  through July 31, 2021, as an additional procurement to the SNS. [**] For CLINs 0004 and 0006, BARDA may accept [**] if such doses are delivered along with the  appropriate number of additional doses (&quot;Additional Doses&quot;). Additional Doses shall be calculated as  [**]% of the number of delivered [**]  For CLIN 0011, BARDA agrees to accept [**] at a discounted price.  These anthrax vaccine doses will have two different [**] depending on the [**]. Vaccine doses delivered  up to or equal to [**] will be charged a dose price of [**] per dose. Vaccines delivered with a [**] will  be charged a unit dose price of [**]per dose. BARDA will not accept any vaccine [**]  For CLIN 001 lB, Emergent shall provide [**] doses, dated l[**] at [**] per dose between November 21,  2023 through March 31, 2024.  For delivery to the SNS, Emergent shall comply with the relevant associated activities and deliverables as  outlined in the Quality Agreement (attached) as signed by Emergent, BARDA, and the SNS. Emergent  shall provide appropriate documentation to BARDA for quality assurance of the final drug product  delivered to the SNS and invoice appropriately.  b2 Reporting Requirements and Deliverables Reports  As part of the work to be performed under this contract, Emergent will prepare and deliver the following  reports throughout the period of performance.  Monthly Technical Progress Reports  On the fifteenth (15) day of each month for the previous calendar month, Emergent will submit to the  COR and the CO a Technical Progress Report covering the previous calendar month. The first reporting  period consists of the first full month of performance plus any fractional part of the initial month.  Thereafter, the reporting period will consist of each calendar month. The frequency of Technical Progress  Reporting will be determined by the CO and COR during negotiations of the contract. The format and type  of Technical Progress Report and Executive Summary will be provided by the COR. The Technical  Progress Reports will summarize progress for the reporting period, such as: management and  administrative updates, technical progress, issues, proposed work, manufacturing and supply chain  management, and a summary of invoices. A Technical Progress Report will not be required for the period  when the same month Annual Progress Reports or a Final Report are due. Emergent will submit one copy  November 02, 2023 Page 7  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv013.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv013.jpg" title="slide13" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv014.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv014.jpg" title="slide14" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno16effectiv015.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno16effectiv015.jpg" title="slide15" width="1365" height="1055">
<DIV><FONT size="1" style="font-size:1pt;color:white">CLIN 0001 CLIN 0012 CLIN0002 Milestone WBS  # #  Milestone  Deliverables Summary (Details  as specified in the Deliverables)  1 I I  2 I  3 I  4 I  5 8 9 I  10 I  11 I  12 16 I  I  I  I  I  Quantity  1 Electronic Copy to Contract Officer Representative (COR); 1 Electronic Copy to Contracting Officer (CO) See Above See Above See Above See Above See Above See Above See Above See Above See Above See Above Estimated  Completion  Date  12/19/2017 1/18/2018 5/24/2018 11/6/2018 11/8/2018 3/21/2021 8/18/2020 12/31/2021 5/12/2021 12/15/2021 10/24/2019 [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Completion of delivery of  [**] doses of AV7909 [**] [**] Delivery of [**] doses of  AV7909 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.92
<SEQUENCE>5
<FILENAME>modificationno7effective.htm
<DESCRIPTION>EX-10.92
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>modificationno7effective</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- modificationno7effective001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno7effective001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">&#61472;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535; &#61480;&#61560;&#61481; &#61560; &#61495;&#61493;&#61505;&#61493;&#61488;&#61489;&#61489;&#61497;&#61507;&#61488;&#61488;&#61488;&#61495;&#61489; &#61539;&#61551;&#61552;&#61545;&#61541;&#61555;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61541;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61499;&#61472;&#61480;&#61538;&#61481;&#61472;&#61506;&#61561;&#61472;&#61537;&#61539;&#61547;&#61550;&#61551;&#61559;&#61548;&#61541;&#61540;&#61543;&#61545;&#61550;&#61543;&#61472;&#61554;&#61541;&#61539;&#61541;&#61545;&#61552;&#61556;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61472;&#61551;&#61550;&#61472;&#61541;&#61537;&#61539;&#61544;&#61472;&#61539;&#61551;&#61552;&#61561;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61541;&#61472;&#61551;&#61542;&#61542;&#61541;&#61554;&#61472;&#61555;&#61557;&#61538;&#61549;&#61545;&#61556;&#61556;&#61541;&#61540; &#61499;&#61472;&#61551;&#61554;&#61472;&#61480;&#61539;&#61481;&#61472;&#61506;&#61561;&#61472; &#61555;&#61541;&#61552;&#61537;&#61554;&#61537;&#61556;&#61541;&#61472;&#61548;&#61541;&#61556;&#61556;&#61541;&#61554;&#61472;&#61551;&#61554;&#61472;&#61541;&#61548;&#61541;&#61539;&#61556;&#61554;&#61551;&#61550;&#61545;&#61539;&#61472;&#61539;&#61551;&#61549;&#61549;&#61557;&#61550;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61559;&#61544;&#61545;&#61539;&#61544;&#61472;&#61545;&#61550;&#61539;&#61548;&#61557;&#61540;&#61541;&#61555;&#61472;&#61537;&#61472;&#61554;&#61541;&#61542;&#61541;&#61554;&#61541;&#61550;&#61539;&#61541;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61537;&#61550;&#61540;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61472;&#61550;&#61557;&#61549;&#61538;&#61541;&#61554;&#61555;&#61486;&#61472;&#61472; &#61510;&#61505;&#61513;&#61516;&#61525;&#61522;&#61509;&#61472;&#61519;&#61510;&#61472;&#61529;&#61519;&#61525;&#61522;&#61472;&#61505;&#61507;&#61515;&#61518;&#61519;&#61527;&#61516;&#61509;&#61508;&#61511;&#61509;&#61517;&#61509;&#61518;&#61524;&#61472;&#61524;&#61519;&#61472;&#61506;&#61509;&#61472; &#61522;&#61509;&#61507;&#61509;&#61513;&#61526;&#61509;&#61508;&#61472;&#61505;&#61524;&#61472;&#61524;&#61512;&#61509;&#61472;&#61520;&#61516;&#61505;&#61507;&#61509;&#61472;&#61508;&#61509;&#61523;&#61513;&#61511;&#61518;&#61505;&#61524;&#61509;&#61508;&#61472;&#61510;&#61519;&#61522;&#61472;&#61524;&#61512;&#61509;&#61472;&#61522;&#61509;&#61507;&#61509;&#61513;&#61520;&#61524;&#61472;&#61519;&#61510;&#61472;&#61519;&#61510;&#61510;&#61509;&#61522;&#61523;&#61472;&#61520;&#61522;&#61513;&#61519;&#61522;&#61472;&#61524;&#61519;&#61472;&#61524;&#61512;&#61509;&#61472;&#61512;&#61519;&#61525;&#61522;&#61472;&#61505;&#61518;&#61508;&#61472;&#61508;&#61505;&#61524;&#61509;&#61472;&#61523;&#61520;&#61509;&#61507;&#61513;&#61510;&#61513;&#61509;&#61508;&#61472;&#61517;&#61505;&#61529;&#61472;&#61522;&#61509;&#61523;&#61525;&#61516;&#61524;&#61472;&#61513;&#61518;&#61472;&#61522;&#61509;&#61514;&#61509;&#61507;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61529;&#61519;&#61525;&#61522;&#61472; &#61519;&#61510;&#61510;&#61509;&#61522;&#61486;&#61472;&#61472;&#61513;&#61542;&#61472;&#61538;&#61561;&#61472;&#61558;&#61545;&#61554;&#61556;&#61557;&#61541;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61472;&#61561;&#61551;&#61557;&#61472;&#61540;&#61541;&#61555;&#61545;&#61554;&#61541;&#61472;&#61556;&#61551;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61472;&#61537;&#61550;&#61472;&#61551;&#61542;&#61542;&#61541;&#61554;&#61472;&#61537;&#61548;&#61554;&#61541;&#61537;&#61540;&#61561;&#61472;&#61555;&#61557;&#61538;&#61549;&#61545;&#61556;&#61556;&#61541;&#61540; &#61484;&#61472;&#61555;&#61557;&#61539;&#61544;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61472;&#61549;&#61537;&#61561;&#61472;&#61538;&#61541;&#61472;&#61549;&#61537;&#61540;&#61541;&#61472;&#61538;&#61561;&#61472;&#61548;&#61541;&#61556;&#61556;&#61541;&#61554;&#61472;&#61551;&#61554;&#61472;&#61541;&#61548;&#61541;&#61539;&#61556;&#61554;&#61551;&#61550;&#61545;&#61539;&#61472;&#61539;&#61551;&#61549;&#61549;&#61557;&#61550;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61484;&#61472;&#61552;&#61554;&#61551;&#61558;&#61545;&#61540;&#61541;&#61540;&#61472; &#61541;&#61537;&#61539;&#61544;&#61472;&#61548;&#61541;&#61556;&#61556;&#61541;&#61554;&#61472;&#61551;&#61554;&#61472;&#61541;&#61548;&#61541;&#61539;&#61556;&#61554;&#61551;&#61550;&#61545;&#61539;&#61472;&#61539;&#61551;&#61549;&#61549;&#61557;&#61550;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61549;&#61537;&#61547;&#61541;&#61555;&#61472;&#61554;&#61541;&#61542;&#61541;&#61554;&#61541;&#61550;&#61539;&#61541;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61537;&#61550;&#61540;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61484;&#61472;&#61537;&#61550;&#61540;&#61472;&#61545;&#61555;&#61472;&#61554;&#61541;&#61539;&#61541;&#61545;&#61558;&#61541;&#61540;&#61472;&#61552;&#61554;&#61545;&#61551;&#61554;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61551;&#61552;&#61541;&#61550;&#61545;&#61550;&#61543;&#61472;&#61544;&#61551;&#61557;&#61554;&#61472;&#61537;&#61550;&#61540;&#61472;&#61540;&#61537;&#61556;&#61541;&#61472;&#61555;&#61552;&#61541;&#61539;&#61545;&#61542;&#61545;&#61541;&#61540;&#61486; &#61523;&#61541;&#61541;&#61472;&#61523;&#61539;&#61544;&#61541;&#61540;&#61557;&#61548;&#61541; &#61511;&#61505;&#61513;&#61524;&#61512;&#61509;&#61522;&#61523;&#61506;&#61525;&#61522;&#61511;&#61472;&#61517;&#61508;&#61472;&#61490;&#61488;&#61496;&#61495;&#61497;&#61491;&#61492;&#61489;&#61497; &#61489;&#61491;&#61494;&#61493;&#61496;&#61494;&#61497; &#61509;&#61517;&#61509;&#61522;&#61511;&#61509;&#61518;&#61524;&#61472;&#61520;&#61522;&#61519;&#61508;&#61525;&#61507;&#61524;&#61472;&#61508;&#61509;&#61526;&#61509;&#61516;&#61519;&#61520;&#61517;&#61509;&#61518;&#61524;&#61472;&#61511;&#61505;&#61513;&#61524;&#61512;&#61509;&#61522;&#61523;&#61506;&#61525;&#61522;&#61511;&#61472;&#61513;&#61518;&#61507;&#61486;&#61472; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61524;&#61516;&#61505;&#61518;&#61524;&#61505;&#61484;&#61472;&#61511;&#61505;&#61472;&#61491;&#61488;&#61491;&#61492;&#61489; &#61490;&#61497;&#61492;&#61493;&#61472;&#61510;&#61516;&#61519;&#61527;&#61509;&#61522;&#61523;&#61472;&#61522;&#61519;&#61505;&#61508; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61525;&#61523;&#61472;&#61508;&#61509;&#61520;&#61524;&#61472;&#61519;&#61510;&#61472;&#61512;&#61509;&#61505;&#61516;&#61524;&#61512;&#61472;&#61478;&#61472;&#61512;&#61525;&#61517;&#61505;&#61518;&#61472;&#61523;&#61509;&#61522;&#61526;&#61513;&#61507;&#61509;&#61523; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61524;&#61516;&#61505;&#61518;&#61524;&#61505;&#61484;&#61472;&#61511;&#61505;&#61472;&#61491;&#61488;&#61491;&#61492;&#61489; &#61490;&#61497;&#61492;&#61493;&#61472;&#61510;&#61516;&#61519;&#61527;&#61509;&#61522;&#61523;&#61472;&#61522;&#61519;&#61505;&#61508; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61489;&#61488;&#61487;&#61488;&#61494;&#61487;&#61490;&#61488;&#61490;&#61490;&#61520;&#61488;&#61488;&#61488;&#61488;&#61495; &#61489; &#61489;&#61491;&#61486;&#61472;&#61524;&#61512;&#61513;&#61523;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61519;&#61518;&#61516;&#61529;&#61472;&#61505;&#61520;&#61520;&#61516;&#61513;&#61509;&#61523;&#61472;&#61524;&#61519;&#61472;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61523;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522;&#61523;&#61486;&#61472;&#61472;&#61513;&#61524;&#61472;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61509;&#61523;&#61472;&#61524;&#61512;&#61509;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61518;&#61519;&#61486;&#61472;&#61505;&#61523;&#61472;&#61508;&#61509;&#61523;&#61507;&#61522;&#61513;&#61506;&#61509;&#61508;&#61472;&#61513;&#61518;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61492;&#61486; &#61489;&#61490;&#61486;&#61472;&#61505;&#61507;&#61507;&#61519;&#61525;&#61518;&#61524;&#61513;&#61518;&#61511;&#61472;&#61505;&#61518;&#61508;&#61472;&#61505;&#61520;&#61520;&#61522;&#61519;&#61520;&#61522;&#61513;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61508;&#61505;&#61524;&#61505;&#61472;&#61480;&#61513;&#61542;&#61472;&#61554;&#61541;&#61553;&#61557;&#61545;&#61554;&#61541;&#61540;&#61481; &#61545;&#61555;&#61472;&#61550;&#61551;&#61556;&#61472;&#61541;&#61560;&#61556;&#61541;&#61550;&#61540;&#61541;&#61540;&#61486;&#61545;&#61555;&#61472;&#61541;&#61560;&#61556;&#61541;&#61550;&#61540;&#61541;&#61540;&#61484;&#61472; &#61513;&#61556;&#61541;&#61549;&#61555;&#61472;&#61496;&#61472;&#61537;&#61550;&#61540;&#61472;&#61489;&#61493;&#61484;&#61472;&#61537;&#61550;&#61540;&#61472;&#61554;&#61541;&#61556;&#61557;&#61554;&#61550;&#61545;&#61550;&#61543; &#61519;&#61542;&#61542;&#61541;&#61554;&#61555;&#61472;&#61549;&#61557;&#61555;&#61556;&#61472;&#61537;&#61539;&#61547;&#61550;&#61551;&#61559;&#61548;&#61541;&#61540;&#61543;&#61541;&#61472;&#61554;&#61541;&#61539;&#61541;&#61545;&#61552;&#61556;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61472;&#61552;&#61554;&#61545;&#61551;&#61554;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61544;&#61551;&#61557;&#61554;&#61472;&#61537;&#61550;&#61540;&#61472;&#61540;&#61537;&#61556;&#61541;&#61472;&#61555;&#61552;&#61541;&#61539;&#61545;&#61542;&#61545;&#61541;&#61540;&#61472;&#61545;&#61550;&#61472;&#61556;&#61544;&#61541;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61551;&#61554;&#61472;&#61537;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61541;&#61540; &#61484;&#61472;&#61538;&#61561;&#61472;&#61551;&#61550;&#61541;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61541;&#61472;&#61542;&#61551;&#61548;&#61548;&#61551;&#61559;&#61545;&#61550;&#61543;&#61472;&#61549;&#61541;&#61556;&#61544;&#61551;&#61540;&#61555;&#61498;&#61472;&#61480;&#61537;&#61481;&#61472;&#61506;&#61561;&#61472;&#61539;&#61551;&#61549;&#61552;&#61548;&#61541;&#61556;&#61545;&#61550;&#61543; &#61524;&#61544;&#61541;&#61472;&#61537;&#61538;&#61551;&#61558;&#61541;&#61472;&#61550;&#61557;&#61549;&#61538;&#61541;&#61554;&#61541;&#61540;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61541;&#61540;&#61472;&#61537;&#61555;&#61472;&#61555;&#61541;&#61556;&#61472;&#61542;&#61551;&#61554;&#61556;&#61544;&#61472;&#61545;&#61550;&#61472;&#61513;&#61556;&#61541;&#61549;&#61472;&#61489;&#61492;&#61486;&#61472;&#61472; &#61524;&#61544;&#61541;&#61472;&#61544;&#61551;&#61557;&#61554;&#61472;&#61537;&#61550;&#61540;&#61472;&#61540;&#61537;&#61556;&#61541;&#61472;&#61555;&#61552;&#61541;&#61539;&#61545;&#61542;&#61545;&#61541;&#61540;&#61472;&#61542;&#61551;&#61554;&#61472;&#61554;&#61541;&#61539;&#61541;&#61545;&#61552;&#61556;&#61472;&#61551;&#61542;&#61472;&#61519;&#61542;&#61542;&#61541;&#61554;&#61555; &#61489;&#61489;&#61486;&#61472;&#61524;&#61512;&#61513;&#61523;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61519;&#61518;&#61516;&#61529;&#61472;&#61505;&#61520;&#61520;&#61516;&#61513;&#61509;&#61523;&#61472;&#61524;&#61519;&#61472;&#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61523;&#61472;&#61519;&#61510;&#61472;&#61523;&#61519;&#61516;&#61513;&#61507;&#61513;&#61524;&#61505;&#61524;&#61513;&#61519;&#61518;&#61523; &#61510;&#61505;&#61507;&#61513;&#61516;&#61513;&#61524;&#61529;&#61472;&#61507;&#61519;&#61508;&#61509;&#61472;&#61507;&#61519;&#61508;&#61509;&#61472; &#61489;&#61488;&#61506;&#61486;&#61472;&#61508;&#61505;&#61524;&#61509;&#61508;&#61472;&#61480;&#61523;&#61509;&#61509;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61491;&#61481; &#61489;&#61488;&#61505;&#61486;&#61472;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61518;&#61519;&#61486; &#61497;&#61506;&#61486;&#61472;&#61508;&#61505;&#61524;&#61509;&#61508;&#61472;&#61480;&#61523;&#61509;&#61509;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61489;&#61481; &#61497;&#61505;&#61486;&#61472;&#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61472;&#61519;&#61510;&#61472;&#61523;&#61519;&#61516;&#61513;&#61507;&#61513;&#61524;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61518;&#61519;&#61486; &#61507;&#61519;&#61508;&#61509;&#61472; &#61496;&#61486;&#61472;&#61518;&#61505;&#61517;&#61509;&#61472;&#61505;&#61518;&#61508;&#61472;&#61505;&#61508;&#61508;&#61522;&#61509;&#61523;&#61523;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61519;&#61522;&#61472;&#61480;&#61518;&#61551;&#61486;&#61484;&#61472;&#61555;&#61556;&#61554;&#61541;&#61541;&#61556;&#61484;&#61472;&#61539;&#61551;&#61557;&#61550;&#61556;&#61561;&#61484;&#61472;&#61523;&#61556;&#61537;&#61556;&#61541;&#61472;&#61537;&#61550;&#61540;&#61472;&#61530;&#61513;&#61520;&#61472;&#61507;&#61551;&#61540;&#61541;&#61481; &#61495;&#61486;&#61472;&#61505;&#61508;&#61517;&#61513;&#61518;&#61513;&#61523;&#61524;&#61509;&#61522;&#61509;&#61508;&#61472;&#61506;&#61529;&#61472;&#61480;&#61513;&#61542;&#61472;&#61551;&#61556;&#61544;&#61541;&#61554;&#61472;&#61556;&#61544;&#61537;&#61550;&#61472;&#61513;&#61556;&#61541;&#61549;&#61472;&#61494;&#61481;&#61507;&#61519;&#61508;&#61509;&#61472;&#61494;&#61486;&#61472;&#61513;&#61523;&#61523;&#61525;&#61509;&#61508;&#61472;&#61506;&#61529; &#61520;&#61505;&#61511;&#61509;&#61472;&#61472;&#61472;&#61519;&#61510;&#61472;&#61472;&#61520;&#61505;&#61511;&#61509;&#61523; &#61492;&#61486;&#61472;&#61522;&#61509;&#61521;&#61525;&#61513;&#61523;&#61513;&#61524;&#61513;&#61519;&#61518;&#61487;&#61520;&#61525;&#61522;&#61507;&#61512;&#61505;&#61523;&#61509;&#61472;&#61522;&#61509;&#61521;&#61486;&#61472;&#61518;&#61519;&#61486;&#61491;&#61486;&#61472;&#61509;&#61510;&#61510;&#61509;&#61507;&#61524;&#61513;&#61526;&#61509;&#61472;&#61508;&#61505;&#61524;&#61509;&#61490;&#61486;&#61472;&#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61487;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61472;&#61518;&#61519;&#61486;&#61472; &#61493;&#61486;&#61472;&#61520;&#61522;&#61519;&#61514;&#61509;&#61507;&#61524;&#61472;&#61518;&#61519;&#61486;&#61472;&#61480;&#61513;&#61542;&#61472;&#61537;&#61552;&#61552;&#61548;&#61545;&#61539;&#61537;&#61538;&#61548;&#61541;&#61481; &#61489;&#61486; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61472;&#61513;&#61508;&#61472;&#61507;&#61519;&#61508;&#61509; &#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61472;&#61519;&#61510;&#61472;&#61523;&#61519;&#61516;&#61513;&#61507;&#61513;&#61524;&#61505;&#61524;&#61513;&#61519;&#61518;&#61487;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524; &#61488;&#61496;&#61487;&#61491;&#61488;&#61487;&#61490;&#61488;&#61489;&#61497; &#61505;&#61556;&#61556;&#61550;&#61498;&#61472;&#61523;&#61524;&#61509;&#61526;&#61509;&#61472;&#61472;&#61522;&#61505;&#61517;&#61506;&#61519; &#61509;&#61517;&#61509;&#61522;&#61511;&#61509;&#61518;&#61524;&#61472;&#61520;&#61522;&#61519;&#61508;&#61525;&#61507;&#61524;&#61472;&#61508;&#61509;&#61526;&#61509;&#61516;&#61519;&#61520;&#61517;&#61509;&#61518;&#61524;&#61472;&#61511;&#61505;&#61513;&#61524;&#61512;&#61509; &#61491;&#61488;&#61488;&#61472;&#61520;&#61522;&#61519;&#61510;&#61509;&#61523;&#61523;&#61513;&#61519;&#61518;&#61505;&#61516;&#61472;&#61508;&#61522; &#61507;&#61512;&#61509;&#61507;&#61515;&#61472;&#61519;&#61518;&#61509; &#61505;&#61486;&#61472;&#61524;&#61512;&#61513;&#61523;&#61472;&#61507;&#61512;&#61505;&#61518;&#61511;&#61509;&#61472;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61513;&#61523;&#61472;&#61513;&#61523;&#61523;&#61525;&#61509;&#61508;&#61472;&#61520;&#61525;&#61522;&#61523;&#61525;&#61505;&#61518;&#61524;&#61472;&#61524;&#61519;&#61498;&#61472;&#61480;&#61523;&#61552;&#61541;&#61539;&#61545;&#61542;&#61561;&#61472;&#61537;&#61557;&#61556;&#61544;&#61551;&#61554;&#61545;&#61556;&#61561;&#61481;&#61472;&#61472;&#61524;&#61512;&#61509;&#61472;&#61507;&#61512;&#61505;&#61518;&#61511;&#61509;&#61523;&#61472;&#61523;&#61509;&#61524;&#61472;&#61510;&#61519;&#61522;&#61524;&#61512;&#61472;&#61513;&#61518;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61492;&#61472;&#61505;&#61522;&#61509;&#61472;&#61517;&#61505;&#61508;&#61509;&#61472;&#61513;&#61518;&#61472;&#61524;&#61512;&#61509;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524; &#61506;&#61486;&#61472;&#61524;&#61512;&#61509;&#61472;&#61505;&#61506;&#61519;&#61526;&#61509;&#61472;&#61518;&#61525;&#61517;&#61506;&#61509;&#61522;&#61509;&#61508;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61513;&#61523;&#61472;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61509;&#61508;&#61472;&#61524;&#61519;&#61472;&#61522;&#61509;&#61510;&#61516;&#61509;&#61507;&#61524;&#61472;&#61524;&#61512;&#61509;&#61472;&#61505;&#61508;&#61517;&#61513;&#61518;&#61513;&#61523;&#61524;&#61522;&#61505;&#61524;&#61513;&#61526;&#61509;&#61472;&#61507;&#61512;&#61505;&#61518;&#61511;&#61509;&#61523;&#61472;&#61480;&#61555;&#61557;&#61539;&#61544;&#61472;&#61537;&#61555;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61555;&#61472;&#61545;&#61550;&#61472;&#61552;&#61537;&#61561;&#61545;&#61550;&#61543;&#61472;&#61551;&#61542;&#61542;&#61545;&#61539;&#61541;&#61484;&#61472; &#61507;&#61486;&#61472;&#61524;&#61512;&#61513;&#61523;&#61472;&#61523;&#61525;&#61520;&#61520;&#61516;&#61509;&#61517;&#61509;&#61518;&#61524;&#61505;&#61516;&#61472;&#61505;&#61511;&#61522;&#61509;&#61509;&#61517;&#61509;&#61518;&#61524;&#61472;&#61513;&#61523;&#61472;&#61509;&#61518;&#61524;&#61509;&#61522;&#61509;&#61508;&#61472;&#61513;&#61518;&#61524;&#61519;&#61472;&#61520;&#61525;&#61522;&#61523;&#61525;&#61505;&#61518;&#61524;&#61472;&#61524;&#61519;&#61472;&#61505;&#61525;&#61524;&#61512;&#61519;&#61522;&#61513;&#61524;&#61529;&#61472;&#61519;&#61510;&#61498; &#61508;&#61486;&#61472;&#61519;&#61524;&#61512;&#61509;&#61522;&#61472;&#61480;&#61523;&#61552;&#61541;&#61539;&#61545;&#61542;&#61561;&#61472;&#61556;&#61561;&#61552;&#61541;&#61472;&#61551;&#61542;&#61472;&#61549;&#61551;&#61540;&#61545;&#61542;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61537;&#61550;&#61540;&#61472;&#61537;&#61557;&#61556;&#61544;&#61551;&#61554;&#61545;&#61556;&#61561;&#61481; &#61472;&#61537;&#61552;&#61552;&#61554;&#61551;&#61552;&#61554;&#61545;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61540;&#61537;&#61556;&#61537;&#61484;&#61472;&#61541;&#61556;&#61539;&#61486;&#61481;&#61472;&#61472;&#61523;&#61509;&#61524;&#61472;&#61510;&#61519;&#61522;&#61524;&#61512;&#61472;&#61513;&#61518;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61492;&#61484;&#61472;&#61520;&#61525;&#61522;&#61523;&#61525;&#61505;&#61518;&#61524;&#61472;&#61524;&#61519;&#61472;&#61524;&#61512;&#61509;&#61472;&#61505;&#61525;&#61524;&#61512;&#61519;&#61522;&#61513;&#61524;&#61529;&#61472;&#61519;&#61510;&#61472;&#61510;&#61505;&#61522;&#61472;&#61492;&#61491;&#61486;&#61489;&#61488;&#61491;&#61480;&#61538;&#61481;&#61486; &#61509;&#61486;&#61472;&#61513;&#61517;&#61520;&#61519;&#61522;&#61524;&#61505;&#61518;&#61524;&#61498; &#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61551;&#61554;&#61472; &#61545;&#61555;&#61472;&#61550;&#61551;&#61556;&#61472; &#61545;&#61555;&#61472;&#61554;&#61541;&#61553;&#61557;&#61545;&#61554;&#61541;&#61540;&#61472;&#61556;&#61551;&#61472;&#61555;&#61545;&#61543;&#61550;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61540;&#61551;&#61539;&#61557;&#61549;&#61541;&#61550;&#61556;&#61472;&#61537;&#61550;&#61540;&#61472;&#61554;&#61541;&#61556;&#61557;&#61554;&#61550;&#61472;&#61472; &#61472;&#61472;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535; &#61539;&#61551;&#61552;&#61545;&#61541;&#61555;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61545;&#61555;&#61555;&#61557;&#61545;&#61550;&#61543;&#61472;&#61551;&#61542;&#61542;&#61545;&#61539;&#61541;&#61486; &#61472;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61518;&#61519;&#61486;&#61472;&#61513;&#61518;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61488;&#61505;&#61486; &#61560; &#61528; &#61489;&#61494;&#61505;&#61486;&#61472;&#61518;&#61505;&#61517;&#61509;&#61472;&#61472;&#61505;&#61518;&#61508;&#61472;&#61524;&#61513;&#61524;&#61516;&#61509;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61513;&#61518;&#61511;&#61472;&#61519;&#61510;&#61510;&#61513;&#61507;&#61509;&#61522;&#61472;&#61480;&#61524;&#61561;&#61552;&#61541;&#61472;&#61551;&#61554;&#61472;&#61552;&#61554;&#61545;&#61550;&#61556;&#61481;&#61489;&#61493;&#61505;&#61486;&#61472;&#61518;&#61505;&#61517;&#61509;&#61472;&#61505;&#61518;&#61508;&#61472;&#61524;&#61513;&#61524;&#61516;&#61509;&#61472;&#61519;&#61510;&#61472;&#61523;&#61513;&#61511;&#61518;&#61509;&#61522;&#61472;&#61480;&#61524;&#61561;&#61552;&#61541;&#61472;&#61551;&#61554;&#61472;&#61552;&#61554;&#61545;&#61550;&#61556;&#61481; &#61489;&#61493;&#61507;&#61486;&#61472;&#61508;&#61505;&#61524;&#61509;&#61472;&#61523;&#61513;&#61511;&#61518;&#61509;&#61508; &#61489;&#61494;&#61506;&#61486;&#61472;&#61525;&#61518;&#61513;&#61524;&#61509;&#61508;&#61472;&#61523;&#61524;&#61505;&#61524;&#61509;&#61523;&#61472;&#61519;&#61510;&#61472;&#61505;&#61517;&#61509;&#61522;&#61513;&#61507;&#61505;&#61489;&#61493;&#61506;&#61486;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61519;&#61522;&#61487;&#61519;&#61510;&#61510;&#61509;&#61522;&#61519;&#61522; &#61489;&#61494;&#61507;&#61486;&#61472;&#61508;&#61505;&#61524;&#61509;&#61472;&#61523;&#61513;&#61511;&#61518;&#61509;&#61508; &#61480;&#61523;&#61545;&#61543;&#61550;&#61537;&#61556;&#61557;&#61554;&#61541;&#61472;&#61551;&#61542;&#61472;&#61552;&#61541;&#61554;&#61555;&#61551;&#61550;&#61472;&#61537;&#61557;&#61556;&#61544;&#61551;&#61554;&#61545;&#61562;&#61541;&#61540;&#61472;&#61556;&#61551;&#61472;&#61555;&#61545;&#61543;&#61550;&#61481; &#61480;&#61523;&#61545;&#61543;&#61550;&#61537;&#61556;&#61557;&#61554;&#61541;&#61472;&#61551;&#61542;&#61472;&#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61545;&#61550;&#61543;&#61472;&#61519;&#61542;&#61542;&#61545;&#61539;&#61541;&#61554;&#61481; &#61515;&#61513;&#61517;&#61506;&#61509;&#61522;&#61516;&#61529;&#61472;&#61516;&#61486;&#61472;&#61511;&#61519;&#61516;&#61508;&#61509;&#61518; &#61523;&#61524;&#61505;&#61518;&#61508;&#61505;&#61522;&#61508;&#61472;&#61510;&#61519;&#61522;&#61517;&#61472;&#61491;&#61488;&#61472;&#61480;&#61522;&#61509;&#61526;&#61486;&#61472;&#61489;&#61489;&#61487;&#61490;&#61488;&#61489;&#61494;&#61481; &#61520;&#61554;&#61541;&#61555;&#61539;&#61554;&#61545;&#61538;&#61541;&#61540;&#61472;&#61538;&#61561;&#61472;&#61511;&#61523;&#61505;&#61472;&#61510;&#61505;&#61522;&#61472;&#61480;&#61492;&#61496;&#61472;&#61507;&#61510;&#61522;&#61481;&#61472;&#61493;&#61491;&#61486;&#61490;&#61492;&#61491; &#61520;&#61554;&#61541;&#61558;&#61545;&#61551;&#61557;&#61555;&#61472;&#61541;&#61540;&#61545;&#61556;&#61545;&#61551;&#61550;&#61472;&#61557;&#61550;&#61557;&#61555;&#61537;&#61538;&#61548;&#61541; &#61489;&#61492;&#61486;&#61472;&#61508;&#61509;&#61523;&#61507;&#61522;&#61513;&#61520;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61487;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61480;&#61519;&#61554;&#61543;&#61537;&#61550;&#61545;&#61562;&#61541;&#61540;&#61472;&#61538;&#61561;&#61472;&#61525;&#61507;&#61510;&#61472;&#61555;&#61541;&#61539;&#61556;&#61545;&#61551;&#61550;&#61472;&#61544;&#61541;&#61537;&#61540;&#61545;&#61550;&#61543;&#61555;&#61484;&#61472;&#61545;&#61550;&#61539;&#61548;&#61557;&#61540;&#61545;&#61550;&#61543;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61487;&#61539;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61472;&#61555;&#61557;&#61538;&#61546;&#61541;&#61539;&#61556;&#61472;&#61549;&#61537;&#61556;&#61556;&#61541;&#61554;&#61472;&#61559;&#61544;&#61541;&#61554;&#61541;&#61472;&#61542;&#61541;&#61537;&#61555;&#61545;&#61538;&#61548;&#61541;&#61486;&#61481; &#61524;&#61537;&#61560;&#61472;&#61513;&#61508;&#61472;&#61518;&#61557;&#61549;&#61538;&#61541;&#61554;&#61498;&#61472;&#61472; &#61508;&#61525;&#61518;&#61523;&#61472;&#61518;&#61557;&#61549;&#61538;&#61541;&#61554;&#61498;&#61472;&#61472; &#61520;&#61541;&#61554;&#61545;&#61551;&#61540;&#61472;&#61551;&#61542;&#61472;&#61520;&#61541;&#61554;&#61542;&#61551;&#61554;&#61549;&#61537;&#61550;&#61539;&#61541;&#61498;&#61472;&#61488;&#61496;&#61487;&#61491;&#61488;&#61487;&#61490;&#61488;&#61489;&#61497;&#61472;&#61556;&#61551;&#61472;&#61488;&#61496;&#61487;&#61490;&#61497;&#61487;&#61490;&#61488;&#61490;&#61497; &#61524;&#61544;&#61541;&#61472;&#61552;&#61557;&#61554;&#61552;&#61551;&#61555;&#61541;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61549;&#61551;&#61540;&#61545;&#61542;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61545;&#61555;&#61472;&#61556;&#61551;&#61472;&#61541;&#61560;&#61556;&#61541;&#61550;&#61540;&#61472;&#61524;&#61537;&#61555;&#61547;&#61472;&#61489;&#61484;&#61472;&#61519;&#61552;&#61556;&#61545;&#61551;&#61550;&#61472;&#61491;&#61488;&#61488;&#61489;&#61486; &#61524;&#61537;&#61555;&#61547;&#61472;&#61489;&#61484;&#61472;&#61519;&#61552;&#61556;&#61545;&#61551;&#61550;&#61472;&#61491;&#61488;&#61488;&#61489;&#61472;&#61552;&#61554;&#61545;&#61539;&#61545;&#61550;&#61543;&#61472;&#61545;&#61555;&#61472;&#61544;&#61541;&#61554;&#61541;&#61538;&#61561;&#61472;&#61541;&#61560;&#61556;&#61541;&#61550;&#61540;&#61541;&#61540;&#61472;&#61542;&#61554;&#61551;&#61549;&#61472;&#61489;&#61488;&#61487;&#61488;&#61489;&#61487;&#61490;&#61489;&#61485;&#61489;&#61488;&#61487;&#61491;&#61488;&#61487;&#61490;&#61488;&#61490;&#61490;&#61486; &#61524;&#61544;&#61541;&#61472;&#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61472;&#61529;&#61541;&#61537;&#61554;&#61472;&#61555;&#61544;&#61551;&#61559;&#61550;&#61472;&#61551;&#61550;&#61472;&#61552;&#61537;&#61543;&#61541;&#61472;&#61494;&#61484;&#61472;&#61524;&#61537;&#61538;&#61548;&#61541;&#61472;&#61490;&#61484;&#61472;&#61542;&#61551;&#61554;&#61472;&#61491;&#61488;&#61488;&#61489;&#61472;&#61537;&#61550;&#61540;&#61472;&#61492;&#61488;&#61488;&#61489;&#61472;&#61537;&#61554;&#61541;&#61472;&#61557;&#61552;&#61540;&#61537;&#61556;&#61541;&#61540;&#61472;&#61537;&#61555;&#61472;&#61542;&#61551;&#61548;&#61548;&#61551;&#61559;&#61555;&#61498; &#61491;&#61488;&#61488;&#61489;&#61472;&#61540;&#61537;&#61556;&#61541;&#61555;&#61472;&#61537;&#61554;&#61541;&#61472;&#61557;&#61552;&#61540;&#61537;&#61556;&#61541;&#61540;&#61472;&#61542;&#61554;&#61551;&#61549;&#61472;&#61489;&#61488;&#61487;&#61488;&#61489;&#61487;&#61490;&#61489;&#61485;&#61488;&#61497;&#61487;&#61491;&#61488;&#61487;&#61490;&#61490;&#61472;&#61556;&#61551;&#61472;&#61489;&#61488;&#61487;&#61488;&#61489;&#61487;&#61490;&#61489;&#61485;&#61489;&#61488;&#61487;&#61491;&#61488;&#61487;&#61490;&#61490;&#61486; &#61492;&#61488;&#61488;&#61489;&#61472;&#61540;&#61537;&#61556;&#61541;&#61555;&#61472;&#61537;&#61554;&#61541;&#61472;&#61557;&#61552;&#61540;&#61537;&#61556;&#61541;&#61540;&#61472;&#61542;&#61554;&#61551;&#61549;&#61472;&#61489;&#61488;&#61487;&#61488;&#61489;&#61487;&#61490;&#61490;&#61485;&#61488;&#61497;&#61487;&#61491;&#61488;&#61487;&#61490;&#61491;&#61472;&#61556;&#61551;&#61472;&#61489;&#61488;&#61487;&#61491;&#61489;&#61487;&#61490;&#61490;&#61485;&#61488;&#61497;&#61487;&#61491;&#61488;&#61487;&#61490;&#61491;&#61486; &#61509;&#61560;&#61539;&#61541;&#61552;&#61556;&#61472;&#61537;&#61555;&#61472;&#61552;&#61554;&#61551;&#61558;&#61545;&#61540;&#61541;&#61540;&#61472;&#61544;&#61541;&#61554;&#61541;&#61545;&#61550;&#61484;&#61472;&#61537;&#61548;&#61548;&#61472;&#61556;&#61541;&#61554;&#61549;&#61555;&#61472;&#61537;&#61550;&#61540;&#61472;&#61539;&#61551;&#61550;&#61540;&#61545;&#61556;&#61545;&#61551;&#61550;&#61555;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61541;&#61472;&#61540;&#61551;&#61539;&#61557;&#61549;&#61541;&#61550;&#61556;&#61472;&#61554;&#61541;&#61542;&#61541;&#61554;&#61541;&#61550;&#61539;&#61541;&#61540;&#61472;&#61545;&#61550;&#61472;&#61513;&#61556;&#61541;&#61549;&#61472;&#61497; &#61505;&#61472;&#61551;&#61554;&#61472;&#61489;&#61488;&#61505;&#61484;&#61472;&#61537;&#61555;&#61472;&#61544;&#61541;&#61554;&#61541;&#61556;&#61551;&#61542;&#61551;&#61554;&#61541;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61540;&#61484;&#61472;&#61554;&#61541;&#61549;&#61537;&#61545;&#61550;&#61555;&#61472;&#61557;&#61550;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61540;&#61472;&#61537;&#61550;&#61540;&#61472;&#61545;&#61550;&#61472;&#61542;&#61557;&#61548;&#61548;&#61472;&#61542;&#61551;&#61554;&#61539;&#61541;&#61472;&#61537;&#61550;&#61540;&#61472;&#61541;&#61542;&#61542;&#61541;&#61539;&#61556; &#61486; 10-6-2022 Adam Havey 10/6/2022 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.93
<SEQUENCE>6
<FILENAME>modificationno8effective.htm
<DESCRIPTION>EX-10.93
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>modificationno8effective</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- modificationno8effective001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno8effective001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">&#61472;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535; &#61480;&#61560;&#61481; &#61560; &#61495;&#61493;&#61505;&#61493;&#61488;&#61489;&#61489;&#61497;&#61507;&#61488;&#61488;&#61488;&#61495;&#61489; &#61539;&#61551;&#61552;&#61545;&#61541;&#61555;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61541;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61499;&#61472;&#61480;&#61538;&#61481;&#61472;&#61506;&#61561;&#61472;&#61537;&#61539;&#61547;&#61550;&#61551;&#61559;&#61548;&#61541;&#61540;&#61543;&#61545;&#61550;&#61543;&#61472;&#61554;&#61541;&#61539;&#61541;&#61545;&#61552;&#61556;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61472;&#61551;&#61550;&#61472;&#61541;&#61537;&#61539;&#61544;&#61472;&#61539;&#61551;&#61552;&#61561;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61541;&#61472;&#61551;&#61542;&#61542;&#61541;&#61554;&#61472;&#61555;&#61557;&#61538;&#61549;&#61545;&#61556;&#61556;&#61541;&#61540; &#61499;&#61472;&#61551;&#61554;&#61472;&#61480;&#61539;&#61481;&#61472;&#61506;&#61561;&#61472; &#61555;&#61541;&#61552;&#61537;&#61554;&#61537;&#61556;&#61541;&#61472;&#61548;&#61541;&#61556;&#61556;&#61541;&#61554;&#61472;&#61551;&#61554;&#61472;&#61541;&#61548;&#61541;&#61539;&#61556;&#61554;&#61551;&#61550;&#61545;&#61539;&#61472;&#61539;&#61551;&#61549;&#61549;&#61557;&#61550;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61559;&#61544;&#61545;&#61539;&#61544;&#61472;&#61545;&#61550;&#61539;&#61548;&#61557;&#61540;&#61541;&#61555;&#61472;&#61537;&#61472;&#61554;&#61541;&#61542;&#61541;&#61554;&#61541;&#61550;&#61539;&#61541;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61537;&#61550;&#61540;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61472;&#61550;&#61557;&#61549;&#61538;&#61541;&#61554;&#61555;&#61486;&#61472;&#61472; &#61510;&#61505;&#61513;&#61516;&#61525;&#61522;&#61509;&#61472;&#61519;&#61510;&#61472;&#61529;&#61519;&#61525;&#61522;&#61472;&#61505;&#61507;&#61515;&#61518;&#61519;&#61527;&#61516;&#61509;&#61508;&#61511;&#61509;&#61517;&#61509;&#61518;&#61524;&#61472;&#61524;&#61519;&#61472;&#61506;&#61509;&#61472; &#61522;&#61509;&#61507;&#61509;&#61513;&#61526;&#61509;&#61508;&#61472;&#61505;&#61524;&#61472;&#61524;&#61512;&#61509;&#61472;&#61520;&#61516;&#61505;&#61507;&#61509;&#61472;&#61508;&#61509;&#61523;&#61513;&#61511;&#61518;&#61505;&#61524;&#61509;&#61508;&#61472;&#61510;&#61519;&#61522;&#61472;&#61524;&#61512;&#61509;&#61472;&#61522;&#61509;&#61507;&#61509;&#61513;&#61520;&#61524;&#61472;&#61519;&#61510;&#61472;&#61519;&#61510;&#61510;&#61509;&#61522;&#61523;&#61472;&#61520;&#61522;&#61513;&#61519;&#61522;&#61472;&#61524;&#61519;&#61472;&#61524;&#61512;&#61509;&#61472;&#61512;&#61519;&#61525;&#61522;&#61472;&#61505;&#61518;&#61508;&#61472;&#61508;&#61505;&#61524;&#61509;&#61472;&#61523;&#61520;&#61509;&#61507;&#61513;&#61510;&#61513;&#61509;&#61508;&#61472;&#61517;&#61505;&#61529;&#61472;&#61522;&#61509;&#61523;&#61525;&#61516;&#61524;&#61472;&#61513;&#61518;&#61472;&#61522;&#61509;&#61514;&#61509;&#61507;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61529;&#61519;&#61525;&#61522;&#61472; &#61519;&#61510;&#61510;&#61509;&#61522;&#61486;&#61472;&#61472;&#61513;&#61542;&#61472;&#61538;&#61561;&#61472;&#61558;&#61545;&#61554;&#61556;&#61557;&#61541;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61472;&#61561;&#61551;&#61557;&#61472;&#61540;&#61541;&#61555;&#61545;&#61554;&#61541;&#61472;&#61556;&#61551;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61472;&#61537;&#61550;&#61472;&#61551;&#61542;&#61542;&#61541;&#61554;&#61472;&#61537;&#61548;&#61554;&#61541;&#61537;&#61540;&#61561;&#61472;&#61555;&#61557;&#61538;&#61549;&#61545;&#61556;&#61556;&#61541;&#61540; &#61484;&#61472;&#61555;&#61557;&#61539;&#61544;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61472;&#61549;&#61537;&#61561;&#61472;&#61538;&#61541;&#61472;&#61549;&#61537;&#61540;&#61541;&#61472;&#61538;&#61561;&#61472;&#61548;&#61541;&#61556;&#61556;&#61541;&#61554;&#61472;&#61551;&#61554;&#61472;&#61541;&#61548;&#61541;&#61539;&#61556;&#61554;&#61551;&#61550;&#61545;&#61539;&#61472;&#61539;&#61551;&#61549;&#61549;&#61557;&#61550;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61484;&#61472;&#61552;&#61554;&#61551;&#61558;&#61545;&#61540;&#61541;&#61540;&#61472; &#61541;&#61537;&#61539;&#61544;&#61472;&#61548;&#61541;&#61556;&#61556;&#61541;&#61554;&#61472;&#61551;&#61554;&#61472;&#61541;&#61548;&#61541;&#61539;&#61556;&#61554;&#61551;&#61550;&#61545;&#61539;&#61472;&#61539;&#61551;&#61549;&#61549;&#61557;&#61550;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61549;&#61537;&#61547;&#61541;&#61555;&#61472;&#61554;&#61541;&#61542;&#61541;&#61554;&#61541;&#61550;&#61539;&#61541;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61537;&#61550;&#61540;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61484;&#61472;&#61537;&#61550;&#61540;&#61472;&#61545;&#61555;&#61472;&#61554;&#61541;&#61539;&#61541;&#61545;&#61558;&#61541;&#61540;&#61472;&#61552;&#61554;&#61545;&#61551;&#61554;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61551;&#61552;&#61541;&#61550;&#61545;&#61550;&#61543;&#61472;&#61544;&#61551;&#61557;&#61554;&#61472;&#61537;&#61550;&#61540;&#61472;&#61540;&#61537;&#61556;&#61541;&#61472;&#61555;&#61552;&#61541;&#61539;&#61545;&#61542;&#61545;&#61541;&#61540;&#61486; &#61523;&#61541;&#61541;&#61472;&#61523;&#61539;&#61544;&#61541;&#61540;&#61557;&#61548;&#61541; &#61511;&#61505;&#61513;&#61524;&#61512;&#61509;&#61522;&#61523;&#61506;&#61525;&#61522;&#61511;&#61472;&#61517;&#61508;&#61472;&#61490;&#61488;&#61496;&#61495;&#61497;&#61491;&#61492;&#61489;&#61497; &#61489;&#61491;&#61494;&#61493;&#61496;&#61494;&#61497; &#61509;&#61517;&#61509;&#61522;&#61511;&#61509;&#61518;&#61524;&#61472;&#61520;&#61522;&#61519;&#61508;&#61525;&#61507;&#61524;&#61472;&#61508;&#61509;&#61526;&#61509;&#61516;&#61519;&#61520;&#61517;&#61509;&#61518;&#61524;&#61472;&#61511;&#61505;&#61513;&#61524;&#61512;&#61509;&#61522;&#61523;&#61506;&#61525;&#61522;&#61511;&#61472;&#61513;&#61518;&#61507;&#61486;&#61472; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61524;&#61516;&#61505;&#61518;&#61524;&#61505;&#61484;&#61472;&#61511;&#61505;&#61472;&#61491;&#61488;&#61491;&#61492;&#61489; &#61490;&#61497;&#61492;&#61493;&#61472;&#61510;&#61516;&#61519;&#61527;&#61509;&#61522;&#61523;&#61472;&#61522;&#61519;&#61505;&#61508; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61525;&#61523;&#61472;&#61508;&#61509;&#61520;&#61524;&#61472;&#61519;&#61510;&#61472;&#61512;&#61509;&#61505;&#61516;&#61524;&#61512;&#61472;&#61478;&#61472;&#61512;&#61525;&#61517;&#61505;&#61518;&#61472;&#61523;&#61509;&#61522;&#61526;&#61513;&#61507;&#61509;&#61523; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61524;&#61516;&#61505;&#61518;&#61524;&#61505;&#61484;&#61472;&#61511;&#61505;&#61472;&#61491;&#61488;&#61491;&#61492;&#61489; &#61490;&#61497;&#61492;&#61493;&#61472;&#61510;&#61516;&#61519;&#61527;&#61509;&#61522;&#61523;&#61472;&#61522;&#61519;&#61505;&#61508; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61523;&#61541;&#61541;&#61472;&#61506;&#61548;&#61551;&#61539;&#61547;&#61472;&#61489;&#61494;&#61507;&#61520;&#61488;&#61488;&#61488;&#61488;&#61496; &#61472;&#61490;&#61489; &#61489;&#61491;&#61486;&#61472;&#61524;&#61512;&#61513;&#61523;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61519;&#61518;&#61516;&#61529;&#61472;&#61505;&#61520;&#61520;&#61516;&#61513;&#61509;&#61523;&#61472;&#61524;&#61519;&#61472;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61523;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522;&#61523;&#61486;&#61472;&#61472;&#61513;&#61524;&#61472;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61509;&#61523;&#61472;&#61524;&#61512;&#61509;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61518;&#61519;&#61486;&#61472;&#61505;&#61523;&#61472;&#61508;&#61509;&#61523;&#61507;&#61522;&#61513;&#61506;&#61509;&#61508;&#61472;&#61513;&#61518;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61492;&#61486; &#61489;&#61490;&#61486;&#61472;&#61505;&#61507;&#61507;&#61519;&#61525;&#61518;&#61524;&#61513;&#61518;&#61511;&#61472;&#61505;&#61518;&#61508;&#61472;&#61505;&#61520;&#61520;&#61522;&#61519;&#61520;&#61522;&#61513;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61508;&#61505;&#61524;&#61505;&#61472;&#61480;&#61513;&#61542;&#61472;&#61554;&#61541;&#61553;&#61557;&#61545;&#61554;&#61541;&#61540;&#61481; &#61545;&#61555;&#61472;&#61550;&#61551;&#61556;&#61472;&#61541;&#61560;&#61556;&#61541;&#61550;&#61540;&#61541;&#61540;&#61486;&#61545;&#61555;&#61472;&#61541;&#61560;&#61556;&#61541;&#61550;&#61540;&#61541;&#61540;&#61484;&#61472; &#61513;&#61556;&#61541;&#61549;&#61555;&#61472;&#61496;&#61472;&#61537;&#61550;&#61540;&#61472;&#61489;&#61493;&#61484;&#61472;&#61537;&#61550;&#61540;&#61472;&#61554;&#61541;&#61556;&#61557;&#61554;&#61550;&#61545;&#61550;&#61543; &#61519;&#61542;&#61542;&#61541;&#61554;&#61555;&#61472;&#61549;&#61557;&#61555;&#61556;&#61472;&#61537;&#61539;&#61547;&#61550;&#61551;&#61559;&#61548;&#61541;&#61540;&#61543;&#61541;&#61472;&#61554;&#61541;&#61539;&#61541;&#61545;&#61552;&#61556;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61472;&#61552;&#61554;&#61545;&#61551;&#61554;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61544;&#61551;&#61557;&#61554;&#61472;&#61537;&#61550;&#61540;&#61472;&#61540;&#61537;&#61556;&#61541;&#61472;&#61555;&#61552;&#61541;&#61539;&#61545;&#61542;&#61545;&#61541;&#61540;&#61472;&#61545;&#61550;&#61472;&#61556;&#61544;&#61541;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61551;&#61554;&#61472;&#61537;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61541;&#61540; &#61484;&#61472;&#61538;&#61561;&#61472;&#61551;&#61550;&#61541;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61541;&#61472;&#61542;&#61551;&#61548;&#61548;&#61551;&#61559;&#61545;&#61550;&#61543;&#61472;&#61549;&#61541;&#61556;&#61544;&#61551;&#61540;&#61555;&#61498;&#61472;&#61480;&#61537;&#61481;&#61472;&#61506;&#61561;&#61472;&#61539;&#61551;&#61549;&#61552;&#61548;&#61541;&#61556;&#61545;&#61550;&#61543; &#61524;&#61544;&#61541;&#61472;&#61537;&#61538;&#61551;&#61558;&#61541;&#61472;&#61550;&#61557;&#61549;&#61538;&#61541;&#61554;&#61541;&#61540;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61545;&#61555;&#61472;&#61537;&#61549;&#61541;&#61550;&#61540;&#61541;&#61540;&#61472;&#61537;&#61555;&#61472;&#61555;&#61541;&#61556;&#61472;&#61542;&#61551;&#61554;&#61556;&#61544;&#61472;&#61545;&#61550;&#61472;&#61513;&#61556;&#61541;&#61549;&#61472;&#61489;&#61492;&#61486;&#61472;&#61472; &#61524;&#61544;&#61541;&#61472;&#61544;&#61551;&#61557;&#61554;&#61472;&#61537;&#61550;&#61540;&#61472;&#61540;&#61537;&#61556;&#61541;&#61472;&#61555;&#61552;&#61541;&#61539;&#61545;&#61542;&#61545;&#61541;&#61540;&#61472;&#61542;&#61551;&#61554;&#61472;&#61554;&#61541;&#61539;&#61541;&#61545;&#61552;&#61556;&#61472;&#61551;&#61542;&#61472;&#61519;&#61542;&#61542;&#61541;&#61554;&#61555; &#61489;&#61489;&#61486;&#61472;&#61524;&#61512;&#61513;&#61523;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61519;&#61518;&#61516;&#61529;&#61472;&#61505;&#61520;&#61520;&#61516;&#61513;&#61509;&#61523;&#61472;&#61524;&#61519;&#61472;&#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61523;&#61472;&#61519;&#61510;&#61472;&#61523;&#61519;&#61516;&#61513;&#61507;&#61513;&#61524;&#61505;&#61524;&#61513;&#61519;&#61518;&#61523; &#61510;&#61505;&#61507;&#61513;&#61516;&#61513;&#61524;&#61529;&#61472;&#61507;&#61519;&#61508;&#61509;&#61472;&#61507;&#61519;&#61508;&#61509;&#61472; &#61489;&#61488;&#61506;&#61486;&#61472;&#61508;&#61505;&#61524;&#61509;&#61508;&#61472;&#61480;&#61523;&#61509;&#61509;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61491;&#61481; &#61489;&#61488;&#61505;&#61486;&#61472;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61518;&#61519;&#61486; &#61497;&#61506;&#61486;&#61472;&#61508;&#61505;&#61524;&#61509;&#61508;&#61472;&#61480;&#61523;&#61509;&#61509;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61489;&#61481; &#61497;&#61505;&#61486;&#61472;&#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61472;&#61519;&#61510;&#61472;&#61523;&#61519;&#61516;&#61513;&#61507;&#61513;&#61524;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61518;&#61519;&#61486; &#61507;&#61519;&#61508;&#61509;&#61472; &#61496;&#61486;&#61472;&#61518;&#61505;&#61517;&#61509;&#61472;&#61505;&#61518;&#61508;&#61472;&#61505;&#61508;&#61508;&#61522;&#61509;&#61523;&#61523;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61519;&#61522;&#61472;&#61480;&#61518;&#61551;&#61486;&#61484;&#61472;&#61555;&#61556;&#61554;&#61541;&#61541;&#61556;&#61484;&#61472;&#61539;&#61551;&#61557;&#61550;&#61556;&#61561;&#61484;&#61472;&#61523;&#61556;&#61537;&#61556;&#61541;&#61472;&#61537;&#61550;&#61540;&#61472;&#61530;&#61513;&#61520;&#61472;&#61507;&#61551;&#61540;&#61541;&#61481; &#61495;&#61486;&#61472;&#61505;&#61508;&#61517;&#61513;&#61518;&#61513;&#61523;&#61524;&#61509;&#61522;&#61509;&#61508;&#61472;&#61506;&#61529;&#61472;&#61480;&#61513;&#61542;&#61472;&#61551;&#61556;&#61544;&#61541;&#61554;&#61472;&#61556;&#61544;&#61537;&#61550;&#61472;&#61513;&#61556;&#61541;&#61549;&#61472;&#61494;&#61481;&#61507;&#61519;&#61508;&#61509;&#61472;&#61494;&#61486;&#61472;&#61513;&#61523;&#61523;&#61525;&#61509;&#61508;&#61472;&#61506;&#61529; &#61520;&#61505;&#61511;&#61509;&#61472;&#61472;&#61472;&#61519;&#61510;&#61472;&#61472;&#61520;&#61505;&#61511;&#61509;&#61523; &#61492;&#61486;&#61472;&#61522;&#61509;&#61521;&#61525;&#61513;&#61523;&#61513;&#61524;&#61513;&#61519;&#61518;&#61487;&#61520;&#61525;&#61522;&#61507;&#61512;&#61505;&#61523;&#61509;&#61472;&#61522;&#61509;&#61521;&#61486;&#61472;&#61518;&#61519;&#61486;&#61491;&#61486;&#61472;&#61509;&#61510;&#61510;&#61509;&#61507;&#61524;&#61513;&#61526;&#61509;&#61472;&#61508;&#61505;&#61524;&#61509;&#61490;&#61486;&#61472;&#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61487;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61472;&#61518;&#61519;&#61486;&#61472; &#61493;&#61486;&#61472;&#61520;&#61522;&#61519;&#61514;&#61509;&#61507;&#61524;&#61472;&#61518;&#61519;&#61486;&#61472;&#61480;&#61513;&#61542;&#61472;&#61537;&#61552;&#61552;&#61548;&#61545;&#61539;&#61537;&#61538;&#61548;&#61541;&#61481; &#61489;&#61486; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61472;&#61513;&#61508;&#61472;&#61507;&#61519;&#61508;&#61509; &#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61472;&#61519;&#61510;&#61472;&#61523;&#61519;&#61516;&#61513;&#61507;&#61513;&#61524;&#61505;&#61524;&#61513;&#61519;&#61518;&#61487;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524; &#61488;&#61496;&#61487;&#61491;&#61488;&#61487;&#61490;&#61488;&#61489;&#61497; &#61505;&#61556;&#61556;&#61550;&#61498;&#61472;&#61523;&#61524;&#61509;&#61526;&#61509;&#61472;&#61472;&#61522;&#61505;&#61517;&#61506;&#61519; &#61509;&#61517;&#61509;&#61522;&#61511;&#61509;&#61518;&#61524;&#61472;&#61520;&#61522;&#61519;&#61508;&#61525;&#61507;&#61524;&#61472;&#61508;&#61509;&#61526;&#61509;&#61516;&#61519;&#61520;&#61517;&#61509;&#61518;&#61524;&#61472;&#61511;&#61505;&#61513;&#61524;&#61512;&#61509; &#61491;&#61488;&#61488;&#61472;&#61520;&#61522;&#61519;&#61510;&#61509;&#61523;&#61523;&#61513;&#61519;&#61518;&#61505;&#61516;&#61472;&#61508;&#61522; &#61507;&#61512;&#61509;&#61507;&#61515;&#61472;&#61519;&#61518;&#61509; &#61505;&#61486;&#61472;&#61524;&#61512;&#61513;&#61523;&#61472;&#61507;&#61512;&#61505;&#61518;&#61511;&#61509;&#61472;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61513;&#61523;&#61472;&#61513;&#61523;&#61523;&#61525;&#61509;&#61508;&#61472;&#61520;&#61525;&#61522;&#61523;&#61525;&#61505;&#61518;&#61524;&#61472;&#61524;&#61519;&#61498;&#61472;&#61480;&#61523;&#61552;&#61541;&#61539;&#61545;&#61542;&#61561;&#61472;&#61537;&#61557;&#61556;&#61544;&#61551;&#61554;&#61545;&#61556;&#61561;&#61481;&#61472;&#61472;&#61524;&#61512;&#61509;&#61472;&#61507;&#61512;&#61505;&#61518;&#61511;&#61509;&#61523;&#61472;&#61523;&#61509;&#61524;&#61472;&#61510;&#61519;&#61522;&#61524;&#61512;&#61472;&#61513;&#61518;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61492;&#61472;&#61505;&#61522;&#61509;&#61472;&#61517;&#61505;&#61508;&#61509;&#61472;&#61513;&#61518;&#61472;&#61524;&#61512;&#61509;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524; &#61506;&#61486;&#61472;&#61524;&#61512;&#61509;&#61472;&#61505;&#61506;&#61519;&#61526;&#61509;&#61472;&#61518;&#61525;&#61517;&#61506;&#61509;&#61522;&#61509;&#61508;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61513;&#61523;&#61472;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61509;&#61508;&#61472;&#61524;&#61519;&#61472;&#61522;&#61509;&#61510;&#61516;&#61509;&#61507;&#61524;&#61472;&#61524;&#61512;&#61509;&#61472;&#61505;&#61508;&#61517;&#61513;&#61518;&#61513;&#61523;&#61524;&#61522;&#61505;&#61524;&#61513;&#61526;&#61509;&#61472;&#61507;&#61512;&#61505;&#61518;&#61511;&#61509;&#61523;&#61472;&#61480;&#61555;&#61557;&#61539;&#61544;&#61472;&#61537;&#61555;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61555;&#61472;&#61545;&#61550;&#61472;&#61552;&#61537;&#61561;&#61545;&#61550;&#61543;&#61472;&#61551;&#61542;&#61542;&#61545;&#61539;&#61541;&#61484;&#61472; &#61507;&#61486;&#61472;&#61524;&#61512;&#61513;&#61523;&#61472;&#61523;&#61525;&#61520;&#61520;&#61516;&#61509;&#61517;&#61509;&#61518;&#61524;&#61505;&#61516;&#61472;&#61505;&#61511;&#61522;&#61509;&#61509;&#61517;&#61509;&#61518;&#61524;&#61472;&#61513;&#61523;&#61472;&#61509;&#61518;&#61524;&#61509;&#61522;&#61509;&#61508;&#61472;&#61513;&#61518;&#61524;&#61519;&#61472;&#61520;&#61525;&#61522;&#61523;&#61525;&#61505;&#61518;&#61524;&#61472;&#61524;&#61519;&#61472;&#61505;&#61525;&#61524;&#61512;&#61519;&#61522;&#61513;&#61524;&#61529;&#61472;&#61519;&#61510;&#61498; &#61508;&#61486;&#61472;&#61519;&#61524;&#61512;&#61509;&#61522;&#61472;&#61480;&#61523;&#61552;&#61541;&#61539;&#61545;&#61542;&#61561;&#61472;&#61556;&#61561;&#61552;&#61541;&#61472;&#61551;&#61542;&#61472;&#61549;&#61551;&#61540;&#61545;&#61542;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61537;&#61550;&#61540;&#61472;&#61537;&#61557;&#61556;&#61544;&#61551;&#61554;&#61545;&#61556;&#61561;&#61481; &#61472;&#61537;&#61552;&#61552;&#61554;&#61551;&#61552;&#61554;&#61545;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61540;&#61537;&#61556;&#61537;&#61484;&#61472;&#61541;&#61556;&#61539;&#61486;&#61481;&#61472;&#61472;&#61523;&#61509;&#61524;&#61472;&#61510;&#61519;&#61522;&#61524;&#61512;&#61472;&#61513;&#61518;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61492;&#61484;&#61472;&#61520;&#61525;&#61522;&#61523;&#61525;&#61505;&#61518;&#61524;&#61472;&#61524;&#61519;&#61472;&#61524;&#61512;&#61509;&#61472;&#61505;&#61525;&#61524;&#61512;&#61519;&#61522;&#61513;&#61524;&#61529;&#61472;&#61519;&#61510;&#61472;&#61510;&#61505;&#61522;&#61472;&#61492;&#61491;&#61486;&#61489;&#61488;&#61491;&#61480;&#61538;&#61481;&#61486; &#61509;&#61486;&#61472;&#61513;&#61517;&#61520;&#61519;&#61522;&#61524;&#61505;&#61518;&#61524;&#61498; &#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61551;&#61554;&#61472; &#61545;&#61555;&#61472;&#61550;&#61551;&#61556;&#61472; &#61545;&#61555;&#61472;&#61554;&#61541;&#61553;&#61557;&#61545;&#61554;&#61541;&#61540;&#61472;&#61556;&#61551;&#61472;&#61555;&#61545;&#61543;&#61550;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61540;&#61551;&#61539;&#61557;&#61549;&#61541;&#61550;&#61556;&#61472;&#61537;&#61550;&#61540;&#61472;&#61554;&#61541;&#61556;&#61557;&#61554;&#61550;&#61472;&#61472; &#61472;&#61472;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535; &#61539;&#61551;&#61552;&#61545;&#61541;&#61555;&#61472;&#61556;&#61551;&#61472;&#61556;&#61544;&#61541;&#61472;&#61545;&#61555;&#61555;&#61557;&#61545;&#61550;&#61543;&#61472;&#61551;&#61542;&#61542;&#61545;&#61539;&#61541;&#61486; &#61472;&#61519;&#61522;&#61508;&#61509;&#61522;&#61472;&#61518;&#61519;&#61486;&#61472;&#61513;&#61518;&#61472;&#61513;&#61524;&#61509;&#61517;&#61472;&#61489;&#61488;&#61505;&#61486; &#61560; &#61528; &#61489;&#61494;&#61505;&#61486;&#61472;&#61518;&#61505;&#61517;&#61509;&#61472;&#61472;&#61505;&#61518;&#61508;&#61472;&#61524;&#61513;&#61524;&#61516;&#61509;&#61472;&#61519;&#61510;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61513;&#61518;&#61511;&#61472;&#61519;&#61510;&#61510;&#61513;&#61507;&#61509;&#61522;&#61472;&#61480;&#61524;&#61561;&#61552;&#61541;&#61472;&#61551;&#61554;&#61472;&#61552;&#61554;&#61545;&#61550;&#61556;&#61481;&#61489;&#61493;&#61505;&#61486;&#61472;&#61518;&#61505;&#61517;&#61509;&#61472;&#61505;&#61518;&#61508;&#61472;&#61524;&#61513;&#61524;&#61516;&#61509;&#61472;&#61519;&#61510;&#61472;&#61523;&#61513;&#61511;&#61518;&#61509;&#61522;&#61472;&#61480;&#61524;&#61561;&#61552;&#61541;&#61472;&#61551;&#61554;&#61472;&#61552;&#61554;&#61545;&#61550;&#61556;&#61481; &#61489;&#61493;&#61507;&#61486;&#61472;&#61508;&#61505;&#61524;&#61509;&#61472;&#61523;&#61513;&#61511;&#61518;&#61509;&#61508; &#61489;&#61494;&#61506;&#61486;&#61472;&#61525;&#61518;&#61513;&#61524;&#61509;&#61508;&#61472;&#61523;&#61524;&#61505;&#61524;&#61509;&#61523;&#61472;&#61519;&#61510;&#61472;&#61505;&#61517;&#61509;&#61522;&#61513;&#61507;&#61505;&#61472;&#61489;&#61493;&#61506;&#61486;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61519;&#61522;&#61487;&#61519;&#61510;&#61510;&#61509;&#61522;&#61519;&#61522; &#61489;&#61494;&#61507;&#61486;&#61472;&#61508;&#61505;&#61524;&#61509;&#61472;&#61523;&#61513;&#61511;&#61518;&#61509;&#61508; &#61480;&#61523;&#61545;&#61543;&#61550;&#61537;&#61556;&#61557;&#61554;&#61541;&#61472;&#61551;&#61542;&#61472;&#61552;&#61541;&#61554;&#61555;&#61551;&#61550;&#61472;&#61537;&#61557;&#61556;&#61544;&#61551;&#61554;&#61545;&#61562;&#61541;&#61540;&#61472;&#61556;&#61551;&#61472;&#61555;&#61545;&#61543;&#61550;&#61481; &#61480;&#61523;&#61545;&#61543;&#61550;&#61537;&#61556;&#61557;&#61554;&#61541;&#61472;&#61551;&#61542;&#61472;&#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61545;&#61550;&#61543;&#61472;&#61519;&#61542;&#61542;&#61545;&#61539;&#61541;&#61554;&#61481; &#61515;&#61513;&#61517;&#61506;&#61509;&#61522;&#61516;&#61529;&#61472;&#61516;&#61486;&#61472;&#61511;&#61519;&#61516;&#61508;&#61509;&#61518; &#61523;&#61524;&#61505;&#61518;&#61508;&#61505;&#61522;&#61508;&#61472;&#61510;&#61519;&#61522;&#61517;&#61472;&#61491;&#61488;&#61472;&#61480;&#61522;&#61509;&#61526;&#61486;&#61472;&#61489;&#61489;&#61487;&#61490;&#61488;&#61489;&#61494;&#61481; &#61520;&#61554;&#61541;&#61555;&#61539;&#61554;&#61545;&#61538;&#61541;&#61540;&#61472;&#61538;&#61561;&#61472;&#61511;&#61523;&#61505;&#61472;&#61510;&#61505;&#61522;&#61472;&#61480;&#61492;&#61496;&#61472;&#61507;&#61510;&#61522;&#61481;&#61472;&#61493;&#61491;&#61486;&#61490;&#61492;&#61491; &#61520;&#61554;&#61541;&#61558;&#61545;&#61551;&#61557;&#61555;&#61472;&#61541;&#61540;&#61545;&#61556;&#61545;&#61551;&#61550;&#61472;&#61557;&#61550;&#61557;&#61555;&#61537;&#61538;&#61548;&#61541; &#61489;&#61492;&#61486;&#61472;&#61508;&#61509;&#61523;&#61507;&#61522;&#61513;&#61520;&#61524;&#61513;&#61519;&#61518;&#61472;&#61519;&#61510;&#61472;&#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61487;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61480;&#61519;&#61554;&#61543;&#61537;&#61550;&#61545;&#61562;&#61541;&#61540;&#61472;&#61538;&#61561;&#61472;&#61525;&#61507;&#61510;&#61472;&#61555;&#61541;&#61539;&#61556;&#61545;&#61551;&#61550;&#61472;&#61544;&#61541;&#61537;&#61540;&#61545;&#61550;&#61543;&#61555;&#61484;&#61472;&#61545;&#61550;&#61539;&#61548;&#61557;&#61540;&#61545;&#61550;&#61543;&#61472;&#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61487;&#61539;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61472;&#61555;&#61557;&#61538;&#61546;&#61541;&#61539;&#61556;&#61472;&#61549;&#61537;&#61556;&#61556;&#61541;&#61554;&#61472;&#61559;&#61544;&#61541;&#61554;&#61541;&#61472;&#61542;&#61541;&#61537;&#61555;&#61545;&#61538;&#61548;&#61541;&#61486;&#61481; &#61524;&#61537;&#61560;&#61472;&#61513;&#61508;&#61472;&#61518;&#61557;&#61549;&#61538;&#61541;&#61554;&#61498;&#61472;&#61472; &#61508;&#61525;&#61518;&#61523;&#61472;&#61518;&#61557;&#61549;&#61538;&#61541;&#61554;&#61498;&#61472;&#61472; &#61525;&#61509;&#61513;&#61498;&#61472;&#61507;&#61518;&#61520;&#61526;&#61507;&#61522;&#61496;&#61508;&#61515;&#61495;&#61517;&#61496; &#61524;&#61544;&#61545;&#61555;&#61472;&#61537;&#61540;&#61549;&#61545;&#61550;&#61545;&#61555;&#61556;&#61554;&#61537;&#61556;&#61545;&#61558;&#61541;&#61472;&#61549;&#61551;&#61540;&#61545;&#61542;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61472;&#61545;&#61555;&#61472;&#61545;&#61555;&#61555;&#61557;&#61541;&#61540;&#61472;&#61556;&#61551;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61472;&#61523;&#61541;&#61539;&#61556;&#61545;&#61551;&#61550;&#61472;&#61511;&#61485;&#61472;&#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61472;&#61537;&#61540;&#61549;&#61545;&#61550;&#61545;&#61555;&#61556;&#61554;&#61537;&#61556;&#61545;&#61551;&#61550; &#61508;&#61537;&#61556;&#61537;&#61472;&#61537;&#61555;&#61472;&#61542;&#61551;&#61548;&#61548;&#61551;&#61559;&#61555;&#61498; &#61520;&#61541;&#61554;&#61545;&#61551;&#61540;&#61472;&#61551;&#61542;&#61472;&#61520;&#61541;&#61554;&#61542;&#61551;&#61554;&#61549;&#61537;&#61550;&#61539;&#61541;&#61498;&#61472;&#61488;&#61496;&#61487;&#61491;&#61488;&#61487;&#61490;&#61488;&#61489;&#61497;&#61472;&#61556;&#61551;&#61472;&#61488;&#61496;&#61487;&#61490;&#61497;&#61487;&#61490;&#61488;&#61490;&#61497; &#61507;&#61551;&#61550;&#61556;&#61545;&#61550;&#61557;&#61541;&#61540;&#61472;&#61486;&#61486;&#61486; &#61509;&#61560;&#61539;&#61541;&#61552;&#61556;&#61472;&#61537;&#61555;&#61472;&#61552;&#61554;&#61551;&#61558;&#61545;&#61540;&#61541;&#61540;&#61472;&#61544;&#61541;&#61554;&#61541;&#61545;&#61550;&#61484;&#61472;&#61537;&#61548;&#61548;&#61472;&#61556;&#61541;&#61554;&#61549;&#61555;&#61472;&#61537;&#61550;&#61540;&#61472;&#61539;&#61551;&#61550;&#61540;&#61545;&#61556;&#61545;&#61551;&#61550;&#61555;&#61472;&#61551;&#61542;&#61472;&#61556;&#61544;&#61541;&#61472;&#61540;&#61551;&#61539;&#61557;&#61549;&#61541;&#61550;&#61556;&#61472;&#61554;&#61541;&#61542;&#61541;&#61554;&#61541;&#61550;&#61539;&#61541;&#61540;&#61472;&#61545;&#61550;&#61472;&#61513;&#61556;&#61541;&#61549;&#61472;&#61497; &#61505;&#61472;&#61551;&#61554;&#61472;&#61489;&#61488;&#61505;&#61484;&#61472;&#61537;&#61555;&#61472;&#61544;&#61541;&#61554;&#61541;&#61556;&#61551;&#61542;&#61551;&#61554;&#61541;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61540;&#61484;&#61472;&#61554;&#61541;&#61549;&#61537;&#61545;&#61550;&#61555;&#61472;&#61557;&#61550;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61540;&#61472;&#61537;&#61550;&#61540;&#61472;&#61545;&#61550;&#61472;&#61542;&#61557;&#61548;&#61548;&#61472;&#61542;&#61551;&#61554;&#61539;&#61541;&#61472;&#61537;&#61550;&#61540;&#61472;&#61541;&#61542;&#61542;&#61541;&#61539;&#61556; &#61486; &#61489;&#61489;&#61487;&#61490;&#61489;&#61487;&#61490;&#61488;&#61490;&#61490; Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as  private or confidential.  Double asterisks denote omissions. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- modificationno8effective002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="modificationno8effective002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">&#61513;&#61524;&#61509;&#61517;&#61472;&#61518;&#61519;&#61486; &#61523;&#61525;&#61520;&#61520;&#61516;&#61513;&#61509;&#61523;&#61487;&#61523;&#61509;&#61522;&#61526;&#61513;&#61507;&#61509;&#61523; &#61521;&#61525;&#61505;&#61518;&#61524;&#61513;&#61524;&#61529; &#61525;&#61518;&#61513;&#61524; &#61525;&#61518;&#61513;&#61524;&#61472;&#61520;&#61522;&#61513;&#61507;&#61509; &#61505;&#61517;&#61519;&#61525;&#61518;&#61524; &#61518;&#61505;&#61517;&#61509;&#61472;&#61519;&#61510;&#61472;&#61519;&#61510;&#61510;&#61509;&#61522;&#61519;&#61522;&#61472;&#61519;&#61522;&#61472;&#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61519;&#61522; &#61472;&#61490;&#61472; &#61472;&#61490;&#61507;&#61519;&#61518;&#61524;&#61513;&#61518;&#61525;&#61505;&#61524;&#61513;&#61519;&#61518;&#61472;&#61523;&#61512;&#61509;&#61509;&#61524; &#61522;&#61509;&#61510;&#61509;&#61522;&#61509;&#61518;&#61507;&#61509;&#61472;&#61518;&#61519;&#61486;&#61472;&#61519;&#61510;&#61472;&#61508;&#61519;&#61507;&#61525;&#61517;&#61509;&#61518;&#61524;&#61472;&#61506;&#61509;&#61513;&#61518;&#61511;&#61472;&#61507;&#61519;&#61518;&#61524;&#61513;&#61518;&#61525;&#61509;&#61508; &#61520;&#61505;&#61511;&#61509; &#61519;&#61510; &#61509;&#61517;&#61509;&#61522;&#61511;&#61509;&#61518;&#61524;&#61472;&#61520;&#61522;&#61519;&#61508;&#61525;&#61507;&#61524;&#61472;&#61508;&#61509;&#61526;&#61509;&#61516;&#61519;&#61520;&#61517;&#61509;&#61518;&#61524;&#61472;&#61511;&#61505;&#61513;&#61524;&#61512;&#61509;&#61522;&#61523;&#61506;&#61525;&#61522;&#61511;&#61472;&#61513;&#61518;&#61507;&#61486;&#61472;&#61489;&#61491;&#61494;&#61493;&#61496;&#61494;&#61497; &#61480;&#61505;&#61481; &#61480;&#61506;&#61481; &#61480;&#61507;&#61481; &#61480;&#61508;&#61481; &#61480;&#61509;&#61481; &#61480;&#61510;&#61481; &#61495;&#61493;&#61505;&#61493;&#61488;&#61489;&#61489;&#61497;&#61507;&#61488;&#61488;&#61488;&#61495;&#61489;&#61487;&#61520;&#61488;&#61488;&#61488;&#61488;&#61496; &#61511;&#61486;&#61489;&#61472;&#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61472;&#61522;&#61541;&#61552;&#61554;&#61541;&#61555;&#61541;&#61550;&#61556;&#61537;&#61556;&#61545;&#61558;&#61541;&#61555;&#61484;&#61472;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61555;&#61472;&#61556;&#61544;&#61541; &#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61545;&#61550;&#61543;&#61472;&#61519;&#61542;&#61542;&#61545;&#61539;&#61541;&#61554;&#61479;&#61555;&#61472;&#61522;&#61541;&#61552;&#61554;&#61541;&#61555;&#61541;&#61550;&#61556;&#61537;&#61556;&#61545;&#61558;&#61541;&#61472;&#61480;&#61519;&#61522; &#61554;&#61541;&#61555;&#61552;&#61551;&#61550;&#61555;&#61545;&#61538;&#61548;&#61541;&#61472;&#61542;&#61551;&#61554;&#61472;&#61556;&#61544;&#61545;&#61555;&#61472;&#61539;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61498; &#61489;&#61486; &#61507;&#61551;&#61554;&#61554;&#61541;&#61539;&#61556;&#61472;&#61542;&#61554;&#61551;&#61549;&#61472;&#61508;&#61537;&#61558;&#61545;&#61540;&#61472;&#61515;&#61541;&#61548;&#61548;&#61541;&#61561;&#61472;&#61556;&#61551;&#61472;&#61506;&#61554;&#61557;&#61539;&#61541;&#61472;&#61516;&#61541;&#61541;&#61498; &#61506;&#61554;&#61557;&#61539;&#61541;&#61472;&#61516;&#61541;&#61541; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61490;&#61497;&#61492;&#61493;&#61472;&#61510;&#61516;&#61519;&#61527;&#61509;&#61522;&#61523;&#61472;&#61522;&#61519;&#61505;&#61508; &#61505;&#61524;&#61516;&#61505;&#61518;&#61524;&#61505;&#61484;&#61472;&#61511;&#61505;&#61472;&#61491;&#61488;&#61491;&#61492;&#61489; &#61524;&#61541;&#61548;&#61541;&#61552;&#61544;&#61551;&#61550;&#61541;&#61472;&#61518;&#61557;&#61549;&#61538;&#61541;&#61554;&#61498;&#61472; &#61509;&#61549;&#61537;&#61545;&#61548;&#61498;&#61472; &#61518;&#61523;&#61518;&#61472;&#61495;&#61493;&#61492;&#61488;&#61485;&#61488;&#61489;&#61485;&#61489;&#61493;&#61490;&#61485;&#61496;&#61488;&#61494;&#61495; &#61519;&#61520;&#61524;&#61513;&#61519;&#61518;&#61505;&#61516;&#61472;&#61510;&#61519;&#61522;&#61517;&#61472;&#61491;&#61491;&#61494;&#61472;&#61480;&#61492;&#61485;&#61496;&#61494;&#61481; &#61523;&#61552;&#61551;&#61550;&#61555;&#61551;&#61554;&#61541;&#61540;&#61472;&#61538;&#61561;&#61472;&#61511;&#61523;&#61505; &#61510;&#61505;&#61522;&#61472;&#61480;&#61492;&#61496;&#61472;&#61507;&#61510;&#61522;&#61481;&#61472;&#61493;&#61491;&#61486;&#61489;&#61489;&#61488; </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.224
<SEQUENCE>7
<FILENAME>emergentbiosolutionscomp.htm
<DESCRIPTION>EX-10.224
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>emergentbiosolutionscomp</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- emergentbiosolutionscomp001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="emergentbiosolutionscomp001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  ${vault:status__v} ${vault:governing _site__c} ${vault:subtype__v} ${vault:title__v}    1 Emergent BioSolutions Compensation Recovery  Policy    Purpose &amp; Scope  The purpose of this Compensation Recovery Policy (the &#8220;Policy&#8221;), is to:  &#61623; Comply with applicable law and any rules or regulations adopted by the Securities and Exchange  Commission, including Section 10D-1 under the Securities Exchange Act of 1934, the rules  promulgated by the Securities and Exchange Commission thereunder, and the listing standards of  the New York Stock Exchange (collectively, the &#8220;Applicable Rules&#8221;).  &#61623; Describe the specific events that trigger a clawback of Excess Compensation from Executive  Officers (as each term is defined herein).  This Policy&#8217;s scope:  &#61623; This Policy applies to all Executive Officers and is applicable to all Incentive-Based Compensation  received by Executive Officers after October 26, 2023 (the &#8220;Effective Date&#8221;).  &#61623; Each Executive Officer shall be required to execute the acknowledgement in Appendix A of this  Policy as soon as practicable after the later of (i) the Effective Date and (ii) the date on which the  employee is designated as an Executive Officer; provided, however, that failure to execute such  acknowledgement shall have no impact on the enforceability of this Policy.                          Policy Owner:   ${vault:document_owner__v}  Policy Sponsor:   Name  Policy Contact:  email  Last updated:   ${vault:effective_date__v}  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- emergentbiosolutionscomp002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="emergentbiosolutionscomp002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  ${vault:status__v} ${vault:governing _site__c} ${vault:subtype__v} ${vault:title__v}    2   Policy  Emergent will comply with the Applicable Rules and take action to recoup Excess  Compensation from current and former Executive Officers    1. Clawback     In the event the Company is required to prepare an Accounting Restatement, any Executive Officer  who received Excess Compensation during the Look-back Period will be required to repay or forfeit  any such Excess Compensation reasonably promptly. For purposes of this Policy, the date the  Company is required to prepare an Accounting Restatement is deemed to be the earlier of the date (i)  the Board concludes, or reasonably should have concluded, that the Company is required to prepare  an Accounting Restatement, or (ii) a court, regulator, or other legally authorized body directs the  Company to prepare an Accounting Restatement.    Recovery of erroneously received compensation under this Policy is on a &#8220;no fault&#8221; basis, meaning  that it will occur regardless of whether the Executive Officer engaged in misconduct or was otherwise  directly or indirectly responsible, in whole or in part, for the Accounting Restatement. No Executive  Officer may be indemnified by the Company, or any of its affiliates, from losses arising from the  application of this Policy.       1. Method of Repayment; Conditions for Non-Recovery    To the extent permitted by applicable law, including the Applicable Rules, the Board shall seek to  recoup Excess Compensation by all legal means available, including, but not limited to, by requiring  any affected Executive Officer to repay such amount to the Company in a lump sum or over time, by  set-off, by cancelling outstanding awards, by reducing future compensation of the affected Executive  Officer, or by such other means or combination of means as the Board, in its sole discretion,  determines to be appropriate. At the direction of the Board, the Company shall take all actions  reasonable and appropriate to recover Excess Compensation from any applicable Executive Officer,  and such Executive Officer shall be required to reimburse the Company for any and all expenses  reasonably incurred (including legal fees) by the Company in recovering such Excess Compensation in  accordance with this Policy.    The Board may determine that repayment of Excess Compensation (or a portion thereof) is not  required only where it determines that recovery would be impracticable and (i) the direct expense  paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered,  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- emergentbiosolutionscomp003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="emergentbiosolutionscomp003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  ${vault:status__v} ${vault:governing _site__c} ${vault:subtype__v} ${vault:title__v}    3 provided the Company has (A) made a reasonable attempt to recover such Excess Compensation, (B)  documented such reasonable attempt, and (C) provided such documentation to the New York Stock  Exchange, or (ii) recovery would likely cause an otherwise tax-qualified retirement plan, under which  benefits are broadly available to employees, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or  26 U.S.C. 411(a) and the regulations thereunder.    Any forfeiture or recoupment under this Policy will be in addition to any other remedies that may be  available under applicable law or Company policy, plan or agreement, including termination of  employment or institution of civil proceedings. Any determination regarding this Policy and any  application and implementation thereof need not be uniform with respect to each Executive Officer or  payment recovered or forfeited under this Policy. Any determination made by the Board under this  Policy will be final and binding on all affected individuals.  Role &amp; Responsibilities  Role Responsibilities  Legal Maintain and implement Policy.  Board of Directors of  the Company  Administer the Policy (unless the Board designates the Compensation  Committee of the Board (the &#8220;Committee&#8221;) as the administrator of the  Policy, in which case references to the Board will be deemed to be  references to the Committee).    Definitions  &#61623; Accounting Restatement: An accounting restatement due to the material noncompliance of the  Company with any financial reporting requirement under securities laws, including any required  accounting restatement to correct an error in previously issued financial statements that is  material to the previously issued financial statements, or that corrects an error that is not material  to previously issued financial statements but would result in a material misstatement if the error  were corrected in the current period or left uncorrected in the current period. Changes to financial  statements that do not constitute an Accounting Restatement include retroactive: (i) application  of a change from one generally accepted accounting principle to another generally accepted  accounting principle; (ii) revisions to reportable segment information due to a change in internal  organization; (iii) reclassification due to a discontinued operation; (iv) application of a change in  reporting entity, such as from a reorganization of entities under common control; and   (v)  revisions for stock splits, reverse stock splits, stock dividends, or other changes in capital  structure.  &#61623; Board: The Board of Directors of the Company.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- emergentbiosolutionscomp004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="emergentbiosolutionscomp004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  ${vault:status__v} ${vault:governing _site__c} ${vault:subtype__v} ${vault:title__v}    4 &#61623; Company: Emergent BioSolutions Inc.  &#61623; Excess Compensation: Any amount of Incentive-Based Compensation received by an Executive  Officer after commencement of service as an Executive Officer that exceeds the amount of  Incentive-Based Compensation that otherwise would have been received had it been determined  based on the Accounting Restatement, computed without regard to any taxes paid.  For Incentive  Compensation based on stock price or total shareholder return, where the amount to be recovered  is not subject to mathematical recalculation directly from information in the Accounting  Restatement, the amount to be recovered shall be based on a reasonable estimate of the effect of  the Accounting Restatement on the stock price or total shareholder return, as applicable, and the  Corporation shall retain documentation of the determination of such estimate and provide such  documentation to NYSE if so required by the Applicable Rules. Incentive-Based Compensation is  deemed received during the fiscal year during which the applicable financial reporting measure,  stock price and/or total shareholder return measure, upon which the payment is based, is  achieved, even if the grant or payment occurs after the end of such period.  &#61623; Exchange Act: Securities Exchange Act of 1934, as amended.  &#61623; Executive Officer: An individual who is, or was during the Look-back Period, an executive officer  of the Company within the meaning of Rule 10D-1(d) under the Exchange Act.    &#61623; Incentive-Based Compensation: Any compensation that is granted, earned or vested based  wholly or in part on stock price, total shareholder return, and/or the attainment of (i) any financial  reporting measure(s) that are determined and presented in accordance with the accounting  principles used in preparing the Company&#8217;s financial statements and/or (ii) any other measures  that are derived in whole or in part from such measures.  Compensation that does not constitute  &#8220;Incentive-Based Compensation&#8221; includes equity incentive awards for which the grant is not  contingent upon achieving any financial reporting measure performance goal for an individual to  receive such award and that vest exclusively upon completion of a specified employment period,  without any performance condition, and bonus awards that are discretionary or based on  subjective goals or goals unrelated to financial reporting measures.   &#61623; Look-back Period: The three completed fiscal years preceding the date the Company is required  to prepare an Accounting Restatement.  References and Supporting Documents  &#61623; Rule 10D-1 under the Exchange Act  &#61623; NYSE Listed Company Manual Rule 303A.14  &#61623; Section 16 of the Exchange Act  &#61623; Section 304 of the Sarbanes-Oxley Act of 2002  &#61623; Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- emergentbiosolutionscomp005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="emergentbiosolutionscomp005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  ${vault:status__v} ${vault:governing _site__c} ${vault:subtype__v} ${vault:title__v}    5   Effective Date: October 26, 2023  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>8
<FILENAME>subsidiariesofthecompany.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0da143ef60ea4c61ab4c648ca070946f_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">List of Subsidiaries</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(as of December 31, 2023)</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:50.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name of Subsidiary</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Jurisdiction of Incorporation or Organization</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Domestic</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">400 Professional LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cangene bioPharma LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maryland</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Commercial Operations Frederick Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maryland</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Biodefense Operations Lansing LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Devices Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Europe Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent International Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Manufacturing Operations Baltimore LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Product Development Gaithersburg Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Protective Products USA Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Travel Health Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">International</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Acquisition Unlimited Company</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ireland</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent BioSolutions Canada Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ontario</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent BioSolutions Ireland Limited</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ireland</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Netherlands B.V.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Netherlands</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Operations Ireland Limited</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ireland</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Sales and Marketing Australia Pty Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Australia</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Sales and Marketing France S.A.S.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">France</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Sales and Marketing Germany GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Germany</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent Sales and Marketing Singapore Pte. Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Singapore</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent BioSolutions UK Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">England and Wales</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>9
<FILENAME>exhibit23-consentofindepen.htm
<DESCRIPTION>EX-23
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7bf27ce5e4da4be6b4d695083735b3c0_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 23</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">Registration Statement (Form S-8 No. 333-139190) pertaining to the Employee Stock Option Plan, as amended and restated, the 2006 Stock Incentive Plan and individual director options agreements of Emergent BioSolutions, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-161154) pertaining to the Amended and Restated 2006 Stock Incentive Plan of Emergent BioSolutions Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">Registration Statement (Form S-8 No. 333-184699) pertaining to the 2012 Employee Stock Purchase Plan and the Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-196232) pertaining to the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">Registration Statement (Form S-8 No. 333-216294) pertaining to the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.17pt">Registration Statement (Form S-8 No. 333-225283) pertaining to the Emergent BioSolutions Inc. Stock Incentive Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-256798) pertaining to the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement (Form S-3ASR No. 333-258634) of Emergent BioSolutions Inc. and Subsidiaries, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.73pt">Registration Statement (Form S-8 No. 333-272433) pertaining to the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan and the Emergent BioSolutions Inc. Amended Employee Stock Purchase Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.73pt">Registration Statement (Form S-8 No. 333-275990) pertaining to the Emergent BioSolutions Inc. Inducement Plan </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our reports dated March 8, 2024, with respect to the consolidated financial statements and schedule of Emergent BioSolutions Inc. and subsidiaries and the effectiveness of internal control over financial reporting of Emergent BioSolutions Inc. and subsidiaries included in this Annual Report (Form 10-K) of Emergent BioSolutions Inc. and subsidiaries for the year ended December 31, 2023.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tysons, Virginia</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;8, 2024</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>a311-papacert123123.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i47040fb1bde6492dba163ad909164a55_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph C. Papa, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March&#160;8, 2024 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47;Joseph C. Papa</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Joseph C. Papa</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div><div style="height:69.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>a312-lindhalcert123123.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3d5cfb9ca72646faacdd0f1375753905_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard S. Lindahl, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;March&#160;8, 2024</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47;RICHARD S. LINDAHL</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard S. Lindahl</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>a321-papacert123123.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i846cba049fed493c98966693e48fa830_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form&#160;10-K&#160;of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;December 31, 2023&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Joseph C. Papa, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-indent:-13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;March&#160;8, 2024</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;Joseph C. Papa</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph C. Papa</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>13
<FILENAME>a322-lindhalcert123123.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6f6be422e97d4304af75c6d7768e87a3_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;December 31, 2023&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Richard S. Lindahl, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58;&#160;March&#160;8, 2024</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%;text-decoration:underline">&#47;s&#47;RICHARD S. LINDAHL</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Richard S. Lindahl</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Financial Officer</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>ebs-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c54bb9fe-5fe3-484c-8c37-1247bde19e06,g:0a179766-9174-4357-afdf-29ab18a19ddc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ebs="http://emergentbiosolutions.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://emergentbiosolutions.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://emergentbiosolutions.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://emergentbiosolutions.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofChangesinStockholdersEquity" roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity">
        <link:definition>0000008 - Statement - Consolidated Statement of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofChangesinStockholdersEquityParenthetical" roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquityParenthetical">
        <link:definition>0000009 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Natureofthebusinessandorganization" roleURI="http://emergentbiosolutions.com/role/Natureofthebusinessandorganization">
        <link:definition>0000010 - Disclosure - Nature of the business and organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>0000011 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestiture" roleURI="http://emergentbiosolutions.com/role/Divestiture">
        <link:definition>0000012 - Disclosure - Divestiture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Longlivedassetimpairmentandrestructuringcharges" roleURI="http://emergentbiosolutions.com/role/Longlivedassetimpairmentandrestructuringcharges">
        <link:definition>0000013 - Disclosure - Long-lived asset impairment and restructuring charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventoriesnet" roleURI="http://emergentbiosolutions.com/role/Inventoriesnet">
        <link:definition>0000014 - Disclosure - Inventories, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipmentnet" roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet">
        <link:definition>0000015 - Disclosure - Property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassetsandgoodwill" roleURI="http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill">
        <link:definition>0000016 - Disclosure - Intangible assets and goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements">
        <link:definition>0000017 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandhedgingactivities" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivities">
        <link:definition>0000018 - Disclosure - Derivative Instruments and hedging activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://emergentbiosolutions.com/role/Debt">
        <link:definition>0000019 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedcompensationandstockholdersequity" roleURI="http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity">
        <link:definition>0000020 - Disclosure - Share-based compensation and stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netincomelosspercommonshare" roleURI="http://emergentbiosolutions.com/role/Netincomelosspercommonshare">
        <link:definition>0000021 - Disclosure - Net income (loss) per common share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuerecognition" roleURI="http://emergentbiosolutions.com/role/Revenuerecognition">
        <link:definition>0000022 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://emergentbiosolutions.com/role/Leases">
        <link:definition>0000023 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://emergentbiosolutions.com/role/Incometaxes">
        <link:definition>0000024 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedbenefitand401ksavingsplan" roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplan">
        <link:definition>0000025 - Disclosure - Defined benefit and 401(k) savings plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Purchasecommitments" roleURI="http://emergentbiosolutions.com/role/Purchasecommitments">
        <link:definition>0000026 - Disclosure - Purchase commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://emergentbiosolutions.com/role/SegmentInformation">
        <link:definition>0000027 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://emergentbiosolutions.com/role/Litigation">
        <link:definition>0000028 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccounts" roleURI="http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccounts">
        <link:definition>0000029 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesTables" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LonglivedassetimpairmentandrestructuringchargesTables" roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesTables">
        <link:definition>9954473 - Disclosure - Long-lived asset impairment and restructuring charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetTables" roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables">
        <link:definition>9954474 - Disclosure - Inventories, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetTables" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables">
        <link:definition>9954475 - Disclosure - Property, plant and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillTables" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables">
        <link:definition>9954476 - Disclosure - Intangible assets and goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables">
        <link:definition>9954477 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandhedgingactivitiesTables" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesTables">
        <link:definition>9954478 - Disclosure - Derivative Instruments and hedging activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://emergentbiosolutions.com/role/DebtTables">
        <link:definition>9954479 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityTables" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables">
        <link:definition>9954480 - Disclosure - Share-based compensation and stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetincomelosspercommonshareTables" roleURI="http://emergentbiosolutions.com/role/NetincomelosspercommonshareTables">
        <link:definition>9954481 - Disclosure - Net income (loss) per common share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionTables" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionTables">
        <link:definition>9954482 - Disclosure - Revenue recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://emergentbiosolutions.com/role/LeasesTables">
        <link:definition>9954483 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTables" roleURI="http://emergentbiosolutions.com/role/IncometaxesTables">
        <link:definition>9954484 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedbenefitand401ksavingsplanTables" roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanTables">
        <link:definition>9954485 - Disclosure - Defined benefit and 401(k) savings plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://emergentbiosolutions.com/role/SegmentInformationTables">
        <link:definition>9954486 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofthebusinessandorganizationDetails" roleURI="http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails">
        <link:definition>9954487 - Disclosure - Nature of the business and organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesGoingConcernDetails" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails">
        <link:definition>9954488 - Disclosure - Summary of significant accounting policies - Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesConcentrationRiskDetails" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails">
        <link:definition>9954489 - Disclosure - Summary of significant accounting policies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails">
        <link:definition>9954490 - Disclosure - Summary of significant accounting policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails">
        <link:definition>9954491 - Disclosure - Summary of significant accounting policies - Accounting for Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails">
        <link:definition>9954492 - Disclosure - Summary of significant accounting policies - Derivative instruments and hedging activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestitureDetails" roleURI="http://emergentbiosolutions.com/role/DivestitureDetails">
        <link:definition>9954493 - Disclosure - Divestiture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LonglivedassetimpairmentandrestructuringchargesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails">
        <link:definition>9954494 - Disclosure - Long-lived asset impairment and restructuring charges - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails">
        <link:definition>9954495 - Disclosure - Long-lived asset impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails">
        <link:definition>9954496 - Disclosure - Long-lived asset impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails">
        <link:definition>9954497 - Disclosure - Long-lived asset impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetDetails" roleURI="http://emergentbiosolutions.com/role/InventoriesnetDetails">
        <link:definition>9954498 - Disclosure - Inventories, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails">
        <link:definition>9954499 - Disclosure - Property, plant and equipment, net - Summary of Property, Plant and Equipment Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails">
        <link:definition>9954500 - Disclosure - Property, plant and equipment, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails">
        <link:definition>9954501 - Disclosure - Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>9954502 - Disclosure - Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails">
        <link:definition>9954503 - Disclosure - Intangible assets and goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillFutureAmortizationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails">
        <link:definition>9954504 - Disclosure - Intangible assets and goodwill - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails">
        <link:definition>9954505 - Disclosure - Intangible assets and goodwill - Summary Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails">
        <link:definition>9954506 - Disclosure - Fair value measurements - Fair Value Measurements, Recurring and Nonrecurring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails">
        <link:definition>9954507 - Disclosure - Fair value measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails">
        <link:definition>9954508 - Disclosure - Fair value measurements - Reconciliation of the Contingent Consideration Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails">
        <link:definition>9954509 - Disclosure - Fair value measurements - Level 3 Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandhedgingactivitiesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails">
        <link:definition>9954510 - Disclosure - Derivative Instruments and hedging activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails">
        <link:definition>9954511 - Disclosure - Derivative Instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails">
        <link:definition>9954512 - Disclosure - Derivative Instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsofLongtermIndebtednessDetails" roleURI="http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails">
        <link:definition>9954513 - Disclosure - Debt - Components of Long-term Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails">
        <link:definition>9954514 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtFutureDebtPaymentsofLongtermIndebtednessDetails" roleURI="http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails">
        <link:definition>9954515 - Disclosure - Debt - Future Debt Payments of Long-term Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails">
        <link:definition>9954516 - Disclosure - Share-based compensation and stockholders' equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails">
        <link:definition>9954517 - Disclosure - Share-based compensation and stockholders' equity - Stock Options Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails">
        <link:definition>9954518 - Disclosure - Share-based compensation and stockholders' equity - Stock Options, Restricted Stock Units, and Performance Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails">
        <link:definition>9954519 - Disclosure - Share-based compensation and stockholders' equity - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails">
        <link:definition>9954520 - Disclosure - Share-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>9954521 - Disclosure - Share-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetincomelosspercommonshareDetails" roleURI="http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails">
        <link:definition>9954522 - Disclosure - Net income (loss) per common share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails">
        <link:definition>9954523 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionNarrativeDetails_1" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1">
        <link:definition>9954523 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionDisaggregationofRevenueDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails">
        <link:definition>9954524 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionPercentageofProductSalesDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails">
        <link:definition>9954525 - Disclosure - Revenue recognition - Percentage of Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionContractLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails">
        <link:definition>9954526 - Disclosure - Revenue recognition - Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionAccountsReceivableDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails">
        <link:definition>9954527 - Disclosure - Revenue recognition - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>9954528 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>9954529 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails">
        <link:definition>9954530 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>9954531 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>9954531 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails">
        <link:definition>9954532 - Disclosure - Income taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails" roleURI="http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails">
        <link:definition>9954533 - Disclosure - Income taxes - Components of the Provisions for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesNetDeferredTaxAssetLiabilityDetails" roleURI="http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails">
        <link:definition>9954534 - Disclosure - Income taxes - Net Deferred Tax Asset (Liability) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesReconciliationDetails" roleURI="http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails">
        <link:definition>9954535 - Disclosure - Income taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesUnrecognizedTaxBenefitsDetails" roleURI="http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>9954536 - Disclosure - Income taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails" roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails">
        <link:definition>9954537 - Disclosure - Defined benefit and 401(k) savings plan - Swiss Plan Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails" roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails">
        <link:definition>9954538 - Disclosure - Defined benefit and 401(k) savings plan - Components of Net Periodic Pension Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedbenefitand401ksavingsplanNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanNarrativeDetails">
        <link:definition>9954539 - Disclosure - Defined benefit and 401(k) savings plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails" roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails">
        <link:definition>9954540 - Disclosure - Defined benefit and 401(k) savings plan - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails" roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails">
        <link:definition>9954541 - Disclosure - Defined benefit and 401(k) savings plan - Accumulated Other Comprehensive Loss Before Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PurchasecommitmentsDetails" roleURI="http://emergentbiosolutions.com/role/PurchasecommitmentsDetails">
        <link:definition>9954542 - Disclosure - Purchase commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails">
        <link:definition>9954543 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails">
        <link:definition>9954544 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>9954545 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails">
        <link:definition>9954546 - Disclosure - Segment Information - Revenue from External Customers by Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationLongLivedAssetsbyGeographicAreasDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails">
        <link:definition>9954547 - Disclosure - Segment Information - Long-Lived Assets by Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsDetails" roleURI="http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails">
        <link:definition>9954548 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage" abstract="false" name="DebtInstrumentMandatoryPrincipalPrepaymentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_ChimerixMember" abstract="true" name="ChimerixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_SOFRSONIAAndEurocurrencyMember" abstract="true" name="SOFRSONIAAndEurocurrencyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SaleOfStockAggregateOfferingAmountMaximum" abstract="false" name="SaleOfStockAggregateOfferingAmountMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_RevenueFromContractWithCustomerTermOfContract" abstract="false" name="RevenueFromContractWithCustomerTermOfContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_ForbearanceAgreementAndAmendmentMember" abstract="true" name="ForbearanceAgreementAndAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AnthraxMCMMember" abstract="true" name="AnthraxMCMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ServicesSegmentMember" abstract="true" name="ServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentMandatoryPrepaymentThreshold" abstract="false" name="DebtInstrumentMandatoryPrepaymentThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DeferredTaxLiabilitiesForeignWithholdingTax" abstract="false" name="DeferredTaxLiabilitiesForeignWithholdingTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_NumberOfProductAndServiceCategories" abstract="false" name="NumberOfProductAndServiceCategories" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_FiscalQuartersEndingIn2024Member" abstract="true" name="FiscalQuartersEndingIn2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_EmployeeTransitionMember" abstract="true" name="EmployeeTransitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_CommercialProductMember" abstract="true" name="CommercialProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SmallpoxMCMMember" abstract="true" name="SmallpoxMCMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SeniorUnsecuredNotesDueAugust2028Member" abstract="true" name="SeniorUnsecuredNotesDueAugust2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ebs_TreasuryStockPolicyTextBlock" abstract="false" name="TreasuryStockPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares" abstract="false" name="SaleOfStockAmountRemainingAvailableForSaleOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum" abstract="false" name="ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts" abstract="false" name="EffectiveIncomeTaxRateReconciliationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_BioservicesMember" abstract="true" name="BioservicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ContractsAndGrantsMember" abstract="true" name="ContractsAndGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember" abstract="true" name="SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_DeferredTaxAssetsIntangibleAssets" abstract="false" name="DeferredTaxAssetsIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifference" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_AcceleratedExpansionOfFillFinishCapacityMember" abstract="true" name="AcceleratedExpansionOfFillFinishCapacityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_EmployeeBenefitsMember" abstract="true" name="EmployeeBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_TravelHealthBusinessMember" abstract="true" name="TravelHealthBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_MeasurementInputProbabilityOfPaymentMember" abstract="true" name="MeasurementInputProbabilityOfPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_NumberOfCategoriesOfPublicHealthThreats" abstract="false" name="NumberOfCategoriesOfPublicHealthThreats" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_RestructuringPlanJanuary2023Member" abstract="true" name="RestructuringPlanJanuary2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_GrossProfitPercentage" abstract="false" name="GrossProfitPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_OtherGeographicalAreaMember" abstract="true" name="OtherGeographicalAreaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_SOFREURIBOROrCDORMember" abstract="true" name="SOFREURIBOROrCDORMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember" abstract="true" name="PerformanceSharesAndRestrictedStockUnitsRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_BARDAMember" abstract="true" name="BARDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_AdjustedGrossMargin" abstract="false" name="AdjustedGrossMargin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_MedicalCountermeasuresMCMProductMember" abstract="true" name="MedicalCountermeasuresMCMProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtTermsDomain" abstract="true" name="DebtTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ChangeinContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeinContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_JansenPharmaceuticalsIncMember" abstract="true" name="JansenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_NonUnitedStatesGovernmentMember" abstract="true" name="NonUnitedStatesGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_ContingentConsiderationObligationsPolicyTextBlock" abstract="false" name="ContingentConsiderationObligationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ebs_A2023EquityInducementPlanMember" abstract="true" name="A2023EquityInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_BioservicesLeasesMember" abstract="true" name="BioservicesLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_FiscalQuartersEndingAfterMarch312024Member" abstract="true" name="FiscalQuartersEndingAfterMarch312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_InventoryStepUp" abstract="false" name="InventoryStepUp" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_NARCANMember" abstract="true" name="NARCANMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_FiscalQuartersEndingAfter2024Member" abstract="true" name="FiscalQuartersEndingAfter2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantConsiderationThreshold" abstract="false" name="DebtInstrumentCovenantConsiderationThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_NoncashPurchasesOfTreasuryStock" abstract="false" name="NoncashPurchasesOfTreasuryStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_UnrecognizedTaxBenefitsNoncurrent" abstract="false" name="UnrecognizedTaxBenefitsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ReservationOfManufacturingCapacityMember" abstract="true" name="ReservationOfManufacturingCapacityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_EbangaMember" abstract="true" name="EbangaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtTermsAxis" abstract="true" name="DebtTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ebs_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_CommonStockNumberOfVotesPerCommonShare" abstract="false" name="CommonStockNumberOfVotesPerCommonShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_DevelopmentBasedMilestonesMember" abstract="true" name="DevelopmentBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_DispositionOfBusinessTransactionCosts" abstract="false" name="DispositionOfBusinessTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_NumberOfShareBasedEmployeeCompensationPlans" abstract="false" name="NumberOfShareBasedEmployeeCompensationPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_NumberOfRevenueGeneratingProducts" abstract="false" name="NumberOfRevenueGeneratingProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_ScheduleOfAccountsReceivableNetTableTextBlock" abstract="false" name="ScheduleOfAccountsReceivableNetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ebs_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_UnallocatedResearchAndDevelopmentMember" abstract="true" name="UnallocatedResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_OtherCommercialProductsMember" abstract="true" name="OtherCommercialProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" abstract="false" name="IncreaseDecreaseInLongTermIncentivePlanAccrual" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember" abstract="true" name="EmergentBiosolutionsInc2006StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_RestructuringPlanAugust2023Member" abstract="true" name="RestructuringPlanAugust2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_CommercialProductsSegmentMember" abstract="true" name="CommercialProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_UnitedStatesGovernmentMember" abstract="true" name="UnitedStatesGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_MCMProductsSegmentMember" abstract="true" name="MCMProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_MCMProductsMember" abstract="true" name="MCMProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_UntilMarch312024Member" abstract="true" name="UntilMarch312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_OtherLongTermDebtFacilityMember" abstract="true" name="OtherLongTermDebtFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ebs_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>ebs-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c54bb9fe-5fe3-484c-8c37-1247bde19e06,g:0a179766-9174-4357-afdf-29ab18a19ddc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4c99be6-fe00-457a-9f8f-a7493fe2f42c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e7712b26-d4a7-414e-af36-3e5b60d6b70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4c99be6-fe00-457a-9f8f-a7493fe2f42c" xlink:to="loc_us-gaap_Liabilities_e7712b26-d4a7-414e-af36-3e5b60d6b70f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c301b5c0-c461-4b30-a47a-2310c34da6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4c99be6-fe00-457a-9f8f-a7493fe2f42c" xlink:to="loc_us-gaap_StockholdersEquity_c301b5c0-c461-4b30-a47a-2310c34da6cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61743da7-0591-488d-9f71-41cb7c74881b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3e70207a-eca5-4404-b5b4-5f48134fdbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61743da7-0591-488d-9f71-41cb7c74881b" xlink:to="loc_us-gaap_CommonStockValue_3e70207a-eca5-4404-b5b4-5f48134fdbc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_eb282914-17cc-4191-bda2-df98984cfa39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61743da7-0591-488d-9f71-41cb7c74881b" xlink:to="loc_us-gaap_TreasuryStockCommonValue_eb282914-17cc-4191-bda2-df98984cfa39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_08eeaa7d-56bc-4bb1-87f3-79d2ce09ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61743da7-0591-488d-9f71-41cb7c74881b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_08eeaa7d-56bc-4bb1-87f3-79d2ce09ebda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6ed427b7-d37f-4434-96bf-86e77c84560e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61743da7-0591-488d-9f71-41cb7c74881b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6ed427b7-d37f-4434-96bf-86e77c84560e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7e5ca970-adde-4301-b452-f541c1f4b874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61743da7-0591-488d-9f71-41cb7c74881b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7e5ca970-adde-4301-b452-f541c1f4b874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cb745bcc-fdd2-4ce0-87c7-59edd45595f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61743da7-0591-488d-9f71-41cb7c74881b" xlink:to="loc_us-gaap_PreferredStockValue_cb745bcc-fdd2-4ce0-87c7-59edd45595f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_248dbab8-7bb0-47f4-8ea8-504beadd246d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1e97cafd-9267-4dfe-abe9-c85562f0a56b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_248dbab8-7bb0-47f4-8ea8-504beadd246d" xlink:to="loc_us-gaap_LiabilitiesCurrent_1e97cafd-9267-4dfe-abe9-c85562f0a56b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_27ad3144-b422-4127-add6-7f0ae975a27f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_248dbab8-7bb0-47f4-8ea8-504beadd246d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_27ad3144-b422-4127-add6-7f0ae975a27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_48b4aefb-423e-425e-8188-19a71225817b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_248dbab8-7bb0-47f4-8ea8-504beadd246d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_48b4aefb-423e-425e-8188-19a71225817b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0ac722a6-702e-4333-b2ba-abeccf7be52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_248dbab8-7bb0-47f4-8ea8-504beadd246d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0ac722a6-702e-4333-b2ba-abeccf7be52d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6fe2b7c7-56a7-4267-9363-d62f1c7845b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ddeb2867-4ea2-4c41-98a5-d8550b4f8e22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6fe2b7c7-56a7-4267-9363-d62f1c7845b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_ddeb2867-4ea2-4c41-98a5-d8550b4f8e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_17bd8247-eeba-4c36-a94e-91a47a09f1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6fe2b7c7-56a7-4267-9363-d62f1c7845b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_17bd8247-eeba-4c36-a94e-91a47a09f1b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5b82bba2-09ce-456b-8b83-dff508182f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6fe2b7c7-56a7-4267-9363-d62f1c7845b4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5b82bba2-09ce-456b-8b83-dff508182f0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_3c443319-898a-463d-9934-88eaa7a6fbff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6fe2b7c7-56a7-4267-9363-d62f1c7845b4" xlink:to="loc_us-gaap_NotesPayableCurrent_3c443319-898a-463d-9934-88eaa7a6fbff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0891dec8-f896-429b-a4ac-8db2213d57a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6fe2b7c7-56a7-4267-9363-d62f1c7845b4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0891dec8-f896-429b-a4ac-8db2213d57a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7d6fc557-2e06-4424-93c1-2cbf0a18a2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8c9ec2ff-4dd7-4ed6-baea-5fda33bdc6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7d6fc557-2e06-4424-93c1-2cbf0a18a2b0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8c9ec2ff-4dd7-4ed6-baea-5fda33bdc6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1bde2e85-ce2e-4bff-b49a-ea416f9cbf07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7d6fc557-2e06-4424-93c1-2cbf0a18a2b0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1bde2e85-ce2e-4bff-b49a-ea416f9cbf07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18a9a84f-2b5f-498c-8110-12beb58d3735" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7d6fc557-2e06-4424-93c1-2cbf0a18a2b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18a9a84f-2b5f-498c-8110-12beb58d3735" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a4c001e7-952b-4c1c-b771-f6a914c4b396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7d6fc557-2e06-4424-93c1-2cbf0a18a2b0" xlink:to="loc_us-gaap_InventoryNet_a4c001e7-952b-4c1c-b771-f6a914c4b396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6c42bf10-e240-401d-becd-4a1f74b0870b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_aa0ebc68-48d6-4b9b-8ffe-3e112942f92c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c42bf10-e240-401d-becd-4a1f74b0870b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_aa0ebc68-48d6-4b9b-8ffe-3e112942f92c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45074710-e627-47d0-bc86-a67c8c0d6938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c42bf10-e240-401d-becd-4a1f74b0870b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45074710-e627-47d0-bc86-a67c8c0d6938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8bec9e19-bef4-408b-8691-c7c6d1b3709a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c42bf10-e240-401d-becd-4a1f74b0870b" xlink:to="loc_us-gaap_Goodwill_8bec9e19-bef4-408b-8691-c7c6d1b3709a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dc924888-22b5-4f95-a9ac-1d5677aa8a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c42bf10-e240-401d-becd-4a1f74b0870b" xlink:to="loc_us-gaap_AssetsCurrent_dc924888-22b5-4f95-a9ac-1d5677aa8a17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_17468ece-5bb5-462b-ab80-baa1e0e4f449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c42bf10-e240-401d-becd-4a1f74b0870b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_17468ece-5bb5-462b-ab80-baa1e0e4f449" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_0ea55250-5d08-4ef7-9029-b3da192ecdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_eecf9603-c714-437b-a0d5-ec93672ba06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0ea55250-5d08-4ef7-9029-b3da192ecdb1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_eecf9603-c714-437b-a0d5-ec93672ba06a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_47f0d24b-3bc2-4215-8985-768ef97a8f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0ea55250-5d08-4ef7-9029-b3da192ecdb1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_47f0d24b-3bc2-4215-8985-768ef97a8f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f22e9832-6b19-4941-8be3-db0385d27e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0ea55250-5d08-4ef7-9029-b3da192ecdb1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f22e9832-6b19-4941-8be3-db0385d27e39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_209cca89-0af5-4bad-bd83-75448c995933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0ea55250-5d08-4ef7-9029-b3da192ecdb1" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_209cca89-0af5-4bad-bd83-75448c995933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_497115d9-46ba-4e18-8e61-a26ffd95a921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0ea55250-5d08-4ef7-9029-b3da192ecdb1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_497115d9-46ba-4e18-8e61-a26ffd95a921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_924f168c-3584-4e66-b700-fad1b886ad14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0ea55250-5d08-4ef7-9029-b3da192ecdb1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_924f168c-3584-4e66-b700-fad1b886ad14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_788841d9-a380-4762-841d-3e6958798418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d28100b2-9d03-4489-a69b-b18c5b7b4313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_788841d9-a380-4762-841d-3e6958798418" xlink:to="loc_us-gaap_OperatingIncomeLoss_d28100b2-9d03-4489-a69b-b18c5b7b4313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_46373812-c508-42f3-8401-a6352f8856e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_788841d9-a380-4762-841d-3e6958798418" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_46373812-c508-42f3-8401-a6352f8856e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a13d957c-b37e-41c4-b69b-248425e618a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_30f16ef3-84e0-4da6-ba54-7ea16b89c704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a13d957c-b37e-41c4-b69b-248425e618a1" xlink:to="loc_us-gaap_Revenues_30f16ef3-84e0-4da6-ba54-7ea16b89c704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_3de649a2-e7b9-4717-a987-e08792ebb3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a13d957c-b37e-41c4-b69b-248425e618a1" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_3de649a2-e7b9-4717-a987-e08792ebb3a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_fbc4718e-439d-4cd9-bf7d-4020a7dea7d2" xlink:href="ebs-20231231.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_449c8879-ea4a-4bad-bc10-b08efa594c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_fbc4718e-439d-4cd9-bf7d-4020a7dea7d2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_449c8879-ea4a-4bad-bc10-b08efa594c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_fa4bd7af-ebac-4889-852f-8c872f497523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_fbc4718e-439d-4cd9-bf7d-4020a7dea7d2" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_fa4bd7af-ebac-4889-852f-8c872f497523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f7e9859f-b2dc-44cc-9b67-4c0cbb26aa34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fd0a8777-6610-4870-b68b-086cdde4bd33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_f7e9859f-b2dc-44cc-9b67-4c0cbb26aa34" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fd0a8777-6610-4870-b68b-086cdde4bd33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_8731936a-f8ce-436c-b0e8-8890d68a82bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_f7e9859f-b2dc-44cc-9b67-4c0cbb26aa34" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_8731936a-f8ce-436c-b0e8-8890d68a82bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a8512be-f9aa-46cf-bafb-c1ab49b77d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fa1c7d5d-1d09-4d69-be74-0f166f9347d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3a8512be-f9aa-46cf-bafb-c1ab49b77d5b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fa1c7d5d-1d09-4d69-be74-0f166f9347d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_24a56aff-7a8c-4647-b3d3-30401a0760fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3a8512be-f9aa-46cf-bafb-c1ab49b77d5b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_24a56aff-7a8c-4647-b3d3-30401a0760fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b9ff5baf-52fb-4e06-8f81-6f35082300bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_47e6505c-ed78-4153-9e2b-4a8ba3c6629c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b9ff5baf-52fb-4e06-8f81-6f35082300bd" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_47e6505c-ed78-4153-9e2b-4a8ba3c6629c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_424af737-373a-4ab0-9450-3f077e495682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b9ff5baf-52fb-4e06-8f81-6f35082300bd" xlink:to="loc_us-gaap_InterestExpense_424af737-373a-4ab0-9450-3f077e495682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_065da091-a53b-4a7a-aae1-5d326c0825ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b9ff5baf-52fb-4e06-8f81-6f35082300bd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_065da091-a53b-4a7a-aae1-5d326c0825ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57328bf8-8921-4e16-ac83-0cfd3ae9c86b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_fa15961f-e4e5-4037-bb9c-f15153aece97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57328bf8-8921-4e16-ac83-0cfd3ae9c86b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_fa15961f-e4e5-4037-bb9c-f15153aece97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_88bd2b8c-e26b-4011-a247-4b12e828cd55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57328bf8-8921-4e16-ac83-0cfd3ae9c86b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_88bd2b8c-e26b-4011-a247-4b12e828cd55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9c760382-f82c-419f-a1ea-6496ee21d4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57328bf8-8921-4e16-ac83-0cfd3ae9c86b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9c760382-f82c-419f-a1ea-6496ee21d4e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_a7ba7990-a6f7-4f44-aae5-27b2f58e8862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57328bf8-8921-4e16-ac83-0cfd3ae9c86b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_a7ba7990-a6f7-4f44-aae5-27b2f58e8862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_875ada70-5ae0-4125-a9cb-ad868f5d5005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7f3d3c07-67d8-4364-af49-a4921344d6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_875ada70-5ae0-4125-a9cb-ad868f5d5005" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7f3d3c07-67d8-4364-af49-a4921344d6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e08fd87b-b553-463c-aa02-fdc4ee0a6205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_875ada70-5ae0-4125-a9cb-ad868f5d5005" xlink:to="loc_us-gaap_NetIncomeLoss_e08fd87b-b553-463c-aa02-fdc4ee0a6205" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_14d79a5f-deaa-4f59-aec9-168f2797227c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cfa52e8e-abad-47a8-8b5f-32ecbc0e03d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_14d79a5f-deaa-4f59-aec9-168f2797227c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cfa52e8e-abad-47a8-8b5f-32ecbc0e03d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed033005-233f-4391-a527-f818432e9c76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_14d79a5f-deaa-4f59-aec9-168f2797227c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed033005-233f-4391-a527-f818432e9c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8335ca67-d820-4f7a-a1a5-f10f55f4e5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_14d79a5f-deaa-4f59-aec9-168f2797227c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8335ca67-d820-4f7a-a1a5-f10f55f4e5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b57e643-72be-4390-9bce-327d70ccf814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_14d79a5f-deaa-4f59-aec9-168f2797227c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b57e643-72be-4390-9bce-327d70ccf814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb9e887d-0951-433d-850f-f5bb052e5e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb9e887d-0951-433d-850f-f5bb052e5e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_45e528e4-e90b-4422-9285-9157d045af07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_45e528e4-e90b-4422-9285-9157d045af07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bdd81deb-736a-432e-8c13-e556c3c8f14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bdd81deb-736a-432e-8c13-e556c3c8f14b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7ca49efa-dff6-4a5e-8661-6df4085291ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7ca49efa-dff6-4a5e-8661-6df4085291ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e8e2e34d-9f2a-4e69-8cfb-6102978ceb58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e8e2e34d-9f2a-4e69-8cfb-6102978ceb58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_47069bb8-2b3f-463b-ac30-5cf03c2188d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_47069bb8-2b3f-463b-ac30-5cf03c2188d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_2c912e44-97ad-46f3-a2c9-7b27035d5ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_2c912e44-97ad-46f3-a2c9-7b27035d5ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_af063f93-e245-422c-810c-f43f0db831b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_af063f93-e245-422c-810c-f43f0db831b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_5906346f-c7de-4d68-81d7-e9140881bde9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd3db24-651b-46ea-b2bd-d32315841dbf" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_5906346f-c7de-4d68-81d7-e9140881bde9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_99c40b33-562c-47b1-8a5a-8b63d58cf98e" xlink:href="ebs-20231231.xsd#ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_99c40b33-562c-47b1-8a5a-8b63d58cf98e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a77cfda7-939d-4062-bdde-115e0c75b5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a77cfda7-939d-4062-bdde-115e0c75b5d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f4eadb92-4e6c-4fbe-97b8-a31d977e895f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f4eadb92-4e6c-4fbe-97b8-a31d977e895f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_a6fc45b0-cbcf-47c1-9223-480246d7e67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_a6fc45b0-cbcf-47c1-9223-480246d7e67e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_eacd46dd-348b-4f3a-96ab-77522256bdea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_eacd46dd-348b-4f3a-96ab-77522256bdea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_c1ab017e-aded-4cd1-87e0-5d48929f1c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_c1ab017e-aded-4cd1-87e0-5d48929f1c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_efc68999-db78-447b-b6ce-90fcd222aea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_efc68999-db78-447b-b6ce-90fcd222aea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7d37a6cf-91d6-42dd-9e96-5b26247469f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7d37a6cf-91d6-42dd-9e96-5b26247469f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_806513bd-1cbd-4db0-8588-64aef64f034a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_NetIncomeLoss_806513bd-1cbd-4db0-8588-64aef64f034a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_577ba294-98d1-4aa5-b808-bc3d569ccd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_577ba294-98d1-4aa5-b808-bc3d569ccd8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_2abaeea8-5aed-4e10-9754-09788ff0505a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_2abaeea8-5aed-4e10-9754-09788ff0505a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_1b2ef92a-2c8b-4244-9ef1-41155501ed04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_GainLossOnContractTermination_1b2ef92a-2c8b-4244-9ef1-41155501ed04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_dc1a671a-0357-4aed-a274-b9175eb35556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_dc1a671a-0357-4aed-a274-b9175eb35556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ba547812-7ab0-409b-83c3-6b27a5884639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ba547812-7ab0-409b-83c3-6b27a5884639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e6b0195e-85eb-4178-b4d0-be2825a5ece8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e6b0195e-85eb-4178-b4d0-be2825a5ece8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fca9affa-d15a-469b-be8f-87e39652dd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fca9affa-d15a-469b-be8f-87e39652dd76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6a09342b-cfdc-40c2-afc6-cf93c6d3c969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6a09342b-cfdc-40c2-afc6-cf93c6d3c969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b102183c-9435-4ecc-9757-c870751bfc39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b102183c-9435-4ecc-9757-c870751bfc39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f1dacea4-6dab-4070-8663-9701067e01b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_ShareBasedCompensation_f1dacea4-6dab-4070-8663-9701067e01b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_fee4dd05-4922-474a-ac2a-40d10ebb42b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9f2d45a-c80e-467b-8ec4-49c829f8e11d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_fee4dd05-4922-474a-ac2a-40d10ebb42b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ae81139-4cd2-4a94-bf9b-4c7b25b1d0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a5781dd2-7d8c-4e36-886c-4feb1daf7c75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ae81139-4cd2-4a94-bf9b-4c7b25b1d0e2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a5781dd2-7d8c-4e36-886c-4feb1daf7c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_38940378-2498-405e-9a28-927be2cd0c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ae81139-4cd2-4a94-bf9b-4c7b25b1d0e2" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_38940378-2498-405e-9a28-927be2cd0c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_4240b547-9a6b-4631-bd50-7da4d7e7b323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ae81139-4cd2-4a94-bf9b-4c7b25b1d0e2" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_4240b547-9a6b-4631-bd50-7da4d7e7b323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_76e7b6be-36ae-4309-bbde-fcb9acc090cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ae81139-4cd2-4a94-bf9b-4c7b25b1d0e2" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_76e7b6be-36ae-4309-bbde-fcb9acc090cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d3bbb4e8-134e-4901-aea7-be07d03524ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ae81139-4cd2-4a94-bf9b-4c7b25b1d0e2" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d3bbb4e8-134e-4901-aea7-be07d03524ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#InventoriesnetDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_02b2c6ee-7f4d-403b-87ff-3078e4c0243d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_fe6c6fba-8a93-486e-a104-4c26192eef97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_02b2c6ee-7f4d-403b-87ff-3078e4c0243d" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_fe6c6fba-8a93-486e-a104-4c26192eef97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_926294b4-b488-4793-886f-879eb0c0b470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_02b2c6ee-7f4d-403b-87ff-3078e4c0243d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_926294b4-b488-4793-886f-879eb0c0b470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_eaa78ba5-da89-4515-ba4f-faf8845a7506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_02b2c6ee-7f4d-403b-87ff-3078e4c0243d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_eaa78ba5-da89-4515-ba4f-faf8845a7506" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2cfdb8e5-44a8-4fca-bec0-efe6e2b46217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ac81e65c-28fc-438f-91fb-f618fe58ac5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2cfdb8e5-44a8-4fca-bec0-efe6e2b46217" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ac81e65c-28fc-438f-91fb-f618fe58ac5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_77d152c4-8c9e-4904-8a1b-640f4bc579bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2cfdb8e5-44a8-4fca-bec0-efe6e2b46217" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_77d152c4-8c9e-4904-8a1b-640f4bc579bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fab9d369-a63d-4210-bdee-267c94d5fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d638e61b-0d5a-4243-b94e-dda3f4da7609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fab9d369-a63d-4210-bdee-267c94d5fdc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d638e61b-0d5a-4243-b94e-dda3f4da7609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_17716b3c-bf58-40a6-8bae-c9d42ea975e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fab9d369-a63d-4210-bdee-267c94d5fdc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_17716b3c-bf58-40a6-8bae-c9d42ea975e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6906f791-6112-4578-a2a5-66a5e3b41181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1c3108b2-25c6-4708-81d7-682d06938a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6906f791-6112-4578-a2a5-66a5e3b41181" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1c3108b2-25c6-4708-81d7-682d06938a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_591fa1bb-34a2-4e0f-bcbe-76db76662dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6906f791-6112-4578-a2a5-66a5e3b41181" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_591fa1bb-34a2-4e0f-bcbe-76db76662dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_98f8aac5-3285-42cb-b6ee-3bf425dcb0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6906f791-6112-4578-a2a5-66a5e3b41181" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_98f8aac5-3285-42cb-b6ee-3bf425dcb0cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f5b2dd6e-36ac-4ae9-9d2f-ce335a250bed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6906f791-6112-4578-a2a5-66a5e3b41181" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f5b2dd6e-36ac-4ae9-9d2f-ce335a250bed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0fa4a0bb-d4ae-4de4-a0cd-6820479b2178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6906f791-6112-4578-a2a5-66a5e3b41181" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0fa4a0bb-d4ae-4de4-a0cd-6820479b2178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4b2c1db4-424c-4249-815e-9d1fd8763e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6906f791-6112-4578-a2a5-66a5e3b41181" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4b2c1db4-424c-4249-815e-9d1fd8763e34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_15b2c534-1095-47fc-83cf-f8abacca9fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_7435e1f4-a7b0-40c2-bd6b-3f8bfe21a097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_15b2c534-1095-47fc-83cf-f8abacca9fcc" xlink:to="loc_us-gaap_DerivativeAssets_7435e1f4-a7b0-40c2-bd6b-3f8bfe21a097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca64af6d-531d-44d9-b2d8-bc0d34873993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_15b2c534-1095-47fc-83cf-f8abacca9fcc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca64af6d-531d-44d9-b2d8-bc0d34873993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_eec9e8b0-7c39-40da-b8f4-1f3ca2ac4c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_946b59f2-2c0a-4267-b1b3-37b78303456d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_eec9e8b0-7c39-40da-b8f4-1f3ca2ac4c9b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_946b59f2-2c0a-4267-b1b3-37b78303456d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DebtFutureDebtPaymentsofLongtermIndebtednessDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6a0444a9-9307-404c-a668-85f624ca88c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_20789f29-12c5-4665-9cf5-9d1a4338543e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6a0444a9-9307-404c-a668-85f624ca88c2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_20789f29-12c5-4665-9cf5-9d1a4338543e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_26270194-edab-43e6-85fe-ac1bec57f2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6a0444a9-9307-404c-a668-85f624ca88c2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_26270194-edab-43e6-85fe-ac1bec57f2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7274d512-0a60-4fba-bd6c-bc9b96935f82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6a0444a9-9307-404c-a668-85f624ca88c2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7274d512-0a60-4fba-bd6c-bc9b96935f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0389788f-cac4-4160-ad28-a1e96a927366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6a0444a9-9307-404c-a668-85f624ca88c2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0389788f-cac4-4160-ad28-a1e96a927366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9128b4f7-5eb0-4592-af62-f97d7f68b2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6a0444a9-9307-404c-a668-85f624ca88c2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9128b4f7-5eb0-4592-af62-f97d7f68b2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_adb59b06-aeb4-482b-b553-f51e6094f9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6a0444a9-9307-404c-a668-85f624ca88c2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_adb59b06-aeb4-482b-b553-f51e6094f9c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_aec2325e-23da-4f34-8067-2238054d1e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_c88b583f-675d-4d0f-a46e-ca5fc5f58429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_aec2325e-23da-4f34-8067-2238054d1e9e" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_c88b583f-675d-4d0f-a46e-ca5fc5f58429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_3d890fd1-6fbf-44cc-a8d7-0d1c1112dc50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_aec2325e-23da-4f34-8067-2238054d1e9e" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_3d890fd1-6fbf-44cc-a8d7-0d1c1112dc50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e24a6c08-5570-4c71-ab3d-08da666fb416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_b3ab52cb-3fba-4372-bc4f-6f548993edcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e24a6c08-5570-4c71-ab3d-08da666fb416" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_b3ab52cb-3fba-4372-bc4f-6f548993edcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_0e7747b3-015d-4e77-a8c0-38bef9ac0eec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e24a6c08-5570-4c71-ab3d-08da666fb416" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_0e7747b3-015d-4e77-a8c0-38bef9ac0eec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#NetincomelosspercommonshareDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e23dfc0-7a11-4d40-bbd6-5bc53f51e932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_51fbbf7f-e11b-4625-95c0-72bd5e38f80e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e23dfc0-7a11-4d40-bbd6-5bc53f51e932" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_51fbbf7f-e11b-4625-95c0-72bd5e38f80e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7978586e-ebfe-4e2e-9d50-22f9b409224e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e23dfc0-7a11-4d40-bbd6-5bc53f51e932" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7978586e-ebfe-4e2e-9d50-22f9b409224e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1722e10c-d4dd-4394-95f1-ee2c02832a60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_b531fb5e-efa6-4ece-8619-9d6b5b452520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BilledContractReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1722e10c-d4dd-4394-95f1-ee2c02832a60" xlink:to="loc_us-gaap_BilledContractReceivables_b531fb5e-efa6-4ece-8619-9d6b5b452520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_4a6192b3-dabb-4a57-a9a7-451636b1e1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1722e10c-d4dd-4394-95f1-ee2c02832a60" xlink:to="loc_us-gaap_UnbilledContractsReceivable_4a6192b3-dabb-4a57-a9a7-451636b1e1ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_6f12e94b-0a14-46d7-8b24-370cca1c40c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1722e10c-d4dd-4394-95f1-ee2c02832a60" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_6f12e94b-0a14-46d7-8b24-370cca1c40c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_946a99c2-7d6a-439f-acc7-3a2ce7f8f6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_45f78c06-d8d7-44f4-ad93-f4bb734d88c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_946a99c2-7d6a-439f-acc7-3a2ce7f8f6c3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_45f78c06-d8d7-44f4-ad93-f4bb734d88c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_8d664147-a25f-44a0-b961-c2f68637dfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_946a99c2-7d6a-439f-acc7-3a2ce7f8f6c3" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_8d664147-a25f-44a0-b961-c2f68637dfaa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d00e7b8f-2328-406c-b131-44c945d6209f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eabfd772-d4a4-4b94-b721-3a2b9ca3af68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d00e7b8f-2328-406c-b131-44c945d6209f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eabfd772-d4a4-4b94-b721-3a2b9ca3af68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7fbc2072-3ef8-483d-940d-eebc586f2222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d00e7b8f-2328-406c-b131-44c945d6209f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7fbc2072-3ef8-483d-940d-eebc586f2222" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7b3f332-2119-48cd-a95d-10326d56af83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5c31ee99-0e9c-481b-93f5-6cc6c0d044c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7b3f332-2119-48cd-a95d-10326d56af83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5c31ee99-0e9c-481b-93f5-6cc6c0d044c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_95d18ddc-53bf-47c7-b3ed-78d5a25e38cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7b3f332-2119-48cd-a95d-10326d56af83" xlink:to="loc_us-gaap_OperatingLeaseLiability_95d18ddc-53bf-47c7-b3ed-78d5a25e38cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a5441b5-5eb2-454a-9144-2b2b3150b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9526add1-5d3b-4811-aa6f-d328ed3283c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a5441b5-5eb2-454a-9144-2b2b3150b4b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9526add1-5d3b-4811-aa6f-d328ed3283c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5e19e716-78d7-44d1-8ae7-e8b996254c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a5441b5-5eb2-454a-9144-2b2b3150b4b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5e19e716-78d7-44d1-8ae7-e8b996254c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dadf1427-63a8-49fb-940b-7dd16460c75c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a5441b5-5eb2-454a-9144-2b2b3150b4b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dadf1427-63a8-49fb-940b-7dd16460c75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2f35174e-fc2b-44aa-ad29-40eefdf1bc86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a5441b5-5eb2-454a-9144-2b2b3150b4b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2f35174e-fc2b-44aa-ad29-40eefdf1bc86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e619091-23d6-44ee-a2fd-eba8ebe278a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a5441b5-5eb2-454a-9144-2b2b3150b4b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e619091-23d6-44ee-a2fd-eba8ebe278a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8fb9fa5e-8877-4faf-8620-e557995bb8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a5441b5-5eb2-454a-9144-2b2b3150b4b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8fb9fa5e-8877-4faf-8620-e557995bb8ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7df2a5f2-57c4-4678-a4d6-ad3907fa9f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d39055f6-5002-469c-8009-d2b97a001cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7df2a5f2-57c4-4678-a4d6-ad3907fa9f0b" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d39055f6-5002-469c-8009-d2b97a001cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f687bf91-0191-4645-86bc-335599f597c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7df2a5f2-57c4-4678-a4d6-ad3907fa9f0b" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f687bf91-0191-4645-86bc-335599f597c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ed2c000d-c069-4af7-9c33-b08130bcc405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7df2a5f2-57c4-4678-a4d6-ad3907fa9f0b" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ed2c000d-c069-4af7-9c33-b08130bcc405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9752f65f-e8d8-4933-afc1-10d6d3ac138a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d308c3ef-cfeb-461b-95f3-dfd3e36e0b42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9752f65f-e8d8-4933-afc1-10d6d3ac138a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d308c3ef-cfeb-461b-95f3-dfd3e36e0b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_87a505a4-49ac-4169-8f08-1fe85f7b134e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9752f65f-e8d8-4933-afc1-10d6d3ac138a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_87a505a4-49ac-4169-8f08-1fe85f7b134e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_da6f2081-632e-4c9a-9fbe-66ca23ee2631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9752f65f-e8d8-4933-afc1-10d6d3ac138a" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_da6f2081-632e-4c9a-9fbe-66ca23ee2631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_393a07ac-a7ff-49ec-8ab6-ed3e07e0aef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6b78f94d-c3e0-41b7-a5c6-060ae7a7a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_393a07ac-a7ff-49ec-8ab6-ed3e07e0aef0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6b78f94d-c3e0-41b7-a5c6-060ae7a7a9a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4d35646e-064c-4cdb-8795-7a86b05f8067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_393a07ac-a7ff-49ec-8ab6-ed3e07e0aef0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4d35646e-064c-4cdb-8795-7a86b05f8067" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesNetDeferredTaxAssetLiabilityDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1dfed0f4-5e5a-4603-82a3-ccbfb725cfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1dfed0f4-5e5a-4603-82a3-ccbfb725cfb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_ef992fc5-9723-4d41-818d-7bf5504d2a11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_ef992fc5-9723-4d41-818d-7bf5504d2a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts_abecbe66-6552-4d56-98d0-7f2808a2f155" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts_abecbe66-6552-4d56-98d0-7f2808a2f155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_37eba4fd-d452-49c5-8c34-752bb430301d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_37eba4fd-d452-49c5-8c34-752bb430301d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_928c2462-9119-411f-8acb-eda4eb288dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_928c2462-9119-411f-8acb-eda4eb288dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1e7070a0-094d-4952-a148-99a91f5c9435" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1e7070a0-094d-4952-a148-99a91f5c9435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_d89da0c3-64d3-46d7-92ce-19c7eb55fa86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_d89da0c3-64d3-46d7-92ce-19c7eb55fa86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_37fc4a33-d07e-4936-84e9-3b786cf8532c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_37fc4a33-d07e-4936-84e9-3b786cf8532c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment_a25bd0b1-abf5-48ed-9ba5-d01053bfe897" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment_a25bd0b1-abf5-48ed-9ba5-d01053bfe897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5dfc9484-8094-4d26-bfc5-7333c53c9e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5dfc9484-8094-4d26-bfc5-7333c53c9e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsOperatingLeaseLiability_e568feb4-c57a-4f6b-ba9c-282c5ca49e11" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_ebs_DeferredTaxAssetsOperatingLeaseLiability_e568feb4-c57a-4f6b-ba9c-282c5ca49e11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_950e6b17-d303-49fd-b3f1-096d989e95b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_950e6b17-d303-49fd-b3f1-096d989e95b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3317e764-b05e-4447-94c0-f4338ed4d818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3317e764-b05e-4447-94c0-f4338ed4d818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsIntangibleAssets_04189520-0e0c-428b-9a50-b7f93663438e" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsIntangibleAssets"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_ebs_DeferredTaxAssetsIntangibleAssets_04189520-0e0c-428b-9a50-b7f93663438e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_433e91f6-061c-4547-be6b-c334b8acabd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17e8dbb6-2170-4752-9563-1c89ed93243b" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_433e91f6-061c-4547-be6b-c334b8acabd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3b064f35-ea86-41f9-898e-7aaeaa84a225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c7bd0903-9aa6-47a0-bc99-a799acf5123b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_3b064f35-ea86-41f9-898e-7aaeaa84a225" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c7bd0903-9aa6-47a0-bc99-a799acf5123b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b2d63b0c-35af-4bf1-876f-017d8a71dc05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_3b064f35-ea86-41f9-898e-7aaeaa84a225" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b2d63b0c-35af-4bf1-876f-017d8a71dc05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_037c2b1d-16d7-4b9b-a8a3-a32cabccb22f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_3b064f35-ea86-41f9-898e-7aaeaa84a225" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_037c2b1d-16d7-4b9b-a8a3-a32cabccb22f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_946d2166-8991-4538-a893-e2944d5cf2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d186e99d-5200-471c-85e4-b363b35dd92f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_946d2166-8991-4538-a893-e2944d5cf2e5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d186e99d-5200-471c-85e4-b363b35dd92f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d86ac04e-f780-4211-8ec1-079ded6c3d68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_946d2166-8991-4538-a893-e2944d5cf2e5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d86ac04e-f780-4211-8ec1-079ded6c3d68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_39877f57-9bb9-48a5-b33f-df13cc2f1a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_c5c622f3-42f6-40ac-97a0-678a5cedfc19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_39877f57-9bb9-48a5-b33f-df13cc2f1a3e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_c5c622f3-42f6-40ac-97a0-678a5cedfc19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f4e5cea7-23c4-4763-b374-16faddea996b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_39877f57-9bb9-48a5-b33f-df13cc2f1a3e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f4e5cea7-23c4-4763-b374-16faddea996b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_03fcb019-bb6e-40a6-b10b-d956daf570db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_39877f57-9bb9-48a5-b33f-df13cc2f1a3e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_03fcb019-bb6e-40a6-b10b-d956daf570db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_e5c131d3-b115-4f49-ad76-a6f044146b2d" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxLiabilitiesForeignWithholdingTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_39877f57-9bb9-48a5-b33f-df13cc2f1a3e" xlink:to="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_e5c131d3-b115-4f49-ad76-a6f044146b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_890df7d1-178e-4d88-af27-2800c77b7b43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_39877f57-9bb9-48a5-b33f-df13cc2f1a3e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_890df7d1-178e-4d88-af27-2800c77b7b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_02e060eb-cb92-49cb-bc29-eafd85d49262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_39877f57-9bb9-48a5-b33f-df13cc2f1a3e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_02e060eb-cb92-49cb-bc29-eafd85d49262" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_922c37ea-3105-4a2c-8303-aa87a93d3a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0c40f920-a9a0-466b-a0de-1e73d284509e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_922c37ea-3105-4a2c-8303-aa87a93d3a49" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0c40f920-a9a0-466b-a0de-1e73d284509e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_be53571c-20eb-426e-b1e1-fa278a17fdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_922c37ea-3105-4a2c-8303-aa87a93d3a49" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_be53571c-20eb-426e-b1e1-fa278a17fdf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_25ee85d5-1ed0-4173-88fd-c59f3ee155d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_25ee85d5-1ed0-4173-88fd-c59f3ee155d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_1707597f-3a9c-4d39-9a5c-a2f1ee61c3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_1707597f-3a9c-4d39-9a5c-a2f1ee61c3c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_5041fb8f-b1c2-4dd4-9336-b0f7d899d1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_5041fb8f-b1c2-4dd4-9336-b0f7d899d1a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_0dc3c3de-dd24-4941-aac8-16e08e18155c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_0dc3c3de-dd24-4941-aac8-16e08e18155c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fe854fa8-6fba-451b-ba56-26b0aa8092ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fe854fa8-6fba-451b-ba56-26b0aa8092ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount_adc2fdb3-fd43-44a1-b6d2-4b431e37eb0c" xlink:href="ebs-20231231.xsd#ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount_adc2fdb3-fd43-44a1-b6d2-4b431e37eb0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts_c33706f9-c937-42c4-9654-5c893b35ece5" xlink:href="ebs-20231231.xsd#ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts_c33706f9-c937-42c4-9654-5c893b35ece5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_660772c5-f162-4867-99b4-fd70183a556c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_660772c5-f162-4867-99b4-fd70183a556c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference_eb55643a-d84d-4854-87cb-d9f4315d1ee4" xlink:href="ebs-20231231.xsd#ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference_eb55643a-d84d-4854-87cb-d9f4315d1ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d3a1e92b-4b7d-4f60-9e0d-229d86d8c4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d3a1e92b-4b7d-4f60-9e0d-229d86d8c4b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_c4899636-29b2-42a0-b7d1-08259f84a9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_c4899636-29b2-42a0-b7d1-08259f84a9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_cdf00b53-2707-4dbe-985c-db4b7c4737ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_cdf00b53-2707-4dbe-985c-db4b7c4737ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_2a6c1b1d-f0c9-48b9-a889-ac8c5c70969f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_2a6c1b1d-f0c9-48b9-a889-ac8c5c70969f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2372ff0e-00fa-4314-a96f-ae552b99f777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_52ad14e6-2543-4d6e-8b63-7d6804f69719" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2372ff0e-00fa-4314-a96f-ae552b99f777" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f9207903-8a4a-42fd-b52c-b6de362bb356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e773d73b-9cb8-4c3a-a593-db7f6dc3b7de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f9207903-8a4a-42fd-b52c-b6de362bb356" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e773d73b-9cb8-4c3a-a593-db7f6dc3b7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_bc88ae73-2836-4fee-b7ac-323993b714a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f9207903-8a4a-42fd-b52c-b6de362bb356" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_bc88ae73-2836-4fee-b7ac-323993b714a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_609f07e0-acbb-4a66-896b-fced925b03e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f9207903-8a4a-42fd-b52c-b6de362bb356" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_609f07e0-acbb-4a66-896b-fced925b03e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9ca17160-9122-413c-bfa7-4a43f029b74b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f9207903-8a4a-42fd-b52c-b6de362bb356" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9ca17160-9122-413c-bfa7-4a43f029b74b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_06891982-aceb-425a-91f2-314e10cdd89a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f9207903-8a4a-42fd-b52c-b6de362bb356" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_06891982-aceb-425a-91f2-314e10cdd89a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_29768a0c-c506-4a3b-995b-746eea9694a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f9207903-8a4a-42fd-b52c-b6de362bb356" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_29768a0c-c506-4a3b-995b-746eea9694a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_7753bdaf-9939-4ae5-9dc6-c669a7911bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_a14f4eb2-03fe-4146-8fa9-9d129fda4be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_7753bdaf-9939-4ae5-9dc6-c669a7911bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_a14f4eb2-03fe-4146-8fa9-9d129fda4be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_2c1ea0ec-8869-4d95-a982-35efd78cc10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_7753bdaf-9939-4ae5-9dc6-c669a7911bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_2c1ea0ec-8869-4d95-a982-35efd78cc10b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>ebs-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c54bb9fe-5fe3-484c-8c37-1247bde19e06,g:0a179766-9174-4357-afdf-29ab18a19ddc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f9865ccf-bf5a-4836-9914-64d7a3930d93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_StatementTable_f9865ccf-bf5a-4836-9914-64d7a3930d93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31a11f36-1a30-4a03-af52-3f441dd22d5e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f9865ccf-bf5a-4836-9914-64d7a3930d93" xlink:to="loc_srt_ProductOrServiceAxis_31a11f36-1a30-4a03-af52-3f441dd22d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31a11f36-1a30-4a03-af52-3f441dd22d5e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_31a11f36-1a30-4a03-af52-3f441dd22d5e" xlink:to="loc_srt_ProductsAndServicesDomain_31a11f36-1a30-4a03-af52-3f441dd22d5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_31a11f36-1a30-4a03-af52-3f441dd22d5e" xlink:to="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_82497249-311d-41aa-a8ed-62816189adb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:to="loc_us-gaap_ProductMember_82497249-311d-41aa-a8ed-62816189adb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember_3a34b994-a3d9-4df7-b621-5505cb789e19" xlink:href="ebs-20231231.xsd#ebs_CommercialProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_82497249-311d-41aa-a8ed-62816189adb1" xlink:to="loc_ebs_CommercialProductMember_3a34b994-a3d9-4df7-b621-5505cb789e19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember_186dd1de-81dd-4bb8-90e6-e7601136e794" xlink:href="ebs-20231231.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_82497249-311d-41aa-a8ed-62816189adb1" xlink:to="loc_ebs_MedicalCountermeasuresMCMProductMember_186dd1de-81dd-4bb8-90e6-e7601136e794" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesMember_abe98f76-f8f9-4a38-8b8f-4abe6d591017" xlink:href="ebs-20231231.xsd#ebs_BioservicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:to="loc_ebs_BioservicesMember_abe98f76-f8f9-4a38-8b8f-4abe6d591017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_bdd905da-d43c-42d6-91a9-32c34a0bb254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_BioservicesMember_abe98f76-f8f9-4a38-8b8f-4abe6d591017" xlink:to="loc_us-gaap_ServiceMember_bdd905da-d43c-42d6-91a9-32c34a0bb254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesLeasesMember_e82ea999-92fa-4e3b-91d0-686f9664390f" xlink:href="ebs-20231231.xsd#ebs_BioservicesLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_BioservicesMember_abe98f76-f8f9-4a38-8b8f-4abe6d591017" xlink:to="loc_ebs_BioservicesLeasesMember_e82ea999-92fa-4e3b-91d0-686f9664390f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_5d184b51-bd6e-461a-97ca-fd87ccbb1171" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:to="loc_ebs_ContractsAndGrantsMember_5d184b51-bd6e-461a-97ca-fd87ccbb1171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afe0b80e-a6bb-4e35-b6c2-b12ab316dc94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afe0b80e-a6bb-4e35-b6c2-b12ab316dc94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_018fbf96-e259-4fb5-b51d-559f5897a091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_018fbf96-e259-4fb5-b51d-559f5897a091" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d21c95d2-f1e9-48e0-b7dc-23a38e4c3ab4" xlink:href="ebs-20231231.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d21c95d2-f1e9-48e0-b7dc-23a38e4c3ab4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_57c9c973-ab90-4034-94e3-035ce000be7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:to="loc_us-gaap_Revenues_57c9c973-ab90-4034-94e3-035ce000be7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2f3a5f31-b4f3-4aa1-b14f-b41664bb226e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2f3a5f31-b4f3-4aa1-b14f-b41664bb226e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b5192a54-9095-4613-89c2-06c849c47419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b5192a54-9095-4613-89c2-06c849c47419" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3f11889f-e028-4f3c-bff4-7b8be131e3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3f11889f-e028-4f3c-bff4-7b8be131e3ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_04c08a58-0c74-450d-973e-9445cea8a3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_04c08a58-0c74-450d-973e-9445cea8a3e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a5fb48f3-14fd-469c-b135-3a007b6d86bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a5fb48f3-14fd-469c-b135-3a007b6d86bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a695da48-5c7f-4e50-aa94-f1e12be7049a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a695da48-5c7f-4e50-aa94-f1e12be7049a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_1a6080ea-2ca3-4016-9fc2-983a6e6ada5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_1a6080ea-2ca3-4016-9fc2-983a6e6ada5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_78078a8c-fd96-43e8-b689-83a34f40147e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_OperatingIncomeLoss_78078a8c-fd96-43e8-b689-83a34f40147e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_76f4d290-119b-4a4b-a76b-d76b0220b419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:to="loc_us-gaap_InterestExpense_76f4d290-119b-4a4b-a76b-d76b0220b419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_198ee681-2e27-429c-930f-de1fc626d3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_198ee681-2e27-429c-930f-de1fc626d3a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7ba79f19-159e-4ea0-b725-ad4602c45f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7ba79f19-159e-4ea0-b725-ad4602c45f19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_249b9a2e-b246-4401-b8b1-c40e6d2da83d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_249b9a2e-b246-4401-b8b1-c40e6d2da83d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e1d22c1-cb4e-4821-875a-a0a343c4f33f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e1d22c1-cb4e-4821-875a-a0a343c4f33f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_27e2eb7a-d07f-4026-8b9e-4dab1ff7ba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_27e2eb7a-d07f-4026-8b9e-4dab1ff7ba1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_68977af1-065b-4305-ab06-da7332963c99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_NetIncomeLoss_68977af1-065b-4305-ab06-da7332963c99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_df7efb71-005e-4290-811e-1ae0f6f5cf34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_df7efb71-005e-4290-811e-1ae0f6f5cf34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_35f715c1-7679-4bde-a09f-6d56cc899683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_df7efb71-005e-4290-811e-1ae0f6f5cf34" xlink:to="loc_us-gaap_EarningsPerShareBasic_35f715c1-7679-4bde-a09f-6d56cc899683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_db986aa2-71cb-4949-8513-38efd4d378f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_df7efb71-005e-4290-811e-1ae0f6f5cf34" xlink:to="loc_us-gaap_EarningsPerShareDiluted_db986aa2-71cb-4949-8513-38efd4d378f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7ae85dd9-dfb8-4f34-8c93-5e9f8b5a6e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7ae85dd9-dfb8-4f34-8c93-5e9f8b5a6e3b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d634c445-84b9-43ae-997e-51858fa49760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7ae85dd9-dfb8-4f34-8c93-5e9f8b5a6e3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d634c445-84b9-43ae-997e-51858fa49760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8182797a-13c8-4b24-bd82-03ecc7c60837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7ae85dd9-dfb8-4f34-8c93-5e9f8b5a6e3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8182797a-13c8-4b24-bd82-03ecc7c60837" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c8f3da6-7274-4353-a89e-ad4db1f2dd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_da4a8489-4ff8-4622-b916-3a4b70444d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c8f3da6-7274-4353-a89e-ad4db1f2dd6e" xlink:to="loc_us-gaap_StatementTable_da4a8489-4ff8-4622-b916-3a4b70444d38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_47ed20bd-e0e7-4897-8bea-2d61352dc54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_da4a8489-4ff8-4622-b916-3a4b70444d38" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_47ed20bd-e0e7-4897-8bea-2d61352dc54c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47ed20bd-e0e7-4897-8bea-2d61352dc54c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47ed20bd-e0e7-4897-8bea-2d61352dc54c" xlink:to="loc_us-gaap_EquityComponentDomain_47ed20bd-e0e7-4897-8bea-2d61352dc54c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47ed20bd-e0e7-4897-8bea-2d61352dc54c" xlink:to="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_773b5098-68b4-4e49-9491-7065adf2cdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_CommonStockMember_773b5098-68b4-4e49-9491-7065adf2cdf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_048cbd3a-1b68-45d8-b3ad-99d4d391408a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_048cbd3a-1b68-45d8-b3ad-99d4d391408a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b81fec46-1e7a-4d66-a31a-f936a671dd01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b81fec46-1e7a-4d66-a31a-f936a671dd01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8491011d-b565-41a4-895e-5b968dcc0b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8491011d-b565-41a4-895e-5b968dcc0b83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4a54bf9d-1c11-4cbc-bbcc-2ec494bfc1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_RetainedEarningsMember_4a54bf9d-1c11-4cbc-bbcc-2ec494bfc1c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c8f3da6-7274-4353-a89e-ad4db1f2dd6e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a5a1370f-2981-46b4-b158-3d2999f67655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_CommonStockSharesIssued_a5a1370f-2981-46b4-b158-3d2999f67655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7459275-4584-42bf-a098-807a279f101f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockholdersEquity_a7459275-4584-42bf-a098-807a279f101f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_cca757e1-4bba-4244-b3ae-f397dbeec619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_TreasuryStockCommonShares_cca757e1-4bba-4244-b3ae-f397dbeec619" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d66e952-5da4-423e-b38f-a8a7aa3ae599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_NetIncomeLoss_2d66e952-5da4-423e-b38f-a8a7aa3ae599" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9295f503-ebd8-4ac3-ad2c-46af3e5c41eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9295f503-ebd8-4ac3-ad2c-46af3e5c41eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e252bdaa-a80b-4974-a091-d648d9060291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e252bdaa-a80b-4974-a091-d648d9060291" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_508dff15-5c07-48e6-85bf-f477d64a12a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_508dff15-5c07-48e6-85bf-f477d64a12a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_82d3c191-6977-4c99-8caa-394204200e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_82d3c191-6977-4c99-8caa-394204200e84" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_19726329-96c5-4615-8740-d13377d2d3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_19726329-96c5-4615-8740-d13377d2d3ac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eec202ec-8227-4443-b2f4-4ee9b5c94608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eec202ec-8227-4443-b2f4-4ee9b5c94608" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6ff2b965-220f-4515-98a0-bd99fc0f6cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6ff2b965-220f-4515-98a0-bd99fc0f6cc0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_50f149ed-9e00-406d-9dd0-5aa194230d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2c6f19db-0aae-4ac7-8f4a-a286c4ba1a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_958000ed-948f-4ccf-9df4-6f9ece636671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesGoingConcernDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfe73d37-cc7e-4dc8-a4aa-7495a3bb866e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfe73d37-cc7e-4dc8-a4aa-7495a3bb866e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfe73d37-cc7e-4dc8-a4aa-7495a3bb866e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfe73d37-cc7e-4dc8-a4aa-7495a3bb866e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfe73d37-cc7e-4dc8-a4aa-7495a3bb866e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfe73d37-cc7e-4dc8-a4aa-7495a3bb866e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_474d9ee5-5bed-43cb-826f-575788baaa54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:to="loc_us-gaap_LineOfCreditMember_474d9ee5-5bed-43cb-826f-575788baaa54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ad6ebbec-90f1-4a22-9dab-f8ee8cebf96e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ad6ebbec-90f1-4a22-9dab-f8ee8cebf96e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a36da7d2-50f2-401c-8a65-0dc5e867b914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:to="loc_us-gaap_SeniorNotesMember_a36da7d2-50f2-401c-8a65-0dc5e867b914" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5d7ddbf6-372b-4d92-af34-73cd1da15b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:to="loc_us-gaap_CreditFacilityAxis_5d7ddbf6-372b-4d92-af34-73cd1da15b29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5d7ddbf6-372b-4d92-af34-73cd1da15b29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_5d7ddbf6-372b-4d92-af34-73cd1da15b29" xlink:to="loc_us-gaap_CreditFacilityDomain_5d7ddbf6-372b-4d92-af34-73cd1da15b29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c112a660-70ab-4b5b-a946-65ad6bc755e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_5d7ddbf6-372b-4d92-af34-73cd1da15b29" xlink:to="loc_us-gaap_CreditFacilityDomain_c112a660-70ab-4b5b-a946-65ad6bc755e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2b0a476b-ebef-43f6-ba89-691dbad8a929" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c112a660-70ab-4b5b-a946-65ad6bc755e3" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2b0a476b-ebef-43f6-ba89-691dbad8a929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_a409706c-f0bc-4820-a4ff-829c2507afea" xlink:href="ebs-20231231.xsd#ebs_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c112a660-70ab-4b5b-a946-65ad6bc755e3" xlink:to="loc_ebs_TermLoanFacilityMember_a409706c-f0bc-4820-a4ff-829c2507afea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_74090736-6d62-454e-8462-5d5c011c494f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:to="loc_us-gaap_DebtInstrumentAxis_74090736-6d62-454e-8462-5d5c011c494f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74090736-6d62-454e-8462-5d5c011c494f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_74090736-6d62-454e-8462-5d5c011c494f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74090736-6d62-454e-8462-5d5c011c494f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_df692c9b-b42d-4332-92df-b2821a5ecca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_74090736-6d62-454e-8462-5d5c011c494f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_df692c9b-b42d-4332-92df-b2821a5ecca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_323b3c03-6995-4c89-a067-0bd689ee95d1" xlink:href="ebs-20231231.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df692c9b-b42d-4332-92df-b2821a5ecca5" xlink:to="loc_ebs_AmendedCreditAgreementMember_323b3c03-6995-4c89-a067-0bd689ee95d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_f44d6218-bd99-42bc-9efc-66dde36d2d4c" xlink:href="ebs-20231231.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df692c9b-b42d-4332-92df-b2821a5ecca5" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_f44d6218-bd99-42bc-9efc-66dde36d2d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a8f72ddb-4cbe-4fe6-baed-efeb3815b067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:to="loc_us-gaap_RestructuringPlanAxis_a8f72ddb-4cbe-4fe6-baed-efeb3815b067" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a8f72ddb-4cbe-4fe6-baed-efeb3815b067_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_a8f72ddb-4cbe-4fe6-baed-efeb3815b067" xlink:to="loc_us-gaap_RestructuringPlanDomain_a8f72ddb-4cbe-4fe6-baed-efeb3815b067_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_33be5009-e1c0-4858-a7df-83ceb6860f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_a8f72ddb-4cbe-4fe6-baed-efeb3815b067" xlink:to="loc_us-gaap_RestructuringPlanDomain_33be5009-e1c0-4858-a7df-83ceb6860f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_ab192c1f-1249-4524-9559-2d5233457b94" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_33be5009-e1c0-4858-a7df-83ceb6860f97" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_ab192c1f-1249-4524-9559-2d5233457b94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_9f7072d4-7adb-475b-a817-db03da76d0e2" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_33be5009-e1c0-4858-a7df-83ceb6860f97" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_9f7072d4-7adb-475b-a817-db03da76d0e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b4a077ab-436c-4899-b201-79e238351f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_LongTermDebt_b4a077ab-436c-4899-b201-79e238351f5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c2cda4b-544e-4b83-a73b-4b04219179d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c2cda4b-544e-4b83-a73b-4b04219179d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_0ba47a82-b87c-4fba-8b41-a7b278f53db0" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_0ba47a82-b87c-4fba-8b41-a7b278f53db0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_8281bb67-2a65-4e64-a11f-72db7744af5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_8281bb67-2a65-4e64-a11f-72db7744af5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_d55bb392-2c92-43db-93b5-6c4a4999da97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_LineOfCredit_d55bb392-2c92-43db-93b5-6c4a4999da97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b1d82739-ce3f-486c-b455-68d588bf4239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b1d82739-ce3f-486c-b455-68d588bf4239" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_83bd84f7-cc32-468d-b8ce-71d1e0bb6b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_83bd84f7-cc32-468d-b8ce-71d1e0bb6b16" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0b4187c8-e987-4bf2-be83-c0bfdfdc1978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0b4187c8-e987-4bf2-be83-c0bfdfdc1978" xlink:to="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_168b0970-90d2-4df9-bcff-b7fe8ae5c8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_168b0970-90d2-4df9-bcff-b7fe8ae5c8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_168b0970-90d2-4df9-bcff-b7fe8ae5c8e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_168b0970-90d2-4df9-bcff-b7fe8ae5c8e4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_168b0970-90d2-4df9-bcff-b7fe8ae5c8e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d818d1-a1cd-495a-80c9-36c893f81f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_168b0970-90d2-4df9-bcff-b7fe8ae5c8e4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d818d1-a1cd-495a-80c9-36c893f81f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_364295ae-5876-4203-8c52-40f30917306a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d818d1-a1cd-495a-80c9-36c893f81f2c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_364295ae-5876-4203-8c52-40f30917306a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_67676fcb-814a-4b13-bd5d-d98b4ab0e41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_67676fcb-814a-4b13-bd5d-d98b4ab0e41f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_67676fcb-814a-4b13-bd5d-d98b4ab0e41f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_67676fcb-814a-4b13-bd5d-d98b4ab0e41f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_67676fcb-814a-4b13-bd5d-d98b4ab0e41f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d766df16-6e7a-4808-ad84-913f16a59c09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_67676fcb-814a-4b13-bd5d-d98b4ab0e41f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d766df16-6e7a-4808-ad84-913f16a59c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_56acd602-57bc-41ed-a248-f7227114d7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d766df16-6e7a-4808-ad84-913f16a59c09" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_56acd602-57bc-41ed-a248-f7227114d7a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e29f4b29-94b3-43e1-8f66-6e390ad5ddf4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:to="loc_srt_MajorCustomersAxis_e29f4b29-94b3-43e1-8f66-6e390ad5ddf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e29f4b29-94b3-43e1-8f66-6e390ad5ddf4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e29f4b29-94b3-43e1-8f66-6e390ad5ddf4" xlink:to="loc_srt_NameOfMajorCustomerDomain_e29f4b29-94b3-43e1-8f66-6e390ad5ddf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9128716f-815f-4171-bd38-4807d76ac75a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e29f4b29-94b3-43e1-8f66-6e390ad5ddf4" xlink:to="loc_srt_NameOfMajorCustomerDomain_9128716f-815f-4171-bd38-4807d76ac75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_596c56ee-23c9-4a65-be14-08dcfbd88334" xlink:href="ebs-20231231.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9128716f-815f-4171-bd38-4807d76ac75a" xlink:to="loc_ebs_UnitedStatesGovernmentMember_596c56ee-23c9-4a65-be14-08dcfbd88334" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_893ac02f-fb84-4149-b0ef-dd14f37195f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0b4187c8-e987-4bf2-be83-c0bfdfdc1978" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_893ac02f-fb84-4149-b0ef-dd14f37195f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_855934cc-ad53-4d31-8109-19b636909b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b74392d-2a7f-4233-a015-e2a3b04c6834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_855934cc-ad53-4d31-8109-19b636909b9a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b74392d-2a7f-4233-a015-e2a3b04c6834" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4cc0c553-5a27-4f02-b8ad-8ac7f1d8895e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b74392d-2a7f-4233-a015-e2a3b04c6834" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4cc0c553-5a27-4f02-b8ad-8ac7f1d8895e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cc0c553-5a27-4f02-b8ad-8ac7f1d8895e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4cc0c553-5a27-4f02-b8ad-8ac7f1d8895e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cc0c553-5a27-4f02-b8ad-8ac7f1d8895e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4cc0c553-5a27-4f02-b8ad-8ac7f1d8895e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f6e2b957-c5ba-4b03-8d1d-0682c67e8155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:to="loc_us-gaap_BuildingMember_f6e2b957-c5ba-4b03-8d1d-0682c67e8155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember_89bc3fa6-01aa-4d61-a774-61d298a8e532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:to="loc_us-gaap_BuildingImprovementsMember_89bc3fa6-01aa-4d61-a774-61d298a8e532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f8b19019-2867-4f7e-8552-5e1dbd63cbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f8b19019-2867-4f7e-8552-5e1dbd63cbbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_caaab316-2459-4ab4-8fed-47e65e8b949f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_caaab316-2459-4ab4-8fed-47e65e8b949f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc87778c-89c4-449c-9268-037a85f5036c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b74392d-2a7f-4233-a015-e2a3b04c6834" xlink:to="loc_srt_RangeAxis_bc87778c-89c4-449c-9268-037a85f5036c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc87778c-89c4-449c-9268-037a85f5036c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bc87778c-89c4-449c-9268-037a85f5036c" xlink:to="loc_srt_RangeMember_bc87778c-89c4-449c-9268-037a85f5036c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d82f0a34-bb78-43c2-a888-089ae9b23bf8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bc87778c-89c4-449c-9268-037a85f5036c" xlink:to="loc_srt_RangeMember_d82f0a34-bb78-43c2-a888-089ae9b23bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59f43e66-9380-43f6-b011-5462faeaeb0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d82f0a34-bb78-43c2-a888-089ae9b23bf8" xlink:to="loc_srt_MinimumMember_59f43e66-9380-43f6-b011-5462faeaeb0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b9d22b5-fa5a-42a6-aeb2-13ae291db1f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d82f0a34-bb78-43c2-a888-089ae9b23bf8" xlink:to="loc_srt_MaximumMember_1b9d22b5-fa5a-42a6-aeb2-13ae291db1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b2210749-3956-4870-9512-e829f2dedc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_855934cc-ad53-4d31-8109-19b636909b9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b2210749-3956-4870-9512-e829f2dedc9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4689f263-7887-414b-870a-e840848c608d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4689f263-7887-414b-870a-e840848c608d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_acecb414-bf89-4818-96ef-ff9b50ea1c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4689f263-7887-414b-870a-e840848c608d" xlink:to="loc_us-gaap_PlanNameAxis_acecb414-bf89-4818-96ef-ff9b50ea1c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_acecb414-bf89-4818-96ef-ff9b50ea1c27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_acecb414-bf89-4818-96ef-ff9b50ea1c27" xlink:to="loc_us-gaap_PlanNameDomain_acecb414-bf89-4818-96ef-ff9b50ea1c27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_58c30de1-0086-4d44-9500-1d9ff80ca5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_acecb414-bf89-4818-96ef-ff9b50ea1c27" xlink:to="loc_us-gaap_PlanNameDomain_58c30de1-0086-4d44-9500-1d9ff80ca5a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2023EquityInducementPlanMember_88cc87da-33a6-48d7-aa33-92500dc27d3b" xlink:href="ebs-20231231.xsd#ebs_A2023EquityInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_58c30de1-0086-4d44-9500-1d9ff80ca5a5" xlink:to="loc_ebs_A2023EquityInducementPlanMember_88cc87da-33a6-48d7-aa33-92500dc27d3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans_f28c2a0b-6ac8-4166-b589-cb5f73c32220" xlink:href="ebs-20231231.xsd#ebs_NumberOfShareBasedEmployeeCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:to="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans_f28c2a0b-6ac8-4166-b589-cb5f73c32220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_875b0394-35ba-474c-a098-f8e1200f29ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_875b0394-35ba-474c-a098-f8e1200f29ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_520becc9-7655-45ad-8520-7d1bcb596d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_520becc9-7655-45ad-8520-7d1bcb596d3c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b5f804b4-35c7-46f0-9c9d-364d2c9c6e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_e004defe-94bd-4791-9c50-e7b9f87637ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b5f804b4-35c7-46f0-9c9d-364d2c9c6e9b" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_e004defe-94bd-4791-9c50-e7b9f87637ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_521dd64f-2550-4578-9788-72917d67fc90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_e004defe-94bd-4791-9c50-e7b9f87637ec" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_521dd64f-2550-4578-9788-72917d67fc90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_521dd64f-2550-4578-9788-72917d67fc90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_521dd64f-2550-4578-9788-72917d67fc90" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_521dd64f-2550-4578-9788-72917d67fc90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_081d4d6b-fc06-4efc-a3a4-686391ee9fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_521dd64f-2550-4578-9788-72917d67fc90" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_081d4d6b-fc06-4efc-a3a4-686391ee9fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_874ef520-d4d1-47d9-9a0a-b22a9ed6556d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_081d4d6b-fc06-4efc-a3a4-686391ee9fc3" xlink:to="loc_us-gaap_InterestRateSwapMember_874ef520-d4d1-47d9-9a0a-b22a9ed6556d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f4d8ce79-1ea2-46f7-8ab8-0a3c0a56a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_e004defe-94bd-4791-9c50-e7b9f87637ec" xlink:to="loc_us-gaap_HedgingDesignationAxis_f4d8ce79-1ea2-46f7-8ab8-0a3c0a56a81f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f4d8ce79-1ea2-46f7-8ab8-0a3c0a56a81f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_f4d8ce79-1ea2-46f7-8ab8-0a3c0a56a81f" xlink:to="loc_us-gaap_HedgingDesignationDomain_f4d8ce79-1ea2-46f7-8ab8-0a3c0a56a81f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1078aea6-877e-4748-9e61-a4dcebc0fa97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_f4d8ce79-1ea2-46f7-8ab8-0a3c0a56a81f" xlink:to="loc_us-gaap_HedgingDesignationDomain_1078aea6-877e-4748-9e61-a4dcebc0fa97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e8da609c-62f0-4dde-a656-39dc6cb02811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1078aea6-877e-4748-9e61-a4dcebc0fa97" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e8da609c-62f0-4dde-a656-39dc6cb02811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0b0197c9-035b-4bd4-b69f-44750c17d803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b5f804b4-35c7-46f0-9c9d-364d2c9c6e9b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0b0197c9-035b-4bd4-b69f-44750c17d803" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DivestitureDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DivestitureDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DivestitureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_74da88a3-867a-4d2e-ae10-f7d5f036b9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_74da88a3-867a-4d2e-ae10-f7d5f036b9d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_74da88a3-867a-4d2e-ae10-f7d5f036b9d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_74da88a3-867a-4d2e-ae10-f7d5f036b9d4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_74da88a3-867a-4d2e-ae10-f7d5f036b9d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a85423ed-46f1-42eb-b28b-b6c5d5ea58af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_74da88a3-867a-4d2e-ae10-f7d5f036b9d4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a85423ed-46f1-42eb-b28b-b6c5d5ea58af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f1636eba-c896-4fd9-9038-6592a678dfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a85423ed-46f1-42eb-b28b-b6c5d5ea58af" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f1636eba-c896-4fd9-9038-6592a678dfa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8297595e-18b0-4b1c-aa49-fd48f78a46ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8297595e-18b0-4b1c-aa49-fd48f78a46ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8297595e-18b0-4b1c-aa49-fd48f78a46ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8297595e-18b0-4b1c-aa49-fd48f78a46ee" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8297595e-18b0-4b1c-aa49-fd48f78a46ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c7ed2c1-db98-4230-83ff-0ee2b80698df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8297595e-18b0-4b1c-aa49-fd48f78a46ee" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c7ed2c1-db98-4230-83ff-0ee2b80698df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_43310554-2308-414f-98d1-43545e9e38e4" xlink:href="ebs-20231231.xsd#ebs_TravelHealthBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c7ed2c1-db98-4230-83ff-0ee2b80698df" xlink:to="loc_ebs_TravelHealthBusinessMember_43310554-2308-414f-98d1-43545e9e38e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_5a920333-633c-4e33-a1f0-6c9b67a5ad29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_5a920333-633c-4e33-a1f0-6c9b67a5ad29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_5a920333-633c-4e33-a1f0-6c9b67a5ad29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5a920333-633c-4e33-a1f0-6c9b67a5ad29" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_5a920333-633c-4e33-a1f0-6c9b67a5ad29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_6ddd5e45-70f1-43e8-afd7-a6a93b14ed4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5a920333-633c-4e33-a1f0-6c9b67a5ad29" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_6ddd5e45-70f1-43e8-afd7-a6a93b14ed4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DevelopmentBasedMilestonesMember_7f15a59b-00f9-435a-b428-7c188d350a51" xlink:href="ebs-20231231.xsd#ebs_DevelopmentBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_6ddd5e45-70f1-43e8-afd7-a6a93b14ed4c" xlink:to="loc_ebs_DevelopmentBasedMilestonesMember_7f15a59b-00f9-435a-b428-7c188d350a51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SalesBasedMilestonesMember_15847d51-9b6a-41b5-8c22-28220fb204a6" xlink:href="ebs-20231231.xsd#ebs_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_6ddd5e45-70f1-43e8-afd7-a6a93b14ed4c" xlink:to="loc_ebs_SalesBasedMilestonesMember_15847d51-9b6a-41b5-8c22-28220fb204a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a98fedcf-b2e7-4bbe-80ad-90998d54bd29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a98fedcf-b2e7-4bbe-80ad-90998d54bd29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_84826903-75e3-45fa-a6f9-abc3ce54cf7d" xlink:href="ebs-20231231.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_84826903-75e3-45fa-a6f9-abc3ce54cf7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_9e8f3814-18aa-45bb-aabf-7fdd45ad0a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_9e8f3814-18aa-45bb-aabf-7fdd45ad0a47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DispositionOfBusinessTransactionCosts_922555e5-aa54-43c6-8096-60960d424824" xlink:href="ebs-20231231.xsd#ebs_DispositionOfBusinessTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_ebs_DispositionOfBusinessTransactionCosts_922555e5-aa54-43c6-8096-60960d424824" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_aed2cac4-60cc-4ae2-93c9-c9963a028eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_aed2cac4-60cc-4ae2-93c9-c9963a028eee" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LonglivedassetimpairmentandrestructuringchargesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8ea77115-deda-4003-bc28-f79361f1b492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8ea77115-deda-4003-bc28-f79361f1b492" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_aeda3f9b-9cff-4bf7-9ee3-6e757125e382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8ea77115-deda-4003-bc28-f79361f1b492" xlink:to="loc_us-gaap_RestructuringPlanAxis_aeda3f9b-9cff-4bf7-9ee3-6e757125e382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_aeda3f9b-9cff-4bf7-9ee3-6e757125e382_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_aeda3f9b-9cff-4bf7-9ee3-6e757125e382" xlink:to="loc_us-gaap_RestructuringPlanDomain_aeda3f9b-9cff-4bf7-9ee3-6e757125e382_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e4b7207f-bf1a-4bf8-bcbe-8b31351a4774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_aeda3f9b-9cff-4bf7-9ee3-6e757125e382" xlink:to="loc_us-gaap_RestructuringPlanDomain_e4b7207f-bf1a-4bf8-bcbe-8b31351a4774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_238b72c7-81b5-426c-8668-1f4eea3d02d4" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e4b7207f-bf1a-4bf8-bcbe-8b31351a4774" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_238b72c7-81b5-426c-8668-1f4eea3d02d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_b2e9e848-c946-4768-a77f-084aed60e94b" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e4b7207f-bf1a-4bf8-bcbe-8b31351a4774" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_b2e9e848-c946-4768-a77f-084aed60e94b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ec6a73c7-3306-4d0a-bd4e-597a680e5c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ec6a73c7-3306-4d0a-bd4e-597a680e5c43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b964e111-426d-4f7f-acbf-1dc567d3fb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b964e111-426d-4f7f-acbf-1dc567d3fb39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_32ba3272-a269-4a32-85e6-0a510f296782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:to="loc_us-gaap_RestructuringCharges_32ba3272-a269-4a32-85e6-0a510f296782" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_65d6aee5-ea13-4740-8994-cb4ffc3d2251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_a627aadc-fcd1-4732-bdda-3555851be278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_65d6aee5-ea13-4740-8994-cb4ffc3d2251" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_a627aadc-fcd1-4732-bdda-3555851be278" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_c6c91c97-9963-4b78-ad80-4db7584b9ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_a627aadc-fcd1-4732-bdda-3555851be278" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_c6c91c97-9963-4b78-ad80-4db7584b9ec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_c6c91c97-9963-4b78-ad80-4db7584b9ec1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_c6c91c97-9963-4b78-ad80-4db7584b9ec1" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_c6c91c97-9963-4b78-ad80-4db7584b9ec1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_c6c91c97-9963-4b78-ad80-4db7584b9ec1" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_e9597c04-5906-48ef-b575-8015ba5ee0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_e9597c04-5906-48ef-b575-8015ba5ee0e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_84e4adcf-8869-42f1-8867-8eabc205324e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_84e4adcf-8869-42f1-8867-8eabc205324e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_63144831-be7a-4084-b7d5-ec7d6d8056c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_63144831-be7a-4084-b7d5-ec7d6d8056c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_f068b2ba-fd67-4b99-8846-462430e5b179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:to="loc_us-gaap_ConstructionInProgressMember_f068b2ba-fd67-4b99-8846-462430e5b179" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3402cd5f-3b41-4875-a488-e2e330811421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_65d6aee5-ea13-4740-8994-cb4ffc3d2251" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3402cd5f-3b41-4875-a488-e2e330811421" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ef62d67c-8ed4-4d56-8160-12bf1452e8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ef62d67c-8ed4-4d56-8160-12bf1452e8b6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_4e63608c-3027-4c71-9735-682321fd0df2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:to="loc_srt_ConsolidationItemsAxis_4e63608c-3027-4c71-9735-682321fd0df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4e63608c-3027-4c71-9735-682321fd0df2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_4e63608c-3027-4c71-9735-682321fd0df2" xlink:to="loc_srt_ConsolidationItemsDomain_4e63608c-3027-4c71-9735-682321fd0df2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c590dc30-2f99-447c-88a6-3e12ed4e1021" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_4e63608c-3027-4c71-9735-682321fd0df2" xlink:to="loc_srt_ConsolidationItemsDomain_c590dc30-2f99-447c-88a6-3e12ed4e1021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_322da45e-b771-471b-9157-c3c396ecad23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c590dc30-2f99-447c-88a6-3e12ed4e1021" xlink:to="loc_us-gaap_OperatingSegmentsMember_322da45e-b771-471b-9157-c3c396ecad23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_fbb6b1f8-1056-4555-a5df-0f31fb66aa66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c590dc30-2f99-447c-88a6-3e12ed4e1021" xlink:to="loc_us-gaap_CorporateNonSegmentMember_fbb6b1f8-1056-4555-a5df-0f31fb66aa66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_79884343-d9aa-4f9e-8da3-51730d580fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_79884343-d9aa-4f9e-8da3-51730d580fb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_79884343-d9aa-4f9e-8da3-51730d580fb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_79884343-d9aa-4f9e-8da3-51730d580fb0" xlink:to="loc_us-gaap_SegmentDomain_79884343-d9aa-4f9e-8da3-51730d580fb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_79884343-d9aa-4f9e-8da3-51730d580fb0" xlink:to="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_b016adba-3080-4a56-a54a-03f6f924c02b" xlink:href="ebs-20231231.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:to="loc_ebs_CommercialProductsSegmentMember_b016adba-3080-4a56-a54a-03f6f924c02b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_a33ee17a-c2d4-4485-aad7-869db044a737" xlink:href="ebs-20231231.xsd#ebs_MCMProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:to="loc_ebs_MCMProductsSegmentMember_a33ee17a-c2d4-4485-aad7-869db044a737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_a0cf73ed-0f7d-4e58-8e26-2d067c6a365c" xlink:href="ebs-20231231.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:to="loc_ebs_ServicesSegmentMember_a0cf73ed-0f7d-4e58-8e26-2d067c6a365c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_623f9e5e-b0b4-4ea8-a3f6-9eb5c363ce73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_623f9e5e-b0b4-4ea8-a3f6-9eb5c363ce73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_623f9e5e-b0b4-4ea8-a3f6-9eb5c363ce73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_623f9e5e-b0b4-4ea8-a3f6-9eb5c363ce73" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_623f9e5e-b0b4-4ea8-a3f6-9eb5c363ce73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_623f9e5e-b0b4-4ea8-a3f6-9eb5c363ce73" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedResearchAndDevelopmentMember_04154d79-42c2-4219-8ae9-cc7ff628b625" xlink:href="ebs-20231231.xsd#ebs_UnallocatedResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:to="loc_ebs_UnallocatedResearchAndDevelopmentMember_04154d79-42c2-4219-8ae9-cc7ff628b625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_0bc4d148-4043-4765-a911-6a24a6915f22" xlink:href="ebs-20231231.xsd#ebs_EmployeeTransitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:to="loc_ebs_EmployeeTransitionMember_0bc4d148-4043-4765-a911-6a24a6915f22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_265549f8-f066-4b2c-abb9-e272fa20fe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_265549f8-f066-4b2c-abb9-e272fa20fe3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_e480fd98-566f-4ae5-8819-55e88f1e9f96" xlink:href="ebs-20231231.xsd#ebs_EmployeeBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:to="loc_ebs_EmployeeBenefitsMember_e480fd98-566f-4ae5-8819-55e88f1e9f96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_cf7878d0-ff57-494a-b4c3-ea7b32b80ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ef62d67c-8ed4-4d56-8160-12bf1452e8b6" xlink:to="loc_us-gaap_RestructuringCharges_cf7878d0-ff57-494a-b4c3-ea7b32b80ab0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8135e06b-227b-4d12-aad6-4a73dc32cc41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72550e0e-9e10-4f6d-8d14-ee19cbb1492b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8135e06b-227b-4d12-aad6-4a73dc32cc41" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72550e0e-9e10-4f6d-8d14-ee19cbb1492b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8a32cf3f-d071-49f8-ac78-a7426cb699bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72550e0e-9e10-4f6d-8d14-ee19cbb1492b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8a32cf3f-d071-49f8-ac78-a7426cb699bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8a32cf3f-d071-49f8-ac78-a7426cb699bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8a32cf3f-d071-49f8-ac78-a7426cb699bc" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8a32cf3f-d071-49f8-ac78-a7426cb699bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8a32cf3f-d071-49f8-ac78-a7426cb699bc" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_73bec6d5-b294-4853-9f76-dec32c8e5642" xlink:href="ebs-20231231.xsd#ebs_EmployeeTransitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:to="loc_ebs_EmployeeTransitionMember_73bec6d5-b294-4853-9f76-dec32c8e5642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_73fc66d6-cf65-4904-b460-e3296697c2df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:to="loc_us-gaap_EmployeeSeveranceMember_73fc66d6-cf65-4904-b460-e3296697c2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_3c237bf3-d225-4b53-b8d9-57ff8b93f406" xlink:href="ebs-20231231.xsd#ebs_EmployeeBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:to="loc_ebs_EmployeeBenefitsMember_3c237bf3-d225-4b53-b8d9-57ff8b93f406" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a593d4f5-c999-4fee-be7b-e5c1d047189e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72550e0e-9e10-4f6d-8d14-ee19cbb1492b" xlink:to="loc_us-gaap_RestructuringPlanAxis_a593d4f5-c999-4fee-be7b-e5c1d047189e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a593d4f5-c999-4fee-be7b-e5c1d047189e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_a593d4f5-c999-4fee-be7b-e5c1d047189e" xlink:to="loc_us-gaap_RestructuringPlanDomain_a593d4f5-c999-4fee-be7b-e5c1d047189e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0ae741b6-067b-499d-a016-7a789010e063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_a593d4f5-c999-4fee-be7b-e5c1d047189e" xlink:to="loc_us-gaap_RestructuringPlanDomain_0ae741b6-067b-499d-a016-7a789010e063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_e55bcc9c-0434-4398-b518-0f168ace19f2" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0ae741b6-067b-499d-a016-7a789010e063" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_e55bcc9c-0434-4398-b518-0f168ace19f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_e95c4e73-8873-4aa5-bb6e-6d7026ed9d50" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0ae741b6-067b-499d-a016-7a789010e063" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_e95c4e73-8873-4aa5-bb6e-6d7026ed9d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8135e06b-227b-4d12-aad6-4a73dc32cc41" xlink:to="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_412e92f3-793b-4447-8cdb-b93e276c6bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:to="loc_us-gaap_RestructuringReserve_412e92f3-793b-4447-8cdb-b93e276c6bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d9b48d92-487d-4dfd-8cce-f6f542868b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:to="loc_us-gaap_RestructuringCharges_d9b48d92-487d-4dfd-8cce-f6f542868b02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_96f96e25-e484-46c9-895d-f4c8f23c0749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:to="loc_us-gaap_PaymentsForRestructuring_96f96e25-e484-46c9-895d-f4c8f23c0749" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_89c5c538-7835-4372-a994-75e52fcdb4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_602087ab-2bf2-48ec-abf3-059f0a761f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_364811bf-8ee8-4498-b8d0-358c0afe5a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_602087ab-2bf2-48ec-abf3-059f0a761f50" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_364811bf-8ee8-4498-b8d0-358c0afe5a69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60211ff2-b200-42c9-9312-7ce1eb2b682a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_364811bf-8ee8-4498-b8d0-358c0afe5a69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60211ff2-b200-42c9-9312-7ce1eb2b682a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60211ff2-b200-42c9-9312-7ce1eb2b682a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60211ff2-b200-42c9-9312-7ce1eb2b682a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60211ff2-b200-42c9-9312-7ce1eb2b682a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60211ff2-b200-42c9-9312-7ce1eb2b682a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_5c5e0f4d-a50e-452a-b836-08021d6fb507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_5c5e0f4d-a50e-452a-b836-08021d6fb507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fafdf39c-1c76-4aa1-974e-2d2411d870b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fafdf39c-1c76-4aa1-974e-2d2411d870b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_88cac5e2-1d4a-4b46-826d-95244ed43337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_88cac5e2-1d4a-4b46-826d-95244ed43337" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_34bc4c92-66f2-43dc-bbed-bc31e9047cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_34bc4c92-66f2-43dc-bbed-bc31e9047cfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_666f292b-3d1b-437e-ac67-4078cb014161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_ConstructionInProgressMember_666f292b-3d1b-437e-ac67-4078cb014161" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_602087ab-2bf2-48ec-abf3-059f0a761f50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3c78de11-9d62-42b5-b235-ab9ff8e41bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3c78de11-9d62-42b5-b235-ab9ff8e41bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a8d031f2-9d0a-4b9f-b502-d060df975e54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a8d031f2-9d0a-4b9f-b502-d060df975e54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9b540080-19e4-4f60-8d07-8e271402b52a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9b540080-19e4-4f60-8d07-8e271402b52a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c42bcbef-a517-4243-9e68-baa1fc6713eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c42bcbef-a517-4243-9e68-baa1fc6713eb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#PropertyplantandequipmentnetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e169cd83-7b3f-430d-bfe1-df95e5b4f495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2ab6995-b82e-459e-9c70-9b1c5b2c1d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e169cd83-7b3f-430d-bfe1-df95e5b4f495" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2ab6995-b82e-459e-9c70-9b1c5b2c1d8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_54374bdf-c45f-437f-9483-b2952a98a4e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2ab6995-b82e-459e-9c70-9b1c5b2c1d8c" xlink:to="loc_srt_MajorCustomersAxis_54374bdf-c45f-437f-9483-b2952a98a4e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_54374bdf-c45f-437f-9483-b2952a98a4e9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_54374bdf-c45f-437f-9483-b2952a98a4e9" xlink:to="loc_srt_NameOfMajorCustomerDomain_54374bdf-c45f-437f-9483-b2952a98a4e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_059726c0-6b12-412e-bbb5-ec6a69100c89" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_54374bdf-c45f-437f-9483-b2952a98a4e9" xlink:to="loc_srt_NameOfMajorCustomerDomain_059726c0-6b12-412e-bbb5-ec6a69100c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_92b69d33-f7d9-4713-9379-91c043dcac28" xlink:href="ebs-20231231.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_059726c0-6b12-412e-bbb5-ec6a69100c89" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_92b69d33-f7d9-4713-9379-91c043dcac28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_04c2f9d0-37a0-4ee6-b682-82926da98023" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2ab6995-b82e-459e-9c70-9b1c5b2c1d8c" xlink:to="loc_srt_ProductOrServiceAxis_04c2f9d0-37a0-4ee6-b682-82926da98023" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_04c2f9d0-37a0-4ee6-b682-82926da98023_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_04c2f9d0-37a0-4ee6-b682-82926da98023" xlink:to="loc_srt_ProductsAndServicesDomain_04c2f9d0-37a0-4ee6-b682-82926da98023_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6068758b-9a79-46c9-b47c-f935c7ad068c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_04c2f9d0-37a0-4ee6-b682-82926da98023" xlink:to="loc_srt_ProductsAndServicesDomain_6068758b-9a79-46c9-b47c-f935c7ad068c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2ec0c343-5ed0-4c78-9104-547a7782a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6068758b-9a79-46c9-b47c-f935c7ad068c" xlink:to="loc_us-gaap_ServiceMember_2ec0c343-5ed0-4c78-9104-547a7782a7cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cdb3644f-e244-410a-883a-8c6594d4a35f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e169cd83-7b3f-430d-bfe1-df95e5b4f495" xlink:to="loc_us-gaap_Depreciation_cdb3644f-e244-410a-883a-8c6594d4a35f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_90969b01-5b5a-4a66-b924-d492e43bc24c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e169cd83-7b3f-430d-bfe1-df95e5b4f495" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_90969b01-5b5a-4a66-b924-d492e43bc24c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_075a0163-b83a-45d3-a00f-32f176b47187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_075a0163-b83a-45d3-a00f-32f176b47187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075a0163-b83a-45d3-a00f-32f176b47187_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_075a0163-b83a-45d3-a00f-32f176b47187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075a0163-b83a-45d3-a00f-32f176b47187_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_075a0163-b83a-45d3-a00f-32f176b47187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_05cc6a47-eaa8-4b82-99e1-53009b19c9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:to="loc_us-gaap_ProductMember_05cc6a47-eaa8-4b82-99e1-53009b19c9f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_86798ca8-f3ce-43ee-9f67-e68f3c9b0f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:to="loc_us-gaap_CustomerRelationshipsMember_86798ca8-f3ce-43ee-9f67-e68f3c9b0f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesMember_68e79568-11ab-4190-83f0-717c1819e212" xlink:href="ebs-20231231.xsd#ebs_BioservicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:to="loc_ebs_BioservicesMember_68e79568-11ab-4190-83f0-717c1819e212" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_98647c11-4811-44e8-88fd-423b9f3bf93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_98647c11-4811-44e8-88fd-423b9f3bf93d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_98647c11-4811-44e8-88fd-423b9f3bf93d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_98647c11-4811-44e8-88fd-423b9f3bf93d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_98647c11-4811-44e8-88fd-423b9f3bf93d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_273af358-636a-4018-bb08-8008736bcb91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_98647c11-4811-44e8-88fd-423b9f3bf93d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_273af358-636a-4018-bb08-8008736bcb91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_23cd94c9-8cb6-4fae-b3be-6d3fa9dc7e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_273af358-636a-4018-bb08-8008736bcb91" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_23cd94c9-8cb6-4fae-b3be-6d3fa9dc7e72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2287ad46-3fec-4b9f-a827-1322e5cdf699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2287ad46-3fec-4b9f-a827-1322e5cdf699" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2287ad46-3fec-4b9f-a827-1322e5cdf699_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2287ad46-3fec-4b9f-a827-1322e5cdf699" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2287ad46-3fec-4b9f-a827-1322e5cdf699_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6cc031d5-39db-4b9b-b63a-23cc9ca68ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2287ad46-3fec-4b9f-a827-1322e5cdf699" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6cc031d5-39db-4b9b-b63a-23cc9ca68ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_fe134382-12c6-409a-8e3b-3ce4bfb1b22e" xlink:href="ebs-20231231.xsd#ebs_TravelHealthBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6cc031d5-39db-4b9b-b63a-23cc9ca68ede" xlink:to="loc_ebs_TravelHealthBusinessMember_fe134382-12c6-409a-8e3b-3ce4bfb1b22e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_4fddc24b-a10a-4870-bfbd-cc67088ceb21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_us-gaap_AssetAcquisitionAxis_4fddc24b-a10a-4870-bfbd-cc67088ceb21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4fddc24b-a10a-4870-bfbd-cc67088ceb21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_4fddc24b-a10a-4870-bfbd-cc67088ceb21" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4fddc24b-a10a-4870-bfbd-cc67088ceb21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_78701e7a-7208-48f2-a5c2-409b750dbdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_4fddc24b-a10a-4870-bfbd-cc67088ceb21" xlink:to="loc_us-gaap_AssetAcquisitionDomain_78701e7a-7208-48f2-a5c2-409b750dbdc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixMember_e91d033c-e0db-4cd7-ba1b-b43d1de9b56c" xlink:href="ebs-20231231.xsd#ebs_ChimerixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_78701e7a-7208-48f2-a5c2-409b750dbdc1" xlink:to="loc_ebs_ChimerixMember_e91d033c-e0db-4cd7-ba1b-b43d1de9b56c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1dfce939-eca3-4cab-8c5d-027bc88fd374" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_srt_MajorCustomersAxis_1dfce939-eca3-4cab-8c5d-027bc88fd374" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1dfce939-eca3-4cab-8c5d-027bc88fd374_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1dfce939-eca3-4cab-8c5d-027bc88fd374" xlink:to="loc_srt_NameOfMajorCustomerDomain_1dfce939-eca3-4cab-8c5d-027bc88fd374_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_67f8b406-a65d-47f6-be29-ade914d7b0b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1dfce939-eca3-4cab-8c5d-027bc88fd374" xlink:to="loc_srt_NameOfMajorCustomerDomain_67f8b406-a65d-47f6-be29-ade914d7b0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_40f7df17-bb55-4729-af7d-9780c0d24a87" xlink:href="ebs-20231231.xsd#ebs_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_67f8b406-a65d-47f6-be29-ade914d7b0b5" xlink:to="loc_ebs_BARDAMember_40f7df17-bb55-4729-af7d-9780c0d24a87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9f71d3db-d4a7-4e3f-917d-d2055994bf57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_srt_ProductOrServiceAxis_9f71d3db-d4a7-4e3f-917d-d2055994bf57" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9f71d3db-d4a7-4e3f-917d-d2055994bf57_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9f71d3db-d4a7-4e3f-917d-d2055994bf57" xlink:to="loc_srt_ProductsAndServicesDomain_9f71d3db-d4a7-4e3f-917d-d2055994bf57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3585ec65-2a82-4038-9220-193230abf433" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9f71d3db-d4a7-4e3f-917d-d2055994bf57" xlink:to="loc_srt_ProductsAndServicesDomain_3585ec65-2a82-4038-9220-193230abf433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EbangaMember_bdb38153-5b25-4028-a0a1-d3e20dbc4bd7" xlink:href="ebs-20231231.xsd#ebs_EbangaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3585ec65-2a82-4038-9220-193230abf433" xlink:to="loc_ebs_EbangaMember_bdb38153-5b25-4028-a0a1-d3e20dbc4bd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ba8bc087-0ccf-4054-a581-9795bfdf9cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ba8bc087-0ccf-4054-a581-9795bfdf9cf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b5101c5-afaf-4548-a271-62f5e6076f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b5101c5-afaf-4548-a271-62f5e6076f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_674c923c-0376-48a9-b609-e557575a53de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_674c923c-0376-48a9-b609-e557575a53de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfd158a9-a54b-433b-961c-413c9c80fdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfd158a9-a54b-433b-961c-413c9c80fdcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_a034e0f8-4d84-4c58-8677-223c0b62e8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_a034e0f8-4d84-4c58-8677-223c0b62e8a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_e4e894b3-c429-4d86-b3f6-3d2a4e0cb034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_e4e894b3-c429-4d86-b3f6-3d2a4e0cb034" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevenueFromContractWithCustomerTermOfContract_644c3bdb-4deb-476a-b962-80f24d1ab835" xlink:href="ebs-20231231.xsd#ebs_RevenueFromContractWithCustomerTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_ebs_RevenueFromContractWithCustomerTermOfContract_644c3bdb-4deb-476a-b962-80f24d1ab835" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f777af68-5297-491c-b194-0bde6c180ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c88a923d-f73a-445d-88c8-041a8f1fb939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_f777af68-5297-491c-b194-0bde6c180ada" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c88a923d-f73a-445d-88c8-041a8f1fb939" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_b9d9a8e5-e3d9-49b6-8a6f-9e857a1fb716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c88a923d-f73a-445d-88c8-041a8f1fb939" xlink:to="loc_us-gaap_ReportingUnitAxis_b9d9a8e5-e3d9-49b6-8a6f-9e857a1fb716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_b9d9a8e5-e3d9-49b6-8a6f-9e857a1fb716_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_b9d9a8e5-e3d9-49b6-8a6f-9e857a1fb716" xlink:to="loc_us-gaap_ReportingUnitDomain_b9d9a8e5-e3d9-49b6-8a6f-9e857a1fb716_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_c4914b3b-cb30-4ff7-a25e-f277c38dc692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_b9d9a8e5-e3d9-49b6-8a6f-9e857a1fb716" xlink:to="loc_us-gaap_ReportingUnitDomain_c4914b3b-cb30-4ff7-a25e-f277c38dc692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsMember_d66c70d0-2b79-4eb7-8e14-f0d253f32336" xlink:href="ebs-20231231.xsd#ebs_MCMProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_c4914b3b-cb30-4ff7-a25e-f277c38dc692" xlink:to="loc_ebs_MCMProductsMember_d66c70d0-2b79-4eb7-8e14-f0d253f32336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4e353fd8-063f-4ef8-ba97-fda409eeb7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_f777af68-5297-491c-b194-0bde6c180ada" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4e353fd8-063f-4ef8-ba97-fda409eeb7b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_189859b7-21d6-4568-b576-023d35649550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_f777af68-5297-491c-b194-0bde6c180ada" xlink:to="loc_us-gaap_Goodwill_189859b7-21d6-4568-b576-023d35649550" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9903083b-357a-4c73-b050-e0410010e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9903083b-357a-4c73-b050-e0410010e5f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8dd9bcdb-7f41-45c9-8630-8deb74b8e90a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9903083b-357a-4c73-b050-e0410010e5f3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8dd9bcdb-7f41-45c9-8630-8deb74b8e90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8dd9bcdb-7f41-45c9-8630-8deb74b8e90a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8dd9bcdb-7f41-45c9-8630-8deb74b8e90a" xlink:to="loc_us-gaap_SegmentDomain_8dd9bcdb-7f41-45c9-8630-8deb74b8e90a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8dd9bcdb-7f41-45c9-8630-8deb74b8e90a" xlink:to="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_308abc7d-0a58-4937-b844-404ffe4e3032" xlink:href="ebs-20231231.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:to="loc_ebs_CommercialProductsSegmentMember_308abc7d-0a58-4937-b844-404ffe4e3032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_74be4052-3d90-41c1-967d-1231e696cdea" xlink:href="ebs-20231231.xsd#ebs_MCMProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:to="loc_ebs_MCMProductsSegmentMember_74be4052-3d90-41c1-967d-1231e696cdea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_3510baeb-5067-4636-9d6d-c856fda9a1e2" xlink:href="ebs-20231231.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:to="loc_ebs_ServicesSegmentMember_3510baeb-5067-4636-9d6d-c856fda9a1e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_935cae7d-1fd0-42c8-8ee5-c291a82c0584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:to="loc_us-gaap_GoodwillRollForward_935cae7d-1fd0-42c8-8ee5-c291a82c0584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31d2dff8-efb0-476c-9e61-67c0afff7285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_935cae7d-1fd0-42c8-8ee5-c291a82c0584" xlink:to="loc_us-gaap_Goodwill_31d2dff8-efb0-476c-9e61-67c0afff7285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_635b5aec-f690-4d8e-81cf-c29cb0796a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_935cae7d-1fd0-42c8-8ee5-c291a82c0584" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_635b5aec-f690-4d8e-81cf-c29cb0796a9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9ea9c902-5fa5-4bd5-a536-dd3bf5c2b0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_123edcdd-ca44-4cdf-8a90-863c3aad409d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:to="loc_us-gaap_GoodwillGross_123edcdd-ca44-4cdf-8a90-863c3aad409d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5d5067dd-7b69-4d6c-9dd5-543db68ede89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5d5067dd-7b69-4d6c-9dd5-543db68ede89" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2206c1a1-05ab-4e92-8636-b9b67cae90e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2206c1a1-05ab-4e92-8636-b9b67cae90e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5e030335-1368-4300-9fe4-c8d33e974334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2206c1a1-05ab-4e92-8636-b9b67cae90e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5e030335-1368-4300-9fe4-c8d33e974334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5e030335-1368-4300-9fe4-c8d33e974334_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5e030335-1368-4300-9fe4-c8d33e974334" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5e030335-1368-4300-9fe4-c8d33e974334_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_72840d59-58c3-4b85-9f7d-b7f4620a4409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5e030335-1368-4300-9fe4-c8d33e974334" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_72840d59-58c3-4b85-9f7d-b7f4620a4409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_012ba1a9-4268-4180-b311-32c7b37d2aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_72840d59-58c3-4b85-9f7d-b7f4620a4409" xlink:to="loc_us-gaap_MoneyMarketFundsMember_012ba1a9-4268-4180-b311-32c7b37d2aa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_e2ffdf55-3994-4011-a43f-df50bfe4e59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_72840d59-58c3-4b85-9f7d-b7f4620a4409" xlink:to="loc_us-gaap_BankTimeDepositsMember_e2ffdf55-3994-4011-a43f-df50bfe4e59e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e94bba42-6282-4474-b716-0996b6aa9176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2206c1a1-05ab-4e92-8636-b9b67cae90e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e94bba42-6282-4474-b716-0996b6aa9176" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e94bba42-6282-4474-b716-0996b6aa9176_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e94bba42-6282-4474-b716-0996b6aa9176" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e94bba42-6282-4474-b716-0996b6aa9176_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e94bba42-6282-4474-b716-0996b6aa9176" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_256ee121-2006-4c43-96b8-8a99019ac8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_256ee121-2006-4c43-96b8-8a99019ac8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b194d6ac-a5e1-4a95-bdca-d5a4dbef4f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b194d6ac-a5e1-4a95-bdca-d5a4dbef4f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_da65ba30-5c59-491f-a6d5-c7cab2436fff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_da65ba30-5c59-491f-a6d5-c7cab2436fff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a70d0e4f-0438-48f9-9b00-6b63478e5f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a70d0e4f-0438-48f9-9b00-6b63478e5f39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_976a3d0d-fa3a-404b-91ed-d98c87b9542e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_DerivativeAssets_976a3d0d-fa3a-404b-91ed-d98c87b9542e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_50b8a1a8-2493-465e-a6d3-9a93a9e99b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_50b8a1a8-2493-465e-a6d3-9a93a9e99b71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47576cbf-82cf-43d2-828e-788e83f7ee7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47576cbf-82cf-43d2-828e-788e83f7ee7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_3944eb1a-8fc7-4c42-99b3-3d3ced74c039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_3944eb1a-8fc7-4c42-99b3-3d3ced74c039" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_21452e9d-ce8d-43e1-81b6-6b894e2f592a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_21452e9d-ce8d-43e1-81b6-6b894e2f592a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d00f13ce-bf49-41b4-81d4-989bd8ccaa74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d00f13ce-bf49-41b4-81d4-989bd8ccaa74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b9e54c3-8d2d-4a57-9bf6-37515db5de65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d00f13ce-bf49-41b4-81d4-989bd8ccaa74" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b9e54c3-8d2d-4a57-9bf6-37515db5de65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9b9e54c3-8d2d-4a57-9bf6-37515db5de65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b9e54c3-8d2d-4a57-9bf6-37515db5de65" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9b9e54c3-8d2d-4a57-9bf6-37515db5de65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_30a9f8ee-276b-4450-9886-b8bfa249834e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b9e54c3-8d2d-4a57-9bf6-37515db5de65" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_30a9f8ee-276b-4450-9886-b8bfa249834e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_8cf10033-9657-4dae-8207-9ece4e1dfb75" xlink:href="ebs-20231231.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30a9f8ee-276b-4450-9886-b8bfa249834e" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_8cf10033-9657-4dae-8207-9ece4e1dfb75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1e142e06-bab4-4597-bf3f-08ccd7c7eac6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d00f13ce-bf49-41b4-81d4-989bd8ccaa74" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1e142e06-bab4-4597-bf3f-08ccd7c7eac6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1e142e06-bab4-4597-bf3f-08ccd7c7eac6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1e142e06-bab4-4597-bf3f-08ccd7c7eac6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1e142e06-bab4-4597-bf3f-08ccd7c7eac6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb4bdf86-039b-45b4-9f41-74b2120d9dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1e142e06-bab4-4597-bf3f-08ccd7c7eac6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb4bdf86-039b-45b4-9f41-74b2120d9dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_cc180ae1-35b3-43f4-9fdd-18b6c159914a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb4bdf86-039b-45b4-9f41-74b2120d9dc8" xlink:to="loc_us-gaap_SeniorNotesMember_cc180ae1-35b3-43f4-9fdd-18b6c159914a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_dcf201c2-0789-4154-9bc5-1ae23d2d7bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_dcf201c2-0789-4154-9bc5-1ae23d2d7bbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7076c55f-a855-4f5a-a4d6-c40b689a7ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7076c55f-a855-4f5a-a4d6-c40b689a7ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c26d67e-6a6b-46ec-9992-2ac63a5768a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c26d67e-6a6b-46ec-9992-2ac63a5768a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_a8bee089-2fff-4856-a059-34230fbd3fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:to="loc_us-gaap_LongTermDebtFairValue_a8bee089-2fff-4856-a059-34230fbd3fdb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e095a631-b6a9-48b9-bd31-a73d80c89863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e095a631-b6a9-48b9-bd31-a73d80c89863" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea28d292-89fa-4350-a2e0-901976e0dadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea28d292-89fa-4350-a2e0-901976e0dadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea28d292-89fa-4350-a2e0-901976e0dadd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea28d292-89fa-4350-a2e0-901976e0dadd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea28d292-89fa-4350-a2e0-901976e0dadd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93f97602-d252-4c4e-bfab-0da85b077cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea28d292-89fa-4350-a2e0-901976e0dadd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93f97602-d252-4c4e-bfab-0da85b077cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2ea44385-29b6-4a5f-9147-f8e2033a4386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93f97602-d252-4c4e-bfab-0da85b077cf6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2ea44385-29b6-4a5f-9147-f8e2033a4386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de89aa60-91df-46b2-93e2-dc6feedb8c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de89aa60-91df-46b2-93e2-dc6feedb8c89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_de89aa60-91df-46b2-93e2-dc6feedb8c89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de89aa60-91df-46b2-93e2-dc6feedb8c89" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_de89aa60-91df-46b2-93e2-dc6feedb8c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a066af7-2bea-4fd2-8dae-c6b7afe1c1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de89aa60-91df-46b2-93e2-dc6feedb8c89" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a066af7-2bea-4fd2-8dae-c6b7afe1c1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d3b83cd4-c9f0-4492-83ee-644f357240c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a066af7-2bea-4fd2-8dae-c6b7afe1c1ba" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d3b83cd4-c9f0-4492-83ee-644f357240c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_397e1368-8d5e-4a5d-9e2e-05ca4415ba5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_397e1368-8d5e-4a5d-9e2e-05ca4415ba5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_397e1368-8d5e-4a5d-9e2e-05ca4415ba5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_397e1368-8d5e-4a5d-9e2e-05ca4415ba5c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_397e1368-8d5e-4a5d-9e2e-05ca4415ba5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0bb1b8f5-18a2-4695-b947-59bb38a21bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_397e1368-8d5e-4a5d-9e2e-05ca4415ba5c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0bb1b8f5-18a2-4695-b947-59bb38a21bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f86f6aa1-3ca5-46fc-be22-b7fdc6e586dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0bb1b8f5-18a2-4695-b947-59bb38a21bf6" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f86f6aa1-3ca5-46fc-be22-b7fdc6e586dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityOfPaymentMember_7cfa67c4-1719-460a-8a9d-f1c289667264" xlink:href="ebs-20231231.xsd#ebs_MeasurementInputProbabilityOfPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0bb1b8f5-18a2-4695-b947-59bb38a21bf6" xlink:to="loc_ebs_MeasurementInputProbabilityOfPaymentMember_7cfa67c4-1719-460a-8a9d-f1c289667264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7d2feb9d-3023-430e-8b94-4d2e3764d50e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7d2feb9d-3023-430e-8b94-4d2e3764d50e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7d2feb9d-3023-430e-8b94-4d2e3764d50e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7d2feb9d-3023-430e-8b94-4d2e3764d50e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7d2feb9d-3023-430e-8b94-4d2e3764d50e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9f8e9812-9659-42df-9cb5-514bf7bbf340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7d2feb9d-3023-430e-8b94-4d2e3764d50e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9f8e9812-9659-42df-9cb5-514bf7bbf340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_6897b712-5564-40e8-a3ed-5e3a29106818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_9f8e9812-9659-42df-9cb5-514bf7bbf340" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_6897b712-5564-40e8-a3ed-5e3a29106818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ddda1d5f-3985-4690-8fbc-2a15b83d70a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_srt_RangeAxis_ddda1d5f-3985-4690-8fbc-2a15b83d70a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ddda1d5f-3985-4690-8fbc-2a15b83d70a3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ddda1d5f-3985-4690-8fbc-2a15b83d70a3" xlink:to="loc_srt_RangeMember_ddda1d5f-3985-4690-8fbc-2a15b83d70a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d42fa58d-a9f5-43b8-badd-442dd26f6fb4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ddda1d5f-3985-4690-8fbc-2a15b83d70a3" xlink:to="loc_srt_RangeMember_d42fa58d-a9f5-43b8-badd-442dd26f6fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1df9b11e-4e1a-4a3e-8fe0-2466574fa539" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d42fa58d-a9f5-43b8-badd-442dd26f6fb4" xlink:to="loc_srt_MinimumMember_1df9b11e-4e1a-4a3e-8fe0-2466574fa539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0159908a-f7b5-4b41-95ad-a92216029182" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d42fa58d-a9f5-43b8-badd-442dd26f6fb4" xlink:to="loc_srt_MaximumMember_0159908a-f7b5-4b41-95ad-a92216029182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53a6c167-75ca-49fe-b04c-fbbc7bc663a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e095a631-b6a9-48b9-bd31-a73d80c89863" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53a6c167-75ca-49fe-b04c-fbbc7bc663a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_89e51145-8e21-421d-a934-e1f757035bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e095a631-b6a9-48b9-bd31-a73d80c89863" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_89e51145-8e21-421d-a934-e1f757035bb2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DerivativeInstrumentsandhedgingactivitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_f86aba09-9516-4f83-ae22-d4869f480e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_69e3580e-c28c-467e-9f1d-1de17d960db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f86aba09-9516-4f83-ae22-d4869f480e47" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_69e3580e-c28c-467e-9f1d-1de17d960db2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d97a352c-ff1f-4140-aa90-87d707c0b73e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_69e3580e-c28c-467e-9f1d-1de17d960db2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d97a352c-ff1f-4140-aa90-87d707c0b73e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d97a352c-ff1f-4140-aa90-87d707c0b73e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d97a352c-ff1f-4140-aa90-87d707c0b73e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d97a352c-ff1f-4140-aa90-87d707c0b73e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_765bb979-9910-4f6e-abfe-e4303f2d5469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d97a352c-ff1f-4140-aa90-87d707c0b73e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_765bb979-9910-4f6e-abfe-e4303f2d5469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f9a1ef3d-76f1-41a0-baa0-ac97e234613b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_765bb979-9910-4f6e-abfe-e4303f2d5469" xlink:to="loc_us-gaap_InterestRateSwapMember_f9a1ef3d-76f1-41a0-baa0-ac97e234613b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e76a2901-64a7-49c2-b794-fd5a9861735e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_69e3580e-c28c-467e-9f1d-1de17d960db2" xlink:to="loc_us-gaap_HedgingDesignationAxis_e76a2901-64a7-49c2-b794-fd5a9861735e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e76a2901-64a7-49c2-b794-fd5a9861735e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e76a2901-64a7-49c2-b794-fd5a9861735e" xlink:to="loc_us-gaap_HedgingDesignationDomain_e76a2901-64a7-49c2-b794-fd5a9861735e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ca965ef2-0271-4238-998b-641b8d55e916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e76a2901-64a7-49c2-b794-fd5a9861735e" xlink:to="loc_us-gaap_HedgingDesignationDomain_ca965ef2-0271-4238-998b-641b8d55e916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_419a066c-4642-4dd0-aff8-5a6042465fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ca965ef2-0271-4238-998b-641b8d55e916" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_419a066c-4642-4dd0-aff8-5a6042465fdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_191ee2a0-a9e1-44d7-96e9-15e4ff9ce832" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f86aba09-9516-4f83-ae22-d4869f480e47" xlink:to="loc_us-gaap_DerivativeNotionalAmount_191ee2a0-a9e1-44d7-96e9-15e4ff9ce832" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_54acea42-08a4-4c4c-a184-e40be5c0d886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_54acea42-08a4-4c4c-a184-e40be5c0d886" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8fdf6d80-ed09-4c02-a2d8-931cae60bbab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8fdf6d80-ed09-4c02-a2d8-931cae60bbab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8fdf6d80-ed09-4c02-a2d8-931cae60bbab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8fdf6d80-ed09-4c02-a2d8-931cae60bbab" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8fdf6d80-ed09-4c02-a2d8-931cae60bbab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1ccdf3ea-028b-4ad0-b189-3ceaedaaccda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8fdf6d80-ed09-4c02-a2d8-931cae60bbab" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1ccdf3ea-028b-4ad0-b189-3ceaedaaccda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8fa82382-9ff4-42ac-ba1b-cfe609d7c8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1ccdf3ea-028b-4ad0-b189-3ceaedaaccda" xlink:to="loc_us-gaap_InterestRateSwapMember_8fa82382-9ff4-42ac-ba1b-cfe609d7c8bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_707ab5a2-b35a-4172-8b79-487d666be4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:to="loc_us-gaap_HedgingDesignationAxis_707ab5a2-b35a-4172-8b79-487d666be4e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_707ab5a2-b35a-4172-8b79-487d666be4e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_707ab5a2-b35a-4172-8b79-487d666be4e8" xlink:to="loc_us-gaap_HedgingDesignationDomain_707ab5a2-b35a-4172-8b79-487d666be4e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_01614d32-51da-4602-b3a7-36cfc8c1689b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_707ab5a2-b35a-4172-8b79-487d666be4e8" xlink:to="loc_us-gaap_HedgingDesignationDomain_01614d32-51da-4602-b3a7-36cfc8c1689b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_69975ddc-2135-4f21-9be6-ad15a3fec407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_01614d32-51da-4602-b3a7-36cfc8c1689b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_69975ddc-2135-4f21-9be6-ad15a3fec407" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_301efa23-d9a0-444b-9b44-4d53a74c3987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_301efa23-d9a0-444b-9b44-4d53a74c3987" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_301efa23-d9a0-444b-9b44-4d53a74c3987_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_301efa23-d9a0-444b-9b44-4d53a74c3987" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_301efa23-d9a0-444b-9b44-4d53a74c3987_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a877c4ce-28ac-426c-b42d-b8e591f76d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_301efa23-d9a0-444b-9b44-4d53a74c3987" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a877c4ce-28ac-426c-b42d-b8e591f76d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_24e2cf97-8b74-46ab-822a-09ebd8ea2ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a877c4ce-28ac-426c-b42d-b8e591f76d20" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_24e2cf97-8b74-46ab-822a-09ebd8ea2ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ff6712ae-5857-4c5f-98bc-7b62b2995833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_54acea42-08a4-4c4c-a184-e40be5c0d886" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ff6712ae-5857-4c5f-98bc-7b62b2995833" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_05e20f4d-abb9-4858-ba96-3126f04e790b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_05e20f4d-abb9-4858-ba96-3126f04e790b" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_251f6fd4-8143-4df3-a4aa-d5129fc07024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_251f6fd4-8143-4df3-a4aa-d5129fc07024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_251f6fd4-8143-4df3-a4aa-d5129fc07024_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_251f6fd4-8143-4df3-a4aa-d5129fc07024" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_251f6fd4-8143-4df3-a4aa-d5129fc07024_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d5ae1b27-1e32-4dcb-a151-12f39f7bf216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_251f6fd4-8143-4df3-a4aa-d5129fc07024" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d5ae1b27-1e32-4dcb-a151-12f39f7bf216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_22da4b03-1b3f-43f9-b2dc-1390fdfc7303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d5ae1b27-1e32-4dcb-a151-12f39f7bf216" xlink:to="loc_us-gaap_InterestExpenseMember_22da4b03-1b3f-43f9-b2dc-1390fdfc7303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_202894ee-51eb-40af-832a-7d2f898ad1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_202894ee-51eb-40af-832a-7d2f898ad1bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_202894ee-51eb-40af-832a-7d2f898ad1bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_202894ee-51eb-40af-832a-7d2f898ad1bd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_202894ee-51eb-40af-832a-7d2f898ad1bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_99593606-e1fb-4355-9c26-0e7878e4eab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_202894ee-51eb-40af-832a-7d2f898ad1bd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_99593606-e1fb-4355-9c26-0e7878e4eab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_ee17628b-a043-4b77-add7-4916cd4e82e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_99593606-e1fb-4355-9c26-0e7878e4eab1" xlink:to="loc_us-gaap_InterestRateSwapMember_ee17628b-a043-4b77-add7-4916cd4e82e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f1f812c7-e089-422d-87ff-b50a3f31466a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f1f812c7-e089-422d-87ff-b50a3f31466a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f1f812c7-e089-422d-87ff-b50a3f31466a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f1f812c7-e089-422d-87ff-b50a3f31466a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f1f812c7-e089-422d-87ff-b50a3f31466a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1a52a96b-c9d6-494f-9133-d1b718551f08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f1f812c7-e089-422d-87ff-b50a3f31466a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1a52a96b-c9d6-494f-9133-d1b718551f08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2821b3d3-217f-484a-96e1-6d344e636bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1a52a96b-c9d6-494f-9133-d1b718551f08" xlink:to="loc_us-gaap_CashFlowHedgingMember_2821b3d3-217f-484a-96e1-6d344e636bcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_7f037e76-0e2b-4c6c-972f-20413db5a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_05e20f4d-abb9-4858-ba96-3126f04e790b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_7f037e76-0e2b-4c6c-972f-20413db5a0f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DebtComponentsofLongtermIndebtednessDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9666ebe1-0ad9-4150-8da4-2af3293aeff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:to="loc_us-gaap_DebtInstrumentAxis_9666ebe1-0ad9-4150-8da4-2af3293aeff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9666ebe1-0ad9-4150-8da4-2af3293aeff1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9666ebe1-0ad9-4150-8da4-2af3293aeff1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9666ebe1-0ad9-4150-8da4-2af3293aeff1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4078245b-7722-4d74-a2cd-33137ff654b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9666ebe1-0ad9-4150-8da4-2af3293aeff1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4078245b-7722-4d74-a2cd-33137ff654b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_f3d809e0-def6-496b-b30b-5213aae3f78a" xlink:href="ebs-20231231.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4078245b-7722-4d74-a2cd-33137ff654b0" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_f3d809e0-def6-496b-b30b-5213aae3f78a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_a4b80680-5dce-49d9-a2f2-bda3930548f3" xlink:href="ebs-20231231.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4078245b-7722-4d74-a2cd-33137ff654b0" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_a4b80680-5dce-49d9-a2f2-bda3930548f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_077ce729-e488-4d9f-a6f2-28d6c1207488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_077ce729-e488-4d9f-a6f2-28d6c1207488" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_077ce729-e488-4d9f-a6f2-28d6c1207488_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_077ce729-e488-4d9f-a6f2-28d6c1207488" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_077ce729-e488-4d9f-a6f2-28d6c1207488_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_077ce729-e488-4d9f-a6f2-28d6c1207488" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_1481ab99-3a88-4f0d-bb81-992bae21b50b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_1481ab99-3a88-4f0d-bb81-992bae21b50b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_516ae889-4a25-4605-8f4d-02ef0abb5ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:to="loc_us-gaap_LineOfCreditMember_516ae889-4a25-4605-8f4d-02ef0abb5ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_2d2a0bd2-e1a1-4bb2-8759-84430acd57fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:to="loc_us-gaap_SeniorNotesMember_2d2a0bd2-e1a1-4bb2-8759-84430acd57fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_74d6fa1e-1a0c-4a1c-b541-9e1871083353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:to="loc_us-gaap_CreditFacilityAxis_74d6fa1e-1a0c-4a1c-b541-9e1871083353" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_74d6fa1e-1a0c-4a1c-b541-9e1871083353_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_74d6fa1e-1a0c-4a1c-b541-9e1871083353" xlink:to="loc_us-gaap_CreditFacilityDomain_74d6fa1e-1a0c-4a1c-b541-9e1871083353_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_db0248b7-6bd3-4625-b64f-956fe629c224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_74d6fa1e-1a0c-4a1c-b541-9e1871083353" xlink:to="loc_us-gaap_CreditFacilityDomain_db0248b7-6bd3-4625-b64f-956fe629c224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_38b3d40d-5db3-44c1-9755-8d151ba9d9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_db0248b7-6bd3-4625-b64f-956fe629c224" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_38b3d40d-5db3-44c1-9755-8d151ba9d9b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b47a28e-33ce-41e0-839a-d0a0c220f4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b47a28e-33ce-41e0-839a-d0a0c220f4fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a5655b63-2894-4119-9e97-2dd4447aaefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_LongTermDebt_a5655b63-2894-4119-9e97-2dd4447aaefd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d1da990d-1989-4233-8812-01645d87980c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_LongTermDebtCurrent_d1da990d-1989-4233-8812-01645d87980c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_e3e5a0ec-f834-4491-aa54-f60bf5aa15de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_e3e5a0ec-f834-4491-aa54-f60bf5aa15de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1d1e5163-2f0b-4117-b2ce-3bc192b4d388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1d1e5163-2f0b-4117-b2ce-3bc192b4d388" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1aa01c45-a433-45df-8ba8-0b40d40e42b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1aa01c45-a433-45df-8ba8-0b40d40e42b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1aa01c45-a433-45df-8ba8-0b40d40e42b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1aa01c45-a433-45df-8ba8-0b40d40e42b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1aa01c45-a433-45df-8ba8-0b40d40e42b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1aa01c45-a433-45df-8ba8-0b40d40e42b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9f8f5fdb-59d3-49d6-96f1-e27ee422c13c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:to="loc_us-gaap_LineOfCreditMember_9f8f5fdb-59d3-49d6-96f1-e27ee422c13c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_de3dfc4c-768e-4e78-80f8-9b95834b9b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:to="loc_us-gaap_SeniorNotesMember_de3dfc4c-768e-4e78-80f8-9b95834b9b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_011a6940-d560-4963-beb9-df2f39b82518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_011a6940-d560-4963-beb9-df2f39b82518" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7718328e-64f5-4abc-9e10-3b446b32bdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_DebtInstrumentAxis_7718328e-64f5-4abc-9e10-3b446b32bdf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7718328e-64f5-4abc-9e10-3b446b32bdf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7718328e-64f5-4abc-9e10-3b446b32bdf1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7718328e-64f5-4abc-9e10-3b446b32bdf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7718328e-64f5-4abc-9e10-3b446b32bdf1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_d5ee955b-901e-451b-aedb-fc7876aaa403" xlink:href="ebs-20231231.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_d5ee955b-901e-451b-aedb-fc7876aaa403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_1bdad43b-f884-4e70-a5df-4ffa527d6114" xlink:href="ebs-20231231.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:to="loc_ebs_AmendedCreditAgreementMember_1bdad43b-f884-4e70-a5df-4ffa527d6114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ForbearanceAgreementAndAmendmentMember_ea9c31eb-0832-49c3-9054-de6d592730b0" xlink:href="ebs-20231231.xsd#ebs_ForbearanceAgreementAndAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:to="loc_ebs_ForbearanceAgreementAndAmendmentMember_ea9c31eb-0832-49c3-9054-de6d592730b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3bd9eddf-e660-4f6f-9439-76d9efda8a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3bd9eddf-e660-4f6f-9439-76d9efda8a57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3bd9eddf-e660-4f6f-9439-76d9efda8a57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3bd9eddf-e660-4f6f-9439-76d9efda8a57" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3bd9eddf-e660-4f6f-9439-76d9efda8a57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d4f82b62-8004-4896-9eda-e6b41fe28f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3bd9eddf-e660-4f6f-9439-76d9efda8a57" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d4f82b62-8004-4896-9eda-e6b41fe28f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_ca3d7077-8062-4a0e-915d-6f73c98b3231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d4f82b62-8004-4896-9eda-e6b41fe28f56" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_ca3d7077-8062-4a0e-915d-6f73c98b3231" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5c46e64d-0b92-4f20-a091-082e85418a63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d4f82b62-8004-4896-9eda-e6b41fe28f56" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5c46e64d-0b92-4f20-a091-082e85418a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba8d6cb0-a3e8-4d59-b8a0-38c64040aa80" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_srt_RangeAxis_ba8d6cb0-a3e8-4d59-b8a0-38c64040aa80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba8d6cb0-a3e8-4d59-b8a0-38c64040aa80_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ba8d6cb0-a3e8-4d59-b8a0-38c64040aa80" xlink:to="loc_srt_RangeMember_ba8d6cb0-a3e8-4d59-b8a0-38c64040aa80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cfc5754a-71db-4e3a-a369-2708d91ae6e8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ba8d6cb0-a3e8-4d59-b8a0-38c64040aa80" xlink:to="loc_srt_RangeMember_cfc5754a-71db-4e3a-a369-2708d91ae6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ad0425ed-8aa4-4f70-91d6-40b0f225b176" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cfc5754a-71db-4e3a-a369-2708d91ae6e8" xlink:to="loc_srt_MaximumMember_ad0425ed-8aa4-4f70-91d6-40b0f225b176" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36262cf8-b443-48d2-aabe-263e42418b7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cfc5754a-71db-4e3a-a369-2708d91ae6e8" xlink:to="loc_srt_MinimumMember_36262cf8-b443-48d2-aabe-263e42418b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8ef793d2-d76d-4a50-87e6-22a9bcd061cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_CreditFacilityAxis_8ef793d2-d76d-4a50-87e6-22a9bcd061cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8ef793d2-d76d-4a50-87e6-22a9bcd061cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8ef793d2-d76d-4a50-87e6-22a9bcd061cb" xlink:to="loc_us-gaap_CreditFacilityDomain_8ef793d2-d76d-4a50-87e6-22a9bcd061cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a2e4eaa1-eb8d-4cc5-a61b-aeb402505acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8ef793d2-d76d-4a50-87e6-22a9bcd061cb" xlink:to="loc_us-gaap_CreditFacilityDomain_a2e4eaa1-eb8d-4cc5-a61b-aeb402505acb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_9b949aaf-39f9-4746-a5b7-4cf6ef71c7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a2e4eaa1-eb8d-4cc5-a61b-aeb402505acb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_9b949aaf-39f9-4746-a5b7-4cf6ef71c7f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_42fd78fa-d722-4e8d-9769-d3a9c707f5c6" xlink:href="ebs-20231231.xsd#ebs_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a2e4eaa1-eb8d-4cc5-a61b-aeb402505acb" xlink:to="loc_ebs_TermLoanFacilityMember_42fd78fa-d722-4e8d-9769-d3a9c707f5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_dcbabf0b-7b61-4d95-a37e-9026e7b58fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_dcbabf0b-7b61-4d95-a37e-9026e7b58fd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_dcbabf0b-7b61-4d95-a37e-9026e7b58fd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_dcbabf0b-7b61-4d95-a37e-9026e7b58fd4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_dcbabf0b-7b61-4d95-a37e-9026e7b58fd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_03777ac9-5827-4110-9ce8-7161569c2a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_dcbabf0b-7b61-4d95-a37e-9026e7b58fd4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_03777ac9-5827-4110-9ce8-7161569c2a4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ed0b0fb7-be0f-41cb-9a83-9228d08215a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_03777ac9-5827-4110-9ce8-7161569c2a4b" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ed0b0fb7-be0f-41cb-9a83-9228d08215a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c91f38b8-2aa4-4f3f-a35c-57b876551701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c91f38b8-2aa4-4f3f-a35c-57b876551701" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c91f38b8-2aa4-4f3f-a35c-57b876551701_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c91f38b8-2aa4-4f3f-a35c-57b876551701" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c91f38b8-2aa4-4f3f-a35c-57b876551701_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98024731-0738-4439-8208-b44ceabdb117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c91f38b8-2aa4-4f3f-a35c-57b876551701" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98024731-0738-4439-8208-b44ceabdb117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_8cc2c390-23e4-416d-9755-475e212a286d" xlink:href="ebs-20231231.xsd#ebs_TravelHealthBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98024731-0738-4439-8208-b44ceabdb117" xlink:to="loc_ebs_TravelHealthBusinessMember_8cc2c390-23e4-416d-9755-475e212a286d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtTermsAxis_926848ae-7eae-4b34-b80e-3d864b3d6969" xlink:href="ebs-20231231.xsd#ebs_DebtTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_ebs_DebtTermsAxis_926848ae-7eae-4b34-b80e-3d864b3d6969" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtTermsDomain_926848ae-7eae-4b34-b80e-3d864b3d6969_default" xlink:href="ebs-20231231.xsd#ebs_DebtTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ebs_DebtTermsAxis_926848ae-7eae-4b34-b80e-3d864b3d6969" xlink:to="loc_ebs_DebtTermsDomain_926848ae-7eae-4b34-b80e-3d864b3d6969_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:href="ebs-20231231.xsd#ebs_DebtTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ebs_DebtTermsAxis_926848ae-7eae-4b34-b80e-3d864b3d6969" xlink:to="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_FiscalQuartersEndingIn2024Member_6c29a81e-ade4-4906-b888-5f3357b7ddce" xlink:href="ebs-20231231.xsd#ebs_FiscalQuartersEndingIn2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:to="loc_ebs_FiscalQuartersEndingIn2024Member_6c29a81e-ade4-4906-b888-5f3357b7ddce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_FiscalQuartersEndingAfter2024Member_53fe59be-db6c-4fa4-b18f-455cd9721aad" xlink:href="ebs-20231231.xsd#ebs_FiscalQuartersEndingAfter2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:to="loc_ebs_FiscalQuartersEndingAfter2024Member_53fe59be-db6c-4fa4-b18f-455cd9721aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UntilMarch312024Member_b195a2e4-c129-4bd9-85e2-24a7bf6ec854" xlink:href="ebs-20231231.xsd#ebs_UntilMarch312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:to="loc_ebs_UntilMarch312024Member_b195a2e4-c129-4bd9-85e2-24a7bf6ec854" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_FiscalQuartersEndingAfterMarch312024Member_49e711f9-6c4c-4ad8-a3b3-033dcaa53a2a" xlink:href="ebs-20231231.xsd#ebs_FiscalQuartersEndingAfterMarch312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:to="loc_ebs_FiscalQuartersEndingAfterMarch312024Member_49e711f9-6c4c-4ad8-a3b3-033dcaa53a2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_29144f85-5a73-4bcd-a1ff-f04c36565388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_VariableRateAxis_29144f85-5a73-4bcd-a1ff-f04c36565388" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_29144f85-5a73-4bcd-a1ff-f04c36565388_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_29144f85-5a73-4bcd-a1ff-f04c36565388" xlink:to="loc_us-gaap_VariableRateDomain_29144f85-5a73-4bcd-a1ff-f04c36565388_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_29144f85-5a73-4bcd-a1ff-f04c36565388" xlink:to="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SOFREURIBOROrCDORMember_aa78f4de-f855-4fa4-8f07-a687c4c4d7a5" xlink:href="ebs-20231231.xsd#ebs_SOFREURIBOROrCDORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_ebs_SOFREURIBOROrCDORMember_aa78f4de-f855-4fa4-8f07-a687c4c4d7a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e0eb9c1c-4791-43c2-98a8-3737736f55d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e0eb9c1c-4791-43c2-98a8-3737736f55d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SecuredOvernightFinancingRateSOFRMember_36ff91e9-91c4-4778-98c9-f96f35e27d25" xlink:href="ebs-20231231.xsd#ebs_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_ebs_SecuredOvernightFinancingRateSOFRMember_36ff91e9-91c4-4778-98c9-f96f35e27d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_f7eee53c-827d-4853-972b-cca60610e154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_us-gaap_BaseRateMember_f7eee53c-827d-4853-972b-cca60610e154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SOFRSONIAAndEurocurrencyMember_aa3bcff7-2cee-467a-b48e-91892e866c66" xlink:href="ebs-20231231.xsd#ebs_SOFRSONIAAndEurocurrencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_ebs_SOFRSONIAAndEurocurrencyMember_aa3bcff7-2cee-467a-b48e-91892e866c66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8e00472f-de0b-48e3-9573-aed3dfdd6f11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8e00472f-de0b-48e3-9573-aed3dfdd6f11" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8e00472f-de0b-48e3-9573-aed3dfdd6f11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8e00472f-de0b-48e3-9573-aed3dfdd6f11" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8e00472f-de0b-48e3-9573-aed3dfdd6f11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ea03f39e-95ba-452e-bcd3-a2964bcdba9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8e00472f-de0b-48e3-9573-aed3dfdd6f11" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ea03f39e-95ba-452e-bcd3-a2964bcdba9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b3342079-71a2-496b-b652-514b1b984e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ea03f39e-95ba-452e-bcd3-a2964bcdba9d" xlink:to="loc_us-gaap_SubsequentEventMember_b3342079-71a2-496b-b652-514b1b984e84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_252be050-bf15-4950-8b0b-25b6713bcb90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_LongTermDebt_252be050-bf15-4950-8b0b-25b6713bcb90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_aca7e2e9-018f-492a-8cae-175838a3683c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_aca7e2e9-018f-492a-8cae-175838a3683c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb68f70a-4e68-4a0e-8355-e438c1a0311f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb68f70a-4e68-4a0e-8355-e438c1a0311f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_c1b21a52-afb4-4586-8ae5-9cb07775612b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_c1b21a52-afb4-4586-8ae5-9cb07775612b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1550dce5-2fa4-49ea-b4e6-5dc191cb695a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1550dce5-2fa4-49ea-b4e6-5dc191cb695a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_c5e5a4bd-f234-4c4f-9785-d16ac596eae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_c5e5a4bd-f234-4c4f-9785-d16ac596eae2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_be9df071-d883-4ecf-91e3-4f2a35cf21be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_Cash_be9df071-d883-4ecf-91e3-4f2a35cf21be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a1f33a7b-aa69-48e5-9584-7ce803454a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a1f33a7b-aa69-48e5-9584-7ce803454a2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_8646206a-05b4-41c3-81fa-0556d9a0a52b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_8646206a-05b4-41c3-81fa-0556d9a0a52b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum_c643fed9-8f32-4dcc-beda-dcf4b3a27756" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum_c643fed9-8f32-4dcc-beda-dcf4b3a27756" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_33841d4a-ad84-4546-b7bb-0a749286d9f4" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_33841d4a-ad84-4546-b7bb-0a749286d9f4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_9a678593-05a7-4b26-bb01-0c1fd05dede9" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_9a678593-05a7-4b26-bb01-0c1fd05dede9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e5aa22fa-f10e-411c-a953-4ee0e953d4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e5aa22fa-f10e-411c-a953-4ee0e953d4f9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_5329727b-4070-4f74-a318-d91626930803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_5329727b-4070-4f74-a318-d91626930803" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentThreshold_95346469-a4e2-4789-8d7a-104cee20558f" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentMandatoryPrepaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentThreshold_95346469-a4e2-4789-8d7a-104cee20558f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage_74c7de28-5151-44b0-a911-7fe3f3473b3a" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage_74c7de28-5151-44b0-a911-7fe3f3473b3a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1e1c8c88-70c9-4ce4-a684-a68a065149ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1e1c8c88-70c9-4ce4-a684-a68a065149ac" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0108d2e7-7eed-4d98-a205-12d25097a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_us-gaap_AwardTypeAxis_0108d2e7-7eed-4d98-a205-12d25097a03c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0108d2e7-7eed-4d98-a205-12d25097a03c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0108d2e7-7eed-4d98-a205-12d25097a03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0108d2e7-7eed-4d98-a205-12d25097a03c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0108d2e7-7eed-4d98-a205-12d25097a03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c0d79b99-2965-4c05-9875-9912ae86eb81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c0d79b99-2965-4c05-9875-9912ae86eb81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c902683a-a9a0-4c69-b73a-5719e3685e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c902683a-a9a0-4c69-b73a-5719e3685e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3b2d32d9-3613-44b0-8f93-acb0c4e9cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:to="loc_us-gaap_PerformanceSharesMember_3b2d32d9-3613-44b0-8f93-acb0c4e9cb27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5756f39b-b01c-4070-9d33-fe7cea32781f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_us-gaap_PlanNameAxis_5756f39b-b01c-4070-9d33-fe7cea32781f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5756f39b-b01c-4070-9d33-fe7cea32781f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5756f39b-b01c-4070-9d33-fe7cea32781f" xlink:to="loc_us-gaap_PlanNameDomain_5756f39b-b01c-4070-9d33-fe7cea32781f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d829bb18-4df9-4347-82e1-2184d0a5cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5756f39b-b01c-4070-9d33-fe7cea32781f" xlink:to="loc_us-gaap_PlanNameDomain_d829bb18-4df9-4347-82e1-2184d0a5cb3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_9edc7784-02c2-45b7-a931-ce0fbd6e497b" xlink:href="ebs-20231231.xsd#ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d829bb18-4df9-4347-82e1-2184d0a5cb3c" xlink:to="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_9edc7784-02c2-45b7-a931-ce0fbd6e497b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2023EquityInducementPlanMember_664b4c2f-77c8-4730-8853-83c504cc2d40" xlink:href="ebs-20231231.xsd#ebs_A2023EquityInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d829bb18-4df9-4347-82e1-2184d0a5cb3c" xlink:to="loc_ebs_A2023EquityInducementPlanMember_664b4c2f-77c8-4730-8853-83c504cc2d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aae6264c-2708-445b-8f8d-691da790842b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_srt_RangeAxis_aae6264c-2708-445b-8f8d-691da790842b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aae6264c-2708-445b-8f8d-691da790842b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aae6264c-2708-445b-8f8d-691da790842b" xlink:to="loc_srt_RangeMember_aae6264c-2708-445b-8f8d-691da790842b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_854b487e-42bb-4db9-b396-2c40792bfdf1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aae6264c-2708-445b-8f8d-691da790842b" xlink:to="loc_srt_RangeMember_854b487e-42bb-4db9-b396-2c40792bfdf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ed1fb5e5-2918-445c-b583-253946c2c64c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_854b487e-42bb-4db9-b396-2c40792bfdf1" xlink:to="loc_srt_MinimumMember_ed1fb5e5-2918-445c-b583-253946c2c64c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66c576b8-71b9-4f5b-b82d-f83c9e81269a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_854b487e-42bb-4db9-b396-2c40792bfdf1" xlink:to="loc_srt_MaximumMember_66c576b8-71b9-4f5b-b82d-f83c9e81269a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_304525ac-a67a-4310-bb9f-5028c37d401b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_304525ac-a67a-4310-bb9f-5028c37d401b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_304525ac-a67a-4310-bb9f-5028c37d401b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_304525ac-a67a-4310-bb9f-5028c37d401b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_304525ac-a67a-4310-bb9f-5028c37d401b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82a511d4-6d09-4757-81c4-6cca990d54b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_304525ac-a67a-4310-bb9f-5028c37d401b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82a511d4-6d09-4757-81c4-6cca990d54b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AtTheMarketOfferingMember_5ca12122-69a4-491e-befd-db3a7e99a8ed" xlink:href="ebs-20231231.xsd#ebs_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82a511d4-6d09-4757-81c4-6cca990d54b4" xlink:to="loc_ebs_AtTheMarketOfferingMember_5ca12122-69a4-491e-befd-db3a7e99a8ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81200336-f3f3-4a6c-a6bf-c1007cf46fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81200336-f3f3-4a6c-a6bf-c1007cf46fc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_81200336-f3f3-4a6c-a6bf-c1007cf46fc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81200336-f3f3-4a6c-a6bf-c1007cf46fc4" xlink:to="loc_us-gaap_EquityComponentDomain_81200336-f3f3-4a6c-a6bf-c1007cf46fc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42b8d30c-b340-4e7d-8b65-884c441f8712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81200336-f3f3-4a6c-a6bf-c1007cf46fc4" xlink:to="loc_us-gaap_EquityComponentDomain_42b8d30c-b340-4e7d-8b65-884c441f8712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_935d6344-2b6d-4b26-94ad-b05dabd93fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42b8d30c-b340-4e7d-8b65-884c441f8712" xlink:to="loc_us-gaap_TreasuryStockCommonMember_935d6344-2b6d-4b26-94ad-b05dabd93fdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans_24b9b2a6-7b3d-4f2a-ad89-4f24e823af57" xlink:href="ebs-20231231.xsd#ebs_NumberOfShareBasedEmployeeCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans_24b9b2a6-7b3d-4f2a-ad89-4f24e823af57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ea0a908f-5665-4235-8c5f-214d43a93e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ea0a908f-5665-4235-8c5f-214d43a93e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15c2571e-391b-46f8-a5eb-18be5266e72d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15c2571e-391b-46f8-a5eb-18be5266e72d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fa1293e8-354e-49bd-b7ff-31e11a138eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fa1293e8-354e-49bd-b7ff-31e11a138eb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b4c582ae-5b20-4239-a60b-b7f08de75ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b4c582ae-5b20-4239-a60b-b7f08de75ccf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum_da00a573-a30d-43ce-a7a0-22505b0468cc" xlink:href="ebs-20231231.xsd#ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum_da00a573-a30d-43ce-a7a0-22505b0468cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_01d06d7b-d0fa-4655-8562-10ceed067b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_01d06d7b-d0fa-4655-8562-10ceed067b95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3dff6aee-b06f-426b-a4cc-6e8855895170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3dff6aee-b06f-426b-a4cc-6e8855895170" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a81e31ef-6c18-4dc3-be66-f2d0de60f251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a81e31ef-6c18-4dc3-be66-f2d0de60f251" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ef377b7a-3d9e-4f12-8f48-0a9b0b85234d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ef377b7a-3d9e-4f12-8f48-0a9b0b85234d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ceec79f1-9daa-4658-b030-dc1bd650456c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ceec79f1-9daa-4658-b030-dc1bd650456c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue_06233158-b9bf-4c8f-b0bf-786bfe331a64" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue_06233158-b9bf-4c8f-b0bf-786bfe331a64" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_123f96f7-5b6e-4086-9ade-e35137f27668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_123f96f7-5b6e-4086-9ade-e35137f27668" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_666f8253-e83a-4cd7-89b5-9d6fec7141db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_666f8253-e83a-4cd7-89b5-9d6fec7141db" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage_1f2e34f8-4079-49e8-ab5f-bb4b65fe1158" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage_1f2e34f8-4079-49e8-ab5f-bb4b65fe1158" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d90ad595-2e9c-4bb2-9368-c1d8abc69f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d90ad595-2e9c-4bb2-9368-c1d8abc69f41" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f6b00ca1-7fe9-4be9-9dba-1bffffbbf128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f6b00ca1-7fe9-4be9-9dba-1bffffbbf128" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d4e988c-873f-446a-911d-506f7497bef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d4e988c-873f-446a-911d-506f7497bef9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_de302779-4737-48e0-97e9-679ffb2890ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_de302779-4737-48e0-97e9-679ffb2890ac" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1a28c861-aa0c-4545-a67f-c9b35a8b3f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1a28c861-aa0c-4545-a67f-c9b35a8b3f20" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommonStockNumberOfVotesPerCommonShare_c020b973-8703-4838-a068-612d033f8046" xlink:href="ebs-20231231.xsd#ebs_CommonStockNumberOfVotesPerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_CommonStockNumberOfVotesPerCommonShare_c020b973-8703-4838-a068-612d033f8046" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SaleOfStockAggregateOfferingAmountMaximum_bc25a4c7-909b-4df1-ac75-71febdd0e70e" xlink:href="ebs-20231231.xsd#ebs_SaleOfStockAggregateOfferingAmountMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_SaleOfStockAggregateOfferingAmountMaximum_bc25a4c7-909b-4df1-ac75-71febdd0e70e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dad12895-d8ad-4320-b77a-9474702c0624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dad12895-d8ad-4320-b77a-9474702c0624" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SaleOfStockConsiderationReceivedOnTransactionGross_5ee9e06e-0a88-46f8-848e-b7c6288df984" xlink:href="ebs-20231231.xsd#ebs_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_SaleOfStockConsiderationReceivedOnTransactionGross_5ee9e06e-0a88-46f8-848e-b7c6288df984" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf638f07-6fae-4c25-a2d2-0c441cc77062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf638f07-6fae-4c25-a2d2-0c441cc77062" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares_12ad5135-7a4f-46df-9c96-3bd9404149af" xlink:href="ebs-20231231.xsd#ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares_12ad5135-7a4f-46df-9c96-3bd9404149af" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4c99a823-eacd-4954-822d-051d65256b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4c99a823-eacd-4954-822d-051d65256b24" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_26029910-179e-41cc-854f-f834ee0b3f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_26029910-179e-41cc-854f-f834ee0b3f87" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_325ae209-31b3-475d-87f9-ec5d768789df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_325ae209-31b3-475d-87f9-ec5d768789df" xlink:type="arc" order="28"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5b15289-9d6a-46c4-b6bd-878cb669294a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5b15289-9d6a-46c4-b6bd-878cb669294a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce8150d1-7c62-4e1b-a492-53193fae2843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5b15289-9d6a-46c4-b6bd-878cb669294a" xlink:to="loc_us-gaap_AwardTypeAxis_ce8150d1-7c62-4e1b-a492-53193fae2843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce8150d1-7c62-4e1b-a492-53193fae2843_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ce8150d1-7c62-4e1b-a492-53193fae2843" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce8150d1-7c62-4e1b-a492-53193fae2843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f21328bc-1c75-4cb4-9950-12ded107550b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ce8150d1-7c62-4e1b-a492-53193fae2843" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f21328bc-1c75-4cb4-9950-12ded107550b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71f2745a-de1d-4ee3-ac8d-78dd982bf2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f21328bc-1c75-4cb4-9950-12ded107550b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71f2745a-de1d-4ee3-ac8d-78dd982bf2f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2ce62ed6-340f-4b8b-8848-64b30b3ef5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2ce62ed6-340f-4b8b-8848-64b30b3ef5ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c298fe47-f152-417d-9ff9-84ca847edfef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c298fe47-f152-417d-9ff9-84ca847edfef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c976be6f-f6c6-415c-9617-a0bd6f16f9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c976be6f-f6c6-415c-9617-a0bd6f16f9db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ec00275d-e0b6-450e-b47f-9d692431b924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ec00275d-e0b6-450e-b47f-9d692431b924" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_63e9b8eb-2c83-4710-898c-c4135fd7bedf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_63e9b8eb-2c83-4710-898c-c4135fd7bedf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c9be72c-2d0e-4fa1-8511-d1fc3ebe47f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c9be72c-2d0e-4fa1-8511-d1fc3ebe47f9" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97dea3cd-8bab-4503-a9a1-e43355289928" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97dea3cd-8bab-4503-a9a1-e43355289928" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_34e94ef7-9488-443c-af83-6d0b45af5be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97dea3cd-8bab-4503-a9a1-e43355289928" xlink:to="loc_us-gaap_PlanNameAxis_34e94ef7-9488-443c-af83-6d0b45af5be9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_34e94ef7-9488-443c-af83-6d0b45af5be9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_34e94ef7-9488-443c-af83-6d0b45af5be9" xlink:to="loc_us-gaap_PlanNameDomain_34e94ef7-9488-443c-af83-6d0b45af5be9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fb763dce-64ce-462f-8606-41fc387e819e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_34e94ef7-9488-443c-af83-6d0b45af5be9" xlink:to="loc_us-gaap_PlanNameDomain_fb763dce-64ce-462f-8606-41fc387e819e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_1d15b59d-11aa-4f47-88b2-e44e5ba31e57" xlink:href="ebs-20231231.xsd#ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fb763dce-64ce-462f-8606-41fc387e819e" xlink:to="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_1d15b59d-11aa-4f47-88b2-e44e5ba31e57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4de83baa-39b5-4033-96b0-4d4932aab5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97dea3cd-8bab-4503-a9a1-e43355289928" xlink:to="loc_us-gaap_AwardTypeAxis_4de83baa-39b5-4033-96b0-4d4932aab5d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4de83baa-39b5-4033-96b0-4d4932aab5d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4de83baa-39b5-4033-96b0-4d4932aab5d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4de83baa-39b5-4033-96b0-4d4932aab5d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722379ba-4116-42f8-93ba-5af4a5b44e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4de83baa-39b5-4033-96b0-4d4932aab5d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722379ba-4116-42f8-93ba-5af4a5b44e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember_32ea15fa-4d69-4cb5-97cf-9032b0bd30f5" xlink:href="ebs-20231231.xsd#ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722379ba-4116-42f8-93ba-5af4a5b44e7b" xlink:to="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember_32ea15fa-4d69-4cb5-97cf-9032b0bd30f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d6cd59a3-d96a-4a20-8e93-ec8c94b879dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d6cd59a3-d96a-4a20-8e93-ec8c94b879dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7895e001-3eb5-43b6-88c3-925f91ff7006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7895e001-3eb5-43b6-88c3-925f91ff7006" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3fbd715-32bd-40c8-9798-6adcfe71b5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3fbd715-32bd-40c8-9798-6adcfe71b5c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5503b0a2-3830-49a4-89de-663c79eabff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5503b0a2-3830-49a4-89de-663c79eabff7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d95c1529-0b16-44aa-8b4d-8cdbeb05df6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e11423de-65ee-4b90-9545-2cfd65cfad2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e11423de-65ee-4b90-9545-2cfd65cfad2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_966e9f8e-1885-4580-a5aa-222e53746c70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_966e9f8e-1885-4580-a5aa-222e53746c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf96c917-ea4c-44af-8ec5-f493f284859d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf96c917-ea4c-44af-8ec5-f493f284859d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6171656a-7fb2-4d29-a374-a136c1d20bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6171656a-7fb2-4d29-a374-a136c1d20bc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f8d5eeb4-0bfb-4d85-a634-9c5ff22b796f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f8d5eeb4-0bfb-4d85-a634-9c5ff22b796f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7bcc739c-d2fb-4a9e-a78d-a8c678195cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e8bfd807-e3ae-4668-8d30-4a6eb8bcfaad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e8bfd807-e3ae-4668-8d30-4a6eb8bcfaad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_f13557ed-6e22-4ee8-bace-8fc8ed25ad42" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_f13557ed-6e22-4ee8-bace-8fc8ed25ad42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_63280307-2b34-49cb-87de-7f8b411ae9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_f13557ed-6e22-4ee8-bace-8fc8ed25ad42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_63280307-2b34-49cb-87de-7f8b411ae9e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_887fc07a-1a82-4445-81eb-d92b53a3213b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_f13557ed-6e22-4ee8-bace-8fc8ed25ad42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_887fc07a-1a82-4445-81eb-d92b53a3213b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2b6c1668-4784-4deb-8978-7b7b189ed488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2b6c1668-4784-4deb-8978-7b7b189ed488" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d86c6f54-37e7-4ad8-b2bd-0ef2891ac5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2b6c1668-4784-4deb-8978-7b7b189ed488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d86c6f54-37e7-4ad8-b2bd-0ef2891ac5ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd63434a-4908-464b-9721-6109e62abc16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2b6c1668-4784-4deb-8978-7b7b189ed488" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd63434a-4908-464b-9721-6109e62abc16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7d9e517-1e62-4e9b-beda-f36546749600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7d9e517-1e62-4e9b-beda-f36546749600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba721a0b-1493-4a1a-ae17-93bfac288596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba721a0b-1493-4a1a-ae17-93bfac288596" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b80c020-a9ed-425d-acb3-afc2b3505778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b80c020-a9ed-425d-acb3-afc2b3505778" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ec78539-f51c-4381-b987-54236a0e0369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ec78539-f51c-4381-b987-54236a0e0369" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24df76e8-b6b7-43d5-bb74-17a51e832fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b9a4ea01-c7b8-4588-903b-2d3f8050a317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b9a4ea01-c7b8-4588-903b-2d3f8050a317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13f13c02-0212-4ac5-9263-a58ae106eaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13f13c02-0212-4ac5-9263-a58ae106eaa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b9c13c29-dc7a-4596-981a-7b28cda71ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b9c13c29-dc7a-4596-981a-7b28cda71ab8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b5efc2c2-5d0f-4823-a851-0faef30346d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b5efc2c2-5d0f-4823-a851-0faef30346d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_326f0df0-adc2-4d90-bafc-cef04439a76b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4e869582-5c67-4796-a9a3-7ca7e0bca9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4e869582-5c67-4796-a9a3-7ca7e0bca9d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_47b7b9a2-ed3d-4c61-bf53-cfc829cf32bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4e869582-5c67-4796-a9a3-7ca7e0bca9d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_47b7b9a2-ed3d-4c61-bf53-cfc829cf32bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_ff827e45-3f11-4e2d-84da-7f10c11cd289" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_ff827e45-3f11-4e2d-84da-7f10c11cd289" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3dcd921-cc9f-4fa0-87d7-93ac53fca286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e45d37e0-0a48-4442-91e0-08f28f227a31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3dcd921-cc9f-4fa0-87d7-93ac53fca286" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e45d37e0-0a48-4442-91e0-08f28f227a31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e5df4170-b66c-48a1-b233-6e4cf7c0d8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e45d37e0-0a48-4442-91e0-08f28f227a31" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e5df4170-b66c-48a1-b233-6e4cf7c0d8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e5df4170-b66c-48a1-b233-6e4cf7c0d8a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5df4170-b66c-48a1-b233-6e4cf7c0d8a4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e5df4170-b66c-48a1-b233-6e4cf7c0d8a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5df4170-b66c-48a1-b233-6e4cf7c0d8a4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b259e022-c49e-4181-a0de-85a9444318dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:to="loc_us-gaap_CostOfSalesMember_b259e022-c49e-4181-a0de-85a9444318dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba8e320d-5697-4f5f-8efb-074c65aa99d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba8e320d-5697-4f5f-8efb-074c65aa99d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_393fbd12-b161-4f63-946f-d84682409e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_393fbd12-b161-4f63-946f-d84682409e9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_efe32b32-2483-4e48-ba68-955108a2fac9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e45d37e0-0a48-4442-91e0-08f28f227a31" xlink:to="loc_srt_ProductOrServiceAxis_efe32b32-2483-4e48-ba68-955108a2fac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_efe32b32-2483-4e48-ba68-955108a2fac9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_efe32b32-2483-4e48-ba68-955108a2fac9" xlink:to="loc_srt_ProductsAndServicesDomain_efe32b32-2483-4e48-ba68-955108a2fac9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_efe32b32-2483-4e48-ba68-955108a2fac9" xlink:to="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember_549409ca-7196-4730-9be6-d83e4446f249" xlink:href="ebs-20231231.xsd#ebs_CommercialProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:to="loc_ebs_CommercialProductMember_549409ca-7196-4730-9be6-d83e4446f249" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember_e6def31f-9a58-436a-94fc-30d526d81d4c" xlink:href="ebs-20231231.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:to="loc_ebs_MedicalCountermeasuresMCMProductMember_e6def31f-9a58-436a-94fc-30d526d81d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesMember_d2199dc1-c4b3-4b57-a172-291d5df84d12" xlink:href="ebs-20231231.xsd#ebs_BioservicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:to="loc_ebs_BioservicesMember_d2199dc1-c4b3-4b57-a172-291d5df84d12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bd25e04c-8b51-4f83-83c0-e9007be779f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3dcd921-cc9f-4fa0-87d7-93ac53fca286" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bd25e04c-8b51-4f83-83c0-e9007be779f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9b2db5d3-10b5-46e3-9337-596fcc208e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8db79d6-7d0b-4629-a25b-75e7eefd5306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9b2db5d3-10b5-46e3-9337-596fcc208e4b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8db79d6-7d0b-4629-a25b-75e7eefd5306" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f2296446-7c3f-479b-a5d2-16a1dff89b68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8db79d6-7d0b-4629-a25b-75e7eefd5306" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f2296446-7c3f-479b-a5d2-16a1dff89b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f2296446-7c3f-479b-a5d2-16a1dff89b68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2296446-7c3f-479b-a5d2-16a1dff89b68" xlink:to="loc_us-gaap_EquityComponentDomain_f2296446-7c3f-479b-a5d2-16a1dff89b68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a4b1303d-088a-4628-91f5-796428e60fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2296446-7c3f-479b-a5d2-16a1dff89b68" xlink:to="loc_us-gaap_EquityComponentDomain_a4b1303d-088a-4628-91f5-796428e60fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4b1303d-088a-4628-91f5-796428e60fec" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_452278f7-7729-48fa-a8a2-8754d13b7e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_452278f7-7729-48fa-a8a2-8754d13b7e3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c19de148-41f7-4644-99e8-e2f1618135e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c19de148-41f7-4644-99e8-e2f1618135e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2bffa6b7-5a7d-49bf-b981-751da66ff5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2bffa6b7-5a7d-49bf-b981-751da66ff5d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9b2db5d3-10b5-46e3-9337-596fcc208e4b" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a91bce8-f4d7-44e2-a903-7ef264f88daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:to="loc_us-gaap_StockholdersEquity_3a91bce8-f4d7-44e2-a903-7ef264f88daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f087fc8d-b24d-46de-bea9-e97527ca225b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f087fc8d-b24d-46de-bea9-e97527ca225b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b2e19341-d0f2-4a9f-99e1-4d2227249de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b2e19341-d0f2-4a9f-99e1-4d2227249de7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7a59fc2a-572d-4411-b01b-a1f902c36f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7a59fc2a-572d-4411-b01b-a1f902c36f8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_21a7863a-b44c-4acc-b287-9eb94847ef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8be5f39b-676b-41f4-a9dd-f73eb73c0f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8be5f39b-676b-41f4-a9dd-f73eb73c0f6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f25826c2-a6fe-44d6-8719-07265398e585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8be5f39b-676b-41f4-a9dd-f73eb73c0f6e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f25826c2-a6fe-44d6-8719-07265398e585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f25826c2-a6fe-44d6-8719-07265398e585_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f25826c2-a6fe-44d6-8719-07265398e585" xlink:to="loc_us-gaap_EquityComponentDomain_f25826c2-a6fe-44d6-8719-07265398e585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f25826c2-a6fe-44d6-8719-07265398e585" xlink:to="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_4b2f673c-71c8-45b6-86b4-9179daa37434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_4b2f673c-71c8-45b6-86b4-9179daa37434" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_99ba6244-2ff7-40d8-a327-5b0db058e6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_99ba6244-2ff7-40d8-a327-5b0db058e6d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5d737692-aee9-4337-a231-2f2ffa24f211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5d737692-aee9-4337-a231-2f2ffa24f211" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_43e1d3c5-eab2-4d5e-a7f2-ede7d9cf9e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_43e1d3c5-eab2-4d5e-a7f2-ede7d9cf9e7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_7ccbb094-6d97-427c-a9e8-5b6310d93f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_7ccbb094-6d97-427c-a9e8-5b6310d93f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_83fac854-8391-40bb-8396-960a116b5146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_83fac854-8391-40bb-8396-960a116b5146" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3721fcc8-27df-402e-8a69-aed53b2e0350_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:to="loc_srt_NameOfMajorCustomerDomain_3721fcc8-27df-402e-8a69-aed53b2e0350_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:to="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_bb869e14-b669-45fa-97e3-c874d559c9cf" xlink:href="ebs-20231231.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_UnitedStatesGovernmentMember_bb869e14-b669-45fa-97e3-c874d559c9cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CustomerTwoMember_502b0afc-66ca-477a-a6a2-e676fe1cbf10" xlink:href="ebs-20231231.xsd#ebs_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_CustomerTwoMember_502b0afc-66ca-477a-a6a2-e676fe1cbf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_6c5c37bd-3a65-4182-815b-5979b3c61ed0" xlink:href="ebs-20231231.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_6c5c37bd-3a65-4182-815b-5979b3c61ed0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_9f661b77-4717-4a69-918b-1ed2776bfd13" xlink:href="ebs-20231231.xsd#ebs_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_BARDAMember_9f661b77-4717-4a69-918b-1ed2776bfd13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a617bbf4-644b-4789-a4c5-9187bf5aaae2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a617bbf4-644b-4789-a4c5-9187bf5aaae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0367b88a-64bc-4fc3-bb12-b98e8aaf6609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0367b88a-64bc-4fc3-bb12-b98e8aaf6609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_6a073eea-8ef1-4952-9a94-180b71442dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0367b88a-64bc-4fc3-bb12-b98e8aaf6609" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_6a073eea-8ef1-4952-9a94-180b71442dd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_41f25527-a499-4066-87b2-ad63502039ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_41f25527-a499-4066-87b2-ad63502039ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8bf0ffac-be91-42db-821a-17de5e5ce7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8bf0ffac-be91-42db-821a-17de5e5ce7cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_ef0d1307-6233-4bac-bf6c-bc1b1c4b8c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_ef0d1307-6233-4bac-bf6c-bc1b1c4b8c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_073804ef-08af-41b2-8681-e985b0f075c6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:to="loc_srt_SegmentGeographicalDomain_073804ef-08af-41b2-8681-e985b0f075c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:to="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f307e22e-9607-4658-aee7-812239947536" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:to="loc_country_US_f307e22e-9607-4658-aee7-812239947536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_6fd8db6c-81f1-4365-a6d8-4c455d6c05d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:to="loc_us-gaap_NonUsMember_6fd8db6c-81f1-4365-a6d8-4c455d6c05d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9354c98b-d035-444e-8c73-651066db0375_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9354c98b-d035-444e-8c73-651066db0375_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:to="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember_31c2d147-8a5e-4043-a758-e7c7f2a71c7d" xlink:href="ebs-20231231.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:to="loc_ebs_ReservationOfManufacturingCapacityMember_31c2d147-8a5e-4043-a758-e7c7f2a71c7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_f16a28b2-a32b-4ea6-a479-9aef425007b7" xlink:href="ebs-20231231.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:to="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_f16a28b2-a32b-4ea6-a479-9aef425007b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6699f2a2-de8d-4f69-a13f-449d532817c2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:to="loc_srt_ProductsAndServicesDomain_6699f2a2-de8d-4f69-a13f-449d532817c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:to="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesLeasesMember_c0be17d6-dd3d-4b6c-91c0-eb84a663ad73" xlink:href="ebs-20231231.xsd#ebs_BioservicesLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:to="loc_ebs_BioservicesLeasesMember_c0be17d6-dd3d-4b6c-91c0-eb84a663ad73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_80d77908-55b9-4fa9-ac79-6e84958a0044" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:to="loc_ebs_ContractsAndGrantsMember_80d77908-55b9-4fa9-ac79-6e84958a0044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_99eb1c7f-2298-468c-a12c-6614e032d728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_99eb1c7f-2298-468c-a12c-6614e032d728" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_d17d525e-ed0c-481b-a624-a31e2efeb2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_NumberOfReportableSegments_d17d525e-ed0c-481b-a624-a31e2efeb2b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4fa9f25d-184d-4e77-a5c2-48c4b459acb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4fa9f25d-184d-4e77-a5c2-48c4b459acb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_650c4e50-b1a9-434d-996c-16624755450c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_650c4e50-b1a9-434d-996c-16624755450c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_32f88514-edc3-43c5-a237-2611cb48cbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_32f88514-edc3-43c5-a237-2611cb48cbdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5ba4389a-1e0a-4350-bd50-7bf488e66b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5ba4389a-1e0a-4350-bd50-7bf488e66b3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_975c9ea4-cc93-430e-8c0c-47108dd34578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_975c9ea4-cc93-430e-8c0c-47108dd34578" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_f0c11c15-8ff7-40a8-ab4e-99fa5dbdeb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_f0c11c15-8ff7-40a8-ab4e-99fa5dbdeb9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a295bfb-d5be-42db-bef9-a7a9a09ec19b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a295bfb-d5be-42db-bef9-a7a9a09ec19b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_31a23ba0-3dc5-4e56-8b08-be891d9a77a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_31a23ba0-3dc5-4e56-8b08-be891d9a77a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_09f0e67f-d641-46b4-9b46-7df3e0c91be1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_09f0e67f-d641-46b4-9b46-7df3e0c91be1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_8d7456e9-6158-4509-a200-0f3779cdafad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_8d7456e9-6158-4509-a200-0f3779cdafad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_97ff830f-653c-4b12-b357-7345717602cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_97ff830f-653c-4b12-b357-7345717602cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_730b83f3-2428-4a1b-8c29-4bea161119c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_730b83f3-2428-4a1b-8c29-4bea161119c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_328deecd-b04d-48d9-80a2-899cd8a24c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_328deecd-b04d-48d9-80a2-899cd8a24c60" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_7b8889a9-360a-4475-aa96-2d59c6d26fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_7b8889a9-360a-4475-aa96-2d59c6d26fb7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_85ff2546-7d0d-41b2-be54-df1dc106fbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_85ff2546-7d0d-41b2-be54-df1dc106fbb0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_0ebcf1e7-9478-467a-bc15-d6e3c603ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_0ebcf1e7-9478-467a-bc15-d6e3c603ff59" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_fbe05050-47ac-43b1-bf61-686ff8c620eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_fbe05050-47ac-43b1-bf61-686ff8c620eb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b2db22a4-8ad0-49ea-ad97-9420d5af3af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b2db22a4-8ad0-49ea-ad97-9420d5af3af7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_eb5dad55-7677-4e36-9cb4-8652910d1217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_eb5dad55-7677-4e36-9cb4-8652910d1217" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3721fcc8-27df-402e-8a69-aed53b2e0350_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:to="loc_srt_NameOfMajorCustomerDomain_3721fcc8-27df-402e-8a69-aed53b2e0350_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:to="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_bb869e14-b669-45fa-97e3-c874d559c9cf" xlink:href="ebs-20231231.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_UnitedStatesGovernmentMember_bb869e14-b669-45fa-97e3-c874d559c9cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CustomerTwoMember_502b0afc-66ca-477a-a6a2-e676fe1cbf10" xlink:href="ebs-20231231.xsd#ebs_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_CustomerTwoMember_502b0afc-66ca-477a-a6a2-e676fe1cbf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_6c5c37bd-3a65-4182-815b-5979b3c61ed0" xlink:href="ebs-20231231.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_6c5c37bd-3a65-4182-815b-5979b3c61ed0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_9f661b77-4717-4a69-918b-1ed2776bfd13" xlink:href="ebs-20231231.xsd#ebs_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_BARDAMember_9f661b77-4717-4a69-918b-1ed2776bfd13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a617bbf4-644b-4789-a4c5-9187bf5aaae2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a617bbf4-644b-4789-a4c5-9187bf5aaae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0367b88a-64bc-4fc3-bb12-b98e8aaf6609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0367b88a-64bc-4fc3-bb12-b98e8aaf6609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_6a073eea-8ef1-4952-9a94-180b71442dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0367b88a-64bc-4fc3-bb12-b98e8aaf6609" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_6a073eea-8ef1-4952-9a94-180b71442dd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_41f25527-a499-4066-87b2-ad63502039ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_41f25527-a499-4066-87b2-ad63502039ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8bf0ffac-be91-42db-821a-17de5e5ce7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8bf0ffac-be91-42db-821a-17de5e5ce7cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_ef0d1307-6233-4bac-bf6c-bc1b1c4b8c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_ef0d1307-6233-4bac-bf6c-bc1b1c4b8c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_073804ef-08af-41b2-8681-e985b0f075c6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:to="loc_srt_SegmentGeographicalDomain_073804ef-08af-41b2-8681-e985b0f075c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:to="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f307e22e-9607-4658-aee7-812239947536" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:to="loc_country_US_f307e22e-9607-4658-aee7-812239947536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_6fd8db6c-81f1-4365-a6d8-4c455d6c05d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:to="loc_us-gaap_NonUsMember_6fd8db6c-81f1-4365-a6d8-4c455d6c05d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9354c98b-d035-444e-8c73-651066db0375_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9354c98b-d035-444e-8c73-651066db0375_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:to="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember_31c2d147-8a5e-4043-a758-e7c7f2a71c7d" xlink:href="ebs-20231231.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:to="loc_ebs_ReservationOfManufacturingCapacityMember_31c2d147-8a5e-4043-a758-e7c7f2a71c7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_f16a28b2-a32b-4ea6-a479-9aef425007b7" xlink:href="ebs-20231231.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:to="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_f16a28b2-a32b-4ea6-a479-9aef425007b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6699f2a2-de8d-4f69-a13f-449d532817c2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:to="loc_srt_ProductsAndServicesDomain_6699f2a2-de8d-4f69-a13f-449d532817c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:to="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesLeasesMember_c0be17d6-dd3d-4b6c-91c0-eb84a663ad73" xlink:href="ebs-20231231.xsd#ebs_BioservicesLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:to="loc_ebs_BioservicesLeasesMember_c0be17d6-dd3d-4b6c-91c0-eb84a663ad73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_80d77908-55b9-4fa9-ac79-6e84958a0044" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:to="loc_ebs_ContractsAndGrantsMember_80d77908-55b9-4fa9-ac79-6e84958a0044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_d17d525e-ed0c-481b-a624-a31e2efeb2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_NumberOfReportableSegments_d17d525e-ed0c-481b-a624-a31e2efeb2b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4fa9f25d-184d-4e77-a5c2-48c4b459acb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4fa9f25d-184d-4e77-a5c2-48c4b459acb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_650c4e50-b1a9-434d-996c-16624755450c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_650c4e50-b1a9-434d-996c-16624755450c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_32f88514-edc3-43c5-a237-2611cb48cbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_32f88514-edc3-43c5-a237-2611cb48cbdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5ba4389a-1e0a-4350-bd50-7bf488e66b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5ba4389a-1e0a-4350-bd50-7bf488e66b3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_975c9ea4-cc93-430e-8c0c-47108dd34578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_975c9ea4-cc93-430e-8c0c-47108dd34578" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_f0c11c15-8ff7-40a8-ab4e-99fa5dbdeb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_f0c11c15-8ff7-40a8-ab4e-99fa5dbdeb9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a295bfb-d5be-42db-bef9-a7a9a09ec19b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a295bfb-d5be-42db-bef9-a7a9a09ec19b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_31a23ba0-3dc5-4e56-8b08-be891d9a77a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_31a23ba0-3dc5-4e56-8b08-be891d9a77a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_09f0e67f-d641-46b4-9b46-7df3e0c91be1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_09f0e67f-d641-46b4-9b46-7df3e0c91be1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_8d7456e9-6158-4509-a200-0f3779cdafad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_8d7456e9-6158-4509-a200-0f3779cdafad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_97ff830f-653c-4b12-b357-7345717602cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_97ff830f-653c-4b12-b357-7345717602cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_730b83f3-2428-4a1b-8c29-4bea161119c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_730b83f3-2428-4a1b-8c29-4bea161119c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_328deecd-b04d-48d9-80a2-899cd8a24c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_328deecd-b04d-48d9-80a2-899cd8a24c60" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_7b8889a9-360a-4475-aa96-2d59c6d26fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_7b8889a9-360a-4475-aa96-2d59c6d26fb7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_85ff2546-7d0d-41b2-be54-df1dc106fbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_85ff2546-7d0d-41b2-be54-df1dc106fbb0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_0ebcf1e7-9478-467a-bc15-d6e3c603ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_0ebcf1e7-9478-467a-bc15-d6e3c603ff59" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_fbe05050-47ac-43b1-bf61-686ff8c620eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_fbe05050-47ac-43b1-bf61-686ff8c620eb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b2db22a4-8ad0-49ea-ad97-9420d5af3af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b2db22a4-8ad0-49ea-ad97-9420d5af3af7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_eb5dad55-7677-4e36-9cb4-8652910d1217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_eb5dad55-7677-4e36-9cb4-8652910d1217" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2c799566-55db-4eaa-8b63-0f60d422bdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2c799566-55db-4eaa-8b63-0f60d422bdf8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b60f7fb-cf0f-447d-ba02-80dbcd641740" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2c799566-55db-4eaa-8b63-0f60d422bdf8" xlink:to="loc_srt_ProductOrServiceAxis_9b60f7fb-cf0f-447d-ba02-80dbcd641740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b60f7fb-cf0f-447d-ba02-80dbcd641740_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9b60f7fb-cf0f-447d-ba02-80dbcd641740" xlink:to="loc_srt_ProductsAndServicesDomain_9b60f7fb-cf0f-447d-ba02-80dbcd641740_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9b60f7fb-cf0f-447d-ba02-80dbcd641740" xlink:to="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember_32b5811d-e66e-460f-99a5-8a429c6751a0" xlink:href="ebs-20231231.xsd#ebs_CommercialProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:to="loc_ebs_CommercialProductMember_32b5811d-e66e-460f-99a5-8a429c6751a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember_151d5f74-da8b-47ac-a7a4-0e8cc335e54f" xlink:href="ebs-20231231.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:to="loc_ebs_MedicalCountermeasuresMCMProductMember_151d5f74-da8b-47ac-a7a4-0e8cc335e54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesMember_d8733611-6197-4568-9486-c424a639e396" xlink:href="ebs-20231231.xsd#ebs_BioservicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:to="loc_ebs_BioservicesMember_d8733611-6197-4568-9486-c424a639e396" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_c3fb4965-91f2-441c-b804-754a939bab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_BioservicesMember_d8733611-6197-4568-9486-c424a639e396" xlink:to="loc_us-gaap_ServiceMember_c3fb4965-91f2-441c-b804-754a939bab7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesLeasesMember_8aaa65d8-b7d8-45f0-8c87-ac52a0be5c72" xlink:href="ebs-20231231.xsd#ebs_BioservicesLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_BioservicesMember_d8733611-6197-4568-9486-c424a639e396" xlink:to="loc_ebs_BioservicesLeasesMember_8aaa65d8-b7d8-45f0-8c87-ac52a0be5c72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_370c5551-6820-44ea-b17d-4e46f0b9fa0a" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:to="loc_ebs_ContractsAndGrantsMember_370c5551-6820-44ea-b17d-4e46f0b9fa0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ca684d5b-818b-470d-b420-ea9121821120" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2c799566-55db-4eaa-8b63-0f60d422bdf8" xlink:to="loc_srt_MajorCustomersAxis_ca684d5b-818b-470d-b420-ea9121821120" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ca684d5b-818b-470d-b420-ea9121821120_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ca684d5b-818b-470d-b420-ea9121821120" xlink:to="loc_srt_NameOfMajorCustomerDomain_ca684d5b-818b-470d-b420-ea9121821120_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ce9cba2c-1b91-4088-bc8a-e82b1bbc3504" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ca684d5b-818b-470d-b420-ea9121821120" xlink:to="loc_srt_NameOfMajorCustomerDomain_ce9cba2c-1b91-4088-bc8a-e82b1bbc3504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_9b816af0-24b0-4ccc-99f9-26c18bcbdcd6" xlink:href="ebs-20231231.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ce9cba2c-1b91-4088-bc8a-e82b1bbc3504" xlink:to="loc_ebs_UnitedStatesGovernmentMember_9b816af0-24b0-4ccc-99f9-26c18bcbdcd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NonUnitedStatesGovernmentMember_ddedcf73-812b-48a3-a4a1-e17dff95982b" xlink:href="ebs-20231231.xsd#ebs_NonUnitedStatesGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ce9cba2c-1b91-4088-bc8a-e82b1bbc3504" xlink:to="loc_ebs_NonUnitedStatesGovernmentMember_ddedcf73-812b-48a3-a4a1-e17dff95982b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4386edaa-e23a-4a60-b02c-f5fca5ca6616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4386edaa-e23a-4a60-b02c-f5fca5ca6616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_120c7f73-9ec4-4ddb-823b-ec901acec507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_120c7f73-9ec4-4ddb-823b-ec901acec507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d71ff768-3d6b-461e-b261-8d1ef9479d26" xlink:href="ebs-20231231.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d71ff768-3d6b-461e-b261-8d1ef9479d26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_144758fc-8873-44cb-9c51-336b0e12fb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:to="loc_us-gaap_Revenues_144758fc-8873-44cb-9c51-336b0e12fb3a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionPercentageofProductSalesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_77c5d13d-f6a6-47f1-931d-3a18919484da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_77c5d13d-f6a6-47f1-931d-3a18919484da" xlink:to="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_015231e0-07d7-4da2-85e4-d78fdf3919ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:to="loc_srt_ProductOrServiceAxis_015231e0-07d7-4da2-85e4-d78fdf3919ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_015231e0-07d7-4da2-85e4-d78fdf3919ce_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_015231e0-07d7-4da2-85e4-d78fdf3919ce" xlink:to="loc_srt_ProductsAndServicesDomain_015231e0-07d7-4da2-85e4-d78fdf3919ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_015231e0-07d7-4da2-85e4-d78fdf3919ce" xlink:to="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NARCANMember_e820ed96-16d8-4c6e-a40c-fde4318b09b5" xlink:href="ebs-20231231.xsd#ebs_NARCANMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_NARCANMember_e820ed96-16d8-4c6e-a40c-fde4318b09b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherCommercialProductsMember_2affebd6-a6a7-4173-b09b-ab51fee87be5" xlink:href="ebs-20231231.xsd#ebs_OtherCommercialProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_OtherCommercialProductsMember_2affebd6-a6a7-4173-b09b-ab51fee87be5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AnthraxMCMMember_331df583-667a-4830-aa8e-b3e264b62172" xlink:href="ebs-20231231.xsd#ebs_AnthraxMCMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_AnthraxMCMMember_331df583-667a-4830-aa8e-b3e264b62172" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SmallpoxMCMMember_57c347a8-c7a4-48fd-b598-d2b9595ac711" xlink:href="ebs-20231231.xsd#ebs_SmallpoxMCMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_SmallpoxMCMMember_57c347a8-c7a4-48fd-b598-d2b9595ac711" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherProductsMember_822de368-c7a2-4b76-95d1-1891b61475b3" xlink:href="ebs-20231231.xsd#ebs_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_OtherProductsMember_822de368-c7a2-4b76-95d1-1891b61475b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3c56ac32-f908-435c-bf3f-e773e89673a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3c56ac32-f908-435c-bf3f-e773e89673a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3c56ac32-f908-435c-bf3f-e773e89673a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3c56ac32-f908-435c-bf3f-e773e89673a7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3c56ac32-f908-435c-bf3f-e773e89673a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9c356a8-89a6-4a25-8bde-bba802fe63ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3c56ac32-f908-435c-bf3f-e773e89673a7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9c356a8-89a6-4a25-8bde-bba802fe63ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_514a3695-3351-4aaf-8cbf-3a689439f866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9c356a8-89a6-4a25-8bde-bba802fe63ae" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_514a3695-3351-4aaf-8cbf-3a689439f866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_91728fe1-5a58-4d3b-8f92-71a4df1928ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_91728fe1-5a58-4d3b-8f92-71a4df1928ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_91728fe1-5a58-4d3b-8f92-71a4df1928ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_91728fe1-5a58-4d3b-8f92-71a4df1928ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_91728fe1-5a58-4d3b-8f92-71a4df1928ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ef3eb6a2-3351-450f-98cf-c7d50580874f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_91728fe1-5a58-4d3b-8f92-71a4df1928ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ef3eb6a2-3351-450f-98cf-c7d50580874f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d515586b-5c04-4b61-91a2-1af2291c3b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ef3eb6a2-3351-450f-98cf-c7d50580874f" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d515586b-5c04-4b61-91a2-1af2291c3b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c060bec2-5b6e-4c33-b579-0dc0c0a9e681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_77c5d13d-f6a6-47f1-931d-3a18919484da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c060bec2-5b6e-4c33-b579-0dc0c0a9e681" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2924c3e4-0592-4fbb-92bd-09f7493c49be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8f6ea6ad-cbfa-4533-b58f-f9a5b21ab9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2924c3e4-0592-4fbb-92bd-09f7493c49be" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8f6ea6ad-cbfa-4533-b58f-f9a5b21ab9e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36915cad-3a53-42fb-8caa-24bd985ae493" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8f6ea6ad-cbfa-4533-b58f-f9a5b21ab9e5" xlink:to="loc_srt_RangeAxis_36915cad-3a53-42fb-8caa-24bd985ae493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36915cad-3a53-42fb-8caa-24bd985ae493_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_36915cad-3a53-42fb-8caa-24bd985ae493" xlink:to="loc_srt_RangeMember_36915cad-3a53-42fb-8caa-24bd985ae493_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f37500c-56b0-4a3c-a2dc-9b3352a717d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_36915cad-3a53-42fb-8caa-24bd985ae493" xlink:to="loc_srt_RangeMember_7f37500c-56b0-4a3c-a2dc-9b3352a717d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2b4900af-cd5a-4032-97c0-f232e0f46e24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7f37500c-56b0-4a3c-a2dc-9b3352a717d6" xlink:to="loc_srt_MinimumMember_2b4900af-cd5a-4032-97c0-f232e0f46e24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb09721f-d200-4543-9f22-9007fee52ff7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7f37500c-56b0-4a3c-a2dc-9b3352a717d6" xlink:to="loc_srt_MaximumMember_fb09721f-d200-4543-9f22-9007fee52ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_eb49c590-29b4-461b-87fa-79f148d1840e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2924c3e4-0592-4fbb-92bd-09f7493c49be" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_eb49c590-29b4-461b-87fa-79f148d1840e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_23482494-0863-4b36-a4be-a2935ffdb6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2924c3e4-0592-4fbb-92bd-09f7493c49be" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_23482494-0863-4b36-a4be-a2935ffdb6ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_289b811d-fec2-4c55-abda-8f4aa93eff67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_289b811d-fec2-4c55-abda-8f4aa93eff67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_289b811d-fec2-4c55-abda-8f4aa93eff67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_289b811d-fec2-4c55-abda-8f4aa93eff67" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_289b811d-fec2-4c55-abda-8f4aa93eff67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_289b811d-fec2-4c55-abda-8f4aa93eff67" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8b56f6a8-27dc-4f64-827d-e7174e0e9c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:to="loc_us-gaap_DomesticCountryMember_8b56f6a8-27dc-4f64-827d-e7174e0e9c23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_359924b2-5a5d-4c2a-8436-561e0fd71831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_359924b2-5a5d-4c2a-8436-561e0fd71831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_3f3ca23d-40da-468d-8413-220faf42b713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:to="loc_us-gaap_ForeignCountryMember_3f3ca23d-40da-468d-8413-220faf42b713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_197c0cb1-9135-4f9c-b288-5f4e55b6ca76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_197c0cb1-9135-4f9c-b288-5f4e55b6ca76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_197c0cb1-9135-4f9c-b288-5f4e55b6ca76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_197c0cb1-9135-4f9c-b288-5f4e55b6ca76" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_197c0cb1-9135-4f9c-b288-5f4e55b6ca76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_b85674b2-62ee-454b-b7a7-59b50466ebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_197c0cb1-9135-4f9c-b288-5f4e55b6ca76" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_b85674b2-62ee-454b-b7a7-59b50466ebb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_7963413b-1fe4-4c34-97f5-18e8d6f8c960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_b85674b2-62ee-454b-b7a7-59b50466ebb2" xlink:to="loc_us-gaap_ResearchMember_7963413b-1fe4-4c34-97f5-18e8d6f8c960" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_32884107-f4ef-455b-a677-2fbe5626bd5d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:to="loc_srt_StatementGeographicalAxis_32884107-f4ef-455b-a677-2fbe5626bd5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32884107-f4ef-455b-a677-2fbe5626bd5d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_32884107-f4ef-455b-a677-2fbe5626bd5d" xlink:to="loc_srt_SegmentGeographicalDomain_32884107-f4ef-455b-a677-2fbe5626bd5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4b6d9d0a-1f7c-4aad-ae91-f8279274ad54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_32884107-f4ef-455b-a677-2fbe5626bd5d" xlink:to="loc_srt_SegmentGeographicalDomain_4b6d9d0a-1f7c-4aad-ae91-f8279274ad54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_191311a4-083a-4ed3-81d2-2618467cd0bd" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4b6d9d0a-1f7c-4aad-ae91-f8279274ad54" xlink:to="loc_stpr_CA_191311a4-083a-4ed3-81d2-2618467cd0bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount_847ae571-ce68-4225-9147-0aa4e51a8d0c" xlink:href="ebs-20231231.xsd#ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount_847ae571-ce68-4225-9147-0aa4e51a8d0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_c3f1ef11-6b3c-4fca-a0d7-2121d9070b64" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxLiabilitiesForeignWithholdingTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_c3f1ef11-6b3c-4fca-a0d7-2121d9070b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6b9cb206-93ef-4992-9ac6-ad69f70672a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6b9cb206-93ef-4992-9ac6-ad69f70672a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLossCarryforwardsSubjectToExpiration_17448cd4-09b8-42ea-a006-2a02d995d9ad" xlink:href="ebs-20231231.xsd#ebs_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_OperatingLossCarryforwardsSubjectToExpiration_17448cd4-09b8-42ea-a006-2a02d995d9ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLossCarryforwardsNotSubjectToExpiration_d9471840-a979-4dbf-bac4-48c5add2d769" xlink:href="ebs-20231231.xsd#ebs_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_OperatingLossCarryforwardsNotSubjectToExpiration_d9471840-a979-4dbf-bac4-48c5add2d769" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e3aedced-1c23-4976-9438-e5e6114d3bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e3aedced-1c23-4976-9438-e5e6114d3bbe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5514279b-c36a-4bf1-84ba-b4ab7b69b9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5514279b-c36a-4bf1-84ba-b4ab7b69b9c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6bec7aa4-9656-4344-b2c7-1aa9df319730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6bec7aa4-9656-4344-b2c7-1aa9df319730" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnrecognizedTaxBenefitsNoncurrent_8ffddd3e-aa78-4222-802e-3b3523552227" xlink:href="ebs-20231231.xsd#ebs_UnrecognizedTaxBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_UnrecognizedTaxBenefitsNoncurrent_8ffddd3e-aa78-4222-802e-3b3523552227" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_489dc485-b0e4-4c21-9c67-8f968fafcdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_489dc485-b0e4-4c21-9c67-8f968fafcdb4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_64926800-b989-4059-a758-24b31e154ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_64926800-b989-4059-a758-24b31e154ff3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3e66d2d0-a19e-48e2-a389-6560ff49ddfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3e66d2d0-a19e-48e2-a389-6560ff49ddfc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d7de6914-3859-4424-8fae-b965456e6c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d7de6914-3859-4424-8fae-b965456e6c9f" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_376f50f4-1057-4a6c-8152-0adb3e9b726a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_376f50f4-1057-4a6c-8152-0adb3e9b726a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_376f50f4-1057-4a6c-8152-0adb3e9b726a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_376f50f4-1057-4a6c-8152-0adb3e9b726a" xlink:to="loc_us-gaap_SegmentDomain_376f50f4-1057-4a6c-8152-0adb3e9b726a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_376f50f4-1057-4a6c-8152-0adb3e9b726a" xlink:to="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_cbb13ddb-8c9e-43d5-9f7e-35abf8ad5268" xlink:href="ebs-20231231.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:to="loc_ebs_CommercialProductsSegmentMember_cbb13ddb-8c9e-43d5-9f7e-35abf8ad5268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_5be19b26-127c-4f55-8287-6e0bcec6c04b" xlink:href="ebs-20231231.xsd#ebs_MCMProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:to="loc_ebs_MCMProductsSegmentMember_5be19b26-127c-4f55-8287-6e0bcec6c04b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_203275d9-f24e-4c53-b0e8-7e8a3e5331a6" xlink:href="ebs-20231231.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:to="loc_ebs_ServicesSegmentMember_203275d9-f24e-4c53-b0e8-7e8a3e5331a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5187d25-0efa-4edd-88ea-6fe66614fb16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:to="loc_srt_ProductOrServiceAxis_e5187d25-0efa-4edd-88ea-6fe66614fb16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5187d25-0efa-4edd-88ea-6fe66614fb16_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e5187d25-0efa-4edd-88ea-6fe66614fb16" xlink:to="loc_srt_ProductsAndServicesDomain_e5187d25-0efa-4edd-88ea-6fe66614fb16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_77cdc7c5-7f3a-4222-9248-c5a6ca86765c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e5187d25-0efa-4edd-88ea-6fe66614fb16" xlink:to="loc_srt_ProductsAndServicesDomain_77cdc7c5-7f3a-4222-9248-c5a6ca86765c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_1d366b39-9b26-43eb-a7b3-c7bb910c08b9" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_77cdc7c5-7f3a-4222-9248-c5a6ca86765c" xlink:to="loc_ebs_ContractsAndGrantsMember_1d366b39-9b26-43eb-a7b3-c7bb910c08b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1c14b8ba-fe35-419b-924d-e22b222890c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:to="loc_srt_MajorCustomersAxis_1c14b8ba-fe35-419b-924d-e22b222890c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1c14b8ba-fe35-419b-924d-e22b222890c1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1c14b8ba-fe35-419b-924d-e22b222890c1" xlink:to="loc_srt_NameOfMajorCustomerDomain_1c14b8ba-fe35-419b-924d-e22b222890c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5ff95b33-b7e9-462f-9e0b-2fb1cd80ccda" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1c14b8ba-fe35-419b-924d-e22b222890c1" xlink:to="loc_srt_NameOfMajorCustomerDomain_5ff95b33-b7e9-462f-9e0b-2fb1cd80ccda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_e9c9d48b-a26c-4143-9e48-ef6df12f6da1" xlink:href="ebs-20231231.xsd#ebs_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5ff95b33-b7e9-462f-9e0b-2fb1cd80ccda" xlink:to="loc_ebs_BARDAMember_e9c9d48b-a26c-4143-9e48-ef6df12f6da1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_72babbaf-34a1-4c3b-9ac9-8d89a960c044" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:to="loc_srt_ConsolidationItemsAxis_72babbaf-34a1-4c3b-9ac9-8d89a960c044" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_72babbaf-34a1-4c3b-9ac9-8d89a960c044_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_72babbaf-34a1-4c3b-9ac9-8d89a960c044" xlink:to="loc_srt_ConsolidationItemsDomain_72babbaf-34a1-4c3b-9ac9-8d89a960c044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_799ca22e-b7da-4100-bed4-a6664b7a25ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_72babbaf-34a1-4c3b-9ac9-8d89a960c044" xlink:to="loc_srt_ConsolidationItemsDomain_799ca22e-b7da-4100-bed4-a6664b7a25ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8132a1cc-14e2-417c-8834-3c4786b6241f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_799ca22e-b7da-4100-bed4-a6664b7a25ee" xlink:to="loc_us-gaap_OperatingSegmentsMember_8132a1cc-14e2-417c-8834-3c4786b6241f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_ee28e980-9854-4ccd-8b5e-5b901f5d133a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_799ca22e-b7da-4100-bed4-a6664b7a25ee" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_ee28e980-9854-4ccd-8b5e-5b901f5d133a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_25d812c9-bd11-47b8-9893-e6e086f070b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_25d812c9-bd11-47b8-9893-e6e086f070b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_dcea717a-d1b5-4ba3-80f7-3a4437d0ea99" xlink:href="ebs-20231231.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_dcea717a-d1b5-4ba3-80f7-3a4437d0ea99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_146d132a-963a-41a1-ab72-63861fe9f765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:to="loc_us-gaap_Revenues_146d132a-963a-41a1-ab72-63861fe9f765" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_463adbfc-6e55-4a19-a667-29f93b9dcf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_463adbfc-6e55-4a19-a667-29f93b9dcf3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6f0439d6-4a8e-4cf8-8fc2-fdaaa23fc872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_463adbfc-6e55-4a19-a667-29f93b9dcf3f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6f0439d6-4a8e-4cf8-8fc2-fdaaa23fc872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_3fee109f-db3d-420e-8e9c-da3841d5562c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_GrossProfit_3fee109f-db3d-420e-8e9c-da3841d5562c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_GrossProfitPercentage_366f4179-3d91-43a8-8397-03a976bcc709" xlink:href="ebs-20231231.xsd#ebs_GrossProfitPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_ebs_GrossProfitPercentage_366f4179-3d91-43a8-8397-03a976bcc709" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_19252944-473d-4d16-9a93-026149ecd9b3" xlink:href="ebs-20231231.xsd#ebs_AdjustedGrossMargin"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_ebs_AdjustedGrossMargin_19252944-473d-4d16-9a93-026149ecd9b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_8e61f1d4-cdc0-418d-b11e-58bda60b343a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_8e61f1d4-cdc0-418d-b11e-58bda60b343a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9682cc7b-d28d-4de8-83fd-3a7b3c1a3d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_RestructuringCharges_9682cc7b-d28d-4de8-83fd-3a7b3c1a3d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_InventoryStepUp_b08ef398-7b79-44b4-890c-4558fa305e89" xlink:href="ebs-20231231.xsd#ebs_InventoryStepUp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_ebs_InventoryStepUp_b08ef398-7b79-44b4-890c-4558fa305e89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_549f216e-a39e-4287-8324-894f0aae01d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_549f216e-a39e-4287-8324-894f0aae01d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0d789d76-b0a5-4b5a-993f-a84c159d933b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0d789d76-b0a5-4b5a-993f-a84c159d933b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_56bfcc01-a867-4a58-8de9-3780118910d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_56bfcc01-a867-4a58-8de9-3780118910d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8a1abd27-1878-4b10-8a5d-6b6abb1ba2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8a1abd27-1878-4b10-8a5d-6b6abb1ba2e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5d8802e4-ea77-42e2-836a-a81ea036a39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5d8802e4-ea77-42e2-836a-a81ea036a39e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8ea5051d-2d94-4658-8a30-8c81b6a31c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8ea5051d-2d94-4658-8a30-8c81b6a31c6b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_19eb398d-0c2a-46a0-b3df-18c5b0cbbd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_InterestExpense_19eb398d-0c2a-46a0-b3df-18c5b0cbbd00" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_eb19343e-9677-4e2a-8f5c-687818f6f523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_eb19343e-9677-4e2a-8f5c-687818f6f523" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2b85c9ae-8009-44cc-a104-a062a316f63c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2b85c9ae-8009-44cc-a104-a062a316f63c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b6410c6b-84d9-4464-97be-1026e6ebbf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b6410c6b-84d9-4464-97be-1026e6ebbf6d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8de4ca2d-f367-4d16-ac10-fb51a97399b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_51b7d2b0-8d2d-41cc-bba4-295f2fffbac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8de4ca2d-f367-4d16-ac10-fb51a97399b5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_51b7d2b0-8d2d-41cc-bba4-295f2fffbac7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8d870430-148a-416c-9702-23b9186c51b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_51b7d2b0-8d2d-41cc-bba4-295f2fffbac7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8d870430-148a-416c-9702-23b9186c51b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8d870430-148a-416c-9702-23b9186c51b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8d870430-148a-416c-9702-23b9186c51b4" xlink:to="loc_us-gaap_SegmentDomain_8d870430-148a-416c-9702-23b9186c51b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8d870430-148a-416c-9702-23b9186c51b4" xlink:to="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_ae1a07db-9b2c-4f22-b042-48e76fdbae1d" xlink:href="ebs-20231231.xsd#ebs_MCMProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:to="loc_ebs_MCMProductsSegmentMember_ae1a07db-9b2c-4f22-b042-48e76fdbae1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_7020feaa-fe46-42e9-97f5-e133c3bb1889" xlink:href="ebs-20231231.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:to="loc_ebs_CommercialProductsSegmentMember_7020feaa-fe46-42e9-97f5-e133c3bb1889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_a46fc306-0886-4a20-8251-97a1825f6d5e" xlink:href="ebs-20231231.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:to="loc_ebs_ServicesSegmentMember_a46fc306-0886-4a20-8251-97a1825f6d5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1143644e-d46b-44ad-8a45-4772b9b5bfb4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_51b7d2b0-8d2d-41cc-bba4-295f2fffbac7" xlink:to="loc_srt_ConsolidationItemsAxis_1143644e-d46b-44ad-8a45-4772b9b5bfb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1143644e-d46b-44ad-8a45-4772b9b5bfb4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_1143644e-d46b-44ad-8a45-4772b9b5bfb4" xlink:to="loc_srt_ConsolidationItemsDomain_1143644e-d46b-44ad-8a45-4772b9b5bfb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ac3d137d-1709-4f90-9d5c-30c1c06d246f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_1143644e-d46b-44ad-8a45-4772b9b5bfb4" xlink:to="loc_srt_ConsolidationItemsDomain_ac3d137d-1709-4f90-9d5c-30c1c06d246f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_81ddaabc-59c7-4d4a-9d20-61de39eb47cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ac3d137d-1709-4f90-9d5c-30c1c06d246f" xlink:to="loc_us-gaap_OperatingSegmentsMember_81ddaabc-59c7-4d4a-9d20-61de39eb47cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_cc11f7b1-10d4-44b4-b978-dfe85635e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ac3d137d-1709-4f90-9d5c-30c1c06d246f" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_cc11f7b1-10d4-44b4-b978-dfe85635e8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_74e96b03-05c3-467f-89b2-ac91c5aaa786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8de4ca2d-f367-4d16-ac10-fb51a97399b5" xlink:to="loc_us-gaap_Depreciation_74e96b03-05c3-467f-89b2-ac91c5aaa786" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9abc4cf8-c096-4aca-bcf8-206b290953a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3da44fd8-e007-4103-99c1-e5e6ca828a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9abc4cf8-c096-4aca-bcf8-206b290953a0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3da44fd8-e007-4103-99c1-e5e6ca828a18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ab26d1de-f716-4330-9b04-3803a27159d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3da44fd8-e007-4103-99c1-e5e6ca828a18" xlink:to="loc_srt_StatementGeographicalAxis_ab26d1de-f716-4330-9b04-3803a27159d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ab26d1de-f716-4330-9b04-3803a27159d9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ab26d1de-f716-4330-9b04-3803a27159d9" xlink:to="loc_srt_SegmentGeographicalDomain_ab26d1de-f716-4330-9b04-3803a27159d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ab26d1de-f716-4330-9b04-3803a27159d9" xlink:to="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0b62c707-cf28-4382-a736-55efbf09b14e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:to="loc_country_US_0b62c707-cf28-4382-a736-55efbf09b14e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_6994f5f9-8868-4876-867d-be22ac0ba7b7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:to="loc_country_CA_6994f5f9-8868-4876-867d-be22ac0ba7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherGeographicalAreaMember_4a3904b6-f835-4074-9be6-278e8e18d439" xlink:href="ebs-20231231.xsd#ebs_OtherGeographicalAreaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:to="loc_ebs_OtherGeographicalAreaMember_4a3904b6-f835-4074-9be6-278e8e18d439" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_602c65a1-a9c0-40f6-96bd-b1c4c845efe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9abc4cf8-c096-4aca-bcf8-206b290953a0" xlink:to="loc_us-gaap_Revenues_602c65a1-a9c0-40f6-96bd-b1c4c845efe7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationLongLivedAssetsbyGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_cfc92773-e80d-4b48-9419-e50a10339703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_09fb9d47-1a89-4c85-8974-aef28cfbd002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_cfc92773-e80d-4b48-9419-e50a10339703" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_09fb9d47-1a89-4c85-8974-aef28cfbd002" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2159ef28-dc0f-4c1b-bf9f-22f7c120af38" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_09fb9d47-1a89-4c85-8974-aef28cfbd002" xlink:to="loc_srt_StatementGeographicalAxis_2159ef28-dc0f-4c1b-bf9f-22f7c120af38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2159ef28-dc0f-4c1b-bf9f-22f7c120af38_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2159ef28-dc0f-4c1b-bf9f-22f7c120af38" xlink:to="loc_srt_SegmentGeographicalDomain_2159ef28-dc0f-4c1b-bf9f-22f7c120af38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2159ef28-dc0f-4c1b-bf9f-22f7c120af38" xlink:to="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_734134b9-96d5-42f5-8c8d-7f8232435c9c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:to="loc_country_US_734134b9-96d5-42f5-8c8d-7f8232435c9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_eedadce9-9092-4d1b-9f63-b813cf90ac81" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:to="loc_country_CH_eedadce9-9092-4d1b-9f63-b813cf90ac81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_1b101942-8c11-4083-aa59-0034bc582e1b" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:to="loc_country_CA_1b101942-8c11-4083-aa59-0034bc582e1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherGeographicalAreaMember_3861465f-23e6-43ef-823c-c03ccf174921" xlink:href="ebs-20231231.xsd#ebs_OtherGeographicalAreaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:to="loc_ebs_OtherGeographicalAreaMember_3861465f-23e6-43ef-823c-c03ccf174921" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_07eb6a31-3d56-4b20-be78-dfe0ce34c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_cfc92773-e80d-4b48-9419-e50a10339703" xlink:to="loc_us-gaap_NoncurrentAssets_07eb6a31-3d56-4b20-be78-dfe0ce34c73f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b7b8d06d-9e1c-4189-af39-732c33632bc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc46b161-a8a7-407a-81dc-8780ef9eefa4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b7b8d06d-9e1c-4189-af39-732c33632bc8" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc46b161-a8a7-407a-81dc-8780ef9eefa4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6f692257-7131-4278-94f7-01117bc75c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc46b161-a8a7-407a-81dc-8780ef9eefa4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6f692257-7131-4278-94f7-01117bc75c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_6f692257-7131-4278-94f7-01117bc75c97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6f692257-7131-4278-94f7-01117bc75c97" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_6f692257-7131-4278-94f7-01117bc75c97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_6cb5854e-3fa4-431d-ae66-0925c3fc284f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6f692257-7131-4278-94f7-01117bc75c97" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_6cb5854e-3fa4-431d-ae66-0925c3fc284f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember_54118a79-d852-49b9-a59d-b6c81374cb40" xlink:href="ebs-20231231.xsd#ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6cb5854e-3fa4-431d-ae66-0925c3fc284f" xlink:to="loc_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember_54118a79-d852-49b9-a59d-b6c81374cb40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b7b8d06d-9e1c-4189-af39-732c33632bc8" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_21ec5e5f-5974-4d63-9f18-6dd774d0ba3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_21ec5e5f-5974-4d63-9f18-6dd774d0ba3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c8dea8f2-1ff1-43b8-a940-376b7005da1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c8dea8f2-1ff1-43b8-a940-376b7005da1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8bc5dc19-389f-48f4-8b1c-0ea0bda9c4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8bc5dc19-389f-48f4-8b1c-0ea0bda9c4e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d6dca8be-c847-41ab-a331-f5211e2ef8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember_865bd445-1c35-487e-8af4-1a0fab728ce0" xlink:href="ebs-20231231.xsd#ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember_865bd445-1c35-487e-8af4-1a0fab728ce0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="6"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>ebs-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c54bb9fe-5fe3-484c-8c37-1247bde19e06,g:0a179766-9174-4357-afdf-29ab18a19ddc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ServicesSegmentMember_e14748de-dcfe-44c2-a265-af72da8be863_terseLabel_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services</link:label>
    <link:label id="lab_ebs_ServicesSegmentMember_label_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Services Segment [Member]</link:label>
    <link:label id="lab_ebs_ServicesSegmentMember_documentation_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember" xlink:href="ebs-20231231.xsd#ebs_ServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ServicesSegmentMember" xlink:to="lab_ebs_ServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2c6029fb-f62f-4fec-a021-2be6ca2692ea_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1c3e85e0-8bde-4716-9798-374f38243a30_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign withholding tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4dccf588-5b6f-4fd0-89f1-2dfb34fef6d7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_14ce021a-c63d-4b86-9c12-39acbf716884_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbaeee29-0793-4aba-afff-efb8eb9d500d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SaleOfStockAggregateOfferingAmountMaximum_84a08aab-8bfe-4d83-af81-764a05e0cf34_terseLabel_en-US" xlink:label="lab_ebs_SaleOfStockAggregateOfferingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate gross sales price</link:label>
    <link:label id="lab_ebs_SaleOfStockAggregateOfferingAmountMaximum_label_en-US" xlink:label="lab_ebs_SaleOfStockAggregateOfferingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount, Maximum</link:label>
    <link:label id="lab_ebs_SaleOfStockAggregateOfferingAmountMaximum_documentation_en-US" xlink:label="lab_ebs_SaleOfStockAggregateOfferingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SaleOfStockAggregateOfferingAmountMaximum" xlink:href="ebs-20231231.xsd#ebs_SaleOfStockAggregateOfferingAmountMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SaleOfStockAggregateOfferingAmountMaximum" xlink:to="lab_ebs_SaleOfStockAggregateOfferingAmountMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ba929a36-8f03-4235-806a-0a597a8f5885_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual life of awards</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47cfe2bd-af75-4950-8a9c-8bc15efdf1d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9c58f5f1-7be6-4f9d-940b-3d49599681f3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_82be5566-ff98-4604-9e05-f3c73172a1bc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_ea5c2f10-a798-4a59-bf29-19fdc3fb3b55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:to="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cbae7e6a-c7f5-46f9-83d1-c2bf1db1eb53_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_5d8d6401-a0d6-4e3b-9470-c2dc3a2b3fe8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c047a132-f14a-40b0-ae41-fa348f39069c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetAbstract_a25f4ad5-d15a-4618-a67b-0dfe64064aef_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable:</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract" xlink:to="lab_us-gaap_AccountsReceivableNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c45881f3-860a-4849-993c-817943d32093_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9ac14d84-f269-44c4-8c74-27ac12213f51_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_2287eb38-e616-46a3-af9c-032905aec6a7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciling items:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4f1d5eac-a2e0-4cdf-8a4f-e0534846ba01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_d6ed9ae9-8bc8-487d-bdcb-02cb8d209525_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_745c15e0-b82d-4a96-ab7e-bab15e36e00a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment of prior year taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_43dcbe73-766e-4381-9673-a5be4cb93209_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AtTheMarketOfferingMember_6fc57e12-74bd-49ec-a4d8-fa8bf92d41ab_terseLabel_en-US" xlink:label="lab_ebs_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:label id="lab_ebs_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ebs_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_ebs_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ebs_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AtTheMarketOfferingMember" xlink:href="ebs-20231231.xsd#ebs_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AtTheMarketOfferingMember" xlink:to="lab_ebs_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_A2023EquityInducementPlanMember_539e4bc4-915f-4240-bb67-5d0be68b6512_terseLabel_en-US" xlink:label="lab_ebs_A2023EquityInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Equity Inducement Plan</link:label>
    <link:label id="lab_ebs_A2023EquityInducementPlanMember_label_en-US" xlink:label="lab_ebs_A2023EquityInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Equity Inducement Plan [Member]</link:label>
    <link:label id="lab_ebs_A2023EquityInducementPlanMember_documentation_en-US" xlink:label="lab_ebs_A2023EquityInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Equity Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2023EquityInducementPlanMember" xlink:href="ebs-20231231.xsd#ebs_A2023EquityInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_A2023EquityInducementPlanMember" xlink:to="lab_ebs_A2023EquityInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a435494d-8da5-4f1a-bece-e72ba6d8a920_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_ae880ce8-0ecb-48a4-9c83-de19102d7196_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_58fbe0ab-3a66-4e45-bb23-96589b020881_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6e01f523-1388-40f7-b33a-7e848756aaf8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d093dd2e-26b5-4188-8a12-76471e629acb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, accumulated Impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b4041c20-a45c-447e-9b0a-ceaf06b8247d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_727081a2-6b6f-45e3-8734-f329068b1afb_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5bf3a8d0-1172-4fd2-b1c0-2b1d7117cd91_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b52a83da-0b25-4910-b003-3eab2116b8ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a8fd0276-ef65-46d3-a4dd-8c7f363e122d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0f0c615d-6765-4428-b11d-9e96a54608d5_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7a9c1a03-4023-4d3e-815d-8c7e2b3f925c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e28dda6e-d8f5-43df-b6ef-541445f46210_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9087091c-2fb7-49d1-a7a3-9d1571d38a53_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f2090297-23ba-4586-a121-8e4c3c40d906_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_abddc465-e7f6-4710-a6ba-2fb12ecfb346_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustment for losses (gains) on hedging activities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_3a4be65d-6627-4169-84da-94d1f83c305f_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_110a5499-ce0a-4989-939f-c8d56a868f85_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_FiscalQuartersEndingAfter2024Member_4b886b91-9b0d-4e38-b29f-683685bbf1e2_terseLabel_en-US" xlink:label="lab_ebs_FiscalQuartersEndingAfter2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Quarters Ending After 2024</link:label>
    <link:label id="lab_ebs_FiscalQuartersEndingAfter2024Member_label_en-US" xlink:label="lab_ebs_FiscalQuartersEndingAfter2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Quarters Ending After 2024 [Member]</link:label>
    <link:label id="lab_ebs_FiscalQuartersEndingAfter2024Member_documentation_en-US" xlink:label="lab_ebs_FiscalQuartersEndingAfter2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fiscal Quarters Ending After 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_FiscalQuartersEndingAfter2024Member" xlink:href="ebs-20231231.xsd#ebs_FiscalQuartersEndingAfter2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_FiscalQuartersEndingAfter2024Member" xlink:to="lab_ebs_FiscalQuartersEndingAfter2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_6e64e556-7794-4a57-8425-d40a1d1576f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Net Periodic Pension Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2364037d-3dd0-4b79-9502-2b3fc0ce37bd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_3a01ab50-c15e-4f60-82e3-c61d2105a213_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d177b28b-e39f-40e0-98a9-db557df2f99b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_b97fdf25-8fd8-44ed-9080-eb728933450b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16d23604-8e8b-4bf8-a771-f81b51b49d11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5043380c-93a4-42bd-9f1e-854e98b27565_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_5fa8ea51-2ea8-4234-b640-8f073efbbaa9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Impairment Analysis</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_8cba0f36-a06f-4c9e-87f3-5ae4dfbb6a17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_14a60c0e-1f86-45e1-9f96-43d6ce6bfbb9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net benefits received</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_c77f4bfd-31a1-4c30-9309-ceda90c3fcbc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated benefit obligation, end of period</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_88f09eb6-2b35-4a07-acc2-4021ca26847c_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payments to be received</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2ad3e3a2-213e-46d5-b152-d676c21cc87d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0537f3ed-eafd-49a2-b506-f9812bbc792c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_537bc1fe-668c-4299-b3cb-b97197b0b738_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Income Before the Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_95aca3b5-46c5-4a80-ba44-9253a4bd80b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_56d1d656-5fec-4650-b5a3-b5946690ebdc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_09f904ca-066d-4704-b9b8-05fbe95db9fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Income Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_78ef3d69-34ad-44fc-87f2-20e2dc5f5fda_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_366f923a-27ac-4665-8098-2c8e2294a9a4_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_43a1abbc-ba32-41c7-bafd-76e83fc3e08b_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, year four</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_54dcbf96-d0be-4657-8387-5ce12ee3ae0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4dbd79da-c96a-402f-9e3d-3a9e61b1a5cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6dec776b-bfe6-4662-b3bf-643197b0c3b3_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bf989755-3f3b-43cc-9477-82cef6b9827e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f7b9e4c7-6895-4a65-ac51-e41c4af43735_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_675f423e-24af-494b-b889-7c871fa4b9b5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_09ca8095-240b-437b-a116-5891a7a48afb_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ab36136a-aca0-4739-8abf-d85f92e80cf8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Property, Plant and Equipment Useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6f5321dd-bcc5-4f40-b9f0-501e8642b94c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1d9a1832-0807-42e2-a14e-cb5cae0ebcf0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_d2409ea0-c493-4bfb-8210-73b53c0188b2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c1c86cde-74db-4e66-a410-007f041abc43_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_42b336f0-1599-47b7-bc18-1685420a2186_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1d6d8009-356e-4664-8ece-1fc26f3c9848_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5ad7d069-9d29-4f47-a0e2-f5287acdacc4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2b3067f8-1e04-4629-9cc9-ee2d40ab3462_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtTermsDomain_f252cb7e-a034-4a2f-8faa-9b3cd5a49088_terseLabel_en-US" xlink:label="lab_ebs_DebtTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, Terms [Domain]</link:label>
    <link:label id="lab_ebs_DebtTermsDomain_label_en-US" xlink:label="lab_ebs_DebtTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Terms [Domain]</link:label>
    <link:label id="lab_ebs_DebtTermsDomain_documentation_en-US" xlink:label="lab_ebs_DebtTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt, Terms [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtTermsDomain" xlink:href="ebs-20231231.xsd#ebs_DebtTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtTermsDomain" xlink:to="lab_ebs_DebtTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9906b32e-075c-4e28-a48b-f8fb17e13bbd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0453969a-f58c-4afb-9199-f8117ee12a38_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SmallpoxMCMMember_c4afeb44-ca3a-4bc2-8d3d-9ab5f38957a5_terseLabel_en-US" xlink:label="lab_ebs_SmallpoxMCMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Smallpox MCM</link:label>
    <link:label id="lab_ebs_SmallpoxMCMMember_label_en-US" xlink:label="lab_ebs_SmallpoxMCMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Smallpox MCM [Member]</link:label>
    <link:label id="lab_ebs_SmallpoxMCMMember_documentation_en-US" xlink:label="lab_ebs_SmallpoxMCMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Smallpox MCM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SmallpoxMCMMember" xlink:href="ebs-20231231.xsd#ebs_SmallpoxMCMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SmallpoxMCMMember" xlink:to="lab_ebs_SmallpoxMCMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EbangaMember_109f4535-a826-4b3d-ac3f-545387272b4a_terseLabel_en-US" xlink:label="lab_ebs_EbangaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ebanga</link:label>
    <link:label id="lab_ebs_EbangaMember_label_en-US" xlink:label="lab_ebs_EbangaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ebanga [Member]</link:label>
    <link:label id="lab_ebs_EbangaMember_documentation_en-US" xlink:label="lab_ebs_EbangaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ebanga</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EbangaMember" xlink:href="ebs-20231231.xsd#ebs_EbangaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EbangaMember" xlink:to="lab_ebs_EbangaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_262a0b51-074d-4e59-a386-25a1e617e13d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d4d335e4-287d-4c4b-b32e-5a00f8867a0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_ec79760b-2c0e-42f7-8c6c-6828d4d62482_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal losses carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4d238798-d3fb-45d6-8427-d96a72120ed6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_BARDAMember_2a261649-239c-4c7e-a319-346a06470209_terseLabel_en-US" xlink:label="lab_ebs_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_ebs_BARDAMember_label_en-US" xlink:label="lab_ebs_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BARDA [Member]</link:label>
    <link:label id="lab_ebs_BARDAMember_documentation_en-US" xlink:label="lab_ebs_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BARDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember" xlink:href="ebs-20231231.xsd#ebs_BARDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BARDAMember" xlink:to="lab_ebs_BARDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_ecef071a-399c-4ae8-8eef-6ce0a216ccf1_terseLabel_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_label_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_documentation_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember" xlink:href="ebs-20231231.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherLongTermDebtFacilityMember" xlink:to="lab_ebs_OtherLongTermDebtFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ebbc70ff-2330-4181-b8de-255d64d32c24_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_3fa84c51-2a08-4b73-aa79-a45d7784adf7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_cf3d6662-c469-4951-8922-b010f29fa0f7_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_80ec239b-848a-4faa-b425-9ecf81be09ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Future Debt Payments of Long-Term Indebtedness</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_806842a3-82a2-4bc4-9713-047eabd8e2c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Medium-term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:to="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b5838332-a4f6-4203-bdb1-1a814056134c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_c85522b0-d4f1-4fde-bdb1-a3633430f956_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, consideration threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Consideration Threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Consideration Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:to="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_f2194610-8ef5-4c1e-931c-d65df85db3c2_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_3e6ce745-a271-4777-9853-7fac5c259682_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_bad8b3a3-061c-4df2-aee5-32d4025a01ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_91d93c04-0993-420e-a731-eeeddf13268d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3983a855-0562-467c-8056-381a7c256af2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_2926c11c-63ee-443c-b867-3290e6cc8663_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_75375a9c-3f31-45dc-a3de-af66d3b54442_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30d4f388-105d-4333-82c8-6fe086dbfe75_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_be577024-2a39-4b53-a9dc-21985f1ecebb_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NoncashPurchasesOfTreasuryStock_c343c8e4-7a80-41a8-8c7b-557ee18d0b64_terseLabel_en-US" xlink:label="lab_ebs_NoncashPurchasesOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock unpaid at period end</link:label>
    <link:label id="lab_ebs_NoncashPurchasesOfTreasuryStock_label_en-US" xlink:label="lab_ebs_NoncashPurchasesOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Purchases Of Treasury Stock</link:label>
    <link:label id="lab_ebs_NoncashPurchasesOfTreasuryStock_documentation_en-US" xlink:label="lab_ebs_NoncashPurchasesOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Purchases Of Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NoncashPurchasesOfTreasuryStock" xlink:href="ebs-20231231.xsd#ebs_NoncashPurchasesOfTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NoncashPurchasesOfTreasuryStock" xlink:to="lab_ebs_NoncashPurchasesOfTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_56efaa7e-5f3d-4d64-b40a-2ee203fa4039_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_eab0b213-9a54-434e-81a5-7072631e24ee_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OtherGeographicalAreaMember_04150f98-43b4-4ead-a5f5-d46ccaa9c866_terseLabel_en-US" xlink:label="lab_ebs_OtherGeographicalAreaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ebs_OtherGeographicalAreaMember_label_en-US" xlink:label="lab_ebs_OtherGeographicalAreaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Geographical Area [Member]</link:label>
    <link:label id="lab_ebs_OtherGeographicalAreaMember_documentation_en-US" xlink:label="lab_ebs_OtherGeographicalAreaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Geographical Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherGeographicalAreaMember" xlink:href="ebs-20231231.xsd#ebs_OtherGeographicalAreaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherGeographicalAreaMember" xlink:to="lab_ebs_OtherGeographicalAreaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59a4e32e-de10-4aed-9b5f-adc76066db54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_0ee70b2b-40df-45e8-b389-d37bed210bc7_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_2bf9f77a-5c07-4d00-900c-7e4ea56d7059_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_41efef64-b1df-496a-a596-9d23804eb9d2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c4a95e23-f811-429a-abaf-0832ad49db8f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RevenueFromContractWithCustomerTermOfContract_03a4bc89-d277-4d08-8d97-8862c99ba658_terseLabel_en-US" xlink:label="lab_ebs_RevenueFromContractWithCustomerTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_ebs_RevenueFromContractWithCustomerTermOfContract_label_en-US" xlink:label="lab_ebs_RevenueFromContractWithCustomerTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Term Of Contract</link:label>
    <link:label id="lab_ebs_RevenueFromContractWithCustomerTermOfContract_documentation_en-US" xlink:label="lab_ebs_RevenueFromContractWithCustomerTermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Term Of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevenueFromContractWithCustomerTermOfContract" xlink:href="ebs-20231231.xsd#ebs_RevenueFromContractWithCustomerTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RevenueFromContractWithCustomerTermOfContract" xlink:to="lab_ebs_RevenueFromContractWithCustomerTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_136a12c9-4113-494f-8c03-7751a184c2cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_7c7deba5-7d03-4763-a983-1e3e9a378fa1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MCMProductsSegmentMember_915d52a7-d923-40ec-806d-5d81c950acd2_terseLabel_en-US" xlink:label="lab_ebs_MCMProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MCM Products</link:label>
    <link:label id="lab_ebs_MCMProductsSegmentMember_label_en-US" xlink:label="lab_ebs_MCMProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MCM Products Segment [Member]</link:label>
    <link:label id="lab_ebs_MCMProductsSegmentMember_documentation_en-US" xlink:label="lab_ebs_MCMProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MCM Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember" xlink:href="ebs-20231231.xsd#ebs_MCMProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MCMProductsSegmentMember" xlink:to="lab_ebs_MCMProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a3fa2398-9549-4145-b70c-62d2ea3d67ce_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_b3c73a96-9ac2-4a91-bd1f-bec83831b9f4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d301ce04-d10f-45de-8297-69a15a3863e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Components of the Provisions for Income Taxes Attributable to Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9b27450b-2bab-4b38-a8a6-bb573c519cf7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_d1f39980-451b-4890-8ae8-0ddddd189f25_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_12fe6b52-5d3e-4d4c-bf68-3a27a3e93dd6_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_5a448de1-75c8-4981-a43e-7ed7eb4645a0_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9ba36d86-bbb8-47ee-979b-1ec5bb0d4698_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_0080bdb1-fedc-4f5b-af0e-2ba667d8e0dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill Impairments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_3cc6771a-8f3c-4a33-a0e2-a69af4d6eca6_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NonUnitedStatesGovernmentMember_aa554a0e-d6b5-49f2-ad09-955a431c2149_terseLabel_en-US" xlink:label="lab_ebs_NonUnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-USG</link:label>
    <link:label id="lab_ebs_NonUnitedStatesGovernmentMember_label_en-US" xlink:label="lab_ebs_NonUnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-United States Government [Member]</link:label>
    <link:label id="lab_ebs_NonUnitedStatesGovernmentMember_documentation_en-US" xlink:label="lab_ebs_NonUnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-United States Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NonUnitedStatesGovernmentMember" xlink:href="ebs-20231231.xsd#ebs_NonUnitedStatesGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NonUnitedStatesGovernmentMember" xlink:to="lab_ebs_NonUnitedStatesGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8be05d48-c5d7-43b4-932d-71317efc14b1_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3f7c8e83-004a-4769-b6c6-4e35bf92b990_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b6e6cfcb-cb7e-4397-ac11-ea32f8055189_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference_39b1eccc-bf57-4240-9e40-96fc0a3bf6f0_negatedLabel_en-US" xlink:label="lab_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference_label_en-US" xlink:label="lab_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Difference</link:label>
    <link:label id="lab_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference_documentation_en-US" xlink:label="lab_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:href="ebs-20231231.xsd#ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:to="lab_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_94581515-6bdb-4953-a869-fde1e3b9936d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b6e7bbd4-34e9-41da-92bd-4e4b39b4968d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AdjustedGrossMargin_cb1c1356-910d-4f62-8501-17ec431ff1be_terseLabel_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total segment adjusted gross margin</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_label_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_documentation_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin" xlink:href="ebs-20231231.xsd#ebs_AdjustedGrossMargin"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AdjustedGrossMargin" xlink:to="lab_ebs_AdjustedGrossMargin" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_401def4a-0632-4460-9026-669c80d17729_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a27d4e9f-4cde-436a-a4eb-ee61802d56ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_7fe1a0f4-4e3f-4e9b-977c-f8e6024ece3c_terseLabel_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Net</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_label_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_documentation_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:href="ebs-20231231.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:to="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_b5cefb27-eaef-4a72-9541-3d9b89407fb8_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f5eb25b4-9965-4d9f-925c-bbd2c364f5c4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3e3d342c-99a6-482b-a577-c5d6f658a5da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Valuation Assumptions, Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_af2dc5c1-1d74-4752-b4bb-491094511dfb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_5f1e0a46-58a3-46c2-ae49-8aa3b612827b_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b98b9a81-f177-47ab-94ad-fd9bf8574dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_619669a6-9540-443f-ad17-824a65c4cd7f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9da2c5a4-4bb1-406c-8507-94a14810a04f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b17034c7-a73f-46eb-8873-6a06e7c09313_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c8d8aec5-0feb-4895-95d6-7830152b55ee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_b122b834-6c0c-4ca5-8efd-c01dc9aeeeac_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and hedging activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_42e6f9b6-b8fd-451d-a5df-b4058ac86591_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_eebb7fcb-a484-456e-b590-5ceae76fca86_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f1d49e2b-9981-4656-90da-da12e6350c35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_f07ac4f1-60a7-4e00-9eed-9b37c5a39313_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c70b9d91-f851-4942-b565-0b87d3b99529_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_c8d87a97-def5-4890-a9b0-7df0eac8cea3_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_77b4406c-577a-4bba-9288-027cd33e6f0b_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtTermsAxis_4496a6fc-2242-4754-8a96-26460af13e85_terseLabel_en-US" xlink:label="lab_ebs_DebtTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, Terms [Axis]</link:label>
    <link:label id="lab_ebs_DebtTermsAxis_label_en-US" xlink:label="lab_ebs_DebtTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Terms [Axis]</link:label>
    <link:label id="lab_ebs_DebtTermsAxis_documentation_en-US" xlink:label="lab_ebs_DebtTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt, Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtTermsAxis" xlink:href="ebs-20231231.xsd#ebs_DebtTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtTermsAxis" xlink:to="lab_ebs_DebtTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_116f05e9-e4de-48f0-80ea-3f30513b4263_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Pension Plan</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_73bc94ad-6f7b-4530-8e50-c26137724615_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_f0af9006-fdbc-4a01-9317-1f3a5d78a8c0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock_bb5dd188-41d6-4a0d-a8a7-a28e0609a29f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments</link:label>
    <link:label id="lab_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase and Supply Commitment, Excluding Long-Term Commitment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock" xlink:to="lab_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_e4989b9f-b3b6-436b-ba45-55f7ef00be5c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_f0b4450d-37ed-4f25-be0e-93b0a8d12521_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_2eaeaba9-b83f-476e-9571-e3ccbf4a434e_terseLabel_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of categories of public health threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_label_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Categories Of Public Health Threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_documentation_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the number of categories of public health threats.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:href="ebs-20231231.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:to="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_4539d7cf-adb0-45d9-a1b2-00153f55ec0a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_17b94d74-7575-4351-9c91-2a7c5e7c5a05_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_7b094e25-d615-4a85-a5e6-6e0d732f969f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_41884cc0-ce72-432c-8ffb-739cc7b56607_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, year one</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_82ab9774-f178-4274-a32f-1e74e3d6256d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_b3002e5d-7edf-4a07-ad77-dcb8e2961e43_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_5880c1b3-8e5b-4cf8-ba66-bce8165daf44_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Actuarial gain</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_08e8e719-c5b4-4ea5-8b02-62e9f0ed0482_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_80083b34-9cc8-468e-8c02-c2bc4ef18751_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cd5f21a9-0e03-4ba7-b2d6-172066e619d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4de64c1a-0294-4601-bc59-9b60bdcf5b64_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9183eee3-f569-462e-8815-e46a9ca1cf65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_03896ec8-643c-460d-aaf6-3518596fb510_terseLabel_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jansen Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember" xlink:href="ebs-20231231.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_JansenPharmaceuticalsIncMember" xlink:to="lab_ebs_JansenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b137bf56-611a-4de9-9cbc-33e87cb5e6ed_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_acdf813b-5823-4945-9480-73eb4abe328a_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_9e18514e-2cd0-4881-a641-f1f0451a6bb1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DevelopmentBasedMilestonesMember_b3b79718-04f5-4461-8d0d-d819f9da5918_terseLabel_en-US" xlink:label="lab_ebs_DevelopmentBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development-Based Milestones</link:label>
    <link:label id="lab_ebs_DevelopmentBasedMilestonesMember_label_en-US" xlink:label="lab_ebs_DevelopmentBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development-Based Milestones [Member]</link:label>
    <link:label id="lab_ebs_DevelopmentBasedMilestonesMember_documentation_en-US" xlink:label="lab_ebs_DevelopmentBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development-Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DevelopmentBasedMilestonesMember" xlink:href="ebs-20231231.xsd#ebs_DevelopmentBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DevelopmentBasedMilestonesMember" xlink:to="lab_ebs_DevelopmentBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f8a228e1-f2d8-4fc6-a572-98fd578d3e4d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4417ba15-93df-48b8-81b1-d88d0babdc9b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7f068975-a200-43e5-832e-638767c263fe_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_a1b28019-b6ef-4aee-8d53-cd66ee9e0c13_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_f99017bf-ec69-4b98-892f-d883fe7aa7fd_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_19daf86e-c434-438c-bafc-f5fef4d3295d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_9997ef49-254c-447a-b006-5dbc0d0e4b47_terseLabel_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:href="ebs-20231231.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:to="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_10d57a4c-7990-4620-8f5b-e81b5fbab664_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d27513a1-51c3-4e3e-8b16-4ffed6b304c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_a0d0d5b5-7cbb-49ee-b6aa-fcb57f235f56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Write off of contract asset and liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnContractTermination" xlink:to="lab_us-gaap_GainLossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_15e019b6-f30a-4513-b129-de66138f35d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c796be1a-5458-4c2e-88cd-74c86ef32d59_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ddd976f2-e751-4f2f-aefe-1c81604dd6f2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ff963acc-3222-4045-b69b-1e1a3e269bc4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_285d48c7-55dd-4a1b-97ea-0fc8fa7fbaa0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments and hedging activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_19c6befa-1869-4e76-9b77-9fe19c40e46c_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UnitedStatesGovernmentMember_7d26d5c3-827f-4c60-bd41-72372fd1cc85_terseLabel_en-US" xlink:label="lab_ebs_UnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">USG</link:label>
    <link:label id="lab_ebs_UnitedStatesGovernmentMember_label_en-US" xlink:label="lab_ebs_UnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States Government [Member]</link:label>
    <link:label id="lab_ebs_UnitedStatesGovernmentMember_documentation_en-US" xlink:label="lab_ebs_UnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember" xlink:href="ebs-20231231.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UnitedStatesGovernmentMember" xlink:to="lab_ebs_UnitedStatesGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_887fea85-0c77-4a99-a712-9b5122b92b58_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitment, year one</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6074375c-4281-40c8-93d2-f37318ee93ee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1477e6e8-0d6b-45a4-81b3-9a7cbe8ba7c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_8aa9abf3-e4f4-4ee0-946f-b92cc14a1a84_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_fbcdd0ab-2a9c-42ba-bba7-94585e56494e_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_243b03ac-2fbc-4f9d-99aa-4b1bd1386159_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7a9f097f-dd05-4999-b616-3acc40cdab73_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_8d76ed74-86bc-4118-8b20-9ef34ce3831b_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_e8073a10-cbf1-4379-916c-dc8763eff206_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit and 401(k) savings plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_240f8e59-c10c-49d0-9346-41c556cfa4ec_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Plan Assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_5d7903db-325f-41f8-b24f-7ce270775748_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, asset, after allowance for credit loss, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage_59ebdf0d-c5a5-4795-bc62-7797af87fc04_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mandatory principal prepayment percentage</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage_label_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Principal Prepayment Percentage</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Principal Prepayment Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage" xlink:to="lab_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_b74c4608-35ff-417f-818e-a739162d290f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign losses carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_48620f0c-0bfc-4b25-a3ae-908483e35d26_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_659a5a5e-783c-4fab-9aa4-3134ce98d7e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3042b8a7-048e-44fd-b539-0f39394f3e21_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1497524-774f-4a81-b5d4-c81e875cf431_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_81a7309c-53e8-490c-bb13-2744c38a030d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swaps gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_d0ef2dcb-9548-43a6-aa97-9b3ac8d7f431_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_27aef9d8-6c26-43ac-9fa6-1d6c2c2ecdce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_29ed2d8a-5549-4d11-ada2-c199fa32162d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6fddb9ad-7e89-4758-8c1b-87b04222fc53_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CustomerTwoMember_03f084fe-f92a-4fea-b49f-6f04c93877d1_terseLabel_en-US" xlink:label="lab_ebs_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Two</link:label>
    <link:label id="lab_ebs_CustomerTwoMember_label_en-US" xlink:label="lab_ebs_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_ebs_CustomerTwoMember_documentation_en-US" xlink:label="lab_ebs_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CustomerTwoMember" xlink:href="ebs-20231231.xsd#ebs_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CustomerTwoMember" xlink:to="lab_ebs_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_225404ae-ca3a-4540-9d9b-6fdbd9130e36_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e447441e-973c-4644-8056-19129fe8e4cf_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_ade9283e-80e2-4dfa-b149-0988ef0f0af7_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_61317a3d-17f1-46a5-a7c2-9b67c367005b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_851fa488-bb8e-4d63-b719-a98afab3953c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_70cf5cb5-d01c-427c-85d8-df863e86ecf0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_757eeda3-22f9-44e8-9af1-d0033d1955d0_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, year three</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_0c665c94-f81f-46ab-9360-78c7a38c052e_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_34457f3e-121b-43a0-a5cb-c75827f4588a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_3dc43781-24af-4a83-a13f-294be30143f5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_68f5b6d2-fcbc-4d79-80ea-0030e52e5b31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CH_a05d1b64-9143-4590-8f5e-b39a536aafdd_terseLabel_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_country_CH_label_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_08110f24-4b44-4985-9e72-96b4164a942d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax Benefit (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_2bcaeb70-f7df-46c2-a84d-18a98f19a33b_terseLabel_en-US" xlink:label="lab_ebs_DeferredTaxLiabilitiesForeignWithholdingTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, foreign withholding tax</link:label>
    <link:label id="lab_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_aed79109-fffc-4f92-bf36-7ea805a8c100_negatedTerseLabel_en-US" xlink:label="lab_ebs_DeferredTaxLiabilitiesForeignWithholdingTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign Withholding Tax</link:label>
    <link:label id="lab_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_label_en-US" xlink:label="lab_ebs_DeferredTaxLiabilitiesForeignWithholdingTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Foreign Withholding Tax</link:label>
    <link:label id="lab_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_documentation_en-US" xlink:label="lab_ebs_DeferredTaxLiabilitiesForeignWithholdingTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Foreign Withholding Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxLiabilitiesForeignWithholdingTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax" xlink:to="lab_ebs_DeferredTaxLiabilitiesForeignWithholdingTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a669a5f7-d991-45db-b865-b869358bc96a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_67edb66f-15ed-4319-8abd-d4aa929f7764_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_181fbc63-f127-415d-9aef-36dcd37c9422_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b307a896-3785-411f-bf1a-7b8baf1e783b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bbd89822-3b0c-42c9-af29-b721df4ae3ab_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_101c2e79-b404-41ce-a8b0-9096137af762_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_6abf2578-e49f-4ca7-81b4-449471512716_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_10eda9b7-3154-486a-928c-bde55fc1ba34_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_ffd4bfad-35bb-4666-82f0-b2f593d6ea63_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8657d2c0-895c-48a7-b7bf-e3da4cda7413_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UntilMarch312024Member_06617cbf-ed6a-4e34-a02a-9481cc85cb61_terseLabel_en-US" xlink:label="lab_ebs_UntilMarch312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until March 31, 2024</link:label>
    <link:label id="lab_ebs_UntilMarch312024Member_label_en-US" xlink:label="lab_ebs_UntilMarch312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Until March 31, 2024 [Member]</link:label>
    <link:label id="lab_ebs_UntilMarch312024Member_documentation_en-US" xlink:label="lab_ebs_UntilMarch312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Until March 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UntilMarch312024Member" xlink:href="ebs-20231231.xsd#ebs_UntilMarch312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UntilMarch312024Member" xlink:to="lab_ebs_UntilMarch312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_280fb07d-dbca-431c-811e-26d6f62513df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchases of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_d7387bae-543e-4257-8955-6a2551df90a1_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_91be8932-194c-4e74-8e51-dd86c3fc1f32_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_de42141f-cfcc-4169-82fa-e7d4f0039629_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bf5126cd-fdb0-4d3c-a37a-d2447cbf1e89_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_92f7408a-eaef-4e2a-97e3-afd65fe08f41_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b4ee5e2d-1969-479d-b645-d124a1713884_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1c5e5d58-5cb7-4c0c-b1b5-317618094a94_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_82112ef9-41e8-403b-a6a1-20280d425deb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_348a8755-000d-415b-9a9e-86a293ad08e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3d53cd23-954d-478b-9730-a38eaeeb05be_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_188d1679-a75c-48bf-86be-54f385660473_terseLabel_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Leases Supplemental Balance Sheets</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ebs-20231231.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_afd6fa42-cd1f-4ffb-98dd-860acc24bdb2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6e52d3b6-476c-40b1-8401-f63dcd25442a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_6f2b2a68-1977-4450-aa67-11697d34081d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_efc7a8c4-f0c6-4a5e-9b0a-6667f24a7981_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, contingent consideration, liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_c8dce13d-0933-40ce-b49d-a6bc3f2140e1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of prior service credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_bac5ba65-fdef-4ac7-9241-a0029dcb9b32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forbearance fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f50a3dbc-e3d2-4685-a97f-68e1277b5bd3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_854fd92b-404e-4ba7-9a64-632b4dd8bfab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AuditInformationAbstract_label_en-US" xlink:label="lab_ebs_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ebs_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ebs_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AuditInformationAbstract" xlink:href="ebs-20231231.xsd#ebs_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AuditInformationAbstract" xlink:to="lab_ebs_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_716ecf65-94f1-462a-8a54-c0cb2fcb69b9_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6aed67ba-76fd-4d35-ae5b-21fd66271066_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_8bca22ab-31c6-4969-a577-36b105e788e0_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant customers and accounting receivable</link:label>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customers, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:to="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_44205520-e652-4567-b67f-f3d0c5c5ffe0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_63624e93-7fe8-4811-b19e-de7d9fbcac14_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_3e3d79e5-bd7a-4061-a7de-d72368e4d749_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total long-lived assets, net</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_fe05a192-1d5a-4a96-8cae-cb1f70363928_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_17285f88-74f3-4be8-8172-90bf9518f500_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_bf760242-6388-4c82-b924-9e96022e7939_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55348b86-afd0-4049-83ce-c69031d73ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e5ff128f-0f0c-4a2b-9b45-f8de36985a5b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_53145436-127e-4d8a-9227-9fc3821c0915_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2d6753bc-a4d2-42d5-bc21-29953649a18f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_37b2ce65-bd01-404c-8cc8-4d1f0f8872fa_terseLabel_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Funded Status of the Swiss Plan</link:label>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:to="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RestructuringPlanAugust2023Member_26943d94-7493-4a09-9603-22e2a27fb5c2_terseLabel_en-US" xlink:label="lab_ebs_RestructuringPlanAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 2023 Restructuring Plan</link:label>
    <link:label id="lab_ebs_RestructuringPlanAugust2023Member_label_en-US" xlink:label="lab_ebs_RestructuringPlanAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan August 2023 [Member]</link:label>
    <link:label id="lab_ebs_RestructuringPlanAugust2023Member_documentation_en-US" xlink:label="lab_ebs_RestructuringPlanAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Plan August 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RestructuringPlanAugust2023Member" xlink:to="lab_ebs_RestructuringPlanAugust2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_73713c59-9522-4c36-b3f4-a01dbbe5e740_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_be355561-a0de-47d1-b829-1e191f9297de_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_31bdc879-903d-4110-8c0c-36db552b66c3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_36de9543-195b-4f6d-9de2-73b3c11e060e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OperatingLossCarryforwardsNotSubjectToExpiration_de51973d-d9f9-465e-b7ac-071b3f9a6979_terseLabel_en-US" xlink:label="lab_ebs_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_ebs_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_ebs_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_ebs_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_ebs_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="ebs-20231231.xsd#ebs_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_ebs_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f3b23986-9cf0-4871-9635-96e9a1eb5be1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0b380047-4592-4f0b-8412-a319669f6376_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36ab4399-8456-4506-b1fa-294a78dc3e05_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4cad7d4b-903d-4662-80f8-5a79bc0b8125_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$0.001 Par Value Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_04235bf5-0c40-4ad3-bf72-2f49ff82cf1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_355e1c0b-1631-4282-84fc-08ca0a072a6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_31ac63da-9fe9-4d0f-ae09-6cf24f977dcd_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_27863e1f-8117-491a-97d5-48f814419a40_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_7df1ff1c-aec6-4c91-a991-a40b73521543_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_15994135-1995-41d9-a33c-35c671876536_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b21b12ad-d9a4-4831-a3d9-54de787cc11b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_6ac88382-70cb-44ca-867c-2fad8446b382_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_37527561-f210-48e7-af73-5018ded71ce8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5dcb51ac-ba6d-484b-8a3f-b0dde16c312c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c82dadcb-2c9c-415c-8f80-1f02927d3c58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Reconciliation of Contingent Consideration Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5a86b308-260c-439f-ab1b-aa2c9a245e4f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and penalties expense (benefit)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e7c5c8ff-5aee-4662-938d-3713528656d4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_95d9cf58-bfa2-480a-8235-ee71c0139a28_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4f5884b6-c76f-4aa4-82b7-c1e486874386_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_1b143e4f-2d76-4a3e-a74b-40e5f220aafd_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_10d4120e-6fd5-4597-8e49-06b3a718b624_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d5dbcf81-263e-4749-b182-b9f24eefca9c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_7bf19e5a-599a-4aaf-aa54-9b03b3b54d90_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation, beginning of period</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_a1e270bc-dc1f-46cf-88ab-8ceff216f1ae_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation, end of period</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UnallocatedResearchAndDevelopmentMember_8ffbb279-720e-4d72-832d-993dc57bcbb2_terseLabel_en-US" xlink:label="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_ebs_UnallocatedResearchAndDevelopmentMember_label_en-US" xlink:label="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated Research And Development [Member]</link:label>
    <link:label id="lab_ebs_UnallocatedResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unallocated Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedResearchAndDevelopmentMember" xlink:href="ebs-20231231.xsd#ebs_UnallocatedResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UnallocatedResearchAndDevelopmentMember" xlink:to="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_08e198eb-f394-498d-a7cb-f9e4478a3641_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OtherCommercialProductsMember_357e9a36-831e-4aed-bda2-719dfc39b4a3_terseLabel_en-US" xlink:label="lab_ebs_OtherCommercialProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commercial products</link:label>
    <link:label id="lab_ebs_OtherCommercialProductsMember_label_en-US" xlink:label="lab_ebs_OtherCommercialProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commercial Products [Member]</link:label>
    <link:label id="lab_ebs_OtherCommercialProductsMember_documentation_en-US" xlink:label="lab_ebs_OtherCommercialProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Commercial Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherCommercialProductsMember" xlink:href="ebs-20231231.xsd#ebs_OtherCommercialProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherCommercialProductsMember" xlink:to="lab_ebs_OtherCommercialProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_c309bed6-368d-4049-afa1-94c70bcb8752_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ae280c44-364f-4087-aba2-bf381f8116bc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid for stock-based compensation activity</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_ba9d25a8-9514-4faf-a673-d4a5f150bdd3_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Billed</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_ddd82d1c-1e3d-49e2-b7bb-abfa85e7c275_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_c00db6a4-2917-4d91-aa8e-ef8efb1fa702_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_6fb56d79-e64c-41f6-9519-d94e69d14d6a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfProductAndServiceCategories_28f18ac6-26c5-41dd-b7ab-aa459e673218_terseLabel_en-US" xlink:label="lab_ebs_NumberOfProductAndServiceCategories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product and service categories</link:label>
    <link:label id="lab_ebs_NumberOfProductAndServiceCategories_label_en-US" xlink:label="lab_ebs_NumberOfProductAndServiceCategories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Product And Service Categories</link:label>
    <link:label id="lab_ebs_NumberOfProductAndServiceCategories_documentation_en-US" xlink:label="lab_ebs_NumberOfProductAndServiceCategories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Product And Service Categories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductAndServiceCategories" xlink:href="ebs-20231231.xsd#ebs_NumberOfProductAndServiceCategories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfProductAndServiceCategories" xlink:to="lab_ebs_NumberOfProductAndServiceCategories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7417900d-5e86-4b09-9645-427aa16c5a79_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_0da15a19-1b8f-4c76-b743-1f1bf29a78b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a240417a-9930-44c8-9d2b-d59fcb383f4c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4add0587-5649-40db-b11c-3486b654a4bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, net of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_38019786-f5d7-486f-a398-42df5f08ec5a_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_cd031c20-a733-43ee-9dbc-d375af1a72ec_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency impact</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3f16dd62-e7ac-42b5-93e1-29f65fe384d5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_abcebf09-bfd9-412c-ae25-5acd31243a90_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0610d4ad-81e5-417f-9394-1e46b57ab939_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6df7e9ff-d14d-4421-8aeb-0dec498d8ba3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e0463036-a787-4984-835d-8dc9e29d7c25_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_835eaf2a-e267-4359-8cb0-f395239c6c8a_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets, beginning of period</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8d8aeb1e-698c-45c7-925c-c185ce0f15ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets, end of period</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d0f524fb-767b-40dd-8bef-4576c31c2cef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_0fec250e-fc97-474d-a4c5-77135c945734_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net benefits received</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EmployeeBenefitsMember_a9ceef3c-d48a-4fea-9fb4-d55cf3ad69c3_terseLabel_en-US" xlink:label="lab_ebs_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefits</link:label>
    <link:label id="lab_ebs_EmployeeBenefitsMember_label_en-US" xlink:label="lab_ebs_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefits [Member]</link:label>
    <link:label id="lab_ebs_EmployeeBenefitsMember_documentation_en-US" xlink:label="lab_ebs_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember" xlink:href="ebs-20231231.xsd#ebs_EmployeeBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EmployeeBenefitsMember" xlink:to="lab_ebs_EmployeeBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_9367379f-f711-49c2-ae4e-f2757793ba31_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9cff8b10-4fa5-43cf-8755-033f5055c121_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation and consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c7599ffa-7a43-4146-b401-51617b3b2bd4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d4a3abf7-62ad-4965-849c-f50f0eb04698_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_65a86bc4-3076-4f69-a691-0c9978318acc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_75e56c86-9d7e-4312-92a7-7e4e46435ad8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_b0a62cc4-bbf3-4f3e-9bb5-d6dbda708223_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_4162527f-862f-4760-8ee6-4740a7c0e3db_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfShareBasedEmployeeCompensationPlans_c416d876-806f-4e57-8386-ed58ed370bcc_terseLabel_en-US" xlink:label="lab_ebs_NumberOfShareBasedEmployeeCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of stock based employee compensation plans</link:label>
    <link:label id="lab_ebs_NumberOfShareBasedEmployeeCompensationPlans_label_en-US" xlink:label="lab_ebs_NumberOfShareBasedEmployeeCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share-Based Employee Compensation Plans</link:label>
    <link:label id="lab_ebs_NumberOfShareBasedEmployeeCompensationPlans_documentation_en-US" xlink:label="lab_ebs_NumberOfShareBasedEmployeeCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of stock-based compensation plans the company maintains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans" xlink:href="ebs-20231231.xsd#ebs_NumberOfShareBasedEmployeeCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans" xlink:to="lab_ebs_NumberOfShareBasedEmployeeCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1498df8c-ae3a-4861-8bb5-d72bb6fa5a7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_861b1683-4a95-4908-aafc-8bcf6fdf091b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember_14025299-7f79-4f17-9466-a0e1b56de076_terseLabel_en-US" xlink:label="lab_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets allowance</link:label>
    <link:label id="lab_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:label id="lab_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember_documentation_en-US" xlink:label="lab_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A valuation allowance relating to prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="ebs-20231231.xsd#ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_abd32f00-c64c-4f28-a997-e5e39c4b3c5b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1af5f4ca-bfdd-4a26-aeb8-115daba77da0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_c06e3e79-79bb-4207-8b8b-8d0709e9f3ba_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment_9fd932d8-1de0-4c2b-a920-28f81fd32b39_terseLabel_en-US" xlink:label="lab_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized R&amp;D</link:label>
    <link:label id="lab_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment_label_en-US" xlink:label="lab_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development</link:label>
    <link:label id="lab_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment_documentation_en-US" xlink:label="lab_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="lab_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_3cba2cfe-f588-42ce-8592-caa564e06bd3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TravelHealthBusinessMember_b9a54dc1-f287-4d17-92e5-aeee7bbd83ce_terseLabel_en-US" xlink:label="lab_ebs_TravelHealthBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Travel Health Business</link:label>
    <link:label id="lab_ebs_TravelHealthBusinessMember_label_en-US" xlink:label="lab_ebs_TravelHealthBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Travel Health Business [Member]</link:label>
    <link:label id="lab_ebs_TravelHealthBusinessMember_documentation_en-US" xlink:label="lab_ebs_TravelHealthBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Travel Health Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember" xlink:href="ebs-20231231.xsd#ebs_TravelHealthBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TravelHealthBusinessMember" xlink:to="lab_ebs_TravelHealthBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_757fce03-c30e-43eb-b4d0-fa3ff54ab4cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for expected credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_2358dd1e-ae8a-4836-a6a1-0654bd134f49_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e392d6f0-8fa3-4996-8abe-ec78b1c005df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2e7df987-f097-44de-8eeb-184ba284dda8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1b6d9fff-fb20-4bc7-8c96-888e7c1730af_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_400b7a10-fe88-4033-9284-a3334a99330f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received from option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b72e9373-f9f7-491a-b74a-4c86a0523941_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8efbef4c-5961-4bd9-9c84-4e5d24e6955e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64016408-3de7-48ca-9575-e661f4ab3f9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_66408b48-72c8-4edd-8b08-d7c407ec8888_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9e41d9a0-0fe8-429d-ac1b-56bfbc09d731_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_de783e9c-d8f3-4013-a630-9e25567b964a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_8aeae4c4-1a6d-45eb-be15-58e46279daeb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Allowance for expected credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_6ab79a3c-d94e-409a-86cf-f05e8a82be89_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Earnings (losses) before taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f138f999-a877-4dc5-9cc3-9b2f7987abd9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SaleOfStockConsiderationReceivedOnTransactionGross_45760131-4aeb-4779-9903-314e167faad8_terseLabel_en-US" xlink:label="lab_ebs_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction, gross</link:label>
    <link:label id="lab_ebs_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_ebs_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:label id="lab_ebs_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_ebs_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="ebs-20231231.xsd#ebs_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_ebs_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c38abbe7-684c-43e8-9e21-1c49818a2ab4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_3efd2fb9-7204-4477-963e-b56a9b22d551_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior to August 15, 2023</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TermLoanFacilityMember_435d1c60-9f0b-4c6e-ad3a-fb4c7cc35482_terseLabel_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_label_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term loan dated December 2013.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember" xlink:href="ebs-20231231.xsd#ebs_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TermLoanFacilityMember" xlink:to="lab_ebs_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bc51f321-64b1-4638-a965-78acfbc4fe20_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities-equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_28ec98e7-7c04-4607-b281-2411b3886181_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_93a1a636-3a05-42c0-a3bb-e1ea2bbbcb07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_08f32997-3926-4dd2-9224-6d18a72cad57_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_8255baba-2207-4f4f-8db0-c967a6e800ae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_706294e1-2693-43a0-bf34-63b274f2fadb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_cbb3570b-488c-47fb-9c64-634c5cadcaa1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CommercialProductsSegmentMember_de033cf3-1466-4884-9da4-b5cc8670c246_terseLabel_en-US" xlink:label="lab_ebs_CommercialProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Products</link:label>
    <link:label id="lab_ebs_CommercialProductsSegmentMember_label_en-US" xlink:label="lab_ebs_CommercialProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Products Segment [Member]</link:label>
    <link:label id="lab_ebs_CommercialProductsSegmentMember_documentation_en-US" xlink:label="lab_ebs_CommercialProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember" xlink:href="ebs-20231231.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CommercialProductsSegmentMember" xlink:to="lab_ebs_CommercialProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_aa0c257d-e17d-4049-84ca-81a0bf925066_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1ec10fc3-a022-473b-8045-e21a74cdb69e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_76f07d7d-b01f-4d23-aa2f-83af8d85a54a_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-USG</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_a77c7274-4df8-4f62-b322-87809f10cdcf_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_dd9e1e6f-3bd6-4022-ba69-bc4f5ce25e40_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_99649ef5-04c7-4f1c-9ea2-b3abf5eee051_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_741a3527-ab7c-4415-8b25-8bd35fbb8ed5_terseLabel_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Target payout percentage</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_label_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_documentation_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:to="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8c9b4fd7-3afa-4ec8-8fc7-fb15638fe2ea_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_54e5fcb6-1e9b-4758-a43d-6f2bb0951e16_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0c06a93c-1f4c-4253-9ab6-ee81cbcea980_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_53ea17ae-1bd8-4cb7-8618-e2b18dbe0039_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_98548b65-9abf-4d0b-b2be-20cdb5a4c280_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, year two</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_36c88dcd-4539-4d95-ba22-472e1a684874_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market accounts</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e65712b4-6cff-4b2c-aa5a-cbfd49bff40e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_7ec5c456-4647-4e6e-887a-42b41c6e5b4b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c63987cc-1d5e-4f6e-a7a4-63eabf893380_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_91568f9b-311a-4fc9-b43f-9acd6cab34ea_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected rate of return</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_393e2b7a-6540-4009-99d2-2b35bb3341d8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_4808f0c0-8889-4d6c-8168-44fd8615a1ba_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_979444c6-4985-42f4-ae1d-85eb9c21ed1b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3335406a-71bb-4a88-86c5-b334147981b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_26250c58-4675-4254-83c7-484de5569609_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_ad6615bf-0837-4656-94ff-d3713e56bfc8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9b8d69e7-9e54-4cc9-85ec-a0759de80948_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Deferred Revenue Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_27dc75d5-e4e1-4767-8449-2486d0fefe84_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_d9c094c1-fef8-4236-8885-ec58e63d6612_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8cdae55d-f967-4bfa-b90c-dee4b98211d0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_65901f3d-c02a-4bf1-b58f-ed18ed8ca917_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on hedging activities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f0afe07f-c0a9-4ff8-a8ab-a7f06cb686fa_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8596515f-3647-4197-ac47-8cb8cd83c131_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SalesBasedMilestonesMember_8d1bf3b4-c945-4bb4-a981-71e018992bd6_terseLabel_en-US" xlink:label="lab_ebs_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_ebs_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_ebs_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:label id="lab_ebs_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_ebs_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SalesBasedMilestonesMember" xlink:href="ebs-20231231.xsd#ebs_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SalesBasedMilestonesMember" xlink:to="lab_ebs_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5160721a-e603-4165-8179-8543335f6411_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_46b10f03-8597-4098-9b89-e35e6e55d6a9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_abc8c37b-4877-4071-9f50-631d55da5e86_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_9a51f0a5-ce91-4d02-ba24-b89f201f688d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_52ac8a6b-c9f8-40c7-99b6-7c8f7d63aa31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bc094940-7fdb-471f-beba-3052c5e5bc22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1b873ece-effd-44ff-b07b-7567f325691b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_53559965-c79e-462b-b3ab-6a7438b0ae53_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0eca66d7-34d9-4282-9a0a-a222df0555ce_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_eb899c3c-4ec0-4593-bc19-8687b812f607_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_27e8a85e-f190-44b9-b944-63ff62e25f79_terseLabel_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Agreement Amendment</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended credit agreement dated October 15, 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember" xlink:href="ebs-20231231.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AmendedCreditAgreementMember" xlink:to="lab_ebs_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_fc16a0a3-45c2-4a10-9fca-226f8e5aa758_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_dbb32321-cdd3-4e46-a581-e9d7585e5173_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_b14e4f90-9b4a-47a4-80b2-5c7ca0db2d0a_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_96c74d06-2889-4764-8cd2-703ac6af1942_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_9cbedef7-6c34-4bde-8499-7ccacc1b44a6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7aadc4f9-8c1c-435c-88c4-185e834b9a92_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_e761ab74-6168-4fd2-8279-11720c6b52a8_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_cb856d3a-14d7-46c8-8d7c-496e80d22672_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_5ca95d81-948a-49cb-91ff-ae4fe6393577_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_98128d4a-7f06-495d-b8bd-49716e9eb901_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8d974b7d-342c-416a-97f2-e7e8659e2b66_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MCMProductsMember_59090115-335c-45c2-bc29-130b6b316f6d_terseLabel_en-US" xlink:label="lab_ebs_MCMProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MCM Products</link:label>
    <link:label id="lab_ebs_MCMProductsMember_label_en-US" xlink:label="lab_ebs_MCMProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MCM Products [Member]</link:label>
    <link:label id="lab_ebs_MCMProductsMember_documentation_en-US" xlink:label="lab_ebs_MCMProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MCM Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsMember" xlink:href="ebs-20231231.xsd#ebs_MCMProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MCMProductsMember" xlink:to="lab_ebs_MCMProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9f1299c5-d638-4a52-b931-7d2ded02111f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_37eef6db-3016-45ee-a1d7-b4f83aa71e2e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of future compensation increases</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_e6396d2f-2150-4d75-8f64-10a39d7f95a7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CommonStockNumberOfVotesPerCommonShare_f7d2510e-1f24-4c42-bbe1-a5f18c52f3d8_terseLabel_en-US" xlink:label="lab_ebs_CommonStockNumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, voting rights</link:label>
    <link:label id="lab_ebs_CommonStockNumberOfVotesPerCommonShare_label_en-US" xlink:label="lab_ebs_CommonStockNumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number Of Votes Per Common Share</link:label>
    <link:label id="lab_ebs_CommonStockNumberOfVotesPerCommonShare_documentation_en-US" xlink:label="lab_ebs_CommonStockNumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Number Of Votes Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommonStockNumberOfVotesPerCommonShare" xlink:href="ebs-20231231.xsd#ebs_CommonStockNumberOfVotesPerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CommonStockNumberOfVotesPerCommonShare" xlink:to="lab_ebs_CommonStockNumberOfVotesPerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_859e9e83-52a5-4a34-8caf-8aa682aff544_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_fb1f4195-92a6-4d04-9040-dc3610cd07af_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_84636286-87e9-47bf-8b3d-578892debca2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_51f66b59-af11-4475-848e-7436ff6dd596_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_babd94fc-1635-4428-84d9-8cc3fa6a9203_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustment for gains on pension benefit obligation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04222690-754e-4a47-a9c7-e169d68f390c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_a6db3246-537d-4a7d-9bc2-e5c997432950_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_8821306b-6e69-493d-9556-8ab23b4bb8bf_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares_43ba0dde-0435-455d-9fd1-2e69d578b3e0_terseLabel_en-US" xlink:label="lab_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, amount remaining available for sale of shares</link:label>
    <link:label id="lab_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares_label_en-US" xlink:label="lab_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Amount Remaining Available For Sale Of Shares</link:label>
    <link:label id="lab_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares_documentation_en-US" xlink:label="lab_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Amount Remaining Available For Sale Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares" xlink:href="ebs-20231231.xsd#ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares" xlink:to="lab_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SOFREURIBOROrCDORMember_d14d3691-6773-4614-81eb-8921904a6b4f_terseLabel_en-US" xlink:label="lab_ebs_SOFREURIBOROrCDORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOFR, EURIBOR, Or CDOR</link:label>
    <link:label id="lab_ebs_SOFREURIBOROrCDORMember_label_en-US" xlink:label="lab_ebs_SOFREURIBOROrCDORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOFR, EURIBOR, Or CDOR [Member]</link:label>
    <link:label id="lab_ebs_SOFREURIBOROrCDORMember_documentation_en-US" xlink:label="lab_ebs_SOFREURIBOROrCDORMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SOFR, EURIBOR, or CDOR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SOFREURIBOROrCDORMember" xlink:href="ebs-20231231.xsd#ebs_SOFREURIBOROrCDORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SOFREURIBOROrCDORMember" xlink:to="lab_ebs_SOFREURIBOROrCDORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_47ca3f8d-dbdb-499d-8a5b-32f06c0e127a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContingentConsiderationObligationsPolicyTextBlock_1fc035bb-347b-4531-9aad-80ba8f236f80_terseLabel_en-US" xlink:label="lab_ebs_ContingentConsiderationObligationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_ebs_ContingentConsiderationObligationsPolicyTextBlock_label_en-US" xlink:label="lab_ebs_ContingentConsiderationObligationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Obligations [Policy Text Block]</link:label>
    <link:label id="lab_ebs_ContingentConsiderationObligationsPolicyTextBlock_documentation_en-US" xlink:label="lab_ebs_ContingentConsiderationObligationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for contingent consideration obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContingentConsiderationObligationsPolicyTextBlock" xlink:href="ebs-20231231.xsd#ebs_ContingentConsiderationObligationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContingentConsiderationObligationsPolicyTextBlock" xlink:to="lab_ebs_ContingentConsiderationObligationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_55e9ec86-390f-4781-b019-1472d57f9b32_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_065ad7ae-c7a2-46a0-b3f9-010e7d7bfa6f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b3c68fca-df16-4de9-bf30-287a700fb769_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_10996cd8-6fc6-48e8-a772-57b9ecccd0a5_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_e14f9e8b-66fd-43cb-8076-3e7e64a68efa_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used, Asset Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used, Asset Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_da9874c6-b032-4fd4-93dc-b908463cc8c5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_7275eaa7-8884-4562-b577-1b3668b222e8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_81d2008e-4673-4f6a-8e26-6186979ed30d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_311de47a-07d8-494b-951f-e9cdba2062a2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_01fc0d17-842b-4274-9be1-a8ccfa780e5e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_434e4e82-ab6b-4cbf-8d97-77033e179eba_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_de7f46bd-eb06-4ea8-99a9-bef424dce9df_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4eacb604-32be-422c-b41b-c64e25d07bd7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_894e4be8-1eae-4bdb-ba65-cb9de182dca0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Matching contributions made by employer</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_964505b0-4ab5-49cc-a1bf-cea97dda0651_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c2c93d78-abc9-4d4a-8c54-159ee70b153e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_b7988940-db74-44f6-afe6-fdcf64d53fc2_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_e0f25036-94b3-4e9c-b24c-2e74b393b0e6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b6a81476-c57a-437f-8743-8372e7f293b8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e6665abb-483b-4ca0-a10f-dfb28bbc00e1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f67f801b-0def-42ae-8ae5-99054fe10f44_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingImprovementsMember_ee81f588-f03f-41f5-94ea-f7d49952ecb4_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building improvements</link:label>
    <link:label id="lab_us-gaap_BuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ForbearanceAgreementAndAmendmentMember_0cf51b2e-f9e4-413f-bb9d-f1142c90c7b3_terseLabel_en-US" xlink:label="lab_ebs_ForbearanceAgreementAndAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forbearance Agreement And Amendment</link:label>
    <link:label id="lab_ebs_ForbearanceAgreementAndAmendmentMember_label_en-US" xlink:label="lab_ebs_ForbearanceAgreementAndAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forbearance Agreement And Amendment [Member]</link:label>
    <link:label id="lab_ebs_ForbearanceAgreementAndAmendmentMember_documentation_en-US" xlink:label="lab_ebs_ForbearanceAgreementAndAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forbearance Agreement And Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ForbearanceAgreementAndAmendmentMember" xlink:href="ebs-20231231.xsd#ebs_ForbearanceAgreementAndAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ForbearanceAgreementAndAmendmentMember" xlink:to="lab_ebs_ForbearanceAgreementAndAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_50ea4d24-bb19-438f-b219-73f0a02213b7_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d8819856-c084-461c-a4a5-6d70aa075830_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_GrossProfitPercentage_7ee43dbc-1124-496d-b711-9160ecea7aca_terseLabel_en-US" xlink:label="lab_ebs_GrossProfitPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross margin %</link:label>
    <link:label id="lab_ebs_GrossProfitPercentage_label_en-US" xlink:label="lab_ebs_GrossProfitPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit Percentage</link:label>
    <link:label id="lab_ebs_GrossProfitPercentage_documentation_en-US" xlink:label="lab_ebs_GrossProfitPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Profit Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_GrossProfitPercentage" xlink:href="ebs-20231231.xsd#ebs_GrossProfitPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_GrossProfitPercentage" xlink:to="lab_ebs_GrossProfitPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember_b1ae79fe-b091-456e-b47c-e32142da3fd8_terseLabel_en-US" xlink:label="lab_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares And Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember_label_en-US" xlink:label="lab_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares And Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember_documentation_en-US" xlink:label="lab_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Shares And Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember" xlink:href="ebs-20231231.xsd#ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember" xlink:to="lab_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_843c3a21-018c-4569-87b9-cdbafb724a0c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Materials purchased under commitment, amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8947963b-d4b0-4c99-8107-fb89ec8d7396_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from at-the-market sale of stock, net of commissions and expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_280a2fe5-1b25-4bda-8b92-f716f3b291c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_aafd9a43-3a4d-40ed-af9d-9098e695f9b1_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6741ce63-1443-48a9-8fa5-a06c697f09b5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_63648a79-ced7-4e43-a022-28b855a6954c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum_fd9c24f5-0a04-48cc-98ae-38f140cac946_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, leverage ratio, maximum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum allowed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_f4452f50-f0e6-41a4-8186-1216a18870b0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9abf7866-7656-48e3-9f21-747f7ccba187_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7c5f4cf5-01dc-406a-8d3c-c3d2bdae262d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_198409f3-8e6e-4097-b88d-0b7faa5dcb5d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c9ffad5-3b43-4901-9624-b2992f4d902e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50f8aa8b-ef1d-4674-a324-1cf329eb6ed5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1e5b1db6-8ce9-46f5-abd8-4e65bf4e9700_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e5a40de9-14ee-4942-9022-028987b9bada_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_eaf317d8-d91d-4afb-ab6b-9082d40d428d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_559dc106-742c-4f63-9f49-801415efcba3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_114161d4-fb91-4308-a939-2c74dd853ee1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_d7c0a31a-7228-4078-a6f3-6084558f3659_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_1c9373ba-f682-4f72-ba98-e7fea1d3e437_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_7aa478bf-4922-473c-9439-aff5db2dea98_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractsAndGrantsMember_8eecb725-c363-496b-b263-897f8b4a044b_terseLabel_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contracts and grants</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_label_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts and Grants [Member]</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_documentation_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractsAndGrantsMember" xlink:to="lab_ebs_ContractsAndGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db86267a-2caf-4dac-9bb0-1a8386dfebac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_242eb582-91ce-4d5e-8285-ac0dc94a685b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_379fbcca-b009-41b5-8cdc-d6536fede4e4_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings, building improvements and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c60f7987-a08f-4e9e-b040-f2421c558612_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_79d15f0f-a873-4c34-ab1c-a8fba0ea7624_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_02c996db-84ec-4a56-bbe0-7322642f7041_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bc434a6f-a77f-41c4-916f-5477fe630275_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9e1737ec-713a-4805-9a6d-d021da9f53b9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_057d86fd-1b79-4917-9437-319427705354_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_38c0ce70-9d5d-4cc3-9751-c1371244e395_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RestructuringPlanJanuary2023Member_cb387cd0-d092-43c5-ac9e-c9663c840afc_terseLabel_en-US" xlink:label="lab_ebs_RestructuringPlanJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">January 2023 Restructuring Plan</link:label>
    <link:label id="lab_ebs_RestructuringPlanJanuary2023Member_label_en-US" xlink:label="lab_ebs_RestructuringPlanJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan January 2023 [Member]</link:label>
    <link:label id="lab_ebs_RestructuringPlanJanuary2023Member_documentation_en-US" xlink:label="lab_ebs_RestructuringPlanJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Plan January 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RestructuringPlanJanuary2023Member" xlink:to="lab_ebs_RestructuringPlanJanuary2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7f0e7950-11ed-4466-ad86-7c01b43aa2e4_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation and remeasurement of foreign currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_be4bc727-7848-445a-a8d1-ea7290b4b9da_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c8866198-424a-406f-9a3f-745e9e83d03a_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b12a0200-59db-4fdc-b0c1-8ec679461dc7_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_96d03d09-bb29-4c14-8c62-b5dbc31dbc2e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_6b889941-58e9-4405-93fd-724587757927_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency impact</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_7ab23609-bfa9-423e-becf-7b61a8ebcba5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_ac2665a0-9512-4b91-b60a-28db8ba0b24f_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased during period, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_ee46a36f-7e63-4553-be57-943848cb6421_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_750e5689-8b6d-4659-91fc-a195678e3833_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_2ae5db22-643b-47f8-a50c-db0a8e226344_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_cc982022-d321-4090-b1d4-cf94e8f2645f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6f7de23e-fe35-4689-8dc5-bbbef8aa2dd0_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_33e1f9ab-752d-44f7-9a9d-c6b5d8da6c18_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5cb7e12e-6392-40a6-9189-4e970bcf107f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_44c68be2-616d-4f4d-a811-528dbf30a200_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_2710dbb7-b63d-4586-8c86-438eccba4307_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_943ca13c-6367-4f87-8ce3-2e799e1da34f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NARCANMember_85294085-443a-4d27-85b7-0f6207aa1ba9_terseLabel_en-US" xlink:label="lab_ebs_NARCANMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NARCAN&#174;</link:label>
    <link:label id="lab_ebs_NARCANMember_label_en-US" xlink:label="lab_ebs_NARCANMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NARCAN [Member]</link:label>
    <link:label id="lab_ebs_NARCANMember_documentation_en-US" xlink:label="lab_ebs_NARCANMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NARCAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NARCANMember" xlink:href="ebs-20231231.xsd#ebs_NARCANMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NARCANMember" xlink:to="lab_ebs_NARCANMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_57a3aa16-3f7d-4600-9105-12e635a00429_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum_a792f4bc-d598-4e88-9434-bf902e01e2a6_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, interest coverage ratio, minimum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Consolidated Interest Coverage Ratio Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_8e6d4691-3781-49eb-960d-43462358d7b6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_BioservicesMember_a0cd5850-80d3-4b19-a025-b22ffa88b861_terseLabel_en-US" xlink:label="lab_ebs_BioservicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Bioservices revenues</link:label>
    <link:label id="lab_ebs_BioservicesMember_aa32a67d-4801-4bd5-a9b4-3cca06190b9c_verboseLabel_en-US" xlink:label="lab_ebs_BioservicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Bioservices</link:label>
    <link:label id="lab_ebs_BioservicesMember_label_en-US" xlink:label="lab_ebs_BioservicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioservices [Member]</link:label>
    <link:label id="lab_ebs_BioservicesMember_documentation_en-US" xlink:label="lab_ebs_BioservicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioservices</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesMember" xlink:href="ebs-20231231.xsd#ebs_BioservicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BioservicesMember" xlink:to="lab_ebs_BioservicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_65932da7-7bb8-4e7f-a853-7e94120e259c_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_9a8e0007-d445-4677-8b6e-f5f9613b973c_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_89453d9b-4976-4985-b237-d4ceeb8098f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_9ba5602b-e806-42f4-9b58-424c5d2e0b87_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases (decreases) for tax positions for prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1e2a324b-0e2d-4cdd-b3d1-72a8d5836946_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_dfedc5b4-cf1c-42a6-b1dd-dd0cc1ae402f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_3dadedfb-c5d1-46e5-b679-5e5faee817f0_terseLabel_en-US" xlink:label="lab_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2006 Stock Incentive Plan</link:label>
    <link:label id="lab_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_label_en-US" xlink:label="lab_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_documentation_en-US" xlink:label="lab_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A share-based compensation plan adopted by the Company in 2006.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember" xlink:href="ebs-20231231.xsd#ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember" xlink:to="lab_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionExpense_ecb57b3c-0ad7-43a7-a4e3-4aa9697fbc2a_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension expense</link:label>
    <link:label id="lab_us-gaap_PensionExpense_label_en-US" xlink:label="lab_us-gaap_PensionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense" xlink:to="lab_us-gaap_PensionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_ed333af2-db96-42a6-9679-ae559b162013_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6199da37-b398-48d0-9029-c2f3fd15dc75_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_df40b6d7-9948-4b42-9453-b29bb76b1a7b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c5871126-d299-4b41-bdc8-c73a67b400eb_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8b64065d-55c4-4622-97b3-b67bfb1da368_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_fa520edd-d269-4c97-897e-a486a26676c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f738ad8d-b75e-4933-8425-07cc11486f7e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_276e3251-ea80-40a6-89ef-08565720917a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_3b3dc2de-1056-4db4-8897-a93ab5aa1ef4_terseLabel_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of revenue generating products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_label_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Revenue Generating Products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_documentation_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the number of revenue generating products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:href="ebs-20231231.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:to="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fa87551b-541b-4a07-98eb-c3ec3deebc62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_880e739e-58f1-4476-a29b-97e8056575ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ba40b008-7a59-434f-9c5f-d7441b6e12a2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9eb6d989-1e35-4bbc-880f-8b184f2e5e18_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for potential dilutive effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_46241db6-863d-401a-af75-8445cc19afeb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Benefit Obligation:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6983cf32-b375-460b-be06-441f40275b4e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SOFRSONIAAndEurocurrencyMember_fc8bb72d-60e1-41fb-9c3a-78d87149a9a8_terseLabel_en-US" xlink:label="lab_ebs_SOFRSONIAAndEurocurrencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOFR, SONIA, and Eurocurrency</link:label>
    <link:label id="lab_ebs_SOFRSONIAAndEurocurrencyMember_label_en-US" xlink:label="lab_ebs_SOFRSONIAAndEurocurrencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOFR, SONIA And Eurocurrency [Member]</link:label>
    <link:label id="lab_ebs_SOFRSONIAAndEurocurrencyMember_documentation_en-US" xlink:label="lab_ebs_SOFRSONIAAndEurocurrencyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SOFR, SONIA And Eurocurrency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SOFRSONIAAndEurocurrencyMember" xlink:href="ebs-20231231.xsd#ebs_SOFRSONIAAndEurocurrencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SOFRSONIAAndEurocurrencyMember" xlink:to="lab_ebs_SOFRSONIAAndEurocurrencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_94b4661b-c685-4a77-9142-7881dcc8a1f1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_65de6c2f-3bf5-4e3c-91e4-f932b8ebadd1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Lease Expense Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_51555c62-b7a5-4d2d-9f12-e3bc94565a92_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db7f5e28-1fa6-4194-9e22-22d7e3c238db_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fd810224-c27b-4708-9c83-6f0238e6bb23_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_3171de51-ea76-4f79-bba5-67bf3d0c3425_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales or services:</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_fb65e3ff-4dfd-4208-8fa7-4e8a734a1fd0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a96e2499-55eb-4860-a20a-6d315746fb4d_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_6054323f-6019-4409-a2bd-3e5dfe3cb050_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a999d7dc-2db7-4a58-9664-bff78657f00e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_af539933-3e7c-4a1f-b038-54a953809498_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f433044f-a99f-4353-b499-37f4d0331f2b_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_87dd04d4-8754-432d-a3d8-fc8bc6a3a81c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized for issuance under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_33b5e9c0-eae4-472f-a54b-2e1fcd788665_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_cc75ca9d-f651-4440-a87a-e64832490846_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a8a77686-3867-4d9a-869a-b8bb5b5a57c4_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_49a6246d-6347-4ce1-b71e-f0315ace6b2c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_f3c9b190-a030-4987-a66a-2e1731f57bda_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, contingent consideration, liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ae50461c-46de-4037-aa0f-f40af47caea9_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_0a4c2892-1406-443e-9419-4749906883f1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a6645600-121f-4006-8862-d31172897f8c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_02e96a17-ea6d-4d73-bf2a-9c81fd0499a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9328d76b-4904-4520-b2dd-09a3e3dfea33_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_3fde5437-1a8e-4f4f-a052-f98745bcc47a_terseLabel_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments receivable</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_label_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_documentation_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:href="ebs-20231231.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:to="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AnthraxMCMMember_5fff40ca-7986-4f1a-967c-a578219997d1_terseLabel_en-US" xlink:label="lab_ebs_AnthraxMCMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anthrax MCM</link:label>
    <link:label id="lab_ebs_AnthraxMCMMember_label_en-US" xlink:label="lab_ebs_AnthraxMCMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anthrax MCM [Member]</link:label>
    <link:label id="lab_ebs_AnthraxMCMMember_documentation_en-US" xlink:label="lab_ebs_AnthraxMCMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Anthrax MCM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AnthraxMCMMember" xlink:href="ebs-20231231.xsd#ebs_AnthraxMCMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AnthraxMCMMember" xlink:to="lab_ebs_AnthraxMCMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c3d5a10f-94c9-410f-8474-f4056743c92c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_5153ec65-a702-42ad-9d01-87facf8ea649_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increases (decreases) for tax positions for prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_bddad57d-6306-418f-bd52-0cc828c6a6fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes receivable and payable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_615d22e9-5975-4ed3-8df9-c507aa670d18_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7ba10182-8f46-4b37-a6db-00a7079105a4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b8f634a4-32a7-47cf-996a-3b2b73675bce_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_d75cdaad-fa52-4aae-ab77-09700fbe7e2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6da37361-53d6-4287-9143-1435a5640719_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_eb1ee6a5-a97a-4058-8c88-50fd3fc98bfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_47929822-aba6-4f6c-aa00-430b7e806ec1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases for tax positions for current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c07c513d-592f-4b48-bbd5-29b5236a1e44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_9b7f496d-eda9-4355-92d2-ad6f508bdb07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, periodic payment, principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f50b3bc1-7acb-4297-8a27-bb28435fd967_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55bfc523-2d94-4e9f-a970-6dcefd927284_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_31ac240b-900a-476d-80a6-2eb313883727_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_074d6cd5-ab22-4bfd-89fe-2ada4bb8d9c6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_BioservicesLeasesMember_37521922-2905-4818-a039-b0e12a3862ee_terseLabel_en-US" xlink:label="lab_ebs_BioservicesLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ebs_BioservicesLeasesMember_label_en-US" xlink:label="lab_ebs_BioservicesLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioservices, Leases [Member]</link:label>
    <link:label id="lab_ebs_BioservicesLeasesMember_documentation_en-US" xlink:label="lab_ebs_BioservicesLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioservices, Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesLeasesMember" xlink:href="ebs-20231231.xsd#ebs_BioservicesLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BioservicesLeasesMember" xlink:to="lab_ebs_BioservicesLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f2a74984-10de-4e9e-baca-9e73d6f4817c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_36930caa-1c28-41cf-b41a-66b878afa82d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3c07033b-c28a-4ae3-acd4-e5a45bc292b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_762b0ba9-02de-4e01-bd5c-04dc0e593edf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_eb82daa9-f415-466c-9faa-ba617e68eceb_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net actuarial gain</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_041e791b-733c-4ad0-a6a8-6f5447a96670_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_8cebb152-3905-4d9f-b077-af32f464821e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 5.6 and 5.6 common shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4f59b6df-3ea4-433f-9e66-2544663d3294_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_64c02520-e016-4051-9ddf-b603b1419a6d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_74489116-63fa-443f-bd26-eb95c97b4d40_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8ec42f3e-0553-421a-8167-cd4b8cc5e9b2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_9ad8c10e-f143-4e6e-8903-94d70182a2ad_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets disposed of in sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_08e30309-94bf-4ea5-aec2-2b31e492c94a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_f72f80ee-bb0d-4942-af44-0954334b6b73_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_5d341756-d94f-44d2-9cec-6f45537c16c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_60fb6ac8-8cc4-4dfd-b4ee-4483d51741af_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_64f6bde4-90c4-4963-b3ec-4e3266703e21_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period expected to be recognized related to unvested equity awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7524b077-3f7c-4acc-901c-a3d860323bd5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_758cb69a-498b-462b-b3d2-294b2bc35e1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_3cb26764-213b-42f8-9b64-bd7ef661e4ed_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funded status, end of period</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_a073c4c7-1a0a-4671-abcd-bd4d0de1ffec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_d924dc84-56f3-4289-8b33-c36a8e6fb275_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0e578531-5d57-4d87-a2ff-d43785ed995a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DeferredTaxAssetsIntangibleAssets_29162034-ff73-4cca-8f9a-7ec2c833911c_terseLabel_en-US" xlink:label="lab_ebs_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ebs_DeferredTaxAssetsIntangibleAssets_label_en-US" xlink:label="lab_ebs_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:label id="lab_ebs_DeferredTaxAssetsIntangibleAssets_documentation_en-US" xlink:label="lab_ebs_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsIntangibleAssets" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DeferredTaxAssetsIntangibleAssets" xlink:to="lab_ebs_DeferredTaxAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_736c7fda-b414-475a-9c87-410c2ef78a23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_dce3b081-a8bd-4f69-80f3-0e5c6d66e690_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9e28e119-f18f-4642-bb0e-fd2c67cbfe95_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6a786ea4-8f83-411b-bc30-f1453c77e6e1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income tax penalties and interest</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_1304cd4f-469e-46a3-8d6a-694ae1c60674_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_e36d5742-aa54-4b3a-adaf-2b28577b548d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_712c9109-9f9e-4d22-9d55-0dadecd7355f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_111e8d63-d1a5-4a87-8e6d-2b535053bf24_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_23e9da56-b9b3-43ad-a1d5-8be1e5c4985a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IRC 163(j) Interest Limitation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DeferredTaxAssetsOperatingLeaseLiability_d649b040-b591-46c9-92a4-101879fd7d2d_terseLabel_en-US" xlink:label="lab_ebs_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ebs_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_ebs_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_ebs_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ebs_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_ebs_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1cf658a7-7223-4520-b50b-878b746b8561_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4af65f4c-ebf4-415d-9e5f-9de496af047d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market sale of stock, net of commissions and expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_e5527d66-b0aa-4108-80a5-1f783f9db315_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_4863d88a-49ec-494b-aa5d-456b0e6ba37a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3e2db07e-60b8-4e26-889c-e299a04fae8a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_586b537e-21a1-4cf6-b955-be38de40df32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_39d935cd-816f-43eb-a710-b9e3aceab4be_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_32e39413-4171-429c-822d-3c7f03103696_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_bde0fe35-e457-4866-bae5-60c98488f1af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal tax at statutory rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum_96eda9fc-6df3-41f8-a96e-2569b06b3663_terseLabel_en-US" xlink:label="lab_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of option as percentage of fair market value at grant date, minimum</link:label>
    <link:label id="lab_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum_label_en-US" xlink:label="lab_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Of Option As Percentage Of Fair Market Value At Grant Date, Minimum</link:label>
    <link:label id="lab_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum_documentation_en-US" xlink:label="lab_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum exercise price of option as percentage of the fair market value of the shares underlying such option on the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum" xlink:href="ebs-20231231.xsd#ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum" xlink:to="lab_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_11940fdf-35bd-460d-bd1f-aa9373abdeb0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_481ecd82-0e59-468a-8372-466fbf64e2ab_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_fdee8718-f736-4a39-98cf-23518f37749c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestiture</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_66f63f98-5542-4203-9cb5-2ce8b0495503_terseLabel_en-US" xlink:label="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impairment of Long-Lived Assets Held and Used by Asset</link:label>
    <link:label id="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_label_en-US" xlink:label="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:to="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_00c5045c-b76b-4a78-a958-1d9abd451e86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4dd8fd91-c88c-4e33-ae62-db65bde668ad_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_00674294-a9b7-42a7-a575-eeeec37c99e0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_cdd7d1e6-0206-4a14-963e-7b83389010ab_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_fccc2b70-4a14-429b-9230-c1efdb487ed0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4abd9e32-4291-4c81-bc45-c075d57dd1f7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4372a8d-31c3-4f56-a2dd-b00881e7a277_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_5b307eab-283b-417e-92da-a83d21dd1217_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0f8b2276-7975-4496-9f3a-131016d4fdcb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2f136fd0-ef1b-4ece-b81f-29bb5290d208_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a291db3b-5300-4f7e-b8ae-15f983e24ad1_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5566447a-9aed-4ad7-81ae-89ef99312f0a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0084a4dd-1ee6-4dae-bb92-ee6f6c0a257e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b959157a-7c9a-4d8d-af8b-d865769964ce_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentThreshold_c97fabc7-20f4-4a75-9864-bada46b1a0bc_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mandatory prepayment threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentThreshold_label_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment Threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentThreshold_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentThreshold" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentMandatoryPrepaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentMandatoryPrepaymentThreshold" xlink:to="lab_ebs_DebtInstrumentMandatoryPrepaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_2aa62c19-5b9e-4db6-989c-a0cc56f9f6e7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, current, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5ba96e7b-530f-490d-a18f-a4e7eccd8944_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_3705f71f-4d43-4363-a46a-fda9723be652_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d0f93acd-fbd1-4e6b-98d8-661cd35cd1cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_443f8c25-54f5-4fed-b706-a10159a1cae9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Asset Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_09f41564-8c5e-478c-a6ea-cacf2889bff0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ef9a3c91-1d97-4aa9-8415-d7eaeda53f94_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5657d238-ec55-4565-8284-54cfe33ec778_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e0a7fe2e-8390-4c32-95d7-b24451083184_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3ed72400-c35e-4706-a2af-45b8b31bbd93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ChimerixMember_8c44c9b7-a14c-467c-ac4c-eebb590b3206_terseLabel_en-US" xlink:label="lab_ebs_ChimerixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chimerix</link:label>
    <link:label id="lab_ebs_ChimerixMember_label_en-US" xlink:label="lab_ebs_ChimerixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chimerix [Member]</link:label>
    <link:label id="lab_ebs_ChimerixMember_documentation_en-US" xlink:label="lab_ebs_ChimerixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chimerix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixMember" xlink:href="ebs-20231231.xsd#ebs_ChimerixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChimerixMember" xlink:to="lab_ebs_ChimerixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ee263197-8268-4768-a2b5-332960c30df7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_52f20ae8-d907-4d34-bd4c-53466a38b94e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c2371ef0-14c8-40dd-9341-ca8ee9516f2a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0391ee57-7a3c-4243-b079-22db26f3b971_terseLabel_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years)</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_7f486420-6db4-41e0-a098-3398ddb9e23a_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_aa87974d-b161-4894-a6c7-654c3918c93a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_3f03f2c4-19bd-420b-a8ff-388be96ce50b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4afda025-3529-46e8-989b-ec272fa9b40d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_abccf358-7c04-4fa8-8781-323be2a9cfe3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal group, total consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_36e1bfec-bec9-472d-9d7b-17a31034ab06_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00abf545-2303-42ad-836a-668e58f85c18_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0892037f-6a78-4272-a73a-fde89c9cd0c4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_9a9c2646-04c0-4789-91ac-cc5ab9239c2f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_41ca2122-f7e6-447a-8974-834fff83d249_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charged to Costs and Expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember_f7b900f8-d0d7-4324-b059-6b4771b05f3a_terseLabel_en-US" xlink:label="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated Expansion Of Fill/Finish Capacity</link:label>
    <link:label id="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember_label_en-US" xlink:label="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Expansion Of Fill/Finish Capacity [Member]</link:label>
    <link:label id="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember_documentation_en-US" xlink:label="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accelerated Expansion Of Fill/Finish Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:href="ebs-20231231.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:to="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_307a72e4-03e0-4dd6-a7bd-fc8a9ceb9ec8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3c344b63-f5f9-4bda-b309-c2a4dc40e04c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_e629cd65-da6d-423b-8553-adbbb30b96bb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_f91becc5-0eb3-46c1-9f46-060cdae7ff0a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3ed79d3e-3cfe-41a2-9528-97a90761021a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_568e7bc2-f23e-4e79-8035-779b4f562041_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5a6a1681-fea2-4f2d-bfdd-d6bef6ecc029_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 200.0 shares authorized, 57.8 and 55.7 shares issued; 52.2 and 50.1 shares outstanding, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_d133c8fd-ffbf-440c-af6a-065e0dfa1749_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ed0a972-834b-445b-87f5-7763039e5f34_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_fecc8f4e-7586-4fc7-9f22-789fc9d44729_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d26adf9f-7286-44b5-bc31-c72c57fb7624_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_17fea6ab-fe9b-43d2-9829-2027a9864188_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment from prior asset acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1f1b2adf-436c-4c30-8948-1c11e6320bf3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State losses carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_551e1cbc-4f33-436e-8a2e-953401e96414_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2e6bd9a7-3ebd-40ed-9075-7fd5db69c5bc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UnrecognizedTaxBenefitsNoncurrent_c8f162e6-aeb1-40f2-a722-3f1de4f8d7b9_terseLabel_en-US" xlink:label="lab_ebs_UnrecognizedTaxBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, noncurrent</link:label>
    <link:label id="lab_ebs_UnrecognizedTaxBenefitsNoncurrent_label_en-US" xlink:label="lab_ebs_UnrecognizedTaxBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Noncurrent</link:label>
    <link:label id="lab_ebs_UnrecognizedTaxBenefitsNoncurrent_documentation_en-US" xlink:label="lab_ebs_UnrecognizedTaxBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns, and classified as a non-current liability as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnrecognizedTaxBenefitsNoncurrent" xlink:href="ebs-20231231.xsd#ebs_UnrecognizedTaxBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UnrecognizedTaxBenefitsNoncurrent" xlink:to="lab_ebs_UnrecognizedTaxBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_191bec3d-0782-4a5b-bff8-a6689bb379f1_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, year five</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_11044a89-caf6-4492-9610-12bb80c15e9e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_9a0d09d7-34ee-451b-ba98-6586273ddb86_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_732e7213-6aca-48fc-890d-7393d28dc22a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c7244b2f-ec84-424f-a7b7-6e390bfce6f8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_1d039ea9-d1b4-4ba2-856e-46a98f2e74f2_terseLabel_en-US" xlink:label="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term incentive plan accrual</link:label>
    <link:label id="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_label_en-US" xlink:label="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Long-Term Incentive Plan Accrual</link:label>
    <link:label id="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_documentation_en-US" xlink:label="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Long-Term Incentive Plan Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:href="ebs-20231231.xsd#ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:to="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_11ebf4d3-5367-43a4-bcd8-5ce8d6544411_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a3e50de8-8758-429f-83e3-b67c03dbcd74_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_de2c4691-8a96-4d13-a160-fb9e3e9d6fce_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3d56f559-df0f-42b3-8d03-72f913835bb1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e75bb805-0060-492d-95d0-d43317d2c5a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7533e0c9-d770-40a1-990e-94f583983fd9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_43b7ee91-20ba-4c8b-8fca-6850257d9dcc_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits, beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6ee808b1-fd83-4056-bd4b-79b6170cfb38_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits, end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_e3646b53-9d23-4034-a8c6-ea8765781806_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a85b18c6-e355-45c0-b43a-8c76f67215ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4fb26c6c-b8e2-43ca-8b43-cb5f36e9ed34_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_6fc23d81-235e-4c2d-931c-94f454da5b83_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MeasurementInputProbabilityOfPaymentMember_60a11534-44f8-43f6-a969-b7b42fdfd6e4_terseLabel_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of payment</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityOfPaymentMember_label_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Of Payment [Member]</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityOfPaymentMember_documentation_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Of Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:href="ebs-20231231.xsd#ebs_MeasurementInputProbabilityOfPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:to="lab_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_7aab3dbd-7e4f-4f88-b2ef-dedf319f9b09_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_6412d952-0201-4523-9114-ebff437b8ad4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6d3dcf4d-9d95-47d1-a812-2f342c9fe1b6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_690af1d5-1181-419f-b946-abb7d2552d68_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitment period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_13a8e516-2d18-4082-b076-9a78b287693e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_4fc4c895-b85c-419b-92ee-0a8cd15b233f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_378ce575-9615-4a26-9b5e-b806c7e777ba_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_988cd3e5-1308-404e-96b3-14c25a87e29d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_ca438ed1-f433-4bc0-a0b0-7d545e6c44ee_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_InventoryStepUp_ff7135d8-6596-4106-b79c-8983e77fb79b_terseLabel_en-US" xlink:label="lab_ebs_InventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment inventory step-up provision</link:label>
    <link:label id="lab_ebs_InventoryStepUp_label_en-US" xlink:label="lab_ebs_InventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Step Up</link:label>
    <link:label id="lab_ebs_InventoryStepUp_documentation_en-US" xlink:label="lab_ebs_InventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory Step Up</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_InventoryStepUp" xlink:href="ebs-20231231.xsd#ebs_InventoryStepUp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_InventoryStepUp" xlink:to="lab_ebs_InventoryStepUp" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_06c39692-5b0b-41f8-bb9e-a01033c2c7ab_verboseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Nature of the business and organization</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5327140d-fc30-439b-b082-4416e88da066_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e917d571-6765-452c-bbdb-c9e73f90570f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2e8532bb-9491-4a74-9b61-aa0545e496a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_0b4ab4a8-02df-4621-8b8f-a4f24f93e27d_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_cd17cafc-c644-43e0-bb71-240afce2979c_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of travel health business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_e59ce487-dca2-4236-b335-4d7eeec2c2fe_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_edd89497-6e06-41cd-ad8d-c165cbb43ce8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0c7b8372-f6cb-4d0f-b24c-632541a1c2dd_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4244ea3f-11b8-499f-b375-d55819b7c620_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DispositionOfBusinessTransactionCosts_9782e35d-857a-4363-99a4-d5ee6b971561_terseLabel_en-US" xlink:label="lab_ebs_DispositionOfBusinessTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ebs_DispositionOfBusinessTransactionCosts_label_en-US" xlink:label="lab_ebs_DispositionOfBusinessTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposition Of Business, Transaction Costs</link:label>
    <link:label id="lab_ebs_DispositionOfBusinessTransactionCosts_documentation_en-US" xlink:label="lab_ebs_DispositionOfBusinessTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposition Of Business, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DispositionOfBusinessTransactionCosts" xlink:href="ebs-20231231.xsd#ebs_DispositionOfBusinessTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DispositionOfBusinessTransactionCosts" xlink:to="lab_ebs_DispositionOfBusinessTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_62699a87-e90b-4923-a39e-e375468568f3_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_75bed160-3963-4110-bba4-22338de4d5f3_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_87410d99-09c0-4ea2-bd88-478d1630a719_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bfc60dc-e2ba-40d3-bee7-a7ad5f9e8c4f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_3baeaf05-a6b0-4cd9-9409-98fe57b6be9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8d8f8ec6-49c1-46f3-88e9-e90589daf1bb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected average life of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d45bc11-3ed9-411a-8d82-4497c03de375_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6471963e-ee0b-426e-864a-2a8156118e5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_f84f1909-5b35-4b7d-8a17-69968bfa3318_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Royalty settlement payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_8e5b2872-02f8-42cb-b88e-0278a230b040_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5cc6b881-8a9c-4a46-8f7a-6cfefd9899d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_d5a85c8d-63f6-4bbb-9eec-ee839701c819_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived asset impairment and restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_d68df2ae-5e26-4d87-9ebd-ff5bc45611eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Loss Before Income Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_fbe0ef6e-09d9-41d2-a77a-ffd02c576b39_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c7751d4c-ddea-454e-a61a-0ebdedfe1d18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts_fd569781-6246-443e-9618-c4af10398bad_terseLabel_en-US" xlink:label="lab_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IRC 263A capitalized costs</link:label>
    <link:label id="lab_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts_label_en-US" xlink:label="lab_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Capitalized Costs</link:label>
    <link:label id="lab_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts_documentation_en-US" xlink:label="lab_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Capitalized Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" xlink:to="lab_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_01597f7f-f07c-46ba-ba3c-77227c4ed971_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_5a5c9fea-292d-4648-a986-aac2c308edcd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_fdb8734e-7055-482f-832d-416846e19217_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f26b3c98-422a-4178-842a-106b2d3e38fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8277216e-52f4-4402-966d-76bbe0ee4306_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3c273f5f-c917-48f8-bb2c-9b1d0fd18bac_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Useful Life in Years</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b04b85c2-ace8-474c-9dbc-76e09f03a42a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1289ff38-f6fd-4c96-9e29-1507dee440a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e9e62bf5-15da-4093-9284-724048305860_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c0b13761-afe1-4bea-8ce0-134ec235df35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_d192a0f3-a29f-4b00-82a5-7ef29ab1d17a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage_3493da36-c767-40a2-b18c-fafc180e71da_terseLabel_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payout percentage</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage_label_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payout Percentage</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage_documentation_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payout Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" xlink:to="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_9229a5f7-7277-488d-a192-db096b1522e5_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_58ffb25c-76d0-45b6-af8b-facef27cc951_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_99efd642-1adb-4b4d-9cad-728d37c13fbf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6a732732-d195-4aeb-a923-e4c144d4c639_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_3832e122-1e7f-4dba-897a-b7dec13b79cd_verboseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fb0475bc-a66a-433a-b37b-914ff0685ea6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_e7fdfa14-957e-479e-b21b-df49e82df56a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0af5359f-0e1a-483b-9760-79a9f92a8b26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94828980-adb6-45a2-893e-c95dfa10f7cc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85c645f6-3191-4c2a-b1b1-63338b037437_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ReservationOfManufacturingCapacityMember_ac210624-b2b9-4bd6-8274-dd86be8e2468_terseLabel_en-US" xlink:label="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reservation Of Manufacturing Capacity</link:label>
    <link:label id="lab_ebs_ReservationOfManufacturingCapacityMember_label_en-US" xlink:label="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reservation Of Manufacturing Capacity [Member]</link:label>
    <link:label id="lab_ebs_ReservationOfManufacturingCapacityMember_documentation_en-US" xlink:label="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reservation Of Manufacturing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember" xlink:href="ebs-20231231.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ReservationOfManufacturingCapacityMember" xlink:to="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_dd3a572a-f69a-477a-866d-879ce4f4a39a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_2cca4c03-4a86-456f-ad28-992b7a2d9be0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_c91c4ea6-02bd-4683-ab0e-f95e6179aa34_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received, after year five</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e95531a0-1f7f-4677-aca2-a6daf493d77f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_3c258d07-062d-4d50-8ff8-20f53bd4186b_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_917d9317-4738-4194-9c91-a1504cfd780a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2e2b3c86-c557-460c-abed-dd4bf734ee7d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_64958f24-d900-481d-8a98-da56457d386c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_65c49b08-168e-4eb4-ac72-1fb5762a5dc1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e050e5fa-ad2e-464e-8f2f-a4364fa2caaa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9a31b025-98a8-4745-aeaa-4869c46bebe8_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_75e1532d-3dad-48ec-866d-47c16a197799_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue_c3488b6b-eb3e-4448-9045-c56515b7d79e_terseLabel_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of awards vested</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue_label_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement Share based Payment Award, Awards Vested in Period, Fair Value</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue_documentation_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of share-based compensation awards vested. Includes options, share units, stock appreciation rights, and restricted stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" xlink:to="lab_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_082adf24-6cd2-4112-a2b6-b16a0c142ef1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_cf1065c7-de37-4cdf-a245-e85afc5a1d85_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_bbff0efc-818c-4bc5-8b55-891cd239f520_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_22068982-08ce-4288-8d3c-5a9f0aa145d7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_81be498c-cc0a-44bd-ab6d-4fe204f86974_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_1e081daf-e295-4ddf-9b46-aec587ddd549_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accruals</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_d16d9e4b-8836-431d-8659-195b3687a062_negatedNetLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Segment restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_efd3f17f-5bc2-4f2a-a14e-e935dcb7cf26_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_76b766a9-e82e-4998-b6b4-c974bdfcc81a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OperatingLossCarryforwardsSubjectToExpiration_6c9e6a95-1f79-46cb-bd76-327bcfaaf2ca_terseLabel_en-US" xlink:label="lab_ebs_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_ebs_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_ebs_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_ebs_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_ebs_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="ebs-20231231.xsd#ebs_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_ebs_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_FiscalQuartersEndingAfterMarch312024Member_17a1082d-c751-4711-bf28-4e4d3208ee7a_terseLabel_en-US" xlink:label="lab_ebs_FiscalQuartersEndingAfterMarch312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Quarters Ending After March 31, 2024</link:label>
    <link:label id="lab_ebs_FiscalQuartersEndingAfterMarch312024Member_label_en-US" xlink:label="lab_ebs_FiscalQuartersEndingAfterMarch312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Quarters Ending After March 31, 2024 [Member]</link:label>
    <link:label id="lab_ebs_FiscalQuartersEndingAfterMarch312024Member_documentation_en-US" xlink:label="lab_ebs_FiscalQuartersEndingAfterMarch312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fiscal Quarters Ending After March 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_FiscalQuartersEndingAfterMarch312024Member" xlink:href="ebs-20231231.xsd#ebs_FiscalQuartersEndingAfterMarch312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_FiscalQuartersEndingAfterMarch312024Member" xlink:to="lab_ebs_FiscalQuartersEndingAfterMarch312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount_75235099-8c16-4d56-99af-1a656e53e244_terseLabel_en-US" xlink:label="lab_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance increase, including CTA component</link:label>
    <link:label id="lab_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount_label_en-US" xlink:label="lab_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Including Cumulative Translation Adjustment, Amount</link:label>
    <link:label id="lab_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount_documentation_en-US" xlink:label="lab_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Including Cumulative Translation Adjustment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount" xlink:href="ebs-20231231.xsd#ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount" xlink:to="lab_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa2d4d4e-7d3a-4a2a-acd7-5c426179f0ed_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_158a8943-9acc-44e4-b591-28e9bc61e7e0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_f1ae9e13-5b09-454a-ac05-622ee83d5649_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f5422506-92d7-4851-b60a-434512fa9f85_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_e80f5c35-69b3-4abd-9c84-b2763e9edf16_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_FiscalQuartersEndingIn2024Member_6eacde21-43fb-4d91-a4e2-ffd485d7bc19_terseLabel_en-US" xlink:label="lab_ebs_FiscalQuartersEndingIn2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Quarters Ending in 2024</link:label>
    <link:label id="lab_ebs_FiscalQuartersEndingIn2024Member_label_en-US" xlink:label="lab_ebs_FiscalQuartersEndingIn2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Quarters Ending in 2024 [Member]</link:label>
    <link:label id="lab_ebs_FiscalQuartersEndingIn2024Member_documentation_en-US" xlink:label="lab_ebs_FiscalQuartersEndingIn2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fiscal Quarters Ending in 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_FiscalQuartersEndingIn2024Member" xlink:href="ebs-20231231.xsd#ebs_FiscalQuartersEndingIn2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_FiscalQuartersEndingIn2024Member" xlink:to="lab_ebs_FiscalQuartersEndingIn2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0abdea82-51b6-4110-b5d0-608de686746e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_06e9c2dc-5694-4414-a364-b05e0b7a47ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c35d137d-e1d8-4158-9e86-b25495aad44b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6c0d82ad-de31-4ff0-8cf3-93054f4464b7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_bdf5a92e-8308-4636-b9d8-0a2b1bffadeb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1d34d33b-6437-4866-bb6e-19acd9c96d3b_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_5528e489-d4f3-422c-9835-30b74f6fd569_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_a31cace2-0251-4140-8c45-2ae34dc59c04_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of travel health business, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3fa5914e-7ca0-4b28-b07d-04446fdb3607_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f864384b-a52f-4a55-afc7-bb6b6893205f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation activity (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_160976bf-09b0-4cee-b205-626c64ddf544_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_83018a67-bfca-48a0-9a7c-7f8af0ef9d9a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_2dc88567-4423-4b21-9501-febffe8d85e2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4baa2c3f-662f-49cd-9cd1-e5b11e0f43e6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent obligations, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7b8a75dc-7aa9-48cb-a49c-ca3f3925bc7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_3799bba0-0e3d-4a29-96a4-da1a92b8706c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_954034de-3482-4e4c-a470-60510d4d94b5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Payments</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_82f26a5b-cae4-48c3-9c4f-ead6458c47a6_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b6c65fa6-298c-465c-bd48-98d1c63a64be_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f60bcbec-45b0-43fe-bcfa-08d67d90fd94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c08f42f1-cd16-4355-a9da-ca389aa48183_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_340b4eba-5128-45b2-9554-5a2710d5651c_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_87600e8b-f7ac-4696-9d9b-87fbd18d1b27_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_35e4356a-ac5e-4e48-a753-6ac967145a7e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_2b19940a-a6ff-4cd0-ab9d-66ab4a15e387_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_738e21e1-9df1-4b3d-b023-56d3c16ead13_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_949fcf23-7e95-484f-b66d-ea6703ad3908_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount_f92c860f-cb19-4ff6-a7ae-855b72789c3b_terseLabel_en-US" xlink:label="lab_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation limitation</link:label>
    <link:label id="lab_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount_label_en-US" xlink:label="lab_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Compensation Limitation, Amount</link:label>
    <link:label id="lab_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount_documentation_en-US" xlink:label="lab_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Compensation Limitation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" xlink:href="ebs-20231231.xsd#ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" xlink:to="lab_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_ef106492-0bbc-4815-8b21-1bf09ee5da92_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_530f0bfc-6154-458b-a91c-54dd8010ab14_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2600983c-4898-4862-ae07-5b6b161d5503_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_14e8fd06-8c26-48f6-a0f4-2d93183f27ed_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_200e90a0-a3d9-4a65-9197-e2bf7bc69217_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market sale of stock, net of commissions and expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f97d1987-cf77-413e-9b6f-7e784d72b71e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of foreign operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_254371aa-f4cc-458d-bf2b-c02276eeccd9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_868db812-39ba-4acc-9327-3972b59cf8de_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d435a98-8e99-4c95-8e43-5670e98b6481_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_21b8d243-7bc5-44bc-a5ed-d7b15804b946_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2be1219e-9d61-4efe-bab0-630e0705750f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_32a87af5-6263-4829-920c-29486deb1012_terseLabel_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.875% Senior Unsecured Notes due 2028</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_label_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Notes Due August 2028 [Member]</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_documentation_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Notes Due August 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:href="ebs-20231231.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:to="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_165f352d-f692-46dc-ae0e-f828a9afeef3_totalLabel_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Bioservices revenues</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_fb4c2567-fa70-433a-acf7-7d9bb33bb96d_terseLabel_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="ebs-20231231.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_cc65e52c-2ac4-463b-a47f-2fd8565acfca_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_97431940-0e8e-4c2a-801b-d74ea2db9ef9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TreasuryStockPolicyTextBlock_dbfca89a-2cfc-4143-ae0d-d886be63033a_terseLabel_en-US" xlink:label="lab_ebs_TreasuryStockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_ebs_TreasuryStockPolicyTextBlock_label_en-US" xlink:label="lab_ebs_TreasuryStockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Policy Text Block]</link:label>
    <link:label id="lab_ebs_TreasuryStockPolicyTextBlock_documentation_en-US" xlink:label="lab_ebs_TreasuryStockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TreasuryStockPolicyTextBlock" xlink:href="ebs-20231231.xsd#ebs_TreasuryStockPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TreasuryStockPolicyTextBlock" xlink:to="lab_ebs_TreasuryStockPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e10b6d6f-f8b9-4026-977d-440b6daa898d_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e48d6d87-bb37-486a-94c7-f6c049860585_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1c3628bf-4973-44ee-861a-daefda2f2f9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_005b6f5d-7c75-40f7-9c83-bc47d881f8ab_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_bdd7191b-5464-429e-bf86-b04de68c0113_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_57856bf2-3bc9-4a69-a7c4-e44a0e01513f_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_f084f6f9-48f0-4a9c-8e92-2c62ec16d1b4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_9681ae48-78c9-452b-9d9d-7c7324562c0d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e262172a-a978-47c3-aea2-2f3f2a688042_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cb8d637e-0c38-43d5-b77f-cb2582ec6cd4_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares-diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SecuredOvernightFinancingRateSOFRMember_1322b62b-7c2f-4244-8895-403a4a845a18_terseLabel_en-US" xlink:label="lab_ebs_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_ebs_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_ebs_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_ebs_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_ebs_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SecuredOvernightFinancingRateSOFRMember" xlink:href="ebs-20231231.xsd#ebs_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_ebs_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_b137f8ab-0272-42d4-8ca6-bca7051a2cb1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, GILTI, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_48d902b8-5530-4536-8009-3f9d7c4d01fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_11b3be1a-f2da-4889-bf4e-a0ce248b4715_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8c618e46-11b6-4b95-9ac8-a63ed66c84d6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EmployeeTransitionMember_970f3a0b-5152-47f3-9f76-366b2257b2e3_terseLabel_en-US" xlink:label="lab_ebs_EmployeeTransitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Transition</link:label>
    <link:label id="lab_ebs_EmployeeTransitionMember_label_en-US" xlink:label="lab_ebs_EmployeeTransitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Transition [Member]</link:label>
    <link:label id="lab_ebs_EmployeeTransitionMember_documentation_en-US" xlink:label="lab_ebs_EmployeeTransitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Transition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember" xlink:href="ebs-20231231.xsd#ebs_EmployeeTransitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EmployeeTransitionMember" xlink:to="lab_ebs_EmployeeTransitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_cfaef2b2-6660-43b0-bc20-4ab81713402b_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_27a6c487-6ddc-488c-9499-2c56245cc55d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3dcd2522-9852-4360-88a9-6d98668e5259_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a537d955-41db-4155-8ff0-871e67b7e5ca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_712dd743-8f35-4886-ac76-3bf480e4de57_verboseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contracts and grants revenue</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_b52a02b9-c13e-43b8-86dd-146d15e6667f_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ec26ae1d-a481-4a9a-8efd-7447c035c390_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted/performance stock units vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CommercialProductMember_efae89d6-4884-4bd4-be64-2bb0201541ff_terseLabel_en-US" xlink:label="lab_ebs_CommercialProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Product sales</link:label>
    <link:label id="lab_ebs_CommercialProductMember_label_en-US" xlink:label="lab_ebs_CommercialProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Product [Member]</link:label>
    <link:label id="lab_ebs_CommercialProductMember_documentation_en-US" xlink:label="lab_ebs_CommercialProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember" xlink:href="ebs-20231231.xsd#ebs_CommercialProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CommercialProductMember" xlink:to="lab_ebs_CommercialProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_82295803-94df-4ff1-8638-7654cf9ed562_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_61e1a228-9dca-49d5-a394-2289151e9ef4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_e62813e5-c2aa-4dc1-80ac-5e0d8035c354_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OtherProductsMember_4cccc06d-ade8-4a16-b69b-3ed1411b13d9_terseLabel_en-US" xlink:label="lab_ebs_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Products</link:label>
    <link:label id="lab_ebs_OtherProductsMember_label_en-US" xlink:label="lab_ebs_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_ebs_OtherProductsMember_documentation_en-US" xlink:label="lab_ebs_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to product sales from other products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherProductsMember" xlink:href="ebs-20231231.xsd#ebs_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherProductsMember" xlink:to="lab_ebs_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cc5e94a8-1e4b-493e-8f66-31d7443f7798_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_985e7de6-62d1-4651-9020-f414d301058f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_a9e6b987-7940-4b74-8da6-0a5701291cbd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d0d42496-1e9c-4439-9a9c-607f3be8b75c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cdefbf2d-88f0-4d46-95d3-f171653380f8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares-basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_9086ceb8-4bc2-43eb-8928-e46ae538e843_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3be1deb2-a89e-4248-869c-2d99b4d1b1ea_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_98a723fb-c4a9-4d5d-a5e5-2e54c685f4ca_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_3486902d-3037-4d21-91e3-db7c23170b47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon the Occurrence of a Change in Control</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d5aad895-55be-4ff4-8ae8-ece0ad12c915_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_cc7fcb3d-0c76-4c3a-b169-21287fbeb599_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock-based compensation activity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_74436298-8956-43d8-8c37-bf11bf16df08_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9f623a34-87fb-4f43-8eda-d63642628125_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts_33ede013-05a7-4cb0-9ed6-9334c5164cdf_terseLabel_en-US" xlink:label="lab_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts_label_en-US" xlink:label="lab_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Costs</link:label>
    <link:label id="lab_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts_documentation_en-US" xlink:label="lab_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to transaction costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts" xlink:href="ebs-20231231.xsd#ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts" xlink:to="lab_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_12fc1b90-8626-4535-bec7-eb047b4ef824_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ce445201-62ca-4501-a833-b51a7cbc5efd_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_938f4bb8-5de2-4f76-a5e4-c9a91632e27b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MedicalCountermeasuresMCMProductMember_00bef4e7-6a10-4123-a0bc-e4140b6cc19f_terseLabel_en-US" xlink:label="lab_ebs_MedicalCountermeasuresMCMProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MCM Product sales</link:label>
    <link:label id="lab_ebs_MedicalCountermeasuresMCMProductMember_label_en-US" xlink:label="lab_ebs_MedicalCountermeasuresMCMProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Countermeasures (MCM) Product [Member]</link:label>
    <link:label id="lab_ebs_MedicalCountermeasuresMCMProductMember_documentation_en-US" xlink:label="lab_ebs_MedicalCountermeasuresMCMProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Countermeasures (MCM) Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember" xlink:href="ebs-20231231.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MedicalCountermeasuresMCMProductMember" xlink:to="lab_ebs_MedicalCountermeasuresMCMProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_7fe28cda-8a6e-4892-9468-f4b0cc7d6dec_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_8fdcd1da-d9c0-4fcf-a4a1-17fb5c2be548_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>ebs-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c54bb9fe-5fe3-484c-8c37-1247bde19e06,g:0a179766-9174-4357-afdf-29ab18a19ddc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:type="simple" xlink:href="ebs-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c352010c-90dd-403b-ace4-76d0abdfac89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_DocumentType_c352010c-90dd-403b-ace4-76d0abdfac89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_d2e107ac-fd01-481d-b589-2cee5a845f89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_DocumentAnnualReport_d2e107ac-fd01-481d-b589-2cee5a845f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e6733c1f-4013-4c2a-899d-0efdbe403193" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_DocumentPeriodEndDate_e6733c1f-4013-4c2a-899d-0efdbe403193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_39079d78-c5ca-4b8b-a624-a7593e2b28eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_CurrentFiscalYearEndDate_39079d78-c5ca-4b8b-a624-a7593e2b28eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4335a6b6-61a6-4997-880b-5e7014878349" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_DocumentTransitionReport_4335a6b6-61a6-4997-880b-5e7014878349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_78a978ed-0cbf-4089-869a-a235a71b3b74" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityFileNumber_78a978ed-0cbf-4089-869a-a235a71b3b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_29681b04-80df-449e-a9e4-4bb7101e4f29" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityRegistrantName_29681b04-80df-449e-a9e4-4bb7101e4f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f050561a-b272-4a2c-8804-2c1e26bfa91f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f050561a-b272-4a2c-8804-2c1e26bfa91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_27f07f9d-b4a9-4cd3-a7b6-f308eedc71ce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityTaxIdentificationNumber_27f07f9d-b4a9-4cd3-a7b6-f308eedc71ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bdd72c91-d0ed-4fba-8a70-441f00a845ce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityAddressAddressLine1_bdd72c91-d0ed-4fba-8a70-441f00a845ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c6905551-d0c4-427c-8ad4-ba99e4933de1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityAddressCityOrTown_c6905551-d0c4-427c-8ad4-ba99e4933de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d5381c98-df82-4d18-a478-2fb70ab3c752" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityAddressStateOrProvince_d5381c98-df82-4d18-a478-2fb70ab3c752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_259be04f-4514-4f9e-a5f8-631c7e2348e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityAddressPostalZipCode_259be04f-4514-4f9e-a5f8-631c7e2348e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f642af9c-a2d5-49c0-956f-cb4102849aa2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_CityAreaCode_f642af9c-a2d5-49c0-956f-cb4102849aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d1d59571-aeb7-4a6a-8c16-62abc5f9a664" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_LocalPhoneNumber_d1d59571-aeb7-4a6a-8c16-62abc5f9a664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_55c61e3a-325f-4f0a-ab54-19ca3a011926" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_Security12bTitle_55c61e3a-325f-4f0a-ab54-19ca3a011926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_43003928-299d-4645-8a7e-0d9f22e13a6f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_TradingSymbol_43003928-299d-4645-8a7e-0d9f22e13a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0fa21605-624d-47c0-9288-aaf21956a02f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_SecurityExchangeName_0fa21605-624d-47c0-9288-aaf21956a02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_d855591a-f6b7-4e96-9911-93398a71e237" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_d855591a-f6b7-4e96-9911-93398a71e237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_4c2ff72e-1a09-45f5-b30f-1e938a00ac4a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityVoluntaryFilers_4c2ff72e-1a09-45f5-b30f-1e938a00ac4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_fe982ac9-e897-4791-a729-d4e6819a4452" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityCurrentReportingStatus_fe982ac9-e897-4791-a729-d4e6819a4452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0356662d-747d-4390-91f5-e88c20cdc4e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityInteractiveDataCurrent_0356662d-747d-4390-91f5-e88c20cdc4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0fc77ffd-a83a-4718-adfe-704a7bf1ef30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityFilerCategory_0fc77ffd-a83a-4718-adfe-704a7bf1ef30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0a9af72f-8b7b-465e-81a2-d0c6a73c4937" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntitySmallBusiness_0a9af72f-8b7b-465e-81a2-d0c6a73c4937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6493f3a2-cc00-4b52-b2ff-03aa1d3aa319" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityEmergingGrowthCompany_6493f3a2-cc00-4b52-b2ff-03aa1d3aa319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8e362a44-658c-43b8-bfff-cfc9746d6bd5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8e362a44-658c-43b8-bfff-cfc9746d6bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_2d2406af-4257-4765-8a91-a418e674f352" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_2d2406af-4257-4765-8a91-a418e674f352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d9dfa3d6-4b4c-41fd-80d0-d8fab6d2c743" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityShellCompany_d9dfa3d6-4b4c-41fd-80d0-d8fab6d2c743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_66dc4f91-240e-4d76-b6db-534d023f8b02" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityPublicFloat_66dc4f91-240e-4d76-b6db-534d023f8b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8fb97cf7-4509-4b66-9282-bcba07d6f1fa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8fb97cf7-4509-4b66-9282-bcba07d6f1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3d9cb760-e708-4ad7-89e3-0db7c93eb18f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3d9cb760-e708-4ad7-89e3-0db7c93eb18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_38f9af5a-a052-4adb-97fe-9f8ca01a468a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_EntityCentralIndexKey_38f9af5a-a052-4adb-97fe-9f8ca01a468a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6918ac88-07dc-4c96-9268-34fcb6fa8a48" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_AmendmentFlag_6918ac88-07dc-4c96-9268-34fcb6fa8a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7efe34d7-7cbc-47c9-a061-24ca6ffe3d86" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_DocumentFiscalYearFocus_7efe34d7-7cbc-47c9-a061-24ca6ffe3d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_24b26a4f-a6e3-40b5-b3d4-f115362929fa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae9742ef-092c-4ac1-ae1c-36de56bae052" xlink:to="loc_dei_DocumentFiscalPeriodFocus_24b26a4f-a6e3-40b5-b3d4-f115362929fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AuditInformation" xlink:type="simple" xlink:href="ebs-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AuditInformationAbstract_30423361-e483-446b-ac13-95676a61e3cb" xlink:href="ebs-20231231.xsd#ebs_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_590a68b0-bf5e-4014-9897-f24fee788786" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_AuditInformationAbstract_30423361-e483-446b-ac13-95676a61e3cb" xlink:to="loc_dei_AuditorName_590a68b0-bf5e-4014-9897-f24fee788786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_22732aa4-d39d-4293-9421-f76b55f3d924" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_AuditInformationAbstract_30423361-e483-446b-ac13-95676a61e3cb" xlink:to="loc_dei_AuditorLocation_22732aa4-d39d-4293-9421-f76b55f3d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_dad362fb-2774-4118-a3af-2bfcda2dc291" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_AuditInformationAbstract_30423361-e483-446b-ac13-95676a61e3cb" xlink:to="loc_dei_AuditorFirmId_dad362fb-2774-4118-a3af-2bfcda2dc291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_13b12e64-caf0-49ce-a8de-5ed2ff40810a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c068de75-0100-4536-8cf6-935e7f284b33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13b12e64-caf0-49ce-a8de-5ed2ff40810a" xlink:to="loc_us-gaap_AssetsAbstract_c068de75-0100-4536-8cf6-935e7f284b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9d6d8eb6-0706-44c1-b7b5-98164d3a1f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c068de75-0100-4536-8cf6-935e7f284b33" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9d6d8eb6-0706-44c1-b7b5-98164d3a1f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15b8344e-40cc-4fc4-9630-ab724cf677cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d6d8eb6-0706-44c1-b7b5-98164d3a1f9d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15b8344e-40cc-4fc4-9630-ab724cf677cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e1622fa9-d879-424f-9c83-afc36885fefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d6d8eb6-0706-44c1-b7b5-98164d3a1f9d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e1622fa9-d879-424f-9c83-afc36885fefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0aa1eda6-6ecc-4661-981d-570a06638d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d6d8eb6-0706-44c1-b7b5-98164d3a1f9d" xlink:to="loc_us-gaap_InventoryNet_0aa1eda6-6ecc-4661-981d-570a06638d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f41c1962-ad04-4adb-a91d-cc3e9484c60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d6d8eb6-0706-44c1-b7b5-98164d3a1f9d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f41c1962-ad04-4adb-a91d-cc3e9484c60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7083e45c-f5d9-4c1e-a07a-b8834d2a87f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d6d8eb6-0706-44c1-b7b5-98164d3a1f9d" xlink:to="loc_us-gaap_AssetsCurrent_7083e45c-f5d9-4c1e-a07a-b8834d2a87f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3400902c-f20b-4f73-8aa1-60c07cbc7e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c068de75-0100-4536-8cf6-935e7f284b33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3400902c-f20b-4f73-8aa1-60c07cbc7e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f385ae76-6383-4f7e-828f-d458676ecc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c068de75-0100-4536-8cf6-935e7f284b33" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f385ae76-6383-4f7e-828f-d458676ecc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_48693453-19d8-4355-97d1-79ea3856eda8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c068de75-0100-4536-8cf6-935e7f284b33" xlink:to="loc_us-gaap_Goodwill_48693453-19d8-4355-97d1-79ea3856eda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_588e3c8d-afaa-4022-adf5-b62c6cdbf10e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c068de75-0100-4536-8cf6-935e7f284b33" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_588e3c8d-afaa-4022-adf5-b62c6cdbf10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4f205370-8928-4602-bae4-0c421f3be1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c068de75-0100-4536-8cf6-935e7f284b33" xlink:to="loc_us-gaap_Assets_4f205370-8928-4602-bae4-0c421f3be1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ccac289-20a6-4e4f-82ba-ea8c7c81a94e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13b12e64-caf0-49ce-a8de-5ed2ff40810a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ccac289-20a6-4e4f-82ba-ea8c7c81a94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_28420a0a-9b23-4edb-adfb-eae1b51a1b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ccac289-20a6-4e4f-82ba-ea8c7c81a94e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_28420a0a-9b23-4edb-adfb-eae1b51a1b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b6b0554d-d232-4a30-82d6-309f191411ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28420a0a-9b23-4edb-adfb-eae1b51a1b2e" xlink:to="loc_us-gaap_AccountsPayableCurrent_b6b0554d-d232-4a30-82d6-309f191411ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dafed6ba-15c2-412d-9097-9e9cb82892ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28420a0a-9b23-4edb-adfb-eae1b51a1b2e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dafed6ba-15c2-412d-9097-9e9cb82892ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f4f4992e-d9e4-4627-933b-ef276c237d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28420a0a-9b23-4edb-adfb-eae1b51a1b2e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f4f4992e-d9e4-4627-933b-ef276c237d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_0dbf927c-c440-405e-a7f9-eb468804d303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28420a0a-9b23-4edb-adfb-eae1b51a1b2e" xlink:to="loc_us-gaap_NotesPayableCurrent_0dbf927c-c440-405e-a7f9-eb468804d303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_339c5df4-bec4-4fe0-96ff-2b61841611eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28420a0a-9b23-4edb-adfb-eae1b51a1b2e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_339c5df4-bec4-4fe0-96ff-2b61841611eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e2ecba9d-5e9c-4e44-a1a4-eed351f1b32b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28420a0a-9b23-4edb-adfb-eae1b51a1b2e" xlink:to="loc_us-gaap_LiabilitiesCurrent_e2ecba9d-5e9c-4e44-a1a4-eed351f1b32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3f97e5a6-c4ff-4b27-9534-0d4231e2195b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ccac289-20a6-4e4f-82ba-ea8c7c81a94e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3f97e5a6-c4ff-4b27-9534-0d4231e2195b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f77ce91d-c42e-45bd-b90f-4b9f311bd619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ccac289-20a6-4e4f-82ba-ea8c7c81a94e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f77ce91d-c42e-45bd-b90f-4b9f311bd619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7e3d908b-d6c3-49c4-b085-554e10e9b2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ccac289-20a6-4e4f-82ba-ea8c7c81a94e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7e3d908b-d6c3-49c4-b085-554e10e9b2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ac797c46-85b5-4b22-84a8-2f9d9c6a1a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ccac289-20a6-4e4f-82ba-ea8c7c81a94e" xlink:to="loc_us-gaap_Liabilities_ac797c46-85b5-4b22-84a8-2f9d9c6a1a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_995922db-e018-4ff5-8940-17fd09bfe3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ccac289-20a6-4e4f-82ba-ea8c7c81a94e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_995922db-e018-4ff5-8940-17fd09bfe3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4c9277a4-6d9a-487c-8aa9-75421c7f6f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_995922db-e018-4ff5-8940-17fd09bfe3e5" xlink:to="loc_us-gaap_PreferredStockValue_4c9277a4-6d9a-487c-8aa9-75421c7f6f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c6a7305a-460a-4c78-a5d7-b57e2e331c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_995922db-e018-4ff5-8940-17fd09bfe3e5" xlink:to="loc_us-gaap_CommonStockValue_c6a7305a-460a-4c78-a5d7-b57e2e331c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_50320297-bd35-4e54-a683-0349218fedd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_995922db-e018-4ff5-8940-17fd09bfe3e5" xlink:to="loc_us-gaap_TreasuryStockCommonValue_50320297-bd35-4e54-a683-0349218fedd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_251f2b31-f7d9-4666-858b-e15be70a1c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_995922db-e018-4ff5-8940-17fd09bfe3e5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_251f2b31-f7d9-4666-858b-e15be70a1c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0cc5a020-1b9e-4ccd-a915-bc10206d2c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_995922db-e018-4ff5-8940-17fd09bfe3e5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0cc5a020-1b9e-4ccd-a915-bc10206d2c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e011103a-3e46-434a-81d0-9f4a6035f3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_995922db-e018-4ff5-8940-17fd09bfe3e5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e011103a-3e46-434a-81d0-9f4a6035f3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c1539f45-1468-400e-b5ed-56590a8f542c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_995922db-e018-4ff5-8940-17fd09bfe3e5" xlink:to="loc_us-gaap_StockholdersEquity_c1539f45-1468-400e-b5ed-56590a8f542c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7c85658-52b8-4d0b-8401-00098ce46073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ccac289-20a6-4e4f-82ba-ea8c7c81a94e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7c85658-52b8-4d0b-8401-00098ce46073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ba9a8812-8e05-4027-bade-d5f09ff40e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77364fce-e62a-44b9-a4e9-8f58faf2fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ba9a8812-8e05-4027-bade-d5f09ff40e4e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77364fce-e62a-44b9-a4e9-8f58faf2fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77364fce-e62a-44b9-a4e9-8f58faf2fe70" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e8e45402-100d-44ea-a418-c44a5292a373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e8e45402-100d-44ea-a418-c44a5292a373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2b2f6d91-7a53-4750-8f44-a8fea8cd7ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2b2f6d91-7a53-4750-8f44-a8fea8cd7ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1eb04b7e-4294-46e0-a8a5-ffab3f1f5e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1eb04b7e-4294-46e0-a8a5-ffab3f1f5e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_74b53a10-f30e-42a5-809f-7f96d8c24e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_74b53a10-f30e-42a5-809f-7f96d8c24e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1949aeeb-5e7e-42bb-be38-59938fd0081e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1949aeeb-5e7e-42bb-be38-59938fd0081e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7461e311-741c-4ef1-8272-c0e6d038cc72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7461e311-741c-4ef1-8272-c0e6d038cc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_593e9880-07ce-4016-9891-8d4242f3abfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:to="loc_us-gaap_CommonStockSharesIssued_593e9880-07ce-4016-9891-8d4242f3abfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d65b7dc6-d052-49ab-b30d-e7b9d556c40e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d65b7dc6-d052-49ab-b30d-e7b9d556c40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_6de866a6-8c2d-4ca1-9057-12b735ed3df4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0c9782a7-05ba-4b50-87ae-194e4564eba9" xlink:to="loc_us-gaap_TreasuryStockCommonShares_6de866a6-8c2d-4ca1-9057-12b735ed3df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a0191c19-6f72-49cd-8e96-04e3fd3b23ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f9865ccf-bf5a-4836-9914-64d7a3930d93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a0191c19-6f72-49cd-8e96-04e3fd3b23ea" xlink:to="loc_us-gaap_StatementTable_f9865ccf-bf5a-4836-9914-64d7a3930d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31a11f36-1a30-4a03-af52-3f441dd22d5e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9865ccf-bf5a-4836-9914-64d7a3930d93" xlink:to="loc_srt_ProductOrServiceAxis_31a11f36-1a30-4a03-af52-3f441dd22d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_31a11f36-1a30-4a03-af52-3f441dd22d5e" xlink:to="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_82497249-311d-41aa-a8ed-62816189adb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:to="loc_us-gaap_ProductMember_82497249-311d-41aa-a8ed-62816189adb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember_3a34b994-a3d9-4df7-b621-5505cb789e19" xlink:href="ebs-20231231.xsd#ebs_CommercialProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_82497249-311d-41aa-a8ed-62816189adb1" xlink:to="loc_ebs_CommercialProductMember_3a34b994-a3d9-4df7-b621-5505cb789e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember_186dd1de-81dd-4bb8-90e6-e7601136e794" xlink:href="ebs-20231231.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_82497249-311d-41aa-a8ed-62816189adb1" xlink:to="loc_ebs_MedicalCountermeasuresMCMProductMember_186dd1de-81dd-4bb8-90e6-e7601136e794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesMember_abe98f76-f8f9-4a38-8b8f-4abe6d591017" xlink:href="ebs-20231231.xsd#ebs_BioservicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:to="loc_ebs_BioservicesMember_abe98f76-f8f9-4a38-8b8f-4abe6d591017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_bdd905da-d43c-42d6-91a9-32c34a0bb254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_BioservicesMember_abe98f76-f8f9-4a38-8b8f-4abe6d591017" xlink:to="loc_us-gaap_ServiceMember_bdd905da-d43c-42d6-91a9-32c34a0bb254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesLeasesMember_e82ea999-92fa-4e3b-91d0-686f9664390f" xlink:href="ebs-20231231.xsd#ebs_BioservicesLeasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_BioservicesMember_abe98f76-f8f9-4a38-8b8f-4abe6d591017" xlink:to="loc_ebs_BioservicesLeasesMember_e82ea999-92fa-4e3b-91d0-686f9664390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_5d184b51-bd6e-461a-97ca-fd87ccbb1171" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00df085b-067f-4985-83a5-42685318bff1" xlink:to="loc_ebs_ContractsAndGrantsMember_5d184b51-bd6e-461a-97ca-fd87ccbb1171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9865ccf-bf5a-4836-9914-64d7a3930d93" xlink:to="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afe0b80e-a6bb-4e35-b6c2-b12ab316dc94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afe0b80e-a6bb-4e35-b6c2-b12ab316dc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_018fbf96-e259-4fb5-b51d-559f5897a091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_018fbf96-e259-4fb5-b51d-559f5897a091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d21c95d2-f1e9-48e0-b7dc-23a38e4c3ab4" xlink:href="ebs-20231231.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d21c95d2-f1e9-48e0-b7dc-23a38e4c3ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_57c9c973-ab90-4034-94e3-035ce000be7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e2816070-3750-4b87-a6f8-ac43478959cf" xlink:to="loc_us-gaap_Revenues_57c9c973-ab90-4034-94e3-035ce000be7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2f3a5f31-b4f3-4aa1-b14f-b41664bb226e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2f3a5f31-b4f3-4aa1-b14f-b41664bb226e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b5192a54-9095-4613-89c2-06c849c47419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b5192a54-9095-4613-89c2-06c849c47419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3f11889f-e028-4f3c-bff4-7b8be131e3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3f11889f-e028-4f3c-bff4-7b8be131e3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_04c08a58-0c74-450d-973e-9445cea8a3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_04c08a58-0c74-450d-973e-9445cea8a3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a5fb48f3-14fd-469c-b135-3a007b6d86bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a5fb48f3-14fd-469c-b135-3a007b6d86bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a695da48-5c7f-4e50-aa94-f1e12be7049a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a695da48-5c7f-4e50-aa94-f1e12be7049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_1a6080ea-2ca3-4016-9fc2-983a6e6ada5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d31742ce-f3eb-4509-a227-2b61c407e8f0" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_1a6080ea-2ca3-4016-9fc2-983a6e6ada5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_78078a8c-fd96-43e8-b689-83a34f40147e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_OperatingIncomeLoss_78078a8c-fd96-43e8-b689-83a34f40147e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_76f4d290-119b-4a4b-a76b-d76b0220b419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:to="loc_us-gaap_InterestExpense_76f4d290-119b-4a4b-a76b-d76b0220b419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_198ee681-2e27-429c-930f-de1fc626d3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_198ee681-2e27-429c-930f-de1fc626d3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7ba79f19-159e-4ea0-b725-ad4602c45f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7ba79f19-159e-4ea0-b725-ad4602c45f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_249b9a2e-b246-4401-b8b1-c40e6d2da83d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f3913fef-3110-4442-a3e4-494c79aebab3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_249b9a2e-b246-4401-b8b1-c40e6d2da83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e1d22c1-cb4e-4821-875a-a0a343c4f33f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e1d22c1-cb4e-4821-875a-a0a343c4f33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_27e2eb7a-d07f-4026-8b9e-4dab1ff7ba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_27e2eb7a-d07f-4026-8b9e-4dab1ff7ba1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_68977af1-065b-4305-ab06-da7332963c99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_NetIncomeLoss_68977af1-065b-4305-ab06-da7332963c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_df7efb71-005e-4290-811e-1ae0f6f5cf34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_df7efb71-005e-4290-811e-1ae0f6f5cf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_35f715c1-7679-4bde-a09f-6d56cc899683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_df7efb71-005e-4290-811e-1ae0f6f5cf34" xlink:to="loc_us-gaap_EarningsPerShareBasic_35f715c1-7679-4bde-a09f-6d56cc899683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_db986aa2-71cb-4949-8513-38efd4d378f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_df7efb71-005e-4290-811e-1ae0f6f5cf34" xlink:to="loc_us-gaap_EarningsPerShareDiluted_db986aa2-71cb-4949-8513-38efd4d378f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7ae85dd9-dfb8-4f34-8c93-5e9f8b5a6e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06ea529b-508f-4a25-9a0c-e3f3e600f824" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7ae85dd9-dfb8-4f34-8c93-5e9f8b5a6e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d634c445-84b9-43ae-997e-51858fa49760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7ae85dd9-dfb8-4f34-8c93-5e9f8b5a6e3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d634c445-84b9-43ae-997e-51858fa49760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8182797a-13c8-4b24-bd82-03ecc7c60837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7ae85dd9-dfb8-4f34-8c93-5e9f8b5a6e3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8182797a-13c8-4b24-bd82-03ecc7c60837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63e14b70-a943-4645-96b9-8d7318679fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b4aa1f9-e719-45a1-8fa3-eb00d9578ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63e14b70-a943-4645-96b9-8d7318679fd1" xlink:to="loc_us-gaap_NetIncomeLoss_1b4aa1f9-e719-45a1-8fa3-eb00d9578ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e61d4693-f893-43e0-ae91-abf7b22e4f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63e14b70-a943-4645-96b9-8d7318679fd1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e61d4693-f893-43e0-ae91-abf7b22e4f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1b9fbc6e-a6f3-41ed-9eec-3b6c31ab9643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e61d4693-f893-43e0-ae91-abf7b22e4f3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1b9fbc6e-a6f3-41ed-9eec-3b6c31ab9643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_0217c1cc-b9d4-4610-b6fe-45a9ebde749f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e61d4693-f893-43e0-ae91-abf7b22e4f3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_0217c1cc-b9d4-4610-b6fe-45a9ebde749f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_39d6006b-f8db-40c7-bc6c-be4cf943e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e61d4693-f893-43e0-ae91-abf7b22e4f3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_39d6006b-f8db-40c7-bc6c-be4cf943e50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_d2af8719-8a94-48d6-b21e-85b7448ee28c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e61d4693-f893-43e0-ae91-abf7b22e4f3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_d2af8719-8a94-48d6-b21e-85b7448ee28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1fcbb08c-7999-435c-b1b2-d9ea1444da37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e61d4693-f893-43e0-ae91-abf7b22e4f3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1fcbb08c-7999-435c-b1b2-d9ea1444da37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a70b9a1-966e-449c-88c0-797e402bc6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63e14b70-a943-4645-96b9-8d7318679fd1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a70b9a1-966e-449c-88c0-797e402bc6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b056e88b-3c61-462d-9dc5-afa2de6f9113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b056e88b-3c61-462d-9dc5-afa2de6f9113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d49c3802-5923-41e1-b4ae-4397d7c07cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b056e88b-3c61-462d-9dc5-afa2de6f9113" xlink:to="loc_us-gaap_NetIncomeLoss_d49c3802-5923-41e1-b4ae-4397d7c07cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b056e88b-3c61-462d-9dc5-afa2de6f9113" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_51efbb17-de7e-4a79-9528-44caf19ffd43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_ShareBasedCompensation_51efbb17-de7e-4a79-9528-44caf19ffd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9c854a99-91c7-4264-bda1-46fa5c0780b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9c854a99-91c7-4264-bda1-46fa5c0780b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1fa3db84-7fab-434d-84af-cc7900ed4d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1fa3db84-7fab-434d-84af-cc7900ed4d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_d43fc591-8469-4844-ab04-5da4c2fe435a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_d43fc591-8469-4844-ab04-5da4c2fe435a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f68a143d-cafa-47be-81a7-7221af11b6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f68a143d-cafa-47be-81a7-7221af11b6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_099df7fa-a4d9-40bf-99bf-25d07679576e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_099df7fa-a4d9-40bf-99bf-25d07679576e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1d3548b4-820c-4a8f-b56e-064b807d84d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1d3548b4-820c-4a8f-b56e-064b807d84d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_625401b9-15b3-44e9-b9f0-c4dcba5e1331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_625401b9-15b3-44e9-b9f0-c4dcba5e1331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_f382e62f-58fc-4540-a035-6b08275a88d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_GainLossOnContractTermination_f382e62f-58fc-4540-a035-6b08275a88d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_48be36b7-5410-45ec-bdef-dd20a5de3e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_48be36b7-5410-45ec-bdef-dd20a5de3e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314378f1-972c-4855-bc52-1c0d017fe05d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6f7514af-b590-4b9d-86b8-4f7fd78050e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6f7514af-b590-4b9d-86b8-4f7fd78050e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_99c50f4f-126e-4c5c-83a1-cd4df33a2d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_99c50f4f-126e-4c5c-83a1-cd4df33a2d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ca3a2b99-448e-4f2a-8268-3e70ba36dd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ca3a2b99-448e-4f2a-8268-3e70ba36dd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2b67ba48-7661-42c3-8dec-5af079d62500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2b67ba48-7661-42c3-8dec-5af079d62500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_24319ed7-3eb5-43e8-961c-b6f1eae318bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_24319ed7-3eb5-43e8-961c-b6f1eae318bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_8ff9895b-9afa-4bda-8b65-ae8c2d886469" xlink:href="ebs-20231231.xsd#ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:to="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_8ff9895b-9afa-4bda-8b65-ae8c2d886469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_55b8bcc6-c03d-4a9d-b337-d2514e80842d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_55b8bcc6-c03d-4a9d-b337-d2514e80842d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_ccd51ddd-32d3-451a-b798-4398acf4ba83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_ccd51ddd-32d3-451a-b798-4398acf4ba83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6eacb4b7-4f06-437a-9f60-eb3ee56d6dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6dae2da9-d6d6-4b30-a8c2-14f3383b7286" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6eacb4b7-4f06-437a-9f60-eb3ee56d6dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_26dccb21-24e9-403e-8abd-9f10d2bc040c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b056e88b-3c61-462d-9dc5-afa2de6f9113" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_26dccb21-24e9-403e-8abd-9f10d2bc040c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7602583d-1308-443e-b677-b4a60531da80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7602583d-1308-443e-b677-b4a60531da80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_66fea22f-c79b-4401-8c8b-29ab5b0482f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7602583d-1308-443e-b677-b4a60531da80" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_66fea22f-c79b-4401-8c8b-29ab5b0482f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1242ce52-455b-49a6-80ef-c05d1f546789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7602583d-1308-443e-b677-b4a60531da80" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1242ce52-455b-49a6-80ef-c05d1f546789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_33f08d17-0900-4aa1-b5fc-9b2bf0455ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7602583d-1308-443e-b677-b4a60531da80" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_33f08d17-0900-4aa1-b5fc-9b2bf0455ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8315996a-73a9-464e-9534-e02df8ba018c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7602583d-1308-443e-b677-b4a60531da80" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8315996a-73a9-464e-9534-e02df8ba018c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_31b9c894-b822-4911-aa8a-639426a4f2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7602583d-1308-443e-b677-b4a60531da80" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_31b9c894-b822-4911-aa8a-639426a4f2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0c48ff84-21f7-4a74-929f-b712c3a57392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7602583d-1308-443e-b677-b4a60531da80" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0c48ff84-21f7-4a74-929f-b712c3a57392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7f6a2c0e-67cc-431e-88ba-f591354ac101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7f6a2c0e-67cc-431e-88ba-f591354ac101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_423204a8-98f0-4d69-8968-dece3ae5bcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_423204a8-98f0-4d69-8968-dece3ae5bcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_9f2bbbc2-741d-4204-aea5-009596b124c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_9f2bbbc2-741d-4204-aea5-009596b124c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_6dcbbd9e-b52c-4f2c-a00c-95048f68caba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_6dcbbd9e-b52c-4f2c-a00c-95048f68caba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_3b3b52e7-a6f5-41a5-aea1-2dd525af4aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_3b3b52e7-a6f5-41a5-aea1-2dd525af4aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5f24f171-ed47-4deb-b193-97710e8a604f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5f24f171-ed47-4deb-b193-97710e8a604f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43c720cb-327b-486f-885a-550f1017da6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43c720cb-327b-486f-885a-550f1017da6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3bccc4fe-dd0d-4abb-8ab4-81039d5c296b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3bccc4fe-dd0d-4abb-8ab4-81039d5c296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_cab26284-9443-48be-a14e-f127c5cf49ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_cab26284-9443-48be-a14e-f127c5cf49ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a77c82cf-ff09-466c-8592-8a03e271f737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259d41b3-622b-4e29-9a61-c88260083f56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a77c82cf-ff09-466c-8592-8a03e271f737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_047d34f2-c7cc-4535-b262-b89d4ba58157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_047d34f2-c7cc-4535-b262-b89d4ba58157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d13f533-e97e-4780-a6f6-00d2f2be1f01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d13f533-e97e-4780-a6f6-00d2f2be1f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56d3a81e-0109-4c7b-9c0f-c851e104b7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56d3a81e-0109-4c7b-9c0f-c851e104b7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3a959b1-9ea2-40f7-976c-b0b49ee50283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3a959b1-9ea2-40f7-976c-b0b49ee50283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9e8c06d2-9215-46ab-97e0-68563d7251f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9e8c06d2-9215-46ab-97e0-68563d7251f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3b973937-b518-44c9-b8a5-3ac7f83dee4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9e8c06d2-9215-46ab-97e0-68563d7251f7" xlink:to="loc_us-gaap_InterestPaidNet_3b973937-b518-44c9-b8a5-3ac7f83dee4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_957bb4b5-459c-4ec7-a7d2-abd94dee36f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9e8c06d2-9215-46ab-97e0-68563d7251f7" xlink:to="loc_us-gaap_IncomeTaxesPaid_957bb4b5-459c-4ec7-a7d2-abd94dee36f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_06184a2f-3bad-4b54-a7a4-59c8310267e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7868b82d-2b67-43e3-b2c7-3fbbad5afa8c" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_06184a2f-3bad-4b54-a7a4-59c8310267e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_781e5c25-dd13-4a22-b4b7-ae756508967a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_06184a2f-3bad-4b54-a7a4-59c8310267e8" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_781e5c25-dd13-4a22-b4b7-ae756508967a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NoncashPurchasesOfTreasuryStock_936d264e-74fa-4320-b22a-79b093486cbd" xlink:href="ebs-20231231.xsd#ebs_NoncashPurchasesOfTreasuryStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_06184a2f-3bad-4b54-a7a4-59c8310267e8" xlink:to="loc_ebs_NoncashPurchasesOfTreasuryStock_936d264e-74fa-4320-b22a-79b093486cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4e7af612-f562-414f-b525-22ce1724e32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_06184a2f-3bad-4b54-a7a4-59c8310267e8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4e7af612-f562-414f-b525-22ce1724e32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cd3bf7c9-20b4-44a6-88df-9bdb233f3f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_da4a8489-4ff8-4622-b916-3a4b70444d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cd3bf7c9-20b4-44a6-88df-9bdb233f3f4c" xlink:to="loc_us-gaap_StatementTable_da4a8489-4ff8-4622-b916-3a4b70444d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_47ed20bd-e0e7-4897-8bea-2d61352dc54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_da4a8489-4ff8-4622-b916-3a4b70444d38" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_47ed20bd-e0e7-4897-8bea-2d61352dc54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47ed20bd-e0e7-4897-8bea-2d61352dc54c" xlink:to="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_773b5098-68b4-4e49-9491-7065adf2cdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_CommonStockMember_773b5098-68b4-4e49-9491-7065adf2cdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_048cbd3a-1b68-45d8-b3ad-99d4d391408a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_048cbd3a-1b68-45d8-b3ad-99d4d391408a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b81fec46-1e7a-4d66-a31a-f936a671dd01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b81fec46-1e7a-4d66-a31a-f936a671dd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8491011d-b565-41a4-895e-5b968dcc0b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8491011d-b565-41a4-895e-5b968dcc0b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4a54bf9d-1c11-4cbc-bbcc-2ec494bfc1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09bf6b52-4075-4695-a60c-8065ffc88ead" xlink:to="loc_us-gaap_RetainedEarningsMember_4a54bf9d-1c11-4cbc-bbcc-2ec494bfc1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c8f3da6-7274-4353-a89e-ad4db1f2dd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_da4a8489-4ff8-4622-b916-3a4b70444d38" xlink:to="loc_us-gaap_StatementLineItems_0c8f3da6-7274-4353-a89e-ad4db1f2dd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c8f3da6-7274-4353-a89e-ad4db1f2dd6e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a5a1370f-2981-46b4-b158-3d2999f67655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_CommonStockSharesIssued_a5a1370f-2981-46b4-b158-3d2999f67655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7459275-4584-42bf-a098-807a279f101f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockholdersEquity_a7459275-4584-42bf-a098-807a279f101f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_cca757e1-4bba-4244-b3ae-f397dbeec619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_TreasuryStockCommonShares_cca757e1-4bba-4244-b3ae-f397dbeec619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d66e952-5da4-423e-b38f-a8a7aa3ae599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_NetIncomeLoss_2d66e952-5da4-423e-b38f-a8a7aa3ae599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9295f503-ebd8-4ac3-ad2c-46af3e5c41eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9295f503-ebd8-4ac3-ad2c-46af3e5c41eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e252bdaa-a80b-4974-a091-d648d9060291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e252bdaa-a80b-4974-a091-d648d9060291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_508dff15-5c07-48e6-85bf-f477d64a12a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_508dff15-5c07-48e6-85bf-f477d64a12a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_82d3c191-6977-4c99-8caa-394204200e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_82d3c191-6977-4c99-8caa-394204200e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_19726329-96c5-4615-8740-d13377d2d3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_19726329-96c5-4615-8740-d13377d2d3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eec202ec-8227-4443-b2f4-4ee9b5c94608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eec202ec-8227-4443-b2f4-4ee9b5c94608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6ff2b965-220f-4515-98a0-bd99fc0f6cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6ff2b965-220f-4515-98a0-bd99fc0f6cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_50f149ed-9e00-406d-9dd0-5aa194230d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_CommonStockSharesIssued_50f149ed-9e00-406d-9dd0-5aa194230d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2c6f19db-0aae-4ac7-8f4a-a286c4ba1a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_StockholdersEquity_2c6f19db-0aae-4ac7-8f4a-a286c4ba1a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_958000ed-948f-4ccf-9df4-6f9ece636671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24718c7b-1ffa-4ec8-97e5-0b09c5e55224" xlink:to="loc_us-gaap_TreasuryStockCommonShares_958000ed-948f-4ccf-9df4-6f9ece636671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ebs-20231231.xsd#ConsolidatedStatementofChangesinStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e5868fb7-dd90-4706-9cd9-5568e125cb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2ee31e84-edc3-44f1-9f72-26a534f5bb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e5868fb7-dd90-4706-9cd9-5568e125cb7e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2ee31e84-edc3-44f1-9f72-26a534f5bb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Natureofthebusinessandorganization" xlink:type="simple" xlink:href="ebs-20231231.xsd#Natureofthebusinessandorganization"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Natureofthebusinessandorganization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4d21014-bf34-4f79-925e-6536b9bcbb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_b95fd8b8-0d90-4802-9eac-70dced62287e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4d21014-bf34-4f79-925e-6536b9bcbb2d" xlink:to="loc_us-gaap_NatureOfOperations_b95fd8b8-0d90-4802-9eac-70dced62287e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="ebs-20231231.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd190cf9-7639-455e-806c-f5f8017341f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_59c8dfd5-bebc-440c-aeb2-a974d466d008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd190cf9-7639-455e-806c-f5f8017341f7" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_59c8dfd5-bebc-440c-aeb2-a974d466d008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Divestiture" xlink:type="simple" xlink:href="ebs-20231231.xsd#Divestiture"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Divestiture" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_76cb8b75-6bae-4c34-a7d0-69ee29f2cd53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_17aa7ce8-76b2-4fa1-9e61-3c76530dcd34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_76cb8b75-6bae-4c34-a7d0-69ee29f2cd53" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_17aa7ce8-76b2-4fa1-9e61-3c76530dcd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Longlivedassetimpairmentandrestructuringcharges" xlink:type="simple" xlink:href="ebs-20231231.xsd#Longlivedassetimpairmentandrestructuringcharges"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Longlivedassetimpairmentandrestructuringcharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ac81b532-a03a-4857-89f7-5c2a6df876f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_bda803c4-5172-410e-be03-669928e83db7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ac81b532-a03a-4857-89f7-5c2a6df876f2" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_bda803c4-5172-410e-be03-669928e83db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="simple" xlink:href="ebs-20231231.xsd#Inventoriesnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e99f8616-16c7-4032-b10c-5a23f0a0f266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_55e54840-7942-4c36-9eab-88b552a298bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e99f8616-16c7-4032-b10c-5a23f0a0f266" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_55e54840-7942-4c36-9eab-88b552a298bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="simple" xlink:href="ebs-20231231.xsd#Propertyplantandequipmentnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_a8a4cfd4-90d5-4b3e-bf7a-ce278a33938b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7500cb77-6479-4f31-8a95-664b34ae6d01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_a8a4cfd4-90d5-4b3e-bf7a-ce278a33938b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7500cb77-6479-4f31-8a95-664b34ae6d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill" xlink:type="simple" xlink:href="ebs-20231231.xsd#Intangibleassetsandgoodwill"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c036b82e-9a90-4c01-b60e-7da7ac1fa68c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1a8e4d0b-3626-4245-9547-fd5c11139188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c036b82e-9a90-4c01-b60e-7da7ac1fa68c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1a8e4d0b-3626-4245-9547-fd5c11139188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="ebs-20231231.xsd#Fairvaluemeasurements"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_90ff679b-3b8d-41d1-883e-3979f682b043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a0cdca9c-261a-470c-a5c7-bd197e3f124b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90ff679b-3b8d-41d1-883e-3979f682b043" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a0cdca9c-261a-470c-a5c7-bd197e3f124b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivities" xlink:type="simple" xlink:href="ebs-20231231.xsd#DerivativeInstrumentsandhedgingactivities"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_90e5cc75-4e17-48ce-9a51-1de1f9df3d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_49bdc9a8-5460-4016-b401-1ef9a0695a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_90e5cc75-4e17-48ce-9a51-1de1f9df3d45" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_49bdc9a8-5460-4016-b401-1ef9a0695a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:type="simple" xlink:href="ebs-20231231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_05cf5cc2-4208-41f7-896e-8d51cdc4c175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_eb543fad-8e9a-4287-b759-22d48f4e2e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05cf5cc2-4208-41f7-896e-8d51cdc4c175" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_eb543fad-8e9a-4287-b759-22d48f4e2e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity" xlink:type="simple" xlink:href="ebs-20231231.xsd#Sharebasedcompensationandstockholdersequity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d7ab3900-b0d5-449f-85b5-ca6d3409cdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f5137413-6647-4379-b96f-de84b2a4fc52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d7ab3900-b0d5-449f-85b5-ca6d3409cdc8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f5137413-6647-4379-b96f-de84b2a4fc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Netincomelosspercommonshare" xlink:type="simple" xlink:href="ebs-20231231.xsd#Netincomelosspercommonshare"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Netincomelosspercommonshare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_41f1cd93-529e-45a8-a201-8ab63d327345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_4b8f1490-d2ef-4b3a-af9d-aed3b29e2ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41f1cd93-529e-45a8-a201-8ab63d327345" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_4b8f1490-d2ef-4b3a-af9d-aed3b29e2ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Revenuerecognition" xlink:type="simple" xlink:href="ebs-20231231.xsd#Revenuerecognition"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Revenuerecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e008fb9-6407-4dd6-a5b8-56f18878e0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6d121013-5637-4db2-8f65-ea092ed5daa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e008fb9-6407-4dd6-a5b8-56f18878e0d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6d121013-5637-4db2-8f65-ea092ed5daa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:type="simple" xlink:href="ebs-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_517220ff-2bb3-43e8-b79a-465e0f4d1ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_43b1ab01-6757-42f7-b4ca-c81fda5e761a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_517220ff-2bb3-43e8-b79a-465e0f4d1ee6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_43b1ab01-6757-42f7-b4ca-c81fda5e761a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="simple" xlink:href="ebs-20231231.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b6fc6fe1-bf25-4dfb-9927-5d62287391a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_daf0f89a-6b09-4f9b-8990-56066aa0afb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6fc6fe1-bf25-4dfb-9927-5d62287391a3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_daf0f89a-6b09-4f9b-8990-56066aa0afb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplan" xlink:type="simple" xlink:href="ebs-20231231.xsd#Definedbenefitand401ksavingsplan"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a8ebf675-0eac-4fbb-b038-5a48ceeef4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4cf2c492-35bc-4a4f-932d-25dbde7d86ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a8ebf675-0eac-4fbb-b038-5a48ceeef4b6" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4cf2c492-35bc-4a4f-932d-25dbde7d86ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Purchasecommitments" xlink:type="simple" xlink:href="ebs-20231231.xsd#Purchasecommitments"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Purchasecommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_4d2a3f51-79a4-4eaf-9dfd-5b223d44791e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock_76ea44ec-0ada-4ba1-ba04-bd40ec674208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_4d2a3f51-79a4-4eaf-9dfd-5b223d44791e" xlink:to="loc_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock_76ea44ec-0ada-4ba1-ba04-bd40ec674208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformation" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_188ea919-bd8d-47f7-9360-17840e35fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_407db19f-3d2c-4a7a-bb4f-0f2f050896db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_188ea919-bd8d-47f7-9360-17840e35fa35" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_407db19f-3d2c-4a7a-bb4f-0f2f050896db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Litigation" xlink:type="simple" xlink:href="ebs-20231231.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a16d521-2485-40c6-8663-1096c8779fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_2eaa95d1-a8b7-4151-a06e-a5f4c1647b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a16d521-2485-40c6-8663-1096c8779fb9" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_2eaa95d1-a8b7-4151-a06e-a5f4c1647b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="simple" xlink:href="ebs-20231231.xsd#ScheduleIIValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_35293438-7000-429b-9c6a-125f2383fa91" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c2a6d640-731f-4714-939c-6c95b3bfaf5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_35293438-7000-429b-9c6a-125f2383fa91" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c2a6d640-731f-4714-939c-6c95b3bfaf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_a890f887-25c9-4d60-9036-6b13404e19ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_a890f887-25c9-4d60-9036-6b13404e19ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_eb404e58-85a9-4f1a-a648-1dac199a7c28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_UseOfEstimates_eb404e58-85a9-4f1a-a648-1dac199a7c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9aec01dc-a805-4375-9388-bc600f30939b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9aec01dc-a805-4375-9388-bc600f30939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_fa6e2b09-50b5-4a90-a525-1c09167ea6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_fa6e2b09-50b5-4a90-a525-1c09167ea6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_f4831874-736f-484e-97e9-bd6b4d449c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_f4831874-736f-484e-97e9-bd6b4d449c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_0d36c2f1-9757-4323-85b4-4a0f0eb7e9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_0d36c2f1-9757-4323-85b4-4a0f0eb7e9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_40278159-bc54-45d5-bc51-ca05c239e67c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_40278159-bc54-45d5-bc51-ca05c239e67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0b051c61-163a-48e3-a594-f6156de5eb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0b051c61-163a-48e3-a594-f6156de5eb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_bde2675b-0226-4213-a6e6-2fe617199ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_bde2675b-0226-4213-a6e6-2fe617199ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_8c9ac2a1-fd81-40c2-953b-8cdb6d048172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_8c9ac2a1-fd81-40c2-953b-8cdb6d048172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContingentConsiderationObligationsPolicyTextBlock_857596e0-ab12-4536-bdc0-08ad2d31064f" xlink:href="ebs-20231231.xsd#ebs_ContingentConsiderationObligationsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_ebs_ContingentConsiderationObligationsPolicyTextBlock_857596e0-ab12-4536-bdc0-08ad2d31064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_a924221f-4b2d-4209-a4db-78efaf74da0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_a924221f-4b2d-4209-a4db-78efaf74da0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cce84bfd-31f2-49e4-919d-56d59a225014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cce84bfd-31f2-49e4-919d-56d59a225014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ad8f8c37-9f06-46f7-8fbb-5f35a157a669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ad8f8c37-9f06-46f7-8fbb-5f35a157a669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_f9877399-3a82-4e87-a335-110c690eb347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_f9877399-3a82-4e87-a335-110c690eb347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8e525966-bc79-4ec7-bfaa-dffeb7778ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8e525966-bc79-4ec7-bfaa-dffeb7778ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_10ac1b39-d05f-49eb-b939-4003c3a1eaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_10ac1b39-d05f-49eb-b939-4003c3a1eaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TreasuryStockPolicyTextBlock_b78068e2-fb43-4801-be82-0fedb80895ba" xlink:href="ebs-20231231.xsd#ebs_TreasuryStockPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_ebs_TreasuryStockPolicyTextBlock_b78068e2-fb43-4801-be82-0fedb80895ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8f9e2e6b-d776-4b90-9d95-c5a87f34f008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8f9e2e6b-d776-4b90-9d95-c5a87f34f008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_811068d9-ecc4-473d-a36f-8903db9c3ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_811068d9-ecc4-473d-a36f-8903db9c3ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_c844a260-937d-4692-baca-dad7324d00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_c844a260-937d-4692-baca-dad7324d00a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_42807f37-dbcd-46de-8dae-2ecadbbc4184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a461ef2-1474-4b2d-b0b2-4f23d1eff57e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_42807f37-dbcd-46de-8dae-2ecadbbc4184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_134c70cc-39cb-42f6-91f4-ac6e1690217d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_354e0791-2218-4d21-b175-bd2da3da2d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_134c70cc-39cb-42f6-91f4-ac6e1690217d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_354e0791-2218-4d21-b175-bd2da3da2d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#LonglivedassetimpairmentandrestructuringchargesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cae43ac2-aa11-4779-9064-3c4f435362ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_07172fec-73a2-454b-a027-b5dbd1328bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cae43ac2-aa11-4779-9064-3c4f435362ea" xlink:to="loc_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_07172fec-73a2-454b-a027-b5dbd1328bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2493fcdf-2efe-4c21-8428-933f3683130a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cae43ac2-aa11-4779-9064-3c4f435362ea" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2493fcdf-2efe-4c21-8428-933f3683130a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f6ba738d-9921-42f3-a2d3-cc8c486c30ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cae43ac2-aa11-4779-9064-3c4f435362ea" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f6ba738d-9921-42f3-a2d3-cc8c486c30ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#InventoriesnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0fdb096c-107b-45b4-8d3f-77b133d213c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_db8f9101-4459-427f-ba46-8951cfb4d270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0fdb096c-107b-45b4-8d3f-77b133d213c0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_db8f9101-4459-427f-ba46-8951cfb4d270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#PropertyplantandequipmentnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_2b7c5755-6bbf-456c-8d52-35a485ded746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_50fd761e-9284-449a-810a-ba6e741016ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_2b7c5755-6bbf-456c-8d52-35a485ded746" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_50fd761e-9284-449a-810a-ba6e741016ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7b154378-fbdc-4777-ae67-dca1af812816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a327c642-84a5-4f05-875a-211e0dff630d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7b154378-fbdc-4777-ae67-dca1af812816" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a327c642-84a5-4f05-875a-211e0dff630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_249a1405-56ef-4e55-be7c-3c7794b1f1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7b154378-fbdc-4777-ae67-dca1af812816" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_249a1405-56ef-4e55-be7c-3c7794b1f1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_576f8145-69cf-40a8-8711-5778131bf21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7b154378-fbdc-4777-ae67-dca1af812816" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_576f8145-69cf-40a8-8711-5778131bf21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_984cbe4e-f9bb-4cac-8b9d-c6df68702200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7b154378-fbdc-4777-ae67-dca1af812816" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_984cbe4e-f9bb-4cac-8b9d-c6df68702200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#FairvaluemeasurementsTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_facd2d54-5174-45bd-b324-731f98fc04d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ad9ff773-3525-495f-8ada-8d0592d03a83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_facd2d54-5174-45bd-b324-731f98fc04d7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ad9ff773-3525-495f-8ada-8d0592d03a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_424079d8-cec1-4c3b-8a5a-f16da0a43ade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_facd2d54-5174-45bd-b324-731f98fc04d7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_424079d8-cec1-4c3b-8a5a-f16da0a43ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_4738437e-b924-41b0-9bbb-07935b9da361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_facd2d54-5174-45bd-b324-731f98fc04d7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_4738437e-b924-41b0-9bbb-07935b9da361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#DerivativeInstrumentsandhedgingactivitiesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_97688d2b-a9d8-4710-95d8-819d874cb042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_21064d6a-36e6-4802-b215-c6028e087116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_97688d2b-a9d8-4710-95d8-819d874cb042" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_21064d6a-36e6-4802-b215-c6028e087116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7cd3e96f-aff9-4a33-9019-1f917948637f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_97688d2b-a9d8-4710-95d8-819d874cb042" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7cd3e96f-aff9-4a33-9019-1f917948637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_65e7c4f0-25b5-4f44-b4a1-9f806d6be22a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_4ab1cdf4-a0b4-4577-9370-2cca947bf2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65e7c4f0-25b5-4f44-b4a1-9f806d6be22a" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_4ab1cdf4-a0b4-4577-9370-2cca947bf2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_bfc6a2ca-b429-4eaf-9c0d-34db260f82f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65e7c4f0-25b5-4f44-b4a1-9f806d6be22a" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_bfc6a2ca-b429-4eaf-9c0d-34db260f82f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e3d41543-ce91-4348-bfab-be77a7086a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6b423750-5284-44d6-a44b-f8378f107ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e3d41543-ce91-4348-bfab-be77a7086a20" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6b423750-5284-44d6-a44b-f8378f107ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cf64c741-daf1-4db3-abb9-8a92a4189894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e3d41543-ce91-4348-bfab-be77a7086a20" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cf64c741-daf1-4db3-abb9-8a92a4189894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_601493cb-1b27-46cf-9481-3cc09776f9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e3d41543-ce91-4348-bfab-be77a7086a20" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_601493cb-1b27-46cf-9481-3cc09776f9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_65686643-7703-4d46-80a6-e5e82f4c6b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e3d41543-ce91-4348-bfab-be77a7086a20" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_65686643-7703-4d46-80a6-e5e82f4c6b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_071c48f0-6001-41b9-a2a8-e0eeea61f4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e3d41543-ce91-4348-bfab-be77a7086a20" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_071c48f0-6001-41b9-a2a8-e0eeea61f4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_7b203738-63b9-488f-a7da-e28cfa106178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e3d41543-ce91-4348-bfab-be77a7086a20" xlink:to="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_7b203738-63b9-488f-a7da-e28cfa106178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetincomelosspercommonshareTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#NetincomelosspercommonshareTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetincomelosspercommonshareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_60593d88-f071-4ea4-8b4c-8403cc28e8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7f539ac0-604b-49fb-9abc-fbffb1f9986d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60593d88-f071-4ea4-8b4c-8403cc28e8f8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7f539ac0-604b-49fb-9abc-fbffb1f9986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f8007f59-a8e2-46fc-80fe-6a51826e7761" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60593d88-f071-4ea4-8b4c-8403cc28e8f8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f8007f59-a8e2-46fc-80fe-6a51826e7761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b0e96469-877b-4351-b8db-070475bb797b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_68741eaa-84b2-4833-964b-aac94b4a9359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b0e96469-877b-4351-b8db-070475bb797b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_68741eaa-84b2-4833-964b-aac94b4a9359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_73db4cbc-7301-4bfd-8d27-4c7fee49d970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b0e96469-877b-4351-b8db-070475bb797b" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_73db4cbc-7301-4bfd-8d27-4c7fee49d970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e697eb9c-58c5-461e-9be4-eedf3d01040f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b0e96469-877b-4351-b8db-070475bb797b" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e697eb9c-58c5-461e-9be4-eedf3d01040f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_c42cb5fc-8d91-453f-af49-dadf4d96f1a1" xlink:href="ebs-20231231.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b0e96469-877b-4351-b8db-070475bb797b" xlink:to="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_c42cb5fc-8d91-453f-af49-dadf4d96f1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0e907068-0b6b-4f88-bcb1-1f94cba7e295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ca5e1173-3db2-4bfa-a8cb-3855051ce683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0e907068-0b6b-4f88-bcb1-1f94cba7e295" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ca5e1173-3db2-4bfa-a8cb-3855051ce683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_b27ef6ad-f475-433d-ae34-b4bda3476973" xlink:href="ebs-20231231.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0e907068-0b6b-4f88-bcb1-1f94cba7e295" xlink:to="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_b27ef6ad-f475-433d-ae34-b4bda3476973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fe6899e0-385c-468c-af25-f62bfb97a779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0e907068-0b6b-4f88-bcb1-1f94cba7e295" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fe6899e0-385c-468c-af25-f62bfb97a779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_40df166b-04a2-4d8f-a0fc-a05a696645a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3b6e6db4-c8aa-40c1-b11a-40ad5f9f78e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40df166b-04a2-4d8f-a0fc-a05a696645a9" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3b6e6db4-c8aa-40c1-b11a-40ad5f9f78e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cb43c743-6ab3-44f4-bf86-42626f1ee781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40df166b-04a2-4d8f-a0fc-a05a696645a9" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cb43c743-6ab3-44f4-bf86-42626f1ee781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_27325687-1b4e-4f1d-9e47-e6aafc64bff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40df166b-04a2-4d8f-a0fc-a05a696645a9" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_27325687-1b4e-4f1d-9e47-e6aafc64bff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a157b241-5027-4093-85be-7f116bdc0410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40df166b-04a2-4d8f-a0fc-a05a696645a9" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a157b241-5027-4093-85be-7f116bdc0410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#Definedbenefitand401ksavingsplanTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_707a6341-edfe-4ccd-9f13-104c35d6c92f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_96d554aa-b8d0-494e-8405-b5a16b85e376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_707a6341-edfe-4ccd-9f13-104c35d6c92f" xlink:to="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_96d554aa-b8d0-494e-8405-b5a16b85e376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_9847b46d-5245-453e-8858-a29d90240ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_707a6341-edfe-4ccd-9f13-104c35d6c92f" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_9847b46d-5245-453e-8858-a29d90240ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_a30cd957-a52e-4bcf-862e-1abe819c9292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_707a6341-edfe-4ccd-9f13-104c35d6c92f" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_a30cd957-a52e-4bcf-862e-1abe819c9292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_58456160-6043-4a92-844f-1fc7e3d6ca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_707a6341-edfe-4ccd-9f13-104c35d6c92f" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_58456160-6043-4a92-844f-1fc7e3d6ca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_385a5cb8-3cea-4257-8f8b-b1c21099cff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_16203c9c-4922-4f78-9b7f-889be92cd538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_385a5cb8-3cea-4257-8f8b-b1c21099cff4" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_16203c9c-4922-4f78-9b7f-889be92cd538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9a83fe38-3948-493e-9530-2d0822a6646e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_385a5cb8-3cea-4257-8f8b-b1c21099cff4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9a83fe38-3948-493e-9530-2d0822a6646e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_f11930d5-b1ff-44d3-999a-dcd3ea49c29d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_385a5cb8-3cea-4257-8f8b-b1c21099cff4" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_f11930d5-b1ff-44d3-999a-dcd3ea49c29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_c8208d72-4228-477c-9d1f-abac8c0b2c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_385a5cb8-3cea-4257-8f8b-b1c21099cff4" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_c8208d72-4228-477c-9d1f-abac8c0b2c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#NatureofthebusinessandorganizationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3468b1e9-7554-46d4-b484-07ae1a10c94f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_04f7da37-8e25-40fa-9444-e14c3583fb76" xlink:href="ebs-20231231.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3468b1e9-7554-46d4-b484-07ae1a10c94f" xlink:to="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_04f7da37-8e25-40fa-9444-e14c3583fb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts_58787057-c2a2-4055-9401-75d4c6c7dbcc" xlink:href="ebs-20231231.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3468b1e9-7554-46d4-b484-07ae1a10c94f" xlink:to="loc_ebs_NumberOfRevenueGeneratingProducts_58787057-c2a2-4055-9401-75d4c6c7dbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductAndServiceCategories_1be82b55-8e92-4b36-940e-fa6149727e52" xlink:href="ebs-20231231.xsd#ebs_NumberOfProductAndServiceCategories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3468b1e9-7554-46d4-b484-07ae1a10c94f" xlink:to="loc_ebs_NumberOfProductAndServiceCategories_1be82b55-8e92-4b36-940e-fa6149727e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3ad5ae5c-918d-467e-8a4b-e893ec4e78df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3468b1e9-7554-46d4-b484-07ae1a10c94f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3ad5ae5c-918d-467e-8a4b-e893ec4e78df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesGoingConcernDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3d8b430f-c01c-4e06-919d-a8eb801f8c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3d8b430f-c01c-4e06-919d-a8eb801f8c4d" xlink:to="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfe73d37-cc7e-4dc8-a4aa-7495a3bb866e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfe73d37-cc7e-4dc8-a4aa-7495a3bb866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfe73d37-cc7e-4dc8-a4aa-7495a3bb866e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_474d9ee5-5bed-43cb-826f-575788baaa54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:to="loc_us-gaap_LineOfCreditMember_474d9ee5-5bed-43cb-826f-575788baaa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ad6ebbec-90f1-4a22-9dab-f8ee8cebf96e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ad6ebbec-90f1-4a22-9dab-f8ee8cebf96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a36da7d2-50f2-401c-8a65-0dc5e867b914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77595c44-e4d3-4848-9030-c24ddf7d0126" xlink:to="loc_us-gaap_SeniorNotesMember_a36da7d2-50f2-401c-8a65-0dc5e867b914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5d7ddbf6-372b-4d92-af34-73cd1da15b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:to="loc_us-gaap_CreditFacilityAxis_5d7ddbf6-372b-4d92-af34-73cd1da15b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c112a660-70ab-4b5b-a946-65ad6bc755e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_5d7ddbf6-372b-4d92-af34-73cd1da15b29" xlink:to="loc_us-gaap_CreditFacilityDomain_c112a660-70ab-4b5b-a946-65ad6bc755e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2b0a476b-ebef-43f6-ba89-691dbad8a929" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c112a660-70ab-4b5b-a946-65ad6bc755e3" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2b0a476b-ebef-43f6-ba89-691dbad8a929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_a409706c-f0bc-4820-a4ff-829c2507afea" xlink:href="ebs-20231231.xsd#ebs_TermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c112a660-70ab-4b5b-a946-65ad6bc755e3" xlink:to="loc_ebs_TermLoanFacilityMember_a409706c-f0bc-4820-a4ff-829c2507afea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_74090736-6d62-454e-8462-5d5c011c494f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:to="loc_us-gaap_DebtInstrumentAxis_74090736-6d62-454e-8462-5d5c011c494f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_df692c9b-b42d-4332-92df-b2821a5ecca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_74090736-6d62-454e-8462-5d5c011c494f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_df692c9b-b42d-4332-92df-b2821a5ecca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_323b3c03-6995-4c89-a067-0bd689ee95d1" xlink:href="ebs-20231231.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df692c9b-b42d-4332-92df-b2821a5ecca5" xlink:to="loc_ebs_AmendedCreditAgreementMember_323b3c03-6995-4c89-a067-0bd689ee95d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_f44d6218-bd99-42bc-9efc-66dde36d2d4c" xlink:href="ebs-20231231.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df692c9b-b42d-4332-92df-b2821a5ecca5" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_f44d6218-bd99-42bc-9efc-66dde36d2d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a8f72ddb-4cbe-4fe6-baed-efeb3815b067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:to="loc_us-gaap_RestructuringPlanAxis_a8f72ddb-4cbe-4fe6-baed-efeb3815b067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_33be5009-e1c0-4858-a7df-83ceb6860f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_a8f72ddb-4cbe-4fe6-baed-efeb3815b067" xlink:to="loc_us-gaap_RestructuringPlanDomain_33be5009-e1c0-4858-a7df-83ceb6860f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_ab192c1f-1249-4524-9559-2d5233457b94" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_33be5009-e1c0-4858-a7df-83ceb6860f97" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_ab192c1f-1249-4524-9559-2d5233457b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_9f7072d4-7adb-475b-a817-db03da76d0e2" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_33be5009-e1c0-4858-a7df-83ceb6860f97" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_9f7072d4-7adb-475b-a817-db03da76d0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3afa9395-5b48-4289-bbad-384e687a5024" xlink:to="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b4a077ab-436c-4899-b201-79e238351f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_LongTermDebt_b4a077ab-436c-4899-b201-79e238351f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c2cda4b-544e-4b83-a73b-4b04219179d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c2cda4b-544e-4b83-a73b-4b04219179d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_0ba47a82-b87c-4fba-8b41-a7b278f53db0" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_0ba47a82-b87c-4fba-8b41-a7b278f53db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_8281bb67-2a65-4e64-a11f-72db7744af5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_8281bb67-2a65-4e64-a11f-72db7744af5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_d55bb392-2c92-43db-93b5-6c4a4999da97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_LineOfCredit_d55bb392-2c92-43db-93b5-6c4a4999da97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b1d82739-ce3f-486c-b455-68d588bf4239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b1d82739-ce3f-486c-b455-68d588bf4239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_83bd84f7-cc32-468d-b8ce-71d1e0bb6b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82da8883-87be-4f07-8b23-77bed52fa527" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_83bd84f7-cc32-468d-b8ce-71d1e0bb6b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_da907562-2b4b-4de2-9eb3-8e58813a8990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da907562-2b4b-4de2-9eb3-8e58813a8990" xlink:to="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_168b0970-90d2-4df9-bcff-b7fe8ae5c8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_168b0970-90d2-4df9-bcff-b7fe8ae5c8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d818d1-a1cd-495a-80c9-36c893f81f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_168b0970-90d2-4df9-bcff-b7fe8ae5c8e4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d818d1-a1cd-495a-80c9-36c893f81f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_364295ae-5876-4203-8c52-40f30917306a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d818d1-a1cd-495a-80c9-36c893f81f2c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_364295ae-5876-4203-8c52-40f30917306a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_67676fcb-814a-4b13-bd5d-d98b4ab0e41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_67676fcb-814a-4b13-bd5d-d98b4ab0e41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d766df16-6e7a-4808-ad84-913f16a59c09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_67676fcb-814a-4b13-bd5d-d98b4ab0e41f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d766df16-6e7a-4808-ad84-913f16a59c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_56acd602-57bc-41ed-a248-f7227114d7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d766df16-6e7a-4808-ad84-913f16a59c09" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_56acd602-57bc-41ed-a248-f7227114d7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e29f4b29-94b3-43e1-8f66-6e390ad5ddf4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:to="loc_srt_MajorCustomersAxis_e29f4b29-94b3-43e1-8f66-6e390ad5ddf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9128716f-815f-4171-bd38-4807d76ac75a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e29f4b29-94b3-43e1-8f66-6e390ad5ddf4" xlink:to="loc_srt_NameOfMajorCustomerDomain_9128716f-815f-4171-bd38-4807d76ac75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_596c56ee-23c9-4a65-be14-08dcfbd88334" xlink:href="ebs-20231231.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9128716f-815f-4171-bd38-4807d76ac75a" xlink:to="loc_ebs_UnitedStatesGovernmentMember_596c56ee-23c9-4a65-be14-08dcfbd88334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0b4187c8-e987-4bf2-be83-c0bfdfdc1978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dd09511a-9e62-4ac7-a5d5-14b0ec46f10d" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_0b4187c8-e987-4bf2-be83-c0bfdfdc1978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_893ac02f-fb84-4149-b0ef-dd14f37195f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0b4187c8-e987-4bf2-be83-c0bfdfdc1978" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_893ac02f-fb84-4149-b0ef-dd14f37195f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_79ac0a26-b5c9-4473-bce2-39fb13f7bdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b74392d-2a7f-4233-a015-e2a3b04c6834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79ac0a26-b5c9-4473-bce2-39fb13f7bdf8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b74392d-2a7f-4233-a015-e2a3b04c6834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4cc0c553-5a27-4f02-b8ad-8ac7f1d8895e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b74392d-2a7f-4233-a015-e2a3b04c6834" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4cc0c553-5a27-4f02-b8ad-8ac7f1d8895e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4cc0c553-5a27-4f02-b8ad-8ac7f1d8895e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f6e2b957-c5ba-4b03-8d1d-0682c67e8155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:to="loc_us-gaap_BuildingMember_f6e2b957-c5ba-4b03-8d1d-0682c67e8155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember_89bc3fa6-01aa-4d61-a774-61d298a8e532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:to="loc_us-gaap_BuildingImprovementsMember_89bc3fa6-01aa-4d61-a774-61d298a8e532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f8b19019-2867-4f7e-8552-5e1dbd63cbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f8b19019-2867-4f7e-8552-5e1dbd63cbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_caaab316-2459-4ab4-8fed-47e65e8b949f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ace4887-b4e9-453d-829b-5ed1faf056b0" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_caaab316-2459-4ab4-8fed-47e65e8b949f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc87778c-89c4-449c-9268-037a85f5036c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b74392d-2a7f-4233-a015-e2a3b04c6834" xlink:to="loc_srt_RangeAxis_bc87778c-89c4-449c-9268-037a85f5036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d82f0a34-bb78-43c2-a888-089ae9b23bf8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bc87778c-89c4-449c-9268-037a85f5036c" xlink:to="loc_srt_RangeMember_d82f0a34-bb78-43c2-a888-089ae9b23bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59f43e66-9380-43f6-b011-5462faeaeb0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d82f0a34-bb78-43c2-a888-089ae9b23bf8" xlink:to="loc_srt_MinimumMember_59f43e66-9380-43f6-b011-5462faeaeb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b9d22b5-fa5a-42a6-aeb2-13ae291db1f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d82f0a34-bb78-43c2-a888-089ae9b23bf8" xlink:to="loc_srt_MaximumMember_1b9d22b5-fa5a-42a6-aeb2-13ae291db1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_855934cc-ad53-4d31-8109-19b636909b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b74392d-2a7f-4233-a015-e2a3b04c6834" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_855934cc-ad53-4d31-8109-19b636909b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b2210749-3956-4870-9512-e829f2dedc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_855934cc-ad53-4d31-8109-19b636909b9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b2210749-3956-4870-9512-e829f2dedc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8b53dd95-0809-4b11-8a8d-5d12ccebf5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4689f263-7887-414b-870a-e840848c608d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b53dd95-0809-4b11-8a8d-5d12ccebf5c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4689f263-7887-414b-870a-e840848c608d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_acecb414-bf89-4818-96ef-ff9b50ea1c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4689f263-7887-414b-870a-e840848c608d" xlink:to="loc_us-gaap_PlanNameAxis_acecb414-bf89-4818-96ef-ff9b50ea1c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_58c30de1-0086-4d44-9500-1d9ff80ca5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_acecb414-bf89-4818-96ef-ff9b50ea1c27" xlink:to="loc_us-gaap_PlanNameDomain_58c30de1-0086-4d44-9500-1d9ff80ca5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2023EquityInducementPlanMember_88cc87da-33a6-48d7-aa33-92500dc27d3b" xlink:href="ebs-20231231.xsd#ebs_A2023EquityInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_58c30de1-0086-4d44-9500-1d9ff80ca5a5" xlink:to="loc_ebs_A2023EquityInducementPlanMember_88cc87da-33a6-48d7-aa33-92500dc27d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4689f263-7887-414b-870a-e840848c608d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans_f28c2a0b-6ac8-4166-b589-cb5f73c32220" xlink:href="ebs-20231231.xsd#ebs_NumberOfShareBasedEmployeeCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:to="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans_f28c2a0b-6ac8-4166-b589-cb5f73c32220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_875b0394-35ba-474c-a098-f8e1200f29ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_875b0394-35ba-474c-a098-f8e1200f29ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_520becc9-7655-45ad-8520-7d1bcb596d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21faa3c9-588a-4f98-95a8-250ef8540b39" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_520becc9-7655-45ad-8520-7d1bcb596d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8eb59796-d35b-44b6-b6a3-97249ebfb387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_e004defe-94bd-4791-9c50-e7b9f87637ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8eb59796-d35b-44b6-b6a3-97249ebfb387" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_e004defe-94bd-4791-9c50-e7b9f87637ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_521dd64f-2550-4578-9788-72917d67fc90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_e004defe-94bd-4791-9c50-e7b9f87637ec" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_521dd64f-2550-4578-9788-72917d67fc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_081d4d6b-fc06-4efc-a3a4-686391ee9fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_521dd64f-2550-4578-9788-72917d67fc90" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_081d4d6b-fc06-4efc-a3a4-686391ee9fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_874ef520-d4d1-47d9-9a0a-b22a9ed6556d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_081d4d6b-fc06-4efc-a3a4-686391ee9fc3" xlink:to="loc_us-gaap_InterestRateSwapMember_874ef520-d4d1-47d9-9a0a-b22a9ed6556d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f4d8ce79-1ea2-46f7-8ab8-0a3c0a56a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_e004defe-94bd-4791-9c50-e7b9f87637ec" xlink:to="loc_us-gaap_HedgingDesignationAxis_f4d8ce79-1ea2-46f7-8ab8-0a3c0a56a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1078aea6-877e-4748-9e61-a4dcebc0fa97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_f4d8ce79-1ea2-46f7-8ab8-0a3c0a56a81f" xlink:to="loc_us-gaap_HedgingDesignationDomain_1078aea6-877e-4748-9e61-a4dcebc0fa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e8da609c-62f0-4dde-a656-39dc6cb02811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1078aea6-877e-4748-9e61-a4dcebc0fa97" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e8da609c-62f0-4dde-a656-39dc6cb02811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b5f804b4-35c7-46f0-9c9d-364d2c9c6e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_e004defe-94bd-4791-9c50-e7b9f87637ec" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b5f804b4-35c7-46f0-9c9d-364d2c9c6e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0b0197c9-035b-4bd4-b69f-44750c17d803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b5f804b4-35c7-46f0-9c9d-364d2c9c6e9b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0b0197c9-035b-4bd4-b69f-44750c17d803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DivestitureDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DivestitureDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DivestitureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e0902062-a144-445a-8c64-dfed28b22e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e0902062-a144-445a-8c64-dfed28b22e11" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_74da88a3-867a-4d2e-ae10-f7d5f036b9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_74da88a3-867a-4d2e-ae10-f7d5f036b9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a85423ed-46f1-42eb-b28b-b6c5d5ea58af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_74da88a3-867a-4d2e-ae10-f7d5f036b9d4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a85423ed-46f1-42eb-b28b-b6c5d5ea58af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f1636eba-c896-4fd9-9038-6592a678dfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a85423ed-46f1-42eb-b28b-b6c5d5ea58af" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f1636eba-c896-4fd9-9038-6592a678dfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8297595e-18b0-4b1c-aa49-fd48f78a46ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8297595e-18b0-4b1c-aa49-fd48f78a46ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c7ed2c1-db98-4230-83ff-0ee2b80698df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8297595e-18b0-4b1c-aa49-fd48f78a46ee" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c7ed2c1-db98-4230-83ff-0ee2b80698df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_43310554-2308-414f-98d1-43545e9e38e4" xlink:href="ebs-20231231.xsd#ebs_TravelHealthBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c7ed2c1-db98-4230-83ff-0ee2b80698df" xlink:to="loc_ebs_TravelHealthBusinessMember_43310554-2308-414f-98d1-43545e9e38e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_5a920333-633c-4e33-a1f0-6c9b67a5ad29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_5a920333-633c-4e33-a1f0-6c9b67a5ad29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_6ddd5e45-70f1-43e8-afd7-a6a93b14ed4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5a920333-633c-4e33-a1f0-6c9b67a5ad29" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_6ddd5e45-70f1-43e8-afd7-a6a93b14ed4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DevelopmentBasedMilestonesMember_7f15a59b-00f9-435a-b428-7c188d350a51" xlink:href="ebs-20231231.xsd#ebs_DevelopmentBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_6ddd5e45-70f1-43e8-afd7-a6a93b14ed4c" xlink:to="loc_ebs_DevelopmentBasedMilestonesMember_7f15a59b-00f9-435a-b428-7c188d350a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SalesBasedMilestonesMember_15847d51-9b6a-41b5-8c22-28220fb204a6" xlink:href="ebs-20231231.xsd#ebs_SalesBasedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_6ddd5e45-70f1-43e8-afd7-a6a93b14ed4c" xlink:to="loc_ebs_SalesBasedMilestonesMember_15847d51-9b6a-41b5-8c22-28220fb204a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7a04df0-b883-415a-b8ed-352dca868bd0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a98fedcf-b2e7-4bbe-80ad-90998d54bd29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a98fedcf-b2e7-4bbe-80ad-90998d54bd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_84826903-75e3-45fa-a6f9-abc3ce54cf7d" xlink:href="ebs-20231231.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_84826903-75e3-45fa-a6f9-abc3ce54cf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_9e8f3814-18aa-45bb-aabf-7fdd45ad0a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_9e8f3814-18aa-45bb-aabf-7fdd45ad0a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DispositionOfBusinessTransactionCosts_922555e5-aa54-43c6-8096-60960d424824" xlink:href="ebs-20231231.xsd#ebs_DispositionOfBusinessTransactionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_ebs_DispositionOfBusinessTransactionCosts_922555e5-aa54-43c6-8096-60960d424824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_aed2cac4-60cc-4ae2-93c9-c9963a028eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8132f10f-e709-4206-a8ef-e113e4d9aaf0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_aed2cac4-60cc-4ae2-93c9-c9963a028eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LonglivedassetimpairmentandrestructuringchargesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_672e132c-b778-4526-9602-0b27cd3fff74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8ea77115-deda-4003-bc28-f79361f1b492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_672e132c-b778-4526-9602-0b27cd3fff74" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8ea77115-deda-4003-bc28-f79361f1b492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_aeda3f9b-9cff-4bf7-9ee3-6e757125e382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8ea77115-deda-4003-bc28-f79361f1b492" xlink:to="loc_us-gaap_RestructuringPlanAxis_aeda3f9b-9cff-4bf7-9ee3-6e757125e382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e4b7207f-bf1a-4bf8-bcbe-8b31351a4774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_aeda3f9b-9cff-4bf7-9ee3-6e757125e382" xlink:to="loc_us-gaap_RestructuringPlanDomain_e4b7207f-bf1a-4bf8-bcbe-8b31351a4774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_238b72c7-81b5-426c-8668-1f4eea3d02d4" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e4b7207f-bf1a-4bf8-bcbe-8b31351a4774" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_238b72c7-81b5-426c-8668-1f4eea3d02d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_b2e9e848-c946-4768-a77f-084aed60e94b" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e4b7207f-bf1a-4bf8-bcbe-8b31351a4774" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_b2e9e848-c946-4768-a77f-084aed60e94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8ea77115-deda-4003-bc28-f79361f1b492" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ec6a73c7-3306-4d0a-bd4e-597a680e5c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ec6a73c7-3306-4d0a-bd4e-597a680e5c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b964e111-426d-4f7f-acbf-1dc567d3fb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b964e111-426d-4f7f-acbf-1dc567d3fb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_32ba3272-a269-4a32-85e6-0a510f296782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0f463f6-b00c-4a26-963b-775d735ec1d1" xlink:to="loc_us-gaap_RestructuringCharges_32ba3272-a269-4a32-85e6-0a510f296782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_22b99eb2-c2f0-4fd5-bd6a-31eb9250bfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_a627aadc-fcd1-4732-bdda-3555851be278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_22b99eb2-c2f0-4fd5-bd6a-31eb9250bfcf" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_a627aadc-fcd1-4732-bdda-3555851be278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_c6c91c97-9963-4b78-ad80-4db7584b9ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_a627aadc-fcd1-4732-bdda-3555851be278" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_c6c91c97-9963-4b78-ad80-4db7584b9ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_c6c91c97-9963-4b78-ad80-4db7584b9ec1" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_e9597c04-5906-48ef-b575-8015ba5ee0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_e9597c04-5906-48ef-b575-8015ba5ee0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_84e4adcf-8869-42f1-8867-8eabc205324e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_84e4adcf-8869-42f1-8867-8eabc205324e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_63144831-be7a-4084-b7d5-ec7d6d8056c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_63144831-be7a-4084-b7d5-ec7d6d8056c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_f068b2ba-fd67-4b99-8846-462430e5b179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_61531125-14fc-4dd7-92d5-3217379f76c2" xlink:to="loc_us-gaap_ConstructionInProgressMember_f068b2ba-fd67-4b99-8846-462430e5b179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_65d6aee5-ea13-4740-8994-cb4ffc3d2251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_a627aadc-fcd1-4732-bdda-3555851be278" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_65d6aee5-ea13-4740-8994-cb4ffc3d2251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3402cd5f-3b41-4875-a488-e2e330811421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_65d6aee5-ea13-4740-8994-cb4ffc3d2251" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3402cd5f-3b41-4875-a488-e2e330811421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e85de3b5-8300-4447-bfb3-f8ed2372d09e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e85de3b5-8300-4447-bfb3-f8ed2372d09e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_4e63608c-3027-4c71-9735-682321fd0df2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:to="loc_srt_ConsolidationItemsAxis_4e63608c-3027-4c71-9735-682321fd0df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c590dc30-2f99-447c-88a6-3e12ed4e1021" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_4e63608c-3027-4c71-9735-682321fd0df2" xlink:to="loc_srt_ConsolidationItemsDomain_c590dc30-2f99-447c-88a6-3e12ed4e1021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_322da45e-b771-471b-9157-c3c396ecad23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c590dc30-2f99-447c-88a6-3e12ed4e1021" xlink:to="loc_us-gaap_OperatingSegmentsMember_322da45e-b771-471b-9157-c3c396ecad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_fbb6b1f8-1056-4555-a5df-0f31fb66aa66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c590dc30-2f99-447c-88a6-3e12ed4e1021" xlink:to="loc_us-gaap_CorporateNonSegmentMember_fbb6b1f8-1056-4555-a5df-0f31fb66aa66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_79884343-d9aa-4f9e-8da3-51730d580fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_79884343-d9aa-4f9e-8da3-51730d580fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_79884343-d9aa-4f9e-8da3-51730d580fb0" xlink:to="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_b016adba-3080-4a56-a54a-03f6f924c02b" xlink:href="ebs-20231231.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:to="loc_ebs_CommercialProductsSegmentMember_b016adba-3080-4a56-a54a-03f6f924c02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_a33ee17a-c2d4-4485-aad7-869db044a737" xlink:href="ebs-20231231.xsd#ebs_MCMProductsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:to="loc_ebs_MCMProductsSegmentMember_a33ee17a-c2d4-4485-aad7-869db044a737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_a0cf73ed-0f7d-4e58-8e26-2d067c6a365c" xlink:href="ebs-20231231.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_18d85546-02f2-4290-ac4a-a0a10f1cab58" xlink:to="loc_ebs_ServicesSegmentMember_a0cf73ed-0f7d-4e58-8e26-2d067c6a365c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_623f9e5e-b0b4-4ea8-a3f6-9eb5c363ce73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_623f9e5e-b0b4-4ea8-a3f6-9eb5c363ce73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_623f9e5e-b0b4-4ea8-a3f6-9eb5c363ce73" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedResearchAndDevelopmentMember_04154d79-42c2-4219-8ae9-cc7ff628b625" xlink:href="ebs-20231231.xsd#ebs_UnallocatedResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:to="loc_ebs_UnallocatedResearchAndDevelopmentMember_04154d79-42c2-4219-8ae9-cc7ff628b625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_0bc4d148-4043-4765-a911-6a24a6915f22" xlink:href="ebs-20231231.xsd#ebs_EmployeeTransitionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:to="loc_ebs_EmployeeTransitionMember_0bc4d148-4043-4765-a911-6a24a6915f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_265549f8-f066-4b2c-abb9-e272fa20fe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_265549f8-f066-4b2c-abb9-e272fa20fe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_e480fd98-566f-4ae5-8819-55e88f1e9f96" xlink:href="ebs-20231231.xsd#ebs_EmployeeBenefitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e8c72316-1a5a-4fc3-b6a1-574fd668aff9" xlink:to="loc_ebs_EmployeeBenefitsMember_e480fd98-566f-4ae5-8819-55e88f1e9f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ef62d67c-8ed4-4d56-8160-12bf1452e8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_96535a9e-fe68-4931-aedf-7cb61e4ce0d2" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_ef62d67c-8ed4-4d56-8160-12bf1452e8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_cf7878d0-ff57-494a-b4c3-ea7b32b80ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ef62d67c-8ed4-4d56-8160-12bf1452e8b6" xlink:to="loc_us-gaap_RestructuringCharges_cf7878d0-ff57-494a-b4c3-ea7b32b80ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_33867deb-3935-4580-88ad-8c40f4d98f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72550e0e-9e10-4f6d-8d14-ee19cbb1492b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_33867deb-3935-4580-88ad-8c40f4d98f07" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72550e0e-9e10-4f6d-8d14-ee19cbb1492b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8a32cf3f-d071-49f8-ac78-a7426cb699bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72550e0e-9e10-4f6d-8d14-ee19cbb1492b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8a32cf3f-d071-49f8-ac78-a7426cb699bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8a32cf3f-d071-49f8-ac78-a7426cb699bc" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_73bec6d5-b294-4853-9f76-dec32c8e5642" xlink:href="ebs-20231231.xsd#ebs_EmployeeTransitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:to="loc_ebs_EmployeeTransitionMember_73bec6d5-b294-4853-9f76-dec32c8e5642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_73fc66d6-cf65-4904-b460-e3296697c2df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:to="loc_us-gaap_EmployeeSeveranceMember_73fc66d6-cf65-4904-b460-e3296697c2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_3c237bf3-d225-4b53-b8d9-57ff8b93f406" xlink:href="ebs-20231231.xsd#ebs_EmployeeBenefitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32fd4d65-9fca-4abe-ae5a-6a1bf14e91af" xlink:to="loc_ebs_EmployeeBenefitsMember_3c237bf3-d225-4b53-b8d9-57ff8b93f406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a593d4f5-c999-4fee-be7b-e5c1d047189e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72550e0e-9e10-4f6d-8d14-ee19cbb1492b" xlink:to="loc_us-gaap_RestructuringPlanAxis_a593d4f5-c999-4fee-be7b-e5c1d047189e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0ae741b6-067b-499d-a016-7a789010e063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_a593d4f5-c999-4fee-be7b-e5c1d047189e" xlink:to="loc_us-gaap_RestructuringPlanDomain_0ae741b6-067b-499d-a016-7a789010e063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_e55bcc9c-0434-4398-b518-0f168ace19f2" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0ae741b6-067b-499d-a016-7a789010e063" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_e55bcc9c-0434-4398-b518-0f168ace19f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_e95c4e73-8873-4aa5-bb6e-6d7026ed9d50" xlink:href="ebs-20231231.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0ae741b6-067b-499d-a016-7a789010e063" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_e95c4e73-8873-4aa5-bb6e-6d7026ed9d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8135e06b-227b-4d12-aad6-4a73dc32cc41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72550e0e-9e10-4f6d-8d14-ee19cbb1492b" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8135e06b-227b-4d12-aad6-4a73dc32cc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8135e06b-227b-4d12-aad6-4a73dc32cc41" xlink:to="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_412e92f3-793b-4447-8cdb-b93e276c6bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:to="loc_us-gaap_RestructuringReserve_412e92f3-793b-4447-8cdb-b93e276c6bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d9b48d92-487d-4dfd-8cce-f6f542868b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:to="loc_us-gaap_RestructuringCharges_d9b48d92-487d-4dfd-8cce-f6f542868b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_96f96e25-e484-46c9-895d-f4c8f23c0749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:to="loc_us-gaap_PaymentsForRestructuring_96f96e25-e484-46c9-895d-f4c8f23c0749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_89c5c538-7835-4372-a994-75e52fcdb4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_226eb136-d34f-4114-b38c-86f74e7608c4" xlink:to="loc_us-gaap_RestructuringReserve_89c5c538-7835-4372-a994-75e52fcdb4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#InventoriesnetDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5d701fbc-02bc-4a6c-89a1-06d14512188a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_49cea9c9-f046-4839-9fe1-b0b2486e053e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5d701fbc-02bc-4a6c-89a1-06d14512188a" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_49cea9c9-f046-4839-9fe1-b0b2486e053e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ca0e72bd-be9a-4460-be9d-32627fea6c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5d701fbc-02bc-4a6c-89a1-06d14512188a" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ca0e72bd-be9a-4460-be9d-32627fea6c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8607628b-6968-4e58-926b-2687525bc83e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5d701fbc-02bc-4a6c-89a1-06d14512188a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8607628b-6968-4e58-926b-2687525bc83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c8d931e2-dabf-4110-8814-ff55105b12dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5d701fbc-02bc-4a6c-89a1-06d14512188a" xlink:to="loc_us-gaap_InventoryNet_c8d931e2-dabf-4110-8814-ff55105b12dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_9e7a8b7a-27ba-4317-b9b5-7e5866f5fa68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_364811bf-8ee8-4498-b8d0-358c0afe5a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_9e7a8b7a-27ba-4317-b9b5-7e5866f5fa68" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_364811bf-8ee8-4498-b8d0-358c0afe5a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60211ff2-b200-42c9-9312-7ce1eb2b682a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_364811bf-8ee8-4498-b8d0-358c0afe5a69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60211ff2-b200-42c9-9312-7ce1eb2b682a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60211ff2-b200-42c9-9312-7ce1eb2b682a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_5c5e0f4d-a50e-452a-b836-08021d6fb507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_5c5e0f4d-a50e-452a-b836-08021d6fb507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fafdf39c-1c76-4aa1-974e-2d2411d870b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fafdf39c-1c76-4aa1-974e-2d2411d870b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_88cac5e2-1d4a-4b46-826d-95244ed43337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_88cac5e2-1d4a-4b46-826d-95244ed43337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_34bc4c92-66f2-43dc-bbed-bc31e9047cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_34bc4c92-66f2-43dc-bbed-bc31e9047cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_666f292b-3d1b-437e-ac67-4078cb014161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e42459-0fdb-469b-a7b1-664666cd78fc" xlink:to="loc_us-gaap_ConstructionInProgressMember_666f292b-3d1b-437e-ac67-4078cb014161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_602087ab-2bf2-48ec-abf3-059f0a761f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_364811bf-8ee8-4498-b8d0-358c0afe5a69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_602087ab-2bf2-48ec-abf3-059f0a761f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_602087ab-2bf2-48ec-abf3-059f0a761f50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3c78de11-9d62-42b5-b235-ab9ff8e41bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3c78de11-9d62-42b5-b235-ab9ff8e41bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a8d031f2-9d0a-4b9f-b502-d060df975e54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a8d031f2-9d0a-4b9f-b502-d060df975e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9b540080-19e4-4f60-8d07-8e271402b52a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9b540080-19e4-4f60-8d07-8e271402b52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c42bcbef-a517-4243-9e68-baa1fc6713eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_74f94396-d416-4e29-8485-eab545eedd03" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c42bcbef-a517-4243-9e68-baa1fc6713eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#PropertyplantandequipmentnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_32635154-8e9d-478a-8047-fbecf65286ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2ab6995-b82e-459e-9c70-9b1c5b2c1d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_32635154-8e9d-478a-8047-fbecf65286ba" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2ab6995-b82e-459e-9c70-9b1c5b2c1d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_54374bdf-c45f-437f-9483-b2952a98a4e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2ab6995-b82e-459e-9c70-9b1c5b2c1d8c" xlink:to="loc_srt_MajorCustomersAxis_54374bdf-c45f-437f-9483-b2952a98a4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_059726c0-6b12-412e-bbb5-ec6a69100c89" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_54374bdf-c45f-437f-9483-b2952a98a4e9" xlink:to="loc_srt_NameOfMajorCustomerDomain_059726c0-6b12-412e-bbb5-ec6a69100c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_92b69d33-f7d9-4713-9379-91c043dcac28" xlink:href="ebs-20231231.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_059726c0-6b12-412e-bbb5-ec6a69100c89" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_92b69d33-f7d9-4713-9379-91c043dcac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_04c2f9d0-37a0-4ee6-b682-82926da98023" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2ab6995-b82e-459e-9c70-9b1c5b2c1d8c" xlink:to="loc_srt_ProductOrServiceAxis_04c2f9d0-37a0-4ee6-b682-82926da98023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6068758b-9a79-46c9-b47c-f935c7ad068c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_04c2f9d0-37a0-4ee6-b682-82926da98023" xlink:to="loc_srt_ProductsAndServicesDomain_6068758b-9a79-46c9-b47c-f935c7ad068c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2ec0c343-5ed0-4c78-9104-547a7782a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6068758b-9a79-46c9-b47c-f935c7ad068c" xlink:to="loc_us-gaap_ServiceMember_2ec0c343-5ed0-4c78-9104-547a7782a7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e169cd83-7b3f-430d-bfe1-df95e5b4f495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2ab6995-b82e-459e-9c70-9b1c5b2c1d8c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e169cd83-7b3f-430d-bfe1-df95e5b4f495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cdb3644f-e244-410a-883a-8c6594d4a35f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e169cd83-7b3f-430d-bfe1-df95e5b4f495" xlink:to="loc_us-gaap_Depreciation_cdb3644f-e244-410a-883a-8c6594d4a35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_90969b01-5b5a-4a66-b924-d492e43bc24c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e169cd83-7b3f-430d-bfe1-df95e5b4f495" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_90969b01-5b5a-4a66-b924-d492e43bc24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26dd8ac8-e7e0-4c09-9abd-46daeab76c59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26dd8ac8-e7e0-4c09-9abd-46daeab76c59" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_075a0163-b83a-45d3-a00f-32f176b47187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_075a0163-b83a-45d3-a00f-32f176b47187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_075a0163-b83a-45d3-a00f-32f176b47187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_05cc6a47-eaa8-4b82-99e1-53009b19c9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:to="loc_us-gaap_ProductMember_05cc6a47-eaa8-4b82-99e1-53009b19c9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_86798ca8-f3ce-43ee-9f67-e68f3c9b0f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:to="loc_us-gaap_CustomerRelationshipsMember_86798ca8-f3ce-43ee-9f67-e68f3c9b0f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesMember_68e79568-11ab-4190-83f0-717c1819e212" xlink:href="ebs-20231231.xsd#ebs_BioservicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26343a8b-9dfd-492d-8166-e273a03d0d04" xlink:to="loc_ebs_BioservicesMember_68e79568-11ab-4190-83f0-717c1819e212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_98647c11-4811-44e8-88fd-423b9f3bf93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_98647c11-4811-44e8-88fd-423b9f3bf93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_273af358-636a-4018-bb08-8008736bcb91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_98647c11-4811-44e8-88fd-423b9f3bf93d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_273af358-636a-4018-bb08-8008736bcb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_23cd94c9-8cb6-4fae-b3be-6d3fa9dc7e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_273af358-636a-4018-bb08-8008736bcb91" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_23cd94c9-8cb6-4fae-b3be-6d3fa9dc7e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2287ad46-3fec-4b9f-a827-1322e5cdf699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2287ad46-3fec-4b9f-a827-1322e5cdf699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6cc031d5-39db-4b9b-b63a-23cc9ca68ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2287ad46-3fec-4b9f-a827-1322e5cdf699" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6cc031d5-39db-4b9b-b63a-23cc9ca68ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_fe134382-12c6-409a-8e3b-3ce4bfb1b22e" xlink:href="ebs-20231231.xsd#ebs_TravelHealthBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6cc031d5-39db-4b9b-b63a-23cc9ca68ede" xlink:to="loc_ebs_TravelHealthBusinessMember_fe134382-12c6-409a-8e3b-3ce4bfb1b22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_4fddc24b-a10a-4870-bfbd-cc67088ceb21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_us-gaap_AssetAcquisitionAxis_4fddc24b-a10a-4870-bfbd-cc67088ceb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_78701e7a-7208-48f2-a5c2-409b750dbdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_4fddc24b-a10a-4870-bfbd-cc67088ceb21" xlink:to="loc_us-gaap_AssetAcquisitionDomain_78701e7a-7208-48f2-a5c2-409b750dbdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixMember_e91d033c-e0db-4cd7-ba1b-b43d1de9b56c" xlink:href="ebs-20231231.xsd#ebs_ChimerixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_78701e7a-7208-48f2-a5c2-409b750dbdc1" xlink:to="loc_ebs_ChimerixMember_e91d033c-e0db-4cd7-ba1b-b43d1de9b56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1dfce939-eca3-4cab-8c5d-027bc88fd374" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_srt_MajorCustomersAxis_1dfce939-eca3-4cab-8c5d-027bc88fd374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_67f8b406-a65d-47f6-be29-ade914d7b0b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1dfce939-eca3-4cab-8c5d-027bc88fd374" xlink:to="loc_srt_NameOfMajorCustomerDomain_67f8b406-a65d-47f6-be29-ade914d7b0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_40f7df17-bb55-4729-af7d-9780c0d24a87" xlink:href="ebs-20231231.xsd#ebs_BARDAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_67f8b406-a65d-47f6-be29-ade914d7b0b5" xlink:to="loc_ebs_BARDAMember_40f7df17-bb55-4729-af7d-9780c0d24a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9f71d3db-d4a7-4e3f-917d-d2055994bf57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_srt_ProductOrServiceAxis_9f71d3db-d4a7-4e3f-917d-d2055994bf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3585ec65-2a82-4038-9220-193230abf433" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9f71d3db-d4a7-4e3f-917d-d2055994bf57" xlink:to="loc_srt_ProductsAndServicesDomain_3585ec65-2a82-4038-9220-193230abf433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EbangaMember_bdb38153-5b25-4028-a0a1-d3e20dbc4bd7" xlink:href="ebs-20231231.xsd#ebs_EbangaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3585ec65-2a82-4038-9220-193230abf433" xlink:to="loc_ebs_EbangaMember_bdb38153-5b25-4028-a0a1-d3e20dbc4bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d1293e84-1ba3-4a4a-baa1-ec66d7c2f65e" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ba8bc087-0ccf-4054-a581-9795bfdf9cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ba8bc087-0ccf-4054-a581-9795bfdf9cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b5101c5-afaf-4548-a271-62f5e6076f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b5101c5-afaf-4548-a271-62f5e6076f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_674c923c-0376-48a9-b609-e557575a53de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_674c923c-0376-48a9-b609-e557575a53de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfd158a9-a54b-433b-961c-413c9c80fdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfd158a9-a54b-433b-961c-413c9c80fdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_a034e0f8-4d84-4c58-8677-223c0b62e8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_a034e0f8-4d84-4c58-8677-223c0b62e8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_e4e894b3-c429-4d86-b3f6-3d2a4e0cb034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_e4e894b3-c429-4d86-b3f6-3d2a4e0cb034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevenueFromContractWithCustomerTermOfContract_644c3bdb-4deb-476a-b962-80f24d1ab835" xlink:href="ebs-20231231.xsd#ebs_RevenueFromContractWithCustomerTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a9cb8c4c-4a6c-4b58-af64-a3e121e5a144" xlink:to="loc_ebs_RevenueFromContractWithCustomerTermOfContract_644c3bdb-4deb-476a-b962-80f24d1ab835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b14072ab-cd31-47af-993d-1b920a0ed59a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_bec24fec-b198-446f-bec7-b546a1cd7bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b14072ab-cd31-47af-993d-1b920a0ed59a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_bec24fec-b198-446f-bec7-b546a1cd7bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9129e871-de7c-4726-b488-e0e86fb6f861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c88a923d-f73a-445d-88c8-041a8f1fb939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9129e871-de7c-4726-b488-e0e86fb6f861" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c88a923d-f73a-445d-88c8-041a8f1fb939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_b9d9a8e5-e3d9-49b6-8a6f-9e857a1fb716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c88a923d-f73a-445d-88c8-041a8f1fb939" xlink:to="loc_us-gaap_ReportingUnitAxis_b9d9a8e5-e3d9-49b6-8a6f-9e857a1fb716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_c4914b3b-cb30-4ff7-a25e-f277c38dc692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_b9d9a8e5-e3d9-49b6-8a6f-9e857a1fb716" xlink:to="loc_us-gaap_ReportingUnitDomain_c4914b3b-cb30-4ff7-a25e-f277c38dc692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsMember_d66c70d0-2b79-4eb7-8e14-f0d253f32336" xlink:href="ebs-20231231.xsd#ebs_MCMProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_c4914b3b-cb30-4ff7-a25e-f277c38dc692" xlink:to="loc_ebs_MCMProductsMember_d66c70d0-2b79-4eb7-8e14-f0d253f32336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f777af68-5297-491c-b194-0bde6c180ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c88a923d-f73a-445d-88c8-041a8f1fb939" xlink:to="loc_us-gaap_GoodwillLineItems_f777af68-5297-491c-b194-0bde6c180ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4e353fd8-063f-4ef8-ba97-fda409eeb7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_f777af68-5297-491c-b194-0bde6c180ada" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4e353fd8-063f-4ef8-ba97-fda409eeb7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_189859b7-21d6-4568-b576-023d35649550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_f777af68-5297-491c-b194-0bde6c180ada" xlink:to="loc_us-gaap_Goodwill_189859b7-21d6-4568-b576-023d35649550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3057f848-f1bb-428d-a38c-71d19bfd56c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e8ff93f5-6c00-43a0-b409-53b230b742eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3057f848-f1bb-428d-a38c-71d19bfd56c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e8ff93f5-6c00-43a0-b409-53b230b742eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6eabe4c2-ea6b-4c4f-a57b-81eb1931cfee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3057f848-f1bb-428d-a38c-71d19bfd56c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6eabe4c2-ea6b-4c4f-a57b-81eb1931cfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bea027ba-9d8f-408f-b3c3-7f0b969b3bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3057f848-f1bb-428d-a38c-71d19bfd56c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bea027ba-9d8f-408f-b3c3-7f0b969b3bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_07dcfe90-4a57-471c-8385-ef753f6d51fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3057f848-f1bb-428d-a38c-71d19bfd56c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_07dcfe90-4a57-471c-8385-ef753f6d51fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_560b04ed-1e9d-46e7-9c39-230d5dd995cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3057f848-f1bb-428d-a38c-71d19bfd56c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_560b04ed-1e9d-46e7-9c39-230d5dd995cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_aff69ec9-fbab-40f8-bc9c-c24c5833926d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3057f848-f1bb-428d-a38c-71d19bfd56c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_aff69ec9-fbab-40f8-bc9c-c24c5833926d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_17a51c20-973f-44fb-94a1-6aaea280191f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3057f848-f1bb-428d-a38c-71d19bfd56c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_17a51c20-973f-44fb-94a1-6aaea280191f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ce4fe9b-196d-42c7-9921-af42165e2e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_cfcd1f97-e596-4cc8-864d-9f351d46d62f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ce4fe9b-196d-42c7-9921-af42165e2e23" xlink:to="loc_us-gaap_GoodwillRollForward_cfcd1f97-e596-4cc8-864d-9f351d46d62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9903083b-357a-4c73-b050-e0410010e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ce4fe9b-196d-42c7-9921-af42165e2e23" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9903083b-357a-4c73-b050-e0410010e5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8dd9bcdb-7f41-45c9-8630-8deb74b8e90a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9903083b-357a-4c73-b050-e0410010e5f3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8dd9bcdb-7f41-45c9-8630-8deb74b8e90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8dd9bcdb-7f41-45c9-8630-8deb74b8e90a" xlink:to="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_308abc7d-0a58-4937-b844-404ffe4e3032" xlink:href="ebs-20231231.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:to="loc_ebs_CommercialProductsSegmentMember_308abc7d-0a58-4937-b844-404ffe4e3032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_74be4052-3d90-41c1-967d-1231e696cdea" xlink:href="ebs-20231231.xsd#ebs_MCMProductsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:to="loc_ebs_MCMProductsSegmentMember_74be4052-3d90-41c1-967d-1231e696cdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_3510baeb-5067-4636-9d6d-c856fda9a1e2" xlink:href="ebs-20231231.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dff5b088-0768-4feb-9634-c7f23ca552d1" xlink:to="loc_ebs_ServicesSegmentMember_3510baeb-5067-4636-9d6d-c856fda9a1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9903083b-357a-4c73-b050-e0410010e5f3" xlink:to="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_935cae7d-1fd0-42c8-8ee5-c291a82c0584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:to="loc_us-gaap_GoodwillRollForward_935cae7d-1fd0-42c8-8ee5-c291a82c0584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31d2dff8-efb0-476c-9e61-67c0afff7285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_935cae7d-1fd0-42c8-8ee5-c291a82c0584" xlink:to="loc_us-gaap_Goodwill_31d2dff8-efb0-476c-9e61-67c0afff7285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_635b5aec-f690-4d8e-81cf-c29cb0796a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_935cae7d-1fd0-42c8-8ee5-c291a82c0584" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_635b5aec-f690-4d8e-81cf-c29cb0796a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9ea9c902-5fa5-4bd5-a536-dd3bf5c2b0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_935cae7d-1fd0-42c8-8ee5-c291a82c0584" xlink:to="loc_us-gaap_Goodwill_9ea9c902-5fa5-4bd5-a536-dd3bf5c2b0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_123edcdd-ca44-4cdf-8a90-863c3aad409d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:to="loc_us-gaap_GoodwillGross_123edcdd-ca44-4cdf-8a90-863c3aad409d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5d5067dd-7b69-4d6c-9dd5-543db68ede89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2f02f7fd-7ff9-4ca5-83ce-f10aebe3fa28" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5d5067dd-7b69-4d6c-9dd5-543db68ede89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e00388fb-7f5a-444a-97ec-efe602712023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2206c1a1-05ab-4e92-8636-b9b67cae90e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e00388fb-7f5a-444a-97ec-efe602712023" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2206c1a1-05ab-4e92-8636-b9b67cae90e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5e030335-1368-4300-9fe4-c8d33e974334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2206c1a1-05ab-4e92-8636-b9b67cae90e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5e030335-1368-4300-9fe4-c8d33e974334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_72840d59-58c3-4b85-9f7d-b7f4620a4409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5e030335-1368-4300-9fe4-c8d33e974334" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_72840d59-58c3-4b85-9f7d-b7f4620a4409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_012ba1a9-4268-4180-b311-32c7b37d2aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_72840d59-58c3-4b85-9f7d-b7f4620a4409" xlink:to="loc_us-gaap_MoneyMarketFundsMember_012ba1a9-4268-4180-b311-32c7b37d2aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_e2ffdf55-3994-4011-a43f-df50bfe4e59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_72840d59-58c3-4b85-9f7d-b7f4620a4409" xlink:to="loc_us-gaap_BankTimeDepositsMember_e2ffdf55-3994-4011-a43f-df50bfe4e59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e94bba42-6282-4474-b716-0996b6aa9176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2206c1a1-05ab-4e92-8636-b9b67cae90e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e94bba42-6282-4474-b716-0996b6aa9176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e94bba42-6282-4474-b716-0996b6aa9176" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_256ee121-2006-4c43-96b8-8a99019ac8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_256ee121-2006-4c43-96b8-8a99019ac8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b194d6ac-a5e1-4a95-bdca-d5a4dbef4f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b194d6ac-a5e1-4a95-bdca-d5a4dbef4f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_da65ba30-5c59-491f-a6d5-c7cab2436fff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a12ca9d-7784-42aa-8cfd-594c115e30ca" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_da65ba30-5c59-491f-a6d5-c7cab2436fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2206c1a1-05ab-4e92-8636-b9b67cae90e4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a70d0e4f-0438-48f9-9b00-6b63478e5f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a70d0e4f-0438-48f9-9b00-6b63478e5f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_976a3d0d-fa3a-404b-91ed-d98c87b9542e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_DerivativeAssets_976a3d0d-fa3a-404b-91ed-d98c87b9542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_50b8a1a8-2493-465e-a6d3-9a93a9e99b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_50b8a1a8-2493-465e-a6d3-9a93a9e99b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47576cbf-82cf-43d2-828e-788e83f7ee7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47576cbf-82cf-43d2-828e-788e83f7ee7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_3944eb1a-8fc7-4c42-99b3-3d3ced74c039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_3944eb1a-8fc7-4c42-99b3-3d3ced74c039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_21452e9d-ce8d-43e1-81b6-6b894e2f592a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f584104-77b6-4d65-8364-2a27c2d44220" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_21452e9d-ce8d-43e1-81b6-6b894e2f592a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dbeb2465-0e0a-4a58-80df-2cbd38248dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d00f13ce-bf49-41b4-81d4-989bd8ccaa74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbeb2465-0e0a-4a58-80df-2cbd38248dd4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d00f13ce-bf49-41b4-81d4-989bd8ccaa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b9e54c3-8d2d-4a57-9bf6-37515db5de65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d00f13ce-bf49-41b4-81d4-989bd8ccaa74" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b9e54c3-8d2d-4a57-9bf6-37515db5de65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_30a9f8ee-276b-4450-9886-b8bfa249834e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b9e54c3-8d2d-4a57-9bf6-37515db5de65" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_30a9f8ee-276b-4450-9886-b8bfa249834e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_8cf10033-9657-4dae-8207-9ece4e1dfb75" xlink:href="ebs-20231231.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30a9f8ee-276b-4450-9886-b8bfa249834e" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_8cf10033-9657-4dae-8207-9ece4e1dfb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1e142e06-bab4-4597-bf3f-08ccd7c7eac6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d00f13ce-bf49-41b4-81d4-989bd8ccaa74" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1e142e06-bab4-4597-bf3f-08ccd7c7eac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb4bdf86-039b-45b4-9f41-74b2120d9dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1e142e06-bab4-4597-bf3f-08ccd7c7eac6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb4bdf86-039b-45b4-9f41-74b2120d9dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_cc180ae1-35b3-43f4-9fdd-18b6c159914a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb4bdf86-039b-45b4-9f41-74b2120d9dc8" xlink:to="loc_us-gaap_SeniorNotesMember_cc180ae1-35b3-43f4-9fdd-18b6c159914a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d00f13ce-bf49-41b4-81d4-989bd8ccaa74" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_dcf201c2-0789-4154-9bc5-1ae23d2d7bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_dcf201c2-0789-4154-9bc5-1ae23d2d7bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7076c55f-a855-4f5a-a4d6-c40b689a7ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7076c55f-a855-4f5a-a4d6-c40b689a7ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c26d67e-6a6b-46ec-9992-2ac63a5768a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c26d67e-6a6b-46ec-9992-2ac63a5768a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_a8bee089-2fff-4856-a059-34230fbd3fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb68d377-e8fc-4aef-8069-3dd79a89e37f" xlink:to="loc_us-gaap_LongTermDebtFairValue_a8bee089-2fff-4856-a059-34230fbd3fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3aebf8b4-bf96-44b1-9696-ef49d37b7a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2c43c112-4651-4dbf-83e8-c1f8b0975471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3aebf8b4-bf96-44b1-9696-ef49d37b7a23" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2c43c112-4651-4dbf-83e8-c1f8b0975471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53f4115e-b17c-44ad-9939-10c0084fa211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2c43c112-4651-4dbf-83e8-c1f8b0975471" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53f4115e-b17c-44ad-9939-10c0084fa211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27435499-e870-40dd-977f-6802c0df1782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2c43c112-4651-4dbf-83e8-c1f8b0975471" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27435499-e870-40dd-977f-6802c0df1782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_47b279b4-dac9-4269-b03c-2f4661ca3ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2c43c112-4651-4dbf-83e8-c1f8b0975471" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_47b279b4-dac9-4269-b03c-2f4661ca3ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ce2ebf64-d44b-4f44-93eb-118c3164a1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2c43c112-4651-4dbf-83e8-c1f8b0975471" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ce2ebf64-d44b-4f44-93eb-118c3164a1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_673c9e22-b35a-4bcc-8776-ebc584b3c2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_673c9e22-b35a-4bcc-8776-ebc584b3c2a7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea28d292-89fa-4350-a2e0-901976e0dadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea28d292-89fa-4350-a2e0-901976e0dadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93f97602-d252-4c4e-bfab-0da85b077cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea28d292-89fa-4350-a2e0-901976e0dadd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93f97602-d252-4c4e-bfab-0da85b077cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2ea44385-29b6-4a5f-9147-f8e2033a4386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93f97602-d252-4c4e-bfab-0da85b077cf6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2ea44385-29b6-4a5f-9147-f8e2033a4386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de89aa60-91df-46b2-93e2-dc6feedb8c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de89aa60-91df-46b2-93e2-dc6feedb8c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a066af7-2bea-4fd2-8dae-c6b7afe1c1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de89aa60-91df-46b2-93e2-dc6feedb8c89" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a066af7-2bea-4fd2-8dae-c6b7afe1c1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d3b83cd4-c9f0-4492-83ee-644f357240c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a066af7-2bea-4fd2-8dae-c6b7afe1c1ba" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d3b83cd4-c9f0-4492-83ee-644f357240c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_397e1368-8d5e-4a5d-9e2e-05ca4415ba5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_397e1368-8d5e-4a5d-9e2e-05ca4415ba5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0bb1b8f5-18a2-4695-b947-59bb38a21bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_397e1368-8d5e-4a5d-9e2e-05ca4415ba5c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0bb1b8f5-18a2-4695-b947-59bb38a21bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f86f6aa1-3ca5-46fc-be22-b7fdc6e586dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0bb1b8f5-18a2-4695-b947-59bb38a21bf6" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f86f6aa1-3ca5-46fc-be22-b7fdc6e586dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityOfPaymentMember_7cfa67c4-1719-460a-8a9d-f1c289667264" xlink:href="ebs-20231231.xsd#ebs_MeasurementInputProbabilityOfPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0bb1b8f5-18a2-4695-b947-59bb38a21bf6" xlink:to="loc_ebs_MeasurementInputProbabilityOfPaymentMember_7cfa67c4-1719-460a-8a9d-f1c289667264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7d2feb9d-3023-430e-8b94-4d2e3764d50e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7d2feb9d-3023-430e-8b94-4d2e3764d50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9f8e9812-9659-42df-9cb5-514bf7bbf340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7d2feb9d-3023-430e-8b94-4d2e3764d50e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9f8e9812-9659-42df-9cb5-514bf7bbf340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_6897b712-5564-40e8-a3ed-5e3a29106818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_9f8e9812-9659-42df-9cb5-514bf7bbf340" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_6897b712-5564-40e8-a3ed-5e3a29106818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ddda1d5f-3985-4690-8fbc-2a15b83d70a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_srt_RangeAxis_ddda1d5f-3985-4690-8fbc-2a15b83d70a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d42fa58d-a9f5-43b8-badd-442dd26f6fb4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ddda1d5f-3985-4690-8fbc-2a15b83d70a3" xlink:to="loc_srt_RangeMember_d42fa58d-a9f5-43b8-badd-442dd26f6fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1df9b11e-4e1a-4a3e-8fe0-2466574fa539" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d42fa58d-a9f5-43b8-badd-442dd26f6fb4" xlink:to="loc_srt_MinimumMember_1df9b11e-4e1a-4a3e-8fe0-2466574fa539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0159908a-f7b5-4b41-95ad-a92216029182" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d42fa58d-a9f5-43b8-badd-442dd26f6fb4" xlink:to="loc_srt_MaximumMember_0159908a-f7b5-4b41-95ad-a92216029182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e095a631-b6a9-48b9-bd31-a73d80c89863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d1eb0643-6ca3-4e29-95ba-5db7822f7c05" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e095a631-b6a9-48b9-bd31-a73d80c89863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53a6c167-75ca-49fe-b04c-fbbc7bc663a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e095a631-b6a9-48b9-bd31-a73d80c89863" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_53a6c167-75ca-49fe-b04c-fbbc7bc663a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_89e51145-8e21-421d-a934-e1f757035bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e095a631-b6a9-48b9-bd31-a73d80c89863" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_89e51145-8e21-421d-a934-e1f757035bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DerivativeInstrumentsandhedgingactivitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_972ab88e-afd1-4b09-a10d-aaaa9c740ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_69e3580e-c28c-467e-9f1d-1de17d960db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_972ab88e-afd1-4b09-a10d-aaaa9c740ebf" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_69e3580e-c28c-467e-9f1d-1de17d960db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d97a352c-ff1f-4140-aa90-87d707c0b73e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_69e3580e-c28c-467e-9f1d-1de17d960db2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d97a352c-ff1f-4140-aa90-87d707c0b73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_765bb979-9910-4f6e-abfe-e4303f2d5469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d97a352c-ff1f-4140-aa90-87d707c0b73e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_765bb979-9910-4f6e-abfe-e4303f2d5469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f9a1ef3d-76f1-41a0-baa0-ac97e234613b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_765bb979-9910-4f6e-abfe-e4303f2d5469" xlink:to="loc_us-gaap_InterestRateSwapMember_f9a1ef3d-76f1-41a0-baa0-ac97e234613b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e76a2901-64a7-49c2-b794-fd5a9861735e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_69e3580e-c28c-467e-9f1d-1de17d960db2" xlink:to="loc_us-gaap_HedgingDesignationAxis_e76a2901-64a7-49c2-b794-fd5a9861735e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ca965ef2-0271-4238-998b-641b8d55e916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e76a2901-64a7-49c2-b794-fd5a9861735e" xlink:to="loc_us-gaap_HedgingDesignationDomain_ca965ef2-0271-4238-998b-641b8d55e916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_419a066c-4642-4dd0-aff8-5a6042465fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ca965ef2-0271-4238-998b-641b8d55e916" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_419a066c-4642-4dd0-aff8-5a6042465fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_f86aba09-9516-4f83-ae22-d4869f480e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_69e3580e-c28c-467e-9f1d-1de17d960db2" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_f86aba09-9516-4f83-ae22-d4869f480e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_191ee2a0-a9e1-44d7-96e9-15e4ff9ce832" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f86aba09-9516-4f83-ae22-d4869f480e47" xlink:to="loc_us-gaap_DerivativeNotionalAmount_191ee2a0-a9e1-44d7-96e9-15e4ff9ce832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f8366646-73d2-4381-b52b-78fb1202b8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f8366646-73d2-4381-b52b-78fb1202b8c1" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8fdf6d80-ed09-4c02-a2d8-931cae60bbab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8fdf6d80-ed09-4c02-a2d8-931cae60bbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1ccdf3ea-028b-4ad0-b189-3ceaedaaccda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8fdf6d80-ed09-4c02-a2d8-931cae60bbab" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1ccdf3ea-028b-4ad0-b189-3ceaedaaccda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8fa82382-9ff4-42ac-ba1b-cfe609d7c8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1ccdf3ea-028b-4ad0-b189-3ceaedaaccda" xlink:to="loc_us-gaap_InterestRateSwapMember_8fa82382-9ff4-42ac-ba1b-cfe609d7c8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_707ab5a2-b35a-4172-8b79-487d666be4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:to="loc_us-gaap_HedgingDesignationAxis_707ab5a2-b35a-4172-8b79-487d666be4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_01614d32-51da-4602-b3a7-36cfc8c1689b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_707ab5a2-b35a-4172-8b79-487d666be4e8" xlink:to="loc_us-gaap_HedgingDesignationDomain_01614d32-51da-4602-b3a7-36cfc8c1689b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_69975ddc-2135-4f21-9be6-ad15a3fec407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_01614d32-51da-4602-b3a7-36cfc8c1689b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_69975ddc-2135-4f21-9be6-ad15a3fec407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_301efa23-d9a0-444b-9b44-4d53a74c3987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_301efa23-d9a0-444b-9b44-4d53a74c3987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a877c4ce-28ac-426c-b42d-b8e591f76d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_301efa23-d9a0-444b-9b44-4d53a74c3987" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a877c4ce-28ac-426c-b42d-b8e591f76d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_24e2cf97-8b74-46ab-822a-09ebd8ea2ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a877c4ce-28ac-426c-b42d-b8e591f76d20" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_24e2cf97-8b74-46ab-822a-09ebd8ea2ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_54acea42-08a4-4c4c-a184-e40be5c0d886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c286984e-ad2d-4131-a3b0-aa356570154e" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_54acea42-08a4-4c4c-a184-e40be5c0d886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ff6712ae-5857-4c5f-98bc-7b62b2995833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_54acea42-08a4-4c4c-a184-e40be5c0d886" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ff6712ae-5857-4c5f-98bc-7b62b2995833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5808137a-db9d-46f2-a7df-97eace95e86d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5808137a-db9d-46f2-a7df-97eace95e86d" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_251f6fd4-8143-4df3-a4aa-d5129fc07024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_251f6fd4-8143-4df3-a4aa-d5129fc07024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d5ae1b27-1e32-4dcb-a151-12f39f7bf216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_251f6fd4-8143-4df3-a4aa-d5129fc07024" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d5ae1b27-1e32-4dcb-a151-12f39f7bf216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_22da4b03-1b3f-43f9-b2dc-1390fdfc7303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d5ae1b27-1e32-4dcb-a151-12f39f7bf216" xlink:to="loc_us-gaap_InterestExpenseMember_22da4b03-1b3f-43f9-b2dc-1390fdfc7303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_202894ee-51eb-40af-832a-7d2f898ad1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_202894ee-51eb-40af-832a-7d2f898ad1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_99593606-e1fb-4355-9c26-0e7878e4eab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_202894ee-51eb-40af-832a-7d2f898ad1bd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_99593606-e1fb-4355-9c26-0e7878e4eab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_ee17628b-a043-4b77-add7-4916cd4e82e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_99593606-e1fb-4355-9c26-0e7878e4eab1" xlink:to="loc_us-gaap_InterestRateSwapMember_ee17628b-a043-4b77-add7-4916cd4e82e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f1f812c7-e089-422d-87ff-b50a3f31466a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f1f812c7-e089-422d-87ff-b50a3f31466a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1a52a96b-c9d6-494f-9133-d1b718551f08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f1f812c7-e089-422d-87ff-b50a3f31466a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1a52a96b-c9d6-494f-9133-d1b718551f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2821b3d3-217f-484a-96e1-6d344e636bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1a52a96b-c9d6-494f-9133-d1b718551f08" xlink:to="loc_us-gaap_CashFlowHedgingMember_2821b3d3-217f-484a-96e1-6d344e636bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_05e20f4d-abb9-4858-ba96-3126f04e790b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f6ac687b-3dfc-4d9f-a6f4-81eaf9c69e44" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_05e20f4d-abb9-4858-ba96-3126f04e790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_7f037e76-0e2b-4c6c-972f-20413db5a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_05e20f4d-abb9-4858-ba96-3126f04e790b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_7f037e76-0e2b-4c6c-972f-20413db5a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DebtComponentsofLongtermIndebtednessDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_71a0a905-3d86-4672-bf97-bb17ade09fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_71a0a905-3d86-4672-bf97-bb17ade09fc6" xlink:to="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9666ebe1-0ad9-4150-8da4-2af3293aeff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:to="loc_us-gaap_DebtInstrumentAxis_9666ebe1-0ad9-4150-8da4-2af3293aeff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4078245b-7722-4d74-a2cd-33137ff654b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9666ebe1-0ad9-4150-8da4-2af3293aeff1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4078245b-7722-4d74-a2cd-33137ff654b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_f3d809e0-def6-496b-b30b-5213aae3f78a" xlink:href="ebs-20231231.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4078245b-7722-4d74-a2cd-33137ff654b0" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_f3d809e0-def6-496b-b30b-5213aae3f78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_a4b80680-5dce-49d9-a2f2-bda3930548f3" xlink:href="ebs-20231231.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4078245b-7722-4d74-a2cd-33137ff654b0" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_a4b80680-5dce-49d9-a2f2-bda3930548f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_077ce729-e488-4d9f-a6f2-28d6c1207488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_077ce729-e488-4d9f-a6f2-28d6c1207488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_077ce729-e488-4d9f-a6f2-28d6c1207488" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_1481ab99-3a88-4f0d-bb81-992bae21b50b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_1481ab99-3a88-4f0d-bb81-992bae21b50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_516ae889-4a25-4605-8f4d-02ef0abb5ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:to="loc_us-gaap_LineOfCreditMember_516ae889-4a25-4605-8f4d-02ef0abb5ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_2d2a0bd2-e1a1-4bb2-8759-84430acd57fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bccb0096-52aa-443b-a09b-a7be034c7367" xlink:to="loc_us-gaap_SeniorNotesMember_2d2a0bd2-e1a1-4bb2-8759-84430acd57fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_74d6fa1e-1a0c-4a1c-b541-9e1871083353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:to="loc_us-gaap_CreditFacilityAxis_74d6fa1e-1a0c-4a1c-b541-9e1871083353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_db0248b7-6bd3-4625-b64f-956fe629c224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_74d6fa1e-1a0c-4a1c-b541-9e1871083353" xlink:to="loc_us-gaap_CreditFacilityDomain_db0248b7-6bd3-4625-b64f-956fe629c224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_38b3d40d-5db3-44c1-9755-8d151ba9d9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_db0248b7-6bd3-4625-b64f-956fe629c224" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_38b3d40d-5db3-44c1-9755-8d151ba9d9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_99776ad0-e8a6-408c-b17e-7d81e5d248c5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b47a28e-33ce-41e0-839a-d0a0c220f4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b47a28e-33ce-41e0-839a-d0a0c220f4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a5655b63-2894-4119-9e97-2dd4447aaefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_LongTermDebt_a5655b63-2894-4119-9e97-2dd4447aaefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d1da990d-1989-4233-8812-01645d87980c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_LongTermDebtCurrent_d1da990d-1989-4233-8812-01645d87980c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_e3e5a0ec-f834-4491-aa54-f60bf5aa15de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_e3e5a0ec-f834-4491-aa54-f60bf5aa15de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1d1e5163-2f0b-4117-b2ce-3bc192b4d388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a742ca0e-ed50-4c2d-85e0-8dea9a35d376" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1d1e5163-2f0b-4117-b2ce-3bc192b4d388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_61a9a2bd-b0ea-48b6-bbd3-cb72edfd0449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61a9a2bd-b0ea-48b6-bbd3-cb72edfd0449" xlink:to="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1aa01c45-a433-45df-8ba8-0b40d40e42b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1aa01c45-a433-45df-8ba8-0b40d40e42b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1aa01c45-a433-45df-8ba8-0b40d40e42b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9f8f5fdb-59d3-49d6-96f1-e27ee422c13c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:to="loc_us-gaap_LineOfCreditMember_9f8f5fdb-59d3-49d6-96f1-e27ee422c13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_de3dfc4c-768e-4e78-80f8-9b95834b9b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:to="loc_us-gaap_SeniorNotesMember_de3dfc4c-768e-4e78-80f8-9b95834b9b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_011a6940-d560-4963-beb9-df2f39b82518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c831a4be-fcd8-439a-bff3-f37790a19abe" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_011a6940-d560-4963-beb9-df2f39b82518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7718328e-64f5-4abc-9e10-3b446b32bdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_DebtInstrumentAxis_7718328e-64f5-4abc-9e10-3b446b32bdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7718328e-64f5-4abc-9e10-3b446b32bdf1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_d5ee955b-901e-451b-aedb-fc7876aaa403" xlink:href="ebs-20231231.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_d5ee955b-901e-451b-aedb-fc7876aaa403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_1bdad43b-f884-4e70-a5df-4ffa527d6114" xlink:href="ebs-20231231.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:to="loc_ebs_AmendedCreditAgreementMember_1bdad43b-f884-4e70-a5df-4ffa527d6114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ForbearanceAgreementAndAmendmentMember_ea9c31eb-0832-49c3-9054-de6d592730b0" xlink:href="ebs-20231231.xsd#ebs_ForbearanceAgreementAndAmendmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f3190abf-b926-4f92-a809-96b27f005da2" xlink:to="loc_ebs_ForbearanceAgreementAndAmendmentMember_ea9c31eb-0832-49c3-9054-de6d592730b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3bd9eddf-e660-4f6f-9439-76d9efda8a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3bd9eddf-e660-4f6f-9439-76d9efda8a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d4f82b62-8004-4896-9eda-e6b41fe28f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3bd9eddf-e660-4f6f-9439-76d9efda8a57" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d4f82b62-8004-4896-9eda-e6b41fe28f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_ca3d7077-8062-4a0e-915d-6f73c98b3231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d4f82b62-8004-4896-9eda-e6b41fe28f56" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_ca3d7077-8062-4a0e-915d-6f73c98b3231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5c46e64d-0b92-4f20-a091-082e85418a63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d4f82b62-8004-4896-9eda-e6b41fe28f56" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5c46e64d-0b92-4f20-a091-082e85418a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba8d6cb0-a3e8-4d59-b8a0-38c64040aa80" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_srt_RangeAxis_ba8d6cb0-a3e8-4d59-b8a0-38c64040aa80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cfc5754a-71db-4e3a-a369-2708d91ae6e8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ba8d6cb0-a3e8-4d59-b8a0-38c64040aa80" xlink:to="loc_srt_RangeMember_cfc5754a-71db-4e3a-a369-2708d91ae6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ad0425ed-8aa4-4f70-91d6-40b0f225b176" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cfc5754a-71db-4e3a-a369-2708d91ae6e8" xlink:to="loc_srt_MaximumMember_ad0425ed-8aa4-4f70-91d6-40b0f225b176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36262cf8-b443-48d2-aabe-263e42418b7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cfc5754a-71db-4e3a-a369-2708d91ae6e8" xlink:to="loc_srt_MinimumMember_36262cf8-b443-48d2-aabe-263e42418b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8ef793d2-d76d-4a50-87e6-22a9bcd061cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_CreditFacilityAxis_8ef793d2-d76d-4a50-87e6-22a9bcd061cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a2e4eaa1-eb8d-4cc5-a61b-aeb402505acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8ef793d2-d76d-4a50-87e6-22a9bcd061cb" xlink:to="loc_us-gaap_CreditFacilityDomain_a2e4eaa1-eb8d-4cc5-a61b-aeb402505acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_9b949aaf-39f9-4746-a5b7-4cf6ef71c7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a2e4eaa1-eb8d-4cc5-a61b-aeb402505acb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_9b949aaf-39f9-4746-a5b7-4cf6ef71c7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_42fd78fa-d722-4e8d-9769-d3a9c707f5c6" xlink:href="ebs-20231231.xsd#ebs_TermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a2e4eaa1-eb8d-4cc5-a61b-aeb402505acb" xlink:to="loc_ebs_TermLoanFacilityMember_42fd78fa-d722-4e8d-9769-d3a9c707f5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_dcbabf0b-7b61-4d95-a37e-9026e7b58fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_dcbabf0b-7b61-4d95-a37e-9026e7b58fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_03777ac9-5827-4110-9ce8-7161569c2a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_dcbabf0b-7b61-4d95-a37e-9026e7b58fd4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_03777ac9-5827-4110-9ce8-7161569c2a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ed0b0fb7-be0f-41cb-9a83-9228d08215a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_03777ac9-5827-4110-9ce8-7161569c2a4b" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ed0b0fb7-be0f-41cb-9a83-9228d08215a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c91f38b8-2aa4-4f3f-a35c-57b876551701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c91f38b8-2aa4-4f3f-a35c-57b876551701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98024731-0738-4439-8208-b44ceabdb117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c91f38b8-2aa4-4f3f-a35c-57b876551701" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98024731-0738-4439-8208-b44ceabdb117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_8cc2c390-23e4-416d-9755-475e212a286d" xlink:href="ebs-20231231.xsd#ebs_TravelHealthBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98024731-0738-4439-8208-b44ceabdb117" xlink:to="loc_ebs_TravelHealthBusinessMember_8cc2c390-23e4-416d-9755-475e212a286d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtTermsAxis_926848ae-7eae-4b34-b80e-3d864b3d6969" xlink:href="ebs-20231231.xsd#ebs_DebtTermsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_ebs_DebtTermsAxis_926848ae-7eae-4b34-b80e-3d864b3d6969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:href="ebs-20231231.xsd#ebs_DebtTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_DebtTermsAxis_926848ae-7eae-4b34-b80e-3d864b3d6969" xlink:to="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_FiscalQuartersEndingIn2024Member_6c29a81e-ade4-4906-b888-5f3357b7ddce" xlink:href="ebs-20231231.xsd#ebs_FiscalQuartersEndingIn2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:to="loc_ebs_FiscalQuartersEndingIn2024Member_6c29a81e-ade4-4906-b888-5f3357b7ddce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_FiscalQuartersEndingAfter2024Member_53fe59be-db6c-4fa4-b18f-455cd9721aad" xlink:href="ebs-20231231.xsd#ebs_FiscalQuartersEndingAfter2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:to="loc_ebs_FiscalQuartersEndingAfter2024Member_53fe59be-db6c-4fa4-b18f-455cd9721aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UntilMarch312024Member_b195a2e4-c129-4bd9-85e2-24a7bf6ec854" xlink:href="ebs-20231231.xsd#ebs_UntilMarch312024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:to="loc_ebs_UntilMarch312024Member_b195a2e4-c129-4bd9-85e2-24a7bf6ec854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_FiscalQuartersEndingAfterMarch312024Member_49e711f9-6c4c-4ad8-a3b3-033dcaa53a2a" xlink:href="ebs-20231231.xsd#ebs_FiscalQuartersEndingAfterMarch312024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_DebtTermsDomain_6a421122-9db6-4983-a1ef-7a59ecd9f8ca" xlink:to="loc_ebs_FiscalQuartersEndingAfterMarch312024Member_49e711f9-6c4c-4ad8-a3b3-033dcaa53a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_29144f85-5a73-4bcd-a1ff-f04c36565388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_VariableRateAxis_29144f85-5a73-4bcd-a1ff-f04c36565388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_29144f85-5a73-4bcd-a1ff-f04c36565388" xlink:to="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SOFREURIBOROrCDORMember_aa78f4de-f855-4fa4-8f07-a687c4c4d7a5" xlink:href="ebs-20231231.xsd#ebs_SOFREURIBOROrCDORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_ebs_SOFREURIBOROrCDORMember_aa78f4de-f855-4fa4-8f07-a687c4c4d7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e0eb9c1c-4791-43c2-98a8-3737736f55d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e0eb9c1c-4791-43c2-98a8-3737736f55d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SecuredOvernightFinancingRateSOFRMember_36ff91e9-91c4-4778-98c9-f96f35e27d25" xlink:href="ebs-20231231.xsd#ebs_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_ebs_SecuredOvernightFinancingRateSOFRMember_36ff91e9-91c4-4778-98c9-f96f35e27d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_f7eee53c-827d-4853-972b-cca60610e154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_us-gaap_BaseRateMember_f7eee53c-827d-4853-972b-cca60610e154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SOFRSONIAAndEurocurrencyMember_aa3bcff7-2cee-467a-b48e-91892e866c66" xlink:href="ebs-20231231.xsd#ebs_SOFRSONIAAndEurocurrencyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7cd48c14-c125-4882-949a-036b9bdb8892" xlink:to="loc_ebs_SOFRSONIAAndEurocurrencyMember_aa3bcff7-2cee-467a-b48e-91892e866c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8e00472f-de0b-48e3-9573-aed3dfdd6f11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8e00472f-de0b-48e3-9573-aed3dfdd6f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ea03f39e-95ba-452e-bcd3-a2964bcdba9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8e00472f-de0b-48e3-9573-aed3dfdd6f11" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ea03f39e-95ba-452e-bcd3-a2964bcdba9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b3342079-71a2-496b-b652-514b1b984e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ea03f39e-95ba-452e-bcd3-a2964bcdba9d" xlink:to="loc_us-gaap_SubsequentEventMember_b3342079-71a2-496b-b652-514b1b984e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ae93383-d8ea-416e-ba10-256905a465d1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_252be050-bf15-4950-8b0b-25b6713bcb90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_LongTermDebt_252be050-bf15-4950-8b0b-25b6713bcb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_aca7e2e9-018f-492a-8cae-175838a3683c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_aca7e2e9-018f-492a-8cae-175838a3683c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb68f70a-4e68-4a0e-8355-e438c1a0311f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb68f70a-4e68-4a0e-8355-e438c1a0311f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_c1b21a52-afb4-4586-8ae5-9cb07775612b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_c1b21a52-afb4-4586-8ae5-9cb07775612b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1550dce5-2fa4-49ea-b4e6-5dc191cb695a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1550dce5-2fa4-49ea-b4e6-5dc191cb695a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_c5e5a4bd-f234-4c4f-9785-d16ac596eae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_c5e5a4bd-f234-4c4f-9785-d16ac596eae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_be9df071-d883-4ecf-91e3-4f2a35cf21be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_Cash_be9df071-d883-4ecf-91e3-4f2a35cf21be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a1f33a7b-aa69-48e5-9584-7ce803454a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a1f33a7b-aa69-48e5-9584-7ce803454a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_8646206a-05b4-41c3-81fa-0556d9a0a52b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_8646206a-05b4-41c3-81fa-0556d9a0a52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum_c643fed9-8f32-4dcc-beda-dcf4b3a27756" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum_c643fed9-8f32-4dcc-beda-dcf4b3a27756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_33841d4a-ad84-4546-b7bb-0a749286d9f4" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_33841d4a-ad84-4546-b7bb-0a749286d9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_9a678593-05a7-4b26-bb01-0c1fd05dede9" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_9a678593-05a7-4b26-bb01-0c1fd05dede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e5aa22fa-f10e-411c-a953-4ee0e953d4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e5aa22fa-f10e-411c-a953-4ee0e953d4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_5329727b-4070-4f74-a318-d91626930803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_5329727b-4070-4f74-a318-d91626930803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentThreshold_95346469-a4e2-4789-8d7a-104cee20558f" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentMandatoryPrepaymentThreshold"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentThreshold_95346469-a4e2-4789-8d7a-104cee20558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage_74c7de28-5151-44b0-a911-7fe3f3473b3a" xlink:href="ebs-20231231.xsd#ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage_74c7de28-5151-44b0-a911-7fe3f3473b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1e1c8c88-70c9-4ce4-a684-a68a065149ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e8c7d43-09e1-4420-a1af-75055c21267a" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1e1c8c88-70c9-4ce4-a684-a68a065149ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#DebtFutureDebtPaymentsofLongtermIndebtednessDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9a70aaee-0188-40f9-98c3-fa8a119fcf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c38d9553-93b7-472b-ae01-0c96c2decff2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a70aaee-0188-40f9-98c3-fa8a119fcf7b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c38d9553-93b7-472b-ae01-0c96c2decff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_93dd1e1c-c268-4ffe-9d84-b835ae95ca43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a70aaee-0188-40f9-98c3-fa8a119fcf7b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_93dd1e1c-c268-4ffe-9d84-b835ae95ca43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afac93e3-ba57-4525-ad33-c3b69a564aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a70aaee-0188-40f9-98c3-fa8a119fcf7b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afac93e3-ba57-4525-ad33-c3b69a564aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1e4e5dde-b335-4ffd-8402-e3aafd6d9914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a70aaee-0188-40f9-98c3-fa8a119fcf7b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1e4e5dde-b335-4ffd-8402-e3aafd6d9914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_dff84c11-9e52-4d3d-aec6-bb8447ac299c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a70aaee-0188-40f9-98c3-fa8a119fcf7b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_dff84c11-9e52-4d3d-aec6-bb8447ac299c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_52d1307b-f100-4617-80f4-0424c9ea61bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a70aaee-0188-40f9-98c3-fa8a119fcf7b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_52d1307b-f100-4617-80f4-0424c9ea61bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2f409614-218f-4793-a85e-4217e2c238d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a70aaee-0188-40f9-98c3-fa8a119fcf7b" xlink:to="loc_us-gaap_LongTermDebt_2f409614-218f-4793-a85e-4217e2c238d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5c07a5e5-e42f-4fd2-9265-52f5603ba13c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5c07a5e5-e42f-4fd2-9265-52f5603ba13c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0108d2e7-7eed-4d98-a205-12d25097a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_us-gaap_AwardTypeAxis_0108d2e7-7eed-4d98-a205-12d25097a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0108d2e7-7eed-4d98-a205-12d25097a03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c0d79b99-2965-4c05-9875-9912ae86eb81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c0d79b99-2965-4c05-9875-9912ae86eb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c902683a-a9a0-4c69-b73a-5719e3685e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c902683a-a9a0-4c69-b73a-5719e3685e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3b2d32d9-3613-44b0-8f93-acb0c4e9cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68be263d-b969-4b35-8e1c-f19ecede0efa" xlink:to="loc_us-gaap_PerformanceSharesMember_3b2d32d9-3613-44b0-8f93-acb0c4e9cb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5756f39b-b01c-4070-9d33-fe7cea32781f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_us-gaap_PlanNameAxis_5756f39b-b01c-4070-9d33-fe7cea32781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d829bb18-4df9-4347-82e1-2184d0a5cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5756f39b-b01c-4070-9d33-fe7cea32781f" xlink:to="loc_us-gaap_PlanNameDomain_d829bb18-4df9-4347-82e1-2184d0a5cb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_9edc7784-02c2-45b7-a931-ce0fbd6e497b" xlink:href="ebs-20231231.xsd#ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d829bb18-4df9-4347-82e1-2184d0a5cb3c" xlink:to="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_9edc7784-02c2-45b7-a931-ce0fbd6e497b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2023EquityInducementPlanMember_664b4c2f-77c8-4730-8853-83c504cc2d40" xlink:href="ebs-20231231.xsd#ebs_A2023EquityInducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d829bb18-4df9-4347-82e1-2184d0a5cb3c" xlink:to="loc_ebs_A2023EquityInducementPlanMember_664b4c2f-77c8-4730-8853-83c504cc2d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aae6264c-2708-445b-8f8d-691da790842b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_srt_RangeAxis_aae6264c-2708-445b-8f8d-691da790842b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_854b487e-42bb-4db9-b396-2c40792bfdf1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aae6264c-2708-445b-8f8d-691da790842b" xlink:to="loc_srt_RangeMember_854b487e-42bb-4db9-b396-2c40792bfdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ed1fb5e5-2918-445c-b583-253946c2c64c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_854b487e-42bb-4db9-b396-2c40792bfdf1" xlink:to="loc_srt_MinimumMember_ed1fb5e5-2918-445c-b583-253946c2c64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66c576b8-71b9-4f5b-b82d-f83c9e81269a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_854b487e-42bb-4db9-b396-2c40792bfdf1" xlink:to="loc_srt_MaximumMember_66c576b8-71b9-4f5b-b82d-f83c9e81269a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_304525ac-a67a-4310-bb9f-5028c37d401b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_304525ac-a67a-4310-bb9f-5028c37d401b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82a511d4-6d09-4757-81c4-6cca990d54b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_304525ac-a67a-4310-bb9f-5028c37d401b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82a511d4-6d09-4757-81c4-6cca990d54b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AtTheMarketOfferingMember_5ca12122-69a4-491e-befd-db3a7e99a8ed" xlink:href="ebs-20231231.xsd#ebs_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82a511d4-6d09-4757-81c4-6cca990d54b4" xlink:to="loc_ebs_AtTheMarketOfferingMember_5ca12122-69a4-491e-befd-db3a7e99a8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81200336-f3f3-4a6c-a6bf-c1007cf46fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81200336-f3f3-4a6c-a6bf-c1007cf46fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42b8d30c-b340-4e7d-8b65-884c441f8712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81200336-f3f3-4a6c-a6bf-c1007cf46fc4" xlink:to="loc_us-gaap_EquityComponentDomain_42b8d30c-b340-4e7d-8b65-884c441f8712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_935d6344-2b6d-4b26-94ad-b05dabd93fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42b8d30c-b340-4e7d-8b65-884c441f8712" xlink:to="loc_us-gaap_TreasuryStockCommonMember_935d6344-2b6d-4b26-94ad-b05dabd93fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad97473f-343b-463a-b3f6-cb762eeeff7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans_24b9b2a6-7b3d-4f2a-ad89-4f24e823af57" xlink:href="ebs-20231231.xsd#ebs_NumberOfShareBasedEmployeeCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_NumberOfShareBasedEmployeeCompensationPlans_24b9b2a6-7b3d-4f2a-ad89-4f24e823af57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ea0a908f-5665-4235-8c5f-214d43a93e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ea0a908f-5665-4235-8c5f-214d43a93e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15c2571e-391b-46f8-a5eb-18be5266e72d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15c2571e-391b-46f8-a5eb-18be5266e72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fa1293e8-354e-49bd-b7ff-31e11a138eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fa1293e8-354e-49bd-b7ff-31e11a138eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b4c582ae-5b20-4239-a60b-b7f08de75ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b4c582ae-5b20-4239-a60b-b7f08de75ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum_da00a573-a30d-43ce-a7a0-22505b0468cc" xlink:href="ebs-20231231.xsd#ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum_da00a573-a30d-43ce-a7a0-22505b0468cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_01d06d7b-d0fa-4655-8562-10ceed067b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_01d06d7b-d0fa-4655-8562-10ceed067b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3dff6aee-b06f-426b-a4cc-6e8855895170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3dff6aee-b06f-426b-a4cc-6e8855895170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a81e31ef-6c18-4dc3-be66-f2d0de60f251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a81e31ef-6c18-4dc3-be66-f2d0de60f251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ef377b7a-3d9e-4f12-8f48-0a9b0b85234d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ef377b7a-3d9e-4f12-8f48-0a9b0b85234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ceec79f1-9daa-4658-b030-dc1bd650456c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ceec79f1-9daa-4658-b030-dc1bd650456c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue_06233158-b9bf-4c8f-b0bf-786bfe331a64" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue_06233158-b9bf-4c8f-b0bf-786bfe331a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_123f96f7-5b6e-4086-9ade-e35137f27668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_123f96f7-5b6e-4086-9ade-e35137f27668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_666f8253-e83a-4cd7-89b5-9d6fec7141db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_666f8253-e83a-4cd7-89b5-9d6fec7141db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage_1f2e34f8-4079-49e8-ab5f-bb4b65fe1158" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage_1f2e34f8-4079-49e8-ab5f-bb4b65fe1158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d90ad595-2e9c-4bb2-9368-c1d8abc69f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d90ad595-2e9c-4bb2-9368-c1d8abc69f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f6b00ca1-7fe9-4be9-9dba-1bffffbbf128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f6b00ca1-7fe9-4be9-9dba-1bffffbbf128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d4e988c-873f-446a-911d-506f7497bef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d4e988c-873f-446a-911d-506f7497bef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_de302779-4737-48e0-97e9-679ffb2890ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_de302779-4737-48e0-97e9-679ffb2890ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1a28c861-aa0c-4545-a67f-c9b35a8b3f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1a28c861-aa0c-4545-a67f-c9b35a8b3f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommonStockNumberOfVotesPerCommonShare_c020b973-8703-4838-a068-612d033f8046" xlink:href="ebs-20231231.xsd#ebs_CommonStockNumberOfVotesPerCommonShare"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_CommonStockNumberOfVotesPerCommonShare_c020b973-8703-4838-a068-612d033f8046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SaleOfStockAggregateOfferingAmountMaximum_bc25a4c7-909b-4df1-ac75-71febdd0e70e" xlink:href="ebs-20231231.xsd#ebs_SaleOfStockAggregateOfferingAmountMaximum"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_SaleOfStockAggregateOfferingAmountMaximum_bc25a4c7-909b-4df1-ac75-71febdd0e70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dad12895-d8ad-4320-b77a-9474702c0624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dad12895-d8ad-4320-b77a-9474702c0624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SaleOfStockConsiderationReceivedOnTransactionGross_5ee9e06e-0a88-46f8-848e-b7c6288df984" xlink:href="ebs-20231231.xsd#ebs_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_SaleOfStockConsiderationReceivedOnTransactionGross_5ee9e06e-0a88-46f8-848e-b7c6288df984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf638f07-6fae-4c25-a2d2-0c441cc77062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf638f07-6fae-4c25-a2d2-0c441cc77062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares_12ad5135-7a4f-46df-9c96-3bd9404149af" xlink:href="ebs-20231231.xsd#ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares_12ad5135-7a4f-46df-9c96-3bd9404149af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4c99a823-eacd-4954-822d-051d65256b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4c99a823-eacd-4954-822d-051d65256b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_26029910-179e-41cc-854f-f834ee0b3f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_26029910-179e-41cc-854f-f834ee0b3f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_325ae209-31b3-475d-87f9-ec5d768789df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1beced30-c27d-40e1-9680-2b37f18295f8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_325ae209-31b3-475d-87f9-ec5d768789df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cf189ebe-96a8-480e-8c10-57eda98318e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5b15289-9d6a-46c4-b6bd-878cb669294a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cf189ebe-96a8-480e-8c10-57eda98318e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5b15289-9d6a-46c4-b6bd-878cb669294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce8150d1-7c62-4e1b-a492-53193fae2843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5b15289-9d6a-46c4-b6bd-878cb669294a" xlink:to="loc_us-gaap_AwardTypeAxis_ce8150d1-7c62-4e1b-a492-53193fae2843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f21328bc-1c75-4cb4-9950-12ded107550b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ce8150d1-7c62-4e1b-a492-53193fae2843" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f21328bc-1c75-4cb4-9950-12ded107550b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71f2745a-de1d-4ee3-ac8d-78dd982bf2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f21328bc-1c75-4cb4-9950-12ded107550b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71f2745a-de1d-4ee3-ac8d-78dd982bf2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5b15289-9d6a-46c4-b6bd-878cb669294a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2ce62ed6-340f-4b8b-8848-64b30b3ef5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2ce62ed6-340f-4b8b-8848-64b30b3ef5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c298fe47-f152-417d-9ff9-84ca847edfef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c298fe47-f152-417d-9ff9-84ca847edfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c976be6f-f6c6-415c-9617-a0bd6f16f9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c976be6f-f6c6-415c-9617-a0bd6f16f9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ec00275d-e0b6-450e-b47f-9d692431b924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ec00275d-e0b6-450e-b47f-9d692431b924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_63e9b8eb-2c83-4710-898c-c4135fd7bedf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_63e9b8eb-2c83-4710-898c-c4135fd7bedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c9be72c-2d0e-4fa1-8511-d1fc3ebe47f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c90692e2-155e-409c-8a6a-50f04dfad820" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c9be72c-2d0e-4fa1-8511-d1fc3ebe47f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_42c929b7-6d90-4836-9b43-b3e115b67f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97dea3cd-8bab-4503-a9a1-e43355289928" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_42c929b7-6d90-4836-9b43-b3e115b67f75" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97dea3cd-8bab-4503-a9a1-e43355289928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_34e94ef7-9488-443c-af83-6d0b45af5be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97dea3cd-8bab-4503-a9a1-e43355289928" xlink:to="loc_us-gaap_PlanNameAxis_34e94ef7-9488-443c-af83-6d0b45af5be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fb763dce-64ce-462f-8606-41fc387e819e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_34e94ef7-9488-443c-af83-6d0b45af5be9" xlink:to="loc_us-gaap_PlanNameDomain_fb763dce-64ce-462f-8606-41fc387e819e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_1d15b59d-11aa-4f47-88b2-e44e5ba31e57" xlink:href="ebs-20231231.xsd#ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fb763dce-64ce-462f-8606-41fc387e819e" xlink:to="loc_ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember_1d15b59d-11aa-4f47-88b2-e44e5ba31e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4de83baa-39b5-4033-96b0-4d4932aab5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97dea3cd-8bab-4503-a9a1-e43355289928" xlink:to="loc_us-gaap_AwardTypeAxis_4de83baa-39b5-4033-96b0-4d4932aab5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722379ba-4116-42f8-93ba-5af4a5b44e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4de83baa-39b5-4033-96b0-4d4932aab5d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722379ba-4116-42f8-93ba-5af4a5b44e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember_32ea15fa-4d69-4cb5-97cf-9032b0bd30f5" xlink:href="ebs-20231231.xsd#ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722379ba-4116-42f8-93ba-5af4a5b44e7b" xlink:to="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember_32ea15fa-4d69-4cb5-97cf-9032b0bd30f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97dea3cd-8bab-4503-a9a1-e43355289928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d6cd59a3-d96a-4a20-8e93-ec8c94b879dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d6cd59a3-d96a-4a20-8e93-ec8c94b879dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7895e001-3eb5-43b6-88c3-925f91ff7006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7895e001-3eb5-43b6-88c3-925f91ff7006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3fbd715-32bd-40c8-9798-6adcfe71b5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3fbd715-32bd-40c8-9798-6adcfe71b5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5503b0a2-3830-49a4-89de-663c79eabff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5503b0a2-3830-49a4-89de-663c79eabff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d95c1529-0b16-44aa-8b4d-8cdbeb05df6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8dbc8b8-95c6-4bbb-8a59-b0c6151db94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d95c1529-0b16-44aa-8b4d-8cdbeb05df6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e11423de-65ee-4b90-9545-2cfd65cfad2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e11423de-65ee-4b90-9545-2cfd65cfad2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_966e9f8e-1885-4580-a5aa-222e53746c70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_966e9f8e-1885-4580-a5aa-222e53746c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf96c917-ea4c-44af-8ec5-f493f284859d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf96c917-ea4c-44af-8ec5-f493f284859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6171656a-7fb2-4d29-a374-a136c1d20bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6171656a-7fb2-4d29-a374-a136c1d20bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f8d5eeb4-0bfb-4d85-a634-9c5ff22b796f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f8d5eeb4-0bfb-4d85-a634-9c5ff22b796f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7bcc739c-d2fb-4a9e-a78d-a8c678195cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77ef4f23-c055-4c34-9e1a-fe3b40d9fc18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7bcc739c-d2fb-4a9e-a78d-a8c678195cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e8bfd807-e3ae-4668-8d30-4a6eb8bcfaad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e8bfd807-e3ae-4668-8d30-4a6eb8bcfaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_f13557ed-6e22-4ee8-bace-8fc8ed25ad42" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_f13557ed-6e22-4ee8-bace-8fc8ed25ad42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_63280307-2b34-49cb-87de-7f8b411ae9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_f13557ed-6e22-4ee8-bace-8fc8ed25ad42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_63280307-2b34-49cb-87de-7f8b411ae9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_887fc07a-1a82-4445-81eb-d92b53a3213b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_f13557ed-6e22-4ee8-bace-8fc8ed25ad42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_887fc07a-1a82-4445-81eb-d92b53a3213b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2b6c1668-4784-4deb-8978-7b7b189ed488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2b6c1668-4784-4deb-8978-7b7b189ed488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d86c6f54-37e7-4ad8-b2bd-0ef2891ac5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2b6c1668-4784-4deb-8978-7b7b189ed488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d86c6f54-37e7-4ad8-b2bd-0ef2891ac5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd63434a-4908-464b-9721-6109e62abc16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2b6c1668-4784-4deb-8978-7b7b189ed488" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd63434a-4908-464b-9721-6109e62abc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7d9e517-1e62-4e9b-beda-f36546749600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7d9e517-1e62-4e9b-beda-f36546749600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba721a0b-1493-4a1a-ae17-93bfac288596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba721a0b-1493-4a1a-ae17-93bfac288596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b80c020-a9ed-425d-acb3-afc2b3505778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b80c020-a9ed-425d-acb3-afc2b3505778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ec78539-f51c-4381-b987-54236a0e0369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ec78539-f51c-4381-b987-54236a0e0369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24df76e8-b6b7-43d5-bb74-17a51e832fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9dcec7d4-1fb2-416b-b049-8d0cc7996f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24df76e8-b6b7-43d5-bb74-17a51e832fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b9a4ea01-c7b8-4588-903b-2d3f8050a317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b9a4ea01-c7b8-4588-903b-2d3f8050a317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13f13c02-0212-4ac5-9263-a58ae106eaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13f13c02-0212-4ac5-9263-a58ae106eaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b9c13c29-dc7a-4596-981a-7b28cda71ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b9c13c29-dc7a-4596-981a-7b28cda71ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b5efc2c2-5d0f-4823-a851-0faef30346d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b5efc2c2-5d0f-4823-a851-0faef30346d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_326f0df0-adc2-4d90-bafc-cef04439a76b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2f1f7782-cffa-42e6-bdd8-186024f67049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_326f0df0-adc2-4d90-bafc-cef04439a76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4e869582-5c67-4796-a9a3-7ca7e0bca9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4e869582-5c67-4796-a9a3-7ca7e0bca9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_47b7b9a2-ed3d-4c61-bf53-cfc829cf32bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4e869582-5c67-4796-a9a3-7ca7e0bca9d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_47b7b9a2-ed3d-4c61-bf53-cfc829cf32bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_ff827e45-3f11-4e2d-84da-7f10c11cd289" xlink:href="ebs-20231231.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83a155f6-a91a-4c8e-a8d7-67b1410afa38" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_ff827e45-3f11-4e2d-84da-7f10c11cd289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f5191abd-4ad6-414d-8289-df76e2260cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e45d37e0-0a48-4442-91e0-08f28f227a31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f5191abd-4ad6-414d-8289-df76e2260cd1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e45d37e0-0a48-4442-91e0-08f28f227a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e5df4170-b66c-48a1-b233-6e4cf7c0d8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e45d37e0-0a48-4442-91e0-08f28f227a31" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e5df4170-b66c-48a1-b233-6e4cf7c0d8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5df4170-b66c-48a1-b233-6e4cf7c0d8a4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b259e022-c49e-4181-a0de-85a9444318dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:to="loc_us-gaap_CostOfSalesMember_b259e022-c49e-4181-a0de-85a9444318dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba8e320d-5697-4f5f-8efb-074c65aa99d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba8e320d-5697-4f5f-8efb-074c65aa99d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_393fbd12-b161-4f63-946f-d84682409e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62c629f6-b051-4c43-98a8-4f4c0b1df61d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_393fbd12-b161-4f63-946f-d84682409e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_efe32b32-2483-4e48-ba68-955108a2fac9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e45d37e0-0a48-4442-91e0-08f28f227a31" xlink:to="loc_srt_ProductOrServiceAxis_efe32b32-2483-4e48-ba68-955108a2fac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_efe32b32-2483-4e48-ba68-955108a2fac9" xlink:to="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember_549409ca-7196-4730-9be6-d83e4446f249" xlink:href="ebs-20231231.xsd#ebs_CommercialProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:to="loc_ebs_CommercialProductMember_549409ca-7196-4730-9be6-d83e4446f249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember_e6def31f-9a58-436a-94fc-30d526d81d4c" xlink:href="ebs-20231231.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:to="loc_ebs_MedicalCountermeasuresMCMProductMember_e6def31f-9a58-436a-94fc-30d526d81d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesMember_d2199dc1-c4b3-4b57-a172-291d5df84d12" xlink:href="ebs-20231231.xsd#ebs_BioservicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_adaa6c0c-a7b2-4aef-8780-877e8a63ace9" xlink:to="loc_ebs_BioservicesMember_d2199dc1-c4b3-4b57-a172-291d5df84d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3dcd921-cc9f-4fa0-87d7-93ac53fca286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e45d37e0-0a48-4442-91e0-08f28f227a31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3dcd921-cc9f-4fa0-87d7-93ac53fca286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bd25e04c-8b51-4f83-83c0-e9007be779f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3dcd921-cc9f-4fa0-87d7-93ac53fca286" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bd25e04c-8b51-4f83-83c0-e9007be779f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6f9e4bcc-90fb-4f77-8645-c53d92510726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8db79d6-7d0b-4629-a25b-75e7eefd5306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6f9e4bcc-90fb-4f77-8645-c53d92510726" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8db79d6-7d0b-4629-a25b-75e7eefd5306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f2296446-7c3f-479b-a5d2-16a1dff89b68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8db79d6-7d0b-4629-a25b-75e7eefd5306" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f2296446-7c3f-479b-a5d2-16a1dff89b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a4b1303d-088a-4628-91f5-796428e60fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2296446-7c3f-479b-a5d2-16a1dff89b68" xlink:to="loc_us-gaap_EquityComponentDomain_a4b1303d-088a-4628-91f5-796428e60fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4b1303d-088a-4628-91f5-796428e60fec" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_452278f7-7729-48fa-a8a2-8754d13b7e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_452278f7-7729-48fa-a8a2-8754d13b7e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c19de148-41f7-4644-99e8-e2f1618135e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c19de148-41f7-4644-99e8-e2f1618135e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2bffa6b7-5a7d-49bf-b981-751da66ff5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_723a8432-058f-406b-b2ea-f360a436db9b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2bffa6b7-5a7d-49bf-b981-751da66ff5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9b2db5d3-10b5-46e3-9337-596fcc208e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8db79d6-7d0b-4629-a25b-75e7eefd5306" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9b2db5d3-10b5-46e3-9337-596fcc208e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9b2db5d3-10b5-46e3-9337-596fcc208e4b" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a91bce8-f4d7-44e2-a903-7ef264f88daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:to="loc_us-gaap_StockholdersEquity_3a91bce8-f4d7-44e2-a903-7ef264f88daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f087fc8d-b24d-46de-bea9-e97527ca225b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f087fc8d-b24d-46de-bea9-e97527ca225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b2e19341-d0f2-4a9f-99e1-4d2227249de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b2e19341-d0f2-4a9f-99e1-4d2227249de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7a59fc2a-572d-4411-b01b-a1f902c36f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7a59fc2a-572d-4411-b01b-a1f902c36f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_21a7863a-b44c-4acc-b287-9eb94847ef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6b0f8d1b-342b-45ab-a6a5-a2aa5ab24b65" xlink:to="loc_us-gaap_StockholdersEquity_21a7863a-b44c-4acc-b287-9eb94847ef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d18b7aa8-c078-4e04-90f2-990363279016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8be5f39b-676b-41f4-a9dd-f73eb73c0f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d18b7aa8-c078-4e04-90f2-990363279016" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8be5f39b-676b-41f4-a9dd-f73eb73c0f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f25826c2-a6fe-44d6-8719-07265398e585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8be5f39b-676b-41f4-a9dd-f73eb73c0f6e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f25826c2-a6fe-44d6-8719-07265398e585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f25826c2-a6fe-44d6-8719-07265398e585" xlink:to="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_4b2f673c-71c8-45b6-86b4-9179daa37434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_4b2f673c-71c8-45b6-86b4-9179daa37434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_99ba6244-2ff7-40d8-a327-5b0db058e6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_99ba6244-2ff7-40d8-a327-5b0db058e6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5d737692-aee9-4337-a231-2f2ffa24f211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb150b56-497c-4743-8718-ec56ca66a21f" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5d737692-aee9-4337-a231-2f2ffa24f211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8be5f39b-676b-41f4-a9dd-f73eb73c0f6e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_43e1d3c5-eab2-4d5e-a7f2-ede7d9cf9e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_43e1d3c5-eab2-4d5e-a7f2-ede7d9cf9e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_7ccbb094-6d97-427c-a9e8-5b6310d93f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_7ccbb094-6d97-427c-a9e8-5b6310d93f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_83fac854-8391-40bb-8396-960a116b5146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76107697-6b1a-4cf3-839e-361b7d9cb914" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_83fac854-8391-40bb-8396-960a116b5146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#NetincomelosspercommonshareDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dc6d90a8-56c5-4f83-a799-3d474ae1f904" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1a1fc91d-eac2-4b36-bda1-e62719bb8fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dc6d90a8-56c5-4f83-a799-3d474ae1f904" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1a1fc91d-eac2-4b36-bda1-e62719bb8fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ddb5d9c5-7b9b-452e-971f-39c0c4aa5a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dc6d90a8-56c5-4f83-a799-3d474ae1f904" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ddb5d9c5-7b9b-452e-971f-39c0c4aa5a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d79cf128-16a5-4e1c-956c-bb303c71face" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ddb5d9c5-7b9b-452e-971f-39c0c4aa5a4b" xlink:to="loc_us-gaap_NetIncomeLoss_d79cf128-16a5-4e1c-956c-bb303c71face" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f9801e24-b1bc-4368-a579-44290b15d150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dc6d90a8-56c5-4f83-a799-3d474ae1f904" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f9801e24-b1bc-4368-a579-44290b15d150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2819f181-061d-4cbf-9765-207873394e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f9801e24-b1bc-4368-a579-44290b15d150" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2819f181-061d-4cbf-9765-207873394e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52ff451-8806-4eea-99ea-92ba7fba3d73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f9801e24-b1bc-4368-a579-44290b15d150" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52ff451-8806-4eea-99ea-92ba7fba3d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f3ba41b-1fa4-47c7-9c6a-4e3b63790017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f9801e24-b1bc-4368-a579-44290b15d150" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f3ba41b-1fa4-47c7-9c6a-4e3b63790017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e01d3b0a-94d2-40bc-9692-379d6dabe363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dc6d90a8-56c5-4f83-a799-3d474ae1f904" xlink:to="loc_us-gaap_EarningsPerShareBasic_e01d3b0a-94d2-40bc-9692-379d6dabe363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_304395c5-2732-442b-a7ec-d522f9b3bd02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dc6d90a8-56c5-4f83-a799-3d474ae1f904" xlink:to="loc_us-gaap_EarningsPerShareDiluted_304395c5-2732-442b-a7ec-d522f9b3bd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_13e1741c-11cb-4ff3-bb8d-1392917923e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dc6d90a8-56c5-4f83-a799-3d474ae1f904" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_13e1741c-11cb-4ff3-bb8d-1392917923e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d81608f0-e8e6-4b8d-abbe-b9eaace22973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d81608f0-e8e6-4b8d-abbe-b9eaace22973" xlink:to="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3721fcc8-27df-402e-8a69-aed53b2e0350" xlink:to="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_bb869e14-b669-45fa-97e3-c874d559c9cf" xlink:href="ebs-20231231.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_UnitedStatesGovernmentMember_bb869e14-b669-45fa-97e3-c874d559c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CustomerTwoMember_502b0afc-66ca-477a-a6a2-e676fe1cbf10" xlink:href="ebs-20231231.xsd#ebs_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_CustomerTwoMember_502b0afc-66ca-477a-a6a2-e676fe1cbf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_6c5c37bd-3a65-4182-815b-5979b3c61ed0" xlink:href="ebs-20231231.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_6c5c37bd-3a65-4182-815b-5979b3c61ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_9f661b77-4717-4a69-918b-1ed2776bfd13" xlink:href="ebs-20231231.xsd#ebs_BARDAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_686a891c-7606-4c5f-b76d-907f098c5087" xlink:to="loc_ebs_BARDAMember_9f661b77-4717-4a69-918b-1ed2776bfd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0367b88a-64bc-4fc3-bb12-b98e8aaf6609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a617bbf4-644b-4789-a4c5-9187bf5aaae2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0367b88a-64bc-4fc3-bb12-b98e8aaf6609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_6a073eea-8ef1-4952-9a94-180b71442dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0367b88a-64bc-4fc3-bb12-b98e8aaf6609" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_6a073eea-8ef1-4952-9a94-180b71442dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_41f25527-a499-4066-87b2-ad63502039ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8bf0ffac-be91-42db-821a-17de5e5ce7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8bf0ffac-be91-42db-821a-17de5e5ce7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_ef0d1307-6233-4bac-bf6c-bc1b1c4b8c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1183bf56-9111-4fe2-b2a8-3683f14c5ca5" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_ef0d1307-6233-4bac-bf6c-bc1b1c4b8c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_073804ef-08af-41b2-8681-e985b0f075c6" xlink:to="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f307e22e-9607-4658-aee7-812239947536" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:to="loc_country_US_f307e22e-9607-4658-aee7-812239947536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_6fd8db6c-81f1-4365-a6d8-4c455d6c05d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_05fd0ff2-8483-47d1-824d-1494a226fcc2" xlink:to="loc_us-gaap_NonUsMember_6fd8db6c-81f1-4365-a6d8-4c455d6c05d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9354c98b-d035-444e-8c73-651066db0375" xlink:to="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember_31c2d147-8a5e-4043-a758-e7c7f2a71c7d" xlink:href="ebs-20231231.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:to="loc_ebs_ReservationOfManufacturingCapacityMember_31c2d147-8a5e-4043-a758-e7c7f2a71c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_f16a28b2-a32b-4ea6-a479-9aef425007b7" xlink:href="ebs-20231231.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_73d8fe71-ee27-4900-b6a8-1b6469784b15" xlink:to="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_f16a28b2-a32b-4ea6-a479-9aef425007b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6699f2a2-de8d-4f69-a13f-449d532817c2" xlink:to="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesLeasesMember_c0be17d6-dd3d-4b6c-91c0-eb84a663ad73" xlink:href="ebs-20231231.xsd#ebs_BioservicesLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:to="loc_ebs_BioservicesLeasesMember_c0be17d6-dd3d-4b6c-91c0-eb84a663ad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_80d77908-55b9-4fa9-ac79-6e84958a0044" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6251ca80-fd60-4f21-af8d-56e1f7801a04" xlink:to="loc_ebs_ContractsAndGrantsMember_80d77908-55b9-4fa9-ac79-6e84958a0044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_99eb1c7f-2298-468c-a12c-6614e032d728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_99eb1c7f-2298-468c-a12c-6614e032d728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f0a323a5-fa47-42e2-83b0-acc4fbb2e3ab" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_d17d525e-ed0c-481b-a624-a31e2efeb2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_NumberOfReportableSegments_d17d525e-ed0c-481b-a624-a31e2efeb2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4fa9f25d-184d-4e77-a5c2-48c4b459acb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4fa9f25d-184d-4e77-a5c2-48c4b459acb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_650c4e50-b1a9-434d-996c-16624755450c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_650c4e50-b1a9-434d-996c-16624755450c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_32f88514-edc3-43c5-a237-2611cb48cbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_32f88514-edc3-43c5-a237-2611cb48cbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5ba4389a-1e0a-4350-bd50-7bf488e66b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5ba4389a-1e0a-4350-bd50-7bf488e66b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_975c9ea4-cc93-430e-8c0c-47108dd34578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_975c9ea4-cc93-430e-8c0c-47108dd34578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_f0c11c15-8ff7-40a8-ab4e-99fa5dbdeb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_f0c11c15-8ff7-40a8-ab4e-99fa5dbdeb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a295bfb-d5be-42db-bef9-a7a9a09ec19b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a295bfb-d5be-42db-bef9-a7a9a09ec19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_31a23ba0-3dc5-4e56-8b08-be891d9a77a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_31a23ba0-3dc5-4e56-8b08-be891d9a77a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_09f0e67f-d641-46b4-9b46-7df3e0c91be1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_09f0e67f-d641-46b4-9b46-7df3e0c91be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_8d7456e9-6158-4509-a200-0f3779cdafad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_8d7456e9-6158-4509-a200-0f3779cdafad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_97ff830f-653c-4b12-b357-7345717602cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_97ff830f-653c-4b12-b357-7345717602cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_730b83f3-2428-4a1b-8c29-4bea161119c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_730b83f3-2428-4a1b-8c29-4bea161119c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_328deecd-b04d-48d9-80a2-899cd8a24c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_328deecd-b04d-48d9-80a2-899cd8a24c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_7b8889a9-360a-4475-aa96-2d59c6d26fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_7b8889a9-360a-4475-aa96-2d59c6d26fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_85ff2546-7d0d-41b2-be54-df1dc106fbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_85ff2546-7d0d-41b2-be54-df1dc106fbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_0ebcf1e7-9478-467a-bc15-d6e3c603ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_0ebcf1e7-9478-467a-bc15-d6e3c603ff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_fbe05050-47ac-43b1-bf61-686ff8c620eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_fbe05050-47ac-43b1-bf61-686ff8c620eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b2db22a4-8ad0-49ea-ad97-9420d5af3af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b2db22a4-8ad0-49ea-ad97-9420d5af3af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_eb5dad55-7677-4e36-9cb4-8652910d1217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4f2ae049-dde2-403d-a32a-238e170352b8" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_eb5dad55-7677-4e36-9cb4-8652910d1217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ea41db24-7b9f-45ff-be62-de5a8f3f2de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2c799566-55db-4eaa-8b63-0f60d422bdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ea41db24-7b9f-45ff-be62-de5a8f3f2de4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2c799566-55db-4eaa-8b63-0f60d422bdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b60f7fb-cf0f-447d-ba02-80dbcd641740" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2c799566-55db-4eaa-8b63-0f60d422bdf8" xlink:to="loc_srt_ProductOrServiceAxis_9b60f7fb-cf0f-447d-ba02-80dbcd641740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9b60f7fb-cf0f-447d-ba02-80dbcd641740" xlink:to="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember_32b5811d-e66e-460f-99a5-8a429c6751a0" xlink:href="ebs-20231231.xsd#ebs_CommercialProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:to="loc_ebs_CommercialProductMember_32b5811d-e66e-460f-99a5-8a429c6751a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember_151d5f74-da8b-47ac-a7a4-0e8cc335e54f" xlink:href="ebs-20231231.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:to="loc_ebs_MedicalCountermeasuresMCMProductMember_151d5f74-da8b-47ac-a7a4-0e8cc335e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesMember_d8733611-6197-4568-9486-c424a639e396" xlink:href="ebs-20231231.xsd#ebs_BioservicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:to="loc_ebs_BioservicesMember_d8733611-6197-4568-9486-c424a639e396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_c3fb4965-91f2-441c-b804-754a939bab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_BioservicesMember_d8733611-6197-4568-9486-c424a639e396" xlink:to="loc_us-gaap_ServiceMember_c3fb4965-91f2-441c-b804-754a939bab7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BioservicesLeasesMember_8aaa65d8-b7d8-45f0-8c87-ac52a0be5c72" xlink:href="ebs-20231231.xsd#ebs_BioservicesLeasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_BioservicesMember_d8733611-6197-4568-9486-c424a639e396" xlink:to="loc_ebs_BioservicesLeasesMember_8aaa65d8-b7d8-45f0-8c87-ac52a0be5c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_370c5551-6820-44ea-b17d-4e46f0b9fa0a" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_36667d87-e7aa-4e27-a26f-211d775d9ac7" xlink:to="loc_ebs_ContractsAndGrantsMember_370c5551-6820-44ea-b17d-4e46f0b9fa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ca684d5b-818b-470d-b420-ea9121821120" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2c799566-55db-4eaa-8b63-0f60d422bdf8" xlink:to="loc_srt_MajorCustomersAxis_ca684d5b-818b-470d-b420-ea9121821120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ce9cba2c-1b91-4088-bc8a-e82b1bbc3504" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ca684d5b-818b-470d-b420-ea9121821120" xlink:to="loc_srt_NameOfMajorCustomerDomain_ce9cba2c-1b91-4088-bc8a-e82b1bbc3504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_9b816af0-24b0-4ccc-99f9-26c18bcbdcd6" xlink:href="ebs-20231231.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ce9cba2c-1b91-4088-bc8a-e82b1bbc3504" xlink:to="loc_ebs_UnitedStatesGovernmentMember_9b816af0-24b0-4ccc-99f9-26c18bcbdcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NonUnitedStatesGovernmentMember_ddedcf73-812b-48a3-a4a1-e17dff95982b" xlink:href="ebs-20231231.xsd#ebs_NonUnitedStatesGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ce9cba2c-1b91-4088-bc8a-e82b1bbc3504" xlink:to="loc_ebs_NonUnitedStatesGovernmentMember_ddedcf73-812b-48a3-a4a1-e17dff95982b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2c799566-55db-4eaa-8b63-0f60d422bdf8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4386edaa-e23a-4a60-b02c-f5fca5ca6616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4386edaa-e23a-4a60-b02c-f5fca5ca6616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_120c7f73-9ec4-4ddb-823b-ec901acec507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_120c7f73-9ec4-4ddb-823b-ec901acec507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d71ff768-3d6b-461e-b261-8d1ef9479d26" xlink:href="ebs-20231231.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d71ff768-3d6b-461e-b261-8d1ef9479d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_144758fc-8873-44cb-9c51-336b0e12fb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e044b21c-4904-477a-825c-4718754cbd40" xlink:to="loc_us-gaap_Revenues_144758fc-8873-44cb-9c51-336b0e12fb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionPercentageofProductSalesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a78ac5be-1717-430e-a270-6843de11731c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a78ac5be-1717-430e-a270-6843de11731c" xlink:to="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_015231e0-07d7-4da2-85e4-d78fdf3919ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:to="loc_srt_ProductOrServiceAxis_015231e0-07d7-4da2-85e4-d78fdf3919ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_015231e0-07d7-4da2-85e4-d78fdf3919ce" xlink:to="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NARCANMember_e820ed96-16d8-4c6e-a40c-fde4318b09b5" xlink:href="ebs-20231231.xsd#ebs_NARCANMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_NARCANMember_e820ed96-16d8-4c6e-a40c-fde4318b09b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherCommercialProductsMember_2affebd6-a6a7-4173-b09b-ab51fee87be5" xlink:href="ebs-20231231.xsd#ebs_OtherCommercialProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_OtherCommercialProductsMember_2affebd6-a6a7-4173-b09b-ab51fee87be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AnthraxMCMMember_331df583-667a-4830-aa8e-b3e264b62172" xlink:href="ebs-20231231.xsd#ebs_AnthraxMCMMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_AnthraxMCMMember_331df583-667a-4830-aa8e-b3e264b62172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SmallpoxMCMMember_57c347a8-c7a4-48fd-b598-d2b9595ac711" xlink:href="ebs-20231231.xsd#ebs_SmallpoxMCMMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_SmallpoxMCMMember_57c347a8-c7a4-48fd-b598-d2b9595ac711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherProductsMember_822de368-c7a2-4b76-95d1-1891b61475b3" xlink:href="ebs-20231231.xsd#ebs_OtherProductsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_17c002b5-229a-4d11-9d83-76a708232f60" xlink:to="loc_ebs_OtherProductsMember_822de368-c7a2-4b76-95d1-1891b61475b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3c56ac32-f908-435c-bf3f-e773e89673a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3c56ac32-f908-435c-bf3f-e773e89673a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9c356a8-89a6-4a25-8bde-bba802fe63ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3c56ac32-f908-435c-bf3f-e773e89673a7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9c356a8-89a6-4a25-8bde-bba802fe63ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_514a3695-3351-4aaf-8cbf-3a689439f866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9c356a8-89a6-4a25-8bde-bba802fe63ae" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_514a3695-3351-4aaf-8cbf-3a689439f866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_91728fe1-5a58-4d3b-8f92-71a4df1928ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_91728fe1-5a58-4d3b-8f92-71a4df1928ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ef3eb6a2-3351-450f-98cf-c7d50580874f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_91728fe1-5a58-4d3b-8f92-71a4df1928ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ef3eb6a2-3351-450f-98cf-c7d50580874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d515586b-5c04-4b61-91a2-1af2291c3b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ef3eb6a2-3351-450f-98cf-c7d50580874f" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d515586b-5c04-4b61-91a2-1af2291c3b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_77c5d13d-f6a6-47f1-931d-3a18919484da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1d309fd3-e567-41e6-9b77-9ce4ac0a8e04" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_77c5d13d-f6a6-47f1-931d-3a18919484da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c060bec2-5b6e-4c33-b579-0dc0c0a9e681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_77c5d13d-f6a6-47f1-931d-3a18919484da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c060bec2-5b6e-4c33-b579-0dc0c0a9e681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5d5f0f1e-3ef5-4f7f-91bd-ac30c435a06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_a264d273-a3ac-4c3a-a833-1642ad1d4b79" xlink:href="ebs-20231231.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5d5f0f1e-3ef5-4f7f-91bd-ac30c435a06a" xlink:to="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_a264d273-a3ac-4c3a-a833-1642ad1d4b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2a8b87be-14bf-4c63-983d-909a42b93490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_a264d273-a3ac-4c3a-a833-1642ad1d4b79" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2a8b87be-14bf-4c63-983d-909a42b93490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c63c2fa1-7e49-47f1-a39c-c2b6ace7b8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_a264d273-a3ac-4c3a-a833-1642ad1d4b79" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c63c2fa1-7e49-47f1-a39c-c2b6ace7b8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5a667e7c-3589-4946-986b-867be097a6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_a264d273-a3ac-4c3a-a833-1642ad1d4b79" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5a667e7c-3589-4946-986b-867be097a6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#RevenuerecognitionAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a4d30dd7-91a8-46e1-8e43-27f9a9c739a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetAbstract_a4e68dff-4274-4fcc-9095-51e1a2de4fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a4d30dd7-91a8-46e1-8e43-27f9a9c739a8" xlink:to="loc_us-gaap_AccountsReceivableNetAbstract_a4e68dff-4274-4fcc-9095-51e1a2de4fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_b65170d1-5b5c-4067-99fb-07cfacd5e022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_a4e68dff-4274-4fcc-9095-51e1a2de4fde" xlink:to="loc_us-gaap_BilledContractReceivables_b65170d1-5b5c-4067-99fb-07cfacd5e022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_65c50294-5da2-4126-b12b-f5196f8c3f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_a4e68dff-4274-4fcc-9095-51e1a2de4fde" xlink:to="loc_us-gaap_UnbilledContractsReceivable_65c50294-5da2-4126-b12b-f5196f8c3f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_af1e6afc-96e2-45a4-8e4e-a671d1838167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_a4e68dff-4274-4fcc-9095-51e1a2de4fde" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_af1e6afc-96e2-45a4-8e4e-a671d1838167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b5965001-d7b0-44f5-9062-89cd0fdaf444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_a4e68dff-4274-4fcc-9095-51e1a2de4fde" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b5965001-d7b0-44f5-9062-89cd0fdaf444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3cd56856-cd60-487f-99da-7573dd76203d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_55abb1e4-21e9-4dd4-9b44-16c8e76fe6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3cd56856-cd60-487f-99da-7573dd76203d" xlink:to="loc_us-gaap_LeaseCostAbstract_55abb1e4-21e9-4dd4-9b44-16c8e76fe6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fe38f77e-03e1-4e62-838c-ab383211860e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_55abb1e4-21e9-4dd4-9b44-16c8e76fe6c3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fe38f77e-03e1-4e62-838c-ab383211860e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_9826173e-ea09-4200-9e1f-a4056ee289ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_55abb1e4-21e9-4dd4-9b44-16c8e76fe6c3" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_9826173e-ea09-4200-9e1f-a4056ee289ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_20125a76-e336-45c2-a408-05fa1259492a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_55abb1e4-21e9-4dd4-9b44-16c8e76fe6c3" xlink:to="loc_us-gaap_LeaseCost_20125a76-e336-45c2-a408-05fa1259492a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c66a41e2-bcb1-4a64-80fc-e111ac86e394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_587e0eda-35ee-44d4-ba68-cf3013ab465e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c66a41e2-bcb1-4a64-80fc-e111ac86e394" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_587e0eda-35ee-44d4-ba68-cf3013ab465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c3f4f4f3-0864-4d9e-9412-2ae75e2659c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c66a41e2-bcb1-4a64-80fc-e111ac86e394" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c3f4f4f3-0864-4d9e-9412-2ae75e2659c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_140a7969-ffc0-4f97-8673-8efb5c87a396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c66a41e2-bcb1-4a64-80fc-e111ac86e394" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_140a7969-ffc0-4f97-8673-8efb5c87a396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_24041d0f-9b87-42f6-a84b-6384086ffe20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c66a41e2-bcb1-4a64-80fc-e111ac86e394" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_24041d0f-9b87-42f6-a84b-6384086ffe20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec32ffb5-ee1b-4b41-acfa-70c934f648b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c66a41e2-bcb1-4a64-80fc-e111ac86e394" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec32ffb5-ee1b-4b41-acfa-70c934f648b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b361be0f-7ea8-4d82-95d6-d714df39f112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c66a41e2-bcb1-4a64-80fc-e111ac86e394" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b361be0f-7ea8-4d82-95d6-d714df39f112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_68907689-a921-4220-b3e6-5b6c46b1a488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c66a41e2-bcb1-4a64-80fc-e111ac86e394" xlink:to="loc_us-gaap_OperatingLeaseLiability_68907689-a921-4220-b3e6-5b6c46b1a488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_fb530527-8225-4881-9f5d-d5935fc71c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c66a41e2-bcb1-4a64-80fc-e111ac86e394" xlink:to="loc_us-gaap_LeaseCostAbstract_fb530527-8225-4881-9f5d-d5935fc71c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_07b46893-ddae-4d15-a3a1-33515a449a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_fb530527-8225-4881-9f5d-d5935fc71c0a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_07b46893-ddae-4d15-a3a1-33515a449a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9f38199d-4de2-463f-95ac-e8731bb14583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_fb530527-8225-4881-9f5d-d5935fc71c0a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9f38199d-4de2-463f-95ac-e8731bb14583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0b3c619d-f2e6-4187-84f6-ce3f34107041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8f6ea6ad-cbfa-4533-b58f-f9a5b21ab9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b3c619d-f2e6-4187-84f6-ce3f34107041" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8f6ea6ad-cbfa-4533-b58f-f9a5b21ab9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36915cad-3a53-42fb-8caa-24bd985ae493" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8f6ea6ad-cbfa-4533-b58f-f9a5b21ab9e5" xlink:to="loc_srt_RangeAxis_36915cad-3a53-42fb-8caa-24bd985ae493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f37500c-56b0-4a3c-a2dc-9b3352a717d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_36915cad-3a53-42fb-8caa-24bd985ae493" xlink:to="loc_srt_RangeMember_7f37500c-56b0-4a3c-a2dc-9b3352a717d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2b4900af-cd5a-4032-97c0-f232e0f46e24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7f37500c-56b0-4a3c-a2dc-9b3352a717d6" xlink:to="loc_srt_MinimumMember_2b4900af-cd5a-4032-97c0-f232e0f46e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb09721f-d200-4543-9f22-9007fee52ff7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7f37500c-56b0-4a3c-a2dc-9b3352a717d6" xlink:to="loc_srt_MaximumMember_fb09721f-d200-4543-9f22-9007fee52ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2924c3e4-0592-4fbb-92bd-09f7493c49be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8f6ea6ad-cbfa-4533-b58f-f9a5b21ab9e5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_2924c3e4-0592-4fbb-92bd-09f7493c49be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_eb49c590-29b4-461b-87fa-79f148d1840e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2924c3e4-0592-4fbb-92bd-09f7493c49be" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_eb49c590-29b4-461b-87fa-79f148d1840e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_23482494-0863-4b36-a4be-a2935ffdb6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2924c3e4-0592-4fbb-92bd-09f7493c49be" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_23482494-0863-4b36-a4be-a2935ffdb6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_43dee40a-0b80-459f-b4be-91a942ce95c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_43dee40a-0b80-459f-b4be-91a942ce95c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b8594350-6364-4e36-a174-77df1b1b4416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b8594350-6364-4e36-a174-77df1b1b4416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f512684a-4f59-452c-85af-0133c2250b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f512684a-4f59-452c-85af-0133c2250b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4216b5ca-a2f0-4810-b58a-d3ed148e664b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4216b5ca-a2f0-4810-b58a-d3ed148e664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7233b134-e7dc-438e-9433-9d002fbe37a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7233b134-e7dc-438e-9433-9d002fbe37a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_79dad2e1-cbde-44bb-8d2d-c03cd9626cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_79dad2e1-cbde-44bb-8d2d-c03cd9626cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a36f85c7-161e-4834-bf27-b22f95e04b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a36f85c7-161e-4834-bf27-b22f95e04b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff2c7e78-fa92-4439-9ac7-a3a097a997e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff2c7e78-fa92-4439-9ac7-a3a097a997e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d1cfb565-ba81-4e76-a20b-ea6d291bafab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9774e95-399b-4f33-9a36-4436a2b57d43" xlink:to="loc_us-gaap_OperatingLeaseLiability_d1cfb565-ba81-4e76-a20b-ea6d291bafab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ebs-20231231.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f0336be0-d2f8-4ae4-a5e4-6b9f667e33cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0336be0-d2f8-4ae4-a5e4-6b9f667e33cd" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_289b811d-fec2-4c55-abda-8f4aa93eff67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_289b811d-fec2-4c55-abda-8f4aa93eff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_289b811d-fec2-4c55-abda-8f4aa93eff67" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8b56f6a8-27dc-4f64-827d-e7174e0e9c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:to="loc_us-gaap_DomesticCountryMember_8b56f6a8-27dc-4f64-827d-e7174e0e9c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_359924b2-5a5d-4c2a-8436-561e0fd71831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_359924b2-5a5d-4c2a-8436-561e0fd71831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_3f3ca23d-40da-468d-8413-220faf42b713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_602882cf-d67d-4282-848d-b5e243308641" xlink:to="loc_us-gaap_ForeignCountryMember_3f3ca23d-40da-468d-8413-220faf42b713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_197c0cb1-9135-4f9c-b288-5f4e55b6ca76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_197c0cb1-9135-4f9c-b288-5f4e55b6ca76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_b85674b2-62ee-454b-b7a7-59b50466ebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_197c0cb1-9135-4f9c-b288-5f4e55b6ca76" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_b85674b2-62ee-454b-b7a7-59b50466ebb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_7963413b-1fe4-4c34-97f5-18e8d6f8c960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_b85674b2-62ee-454b-b7a7-59b50466ebb2" xlink:to="loc_us-gaap_ResearchMember_7963413b-1fe4-4c34-97f5-18e8d6f8c960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_32884107-f4ef-455b-a677-2fbe5626bd5d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:to="loc_srt_StatementGeographicalAxis_32884107-f4ef-455b-a677-2fbe5626bd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4b6d9d0a-1f7c-4aad-ae91-f8279274ad54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_32884107-f4ef-455b-a677-2fbe5626bd5d" xlink:to="loc_srt_SegmentGeographicalDomain_4b6d9d0a-1f7c-4aad-ae91-f8279274ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_191311a4-083a-4ed3-81d2-2618467cd0bd" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4b6d9d0a-1f7c-4aad-ae91-f8279274ad54" xlink:to="loc_stpr_CA_191311a4-083a-4ed3-81d2-2618467cd0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4e569499-f17f-43a3-9ebe-be696fde3e5e" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount_847ae571-ce68-4225-9147-0aa4e51a8d0c" xlink:href="ebs-20231231.xsd#ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount_847ae571-ce68-4225-9147-0aa4e51a8d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_c3f1ef11-6b3c-4fca-a0d7-2121d9070b64" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxLiabilitiesForeignWithholdingTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_c3f1ef11-6b3c-4fca-a0d7-2121d9070b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6b9cb206-93ef-4992-9ac6-ad69f70672a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6b9cb206-93ef-4992-9ac6-ad69f70672a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLossCarryforwardsSubjectToExpiration_17448cd4-09b8-42ea-a006-2a02d995d9ad" xlink:href="ebs-20231231.xsd#ebs_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_OperatingLossCarryforwardsSubjectToExpiration_17448cd4-09b8-42ea-a006-2a02d995d9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLossCarryforwardsNotSubjectToExpiration_d9471840-a979-4dbf-bac4-48c5add2d769" xlink:href="ebs-20231231.xsd#ebs_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_OperatingLossCarryforwardsNotSubjectToExpiration_d9471840-a979-4dbf-bac4-48c5add2d769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e3aedced-1c23-4976-9438-e5e6114d3bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e3aedced-1c23-4976-9438-e5e6114d3bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5514279b-c36a-4bf1-84ba-b4ab7b69b9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5514279b-c36a-4bf1-84ba-b4ab7b69b9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6bec7aa4-9656-4344-b2c7-1aa9df319730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6bec7aa4-9656-4344-b2c7-1aa9df319730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnrecognizedTaxBenefitsNoncurrent_8ffddd3e-aa78-4222-802e-3b3523552227" xlink:href="ebs-20231231.xsd#ebs_UnrecognizedTaxBenefitsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_ebs_UnrecognizedTaxBenefitsNoncurrent_8ffddd3e-aa78-4222-802e-3b3523552227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_489dc485-b0e4-4c21-9c67-8f968fafcdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_489dc485-b0e4-4c21-9c67-8f968fafcdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_64926800-b989-4059-a758-24b31e154ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_64926800-b989-4059-a758-24b31e154ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3e66d2d0-a19e-48e2-a389-6560ff49ddfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3e66d2d0-a19e-48e2-a389-6560ff49ddfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d7de6914-3859-4424-8fae-b965456e6c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cbb98f86-7193-4a1f-80ac-3422cbf6a4e4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d7de6914-3859-4424-8fae-b965456e6c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b95c3a59-b11e-43d5-af96-d6c41c2c75b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6f55946b-f6c4-449c-9cef-1ef12856718f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b95c3a59-b11e-43d5-af96-d6c41c2c75b3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6f55946b-f6c4-449c-9cef-1ef12856718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d38bc0db-1c74-4d9e-94fb-3a72a53c4342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6f55946b-f6c4-449c-9cef-1ef12856718f" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d38bc0db-1c74-4d9e-94fb-3a72a53c4342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f0c3a3ef-55cb-4638-9718-b32358f9b6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6f55946b-f6c4-449c-9cef-1ef12856718f" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f0c3a3ef-55cb-4638-9718-b32358f9b6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_54b22d05-c78b-45b0-8ffc-c7ffdb3f4d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6f55946b-f6c4-449c-9cef-1ef12856718f" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_54b22d05-c78b-45b0-8ffc-c7ffdb3f4d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a86353f3-1654-42d8-8682-06eff35f6f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6f55946b-f6c4-449c-9cef-1ef12856718f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a86353f3-1654-42d8-8682-06eff35f6f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9a81d285-750e-4906-9a79-763e79edd13d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b95c3a59-b11e-43d5-af96-d6c41c2c75b3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9a81d285-750e-4906-9a79-763e79edd13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7ebf4249-777e-4a3b-8530-70e656b0e43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9a81d285-750e-4906-9a79-763e79edd13d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7ebf4249-777e-4a3b-8530-70e656b0e43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_aa68a21c-69b9-474b-a85f-2f5ee0e21653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9a81d285-750e-4906-9a79-763e79edd13d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_aa68a21c-69b9-474b-a85f-2f5ee0e21653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a4e360f3-5f4c-4d8d-80e4-c0a3c6edfdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9a81d285-750e-4906-9a79-763e79edd13d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a4e360f3-5f4c-4d8d-80e4-c0a3c6edfdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_10e2395b-8504-4ee9-a455-a31d134eb1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9a81d285-750e-4906-9a79-763e79edd13d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_10e2395b-8504-4ee9-a455-a31d134eb1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a67d25e5-4ab3-475a-b914-7b857bd2b2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b95c3a59-b11e-43d5-af96-d6c41c2c75b3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a67d25e5-4ab3-475a-b914-7b857bd2b2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesNetDeferredTaxAssetLiabilityDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f1125620-4d54-4d61-b901-271cea1da56e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f1125620-4d54-4d61-b901-271cea1da56e" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_559f0068-2271-46e6-8f6a-1c42d86f4fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_559f0068-2271-46e6-8f6a-1c42d86f4fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a8b4f375-87b5-4edd-973e-8d58e3376a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a8b4f375-87b5-4edd-973e-8d58e3376a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5d11a6c4-55d8-41af-82a4-7a998016bdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5d11a6c4-55d8-41af-82a4-7a998016bdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_99ae7395-8df5-43c1-aa6d-a588cefbd228" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_99ae7395-8df5-43c1-aa6d-a588cefbd228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_fd156cf2-5ccf-40d8-ac56-eeae4320b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_fd156cf2-5ccf-40d8-ac56-eeae4320b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_51cdc30d-a5ac-4d59-bcb0-f13f62ab7539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_51cdc30d-a5ac-4d59-bcb0-f13f62ab7539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_0608593c-a91d-4f58-9373-0f5c1bebad51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_0608593c-a91d-4f58-9373-0f5c1bebad51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsOperatingLeaseLiability_4a370e85-e63c-46ea-ad39-4dc282d4a4c8" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_ebs_DeferredTaxAssetsOperatingLeaseLiability_4a370e85-e63c-46ea-ad39-4dc282d4a4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts_cb279c56-1c41-44f8-b929-610eea427b5b" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts_cb279c56-1c41-44f8-b929-610eea427b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment_c54fa61b-1862-42c0-9df7-bda15bed089b" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment_c54fa61b-1862-42c0-9df7-bda15bed089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_169c59ab-1a71-4a86-9321-b1adf4eca727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_169c59ab-1a71-4a86-9321-b1adf4eca727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b122517c-9d61-422a-affc-e6a3fc2c6ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b122517c-9d61-422a-affc-e6a3fc2c6ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxAssetsIntangibleAssets_d3ad0b5c-5fcd-4e9a-bafb-f1a625372ce1" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxAssetsIntangibleAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_ebs_DeferredTaxAssetsIntangibleAssets_d3ad0b5c-5fcd-4e9a-bafb-f1a625372ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b44d5a93-7d75-43f0-a650-ea9708dde664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b44d5a93-7d75-43f0-a650-ea9708dde664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e0b9fc0a-6c8c-4119-902d-d19a872757d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e0b9fc0a-6c8c-4119-902d-d19a872757d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e6385669-fce8-4b47-a405-fbcfa8fec072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e6385669-fce8-4b47-a405-fbcfa8fec072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_678dd8a1-12fd-4deb-a3b5-bde2fbef6bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_678dd8a1-12fd-4deb-a3b5-bde2fbef6bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7e693d3d-3849-4a27-b45e-ebceb86d93f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5a321170-c87a-444d-a515-ef015e236ac8" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7e693d3d-3849-4a27-b45e-ebceb86d93f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a51c75e4-6603-439c-80e6-1ed131290c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f1125620-4d54-4d61-b901-271cea1da56e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a51c75e4-6603-439c-80e6-1ed131290c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_68c5078f-50f6-46e8-9672-f5e7e3cccc58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a51c75e4-6603-439c-80e6-1ed131290c87" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_68c5078f-50f6-46e8-9672-f5e7e3cccc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ee951074-74d6-4307-8469-a1ad7150b39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a51c75e4-6603-439c-80e6-1ed131290c87" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ee951074-74d6-4307-8469-a1ad7150b39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_add412b3-f3d3-4863-8e2c-3cdffd9dcefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a51c75e4-6603-439c-80e6-1ed131290c87" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_add412b3-f3d3-4863-8e2c-3cdffd9dcefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_90528ff7-4313-4123-8739-a58136d74ca1" xlink:href="ebs-20231231.xsd#ebs_DeferredTaxLiabilitiesForeignWithholdingTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a51c75e4-6603-439c-80e6-1ed131290c87" xlink:to="loc_ebs_DeferredTaxLiabilitiesForeignWithholdingTax_90528ff7-4313-4123-8739-a58136d74ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_61207d29-c7ad-4953-ad12-88df299757d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a51c75e4-6603-439c-80e6-1ed131290c87" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_61207d29-c7ad-4953-ad12-88df299757d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_2c8c44b8-f2a1-4218-ad57-f6bd2611aff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a51c75e4-6603-439c-80e6-1ed131290c87" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_2c8c44b8-f2a1-4218-ad57-f6bd2611aff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_761201ea-8064-4bf1-a59b-221394f96946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a51c75e4-6603-439c-80e6-1ed131290c87" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_761201ea-8064-4bf1-a59b-221394f96946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_201d2ce8-efcc-4a74-a47a-7fcf1d201b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f1125620-4d54-4d61-b901-271cea1da56e" xlink:to="loc_us-gaap_DeferredTaxLiabilities_201d2ce8-efcc-4a74-a47a-7fcf1d201b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e33fe73e-279f-4de4-b03f-f2bc02524c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e33fe73e-279f-4de4-b03f-f2bc02524c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d68e1090-9ccb-4e15-9274-77b5e8c17d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d68e1090-9ccb-4e15-9274-77b5e8c17d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d764a977-eda8-4981-b70d-9d83e33c8e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_d764a977-eda8-4981-b70d-9d83e33c8e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c147371b-29b9-4d31-a3e7-18f83e5086de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c147371b-29b9-4d31-a3e7-18f83e5086de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5fbd8963-4726-44f7-892c-a07124eeeca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5fbd8963-4726-44f7-892c-a07124eeeca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5ada63ff-fc33-424b-8f3e-4b6a34f9d132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5ada63ff-fc33-424b-8f3e-4b6a34f9d132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7005ecd0-e221-4085-8b29-32be6f139fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7005ecd0-e221-4085-8b29-32be6f139fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_99e2a8d6-e233-4fc9-b910-b89fbf099e67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_99e2a8d6-e233-4fc9-b910-b89fbf099e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6af3fe50-e823-4317-a538-7f90cc077b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6af3fe50-e823-4317-a538-7f90cc077b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_f01649d4-2800-4420-ad8f-d3febccfb0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_f01649d4-2800-4420-ad8f-d3febccfb0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_4f957b88-bbf1-4007-bc5d-06d710d79766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_4f957b88-bbf1-4007-bc5d-06d710d79766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts_3540a48f-6033-4a22-8d7d-500d36bef4a6" xlink:href="ebs-20231231.xsd#ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts_3540a48f-6033-4a22-8d7d-500d36bef4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount_572e4b8a-13b9-48cd-8a58-fbefbfbb0913" xlink:href="ebs-20231231.xsd#ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount_572e4b8a-13b9-48cd-8a58-fbefbfbb0913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_c53d8a6f-587c-4c54-8647-5da7e2db544a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_c53d8a6f-587c-4c54-8647-5da7e2db544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_8bfbcf94-4abe-490b-ba04-05fca457edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_8bfbcf94-4abe-490b-ba04-05fca457edd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_c63d59d1-2bdc-49ad-a799-2770411e2b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_c63d59d1-2bdc-49ad-a799-2770411e2b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference_de4d23e7-e292-4984-a2ba-18069c52b147" xlink:href="ebs-20231231.xsd#ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference_de4d23e7-e292-4984-a2ba-18069c52b147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_776bbd98-c532-4f01-a065-ec4cc16592f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b49913-c197-4c71-ab80-0f5ac22052d0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_776bbd98-c532-4f01-a065-ec4cc16592f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#IncometaxesUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1406a3a4-bb0e-44a3-9525-815a30435dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a09f65b7-3b88-4b7f-a62c-e16893bcc438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1406a3a4-bb0e-44a3-9525-815a30435dd1" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a09f65b7-3b88-4b7f-a62c-e16893bcc438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6c1c1c80-2f71-4433-8dd9-b97e4bfaa9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a09f65b7-3b88-4b7f-a62c-e16893bcc438" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6c1c1c80-2f71-4433-8dd9-b97e4bfaa9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f23608a7-13da-4b83-a9d6-5fefa84d96ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a09f65b7-3b88-4b7f-a62c-e16893bcc438" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f23608a7-13da-4b83-a9d6-5fefa84d96ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_58b7a046-03b9-443d-9462-532954a6a23c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a09f65b7-3b88-4b7f-a62c-e16893bcc438" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_58b7a046-03b9-443d-9462-532954a6a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b8e09d7a-0e0c-448a-b6df-e6425d395cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a09f65b7-3b88-4b7f-a62c-e16893bcc438" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b8e09d7a-0e0c-448a-b6df-e6425d395cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_db356128-4feb-4035-b5aa-c9e7fa22d3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a09f65b7-3b88-4b7f-a62c-e16893bcc438" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_db356128-4feb-4035-b5aa-c9e7fa22d3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e1082e3e-7e9b-4d51-b5f6-796f5f3ce6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a09f65b7-3b88-4b7f-a62c-e16893bcc438" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e1082e3e-7e9b-4d51-b5f6-796f5f3ce6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c39b8a26-8755-497b-8018-8f8582e175c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a09f65b7-3b88-4b7f-a62c-e16893bcc438" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c39b8a26-8755-497b-8018-8f8582e175c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b80f71d3-b490-4f52-8066-d01440e045cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b80f71d3-b490-4f52-8066-d01440e045cd" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_da80b4e6-d039-48f4-a9f3-b8a3b7b96b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_da80b4e6-d039-48f4-a9f3-b8a3b7b96b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_bab8c4b0-65e6-4936-9d99-3079395ecd16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_bab8c4b0-65e6-4936-9d99-3079395ecd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_e3ebcadd-4e57-447e-a1ac-b8fe645fc6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_e3ebcadd-4e57-447e-a1ac-b8fe645fc6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_c63bedda-15ab-4e99-a9ca-a9a40874371d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_c63bedda-15ab-4e99-a9ca-a9a40874371d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_8424d44e-1435-4bf6-81d7-af465198e961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_8424d44e-1435-4bf6-81d7-af465198e961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_a07d581c-200e-4378-8fda-874d63d9e866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_a07d581c-200e-4378-8fda-874d63d9e866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_34f988be-8d77-42a9-bbfc-c16daae197c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_34f988be-8d77-42a9-bbfc-c16daae197c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_be353833-7c8e-4899-8b7a-27d195feb61b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de995312-696d-4428-b424-f469483e468c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_be353833-7c8e-4899-8b7a-27d195feb61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b80f71d3-b490-4f52-8066-d01440e045cd" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ecea44e1-e586-4548-857c-f044c33c36f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ecea44e1-e586-4548-857c-f044c33c36f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_8f501636-fc7d-45de-bcc0-1eea2bb048df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_8f501636-fc7d-45de-bcc0-1eea2bb048df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_e9958304-43ee-490e-8c35-52cd1f2a35f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_e9958304-43ee-490e-8c35-52cd1f2a35f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_144dadf4-e509-499c-bbd2-b1c3316312a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_144dadf4-e509-499c-bbd2-b1c3316312a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_604ad929-228f-433e-a3db-ac5c61bb26b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_604ad929-228f-433e-a3db-ac5c61bb26b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2addfe84-c7f3-4b51-9a85-763bb44586cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2addfe84-c7f3-4b51-9a85-763bb44586cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_273ec909-95e5-495b-bdbd-2b94f75ee390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_273ec909-95e5-495b-bdbd-2b94f75ee390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4c324181-89c0-4b13-9eb9-e6a856e94a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4c324181-89c0-4b13-9eb9-e6a856e94a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_42f06392-f12b-47a2-8904-5ea775b394bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42ed76d5-01f5-43a5-88d8-2216dc1e0846" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_42f06392-f12b-47a2-8904-5ea775b394bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_d1782b06-c96f-4cbf-bcde-e86a45c8fd09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b80f71d3-b490-4f52-8066-d01440e045cd" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_d1782b06-c96f-4cbf-bcde-e86a45c8fd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_363ab9f4-8063-43ab-82f9-472f1f49b647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b80f71d3-b490-4f52-8066-d01440e045cd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_363ab9f4-8063-43ab-82f9-472f1f49b647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8873623-9fc4-4575-80ac-704fc30918e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_dd355b67-a169-4573-ba47-19031d218851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8873623-9fc4-4575-80ac-704fc30918e3" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_dd355b67-a169-4573-ba47-19031d218851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_9d81da79-4723-48d2-95b6-ef9832b92647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8873623-9fc4-4575-80ac-704fc30918e3" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_9d81da79-4723-48d2-95b6-ef9832b92647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_407a9880-aecb-4b93-b006-8a8c67b1f142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8873623-9fc4-4575-80ac-704fc30918e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_407a9880-aecb-4b93-b006-8a8c67b1f142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7009e987-7788-4fd4-abcc-5581c5878e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8873623-9fc4-4575-80ac-704fc30918e3" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7009e987-7788-4fd4-abcc-5581c5878e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f649e8aa-62de-45f1-a118-77d75e91ff8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8873623-9fc4-4575-80ac-704fc30918e3" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f649e8aa-62de-45f1-a118-77d75e91ff8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_16ce8608-ee56-49fd-a04d-ff55daaa97ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8873623-9fc4-4575-80ac-704fc30918e3" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_16ce8608-ee56-49fd-a04d-ff55daaa97ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8be59af6-0b24-4548-a7a2-a79e7618fbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8873623-9fc4-4575-80ac-704fc30918e3" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8be59af6-0b24-4548-a7a2-a79e7618fbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#Definedbenefitand401ksavingsplanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9a182bad-a72e-44f1-8c3e-a8d57504715d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense_13ea145f-bd1a-4fe1-bbbd-6f0170038652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9a182bad-a72e-44f1-8c3e-a8d57504715d" xlink:to="loc_us-gaap_PensionExpense_13ea145f-bd1a-4fe1-bbbd-6f0170038652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_d08d2639-b26f-4dec-b942-7458307235b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9a182bad-a72e-44f1-8c3e-a8d57504715d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_d08d2639-b26f-4dec-b942-7458307235b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_30cc8384-defd-4cad-9a3a-9056b2c7bccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5f937717-6564-4850-90ee-d698792ecdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_30cc8384-defd-4cad-9a3a-9056b2c7bccb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5f937717-6564-4850-90ee-d698792ecdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_48c7d4ae-d149-42d8-9266-ea99d0d89a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_30cc8384-defd-4cad-9a3a-9056b2c7bccb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_48c7d4ae-d149-42d8-9266-ea99d0d89a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_096044ae-c3b0-4f3b-8793-123a3781bcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_30cc8384-defd-4cad-9a3a-9056b2c7bccb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_096044ae-c3b0-4f3b-8793-123a3781bcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a3f42940-d21e-4e5b-ada4-09b71463a9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_f9df3d29-90f9-45d6-b233-49e305067d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a3f42940-d21e-4e5b-ada4-09b71463a9f7" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_f9df3d29-90f9-45d6-b233-49e305067d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_65297a3a-9358-45dc-9e8a-b0f54299f869" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a3f42940-d21e-4e5b-ada4-09b71463a9f7" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_65297a3a-9358-45dc-9e8a-b0f54299f869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_fc7d7966-4615-4fe7-81c8-4769ce18465f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a3f42940-d21e-4e5b-ada4-09b71463a9f7" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_fc7d7966-4615-4fe7-81c8-4769ce18465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PurchasecommitmentsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#PurchasecommitmentsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PurchasecommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_70b144cc-935e-4d2e-a2cd-bbd87920637d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_bd642347-ba9a-4171-a9d0-03bebd352984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_70b144cc-935e-4d2e-a2cd-bbd87920637d" xlink:to="loc_us-gaap_PurchaseObligation_bd642347-ba9a-4171-a9d0-03bebd352984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_7d82daad-8f2a-48f4-a2f2-855c2c9bde99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_70b144cc-935e-4d2e-a2cd-bbd87920637d" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_7d82daad-8f2a-48f4-a2f2-855c2c9bde99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_d4ac9a8b-b70a-43f4-9ed0-5dc9ab03547a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_70b144cc-935e-4d2e-a2cd-bbd87920637d" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_d4ac9a8b-b70a-43f4-9ed0-5dc9ab03547a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_3657022d-a780-4492-ace6-fe0757e29584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_70b144cc-935e-4d2e-a2cd-bbd87920637d" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_3657022d-a780-4492-ace6-fe0757e29584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_044735f7-e6b4-44e0-9dd9-8e858bbb0e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_714ab28e-6b9b-42c2-81a9-d5521a6cd552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_044735f7-e6b4-44e0-9dd9-8e858bbb0e26" xlink:to="loc_us-gaap_NumberOfReportableSegments_714ab28e-6b9b-42c2-81a9-d5521a6cd552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e0db6020-149c-4734-98f5-25924bb23d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e0db6020-149c-4734-98f5-25924bb23d8e" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_376f50f4-1057-4a6c-8152-0adb3e9b726a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_376f50f4-1057-4a6c-8152-0adb3e9b726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_376f50f4-1057-4a6c-8152-0adb3e9b726a" xlink:to="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_cbb13ddb-8c9e-43d5-9f7e-35abf8ad5268" xlink:href="ebs-20231231.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:to="loc_ebs_CommercialProductsSegmentMember_cbb13ddb-8c9e-43d5-9f7e-35abf8ad5268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_5be19b26-127c-4f55-8287-6e0bcec6c04b" xlink:href="ebs-20231231.xsd#ebs_MCMProductsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:to="loc_ebs_MCMProductsSegmentMember_5be19b26-127c-4f55-8287-6e0bcec6c04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_203275d9-f24e-4c53-b0e8-7e8a3e5331a6" xlink:href="ebs-20231231.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b2a3602c-e582-453e-9b8d-9b53826d3d59" xlink:to="loc_ebs_ServicesSegmentMember_203275d9-f24e-4c53-b0e8-7e8a3e5331a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5187d25-0efa-4edd-88ea-6fe66614fb16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:to="loc_srt_ProductOrServiceAxis_e5187d25-0efa-4edd-88ea-6fe66614fb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_77cdc7c5-7f3a-4222-9248-c5a6ca86765c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e5187d25-0efa-4edd-88ea-6fe66614fb16" xlink:to="loc_srt_ProductsAndServicesDomain_77cdc7c5-7f3a-4222-9248-c5a6ca86765c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_1d366b39-9b26-43eb-a7b3-c7bb910c08b9" xlink:href="ebs-20231231.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_77cdc7c5-7f3a-4222-9248-c5a6ca86765c" xlink:to="loc_ebs_ContractsAndGrantsMember_1d366b39-9b26-43eb-a7b3-c7bb910c08b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1c14b8ba-fe35-419b-924d-e22b222890c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:to="loc_srt_MajorCustomersAxis_1c14b8ba-fe35-419b-924d-e22b222890c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5ff95b33-b7e9-462f-9e0b-2fb1cd80ccda" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1c14b8ba-fe35-419b-924d-e22b222890c1" xlink:to="loc_srt_NameOfMajorCustomerDomain_5ff95b33-b7e9-462f-9e0b-2fb1cd80ccda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_e9c9d48b-a26c-4143-9e48-ef6df12f6da1" xlink:href="ebs-20231231.xsd#ebs_BARDAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5ff95b33-b7e9-462f-9e0b-2fb1cd80ccda" xlink:to="loc_ebs_BARDAMember_e9c9d48b-a26c-4143-9e48-ef6df12f6da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_72babbaf-34a1-4c3b-9ac9-8d89a960c044" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:to="loc_srt_ConsolidationItemsAxis_72babbaf-34a1-4c3b-9ac9-8d89a960c044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_799ca22e-b7da-4100-bed4-a6664b7a25ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_72babbaf-34a1-4c3b-9ac9-8d89a960c044" xlink:to="loc_srt_ConsolidationItemsDomain_799ca22e-b7da-4100-bed4-a6664b7a25ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8132a1cc-14e2-417c-8834-3c4786b6241f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_799ca22e-b7da-4100-bed4-a6664b7a25ee" xlink:to="loc_us-gaap_OperatingSegmentsMember_8132a1cc-14e2-417c-8834-3c4786b6241f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_ee28e980-9854-4ccd-8b5e-5b901f5d133a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_799ca22e-b7da-4100-bed4-a6664b7a25ee" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_ee28e980-9854-4ccd-8b5e-5b901f5d133a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d3b835da-fe1e-41c6-ba16-3dc093a1d39b" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_25d812c9-bd11-47b8-9893-e6e086f070b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_25d812c9-bd11-47b8-9893-e6e086f070b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_dcea717a-d1b5-4ba3-80f7-3a4437d0ea99" xlink:href="ebs-20231231.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_dcea717a-d1b5-4ba3-80f7-3a4437d0ea99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_146d132a-963a-41a1-ab72-63861fe9f765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_03569d59-155e-4137-b3f9-7222e3368153" xlink:to="loc_us-gaap_Revenues_146d132a-963a-41a1-ab72-63861fe9f765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_463adbfc-6e55-4a19-a667-29f93b9dcf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_463adbfc-6e55-4a19-a667-29f93b9dcf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6f0439d6-4a8e-4cf8-8fc2-fdaaa23fc872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_463adbfc-6e55-4a19-a667-29f93b9dcf3f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6f0439d6-4a8e-4cf8-8fc2-fdaaa23fc872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_3fee109f-db3d-420e-8e9c-da3841d5562c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_GrossProfit_3fee109f-db3d-420e-8e9c-da3841d5562c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_GrossProfitPercentage_366f4179-3d91-43a8-8397-03a976bcc709" xlink:href="ebs-20231231.xsd#ebs_GrossProfitPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_ebs_GrossProfitPercentage_366f4179-3d91-43a8-8397-03a976bcc709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_19252944-473d-4d16-9a93-026149ecd9b3" xlink:href="ebs-20231231.xsd#ebs_AdjustedGrossMargin"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_ebs_AdjustedGrossMargin_19252944-473d-4d16-9a93-026149ecd9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_8e61f1d4-cdc0-418d-b11e-58bda60b343a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_8e61f1d4-cdc0-418d-b11e-58bda60b343a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9682cc7b-d28d-4de8-83fd-3a7b3c1a3d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_RestructuringCharges_9682cc7b-d28d-4de8-83fd-3a7b3c1a3d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_InventoryStepUp_b08ef398-7b79-44b4-890c-4558fa305e89" xlink:href="ebs-20231231.xsd#ebs_InventoryStepUp"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_ebs_InventoryStepUp_b08ef398-7b79-44b4-890c-4558fa305e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_549f216e-a39e-4287-8324-894f0aae01d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_549f216e-a39e-4287-8324-894f0aae01d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0d789d76-b0a5-4b5a-993f-a84c159d933b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0d789d76-b0a5-4b5a-993f-a84c159d933b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_56bfcc01-a867-4a58-8de9-3780118910d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_56bfcc01-a867-4a58-8de9-3780118910d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8a1abd27-1878-4b10-8a5d-6b6abb1ba2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8a1abd27-1878-4b10-8a5d-6b6abb1ba2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5d8802e4-ea77-42e2-836a-a81ea036a39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5d8802e4-ea77-42e2-836a-a81ea036a39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8ea5051d-2d94-4658-8a30-8c81b6a31c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8ea5051d-2d94-4658-8a30-8c81b6a31c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_19eb398d-0c2a-46a0-b3df-18c5b0cbbd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_InterestExpense_19eb398d-0c2a-46a0-b3df-18c5b0cbbd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_eb19343e-9677-4e2a-8f5c-687818f6f523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_eb19343e-9677-4e2a-8f5c-687818f6f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2b85c9ae-8009-44cc-a104-a062a316f63c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_584c8365-7b96-48a8-ab63-cec468e57c95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2b85c9ae-8009-44cc-a104-a062a316f63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b6410c6b-84d9-4464-97be-1026e6ebbf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0e9a5fde-4c77-4a11-8748-6c04a7148d7b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b6410c6b-84d9-4464-97be-1026e6ebbf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_178c50fa-3aa1-4225-8b95-7d8b226f3bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_51b7d2b0-8d2d-41cc-bba4-295f2fffbac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_178c50fa-3aa1-4225-8b95-7d8b226f3bf5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_51b7d2b0-8d2d-41cc-bba4-295f2fffbac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8d870430-148a-416c-9702-23b9186c51b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_51b7d2b0-8d2d-41cc-bba4-295f2fffbac7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8d870430-148a-416c-9702-23b9186c51b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8d870430-148a-416c-9702-23b9186c51b4" xlink:to="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_ae1a07db-9b2c-4f22-b042-48e76fdbae1d" xlink:href="ebs-20231231.xsd#ebs_MCMProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:to="loc_ebs_MCMProductsSegmentMember_ae1a07db-9b2c-4f22-b042-48e76fdbae1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_7020feaa-fe46-42e9-97f5-e133c3bb1889" xlink:href="ebs-20231231.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:to="loc_ebs_CommercialProductsSegmentMember_7020feaa-fe46-42e9-97f5-e133c3bb1889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_a46fc306-0886-4a20-8251-97a1825f6d5e" xlink:href="ebs-20231231.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c24742ad-850c-40bf-89f6-1ff60c81de0f" xlink:to="loc_ebs_ServicesSegmentMember_a46fc306-0886-4a20-8251-97a1825f6d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1143644e-d46b-44ad-8a45-4772b9b5bfb4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_51b7d2b0-8d2d-41cc-bba4-295f2fffbac7" xlink:to="loc_srt_ConsolidationItemsAxis_1143644e-d46b-44ad-8a45-4772b9b5bfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ac3d137d-1709-4f90-9d5c-30c1c06d246f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_1143644e-d46b-44ad-8a45-4772b9b5bfb4" xlink:to="loc_srt_ConsolidationItemsDomain_ac3d137d-1709-4f90-9d5c-30c1c06d246f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_81ddaabc-59c7-4d4a-9d20-61de39eb47cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ac3d137d-1709-4f90-9d5c-30c1c06d246f" xlink:to="loc_us-gaap_OperatingSegmentsMember_81ddaabc-59c7-4d4a-9d20-61de39eb47cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_cc11f7b1-10d4-44b4-b978-dfe85635e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ac3d137d-1709-4f90-9d5c-30c1c06d246f" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_cc11f7b1-10d4-44b4-b978-dfe85635e8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8de4ca2d-f367-4d16-ac10-fb51a97399b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_51b7d2b0-8d2d-41cc-bba4-295f2fffbac7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_8de4ca2d-f367-4d16-ac10-fb51a97399b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_74e96b03-05c3-467f-89b2-ac91c5aaa786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8de4ca2d-f367-4d16-ac10-fb51a97399b5" xlink:to="loc_us-gaap_Depreciation_74e96b03-05c3-467f-89b2-ac91c5aaa786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0d4d6c1d-b7f6-4c28-a4ff-226b789f3ded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3da44fd8-e007-4103-99c1-e5e6ca828a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0d4d6c1d-b7f6-4c28-a4ff-226b789f3ded" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3da44fd8-e007-4103-99c1-e5e6ca828a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ab26d1de-f716-4330-9b04-3803a27159d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3da44fd8-e007-4103-99c1-e5e6ca828a18" xlink:to="loc_srt_StatementGeographicalAxis_ab26d1de-f716-4330-9b04-3803a27159d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ab26d1de-f716-4330-9b04-3803a27159d9" xlink:to="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0b62c707-cf28-4382-a736-55efbf09b14e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:to="loc_country_US_0b62c707-cf28-4382-a736-55efbf09b14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_6994f5f9-8868-4876-867d-be22ac0ba7b7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:to="loc_country_CA_6994f5f9-8868-4876-867d-be22ac0ba7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherGeographicalAreaMember_4a3904b6-f835-4074-9be6-278e8e18d439" xlink:href="ebs-20231231.xsd#ebs_OtherGeographicalAreaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_73706b37-5d5f-4b47-9199-04ee2b039503" xlink:to="loc_ebs_OtherGeographicalAreaMember_4a3904b6-f835-4074-9be6-278e8e18d439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9abc4cf8-c096-4aca-bcf8-206b290953a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3da44fd8-e007-4103-99c1-e5e6ca828a18" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9abc4cf8-c096-4aca-bcf8-206b290953a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_602c65a1-a9c0-40f6-96bd-b1c4c845efe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9abc4cf8-c096-4aca-bcf8-206b290953a0" xlink:to="loc_us-gaap_Revenues_602c65a1-a9c0-40f6-96bd-b1c4c845efe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#SegmentInformationLongLivedAssetsbyGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c7f91b50-a11e-403c-ac9e-1a957f93e64f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_09fb9d47-1a89-4c85-8974-aef28cfbd002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c7f91b50-a11e-403c-ac9e-1a957f93e64f" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_09fb9d47-1a89-4c85-8974-aef28cfbd002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2159ef28-dc0f-4c1b-bf9f-22f7c120af38" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_09fb9d47-1a89-4c85-8974-aef28cfbd002" xlink:to="loc_srt_StatementGeographicalAxis_2159ef28-dc0f-4c1b-bf9f-22f7c120af38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2159ef28-dc0f-4c1b-bf9f-22f7c120af38" xlink:to="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_734134b9-96d5-42f5-8c8d-7f8232435c9c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:to="loc_country_US_734134b9-96d5-42f5-8c8d-7f8232435c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_eedadce9-9092-4d1b-9f63-b813cf90ac81" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:to="loc_country_CH_eedadce9-9092-4d1b-9f63-b813cf90ac81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_1b101942-8c11-4083-aa59-0034bc582e1b" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:to="loc_country_CA_1b101942-8c11-4083-aa59-0034bc582e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherGeographicalAreaMember_3861465f-23e6-43ef-823c-c03ccf174921" xlink:href="ebs-20231231.xsd#ebs_OtherGeographicalAreaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a3db6b83-ea53-428d-ada5-4dab63350012" xlink:to="loc_ebs_OtherGeographicalAreaMember_3861465f-23e6-43ef-823c-c03ccf174921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_cfc92773-e80d-4b48-9419-e50a10339703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_09fb9d47-1a89-4c85-8974-aef28cfbd002" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_cfc92773-e80d-4b48-9419-e50a10339703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_07eb6a31-3d56-4b20-be78-dfe0ce34c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_cfc92773-e80d-4b48-9419-e50a10339703" xlink:to="loc_us-gaap_NoncurrentAssets_07eb6a31-3d56-4b20-be78-dfe0ce34c73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="ebs-20231231.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_35c6c5a2-ab45-41cd-bbdb-d5910809a8bc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc46b161-a8a7-407a-81dc-8780ef9eefa4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_35c6c5a2-ab45-41cd-bbdb-d5910809a8bc" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc46b161-a8a7-407a-81dc-8780ef9eefa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6f692257-7131-4278-94f7-01117bc75c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc46b161-a8a7-407a-81dc-8780ef9eefa4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6f692257-7131-4278-94f7-01117bc75c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_6cb5854e-3fa4-431d-ae66-0925c3fc284f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6f692257-7131-4278-94f7-01117bc75c97" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_6cb5854e-3fa4-431d-ae66-0925c3fc284f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember_54118a79-d852-49b9-a59d-b6c81374cb40" xlink:href="ebs-20231231.xsd#ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6cb5854e-3fa4-431d-ae66-0925c3fc284f" xlink:to="loc_ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember_54118a79-d852-49b9-a59d-b6c81374cb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b7b8d06d-9e1c-4189-af39-732c33632bc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc46b161-a8a7-407a-81dc-8780ef9eefa4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b7b8d06d-9e1c-4189-af39-732c33632bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b7b8d06d-9e1c-4189-af39-732c33632bc8" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_21ec5e5f-5974-4d63-9f18-6dd774d0ba3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_21ec5e5f-5974-4d63-9f18-6dd774d0ba3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c8dea8f2-1ff1-43b8-a940-376b7005da1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c8dea8f2-1ff1-43b8-a940-376b7005da1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8bc5dc19-389f-48f4-8b1c-0ea0bda9c4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8bc5dc19-389f-48f4-8b1c-0ea0bda9c4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d6dca8be-c847-41ab-a331-f5211e2ef8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea57604-16cd-4344-b8cd-2aa2beefa22b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d6dca8be-c847-41ab-a331-f5211e2ef8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember" xlink:href="ebs-20231231.xsd#ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ebs-20231231_g1.jpg
<TEXT>
begin 644 ebs-20231231_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M &22I"I>1@BCJS$ #MR3P* &PSQW"[X761<XRC!AGTR"1F@"6@ H * "@ H
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@">V\3Z1>RK
M!;7UG-*YPL<=Q"[L<9PJJY8G )X'2@#<H * "@ H * "@ H * "@ H * "@#
M.U#6+'2=OV^Y@M/,SL\^6.+?MQNV[V7=MW+G&<9&>HH S?\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
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M_A,="_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\
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M_BJ #^U;+_GXA_[^I_\ %4 ']JV7_/Q#_P!_4_\ BJ #^U;+_GXA_P"_J?\
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C
M8?\ @7!_\<H /^$QT+_H(V'_ (%P?_'* 'Q^+=%E81QZA9.[D*JK=0$DDX
M#Y))X ')- '04 % !0 4 % !0 4 % $4T\=LAEF98XUY9G(50/<D@#\30!A'
MQ?H:D@ZC8@C@@W4&0?\ OY0!JV6IVFI*6LYX;E1U,,B2 ?4H2* +M !0 4 ?
ME;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H * "@ H *
M/,OC)_R*.H_[D/\ Z4PTF!\C_#'XB3^ K_+[I-.N2!<PCDCL)8P<#S$],@.N
M5.#M94,^^[&^@U*".[M'6:"90\<B'*LI&00?Z=0>#@U0BU0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'AWQA^)X\(VYTK3'!U2Y3EA@_9HV&-Y])6_Y9*1P/WAX
M"!T!X)\"6+^+868DL8;DDDY))C.23W)[FD,^[*H04 % !0 4 % !0 4 % !0
M 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14
ME S]#:H04 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0
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MWQ-X=VI%=M=0KC]U=CSUPO10S$2HN.,)(HQCT& 9[QX:_:)TZ]VPZY;O8N<
MS19FASW8K@2H/91,?>G<1[WI.M6.NP"ZTV>*ZA/\<3A@#UVM@Y5O56 8=P*8
M&G0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY
M_P"1LG_ZX6__ *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0 4
M % !0 4 % !0 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\
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M9^T;_P C';?]@V+_ -*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &WX:_Y"UE_U]V__ *.2@9^F
M]4(* "@ H * "@!LDBQ*7<A44%F9B   ,DDG@ #DD\ 4 ?+GC[X^M#(]AX6"
MMM.UKUU#@G/_ "[QL"I';S) P;)VQXVN5<#@]/\ AEXS^(!6^U-Y(XWY674)
M7!P>?W<.'D52#\OR1H1]TXI#.TA_9HD* S:JJ/W5;,NH^C&Y0GCU4?UIV$<W
MJ?P#\2:(?M6DSQ7;1\KY,C6\XQSE=^$_*;.>@-*PP\,_&;Q!X.N?[.\2)+=Q
M1MMD2<%+R+W#M@R==V)=VX8"R(#F@#ZZT+7;+Q)9QZCIT@FMYAD$<%2/O(Z]
M5=3PRGD?0@FA&O0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!]B?LV_P#()OO^OM?_ $2E- ?1U, H
M * "@ H * "@ H * "@#S+XR?\BCJ/\ N0_^E,-)@?GU2 ]W^#?Q0/A6X&CZ
MF_\ Q++A_D=CQ:RL?OY_YXN?]8,@(?W@Q\^XV&?;2L' 92"",@CD$'H0>X-4
M(6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M 4 % !0 4 % !0 4 % !0 4 % !0  XY% 'JGA/XQ>(/"I6(S&^M%X\BY)?
MZ8CE_P!:F!]T;C&/^>9H&?5/@OXOZ)XP*V^\V-ZW'V><@;SZ0R\))[+\DA[1
MX&:8CU6F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
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M315(SR.@04 % !0 4 % !0!]<_LU?\>6H_\ 7>#_ - >FAGTS3$% !0 4 %
M!0 4 % !0!\6?M&_\C';?]@V+_TINZE@> 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;?AK_D+67_ %]V
M_P#Z.2@9^F]4(* "@ H * "@#Y=^/WCV2WQX8L'*%T$EZRD@[6YC@^C+B23'
M52B]"P*8S6^#/PJATRWB\0:O&)+R=1);1. 5MXSRDA4\><XPRG_EFI&,.6V@
M$&N_M"_V)J-UIO\ 9?F_8KF:W\S[9MW^3(T>_;]E;;NVYV[FQG&3UHN(RO\
MAIC_ *A/_D]_]QT7 V]$_:-TV]F$6IV<M@C''FI*+A5SW<>7$X7U*JY]C1<#
MTCQMX'TSXCZ<K IYYC#VEXF"0&&Y/F'WX7SEEY&#N7#8- 'RO\/?%-[\,/$#
MZ;J>8[9YOL][$3\J,#M6X7J#LR&W+D20DXSE"%L,^[001D<@U0C\K:D H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#[$_9M_Y!-]_P!?:_\ HE*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_
MY%'4?]R'_P!*8:3 _/JD 4 ?5'P1^*6/+\,ZQ)Q]VQG<\^UL['_R 2>/]5G'
MEJ&AGU53$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!ROC+Q?9>"M.?4KXYQ\L40.'FE()6-
M>#C.,LV"$4%B#@ @'YZ^)?$E[XKOY-3U!]\LIX49V1H/NQQ@D[44=!U)RS$L
M23(S!H$>R? ;_D;(/^N%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % '
MQG^T?_R';3_KP7_T?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H ]%^$O\ R-FF_P#79O\ T5)0,_0V
MJ$% !0 4 % !0 4 % !0 4 % !0!\K?M,_\ ,)_[?O\ VSI,#Y6I % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %  #CD4 >\_
M#[XX7_API9:T7O[ 84.3NN(1_LLQ'FH/[CG(  1U VD&?8VC:U9:_:I?:=*E
MQ;R#Y70]^ZL.JL/XE8!AW%4(TZ "@ H * "@ H * "@ H * "@ H * "@ H
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M /A'X\_\C9/_ -<+?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5"
M"@ H * "@ H * "@ H * "@ H ^;/C1_R%+?_KU'_HV6O"QGQK_#^K/L\H_@
MS_Q_^VQ/':\T^C"@#3TG5[K0[E+RR<QRQG\&'=6'1E;H0?T(!JX2=-J4'9HP
MJTH5X.G45XO\/-=F?5W@WQK:^+(/EQ%=QC][!GD=MZ9^]&2?JI.UNQ;Z&C65
M9=I+=?JO+\CX+%X.>$EKK3?PR_1]G^>Z\NTKK/-"@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!EZUK-KX?LY=1OW$5O;KN=C^051W9F(55'+,0!UH _/OQ_XZN_'>HM
M>3YCMH\K;09^6*,GOS@R/@&5NY  PBJ!(SA:!!0![)\!O^1L@_ZX7'_HLT#/
MNZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/-
M@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /1?A+_R-FF_]=F_]%24#/T-JA!0 4 % !0 4 % !0 4 % !0 4 ?
M*W[3/_,)_P"W[_VSI,#Y6I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 =KX(\>:CX%N_M-BVZ%R//MV)\J91ZC^%P,
M[) -RYQRI96!GWIX0\8:?XTL5O\ 3FR/NR1-@20OW2103CU5@2K#E3UQ0CJ:
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H AN;F*RB:>X=8
MHHU+.[L%55'4LQP !ZF@#Y,^(WQWENR^F^&&:&'E7O<%9'['[.#S&O\ TT($
MAX*B/&6D9\T.[2,7<EF8DDDY))Y))/))/4T"&T % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0![?\.?C/?>$REAJF^^TT84 G,UN.
MG[IF/SH!_P LG( P-C)R&!GVAHVM66OVJ7VG2I<6\@^5T/?NK#JK#^)6 8=Q
M5"-.@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+
M?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M3=U+ \ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%8]2M@!<PCC/831CO&_<=8WRIX*,[ ].I@% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $-Q<16D33SLL44
M2EW=R%55499F)P  .23P!0!\(?%?XER>.+S[-:%DTNU8^2AX,K\@SN.N2,B-
M3]Q.P9FJ1GD5 @H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KL
MW_HJ2@9^AM4(* "@ H * "@ H * "@ H * "@#Y6_:9_YA/_ &_?^V=)@?*U
M( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H ZWP7XQO?!&H)J%D<K]V:$DA)H^Z-CN.J-@E&P<$9!!GZ#^&?$EGXK
ML(M3T]]\4HY4XWQN/O1R#^%U/4=""&4E64FA&]0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!DZYKMEX;LWU#4I5@MXARQY))Z*JC)9V/"JH)/T
MS0!\,?$?XJ7WCJ4P1YM=,C;,=N#RY'22<CAW[J@^2/@ %LNTC/*J!!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =KX(\>
M:CX%N_M%BVZ%R//MV)\N91ZC^%P,[) -R]]REE(,^\?!OC/3_&UD+[3GY7"S
M0M_K(7(SM<=P>=CCY7 .#D,!0CK* "@ H * "@ H * "@ H * "@ H * "@
MH * "@#X1^//_(V3_P#7"W_]%BI&>-T""@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@
M9]W50@H * "@ H * "@ H * "@ H * /FSXT?\A2W_Z]1_Z-EKPL9\:_P_JS
M[/*/X,_\?_ML3QVO-/HPH * "@">WN)+.19X&:.6-@R.IPRL.001T---IW6C
M1$HJ:<))--6:>S1].> OB''XB5;&^(COU'!X5)P.Z]A)CED'!P63C*K[U#$*
MI[D])_@_^#Y?<?$8W /#-U:6M+\8^3\NS^3[OU*O0/#"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M='P Z$' .5%".NH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MS%55F !\">/O']]X\O3<7),5K$2+>V!RD2GN>FZ5N-\A&3]U0J!5$C.#H$%
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MJ?%T??U\_P _7?XS'9>Z-ZV'5X;RCUCYKO'\O3;V*O4/G0H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * /L'X >.CJ-LWAN]?,UFN^U+'EH,_-%GN86(*CD^6V  L5-
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH ]D^ W_ "-D'_7"X_\ 19H&?=U4(* "@ H * "@ H * "@ H * "@#YL^-'
M_(4M_P#KU'_HV6O"QGQK_#^K/L\H_@S_ ,?_ +;$\=KS3Z,* "@ H * "@!0
M<<C@B@1[_P##_P")?F;-+UE\-]V*Y=OO>B3$]^RR$_-P'Y^8^QA\3M3JOTD_
MR?\ G]Y\GCLOM>OAEIO*"6WG'R[KITTT7NM>N?+!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\$_'+_D;KS_<MO\ TFBJ1GD= @H * "@ H *
M "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H ^+/VC?\ D8[;
M_L&Q?^E-W4L#P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(C<<46 ^NM"T*R\-V<>G:;&(+>(<*.I)ZL['EG8\LQY/T %4(UZ /RMJ0"@
MH * "@ H * "@#[@^&O@+P_JGANPN[RPMIYY8B7D>,%F/F.,D]S@ 4QG<_\
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M H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
MH * /4_@WI%GK?B2&TU"%+F!HIR8Y!N4E8R5./4'D4#/L;_A67A?_H&6G_?H
M4Q!_PK+PO_T#+3_OT* #_A67A?\ Z!EI_P!^A0 ?\*R\+_\ 0,M/^_0H /\
MA67A?_H&6G_?H4 '_"LO"_\ T#+3_OT* #_A67A?_H&6G_?H4 '_  K+PO\
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MD\,["I&>/4""@ H * "@ H * "@ H * "@#MO#'P\UWQ<0VFVKF$G!N)/W<
M]?WC8#XSRL8=O]F@9[_X?_9OMX@)-<O'E;O%:J$0'T\V0,S#Z11GWIV$>Q:1
M\,?#.AX-KI]NS #YYE-PV1W!G,FT_P"[M]L#BBP'<11)"HCC4(B\!5   ] !
MP/PI@/H * "@!KQK*I1P&5A@@@$$>A!X(H X76/ACX9UL'[3I]NK$'YX%^SO
MD]R83'N(Z_/N'J".*5@/'/$/[-\#@R:%>-&W:*[&Y3])HE#*!Z&*0^]%@/GS
MQ-X"UOP@W_$TM7CBS@3+B2$YZ#S4RH)[*Q5_]FD,X^@04 % !0 4 % !0 4
M% !0 4 >A?#CQ[<> ]2%PNY[*<JEW"/XT!X=02!YL>2R$XSED)"N30,_06PO
MX-3MX[RT=9H)T#QNO1E89!'<>X(!!R" 015"+= !0 4 % !0 4 % !0 4 %
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M!EI_WZ% !_PK+PO_ - RT_[]"@ _X5EX7_Z!EI_WZ% !_P *R\+_ /0,M/\
MOT* #_A67A?_ *!EI_WZ% !_PK+PO_T#+3_OT* )(?AQX:MI%FBTZU22-@ZL
M(QE64Y4CW! (I@=K0 4 % !0 4 % !0 4 1RPI.ACE571N"K ,I'N#D'\: ,
M)O"&AL<MIUB2>I-K 3_Z+H U;+3;735*6<,5LIQE8HTC!QTR$ '';TH N4 %
M !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?_1DE- >B4P"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_ -OW_MG2
M8'RM2 * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@
MH * "@ H * "@ H X/QQ\.]+\=0;+Q/*ND&(KJ,#S8_0'IYD>>3&QQR2I5CN
MI ?"?B_P??\ @J^;3]17!^]%*N?+F3/#H2!]&4_,IX(Z90SE:!!0 4 % !0
M4 % !0!]@?LZ^*#=V-QH,S9>S;SX 2<^3*<2*!V5)3N^LU- ?25, H * "@
MH * "@ H * "@ H * "@ H ^7_CS\1/(0^%].?YW -\ZG[J'E;?([N,/+_L;
M4YW. F,^3:0@H * "@ H * "@ H * "@#K?"?@?5O&D_D:7"752!),^5ABS_
M 'Y,$9QR$4,Y&=JG!H&?6W@SX%Z-X>"W&I@:I>#!_>+BW0\<)#DA\'(W2E@>
M"$0\4["/;418U"( JJ   ,  <  #@ #H*8#J "@ H * "@ H * "@ H CEB2
M=&BE571P596 96!X((.00>X/!H \&\:_ 33-;#7.AE=,NCD^7@FU<^Z#+0_6
M,% !Q$2<TK ?)/B+PQJ7A2Y-GJL#6\G52>4D7^]&XRKK[J3@\, P("&8% @H
M * "@ H * "@ H * "@#Z/\ @1\0SI=P/#>H/_HMTV;5F/$4[=8L]DF/W1G
MEZ#]XQ AGV'5""@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_
M /18J1GC= @H * "@ H * "@#ZP_9H_U.J?[]I_*XIH9]14Q!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\ C_\ ;8GCM>:?
M1A0 4 % !0 4 % !0 4 >M^ /B,^A%=.U(E['HC\EX,]!ZM%ZKU7.5X&T^C0
MQ'L_<G\'XK_@>7W'S^.P"KWK4-*G5;*7^4O/KU[GTM#,DZ++$P=' 964@JRD
M9!!'!!'((KW4TU=;'Q33BW&2LUHT]TR2F(* "@ H * "@ H * "@ H * "@
MH * "@ H * /@GXY?\C=>?[EM_Z315(SR.@04 % !0 4 % !0!]<_LU?\>6H
M_P#7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % 'SC^TE_R";'_K[;_T2])@?'=( H * "@ H * "@#U7X)_\CCI_P#V]?\
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M@SZ\TW3;72+=+.QB2W@B&$CC4*H'T'4GJS'+,<EB22:H1=H * "@ H * "@
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M]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\Y_&FWE%_;7&UO*-OL
M#X.W>)'8KGINVD''7'->'C$^>+Z<MK^=V?8Y1)>SG"ZYN:]NMK)7]+GBU>8?
M2A0 4 % !0 4 % !0 4 % 'I?@3X@3>&7%I=[IK!SRO5H2>KQ_[/=H^AZKAL
M[NZAB'1?++6'Y>:_R/%QN!CB5[2G:-5?=+R?GV?WZ;?45I=PW\*7%LZRQ2#<
MCJ<@CV/Z$=000<$5[\6I)2B[I['PTHRIR<)IJ2T:>Z+%40% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_W+;_ -)HJD9Y'0(* "@ H * "@ H
M ^N?V:O^/+4?^N\'_H#TT,^F:8@H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /G']I+_ )!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!ZK\$_^
M1QT__MZ_]([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#\K:D H * "@ H * "@ H _0[X2_\BGIO_7 _P#HR2F@
M/1*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
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M * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!\K4@"@ H * "@ H
M* /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H * "@
M H ^6_VB/!X9(?$MLN&4K;W6!U!_U,IP.QS$S$Y.8E' I,#Y1I % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H *
M"@ H * "@#]#OA+_ ,BGIO\ UP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0
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M&?/- @H * "@ H * "@#Z/\ V;?^0M??]>B_^C5H0S[#JA!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!\K?M,_\PG_ +?O_;.DP/E:D 4 % !0 4 % !0![)\!O^1L@_ZX7'_H
MLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 87B?1(_$>E76ER@$7
M4+HN>BOC,;_\ D"N/=><CB@#\S9(VB8QN-K(2I!Z@@X(_ U(#* "@ H * "@
M H * /NKX":B;[PM'$?^7.XG@'T)$X_+S\?3%- >T4P"@ H * "@ H * "@
MH * "@#R/XS^,#X4T)XK=MMYJ)-O"1U1"/WT@X_A0[ 005>1&'0T@/@FD 4
M% !0 4 % !0 4 % 'V'\&?A0-(2/Q#K,?^FN-UK X_U"$<2NI_Y;,"=JG_5+
M@G]X?W;0SZ/IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /DKXS
M_"867F>(]$3]R27O+9!_J^I:XC _Y9D\RH/]63O7]WN$:&?,5(04 % 'L?@3
MX,:MXNVW5T#IVGMR)9%_>2#K^YB)!(.1B1]J8.5WD%:!GV%X3\$:3X+@\C2X
M0C,,23/AIY>_SR8!QGD(H5 >0HJA'6T % !0 4 % !0 4 % !0 4 % !0 4
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M * "@ H * "@ H * "@ H * "@#YQ_:2_P"038_]?;?^B7I,#X[I % !0 4
M% !0 4 >J_!/_D<=/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _*VI * "@ H * "@ H * /T.^$O_(I
MZ;_UP/\ Z,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0
M4 % !0 4 % !0 4 % '1>%?$][X/U"/4]/;$D?#(<[)8R1NBD (RC8'N&"LN
M&4$ S]"_"7BJS\8Z='J=@?E?Y9(S]^*0 ;HW]USP>C*0PX(JA'2T % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?'_QK^*?]J._AW1Y/]%C8K=S(
M?]<ZGF%"/^62$'>>1(PP/D7,DC/FV@04 % !0 4 % !0 4 % !0![)\!O^1L
M@_ZX7'_HLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7
M_P!'SU+&?/- @H * "@ H * "@#Z/_9M_P"0M??]>B_^C5H0S[#JA!0 4 %
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MP)\9?%1\3^(9EB;=:Z?FUAP<J2A/FN,<'?)N 8?>14YXJ1GE% @H * "@ H
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M-'^IU3_?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H CFA2X1HI5#HX*LK
M%64C!!!X((X(-)I-6>PTW%J479K5-;IGS/X^^'+Z"6U#30TEB>73JT&3^;1>
MC<E>C_WCX-?#NE[\-8?E_P #S^_N_M<#CU7M1K653H]E/_*7EUZ=CR:O//H
MH * "@ H * "@ H * "@#H_#/B>[\+70N;0Y4\21,3LD7T([$?PL.5/J"0=J
M=25&7-'YKHSBQ&&ABH<E3?I);I_Y=UU/K/PYXDL_$UJ+JS;D8$D9^_$Q'W6'
MY[6'RL!D'J!]'3J1JQYH_-=4? XC#SPL_9U%Z/I)=U^JW1OUL<@4 % !0 4
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M: ]$I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!YE\9/\ D4=1_P!R'_TIAI,#\^J0!0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M6.-!T"J,#ZD]68\LQ+$DDFJ$7: "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H S=7T>TUZTDT_48EGMI@ \;$@'!##!4AE(8 AE(((!!% $F
MFZ9:Z/;I9V$4=M!$,+'&H51[X'4GJS'+,>6))S0!>H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H *
M "@ H * /K#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4
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M!0 4 % !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_P!RV_\ 2:*I&>1T""@ H *
M"@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!Z
MK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@#]#OA+_ ,BGIO\
MUP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD 4 %
M!0 4 % !0 4 % !0 4 % 'LOPC^)K^"KO[#?,S:5=-\XZ^1(>!,@_NG $JCD
MJ P!90K S[JBE2=%EB8.C@,K*0RLK#(92,@@@@@C@CD50A] !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >/?%GXFQ^"+3[)9%7U6Z4^4O!\A#QY[KZ_\\E88
M9@2051E* ^$YIGN)&FE8O)(Q9V8Y9F8Y+$GDDDY)/4T@(J "@ H * "@ H *
M "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5""@ H * "@ H * "@ H * "@
MH * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4 ?1_[-O\ R%K[
M_KT7_P!&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/_;]_P"V=)@?*U(
MH * "@ H * "@#V3X#?\C9!_UPN/_19H&?=U4(* "@ H * "@ H * "@ H *
M "@ H * "@ H * /B_\ :."CQ!:D'YCI\8(]A<7.#^))_*I8'S[0 4 % !0
M4 % !0!]'_LV_P#(6OO^O1?_ $:M"&?8=4(* "@ H * "@ H * "@ H ^4?V
MD?$!,EEH<9.%#7<HSP2Q:*'\5 F//9@:3 ^6Z0!0 4 % !0 4 % !0!]P_ O
MP6/#VCC5+A<7FI@2<CE+?K$GMYG^M;U#1@C*4T![C3 * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _*VI *
M"@ H * "@ H * /T.^$O_(IZ;_UP/_HR2F@/1*8!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_
M )%'4?\ <A_]*8:3 _/JD 4 % !0 4 % !0 4 % !0 4 % !0!]*?!/XI?V8
MZ>'-8DQ:R';:3.>(7)XA<G_EFY/R$G$;?*?D;* SZ^JA!0 4 % !0 4 % !0
M 4 % !0 4 % !0!P?Q"\>6O@+3C=2XDNI<K;09P9'[DXY$:9!=N.R@[F6D!^
M?>L:O=:]=RZA?R&:XN&+NQ]3T '154855&%50%  %(9FT""@ H * "@ H *
M"@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@ H * "@ H
M * "@#XS_:/_ .0[:?\ 7@O_ */GJ6,^>:!!0 4 % !0 4 % 'T?^S;_ ,A:
M^_Z]%_\ 1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_V_?\ MG28'RM2
M * "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H * "@ H * "@ H *
M"@ H * "@ H * "@#X?_ &@[L7/B<1C'^C6<$1Q[M+-S[XE'3MCOFI \-H *
M "@ H * "@ H ^D_V;(B=2OY.RVT:X_WI,_IL_6A#/K^J$% !0 4 % !0 4
M% !0 4 ?G7\3]:_M[Q+?W0.Z-)C!'CIL@Q"I'LVPO]6-2,X&@04 % !0 4 %
M !0!VGP^\,'Q=KEKIC F%G\R<CC$$?SR<\X+ ;%./ONM S]'$18U"( JJ
M,  <  #@ #@ =*H0Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^
M$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H * "@ H * /K#]FC_ %.J?[]I_*XI
MH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'CA0 4 % !0 4 % !0 4 % 'P3\<O^1NO/\ <MO_ $FBJ1GD= @H * "@ H
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M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
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M H ^N?V<?#@@M+O79 -]PXM83SD1QX>4CMM=R@Z]8CT[M ?3-, H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+?_T6*D9XW0(*
M "@ H * "@ H ^L/V:/]3JG^_:?RN*:&?45,04 % !0 4 % !0 4 % !0 4
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MWK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /RMJ0"@ H * "@ H * "@#[0^'7Q/\-:)X=L;"^O5AN((BLB&
M*=BI+N<96)E/!!X)IC.U_P"%R>$?^@BG_?FY_P#C-%Q!_P +D\(_]!%/^_-S
M_P#&:+@'_"Y/"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3P
MC_T$4_[\W/\ \9HN ?\ "Y/"/_013_OS<_\ QFBX!_PN3PC_ -!%/^_-S_\
M&:+@'_"Y/"/_ $$4_P"_-S_\9HN ?\+D\(_]!%/^_-S_ /&:+@'_  N3PC_T
M$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\ OS<__&:+
M@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/"/\ T$4_
M[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\ \9HN ?\
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MN%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\
M1\]2QGSS0(* "@ H * "@ H ]N^!WBK2_"FHW<^KSBUCEMPB,5D;+"16QB-'
M(X!.2 />@9]+_P#"Y/"/_013_OS<_P#QFG<0?\+D\(_]!%/^_-S_ /&:+@'_
M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
M\9HN ?\ "Y/"/_013_OS<_\ QFBX!_PN3PC_ -!%/^_-S_\ &:+@'_"Y/"/_
M $$4_P"_-S_\9HN ?\+D\(_]!%/^_-S_ /&:+@'_  N3PC_T$4_[\W/_ ,9H
MN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\ OS<__&:+@'_"Y/"/_013
M_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/"/\ T$4_[\W/_P 9HN!Z
M!INHV^K6T=[9N);>= \;@$!E/0X8!AGT(!]J8%V@ H * "@ H * "@ H * "
M@ H * "@ H ^5OVF?^83_P!OW_MG28'RM2 * "@ H * "@ H ]D^ W_(V0?]
M<+C_ -%F@9]W50@H * "@ H * "@ H * "@ H * "@ H * "@#C?'_B=/".B
M7.I$@2JAC@!_BGD!6( =]I.]A_<1CVI ?G S%B23DGDD]2:0"4 % !0 4 %
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M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
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M@ H * "@ H ^<?VDO^038_\ 7VW_ *)>DP/CND 4 % !0 4 % !0!ZK\$_\
MD<=/_P"WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /1?A+_ ,C9IO\ UV;_ -%24#/T-JA!0 4
M% !0 4 % !0 4 % !0 4 % 'F7QD_P"11U'_ '(?_2F&DP/SZI % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!IZ-K%UH%Y%J-@YAN+=@R,/R((/#*PRK*>&4D
M'@T#/T&^'_CFU\=Z<+R#$=Q%M2Y@SS%(1U'.3&^"8V/4 @_,K ,1W-, H *
M"@ H * "@ H ;)(L2EW(5%!9F8@  #)))X  Y)/ % 'PY\8/B<WC"Y.FZ<Y&
ME6S<$<?:9%X\UAU\M3D1*>H_>, S!4D9XE0(* "@ H * "@ H * "@ H * "
M@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "@ H * "@ H *
M "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z,_#+_D5],_Z](OY4P.YI@% !0
M4 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0 4 % !0 4
M % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'Q+\=?'*^(M272+-MUGII8,RG*R7)X=N#@K$/W:G^\92"0PJ1G@] @H
M * "@ H * "@ H _2/P!I!T+P_86+ J\=M&S@C!$D@\V08]I'8?X4P.OI@%
M!0 4 % !0 4 % !0!\Z?M(7IBT>SM!_RVNS(?I%$XQ^<H/3L.1W3 ^.*0!0
M4 % !0 4 % '1^#],&LZU8V#?<N+N!'_ -PR+O\ R3<:!GZ7U0@H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_ /18J1GC
M= @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#]./#7_ "";+_KTM_\ T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'QG^T?_P AVT_Z\%_]'SU+&?/- @H LV=Y/I\R75K(\,T3!DD1BK*PZ%2,
M$&@#[;^%GQ<@\8(NFZF4M]50 #HJ70 Y>,=%EX)>(<?Q1_+N5&![=3 * "@
MH Y?Q3X3M/%5MY%R-LJ F&8#YHV/Y;D/\2'@CD88!ASU:4:RL]^C[?\  \CN
MPV)GA)\T-8OXH]&OT?9_IH?)_B#P]>>&KIK2]7:1DHXSLD7^\C8&1ZCJIX8
MU\[4IRI/EDO\GYH^^H5X8F"J4GZKK%]FOZOT,*LCJ"@ H * "@ H * "@ H
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M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0
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M 4 % !0 4 % !0!\K?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0![)\!O\
MD;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0 4 % '@WQC^**
M>&+=M&TMP=3N$Q(ZGFUC8?>..DSJ?W8R"@/F''R;D!\3$YY-( H * "@ H *
M "@ H Z_P%H)\2Z]9:<5+1RSJTH'_/&/]Y+ST'[M6 )[D#DG% S](ZH04 %
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M !N@ _X6UXL_Z"4W_?,7_P ;H ^Y/ ]U<WV@Z?=7SF6XGM(99'.,L9$#AC@
M9(89P.M4(ZF@ H * "@ H * "@ H * "@#X1^//_ "-D_P#UPM__ $6*D9XW
M0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _3CPU_R";+_ *]+?_T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'QG^T?\ \AVT_P"O!?\ T?/4L9\\T""@ H DAF>W=98F:.2-@RLI*LK Y#*1
M@@@\@CD&@#[(^$_QB37PFC:ZXCU #;#<,0J7..BMT"SXZ?PRGIAR%9@?0U,
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M/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _*VI * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H ]%^$O_ "-FF_\ 79O_ $5)0,_0VJ$% !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'I7PS^(=QX"OP[;I-/N"%N80>W02QCH)(^O^VN4
M)&0RFPS[]L+^WU2WCO+-UF@G0/&Z]&5AD'U'N" 0<@@$$50BW0 4 % !0 4
M?/?QH^*/_"/Q-H.DOC4)E_?RJ>;:-AG:I'2:13P>L:'<,,R,J ^,:0!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0
M 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]&?A
ME_R*^F?]>D7\J8'<TP"@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/\
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MKD#W,I!/X[1^52QGS=0(* "@ H * "@ H ]Z_9UB63Q),S=8]/F9?J9[9/\
MT%C_ #H0'VQ5 % !0 4 % !0 4 % !0 4 ?,W[2O_'EIW_7>?_T!*3&?(U(0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z5>!T,
M?A[2T/5=.LP?J+>,50'44 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__
M *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?IQX:_Y!-E_UZ6__HI*H#:H * "@ H * "@ H * "@ H *
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MD@(W5K?GMW:+U3JO5.ZMZ%#$.E[D]8?^D_\  \ON\_ QV 5>]6BDJG5;*?\
ME+SZ]>Z^F89H[A%EA97C<!E92"I!Z$$<$?2O>335UL?%-.+<9)IK=/1HDIDA
M0 4 % 'Q=\?/">H6FL2:^4WV%V(4$B9/END2Q[)1CY2Q3*'E6!QG<"*D9\_4
M""@ H * "@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0
M4 % !0!ZK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /1?A+_R-FF_]=F_]%24#
M/T-JA!0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD
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M\D(#URSD N0 9X?0(* "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H
M* "@ H * "@ H * "@ H * /C/\ :/\ ^0[:?]>"_P#H^>I8SYYH$% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?HS\
M,O\ D5],_P"O2+^5,#N:8!0 4 % !0 4 % !0 4 % !0 4 % !0!\K?M,_\
M,)_[?O\ VSI,#Y6I % !0 4 % !0 4 >C_"KQ)9>%-?BU+4F:.W2*9254N<N
MA5?E7)ZT#/J?_A?'A/\ Y[S?^ \O^%.X@_X7QX3_ .>\W_@/+_A1< _X7QX3
M_P">\W_@/+_A1< _X7QX3_Y[S?\ @/+_ (47 /\ A?'A/_GO-_X#R_X47 /^
M%\>$_P#GO-_X#R_X47 /^%\>$_\ GO-_X#R_X47 /^%\>$_^>\W_ (#R_P"%
M%P#_ (7QX3_Y[S?^ \O^%%P#_A?'A/\ Y[S?^ \O^%%P#_A?'A/_ )[S?^ \
MO^%%P*EU^T#X7MQF,W<_M' !Z\?O9(Q_3D<]<%P//=9_:2F=2FD6"1GM)<R%
M_P#R%&$ (_ZZL/;U+@>%^)?'.M>+FSJMU)-&#E81A(5/;$2!4R.@8@MZL<FD
M,Y*@04 % !0 4 % !0 4 % %W3M/GU:ZBL;13)/<2+'&H[LY 'T'.2>@&2>!
M0!^DWA;P_#X6TNVTFWY2UC"ENF]SEI']M\A9L=LX' J@-^@ H * "@ H * "
M@ H * "@#X\_:2_Y"UC_ ->C?^C6J6,^<*!!0 4 % !0 4 % 'T'^S@^-?ND
M]=/<_E<6P_\ 9J$!]GU0!0 4 % !0 4 % !0 4 % 'S-^TK_ ,>6G?\ 7>?_
M - 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!^F'@\8T/3@?^?&U_P#1$=4!T5 !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % 'Z<>&O^039?]>EO_Z*2J VJ "@ H * "@ H *
M"@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ6,^>:!!0 4 % !0 4 ?3
M'PF^,QTX1Z'XADS; !+>[<DM%V6*8\YB[))UCX5LQX,8,^N58. RD$$9!'((
M/0@]P:H0M !0 4 5KRSAU"%[:Y19895*NC#((/\ (CJ",$$ @@@&IE%23C)7
M3Z%PG*G)3@VI)W370^7/'7P_F\,.;JUW36#GANKQ$_PR8'3LK]#T;#8W?/U\
M.Z+YHZP[]O7_ #/N<%CHXE>SG[M5=.DO./GW7W:;>;5Q'M!0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 ?./[27_()L?\ K[;_ -$O28'QW2 * "@
MH * "@ H ]5^"?\ R..G_P#;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4 %
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M^-<UN[\17LNHZA(9;B=MS$]!Z*H_A1!A44<*H I#,J@04 % !0 4 % !0 4
M.1&D8(@+,Q   R23P  .22>@H ^X_@_\,5\'VHU+44!U6Z3D$?\ 'M&W/E+_
M --&&#*W&#^['"L78'%?M+_ZG2_]^[_E;T,9\GTA!0 4 % !0 4 % 'LGP&_
MY&R#_KA<?^BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0!\9_M'_P#(=M/^
MO!?_ $?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /T9^&7_(KZ9_UZ1?RI@=S3 * "@ H * "@ H * "@
MH * "@ H * /E;]IG_F$_P#;]_[9TF!\K4@"@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /JC]GWP*<MXHO4P
M/FBL@P/^[+./;&84//67(R%-- ?55, H * "@ H * "@ H * "@ H ^1?VE(
M-M]ITV"-\$R9['9(AP.V1YF3[$9[4F,^9Z0@H * "@ H * "@#W#]GVZ-OXH
M\L''VBTGC/ YP8Y?PYBSD<\8Z$T(9]Q50@H * "@ H * "@ H * "@#YF_:5
M_P"/+3O^N\__ * E)C/D:D(* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#].?#BE-*LU8$$6MN"#P01$F01ZU0&S0 4 % !0 4 %
M!0 4 % !0!\(_'G_ )&R?_KA;_\ HL5(SQN@04 % !0 4 % !0 4 % !0 4
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M(X- 'QQ\6/@X^@&36="0R6!)::W4%FMNY9>I:#U[Q#KE,LLC/GB@04 % !0
M4 ?7/[-7_'EJ/_7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?
M_(XZ?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KLW_HJ2@9^AM4(* "@ H *
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M7GC;47U&\.T?=AB!.R&(?=1<]_XG;JSDG@8 D9R5 @H * "@ H * "@ H *
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M &_?^V=)@?*U( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /0/AQX%G\=ZHMJH9+.';)=RC^"//"*3QYDI!5!R
M1\SX*HU S]";*SATZ".TMD$4,"+'&B]%10 H'T [\^O-4(LT % !0 4 % !0
M 4 % !0 4 % 'S!^TM;EK?3+C'$<ERF>>LBPL!Z<^6??CCO28'R92 * "@ H
M * "@ H ]'^$>H#3?%>G2GI),T!_[;QO"/R9P?P[]*!GZ%U0@H * "@ H *
M"@ H * "@#YF_:5_X\M._P"N\_\ Z E)C/D:D(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#]0]*_P"/*W_ZXQ?^@+5 7Z "@ H
M* "@ H * "@ H * /A'X\_\ (V3_ /7"W_\ 18J1GC= @H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]./#7_()LO\
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M0@H * "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H ^<?VDO^038_]?;?^B7I,#X[I % !0 4 % !0 4
M>J_!/_D<=/\ ^WK_ -([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#\K:D H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14E S]#:H04
M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH _1GX9?\BOIG_7I%_*F!W-, H * "@ H * "@ H * "@ H * "@ H ^5OVF
M?^83_P!OW_MG28'RM2 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * -[PUX;O?%=_'IFG)OFE/).0D:#[TDC ':BCJ
M<9)PJ@L0"#/T(\%^#[/P3IJ:;9C)'S32D8::4@;G;T'&$7G:@"Y)R36PCK*
M"@ H * "@ H * "@ H * "@ H \)_:&LOM/AI)@.;:\A<GC(5DEB(SUP6=,@
M8R0">E)@?$=( H * "@ H * "@"[IMZ^F74-Y$2)+:6.92."&C<.I!['(% S
M]/K2YCO88[F$[HYD61#ZJZAE/X@BJ$3T % !0 4 % !0 4 % !0!\S?M*_\
M'EIW_7>?_P! 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % #D4NP5>K$ ?4\4 ?J7;PK;1)"F2L:J@SUPH &<8&<#G@50$M
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M=( H * "@ H * "@#U7X)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4
M % 'VO\ #CX<>'-8\.6-[>V,4UQ-$6DD8R L?,<9.' Z #@4QG;_ /"I?"?_
M $#8/SD_^.46$'_"I?"?_0-@_.3_ ..46 /^%2^$_P#H&P?G)_\ '*+ '_"I
M?"?_ $#8/SD_^.46 /\ A4OA/_H&P?G)_P#'*+ '_"I?"?\ T#8/SD_^.46
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MD]N=:TM/^)E;)^\1>MS$HZ8[S1@?N\<NN8_F(C 0'Q000<'@BD E !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!Z3\,_A]/X\U#RSNBL+<AKJ8#H.T2'
MIYDF,#^XNYR#@*P,^_K"PM]+MX[.SC6&"!0D<:C"JHZ ?U)R2<DDDDU0BW0
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M_P#'*+ =S86$&EV\=G:((8(%"1HN<*HZ 9)/'N:8%N@ H * "@ H * "@ H
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M)[>5CRO?_4-%^.:: ]5I@% !0 4 % !0 4 % !0!\S?M*_\ 'EIW_7>?_P!
M2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &
M]X6LO[2UBQL_^>]W;Q_0/*BDG@\ ')X/':@9^FE4(* "@ H * "@ H * "@
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M?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE, H
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M *-6A#/L.J$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'RM^TS_P PG_M^_P#;.DP/E:D 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'J?@
M'X3ZIXW=9R#9Z=GYKF13\X!P1 AP96R""V1&N#EMP"D&?;?A?PGIO@ZS%CI<
M7EIP7<_-)*X&-\KX&YCZ !5Z(JKQ5".DH * "@ H * "@ H * "@ H * "@
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M4 % !0 4 % !0!ZA\&M._M+Q98J?NP-).WMY43LG_D38/Q_"@9^@54(* "@
MH * "@ H * "@ H * /A'X\_\C9/_P!<+?\ ]%BI&>-T""@ H * "@ H * /
MK#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO3>TOT?9_@^G9=S78>6% !0 4 >,?%'X2V_C2,W^GA+?5D'WNB7( P(Y<='
M "2XR/N/E=I1 ?#]_87&ESO:7D;03PL5>-QAE8=B/U!'!&""0<T@/J[]FK_C
MRU'_ *[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_ .1QT_\
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M0 4 % !0 4 % !0 4 7]+TRYUFZBL;*-IKBX<)&B]23[] !U9B0JJ"S$ $T
M?H%\.? 5MX"TX6R8DO)]KW4V/ON!PB]_*CR0@/7+.0"Q >P'H-, H * "@#Y
M=_:7_P!3I?\ OW?\K>DQGR?2$% !0 4 % !0 4 >R? ;_D;(/^N%Q_Z+- S[
MNJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_R';3_KP7_T?/4L9\\T""@
MH * "@ H * /H_\ 9M_Y"U]_UZ+_ .C5H0S[#JA!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\
MK?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!U7AKP3K'BZ3R]*MI)ESAI2-D*>N^5L(#CG:"7/\*D
M\4#/JCP3\ ].T0K=ZXRZC=+R(@"+5#_ND!IC[R!4YP8B0#3L(]^1%C4(@"JH
M   P !P  .  . !TI@.H * "@ H * "@ H * "@ H * "@ H * "@ H ^%_C
MSH7]D^)6ND&(M1B2<8& '4>5(/\ >)02-_UTJ1GBM @H * "@ H * "@"[IN
MH3:3=0WULVR:VD26-O1D8,/PR.1W'% 'Z4>&=>@\3Z9;ZK;?ZNZC#;<YV/TD
MC/NCAD)[D9'!J@-V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H Q_$&LP^'M.N-3N/]7:1/(1G&XJ/E0>[MA%]V% 'YGWMY+J%Q+=W
M#%YKB1Y9&/5G=BS'\6)-2!5H * "@ H * "@ H ^E?V;=)\W4+[4R.+>!(%)
M_O3/O./<+#@GKAL=":$!]>U0!0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?0W[-__
M "';O_KP;_T?!0AGV95""@ H * "@ H * "@ H * .,\8>"[7Q9!A\0W<8_=
M3@<C_8?NT9/;JIY7&2&Y:U&-9=I+9_H_+\CTL)BYX26FL'\4?U79_GL_+Y1U
MC1KK0;EK.]0QRISZJRGHR-T93V(]P<$$#YV<)4WRR5F?>TJL*\%4I.\7]Z?9
MKHS+J#<* "@ H * "@ H * "@"U9WDVGS+<VSM%+&<JZG!!_^N.".A&0<@U2
M;B[Q=FC.<(U(N$TG%[IGU'X%\?P^)XQ:W6V&_0<KG"S #EX_?NT?4=1E<[??
MH8A5?=EI/\_3]5_2^&QN!EA7SPNZ3Z]8^4OT?7UW](KN/&"@ H * /+/B5\,
M+/QW;F:/;;ZG"A$,^,!P.1%-@99#R%;EHR2RY&Y&0'&_ 31;SP\-6T_4(V@N
M(+B!61O]Q\,I'#(PPRLI*LI!!Q0AGT+3$% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!\X_M)?\ ()L?^OMO_1+TF!\=T@"@ H * "@ H *
M/5?@G_R..G_]O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_
M -&24T!Z)3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H *
M "@ H GM?]='_OK_ #%(9^I=6(* "@ H * ,[5M*MM<M)=/OD$MO<(4=#W!Y
M!'HRD!E8<JP# @@&@#\^OB%X$NO >HFTES):RY>UGQQ)'GH<<"2/(61>W# ;
M'4F=AG!T""@ H * "@ H * "@ H * "@ H <JER%4$L2  !DDGH .Y/84 ?<
M7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:-QYK=O\ 5J<!B[ ]NI@% !0 4 %
M'R[^TO\ ZG2_]^[_ )6])C/D^D(* "@ H * "@ H ]D^ W_(V0?]<+C_ -%F
M@9]W50@H * "@ H * "@ H * "@ H * "@#XS_:/_P"0[:?]>"_^CYZEC/GF
M@04 % !0 4 % !0!]'_LV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQGO@9Q^63^9H 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /G']I+_D$V/_7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_Y''3_ /MZ_P#2
M.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _*VI * "@ H * "@ H * /T.^$O\ R*>F_P#7 _\ HR2F@/1*8!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >9?&3_D4=1_W(?\ TIAI,#\^J0!0 4 % !0 4 % $]K_ *Z/
M_?7^8I#/U+JQ!0 4 % !0 4 <IXS\(6?C739--O!@GYH90!NAE ^5U_DZ\;D
M)7(R" #\]/$?AZ\\*W\NF:@NR:!L9'W74_=D0\91QRIP#V8!@0)&8= @H *
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M "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@ H *
M/9/@-_R-D'_7"X_]%F@9]W50@H * "@ H * "@#,UK1[;Q!93:;?+YEO<H4=
M>A]0RGLRL R'LP![4 ?G3XR\*77@S4Y=+N^?+.Z*3&%EB;[DB_4<, 3M<,N2
M5J1G+4""@ H * "@ H * "@#V+X0?$9O!5_]DO6/]EWK 2YY$,GW5G ]!PLH
M'+)AL,T:@@S[N1UD4,A#*P!!!R"#R""."".AJA#J "@ H * "@ H * "@ H
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M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^,_VC_\
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M_E\U_=\NGIM[57JGS04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!\X_M)?\@FQ_P"OMO\ T2])@?'=( H * "@ H * "@#U7X)
M_P#(XZ?_ -O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_T9
M)30'HE, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /,OC)_R*.H_P"Y#_Z4PTF!^?5( H * "@ H *
M"@">U_UT?^^O\Q2&?J75B"@ H * "@ H * /+OBC\.H?'=AF$+'J5J";:0X&
M[N8)#_<<]"?]6_S#@N&0'P-=VDUA,]M<HT4T+,DB.,,C*<,K ]"",4@*] !0
M 4 % !0 4 % !0 4 >[?!OX8'Q5<#5]30_V9;/\ *C#BZE4_<YZPH?\ 6'D,
M1Y0S\Y4&?;:J%  & . !T JA"T % !0 4 % !0!\N_M+_P"ITO\ W[O^5O28
MSY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@ H *
M"@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1_P"S
M;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!
M\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
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M 009^AGA[Q!9^)[&+4]/<203+G_:1A]Z-Q_"Z'AA^()4@FA&U0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 R65($:65@B("S,Q"JJJ,EF)P  !
MDD\ <F@#X.^+GQ&;QO?BWM"1IEFS"$=/-?HT[#@\CB,'[J9. SN*D9Y#0(*
M"@ H * "@ H * /H?]GGPQ_:&JRZW,O[K3T*1'L9Y@5XXYV1;\]""\9H0S[+
MJA!0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?\ ZX6__HL5(SQN@04 % !0
M 4 % !0!]8?LT?ZG5/\ ?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /C/]H_\
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M>DP/CND 4 % !0 4 % !0!ZK\$_^1QT__MZ_]([B@#[]J@"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\K:D H * "@ H *
M "@ H _0[X2_\BGIO_7 _P#HR2F@/1*8!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_D4=1_W(
M?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$% !0 4 % !0 4
M% 'SY\:?A@/$$#:]I2?\3"W7,\:CFYB4=0.\T0''>1!LY98U*&?&'2D(* "@
M H * "@ H * /2/AI\/I_'NH>4=T5A;D-=3#LI/$2'IYLF"!V50SG. K S[_
M +"PM]*MX[.S188($"1QKP%51@#U/N222<DDDDU0BW0 4 % !0 4 % !0!\N
M_M+_ .ITO_?N_P"5O28SY/I""@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?
M=U4(* "@ H * "@ H * "@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$%
M !0 4 % !0 4 ?1_[-O_ "%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /
ME;]IG_F$_P#;]_[9TF!\K4@"@ H * "@ H * /9/@-_R-D'_ %PN/_19H&?=
MU4(* "@ H * "@ H * "@#Y+^//P[^S.?%&G)B.0@7R*/NN2 MQ@=I"0DO3#
M[7Y+N0AGS#2$% !0 4 % !0 4 % $UO<26DJ3P,T<L3*Z.I(964@JRD<@@@$
M$=#0!]_?"WX@Q^.M-#3%5U&U 2ZC&!D_PS(!_!)@Y ^XX9<;=I9@>G4P"@ H
M * "@ H * "@ H * "@ H * "@ H * "@#&\1:'!XDTZXTJZ_P!5=1E"<9*M
MU1P,C+1N%=>VY1GB@#\V=9TBXT&]FTV\79/:R-&X[94\,O3*L,,I[J0>]2,S
M*!!0 4 % !0 4 % !0!Z1\./B+=^ ;S<N9K"<C[3;YZ@<"2//"RJ.G9Q\K?P
MLH,^]M%UFT\06D>H:?(LUO,N58?JK#JK*>&4X*D$$50C4H * "@ H * "@ H
M * "@ H * "@ H * "@ H *  D 9/ % 'QU\9?BQ_;3/H&BR9L5.+F=#_P ?
M# \QH1U@4@98?ZUNG[L R2,^<J!!0 4 % !0 4 % !0 ^.-IG6.,%G<A54#)
M))P !W)/ % 'Z,_#SPHO@S1+?3<#S\>;<L/XIY #)R"00F!$I'5$4]2:8';4
MP"@ H * "@ H * "@ H * "@ H ^$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H
M* "@ H * /K#]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4
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M0>001P01R".M>WOJCXYJVCT:'4Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M5O28SY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@
MH * "@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1
M_P"S;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[
M9TF!\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@
MH * "@""ZM8KZ%[:X1989D:.1&&59&!5E(]""0: /SW^)?@67P)JC6P#-93[
MI+24\[H\\HQZ&2+(5^F05? #BI&>>4""@ H * "@ H * "@#IO"/BF[\&ZE%
MJED?FC.V2,G"RQ-C?$_LP&0<':P5Q\RB@9^B7A[7[3Q/80ZG8-O@G7(S]Y&'
M#1N.SHV58<C(R"5()H1M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '
MS+^T#X&^U0KXFLU_>0!8KP*/O19Q',<#),9/EN3D[&3HL9I,#Y'I % !0 4
M% !0 4 % !0!Z#X!^(NH> KKS+<^=9R$>?:LQ"..,LG7RY0!A7 /HRLO% S[
MJ\*>+]-\96@O=,D#@8$D;8$L+'^&1,G:>#@\JP!*L15".GH * "@ H * "@
MH * "@ H * "@ H * "@"O=W<-A"]S<NL,,2EGD=@JJHZEF. !0!\;?%/XRR
M>) ^D:&6AT[[LLW*R7..J@<%(3_=/SR#[VU24,C/GZ@04 % !0 4 % !0 4
M% 'O?P&\%'7-4.M7*DVFF,#'D</='F,#U\D?O3@Y#^5G(8T(9]KU0@H * "@
M H * "@ H * "@ H * "@#X1^//_ "-D_P#UPM__ $6*D9XW0(* "@ H * "
M@ H ^L/V:/\ 4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?\ \AVT
M_P"O!?\ T?/4L9\\T""@ H * "@ H * /H;]F_\ Y#MW_P!>#?\ H^"A#/LR
MJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0 V2-95*. R,"K*P!!!&""#P01P
M0>"*5KZ/8:;3NM&MGV/FWQ]\-VTC=J.E*7L^LD0R6ASU*]VB_$LG?*Y(\.OA
MO9^_3^'JNW_ _(^SP.8*K:C7=JG26REZ]I?@_70\>KS3Z(* "@ H * "@ H
M* "@ H ]4\!?$23P\5L;\M)8$_*>KP$]U[F//+)VR63G*MWT,0Z7N3UA^7IY
M>7W>?@XW +$7JT;*KUZ*7KV?9_)]U].6]Q'=1K-"RR1R*&5E.593R"".H->^
MFFKK9GQ,HN#<9*S6C3W3):9(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?_(XZ
M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE
M, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_
MUT?^^O\ ,4AGZEU8@H * "@ H * "@ H * (Y8DG1HI55XW4JRL RLK##*RG
M((()!!&".#0!\(_%KX:/X(O/M=FI;2KISY3<GR7.6,#DY/0$Q,3ET!!)9&-3
ML,\?H$% !0 4 7M,TVYUBZBL;*-IKB=PD:+U)/Z  9+,<!5!8D $T ?H%\./
M -MX"TX6Z[9+R?#W4X'WGQPBGKY4>2$'&3N<@%B ]@/0J8!0 4 % !0 4 %
M!0 4 ?+O[2_^ITO_ '[O^5O28SY/I""@ H * "@ H * /9/@-_R-D'_7"X_]
M%F@9]W50@H * "@ H * "@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ
M6,^>:!!0 4 % !0 4 % 'T?^S;_R%K[_ *]%_P#1JT(9]AU0@H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H ^5OVF?\ F$_]OW_MG28'RM2 * "@ H * "@ H ]D^ W_ "-D'_7"
MX_\ 19H&?=U4(* "@ H * "@ H * "@ H XOQ[X,M_'&E2:=-A)A^\MY2/\
M53 ':3CG8V2L@'52<?,%(0'YWZGIMQH]U+8WB&*XMW:.1#V93@\C@@]589#
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MOXF:KXZDVW#?9[)6S':1D^6,=&D/!ED _B8 #G8B9(*&>=4""@ H * "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_ -&24T!Z)3 * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H * "@ H GM?]='_OK_
M #%(9^I=6(* "@ H * "@ H * "@ H R]:T:U\064NG7Z"6WN%*NO?U#*>S*
M0&5NS 'M0!^>_CWP1=^!-2:QN,O ^7MI\866+. >,@.O21,Y4X(RK*QD9Q-
M@H <JER%4$L2  !DDGH .Y/84 ?<7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:
M-QYK=O\ 5J<!B[ ]NI@% !0 4 % !0 4 % !0 4 ?+O[2_\ J=+_ -^[_E;T
MF,^3Z0@H * "@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "
M@ H * "@ H * "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % 'T?\
MLV_\A:^_Z]%_]&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@
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M!F[JFU?E)D6F@/?J8!0 4 % !0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?0W[-__
M "';O_KP;_T?!0AGV95""@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H /^%A^)?^@I?_ /@3+_\
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M9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$%
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M4+R>"64AXY)Y&1AY;G#*6((R >>XH ^YJH04 % !0 4 % !0 4 % !0 4 %
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M,^@*,!TYZTK@>3Z[\1O$7B/*WU].T;<&*-A#$1Z&.((K?\"#'OG- SB:!!0
M4 % !0 4 % !0 4 % !0 4 ?0GP4^&)U^==>U6/_ $"W?,$;CBXF4_>(/WH8
MB.<_+(_R?,JR+0,^SJH04 % !0 4 % !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % &UI/B/4]!#C3+JXLQ+M+B"5X]^W
M.W=M(SC<<9Z9/K0,U_\ A8?B7_H*7_\ X$R__%4 '_"P_$O_ $%+_P#\"9?_
M (J@ _X6'XE_Z"E__P"!,O\ \50 ?\+#\2_]!2__ / F7_XJ@ _X6'XE_P"@
MI?\ _@3+_P#%4 '_  L/Q+_T%+__ ,"9?_BJ #_A8?B7_H*7_P#X$R__ !5
M!_PL/Q+_ -!2_P#_  )E_P#BJ #_ (6'XE_Z"E__ .!,O_Q5 !_PL/Q+_P!!
M2_\ _ F7_P"*H /^%A^)?^@I?_\ @3+_ /%4 '_"P_$O_04O_P#P)E_^*H /
M^%A^)?\ H*7_ /X$R_\ Q5 !_P +#\2_]!2__P# F7_XJ@ _X6'XE_Z"E_\
M^!,O_P 50 ?\+#\2_P#04O\ _P "9?\ XJ@ _P"%A^)?^@I?_P#@3+_\50 ?
M\+#\2_\ 04O_ /P)E_\ BJ #_A8?B7_H*7__ ($R_P#Q5 !_PL/Q+_T%+_\
M\"9?_BJ #_A8?B7_ *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H ]6^#
M'B_6M8\2PVM_?75S T,Y,<LTCH2L9()5F(R#R/2@#[+JA!0 4 % !0 4 % !
M0 4 % !0 4 ?&?[1_P#R';3_ *\%_P#1\]2QGSS0(* "@ H * "@ H ^AOV;
M_P#D.W?_ %X-_P"CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M-&5./W<;#][D89AY7/S[4,^U54*  , < #H!5"%H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
M* "@ H * "@ H * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4
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M H * "@ H * "@ H * "@ H ^<?VDO\ D$V/_7VW_HEZ3 ^.Z0!0 4 % !0
M4 % 'JOP3_Y''3_^WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /L3]FW_D$WW_7VO_HE
M*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0 4 %
M!0 4 % $]K_KH_\ ?7^8I#/U+JQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!\N_M+_ .ITO_?N_P"5O28SY/I""@ H * "
M@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H
M^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4 % !0 4 % !0
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M&2QXMYCPLH[!'X27T 5\_(0QL,^Y 01D<@U0@H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /GOXL?!U?$6_6=#41ZA]Z: 85+GU=>@2?U)^67OA\LR
M^-IH9+9VAF5HY$)5D8%65@<$,#@@@\$'D4@(J "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /8OA?\ "FY\;3+>W@:W
MTF-OFDZ/.5ZQPY[=GDQM7D#+\ &?<>G:=;:1;1V5E&L%O H2.-!A54?J23DL
MQ)9F)9B6)-4(NT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?
M_KA;_P#HL5(SQN@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0
M4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@ H * "@#Z
M&_9O_P"0[=_]>#?^CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % '(>+O!MIXL@V2XBN8Q^ZG RR]]K#C<A/52>"25(.<\M:C&LM
M=)+9_IZ'HX7%SPDKQU@_BCT?FNS\_O/E#6M$N_#]RUG>H8Y%Y!_A=<D!T/\
M$IQP?P(!! ^>G"5-\LU9_P!:H^]HUH8B"J4G=?BGV:Z,R*S.@* "@ H * /H
MCX*?\>MY_P!=8_\ T!J]G!;3]5^I\?F_QT_\+_-'MM>L?,A0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?./[27_ "";'_K[;_T2])@?'=(
MH * "@ H * "@#U7X)_\CCI__;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'V)^S;_R"
M;[_K[7_T2E- ?1U, H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?
MGU2 * "@ H * "@ H GM?]='_OK_ #%(9^I=6(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /EW]I?\ U.E_[]W_ "MZ3&?)
M](04 % !0 4 % !0![)\!O\ D;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4
M% !0 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H
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M[."VGZK]3X_-_CI_X7^:/;:]8^9"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_
M .1QT_\ [>O_ $CN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
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M?8_P[^"UAX2*7^I%;[4EPRDC]Q W_3)6^^X/25QD$ HJ$9+L(]OI@% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__ *+%2,\;
MH$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0!
M\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H ^AOV;_^0[=_]>#?^CX*
M$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9.
MMZ':>(+9K.]3?&W((X9&[.C8.UAZ]",@@J2#E.G&HN6:T_%>:.BC6GAYJI2=
MFON:[-=5_2U/D_Q=X.N_"=QLE_>6TA/DS@?*P_NM_=D ZK^*DCFOGJM&5%V>
MW1]_^#Y'WN%Q<,7&\=)KXH]5YKNO/[SD*YCT0H * /HCX*?\>MY_UUC_ /0&
MKV<%M/U7ZGQ^;_'3_P +_-'MM>L?,A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?./[27_()L?^OMO_ $2])@?'=( H * "@ H * "@#U7X
M)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?8G[-O_ "";[_K[7_T2E- ?
M1U, H * "@ H * "@ H * "@#S+XR?\ (HZC_N0_^E,-)@?GU2 * "@ H *
M"@ H GM?]='_ +Z_S%(9^I=6(* "@ H * "@ H * "@ H * "@ H * "@ H
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M^P\-6PLM+@2VA7G:@Y8_WG8Y9V/=G).,#. !5"-B@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H ^$?CS_ ,C9/_UPM_\ T6*D9XW0(* "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H *
M "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_UT?^^O\
M,4AGZEU8@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\ 1\]2QGSS0(* "@ H * "@ H
M^AOV;_\ D.W?_7@W_H^"A#/LRJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 07-M%>Q-;W"+)%("KHPRK ]014M*2Y9*Z?0J,
MG!J<&TUJFMT?,?CSX=R^'6:]L0TM@QR>[09/"MW*<X5^WW7YPS>#7P[I>]#6
M'Y>OEY_?Y_;X+'K$)4JME5Z=I^:[/NOFNR\MK@/=/HCX*?\ 'K>?]=8__0&K
MV<%M/U7ZGQ^;_'3_ ,+_ #1[;7K'S(4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\C_\,U7O_01A_P"_#_\ Q=*PP_X9JO?^@C#_
M -^'_P#BZ+ '_#-5[_T$8?\ OP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-
M5[_T$8?^_#__ !=%@#_AFJ]_Z",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KW_H(P_]^'_^+HL ?\,U7O\ T$8?^_#_ /Q=%@#_
M (9JO?\ H(P_]^'_ /BZ+ '_  S5>_\ 01A_[\/_ /%T6 /^&:KW_H(P_P#?
MA_\ XNBP!_PS5>_]!&'_ +\/_P#%T6 /^&:KW_H(P_\ ?A__ (NBP!_PS5>_
M]!&'_OP__P 718 _X9JO?^@C#_WX?_XNBP!_PS5>_P#01A_[\/\ _%T6 /\
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M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
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M^"USX*UB/5I;R.X6..1/+6)E)\Q2N<ER.,YZ46 ^@:8@H * "@ H * "@ H
M* "@ H * "@ H * "@ H \)^(OP4A\97XU2PG2QGD7%P&C+K*PX60!67:^/E
M?J& 4\-N+*P'GO\ PS5>_P#01A_[\/\ _%T6&'_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KT?\Q&'_ +\/_P#'*+ ?37AFPO\ 2].AL]4G6]N8
M%V&=5*F15X0N&+$OMP';/SD;CR33$;U !0 4 % !0 4 % !0 4 % !0 4 %
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M,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\
M%T6 /^&:KW_H(P_]^'_^+HL ?\,U7O\ T$8?^_#_ /Q=%@#_ (9JO?\ H(P_
M]^'_ /BZ+ '_  S5>_\ 01A_[\/_ /%T6 /^&:KW_H(P_P#?A_\ XNBP!_PS
M5>_]!&'_ +\/_P#%T6 /^&:KW_H(P_\ ?A__ (NBP!_PS5>_]!&'_OP__P 7
M18 _X9JO?^@C#_WX?_XNBP!_PS5>_P#01A_[\/\ _%T6 /\ AFJ]_P"@C#_W
MX?\ ^+HL ?\ #-5[_P!!&'_OP_\ \718 _X9JO?^@C#_ -^'_P#BZ+ '_#-5
M[_T$8?\ OP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-5[_T$8?^_#__ !=%
M@#_AFJ]_Z",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718 _P"&:KW_ *",/_?A
M_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\ WX?_ .+HL ?\,U7O
M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
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M>/DQC'>@1[?3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * &NBRJ4<!E8$,I (((P00>""."#P12WT8TVG=:-;'SEX_^&S:9
MOU/25+6O+2PCDP^K(.IB[D=8QSROW?$KX;DO.G\/5=O^!^1]C@<P52U#$.T]
MHR_F\GVE^?KOT7P4_P"/6\_ZZQ_^@-6V"VGZK]3CS?XZ?^%_FCVVO6/F0H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /,OB?X E^(%G!:0SI
M:FWF,I9T+@@H5P &7!YSFD!XI_PS5>_]!&'_ +\/_P#%T6&'_#-5[_T$8?\
MOP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-5[_T$8?^_#__ !=%@#_AFJ]_
MZ",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718 _P"&:KW_ *",/_?A_P#XNBP'
M7>!/@?<^#];MM9EO8ITMO-S&L3*6\R"6(88N0,&3=TY Q181]%4P"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H Q-)T&TT6:X>R3RA=,LCH/N
M!AN!*+CY0>I . ?N@#BL84XTW)PTYK-KIUV.JK6G6C!5'?D32?6VF[Z_GW-N
MMCE"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
+* "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ebs-20231231_g2.jpg
<TEXT>
begin 644 ebs-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !H +<# 2(  A$! Q$!_\0
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M'B_+7'FC&6GDO\SGEX=YTIJ,G#7KS/\ ^1/T"\RCS*_/D?M<?$X_\Q>T_P#
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MRI)+V;^]_P"8?\1"X@V]JO\ P&/^1(?V'?%."%\0Z. >K%)<G]*/^&&?%?\
MT,6C_P#?,O\ \3115RX3RJ>]-_\ @3,X\?9_':LO_ 8_Y"_\,->*_P#H8]'_
M .^9?_B:/^&&?%7_ $,6CY_W9?\ XFBBLWPCE"_Y=O\ \"?^9K_Q$#B#_G\O
M_ (_Y%W1_P!AG4VO$.M>)K5+,'YEL(&:1AZ M@#\C7T[\/?AUHOPWT./2M#M
M/LUJIWNS'<\K]W<]R:**]; 9/@LM;EAJ=F^N[_$^<S7B/-,[2CC:W-%=$DEZ
8V25_F=<JXIU%%>X?.!1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ebs-20231231_g3.jpg
<TEXT>
begin 644 ebs-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !0 '<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "D
MI:2@!M+_ )YJ&:=+:,O*RH@&26/]:R3XST9>#?P_]]5YV(S#"8-J.(JQB_-V
M+C3E/6*N;G';FC_/6L3_ (331?\ H(1?G5+4/B3X:TF)9+S6;6V5N 9'QGZ"
MN6.=9;)J,<1%O_$B_8U%]DZD8[4AQ7+6WQ,\+W<(EAUNUD0]&5\_TJ;_ (6'
MX<_Z"]M_WT?\*]>$E4BI0=T^J,=5HSI:*YZ'Q[X?N)EBCU>V9V. -V/YUOA@
MP!!R.V*T =1110 4444 %%%% !36]:4L!U.*0LI[C\Z5P/.?BU>3QV]G;J66
M"0DO@XSCH#7F>/I^5>^:_H-IXBLS;W0'JK@_,I]17&_\*CBR<:D^WL-HK^:>
M..#,YS;-98O">_"5M+['T>!QE&E2Y)Z-'FZJ-P!]:\$\?74VH>*[[[1\WDN8
MXT8<*HZ8':OL-OA%'_T$9/\ O@5RWBK]F#3?%$ZW/]JS6EU@!I(T!#@>H/>O
ME<KX#S_#56ZE'?S1U5<=0G&RD?-GP_F>/6&@4?NI(R67'''0UZ'Y*?W17IVA
M?LNZ?H,;>5K-Q).XPTC1C/T'H*UO^&?X?^@S-_WZ%?TWPS@*^5Y?'#XJ5Y?E
MY'S&)G&K4YHK0\;,2,,;1^5?0OP8U*ZU'P7%]I=I?)D:*-VY)48QSWK!A_9_
MM1(OG:M.\6?F54 )'IGM7IVCZ1;:'I\-E9QB*WA7:JC^=?4R::T.=71>HHI,
MBH*%HHHH ;N[52U;4H]+TVZO)/\ 5P1M(WT S5W;WJGJFGQZGI]S:RX,<T9C
M;Z$8_E6<^;E?+N5"W.N;:^OH?GMX\_:0\:^,=>N;BTUB;2-.$C+;6UKA?E!P
M"Q/))'-<W_PN#QU_T->H_P#?8_PKL_'O[+GC7PMKUS%I>G'6-+DD9[>:%QD*
M3D*P/<=,US?_  H/XA8Y\+W1_P"!#_&OP;%QSKV\^;GO?I<_K3+ZG#'U:G[-
MTTK+>U_G<S;CXS>.H8=__"5:AGH/G'^%)H/[1'Q!\.ZI%?'Q'=7T:L/,M[G#
M*Z]QTX..]:%Q^S]\0YHRG_"+W(/4?,/\:- _9=^(VO:G'9S:$^G6[$"6XG88
M5>^!W/M4T(YQS*W/^)Z4ZG"_L9^T=*UO[MSZ_P##?C:]\3:%8:I!=RI'>1+*
M%)Z9&<?A7S)\:/VD/&-YXLOM(T36[C2M,L9#"6@($DSCJ2<<#T%?4'AWP%?>
M&=%L=-M[.3R;2-8U+8R<  G\:^;?C)^R[XR_X2J[UKP[I+ZE87\AE>W5AYD3
MGJ,'J/>OU?!JLK>UO>Q_-&8/#7E]7MRWT]#SK2OCIX_CNECE\7:G+&YQ\THR
M"?3BNBF^,'C>WB=SXKU/"@DCS1V_"LS2_P!F_P")!N5EF\)7D:(<[3C)/YUO
MS? ?X@S1NC>%+S# @X [_C7U.&OR^\?&XFW/[AQ4?[0WQ)M[Q;J#Q?J"E3E8
MG8,F!V(QSFOK/X5?&#5_B)X)M-8>\E@N\F&XC7[HD'4CV/6OEE?V8_B?)>BW
MC\*7 WMA9I" B@]R<U]6?##X-ZM\._!EGHWV22>X4^;<2*.&D/7'/0=*VG;H
M<\.;J=/_ ,)/J_\ T$9OSJWIOC;5-/ND>6Y:YAR \<G/'<@^M5_^$4UC_H'R
M_I5K3?!&J7]TB2V[6T&07DD..,] /6LC76YZO;S">&.5?NNH8?B,T46\(MX8
MXU^ZBA1^ Q14FA+1110 S;NI=HQTIU-:@#RWX^?';1_@-X2&KZC&UU<S/Y5K
M9Q$!II,9QST'<FOD1O\ @I%XL:1BOA/3U3/R@SMG';/O7I7_  4,^&^L^*/"
MNA:_I5M+?0Z3(PNH(5+,$;^/ Z@8YQ7Y\-,JD@A@0<$%2#GZ8K";:EH?TAP)
MPOD.:96L3C$IU&W=-VM\CZ\;_@I!XO\ ^A6T[_O^W^%4;S_@IKXLM6\M?">F
MN_?,[_E7RC]H3U;_ +Y/^%<_J0\NZ=CN*L<AMIJ>=GW6,X*X=IT[PP\?O?\
MF?IW^S[^VY%\:/M&FSZ1'I7B&V3S3;&8LDR=RA]NX->T?\+.O/\ GRA_[Z-?
MG-^Q#X#U:^^)!\5&VEM]&L+=T-Q(I42NPP%7/7WQ7W+YG6NB%Y*[/YCXLP&#
MRW,I4,$_=T\[/L=LGQ0N@PWV,93/(5SG'M7<:/JT&M6$=U <H_8]0>X->)*V
MXX +'H H)/X5ZMX#TV?3-# G79)*QD"'J >F:K0^.1TU)2T4BPHHHH ****
M"FMUIU% $,D*31['571N"I&0:YR3X9^%99&=_#NFLY.26M4_PKJ/:FD4S6%:
MI2O[.37H['+_ /"KO"/?PYIG_@(G^%(?A;X19>?#>EGV:T0_TKJL&B@T^M8A
M_P#+R7WLS[+0=.T^U6VMK&V@@7[L44*JH^@ P*F_LVT[6L/_ '['^%6^?I2'
F'3.*1S-N3O+5E==-M8V#+;0J?[P0 _RJS2T4 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ebs-20231231_g4.jpg
<TEXT>
begin 644 ebs-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "; <@# 2(  A$! Q$!_\0
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MGP/H5SK6MWL=AIEKM\ZXE!VIN8*,X!/5@/QK:S7B_P"V%Q^SMXN/!.RW//\
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MW>O_ (E^1*OWJ^^OV'_F^!5L/^HA=_\ HPU\"K]XU]]?L/\ _)#;;_L(7?\
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M5/\ ^@U^8]K_ ,>L/^XO\J_3?]H@AO@/XX8'(_LF<@_\ -?F1:_\>L/^XO\
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M^'O^PY'_ .B9J^'U^Z*N)^Q<!?\ (G_[>?Z$-]_QXS_[AK]9_ ?_ ").@_\
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M*_1S-+J?C'B#B/:9E"E_+%?>V_TL.VBD8#TIU(WW32/S ^9/V\='%U\*],U
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M-893&0X4J#D>S&O-E_8F^%V #IU^<=_MLE>_-24CR</F.-PL/9T*LHQ[)V/
M9OV(_A;)&R'3M0VL,'_3I*]PTG3X=)T^VLK8%;>VB6&-6Y(50 .?H*OYIO\
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MBE85;,L=B.7VM:4K.ZN]GW/ _P#AB7X7[0/[/U$_]OST?\,3_##_ )\-0_\
M YZ]]S10:K/,R_Z")?>SF/A_X TGX:^&;7P_HD<D.FVQ8QI*Y=AN))R3UY-=
M/_.@T@Z9IGD3G*I)RF[M[L4YKA?BE\'?#7Q>T^RL?$=K-<16<_VB$P3-$RO@
MKU'L37=CI^-)ZT%TJM2A-5*4G&2ZK<\#_P"&*?A@W73]0_\  YZ!^Q-\,,\:
M?J&?^OYZ]\I1WIGJ_P!N9E_T$2^]GGWPN^"OAGX.QZE'X;MYX%U%TDG\^=I<
9E00,9Z<$T5Z!14'D5JD\1-U:TG*3ZL__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ebs-20231231_g5.jpg
<TEXT>
begin 644 ebs-20231231_g5.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !M &T# 2(  A$! Q$!_\0
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MOY]:IW6BV-\Y>XM(9Y,8$DT8=@/0%@<#VZ4 ?C0)2O.[[O7DD#'RYZ]/7/\
M=)QWH63:P*KTPHXV@<G / QU'K^9&?V.;P_I7F>7_9ED-RDAA;ID8P/3WH7P
M]I4C2 :99KM.WBW3T!S]WWH ^9O^">+#_A5OB/:I(_MP[6 (!'V: =AZ'./_
M -=?5K+N[D'&,BJMKI5K8@K;016Z,VXK'&HYR#Z>W^<5<H Y/PO\-_#W@S5-
M9U+1=%M-+O=:N%N=0E@BPT\H4 ,<$\ [FVC W.[_ 'F9CU2]2VW!Z>_'^?UI
)U% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ebs-20231231_g6.jpg
<TEXT>
begin 644 ebs-20231231_g6.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !G &<# 2(  A$! Q$!_\0
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014G@BA0*6BB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ebs-20231231_g7.jpg
<TEXT>
begin 644 ebs-20231231_g7.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !] '\# 2(  A$! Q$!_\0
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M/RJ#D<C+E2H[D 'JM%<%\)_BMI/Q:\,KJ6GR;+N/$=[8[R7MI&Z@D=5Z[6P
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MY)R=9T#(.0?M%Q^?^JZ]_J30!\\[<94\$CD$!1GUZ>@(Z<'G/-*.&'H3G&W
M]>G^>E?08_8A\<KP-5\.@9Y'GSGN#WA]OT[YX^>/'6GKH6L7.D6FKV&JB%O+
MEOM/9G@D;^)8W91O P1N P>Q.: ,#6M>_P"7>T8C(&^0=AG&!^O/Z&OJW_@G
M'"__ !<&9N-PTY,KR<C[42.G'WE/7^63\@?V)N(^=06R.YZ@Y[<],8YZ#BOM
MG_@GIIS6OAWQI/G*R7=L@;!SA4=L<CG[_P"1H&?6K;?FW #ZCIUYZ>])O$BG
M!!'4\\#COV_G7Q7_ ,% _B-K5GJGA[P=I.IW&F6DUH=0O3;RLAN=[-'&A*GE
M!Y<A*]"2I(^48],_8)4P_L]V<94*L.HW:@G@8WAN..F6:@1]#^<GF/AN%.6Q
MP>!S_(?YXIX^5LG<J@9^8Y[?Y_+\:_,7]J;5M6\/_M8>,]7T/5;G1M3BFL?+
MN;238ZE;*WXR#C'0$'@@X(Z _HE\+_%<GCKX<>&/$4JI'/J6G07<JH"$C=XP
M74=. V1CGI0!^6/CV\ETCXF>*O+;'E:M>(><\"9P<]<CMD'CCIVT=-U&/48"
M4R&7AD/8_P!1S_GFF_%32R?BKXU<2+_R']0!.6QQ<2$\Y/IW)_*N=M=/GL95
M>&55D4=0I(/(SD'J"<<?CUH&=@W3\_ZT8ZC^GUKTGX2? G4_C/H<M_H.O:&L
M]N^R[L+J69+BW)SC<!$0589(921P1G(8#NO^&(O'./\ D+>'O^_\_P#\9H$?
M/;<K]?U_G7UA^PC]WQN?>RY_\"/\]?\ $\DW[$7CE@?^)MX>_P# B?\ ^,U[
MA^S9\$=;^#:^(O[9N]/NFU(VYB^PR.^WR_-SN+HO_/0>O?ZD ]I9CV]>?T]J
M9)<+"N^1U1 3DGC SC.<_2G2*>>,G^'C/OC]*^%_VHOVEM4\3:IJ?@W0OM6E
M:';LUO?-(K0SWC _,G(!2+AA@X+ \X7<* +G[3O[4S^*_MGA#P?>>7H[ Q7V
MIPN0UWP08HF5C^Z!R&8??Q@97._Y@_BSCYF/0@8.<\=^[8_Q[JJD8&3G.<G@
M$\<GOGK^GH#2KA<;?D/IC&.G/K_D4%I#6PO\0;!!(;IC(Z_D?UKZ[_8E\?>%
M_"WA'Q!I^L:_INCW\M^LJ17]TD+/&(D4,-Y&0&R, G!]*^1'(6//W0!G [<?
M_6_/\*<JGSD"CA6!POH&P<?B!GZ=L\@F>J_MM>,-)\9_&:.YT74[35[.VTBW
MM?M%C.L\>\23R%=RL02!*IQQU]JN_L\_M':_\'_"UUHJ:59ZGILDYN+?SBT<
MD+,H4Y8#YE^4$#&>6YP0!XIH>A&15N;GH0&$>!SR<D\\=?\ $^O3;0H !P.G
MZT$F#\2O%&K>-_&^J^(M:2$:EJ,BR2_9PPC&$5$"Y+' 5% R2>.<GK]Z?LM_
M%;P?I/P%\+VNJ^+=&L;^RAF2XMKJ_AAEB43R[0RE@0-N,9ZCGGK7Q#J%C#?P
M[95SMY5NX//0US5OILNFWC1R#>N#AU.01N ]^>3]>!SGD Z[XCWMIJ?Q(\67
MEC,ES97>M7L\$\;;EEC>XE=74Y.00^X'T(]LX! 8$<-D9]1SZ9_']*;PP_O<
M=OXN/Y?_ !77YN7,H8D'!!Z\>Q'^'YT%HV?!?C;6?AUXFM-?T"\-EJ,'\3#,
M<D9.6CD7C<APN1VP",,JM7Z*? _X[Z1\:/#YN+;_ $+6;4*+_3';<T+$??5L
M#=&>H;\#@\5^:6X9SN'KUP/Y^H_#-:/AGQ1JO@O7K36=#OI-.U2U/[JXC 8K
MD#((8$%3\V5.03G/0X"6C]:3)U^91]?_ -?^<&G*VXGD'Z?Y_P XKRC]GGXW
M+\:O!TE])8RV.I6#""]'EO\ 9VDV@[HI"-I!ZE,[ES@Y&UG]74]1N!QZ?4_Y
M_"@0UE+-TR?RXQZ__KKQ']HO]G"Q^+]@^J:6L6G^+K=,17)&U+M0#B*3W&!M
M?'&!U' ]MDQN]\9QCD__ *O\*-N. /8\X]>E 'Y':QI%]X;U:\TS4K22QO[-
MS%/;2J%9&Y/3I@C:002"#D$C)JNS;6(/'7KQS@=?\] ?P_1G]H3]GC3?C1H_
MVJ#R]-\4VD;?9=0(P) .1#+C/[L]0<$H3N'\2M^>7B#P_J?A'6KS2=8LY-/U
M6R=HY[>3JK  CG."IVC##(8$D$CYB%7,]I%7&3@=/FX]N>?3'Z].2OUG\ OV
M5/)\.S^,/&]F1.MM)-I^C7"_<^0E99P1][N$[$DGD[5W_P!F']E9?#XL?&?C
M:S']I+B?3]'N1Q:="LLRD?ZT=53_ )9D GYPHB^F_$0_XI_4P=S#[)*.>/X&
MYXQ_G%!)^649W*ISGCJ.W;U]_P!34G<'UQ_6HX\LJD\].>OI_@*?Z=.W^?UH
M #VYZ\9[?YZUZ_\ LS_#W1/BIXF\1Z'KT'GV<VBR,DJ-B2"3SX\2(V2589^A
M!((()SY!Z8]_\_Y]*^A/V(O^2H:R?FXT9L<'(!GA./\ /UH \7^,GP9USX-^
M)9-/U-?M%C-N>SU*-<1W"9?G&3M8!AN4G@XY((:N"#_.>,'MD\GEA[>G?V]"
M:_5WQQX'T;XA>'KC0]<M%N[*4KM#L0R. <.A[,N<@_4'C-?G1\;/@?K/P4UX
M6U\&N]%N&Q8ZFH 64#^%A_#(!C(Z?*"#CH#1YSY@9AM/&./TQ[]N_P#>'7.*
M]9^ 7[/>J?&C5O.D:33O#%LV+N_5?F?H?*BR""Y!ZG( ))SD;[G[/?[.FI?&
M+4!?WOFZ?X5MI-LUXHP\[9&8X>.HS@MT7:O<8K]!_#_AW3O">CV>DZ39PZ?I
MMHHCA@@!55'/YGU).222>: (?#?AG3/!NA6FD:191V&G6:;8H(QP!P6)8CEB
M<DL3DDDDYK84\D;@?I]3_G\*BZ1C@\+],#C(!Q_G^4JMDGY@?I]3_G\*!#9&
MP>2!P<?XTC';DDXP"2?3B@MN9^V#MZ^N.:$R^6Z')'Y$@?UH -OE] J8[XP-
MH[?K_.N;U[X=>&O$OB;2/$.K:/:W>LZ3N^QWDB_,G?!!X;!RR[L[3EE()S72
MN F&QGD#T/)'>FJVXH1P77?^@'X]: !F.WK\V<<?0_\ Z^_TJAXD/_$BU4[<
MG[+*H_[X)[_Y_I?^\VSLVX_R%)/:I=0RPR@-'*A211D;@00>AXH _*.%@8U(
M(88XQSZ=_P#/6I,@X&<_Y_S^=?H6/V7?A@O3PL@_[?+C_P".4O\ PR_\,?\
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M<_,>/O'Y3CC/;_/\I%;)/S _3ZG_ #^%5UF# #;C. ,'H#MX''O5D9[D'\*
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ebs-20231231_g8.jpg
<TEXT>
begin 644 ebs-20231231_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ0^,OPXOI+37;'1H++2[Z XDM);V\@LA.A[/&+@NI[,@KX1_X)F_#3PEKO\
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M>;?\N'_T[B+*-JZ_Z>2_0_%S_@YTBN_@;\4/A;XH^#6N:IX5N_%.GZR^O_\
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M;1?B%_PJ36/VIOAQ:>*_[133_P#A&+GQQ81ZA]K=@B6_V9IA)YK,P4)MW$D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OS#_:C_X(P?'KX,?MHVG_  4._P""87B'0K;Q!#K,FJ:I\/=?
MF-M;SS3!ENDMY1\GDSK)('A<Q[-[%)!\BI^GE%=&&Q57"R;AU5FGLUYG-B<+
M1Q44I[IW36Z?D?,?AC]JW_@H3XFTB/2KK_@EUJ6A^(&C"37.M?%;1?['@EZ;
MS/;O+</&#S\ENS8X]Z[/3_V7_&/Q1_9K\;?!;]KGXECQ9?\ Q(BO!X@;2;7[
M-8Z/'<6Z0)::;&^YTA@$:NCR%G>4O*V"^T>TT4I5_P"2*CZ7_5LJ-#^>3EZV
M_1(_,#]EC]CK_@H#^P/^Q_\ &G]A#PY^SH?B(GC2[U)_ GC_ $+Q3I=I81?;
M[&.R=[V&\N8KB#REB27;%'-N8L@;&'/N?_!,'_@G1XA_X)F?L;^(/#!LXO&'
MQ&\3LVH:]!I%S'##+<"+R[>RAEN#&OE1@L3(^"3)(0#\JU]F45O6S"O6C*+2
M]YINW5KOK^5C"CE]"C*,DW[J:5[:)]M/SN?EU_P0X_X)Y?MK?\$Y/'OQ#U;X
M[?!B"[L/%6@6RV$OA_Q-83NMS:M-(L+*\R8\WS-JMG ;;NVJ2RU?^"17_!.S
M]N+]B;]M?QU\??C;\$[5M!\::%J%L@T/Q38W$]I-+>Q7:!D:5 RD1,F0<AF4
MXQDC]3Z*NIF=>JZCDE[Z2>_3;J9T\KP])4U%OW&VMNN_0_*[]@__ ()V?MS_
M  '_ ."LWC#]MSXG?!*RM_"GCK7?$,TL%CXKL9[G3(]3O3<1NZ>8!((\J'"$
MMC)4,0%/@7[9\GQ"A_X.9+*X^%%KI5QXBBUWP_)I-MKDLD=I<2KHEL?*E>,,
MT:N 5WA6V%@VUL;3^YU?G+\2_P#@D)^U-X\_X*@V_P#P4HM_B[X"MKFRU^PO
M;7PH]M>LC06MK%:K$T^W.]XX\EPF S<*0,5V83,%4KSJ5K+W'%;Z[6[G'B\N
M=.A"G1N_?4GMIW['&_M.?\$]/VUO^"J'[?G@CXE?M*_L_6OPK^%?@2PM[:^M
M;SQ?8ZK<ZPJ7#7$Z0BT9L><62(-($"HN\Y;]W6]_P6S_ ."<_P"W;^UI^TW\
M+/C?^RW%H^N:3X.L8D&@:SJT4$.GZA'>-<->/',566.5?(C8)E\6X&W!%?I3
M8-?/8PMJD44=R8E-PD$A>-9,#<%8@%ESG!(!(["I:XXYG7A4A**24$TETUWZ
MWU]3LEEF'J4YQDVW-IMZ7TVZ6T]#\D?VQO\ @F%_P5,^,'[?'PF_;<?2/AOX
MKUC0YM#O-;L-"U*32M-TF?3[XW M\W3R3SPL-I,Z*SEF<>2H5=WJ?_!<[]A#
M]LO]O_PG\,O GP3^&^E7UQX6^U7OB+6)]=M[.TDN9XH4\JW260RE08Y"2X&
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MH)C<Q,Z%E)P2K,N1P2.:LT45YIZ84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLVYXA_:C2X^*&O\ PA^#GPQU3QOK'A&SAN/%ATZ^MK:#3FF4O#:B2=U$MTZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[X\LLHZX/2N?ZY*I_"@Y>>R^\\+_ %OK8W3*\%4K=I->SA_X%+_)'V)\;?\
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M  7W^/OQEUN3P5^Q-^QW=ZC>MQ!/J<5QJERP/ ;[)9A0A^LCCUK+_P"&8_\
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M\0/%O@ZX?/EP-<1ZC:1^GR2A93^,U>2'_@DA_P %4OV7";C]DG]L<:C86_\
MJ=*@U^ZTTRXZ9M9?,M3_ ,"?BOU;HK&6!PS=TK/RT/(Q'!'#M6?M*5-TI_S4
MY.#^Y.WX'Y2']OC_ (+A?LH?N?VA_P!F1O%NG6_%UJ=QX6\Q54=_M>E-Y"GW
M96S7>?"C_@X\^!>L2)I_QO\ @'XF\-3YV2W&B7D.I0HPX)8/Y#J/8*Y'3GK7
MZ/UP?Q7_ &7?V<?CI&Z_&#X&^%?$4CC'VK5=$AEG7_=F*^8A]U8&H^KXFG\%
M3[U?\3#^P.),#_N68RDOY:L5/[Y:2_ \Z^$G_!4[]@/XT&*#PI^TQX?L[J7
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MDG^1L4445H=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#*[/#X>*?=KFE_X%*[_$****Z#W0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***J:[K^@^%]*FUWQ-K=IIUC;KNN+R^N5ABB'JS
MN0%'U- FU%79;HKY<^-W_!9+_@G[\$/.M+CXU1>*;^+/_$O\%VQU OCL)U(M
M_P Y17RQXR_X+^?'+XOZW)X)_8G_ &/;S4[Y^()]5BN-3N6!X!^QV078?K*X
MSVXYYJF,PU-V<KORU/F\=Q?P[@)<DZZE/^6'ON_;W;V?K8_4JO.?C1^UW^S#
M^SO"[_&GXZ^&O#\T:[OL%YJ:&[8>JVZ%I7_X"AK\YO\ AF__ (+R_MM?O/BY
M\5Y_AWH%V?FLKC5TTI#$>J&VT]6F?_=GP2>I[UZ-\%_^#<_X$:#,FL_M!?&K
MQ%XNO"WF3VFD0IIUL[$Y(=B997'7Y@\9/7CI6?UC$5/X=/YRT_ \_P#U@XAS
M#3+LOE%?S5GR+_P%>\UZ,U/C=_P<2?LK>"O.T_X)_#SQ)XXNTSY5U.@TNR?T
M(>4--^!A%>2_\-R_\%N?VU3]G_9L_9_D\%Z)=<0:K::$L*M&>I-[J9\MB!WB
M56]!FOT%^"/["/['_P"SIY,WP@_9[\-Z7=P8\K5);'[5>KCTN;@O*/\ OJO6
MJ/88JI_$J6\HZ?B']A<39C_R,,>X1_EHKE_\G?O?@?E9H'_!"[]L']HC5H?%
MW[<'[8\TTI;S/L<%W<ZS<(#U027#1QP'_<#J.@%?37P1_P""(G[ 'P<\F\U3
MX;7GC34(L'[9XQU$W"$]_P#1XQ' 1[-&WUZY^N:*N&#P\'?EN^[U.W!<&\.X
M*?M/8J<_YIMS;\_>NK^B1E^#_ _@KX>Z)'X:\ ^$-+T/3H?]5I^CZ?';0)]$
MC4*/RK4HHKJ22/IHQC"*C%62"BBB@H**** "BBB@ HHHH **** "BBB@ K \
M?_"GX7_%?3/[%^*/PXT'Q)9X(^RZ[I$-W& ?]F56%;]%)I-69,X0J1<9JZ?1
MGR9\6_\ @B3_ ,$\_BKYMQ:_"6Z\*7DN<WGA+5Y;;;_NPR>9 OX1U\W^-?\
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M3]HF07'A[X.ZCX9L[CE[G4[2+2P%/\6;UO.(]T!->E>#?^""W[1?Q$GCU/\
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MY[9KP3XLO\0OVE!(?'O_  3_ /"FN/,/^0CJ'P^N);E?]VY+!E_ @UX?=?\
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M#^SEJ.@Q:MKGQ/\ %=M/(F3I\OAN&.:,XSAML\J9[<.:]#"\*Y3B%>&+G/\
MPX>I;[WH<%#B;A3$)N.-CIW37_I5KGWC_P )]X$_Z'72/_!E%_\ %4?\)]X$
M_P"AUTC_ ,&47_Q5?F[\3/"'A[3H1%\&_#VKZQ,00TGB?5H--B4YZCR(KIG]
M<$+7G4?@7]J"25C-8> H4+':JZM>R$#MD_9US^0KL7!>7MV5:K_X)?ZLY:_&
M7"-"?*\2V_*$FOOM8_5S6?B[\*/#EDVI^(?B=X>L+9/O7%YK4$2#ZLS@5\\_
M&W_@L/\ L:?!WSK/2M8\0^-+^+(^Q^#O#TTZ$]O](E$<!'NKM]*^6?!/PQ\0
MR(MQ\1_%5E"P^_::)I3RAOI++,N/^_9KJY_A_P##%?\ CV;7G]/,N85_E&:V
M_P"(?X>JO<Q$UZTU_P#)HY<3Q7P_7I?N,<J;?5TI2?W)K\4<A\0?^"YW[8GQ
M6OY/#?[)O[&5Q9%V\M+_ %FSNM3G4'H^R)8HX3_OEU'>N;_X9C_X+#?MI_O_
M -HO]K+3/!.B77,VEW7B^"V5HSV^Q:9\CD#^&8J?4YKT^/X:^%+K_CSTS6G_
M -V\C;^4%6(_@C]J.+/POXB?L-J[OY0UC+PSP<G^^QL_3EBE^$SYB<^',?)O
M'YK7K+^6,)4XOU48Z_>-^"?_  05_8E\'F+4?C?^T%?>-;M2#):VFI0:79/Z
M@JCO,?J)5^E?7OP5_9S_ &&_V=DC;X,?#GP'H5Q$,)J,'D27A'O<RLTS?BYK
MY+B_9O\ %5W_ ,>7@+Q2^>FW3W;KTZ15;MOV4/B-/@I\-O$W_;33G3^:"G#P
M]R##[8Q+_MV-_P#TH]C+\5P-E=G@\/--=52;E_X%+7\3[V_X3[P)_P!#KI'_
M (,HO_BJ/^$^\"?]#KI'_@RB_P#BJ^&+;]CKXGS?<^&6K_\ ;0A?YD5H6W[$
MGQ8GP$^%T_\ VTU*)/YRBB7!_#T/BS&/_DG_ ,F>P^*< _@P^(EZ4O\ [8^U
M_P#A/O G_0ZZ1_X,HO\ XJC_ (3[P)_T.ND?^#*+_P"*KXWMOV$_BP^-_P /
MK>+_ *Z:O$?Y2&K]M^P1\3W'S^'=(C_ZZ7X/\@:YY<,<,Q_YF4?_ "7])D_Z
MR*7P8+$?."7_ +<?7/\ PGW@3_H==(_\&47_ ,51_P )]X$_Z'72/_!E%_\
M%5\K6W_!/[XC.<.GAB+_ *Z3N?Y1&KUM_P $^O&@QY^L^&H^G^J21OK_ ,LA
M6$L@X7C_ ,S%?^ _Y,3S_'2^# 5?FXK]3Z;_ .$^\"?]#KI'_@RB_P#BJ/\
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M<.YUGVA"3_-)?B?JM7GWQF_:M_9L_9YMWF^-7QO\->'9%3<+/4-4C%TXZ_)
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M_B;P_ >B0--Y3 ^]PCG\FJ]\/OV:--^&EX-0\">(?%VE3[L^?IWB.>S<GUS
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M"M?1FZD/U>8NS?B36K!\*?A=;<VWPVT"/_<T> ?R6M^BN.6.QLMZLG_V\_\
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M_P +7_;K\9G_ (D/PY.EA_ND:.(<?C=L17SRX]\-Z\O]BHXC&R_Z=TJL[_\
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MT^.+'_?*BM6G_J?XDX__ '[B!P7\M&A"/W3;<OP)_MSA7#?[OEO,^]2I)_\
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M=57PVLZ6&KZ2\JFY6:YFG(DBD0;"IE"@AFW8Z+CFGH/@S_@H98>,/$&DZO\
M&OX<7GAF_P!4GET'5YO"]S_:NF6KL2D'DQR1P2E%(579B<C<V\'90!\C?M4_
M%7XY?&3_ ((F>+F^,7[_ ,6>$O&">'/%]];K\M\UAK$4!GX !RPBW$#!96;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVS]5U.2,YD@T5K*P9O;8WVE\?3GWKZLC_89^)GBF03?$;XT^<V<MM6:\.?\
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M<GZ2SL/TQ7YGF&:\>9UB7B,;4A.;WE.52<OO9YM1> ]&7-5JYCB)>2H0B_\
MP*\CR;Q#_P ' 7[&VEYCT/P)\0-3?^%DTFTBC/XO=!O_ !VN$\0_\'%G@.W)
M'A/]ES5[WGY?[1\3Q6V?^^():^S_  ]^PW^QIX6PVB?LK_#^-U^[++X3M)9!
M]'>,M^M=YX>^'G@#PCC_ (13P-H^F8Z?V?ID4./^^%%</U/B6I\6*C'TA?\
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M_NQ(%'Z5)117(VV[L[$DE9!1112&%%%% !1110 4444 %%%% !1110 4444
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M111709!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_F?8?C[_@XH_9^M[E],^"7P \:^+;M<B/[88;"*0^JE#/)CZQ@^U>7>*/\
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MJ/AVUS_STO2<?]\Q-5^V_P""??[0TY']H_$KPY$">?(DF;_V@M?9-%<<N/\
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MYC3B[,****S$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^Z;#]@#PXN/[8^*.K2>OV*R@A_\ 0Q)6W8?L)_!>U(^W:GXAOL=?M&J*F?\
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M[TY?<SWVBO*](_;H_8GU_ T7]K_X7W+'^"'Q[IQ;OU7SLCH?RKJ=(^.WP/\
M$! T'XR>%+XL<+]C\16TN>W\+FO+K93FF'_BT)Q]8R7YHS=*K'>+^XZNBH;'
M4=/U. 7.FWT-Q&<8D@E#J>_45-7 TT[,S"BBBD 4444 %%1WEY::?:2W]_=1
MP00QEYIIG"I&H&2S$\  =S7R-^U!_P %O?V"OV;/M&CV/Q&;QYKL.5_LCP0J
MW:*_H]T6%NHSP0KLXP?E[5[&3</YWQ#B?J^6X>=:?:,6[>;>T5YMI&M&A6Q$
MN6G%M^1]>UQWQF_:#^!_[._AL^+?CC\5M"\+6&"8Y=9U%(6G(ZK$A.^5O]E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS3[-=#S&FG9A1114""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ"UC4K22[ETGX<^&SJ4]A;*P19[A0R^4CON5"?O&-_[IKS#_ ()A_M?? _\
M:,^%7A/X9)IMQHOQ#^'O@NST^\T'6XC'<FU%O;H;NWSCS8)1'"V0,KE,@ JS
M5/VB?V7_ /@H!X.^,GBK]JW]DK]IK3;^_P!5CMO/^&NO^&XUM+NTM$816B7!
MD9MWS2D8\K+S.=Z;C0![Y\(OV@K+XD?!B;XW^-OAOXG^'6G6J74UY8?$"P6P
MO+6V@SON)8M[&*/"L06P2J[L8()XK3?VZO#9\,^'?BSXK^%VO:#\._%NHP6>
M@^-=3E@"?Z0VVUN+FW#F6UMISM$<K X\R,R+&&S7SI^W!^V-=_M&_P#!&7Q!
M\9?#VAW.@:EK%Y::)XETEV/F:=<IJ$45U!D@$JVP@9&=DH! .0/7?^"A_A+1
M+#_@E#XP\*?9T^QZ;X#L%M4P,*;=[9HL?1HUQ]* /J2BO/OV2O%&M>./V5?A
MGXT\1SO+J.K_  _T:]OY922SS2V,+NQSW+,3^->@T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Y%^T1^P9^R#^U7#*WQT^ F@ZQ>RKM.LQVQMM07CC%U 4FP/0L1
M[&O7:*[,#F&/RS$+$8.K*G-;2A)Q:^::9<*DZ<N:#L_(_+CXV?\ !M_9:%K7
M_"??L3?M,ZOX7U:V<RV%AXD=SY4G;R[ZU"RP@=!F.1O5O7B/^&CO^"]7_!.7
M]S\:_AY<_$_PC9??U.^M#J\0A'60WMH1<1=.&N<X_N\\_K]17Z7AO%S.L306
M&S_#TLPI+3]]!>T2_NU(I23\WS,]&.:UI+EKQ51>:U^3/SS_ &<?^#C;]D+X
MFF#1_CSX3USX<ZE)A9+J2,ZGIP;I_K8%$R\_WH0!W:ON/X4?'#X.?';P\/%?
MP8^*&@^*=.(&ZZT+5(KE8R?X7V,2C?[+8([BO-?VC?\ @FS^Q-^U5Y]Y\7_@
M#HLVJ7&2^OZ5$;#4"W9FGMRC2D>DF]?8U\._%C_@W4\??#+Q"?B/^P3^UEJN
MA:K;9:RLO$%S+:7$??":A9 ,/0 PCMEN];_4O"/B;_=J]7+*S^S47MJ-^RFO
M?7^*>B[#Y,JQ/PR=-^>J^_?[S]5:*_($?MT_\%P/^"=A^R?M6?!*;Q]X5L^)
M-:U&P%PBQ#N-2L,JA/7-R'?KD<<?17[./_!PU^Q%\7_(TGXMPZS\-M5EPK_V
MQ;F\L"Y[+<VZE@/]J2*-1ZUYV9^$O%^$PSQ>!C#&T/\ GYAY*JO_  %>_P"O
MNV7<SJ97BHQYH)3CWB[_ /!/O2BL+X>_$_X;_%OPY'XO^%GC_1O$FE3?ZO4=
M"U.*[@8^F^)F&?;.:W:_-JM*K0J.G4BXR6C35FO5,\]IQ=F%%%%9B"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\N^)'Q=^)?PN^-%G#??"KQ%KG@+4O#Z
MB76/#>FB^ETO4DG?(DMXLW+QR1,OS(CA6B Q\S$>HT4 ?$/[*OP8U[XS_&/]
MG_\ :3T/X>WWA[1?AO\ !J'3=4\0ZI9_99O$US<:='!%;11-B1[> -)*)G4*
MS. FX?,/:]!_:X^+6H>,/$'P^UC]B'XCVNIZ9JD]OHUY"+632M5@5B(KC[<\
ML<<(889E(8J#@;V&VO;[.SM-.M(M/T^UC@@@C6.""% J1HHP%4#@    #I4E
M 'SAKO[!-EXS_8;\8_LO^*-6LX];\<W>HZYJVI6J,;:#6[J\-\K1@@,8(IQ$
M@X#-'%R 6(KB_B]X>^/_ .U!^QMI'[%U[\+->T#Q?JUOIFD>/M>U"QVZ9I=K
M:RPM=7D-SGR[SSA!B**$N_[X>8(]K$?8=% &?X2\+Z-X(\*:9X+\.6WDZ?H^
MGPV5A#G/EPQ1K&B_@J@5H444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?
MQU\// /Q/\/3>$?B5X(TCQ!I5Q_K]-UO3HKJ"3ZQRJRG\J^+?VCO^#?/]ACX
MS>?JWPQM-7^&^K2Y99/#]R9[$N>[6LY8!?\ 9B>(5]U45]!D7%?$G#-7VF5X
MJ='NHR?*_6+O&7S3-Z.*Q&'=Z<FC\@7_ .">7_!:O_@GBYO_ -CWX^R^-_#-
MH2T>B:?J *^6.N[3+\M$I(XQ SOZ'BM[X?\ _!Q%\:_@QJS?#O\ ;M_8\O\
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MY+^//C7]H?\ :=_X)1_&CX=_&**#5?&OP=\<_P!CZUK.EQ8BUF+3KBWDENL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA7I7UMX?URP\3:!8^)-+<M:ZA9Q7-LS#!,<B!E)_ B@"Y1110 4444 %%%%
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M@  ,^)G_  3!_9_^+7Q,UGXM^+O&_P 1?[:UV8/?36/CBYMT"+GRX42/ 6-
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M0+$G\*+DUV5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6NBWLR/J$.A:JUH]TBY_=2.HRT9)!*="5&>F* .0T3PY;_M%?%#1_P!HKQA
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M15R?<M(U;2]?TFUUW0]0AN[*]MTGL[NWD#QS1.H9'5APRE2"".H- %BBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***XWX^?&!/@)\*=;^+U_X*U37-.\.Z9/J&
MK6^CR0">.VA0R22*)Y(U;:BLV V< X!/% '945\UVG_!2+3F^!%G^T_J?[*?
MQ-@\ 7=D+P^(;==(NOL]J21]HDMX=0:=8Q@ECY9*@9( KW;X7_$[P)\9_A]I
M/Q3^&7B.#5M!UNT%SINH6^0LJ$D'(8 JP(*LK ,K*00""* -ZBBB@ HHHH *
M**\R_:]_:-F_91^!&M_'+_A6FI>*+?1(!+=6>GWL$'EJ75 \CRMD)EAG8DC#
M^[CF@#TVBO /VI/VYY?V9_V3]+_:E?X*ZEX@M=1T^QN9[&SU>"&*Q:Z6/RUE
ME?\ >$%Y0H:.%^F2%&*]_H **\;_ &A_VNIO@UXD3X??#KX#^,OB3XF%BE]?
MZ3X1L5:/3;9V98WN9Y"$C:0I)LC&YVV,< 8)E_9 _;0^%_[9'A;5M4\%:5J^
MB:UX;U#[!XI\*^(K3R+_ $FY^8!94!(P2C@'U1@0K*0 #U^BO$]6_;0TRXF\
M8ZK\,?A/KWB_P[\/;R:T\7>(-(GMT1+B! ]S!:1R2*]Y) I!D"[1GY4+OE:[
M36_VD/@KX?\ @&_[3NH>/+3_ (0A-%355UR/+));N 4VKC<78LJ"/&XNP7&[
MB@#N**\>T/\ :VCMO%/A/P_\7?A+K?@>#Q]*8/!U]K-S;2+<71C\U+*Y$,C?
M9+IXP62-MP8JR[]XVG=^+_[16@_##QIX=^$VB^';SQ)XT\5B>31?#>FRQQL+
M>%=TUW/+(P2"!,@;CEF8A45SD  ]$HK@?@O^T%X<^+^L^)/ TVBW>A>+/!U[
M%;>)_#.HO&TUH98Q)!,CQL5E@E0[HY%/(!#!64J.^H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O -7_X*G_\ !/30-6NM"UG]K#PI;WEE</!=V\EQ)NBD1BK*
M?DZ@@C\*]_KXK\3_ /! K_@GGXO\2ZCXLUGPWXJ:\U2^FN[MH_$\BJ99'+L0
M-O RQXKZKA>CP95J5?\ 6"K6@K+D]C&#;>O-S<WRM;S.G#+"-OV[:[6M^IZ;
M_P /9?\ @G%_T=YX1_\  F3_ .(H_P"'LO\ P3B_Z.\\(_\ @3)_\17DG_$/
M1_P3A_Z%GQ;_ .%5)_\ $T?\0]'_  3A_P"A9\6_^%5)_P#$U]?]3\$_^@K&
M_P#@%$Z^3)_YI_<CUO\ X>R_\$XO^CO/"/\ X$R?_$4?\/9?^"<7_1WGA'_P
M)D_^(KR3_B'H_P""</\ T+/BW_PJI/\ XFC_ (AZ/^"</_0L^+?_  JI/_B:
M/J?@G_T%8W_P"B')D_\ -/[D?;6CZMINOZ3:Z[HUXEQ9WMLD]K<1_=EC=0RL
M/8@@_C7P]^T5XA\2^%_^"VGP\U;PGX!O/$MXOP3N%72K"]M[>1U-WJ&6#W$D
M<8 ZX+9/;-?;?ACP]IOA'PUIWA/1E=;/2[&&TM1(^YA'&@1<GN<*.:^-?BW;
M?$^/_@K!X4_:4T/X >.M7\&>'_AM-H%_JVGZ P)NVEO)/DCE9'=!YJ#<!@DG
M&0,U^4U.3VCY-KZ7WMTN>8[7T/=O!'QE^+OC;]H>V^&OQ _9^O\ PCHB>$;K
M5;2ZU?4;&\-_>1W=I&!&;6201&%923E@6\]3CY<GS'3OC;^V)XO_ &\_B!^R
MII/C_P (6&E:3X+L]5T?5AX8D9K!9Y4!=H6G8W,X!:,9ECB_Y:%#CRV]"\5?
MM#_$[Q;JVB>"_A1^SKXZL+_5]6AM;[Q1X@T&*WM-$L"ZM<W!+R,7D\M2(TVE
M3(4+<#!\_P#AOHOCNP_X*H>/OB[J7PM\3V_A/6? %CHNE^(I=$F^SSWD$J.Z
MX WJOW@'90AV'!P5)@1E?L[_ !:_;D^+_CCXL?LJZS\8?"UEKOPS\0VT$OQ*
M7PF)9KNTNH6EMT33Q(D*RX1BTC.5484(Y/F++\#OV_O'7AW]C7XK_%[]HBTL
MM8\2?!SQMJGA;4)](@^S1:Y=6\D,5NX09$/FRW$<9P"!C<%YVU=_9!T[QMX0
M_;+_ &B/B3XR^%GBO2M!\;ZCI%YX7U.[\/3[;V*RM)XYL*JET8D@HCJK/D #
M=\M>8?"[]D_XH_&_]F+]IW]GGQ;X$USPEJ/Q'^*FK>*O!]UK^FO#!<0O<6UQ
M:%I%W!"9;= ZGYPK$A6P< ';?&7]I7]K?X1Q>%?B5\.H?&OQ)>768(/''@&V
M^!VK6<"6DBDRSZ?.UHLJ&(J JS22[MX)Z$5J?$OXW_MH7G_!06^_9$^'/COP
MA8:9J7PGF\1Z+J=QX9=VTMFOOLZ23HT[&ZD7RV0!6B3]^'9&\O:T/P(_:E_;
MY\=^'K+X#^/_ -C+Q%X;\<00+8:Q\1-0N(?[#@"C8^HH3G[1)@;UMX]ZN^ 7
M5"2MS4])\?1_\%<[3XU1_"?Q3)X/3X/GPC-XD319#;IJ/]IO==,;S%M(7S0I
M3)SG;\U %[5_CK^T;X-^*_P5_8P\>^--(_X37QGI6I7_ (T\<:+IBB,0V<4D
MBQV4,RF/SI-JAG="J!681_, L7PO^.G[53?\% /$W['^M^._#&J^&O#FA6WB
M*+6-3\+2?VK>6$Q1#;M+;7$-O%*DCX#_ &<AE!)4'BL[_@HUJ'B6'XT_"2?P
MO\ ?$/C"XT.75-934? 5_#'X@TMTCBA7REDR/LKM,/-#*R.5C0]=KG[*W[0?
MPYT_XY7-GXU_97^,?@OQC\1KF.";QS\2?#RB+5IH(':&S^T1-Y5N1''(4A2.
M.,[6.-QY *%Y^US\8_CS\&O$'QO^ OC7Q-HT\4^H_P#" ^'],^$&H:O9ZO%:
M3211_:[I;217:Y>%L?9Y8Q"LBJV]T8U0^-?[:W[86A_ /X$?&/2O ECX.U3Q
M]\0]*\,^+O!7B?P]<6U]%<RSSK)LEG8_9X)5MCMW0.X297#G&#@_LU>(OVQO
M^"=CZG^R-?\ [(7BCXE^#[77+NX^&_BKPC/%L6TN)FE$%T9"%@P[L69V7:6?
M ==K5UW[=WA']H/Q]\/?@CI][\-=5\0^)="^,VD>,/%<'AG3VGMM+L(9+IF@
M6;:BS-$LR1*1AY!%O*KN% &YJWQF_:P^ W[<'PR^$_Q@^)?AWQ5X5^+L&KPP
M:?I7A?[ WA^[LK=9P(Y#-(]PC;T3=(<G+':N *Y#X/Z+\<]5_P""L?Q9TF\_
M: N9$TCPEH<H27087C^PR2><+&)"W[E 7?YP2[%BQ))KIOVN-.\;>,/VU/V=
MOB=X.^%?BS5- \#WNM77BC4[7P[<!;*.^LX(X?D90[L"&+JBLR8P1N^6GV'A
M3XU?"C_@I_XT^)^G_ W7/$'AWXA^#=(LM,U_39H$L[">V(247;R.&B4*&;Y5
M=R,!4<G  /K"O@/]@SXA>.?!/[6G[547A+X$>(_&*3_%1VEET'4=+@%NPDN\
M(XOKNW)+9X*[@,'..,_>NIZC!I.GS:G=1SO'!&7=+6UDFD(']V.-69S[*":^
M(OV);[XK? GX_?'SQS\0/V8_B.FF?$'Q^VK>&[BS\/++YEL)+C!=?-#1L1(A
MVD>N<$8H P_@#XR?X\_\%?=1^*'QTL'^&?BKPSX*;1O!OPUUA'_M#5K4^:[W
MK3JOV:90)9R$BDD.%S]V(LWN/@?X^?':X_X*9^(_V7_&7B#1+GPE9?"W_A(]
M'@TS1FMYED>_@@432/+(9'53(,KL1MP.P$5Y[>? 'XY?M:?\%&?!/[5OBKX0
MW_P^\$?#/2GATU_$%U;C5=>N"92!Y-O))Y$(:7.)#DJ&XS(0G1^'] \>P_\
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M0DFTDXR@' R#SGG?@5\:OVB?C'!^T3\,-8^*\-GJ'P^\42Z3X9\2VN@0">"
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MI_AY%XP\.Z_I_AQ=+DMX_M@M9+5HDDD!7<6*L69L)R3NP.:^$W[57Q0_:?\
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MWX^_Y\X?_P "F>J_\/3?^">O_1V'A3_P(D_^(H_X>F_\$]?^CL/"G_@1)_\
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M@D"&]CTR"%)ACHX6XD?/J,U]$6OPL\2?LN?MO^-?VAM%\(:MK'@CXKZ%9?\
M"0CP_ILE[<Z3K-B"D3M;1 RO!-$\AWQJQ67.X*K!JK_ C]D;4?'GBOXY_'/X
M^>&I],N?C>@TB'0+B1&N=.\/Q6AM(EE*%E2>5/WCH"VS:@)W!@ "+]E+PEH<
M7_!(3P_X8FMT-E?_  <N7NXR!M87-I+)+GZF1L_6KG_!'GQ3K7B__@G!\,M3
MUZ=Y)H+&]L8Y)#G,-MJ%S;P@>RQQHH_W:Y#P)X>_:*^%'[#&I?L+I\*]:U/Q
MY9:/?^%_#>OVUF5T:[L9S)';ZFUWS' D4$JEX7/G;X2JQMN4GZ+_ &8?@7HW
M[,_[/WA+X$Z%=_:8?#6CQVLEWLV_:9^7FFQ_#OE9WQVW8H [RBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *QO&7Q"\%?#VUAO?&OB.VTZ*XD*0/<L0'8#) P/2MFN5^*GP<\%?&/3[3
M3/&L%Q)%9S-+ +>X,9#$8.2.O%>9G,\WAEE265QA+$67(JC:@W=7YG'7:^W6
MQUX".!EBX+&.2I_:<;.6W2^FY0_X:8^ W_14-+_[^-_A1_PTQ\!O^BH:7_W\
M;_"N8_X8<^ O_0.U/_P9-_A1_P ,.? 7_H':G_X,F_PK\Z^N>-?_ $"X+_P.
MJ?4>PX!_Y_8C_P !@=/_ ,-,? ;_ **AI?\ W\;_  H_X:8^ W_14-+_ ._C
M?X5S'_##GP%_Z!VI_P#@R;_"C_AASX"_] [4_P#P9-_A1]<\:_\ H%P7_@=4
M/8< _P#/[$?^ P/0/!OQ5^'?Q"N9K/P5XMM-1EMXP\Z6S$E%)P"<CUKC/VZ/
M^3)?C%_V2SQ!_P"FVXK=^%?[/_P[^#FH7>I>"K:[CEO85BG-Q=&0%0<C&>G-
M<[^W"-;U3]D_XA>!?"GA#6-<UGQ/X*U72-'T[1].>=Y+BXM)(4W,!MC4&0$L
MY48!QD\5]_D,\^J99&6<PIQQ%W=4G)PM?2SEKM:_F?-9E'+8XMK RDZ>EG-)
M2VUO;3?8^,/AU^UQ?^&?^"<WPM_9%\.?"75D\5?%7P9/X;\*:YXD:WM-"D>9
M7A>1KGS68D"4;8M@9V*K@;AGZP_9;_9>\3?LC?L0Z3\ =%^(Y77="TRZN)=>
MM;1)8A>2RRW+A(YE(:$.Y09"LRC/RL>/+_@O^R-9?M'_ /!,;PY^R7\<_!&M
M^%?$GA_18T@GU/2WBFTC4HWE^SW<$GW)1_>"/G8Y5MI:N]_8P^)_[2OB+X='
MX%?M=_"'Q#I7C#1TGTJ3QBEGY^F:]%&K*EXLR$['=5R=X4.V"IR^Q?9.$XOX
M4_M5?'WXH_\ !(]_VP[CQA:6'C>P\,Z[K+W%MI$36MRUC<WJ)"\+@@(R0("5
M*MD9SC(-GQY^W%XA\"_LS_L^_$;XD^+X_"]K\4[731XS\>0Z8DL>C/-I9NLQ
MQNKQQM+/M0/(KI&GF,5;;QY)\%M$_:;^'_\ P3-\9_L$W_[)7C(^*M \*^)=
M..MO#$-)U"*X>[F1[257:2ZE?SPB11QG<V-S("2/7OAU/\1/"7[*/P;^#?QN
M_9$US6?#@\(Q^'_B'H%QI-KJDEF+:SMD@O3!#)*9(S(C#RP/. 8MY>Y " =R
MWQ,^-?PO^%7Q/^+Y\9V?Q.\/:-X0&M_#J^L+>V5M1\NWN7EAE>T 29O,CC^>
M-%4HZ[5W!JPOV:/C1XV_: C^'WQ3^#W[4>G^.?#U].__  LO0Y-*L89M*+Z=
M<O&(EB1)K8+=K ACF,KLK B0J"6\]_9N^ _Q)_9:OOCGXW_91\#^)(/ %YH=
MO>?#GP-XC@N(9+G6DB=Y_L]O=@3P0L=D>955G)[K&IJOJ'[,WACQ9^U=\,/V
MBOV2O@EXL^&GBB+Q$)_BLEYX?GTG3GT@QLUQ!,& M[JXDDVHIM3(K%VD<_*K
M  [S4/VG_&GQN\2?$#2?AI\1O$OA"S\'>)+OPYHUWH'PJOM?%]J%JJBXGN94
MM)HA")F,:PQE),1%VDQ(JKY[\9_C?\:OCY_P1P^)'B_]H?X0:GX+\7VFDS6&
MKZ=J6C7%@+EHYH"MU#%<*'$3JZ^H#*X!XI?#&H?M8_\ !/3]H?XB^']$_9A\
M2?%'X8_$7QA=>*=!O_!Q62[TF^NR#<6\L;?=3<% +%5 0,&)9U7T#]L32_VA
M?BS_ ,$^?'7AWQ!\+[^7QGXVMMFC>"=#C%X^E1,\.RWEN(P$9E2-I9)"=H>1
MD0L%3(!Y_P#\%-O^4,,/_8O^%/\ T?95]RU\4_MU>"?BC\7_ /@ECI7P3^'W
MP@\4W_BV]TO0[5]!&BRI+:R6;VSW'FLP"*%\L@-N(<_<W $C[(\-:]#XGT&U
MUZ#3KZT6YBW?9=2LWMYXCT*O&X!4@@CT/4$@@D =:Z3HFBW%_J]K9P6\E_,+
MC4;@ *976)(P[GVCC1?8**^5_P!G7PO>Z5KW[1?[>WAJQ^S6?C\++X+@\O N
M['2K!XH]0"_W;J8/*F1\R;'Z25;_ &R/CA\>+CXBQ_!SPK^QOX_\8> X80_B
M>_T/R(%UUR 5L5>1P1:X/[X@ RX\KB,OYG;_ +/'QU^-OQW\37_A3Q_^QYK'
MPY\*6.B%9)?$]U$\E_,[*B6\,</RK&L8E+DD]4  Y- '!_\ !%G2;=O^";O@
MK4KS_2)M;N]9NM2DF.XSR-JEU&2Q/WB5C4'-?#GA;Q=KVM?\$TOA;\%Y[N4Z
M'/\ M31Z P=B5DT]7:Y$)SU7SIB^/5*^VOV:?#GQ?_85^"'B;]EK2_A/XC\3
MW.C:QJ,OPGU#2;'SK35+2[=IH$N;@D1V<D4TD@E\\HNT;D,F<5BZI_P3#US1
M?^":N@?LR^$=;LYOB!X3U2'Q9INJ2,1;S^((Y7F92QP?+*R26ZN<<;&(X(H
MN_\ !<C4+GP]^Q"GC?2K@PZGX>\=:/J6CW*G#0W4<K!74]B S=*J?!76-0\9
M_P#!;#XJWVNA_P#BF?A'I>G:3%+SY,,YLKJ0+Z?O9'S]3ZUT7[2?@OQM_P %
M -+^'WP9G^$OB/PQH%GXJLM?^)EQXET\VR6\5JCG^RX"W%W)+*X'FP[X56,M
MO)*J=SXD?!WQ1\&_V[+#]M+P;X6U#6M!\1^#7\,?$#3]'M&N+NS*2)-:ZC'
MF9+A?W:PNL89U7:P5OFV@'$3ZM=^&/\ @N?%I&BLRV_B7X#*VLQ+]UY(KZ7R
MY&']X")%![!B.]?9%?.?P#^"/BOQE^V7XV_;B\?^&+O18;_P[:^%_ >CZK&$
MO%TZ-EEGNYXLDPF68?)&V)%0'>JEMH^C* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0@ @EL[AR"&50#N***JZWK>D>&M&N_$7B#4H;.PL+9[B]N[F0)'!$BEG=F/
M4*"2?04 6J*** "BBO&?VF/VNYOV<OB3\-OA]<?"/4M6@^(OC&S\/P:ZNI00
M6ME+/(%)*Y>5W5<OM\M5;&/,!Z 'LU%%% !1110 45XS^V1^UU-^R-H'ASQ!
M-\)-2\16WB'Q19:(+RWU*"VM[.6Y<JID+%I2<*Q 6(J< %ES7LU !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>(ZK_P %(OV%]$U.YT;5OVF?#4%U:3O#<P23ONCD1BK*?EZ@
M@BO;J^1_$7_!$S]A?Q1X@O\ Q-JV@>)6NM1O);JY*>(G53)(Y=L#;P,D\5Y^
M/EFD5'ZE&+?7F;7I:Q]?PG1X&K5*O^LE6O"*2Y/81A)MZ\W-S_*UO,]#_P"'
MFW[!'_1T?A?_ ,"'_P#B*/\ AYM^P1_T='X7_P# A_\ XBO,/^'%_P"P/_T+
MWB?_ ,*23_XFC_AQ?^P/_P!"]XG_ /"DD_\ B:\SVO%7_/NE]\C[7ZEX#?\
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M%OP+9>&OBA\,OA]J6O:?/H%[)/8:M9BS9X;NW:10Z%7>$%6R07'.0RKOZ_\
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M=X-/PT\1^'O!OA#Q=!XL\;7/BG2VLFDN;:-UM],A1^;@L\K^9+'F%47*R,Q
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MLC+GE4#OA3PO[5/PVN?V\/BS\)8?AS\%_%&B3>!O'5KKVN_$#Q3X:GT@V-A
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>emergentbiosolutionscomp001.jpg
<TEXT>
begin 644 emergentbiosolutionscomp001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M4/\ <B_]%K7$UVWQ9_Y*-J'^Y%_Z+6N)KT*?P(\ZI\;"BBBK("BBB@ HHHH
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1D[(<J<HJ[.7-)3U1I'5$4LS'  &237J_A?X+7%_:QWNO736:. PMXQ\^/\
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MX<L=4F@OKVPMC<06JJURB_>"'/S >V*TIH+?5;830L-V.&_H:[3X!*&O]:!
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MB.[^+/\ R4;4/]R+_P!%K7$UVWQ9_P"2C:A_N1?^BUKB:BG\"+J?&PHHHJR
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!M**6FT .HIM*.E "T444 %%%
M% !1110 4444 %%%% !1110 4444 %-(IU% $?2ES3B*90 ZBD!I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!,"CK2TG2@!**4TF* "BBB@ HHHH
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M844459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #:*=3:
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M7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\ A2OA?_GOJ7_?Y?\
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M?_GOJ7_?Y?\ XFO1J*/:3[A[*'8\Y_X4KX7_ .>^I?\ ?Y?_ (FC_A2OA?\
MY[ZE_P!_E_\ B:]&HH]I/N'LH=CSG_A2OA?_ )[ZE_W^7_XFC_A2OA?_ )[Z
ME_W^7_XFO1J*/:3[A[*'8\Y_X4KX7_Y[ZE_W^7_XFC_A2OA?_GOJ7_?Y?_B:
M]&HH]I/N'LH=CSG_ (4KX7_Y[ZE_W^7_ .)H_P"%*^%_^>^I?]_E_P#B:]&H
MH]I/N'LH=CSG_A2OA?\ Y[ZE_P!_E_\ B:/^%*>%_P#GOJ7_ '^7_P")KT:B
MCVD^X>RAV/.?^%*>%_\ GOJ7_?Y?_B:/^%*>%_\ GOJ7_?Y?_B:]&HH]I/N'
MLH=CSG_A2OA?_GOJ7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\
MA2OA?_GOJ7_?Y?\ XFC_ (4KX7_Y[ZE_W^7_ .)KT:BCVD^X>RAV/.?^%*^%
M_P#GOJ7_ '^7_P")H_X4KX7_ .>^I?\ ?Y?_ (FO1J*/:3[A[*'8\Y_X4KX7
M_P">^I?]_E_^)H_X4KX7_P">^I?]_E_^)KT:BCVD^X>RAV/.?^%*^%_^>^I?
M]_E_^)H_X4KX7_Y[ZE_W^7_XFO1J*/:3[A[*'8\Y_P"%*^%_^>^I?]_E_P#B
M:/\ A2OA?_GOJ7_?Y?\ XFO1J*/:3[A[*'8\Y_X4KX7_ .>^I?\ ?Y?_ (FC
M_A2OA?\ Y[ZE_P!_E_\ B:]&HH]I/N'LH=CSG_A2OA?_ )[ZE_W^7_XFC_A2
MOA?_ )[ZE_W^7_XFO1J*/:3[A[*'8\Y_X4KX7_Y[ZE_W^7_XFD_X4IX7_P">
MVI?]_E_^)KT>BCVD^X>RAV/./^%)^%O^>VI?]_E_^)H_X4IX7_Y[:E_W^7_X
MFO1Z*/:3[A[*'8\Y_P"%*>%_^>^I?]_E_P#B:/\ A2GA?_GOJ7_?Y?\ XFO1
MJ*/:3[A[*'8\Y_X4IX7_ .>^I?\ ?Y?_ (FC_A2GA?\ Y[ZE_P!_E_\ B:]&
MHH]I/N'LH=CSG_A2GA?_ )[ZE_W^7_XFC_A2GA?_ )[ZE_W^7_XFO1J*/:3[
MA[*'8\Y_X4IX7_Y[ZE_W^7_XFC_A2GA?_GOJ7_?Y?_B:]&HH]I/N'LH=CSG_
M (4IX7_Y[ZE_W^7_ .)H_P"%*>%_^>^I?]_E_P#B:]&HH]I/N'LH=CSG_A2G
MA?\ Y[ZE_P!_E_\ B:/^%*>%_P#GOJ7_ '^7_P")KT:BCVD^X>RAV/.?^%*>
M%_\ GOJ7_?Y?_B:/^%*>%_\ GOJ7_?Y?_B:]&HH]I/N'LH=CSG_A2GA?_GOJ
M7_?Y?_B:/^%*>%_^>^I?]_E_^)KT:BCVD^X>RAV/./\ A2?A?_GOJ7_?Y?\
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M]3_[_K_\17I=%'M)=P]G'L%%%%06%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3@'M]:FG64VT:XC!SHQ4OO\ (UYIH[>"2:9UCBC4L[L<!0.I-97_  EGA_\
MZ#%E_P!_13_$_P#R*NK?]>DO_H)KR7P/X9L_$UW=Q7DL\:PQJRF$@$DG'.0:
M52I*,E&*W'A\/3G3E4FVDCV.SU;3M1)%E?6UP1R1%*&(_ 52\3>(H?#6EB\F
MA>8O((TC4XR2">3V& :\B\1Z7_PB7B>.'3;R1W15E1_XT))X./I^1KU/Q9?6
M%GX;6;6+ W4+NBM".H8@G(/;'-*-5R4D]&BIX:$)P:]Z,OO+/ACQ'#XFTQKN
M*%X620QO&QS@X!X/<<UM5SW@R]TR^T(OI-B;.V29D\L\DM@$DGOU'Y5G:[\1
M]+TB[>T@BDO9XSA]C!44^F[N?H*M5%&"<F8RH2G5<*<?D=E17(^'_B#IFN72
MVCQO:7+\(LA!5SZ!O7ZBH/B=J-S9>'(H;=F07,WER,O'RX)Q^--U8\CDM11P
MU3VJI25FS:G\7^'[:<PRZM;AP<$*VX _4<5JVMY;7T GM)XYXCT>-@P_2O)?
M"'@K2O$6DM/-J4BW>X@PQ%<QCL2""3FNT\(>#6\,3W<KWK3F7Y4"Y5=O7)']
M[^7XU%.I4E9M:,UKT*%--1D^9>1UE%8?B'Q5IOAN)3=LSS2#*01C+,/7V'O7
M-V?Q7TZ:X"75A/;Q$X\Q7#X]R,#],U<JL(NS9C##5IQYHQT.YOKM+"PN;R16
M:.")I6"]2%!)Q^58GASQE8^)KF:"T@N(VB0.QE"@$9QV)JWKD\5SX0U*>"19
M(I+&5D=3D$%#S7GWPF_Y"^H?]<!_Z%4SJ-5(Q6S-:5&,J$YO='K%%<E=^/K*
MT\1_V*UG<-+YRP^8"-N6QS^M:?B7Q'!X9L8KNX@DF627RPL9&0<$]_I5^TC9
MN^QC["I=*V^QM5&L\+2&-98RXZJ&&?RKG/\ A-K,>%AKQM9_(,OE>6,;LYQZ
MXKR[0?$<6E^+)=9N(9)%D:1BB$9RV?7ZUG.O&+7F;TL%4J*3>EOS['LVO:S#
MH&D3:A/&TBI@!%ZL2< >U4/"GBN#Q3;W#QVSV\D# .C-N&#G!!P/0U!=^(=-
MU#P-+K%U8/-8OPUN^"3^\V?SYIG@;4-'OK"Y&CZ<UE%'( X8Y+$CKG)-/G;F
MK/0CV25&3E%W3M?H=717*>(?'VEZ#<M:!'N[I?OI&0%3V+>OTS5;1/B3I>JW
M:6MS#)92R'",[!D)],\8_*J]K"_+?4A86LX<ZCH=I165XAUV'P]I9OYX7E0.
M$VIC//UKG9_B?I$6FPW$<,TEQ+G_ $<$ I@D?,>@SC/>G*I&+LV*&'JU%>*N
MCMZ*Y7PQXYLO$ER]H('MKD+N5&8,& ZX/K[5<\2>+=/\,I&+D/+<2#*0Q]2/
M4^@H]I'EYKZ Z%13]G;4WJ*X"P^*FGW-RL5U83VZL<!U;S,?4  _EFN_!R :
M(3C/X6*K1J4G::L%9%[XIT/3IC#=:G;I*#@H&W$?4#.*YWXD>(YM)L(=/LY#
M'<70)=U."J#CCT)/\C7/^%_APFK:7'J&I7,T2SC=%'%C.WL22#U]*SG5ES<D
M%=G12PT/9^UK.R>QZ?8ZE9:G!YUC=17$8X)C8''U]*M5QWA?P*/#FL7%Y]M>
M9"NR%1E>#UWCH?;\ZT/$?C'3?#96*X+S73#<L$6,@>I/85:FU&\]#&5)2J<E
M'WCH:*X+3OBIIMS<K%>6<UHC' DW!U'UX!'ZUUVJ:K#IFC3:F09H8D#XC(^8
M''0_C3C4C)73%/#U8249+5E^BN('Q/T?^RVNC#,)O,*+;<;FX!W9Z <_I2Z/
M\3-*U&5XKR)K JI8,[[E..2,XZ^V.:GVU.]KEO"5TF^78[:BO/G^+&G"\V+I
M]PUOG'F[@&QZ[?\ Z]=E<:O;0Z%)J\9,ULL!G&SJRXS51J0E>S(GAZM.W,K7
M+]%<*OQ3T<V4DQMKD3!MJ08&6]\] *GT'XCZ=K-^EE-;R6<TIVQEF#*Q],\8
M-2JU-NURWA*Z3;CL=G15;4-0M=+LI+R\E$4$8RS'^0]37"R?%FQ6XVQZ9<-#
MG[YD ;'^[_\ 7JIU(P^)D4L/5JZP5ST.BJ&CZQ9ZYIZ7MC)OB8X((PRGN".Q
MKFK7XF:/--<I<136PA0MN?!WD$#:H'?G]*'4BK7>XHT*DFTEMN=I17G]O\5]
M/DO%CFL)XK<MCS=X8@>I7_ FNVO-0M;#3Y+^YF5+:-=Y?J,=L>N:(U(RU3'4
MP]2FTI+<M45YW+\6;)9RL6ESO#G[[2!6_+G^==?IGB*PU717U6%I$MHPQD\Q
M""NT9/3K^&:4:L).R8ZF&JTU>435HKS^\^*^G12E;2PGN$'\;,(P?H.36]X9
M\8Z?XFWQ0J\%S&-S0R8Y'J#W%"JPD[)CGA:T(\THZ&_)-%#CS9$3/3<P&:<"
M&4,I!!&01WKQGXA>)(=<OX;6"*6,6+RQN7Q\S9 R,?[M=EX,\96NJ"ST:.UF
M26"U4&1B-IV  U$:\7-Q-9X*<:2J??Y#H?B+93>)AI LI0C3^0L^X<MG'W<=
M,^]=G7GT&M>&CXZ-NFALNI?:FB^T<;=X)!;&?UQFNOUK7;#0++[5?RE5)PB*
M,LY] *=.>C<F37I+FC&$6KK[S2HKSM/BS8FXVOIEPL.?OB0%L?[O_P!>NYTW
M4K35K&.\LIA+"_0CL?0CL:N-2$_A9E5P]6DKS5BW17&6_P 2M(>[N8;B.:V6
M!6.]\'>00-H YR?Z51A^*^GO>".33[B.W+8\W>"0/4K_ /7J?;4^Y:P==_9/
M0:BN;F"SMWN+F5(H4&6=S@ >]/1UEC61&#(P#*PZ$'O6%XW_ .1,U/\ ZY#_
M -"%7)VBV8TX\TU%]63_ /"6>'_^@Q9?]_15VSU2PU$$V5[;W&.OE2!L?7%>
M0>!_"=GXG6^-W//%]G*;?*(&=V[.<@^E5_$>D2^"?$-O]@O79M@FB?&&7DC!
M]>GXUS*O/EYVM#T7@J+FZ49/F/<J*I)J,*:/'J5TZPPF%979CPH(!_K7%7/Q
M8L([DI;Z=/-"#CS&<(3[@8-=$JD8[LX:>'JU&^17L>A45EZ%K]CXAL?M5D[8
M4[7C<89#Z$5G>(O&^E^'9?L\F^XN\9,,6/E]-Q/3^=-SBES-Z$JC4<^1+4Z6
MBN*T'XCVFM:G%8-I\\$LQPA4^8,^^ "*VO$/BK3O#<*F[9GFD&8X8QEF'K[#
MWI*I!KF3T*EAZL9J#CJS;HKSZS^*^GRW 2ZL)[>(G'F*X?'N1@?IFNKU77K?
M3-".KHC75L K9A(Y5C@']12C5A)73'/#58-1E'<UJ*Q/#7B:U\36<UQ;Q21&
M*38R28STR#Q^/Y50UCQU9Z3KHTC['/<7!*+^[(QN;H.?J/SINI%+FOH2J%1S
M<$M4=5169KFO6'A^R^U7TA )PD:C+.?0"N/@^+%@]R%FTV>.$G'F*X8CWQQ_
M.E*K"+LV53PU6HN:$;H]#HJA/J]M'H<NKQ-Y]LD!G!3^)0,\5S47Q+TE]*FO
M7AFC9'$:0'!:0D9X]O>FZD8[LF%"I-7BCM**X=/B1#_8PU272;A8#<&W^20-
MA@H;V[']*Z?0]8@UW28=0MU94DR-C=5(."#1&I&3LF.I0J4U>2T-&BN5LO'5
MIJ'B0Z+;V<[2"1X_-R-N%SEOIQ754XR4MB)TY4W:2L%%%%40%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5Y1\6O^0IIW_7%O\ T*O5Z\O^*5E=76IZ>UO;33!86!,<9;'/M6&)_AL[
M<O:5=7\S-T_P!XBO=.MKJ#4;=(9HED13/("%(R!@+7INEV4^G>&H;.YD62>&
M J[*203@]SS7F=EXO\76-C;VD.FGRH(UC3=:.3@# S^5=QX4U?5=9T6]EU6W
M\J9&*(HB*9&WT/O6=%P3M&]S?&*LXWFU9/H>;_#_ $VTU3Q0L-[ LT21-($;
MH2,8R._7I4GQ%L+73_%'EVD$<$;P(Y2-0JYR1P!TZ5?^&UA>6WBHR3VD\2?9
MW&YXRHSD=S3OB787ESXH1X+2>5/LR#='&6&<MZ5CR_N=M;G9[3_;+7TL;/BW
MP[I-A\/_ #;6QACFB$3"4+\Y)(!RW4]35;X>7<MIX,UR>,_- 7E0>XCS_05T
M'C2":;P!+%%$\DA6'Y%4D_>7M69\,["5-#U*WO+:2-99=I61"NY2N#UK=QM6
M5NQQJ=\+)R=_>_R.!\-:HFFZG)>SZ4=4DV_*&;[K$\MT.35G5+^;4O$5MJ=E
MHTE@Z,A*1@D%PV=WW1[?E5]K#7_A_KLES:V[3VK J)-A9)$SD!L=#_GI72Z%
MXTU_6]9MHUT;;8EL3.BM\H/?<>..N.IK",=.23L_0[*D]?:P2:MO?\+&9\6_
M^/S2_P#KG)_-:Z'P;X5TB/PY974UE#<7,Z"9I)4#$$\@#/3'M6+\5+.ZNKO3
M3;VTTP5),F-"V.1Z5VWA>-XO"VEQR(R.ML@*L,$''I6\8IUI71PU*CCA(*+_
M *U/-?B%;2V?C6*_NHFDLI?+9>."%P&7Z\'\Z3Q]KVD:^-.CTD&66/(9A$5(
M!QA.1S5KXE2W%OXIT^:81W%HB*\=NS9!PWS K[\<]_PJK9>.]+T^X$UOX3M(
MI1_&D@##Z';Q6,VE*46[)G724G3IU%&[2Z-)?,ZS6(Y="^&#A(DANS:Q13%%
M .3M5LXZG!(S7 ^%-;BT5)Y#H/\ :,KD 2D_<'H/E->E6>IV'C[PU>VT:O"6
M7RY$?DQMU4^XR,_A7 Z?=^(O %[/ ]B9()#\P928WQT96'^?45=3XHR3T,L/
MK"=.2]Z^U[#=!FGE^(=K?6NFR64,T_,04[4!7#<X''4TGQ,_Y'&3_KC'_*NV
M\*>)]=UW57^U:3Y&GF,[9%0@*WU/7/M[5R7Q&T^]N/%LDD%I/*GDH-R1EAT]
M0*F<?W6FNII2J-XE*2M:/>YT7C;PYI&G>"9'M+"&*2!H]LBJ-YRP!RW4]>]1
M_"V-+GP]J%O.BRPM<<QN,J<J,Y!^E;GCZ&6?P7=QPQ/)(3'A44DGYQV%97PM
MM;BUTB^6X@EA8S@@2(5)^4>M:\J59670Y5-RP<KO6_\ D<4EK;GXFFU\B+[-
M_:13RM@V;=_3'3'M7M5I8VEA&T=G:PVZ,=Q6*,("?7 KR'Q9IFIZ!XR?5X+=
MWB:<7,4H0LN[.2IQTYS^%>A>#_$-WXAL)Y[NS^S/'(%4!2 RXZ\]><_I2H-1
MDXO<K&J4Z<:D7I8O>)_^15U;_KTE_P#037C?A30=1UVYN8].OA:M$@9R79=P
M)]J]E\2(\GAC5$169VM) JJ,DG:>E>0>'=0U[PS//+9Z3)(TRA6$UNY  .>,
M8I8BW.K[%8%R]A-0W':CI&H^"-;L[V]CMKW<Q>-F+,K$8SG.#D9%=EX\OX]4
M^'UI?1 A)Y8W"GJ,AN/PKF+ZW\6^.+Z#[18/%''D(3$8HDSU.6Y/0>O2NJ\9
MZ.]E\/[/3+6.2<P21K\B$DX!R<#WJ8I\L^5:&E22<Z7.USWUMV*/@ZZDLOAC
MJUS"2)8WF*$=CL7!K(^&6EVFHZS=S7D*3^1$"B2#<,D]<'Z?K74_#[3FD\&7
MEC>P21K/-(C(ZE25**.]<<EMK_P^UR2:*V,T+ H)"A:.5,Y'3H?\]*&K*$FM
M$":DZM.+M)O07XC:=;:3XGB>QC6 2PK*5C&T*VXC( Z=!7IL^G6_BGPM;Q:@
MIQ<01R[EX*.5!R/SKS.'3-<\?>(%O+NW:"VX5Y=A5$0=ESU/7\37=^-;;7?[
M$A@\/J5CC(\P0MB7:N-H7V]<<]/>JI_:E;1F=?\ Y=4N;WEU['#:I\/M=T20
MW6G2&Z2/D/;DK*O_  'K^1-;G@#QG?7^HC2-3D,[.I,,S?>R!D@^O //7BL=
M/'WBRVA^QRVRM/C:'EMF$@_#@9_"M/X>>$[^#5/[:U&%X BL(4D&'9F&"2.P
MP3U]:B%N=>SOYFM:_L9?6+7Z-'/ZUG6OB6]M=,3&]\MMC/1 P7 _#^==?\1=
M!TR#PN+FVLX+>6WD0*8D"Y4\8..OK^%9?CKPKJ%OK9U[2HGE5F61Q$,M%(/X
ML=QQG\ZR=4U_Q)XRAATP:?PKAF6")AN;IEB3P*'[O-&2U8XWJ>SG3E:,=S=\
M'W<L_P --=@D)*P13A,]@8\X_/)_&J?PF_Y"^H?]<!_Z%78:-X6;2_!5SI!9
M3=74,GFL.F]UQ^0X'X5P'@>?4- \6K9S63J;DB"4.A!3G@C\:JSC*',9J4:L
M*RAU(]:_Y*F?^O\ A_FM==\5_P#D7;/_ *^Q_P"@-7->/=)O].\6/JT$,AAE
M9)8Y57(5P!P??(S^-1ZU=>*?%FD?:[FQV65LP*I%$P\QCQD Y)QGZ"I;MSQM
MJS514W2J)JR1V7P^M+:]\#PPW5O%/%YSG9*@89SZ&N"^']I;WGBV*&Z@BGB,
M<A*2H&7IZ&O1OAW!-;^$88YXGB<2N=KJ5/7T-><FWU;P/XI-PEHSB-F$;,A*
M2H>.H]OR-5-6C"36QG2?-.M!/5[?B>C>.;:"T\ 7\%M#'#$OE[4C4*H_>*>@
MKGOAE,UMX?UJ=1EHSO ]2$)K2U?4+SQ#\,+JYDLGCNI"H,*(W:5<8'4\8J#X
M7V<\&F:E'=6TD8>11ME0KN&#GK5O6M%KL8Q]W"SC+?F_R.4\ 6,&M>+F;4%6
M<)$\Y609#MD#D=_O9J_\4-)L]/U"QN+2".$W".'6-0H)4C!P._S?I5:\T?6O
M GB(W]A TUJ"?+DV%E9#_"^.A_PID\?B#X@ZQ#(]IY4*#9O"%8XESR<GJ:PV
M@Z;7O';>]95U+W+'0>);N6]^%&GW$Q+2,8MS'J2,C/Z4GPTT+2[[1+F[O+*&
MXF-PT0,R!P%"J> >!U/-:GCG3#;^!(=/LH9)! \2*J*6) !&>*7X8V\]MX:N
M$N(9(G-VQ"R*5.-B<\ULH_OE?L<;J?[+)Q=O>.'\,1K:?$N&&'Y4CNI8U'^S
MAAC\JWOB5X=U&YU*/5K6%[B 1!)%0;BA!)SCTYK,T33[U/B8LSVEPL7VV4[S
M&0N/FYSBNI\5^(O$FB:TDEIIWF:8J8)*;PY/4DCE<=!_6HBE[-J7<WJ3E]8@
MX6OR]3(T;QQHM]=6D>M:1;6\\+#RKF-!M1NQ(ZJ/SKU#J,BO$;]=3\=:Y'+:
MZ.+=BH1W13MZ_>=L?YQ7M5O%Y%M%"&+>6@7)[X&*VH2;O?;N<>.IPCRVT?57
MO8\D^*R./$EJYSL-HH'U#MG^8KT_09(Y?#VFO$1L-M'C';Y1Q6/XV\+'Q)IB
M&W*K>VY+1%N P/52?? _*O/=.\1>*/"$3:>UH?+4G;'<PL0I_P!D@CC\2*AO
MV51M[,U4?K.'C"#]Z/0]JKP^VC7Q!\2=E]\Z37C[U/=5SA?IA0*Z_P %W_BS
M4];EO=01AI\B882J448^[Y8_F?S.<5C>+/#6J:'XC.NZ3"\L+2^>#&NXQ/G)
M!'IG/YXHJOGBI):)CPL%1J2IN2NUHS1^)VBZ?:Z/:7MK:PP2K.(CY2!=RE2>
M<>FVF:;=RW7P=OEE)/D;HE)_NAE(_GC\*PM3U3Q'X[EM[-=/PD;9VQ(P7=TW
M,3TKN+_0CH_PTN=+A!FF6'+;%)+N6!.!_G@5*]Z4I16EBY?NZ=.G4=Y<R^1R
MWPPT?3]2FU&:]M(KAH!&(Q*NY1NW9X/'85AWNF6G_"PVTT1!;1K]8S&O "EA
MD#TZUV'PJM+FU75OM%O+#N,.WS$*Y^_TS6'>:?>GXH"<6EP8?[11O,$9VXW#
MG..E0X_NXZ=355']9J:Z6_1&A\3=&T[3K#3I+*SAMVWM&?*0+N& ><=:U=)=
MG^#DNXYQ:SC\-S4GQ2M;BZTS3UMX)9BLS$B-"V./:G:9#+!\()XYHWCD%M<9
M5U((^9NQK6UJLK=CG4N;#4[O7F_S.=^&&F65_J5])>6T4YAC4QB1=P!).3@\
M=JS_ !_86^D^+2+%%@5XTF"QC 5N>@[=,U5\*:QJ^AO=WFF6BW,855G#(6"C
MG!X.1WYZ5>T_2=8\<^)/MM["R6[,#-+L*HJ#^%<]\<?J:P34J:@EJ=K4H5Y5
M9/W;&Q\4-0GELM&@)(26,SN.Q;  _+)_.LRQ\1VUOX=&F#PF)E>+:\Y;EV(^
M_G9^(YXKN/'?A>37]*B:R4&[M"3&F<;U.,K]>!CZ5QNE>-/$'A^S32I]+,IA
M&R,2QLKJ.P]Q6E1.-1MNR?E<YJ#C/#J,%=I[7L:?PI6ZAFU.&6*1(BL;#>I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^G-,_G^29O-P./O'&.W/Y5V%.,U+84Z4Z=N9;A1115&84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &?KK7ZZ)=G2T+WVS$(! .2<9YX
MXZ_A7G6G^"_$.OZW'>^)6984(W[W4LX'\("\ ?EUKU6BLYTE-W9T4L3*E%J*
M5WUZB !0   !P *6BBM#G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH A:TMFF\YK>(RY!WE!G(]ZFHHH"X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;LCC58B&4X(/ERT >M!U9F56!*]0#TI<CUKP&31;+P-\9_"4/AN[N9&U*/\
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M924A4"%P =H) QZ"M6RT#7;CQ)%XC\036#3V-K+#96>GAR@+X+,SO@DG:!C
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M\_*>1BM '/2O*['2M1\0>&O'FG:?="*Y?Q'/MWR,JNJ^23&67E0P!7(]:W/
MTFE66IZAI$/AZ3P_JJ11S3V?F[XI$RP62,@[2,Y!. ?7I0!U$FL6D6OP:*Q?
M[9/;O<H OR[$95.3ZY85H9Q7F6M>&-&U3XUVBWMBLPGT>6>0%V&YUDC53P>P
MXJ33M#T_QMXM\52>(X3=G3[Q;.TM7D8+;Q>6K!U (PS$D[NO'% 'I-%><^#[
M&3Q3X/AM;_5-0*:3K,JVUW#/M>YCAD(3>W\2D<'UVCG->C4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %9\NBV4VO0:T\;&^@@>WC?<<!&()&.G4"M"B@"A+HUE/KEMK
M+QL;VVA>"-]QP$<@L,=#]T5%'X>TR.[U:Y-L'?5@@O%D)990J; -IXQMX]ZU
M** .<TCP3I>B7D,]I<:F8[?(M[:74)7AA!!&%0MCH2.<X[5S?QJ\,:QXK\&V
MMAHEF;NY2_29H_,1,($D!.6('5A^=>CT4 <?X9^&7A;PIJC:IIFG&.]92 \D
MK/Y0/4)D\>F>N.,U!??"3P9J7B"XUJ[TKS+JX+-*IE81LYZMMSC/?Z\]:[>B
M@#DIOAMX8GT#3-$DLY38Z9*9K5//?*L2223G)Y)ZUA?&CPMK'BSPWIEIHUC]
MKEBOUEE3S$3";&!/S$>HKTJB@#DO#/PT\+>$=2EU'2=/,=U("HDDE:0QJ>H7
M)X_G[U4UCX1>#-<UM]6O-+/VB5M\PBF9$E;U90>I[XQFNXHH Y7Q#\.O#7B:
M"RBOK%D^PIY=JUM*T1B3^Z,'&.!VJ2U^'_A>S\*R^&H]*B.ERMODB=B2[\?,
M6SG=P.<\8XKIJ* .2\+?#;PWX.OY+[2;:=;EXS%OEN'?"$@[0"<8R!V[5M:Y
MX?T[Q%9I;:C"S".02Q21R-')$XZ,CJ05/TK3HH QM"\+Z;X?>YEM!/+=71!G
MNKJ=III<= 78DX'8=*M:+HUEX?TB#2].C:.T@!$:LQ8C+%CR>>I-7Z* ,.Y\
M)Z;<>(TUY7N[>^ 19#;W+QI.J'*B10<,!D]?I4UMX;TRTT[4K"&%A;ZC+--<
MJ7)+-+G>0>V<]NE:U% &/#X8TJ"71)(X7#:+ T%D?,/R(R!"#_>^51UK/3X?
MZ&MY%,QOY((IA<1V4M]*]ND@.0PC+8X/..F>U=110!%<VT%[:RVMS"DT$J%)
M(Y%RK*>"".XKE[+X<>'[&ZMY4%_+!:N)+:SGOI9+>!AT*QLQ'';.<5UM% '-
MZOX'T;6-1EOY#>VMS.@CN7LKN2#[0@X"R!"-W''KCO5R3POH\EAI=BMFL5KI
M<\=Q:11$J(W3.T\=>IZ]:V** *']C67_  D USRV^WBU-GOW''E;]^,=.HZU
MR7CGPDC> M?L=%LI)KC4[V.[FB#%C(YEB+D9/ VIT]J[RB@#G-,\$:-I6K)J
M<8O+BZA4I;->7<DXME/41AR=N1QZXXI=3\%:3J6J2:D)+ZRO)E"3RV%Y);F=
M1P ^PC=@<9Z^]=%10!EGP]IIO=)N_*<S:5&\5HQE8[%=0K9R?FX4<G)J.?PO
MI-S=:K<36[-)JL,<-W^]8;T0$*!@_+]X\C%;%% '.Z;X*TG3KUKQFO;ZX\EH
M$?4+M[CRXV^\J[R< X&>YJE!\-/#D,<$3)?30VLJ2VL,][*Z6Q5@P\M2V%&1
M^7'2NOHH P]1\)Z;J6NV^M,]W;W\*"(RVMR\7FQAMP1PIPRYYP:DB\+Z/'8Z
MI9&T62VU2>2XNXI26$CN &//3[HZ=*V** .;TCP-HVCZC%?Q_;;FXMT,=LU[
M=R3_ &9#P5C#D[>./7'&:U;#1K+3+S4+JUC99M0F$]P2Q.YPH7(STX Z5?HH
M H:)HUEX?T>VTK3HVCM+92L:,Q8@$D]3R>2:;IVAV&E"_%K"0+^Y>ZN [%@\
MC@!CST& ..E:-% '.GP/H)\.0Z";60V%O)YMN/.?? ^208WSN4@DXP>.G2K&
MF^%[#3K6[@:6]OENT\N<ZA=/<%TP1M^<D 8)X YSS6U10!S>C^!M(T.\AN+.
M34"MN"+:WFOI9(8 1@A$+8'!([XJO+\./#DUW)(T%T+:6;SY;!;J06LDF<[C
M%G:>><8Q[5UE% &3XA\-Z9XHTDZ9JL!EMBX<!'*$$>A'(X)'T)J75-!TS6='
M.E7UHDEEA0L8)79M^Z5(Y4C'!%:-% &'IGA6RTM+D"ZU*[:XC\EVO;Z28A/0
M;C@=>HYI^RW\)>&8;?3M.O+NWLXUAAM;4"24KT&-Q&<=R36S10!R7P_\.2:!
MH]W-=6J6M[J=Y+>S6Z-N$&\_+&#WVKCIQG.*WM1T:RU6XL)[N-GDL+C[3;D,
M1M?:5R<=>&/!J_10 5R1^&_APW1D,%S]E,WV@Z?]JD^R&3.=WDYV]><8Q[5U
MM% &7<:!8W/B*SUUO-2_M(G@1HY"JO&W577HPSR,]P#58>#]#/A^YT*2R$NG
M7,KRR12.3EW;>2#G(.XY&.G:MVB@#F[+0++PI!=:C;C6-2G$6P++=/<RE <A
M$#M@?I]:H^!]!FM+[7?$-Y8?8+O6KH2K;,06BB484-@D!F)9B >K5V5% &+X
MLT>76_#MQ:VK*E[&R7%H[=%FC8.F?;<H!]B:BU;PS9>)4T^[U!+JSO[52T<M
MI=-%+"7 WIO0\@XP?I6_10!G6>B6-CJUYJD*/]KO(XHIG9RVY8P0O!_WC]:I
M_P#"'Z&VAW>C260DL;J=[B6-W8GS';<6!SD'=R,=.U;M% &+HOAFTT.=YXKO
M4KJ5T\O=>WTD^U<YP QP/KC/O6U110!0U#1K+4[O3[JZC9I=/F,]N0Q&U]I7
M)QUX)ZU?HHH Y.?X<>'+B[EE>&Z%M/-Y\U@EU(MK+)G.YH@=IYYQC![BMB\\
M/V%[K6G:NXE2\T]72%HI"H*.!N5@.&' X/I6I10!B#PCHG]BWVCR60EL+Z:2
M>XBD8MN=VW,<YR.>1CIVJI:>'['PE#<:E;+K.ISI%Y:QO=O<R;,CY(U=L#L?
MPZUTU% ''^!- FT]]:UN\L18WFM7C7!MBP+0QC[BL1D;B2S'!ZN:["BB@#GM
M+TN[C\0:[K5Y$/.N2EM:QAP<6\8.WGL6=W;V!%,\"^'7\,>&EL'41EIY9Q L
MID6 .Q(C#'EL#&3W.37244 8,G@_1Y+&_M/*F2.^O#?S-'<.CB<X^=64@K]T
M=..*DT3POI^A7-Q=P/=7%Y<*J2W5Y</-*RKG:NYCP!D\"MJB@##USPIINOW=
MK>7#W<%Y:AEBN+.Y>"0*V-REE(R#@<5!J_@G2-9U%M0D-[:W<D8BFELKN2 S
MH.BOL(W#Z\UT=% &#=>#=#N=(TW2OLAALM-GCN+:*%V0(Z9QG!R>ISGKG/6M
MZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHKCK3XI>#[WQ/_ ,(_!JRM?&0Q+\C"
M-Y.FT/C!.>/?M0!V-%%% !17GUF-4\>:OK$PUR_TK1M/O'L;>+3V6.2:2/ >
M1W()QDX &.E;MQJB^"_#D!UK4;K5)S-Y$#+"OGW+L3LC"K@,V.,\9P2<4 =)
M17.Z+XN@U759-)N=.OM+U-(O/%K>HH,D><;T9696 /!YR*Q6^*NE?V<-332=
M8?2TE,5S>BW41V[;]GS?-DC."2H. 1WXH [RBN5L?'=G>:]9Z7)IFIVBWZNU
MC=7,(2*YVC<=O.X<<C<!D5#/\0(/MNI6>GZ%K6I3Z;.8;H6L"D+@ Y#,P#9S
MP!\W'0<9 .PHKSSQ+KMMKEEX$U72[AVM+S7H"",J2/+E!5A[$8(]176:;XCL
M=2.JA1+;MI=P]O<K. I7:H;>,$_*5((/I0!KT5DZ=K\&I^%HM?@M;H6\MN;F
M.%T E9,$C SC) R.>XK,NO'^BVFB:%JS_:#;:S)%';[4!9-XSN?G@+T8C./>
M@#J:*Y;Q+XATY(-=TF=M0C-GI+7US/9$*\<9W !&SQ)\K$<8XZUA:KXSN]%U
M3P=I^GV&KWUG>0,[MLCDEN4$!*C<S#YP<,W3ZGI0!Z-17FU]XADT_P"+1<:?
MJ5U)<>'86CL($#.&,[D[LD(N!P23CMD\5V/AKQ):^)]-DN[:&XMWAG>VN+>Y
M0+)#*GWE8 D9Y'0]Z -BBN<USQ6^CW$L47A[6=16"/S)I;6%=BKC/!=EWG'9
M<U'?>/-'L=(T;4PMW=6^KL$M/LT)=V8H6 *]<G&/KUQR: .GHKG-$\80:MK,
MVCW.F:AI>I1P_:%M[U%!EBSC<I5F!P< C.1FL9/BGI\NDC6(=#UR324)^T7H
MMEV0X."2-V6 QR5! ^N10!WE%<1<77G_ !;T-H9B]M+HMQ(NUOE8&2/!_(U+
MHFOZ+I/AC6=6DU#4FL;34+A9Y-0D\QU</M*)C/R[L!1UYH [*BN?T;Q/+JLT
MB3>'M9TY1$9DDNX5Q(OI\K,0W/W3@U2M_'D+:I8VE[H>L:=#J$GDVEU>0JB2
M28)"D!BRD@' 8#- '6T5YG9^(I]*^(WC6"+2M4U60R6;+#9H"(U%N,DEV51D
MGIG)]*E\4^([7Q!X3\/:IIDDR12Z]9QNC@I(A$VUD<=B"""* /1Z*YW5O%T6
MGZLVE66EZAJU]%$)IXK%$/D(<[2S.R@$X.%SDXZ5IZ-J]IKVDP:E8LQ@F!P'
M7:RD$AE8=B"""/44 7Z*X'P-JC6/A'6+V:*[N_*UB\416\9ED;]\0 J_C]![
M"MC2_&<6H:I<:7<Z/J>G:C%;&[2VND3=-$#C*%6()S@$$CJ* .FHKD[CXB:)
M;>%M)\0R"Y^QZG*D4*J@+H2"26&> H5MV"<8[UL_VY;'Q-_8 25KL6?VQG &
MQ4W[ "<YR3G QV- &G16-K>O2Z3+%#;Z+J>ISRJ6"V<2[5 _O.[*H^F<^U9Q
M^(&CKX/?Q+(EW':13BWGA:(":"3S!&59<]03S@GCIF@#JJ*Y;3O'%O>^(+?1
M[C2=4T^6[C>6SDO(51;@)@MC#$@@'.& ./2J.L^.K>1-8LM/TK5;^*S22"ZO
M;2%6BADVG*\L&8KWV@XH [>BN8^'+O+\./#SR.SNUA$2S'))VU!J7CZ#29W>
M\T+68M,BG$$NI/ JPH2VW=@MOV9_BVX^M '745S>L^,[/2-=31!8:A>ZE+;?
M:8H;2(-O7<5QDD!<8R2V![Y.*JP?$/2Y-"?59K2_MT@OUT^\AEC4/:2%@N9/
MFQMRR\@GJ* .NHK,O-<M;/7M-T=DE>ZOUE=/+ *HL8!9GYX'( Z\FJGB/Q;I
M_AB6PBO8KJ1[]WB@6WCWEG5=P7&<Y;H/<CIUH WJ*P+#Q7#=ZM8Z5<:=?65_
M=VDEV(;A4_=HCA"&*L>3D$8SQ6+XP\0P:AX.\;V5H)X[C2K5XI7("@LT6\%2
M#GH1Z4 =S17+-XG@T71]#MOLUWJ&HWELA@L[50TCA4&YB6("J,C))'6D/CW3
M(]#N]1N+:^@FM+A;6:P>(?:!,V-B!0<'=N4@@X(/6@#JJ*RM%UB?51.MSHVH
M:9+"5REXJ8<'."K(S ].>>*IZYXMM](U.#2K>PO=3U2:(S"TLE4LD8.-[%F5
M5&>!D\F@#H:*Y<>/=(_X16_U]H[M(M/<QWEL\86>!P0"K*3C/(/7&.]:.A:\
M->2::+3KZVM5*^1/<H$%RIS\Z#.[''\0'44 :]%<M#XYM+O7[C1K'3-2N[FU
MNQ;731Q+Y< (4B1F+#Y?F.,?-\K<<57E^(NGQF6Y33=3ET:&8PRZLD2_9U8-
MM)^]O* \%@I'% '8T5SVK^+(M.U9=)M-,OM5U#R/M,D-F$_=19P&9G91R0<
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M:J)H@0"5VL>02,@X/- '345QTGQ%T]#)=+INI2:-%,89-72)?LZL&VD_>WE
MW!8*16]XBN[ZQ\-:G>:9!]HOH;622WBQG>X4D#'?GMWH TZ*\Z\$QG6K>PUC
M3_'NH:A/A7O[69HWC)(^9/*V@Q'/3Z=ZW=1\;P6>HW=G9:1JFJFQ ^VR64:,
MD!(SM)9AN;&#M7)YH ZBBN:U#QOI=G8Z7/:I<:E-JR[[&VLT#23KC<6P2 H
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M[U!]ZN?$"SO;/Q$8--#!?%T":7.4_P"6<BL/WA_[8M*/^ BO4JP8O#"GQ/\
MV[?:C=7LL(=;*"0(L5H'^]M"@$DCC<Q)QQ0!LV]O%:6L5M @2&)!&B#HJ@8
M_*O(=+\(:AJ+:UX;NK.>&QTBUO;;39I$*K(;B3?&R'HVQ5 XZ9Q7L=% 'E&G
MVFKZQ\/O&VM7^FW<&JZO9O"EI)"RR[8[;8H"XSRYD(]<U=UB.XTJ3X>ZQ/97
M;VFF(\=X(+=Y'A\RVV E%!;&[@\<5Z510!Q=E%/<_%E]52UN5LIO#L*I-)"R
M#<9W;8<CAL$$J>14G@.SN;2X\6&YMY81-K\\L1D0KYB%(\,N>H.#R/2NPHH
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M>>AX\T[EXZ#"YP2!CFH_#S3VW@7Q-X6FL+]-4B347"&TDV2J[.4*/C:V[>,
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M0K,3\@/WL@Y'KCBO8** /.)]5?Q/\0_!][I^E:JMC9-=^?<W%F\*(SP$!?F
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M\"X;;NYW=B .]>M5SVL>&I[W6X-:TW59=.U".W-JS")98Y(BV[#*W<'D$$4
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M",,)EQN^T_=SGK[4_P .ZC9Z#XH\;P:G<Q6S"[74 TK!=T#0J-PSU *,#[T
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MM,7VSRO.\C>-_EYQNV]<9XS63<>*=(GADM].US3#?R6LD]OOF#+A0?G8 YV
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M1G%=OJ7@B&[U:ZU+3]8U/2+B\55O/L,B!9\# 8AE;# <;EP:F/@G1QH^C:7
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MRW26&^GE%S9LTT0,>6.X*5)[D'<>:VKV*7Q7\1=0T2[OKRVTO2K*&46]I<-
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M7%SI-S;P7'DW4D#(DRC&QRI 8#V/->4^'(_#.B1:1H/BWPK'I.L6\D:PZA)
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M<'K69H?CV\O=*\6J]SI>H76A6_GPWEB#Y%PIC9UR-QP04(.&^E 'HM%>;_\
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MHY4C?<H=(I$;:>ZY4D'T(H ]1HKBX?&L]GHGBJ?5XH4OM!EE5DC!"RQE=T+
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MB02J5*LO)^4X8@-VR:S+9'^'OP^O9;^_6^&GQS3I(8A&6!)95(!Y8DXSW)H
MZF*XAGW^3-')Y;%'V,#M8=0<=#[5)7E/P^6/PWXGM]*:\BG?6],6]F*2!O\
M34),PX]0X/\ P"M>TUSQIX@NM>32/[%M8M+U"6TC:YBD=IRH! (# +PPRW.<
M]!CD [^BO.G^(&J7WASPIJ&DV-H+K6KMK26&Z9ML3JKAN5YP&3T.1QQG(T]*
MUW7K'QE'X=\0M87'VNT>ZL[JRB:(91@'C969NS @YH W8?$NBSZ7:ZFNIVPL
MKN016\SOL61R2 HW8R<@\>U:M>0^&]1_LWX0^#&^Q6=T)]5BM]MU%O";[AQO
M7T<=CVKK+[7=>U7Q9?:!X<-C;+IL4;WMY>Q-+\\@W)&B*R_PC))/?I0!V55M
M1U&TTG3Y[^^G6"U@7?+(V<*/7BL+6+SQ!8Z):2O?Z!I\P7_3KR[+^3&>WEJ2
MN<\_>88]ZXG4_%<WB?X2>,TNI;*>XT\/;FYL2?)G7"LKKDG&0>1D\B@#UI'6
M1%=#E6 (/J*K6VIV5Y?7EE;W"R7-DR+<1C.8RR[ES]1S7$2Z]XJ\.+HM[JZZ
M5)I-[/#:2P6R.);7S.$;>3AP#C/RCVJ&TUJ#P[XE^)>L7*LT-FUK*57JV+88
M ^IP/QH ](J*XN8+6(RW$T<,8X+R,% _$UYY8^.M2@U#1VU'5?#MY#J=PEL]
MGI\F9K1W!V?-O/F '"M\J]<BKGQ>:%? ZM<)O@&H6AD79OW+YRY&WG/';O0!
MVEM?6=[N^RW4$^WKY4@;'Y58KR2!M UKQUHA\$:.UG<Z?<^9JES%8-9HENR-
M^[<%5+%CMP,'IFNMTCQ3>W^B^*;R6*W$FDW]Y;0!5.&6( J6YY)[XQ^% '1W
M.IV5G>V=G<7"QW%ZS);QD',A5=S ?0#-6Z\SEU.;6]5^%FJW*QI/>":>18P0
MH9K0D@9)..?6I+SQW?WNI:NNEZMX=T^#3)WMEAU.3][=R)]_HZ^6N?E!PV<$
MT >D55O-3L=/EM8KR[A@DNI1# LCA3(YZ*OJ:X34?B!=7-MX8DL)['2+?6K9
MIVOM21I(HG 7$(PRC<23R2.!QFNDET6ZURST9]8FLFEL[E;MS:Q$I(Z',91F
M)*CH3USTSCJ 78?$>CW,=I);ZC!-%=SM;021MN5Y5#$KN' /RMU]*U*X'Q)X
M?30?ACJY@=&N[9WU82I&(P)T?S<JH^Z/EP!D\=2>37=02B>WCF7A9%##\1F@
M"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD_C5_8H<OM&\C!;')'I^IH YKQMH5_K=AILFEFW^VZ;J,-_%'<,524IN!0L
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MD,<K,6QR 26]<9[XKI](T+6[WQ>/$OB);*W>VM6M;*SM)6E"!B"[L[*N6.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MYJW^('A2[\1'0(-;MGU,.4\D9P6'50V-I/L#FNE/(KYZT7X!:WIWCRUO9=2M
M3I-K=K<+,K-YSJK;@-N.&. "<X[\T ?0M%%% 'G6GGQ1XBU_Q,EKXJFT^+3K
M_P"SV\ LH)8]OEJWS97<>6/\5:GA_P :!_#FJ7?B1H+.ZT6Y>TOVCR8V9<8=
M!UPP9<#KDXK!T3Q/I_AGQ-XQBU".^,]QJGFP106,LIE7RD'RE5(Z@CDUFWWA
MC7;OP/JNKRV=U!?WVMQZNUC#M,Z0(R@( 009 J[L8/.!C/% 'H.D>+['5M1&
MGM::A87;Q&:**_MC"9D! +)GKC(R.HSTJ+2_&^G:S>Q0V5GJDEM,[1PW_P!C
M;[/(5SG#^G!Y( XZUS_AW^PM8\265_;^)-?U:[L(I9$CNH-J1!EVL&Q"N&YX
M4G/'3BLK2M1M]+U[2K/P9?:D]M<WFR]T*[M7V6<39+N"R@Q;3_#D@D\4 =E>
M^/=+M=3N;&&UU._:T8)=RV-F\T=NWHQ'<#D@9(I^I^.=*TS5IM)\F^N]2B2.
M3[):6S22,KY^8 =AMY)QC(]17+>%]?L_!*:MHFNQ7<-__:5Q<0E+627[<DC[
ME9"JG<>0".HQ6SI$+GXM>(;HPN(WTVS5)&0C/,F0"?PR* *.O:@$\.?$)[/6
M-1EN;6)\I(=HM'\G<!$1@XY!SZU<T3X@:6UOHUI<Q:E$+M(H(;^XM76">4J/
ME$AZDG.">#V)K U"UN#I/Q7 @E)F)\H!#^\_T91\OKSZ4W6=7@\4>'-#\*:7
M!>-JWGVAN$DM9(_L2Q,K.[E@ ,;<#!YSQF@#M]6\8V&E:DVG):ZAJ%Y'&)9H
M;"V,QA0]"^.!G!P.IQTK4L=5L]4TB+5+&4W%I-'YL;1J26'ICKGMCKGBO,[V
M)= \>>(9M8US6M'M=2DBN+2YLXU:*8",(48F)R'4KP,C(-=[X/TZQTSPQ:V^
MG37DUHQ>9'O$V2MO=G)*[5QRQXP.* .<\+^.I_$D>N02Z?J$+07-S'!,UF\:
M(B 85V/23KD=:SO!/Q%T^U\&>'DU+^U)C)''!-J3V[O LS' 5Y3U.2 3R >"
M:L>$;Z"PN?%V@77FQ:G-JM[=Q0M$W[R%P&5PV,$$>]95W9W)_9NLK86\OV@6
M]I^ZV'<"+B,GCK0!W^L^++'1[^/3_L]]?7[Q^=]EL+<RNL><;V[*,\#)Y[9K
M0TC5[+7=,AU"PE,EO+D#<I5E()#*P/(((((/I7G.N0?V)\1]6U#5-8UC2=.U
M.WM_L]Y8QJT>Z-2K1R$QN5/.X= <GO79>"[#3[+06DTVZOKJ"[N);HS7R;)'
M=F^9MNQ< D9''.<]Z (T\<:=/JTEC;6>J7,<5S]DDO(+-G@27."I8<\$X)Q@
M=S3+[Q]I=GJM]I<-IJE_?V+*)X+*S:5E#(&#9'&,,.^2<X!Q7&ZAJ5OH^LS2
M^#[W4XM6N-0'VG0)[1S#<,T@$C@,O[O(R^\-CBKFG^*=*\-_$+QP=4DGB62X
MM2CI;22*Q%NORY4'YO0'KVH [ >--";PO%XB6[+6$Q"1[8V,CR$[1&$QN+[N
M-N*=I'BRPU:>YMFAO-/N[:,326^H0F%Q$<_.,\%<@C(/'?%>8R:!JZ>#--UB
M2WU&T1?$,VKS6UJ@-Q;6\I<!@A#?,H8-C!(!/<5KKI.F^*+36Y=%\1:SJVIO
MH\]E')>1A(E$F#MW")!NW*.,Y SQ0!UND^.M-UN^AALK+57MKAF6"_-DXMY2
M 3P_IP>2 #CK7,ZWXB;2OAIXIOM-U/5KZX2\NK=9Y(\O:R9P0"H^6-<<,>F?
MI6MX0\9:5+IND:'Y%Y;:I'"EO+8M9R V[(N#N.W 7CALXY%<Q+:7/_"I/'L/
MV>7S9-2U HFP[F!DX('?- &SH/\ 9MG)X5AMKSQ!8/=RSL+6[,A^UNL0+&7S
M,D+A=PQ@9)P.:W;WQ[I=KJ=S8PVNIW[6C!+N6QLWFCMV]&([@<D#)%9NLP3-
MXT^'KK$Y2(W7F,%.$S;$#/IS67X6U^S\$QZKH>NQ7<-__:-Q<0E+627[<DC[
ME="JG<<$ CJ,4 >CW=Y;V-E->74RPVT*&221S@(H&236!IGCG3=3OK>T%IJ5
MJUVK/9O=VC1)= #<?+)[XYP<''-,^(FE7FO_  ]U:PTY6:ZFA5XX^A?:RN5Y
M[D*1SZUS6BG0_$&L:2&\2>);R]M9A<I8WEN%$$BHP(EQ"NW +#[P!SQF@#L(
M_&&CR^#W\4"9QIB1/(S,A#C:2I7;_>R",>M1ZEXRL-.NH;-;34;V^DA%PUI9
MVQEDBC/1G'1>>,$Y..,UP]SI5V/%L_@E;:7^R;W5H]9,FP^7]GP9)(L]!F9!
MQZ/4FKP_V'\1=<O=6UK6=(L-4CMWM;NQC5HG*)L:-R8WVL#R.@(8T =E<^//
M#]IH^FZK)=O]CU&4PP.L3$EP&.TKC<&RI7&,YXQ2:9XWT_4Y=0MULM4M[VQA
M^T/9W%HR321G.&1.K9(QQSGBN1GTFUM;?P4VDR:A=VLOB![MIKR(K(2ZREF*
M[%V@L<C@=1ZUT'DR_P#"ZC/Y3^5_PCNSS-IV[OM&<9]<4 5?"'Q%BU7PU=:I
MK%O=VD=K]HEENGM'2#RTE95"MSN?;@$#G(-=%HGB:'6YVB73=5LV$8E4WMHT
M2NI.,AN1W'!(/M7"^$;W2(O 6I^%]<M;J6>UDN_MUBEK(S^4T['<NT<C#J05
M.>XZ5?\ !FJSGQ3_ &7I.L7NM>'ELS(TU["0]I(& 6/S2JE\@G@Y(QUH T?%
MOC:;P[XIT'3(["]N(KQY#/Y%HTI=1&Q"QD=6# $CL.:SK_Q4--^*:&5=2D@N
M/#\<D.G0PN\C2&=B3Y0Z,%').,8P35OQY.NF>)_!VMW2R+IUE=W"W,R1LXB\
MR%E4D $@9XS3[-OMGQ@&H0*[6DWAJ,QS%" <W#$#D<'!!QUH V-/\9:5J7AZ
MXUJ$7:P6TC0SPM;.9XI%(!0Q@$[LD<#UJ/2_&MAJ=_<:>UEJ=E?16YN5MKRT
M:.26('!9!SNYP,=<GI7&)?:OH&A>.;W3H)4F;Q&Q\WR#(8H6$(>54_CVC)].
M/:C13!=_%'1+VPO]8U2V^P7227]ZC"-FRAPF551[[1C\N #H? WCB;Q1/J,%
MQI]]$8;VXCBE>S>.-8T;"JS'@2>HZTGB?QS+H'C/1=(33K^X@N4G>?R+-Y6<
M*@*B,CJ03\V.@Q5;X>W\%CJ&OZ!=>9#J9UB\N5A>)ANB=]RN&Q@@@^M/\;74
M>D>./!VMW@D33;;[;%/<+&SK$TD:A-VT$C)4B@#6U+QWI6FZB=-:#4+C4O)C
MG6SMK5I)61]W(4>FTYSC''J*;IVK6%KJ_BJXN-8O'CLFB>YBNL"*S'E;\1X'
M0@Y/O5'2D\_XMZI?I&Q@ET6U\N8H0""[G )_#BL2]L]__"UOM5I-)!+'&RJI
MV&0"U'W6/'4>] '1P?$73I[^QL_[*UN.2_YM6DL6 E7C+#G( !!.<$#G%/U7
MXAZ1I,M^#;:E=0:<VR\N;6U,D4#8!*LV>H!&<9QGG%<CX<U[3-3UOP[/K7BR
MRFN+&,QV4$=C+;>9-(FPEV<D%L$@*,<G/H*S;S4;:WU#QEH$^O0Z1IU]J,HN
M(I;&2>8+)&GF-'(OR /D\$$KUH ]*N_&>GV=A83R6VH-<7^[[-8);,;F3;U.
MSL .<G P1SS3?^$YT5?#UUK4SSV]O9SK;W4<\126WD9E4!U/3[ZG/3!S7&>(
M$M8O$F@^([75M0@\-MI36*:AI867R2'#*7RCX5@,9 X*C.*K>(-,TZY^&_B2
M^TB^U75WU"ZM!-->0X,ACEB&4 C3<NWC(!''7B@#TO0]>@U^"6XM;6]B@5L1
MR7-N8A,N,ATSR5/K@5EZQX\TW1;BX2XL=7>WM2!=7<5B[0P]#DMQD $$E<UU
M.,# KQOQ'K%SK%IXMT_5;[6(]0B^TV]AH]C;NJ21;"(Y&95RZMU)+;<<8]0#
MV%)8Y85F1U:)E#*X/!!YSGTKFM.\>:7JU_%!8VFJ3VLLIACU!+)S;.PST?TR
M"-V-OO3K&PN+[X7VVGQL8KF?1E@4MP4=H0HSZ8)K&\$>+=,M=!T7PY<6UY:Z
MS;0Q6<UB;.0LCJ I<D+MV'&[=G&#0!8\&ZH\</C*ZO[B>2&SURZ +;I#'&J(
M=J@9.!SP!6EIGC?3]2UF'2GLM3L+JXC:2V%_:-"+A5^]LSW .<'!Q7):=J6I
M:+HOQ&?3+5Y=7M]7FN8H&B8DHZIM<#^(85C@==M4;66#4O'O@V]L=5UG6A'-
M<?:;RYA9($+6[X55VJJGV XX!- '=S>.]#M_",GB:669=/CE,+#RCY@<2>65
MV]<Y!_#FM&ZUVRAU&RTT2,US?PRS0;!D;$ )8GL/F&/7->=1:+-/\0;WPK/:
MRMH[7\NMERAV,LD.S9GI_K79L>U6/AU!?WFJW5SJ4,J2Z)IJ:)&TB$>8R.YD
M<9ZY"Q<B@"/P-\1K&Q\ :-)JPU:95C"76IO;220QN6(^>4]>H!(R!T)KNM9\
M36^C2Q0"PU._GE3S%CL+1IL+ZEONC\\UY9INNP#X*0>$DLKZ37[JP:TBL6LY
M%8F0D!]Q7;M ;=NS@8]:Z+5M2NM)UO3O#^K:M?Z;I,.EQ;)[&!F>]G!VLF\*
MQ&  =HP3NZT =6OC?03X57Q&UVR:>QV#=&WF>9NV^7LQG?N&,?TK'U_Q2=3\
M!>)Y+:SU?3+JUTZ613=VSP.,HVUE;IU!Z'(QVKB-/TZ^MO"=GJ8T_4)K?2O%
MDU]/:RQLTYAW,-Y4\LR[@WYUVGB+Q-IOBGP#XHAT9KBZ*:9-EQ:R*I)1L*"R
MC+>PYYH VM-\06D,>@Z5+)+/J-[9),$0%RJ!!F1S_",\9/4\#-:6M:U8>']+
MDU'4IO*MT(7A2S,Q. JJ.22> !7GOA/3]2\':QIEUJ4TFH0^(+6&&>Y,6#:7
M"J3''P,B(J=HST9<G&ZM_P"(MK<M::'J<-K+=PZ3JL-[<P0KO<Q ,I95'WBN
MX-CV- &CI/C/3]5OI; VNH6-^D)G%I?6S1221_WD'\0SQP<URGPXOTU_Q'K^
MJ7<.LF^2_N(X7N1*D$4"LJK%M)V!QU(QN'-6?[2M_&7Q%\.7VAK--8Z1'<R7
M=XT+QIF1 BQ L!EL_,1VQ6C\.H98;;Q()8W3?XAOG7<I&5+\$>U %'6+_6+S
MXDW&BV_BA]&LH=,BN5"00/O=I'4\R*3T K>35$\,Z79G6=9GU);JZ$"7S0QJ
MJL_"AO+ 4+D8W8ZGFN+\3#PW#\6;F?Q3IRW-FVCPI TM@]RHD\UR<;5;!Q6I
MK>HZ/JO@'^P_#.GK-%J4ATZVMS9O#'"3\S2%652%0'?D=P,<T =8/$VE_:=6
MB:<HFDJK7D[C$49*[L;NY"\D#ID54T3QE9:]=QPVVGZM#'-&98+FYLGCBF48
MY5CTZ@C.,]JX&30]2/PW\4>"5MY)M8M9/M G(/\ Q,HVD$@?<>KL%*$9X( Z
M$5V5CXOTGQ1:OI6F->17T]LZM&]G*GV4[2,2$KA2#QUY[4 .3XAZ))<J%COS
M8O/]G74_LK?9#)NVX\STW<;L;<]ZL:GXUT_3=5GTY+/4KZ>V17NOL-HTPMU8
M97?CN0,X&3CM7FVB6.F3^&+/PIK^O>)K.^14M)])2!2NY6 !0K <ID!@VX\=
M36[XRO-,TS6]2U#3-4U32/$HB4"..T>2'42J_(NPJ5DZ[,J01S0!UVJ^,;#3
M-0CT]+/4KZ\: 7+065JTCQ1$X#..,9(/'7CI6U%>PS:<E^"Z0-$)LRH495QG
ME2,@X['FO.-?O-/$]GJ>H7^I>&O%/]G1;YK:V>2*4D;C$5*LLNUB>.O/6NRT
M"74-<\%6;ZY;?9;Z\M,7,07:5+#!X/0XYQVSB@#F-$'BGQMI:^(8_$<NBVMR
M6>PL[>UBD"Q@D*TI<$L6QG ('-=+J?B6W\-VFGP:FTMYJERNR.WL;<M)<.HR
MY1,G"CKR<#UKDO"OBVU\&^';?PUXFBN[34M-4V\82TDD6[0$['B*J0<C''4'
M-3ZIJ!TWQQHOC#4;&\@TFXTE[20R0%GLI&=9 9%7)7(&W/8CF@#I;'QEI-_H
M^I:BIN(?[,5FO;:>$I/!M7<0R'U R.Q[&LS_ (6CX<62V:7[?#970/D:A+:.
MMO*VW=L5\<MP<8')&!FN=D$FNMX_\16-M.NF76C?8[9GB9#=ND<F752 2!N"
M@XY[5:U>UF;P5\.HQ!(7BU+2V=0AR@"<DCMB@#J]#\8:?KNIW.FQV]_9WT$:
MS&"^MFA=XB<!U!ZKGBL@?%3P^UD+^.#59=.5ML]ZEBYAMSG!WM[=\9QGFI'A
ME_X73#/Y3^5_PCSH9-IV[OM"G&?7VKA/#WBFPB^#;^'H[>\N-7NH;NVM[1+6
M0^<TDD@!5L;2HW<G/&#WH ]2UCQ7IVCM:1%;F]NKQ2]O;6,1FDD08RX X"C(
MY) YJNWCK0X_#DFNS32PVD-PMM<++$4D@D+!=KJ>5(+#/MS7"7^CW/AC7]#N
M]5U35+"P308=-DO]/17$<T9R1)E'PK9R#CJ.:?K6F6+_  ^U*[T>\U35/M^K
M6DTLUY$0TC++$I90$3*[5'(&.#S0!V^E^.-,U36TTE;?4;6XFB::V:\M&A6Y
M1<9,9;KC(." <4EIXXTZ^U/[):6>J3P?:#:_;H[-FM_,!VD;QV!XW8V^]4O$
MD,K_ !+\$2I$[1Q_;][A20N81C)[9KE_[2M])UR!?!M[J:W-UJ(%WX?N;1_+
M"N_[UQN4&'&2V0=OM0!VFM>.M/T.XN8Y[#5YHK0 W5S;V+O% , Y9N,@ @G;
MG K.\5^/#HFJ>'(+*UNKNWU&7>\EO:M*)(C&Y C(ZOD*<>G-<UX@UBXU2;Q3
MINK7^L0741F@T[2+"W91/%L^65G5<N&).<L% '-2W;-I?A;X8ZI>13)::>(/
MM;B-F,(:V*@L ,@9.#Z4 =C!J$%WXXM%%_J4,\ND?:!IDL>R((9 -[ C(D!.
MW%5G^)6@I*S[;\Z<DWD-J@M6-HKYVX\STSQNQMSWK/E4ZQ\3H[JR:3[-=>%Y
M%BN=C  M,N.HX..<=:YN'68;;X3R>!Y--N_^$D%D^G#3A;.2TARHD#8V[.=^
M[.* /1-9\8Z5H>IQ:9<"YEOIX#/!!;0-*\P#8PH'4]_H"<\58\.^);'Q-9SS
MV:W$3V\S07%O<Q&.6&08)5E/3@@UR]AIUS8_$S089@TGV;PRT$DX!*EQ)&#S
MZG!-7?!\,L7B_P ;.\3HDFH1,A*D!AY"9(]>: ,/7=2CU7XP6FAWL&MO8VUB
M)$CM5FC0SM* )6*$9C XW'Y0<BNJL/'.E:KJYTW3X;ZYECGD@N)([<F.V9"R
MGS'Z+DJ<=SQQR*H^3+_PNHS^6_D_\(Z$\S:=N[[1G&?7%4_!>FSS>%O%5HJM
M;S7>K:B$=E*GYF(5O?MS0!?'Q*T RA]M_P#V<9O(&JFU;[(7SMQYGINXW8VY
M[U?UGQEI>B:JFE3I=SZA)!]HAMK6W:5Y5W%?E [\$G. !WKSQ]9AD^$R^!UT
MV[_X23[$--_LXVSY$@&WS=V-NS^/=G%=38V-Q:_%BQ64/(L/A@0M/M.UG$ZY
MY]3C- $O_"T] ;3WO(;?59Q!N^V1163L]EM)#><.B8P>,YP":[&UNH;VTAN[
M:0203QK)&Z]&5AD$?@:\^T*VF30OB*K0.#+JEZR H?G!A3!'KFNF\"1O%\/O
M#D<J,DBZ;;JRL,$$1KP10!Q_AJXU_P 1VEU>3^/)K%Q?W$"6R6MJ=JI(57[R
M9/ %=RNO6-MK#:+=7#I>16@NC),H598QPS ].#U';/I7E7A2;P+IT%Y_PD6D
MQG5TU.YD\V72)97QYK%"'$9[8QS6YX^TZY\>WEOIFBQ;7L+1KU[N160/YB%4
MML\$"09W^@ [T =:_C;2$T"QUC%TT5^VRR@2!C-<'G&Q!R<@9R<<<\5-IOB[
M2]0L[^XD,UBVG#-Y#?1F*2 8W!F![$ D$9!Q7">(9VU4>#_%,2ZIIFFVB3P7
MBV4(,U@SJJ\H4;Y04*DA>A!'!J/4M M/$GA#Q3/X>U?5M9U"ZM886DO$V+*(
MW\P(A$:!B1N'&?O 4 =SHGC.RUZ[CAMM/U:**9#)!<W%D\<,RCNK'IP<C.,]
MJ</&NCGP6?%@>;^R@AD+>7\^ VS[OUJ+0?&^C:[/;V5DMVMTR$R6[V<B?9L#
ME9"5"KZ=>3TKRQM46'X&WO@\6=])KUK'+#/:):O^[ F+;RV-NW;@CGG( S0!
MZ!KWCV32/'=AHR:;J-Q;/:RRS?9[%Y6<C9L,>.H&6W8Z'%6KK7;'2/$>OWEQ
MJ6I2K8Z?%<3V(0-%"GS?.@ZECM.>>WTQF^)[V'0OB)X<UG4/,BTX6-S;-<+$
MSJDC%"H.T'&<''TJS86@N_BAXE\Z!GL[G2K6,EE.UP3)D9^A_6@#H[_Q#I^G
MVFGW,LC/'J$\5O:^6NXR-)]W'MC)SV K+U'Q]I&G7EW!Y&H7,5B=M[=6MJTD
M-J<9(=AW Y.,X[XKDO!MEJ%UXCTS1=0AF^S^$(YXQ+(A"SNS&.!AG@XA!/'0
MFLVQ@MM#?6M&\0^(/$&ERRWUQ*D5M KQ7D4K%@R'R7+$@X(SD$4 >RQ2QSPI
M-$ZO'(H9'4Y# \@BGU1T6Q@TS0M/L+9IFM[:WCAB,WWRJJ -W YP.>!5Z@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **X^[\7ZI>:Y>Z7X8T--2.GL$N[JXNA!"DA&
M?+4[6+,!UXP.]2Z=XX@N]#UB[N[-[#4-'#"]L9Y!F-@NY<,.&5AT;O0!U=%>
M7?\ ";Z[;>!]/U>?4M&EO]:N+6&U18BL=GYI&[?\Y+[0P],'K79:5<ZW_:D-
MI>W&F7EI]B\UKNW)CDDD+D#$66 3;CG)YH WZ*K'4;$7PLC>VXNR,B RKYA'
M^[G-%QJ%E:310W-Y;PRRG$:22JK.?8$\T 6:*CEN((,>=-''E2WSL!P.IY["
MJTFL:7%!#/)J5FD,_P#JI&G4+)_NG.#^% %VB@$$9!R#6%X<UBXUK^U+UC&N
MGI>/;V>!RRQ?([D]P7#X]@/6@#=HJM::C8W^_P"Q7MO<^6</Y,JOM/O@\4)J
M-C)>M9)>V[7:C+0"52X^JYS0!9HIKNL:,[L%11DLQP *BM+ZTOX?.L[J"YBS
MC?#('&?3(H GK&TKP^FEZ_KFJK<-(VJRQ2-&5P(]D83 .><XS5^+4K"XNWM(
M;VVDN8_OPI*I=?JH.12W>HV5AL^V7EO;>8<)YTJIN/H,GF@"S17,WGB.:T\?
M6FC.UNFGR:9+>22OP59'51\V<!<,>U=#;75O>P+/:SQ3PM]V2)PRGZ$<4 2T
M5B2>*M,B\5?\(_),B7/V7[27:10H^?9LZYW=\>E:5SJ%E9RQ175Y;P22G$:R
MRJI<^P)YH LT5')/#"0)98T)!(W,!D 9)_ 5"NIZ>]O]H6^MC"4,GF"5=NP'
M!;.<8SQF@"U15-]7TU+6*Z?4+1;>4XCE,RA'/H#G!JY0 45D:/J-X^C/=ZV=
M/MI$DD#-;S[X@@8@$L<8..O^16C;7=M>P">TN(IX6Z21.&4_B* )J*KW5_9V
M/E_:[N"W\P[4\Z0)N/H,GDUB>#=?NM?TF\N[U84>#4+FV'E@J-D<A4$Y)YP.
M: .CHJK;ZE87<,DUM>VTT46?,>.565,=<D'BN$T+Q5XCUWP_J.OV=UHKJ9)$
MM-/ES'Y06;8&EEW'JJL<;1DXYH ]%HJ![N"W0FYGAB98_,?=( %'<\]L]Z=;
MW-O>0+/;3QSPO]V2)PRGZ$<4 2T56MM0LKUY$M+RWG>(XD6*56*'T.#Q6;XD
MU^#1]%U26&ZM?[1MK*:YAMY'&YBB%A\N02..U &W16?H-]+J?AW3-0G"":ZM
M(IG"#"AF0,<>V36)X3\6+JVCFXU:YLK:X>^N+:)-X3>(Y"BX#'). ,XH ZNL
MOQ%HD7B/P_>Z1--)#'<IM\R/&5(((//!Y X[]*O7-U;V4#3W4\4$*_>DE<*H
M^I-"W=LUNEPMQ$8'QMD#C:V3@8/0Y- '+7'A36=9^R6_B'7+6ZL+:>.?R;2P
M\AIF0[EWL9&XR 2% S26_A;7M*>^@T;Q#;06-W<RW.VYT_SIH6D8LVUQ(H/)
M.-RG'O74)?V<BSM'=P.MN2LQ60$1D=0WI^-02:BESI%S=Z3/:73K&YB;S@8B
MX' 9AG SC/I0!'X>T.U\-:#::19%V@ME(#2'+,22S,?<DD_C6G5#3KR5]+LI
M-2:UBO)H0\B0R[DW;<ML)Z@>OI2M>+J6F7+Z-?6LLVQDBF5A*B28XW8/.#C(
MH O45E>&M9&O^';+4C'Y4DR8FB_YYRJ2KK^#!A^%:M !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>%/#Z
M>%O#=KHZ7#7"P&0B5EVD[G9^F3_>Q^%;-% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '!_#>1+6Z\4Z/.P348-:N+B2-OO/'*0R2?0CO[5B3Q6FN
MZY\2;U(HKG34T^*U9F4/')<11NQQV)0E?H<5W>N>#O#WB.>.?5M+AN)XUVK+
MED?;_=W*02/;I5VUT33+'1_[(M+&"#3S&T9MXUVJ5;J./7)R: /)[[0-&'PT
M^'K#2;$-/J&E^:?LZ9D\P()-W'.[ SGK@9KI)HCI_P 5[F+3+>.-H/">+:&-
M %!$[;5 ' '08KLGT'2Y+"QL7LHS:V#Q26L?.(FC^X1],5-_9EG_ &L=5^SI
M]N,'V;S_ .+R]V[;],\T <-\.-"\.WO@C1]7FL[.[U&8K<SWLZ*TQNMW)+GG
M<&X K TS2M1\27_B_P _1-!U&X;4I[6634;EUFAB'$2J!$VU=N""#R237H7_
M  @GA?\ M?\ M4:-;"[\WS]PSM,G7?LSMW9YSC.:?JW@KP[K=_\ ;M0TN*6Z
M*A&E5F0NHZ!MI&X>QS0!Q&J:%)<:]\-=&\0NE\Z6UVEUM8LEP4BC/S9QN!*@
MD'KWK1\0^$WMM?;6=+TG1M5M8;!;672+I53RD#,V83@JN<G(( ..M=L=&TXW
M-A<?8XA+IZ,EHP&/)5E"D*!QC  _"J&K^#/#VNWAN]1TR.6X*A&D5F1G7^ZQ
M4C</8YH F\+ZC8ZMX6TR^TR V]C-;H8(2NWRU P%P..,8_"N)TC4-/TSX'6,
MNIV/V^)U$#VA('G3/,5VDG@#>>2?>O2;>WAM+:*VMHDA@B4)''&NU44#   Z
M"N>L/"D*66LZ/J,-O=Z+>73W$$#9)42'>ZD8XQ)N8$'OVQ0!QVGV-SH_Q<T)
M7L-&TQKO3KE9+72\XV+L*[SA0V#G!VCH:72]-C\#WVD0ZGI&F:I976H^78ZY
M !]I669F*F4$98G<1N5NG:NXTWP;X>TBXBN+'2H8IX@RK,26?#  @LQ)/  Y
M)J.Q\"^&=-U&._L]'@BGB8O%@L4B8]2B$[5/N * ,#XJ/<M;^'K-8[>2RN]5
MCCN8[F4QPR_*Q1)& /RE@.,') '>H[/2;WPYJVJ^(M2T[1].TE-)D%W::7*S
M^<4.X.5,:#(7>N?<5W6HZ=9:M82V.H6L5S:RC#Q2KN5OPK.TKPCH.BI<+8Z;
M&@N4\J8R,TA=/[I+DG;R>.E 'F-W:M:7?@75K70]%T2&XU6W2WCM#NN6BD5L
MAV  (*D9'S<D<UT7A[2],\0^-O&,FOVEM>W]M=K;10W48D$-KY:E-JMT#$L2
M1U-='8^ ?"VG2126NC6Z20R++$Y+,8V4Y&TDG: >PX]JGUGP;X>\07:7>IZ7
M%/<*NSS061BO]TE2-P]CD4 <IJFB:3J'Q6T"RFLX)["#0Y6A@(S%A9(POR]&
M '0'(X!["KO@*V@T[Q1XUTZSB2"RAU")XH(QM1"\"%L <#)KK(=$TRVN[:Z@
MLH8IK6W^RP,B[?+BR#L ' ' _*I+;3+.SO+R[M[=(Y[QU>X<=9&50H)_  4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N(U
M#_DM&B_]@:Y_]&1UV])@9S@9]: .(U1%;XR^'BR@E=*NRI(Z'=&,C\S7.ZL
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M** "BBB@ HJG_:ME_;/]D?:!]O\ L_VKR<'/E;MN[/3KQ5MF5%+,P55&22<
M"@!:*I6.KZ9JC2+I^HVEV8^'%O.LFWZX)Q5V@ HHHH **** "BBB@ HHHH *
M**;)(D,3RRNJ1HI9F8X"@=230 ZBJ]C?VFIV,5[8W$=Q:S+NCEB;<K#V-6*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M***  \#->(:3^T'%J7C6#2SHVS2[FX%O%<>:3*-S;5<KC&,XR.WJ:]OKA++X
M0>#[#Q4/$$%C*+E9?.CA,F88Y,YW!?8\@9P.PH [NBBB@"*YMH+RW>WNH(YX
M)!AXI4#*P]"#P:\XTOPQH#_%GQ!:OH>F-;QZ=:.D)M(RBL2^2!C )P*],KG;
M'0+JV\>ZMKSR0FVO+.""- 3O#(6))&,8^8=Z .6EBUEOBWK-MH,EC:L=)M0\
M]S&9!$H:3 6-2,D^Y &.]-NO&.H3_#:_OM1L=.GU'3]573KA'B+P2,MPB%PI
M.>C9'/!KK+30;FW\?:GKS21&VNK&"V1 3O#(SDDC&,?,.]<]<^ ]3F\):[I*
MW%H)]0UQM1B8LVU8S.DF&^7.["GH",]Z )==\4:M'XU?0;;4]*T9$MHY;:34
MH&<7SL3E4.]0 N #C+<UW4/F^1'Y^SSMHW[,[=V.<9[9KDO%FE>(M8CO-.BT
M_0+_ $RYCVQ_;FD1X&*X+$!6#\\C&TC]:W]!TU]&\/Z=IDERUR]I;1PM,W5R
MJ@9_2@#Q'P]/X0O/A.FF/HO]H>()(9TC6WTQWF,ID?81*$P,97G=QC\*] 35
MO$D<^A>$+*6U364TF.ZU*^NT,RQ@83Y5##>S.&ZD# S6[X%T"Y\,>#;#1[R2
M&2XM_,WM"25.Z1F&,@'HP[55UW0-67Q1;>)O#[VC7J6ILKFUO&9(YXMV]<,H
M)5@V>QR#0!SVLZ_J-[X+\=Z%K26_]J:7I[EIK8%8YXI(F*.%))4\$$9/(K4@
MU-K;6_ >GBUM9%O-/F8S219EBV0QD;&_ASGGUIB^"M3O='\5S:I=6O\ ;7B"
MV-N1!N,%NBQE(T!(R?O$DX&<]*M6WAG57U7P=J%T;2-M'M)X+J..1FW,\:(N
MPE1D?+DYQU[T 5M+UKQ7XK:ZU/1)]+LM)ANG@MH[J!Y7N@C;6<L&&P$@XP">
M.:T;/Q1+;:SXEL-:\F)=+1;V"2-2OF6C(3N.2<E65P3P.G%9NFZ!XM\+M=Z;
MH+:/<:3-<R3VSWKR+):[VW,NU00X!)QRIYYJA\1],75O$7A^PL[E%OM19["^
MB3[S6)Q)*3Z8V #/]\T =EX3O]1U7PMIVHZK%%%>740G:.)2 BMRHY).0I7/
MOFN*\3>-]8\+W9N;O6_#LRQW*))H\"L;CR6<+NW[\[P"#RH'6O30H5 B@*H&
M !VKR@_#_P 5'P1<>$U?1(X&E$C7^Z0S79$HD!<;?E;@9;+=,8[@ Z35=;\1
MW'CV3PUHSZ=;Q#38[QKJZB>1HR9'0@*& ;.%ZD8YZ]*R+OQ[KFE^%/$S7D%E
M)KF@W4$+E%80SI*R;7QG*DJQXR<$?A3]3;6D^,MP^B1V,TXT"+?%>.Z*R^>_
M1E!P<^H.?:LOQ?X=OM(^&'BK4-4N8)M8U6ZMY[AH%/E1XEB5$7/)"@=3@F@#
MHKG6_%/AW6]&.NRZ7<Z=JMVMDR6D+H]K*P)3#,QWJ2I!)"_3M6/;WK:;I7Q1
MOE@@G:WO9I1%<)OC<BW0X9>X]JVY- \3:_KNE3>(FTN'3M*N/M:1V+R,US.
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MP,+SSFKFHZ+XA\2:=I^GZR=-@M6N/,U..TDD831+RD2[E'#'&[..!@9S5,>
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M\S!=BCKW)KG8_"'BZR\-3>#K&[TO^Q75X([^1G^TQ6[DY3RP-K, 2 VX=N*
M+]_XLU>^U[0M/\/"R$&KZ8]ZMQ=HQ,0RA#;5(W<-]W(Y(YXYSK'7?'6IKK>G
MPRZ+#>:),T<ETT#LMU\H= $W#9P>3D]>!701>$WL_%>A7]H\2Z=I>ER6 C9C
MYG.S;CC&,)SS4NC>';K3M4\474LL+)JURLL 4G*@1*GS<=<CMF@#!E\<ZQ>Z
M+X,NM)M;);G7R4D2YW;(R(F8D$'. 1G'<#'&<BW9>)-8T7Q-<Z+XGFL[F+^S
MWU&WO+2%HOE0XD1D+-R,@@@]*YO4-$U;P[8_#;1X);-]3L[F2,,^XPLPA<D<
M8;!'&<<=<'I74:?X7U35/$%WK?BG[$KO8MI]O9V3LZ1Q.<NS.P!+-P. , 4
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M6A_PE\5KH-UJNL:7J&EBVD$1@N$5GD8XVB/8Q#Y+ #!Z_2@#HZ*YW2?%@O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY>M?$.QUC2-(O+"RLM/F@NYI[-K8SLQ39$%8 MMVL<XP,]:ZGPQXBB\3Z/\
MVA'9W5F5FDADM[I-LD;HQ4@C\*UY$$D;(2P# C*G!'T/:JVF:;::1I\5C91>
M7!'G +%B23DDD\DDDDD\DF@#S/4_$$VN>+A_:^@>(5T/2IM]K;1:7,_VR9>D
MKD#&Q?X5[GD]A6Q>7DFB^-HO%+Z;J,FE:II<<$ODVCR2V\J,77?&H+ %7(Z<
M$8-=_10!YG9ZAK'A;PCK.O+H%_<ZGK6J2W-O8) SO"K +&90H)4!4!/N<=:M
M^!;V*UBNXSINNW&M78:[O;R\TY[=;B4#A%9P H'"JO8?C7H-% 'E'B*YA\1/
M;/H?A?5+#Q<;F%OM<FGM ;<!EWF6;&UTV C&6!XXKN/&]A+JG@77;&!2TTUC
M,L:C^)MIP/Q-;]% 'GWB^:76/!WAC7+"VFNX+?4;'4I4MD,C^2.6*J.21NZ"
MK%TTNL>/_!^KVEG>"R6UO@\DML\?EDA N\, 5S@XSC-=9I>EVNC6(LK)62W5
MW=$+9";F+$#T ).!V'%7: /,-9\,:EKFI?$FSA@DB_M&TLEM)9%*I*Z1L2H;
MH>< ^F:-#M=+U74-*BO+7QB+^WF2=H+]KAH+>5 2"6;Y",\ @G.:]/HH *X_
MXI6=UJ'PUUJUL[::YN)(T"0PH7=OWBG@#D\"NPHH X[0M=T235(H+'PKJEA/
M,"GGR:*\" 8S\S[1@<?GBJ7A_3KV'1O'D<MI.CW6JWLD"M&095:)0K+Z@D<$
M5WU% 'DU]X>U)_A[X%NA::B9='2%KNTM&:*Z"&'8Q3H=ZY^[U/(JW%X>TWQ)
MINNC2SXB-_/I<EC'=:QYZKA^=B^;@_>49P.]>G44 <9X5\5-)9Z7HMSH.L6N
MH11+!<(UDPAA*K@MYI^0H<<8))R.*S/#<D^F7OB[0[K3[]+J\U*[O;>06KM#
M)$Z J1(!MSP1@G.>*]&HH \NAT;4;?X2^%KR*QN?[7T+[/=K;>41*P7Y98]O
M7)1F&/7%.F\*:IK'PGU=/(>+6]9N#J;P2'8P;S5=(B3]TA$1>>AKT^B@#S?0
M+;1]5UK36>#Q@;RU<SA-4-P8K:0*1\S/\A."0-I.<UH_$E;A8O#-W!97EVEG
MKD%Q,EI TSK&J29;:H)QR/SKMZ* //[AM0\<^)M#9-(O]/T72;K[=+/?P^2\
M\RJ5C5$/S8&XDD@5SNO_ -HZO#XKL=7LO$EUJ9:XBTVTM4E2T$&TB)]R$(_J
M=Y))X [5[%10!YEJ,%WI=M\.=7FL+V2WTN/9>I!;M)+#OMM@)11NX;@\<5!K
M%C]F\;W.OWB>(TTG5[*W*3:7YR/!(@(V2QQ_.,A@1D<'(KU2B@#G_!UA86.B
MN^GP:E%'=7#W#C4M_GLY."S;_F&=H//K4WB^]33O!NM73]([*7 _O,5(4#W)
M('XUM52U+2[75X(H;Q6>**>.<(&P&9&W+N'<9 ./84 8VG7<OAVP\*Z!)IM[
M</+:K;O<01[H[<QQ+DR'MGH/H:Z:BB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "F[T+E R[P,E<\XIQZ<5\K^'?!
MWQ"@^+=M<W%GJ"727PDN=096\IX]WSG?T8%<\9YSC% 'U11110!'/)Y-O+*!
MG8A;'K@5P_AWQ-XS\1Z/8:M;Z'HL=E=J)!OU"3>%)]/*QG\:[6^_X\+G_KDW
M\C7FGPOT.-?!WA[46\3ZLN(5<V/VM!!U/R[=N<>V: /0M1UW2-':-=3U6RLF
MD^X+FX2,M]-Q&:M37=M;VC74UQ%';*N]IG<! OJ2>,5P>JSQ:UXFU^RM--T&
M :?#''J.I:I#YC,'3<%"@J=H4]2P&>W%<?I$B7G@[X70:RX?1)+B5+GS3^[>
M1 XMU?/!&1P#QP* /0O%_C"*T^'NK:]X=U"RO);5!LDBD69 VY1@X/H:Z*#6
MM*NM1ETZWU.SEOHN9+:.=6D3ZJ#D5Q7Q0M=,M/AEXH6P@M(9VAB:<0(JL?G7
M:6QSTSC-)XCT;3=%\5^!&TRQM[1EOY( T,84E# ^02.3G'>@#I/&GB&?PQX=
M;4;:UCN9O/AA2*20HI,CA,D@''7THTJZ\6/>@:SIND6UGM):2VO9)'![<-&H
MQ^-8OQ<3S/ C)YC1[KZT&]#@K^_3D'UK:T'1H]*NI''B/4]3,B[1'>W22!>^
M0%4<T :O]J:?]B2]^W6WV20@)/YR^6Q)P,-G!R>*CO\ 7-)TJ6*+4=4LK.2;
M_5I<3K&7^@)&:\GTK[+_ ,)_;Q$R#P:VJS-IF0/*.HA1D#_IGN\TIVW@X[5=
MTRSU35/%WC.-K70;FZ^VF)TU17:46NQ?+"@# C()/USF@#U*\OK33[5KJ]NH
M+:W3EI9I B#ZD\5#!K6E7-G'>0:G9RVLKB..9)U*.Y. H8'!.>U>9Q:5]@\1
M> M$\1W,%[8P6,_V=R=T$URNT1_>X8B,_+GOTK6^(4.F6&@6+64=I!%%X@LI
M;OR%50C>8N6?'0XV]>V* .^DO+:&=();B%)G5G6-G 9E7J0.I R,FN>T;QMI
MGB$:I!I]W9+=VD\L$227"L)=B@^9@'.S)ZCT-9.JW-M<?&7P];)+%))'IEV9
M8P02H8IC(]\&J'@BPL(=/\;O':6R3PZS?QHRQJ&1-HPH.,@8[4 =MH>I27.F
MV*:C>:;)J<T'G.MC+NC<9P6CR<E>G-:*W5NUS);+/$9XU#O$'&Y5/0D=0#@_
ME7DVFI_9G@+X>^*4X&FK%#=-_P!.TX$;D_1BC?@:CU8WEW\-/&7BJV+"76+D
M;'7.18QR+$.G.#&)&..S&@#U.QUS2=4GE@T_5+*[FA_UD<$ZR,GU /%4O%7B
M6/PSID4_V:2\N[F=;:SM(R T\S=%R> ."2>P%<OI_AW49M7\.:E#_P (U:6M
MFS&)M-#AIX6C(*#(P5Y#?\!!JS\0W73M6\):[<\:?I^I%;IS]V(2QLBR-Z ,
M1S[T /?Q9XBT&ZLF\5:/80:=>3+ +NPNFE^S2-PHE#*O!/&X<"H]5\4W$_Q'
MB\.6>O:?IMM;VBW,[2*DCSR&0KY(W,-IVC/'/(J/XK7EO?>#5T.UFCFU'6+B
M"&SBC8,6/FJQ?C^$!2<]!Q1'IMC+\;[TR6=NY_L*&7+1*?G\]QNZ=<#&: *N
MD>+=6UYO$FH6'B#1$2QFG@M+&XV^7LC("SR2!MVT\]!CD<UW<FIVVG:5%>:M
M>V5LNQ?,F:4)%N(YVLW;/2O)XK&T@^%?Q$EAM8(Y!?:E$'2, A _"Y'8>E;;
MQ6MW\2O#-MK*QR62Z$9-/CG ,;76Y0^ >"P3&* /08]5TZ;3?[1BO[5[':6^
MTK,ICP.IW9QBDL=7TW5+1KO3]0M;NV4D-+!,KH,=<D' KSWX@0V\$WAJSTV'
M2H]+?5W%W'*-ML;C83&)0GJW.#WVYJ_:Z!JEEJNN:K>-I$"3Z289;73@PWN-
MQ21@>^"RY_PH [*WUC3+N[%I;:C:37)A$XACF5G,9QA\ YVG(YZ<BF:AKND:
M3+%%J.J65G)+_JTN+A8R_P! 2,US7PKTFPL?A[H=S;VL27-Q9H\L^T&1R0#R
MW4C@ #L !VJAXETF>QU[6?$FGKI&K(;1$U'3;\C<B1J6&Q^0F5.2K#!ZYH V
M;WQ.UC\08],N;JV@TG^QGOI)92%"N)D0$N3@##5T-IJ5C?V(O;.]M[BT()$\
M4JNF!U^8''%><VR:5XG^)OAZ]?3XVM)/#!N[>":,8CS*FWY>F0&(_EVJK;WV
MF^&M/^(AGTR*ZTV+5(U6PPJQNTJ1#!R,*I9@2<<4 >E:=KND:O)+'INJ65Z\
M7^L6VN%D*?7:3BN%N_&VL0_#SQ-K2-!]LT[59K2 F/Y1&LZH,CN=I/-4XK>[
MT_XM^%EN?[%MYY[.[22VTN(H5C"*RAV)^<9''RKT/X9.H_\ )'?'/_8?N/\
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MNEP0+%/H\G]K01(/+(W@1%U'&XY8<\X]JF^$5I;0>!HIHK>*.62ZNE=T0!F
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M , +#5;NXDGOHTM[H3R-ES(DZD'/KQBNPL]/N+#QMK $,AL-7@2X\Y1\L<Z
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M_NF5I(U\ACN)(P=H[D'.!G-=3K_A0:OJEGJ]CJ=SI>K6B-$EU JOOC8Y*.K
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M6NG6=M(^Q"PS^]<]=H#$E1VXZTZV\1>(;'7X] URWTTWE];2S:=<VA<12/&
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M(.W9OW@<8!VDUTWC72+_ %WP;J.F:;<+%>3HH1F8J& 8%E)'(# %?^!5T%%
M'GFG^&M8F\5^&]3;0M*T33]+6X0VEK,'?]Y'MSD*JXR!QUZDGM6CI'AG4++P
MUXIL)?*\_4[V^GM\/D;9<[,G'!]:[*B@#)\+Z=/I'A/1]-NMOVBTLH8)-AR-
MRH <'TR*X_PY9^-O"^GSZ=!X?TR\B-W/.DS:H8R1)(S#*^4<=?6O1J* .(\0
M>$;WQGJ.S66%KIMM:@VB6\I9A=L.9B>/]7T7UR35/5O"VNZO9^']6OK+2[[7
M-*$D5S:7!!M[Q& !()4[6^56''!)'2O0Z* .(/A0Z]X5UK2KSP_IOA_[?%Y2
M?8F61^.0S[44<-@@9/?I5_0;KQB9K6SUC2=.CBA7;<7L5Z7\XA< I'L!&3@G
M<>!FNHHH \G;PEXQC\#:KX)MK3319N;CR-1DN23(CNT@3RPO#9;!).!UY[]'
MK^B:U'K/AG6]*M(+V;2X9K>>UDG\G>)$4;E8@C@K^.:[6B@#F-,T2^A\=ZMK
M=PD2VU[8VT*HK[B'3>6!XZ?,.>]9'@[P7J&A^(IIKYX6T[3XI;;1U1BS+%+*
MTC%AC@@;$'LM=]10!YHG@Z^T+4]32U\*Z)KMG>W4EU!/=.D<MN7.61]R-N4'
M)!'..U>@1V43:4MC+;01PM#Y3P0C$8!&"J\#CMT%6Z* //=+L?'/A725\/Z;
M8Z;J=K #'8ZA<79B,4?\(ECVDL5Z?*>0!2W7@&[M_A];:#:7"7-]]OAO;JXE
M.SSI/.$DC?H<#V%>@T4 <WJ&AWES\0-%UJ/R_LEG:7,,N6^;<Y3;@=_NFL*X
M\!WFHZ/XQL)YX[=M6U(7EG,IW;"HC*%A_O1\CTKT&B@#E;%O%&L12:;X@T:P
MM+.2W>&YG@O3(92PVYC78-HZ_>.:Y_0/"FI:/#9:/<^$/#M]';,L?]K%D1GB
M!^\T?EEO,V^^"><UZ510!S>CZ'>6/CCQ-J\WE_9=26T$&ULM^[1E;([<D4OA
MS6]1U36_$-G>16GV;3[I8K:>U8L'4KDJY/\ &O&<=-V.U='3(H8H$*0Q)&I8
ML0B@#).2>.Y))H \W^U:W:?%CQ1)HVF6VH'[%9"6&6Z\AAQ)M*MM8'OD'';%
M.G\":Q-X$U6TEEMI-;U;4X]1N=C$1(1+&VQ21DA43'N:[Z'3+*#4KG48K=5O
M+E$2:49RZIG:#],G\ZMT <UXQT"]UFWTZ[TN2%-3TN\6[MA.2(Y, JT;$<@,
MI//8XJA8Z3KNM^,+#7]>LK;38=+AE2TM(;CSW>24 .[-M  VC 'OFNTHH X&
MS\%:A!\0'O':'_A'XKJ74[>+<2_VJ2-4;*XQ@?O&!]6J2^\$7.K7_CE+F2.*
MUUZWMHK>13EE:.,J2P]F(^M=U10!YKJ&D^-_$&E:3IM_IVF6W]GWMK//<K>%
M_M(B<$E%VC;P">3[>XLZMX2NK3Q?J&N6?A_2M>M]32/SK>\94D@D1=H9&96!
M4J!D<'(S7H-% '":IX9U4V_A[5])TW3+/5M(FEE.G12;8)$E4JZ!PHPV,'.W
M&<U-I&E>(;CX@'Q-K%I9V5N=*:R2WAN#*Z'S5<%FV@'/S=.G'6NUI" P((!!
MX(- '.^"M;U+7M#DN]4AM$G2ZF@5[-BT,JHV R$\D=1GOBD\/:'>:9XE\3W]
MQY?DZE=12P;6R=JQ*AR.W(-=#%%'!$D4,:QQH JH@P% Z  =!3Z /,]/\#:W
MIGA+PNUL;4Z[H$\TJQ/(?*F25G#IN X)5A@X."*V]*TC6M3\8IXEUZUM[ 6E
MHUK9V4,_G$%R"\CO@#)P  *[&B@#S;2?AY=QW'B2UU!H?[,N+>XM-,5&R8XY
MY'D?(QQAB@'^[4NE> ]0OO .MZ5XBFB75=9<O/-"V\(55%CY.,@>6IQ[FO1*
M* .%\/:/J,%_9IJ'@OP[:M!S+J-LZ98@<-&@C!!)P>2,<]:CO?!6H3_$!;R-
MH!H$]S#J5S&6(?[5$C(N%QC!/EL3ZI7?44 <!K?A.Z@\87>OV>A:7KL.H0QI
M<VMZ522*2,$*\;,K#!7 (XZ U8OO#-]?6/ACR=,T[39+'6$OKFVM7_=H@60?
M*0J[FPRYX'>NWHH YS7M;U'3?$OAVPLX;2:WU">2.Y1V/G*H3<'0#C:,'<3Z
M@=Z/'FA7?B3P=>Z;8M&MVS12Q>:<*6CD5P">V=N/QKH/)B,XG\I/."[!)M&[
M;G.,^E/H XV]TS7-?U#POJ5WI\%A)IU])-<0?:A+A#$R@A@HR<GI4E_X;U.Y
M\::IJMM.EO%<Z%]@AF#?/'-O=@V/0;@<UUU% 'D]IX+\0/I7A[3O["TC35TO
M4+6YNKB.Y\R2\,;#<XP@QGEOF))/'O73MI6MZ7\1;O6+&Q@O=/U2"WAG9KGR
MGMC&6!;!!WC:V<#'(QQUKL:* .;\:Z'>:_I-E;67E^9#J-M<MO; V1R!F_'
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M\#O7844 <W;Z'>1?$>^UUO+^QS:9%:IAOFWK(['CTPPKI*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH :[B-&<YPH). 2?R'6N5MO'MI+JEE9W6D:SI\=_)Y5I=7ML(XI7P2%^\6
M4D X#*,UOZQ->6^B7\VG0B:^CMY&MXCT>0*2H_$XKR!C+K;>$KE6\2ZCJD6K
MVDVHO=0S106QR=Z^60J#!/50< ')YY /1=3\;VECJ\^EVFF:IJUW;(KW2:?
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M#)=:Q-:M96<;:5-8H$R';:) =SDJ#U[<"@#:F^(NEPR32BQU.72X)C#-JL<
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M7 4L@9N"P&1QTS6EX.T6*_U[QM#+9ZJNE:E;6L4<FI^89)T,<BL<R$MWZ'!
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M :EJ5U?6Z?8[=$$MU<*$!+MR!G!!9B0,FIX/&-J\NEPW>G:E82ZC<26T:W<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,CQ'H*>(=-CMC=2VLT
M%Q'=6\\0!,<J'*G!X89[&LZ+PK>W>JV%_KVM'4?[/D,MM!%:K!&LFTKO898L
M0"<<@<]*ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K(\+Z!#X7\.6FC03/-%;!@LC@ G<Q;G'^]6O10 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5@:SX9.NZK:S7NI7!TRW=)O[-5$$<DJ'*L[8W$ X.W.,J*WZ* "BBB@ HHHH
M **** "BBB@ HHHH **** "L?Q%HMSKUB+*+5[G3H'RMQ]F1"\J$8*AF!V_4
M<UL44 065G;Z=8V]E:1"*WMXUBBC7HJJ, ?D*GHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"EJ]X^G:->WL:JSV\#R*K="0">:\P_X6
MQJW_ #X67Y/_ /%5Z/XG_P"15U;_ *])?_037SU7'B:DHM<K/6RZA3J0DYJY
MWW_"V-6_Y\++\G_^*H_X6QJW_/A9?D__ ,57 T5S>WJ=ST/J5#^4[[_A;&K?
M\^%E^3__ !5'_"V-6_Y\++\G_P#BJX&BCV]3N'U*A_*=]_PMC5O^?"R_)_\
MXJC_ (6QJW_/A9?D_P#\57 T4>WJ=P^I4/Y3OO\ A;&K?\^%E^3_ /Q5'_"V
M-6_Y\++\G_\ BJX&BCV]3N'U*A_*=]_PMC5O^?"R_)__ (JC_A;&K?\ /A9?
MD_\ \57 T4>WJ=P^I4/Y3OO^%L:M_P ^%E^3_P#Q5'_"V-6_Y\++\G_^*K@:
M*/;U.X?4J'\IWW_"V-6_Y\++\G_^*H_X6QJW_/A9?D__ ,57 T4>WJ=P^I4/
MY3OO^%L:M_SX67Y/_P#%4?\ "V-6_P"?"R_)_P#XJN!HH]O4[A]2H?RG??\
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M/_\ %4?\+8U;_GPLOR?_ .*K@:*/;U.X?4J'\IWW_"V-6_Y\++\G_P#BJ/\
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MG_\ BJX&BCV]3N'U*A_*=]_PMC5O^?"R_)__ (JC_A;&K?\ /A9?D_\ \57
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MK_\ \!V_PH_X1C7O^@-?_P#@.W^%?0M%9?5(]SI_M6?\J/GK_A&->_Z U_\
M^ [?X4?\(QKW_0&O_P#P';_"OH6BCZI'N']JS_E1\]?\(QKW_0&O_P#P';_"
MC_A&->_Z U__ . [?X5]"T4?5(]P_M6?\J/GK_A&->_Z U__ . [?X4?\(QK
MW_0&O_\ P';_  KZ%HH^J1[A_:L_Y4?/7_",:]_T!K__ ,!V_P */^$8U[_H
M#7__ (#M_A7T+11]4CW#^U9_RH^>O^$8U[_H#7__ (#M_A1_PC&O?] :_P#_
M  ';_"OH6BCZI'N']JS_ )4?/7_",:]_T!K_ /\  =O\*/\ A&->_P"@-?\
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M.W^%'_",:]_T!K__ ,!V_P *^A:*/JD>X?VK/^5'SU_PC&O?] :__P# =O\
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MVYI'_04LO_ A/\:/J:[A_:TNR/"?^$8U[_H#7_\ X#M_A1_PC&O?] :__P#
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M]N:1_P!!2R_\"$_QH^IKN']K2[(\)_X1C7O^@-?_ /@.W^%'_",:]_T!K_\
M\!V_PKW;^W-(_P"@I9?^!"?XT?VYI'_04LO_  (3_&CZFNX?VM+LCPG_ (1C
M7O\ H#7_ /X#M_A1_P (QKW_ $!K_P#\!V_PKW;^W-(_Z"EE_P"!"?XT?VYI
M'_04LO\ P(3_ !H^IKN']K2[(\)_X1C7O^@-?_\ @.W^%'_",:]_T!K_ /\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN#WJ.MJ1(I- O3;';!'?*R"1N2I5@,>I]0*Q:$#5@HHHIB"MCPK_ ,C3IO\
MUV%8];'A7_D:=-_Z["D]BH_$CVZBBBN<[PHHHH **** "BBB@ HHHH ****
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M6K2YO-,\>16@D+KJ$$I6)=S,JI"S #N< \=ZO6Z:?K4VEB3QR;T?:(YX+;;
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M 'Y8X55F^I S3IM-L+BZCNIK*WDN(_N2O$I=?H<9%6J* &I&D2!(T5%'15&
M*K7>F6%^R->65M<-'RAFB5ROTR.*MT4 ,>&*5 DD:,H((#*" 1TH:*-V1GC5
MF0Y0D9*G&./2GT4 -=%D0HZAE88*D9!%5[?3;"TB6.VLK>&-&WJL<2J W3(
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M;_UV%8];'A7_ )&G3?\ KL*3V*C\2/;J***YSO"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=9\11Z3=P6<=E=7MY.K2+
M!;("0@P"Q)( &2!^-;5<S<?\E*L?^P7-_P"C$H SM=UW4+[1MB6>I:.[7=O%
MYKE59E=P"%()[5>MO!,-FKK;ZUK$2N[2,%NCRS')/3J36SJNEV6OZ>;2Z+M"
M75LQ2%&#*<@@CD$$5D?\(+IW_/\ ZS_X,YO_ (J@#/UOPFMG87>KQZUK!OK6
MTE\J4W1)48R1TZ94?E6E_P )%>6EK9HNB:C?E[:.1IX I4DKSU(YJ.3P%I<L
M;1R7FKO&X*LK:E,01Z$;JZ6&%+>!(8QA(U"J/0 8% %#1=:CUF&9A;SVTT$G
MES03KAT; //U!!K3KG]"!'B'Q)P0#=1X]_W*5T% !1110 4444 %%%% !111
M0 4444 %%%% !7,>(_\ D9?#7_7S)_Z!73US'B/_ )&7PU_U\R?^@5%38VH?
M'\G^3.GHHHJS$**** "BBB@##\2>)K?P[!#N@EN;JX)6"WB'S.1UY/  XY-<
M5?6FJ:Z@O?%FH0Z=IF=R6A?;'^/0R'Z\>U=MX@T:WOQ#J#W=Q9SV =TG@VDA
M2/F!# @C@=NU<7I.N>&(9;>\FT_5;V>9D5;V_59&&X@ @;OE&2.@%-$OS-33
M&(54\-:&TH P+^_!AB'NJD;B/H!]:SM0\9:AX?O)4;58->G1L36,%FR>6?19
M%R,CT;\Q7I8 QP,5YS>QOX*>X5&T&=+FY>:(7\_D2_.<D$X(;!)P:+CM;8T+
M/QHVM7$%O;^%KV3S,%C.8U6/USR>E7O%NGVJZ=9RQVL:RK?VI#(F"/WJ^E11
M:[JUMIOVR30M/BBV[C+'J2"/'^]MJMI\E]XPB,C>)K6&!3S;Z.ZLRGC[TC9)
M_ "@+=SM^**Q]*T%]+N6F;5]2O 5V[+J8.H]\8'-;%(84444 %%%% !0>E%!
MZ4 <UX%_Y%I?^OB?_P!&M72US7@7_D6E_P"OB?\ ]&M72U%/X$;8C^++U844
M459B%9GB'5/[%T&\U )YCPIE$_O,> /S(K3K%\6Z;+JWAB]M;=0UP4#Q*>[*
M0P'Z8H Q+7PA;PZ9-JFNHFI:Q)$9)7N!OCC.,[40_* .G3M7-P3G2//U?1[?
M[//!^]N;2$XBN8A][Y.BL <@CTKM[#7;;Q%X<G> [;M8BD]J3^\ADQRI'7K^
M=<1<QW%K#)81!3JNH(;>WMCRP5N'D8=E"YZ]ZI6LR)7YE8]5MYDN;:*>/[DB
M!USZ$9KE-4N[8?$312?+FQ#/;'!!,4K;77([$JK5KZAJ5IX5\-">\E_=VT*H
MH[R,!@ #N37FFG1W][I=Y>RC=K/VD:JBC@[D_P"68_X!\M)(IM+0[>11IOQ*
MBEV(L6J61CR."9(CGGUX;]*ZB>58())G^[&I8_0#-<MKB?\ "2^&++6]%82W
M5LRWMGC'SD=4.?49'UQ6O87]MXF\/&:!ODN(FC=3UC;&&4CU!I#.=T/0T\50
MQ^(O$"M="X_>V=G(?W4$1^[E0<,Q'))]:Q+FR@&KS'2XX],U",E;>:T78K$'
MA70?*P/3IFNE\$:K$FEQ^'KME@U33%%N\#\%U48610>JD#/%<_JKKI&H37]X
M&7]Z?L\(^_/)GY55>IR:I6ZD3;TL=WX>U;^W-!M-1\LQM,GSH?X6!(8?F#6G
M6+X3TZXTKPQ96EV1]H52\@ X#,Q8C\,XK:J2PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *^?)?]<_\ O&OH.OGR7_7/_O&M*?4Y\1T&4445J<QN:?H*
M:AX>N;V.5OM<4I6.+M( NY@/?&3^%4Q81GPZ=1WMYHNQ!M_AQL+9^M:5E=2V
M/A*.Z@;;+%JBLI_[9FKFLPV__"*"YLP%MKN_69%S_JR8V#)^!!_#%3<TLK&"
M=#U1;(WC6%P+<+N+E#T]?I[U'::5?WP4VMI+,&)4%%R,C&>?Q'YUV6EZ<NG^
M)6M/LUY<.D#K->2N1&08SP%QTZ 9)K >61/ D**[!7U!]P!X.$7K1<'!(HIH
M&K2/,B:=<%H#B0;#\IQG'Y56M+&ZOY_)M8))I ,E4&<#U/I7575S.WBKPUF9
MS^YM#RQ_BQG\^]$*6[Z;KL(MIYW6_P!TL5M($<Q MC^$Y4'MCTHN'(CD[JTN
M+*<P74+PRCDJXP:AK7UJZ66WL(%L;FV6"-@AN'W,ZEB1SM' .16131#5F%%%
M%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;'A
M7_D:=-_Z["L>MCPK_P C3IO_ %V%)[%1^)'MU%%%<YWA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<S<?\E*L?^P7-_P"C
M$KIJYJX_Y*58_P#8+F_]&)0!R</Q M]%\<7FCW,<WD-,0TG!5&VELXSGH/2N
MJ'Q!\,LH9=08@]"+>7_XFO*->GNA\2;M4TN%T$I G\@[R-I.?,Z=>,5UGA[Q
M=J]GBSFT,R1DXC)N4&T_4]JMK2YG&5G9G;Z9XLT;5[P6EE=-),06"F%UX'N0
M!3==\0MIT\6G6%N+S5)U+QPEMJH@ZN[?PJ/S-/TW4-4N;H)=Z&;2(@GS?M"/
MSZ8%><ZSK4SZ?K6IP;H9;O5S82W)7<;>WBPI('4@'<V/?-06WH;CW]_YC&Z\
M521SGJMA9)Y2GZODM5J'Q1J-A$;9[JVUB\N<)81PQF*5F[F5>0JC@EJP;[PA
MJFF^5-X<=M7T^Y0;1+,"T3G^/?W0]3Z=JTK>"#P/#%!'LU#Q9JF$![#_ .)C
M7/X_6F[="4Y7U-[1-:U6/6CH>OI:F^>'[1#+:9V,F<$$'E2#^==17,^#K&VC
MM;F_,SW6HS3/'>74BX+NC%2%'9 0<"NFI%A1110 4444 %%%% !1110 4444
M %<QXC_Y&7PU_P!?,G_H%=/7,>(_^1E\-?\ 7S)_Z!45-C:A\?R?Y,Z>BBBK
M,0HHHH *0G )I:0C((]: //)_'5_J^E7*V?AV8Q3QR1Q2/.!D<J"0 :YE=-U
M"'2((8[8O/"(V"D$!BK XSCVKMHM,\4>'=$>&SU#3I[:SC=HEDMGWLHR0#AN
MO:MB[U:\7PFNI6UNOVR2*-EB<$A6<@<@<X&<_A5)V(E%OJ9%IXWO9;^TMKK0
M)K>.XE6'S?.#!2>F1@5Q,%JVH7FH7LT37-S)=RI*[INV[7("#C@ 8XKT(Z3X
MCO;NS.H:AIQMH)UG98+=E9BO09+''-,U"WN?#6ISZU80M<6%R=U_:1KEPW3S
M4'<X^\.X&:5]1N+:L>>CP[B4?NKDVH;S%LR#Y(D_OA>F:?-#-I5_I^HVL#07
M:W44:%1L\T,X!0^H(SQ[5ZQ)KFF1Z-_:QNXOL.S>)0V01V ]3VQ61IEC=Z[J
M46MZM"88(N;"Q<?-&?\ GH_^V1T'8>]/F)5.SO<Z@=****DT"BBB@ HHHH *
M#THH/2@#FO O_(M+_P!?$_\ Z-:NEKFO O\ R+2_]?$__HUJZ6HI_ C;$?Q9
M>K"BBBK,0) KG;_QOHEE=M:)-+>72YW0V4+3LN/7:#C\:J^*)Y]4U:P\,6LY
MA%TK3WDB-AU@7 *CT+$XSZ UT.G:78Z3:):V%K%;PH,!8UQ0!P>JFPUO?J+>
M"=3=@I+3AUMG(]_F4G\:RK/Q!-I+M_8/A6WM#(/GFO;G<Y/;D;B?IFO4-5_Y
M!5U_UR;^5>5'K515S.<FMBM<&_U2[2_UV_%S+$,I$J[(8?<#U]S6IX.TZ[\1
MZQ#JJ,\.BVC$QN,@W4@XX_V!S]35+3=(3Q/XHCTBY9A800_:KE%./-^;"H?;
MN?6O8(H8X(DBB14C0855& !3D[:(4(M^\SC7>7P+JLLK@MX;O)-Q*K_QXRL>
M20/^6;$_@:MWOAJ7[6^K^&=16QN9QOE7;YD%P<<%E]?]H5T\T,=Q"\,T:R1N
M"K(PR&![$5RGA^V?P[XEN?#\4COILL/VNS1CGR!NPR _W<D$#M4&IGZG8:UJ
M+*-=\)V.H&,#9/87>R0?BVTCZ9K'T_6]!\/7IE?PEJ4-PGR^:[+<,OT.XD?A
M7JQZ5Y3JG_(3N/\ KH:J*N1.3CL=?I?C_P /:K="U2\-O<MC$5U&T+,3V&[&
M?PKIP<UXQ<VEO>0F&YA65#V85U7PZUBY+WN@7LK2M9!9+:5VRS0MG /J001]
M,4.-@C.^AWM%%%26%%%% !1110 4444 %%%% !1110 4444 %?/DO^N?_>-?
M0=?/DO\ KG_WC6E/J<^(Z#****U.8=YLGE>5O;R]V[9GC/KCUI?.E\GR?,?R
MMV[9N.W/KCUIE% %DZC?,D:->7!6+_5J96PG;CGBH?-D,0B+MY8.X)G@'UQZ
MTRB@+DAGF,B2&60O& $;<<KCI@]L4L5S<0S^?%/+'-DGS%<AOSJ*B@"2>XGN
MI3+<3232'JTC%C^9J.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "MCPK_R-.F_]=A6/6QX5_P"1ITW_ *["D]BH_$CV
MZBBBN<[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N9N/^2E6/_8+F_P#1B5TU<S<?\E*L?^P7-_Z,2@#RG78;IOB->,FJ
MPHIE)%N9SN VD8\OH>>:?]@UOMK4?_@(/\:J^((M*_X61>R2R78G\X[@%'E[
MO+/?K]W)JMYGA3_G\?\ [_2UHCG9Z3X,U+6!?):ZIK23PA2L:?9@A8]OFS1J
MEFFGZS?:9<!(;74YOM=G<, $$Q4*\3'L3C(]<FN$TF30_MZG3;EFN0"0/-<\
M?CQ7J>DWUGXCTYM+U:&*=L<I(,AP._U%)KJBXR3]UG'Z?=>(?!C36=AI[75E
M*#Y5M(=HMI#_ !*>Z=R/RI]C:SZ)))KFK,USK%T<0H1B2ZE_A1%[(/T%=%:^
M'S->WUEIOB/6;6.SD6-XC(L@&5#?*7!.,$=ZV]*\+6&F7/VQFFO+_&/M5W(9
M) /09X4?3%3<KE?5DOAK3)=)T"UM;A@US@R3L.AD8EF_4FM:BBD6%%%% !11
M10 4444 %%%% !1110 5S'B/_D9?#7_7S)_Z!73US'B/_D9?#7_7S)_Z!45-
MC:A\?R?Y,Z>BBBK,0HHHH *R-9O]:LY(AI6CQWZL#O+W0BV'MU!S6O0: .3C
MG\5:VLD:FPT94;9*4D^U2@XZ#@*IP0><U#-9VNFR.L_BO6/-'WP95//TV8'X
M5K>'_P#C\UW_ +")_P#14=8^O_#ZVUJ>6Z:]O6G<D[)+A@@'H N,"A"=[:&!
MJ?B2YT!S=67B.\U([E"V-S!&?-RP&U6 # G/'!KT_P U5@$LI$:[<MO.-OUK
MR2R\+:QX/N-UCIUE>#=F.2ZA\R2(^H<<GZ'\ZU'\,ZGJ<4E]XKUAQ:*-S)(P
MCA0?[@./^^B:=B5)D=_J'A6SUHW&E17.K3"0R+8VAS:I.>LF3\H;Z9]<9KI_
M#OB>^U+5)M-U32Q97*P"XCV2[U9"V.<@$$'\ZR=+MGNXU@\,6"VEEC_D*W47
M7_KE&<9_WC@?6NIT;0+71Q)(C23W<P'GW<[;I9<=,GT]AP*"E?J:M%%%(844
M44 %%%% !0>E%!Z4 <UX%_Y%I?\ KXG_ /1K5TM<UX%_Y%I?^OB?_P!&M72U
M%/X$;8C^++U844459B<Q:J&^)FI,0"5TJWVGTS)+G^0KF-8U74XOB-B/4;A(
M(KZTM1;AOW921"6R.YR.M=/9_P#)2M4_[!=M_P"C)JX[7/\ DHDO_87T_P#]
M%M0!Z9JO_(*NO^N3?RKRD]:]6U7_ )!5U_UR;^5>4GK6D#&KN:7@'_D>]4_Z
M\8__ $*O4*\O\ _\CWJG_7C'_P"A5ZA4/<TA\*"L&4?\5W;G_J'O_P"C!6]6
M#+_R/=O_ -@]_P#T8*11O'I7E.J?\A.X_P"NAKU8]*\HU3_D)W/_ %T-7 RJ
M]#F52:/5+:Y%U,1/>7%N\3-E-J(I7 ['.:ZCP@H7XA(PZO8N#^##'\ZY5B?[
M2TT9./[1O3C_ ( E=7X1P?B!%S\RV4G'U9:'L)?$CU2BBBH-@HHHH **** "
MBBB@ HHHH **** "BBB@ KY\E_US_P"\:^@Z^?)?]<_^\:TI]3GQ'091116I
MS$T5K<3J6A@ED4'&40D9_"HWC>)RDB,C#J&&#7H/A$:B? E^-).+[[5^[^[Z
M)G[W'3-+XDM)]1L-#T_4'A_MR6;:[+C*H<Y)Q_P'\0<5/-K8U]GI<\[JTNG7
MCZ<^H+ YM$;8TO8'CC]17:?\(MX?NK^YT.TFNUU*WCW><Y&QCQQC\156V1H_
MA;J*,,,MX 1[[DHYA>S[G+W^E7VF+ UY;M")UWQY(.X?A]:IUW.J>'#>ZCH-
ME'=W+_:;?<S3R%_+4 $[1V^GTK,UF'PQ92M:6L=\]Q;SA)79AM< _-CWXQT%
M"D)PL<S17;GP?9'Q5';K)(=*>U^U>9NYVXQUQZX/T-<YI-G;:CXEMK4!A:RW
M& &/.S.<9]<4[H'!HI)9W4D!G2VF:(=9%0E1^-05W/B+Q=J>EZ_+9:>T<%K:
MXC6(1J0>!UX_E5#2M&T[^PI=?UMIWA:79'%!@%CGD_GGTZ4KZ78."O9'*T5V
M<WA.Q77=($$LKZ9J2EDR<.ORYQG\15H>%] N/[6L;66[-]9*S^8^ O?  [XZ
M&CF0_9LX+'&:*]#TP:*GPZD>Y2[-LTR_:-FW>9/E'R^W2LCPUH^DZE //LM4
MN96E*,T*@1QCL2?Q_P#K4<P<FQR=%=HG@J ^*KNQDN76PMHA.S\;]IZ#Z]>?
M:J]G_P (Q-XBTU+*'4%0S!6WE>6R-A^F>O\ *CF%R/J<GTHKMO&"Z++XM6*9
MKF*4RH+N3C8$VKC;WZ8[5S&LPV$&JSQZ9,TUHI&QVZG@9_7--.XI1L4****9
M(4444 %%%% !1110 4444 %%%% !6QX5_P"1ITW_ *["L>MCPK_R-.F_]=A2
M>Q4?B1[=1117.=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7+:U]KT_Q=9:Q'I]S>6JV<ELXM@&=6+*P."1QP:ZFB@#A9
M7T>?5#J4O@C4'O3UF:S4L>,?WO2K'V_3O^A,U'_P"3_&NRS10*R..&HV"G(\
M':D#[62?XU+#K5O;R>9#X4U6-_[RVB@_^A5U/G1>=Y/F)YN-VS/S8]<4YF"@
MEB !U)H"R.?\,QW,EWJ^HW%G-:)>7*O%%/@/M6-5R0"<9(-=#2!E+%01N')&
M>:6@84444 %%(S*H)8@ =S0&4D@$$CJ/2@!:*** "BBB@ HHHH **** "N8\
M1_\ (R^&O^OF3_T"NGKF/$?_ ",OAK_KYD_] J*FQM0^/Y/\F=/1115F(444
M4 %9NIZ'9:O)&]WYY,8(41SO&.?7:1FM*C- '-R>"-)\MOLC7EE.S;_/M[IP
M^[IGDD'H.HIXTGQ&BA5\21L , O8J6/U(8<UT.:* .>.D^(R!_Q4D0^E@O\
M\520^%1<7:W6N7TFJR)_JHI$"0I[^6."?<YKHJ0L 0"1D]!ZT      P!V%+
M2*P894@CU%+0 4444 %%%% !1110 4'I10>E '->!?\ D6E_Z^)__1K5TM<U
MX%_Y%I?^OB?_ -&M72U%/X$;8C^++U844459B<;J=\/#GC=M5OH9/[-O;*.V
M^T(I812([MA@.0"'Z^U<\]E>Z[XA77K.RG-C/JUH\;.NTF.-"&<@\@9KU(X[
MTOM0!!>PM<V4T*D!G0J"?<5Q?_"%7O\ SVB_.N[HIIM$RBGN<+X8\/7VD>-K
M^>>(FWDLT59A]TL&Y'UKNJ**0TK*P5C26TY\8P70C;R!9,A?L&W@X_*MFB@8
M5Q=YX0N[B[EE66,!V)&:[2BFG8F44]SQ35_#NI:3Y.H36LKP6FI7)D,:[CY;
MHN),>F1BMGP#;SW_ (LGU>."5;&&U\D2R*5$CELG;GKC'ZUZEUI ,=*+Z!RJ
M]Q:***104444 %%%% !1110 4444 %%%% !1110 5\^2_P"N?_>-?0=?/DO^
MN?\ WC6E/J<^(Z#****U.8Z&RU^"T\'7ND;9Q=3S"1)%QM RG4YS_">U8]E?
M36.HP7L9W2Q.'&[G..QJM12L-R9W1\8:+;W=QJ]GI]R-5GCV$2,/+4\<]?8=
MORK)L-?LU\*:AI%]'.9)W,L4D>"-_!&<GU4?G7-T4N5%>T9UUWXQB_M'1KRS
MAEW6,7ER++@!\@ XP3VS537K_P .Z@DUQ8VEY'?SN')<C8IS\W )SFN<H!((
M(.".]/E0.;>YZ)>7=UH_P]2&_B\F_D5K6(,?F\LGG/X#'Y5P-K<RV=W#<PMM
MEB<.I]P<T7%W<W;A[FXEF<# :1RQ _&H:$K!*5V=I<^(?"^IS+J&H:3<F^VC
M>D;#RW('&3D?R_.J>E^(=-_LB?1]5M)S8M*983"P+Q\YQSC/U]S7+T4N5!SN
M]SKY_%]J^NZ5-%;2QZ;IRE8X^"Y&W&>N.P[TVQ\4V5KK.M7CPW!COE81@ 97
M/KS7)44<J#G9U&BZ]ID7AVXT;5H+EH7E\Q7M\9[<<GV_6K-CXHTJ+P];:?<P
M7N^TE,D8A<(LO)(WG/OSUKCJ*.5 IM':MXVMU\43:@EM*]E<0+#+$^ W'<<X
M_P#UUD7E]H=K>V5SHEM=*\$PE?[0PPV""%&"?3_]=8-%/E0.;9U6M:SH&IZS
M;:D+6\9VD4W43XVLH &!@]>*Q-9GL;G59YM-MV@M&(V1MVX&?ISFJ%%"5A.3
M84444R0HHHH **** "BBB@ HHHH **** "MCPK_R-.F_]=A6/6QX5_Y&G3?^
MNPI/8J/Q(]NHHHKG.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KSK4IM3DTV_T"TNYEOSJDOERASN6(+]H7GT^ZGXUZ+6
M(GAU4\82Z\)SB2U$/D;> ^>7SZD #\* .?\ ^$PB:XEUA&)M8K"V5(VDV*9K
MA^ Q/ P N3V!-;FA>(6U._N;&4V3RQ1K*)+*Y\Y"K$C!. 001^HJE;>"(+71
MM0L([DA[F\^UQ2[,^25(,8QT(7:!CN*V=*M-0MS(U_/9R$@!1;6YC QG).6.
M<_I0!R=K?W6GZ[XAO'T^VN+A]0CM;;;*1(6,:;5)*_*H!+'\>#5CQ!K-VVC:
MYI&I6T4%V-->YC>"0NDB?=/) ((../<5J77A=IDU%HKTPW%S>I>P2B//DNJJ
MHXS\P^4YZ<$U!-X5N]1CU*;4K^*2]NK-K*)H82D<*'D_*6)))P3SV H JW.J
M+H_BS7[QHVE*V%BL<2G!=VDF55]LD@5>G\0:KI[30W^FP?:#:2W-N+><NLAC
MQN0Y4$'YACKGFEO_  J=0OK^XEN@HN[6"(;$^:*6)V=)%.?5LX/I5BQT;4#J
MB:AJ]]!=20PM##'! 8U7=C<QRQ))VCV SZT 58O&=K+K=G9+'_HUS9"Z^U;_
M )58J7"$>NP,WX5?M]7N+GPS#JJ6\4<DT*S+'/-L50>1N;''!STK ?X>1GP]
M=:8FH.DDMWYT<XCYCCQL$8&>GEY3/OFM_7M$_M;1%T^)XXMCQN@DCWH=C!@K
M+D94XQ0!S.J>(3K'AG7+9S:M-:B$^9:3&6-U9AC!P.>""*WM,_Y'77O^N%K_
M "DJG)X4OKNVU?[9J4+7%_%%&OE6^Q(?+)( &XDCGN:V+32Y;;7K[43,K)=P
MQ(8]N"K)NYSGH=U &I1110 4444 %%%% !1110 5S'B/_D9?#7_7S)_Z!73U
MS'B/_D9?#7_7S)_Z!45-C:A\?R?Y,Z>BBBK,0HHHH *Y37-3DT3Q$]T[N;:7
M2I6$9/R^;$P(P/4AS]<5U=8GB/P\OB!;!6G,(M;I9VPN?,4 @H?8Y'Y4 <OI
M<VHQ66G>'KF]FEOXM45)YBYW-&$^T'GTY"_I6A!XZ2XN(94%BUE-="V51=@W
M'+[ _EXZ9[9SCGVK7'AU!XP_M\3G_CU\@P;>-V?OY]<?+5?3?#U]I4ZP6UW:
M'34F,B)):YE122=@?=C&3P<9 H OZWJ4^G6\<D)L5#-AI+RX\I%].QR?:N?L
M=:77M:\.7JHJ'%[$ZH^Y=R%5.#QD9'!]*U]<T*YU#5-/U&SN+=)[)9%5+F$R
MH=X'S  C##;P?0D55TKPI/IL^GS/?BXDMY[J65C%M\SSB6. #Q@XH 7PC<QV
M?@*VNIFQ'#'+(Y] '8FF#Q+JD$=A<7VE10V^H.(H DY9XW8$H)!M &<8R"<$
M]ZTM)T,6'AS^QKF19XL2(2%VY1F)P>>N#BLZV\-:BTFG1:GJJ7=GIT@EA58-
MDDC*,(9&R0< ]@,GF@".W\:F>70%^P,JZDI^T'?_ ,>C] IXYRX*]N13XO$V
MHW]W!;:?IT+-.DTB2S3E4"))L!.%).[KQ4<G@IC!KB1:BT<M_(LEL_EY^R%6
M+C SS\Y9NW7%:NG: FG75A)'+E+2Q^QA2OWN5.[/_ ?UH L:'J;:OI4=U)$(
MI=SQR1AMP5T8JV#W&0:T:S]&TW^RK%K;S?,S-++NVX^^Y;'X9Q6A0 4444 %
M!Z44'I0!S7@7_D6E_P"OB?\ ]&M72US7@7_D6E_Z^)__ $:U=+44_@1MB/XL
MO5A1115F)D>)UG/AK4'MG=9XH6EC*$@[E^8#\<8KF7\03OXTMM0CF8Z+M2Q;
M!^0O)&9@_P"&$7_@==VZAT9&&588(]17(Q>!4A\#2^'%OGWLQ9+HI\R$-E>,
M]E"KU[4 5+#Q5);V-E"LMI]INXGOVDO[KRE6.21BBC@DG'&.P%;;ZO#J?@>Y
MU1H28VM96>))2,E00P#CW!P1]:;<^')HKJTN=)GMX7@MEM7BN(/,22-?N]""
M".>?>M"XTV6[\/3Z;/.GG36[0O+''M7+ C(7/'7IF@#*.M:E]K.GZ7IT+B"R
MAN#)<7)48;< G"DD_+U-5X=>U/4=;T:2SB@6QN]/>Y>.64AA\T>>BGD;CCGG
M)Z5M6>D?9;^>Y\[=YMK#;[=N,;-W/X[OTK.M_#5U8+HQL[R+?86S6LGFQ$B1
M&*DD888/R#UZT 4;7Q['=RVL\:V36-U<BWC5;L&X&YMJN8\="<<9R <UH6NO
M:G=Q:A<I86D5K:S2P(T]T4\QD<J6)VD*O!]32:7X>OM(>*UMKRT.FQ2%HT>U
MS*J$D[-^[&!G .,XI;SPPUQH4VGK<)N>]-X#)%N0DS>;L9<\KV- %2#QK_H>
MHM+#;W%Q:/"D8LI_,29I3M0!B!@[N#Z=:77M2\1VFC"4V]C!.;NW16CN&8%6
MD (.4]P/H33SX2NKN/4FO]24W%V(#$UO!L6V:%BR%02<\D'GWJ>ZT36=2TV:
MWOM4MC+NB> PVI54=&# L"Q)R0.,B@#?MS,;=#<*BS8^<1L64'V) S^52U#:
MBX6V073QO/CYVC4JI/L"2?UJ:@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^?)?]<_^\:^@Z^?)?\ 7/\ [QK2GU.?$=!E%%%:G,:-EI+75JUW-<PV
MEJ'\L2S9^9L9P H)-31^';R749;)'@+I ;A7W_(Z8!!!]"#WQ6EIMVMUX=AL
MH#I_VNVF=O+O53#JV.5+<9!'(I;>_?\ M.^%]<68*:7+!&8&41_=X48X)R2.
M*F[-.5:%$^&F^S+=IJ5B]H&*2SAV"QMZ$$9.>V <U4O='ELK^"V:>!UN$62*
M</B-E;H<GIWZU8CGB'@V> RIYQOD<1[AN*[&&<>E7R^FW=[X=BO)XS;):A)O
MGX4[F(#$=.<9]C1=A9,S+K1##I\E[;WUM=Q1,$F\DMF,GH?F R/<5M:7#*OB
M?1UN8K4!['>@A3 *F)\%O5O4T7$YA\/:O;74^F)))Y7DV]H4Z!QGE>OXDFGV
MMY:CQ-H,AN80B:<D3OO&$?RW&">QR12N-))HXVBG2(8Y&1L$J2#@Y''N.M-J
MS(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K8\*_\ (TZ;_P!=A6/6QX5_Y&G3?^NPI/8J/Q(]NHHHKG.\**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-PSC//I2]J\L
M\27MK/<WM["FFVES;:C%!')(2UY*ZR(#MY&Q2,^N1DXYH ]2W#.,\T%@.IKS
M6_70'@\627DD+:G'<R"$&3,T;&-?+\L9RI+=-O4U<V:5-XA*^*7LS<)H]JS)
M=R#:&W2>80"<9SWZT =;+JWEZ\FEB$LS6CW0<'^ZRKMQ[[JMVUP9[6*:2)X&
M= QCDQN0D=#CC-<'X?=_[2TOS6?YM$N?*\PG<8_.79G/.=FVH].&G7-]I$.O
MO&UK_8D#VJ71_<L_/F'G@N!L]\$^] 'HQ8#&3UJ@NI@Z[+IACQLMDN/,W==S
M,N,?\!_6N!\2W6DW:W\5NNDQPV>GJT=W=R%W(96*>2N?;[P.<^N*NXT:\\26
MCZ^UJY;1('47;@*QW,6.#P3T^F: .RFU,1:Y:Z;Y>?/@DFWYZ;"HQCWW_I5X
M,"<9&:\\T.207FDFW8E3::A]A\P_>C\U#%U[;<8]JK^$[0SOHEY]KTF*]4DW
M)21OM4[;&$B2 ]3NY(/3;Q0!WB:GOU^72_*P8[9+CS,]=S,N,?\  ?UJ^&!S
M@]*Y'5+R+3_$^L74T;2)%HBR&-#AG"O(2!_GO7/6%G!=ZZ=.@?2X?MVCW'G0
M:8Q(0[H]C.V?F8;FP< ]: /3\BC<,@9ZUY0-=O55?%CE\PQ_V6R<X,HCR>/7
MS\)FK=Q:V7AV6*XD;3]3:UCMXI[>=\74+  9B/?).[;QDYY[4 >F$@#)/%&X
M8SFN:\7W$'EZ?936MG,;J8A3?/M@3:I)+?WCCHO?\*Y2VB@O=$TZS\V*>R_X
M2,Q+]F)2(IM8[5&3\N2>,XH ]0# C(/%44U(/K;Z<$^[;K/OSURQ7&/PKA;^
M&#3)]=L8A]ETD7MB;A(SL2.)P/,QC[JG SCL36QH,>BP^-KZ/11:B-;"+S5M
M2-H;>^.G&<4 =C1110 5S'B/_D9?#7_7S)_Z!73US'B/_D9?#7_7S)_Z!45-
MC:A\?R?Y,Z>BBBK,0HHHH *S-6UJ'2C!%Y,]S=W!(AMK=07?'4\D  <9)('(
MK3KE]4N(=+\;V&H7SK%:364EJD\APB2[U;:3VW <9_NT ;>F:@VH6[226=S9
MR(Q5HKA0"#UR""01SU!JX&!&0>*X_P 3ZM8:C96JQ7:RZ;'J,46HR1-\BH03
MAF'&W=L#<]#S6+J<=BBZ_:Z,X73OL]L)5MGQ&DQEQ\FW@,5QG'M0!Z3O7&<B
ME+ =3BN+'A?1CXNFM381&U.GK(T!'[MGWLN\KT+8XR>:Q;3^S;C4O"<6M2PO
M"=(G"K=2?*[!X@,@G#'&>M 'H-]J(L[K3X?+W_;)S"#G&W]V[Y]_N8_&I;.[
M:ZMO.EMY;8[F7RY<;N"1G@G@XS^-<-I+P Z6ULY_LW^W9A9%B=OE^3(,+G^'
M?N [8QCBJ\-Q!+HNG6-S;V$K2W=]()=2?]S&J3,#Q_$WS# XX!YXH ])W #.
M:-P(SGBO,+""WU*U\*6DKI<V9U6]0"/<(WC59MH )^YP, DC%2/'!9OJ5A)B
M'0XM?C2= =L<<30(VWV0R%<]N3VH ]+W#&<\>M*"",CI7GNO+IL7]FVVD'2U
MTMKUA>(S_P"C^9Y?R*^W@ ^G3.VMKPR;?2K::.74-.\NYO"EO#:RYCC8H,QK
MGOD,V!ZF@#J**** "@]**#TH YKP+_R+2_\ 7Q/_ .C6KI:YKP+_ ,BTO_7Q
M/_Z-:NEJ*?P(VQ'\67JPHHHJS$*;O7GGIUK+\4DCPEK)4D$64V".H^0UR&KZ
M7;:??Z+9I%IZV,L,C-_:!;RY[CY,%S_$^W<1N]Z /1"P'4XH+ =37FEQIT$%
MC:O+?Z%?-;I.R65S+^Y,1D)_=L2=I7&W.#Z<5=2;P]J>O)<:LMO%%)H]M-!;
MWC@!5+29^4G!(&!GJ* .^+ #)/%&X#O7E^BB&XN],A\1E6TLV4K6"WA_=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *V/"O\ R-.F_P#785CUL>%?^1ITW_KL*3V*C\2/;J***YSO"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@-E:M.9S
M;0F4C!<H-Q'UJ>N1O/%-_9OK-Y+;VR:9I<ODDESYDSE5*@=E&7 ).: -NRT6
MWM;FZGD2.:2:Y:X1VC&8\A1@'_@-#:+!+K4^H3I',)(8HA&\8.TH7.>?]_\
M2N=B\:3P?:$N#IU]((/-A&GSEAO+J@C8GIDNN&^O'%:,^J:[IE@TM_;V$UQ-
M)'%:QV\C*/,=MN&)'09SN';/% '0&&)I%D:-2Z@A6(&0#UQ39K2VN(EBF@BD
MC7HKH"!^%<Q=>*+_ $-;Z+5[:"6XALVO(3:$A954A64AN002O//!SVJ)/$>M
M6]]J$%VNG2I:Z:;X-;%^?O84D_[O7N* .K>RM9)$DDMH6=!A69 2H]CVHEL[
M6X4"6WBD Q@.@.,=.M<_;:MJ_P!LMX=4MK-8+ZVDDB6!V+1E0#M8D#.0>HQC
M%9D6MZA9^#M$N])M[%%NK>)8+.5I&=I'&0JG/0#DD] ": .V,,1=',:%H_N$
MJ,K]/2F+:6R3M.MO$LS<&0( Q_'K7):EXQN(+Z[M()=+CET]%^T)=3E#-(5#
M%(_08(^8YY/3BM34[^WN]#TJ]:V,D=S<6SHCL5*%V&"<=QGI0!NM#$T@D:-2
MX7;N(&<>F?2HX;2UM5_<6\4(&?N(%Z]>GTKEM0\1ZU"VN7%K:69LM'DQ)YDC
M>9,HB21@N!A3ACR<U/?ZOJM]<ZA:Z3!:>39Q@3273-^\=DW;%V],*1DG/7I0
M!TBQ021#:D;1L=XP 03G.?ZTCVEM).L[P1-,GW9&0%A]#7,^$-2<V.E:88U"
MKH]O<;P><G*X_2JTOC"^>UTJ2-+*S6\CD=KB\9A"K*VT1Y'0GD\GMT- '83V
MT%U'Y5Q#'*F<[9%##\C2B")0 (T !R %'!]:Y@7>M-X\6W6:U^Q?V>DKQY8]
M7()';/'7TJOHWBK5;J/2;_4;2V@T_4V\J,1LS/$^#M+'IAMI'MD4 =@88V#@
MQJ0XPV1]X>_K3(+6WMEVP01Q+Z1H%'Z53T?49-46[F,:K EP\4# Y+JAVEC_
M ,"#?@*TJ "BBB@ KF/$?_(R^&O^OF3_ - KIZYCQ'_R,OAK_KYD_P#0*BIL
M;4/C^3_)G3T4459B%%%% !3)88KB,QS1I)&W574$'\#3Z* (DM8(H/(CAC2'
M&/+50%Q]*2.UMX8?)B@C2+KL5 %_*IJ* &[%W;MHW8QGOBLFYT"WNM=MM0E$
M;106TEO]G:,%3O9&S^&S]:V** (VMX61$:)"J$%05&%(Z$>E,EL[6>,1RV\4
MB!MP5T! /K]:GHH 8(8EVXC7Y22O'0FD,,3*ZF-"LGWP5&&[<^M244 0+96J
M6YMUMHA">L80;3^'2E2TMHXT1((E1#N150 *?4>E344 %%%% !0>E%!Z4 <U
MX%_Y%I?^OB?_ -&M72US7@7_ )%I?^OB?_T:U=+44_@1MB/XLO5A1115F(C*
M'4JP!4C!![U%<16\D#+<I&T(&6$@!7'OGBEN7>*VEDCV;U0E?,;:N<=SV'O7
M ZAXDN-0T;7]-N)M/N#_ &5-.DMBS,HP-I4D]?O#D>_ H [EK.QE5('M[=Q&
M 40HI"CU [56;1;>76)[Z=(YEDACB$;Q@A=C.<\_[_Z52LO^1ME_[!<'_H<E
M02Z_>GQ2^F*;&VCC9 J73,LER",EHST..F.>0>E '136T%S'Y<\,<J#G:ZAA
M^1I6$42AF"*J="< +V_"N0\.:AKC:=K-S>364@AO+A(O,D9 I5R,,QSA /:L
MV^\3OJ6CZWIUU+93/;0P3BXM"WE,K28Q\W<%3SG'- 'H$EM!,CI)"CH_+*R@
MAOJ*016]NB82.)$^5< *%SV'I7+R>,U_LF^U>%(&T])TM;21I<>=(7V%F/\
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M5_>ZI=QAI92(8R)'9F)X)'' [DB@#OC&A8L5&2,$XZCTJ.&UM[=0L,$42KG
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MZ<8Z=Z$VPE!);F/1115&84444 %%%% !1110 4444 %%%% !1110 5L>%?\
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M]*H:OIRZ1X'AT&!YKB]V".R=(B3YP.4<XR% ."2>, UUKW$,<8D>5%0]&9@
M?QJ08/- %/2-/32M(M;%&+""((6/5CW)]R<G\:NT44 %%%% !7,>(_\ D9?#
M7_7S)_Z!73US'B/_ )&7PU_U\R?^@5%38VH?'\G^3.GHHHJS$**** "BBB@
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MC%*2NK%PGR.X4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC3IO_784GL5'XD>W4445SG>%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\^2_ZY_\ >-?0=?/DO^N?_>-:
M4^ISXCH,HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K8\*_\C3IO_785CUL>%?^1ITW
M_KL*3V*C\2/;J***YSO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *PI_%-O%J%S9Q:?J5U);,$E:WM]Z@E0V,Y]"*W:XW3
MKG5(/$GB,6.G0W2&\0LSW/ED'R4XQM- '4V-W]NM5G$$\&[/[N=-CCZBK!.
M37,ZK<:E?ZKIFCI,VG^?#)<W;PL&<*I4;$8CC)8<XZ"F6[W.A^*(-)>]N+RS
MOK>22$W#!GB=,;ANQDJ0W?H10!>@\1+/IFC7@MV U*18PN[_ %>59L^_W:W*
MX6P_Y%CP7_U]1?\ HJ2M QW7B'7]2@;4+JUL=/9(%CMG\MGD*ARQ;&< , !]
M: .JHK@9]5U;3UF@DO9)SI&I0">4@ S6L@'WL#&1NZ_[.:M?VU?)X\P\Q_LA
MW^P)'CCS@GF;L_FM '4W]^M@L!:"XF\V58AY,>[:3W;T4=S5NN)BU._DTVVU
M 7<FR]UM4B'&!;[R@4>Q"Y_&K3V][JWB[5+-M4NK>PMX8&$-N0C%F#<[NH''
M04 =917!-K&IV7A/44:]=I;/4S9&]=062'>H,A[$JK=?;-3VT/E>,[*UL]<O
MKRV:V>>:,W(D","NTDXZ-EN/;B@#K[F[@LT1[B01J\BQ*3W9C@#\2:JW6J"V
MUG3]/,18WBRD/G[NP ]/?-8WCBS-S:Z6?M-Q#C4;=,1/MSF1>>G4=JK:WILY
M\0^&[*#4;F,[;G?<,0TI7:N0"1@'WQQ0!V=%<E:7,^A:_J=A)>7-W9Q:>M\@
MN'WNAW,&4-Z':.M<['KEQ/H0U==2U9M9:/STMX[:3[.3U$>W;@@CC.<]\T >
MGT5P>HWTPUR5]:O=3TW3Y(HVLIK?Y8D)7Y_,;!PV[^]QBI]>UDKJVG:3_:%V
MEFUJ;B>YM8R\LPR H!0':"<DD#Z4 =K17+>%K^674;^S6:^N;*-8Y()KR)E<
M$Y#)D@;L8!_&DNVN];\5W&DK>3VEA96\<LIMVVR2R.3@;NR@+V[F@#JJ*Y/4
MDU"SDTK0+34[@M>2R&2[E*F5(4&2JG'WN0 2/6@&Z\.^)=,LA?7-W8ZEYD96
MZ?>\4BKN!5NN" 00?:@#K**X2TM=3U?3]9O)=<O87MKNY2T6!@JQA&.-W'S?
MCQBHII=5M?"MAXFDU>YDO9#;R20C"P%)&4% GT;KG.: /0**Y*]2^U+QQ-IH
MU.YMK!+".9HX"%9F+L/O8R!QSCVJII>GZGJ+:M:W.O7PCL+AH+5HF"OC:&!D
M;'SD;L>G'.: .LO=06QDM4:WN)?M$HB!AC+!">[>@]ZEAO(+B>>&*0-) P65
M1_"2 0/R(KD[;6;^XT/PK<R3D375TD5P5&!(-K@_F5S2^'=**>)M=E.H7S>5
M=I\C2_*^8E^\,<]?T% '945YY!'JMYX2U'6Y-<O5NK9[I[9(V"QJ(Y'VAACY
MONX.>WI5R5=2LK#2-;?5[J6YN+BW6XB) A9)2 55.V-PP<YXY- ';T5PE_K<
M=]XEU&RNKW4K6UL"D2)8Q/F1RH8LS*IX&0 /8YJ*36=8D\(.T=S-#<QZI':P
MW4T&UI(C(H#%2!G@X/3.* /0*A@NH+EYDAD#M"_ER ?PM@''Y$5S9M;K1O$&
ME(NJ7MS%?-)#,EQ(&&X(7#+Q\I^4\#CFJOA_2YXKC7I[>_O))XKR18TEE!1V
M\M<%ACGDT =I5'5-1&F002&,OYMQ%!@'&-[!<_AFN5\+7:R7=M'J&K:G!K(4
M_:;*\(5)6QSL!&"H/(*'IUK5\:I-+HUJEM,(9FU"V"2%=VT^:O..] '1T5RA
MM[K1/$^DQ)J=Y=07XECFCN7#C<J[@R\#;T(P..:Q4UQ-9N;^XN=2U:T$5Q)!
M:Q64+E$"';N8A2&)()P> ,"@#MKK4A;:O86!C+&[$A#Y^[L /3WS5^N)TV^N
M]1O?"=U?1M'=/#="4,A0D@*,[3TSC/XU+IUC>ZW=:M)=:U?QQ0WTL-O';.(_
M+ QU.,M^/% '8T5PCZGK-SX4X>YFEL]0>UO9;-!YSQ(Q!9!ZGY<X]\5O>&9[
M&XM96L=5N;Z/< 4N7W/"<?=.0&'T- &[17/6^H3V'BC4K*]G+6TD(O+5G_A4
M#;(N?8X/_ JQ+?4M5U&'1[07DL#ZU+/=-* -\-LO*HF1P2"G/;F@#O**Y6/[
M7H'B?3[ 7UQ=V&HI( MR^]XI$&[(;K@C/!]*;I^I7DOPVEU![AVNQ:3.)>^X
M;L']!0!UE8R>($.FW-Z;2X=8+I[8QP)YCL5?9N ';O[5HV+M)I]M(YRS1*Q/
MJ2!7(K=3V?A759[>0QRC5Y &'7!N0#^A- ';#D45SMM?S:?XFU6TO[K-J\*W
MML7.-B ;9%^@(!_X%7.3:_?1V&E17-Y=1'69IKII88B\D%N.5C0 '!P5YQQS
M0!Z+17'>']0E_P"$D:QMI]1NM->U,N^]B<-%*& P&8#((.<>U7-8GNM0\2VN
M@V]W+:0_9VNKF6$@.RA@JHI/3DDDCGB@#I:*X]IK[0]3O-,-]/=6TNGRW-J\
MY#20NG# MW'S C/H:6\U.]C^&4.HK<.+QK.!S-W+';D_J: .OHKE-:%_>^+]
M-TN#4)K2SELYIK@0X#-M9 ,'L?FZ^F:OZ_#>VOAB4Z9/,;JU02QECN:79R5)
M[[@"/QH W**YFXU=]4U'0;?3)RL5RIOIG7O H&%_%F7\C6#XCU-;2'4;FPUG
M5[O4+;?(HMH]UO"5YV. -N.QR<T =I<ZH+?7+'3#$6-W'+('S]W9MXQ[[OTK
M0KEIYC<>+O#,QX,EE<N?Q$1J?0+VYNM'U*6>9GDBO+I$8_PJKL%'X"@#HJ*\
M\/B&[?0O#-M->W,37UL9KJY@B+RE5 R%P#@DL.<<8K2T2[N)M2O=/L;W4);1
M[7S(9[V!MT$N<8RP&X<@X.>AH [&BJNG0W-OI\$-Y<_:;E$ DF"!-[=S@=*M
M4 %%%% !1110 4444 %%%% !7SY+_KG_ -XU]!U\^2_ZY_\ >-:4^ISXCH,H
MHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K8\*_\C3IO_785CUL>%?\ D:=-_P"NPI/8
MJ/Q(]NHHHKG.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K,TW2WL=1U6Z:4.+V=954#&W"*N#_P!\UIU!)>6L,Z02W$23
M2?<C9P&;Z#O0!F:WHUS>W5GJ&G72VVH6A8(TB[DD1L;D8>AP#GL146GZ+?-K
M#ZOK%S!-=+$8;>*!"$@0\MR>23@<^U;]% ',0>';^#0]'LQ/;&?3;A9%;#;9
M$ 9>>X.&_.IKK1]4MM9GU+1KJW3[4JBXM[E"49P,!P1R#C QWQ70T4 <]:>&
MF71=2MKZY%S>:F&-S.$V@DKM "]@H  ^E4Y?"-U+X,&E-J"_VF)/M O=G_+;
M?NW8_$BMO4/$&E:5>VME?7L<-S=MM@C;.9#D#C\2*TJ ,.7P\/[(TC3X)51-
M/F@?)&=PC[?4U:M-,>WUW4-1,@9;I(D"8Y78&_GFM*JVH:A:Z78S7M[,L-M"
MNZ21NBB@#C?$NF/I^@7UJ9X]VK:LC1NXQ''O9>)/5?EP1WSBI8)+WPM=V-N;
M;13%?7*PF*QB,4G/\>.<@=3[5T=O=:1XGT59XS!>Z=<@XWKE6P<=#[BLV=?"
MGA":"YG2TL99SY44C*2S'^Z#R10!H>(-+FU;3DBMIDAN(IX[B)W7<NY&# $>
MAQBH5TJ^N=3TO4+V:W$UFLP=(0=K;P ,$^F*VQR*BN+JWM(_,N9XX4SC=(X4
M9^IH SFT;S/$D^IR.K0RV*VAB(YX=F)SZ8;%9MCHWB'2;5=-L=1LFL8SB&2X
MB9I8X\_=P#AL= >*Z=65U#*05(R"#P12T 8%_8^(9);N.VO;"2UN%VHMQ <P
MY&#T.''?!Q57_A%;BR@TF32KU([[3K<6VZ9"4GCXRK =.1D$=*Z@$'H0?I2T
M 4--CU1?.?4YK5RQ'EI;H0$'N2<G/X5GZCHM\-<76=(N88KEHA!<17"DQS("
M2IXY##)Y]ZWZ* .:N] U6_M;:XN-2A35[2<S6\T4.(T!&#&5SEE(ZGK4EIHN
MHW.MPZKK5S;2/:JRVL%LA"1EAAG)/))''M6Y<W$-I;2W-Q(L<,2EW=NBJ.2:
MJ:1KFFZ]IXOM-NDN+8L5W@$<CJ.: *^FZ,]AIVH6K3*YNKB>8,!C:)"2!^&:
MK7?AR2Y\'6VABX57A2!3*5X/ELIZ>^VNAZT4 94>DNGBB?5_-4I):);B/'(*
MLS9S^-.TW2GL9]3D:4/]LN#, !C:-JKC]*TZ* .;MO#,L&EZ)9FY0G3;@3,V
MT_/PW ]/O5/!I6I67B&\N[6>V:RO722:.16WHRKM.TC@Y '7I6[10!@6OAZ2
MW\*WFCFX5GN/M&)-O"^:S,./;=^E37FB276BV%@)U5K62W<OMX;RV4G\\5LT
M4 <]<Z-J-KK<^IZ-<6R?:E475O<JQ5V485P1R#C@^N!3[S1M0U/1X+:^O(&N
M4NH[AGCB*IA'#;0,YZ#&:WJ* ,Z_TU[S4M,NED"BSE>0J1G=F-EP/^^LUGQ:
M1J]IJ6HM9WELEG>R&;+1DRQ.4"\=B,@'FNAHH Y=]"UK4;S3&U:\LFBT^<7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-D
M198VC<95@5(]C3J* //X_@YX4CO!,8[QX@V\6[W!,>?Y_K7?1QI%&L<:A44
M*H& !Z4ZB@ HHHH YI_ >@3>)F\03VKS7Y8,#+(652!@$+TKI>E%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH.L;%0P!_ @_C5JO./#7AVUG\>>,9VN]35XK^,A4U"95.^W0G<H;!QN.,]
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M"?X5W$ =  *@^'U]>W?A6SBN;%HH+>WCBMKO<-MY&%P)%0_,@( .& Z\9ZT
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M9IM6GMKEO.)\Y4%PJASQO^XO4<D9ZT >FW][#ING75_<%A!;0O-(5&3M4$G
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MTF>R=666**U<%@1C'S.1CUXJOIO@K0M$NEO-,LF2XB1E@62ZE>.+(QA59BJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>emergentbiosolutionscomp002.jpg
<TEXT>
begin 644 emergentbiosolutionscomp002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M4/\ <B_]%K7$UVWQ9_Y*-J'^Y%_Z+6N)KT*?P(\ZI\;"BBBK("BBB@ HHHH
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1D[(<J<HJ[.7-)3U1I'5$4LS'  &237J_A?X+7%_:QWNO736:. PMXQ\^/\
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MX<L=4F@OKVPMC<06JJURB_>"'/S >V*TIH+?5;830L-V.&_H:[3X!*&O]:!
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MB.[^+/\ R4;4/]R+_P!%K7$UVWQ9_P"2C:A_N1?^BUKB:BG\"+J?&PHHHJR
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!M**6FT .HIM*.E "T444 %%%
M% !1110 4444 %%%% !1110 4444 %-(IU% $?2ES3B*90 ZBD!I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!,"CK2TG2@!**4TF* "BBB@ HHHH
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M844459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #:*=3:
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M7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\ A2OA?_GOJ7_?Y?\
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M?_GOJ7_?Y?\ XFO1J*/:3[A[*'8\Y_X4KX7_ .>^I?\ ?Y?_ (FC_A2OA?\
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MLH=CSG_A2OA?_GOJ7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\
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M7_?Y?_B:/^%*>%_^>^I?]_E_^)KT:BCVD^X>RAV/./\ A2?A?_GOJ7_?Y?\
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M]3_[_K_\17I=%'M)=P]G'L%%%%06%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7B>KW\>E_$V>^E1GC@NP[*G4@ =*]LKQNYBCG^+9B
MEC62-KT!D<9!&!U%<V)VC;N>AE]N:=^S'^+?&:^*[2WTS3["<9E#_-@NQP0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA^*WU!CYH8E4+9*+V7/Y_G6[112;N4E96"BBB@84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?L9C?*8[#2H"LUNH<8,SDY)X&,_6N[$GA^W^._B5O'JVQB:$?83?H&AV87&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3#&Z\/RQ_>CLPP.>E=-/KWB+6_$NJ:7X;_LZVMM**1W%U?1/+YLS+NV(JLN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &2N8X7D"-(54D(O5L=A[UR=S\1M&M?">D^(GCNC::E*L4:*BET)#%BP
MS@!0C;L$XQ77UY)IOA&]OM=UCP[>V4\6BV2WYLIFC(C?[7M*[#T.P-*#CIF@
M#M?$6O0 ZMH*),;I=&FO6D4#8B\H 3G.XG...QKF/"7CR/3O"/A:*[TC5!8S
M6]K9G4W11%YS*%'!;?MW<;L8],CFF^$[+6;_ ,.^)M7U?3[JWU.[LDL4@FC(
M=A#;X)4'DAI'D(]>*=J6DZC)\&/#E@EA<M>0C3?,MQ$QD38\>[*XR,8.?3%
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MW7<(%P6>3:>I"@X'J17*Z.KVGB;2H_"5AX@TZVEN&.J:;?6TB6D$15BQ4O\
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M</:7"9P'4J?+"$8)!QCGBNZM]/N8OBY/=BVF%E_8,4"SE#L+B=CMW=,XP<4
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MCA_+'S$9!4X&15GQJ]]XQ\+Z:=*LM5LI!K=MLEEM"LD:!N9PAY"C.<L!T]*
M.PL?$-MJ>N7^F6<4THL,+<70 \E93_RR!SDN!R<# SR<\5SOC,WMWXU\)Z/!
MJM]86UZ+PSFSE",VR-67D@]\_G3_  AIMWX1UB[\,^3=3Z.X-Y87K*7VEC^\
MBD?'WMWS GJ&/I4/C7PY'XA\<>$([S3I+O38A>FY.UMB$QKLW,.F2./7% ":
M-J%WH?CV_P##]QKD^IZ9%I?V]YKPH9+1@^TJSJ!D%?FYY&*NV?Q M[F6RFDT
M;4[;2;^58;34ID01R,W"94-O56.-I*C.1TS5JZ\%Z7!X1UC1-#LK;3SJ%K+"
M7B3&69"H+'J<9[UQ6@Z9875MI>D:Q8>,5OX&A6:VEEN'M4>,@A]^?+,8901@
M^G% '8MXXAD\27>@V&DZC>WMG/'%<F)4$<2.JL)"Q8#'S=.IVM@<53T?Q'HF
MB^&=:U1KC4VM;?5+B*3[6_G2-,'V[(AD_*6P%'OSWJ?PM975MXT\:7$]M+%#
M<W=NT,CH0LH$"@E3W .1Q7)_\([K$G@^^DAT^9KNQ\5RZK%:2+L:YC2<MA<]
M<J20>^!0!V>E^,UN]9M])U+1]0T>[NT:2T6\"%9PHRP!1F 8#DJ<'%4M5\<Q
MROJUEIFC:GJ,%B'@N[RU1/+ADV\J,L&<KGD*#BJ-Q=S^-?%GAQ[+2M2M+/2I
MWO+JYOK5K?#;"JQ*&P6)+<XX '6J6BW=[X6LM=\-W.A:K<W<UY<S6<UM;%XK
ME)264F3[JD9P=Q&,4 =+\-7=OAGX?=BSN;)"<GDG%17'Q'T>U\%6WBF6"\%I
M/*8A"$4RJP9@P(SCY=CD\]%-6OAW:7%C\/-!M;N"2"XBM$62*52K(?0@\@UR
M%CX6O+GQKJ6A7EC.- AFO+^&=HSY3M<Q(FQ3TROF7'';(H [J_UZS75QH96X
M:::PEO&DA( CB4A<[LY!);C'H:X>6ZMI]&^&LVG37[6DVIH4:]EWS,IBE/SD
M'DU/X!T[69H=8U'6K&X@O(;&'28!-&5:188SN=0>JL[D@]\51@T[4+'P3\-F
MFTZ\W:??0M=Q+;LTD(,<BY90,@ D9XXS0!TWA5V;XA^.E+$JMQ9[03P/]''2
MJ'B759=*^*^C/%9WE\[Z3<*EM:J"SMYB8SDA5'!Y) %:'AN&XM?B1XR$]K<1
MQW;6L\$S1-Y<BK"$.'QC(;C'6JWB.6YTOXEZ5K)TO4+NPATN>*:6TMS+Y9:1
M",@<GIT&3WQ@&@#6TOQOI][9ZM+?07&E3Z0-U_;W@&Z%2NX-E20RD X(/.*B
MT_QNEW?6,-YHFIZ;!J)VV-S=J@29MI8*0K$HQ ) 8#./7BN2O/#NJ>-K7QMJ
M4-G<6"ZI:06NGQ7:&*27RLMN93RH9C@9YQS5O0K72]5U/2TN[+QD+ZWF6<Q:
MA)</!;RH"02SG8PSD @G.: .Q\3^*;'PI:6=S?QW#QW5TMJ@@3>V]E9AQU.=
MF.,G)%5+CQE]CTZSDNM$U&/4KZ5HK32_W;3R[1DMPVU5 Y)+<57\>65U>S>%
M#;6TLX@U^WFE\M"WEH$DRS8Z $CGWK.^(&CW,FOZ#KJ1:I/96:SP7::7*Z7$
M:R!<.H0AF *X('.#T.* -NT\:V#:?JMSJ<%QI4NDJ&O;>Z"EHU(RK H2&#8.
M,'DC'6J$/Q$43::M]X<UFPBU2YCM[.:>./:Y?INPY*<#.",XKG=2\,6VO^"_
M$AT"VUQ]0NHX%#ZP90UP(9/,5%\WG'WAR /FH\3^*!K]SX.C31M6LRFOVKS-
M>VK0K&^UQL!;&X\GE<CCKTH ]!T_7[;4M=UC2(HY5GTIHEF9P-K&1-XV\YZ'
MG(%<UJ/B;2-?\+Z)JSG5K:VNM7B@A%M((Y/-$S1@/AL&,LIR,],=ZJQWUUX8
M^(WB>6?1M4NX]7%K+9/9VQD1RD7ELC-]U#D?Q$#'-8MCHFKQ_#+PI9RZ9=)>
M6_B*.:> 1L6C07;L6/'W<$'/3!S0!VFH^.(;3Q#=:!9Z3J.H:G;I'*8K=4"E
M'!^;<S  # !SW88SSAM_XZBMKN_CL=%U/4[;36*7UU:JFR%@,LHW,"[*.2%!
MQ]>*9H]E=1?%#Q/>26TJ6TUG9K%,R$(Y42;@IZ'&1GZUQT&D)H&I:U8ZS#XL
M*W-_-<VLNDR7#P7$<K;L$1G"N"2#NQGKF@#O-6\:6&GP:7]C@N-4NM57S+&V
MLP"TJ;0Q?+$!5 (Y)[U@^#-2FU/XD>+I9K.[LG%O8AK:Z #1G;)GH2I!]0>:
M@O+ ^$?$OAS6K32M0GT6#2FTQXH8FFFM 2KHS*,L>FTD9Q5[P@;R]\?^*-7E
MTN^LK.[M[(6S7<)C,@02 G';Z'D C(&: $\0^,M5TOXA:;I%KH^HW=J]K-))
M' L/^D$;-K(6<$!<L#G')[UJZIXS6TUB72=-T?4-7OK>-9;J.T" 6ZMRH9G8
M#<1R%&2167XJ>;2?B!X?UY[&]N;".TN;:5[.W:=HW;85RJ@G!VD9Q5>"\G\'
M>,/$-U>:5J=U8:P\5U;7%E:/.0PC"-$ZJ,J<@8R,<]: .QT'7;+Q'I$6I6#.
M87)4I(NUXW4X9&7LP(((K'7QQ#<^(KK0[#2=1O+JSN5@NFC5!'"K!2)&8L./
MF/ ^8[6XXIGP]TN^T_1]0NM0MVM9]5U*XU'[*Q!:!9"-JMCC. "?<TWPC975
MKXH\8S3VTL4=QJ,;PNZ%1(HA094GJ,@CB@!MS\0K6$W=S#I&I76CV4C176J0
MJABC*G#D L'=5.<LH(&#UQ5K5?&MOI^NQZ+:Z9J&I7\MFMY$EHBE60L5R79@
M%Z=3@<C&3Q7GNE:%!HNE7'AO7K7Q?+*DDT:+I\EP]M=Q.S$%=AV+D-\P;'.<
M]:W+V_@\,_%N#%C?W%K%X:CAQ:0M.\:B<X+*/F(XQD ]: .JTGQC:ZMI6HW2
MV%_%=:<YBN]/:+=<(X&0 JDAL@@@@X-0Z=XS-UKD>D7^AZCI=W<0O/:+=>61
M<*F-P!1R PR#@URBIXF&D^-?%>EZ==VE]JLL LK5XA]H$,2JC2>6?XRI<A3S
MP*CTVP6Z^(?A;4M-T[Q$]K EVMU?ZMYV69HL*,2'*\@]%522 ,]@#LT\;Z8_
M@>3Q68[A;2)&+P,H\X.K%#'C.-VX8QFMB^U6UTO1YM4U!_LMM!#YLQ?J@QD@
MXSD]L#O7FUYI5POQ&_X11(R=)O[V/Q!)CD*$!\Q"/1IEB;T^8UV/Q T.Z\1^
M!=4TNQ"FZE17B5C@.R.KA3]=N/QH K6/CV*>^L(-0T35-*AU)MEC<WB($F8C
M(4[6)1B.@8#-22>.(6\2W>@6.DZC?7UG-&EQY2H$B1U5A(6+ 8PV,=25.!QF
ML#6=1N_'3:'I=GH>JV4D.H07E]+>VK0I;+$=Q4,>'8G &W/7-;7AFQNK?QWX
MUN9K:6."YN+4P2NA"RA8%!*GO@Y''>@#-^+U]/;^&;*RCL[RXAOK^"&X^SLJ
MYC\Q<QDE@<OT&..N2*O1^(;#PY;:;H.C^'+UKV6W-PFDVXC#6T98Y:1B^Q1N
M)'WCD]*D^(EE=7VCZ7':6TL[IK%G*ZQ(6*HLH+,<=@.2:I:DUQX8^(MSK\VG
MWMYI>HV$=NTMG T[V\L;,0&1<MM8-U ZB@#2'C[2_P#A%=2UY[>[C&F,8[RS
MD0+/"X(RI&<=P<@X([UROQ"\6W>H?#Z_:TT75X+.XF@ACNSLC\Z)Y%!(&_<H
M8?*,@$[QT&:JZIH^K:KX/^(&L#2[N&77#%]CL&B/GE(E5 Q0<AFP3CKQ75_$
M6PN[[X?O:V=K-//Y]H1%$A9L+-&3P/0 D_2@!+76M/\ #6G:=I&D^&KV.]ND
M>:+1X1&)(D#89Y&+[%&2.=W).!4&N^)M*U;P5=W5XNL6(MKV*VNH+>017,,W
MF( I(.,?,IR"05/%4?&.D2V_CRV\03QZU)I<NG_8I7T>602P.LA=2RQG<R$,
M1P#@BJ>LZ'!<?#W4I-#T_7))[W4;6607ZRO<3;)8OGP^6VA5[XX6@#8U#QEJ
MMI\3UT.'1M1N;)=.:4QPK#\[&1 )06<'8 2I'!R>AZUWM<'K<LVB?%.RUR:P
MO[C3YM'>Q\RSMGG*2^<K@,$!(! ZUWE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !116/_PE?A[^UQI/]MZ?_:!;
M8+;[0GF;O[N,]?;K0!L45GZAKVD:5YO]H:I9VIB02.)IU0JI) )!/0D$#U(H
MAU[2+FSM;R'5+-[:[D$5O*LZ[97.<(ISRW!X'/!H T**@EO;6"Z@M9;F&.XN
M-WDQ,X#2;1EMHZG Y..E5M6U[2=!A2;5M2M;&.0[4:XE";CZ#/6@#0HJDFL:
M9*EF\>HVCI>DBU99E(G(&<)S\W )X]*F%[:M?-8BYA-VD8E: .-X0G 8KUQD
M$9]J )Z*R5\4Z ^L'2$UJP;40=OV47"F3/IMSG/MUKG=$\=6<,FNCQ'K%C:"
MWUJ>SM//D2+,:*A [9QN/- '<44B.LB*Z,&5AD,#D$>M<#I/B/QKXA%]<:98
MZ EK;WT]HOVF>8.?+<KDA5(YQ0!W]%5(+Z$W"6$US;?VD(!-);QR L%Z%@IY
MVYR,XIG]LZ6+":__ +1M/L<#,DMQYR^7&RG#!FS@$'@T 7J*SM+U_1];M9+G
M2]3M+R"(XD>"96"?7!X_&F:7XDT/6YIH=*U>QO98?]8EO.KE1ZD ]/>@#4HK
M)@\4:!<ZLVE0:U82:@I*FV2X4R9'48SG(]*&\4: FL#2'UJP742=OV4W"^9N
M]-N<Y]NM &M167XBUZT\,Z#=ZO>AVAMU!V(,M(Q("JH]22!^-8NGWWCN2YM;
MB^T?1X[*=U$EM%=.;BW4]RQ78Q'<#'L: .NHK*U3Q-H6B3Q0:KK%C932\HEQ
M.J,P]<$]/>KEQJ%E:QPR7%Y!#'.P2)I) HD8@D!2>IP">.P- %FBL2+QCX9G
ML;F]BU_37M;5@L\RW*%8R>@)SW[>M7(];TJ;2EU6/4K1M/;&+H3+Y9R=H^;.
M.O'UXH OT5E67B;0M2U&73K'6+&YO8L[X(KA6<8Z\ ]N_I1J/B;0M'O(K34M
M8L;2XE^Y%/.J,P]<$]* -6BJ5[K&F:;_ ,?VH6MM^[:;]],J?(I +<GH"0,^
MXINGZYI6JZ>VH:?J5K<V:9WSQ2JR+CDY/; ]: (=;T&WUR32WN)94.G7R7L7
MED?,ZA@ <CI\QZ5JUEZ5XDT/77E32=7LKUXO]8MO.KE1ZD ]/>H[;Q7X>O-5
M.EVNMZ?-?C(^SQW"L^1U& >H]* -BBN6C\?:&WC*Y\./?V4<T,<>UVNT!DF9
MV4PA?[XVC(Z_,.*T-$OKJ:/5)-0U#3+A+>]ECC:S8XAC7&$E)/$@_BH V:*R
MM*\2Z%KDTL.E:O8WLL7+I;SJY4>N >GO3;_Q5X?TM6-_K>GVP64PMYMPBXD
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MW339)9I(MJI/VI7+$;V&<;#@@''44NG^*- U:^DL=/UFPNKJ/.Z&&X5V&.O
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MT&'6%TB36;!-18@"U:X42$GH-N<Y]JU: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"?%6K
MMK/PTDUNW.AZ58RWB2V=E%#FZ>03CYB^X!7X+$!2<9R>M>[5C+X2\.+<7-P-
M!TWSKK_7O]E3,G.3NXYYYH YI[&TO/CE(]S;Q3-!X?C>(R*&V,9W&1GH<$C/
MN:Q=,T ZQX7\=:98*(KBW\03SV&T8$4R".1-OH-P_4UZB+.U%\;X6T7VLQB(
MS[!O* YV[NN,G.*H:A!=Z=8W#^'=,L'O;B;S)%E?R$=B,&1BJDL>!VR<=: .
M3\'ZFGC;Q9)XF5<6UCI\5G"IZ+/*!+./JH\M#]#5_P 4:5)<>*+#5-)U73H=
M<L[61%LK\;XYH7(R< ADY7&\9]*UO"/A[_A&?#\=B\J373R/<74R+M$DSL68
M@=ADX'L!5O5O#VC:Z(QJVE6=]Y?W/M$"N5^F1Q0!YO+K]MJP^'^KM:0Z;;KJ
M]Q;R(C#R4D"2)\K# *LP.#WS5RYOFO?B3XJ.B7"3WD7AI8XC"V[;.'D*C([Y
M*UWUSH>DWFE+I=SIEI+IZ@!;9X5,:XZ87&!BGV.C:9IA0V&G6MJ4B$*F&%4Q
M&"3M&!TR2<>I- '(_#V3PRG@+P^87L!)LC!\PIYGVLC#YSSYFXM[UE^&=*T^
MZL_B)//902S2ZM>0O(\8+%!&I"Y],DG\:[E/"^@1ZL=631=/742=QNA;(),^
MN[&<^]7H;"SMUN%AM((UN7:2<)& )788+-ZD@#)- '/_  X=I/AMX<9V+'^S
MXAD^R@5Q'@K2M,N8]6N;KQ/J-A*-:O/]&AU/R8\"4\[/?]:]:MK6WLK:.VM8
M(X((E"QQ1*%5 .@ ' %8\W@KPK<3R3S>&M(DED8N[O91EF8G))..230!R7Q+
M:ZNKW21X6);Q0L,\T$D+#BUV$/N[$,Q0+_M8/8UF7[Z$VD?#HP8'A+[61.)O
MNB41MY8E[9\W=NSQNSFO4[?3+"TF\ZVLK>&7REAWQQ!6\M?NID#[H[#H*C.C
M:6UE<61TVT-K<NTD\!A79*S')9EQ@DGN: .+^)DEJ? NLKI+6AF#6YU 08+"
M#S!DN$^;;M#?\!#4MCI5[=^(= U675?#:0622F)=-B9&FA:,@J"7(* [6Z<8
M%=CIF@Z1HML]MIFF6EG#(<ND$*H'^N!S^-0Z=X7T#2+N2ZTW1=/M+B3(:6"W
M1&(/49 Z4 <%I$G_  A;Z#8PS:5KGA^]O_)L+F+'VJ!Y2Q#$C*R 9(+#!P>:
M1I1X++WUG/I.N>'KW5_,9./M4$\LN"489$A5CG! 88Z\5WMIX6\/Z?J3:C9Z
M)I]O>MG,\5LBOSUY [T)X5\/QZM_:J:)IZZANW?:1;()-WKNQG/OUH POBE;
M3R^##=00O/\ V?>6][)"@R7CCD#, /ID_A6VGBSP_)8VMXFL61@NV1(&$P_>
M,Q 50.N<GIV[ULUCVOA3P[9:D=2M=#TZ"]))\^.V17R>IR!P: .0\+'2AK_C
MG^WS:"__ +0?S?M>W_CRV+Y7WOX,9]JY:VMA>?#OP/;7<1ET^7Q0BVT<XSNM
M2TWE@@]1MQC/;%>N:GX;T/6IXI]4T>QO98N$>XMU<J/0$CI[5<FL+.Y6W6>U
M@E6WD66$/&"(G48#+GH0"<$>M '"'2--/QR!-C;G;X?$JCRQ@.)RH;'J%)&?
M3BN3U2.*#X3_ !%MT54MXO$,JH@&%1?-A. .PY->T?8[7[=]N^S1?:_*\GS]
M@W[,YV[NN,\X]:YSQGX6.L^"]6TG1X+6WN;Z1)F)&Q7?S$9F8@<DA>OTH P/
M%@T<ZOX&@T 67VU=5C> 6>W*V@1O-QM_@VX]JR=%@U.\U3QI:RS^'TGDU*9;
MJ/4X':8P$#RCD./W>S&.,=:],T_P[HFE7DUYI^D6-I<S?ZR6"!49OJ0*;J?A
MG0=:N([C5-&L+V:,822XMU=@/3)'3VH X&#0XH?&G@'3=0D@U/['H]QMG*[D
MD*^6%<9SVZ'\:!I>F7>M?$W2+RZ33=-N/L:O*&$:QM) ,MSQRV,^M>E#3[(7
M$%P+2 36Z&.&3RQNC0XRJGL.!P/2FOI>GR-=L]C;,UX +DM$I\\ 8 ?CYL#C
MF@#B-*UZ[T/7)-'UJVTV\EATI[N&_P!,CVL\$9 */'SM)R",':>U<GJ]]+>Z
M+X-U,/H.GV\^K6<UCIMC#F:-6<9S)N X!PP" 9XS7K>E>'=%T+S?[)TFRL?-
M_P!8;>!4W?7 YJ&U\)>'+)Y'M=!TV%I'61REJ@)93N4].H(!'H>: .9L(K*/
MXSZZ)HX%=]-M9(@Z@%CO<%A[YQS7):AYG_"">,L[_L7_  ETOV_9G/V;S8_,
MZ<XQU]LUZW?:#I&J7EM>7^F6=S<VQ#0330JSQD'(VDC(YYJS#86=NDZ0VD$:
M7#M),J1@"1V^\S>I/<GK0!P/B8Z6?%7@?^P3:G4/MOR_9-O_ !Y>6WF9V_P?
M=QVSTI?">E:?>>(?'LMS9032/J1A9Y(PQ*>2AV\]N378Z7X;T/1)99=*TBQL
MI)?]8]O J%AZ$@=/:KL%E:VSSO!;0Q/</YDS(@4R-C&6QU. !D^E '*_"EVD
M^%OAXNQ8_9<9/H&('Z"LCP)IT8LO&5_:6\9U1]:OTBF906R&.P GH,DG'N:]
M"M+.VL+6.UL[>*WMXQA(H4"*H] !P*2VL[6R$HM;:* 2R-+((D"[W;[S''4G
MN: /&?#NDZAKOPTL;*'5/#MHF]&>62"074-T'!)9B_\ K=X].<^AKK]4U4W_
M (NUG3K5=#T\:?;1"^U#4H1*\B.I8*J[E^0 G)9L9/2NGD\*^'YM6&JR:)IS
MZ@&W?:6MD,F[UW8SGWZU)>^'=$U+4(;^^TFQN;R' CGF@5W7'(P2,T >7^$]
M,35_AGX-:+6;6TU6RN+B;3Q=J'CG*R2)M*$@D!2.0<KP:36];_M?1K:#5;&S
MM;2P\306^MM:-NMIEVYWDX'R[C'N#<C S7J-UX<T2]TY=/NM(L9K)6+K ]NI
M16))) Q@$DDY]ZFMM&TRSTPZ9;:=:Q6!!4VR0J(R#U!7&#F@#B]3-D?BUX5_
ML8PFY^S77V_[/C_CVV#9OQVWXVU@Z1I6GR_"OQS<264#3R7&J%Y&C!8E6<KS
MUX(R/2O3M)\/Z/H2R+I.EV=B)3E_LT*Q[OK@<U.FF6$5G/:1V5NMM.7,T*Q*
M$D+_ 'MPQ@YR<YZT <!'K$KQ>#M)MK;33J<^D+=+?ZDF]84"1A@@!!9R2"0&
M' R:Y)F'_"M/B=$EW;74:W[D2VJ!(F8K'N*J"<#/N:]CO_#FB:K:V]KJ&D6-
MU;VV!!%- K+$ ,84$<#  X]*E&BZ4+:>V&FV8@N,>=$(%VR8  W#&#@ #GL!
M0!Y]XK&BFV\$V^@BR^W?VK;-9BSVY$(YE(V_P;<Y[=*GL-(M_$&O_$K1KDC9
M=RV\9]5S;+AA]#@CZ5VMEX<T33M0FU"RTBQMKR;/F3PP*KMGKD@9YI+VP6T>
M\U72M+LY=9EC5"\C>49@",!I I. /8]!0!P?A74+GQ?XDT1+X'SO#=G(;]3S
M_IS,T S[[8Y&'^^*T/B4MBVK>#%U,6YLSK'[P7&/+_U3XSGCKBM[PCX?N-%M
MK^YU!X'U34[IKN[: '8K' 5%SR550!D]3D]ZB\6>&Y?$&H^'W$=O+:V-Z9KJ
M.?D/&8W7 &"#RPX- &*ILY/C7;'2/))BT>0:DT&-N"Z^4&QQNX)'?'M67X,T
MYHOA+K=[I5NHUB<ZB8YD7,AD#R*@!Z]A@?XUZ-I6B:5H<#P:3IUK8Q.VYEMX
MEC#'U.!S5BTL[6P@$%G;16\(8MY<2!5R3DG [DDG\: /(=7.@'X&:6-(-M_:
M'EVO]GB''G_;-R9QCG?NW;OQS72Z;86UW\8]>FN[:&::+2[0(SH&V[C)NQGI
MG%=7#X8T&WU9M5AT:PCU!B2;E+=!(2>IW8SD^M7DL[6.\EO$MHENI55))@@#
MNHS@$]2!DX^M 'C5GH^FQ_!#Q<ZV-N'$U]AO+&1Y<C;,'_9P,>E;U^;";XC>
M"'U4VS Z3,T9N=N#+B/!&?XNOO7H0TG3EL9K$6%J+2<L98!$NQRQRVY<8.23
MGUKGM9\(1ZQXQTJ]N;2SGTBVL9[:6WF0,"6*%<*1C V_AQ0!S5O%:W?BSX@'
M2XXI-..G1)/Y2@QM=A')QC@L!MSCOC/-4;[[(W[-!:V\DN='M_-,>,[AM!W8
M[Y!Z^]>K:=IEAI%FMGIUG!:6R\B*",(H/<X%4[;POH%G!>PVVBV$,5\,721V
MZJLPYX8 <CD]?4T <KXIO(?"7B33/&#G%A/:/87[ \8"F2%O^^E9<_[8K0\'
M_9_#7@_37UJZAM;[59S/,9G"F2YG)?8,]3SMQ_LTGB+PU?:XEGX=AM+"U\,1
M-"\[!R9'2-@PA2/;A1E5&[/3/%=/>:=9:B(!>VD%P()5FB\V,-Y<B]&&>A'K
M0!SOQ._Y)EXB_P"O)Z?X:\-S:;%:WA\0ZU>YMP!;W<R-$,J.P0'CMS71W5K;
MWMK):W<$<]O*NV2*5 RN/0@\$5*JJB*B*%51@ #  H \=T0Z /@GJXULVW]H
M8N_[3$VWSOM>Y\9SSOSMV_ABKL5A)J'B?X:Q:]!YUTFD3R3).,_O0D/+ ]2#
MSSW&>U>@S^&-!NM575+C1K"74%(*W+VZ&0$=#NQG(]:O/9VLMY#=R6T3W,*L
ML4S("Z!L;@#U .!GZ4 9/C%53P'KZHH51IEP  , #RFKS?6AHO\ PI;P_!I(
MLCJLOV'^SQ;;?,^U;HRQ&.=WW]Q^N:]3\0V$VJ>&=5T^W*B:ZLYH(RYP-S(5
M&?;)K-\-^#]*T:RTV=])T]=8@M(H9KN*!=Y94"L0V,\X//>@#&TZ\M=/^+OB
MG[9<16XDTZSE0RN%#(OF!F&>P)YKB9#!J'P>ORK;[>X\3'#*2-RM>#D=QP:]
MAU+P]HNL7,%SJ6DV5Y/!_JI+B!79._!(]:E;2-,>V>V;3[4P/-Y[1F%=K2;M
MV\C&-V[G/7/- '#?$>RTFSA\'VT]O9P::NO0!XW15B"^5(,$=,=*DG-G)\9M
M(_L;R#+%I=Q_:)@Q@1DIY0;'?=D@=<5N>,/#LWB&70!&D#P66II=7*3='B".
MI &#D_,.#6MI6A:3H44D6DZ;:6*2'<ZVT*Q[C[X'- 'EFA'0!\%=8&N&V_M#
M%W_:8FV^=]KWOC.>=^=NW\,5JV^E:G+#X;U:+5=/C\4VNB1Q7-CJ8W"6-@"2
M<'<C;E(+ 'N#7<W'AC0;K55U2XT:PEOT(*W+VZ&0$=#NQG(IVK>'=%UWRSJV
MDV5\8_N&X@5ROT)'% 'E=SKDVO:AX&U*WMM-TVRD6[2&*]0R6J72MM&-I4$D
M*^P^YQS6U<>%5N[#Q2FN:_I%K'JS6JN;)=D<,Z-E6978@ESY8(.-P'O7H%QH
M^F7>F#3;C3[66P"A1;/"IC '0!<8&*@MO#>AV>F2Z;;:/816,O\ K+=+=1&_
M^\N,'\: .?\ #&L7J^*[SP_J]MILFH1627(O].&U98MQ4*ZGE&!R0,D8)Q52
M<VH^-6=7,87^QU_LOS\;-WF'S=N>-^-N>^/:NNTG0=(T**2/2=,M+%)#EQ;P
MJFX^^!S3]4T72]<MA;ZKI]K>PJ=RI<1*X!]1GH: /*9TMI- ^*W]G+&VB!2U
MMY8!B$XM_P!\4[?>V].]>H>'8(H_#.FHD2*C6D1*JH .4&:L1Z5IT6EG3(["
MV33RAC-JL2B(J>J[<8P?2K4<:11K'&BI&@"JJC  '0 4 ><>!H[./2_&2*D"
MW*:SJ"[0 '5<Y ]<8KG)=,L;7]G/3+J"TACN +.X$JH _F&= 6SUS@D9]*]:
M'A[1AJTFJC2K+^T)%*/<^0OF,I&""V,GCCZ5,VD::VF+IK:?:FP4*%MC"OE@
M*01A<8X(!'TH XJX2VD^*GB!+R806K>&XEFE+[=B&23<V>V!DYJOX>N+CPMJ
M_AWPY<G2M5L+F*2'3-0M%"3QJB;OG7D$$#&]2,GJ.:]!-A9M=271M8#<21"%
MY3&-S("3M)ZD<GCWJEIOAC0=&NI+K3-&L+.XD&'EM[=48CTR!TH Y?XI13SV
MWA:*VN3;3OXAM5CF"!_+;;)AMIX./0UJ:?X0N(M;AUK6-;N=7U"UC>.T\R)(
M8H-XPQ"(.6(XR2>*Z*YLK6\\G[5;0S^1*)HO,0-Y;CHRYZ$9//O4] 'C>C'0
M!\#]5&LFV_M#9=?VB)L>=]LW/C.>=^=NW\,5K6!O5\7_  [_ +4+"^.AW G\
MS[QDV0[L^^<YKN9_#&@W.JKJL^C6$NH*01<O;H9 1T.[&<CUJU=:987MU:W5
MU9P37%HQ>WED0%HF/!*GMF@#QN_)'@GQ'YV[^S?^$SD_M+;G_CU\Y-^<=NF?
M:O4+G3_#>M6$^DQG3V^V6+1!;<IO\@X&5QSM!(QVSBM:+3K*"*XBBL[=([AV
MDG18P!*S?>+#N3W)ZUFP^'].\/6MW/X<T'38;UUX2-%@$A]&=5) _ T <+X9
MN[KQ-KGA[2+_ .:?PQ%+)J(/(:Y0F"$GW*AY!]17I5GJEAJ,MU%9WD%Q):2F
M&X6-PQB<?PMCH:QO">@76E-J>I:H;=M6U:X\^Y^SYV1JJA4C4D D*HZD#))J
MSH7AY-(U#5]0=H6NM3N/-D\F+RT"J,*,9.6QDECU)/;% '-B*RC^.%UY\<"F
M308G3>H&YA.^2,]^E1>%-*T^\\2>/9KFR@FE?43"SR1AB8_)0[>>W)KL]1T'
M2-7GMY]2TRSNY;=MT+SPJYC/7@D<=!5J"RM;:2>2"VAB>X?S)F1 #(V,9;'4
MX &3Z4 >'V4EX?"'PO9IK-+(-,K/J",]NLP4B'> 1S]\+SUQ7H_AG2+ZV\5Z
MKJEYJ&DR27-O#'-;:=&R ,I8K(X+$Y()&>X4>E=$=&TMM*_LHZ=:'3MNW[(8
M5\K&<XV8QUINE:%I.A0O#I.FVEC&YRZV\*IN/J<#F@#C4-F?C5J/]L&'S$TJ
M$Z9Y^,;"S>:4SQNSC..<>U86D:SI.B^&OB#J4-E:7^G)K3*ENFWR9-ZQ(,G!
M7;N;)..F:].U70=(UU(TU;3+.^6(YC%S"LFT^V1Q4B:/ID=K<6J:=:+;W'$T
M2PJ$D^4+\PQ@\ #GL!0!YK_I47Q:\(B\OM'DN9+:[1[?3("@BC\L%0S%B7!(
MXR%'!P*M^$HEBMO'T=@D*:JFKWGV50 '4F)=F.^,]/QKN-/\-:'I/E?V?H]A
M:F%F:,PVZJ5+#!(('4CCZ4_^P=(_MD:S_9EG_:87;]K\E?-QC'WL9Z<?3B@#
MRCP]I-[KGP[T:UM]4\-VL"O XD\AQ<Q7*NI.6+_ZTL"#QSD^M=W\3X5F^&?B
M &,.5LW<9&<$#K_.M8^%?#[:M_:IT33CJ&[?]I-LGF;O[V[&<^_6M62-)8VC
MD17C<%65AD,#U!% 'FGC.WTZ]\(>$X(X[:6TN-9T]940 HX;KG'7(-7[VUBL
MOC!H_P!B@B@>71;E#L4*&"O&5!QV!KJ;3PQH-A;+;6FC6$$"SBY6..W4*)1T
M<#'WAV/45>:SM7O8[Q[:)KJ-"B3% 753C(#=0#@<>U 'BWAO2]3USX:S:=+J
M/AVU:2207LES"_VJ&Z\PY9VWC$@;!!QZ5[;$KK"BR-N<* S8ZGN:R[GPKX?O
M=3&I76B:=-? @BXDMD9\CH<D9R*UZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6U'Q]I5C
MJ5QI]O:ZGJ=Q:G%T--LWG6W/H[#@'V&3[5U)SCCK7"_" *?AU9RMS=RSW#WA
M/WC.96W;O?I^&* .QT^_MM4T^WO[1R]O<()(V*E25/3@X(_&K-<3XMGN]2\8
M:#X7CO;BRLKR*>ZNI+:0QRRK&%Q&KCE02V3CG K/MIKSP[XIUSPU%J%Y=6!T
M4ZE;-<S-+);,&9"H<_,0< C)XQ0!Z-17BDD&K6WP[\,>*H_$NKG5YWLXWDDN
M"T120A"IB/RG .<D$DC)-=596D_AKXGZ?IT&JZE=VFI:=/)/'>W+3#S8V3#K
MG[I(8@@8'M0!Z#17DNB:-=^(?">L:K>>)-;CN[>[O5M'CO71+<)(^WY1]X<?
MQ9XX&!5\Z[!K_A'PM)J=QK+:CJ%IYW]GZ/(8GNB%&YF(*[4!Y^\H^;O0!Z71
M7C4>L:Q:?#?Q[;-<:C;S:3,RVC7-R'N8$9$8*9%8Y(R<')X/6MK4+*\\.ZYX
M2U2+6]4N;C4K];6]2XN2T4RO$[9$?W4P5XV@8H ]+IDK^7$\@1GVJ3M09+8[
M#WKS:Y\0W_ABR\9:7-<3W%[;N+C26E<L[I<G;$H)Y(27*_3%=S86<VE^&H+2
M:ZEN+BWM0CW$CEGD<+RQ)YR3S0!+H^HMJVDV]\]C=6+3+N-M=ILECYQAAVZ9
MJ]7DMH?$&K_#/P?>J^IZA:A3)JL5G=&.[N$PP4J^X$X;!(# FNX\%7FF7FA-
M_9=Y?W$4,[QR)J#NT\#CK$^_YAC(ZY^IH Z*BO.M#LKO7?&WB:2^U?4C9Z7J
M<9M;2&X9$#>6C'=@Y9>!\G3EN#FN5L=3UKQ#X:D\16]OXKDUZ<R36;VS@6<>
M&.R(1[PK)P Q923S0![?17G>R[\9>.]1TR_O;^PL-(L[9S:6=RT#2S3*6+,R
M$,0N, 9QFL7^T-4L_AM\0S_:]_-<:=J5Q!;7,LY,L:*D6T!AC'4].Y)[T >O
M5GV.J->ZCJ-HVGWMN+-U03SQA8[C(SF,Y^8#H:YCQ3?W=O)X(\BZFC%SJL,<
M^R0CS5,+DJWJ,@'!]*R;W5=02#XIE;ZY!LH@;4B5OW!^R!ODY^7GGCO0!Z;1
M7E.J2:CX=\"Z?J<>J:I=ZMKLMG;33^;O,0DY/DQD[5.,J/<@DYYJUI,VHZ-K
MR36&G>)5TDV<[7J:Q,95\Q%#(Z$NQ#'# @<<CB@#M_$NMIX;\-W^LR0-.EG$
M93&K8+8[9K1@E$]O',!@.@;'ID9KQ;5=(N-5^"]]XKU#6]3FU.]L3=.J73"W
M56.1$(ON[0,#IG/.:]>2U6]T&.V:6:)9;=5+P2&-URHY5AR#[B@"33=2L]7L
M4O;"<3VSEE60 @$JQ4]?<$?A5NO%?#$TWA/X%W'B:QNKR2^,,J(D]PTD,;&X
M9 ZQD[01G)XYYSUK?UK3+KP-!H^LV>N:I>3O?6]M?1W=VTL=VLK;6(0G"L"<
MC;C&,<T >ET5R'Q0O;O3OASJUW8W,MM<QB(QS1,59294'!^A-8VMZ=<>#M9\
M-ZC9:UJMU)?:I%87D5Y=-*EPL@;YMA^52I&1M % 'I%%>=:!8W>O>-?$LE]K
M&HFTTS54^RVD5PR(&\N-CNP?F7@83[O+<'-<M9:GK'B/P]<>(((/%;ZY.TLE
MB]HX%G#M=@D?E[PK+\H#%E)/- 'MU%><7<-]X@^)46EWFHZE8V;>'XKJ>SM+
MEH@93,RD$CD=<':03@9.*CTK4QHT'C71=4UV^73='EB$&H-)YEQ$DT8;8&()
M9@QP,@GD>U 'I=%>5:)<W>E?$71+6VA\0V^G:K;7(DCUF[\WS6C56$BJ79D/
M.#G;UZ59\+Q7=]<>(]=U'5=2N5TG6+Y+2S6Y98PJ,3A@#\_7 !X  P.M 'IE
M%>)6%]KVH>&[3Q#9VWBNY\13[+I9%<"R<%@3$(]^WR]N1G;NSSG->L^([RTL
M/#M]<WVH2Z?;)$=]U#_K(\\ KP?FR0!P>30!J45Y3HUS=Z5\1="MK6'Q%;Z=
MJL%RLJ:S=^;YK1H'#JI=F0]CD+UZ5!;Z=?:[X=\8:G=>(=92;3M1U!;%8+QH
MU@\MBR\#[WIAL@ 8 % 'KM8LWBK2H/%D'AIYG_M*:'SD4(=N/F."W0,0C''H
M*?X6OYM3\(:+J%TP,]S8032MTRS("3^9KQN]\0BYL=3\60Z7J\MXFM)J-K<1
MV,A@-I!^Z \S& #'YA/;+4 >]T5P&ISR>+/'UMH*:E=6VC1:4NI,+.9H7NB[
ME5!=<,$ &>",DTWQ%#=Z;+X8\(6&KZC%#JMW,)KZ2X+W"Q1H9#&LAY!/"@]0
M!0!Z#17!^)HY?A_X"UF^TB^OI9F\M8?MURUP(&=UCW*7R<#=NP21D52UC3;G
MP+/H.I6.M:K=O<:C!8WT5[=M,MRLIVE@K'"N#@C;CTH ])HKCO"=[=7/BCQG
M#/<S2Q6]_&D*.Y(C4PJ<*#T&23Q7&VFJ:Q>?#/P ZZS?0W=_JR6\]VLI:1D;
MS@<EL[N@ZY&0/2@#V.LP:Y:3Z/>:C8++?I:F53%;(2[O&2&10<9;((]ZX[3]
M/ET?XDW'AZ'5=4FT[4-$>Y=;B\>1XY1*$WHY.5)#=NX!K"\'Z:=-^&/B;5[?
M4=2%TD>IH@:\<HA5GPX7. ^5!W=>OK0!ZS871O=/MKMK>:V,T2R&&==LD>1G
M:P[$="*L5Y?=3ZEJ,OPVL5UB_M5U*QE-Y)!*0\N+='Y)SR3GYNHR2,'FK.C_
M -I:)X@\9:'IM[=WBVUA#=Z>E].TQCF=)/EW.<[2RJ<$T >CUG:[K5GX=T6Z
MU:_+BUME#2%%W'!(' ^IKR72?LVO-X3_ +*U[7[O4KEEDUI5U"X4*GE$NS@$
M*F'VA0, @]Q7;?%S_DE>O?\ 7%?_ $8M %RU\?:3/J%M975MJFFRW3B.W.H6
M$D"2N>BAB,9/89YKJ:\MU&ZU[Q1XJTCPOK=A8Z/#$\>J!TN6N&NA$V=D9V*
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M\X.[/ XQ0![)17EFM>(]0U*/P;I[C5&BU/3OM]\-*(2>8A$.Q6RI5<N2<'.
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M]9:?<:/)/<Q6LQC,F)$P 1]T\CYASC(SS4FCP+9_%'7[>-Y&6'1;-%:1RS$
MR $L>2?<T =AHVHMJ^DV]^]C=V+3 DVUXFR6/!(^89..F?H:O5XS;>(]5E\
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MDA*HI,C$.I9R6S\P( Q7>^$9]6F\(Z?)KD4D>IB(K.LB@,2I(#$#@$@ \>M
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ME7-]<LOF% " JA0%51D\ =>N:VM/O[75=/M[^RE$UK<1B2*0 C<IY!P>:LT
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MZ=<"XMIX" ZD#!7D'*L.".]9]]X,636+G5-*UK4='GO-OVM;0QLDQ P&*NK
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M@:>63>'+LQ!!8D#/'Y5U-4]0U6QTMK07LXA-W<+:P9!.^5@2%X'?!Z\<5<H
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MPW".H96 W-@]01DX(JK<:UXAUWQ3JFD>'I[&QMM)\M+B[NH&G,LSKN"*H9<
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M\^U=]JDQ[]V'&22!@C&!ZU6F\ ^*3X4UGPS!)HBP7TDTAU)S(9[C>Y<"1=N
M>0"V6P!P*Z37?#^M_P#"1:-KVB?8);FRMI;2:"\D>-71]IW*RJQR"O3'(H ?
M\3FOD^&^N-930QL+.3SC(A;=&4(8+@C#<\'G'I7+>)EUR#P!X<:]EL;R[_M?
M3VMEAC:%,97:KDLQSGJP_*O0O$>D-X@\+:EI!D$+WMJ\._J$9EP#[C-<S/X<
M\2:QX;TBPU,:7!<Z=J-I/NMYY'62*$@L>4!#'!P.GO0!-8:UXBTWQO;Z)K]Q
MIUU!?V<MS#+:0-$86C*[D.6;<N&Z\&N8;XH74ND3>)8-;\.QV<;,\>B22#[5
M+"K8R6\SY9" 2%VD=!7=:AX?N+SQSI&MK)#]EL[2X@DC8G>QDV8P,8Q\ISS6
M!H_A;Q%X;MUT?3[;0+W2XI#]FN;S>L\418G8RA2'(S@'<,\9H Z#QCK4ND^
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M$TDF%&/O8<<=,YY[UT5UH-S+X^L/$ EA%K;:?-;.A)WEG=6!'&,84]Z ,/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0C<FU-Q4D$C(QCBN-CBMM,\'>%6U:XU);N_U.WFD>REV&2ZF)<B3GF/)((]
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M+!*A22-URKJ1@@CN"*\YU/7I;/XI:5=?V9J,LMQX?DV:?$@,OF&9#AOFV+@
MY8MCCKTST>F^.=,N]"U/5+V.XTP:5(T5]!=*-\+* ?X20V01C'7- '20PQ6\
M$<$$:QQ1J$1$& J@8  [#%/KDK#QW%<:A8VNHZ)JFDIJ)VV,]ZB!)FQD*=K$
MHQ'(#8S3SXX@E\1W6A6.E:C>WMG<)%<F)%$<*LJL)&8L!CYNG4[6XXH ZJFR
M1I-$\4B*\;J596&00>H-<?H6KV]KI&LW.EVFN:H8M7N(989)4DE$@8!O+W,
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M[';NZ9P<X]*Z^B@#SOP+?SZ!HNJ:/=Z1JAO[&>\NMB6C[)T,C.OER8VL6##
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M_5_LBFSU#3K.7=*"-PB=5!'!/*R 8YKTFB@#+\-R:I+X:TV36T5-4:W0W2J
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M?V3[9_:=M_9OV3&[R?\ EITYV;,[NWK0!Z1=7=M8V[7%W<16\"D!I)7"*"2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM/\ #.A:3Y7]G:/86IB9GC,-NJE688)! SDCCZ5>MK*ULA*+6VB@$TK32")
MN]VY9CCJ3W-3T4 8[>%/#SZM_:K:'IS:ANW_ &DVR>9N_O9QU]^M:=Q;07EM
M);7,,<T$JE9(Y%#*P/4$'@BI:* ,K3_#.A:3Y7]G:/86IB9GC,-NJE688)!
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M])M)[73](L;6WN 5FCB@51*",8; Y&">M:E% %1],L'MK:V>RMV@M61K>(Q
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M]&\,/:6J1V,5]=7MY"TNT2_ZN-4#+R0"22>E '66.JV6I37D5I<"62SF,%P
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MC3+V7RK34;2XDQG9%.KG\@:H>-/^1$\0_P#8,N?_ $4U>3S?\([K/@#2-/\
M#.D&3Q7Y%KY%S:Z<\302C9ND:;8  ,')R<^] 'NE4]3U6RT:R-YJ$X@MPZ1[
MR"?F9@JCCU) KF+O6O$&L^*]1T/P]-8V<>E1Q&[N[N!IB\LB[E1%#+@;>22>
M_2N:\3>(;C7_ (:WZW]O'!J6GZS;V5XD1)C,B7$9W)GG:001GUH ]-_M.Q_M
M4Z7]KA^WB'S_ +-O'F>7G&[;UQGC-6ZY&YUQ+/XD7-I/;6JV\&@F]>Z\K]^
M)B"N[^Y@9QZU7\-:CXP\0V]CKS2Z5::7>$2I8- [2BW/1C*&QO(P<;<<T =M
M4=Q<0VEM+<W$J101(9))'.%10,DD]@!7$KXWO+/P?XBO-1A@_MC19Y;9HHU(
M25R1Y!"DDX</'W[FNBU"XN[3P9=W-[';RWL6GO),FS,32",EAM)^[G/&>E &
ME:7=O?V<-W:31SV\R!XY8VRKJ>A!J:O-;OQC?V>@^#5AETS18-6LEDFOY[<F
MVMV\M&6)5#*%W%CC<V %[UWFD->OI<#:A/:7%R02TMHI6)QGY2H))Y&.YYH
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M61,J):1.K6LD:;\;F8[P0",X'/85FS>,;O2_!OC36;:QL(Y]+UB:!%CB*K*
MT8W/@\N0QR?84 >E45PS:WXITCQ5H=MK+:9)8ZQ))#Y-K&X>U=4+J-Y/[P<$
M$X7Z50U3Q7XFGLO%6JZ3<:7:6F@32PBVN[=I'N#&@9F+!UV@Y^4 '/XT >D4
M5GZ'->7.AV=Q?R127,L0D=HH3$OS<CY2S$<$ \GFM"@ HHHH **** "BBB@
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MSIFKI=W%H(BTPC2[=CA>K':0>.HYKUC3=0AU73XKV".X2*7.U;B%HGX)'*L
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M!J)M4^],D9(95S_%ALCW%9;W4WC/QMX=NK'3=1MK'2&FN+FYO;5[?+M&46)
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M031K)&Z]&4C((_ UY'X)FMO$/A[3[G4_B-J<&K7+NK6D>I0(=WF,JJ$*ELD
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MJHHCM\'&YF+<@\X R>#P.,Z>O^(;7P_;P--%/<W-U*(;:TME#2SO@G"@D#@
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M5W!R0^Q5([LP].M<7K5[+9?$#Q+':WFI6$5S#;+.UAIC7WF-Y9&[*Y\IPN
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MF(B?WLA+ QJ<<@QMR>QH Z[4?&\5KJ%Y:6&C:GJHT_'VV6S1"D!QNV_,P+L
M02JY(SZUT&GW]MJFG6U_9RB6VN8UEB<?Q*PR#7EBZ6OA_P 0:_#K \5)%>ZA
M+>VD^D/<-#*LF#L*Q9VN#D<@9&*])\/:?::5X>L+*Q@G@M8H5$<4Y/F(#SAL
M]QGF@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $;=L;;C=CC/K7BNF_V(?@#K$U]]C.J2079O6N-OFF\W/C=GG?G;COTQ
M7M=8\OA/P[/J4NHS:'ITE[*I62=[9"S@C!R<<Y''TH XU/\ D:?A?_V#+K_T
MGBJ;P1IMN^M^.-02VB?4!K,L44KJ"5 C0@#/3DYX]O2NZ_LVQ$MK+]CM_,M%
M*6S^6,PJ0 0A_A!  X]*?;V5K9M.UM;0PM/(99C&@4R.0 6;'4X Y/I0!XMX
M<T?4]?\ AG]A^W^'K8R2-]JFN(G%W#="0DL[;^) W0X].U=9I*V;?%SQ*NMF
M%KU;2U&G_: /^/?8?,,>>WF9SBNLN/"?AV[U4:I<:'ITM^"&^T/;(7R.A)QR
M?>I=7\.Z-KZQKJ^E6=\(CE/M$*N5^A(XH XOQ-#H[^,/ $MO%8MIYN+F)6C5
M#$1Y#!5!'&,]!ZU=MDA;XS7T.U#$WAV%0F!M*^=)QCTQ747GA[1M0TN/3+O2
MK.:PCQY=L\*F-,=-JXP/PH_L33;>>"\MM,M!=V=N;>U<1A3''CB,$#A?;M0!
MYC:12236'PTE)9;'5C+)NYWZ?'B>+/L6:./_ (":ZKXK^9_P@<_WQ9_:;<7V
MS.?LWF+YG3G&.OMFK?AW0]2/B._\3:[#:0ZA<P):06]LYD6"!26P7(&YF8Y/
M'&!74NB21M'(JNC AE89!![$4 >=^)UTM/$_@<Z +4:@;X!?LFWFR\MO,SM_
M@^[CMGI4W@+3;*3Q+XTU"2VC>[&MO$LK+DJHCC8 9Z<DGCV]*ZO2O#.A:'-+
M-I6CV-E++P[V\"H6'ID#I[5>M[*UM'G>VMH86N)#+,8T"F1R "S8ZG ')]*
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MXXI-1#V.K6EY)]EBA+ )#(BMA!_"2RD')YKO_$E[9Z?X<O[F_OIK&U2(A[B
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M_9["6Y!AC&" O"AF4 \!F('%=35"/6M-DGU&%;N,/IN/MF[*B'*[QDGC[O-
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M?]]&",$%FW;@0!D,#FNEHH YNP\%Z?8Z=JUL]S>75QJR%+V^N) T\H*E1S@
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MF*@-T/88XZ]:JZ3X6\0:=H>O>'&&G/IUTMXUI="9Q+NF)*JZ;< #<<D$]N*
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M5;P9H-UX<T:>SNY(GDDO;BX!B)(VR2%@.0.<'F@#F=.U3Q+IFC^%/"47D?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 5Q86@U$Z@+:+[8T0A,^T;S&#D+GKC))Q
M2WME:ZE9RV=[;QW%M*-LD4JAE8>A!ZU/10 @ 4  8 X I:** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C#HNEV^K3ZK#I]LFH
M7 "RW2Q 2.  ,%NN.!^0J]110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
MC,$4LQ 4#))Z 5S>D?$#PQK^O2:+I.JQWEY'&96$*L4V@@'#XVGJ.AH Z6BB
MB@ HJAK6KVN@:-=ZK?%Q:VL9DD*+N./850T;QCHVN^%G\1V=PW]G1K(TCR+M
M9 F=V1VX&?IB@#>HK \)>,=)\:Z9-J&CM,T$4Q@8RQ[#N"ANGT85OT %%96G
M>)-)U;5]2TJQN_-O=-95NX_+8>66SCDC!Z'H363X-\<6WC*XUB&WLY;8Z9<_
M9W,C [SEAD8Z?=H ZNBBB@ HK#\8>)8?!_A>\UV>W>XCMMF8HV +;G5>I_WJ
MO:+J::UH6GZI'&T:7EO'<*C')4.H;!_.@"]117'^.O']MX*&G0?V?<:CJ.HR
MF*UM(#@N1@'GGNR@<'.: .PHK%/B%;3PB?$&K6<]@L=M]HN+9OFDB &2#ZFN
M1L_CGX&N[F.%KVYMA(<+)/;,J9]R,X^O2@#TBBD5@RAE(*D9!'0TM !1110
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MI4BO;Q&"QV^2 21@Y _#H:[R@ HHHH **Y?PM\0= \817SZ3/*QLL&9)8]C
M'."!W'!J[X6\5:9XQT?^U-):5K;S&BS*FT[AC/'XT ;=%%% !117+^,/'VA^
M!S9#67N%-YO$/DQ;\[-N<_\ ?0H ZBBN1\+?$OPQXPO7L=+O7^V(I?[//$8W
M*CJ1G@_@<UUU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?OYES)=3%I'?LP(P 1@<@?7-5?#7PCT#PWK,.JBYU'4;JV79:F^G#K;KT&T
M#ID_3M0!YI%I^I^*O$7Q)MY_$FK6UII4TT\-O!.0K.#)M!S_  C;]T8Z^U0W
MGC;7T^ FA>7J,Z75[?/92WI<^8(E+$#=UST&>N :]DT[X?:1IE]XDNX)[QI/
M$&[[6'=2$W;L[/EX^^>N>U4U^%?AW_A!!X0D-W-IZRF:.621?-C<DG<&"@9Y
M(Z=#0!YJWA9/"/QT\&Z?'JNH:A&T#2![V7>R$B0$+QPI(SCW-)IXO-=M/B_;
M76JZ@L=G/)+"$N#\H1IVV#.<*=H! ZBO0-$^#^@Z)K>G:RE_JUU?V!.R6YN
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M-9W?ELT2@###&,G R0!G\!6[X5\*Z9X.T./2=)1U@5B[-(VYY'/5F/KP/RH
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M-&3%#$$:>15ZR.QVJHY R<<]*N^'O$MIXBBN?)AN+6ZM)/*NK2Z0)+ ^,@,
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M< =Z .GO/%UO'+K,%G97M[+I42/,;=%*EV&0BDL,L%PQ[ 'KGBL7PEX]:Y\
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ML$,#@89E7')ZURZP7>A_"_P1'>:==QW%MXE1VM-F9?\ 7SD  GDD8QSSD>M
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MESI1!O+>]50T2E2ROE205(!.0>QK!73[W_A)_AW+]DG\NUTZY2X?RSB%C#&
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M,06&3$J\C#;PIP0&*@&O5;R[@L+&XO+EQ';V\;2RN?X549)_(5X]J^IWM_\
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MO^)H="GL;1;*ZO[^_9UMK2U"[GV#+$EBJ@ $9)/<5AJ9/^%Q6]_]GN?LEYH
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M@,UU]>9ZWJL_CFVT?1;'1=4M+I;ZWN;UKJT>)+)8V#-\[ !F.,#:3G/:O3*
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M:0FP-;?9XXVF52"%D<#)' SC;FNRK UK6&D\,KJ6B:OI42R/'Y=Y=MNMV4N
M1E3U/0>_%5XM8O6^*%QHAE'V!-'CNECVC/F&9E)SUZ <4 =/16+#XO\ #EQJ
MXTF'7-/DOR2HMTN%+%O3&>OMUK$NO&,6D>/]3L=7U.VL])@TZ":/SRJ#S7=P
M?F/))"CCVH [6BN/\:>*3:?#B^\0>'K^"4J(S!<1%94.954^H/!(KH-7UW2=
M!MUGU;4;:RB=MJM/(%W'T&>OX4 :%9.EZ!!I6K:QJ,4LCR:I,DTJMC"%4" +
M^ [U?L[VUU&TBN[*XBN+:4;HY8G#*P]01P:AUB::WT6^GM[BVMIHX'=)[K_5
M1D*3N?\ V1U/M0!6UW0(->_LWSY9(_L%_%?1[,?,\>< Y[<UK5D0ZU:6>DV$
MFKZKIZ3S6PE:590D4NU07=-Q^[SGZ$5/I&NZ3K]LUSI&HVU["C;&>"0,%/H<
M=* -"BL>T\6>'K_56TNTUNPGOUR#;QSJSY'4  \D=_2LCPEXF>Z\,W^J:[?0
MQ1V^HW,!GDVQHB+*40$\#T'O0!U]%5Y[ZTMKFWMY[F*.>Y8K!&[@-*0,D*.^
M ,\5F:OXKT/2+C[#>:S8VU^Z$QP2S*KDXXX)[]L]: -NBN$\.>(-8U3PCX0U
M&;4].BN+]U^U_:EVM<##96(+@;^,_A71ZCXK\/Z0)/[1UJQMC%((G$LZ@JY
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M@N5D!CVCJ=W3 P<_2JFD>)]"UYI5TG5[*]:'F18)E8J/4@=O>@#6HKE/#GQ
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MO5@=9#A86=/=>1G(ZXK:\9>++/P;X=FU6Z,3.N%A@>81F9B1\JDYYQD]#P*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*D/MQZG&,>]3V'CKPW=>'(-8;5K."V:-2RO* T;=T*]=P/&,9KI:R?\ A%]
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M:6_P-\*W,-M%'.MU83B14 ;S#,H+9ZYP2,UKW3:FGQ@U@)>:1:S26%N+$ZG
M\FZ$;O,$1#KCY\[AR3QZ5Z,=+T\V,5B;&V-I$5,<'DKY:;3E<+C P>1Z5'JF
MB:5K<*1:KIMI?1H<JMS"L@4^HR.* //E<^%= TS35DT;4Y]3UF8VDSIML[-F
MW.<#+'Y2' 4$')QD55T9Y!XW\;QOJ5G?2-H\33R64(BC\P"08V[FY XR3FO2
M9M!T>YTI=+FTJRDT]<;;5H%,2XZ87&!4EMHVEV2;+73K2!?*$&(H%4>6"3LX
M'W<D\=.30!Y-=:?9VO[/VA3P6L,4RG3[@2(@#"0S1Y?/J<GGWKH?$<+:3KNN
M^(=&U/2+B;[*BZKI>H$<K&I*[7!S&2IZ$$'-=VVF:>]@E@UC;&S0*$MS$OEK
MM(*X7&!@@$>F*JZAX:T+5;M+O4=&T^[N(\;99[9'88]R,T 4Y/$%L/A^WB)[
M%S:_V;]L-H0,[/+W;#VZ<5YUJ%W<3ZGX!NYK[1(FEU*)K?3]-APT,+QMG]YN
M^9>0#A5&2*]C**R%"H*$8*D<8]*S+/PQH&G?\>6B:=;_ +T3?NK5%^<9PW Z
MC)P>V: /-_$$MQH6H^)O"=FQCD\2RPS:=C^%K@^5<G_@.TO_ ,"KH-2O5L?$
M]EX8TF+2;"2STI9?M^H1[S'!NV".-05)^[D_, ..#7:S6%G<7<%W-:027-ON
M\F9XP7BR,':QY&1UQ5?4M!TC6)(9-3TNRO7@.8FN(%D*?3(XH \9A=6^#VNI
M'<17$">)@L4D*A8V3[5$04 ) 4Y) 'K7>&=+?XT7TCY.WPY&VT=6Q.Y.!WKK
MFTG36MI+=M/M#!+)YTD1A7:[Y!W$8P6R <]>!3I--L9=1BU&2S@:]A0QQW!C
M!D13U ;J![4 >+:]J\FK>"]%U9)]#TZUFU*VFL=-M(@9U/G#DR;AA@,Y"IZC
M-=>KZ7'\<-0>_:T6<:-!]G:<J&'[Q]VW/MC.*ZZ'PMX?MY)Y(=#TV-[A@TS+
M:H#(00P)XYY /U&:EU#0-&U;S/[1TJQNS(%#F>W5RP7.W.1VR<>F3ZT >.ZH
M89/AY\1;G3MHT:75HVM#'_JV(>$2LG;:6!Y''!KI-9DU!?C KQ7FE6YDTE!I
M\FI0M(C?.WFB,AU ?[N>I(QVKT1M+T]M,.F&QMC8%/+-KY2^5M_N[<8Q[5#>
M:#H^H:?%I][I=G<6<( B@F@5D0 8&T$8&!QQ0!SGAK['X1T?4+G5M<TLP7>I
MO(KV_P"Z@B=]H,:@LV#N#'&>YK6\;_\ (@^(_P#L%W/_ **:H]<\(6.J^'H]
M!MX+.STTRJ98H[9<>6#DB,# 1B<#=@X!..<&M^:&*X@D@GB26&12CQNH964C
M!!!Z@CM0!Y<]I;WNL?"B&Z@CFB^PS/LD4,-RVT9!P?0@'\*BUF&[AU[XF1Z.
MA2ZDT>VD581@L^R4$C'\6!]>E>H#3[(/:N+.W#VBE;=O+&801@A./E& !QVI
MZ6EM'=2W26\2W$JJLDRH [A>@)ZD#)Q]: .9\(W?A8>&] 339M."&%5M%#)O
MW[/F '7?C=GOUS7GUW\WP+\5A?F,>K7#.!R5 NP3G\!FO6;;PWH=EJ3ZC:Z/
M807SYW7$5LBR'/7Y@,\U/#I&FVZWBPZ?:QK>L7N@L2@3L1@EQCYB>^: .*\1
MZMIU_P#$3P)#9WL%Q(+BXE(A</A#;O@G'3/./7!]*H>%+C1H;#QJ=<DLTU$Z
MG=?;OM97<8_^67WNJ;<;>WI7?6/AS1-+6-;#1["U$<AE3R;=$VN006&!P<$C
M/H<4MSX?T:\U*/4KG2;&:^BQLN9+=6D7'3#$9XH \KT?_D2_A1_V$$_]%RUT
M_A;3[.X^(GCR>>UAEE^T6T6]T#'8;=<KSV/<=Z[1=*TY(K:)+"U6.T;?;H(5
M A;D908^4\GIZU+%:6T$\\\-O%'-.0TTB( TA P"Q'7 XYH \6L&\KX3^!;@
M>7+);:U^YMIG"1S$2S *S'A<+D@GNH'>N]\,6LW]O:]XEOEM+-+M(5%O%<+*
M8UB5LR2,O&XY[=E'-/\ %?A>6\LM*@TK3M/GL+*Y::;2)L107*E6&.%(R&;<
M 1@GK67I'@JXC\2?VU;Z)I'AY8K*6W2UM<2"X=\8:8*%4JN. .3D\B@#N=.U
M&RU>PBOM/N8KFTF!,<T3;E;!P<'Z@BO,_"=SX9M=&\</JSZ>O_$YO_M@D*;V
MCWG (/)'7 ]>E>@^&]"@\-Z!;:5;L'2'<S,$"!G9B[$*.%&YC@#H.*2X\+^'
M[N=)[C0]-EFC=I%=[5"P8G);)'4GG/KS0!YAHAGTVW^$LVKOY&R.ZC9YCM"[
MX#Y:DGH2, "NAT:ZL]5^)OC$VLL5U$-/M(B4(92P\W(ST.#Q]?I7<ZEI6GZQ
M:&TU.QMKRWR&\JXB#KD=#@]Z6TTS3]/(-G8VUL1&L0\F)4^1<[5X'09.![F@
M#D?A(]HWPUT00M"9A;8E"$;@0Q'S=_SJ*QLK6X^-6MSS6\4DL.E6OENZ@E,M
M)G'IG%==8Z'I.F75Q=6&F6=K<7)S-+! J-(>OS$#GFK*VELEW)=K;Q+<R*$>
M8( [*.@+=2!D\>] 'BL\:P^ M4@9-NC6_C*1;Z-1\JV8N!N&!_#G&:ZS7Y=/
MG^(/@O\ L1[>2^5YC*;4J0+/RSG=M_ASMVY[]*[R*PLX8IHHK2!(YW9YD6,
M2,WWBP[D]R>M5M,T#1]%,ITK2K*Q,O,AMH%CW?7 YH Y'P +.'Q!XQ@(@2Y7
M6Y"D? <(8DQ@=<'!_6K'BI@OQ+\!EB /,OADGN8.*ZAM#TEM775VTRS.I*NU
M;LP+YH&,8WXSTX^E2W>FV.H/;O>6<%P]M*)H&EC#&)QT9<]#[B@#R^7_ )%/
MXL_]?5U_Z3)4GB'1=+&@_#B$:?;"(ZG:H4\L896A<L#Z@D G/7O7IATRP,5U
M$;*V\N[)-RGE+B8D8)<8^;(&.:=)86<J6Z26D#K;,'@#1@B)@, K_=(!(!%
M'#M#%;?&#4U@C6-9?#2/($& S"9U!/OCBN5B6%?A1\-IYUC$<>K61D=P,*FY
M\Y)Z#I7L9LK4W;79MH3<M'Y)F*#>4SG;NZ[<G..E0R:/IDNE?V7)IUHVG[=O
MV4PKY6.N-N,4 >?>)WN4^*.A/;76E6]J=-E6QDOXC)!]H\P;PFUU ?9C!ST!
M%9'B;2IM.\-ZE=7VI:?=:=>Z[9RZK%IT92&&(%%EW#<Q&["%N>^>]>IR>'M%
METE-)DTFQ?3D^Y:-;J8E^BXP.IJ6UT;2['3VT^TTZT@LF!#6\4*K&P/7*@8.
M: .%UV?1Y?BAX"33Y+)YE:[XMRI*Q?9VV].B]<=NM7_B_&K_  NUEB@8H(F!
MQG:!*F3^6:Z2P\-Z'I90Z?HVGVIC<R(8+9$*L002,#@X)&?0XK1FABN8)()X
MDEAD4J\;J&5@>H(/44 >?>-)-./B'P7-</;GP\+Z4SL"ODB<Q'R"W;[V<9[X
MJ2&6TD^-!ETEXBB:.W]J/"1LW>8/*WD<;\;NO.WVKKH/#VBVNER:7!I-C%I\
MA)>U2W41,3U)7&#T'Y4ZQT:PT>QDMM'L+.Q1LD)# $0MCJ0N,T 2Z9JEAK-@
ME]IMW#=VLA(66%@RG!P>?J*\\\(7'AVVO/'LFJR:<DG]LW'VC[04W&#8F,YY
M*YW>V<UVWAC0(?#6BII\3([&1YI62,1J7=BS;4'"KDX [ "G7?A?0+^42W>B
M:;/()#*&EM48[SU;)'4X'/M0!YCH]M<Z7\,/"'BATD6719GE8/\ >^P2R,K
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M \5QC^ Y=3GT](_".A^'6MKF*XEO[.56FPC [8]J*?FQC+'@'H30!ZA1110
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M\4/HEGH@F:SAAEU*4W046YE!(5!M_>'"G^[6WHNI2:OI,%]+I]WI[R@YMKM
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M1[F"^6[NFE6;;$75MI^52"/X0!CC% '=6NIV=[>7MI;3B2>RD6.X0*1L8J&
MR1SPP/'K1>ZG9Z=):1W<XB:\G%O "I.^0@L%X''"GKQQ7GO@/P];P^-O%=R+
MW4W>SU((BR7TC*X,*_?4G#D9X)SC ]*G^)>D1:AK_@XR7-[%YNJ" B"Z>, >
M7(=P"D8;MN'..* /1J*\^U*UDU/QU8>#FU"_ATFSTG[;*([IUFNF\SRU#R@[
MR !D\\DC-6_!\]UI_BSQ%X8DO+B\LK!;>>UDN9#))&LJMF-G/+ %<C/.#0!U
M?]IV8U<:3YX^W& W(BVG/E[MN[.,=3CKFJ.D>($U;6M;TY;=HSI4Z0LY;/F;
MHP^0,<=<5Q=WX>M[WXXN)+W4T!T1;K$5](F&\_;M&#PG'W>F><5'IGAJ+Q#X
MW\<)<ZCJ,$"7D(6*SN6@&\P)\Y*X+$<8!./8T >HT5XU#XHUB]\!>"+26;4I
MYM6FFBNYK%@+F6.'?\JL2,,VT9;(. <<UU7@V/4K3Q'>6\6GZW:Z"]JLD::M
M,)6CG#8(1M[MM*D'!/4'UH Z37_$NF^&[>&2^>5I+A_+M[>",R33O_=1!R3^
M@J+0O%%MKL\]LMCJ5C=0*KO!?VK1-M.0&!Y!'!Z'M6#<[7^.=D+G!1- =K/=
MT$IFQ)M]]FW\*Z+Q9JTVA>$=7U6W0//:6DDT:D9&X*2,^V: -BBO)]7L+OPI
MX'M/&-MKFIW.K0_9Y[HS7;O%>"1E#)Y9.U1\YV[0","M2>PF\0_$[7-+N]5U
M*+38;"UE^RVUTT2LY,@SE3D?0$9XSG H ]$HKQ*.RU&Y^%VKZY<>(M9?4=&>
MYCLI!=LH002$+N P)"<8);/%=-J7VK7_ ![H-A+J=_:V5UHDES<0V=PT0E;?
M'P2.1UZC!QQG!- 'H]%>=:%=?\(_KOC#0KG5KLZ/I]M#=Q7%Q,99+19$;>N]
MLD@;=PSG\:Q(+J;3/$_A>_TN+Q)'9:C>?99Y]6O"Z7BO&Q#>4SEE(QD':OTH
M ]@HKS2PT>7Q5XE\8V^H:SJR6MI?*EM!;7CQ+$3"AW J<G!Z*3MSDXR:I:-K
MFJKX3\#>*[N^N)(@_P!AU,-(=LB2,8TE<=,JX3GK\QH ]8K/CU.1]?FTPZ=>
M+'';K,+UD'DN2<; <YW#KC%8?A6YN=7\0^)-6>XE:Q6Z%A9PESL A&)' Z9:
M0L,_[ J"*\NC\6-5M#<S&V31(95AWG8KF60%@O0' '/M0!V=%>&K#J$7P7LO
M&KZ_K$NM6\<4T;O>/Y8 E"["@.U@1U+9)/?M7M&IW,%II5W<W5R;6WBA=Y)P
M<&)0#EAP>1UZ4 6JQO$WB!/#>F17KV[3B2ZAMMH;;@R.$SG';.:\WANIM,\2
M^%]0TJ/Q)'9ZC>BUGN-6O"Z7B.C$-Y3.64\9!VK]*ZOXI?\ (K6G_85LO_1Z
MT =M17'V=Y<M\7=4LVN)3:IH\$BP%SL5C(X+!>F2 .:Y#4=8U2+X:^.KN+4;
MI+JV\0316\WFMNB07$8"J<\* 2,=,$T >OT5Y?J^@W.E>./#EA:>(=;6/6EN
M8M0=[LLTOEH) 5SQ&3@C* 8!XQ3K!KG19OB'HMOJ%[)::?91W-F9[AI)(&D@
MD+!78[L94$<\4 >G45XYJ%G=Z-\+=.\;Q:[J\NM0VUI=,TUX[1S!R@,1C^[M
M(8CIG."237IWB6#5+OPSJ,&BSB#4Y+=EMI&.-KXXY['W[4 :M%>:>';JPLDU
M*QVZ_INMKISR266IWDDP? YFC<LRMSQE2/H*K7NJZ@OP'T74%O[D7LB6&^X$
MS>8VZ:,-ELY.02#ZYH ]4HKSW4;*?7?BK>:1<:IJ,.F)H\,[6UK<M$'?S9%R
M2O(XZX(S@9R!BN9MM,OKSP!XGOKGQ%K3W.@7%]!I[K>,FP0$E2^W'F$]"6SQ
MP,4 >T45C6>JS'P7!K$J>9.=.6Z91QN;R]Q'YUYU]AO_ /A6'_"=_P#"0:C_
M &_]C_M+S/M3>1TW^3Y.=FS'RXQG/.: /7J*\UO3=^*/B!I5@^HW]CIUUX?%
M[<6UM.T9<^:/ER#E?O#)&"0,9P:WO'FIW7A?X?7EQIDA2XB2*WAFD.\Q[W6/
M>2>I ;.3W'- '645YMJ^F2^!;OP]J&G:MJEPUUJ4%A>Q7EV\RW2RY!?:Q(5P
M>1MQW%0S^(-0\.:3XSTA[B>XU&VN%.EM+(6=ENSB$ GD[9"P^BT >GT5Y1JD
MMV/$]EX4NEU_4;'3=)BEE73KC9+=3,Q7?+(9%8J-O0'J>>@J'4KOQ)8> +B-
MI=4T^2/7+>+3Y[UPT_V=I(\!R&.X EEY)R ,T >NU3M-5L[\WJVDOG/93&"=
M54@K(%#%><9.&'3CFH-%T.#1+&2VBNKVX,KF22:[N6ED9B "<D\=.@P/05PO
MPVT""VU?Q1=K>:D\EKK5Q BR7LCHX\M.74G#-S]X\\#TH [[1=2DU?2(+Z73
M[NP>4'-M=H%E3!(^8 GKC/T(J_7CEMJ6K7?PN\ NNL7T-U?:O%;SW:2DRLC&
M8');.>@ZY' ]*TH_#SP_$F;PS'KFM#1[C25OYH3?2,[2B4Q\2$[U4@Y(4C)
M[<4 >HT5X\/$&K:)X UVSM[R\GFM?$3:1:W+L))XX6=,'+'YF <@$GKBMKP_
M!J-CXMTX:;IGB:WTV:.5-1.KW(F0D+E)%S(Y#;A@XP"&Z<4 >CUC:)X@36=1
MUJS6W:(Z7=_968MGS#L5LCCC[V/PK9KR[0_#$'B#Q1XU-UJ&IPQIJ@5(K2[:
M !O)3Y_DP6/3&20,=* /4:*\DTK7=7C\,>&_$EWJ$\\6G:E+IVH.7(2XMVD,
M*S,.A*D(<_[U=?X:N;G5_%?B34VN)3803+IMI#O.S,0S*^WIDNQ7/7Y* .LH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KA&^%FFR:1)HLFLZRVC[MT%B)T$<'S;N"%RP!Z!B0/K@UW=% &6N@VJ^*
M9/$(>;[6]FMD4R-FP.7!QC.<GU_"L\V^F>"K+5;[9?W*:A?-=2QQ0-.YD< ;
M55%SM^4=?7DUTE% '&_#/PV_AWPL?M%NUO=7L[7+P.VYH5.%CC)_V8U08[<U
MI:YX4BUC5;358=2OM-U"VC:%;BS9,O&Q!*,'5@1D ].#7044 <K!X!TJ#1=<
MTL7-^\6M$M=22S!Y-Q0(2&(ZG&><\GTXK1O/#5E??V+YLDX_LB99K?:P^9E0
MH-W'(P3TQ5C6M>TSP]9+=ZK=K;PO((D.UF9W/155023P> .U4V\8Z"NH6%A]
MN)N[Z-)8(5AD+%'X5F 7Y ?]K% $&J^#X;[66UBQU34-)U"2-8IY;)DQ.J_=
MWJZLI(R<'&13M3\'6>JZ38VES?:A]JL'\VVU%9@+F-^<MNQ@Y!P1C&.U=%52
MQU2RU)[M+.X65K2<V\X /R2  E3GV(_.@#*A\)Q/HFHZ7J>IZCJL>H(8YY+N
M5<A2,80*H5?P'6JP\#6T_AQ=&U'5=2OUBE26VN99$6>V9  AC9%&",=3G.3G
MK74T4 86F^''M(KJ/4=9U'6$N8O)=+TQ[ G(("HJC)!Y)R36$?A=82:8NE3Z
MYK<VEPLC6UFUPNR#:P90#MRP&, ,2 /?!'=44 5[^SCU'3KJQF+"*YB>%RAP
M0&!!Q[\UR^F> 3I4=I#;>*_$?V:U"+';M<1;-BXPI'EYQ@8ZUV%% '-3^!])
MN['6[:Z-Q.VL2^;<3R./,4@#RPA &T)@;>./>C4O!T-_<V=_#JNHV6JVL MQ
MJ%NZ>9-'UVR J489Y^[P>F*Z6B@#G;SP?9ZGX=32-2OM0NS'*+B.]DF N(Y0
M<AU90 I&>,#&.,4ZQ\*B&SO[;4M8U/5TO83;RB]D7:(R""%5%4 D$Y.,GUK5
MU#5++2HHI;ZX6%)ID@C+ G=(YPJ\>IIHU:P.ISZ=]I07<$*SRQG(V1DD!B>F
M.#^5 '+6OPTL85TQ;K6M9ODTN>*:Q2XG7;#Y9!5<!0#T R<G' (YK5N_"<4_
MBE/$%KJ5]8W1C2*YCMV3R[E$8LH<,I]2,C!P:V;"_L]4LHKVPN8KFUE!,<T+
MAE;!P<$>X(JQ0!DZ3X=LM(CU2.$R2IJ5Y+>3K,01ND # 8 ^7CH<_6JOACP=
MIGA329]-LVGN(9WW2-=,'9AL"!2<#Y0J@ >@KH** .4TSP.NCS0)8Z_K,6F0
M2!XM.\Y#$N#G9N*;]G^SNKI+RSM]0LI[.[A2:VG0QRQN,AE(P0:GHH X=?AE
M8O#%8W6MZW=Z-$P*:7/<@PX!R%8A0[*,#"ENPKH[W0+.^UK2-4D:5)M*,IMT
MC("'S$V'<,>G3&*U:* ,NRT&UL-?U768GF-SJ:PK,K$;%$2D+M&,CACG)-9
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M &622RD5?-BW;MK!E/0DX(P>:V=0U2RTM;=KVX6$7-PEM#N!.^5SA5X]:N4
M<FOP\T9/"VH^'DEO%LK^Z^UR-YH:0/N1N&(/&4'7)Y/-;&HZ#:ZGJ^DZG,\R
MSZ7))) J$!6+H4.[CG@]L5J5%=75O96LMU=31PV\*%Y)9&"JBCDDD]!0!AP>
M$XK3Q5<Z[9ZE?6_VME>ZLT9##,ZKM#$%2P.,=",X%3^)/#=OXEM+:.6YN;2>
MTN%N;:YMF DBD4$ C(((P2"".]:UO<0W=M%<V\J2P2H'CD1LJZD9!!'4$5)0
M!S6I>#8=173YSJNHP:K8(8XM3A9%F93]X.-NQ@< XV_3%7/#WAJS\.QW30S7
M%U=WDGFW5Y=.'EF8# R0   .   !6S4-U=06-I-=W4R0V\*&221SA44#))-
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M&UUQ,?-!(2V6/?(W!'S<JHSW:K.DZ#>6?C3Q!K5PT!@U*&T2-$8EE,2N&SD
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MF!VKEE()')Z'K5"VUVYTKXF>-8K32+_59W%DRPVVT!%$/)+.0HZ\#.3V'!H
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M+F+8X&?F*A]Z@X."1SQZT =315#6-2?2K(3Q:=>7\C.$2"T0,Y)[DD@ >I)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJME]K7:7VQN!GTR0,CJ PSSQ7JU% ')>&_%<MZMAID_AW6;.]6,1W/FVA6&
MJO)\P_*RDC VDDY'%8.F:3J,?P>\2V#V-RMY/_:7E0&(AWWM)MPO4YR,>N:]
M+HH PK339;OP%!I<NZ":73%MVW#!C8Q;3D>H-<!)<ZM<?#1/ @\-ZDNM_9$T
MUF:W/V50 $,WG?=*[1NXYSQBO7** //=6BG\-^.]"U5['4+VPBTB33WEL[9I
MV63<C*6502 0IY]:T_#ME=0?$3QE=RVTT=M<_8O(E="%DVPD-M/?!X/I77T4
M >-)X7U8^!-$N#8:CYVEZS<W,]I;NT%R\+R2@M&00=V&# 9&1GUKJ?#5CI-S
MJ-WJ-E:>)3=1V;6XGUAI\;6()1!*<YRH)P,>]=Y10!ROPVLKG3OASH=I>6\M
MO<Q6P62*5"K*<G@@]*C@L;M?B]>7YMI19MHD4*S[#L+B9R5W=,X(.*ZZB@#S
M?3]*U"/P#X^M7L;A;B[O-4>WB,9W3!P=A4=PW;'6L[4M O+23PGK5Q:ZT]I!
MHR:?>QZ7+)'<V[81@Q5"&9<@A@.F <<5ZS10!YE-;S67A#6M3\)V?B%+^ZFA
M6:6^$CW4D2D!GB64EB0C,!D#IP.E0:+IPE^(^AZGIVE:\MBEI<I/?:H9BTCD
M)C(D)9>_90>V<5ZI10!YKI>DZC'\)?%-C)8W"W<[:GY4!C(>3>TFS:.ISD8]
M<TNIVFG+HOAZ'5]&U^.\MM.B$.I:7#(9;=]H#1DQY8'@<,NW\:])HH Y[P2^
MM2^$;-O$ D&H'?DRJ%D*;CL+@<!MNW(]:XG2KK4_"_@:Y\&2>'=4N]3B6XM[
M62"V+6]RLC,4D,OW5'S_ #;B",&O5Z* /.K+PW?Z1XA^'MLT4D\>EZ9=6]S<
M(A*(_EQ 9/;)!QGTKJ?&6C3>(/!NKZ3;.$GNK9XXR3@;L< ^Q/%;E% '(^&O
M%4MW'I^EW'AW6;.]6,1W/F6A6& JO)\P_*RDC VDDY'%<UH]YJ/A#PI>^$Y?
M#VJ7M_')<)926]L7@NED=F1FD^ZGW_FW$8QWKU.B@#S;3_#.H:-JOPWM'BDG
M73+2[CNYXU+)&S0J "W8$Y SUQ6WX?L;N#XC^,;N6VECMKE;'R960A9-L3!M
MIZ'!/.*ZZB@#QZWTC6+3X8>$HO['OI;NQ\0"[FM4BQ*(UN)GS@XQD$8)P.1Z
MUT,<UUXN^(.AZE;Z7J%EIVB1W#R3WUNT!EEE0($16Y.!DD]*] HH \B&B:K_
M ,*\6T_LV[^T?\)-]H\KR6W>5]KW;\8^[MYSZ5U^N6-W-\2_"5Y%;2O;6\%\
MLTRH2D998]H8]!G!Q]*ZZB@#PSQ#:ZMKOA/7;74])\2WWB9GE"1*LJV<*!SL
M,8!$;C8!_>8FNU\2&YTGQKX8UU]/OKJQ@L[BVG-G;M,\3N$*Y503@[2,XKOJ
M* /.KKP_?:UX@\>PK#-;PZKI-M;VUQ+&51G\N4$9]BPR.V:S-4N=3\3> [;P
M5'X=U2TU25(+6ZDFMBMO;+&REI!+]UAA?EVDDY%>L44 <AHMC=P_$WQ1>26T
MRVL]I9+%,R$)(5$FX ]"1D9^M+\.[&[L-&U*.[MI;=WU>\E194*ED:4E6&>Q
M'(-==10!YW97=SX(\1^(TO-'U2]M=3O/M]I<V%JT^XLBJT3!?ND%>,\$'K64
MWAK6+?X?V,<UA+]NNO$46I36L0WFW1[@.0<=E7J>@YKUFB@#.\0123^&]4AB
M1I))+25411DL2A  'K7"7NDZB_PP\$V:V-R;JUN=,:>$1'?$$*[RPZC&#G/2
MO3** ..U'3KJ?XJ:==K;S?9!H]Q"]PJ':CM(F!NZ X!./:N'T7P];:?H2>%_
M$.G^+Y;F+=;-'9SW+V=S&6.&4JWEJI!&0<8YXKVFB@#S;6FNO^$QN[+5[+Q#
M<Z0EO"-+M]+$BQ3-@^9YKQD?-G  =@N.:R=*T'5K?X>>![*33+J.YL_$2S7$
M)C):&,33'<W^S@@YZ<BO7Z* ..OK.[_X6O8ZBEG/):QZ+/&TBI\N\RH0FX\9
M(!P":YO2HY+;Q-I8\)Z9X@TN*6Y)U33KRW=+.*(ABS+NRH?=C'EG!^E>JT4
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M4*302:O&'C<95AMFX([B@#US2/$6BZ_YW]D:I9WWDD"3[/,K[,],X]<&F?\
M"4Z =9_L?^V;'^TL[?LOGKYF[TQGK[=:Y.Z@:W^+]TNG1I%<2^%W*A  &D6<
M!"?IG%<IX=TR_P!<^&=GIR:QX=LX]Z>8TMNXNH;H."2S&3_6[QUQSGI@T >K
MZIXHT'1+J*UU36;&SGE&4CGG5&(Z9P3P/>KMYJ%G86$E]=W4,%I&N]II) J
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MMK;2=T5U_P )&2))?M&_/FD$;=N=A*8STKJIKO3;WXKZ%J3&#[+?:!+)%)*
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M"1VUQ93>(+8.BA61P8Y#@@<'(Q3K^W>V^+D@TR)(KF7PQ-MV* &=9E"9^F:
M.M'BG0#K/]CC6;$ZEG;]E\]?,W>F,]?;K3O$NJ2:'X7U7588UDDLK26=4?HQ
M520#CMQ7DWAW3+_7/AI8Z?'K'ARSCWQEVDMW%U#=*X)+,9/];O'7'.>G->E?
M$#_DG7B3_L&7'_HMJ ,*3Q=XHTC2].UK6=.TF72KMX%<V4\@FA$I 5MK+AL%
MAD UUVK^(='T"..35]3M+%9#A/M$H3<>^ >M>2ZUI^E:5X&TO6K;Q+=W&KV<
M5O/96-S>_:HY9\+A!"V>>2!MP5Z@\5U&FRVR_%S6Y-=$,5T^G6ITX7!&!%AO
M."$_[?6@#N1JFGG31J0OK;[ 4\S[3YJ^5M]=V<8]ZK:1XDT37S*-(U6SOC#C
MS!;S!RN>F0.WO7F>FZQ::-X:\47-M8VM[HMQX@$&FQ3X%MN=D#/G! B$F3D#
M&1Q5[3&N8_C18K=:EIEU=/H\RSII\'E+&H="JMEV)]03CZ4 =]#XDT2XOK>R
M@U:RENKD.T,,<RLSA20Q ![%6'X'TKEO&?Q T^RT>YCT+7+"35H+F"-H4E21
M@K3(CC;SV)!]*PO"M@T'P;U^]TNW"ZK-_:++*B_O"X>15P>N0!P/7ZU3\0S>
M&1\&-"BTY[#<9+'[.JE?,\SS$\SWW?>W=^N: /9JYKQ3XVTKPI=Z7;WUQ;(]
M]<K$PEN%C,,9#$RD'^$%0.PR>M;+:KIZ:LFDM>0#4'B,ZVQ<;S&#C<!Z9S^1
MKC_B*ENNJ>#9[A8Q&-<C1WD P 8Y, D^] %B]\8PVOC73XVU2T30)](EO6G9
MT\MB)$56#^F&]><UT^F:QINLV OM-OK>[M<D>=#(&4$=02.AKC-0L[&]^,FA
M>9!!-%#HT\D(*AE5A*@!';.":Y;7HKB#2/BG;Z8A15O+:1XXE. C1QF8X'JN
M[./>@#U/3/$^@ZU=2VNEZQ8WD\0R\<$ZNP'3. >GO4'BKQ(OAK3894M7O+Z[
MG2UL[1&"F:5N@R>@P"2>P%<O8:9=ZGJWAJ^&L^&A;V3M):KIL#(\L1C93&N9
M#\N""1C^$>E6OB*W]FW_ (7\0S*QL-,U'-VP&1%'(A3S#[*2/SH UM(G\:+J
M42:U9:*UE*IW/8S2!X#C(!#CYP>F1BKM[XK\/:=J::;>ZU86]Z^,02W"J_/3
M()XSV]:E'B/17NK.V35;.2>\)%O'',K&7 +$C'; //2O.?#,N@1_#KQ)'XC:
MU%_]IO/[76X*^89-[;>O/W=FW'X4 >FWNJZ=IA3[??6UKO5W7SI53*J,L1D]
M ",^E9O_  FWA?\ LK^U/^$@T[[#YGE>?]H7;O\ [O7KCG'IS7GUE9S7=Q\)
MH-<@$TPMKEI([A=QRL"E"P/<84\]Q6[X>TG3F^+/C5VL;=F6&RVYC!QOC;?C
MTW;5SZXH [636-,BL[>\DU"U2UN2!!,TRA)"02-K9P<@$\>E0:3XDT37GF32
M=6LKYX?]8MO,KE?<X/3WKQZ(60^%'@B/4/)^P)XG"2"?'EB,3SC#9XVX]>,5
MV=\]C<?&'PV-',#30V-T=0:WP<0$*(@Y'^WT% '4R^+O#D&K+I4NN:>FH,VP
M6YN%W[NRXSP?;K5G4-=TG2BXU#4K2U,<7G,)IE0A,[=W)Z9X^M>.>,=9.N?#
M36]3ADT32M/:XD\FS6$-=S2I+C<S;@$<D%L!2<=Z[.:TM[[XU:<]U!',T7AU
MYH_,4':_GJ-P]#AB,^] '6VWB/1;RSMKRVU6SEMKJ4002K,I620Y^0'/+<'C
MKQ5R6]M8+NWM);F)+FXW&&)G :3:,MM'4X!&:\NM] .KVGQ"TVP58;B'5UN[
M'8,".X6*.12/3+#GZFM;P;J:>-?%4WBA5Q;66GQ64"GHLT@$LX^JYC0_0T =
MEJ^NZ3H,"3ZMJ-K91NVU&GD";CZ#/6N?\2^*?LO_  B]UI6H6SV&H:FL,TZ,
MKH\/ER,<-T'*CD>E-\5:8;KQ)IFHZ9K&GVNNV4$OE6M\ \<T3D!LJ"&7E1\R
M_3FN3U+4;7Q;HW@I[C3+:&(^)#;S6T>'@=D$P8J< ,A(STYS0!Z7I'B+1=?$
MQTC5+2^\DXD^SS*^S/3./7!J&W\6^';O5O[*MM<T^:_R1]GCN%9R1U  /)]J
MYB8V^E_&.YN(X L8\,--*D2@%]D_''<XX%<?K.I2ZCX<\*ZH)M"T^WFU6SFL
M=,LH09HP9!UDW#D _, @';- 'H$>OZ@WBWQ;8&5?L^G6%O-;+L'RNZ2%B3WY
M4=:T_!>IW6L^"M&U*]</=75I'+*P4*"Q&3P.!7,1$?\ "P?'RY&XZ5:D#N1L
MEK:^&K*WPT\.%2"!81#@]\4 )H'Q T/Q!KFH:5;7]D9[>?RK<)=*[70\L.70
M#J!EAQG[IK2B\7>')M7&DQ:YI[Z@3M%NMPI<MZ8SU]NM<OX,:RL_%'C=72%9
MXM3WI&%&_:8$/RCKS@UQOB#5I-6\#Z3K$<NAZ;:3:C;36&G6L(,X/G#DR;@
MP&20J>HS0!Z;9:S>S?$?5M'DD4V5MI]O/&FT9#NSACGK_"*UCKVD#26U4ZG9
M_P!G)G==><OE#!P?FSCKQ]:\L\7VGB+4?B%XCL= 6/\ >Z-;M<L9"KO&K2'R
MD(Z,_P!W=V&?:IO$.HVM_;_#^]T8V%IH7G2*%OHBUO!,(]L22*&&&4B11SPU
M 'I^E:UIFN6ANM*O[>]@#;2\$@< ^AQT/M4>K^(=&T"-)-7U2TL5?A//E"%O
MH#R?PK \-:3>P^+-4U:[U/29I;BVABFM].C9!N4L5D<%V.2"1GT'M46OZQ(_
MC:/1;&/2;6\BT_[5)J6HQ[RD3.5V1J"I/*DGY@!QUH L>,_$KV7@@:UH5[!(
M)+BV6*>/;(C(\R(V.H/!(J>VUF]D^)E_HK2 V,.EPW*)M&1(TCJ3GKT XKR^
M&1/^%.:VJ7,4]O%XEQ%+$H6,I]JC.5 ) 4Y) SWKT"S9?^%U:F-PRVA6Y7GK
M^^DZ4 =5JFL:;HEK]JU2_MK*#./,N)0@)]!GJ?:ETW5M.UFQ%[IM];W=J20)
M89 RY'49'>N<\7:NUMKVA:3:VNG&_O3-)#=ZBNZ.W"*-Q4#!9CN  !'?FO.9
M6O3X<^*<6G7T5[()8':6PC\M&!1?/*J&;!VA@>3R#0!ZS;^,O#%W/<0V_B#3
M))+9&DF"W2'8J_>8\]!W/:LC1_'VG^*/#>H7.EZCIMMJ,$=PPCGN!(L*HS*L
ML@&"$.%;Z'K6IH\WA9[+3(M+?3&B> K9)&4W&/;DA1UZ#GZ<UP?AG[*OP/U^
M)/)%U';ZHDJC&]</+P>_0C\Q0!Z-'J]OI_ANUU+6=2L(T\B-IKM9 D#L0.4)
M/W2>GX5+I^O:3JNG/J&GZE:W-G'G?-%*&5,#)R>V!ZUYQ(8$O?A@^JE!I(L"
M%,V/*%UY">7NSQG&_;GOTJ6]:VD\?>+'T@QFT_X1QAJ!@QL-SEMF['&_9N_#
M% '<IXM\.R:E!IT>N:>]Y<*KQ0+<*6<,,K@9YR.1ZBGZIXIT#1+J*UU36;&S
MN)1E(YYU1B.F<$\#WKS.\TZRM/@AX4GM[6&*99=,N!(B -YC/'N;/J<GGWK:
M\1Q-HVL^(?$>D:AH]YFW0:MI5^1G$:<!7!RA*G[K @DY[T >CJRNH92&4C((
M.012U3TF^34]&L;^.)H4NK>.98W&"@900#[C-7* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RI?#
M&@3ZC)J$NBZ=)>2J5DG>V0NX(P03C)R./I6K10!3N](TW4-/&GWFGVMQ9  "
MWEA5HP!TPI&!CM26&D:;I5F;/3]/M;2V.<PP1*BG/7( P:NT4 9MEX>T73;2
M>TL=)L;:VN"3-#%;JJ29X^8 8/XTFF^'-#T991IFCV%F)AB3[/;JF\>AP.1[
M5IT4 5AIUB-._LX65N+'R_*^S")?+V=-NW&,>U+)86<RVZR6D#K;.'@#1@B)
M@, K_=(!(R*L44 0?8[7[:;S[-#]J,?E&?8-Y3.=N[KC))QTJ)-(TV.WM;=-
M/M%AM'\RVC6%0L+<\H,84\GD>IJY6-XJ\0)X7\.W.L26[7"P-&IC5MI.]U3K
M[;L_A0!I_8[;[;]M^SQ?:Q'Y7G[!OV9SMW=<9YQTS5"3PQH$VJC5)=%T]]0!
MW?:6MD,F?7=C.?>M6L;0O$":W=ZS;I;M$=,O6LV);/F$*K;AZ?>Z>U $E_X9
MT'5;U+S4-%T^ZNDQMFGMD=QCIR1FM4# P.E%% &?9:#I&FW%S<6.EV=M-=<S
MR0P*C2_[Q YZFF:=X<T31[B6XTS2+"SFE_UDEO;I&S>Q(%:=% $-S:6U[$(K
MJWBGC#*^R5 PW*<@X/<$ CZ54T[P_HVCS33:9I5E9RS?ZU[>!8R_U('-:-8W
MA[Q GB :KLMVA_L_49K Y;.\QX^;VSGI0!)J'AG0=5O$O-1T;3[NY3 66>V1
MV&.G)%:FQ=FS:-F,;<<8]*6B@#)L_"WA_3R39Z'IMN3(LV8K5%^=3E6X'4=C
MVK#@\#6EUXJ\1ZCK>G:??VE_-;R6J31"4ILB"-D,..1V[5V5% ',>+O#<NMZ
M?I%I9);I%9ZG;7+QO\J^5&V64  ]N .E:^F:#I&B^;_96EV=CYIS)]F@6/>?
M? YK0HH AMK.VLD=+6WB@1W:1EB0*&=CDL<=23U-41X;T-=6.K+H]@-1)S]J
M%NGFY]=V,Y]ZU** .2U'P?'J_CTZKJ5I97FE-I/V,P3H')E\[>#M(QC'?.<U
MT":1IB:7_9::?:+I^W9]E$*^5M]-F,8J[6?H^IOJUI)/)IUY8%)GB$5V@5F"
MG&X $_*>QH LW%E:7<"P7-M#-"K*RQR1AE!4Y4@'N" 1Z55U#P_HVK74-UJ.
ME65W/!_JI)X%=D[\$CBM&JFG:G9ZM:FZL9Q-")'BW@$?,C%6'/H010 '2]/-
MC-9&QMC:3EC+!Y2['+'+%EQ@Y)R?6JZ^'-$32/[(72+$:;G/V3[.OE9SG.W&
M,YK3JIJ6IV>D6+7M_.(;=61"Y!."S!5''/+,!^- %:'PWH=OI4NEPZ/81Z?-
M_K+9+=1&_P!5Q@_C5V:RM+FR:RGM89;1DV- \89"OH5/&/:IZ* &&*-H3"T:
M&(KM*$?*5Z8QZ5G7?AK0K^SMK.[T;3Y[6V_U$,ELC)%_N@C _"M2B@!KQQRQ
M-%(BO&RE61AD$'J"/2LVT\-:%86RV]IHUA! DXN5CCMT51*.C@8^\.QZBM2B
M@"%K.V>\2\:WA-U&AC28H-ZJ>2H;J <#CVJA/X8T"ZU,:G<:+I\M^""+E[9#
M)D=#N(SFM6B@!" P((!!X(-9-IX5\/6$C26FA:; [2+*6CM44[U.5;@=0>0>
MU:]% %8Z=8M)=2&SMS)=H$N&,2YF4 @!SCY@ 2,'UJ6*WA@MDMH88XX$01I$
MB@*J@8  Z 8XQ4E<C+\0M.74+VRM]*UR]>RG-O,]II[RHKC!(W#V(_.@#9T_
MPSH.DW;W6G:-I]I<2?>E@MD1C^(%+/X:T*ZU1=3N-&T^6_4@K<O;(T@(Z'<1
MGBKMG<B]LH+H130B5 XCG0HZY'1E/0^U3T 9]YH6DZA?VU_>:99W%Y;$&">6
M%6>,@Y&UB,C!Y^M6(;"SMXYXX;6"-)W:294C $C-]YF ZD]R>M6** ,W3/#V
MBZ+)+)I>DV-D\O\ K&MK=8RWU(%6X;*UMVG:"VAB:X?S)BB!?,;&-S8ZG  R
M?2IZ* (;6TMK&UCMK2WBM[>,82*) BJ/0 <"J-UX;T.^U)-1N]'L)[Z/&VXE
MMT:08Z?,1GBM&66."%YII%CBC4L[L<!0.22>PKDK;XCZ1=S0F&RUAK":011:
ME]@D^S.Q.!AL9P3QG&/>@#JI;.VFN8+F6WB>XM]WDRL@+1[AAMIZC(X..M/F
MACN(7AFC22*12KHZ@JP/4$'J*?10!F6GAS1+"VBMK32+"""*?[1''';HJI+C
M&\#'#8XSUJZ;.V-Z+TV\)NQ&8A/L&\(3DKNZXR,XJ:B@#*D\,:!+JHU231=/
M?4 =WVEK9#)GUW8SGWK1N+>&ZMY+>XBCF@E4I)'(H974\$$'@BI** ,FR\+^
M']-N%N+'0M,M9UZ206D:,/Q S4^J:'I.N1)%JNFVE\D9RBW,*R!3[9'%7Z*
M*DFEZ?+IATV2QMFL"FS[,8E,>WTVXQBHK#0='TL1#3]*LK7R0RQF&!4*!L;L
M8'&<#/K@5H44 0VMG;6,'D6EO%;PABWEQ($7).2<#N22?QK-C\*>'8IYYH]!
MTQ9;@@S.+5,R$$,,\<\@'ZC-7?[3L_[7_LKSQ]N\C[3Y.#GR]VW=GIUXJ+3M
M3>_NM0@?3KRU%I-Y2R7"!5G&,[XSGE?>@"I-X?2Y\86VO3O"3:6S06Z+$ ^7
M/S%GSDC' 7@#+'G/&CJ&FV.K6;V>HV<%W;/C=%/&'4XZ<&K5% %.VTC3;-H&
MM=/M86MXC#"8X54QQYR44@<+D#@<5+%9VL$T\T5M#'+<$-,Z( TI P"Q[\<<
MU/7-6?BBZU+Q=?:/8Z3YEEI[K%=WSW 7;(R;P%CP2W503D=: -"P\,:#I=Z]
M[I^BZ?:W3YW306R(YSUY S6G)&DL;1R(KHP(96&00>Q%.HH R]-\-:%HUQ)<
M:9HUA932##R6]ND;$>F0.E%WX;T._P!1CU&\T>PN+V/&RXEMT9QCI\Q&>*U*
M* (9;.VFN8+F6WBDGM]WDRL@+1[AAMIZC(X..M$=G;0W4UU%;PI<3A1-*J /
M(%X7<>IQDXSTS4U% '*>)O":ZG::%9Z;;6<%K8ZO%>S0; B&,;RX"@8));..
M^36WI>AZ3HB2)I6F6=BLIW2"VA6/<?? YK0HH R#X6\/-=W-VVAZ:;BZ!6>4
MVJ%I0>H8XYSWSUK0%E:B\%X+:'[4L7DB;8-XCSG;NZ[<@''2IZ* ,G4H+VQM
M+B;P]IVGOJ%Q(&D\]C"KG&-[,JDL1@?AWJ'PEX?'AGP]#8-*LURSO/<S*NT2
M3.Q9R!V&3@>P%;E% &?JN@Z1KB(FK:79WRQG*"Y@63;],CBI1I6G+#:PBPM1
M%:,'MD$*[86 (!08^4X)Z>M6ZQKOQ EIXLTW03;LSWUO-.)MW""/;QCOG=^E
M &G]CM?MOVW[-#]K\ORO/V#?LSG;NZXSSCIFLZW\*^'K1Y7M]"TV)I7#R%+5
M 68'<">.H(!'OS4^DZF^J)=M)IUY9?9[EX +I IE"X_>+@G*'/!]JT* *ITR
MP.IG4OL<'VXQ>0;GRQYACSG;NZXSSBC3]-L=*M%M-/M(+2V4EA%!&$4$G)P!
MQUJU6-IWB!-0\3:WHJV[(^EBW+2ELB3S5+# [8Q0!9?0M)EU=-7DTRS;4HQM
M2[,*F51C'#8ST)%01>%?#T$L\L6A::DEP0TS+:H#(00P)XYY /U&:;XB\0)X
M>AT^1[=IOME_!8@*VW:9&V[O?'I6S0!"MG;)>27:V\2W,B!'F" .RC. 6ZD#
M)X]Z@;1M+:SN+-M-M#:W+M)/"8%V2L>2S+C!)[DU=KD)/B'IPOKVTM])UV\:
MRN&MII+33WE02+U&X?4?G0!T&EZ)I6APM#I6FVEC&YRRVT*QACZG YINI:!H
M^LR0R:GI5E>O <Q-<0+(4^F1Q5NTN!>6<%R(I8A-&KB.9"CKD9PRGH1W%34
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MB^CE9]^R/IL(&,8_6O4ZXUOA\D>HZA>6/B77K#[?<M<S0VTT03S" "0#&3T
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MQ:&UL56)F(88VN\B@*FTD-DX^[Q0!J>$+FZU;5_$6LR7$S64EY]CLH2Y,:I
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MF LOO9$0C\S;Y>/E.5SWZUZ3HG@YM$N;<KXAUJZM+52MO9W$R&- 1C!(4,X
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MD+KDDACR> !U)K;\$>)G\1Z??">>SN;BPNVM7N;)LPS@*K*Z\G&0PR,G!!H
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M#D'<!TXKCO#NH^*]&^%]QK>FSZ9'8:=/=S?9IH6=[E1.Y?+A@$[@  ],YYP
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M X,<-EN#$F:0M\X"C)(V\C ZT >@45YWI/CW[+JUW8ZAKNDZW;QZ=+J"W>F
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M)Y=O;QM+*Y!.U5&2<#GH*R_$UU?6>EB:SU+3--4/^^N]1!*1)@\@;E!;..I
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MB@#D->\-:D?$\7B/0_L$MT;;[)<VE_N$<T88LK!E!*L"3V((-;VBQ:A%8?\
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M0VE&QNXO,;<C[_,!3Y<,,\<XXY]J7QAX?U/6KC1+K2KBTAGTR]-U_I2L5?\
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M /S*Y^7_ &3C(KNZ* /)_#$7BZ6'Q7#H$FDI!-KU\GG71D$ENQ?!8!00_&"
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M068X[ <DUG_$+1KF?6] UR.'4[BTL//ANH]+E=+A4D"X=-A#, 5&0.2#TXH
MVK/QI8O9ZK+JEO/I,^E()+V"ZVEHT()5@4)# X.,'J"*70_%5SK-Q'O\-ZK8
MV<\9E@N[D1A64?W@'+(3G@$5Q][X6M?$?A#Q&NAV^N#4+J"*-9=::8&?RW\Q
M47SCNQG(R0!\U=18>)O^$E@.E'1-;L+B>W=)WN+-HX[8[2,;S@-STVYSUXH
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MFP"(EX]ACW[EZC&#GTQ0!Z51110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** ,K3-!MM+U;5]1AEE:75)4EF5R-JE4"#;@=,#OFM6BB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/UK=JM-IUE<7MM>SVD$EU;;O(F>,%XMPPVT]1D=<59H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HI'=8T9W8*JC)8G  ]:R_^$G\/_\ 0<TS_P "X_\ &@#5HK/77-,?4+6P
MCO(Y+BZA:>!4RPDC4@%@PXQR.]:% !114%W>VMA#YUY<PV\6<;YI BY],F@"
M>BJMGJ5AJ(8V5[;7(7[Q@E5\?7!JU0 4444 %%%4[O5K&QO;&SN9Q'<7SM';
M(5)\QE4L1P,#@$\T 7**** "BBB@ HHHH **IZGJUCHUJMSJ$X@A:5(0Q4G+
MN0JC@'J2!5R@ HHHH **** "BBJVH:C9Z382WVH7,5M:P@&2:5MJKDX&3]2!
M0!9HIJ.LB*Z,&1@"K Y!'K3J "BBB@ HJG<ZK8V>HV.GW$X2ZOBZVT>TGS"B
M[FY P,#GFKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%8^L
M>*='T&ZM;74+ITN+K/DPQ022NP&,G:BD@#(Y/%:-W>VEA#YUY=0VT6=N^:0(
MN?3)H GHJE9ZSI>H3&&RU*SN90NXI#.KL!ZX!Z<BKM !1110 4444 %%%5K[
M4++3+?[1?WEO:0@X\R>547/U)Q0!9HJ&UN[:^MDN;.XBN('Y66%PZM]".#4U
M !1110 4444 %%%% !1110 4454U#5+#2HHI;^[AMHY95AC:5PH9VZ*,]S0!
M;HHHH ***ANKJ"RM)KNYD6*"!&DDD;HJ@9)/X"@":BHK:XCN[6&YA+&*9%D0
MLI4X(R,@\CZ&I: "BBB@ HHHH **** "BBJE_JEAI:0O?W<-LL\RP1&5PH>1
MONJ,]SB@"W1110 4444 %%4[C5;&UU2STV:<)>7BR-;Q;2=X0 MSC P".M7*
M "BBB@ HHHH **@O;VVTZQGO;R9(;:!#)+(YP%4#))K+T?Q=HNNS116%S*TD
ML;21K-;2P[U4KN*[U&?OKT]: -NBJNHZE9:182WVH745K:Q &2:5MJKDX&3]
M2!5E65T#HP96&00<@B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!KHLB,CJ&1
M@0RL,@CT->;WWAO0E^+VCVJZ+IPMWTFX=HA:IL9A(F"1C&>>M>E5SMUH%S/\
M0-/\0++$+:VL)K5HR3O+.RL".,8^4]Z .9\0V][;_$_P[::!'96T@TJZ1#*A
M\J!-\>2$7&[V7(Z]:FM_'.H:)I/BW_A(1;W5WX>D0"6V0Q+<"1%:/().TY8
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MY?O,P&XYSV%:,OA_Q-X@U/21K\NE1Z7IEREX!9&0R74J#Y-P88103DC+=.M
M">,]>UC19IY(?$7A_38TBWVMK=Q-)-=,!D@_.NT9X^4&GZ?XUN[NX\(WDL$4
M>E:_:E6X.Z&ZV[U7=G!5@' XSD"H7\+>(K3Q%K]QI[:0\&LL&-[=;S<6R[ A
M0*!AU&,@;EZ\U2UW2D\,_!JVT^^O(%U+28(I;22,D[KF)@8P@."=S87IT8T
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MWTZ&ZCE1B=[&4(%V\8XVG.33/&N@7NOZ1:KITL"7UC?07T N,B-VC;.UB,D
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MWFQ9P65D9@<$@$9R,BHM5GL8_'OA^":745O)8+IH$AEQ;L%"[O,7/)^8;>*
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M61F'!P".HS7$>#/&<NB>#9Y'T+5[ZTM+R[:ZO(44I$OG.<C<P9\#D[00/PH
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MVN(;$0S,A"2%4<-M/0XR,^F:XV72M2M?AW&9--O2]MXH^VR0I S2>2+HMO"
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MTDSL0-N,\@@UZQ10!YSXBGOD\365IJ<6O'0/[/4QII,<N9;G<0RRM%\ZC;C
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MLO&/VRVD\\)JCW+0VT@4C)9SL)Y(!7.<^E>DT4 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^T+K[<'<?:?.;S!_I97&[.>G'TXJ]KMNMUXR\70NTBAO#4/,3E&X><\$<]J
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M3*/L.?0FL,:UYOASQ#XDO[C4GL=1O%M--M[.X,;>6KB)#&<@(9'W$MQP1Z4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>emergentbiosolutionscomp003.jpg
<TEXT>
begin 644 emergentbiosolutionscomp003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M4/\ <B_]%K7$UVWQ9_Y*-J'^Y%_Z+6N)KT*?P(\ZI\;"BBBK("BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ;2BEIM #J*04M !1110 4444 %%%% !1110 4444 %%%% !1110 4A%+
M10 SI2T$>E(* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DQQ
M2T4 -HI<4E !1110 4444 %%%% !1110 4444 %*>>E)10 4$ C!H_G2XH @
M92I]J;5@C(P:A92I]J3*0VFXIU)2&-(II%/(I*!D9%-(J0TTBD,6&8Q-@\J:
MOA@RY'0UF$5)#,8FP>5_E0G83C<O]324 AAD'(/I15F=@H-%% T)1110(0TE
M.I"*!H913J;0 E%+24#$(I*=2$4F,:13:?24@(Z0C-/(IO>@=QA'%203&+@\
MJ?TII&:81BD/<T@V1QS252@F,9P?N']*O###(Y%4F9M6$HI<4'%,0E%%% !2
M4M)0 4TBG44#0PBDIU(10 E)2XHH [_XL_\ )1M0_P!R+_T6M<37;?%G_DHV
MH?[D7_HM:XFHI_ BJGQL****L@**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;2@TM-H =12 TM
M !1110 4444 %%%% !1110 4444 %%%% !1110 4A%+10 P&EH(I.E "T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EHH ;12]J2@ HHHH **
M** "BBB@ HHHH **** "EZTE - !00",&E/2DH @92I]J2K! (P:A92I]J3*
M3&4A%.I*0QA%)3R*:10,81S3"*EII%*PQ89C$<'E35X$$ @Y!K-(J2&8Q'!Y
M7N*$[":N7J* 00"#D&BK,PI*6B@8E%%% AM(13Z;0,;12D4E "44M)0,0BDI
MU(12L,:13<4^D-(".D(XI](12&B(K4L,YB.&^Z?TII%,(H'N:.01D'(-+BJ,
M,QC.T\J?TJ[N! (.15)F;5A<&DI113$)1110-"44M)0(0BD-.I"*!W$--IU(
M10!WWQ9_Y*-J'^Y%_P"BUKB:[;XL_P#)1M0_W(O_ $6M<344_@153XV%%%%6
M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1D[(<J<HJ[.7-)3U1I'5$4LS'  &237J_A?X+7%_:QWNO736:. PMXQ\^/\
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MX<L=4F@OKVPMC<06JJURB_>"'/S >V*TIH+?5;830L-V.&_H:[3X!*&O]:!
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MB.[^+/\ R4;4/]R+_P!%K7$UVWQ9_P"2C:A_N1?^BUKB:BG\"+J?&PHHHJR
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!M**6FT .HIM*.E "T444 %%%
M% !1110 4444 %%%% !1110 4444 %-(IU% $?2ES3B*90 ZBD!I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!,"CK2TG2@!**4TF* "BBB@ HHHH
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M844459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #:*=3:
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M7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\ A2OA?_GOJ7_?Y?\
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M?_GOJ7_?Y?\ XFO1J*/:3[A[*'8\Y_X4KX7_ .>^I?\ ?Y?_ (FC_A2OA?\
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MLH=CSG_A2OA?_GOJ7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\
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M7_?Y?_B:/^%*>%_^>^I?]_E_^)KT:BCVD^X>RAV/./\ A2?A?_GOJ7_?Y?\
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M]3_[_K_\17I=%'M)=P]G'L%%%%06%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M29&<9&?2@!:*** "BD!!S@@XX.*6@ HI 020"#CK2T %%%% !1110 4444 %
M%%% !1110 4444 %%)D$D C(ZBEH **** "BD9E1"[L%51DDG  I: "BD9U7
M&Y@,G R>II: "BBB@ HHHH **3()(!&1U%+0 4444 %%%% !1110 4444 %%
M%% !112 @D@$9'6@!:*0D#J0.W-+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 444A(! )&3T% "T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)
MO7>4W#<!G;GG%+0 44@=2S*&!9>H!Y%+0 4444 %%%% !1110 4444 %%%%
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MCA7:6(Z!V#,0#TP* .ET_P 873^(;31M8T"ZTF:_CD>S>2>.59=@RRG83M8
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ME2551@20<@ ]<T =CJ?CVUM+S2K2PL+K4Y]6M&NK%;?:!*!MP"6("C#;LG@
M'O@5JZEK\>B>%9M=U:VDMUM[<33VZ,)&1L#Y 1P3DXSTKGH=!DLO'/A=['3I
MH-+LM(GM\,=P@),>U&;)R< ]STZUU&NE1H=V'TM]4C9-KV2!295/# !B >,G
M&><4 9UCXAU*2UNY]4\.7.G1P6YN$8W$4JR #.W*G(;VQCWJ*?QK:P>"M/\
M$QM)C!>_9]L((W+YS*HSVXW<US'A[2[U]5U"RT:TUFP\-S:;)$;;5MP6.X8X
M40AR6"XW9_AZ8K(==>O_ (:Z3X83POJD5YITEHEU),@6,"*5,F,Y_>9QGC@#
M)SP 0#O=5\7RP:[)HFC:-<:QJ%O$LUTL4J11P*WW0SN<;CC(4=N:Y_Q;JLT7
MBWP!J+:7>F=FO"+%0IFW-;X"G!VC!/)S@#))XJR6O_"'CK7M0?1M0U'3=:$$
ML<UA%YKPR1IL*.N<X( (/2K.I0:AJWB_P-JHTRYMXH&NWN4E"DV^^ JH<J2
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MMXW[=N<=ZYC0;G4_A];7'A^Y\/ZIJ.GQ7$LFG76FPB8-$[%]CC(*L"Q&3P:
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M %^BN&T+Q='X@^)%W:Z;J2W.DII$<HC5<;)O-8-D$!@=N.#[5L+X[\+MJ_\
M92ZU;&[\WR0N3M,G]S?C;N]LYH Z&BLG6_$VC>'$A;5K^.V,Q(B0@L\A'7:J
M@DX]A2VOB71;U=.:VU&&5=2+BS*DGS2@)8#W !R#Z4 :M%4QJMB=0N+ 7*?:
MK:)9IHN<HC9PQ]N#^58T?Q \)S7MK:1Z[:--=!3" 3M;<,J"V, D8X)!YZ4
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M%H-W8W4TKM@+(5*!#R,YR2 !US74Z-XDT?Q!8RWFEW\5Q!$Y25AE3&PY(8,
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MM&2# "1]">:[C[/#OC;R8]T0*QG:,H#U ].E*L,22/(D:*\F-[!0"V.!D]Z
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MMKV:R-Q<7,UK()%AMVCVX9EX&YBN!7*WB37'P[\6QVS!A;^*IYKR-4\PB 7
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M[N([BYL;6:>/[DDD*LR_0D9% '+>)[N'59O!3VA9OM6K1W,6Y"K>6L$K$D$
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M,\BJ?/0';N)QGT'%7OB.D]Q=^%+.&]N+1;K5Q#+);N5<H8I-P![9'?MU'(H
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MBCNN,9=1W(X)&">]:E]X;TN_\-G0'M_*T[RUC2.$[/+"D%=I'0@@$'VK6HH
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MX.!6]3=Z[]FX;\9VYYQZT <S=> ])NM5O+XW&HQ)?$->6L%VT<-PP&W+J.Y
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M?+Y;,&/'KE1S6C110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[^PI]Y2>=IQCUH YG4KO5O$OC#X?:MI^H0V'V^QN9H8Y+7S?(8Q(7!^8;LY
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MY1HRX<,"G.01^-9H\ :DWA/Q9I5QJD,]WKL[3BX\HHJ%D0'*CH,J<=>,<DT
M3:UKGB%_%.BZ%H\UI;C4-.DGEGFBW^25*?,%R-W!("Y R0>V*S-4\9W$7B*X
M\/R^+=,T=M+@A%Q>74"L]W.Z;CM0L J 8)ZG)P.E=4WAN=O&&D:UY\?E6.GR
MVC1X.YF8H01[?+52^\.ZU8^)[S7/#ES8;M1CC6]M+]7V,R#:LBLO(.W@C&#B
M@#"?Q[J]UX-T/4-/%B^H7>LKI<K')@D.YTWJ>NT[5;UP<5*M]XUB\9R>%6UG
M3IFN+ 7Z:@;':UNH?8R+&&PQ)*X)/ SG-;NL>'=3US3]!6\NK07EAJD%_.T,
M;+&X0L=J@DGH0,D]NU6FT"8_$%/$?G)Y"Z4UCY6#NW&57W>F,#% ')+\0-2T
MGP9K$^IO:3ZKI^KG28[AE\J&5B5VR.,_* &R0#_#4WA[QE*_BVPT=_$^F^((
MM0BE.^TA6-[:1%W<A6(*$;L9Y!'4U=D^'[W.E^(+26_$4U_JYU2SN(ER;:0;
M"A(/4@ISZ@UM:+'XJ%UG6Y-&^SK&1BRCDWR-QAB6.%'7CGKUH X1?%'C6Z^'
MUQXPCU'3H8[(S-]C^R%OM*1RLK;GW?(<*0 H[9SSQ;\3KK6H_$CPA)I^K0V:
MW-I=2VX>S\WR?W<9;/S#=G(],8[UL6W@BZ@^%M[X3-W";BXCN5$X!V#S9'<<
M=>-U3ZWX8U:2]\.:IH]Q9"_T>*2$QW8;RI4D15;E>01M!% &3J_B36(O&=SH
MTNOV6@QQ11&Q>[L]R:@[+ESO+  !OEV@YKN-5U)-&T*\U.Z^=+.V>>38,;@B
MEC@?A7,^)-#\5:Y97NF&709M/O8MA^T02%[8E<,5&2'P<L"=I!KH4T.W/A==
M N'>XMOL0LY&<_-(FS823ZD4 <-<:_XQTCPI!XTO[RQFLF6.XN=)CMMIB@<C
M[DN[)=0P)R,'FG26VK3?'820:K D)T5)=IM-Q,'G\QYW=2<G?VSC'%3/X*\3
M7VA6_A74]6T^3P_#Y<<D\43BZN(4(*QMSM7. "PSG'2NE'A^5?'_ /PD0FC$
M']E"P$.#NW>;OW>F,<4 7M3T32M5FMKG4[.&Y-IN:+SQN1"1RVT\9P.I'':O
M,([]M(\%_$#Q'H"BUTJXE/\ 9@C&U=P01O,@' !?)&.NW-=IX\T#7O$FG0:=
MI-_:6MH[DWJ3A\SIQB/*<A3SNQ@D<9ZTEOX?UC4M OM!\1#1UTV>U^S11Z7%
M)&8QC'\9(X&,8]* ,+0SH&AW>@6=QX.ET])'$6GZI<0Q;Y)BAY?!+HSC<?FY
M/?!Z:?Q2_P"1:L/^PO9?^CEHA\,>)-0O-&C\0:CI\UCI$ZW,;6L;K+=2HI5&
MDR<+C)) SD^E;WBKP]'XH\.W.E/.UN\FUXIT&3%(K!D8#O@@<>E &'\4/^17
MM/\ L+67_H]*[1U+(RABI(QD=17#-X;\5Z[>::GB:_TG^S["Y2Z,>GQ2![J1
M.4W[CA5!Y(&<XKHS:ZX^OW<AU"W32'M D$21?OHY\\OD\$8[?IZ@'F^EBR\$
MZ-%X?\;^&(GL$E(&MI L]O,2^0\O&Z-LD<G/UKUFXG\FSEG0;]D9< ?Q8&:X
M74?#7CC6M(F\/ZGK.CR:;.OE3WT=LZW,D??Y,[ Q'&>GM746ECJUKKQ N[8Z
M EDD4-KY9\U90?O%NXV\?YY .7^&FBZ=?^![;5]0M;>]U#6 US>W$\8=I69C
M\IS_  @8 '08KNK6U@L;2&TM84AMX4$<<:#"HH&  *XFR\,>*O"ZS:?X8U#2
MFT=Y&D@AU&*0O9[B250H<,N22 <=>M;\=EXCAO=%']KV\]I!&ZZD9+<+)<OM
M^5DQPO/./YT 0>,_$;:#IL,%HT/]K:A)]GL4E8!0Y',C?["#YC] .]>?:%)%
MX5TWXDIIVH"XN;2%9TN#(&>67[*&:7KSER2?3->K:EH>DZSY7]J:797WE9\O
M[5;K+LSC.-P.,X'Y"N:TOX=:38:IXDF-A8):ZLJQ11V]NJ-#$8@CH"!P&()X
M]: .>U+1-/\ #GA+P9J>FVT4-];7MDK7$:@23+,0DH9NK;MQ)SWK2\=:381^
M,?!VK+:H+^35TA>?^(IY4AV_3(%2V7@WQ!+_ &)IVM:E8SZ/HLR30&&-A/<M
M&,1>9GY1MX)QG) Z5-XJ\/>*];UK3[BSNM&BM=-O%N[99HY2[,$*X?!QCYCT
MQVH N>)2;GQIX0T]^8#/<7C+_>:*+"?D9,_4"J?C'5]1T^]9(/%FF:5^ZW6U
MHUF;B>9N^X;L[<\?*OXU-XD2[L)?#'B"^,)ETZY\J^: $1K'.GELPSSM#F,\
M]@:8_ACQ!9^*]9U+2;W3%M]7\LRRW4+O/;[$"80 @,.,@$C!/>@#,U/7I->^
M$VD>*VC6*[AGM+T*O0.)E1P/8@N/H:W)2;OXLP12<I8:,TT0]'FEVD_7;%C\
M36'-X?ETGP7X9\"-,MQ//=1B5XP0/(BD\Z1N>@P%7ZN*W=34Z9\1-(U1_P#C
MWU"U?3)&[+(&\V+/UQ(/J1ZT 8^L:386/QE\*7UM:I'=7L-^;B4=9-L<>W/T
MR?SK?\4VFF6ZC69_#$FN7J)Y"1PP)+(J')X#D #/7'/(ZUCZQX>\97_BW3];
M@N]!1=--PEK')%,2R2A1\^#U 4=,#.:VM3@\7)>)<:1>Z5)$T*I):WL3JJ.,
MY='3DYST([#F@#B]#T^&?X(:W%'/&,B\N(X(]P^P2!C(L.& (*,!U Y_.O1;
M'4UF\-VVJW'RJ]HMS)@= 4#&N*O]$N_#G@+6+%[I+O6_$=VZ,T:;$,]QA"$7
M)(54!/)Z*37>PV,$.F1Z?MW6Z0B#:>ZA=N/RH \Z7Q!XSF\'-XYCNK%;,1&\
M71C;=;8<\S;L^9L&[IC/&*T=2\1ZYJ?BO2](\/W%M;6VHZ2;\W,\/F-"-Z_,
M%R-QPP&"<<Y[8-8>"/$\?AUO"$6L6 \/,#"+DQ/]L6W)YBQG83CY=WIVKHHO
M"YM_&ECK%O)&EG::2VG)!@[AEU8'/H N* -^V26*UACGF\Z94422[=N]@.6P
M.F3SBI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HI#D@X.#ZUYMXDT[4O"MMIVK0>)M6O=7FU&" P33?N+OS' 9!"/E4;=Q
M&.1MZT >E45YKXEU^UO/&5[I6I^(KC1=)TR"(NMI.8IKJ>0%OO+\VU4 ) [M
MS7;>'1 - M3:ZM+JUN5)BO)9%D:123C+* #CIGKQSS0!J45QW@J[N;G7/&*3
MW$LJ0:N8XED<L(U\I#M7/09)X%.\&W=S<Z_XPCGN)94@U4)$KN6$:^3&<*#T
M&23@>M '7T5Y[\2+R2UU'0QJ5SJ%KX7=I?[1GL6=2KX'EB1D^94)W=.^,UT/
MA&RTZUT^2;1];N=4TZ=@T/G7?VE8L#D(YRV/8DX]J .AHKB?%EU?:KXLTGPC
M8WT]A#<P2WM_<6S;9?)0A0B-_#N8\D<X%;&A^%;?P]>2RV6H:F\$D>UK6ZNV
MGC#9SO&_+ ]N#CVH WJ**\M\?>)=5N+LQ:%=R6UAI-[;1WUS$<>=-)*B^0#Z
M*K$M[E1ZT >I45Q'Q5;5+7P-?ZEI>LW6G26<1D*VX7][RH +$%EQS]TCK757
M4%Q>Z28;>^ELYY$7;<QHK,AXR0&!!_$=Z +M-61'=T5U+)@,H/*YYY]*X_X9
M7M[>>#!+J-[->3QWES$9YVRS!)649_ 5'X.NYD\$R^(TL9[Z^U69[YH82H=P
M[;8U!8@ +&$')X - ';$@#).!38Y$EC62-U=& 964Y!!Z$&N8TCQ7=W7B(Z#
MK.B/I=[);&ZM_P#2%G2:,,%8;E PP)'%-\#L;2/6="_Y9Z3J+PP#^["ZK+&O
MT DVCV44 =716!K6M:W8W1@TKPS/J86,2/*;J.!._P JYR2W'3 '(YYK-G^(
MEBGA71-?@L;NXAU6Y2UC@C4>:KMO^7'<AD*]?QH [&JCV&GK??VD]I;"[5-G
MVIHU\P)Z;^N/;-8.C>+;J]\23:#JVB2Z5>BU^V0;KA)EEB#;2<KP&!(XY^M<
MGXM\9WGB#P!XAGTWP]<RZ$]K/"FI&=%+X!4NL9Y*9'7.<<XH ]5!! (.0>AI
M&8*I9B  ,DGM69IDDL/A2SD@@,\R62,D(8*9&"#"Y/ STR:\^T3Q%KNO_#3Q
M')JFG2+#]EU'9>/<(V2&<"/:.1M'&>GR^] 'JBL&4,I!4C(([TM>:>'/&MWI
M?ASPI'>>';J'2;F&UL4U!YD!\QD"J3%]X(2.&)Z<XY%='J'BR\&M76E:%H<N
MK3V*JUX_VA($B+#*H"WWG(YQT&1D\T =116=H6LVWB#1;;5+0.L,ZD[)!AD8
M$JRL/4,"#]*P=(\;SZYJ=S!9Z)-]BL;N>UO;Z6=4CA,;,/E!Y?( )QT##F@#
MKZ*XB/XA2O:PZP^@7,?AN:58TU)IDW;6;:LIB^\(R2.<YP<XJUJ?C&\BU;4M
M/T;0I=4?2XT>]?[0L(4LNY43(.]MO/8<CF@#K:*X[3_'?VRT\-SS:6\ UZ8I
M !.K[5\LN&./4#&.HK4D\01R>*+WPZ(&$D.G+>&;=P0S,FW'K\N: -M'61 Z
M,&4]"IR#3J\^\ 7]WI_P@\.RV.ESZE<-"$6&)T3&2WS,S$ *,=>3R.*U=,\7
MWM])J]A/H,EOK6FHDIL?M*,LR/G:R2<#L<Y QB@#K**\HT?Q+>ZQ\&KS4/%&
ME7$]D+%Y'N%NU5[L;CD#;RF, <UUE]XH72VTK1](TN;4=2NK4316@F""*%0!
MODD;.!R!GDDT =717)0>.HFT/7KN[TV>TU'0HFDO=/=U+ !"ZE7'!5@#@_7B
MJL7C^X^UZ/)=^'+NTTG5IDM[:]EF3=YCC*;HARH;'!)^H% ';U#<6MO=HJ7,
M$4RHXD59$# ,#D,,]P>AKF)?&-]/KFHV&C^'IM1BTV5(;N474<3!RH;"(WWL
M CJ5]LUJ^*M0O-+\+:E?6-LUQ<0V[NJJZH5P#ELGCCKCOB@#6=TC7<[*J^K'
M IU>/Z]K.JZK\"%O-7T^6%S%IL@G,JRM=9EB)<*O*D]<'GFNSLO&5XWB:QT?
M5?#USIBZBDCV,TDZ2&0H-S*ZK]QMO.,F@#K:K6>G6.G(Z6-G;VJR,7<01*@9
MCU)P.3[URMUX[N0=1NM,\/W.H:3ILCQW5ZDZ(24_UGE(>9-O.>1D@@9J74_'
M26VK6&F:7I<^J7.HV/VRT\IPBNN1]YFX48.<GZ8)(H ZZBN3N?%NH'43I>E^
M'WO]2M[>.:_C%TD<=J7&1'O(^9C@\ 8QSD9I8O'=G/;Z!-%:3_\ $WO'LRCD
M*UO(@?>''J"A'% '5T5CKX@C;QE)X<\AO,33UOO.W<$&0IMQZ_+FN1C^*DTO
MARV\2CPO>KH+;?M%V\Z Q9;:2J=74$X)X[XSUH ]&IJNC%@K*2IPP!Z'WKF]
M<\62V&N0:'I.DRZKJLD)N7B698DABSMW.[=,G@  DXKF_!>M1V5QX\UC58)-
M/C@OQ+<12D,T6V!,C*D@].,=>* /2J*Y"R\9WK7FG+JOAVYTRRU.016EQ).C
MG>5+*LB#E"P!QR>>#BETOQI<ZUKEWI^G:%/+#8WTEG>7;S*D<6TXRN>7)Z[1
MT!&3S0!UU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W5
MK;WML]O=V\5Q _WHI4#JW.>0>#S4U% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !&>M%%% !CG-&,
MT44 %%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!';:C-M+8&<#J:\JL]5UJ[\4OK^O>#=?E>V+1Z9:0
M1Q-';(>#(29!ND8<$XP!P*]6HH X.X@NO#7CK4O$*:'=ZC:ZO:PJ[6<:O/;R
MQ@C:5)!VLNWD'@KSZUJ> -(O-'\-NE] +6:ZO)[L6BL"+99)"PCR.. >W&<U
MU%% 'GZ2:IX,\6:],-!U#5-+U:9+N&73U61XI=@5T=2PP/E!!Z<U/X>@UG0O
M#WB#7[K2))=4U&[DODTR.0%U7:JI&6&1NPN3C/6NYHH YG5/$&KV"6-Q_P (
MM>7EE<0!KE+61'GMY"!\AC) 8=02#^%<WX=L]0TB]\4^)M/\,7%E9W,,9M='
MRD<MQ*@;<Y121&3D#'4XSBO2J* .&UZRUG^U-!\9:9I;RWEO;-#?:89%$K0R
M!6*J3P71AT[UK:1XCU+5[N7'AG4;&RCA+>;?E(Y'DXPBH"<C&?F) Z5T=% &
M9H.H7>KZ';WM]IDVEW,H;?:2L&>/!(&2/4 '\:\]\2_#&2S\+"ST75=>N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !117,0^*[FXN_%%M;:2]Q-HKHD<4<HW7):,/@9 "]<=Z
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M'DH3R&7/."#0!P-\FNZ7X-M+?4(KRR5/$ULEE'/=++*+5I$(1G5FS@EEY).
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M7AS3=$W74,.F&-K.>&;;-"R#"L&]<$CD=Z -*>UBT_P[-:VH9(H+5DC!=F(
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M_5=KFXOX$MYP6^4HF[  [?>- 'F=I_R(OPH_["-K_P"B9:[#XJ?\DO\ $/\
MUZ'^8J=/ 6EQ^']+T=;F_$.EW*W-G+YX\R)ES@!L<J Q&".E;6M:/::_HUUI
M5\'-K=)Y<@1MIQ[&@#SS7]#MO"2^&];TJXO1J<VI6MK.\MW)(;Q)3AU<,<'C
MD8 QCC%4RMUXI\1^))+_ ,/ZMJJV5^]E:&UU".W2T5%7!53*IWDG=NP>P'3%
M=M9^ ]*M-6MM0>XU&\-F2;."\NVEBMB1C**>^. 23CM4FI>"K"_U:;5+>]U+
M3+RX55N7T^Y,7GA1@;Q@@D#@'@^] %OPFNKIX4TU->4KJB0A+C<ZL2PXR2I(
M)( )P>IKRZUN+RY^$O@D#4+N&:ZUZ.![B*4B3:T\JG#'V_D*]DM;9+.TAMHV
MD9(D"*99"[$ 8Y8DDGW-84/@G1X-$TK2$6?[+IEVMY;@R?,)%=G&3W&6/% '
M/Z?I5OX8^*]I8:6]Q'9ZAI4TMQ#)</*'D21,/\Y)W88C-;7C>XTW[)8Z??0Z
MA=S7EQMM[&PF,3W+!22K$,HV <G) X%;$NB6<WB&VUMP_P!LM[=[="&^78Y!
M.1ZY457\0>&K+Q$MHUQ+=6US9RF6VNK27RY8F(P<'T(."".: /-=-U/4O"D?
MC^"VLY+*.PT^*]L[*2Z-R+=V1\D,>Q*ABO(XIOB3PEIVF^ ])U:.XO+C49KN
MQDN+N2[D?[27E0DLI;:1DY''&!7HFE^"](TNXU"=%N+B7485AO&NYFF,ZKN^
M]N]0Q'IC  &*RT^&&AK;16LEWJT]G;R)):VTU\[1VQ5@PV+^&.<X!(&* *!T
MZ#QE\2/$-EK4D\ECHT=M':V:3O$A:5"[2MM();^$'MBN4</IGPC\=);7%P&@
M\03(DK2L9,">(9+=2<=3WKTS5_!FGZMK"ZLMUJ&GW_E"&2>PN3"TT8.0KXZX
M['K[U&G@#0H_#-_X?CCG73[Z?[1*OG$MORK<,<GJ@ZY[T <SK'AK2M3^-ELM
MW%.XFT:2=PMU*GSK*B@C:PP,=AP>I&:BU/7-0T;4/BC?6DCM-96]H]NK'<(R
M8/O =..OX5VFN>$[+7=0M-0>ZOK*^M4:..XLI_*<HV,H>#D9 -68?#NG1:AJ
M]X8C(^KK&MVDAW(X1-@&/3;UH \]US0[?P=X6TWQ-I-[>/J\<]KYT\EU))_:
M D=5=74D@Y#$C XQQ6@^CP>(_BEXAL-3GNY-/AL;1_LB7#QQNQ\P9;:03CTS
MCGD' QM6/P[T:QN[.0W&I7-O8N)+.RNKMI(+9A]TJI].V2<=JW+?1+.VUZ]U
MF,/]KO(HXI26^7:F=N!V^\: .<^&,LW_  C5Y9RSRS)8:G=6<+2N6;RTD(4$
MGDX'%8WASPUI3?%SQ;.8IS):-93PG[5+A7='9B1NPPSV.0.P%=YH^B6>A07,
M-D'"7%U+=2;VS\\C;FQ[9JE/X3LI?$XU^&ZOK6\946=;>?;'<A#\HD7'.,D=
MN* .$T31(/%W@W4/%>JWUY'K4LET\5PEU)']@\MW5$100  %!.1SDYKNO!NK
MW&K^!M(U;4,+//9I+,Q& 3MY;V!Z_C5"]^'6BWMU=OY^I6]K>R&6\L;:[:.W
MN&/WBR#U[X(SWKJ4MH(K5;6.)%MU01K&%PH4#&,>F.* /%=8DABL+'Q7X>TS
M5HT&H0%=8O=08M<H\H4CRBQ)C8''(7CM74W&D0^(?BKK6GZC/=OI\>FVLAM(
M[AXXW8M(,MM()QZ9QZYP,:2?##0ELH[&2YU6:RAD62VM9;UC';%6##8OX8^;
M. 3BNCAT2S@\076MH'^V7,$<$A+?+M0DC ]?F- 'EUG]OM? E]>VEQ=3/X4U
M^X,*M(6:2UBDP\;$GYAY;-U_NBNPT:Z/B#X@ZCJ4$[/INFV<5I!M8[))90)7
M;ZA3&/Q-6[J"S\'Z1?&RTG4-2_M"\EG>VMX_-+2RY+9[*A(QD\#-)\/?#3^%
M/!ECILRJ+K!EN-K;@)&Y*Y[A1A0?110!DZW;KXE^)T7AW4I9O[)M=*^W?98Y
M6C%Q*TI3+%2"54#IZFN?O;18](^(WA=YKFXTS2K-;JR$EPY:!G@=_+WYR5!4
M$ D\'!S7H>N^%;#7Y[:ZEENK2^M=P@O+*8Q2HK?>7/0J?0@BC2_">DZ5I-YI
MT<4D\=\7-Y+<2&22Y+##%V/)R.* /.M;T.RTWX+Z8+'SH'O)--DD?SGD(<O'
M\R[R0O7H./:MIM&M_"OQ/\-1Z7+=JFJP7B7HFN9)?/,:*RNVXGYLD\^];D'@
M'3(=!_L66]U.ZL5EADB2XN=_D^4P9%0XX48''M6S>:)9WVM:;JTP?[5IPE$!
M#87]XH5LCOP!0!Y!IT.L>*_#]WKB:#K-SKMQ+.;348M2BB2U=7941$,HPJ[0
M""O/.<YKI+W39O$7Q,M-,UF:YCMCX=CN+NR@G9$DE$Q!!*GH"3T/.!VKHYO
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M03CTSCUS@5RUOH$=U\-O$]]<ZAJ4UUH4U]%IDC7D@-LL!8IMP1D\<ELG&!T
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M@ HHHH ***\K\3^-=4\-W,MXWB?2;QK>Z19M'MK0DK$SA?FD#$JX!SS@9[4
M>J45R]KXAN+;QGK>D:K)$EM#:1ZA9R!<?N.5DW'OM8?DPK+MM?UJ\\!V6MW>
ML:9HAO9&F,]W#D16[$F)5!8 N5V]?4\4 =K>WMMIUC/>WDRPVT"&261NBJ!D
MDU2'B+2FN=)MTNU=]6C:6RVJQ$R*H<D'&!\I!YQ7#:5XUO[OPYXVBFN[;4I]
M$MFE@O!:F)+A6A9UW1GT*D'L14TUR][XN^&5U($$DUE=R,$7"@FWC)P.PYH
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M()  R3D\GGH,<UXO'&K:EX(\*WMN+:TO]<NELY+AT+10,-^Y@N>22A"@GJ:
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M$>A2ZI!-=ZOJ!O?M+1E5!+1L<J.G*'@9ZBNEUW0)M6U_P]J$<T:)I=S)-(K
MY<-&R8'XFM^B@#AK?PMXET:^U6WT/4=-32=3N7NC]JB=IK5Y/O[ "%<9Y )&
M,]ZBM_ %[9^$O#EI::A!'K6@$M;W#1EHI-P(=&7@[64XXY&*[ZB@#F3IOB+5
M- UBQUA])BDO+5[>!;)9"$+*REF9NO4< #&.IK6T'3WTGP[IFFR.KR6EI% S
MKT8H@4D>W%:%% '%R>&O$-EXPU?5M(N]+$.K+$));N)WFMMB;<( 0&7O@D<G
MO7+ZQX=O_#/A;P!H5O>0&]M=:58YVC+1EBLS#*Y!(YP>17KE0SVEM<M"UQ;Q
M2M"XDB,B!BCXQN7/0\GD>M '+Z3X=UFX\5+XB\27-B]Q;6[6UG;6*OY<08@N
MY9N2QP!Z >M<7X-TGQ5K/PW73+'4-,MM*O9;J*29XG-Q"AGD#A<':Q/."<8S
MWQFO8JAMK2WLH!!:6\4$*DD1Q(%4$G)X''))/XT <P_A*:S\2>&K[2W@6RTF
MSDL9(9B=WE$(%*D#DC8.N*HM\/I9_#>KZ;+?K%<W.L2ZK9W,2Y^SR&0.A(/7
M&,'ZFN[HH Y+^RO%FL:5J6G:[?:5!#=64ELK:='(7WN,>82Q&,#/RC/7K61#
MX,\2W,'ANVO[O1X+30[N&=(;*%_WPC4KDD_=.#]T#&2>:]$HH XB3P[XITWQ
M/KVL:'>:2RZJ\),%[')^[\N((&W*>N0>,<\<BJUQ\/KR'P9::;8WT,VJP:I'
MJTMQ<J52XG$F]LA<E0>G'H*] HH Y"^\.ZU8^)KS7?#L^GEM1CC6]M+\/L9T
M&%D1EY!V\$8P<5TNFI>II\2ZD]N]Y@F4VR%(\YZ*"2>!@<GGVZ5:HH \\N?
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MCV%=XEI;17,MS';Q)<3!1+*J ,X7[H8]3C)QGIFIJ ./TOPYKA\;1>)=8O+
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M'/$.C^(M3U+PS=::;?5&66YM=05\1S!0ID0IUR ,J>XZUE?$I9G\.Z3:1ZC
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M<@"K&J>'=4UF#PX]Y<V8N]-U)+ZX,,;+&X57&U 23_$.2><'ITKJJ* ,#4]
MFOO&6@ZVDT:PZ;%<H\9!W.954#'TVT:1H$VG>+/$>KR31O%JKV[1HH.Y/+BV
M'/U/-;]-1UD4,C!E/0@Y!H X.T\ WEOX+\,Z&UY 9M(U2&^DD .UU25I"H]\
M-CFM_3= FLO&>NZV\T;0ZC#;1I& =R&(,#GZ[JWZ* //)OA]J'_"+#3X;RS:
M[AUM]6B69&,$N9&<1R#KCYNW<"M32?#FMKXV_P"$EUB\L6<Z:UB+:TC8+'^\
M5QAFY;H<GCJ.*Z^B@#@=,\':[8>&-;\+M=:<^EW,%VEG, XF5IBQ D'W<#>W
M(Z\59NO!^I01^'K_ $>\M8]9TBS%FWVA&,%S$54,K8^8<J&!'Y&NUHH XNT\
M(:E.=>U+6;RUDUC5;,V2"W5A#;1!6"JN?F;+,6)/X 4Z]\&W5UX T3PZMU")
M]/\ L6^4@[6\@H6QWYVG%=@SJ@R[!1G&2<<TZ@#(\3Z!!XH\.7FCW$CQ)<*-
MLJ=8W4AE8?1@#^%<]_PC7B;6[[2AXGO],:QTRX2Z5+&-P]U,GW&?=PH!YVC.
M37<44 8&E:!-I_C#Q#K3S1M%JBVJQQJ#N3RD93GZ[JWZ** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *X>3XAO]DFUB#0;F;PW!(4DU,3("55MK2+%]YD!SSG. 2!7;NH=&4YPPP<
M5XWHWA*UTC2QX=UKPEKNHSQ,T*W%G=R?9KF(L=K']ZJIP>5('3OF@#NM3\93
MVWB270-,T2XU._6TCNUV2I'&49F'S.W"XVCU)SP.#6./B?<S:#/J]MX4U"2V
ML"ZZGNFC0VS(2'5<_P"L*@9.,#&.<Y U;'2;JV^*%]?+;.FGG1X+>*7^$LLC
MDK]0"*Q[+0M4C^'?C>P>RD%U?76IO;1'&91)NV$?7(H WM:\9QZ9<:);V>FW
M.I2ZRDC6JVY52=JJW.X@ $-DG/ !JM;>*I=4&M:+J>E2Z7JMK9-/Y#RK*LD3
M @.CKU&1@\<&N=UF6[T;7/AHW]G7%U<6UI<I):PE?,XMT#8#$ D<G&><<5J:
M=8ZIXA\5ZOXDGTRXTVW.E?V99078"RRY8NSLH)VC.  ?K0!#X9\21>'OA;X2
M46LU[?7MM%!9V<) >9]N3R>%4 $ECP!6Q:^-+EI]0TZ_T*>SUJULVO8K+SED
M%U&./W<@X)SP00,$BN5T[1]:M/"O@;5XM(NGO?#H>&ZTYP$E='0QNR9."1@$
M<C(K>TN'4/$7C^'Q'-I=WIFGV%B]K EXH2:>21@6.T$X4!0.>I- &G/XTLU\
M+Z3K=M"]P-5DMXK6!6 9GE(&">VT;B?]TUG7?CZ\^TZS;Z7X9N]0;2)FCN7$
MZ1IM"!LJ6^\V"?E [<D9&</P]I$Z?$>70BH.D>'IIM1ML'(#7('EH1VV9GQ[
M$5OZ!I-_:W/C9I[5T%]?/);$_P#+53"BY'X@B@"NOQ*\R#3-370+U= OY8H5
MU&21%*M(<*3%G=MW'&[\LC!.QJWBFXM];.BZ-I$FJZA%")[A1.L,<",2%W.W
M\38.% Z#/%<I-X>U9O@UH&D"QE.H6[V1E@XW($E4MGZ $T[Q!X<%GX[O]:O-
M&U35=-U*"%=VF7$B26\L8*X9$==RL,'/."#ZT ;ES\0[.V\/V&JG3KQWN=0_
MLV2S0 S0SY8%",X)#+C@\Y!J33O&-_<:W=:+?^'9['4ELFO;6$W,<@N4!VXW
M#A6R0,'USFL6]\.[M#\,C1M"O+)%\107]Q;W$F^5%!;=(Y+MU&T]>_K6W=:;
M>/\ %73M36W<V4>D3P/-_"',J$+]< T 9_PV\1Z[KUE<OJFFRI"+JYV7;SQL
M 1*0(MJ\_*.,]/E]ZV-<\52:=K-OHFEZ7+JFK30FX,"2K$D40.-[NW3)X P2
M<&LKX?)?:.M_X?O]*O87CO;FX2[* V\J/(67:P/4ANF.QI=7@U#P_P"/SXE@
MTNZU.PO+!;.XCLU#S0NCEE8*2-RD,0<="* + \?VZ^&-:U2XT^XM[S1<K>Z?
M(R[T8 $88<%2#D-WK6\/ZU>:XDMS)I$UC8L%:TEFE4O<(<_,4'*=C@\\]JX6
M]\/ZUJWAOQ[JSZ9+;WFO11QVFGL091'$FQ2V#@,V2<9XXKTRQ1H]/MHW&UEB
M4$'L0!0!R$&L:7I&H^.]0@LKG[1IP2:\+3EA.5@WC8#PG'%$7Q!G-QH\UUX<
MO+72-6FCM[:^EE3=YCC*;HA\RJ>Q/Y"J%YH6J2#XF[;*0_VG %LNG[\_9=F%
M_P"!<59US1M1N?"7@VUAM)'GLM0TZ6X0=8UCQO)^E &C>>,+TZ_J&E:/H$VI
MMIHC^V.+F.(J77<%0-]X[>>H';-96H>*/$4'Q3BTFUT6>XLQI;3>0+J) ^94
M'F\GC;DKC.3G/2JWC:S-YJ%[+9^&-<BU](]FGZMIKJHE./E\Q@X 4-P0XZ#C
MK5B\CUG1O&^C:_>:9=ZD'T0Z?=-I\8<I/YB.6*DCY3@\T /GU6'3K[Q[<:/I
MMS)JEFL#7!-U\LA,.X,H8X7:I.0.N/I3-'\;ZE8?"Z'Q%KFDSGR+.U<2?:(V
M:\W[5+@#[O+ X/K5FUT+4)=>^():!HXM42!+25_NR8MMA(^C<5B/I^KZY\%)
M_#*Z+?6FJV-C;P>7=(JK.\14D1MDA@?+Z\?>% '>:KX@CTO6]%TQX'D?599(
MD<$ 1E(R^3Z],5R_A/Q/XAU/QGX@LKO1YELH;M(]S7,1%F/)!Q@'+;CSQG&[
MVJ*>XUCQ/XO\)ZBGAS4+"QL+B9KA[T*CAF@9>%!)V@X&XXR2,#K5S0TOM$^(
M'B*&XTJ]DMM6N8KBWO84#0J!$%8.<Y4@KCISF@"OH7BC1M"\ VU]86%[LN;^
M6UM+$S&6::<RNNT,Q[E2>3@"MK2?%EQ<:ZNAZUH\NDZC+"9[96G6:.=%(#;7
M7^(9&5(Z<UQUEX7URT\$:!<Q:>[ZEHVL3WS6+,%::)I9<A23C=M<,,UN6Z:C
MXK\=Z/K+Z1>Z7IVC0S[3?(J2SRRJ%VA 3A5 SD]30!%)\3;EM%NM9M/"U]<:
M;8R2I>3F=$V"-RK% >9, 9/0#.,Y!QW<=W!+8I>+(OV=HQ*)#P-I&<_E7GNG
M:#JD7P?\0:5)92K?W U'RH#C<_F/(4Q]<C\ZZZVTQ[GP3#I-QNA>73EMI/5"
M8]I_*@#G1\29!IZZZ_AV]3PRS@#4C*FX(6VB4P_>"9[]<<XK(\3&75?C!I%C
M<^'4U6PBTZ22))I8C&=SQAI@K?W<XQU/45&Z^))_AVG@,^&[M-2^RKIS7IV_
M8Q$ %\[?G)^49VXSGM72QZ)=VOQ(TBYCAD>PM=#DM#<'IO\ ,CP#[D*30!L^
M)?$=MX9TV.YFAFN)IYEMK6U@ ,D\K?=1<\=B<GH :P]8UBZN/!?B!_$WANYL
MK:WM&D>.*]1_/3!)"NA!5ACGCN.34_CO2M1NDT;5M+MOMEUH]^MT;3<%,T>T
MJX4GC=ALC/I537M0U#Q9X'\1V=KX=U2T=[%XX!>(B--(RGY54,3QQR>#F@#6
MTCQ!;?VQ:^'DM98?^)7%>6SO)N#QY"E<GG<ORYSUSFL/Q%XDTK5_#NH27NGW
M4MA9:S%8JT5P8S+(LB*7!7'RAFQ[[32^)]-U:TTGP[KFCV#W6KZ0OEM;+C=)
M')%L=?P;8W_ :KZMX3O;/X6:7H=I ]S>PW-I+/MY+/YRR2O^98T :&G?\EEU
MW_L$6O\ Z,DK3\1^*SH.JZ5IL.E7.H7>IB;R(X&5?FC"DY+$ ##=<\8/6J5M
M9WEM\6M0O'LYS97FE0QQW*KF,.CN2K'L<,,>M9OCB\FT_P"(?@FZAL9[YD6_
M)@M]OF,/+3)4,0"0.<9YQ0!L:7XRDN;G5=/U32)=-U33K<736S3+*LL1!PZ.
M.",@@\<&J^C^/AJ>BR>(+C29[#0$LOM)OIY5RS #<BQCYB/O -QDKP.16?96
M.J:_XCUSQ-/I=SI\+:0=,L;:Y $TO+.SLH)V_,0 ":?'X4OM5^"%OX9E7[+?
MOI<<6V3^"10" WMD &@"W;>/+I)M.DUCPY=Z7INI2K%:W<DR/AW^X)4',>[\
M<'@XJ>\\97;ZU>Z9H&@3ZN^GX6\E%PD,<;D9"*6^\^.HX R,FL+5IM<\;6.F
M:#)X;O\ 376Z@FU&YN0@AB6)@Q$3!CO)( &!T/.*L6$FJ>"M>\01/H.HZG8Z
MI?-J%K<6"*Y#NJAHW!8;<%>#TP: -S4_%<]OJ%KI6FZ-/?ZM-;"ZDMC,D2V\
M><9D<Y ).0 ,YP>W-0_\)Y9IX>DU":QNDO8[S^SCIHVM*;K( B!SM.<A@V<;
M>:YWQ#H,I\7Q>)+[0=3O;*]T^."XM["Y99[2922,B-UWKAB#@G!&>],U?P=%
MJ'A&UGT7P_?6KV^JKJ,FGW=VRSW0"F-OG\PE&*GC+#IVS0!U>F^+)GU.73==
MTIM'NUMFO$W7"S1R1*0'(=>A4D9!'<'FN#\>^+K_ ,0_#+4[F#PW=Q:+<B/[
M/?R3)N9?-3#F+.Y5..#R>1QBMS3?#NDZQ'J*6GAS6],N)=/FM5O-4F=MGFC:
M556E8GL20,<=:Q-5_P"$DU'X4GP>/">HKJ=M;0VTDOR"W98F7YD?=\V0HX [
M\]* .YDETX_%*& VT_\ :?\ 8[2+/YQ\L1><!MV9QNR<YK$/Q0G?0'U^W\+7
MTND6[NMW<F9%*!7*L44\R 8R>@[9X.-=]-O#\6H=4%N_V$:&]N9_X?,,ZMM^
MN 37/6?A_5H_@9J6BO8RC4I8KP);G&YB\LA7\P0?QH ZG5O%3VVJ6>DZ3IS:
MGJ-U;M=B,3")$A! WLY!ZD@  '\*R(/B.YT&]U.[T&XMW@OETZ*W^T1LTMR7
MV%">B@'')XP<C-8_B0W=IXJ\._98]42\M]'=97TB*.:X4%HP%D23*^7D-CC.
MX<=#5G3+O0Y/#&HZ'!X<U?5'BG$FJ6-_$JW3F4E_/(8@.21D;3GCC&* .VT7
M4-3ODF&J:*^FRQD;?](29) >ZLO/'?('XUJ5YQX;;6=#@\07ECI&LRZ-%%&V
MFZ9?RYG,@SO5-Q9E3[N V>AP*['4K_4(_"EQ?6EA*=1^R&2*TX+"4KPA[<-P
M?I0!P4>NZC_PGJ>(3>S_ -@S:JV@K;^8?*X0 2A>F3.K+N]#75ZQXOET_P 3
M+X>L=%N=1U"2S%W&(Y%1-N\J=S-PH&.O/4 "N3F^%"1_#S['#?:J=6BM1,D?
MV^0P_:P-^1'G;S)ST[YK<TBVU6\^(5GKM[I\MM'+X;2&;<!B.<S;FC^HYH =
M%\1(O^$>GU6[TJ>U:RU)=/U&!I%8VI+*"^X<,HWJ<CL?:M^[UZ.V\3:;H:0/
M+/>0RSNZD8AC3 W-]68 5SVB>&I+J+QO8:K:O'::KJ,IC+8^>)HD7</Q!_$5
M1^&$=_J,VH:WJV&NK=$T:)P<AUM\B1P?1Y"Q_P" T =/XE\3KH#6-K!93:AJ
MFH2-':6<3!3)M&68L>%51U/N*Y;0=1N;CXLZO<ZII[Z7+%H</FQR2K(H E<[
M@Z\%<>N#P>*T_&%GJ-GXI\/^)['3YM1BT\3P75M;X,OERA<.@)&2"O(ZX-9U
MKINI>(_&6NWUUI-YIFGZAH:V,+W.W>3O?)*J3M/S9P3G&.F<4 :$/Q ED@MM
M5ET"ZA\.W4J1Q:B\R;L.P5)&B^\J$D<YS@@XJKI_B?Q#/\4-9THZ/-)80);*
M!]IB @5F?]]C.3N&#M'(VUA:#X:LX;&PT/6_!NN37T!C@FFCO)&LW"D 2@F4
M+MX#;<9'0"ND5+[1?BEJ-Z^E7MU8ZO;6L4=S;('2%T+!O,Y!488'/I0!)<^/
MIA'?:A8^'[J]T.PD=+F_29%)V'$C1QGEU7!R<C.#C-6=8\;K8:Q8Z5I^ESZG
M=ZA9FZM!"ZJK@$#EFX48);<?3')(%<1I_A2WT*"ZT75_"NNZHPGE^SW-A=R>
M3<Q.Q8!AYJK&1NP00!QGG-=B-$GMOB1HUS:V;IIEKHLMJ'SD1G?'M3.<YPOZ
M4 +<>-;]-9DT2T\-W-UJT=G#=/"EPBQIOW;E:0\#!7' .<\# .,W_A:$\N@2
M:W;>%=0DL;,LNHL\J(;9E;#JH/,FW&21@>^<@:]AIMY%\4=8U)[=ULIM-MHH
MYC]UG5W)'X9'YU@VN@:JGPM\7::UE*+V[GU%K>'C=()&8ICZY% &]>7FE3>/
MO#I,$\MY<65Q+:W"S,L:IA,Y3H20PQGI69+\2KIM,U#4['PM>W5CILTT=[-Y
MZ1A1$Q#% >7X&XXP!G&<YJ:+1]0'B_P==FUD\BSTJ>&X?M&Y6,!3[_*?RJKI
M6AZG#\-/%>G26<BWEW+J1@B.,R"0OLQ]<B@#I[_7;P6-C<:+HT^J_;(_-0K,
MD,:(0""[,<C.>  >]<QK/CJ^N/AWX@U"PTR>UU73C-:W,+3)NM) F?,#=' R
MI&.M5-1L=6@M?"=M?Z;JUWHD.F+%>6FFL0_VD*@42@,I* !N,XSUJOI7A/4S
MX/\ 'NG1:,=-;4Y)&L;5G4C#0J%&02,YX/. <\GK0!IZAJQO?"6AS^)M%NH6
MDU.SCA5+T;G=B-LI*'IDG*FMK4_%US'KUQHNAZ)+J]Y:1K+=XG2&. -RJEFZ
ML0,X].]8&HKJ7B+PCX?ABT34;6XL=5L#/%<Q!"%C92[CDY4<\U:/]H^$/&FN
MZ@-%O]4T[6?)F1[!%DDAE1-A1U)!P< @]!TH O3?$+3XO!C^)!:712&Y6UN+
M0KB:&4R"-D(&>5+9P.OXU)8^,KN3Q-9Z-JOA^YTO^T(Y)+&62=)/-V %E95^
MXV#G&37*W7A76W^'>K>;8D:IJ^MIJ;64;!C IGC.TGH2$3)(]ZZKQ!IMY=>/
M_!]]!;N]K9M>?:)1TCWP[5S]3Q0!?\5>*+?PGI]K>7-M-<)/=QVH2 9?+YQ@
M=^F,>]9\_C#4+2"R@N/#LRZU?R.MKIJW4;$QH 6D>0?*BC(SUY( SFE\=Z;>
M:E#X?%G;O,;?7;.XEV_P1H^68^P%9GCSP[+=^(-'UX:==:G:VD<MO=VMG.T4
MP1\$.FUEW8*\KGD'VH TE\>6]KI&LW6L6$]A=:.%-W:!EE)#C]V48<,&Z#IR
M#G&*B@\9:R/$6G:-?^%7M)+]&EC?[=&X"*5WYX'S*&!*C/L37.ZMINE0?#OQ
M3=6?AV^L'NH%AQJLSM)<$'Y-H:1F!#,=HX);%2Z-J=G8^(]-N]>3Q4UX_P#Q
M+[&XUBTC2*)I"/E!B&-[%0-QZXZT ;NN>-M1T$7%]=^%[M=%M9=DUZ;B/>%W
M;?,6($DKGGJ#CG%6-<\9-I?B&WT*RTBXU+4+JT-S D4BHK -M.YCPH YR?8<
MDBO.M<T+6=9\-:Y9:CX:U;4?$KO-LNI91]ECCWDIY.7P/DP  N<DY]:[Z+2[
MX?$^PU(VS_8X]!>V>;L)3*AV_7 )H ?=>,K[^USH^E>'IM1U&W@CFOXUN4CC
MM2XR$+MPS'G ';G-<5IEW8#X7^)+O5["[>U;Q#,9+9)C%*K-<H "RG@@L,X/
M8UT@.I^$_'6O7O\ 8=_J>GZUY$T,MBJNT4B)L9'!88!P"#TK"D\.Z]/\+?$%
ME+I4L>HW>N&[2U#!CL-U&^01P0 #S[4 =GJ_B^:P\3?\(]8:+<ZCJ#6:W:".
M143:793N9N% V]><Y  J*R\?6;^$]5US4;.>Q;29I+>]M21(Z2ICY5(X;.Y<
M'@<TY=-O!\6I-4^SO]A.AK;B?^'S//+;?KCFN7U/3;G3_!/Q&-]9H%O;^:6V
M6<X$P9(U0K@YR6'RCNP% '0P^,M97Q#IFD7WA62UDU!6DB?[=&P5%V[\C ^9
M0P)49]B:9\2=?U?0=/TIM)M))6N-1@BDD25$P#(O[OYO[XR,]!WK$T;4K.P\
M0Z9=Z^GBMKHXL+&XU>TC2*%I,#;F(8WM@#<V<XZUT?Q%TZ^O_#UK)I]K)=S6
M.HVUZUO%C?(D<@+!<]3CM0!@^)]4OXO&7@.^FT6Y%\1?@:?%(DC[C&H W@[<
M="3G %;$/BM=7TSQ/IVLZ//876F6I:[M1<!O,B>-B"DBXZA6'L:9>1WNN>,?
M!>LPZ9>V]K;B^^T+<QA'AW1A5W#)QDCBH+S1=2D\2>.;A+20PWVD0P6S]I7"
M2@J/?+#\Z );7Q5%INB>%=.T/2)[NXU.P6:TM9;H+Y<*QJQWR-G) 8#H<UUV
MF75S>Z?%/>6$EA<-D/;R.KE""1]Y200<9'L>U<'<:;"G@KPOINN>%-2U#[-I
M\*F:RP9K.98U! VL'!X/*\<#-=%X$AUF#PRJ:VUR9O/E-N+MP\ZP;CY8E(X+
M[>M '':39V>KZAXLN=8\3ZK8M::Q/#"T>KR0+#$JH1A=VW )/48K1\.^.+JW
M\ Z+=:A%<:IJVH3R6UC%&H22\"NP60YP%&Q0Q8\=^]2^&?!&GRZKXEOM=\/6
M<T\VLS2VTUU;)(S0E4VE20>,[OUJ_P",=+OH]6\.^(=+L6O3HTLHDLHB%=X9
M8]C%,X!9< @<9YH N:+XJDU#5[C1-4TN72M6B@%PL#2K*DL1.W>CKUP>"" 1
MD5P_AJ73HOA+X'&I6T\ZRZI!%"(9C'LE:9PK'!Y4=QWKI-+@U'Q%X^3Q)/I=
MUIFGV5@]I;I>*$FGD=@68J"=J@*!SU)KG=+T'6/^%=>#],?2[J.[TO7K=[F-
MU VQI,S-(.>5P1S0!V&H>,+H:[=:/H.AS:O<V2JUXXN$@CA+#*IN;[SD<X'3
MN:NV'B477B+^Q+FPFL[IK".^C$K*=RD[77C(W*V >3U%<[ VI^#?%FOS'0]0
MU/3=7G2[@FL$61XY-@5HW4L"!\H(/3FF_$"YO;#0M)\96]DT.J::P#6CNI8K
M.!&T602"0Y0\?W: .KT'7H]?74)8('C@M;R2T21B")C'@,R^V[(_ UE^(/%>
MK:*;VXA\*W=UIUBN^>Z^TQ(64#<QC3)+8'KCH16GX5T4>'O"VG:5G=);P@2O
M_?D/+M^+%C^->=ZUI6J:G<^)[35O#VJZM?S23+I4GF@644!3$9&6"AAR3\I8
MF@#LM5\;P6,NA1V6G76I/K<,DMFMO@%MJJPSNP "'SDG@ TFD^-DN!KD>M:>
M^D76BHLMW&\JRJ(F4LKJR]>%/&.U8UAH>IQ7_P -'>SD5=,TV6*\)Q^Y<V\:
M@-_P($?A3=8\*:CK6M>.X5B,,.J:9;06L[_<>15DR/H"5S]: ,CQAXFU/7?#
M>ESS>&KNQTVYU.RDMKF6>-F*^<I4O&#E,CIU]\5ZQ<S&WM9IEADF:-"XBB +
MO@9PN2!D]N:\OUBZ\0>(_#&E:2/">IVUW:7=F]X\NQ8E$<B[C&0Q+CC/ Z9^
MA[[Q4NK-X5U-=!(&JFW;[,<@?/CC&>,^F>^* ,FT\8WZ^(-/TO6O#L^EC4MX
MLYFN8Y@SJNXHX7[IV@GJ15:?Q[>R7&L0:1X8O-0?2;AX;EO/2),*H;*EOO,<
MGY0.W)&1GF;/0I+KQ+X4U"P\,:O;?9+IFOK[5)-TS$Q,.<LS$9ZG@9(Q[=7X
M7TN^LI_&+7-L\8O-4EFMRW_+1#$@!'MD$?A0!:T_QM9:C>:!'%;RK;ZY:/<6
ML[$<.H#&)AV;:2?^ FM#3=>CU/7=7TV&!PFF-'').3\KR.NXJ/\ =!7/UKA/
M[&O-*^"VCW%Q";;5?#T::@J2$ JT1)="?]I"R_C75^ ;&:U\*Q7=VA6]U.1]
M1N0>H>4[@#_NKM7_ (#0!T]%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445SW_"=^%SJRZ6-;M3=M+Y
M(4,2ID_N;\;=W;&<T =#16-JWBS0="G:#4]4M[:<1K)Y3D[V5B0"%'+<J>!G
MI3H/%.AW6@OKD&IV[Z9'G?<!OE3!P0>X/(X- $M[H=I?ZWI>K3>9]ITWS?(V
MMA?WB[6R._ K2K!LO&OAK4M7&E6>LVLUZ=VV-6X?'7:W1L>Q-9>EZQJ%SX@\
M<6LM^L<.GO$MH\D8*V^ZW#$D#!8;CGDT =E4=Q#]HMI8?-DB\Q"GF1G#+D8R
M#V([5AVOB"RTOP?8ZKK>MVDL;PH6O@OEI.S#(*K[]@/RJ6V\7^'KO1I]7BU:
MV^P6[;)IG;8(VXX8-@@\C@]<B@"70?#MEX>@G2U:>::YD\VXN;F0R2S/C&68
M^@  '05K5A:;XR\.ZO;WL]CJL,J62>9<Y#*8DP3N(8 XP#SBL/0?B'I_BO0]
M4-GJ-K9ZA;I<NI(,@BC1BJS,,#(QM8CWH [FBL%/$%CI'A6PU/6M9M6CDACS
M>!=BW#,H(*+R?FZ@"K6F>)-'UG3IK_3M0AN+:'(E=3@QD#)# \J<=B* -2BN
M=C\>^%9M0M;"+7+1[FZV>2JL2'+ %1NQ@$@C )SR*WIYX;6WDN+B5(H8U+O)
M(P554<DDGH* )**P=(\:>'-=OVL=,U:"XN0A<1KD%E'=<@;A[C-1ZCX\\+:4
MTBWNM6T3QRM"Z9+,K+C=D $@#(YZ<T =%16;J/B#2-)TE=5OM0MX;%PI2=GR
MK[N5VX^]D=,9KF=!\7)X@^(U[:Z=J276DQZ5%,J( -DQE96SD;@< <'\J .X
MHK%U6ZN(?$6AV\6K6]K'.\PDM)(=SW>U,@(V?EV\D^M5]1\>>%M*=X[[6[6%
MXY6A="22C+C.0!D 9')XYZT =%16$OC3PVVM1:.NLVC7\I 2)7SN)&0NX<9Q
MVSFC5/&?AS1;B:WU'5K>"XA*AX227&X9'R@$GCG@4 ;M%<7XP\3E?!-MK/A_
M48WCGO+9$N(<.&1IE5ASGL2/45T&L^(](\/1Q/JM]%;><2L2G+.Y'7:H!)QW
MP.* -2BLH>)=%.E6VJ#4[;[!<R+'#<;_ )&8G &>QR".>E9\/Q"\)7$-U+%K
MUH4M<&4EB,9. 0"/FR>FW.: .EHK,TWQ#I&KZ0VJV&H036";M\^[:J;?O;LX
MVX[YQ5?1_%V@>(+E[;2]3AN9D7>4&02N<;ER!N7W&10!MT5S5U\0?"5FT:W&
MO6B&1B@^8G:0Q0[L#Y1N!&3@<&JOB3XA:1X:\2:3I-Y<P(+L2-/([']P@0E&
MP!SN88H Z^BL+5/&7AW14@;4-5@A-Q&)8DY9V0_Q;5!.WWQBL[Q3\0-)\/\
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MLK.5IX;.VBN9 !+-'$JM)]2!D_C4OV*T^TR7/V6'SY4\N27RQN=?[I/4CVH
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M?$V@Z@_C71M0>S$LEO;65JL;R(T95A_K6(494XQU45W\<$432-'$B-(=SE5
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MF":%4PP1C(H&U]V5]\UFZGIK:)8>#KBW\0V4VD1:G=S/J7V4/:PR2[C&=@?
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MTDMK/&LSA3(GD 90=6Y&,#)SQ7*V$,=Q\*/A_#/"'C?Q)$KQR+D$&>;((/\
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M4B6*PE BSN& Z_?W;NOO7DVGZ-96/[-]Y?P)*+B[TLF8M.[J<,<84DJOX 4
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MIB?^S&# CS/GYD\P_-C^\:L1^+=$DT_2+TWH2'5W2.R+HP,K,,J,8X/UK:H
MS;[0[/4-5TO4IQ)]HTQY'M]K8&70HV1WX-9-WX%T^?4[F^M;_5=->[;?=1V%
MV8DG;&-S#!PQ'4K@FNHHH RSH%D=<M-8/FF[M;5K6,F0D;&()SGDGY1SFBU\
M/V%K?ZO>(C-)JS(;I7;*MM0( !V&T5J4A(4$DX Y)H Q/#?ABV\+VKVEE>W\
MUKA5B@NI_,6!1G"IQD#GOGH/2K=EHEGI^L:GJD D^TZDT;7&YLC,:;%P.W%4
MX_&.A3Z;IFHP7HFM-3NA9VLL:,0\I+#'3(Y5N3Z5>MM9LKS6;_289&-Y8+$]
MPA4@*) 2N#T/W30!C77@33YM1NKRTO\ 5=--X_F74-A=F*.9^[$=F/<K@FK.
MM^$-/UN>TNVFO;._M%,<-[9SF.94/52W.X'T8&M"YUFRM-9L=)FD87E\DCP(
M%)#", MST'WA5^@#GI_!NEW?A]-'NWO;F-)?/2YFNG:=)<Y$BR9RK GC&![8
MIVB>$;#1+^;4?M%[?ZC-&(FN[^<RR",'(1>@5<\X Y/6M^J6KZM9:%I-SJ>H
MS"&TMTWR/@G Z< <DDD #WH H6'A/2M.\37_ (@MXY%OKY=LN7R@^[DJO8G8
MN?7 JMJ'@BPO-6GU*VOM3TRYN0/M)T^Z,2SX& 6&",XXR,'WJQIGBW2]3O+>
MR!N;6_N(FFCM+RW>&4HIP6VL.G\ZW: ,EO#MB^IZ3J#&=KC2H9(;9FE+?*ZJ
MK;B<ECA1R3FJVM>$K'6=0AU(7%[8:C%&8A=V,_E2-'G.QN"&7/."#CM6_5+5
M]5M-#TFZU2_<QVMLADE95+$*/8<F@#,O?!VF:CX>BT:\EO9XX91/%<R7+-<)
M*"2)%DZA@2<=NV,<5'I?@G3M+UF+6#=:C>:E'"\'VF\N3*S(Q!P1T &WC '4
M^M=%'(LL22(<JZA@?8TZ@#,UW0;#Q'IWV+4(W*+(LL4D;E)(I%^ZZ,.58>M4
M]$\)6&B7\VHBXO;_ %&:,1->7\YED$8.0BG@*N>< <GK6_10!G:%HEGX=T>+
M2[ .+:)G9?,;<<N[.>?JQHNM$L[O7=/UB4/]KL(Y8X<-A<2 !LCO]T4MSK-E
M::U8Z3-(PO+Y)'@0*2&$8!;GH/O"EU76;+14M7O9&1;JZCM(L*6S)(<*..G/
M>@##U+X?Z5J%]>7*76IV2WQS>P65VT45R<8)=1W(X)&">]:<OAC2Y'T8I 84
MT=]UG'$=JI\A3!'<8-;%4-(UG3M>L?MNEW27-OYC1^8H(&Y3@CGWH ;=Z)9W
MNMZ;J\P?[5IRRK!AL+B0 -D=^%%9>H>";"\U:?4[:^U/3+JY %R=/N3$)\#
M+C!&0.,C!]ZZ6H+V[AT^PN+VX8K!;Q-+(P&<*H)/'T% %!O#EB^I:1?L9VGT
MF*2*V9Y2V5=55MQ.2QPHY)S5>U\)V5CXEN-;M+N^@>Z?S+BU2?\ T>5]NW>R
M8ZXQT/4 U/'XGT=QHW^F*K:S'YE@C*09AL#^G'RD=<5KT <K#X!TZTO&DL=0
MU>RM&F\YK"VO6CMRY.3A1RH)Y(! ]JFU7P5I^IZTVKQW>HZ?>R1B*>2PN3#]
MH0= ^.N.Q&#[UTE% &5X?\.Z?X9T]['3$=+=YGGVNY?#,<GD\X^M9NH^!-+U
M'7+C53<ZC;27:)'>0VMTT4=TJC $@')XXX(XKIZ* .=B\$Z-!HNEZ1%'*MII
MEXM[;*'Y6179QGCD98\5HRZ)9S>(;;6W#_;+>W>WC(;Y=CD$Y'KE16C10!QD
MWPRT.9;VW%QJ<6G7C.\NG17C+;;VZL$'3GG&<9[5IZEX.TS4K/3H2]U;3Z:@
M2TN[68QS1#:%(##J" ,@@@^E=!6 GC+17T2VUA;A_L5S="TC?RFR93(8\8QD
M?,",T ))X/LKGPU>Z%>WFHWEO>Y\^6YN2\IZ=">%'RC@ "M]5"(JCH!@4M%
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MHUT)/LBF(@(V&_=LK+S]5%2W>B6=[KFFZO,'^U:>LJP8;"XD #9'?[HK1HH
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M,N"N-HK>HH P=&\)V>CZE+J;7E_?W\D(@^TWT_F.D6=VQ<  #/)XR<5O444
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M]+NTE6/RUW)\LZ]3W*L,DX!ZU9\$ZI?Z[X<35[X@"]FDFM4";=EN6(B!]25
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M0],\7Z:;2QN]5TJYTVU 3S_LT@N9D P WS;0W3+<_2KOC+P_)XH\+76D13I
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ME*'RED61U,I7TVH3CU]JZ[2] DT_Q=K^M-.CQZFMLJ1A2"GE(RG)[YS7/_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEAZK7,HNQUE%,AFCN(4FAD62-QN5U.01Z@T^K,0HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI?4]:G%25+WK.VW<[WX;WAM_!5Q/>2%;>WGD*LW14"@G]=U99\;^)]=NYO\
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M=Q%XFCU#P==:W8 !XH)'\N3G8ZKG:<=>WX&J'BV[LF^',KHZ&&:&,0 'J<C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\?\ WV*^/:EMK:XO+A+>U@DGG<X2.)"S,?8#DTOJ_F'UGR/KW[3!_P ]X_\
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MC_WA_.OL&+_4I_NBOCZ'_7Q_[P_G7V#%_J4_W17+B.AU8;J/HHHKF.H****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?$$*7'AS4H91NCDM
MI%89QD%3FO/?^%<^&/\ GP;_ +_O_C7HVM?\@.^_ZX/_ "-8==-+X3FK?$<K
M_P *Y\,?\^#?]_W_ ,:/^%<^&/\ GP;_ +_O_C6)8ZMJ#_'/4M+:]G:P2P#I
M;%SY:MMCY"],\G\ZZ?Q7XKL_">G1W%Q%+<3SR"&WMH1EY7/85:F9N'0I_P#"
MN?#'_/@W_?\ ?_&C_A7/AC_GP;_O^_\ C4.B>/X+^;4;75=-N='O;"W-U-!.
M=V80,E@0.<<=N]83_%V00VETGA6_:ROI3%9S&909F!QC&.#GWI>T7<?LWV.C
M_P"%<^&/^?!O^_[_ .-'_"N?#'_/@W_?]_\ &H-?\;W^CRK%;>%-4OF%NMQ,
MZ#;'&I'(W8.2,'(P.E<C\1O$UMXF^$UIJ^GF6))+Y%9&.&1@'!!Q_GI0YV!4
M[G:_\*Y\,?\ /@W_ '_?_&C_ (5SX8_Y\&_[_O\ XUT=E_QX6_\ UR7^0J>J
MNR;(Y7_A7/AC_GP;_O\ O_C1_P *Y\,?\^#?]_W_ ,:ZJBB["R.5_P"%<^&/
M^?!O^_[_ .-'_"N?#'_/@W_?]_\ &NJHHNPLCE?^%<^&/^?!O^_[_P"-'_"N
M?#'_ #X-_P!_W_QKJJ*+L+(Y7_A7/AC_ )\&_P"_[_XT?\*Y\,?\^#?]_P!_
M\:ZJBB["R.5_X5SX8_Y\&_[_ +_XT?\ "N?#'_/@W_?]_P#&NJHHNPLCE?\
MA7/AC_GP;_O^_P#C1_PKGPQ_SX-_W_?_ !KJJ*+L+(Y7_A7/AC_GP;_O^_\
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MWTVU;$]WOC&%[LJ;MS*/7BI+BYT^3QMI*XN6NI;*:2%TE(BV97.Y<\GD8/\
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M )\&_P"_[_XT?\*Y\,?\^#?]_P!_\:ZJBB["R.5_X5SX8_Y\&_[_ +_XT?\
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M1_PKGPQ_SX-_W_?_ !KJJ*+L+(Y7_A7/AC_GP;_O^_\ C1_PKGPQ_P ^#?\
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M\<Y'3T-=%1[9=@]B^YR'VB/_ &_^^#_A1]HC_P!O_O@_X5U]<8?B;HK^-O\
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MUB_TN..X$]B(S*SPLL;;QD;6/#>^.E'MEV#V+[F!]HC_ -O_ +X/^%'VB/\
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MVH]LNP>Q?<Q/M$?^W_WP?\*/M$?^W_WP?\*Z^BCVR[![%]SD/M$?^W_WP?\
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M]1T^VO85D6*XB65%E0HP##(R#R#STH]LNP>Q?<YC[1'_ +?_ 'P?\*/M$?\
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MM=V)1%ME66-F'EJ!N4J0.2Q)[UH2:WJ0UOXAP"[?R]-L8)+-<#]RS0.Q(^I
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M:M/.42.-51 JMMR6Y;' 'O5N#5O%4OAWQ-::,=6NY+0P/IUW?V1AN'C<_O5
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M/WBZ3PYHRZIJ#VB*(WE$:1KLA)9B2,] ,9')J2CW^BO*]-^,UO+\+KCQ9?V
M2Z@N39_9(GXEFP",$]!@Y/7&#UJ;PM\2]7O/%EEH'B/2[&UEU&%I;26RNA*
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M@9 <@D'@'D8Z=* /3Z*\I@^,$G_"N=9U^\TZ*#5M,O/L;V.\X,A8 <]>[?\
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M  @@;CSCM4]]X\=E\,MH>G#4/^$@CD: 23"+9M0/\QP< 9.>I&#@$T =K17
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M,RC:3R2>>AZUJ6'B;6+3Q)9Z'XETZSMY=0C=[*XL9VDC=D&6C8,H(8#G/0T
M==17&^'/%6M^)=3N!;Z1;0:997T]I<W$TYWN49@/*4+ST4DD@<D#.*N^(_$E
MWI^J:?HFCV45YJ]^KR(LTICBAB3&Z1R 3C)   Y- '2U0L-<TG5+FYMM/U*T
MNI[4[9XX)E=HSS]X \=#^5<Y:>*-7NEUK1KK3K6W\0V$ F1%N&,$\;9Q(K[=
MP&0005X('K5+X.QW:?#O3#<6EG#$T*F"2!RSRJ223("HP<GL30!W]0VMY:WT
M GL[F&XA)*B2%PZD@X(R..""/PK@/!^J>*KSQQXEAO(+(V4-[&DJ_;)'-O\
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M1) [W'&!M"LV#G![#K]*]%HH \%3P#X_\-Z-KG@W0[*PO-$U69F2_EG"-"C
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M74HH&#HCQ!P0Q'J2?QD%?0M8NA>$M \,M.^CZ7!:23G,KIDL_P!6))Q[5M4
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MV)VMUXJ;3O">KH/'$IT>STY-8TZ."RM+:52JLL4J;3@  Y9<\8YX)QFO2Z*
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M34UC9DE,2S6TB+M./,X*, #UR".E=OX>L8]/T2W@CTFVTGJS6=L5*1DDGJH
M)[G Z^M:E% 'C.H>"O$5[X<UW2Y?#-I=ZU=O,?[=N+J-C*A<L@0'+H=N%"_*
MHQG-=9?Z7KNB>,D\0Z3IBZI#=:?'97=JMPD4D;(Q*NI?"D<D$9]Z[JB@#S1/
M"_B*Z\/^/4N[*"&]US+6L,=P'7F *%+''((P20!D''%;.L^']1O+7P8D,*LV
MF7\$]UEP-B+$RDCUY(Z5V5% '+?V+??\+,NM:\M?L,FBI:*^\9\T2NQ&.O0C
MFN<T_P 'ZU;^"_ FFR6Z"ZTG4XKB\7S5PB+YF2#G!^\.!7IE% ',2:->M\3X
M-;$8^P)H[VADW#/F&96 QUZ \UB:+HFL:)\.K'1[KPY:ZN?.G^UV4EQ&/D:5
MW4KN!1CRIP2*]"HH \L3P/K-UX \5:/';#3H=18-IFF2W/FBV"A25+ D ,RD
MX!(7-;6JV>O>)K;PU<3Z*VGSV&M0W-Q!)<QOB)48%P5.#RV,=?:NYHH XKQU
MHVI:EJ>B7$6E#6=*MFE-WIAG6,2,0/+<AR%<*0W!]:S]%\(:IY7C:.YT^STQ
M-<A2.UAMY T<0\@QX. .02,\8SG&>M>BT4 >:C0O$>J>"M%M)-)33]7\.S6L
MUJ)KE'BNVB4JPRA)56&>HSDBM*&PU[Q+XOT?5M7TD:/9:.)9(X7N4FDGFD79
MGY. JC/?)/:NXHH YCP1HU[HFG:G#?1B-Y]5NKF,!@V8WD+*>/;M5?Q+I.JP
M^*-,\4:+:I?3VL$EI<V32B-I87(8%&/ 8,N<'J.XKKZ* .+T71M7O?$.K^)M
M8M$L;BZLUL;2R642-'$I9B78?+N+-T'0=S6EX$TF\T+P-H^EW\8CN[:W$<J!
M@P!R>XX-=%10!Q>D6&M:)X\UU_[+-SI>KSQW"WJ3H/(VQ!65D)W'E1C&>M4+
M/PIJ\/P=U3P\\"#4KA+Q8X_,7!,DCLGS9QR&%>AT4 >:Z]X)F?5M(UMO#]EK
MPATU+"[T^X*!EVG<LD9?Y<@E@02,@UU?A/38=/TV7R_#=KH!EE+&VMV1BP
M#,4&W/7@$_6M^B@ HHHH J:I_P @B]_ZX/\ ^@FK*?ZM?H*K:I_R"+W_ *X/
M_P"@FK*?ZM?H*K[)/VAU%%%24%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 4M7_P"0->?]<6_E5VJ6K_\ (&O/^N+?RJ[5/X5_78E?$_Z[
MA1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>)OB)X(DT:X:\@@FNC+/'&WEH6MVPI8C&[@\=1WH [[4M9LM)FL8KR1HS?7
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M _F2O*S["H(Y7Y@=PXXZYH ]7UKQ/INA?9DN6FFN+K/V>VM(6FEEP,DJJ@G
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MUQUH D(R,&BD)"@DD #J37)7OC>&7X<7OBO2$#^5:R3Q17 YRI(^8*>F1ZT
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ME5VJ?PK^NQ*^)_UW"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_$T?V?)_P!!&\_-/_B:++N%WV+M%4O[/D_Z"-Y^:?\ Q-']GR?]!&\_-/\
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M[15+^SY/^@C>?FG_ ,31_9\G_01O/S3_ .)HLNX7?8NT52_L^3_H(WGYI_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>VSW4(W2P+*I=!ZLN<CJ.OK4*Z[I#V#WZZK8M9HVQ[@7"&-6XX+9P#R./<4
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M3X_L1NQ.3)<%9-OV>W5D5Y3P<X+KQQGGFNIDGBBV>9*B>8VU-S ;CZ#U/!H
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M^E:]O<074*S6\T<T39VO&P93VX(H DHKE_&GBN'0?#>KSV-[9-JUG;&9+9Y
MS<=R@.<5OVUW'+';J\L8N)81)Y>X9(P,D#KC)H LT5&D\,LDD<<J.\9 D56!
M*'&<$=N*@MM4T^]N);>UO[6>>'_6QQ3*S)]0#D?C0!;HK&\3>);+PMI7V^](
M*F6.)8PX5F+NJ9&>PW9/L*T/[1L?L)O?MMO]D R9_-7RQSC[V<=: +-%06EY
M:W]NMQ9W,-S W22&0.I_$<5DZKXLTS1]?TS2+N:-);X2D.TJJ(@B[LMD\9S@
M4 ;M%<JOBDQ>.-2TV\N+2#2[73H+I9Y&"_,[L#EB<8PHQ72PW,%Q;+<PSQRP
M,NY94<,I'J".,4 2T55LM3L-25VL+ZVNE0[7,$JN%/H<'BI9;F" @33QQE@2
M [@9 &2>?0=: ):*H?V[I!L#?C5;'[&&V&X^T)Y>[TW9QFK375NMK]J:>(6^
MW?YI<;-OKGICWH EHJG;ZMIMW:/=VVH6DULF0\T<RLB_5@<"J'A?Q1I_BO2(
M;^RD4&3<3 9%+H Q7) /&<9_&@#;HJI:ZII]]/+!:7]K<30G$D<4RNR?4 \?
MC2/J=BLD<(OK7SY69(HVF4%V7J .I([XZ4 7**R-&U&Z?P[#?:W+IT,^UFF>
MUFW6X&X@$.WMC/OFI9M7MIM#O-0TR[MKI889&62*02)N52<9!H TJ*QO".J7
M&N>$-(U6[""XN[2.:01C"[F4$X'I5R?6=+M=GVC4K.'S',:>9.J[G!P5&3R0
M>U %VBHKFZM[*W>XNIXH(4Y:25PJK]2>!3;>^M+NT%W;74$UL02)HY R8'4[
MAQ0!/15,:MIINXK0:A:&YE4/'")EWNI&<A<Y(QWIU[J5CID2RW][;6D;' >>
M58P3Z9)H M45!+>6L%H;N6YACM@H8S.X"8]=W3%);7UI>VHNK6Z@GMSDB6*0
M,G'7D<4 6**IKJVFM=16JZA:&XF3S(X1,N]UQG(&<D8[BG6NI6-[+-%:7MM/
M)"=LJ12JYC/HP!X_&@"U15&76M*MVB6;4[.-I6*1AYU!=@<$#)Y(/%96L:[=
MV/C?PUH\(B-MJ279G+*2P\I%9=ISQR3F@#HZ*RM)N]0GDU/^T?L"QP73I;FU
ME+'R@ 1YF?NOSR*M66JZ=J1D%A?VMT8SB003*^P^^#Q0!;HJE/K.EVNS[1J5
MG#O<QIYDZKN<'!49/)![58N+F"SMWN+F>."%!EI)7"JOU)X% $M%5[>_L[NT
M^UVUW!-;8)\Z.0,F!U^8<4EEJ-CJ432V%[;W4:G:7@E5P#Z9!H LT5#=WEK8
M6[7%Y<PV\"_>DF<(H^I/%5+W6K.UT"YUB.X@FM886E61)04? X ;IR>* -&B
MN5\ ZIJFN>'H=6U+4[&[:\CCF6"TAV"UW#<8V.XEC@CK@\5<T;Q=I>MZIJ-A
M;7$7G65QY 'FJ?..Q7+( <D#./P- &]17)>"_%\>L^%M+O-7O+&WU&]:54A\
MP1E]LKH-JDY/"C\:Z6\O[/3H//OKN"UASCS)Y BY],GB@"Q13(I8YXDEAD22
M-QN5T8$,/4$=:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !VXKY5\.^'_B'%\7K>>>VU);Y;T-=W;JWE-%N^<E_NE"N<
M#Z 5]544 %%%% &7XCUB/P_X:U+5Y<;;2W>4 _Q$#@?B<#\:^6VB\36GPZLM
M6_X1R9([?4QJXUHSJ=S,0H^3J 2$YSV]Z^K-4TNQUK3I=/U*V2YM)<>9%)]U
ML$$9_$ TR31-,FT0:+)90MIHB$/V8K\FP8PN/08% 'AWB?4=)\3_ !?\,2>)
M957PU<Z8ES:I/)MA+.K'YCP =V ?H :E^*Z:+9^$_#-AH,D,?A*74W%ZUB^Y
M,AAG+ G/_+0_\!'H*]<O?!'AG4-'MM)N]%M9;&UR((F7_59Z[3U'X&IHO"7A
MZ#06T./1[,:6QRUMY0*,?4^IX'/7B@#S?Q=;>&M'^%WB9O !L!.T,'VMM/F$
MC"(L!R03@;=_X9-<!?V_AW3=)^'=YX/EA_X2266+SQ;R[I&<A=PD&>/G)&#V
M)'2OH71/!_AWPY#/%I&D6MJEP-LVU<F0>A)R2.3QTJ#2O ?A70]3.HZ;H5G;
M79SB5$Y7/7;GA?PQ0!Y=IFL:;H/QY\<3:M?064;V(V-.X0,=L1P,]3CL.37(
M:1_R;#K_ /V%U_G!7T+J7@OPWK&KQ:MJ.C6ES?18"S2)D\=,CHV/?-*/!WAU
M=%N-'&D6PTZXE\Z6V"_([\'<1Z_*/RH \,U/P]IGAS6/A-?Z5;FWN]0DA>[E
M#L6E8F$DG)_VV_.K]IH/AB#]HW6[+5+:TAL1;)/;).^Q3.1"V5)/+$ESCZU[
M3<^%]$NSIAN--@D.EX^P[A_J,;<;?^^5_*H=8\&>'/$&H0W^JZ1;W-W#@1S,
M"& !R 2",@'UH \>MO\ D>OB[_V"Y_\ T"N-OO#6E0? #2O$<=KC5Y=0*-=;
MVW;0TBA0,X PH_*OIE?"VAK=ZC=+ID GU*,Q7CXYF4C!#5%)X-\.RZ#%H3Z1
M;-I<3^8EJ5^16R3G'U8_G0!Y%X\*GXI^'+J[L+?7P^C;FTNXF2,+]X;\O\AR
M3TZ_*?05V'P:\''POX9N)[N&T34+V=G?[/()/+CXVQE@2#CD_P# JS/'W@35
M]6\9VVJ+X?LO$.CQ60MHK"2\^RM"V<[MPQG\SU/'>M+X5^ ;_P (W6L:A>1P
M6*:@Z^3IEO,TJ6ZKGJ[?>;G'_P"O  .,\3V_B&Y_:$O4\,7L%IJ8TP,CS(&5
M@$&5P01D\<UG^$9;A_AGX^UZ&\N9?%LNY+\,H5X5!.2H'3@OSQ@K@ 8Y][&@
M:2->.N"QA&J-'Y1NL?.5Z8S3+/PWHVGZI>:G::=!#>7F?M,J+@RY.3N['F@#
MYV\'>'[K48_"5YI4OA6QN+>ZCD\Z*^9;R?!^='0]20#QCZ<&K7BVRT_PQXJU
MW7KJ+0?%.E7E_P#Z1!+<XN[1]Q)1<'(P3CC.0!D"O;[/X>^$=/U9=4M/#]C%
M>*V]9%CX1O55Z*?H*2;X=^#[C5O[4E\/6#7A?>7,?!;KDK]TG/<B@#R/QAI7
MAN;XZ^&Y=1M+>#2=3L!/<BX/EH[E90NXYX/$8_ 59\?W.A:EXZFT.TT;01<V
MFF*)-2UBY=(EB"AE6-5(W, XP>OX"O8-?\)Z#XH2%=:TN"\\DDQF0$,N>N",
M''M5>^\"^%M2N[2ZO=#LYYK2-8H6D3.$7[JD=& ]\T ?/%O:QZA^S9<W5Q%Y
MTVFZJ4MG.?W*N8MP'L2Q_.M_QS%IVG_!70U\-_9UL+NYMVU0V\A96D\H'$F"
M2.0,CU KW*U\+:%9Z/<Z1;Z5:IIURS--;!,HY.,DC\!^50Z=X+\-Z5I%SI-G
MH]LFGW3;I[=E+I(?4AL^@_*@#ROP)X?O(/'J:K:2^%[6S.FO'/9Z+>M)YB8^
M5RIS_$5YSV]:\[TOPWI-Q\ ];\0S6N_5+;4$AAG+ME$W1?*!G'_+1NW>OI;0
M_!'AGPW/+/I&C6MI-*I1Y$4EBIZC)R0/84Z+P9X;AT*;0X]'METN>02RVH7Y
M&;CD_P#?*_E0!X7>Z#IWA_6?A'J.F0&"\U-H9+R;S&9IF8PDDY/?S'_ U3U"
MVO-;^)GC2WU&'0);KS6BA.N7+PF*'+!##@XSMV'/T(ZFOH:?PMH=R=+,^F6[
MG2L?8<C_ (]\;<;?^^5_*J^N>"/#/B6Y2YUC1K6[N$&!*ZD-CT)&"1[&@#P[
MQKI5W9?#/X?Z9J5Y!=N+XH)[68NC1,?DVOQG"D 'VK;M?#FDZ!^T/;:-I=FM
MOIUUI+K-;JS%7#(^0<G/.T5ZY=>$] O+*RLY])M6MK%@UK$$PL)'=0.E3OH&
MDR:]'KC6,)U2./RDNB/G"\C&?Q/YT >*_!S2/#L'CKQ/'<PVL>I6.HLFG)(^
MV1%S*K! 3SP.>M>Q^&M+T32=.F@T$Q&U>YDDD\N8RCS2?G&<G!!XQVJ,^#/#
MA\1+X@_LBW&JJVX7*@AMV,9(!P3COBK^E:-IVAVSVVF6D=K#)*TS)&, NQR3
M0!YK=KK/BCQ3XLN-/T:TU'3_ "#H2//>^1LVC=-M&QL_.X&>/N"J-U='Q#X"
M\$V6J+NN;?Q#!IFH1[CDO&)(V!(]0 3_ +U>N:?IMGI5L;>QMT@A+M(50=68
MY8GW).:J?\(WHWFF3^SH-YO!?DX_Y> ,"3_>QWH Y2WTVQT?XSVT6FV<%G%/
MH,AECMXQ&KE9D"D@<9 )&:TO&EW:M>Z)I#:+9ZKJ%]/(UFEZ0(8C&A+.QP>@
M/  R<]NM=(VG6;:HFIM;H;U(3 LV/F$9()7Z9 -5M:\/Z3XAMXX-6L8KJ.)_
M,CWY!1O52,$?@: /)4DU/1K;XIP6#6<5S;VUM,L>F(4BB=HG\PJ,G#;5R3QR
M,\5Z%X?T+PU8Z#I5WHMAIYE6VW65R(U\R1C&<G?U)(SGGUK9TSP]H^B^=_9N
MFVUKYR*D@B0+O"YQGU^\WYFJ6G>"/#.D:F-1L-%M+>Z!8HZ+]PGKM'1<^P%
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M;1AT7YMK$%@3U.2J\GT% 'DEIX?TF7X :MJ<FGP/?E;N47+H#(K)/($VL>5
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MN30!Y3X;O+2/X4^#=.FT>VU6[O[ATLX+LA85D5I&+N2#P!GH"3VJ;1()M/\
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M[QCXUT_1XXXM-.AB>[AA $<5T0X& .%+( 3CK@&N]O?#6BZCHT.D7FFV\UA
MJK#"R\1A1A=IZ@@<9'-+IOAS1](TR73M/TZ"WM)MWFQH/]9D8)8]6)'&2: /
M*KG0]+L/@]X4U:UL8(M16739_M80>:79XP27Z]"1C.,8'85TUC96&L_%SQ+'
MK=O!=2VEK:KIT-R@=5@9"9&13QR_!/T%=G)H6ERZ3!I3V436-OY?E0$?*FP@
MICZ8&/I5?6_"NA>(GB?5M,@NI(01'(V0Z@]0&!!Q[9Q0!R/B&QTQ_&G@O1I8
M+8>'MMRT-LJCR'N$4;%(Z' +$#US4*6]MIOQ%\36&CQQPV#Z")[V"  1I<[F
M"G X5BF2?7 -=M<^&-#N]$CT:?2K5M-BQY=OY8"ICH5QT/)Y'/)IVE^'-'T2
MPELM-T^&WMYB3*J#F0D8)8GECCU- 'D,_AW28_@OX6OH[&*.^>>P9KI!MF)=
MU5OW@^;[IQUX&,=!78/I.GZ'\7- 32K*WLDN-*NHY4MXP@=4:,KD#KC/6NQ;
M0-*;2;?2VL838VY0PP8^5"A!7'T(%3R:=9S:E!J$ENC7D"-'%,1\R*V-P'UP
M/RH \J\-:)X9N? 7BJ]U:RLI#]MOQ<7$J*SH%D;;ACRN,Y&,<G/4U-HLEY+J
M?PGDU N;EM-O"Y?[Q_<1X)]\8K7\-?#72A:SS>(=$LYKXZA<3HS8;<C2EDW8
MX;@]&SBNSOM%T[4KJQN;NT26>QD\VUD.08FZ<8_ETH \XL]2L-*\.^/[C4K$
M7]LWB*6(VIP!*SB%54D\ 9(R3T%%I9W6D_%OPXLMIHNGR75A=));:6I&(U"L
MHD.!NYZ':.A_#T.3P[H\ME?V<FG0/;:A(TMW$RY69SC+'W^4?D*KZ9X/\/:-
M/#/I^DV\$\.[9, 2XW#!^8\G@ <F@#SK2O#VCZAX-\?WMYIUO<77]H:HJS2H
M'9 K,5VD_=P3GC'/-2P>5J^I?#6SUW;-ITVC_:$CGYCGNQ%'C<#PQ"EB >YK
MTV'1M.M[.[M(K.)+>\>22XC XD:3[Y/U[U!>^&M%U'1H=(O--MYK"!56&%UX
MC"C"[3U! XR.: .)^(UE:Z;HNFV6E6>G06-WK<*ZC$?W,#Y4D";8#A21'GCT
M]:T]!\-ZO8^,AJTUIH>G6S636\UOILCGSCN4HQ4HH^7YAGKAL5T%IX5T&QT>
M?2;?2;5;"X),T#)N$I/=LY+'@<GT%)HOA30O#TLDNE:;#;2R*$:099BO]W))
M('MTH YG7K>VU+XN:)8:Q''+IRZ9-/9PS &.2Z#J&X/#,(SD>F2:R!8V,6L_
M$/2;&V@;1DT^.>2V" PQ711R=J] <*C''<"O1=9T'2O$%HMMJUC#=Q*V]!(.
M4;U4CD'W%)I_A_2-*TJ32['3X+>RD#"2)%X?<,,6/4DCN>: ,CX<65I9_#W0
M3:VT,!GL()93%&%\QS&N6;'4GU-8?P_T;2H/%'B^2+3;*.>UU8K R0*&B0PI
MPIQE0<GIZFN_M+2WL+."SM8EBMX$6.*->B*!@ ?A6>?#&BGQ ->_L^(:H!C[
M2N0QXV\@'!.#C)'2@#Q^U\/Z2?V=[[5#I]N=0,=Q,+HH#*KI.X4JW5<8' P.
MOJ:Z'5%U'5/BA;0-9Z5>F/18YK.'5)&6/<S'S70!&!?A0>X'UKT-?#^DIH3:
M(MA"-,965K;'R$,2Q'XDDTS5_#6C:];0P:GIT-RD!S"6!#1_[K#!'X&@#,\#
MZ'?Z#I^H6][]AC26^DGM[>R=FBMT8+E!N48&[<<8P-U=15+2])T_1+%;+3;2
M*UMU);9&,9)ZD^I/J:NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7)77Q)\.6MU/$);RXBMG*7-U;6<LL
M$##J'D52HQWZXK6\537-OX0UJ>S+"ZCL)WA*]0XC8C'XXJEX M[2W^'N@1V:
MIY#6$3_+_$S*"Q/N6))]Z .BCD26))(V#(X#*PZ$'H:=7"ZL][XB^(;^'%U.
M\T_3;+3UNYOL4OE2SR.Y51O'(4!3TQDFL&_UO6-)\,^/]'.J7,\^A11R6=^[
M?OMDJ;U5F'5EP1GJ<B@#UBBO+-6LM;TO5_"\MOXKU4S:U,;:\\QE:,!HR^Z*
M,C;&1MP" ??/?1T9[[1/%WB30?[5O[ZTCTV*]MVO9C+)"[;U8!CS@[0<=J /
M0J*\;CCUM/A);>-?^$JU=M6M[);L*\P^SN%_@:,##9 ZGDDYSVKI_$=]:ZG>
M6,']H^(A=RV:SC3-$?8ZAO\ EH[@#;Z#<P''0\T =[17C\?B37I_A783C4;B
M#4X]<CT\W,@4R%1<;/G .&., C.#CWK>CM;WP[\1M)TU=<U6^M-7LKGSTO;C
M?LDCV$.F -A.XC"X'M0!Z%17EIU_6(_!,_AYKZ;_ (21-5&BK=$_O#N;<LWK
M_J"6SZBNM\<KJ$/@34Y=)N9H;ZT@^T12*QW-Y9#E2>^X*0?7- '2UGZSJRZ-
M9+<O9WMV&E2+R[.'S7&XXW$?W1W-<'=>++R[\;:1J5E=R+H*"TMKB$'Y7>[1
MV5C_ +O[C_ONJEYKNK2^#[S78M0N$6]\21QVA5R MLLZQ;1Z!MK$^NZ@#T[^
MT+3^T_[-\]/MGD^?Y/\ %Y>[;N^F>*HZ3K\.KZIK%A'#(CZ7<+!(S$8<E ^1
M^!KB;C0C=_'&8'5M5B']BI<@17.W'^D$>7T^YQG;ZYJ+2O#\VO>,/'"?VWJ>
MGPK?QA5L)?)8N8$^9F R<<87IUSGL >I45R_PYU:\USX?:-J-_)YMW+"1)(1
MRY5BN3[G;FN%\9:Q);V6L:UH6L^)[V[T^9G\Z)E73X2K<Q%3M610/E. QSWH
M ]BHK@-:EU'5OB#H^DP:O>:?8W6D2W$Z6K ,Q#IC!/W3SC<.<9 QG-9=N-?7
M2O&NB:?K%_<7>BW4<VGSSREY6!C67RF;JP/*\_WJ /4ZQ/$_B-/#EG:N+.6]
MNKVZ2TM;:)@IDD;) +-PHP"23Z5A6_B&3Q/XI\-II=S)'8?V>VJW:HV-X<;(
MHVQ_M%R1_L52^)VE_;]5\'G[=>V^_6$AQ;S;-N8Y#O''##& ?0F@#K=,UR6]
MU!]/N=)OK.YBMTGD:1 T(+?P+(#AF'?%;%<''?7UOXS\2Z<+ZYDM[/1('A$D
MF2KXD!?_ 'CM&37+,^MV?PUT/QH_B759M1'V-GA:;%O)&[HA1HP,,<-DL<DG
MG(Z  ]EHKA?%LMK=ZZ-/35/$DEXEN&_L_0W$?EY)Q([\ 9Z ,^..E<W%XDU^
M_P#ACX5N1J4UMJ5QK<=A-<[5+,HEDCRPZ$X4$CH2* /7J*\_L8[SPU\2K?3!
MK&IZA8W^F37$D=]/YI26-U^9./ER&(P.*B\&6.H>+M&L_%E_XAU:&XNY3/%:
MVEQLMX8PY C\O!#<#!+9/- ':V6K+>ZIJ-@+.]A:Q9%,TT.V*;<N?W;?Q8Z'
MT-:%<5I>K3GQ9X\BO-2>&RL3;&)W8;;93;!F8 \#G+>E<M!JUQI_B3PU>:9?
M^*+NQU&]%K//JK8M[E71B&1&PRG(R"$ Q^H!Z/I6OPZMJVL:?'#(CZ7.D$C,
M1ARR!\C\#6O7$^#/^1S\=?\ 81A_]$)576H]2UGXIG08]:OK#3/[%2ZE2SDV
M.SB9U^5OX<\9(Y(4"@#T"BO)9M5N=:\0ZW;SW'BM+72[@6-HNCJ^ 512TDCC
M[[$GH>,=CFK$VH>)=2'@*QO;Z^TF\U W45^8D$<CB.,D$J00I(7/3C=Q0!ZE
M17G5I>7GA'QMJ6CG4;_4]..BOJL:7LQEEB='VE0YYVL".O0BLKRM='PW_P"$
M\_X274/[7^R?VEY'F_Z'LQO\GR>F-ORY^]GG- 'K55EU"T;4GTX3H;Q(5G:'
M^((20&^F5(_"N!OKC4O$OC[3=-@U:^TW3;O0!?3QVLFR0GS0 %;^$_,,D<X&
M.,U5T_P[_P 7CU!/[9UC%OIMK,";LDN/,?Y&..4XZ>Y]: /0=+U9=4>^5;.]
MMOLERUN3=0^6)2N/G3^\ASP:T*\GU'Q!J\/@#X@WL>H3BYL=9FBM9-YS$@,6
M%7T')X]S6G>VVI>&O%WA>X'B#4[[^U+E[:]AN9087S$S!DC Q'@KQCMZT >B
MT5Y%XCU@/JWBR'5_$VH:5J%F -(L[2Z,7F*8@4947_7,SD@CG'3BO1O"UM=6
MOA?3DOI+E[QH$>?[3(9'61AEE)/H20/I0!KT5Y+X:O\ 5;?X;7'CG4=8O[Z[
MMK:Z,%HTI$&$9U7>H^^<C.XG@<#&*33+S6HI=$OK1_%MY?3W$(U 7D#"TDB<
M@2%5^[&%SN4KC@<YH ];HKSK2+;4/&FIZ]J5QKVJ6$5CJ,UA96UC/Y:1B+ +
MN,$.6/.&R,5E:7X@U>?P+\.[R74;AKF_UB.*ZDW\S(?.RK>H^4<>PH ]:/ K
M/T75EUO2X[]+.]LUD+#R;V'RI5PQ'*]LXR/:L)M0NQ\7H].^T2?8CH+3F#=\
MGF>>J[L>N.,UQR:_KC_!G1=1AU29=3FU1(?M,A+$@W;)AO5<8&/3B@#UZBO,
M?$LEYX<NM#\.0ZIX@NDU26>XN[J)C-=E8T7Y(\#Y 203M P,XZU =2UK3_#G
MC)8&UZ.PM]+:YL+K5%99XI=C[U#MRP&%8$\C)H ]5HKR;4K;7=.B\):G!XJU
M0W>LW45I=B1E:$++$S92(C:K+C@\^^>^G9W=YX2\9ZYIK:EJ&IV$>AC542^G
M,KI(KNI56/."%'% 'HU%>,6&K:]<:+I^O6K>++O6YS#</%]G;[!(CL"T:I]T
M*$)PPYR <UT<=GJ'B7Q]XMTV?Q!JEGIUB;7R8;*;RF#/""3OQD#()P, D\YH
M [N_U"TTRU^TWLZ00[T3>_3<S!5'XD@?C5FO$M6EOM?^#NC76H:G>-=0ZHEK
M))')M\X+=^6&?CE@%!!]>:]ATRP_LS3X[3[7=7>S/[Z[D\R1LDGEN_7'TH N
M45YIIVM:G)\'_$VI/?3M>V_]I>5.7.]-C/LP>V,#'TIU_<ZKJ.M^!]-BUF\L
MXM1TR>2[>!AODVI$V<G.&Y/S8R,G'/- 'I-9'B+7X?#EC;W4\,DJS7<-J A&
M0TC!0>>PS7"1Z[J/@^'Q_;"^N]2BT6&"XLFOI#+(IEC)VLQY90P!^E4O%'AV
M\T_PSH>H7?B+5;^[FU.Q:Y2><- [-*I^5,80 ]-N..N: /7Z*\OUG6;C5O'6
ML:7/)XCCL-*2&../1$8%Y'3>7D=>>A "].":@O-5\4OX:\*V\MY>Z=J%SKAL
M7N)H@DLL&V4*[)TW%0K8/&X9H ]7HK.T_3'TG2#9V]Y=7<JABD]_,97+')&Y
MO3/;TK@O!EU):ZS96?B/4_$-KXCD#B6VOI=UI>-@Y,. 4P.H"E3QSF@#TZBO
M%+;7M9\0:%=>(+>3Q6-6D>5["&S@8V2!&(2,J/E<': Q/.2>F*Z@SZEXP\9S
MZ1/?W^DV.G:?;W$\%E*8999I@3@N/F"J%(P,<]: /0Z*X;7'OM"U+P5IL.J7
ML\<NHO#/)/("\Z>4[ .0!NQQV[>M6EU"\_X6Q>Z?]ID^QIH4<ZP;OE$AF<%L
M>N !^% '2ZC>C3=-N;UH+BX$$;2&*W3?(^!G"KW/M4,>LV;)IOG,]M-J*YM[
M>==LA.S>5*]F"@Y'M7F6@G6)?A!=^+KWQ#J<^I'1KDPH)RL46U6VMM'WGRN=
MQYR>.*?K>G2ZQXA^&\LVK:G#)>6\@=H+C8586I8NO'#')!/<4 >E#5E/B!M(
M^QWH9;87'VHP_N"-VW8'_O\ ?'I6A7"S:K=Z3\1+RT-S<SV-EX86Z\EY,[Y%
ME<%S_M$*!FN0L=8UZ[T&R\06K>*[K7)S'<F%;=OL#HS M$J?=V["0&^]D9S0
M![35/5M032-&OM2D1GCM+>2X9%ZL$4L0/?BO//$4]W8>*]1N/$>H^(-.T@F+
M^SK[39#]F@7:-WG*H/S;\\N"N/2NQ\8LK^ -?='#JVEW!# Y!'E-S0!IZ7?I
MJFD66HQHR)=0).JMU4,H8 _G5NO.Y;JTC\#>$K2XU75K:6XLH1%::2/W]UB)
M<@$ L .I(*CU-8MGJ/B"7PIXXTZVN]5BN]&D2>Q>^D#72IL67RW920V<$<DG
M#8/H #UZBO,;KQ;>7GC'1M3LKN1="C6SANH0?D=[Q7*D_P"Z?(_[[IKW7B;6
MO"VJ:KI=Q?317&N-MBM90LWV")O+80$\*Q*%NV<GO0!ZA45U.+6TFN#')((D
M9]D2[G; SA1W)["N:\#WNFW5G>16&J:K=/#*!-;:JS&XM&(^X=XW8/7DD=<&
MMS6I9(-!U&:)RDB6LC*RGD$*2"* 'Z7?KJFEVU\MO<6RSQB00W,>R1,]F7L:
MMUY4=3UF^T#X;11:S=6T^J(%N[A"&>0&W+$G=D$]P2#@X/:M+2[F[\+^,]?T
MI]2U#4K"'24U.-;V<RR(P9U958\X.T<=J /0ZR-$U^'7)]6BAADC.FWS63ER
M/G955LC';YA7,>#-(U'6](TKQ1J/B/53?7@6[:W@GVVJHW(B\K!&-N 3][/.
M:Y^6^NM-\&_%"\LIY+>YAU>=HY8VPRGRXN0: /7J*XOQ1J5[:W'@M8+J6,7>
MIQQ7 5L>:AA<D-ZC(!_"J&FV]_XU\0>(+J?7-3T^UTR_;3[2VL)_* **I:1^
M#O)+<!LC Z4 ;FG^-K;4?#.G:Y#IFHR17UT;58H(O->,B1H][X/"90DGMD5T
M]>->'[^]T[X2^#C:W4L3R^($@E9#M+HUY*&4X['N*Z6\AU#7/B;J>C'6]1LM
M-BTVWG,-G+Y;,Y>0</U7WQ@G YXY /0**\F37=<L_AEKP74KF6;2M8ET]M0?
M#SI;+,H:0\<L$8\X[9J[X;6&\^(2KHOB75M5T6WL/.F9M0:>%;@OA4+'()*E
MB5SQ@=.E 'IE%<OXTNK2*WLK:XU75+22XE(BMM*&;BZ(&2HP"P ZD@C'<UQN
MFZWJUMX=^(=BUQJJ'2;8S63ZC(K74(>W9P&=2<X(R#DG!YH ]:HKRNY35]'L
M_!_B$^(M4NKK4+ZSM[N"64?9WCF&"!$!@$<8/7U)K1F\37GA63QG:W\\MQ):
M)_:.F&4[B\<HVK&/991M_P"!"@#T.BLSP]9WEAX=T^UU"YDN;V.!!<32-N9Y
M,?,<_7/X5YEH.IZO8_"F3QW?:S?WU_%9RB"V>4B!<.44LG\;9&2Q/L,4 >P4
M5Y5IEQK%IJ>B3V;^+KR>:Y2/4O[1@86SQN"&=5/$>TX(VXX&#FK.E1:EXNAU
MOQ#-K^J61MKRX@L+:SF"11)"2H+I@AV)!)W9':@#TRD8[5+8)P,X YKRS2]=
MU67P_P##2:34+AI-0N MVQ<YG'E.<-Z\@'\*Z:/4+L_%RYTXW,GV)="CG$&[
MY!(9W4MCUP * -_1=576M)@U!+.\LUFSB"\B\J5<$CYE[=,_0BK]>/6^MZ]=
M_#3P)-#K%Q#?ZEJJVT]VQWLR-YP.<_>Q@$ \9 K2\0W%SH^LZ/X3AO\ Q%/:
M2P37MU<6SM/>2@, J!^JKDDDC'& ,9H ]/K(UG7X=%O=(MI89)&U.[%K&4(P
MC;6;)]OEKSV?Q'X@T+PMX@$"ZJL:SVT.E7>L1'S4\Y@C;BWWPAR03GJ <U-K
MWAR30O$/@IFUS5M0WZNHD6^N/-4OY3_.N1\O?@''/3B@#U.BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 0@,"" 0>"#7$Q_#V:Q26RT;Q1JNEZ/*S,;"$1L(]QR1$[*6C')X!XS7;T4
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M;&$(0)@>V!6M10!D^&- @\+^'+/1;::2:&U5E5Y,;CEBW./K7,3?#))M)O\
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M@[6QQD=<<BL3Q=H]W<>)_ MG#J-^LD+W0.H(%,JD0<,WR[>2,$$8.2*]$HH
MYS0O"2:5J%[JE_J%QJVJ7D:PRW-RBJ!$,XC5% "KSDCN:R/^%:1?8_['_M[4
M?^$;\S?_ &3A-N-V[R_,V[_+S_#GIQFNZHH R!X>MQXLC\0+(ZS1Z>;!80!L
MV&0/GUSD8JGJ'A62?Q5%X@L-6N-/N3 MM<HD:2)<1*Q8 A@=IY(R.<&NCHH
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M,'6[[3=1M=3GTW4=.,GD7$2(XVR !U96!!!P/IBJ-OX"MHK7Q'%-J=]=2Z_
M(;J><J7&$9-RX  X;IC P,"NNHH P+[PI:W^DZ+I[W$RQZ5<6]Q$RXRYA^Z&
M]CWQ7,:]:V?C'XB:+!9Q7#KH\DCZE/Y3)%M5E9(22 ')D16P,@!2:[V[U"TL
M#;B[N(X3<S""$.<>9(02%'J3@_E5F@ K TCPEI^E^#4\+OON[ 120OYV,NKE
MB0<?[QZ5OT4 <QHWA;4=(GMHSXIU*ZTZU&(;2:.+)7& KR!=S  ^H/ K/OO
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ML07LV]L?NT#9QZGD<4 9>I>*-=TEM-T>Y&B_V]?F63S#(Z6MO"F,LV?F8Y(
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M3M#&6/ STS7944 >$>)]2O/$/@S7H=2N-=DU\-*HT>VMY$@MT63Y2VU0'7:
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M(DE1I(L>8BL"4R,C([9J*34;&*R^VR7ENEI_SW:50GI][.*\:.L3>'O[0\6
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M*R@N_(L+,QI.@=%)\P$[3QG'&<9&3ZFN2O;&V/P*\66QMXWBT_4[Q+160-Y
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MX!..M '>76J:?8RQ17E_:V\DO$:33*A?Z GFIY+B&$J)98XR^=H9@-V!DX_
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M^'M!O9+S2])M[:YD789$!)"_W5S]T>PP*T;/3;/3WNFM+=(6NIC<3E?^6DA
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M-UW1M*DAD>757E2-UQM3RT+G/U K7H P;OP7X;OM7?5+K1[6:\DQOD=<AR.
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MAH(V7&$(0OD^V%H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR([\2#^,]AG@!5P.N<&QUK7KO0++Q#:OXKNM<F,=R8%M7^P.C,"8E3&W;L)
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MP@R(D<>U\=$4 #IUZG/)X&)K7P=:VOA+4_#RW,Q@U W)>4@;E\XL6QVXW<4
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MD;%EP0V2"&6@#KJ*\]G\:ZYHWB'2;/6_[ \O4;M+0VEE<L]S;,^=K-NP&7.
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M<]* .WI&=4&68*/4G%>??\)+XRAU+P[#<P:$(M;)V!#*6APGF%2<_,=H/S
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MY'S+R<' SUH [BBN*O/$7B2VO-,\/1VVE3^(KR.2XE=3(+6W@5L;B#\S$D@
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MVGR@I<JVY&*G(!4CD9QBKVD:#=6OC+Q3J=TD1L]46U$*[LDB.(JX8?4UT]%
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M"IN[NZ.@6!FNPPG<P@[]WWOIGOCK6Q_9]F=274?LT?VU83 )]OS",D,5SZ9
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MMNT:S!.K8(&YN3CDCOC-<=_P@;72V,.E^#5\-W<,T3OJ0OE8Q*C MY81B7)
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MV=OI]E!9VD0BMX$$<<8Z*H& *GH **** "BBB@ HHHH **** "BBB@ HHHH
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M;T_[9':7EJOF/'Y=Y"8G^4D9VGL<<5P7@G0V3X@^+9SK&JR?9;Z(;'N 5FS
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MGD$;LYP<'&<UJ^$FO=,\;>(O#TNIWNH65O#;7-NU[+YDD9D#AEW'DC*@CTH
M[BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\5O<0G 54167@]>0YK=HH X.#X:M]BTVROO$NI7EII<\,MC"R1HL8B8%0VT
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M]I&,C_7#,1^%;M% '(S^!Y#JVIW%GK]]966JOYMY:0I'\[[0I*R$%DR ,X_
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M6CCCCQL*X*J.2<_>)[<8R<]C10!S</A66R\77>N6.KSV\-\R/>67E(Z2LB;
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MT-$(\M^ SQ5NUT"&U\4:AKJS2-->P10/&0-JB/=@COSNK7HH **** "BBB@
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M\ >&]&C$7VO3Y+!IP7^7$)3?@]_NG% %"VO/%,GQAU2VB.G&TBL[?=')++Q
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M!-X=LM/GAACE-UJ-O9L')&%D?:2,=Q1>Z_-:^-])T%88VAO;6>=I"3N4QE<
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M6$CDP3D$JCAOO X(##'(Z4:OI6O^,_#%]9:C8VNC7 >*:P(N?M!66-MX+X4
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M1(RI(!(((Y!!(- &Q17.:KXQM=-U=]+@TW4]3NXH5GG2P@#^2C$A2V6')P<
M9/'2L77?'MSIOC+1-.M])U2>UNK::>5([/+R?*A3:"0?ER=PXQD4 =[63K'A
MK2=>D@FO[=S/;Y\F>&9X94!Z@.A#8/IG%4-5\:6>FZD--@T_4]2OQ")Y;:P@
M$C0(>A<D@ GG SDXZ5)_PFVA?\(J?$9NR-/!VG,9\P2;MOE[.N_=QB@"_I&@
M:9H2S#3K7RWG8--*[M))*1T+.Q+-CW-:5<7J?B9]5\'^(PNDZQI<T.F3RHU[
M;^5N!C;!5E8C(QTR"/2K&@>(K:WT?PIIDIGN=2O]/AD"1C>RH(UW2R$GA<\9
M/4G R: .LHK*U_7[/P[81W5VLTAEF2W@@@3?)-*WW44>IP>I XK/F\:6=EX=
MO=:U+3M3T^"R=4FBNK<*_P Q4 K@E6'S#D$]Z .EHKE;/QYI]SK%IIT^GZK8
M_;219W%[:^5%<$#.%.<@D<@,%)KG[>^"6OQ)DOK^_@MK:\8^=:2?OH4$"$^7
MGH>M 'I5%>>ZOXVN-#UWPKIEK9:K?6MW;N\KBW$DMPHBRN#D9<'!;ZUN7_C6
MVLM0_L^#2M6O[Q+=+B>&SMPS6Z-G;ORPY.#\HR>.E '345';S+<6\4ZJZK(@
M<+(I5@",X(/(/L:R]?\ $=IX?6T6:"ZNKJ\E,5M:VD8>65@"QP"0   222 *
M -BBN#\7^.[K2O!$FK66DZG;W1G2$)<VF#$?,4'<,XP02 02"2*V+OQI96&C
MVU]>6.I0374WD6]@]O\ Z3,_HJ ^@SDG&.M '245@:+XNT_6)KRV>&ZTZ]LT
M$EQ:W\8BD1#T?@E2O!Y!/3FJVD>.;/6[R!++2M8:RN&*PZB;3%O)@'D'.X*<
M'#%0/>@#J**\[\,>)(-%T3Q'?:G//*%\1WEO!$N9))&,F$CC7N?0?TKT#S56
MW\Z7]TH7>WF$#8,9.3TXH DHKR;QUX^@U?P+>-I5EK,5O+- MOJ?V<I!+B=,
M[6!W $ @$@ ].]=;?:K9:;XTOY9+O5I9[71?M3V$9#6_E"0_.J]Y<J1]* .L
MHK$NO%>F6OA^QUK=++;7[0+;+$H+R-*0$ &>O//T-4-,U73+/4?%=U-JM^T5
MC.K78O7!AML1AL1 =%P<GWH ZJBO+/$?C3^V7\*BTT_6K"*?7;1HY[FW,4=Q
M$2<@$$\'(.&QD=J[#5?&5IIVJ2Z;;Z=J>J7<$:R7,>GP"3R%;[N\D@9(!(49
M)':@#HZ*YF\\>Z%9V&D7QDGFM]6)%H8(6<NP4MMVCYMQQMQC.>.*ET+QA9:Y
M>7UD;2^TZ\L55YK>_B$;A&SAQ@D%>#SGB@#H:*\F\>^/[?5? &J-I-GK,=NY
M1+?55MRD$A$JYVN#N .",D 'IFNWU;QA;:7JW]E0Z=J6I7JPBXEBL(0YBC)(
M!8LRCD@X R>.E '145%;3K=6D-PJ2(LJ!PLJ%'4$9P5/(/L:I:[KMAX=TQK_
M %"1UCWK&B1H7>5V.%1%'+,3T% &E17/:-XPL]7U1]+EL=0TS41%YRVVH0B-
MI(\X+*02" >O.1Z5#HWCG3]?U%;33;+49U$DL4]P( (;=T+#:[9ZG;D 9X9<
MXS0!T]%8FO\ BBR\/R6EO)#=7E]>%A;V=G'YDLFT98@$@ #N20*SG\=6D_AO
M5]0M+._%YIJE;BPD@Q<0L1E2R9QMQ\V02, ^E '645Y+K?BV]UKX(3ZG-!?V
M-VL-D\ER\?DK*6ECW-&0>5Z^G!%=EI_CK3[_ %ZVTEK#5+.2\1WLYKRV\J.Z
M"C+;,G.<<X8 XH ZBBN4O_B!IME=7J)8ZI>6U@Y2]O;6VWPVS#E@QR"=HY.T
M-CO4NK>.=*TG4+?3_*O+V\NK87-M#91>8TZDX^7GKC)YP,#.: .FHJE<:K:V
M6C-JM^S6=M'#YTOGC!B&,D,!GD=,#/-9.B>+H]=N%BCT;6;2*6(RPW-W:;(I
M5&.A!)&<@@,!F@#HZ*\E\#?$.TTGX?:.^I6VKW$*9CNM2$!>"%FE(&]V.3U7
M) ('3KQ7?ZUXD71[A+>/2-6U*=T\PK86V\*N<<LQ5<\=,Y]J -NBN8?Q[H<?
MA6V\2/),NGSS+ 28COB<OL(=>HVMG/7IQFG:3XVLM4UT:.^GZI874D)GM_MU
MMY0N$! )3DGC(X(!YZ4 =+17&:A\2M,L4NKA-,U>[L+6?[-+?6\"F$2!MI4$
ML"<,<;L;<]ZT-0\8VM@UE;C3=3N=1NX?/73[>$-/''T+."P50"<<MUX&: .C
MHKF)/'FD)H4.J+'>2&:Z^Q)9K!_I!N,D&(H2,,,'J<8&<XK5T;5_[8MI)6TZ
M_L'C?8T-[#L;. <@@E6'/4$T :51O!#)-',\2-+%GRW902F>#@]LUS5OJ5E;
M>*O%$AO]3EDLK:"6XM9&!@A78Q!A7L2%.?>JD'Q-T:X.G2K8ZJNGZA)'%#J+
MVNVW$C]%+$YZ\9 *Y[T =I14-U=06-I-=W4JQ6\*&221S@*H&23^%8&B>,[?
M7KJ&.WT?68;:X4O;WMQ:;(95 SD')*@CD;@,]J .EHKDI_B!86MY%'=:5K-O
M9R7 MEU":SV0;RVT9R=P!/&XKCWJQJWC6QTK7&T06.I7NI"W6Y6WL[?S"R,6
M&<Y &"O.X@<CKF@#I:*X?5_%ND:S\/=7U+[7J^FPVC>3=_9U\J\M9%9<K@]#
MR/P-1ZYXVN]%\=:9HD6F:G=VS6DLDWD6PD>8C9M9#D9 RV[W(H [BXMX+J%H
M;B&.:)L;DD4,IP<C(/O4E<_K7BM-'N3;IHNM:@Z1B60V5IN5%.>K,5!/!X4D
M^U8'BC78=6T_P/J>E73FTOM=MB&0E=Z%),JP^HY![B@#N_L\ N3<^3'YY3RS
M+M&XKG.W/7&23BI*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:JK/H]\JJ
M68V\@  R2=IKSS_A'M1U7]GVUT:V@>/4#IT)$##8Q9&5RAST)VD<^M>G44 >
M9Z&NB:YK.E;]1\5SWUK+]I%K?PR!+:158?O"8PHZD=><\54GT:^'C&7PBMG.
M=%NM636VG\L^4(L%WB)Z<SHIQZ-7J]% '#S021_%75+R6QGGL_\ A'40A(BP
ME(FD)0=BQ';WK$\-W(LO%&E:?X3N=9ET:3S!?Z=J%M*([!0I*['D4%3NP-F6
M!Y^M>IT4 >.6>DZG%\/=!O5TZYF?2/$,M_/9B,^:\0FE!*J>20'# =\5T OD
M\9?$'P[?Z1;W?V#1TN9+F\GMGA4M(FQ8EW@%CW/&!@5Z'10!YQH=E=)X \;P
MO:S++-?:HT:-&0SABVT@=P>V.M59X='A\*^$AK/]M:7J%MI4(@U*Q@EW0-Y:
MAHV*JW)Q]UEQQ7J-% '.>!KW6+_PM!/K:R?:C)(J22P^2\L08A'9/X25P<5Q
MP\.ZEJ_@GXBZ7!#)%=7FLW3VPD!3S1MB(P3V;:1GI7JE% 'EVN:ROC;2=)T#
M2],U"'4#>6TMTL]G)$NGK&P9BS, N>,  G.:W_#MK-%\2_&MS)!(D4RV BE9
M"%?$39P>^#UQ7944 <QXX31Y=)MTUNWU!K<7"NES8QR,]I( =LN8\LN.F0#U
MYXKBKD:]K_PV\9:?')?:K9H@72KJZMC%<7*!0SC;M4M@C ; W5ZY10!YKK>I
M)K-OX8\4:7:WMY9Z-?$WEN+61955HMI<(P!8H6!XSWQT-2K(?&OCVSU+2HKJ
M+3=/TZY@>^FMWA$LDVT!%#@$[<%B<8!KT6B@#SCP+XBA\/\ AW3/"VI:;J,&
ML69%JT$=E(ZO\V/-5PNTH0=Q.?6L&;PGK=YXC\4ZY:23>;INK+>Z?821XBNI
M%C3<22/FRH*J1]TY->RT4 9UIJ4.I^'X]2%K<>5-;^8;:2(B3IRA4_Q=1BO/
M/#URMCXFTFQ\(SZRVERNXO\ 2[^UD$5C'M)!5Y%!0AL#:&(.:]4HH \<\-^*
M[73? ^KZ7]@U&YU&:\OTM8(K*1UN&:5P ' *X!/.2,?E6E!I%UX=U3X86UXD
MC?8K:XM)Y40NJ2O"@520#@9! )XXKN?#>@1>&],DL8IWF5[F:XW. "#(Y<C\
M,UL4 >6C2-0NO!OQ,M(K.8W%WJ-XUNA0@R@PQXV^N2"!BKEUJWAO7O!6F?VA
M;ZOY-N\2FXM[.=);&=4^_D+N&,D;@",G%>C44 ><Z%XLO=&\-Z[JFJ?VKJVC
M6$ZBQNVL]ES/$0-Q*D+D*2?G(&0">U=?KK?;?!VIO;JTGGZ?*8P%.6W1G''K
MS5G5M)MM:L&L;PR&VD(\V-'*^8HZHV.JGH1W'%70 H    X % 'FVHZ!J.I_
M C3-,LX)1?1:?92_9Q\CL8_+=DYZ-\IZ]\4[0$T/6=?TV9-3\4W=[9,TZPZA
M#(J6[["I#DQ@ X8C&>:](HH \H@T:^'C%/"!LY_[%@U9M;6?RSY7E;=ZPYZ<
M3L3CT%)?6BZ#XZU^?6-0U^PLM2DBN+6ZTY7>-\1A&C?8C$,"O&>H->L44 >9
M2:+!:/X!CTNWU"2RCU.:X9KN)O,3>DC%G! V_,W<#J*TO&W]AKK%O/?3:UI6
MI10$6VJZ?;R,"">8B55E;D [6'?CO7=T4 >/7T.OWEIX/\3Z^NJP&WBN8+]]
M/B*7$*N1Y<IC ) (0;@!QG\*['P5:Z0]YJ.K:;>ZQ>R7"Q0RW&I1NH<)N*A-
MR+D#<>:["B@#SCQK)I-OK=Q=QW&N:1K\=N%@N[*TDDCNQ@E4("LDF"<8.#SU
MJO?W^H6.M^!?$?B*SGAVV-Q%?M!;O(()I$0@,J D9*D>QXKT^B@#SJ#4XO"/
MCGQ#J&JV]Y_9^M"WN+2\AM9)1E(]AB8(I*MQD CH:PFT+6#X6;7AI5R2?%0U
M_P#LS9^^-OG&-G]_'S[?ZU[%10!Q>I^)K'Q1X2\0VNDP:A*PTN?YI+*6)=QC
M8!!O49?V&:YSPAI&J>#;C0M4NVN=0AUJS@M+XM#\]E(JYAP ,K& =C9Z$!CU
MKU>B@#FO&Z:1+HD<>M6M]+:^>K+-91R-):N,E9<Q_,N#QD9Z^F:\XU[4-3NO
MAEXPBENK[4='MY+4:;?7MN8II@9$+J<JI8*< ,0,Y/I7ME8_BG0(O%'AR[T:
M:=X([G9F1 "1M=6Z'_=H X_6]57QMKGAS3=)LK\&PU./4+Z:YLY(5MEB#?(2
MX&68G&!GOVK.O;>X.F_%6P%M<&YG+30H(6/FHUNH!4XPW((P.:]9HH \WUYV
MTC5/A_K5W!<BPL8IHKJ2*!Y#"9+=57<J@G&1CI3/%UUHW]IOJ=M<Z]I&MFT0
MVUY9V4K)>*1N1&3:5?!."K $9KTNB@#E-,\5W$'_  C.F:]87,.KZM;%G9(O
MW,<JIN9&.?E8@$XYZ4WQTFB26UB-:CU.()*9(-0T^.0O:2 8W;HP2N02.00>
M];\ND6L^LV^J3>8]Q;1LD"LYV1[OO,%Z;B.,^G'<YO4 >1:DVOZW\*->29;W
M44M[Z-K">6U,5Q=6T<L;EC'@$D8?!P,@9Q6QKVIQ7NL^%O&=A!>7FDZ=)<PW
M02UD$D0E0*)!&5#$*1@X!X/%>BT4 >6WMG<>/?$.M:CI$5Q!8'P]-I4-U<0M
M#]HFD;=\H8 E%QR<=2<5M>$/%MI_9FD:#-INIVNJPPQVT]JUC(%A*+@L7V[-
MG'!SW%=Q10!XI8^&]<L[O6O%L/VF>;2_$%Y/;:4T6%E@9R)67(R793E6']S
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD1#;7\M,'S I[G;G%;NL>+KRT\3P:!I6BMJ-W<6)O4?[2L4:J'VG>2"0.1R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** #K7D&F? #1]-\8Q:RNJ3O8P3BXAL3$
M 58'*@OGE0<=L^]>OT4 %%%% %/5X9+G1;Z"%=TLEO(B+ZDJ0!7S_I/A7Q[;
M> +CP@? =J[7+.?[0N;J$F+<1R!G.1C@Y_"OHRB@#Q35/AWXE\/+X,UO1XX]
M7U'0;<6]S:^9L\Q<L?D+=AO9?7[O':KWA;PIXLOO$GBGQIJ=M'H^J:E8O:V%
MMYH<Q':H5V(]-B>YYX'%>NT4 ?+DWPT\8WVAV\+^#F758+SS+O4YK]7FN@2<
M  M@*!C)SS@>]>L1^&=87X^S>(C9-_9+:?Y(N=ZXW[0,8SGMZ5Z710!Y%XET
M'Q5X>^+;>,_#VC+K,%[:BWG@$ZQLC *O4]!\BG//<'%+\.=#\5^$K;QIJ6H:
M$'O[N<7-M:QW"[9V^<D*V3@98=:]<HH @LIIKBPMYKFW-M/)$KR0%@WEL0"5
MR.#@\9]JYN#2;Y/BK>:NT!%A)H\5LLVX8,@E=BN,YZ$'IBNKHH Y6/2KY?BM
M<:P8#]@;18[83;A@RB9V*XSGH0>F*YB[\#ZKJ?ASQ7:-;HES/XA;4[))G 2=
M%$9 )!X#;6'8BO4:* ."\+Z1IW]MP7*^!;W2;BV1C]JNIT98W(VE4Q(Q;(+<
MX%7/B!8ZE=+X=NM-TZ:_;3]8BNY88716\M4D!(WD#JP[]Z[&B@#@WM=;\4>+
M]"U*?09-&M-)DDF::YFC::;<A7RU$;-A><G)[5G:;!XF\*>'+SPG:>'9]08/
M.NG7\<T8@,<C,P,NY@RE=QR #G'%>FT4 >7WWA?4=&L_"VERZ?>ZYH5A9-!=
MVEE*J&2X^7:[JS+O3[W!.!GFJ:>#]87P5X[L8-!BL)-3E#V-E!)'MV^6@P",
M*#D'/;.<$CD^N44 <=XST74[W1]$N]+MUN+_ $>]AO1:LX7S@JE60,> <,<$
M^E48UUS7_B#X?UJ7P_=:=IUE;W4;M=2Q^9N=5QE%8X&5P#G)YX'&>_HH Y3Q
MOH^H7R:1JFDPK<WVD7JW2VS.$\]-I5T#'@-AL@GCBJ-K;ZMXG\<:5KEWI%SI
M.GZ1!.L*7;)YT\LH"GY49@%"CJ3R3TKN:* .5\!Z5?:1I>I0W\!ADFU6[N$!
M8'=&\A*MP>XK*O%US1OB1JFKVGAR\U.TN["""-[>:% '1G)!WN#_ !"N_HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*P55D=R[PE3R2K,1N7(^A!%;/C'1;CQ!X7N],M;F.":8H5,N=C[7#%&QSM8
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M"R!8<C<.AP>1F@#2M?%&DW5FMT+@QQ/?-IZ&12-TX<IM'U8'%;->*SZ?%?\
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MU<1(8SD!#(^XEN."/2@#TBBO,O#2ZMHWQ#M=-GM[FRLKW3II3:S:M)?9='C
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M44F08.-IWD*1G(/04 >R45RO@JSUJPBU&WU2.6.U\\/8QSWGVF6.,J-RE^I
M8'&><'':NJH ***X'7/$,G@OQ7J5S?3S2Z;J&G-<VD3N6"W,(PT2#MO4J<#N
M#0!U6MZ[;:!:BZNX+M[89,LMO THA4#)9\<@8[X[5HPS1W$,<T+J\4BAT=3D
M,",@BN>TK2KF'P +#7+Z5[J:TD-[<2N6*-("7P3_  KN( Z  5!\/KZ]N_"M
MG%<V+106]O'%;7>X;;R,+@2*A^9 0 <,!UXSUH Z:YN(K2VDN)W5(HU+,S'
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M+3SZ;\4+L:=;'4/[0M;;[<B,$-D$9U20EN&#!F^4'=\N0"* .VHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBD8!E*G.",<'% "!U+%0P++U /
M(IU>57FEZ1I/CSP]9Z5HTVBR17A\S5ID(6^4HV8!)DF1G)!^<C[IQDUZK0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<;%\-]
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MLF.F7<EB!V&<"I=.T+3-)O+^[L+.."?4)?.NG7.97]3GZGIZGUK1HH YJ]\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>emergentbiosolutionscomp004.jpg
<TEXT>
begin 644 emergentbiosolutionscomp004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M4/\ <B_]%K7$UVWQ9_Y*-J'^Y%_Z+6N)KT*?P(\ZI\;"BBBK("BBB@ HHHH
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1D[(<J<HJ[.7-)3U1I'5$4LS'  &237J_A?X+7%_:QWNO736:. PMXQ\^/\
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MX<L=4F@OKVPMC<06JJURB_>"'/S >V*TIH+?5;830L-V.&_H:[3X!*&O]:!
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MB.[^+/\ R4;4/]R+_P!%K7$UVWQ9_P"2C:A_N1?^BUKB:BG\"+J?&PHHHJR
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!M**6FT .HIM*.E "T444 %%%
M% !1110 4444 %%%% !1110 4444 %-(IU% $?2ES3B*90 ZBD!I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!,"CK2TG2@!**4TF* "BBB@ HHHH
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M844459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #:*=3:
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M7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\ A2OA?_GOJ7_?Y?\
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M?_GOJ7_?Y?\ XFO1J*/:3[A[*'8\Y_X4KX7_ .>^I?\ ?Y?_ (FC_A2OA?\
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MLH=CSG_A2OA?_GOJ7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\
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M7_?Y?_B:/^%*>%_^>^I?]_E_^)KT:BCVD^X>RAV/./\ A2?A?_GOJ7_?Y?\
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M]3_[_K_\17I=%'M)=P]G'L%%%%06%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7\N:X\@!(&R?E+9PS8&< ]#7+>"_#VJVWB'QM.-!UFSM+S195M!?(SR2%E&
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MR\,VE:I;WEU;+ QF6-)V+$)C)."#CTKU?3K^'5+"*]@2=(I02HGA:)^"1RK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!SOA3P7IG@Y+]=,>Y87TYN)?/<-AO; &!71444 %%%% ')
M>)?AWH_BW7+34M7GOIH[955;$3 6[D$D%EQDGYL=>E=8    , = *6B@ HHH
MH **** "BBB@#$\0>'AK;V%S#?36-_I\IEMKF)5;:64JP96!# J2/ZU!I_A>
M2+6XM9U;59M3OX(FAMRT211P*V-VU%'4X&22>!VKHJ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"J[<G&2"Q )X-=/XMO5?5DM(O%.K6LQMP\6GZ/9K/+G)_>.=CG:>.#M'!Y]
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M -E=O=CD]>.*V="N-5TGQYJ?AR\UBYU2V.FQZA#+=*@DC8NR,N44 @X!Z<4
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M(P,#D\5S$_PSU.;PQ/X6_P"$LE70BA2"'[$IF1<Y5&DW?,H..@!.,9Q7HU%
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M7Y\4J@, QX# J",\=:BT/2M8O_&<_BG6K)-.*V0L+2R$RRN%+[W=V7Y<D@
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MN\)Z;%86,[)X8L_#[2R?\>]L8R74#AG* +GD\ GCOS0!!XDU7Q)I[ROIEEI
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M'6HM2O5M)+1[1(I44J295*'HN.<C&#6YK7C;2M#NIK>XAU&=K=0]R]K8RRI
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M7-1>*M.UG2]62&>]TZYM+9GF2XMFBGMU*G$@1AR."1U&1BG>'M?L)(-'TO\
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MIQ7IM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$;SPG)'/%K]K8RVTVG+;N9 X)+/P,;3RV[I@U[)I0(T:Q!&"+>/_ -!%7**
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M"692<,&!/7)-=A=ZE::#\8WGU2;[-!?:/#;VTL@.V619FR@/][Y@<>]>A44
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MT]Y/LUO-*J@HK%48'JS;<88CVH ]-AFBN(EEAD22-NCHP(/XBN<\4>)VT?\
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M[%%/#/")894DB/1T8$'\12^;&(Q)YB[#T;/'YUYLEE;:'\0]:TC1(4M]/N-
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M$88R$DC!(QTYK.L_ASX4L)8)8-)&^WE66 R3R/Y+*=PV;F.T9 X& <<UU-%
M"$ @@C(/4&L.'P;X>M_#<OAZ+3(UTF8DO;!FPQ)!SG.>H'?M5F#7K6X\37F@
MI',+JTMX[AW(&PJY8  YSGY3VK4H S9O#^E7&FV6G2V:&TLFB>WBW$",Q8V8
MP>V!4&I>%=&U;5K;5;NU8WULH6.>.9XFVAMP5MC#<N><'(K9K+T37K77EU V
ML<R?8;Z6QD\T 9>,@$C!/'/'0^U $UIH]A8F^^S6XC^W3-/<X8GS'8 $\GC@
M#I5*?PCH-QX?M]"ETZ-M.M]OD1;FS$1T*MG<"/4'-3:MKUKH]]I5I<1S-)J=
MS]FA,8!"MM+9;)'&%/3-:M &5HGAK2/#L<R:9:"(SL&FD=VDDE(X&YW)8X]S
MQ63#\-?"$'FA-&CV2-OV-+(4C.X-\BEL)R!]W'ITKJZ* ,;6?"NC:]=VUWJ%
MJSW-L"(IHIGB< ]5RC D<=#Q5W5-*LM:T^2PU& 3VLA5FC)(R58,.00>" :N
M44 4]5TFPUO3Y+#4[6.ZM9,;HY!QQT([@CU'-8Z>%+71=(U0>'H?+U&YMFCC
MENYY)\L%.P$R%CM!/3I6[;WEM=23QV]Q'*]O)Y4RHP)C? .T^AP0<>]3T >,
M1^$)SH-MI^B>'/$&D:ZBQI]NDU(K;P,"-S_+*0PZ_*J<YZ"O1;KP-X=O]4DU
M*[TY9;J8+Y_[QQ',5& 7C!V,?J#7144 9-OX9T>T_LKR+)4_LE62QP[?N0R[
M6 YYR..<TS7/"NB^(WMY-3L_-FMR?)FCE>*1,]0'0@X/IG%;-% &7HWAW2/#
MXG&DV,=H+AE:41YPQ"A03D]<#KWZGFH]<\+:/XC>V?4[5I9;8L898YGB=-W#
M ,A!P<#(SBMBLOQ#KUKX:T=]3O(YI(4DCC*P@%LNZH.I ZL* *FL^"] U^Y2
MYU"Q+W"1^5YT<TD3LG]UF1@6'L<UKV-C:Z;8PV5E;QV]M"H2.*-<*H] *L44
M <U<^ /#%YJ%U>W&E+))=,7G0ROY4CD8W&/=LW?[6,YYZUIIH&EQ3Z9,EHHD
MTN)H+-MS?ND90I YYX4#G/2M*B@#)N;.'2I-1UJPTN2[U*Y2,2QPR!7G"<*/
MG8*,!CZ5E>"/#]QI2ZMJFH6L5MJ6LWC7<\$3!A"O1$+#AB!DDCNQKJZK17]K
M<+<-;SQS?9G:*81L"4< $J?0X(X]Z (M7T>PU[3)=.U.V6XM)<;XV)'(.001
MR"" <BLJX\">'KNSLK6>SF=;$N;>3[7,)4W'+#S-^\@]P3BM#P]KEMXDT"SU
MBSCECM[N/S$68 .!G'(!([>M:= &!'X)\-PV<]G%I4*6T\T<\L*LP21TQM+#
M.#]T9'0GDY-:3Z182:Q'J[6X^WQPF!9@Q!\LG)4X.",\\YQVJ[10!S=KX"\-
M66HK?6VG&*1)?.2-)Y!"LF<[A%NV Y]!1>^ O#.H7\UY<Z;NDG<23(L\BQ3-
MZO&&",>.X.:Z2B@#&\6V%QJ7@S6]/LHO,N;BPFAAC!"[F9" ,G@<D5D>&_A_
MH6EP:7?/I2IJ5M G#2LZ0R[0&*)N**<YY45V%% &!?\ @GP]JFK/JEYIPDNI
M%59CYKJDP7@>8@(5\#CY@:L1>%]%@L]-M(K!%@TR;S[- S8B?YN1SS]YNN>M
M:]% '/:EX'\.:OJK:G>Z:KW3J%E99703 =!(JD!Q_O U(_@WP_)I=AIC:;']
MBT^Y%U:PAV CE#%@PY]6;@\<]*V;BXAM+:6YN)4B@A0R22.<*B@9))[ "G12
MI-$DL3J\;J&5E.0P/0B@!U4TTJQ36)=66 "_EA6W>;)R8U)(7&<=2:EBO+:>
MZN+:*XC>>W*B:-6!:/<,KN';(YJ>@"AJ^C:=KVGM8ZI:1W-LQ#;'R,,.C CD
M$>HYJOHGAC1_#HG.F6GE27!!FE>1Y9),=-SN2Q [#/%:]9?AS7K7Q/H%KK%G
M'-';W(8HLP <;6*G."1U![T 6-*TJRT33(-.TZ 06D (CB!)"@DD\DD]2:'T
MJQDUB+5F@!OHH6@2;)R(V()7&<=0*N44 9D/A_2K?2[S3(K15L[QI6N(MS8<
MRYW\YR,Y/2H=1\)Z'JNE6FF7E@DEK9A1; .RM#M&!M<$,#@=0:V:* ,.'P=X
M?AT.XT8:;')87#;YHYF:0R/Q\S,Q+%N!SG(P*-*\(Z+HRW L[:7-Q'Y4K37,
MDS%/[N78D#GH*W** ,J3PUH\OA^+0GLE.F0B-8[?>V%"$,O.<\$ ]>U1ZWX5
MT;Q%+;3:G:M)-;;O)ECF>)U#=1N0@X..G2MFB@"G;:58V>HWNH00!+N]\O[1
M)N),FQ=J]3@8''%0Z5X?TK1)KV;3;*.WDOIC/<LI)\QR2<\GCJ>!QS6E10!S
M=WX"\-7NHS7\VG$33MOF$<\D<<S>KHK!6/U!S72444 %%95QKUK;>);'0GCF
M-U>02SQN -@5"H()SG/S#'%:M !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &3XIN;BR\(ZU=69(N8;&>2(CJ'$9(_
M45G^ ;&RM?AYH<%K&A@EL8I'XR)&= SD^I))S72LJNA1U#*PP01D$5P\'@/5
M-+A?3M"\6W>GZ,S,5M/LT<KP!CDK%*W*CDXR#B@!=6N-1U[QZWAFUU.YTNPL
M[!;NXDM-JS3.[E50,0=J@*2<#)SBL2]\1:WI/AGQWI4FI27%_H$<;VNH%5$C
M1RIO3=@8++@@G'/'%=5JG@^6?4;/5=)UB?3]5MK;[&US)&)Q<0YSB16QN.><
M@@Y)JO\ \(!"_A?7-,N-2GGOM;RU[J$B#>[8 &%' 50,!>U &!JJ>)M+U;PU
M)#XJNWEUR4VUTDL,9ABS&7#0ICY2-I R6[9SSG1T:YU/1_%?B+0)M7N]1MX=
M/BOK:6[*M+$S;U9=P R,J"..*Z+4O#4>HW.@S-<LATB?SU 7/F'RRF#Z=<U%
M=>'TAUS5_$ N&,ESIHM3#MX4)N;.??=0!P,4WB9?A5;>-SXJOI-1@LUNOLS)
M&+:1!U1E"Y)(S\V<Y/&.E:6M>*I=4\5_V4;S6[#3K>QAN7_LBSDFFEDER0&9
M4?8J@>@R2?2J?@[P9?Z_\.="M+_Q#<G0Y;>.2;3A;HK. <^7YHYV9'3&<<9K
MM-7\*37.M1ZUHNJMI.I" 6TK"!9HIH@<A60D<@DX(((R10!Q]QXC\2+X-LRE
MU=V]X/$,6GPWE[9&)[B!G&UWC8+G(;!P!DJ>E;-C_:GA_P")%CI,VNWVIV>I
MV$TSK>;"8Y8V7YDVJ, AB-M;%]X5N-6TC3K34M8DN;BSOXKXW'D*F\QON";5
MP .W<_6KEWX?2Z\6:=KQN&5[*WF@$07AA(5YSVQM_6@#B=#U.\C\3)!XGUW6
M--UB2]D6*TDC06-U'N.Q(FV$'*[?X@^<TSQKJDL4FMSZ7XFUZ74-/C:1+;3[
M96MK4JF[;,VS!S@DY;(!Z<5T$_@O4]0GLXM6\337VFVETEU' UI&DKLAW('D
M7J <=%!/K4,WP_NS_;5G;>([BVTC5YI9Y[5+9#('E'S@2'G:?3&<< B@#G]=
MBNO$?B3X<W_]K7]BVI02RE;5D A;[,7+)N4\G=M.<\=,'FN@EUJ\TKQ_>6,M
MU/<6%EX;6\,;XR\BRN"Y('WB%^GM5J_\$O-IGAV*PU5[._T%52VNS ) P\OR
MV#(2,Y'OQ5^#PR%\3?VY=W?VF=]+33ID,059,.7+XSQDL>* .',OB8?#W_A/
M?^$CN?[0^S?VC]@VI]C\G&[RMFW=]SC=NSFM6\U#5?$'CS3]+LM7N=,TV[T$
M7\H@13)GS0,*S A3AADX/ XQG(E_X5O/_9O]@'Q)=GPQN_Y!WDKYGE[MWE>=
M][9GC&,XXS71KX<A3QA%X@28J8]-.GK;A %"F0/NS^&,4 9'@*]U!G\0:3J%
M_-?G2M2:WAN9\>8T9174,0 "1N/-8USI5UJWQ?UB"'5[O3HAI-L96LPHD?YY
M, ,P.T?09/J._8Z+X?31M1UF\2X:4ZI=BY92N/+.Q5P/7[N:S-2\(7TWB:ZU
M_2M?ETZ\GMH[8J;9)HRJ%CR#R3EN,$8QWS0!C:3KEY!H7BC3M8\1-;OHM[]G
M35WC0R&)@K+E<;6?#;>G)QQFJ_AC6;ZV^($.DQWVN7FFWVGR3H=9@\MQ(C+\
MR?*K;2&Y! K8;X=6Q\+3:4-3N3?S7JZC)J3JK.]T&#!ROW<?*!MZ8_.K-EX/
MO5\26VO:EK\][?06TML MND4:J^TY51G!!7/);.?08H YWPCJ=Y_;EK;^)=>
MUBR\0O))YNG7,:+:7(YP(#LP0!@@JV[@YK)_X2G4==MM4U:'5/$=M>1SS)IM
MI8:5++:@1L542$1,)"Q7YOFXSCC%=FO@S4KN_P!-?6?$DNHV>FW*W5O";1(Y
M&D4$*9)%^]C)Z!<]Z4>#=2TZ\O&\/^))=-L;R9KB6U:T2<1R-RS1,Q^7)YP0
MPSVH RAJ.L^,/$UKH_VV\T.VM]*@O[U+8!)VFEZ1Y8':JX.>,YX-3?#FWFM-
M;\9V]Q=R7<L>J*IGE50S_N4P3M &<8Z 5K:QX1NKO78-=TC6I-,U-+?[+-(;
M=9DN(L[@&0X&0<D$8ZU8\,>%O^$<FU29]2GOYM1N!<2R3JH;=L"G[N!CC.,#
M'3M0!BW,NI>*?'>K:)#J]YI6G:/! 9/L1599Y906!+,#A54= .2:P]0\5:]8
M^ ?%$+7^_5M#U&*UCOO+ ,T;21%691QG:Y!Q77ZMX3N9]>;7-$UA])U"6$07
M)^SK/'.BDE=R$CYADX8'IQ567X>VLG@V^T$W\[3:A<+=W=_(H:267S%<L0,
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M8&O8;.!K6SA@:>6=HT"F64Y=R!]XX[FN>'@?3I7\3"[/VB+7W5IT* % $"
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M>+4/[3TN2*./Y"5E1C$H3Y@!MR1AO;-=:OA&QD\"P^%+QWGLX[..U,@^5CL
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MY6,+D2>8FPY/;'6L=/!FI:;<W:Z!XEETW3[J9IWM&M$F\IV.6,3-]T$\X(8
MF@#*N[W7M?\ &VEZ1%J5UH]K=Z"+Z[CB0":-O, *J6!VME@"2.@/?FL^[UZ>
M_P#$NJZ9-J_B2UL](,=K =*L))WFDV!FDE=8F!.2,+QTSCFN\_X1Y/\ A,H_
M$9N7,B:<UAY148(,@?=GUXQC%9]]X2O5UZZUC0-;?2KB]5!>1M;+/%,5&%?:
M2"K8XR#@X&10!:\'W^I:OX/L[C5HYK>_97CE,D!A<E790^QA\NX -C'>N0^'
M.D7$4_BJZDUO4IU@UF\@:"5H_+E(51YCX0'=]"!P.*]'L8)K:QAAN+I[N9%
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M<560-DR>9;,YR.V.E '<12QW$*30R+)%(H9'0Y#*>00>XH6:)IGA65#*@!9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS7HM9&B>&=+\//=2:?#*)KME:>::=YI)-HPH+.2< =!0!P_ASPFU@^GV5_\
M#G13<6S(LFK1/ $;;_RU5=OF;CC."!SWK2M++Q+X1UG6UTS1$UC3M4O&OXF6
M[2%X)7 WJX?JN1D%<GVKO:* .)\1:?KP\2>&_$=EI27TUE!/#=V<5RJ%3*J<
MHSX! *GK@XQQ6WXITJX\0>#-4TN+;%<WEF\2!SPKLO )';/>MNB@#SV[TGQ%
MK/AS1K@Z0FGZUH5U%/!;SW*.ER%3:Z[DSM# G!/.0*N6FG:[XA\9Z9KNL:6N
MD6ND13"WMVN$FDFEE4*S$IE0H4<<YR:[:B@#F/%.C7NJ:QX8N+6-7BL-1^T7
M!+ ;4\MUR,]>2.E%OHU['\3+[6FC46,VEPVR/N&3(LCL1CKT(YKIZ* /,9_"
M7B%/!VIV4, >2;Q!+?26BW(C^UVC2[C'O!^7</7'H:N>'?#>H6_CV#6AX<LM
M#TQ-*DM%MX)(RX<R(P+A!MY /0GIR><5Z%10!YUHNB>(-/\ #/B'PO-I(,4J
MWS6E^MRA28REBBE<[E/SG.1CCK5G4O#&J7/P[\,Z1%"AO;"33VG3S  HB*;\
M'H<8/UKO** /,]6\&&T\7ZIJI\(6'B6SU,I+B4Q+-:R*H5A^\X*-@'@Y!SQ6
MI<>&;IY?!SV6CVFFP:=>O<7-I;NNR -&XXP!N^9N<#N:[BB@#F+/1KV'XDZI
MK+QJ+&XTZ"WC?<,EU=R1CKT85RTWA'Q#'X*NK"*V$LCZ]+>S62W(C^UVK2EC
M'OSA=P(ZD=,&O4** //O#?AS4+;Q\FMGP]9:)IHTE[-+:WD0L'\U&&\(-N2
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M,$@'WXH R=*\6K<W7C#Q#--X@:[L);A+*'R+@6\<2HBH&CQMW[FW$,,@?,<
M9K=\#:]I>E> 8-<U&_UB26Y6%9VO_.D::X90<0(P^8$MQL&#CVIFB1N/#/Q)
M!1@6U74"HQU_<)TK*U.TNX_ _P .M56>\MK/3886NYK6%99+</;A1+L96!"D
M\\$@,30!Z+H_BG3-9%TL9N+6>T :XM[V!H)(E()#%7 ^4X//3@U1T_Q]HNJ7
M"QV<>I20R!S#=#3YO)GV@DA'VX;@'ZXXS7(3:7:^*-)\2W.B>*KS7M4ETAK%
M6>.-(]K$L$#)&H+$@CJ<;N>M=+X3\;>'KZRTK2+65XM0$*PMIY@<26[(G*N,
M?*!C&3QTH ;X(\=KXJGU"WDM+J.2&\GCA?[%+''Y2-A=S,,"3'5<@^PK:UWQ
M3IOA^2W@NC<37=SGR+2T@:::0#J0B@G ]3Q7+_#K4[.TO=?T"XG$6JC6;R<6
MK@AVB9]RN/52"#FEUB]M_#'Q3&NZR3#I=WI(LXKUE)CAE64L48C[NX$$$]<4
M 7];\<63_#W6=<T>:9Y;:&6, 6[^9!.%.!(A&5P<$Y& .>E2?#@02>$[>ZBN
M-7GEF5&G?4WE+-)L!8J).BDGC;P:Y-MVJ:-\3O$%G%(NEZE8E+-F0KYYCMV5
MY%4\X)( /?%>C>&@1X5T<$8(LH<@_P"X* -2BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&944LQ 4=2>U<
MA?\ CB*3X:W?BS2(U<QVK3Q0W(YX./F"GV]: .PZT55M+V*YCB4RQ?:&B61X
ME897(!Z=<5-)<00NB2S1HTAP@9@"Q]!ZT 248'I17+S>-K:'QY%X7-K(=Z -
M=[AL29E9UB(]2B%OQ% '444R6:*",R32)'&O5G8 #\32B2-HA*'4QD;MX/&/
M7- #J*CAGAN8Q)!*DJ'HR,&'YBDBN8)RXAFCD*'#A&!VGT..E $M'6FAU;=A
M@=IP<'I0)$(4AU(;[ISU^E #J*BBN8)U9HIHY%0D,4<$ ^AK&L?$L>N>&[G4
M]%B$TR"=88+B01[WC9DY()PI9>OH: -/4['^TM.GL_M,]L)EV-+ 0'"]P"0<
M9&1GJ,\8/-2VEI!864%G:QB*W@C6**->BJHP!^0J.QGFDT^UDO8XH+J2)6EB
M23>JM@%@&[@'O4T,\-Q'YD$J2IG&Y&##\Q0!)14!O;02M$;J$2)]Y/,&5^HK
M,\6>(%\*^&+W6GMFN5M0I\I7VELL%Z]OO4 ;5%<>?&FHZ??6,/B#PU/IMM>S
MK;17274<Z+*WW5<+@J">,X(KK);B" H)IHXRYVH'8#<?09ZT 245'-/#;1F2
M>5(D'5G8*/S-9VL>(+'1!IYNBS"_NX[2(I@_,X)!.2/EXZT :M%127,$4/G2
M31I%_?9@%_.J.N:]9Z!X?NM:NBSVMM%YI\K!9Q_LY(!/XT :=%1QSQ2P^:DB
ME,9+ C HBN(9X?.BFCDB_OHP(_.@"2BHA<0&80B:,RE=P3<-V/7'I2Q3PS[_
M "I8Y-C;6V,#M/H?0T 2=**C^T0"X%OYT?G$;O+W#=CUQUHDGAA1WEEC14&6
M+, %^OI0!)WHK,US7;/0/#]UK5T6>UMHC*WE8+./]G) )_&K\,T=Q$)(G5E(
MZ@YH DHZU%)<P12I%)-&DDGW$9@"WT'>I"RJ0"P!/0$]: %HJ.&XAN4WP31R
MH#C<C!AGTXK.U#Q!9:9K.F:7<%A/J)E$1&-J[%W'=D\<<#KS0!JXYS1UKFX_
M$DG_  G=[HDHMTLK?38KP3$D-N9V4@G.,845T2.DB*\;*Z,,AE.010 ZBHX;
MB"X#&":.4*=I*,&P?3BEFFBMXC+-*D<8ZL[  ?B: 'T8K*UGQ#8Z';V4]RS,
MEY=0VL1CP?FD8*IY(^49R3Z5HM/"D)F:5%B R7+ *!]: )**;'(DL:R1NKHP
MR&4Y!'UIB7,#SO"DT;2IRR!@67ZCM0!+17.^#_$$_B#0)-0O$AA9+NX@Q'D+
MMCD9 >2><#FNA+*%+%@% SDGC% "]:*B%S T_D":,S8W>6&&['KCTI9;B"%6
M:6:.-5QN+, !GIF@"2BLW3;K4KB[U%+ZS@@@AGV6KQ3[S*F!\S#'RG/;_P#6
M;L=S!-(\<4T;O&<.JL"5^H[4 2T5']H@-P;?SH_. W>7N&['KCK4E !1445S
M!.SK#-'(T9PX1@2I]#CI2O<01XWS1KE@@W,!ECV^OM0!)THK+UO7[/0([)[S
M?B[NXK2/9CAY#@$Y(X'<UH-/"D)F>6-8@,ERP"@?6@"2BJ]Q>P6^GRWS2*T$
M<9D+*005 SP:@T76+77=&L]3M"1#=0).JOC<H89 8 G!YH OT5%!<P7(8P3Q
MRA3@F-PV#Z<5A^"M?N?$OAQ=2NHHHY3<3Q;8@0N$E9!U)YPHH Z&BHFN8$G6
M!YHUF<96,L S?05@6OB223QIK6CW(MXK/3[6WF68G:29-^=Q)QCY1B@#I.M%
M-#HT8D5E*$9# \$>N:9!<07*%[>:.5 <%HV##/IQ0!+148N(#(D8FC+N-RKN
M&6'J!WH2X@DF>%)HVE3[Z*P)7ZCM0!)17-:!XF;4;S7XKXVUO'IVIFRA;.W>
M B,,Y/7+'I72,ZHA=V"J!DDG  H 7KUHJ);B*6W,T$B2I@D,C!@?Q%8G@O7I
M_$G@O3-;O$AAFNH3)(L>0B\D<9)XX]: .@HKFW\2R-X[T_1+?[/+97.GS71F
M4[FW(ZJ "#C'S'M70-<0).D+S1K*XRJ%@&;Z#O0!)13))HH59I940*-S%F P
M/4^U+YB>6)-Z[",AL\?G0 ZBF)-%([HDJ,T9PZA@2OU]*;%<P3QM)#/'(BG!
M9'! /U% $M%9.@^(K#Q%HZ:G9L4A=I%VRD!AL=D)(!/&5)'L16H75=N6 W'
MR>M #NM%1R7$$7^LFC3Y@OS,!R>@^M))=6\04R3Q(&;8-S@9;T^M $M%%!.!
MD]* #K144%S!<J6MYHY5!P3&P8 ^G%"7,$DSPI-&TJ??16!9?J.U $M%-=UC
M0N[!549+,< "FQ3PSPB:*5)(CT=&!'YT 245%]I@,RP^?'YK+N5-XW$>H'I2
MR3PPJS2RHBH,L68  >IH DQFBN=\:>(9O#G@G4=<L5@GEMXU>,29*-E@.Q'8
M^M:%Q=ZDFMV%O!9P/I\L<C7%PT^UXV &T*F/FR>OI_, TJ*B>Y@CF2%YHUE?
M[B,P#-]!WHFN8+<H)YXXMYPN]PNX^@SUH EHZ5SWB+7[G2-9\.V<,43QZG>F
MWE+@Y51&S97!ZY4=<UNPW$-RA>":.50<$HP8 ^G% $E'?-<]X(U^X\3>#-/U
MJ\CABFN5=G6+(1<.R\9)/0>M;L,\-S'YD$J2H>-R,&'YB@"2BBHFN8$G6!IX
MUF<96,N Q^@ZT 2T4QY8XP2[JNU=QR<8'K]*(I8YXUDBD62-N0R'(/XT /Z4
M5S6N^)WT[5M M+(VT\>H7YM)VSN,8$;-Q@\'*CK6KKNLVOA[0[S5KP.;>TB:
M5UCP68 =!D@9_&@#0HZUS/B'Q-)IB>'Y+%894U/5(;*0OD[$=68D8/WOE'K7
M117$,^_R9HY-AVML8':?0X[T 245']H@^T?9_.C\[&[R]PW8]<=:DH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *NI65MJ.FW%I>6\=Q;RH0\4BAE8>X/6O'-,TC3;/]FV[O[6QMXKNZTM_
MM$\<8#RX<XW'OBO;:YNW\!^&[6TU"SAT]EM+]2L]O]HE\L@G)"KNPF3S\N*
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MUS+,53(.T;V.!D#@>E 'E6D:+IMK^SOJNH6UA;QWTUG=I-.D8#NJSN ">I
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MMU<!KBXT^ Y=OFD;RP3]3WIGCB]TZU\/"'4M/?44O+F*UALU;;Y\K,-BDY
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MTF<[S$&V$YYSBNDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2WVGV>GWB1VR6:('!:%&^9B#E0>=HQU.3TP >BU#=W*6=G/=2!BD,;2,%ZD
M9./RKG_A[K-WX@\!:1J=^P>[FA(E<#&YE8KNP/7;G\:Y2V_MGQCH.N>(G\07
MMC KW4-E96RQ^4(H]R?O0RDN6*G/(QGC% 'H6BZM!KNB66K6J2)!>0K-&LH
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MFY90&E6-R S <9QC\JS+4:OXTU[7S'K]]I-CI5V;"VBLM@+2*JLTDA93N&6
M"\# H ZKQ'X@M?#6D/J-U'-*/,2*.&!0TDLCL%55!(&23ZU;TV[FOM/BN;BQ
MGL97SNMYRI=,$CDJ2.<9X/>O(M?O]1\4^ ]$GOK^:WOK3Q#'87+6H54ED6<(
M)0"IP1@,,<9)X(KU'4(=4L?"=U#I<[WFJQ6CBVEN2NZ24*=I; "Y)QV H UZ
M*\]\%:G'+/+!/XAUI]66T+76EZM$L;H_&9$&P?+G(^4E>16=)XFUD?L_0^(!
M?R?VJT$3&YP-Q)G52<8QT..E 'J=9>IZ]:Z3J6DV$\<S2ZG.T$)0 JK*A<EL
MD8& >F:YK4;C4_$GCVZ\.VVJW.EZ=IMI'/</:;1-/)(3M 9@=J@+V&236=XP
MTW4(=1\"V$>L327@U"91?S1(TF/)?G: %+!> <=0"0>E 'I5%</X<DU+2?B#
MJ?ARYU>[U.S_ +/BOH9+PJ9(V+LC+N4#(. >G%5_&GB*>+Q98>'4O-2LK5[1
M[VZGTRT>>=P'"*B[4;8,Y);'8#(S0!Z!37=(HVDD8*B@LS$X  [UYA'J_BN;
MPMKMMI?]KW+6EU"+2\N;(PW<MLVTR!5D50\B_. <<\=ZL0W%MJG@CQ)%IOBO
M6+B2&V9I(KQ42YM&"DE6#1@X;&.0>^#0!VFH^(;#3=$CU@M+<V<GE^6]I&9B
MX<@*P"YR.0<UJUY);OJ7AKX*:9J-IK5])-/#IOEB;81;JS1AD3"CY2&(YR?>
MM_57UC5OB;-X?@URZT[31H\5U(+54\PN9I%^5F!VYXR<'H,8H [RBO(+=_%%
M]X,\1W\OBR]CN/#L]Y!;&&*-?/,&6#394[\C P,#C/)KI=7UE+WP_P"'Y[K7
MK_3)=0MEF^RZ7 )+BY9D5L)\K, N>2!W&2* .UN+B&TMI;FYE2&"%#))([85
M% R23V %/CD26))(V#HX#*RG((/0BO'+C4M4UCX6^-[*[U'45?29)HXY9T1)
MY8?*#".48Q_$02,$\=*U]3U&_P#"/@K0K6#5]1N+C5KB&$74D GDM8S'N;RT
M1/F("X (/)SVH ].HK@/"6IWH\5OIT-SKU_I$MFTWGZM8R1-!,K*-H=HTW!E
M8G'."OO6EXSNX(YK&UD\0:G8/,'*V>E0"2YN2,<C",RJ.<D #D9(H ZVBO(5
M\7:[#\*?%-U]LN?[0T?4#:P7-S$JS% \97S%'&[#D&MVY76_#?C3PWYWB&\U
M&+5II;>\MYT18@PC+JT2J 4 *],GCO0!Z [!$9CT49-9OA[7+;Q+H%GK-G'-
M';W:;T68 .!DCD D=O6N-TT:SXRN=<U0>(+W3;:ROIK*RM;18]F(N"\H93OW
M'/'&!6E\)O\ DEGA_P#Z]O\ V9J .SHKS31K3Q!XL;Q'(WBO4+$66KW5K91V
MJ1A4V$;=Y*DN!D#'' ]ZIIXL\0:_X>\!SV=\MC=ZQ/+;W<BQA@=J.&8*>,Y4
ML.V<9XH ]7HKSZZ35)?%5AX)MM?U&&W@T]]0O+\LANIP92B(&VX4 YR0.@ J
ME+?^)8+;Q?X<MM5FN=1TB"&]T^]=%\V1&!;RI,#!/R%<XY#4 >G5GZ/K-MK=
MK+<6L=PB13O PGA:,EE."0#U'O7,_P#"2S^(->\*6^D7#16MU:MJU[MP3Y.T
M*B'ZN_/?Y#6 OBS73X/5(+W&IZCXDETF"ZD0-]G0RN VWH=JJ0,]\4 >@7NO
MVMAX@TK1I8YC<ZFLS0LH&Q?*4,VXYR.",8!_"M6O,9]&NM&^*7@R.;6[_4XW
MBOBOVW8S(PB7.&51P>.#G&..M9/_  E>HZY:ZGJ\.J^(;:\CGF33;.QTJ26U
M C8JHD(B82%BOS?-QG'&* /9**RX;O4+WPK'>PVPAU.:R$J6\P*A)BF0K \C
M#'!KC? NI/+J4%MJOB#6EUXVY:[TK4XDC5WXR\7R#*@YQL8\8S0!Z-17F-KX
MDUA_@3?ZZU](=3CBNBEQ@;@5F=5[8X  K0OK[5=?\6V'AFVU2?3;:/2EU&\N
M;8*)I2S;%12P(49!)('M0!U6M:]:Z&^F+<QS.=1O4L8O* .UW#$%LD?+\IZ9
M/M6I7FGCK3;^RTOPC8IK$]Q=_P#"10B*]NHT=URDNTD*%#$#UZXYK0T9M3T7
MXE/H$^M7NIV-UI1OE-[L+Q2K*J':55?E(;ICC% '=T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",JNC
M(ZAE88((R"*X>W\!ZMI4#Z=H7BZZT_1F8E+0VJ2O K')6*5N5')QD'%=S4-W
M>6MA;M<7EQ%;P*0#),X1020!R>.20/QH YS5/!\TVHV>JZ1K,^GZK;6HLVN9
M(Q<"XASG$BDC<<\Y!!R35;_A (7\,:YIEQJ4T]_K>6O=0>,;F;  PHX"J!@+
MVKLJ* .#^*-J1\/XK5)'4B\LHQ(F-P_?(,CKSWK0LO!]Z_B&TUC7M>DU62P5
MQ91?9D@2)F&&=@OWGQQG@#G KK** .*G\"7T,NHPZ+XDN-,TW4I7FN+5;9)"
MCO\ ?,3DY3=]#@G(Q6@W@RQ0^&DLY&MK?07+0Q!=V\&,I@G\<Y[FNEHH YC6
MO"UY>^);?7]*UDZ;?):FSEW6RSI)$6WX )&U@>_Z55M_A];1^%]?T.YU&YND
MUFXDN)KB0*)%=U4$\#!Y7/0#G&*[&B@#DW\(W]]I^DP:OKGVR?3=2BOHYDM!
M%O$:D!" QZY)W?I1?^$+Y=<O=5\/Z\^DRZ@%%Y&;59XY&48#J&(VOCC/(.!D
M5UE% '(_\(!8Q^'M+TBWNID6QU&+47GD >2XE5][%CQRQ/7M6K=>'TNO%NG:
M^;AE>RMYH!#MX<2%3G/;&W]:V:* ,C6M-U6]:WETK6VTV6+<&5K=9HY0<?>4
MX.1C@AAU/6L%/A['_9(MIM3EENI-8CUBYN?*5?-E5E. @.%4A0._XUV2S1/*
M\2R(TB8WH&!*YZ9';-/H QKSP^EYXKTS73<,KV$$T(A"\.)-N3GMC;^M<F_P
MPNI/#,GAEO$]P-$5LV]NEJ@=1OWA7?.7 /IM[9/:O1:* ,*;PXS>.+?Q+%>F
M,I8M8S6YB#"1-V]2&S\I#>QS[4>$_#C>%M)ETT7INH/M,LT&8@AC1V+["<G=
M@EN>.O2MVB@#&TSP^FF^(M<U=;AI&U9X7:,K@1^7&$X/?.,UCQ^#=3TRYNET
M#Q+)IVG74S3M:-9I-Y3L<L8F8_*"><$, 378T4 <SK_A:ZU+6M.UG3-7.G:C
M9Q20&1K=9EDC?!(*DCG*@@@U5D\%WR:UJEW8>(9K.TU5EDO+=+9&<N$"$QR'
M[F0!U!QVQ7844 <A9> X;+3?"UFM_(P\/RF1&,8_??(RX//'WOTK6T?P^FD:
MMK5^MPTC:I<+.R%<",J@3 /?[N:V<C.,\T4 8WA3P^GA;PS9:+'<-<):JRB5
MEVELL6Z?C6#_ ,(#>6TNI6VF>)+BQT;499)IK);9'9&D^_Y<A^X#Z8..V*[>
MHA<P%96$T96(D2$,,(0,G/IQ0!RDG@*,>']!LK74YK;4="0+9:@D8+#Y=K!D
M/!5AU&?QJQI/@_R+^^U/6]0;5]1O;?[(\C0B*-(.28T0$X!)R<DYK:TO6=+U
MN!Y]*U"UO8HW\MWMI5D"MUP2#UY%7J .0T3PAJ^A&ULK;Q5<-HEHX,-F]K&9
M @Z1F4\E>W0''&:K2^ +L7>LQ6GB.XM=(U>9[BYLH[=2_F. 'VRGE5;'( SZ
M$=:[BB@#EK?P7%;_ /")XO7;_A'8FC3]V/W^8?*R>>/7O6A9>'TL_%6JZZ+A
MF?4(8(FB*X">7NP<]\[OTK9HH XY/A]:KX5313?SK+!>O?VM[&H62"8R,X8#
MD'&XC!ZC-:^C:;K=G+(^KZ^-1!3:D:6:0*O^T<$DG\0/:MJB@#CAX!A'PR/@
MK^T)/*,)B^U>6-WW]^=N?PZU;U_PM<ZGK.G:QIFK'3=0LHI(/,-N)DDC?&05
M)'.5!!S734R.:*8,8I$<*Q5BK X(Z@^] ')2>"[Y-;U.\L/$4UE:ZJRO>0);
M(SEP@0F.1ON9 '4'';%1O\/U7P9HNA6NJ20W&C3QW%I>>2&Q(A;!9"<$88C&
M:[2B@#GHO#4[>(-*UN^U+[1>6-I+;.5@$:R[RIW8R=N-O3FL:3X>W<=M>:3I
MOB6YL= O'=I;%+=&= Y)=(Y3RBG)XP<9.*[2ZO+6RB66[N(H(V=4#2N%!8G
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MOP[URG_"!WEM<ZE%I?B.XL=(U*9Y[BR6W1V5W^_Y<A^X&],'';%=K10!QQ\
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M^R:W%?7-G;R)MBC4."<@ %L%<@?KC-:TVC7K_$ZUUL1K]@CTB2U9]PR)#*C
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MY?ES@G'.,<XH [2BN&T62QMM5\/V]GKNM)%<0W,B6.H)(SW.W 9G:4;TVG!
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M''"GKTQB@#>K)A\-:3!K\NN+:EM2D4KYTDKOL! !"!B0F<#.T#-3Z/J\&MV
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M6\JRQ31-#-;R;"1N5@"#W!H ZFBN#T?4I)M!^'\EWKMW!<WEO&6C">9]N?R
MQ#L02.A.>_UQ6OJGCK1=*U*;3W-Y<W%NH>Z%E9R3BV4\@R% 0O'..N* .EHK
M!U?Q=INC31P20ZA<W$D0F$-G92S,L9S\S;5^4<'K7/>-?%5O)X&TO7](U-H[
M*;4;4FYC9D_=>: X;H0, @@^A!H [^BN=TKQMH^KZL-+B-Y;W;QF6%+RTD@\
M]!U:/>!N%9/A#7A;Z+XFU'6M186UEK=ZGFW$A(BB5\*HSV'0 ?A0!W%%8&C^
M,-+UJ^-C"MY;71C\Z.*]M)(&ECR!O3>!N'(Z=,USOQ3UYM-MM$TY)]2MUO\
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M,\3KKLVIQ:>_B222*\>-UGB;;$R3$A<H<\Y( YYZU+-J>J^(?"'C31[74?\
MA(;&#3\V>I1PA6D<ABT1*_+(P '*COSR:]>HZ4 >2ZAXHTOQ*/ D.D2R71M]
M6MGN'2)ML!$3KM<D8#9/3V-='X3A"_$7QW*8\,UQ9@/CJ!;KW_.NWHH \1TS
M[/I.G:KX=\1>+]0T>X:YN1)9_986%U'*[$/&3$S2;@W8D@\<<5Z;8:OI6D:C
MI?A 3W#7@T]7@:6,_O(T&W);&-W&2*Z&LYM'ADU]-8EEEDFBA,,$;$;(0Q!<
MJ /O-A022>!QC)R :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGK0!W[7UHMX+1KJ 7+#(A,@WD>NWK6+=:]=0?$#3M!5(C:W-A-<NQ!WAD9
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MSY0 RNT@ $L,GM0!ZS=7MK8QA[NYAMT8X#2R! 3Z<T^2>&& SRRQI"HW&1F
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M%TV(JR6RC:H*L&!X[[AGW-6K[3++4FM6O+=9C:3K<P;B?DD4$!A[C)_.K=%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "J2:QI<FI-IL>I6;7Z#+6JSJ95'NF<_I5WM7S%H'PC\<6?Q,M+
MFXB98;>^%Q)J?G*5D4/N+#G)+#/&._- 'T[1110!5U*Y>STN\NHPI>&!Y%#=
M"0I(S^5>0>&/'GQ4\7:2NJ:5H7AZ2T:0Q[G9T.1UX,E>LZ[_ ,B]J?\ UZ2_
M^@&OF3X<3_#^PT^SU#Q!XDU2RU6VN_.%M#O,)"L"N0L9SG'/- 'TI_PE&B_\
M)!)H)U"-=4CC\UK=P5.S&<@D8(P<\'U]#45EXR\/:AH=QK=MJL!TRW8I+=/E
M$4C'&6 SU'3UKR#XT!M?\7V-AX:ADDUZQT^>>[GA;!6W*']V>Y)!; _VP/XJ
MS/%DEIJGP \-S>'X9#I=C<HNHP(<LCA3N+X]6;.?]M30!ZEJ'Q(T75O"'B*[
M\+:S%/?Z=8RS@B(@H0IPVUUP1GZBLWP+\5M&N_#>BP>(O$%L=?O PD4IMY,C
M!0VU=J'&WKC]:K7_ (F\$:Q\/O%%IX4:T69-%=Y8X;8Q,$", #\HS@GWQGWK
MS#Q#I=A;?LZ>%]1@LH([Z746\RY2,"1N9^K=3]U?R% 'T)XA\>>%_"LZ0:UK
M$%K.Z[A%AG?'J54$@>YJ6;QGX=M_#L?B"358!I,I"I=+EE))QC@9!R",=J\I
M^(OBA&^(<NAW4NEZ-;Q:>"VJ76FB[FG!&?+0$$8RQ'U!]A7#VC.?V:]11R?D
MUT* >WRH<?F30!]#V'Q \*:IKYT.QUNVGU'D"),D,0,D*V-K'KP#VJ'6?B1X
M/\/ZFVFZIKD$%XOWX@KN4[_,5! /L:\MU_2[#2O'OPL.GV<%J94C\PPQA-_*
M=<=3R>OK6!JSI#XK^(&B0:EHMK;ZI>!9IM99HY8SN+,8\ Y4$D#_ (": />1
MX[\+_P#".G7SK-N-+#F,7#;@"X_A (R3[ 5:\/>*M#\5VDESH>HQ7D4;;7V@
MJR'ME6 (_$5X?\1["'3=$^'\VF:A;7&@V/[F34$A$\ E&P>8Z#AL[6XYZ$5U
M?PJL;2;QEKFM6WBJPU>6:VCCN8;*R-NBDD;6QT/"L./7F@#JOB1XPO?".CV)
MTFV@NM5U"\CM+6"8$JQ;J< @^@Z]2*G^'7B]_&G@RWU>YCBAN@[Q7,<>0J.I
M[9)(^4J>3WKSOQY<:WXD^-.EZ7X;BL[BZ\/VWVLI>,1$)&()+8YX!BQ[U@^'
M%U_2Q\1?!4\4<6KW-H]]#!:$E-S#+K'GDY1U '7B@#V.V^)7@Z]UG^R;;7K:
M6]R0$0,58@9(#XVGIV-8'A;XP:/XB\7ZCHK2V\42S)%ILJEB;O.<\8XZ#\ZY
M[X0^)/ L'A[0]'9;6'Q$SR1,LEL?-,AW9._;W7CKWQ5+X>S:%H?QB\8:;JD5
MM;7<^H*--CD@Z?.Y 3CY<ADQTXH ]NLM2L=2$QL;N"Y$$K0RF)PVR1>JG'0C
MTKD[[7O$.J>,M1\/^'Y=,LO[,ABEGEOHGE:8R D!%5EPH Y.3R:W?#L_A^>/
M4#X?^R[$O9%O/LZ;?](XW[N!ENG-<SXG3P+KFMS0:GJL>EZ[IR@+=K<FTN(U
M(W JYP'7GW'6@#J(-3GTSP]]N\42V%E+"#]HDBE/DCG (+ 'GCCKDXYI^B^)
M-'\0I,VE7\=SY) E4 JR9Z94@$9[<<UY'=:IK.I>$O#^HW^I))I]AX@DC_M6
MXM=Z2PKN6&XD0%05W'&<@9P:W[S3+W4?^$@U&R\5Z=JVKMH4UI';Z=;B-OF.
MY&)$C\Y# ?[U '96?C?PSJ&KC2K36;6:\+%%1&)#,.2JM]UB/0'-:,.LZ=<6
MUY<PW<;PV4DD5RX/$3I]\'Z5S7@KQ%X6;PMX?LK*_L8Y#"D,5IYBB590GS*4
MZAOO9_'UKE]-US3-*\._$#3[Z]A@OFU74-EJS?O9/,4;-J=6W9XP* /1;CQ/
MH=I96EY<:G;16UW$9H)7?"R(%W%@?]WFLV'Q%!?:W97=IKUK_9,EA+<&T: B
M20*V#*&."%'3&/\ ZW%VUM!=K\'XKB)98_LS/M<9&Y;0,I_ @'\*Z:]_Y+3I
M/_8#N/\ T;'0 _PM\0M+\6'4;6TO+>.\@GG2%02^Z)#A9<<<'(.*T=*UZVLO
M!=IJVLZ[9W,7E[GU!%\J*7).-J_D,#J>U<[\/[VU2P\3Z<]S"M\NLW[&W+@2
M;2^0=O7&#UKC[?[3!X%^&5\;R&RT^W=_.NKB#SH8)61A$[KN7C.X!B0 6!H
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M04D%A9VT4D4%I!%')]](XPH;Z@#FK%% %*VT?3+.&6&UTZS@BF_UJ10*JO\
M4 <_C3WTRPDM4M7L;9K9#E(3$I13SR!C ZG\ZM44 5I]-L;JXAN+BRMYIX>8
MI)(E9H_]TD9'X4TZ7IYMVMS8VI@=][1^2NTMZD8QGWJW10!7>QM))(9'M8&>
M'_5,T8)C_P!T]OPKRB\^%WB)=8UJ6WE\,ZE;ZI</-]HUBR::Y@W<;4.", 8
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M0 4444 %%%% !11TKQW3/V@=+U+QE#HXTF:.PGG%O#>F4%B2<*Q3' )QWR*
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M3+J4,KV-U8[Q&9(QN:-U;)'!R"#SCI7":9_PDB^ /B(__$I$9NM2,S#S-_F
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M]2UEM974(K0+9Z@]M;S6C%DEC 4CD]6&<''&01VKHZ9##%;Q+%#&D<:]$10
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M7<6U9,9V,""IQWP0.*Y[P_H^HP7]HM_X+\.VC0<RZA:NN78#AHT$8*DG'4C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!U)SQC/';G%7PW\3]6T_1?%OVB^DUN'2[99["_GM3 TA8A=KKUP&8>_!YZ8
M/5O%7B_2?!MA!>ZO)*D,\P@0QQESN()Z#V!K>KY:\;1>++WX<Z#X@U_Q$+^W
MU.]25+/[.J^0Q5]I##_9SD8'4=:]]^(VHW6D_#O7;VQ9DN8[5@CKU3.%+#W
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M)XKAH_%GQ$O/A@WC+_A*ECBL+H0>0MLF^;+ ;G;&.-X&,8P/6@#Z5H) !).
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)!1@PVG!(YR.]3:5X6_LRQ\06WVSS/[7O;B[W>7CRO-4#;U^;&.O&?:NBHH
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M5;2QW?G-')M+*DJ[1M)"MT+#(Q6-J7@G4=;'Q LY5%O'K$EN]E,[ JYCB3J
M20-ZX.12^'-#M/[5L3<?#R33KNW;?)>-<1O%$X!P8\.6;)_V1C/- $\OC_6K
MBWUNXTKPN+F#1KJX@N9);T1B01$Y\L;22V!G!P!D#)JOXN\6:N]GX-OM M-]
MKJE[;R M=>49 \;,(6&TX!')/.,8P:T-"T'4[/P]XQMI[4I-J&I7\]JN]3YB
M2#Y#P>,^^/>LV]\/:U;^ ?!"PZ<]Q?Z%/9SW-FDB!V"1%'523M+#=ZX.* .\
MCO7@T?[=JD<=FT<)EN$63S%BP,M\V!D #KBN-'Q#U.+2H/$5YX;:#PS,RD77
MVH-/'$Q 65XMN IR#@,2 <UU5U;-XC\+75I<V\]B;^UDA>*7:7B#J5YVDC/.
M>#7 W-CXLU7P/#X&FT!K>;R8[*XU0SQM;"%, R( =Y8JOW=HP30!)JAOKWXX
MVD+Z)9WMK%I.8S/<C"1M,N^8*4/S#[NWN!U%=)X_D:31+/2E8J-7U""PD(//
ME,V9!^**X_&DCT2\B^)\.J) ?[-CT(V8F+C_ %GG!@N,Y^Z,YQBCQ^IATK3=
M5/\ JM+U2WNYO:+<4=OP5R?PH )'TM?BC:6G]EK_ &@-&=TO1*1LB$JKY6SI
MU.<_A2^ V-O9ZMHW_+/2=3EM8!Z0D++&/H%D"CV6G2:3?/\ %.VUE8,Z>FC2
M6QFW#B0S*P7&<] 3G&*9X%!N8]>U<<Q:EJTTL#?WHT"PJWT/EDCV- %S7-4\
M16=PT>CZ!!>1)'YCSW-\L"D\_(H"L<\=3@<CFLF;XC0_\(CH.OVFEW%T-7NT
MM%M4<"1)&W@@$\$AD*]0.^16?KFDZC<>-[Z?4O#,OB'3I(8AIB-/']GMF /F
M>8CL "6P=VUCC@>E4M,\(:Y:^!?!>F26*K=:;KRW5U&DBXCB$LS;@<\C#KP.
M>>E '16'BW6'UZ[T/4] BM=1%@U]9K%>^:DZAMNPML&UMQ7L>OYO;QW"_@73
M_$5M9&6>_>&"&R,FTF=W"&/=C^$[LG'\)J6?2;Y_BE9:PL&;"/2);9YMPXD:
M5&"XSGH#SC%<QIVC3?\ "UY](7:VC:=,^N*H.=D\Z[%0CMAO.<?[PH VOBW<
M7EO\,=:-I")-\)29C+L\N,\%AP=W88XZ]:IVRV-IKG@JVOO"]I9ZA*;O[,;:
MYRMKMB&6PJJ'+* .1Q[UN_$'2[W6_ .LZ;IT/GWEQ!LBCW!=QR.,D@"J^KZ/
M?W/C/P=?PVY:VT\77VJ3<H\O?"%7C.3D\<9H H2^.]:N?[;.C^&!=)H]U+!/
M)->B)9/+ .$^4DL0<X( '')S6T/$5]J7AO3-6T#2/MS:A&DJI-<+"L*LN<NV
M">.GR@\UG^'-$U&QL?&$=S;&-]0U6ZN+4;U/F1O&@4\'C)!ZX-<Y)X>UVU\)
M>"K*ZTFZOK"Q@,>K:9;7"*[OL CS\P5U5LY7=@Y'7% '1V'CB:72/$LE_IB6
M^I^'XV>XMH[CS$D'EF1"K[1PP!ZC(JI'X_U11HE_=^&S;:+JTT-O%<-=AID:
M4?(S1A<;2?\ :S@Y('2LO2_"FJ06?C\1>'X-+BU>Q2.PLH)(\9$#IM.W"JV2
M,]LMU/6M75_#VJ7/@?PGI\-J6NK&ZTZ2YCWJ/+6(KO.<X.,'IG/;- %Z]\6:
MG/X@O='\.:+'J,FGJAO)[BZ\B-'8;A&IVL6;')X '&339;JSE^(&@+>Z+Y>K
MRZ;-*LYN"3; %-T>!\K<M][VXZU2C@USPCXJURYM-#N-8TW5Y4ND-K+&LD$V
MP*RN'9?E. 00>*NMINK7OC[P_K<^G^1#%ID\=R!,KB&5RA"9ZMT/(&.* (=>
M\9ZWX=674;_PY'%HD,XBDG-^IGV%]OF",*01R#C=G'I1_P UP_[EO_VYKAM4
M\(:]JGA35-/N_"3WWB:21R^L75S$R,OF;E\DEBR_* H4!0.YKT"33M0A^+%K
MJPLY)-/ET9K)IT9<12"7S/F!.<$< @'F@#KZ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF32I!#)-(VV.-2
MS'T &36%IOC;P]J\KI8:@)DCMA=23>4ZQ)'@'YG("@X8$J3D=Q0!T%%<_I/C
M;0-;ODLK&]=II5+PB6WDB$ZCJ8V=0' _V2?6JEY\2/"EE)<1RZFS-;2O%<"*
MVED\@JQ5M^U3M&0>3P>V: .KHK+U'Q'H^E:/'JUY?Q)8RA?*E7+^;N^Z$"Y+
M$]@,U'HGBC2/$(G&G71>6W($\,L3Q2QYZ;D<!@#V.,&@#1O;5;ZRFM7DFC65
M"A>&0QNH/=6'(/N*JZ+H=AX?L/L6G0F.,NTCL[EWD=OO.S,268^IK!F^)?A@
MV$]S9W[W0CMOM&Z*UE=0#C:&(7Y2<C@X.#GI6;#XX@\1?#U=4AUMM$NU2U:Z
MN18/(L+R,HV*KKAP3E<C.,YS0!Z#16'JWC#0M#O39:A?>7>>4LRVZQ.\CJ20
M-JJ"6.5;@9(QGI3[+Q9H>H>'Y==@U"/^S8=WFS2 IY97[P8, 01Z$9Z>M &S
M17,67Q \.ZAJD.FPW%VM[. T<4NGW$993P&^9  I]3Q6MK&O:7X?@AGU:]CM
M(9I?*223.TMM+8)[<*>3Z4 :-%<I'\2?"DL=PRZDXD@95:!K659F+ E=L97>
MV0"<@'I6I9>*-%O_  ^VO6^H1?V8BLSSOE FTX8,&P00>QYH GT71K+P_I,.
MF:?&T=K$6**S%B-S%CR?=C6A6'HOB_1-?NWM;"YD-PL?FB*>WDA9X\XWJ'4;
ME]QGK56/X@^&9=3BL$U%C)--Y$<OV>00O)G&P2[=A.?>@#IJ*P-6\:Z#HE^U
MC>W<OVB-!)*L-M)-Y*'HSE%(0<=\5H)K6GR:O'I27(-[):_;%B"GF'<%W9QC
MJ0,9S0!?HK'E\4Z+#::K=27H6#2I#'>OY;_NF !QTYX8=,]:AA\:>'Y[74;M
M-046FGX%Q<O&RQ#)(^5R,/R"/E)YX[T ;U%8NB^*]'U^>6WL+B3[1$HD:&>W
MD@DV'HP5U!*^XXK)\/\ B&)?#VI^*]7OS#I]Q=2/!YA.V&!&\J, #NVW=QR2
M^* .PHKFCK-MXNT34[30[V[M;^.+Y6D@DMY(G()C;#J"5)7Z$9%:'AK6!X@\
M,Z=JP38UU LCI_<?'S+^#9'X4 :M%<5X<^(NG:]XGU/1U+@PW BM"+:8>8OE
MAF+$KA2#N SC( ]:Q_!_Q)TFU\+6O_"0:P[7IN)TEE:)Y!$//=4$CJI5.-N-
MQ'&.U 'IM%8NM>*]'T"6*&_N)//E0ND,$$DTA4=6VHI('N>*Q?$_Q$TS2/!"
M>(M-GCO([AE6U/EN5<[PK X&5(&>#CD8Z\4 =)K&C66NV:6M_&SQ)-'.H5BO
MSHP93Q[@5H52TK5K/6[%;VP>1X&8J#)"\1R.ORN ?TK&G^(/AFWU+[#+J+!Q
M/]G:46\AA67.-AEV[ <\=: .FHK$UGQ?H>@7/V74K[RKDQ"985B=W=2Q4;0H
M.XY!X'/&>E0ZEXWT#2I(HKJ[E\V2$7'E16LLKI&>CNJJ2@_WL4 =#14-I=V]
M_9PW=I,DUO,@>.1#E74\@@UQ_BOX@:'8:=K=C;ZFRZC;6TJ^9%#(R0S;#M5I
M I16SC@GK0!UUE86FG6_V>RMXX(MS/LC7 +$Y)/N2<YJQ7+:;XGL],\":!J6
MMWI$MU96_.UI))Y6C!(55!9F/)X%1:M\0-(M?!NI:]8SF8VBN@B>"166<*2J
M2)@,F>.2!P>M '745S>F>-M&O?"YUR:[%O;0HOVAY89(@CD X 8 MR0!C.>V
M:M:1XLT;6S<+9W,@EMD$DL,\$D,BH>C;'4$J<=0,4 ;5%<S;?$#PS>1SRVVH
MF6"WM#>S3);R%(X@ Q);;@-@@[?O>U1K\1_"37@MO[9B4LC.DSQNL+[1E@LA
M&PD#J : .JHK$T/Q9HOB2:Z@TR[9Y[;!EBEA>)U#=&VN 2#ZUFZ-XFT[3O"-
MCJ.K^)H[^&XN'A34I;;[.LC;WPI4#"XVD9.!\N>] '6T5A:)XQT/Q#?3V.G7
M;O=0H)6BE@DB8H3@.H=1N7/<5!+X\\-PZHVGOJ/[Q9A;O*(9#"DI.-C2A=@;
M/&">O% '245AZUXPT/P_>0V>H7;BZE0R+!!!)-)L'!8JBDA?<\5D_#G6IM>T
MW6KN2]:[A&M7<=M(3D>2&&P#VP>* .RHKG]:\;:!H%T]K?W<@GC022I!;23&
M)#_$^Q3M'UQ5B]\5:%IVGV6H7>IP16=]C[/.2=DF4+CD<#Y03S_.@#8HK$T/
MQ=HOB.XN;?3;IWN+8 RPRP20N%/1MKJ"0?45QWCWXDZ3'X2UJ+1-7D7485\N
M*XBB<1^8&&567;L+8SP#0!Z913%8"$.QX"Y)KE$^)W@^7R&CU<-#.55;@02>
M2K-T5Y-NU#ST8@COB@#KJ*P]9\7Z%H%S]EU*^\JY,0F6%8G=W4L5&T*#N.0>
M!SQGI4>I>-M!TEX([JZE\Z:$3B&*UEED6,_QNJ*2@_W@* .@HK#OO%^A:?IU
ME?2WPDAOO^/06\;3//QGY%0%CQUXX[T\>*]$_P"$?.NO?+'IRDJ9949"&!V[
M=I ;=GC&,YH V:*QM'\4Z1KHN197$GF6P#30SP/#(@/0E' ;!P<'&*S(_B7X
M1EEM$BU8.MTR+'*L$GEAF^ZK/MVHQR.&(/K0!UE%<5J'Q%T[3?'H\/7!<1+:
M&221;:9V$N]0JC:I!7:2<],\9K6U?QKH.AWK6=]>.+A$$DJ0V\DWDH>C2;%.
MP>[8H WZKVMA:633M:V\<37$AFF9%P9'/5B>YK.U7Q5HFC:=;7]Y?H+>[(%L
M8E,K3DC(V*@);CG@5S_A+Q/_ ,)#X\\2):WLD^G06]H88G5D\IR)-X*L 5.0
M,@B@#N:*PK^Z:/QCH]L-;^SK-#.W]F_9MWVK:!\WF?P;<@X[YJC>_$CPG8-,
MLVJ9,$KQ3^7;RR>2RL5;?M4[1D$9. <<9H ZNBF12QSQ)+$ZO&ZAE93D,#R"
M#7.)\0?#,FIQ6"ZBQDFF^SQR_9Y!"\N<;!+MV$Y]Z -]+.V2]EO%A07,J+&\
MN/F95)*C/H"S?F:GK$UOQ;HOAZXAMM0NG%U,I>.W@A>:5E'5MB D#W(Q27GC
M'0;'1K359]046EY@6Q6-V>8GLJ ;B?;'% &Y16'%XOT*709];-\(;"W8I-)/
M&\1C88^4JP#9Y'&,G(Q2Z)XNT7Q#<RVVGW3FYB4.\$\#PR!#T;:X!*^XXH V
MZ*P++QKH&HZI%IME?&XNI&D79'#(0A0L&WG;A.4;&[&<<9KD/'GQ)TH>$=6C
MT+5Y%U"-DCAN(HG$9<2+N5)=NQCC/ /K0!Z=16/K?BC2?#[PQZA<2":8%HX(
M8'FD8#J0J G SUZ4Q/%V@R>'%\0+J,?]EEE0W&UL*Q<( 1C(.X@'(X[T ;=%
M<]I?C?P]K.K_ -EV-_YETR&2,-"Z+,HZM&S*%<>ZDTR]\>>&[#5)-.FOV-Q$
MX28Q6\DB0L>@=U4JI^I% '245A:SXPT30;M;2^NI/M)3S3#!;R3NB?WV"*2J
M^YQ6K:WUK?6$5]:3I/:RQB2.6,[@RD9R,=: +%%8<GC'P_#X>MM>DU*-=+N6
M5(;@HV&+' &,9'(/4<8YJSJ&KV<%RVEF]\B_DM9+B/$9<HBX!?IC@D<'K0!I
MT5YY>?$"W\.>'O"[S:H=6?49HEDO392)YD+9W2!%'#<#"]?:GZOXSMK+QKH%
MP^I20Z-=:=<2E&C<&5PR!/W9&XMR<#&?:@#T"BLK0?$>E>);26XTJY,JPR&*
M57C:-XW'\+*P!!Y[BN?U/XBZ?I7CQ/#]R7$(M&EED6VF=EEW(%4;5.5*L23T
M! &1TH [6BO/(O'%KHOCCQ;:ZSJ,WD026OV2V2)YF53 &<JB G;D@D].:ZQ_
M%.B1^'8]?;481I<BADN.<-DX  QDG/&W&<\8H UZ*R-$\3:5X@,Z:?.YFM\>
M=#-"\,B9Z$HX!P<<'&*-;\3:5X>\E=0N'66?/E0PPO-))C&2$0$X&1SC'- &
MO4=Q;PW=M+;7$:RP3(8Y$89#*1@@^V*S;#Q-HVI:$^M6VH1'3HPQDF?*"/;]
MX,&P5(]#5?1/&6A^(;EK?3KF5Y!'YP$MM+$'CR!O4NH##)'(]: -E+>*.U6V
M1,0J@C"YZ+C&/RI+2TM["SAL[2%(;>!!'%&@P%4#  K"L/'GAS5-433[*_::
M61VCCD6WD\F1U!)59=NQC@'H>U,U#X@>&=,U&6QNM2VR0,$G=89'B@8]!)(J
ME4/U(QWH Z:BJ,^LZ?;:AI]A+<J+G4 YM4 )\T(NYL$# P.>33#KNFB]U"S-
MR/M&GPK/=)L;]VC D'.,'A3TSTH O2QB6)XR64.I4E3@C/H>QK-T/P[IWAZ&
M=+%)3)</YD\\\S2RRMC +.Q).!P/2LN'XC>%+F\L[:'50YO&1()!#)Y3.PRJ
M>9MVACG[I.>QYJG=?$73K/Q^WAR<N(EM0YD6VF9O.,FT+PI&W'.[IGO0!VM%
M<Q:ZW;:?<>)KS4/$'VFSL)5,L1M2GV!=@8KD#,F00<\U):>//#=]K,.E6VI"
M2YG+"$^4XCE*C)"2$;&(]B: .CHKG=8\<^']"NYK6^O)1+;H)+CR;:680*>0
M9"BD)GWQ6KI6K6>MZ?'?V$CR6TF=C/$\9./9@#^E %VBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"EJ__ "!;_P#Z]Y/_ $$UYHNEW-Y^S9;V6DP$W$FFQ2>5$O,@W*\@
M [E@&X[YKUCK2 !0   !T H \RTF;3/$FKZ X\>0:A+:S?:;:QCMHHY01&P*
ML%^9!M)!!Q53PQXN\-Z!8^,8-6OK>*?^V[YS;/P\ZEL */X\XQ@9KU5+>&.1
MY$BC61_O,J@%OJ>]87AKPR-#34A.\5RUUJEQ?QMY?^K$C9QSW'K0!YW9V5UX
M9T'X:7^OQO'8:;YPO2ZDBV>5#Y+..P7.W)Z$UT6GWUIXA^++:IH<T=U86FD-
M;7=Y =T4DC2!DC##AB ">,XS7H3*&4JP!!&"#WIL44<$8CBC2-!T5%  _"@#
MSOX>6@;X%6D-M"/,FL)_E0<N[%_S)KG[O5].U']GZSM;.]@GN;.'38KF%'!>
M%A/$,.O53E3U]*]F50J@*  .PIBV\"%RL,:[SN?"@;CZGUH XM$5OCE*Q4%E
M\.IM)'(_TANE<E?0QOX%^):OO58]>DE4HN0KKY# L/[NX M[9KV3:-V[ W8Q
MG'-8GBO09/$&@R6-M<);3>='.K/'OC=D<,%D7(W*=N",T <OX=U.V\0>-+;5
M+SQ#X=EN[>SDMK:STN\\UI-Y5G=MV#_ ,* <<\U=^(J+)=>#E=0R_P#"16_!
M&1]R2E/A/5-7U?2[O6AH]M%IMR+I$TZ)C)+( 0,NV-J\Y*@'/'-=J5#8R <'
M(R.E '$+$A^.DC[%WCPVN&QS_P ?+5Q=[9W=QX)\5FT60QVOC"2XN$BC\P^2
MDB,V$Z-C[V.^*]KVC=NP-V,9QSB@*%S@ 9.3@=Z /.M&DL-:\3Z;J4?CB#7;
MJQ@FEAM;>&)6*.H5@VSD<[>#CD5Q>O\ B=O$O@F"]NO$:?;Y+R!_[#LX4 M<
M3J,2DJ9 0/XB5!.!CG!]VBMX82QBACC+G+%% W'WH6WA5G988PTARY"C+'W]
M: /-/%FHZ;H.O:SK&D>*[73-<2%#=Z=>J&CO=B9C 4X;)!VYC)],9S1)X@M]
M/^(^AZ]KY328=0\-&/-RVU8YS(DC1ECT(![UZ7)!#*Z/)%&[H<HS*"5^GI2R
MPQ3J%FB20 Y =0<'UH \7NKN*_\  7Q2NX _DS7C/&70H64Q18;!YP1@CV(K
MIOB%931^"-!DLMT%GIU]:7%QY,(D\J! 1N\O^(*2K8]%]J]#**0P*@ANO'6G
M4 >?^'EL-9\6V^I1>-K?6[NULY46*VCB7;'(5SN*>ZK@&J.E0Z+/\$]-L]?N
MWLK6(+;R7"$AH)XY2H;.#MPZ=3QZUZ5%!# &$,4<88Y(10,GUXJAI>BQ:5/J
M1AD9H+ZY-SY# ;8W8 /CV8@MCU)H Y?P9XEO+S7-3TF;6+/7;"SMXYDU>V15
M +$@Q2%24+ #.5QQU%7_ (:*R_#W2G92HF$DZ _W))7=?_'6%;6J:1'J&A7>
ME02&RCN8S$SP* 55N&QZ$C(SVSFKUO;Q6EM%;01B.&%!'&B]%4#  _"@#@O"
MFI6.G_$'Q?IEY=PV]]=ZA%+;P2N%>9# O* _>^Z>G3%<]I\4?_#.6L_(OS1W
M[-QU(FDP3[\#\J]?,,33+,T2&51A7*C('L:78FS9M7;Z8XH \WU#Q5);:Q8:
M+<Z[;^'K(:3%=?;940RW+'@I&9,J,8R>&)SP*Y959_@7XE\LW$R1:U))NECV
MR>6MTC%F7 P< DC QSP*]O>"*0H9(D8H<H64':?4>E/VK@C:,'J,=: *FFZK
MI^LV@N],O;>\MR=OFV\@=<]QD=Z\1\7^*7\1_#[6Y+WQ MM>>9(B>'[6%/,C
M$<N,S95GZ+N+#8*]WBAB@C$<,:1H.BHH _(4@MX1(\@ACWN,.VT9;Z^M '$&
M*.7XW6DDB*SQ^&V9&(R5)G R/P)'XUSYN)=#\?\ B=-1\51>'VO9H[FWDN8(
MBES"(PHVR2=U((VY_G7K6U=V[ W8QG'.*9-!#<*%FBCD .0'4'!]>: ,3P5I
MUKI?A&PM;&_-_:X>2*YVA=ZN[/P!T W8'L*\WT77])T;X5:YX=U*ZC@\0HM]
M#<6C@^?/,Y<JP7JX(9?F&1CV%>SU&8(3-YQB0RXV[RHSCTSZ4 >/7?VBQ@^'
M6KRZF=,TZ/1A;F^,"RI;RO%'@MNX4, 5W?XUI7-A;WOA#QWJ&G^(T\0W5[IY
MAE:WC0*&CB? &SAB0P'X"O46C1HS&R*4(P5(XQZ8I(XHX8Q'%&J(.BJ, ?A0
M!Y-XCU.VUGP'X7U#2-4CEM-+O+26_EME6<VRB,C>Z<_<8@D$<=>U:^D+8:IK
MT^JQ>-+?7;NWTR6'R[:.(!8W*GYBGNHP#ZFO08H(H5*Q1)&&.2$4#)]:(K>&
M!2L,,<:DY(10 3^% 'E^DPQP_LU2K$BH&T*=R%&,DHY)^I-3^(((?^$>^&R>
M4FU=5L0%VC _<O7IFQ=FS:-N,8QQ054@ J..G'2@#BD 'QQFP,;O#B$^_P#I
M+5P^GHLGPN\!HZAE;Q/&"K#((^TS5[;M&[=@;L8SCG%)Y:8 V+@'(&.AH XC
M4E8_&32_+(61M#N5W?\ ;6/'ZUP>A16\G@5O"NN>-8M)G7?:7>ESVL0F#ESR
MN?F?<2&##/6O=-HW;L#/3.*8UO"TRS-%&95&%<J-P^AH \YL=5TWPK\3?$Q\
M17L5FU[!:/8W5TP198DCVNJL>,A\DKU.:O\ PLG2YTKQ!<1!A%-K][*F]"IV
MLX(R#R.".#7<20Q3;?-B1]IW+N4'!]13@ ,X &3DXH \WUGQ29O%6M:/?>(4
MT&ULEB6&&*%&N;_>F24WJV1D[0JJ3G/TKG=&0/X%^%:2KNQJR@AQG&%FQ^6*
M]H:&)I5E:)#(@PKE1D?0TNQ, ;5P.1QTH \]UB"XG^*VHPV9VW4WA*1(F!Q\
M_GD*<_4UQ^I>)=!_X4 =!AN(X]5ALH[>;3PI\Z.5&7S"R=0,AF+'CWKW/:-V
M[ W8QG'.*9]GA\QY/)CWN,,VT98>Y[T -?\ X\F_ZYG^5>):;XET*7X!0^'H
MKB&XUBYLFM8=.09F>9V.TA.N,D-NZ<=:]QD3?$Z9QN4BL/PAX<'AKPQIFERO
M%<7%E#Y7VA4P2,D\=P.: .9L+)H?B]I<5V%EN;;PJ%+GG#B95)!]^?SK)EGF
MT3XC>)?[0\4Q^'_MS0SVTUS!$8[F)8PN%=^,J01MSWSWKUG:-V[ W8QG'.*9
M-!#<*%FB210<@.H(!_&@#R]]-\-Z9H/AW;XR^P7<+7-QIFK.J)&PD;,BD,-A
M4[AA<@\<5F:MK6KZ_P"&=%UN[N(TM=*UYTGU&TM]\4D2JRI=+&V?E#-SU .2
M*]DEABGC,<L:2(>JNH(_*G!550H4!0,  <8H \_T&.QU'Q#>:O#XQ@UZ[BTQ
MK9DMXX@J(S!@24XSE3P?4US$T:)^R_;;45?]'@?@8^;[0AS]<U[)%!#;H4AB
M2-2<E44 9_"G;$V;-J[?[N.* . UC4K'1/C)97NJW<-E:3Z%)!%/<.$1I!.K
M%0QXSCG%8-M<R:'XM\56VJ>+8= ENK]KN+[5;Q%;F!D4(5>3[VW!7:.F/>O6
MY8(IPHEB20*=PWJ#@^M$MO#/M\Z*.3:<KO4'!]1F@#R>WBTSP=XC\&7=[J F
MT"/2I[:TU&<;8XYG97!8]$RF5&<=*VO!^IV>K_$_Q=>Z?,)[5[6Q"3(#MDP)
M 2I_B&01D<<5W\D4<T9CE170]589!_"E5%3[J@<8X&.* .+US_DKGA+_ *\K
M_P#E'6+X?BC/@#X@?(OSZCJV[C[WWNM>GE06#$#(Z''2@(H! 48/48ZT 8'@
MMV7X>>'GVEV&E6QP.I/E+7DOB#Q.WB7P1#>77B-/M\EY _\ 8=G"@%KMG48E
M)4R @?Q$J"<#'.#[R    , = *8MO"K.RPQAI#ER%&6/OZT >>QZII_ACXK>
M(;CQ!<Q64>I6UL=/N[E@D92-2)(PYX!W<XSSD&H]7UO3(?'WAOQ5=7"GP]+8
M3VUO>LI$4,[,OS$D?*&4%03UKT:6"*X39-$DBYSM=01G\:<\:21F-T5D(P58
M9!'TH \Y\:ZQIVL:;HNM6%PFH:-I6MQ2Z@]N"Z*JJ?GX^\JEE)QD?E3Y=4L/
M%'Q2\-W'A^ZBO8]-M[E[^ZMF#QK'(@6.,L."2W.WJ,$UZ&D:1QB-$54 P%48
M 'TIL4$4";(8DC7.<(H S^% 'G/@JREF^&WB2+3U"7MU=ZDJ,O!,A=U4Y]>!
M^5<OK/B;0)?@)'H=K<Q)J<5I;P2Z>%/G121NGF%TZJ,AB6.!^=>XA0HPH 'L
M*8+>$2/((8][\.VT9;ZGO0!Q'BOQ1+8^+K71)M:MO#]B]B;IM0F1"TK;]OE1
MF3Y 0/F.03R,"N#.R3X/^,0)9KB)O$F5DN(]KR*9X#N9=J@$YSC Z]*]TDAB
MFV^;$C[#N7<H.#ZBE*(0057!.2,=30!Q7BE57XC> MJ@8FO5&!T'V<\?H*QO
M ?B71/"N@W6C:_?PV.M6U].;N*<XDN&>5F611UD#*5P1GI7IY4$@D D=#CI3
M&@A>596B1I$^ZY4$K]#0!Y3)<2Z)\1/$PU#Q3'X?^W/#<6TUS!$8[F(1A<*[
M\94@C;GOGO7=>"=/M-,\)65O8Z@=0M29)8[G:%#AW9^ . ,L0/:MR:"&X4+-
M$DB@Y =00#^-24 >+6FB_P!KZWJ'P^E4BTTR>_NU!'RK'/&!!^1N)3_P"M/P
M3?3>)UUWQ%=*WFVVE0Z5\PZ2I&9)Q_WVX'_ :]5"J&+!1N/4XYH"*H("@ \D
M 4 >.&:.T^%WPUO[AQ':6FHV4MQ,W"Q)L<;F/89(Y]ZZ:[N;/4_BQX7O+2:&
MZMVTN\>*:-@ZGYHQE2./49%=VT4;Q&)HU:,C!0C((^E"11H%"(JA1A0!C ]J
M .,\* +\2/'@ P/.LCCW-N*J:WJ5CH?QATZ_U6[ALK.;0YH(Y[APB-()D;;N
M/&<<XKT * 20 ">IQUILL,4X EB20*<@.H.#ZT <5X61/^%F^/'VKO\ ,L1N
MQSC[..*X"VBN8?ASX0U%+A[73]/UFZ>YG2$2BW!EF5)"AXVJ3U[9S7NP4 D@
M $]3CK0%4+M"@+Z8XH X;PK'8ZAXLN-8A\80:]=1V(MG6WCC"HC/N4DIP3D'
MCMDTOB[Q/-IWBFPT:35[;0;*>TDN'U.X12796 \J,O\ (&P=QR#VXKM88(;=
M-D,21KG.U% &?PI988I@HEB20*=PW*#@^M 'AD-O+??#_P 7M:M=ZE:Q^)5N
MIP\6)+F >2[G:%4<CYN ,BO0M4\2Z1XL\+ZMI7AG5[:[U*YTR9H([=\LN5P
M<?<.2!@X/Y5V8 &< #/)]Z9'!#"6,421ESEMJ@;CZF@#B_!7C#PR_A_0](M[
MZ""^$*6W]G'B:*15PRLG48(/)&/?FN:T#7]$\-^ ]9T#Q!-''K,<UVMS9RC]
M[>-([%61>L@=64 C->LB"%9FF6)!*PPSA1N(]S0T$+RK*T2-(GW7*@E?H: /
M)0)?"R?"VZ\0RBUBLH)[>ZFF.%A=X $5CVZ8_"K=AJ=KK'BKQ_>V,AEM7TBW
M$<P4A90$F!92?O+D$9'!QQ7J$L4<\9CEC21#U5QD'\*4(@& JCC' [>E 'DF
MHQHGP"\-;$5<#3'&!C#&6/)^O)_.MS4-2L=%^-"7.J7<-G!<Z"(899W"+)(+
M@DH">"V"#CWKO]B[0NT;1T&.*;)!%-M\V)'VG<NY0<'U% 'D>K_\@3XN?[X_
M])TK<\51I'IOP^$:*H36;-5"C&!Y3\"O0MB'=\J_-UXZTI53C*@XY''2@#R#
M4M4&F>*O&>DQ:MH>G1:B\?F-K$YBD5G@56>-<8D3&, D<@]J]-\.PV=MX;TV
MVT^\2\M(+:.&*X1PXD5%"YR.#TKG/^$9U[3]4U6;3VT6\M]0N3=;M1B<RPL5
M"[<KD.HVC ^7 XK;\)^'(_"V@1Z:DWG/YDDTL@0(I=V+-M4<*N3@#L* -NBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ IGFQB01EUWL,A<\D?2JNK_P#(%O\ _KWD_P#0
M37C4GAS1;+X$6?B.. 1:W#8P7$&H;R9UE!4(JL3G'10O3':@#W!W2-2SLJJ!
MDDG  JA;W>I2:W=V\MA''IL<2-;W8G#-*Q^\"F,KCU[_ ,N$O=&M?$?Q=AM]
M9@\Z >'(II;1C^[>03N!O7^(#<< \9P>U30QI#X\\<11J$C31K554#  "2X%
M 'H9EC$BQEU#L,A<\D?2EDECB3=(ZHO3+' KP^3P]IEA\&M \2P6^-;A^P2I
M?,Q:4$R1KM#$_="G 7ICM76)I=AXK^*/B*V\0V\=[#I<%LMA9W W1JLB%GD"
M'@DMQGMC% ':WEUJ46KZ=!:Z?'/8S>9]JN3.%,&!E,)C+Y/''2KSRQQXWR*N
M3M&XXR?2N#U:PM=+^(/P^L;*(16T"7Z1Q@DA5$*\<\UE>&?"?A[Q!+XSN-<L
M8KK9KEW$'G8D0IA22F3A#R26&#TYXH [3Q#K\^CZOX>LX8HW34[TVTC/G**(
MV;(QWRM;SRQQE0[JI8X4$XR?:O'-&O+N^\.?"V>]D>68ZE(HDD^\Z*DRH3]5
M"FI(+"Y\4^(O%<E_X7LM;E@U"2RC>[O_ "FMH54;!&I1MF0=VX$$D^U 'K\D
MB1(7D=44=68X IP((!!R#WKS*_\ "/B"\T3PO+J-K8ZW=:5 Z7FF7DW[NY)
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MAE%?RRR+/JD4,C"1E9D"3+C<#G[HQUKI$TO3?"OQ8TFVT&WBLK>]TVX?4+:
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MU_=09WD'T,K/_P!\B@#L))(XEW2.J+TRQP*HZ[K-KX>T.\U>\$AMK2,R2",
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M.NW!P: )QI%B-<.L^1_Q,#;"U,VX_P"J#;MN,XZG.<9J/^P]._M"^O\ [/\
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MA&%4R0W$D8D"G*AU5@' /9@:IVW@#PY:7T-U%:38MY?.@MWNI6@BDZ[EB+%
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MG@GP_?:)9Z.]@([.R8/:B"1HVA89^974A@>3DYYSS4FF^#]"TAKEK&Q$3W4
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M2QA2 .1M)&>OOFO4JXB7X?&3PEJ&A?VF!]KU0ZAYWD?=S.)=F-W/3&<^^.U
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MFQ-KNN>*;WPY::_<6-MH=K;BYNXX8FGNYY%+ G<I55 &2 .2?2LR^\9:_9>
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MTNIHD26-D8*Z-L ##Y@0<#N*XY/$'C(?"^R\<OXA5YHS&6L/LD:PS(9A&=Y
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M>XOE@3.3\BC:Q)X[@#D<UBM\18Y_"VAZK8:<9+K6+G[)#;3SB)(Y1N#!Y,'
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M;J=Y;GR888V)"98*Q+-@X '09JC<_$-;;P[;:DVD7#73:H-*N+%)%+Q3;BI
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M[6[@MW19HGC8E74.0&4AB",Y[U2\5Z%J/B6/0=?N/#OFS:?),)]'EN5WR0R
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MQSK\,ND7,UCJUVMU#?Q/'Y<8\H*0X+!@<KC@'.:[:B@ HHHH **** "BBB@
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MUE:327-K;Z!.L$TJX8KNCP2,#!P:6.WEN-4^*MO!&SR2Q1K&BCEF:SQ@>Y-
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M'=./W=O.9 WS'^'<O )],4 =':^,=#N]"O=9BO"+2Q#&[WQ.LD!498/&1N!
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M&XKTSWQ[41R1R@F-U< X)4YYH =137D2-"\CJBCJ6.!2Y! .1@]* !45!A5
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MQ6STGP_&9>O[N:8>9+C'=5C _&NYA\.Z5;^(KG7XK0+JES$(99][99!C QG
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M>XMM4=!DDD_C0!XWXQM['6/#?B+Q#HOARV06TLL@UNZNV6X,L;X+0@!B &!
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M:SE26Y(-RD%U+%'<$=Y$5@K?B.>] &;I'_)6O%?_ &#[+_VI7%M(J_LL1DN
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MZFN))971B"0S,Q+<J,9Z=L4 9'CKPW>ZS?:3?V]C9ZO!8&4S:1>OLCN-P #
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MDUD2^.=8T#PYXBM;^XBO-5TK4(K&"\:':L@FVE'=$[J&.0HYP/6@#U*BO-]
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MACP??ZQ!"LT\*JL,;]#([!%S[989JK86&NZ%#+JFL^)IM2BBMGDN;8VL2(&
MSF,J P P1@DYH ZJBO+?[2\8?\()_P )Y_;B[_L_V_\ LC[/']G^S_>\O=C?
MNV<[L]>,8K4U'6=:U?QGI.E:1J@T^QO]':]=S;I)(OSI@KN& V&QSD<G@G%
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MN=<T;XB0Z'J.MR:K:7VG272&:".-H9$=00-@'RD-T.<8ZUW- !1110 4444
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MK,%^=-W&S@M;7R$WL-ID?+-N;&< 8 S77T4 8GAOP^= .KYN?/\ [0U*:_\
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MGS=V-O;.W..*Z/\ X1I%\8V>NQ3B.*UTY[!;81]BZL#NSQC;C&*WJ* .0N?
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MA+L3P.@P!G-.T7PUXDT)+73+7Q%;2:+:LHB2>Q+7(B!XBW[PN,<;MN<5V%%
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MX7%II\!GG^VVTNP,%^5)E9CDD#@ F@"A8_V?#X[T>UG\.06&JG2II5>WN,I
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M#TK9HH QM'\-66CW<]ZLEU=W\ZB.2[O)C)(4'(4'HJY).% &:V:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *S]4T6RUA[![Q&8V-TMW!M8C$B@@$^HPQXK0HH **** "BBB@ H
MHHH YV]\'V=SJUQJ=M?ZEIUS=!1<FRN-BS;1@%E((R!QD8-:6C:+8Z#8_9+"
M)DC9VED9W+O([<L[L22S'U-:%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !10>E?+GA_P")/CZZ^*=K;7%U<NTU^()],*_N
MT3=AE"X^7:,_-UXR3UH ^HZ*** (KJX2SM)KF7/EPQM(V!S@#)K(\*>*M.\9
M:(NK:6)Q;-(T8$R!6RO7@$U<UW_D7M3_ .O27_T UY]\ /\ DF$7_7W-_,4
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M_M$$H9CPI#LQZ[MQ(^E>?_$"VD\3?%7P-!<?;-*>^LOWJQ/MF@R6++N['J*
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M>)7<R2#YBI!X] 1GC.<"@#T6BO%+?17N_AUXGOKG6-7ENM!GOHM-D^VNOD+
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M8&.N,<UMUY_\.K)-.\0^-+..6>6.+48U5IY3(^/)3 +'DXZ<\\5Z!0 4444
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M\<D\5[310!G:(NHMX>L%UK8VHFV07>T#:9-HW=..N>G%8-O\.M,M_#M_X?\
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M"P P "0  ,54MOAWIT,NFR7.J:Q?/ILR36?VJZW"+:" H4* 1CN03QUKKZ*
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M,,\\CKS7144 8GA_PMI_AI[Y[%[EWOI5FG:XF,C,X4+NR><G&3[GMTK;HHH
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M6TY4L@&6;>AVD9.#6AH'B&]U.7Q2LXB TO4)+:#8I&46-6&[GDY8^E4D\/\
MB77-9TFY\3S:7'::5-]ICAT\R,;B<*55V+@;0,DA1GGO40\,>)M/US71I-WI
MB:7K,_VAY9U<SVSE C[5 VMT!&2,=\]P"BOC;7Y_"?@N^M8;%]0UR<0RB4,L
M:YC<Y&"2,%0<=\8XSFM'3-5\31>*]2\+ZC?6%Q='35O[*]CM&14RY0J\>\Y
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ME7<S,I<Y(X &X9+"HE^'U_+\/_$/AZ[U&W>\U2\FNUN(XRJ!G<.,KVY'(R<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQT.QM[A,[)$A&4S_ '?[OX8K<HH **** "BBB@ HHHH **** "BBB@ HHHH
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MX;@26<:EG=0<KCJ".N?:J52+V9E*A4BDW%ZB:IXBTC175-0OHX789"<LV/7
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M17"^!O&%I=6%AI-U<W$VJ.9-S2 MGEF&6/\ LXK5UCQWH>BW;6LTLLTZ'#I
MF[:?0DD#-"JQ<>:XI8:JJCII7?\ 6ITM%8^A^)M+\0J_V"<F1!EXG7:RCUQZ
M?2MBK335T92C*#M)684444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?43Q=X6TC2_!$5S:6H2X0QYER2S9ZY_.DT2_GM/A#?S1.0Z.\:$=5#,H./\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY2PB5O(5N5W%F4;B.0HR<=JV-*U2TUK2K;4K"7S;6X0/&V,''H0>A!X([$4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-@C(RI (/L1FIJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX&0RD$''?VKH[[_CPN?^N3?R->0:!&_AWP9X8\5P<6<^G1V&KJ.GEG(BF/\
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MKRW5YB1$IE4%R."%&>?PKA7L+'0?BYHEOH-M#:+?6%R=2MK9 B>6FWRI&4<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]N6FMXXI()@A=2NP %3@C!Z<<UT7B?P]#XFT8V+SR6TT<J7%M<Q@%H)D.Y'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M];1++=".5(D@5ON@LYQN(&0H[<U!-\0],B\(_P#"1"VNS$ETMI<6Q3]]!*9
MC*RC/*D]!U[=: .OHKE-.\93S^);?1=3T&\TJ2]A>:RDGEC?S@F-P(0G8P!!
MP:T_$=FUWIHWZY/H]K$WF7,\+HC&, Y&]A\@S@DCG ]Z -BBO+-,\3W>CZ1X
MRU"SU*XUG0M-@633;RZ;S-\VP[T$F!YBAMO/;)&35LQZSX2G\,:C<Z[?Z@=3
MNXK+48+EPT>^53M>-0!LVN ,#J#0!Z117E_Q+\4:LL-Y:^'KI[:/23#+J-W'
MUWO(JI I]2&WMZ  =Z]/9@JEF(  R2>U "TR6:*!-\LB1KG&78 9KAS\2A]A
M;6D\/W[^&E<J=5#I]T-M,@BSO,>>_7'.*QO&+MJ_Q/\ #VGW'A[^V--6SGFC
MB>6(Q2EM@,FUC@[0>_//% 'JE(2 0"1D]*XSXDZ_JOAW0;232+25WEO((FEC
M>-0@,B#9AC_&,KD#COBL?Q3JUY'XG\!ZA=:+=QW?GWH_L^-DEE+&$JHRIV\\
M'.< =<8- 'IE%<OHOC);ZYU>SU?3I='O-*C6>XCFE61?)8$APZ\$?*<^E5;3
MQY),UA=76@7MGHVHRI#:W\LB')?B,O&#N16.,$^HSC- '945SOCRYU>T\$:I
M/H2R-J*1 Q^4NYP-PWE1W8+N(]P*P_!5OH5]<0ZEX?\ %^K7P12+JUNKXS;R
M1C]Y&_S(P//&WICI0!WU%<?KGC:]T+[3>7'A?4/[&M)-D]\98@0N<%UCW;F7
MWX..<5/KGC1-*URUT:UTNZU&^O+5KBV2!E ?# 8+,0%&"3N/&!ZD"@#J,C)&
M1D=J6O+[;6-3M/B?K[6OA^YO+ZXTVQ9[:.:-5A(#E@\C$#J<#&<_2NLTOQ>F
MK>';K4K;2KY[NTF:VN--4+YR3*0"G)"]P<YQCF@#I*I7>D:9?S)->:=:7,J?
M=>:!79?H2.*Q=&\67%YX@?0M6T6?2K\VQNH5>9)4EC#!3AE. P)&1[UBO\3W
M;19M:MO#&I3Z7:22)>7.^-?*".58JI.9,8R<<#.,Y!P >@ !0   !P *6N<U
M;Q8MI>6>GZ7I\VJZC>0FYC@B=8U6$8'F.[<*,D =235*3X@6T.AO=R:;=)J*
M7ZZ:VFED\P7+8VKNSMVD$,&SC!_"@#L**S-%U'4+^*;^T=&FTR:-@ KS)*L@
M(SE64_S K$\>ZMJ%I;Z5I&DW'V:_UF]6T6YV@F"/!:1U!X+!1Q]: .NHKS3Q
M+I5U\/\ 2!XFTO6]8N5LI(S?6M_>-<)<PLP5CAONN,Y!7'3I72WWC;3])U+4
M[/4T>U%E9B^CE8@K<Q=&*?[0;"[>N2/6@#I<@$#(R>@I:\_U"[EOOB%\/[N>
MTDM)9K34)&MY""T>8XCM.._K5Z[\>R(VH7.GZ!>W^DZ;(\=W?12(H!3_ %GE
MH3F0+SDC'(.,T =E16'IWB>TU+Q!<:3'&RLMI#>V\Q(VW$,F1N7Z$8.?45-X
M?UZ+Q#:W5U;PNEO#=RVT<C$$3"-MI=?]DL"!]* -:BO,?'6MZK'XBGNM+N[A
M+3PQ;0WM]#"Y"W!DE&Y''<"%';_@0KK]?\5VNBV]AY-O-J%YJ3[+&TMB-TYQ
MN)R2 % Y+'H* -^BO//&?B[Q%IWP\U744T&[TV_@(CWF>&01 XQ(#GYAR!C&
M<GIP:[/1[V]O[ 37^ERZ=-N(\B25)"1Q\V4)'/\ 2@#0ILDB1(7D=40=68X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*7 (=P6=LN#AL;LG)%>ET4 <=J]Q>>,O _B&RM=&U"RDELY(;<7\:Q-,[(>
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MYKO4X%4W,K'YF+!CER3GZ#VKL:* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HQ/
M"9S )8S,HW&,,-P'KBI.U?+/A[P#\0+;XKVMS<6=ZDT5\)KC4FSY3INR[;^C
M!ES\O7G&* /J:BBB@"*YN([2TFN9<^7"C2-@9. ,FN*T3Q'XQUNSL=;M]%TE
MM(O"KI +QA<K$QX<DKLR!R5_#.:[2[N;>SLI[F[=8[:&-I)7;HJ@9)/X5Y1K
M<5CX,T0^)O _B$):M*C+HXF$]K=EW *QKR48YS\OIT% 'IFJZ_H^AB,ZMJEG
M8B4XC^TSK'N^F3S5B?4;*VL#?SWEO%9A0YN'D"Q[3T.XG&*\T1=5G^*GB9$;
M1ENC#;_9TU2)W8VWE\^7AA\N_?N]^M4KC24T5O FG:U>6=UH0U&[:1H_^/99
M"&:W3DGY5)8 'T% '>ZCXYT"T\+7VOVVJ6-Y;6L;D>5=)B20*2(P<_>., =?
M:HY?$ZZKH5C?Z!J^B RW,$<QN;@.B[L%H@5/^MY  -4O'<&E2> /%<=G%9-<
M+8R23+"JE@WEG:S8YS@'!/85C>)4LU\!>%&LU@"/JFF,3"  Q++R<4 =[JNO
MZ/H:QG5M4L[$2G"?:9UCW?3)YJPVH626L5T]Y;K;RE1',95".6("@'.#DD >
MN:X;25L7^*OBW^V1 UV(;;[$+G'_ !Z^6=VS/;?NW8[]:XZ>**;X7ZS! H;1
M6\4JFG@?<-N;B/A/]C=OQB@#V&P\0Z-JMY/9Z?JUE=W,'^MB@G5V3G'(!]>*
MI>)?$,VC/IUE862WNJ:E,8;6!Y/+3Y5+.[M@X55&> 2>*P-8L+/3?BEX)%C:
MPVP>WOX6$,80%%C0JIQV!Z5M>*]'@U*72KE-732M4M+@M8W#!6#,R$,A1B-X
M*YR 0>,T 0Z?XLN3_;%GK&GQVFJ:5;_:7BBF\R*:(ABKHQ4'&58$$<$5%X:\
M1>*-<CTZ]N?#EE::;>0K-YRZD9)$1EW+\GEC)Y'&:YG3XH)_&GB>]UC71>:?
M!I,>G7U\=L,*2.[$HF,A0JE<\D@OR:FO;&T\):YX2B\-ZM>RRW=VEK+927SW
M"36NP[I-C$A=@ (*X Z4 =!XZ\=Q>#;>W$=F;^\F(8P+)L\N+<%,C'!P-S*!
MQR3]:Z^O#_&-GXIM/#'B34-7T*T>>_G@WWBZ@#Y,*S)Y42)LZ#OSR6)]J]@\
MW4IM!>5[5+;4F@8B%9?,5),' W8&><=A0!&?$NA+JXTDZS8#42=OV4W">9GT
MVYSGVKE?%_BJ6'QCI/ANR\16.CF>*6:YN)/+=U(VB./:YP"VXGGDXXKE84\.
MG]GR5Y?(^W?9G+LV/M']H9/4_>\SS,>^/:N@:U,WQ*\(-J5O$]ZVB3-<;T!)
ME'E9)]P<T =1XL\66'A#3(;J^EA+RS1PI'),L9?<ZJS#/4*&W'V':L[5_%T<
M7B#PJ-/U*SDTC49+O[3<)(CQE8HF;(?.!AASSVJK\68H&\)VLT\<96+4[0L[
MJ"$4S*#R>@]:@\7:=IUWXW\!6;VMO)9_:;QO)V QY$)8<=/O &@#L]+UO2]<
M@>?2M1M;Z)&VL]M*L@4^AP>*CM_$FAW>JOI=MK%A-?QYW6T=PK2#'7Y0<\=_
M2N U&"XLO%_CV/1(O)NI/#\4L:P+@M,!*%( _BZ8JIH6BWFL>$_#)L[[PU;V
M5O-;3V\MO$XG#J067);[[?,K#ODT =_XTU^7POX0U'6H8$GDM4#+&Y(#98#D
MCZUC7'BSQ!X=EM9?%&DV":9<2I"U]IUTT@MV8X7S%=%.TD@;ATIWQ<_Y)7KW
M_7%/_1BU0^)^J66I>#W\-6-S#=:MJ\D5O;6T3AV^^K%R!T50"23QQ0!VFJZ[
MI&A1I)JVIVEBDAPAN9ECW'VR>:LK?6CV(OENH&M"GF>>) 8]O7=NZ8]ZX2P2
MS;XP>(%UGRFG6PM1IGVC'^HPWFE,_P"WUKBKDP#PWJ$<1 \(MXPB1]IQ#]E)
M'F =O*\W'3CK0!Z#-XVMK_QIX9T_0]5LKVQO3=K=_9Y%EP8X@R#(^[SGZUM:
MWXHTC2?.LYM7L;?4C"S0V\LZAV.#MPI.3D_G7*ZRND)\6_!"6"V2W BO=X@"
MAA'Y/R9QV^]C\<5F^&1HS^$_&,^M"S.IF^O!J!NMI88)$8.[^';MV]O2@#N_
M!>J76M>"M'U.]96NKJU265E7:"Q'/':LS6_$6O1^-(/#FA66FRR/IYOGDOIG
M0 "0)@;%;GD?K5#P</$!^&WA;^PWTQ1]@3S?MR2'L,;=A'OG/M5/6-*N=7^+
M]C;G5;S3IU\.L\DVGLJECYZ@K\ZM\N3GUX% '9Z=?:C;68;Q,VE6EQ).(H1;
M7#%'R!@9<*=Q.>!Z4[_A*?#_ /9KZE_;>G_84D,37/VE/+#CJN[.,^U<;X_T
M=8?#/AW2KR\N]1CDU^TCEENW!DD5G.02H4=#C@=*U/$]U;Z?JV@:%IVDZ4;V
M[:9[66\C AMA&HW$*!DL00  1]10!TMKK>E7NEOJEMJ5I-IZ!F>Z293&H'4E
MLX&.^>E1Q>(]$GU7^RHM7L9-0QG[,MPIDQC/W<YZ<_2O)[<LFC?%NW^V6=TJ
M6^\O91>7"9&MCOVKN;!R,'D\@UL:UI=AIWAGX>RV=G!!(NKZ?AXT ;YP=^3U
M.[//K0!UNC:W=W?C;Q5IMQ(GV/31:& ;0-OF1EFR>_(K;2]CO-,:\TR:"[5X
MV:!XY T<AYQ\PXQGBO'O$L.O7?C3QU;Z9;";3E6PGU)%D*RW$*Q_-!'CD%UW
M\_[./XJ]>T6[T^^T2RNM*,9T^2%6M_+&%"8X ';'3';% ''7OQ&E@^%EEXLM
M]/2:]NPBI9[R 9,D.N>O 5S^%;E[XHV:CX8M;&))EUMV<.QQLA6(R%A[_='X
MUP/ABV6Y\:#PG(NZVT/4-1O&B;IY<@40_I<2?]\U+\._,O/%EKIT[%V\*Z;/
M8,3_  R-<%$_.*%?SH ]&G\4:!;:HFF3ZUI\=^[!5MGN4$A)Z#;G.3Z5GSZU
M>Q_$NST177[#+I4MTR[1GS%D10<_0GBO-_%^HC7/AYXCU.VBT+2M,^T3*D;0
M;KNXF23&XL&4(Y89'#'%=@DA?XN:&\C9=_#LI)/<^;&: -CP+K5[KWA^6[OW
M5YEOKF$%5"C:DK*O ]@*IWWB37[[Q3J.A>&K+36?3(XFNY]1F=06D4LJHJ G
MH.6/Y5'\+"/^$3N1GD:I>Y]OW[TS7-'\->(->NKFSUYM*\1V*B*:YLKD1R*,
M!@)$/#KR.H]L\4 7-5\;#PWH6G7?B&WM;&_NKE+=K4WBD &0*T@8CE5!#'C@
M'G%;G_"0:+]DBNO[7L/LTR/)%+]I38ZI]]E.<$+W(Z=Z\IU+5[CQ#\/M)OM9
M-M=/9^)8;8WZQA8[B))POFCL%;'...*Z3Q9INGWOQ!\!V<EM#)9AKYO)"CRR
M5C5AD#@X8 X]10!UMQXHT&TTR#4[C6;"&QN/]3<27"JDG^Z2>?PJZ-1L3I_]
MH"\MS9;/,^T^:OE[?[V[.,>]>;ZA'J"_%^XAMSI$3#2XAIRZC$Q79N;S?*"D
M -G&>^,=JR=?TB^T3PUIL,UYI,NGS^)?/G"(WV*!6!*QNN>(Q*,D9P"1F@#U
M.R\2:'J-A/?6>L6$]I;_ .NGCN$9(O\ >.<#\:H>$?&>E^,--6XL[BV%QF3?
M:)<+))&JN4#,!R < CCN*R]'T&_;QB^J:C<Z(PDT\VTMK81,/-4N"CN&)R!A
M@#_M5!\'XK1/A[8&..%;H27"2E5 ?B=^&[^GZ4 7]9\1:\GC6+PYH=GILCG3
MOMSRWLSH /,V;1M4^Q_.K/AOQ+=ZEJ6J:/J]C%9:GIGEM+Y,WF121R E75B
M?X3D$<5SFNZ??ZC\9(X=.UB?2IQX=9O.ABCD)'VC&TAP1C)!XYXKF)4N$^%?
MB^222YE\4K.D&NR2ON<HCJ"5"@8B,18C Z%O2@#US3_$FAZM/-#IVL6%W+ ,
MRI!<*Y0>I /3WKE?!OBB;Q3XFUF5?$5DUG9W<MO!ID C8R0IM G+9W$$GJ/E
MJ&PT2^OM8\.:@+WPU';699H!IL3*TT+1E3&N6(*\@X_V17-O;2P?#?XD2:7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/"OA^VU9M6@T6PBU!B2;E+=0^3U.<=3ZUKT4 0+96JWSWRVT0NWC$33A!O9
M20I;K@$GCWJK/H&CW-G<6D^E64EM<RF:>)X%*R2'J[#'+>_6M&B@#.T[0-'T
MBPDL=/TRTM;67/F0Q0JJOD8.X8YXXYJ"P\*>'M+"BPT33[;;*)U\JW52) "
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWIG'&?2N,T_39-!^&OA;Q)8ZKJ9U'_046%[MFBE21T0PB+[N-K'&!GC.<\T
M>NVVHVEW=7=M;SK)-:.(YT'6-BH8 _@0?QJU7G'AKP[:S^//&,[7>IJ\5_&0
MJ:A,JG?;H3N4-@XW'&>@  X JA9ZQJEY%8^ Y+^Y_MFVU%H;ZZ65A*;*+$@E
MW Y!D5HTSW+-0!ZM17G,6C?\))XN\7QZAK.KPVUG<0K;QV]^\*0YMT8L I'.
M3GGCOCK6#:Z]KWB&Q\'Z?.EU=+=Z=-<W"P7GV-[QHW5%)D&#C:=Y"D9R#T%
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M\+^);J]B2.ZDNH[.U,H_<6XA;:SC/#R$[CGH-H[5[!0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<;%\-] @\0PWT6GQ?9(X6
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M ,G)R#\HY'<9Z\U%-X'\/SZ/'I<UK-);13>?&SW<S2QR8QN60MO'''!KHJ*
M.>M? WANSLK^T@TQ%AOU1;H&1R9=F=I+%LY&2<YS[TEKX3L]$$USH<2IJ3H(
MUN+^6:ZVID$KEGW >P(&<5T5% &#Y7B[_G]T3_P#E_\ CM'E>+O^?W1/_ .7
M_P".UO44 9$VC_VUH4^F>)([2\BGXE2%'C1E!!'5B0<C.<U9N8[FRTH0Z-:V
MK2Q*J0PSRM%&%&!C<JL1@=.*O44 8GA31)M!T,6MU-'-=2SS7,[1 A-\LC.0
MN><#=@9]*OZII5CK5@]CJ-NMQ;.02C$CD'(((Y!!&<BKE% ',^%_!FG>&Y;F
MXBMT:ZEFE*3M(\CK$S[@FYR2.V<=2.<TNJZ/JJ^*[7Q!I'V.61;1K*>WNY&C
M!0N'#*RJW((/!'.>HKI:* ,[5M"TS75M5U.SCN1:7"W, ?/R2+T/'7KT/%1:
MYX:TGQ$MO_:5NSO;,6AEBF>*2,D8.'0A@".HSS6M10!AV7@_P_I^GW]A:Z9$
MEKJ Q=1%F82_+MR<D\D=3W//7FH-+\!^&]&O[>^L[!A=VP80SRW$LKH"NTJ"
M['Y<$\=*Z.B@#&F\*:)<:-/I,M@K64T[7#Q[V!\UGWEPV<J=W.01CM2GPMH[
M6&GV4EL\L&GW*W=L)9Y'9)5)(8L6+,<L>I(YK8HH X[QGX<GUN\M)8O#VCZH
M(D9=]Y=202(2>@*(VY/4&I-"\#6-GX-&@ZM!;7*RS27,R0J4C21W+XCQ@J%R
M I&#QVKK:* ,G1?#>E>'_/;3[=UEN"#---,\TLF.F7<EB!V&<"I=.T+3-)O+
M^[L+.."?4)?.NG7.97]3GZGIZGUK1HH YJ]\ ^&M0O9[J?3W#W+;[A(;F6*.
M9O5T1@K'U)'/>MF#2K*VU*XU"& )=7$4<4L@)^9$SM&,X&-QZ>M7** *,.C:
M?;KJ"Q6X4:A(TMU\Q_>,5"D]>/E4#C'2HH/#^EVSZ8\-H%;2X6M[,[V/E1L%
M4CKSPJ]<]*TZ* ,D^&=';09]#-DO]FW!D,L&]L-O8NW.<\L2>M8'C'PS<:UJ
M5M/#X<T74UCAV"6]NI()$.3P=B-O3IP>^:[6B@#"\'^'SX8\,6NE,\3R1EY)
M#$FU-[NSL%'906P/8"I+F+Q,;F0VMWI"P;CY:RVLC,![D2 $_A6S10!SL_AQ
M]=A5/$OV:=H7WVTE@9K9XSC!.X29].AJ>W\(:%;:>MC'8CR1<I>'=*[.\RD%
M79R=S$$#J3TQ6W10!CW/A;1[O78];DM7&H)M'FQSR1[]IRN]58*^/]H&J-S\
M/_#-W>37,FG,#._F311W,L<4K]V:-6"$GOD<]ZZ:B@##EB\4F9S#>:,(MQV!
M[24D#MDB3K3?*\6X'^FZ)G_KTE_^.5O44 8UM;:[+*8M5FTF>R=666**U<%@
M1C'S.1CUXJOIO@K0M$NEO-,LF2XB1E@62ZE>.+(QA59BJ ].!TKH:* .<\/Z
M-J5OK>K:WJQM$NM06&(06CLZ1)$&Q\[*I8DNW\([5T+HLD;(ZAD8$,#T(IU%
M ''V/PZT*P\1G4(K&/[-'#$(('ED=8I59SN"L2H^\N/0@D8K3\5:+=:U8V9L
M988[RQO8KV$3Y\MV0GY6(Y ()&1G%;M% &?)8_VQH4ECKEI;D7,1CN;>*5GC
M(/& Q"GIWP#4<_AW2+GP\- FL8VTM8EA6WR<!5QMP<Y!&!@YSD9K4HH P-)\
M%Z#HNH)J%E9.+U8VB^TRW$DLA1L$@L[$D?*,9Z=L9-4S\-_";3O*VDAMTOG"
M,SR>7&^[=N1-VU#G^Z!W'0FNKHH H'1=.-U?W+6J-+J$2PW18DB5%# *0>,8
M9A^-9]KX,T&ST6[T>*TD.GW:;)8)+F60%<8V@LQ*C'88K?HH QM2\*Z/JUO9
MPW5O(!9+MMGAN)(GB& ,!D8'H!W[5$W@SP^V@OHC:<IL9)/.=3(^]I,YWF3.
M_?D#YLY]ZWJ* ,'2O!F@:+/-<6-CLN)X?(FF>9Y'D3.<,S,23[GGMTJOIWP_
M\,Z5=VMS::>X:TYMTDN99(X3C&Y49BH/N!FNFHH QY/"VCR^(!KAM774?EW2
MQSR()-HPN]58*^!P-P-5-)\/2V_C#6_$-ZL'GW8CMK41<E+=!_$<#YF8DGKP
M%YKHZ* .'_X5W8:CXF\0:EK4'GPW\T30K%=2IE%B5"LBJ0&&5/!R,5T.I^&-
M&UBRMK.\L$,-KC[-Y3&)H,# V,A!7CC@BM>B@#GX/#S:%:-%X:%M;O+)OG>^
M,MPTAQ@'<7W9^IIWE>+O^?W1/_ .7_X[6]10!@^5XN_Y_=$_\ Y?_CM6;W0;
M/6[6P77+6WNYK29+E"H9569>C 9SCGH21ZYK5HH Q?$]KJ^H://I^DI99NXG
MAEENI67RE9<;E55.\\G@E?K5_2[%=+TFST]'+I:P) K$<D*H7/Z5;HH R->\
M-Z9XB@1;^V\R2$-Y$@D:-HRPP<,I!&<#/TJ/PMX:L_#&BP6=M!$D_E1BYE7)
M,KJH&2QY(XXST'I6W10!S5AH^JZ5XKU.[M_L<VF:I,EQ-YDC)- ZQ*A"@*0X
M.Q3R5QD]:U)="TR?7H-<DLXVU.WA:"*X.=RH>H].Y_,^M:-% &#JW@W0M;U%
M=0OK-FNA&(F>.>2+S$!R%<(P#CD\'-$O@OP]+X>AT$Z<JZ;!(9H8HY'4Q/N+
M;D8'<IRS=#WQTK>HH P+#P5X>TR&^CM=.""_@^SW;-*[-,GS#YF+$D_,><Y]
M^!4FI>$=#U6VL8+NS8K8+LM6BGDB>)<!2 Z,&P0 ",\XK;HH S_[$TXZM;ZJ
M;8&^MX#;13%VRL9()7&<'H.3S5;_ (1;1QX@;75M734'P7DCGD59"%V@L@;:
MQQQD@ULT4 8,_@W0+C1+/1WL,65DP:V5)G1H2,\JX8,#R>_>KEIH.F65S]H@
MML3?94LR[R,Y,*$E5.XG/WCR>3GDUI44 <S;> ?#MC<QW-E8M%)"_FP1&YE,
M$4G4,L6_8.?0"K'E>+O^?W1/_ .7_P".UO44 8/E>+O^?W1/_ .7_P".U<T^
M+6,RKJTVGS1LN%6V@=/KG<S9%:5% &;I.B6'AW2!IVBV<5O;Q[FCAW';N))Y
M)R>I]ZSO#VC:E:ZSJ^M:L;5+O4?)006KLZ1)$& ^=@I8DLQ/ [5T=% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %,FABN8)()XDEAD4J\;J&5
ME/!!!ZBGT4 <I>> -$GU[1]2M].TZV2P>5Y(4LD FW)M7)&,;3R.#^%=7110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>emergentbiosolutionscomp005.jpg
<TEXT>
begin 644 emergentbiosolutionscomp005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M4/\ <B_]%K7$UVWQ9_Y*-J'^Y%_Z+6N)KT*?P(\ZI\;"BBBK("BBB@ HHHH
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1D[(<J<HJ[.7-)3U1I'5$4LS'  &237J_A?X+7%_:QWNO736:. PMXQ\^/\
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MX<L=4F@OKVPMC<06JJURB_>"'/S >V*TIH+?5;830L-V.&_H:[3X!*&O]:!
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MB.[^+/\ R4;4/]R+_P!%K7$UVWQ9_P"2C:A_N1?^BUKB:BG\"+J?&PHHHJR
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!M**6FT .HIM*.E "T444 %%%
M% !1110 4444 %%%% !1110 4444 %-(IU% $?2ES3B*90 ZBD!I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!,"CK2TG2@!**4TF* "BBB@ HHHH
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M844459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #:*=3:
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M7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\ A2OA?_GOJ7_?Y?\
MXFC_ (4KX7_Y[ZE_W^7_ .)KT:BCVD^X>RAV/.?^%*^%_P#GOJ7_ '^7_P")
MH_X4KX7_ .>^I?\ ?Y?_ (FO1J*/:3[A[*'8\Y_X4KX7_P">^I?]_E_^)H_X
M4KX7_P">^I?]_E_^)KT:BCVD^X>RAV/.?^%*^%_^>^I?]_E_^)H_X4KX7_Y[
MZE_W^7_XFO1J*/:3[A[*'8\Y_P"%*^%_^>^I?]_E_P#B:/\ A2OA?_GOJ7_?
MY?\ XFO1J*/:3[A[*'8\Y_X4KX7_ .>^I?\ ?Y?_ (FC_A2OA?\ Y[ZE_P!_
ME_\ B:]&HH]I/N'LH=CSG_A2OA?_ )[ZE_W^7_XFC_A2OA?_ )[ZE_W^7_XF
MO1J*/:3[A[*'8\Y_X4KX7_Y[ZE_W^7_XFC_A2OA?_GOJ7_?Y?_B:]&HH]I/N
M'LH=CSG_ (4KX7_Y[ZE_W^7_ .)H_P"%*^%_^>^I?]_E_P#B:]&HH]I/N'LH
M=CSG_A2OA?\ Y[ZE_P!_E_\ B:/^%*^%_P#GOJ7_ '^7_P")KT:BCVD^X>RA
MV/.?^%*^%_\ GOJ7_?Y?_B:/^%*^%_\ GOJ7_?Y?_B:]&HH]I/N'LH=CSG_A
M2OA?_GOJ7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\ A2OA?_GO
MJ7_?Y?\ XFC_ (4KX7_Y[ZE_W^7_ .)KT:BCVD^X>RAV/.?^%*^%_P#GOJ7_
M '^7_P")H_X4KX7_ .>^I?\ ?Y?_ (FO1J*/:3[A[*'8\Y_X4KX7_P">^I?]
M_E_^)H_X4KX7_P">^I?]_E_^)KT:BCVD^X>RAV/.?^%*^%_^>^I?]_E_^)H_
MX4KX7_Y[ZE_W^7_XFO1J*/:3[A[*'8\Y_P"%*^%_^>^I?]_E_P#B:/\ A2OA
M?_GOJ7_?Y?\ XFO1J*/:3[A[*'8\Y_X4KX7_ .>^I?\ ?Y?_ (FC_A2OA?\
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MLH=CSG_A2OA?_GOJ7_?Y?_B:/^%*^%_^>^I?]_E_^)KT:BCVD^X>RAV/.?\
MA2OA?_GOJ7_?Y?\ XFC_ (4KX7_Y[ZE_W^7_ .)KT:BCVD^X>RAV/.?^%*^%
M_P#GOJ7_ '^7_P")H_X4KX7_ .>^I?\ ?Y?_ (FO1J*/:3[A[*'8\Y_X4KX7
M_P">^I?]_E_^)H_X4KX7_P">^I?]_E_^)KT:BCVD^X>RAV/.?^%*^%_^>^I?
M]_E_^)H_X4KX7_Y[ZE_W^7_XFO1J*/:3[A[*'8\Y_P"%*^%_^>^I?]_E_P#B
M:/\ A2OA?_GOJ7_?Y?\ XFO1J*/:3[A[*'8\Y_X4KX7_ .>^I?\ ?Y?_ (FC
M_A2OA?\ Y[ZE_P!_E_\ B:]&HH]I/N'LH=CSG_A2OA?_ )[ZE_W^7_XFC_A2
MOA?_ )[ZE_W^7_XFO1J*/:3[A[*'8\Y_X4KX7_Y[ZE_W^7_XFD_X4IX7_P">
MVI?]_E_^)KT>BCVD^X>RAV/./^%)^%O^>VI?]_E_^)H_X4IX7_Y[:E_W^7_X
MFO1Z*/:3[A[*'8\Y_P"%*>%_^>^I?]_E_P#B:/\ A2GA?_GOJ7_?Y?\ XFO1
MJ*/:3[A[*'8\Y_X4IX7_ .>^I?\ ?Y?_ (FC_A2GA?\ Y[ZE_P!_E_\ B:]&
MHH]I/N'LH=CSG_A2GA?_ )[ZE_W^7_XFC_A2GA?_ )[ZE_W^7_XFO1J*/:3[
MA[*'8\Y_X4IX7_Y[ZE_W^7_XFC_A2GA?_GOJ7_?Y?_B:]&HH]I/N'LH=CSG_
M (4IX7_Y[ZE_W^7_ .)H_P"%*>%_^>^I?]_E_P#B:]&HH]I/N'LH=CSG_A2G
MA?\ Y[ZE_P!_E_\ B:/^%*>%_P#GOJ7_ '^7_P")KT:BCVD^X>RAV/.?^%*>
M%_\ GOJ7_?Y?_B:/^%*>%_\ GOJ7_?Y?_B:]&HH]I/N'LH=CSG_A2GA?_GOJ
M7_?Y?_B:/^%*>%_^>^I?]_E_^)KT:BCVD^X>RAV/./\ A2?A?_GOJ7_?Y?\
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M]3_[_K_\17I=%'M)=P]G'L%%%%06%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF\8/?RQZ);:3%:Q("LU^[N9V/50J$; .F3GZ4 ='17"CQ]/>^#M#U'3K"/\
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MV%G R,8. !^0KV)K&T<0AK6!A!_JLQ@^7T^[Z=!T]*<UK;O<I</!$TZ#"RE
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M/6_@]XV\2VL4C:CX@NFG54&6:W27)4?AY@QW %>^/:V\EL+9X(F@  \ID!7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5G2:YI\6MII$ES&MX\1E"%@. 0,=<YYZ5HUXA<:6/!NJ.^
MOZ#IVN:?':S7$U]$5,[HTZGSG5QRZY ^5NG3TH ]AU?5[/0]-DO[^0I A5?E
M0LS,Q"JJJ.222  /6I;"\^WV4=R+>XM]^?W5Q'L=<''([=*Y'QC<3W>LZ%I=
MS;&UTM]1MYO[1=@RR2HV](0HY4LP W-@=ADD5;\<W-UI%MIWB&WGF6#3+M6O
M84<[9+9_DD++T)7(<9Z;30!UE%>=MKJR6'B[Q1?7=]_8RG^S[*.TF*DJAV-)
M'@@!VE8@-Z*.:HZ+'K&A^/\ 0[62UN["SU&"Y$EO<:S)?&0HJL&(<81AZJQS
MF@#U*LQ]>L(]6N]-DD9)[2U6\F)7Y5C8L <_\ :O/3J^H?\ "A9=0_M"Z^W!
MW'VGSF\P?Z65QNSGIQ].*O:[;K=>,O%T+M(H;PU#S$Y1N'G/!'/:@#T&TNH+
MZS@O+602V\\:RQ2+T96&01]0:FKB/!.@V\'PWL_+U'48CJ&D0^9,][(_V?,/
MWHMQ(CQN)^7 X'H*?XFTK6&\,:/9Z-<W>HQ6[QB["7WDW%[ J$<39'S$[6/(
MSSSS0!U5_J-IIENL][.L,32)$&;H7=@JC\20*M5XSK:Z=J'@Z>RC.OV<UEK=
MDEQ9W]Z[26Y>2, *X=LJ5;</F.#R,'%=/XCM+:UDTKPS9Q:WJ5W*)KE(O[9E
MA^0%0S2S%MQ +  <]>E ':ZAJ-II5D]Y?3K!;H55I&Z LP4?F2!^-6J\1U%;
MZ[^&WB?3]5FNE.EZW!'"GV]YFC0M"=AEPID \QB-PX./[H-=M>VS:#XL\':=
M:7^H-;7%S=^:MQ>23&3_ $=B Q=B2 1D ]#TH [BBO/[N37+_7/'NGZ1J#17
M:6MFMEYDIV0NR/G;U"D^N.N#2>#I8++Q*=.NK+Q!IFIR6C2?9]0U$W<$ZAE#
M.C;V&X$C^[PW3T /0:*** "JNH7HT^R>Y-M<W 3'[JVCWN<G'"]ZYOQ1>SZ#
MXFT+66NI%TN5VTZ^C:0^6GF<Q2D= 0XVEO1ZE\#3W>IZ;=Z]=33,FJW+3VL4
MCG;#;#Y8@JG@95=YQU+4 ;FDZM9ZWID6H6$IDMY<@%E*L""0RD'D$$$$'N*N
MD@#). *XGP3//;:GK.DVUL;K2XM0N9%U)6"JLCN7>$J>259B-RY'T((K9\8Z
M+<>(/"]WIEK<QP33%"IESL?:X8HV.=K %3CL30!=TO6]/U@3_8KA)#!*\+J&
M!(*G!/!Z<<&H-5\1V6E7UM8/'<W-[<*SI;VL)D?8I +G'"J"0,GUKA/ TUMI
M_B-;#4/#%E8ZA<7-ZMK>V15D.Q\R1?=5E4<8R,'':MS0YY]2^(]_=ZC;'3KR
MVTY;>&Q=@[20M(6,VY?EP6 7 )(QSC(% ';45P6N>(9/!?BS4;J^GFETW4-.
M:YM8G<D)<P##1(.V]2IP.I!JE>PW5MH7ASP_J(U;4]>O5EN9(X-2>U!8#=)O
MD!R$4N %&>@XXH ]*HKQN34M;TWP)X[M)KFYMIM+GC%MB_>XDMU=(V*B8A6(
MY/7IDCFNYU^\GB\=^#[>*YD2&X>[\V)'(60+#D;AT.#R,T :5KXHTFZLUNA<
M&.)[YM/0R*1NG#E-H^K XK9KQ6?3XK_PII:RRW,8_P"$SDCS!.\1PUVX)RI'
M(['J.U>F76@P1V&E6::QJ-JEI>I.KF\9I+@@L?*=W)+J<_=SV'I0!O45PM_;
MGQ+\1;S1K^]O8+"PT^&XAMK6Z> SO([AG9D(8A=H &< FN<LM0OY/#^GZ5_:
M]]]GOO$]SI\EZ;EFF\A&E*H)"<@ML5<@YQG% 'KM%></I=U;^)=7\(Z7JNH1
MVMWHINX6DNY))+.<2;%*R$E@K=<9_A/J:71/$=YXQU3PY;1S2V[65NUYK"1N
M5_?*6A6%L=BXD;:>H04 >C45XS9+XH\4:/=ZS:6VH'5GN)Q;72ZQY45L4D95
MC,&=NT;0&# EN3GD5T9T^]\0_$#6+&[UK5;.U@T^SD-O8W9B7S&,N2&'(Z=B
M,\9S@4 >AU5FU&VM]1M;"0R"XNE=H@(V*D( 6RP&%ZCJ1GM7FZ:/+KC>-;BZ
MUO6E.GWLD=FD-_)&D)6"-@P"D9.3T.1[<G-_3-8U"^U/X=2S7<N;_29Y[I%8
MA97\J$Y91P<%B1Z9- 'H=%>+2VUY_P *QU3Q:==UDZK97-U);$WS^7&([EU"
M[,X92!@[L\<= !76SVQ\4_$#5M,U&^OH++3+2V>WMK6Z>W\QI-Y:5BA!;&T*
M.<#GUH [RBN1^&MQ/<^#4>>[GNV6\NXUFGE,CLJSNJY8\G@"NNH *JW^HVVF
M11RW)D"R2I"NR-G.YC@<*#@9[]!WKGO'5EK5[96"Z2D\\*7.^]M+:[^RS7$6
MTC:LF1C#%21D9 QFN4;5HX?#J0:9+KEC<0>(;*"ZM=1NF>6#?)'E ^YLQLIS
MC<0<F@#TR#4;2YOKNRAG5[FTV">,=8]PRN?J.:M5YUH6@VTOQ0\6W)NM1#V\
M]I,J)?2JC%HMV&4-AESP 00!P.*YO2E\5^(_#D?B"RM;XZS/(TT5V=9V01[9
M#^Z-OG;L &T@C/4YS0![310.G-% !37;9&S[6;:"<*,D_2L+QMJMWH?@C6=3
ML1FZMK5WB)&=K8^]COCK^%0:%X6M=-EM-0BUC5KJ9H_WCSW\DL=R2OWBC$J/
M4;0,?2@#1T;Q!9:V]U% MQ#<VC*L]M<PF.2/<,J2#V(Z$<<&M6N)EGGTWXH7
M']G6QU%M0L[<7T2,$-DJ.X20EN"&#-\N=WRY (KM)!NB<;RF5(W#M[T 4!KF
MGG6Y-'^TQB\2)92A8<ABP '.<_*>/<4[6-9L]"L/MEZ[A"ZQ(D:%WD=CA451
MR23VKR&TTU?!6L>5X@\/:;J=I;6]IOU&V(,H+7$@2X97&XR%B-VUB> >>@[?
MQ1//>>+?#^F7EL;/3H]02XBOG8,+F9$8K"H'W2<DY;&=N!G- '7V5U]MLX[C
MR)X/,&?+G38Z_4=JGKD_&-U<Z+?:)K\=Q*MC;70MM0B#D1F&;""1ATRC[#GT
M)K#&M>;X<\0^)+^XU)['4;Q;33;>SN#&WEJXB0QG("&1]Q+<<$>E 'I%%>9>
M&EU;1OB':Z;/;W-E97NG32FUFU:2^RZ/& ^7'R'#$8!(/X57CU?4#\!],U Z
MA=?;G>V5KGSF\QLW2JP+9R>,@^W% '?OXCTV*\U:VFF,1TJ!+B[=U^5$<,P.
M>_"-FM.*5)X4FB8-'(H96'<'D&O+/%%NMS<_%%&:10-&M7S&Y0Y6.9@,CMQR
M.A&0>#74Z5X=MH? QM8]6U.V6\M$+73W\CO!E!S&SD[/PXH ZVBN+\7Z;K,U
MCHT6F?:]0L8"?MUO;WWV:XNDV85A+D9P>2,C.16"FKQ+I6BQ:9<:U:F/Q/#:
M7=OJ-RS2Q$J28BVX[D.5(&X@Y_"@#T^:58(9)7SM12QQZ 9JMI.IVVM:1::G
M9EC;7<2S1%A@[6&1D=JY>_N[@_$34;/[1*;8>'?-\C>=@?S7&[;TSCC/I7&:
M?ILF@_#7PMXDL=5U,ZC_ *"BPO=LT4J2.B&$1?=QM8XP,\9SGF@#UVVU&TN[
MJ[MK>=9)K1Q'.@ZQL5# '\"#^-6J\X\->';6?QYXQG:[U-7BOXR%34)E4[[=
M"=RAL'&XXST  ' %4+/6-4O(K'P')?W/]LVVHM#?72RL)3918D$NX'(,BM&F
M>Y9J /5J*\YBT;_A)/%WB^/4-9U>&VL[B%;>.WOWA2'-NC%@%(YR<\\=\=:P
M;77M>\0V/@_3YTNKI;O3IKFX6"\^QO>-&ZHI,@P<;3O(4C.0>@H ]DHKE?!5
MGK5A%J-OJD<L=KYX>QCGO/M,L<94;E+]2 P.,\X..U=50 445P.N>(9/!?BO
M4KF^GFETW4-.:YM(G<L%N81AHD';>I4X'<&@#JM;UVVT"U%U=P7;VPR99;>!
MI1"H&2SXY QWQVK1AFCN(8YH75XI%#HZG(8$9!%<]I6E7,/@ 6&N7TKW4UI(
M;VXE<L4:0$O@G^%=Q '0 "H/A]?7MWX5LXKFQ:*"WMXXK:[W#;>1A<"14/S(
M" #A@.O&>M '37-Q%:6TEQ.ZI%&I9F8X 'XU!I>IVFL:=!?V4JR031K(N""1
MD9P<=#STKF_'F@7FLPZ?<6@LKC[ \DSV%\2(;@%"N3@'YESD$@C)K)^'FHV\
M.C7%K:^&5M-8M]/M)I8H'C O5:,^6^_@;CAL[L$>IH Z\>([*3Q ^BP1W,]S
M#C[0\4),4!*[E#OT!(YQ[CUK7KC_  $3<KKNHSXBO[O4F:ZL^<VC+&B",G^(
M[54[AP=W&1S7.76L:G86FK^"DO[@ZS/J*V^GW+R%I1:W&7\S<3D^6JS#/;8M
M 'J=%>>>(HAJWB-M'TZSU6^NM.M(O.(UJ6RAB#[MA)4EGD.#DX/ '-9NAZWJ
MMSX?^'\UW?SF:;5I[:Y;SB?.5!<*H<\;_N+U')&>M 'IM_>PZ;IUU?W!806T
M+S2%1D[5!)P/H*KVVMZ?=26,4<X$U];?:H(F!#-'\N3^&Y?SKBO$%W<2:QX\
MM&N)6MXO#B.D)<E$9EGR0O0$X&?H*S$T.WU3Q7X+6:YU"(2>'7R;:]EA(VB'
M&-C#'WCG'7 ST% 'K%5;74K.]>[2VG65K24PSA<_(X4-M/OA@?QJFVFI_P )
M%:7@U2Z5H;5H18^?^[D!(_>,IY+#&,^]<AX(T&V7Q-XJO1=:CYMMK,@5#?2F
M-@88SEDW;6/S'!(/0>@H [*V\0Z9=QZ<\=P5_M+<+598VC:0J"Q&U@", $\X
MJ1-8M)->FT92_P!LAMDN7&WY=C,RCGURIKR:PLV\06/PPGU&_P!1>>X%PLDR
M7LJ.<0R-G<&!W<8SU(XZ5NZG<2^'?%7B6YL?,FFL/"D3P^<YD9F1YR"Q.2QX
MY)Y- 'I=%>5Z%IWB1I-!U2TM[\/))%)?7ESK7GQW4+CYSY6=HZY7:!C %>J4
M %%%<SX[_M"#PTVIZ9+,MSI<J7WE1.5$\:',D; =04W<>N* .DD?RXV?:S;0
M3M49)]A69HWB"RUMKJ.W6XAN;5@EQ;W,1CDC)&5R#V(Y!'!K$\/:H_B?Q=J&
MK6EW*^BV=O':6ZHY\N:5P))'(Z$J#&H]/FJ%IY]-^*%V-.MCJ']H6MM]N1&"
M&R",ZI(2W#!@S?*#N^7(!% ';4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 45Y!X6TO3_"S:))XC\&?9-0N+KREU8M%(1<.[% VUB5!S@'
MZ9Q7K] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5QL7PWT"#Q##?1:?%]DCA8"V:21D$F]6#!"2H P>,=<<5V5% &'XKT2?7=&
M2"TFCBNX+F&[@:4$H7BD#@-CG!QCCUJ[';S:CHSVNMVEJ'N(WBN((96DC*G(
MP&*J3E?8=?QJ_10!EIX<T=/#@\/BPB_LD1>3]F.2NSTR>??.<YYJEIG@?P]I
M%_!?VED_VV ,L=Q-<RRNJL,$9=CQCMT%=#10!RD_PW\)W,]Q+-I(?SY#*\9G
MD\L.3DLJ;MJL3W %;XTJQ_M.?4?LZF[G@6WED))W1J20I'3JS=N]7** ,'3_
M  ;H6E:?>Z?9V;I9WL9AF@:XE=-A!&U0S'8,,W"XZU)>>$]%OM*L=,EM76UL
M%5;413R1O"%7:-KJP;IQUK:HH PH_!V@1Z)=:/\ V>KV5VV^X621W>5N,,SD
MEBPP,'.1@8J"X\!^'KFSM+:6UN&%HS-!+]LF\Y-WWAYN_?@\<9QQ7244 85M
MX,\/6FD7VDP:7$MC?-NN8=S$2-@#)R<@_*.1W&>O-13>!_#\^CQZ7-:S26T4
MWGQL]W,TL<F,;ED+;QQQP:Z*B@#GK7P-X;L[*_M(-,18;]46Z!D<F79G:2Q;
M.1DG.<^]):^$[/1!-<Z'$J:DZ"-;B_EFNMJ9!*Y9]P'L"!G%=%10!@^5XN_Y
M_=$_\ Y?_CM'E>+O^?W1/_ .7_X[6]10!D3:/_;6A3Z9XDCM+R*?B5(4>-&4
M$$=6)!R,YS5FYCN;+2A#HUK:M+$JI##/*T4848&-RJQ&!TXJ]10!B>%-$FT'
M0Q:W4T<UU+/-<SM$"$WRR,Y"YYP-V!GTJ_JFE6.M6#V.HVZW%LY!*,2.0<@@
MCD$$9R*N44 <SX7\&:=X;EN;B*W1KJ6:4I.TCR.L3/N";G)([9QU(YS2ZKH^
MJKXKM?$&D?8Y9%M&LI[>[D:,%"X<,K*K<@@\$<YZBNEHH SM6T+3-=6U74[.
M.Y%I<+<P!\_)(O0\=>O0\5%KGAK2?$2V_P#:5NSO;,6AEBF>*2,D8.'0A@".
MHSS6M10!AV7@_P /Z?I]_86NF1):Z@,7419F$OR[<G)/)'4]SSUYJ#2_ ?AO
M1K^WOK.P87=L&$,\MQ+*Z KM*@NQ^7!/'2NCHH QIO"FB7&C3Z3+8*UE-.UP
M\>]@?-9]Y<-G*G=SD$8[4I\+:.UAI]E);/+!I]RMW;"6>1V2522&+%BS'+'J
M2.:V** ..\9^')];O+26+P]H^J")&7?>74D$B$GH"B-N3U!J30O UC9^#1H.
MK06URLLTES,D*E(TD=R^(\8*A<@*1@\=JZVB@#)T7PWI7A_SVT^W=9;@@S33
M3/-+)CIEW)8@=AG J73M"TS2;R_N["SC@GU"7SKIUSF5_4Y^IZ>I]:T:* .:
MO? /AK4+V>ZGT]P]RV^X2&YEBCF;U=$8*Q]21SWK9@TJRMM2N-0A@"75Q%'%
M+("?F1,[1C.!C<>GK5RB@"C#HVGVZZ@L5N%&H2-+=?,?WC%0I/7CY5 XQTJ*
M#P_I=L^F/#:!6TN%K>S.]CY4;!5(Z\\*O7/2M.B@#)/AG1VT&?0S9+_9MP9#
M+!O;#;V+MSG/+$GK6!XQ\,W&M:E;3P^'-%U-8X=@EO;J2"1#D\'8C;TZ<'OF
MNUHH PO!_A\^&/#%KI3/$\D9>20Q)M3>[L[!1V4%L#V J2YB\3&YD-K=Z0L&
MX^6LMK(S >Y$@!/X5LT4 <[/X<?7853Q+]FG:%]]M)8&:V>,XP3N$F?3H:GM
M_"&A6VGK8QV(\D7*7AW2NSO,I!5V<G<Q! ZD],5MT4 8]SX6T>[UV/6Y+5QJ
M";1YL<\D>_:<KO56"OC_ &@:HW/P_P##-W>37,FG,#._F311W,L<4K]V:-6"
M$GOD<]ZZ:B@##EB\4F9S#>:,(MQV![24D#MDB3K3?*\6X'^FZ)G_ *])?_CE
M;U% &-;6VNRRF+59M)GLG5EEBBM7!8$8Q\SD8]>*KZ;X*T+1+I;S3+)DN(D9
M8%DNI7CBR,8568J@/3@=*Z&B@#G/#^C:E;ZWJVMZL;1+K4%AB$%H[.D21!L?
M.RJ6)+M_".U="Z+)&R.H9&!# ]"*=10!Q]C\.M"L/$9U"*QC^S1PQ""!Y9'6
M*56<[@K$J/O+CT()&*T_%6BW6M6-F;&6&.\L;V*]A$^?+=D)^5B.0""1D9Q6
M[10!GR6/]L:%)8ZY:6Y%S$8[FWBE9XR#Q@,0IZ=\ U'/X=TBY\/#0)K&-M+6
M)85M\G 5<;<'.01@8.<Y&:U** ,#2?!>@Z+J":A963B]6-HOM,MQ)+(4;!(+
M.Q)'RC&>G;&35,_#?PFT[RMI(;=+YPC,\GEQONW;D3=M0Y_N@=QT)KJZ* *!
MT73C=7]RUJC2ZA$L-T6)(E10P"D'C&&8?C6?:^#-!L]%N]'BM)#I]VFR6"2Y
MED!7&-H+,2HQV&*WZ* ,;4O"NCZM;V<-U;R 62[;9X;B2)XA@# 9&!Z =^U1
M-X,\/MH+Z(VG*;&23SG4R/O:3.=YDSOWY ^;.?>MZB@#!TKP9H&BSS7%C8[+
MB>'R)IGF>1Y$SG#,S$D^YY[=*KZ=\/\ PSI5W:W-II[AK3FW22YEDCA.,;E1
MF*@^X&:Z:B@#'D\+:/+X@&N&U==1^7=+'/(@DVC"[U5@KX' W U4TGP]+;^,
M-;\0WJP>?=B.VM1%R4MT'\1P/F9B2>O 7FNCHH X?_A7=AJ/B;Q!J6M0>?#?
MS1-"L5U*F46)4*R*I 894\'(Q70ZGX8T;6+*VL[RP0PVN/LWE,8F@P,#8R$%
M>.."*UZ* .?@\/-H5HT7AH6UN\LF^=[XRW#2'& =Q?=GZFG>5XN_Y_=$_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>fifthamendmenttoamendeda001.jpg
<TEXT>
begin 644 fifthamendmenttoamendeda001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP+HVJIL@8]%9G906]ADCO7#?#"\MM'\-:1]IU-[BXO+>WM(]/."]NZR2;CM
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOUTW39[LH9&1?DC!YD<G"H/=F( ^M5O#4%Q:^&-+M;NW>"X@M8HI(V96PRH
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MCS*1$0JD,"2=S8'/7IQ7>:WH.HVG@_4+*WU[45N)+Q/L=XURYEA61T7#'(W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%<MXBU_4],\4:!I%DMH4U=YD\R9&)B,<>_/##.>G;'O0!U-%<OJNJ
MZ_H^BZ[?S+ITHT^T-S"T:N!(55V=&&[*G"K@Y/WNE9VH>+=9M-"\*WZ1V#2:
MY<VUNZ&-\0F9"P(^;G&,=L^U '<T5ST\_BB&22.*+2[G*+L=0Z!'+H#O7).-
MC,W']VLJUU_Q->>*=8T&)=(\[3H(9A(R2!9#(&P/O<8V]>>M ';45R-MXCU>
M3QW:^'IX+2*.32AJ,C;6+H=X0Q_>QU/WOTJ:#7]1D^(MSX<9;7[+#8I>B4(V
M\AG*!/O8XP3G]* .HHHJ"]O(=/L;B\N&VP01M+(WHH&30!/17/\ @WQ*?%/A
M\7TML;6[BFDM[JU;K#*C$%3^&#^-9VB^,;FY\>:KX7U.WAB>!1)9W$60MPH
M+C!)PR[UXSZF@#L:*X_Q/XQN-(\4Z%H5C;Q22:A.(YYI<E8%8,5X!&2=C\9_
MA]Z>^O:S)X]N/#=O]@5(]/2^6>2)R2&D*;2 X],Y_2@#K:*Y/6M8\1Z1X;U#
M44MM/NKBTFQ'$@<"Y3Y1P<G:VXL,'/3M3T\81:KX"NO$FC%"UO;RRO!<*<I)
M&I+1. 05;(Q^O- '4T5R&LZ]K>F^*?#VB0_V?(VK+<;I7B<"(Q(&. &Y!SZC
M%2-XIO-*\3V.B:]9PQKJ.Y;*^MG)CDD49,;J1E&QTY(- '5T5QV@>,;F]\:Z
MMX9U.WABFMAYEI-%D+<H#A^"3@@E>,]Z/$?C&YTSQCH?AZPMXI'OY"MQ/+DB
M$%6*@ $9)"/QGC ]: .QHKD?[>UJ?QW?>';?[ D=O9QW:S21.20[%=I <=,=
M?THUS6O$>C>&[S48[6PN[BVN%1(8]X%RA**-IR=K;F(P<\B@#KJ*Y?\ X2Z+
M4_ 5QXET1HG\FVDF,-PIRK(I+1L 058$8_QJ'Q+K7B+0='U;55BTU[;3X/-4
M.KAIR%RV,-A1DX'7H: .NHK"T6\URZ>UFOH[$V=Q:><'MPZLCG:0I!)R"&//
M^S6[0 45Q7BGQ'XB\.Z;+J7V;3C;_;4MH8G#ERKR! [$''?./2KFI^)+WPOI
MFHZAX@CMI+>!8OLQL@P:>1R5\O:Q/.=O?HWM0!U-%<OJ6J>(M&T276KNWL9X
MK>/SKFQ@5A(B 9;;*6P[*,G&U<XZBM_3[^VU73;;4+.026US$LL3C^)6&10!
M9HHKF+WQA#9>/-/\-O"?+NX7S<_PK. &6//J4#'\5]: .GHKE/'OB;4/">CP
MZG8V<5Z@FVS0,"'\L*SLRD'J%0\$5LW&MVD7AXZU$WGVK0">+9UE##*!?=B0
M![D4 :5%><P^/=8D^$TWC1K6R6>,.WV3#%<+*8R-V[KQG./\:ZJ.;Q #:2.^
MFRQ2LHD1(W1U4CJN7(..#CTS0!N45QFE>-I/^$WOO"VM0Q07"/BQNH@1%=?(
MKLG/1P'4XR>OYZ4VJ:JEWKD:-9[+"!98<Q-E\JS8;YO]G&1Z_A0!T-%<1I7B
M/Q1J7@RT\1P:=IUWY\ N/L,;O'(5ZX5SN!;V(&?6F:CX^:;PSH&NZ$();;5K
MZ&SV7*-NB,C%23@]5((([^M '=45D0MKB7\<5P^GRP/&V7BC96C;^$E2QRO7
MT[5@>'O$/B;Q!8:E<P0:2'L[Z>S6%_,7S3&V,[LG;GZ&@#MJ*P?"GBB'Q1I]
MQ*+:2SO;.=K6\M)&!:"5>HR.H[@]ZWJ "BN:\;>+%\(:*E_]F:Y8S(&C09*Q
M YD?Z*@)^N/6MB]GN'TI[G3)+=I/+\R)I06C<8R.A!P?7GZ&@"[17)^"?&:>
M,M$>3RA8ZM;@+=6DH)\IB,JP&02C#D&J&I^+M:T_PMHVJK%I[SZC>PVK1E'"
MIYC;00=V3C]: .[HKD-:\4ZEX3>UN=<M;672)I5AEO;1F4VS,<*7C;.4SQD-
MQZ5U] !17/\ C;7+OPSX1O\ 6K..&62S02&*8'#C(&,@\=?>L^3Q5J.E>(]"
MTO5K:UEAUD.L%Q:EE,<BJ&VLC9R"#U!_"@#L**Y*XU[6#\0&\-6WV%8_[-_M
M!9Y8G) \WR]A 8?7/Z5)J_B2^\-^&M3U35(K24VTR1P/"Q2-PY1 7SDKAV;/
M7A: .IHK AO==AU"SCN!87ME<H[?:;5&0HP7*KM+,"#_ 'L]NG-8MWXB\46.
MN>'=)N8=)6XU@39*K(1 8X]Y'WOF].U '<T50TZ>_%E*VKI;Q31.X+0D^64'
M(;GD<=?0YK)\&>+D\66E^YMVMI[2Z:)H7&&\L_-$Y!Z;D*GZYH Z6BN)\2>(
M_$F@V\%TUOIOE7.J)8PQL'+!'D**['..F#@#OUIWB?Q%XB\+^&-7U:XM].F-
MDL;Q;%<+,K-M8')RI'7N#D4 =I16,DFO1W-IYKZ=-!(^)5CC='5<'YERQ!P<
M9'I6-I>O^(=5U_Q!ID*Z8HTF9(@[I)^^WH''1OEZX[T =E17.>&O%1UJ]U+2
MKZS^P:QICJMS;>9YBE6&4D1L#<I'L".]='0 45S3^(KG4?$]YH.BI!OT]$>^
MN[@%DB9QE(U0$%F(&3R !CJ3BEN]3U^Q&I+/;V3+;61N;>Z17V3,N=R,F<IC
M"_Q-US[4 =)17GB>/=5L_#WAS7]2LK.33]8DAB=;9F62W,H^4X.0X'?H?K6S
MK^OZIIWB[0-%LULRFK"X_>3(Q,1B0/V8;LYQVQ[T =516&USKEO%J)G.GOY$
M DADC1@"XW%E=2V1P%P0>]8FC^)/%&J^#+3Q';Z=IUT9X//^PH[QN5]%<[@6
M] 0![T =O17"ZKX_+^!].\4:$D,T%W<10&*Y4AE+OL(.#P5;.1SG'6K7BK7?
M$7A[1=7U=(=.>UT^,.BNKAY_E4L>#A1DD#KTH ["BL;2;C7)KB)K^.R:TFM_
M-62W#*ROE?E(8G@@GD>AK9H **P_%VOOX:\-7>I0VQNKE$(@MQUE?&<?0 $G
MV!J_IVK6FIZ+;:M!*/LEQ LZNQQA2,\^F.] %VBN7T36]5\4V7]JZ8+2STR1
MF%JUS"\LEP@)'F$!EV D' Y.,'CI5/Q%XIUO0/ VH:Y/86D=[8S%'MRS-'(G
MF!596X/(8-T]J .THKDI/%&HZ5XNT?0M6MK:1-727[-<VI8;'C7<RLC9XP>&
M!_"BXU[6#\0'\-6WV%8_[-_M!9Y8G) \WR]A 8?7/Z4 =;17*:WKFMZ%X3UK
M5IH["6;3PTD6P-LFC502#\V5;=N'?I5NUN_$$MKI]VS:;)'<&(O$L;HX1L$[
M26() R<8YP: .@HKCM/\8W)^(E]X6U&WA1 FZRNH\@3LJ([H02?F"R*>.P-+
MXP\8W&@:QH6E6-M%-/J5Y';RR2Y*VZN2%) (R25; _V&H ["BN2N=>UD>/E\
M-6_V (VFF_$\D3DC$@C*8#^^<Y_"I-7U7Q%I7A[5M0$6FSSV(,L2J'"SH%!*
M_>)5L[AW'3I0!U-%<QIOBZ/7O!MQK6FJL5U;QR>?:W"DM!,@RT;@$$'(Z_0U
M'J&K>([31[C4XX]--O;:=]K8NCYDD"LS(H#<  +R<\GI0!U=%<SX;U77M6LM
M(U*ZAL/L.H6BSL(0X>$L@90<D@CDC/'.*Z:@ HK*GU?=X@CT:U"M.L(N;EVY
M$41;:HQ_>8AL>@4GT!P=?\=01^$]?U/P_<V=S<Z265ED.]&*A2V I!(!;&?4
M&@#LZ*K6M];73-%'<0O/&JF6-'!9,CN.H_&JFGWTD6BI<ZO?Z<7#,'GMVVP_
M?( !8GG& >>H- &I14<,\5S$LL$J2QM]UT8,#]"*DH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\Z\>/8S?$+P+:W5UY2F>[+[+DPNN8<#YE(89.!UY
MZ5Z+2%5)R5!/TH X[Q5I]IH/PT\40I<2>5+973J;F=G;<\9^7<Y);GID^U<E
MXAN]/G\#_#6)[V,(VHZ=N*7&Q@HB(8AE(*X)Z@C%>O$ C! /UI-B?W5_*@#/
MTC1[;2?M36LMQ(MU*)B9[AYB#L5>&<DXPH[UR6@7EL_QE\61I<1,YL[,!0X)
M) ?(_#(S]:[^D"J#D*,^N* /.-0%C>_'6"VFO&1AX?90(;IHFW_: =N48'ID
MX_&ETC[#9_&_4K6&\:1CHD2XFNFE?<)FRN6)/ P<>]>C;5SG:,^N*-JYSM&?
M7% "UR_B2[74=6L/#=K>VL5W(WVR991O_=1%2%*!E)W.4XSR%:NHI-HSG SZ
MT >;6-T?!_Q6GL=1O[,P>)(/M">6GDJES'A2-I=L;UP<YY(Q53Q&@G@U;Q'H
MTD=QJ?A[6#>*D3@EXO(B6:/CL5S^*UZH54G)4$_2@*HZ*!^% 'E&OR);ZMX+
MOM0D2WOM0UO[9-'*X#1(8F5$/IM78I[;L^M6KRYT>3XVW8OM32W1-"B3<E\U
MO\_GL=I*LN3@@XKTTJI.2H/U%)L3^ZOY4 <+>:CH=KX,O[2PU-+BUM+E UR]
MQYB[WF$A3S"268!AG))Y&><UC_$#2+WP]:ZQXE\.Q>?8ZG9R1:O91GAMR%5N
M4_VES\WJ.?4UZGL7&-HQ]*, KMP,=,4 >?>,-1L;3XJ>!C<WEO"(UORYDE5=
MNZ)0N<GC)Z>M,\2R1^,_%OAFQT9Q=6^EWZZC>WL1W11! =L>\<%F)Z Y&,FO
M1"JDY*@GZ4N,#% 'E.O@-:WOBG1Y([G4/#VL27#)"X8R6Y1%FCX]5Y_X#1K3
M)9^)/!%SJ,L<%_?:K+=W$<C@-'NA*HA_W5V)[D>]>JA5'0 ?04%5)R5!^HH
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M"/J*Z.D  &  /I2T <5X>62/XJ>-!.#F6&PDASWC$;J<>V\-7&:A=6%O\/\
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M0<$ \XYJ"32?%5[)HMU?:'-+J-AK9N+B;[5$(VA_>!3"N[Y5 9,Y 8D=&.<
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MN5BN;78Q:1F'S&;T8=OSJ_JFEZO;>+=#\3QV9O6AL9+*_M[=E#KN*MO3<0"
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MZM]!\9:IX8CU#[;;7L2ZE:SLV2TN LX)]2P#X]&- 'H5KJFGWT\\%I?6UQ-
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M/A7]PR[3GW-0?"< >$+C Q_Q,[S_ -'-0!W-%%% #)98X8GEE=4C12S.QP%
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MO)X*X/4]:OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?=+!:Z/9R6<-NT.XLK[<DMN'/R ]/6NIJ.>XAM83-/(L<8(!9C@9)P!^)(%
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M@L+BPM7OX+N5 9(74".-@3YIR1E>G YYK0H P[[PM8WWBG2=?<;;G38I8XU
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M^YL- M].6ZC>:"!84G,) .T  E=WMZU=2XADN)($D5I8@I= >5!SC/UP:DH
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MLF5[8&5]T148!5L[A@<=>G%0_P#"%^'/L=[:#2;=8+V19;A%R SC!!&#\I!
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ML%E:Q6MK"D,$2A(XT&%51T % &5/X0\.W,%]#-HUF\=_,)[I3$,2R#HQ]_\
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M 10!S&FK(O@_6]<O_%&L6LEI=W]K'-Y[2K&GG%$_=DX9AP%)Y!/7@8MEKO\
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M5Y<)L^\<,2V_.W@CVVU!X>DU7Q)HVB^)8]:6TF^UAKP&>1U<%RK6YB)V*<D
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M2/M<*>< 7Q][E!R?2K%FMMI</Q%O3JEWIWEWS(+I9'E,>Z&+!"%L,V3@'KR
M"!7>S>&M(GAL(7LPL6GN)+1(W9!$P& P"D<\GGW/K3+GPEH-Y/J$UQID,CZB
M@2[W9Q*  .1G . .1SP/2@#G= GO;?X@:EIDGVF*T;2(+I+:>[:<HYDD4L22
M=K$*,@$CC.37.:+/<VWPY^'$EM=7$/F:E;P2K%(561&,A*L!U' ZUZ%:^#]!
MLKI;NVT]8[D0?9Q.)'\S9SQNSDGD\]<<9H7P?H26%C8I9,MK82B:UB$\@$+C
MHR_-P1DX],GUH YGQ#!-JGB-?#FC:EJ4=[(XNM2O8[Z55LH"<JBJ&VAVQA1C
MIEB*AS?^*;KQ)86>KFRN-.G2&UE%W*&@C\I&24J#B0,2QRV<CCI77#PIHZSW
M<\<$\4EY(9+@Q7<R>:QXR0K#/''TJ"^\#>&=2O[>^N]'@EN8(UB1\L,HO16
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M6:PBS>.YDB:)7A5UF"J0'^9CUXPN/7,^D7D^O^*[S1]2U&21-/TNTDC:UE:
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M1JK-)+I\T<:*"69F0@  =22:YIG2+Q5X,EMK<NL6CW,;+&F "4BVH3C"DE6
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M\&ME54$NS,T4(5%R>268 <]ZZ >)VBUG^Q[O3I8-0EMFN;6/S%9;E5^\JMP
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M1+)-+(_F332XWR-@#)P .@ P !@"K=%% &);Z T'BZ[U_P"V%FN;9+9H/+P
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MWSMQT._'7M7344 <+X>TGQ9X?=]"2+3Y='6X>2WU%IB)HXF<ML,>W#.,D Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH8[J<(KLS;B AXR *['PU]DDTHW-A<74UI<2M)";F1W91]W +DMC*D@'IG%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7]BFKW;3[;='",X25URJ$DXPOOTJK)=0V'QBG:Z8Q)<:'$D3%3ABLTA89Z<
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MN<_-U'2N/F>VT#XGV]Q<K!9Z-<Z4T5K. $A2X,N^0$] SC:<G[VVL:+0+UO
M>MW-E&0UIK<VKZ&F, (CA@%'97Q)CU#^] 'I*:QIDAN!'J-HYMN9]LZGRO\
M>Y^7\:;<ZYI-G##-<ZI90Q3 -$\DZJK@]""3R.1^=>>11:G-XG^T+;2I8>,K
M8&9"H!M1'CEO1G@)'KOP.U.UF^T_3_&FOZ;XFN;RST_5+>%+)HXMT<\0CV/$
M"%8A@Q8X']^@#T&\US2=/9UO=4LK9DC\QA-.J%4R!N.3TR0,^I%7@00"#D'H
M17F=GINCCXDZ582VD9@3PT8%@O '<'S$VH^>K[,\'G&:[K3=>TO5;_4-/L;@
M27.FR"*YCV,OEDYQU R.#R,CB@"/7?$NE^'19_VC=1Q->7"00JSA<DD GGH
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MW$-W;QW%M-'-#(NY)(V#*P]01P14E8'@ZRTVP\/I%I"7"Z>\KRPF?(+!FR6
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MQF!W8(Z]1SB@#IZ*Y:\\9K:V^MI_95V-0TJS%X]K(T8\R,AB"&#$8^1L]^.
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M\^PLH)4TV.&X6))2F'6 812>H7V'3-6JK7^H6FEV$U]?3I!;0J7DD<\*!WH
MX;PCH_B'1(;30;S0M/:WL&"1ZRLJ$RPJ<K^[QN$F,+R0!UR<8-.[\,Z[/X)\
M4:8FF,+K4=8>[MU,T>#&TJ."3NX.%/'J17I-M<17=K#<P/OAF021MC&Y2,@_
ME4I( R3@4 <5<Z!J5UXMUJ8VH73M9TF.T>?S5#6[+Y@(*\Y/[P8QQQUJ+PG:
M>([*WM-/U3P[I\!L$"-J,$R,;H*,+L3 *LW&2Q&.?7CK=,U>PUF&:;3KI+B.
M&9H'9,X#K]X?AFDL=8T_4KJ\MK.Z2:6S<1W"IG]VQ&0">G3TH X>S\(ZQ/\
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M[!E(& <!NG%/U73=7N?%WA;4#:":*Q-RUT\4B@)YJ;5"AB"V.YP,CGVKKJ*
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M\Q <;E.&'/H15V@#EO%.CZA/KOA_7]-C%Q-I,LHDM=X4RQ2H%;:3@;A@$ D
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M92JR2A0<$YQP!QS[GWKGX/ARMO:Z=:IK]^+?3;\WMHFR/,>=^5)*Y;_6-R:
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MV_2WUF-!<Q[(R3(J! ^[;D9"@E1@9]!Q0!%<ZA?P?%&X\R_QIUMH8N_(\K.
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M_*8!H\ECNR&'/'(Z5/-X"6X\.ZUHSZI)Y.K7CWDT@A7<C,P9@O.,948SGO\
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M@'&>: /:J**\C\07D3?:]3T^=VE@\2P6YNYY<3*XDC1X(P!Q$!G@GGYN.<T
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MXMW(+12H&5L'(R#P>0#7+:E\2O#EIIDMW:WGVUU6%EC@C=LB8X0DXX!/^'7
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MQ\RXSG.1CUSQ0!>U+2=.UBV%MJ=C;7D .[RKB(.N?7!XJ)- TB.Z%TFF6BW
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MYP",DBIKJPUZUBMY+/69+J03Q>?'<P18:+>OF;-BJ5.W=C);\^: -YE#J58
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M,]>!5JN8^'FJWFM^!-+U+4+C[1=3J[/+M"[L2, <# Z =*Z>@ HHHH ****
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MFD?S/,V?,N5&/N=.<>ISP ='K-_/IFFO<VUC-?3;T1((NI+,%R3@X49R3@X
M)KE;OXAFTTKQ-<_V=%<3Z"4,J6]V&CE5EW A]O!'((QP16WXOTC4-;T$VFFW
M,4,XFBD*S9\N9%<%HWV\[6 P<?2N7U'P/KU];^*XA/I2+KMM!$J('40%$V8Z
M'( ]N?1: -ZW\6S)XB;2]5TU;&)[![^"?[0),QH0'#@*-K#<#P6&.]<SXDU*
M?7/^$(U4Z7#%9W&M6TEM,TN9@C*Q7<NWY=PP<!CC S[;VH>%[[5?$5M>77V5
M;,:5/IUPB3,7/F[<E?DQQM[^M947A#Q5_8_A[29[K2GAT.^@FBN09-\T4095
M#)C"M@@?>.?;N >AR1I+&T<B*Z,,,K#((]Q7S_IT5A<?#ZVTC2+(Q^+KN_N/
M[.N(HC"R^7<$EO/( *J@Y4$G'&/3Z D,@C8QJK28X#-M!/UP<?E7GVG_  \N
MQX%_L.^N+>+4+:ZDO;"_M68F"9G9U;!4="V".XSTH Z34_$']D36.FNT$NHS
MP-*3-+Y4>U-H9B0I(RS+@ =SZ5E6_P 08IK/3FGLUL;J\NI;3;>S&.)7C&>)
M-OS!N-IP,Y]L4W4M!\57-SI&N6ESI<.O6,;V\\;&1K:ZB?:6!X#(=R@C&?J:
MO7VBZMJ>GP6^JPZ3J<4V\WMI,&2+)V[/+.UB-N#R>I)/'& "E?\ B'7T\3^&
M+!+"V@2^^TM/$]RV<Q+C&X)]WY@P..>.G>>]\:RZ?J%M%=:7Y-O<ZH--B\V?
M;,^3M$RQE>8RW?=T.?:J-EX(U32T\+-:7UO))HS7*LMR78"*;HJGJ=@P!G&0
M.U5;CP3XCF$B_;-,D9-;34X[F42&65%DW+&_IM'RC&1@#[M %ZR\77]OJ/BZ
MXU>*W73M'F5%\F4E@/*5@ "H!+%NN1@G'09JU%XX2'4YK;4K2.&UCLGO/MEM
M,TT2A.71SL7:V.1USS56Y\$7M]+XKM;B\MUT_7=D@DC5O.BE6-4Z=, H&Z^W
MO4\.@^)M9T.\TCQ5?:>8)K5[;?IZ.'E++M\Q]W ('.T<9[\8H QM:O+K4_$O
M@+49]+AMHY[UGBD\[?*JM!(0CC:,$C!P"1D?C78^+M9D\/>$-6U>) \MI:O)
M&IZ%@/ES[9Q7,P^&/%4P\,QWUQI)_L.Y#F:,R%KA!$T8)4@!6PW(R1GN.A[;
M4;"VU73;K3[R/S+:YB:&5?56&#_.@#FO"?AS3YO"FGW.I6T-_?WMM'<75U<H
M'DD=U#'YCR ,X '  &*KRZK>>%+S3O"NEZ2^I226L\UM)+=B/(1@=K$@GHX&
MX]3VYXMZ!IGB;P]IL&C!M.U"SM5$5M=RS/%*(QPH= C!B!@9##..U/GT'4Y/
M&6C:OYUO+!96T\$Q=BKN92I)50I  V<#/0]>* *>I>/7L[>\E@TU+E[!ECNK
M=;G]\7VJSK$H4A]N[')7)!JSJ.O?VO'JVFZ=IT5\EK:*]T+F3RQF1"RQ@;3E
MMN"<X R/?%9?#WB?2?$6I3:%?Z;_ &5JDWVF:.\1S);2E0K-'MX8':#@D<_J
M#PQK>E^)-6OM)N+.>SUB*,7*7C,KQ2HFP.I4$,",94[>1U% &+X0U"VMM#^&
M]G/I4=Q)=6K"WO&89MF6!F; QGD#'4=:Z/P=K6KZO?>(!J,-LL5IJ<EM'Y4S
M,4"I'A<%1D<D[L]2>,5F:5X,UFP@\%QRS6$G]@+(LQ5W7S T1C^7Y3T!SDXS
MTXZUM^'=#U#1=6UQY)K:2QO[Y[V+:&\T,ZH"K=@!M[9SGMCD V=2OX=*TRYO
M[C/E6\;2,!U.!T'N>@KA/!-Y>Z1XRU7P_JUXMQ+J,2ZO;N&# .V%GB!]%8#
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M -IY(QSC'4UH4V,N8U,JJLF/F"MN /L<#/Y4Z@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL/Q1
M>7%G96GV>_2S,MY'&[;-\LB'.4B7!RYQZ<#)XQF@#<HKRR\\4>((O!'BFYCO
MI8;S2=6%M!)-%$S^43#\KA1M) D(R/05LLVO?\)]-X?_ .$BN!:W.F&]\P6\
M/F0.LH0K&=N IW#[P<\=<G- '=45YMH_B[5[_1/#5I+*7U#49[R&6XC"(SBW
M9U^4$%0S84GCH&P!P0NJ7_C#1]*MENM1B29]=M[>&0I'(\EK+(% E  &X<C*
MXR/0\T >D5FS:[90>(+71',HO;F)YHQY3;"J8W?-TSR.!ZUPVH^+-6\*R>+H
M;B^;4?L$5G+9R7,:*4>X9H\-L"@J& /KC(SWJ?5([C2?B5H%S<ZA<7RQZ5?/
MB5$!!41%B-JCKQQVQ0!Z)6;K>NV7A^R2[OS*(GE2$&.)G^9V"KG'09(Y.*Y7
M1M0\4:G#H&N13H;"\19;Z&5X_+$;KD>5M7<&4D  DY[\US^N:C>^)OAC:>(Y
M+^1(KO4K9ULU1/+6/[6JJN<;MPP"3GKGMQ0!ZY6;'KME+XBFT)3+]NAMQ<NK
M1,J["VT$,1@\@],]*TJ\_P!3LKZ_^+5Q!8ZI)ILA\/QYGBB21Q_I$F -X(^O
M!_#K0!Z!17ET?BCQ%'X6LM<O+\A-*U22QUD0PIMN(4D,9F&5)7!VD@$#&[I7
M<Z-<W&H7VI7GVII+ 3>1:Q[5V_(,.P(&3E]R\D_=SWH V*S+G7["UUG3=*D>
M0W.HAVMRL9*,$4L?GZ=!TSGD56\9F9?!&N26]S-;31V$TB2PD!@50G@D''3Z
M^F*XDVMR;WX:0QZA*)7MYR)W1"T8-H.% 4#@=,@^^: /4J*\UM/%>KVNFRV$
M]VUU=CQ(VC17;+&CE-OF D8";\94'&,D'!Z5U/AU/$$.H:E#J\RRV19'L6=T
M,Z@CYU?8H! (X/7!YH V[JYCL[62YEW^7&NYMB,YQ[!02?PK#M_'&AW>GP:A
M!)>O93E?+N!I]QY9R< [MF ,]SQ6W??\>%S_ -<F_D:\^^&*ZT_@/PJ@2R;2
MFB83CYC(4VR8R#Q][;F@#TBBO/VUW5]8T+Q1K&GZBUI+I-W<PVUOY:-&WD#D
M29&X[R#T(P",<@DV-#\1ZAK7BNTB^T20V-_X=BU);?8F897?'#;<G ['(H [
MBF22I&"6)R%+;5!+$#K@#D_A7F%EXC\1:AX>\%3C5S'<:I?36MU(+>,[U FP
M0-N 1L'3CU!Z5HZ19:E;?%.2UO->O;UH=$AD9GCB17)F<$;0N #M!XP<]^U
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M<V^I&X6/7(+1HX(D^SQPNZ(8W9AN,GS$G:3@X!QTH ]%W*6*[AN !(SR ?\
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M>RTFSFM4U+5KA'A:WB-U=>:;>,\%8P1@< #)!/ YJ2+P7800:'"EW>A-$/\
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M&P9 6(X (R  !U]3GHX[F"9V2*:-V4D,%<$@CKFG/+''C>ZKD$C<<<#K0 Y
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M6VG.".H/O3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-W #)_=XQC%>H26%G- L$MI \*'<L;1@JI]0,4Y[2VDE662WB>1>C,@)'XT
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M:E!.?NFU8EXX?PE!^JHPKTJ:V@N-OGP1R[>F] V/SI[1QLI5D4J1M((X(]*
M/'-%U'38/ABYO0)H)/$;QC]]LB5S<[E:5AG$? )]1QWS6EH>G:9XGU/Q]X?N
MKJTN8;N2%Q]G4!03 H,J+DXPV.<GD=:]+&GV0B>(6D'ER<.GEC#?48YJKJMG
M?-82C1)K2SOV*8FF@\Q=H/0@$$\9 YXH Y7P5+=Z[+;RZM:".ZT"-]/D)3 :
MYSAW7VV*A!'_ #U8=JV_'C*OP^\1EF ']F7 R3_TS:M32M/_ +-L%@:8SS,S
M233%=OF2,2S-CL,G@=A@=JM2PQ3ILFC21.NUU!'ZT <_;W6C1^"-+.M2V0L)
MK:",_:RIB=BHV@[N#S61X<L-,\.>(=>NM(GB@\-?94GF5'_T>&X!?S"G91L"
ME@.G'X=FUG:O;&V>VA:W/6(H"I[].E*UO']D:VC2-(RA0+L!4#&/N],>U #+
M+4+34K"*_LKB.>TF3?',C95E]<UQDWB_PIK>M6SS:_IK6]A<9MK=;A6DN+CE
M P0')"Y(48RQ.>@4GL=/TZWTW3X[*W3]RF>"!\Q8DL2!QR23P,<TY=.LD<.E
MG;JRG((B4$'\J //[&1?#R_$2"^(61[F2_B!ZRQRQ )M]?F4K@=^*FT[6K3P
M9X*T#P[J&K6.GZPU@@/VN94%N,?,Q!/."< =R/0$COI+:":6.66&-Y(CF-V0
M$H?8]J;+96D[[YK:&1^FYXP3^M &!I&H^%[?P[9V.GZO;+8-FUMI5N0IF8#Y
MMCY&YLY)([YK*\)3IX8T_P 0F_U=IO#UE>9M+Z[DW':RJ7!?^("1BN?7(KLI
M=/LIH%@EL[>2%3E8VB4J#Z@8Q2W=FEU8O:85(W7;]P, /8$8^F10!7U&^MD\
M/7=_N>:U%J\VZV;+.FPG*$=R.E>7Z!>:4_BSP>(;C3A9W&BSVXMXG#X7]T5B
MD<G]X_4G('.>.]>M6EK#8V4%G;IL@@C6*-.NU5& /R%-6QLT146U@55W!0(P
M -W7'U[T >+Z+9Z;:^ _ >I016\=X=>BB^TC&_89I5*;NNW';I5K5;_3[OP=
M\1[;6GMQK4=S<XCN"!)Y:K_HY0'G;@ C'?)[UZ[_ &=8[0OV.WV@Y \I< _E
M2RV%G/+YLUI!))L*;WC!.T]1D]O:@#):_M8_ +W[-)-:1Z896-JV791'D[".
M_!Q[UYUI.HZ7%XGT&2*^LX+27PY/$JV3Y:-1Y15"^?GD R>@[G%>Q8&,8&.F
M*A2RM(U14M855 0H6, *#UQZ9[T <#X,:ZT[Q#9:5>Q:??H=+9M/UBP&WS;=
M60;94['E2"#@\X[U8\26.GW7Q6\+I<V\$IEL;T2*Z@^8!Y14,.X'S$ UVUO9
M6MH7-M;0PF0Y<QQA=Q]\=:5[6WDE$LEO$T@Z.R D?C0!XI>6&E0?#;Q9=106
MRS:?KTR6<H S;*+E"JQG^ <G@8ZFM#X@ZAIL\?CF"*2WAO8K* 2&Y??),0A=
M/(7(VJ,Y+#/.>!C->L?V=9!2OV.WVDY(\I<$_E[FG&RM"23:PDF/RB3&/N?W
M?I[4 <#XAEAT74=&\?6$ O(VA%C?FW4,TT4F/+<$=2) HSW#5V6@:9_96CQ0
M.L8N9"T]RR# :9R6<_3<3CVQ56YTC4KS6T:>_MQH<1CECLDM\2&1.1N?.-H8
M!L =0.V<[M 'F5A86$^N?$J*"UMGD'EHBI&I(S:*"!]6S^.:S-,U329Q\*0M
MW:2/% 8IB'4[";-EV,>Q+<8/4UZU'9VT,ADBMX4<]65 #^=-CL+.+_5VD"?,
MS?+&!R>I^I[T >5:#H&B7/@'Q3>)IUI-=V]QJL<,@0,T:[GPJ^@Q@@#USWIR
M#2+VP^&5O$;26W>4+,D97:S?8VW!L=3D@$'UP:]6AMH+<,(((X@W78@7/Y4S
M[!9X0?9(,)]P>6/E[\>E 'C]S<PZ-;>(HH#]GT:U\4PF\2WC4K#;M$A8[,$;
M?,VDC&.O%.\66/AMO!GBK4M+U8:BMRUI),Z-$8(Y1(H!0HH D*_>QSC&>HKV
M!+.UC#A+:%?,&'VH!N'OZTQ=/LDMUMUL[=8%.5C$2A0?4#&* (M,TG3=)AE3
M3+."VCGD,SB%0 [D %CCJ2 .:O4U$6- B*%51@*HP *=0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7'_ !#OI]-T[1[N&]GM5&L6B3>4Q >-I0&5L<D8[=Z["N7\=:=>ZAI-@UC;
M/<R6FIVMX\494,T<<@9MN2 3@=,\T 6-.\::-J+ZC'YL]I-IZ>;<Q7L#P.D>
M,A]K ';QUJQ9^);&[U@Z25N+>^,/VB.*XB*&6+.-R_0XR#@C/(KDO$?A;4/%
MEYK&I6L36;2:.-/M1<C:TS^;YI+#JJY55YYY;C&,ZGA<R7UY%<W'@J/1+J",
MK-/+'%DL>JQ,A)*]R3@< 8.> #H-2UJUTRYM+6022W=X7%O;Q+EY-@RQYP
M.Y(ZCUK-;QQH2Z9IFH>?.;?4I_LUNPMW),F2"K<?*0588//!QFH?$YU;^W-&
M%MI]U=:6?.%V;-U297POEC<64JA^;.TCH,\<'C]/T36[;PMX;T^71+I)=/\
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M:6NC7#,WB"2Z:1#$6DM9)MY:'+??"^H&#TYZ '1:QXZM-.\.:YJ,-M<276D
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M8!SG/3K6A\-[&^TOX?:18:E9RVEU;P['BD*D]2<_*3Z_7VH FM/'6BWUZ]K
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MW43*!"XE9B6R0>C9& >: -/_ (3#2=]LS22K:W4_V:"\,9\F27)&T-[D$ G
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M. "<]>F16/'#JVA>/]=NSI5U?V&LQP-#-;%#Y,D:;"CAF& >H/3DT -\%>*
M/ _AK[?-<WVJW]HTJHOSRRA>78DG'&1U/< 5<OO'EFEKX?NM.@GO+?6;D0QR
M)$?D #%@0<'=\I&/8^G/->'++Q'INA^$M.O-#OA9P6<L5TEO)&LRRY79N;>"
ML9&2<$'(&?0QZ9H>NV/A#PA')HER9]'UAY;BW1XRYC/G#>N6 (_>+U(/7C%
M'=:GXNTO28YIKHSBVMW6.ZN$B+1V[-C <CI]Y<XSC(SBKFNL_P#PCNH/!.\3
MBVD=)8CAE(4D$&N%BTR_T[7-9L;_ ,&1ZS!J5VUW:WA6%HTW@$QS;SD!2#R
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MH P6).[N,!2?05R&@ZK+H_@(32Z79W'F>))()8I&RD+/=E0R#;\VTGCIT!H
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M0C!I:* &111P1+%#&L<:#"HHP /84^BB@ HHHH **** "BBB@ HHHH ****
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MNE6AL6DEMBT-U 2#M=-V001D$&O0:* .5NO#&I7>H:!>S:K%+/IEQ)<3,\!
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MDT8VP*1B JT,H*X&_.'W L<#I@>O.W110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Q?C&_U#1/$?AK4$OYH]'G
MO19WT V[<NI$3Y(R &Z\]Q7:5A>,M"'B7PAJ>DCB6>$^2W3;*OS(?P8"@#!T
M?6;J#XL:SH%WJ<]S;-:QW%E&X4+$PQYD>0!N.'1N2< U2\3:EJVG_"_6O$-G
MJ]VEP9#/9.=A"0^8%0 %<$,OS<Y/S=>*@U/PEKUYX>\.:E"_E^)$N?,O90.4
M6Y&R8?\   5Q[1BMSXD:7/=_#74=&TFREGGEA2&W@A7/"LO&>@  [^E %/Q_
MKDFE> FNM)UTI?PO JR)(CN^^1%;(((/!/;BG>*=0N=,\<>%=/\ [<N++3[Z
M.[^U%I$&XQHI0[F!P<G\:9\0=);4_A^]MI6C227TSP,D<=N%=0LJ,V<XQP#W
MYJ3Q)'<W7C_PGJ<.EWMQ96,=W]I=8#\GF1J$&#@GD'ITH TDD\S3==N+#Q%/
M>Q10[$</&Q@F5"Y*LJX.0Z<'/2N,A\3:Y:>$_!VJV^MS7^K:I+ L^G2I&PG1
M_OE0JADV]=V<#O7:37+26NL166AW<$4ML[N[0[6GG90BA5!]%Y)P/N^]<?HW
MA?5-#\,>'=>TC2WBU[3;9;74; J$-[#GYUST+@_,K9]O:@#H/&.IW6G^-/"M
MHNL2V%AJ#W*W>&15.R+<G+ XY_/-;FAO'->WDEIKTFIVR;8G1G1Q%(!N.&4#
MJK+D'/05SOB/[5J'C'P=JD.D:A+:V+73W0-OS%OBVJ"#U.?3/2MI=4>UEOYK
M#P]>A/),\F80C7$V J(HSUPO). ,#WP 9>K^++[3O'VF184>'WF.F7$GI=R*
M'3\  JY]7;TJSX_U^;P_;Z5/)+<6VDRW?EZC>6Z;G@CVG;V.T%]H+8R!TY(K
M,U?P4FI?#RYA>;4CJ,L)NMHDD'^ED[]PCS@?O/R%:MGK6LSZ-H\FH>'[IVFB
M:+5;?RU)B;:/F )^=2<\#)PW3C% %_P\)9+FXO+;6VU31IX8C:,71]C OO =
M1EAC9UR>O-;]>=>'M$_X1WQ'KVL:#I5[;Z')8AAIVPQFXN@228HVP5&W"\@
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ME!Q[GZUF:OI-TUEIFN:7X26..UU!KF?2-D:37$;Q&-I& )7S!G(&<X R<\4
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M ';VGB'3[[4]1TV!IC=Z<%-RC0NNT,"5P2,-D XQFHG\4Z<+**ZC%U,LMO\
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MVIS1+''Y6#N@+(3DOT"M@<5UL_B6^NI-;_L6S@N5T=_*E$LA4SRA [(F =N
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M=VTS;8KB*1O1'!-35YM\/_"^BZW\(]%@O=.MW,MKDS+&%D5MQ^97'(8>M1>
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MVVWS,=\C(<.Z\8 5L@>N#TXKMM5U8:%X4GU1H6F%K;"0HN>< >@)P.IX/ -
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M6W>0Y=000"N>1GD9[UV5Q::B=#6VMKN%+]40"<Q'RR01G*YS@@$8SWZUHT4
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M+V[)<2)Y;$8)PK $D$CGM534?!>B:I?7MY=03&2]@\BZ5+B1$F4*5!9 =K$
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M/#\.-4NH39)<1>)\Q2J5#(!>@C:>H&S)&.V: /7/$6LQ:/I-U*MY9P7BP/)
MERPP[*,XVY!/IP>]/\-:C-J_A71]3N0@GO+*&XD"#"AG0,<#TR:X";5[&'4O
M'UAKL\,=W=Q;K(3D 7%KY&$6+/WL-OR!W8UV/@&6.;X>>'#&X8+IMNAQV81J
M"/P(Q0!=UGQ'I>@O9IJ%W%#)>3+#"KN 6)ZGGL!R3_B*R;#Q4P\5>(;'5+NP
M@T^P6U:VF)\O=YRN<,S,03\HQC%5/B)+!:R>%;NZ=([:'786EE?A44QRC+'L
M,D#\:P+IM'O?$_Q$>Y-I)MTNV">=MRO[F3/!Z')4'\* /3;N_L]/@$][=P6T
M).!)-($7\R:FCD26-9(W5T8!E93D$'N#7D&GZ];Z:_A.[UC5);/2KGPY#;Q7
MH5'C6X&#(CEE8*2H7T^[BO1/!UCI^F^%[2UTHW)T]2YMS<'YBA8G(X'RG.1Q
MTQ0!!X[UZ\\+^#[[6[*."62T56,4RDAP6"XR",=<]ZJZQXDU3PS<Z.VII9W=
MEJ-Y'9%[9&BDADDSM.TLV]<CGD$>]4_C%/%%\+-;225$:2-%16;!8^8O ]:Y
MWQ=_9HN?#]_X5U%M4UZ&\C$%K]M:^0QGAV969A& /XQ@CUH ]2NM2L+*2..[
MO;:W>3A%EE5"W;@$\T76I6%B2+N]MK<A#(?-E5,*" 6Y/3) S[UP-O=646L>
M.M.\3O$CW3AXA.0!/:&(*H3/WMK!N!T9O4UB^'].@?Q1X1T_Q+%:S7[>')8[
MB&Z"LS-OCVJX/5MF1@^AH ]7.JZ<LRPF_M1*SB-4,R[BQ&0H&>I'(%*NI6#7
MQLEO;8W8Y, E7S!_P'.:\^\/Z=I%SXY\;1VEMISW=O-;26@*(WDN(%PRC^'#
M]2.XK(C==2^%FBZ=:OL\56E] !"Q_P!(BNEF'G.PZC*F1B3P0<]Z /53K&F!
M)7.HV@6)@LC&=<(?0\\'@U*M]:/)#&MU SS+OB42 F1?51W'TKS[7]&E_P"$
MMU70HK<FP\6V@,D@3*P2Q865_8F-E(/]Y14>FG7M9\!:K</!)'K=AIL^DP8X
M9YT!621#_ME8\>ZT >A0:II]U--#;WUK++!_K4CF5FC_ -X \?C2V^I6-Y*8
MK:]MIY @DVQ2JQVG@-@'I[UYSHMYX2\12:=J$6H3W%W8V4D4EM*D<:VD13#)
M, BC (  /?D=S6K\)K+3!\/]$OK6WM?M;68BFG15\PX.2K-UX/8T =V3@9/2
MN?U[Q%';^%M8U'1KVQN;FPM)+C;O$J_*I;#!6!YQCK5SQ(MJWA?5UOI)8K0V
M4PGDB^^J;#N*^X&<5YO<ZC>0^'_%EAJ5UIVIJOAYS!K5IA/-C*NJ1RJ"5#Y)
M(P><F@#TC1=8M]3LK4-=6S7[6L4\T$<@W)N4')7.0.>]6H-3L+JYDMK>^MI;
MB/.^*.569<'!R <CGBO,HI]+L/$'@":T%N&DTFZ$BVY4/-^ZC(''))8-CWS5
M'0-7TV?7?A]/:7$$5J(KJ!+2'<_V4M$,1.YR6DR.<XZ9QW(!T-YXSURW\$^*
M]646!O-'U&:VB_<ML>--@!(WYW?,3UQ[5Z&#E0?:O%]2OK1_AG\1PMU"Q;6;
MC&'!SDQXQ]<'\J]E@ECF@CEB=9(W4%64Y!'J#0!S_B+7+W2=?\.VT)M_LFH7
M3P7!D0[E B=P5;.!]WN#6U%J=A<637L-];26BYS.DJF,8Z_,#CBN/\>/9/XF
M\%V]XT!1M2<M'*1@CR)!R#VR0/QKEI=3TC3H_%\;Q6\EF/$=JRJ)"L-N2(?W
MS[3]Q77)'0D8H ]676-,:T-VNHVAM@VPS"==@;TW9QGVJ7[=:;H%^U09G&81
MY@_>?[OK^%>=>'H-/\0^(/'NCW-TEY#J MV+HFU75K=5+H.F,]#DYP#D]:L>
M'FUO5?#-V)XGCU;1K.?3(7(QYET 5,J^Q"Q$'_:<4 =W#J5A<7<EI!>VTMS%
MS)"DJLZ=N5!R*M5Y=X/N_#NO2^&WCO[Z36M*B,?V'RUC:T.S;() $!VY&.3R
M<=Z]1H S[*:YDU/44FN[.6"-T\F*$'S(1MY$G)Y)R1P.*FM=2L;YY$L[VVN&
MC^^L,JN5^N#Q7ENMVM[Y7Q2AT6%OM+-:-Y< PSJ84,@&.Y7?[DFMNYGL-;\8
M^$-0\/S02110S_:VA(VI:&/A) .@W[<*>A!]#0!UNGW[)9SS:CJ.GR 73QI)
M VU%7=A$8DGYP, ^_:GSZ_I%M8WE[+J5H+>RS]I<2J1$1V;!X/MUKQ^XDTIO
MAKJ:;[38GBIO* 9?E4WBGY?0;,GCM[5MZPE@GBGQE9::MNOG^%1B"WVC>X\X
M#"CJ0I7\"* .GO/%TDMSX4FTN2UDL-8N?)F##<Z9B:0 $-@$;0""#72Q:G83
MK,T-];2+#S*4E4A/][!X_&O-9-6TV>Q^&;P7ENR+=1@L' &1:NI_)B ??CK5
M_5[&\T?QC=6.GPO]B\6)M=XQC[-<( )7]MT.2/5D]Z /0H9HKB)989$DC<95
MT8$$>Q%4M2FN8IK 6]W9VZO<A95N0<RI@Y6/D?/G'KWXJ[%%'!"D,2*D<:A4
M51@*!P *XGX@26D.L>#9)GA28:W'AG(#!/+DSSZ9V_CB@#8\8>(5\/\ AW4;
MJWN[&/4(+62X@AN6SYFU2<!0P)SC'%78-:M(=&L+S4[RUM6N84?,LBQ@L5!(
M&3[UYEJ.JV4?A_XE:7KDL46L2R74D,5P0'F@\K]P8P?O !>W0@GBGQZSIMKJ
MQ@\0:I+8Z9J6BVL=E/L0Q2J%82Q;F1L-ELXXSD>U 'JL^H65J<7%Y;PGRS+B
M255^0=6Y/09'-9^I^*=&TFVL;BYU"W\N^F2&V995(D+$#(.<;0#DGT%<+:V&
MAVGC_P +6013!%HDZQK?8,I4/'Y>\'G.T$@$9 ';%8]I=6,/@O1)?.@6RL?&
M#%V##9!%Y\N"3T5?F'MR* /5TO7_ +6N&?4=/.GI:I*L8/[U#DDNS9QL(QCC
ML>:Y.+Q5K&OZ?+J>@ZKH%K;17,T,J7X8F.-'9%E+*XY)7." ,-UXY=IESIP^
M+NM-%+;JLFC6SOR%R0\A)(]0I7.>V*X^>XTV?X ZY^]M9&6[N2OS*2&-TQ7'
MN0<CVH ]DO-1LM.C22_O;:V5C@--*J GVR:==WUK96WGW-W;V\9X62:0*N>W
M)(KSO6]9T^Q\<WB:]JDEEI6I:9%'97(5&@E +^;'N9& )W*>,9&/:HK"ZT_P
MOXRT*&]FFM=!&B-!IEQJ+;0LOFY8,S8VL8PF,X.!CKD4 ==X*UV[\0:1=W5X
M;=I(;^XME:W4A&6-RH(R3U SUKH)98X8GEE=8XT!9G<X"CU)KB?A;+:MH6JQ
M6A3RX]9O0J(,!5,K%>.PQ6C\0KRSL?"$TM_:_:+8SP*P9V1(SYJX=RO.Q3@G
MU QWH W8=4T^XM9+J&_M9+>(D22I,I1,=<D' IT&HV-S<O;6][;RSHH=XHY5
M9E4]"0#D ^M>/ZE?6$\?Q.6:^M[O[1I<$T4@0*DC>1( R=01G: <GMR:V[1M
M*M?&W@0V36D;3Z5<K(8BH,F5B*YQUR0QY[YH ].JK/J5A;7,=M/>VT5Q+CRX
MI)55GSTP"<FK5>4^?;/X>\?Z1KI0:I+=W,D<4G^LGC91]F:,=6Z*JXZ%<=:
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M,DCD@=37(^!]<$.E:S-=O>R,VOW%M;07#F2;/&V(;B>@![X !.<#- '?@ #
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M<K$*2KGKW'XUZA10!PFJZ'J.L:MJFN+IT\,C:')IEM;2/&))7D8L2<,5 &%
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M5;@,2.3QD5U-% '#^*=/U_4M8O[5=.-[I,^F&*UVW"1QQW!W;C*I.6X*[>&
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M]\HW8Z@8XYY] T_4+35=/@O[&=)[6= \4J=&4T 8>H>+K0VFOQZ3=6LVH:3
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M>'6?#=_XP^'EQI%U9&)([F)1&RYB4P86-A_"<\8/>NE^)\1E^&?B !-Y%HS
M 9QCG/Y9H ?/XI>/QEIUBL]D=(NM/GNFGSRK1L@^]NVX^8]NU=']MM?L?VS[
M3#]EV[_.\P;-OKNZ8KSZYN=$U;XD>&2DME=6ATJZ9!E61COBP1V/1L?0^E<U
MI^J0Z9X>T>Y:Z>'0K+Q#?)<RVRJXME+RB%BI# ("P[<9!':@#VBVNK>\@6>U
MGBGA;[LD3AE/T(XIE_>PZ;I]Q>W!(AMXVD? R< 9X'<USW@RWT9%U.\T.^GO
M;:]N?/DG8KY3RD88Q[5 [#) QGOD&E\170U+6K#PY:7MK%=$_;IUE7S/W<9!
M52@92<N5/7HC4 6?!OB0^*?#L=_+;_9KM)'@NK8GF&9&*LI_0_B*J^.O%#^&
M_#]S<V-Q8G4(?+(M[ALEE9PI(4,#WS^%<]I=T?"/Q5O-,U"^M#!XBA%W'Y:>
M4J7*?*PVEFQO7!SGDCBN7U+5K"7X3:_8:O- OB*+4FDNX)B!,9/M(*N >2OE
M[0".,#'04 >T7&I6-IYGVF]MH?*VF3S)579N^[G)XS@X]<4X7UHUV+074!N2
MGF"$2#>5]<=<>]><1Q:%=^.O'+2KI\T3:9:OEMA4DI-N;ZX*Y/N/6LG2CIMM
MH/PMNXVM8[M[B-))@5#L#;NK!CU/.T<^PH ]3MKN9+G4VO;RP-K#(/*\LE6A
M3:"?-).,YR>W&*MQ7UI//)!#=0231@%XTD!90>A('(S7D&KG3?[!^*\*FUV"
M4.B#;@/]G3D#UW9_'-;D*Z/:?$+PP+7[%&ESHMRLVPJ!*,Q$;O[W\1Y]Z .W
MT^^DCTC[3JU_I[,)'#3V[;80-Y"C+$\@8!YZYJ*^\4Z+I\NGQS:A;YOY3';D
M2J0V 2QSGH-N"?4@=Z\W\/"";X=Z EAK5MIE]!K%VUC)(JO"TGF7&(W7(X9&
M.,<]".U/;4XY$\'W^JV5GIR6^NW<-S)&^;=G*39=&/\ "SDD9[\4 >J-J-DD
MPA:\MUE+! AE4,6(R!C/4CM21ZE8S7$EO%>VSSQ F2-95+(!UR,Y%<#X?L]"
MN?B%XTF:SM+F6VN+2XA01JSHP@!+(.S;NI&#GK7/Z'J^ESZS\/I[2XMHK0?:
MX5M(V+M;[XCB.5R26D+8X.,GH#UH ]&'B:VUK0KZZ\/ZGIPE@=HUFNFS""K;
M2S;2#M.#@YYZUMB]M3=?9?M4)N1UB$@W],_=Z]*\7OIM-_X4WXJM)6MOM=MJ
M5SOC;&^)C=$KGT)!X]LXKM?&!;1=:T7QE86YNMG_ !+[M( "TT,Q'ED'VE"?
M]]&@#L3J-BMM)<F\MQ!&=KRF5=J'T)S@5+!/#=0)/;RQRQ.,K)&P96'L1UKS
MOQ+)_P (O>>%9M2NY;;31)<&^O8HU9([N0 K(VY6 !8R@''&[M71>"K32;;3
M;V31+J>ZLKJ\DN!-(5V.[8+&+: -F<]!C.: -K5=032M*N;YT9Q"A98UZR-T
M51[DX ]S5#PCX@7Q1X7L=6$8BEF3;/%_SRE4[77UX8'\,50UJZ_M?Q+9Z'8W
MUI'/9@7]PDJ>;R#B)2@93][+]>#&OK6!X:NAX5^).K^&KZ]M635P-4M?+7RU
M69CME0*68@G 8#/K0!Z"=0LA=&U-W;BX')B\P;_RSFDFU"RM[B*WGO+>*>;_
M %<;RA6?Z G)KQV"?0M1M(?#NH:YHX-IXBDNWFO)U6655F=BIC8?>8DISP5Y
M]JO7,^BW5_XG\-^*-3NK*XGO_,@M4C0-<0X7R3"2A8D;0 %.010!ZG<:E8VG
MF?:;VVA\O;O\R55V;ONYR>,X./7%5+WQ'I6GZM8Z9<7D*7=X&:*,N =JC.X^
MV< >I/UK@#::++XR\<K=Q6CLNDVI83["0VR4.3VW?=R??WJMI%[9I)\++R[G
MB\LZ3/"TKD$&3RH0J9[MD$ =<B@#TOQ#?7.F>'-2U"S$1N+6VDG03 E254M@
MX(/;UJ/0-9BU72M/DDN+?[?-9Q7,T$;C<N]0<[<Y R>]1>,I$B\$:\\CJB_V
M?.,L<#F-@*X&P;2[#5?AK/:BW2673IQ*8=N^7_1U.#CEB6'?O0!Z?'J5C-<R
M6T5[;O/$"9(EE4L@'7(SD4)J5A) \Z7MLT,?#R"52J_4YXKR'0]8TN;6?A]<
M6ES;P6BR7<2VB,7:VWQ-B.5R23(6QQQD] >M='!I\VF^,=5\*QVQ_LK69%U1
M6"_(B<"YC/\ O,$&/24^E '=S:E86S0K/>VT1G_U0>55\S_=R>?PJU7E.J7>
MD/XE\5Z#XLU2>P2_:,VRE$VW-N8E4+&Q1CN5P_"G.XY SFO3-.A$6E6D.)BJ
M0(G^D',G"@?/ZMZ^] $.FW%RT%V]]=6,OEW$@1K;(5(P?E#Y)^<#KVJ:*^MK
MVUDFL+NVF"@@2)('16QWP:\D.^Q\)7[PPXTNV\9R/J$<:_*+59\MD#^$':2/
M0'M707\=I=^.]1OK.2WETJ30774G5E:%WWYBW'H6V[_?;CU% ':Z=>,-+LFU
M&]L7NIHQNDMVQ%(V,GR\DDC@GZ5!J?B?1]*T.36)[^!K).%DCD5@[9P%4YP2
M3QBO+]/72[G1/A0+G[+(3F-PY4Y7[.X*GVW8&/6F:O\ 8T\*?$:WM?)\B#6(
M)A'%C;&O[@NP Z#(;/T- 'HEQXCGC\;Z9ID<EH^F7EC/<F9<E@8R@^]G;CYC
MV[5N+J5B]NUPM[;- APTHE4J#Z$YQ7&76H:?<_%/PR]K=6[Q2:7>>68W&&!>
M+&/4'!QCKCBJ=GID^G>)KSP6EJ?[&O;@:K"X7Y(X-V9H?3_6A!C^[*?2@#T@
M,K*&4@J1D$'@BL[3+N8:*ESJEY822KO,L]J=L& Q'!8G&!@')Z@U?F$302"<
M(82IWA\;=O?.>U>+:'J4-CX+\ 7%Q(@T"'4K@7S@YCC;=+Y)?T4.0<G@$*?2
M@#T7P]XCGUCQ-XAL&DLY;+3_ +.;::WR=XD1F.XY(.,8XQTK=M]2L+N*66VO
M;::.(XD>.56"?4@\5Y'JM]!)??$271)$N-YTVXD6S*NTT*X\\KU#?+N!ZCGG
MK6A?OX5UG2/$>N:=J\FIR2:%+#.[",0HH!:,.%10),DXSR #[4 >F)J5A+*T
M4=[;/(L8E95E4D(>0Q&>GOTK'7Q+;ZWX<NK_ ,/:EIXDC=D2:Z;,2[9"I9MI
M!VG:V#GG@UQ6G+I5KKGPT>V^R1R7&GSK*R%09<VZ<,?XOF'?O6/<3::?@-K%
MK(UM]KM+N82QMC=$_P!L8J#Z-CIWQ0!Z5KWB9;+7M.T*VN[."\O$FD,UQ\RP
MA N 5W*<L7&.1P#5KP]/K<D=RNO3Z2UQ&RCR]/+D1_+SNW'/)R1P,#UZUSVM
M7.GO\5_"P,ULQ>QO#RRG.?*V_G@X^AKF=1E\E?B*-+7>(M1LIIX;0*7:$)$9
ML+R#D!\Y'/.: /6K2_L[]7:SNX+A4.UC#('"GT..AKGKSQ0Z^-]$T>RN+&XM
M+U;@7&QMTD;1H& R&P,Y[CM7&:S-IVJ:'XBUWP?JUYJFJ2Z3Y,KP!0JQA@<$
M(B_O=I?'\0 /M5U]9\-ZAX[\!7.CW5DT/V>[B3RF7,:F)=D; ?=.<@*>^: /
M3)98X8FEE=8XT&6=S@ >I-0QZC8S6CW<5[;R6R9W3+*I1<=<MG KGOB#>V5A
MX:CDOX!+ U[;+N>0I%$WFJ5DD(_@4@$COT[YKSK6+RPN-,^*,<M[:W1D@@N(
MF"A4=O(4;T'/&< ')SZF@#VB*]M+B>2"&ZADFB ,D:2 L@/3('(S4S,J*69@
MJJ,DDX %>=6HTNS^)GAH6'V6(W&BW ?R2H,OS1%<XZG[Q_.M7XDR3P>'[&X5
M&>PAU.UDU)5&?]%5\OD=U!VDCT!SQ0!M:EK"#P[J.HZ3<VES);022*0_F)N5
M2<':?;UIGAS7H=7T/3)Y[FU%_<6,-U/!&X!3>@8G;G(7)[UR&L1B]\8:K>Z+
M(DUK+X<F2]:W(9)),_N0<<%\;\=\?45E:9INEW6E_#J?08[7^V87MWNI;7;Y
MBP"$B<2D<XSA?F_B(% 'JB:E820/.E[;-#']^195*K]3GBH8+BYEUF9?M5B]
MC]G1XHH\F8,2<LQSC81C''K7%0Z?-IOC'5?"T=L3I6MN-35E7Y$7@7*'_>(0
M8_Z:FJ^H^8/'?C.'1&B759/#T9A6(@.TV9<?\"Y7]* /1(M0LI[B6WBO+>2>
M+F2-)5+)]1G(I/[2L/($_P!MMO*+;!)YJ[2WIG/7VKS99+35=%^'SZ$\8U*V
MNX Z1G]Y#"$(N5<=0.,-G^+'<BL36=1L+7P-X[TN:XB2^&O23?92?W@1IHF#
M[>NTC^+I[T >RSZA96TZ07%Y;Q3.,K')*JLWT!/-6:\N\2WSV6L:MJ>EWEEJ
MMHTEJ-0T><CS6.U#');L#G)!4@$8)!QS7?>(UOG\+ZLNF;OMYLYA;;>OF[#M
MQ[YQ0!:AU"RN;B6W@O+>6>'_ %D:2AF3Z@'(IG]K:;AC_:%IA4,C?OEX0'!8
M\] >,^M>=^%[CPKX@N-"NXM3N9[^PM9(GLF2-!;(4Q(DZA!\@(Q\QQG&*YE=
M.T%OV>+N_6UL&O%@GB%QL4R _:"0H;J. N!]* /;?[0LO*FE^V6_EP,4F?S5
MQ&WHQSP>1UI5O[-K/[8MW ;4\^<)!L_[ZSBN#UV'3M%\1>$;ZUM[6#0);J5[
MR:)5$9G:(+!(Y'!YW ,>Y%<QXRM[==-\?74;0_V/+/8M V1L^U;E\YHSZXV[
MB.^>X- 'LT%S!<AS!/'*(W,;^6X;:PZ@XZ$>E2U3TW3]-L+=O[,M;:WAF;S6
M^SHJJ[$ ;N.IP!S[5<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK+UWQ#I_ARTAN=1>5(I9D@5
MDB9P&8@#) X&3U- &I16%#XJM+F!&AL]1:X<R;;1[9HYBL9 9MKXPN2,$]<@
M#GBDM/%^EZC:65QIS2W9O5D>**),28C($F0Q&-I(!!YR>] &]16+;^*-/N+W
M3K15N%FU&V:YM@\17>B@%L^A&Y>#CK7-^+/$2ZAX7BO](O+NW:WUJ"SFVDQG
M<+A4D1O4<D>AH [ZBN;B\5^;XSU#0C87(CLK:.9IA&6W%R_0#G&$P.,DY_&E
MIGBW0=-\+Z3="^U*YL[^Y:WMI[J.265W,C##'''(( /.  !0!V-%8-IXPTBY
MMM5GEDFLQI7-XMW"T31*5W!B#S@CD4Z#Q583:S#I#Q7D%]/"+B**2V8[HNF\
MLN0HSP=Q!!(R.: -O:NT+M&!C QTQ05#=0#]17+>/M<N=$T*$VB3^;=7<%N9
M(ER45Y45L'LQ4D#WJE#XCTKPSJ%Y823Z_=W$L0OELY8);AX8R0I"$@L1G)(R
M0.>G2@#M=BD ;1@=.*/+3^XOY5AWWB_2[!+J:7[0UI9R".[NHXBT=NQP<-WX
MR,X!VYYQ3;KQCI=MJ<VFHE[<WD5LMUY5M:NY>-B0"IQAAP>1Q[YXH WMB8(V
MK@^U*%4 @* #VQ7,VOC[0[PZ6\#W36VILL=O=&V<0F0@D1EB,!N",>HQUK;U
M75+/1=,GU&_E\JVA +M@D\D   =220!]: +7EI_<7\J-B8QM7!]JP)?&>EVU
MOJTMVMU;OI*+)>0M 6=$8%E;Y,@@@'D'C!SBGZ?XNTS4M6BTV(74<T]N;F!I
MK=D2=!C<48_>QN'YY&10!N[5V[<#'IBD\M,$;%P1C&*JZCJEMI<<+7#,7GD$
M,,2#+RN02%4>N 3Z  DX K'N?'.C6>FZG>737,)TM@MY;F!C+"6&5)49X(Z,
M#M]Z -XVT8MF@B5848$#8HXS[8Q^E-LK.'3[..UMU(CC'&3DDDY)/N22?QK#
M;QMI:ZG)IQAU#[7Y/GPQ_8WS<IG!,?'S8)&>GKTYJKJ/BC1-2\*VVI->ZE;6
MDUY'"'MD>.5)1*%\M\#Y1N&TYP"/K0!UI1222H)/!XI-B<?*O'3BLJ[\16EI
M<W$/E7$WV9D6X>%-PA+XVAN<]"#P#@')Q0WB*T%VT*17$B)<K://&F8TE./E
M)SD=1SC&3C.>* -41QB0R!%\PC!;')'IFE(!&" 1[US=AK>CPW?B2Z.HW@2R
ME4WHO-PCMR(P<1JP&%(P>.I/'6K<7B>Q;4!83Q7=K=O ;B&*:$AIHQU* 9R1
MD97[PSTH V0BJ<A0/H*22*.5-DB*Z]<,,BN8L?B!H>HG3&@-YY&I2&&VN'M7
M6)I/FPA8C 8[3@?UXK?U'4;72K&2\O)?+@CP"<$DDD   <DDD  <DF@"R44]
M5!QZBC:N[=M&?7%9%MXDL[B_N=.:&YAU""#[0;26/$CQ] R8)##/'!X/!Q7-
M>#9[GQ5'%KEQ=ZI;7$-]<@QK(5MY8A(\:QE#E3@*O( .0>>: .Z:*-I%D:-2
MZ_=8CD?0TX@'J >]86J^+]+TB6]2?SY!I\237KPQ[A;(^=K-W/W2<+DX&<5L
M37*Q6;W*(\RJF\+$,LXQG ^M $N!DG R>II!'&)#($7S",%L<D>F:YGP]XRA
MUCPO8:O/:S0O?'$$ 3+2$Y(5/7Y023P."3@"K5OXOTFXM+F;S)8I;:Y%I-;2
M1D3+,<;4VCJ3D8(R".<\&@#="JO10/H*&57&&4$9SR*\^\<>)TNO _B$Z==7
MFGZGI3Q+.@/ER1%F4C)!((92>0:Z*/QCI3WE]:NMY%+9V_VIEDM9 9(<D;T&
M,L,C'2@#>V)S\J\G)XI0B@Y"@'UQ7-Z=XYT?5+O3((!=J-3B,EI++;LD<N%W
ME0QXW!><>Q[BDTO7='BAUZ^74+YH;:^,=S]L#_NI-J?NXU(SMY7  Y+<9S0!
MT:0Q1G*1HIR3D*!R>M/(R,&N>D\::1;'45OFFLI=.A2>>*>/YO+<X5EVYW9/
M&!SG@@4KZY;ZI;ZQI\1NK._L[</+&X"R('4E&4@D'.T]#QCM0!O>6G'R+QP.
M*#&A4J47:>",<&N?\!W4]Y\/]!NKJ:2>>6QB>261BS.Q49))Y)JLWQ$T%8Y9
M?].\B"\^Q3S&SD"02;@OSDCY1N8#GGVQ0!U2JJ*%10J@8  P!1M7=NVC/KBL
M'5/&.E:1+?)<&=DT]8VO9(H]RVP?[I;N>.?E!P.3BHIO%3)XW_X1Y-/N9%6Q
M^U-*B ALN%7'/3[V2>^* .C**3DJ"?7%-,,3.7,:%R "Q49XY%847C/2)]+T
MO4HWG-IJ=R+6W?RB/WA8J PZCE3STXID?C;2IM8ETN&._EN8;E;:;99R;8F9
M=P+G'RJ1_$>#].: .AV)DG:.?:CRT_N+^58D?B[2Y+^PM3Y\:ZCN^Q7#QXBN
M"!G"M[CD9 W#IFCQ7?6%CIMN=0N[^UCDNX422RW!BY<;59@.%)P#G&02* -O
MRT_N+^5'EI_<7\JYZ_\ &NE6&H7]@8K^>[L8EFFB@M'<[&SR..1\IYZ=LYXK
M9L=0MM2TNWU&SD\ZUN(EFB=0?F4C(XZ].U $[0QNA1HT93U4J"#2[%"A=HVK
MC QP,5YEK_C"ZUGX;:OJMJM]I<MI>B)'5MAVK<+&06!ZXSD#IFNTLO%>F7FH
MWMB3<6T]I"+AQ=PM"&A)(\Q=V,KD'F@#:"J#D* ?7%((T'1%&#G@=_6L:V\4
MZ?<:M;::RW-O<7D336GGQ%!<(N-Q7W ()!P<'.*S?%^O7EIJ^@^'=,E$%]K,
M[J;C:&,$,:[I&4'C=C &01S[4 =7L4Y^4<G)XZFEV@C&!@=L5A7&A7<(M7TW
M5;Y'CN(FG6><RK/&&&\'=G:<9^[CTZ5!:>.='O;Z2U@%Z?*N);>:9K218X7C
M7<V]B,(,9QG'2@#HW19$*.H93P0PR#2@!5"J  !@ =JQ;;Q5IUQJMKIS+<6\
MUY$TUF9XBBW"* 6*GU (.#@XYQ7,^*?$WVJ;PO+I<U_';7.MP0BXCRL-RFXA
MER#D@XXR & .,B@#T#:N[.T9]<4C1JV> &/\0'(KC[WQ1I^D?\)=J5NVIWMQ
MIL<;W-I)N$<1$9*^6&QA2!N8C@]>:Z72+YM2TFVNWA>)Y8U9E==O)'8>E '-
M6G@_58[#^R;[5[&]TW:8R\FF_P"E.IZ[I#(5+')RVS)Z]:ZX01 QGRUS&,(2
M.5'L:X_XAZ[J^E::IT)!)<VH&H72^MM$REU^K9Q[A6KHVUS34\/C79+I$TW[
M.+GSST$97=G\NU %_8A).U>?:EV+Q\HX.1QTK"3Q;IYU9=+EAOH;YX/M*0M:
M.Y:+^]E P'/&"0<X&.1573O'^B:I +FW^V_96B,JW#VDBQL?,$>P-CERQ "C
MGGUXH Z<@$8(!'O2;$X^5>.G%8L/BS2WGU"WN6EL[FPC6:>&Y3#"-ONN,9#
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MW:,A2,Y_@/3BN:DT/6V\!WNGC1[G[7)X@-ZD6Y,F'[4)=V=V/NCIG.:]5HH
M\[\2Z)J%UK=WJFAVNH:?KBM"L%S$P-O>QX7*SJ3C"Y<<@' &,]*6ZT/4%\5#
M5-%MK_3;]]147B;PUG>VX8!I&7) ?8.",-D=,'->AT4 >8ZKX6UG6H/'MM#;
M/;/J-Q;3V,DQ79,8DCX."2 6CQSC@YK;GM;WQ!XC\.ZQ+IEU8KI"3S3I-MW&
M1X]@B7!.[J23TX'KQV=% 'E=AH>M0>!O!FGR:1<B[T[5X[BZC!0^7&KR$MG=
M@\,.!DUUOCS1[_6- A_LM5DO;*]@OHH&8*)C$X;9D\#(Z9[XKIZ* .16QN-6
M\;6'B)K*YM+>PL)8=DR@22R2%3MV@GA0IYZ$L,9YI_P\L[[3?#!L]1LIK2X6
M[N9=DA4Y629W4@J2.C"NKHH \V\9Z=X@U=_%.G#2;FYMKC3PFF/!*B1%MAW^
M;\P+/N.%!!'3IR:[O2Q,VB6JSV[V\WD*K1.060XQ@X)'Y&KU% 'DMKH'B"U\
M$>%MWA[[3=>'Y2MQIT[QG[4A5D9DY(R-P*YQGGVSIZKI.IWFDV>L:+X7ATZY
MLM2AOAIS"**:Z5%=&#E"5#8<[02<;?? ]'HH X'Q6-:\3^ =6B@\/W-M/<B)
M+>UE:,3L0X9F;#%0,#CG/!]14FJV6HS^.+C48=,NGM7\/RVBN-HS,T@8)@MG
MIWZ>]=U10!YM8Z/J\.G?#J%]+N ^D8%\,I^ZQ;M'_>Y^8CIGBH+KPYKUWI7B
MH6MBT5X^N1ZI8).RA+A8_*(4D$XR8SUQVKU"B@#B=3U3Q/JWA:_N-.\.S6%X
M(T5(+MHFED.\;]@R5X7=M+=21P,<T=,T[4[?Q/K]Z-$OX[2_TN%(FGG220NG
MF95OG)W'<.Y '4CI7HE% '/>!;.ZTWP+HMA?6SV]U:VD<,L3D$AE&#R"0:XR
M]T/6I_ GB[3X](N3=W^LR7-M%E 9(VE1@V=V!PIX)!KU2B@#R_QEIWB+78/%
M-@-&NYHKBU3^S&BE2.(_(-WF#<"TF[( ((X&,<FMV*UU1/B'9:NVDS_9;C1U
MM';S(_\ 1Y!+O(?YO[I_ASSQ[UV=% 'DMKI'B"#POX?T3_A'[MIM(UR.XFE\
MR())$)G?=&2W/RL.N/2NFT72KZ36_&@N;2>T@U25#;3MM.Y?(6,D8)(((/7%
M=I10!YUX.T^^MX=-TK4_!5K;WNFA4?52D+1.$&!)&1\^]@/08R23V.W\0+&]
MU+P_;V]A9RW4PO[68I&5&$CE5V/) Z UU5% '%+9Z@GCCQ%J!TZY-K=:9!!!
M(-O[QT\PE<9R/OCK@=:T_ =E=Z;X%T:POK=[>ZMK5(98G()#*,'D$@UT5% '
ME5UH>O?\*[U[05T6Y>Z?5))H662/;,C70E#+\W V]<XYXY[:OB#0-1U[Q7JH
MBM9H+2^\-R:<ET^ JS,[, 1G.,'T]J] HH X;PG%=SSV0O\ P3;Z5?62%9[U
MDA*LVW:?)93N^;J<@ #(YJUXST"_N]4T+Q'I$2W&HZ+,[?9F<)]HAD7;(H8\
M!L<C/%=?10!D6NK75^8UATF\MLD>8UXBH$'<8#$L?3''OZ\QI>@:C>^'_&^E
MW%M+8OJU[=O;2RE<%)8PJM\I..0>#S7?44 >=Z)I][JE@MA>^#8-&U"&VD@E
MU(I"5#-&4W0%#NR203D  9&2:SHK/Q$_A?PGHTOAN\6ZT/4;3[0Z21>4\4((
MWHQ<9R,'D#T],^JT4 >=7^A:M?S_ !&CCT^5!JUFD=B[LH69EMRA'7CYCWQ7
M9:!)<-H%G]JLIK25(55H92I<84#G:2.WK_A6G10!RNGZ-_;-UJ>HZO:ZA:S7
M$ODI%]J>,?9TR$&(WP<Y=N>1O(KE+/3;_3OAKXC\,ZII%P]E 9HM+,LR*;B%
MV_=)D,2'#$  ]?E'M7JM4M5TFQUO3I+#48!-;2$$KN*D$'(((((((!!!S0!Q
M6AWLB^)K6\UG1=?BU$VAL(+BY@A$1 _>,/W;M\[;.IP. !CO2M/#6N2?""RT
ML:>(]7L+E;E;.Z9=DY2<R!"02,,./KUKN=,\.6.ERB5);VYE4$(]Y>2W!3M\
MN]CMXXR.:UJ /.+[1KOQ/X6U-;#PG;Z#>O"@C%S'$'GD219 A*$_N\ICYNN[
MH,<R"WNM5\/:LT?@9=(O7TV:VY2'S99'7 2-E/W,\DMCMQUQZ'10!Y_%IFJ"
M^^'TATRX"Z7 Z7IRG[DFW\L _-S\WIGCFLN[\.:[<66OS0:3OG7Q"FJVUK<L
M@2\B5$4IG) )PWWO:O5** /-=:TZ[UOP+KR:=X-_LN[O+46\<)2%)YFSW*G
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M"6*XV<>1P0ZD<$XZ'G-=!8WFBZ%<:DHU=IPRF^G,MP9OL\:JB<L22 <9 /\
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MZ D?0U-10!%);02OOD@C=]I3<R G:>H^GM47]FV&T+]BMMJG('E+@'\JM44
M1S6\-RFR>&.5,YVNH89_&HO[.LMV[[';[L;<^4N<8QCITQQ5FB@".&WAMDV0
M0QQ)G.U%"C/X5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5WMK?R7&IWUFUA=0I:^7MN)% CGW#)V'.3MZ'('-7:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB;:J6%T4'#!0%.\?=9LD$8]ZU]9@^U?&G28A=36Y_L2<[H6 ;_6KQR#_ )%
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M2>6>VL[>&67F22.)59_J0.:LUE+XDTF33;'4(KQ9;>_(6T,:LS3$@G"J!G.
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M:;8V4LDMI96T$DIS(T42J7/N0.:I67B?2-0UA]*M[ES=K$9E5H719$! +(S
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MD,#U!%0W5C9WUH;2[M8+BV( ,,L8=#CI\IXKF[B^O1\4;/3TOI?L$^CSS>0
MNT2+)&H8<9)PQZDU!X-UYU\*7%[K6H/,T>I7-L)I%RSXG9$4*HY)X  '/84
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MGPV+645C;):-G= L*B,Y]5QBF3:)I5QIXT^;3+*2R!R+9X%,8/\ ND8J]10
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MZ59T?3K_ $_Q+93Z,FI6]A<7,SZCI=["QAMR0Y,L,C#C+8^52<[SP,''H]%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"N-V3CAN1Z=J /3**\H\-[/$6F:-K<^O6UIJ\%\/M0CA(N7DWE6MY,R<J<X
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M R0#C&<<XSG'.*Q/B)XL&E>%=2?2]2>#4+9T3S(X/,17++E&8J5#;6Z9!Z4
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MP1SFX-J;AI!"Y09954 @8(.3D]!CK4NOWUO:?V;'+K/]FO/?1)& BL;D[O\
M58(/#9P2.GK0!;.BZ6VDC2CIUJ=."A1:^2OE@ Y&%QCKS3?["TDV$E@VFVC6
MDIS)"T2LLA]6!')X'7TIL^O:;;7?V:6=A()4@8K$[*LCXVHS ;0QW+P3_$/6
MK5]?6NFV<MY>3I!;Q#+R.>!V'XDX&.^: (;C1=+N]+&EW&G6LM@  +9XE,8
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M>6ZUF*X@$EK([31DP'<, YX1B?3&#C@5N^);#4=5\7:PFFV]TC77A>2T@N#
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MN8 @9(-=C10!YG#!=V.C^-M U#3[NXN=0NKN:S9(&=+I)EP@#@;00?E.2,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU*X;POJOQ$N=-=X?+@TP[LE_)1BZNR\Y "EFP.E=7IFAA-=-PNNQS6%_8_\
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MYQIFH37VK^#M%OY)#87'A_[5@N1]IN (QAC_ !;5+-CU.3T%8VHSZE%I6JV
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M(#=!][/'3&35HZI>>'I?#7B[6)+K[-J.G);:G"78K#<,@=)!'G +$,AP.I%
M'I]%9?AZQFL-&A2Z9S=2EIYPTA?8[G<5!)^ZN=H]@*U* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\LUJ)EG=EC,ZA,F4+V!Z^G.*GF\4Z%!;0W,NJ6RP31I*DN_Y-C_=8GHH/8G
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M2Z(L4\-R]@)-T+2>64D*QX8C"%3Z9JE<:7I#6%G-I$FI^'WFOI[VTU%TD?\
M>L@#-*DN<(^3PV,X!XW5Z710!Y=%=:H;SP1JNKZ<Z-#=7\<[V=LY5BZNJ2;
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M6R+"&_U4K18VY]B<9KFO#%YHFL7>DW;:1JT.K:7"XF^V?:%6QRFUQESL;.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO3(FEG<!KEED"&*(\<-V9L$#TY/89 +.D:]9:Y-J*6+^8EA=&TDD'W3(%5F
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MG6$R*)74NJ9Y(& 3CT&X?F*\WNK^_NXO"L<NJ7,&KZW=1W4T4$[*D-HJF5D
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M+9/ED*#M&.I/.1@ [VBN;\9:M>Z=9Z=:::PCO=4OH[&.<J&$ 8,S/@\$A4;
M/&<5AWVIG2?%.K6Z75Y-I.GZ$US?[[J1BDV[,8#9RC% Y^4CC!]* .HBUQ[N
M^DAT^R>ZMX+K[+<3B15".!EB ?O!3@''<X&<&MBN8^'VC'1/ ^EV\AD-S+"+
MBX\R1F/FR?._4G')/\ZZ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHKF_'FM7WA_P??:GIOEF]@7=%&Z;@Y')&,CHH8_\!H NZ[I4FIK:M#';/+;S
M"5/M)?:K#HP"D?,/7ZUCWVBZU)?IK!M-)N-2MD(@96E5@#U527  /?U]ZT;S
MQ-;Z?X/CUZ==X>U6=(E.#(2F_ _#))[ $G@5#X4UB^NO!]CK7B&XM;>6\B68
MJ!Y:1*_*+ECR<%>O>@#G_#'A37[#28#?6^F->B=[J43O)(#.SERX ;9G)X;
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M;8V!R"OS97GTQU/K5O2=7U;Q3X+T[4=,FM+.ZNTS)-+$TJ)@D$JFX9R1QEN
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MZA<XR% )QGN3\M!(K[28_&HMX6DUO4]0(L4'5U:&-8WS_<4[B3T&TCK7HE%
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M'V*GOP!V%8=EI]YJG@[PII BGCEU74/[2U&9HB  &-P^<]]Y11GKCN*]8HH
M\INK."ZT/XASL+G3TE;[#$T4#$^7"FT!1QO+.TG /(;KS6OX=&D>*O$5EK*7
MVEROI5E]GATZT?>8&8J2[;E5AC:H4;1C!Y].LU?1QJCV,RW,EO<64_GPNH#+
MN*,A#*>",,?0CL13+;1$361K%W*)[]8&MT=8A&JHQ5B,<DY*KU)QCC&3D Q?
M&]T4O?#]C<I-_9-U>-]M:.)I P1"T<;!03AGVY'?&.]<X^JSQQ>/O$0LIX+T
M[-.LT>,@_*H2/GH2TDIX&>@]L^IUF3Z.;N_$UW=R3VR3)/#:LBA8W48'(&2
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M8X8Q\K_:'< JL6T_-G<!VYSV&:ETO74U+4]0T\VLL,]B(C+N967YP2%RI(W
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MH0L>X* 2&X8G/'3@\UG:#XS:_P! 76+^T>!+V[,6G6Z%7>9<E5"X/).UF).
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MN9I& X+$*,#. /4\6M0TBYNM;T/6S'&]SI\4\<D"OQ^]502I(YP4 YQP3]"
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M;< X)Z$G..3CL!B]+X>U(Z[X9FB2S6QTF"53'O;Y'8*B[1CYL1[USQR<X[4
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MH4M8?)E,ACA5"H!RHP<LS<=S[5O>&(-6M/#EC::UY#7UO"L4DD$A=9-HQNY
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MLD,']C?;;E1$<Q.6"J2=W0XD.W P%ZYK%TSQOXCO8O"LQCM"VLSSE8/)93)
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M4 ,FACN()(94#QR*4=3T((P1618^&;2SGT^5Y9;@Z=!]GLA+C$*X"D\#EBH
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MLK'[!;19&R*,D$D#&=QVJ,YZ"MBLSQ%JW]A>'-1U;8C_ &.W>;8[%0VT9QD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KA_'"_P!L^(_"_AE960373:A<%"-RQP+E
M>OK(4_*NXJHVEZ<]\+Y["U:[7I.85,@_X%C- '-ZR]QX*\+>)-;2YN-1N50S
MPFY.XH @55X ^4-N;CU-93Q2:78IXAENX;FXTO39[P)!,99;]C'RTC8&$]%
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M]C;1VUI;Q6\$8PD42!%4>@ X%5[/3DM)K_ 4PW<WG%".C%0K#'H=N?\ @1H
M\UM= EC\.>&&C,H\2:CJ$>HRRK(VZ)7?SIR1G 0*2A'0DJ.I%=3ITLFI?%+5
MKF+/V/3=/BL6;LT[MYK ?1=F?3-="-.BM+=UTNWM;25P%WK$  /7 ZX["G:9
MIEMI-F+:V4[=S.[L<M(['+.Q[L222: .3\56]EK/CSPSI5W'$\=L)=0E$@'.
M (XU_%W)Q_L5R6LB35=)\5:N\QB35M3CTK3BLA0,$80B0D$?*I\YP.G4GH,>
MO-96KWJ7K6T)NT0QK.8QO53U4-U ]J8VF6#V\5NUC;&&%Q)'&8EVHX.0P&,
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MC-<ZO@>"74K*^72M-TJ[MYXYGN]/E?S90IR4;Y5R&Z'<6X)[\T 7?',O]F^
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MJ17'C.WT*ZN!!86]B=0N5+8^T9?8D?J5R&) ZG:.A(/41V=M%=374=O"EQ,
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M/B'5]%S':0V4%DQDD9HFOI)MH=LGDHK*6/O@\UZ5<V=M>(J75O%.BG<%E0,
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M1+-,LR-$4C;=ACO X^5N?:H[7Q'I5YJ,6GPW#F[FA:XCB:%U+1@@%QE1\N2
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M[B6).X<8).>QYFULM;N?#7A32I-#O57[<ESJ[SJH:29,RL3S]UI0/F/;&,T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=%*(H'\?S*-N3R1S0!UE&<5AZ;K\U]KUSI<MB(V@MTFDDCF\P1LQ($;X  ?
MS@$\?AG!^)PCO]/T?06M3=/J>HQ*T2(&?R8SYLA7/LF/^!4 =U17FF@7^GP>
M)_$/B2()HVB:?:"UN[!E$;^<K;S,\:\+\ORKU+ _2NIC\42+J&CV]YISVJ:O
MO%MNDS(K*A?$B8PN5!Z$X/!H Z*BN3T[Q?>:K(R6>AO,L>H2V4LRW \J-4R#
M(6(!(+*1@ GH3U&8M,\>?;]+MM6DTM[?2FCGEN;UIU,=NJ9VGH"VX '@<9[G
M( !V-%<TOBQUFT?[3IKV\&L.T=J7E_>!MA=1(F/ER%/0G!QD>D!\=6T&DR7E
MY9O#-%JG]FO K[\/YJQ[\X'RX8-^('4T =916#>>)DL+J[@N+23*3Q6UH(W#
M-=22+NV@<;2.IR< ?-G%9M[XX>QTW7+M]-20:4\49,5SF.9WP-BN4'S!BH(Q
MCD<]10!V%%9FEZG=ZA<W:RZ9+:VT>PP3R.#]H# DD*.5 XZ\G/05CW'B^[75
M=>L+32%N&T>%)9)6N=B-N4OMSM.&V@<<]1R.M '5T5R4?CE+B;0UM--EG&KV
M#7T2"0"1  I"E2,<EP,YQPQZ"IAXN(ML36*VUY#:+=WT5Q<!8[,,#M5Y #\Q
MP< #MSCC(!TYY&#6'#X5L8-/_LR.:[&E[3&+(S?NPG]S.-VWMMW8QQTXJ&P\
M4MJ?V2"VTZ5=0EM([NXMYFV"T1Q\HD."=Q(. !G@YQ2Q^*EDCLHC9207]Q;&
M[DMKE_+%K$."TK$?*,\#C)]!@X .@50JA5 "@8 '05&MS \[0+-&TRC+1A@6
M ]2.M<]8>+UU"STWRK%QJ&H"1X;4OP(D8J96;'$9^4@XR=Z\5RBZD5C\6^([
MC3A(;N\CT2*"*X*,ZJ?*.R0#.3+(_/!P,\$4 >HT5RTWB-=(UP>&[>Q:<V^G
M+<(YN<G:#L4.6''W6)8D\+W) ++'QLNHV?AWR-.D%_K<!N8K9Y,+%&H!9G?'
M3YEQ@9.X<#G !UE%8'AKQ(_B&344.G/;K874EH\OFJZ/(APP7H2.G) J#^V]
M2N/B!)H\$-L--LK-;BZF\T[RTA(12-N!C8YQGG@Y'0@'0Q7,$[.L,T<C1G#A
M&!*GT..E2UYCX.\1K;FVN8M.:8>)]7G?SE<+Y:[6,>!C+ 1Q*2> "W<Y Z6_
M\9QV\4T]E9_;(8KM;($2[6GFW!66%<'>5YST'RGG@D '4T54U/4K71]-GO[R
M0I!"N6(&2><  =R20 .Y(K(A\27;^([;19=*\J>>S>\+&X!$2 A0'POWB3C
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M+&YGB*R6[NLPCSD8)'#<52L/">FZ=<:1) AQI-HUI: ]55MH8L>YPH_,^HP
M;M%%% !1110 4444 %%%% !1110 4444 %4M0TR'4_($TMRBPR;]L,S1B3@C
M:^T_,O/0U=HH 155%"JH50,  8 %+110 4444 %%%% !5"'2+>&^:\9YYI=[
M/&)I"XB+ !M@/3@?AR!@$U?HH **** "BBB@ K-UW18/$&DSZ9=S3QVMPNR9
M86"EU[@G!./I6E10 R)/*B2/<6VJ!N.,G'TXI]%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7.W&AWL/BVXUZP:VDDN+!+,I<,
MP\HH[,&& <@[^5XZ#FNBHH \\MO#]N;GP_I5E=B_ACOY=:U*]4@^=,"P4G'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>fifthamendmenttoamendeda002.jpg
<TEXT>
begin 644 fifthamendmenttoamendeda002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS6:UMMP:7R55?F=F;'&Y023R3WJK+\0-)ATG^T&M[["7RZ?/ (@9;>8L%VN
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M]X0"68EQDY/'<GBM>WT74=5/A>.^L'L8M$99I3)(CF658C&JIL8_+\Q8DX/
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M ,H'.3C%16UMJ>C:]JUK#IFD:G8:A>27=OJ$UU&IMC(<LLB'YF ;)&WKTX[
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M?! /X4 4-)\.M+HMO+J6HZA-JDT2O-=)=NFV0C)V*#M50>@QCCG/-56\3_\
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MU^MQ'#)>0JOE;2N+:/&#G@ <8Q[YK7LO$.J:'J.C6NI2VLVFWFD2W*)#"5>
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M6S,R+(F<$JQ4]?<$5<KR3PWJ^L:%X3TN]@EM#I\NO2V<MNT+&1EENW0N'W
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M7TYYY( /M,IN5(^4(I/[L#DM[@9'< [>J6FZOI^L)</I]U'<);S-;RLG19%
M)7/?&1TKEM+\87FO?\(W96XBMKS4]+_M.YDV[A$@V#:@)ZEGZG. #US1\-UG
M2/Q0MRZ23#7[D.\:[58[8^0,G'TS0!VU9B>'M(CU^775L(?[4E01M<D98J!@
M?3CC([57\0ZA>6+:>MO+;P03SE)YI!OD4;&*B)!R[E@!@9XR<&N3B\?7R>'+
M;4-00PVZ:E<V5]?0VK,(4C9E5VCY*[B%!)SCGU& #T>BL[0;Q]0T6WNWN[6[
M,NYEN+3_ %<B[CM(Y..,9&3@YK1H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\4:$/$WAV[T9[E
MK:*Z79)(B!F"YSQG@'CWK7JGJVJ6NBZ1=ZG>N5MK6)I9"!DX SP.YH R=5\,
MSZE>:1J":K):ZAIOF*L\4*D2)( '!5LC/RKSV(Z=JS/^%>*NFS62:S=%9-6_
MM;=)&C%9 ^\ <#C(&<YSVQ70Z9J=]=WUS;7FDRVBQHDD<_F"2.4-G@$8(88Y
M&/3!-1>)_$"^&=&;4I+26YC66.-EC91MWN$!.3TRPZ9H 9J7AS^T->TO6$OY
MK:YL8Y(B(D4K*C[2RG<#CE!R.>M9,_@'[1X?UG1WU5Q%JM\U[+((1N1F97(7
MG&,J.N>_X;*>(%;QC)X=-I*LB6(O1.S+M92^S  .>N>N.E;- ')WO@RXD\02
MZUIFOWFEW%W&D=^EO&C)<;1@, X;8V.,C/&*NVGAD67B@ZU%>-M^PI8"W*9
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M)55(3GIA1USWKG_$B,_BD0WFK7VG?9K2*&"5M)6[@N2<EF0%&"-]T$9!.!V
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MMEJL2.OF,FUG0D94D8R._MVZ72K :5I-IIXGDG%M$L0DD #,%&!G  _2KE%
M'-ZUX4.NQW]I>7Y?3;YXWDMGA#-'M"C]V^?ESMSR#C)Q@U5D\$21Z]>W^F:]
M?Z?:Z@XDOK*%4*2O@ LK,"8R0!DKS[CBNNHH PX/#:6OBNXURWO9HA<V\4,U
MJ%78_E[@ASC(P&/ /I6K>0O<V<T$<HB>1"@<KNVYXSBIZ* .13P' GAG2-(_
MM"43:/(DEA>J@$D;+P-PZ,""01QD>_-37W@Y=3L]86[O2U[JUL+.>Y2( )"
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M\OFN)8CC!VR [AQQUZ4VX\-Z1=Z4-+GLD>RW^88=S ,^[=N;!RQW<Y.>>>M
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M:-_T"+#_ ,!D_P * .P^V6O_ #\P_P#?P4?;+7_GYA_[^"N/_L#1O^@18?\
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M5+N>6YEF4':7;IUYP./S-5-*\#RZ?\-KGPS]K47=U%*);E0<,[YY]<8P/H*
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M )&'6/\ MC_Z :UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM>#?^1,T;_KTC_\ 0:JU:\&_\B9HW_7I'_Z#0!N4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <]XR_P"0-;_]A"U_]')452^,
MO^0-;_\ 80M?_1R5%0 4444 %%%% !1110 4444 9.G_ /(PZQ_VQ_\ 0#6M
M63I__(PZQ_VQ_P#0#6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5DW/_(W:;_UXW7_ *'!6M63<_\ (W:;_P!>
M-U_Z'!0!K4444 %%%% !1110 4444 %%%% !1110 4444 %9/A;_ )%72O\
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MHW_7I'_Z#0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQQVW;@/;D]JSM!\76ECX7?Q)_8L,.HZ]?F*WMK=CNNGSM4L3TYW9.,<],GD
M]-HKF=$\2SWWBS6/#]S%$9=/CBD\^'(4[U!*D'/(SU[^@KIJ "BBB@ HHHH
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M$S1O^O2/_P!!JK5KP;_R)FC?]>D?_H- &Y1110 4444 %%%% !1110 4444
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M!_X ?_;*/^$=UG_H.P?^ '_VR@!:*3_A'=9_Z#L'_@!_]LH_X1W6?^@[!_X
M?_;* %HI/^$=UG_H.P?^ '_VRC_A'=9_Z#L'_@!_]LH 6BD_X1W6?^@[!_X
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M .V4 +12?\([K/\ T'8/_ #_ .V4?\([K/\ T'8/_ #_ .V4 +12?\([K/\
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M$U&""'59/.9)[8R&"3G)4A@".3P1QQ77?\([K/\ T'8/_ #_ .V4?\([K/\
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M70\<=P)[>;[+C8-VXJPWG<,DGM7H7_".ZS_T'8/_   _^V4?\([K/_0=@_\
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MO#308@G@<+==C<J%<Q?7RV#?B* .IHJ">]M;5XTN+F&%Y,[%DD"EL#)QGK@
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MI@..?EP>"2AXZX]'K$&@WHSCQ-JPSU^2V_\ C-+_ &'??]#/J_\ WQ;?_&:
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MQ##CDB-MY 'I@9_"O2[/Q'H\[:7;0WJ/+J$3O:!5)$JH 6(.,8&12?V'??\
M0SZO_P!\6W_QFM*RMGM;<1RW<]VX)_>SA WT^15'Z4 6**** "N \=W=M#XT
M\#K+<1(4U"1F#.!M!B8 GT&2!7?T4 <-X\:S?Q%X,ANFA*'5&9DD(P1Y,@R0
M>V2!]2*XW7WT_P#X1;XG6T;6VP7R20QJ5QO,40)4>NX'IW!KVNB@#S'QC=>3
MJ%]J.DZK8RRG2XQ>:3>X,5_;YD*^4P.0_P SCC()*YKTFUE:>TAF>)H6DC5C
M&_5"1G!]Q4A4$@D XZ4M %'6-6M-#TBYU*^D$=O;QEVR>3@=!ZD] *\Y\4:'
MJL7@(:T-4T]KS3YO[:C9(3\TV2[*)-^&!!*#CD!17JE% 'F>L:OHOB/Q!\/]
M31K:2*XGF8B0J2H-NWRMZ88@8/>L6^BT@^'_ (IA4LRWG2&' 7.3;IC;]7!Z
M=QZU[-10!Y3<:W96/B1&U_5)K32]3T:WCM+M51X9"-_FQEF5L,=RGMG ST%.
M@T[0['QKX+LHH_\ 1H=-NUC6]P9-N8S%NW<] 2H/('8$5ZF0#U /UI: /$[/
M4(K#2["<LIT"R\67;7@CY2&,O)Y+,!TC#E6STZ&G>([[2+V3XF2V\UK/'<Z5
M:O#(A#+*X2094]&.2HR*]J(!&#R*0 #H * /-9HM%/C_ ,&>6EB4?3+G=@+A
MC^Z*9]>=Q'OFL"'4$L-"DNX99!I%AXNN9+O[&JOY,!,FQ]N"-@9E;H>F1TKV
MJB@#QWQ1'X<N/!'B#5=,O)+U;^\LG>ZEP(Y)5E0'RP%49"#YB!^.0:U-32Q7
MQYK=KIRVZB?PH56*W  =P[[0 .IVD?@:]-  & , =A2T <3X2\5Z':>#/"=O
M-J$:2W=M!9PC:Q#S+&H*9 P"#QSWXZUVU5KNQBO?)$Q8QQ2++Y8QAF4@J3WX
M(!_"K- ')>/M0L]-T_29KV&,H=4@"7$S,(K5_F(EDVD9 QC!(&2,D5YSJUS9
M2>#?B!;RW"S2'6(IHVDCV%MP@PP&!C.&QCJ 3SR:]SZT4 >6ZWMA\<:I#X=,
M$=[+X3E%LEL5&Z42$QXQ_%@Y'^%4EUO0;VV^' L9H1-9WB130@?O+8_9W5D<
M=5.X#KUQGFO7Z3: <@#/7I0 M<7\1Y([>S\/7<[!+>WUVTDFE;[L:98%F/8<
MCFNTHH \SDDTF]\?>+9+DVLB?V+;A?. X&)=PP>AP5S]16)I&N1Z38^";[5=
M1GM-(?0OL@O(U5TAN<IE7)5MN57&?]G'K7L](0&&" 1Z&@#!\&V.FZ?X=CAT
M<W!T]I'D@:?JP9B25&!A222.!QR."*WZ** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]7UBWT:&
MW>=)9'N;A+:"*( M)(W0#) '0G)('%:%<[XOCUN2SL1H\,DZ"\0WL$,RQ2R0
M8.X(Y( .=O<$@$9H AN/'FEVNA:AJL]M?(FG7?V.ZA\H-)')E1V8J1\ZG(..
M:<?&MN-6N-*_LC5C?QPBXB@\A0;B+.W<A+8 !Z[RIY'K7'77A7Q!_P (MXNT
MN#0T1M2U..ZM$BN8]NS]R2.2,8\MLY[D8R.:ZMK+4C\2HM9_LV;["-':U+^9
M'D2&57QC=GH,9]?;F@"[9^+].U#1K#4;1+B3[>S)!;;0LI==V]2"0!MVMDDX
MXZ\C-%OB'HZ6(N9(+Y6745TV: 0AI()R0 &VDC'(.5)SVSTKE;?PKXBLO#VA
MW,>C0W5]I5]>22Z;<31[;B&>1F^5LE0P!4C..0?QV-8TK6-2T33C!X>BLY5U
M>UNWLX)8LQQ1.&8NV0I8X. ,]N: -RV\::9(-8^V176G-I*+)=)=Q@$1L"5=
M=I;(.#@=<C&,UAW.K7$OQ0T$&UU2TB?3KN1X)G!27'E[2$5V&X9/8'D53\2^
M$M:U[4/%@M[8VZZA:6:V<\LB;6D@D:3:P#$@$D#./6M 1^(=3\8^'M9N/#LM
MG%9VEU%<H]U"Q5W\O&W:QR/E.#Q[@=P"U#\2-)EL=/U#[!JBV%[<&U2Y:V&U
M)=[(%8!MW)7C (Y .#Q5^U\9:?-)JL=W!=Z?+ID:RSI=Q@$QMG:Z[2V0=I&.
MN>,9KD;?PYKT7P^T72FTF7[;::RMY*@FBP(Q=--D'?@G:<8]?SJUX@\*ZOKN
ML^)_*MC;0ZAIMM#:W$KH5\Z)V?#*&)VDE1T]: .B;QI8PW]S8W=G?6MW#:&]
M6)T1C-$#ABFQF!(/4'!]L5'IWCO3M2NM(A2RU&%-7@,ME/-"JQR$)O*?>R&"
MY/3!P<$UGV$.MWNE7GVKPA::3<BTDBQ#-"[3R,N!L*\*G4_,0>G%4[/0=:AM
M/A[$^ER;M%4+>_OHOD_T<Q<?-\W)SQV]^* -/1_'!N[/4;N_TVXM4@U-M/A3
M=&2[AUC"9#_>+$G)PHSU.*Z33M0_M 7&;2XMGMY?*>.<+G.U6R"I((PPYSZU
MQ%OX?U&/3->TG4O#J:C87FL376W[0@\Z&5]P*98;67KR1R!CKD;W@O2=2T:T
MOK6[GNY+(7.=/CO)1+-%#M7Y68$Y&[=CDD#&?0 %R^\2V]G=7ENEI=7;V4:2
MW/V<(?*5LXR&8$\ G@'BH-8\86&C1WLTMO=3VU@RK>3P*I6W) /(+!C@,I.T
M' -8/B[PW?:MJ=S>Z;I]S::S B+I^K6ERD888!*3*6RR!LY^4\'CWB71M=T?
MQ-JP3PW8ZW8ZG.+J*[DECC-M(4565PP+%,KD;030!NV7BF:^\;W.BQ:?*;.&
MSAN%NE>,JXD+8;[V=N%P.,YSD 8-,^(NL7NA^"KZ[L(YO/(2,2QE1Y6YU7=R
M0<_-QC/.*9::5JEC\0YM0%HDUA=:9!;-<(ZH(GC9R1LZX(88QD>XJ7XA:;J&
ML>#+S3M,M&N;J=HMJAT0 +(K$DL1V4T -LI+31-3EBM;;5I+Z_B^T'2VN$D\
MA4.TN-S[5W$C^/D]N&HD^(&C)86%VL=[(MY>&Q6-(,O%<#.8W&>&&T\<^V:A
MN].U2T\>P>)K6PENK:XT[[#<VJR1K+"5<NCC<P4CD@@-Z'FL23PGJ]N+&XAL
M&EFF\3G6KJ))8QY$95D"Y+ %L%2<<9SSTR ;-MXRNM1\56.D+H.I6T%S827,
MGV@)'*F)5CR5WY &6)QR<C -8_@SQ;'I6@6L&HQZG.D^K7%F+YP9$1VN'6-7
M=FW'/ R 0.Y%;^H:=J<7Q%T_6K6Q^TV?]FRV<I$JH8F,B."03R,*1QGGT'-<
MTOAO7AX$@TPZ1+]K37/MQ3SHL>5]J,V<[\9V\8]?SH ](OIDM[">:1961(V+
M"($N1CMCG-<KIWB[1M-T#PVEM#JDMOJD82R+H99#A"P#DDG) /<_E74WOF-I
MT_EPM)(T3!8P0"21TR3C]:\^TWP]KEKH_@"VDTN3S-&ES>8FB^0>4\>1\W/+
M \=J .ST'Q#;>(([LPV]S:SV=P;>XM[I0LD;@ \[2000P(()ZUS'C?7!H?B7
M3)-;-_#X8D@=)+BS>1%CN2PVF4QD-MVYQVR>AQQJ^%].U"R\0>)[F[LG@AO[
MU9[=V=&W*(D3HK$@Y4]>U6M3O;Z#5Y(6TY;_ $J6V57198@ZR;FR-KL RE2,
M\]A@')H @TJ\M=(TB>\&K2:I8W=VIL'\_P ]F#JBK&K$\_,&Y)Z<D]33HO&V
MEL^HPW"7%K=V$D4<MK*JF1C+Q%LV,P;<3@8/7KBN'_X0F\MM'U";2+>TML:Q
M%J=CHMQ,AC"HFUT8@E5+Y8X!('R\^FGJFG:MKGA\75IH^G:)J-G=6]Y:V;3Q
ML9GB;<0[I\H!' YZ\G'8 V=;\=#3=&\031:5>#4-(MQ,]M,$ *L"5?<&*E>#
MG!)X/%37&KV<NK^%X]0MM2M[^Z>0VRJX$>X1,6\S8Q4C:"0.>W JCJYUKQ7X
M)UNSN-/@TR>YLGA@M9+N.1FD(/)93M Z <]R3BF7D6I7VK^#;YM.\I=/EE>[
M3[5$QB#0M&/XN3EL\9X_*@#8O/&NFV5O<7KPW3Z;;7!MY[^-5,43AMK9^;<0
M&X)"D Y]#3;WQK9VFJ7VFQ:=J=Y=6=NERZ6T (>-L\J68 _=/IGMFN6AT+5+
M7P9K7@SR(YHKJ6=;34//C\L13.6)<%M^Y=S<!3G P?33L]/N=.\7ZI<QVK26
M+:1;V5O)Y\69&C+]B^1G<.3[T =?I6IVNLZ3::G9.7MKJ)9HF(P=K#(R.QKG
M=;N+N#XD>%88[ZX6UNH[SS;8-B-BD:E20!R?F/7-3^!+>72/ ^D:;J 2"[M;
M=89$,J-R.X*DC%5];@N;GQWX:U"WM_-L[%;H3RB:,;?,10N 6!/(.>/SH ZY
MF"J68X &2:YS3_&.G:M<Z=;);WL*:K!)+932*JK.B8W8VL64X((W ''O6_.9
M7M)3:LGG%#Y3-RN['&?;->;Z5HGB5M<\)ZI?Z,PN[)9X]2N)KR-W=G0#>N"?
MDR#A1TSC:.M #/"?C:WT+PU&NK1:M+;_ -I7,$FI.C210YN'5!)(QW8Z#(!
MZ$UV5_XLL['^T&2UO+N'3<?;9;9%98/E#$$%@6(4AB%!(!]>*Y./POK%QX)U
M#P?<:>T0N[V9FOO-C:(0R3F0L!NW[MIP 5'/?'-7[/1]9T*Y\464&G-?V>K3
MO=VLRRHHC>1 K)(&8$ %005#<>_% &\GBNPEUO3M,BCGD_M&V-U:7*A?)EC
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MTD!A)]-P,7L5;UKLM9NKNSTFYFL+87-X$/DQ&14#/CC)8@ 9ZUQ>N>#+"^\
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M-N=R3/<RAG)+_-QN( VGMGG-;,_BGQ!I!NX]1TY#'+<VUMIEVZ",2/,P0B1
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M@>>Y>-68@#*Q#Y1W?YO?RB.].\%>*9M2^'?V^YB>?4M-CDM[R%?OO-".1]6
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MFSTC7!-#ITFH>'KN,7S1P.R3VK*'\Q%W@JX0DD$D<4 =I_PB_A__ * 6F?\
M@)'_ (4?\(OX?_Z 6F?^ D?^%,LM4GU'7)4M9;>32X;:-VD5"6>5\L &W8P$
MVMC'\:\U!KVI:A::C:6UM+;6]O-%(3*\9FE:4;=J)$I#,,%B2,X [9S0!L6=
MC9Z?"8;*T@MHBVXI#&$4GUP._ JQ6'X-UR;Q+X/TO6;B)(IKN /(D>=H;H<9
MYQQ6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+&%#*[)"6Z^6A)5,Y/W0.I]: .+T+3[G4+?Q+?7&MZP9-.U.^AMU6]<*$"
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M#Y$KK*Z^<F,8< @/Q_>S3[?PIHMI/8S6]EY3V,1AMBDK@1(>J@9Q@X&?7 H
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MUQBUNGA3S6:0%TVG*@[0< _7-=)=^!_#^IWEM?ZGIT5Y?P1+&;E\AI0/[X!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV.G>@#T^BHK=9UMT%S)')-_$T:%%/T!)(_,UE>*=5&DZ'(ZW"07%PRVT$CD
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ME,H00%P6'!!S[5TNI^+-5=M7&@V:W,FF3B#[.UK*YN7"JS*)%PL?#8&<\CG
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M*OVTXN;2&<+M$J*^/3(S0!YY)'?7_AS4=-U?6-6O+B\M7M%G'AZ>-(T888[
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MK=O';D-H-QF((A0'(QN)#'/ Y_*O1:* /+6TI[8:-=:3JFKV6IZ=8IITD_\
M8$\D=S N,!HR."",Y![FNOT_7+>RLHX)4UNYE&3)-)I4X+L3DG 3 &3P!T&!
M71T4 <1XD_L[7S8W,::W9:GI\IFL[R/29V,;$88%2F&5AP1WJQ;:U>.4.I37
MTH0[@MKH-U"&8=-V2Q([X&/<D<5U37,*74=LTBB>1&=(\\LJD!C^!9?S%2T
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MU ! XZ,WK6CXB\4V^@:!=:LL#WL=M*L,JPLHVL6"\DGL6&<9-;U ' ZN$O\
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MMYK],8F8'+8Z;@.&QQC(/2C4_!OAW6=5BU/4-)M[B]C 42L#D@= P'##V.:
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MS#]J1<LT0<?=) SZ<<\9KA=0U"'5_#^D"$:E9S1^*[:&>WO'+S6LF02@8DY
MR"IZ8(KT_4-,M-4BCCO(BZQ2"6,J[(R.,@,"I!!Y-4Y?"^C3P10RV>Y8KC[4
MI,K[O.[2%LY+#L2210!P\UT=%N/'>G-K6HVMC;I9O!,97N)87F!#!"[$Y9@
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ME8A,T23*6"'!W$9Z<C\Q7GFI7T-[JWCVXACG:WNO#\202-;N%E(288!(ZDL
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M@AC4L">HRI&10 >&?$MSX@L[3Q"-:LH=.)E^V64BK^Y7<RQ$..0W SNR#DX
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MO*NG,<#_ &A<2,#@@<]<\5<U'6=,TE0VH7UO:@C=F60+QW)]![]*\HU&.!_
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MW\!1^6(YH-;@>9-F&C =]S,.H !&2>Q'K0!ZQ<ZYI5E=I:76HVT-P[*BQO(
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M1HF>"0. XZKD=ZMU%;I;I%NMDC6.0[\Q@ -GOQU^M2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45GZOJ\.DQ6^]&EGNIUM[>%,9DD.3C)Z  ,2>P!Z]* -"BN:;Q<MI;WIU+3;
MJUN+:ZCM$C W+=228$8A<X# E@.V.<XQ2MXM%KJ5WI=]ITL6H069O8HHI%=;
MB('!V,=OS ]0<=1C(H Z2BN/TOQXNH3: 9-'N[:TUN/-K<2.A&_RS)M*@Y P
M#@]R/3FM#2_$XU>:-[2T\RQ>XEMS.DP+1-'NSYB8^7)7CD]1G&<4 =!17&I\
M1=-DO-,5$62SU.?[/;313H[[SG87C'*JV.#[C(&:B;XC*EE<W[:%?+8V>HFP
MNYFDC_<L)!'NP&.[YF&<9X[GI0!V]%<OI6OZE?>/-=TB6S1+*PCM]CB0$_.)
M&W$8[X48[8]Z-<U_4K#QEH&D6MFDEO?+/)(YD +>6H^4 C@?,#GOC% '445R
MU[XUBM;'4-4AL9;G2M.G:&ZN(W&X%#B1D3^)5.<G(/RG -=-#-'<01SPN'BD
M4.CKT92,@B@!]%96HZTEGJ5II<$/VC4+M'DCBW[55$QN=FP<#+*. 221QU(P
MKCXB6EOISSOIEX;B#44TVZME*%H)68 'K\RG<"",YSV[ '9451TJ\NKZR,UY
MILVGS"1E\B61'. <!LJ2,$<UB67C1+G4M(M9M.GMDU?SOL;2G$G[L$GS(R 4
MR 2.3[XH ZFBL7Q)XC3PY#8R265Q<K=WD5H/)*_(SM@$Y(/Y9_"LK_A-;PW>
MJV">&[PZCIR),T'GQ;6B8$JV_.,_*1MYY]N: .OHKG+?QA:ZC;:,=-A:>YU:
MV-U!"[!-D0 +,YYP 65> <D^F2(8?'-C)9REK:>/48K\::U@Q7>;@\@ YP5*
M_-N_N@GJ,4 =317F]C</!X]\:37NFR?)I=LTMO%*'\T?O<E"Q7@CCG;T/XLU
M;5B?!_@I=&TXQ:7J-U9I]G:4?ZHJ6$)SU!V@$]" 0>M 'I>:*X;1H?#WA_QG
M>V=OHSZ==?V:;Z:X:;,2Q-)\R(NXA5#!C@ #K@<UKV?BB2[N=,_XE%XMCJ<;
M26UTHW[0%W#S5 _=[EY7D^AP>* .BHKEK'QFMUJ.E6DVF3VW]K0RS6?F,/,Q
M& 2)$.-A(.1R??%<]-XL;4/A]XAU'Q'H;7-A!=3P26T$R\HDFS&<J< @9/4Y
MX% 'I5%8UUKGEZJVD:?:_:[Z.V%S(AD$:QH20H+8/S,0<#'8Y(XSCK\0[.>#
M1Y+33+Z<ZE<26@C&Q6AFC#%HW!;ALJ1Z=\XH [&BL3P[XA_MT:A'+92V5W87
M)MKB"1U?#;0P(8<$%6!I+KQ"XU"^L--L6O[C3XDDN560)MW E47/5R!G' P1
MSS0!N45QS_$*UG30WTO3+S4%UJ*5[4QE$^:-261MS<,",'/ YY/2MVXUAK+P
MT^KW>GW2/';^=)9QJ))0<9* *<$YXZXH U**YE/%VR^U2PNM.D6]T^S2]:*"
M59/,C;=P"=N&!4Y!QVP35&W^(!F70IFT&^6VUJ(&TD#QDM(8_,"%<\9 /S'
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M"NT^&4QER2P(  ._U[53\#Z''8:AK%Q;W(GTQ+J2'3%'W88V(>95/<>;E?\
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MYB*/N,B@\#T &.G%>D0>&X;?Q4^O1W<XD>T2S^S@((A&K%E ^7.06/>LRZ\
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MT+$9]LT 4=)\666K^)M8T.%66?3=F6/24'(8K[*P*GW%;LA<1L8U5GP=H9L
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MXK8U&%O#7BS4=-L[<&W\50C[&P3<(;D?+(#_ +.QO-QT^5J /29"XC8QJK.
M=JLV 3[G!Q^1K&\(:])XF\,6FKRVRVSW!DS"K[PNV1DZX&?N^E:EG9P:?906
M=L@2"% B*.P KQK1K&VMO!G@?5X5*W[:\L'V@.=WEO/*K(.>%([=,\]: /;*
M*\<U2]L7N[34[&=$8>+8X7N+F4&Y8^:$D08QLB R ISE<9Q6YJ*GPWXYN190
MHT/BBT$=N0FY4NTX.1TV,C[SZ[&- 'H]%>::C'IUMXQ3POJ$MA;:6ND1_8([
M^+?'(V]Q*02RCS,;.>3C)&,G/8^$[9+/PM86L6I3:E%$A1+R7[TJAB <]QC
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M#P6^X,]0/J: .XHKQFV@GNM/\)PWL]Q+!'XEN+2UE:9MTMJJS!,G.3]T 'T
MKL/ ]O#IWB+QAI=F@BL;:_B:&!?NQ[X$9MH[ G)Q0!VU%>?>*XX=!\9V6L-9
M"YM=7MI-+N(0N0\^-\/XMM9,_P"[GI53P-:2,T/A?484>;PS=2---LP)=PS
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MI,<-S"FEV2Q77_'PBVZ!9?\ >&/F_&DLM"TC375[#2K*U98_+#06ZH0F2=O
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MRS0PVDLC!&SA@%4Y'!Y' [TVV\;:!>76GP6]V[C4!_HLX@D$,K;=VP2%=N[
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MC+!<+RPZ;?O9XQ5/4?'^F6_AV+5[*.XNDDO4L2GV=U:*0R!&#J1E2,]",DX
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MI I(W$C/4\8SSFL#5]+O]%^(</BVRLIKZSN;+[#?P0 &6/#;DE5?XAV('/<
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M T:S31QF1MB!V W-Z#/4U)0!Y-J=MKM\\+SZ#J/VFR\217)CMU58/LZS9#H
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M.,]\5FZC:S:[XFT[78+*]@M].TZZ2036[))+)*%"QA2,G&UB2.,D8)YQW5%
M'-_#^VN++P%HME=V\MO<VUJD,L4J;2K*,'Z_6H/$\FHKXAT58M.NKC3F683S
M62KYR.0NQ=Q(*(W.2".0,D#KU=% 'DFEZ7JUOX5\(V,VCW\<VG>(7N)P8]^V
M+?.=^03D?O%]SSC/6NETW2/M_BCQO#J%C,-/U3R$1I(RJS((!&^"?0\?J*[:
ML_6=(AUNP^QS7%Y;KO5_,M+AH7!!S]Y3G% '.?#^RU)+*2;5Y5FGLRVEVTJG
M/F0PNR^9[,Q&#_N"K7C_ $K4-4\.1_V7'YUU9WD%ZMON \\12!BF3QDXXSW
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MPV:I& +:'&R(?W1CCCIQ5VB@#SJ\L;Y]0^(K+I]VRZA8Q169$+8G80,A"_\
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M<9X5CCKQ7J]% 'FWB/3]0N=4N]6T.WU73==VQ+&AC,EKJ"8'R3#E 1EE))!
MZ$]O1R"R$9P2,9':G44 >41:!JMQ\+6\!W-C<+J:2BW%SY9\EHQ,'$XDZ?=Y
MQG=D8Q74^&[>YA\=>+KB6TN(X+N2V:WFDC(64)"$;!]F'X]175&X@%R+8S1^
M>4,@BW#<5SC..N,G&:DH P/&C:BGA2\;2K(7EV"F(?+5R5WKN*JW#,%R0#W
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M96@>)2IB=5R1G.X'IUYKN** .:\!Z)<>'_"%K87:[)O,EF:($$1>9(SA...
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ML>#Q\W"Y[=:?/X7\0V6LP:QH6HV$-S+9Q6E_;7<3R0R^7G;(I4A@PR1CI@T
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M0C<#.0<G!P",<]:V8/#GB'5=$O-)\5:K9W%O+:O;!K&%HWDW+M\R0L2-P'0
M 9.>>,4X/"?B:1O#:WVIZ:XT.?<LJ0/NG3RVC!8;@ V&[9&>?:@#IM?UR/0K
M2V<Q^;<7=U':6T6[:'E<X&3@X &23@\ \'I61<>+KO3]2U+2KS3X3?VVGMJ-
MMY<Y$=S$IPPR5RK ]L'.0?I?\6>'6\1Z;;QPW(MKVRNX[VTF*[E26,Y&X<94
M@D'ZU2NO#5]J5Y>ZI>-:)J$NFOIUO'&S-'&KG+N6(!))V\8& N,\YH M^%=:
MU;7K"#4+W3(+.SNK2"XMV2Y\QV+KE@R[1C'&.3D'UR!1NO%&LG7]:T?3](M)
M)=.MHKE))KLJLBOOX.$)!^3&.1UY'?:\-Z=/H_AK3=+N7CDELK:.W+QYPX10
MH//3..E9B:!J$7BK6]722U:/4+.*VCC+,"ACWX)..<[SQ[4 9]CX[O;M?#5]
M)I,4.EZZRPQO]IW31R-&SC*[<;?E89W9Z' Z5-=^-+A=&U37;'3X[G2],GDB
MF_?%995B.)708QA2&P"?FV]1Q56W\%ZG;Z!X2TW[1:,=!N8YW?+#S@B,@ &/
MER')[]*D3P9?VFFZ[H5I=VXT?5I9I S@^;:B;_6*HZ,.25)(QGG=B@"W/XB_
MMXZC8Z/:VU[#;VD<L[7+E5<RIO2,#!Y*X))Z;AP><<WX3U*.R\(?#FWFTNVN
MENP(H[B1OGMG$3MN4;3R0",Y'6MR#P?J.B>(+V[\/W5I'8:A;PPW%M=(S&)H
MD\M'0J>?E !4XZ=:K:?X(U6QTCPA9->6<IT&;S78*R^:-C)M'7LY.?;H* (;
M2WNM;\>>,-/U.PL;RS%O:1&&:9B FV1E ^3NQR?3J,XJQH7BZTC\(Z++::3;
MV$FHSSPP64&3'%L>0NWR+DCY">%Y+#IR1KZ9HFHV'BW7M89K5XM26$)$&8-'
MY2LHR<<YS^'O6##X"U:U\+:/:VFIV\&LZ/=RW-K<B,M%()&<LCKUP0Y'!SP#
M0!>M_'-P86M[K2)(=2?4%L+5&WI%<E@6$BLR@[0H8G@D8QSD57\,)<)\4O%G
MVFWMXI39V1)@.5D_UOS<@$'MWZ=:L:KX5UW6=/L;NZU6TCUZQO$N[9H86%LF
MT%3&5)+$,&.6SGIZ8JYHN@ZO:^+=1UW4+JR(OK6"%H+>-_E,>[D,3T^<]ORH
M H^/;C48]4\*06J0-#-JZ;A)*R[V$<C!2 I^7(!SZ@<=ZCTO5K^V\1:OHFE>
M'-/@BL[J&:\E6\*JPF&YY -G+#&<<=#S6QXET.^UC4-#N+62W1--O1=L)2V9
M,(R;1@<<.3GGZ4FE:#>6GBK7]4N7MGMM56$")"Q9/+0IR2,'.<]L>] &9+X\
MDA\.VWBAK!#H$TRHT@E/G1Q,^Q9BN,8S@E<Y .<]J;?>--8A?Q.MKHMI)_8&
MUY3)>E1+&8A+\N$/S;3T/&>YIEMX$O(_"P\(3W4$NA).&24[O/, D$@B(Z9R
M-N_/3^'-69?"FI22>,6$UH!K\82/EOW.(1%D\<\#=V]/>@"6S\77LVNZ);7.
MF10V.MP/+9RK<;I5*H'Q(NT 94]F/2G^/-6U/2-*L)-,\D//J5K;R-(Q!VO*
MH(& >O0GL">#4,?A?4EOO",YFM-NA0O%* 6S-NB\O*\<8 SSGT]ZTO%NA7'B
M#1XK>TGB@N8+N"[B:52R%HY X# <X.,<4 5#JD@\>QZ;)H]E]N.D/<)>"7+8
M$B*8L[,A=QSGGH#BL>U^(6JSZ+H6LMH, LM4NQ9[%O,RI(SLJD J%*Y4 DD'
MGI6V="U/_A-(-?::TD$6F-9-'\R;F9U?<.#@97&.>.<]JQK?P/JMOX1\/Z+]
MILVDTK48[UI?F E"2%PH&."=V,\XQWSP 7H_&TUDWB&'6["*"?1TAEQ:S&59
MEESL +*I#;EV\CN*MZ5XEOKOQ&=*NM+=87MO/CO(4E,08'!C8NBX;N#W'850
MU'P1/K&H^)GN[F..UUFU@@3R23) T6XJ_( /+9QQTK4\/67B>$J?$6IV-SY*
M;(Q9P-'YI_OR9)YQV  Y/7C !3\1ZOK%IXS\,:=8BW-M>-<-*))&4N4B)P2
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MW[1W,<C!L-&S.O!+N2-PZ\=ZVM0\76AM-?CTFZM9M0TF!G=';<N\(6*X!!.
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M/BR2.U^'FL>?(4 TN9<SN-Q/E$8)Z$_UK?:*-G5V12R?=8CD?2G$ C! /UH
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MC#*<8#;2H; XH J:5JUAKFF0:EIERES9S@F.5.C8.#U]P15VJUA8PZ;:+;0
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MU.""/0EE:UDDWY;S6!:,*[*,@ <$<BJFL>#-9O)=3\064*)J<NK6>HP6$L@
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M&[<.4?!*@''TK%31-9UG2?"^EZGIYM)-'NX+BYN/-1HY3 I"^7@EOF.#\P7
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M(^/+4!20V_<-I!(.>O6JU]X[L=,M]6DO=/U&!]+C2:XB*(6\M\X=2'*L.""
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ML[20L?+<0"3*@,,KD_=]NHS0!WE5KV_MM/B62YDV!FVHH4LSG!.%4 EC@$X
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M%/,3IM]]E:$1OM:P/[N1NF"=Y+@^@7TH ]?HKGO$6O2Z=/H=O:^6%U6\%O\
M:G&Y(U*,P(YY+;0!VR>_0X,7C+5[>#6#=I:S-;:M'I-HT4++YKNR .V7P<;^
M5&.5(R,\ '?T5P6I^(?%FDZ7XBNI;* P6-D;NSNYX=H=E!+1LBR$YXR&&!5F
MTUW7D\3Z9IU[+8-#JVG2W$/E0,#;R)LX)+?.#O\ 1>E ':45Q_PRN=1OO!=O
M>:C>+<R337#;O+VMGSY,Y.2#[  8'%=1?WL6FZ==7T^?)MH7FDP.=J@D_H*
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M EB<L?7C\ZC\(Z5:+J.L^(;:WF@35IUDB29&0[ H!?8P!0NVYCQDC:37544
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M8+QCC(&?TQ5J_P# MOJUYKLNH71E@UFUBMIH4CV^6(\E&5LGD%B><]JTI_$
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M1A2 W]HVF"1D ^<M5=(C<?%6Z'B:3S-7CMV_L:1%V0/;'[^Q>3Y@/#9)XQC
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M .(TR*Y^SZ-XHLM?2:-[.0O;)YC_ -H,8BP#9<@.I4G(&1R.!Q6-+Y6J^#?
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M;>.>V4K!(06:,'&0I).!Q^':KVHZ18:M]G^W6ZS?9Y1-#N8C9(.C#!ZCL>U
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ML223M.1G)X KH*@M+.WL+9;:UA6*%<D*OJ3DD^I)))/4DYJ>@ HHHH ****
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MM=8M99;S(MPK9$A&> >F>#QU/:L:X'C5=.U'R-1MWN8]1S9LU@0)8<?ZHC/
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M=YI:WE\S?EEC(;:P..AY44 =>->TMM/MK^.]BEMKK_CW>',AF."<(%R6. >
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M_9GG"2B'[05=2NV/NQ)& /K7":QX6O;[Q#KN@11O'HNOPK>RW"]()D&Q@/\
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MPMY<3:H8HY+=HWD\POL*A@"<@KBK'B2?[;\#[B*.WN%EEL(K2.*:%HW:5MB
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M\^V0(8BVTQL&QCIMQG/MC->6:';7$6C_  QBGT^\5[*63[2KVDG[C]RZ@O\
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M:OJ-E-Y5S9VDMQ&2H8$HA8 @]CBL'[9XKC\%6OB"SOK:^N39)=RV4]N$64%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/<&K] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTV>PT+Q5KNH126TFMZ@DT%LZD2+$K*$W+U#$98CL.O>@#H;;QD=:\!ZCK.G
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M!XY.1TK8\%SZK_:VI6=]>V^KVT,,)@UB*,(TH)?]U)CY2R]<C^_SR: .DO\
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M(/"ZVL\DB[U,V],J6/!8C<<=2.: .T3Q3H$EY':)K5@]Q),8$C6X4LTF,E0
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M6P"H+J"21WX(&:DU?QO;:6+E/LP:YM+=;BYMI;F.-T!!.Q>2'? S@''3GD4
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MV4.DMHSO]KC)3;M>-FP> =C#/3)'K7IODQ_\\T_[Y%-DM;>:-HY8(G1AAE9
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MM;Q;/5/(BA,>T;F2%4&<\*"P&/J<YKO-*T]M-L_*ENYKR=VWS7$V TC<#.%
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ME$_<*1C)V@%VQQN8GOZF@##TWQ7XB'A72-<OI;&8ZPMM!;6T-N08YI#RQ8N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ_,\FN<M?&MI=7FFQ?8KR*'4Y9H;2>15 =XPQ.5SN4$(Q&1VYQ0!TU%<C/\
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M/XUT= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHV^+[#<W2(+B%U"L-YSAAM4@GW_&#6I;S5]*TIS%ID%Q#J]M>O:0WT1$443
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M+8W4!=Q//<DGVQ6;I'AS5]#LH],M-?63381L@6XM-\\2#HHD#A3@< LA]\T
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M&>&^4*K$*,'&!UP*;XB\,2ZWJ^BZG;Z@+*YTJ9I8V$&\N&&UD/S#Y2.HZ^]
M&+KQ7PY\3]$UTD1V>KPMI5VQX42#]Y"Q]SAEK \*ZM=:+-XETA8UMY=29=5T
M=,=%NFV $=MKE21VR:]"\4>&;/Q9H9TJ_)$9ECEWJ.048-QZ9 (^AI+[PO8W
M_B?2->D&VYTR.6.)0.&#@#GZ8./K0!A>)] U>P_X1_4/"L5O<3:'')$NG7#;
M1<1,JJ=K?PN HP3ZGZ&UX*\0:7X@NM5N+>QN--U=6C74K&Y3;)&X!"L?4$<
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M9+0O_P 3MI/)C(!9F21FQD@9))/6NBU+PU-J'B[2=>%^L?\ 9J2I'!Y&X.)
M V6W#T&,#\Z/$/AJ;7=3T>\2_6W&EW/VI$,&_>^"N"=PXP3TH YOQ%=W-U\1
M_ @N--GM MS=X,KQMN_T<]-K&ET^XNK?XO>+#:V)NB;*RW 2*F.']:Z+6O#4
M^K^(=$U9=02!M)>22.+[/N$A=-C;CN'&,XQ^M0Q>%]0M?%6J:]:ZM LNH1Q1
M/%)9EE58P0N,2 YY.: -?1#)+IB7-Q9BSN;@F6> '.U^A&>YX'(Z]:XK5Y-?
M\&>)M7UR#2SKF@:D4DNXK?FYM2B!#A3]],#..V3TZGM]+LKJS2=KV^-Y<32[
MR_E^6J#  55R< 8]3R2:H?V/JUM?ZA<6&LQ)'>2B7R;FT\T0D(J_(0ZGG;GG
M(S0 GA7^P[SP_I^HZ'M>R-N8[9\8*1[N4QVP1@C_ &?:L'X2VT-Q\+/#S31J
M[0F62,GJK>;(,C\"1^-=-HF@Q>'O#L6D:=+CR@Q$LJ[MSLQ9F(&.I).!BJWA
M/PW+X4\+0:'%?+<"W#B&9X<$;F+?, W/+=L<4 <5\1+T7EQ<W]G>!+WPR\=Q
M9P[B!/,,/*#CJ/+PH]RPKT73[FQU_3=-U:%5EB=%N;=CU7<A&?KAB/Q-1Z+I
M4VE:,+*6Z2ZEW2.TYBV[V=BQ++DY)+$GD?A5'P?X9F\)Z*=*&HBZMDD=[<-#
ML\D,2Q7[QRH)X[^] &'X"MH;R3QQ;W$:R1/XBN RMW^2.H-%N;NW^*GCLVE@
MUV2NG[@)53'[EL=?6NE\->&Y?#USJ\K7ZW*ZE>O>NOD;-CL " =Q^7"CW]ZK
M6GA?4;#Q+K.MVNKVXEU7R?-CDLBRH(E*KMQ(#T/.?TH V=$+OHUK/-:"TN+B
M,3SP#^"1QN<?]]$UR'P^F?5/$OC35+SYKR+5GT^/=UCMX@-BKZ Y)/J>:['2
M[*YLH)?MEZ;RXFE,CR;-BCH JKDX   Z^IZFLT^&WM->N]8T>[2SGOE47D4L
M/FQ2LHPK[0RE7QQD'!'49YH P())-.^.5S86O%IJ.BB\NHA]WSDEV"3'J5P#
MZ\>E97PPGO9_AKX>TU]%\_3;DS13SM(I4(7E.=O7[P _'-=OI_ATV-Y?ZH]T
M+C6;U51[J2+Y41?NHB \(,DXR22<DFD\'>'&\)>&K;1!>?:XK;<(Y#%L;#,6
M.>2#RQ]* +GB%0WAK558 @V<H(/?Y#7">'+B;X>7]CH=_*[^&M3V_P!F74AS
M]DF89-NY_NDY*D_3Z>A:I:2:AI=U9QS+"T\31>8R;]H88)QD>M4[WP]:ZOX8
M;0]7"74$D(BD94V9QT8#)P1@$'/44 <!KY:/P)\-&CB\QUU33"J @;CY3<9/
M2N]L)[R\UN<WND_91;0)]GF,@<OO+;QD=,;$X]ZRM1\$R7FB>'-,AU00IH<M
MO/%(UOO,KPKM7=\PP#W _.MB'3]4;48+F]U6*6& ,5@@MC$&8C +$NQ. 3QP
M,G/84 ><+:):6?C/X?.B$7,ZR:8CC@1W1Z@>D;[F/TK:\(:M+XFT7PY878_T
MNQ+G4D/.V2V/EJ&]"7*N/]PUU-UX8LKOQ?I_B1\_:[*VEMT&.&#D8)^@WC_@
M9I-&\,66AZOK>I6N?-U:X6>48P%(4# ^IW-_P*@#7G@BN;>2">-9(95*.CC(
M92,$$>E>9Z)!J&D:M=_#3<[6)C^UVEWO^:/3V8AXSWWAOD!]&S_" ?4*YX^&
MICX['B?[>F18_8/LWD<>7OWYW;OO9[XQCM0!SWB?$GQ)\$^'V14TD+<7/V<#
M"221)^[&/1.H'T]*?\6Y9-.\,6>MV?RZEIU_ ]LZ_>.YPC)[A@2".]=/KWAV
MWUW[',97MKZPF\^TNHP"T3XP1@\%2."IZC\#5>X\.3ZM>64VN7T5U#92BXAM
MH+<PQM*/NN^78MMSD#(&>3GB@#CM7UQ?#OQ,\2ZF^FW5]##H=N\J6X4D+O?)
M8$CCUP#@ \5<\/Z))H?P<U.&2Z@N%N;2[NXQ;,6AC21&8(A.,J ?0=371V_A
MB6'QG>^(7ODD%W;):O;&WX"*21\V[KR<\8]JIV?@N;3-%U31+#5=FE7@E6"W
MEM]YM%D!W*C;A\N22 1Q0!ROP\U:WUJ#0]"UF)K5K'3+6?3[.8#9> 1*?/!Z
M-M.<)_#C<<G[OK%<5??#U+[P=I6AMJ/E7>E"(66I10;9H0@ !7YN"0 #V/IT
MQNP:=K*OIIGUT2"V9OM(2T5?M8*X7=R=I!YRN,],4 ;%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117!>.==_L/
MQ#I4FLM?P^&)(9%FN;-W01W!9=AE:,A@FW=C'&3SG' !WM%<'J8>U^&_B;4-
M/UVYO(/(FO-.NH[QG:-5A&%#@Y(#JQY)Z\Y--T.YT>]L?#R1Z_>OJURL,I5=
M2EEWLJ"20.A<K@A6!X[T =]17#Z+?3^,O$NOF:YN8=*TF[.GP6]O,T)DE49D
M=V0ACR0 ,XQV)K5;PU<M>7*?VSJ*Z=+Y#)$+I_,C*&0NHDSNPVY,\D\$9QC
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M?S=CJP+?>X8#!QG!) H [6BL'4_%=MI<%S*]E>3?8X1/>+"(V-LI&[YLN,D
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M1W144X9B>6PRY)/?)/>M?0->M?$6FF]M4FBV2O!+#.FV2*1&*LK $C(([$T
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MW,]LT:N[1'.'78Q4C((//'?%;&CZTFLB=H[*^MTB90KW4/EB8%00R<\CGVH
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MOEU&R6Y6":#+NACF4!U*L5.<$CJIZ&K5 !1110 4444 %%%% !1110 4444
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MGBI]3T_4)?B)HNIPV,DEC:6=S#+,)$&&D*%>"P)^X<\=Q7544 >7?\(YK_\
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M1MYCPQ%%6/8QR"3G)QP/4\5/"^AZUHICT*Z\,6$\-M.3#K9>(AH=Y8$I]_S
M#CTSSGU](HH YSQQHM[KOAE[?3O):]@GANH(Y_\ 5R-&X?8WL<8_&J6F2ZRE
MC<7T?@RWTR[$7EQVJ30L\KDCDLI "#'KD^@P,]5=7EO8P&:YF2*/(&6/4GH!
MZGVJ/3]1LM6LDO-/NHKFVDSMEB8,IP<$?4'C% '%Z-X8U+0;[5="@@DE\/ZG
M THN@T:M;7+@K( @(.T\,,#Y3P..C/".EZU:V]GI&J>%K"V>Q01/J\<D3"=5
M& R*/G#L,9SC')]J]!JI-JEA;ZC;Z?+>0)>W(8PVY<;Y  22%ZX !YH X_P7
M;^*=#TZT\,WFDQBWL&\M=5%PACE@!RN(Q\X<CY<$ #KGL<75/#OB0^'?%6A6
MVBF8WNK-?V]S]IC6.2-YDDV@$[@PP<Y ''!/ /IFH:A9Z58R7M_<QVUK%C?+
M*VU5R0!D_4@59H X6Y\/ZI>>)/$ZO:&.QU[2XK;[4)5_T=E256!7.2?W@(P,
M>]0^'=+UJ>QCTO5?"]CIDT$#02ZG$\3^=\A0-$%^8$Y!.[&.1].U&J6!U7^R
MQ>0&_$1F-L'!D"9 W%>H&2*MT >5Q:/XJ'A/PYH$V@,9]$U&U=[E+F+RIX86
M^\F6W9*@<%17H'B*"XN_#&J6UM TUS/:2Q1QJRC+,I Y) ZFM2B@#@+#1M8A
MU3P--)I<JQZ5IDMM>-YL1V.T<:C'S\C,9Y'J*U_!&G7^FP:TM_9O;&YU>YNX
M@SHVZ.1]R_=8X..HKJ** /-/&>A^)M=3Q1I_]E_;+>XMD72I/M2)%'\@WAD)
MSYA;.&(QC'*UL65EJZ^/)]9GTB6.V?1HK4;9HF/FK([E?O>C 9Z9SVYKLZ*
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M /G)W+^[/W<GIQ7HM% 'F_AW0]:T:9]#N/#%A=01W+O;ZTSQ$>4SEQO0_.7
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MGC<QV[6\IP92';(V ,2-W.,"F>.GD@OO!4#7]M'=IJJL963"X$,@W%-V=I)
MZ]^M7]4\"OJB7MS)JGEZK<W-M/\ :4@S&@@;,:>66Y7.2<MR3GL  #/G\=:G
M#I'B^:*.SN)]"1)8I3%)%',C1[^4))XY&0<'@BH]?U+Q<D6@R2W>F6L5_J]K
M&B00R.VQE+[7)8=&7G&,CTYS>NO 5W>)XD$NO%CKUO'#/FT7$95-A*X8=N@S
MQW+5J:QX9GU;1]*M?[16&\TVYANHKA;?*L\8(Y0MT()_BH SF\77/_"5RZ"]
MS8VM[%/"L=O=0NAO(6"%Y(G+XR,N HW'Y.>O':5RFI^#Y]:7[/J.I1W%JMW%
M=1%[7]_"4*G"2!L+DKUV]&8>F-#2(M8CUK6&OKXW.GO(ALU:W$1A^]N0$<NH
M^3YCU)- &;J_B74/[3U/3M&B1KG3X4=O,M))A+(X+*GR$;!@#YCG[W3CFOJ/
MBG7+?3HKIK*VTUFTPW1BN@9I&N!UA"(P;"@9+X(P1TP:M:IX2OY?$KZ[H>O/
MI5Q<1+#>1FV6>.=5SM;!(VL 2,\_3U9=^"IY=6EO+?6YHDN-.&GW*RPK*[J"
MQWJQ("L2QSP0?0<4 )I_BN[UZ73;33DM[:ZN=(BU29YT:58Q)PJ!0RD\ALG/
M 4<<\9&K3:W<>)/ ,MY9VMIK#->B2(R%XD;R",Y')&.<9]LCK5N+X?7UBNBW
M.F>(WMM4TVQ73WN&M%>.XMQC"M'N&,$9!W=2:UIO"L\NKZ#J']J%WTIIG;SH
M=S7#2J5<DA@%ZG  P/IQ0 _PAK=[K-IJ4>I);B\T[4);*1[=66.39M(8!B2,
MAAQDU7;7]4U2[UV'0ULQ_9#B'%S&S?:)M@<J"&&P<A<X;G/''-[P[H$NA2ZL
M\EXES_:-\]Z0L/E^6S!05^\<CY1^M53X6N;/7-4U'2-36T7554W4,MOYH$BK
MM$D9W+M;&,YR"0#]0#E[W7;KQ1??#W5=.GAMK>^GEE6&:%I-D@MY0=Q#KN Y
M Z>N>U=CK[WNA^%M0N]!M+,W<"/<^0T1"2MRS\*0=QY.>>:H-X)2W?PTFF7B
M6MKH.[R8G@,ADS&4.YMP[,3TZ_E768R,&@#BH/&KR^*]&LO/LVTO5--^V13"
M)@^_;N"D[L %0[#O\A'O69JESJE[XE\!W96U%Y.UZ\649$1&@)7<,DYVX)&1
MSQD=:TA\,]+'AV/1Q<3>7%J O(Y/XD3>?W0YX7RR8_Q)]JV=5\/RZCXCT35H
M[Q(5TLRE83!N\SS$V'G<,8'3CK0!R]YXTU>'P)K^H3VFG37^D:@UE*-CB&4!
MD 8*22.''!/4=:Z&[UK4KS6M5TG1!:+<:;;1RR-=(SB220,40 ,N!A>6R?O#
MC@UF77@&XNO#_B#26U>-5UF^-Z\@M#F(DH2H&_D?(O/U_"WJ'A'4)/$8U[2-
M=.FWL]NEO?+]E$L=PJYVL%9OE89.#D\?J 8T\FLW'Q)TF2."UL]4E\.RF5)B
M98X6\Z(D?*1OP>.H]<UT_@W7+CQ'X7MM2NXHXKEGEBF6+.S?'(T9*YYP2N>?
M6H8_"\T/BBUUF/4MWV>P:R$<T)=GW,KEV8,/FW*.V.M6?"F@/X:T0::]VMT%
MFEE$@B\O_6.SD8W'NQ_"@#-@U_7-7MI=1T.VLY[6+4&M?LTN5DEC23RY) ^X
M!3D,0"IR!ZG 9+XFU6_MO$%WHL=F8M&GDM_*N$8M<R1H&<!@P"==HX;D9HL_
M!5YINJWQL-?F@T6^N&NIM/\ LZE@['+A)<Y56/48R,G!'6ICX0GMKS6FTS5!
M:VFLL9+J![?S"DK+M9XVW#:6&.H89&?:@"#1_&,^N>(=.MK9(5L-1T0ZG"SH
M?,C;>B[6^;!'SGICIUK-B\<:W-X?\/WT=II[3:CJ\FFRJQ=5&UY5#+R2.(N<
MYZULR>##:ZGI%[HE^-/_ +/L3IQC: 3![<E2 ,D88% =W/N#5&U^']Q:Z5I%
M@NM!UTW5&U)&DM<EV+.=IPPX_>-S].E &-XF\4>(4\*>,[1Y[.#4=(:)/M-M
M"P62*55/ 9R5<!B,Y/L*Z>_U_48-5_L2"2!K^.S%U+.+"66/YG94 C5\C[C9
M);L..>*^H^ VU0>*5GU,*FO+$"$M\& QJ%4@ECNZ#(X_"GZEX/U2YU.RUFQ\
M1-9:U#;FVN+C[(KQ7,6XMM,9(Q@DX.<CWH SO^$L\5SW'AZQ72;&PO\ 5;:Y
M:2*\+GR9(<<_*>5.00.N#2?\)'XUN;S7["RM=$-WHZP,V_S2LQ>(2%5Y!&3P
M">G'!SQMMX5N3KNB:H=6,C:8DZL)8-S3F;&\DA@%Z#  P.G2N?TD7-_\0?',
M&GZK;0"4VJG,7FL,0!2R888(.1R",X^A +8\;7^H:'I^K6,5I:6UWIK7:-<
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M@JNUXNPD$'J N-V1UZ5F^%=;NISXG;5[V-HM.U62".5E6-8XECC8 X]"QY-
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M*[5A:D+<(5(>(GD!D(W#/;(KF_!NKZCXIM=/UY-6VVTJR&ZTYK=2J@D^7L?
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MN1&83*CM&S1GG8Q4C<O^R<BG2Z#IDUY97;6BB>Q4I:LC%?)4C!"@$  @ 'U
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M_#-Q9PSO8O!%#,6C(11M&Q5QU.>F,DUZW10!P'@W4[34-.T+3;GP_=1:QI$
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MJ$NLXB5T8J<J.?EX^O.*Z&+2]3B\;:SK'V13:W6GPVT0\T;BZ%R<CL#O]>U
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M+5(M3MH8KV*:<V_ES1@@2*=K?(03E>M6;_2-=A\6:/KEM%;7\D=C+972M+Y
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MO#%C9ZG=->WT$6V24MN+GG W'&2!@9/7&: .:^(M_K"6V="D(ET=4U6Z1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<IKOB
M22T\7:9X>2\M]/\ MMO),MU.F[S&5E B3) W<DG.>!@#G( .KHKD=4U3Q%I'
MA'Q'J%RUD;O31)+;2+ PCGB6)7&5W9!+%@<'M4^G76OW>E:1?MJ&G$W@@D>
MVC+N5@&<*WF'D+N(X/2@#IZ*Y6VUZ^\0^(]4T[2)(K:RTIU@N;MX_,:6<C)1
M!D !1C).>3@#O4['Q7]MN;1)=/\ +'D&&\:W8C:3)Y@9-XRPVH!@@?-GVH Z
M.BN!L-8\7:GK'B?3+:]TD3:0\:0EK%\3,\0?YOWOR\G'?UK0A\0:D/B-?Z+<
M36BZ9:Z<E]N\DB0;G*D%MV, *3G% '745R7A_6-7\7Z3_;5E<0:?8SN_V*.2
MW\UW16*AY/F'WB"=HQ@=SVS9?&6L7OA36+C3XK2'7=&N&M;JUE0R1R." "IW
M*0K Y!/3H>F: ._HKD+;QE_;7@/4-:TT+;:A8P2FXM+E"QMYXU):-QD'J.O'
M%=3"9ELT,K":8)EBB[0Q]@3Q^= $U%<'=7OCW3[O3!=7?A\B]O8X/L\5K*7"
MG+/ABX!VHKG..<=*[R@ HHHH **** "BN4\9:YJFBWGA^+3I+55U+44L9//A
M+[0RL=PPPY^7I6E%-J-GJ#G4=2T^2QCMS)*1"86B;<-I)+D;2 _8?=ZT ;-%
M95MXET*]O8;.UUBQFN9X_-BBCG5F=,9W  \C'/TYK.A\8Z3J]EK:V.L6EH]B
M\D'VF9E*HP5?WFTD94,V/0XZ\T =-16+_P )'I&G6-M_:6NZ>)3;+,TK2K&)
M%P,R!<\*2?U JQ<>(=&M1";C5+.(3*K1EYE 8-]TYST/8]Z -*BBN2N?&+6W
MQ#L] > "PN(GB%UV^UA5D$?_ '[.?<L!VH ZVBH+J\MK*-9+J>.%68(I=L;F
M/0#U/L*H?\)1H'V=I_[;T[RE8*S?:4X8\ 'GJ2#QUXH UJ*RT\2:)):/=1ZM
M9R0)*T#2),K 2*,E>#U YQZ5/_;&FG3H]0%_;-9RX\N=904?/3:1U_"@"[16
M8OB+1&M[:<:M8F*Z8I _GKB5AU"\\D=_2JY\8^&19->G7]-%JLODF7[4FT/_
M '<YZXY^G- &W15.\U73]/MUGN[R"&)QE6=P PQGCUXYJ&3Q#HL2V[2:O8JM
MS&982;A )$ +%EYY4 $YZ<4 :5%<[J/C?0+#0X=774;>XM)YUMXGAE#!W9@N
M,CIC.3Z 5OPS17$*30R))$XW*Z'(8>H- #Z*@O3<BPN#9!&NA$WDB3[I?!VY
M]LXKC9]6\40>-[#PZVHZ6PN;&2Z:<:>XVE&5< >=T.?6@#N:*X=_$>JZ/XKT
MZQU^_P!/ALWL+F>XD6/REW1R(JMN9C@%6'&>IQS6YJ&LVEQI5E=V'B"PM8KJ
M>(0W+E9$G&\9C3YADMRO'(- &Y15&YUG3;.Y%O<W]O%,2JA'D .6.%'U)X [
M]JO4 %%<E9>,6N?B%=>'Y( EH;<M97!Z3RQMB=1_N[E&/]EJW;S7=(T^=X+S
M4[.WF2(S-'+,JLJ @;B">!D@9]Z -"BLA/%7A^1K)4UO3V-]_P >H%PO[[G'
MR\\\@CZC%6+_ %O2]+=4O]0MK9FQ@32A>"< G/0$\9]: +]%9=[XET/3GG2]
MUBQMW@4/*LDZJ4!Z$C/&>WK5F35=/BL8KU[V 6LVWRIO,&V3=RNT]\]L=: +
M=%<7X8\8QWAUV75=6L/L]OJIL[292L:.OEQE5&2<MECW)K;/BWPX(;J8Z[IW
MEVC!)V^TIB-CT!YX)P?R- &S15-]5T]+"*^:]M_LDH!CF\P%7!&1M/?(]*@'
MB+13;6UP-6L?)NFV6[^>N)6SC"\\G/8=* -.BN>O_&_A^R\-WVNQZG;7=I9Y
M5S;RA\R <(,=SQ^>>E;-O>VMU9B[AN(I+<@MYJ."N!UYZ<8- %BBL72M5MX]
M#ANKS7+._6261$NX0J)(=[850"<D 8X)SM)K3MKZTO+,7=M<PS6S D31N&0X
M)!Y''!!_*@">BN UWQ\ESX)U+6/#=[;^;9W2PG>N\E?.6,G;D8SDD$@]*["Q
MUK2]3N+F"QU&UN9K5MLZ0RJYC/\ M 'CH?R- %^BJ%GK>EZA=/;6>H6T\Z('
M:..4,VWINQZ9[]*EOM1LM-B$M[=16Z'@&1@,\9X]>.: +5%9K^(=%C2V=]7L
M52Z0R0,;A<2H 6++SR  23TXJAJ/C;0=/\-OKJZC;W-F'\I'@D#!Y"<!01WS
MU].M '0T5BC5;>?7;9;?7K$P&UDD:R4JSR#*XE#;LA1R.F.>M2VWB;0KR=8+
M;6;":5HWE5([A6)120S<'H"""?8^E &K15&QUC3=3EEBL;^WN)(<>8D4@8J#
MT)'H>Q[T7^M:9I1 O[^WMB5+XED"X4=6/HH]>E %ZBJMSJ5E:1Q23W44:R_Z
MLEA\_&?E]>.>.U4QXH\/M''(NN::R2N$C9;I"&8] .>30!K45E?\)-H9TV+4
M1J]D;.7<8YUF4HP4X8@YYQW]*GN-9TRULXKR>_MDMI5W1RF0;7&,Y4]QCGCM
M0!>HK-?Q!HT8MB^K6*BYC,L!-PO[Q I8LO/*@ G/3BJ__"8>&_LL%U_;VFB"
M>0Q12&Y3#N#@@'/49'YB@#:HJEJ&KZ=I*!]0OK>U4@L#+(%X'4\]AD9/:HKG
MQ#HMFP6YU:QB)A\\![A1^[X^?K]WD<].: -*BN?U'QKH6GV>F79U"WE@U*=8
M;:2.4%'R<%MW3"C.3[8ZUO(ZR(KHP9& *L#D$>M #J*HW^M:9I;!;^_MK8E2
M^)9 N%!P6.>@]^E,N]?T>PD\N[U2R@?RC-MDG53Y8_BP3TY'/O0!HT51CUK2
MYM*35(M0M7L'&5N5E!C/..&Z=>/KQ6#X8\17&L^*O$MF;NWN;*Q:W%L84QMW
MHQ8,<G)!&#].@H ZRBJ-WK.FV,PAN[^WAD^7Y9) "-QPN?3)X'KVI#K>E*MX
MQU.S"V6/M1,Z_N,\C?S\OXT 7Z*R[GQ+H5FFZYUBPB4P?:,O<(/W7&'Z_=^8
M<^XJ>/6-,FTQ-3BU"V>Q<92X64%&YQPW0\\?6@"[166OB31&M8KD:O9>3+-Y
M$;F=0&DSC8.?O9.,=:1/$^A2VB7<>L6+V[[]LJSJ5.TX8Y!Z ]3T&10!JT5G
MWFN:5I]O'<7FHVT$,B>8CR2@ KQ\WTY'/3FI+O5+&SMXY9KVWB68?N6=@0_&
M<CGYN.>.U %RBN2\&>)GU/PO-JFK7UJ0E[<0+.F$C95E*)CD]0!CDYSWK>BU
MS2I[#[=%J%M):[_+\U9 5WYQM_WL\8ZT 7Z*KV=]:ZA!Y]G<17$6XKOB8,,@
MX(R.X/!JN-<THWXL1J-J;HN8Q%YHW%P,E1_M <XZT :%%8\GBSP["P637-.4
MF?[.,W*?ZS@E.O7YEX]Q5Q-6TZ74I--CO[9[Z-=SVRRJ9%'J5SD"@"Y14%I>
MVM_$TEG<PW$:NT;-$X8!@<%21W!ZBIZ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N1\6KX=U:Y.A>)[-&LG@$\=U*I5(WW$$>9TC; &.1GFNNHH \CA
M2^L_AOXWTY]0N=1TA(9;?1KFYRTLZM#RBGJX#':".N#CBMG1'\,V6C>'[N.,
M-JMO!$L<,(;S&E>/RRK#MRW)/3&3TKT.B@#SKP[*G@?Q1XDL=9)MK+5-0;4K
M.^D!\E_, WQL_164CH<9'2NZLM0BU N]L&>W4#;/C"R'_9]0..1QSQG!Q;HH
M X/P9-&_C_QPP;Y9[FV:)NT@6$*2I[@$8.*KF.'4/BWKELTFV*YT)+3S!TW[
MWW*#T+ ,#CK7HE% '!> ]0A\,>$;;0-?E2QU#3-T#+*=HG4,2KQ?WP01TR<Y
M!&:R[33YK'0_%FOW\;VK:W?I+;V\BD2")6 0LO4,1EB.H'7O7J-% 'F?Q!\/
MWUI;ZAXI\+H)IKJR>WU.S0Y6\A*$"1<?\M$SD'N./8^E1_ZI/H*=10!SQ5M1
M\=!B#Y&DVGRDC@S3'^:HG_D6M2SU6TO[Z^LX&D,UC(L<X:-E +*&&"1AN#VJ
M[10 4444 %%%% 'G_P 3C;RW7A*&<;XTUJ*:=<$[8@C@LV.BY(YK1M[CPY9W
MMZNE!6>[M2UR8\F-$C#88D\9)<#&<GTX-;M]I'VZX\W^T=0M_E V6\VQ?KC'
M6JW_  CG_49UC_P*_P#K4 ><Z2L-OX3^&*A%CF@O4,X"X:/,,BL6]/F*@Y]1
M6C#*L/ASXDZ?/'*EP]U?3*C1-AE>%0A!Q@[CP .37:_\(Y_U&=8_\"O_ *U'
M_".?]1G6/_ K_P"M0!Q5FMI<>)/A^)DCD5-%FBDWID([)$ K9Z$X<8/H14-S
M)I=MKGB7P]XHM]2$6HW DLTMHY6CNX3&BK&NP<,I3&..U=W_ ,(Y_P!1G6/_
M  *_^M1_PCG_ %&=8_\  K_ZU %BZOH- \.&[N$D6.UMP?*!,CDA>$!ZLW&/
M>N"\2>&]0?X?-J,>L(]_:2?VQ#MB4J;H$N0K#D@DE /0@5VO_".?]1G6/_ K
M_P"M1_PCG_49UC_P*_\ K4 <CX@\1V5Q#X-\4AY(#'<.6AEAD*(7@8.DFU2R
ML.QVG\CFL/4Y-&NOAMXE^P7\-_<WVJQWD\$,;9B+SQG8%8!B-J$YP,X8X%=M
MJW@>XOIH+JR\4ZS97<*LBR^8LHVL5+#:P_V1R,=*L6'@YK4&6X\0ZS=7CHJ2
M7#3*A9020,*N  6;\Z ,/Q/=6N@^+=(U>XCN(M!FM)H'N;!&(AF9HV#OL&<,
MJ 9]A67>+8>'7\/ZM9VFJ0>&!/=F:1!*9(WE"E9BA^=5)#CIT;..<5WG_".?
M]1G6/_ K_P"M1_PCG_49UC_P*_\ K4 <'J=KHBVN@3:7;3BSNO%$=Z[W(<F7
M,;!YMK\JFX@9( []"";<BVO_  D7Q)D9(_WUC"B,5'[S]PRL >_.T$#O@5V/
M_".?]1G6/_ K_P"M1_PCG_49UC_P*_\ K4 >>66I+HA\)ZAJ[7\6DR>'X;/[
M3;J[?9[E<%ED"@D;@ .G5/;B[_9^DV.M^ H-/LI8-.CNKR6..Y#%D5XVVLP?
ME SD$ XZCH>!VW_".?\ 49UC_P "O_K4?\(Y_P!1G6/_  *_^M0!YO>_\@'Q
M4\:.T<?BV"[(C0G]R'@+2 #JN5;D>AKU*WURRN=433HS-]I>U%V T#J/++;0
M<D8SGMU]JJ_\(Y_U&=8_\"O_ *U:UM!]FMDA\V678,;Y6W,WU- $M<'J,T8^
M-.CMN^1=*GB9_P"%79U*J3T!(!XKO** .)U8P?\ "V]"DEV;8=-NAO8<([-'
MMY[$@-C\:X\,B_#N*$+@Q^*?,2/:<K']LW[@/[NWG/3%>S44 >9>(9;BP\1Z
ME?:'>K<RO=6PO-#NH]RW9VQ;9(&'(8+MY&1E"3C%=QXBU==$T2XO!@S[=D"'
M)W2'A0<=L\D]@">U:M% 'EWB_0;S0/#6DZW::D][<Z#<)<0((5#7 8XE7*\D
MNK,3ZUIRWMCJ/Q1T#4(F1X#I%P1(RXV,SQE0<_=; ;@\\&N^HH \7D2!/A=J
M\<42K,?$1EC1$^8K]M5@P'7&S)!]*U;Z[TV#Q-XDTGQ.FI&UU=TDLWMTE>.[
MA,*(8U\L'Y@5/''WLUZG10!Y[IT-E:_$UA+"L,4'AR" ><V_RRLC[D+GJP4C
M/.2.:YGPQ>2:-IWP_P!0U%)ETFVM;FVG<QL1:W#$!#(,97*@J">F[WKVBB@#
MQ349+>XT+Q>B02%9_$UM/&&MV D3=;EF&1R,*Y/MS78QFR'Q?NK@^2(AH,:"
M4@;<B5R1NZ9V$''I[5W5% 'BFBW;Z/X8\$ZE>I?+I-HMY;7C6ZOOM7=QY;LJ
MC<!@$=. WO6IJUIHBZ9H<FF6LXLKOQ1%>NUT'/FY!\R7:_*IGU '?H1GU>B@
M#R'Q-"]T/BC#:1-*\UI:M&L:D^85C(?;C[Q& #CI7J=C?6][IL5Y"Y^SNFX.
MZE./7# '%6Z* /(-#@BE\#:'&NK3:+J%OJ%Y):W?E@I$QDEPLJMQM9'XSCM@
M\\]_X+N[Z]\-12ZC:06]SYTP8VX(CFQ(W[U >=K_ 'A]<UT%% 'C-[(!\*?$
MNE20S"[36)=T+0MDAKP.,<?-E?FXSQS6IXJMYK[Q9K5MHNWSKCPHT$!BX5W\
MQB$!'&[:>!Z'/2O4J* . \+WOA_Q%K&G:C:6VJ'5;*!XY%N5E0689<,C;@%)
MR  !GID=*/%E^NA^.=.U/5#?1Z++8/:BZM0[""8N&^<("0&  SZJ*[^B@#RU
M[#2++5/ L6GV<L.G+J%U.B7(8LJM$^'(?E SD$ XZCH>!GZJID\+?$%+>-W!
MUR&Y5(T)+1AK<LZ@=1\C9(]#7L5% '"W-[;7/Q2T.\C8B Z3<@R.A4#+QE0<
MCC(5B,]0*YNPT^2X^$6K?V99>;J,=_<2F)$VRR1_:M[*.,_/&N!ZC%>O44 <
M5X7NO#VO:]_;FE)J,UXMF;>:XNA*@B7<&$1#X!;.3QG&#SR,YOC"\1O$&LV'
MV::VGFT,K'<16[2R7O\ K/W2G!554G)XR=W4 5Z/10!Y(FL6ND6_@'6)998S
M%I#V[I<6\PC(\N(-RJ,5?<!CY<$ \CC-=ET4>%?#D%E?P:BB^)H[BY,<9"Q;
MG=V!4C*HH<#)'0Y[UZ+JOA^[N]9CU;3M:N+"Y6#[.Z>4DL3INW?=8<-D]01G
M STK1T[3OL*R/)<275S,099Y H+8& ,*   .@'ZDDT <-KUW:^'/'BW&II=V
MVB7FG+#!<6<;F..82.SJP0'&\.ISCG%9N=/\(:QH\LEMJMAX9DTY[:VD7S7:
MWD,S/B0#+*'4J0#TV@$#''K%% 'E_P!@TJPUGP#!I]G+;Z?%=WDL:7(8LBO$
M^UF#<H&<@@''4=#P*-]';MX8^**I$AEN;F4P@)S+F% -O][YPV,=\UZ]10!Y
M;<ZI::9XG:77GOUTK5-*MHK6ZMUD>/<F_?$VP$Y._(X]:L6MEIVG^./"$%O:
M/;6EKI=TL27)+-""T9C#%N58@-@$Y'([5Z510!XU;L(/#VFS;)/L]IXSEGDV
M1L?+A:27:V ,[3N7!Z<UZA9^(M.OM;N='ADE%];1)-)')"R?*P!&"1@XW+G'
M3/-:M0+9Q+>O>'<TS)L!8_<7KA1VR>3W/'H, 'GOC*\5M<U[3Q;36T\NAE8Y
MXK=I9+[_ %G[I3@JJJ3SQD[NH JKI$MM<>(?A],Z<0:)*CM+&5V/LA SN'!.
MU\>N#BO4Z* /%K*YDTW^S-1DBE;1;'Q/J$EVL<981K)Y@AE*@9V MG/3D&NO
M\(W=O=_$+QA<6RR&"X%D\<WDLJ28B()#$8/;ZUW5% 'F?BJ2YL->U6_T6]66
MZ+0I>:'=Q[DOQM7:T)^\'P<<9&5YQ46K7<>G:]\0K:Y299M1TZ)[1%A9O. M
MV1B"!C@]?2O4:* /)],N-/@\4>!Y=05(57PVZ;KJ/9L<>2.=P&W^(9/K[U12
MSN/#]M'K(M;Q?#J^([J[\NU1@\-O)$8UE51R$#[FP!]ULCK7I5QH$D_C"TU\
M7@7[-;/:B#RL[E<JS$MNZY48XK<H \DUZ'09]#COM*@N9+:_UVRGFFN%D_TC
M;(OF.$<9VA1RV #SZ5M^+H5M=72\T75H=)U.*S9U2>(-:7T;,28V'][<,Y!W
M?-W[>@44 >3+JD5AK?F>*;+4--L=7TBT2!8$D>.)E5A);ML!(.7X!'<]ZN64
MEOX4\:Z6UU:W-EH3Z*+33VF#N()!*6,;GDJS+LZ_W0.U>FT4 >*V%S)IVB:9
MJ36NH#2K'Q!?M>"""1'B21I%CE"XR57=SCH#6[<67A^ZTLWVDWNHZ8+W5$N(
M=6=7(^TB)_WA20?ZL@;"2 "3[9KTVB@#FO ]WJ-YHUPVIPVPN([R6/[3:J5B
MNU&/WR@]-W/MD$BO/[G48[@:1(EK<V?V7Q3YD^GQ6CL( 7DS([;269B=W! P
MV #C->RT4 >.:G'!+X/^)P2)6GN;^0P@)\TH\N+;M[L-P;&.X-=-XJ^UZ;=:
M-XPT: 7=P$73[B%3_KXIB!'S_LRE#]&:N]K&?0II_$/]HW.JW,UFA5X-.*((
MHY N-^0-S=2<$X!Y[# !=TG3UTO2K>R#F1HD^>0CF1SRSGW9B2?K5RBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "L;Q'XCM_#5K:W%S:W4\=Q=1VH^SJ&*L[!02,@D<]@36S7%?
M$QI%T32&A022C6[$HA;:&/G# SVH FC^(%LKZQ!>Z/J5G>Z7:_;7M)1&7EM^
M?WB$.5(&.1GKQ5+5O%MCJ'A66\U3P]JZZ4QM'1]RIYOF.I0@K(& #;<]^1P0
M:DUCP]J.L7VM:N+,PSSZ+)I5I;O(F]BY+,[D$J!G:!@DX!/<"C6]!U:_^%]G
MH4-HO]H)':(Z-*H4&)T9CN[@[#CZCI0!OW?B!8M1N=/L;*>_N[2%9KB.%E78
M&SM7+$99MIP/;DC(SDM\0]/ECT9]/L+^_&KQRM:^0J#+1J2R,&8;6!&.>.O/
M%$6EZIH_C75-;M+,WEGK$$'G0B55D@FB4J/O'!4J><$D$=#65IG@W4M%O_"9
MCA2>/3Y;R>^D20 ![@'A <$A2WMP/7B@#MEU)5T/^U+JWGME6W^T2P.N9(P%
MW%2%SEATP,UF:9XKAO\ 5H=-FL;FSGGL?[0A\XJ0T6X*<X)VL"RY'OU-:>LQ
M7\^AW\6E3)!J#V[K;2N.$D*G:3^.*XC2=$U;3/$NGZ_?:;96=M#I,MM?R/>>
M9)NW(YD=MOSYV'J3QU(Z4 ; \?6;P:5=1:=>S6>K3&"RFC\O]XPSC(9AM#!6
M(]AS@\4ZT\<PWE]=PKH^HQP6-U);7EU((Q';E(PY9B'/RD'MGWQD9Y#08M3T
MW3-(NK[PP9M*LY#=6I@U.-HX/,SAXXF56. Y"J6)&<#G%=-I/AN^EL/&&GZA
M";:'6KN>6*175B(Y(ECY /##:3Z<]: +5KX]TRXUC3]/DC>'^T8WDM)6DC8-
MM7<0P5B4.WD _P ^*9'\0=+DOM,@$4GDZHQ2SG62,AVQE05#;EW#ID?7%5O#
MUEXHDL(]'UW3=/MX;>$P2W]O/O:Z7:5!5-H*$\$DGMP.>&>$['Q7I-I::)J.
MFZ>;;3U$:ZG%,"UQ$G"@1%?E8@ $EL=2* )%^)%H=-@U-M&U1-/>\-E+.5C/
MDR>88QE0Q9AN ^Z#U]>*T;;QC:F^U2TU*SN=+DT^U%[)]I*$-;G=\X*,W0H<
M@\US!\+:Z? #Z-]A7[8=7^VX\]=OE_:O/ZYZXXQCK[5H:WX5O]?\2:T\D)M[
M'4="&FK,74LDF]VR5!Z?./R_&@#1M_'5E-K,&E-:3K<W5N\]JJR1/YVP99.'
M^5P#G!P/>H--^(=IJ4>B7(TK48;#6)/)M[N4(%$N&(0@-NY"GG&,]ZD\.OXK
M$<<>M:/86[6L9#SVUP)#>,!@;5*C8#U.3GMCFL*P\*ZY:^$/!>EO9*;C1M0C
MN+K;,NTHH<':<\D[QP<=#0!J:7XYD:T\0WVJV$EK:Z=J+6B'?&1QY:!2=W4L
M^<GY0#UXKJ-/OY;R2XCFLIK9X&"_.RLL@(!W*0>1SCG!R#Q7)VN@ZQ90>)[.
M32K&_M-0U)KN-)9AB>.0QAT*D8!"J_)[XJ_X,\/7'AY]3BC^T0:1+(C6-C<3
M>:UL OS@')PI.,+DXQ[T 3ZWXP@T5M29K"[GATN!)[R6,* J-G&W<1O("DD#
M^?%%YXO2#7ET:VTF_O+N2R^VP^3Y821-P7AF88Y/\6.G&<BN?\6^&_$6N3^)
M+46MK>6=Y8B/37FN-HM6V$.-F#\Y8YW>G&1C%:-CI6L1>,[#5[FP58(=%-E(
M(IU8B7>K\9QD87&>.3Z<T 7K/QK8:AHVE7UK!</-JDC16UH0HDWIN\P-S@!=
MC9.>W&20#E^!YI9?%GC02Q7$.R]@ AGDWE/W*DX.3P221['H.E8^G^$O$>E:
M?X:OH+2&34-%NKTRV;3@+/#<.S':_0,H*]<=#^/3>&-,U>U\3>)-2U"SAMX-
M2F@EA"S^8PVPJA! &.WKU]1S0!I:CX@6TO9K*ULY[Z[@M_M,T4)4;$)(7))'
MS-M; ]CTJ&+Q7;78L([&TN9[N]M3>);.HB>.(8&9-Q^7D@8YR?8$C*U'3?$.
MD^-Y]=T2RM]1M=1M8[>ZMI;GR&C>,ML<,005PQ!&,T^?1M9L_&%CXF1([YWT
M\V%_;1,$(&_S%:/=@'!)7!(.,'K0 ]OB%IPL;.Y6QOW-QJ/]F20JB[[>X&<H
MXW=>#]W(Z<\U6U7Q]+;^&_$MU!I%S#J>BIF6UN7C^7<FY'W*Q!7'. <\8JA/
MX/U2,6US%;I)<3^)%UJZC64 11@%0@)QN;;M]LYYZ9EU7PKJ^IR>/$6!(DUN
MTBBLW>08W)$4.X#)&21CKQUQTH WY?%*6L%G%/;.-0N(#,+>2:)"%7 +%BVT
M9)&!G/MP<4+3XCZ;J":*UE87\YU8S)"$5,I)$K%XVRW#?+C/W><YQ5*^TOQ1
M!JNE>(K'2[*YN$LC8WNF270'R;@RLDA7&X'.>.A[]:MW6DZW=>(O"VI36< %
MC+<2W202C;$)(BBJN<%\9!)P,\X]* &R?$:&+2K^_DT'5 NF3M#J*_NLVVW!
M)SOPXPP/RYXZXXS>U'QFEIK<FCVNC:C?WJV:WB+;B/;)&6VY#,PQR#UQ[9S6
M#=^&=:N/#GCBP6R FUNYDEM,S)@*T:)\W/!&PGOU%/BFO+3XJQ;=/DF<>&XE
MDB21 RD3MZD C/O0!MZ?XYTS5=,TRZL8KB6?4I)(H;1E"2J\>?,#Y.%VXY.>
MXQG(J"\^(%A8:/JU[<6-Z)](E2*]M $,D1?&QOO8*-D$$$\=N#6/;>"-4T>X
MT76K417&H6MY>7-Y:+)M5TNCEEC8X&4PN,X!P>E)X@\'ZIJFF>*[JWME74-<
M-M'%;O*H$4<.,%VZ;C\W3/\ "/4T =(OBJ9[J*S_ +!U**ZGDE6&.8(H=(U5
MC(6#$*#O  /.>W!Q5'Q L'TG1-1BL+^6'5[@VT(1$+)*-V58;NN489&1QU I
M^OV>MWVLZ1-!9Q76EB.07=C-<",>8=NQVP&#JN&&WGKG!P,<WIOA3Q!9^'_"
MVGRV$!;2=8>\E,5P"&B)FZ9QS^]&!Z#J.E '3VWC:R>TU26^M+FPGTRX2WGM
MIRA?>X4Q[2K%3NWJ!SUZXZU%%\0-(6XU2WOMUI+IUL+N3+I*KPDXW*4)R<\8
MZY(ZYK%U3PAK6I77BJ:!8K6:\N[.]TZ65PRF2W5,"0#D E/?@_A5O4=$U_QE
MX1U+3-5L+/1)9X D2PS^?NE5E<.2%&U<J!CDX)ST% &V/%*QZO:Z7>Z==6EU
M>Q/+9K(R$3%!EDR&(#@'.#QCH35:#QU8W&BZ'JJ65X+;5[M;2+(3=$[,RC>-
MW3*GIFHO[*U/7M:\/ZAJMDMB=),DT@$JOYLS)L 3'\ RQRV#T&.M<Y:^%O%$
M'A[0=%&GVFW1]82Y\]KOB>)9';( 4E>&'7G/;N #M(/$T=W>216MG//#%>&R
MEG1DQ'(.I9<Y"YXSCKVQS5_5]6M=%T]KRZ+%-Z1HB#+2.[!511W)) _^M7'S
M^%KVX\56^LVMB=,U)+_=<7MO.!%>6@8_+(@.6<K@<KP>=W:MOQKH%UX@T.*.
MPECCO[.[AO;;S20C21-N"MCL>10 2>+X;6^O+"]T^Z@OK>T-ZD *-Y\(.&*-
MNP2#U!(/U'-5+/QVEYIMO?KH>JI;W:VWV1V1,3M,< ##?+M/4M@8Y&01F'4=
M$U'6]6_MJ:P:VDMM,GM+>V:5&=Y9<9)(.T* HQSDY/ P,PG1O$=M\.] TNSB
M5;RQ^S17MN+C9]HAC&'59!TS@'MQD=Z &^*==BUKX?\ C&)([FTO-+@FBF3S
M,%7$6]2K*>5((/\ ,5V&D$G1;$GD_9X__017 GPGKBZ1XXL8M,LH$UI/]$2"
M<;5+0K'@C:, $$D_D*[W3HKB+1+:%T\FX2!4(8A@K!<=NHS0!C6'C2VO;[2H
M#8W<$>K"7[%+*%&_RP2=RYRN0"1D=.N#Q4-YX]LK2TEOEL;NXL(K[^SVGBV?
MZ[=LX#,/EW_+N]>V.:Y[3?#7B@:GX7U&_P!/LWOM.GF^WW37FY[C?&R;P=O"
MC.0O;I@ 52MXK^2&^O8?#L>H^'Y=3EU%/L^JQI"^QR1)L=0>JAB-^TMSC!H
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M^J.8[.X62-@[8RH*AMR[@.,CZXJ"[T/4;[Q-H%V]FR6EKIUQ:7)\U=RM*$'
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M=,J<Y4X/'!''K:C\4:OIFN::NKS6DMAJ&ESWI6" JUNT2HQ^8L=X(<]AR.U
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MN74?Z0>0FX?^A<>]+HWC;4M<TS0(8[<+J&H6D]S<- BL$$3B,[%=@.6;/).
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MWUT+B6X@$I8IALG).3DY.<\\5UE !1110 4444 %%%% !1110 4444 %%%%
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M1-VTCG.?F/6LV#X?+96^AM8:O<6U_H\)M8;H1*WFP'&8Y%/#= <C&#S7:44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *X'QWJ[:)KVF7FL07LGA;R9$N)+0OB&<LNUY0AR4VY [9/3.*
M[ZL6_EU>#6-T.GB^TM[<+)&LJ+()-Q^ZK$*00><D=L9YH YC45@C^&7B?4=)
MURXO+5X)[RQN8[UW>';  %#YW<,K'!/?FET*;2+NP\-Q#4=5_M.Y6&3<;NY(
M9D3S'#!FVD$*P(Y^]5:/P9>VGACQG!I^G+:_V\'6TTU)4"VVZ+868YV@LV6(
M7( P!FM[3_[<M?#^EZ<NA[;NVAAA,\L\9CB(4(T@P23@;L# STXS0!GZ%=2>
M,_$OB&6[FF&EZ3>'3K:TCD9%:1 #)(^TC<<D  \ #IGFMAO"FZ\N1_:FHKI\
MWD,+=;R4,A0R%@KAMRJVY,@'^''3IFV6BZKX3\3ZO>:99?VCI.KS?:I8(Y52
M:WG(PY <A65N#]X$'UKJK*2]G+S74 MD( C@+!G'J6(XS[ D#'4YX //M$T8
M:MXI\;:7+J>L)#:2P1VC)J=QF#? &)'S\_,<\YJW]J:Q^+&L--=7C6=KH:7G
MV?[3(8P^]MS!"=N<+Z5I>&=*U.Q\8^*=1N[(Q6VIS0R6[>8C$!(PAW '@DC(
MZTR/1;^3XEZCJMQ8$Z5=:6ECN,B$DAV8DKG.TAL>OM0!!X*@?Q;X5M_$&MS7
M$EUJ.^5(X[AXTMH]Q")&%(P0 ,M]XD]>E81O]0U?PUXLT.YU*\CU'0KSR+;4
M(9FCD,;D&-GV$;F X.>#CWKI?#&G:MX-T4:"MA)J=I;._P!BN(98U)C+%@LH
M=A@C.,KNR #[55A\*7^G^'=:D\I+O6M9N_M5P(G"QI\PVHK-C*JHQG&2>P[
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M()]2UJT61)Y(FQ'&D"NY8;\N^2!U4'=G'&#N^']?N[S7M9T'4HX?MNF&)Q-
MI5)HI 2K;225(P01D],CK0!J_P!BZ5_T#++_ +\+_A1_8NE?] RR_P"_"_X5
MS/B_Q3JV@)JL\*V20V5F+F".16EDNB-Q<81@8U  &X@C+=>,4^X\0ZY<^+;;
M1M.73X8;K23?I-<([M&P=%P0&&X?-TR/7/&" ='_ &+I7_0,LO\ OPO^%4[2
M'PW?W%U;V=OID\MJP2=8XD;RV(R <#@^U<]I/CB]U32O#L/DVT6KZM/<PL<,
MT48MV<2.!G)SM&!G^+D\4_P8MTOC?QNMX\+SBZM<M"A12/LZXX).#C&>>N:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+3Q)HCK<,NKV)6VSY
MS>>N(\-M.XYP,-QSWJ'_ (2_PSS_ ,5%I''7_38__BJQ_ 5K!>>$9H;B-9(_
M[5O'VMTRMW(P_4 U6TI$?XQ>)T=596TRT!4C((R] '76NL:;?7DMI:7]O<7$
M2+))'%(&**WW2<=,XXJ[7F[1:A8?$+78=!6RA:WT2T"?:E9T55:7"[5()SC&
M<\>]:-CXWGU>RT-;2%8+S4=-_M"0FW>X6(95=H52"<LQYR,!?>@#MZ*Q_#.H
M:GJ6BI/K&G_8;Y7='CY"M@X#J#R PP<'D=*YFS\7Z\T.N:G>0Z8FE:)=W<-T
MJ"0S2)%&&4ISC.<9SUSVQR =]17'VFN^))M5LHO[/BFL[NW=GF%M)"+20+N4
M,S$^8IY&0 <CWK&L?''B2XT'POK3VVE&#6;A+1[=1(K([[]KA\D  KR-I/OV
M !Z337=8T9W8*JC))/ %<;;>)=?5_%&GRVMA=ZEI"Q20-$3!%*LJ%ANWL=NW
M!R=W(':G:7XJOKW5];TP-9W1L[.*ZMKF.%XHY ^\8(+-D93AE."#[4 =58WU
MKJ5C#>V4Z3VTRAXY8SE6![BK%>>V/C'6;G3O!+6MIIJ'78G\Q2'"Q%86<;0#
MT&.G?IQU$UOXXOX--O8;^&T?5H=:71H#"&2&61PI5R"25 5B2,G[IP>: .Q3
M5+"74Y--CO(7OHHQ+);JX+HI. 2.WXU;KS6[U.X\/_$;6M4U9X)TL_#0G!MH
MC'N59G.W!9N<Y&<]Q6[:ZUXDDUFWMVL(IK.YMW8W MI(1:R@956+$[U;D9 !
MR.G- '6T5R/@;6_$'B32;+6=0CTV&QNK8NL4 ?S5DWD<DG&W ^N:M/K=_J7B
M+5=&T=[2&32X8FFDNHFD#R2AF50%9< * 2>?O=.* .@N+B&U@:>XE2*)/O.Y
MP!5?3M5L-7@>;3[J*X2.0Q2%#RCCJK#J"/0UYSK7B&]\3^%?"VI6YBLFEUVV
M@N+>2,R;9DF((R&7*ADSC'/'(KNM32?3O#FI7-D;6'4/(>9YUM_E>4)]XKNR
M?N@<D]!UQ0!=NM4L+*ZMK6YO((KBZ;9!$[@-(>N%'4U)>WMMIUE->7DR06T"
M%Y)7.%51U)KS"6;4Y_#7PSN9IH;F\FN[>1'960?-:.?G.6).<DD8SZ"M:X\7
M:S;^'/&!N[?3I]0T%F!*QNL,\9B6094L2#AL$9H [Z.1)HDDC8.C@,K*<@@]
M"*=7#ZSXTGTZ]M;%I['3Y+K3TGM)[V)C!<3G=F(.&4(1A>I)._VYZW4;B>UT
MBYN8%C:>*%I%5R=I(&><=J +=%><VGC;Q&EGX5UC4;/33I.MO!;NEOO\Z"25
M?D?)."I/;&1D<FKMSXPU6QUC3X+J*R"W6K'3WM8PSR0H=WER-*K%0Q"AMA .
M&]B: .YHK@-7\<:G;:5XBU.RM[79HU^MD;69&,DW^K!8$,,9,GRC!SCWXO:A
MXEU<W>HZ=ID4#7^G6\;2@VLLR2S.I8(-K#8, ?,<_>Z<<@'8U6L-1L]4M1=6
M-S'<0%F021MD94E2/P((J/3+JZOM&MKJXLVL[N6$/);2G/E.1RI(ZX/>N*MO
M'5S!X(T_6KV"VM$FU":VNIXH'DAM46251(R@YP2B@G(&7S[4 >A56M]1L[NZ
MNK:WN8Y9[1PD\:MDQL0& /IP0:K:%>RZCI$5W-<6=QYC.4FLSF*1-Q",.3U7
M&1DX.:Y2\\7:K9V7CB>.TL//T)@T7#8E7R5D^?G)."!VZ4 =[17&VGB'7?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#YSC '&.HZ]J-:\/S:CK6DZO:7JVUYIHF5!+#YL;K*%# @,IS\HP0?P-;M%
M'(:GX&&H>'=3TX:AY=UJETEU>79@W%F5E("KN&% 15 R>!W)S4.K>!+G5+C7
MV&N-#!KEJD%S&MJ&*LJ% 48MPO.2O/?!&:[6B@#F+3PM>6OB*VUAM5262#3?
M[/V/:XW#<'W9##'(''IWSS6;;?#Z>#2=$TYM6ADBTN_DO5W6?^M+F0E6&_I^
M];]/Q[FB@#D]-\)ZGHFBZAI6EZ_]GMY'9[ FT$AL06SL7<Q#*.0 1QG\*@\3
M7$4_B[PE:1RB6XM]19YE4<HIMI1N/H.1^==G10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY1DX!ZCD_6@"U17.ZYKUS9:MI=G9QQNDU['!=2/SL#*S!5_VN,^PQ_>%=%0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_KWA"T\07UO>7&H:K
M;R6Z%(Q97KP!<]3\N.3_ $KH** ,G0O#UKX?AF2WN+VY>9P[S7MRT\AP, ;F
M.<#GCW/K6M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:]IKZSX>U'2XYEA:
M\MI+?S63<$WJ5)QD9QGUK1HH S;S3)+W1H]/DF4 ^6LQ"\.BL"ZXSP& *_0U
M'JNF7>J^?9S7%M_95Q$(Y8O()E/7=A]V,$8_AR/Y:U% &5+I,TGBNVU@7"".
M&SEM3#Y9R=[HV[=GMY8&,=ZR5\$6[Q6]C<3^9IEK+<RP0!,,#,'4@MGD*)9
M..X].>KHH X^?P*+ZRA@O;X/+:V LK::.+:1AXW#L,\G=#&<<#AO7B\?"-G>
MW]U?ZH!/<W!B/[EGB">6K*N,-G/SOSGH<=JZ*B@#F=%\-7GAS2H-/TN]MQ$)
M9I)VN(7D+;VRNW]Y\N!P>N>O'>_:S:?H-E;Z5&MUY=I$D2[;61Q@ 8Y5<'\*
MUZ* .5U'P7I.M75GJ,8FAD6[6\DR\H\S (QM+#:3D<X[5U5%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>fifthamendmenttoamendeda003.jpg
<TEXT>
begin 644 fifthamendmenttoamendeda003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "B@YQQUHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!&8*I9B  ,DGM68?$NA!-YUK3MF[:6^U)@'TSFM2O)+6S\_X/ZW;W$1/
M^G2*3$ &<"<+Q\N >"._KWQ0!ZI->VMM:&[GN88K8 ,9GD"I@]#N/'>E-U;K
M:BZ:>);<J'\TN NT]#GIBO(=4U"]\+>%]8\%ZT\LR-9R-I-^P&V:, ?N^.C*
M/T].,^QXW+A@#D8([&@#-?Q'H:6ZW#:Q8"!V*K*;A-A(P2 V<9Y'%6WO[.)H
M%DNH$:XP(5>0 R$_W0>OX5X9J=K)!I&N?#J&W$MW'J"W%AD-S"RM(2 "<8"X
M_P"!].]>A^%]73QI?:5J[!#]AL0[B,D*EU+E6 !]%4]>@<=<T =0==T@+<,=
M5L<6W^O/VA/W7./FYXYXYJI'XP\-2R*D>O:<S,I8 7*=!G)Z^QKEO!5M%?>)
M_'$5U$KH-5C?:>F4)93Q[J#_ #JYI<4,_P 4_%4,J*WF65LK @Y*E2".N,?K
M0!U.GZYI.K.Z:=J5I=N@RRP3*Y ]2 :636--BN[BTDOH$N+>+SYHV< I'_>/
MH/>O-M7T;4K/QUJ&L>&4'VC2+6T3[$#@7$!5]T?UPBX^E7=+UFP\4:AXEU?3
MY$(DT.%/G(_=,?/W*XZ @@9SVYZ&@#M!XGT%L[=9L& QEEN%(&3@<YQU-6;S
M6--T^;RKR^MX)-GF;9) "$SC<?09(&>E<#X).I3^ =#TQM!A?3)U"33-<[LQ
M,26;: "#D^O%2:Q!XB\+^+-4\1:-:KKEE>)&EY:"3]];E%XV^HPV<8S\WXT
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M(7=DGD # ^[5NZO_ !580:'<:A>Z9/\ ;]3MXU066&A613D!MV..1D#/OVH
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MB&/7-#TVXGFM4U"YM5GDMHW&1D<D*23B@!-#\,1Z'JFJ7\5Y+*^I3>=,CJH
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M]N+2^BB\F3R=NRX3.0'!'.*JZ7X0FT<W_P!CUZ]3[=</<RYBB.)&ZE?DX_\
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M?0CGK5'13KVKZ#JB&%H=2\/Z?+I=M(JDB6?D,R\]=J1@<=6)'I7J]( !T %
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MV;H-P 4?0^M<1XAMFM?A_P",5C=5TJ[U&-]+4' D^=2_EK_=R#R.N":]NHH
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M*L?P\UD--Y;/!L3C)8DCY0/?I6'<WMG-XP^']S'<P*'M+E78$'=F- JD^[9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M="@NS"[K<$RO$'V&51C YZ*3R.XS0!W5%<3/XRU"WF\00R6UFC:?:I>VA9V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(1DCDC'ZTM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8GPXL_(AU*9U*R&98R"<]%W?^S?I5O0='GN[R37M5&;F09AC92/+XQG!Z=2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGK6A%+'/$DL4BR1N RNAR&!Z$'O40L+,*5%I  3N($8ZYSGIZU.JA5"J  .
M!VH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG][<QW<J2./0L&Z=,#H,"F7'@O1;K3H+":*X>"&X-T,W,FYI2<[V;.6//<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9W$J.V2 ,D]L\XQ=3M[XW_ASQ##X;FM;*ROKF6:TMX@9U210HD9%ZL2"QQG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0VOCQ+E-*O18C^R]3O6LH)UE)D5]S*I=-H !*G^+(XX] #L**\V\'^)Y=/\
M#^GV#6_VC-M?3I,\Q#$P3$;6R#U!'S9[=*NZ/XRO_$&N:;%#9PQVM[H[WGDO
M<<[_ # N"=N>,$<=CGVH [RBN$\/>*OM>GZ=IFC:;!!=R64MTL%Q=LRHJRE
M Q&YLD'GM[]*K_\ "R;J]@CETO2;=T;2I-29YKLC8(V*NFT(<G(P.1U[=* /
M0Z*XI/'<DVH:9$+.*VM[^"UFA>ZE*>;YI^94;&TL@P=I(+=O=OQ!MA)>^%I>
M KZQ#;RCH9$8,=I]5XY% ';T5PB^.]16[N'GTFV6PM]8&E.Z71:0N=H# %0,
M98=2.OMDZVC^)+W7)X;FSL8'TI[B:W>7S\21F,D!BN,$,1C Y&0: .EHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,\^M &G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*UQJ$XNK>182C6LRC"LK;B?KZUC^'/'FN7":$;Y[2YEO[V6TN+>./:\*H?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*",CKBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>fifthamendmenttoamendeda004.jpg
<TEXT>
begin 644 fifthamendmenttoamendeda004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *15"C ]2:6B@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBD&<<D4 +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(1D
M$ D>X[4M !1110 4444 %%%% !1110 4444 %(I4@[2",GH<\]Z6FQ_=/S;O
MF//X]/Z4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D4Y
M'4GD]1CO2TU,;3C'WCT^M #J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ IJ=#\NWD_SIU-0[E)']XCK[T .HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 165@2K @$@X/>EI
M  .@Q2T %%%% !1110 4444 %%%% !1110 4444 %,C.5/7[QZ_6GTR,Y4]/
MO$<#'>@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"XTZSNKVTO9H%>YLRS02'K&64JV/J#6/X4\,IX=&IR!((7U"[:Y>"V+>4A(
MXW<Y.,D\#T Q0!Y[\2KV[2/Q1?:=?7C3::;4"47+0)8M\IV1J"?,9MP+9  !
M R<8K0\;-J,.KZS?W N;S0H88XFET^]9)]*<)O:0Q J'!#*QYSC':NVU/P5X
M;UF:ZFU'1[:XENU59G=3EMH(!]F .-PY]ZBE\">&9I [:6HPJ(R)*Z(ZH %5
MT#!7  '# C\S0!T2L'174Y5AD&EH  &!P** "BBB@ HHHH **** "BBD P.I
M/UH 6BBB@ HHHH **** "FQYVG.?O'K]:=3(_NGK]X]?K0 ^BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHKF_'&K2Z9X=>.V,BW5ZZVL<B1LWDAR%:4[1P$4ELG
MCB@#)\+>/3K_ (XUC1GB,=JL2W&F2-@>?$"8Y&'J-XR/;TKI=;UW3M(MV2[U
M*&SFDC9HRY&<#JV/09')XYKSKQ+X>O\ P@_AK7K/4+S49-*GCLTMHK)-QM&&
M)%Q&N3A1D9Z<GJ:T%U9-/\<^(+[4+6]GTW5["V.FW,-I),C(J$-&0JDJ2SDX
M(YS0!I>$?'%DW@C0[[Q'K5G#J%_ TI\Z18S)@MDA>. !Z5K+X]\)NL+)XAT]
MA-)Y2!9@26R!@CMR1UKS7P]"W]E?"Q+FPND^R3W G$UHZB([&"ELKP"Q7![G
MIT-1ZI9B7P/\28(=/G,][J[26JI:ONG!\LAD^7YAE7.1QU/>@#U.\U%(O%EG
M;G7[2"-;666?36">9(.,2Y/*JN&]C^%-A\<>%[BZM[:#7K"6:YE\F%8Y@V]\
MXP"/?IZU@7\RR?%'PS=HLC6ZZ9<!YA&VU2^PJ"<8!.TX!]*XF*W(^&2Q_8I_
MM(\3"Y"?97#A?/W>9C;D#R^<^E 'J<.J0CQ3J>[Q):26EK:(TUAA ;1@23(\
MF> 1V;TS575_B'X>TS0M0U)-0AG-I")/)4D,Y8'8 ,?Q%3@^Q-<OJQMI?&/C
M5KNSO+BQGT2*)A#&P,NW?O5&Q@L PZ9/UK%U:#6'\*^+=,AN)_$%NNDQ?9[J
M>R:*= )#^Z;@;V5<MG&<]10!Z5%X[\-?9(I;G6K&W=X//:.28*RJ,9.#SC)Q
M[]JLR^+?#T%REO-K%G'*^S >0 ?.,H">@+#D ]:XB>XM=8\=>!Y7M)Y((K*Z
MCF:XLW"JSHJKN+#C<5<#/7\:YWQO*\D7BFUBM+NQ*7]H%M+:Q=Q<HC1 3L^T
M@*%7 5<8VC.2<4 >EIX\T1_%USX>^V0+-;PAWD:0 ;R6RGU 4DGMFF:5XHTZ
MPT6Q;6/%%E?RWDTBV]W$@1)_WA 5 N02.%XZXK&TW5+>V^*6LW=Q#>1VVHZ=
M:-;R/9RA65 Y<ME?D R,[L8R*QO#^A2Z[\$(+&V5HM9T^::ZM-Z;7AN$G>2/
MANF00/HU 'J#ZOIT=Y<6DEY$D]M#Y\RNVWRX_P"\2> .#S[&H].U[2M6FEAL
M+^"XEB57=$;D*>C8]#@X/2O.;_2M=\3?"G6]4:S?^V-:\FY6S#898(V0K#T'
M)57/3JY%:7@]]+U;Q6-6L=+U]+I+(PW-SJK2KY0+!A" YPQSD\<#'7G% '>:
MA?0:9IUS?7+%8+>-I7(Y. ,\>]<Y\/\ Q/=>)=%NO[3MS:ZM8W<MM=VS8S&0
M<KT[;2!GN0:A\9.^K:II7AF"[>T,\GVJ><0[P%C(*)\P*DLX!P>R-ZUA6UO/
MX+^*2SW-_=:A!K]OMO)1;!5@F0A86?8 %##<H)ZF@#NKWQ-H6G71MKW5K.WE
M!VL)9E4*V-P!)X!(YP><4E]XHT'34C>\U>RA65!*A:9>4/1_]W_:Z>]>/7^J
MZ7]I\1Z'>78M[&7Q#]MDN);6X:6,QM&75=D;*<E" =X(!Y':M?5+C3+/Q7K-
MUJPUFZT77[6WDL[C3HY'ADCV%#"VSZ[A_O'IW /2;SQ5X?L))([O6K"%XXA,
MZO<*"J'&&QGH<C'KVK.UGQ[H>D76CP&]MY3J;C8R2@A8MK-YG';Y<#US[5R6
MCVMA8_$*T-Y8FUM[7PK'!MNCYODD.6,9<CEA&><=O:L#19)-/\*?#*YN(+D1
M6%W<"Z"0LS1,5?:"H&<G(P,=_>@#W,$, 000>012T@.0#@C/K2T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2+G'.>IZTM-1MX)XX)''L: '4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?8P.UAV..AY''O4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(!C/7FEHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *:F,''J>^>].IJ8P<>I[8[T .HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDLT4$9DFD2-!U9V  _$UR]
MU\1/#L8F33[B;6;F+ -MI,1N7.?=?E'U) H ZNBN-_M;QSJX_P")=H%CI$)
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M3)'"V0VP%AECPHQW;/:@#%U74['Q1JIU'4+\6_@[1)@V\G":A=*>,<9=$(P
M,[FZ9Q5!]9U/XB>,+6[\-V2K8>'W;>VJ[X4>Y<8#!%!9MBY(!V\M^>@-%'AC
MP_)XDUFWCDN=.@":3I<9+Q6/18XU_ORL2H+GG)(''7JO!FBRZ%X9MX+K#:A.
M6NKZ0?QW$AW2'\SCZ 4 <%X,\+W7BR77=7\0:Y>O/)J$EE-%8,+9)$@R@!(^
M?:>3M# >N:]+TC0=(\/VOV?2=.MK*+^(0QA2WNQZD^YK#N/!MW;:A>7?ASQ!
M<:-]NE,]U!]GCN(GE(P9 KC*L>,X.#@<5>C\+),C+K&I7NKAG#F.Y95BXZ#R
MT55(^H/OF@"IJ'B:_OIY;#PI91WUPF!)?3L19PG/(W#F1ASE5Z=R*\RU>#;\
M1;?3 XUW7X]EW.\J;5EN@,Q1#M'#&I,A //RYR2*]=\3:U;>$O"-_JIC1(;*
M M'&!A2W1%]LL0/QKC/@_P"%[RSTZ[\5:X%?6M<;[06(^:.)N0/0;CS@=MH[
M< &VOAGQ?L$I\=3)<N,R)_9T+0@^B C<!]232IH'C.\1X]2\81P1\;3IE@L;
MGURSE\?@*[&J.M:O9Z#HUWJM_)Y=K:Q&1SQDX[#/<G  [DB@#R;QAH^AZ'=/
MHUK+.]W?0->:YJ=S*9KE;%#@J&/0N<( .OY5HSWWB/1+72/&%Z[6.BI+'#-H
ML2@1V=DXVAG&,EPVPG^Z,C'6J7PUT*_\8WMQXW\30@+=7"SVD&2-WEY$;$#^
M%02%'<Y8YXKU^>"*ZMY()XDEAD4H\;C*LIX(([B@!8I8YHDEB=7C=0RNIR&!
MZ$&H;W4;+3+=KB_O(+6%?O232!%'XFN9C^'.EPP&T@U/7(+#!"646HR+%&,Y
MPN.0.V,X%6=/^'OA33;L7<.C02W><_:+IFGDSZ[I"3WH I+XUNO$,<L7@W37
MO", :C>HT-F,GD@GYY,8/"C'3FO.[Z70[KQ_+!X^\0WSV]@P5+:\CDBM[F<D
M?.B*NT1* !R26ZDXZ^[@8&!TI&177:ZAAZ$9H YF'XB^#KA@L?B33BQ&0#,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\(]9<'/*'_&C_A6_@WYO^*=L?F !^3T__569IGC+7)]>\.0W^G64-AK]M)/
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MB2!^-8?PUT2[TOPN+W5 3K&K2M?7K-G<&?E5.>FU<#';F@"8?#/P6H 'AVS
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MHHHH **** "BBB@ HHHH **** "BBB@ HHHH :R*^W</NG(Y[TZBB@ HHHH
M**** "BBB@ ID6=IR/XF_F:?3(L;3@Y&YO3U/I0 ^BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?[W4ET48Y/''&:3P-J+VU_JLNIV%\^OZB@U.["1 K#!@B"+.?O;5("]<Y^M
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MJ-VEI$8E!57;NQ)&!@$_@:V* "BBHC<P"Z6U,R"X9#((MPW%00"V/3) S[T
M2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3(L[3G'WFZ?4
MT^F1#"'']YN^>YH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 R4#RY#@9*D9KBOA*OF?"?00&(/D. PP2IWL,CM78W=LMY:O \DL:OU:*0H
MP^A'(JAH7AVP\.:4-,TPSQVB@B.-YF?R\Y)VELD<DF@#R>[N+_6? GAVXO\
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M+M&?X&*D9'L: .+\0Z[X@M;&*]OKZ^6RDTM%:_T4)+%:78#>8\JXW&/.W!'
M /&>:U;_ ,1WNE^.;UAJ4EYI\'AE]32T 79O#XW A<D$+QR<9/8BMRZ\!Z-<
M":.-KNTMYX([:>WMK@I'-$BE50KZ;3CC!(JVWA+26UP:L8G\_P"Q_8#'O_=&
MWZ^64Z$9)H \_P!1AU"_T7P#K5]KDUV]UJ]I-/$H7R"7#, H4 C;T')]\FIK
M+6/%>MP7&N6M[:V\=KJDD;K/?>7'%#')M:.2+RS\Q5<[M^<MQ@9%=+'\,O#T
M:642MJ8M[&X%Q:P?VC-Y<+#.-HW?+]X].?US/)\.O#,FMR:M]AD2>:99YXTG
M=89I%.0SQ@[6(//(ZT <#JVI^)K?P]XUUF/Q3>[]#U8I:Q".,(RCRCM?Y02,
M-C P,Y/.:Z"TLY)?CE?%[^^*II$4ZIYN%YE;Y,?W/:N@F\ Z+<6&K6,IO&M]
M6G^T7B?:&'F/W/MG Z8Z"K1\(Z6VMVVLR&Z>_@@2W,OVAE$JH25WJ" Q!.>1
MUH WJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $) (!(YZ>]+110 4444 %%%% !1110 4444 %%%% !1110
M5%!]QN,?.W_H1J6HK?\ U;<Y_>/_ .A&@"6BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *B@SL;(Q\[?^A&I:CA^X>,?,W\S0!)1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %,BQM./[S?S-/ID7W3U^\W4
MY[F@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !112 8SUY]Z %HHHH **** "BBB@ HHHH **** "BBB@ I
MD1)4Y&/F/\Z?4<(PAZ??;I]30!)1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %1PXV'']]OYFI*9%G:<G/S-_,T /HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "HX<[#DY^=OYFI*C@SL;(Q\[?S- $E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%;X\ML9^^W7_ 'C4
MM1P_<;D'YVZ#W- $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5'"<HW3[[=/J:DJ.'&QL #YVZ?4T 24444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'.."/QI:** "
MBBB@ HHHH **** "BBB@ HHHH *B@^XW!'SM_P"A&I:CA^X><_,W\S0!)111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(0"0>>/>EHH **** "BBB@ HHHH **** "BBB@ J.'&PX_OM
MV]S4E,B^Z?\ >;^9H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %1P_</.?G;^9J2F19V'./O-T^IH ?1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %1P_<;( ^=NGU-25%  $;&/OMT_WC0!+1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %1P9V-D@_.W3ZFI*CA&$;_
M 'V[Y[F@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CB&
M$/'\3?S-25'#C8<?WV_F: )**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ ID8(4Y_O'M[T^F1C"G( ^9C^IH ?1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %1P?<;*D?.W7ZFI*CA^X< CYVZ_4T 24444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<(PA^7;\[<?B>:DID
M0PAR /F;U]3ZT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "F1?=/^\W;W-/IL8PIXQ\Q_G0 ZBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *9& %.!CYCVQW-/IL?W3QCYCVQWH =1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %-CY4_[Q_G3J9&25.3GYCW]S0 ^BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CA_U9Y!^=N@_VC4E
M1PY\LY&#O;_T(T 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !3(AA#_O-_,T^F1?</7[S=?J: 'T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !45OCRS@,/G?[W^\:EJ.'[A_WV_\ 0C0!)1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 (0#U -+110 4444 %%%% !1110 4444 %%%% !4</W#@8^=O_ $(U)4</
MW#SGYF_]"- $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M%;C$9&,?.Y_\>-2U'#]P\D_,W7_>- $E%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5%;_ZL_P"^_P#Z$:EJ&VQY/']]L\8YW'/ZT 34444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "H+3/D'(_C?_P!"-3U#:EF@!8,#D\,,'J: )J**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"T79;*/FZG[R[3U
M/:IZ@LR#:H0  23@#'<T 3T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ("26!4C!P">]+
M110 4444 %%%% !1110 5!:9^RIN()YY'UJ>H++'V2/"[1SQ^- $]%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 57LCNM$(;=UY]>35BH++'
MV2/:21SR<>OM0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %063;K2,@YSGG\:GJO9?\><?X_SH L4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(#D D$>Q[4 +1110
M4444 %%%% !1110 4444 %%%% !4-H5:U0JVX<\_C4U5[+/V./<<GG^= %BB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!&W%3M(#8X)&0#]*6BB@ HHHH **** "BBB@
MJ"TS]E3)!//3Z_05/5:PS]BCRNT\\8QW/:@"S1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %060Q:1@^_KZ^]3U6L PL8@R[" ?EVXQSZ4 6
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBFL'+)L90H/S@KDD8/3G@YQZ]_J !U%%%
M !1110 4444 %5[ !;*(*& QT88/6K%5K!MUC$<@\'H,=_2@"S1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %5K $6,0.W./X>E6:AM0%M8P
M"3\N<D8- $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !2 YSUX]J6B@ HHHH **** "B
MBB@ J&U*FTB*D$;1T.:FJ&T;?9PM@#*#IG'ZT 34444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !3(<^1'G&=HSCITI]16W_'K#GKL7^5 $M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R'(@CR-IVCCTXI]
M16W_ !ZP\ ?(O &,<4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !45M_QZPYSG8O7Z5+4=OG[-%NSG8,Y.3TH DHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "HK7_CTA_P!Q?Y5+4-F<V4!SG,:\^O%
M$U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#:9%E!GKY:Y
M_*ICTJ*V.;6$DYRB\^O% $M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 'I45KC[)#@8'EK@8QVJ4]#4=O\ \>T7&/D'\J )**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!#T-,M]PMHMWWM@S]<4\_=-16C
M^99PM\W*#[P(/3WH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** $/W3]*9!G[/'DY.T<_A3ST--A_U,?&/E''IQ0 ^BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH 0]#3( !;Q = @QQCM3V^Z?I3(!BWB'^
MP/Y4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-]T_2H[
M; M(<=-BXQ]*D;[I^E1V_-K%@@_(.1]* ):*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@!'&48'N*9 2UO$3G)0'GZ4Z0[8G88X!/)Q1&ACB1
M"<E5 SCK0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :Y
MC8L 5P<@]Z=2,0$8DX '4TR $6\0;@A!G\J )**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@".<XMY2>R'^5/4;4 P%P,8'05'<G%K,<X^1N?
M3BI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CN!FVE''
M*'K]*DJ.?'V>7(R-AX_"I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH BN?^/6;/\ <;^52U%='%I,2,XC;^52T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!!>?\>-QQG]VW'KQ4]07G_'C<<X_=MT^
ME3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#=@FRG Z^
M6V/RJ:H;K_CSGYQ^[;^534 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!#=_P#'G/QN_=MQZ\5-45R ;68-G!1LX..WM4M !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 171VVDS9 PC')&0./3O4M1W&X
M6TNW.[8<8]<5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M $<XS;R#&<J>V>U25'/_ ,>\N3CY#S^%24 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!'/_P >\F!GY3Q^%25'/_Q[R_[A_E4E !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#!P<9XS6=X9\,WVK:9>Z;/+=V]BCQW5K>2:9]CN([Q7)W[69B_09+8X.!GL
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M;7KJXM["RFL(8?(C0>5( #D@9)X'/L.G.9K?X?RQP:#;W&MO=0:3%+ 8Y+5
M)HG01E?EQC" C//)).>E $VG>-+N\FT1IM&\FTURW:6QE6YWG<$,BI(-H"EH
MQD8)P015/0_B+/K"Z9<-H;0VFIVUQ-:E;@22,\.=R%0O?L<UH:5X)_LV?3/,
MU:>ZMM(1TTV&2-1Y.Y"@+,.7VH2HZ=><G!%+2_AW)I5GHEM#K<NS28;F*-A
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MMY,7EF&2$YCD0[CR&R<'V].=&R\-:G:QQ22>)KZYO?M$4D\\D2!98DW?N@@
M"@ACD]<\YZ  '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<=2A YQSBI:CN,_9Y-N,[3C(J2@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH CGQY+9SCCI]:DJ.;/E'&,\=?K4E !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 1SX\ELYQQT^M24R4D1G:,FGT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!'/CR6R<#C^=24R5#)$5'?%/H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>modificationno15effectiv001.jpg
<TEXT>
begin 644 modificationno15effectiv001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M?[<UQ"D<31 J2KL"V%R5;Y1DX!]J .[HKFH?%]BD]O8,)I[C,,$KIL(65T#
M$%@W<9(! W#)ZX99^-[:^">3IFH+YUM-<6YE6-1-Y1 =1AR0<D=0![T =117
M(0^+)Y(-+O9K>XB^TZ3+?&T"1L)"HC;(??QC=P".=W.,8JEHOB#^SH5O=7OK
MX"728[Z>&X",H8D M&P8XW$@!.G3ITH [RBN;C\76=[*UC!;WAOV9XQ!&8R^
M BL7#;BF '7G=U.,9JEI6L7:?"M=7N;F?[5'922O.465U*YRVTD!B .F1G%
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M*[E=8TQ'%(6 )RX/!5@0,GCC(H ZVBLW5M<M-'-LD^YYKERD,2LJEB 6/+$
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M\2"U\*0Z[96LERDZP/'&2%.V5E )R>P;I_\ KK(C\32:9XDUA+Z#4)+/SK1
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M6)<[CD#)(!(![9Z5<7QA8_Z2DMM>0W$-Q';"WDC4/(\@R@7#8Y'/)&,'.,5
MWC%'U6RL+?3KEII;N2UN8W**T#+$9!GYL'(P00<8SWXH )/"5Q-!9M+X@OWO
M[*0O;7ACBW("NTJ5V88$'G(SG%-O_!8U(ZB9]8O2;^SCLY3LBSM0DY'R]26?
MV^;IP,7=*\5Z;K-^+2S+L7B>6*3Y2LB*P4D8)(Y(^\!D'(S2+XLL&N(D$=Q]
MGENVLH[O:/*:89!4<[NJE<XQD=: )-7T#^U?L$Z7]Q:W]BQ:&[B5"WS+M8%2
M"I!';'I5*_\ ![:C=VUY/K=^;JT9&MI@L0,1&=V,)@[\_-QR !TJ*+Q[8SB$
MQZ9JK"=)7A_<+^\\HX<#YNH]\ ]C3I/&%G%*M\]Q*-/;21J"QF 9*EAAMV[K
M\P&W&.^: &R>" VGZCIL6MW\6G7OFDVJK$5C,I)?!*YP2S8&>,_2B[\$+=W$
MLIUF_B\_[,\RQK%\\D!!1^4./NC(''%6E\86+7-G;"VN_M%T25BPA(42"/?P
MV&7)SE=WR\]*CL?$\9_T=_/O+V6[N8HH(X5C8+$WS=7QA<@;B1DD<<T 1+X'
MA2[C:/5;Y+..^:_2SQ&461MVX E-VTESQGN?P;'X%B32!I1UC4#9P.CV*?NP
MUHR,&4JVW+8(P-V>.*D?QWIODQ206E_<B2UDNML,0RJQOLD#98893P1^6:N0
M>*K"ZU6#3[=)Y99HHYMRJ,(KJS*6!.[&%Z@$ D ]: )-'T)M)EU"=M2N;N>^
MD661YEC&&"*F0%4=E'Y?7.?I_@]K!]*8:M-(-.GFF0-$@W^;G<#C_>;'U]JZ
MBB@#FX?!UM!+&B7D_P!BANVOH+4A=L4S;CD'&2H9F8#U/IQ4$'@A;>*QC35[
MS%G!<0H2D?(F.6)^7MQCZ5U=% &&WAN-O",7AXWD_EQ0I%'<87S!L(*'IC(V
MCMVJC=^"OMJ:@)M9O"U\]O)*PCB!W0D%2/E[E03]*ZJB@#$TKPZ='O[B6VU.
MZ^Q32O/]A94,:R.<L0VW=C))QG&33$\-26VJWMY8:O=VD5XYFFMD2-D,NT+O
M!921T!(S@D5O44 <<WP_B-O?P)K5^B:@J?:AMC/F2*<^;RO#'OCV]!5B[\%B
M[GOIFU>[5[RZM[IRJ1_*T.-F/EZ?*N?I74T4 <Y:^$H[><,=0N)(HKR:]MXF
M5 (II=^3G&6QYC8!]><\4FD^$4TA]+:#4[IOL$,EOAE3][&[!MK?+Q@J,$8-
M=)10!SU_X4BU#4+^>2]G6VU!(DNK957#B/. &QD YP?Z5 ?!4#6VI6!U*\_L
MJ^,K&R&S;&\A)8JVW</F)8#. :ZBB@#D[_P2^J6MO%?Z_J%Q)#O7S&CAY1TV
M$;=F,X_BQGD\TR?P%'/&R?VUJ$8EM8+>X\M8LR^228VY0X(R>G7BNOHH Y"\
M^'NGZC>7=U>7=S)-.CH)4"(ZY=9 2P&6VLB[<\ <5O6VGW46E2VESJD]U/(&
M'VF2.-67(QPJJ!QUY!K1HH Y[2_"JZ5)I+PZE=-_9]H;/#*F)HL@J&^7@C Y
M&.E,OO"2WM_J%VVHS 7PB$D#Q1O%B/.%*D?,#N.0?;TKI** .?;PG;#PE;^'
MH+J>*&V,313<,X:.02*>1CJHXQTXJ-O!\)O4U-+Z==66=I_M>U3N+1B,J4QC
M;M5>.N0#G-=)10!S47@Z&UDM9;+4+JWEB2X21PJ,9O.8.Y8%< [P",8].E.T
M?PE'H]YITZ:C<S"PL/L$:2*F&CR""<#.?E7\JZ.B@#FKWPN]X==LQ<&+3]90
M-,R8\R.3:L;8!!&&15^A!]>+EEI$Z:[_ &C=3"3R+06=N?XF4D,[MP "2J\#
M@!?? V:* .9O_!RWTVHR'5;N/[=<07#!$C^1H2"@7*],JN<YZ4^/P?:Q7(Q=
M3FQ6^.H):$+M6;);(;&=NXEL>OMQ71T4 8MCX?\ L'A^?1TO[AXG$BQR.J;H
MD;^$8&#C)Y.:RIO <4]F]JVKW@C?3%TLX2//E*>OW?O=1^-=?10!RH\$H-?B
MUC^UKSSHYTN"I2,AF$7E-D[<X*D\ X&3C&>&V_@C[$;.2SUR_@N+1'@CF"1$
MF!B#Y1!0@X(R#C/6NLHH YR;PDL\6OQOJ=T5UI0DWRI^[&P1_+\O=0!SGUJI
M)X$5]4AU!=9O5GC>&4'RXCEXXS'G)7(!4GY1QDDXR:ZZB@#GX?"D4?A";PZ]
M]<O!(CIY_P JR*&)/88ZD]O:J=KX'6UDA;^V+QA%?C4 OE1*#)LV$8"# (SP
M.F:ZRB@#D[;P,EG);W%MK-_%=PO.?/58LLDS^8Z$%",;N1QD5<_X16%/!2>&
MTNIFCB@6.&>0 LK*04;  !P0/RKH** .7O\ PI+K1N[B]OY;>:^TX6%Q%;A6
M15R2=I9<]6;D^M7K#1YXM;.H74PD,-HMG;G^)ER&=VX !9@.!P OO@;5% ',
M7O@U+ZYU&:349BM_,DLL$D,;QG:A0*5*\C!'7NH/:K4WAB ^'+'1K>[N8%L3
M";><%7=3$05)W @].>*W:* .7;P8K2L[:M=G=J:ZF1LC_P!8H"@?=^[@"KN@
M^'3X?5K>#4KJ73UW"WM)53;""<X#!=QQT&3P*VZ* .5U70'BT[5K:WDN[E-8
MG $:A +1WP&E#8!PN W4\@8JM?Z1<+XNT2VT[[9965MIT]NUQ#$&"AC'M3<P
M(!(C//KCUKLZ* .<L_"$&E:DESI-]<V-N8XHIK6,(R2B(;4R64D';P2#R/?F
MI]3\-I?:E)?P7L]I/-:_9)S&JL)(LDCA@<,,M@^YZUN44 8FD^&H-&U.:ZM;
MF80/:PVJVQ"[$2($)@XW="W4]ZIR^#5EN[B<ZM=KYVHQZB4"1X#H H ^7IA5
M'X5T]% '+P^#5AN[>X&K7;-!?S7X!2/!>52K*?E^[AF]_F]A3H/!L-O#;VZZ
MA<FWLXY([&,A/]'#J5ZX^;"D@9[=<GFNFHH YR#PF+>'0HTU2Z_XDR,D)*1Y
M<%"@W?+V4XXQ5./P#"EM!;G5[XQ16,]B,!%)24Y8Y"YR"%Q_N^YKKZ* .1MO
M BVMO*D>LW@D:ZANTD6*%?+DC0)D*$Q@J ,8[?7,R^"XX[U[Z/4[D7HO7O(I
M2B'RV= CKC&"I4#@\Y .:ZBB@#F(_!<$%S;SP:C=1R1)<ACM0^8]P=TCG*]=
MP4@#@8Z5:/AB+_A$(/#PO;@1V\<217.%\Q?+960],'&U>W.*W:* .5NO!?VS
M[<9=8O-UY<6]Q(PCCR&AQMQ\O<JI/TIL/@6WAUF74!J=V5E-SNA*QX*SX+J6
MV[CRHQD\  =.O644 8A\.K)X2.@7%_<2IY/DBY(02 #[IX&,C [=JS[SP4;]
M-1%QK5XS:A' DSB.(']T<@C"\9.<UU=% &'IOAUM*U2XN;;4[H6EQ,]Q)9%4
M,?FM]Y@=NX GG .,_E3;KPM;WNHZM<W5S/)#J=HMG-;84*$&[!! SGYV[]_8
M5O44 <#XBT'48=,TJSDO=2U*".\5WG^S12O B(P7]VJ@ODD9/)[U:T_PI>7E
MK;7-Y?36<\-M/9Q16\$<:B%Y,J2H! ;:L9(''!'<UVE% '+6'@BVTMK22QOI
M[:2">:8^5'&$;S=NY FW"K\JX Z8/K3#X&A.BV&F'5+PK93O+'(5C)(<,"I!
M7:?OG!QD5UE% '(+X#3["UJ^LWK(VEC2B=D0_=#O]WK@D9_KS6Q8:$;#56OE
MO[A_,M8K>6)U3;(8\A7X&0>3P,#VK7HH YF^\'B\^W(NK7D$-W>17IC1(R$D
M3:>"5)P2B'!]/>K0\.&'Q!-JMKJ=U;BZ*-=VZ*A29D 4'E25X !VD9Q6Y10!
MQ=K\.K:UM[N :M?/'<6GV0Y6(%5#EU;(7)8%FY.<YYK1@\(Q+XBM];NKZ:ZN
M[<'8[QHK9,80@E0"5ZMMZ DFNCHH Y6^\$17FOMJR:K>V\C3K.$C$9VL(S$<
M,5+ %2>,X!)(Y-7=!\.6WAF.^EA=Y9+EEDFVQJ@8JN,A% &3C)/4DUNT4 <+
MX5\,SS^&;8:G->0W,<,T$,4D2(;82$AB!CYB1W.>OUK:@\+" Z#C4KEO[&0I
M'E4_>@IL^?C^[QQCUKH** .7;P+IRZ7?65M-/;_:[T7I==K;&#APH5@04SGY
M2,<FFVO@>&VALXO[3NY([=[G(=8_WD4[!GC.%Z9'48/7VQU5% &1H.B2Z':"
MT.J75[;QHL<"3J@\I!P!E5!;C R<]*H6G@VWLA:Q1WUP;:Q:22QA95(MV<,,
MYQEMH=@ >F><\5TU% &=H.D+H.B6FEQW$MQ':H(T>4#=M'0'  X'%:-%% !1
M110 4444 %%%% !1110 4444 %%%% $<D\,) DE1">FY@*9]MM/^?J'_ +^"
MN?\ $W@/0/%US#/K-K--) I2,I.\8 )S_"1FL3_A2?@;_H&W'_@;+_\ %4 =
MW]MM/^?J'_OX*Q=7TVWU#4[34K36_L%[;(\/F1F-P\;D$J0V1U4$&N>_X4GX
M&_Z!MQ_X&R__ !5'_"D_ W_0-N/_  -E_P#BJ -1?#6G*\D1U@O8RWB7\MN[
M(2TZE6SN[ LH8C'7/0'%,M?#<%K)92+XAR]I=W%XI*Q\O-NW ^WSMCZ^U9W_
M  I/P-_T#;C_ ,#9?_BJ/^%)^!O^@;<?^!LO_P 50!9'@S3I-.LM/N=<,UK:
MVT]KM_=J7CE #9(Z$8&#2R^$+2\\QK[Q-<7$IMXH(Y<PJT9BD\Q'X7E@V.O7
MG/M5_P"%)^!O^@;<?^!LO_Q5'_"D_ W_ $#;C_P-E_\ BJ -HZ4TMYIUY<>)
M3-<V0EVL8XE#%UV] .@X-06'ARVTV+2UM?$!5["UEM [",^9&Y! ([$%5Y'I
M[UF?\*3\#?\ 0-N/_ V7_P"*H_X4GX&_Z!MQ_P"!LO\ \50 Z3P+8O9V-N/$
MDBBSMH[=&*Q-Q')YB$9'RG( ./O!1GI6[I6FII=Q-(-?\U9KM[J5"(P'++MV
MGOC.T\8Y'I6!_P *3\#?] VX_P# V7_XJC_A2?@;_H&W'_@;+_\ %4 =1K]M
M::[H=WI9U**!+E#&\BE6(4]<9/6JMSH]AJ<\<NL:FEZ(HWCCBRJ1KO4HS8')
M8J2,D\9. *P?^%)^!O\ H&W'_@;+_P#%4?\ "D_ W_0-N/\ P-E_^*H OMX3
MTRYL/L=_K)N4CL)-.MV+(K11.%!)(^\V%7GIQTY--;PO%(99I?$\DMU)+;3>
M:ZQ;0\)RIV@#@]QFJ7_"D_ W_0-N/_ V7_XJC_A2?@;_ *!MQ_X&R_\ Q5 &
MC+X6TZ>Z2>;6 Y:6:6Y4[,3F6,1L/]D;  ,>G<UJ:#:KHMF+277S?0QHL< F
M\M3&BC &5 +'&.3Z?6N:_P"%)^!O^@;<?^!LO_Q5'_"D_ W_ $#;C_P-E_\
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M] VX_P# V7_XJC_A2?@;_H&W'_@;+_\ %4 =W]MM/^?J'_OX*/MMI_S]0_\
M?P5PG_"D_ W_ $#;C_P-E_\ BJ/^%)^!O^@;<?\ @;+_ /%4 =W]MM/^?J'_
M +^"C[;:?\_4/_?P5PG_  I/P-_T#;C_ ,#9?_BJ/^%)^!O^@;<?^!LO_P 5
M0!W?VVT_Y^H?^_@H^VVG_/U#_P!_!7"?\*3\#?\ 0-N/_ V7_P"*H_X4GX&_
MZ!MQ_P"!LO\ \50!W?VVT_Y^H?\ OX*/MMI_S]0_]_!7"?\ "D_ W_0-N/\
MP-E_^*H_X4GX&_Z!MQ_X&R__ !5 '=_;;3_GZA_[^"C[;:?\_4/_ '\%<)_P
MI/P-_P! VX_\#9?_ (JC_A2?@;_H&W'_ (&R_P#Q5 '=_;;3_GZA_P"_@H^V
MVG_/U#_W\%<)_P *3\#?] VX_P# V7_XJC_A2?@;_H&W'_@;+_\ %4 =W]MM
M/^?J'_OX*/MMI_S]0_\ ?P5PG_"D_ W_ $#;C_P-E_\ BJ/^%)^!O^@;<?\
M@;+_ /%4 =W]MM/^?J'_ +^"C[;:?\_4/_?P5PG_  I/P-_T#;C_ ,#9?_BJ
M/^%)^!O^@;<?^!LO_P 50!W?VVT_Y^H?^_@H^VVO_/S#_P!_!7"?\*3\#?\
M0-N/_ V7_P"*K$UGX3^$++7/#]I%I\_E7]W)#-F\E)VK!(XQ\W'*#\,T >K?
M;;3_ )^H?^_@H^VVG_/U#_W\%>4W/PY^'MOXJLO#_P#8NHO<7*.YE^TSB)-J
MEL;B<$D#H,X[XXK;_P"%)^!O^@;<?^!LO_Q5 '=_;;3_ )^H?^_@H^VVG_/U
M#_W\%>-S_#_PDUY?#3?"%]?V6GW MKF:/4Y!(7X+B./)W[0PSDCOC.*COO W
M@VW_ +4N[7PI>76E:5(T=W=#59%?* &0I'GY@H/.2,D$#- 'M'VVT_Y^H?\
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M]S;V-K;3&0O+,A0L[= ,&MWP%X"TWPQHFF23:591:Y#;^7/=1*"S,>OS=\T
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MY)/6NAH \[N/A+IIL-/MK2[N(C%!):W;O-))Y\4B$/M5F(1M^U^!C(Z5)=>
M=2U2]>\U._TMKI;.>U6YM; Q2SF2(QAI6+G( .<#OZ=*] HH XC3/!M_I^G7
M%K;IH.FS26GDK>Z=8[9=PQ@MGAE..1WJWX7\+7.CZS?ZI=+IEN]U#'$;?2X#
M%$2I8^8P).7.[&?0=ZZRB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ/\ A0!T5%<[_P )UX7_ .@U;?\ ?1_PH_X3KPO_ -!JV_[Z/^% '145SO\
MPG7A?_H-6W_?1_PH_P"$Z\+_ /0:MO\ OH_X4 =%17._\)UX7_Z#5M_WT?\
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M8+:2VM(R8U,*.AC)+*H+L%) +9Q]>:O2>!M%699+"VCT[_1)K.1;2)$$L<@
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MAO*7SKA8F0G<1N"G<,'ZBKGBSQ?<:#K,EC#'I\<:QV;?:+I6*IYTTL;%L$<
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MP.>:V: "BBB@ HHHH **** .5_YJO_W!3_Z.%=57*_\ -5_^X*?_ $<*ZJ@
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M'?\ 0MZ=_P!^!0!T7GP_\]4_[Z%'GP_\]4_[Z%<[_P *[\'?]"WIW_?@4?\
M"N_!W_0MZ=_WX% '1>?#_P ]4_[Z%'GP_P#/5/\ OH5SO_"N_!W_ $+>G?\
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M#O\ H6]._P"_ H Z+SX?^>J?]]"CSX?^>J?]]"N=_P"%=^#O^A;T[_OP*/\
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MBM_"7P[NYA#;:9H4TIZ)'Y;-^0- '7^?#_SU3_OH4>?#_P ]4_[Z%<F?!G@
M7?V0Z1HOVG./)VIOSU^[UJU_PKOP=_T+>G?]^!0!T7GP_P#/5/\ OH4>?#_S
MU3_OH5SO_"N_!W_0MZ=_WX%'_"N_!W_0MZ=_WX% '1>?#_SU3_OH4>?#_P ]
M4_[Z%<[_ ,*[\'?]"WIW_?@4?\*[\'?]"WIW_?@4 =%Y\/\ SU3_ +Z%'GP_
M\]4_[Z%<[_PKOP=_T+>G?]^!1_PKOP=_T+>G?]^!0!T7GP_\]4_[Z%'GP_\
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MYJC_ $>)H]KLC!L?,6!4@YJPOPUGBL)((KZ!9&TJ>R5]KG;+<2;II1N9FY&
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M:V?#>AS:-)<;[#0K1)0O_(+M3"6(S][UQDX^IKH** .?\>?\D]\2?]@NY_\
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M"S226!9I "" Q*<C@=?04 6])2Z3QVXU&PL].E%BRVR6>72Y0NA8M(57+(0
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MX2_Z#"?]^9/_ (FC_A8_A+_H,)_WYD_^)H ZFBL;2?%6BZ[/)#IE\MP\:AG
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MG<6[3(MU"%\RX,9@B$AC7.TL%S@'N,4 =KJ&NZ3I,L<6HZG9VDDBED2>=4+
M=2 3R*677-)ATY-1EU.S2QD.$N6G41L>>C9P>A_*L9]1TY?$>@S)>P_9GTNY
M,<CR ;E+6^#D_2LB\U"*2UU>WTYX9(]9U!;>U"RA%F'E)Y[(W3HKC</X_<T
M=Q97UIJ-HEW8W,-S;29V2PN'1L'!P1P>014]<KX;N9+;7M7TRY@BM&E=;V"W
M6=7(# *X&.GS+N_[:5U5 !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 FT>E+@>@HHH ,#T%&!Z"BB@ P/048'H*** # ]!1@>@HH
MH ,#T%&!Z"BB@ P/048'H*** # ]!1@>@HHH ,#T%&!Z"BB@ P/048'H***
M# ]!1@>@HHH ,#T%&!Z"BB@ P/048'H*** .5//Q6 _Z@I_]'"MS4=:TK1Q&
M=3U*TLA)G9]HF6/=C&<9//4?G6'_ ,U7_P"X*?\ T<*E\1WLDNK:9I-I%'=3
M>9]LFMS.(R4C^[U_Z:%&'KL- &])>VL5B;Z2YA6T$?FF<N FS&=V[IC'>J=C
MXBT;4O/^QZI:3&W7?,$E&8U]6'4#W-<C!>6$?@Z;1M7O%TXV-_':QO'(LGD$
M2+);Y.,8 V*<C'RL#6QI%Z9/$]Q'<SZ;>SI9*QOK-2FQ-YPDBEF SR0<\X;@
M4 :MEXET+4KA+>QUG3[F9P2D<-RCLV.3@ \TEOXH\/W=REM;:YILT[ML2*.[
M1F9O0 ')/!KFO#4%[K>B:/$TFG)8VDD<^Z&8RS,58E01M 3/?EN,COFLV:XO
MI=.G;S;.308]:EDO&A7?<0H+AF#\G:%# $G&0N2.E 'IE4-0US2=)DCCU'4[
M.T>4$QK/,J%@.N 3S6=JL/BR:],FC:EHT-D5&U;FSDE?/<[ED48_"L[69-1@
MN/#4=UJ>F0ZF)Y3),T#>2?W,G1#(#Z#[W6@#HEUS27TUM234[-K%3M:Y$ZF,
M'.,%LXSGBEMM9TN]T^2_M=2M)[.+/F7$4RM&F!DY8' P.:XQ-7GTN#Q+G4+&
M[U"XEA\BYM\11&:5!$D>TLV"FQ6;YB=K \=*O:%(=$\1R6%S;1:?;W5E&\,9
MNE?YH0$8GIUC\O\ []F@#H;#Q#HFJ3B#3]8L+N4KO$<%RDC%?7 /3D?G3)/$
M^@17CVDFMZ<ERC^6T37*!E;^Z1G@^U<3X>FOS;>"IM1DLSI$=O&+>:U7+).8
M"BI*Q/ *LPX'+8!Z@'?M]3T>VNO%2ZE=VBP&^"R1RNIWC[+ "NWOGD8[]* -
MN_U_1M*N$M]0U6QM)G *QSW"HS Y (!/L?RK1KSV,W6I6^DZ)-9K?266E*;^
M"2Y5'666/RP#G.2%\W/^^IKI_"6H/J'ANU-Q*DEW;@VUR4<-^]C.UCD>N-P]
MB* -NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** $VC]<TN*** # ]!1@>@HHH ,#T%&!Z"BB@ P/048'H*** # ]!1@
M>@HHH ,#T%&!Z"BB@ P/048'H*** # ]!1@>@HHH ,#T%&!Z"BB@ P/048'H
M*** # ]!1@>@HHH 3 /:EZ444 %%%% !1110 4444 %%%% !1110 4444 0W
M-I;7B!+JWBG0'(65 P!]>:1[.TEG2X>VA>9!M60H"RCT!ZCJ:CU.V@O--N(+
MJ5HK9T_>NK[/DZL"W8$9!]B>E8/ABRMCJ5UJ>DV$6GZ1-"L<,<48C%RP)/G;
M!@ 8. >K#GIMH Z".PL8;IKF*TMTN2N#*L:AR/3.,XH^P62W7VD6EN+@G/F^
M6N_/UZUQ5G86L>AZ+KZQ1C6)[Z!IKL "20RRA)$9NI7#$!3P-JXZ"KMYI-AK
M5]XEFU.".>6TVPVSN/FMT$"2;D/\#;W8[A@_*/04 =4;*U-V+HVT)N0,";RQ
MO'&.O7I4B11Q%S'&J%VW-M&-Q]3ZGBJNCSR76B6%Q,VZ66VC=SZL5!-5/%-L
MEQX;OW:2>-X;>26-H)WB8,$.#E""?H>* -2>"&YB,4\4<L9ZI(H8'\#4,6FV
M$"2)%96T:R#:ZI$H##T/'(K#NGN/#_@W[7I>)IU5)2M[-)+YA. 1N9B5SZ\@
M>AIPUC4M*N;B+69+2X2.PDO0]G \941D;EPSMNZC!XZ=* -HZ;8M:K:M96QM
MU.Y8C$NP'U QCN:=#8VEO,\T%K!%*_WG2,*S?4CK7':LNN7$6AWU_P#V4\3:
MA:OY<4+B2VW.OW9"Q#_W3\JY!)]B7'B_4IIM0>QCQ':3RP1V[:1=SF=HV*G]
M\GRIE@0,!L#!/H #KGTO3Y%19+&V8(,*&A4[><\<<<U)+96L[1--;0R-$<QE
MXP2GTSTZ#\JYL:OK]]XA&GV?V&TA>PBOLW=N[RQ;BRF-D#KDY7.<C'3!ZU%>
M>+;RTLX[=X8_[1;46T]I8K>6:(%8S+Y@C3+GY /ESP21NP,T =4+2V%T;H6\
M0N",&78-Y'IGK4U<='XDU@V&L$Q(\EG:?:H;N33;BVB<C<6C*2'.0%ZAC][H
M,<W[#4=:CU'3XM4-@\=_$[A+:)U:!E ;:69CO&"1G"].G/ !T5%>?:W<ZQK?
M@Z/5R-,:PG:&XBMF@?S8XV==K^:6QO (.-@[C/>M"^\4WS:UJ-E9$6Z6,BPE
MGTFZN_-<QJY^:+ 0 .H[GJ< 8R =C17)G6]?O7T1;2WM;%]0MWDFCO89&>W9
M-N>-RE@<X .T]\]JF/B"^AT69I8K>34$OQIZ%0R1,[.%5R,DJ,,"1D], \T
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MWW#@EF4!P#@$X7KGMBI;'7/$M]8WUZMGIBI93SP&+S'+7!B=E)#=$SMXR&H
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M** "BBB@ HHHH **** ,CQ-876J^'KNPLX[9Y9UV$7+E4VYYSA6S],50MO#
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MEL"MF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9#C^$[W4 =^2,@9KMJ* .'D\0Z9K^K""YOX;;3K:Z58[7=B:[G5Q@LHY6,.
M0.K$9.%^]HW6IV>A>++VXU*3[/#=V5NL,K*2)'1Y=T8QU;YU(7J=QQWKIZ*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!RO\ S5?_ +@I_P#1PKJJY7_FJ_\ W!3_ .CA754 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%)G&<X'I1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:
M*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
M6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
M %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: .6_YJO_W!3_Z.
M%=57)[O^+K]/^8)Z_P#385U>: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BD
MS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %H
MI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!
M:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
M 6BDS1N% "T4@(-+0 4444 %%%% !1110 4444 %%%% !1110!B>)?LT6G_:
M;S7+C2((F&Z:&1$SDX .Y6ZD]N:S+#1%U2RCO+'QKK5S;29V2Q3P,IP<'GRO
M4$5)X^TR\U+1K)+."XD,%_#<2&T*B=$4DEHMQ W9QU[$]ZC\"Q7FE:5'IE[8
M7L3R375RDLX5CL,Q*^:RDCS6WYP..O3% $!L;,17TA\>ZMLL&V79^TP?N#C.
M&_=<5*VD1)JL>EMXXUE;^2(S);FX@WL@."P'E=,UQWB+P9K;6/B74](M7^WW
MM]-#/;'C[9:MMVL/]I&R0?3<.]:%_H'B>75KGQA#'%]IAU%)(+ VY^T-;1EH
MM@DWX ='D?;M/+#GT -98M-?29=57X@ZJ;"*3RGN/M,&Q7W!=I/E=<D#\:8Q
MTI-1;3V^(.K"[67R6B\^'<'_ +O^JZ\BN(G\&>)#X??1XM+E%G-'_:4JC'-R
MI>,1X]2/*D_X!78:9#J>G>)-5,C^(H89M6>=(K6UA>WE0[>2S(6 ."#AAQTQ
M0!JW^D1:6D+W_CC6;99Y5@B,MQ H>1NBC,74XIO]F6_VJ\MO^$ZUCS[)!)<Q
M_:(-T2D9#,/*X&.:J>,/#.K>,-<:UCD@M-.L[)T26YMVE$LTP*ED"NN&10,-
MS@N>*YAO#7B?4K+6?$)T^2U\2?9XHO+<@"\3R!'-'P>A(W+Z,![T =%-<:);
M3^1-\1]2CDPA(>Y@  <!E)/E8&00?QK3U#1DTJPEOK_QMK5M:1 %YI9X%5<G
M R?*]2*YVPM]5TW3M?TU_#VH74VH6MO%"%11$3]CCC(9F(  8$'Z=ZU]9\/:
MQJ-KX;T")H!;V42SWES<P&:&1XE54C*AE+98E^H^X/I0 FHQ:;I,D4=_X_U:
M!I8_,C#W$'S)_>'[KI[U%<RZ-9B$S_$74T$T(GC/VF AHSD!@1%TX//M6=X<
MCUWP[JUHNIZ1J%XMA82Z;'/:Q!A,JS Q, 6X!3'4]0>:=X<M-5\+ZRUS=Z%?
MRK<V3E8;1%D$3/=SRB(G<%!"R*.N* -"\?2+!XTN?B'JL;2PK<)_I$!W1MG#
M@B+H<'GVI+B;1K5HEF^(NJ*9H5GCQ<0'=&V=K#$70X//M63I7@[Q5;-*MGJ$
MFC7(T:*-'2..6/S3/<2>4Q93]T2*,KZ]ZBTS3=3TN_@>*U\1Z5 -(M;;98PP
MW#>9&\V\.SHV<;@01C(;\  ;=S)I-I>):3_$#64F<1D RQ8&_P"YN;R<+GMD
MBGL-,35_[*;Q]K0O/-$/EF2+'F$9";O)QNP>F<UE:]9:L=4OY],TS6$O;T6[
M1Y2.:SO,(HS<HPQ&PP5.,<*"*EGL-5@\42+I^F:G \VKI/+$ZQSZ?-%O4M-N
M8;HY-HSA2"&'?K0!KZK96NB"+^T?'&N0-,2(T,D+,^.N%$1) [GM5:=M)MH+
M6:7XAZJ(KN,R6["X@(D48!(Q%T&1^=:>KK=Z5XTAUX:?=W]H^GFS*VB!WA<2
M;\[202&!P2.FT9KGM&\+:VVNV-TTM[HT<D.HSDVPA9H?.N8Y$A;>KKG;DG Z
MJ>?4 VI],@M=)_M6?QQK4=CL$GGM- %*GI_RR[Y&![U5B&F3:9<:BOC_ %@6
MMLP29WEA4QL<84J8L@G(P,<Y&*U_&%A>3Z9ID]K#+?/IM_!=R0*5#SHF0V,X
M4L,[@..5XK%U%-2UF5-7@\-S6\-EJ-M=>6ZHES?*B.K97/\ !O!4,<G:>G%
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M+X9F?;M\8:ZVX;EQ- <CU'[KIR*R?'D-_JDXLK.&620:5<36L XS.Y2$.?\
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MFO6>&T9%,2H(YO\ 1MN?O_>,I+?=)&,9QC(!V@\*W)&1XMU__O[!_P#&J/\
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M_@-?%\5OJ=UK_P!KFD\E/*@N J;Y@&+[?G; )*CHJ\9 H VO^$4N?^ALU_\
M[^P?_&J0^%KA1D^+=> Z<RP?_&JY'1(O&]Q++%J+:M!;2R0L[EE\P*L4S2!3
MDXW/Y2<!>F0!2V6F^*=1U#1K/7!JKF&XM)I9-R"V\N.%9#OP<LYG4CIV';J
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M\6:;>:5%?7<\5@9+7[=Y-Q* RVY/RR-Z C!/H3B@"NWA:Z49'BO7C]98>/\
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M  'M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M -&M3?\ A"+-2#_;'B(X(X.LW!'_ *%3? $*V^A7<*,[!-2NUR[9/^M;J>]
M'54444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'I_A7544 <K_ &[XK_Z%$?\ @>G^%']N^*_^A1'_ ('I_A7544 <K_;OBO\
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M?V[XK_Z%$?\ @>G^%=510!RO]N^*_P#H41_X'I_A2'7?%1Z^$?ROT_PKJZ*
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MJ5E+I4:2W5I<P!9@C<*RC<0P//0]J )]1\#Z?J6NWVH2R,L&I61L]0M ORW
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M (W3\1_.N0\+:;8:GHM[%?V5M=QIJUVRK/$L@!\UN0".M=>W3\1_.N:\$?\
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MP[/-86E_)%;R%OO90'C/<# K7T'PII7ANXO)M-B>-KL1*X9]P5(TV(B^@ H
M\[CUJ+QCK7PTO+A"6N$U&"[B.5(D6WV2#'4<@^^"*MZ/X)\/?\+0UNR_L_\
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M X0M'-;/(4WJ-WWE(PPSZ'H: .G_ .$_T[_H%>(/_!1/_P#$T?\ "?Z=_P!
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M_P %$_\ \3758%&!0!RO_"?Z=_T"O$'_ (*)_P#XFC_A/]._Z!7B#_P43_\
MQ-=5@48% '*_\)_IW_0*\0?^"B?_ .)H_P"$_P!._P"@5X@_\%$__P 3758%
M&!0!RO\ PG^G?] KQ!_X*)__ (FE'C[3N^EZ^/KI$_\ \374X%&* *>E:I%J
M]E]JAANH4W%=MU T+\?[+ '%7:11M&*6@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#E?^:K_P#<%/\ Z.%=57*_\U7_ .X*?_1P
MKJJ $;I^(_G7->"/^05?_P#84N__ $:U=*W3\1_.N:\$?\@J_P#^PI=_^C6H
M Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3?\ Q5 '2;AZ'\J-P]#^5<W_ ,(3I_\ S_:Q_P"#*;_XJC_A"=/_ .?[6/\
MP93?_%4 =)N'H?RHW#T/Y5S?_"$Z?_S_ &L?^#*;_P"*H_X0G3_^?[6/_!E-
M_P#%4 =)N'H?RHW#T/Y5S?\ PA.G_P#/]K'_ (,IO_BJ7_A"=/\ ^?[6/_!E
M-_\ %4 ='N'H?RHW#T/Y5S?_  A.G_\ /]K'_@RF_P#BJ/\ A"=/_P"?[6/_
M  93?_%4 =)N'H?RHW#T/Y5S?_"$Z?\ \_VL?^#*;_XJE'@K3P>+_6/_  92
M_P#Q5 '1@Y%+5/3--ATJT^S027$B;BVZ>9I&R?=CFKE !1110 4444 %%%%
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M9,;E%M*2N>F1MXI?^%C>%?\ H)M_X"S?_$4 =317+?\ "QO"O_03;_P%F_\
MB*/^%C>%?^@FW_@+-_\ $4 =317+?\+&\*_]!-O_  %F_P#B*/\ A8WA7_H)
MM_X"S?\ Q% '4T5RW_"QO"O_ $$V_P# 6;_XBC_A8WA7_H)M_P" LW_Q% '4
MT5RW_"QO"O\ T$V_\!9O_B*/^%C>%?\ H)M_X"S?_$4 =317+?\ "QO"O_03
M;_P%F_\ B*/^%C>%?^@FW_@+-_\ $4 =317+?\+&\*_]!-O_  %F_P#B*/\
MA8WA7_H)M_X"S?\ Q% '4T5RW_"QO"O_ $$V_P# 6;_XBC_A8WA7_H)M_P"
MLW_Q% '4T5RW_"QO"O\ T$V_\!9O_B*/^%C>%?\ H)M_X"S?_$4 =317+?\
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M7<8KG]!\,SZ#%:6T?B#4[FRM81#%:SI;[ JKM4$K$&X '\7US704 &*,444
M&*,444 &*,444 &*,444 &*,444 &*,444 <H!CXK].NBG.?^NPKJZY7_FJ_
M_<%/_HX5U5 "-T_$?SKFO!'_ ""K_P#["EW_ .C6KI6Z?B/YUS7@C_D%7_\
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MB>)O^AO;_P %T5']B>)O^AO;_P %T5 '2T5S7]B>)O\ H;V_\%T5']B>)O\
MH;V_\%T5 '2T5S7]B>)O^AO;_P %T5']B>)O^AO;_P %T5 '2T5S7]B>)O\
MH;V_\%T5']B>)O\ H;V_\%T5 '2T5S7]B>)O^AO;_P %T5']B>)O^AO;_P %
MT5 '2T5S7]B>)O\ H;V_\%T5']B>)O\ H;V_\%T5 '2T5S7]B>)O^AO;_P %
MT5']B>)O^AO;_P %T5 '2T5S7]B>)O\ H;V_\%T5']B>)O\ H;V_\%T5 '2T
M5S7]B>)O^AO;_P %T5']B>)O^AO;_P %T5 '2T5S7]B>)O\ H;V_\%T5']B>
M)O\ H;V_\%T5 '2T5S7]B>)O^AO;_P %T5']B>)O^AO;_P %T5 $>@_\CWXM
M^MI_Z*-=37&VWA/6[74+V^B\52"XO2AF;[!%SL7:/IQ5W^Q/$W_0WM_X+HJ
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M6\CQ745SID*26[I]]7'(!'7J: -3_FJ__<%/_HX5U5>*1>*(I=(O?':^)M3
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M:_L3Q-_T-[?^"Z*C^Q/$W_0WM_X+HJ .EHKFO[$\3?\ 0WM_X+HJ/[$\3?\
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M?,,M#D'!@CC<G(ZEE8_C6A_PC&J_]#AJ_P#W[@_^(H_X1C5?^APU?_OW!_\
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M &,  C!R!]:V-4^%^CW']D6NGVD5OI]O?M=WD?G2!YLQE/O@[LY(ZGH*U_\
MA&-5_P"APU?_ +]P?_$4?\(QJO\ T.&K_P#?N#_XB@#'N/!-_HOB#3M0\'0:
M3;VUK92VIM[MI "7D5RV5!).5ZDU@ZG\,-<U.YN+NX_L6XDGU5=0>WF:7R6'
MD>65.%S][D>V*[;_ (1C5?\ H<-7_P"_<'_Q%'_",:K_ -#AJ_\ W[@_^(H
MY35?A_K=]H6G6$=AX6,-LLR-I\L4AA3><B2.3'F*V<Y (!KLM%T&ZTSP-;:%
M<7GVFZBLC;M.V<,Q4COS@9Q]!4'_  C&J_\ 0X:O_P!^X/\ XBC_ (1C5?\
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MS_PC&J_]#AJ__?N#_P"(H_X1C5?^APU?_OW!_P#$4 =-17,_\(QJO_0X:O\
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MQ:F,Q&-W15*+M0[ 0I(7@$CIQ4VJ^%=$UN^BO=1L%FN(E"!][+N4-N"L 0&
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MCVK-(HVF4R]F[2$L#U!/&*;_ ,(!X9^SRP_V:=DID,A^T2[G\Q!&^6W9.Y5
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M99Y!+O888^8&WG( !R>0 .U,F\!^&)FA+Z3$!#&D:(CNJ;4^YE00&*]B02*
M.(L/'6M#5$O=1FE72U-N@AB,3%PUD]PS/^Z!).T?=*@'C&.NG8_%"ZO8H0/#
M[+/>&W6SS-(L3-*Q 5W:)=I &3M#@]C760^$="@,1CL%_=/&Z NQ&4A,*Y!/
M.(R5P>O?GFJT?@'PQ%!/"NEKMF" EI9"R!#N4(Q;* 'D!2,4 8$WBCQ GPNU
MG60(!J]O<W42@L"L(2=HQ@[<-M XR.<<]:</'NH:= S76EBXM+6Z.G371NQY
MSW"Q[B=@C5=A8$9!'KM[5U,'A?1K;P_)H45GC39"Q>$R.<EFW-\Q.[DDGK4=
MQX/T&ZU*74)M.1KB7)<[W"EBNPMLSMW;>-V,^] &=)XMU"#P5;Z]-HT0N+N2
MW6WM$NR01,R*FY]@P<OR #TZFLA?B=/'J4]O<Z$_DVDS6]U);O+*8Y$3<Y'[
MH(4!&,EP>^VNUET;3YM,MM.DM]UI;-"T4>YOE,3*T?.<G!5>O7'-4Y?".@S:
MQ_:LNG(]WO\ ,)+ML+[=N\IG86QQNQGWH YJZ^(>HV.GV%Q=Z!$CZF8C9!+Q
MI5971W._9$74J$Y 5@=PP>#BM'\2+U[J(KI$PFN1:P1V<\OE(DLLUQ'NW&/?
MM/E Y(Z$84'.>D3X?^%XX7B32P Q7#>?)OCVYVA&W;D W-@*0.3574/AQH-W
M;VEO;VRVL4$L+.J,Y\Q(VD8+G<"#NE=MW7)[T 5_#_B_5-;\7K8264-M:QVD
M_P!HC$V\K/%<&)MIVC<O''3KTXJOJGQ U&V2]EM=&A:TCO+C3H)WN\.;B-';
M+1[,!"4(SN)]JZJR\-:1ITUK-9V8ADM8WBB9';[K'<P;GY\MS\V>>>M02^$-
M!FU*;4)-.1KB7<7.]MNYEVLP7.T,5)!8#//6@# _MC7(?A_X?EFO#_:FK36T
M$EYL1O)\XY+ !57(!P 1P2,[N^9XBUKQ)X=U"70[#4GOY+@V30W-UY22P"6<
MQ,,K'M;.!@E>,D_-@"N_FT;3KC1AI$UJKV"QK$(6)X5<;<'.<C P<YR,U1M?
M!VAVD;*EH[LT\5PTLUQ)+(SQ,&C)=F+$*1P,X]N: .!T[XE:U96FV^L#J-]-
M]INA&KMMCACE:)43RH"2Q*-][ XSN&<#=G^(6IBSO+ZW\-E[."\%GO>=]X;:
M&+O&D3,J@''&XY[8YK=NO _AR]M8K:?30T47F;0LLBDB1B[J2&!92Q)VG(]J
MEG\(:#<V3V<FGKY+7/VO"2.A67&-RLI!4XXX(XH N:%JBZWH5CJ:HL8NH5EV
M+() I(Y&X<''2M"JUA86NEV$-C90K#;0*$CC7HHJS0 4444 %%%% !1110 4
M444 %%%% !7%Z9X?T[6]5\07&H)<321ZDT2$74J!5$49  5@.I/YUVE<X?#>
MH07]]<:?X@N+2.\G^T/"+:)P'*JIP6&<?** ,#4HX?"5_KT^FFXB2#0)+H+Y
M[2$.K/AAYFX \=P1Z@UI:?XUFN?&0\/W&F&W1@WE7$LI#3;4#;E4H%8')'RN
M2-IRH%7(O"?GSWTFLZE-J:WEF;&2-XUB'E$DD?( ><GFK5MX2T*TUDZO!8*E
M[N+[P[8#%=I8+G:&(X+ 9/K0!@7GQ!EA\63Z-::-)<QV]U%:2S!I-P>0*=P
MC*[5WKDEP<9(!XSEI\2M2U>:UBTO28X/)U6"POS-=*VV1F8/&F%.X *#OXZ\
M#@UV-]X/T'4M4_M*ZL ]WN5BZRN@+*,*Y52 6'&&(R,#!X%01> _#,'E^1I:
M0F-(T4Q2NA C8LAR&^\"3\W7D\\T <K#\6Y9[-[V+P[-);.FZW99) 6_>I&
MY:(*I._(VL_0CBKUQX]U0M/IL.C6XUB.2ZC9/MI\I5ABCD+JYCR2?.0!2HYS
MDXK<'@/PR)Y9AI:[Y#DCS7VI\X?Y%W80%E4D*!G'-2W_ (,\/ZF)OM>GB0S3
MM<.PE=6+LBHW(((!55! X..10!R&E_$^YD_L^UDTN6\80V2WMP@DW&2:-'+*
MJQE-HW@G+KWP..=3PQXMU3Q#XDM3+:1VFEW>DM>VT:RB1G'FJJL_R@JV#]T$
MCGK6S_PA'AS[3:7']F+OM%B6(>8^W]T (RRYPY4 8+ D8%-@\#>'K.2YEL[)
M[66XB,+/#<2+M0L'VH-V$&X9P !U]30!T54M89DT2_=&*LMM(00<$'::NU%=
M6ZW=G-;.2$FC:-B.H!&* .4T/P=HEUH&FW$T%R\LMK$[L;V;EBH)/WZS=-U2
M70H+2TMQ<RQOK5_;K") Q9(TF=4R^3_ ,8(YQSC(.Y:^'-:L[.&UA\57(BAC
M6- ;.$X4# _A]JFL_"-A'91P:B3J,B7,]UYDRA<O*'5\JN!@K(PP1CF@"CX9
M\:OKVDZG=W&G+:3V"AGM_-8MRF[#!T1E/4<K@XX)%9D?Q(O3!")M!CCNKV"R
MFL8EO=P<7+E%$C>6-A!4DX#5U.E^%M&T:TN;:PL_*BN5"39E=RR@8 W,20 "
M0 #@=J9+X1T*: 0R6"L@M8K0 R-E8HF+1@'.05))##GWH P-&\8:OJOCB'2)
MK""UAAANDO$6?S/WL;189&V E<2+UQ]XY^Z,A^(4\OB:?2;/1'N(HKQK'S=\
M@/F!<[CB(H$W8!._/?;716/A;1=-FM)K.R\J6U\SRY!*^X^9C?O).7S@'YL\
M@'L*AN_!GA^^U&34+C3\W,A+,RS.@W%=N_:& #[>-V-P]: .2M?B3J&NR:8^
MEZ6D%L=5BL+QIKE6._RW:1%"J<A=H^?C/8=Z;;_%J6YL'OH_#LSV[Q"6W*R2
M#=F5(PKEH@JD^8"-I<<$9KK(? _ANW=&M],2 IY.WRI'3!B!$9X(Y )&>I!(
M.134\!^&4EED72U#28R/-?" .LF$&["#<JG"X!Q0!BR^/-39Y--AT:W_ +82
M>YA:/[:?) ABCD+!S'DDB5  5'.><5G:7\3KMX],M7TN6^F^RV+7LZ!PYDGC
M1B45(RF &R<LO?'2NQOO!V@:DLPN]/#F:X:Y=A*ZL9&0(Q# @@%54$#@XY%1
MMX'\.-+9R'3%S:1Q1Q#S'V[8L>7N7.'VX&"P)% &-X?\7ZGK_BG3A]ECM='O
M-/NKB "42/+LFB16<;1L.&;@$CYO45W5<XG@7P[%<W-Q!8O!-<Q/"[PW$B;4
M=@S! &PF6 /RXYSZFNC P,4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '#75QJ^KW_B:2WUNYTQ='<0VT,4
M<95B(5E,DF]26!+XP".%]3FN3_X3CQ9?ZE;3J\=II\T]K&Z0R(616M/M+X#0
ML2Q&>IQQMQSN'I6J>$M$UJ[-U?69DE= DFR:2-9E&<+(JL XY/# U.?#FD&\
M^U_8D\[SUN-P8@>8L7E XSCB,[<=/QH XBS^*=]>6L,L?AMLW8MS:DRRI&3+
M(L85W>$ $;U/R;P1GGCG9TGQI>W?BXZ!J.D)8R;7VOY[-O9%4DINC574Y.-K
M$C;RJ]M&V\"^&K.;S8-+1'#QNI\QSL\MPZ!<GY5# ':,#CI5FW\+:)::W)K$
M%@B7[LSF0,V-S<,P7.T,>Y R: .=U#QSJL&M26-EH5M-$-472DFEOC&6F:$2
MABHC.% X/)/H*;8?$C[9H]U?/I7EO;):%XQ<9!,\S1$ [?X2N>G/M74GP_I1
MN?M!M!YOVS[=NWM_K_+\O?U_N<8Z>V:SY/ 7AB5H&?2DS %"8E<<*Y=<X;YL
M,21G.,T <IK7Q'U>-M5LK728K2[MI!Y!N)F#2(+A(B<&/:0P?(*%P ><' /2
M>,/%\WAC[#'#8Q74]T)&V-*XVA "<+'&[MDD#(7 [D<59_X07PUYMU)_94>Z
MZ#"3YWQ\S!VVC.$RP!^7'(!JWJGAG2-:^S?VC:>>;962)C*X(5@ P)!!8' R
M#G.* .2C^(.HZQHUW?Z3I,26L%K&TL\MV!)%)+;B92J%<.%WJ#D@D] :9HGQ
M$U'5M)TEK72(YY[ZX%E&]Q=>26D6 R/(ZJC;%^7@=2"#@#&>B?P#X7?R0VD1
ME88DA1?,?;M1=J9&<,5' 8Y(P.:MV_A31+748;^"Q"7,.PHXD? *QF)3C."=
MC%<D=,>@P <F/B;=3:;+J%MH<;P65A%?:@'O-K1J[.NV,;"'($;'DKV%/E^*
MMO#++;/I<GVN)98VB$PQ]I65HXX,[>L@1F!QP,<'-=$_@?PW(MJKZ7&RVRA(
MU+O@J&+!6&?G 8D@-D#)JPWA70WNI+EM.B,TEXE^SY/,Z#:K]>H'X4 >?:=\
M4]2@TFVCFTU]3OE@ENKAD$@)07$L:H@CB8%L1G[VP<#GKB]J'Q%OX;Z*_6Q6
M+1(9-05P)=TUP;:-\@H4^3YE.,,>G.*Z>3P#X8FM8+:72D>* ,%4RORK.7*M
MS\Z[F)VMD<]*+OP+H%S<W5Y'9)!?7$<R>>I)"F1"KL(R=A)!YRO/?- '/77Q
M)U#3YI;*^T*!+_[1!#$D-U)-&PEB>7)*Q%Q@(1@(<GVYK8?QE<)X$7Q#_8\B
MW+3) +*5VCR[3B$'<R9VDG<"5!QV%5=!^&FFZ997L&I2_P!HM=2Q2%@K1>68
MU*J5(<L&P3R&[X&!Q71IX<TB+18M'CLD33XG61(58@!E<2 YSDG> W)Y/7-
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MM0G)5020BY .%P.*RM7^'.@:E:WJ0VD=M/>,&DE^9QCS5D<!"V%W%.<8]>:
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MT5+LLSE)HX=K_( H+2*<C=QFNH\-:Y>:PVJ0:A8PVEUIUY]E=8+@S(_[M'#
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MBWNVD9I;>18V&#&,*6;@\GCI75V?@;PU83^=:Z5'$^^-QM=\ QMN3 S@ $\
M<59;PMH;IL?3HG3-P=KY8'SVW2Y!/.X\_P L4 <K:?$#6+R]@TV+PZBWT\[1
M1O/+-!"0(C)NS)"'.,%2-O7'//$_A7Q?K/B34;R:.QMQ9FRL+B&!KC#1^;N\
MS)V<X ;'KL7IN..@T[PAH.E3QW%EIZ1SQNTBREV9]Q782222?EXYZ=J8/!^C
M0PQQV<#VGEI!$&@E8$QQ2!T4\\C(QD\X)&>: ,GQOK^HZ>\UKIMQ]FD@TB]U
M)Y=BL28E"HHW C[SAC_N =S5(>--5&FO->6T5K<V L;J=(9?-2XM[ABF"2JE
M7&&.!QE1S@FNHUOPY:ZY=6DUP2/)2:&5,'$T$J;9(S@@@'"G(Z%15,^"-(AM
MXK2QA6TM/M,=Q<QJ"QN!'RB%F)(4,%..F!C@$T 5_'6I:A8)HD6GSWL37>H>
M1+]ACB>9D\F5\*)05ZJI^@-<]8_$2ZT33[D:Y%<7'ESW<4#S[(YS)&$>."14
M79O=6R"O& .,UWVK:)I^N101ZA"\@@E\Z(I,\;(^TKD,A!Z,1U[UCW?@C3YW
MTN&$1PV%E>_V@\'EEWGG PK-(Q)XSDYR3@<@4 ,\3^++KP_;Z6JZ?%)>WV08
M6ED;857+ ".-W?D@9"X[G%9&G_$+4->T][O3-(@2WAM[=[F2:\"O&TT8<; 4
MPX7(ZD$] ,UU^K^'M*UTP'4K19S 6,1W,I7/!&01P<#(Z&J!\">&";;_ (D\
M&+9$CC7+8"K]W(SAL=B<D=J .5\/?$?4]4\.Z3+%I,=Q=7-Q!I_F7%SY+/,;
M<RO*R*AVI\N1C[P.0 ,9G/Q)OY;"6YMM$@<V>GO?WRR7A7:J2R1E8SL.X_NG
M/.WMZUU<'A+0K:ZMKF'3T26V$0B8.WR^4C1IQG!(5V&3S@_2HIO!/ARYC@CF
MTJ%T@W; 6;D,Y<JW/S*6).ULCGI0!S,_Q8M;9YHI=+D$T/VA'03=)5W&!.G6
M948CTZ<YK+L?B=JUM8B";36U'4 ;RXE"B0@1QW#QI&OE1-DX7&Y@HX&3S7H4
MOA?1)[J>YETZ%IKB>&YE8Y^:2+'EL>>V*J3^!?#5S;I!-I4;QJ\K@&1\GS'+
MN"<Y*EB3M/'M0!R]Y\0M1>_L[R&R%OHT5]<P7&9,SRF&UDD93&5^4;EX(;/R
M^AI6^(&J?:8(;S38[5]]I,!:W8D$D<T<S!6+1\8\K!Q^!]>IF\%>'Y=0.HII
MT45[A@LT>0%+(8RVS[I.TXY'/&>E8WAOX9:;HGVAKR;^T'E,)7]V8E3RU=5(
M 8\XD;OCI@#% %6'XC:BT%OYVA01W-_;V4]E&MX64BYD**)&\L;<8R< ^E::
M>-+J/P3JVNW6EQBZTV>>![6*XRKM&^PX<J."?:K6L^"=-U+2#96H6SD%O!;1
MR[?,V11/O1-I/0'/((;G@@T[0_!EAI7A630+AC>6\TDDD^X% Y=MQ  .0/Q[
M=: ,)_B%J=OX@?29] #R6T\%O=FU:>4!I<$%&$.W"JZD[V4]<#@99)\2+^+0
MK767T.'[)J)C&GA+IGD8NX4>8BQEAP=WR!_3J1767GA70]0U:/5+K3HI;R-E
M82$D LOW2R@X8CL2#CM58>!?# -P?['@S<##\M\HW!ODY^3Y@#\N.0#0!R4O
MQ+OH-]U+H\ZR10LIM'D,4<C?:88E<&2(.!B7/('0C'>M*P\7:U?^-+#29;*U
MMHXY+R"^5)S(&:-(75D)0'&)5XXZGT&;^I?#K0+S2386UI':JS)O<;G+H)DF
M=6R>2QC +'G^5:UIX7T6Q^R&VL4B:T=Y(75FW!G^^2V<MG SG.<#T% &%J_C
M:_L-3U**TTF">STVYMK6XEDNC&YDGV;=JA""H\Q,DGUP.*RK7Q%XEB^$EOK[
MS0SZK<SPN#(RA%229$VC$8P,''()&2<G KL[KPQHMYJ\>JW&GQ27J%6$ASR5
M^Z2N<,1V)!([5(= TLZ$NB&S3^S50(L&XX !R,'.<@@'.<\4 >>/X]UVRT34
M'OK9"C-J@M;N"=1*/L[O@;#&5  &T$[ONY(YKI=/\9W%SXU?0+C3!;1'S!#/
M)(VZ;8JMN7*!&!R>%8L-O(';5E\(:#-9+9RZ>KVZ^?A3(_\ RV),O.<_-N/Y
M\4^W\+:)::R^KP:=%'?L68R@G[S##,!G 8CJ0,F@#E]3^),FG>)I=-&F1S6L
M=T+1IDE<MO,>_)(C,:\\;2^[OBJL?Q)UDI'-+X>LXX#:6E^V+]F98;B38HQY
M0!<')(SC'>NLN/!7AV[U%]0GTR-[EY1,S[V \P#&[ . <<9QS4Q\*Z(8?*-@
MFS[/#:XWM_JH6W1KU_A)S_/- '%/\6+A8;N\3P]-+91I<M$X,JDF(D?.S1!!
MNP<;6;!P#[:G_";ZJ-4.B'1K0:RUY]G1/MK>1M^S^>6+^7G./EQMZ]\5L2^!
MO#4]Q<SR:3"TERKK)\S ?/R^T9PI;N5P3WJS?^%=$U-KAKS3TE:XE6:1BS!B
MZIL# @Y4[>.,<4 <%IOQ)UQ?#UO.VE07TD-O9M=3R77E%WN9#&H55C(X(Y/'
M%6[GXG7]O*;%="274HC<^?'%)-+'B%PGR&.%FRQ/5E4#N>:ZZ#P?H%M:&UAT
MY$@(@78';&(6WQ=_X6Y_GFFWO@SP]J*,MUID<FZ625CO926D.7R0<X; RO0X
MZ4 <XOQ"U*X??#H4<5LUW]A1I[HK*)C;^<NY-F !PIYR/0U=M/%>HP?#SP]J
MUS:Q76JZFMK$J>;LC:2; #,P7Y1@[B IQT&>M;\?AK1HE58["-%2Y%VJJ2 )
M0GEA@,X^YQCI[4O_  CFD?V$FB&R0Z<F-D#,Q"8.X;3G(P>F#Q@8QB@#C9_B
M/JL;W]LF@VS7>FP74]YF^(CVP%<A#Y9+%@XQD#'.:V_$OC)]$AT@6MB;FXU0
MMY:L)"J*J;R2(D=B>@P%]^ *T(?"&@6]N\$6FQI');26K@,V7CD.7!.<DDCD
MGGWJSJ7A_2]7LH;2^M%EA@(,7S,K1D#'RL""...#TH X6Z^*T]N+5SH10&&"
M6YBDDD\R(R2%",+$0H&,@R%-V1@4_5?'&OSZ-#J.F:;;16MQ?QV]J[78\R3;
M=I"R.A3Y0XW<KN*CWQ72R^ ?"TPC#:- %CC2)41F5=J'*Y (!(/0GFI&\$>&
MVU WQTF$W/G"</N;"R!P^Y1G"DLH)P!G'.: *UOXND3PIK6L:C8K'+I#W"3P
MV\ID5S$,_*Q4'!&.HXJD_BWQ FH66E-H>GC4KX/)"/[1)B$2H&)8B/<&R0N-
MN#R<\5U46DV$-O=P):IY-X[R7"-\RR,_#9!]?3I6.O@'PNMN81I,8!</O\Q_
M,R 0,/NW 8)&,XP: .=T_P")]SJ7^D0Z'&ME%)91W+O>?O%:Y*JNU0F"%9N<
MD9'(]*W/#7C0>)-2:QCL##+;V[/?9EW?9IA*T8B/ R3L<YXX XYX6R\ Z)::
M_/JWV2)G)A^S1!-JVXB0(H !P<8R,C@]*O>'?#JZ%_:,\DR7%[J-TUU<S+%Y
M89B   N3@ #U/))[T <5KGQ'UF+P[=7]EI=M#%<Q7HT^=KDLZM;[LLZ%,#(1
MB ">0 <9R-G7-6U_1++PQ!'+'+<73R1WLDKJ22MM)(<$1@'!4G(5<[0, ,<;
M+^"O#DDMY*VE0EKQ)(YN6P5D^_@9PN[N5P36AJ.CV&K101WUN)5@D$L7S%2C
M $9!!!Z$CW!(- 'GUG\2=5T_P_:OK&E12WTUA8SP-#,S^<9V\L%PL>5.1N(0
M-UP,FM^#QO*O@K5=?O=)FADTYI$,&'03%0"I4R(K!3N R5&,'KBM>3PIH<MO
M]GDTZ)XA:QV85B3B*,Y11SQM/(/7/>I;/PYI%AI$VE6]A$+&?=YT39<2EN&+
MELEB?4T <)KWC'Q4NJ6VBV]E9V=_'=*9VBO-R21F"255#-"<9\I@?ESP #\V
M5K:%\2-8BLK&WN].FU.Y\BUGO)D#LQ^T88!!'!L 52#ARO<9;&X]Y:^#] LA
M&(-.12DK3!R[,Q<H8R2Q.3\C,.3P#Q39/!7AR9[-Y-*A8V<<<4(+-C9']P,,
MX?;CC=G% %?1/$NH:KX:O-<ETJ..-%E:U@BN=\DVPL,-E5"DE>.O7FLOP[\0
MI=8OK6QN=,2WN9I9(W42N#%MA$@RCQJP)R5Y '&02*ZR'1]/M](;2H[6/[ R
MNC0-\RLK$E@<]0<G\ZRE\!>%UM!;#2(O+$OF@EW+;MNW[V=V-O&,XQQ0!R>F
M_$;5;F[N-1:PB;2/L^G3/$;C$EO]I^7Y,)^\Y.3DKP.*?)\2]:^SFYB\.V?D
MFQNK]-^H,&\JW?:^0(OO$D;1[\D5U4/@7PS!<V]Q'I,0DMTB2(EW( C_ -6"
M"<';VSGGFK/_  BFA_9_(^P)Y7V6:SV[V_U,K!I%Z]R ?7TH \[U?Q[XBB;5
M'TWR_)@L]2F!N)%+(T)BVE0(^0N_A2>=QR>!G</Q'NH]<:P?1))(;:XBM;J6
M$3.4=D5F8$1;-BEA]YE) )QTSTK^#] D!#Z;&P;SMP+-\PE 60'GD, ,@\<
M]12#P;X?_M"WOCIL;7,&PH[NS<H-JLP)PS   ,<GCK0!B>%?%&KZ_P"(HFNK
M>&UT^ZT>._MH8Y?,.'<X+$JI#8P"!D>];>N:]<Z%X9DU.XL$>Z$B1);)/E2S
MRB-,OMX'S*2<<<]:DTGPIH>A7LMWIFGQVTTJ>6Q1FQLSG: 3@#/8 5.FA67]
MB/I%RC7=H^[>MP=Q;<Q;K[$\>F!Z4 <Q;^-M7F\1Q>'O[%M!J*SRI<.+UO*1
M$2&3<I\O+$K,!@@8(ZU/XE\67&B:U<JD;26VGZ>ES)"N ;B2:;RHEW$':H*L
M21ZCTP=O3_"^BZ5+!+96*12P^9LDW,6S)MWDDG+$[%Y.3\HINI^&[/5-5CO;
M@*RFVDM+F!UW+<1,00#Z%6&0?<^M &7'KFL0:]I<&IP6]N+JXELG@MYQ,A81
M><DH8JK#A'4J0.H/N><\6^(/$%IK'B4:?=:LL>FVL4T"VEO;O C%&8F7>N_;
MQSMYQG%==8^#=,TW5K:[LT\J&V$CI!RQ:9P%,K.Q)9@@VC/0$^O$U_X0T/5+
MZ>\O+-Y);A528?:)%250, ,@8*PP>XH R]-\<C4/$,6A"Q!OO.D$VR;*I;K&
MKK./ER0_F1@#U)Y.*["L/3?#<=CXDU'7)98Y;FZCCMXPD(C$,*9(3J<G)Y/'
M0<#%;E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 <9?_$?3M,\17^DW=I/&+*&2:24L@+*D7FDJA.Y
MEQD!@.HQ[U1M/BO8WOEQ6^EW$UU-/##%%!<0R!C*LA7+AMJX\MMP/(R#S6]=
M^!]%O]5DO[Q+F?S"[-;27#F#<\9C9@F< E"1^/K67?\ PXM+A;!(-0U$""]C
MN))9KV1Y%2..146-L_+@R ^^.<T 5-3^+6FZ98V]S-I\XWQ2R21//$CH8Y&C
M=%!;+L&1NG&,<\U9O/B5!9Q7%PVDSK:QWSV$=Q-<PQ))(A;<?F;('R\=R3C%
M6KKX:^'KN#R2M[$C6IM)?)NW4S(69SO.?F.YV;)ZECG-6Y? ^D2PPQJUW"\%
MW+>130W#)(DDF=^&'8[B,4 <S;_%F%Q>7TVGNFF+;6CVQ+HK-+,\B%68M@+E
M#SQ@(Q/45HWOCTW7P\U3Q#I42QW%G+Y.V0K(FX.H)#*<,"&!!!_E5V#X=>'[
M:V^SPI=(GE)&"+E]P*2-)&X;.0ZLS8;KR0<U=D\(:=-X:N="EEO);>Z??-++
M<&25VW!L[FSZ#CI0!R^J?%JS@;5+;3[,S7-LMU'"QEC.Z6%&8[HPVY4^1N3C
M./<4+\3I;$7K:QIGV?;<VUM;+YT:!GDMQ*V]R^ !R<^A Y.:Z-_ VC27=S,_
MVPPW/G%[073B#=*")&" X!8,WXDD<TQO >CLK_O+Y96:*03+=,)$DC3RUD5A
MT;9\I]1U% %?0?'L/B/4;:TL-+NF#P>?/,9(]D(\R2/KN^?+1'!7(((--O/B
M#;V=W<[M+NVL+>[>Q:\5DP9U3<5"YW8XVYQU]N:V=(\,Z?HMR;FU-PTS6ZV[
M//,TC,H=WR2W)):1CG_"J=UX'T6\OY[J5;G$TC3/ +AA#YK)L,NS.-^._P"/
M7F@".7QK#9^"6\4:AI]Q:6Y6-XH7D0NZR%0A)!PN2XSD\<YKF7^+EL+\3&'9
MI]M;73W2HR2EI$\G9Y<BMM(/FX]CUQBN[N- T^Z\/IHD\;O9)$D2C>0P"8V$
M,.0P*@@CN*Q_^%>:'(^^Z:^O&:*:*1KFZ:0R"39N))Y!'EIC&,8]: ,^Q^)M
MKJ<J6=CI<USJ3S&-+>&XB9& CWEO-#;< <8ZYXQWJ.S^(=_-?W5K+X<NS.]^
MMI9VX>-'_P"/99V$A+X! R?Q Z@UL'P+IAB7==ZHUTLWG+>M?2&=3MV$!\\#
M;QCI^/-/T_P-HNE:A;WEFEPC02"5$:=G7>(3#N.[))*$ \\X!H QG^*-K#8Q
MW\NC7ZV=S$TME(K1L;E5D2,X7=\I^=2,]1[T7?Q'ALIF>^M+FS%H;E+JVVI*
MS-&D3C:X;'(E7'J3SC&:T_\ A7F@89-ET8QQ#$URS);CS%D(C4G"@LBY]ACI
M4]WX'T2^NKJ>Z@DE-TTS2HTAVDRQI&W3I\L2X]#S0!H:9JEQ=6US+J&F3Z:\
M#899G5PR[0VY64D$<X^H-<['\06ELK&Z3P]J'EZFT2Z:2\0%QY@9AD[OD(52
MQ![>_%=#I&@VNC1W"Q2W=P]PP:66[G:9VP, 98] .PK'3X=:$D:(K:@/)VBT
M/VV3-H%.0(N?EQT^G'2@#+N/BG;V\5PW]@ZB[64?F7R!XOW&)FA*YW?,=R'&
M.".XJ2?XE_9S<POX>OC>6@N6N(%EB(C6!(G=MV[!^69<8[\5JCP#H2VMS;B.
M?;=0+#.S3%FD E:7<6.26+NQ)]ZFE\%Z1->W]VZ3>;?1SQ38DX*S+&CX].(4
MQZ<^M %#2?'L&J:O;:9-I5W:3W++Y7F,C#8T+3*QVDX^5",=C56#XF6MRJ30
M:/?-:@6K3SEHP(A</L3C=ECGKCH*U;CP+HUQ.L_^EQ3IY7ES07#1NGEHT8P5
MP>59@?7--M/ 6B66G26,*7 @D6V4@RY.('WQ\_7KZT 4-'\=R:B([>VTR\U&
M:,*]W+"J1B%7F>-/E+DD_NV)QV&>^*QKOXO)*DT.E:89+M"C(K3Q.-GVB.)@
MP5_E;]X, GOSTKI?^%?:&!&J?;(U"[)5BNG03J)&D"R!2-P#.V/8D=*KQ?#+
MP]#$D2F_*1PF"%6O'(A3S$D 09^7#1J1].<T 5$^(ODP70&G76H26B75S=-$
M(XO)@BGDBS@N=Q_=MT/.W/&<5H:7X\@U768+.+3+N.VN+J>TANW9-KR1 LWR
MYW8(4X)'7BGR_#W0Y8O+/VU0PE68QW3H9TDD:1XY-I&Y2SMQ[GUJ_:^%=+L[
MBUF@216MKN>\B&[@22A@_'IAS@=J *>L>.=-T/57T^]BN%E5[=5*J"'64N-X
MY^ZOEN6] *PK'XE37.LWW_$IN'TB.YMK>.Y!12GFN8U8C=E@S8(P.%(S74:O
MX2T?7-06^O[<R3K:2V8;=C]W(,-^.,X/;)J&+P3HT%JUM%%*D)-H=HDZ?9BI
MB_\ 01GUH P[#X@37VF$V>F7>H306Z2W4\:)&L7F%@AV%R3C;DX)P.?:M#P7
MXNN/$$%M!?Z;+9WCZ=!?;BRE)EDR-P )*\J>#S@BE;X<Z"8$@7[;'$(EBE2*
MZ=%G56+*) "-V"QQ^72MC3?#MAI5Q!-:K('@L8K!-SY_=1DE?QY/- ',3?$3
M[%-J,']G75_):&\G<Q!(A'! X5OO/\QY&/7T%1^(?B)<P:#K-[HNDW$T5BKQ
M_;7V&-)EC$F&3=NV\@9]3CWK>/@G1S+J$A6?=?PW,,W[S^&=@TF/3D#'I5+4
M_AMH.JQ7,,S7\<%P,R0Q73+&7V;/,V=-VT 9QCC.,T /F\?:;:V@N+B&X6,7
M-U;NP .#;QO([=>A$9Q]16(_Q.>PNKU]6TUK2'%FEG!)-&&9IEE8EI-VT+MC
M_ @CG(K??P!H4FI->R)<N&>61K=KAC"6EC,<AV9Q\RL<U'#\.]$ACF42ZBTD
MC0LD[WCM+"8@PC*-G*X#L/<'GO0!FK\5=-=M+ T^X OG*;VEC50PE\HA&+8D
M.?F^4_=P>^*U/&'CBT\'FW6XMC,TT<D@_?QQC"8R!N(+,<\  ]^E+-\/]%N(
MH(II-1=(QB16OI"+@;_,_>9/S?,2?TZ<5<USPCIGB"[CN;MKJ.98'MF:VN&B
M+Q/@LC;3R,@4 )J7BB.RT?2[^VL9[QM3DBBMH4958F1"RY+$ # YKBM0^,<,
MFD7KZ1IS/>+!*UMOFB?#(P4F1%?*CDD9Z@5W[:!8M9:5:$2>5I<D<EO\W(**
M47/KP362_P /M$=+F(M??9IDD06WVM_*B#MN?8F<+D_EVQ0!B+\5;&SN9+"]
MMY9;BU+P7#H\08S)&7<>4')"Y!7=R,^W-+<?%JQLI8X[S2KBW<PQ7#QR7$.]
M8I#\A5=V7; )*CI]36_=^!M(O+RZG=KU$N2[RV\=TZPM(Z%&?8#C<0?IGG&:
M?=^"M)NYH92U["4AC@D%O=/$)XX_N+(%(W8R??DT 8[?$ZR@A>ZNM*OH;,QW
M+0S$QL9C!((W4*&R,LPP3C/M1JWQ)30Y([;4]&N+2^D\QQ#-<PHK(@4[E<MA
MLEP !SD-Z9K7D\#Z'-9PVDT,DD$*7,:HTAY$[[Y.1SG(&#VJNWP^TAR93=:K
M]L.X->B_D\]E8*"A;/W<(O'MGK0 _5O%,T.E>'M1TRT:>'5KNWC(DPK)%*I;
M."1AL8]:;H7C>+6[ZSA&FW5O;ZA%++8W,C(5G6-@&R 25Z@C/:M>\T"QO=.L
M[%Q*L5F\<ENR2L'1H_NG=U/XYS532O"&DZ-J O+5;@M&KI!'+.SQVZN07$:D
MX4$@?ECI0!RK?$#7%UTVJZ)Y\2W=_!Y<;HK,D C*MN+8'WFSZY%6G^+&CB_M
M;9+>5EFCM7<F6-73SPK(!&6W/@,I; XSWQ70)X0TJ/59=143B60S,5\TE TH
M42$#MG8M5X_ >C0R6K0M>PK;QP1M'%=NB3B$ 1F0 @,0 /KCG(H ;XL\;6OA
M*XLH;FSFE%UN(D#I&@VE1C<Y +'=PO?!K!\2_$U]/T74;JRTR9$5[FVL[V4H
MT<EQ"K%@4#;@O[M\'OM[9KJO$'A33?$NW[>UV%$;0NL%R\:RQMC*. <$' ]Z
MSK_X<>']16ZCE6[6&X\UA MRWEQ/("'D1#D*Q#-SC^(^M %.T\>2RW%Q96^F
MW>J7L,EP[QP*D>R&.39QN?YCG@ <G!X%4+;XDW,,VH27=DTMA:VC3>=^[A8O
M]KD@ .Z3 7Y!R?[I/&0*WY_ &B3%R&O87D:8RO!=/&TBRMN=&*D94GMV[5&_
MPX\/O;" )=(H7:"EPP/^N,ZGZK(Q(/OCF@#F;GXKRW2R2:?9&.VBM;QYI\I/
MLDA$1!7#@,N)1]2P[ UN7WQ)M;!;JYETF\.G0S7-LEVK(1)+ CNZA=V0#Y;@
M$]QVS5B3X:Z!+#.CF^9K@S&61KIF=_-1%D!)SD'RD/L5XJ>\^'^A7TMVTR71
MCN?.9H!<MY222JRR2*F<!R&;G_:/K0!;\/\ B3^W+B\MY-.N+&>U$3F.9E8E
M)%+(?E)P< Y':N9N/BYI5K>WUO)8SM]E6=L131.[>4<,"H;*D]1G]*[2STBU
ML=0NKV$/YUTD229;(Q&"%Q^!-<Z_PR\/2 HWVXQ#SA'$;IBD0E.7"J>!D\T
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M=F)TE6.2(YD)#*\K2D$=#AG8CZTR3P?I$I'FQ2.OVJ>[*L_#/,C(X/L5=N*
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M:+-)$B(;@!]N[([_ '161?>"=*U"[N)99+U;>ZD$MU9QW#+!<,,<NGOM&0,
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MM&:S54@)3.U5.5'O@\C.<58_X1O1O)CA.G0-%'%+"J,NY0DI!D7!ZAB!GZ4
M<3#XP\36VNZCI<MK87%ZU\T4:F=A# B6D<IP=FYLY/!Z$]<5$OQ1U1+"VFN-
M%@\Z_M[.XLT@DDEP+AG4!PJ;B0(R<*#G('O7;6'A'0-+96L=+@@*NT@*Y^\R
M[&/7NHQ3G\*:%):"U?2[=X!;1VH1ER!%&244>FTDD'K0!Q;_ !(ULVMTR:#
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M+C9G*;@P7Z @$>F.,5$_@?2Q-I,=M&EMIVFW1O4LXXQAY\$!RQY&-Q.!U.*
M*_C/Q9J7ABRLIK?2TN6D222X.YV6$(H)X12V"3C=C"XYZU1N_'LDFE226UO&
MK27\]A'(DN[&VV:82#CG[H&/?-=3K'A[2-?6)=5T^"[$))C\U<E<]0#Z'C([
MU6?P=X<DU#[>VCV@NO\ GHJ;3]PIV_V3CZ8]* ..T[X@:Y'IND6MUIUG<:C?
MVUC+!(+E@C+.2NZ3Y.&!7) !!SQTJ&X^(>LMIV^[L(+9)A<+')9W),@>WN(X
MG/S)@*Q8XX)P*[BQ\'^'M-15LM(MH LB2C8N"&3.PY]LG Z<FI)/"VAS0I#)
MIL+1H92J\\&1Q(_?NX!_"@#SV'QYXCTZ:2\U)+>XLK>'5YI(HFPS_9[A409V
M<8SM'JI+'D8K4L_B!K5U=PZ8=%BBU"XN(XH))Q-#"0T4DC9#QA\CRB.!@[A[
MUUW_  B^AF=ICI=L9&>60DIP3*,29'3#8&1T)Y/-5T\$>&(["6R71+06\LBR
M.NS)+*,*<]> 2!SP"?6@!O@;4+S5?!FFWU_)YEU,C&1N.3O8=@/2J'C/QC>>
M%[JT$.G)/:M&TMQ<.S[8E#*.=BMM&"3O;"C&*W/^$?T]-&@TFWB-K9021O''
M =NW9() ![97GV)HU;PWHNNRPRZIIMO=R0@A&E3) ."1[C@<'B@#E[[XCBPT
MP7SZ<'4/J2E$EYQ:EP"./XMH^F>]4M2\4>+;?Q#I]JMMI0D-I=7$D*7;-&R*
ML3*6^3<""64= <Y[5UZ^$?#RZE+J(TBT%W+O\R39]_>,/D=#N'7UIMCX.\/:
M9)YEEI-M!(4>,NB\E7 # GTPH^F.* *=[XJG3P[H%]9V4;W6M/!%#'+(0D32
M1F3+, 20 IZ#DXZ5S<'C/Q';ZYJ+75M8265O<V-K/''=%_*:63RCY9"\\D,0
MV,=.N:[RYT+2[S2(])N+&&6PC5$2!AD(%QMQW&,#!JO;>%-!L[9[:VTNWAA=
MXI&1%P"T;;D/U#<_7K0!PD_Q9O()+AQH\<UOY=P]LR/(JR&)U7 =D"MD-G*9
M Z5KGQIK?]IMH@TVP_M87K6P8W#^1M%NL^<[=V<,%QCU-;8\"^%Q+)(-$M \
MF[<P7!PQRP]@3S@5!XF\$6/B*$A7%K,]R+F63R5E$K"/R_F#?[.!QCIW&00#
MEH/BKJ%W%:RVV@M*HM+6YN0BRO\ ZXGY594*K@#.7(R>.V:Z'QAXMU'0+EX-
M/T^VN?)TVXU*9IYF3"0E05 "G).[CI5NT\!^';>QTNVGTZ&[?3H(X(9IU!<A
M.F[L>><'@$\5KWNCZ?J+R/=VL<S26TEHY;/,+XW)]#@?E0!P<WQ&U>WG^PR:
M5:'4'EC"1PO--E&A\WA4C+,1D G  ZY%3Z-\39-5DTRT;2ECOM2^S26\0F)#
M0NK&63[O\'ER#'?Y>F:ZF]\(^']1D,EWI5O,Y*MN=>?E7:/_ !WC%06'A"QT
M_P 00ZG#L6*TM#:65JD05+=&(9\'J22/P&1WH P?$WBO5]!\6ZA]GB@N--LM
M&COIX99"C "60,4PIRQ '4X^4>M2:7X^O=3\5#3TT>0:>U]/8B?RY<J8@V7+
M%/+()0C:&R,CW%=)J/A?0]6U&/4-0TRWN;J-519)5R0JDL!Z8R2<4Y/#.B1Z
MV=933+9=1))^T!/FR1@M]2.">M ',:MXUUJUU^XL+'2K*2"+4H--$LURRLTD
ML*R!L!#A5W<\Y/M6/>_%B_M+".X&DP2O%;M->)&TK[-LSQ'E4(0'RR07(SG&
M.*]$?0],DN6N'LXS,]REVSG.3*J!%?ZA0!6=<^!O"]X +G1+27",GS+G@L7(
M_P"^F8^Q)Q0!R&I?$+4[:\BU7[-$NC0_VD!!'(3+.;8%?G!7"Y921@\ \YKH
M?#?BG4M:@U6.]TUK.6TA26.012HK[U8X E16RI7KC!R*U1X2\/C5)=3&D6OV
MR4.))-GWPXP^1T.X=>.>]3:5X<T?1(9XM-TZ"V2XQYNQ>7P, $]< $X';- '
M!Z)\0M7MO#5A<ZQ903DZ9;ZA)/%,=Q@+K'*[#: & ._ XQD<8K5UCQ9>W?P]
MN==T\&T#7\<5K*K!C)#]I2/?R.-PW<>A%:LO@;2(-#O]-T:W@TK[;#]GEFAA
M#-Y>""HS[$_B<\UJ-H&F2:%!HLEJKZ? D2)"20 (R"G3T*@_A0!YOJ_Q.UJ7
M2=5FT[2C;QB*\%M=-'+^Z,&[YV+1^6V=C?*"<' /?%T^.]?TZ\OK2ZLH+FYE
MU;[';+"))%B5;9)7X2,NW7(XSECG 6NR/A#PZU[<WC:-9M<72NDSF,'>'&'X
MZ?-W]>]$O@_P]/!+#+I5N\<OEEP0<DHNU&SG.X+QGKCC- &-X7\8:MXDU5+<
MZ3#9P0VR379EE<2!G:5 $4J.,Q9^;!PW3-4=1^(>H6"7=^=*MGTR*\N[&/\
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MVKOR"?.VGYC@@GGI3K/QIJUUJ<EE9"T@FN[IV6:^9Y(HE2TMY=H 88R93T(
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M.\*P:0B;6(PQ7#=2.#CM0!BV/Q%\2WGV2#['IR3WS6ODO(A41B8L#E!*6<#
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MR/%$'P9%8@-][<C*I &<GI67XA\9:]!K,>G7-U:LUM#-</)IK/$DJM97#JC
ML2"K1 @Y[J<"NI'@_7!J,NHC4M$^W2J4DN?[&3S'4C!!;=DC'%5X_ 6IQ0I#
M%=Z#'"C.RQQZ*BJ"ZE&. V.5)!]CB@#+U'QQJS>&]8O%ETVVM+-)+41332)=
M2.+;S Z.&ZDD8&,XR=U-'C7Q!IXN(1+;7-Q-JUU%"K0/(R0QHIP%WJ,#<,EG
M7&>];,_@75;FX:XGO-!EF:+R#(^BH6,>-NW);.,<8]*2Y\"ZI>2,]U=Z!.[.
M)&:71(V)8# 8Y/7'&: .<TOQUK.H31:G<E3;336+):P,R[-]M([J.>067H?;
MTJ^GQ"\0B/2U,6D33:M;VMQ!Y0D MQ-*D>V3YCN($@.1M^Z>*UX_!6LPS031
M7^AI+ %$3IHR QA<[0#NXQDX^II(/!.L6I<V]]H4)DE6=S'HJ+ND4Y5SAN6!
MY![&@"W'XLO8/!.M:M>K9_;-,FN;<LJNL,C1N54[?F8 \<9/UKG]+\?>)=3U
ME-$6VL(;U[KRC-/;.@1?(,N3&)2<Y7'WAU' K>/AGQ(;6XM3K.E&WN&9IHCI
M*E9"W+%ANP<]\]:K67@C5]-DCDL;[0[5XSE&@T9$*G!7(PWH2/H30!S]SX_U
MK6M'ADMWL]/")IDMP 6\V4SS ,(CN&% &#D'()'&*U/B7K&MZ9>;--O?L\']
MC7DY5<AC(CPA6!!X(WC'L6]1BU)X%U27[+YEYH+FT 6V+:*A,(!R GS?+@\\
M58O_  IX@U7R_P"T-6T>[\O=L\_2%?;N&#C+<9'!H R[GQ?K5GK;V6H?86N;
M&:<;X9'MX) ++SU#[F( !."2<=\"M7PMXRO-3T+6+O54MH;G31O=%C>,!?*#
M@L,OQUY5FR!G Z4C^%/$,MRUS)JVD/.Q+-(VDJ6)*;"2=W]WY?IQ1IWA/7=*
MMWMK'4=%@M7W%X(=(6-')&.0K#\?:@#G-/\ B5XBO+J&P-G8+=71M/)DD@>-
M%$QD!.WS"S ; 03L)YX'!I7^)/B*PTO[?>V>FSK+!=^5';QR*1)!<1P;F)8Y
M4ERV." .M=#:>$=3L&1K2U\(6[(P93%H[H0P)(/$O49/YU8'A_7E55 \+[56
M5 /[+DP%D.Z0?ZWHQ )]3UH PK3QQXGO=1BTE+;38KMI95,\L;8"I$L@S$LI
M*G)QRW((/M5*;QYK.M6NGR6\EI81>=I#3Q@MYTIN'1F"'(&S!VD$'(W<C%=-
M9^&=9TY8ULHO"ELL18QB'270*6&&(Q+QD  ^N*:_A359)+21[;PDSV:JELS:
M0Y,*J05"'S?E (&,=* .<D^(/BPV#7L<&C+'_95SJJHT4K$) X0H3O&2V00>
M,<\&IKCXEZS'J%\T>FVPLK>XN+95E&UB8XF;=O+_ #9*_<"9VG.:Z'_A'-<\
MGR=OA;R_(>WV?V7)CRF.63'F_=)Y(Z&FR>%]8FOGO98?";W;QF)YVTER[(1M
M*EO-SC'&/2@#!N/%OBB>6RM7DT^WF>YTN<M!&X'E7#.&B;+')!0<C&03P*[?
MQ3K;:#X7O=4@\EI(5 C$H8J79@H!"@D\D# []QUK!O\ PMXBODV&;PLJLB(X
M?1W<.J',8.9>BDG'IDU';>#_ !'%I#:;+K&CO;2-(TL1TK<C[W+D$,YXW,3C
MI0!DZ?\ $#Q)J5\VEQ6VGPWB37"O+/;NH"QPQR#,8E."2Y'W_0\<BHI?'6L:
MU_9C6\EI80?:]($\0+>=+]H\N1@ASC9AMN"#D!N1BMRT\$ZQ8,K6=_H=N5#
M&'1D3&0 >C=P /P%-;P/JSS6DSWNA-+9JB6TAT5"T*J05"'=E0"!C'2@!WBK
MQ-J&BZ_>1V"122K8VK1QSRX4L\[H=J%E#/@< $%L 9J3_A,=0E^'MMK=O%:-
MJ,UU':%&1UC61K@0G*DAAC/(R>1C)')6\\)^(-0,OVW5='N?.C$4GG:0K[T!
M+!3EN0"2<>II4\*^(H["*Q35](2SA96C@725"(5;<I"[L A@"/?F@##;XC:]
M::I<Q7.G6LUO9W3V<HC0QF1TB+%D9I#U(X3:3M[T^Y\?Z]:VVEK_ ,2>YNM5
M\F2%;57=H$>.1R'C+C=]P -N7/S<#'.LWA#76U4:JVIZ*=1"[1=G1T\W&,8W
M[L].*KCP#J*VMQ:K<>'A;W#!YHAH<861AT+#."1[T 95G\1=0C+ZK>VT*6T:
MV2WVV8M'#&\]Q"TB@,0.40GDG!())6HC\4M=F;SH-*MDMT@BNB)5(\R*61A'
M\Y=1&=@4Y(;+$C KH/\ A#-:^S2VW]HZ(+>6%8)(AHZ;7C7)5"-V"HW-@=LF
MB?P9K5U+:RW&H:'-): "V:31D8P@= A+?+CVH J:)XHU77/&.D/+<6T5A<+J
M"K9P[A(OE2*@,N203P2, 8R1S3KKQWJL&N7T2QZ<UG:ZI_9WDX;SVS#Y@DSN
MQ@'J,<@'D8JW#X.UN#5'U.+4=%2^DSYERFCHLC@]<L&R<XJC;>!?$EGK-]J<
M6I^'Y+B[G>4RSZ07D5655*!O,!"X4<>Y]: *$?C?Q!&UI=7"6/VG4K&PD@5?
M,$%N+B;8#(I8Y*Y.2,9X'%:ND>+]?U3Q/'H872@UO+<"ZN41RLJ1-"/W:[_E
M)$V.2V"IZUH-X=UUX3"Z^%FB,"VQ1M*D*F%?NQX\W[H[#I2VGA[7K(PBT?PU
M:+%&8D-MI;H8XV(+*O[S !(!Z=0* ,G4?$VNZ=XLU:SAFM'BEO;&SM/M",4M
MO,C9F9@",_=/&1DD<U)J?B;6+KX:ZKJ$$MM;ZG:7;VOGP!C$^R<(64$Y (]S
MCGFK-UX0UV_:9[S4]%N&GC$4IET=&,B Y"MEN0#S@U(/"_B-=-_LU=8T@6&S
MR_LPTE?*V^FW=C'M0!A6GB_Q!I%Q>2WGV:]L&U+4HHXP'\X>1')* &+$;?W9
M4+CC@Y[5L^"O%^JZ]/<1ZG:6Z 6<5W&85V-\^?EV&1B1P,/P#SQ3H/"7B"V$
M(@U;1XA#(TD032%&QV!#,,-P2"03[FDTWPCKNCM*=-U+1;3SF#2?9](6/>?]
MK:PS0!STOQ-URUT6VU&6'2)!?V*WD$:;U^S W$,164[CGB;.0%Y4\59O?B#K
MUM=+I<=M937JW=Q ]W# SPLL4<3Y"&0$$^;@_.<;3U[6]3\":UJ.GW5I%+X9
MLC=S1S7,MOI+!IBCAP'_ 'GS E1G/OZU8B\'ZX=,73;O_A$KFPC8-%;/HC".
M,\\A1)C/- %'3_'VO7TT%P;338K+[5I]M-&&:1V-RJ$E75MN%+\<'(].M4]+
M\=ZZ=*2>**S:UM(;%Y_M!DDEE^T3-&0&W<$8SD@^E=0- U]<A?\ A%P"\<F!
MI<@^:, (W^MZKM&/3 Q4:^&M<CMY((E\+1QNJ*RKI4F"$.Y,CS>=I.1Z&@"K
MH?C+5=3\1V$,_P#9JZ?J'VSRHHU?SX?(D"#>2V#GK]T8Z5G_ /"5Z[I&K:G/
M(8+O2_[:FM$A8.9UQ;>:-C9VA<KC;M/4\U5TGX8^)=*\2R:XGB/3'N9#*2QT
MOD&1@S<A\MTP-Y; X%=%_P (OXC$F\:QI(;S_M.?[*7/F[=N_P"]]['&>N*
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MWGFN@UPT<(1G;[+/R^!DGGOZUZY9WEMJ%JEU9W$5Q;OG9+$P96P<'!'N#4]
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ML/H2J_E5B@#P_5?$OC".RTK4&U>[BM]8:ZF5/+2(0(K_ +F-2()&+%6SR,L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!>X>)IA/):+:;68!T #>8N 2!R6R!G/(KT2N!_M30?[1.H_\(%J_VTMO\_\
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MO\:0^-E; _X1KQ*#V/\ 9K<?K0!U=%4-(U+^U;(7(M+RU!./+NXO+<?A5^@
MHHHH **** "BBB@ HHHH **** "BBB@!I4GO^-.HHH **** "BBB@ HHHH *
M*** "BBB@#+G\1:1;:[!HDM_$-2FC:5+<<L$49);'"C'KC/:JOA[QCH/BI[E
M-'O?M#6^TN#"Z?*V0&&X#<IVGD>E4-5\,RR_$#1->L;:V000W2W<V &=G1%C
MSW;&W'L*P]!T7QAI/BB^URYTO3&>_P#(M[F&UO'VMM=MUP/,&5 4@",'GZT
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M^[0XP?N_-]Y?NYZUFZ+IWB#4_&R^(];TVWTI+:P:RAMH[D3M(6=6+E@  /E
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M&O7AL[&3RKKSH'22%\@;60C=G+#MWJ&^^(_AG3XK&6:ZN6BOXDEMI(K&:19
M^=H!5#\QP?EZ^U<_JOASQOXF&GQ7TFEZ=$=2^WR>0OG"!8U'E(P.WS27R3T
MP/I4>F^"?$%EH>C:/.T$\6D>(TO(9E(3=:#<V=N3@AG(VYZ8H Z3_A8_ADZ>
M;Q+NX<?:OL:PK9R^<TP4,4$>W<2 03QQ4D/Q"\,2Q64AU+RC>71LHTEA=&6<
M8S&X(RAY'WL=17'P^#/$FF>([GQ':6<%S/;ZY>W<-E)<B,7$$\2)D-@A6!7H
M1ZTV3X;ZIK^H_;=<M[>!=0O;BXNK>&;?]E5K;RHR&P-SA@&R.,T >FZ?JEEJ
MD5Q+9S"1+>>2WE)4KMD0[6'('0CKTK"T_P"(OAK4[Z*UM[N8>>76WFDM9$AN
M"N<B.0KM8\'H>:J>"?#.K:=X*OM*UZ=3?W<]R\L\39W>83\X]SG.*P;3PKXJ
MNK#PYX=O]/L;:PT&>.;^T([K>;KRE94"Q[05SNYR?6@#L= \;:'XGF$>E2W4
MNZ,RK(]C-'&R@@<.RA3U]:@U;XA>&]$U.6PO;N420%!<R1VSO%;E_NB1P"JY
M]S57X=^#IO"OA^R2\N[U[T6PBF@>\>6",YS\B$[5_#WK.F\/^+M)U778=!BT
MN6TUF\%V+N\D.ZU8JH<&/:=X^7Y>1[T ;5W\0_#5EJ<UC-=RCR)A!/<+;2-;
MPR'&%>4#:IY'4\9YJTOC;PZ\M_$NHJ9+"[CLKE?*?,<KML5<8Y!;C(X]ZXJ^
M\(^*5TG7?"EK9V<^FZQ>RW/]JR7.&@25PS!HL99A@X(.#QTJI?\ PRUAM1_M
M*Q,4=P^NF:Y0R#$]GYJ2J3_M*R9 Z_,: .R;XE>%UOI[-KJ\6X@4O*ITZX&Q
M1G+$[, <'GIQ5K0_'?A[Q%?+9:==RM</#Y\:36LL/F1\?,I=0&'(Z>M9VJ>&
MM1N_$7B>\B2/R=0T1;* E\$RCS.".P^8<UREO\/?$F@Q0RZ;*]_<S:']@#7E
MZS'3IRJAFBR<>6>> ,C:,<<4 =]8>.O#6I:+?ZQ:ZI&VGZ>[)<S,C*$( /0@
M$YR,8SGMFJ,7Q-\,20W$C37L36X5I(I-/F$@1LX?9LR5X/S8QT]17&GX5>((
M+?5=*CU2TN+*^TZWC6;R/("3VS+Y09 6R"JX+?IQ79V<'BW4UU5]9M-,LHY;
M(V]O;6TIE=I/FR[2%1A>>%_R0"(_%3PH;>":*YO9A.&:)(].G+.J@$N!LR5
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M#OQ/IB:.\NDRW!M]+-I*EKK)LV63[1+)]Y,[AM9>.F3[5J^(_!GB?4?$!O\
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M2I;HXRID95(3(YY[5R7C?X=:MK]_XDU+3S%%?3QP)8R%P/,3RGCGC;T!5OS
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M@ HHHH **** "BBB@ HJ"ZO+6QA\Z[N8;>+.W?+($&?3)JE_PDNA?]!O3?\
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M (270O\ H-Z;_P"!2?XT :E%9?\ PDNA?]!O3?\ P*3_ !H_X270O^@WIO\
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ME%9?_"2Z%_T&]-_\"D_QH_X270O^@WIO_@4G^- &I167_P )+H7_ $&]-_\
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MKW'B@:#HTMG:R1V0O)[BZ@:8$,Y1%55=>ZL22?3CF@#1_P"$7T#_ * >F?\
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M'I^G:;9I=K/)(&:1"\JESC@ ^7P.OYX !J_\(OH'_0#TS_P$3_"C_A%] _Z
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M,_\  1/\*U:* ,K_ (1?0/\ H!Z9_P" B?X4?\(OH'_0#TS_ ,!$_P *U:*
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M+QK,DB+L3:%0( %+#&WG<<YIB^ +>.2*ZBUO5DU%+EKEKXM$TLCM&(N0T97
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MH0 %58D'&2<9SBNYHH Y#3_!HC\7P:S=1VRP:;9K8Z9#$S,0@S^\?( #88J
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MCM!$-.P$>,*KRKY9C99&QE@RL<^M.TGP9;Z7>V=S)JFI7PL$:.RBNI$*VZL
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M^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C=
M'445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^
MA<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-
MT?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\
M&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_
M &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\
M!F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_
M^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C=
M'445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^
MA<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-
MT?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\
M&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_
M &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\
M!F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_
M^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C=
M'445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^
MA<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-
MT?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\
M&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_
M &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\
M!F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_
M^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C=
M'445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^
MA<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-
MT?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\
M&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_
M &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\
M!F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_
M^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C=
M'445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^
MA<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-
MT?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\
M&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_
M &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\
M!F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_
M^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C=
M'445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^
MA<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_ &EXS_Z%S3?_  9G_P"-
MT?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\ !F?_ (W1_:7C/_H7--_\
M&9_^-T =117+_P!I>,_^A<TW_P &9_\ C=']I>,_^A<TW_P9G_XW0!U%%<O_
M &EXS_Z%S3?_  9G_P"-T?VEXS_Z%S3?_!F?_C= '445R_\ :7C/_H7--_\
M!F?_ (W1_:/C,\?\(]IH]_[3)_\ := '4=:*I:5+J$MGNU*TBM;C<1Y<4QE7
M'8[B!_*KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!C^*O^13U;_KTD_\ 0:LZ)_R -._Z]8O_ $$56\5?\BGJW_7I)_Z#5G1/
M^0!IW_7K%_Z"* ,#6O'/]C7FJQ_V3/<6^E1)+=3)/&I"LN[Y58@L0 >!74RR
MN+1YH(C*^PLD>=I<XR!D],^]<-XA^'\VMZSJ]V%T=EU&%(EGNK0RSVI5"NZ,
MY&#SD<CD"NRL8[V$S1W4D4D*%5MV7.\J%&2^>"V[/3MB@#F4\=3K9:E>76@S
MV]OI]P+:9OM$;?O"R+@ =OW@.?:K>O\ C6VT.[-JMJ]W+Y44BB.10"9)UA"Y
M/3EP?I4-YX->\T+7=->YB(U34/M>6CRJKNC)4CO]PC\:SM?^&MI>SRR:1;:7
M8QR00QO;_9 (Y"EPDOSA<9!";?QH ZW2;^\ODE:[TXV14@*#.DN[_OD\5SS_
M !%T]8M>D6TN"-)1I%)*@72*[1LT9ST#JRG/MZU=TG0[[3-)U&WM;70].N)D
M/D-IUJ8T$FT@,X[X./UKF=4^$L)TBUM=%OY;>9+62TN&NII9DFC=?F^5F(3]
MX%?Y0!UH W'\=QVAU"+4=*N+>ZM8H9$A26.7S_-<QQJI4X#%QC!QUSTI+SQU
M)HXN$UK1IK2:"%+DK'.LJM 9%1W##'W"P+#'0\9K*E\"0VUMJ%W>7.D:.DD<
M C%A;>3!'-%+YD<K@MACNP,<<9&>:V/[ N;BYOM5\5WE@T7]G2V1CMT,<20.
M0TC.SDG)VKZ  =\T 2:_XVAT75X=+AL)KVYD6(GRY%54,CE(P23QG:Y^BUL:
M?J%U<V,UQ>:>;-HR<1^<DFX 9SE3BN"LO 4USH,]I-JVGZOJ4>H6[W,D\6^-
MD@C4)"Z@_P!TACZER>]=EH6C2Z;I=S9M9Z39B5B533(#$F2,$D=SP/RH Q+#
MXFZ7J/A^QU6"UN ;F9H7MWP)(6$+S#=[,B @CJ&%:=]XQMK'3-*OGM9634;>
M2=%!&4"P-,0?P7'UKGI_AW:6,7AZ_N=2BMH]'LE@U)S\D=RB0-&'.3@%=[X)
M[,1VIZ^"]9N-.LK34=:L)+#3;*:"TDBMV5Y-\!B5Y"7(X5B>!R: -"'XBZ?-
MIOAVZ%I<+)K5W]E2 XW0L&*L7]@V!_P(5%9_$5+B*RGGT>X@MKZ.9[:3SXWW
M&-&<@J#E<A&YQUQZU0L?ATQU*VU.+5HIK6.6UN+5%3*J%"&4J<\^88T8&HM,
M^&5Q:0VD3/I%N]JDRFYM+0K/<[XW3$CYY7YP2,')4=* -P>-KA/#MQKMSH4L
M-C%9&\4BZC=G7 (7 .02#WJ+4/'TFCR7$.IZ'/!.EH;J-%N8Y/,42(A&0?E.
M9%Z\'GTK)3P');^'YM">+PU937M@U@EU;6ICGE;9R2<_-]W<1[9JQK?PULU7
M4WT,V&F6M_:"*\@> >42C*RN,8VC 8,.AR#U&: -JZ\5WUC8_:+K09$=[F&V
MAB6[B<R/(VT<@X&#CKZU?T?7FU'4+O3KO3YK"_M425H9'5PT;[@KJRD@C*L/
M4$5S4?A*ZN-*C;3H?#5GFYM;V&33K8I'-Y;[QN(/S CH1ZFK6@WVGCQ7J,VH
M^(=+N=;FC6V-M:G8L*0EV*@%B68%V+'MCH,4 6[#Q==:E/;SVVA7,FD7%RUO
M%>I(&8X)7S#&.1'N4C=GI@XQ447C=I([?4#I$RZ'<7*VT5_YRDDL_EJYCZA"
M^ #G/(.*Y_2;^SL%BTZR\>^'UT.SN#=#R94^T>3O+>4QW[=N6"[L9(XZG-3:
M-IL.KV<7A[2_$VC7OA^RN8[C9:'?<A%E\Q(V(8J &4#=C) Z9YH U=.^(^F:
ME9230VUPL\>HQ6#V[X# R2^6D@]4)SS[$=J<WC>\A_MIKKP]/"FCV[3W3?:H
MVQB(R  #KD#'MFN:M?#_ (>U5M!33O%6F2ZGI5X;F8VUPC>?;BX,Y1E#9P#@
M@GH<^M;#G1-<MO&OV+Q'ITBZI9$.RR@BV00&,R-SRO?/2@#8L/%DL^LVNFZA
MI,EC)=V[W$#FXCD!5-N[.TY7AAU&*J6?Q%TZ]T*_U1+2Z7[-+''%;L!ON!*0
M(63G&)"PQGISGI7*SZ3X3'VN?POXG\/Z:L^G_9-4\F2,CRB57S%P?D;DC/0E
MAGD"ICX:\+:C=8\,>*;..-H(K?RS?&[*S1R"2V*[G.-I1QM&,@G&* .P'B+6
M(XKL7'ABX2XMT27:EPC1R(=V2LAP-RE>5Z\@]ZH_\+"M[?0K#5]2TV>TM[Z,
MSPCS$D;R1"TQ<@'C@ 8ZY85=TZ#5I[O4_P"U]:L991;+";.S0K'!G<?,;<Q;
M<P/L,+WZUAVOAC2=8T_3=(N-:L[R./PV+*!+>0%F5MJO<*,_=/EH ?K0!JR>
M,[FP_P"0QH<UCYEI-=6_[])/,\M-[1MC[K[>>XX//%5+OXB'3+9;C4M#N+=)
M;&6]@VW$<A=8T#D$ Y7(/4\57O-)O-:LX;O6_$.D-;+;S6EE-:H42::=/)#L
M2Q&>2 J]SU[5S]YX?\'LLMGH/B/P]8WMSIDNFWT:21XE^0X< '*L&&3ZC.>@
MH ["_P#'3Z-#<-J^B75I(EG)=P+YT<@G6/&]05/##<IY['VJ:[\67UA9?:+K
M0)$9YX;>%%NXF\QY7" 9!XY(Y-<KJ:V/C"TOC>^,?#CR0:;/#"EG*"D*R;0\
MLA+DD *!T &:NMX7L;NTL[&9/"=I;ZA<V]Q$EA;A/MR1.)2N,X<% >F>N>E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#'\5?\ (IZM_P!>DG_H-6=$_P"0!IW_ %ZQ?^@BJWBK_D4]6_Z])/\
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M26P\06&H6R7<<U]80+<DS/,'=6B\LAHG/SJP QC'%>N44 >9Z)-JGANY@O\
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MEMLT98_D":I76C:K=?$&^N[2_NM.MSI=M'YT4$;K*PEF)7+J>0&!X_O5V-%
M'C/AFRUC0V07!US3]VF6<9^RZ5]HWLGF[@V4;:1N'''6NT\7V.I>(FT?2K&!
M/LK.+V[DO(6,16/!2)U&.6=@=O\ L&NRHH \LT#^V_#5_82ZKI&H7<5A:W&D
M&6S@:0LJR(\,@7J4*<9YP5.:OZ9I&HKHOA#SK">.2/6[B[FC9<M#'(+IE+XZ
M?ZQ ?0G%>B44 >9ZQX=URZL/'[6UW>VZ732F"TCMXV%W_HD:\%E+<D%>#V]:
M<\-WI-EXGTVZT2_OY]8^>V>"V\Q)%:W2,1NW1-K*1\V!@Y%>E44 >47'A;Q6
M;/Q%#9W;1N]M:1/$T*D7H6W1)0DC X)PP!P>>M31Z3=R:#X^CMM+OHDO--A2
MRAFA82/BR"A1GJP/RG'?BO4:* .,\:Z!-JOAO3Q:K<QW\,\$2RVO$L<4C+'/
MSZ>6S$^FT'M5CQ-HI@T#2(=+LC)::5>V\[64*@EX8SC:H/4C(;'?;ZUU=% '
MEVMV.H^(]3N]4T[3]0LH)9=+A#S6QCE=X[HNTOEL,X16'+#L>PKM-1L+U/!V
MJV<EW-J-U):3JCM&BLQ*$!0$ 'Z5NT4 >=7VB>(&\#VFA1WEQ=3ZHD%K(9K=
M42SB"9EW% #@J-G)SDC%9=CX?\36OB:STH*+2WL[RXN;>_MK7=;QQSQ$E%5B
M<8DWC&>-PKUFB@#@_#^F>(K3PCKUE$5A\2RW<KM>7*X@FD8*!-'M7A=H'&#A
M@0<]:YWPYH&J^'M$O[34-$N'":H[PW=BWVBXA9H55IU65/GR>,X)RS<#%>O4
M4 >=6FCM<?"^/PSJ>E7)NH=,DECB\MMA*EA&K$':9/NDID\]JIZWINH0VR[M
M'O+W[9X8_LR)(80_DW'</G[@.Y>3Q\E>HT4 >3RZ/K(UBS&FZ5>6EW917:2%
MT0VQ=XGQ<)(,,TCOLX).!G@8S67'8WLTUK=Z'9:N&DT33X;":U+I"DZ.^\38
M(4[03D,"!D]SS[93(H8H$V0Q)&FXMM10!DDDGCN223[F@#E-"OA#XBU\1QSR
M65QJBPPM#$7191 OFDD?=7<I!)XW9'4UUU1PP0V\?EP1)%'DG:BA1DG).!ZD
MDU)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )NYZ&C(]15+4[:_N;8+IU]'9SA
MP?->#S1CN-NX?SK(_LCQ7_T-%G_X*O\ [;0!TF1ZBC(]17-_V1XK_P"AHL__
M  5?_;:/[(\5_P#0T6?_ (*O_MM '29'J*,CU%<W_9'BO_H:+/\ \%7_ -MH
M_LCQ7_T-%G_X*O\ [;0!TF1ZBC(]17-_V1XK_P"AHL__  5?_;:/[(\5_P#0
MT6?_ (*O_MM %WQ41_PBFJ@=[63'_?)JSHN!H.G D9%M'_Z"*Y7Q'I?B>/PU
MJ;2^)+22,6TA9!IFW(V],^9Q5C2-*\4/HMBR>);1$-O&54Z7G VCC/F<T =A
MD>HHR/45Y_J^JZMHMT]M<^*5DFCA\^9;;0'F\F/GYWV.=HX/7T/I6O%8^)9[
M5+J'Q792P.@D1TTK<&4C((Q+SD4 =3D>HHR/45YJGB>];[9N\521BRC:2Z:7
MPO<1B%0F\[BQ !V\@'DY&,YK0U>^U70HP^H^,K2%3;R7(/\ 8S-^[CV[SQ(>
MF]>.O- '=9'J*,CU%>=W6NZE9ZE)92^+$)BECAFG30':&*1\;5>0/M4G<O4\
M;AFK>KW6NZ+-;07'B9);BY#F*"UT)II&"XW-M60G R.?<4 =SD>HHR/45P^E
MW>K:RZ)8>,;.5GMDNP/['*_NW9E4\R<'*,,=1CD5F'Q3<A-Z>,/.00+<L\'A
MJ>54C8L S%6.T?(W7'0T >EY'J*,CU%>;S^)+JWFF1_&4;)!L\Z>/P[,\,8=
M5=2TJL4 *NIR3T-::RZTVG7U^/&%F;:Q:5;A_P"QS\ABSOX\S)Q@].O:@#M<
MCU%&1ZBO./\ A(=073[B_E\4R06EO#Y\D]QX8N(DV9 R"Q ;J.!DU8N=7OK3
M[!YWC>Q']H6\EU:XT=CYD2)YC-Q)P O//7M0!W^1ZBC(]17G"^(=0-A/?OXJ
MDALX(/M#SS^&+B)/+XY#,0&ZC@9)JU/J>J0K;,OB^&X^TV_VJ!;309)S)%E1
MN 1R<9=?SH [W(]11D>HKS9?$UT="DUM_&*0Z;'L_?S>'9HP^\X79N8%_P#@
M.<=ZV8EUZ;4!8Q>+[)[@VZW05=)R#$3@,#YF.H]: .PR/449'J*XG6+C5] C
MMGU3QG8VZW,ZV\1;2"=SG.!Q)P.#R>!W-5=4U36]+U!K ^(_M=VD7GR0V>@M
M,T:'@%MLG&<' ZG!H ] R/449'J*\X;Q'>@Q"+Q;]I\RUCNP;3PW-.!$^=K$
MHQVYVMP<'@T#Q'>NZK;^+#=[H8YP;/PU/. C@E"2A(&0#P>>* /1\CU%&1ZB
MO/6UG51J$UBGB:66>&18I?)\,7$BHY56 9E)4'#*>3QGF@:Y=FRUB\_X3BQ$
M&CRM#?,=&8>4Z]1CS,G\,Y[4 >A9'J*,CU%>=?V]J37;VT/BB2XDC*!S;^&+
MB55+HKJ"RD@?*RGKQFIDU>^>'4Y5\<6)73)_L]X!H[9BDR%P1YF3R>HXZ^AH
M [_(]11D>HKSVSUG5;_5FTN#Q++]K7&])/#%P@0'.TLS$!0=K8).#@T^_P!5
MU/39;N&?QA;F>T>&.2&/1&=R\N?+50)/F)P>!GIS0!W^1ZBC(]17#6%YK6HZ
M==WT7BN%(K-G2Y2;0VCDB95#$,C2 _=(/3D$51C\0ZA)83WY\4R16<-N;E[B
M?PQ<1Q^6,<AF(!ZC &2: /1\CU%&1ZBN"EU/5(XK:1/&$%P+JV-W +70GG:2
M(,BEE".2>9$]^<]CBE%XGO)K!+U/%<A@DE6&)O\ A%[C,KG=@(,Y?[C9QG&.
M: /2LCU%&1ZBO.I-=U2);<OXEG5[AG6*$^%KGS6V!2QV9W8&X<XQ^1II\1WO
ME6[IXN\UKAI42&'PW/)*&B($@:-6+*067J!UH ]'R/449'J*\[GUW4[=X8Y/
M$TWFS0F<1+X6N&D5-Q7<R@Y7D'[P%7);S58M!CUL^-+%M-DV;9TT@L#O8(O
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M45S?]D>*_P#H:+/_ ,%7_P!MH_LCQ7_T-%G_ ."K_P"VT =)D>HHR/45S?\
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M ."K_P"VT =)D>HHR/45S?\ 9'BO_H:+/_P5?_;:/[(\5_\ 0T6?_@J_^VT
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M7EU:P/I=K;2+8W"JLK S&12<;L#> ",9R:]+HH X2V\ )/J&O0W<UY!H]S+
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MHS%0REAU /(H XBTL->U"?PW9WVD+8PZ+*LTUU]H219F6%X@L84[L'?G+!<
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M7S-W_+<-A6*YY(1I #C@&FW]MJND^+;K6M/TQ]4BOK.*W>*.=(WA:-G(/SD
MJ1(<X.05Z'-=710!YUX=\"7]KJJSZC/<6ZBP4$V-VT8\UKB>5D.T@L%$J@$C
M!KN=,A6"VD5+%;(&>5O+4J=Q+DE^/[V=WKSSS5RB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAB9K7"J<$Y)/ 'K1=I/J'A.>QM9I;F[)LRL?]@2V^S;<19)) #@=2,] 3VH
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MJ$V[*I//*)!$OLJJ<#LI7UKO* .;_MKQ+_T*9_\ !A'_ (4?VUXE_P"A3/\
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M?_!A'_A1_;7B7_H4S_X,(_\ "NDHH YO^VO$O_0IG_P81_X4?VUXE_Z%,_\
M@PC_ ,*Z2B@#F_[:\2_]"F?_  81_P"%']M>)?\ H4S_ .#"/_"NDHH YO\
MMKQ+_P!"F?\ P81_X4?VUXE_Z%,_^#"/_"NDHH YO^VO$O\ T*9_\&$?^%']
MM>)?^A3/_@PC_P *Z2B@#F_[:\2_]"F?_!A'_A1_;7B7_H4S_P"#"/\ PKI*
M* .;_MKQ+_T*9_\ !A'_ (4?VUXE'7PF?_!A'_A724'F@"GIES>7=GYM]8_8
MIMQ'E>:LG'8Y'%7*0 #I2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &/XJ_P"13U;_ *])/_0:LZ)_R -._P"O6+_T$56\5?\
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M=3\26\"0Q>$46.-0JJ-23@#_ (#0!U%%<U_;/BC_ *%-/_!DG_Q-']L^*/\
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MVSXH_P"A33_P9)_\31_;/BC_ *%-/_!DG_Q- '2T5S7]L^*/^A33_P &2?\
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M '2T5S7]L^*/^A33_P &2?\ Q-']L^*/^A33_P &2?\ Q- '2T5S7]L^*/\
MH4T_\&2?_$T?VSXH_P"A33_P9)_\30!TM%<U_;/BC_H4T_\ !DG_ ,31_;/B
MC_H4T_\ !DG_ ,30!TM%<U_;/BC_ *%-/_!DG_Q-']L^*/\ H4T_\&2?_$T
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MK7I.AQW=I91Z?<VS*MG!#$EPTPD\\A!N/8\$8R0,]: -2BBB@ HHHH ****
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MQ% 6)Q\R$R)\W& <D=J -;_A8?AG_H(-_P" \G_Q-'_"P_#/_00;_P !Y/\
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M^4L$<<IBRS!&.2W0!?7)XY -3_A8?AG_ *"#?^ \G_Q-'_"P_#/_ $$&_P#
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MTFPAH_,4%RNT$I\V"<X[5HZQJ$.DVT$C)"7GN8K>-9#M#,[ =0I[9/3MU'4
M&7_PL/PS_P!!!O\ P'D_^)H_X6'X9_Z"#?\ @/)_\34</Q \(W$$\\6I1F*&
M(3,YMY &4ML&PE?G.XA<+DYXJ,>/=#EU*PMX"&M[E)"\\D;1F%UECA5&1EW9
M9Y,<XQB@"Q_PL/PS_P!!!O\ P'D_^)H_X6'X9_Z"#?\ @/)_\31JGCCPSI'G
M+<7BM+"TBO'#;O(R&, N6VJ=JC<,L>.>M9FE_$G1+K2XKW4!%9><%$<,8>>0
MOY*2NNU8\Y42+TS^'2@#3_X6'X9_Z"#?^ \G_P 31_PL/PQ_S_M_X#R?_$TU
MO'GA1+FW@_M!2UP(?+9;:1DS* 8P6"X5F!! )!P:NZMXGT/0]0M[#4)_+N;A
M0R(EN\F%+!=S%5(5=Q RV!0!4_X6%X8_Y_V_\!Y/_B:/^%A>&/\ G_;_ ,!Y
M/_B:@O/B!X:M[?4V@N5N)["WGG,8A9%E\K[RI(5VL0< [2<9J&V^(>@BT6;4
MWBM)'=U$<223E A"NS[8_D <LN3\O'7L "[_ ,+"\,?\_P"W_@/)_P#$T?\
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M"M"T2PJ?,)5DSD':"&V]<\]" ._X6'X9_P"@@W_@/)_\31_PL/PS_P!!!O\
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M#OVX 4@YZ<UC:1\1?#^KZY<:;&?+4,HMKAHG"3CR1,QR5 3"YX8Y.": +O\
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MDMI),SI]C$:$.BHHC ;Y-NTG)+9WMTXQGWO@"[O_ !#J&IR:VL0NK:>W!@M
MDVV1=H61PV)%3JN5!X'-=S10!P*_#V_6$,-?B2[1[0PNEC^[CCME;RX]A<Y7
M>VXY.?YC+?X:WNIW.I6NH7!$3V<D:7S!3Y]S-,)9)!$&^51L1-I(. ?K7J5%
M 'G]I\-Y].M+673]6M[758+IKG[0E@#$=T1BV^67SP"2"6)SGMQ6F_A"]>#7
M8FUHNVJ:?%9">2WS+&51D+DA@#G>S8 &"376T4 <C+X%BDDE O2MO)-8GRO*
MZ0VN"L6<]W!)/OC'>N>@^$<L<FJRRZ\)+B^L+BQ$_P!E/F8E8$N[&0[VP".,
M#![5Z?10!YQJGPM?5?M$D^J6S3O>17<6^R+1KM@$)1D\SYEP,CD$'N:W_#W@
MN#P_J%O<QW"R+;V'V..-8%C 8R&21_EX&XE> .-O4UU%% '"ZQ\,K36=5U&]
MGU&=!?3Q2-&J#Y(PFR2,'/\ RT'4]N*5_AO#+;26\FHN(Y)[ZX8)%M^>X0QK
MCG@(C%0._'2NYHH \ZT;X61Z8;)YK^WD>"\AN)!!9^6)%B5PB\NQ^\P8DDCC
M@"K?ASX;PZ%XFEU>2[BN0)YY[<>05D5I22=SER#@,RC"KUYKNJ* .%\2?#A?
M$$MS<MJ$8N9+]+Q/.M?-B55A$0C*;ANXRV<CDUF:I\((]0CLK9-52.SM[>.(
MQ-:9PPD,CO&%=50ON(/RD\#FO3:* //;GX:W-]JM_=W.N1^7>%5E6&R$;3QB
M9),2D-M=@J; VT'#'.:6X^&][>175O<^(F>V?[8\"K:!6BEN=P=BV[Y\*[@#
MC&[O@5Z#10!Y[IGPOCTGQ#<:I:WUL!YLL]HKV>YXI'4@;FW_ #*N3@ *>Q-=
M+9:9=GQ=?:O=*J(+2*R@P1F0 L[N0,X!+  =?E/J*W:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#F_%DL-K!:E;2YDFDOK:5VMK.28E8Y4)+%
M%/09Z_A53Q6L;0Z8HL$_LYI'N))?[)>[>*0\KB(*2K,7<EB.,$'ELUU]% 'G
MVE/;V_A3Q!!JNBZA=VAN2RV9TMU,Z.B;=D:C RP)X^Z>6VFIO"=E_9NNJFI6
M<T^H2V:?9KX6;A(( .+<N4 5E]3@MW ("UW=% !7+ZSJL-OXITS=;Z@ZVPE\
MUX=/GE0;D&W#*A!_ FNHHH YO5K^.P\7Z;/+;WSPI87*,]O8S3J&>2 J"44\
MD(W'M[BK>@QS-)JE_+!) M]=^=%%*,.$6*.,%AV)\LG'4 C.#D5LT4 8GB_<
M?"&JJD4TKO;LBQPQ-([$\ !5!)Z^E8-GIMS;>+;".VM)9-!N//NXB\3+]F9U
MP\3*P!4,3N (ZLP["NYHH \Z9H[72=+TUM$OWNM-U)&+1Z=(RP1B?.Y&"X8%
M<<)DX/(&#B&TT/29=6MYF\/-L.N3M(9-+=05:)PC'*?<W;>?N@X)Q7I=% 'E
MVGI"MWX:FU/0-2N+;3]%%O,SZ;*X@GR@'R%<L<*XRH;&?0YJ_>Z1>3Z+-+8V
M<MOIK:LMV+%K;<3!Y85OW&1P9?WFSJ<9QD[:]"HH XGP[;P)J-_?[;IK9K39
M,BZ+):1R8)/^K;YG?&X<+T..>!47@O2-"5IB-%GBO_MEQ<))=Z=-'Y:>>YC$
M;2( HVL"%4CJ>.M=W10!SBP:=_PL9IQHU\-2_LS:=3VG[.8O,_U6<XWYYZ9Q
MWKHZ** "N7^(7_(G3_\ 7U:?^E,5=15;4-/M-5LI+.^@2>VDQOC<<'!!'Y$
M_A0 2Z?9S3K/);1-*KK()-OS;E! .>O )'XFA-/LXKI;F.VB295=0ZK@X=@S
M=/4J"?>IXXUBB2- 0J * 3G@>YIU '-^%/\ C_\ %'_88;_T1#7254T_2[+2
MHI8K&W6%)9#+)MR=[D %B3U. /RJW0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIAD",X!W$[E(1AG@YQQSP ;U%<3/IM_K'C6^COH]/N+2WA@\N.3S/D1FDR0
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MZY(XY))^M,U:POX=.L8]+U:^CN[C4!-!%+=R.83]E9A#(68ED+Q[B&_O$8H
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M>QH IZ+IT>DZ+9V,0?$,0!,AR[-U9F/=B223W)-6;RW^UV<UN)I8/,0KYD)
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M&3;&K[=Q *GG*J><]*IVOA..VCL83J^I36UDT;0P2M%M&S[H.$!.,#O70T4
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M/-9[Z=G8(25&XON !8G&<<T 4/#VF6EGJ"7,NEVFD:BZW$*VMJ%"RQ!TPY(
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M=RJJC@D; P7!VC(Q@XYS4D&CV5OJESJ42RBZN5"RL9Y"K =/E+;1CV'<^IH
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MPW42(LTT"R*C$[0Q7(!/IFH-"U"XU+3WENHHHIX[B:!UB8LN8Y&3() /.W-
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MI51[:3>A178*<^N ,CL<BF0>(]&N;X64.I6[W!<HJJ_WF&<J#T)&#P.>#Z4
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M &+!0$.T<DX+-W/3K2^%HKK3=/NH)?#ES:RM-<7;-OMSY[O*S 960_/@@9;
MXZ]*ZJB@#SJ'0M8'AZ*U.CRK.- CL2OFP\2QDY&0_1N"#T]<5I:Q9W]SK,EX
MNBZJC/!'''<Z;?QQR'&3LE1G"$*S'!^;J>W7LZ* *&B6UQ9Z#I]K=^5]IAMH
MXY?)4*FX* =H   STP /855\31ZE)IL8TT3L1.IG2V=%F>+G(C9R%!SMZD<9
MP0<5LT4 <1I%IK%O=ZW<3:1J.RZLXUMQ<7D4LA93("C'?A3\X(&2N,_-GBK-
MM9ZA!:^$(5T:=!8D"Y"R0@0 0/%_?YY8'Y<\ ]^*ZZB@#@=1L-<3P=?^&H-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQN6, PK<D)C Y&/PJ35]#\2V=U/;V1U1]'COD=U+SW#N#:IR-LJ.R^;NR ^
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MY+?:3:*3"4!W8 *LTNW'4CFK?C&PUV?7[YK6+5I))+:W72);.=DA@F#L9#*
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M6UKYS;(_/E5-YQG R>>*X*+2]?B^"]K8:?%=6VIH$WQ-D3"/SLN.&4[BF>C
MGL03FN5NO"FMZGIL\EQ!K,NVSU3[*C&:'83#$(T"F9VPSB3Y7;GD$8Q0![79
MWMKJ%I'=V5Q%<6THRDL3AE8>H(ZT^6>&#9YTJ1^8X1-[ ;F/0#/4^U>2+HOB
MRU\5PQ0R:DD27%O]DD"RRQI;+&H97=I@@&=X8,C,2<@GC#+;1M2G30GNM+\2
MM=V5U:S:G+/=.T;RKN#M&N\EN6SE?EVXXH ]BHJO!>+/=W5N(9T-NRJ7DC*H
M^5!^1NC 9P<=#Q5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN %>38KW6Y209#Y9"C@X;/>L74?'":7%XLT^/7PLFK7<QMG^T9:VQ*P<CGY
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M!OM4\R!GGVVS%=['EL$#&?2L[5K.ZC76[^.QMH;9-<:)]76YD$UB@9?G\M0
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M?#'Q)J,$2-J5E<SG^SVF9Q9-\H\O<_+ ??XX(;CB@#JM_C;_ )X:)_W]D_\
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MEN] U+PW;6L4#IJFI)9S&4$E4()RN".?KFEL?$MW=?$C5?#CQ0"TL[**XCD
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M)[TX@'J*\MUKX5:UXF\07]YJWC744T]YBUK9VI*B-.P/.W(Z=#G&2:X;5O\
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M#S+/I4KS0!& 4EEVG=D<C'IBM>@ HHHH **** "BBB@ HHHH **** "BBB@
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MC1U#\"1_Q:G3_P#KM/\ ^C#6C\0]'U'6/A+?:596KSZA)! JP*1DLLB$CTX
M/Y4WX0Z+J.@?#JRT_5;5[6[264M$^,@%R1T]J .'_:5 _L303CG[3+_Z"*U?
MC;',_P &[5HL[$FMFEQ_=VD?^A%:=\=_"^M^)](T>+1=/EO)(9Y&D6,CY05
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M%9_]^Z -_P V/_GHGYT>;'_ST3\ZP/\ A _"O_0"L_\ OW1_P@?A7_H!6?\
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M=RVQ3C?O"LW 8K@Y'8BK6AZ5X7UXQR6_@>>*SD+A;R9(!&=I(/ E+\D$#Y:
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M@<@9YR>G:NP^$L#VOPKT".9=CF!I,'T9V8'\00:TO^%?^#O^A5T;_P  8_\
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M.P5(DE'V=%8<;FC5%.#D*K#TJ[XG\.>+=2\0ZE<Z>\L5O+ 886-Z0JAD";D
M(VD!G8A@>5!!S@  ])BDCFB26)U>-U#*RG(8'H0:=7D&B66M>(-05(CJD4$>
MQ+V[:\F07 :<2$HK$%,)'LP "!+CBK4?@_QC]IL@+N6**$+)"?MK$6Y$SR,K
M<DOP43H05&,CN >HFXA%P+<RQ^>4+B/<-Q4$ G'7&2.?>DM[F"\MH[FVFCF@
ME4-')&P96!Z$$=17GV@>&]<L[?6KY[.6'4WTE+2V^T7WGM-. [/(6)(7<Y3C
MC[N<#H,K_A'_ !%IPTW3]*DN]-:>1+86WVIYU@MU@=))RV2JG<5*KGJJ]S@
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MN6)+GG Z#BM^BB@ [5S6J?\ )0O#O_7I>_\ M&NE[5S6J?\ )0O#O_7I>_\
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M,A=QX&3QD]*9+;)Z*X7P'XG\0ZWKWB33/$-K96T^F/;A(K0E@OF*S8+$_,0
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M&8DC4+OX+2O(N<]$Z4 =K_:/B7_H VW_ (&__8T?VCXE_P"@#;?^!O\ ]C7
M:GX[U_4;W4],LI4M(G5H8YS;%7MF-S% &)$G7#NW.TC ./74'C[6+V=K+38K
M1KI9)8G,EO)B)C=)!#N&[KLWNPSG 'X@'5_VCXE_Z -M_P"!O_V-']H^)?\
MH VW_@;_ /8US?@_Q3XDU7Q9=:9J26QM[;STEV6YC92D@5&/S, 6&3@]CD9
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M&VMY+.>"** ))+)! _[^6.U:>6-26Y!8QJ!SW/(&" =__:/B7_H VW_@;_\
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M9Y"^7WNZM_NGJ>M=!I6L:M>:]ID%W<+(5N[^-S!&T:2Q183>RECC$G .?YT
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M/(4@CG/\0(S;;6\)+J+:AK5QXE@>ZGETN)I#$JH)-L31XV*F%4!L;B2,$YH
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MH" #I\QZTBTC8M[S5+A98KNPCMY /E$<^_/UX&*ACO/$42[8]"MB/4WHY_\
M':\^\5ZIKUU>WDMI<R6]IIYE80HLJR7/EQ1N06212 9)8T]1@\]0;5SX[UW3
M+:5+>6PE:VF:UDM9+>5I+5$E\H322M(%;< 6PQ4G<#DX)H0Y/HCNO[1\3?\
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M;1A?RR?SJ?\ XK;^[H'YS5K:)J#ZMH5AJ,D'D/=6Z3-%N#;"R@D9'7&>M7Z
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MVERMH<:7D+0NRF;*@C&1VKM:* .7B3QI%"B!= ^4 =9J?_Q6W]W0/SFKI:*
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M6"7R5WQB/&P ]?EP,>E,_P"$,\,>7=1C0--"79!G ME'F$'(SQZ\_6MRB@#
M;P-X4=(T;P[IA2,ED3[*FU2<9P,8YVC\JFN?"?A^]@E@NM'LYXI;@W+++$&!
ME( +<]"0 *V:* &0PQ6\*0PQI'%&H5$10%51P  .@I]%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ]770-&2-HUTBP5&*L5%L@!*L74XQV9F8>A)/4U:2QM([>2W2U@6"4NTD0C
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>modificationno15effectiv002.jpg
<TEXT>
begin 644 modificationno15effectiv002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".82F%Q R)+CY6=2R@^
MX!&?SKD_"_B;4_$'PZ3Q'(EG#=2PRRI$L;%%V%A@_-DYV]>.M=9--%;PO--(
MD<2#+.[8 'N37E'@&QTU_@O!<SWEU')':SB51J,T:HVY\ H' &>.,<Y]Z -F
MY\;ZS#\--,\5+%8&>\:#= 8WVJ)7"C!W9R,Y]_:MGQAKVI^';329+46DKWFH
M06,GFQM@>8V-XPW;T_6O/=0NK5OV?- @:X0/NLT91)A@5E0L..00.3Z5N_$.
MUTRPM/#=Q%>W#9UVSD'G:A+,NP/DMAW(P!W[4 =+)X@O;OQ==>';&XL+:YL[
M6.=VNHF<SE\_ZM ZX4;>3D\L!CO3+WQ;=Z1X>LY]2L$_MB\O6L;:RAD.V27S
M&5?F(R%VKN+8Z=NU9GBJT\)>)]2FM=7NETW4K (]GJ4<X@D567<"DG ."3E>
M<<'C-<ZT'B&_\,^&]>OS+J3Z%K+NTR1$27=D&*"<(.2=N& [CGZ@';:YKNK>
M%-.75]5-E=:;&Z+=BUA>.2!6(7>,NV\ D9&%..?:K/BCQ!=:+;Z3/906\\-Y
MJ%M:2.\A^5)7"[E '/!]1^-8OCS4[3Q'X,N]$T.YM]0U#5%6""*WD#[06&YW
MQ]U5&22?IU-)XY2#2O#GAFSDN$'D:MIZAG8 E4D7+?0 9/I0!T&MZ[)9ZQI.
MBV2QF_U)I&5Y062*.-<NY ()ZJH&1RW7BLB7QW]CTC4C<6Z/JUCJ"::+="56
M::0KY3#.2%8.&/4C##G')XAA%G\0/#?B"5U&GB"XLYIB?DB9PK(Q/8$J5SZD
M#O7):AHUW>_VSXI@B>2V7Q'9ZA$J DS6]L%1W4=P?G(]0N1U% '>1^(;VUUV
M[T.\ABN;]+$7UJ;93&LZ[BA3#%MI#;><D88'C!JI9Z_XCL?%UCHOB"TTYHM2
MBE>UGL&?]VT8!9'#]>#PPQ]*I275I<?$>3Q(MU$=&TO16BEO%;=&9'D#;01U
M(5<D#^\OK3M"\6^'=?\ $D-VE^LVHRHT%E:)&Q,$1^9R3C 9MH+'. %4#/)(
M ^7QS.NBWGB5(H#H5I>FV8;3YLD:R"-Y@V< !LG;CD+U!.!K^(M>O-'U'088
M+>"2WU*_6TDD=SN3*.V0H&#PG7/X5Y\;*6W^$VI>!Q@ZV;R6SBMR?GD62XWK
M*!UV;&W%N@P?2NI\<2V]G=^"X9)T7RM:B)WL 0HAE7<?;) S[T =!KVOKH[6
M5K##]JU+4)3%:6P;;O(&69CSM11R3@_0DBJ^M:Y=Z#I]DDWV>XU+4+R.SME1
M&2/>_<Y8G"@,Q]<8XS6'XFT^U/Q)T34=9AAETAK">T5KA08HYRRL-V>!N4,!
MGN,=<5S46C7-C!::E#O;0M,\4-<6J\E8K-EV,Z_],U=F([;<GI0!VL_C1-&?
M7[?6A'YVD6JWN^!2HN(6!QM4DX;<I7&3V/? ?!XEO;+4](M-;2VC&K0221-"
M&'D2(H=HV))W?*3AAC[IXYKC_%6@W/C&^\8WFEXFA.C0V-LZ'*W$JR&9E4]#
MCY5SZG'8UIZRD?C?6_"\>G2AHK>"XN;MU_Y=]\/EJC>C%G/RGGY6]* -&V\;
M7+Z5I7B">&%-&U.\6VC0*1+$CL5BD9LX()"Y7 P'ZG'-KQ+K7B319([ZVL;&
M?3!=0V[VY9S<R!W5-R$?*#EOND'@9R.@XY+>34?AQX9\)* NK0WEO!=VX/SP
M+!)F1V'9<)D'H=RXZBMSQS-I7B'3[JWTG6''B73)?]#@M;IED6X'0&/."#G!
M8@@ GG&: .AOM<N7\4Q>'=-\A;H69O9YIT+K&F[8JA0026.>XP%/7-97_"P8
MWT"PGBL]^KWMZVFQV/F8 N$8J^6QPB[2V<=,<9-,D4:'\4)-6U&6.&SO](2$
M7$C;8UFB<DID\#*MD9Z[6]*XV+1-0TN'0O&,MI.UO!KM[J%S;K&3)%;W)VB3
M9U^4!6(Z@-[&@#TRXF\26*VTA&GWJO<11S)%"\31(S@,XR[;L GCY?7M@KXR
MUB[\/>$M1UBS2%Y;.(S>7,I*N!VX(Q]:GMO$VCZAY8TW4+:_>0C:EK*LA /\
M38/R@=R<>G7 K&^*,L<?PTU]7=5:2T9$!/+,>@'J: (H_%VHZ?X@T#3=8M[6
M2'7(G:WN+7<OE2*@<JZL3Q@\,#^%1Q>.9WT2V\3-% -!N;T6RC:?-2)I/*68
MMG&"V#MQPK=<C%7M%\.:/>6NG:P&DNKI;(103R7#2B%64!M@)PI/0D<]LUPZ
MV,MS\)-/\#<#6A>16<UN#\\:QW =I2.NS8NX-T(8>M ':W?BB^FNM?&DPV\D
M.AH/.$H8M<2[/,:-"" F%P,D-RW3CE8/%IUW4[&PT%H0;C35U-Y[A"ZI&YQ&
MNU6'S$YSSP%[YK"AD7PS/X[M;PXFO9GOK)3]ZZ$D04)&.K,'4K@<\CU%5?".
MD/X&UZQ.L2QV\%QX?MX#/*X")/$27CW'C.'R/7!]* .RTKQ+)K/A*75K6UC%
MY")8Y;:24A4FC)5U+ $XRIP<<C'2GZ%XB6^\#67B/4?*MDEL5NY]N=L8V[CU
MYP*PO!]I)I?@'4[N_!MOM]Q=WVV;Y3&DC,4SGH2,''O4W@O4].T_X2:->7\\
M:V=OI\2W#$;@F% (8#/0]?2@"QX0UW6O$3&_EET&32'4F+[!</-,C9!"/QM!
M /.#UKK:XC1=.TI_'7]M>&&M_P"S[BQ=+][,CR)I=Z&(C;\I<#S,D<@$9ZUV
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OB"]N
M-,\/:CJ%KY1FM;>2=5E4E6VJ6P<$8SCK6E6'XSFCA\$ZXTLBH#83J"QQDF-L
M#ZF@#G+;QQJEK#X3N]5M+22S\1>5&C6NY7MY94#("&)W#L2",>E=JNIV#7QL
M5OK8W8SF 2KYG R?ESGI7(>!_#^D7WA;PKJLN^[N;+3X1#YD[.EO)Y:AL)G
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M0JEH]W97VD6MQIHQ8L@$&$*#8.!@'H,#CVQ5V@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0J",$ CWI:**
M $  )( &>M+110 4444 %%%% !1110 =:*** "BBB@ HQS110 4444 (% S@
M 9Y.*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .8M_#>L6=Q=);^(LV%Q/).T4]DLD
MJ%R20LF0,#.!N5L# Z"N@L[."PL;>SMTVPV\:QQKZ*HP/TJ>B@ HHHH *  .
M@Q110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQD5NUYAI_A:VO?'GCJ.*\U&"<Q0+%*E],-C2POEL;L'!.5!^[CC%.\,Z_?\
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M]U=PV<0D_>RJT<88%@!A/-/XB@#L=3\06FEV5O=M!>W4,^/+-C:27!P1D$A
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M)1@#@^HXJEHWCO2=?FMTT^VU62*X)$=PVFS+"<9Y\PKMQP><UGW)2?XTZ?\
M9"#+;Z-,+TK_  HTB>6K>^0Q _&LWX2IXB_X0S0V>XTO^Q_+?$8@D^T8W-CY
MM^WK[=* .ZO-9LK#5-.TZXD9;C4#(MN-I(8HNY@3T!QDC/7!J)/$6F/XGD\.
MK<9U..V%VT6T\1EMN<],YQQ[UA?$F-H/#MOKD:DRZ)>PW_'4HK;9!]-C/^5<
M>)HH=<M_B(SK]GFUZ6R>;/R_8R@MU;/]WS(PW_ J /27\4:/$-7>:\6*+2&5
M+R60$)&2H;&>YPPX'<XZUGV7C[1+R_M;1UU"S:\;;:R7UC+!'<'L$9U )/8<
M$UP=U$5^'>BZS?+MM]4\20:KJ._[HADFRN[_ &0OE#\*ZSXJM')X+6VC93?W
M-]:I8 'YFF\Y""OOM#'Z9H UM7\:Z3HVK-IEPE_+<I MQ(MK8RSB.,D@,Q13
MC[I_*K*>*M&EMM)N8;P30:M+Y5G)&I(=MK-@^G"GKW&*XO61XC_X6?K3>&I=
M/6[70[<[;R)G#_O)<!2K#:<]R"*P;FW,_@'P##X7NG@N9;Z7R9KD M'<-%.7
MW < B0L.G'H: /6K'6['4M2O[&TD:66P98[AE0[%<C.S=T+ =0.F1FM&N2^'
MUYI@\(1P6T!L9;%FBU""=\R13CF0R,>I)^;=W!S75/+''"TS.HB5=Q<G@#KG
M/I0!E'Q1I(\5CPT;G_B:&#[0(MIQM]-W3..<=<<U7UCQEI>B:JNF7$=_-=F
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MXZ&DA\+Z';V26<.FP16R7*W:1(-JK*I!5@!TP0..G%:Q95QN(&3@9-*2!UH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIUI<7$'^JEFA5WC_ -TD9'X5)'I]E";<QVENAMD*0;8P/*4X!"\?*#@<#T%
M'D%ZJZ5X5\4:5 [VVBP>)8;>98W*BWM)/),JJ?X5^9NG0,:V=%L?#FG?&."W
M\.BVCC&B3&:&U?,:,98L' .%)&,XZ\$UZ-]AM-EPGV6#9<DF=?+&)21@EO[W
M  Y["HK+1],TW9]ATVSM=@94\B!4VAB"P&!QD@9]<"@# \7Z;H^IW=@+C7/[
M'UJU#RV-S'.J2*#@/\K<.AXR#^E<-J>N7_B#PEH4FH:C%%+;>*DM%U6V5529
M4#@3J&RH[^HR#VKUG4-)TW5HUCU+3[2]1#E5N85D"GV# T3Z3IMS9)97&GVD
MMI'C9!)"K(N.F%(P* .#\96LUS\+=9@M];E\0R1217$C?NB_EK(C,F(E QM1
MCR,GFNOL_%OAZ^CLVM=9LI?MA MT292SDC. O7/J.W>KUCI6G:6KKI]A:VBR
M$%Q;PK'NQTS@#-1VNAZ18WCWEII5C;W3YWS16Z([9]6 R: .<T?_ )*QXH_Z
M\+'^<M<;XA@FGTGXCF&)IA#JUI/+$@R7C1('<8_W5)_"O7UMH$N9+A((UGD4
M*\H0!F S@$]2!DX^M$5M!#)-)%!'&\S;I65 "YQC+'N< #GTH X3Q_XDT75/
MAW?6UA?VM]<:K#]GLH() [S2/@+A1SP3D^F*HZOX;77?&MUHUQ,4G'AJW\JX
M7[T4R3N4D!]0P!KO;70-&L;QKRTTBPM[IL[IX;9$<YZY8#-7/L\ NC<^3']H
M*",R[1O*@YVYZXR2<4 >;_#?6;G6_&7B6:_A,.HP6EE;7L6,!9HS.K8]CC</
M8BM3Q?>6L_C'P=90W$,EU%JK-)"C@N@%O(<E>HX(/XBNSCM+:&XFN(K>))Y\
M>;*J -)@8&X]3CMFHETO3UU)M26PM1?.NUKD0KYI7I@MC./QH J6+>(3J<PU
M"/2QI_S>4;=Y#+U^7<" .G7!ZUSGB&[MK+XI^&)KNXBMXOL%\-\KA%SF+C)K
MN:IW^D:;JGE_VAIUI=^7G9]HA63;GKC(..@H Y'6;RTF^)/A*[CN(I;7[#J+
M&5'#)@"+/(X[&L>TN(?".M:%:^%]?AU+1-5O/(&DF19C;HP9C)"X^8(N,D'(
MYKT>#2]/M1 +>PM81;AEA\N%5\L,<L%P.,GKCK4=GH6D:?=275EI5C;7$GWY
M8;=$=OJ0,F@#G'_Y+3#_ -BZ_P#Z4)1\4[>:?X>Z@88GF$+P3RQ(,EXTE1W&
M/]U2?PKK?LT'VH77D1_: GE^;L&_9G.W/7&><5+0!Y_X_P#$FBZI\.[^VL+^
MUOI]5@^SV4$$@=YI'P% 4<\$Y/IBJEQIFJ3?%.&VL=9;3YX?#<(DF6!)O,Q.
MXQANG/.:[JUT#1K&\:\M-(L+>Z;.Z>&V1'.>N6 S5S[-!]J-UY,?V@IY9EV#
M?LSG;GKC/.* (T<V&F![ZZ\PV\.Z>X90N[:/F8@<#H3@5XM*WB*?PE)XJC\.
M.9CJ0\01W9NDW>4O 39]['D#;CWKV^:&.XA>&:-)(I%*NCJ"K \$$'J*!#$(
M! (D$(78(PHV[<8QCIC':@#B?'-W#?Z/X4O+9P\%QKNG2QL/XE:0$'\C5CXJ
M_P#)+]?_ .O?_P!F%=1_9]E]G@M_L=OY%N5:&/RAMC*_=*C& 1VQTJ2XMH+N
MW>WN88YH7&'CE4,K#W!X- ')?$B]N8_"/]E6"L^H:S(NGP(K!20_WSD],('Y
M[<5B:3-?Z)\2($NM&_L>RUNQ%I&@N$F4SVZDH<KT_=DC'?:*](DMK>6:&:2"
M)Y823$[("T9(P=I[9''%$UK;W+1-/!%*T+^9&70,4;IN&>AY/(]: //OAKK^
MD:/X M]-U/4+2QOM*:6&^AN)E1HW#L22">0<Y![YIMW8W6L_%JZ;3M<N]-']
MA6[^9;1QL9%,TF,^8K<=^,5W-SH>D7EZE[=:58SW28VSRVZ,ZXZ88C(JT+:
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M&VOK2"Z@8Y,4\8=3^!XI;.QM-.MEMK&U@M8%^[%!&$4?0#B@">BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF>1]H^T8.WR\9W=,]*\Y^''Q%E\06>LZWKNOV,5G;$L;(0>7]D0L0C&0_>W
M$8ZYQZXH ]6HKFM%\>^&O$QN8=$U:&ZN(8S(8MC(V/4!@"1TY'K7 :1\1/$5
MWX7\!WTUQ"9]8UAK2\(A4!HQ(5P!V..XH ]DHKF=<^(7A3PWJ(T_5M:@M[O
M)BVLY0'INV@[?QQ6A;>)M%O-533+;489;M[47B(F2&A)P'#=".>QH UJ*YY?
M'7AE] .NIJT+:9YWD>>%8CS,XVXQG/X4EQXZ\,VOB!="FU:(:DTB1>2$9L.W
MW5+ ;03D<$T =%15&VUG3;S5+S3+:\BEO;+;]H@4_-'N&5S]15Z@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+QEJ-YI/@[5;S3K:
M>XODMV6WC@C+N9&^52 .3@D$^PKQG4?A_P"-=!\!Z)=P7%M=/HDT=]!8V]HW
MV@2,P+@L"=V">>.B^U?0=% 'B6I>"7\=?$KQ!/=VFHV=M=:-"]I<%7B592B8
M5NS8Y!4^AKIO!3:A<?!VYTZ\T>:QU"SM;BS:W^S&+S&"G#*N!G=D<CJV:]'H
MH \ETS2M13]FQ]->PNEOSI\Z_93"PER9&(&W&<X]JR[G2M:\.S?#WQA#HU[?
M1:=H\5E?V<$1,\0,>,[.N1O.?]W!QFO;J* /'OB%K%]XZ^&.L1Z;X:UN$1S6
M_E"YM"LD_P ^6VH,G"X'/O[5#\0=;N?&_P --0LM.\,^(8;BWEMF,=WI[(T@
MW<[ "2<8Y],BO9Z* //_ (<#PY;3WUOH'A76M%,B(\SZA;21K+M)  +L>1N/
M K,\:6VJ>&_BCI?C:UTF[U33?L1LKR*SC\R6+EB&"]QR/R/3(KU.B@#A_P#A
M8=S)I(U*W\(:^T+7D=K'');[)6# DR;.2$& ,]R:YSXRW]S>)I>D66AZS=RV
MFHP7TDUO9-)$44-D!AU;D<5ZW10!RZ>,9)[[088?#^K^3JHD+2RVY3[)M_YZ
MC^'/;FNHHHH Y[QI=6EMX=D&H:%=:U8S.(KBUM8?-<(<G?M[@$#IR.O:N"^$
M^E7-CXLUR?2;'5M/\(R1+]FMM25E8S9&2BMSC[PSWR,]./7J* /./AC9WFER
M^-9KVRNH%DURXFBWPL#*G4,@(^8'MCK7$VG@7QGXH\(^(+^::VLO[>GDNY;"
M[M&^T91B8UW$C;]T8XZ'WKWVB@#QKQ,=:\2?L[11RZ7?G5@L$4ML;=_-9HY5
M4MMQGD+N_&MGXQZ;>ZC\,H;:TL;F[E6YMV>&")G?:,YX'->F44 >(W]GHT_P
MT\5Z;X3\'Z]ILTL,3O'=6DH,Y$@P$W,Q) R<"J'B;PAX@/B#3[#2[2Y73?$]
MC9P:JZ1-B!HBNXL?X3M'?KEA7OM% 'C4^@W\6H_%B.WTRY6"YTZ"*R"P-MFV
MV[+MCX^;' P,T_X36VA:7-IL$7@_7M/UU[/R;J^N;25(20 S<LV!DJ,<#M7L
M5% 'G5GI]ZO[0&H:@UG<"R;0EC6Y,9\LOYB':&QC/!X]JP+GP-<^)]3^)%I/
M:S6\D]S;3Z;<R(54RI&V&5CU&3M)'0-7LE% 'EGP5M]<6V\17FOV%S:7MW?"
M1_/A:/>VP!F&1R,^G%0WSZAX$^+.L>()M&U'4-&UJVB'G6$!F:&1 JX91T'!
M_,>AKUFB@#QNTTW5_$VM^,O&,NCWMA;7&B2Z?I]M<Q%9YODR6V=1RO'KNXSB
MM?X3^!++2/#FD:S/;W]OJY@82Q3S2*%R2/\ 5DX'&.U>FT4 >>_%S3;V70]*
MUK2[.:[O]%U*&[2*!"SNF<,H Y_ND^PKSR[\/^(= \&^%_%5EI=Y-KXN;R6\
MAB@8R#[2&P64#(P .O<U]"T4 >.Z[X#U1/@EX?TW3+4RZGI4L&H/:XPSR88R
M+[D&0\>U1>,-;U'XGZ+:^%])\,ZU927-Q&U[<:A:F**V13D_,>IS^>*]GHH
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M,>NXC/OQ7NE% 'S]>VNH:79?$'P[<^%=3U#4=6O)KJTNH;7S(WC;E6+]BO)
M&3DX'-=%X=TC48O'7@6>;3[I(+?PJD$[O"P6.3;RC$C ;V/->OT4 ?/MUX?U
M8_!;Q99KI%[]LFU]Y(H1;-YCQ^9'\RKC)7@\CCBMCQ3I^J:3\4;S5YWUVWTV
M_P!/CABNM*LUN2I4 -$X96V@D$].<_7'M5% 'A,FAGPL? &L6ND:Y?Z'IK78
MEMY[7-S"9"=KM&.G)R/H.YKI_A9:W:^*/&M_/HEWI-O?7,$UO%<0^62I5S],
M\@D#H3@\UZ?10!X]X^OO$LOB?6M)2'5(--GT\)9_V;IB3_;G9,%9)&4[0"2.
MV!S]<:?3I;#P+X0NOL_B/3_$=A82?9+BRL&F56)/[J5".,\8R!P3UKWJB@#$
M\)3:K=^$=-FUZV6#4Y( ;B(+MP?=>Q(P2.Q)KQJW\*ZY/\ XK2/2+HWEOJAN
MIK%XBDDT2N<KM(R>H./;BOH"B@#R.U:X\8_%+3->TW0]1T_3],TZ:*XEO;4P
M&5F5@L:@_>QNS^?MGG-"T'6(O!OPSADTJ^26UUYI;A&MW#0IYK'<XQ\HQSDU
M[_10!XE+)=^%==\>VFI>&]4U&3779[&>UM#,DR,K 1LPZ8W#CZ^V<C6/"_B?
MPCX4\(:E8:==76KP6%UIUW%;H9&19@[1YVY^X7/MD"OH2B@#Y]TKP/K.F>,M
M,\&-8W+^'HKZWU>2Z,;&(ND&'4MC'+C&,^E;6I?VEI'Q'DE\(VVNI<WVI)_:
M=C=6.ZSE0'YIEE/"COG.>>V,5[110!SFD75K+XQUZ"+P]+97$0A\W4F@"K>Y
M7C#8^;;T[UT=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M9GB.>6V\+ZM/!(T<L5E,Z.IP58(2"/QKE[#QE=VVF^&-.33+O5=4U'1X[L,L
MBJ"0L>XNS=!\Q.?7C!)H [NBN07Q]:_\(O+JTNGW27<5X=.;3P5:0W6\((P<
M[3DD'/3'-95AKM]-\47.K6%QI2VV@222123+)&0)D.]64X/&0> 1@T >B45Q
M]CXZ>XDTN>ZT.ZM-+U:58K*\DE1BS,"8]Z Y0,!QUZC.,U3E^),B6-[J:>'+
MY]*T^YEM[R[$B#9LD*%D4G+@8!.,8SCG!H [RBN<U+Q3+%JZ:5H^ER:K>_9A
M=2!9EB2.(DA26;NQ!P .Q)Q5"7XA6YTW1;JSTJ]NI=5GEMH[5-HDCEC#;E;)
MP,,A!.< <]* .RHKCE^($%OI.L7&J:9<V=]I4L<,UDK+*SO)M\H(PX;=N [8
MYS6;;:SJE]\4])@U'2KG2V32[IS$\ZR1R O%@AE."1R""./H: /0Z*XN'X@"
M6*UU(Z-<IH%W<K;0ZB94Y+/L5S'U"%L 'KR#BEU'QW<V^IZU96'AR\OSHY5K
MJ5)41-AC63Y=Q^9L$_*/3J,C(!V=%<!>^--7E\5>'8]&TQ[O2]3L)+M098T:
M88C(/S<KM#<CON]JAC\1_P#"/>(_&-[=)+-9QZI8PN0_%NDD$2E\'L"P)QZT
M >BT5DQZ['-XKFT&*!W>"S6ZFG!&U-S%40^Y"L?H/>FZQJFJV4R1Z9H$VI?(
M7=Q<1PHO^R"QR6_#'O0!L45QLGQ!MWTOP_>6.EWEXVN%UMX$VJZNJDD-DX&"
M""<X !-/B\>V\.C:W>:KI]Q87.C2+'=6FY96)<*8]C#AMVY0.G)H Z^BO.O[
M;U6_^)?ABWU#1[K2C]EO',;SK)'*"L>.5.-RX.01QD=<UT_B;Q,/#ATU!I]S
M?3:A<FVBBMR-V_8S#J0,?+C)(QG/:@#>HKCX_'T%OI^MS:QIMQI]UH[1BXM0
MRS%_,_U6PKPVXG Z<]:EM/%]Y_:]OI>K>'Y].NKV*22R!N(Y5F*#<R$J?E;'
M//'7GB@#JZ*XSP#XCUS7XM0.JZ<84AO;F))_-C(&R4J(MJ\Y4<;N^*U]<UG5
M=-D8:?X>GU&..+S9)1<1Q+W^5=QRS<9Z <CF@#<HKDY_',,EGH$FE6$E[<:Y
M$TUK"\JP@*JAFW,<X(W 8&<\^F:Z6UFEFLHII[9[>9D#/ S*S(<<KD'!_ T
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MHR0NX_,W!.T?GR,]-=>,8W.E0Z-82ZE=ZG:_;88A(L02#"_.['I]Y0!@DDT
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M@@^HZU=\.:Y>Z[:K=SZ0UE;31)-;R_:4E$BMSSMZ'&/4<]: -RBBB@ HHHH
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M E25.<$=13J /!O"%S%I-IX=U20Z9JCS7*I#:)J4K7$3RL5:1;<EHUD 8E@
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MD+Y2)SQP<J:J^(=*UAO%6BZ[I,%K<FTAGMIH+B<Q?+)L(8,%;H4Z8YS7544
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M6MRL_0M.;2/#VFZ8\@D:SM8K<N!@,40+G'X5H4 %%%% !1110 4444 %%%%
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MH(=>YQS6AJ.I^+;#5_#^@QWFES7NHQW33W;6KJD8CV%2L8?D@,1@MR<'(Z4
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M(B!PS* 6)[9 -9GC.QT_3]8TQT\-?V1!%K$-Q-XA*H>K9/*$O\Y.W+X S]*
M/6J**X?7?$VI67C)=+;4+'1[,Q1-;37MJTB7LC$[D$FY50C &.IW9]J .XHK
MS_Q!XTNHO%=YHEGJ-KIBV,$<DDT]C+<F61\D( A&U0 ,D\G/'2LF]UCQ'X@N
M? 6H6MU#I4E[+.DEO+;.X$JQ2[F(WJ60A>%.",@Y/2@#U5F"J68@*!DD]JHZ
M5K>EZY#)-I6H6U[%&_EN]O('"MUQD5E^-DOO^%?ZR+>YBCN5L)2\C1%E8!#N
M &X8)&<')QGO7,:/J.OVFE^%O#=E=:=]MOK'[3]K:T8);6T<<8"^7O\ G?+
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M5N&4C'''0<UER^ ([S1-=M+[5)[F_P!;14NKYHU4A5&$5$' 4<\>I))KL:*
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MXX'&:;IND:AIVNZ;8V<LT/A_2M-%NJNP8W,AP%SW^14Z\9+\=ZZBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"EJ]TEEHU[<R7B6210.YN9%W+#@'YB.^.N.]<#HFMZG-XN
M@TA-9UFXL]1TZ>5)]1T]('BD4IB2+]VH(P_1@<8'K7?ZKIEIK6E76F7T?F6M
MU&T4JYQE2/7L:Q],\&6>G:O;:J^HZG?7EM"]O')>7 ?$;;>,  ?PCGJ>Y/&
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MB&36P9/M<EJEHV6^78K,PX]<L>:R[CP5:2:C=WEGJ>JZ:;Q_,N8;*Y"1RO@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ7MI_#FEZP-)E"W^L#2A'YPRA)(WYQR..GZT >B4444 %%%% !1110 4444
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M2Q2R0B195WC"C/ R2O//3I6E\.&T]O@EJ?V-9EN1'=_;UF;+BYV'=G@8!&W
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M6L$<$$:[4BB0*JCT ' %5X='TRVANH8-/M8XKMVDN42%0LS-]YG&/F)[D]:
M/']-L]"T#XI^$K?P/>^=!?6TQU..&Z:970)E9'R3@DY/;D"N8T__ ))IX4_[
M'-/YM7T!I7AK0]"DDDTG2+&Q>7AVMX%0L/0D#I[4J^'-#2UAM5T>P6WAG^TQ
M1"W3:DO]\#& W/7K0!XYJ$&A>(?&?CO_ (36_,4VFJJZ;%+=-$(8]A(>-01N
M)^4]^3[U4AU;4M'\+?#CQUJLMPYMY);.\9R2SP2%Q&S>N%&<]\BO:]3\+Z!K
M5TEUJ>BV%Y/&,+)<6ZNP'IDCI[5:OM*T[4[#[#?6%M=6G'[B:)73CI\I&.*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HJIJ9U$6$ATI;5KSC8+IF6/J,Y*@GIFN2\-Z_XMUK5+Z">ST2*VTZ^-G=
M,DTI=L*K$H"N#PXZXH [BBN(\&?$#3=9TC2HM2U:Q76[M6S;JP4EMS #'8D
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M=]J@9_2KE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!'<7$-I;2W-Q(L4,2%Y)'. J@9))] *X*X\?V^J
M>)?"]GI$]W%%>W;F19[1XA<P>2Y#(74;EW!3D>WK73>,=*N-<\&:QI=HP%S=
M6DD463@%B. 3V!Z?C7)>?JVNZWX.8>&=0L8=-N&:[DN551&Q@=<* 267/\7
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MSQ6^CP^+;F.]:Z?3K2.2&TCLF)MW:-BI9AG<K$ D\!0.:JV\NI^%?%7B)O[
MU'4HM4GCN;2>S"L"1$J&.0LPV8*\$\8-,U'1M2FN/B*Z64I&HZ7%%:8&?-<6
M\BE5]3D@?C0 OAC6+E[7PV9_$&H22ZC*_F1:AI^QIV$&\JA"IL0$%@<'/3-;
MDOCK0HK]K9IKCRTN!:O=BUD-LDV<;#+C:#D@=< \=:S)=)OSJ'@!Q:R%; /]
MJ./]5FU9!G_@7%<KIOA=[739?#>M:=XIN1]JD_X\YQ]DG1I2ZOG< O4$@X.0
M: /0-7\::-HVHM87,MPT\<8EG\BVDE6W0]&D*@A!P>OIGI4?P^U.\UGP#HVH
MW\YGN[BW#RR$ ;CD\X'%8^[5/#OC3Q'.F@WNI1:QY$MK+;!2H9(Q&8Y&8C8,
MC.3Q@GOQ6O\ #S3[O2?A_HMA?0M!=06^R2-NJG)H @LO&.FZ=X3L-5UC65N8
MKJYDMTNUM&B$CAI,+Y8R1@(5]R/>K^G>,=&U*UU&=9I;8::-UY'>0/ \*D%@
MS*X!P0"0?:N.T[P_JL?A#P9:R6$HGL]?-S<1D<QQ[[@[C[?,OYBIO%/A?5=9
MU#QI%:6Y O\ 2+6*VD8X661&D8IG\A_P*@"T?'D.K>-/"]AI<UW#!=O<-/%<
MVCP^?$(&9'7>H)7<,Y'XUKZ+XGM&>"TN]5%W<7E]=6]NZVK1+NB8YC/494 C
M)^]CBL7[3JGB'QGX2O1X;U"PM-/:X-S)=JJ[&>!E"@ DE<X&[@<C&>U(^&]5
M'@:]DALI!J]AKMQJEC$>#)BX9@![.A8?\"H ZC6O$UK')+:6NJBTN;2^M+>X
M=K4RJ3*PVQCH,L".?X<@FHO$?CK2=(_M&R\^X^V6UN6EDAM7DCMF924\QPI5
M,\'G\>*YX^'=5D\%V<TME(=5O]>M]4O8ART0,ZM@_P"Y&JC_ (#4KQZOHE[X
MNTY- O=0.L3M<V=S#M\HAX50K(Q/R;2I['(/&: .A\+>(X[G0_#$&H7+2:KJ
MFF+= [/]851"[$@8'+C\ZO-XHTM;74;@23.NGW/V2=8H'=_-PIVJJ@EOOKT'
M>N+M[#5=#M_ .IOI%[=+IVE/9WL%L@::)GCBP=I(R 8R#Z5';1>*[7P_XBN[
M73+RQNKW7A<-%'Y;W M&2(.8\Y4O@$=^0<9P* .@U7QC;WO@[Q-<:5)<VNI:
M98RR-%<V[12PMY;,C%7'0XR#R.*MGQ?8Z=:Z=!>?;+F^FLDN9([2TDG94( ,
MC! <#.?UQ7%Q:)JUS#X[ECL-8:/4-%2"S.HL&FF<+,", \<L, X/(]:O^([*
M\@M[&?3--UV'Q%!ID<5M>6"H8G;'$,P8XVAN3N'&>#0!W6M:LFCZ#=ZH8I9E
M@B,@2*)G9O3Y5!./7C@9/:L31_'FG7O@V#Q#J"SV,9BB,HEMI%!D=00L65S(
M"3@%<YK;N+>[O/#DMO.(Q>S6A1PI^7S"F#CVR:\^CL]8NO 'A9$T*^6\\-W-
MF]Q9S*J-<"*,H_E?-AL9W#.,XH [C1O%6FZY=SV=O]I@O8$$DEK>6SP2A#P&
M"N!E<]Q3]:\2:=H+6\5VT\ES<DB"VMH'FEEQRQ"*"<#N>@K!TN.]UWX@)XA;
M2[S3K&TTU[-?MB".2=WD5C\H)(50O4XR3Q2Z]%?:3X\L/$D>FW6HV/\ 9\EC
M*EHH>6%C(KAPI(R#@@XZ<4 )KOQ&T^P\'3:]IL4]X8[A;9H3;R*T4FX!ED&W
M,9 /\6,G [BH-<\:I9:WX5N1)>V^FWINUFMY+-UEE95 1?+*[\[N@ YSZ5D7
M_A_6=3\)>,KY=,FAN=7NX;FVT]ROF>7%Y8RP!P'8(3C/I7072W>M^+/"&KQZ
M9>6]O!]M\Y;F,(\.Z,*NX9.,D<4 :=OXTT*XT*ZU@W3PVMI*8;A9X722*0$#
M84(W;CN&!CG(Q3[#Q=I5^MZ ;JVFLHO/GM[NV>&58\$APK $C@\C/3%</KWA
M;6+V3Q+/;VEP=NNV>H0QQ.(WN(XXHP_EL> W!P3W6M+3]*ANUUB]@T_Q)]N?
M2Y+1)=6?[P;GRU!;.<C.<8]^: .H\/\ BO2_$XD?2FN)8456$[6[I&^?[K,
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MVNO2R6ZW,L84Z?=H-H=I,DXVKN . _ ZU'XAT#5;NQ^)$<%C*[:D;?[& /\
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MT?4(]8\ 2O:2+'8:3/#=,1Q$YC@ 4^Y*M^5=Y0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45%=3FVM)IQ#+,8T9
M_*B&7? SA1W)[5@:9XJENM>31M2T6\TN[FMVN+?SY(Y%E12 PRC'##<.#ZT
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ML/"&HV!N;59]?2">%SM=2JS*\;X.#AE]P<"NH\2^(;;PQI(U&ZAGFB\^*'9
MNY\NX48'?KT'- &Q17%KX^N&U*;2?^$4U<:PL2W$=F6A^>$Y'F&3?L7!&,$Y
MR0!GG%ZS\;Z??67A^Z@@N-FM3M;Q!E :)U5RP<9[&-AQGF@#IJ*YK4/&NGZ8
M_B 7,,X71(H99F4 ^9YH)4+SUXQS@<UE>*_%^NZ5X%U+5H?#]S:7EOMVB66&
M154_\M#A^0.A YR1P1S0!W5%4],N[F]L5GN].FT^8D@V\TB.P]\HS+S]:\X\
M,^.IM'\,S7&H:7JESI]MJ-S'=:F64I"#<.%P&;>RJ"N2H('3L0 #U%T26-HY
M%5T8%65AD$'J"*P+'P/X<TZ[@N;;30KV[;H%>:1TA/JB,Q53] ,5%J7B]K;4
M[NPTW1KW59;&-9;PVS1J(@PRJC>PW,5&=H[8]:V]*U.UUG2K34[*3S+6ZB66
M)B,$J1D9'8T 6Z*XO2OB+::EH]SKDFE7]IHMO;O*U].$"NRD HJAMQ/. <8)
M!&:T--\6/<ZO;:9J.BWNE3WD3S6GVAHV$H7!9?D8[6 (.T_TH Z2J=GI5E87
M5[<VT 2>]E$MP^XDR,%"@G)[  8'%<B/B;;FP;5/["U,:/#<-;W-^1&$A82%
M,[=VYE!QDJ"!GU! ETS4KFW\7^-G\N[O4MWL_)M82&/,(R$#$ 9/)Y [F@#M
M:*YO3?%RSZC>Z?JNFW&D7=K:B\9;B2-U:#)!<,C$<$'(I-$\6RZR8K@Z#J-I
MIEQ$9K>^G,>QT R"RABR CD;AS[4 =+17(6?CZ&Z?3YY-'O[?2=2F6"RU"0I
MLE9L[,H&WJK8^4D=QG&:Y[QUXYFN/!OB,Z5I>J?9(!):C5H654693@X ;?M!
MXW@8S[<T >H44R(DPH3R=HKS[XB7M_)XD\-:+%IFHW5C=2RR3)9WB6YN2L3D
M1[O,4C;@.<D \8)/% 'HE5[^QMM4T^XL+V(2VMS&T4L9)&Y6&",CGI7,W7C+
M['<7MGI>A:EJL.E )>3P/'B,A0VP;W!D<+@D#/7KFEO_ !]90)H9TZPO-4?6
MX'FL4M@H+[0APQ8@+P^23P-IS0!U4420Q)%&NU$4*H] .E/K.O=9M]+\/R:Q
MJ:/:0PP>=-&V&:/C)7C()SQQU-9>G>+9+G5K?3=0T2]TNXO(7FL_M#1L)@N"
MR_(QVL 0<'^E '2T5RFF^/;#5)]/L[>UN?[1N9Y89[-MOF6GE?ZQI><  [<>
MNX8IR>,98]6L+34?#^HZ?;ZA,8+6YG:(AI-I8*RJY9,A3C(^N* .IHKBM1^(
MD=E/K"PZ#J=W#HTFV_GB$82- BN6&YANX8_*.1@DXR,V]-\;PW^M6-C)I-_:
M0:E&\FGW<X4+<A!N/R@[D^7YAN R* .JHKA7^)D"6=SJ(T'5&TJSN7M[R] 0
M)"5D*%@I;<X& 25!P#Z@@2#6H].\>^)KJ]NW73K31[6X;+$H@W3%F ]2 .G7
MB@#MJ*YC3?&#76J6-C?Z+?:8=11GL7N&C82[5W%2$8E&V\X/H>XQ73T %%<M
MK'C&71)I)KOP_J*Z5%,L,FH;HMJ[F"A@F_>4R1SC\*GE\5.WB.YT>PT>[O39
MF(7DT<D:K#Y@RO#,"W')P/S/% '1456O[I[*QEN([2>[=!\L$ !=SG&!D@?F
M0*R-%\3OJ6L7.CWVE7.F:C! ESY4SI()(F)4,K(Q'52"* .@HKFM>\7C1M;M
M=&M])O=1U"ZMWGABMM@!"L <LQ 7KG)XXQU(IE]XQ>"^NK.PT._U&6QB26^\
MAHU\C<NX)\S#>^WG"Y[<\T =117*R^.()Y=.AT73KG5IKZR^WQI$\<>V#(&2
M9&'.2!M^N<5J0:_#-XD.AFWFCN!8)?$OC 5G*;3@_>!4^U &M17G^L>)/[9M
M?"U[8FXMHW\2BTD4M@N$\Y&!P>5)3./I5SPMXIUK6/$VN:?>Z+/#:VEWY23&
M2'$(\I6"L%<EB2<@@$889Q@T =I16%KGB5=(OK33;:PN=2U.[5WBM;<JI"+C
M<[,Q 51D#GJ3@5ROBOQO<S_#GQ!=:98WUIJED6M;J%G19;-BN?,SNP1@C!4D
MG((Z' !Z/16+X6LQ8^'X8Q8WEB22S07EU]HD4],E][CG&< ]^U<KX1\4-I_P
M[\,B6*[U/5-15XX($<&24J6+,6<@!0!R2?2@#T2BN;M/%IO+&_,>BWYU.PF6
M"?308S(K, 5(;=L*D,#NSTS5-_'T=MIVMSW^C7UK=Z,L<MW:%D=O*?HZLK%6
M& Q/.?E- '854@TRSMM1N]0A@"75X$$\F3\X0$+QT& 3TK-U#Q%:Q:E;:5&)
MI9;RSFN_-@(_=1(!\Y)]2P Z\UAV7C6"QT/PO#!9ZOJMQK%FTMJ&*-,^Q4)\
MQLA0</DMTX/M0!W-%<G%X]LVT"[U&?3[R&ZM;P:?+IY"F7[02H5%(.TYWJ0<
MXP:L:%XIN-7UR_TFYT.[T^XL8T>9I98G7Y_N ;6).0&YQCY2.M &EK&@:7KT
M<*ZE:B8P,7B=79'C)&"5=2&''H:=I&AZ;H4,D6FVJPB5]\K%B[R-C&69B68X
M]37-ZEXIUJT^)%MH=OHL]S8O8O,622%2Q#QCS 6<$*NX@CJ2> 16)IOC.ZT2
M?Q?+/I6J:C9V6L323W$;*4MH0D? WL"V,,2JC@<]Z /3Z*YW4?%:P7]MI^EZ
M=<:K?3VWVL10.B!(<X#LSD 9/ '4X/I6AH.MVWB'28]0M4EC4N\<D4RX>*1&
M*LC#GD$$4 :5%<?=_$""V^V7::3?3:-8SFWNM20Q[$96VN0I;>RJ>"0.QQG%
M2ZGXV-GK5]I%CH>H:G=V<$=Q+]GV!!&P8YW,P&?EX'4]NAH ZNBN+L/B-::A
M)I4T>DZC'I6J2K!;:A*J*C2L"0I3=O X(W8P2...:6\^('DW&KQ6GA_5+Y-(
ME*7LL/EA44*&)7<PWG!^Z.>.<9&0#LZ*XE=9CO/B)I%U;WC'3+CP_/=KEB$(
M,D)#D=,[3U]Z=!\0XI([*^FT34;?1+V9(;?4Y/+V,7.$9D#;U1CC#$=QG&:
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M&GV]O&0WS;T>0MQZ885RUGX1U[2-%\,75M;V]QJ6BW=W(]HTVQ98IVDSM?!
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MBJ358[P01OH\VG IGS$=W5@X[<8_.@"E:>+]2C\4:=HVKZ;86YU'S!#]DO\
MSWB=$+E9%V+C(!Y!(R,5Q\G_ ""KO_L?D_\ 1Z5LZ#\/M2T[5O#ES.FAP1Z-
MO5FLH&$MUNA:/>[$=<D$CGJ3FM!_!%XUG/#]J@S)XD76 <'B,2*^SI]["_2@
M#=\6^(#X7\-SZNMHUV89(4\A6VEM\JIP?7YL_AVK,LO%]]!K<^F^(M+ATXK8
M/J,4D-UYZ^4A =6^5<,,@\9!SP:TO%^AS>(O#DVF02QQ2/-!('DSC$<R2'IZ
MA2*KZKX7.J^*$U":5?L;:5<:?+&,[SYK(<CMC"G\Z ,B+QUJT=EINM:AH$5M
MH.HRQ1QS+=[IX5E($;R1[  "2N0&)&>].\.ZSXFO/B!XCT^[M;0Z=:S0J,79
M+0*T6Y=@\L;MW!.2-N3C..8(?!WB.YTO2_#^JZAITFBZ?)"QE@C<3W*0D&-&
M!^5>57)!.<=JVK/0]5T_QSJ>JV\UF^F:H(FN$D#":-XXR@V8^4@_*>?>@#SW
M4;FXU?PAX&@L-&MY=,O-1^:TO=0=_,9?.(C=F1BR?+NR<\@#'>NU@\7V^D:7
MXA@N].BL3X<B0BVADW(\1C#1[#M&,D% ,<$5%I_@>\L]!\)Z>]W SZ+?&ZF8
M XD7;*,+QU_>#KZ&L[QEHBZM\3?#UM!*0MU SZI"!D26\$BR1[O^VAV^X)H
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M9E@!RD@:1F9<]OG&,^G- $<'C'6;>?2)=;T&&RT_5ID@@DBO#+)#(X)195V
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M2Z=:0V@<Q1"3EG9FY))"]A@#OFNET'3WTGP[IFFRNKR6EI% S+T8H@4D>W%
M'+6^L^)G^*>H:6+6T?3([2"3:UV041GD'F >7RYQ@KG VCGFN<\,^*-5\.^%
M+B].BQRZ+;:M<I<7)NMLI#W3 LD>TY"EAG+ G!P.]=M/H>JP^//[>L)K,VES
M:16MW%.&WJ$=F#(1P20Y&#6;)X'O'^'>H>&Q=0?:+JZEG67!V /<&4 \9SCC
MZT .UCQW/;:SJ5AIEII\W]EJIN6O=0%N9'9=_EQ#:VX[2.3@9.*Z;2-8M=9T
M&SUB E;:ZMUN%W\%5(SS[BN6OO!M_!XEU+5-,MM#O(M2*22Q:I"2T,BJ$RC
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M$4)FD$40D<+O<Y(5<]3P>!Z5-7#_ !+:[2+PNUC'%)=?V]!Y2RL50MY<N-Q
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M+ C^4#Y)9,L.<DCD\C'%11CQ!!-\0-2TG6(K&*QOY+A83;+(9W6WC8JY;HN
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M=S-Y[0)$QGA/F'[HP,Q'&/\ 8SW-9&A^,O$-_I&CZ9>21Q>(YM7%K=XC7Y8
MGGLP7&!^Z*KGU/K79^*_".F^,+&VM-2:=$MYQ,K0,%8\%2I)!^5@Q!'>DC\(
M:9'XTD\5*9OMTEOY!C+#RAT&\#&=V%"YST% '*-KNO?V#J\VG(X,/B.>VGEL
M[19)8;56Y=8\8=QQDD$X).#BI-3\8S6OAC1?[+UB34IM3OC:_P!H1V.^6-0&
M9OW*CF0!=N-H]2.*Z0>$DM[6ZBT_5]2L)+B_DOVF@>,MOD^\N&0J4]B#VYJ
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MY%&T%W=L;54D#[PR6[URD>O:[<_#O3BNI75OJ!\0IIOVF4(TH3[28QO ^5F
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M^T]179IEM<>6L^%;,LHV$8^YQT]S0!WT]S!:HKW$\<*LZQJ9'"@LQP%&>Y/
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MA/WO)$:>4/\ =QG'XUQ7BBT2;2OBD+2>6&QBN()0+=MJ//Y(\Y3ZC)4D>HH
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MC:V$LZK=72NT$1SEPF-Q'TW#\Z ,6'P)H,&FWVFI!<?8;UU>2V:ZD,:$/O\
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M3%"\Q=RH/)^8EB!GK44OA_2)]-N=-ETZV>RNI&EF@9 5D=FW%B/4MSGUHM=
MTBQEM9;73K>*2TA:"!U0 QQDY*@^A- &E1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?;>7?$"U?S1B<D;@$/\ %D#/% %VBL;6M;2SLKS[#=::;VU>$2I=W'EI&)&
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MW]S:6NF2:=-=2SSML*NLD:J-Q.,'>>,=<5MQ:UI<^D_VM%J-H^G;2YNA,OE
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MY5,?FZ=YZW5N8E4!7QSM(8;1T//>O3]!T6V\.Z'::19O*]O:IL1I2"Q&2>2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Y&/5O%FH:AJ::9::+]FL[MK93<S2AVPJMDA5(_
MBKKJY[PM_P ?/B'_ +"TG_HN.@"#S/'?_/MX<_\  B?_ .(H\SQW_P ^WAS_
M ,")_P#XBNHHH Y?S/'?_/MX<_\  B?_ .(H\SQW_P ^WAS_ ,")_P#XBNHH
MH Y?S/'?_/MX<_\  B?_ .(H\SQW_P ^WAS_ ,")_P#XBNHHH Y?S/'?_/MX
M<_\  B?_ .(H\SQW_P ^WAS_ ,")_P#XBNHHH Y?S/'?_/MX<_\  B?_ .(H
M\SQW_P ^WAS_ ,")_P#XBNHHH Y?S/'?_/MX<_\  B?_ .(H\SQW_P ^WAS_
M ,")_P#XBNHHH Y?S/'?_/MX<_\  B?_ .(H\SQW_P ^WAS_ ,")_P#XBNHH
MH Y?S/'?_/MX<_\  B?_ .(H\SQW_P ^WAS_ ,")_P#XBNHHH Y?S/'?_/MX
M<_\  B?_ .(H\SQW_P ^WAS_ ,")_P#XBNHHH Y?S/'?_/MX<_\  B?_ .(H
M\SQW_P ^WAS_ ,")_P#XBNHHH Y?S/'?_/MX<_\  B?_ .(H\SQW_P ^WAS_
M ,")_P#XBNHHH Y?S/'?_/MX<_\  B?_ .(H\SQW_P ^WAS_ ,")_P#XBNHH
MH Y?S/'?_/MX<_\  B?_ .(H\SQW_P ^WAS_ ,")_P#XBNHHH Y?S/'?_/MX
M<_\  B?_ .(H\SQW_P ^WAS_ ,")_P#XBNHKS?XK^-M>\'_V,NA6]M/+=M,T
MJ3(6RL:AB!@CMF@#H/,\=_\ /MX<_P# B?\ ^(H\SQW_ ,^WAS_P(G_^(K&C
M^($FI^)/ \>EF$Z9KT%S+.&7+H8X\A0<\$-D'Z5?7XH>%FU:+3S=7*F:?[-'
M</:2+ \N<;1(1C.>/2@"UYGCO_GV\.?^!$__ ,11YGCO_GV\.?\ @1/_ /$5
M7UWXG>%O#NHWFG:A>RK>6FPRPQV[NV&7<",#! ')/;(IEG\5?!^H:Q9:9:ZH
M99KPJL,@A<1LY (3<1@-R..Q.#SQ0!;\SQW_ ,^WAS_P(G_^(H\SQW_S[>'/
M_ B?_P"(J'5OB5X9T74Y["[NYR]J56ZEAMI)(K8MT$CJ"%KK(Y$FB26-U>-P
M&5E.00>A% ',^9X[_P"?;PY_X$3_ /Q%'F>._P#GV\.?^!$__P 17444 <OY
MGCO_ )]O#G_@1/\ _$4>9X[_ .?;PY_X$3__ !%=110!R_F>._\ GV\.?^!$
M_P#\11YGCO\ Y]O#G_@1/_\ $5U%% '+^9X[_P"?;PY_X$3_ /Q%'F>._P#G
MV\.?^!$__P 17444 <OYGCO_ )]O#G_@1/\ _$4>9X[_ .?;PY_X$3__ !%=
M110!R_F>._\ GV\.?^!$_P#\11YGCO\ Y]O#G_@1/_\ $5U%% '+^9X[_P"?
M;PY_X$3_ /Q%'F>._P#GV\.?^!$__P 17444 <OYGCO_ )]O#G_@1/\ _$4>
M9X[_ .?;PY_X$3__ !%=110!R_F>._\ GV\.?^!$_P#\11YGCO\ Y]O#G_@1
M/_\ $5U%% '+^9X[_P"?;PY_X$3_ /Q%'F>._P#GV\.?^!$__P 17444 <OY
MGCO_ )]O#G_@1/\ _$4>9X[_ .?;PY_X$3__ !%=110!R_F>._\ GV\.?^!$
M_P#\11YGCO\ Y]O#G_@1/_\ $5U%% '+^9X[_P"?;PY_X$3_ /Q%'F>._P#G
MV\.?^!$__P 17444 <OYGCO_ )]O#G_@1/\ _$52L-7\;7]SJ,$=GX?5K&Y%
MM(6N)L,WEI)D?)TQ(!]0:[6N>\-_\A?Q5_V%E_\ 22WH @\SQW_S[>'/_ B?
M_P"(H\SQW_S[>'/_  (G_P#B*ZBB@#E_,\=_\^WAS_P(G_\ B*/,\=_\^WAS
M_P ")_\ XBNHHH Y?S/'?_/MX<_\")__ (BCS/'?_/MX<_\  B?_ .(KJ**
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M_P#GV\.?^!$__P 11YGCO_GV\.?^!$__ ,17444 <OYGCO\ Y]O#G_@1/_\
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MZEE5\^7'V52,8Q0!WE%<OO\ '?\ S[^'/^_\_P#\11O\=_\ /OX<_P"_\_\
M\10!U%%<OO\ '?\ S[^'/^_\_P#\11O\=_\ /OX<_P"_\_\ \10!U%%<OO\
M'?\ S[^'/^_\_P#\11O\=_\ /OX<_P"_\_\ \10!U%%<OO\ '?\ S[^'/^_\
M_P#\11O\=_\ /OX<_P"_\_\ \10!U%%<OO\ '?\ S[^'/^_\_P#\11O\=_\
M/OX<_P"_\_\ \10!U%%<OO\ '?\ S[^'/^_\_P#\11O\=_\ /OX<_P"_\_\
M\10!U%%<OO\ '?\ S[^'/^_\_P#\11O\=_\ /OX<_P"_\_\ \10!U%%<OO\
M'?\ S[^'/^_\_P#\11O\=_\ /OX<_P"_\_\ \10!U%%<OO\ '?\ S[^'/^_\
M_P#\11O\=_\ /OX<_P"_\_\ \10!U%%<OO\ '?\ S[^'/^_\_P#\11O\=_\
M/OX<_P"_\_\ \10!U%%<OO\ '?\ S[^'/^_\_P#\11O\=_\ /OX<_P"_\_\
M\10!U%%<OO\ '?\ S[^'/^_\_P#\11O\=_\ /OX<_P"_\_\ \10!U%%<OO\
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M_P#U^VZ1:)8:+86<<<D<=O;QQ*DC!F4*H !(ZGCK6)O\=_\ /OX<_P"_\_\
M\11O\=_\^_AS_O\ S_\ Q% '445R^_QW_P ^_AS_ +_S_P#Q%&_QW_S[^'/^
M_P#/_P#$4 =117+[_'?_ #[^'/\ O_/_ /$4;_'?_/OX<_[_ ,__ ,10!U%%
M<OO\=_\ /OX<_P"_\_\ \11O\=_\^_AS_O\ S_\ Q% '445R^_QW_P ^_AS_
M +_S_P#Q%&_QW_S[^'/^_P#/_P#$4 =117+[_'?_ #[^'/\ O_/_ /$4;_'?
M_/OX<_[_ ,__ ,10!U%%<OO\=_\ /OX<_P"_\_\ \11O\=_\^_AS_O\ S_\
MQ% '445R^_QW_P ^_AS_ +_S_P#Q%&_QW_S[^'/^_P#/_P#$4 =117+[_'?_
M #[^'/\ O_/_ /$4;_'?_/OX<_[_ ,__ ,10!U%%<OO\=_\ /OX<_P"_\_\
M\11O\=_\^_AS_O\ S_\ Q% '445R^_QW_P ^_AS_ +_S_P#Q%&_QW_S[^'/^
M_P#/_P#$4 =117+[_'?_ #[^'/\ O_/_ /$4;_'?_/OX<_[_ ,__ ,10!U%%
M<OO\=_\ /OX<_P"_\_\ \11O\=_\^_AS_O\ S_\ Q% '445R^_QW_P ^_AS_
M +_S_P#Q%&_QW_S[^'/^_P#/_P#$4 =17/>&_P#D+^*O^PLO_I);U!O\=_\
M/OX<_P"_\_\ \16)H+^,_P"U/$GDP: 7_M,>=OFF #_9H/NX3IMV]>^: /0Z
M*Y??X[_Y]_#G_?\ G_\ B*-_CO\ Y]_#G_?^?_XB@#J**Y??X[_Y]_#G_?\
MG_\ B*-_CO\ Y]_#G_?^?_XB@#J**Y??X[_Y]_#G_?\ G_\ B*-_CO\ Y]_#
MG_?^?_XB@#J**Y??X[_Y]_#G_?\ G_\ B*-_CO\ Y]_#G_?^?_XB@#J**Y??
MX[_Y]_#G_?\ G_\ B*-_CO\ Y]_#G_?^?_XB@#J**Y??X[_Y]_#G_?\ G_\
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MNE!S]XCG'7D]#4C^%=:N8/BG"MA*K:HZFRW\"?"M]T_D/QKM]_CO_GW\.?\
M?^?_ .(HW^._^??PY_W_ )__ (B@#@H[+7-9M/AP6\/:C9G1KV.&Z6XC (5(
MXP9.O"D@@9]*I_8/$?A[2?&GA8>%;_4I=;N[B6TOX IA99@%!D8GY2O7GOGI
MUKTG?X[_ .??PY_W_G_^(HW^._\ GW\.?]_Y_P#XB@#D-%\'ZKI'C_P:9K9I
MK?3=!-M/=*,QI+\W /X\>U;7PNT>_P!'MO$R7]G);?:-=N9X ZXWQD+M8>QP
M:U=_CO\ Y]_#G_?^?_XBC?X[_P"??PY_W_G_ /B* .HHKE]_CO\ Y]_#G_?^
M?_XBC?X[_P"??PY_W_G_ /B* .HHKE]_CO\ Y]_#G_?^?_XBC?X[_P"??PY_
MW_G_ /B* .HHKE]_CO\ Y]_#G_?^?_XBC?X[_P"??PY_W_G_ /B* .HHKE]_
MCO\ Y]_#G_?^?_XBC?X[_P"??PY_W_G_ /B* .HHKE]_CO\ Y]_#G_?^?_XB
MC?X[_P"??PY_W_G_ /B* .HHKE]_CO\ Y]_#G_?^?_XBC?X[_P"??PY_W_G_
M /B* .HHKE]_CO\ Y]_#G_?^?_XBC?X[_P"??PY_W_G_ /B* .HHKE]_CO\
MY]_#G_?^?_XBC?X[_P"??PY_W_G_ /B* .HKF/'W_(MP?]A33_\ TKBI-_CO
M_GW\.?\ ?^?_ .(K#\6-XK.E6@U2'15L_P"T[#S#:RRM)_Q]18P&4#KCOTH
M]$HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[CMO'=W+:R1Q:BFFQVN\8,KYP53'\8) ';.,\9H [6P\<:/J&H2V"+J$%S%
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M[A-PQO1G^5OH174T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7,>/O^1;@_P"PII__ *5Q5T]<QX^_Y%N#_L*:?_Z5Q4 =/111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX[_Y]O#G_@1/_P#$4>9X[_Y]O#G_ ($3_P#Q%=/10!S'F>._^?;PY_X$3_\
MQ%'F>._^?;PY_P"!$_\ \173T4 <QYGCO_GV\.?^!$__ ,11YGCO_GV\.?\
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M_P"!$_\ \173T4 <QYGCO_GV\.?^!$__ ,11YGCO_GV\.?\ @1/_ /$5T]%
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MD@M[&3RKI+B!XY87XPIC(W9.X8&.<C% $'F>._\ GV\.?^!$_P#\1534]/\
M%VL:?+8:CIOAFXM9<;XWGGP<'(/W."" 01TK3T?Q?IFMZK/IEM%J$=Y;QB26
M.YL98=BG[N2R@#/8=\'T-5/$&MZHWB.Q\,Z";:*^N+=[NXNKE#(MO K!<A 1
MN8L<#D#@T 9.E>&O$>BW;W=EIGAX7+)Y9GFOKN:0)G.T-("0,]AQ6SYGCO\
MY]O#G_@1/_\ $55T[6-<TGQ?;>'M?N+6^CO[>2:RO8(#"Q:/&^-TW,.C @@U
M+9_$GPS?R68M[N=H;MUBBN3:2B#S&Z1F0KM#^Q/M0!+YGCO_ )]O#G_@1/\
M_$4>9X[_ .?;PY_X$3__ !%2ZIXVT32+VXM;F6Y=K4*UW)!:R2QVP(R#(RJ0
MO'//;GI3M7\::)HEU!:W5Q+)<W,/GP0VT#S-,F<94(#GU^@)H @\SQW_ ,^W
MAS_P(G_^(H\SQW_S[>'/_ B?_P"(J34_'&BZ1/)'>&^6.';Y]PMC,T,&X C?
M(%VC@COQGG%5-8\=0:1XRL=">RO)8[BWDE>:&TEDP04V[=JD,/F.2.G&<9H
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M2^-=:N]!T!+VR\OS3>6T)\Q<C:\RHWXX)K6U75;+1=.EO]0G$-M'@%L$DDG
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M[^'/^_\ /_\ $4 =/17,;_'?_/OX<_[_ ,__ ,11O\=_\^_AS_O_ #__ !%
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M?_/OX<_[_P __P 10!T]%<QO\=_\^_AS_O\ S_\ Q%&_QW_S[^'/^_\ /_\
M$4 =/17,;_'?_/OX<_[_ ,__ ,11O\=_\^_AS_O_ #__ !% '3T5S&_QW_S[
M^'/^_P#/_P#$4;_'?_/OX<_[_P __P 10!T]%<QO\=_\^_AS_O\ S_\ Q%&_
MQW_S[^'/^_\ /_\ $4 =/17,;_'?_/OX<_[_ ,__ ,11O\=_\^_AS_O_ #__
M !% '3T5S&_QW_S[^'/^_P#/_P#$4;_'?_/OX<_[_P __P 10!T]%<QO\=_\
M^_AS_O\ S_\ Q%&_QW_S[^'/^_\ /_\ $4 =/17,;_'?_/OX<_[_ ,__ ,11
MO\=_\^_AS_O_ #__ !% '3T5S&_QW_S[^'/^_P#/_P#$4;_'?_/OX<_[_P _
M_P 10!T]%<QO\=_\^_AS_O\ S_\ Q%&_QW_S[^'/^_\ /_\ $4 =/17,;_'?
M_/OX<_[_ ,__ ,11O\=_\^_AS_O_ #__ !% '3USWAO_ )"_BK_L++_Z26]0
M[_'?_/OX<_[_ ,__ ,16'H#^,_[4\2>3!H!?^TQYV^:; ?[-!]W"]-NWKWS0
M!M^--/N[\^'?LD#S?9];MIY=H^Y&N[+'V&17.:9X6U6'Q\VG2P$>%[&\DUBT
M?LTT@ $6.P1VE?\ %:Z3?X[_ .??PY_W_G_^(HW^._\ GW\.?]_Y_P#XB@#E
MK6U\2:/X)L;>WMK^!6UBY:_%G&K7*V[32L"@;/4E.0"<'BLZ7P_K-SX0\?QI
MIVJ-)J+Q-9I>D-/,!&@R<<9X/'4=#S7=;_'?_/OX<_[_ ,__ ,11O\=_\^_A
MS_O_ #__ !% ":QI]U-\0/"][#;LUK:P7J32J/ECW+'M!^N#^5<++9Z]%X!;
MP>GAS4)+JWU$.]R OD-%]K\T.C9RV01\H&1SG&*[O?X[_P"??PY_W_G_ /B*
M-_CO_GW\.?\ ?^?_ .(H KFQU.+Q_KNHVMMD2:/!%;22<(\RO*=N?Q7/UKE-
M)L]?U#Q+X1OK^V\027%K+(VI27RHD$4C0.I$:KCY=QP".,8YR:[/?X[_ .??
MPY_W_G_^(HW^._\ GW\.?]_Y_P#XB@#'\,SZGX9N+[1)_#^HW,DVJS3Q7D*J
M8)(I9-V]G+#:5!.1UXXSFI-'M+ZWUCQ=I$^G7:+J=U)=6]YL!@*/"B %L\-E
M3QBM3?X[_P"??PY_W_G_ /B*-_CO_GW\.?\ ?^?_ .(H XVSCUR[T7P1HC>&
M]1MWT6]M?ML\P41J(D9,H03O!ZY' 'UKL/!FG7-A<>)GN;9H3=:U-/$6&/,C
M*1@,/;@T[?X[_P"??PY_W_G_ /B*-_CO_GW\.?\ ?^?_ .(H Y;PYH&J6UE\
M/$N+"9&T^6[:Z#+_ *G='(%+>F21^=5/&5C>V[>+Y/L\BC4=3TM;(K@/,Z^4
M#Y6>-X*G&[CCGBNTW^._^??PY_W_ )__ (BJ6JZ9XLUNQ:RU+3O#-Q;L0VQI
MYQA@<@@A<@@]QS0!5\'3O%XMOX=:BU1/$%Y:)+NO$@"-;QL5 3R691AI#G/)
MS5KQ#;:CI'CBQ\566G3ZE:FQ?3[R"VP9D7>'215)&[G((!SSWJKI/ASQ)HD\
MMQ8Z;X=6XE4(\\MY=32%1R%WN"<>V<5K[_'?_/OX<_[_ ,__ ,10!GV4>H>*
M/'.GZY/I5WINF:3;S);B\4)+/-+M#'8"2%"KU."2>E<3X?;4_$'PHT/PO;:#
M>H\TL+?;B%^SI$DXD,F_/WOE(VXSFO1M_CO_ )]_#G_?^?\ ^(JGI>G^+]&T
MV#3M/L?#<%I NV.,7%P=HSGJ5)[T <W<:%<:?K?B2#4;3Q-<6NIW;W,+:3)F
M*5'15*.,C:PP1\V 1BNCL-#DL_'ND3PV4R:?:>'VM$>3#&-A)'A"W/S;0?R-
M7=_CO_GW\.?]_P"?_P"(HW^._P#GW\.?]_Y__B* .,\;6_B;5HO%&G2VNNS&
M1&33(;$(MJ\/ECEVZEMV[*DYZ "NAU>*^T[Q7X8U9=,O+RV@L9[2<6J!WB=_
M**DC(X^0C/:M+?X[_P"??PY_W_G_ /B*-_CO_GW\.?\ ?^?_ .(H Y;4_#FL
M30>))X+!Y9$\16^I06[$+]KBB6$LJD\<[6QGN*TF6_\ %/B^PU6/1[_3[/3+
M&ZC+WL8C>>28* BKDG VDYZ9QBM??X[_ .??PY_W_G_^(HW^._\ GW\.?]_Y
M_P#XB@#G(-!U-/AWX%L?L$HNK*^L)+F+;\T2HWSD^F.]2RP:A:^-DE\/:?K5
MFUQJ .IQSJIL9XNCS DG#D!<;<$GJ.M;V_QW_P ^_AS_ +_S_P#Q%&_QW_S[
M^'/^_P#/_P#$4 1?$>SO+WPD4L;2:[FCO+6;R81EV5)D9L#Z UC^*VU#QAH$
M+66BZU:2Z;J%O>-#,JP2SHI.X1'<1N Y&<<@5N[_ !W_ ,^_AS_O_/\ _$4;
M_'?_ #[^'/\ O_/_ /$4 <[%9WBVFM:OX?L?$!UY=/\ (MIM:(PWS;MB*QY(
M.3R,9/7FH=$TS4KWQQ!?&+Q +4Z1<6[76K!582LT9PJKC;T)Z '!QTKJ-_CO
M_GW\.?\ ?^?_ .(HW^._^??PY_W_ )__ (B@#ATMM<;P-H/A;_A&+]+O3+RT
M%S.540[(IERZ-GY\@9X' SGISZ_7,;_'?_/OX<_[_P __P 11O\ '?\ S[^'
M/^_\_P#\10!T]%<QO\=_\^_AS_O_ #__ !%&_P =_P#/OX<_[_S_ /Q% '3T
M5S&_QW_S[^'/^_\ /_\ $4;_ !W_ ,^_AS_O_/\ _$4 =/17,;_'?_/OX<_[
M_P __P 11O\ '?\ S[^'/^_\_P#\10!T]%<QO\=_\^_AS_O_ #__ !%&_P =
M_P#/OX<_[_S_ /Q% '3T5S&_QW_S[^'/^_\ /_\ $4;_ !W_ ,^_AS_O_/\
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M?Z,8_L_R(1'W,A)88(');%36_C'2I["[NRE_"+4H)89K"9)?G.$PA7<V3P,
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MM8KV22Z<BSNA92!(79GG(!$: #+MAAPN?TH J;_'?_/#PY_W^G_^)HW^._\
MGAX<_P"_T_\ \34&L>+H+OP3XEO-(FGM]0TVSE9HYX&BE@D\LLA*.._4'&#5
MN;Q=8:79Z9%>M<W.H75JLPM[2V>>5EP-SE4!PN3U.!0!'O\ '?\ SP\.?]_I
M_P#XFC?X[_YX>'/^_P!/_P#$U8D\;^'HM @UQ]05=.FF$ E*,-LF2-K+C*D$
M$$$<4:?XST;4A?B-[F&6QA\^>&ZM9(9!%@D.%< E3@\B@"OO\=_\\/#G_?Z?
M_P")HW^._P#GAX<_[_3_ /Q-01_$[PK(8C]MG6*="]O,]I*([@C&5C;;AVY
MVKDYXZUH6?C+1+S2;[4S<O;0:>Q2[6ZA>*2!L X9& .2",<<YXH K;_'?_/#
MPY_W^G_^)HW^._\ GAX<_P"_T_\ \35FP\8Z3?O<Q W=M-;P&Y>&[M9(7,(_
MC57 ++VXJOIOQ \/:M>V=M:7,Y^V@_99GM9$AF8#<460KM+ 9R,]B.M ";_'
M?_/#PY_W^G_^)HW^._\ GAX<_P"_T_\ \34/A[QS%KOB35=(^PWL1M+CRHI&
MLY55AY:L2[%0$.2< D9&".M7-:UJ[L/%OAG38?+^SZC)<+/N7)PD1=<'MR*
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M_GAX<_[_ $__ ,31O\=_\\/#G_?Z?_XFNHHH Y??X[_YX>'/^_T__P 31O\
M'?\ SP\.?]_I_P#XFNHHH Y??X[_ .>'AS_O]/\ _$T;_'?_ #P\.?\ ?Z?_
M .)KJ** .7W^._\ GAX<_P"_T_\ \31O\=_\\/#G_?Z?_P")KJ** .7W^._^
M>'AS_O\ 3_\ Q-&_QW_SP\.?]_I__B:ZBB@#E]_CO_GAX<_[_3__ !-&_P =
M_P#/#PY_W^G_ /B:ZBB@#E]_CO\ YX>'/^_T_P#\31O\=_\ /#PY_P!_I_\
MXFNHHH Y??X[_P">'AS_ +_3_P#Q-87BUO%ATFU&IQ:*MI_:=AO-M)*9/^/J
M+& R@=<?A7HM<QX^_P"1;@_["FG_ /I7%0!T]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<OX,^_XC_[#5Q_)*ZBN
M,L].\7Z/>ZM]@MM#N+6\OI+J-KB\E1P& &"!$1V]: +?CS_D!6?_ &%]/_\
M2J*NHKC-3L_%VL636=_HWAR: LK[?[2N%^96#*01"""" ?PJQ"WCF"%(DTWP
M^510HWZE<,<#U)A)/U- '5;0&+ #)X)QUI:YC[1X[_Z!OAS_ ,&$_P#\9H^T
M>._^@;X<_P#!A/\ _&: .GI-H#%@!D\$XZUS/VCQW_T#?#G_ (,)_P#XS3)7
M\<S0O$VF^'@KJ5)74KA3@^A$.0?<4 6?"/\ QZ:I_P!A:[_]&FNAKC--L_%^
MD6AMK'1_#D41=I"#J5PQ+,<L26B))).:N?:/'?\ T#?#G_@PG_\ C- '3T5S
M'VCQW_T#?#G_ (,)_P#XS1]H\=_] WPY_P"#"?\ ^,T =/17,?:/'?\ T#?#
MG_@PG_\ C-'VCQW_ - WPY_X,)__ (S0!T]%<Q]H\=_] WPY_P"#"?\ ^,T?
M:/'?_0-\.?\ @PG_ /C- '3T5S'VCQW_ - WPY_X,)__ (S1]H\=_P#0-\.?
M^#"?_P",T =/17,?:/'?_0-\.?\ @PG_ /C-'VCQW_T#?#G_ (,)_P#XS0!T
M]%<Q]H\=_P#0-\.?^#"?_P",T?:/'?\ T#?#G_@PG_\ C- '3T5S'VCQW_T#
M?#G_ (,)_P#XS1]H\=_] WPY_P"#"?\ ^,T =/17,?:/'?\ T#?#G_@PG_\
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M8RQ*E<@[3NZCN.:V_M'CO_H&^'/_  83_P#QFC[1X[_Z!OAS_P &$_\ \9H
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M\.V>NP27FJ)+?M<['O&A(59)(U8D;L*H (SP3CI70?:/'?\ T#?#G_@PG_\
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MS_P83_\ QF@#IZ*YC[1X[_Z!OAS_ ,&$_P#\9H^T>._^@;X<_P#!A/\ _&:
M.GHKF/M'CO\ Z!OAS_P83_\ QFC[1X[_ .@;X<_\&$__ ,9H Z>BN8^T>._^
M@;X<_P#!A/\ _&:/M'CO_H&^'/\ P83_ /QF@#IZ*YC[1X[_ .@;X<_\&$__
M ,9H^T>._P#H&^'/_!A/_P#&: .GHKF/M'CO_H&^'/\ P83_ /QFC[1X[_Z!
MOAS_ ,&$_P#\9H Z>N8\??\ (MP?]A33_P#TKBH^T>._^@;X<_\ !A/_ /&:
MH:KIWC/7;>WL[NTT&"W6\MKB22*]F=PL4R2$ &( D[,=1UH [:BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP\NK7/V6 Q*"%;CELD8'/;->/S7GB34=>\/^&)X=5G2V\.P7#VEEJ"V4DDQ
M#.SL1NV]-OJ,^M3W,7B&!?AM;^)RS:C#KKIN>9979 1MW,I(+8X]>.: /7M$
M\0VFO/J"6L5U&;&Z:UE\^$IN9>I7/4>]:U>#7-]XANO!_CK4;/5[_P"U:+XD
MEN(0+A_]2C#='U^X%).WI\M7)?&FIZS=>+_%VC7EQ_9NE:/%!9PAR8C/(H=I
M"G0LF2.1Z4 >VT5XKX'M/& U?PUJT$>JG3KN$G4IK[5X[B.Y#)D.D>XE2#DX
M R!QZU'\._M!\ :AXRUWQ3KCB&"ZMPJS[Q#'D_,H;.Z0'D$GC@=!0![=6'X7
M\4V/BVPN;RPBN(X[>ZDM7$Z@$NF,D8)XYKR?POJ.H67Q*\+);-X@@TS6;::1
MDU;45N3<J(RZ2;0QV'IUQ[=ZY>RMI+3X=^)O$=IXHU"QO].U>0V]I!<[(LET
M&60<L6!/7^[Z9H ^@(O%-C+XTF\*K%<?;H;(7K2%1Y90L%P#G.<D=L>];E>)
MOK-[;?$?6M;2(?;X_!'VL1[>!("C8Q]:J^"HO&=W-X8UZU75I(KF96U*ZN]7
MCE@N(F/S;8=V5*\X &1C% 'NU%>->'I]2T+XBV]OXLFUA[S4;J8Z?>PW_F65
MRFTXC,710 01QUQVKT'Q%?>+K6\B7P]HVGWUL8\R/<W9B97R> ,'C&.: .DK
M*3Q)I4GB2?P^MR?[2@MA=21%& 6,D#.[&.XXS5'PY>^+;JZF7Q#H^GV, 3,;
MVUT92S9Z$8&!BN&N;(:C\<_$MF;BXMQ+X<"^;;2;)%^>/E6[&@#U'3=3L=8L
M8[[3;N&ZM9,A)H7#*V#@X(]P15NOFO1+J^\,_ 6'5M)U2_6ZU*\%I(HN?DM4
M\V3+1 \1LV "WOGBNWT&Q\6:-?:T\MOJ=GH<FD2NB7^JI=R)<J.'1E8L 0?I
MG\* /7:*^<84U]/"7@CQ!'XOUL7^L7Z:?+NN-T<<3,R#"'@D!<Y.<DYKO_ 2
MWNC?$OQ5X9;5M0U"PMH;>XA-_.971G4%OF/KN_04 =AJWC7P_H>OV.AZEJ M
M]0O@I@C:-B&RQ498# R01R:NKK^FMXD?P^)S_::6OVMH=C8$6[;G=C'7MG->
M4_$?PPGB_P"*L6D;MD[^'7DMI,XV2K,2IS]>#[$UA>$_&.H:AXOUC6)H6&M:
M7X1FAN8W7DW$,O<>^ 3]2* /H6BOGUI]2TCP7X6\:VOBC5;O6=1OHDGMY;LO
M#.'+;HQ'T&, <=/;C'O,6H64][/917<$EU;@&:!) 7C!Y&Y<Y&?>@#-\2>+M
M"\(V2W6MZA':HYPBD%G<_P"RHR3^7%:<=];2Z<FH"4"U>(3"1OE 0C=DYZ<5
MPGQGL;&3X;ZS>RVT#7D<")%,R NJF5,A3U /M65XWU*Y3X>^&=(AMK^6RU**
M&/4)K&!I7CMU12Z@+T+9 Y[9H [KPQXRT+QC!<S:'>-<QV[A)"8G3!(R/O 9
MJMXB^(/AOPKJ46G:O>R17<L7G)'';22$IDC/RJ>ZFN#^#.J64OB?QA9V=C=V
MT,EWY\*26Y18HU^4(W]UN1\OH#Z4[Q@FKO\ 'K2ET2\L[2\_L,XENXRZ;?,D
MR, CF@#U+1=9LO$&DPZGITCR6LV[8SQM&3@E3\K $<@]JOUYCXRNI)I?#NA7
MMSK%]K=S%*YM="N1:13D 9=W8C &#@9]?:N%'B3Q!_PIVX==7OXKRT\2"SAN
M'N-\JQC!"LX/SX)^A^E 'T117CGBK1M1T'5_!/AVR\4ZX%U"\N5N;M[HF5PR
MID9Z=VQD':3D5D2:]KGA#0?B3I]EJM]=C2)K5;*>[D,LL(F.&.X^@Z>_- 'O
M58GB?Q18^$["VO+^.XDCN+J.T00*"0[YP3DCCBO,O#T/C'1-0CU6"UU,:2VE
MS27 U'5H[P3RK&721 &)!) !QV-<=?VLEW\/_#'B2\\3ZA?:AJ6KQF>TGN=\
M1(=A\J?PE< <?WOI0!]">(?$>F>%M*.IZO.T%HKK&TBQL^"QP,A03CWHUWQ)
MI7AO3$U'4[GRK:21(D9$9R[-]T *"3FH/&.A+XF\'ZKH[ %KFW98\]I!RA_!
M@#7D'AC6'^(%_P" ="FRW]BQ/>ZDC=GA/EQ;O?(!/^]0![W6(WBFQ7QJGA4Q
M7'VY[+[<)-H\O9NVXSG.[(],>]>.>/\ 5Y9F\2ZKH5WXG:?2;I8I+P:BL-K:
MR!E!C2+(+CMT/)]*V;^[N)OBHMZ'9;E_!32[TX(<LQR,=.: /9:*\(/B:];X
M8_#ITUNX-_=:U"D["Z;S98P\@8,<Y9?N@@\=*9J5QXK\6>+/%\6GQZO+<:;<
M?9[ 6>JI:QVN,[7:-F&_<1DGTR/H >\22+%$\CG"("S'T K \+^-_#WC);EM
M"O\ [3]F*B53$\97=G!PP&0<'\JFLWU!_!$+:L%&HG3P;G801YGE_-@CCKGI
MQ7@'A'51\/-%\+^+O+9K+4M/O;.Z51UFCFD>(GW/"_0&@#WBT\<^';_Q5/X9
MMM0$FK0;O,A$3X!7[PW8VY'UKHJ\$\#Z1+HOQ'\+2WQ/VZ_T:XU"\=NIDE=F
M.?<+M'X52GUVZ2]\/^(M#N_$[6EYK26QOM1U!&BND+D,@@!R%X..  !ZXH ^
MB**\)U*VU77-3^)4S^)=9M8M#S<6=O;711 XB9AGOM^3&!CJ35ZXUMO$.B^#
M[&XF\0WNLWFF?:&M=+O%M5D  !DE<D<Y4X&?7VH ]HHKYYMO%>LR_"W1H[G5
M-1D:3Q ;*;R)_P#2YK=06*+)GD]LY&>!FKDMQXD\+?#KQ9XBANM:A6>X2#3(
M]1NS-);P%P"Y4DA6Y(!Z_P Z />J*\<\/V'BW2]4DN5AU6WT2;2I3,;_ %>.
M[+3!"5ECVL2">.G'-<E"/$$?@CP9XEC\7ZV-0U345T]P]QNCCB9G3A#U(V9R
M<Y)]A0!](45XE'J6K^"=:\?:99ZMJ&H0V&E)>VK7\QF>.0J,MD]OF)Q["CP/
M:^,6U/PQK%O'JK6-W'NU.>^U>.>*Y5TR&2/=E2#G  R.A[T >VU4.J6"ZLNE
M&\A&H-#YXMMX\PQYQNQUQGC-?/$DFNM\,]7\8_\ "5:V+[2]5:*UA%T?*"^:
MH(8?Q??/4] !TKJ;S0X[[]H&S:75=3@,^C)?9BNRA#"0CRE_Z9G;DKZDT >J
M>(?$FE^%=*.IZQ<&WM ZQ[Q&SG<>@PH)JAX>\>^&O%-Y+9:3J/FW<2[W@DB>
M)]OJ X&1R.E<K\>=W_"N!MQN^WP8STSDUCZ-+JC?&;4+GQ6+5->L-()T^"P0
MB"XBY)(9CN)R2,$>OI0![-17SUX6E\<:_IVE^)M/&JSWLE_ON;J35HA:O%O*
MM%]G+?*,8P,9[CJ*T=0N;_6M5^(.K7/BG4=,G\/EH["VM[GRXU"JV"R'AMY4
M#ZGZ4 >Z5F>(-=M?#>BSZK>1W$D$.T,MO'YCG+!1@?4UY1HNNZC_ &Q\*?M.
MJW7DWEC<&Y\RX;;.WE_+OR?F.<8SWK+UCQ)J;^#_ (GW=IK-V?LVK0I:3173
M?ND,R@B,@_*,<<4 >]Q2":%)5#!74, PP<'U':GUX]?6>I>*/BU_83^(M6L-
M/70X;R2.SN"A=PP ]0.6R3CG%<_/<>,/%NK^*[C34U=[[3]1>VLWMM5CMH;1
M4/ :)F&[(!R2,'\Z /H&BO(-6AUK7_BCH^@WFMZEIL5QX=2>^BT^XV!I0[;L
M$9 YQ\PY(&.AKB?.\01?"^Z\5-XLUI[[1]3^R6T9N"(S&)%'SCJY.[J2> !T
MH ^E:*\/\17GB+Q-\2-?TBUBU::/3K6'[)!I^II9^6SH&\UMQ&_D^^!4NIMX
MJNM0^'&B:MK-]IU]?17<6H/97(W.% P<J2I8J/O<X+$CF@#V*_O[32[&6]O[
MF*VM8AF265MJJ,XY/U-312QSPI+$ZO&ZAE93D,#R"*^>-8@O'\!?$+1;G6=3
MN;;0M0C:U::X+.ZL<;)#_$O.<=,@&NJU3P]KL'@+PY%X?O\ 5-3M@5NKZU&I
M&.XGC,:_)')U"K_='J* /8*R?#OB&T\3:<]]9174423/"1<PF-MR]3@]JS?A
M[JMAK/@JQNM-FOY;?YTSJ$GF3J0YRK-WQT!] *\RTAO%OB+X6$Z9J%Y=7::Y
M*9XOMQBGN+=?O1)*3E>WX9^A /=:*X[X::K8ZKX59K%M3 M[F2":+4YC++#(
M,$IN/4#(Q]:\[;Q+?0_#CXCR3:U<)>V^M3Q6S/=,)(EWH%5#G('#8 ]Z /=:
M*\5O)+W6_B#X:T2X\2:GI]E>^&HI9A;W1C:>3+'@G^(XY(Y(!'0U@CQ5KL/P
MVN]/37;IH5\3_P!DIJQE)D%MC.=_7MUST.* /;3XHL1XT'A7R[C[>;'[=OVC
MR]F_;C.<[L^V/>MNO$--L[3PM\9M1C.NWUY:VGAJ25[BYF$TUNH<,5W8YP/F
M (_B%4-'U6^M?&7@Z]TZ;Q)'IVL3O&TFK:BLPO$P/F\L,=A&<]!U&* /<[35
M+"_N;JWM+R&>:T?R[A(W!,3>C#L:MUX?X#TD:/XJ\>W\.I:G<7&DS/Y4$MT6
M6Y/EN091_&W'!JAX1_X3?5[;0/$=B-5GFFO0U]=SZO$;::$N5=! 6^7'   S
MP<#I0![;X@UNV\-Z!>:Q>)*]O:1^8ZP@%R,XX!('?UJSI][%J6FVM_"&$5S"
MDR!Q@A6 (S[X-?/6L&Y\2>#?''B+4_$NH07=KJ$EG%IXN=L B!4+&8SUSD_B
MN>N:]ITJ[AL/AG8WEQ,\$$&CQR22QC+(JP@E@/4 9H Z6BO ]$U6^M/&_@Z[
MT^7Q''IVL/(K/J^HK/\ ;$VC#>6&.PC.>@ZC%;&BSZEH7Q(@C\5SZP\^I7LO
M]FWUO?[[.="/EB:'HH&?3KCL,T >D>*_%5AX/T==1OX[B59)E@BAMDWR2R-G
M"J"0,\'OVK1TR].I:;;WAM;FT,R;C!=)LDC]F&3@UYC\<-*6\M?#,YO+R(G6
M(+;9#,54!]QWX_OC'#=LFH[FSN-<^)S^#KS7]7M=+TK28Y(1#>&.:Z?Y09'?
MJY&?S&?6@#T+Q+XIL?"T>G27T5Q(+^^CL8O)4'#OG!;)'R\'ID^U&B^*;'7=
M8UK3+6*X2;2)EAG:10%9F!(VX)R.#UQ7B#ZOJ&K>!O#JZA>R7WV+QK%:07<I
MW--$H)5B>_4C/M6C=:W?^'8?BWJ>F,4NX[ZW5) ,F/<Q4M]0&- 'O-%>+?9K
MGPOXM\%PZ;XEU;44UZ-TOHKB\:42*4!\U?[N-Q((]/K7)7OBOQ2OAJ+PU:ZG
M>-K6@7U[/?3&=_,>"WPR[FSEE.\C!X^44 ?2U%>,6FI>(/'?_";:QX<U::WC
M,-O8Z6K7!6,/A6EQSA7.=H;K\W6M'P7=17>@^)M#EOM;T+5K2%5O6U&^\\6C
M,AQ+'(3P#U/(Z#'K0!ZM15#0XO(T&PB.HG4MENB_;68,;CY1\^03G/7J:OT
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MY7FO$R2)G<88G)[CL*9HWA70_#^DS:5IFFPP6,[,TL'+JY8 '.XG.0 *V**
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MR.ICW'+ ,&#8)/0G%3IX#\+QZ0^DIH\*6#W0O# K,%\T8PPP>.@X''M71T4
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M?] 7Q'_X)KC_ .)H_P"$XM/^@+XC_P#!-<?_ !- '3T5S'_"<6G_ $!?$?\
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M'_"<6G_0%\1_^":X_P#B:/\ A.+3_H"^(_\ P37'_P 30!T]%<Q_PG%I_P!
M7Q'_ .":X_\ B:/^$XM/^@+XC_\ !-<?_$T =/17,?\ "<6G_0%\1_\ @FN/
M_B:/^$XM/^@+XC_\$UQ_\30!T]%<Q_PG%I_T!?$?_@FN/_B:/^$XM/\ H"^(
M_P#P37'_ ,30!T]%<G;_ !!TV[@6>WTOQ!+$WW7CTB=@>W!"U+_PG%I_T!?$
M?_@FN/\ XF@#IZ*YC_A.+3_H"^(__!-<?_$T?\)Q:?\ 0%\1_P#@FN/_ (F@
M#IZ*YC_A.+3_ * OB/\ \$UQ_P#$T?\ "<6G_0%\1_\ @FN/_B: .GHKF/\
MA.+3_H"^(_\ P37'_P 31_PG%I_T!?$?_@FN/_B: .GHKF/^$XM/^@+XC_\
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MG_0%\1_^":X_^)H Z>BN8_X3BT_Z OB/_P $UQ_\31_PG%I_T!?$?_@FN/\
MXF@#IZ*YC_A.+3_H"^(__!-<?_$T?\)Q:?\ 0%\1_P#@FN/_ (F@#IZ*YC_A
M.+3_ * OB/\ \$UQ_P#$T?\ "<6G_0%\1_\ @FN/_B: .GHKF/\ A.+3_H"^
M(_\ P37'_P 31_PG%I_T!?$?_@FN/_B: .GHKF/^$XM/^@+XC_\ !-<?_$T?
M\)Q:?] 7Q'_X)KC_ .)H Z>BN8_X3BT_Z OB/_P37'_Q-'_"<6G_ $!?$?\
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ME((9<YQC';'3UH ^H:*RK+Q%I6H:W?:+;W:R:C8*ANH0C#R]PR.2,'\":U:
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MP#G!]<UWGAW0K#PE\=IM*T6)[:QN-!$\L/F,P:02XW'<3S@?J?6@#UNBBB@
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MHHH **** "BBB@ KE_&W^HT+_L-6G_H==17+^-O]1H7_ &&K3_T.@#J****
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M;1MN;)0/L!.,GG':@#G?[<\/>9=2?\(CJN^[&+AO^$?DS,/]L[/F_&G7FO\
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MJ;;6+*[U>^TN&4F[LEC:="I&T2 E<'O]T]*=IE[->Z<MS=64EC(2X:&9U8J
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M?$?_ ()Y_P#XFC_A.+3_ * OB/\ \$\__P 372NZ1C+LJC.,DXI001D$$>U
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MY84X?^\P S7H=<OXV_U&A?\ 8:M/_0Z .HHHHH **** "BBB@ HHHH ****
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M;6+RK>&.*/).R-0HR3DG ]22:DH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N8\-_\C9XQ_P"O^#_TEAKIZYCPW_R-GC'_ *_X/_26&@#/^*^#X)YG
M, _M"S_? @&/]^GS<\<=>>*9?ZEIVC^#-<N;K79O$\$4.Z6$S0[@I^7;F)5V
MJ2>2<\ UVEU:6U[;M!=V\4\+8W1RH&4XY&0>*KVVC:79K*MKIMG LJ[9!% J
MAQZ' Y% 'F7AF.&Q^)4MK:6VB64<V@R22VVC2[XR1+'L+_*HW89L''(-4;+0
M=-L/V>KK5(+9?[0NM%/G7+',CC PN3_",  = !7KEGH^F:> ++3K2V #*/)@
M5,!L$C@=\#/T%2_8;3[#]A^RP?9-FSR/+'E[?3;TQ[4 <"-"T[PYX_\ "+:5
M;BW>^M[N.[=22UR%C5P9">7;=SD\\UR.@:9<:QHL-]/=^'K+7AJ)>>_N)66^
MCF6;F,Y[$#8$Z;2.*]O:W@>:*9X8VEASY;E02F1@X/;(JL^B:3)J U!],LFO
M001<-;J9!CI\V,T >4ZE!X=O3X^N?$SVXUBWN7CM6GDVRPPB%?(\KG(W$G[O
MWB3G->C^"?\ D0_#O_8,MO\ T4M:,^DZ=<WB7D^GVLMTB[5FDA5G4>@8C(%6
M8HHX(DBB18XT4*B(,!0.  .PH \?\IEU2;X9;3Y,FL"[5<?+_9QS<,H]O,4Q
M_P# JO\ CJ;2=2UK6K.;2-$>XL-.1I;S5IRK!7#%1 NT\C'+ CD@5Z=]DMOM
MGVS[/%]J">7YVP;]F<[=W7&><5%<Z5IUY=175U86L]Q#_JI9859T_P!TD9'X
M4 >=^'YY;K6/AM//(TDLGA^=G=CDL2EODD^M8+:MI\/P8@TJ2\A741JPA-J7
M'F!UO]Q!7J,+S7LT=C:1& QVL*&W0QPE8P/+4XRJ^@X' ]!4!T72FN9KEM,L
MS/-CS93 NZ3!!&XXR<$ \^E 'EFJ6)UOQMXKMM4307DB\J.V_M:1E>" Q AX
M?[HW%B6'.1[5Z=X<BG@\,Z7%<WR7\R6L:O=QMN6<A1\X/?/7/?-37VCZ7J;Q
MOJ&FV=V\?W&N(%D*_3(.*N*JHH55"JHP !@ 4 +1110 4444 %<OXR_U_AG_
M +#4/_H$E=17+^,O]?X9_P"PU#_Z!)0!U%>;_#?7M)T+P:='U?4;6QU'2YYX
M[V*YE6-@QE9M_)Y#!@0>]>D52N=&TN]NDNKO3;.>XC^Y++ K.OT)&10!Q6G:
MM8:9\4M9GO[J*"'6=/M)M.GF;8DJ('#JI/?+ XZX.:6RN++7?B=J^IVDZ2Z5
M9Z*+"ZNHW_=F4R%RH<<$JO4@\;J[B^TVQU. 07]E;W<0.1'<1+(N?7!%.M[*
MUM;46MO;0PVX! BCC"H!Z8'% %3P_%IT/A^PCTB;S].6%1;R>89-R=CN/6N<
M^&DT=OX'=[J1(Y(K^]^U.[8"M]HDR23TXQ78P00VT"06\210QC:D<:A54>@
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MZC0O^PU:?^AUU%<OXV_U&A?]AJT_]#H ZBBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH P/'/_)/O$G_8*NO_ $4U:^G_ /(-
MM?\ KBG\A61XY_Y)]XD_[!5U_P"BFK7T_P#Y!MK_ -<4_D* +%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !7,>&_\ D;/&/_7_  ?^DL-=/7,>&_\
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M3OC-+<:XDM[H#6&HV)M-2=]NY6=KA1&7'EL. >,G/8>M &[16$GC+P_)K/\
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ME4*"=Q'0<=JZ*@ KE_&W^HT+_L-6G_H==17+^-O]1H7_ &&K3_T.@#J****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \<_\
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M(Q 0T(V2;V<8RO)Y)]>:]1HH Y3XCVMS=^"+M+2VEN98YK>;R85+.RI.CMM
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MTWQKGPY'K"S7NHI_:5C<6+&T=.%>=92N%.T \,<D ;<UZ110!PVFS76E^/\
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M;.Y>"383DJ2I&1D9P: ,[X?-8+X8^RV4UU));7,R7?VJ'RI%N&8R.&3HO+Y
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M?]@JZ_\ 135KZ?\ \@VU_P"N*?R%9'CG_DGWB3_L%77_ **:M?3_ /D&VO\
MUQ3^0H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S'A
MO_D;/&/_ %_P?^DL-=/7,>&_^1L\8_\ 7_!_Z2PT =/1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7+^,O]?X9_P"PU#_Z!)745R_C+_7^
M&?\ L-0_^@24 =17.67C73M1U(6MI;:C- 9FMUODM6-LTBD@@/\ 4$9QC/>N
MCK@_!(USPYIECX7N?#URXM)'C.HB:,0/%N9A(/FW[B"/EV]>] %^?XBZ)!+*
MS17[:?#/]GEU)+5C:HX;:07] W!8#&>]6=3\;:;INL3:2+;4+S4(H4G-O9VQ
ME8QMGYN.,#;SG'48SFN,32/$=OX N? *Z!-)+)YMM'J?FQ_9C"\A/FM\V\,
MWW=N<BKBWU]H?Q-UE;+1KK58ETJRC<6\B"12#+M.'(!!YR<Y''![ '6:;XQT
M?5KC3(;2:1_[3MY+BU<H0KB,@.O/1P3R/8U?TO6;36'OEM"["RNFM)69< R*
M!N"^H&<9]0:\TU/1M1\)?#/3];ECB36M'OWU(PJ_R_OI6#P!O=9<<=2!BN_\
M':,^@^%+"QG.ZZ">;=/W:9R7D/\ WTQH W**** "BBB@ HHHH **** "BBB@
M HHHH **** .8^'G_(D6/_72?_T<]=/7,?#S_D2+'_KI/_Z.>NGH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7\;?ZC0O
M^PU:?^AUU%<OXV_U&A?]AJT_]#H ZBBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH SO$&FMK/AO5-+201/>VDMNLC#(4NA7)'
MMFL6&T\=001Q+?\ ATJBA0393YX&/^>M=710!R_D^._^?[PY_P" 4_\ \=H\
MGQW_ ,_WAS_P"G_^.UU%% '+^3X[_P"?[PY_X!3_ /QVCR?'?_/]X<_\ I__
M ([7444 <OY/CO\ Y_O#G_@%/_\ ':/)\=_\_P!X<_\  *?_ ..UU%% '+^3
MX[_Y_O#G_@%/_P#':/)\=_\ /]X<_P# *?\ ^.UU%% '+^3X[_Y_O#G_ (!3
M_P#QVCR?'?\ S_>'/_ *?_X[7444 <OY/CO_ )_O#G_@%/\ _':/)\=_\_WA
MS_P"G_\ CM=110!R_D^._P#G^\.?^ 4__P =H\GQW_S_ 'AS_P  I_\ X[74
M44 <OY/CO_G^\.?^ 4__ ,=H\GQW_P _WAS_ , I_P#X[7444 <OY/CO_G^\
M.?\ @%/_ /':/)\=_P#/]X<_\ I__CM=110!R_D^._\ G^\.?^ 4_P#\=JA8
MZ'XUL-1U.]CU+0&DU&9)I0UG-A2L:QC;^\Z80=<\YKMZ* .7\GQW_P _WAS_
M , I_P#X[1Y/CO\ Y_O#G_@%/_\ ':ZBB@#E_)\=_P#/]X<_\ I__CM'D^._
M^?[PY_X!3_\ QVNHHH Y?R?'?_/]X<_\ I__ ([1Y/CO_G^\.?\ @%/_ /':
MZBB@#E_)\=_\_P!X<_\  *?_ ..T>3X[_P"?[PY_X!3_ /QVNHHH Y?R?'?_
M #_>'/\ P"G_ /CM'D^._P#G^\.?^ 4__P =KJ** .7\GQW_ ,_WAS_P"G_^
M.T>3X[_Y_O#G_@%/_P#':ZBB@#E_)\=_\_WAS_P"G_\ CM'D^._^?[PY_P"
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M)*$>RG(W*<J?];V(!JSY/CO_ )_O#G_@%/\ _':ZBB@#E_)\=_\ /]X<_P#
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M I__ ([7444 <OY/CO\ Y_O#G_@%/_\ ':/)\=_\_P!X<_\  *?_ ..UU%%
M'+^3X[_Y_O#G_@%/_P#':/)\=_\ /]X<_P# *?\ ^.UU%% '+^3X[_Y_O#G_
M (!3_P#QVCR?'?\ S_>'/_ *?_X[7444 <OY/CO_ )_O#G_@%/\ _':/)\=_
M\_WAS_P"G_\ CM=110!R_D^._P#G^\.?^ 4__P =H\GQW_S_ 'AS_P  I_\
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M_P!X<_\  *?_ ..UU%% '+^3X[_Y_O#G_@%/_P#':/)\=_\ /]X<_P# *?\
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M9;6]BNV%M:RJ[;&S@%I".?I78T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDFKM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M./-EC3()&Y@,@#)/X"O)-4%K+\0-12YN?#<6GMIML-,_M>#S(6MRK;_)(=5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR[*]N[3RX+EN@"-DGGMD"L>^\!:G?^)_&ZQ6ZVNGZII,-I8S;UV[E0#& =P
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M4LY;:#[9Q0!U-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>modificationno15effectiv003.jpg
<TEXT>
begin 644 modificationno15effectiv003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M )Z*K7FHV6G(KWUY;VRN<*T\JH"?09-.MKVTO+;[3:W4,\'/[V*0,O'7D<4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1?99GWMN1CN.P<?(.@%;NM_$GQ]JT-I#'\-=4ABBG2:='MYI!-M((7_5C R
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MSXD\6Z)KP^'NKVQTB3S(8?LLSASD$[CL']WL!79CXO>-,#/PHUHGOCSO_C-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU##'H>16GK7PTU&<^+K'3I+<67B:>WG::1R&M65]TF5Q\V>HP1R<''6M#4/
M-QI_B.'6-"2*0?V*VD/!+)LP  (WS@YQ@ CT'&>E %WX4^)+GQ%\.=,OM2GW
MW8WPR2.>9"C$!CZG&,GUKFO'OBA_#'Q M[KQ%IMS>^%9K-8X'AR4AFW99BN<
M%L8Z\@=.];ND_"/PW%X3TC1];L8]2EL$?]Z7=!O=MSXP1QGIGL!6G%I&H:;-
M=Z?%IEG>^&FABAM[)Y?GC"H%(PX*LAP.ISP3SF@#B/&'C=?#'PL.I>%]7>_&
MIWQBM;N61I'@5E+$$OSN7:5 ;D9'I6WXKT Z#\,+B_L+Z\BUG3K9;D:A]H<R
MRR+@OO)/S!N?E.1STJFGP=MKGP!JF@3RI:RWFHOJ-N(27CLV/"(,X+ +P3QG
M)]!6MK6C^+?$'@@>&9X;&VN)XDM[O4!.70H,;F1-H8E@.AP!D\T <!\0_%=[
MKGP2\-^)H9I;/4+F]6&:2VD:,G"S*PX/W2R9Q7O%M#';VT<42A45< "O,?'?
MPSO=4^'FC>$O#@MDBT^=)?-NI2N[:K@]%/)+Y-===KXFOY+"V^Q6-K:><C7D
M@O&=S&O)5!L'4@ DGIGUH D\::ZVA>"M9U2T=#<6UJ[1<@X?&%./8D5Y?H_B
M*[T#6_ $QN)Y(]:TIWU$/(6\^3;O$AS_ ! GKZ<=*[L_"CPA;Z?J5OINE)92
MWUI):-,DCL55L<X9B." ?PK)T/X>7XUCPQ<:Q]F$/AVP>UC$;E_M+D%0V,#:
MH7GGG/L,D X2U\7ZI!X/\/>,WNI6U"\\1-%<G></ 0V8L=-H"C ['D<UVWQ$
MN]0LOB/X#A@U.\6TO;YA-:JX6,[#'C@ $_>/WB:JVOPIO8]/TKP[-) ='TW6
M6U);C>2\L7.V/;CALD@G.,#(ZXK=\;>%=:U_QCX5U6PCM/LVBW+32^=.5:0,
M4.% 4]-AZF@# ^,.KRP:A86EQ:^)DTB")I[B\T8^6 Y. &<@J< ,<9'WA7:_
M#Q])E\%V4FBZE>:C9ON87%[)OF+;CD/Z$=,>P^M6-0N/%46O0BQT_3+O1I(0
M)1).T4\<F3DYP5*XQQC/6I/"GAR#PQI,EG"J+YUS+=.D8PB-(Q;:O^RHPH^G
M:@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;F[M[.(2W,R1
M1ETC#.< LS!5'U)('XU-7E'QE)UG1+W3;345MY]+C2^$8<!II<Y5!WR$#-CU
M9* /3M0U"TTJQEO;Z=8+:(9DE;[J#U/H/>H-.UO3M7T[^T-.NENK3G$T2EE;
M'!Q@<X((XK%\%Z];>._ %I>W"I)]J@,%Y$>F\#;("/0\GZ$5YU\.]1O/"FH>
M(OAQ)*WVZ&YW:6[#),<G5\>BJ1)C_>H ]0N/&WAFST^WO[G6K2&TN&989I'V
MK(5Z[<]<5)9>,?#FHZ?=W]IK5G+9V@!N)UE&R+/3)[4R^\)>'+FVM/[2TRUN
M;?3H#' ET@D2),#)PW&<*.?:O+K_ ,&WVK_!R:;P[I\4,^HZE_:PL856,-!N
M/EQ@<#A!&V/4'O0![!IVM:=JS3K8W22R6[!9H\%7B)&1N4X(R.1D<U'8>(M(
MU2Z-M97\,TNTNJJ?OJ#M+(>C '@E<@&O$=5U._N_'GCO5=.M;NS$?ADBZCE7
M:R2%%VY )PP&2/H:-.FFM;WX--;9#O#,C;>Z-M#?H30![6WB?1$U(:>VI0"Y
M,WV<*6X\W&?+W=-^.=N<^U:U?-/B33-:\/?#W4/#NI:?=?VE/XC6XL;Q,%+A
MG'!5@<[N#QUYKZ2@$@@C$I!D"C>1W..: &O=6\=W%:O,BW$RL\<9/S.%QN('
M?&X?G4U>$?$;7Y+#Q5HWCBROUEATR]:S:S1QGR/NL^/]HB09]#&:[;XE>+]1
MT'PYHFJZ!=0D7]]# &DC#H\<BLP/KV'3U- 'H-4-4UO3-%L3>ZE>PVUJ'V&:
M0_*&SC!/;GBO/].\5>(7U[QUH-UJ$,DFDVJSVETELJ%"T>[&W)! R,9STYS7
M"7CWUS^S ][>7SW)N;@/M=1E6^UMN);JQ)YYH ^B$=9(UD1@R, 5([@TZO-/
M#'B37$^(S^%;^[AN+1M&CO(FC@$9A;Y1M')R.3USVJO\/_$'C7QC ;U]0T^*
MTL=6DM[E3;?//$JJ< CA2,]>^?;! /4Z*\>O/B%XCT[6]'CNI+?S;G6SIUW9
M0A988XF8!")%&1( <E2Q[95<XK4\8>*/$7ACQUIUD]Y&-%UA6@M9FB0&VN3@
M#><<H"0>Q(/7CD ]*FE2"%Y9"0B*68@$X ^E9VC^(]'\0Q22Z1?Q7L<9VN\.
M653Z9Z9YZ5H0(\<"))*TSJ,-(P +'UP.*\6T>['PQ^+6N:(\;?V7K47VW3XE
MXS-R1&O8$G<@^B4 >P6&K6.J&<65P)3;R>5, I&Q^ZG(Z^U7:Y36FU7PSX#N
M9]+6SEU.,>=+)<RB*(N[[I7)8@#JQ )]![5RND_$:\@UWQA;7<CW^GZ/IZZA
M;220B*5P8PQ4X5002W!VCCGG- 'JM%>=^'=?\47.F:?XGO+BUN="N-+DN[N)
M4"O!*N6"QX&2,8'S$\@G/:CP;K7BSQ/:Z%KZW%HVDZ@MQ]MM]H4VNUF6/RCC
M+'C!W$]^!0!VNDZWIFNP33:7>PW<<,S02-$V0KKU7]1^=7Z\&L_'&L:5\)M?
MURP2PM;RTUUX!Y%HB)(#L!+*!RQW9S["NMTGQGK5I\0M5T;6+F&[LH-&&IJ8
MH!&8R-N5')R/F/7)X% 'IE%>8^$/&7B7Q"/#^J+:2W%AJ3W"WL:6^V.S4,1$
M4? +=,-DG\*].H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*R]*T9
MM,AO$-_<73W4S3-).J;@S<<;5 (   !SP *U** .4\%^ K+P,EY%IM_?2VUU
M)YK03E"B/ZKM4$<8'X"M/_A&=-_X2[_A)O*_XF/V3[)N[;-V[/U[9].*V**
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M/:!M&W"@C@8ZUEGX5:8? S>$&U75#IAE$BY:/>@#E]H.S&-QR203[XXKO:*
M.5L_ MI9^+E\2IJ-Z]ZMD+':WE[#& .<!<YR >OZ<5/X.\'6G@NPNK.RN[JX
MBN;EKEOM)0D.P .-JCC@5T=% 'G$/P:T6"UM8(]7UD+::A_:%OF=&\N3.< %
M,'.!R<GCZYV?%/P_L?%\%Q#JE_>,DAC\K9Y8-MM)/[LE3@MGDG).!Z5UU% %
M>QMGL[""VDN9KIHD"&:;&]\=VP ,_A6?J?AG3=6US2=7NXMUWI;N]N>WS+@Y
M]<<$>A%;%% &'XN\+6?C+P[-HM_-<0P2LK%X& 8%3D=01V[BLJP^'&E6.N:C
MJDE[J%X^HV8L[R.ZD5UF0*%RWR@YP!T('M78T4 <CX6\ VWA:V>QAU?4KO3!
MO\JQN74Q1AL[APH+#D\$XYSC/--\+_#ZW\(R2QZ=K.J?V<9&EBL))%,43'T.
MW<1[$X]03S7844 >>_\ "HM(/A2_\.'5-3-E?7OVV5MT6_S.,X.S 'RCMVK8
MM? =C;>+9/$;7MW/=260L9(I/+\IX@ .0%!S\H/7]*ZJB@#D?"W@"V\)2/%8
M:OJ3Z8)6EAT^5U,43'T(7<1Z G'<Y/-==110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 51UFYN[/1[NYL8X7N(HF=5G8A> 3S@9J]63XDO[:QT&]^T2A6>W
MD5$ +,YVG@*.3U'2@#%^&/B6_P#%O@>UUG4O*%S/+*"(EVJ '(  ^@IGB/Q1
M<P^//#_A&QE^SR:BDL]Q<!0SQQHC%0H8$9)4\D'@>_'+?"[6T\-?!X_:;:8W
M]CY\IL74QRR?,S *&'.1Z9J.^OHK[Q[X+\>S(;6U-G+!>0,V^2U+(Y3<J\X)
M<C...,XS0!V/PW\73>,?"[7ETD:WMK<R6EQY8PK.N#N [9!!QZYK-O?&.I:U
M\1I/!GAZ2*U%E#Y^HW\D?F,@^7"1J>,_,O)SU/'',7P8T>32/"%T;AE%Q>WT
MEVT.X%HE8 *& Z$A<X/K6 (U\#_&;4?$4CBYT/6(2DLUM^]:UERI.]%RV,J>
M0,?-[4 >D6\.OVFN6T4M]'>Z4T,ADDDA"3)(-NW)7"E2-W101CO3[+Q=H.HW
MD5K:ZC')+.SK =K!)BGWQ&Y&U\=]I.*S+WQ'8>(M(U*PTN\$?G64L:7DI\E5
MD9<* &PS=<Y P,=<UY/I-K/<Z3\.=&C)MKW1M1EGU R?(L"++N^^?E.X=,$Y
MS0!Z]=_$3PG8O=I<ZU#&]G((KA"C[HF)Q\PQD#/&>G3U%0>(_B!I?A_5M%TU
MBTTVJ."K1HS*L6,E\J#N[  >N>G7R+5 \MM\5U2VN&;4;BW-EB!SYX64Y*<<
M@<']:W-5F$>I?"S4]DLEOI]OY5V(T+/ QC089!\PY!ZCM0!Z7?>/O"VF37<-
M]K$-O+:(LDT<BLK*K8V\8R<Y'3-3W_C+P_IL1ENM158UB2:1DC>01H_W&<J#
ML![%L9KSW2_L-Q\>?$%_>PJ;"?34ABFGCS"S8CW*&/RG@$=?6L3X@W)OM=\6
M66G:2\:RZ9&JW=H@;[<5VG:S$X 49 51N)7OTH ]HOM?TO3K:VN+B\39=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW_"B/ /_ $#;C_P+D_QKM?#WA[3O"^C0Z3I4316<18HC.7(+$D\GGJ36I10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP#U.=H';/;F+7P1XIA\%^!-.;1)OM6D:NUU=H)HOEC\W?D'?@Y!Z#T->[T4
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MHH **** "BBB@ HHHH ***0D $DX ZDT +1110 4444 %%%% !1110 4444
M%%%% !1110 44F1G&1GKBEH **0D#&2!GBC(R1D9'.* %HI"0" 2,GH*6@ H
MHHH **** "BBD+ 8R0,G SWH 6BBB@ HI"0.I [<TM !1110 44C.J %F"@G
M R<<TM !1110 44@8$D @D<'VH)"@DD #J30 M%%% !12$@=2!VYHR,XR,]<
M4 +112 @D@$''!]J %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MII,6R&:X("AY) 7&$R'.U1QR-HP:T=/\:PMX=\,W\6G2+;:M<I9(C3;GA)W
M$DCYA\AYSGI5ZVT;4HO']]KCBT^Q7%E%:JHE;S!L=VW$;<<[\8SVKFK3P5XD
MMM%T'2/-TK[/HNJ+=1R^9(6GB!D(R-N$;#@8Y!ZY&,$ W(/&&H7FM:AI]GX;
MN)AI]T+>XD-S&NT&,.& )YZC@'O^%5=+^(+ZA!X?O)-$FM]/UJ7R(IVG5F24
MABH* 9VG81GCGMCDZ.B:-JFF:UXDOIELV34KA9X%29L@K&J8;*<9VYR,]:P[
M+P7K=KX9\):66T]I=$ODN9G$[[9%4.,+\G4[^_I[T 7(_$^EZ5)XLOVTK[')
M8W<,=W(SC]^[(@1V(R%4!ER><#)JC\0[J34OAKK3W5E$@A:!X)8I?.24%T.]
M&VCU(Z>O8UIP^'M:MKWQ/<HFF2?VK=0RQ132,R&-51'23*<;D5N1G&ZLBY^'
MEZGAGQ!I6EBSLH=3FAD@LOM#M!:[2&<J=F1N(^Z  ,#Z4 =1IOB2:Z\3W.A7
MNF/93I:K>0L9ED\R(L5.<?=8$=,GKUJUJVKW%A=VUM;6!G::.25IY9#%!"J8
M^_)M;!)88&.<'TJC'HVI'X@+K\@M%M?[,^Q,BRL7#>9OR!L ([=??VI-=T?5
M[SQ)I6H6;V4UE;1R)+:WC,%5V*[9E"@AF7! !QU.",T <YK6KVOB;3/ 6O06
MYB^T:W#M#X+)\DH9<CJ,K^.!6IH,4<7Q4\7>6BKOM+!FP,9)\[)K.L?!6O6G
MAKPSI;RZ;))H^J"\=Q(ZAXP9, ?*?F/F?08[]:Z/3=%O[3QQK6L2_9C:7\%O
M%&$D8R*8M_)&W'._UXQ0!!KFMZK9^-?#^D6EO;O:WJ7$DC/,59O+4<?=.!\X
M/N1V[\IHNOMX2M/%=W'I+3:;!XBE^T2)*J>4C")<JO\ %C.2...]=CKNB:C>
M>)]!UC3WM?\ B7_:(Y4N"PRDJJ-RX!R1MZ'&<]17/WG@O6[KPMXJTH-IZS:S
MJ+7<3F=]L:L4X;Y.HV=O7VH V]<\90Z5/?V]M#!<SV$*RSQ270B9L@L$C&#N
M? SC@<KSSQO:;?Q:IIEKJ$"R+%<Q+*BR+M8!AG!'8^U<M<Z)XHL/%5UK&A2Z
M6T.IQQ"]M;UY,1R(NT/&RKS\N 00,XZCMUUM')%:Q1S3>=*J@/)MQO;N<=OI
M0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 445Y9>>)/$]OX>\1ZR-7B_XDVL-;I +1
M LT0:,%6)R1PQP1@Y[GH #U.BN*U/5];U/6-=TO1&FAN-,CB6)HQ"5>5TW@R
M>9SLY4?+@\-STPVSU77O$%UJNF17<6EZEIMG;[A$JR(US+&7.2P.8P<#C!/S
M<]* .WJHFEZ?'J#7Z6-LMZXVM<")1(1Z%L9KE[G6-8NM9&@Q2/'>0:9%=3S6
M B(:5V9?E$W\ *'MD[AR,<T-0\2>(-&TW29O$:364+6\BZA>Z9"MPD$X8!6<
M$,1&5!.0.#QF@#T*BO.M9\67NF_9C>:G):Z?<V$+6NLVT"2VKW#9W>:=I**?
MD*XP,$\^DGC3Q'JVDP:]=V&HH?[/M(KBWM[:)9 .I8W!9< -P%"L"1D@&@#T
M&BN'U&^\0W_CG^Q-.UB/3[>71Q>*_P!D65D?S0O\1YX_F>^"(AK^KZ=?^(M$
MOKYIM241R:0YB1?,CE(1. O)63ACZ8.!0!WM%4+TW]KH-R;/%UJ,5LYA\W"B
M64*=N<8 RV/2N&@\>^1H>MWYO+E[S3[6,R:9J5NL,UO,6*[FVJH:,Y7D$]#S
MS0!Z15=[&TDO8[U[6!KN)2D<[1@NBGJ W4"N0N;CQ;8O?S^<QT\:=)(DEXL)
MDBN%!(VB/ 9" >#R#WQ6>;OQ@?ATOB:+6Q/=/I]M>BT2SC P%#2@'!)+*<CC
MAAQP<4 >C,P12QS@#)P,U6TZ_@U33H+ZV\SR9T#IYD;(V#ZJP!%8]KJ<VLR3
MWFEZ@?L"62&-C&K*TKKO!Z \(4.,X^?VKG] \5ZEK&F^#K2:Z\J\UBREN[BZ
M2-=V(PORH""H)+CL>%/KD 'H5%<5<:KKNF7.E:'>7*W5]?7%SMN;18UD,,8W
M*"'P@D(9<\8P#@=Q5N=7\6:-I EU2WN9H8M0=99[&..2Z%GM)1VC *[@V VT
M=!D"@#OZ*R/#&HQZMX?M[V'4TU*.4N4ND0+O7>VT%<## 8!&!R#4/BS6Y-"T
M>.:W"&YN;J"SA,@RJ/*X0,WJ!DG'?&* -VBN.6[U:V\>MH;ZO-/:2:/)=JTD
M,0=)1*J9!5 ,8)X([GKQC+T[Q5K%SX<\!ZC)=+YNKW207BB)=KAHY&R.,@Y0
M=/>@#T6LRTU_3KZ;4H;>21I--;9=*87!1MN[ !&6XP>,YS7'S>)=8MM6TIOM
MZ745UK;V$R01*;9(SYFU5<J',@V#=@E0=P/85-I<D\.O_$26UD6.>.:%T=EW
M $6J'IWH ZS^W+'^R;74F>18+H)Y"M$PD<O]U0F-V[VQZU6T;Q3I>O7,]M8M
M<&6 9E66VDCV$,5*DL -P*GBN'O[B_UO1OAKJ-QJ,\=Q>75O)*8DC \QK:5B
MX!4\]1CISTK=NO$=_I/BG7X+F87-AIVB)J$<0C"L6!DW9(ZD^7].>E ':UGZ
MGK=CI$UC%>R.CWUPMM!B)F#2-T!(&!T/7'0URMMJ_B2 6&M3;IM'>R>XOEE\
ME0G[O>C0;#N(SD88G@CG-8^J7&HZMI'@/7+J_+"_U>SN&M%C3RXPZLRA2!NR
MH.#DG//2@#U*J-_HNE:JR-J.F6=XT?W#<0+(5^FX'%9/C[5+_1/ VK:GIDR0
MW=K 9$=XPXX]CQ_.N<UOQ+X@\&ZU#-J-Y%J>G7MA=W"P+;B(V\L$7FX5AR58
M<?-DYH ]%1$BC6.-51%&%51@ >@%.KCM.G\53ZGITXE+Z9=6S&X:X$($4A7<
MC0B,Y*DY!#$\8.>M8VB:MXPOO <?B47WV^>2$C[!!:1JQQ/AG1CU<1AL*1@G
M'7N >E45YTGCD/I,3V&J/=2WVL0:;']JMQ'-8EP-PD3:OS#:Y'&"2.N*L:IK
MNM:-KFK:,+W[0/[&DU.SNIH4WQ/&=K(P4*K Y4@X'<'- '>T5Y]I&N:^NI>#
M'O-32YAUZQ=IH/LZH(W6!9 RD<Y/(()QSP!6;/XD\3P>'M9UHZO&?[*UQK06
MXM4"SQ"9(]K'DCAN",'/4GL >IUGQZW8RZ]-HJ2/]OA@%P\9B8 1D[00Q&#S
MD<$]#7*WNL>(M8GUV/P^9([C3+H6T"D0F*1@B.?-W_/@[B/EQ@ 'FI;)Y)/B
MV\DJ*DC>'(2ZJVX ^>^0#W^M ':T45Y9?^(_$\'AGQ5K":O&'T/5)(HHA:)M
MEC7RSL?.3C#'D8.>YZ  ]3HKC$U/6=/\<MI=SJ4-U;W.DRWJ"6%8D@D1U7 (
MYV$/SN)(QUJGH?B'5I?$VBV%Q?M=V^HZ9+/),(52/SD,>6@.T,4^<X+ Y&T@
MGF@#O@0<X(..#[4M>6Z%K.H:/X9N9VOKF\N;WQ%-I\;3"/*DSLNX<*-VU> 3
MMSCC'%6_$6K>,=!\-^([XW 2*WCCFL)[E(6F'($B,J?(1D@@X^N: .\OM1M]
M.^S>>)?](G6WC\N)G^=LXS@' XZG@5;KB=;NO$.@-HYDUF.Y%]KD$#K]D5-D
M+CF,')Z%3R><'KQFJ7BKQ+K&D?VM=VM^L@LKNV1+:WB5XTC=HPPG9ER'.\X"
M-D#8<<F@#LXM;L9M=GT5)'^WP0K/)&8F4!&) (8C!Y!Z$]*T*XZ#_DLE]_V
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M#L^8C/&&)XQSFNSH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW>IZC>WDEQ<_VC:+9W,$I7RVB&<# 4$'YFYSW^E;V]=P7<,GMF@NH8*6 )Z
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M+VT1U\N9BH5N2N\950"%840>(Y]7U74++1+:&:/3I?(N;JXE*IYV,F-  2Q
M(R>,9[\X-.\3M?MJU@;1(=9TO'GVCS?(P8;D=7"\HP[[<@C! H I:W:1>(]2
MM_#DNA72V5C<07+7DL:K;[4&X+&0<L2<(1C@%O;/7U@^#O$$WBGPQ9ZU+9I:
M+=H72)9C(0,D<G:O/%;U '*7G@'3;RTUFT:\U".VU:<SW$,<J[0Y*EBN5.,E
M5SUZ<8R<Z#>&;677QK$]S<SSFR-B\<FSRWB)R00%ZD\]?TXK;HH YGP_X'L?
M#DR&UU#5)[:'/V6SN;G?#;9R/D&,]"0,DX!.*Z:BB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KSSX:,=$N==\,:D?*U./4IKN,/P;F"0@K(O\ >[@XZ=Z]#JM>:?9:@BI>
MV=O<JIRJS1*X!]LB@#S*_P!4UYD^)<6FWUU</IT<26"!]QBW1;I-N.2PYQG)
M&!6A/;:>^M^"KSPW' ([Q9$N%A VS69B)/F ?> ;;C/\3>]>@VUK;V<(AM8(
MH(EZ)$@51^ J.VT^RLGD>UL[>!Y3F1HHE4N?4X'- 'GFA:8EGK&H>!'LU-C!
M>C5(F,8V&U8[U7/<B4;.>J@^E9]XVCZSJ/B;2_$6LKINH0W^Z %46X$("F%H
M&8;NW1>Y/&6Y]:$:"0R!%WD!2V.2!T&?Q/YU#+86<]U%=2VD$ES%_JYGC!=/
MH<9% ' :1H.DZG\2O%(OK2.XDMQI]Q&).J2['._ X#9'7W/J:Y=].TZW\#:G
MJD4$2WMEXI9;:X_BA7[<JX0_PC:3P.M>SI86<<[SI:0+,^=\BQ@,V>N3U-1?
MV1IGEF/^SK383N*^0N"?7&* /-=0T?2KW5_B:MU:03"*UAE19!D1O]F8[P.S
M9YSUZT_3;6UM=;^&NH0(B7NH6<HN[C/[RY'V4/\ .W5OF (SG':O2!I6G#S,
M:?:_O!A_W*_,.O/'/2E&EZ>IB(L+4&+_ %9$*_)SGCCCF@#RSPR=)URWT>?4
M-:^S^)K/4,W%M&D:W;3AR'1N-[1D$Y[;1VV\9VI:;IL?@CQQJ*01"[L/$$C6
MLW\5NPDA^X?X3],9Z&O9UL+-+UKU;2 7;+M:<1C>1Z%L9Q4?]D:;L9/[.M-C
M'<R^2N"?4\>] '&!-)M?C-?3726<4C:-!+&\@4$MYLH+ GO@#)]!7;:?J-EJ
MUC%?:?=175K*"4FB8,K8.#@CW!%*UE;$JRV\ DC0QQL8P=BGL/;VJ+2M+MM'
ML%L[5 L89GPJA1N9BQP!P!D]!TH \EU74M+:\M[ZUN+:W:/Q:BS-<2 W1(DV
M2$G(\N/' 4Y^7'(Z5LZJ\EAXDFU3R;+6=(FU:V67'RWEA/F-4VG^-,[3MX.&
M/;->BG3K%GD<V5N6E97D8Q+EV'0GCDCM1_9UC]L^V?8K?[5_SV\I=_\ WUC-
M ')_%F.*3X::L90OR")E)XVGS%&0?QK U^V;0_%VO)X;@%O=S>%I;@) ,-+,
MLI"R'NSX)Y.2:]/N+6WNX_+N8(IH\YVR(&&?7!J--/LHYUGCL[=9E&U9%B4,
M!C& <>G% 'FNG#1;U8M;\*ZRD^JC2YUBL[-(U+?)E?/51G*OC!;^(^]'A/\
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M9W,5G)?6X9#=PQX9U+$]2,CKC&3TK=FT^RN+J.ZFL[>2XB_U<KQ*SI]"1D4
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M3K&YE$MQ9V\L@Z/)$K$?B10!0T3PW9:%/?W4+SSWNH2B6ZNKA@TDI PH.
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MY0LT\\BW*J0-WRA"NX<X&ZKPT32001I=D"._V=/\*OT %%%% !1110 4444
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M2,*$C4X.-V%R<'^+':JG@J'4]!^'XAN-)N#?VSW$@M-R!I-TKNH4[MO(8=Z
M,[P-J\NL:Y<&^US6(M3CC,D^AW]LD"PACU0;=S(#P#N/;->AUS-O:2:WXDTW
M79=-N-/^Q6\T8%SL$LADV_+A6/RC:3R>I&*V=,O;B^MY)+G3YK%UF>,1RLK%
ME5L!QM)X(YH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !114-W-);VDDL5M)<R*,K%&R@
ML?3+$#]: )J*Y3X?>,CXZ\.2:Q]B%FOVEX4BW[SM4#DG YYJWXT\3/X1\,W6
MLKITM\MNH+(DBH!D@ DGG&3V!H Z"BL[P_J3ZSX<TO5)(UC>\M(KAD4Y"ET#
M8'YU@6GB^XUKQ+K6D:0+$2:0ZQO%=2,))V(R=N/NJ#QNPW/;U .PHK.T[4VG
MT.#4=1B73W9-TT<L@Q"<X(+' X/&:M+>VCV?VQ;J%K7;N\X2 ICUW=,4 3T5
M674;%[07:WENUL3@3"52A_X%G%$.H65Q.8(;RWDF"!S&DH+!3T. <X]Z +-%
M0?;;07@L_M,/VHKN\GS!OQZ[>N*GH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CGECAMY))
M75(U4EF8X 'N:DKD_'/@@>-K6T@.L7NG"W=F)M3CS,XX/TQ0!QGP,U.TT_X3
MWMW<2@16=S<3S!?F94558G YZ"M/X@^(]-\1? W4]7L92+6\@7R?-&QB1*JD
M8/?(-9:_ 9$SL\9ZXN1@X?&?UI/^%"Q^6L?_  F6M[$&%7=P/H,T >@> I8Y
M?A]X=:-U<#3;=25.<$1J"*\]\4^%/#GC'4M5UK3=8_L#Q-IDTD<TRS; QCX5
MV'! ( ^9>G(.<5V/@7P"/!!OMNM7VHBZ"<71R(]N[I]=WZ"N3O\ X$0:A>27
M$OBS6/FE:55)!"%CGCGCK0!CZOX@UY/"OPVUWQ-'*+1+[S-38QXZ,!#(ZC_9
MRWU_"K7B_3]*LO#NB-X9N#/X<E\21W.HR)*9(1N8'[W3RP?P!QGFKLGP($T;
M1R^-===&&"K/D'\,TG_"AU\GR?\ A--<\K&W9O\ EQZ8STH QM6%S(WQ=EM_
MFT9H8]I7F,SA!NV]L^N/;-5]-6T?5/A)_P (_P"1_:*P$W_V;&\1;4W^9C_M
MIU]ZV+OX ,VFO:6OC+5%4C CF&Z+'?*@C-%A\ 6MH4\SQCJB3A0A:W^1=HZ
M#.0/:@#-\(!-7N[[2];UM=/U^R\2&_$/DYN9W& -I+?,A&00!PHSTKWNO'A\
M!HQ<?:/^$RUOSL;?,W?-CTSG.*]@ PH'7 H 6BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFBD0&*54",CAV'!P"",XY%97A[PCJ?AW5O", M6N+;3=-N+>YN4D0*LDK(_
M+!BH*L.GI0!:TG739>*?%TUS+?2VR&Q-O:N69U:2,DHB,>"2?NC^E=S'*TD
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M>,-2?Q%HNFW\%HK:E]H66"'+-9O&I<*T@8HYP.0,$&IOA^ !XH &/^*AN_\
MV6@#L:*K:A/-;:=<SVZ(\T<3.BR,0I(&>2 :XK3_ !GK<F@:3J]_:V"1:PMO
M'9QP"5W65P68LH'*A5+ #GMGO0!WU%</=>,]6TC1O$%[J6E%TT[RS:W*PO!'
M<AR!RKY9=A/S=>.15Z#6]:;QG/X>=;%U2P6]%VB.N S,@4IN/.Y<_>&1]* .
MJJM::C97[SI9W<%PUN_ES"*0-Y;8SM;'0^U<;9>-]0N_#GA'5FMK9?[:O4M9
MX@&_=[@YW*<_['0CO46DW5W8:E\0;G3[1+JZCOXVCA:01JQ^SQ=6/  ZGZ4
M>@45P;>+]1N(O%-G;7%D\^F:>EY;7L4#>7(&5S]PL<X,9PP8@Y]L%^@>(-2E
MM/#FB"XMY=2N])6_DN9(F*QQ!4497?EW+-UR!P3CM0!W-%>?7GC[4K7PYJUP
M+"U.IZ3J,=C<QEV$;AW15=.^"'!P3QSR>]^]UWQ'HE_I/]L1Z4+"]OC:RRVP
MD8PA@?*R6(^\?E)Q@$@\YP #LJ*S-*OKF_N=1=_*^QPW)@MV12&?: ').>S[
MEZ#[I]:L:I<75II-W<V5K]KNHHF>* R!/,8#A=QX&3WH MT5Q5CXOOI]6U+3
M?]!NY+?3$OX9X \<;$LRE"26W %?O*<=NU5]'\9ZU=-X2N;ZTL$LM?CQMA+^
M9%)Y1D!R>"IVD8ZCCDT =I?ZC9:7;&YU"[@M8 <>9-($7)Z#)[U9KRSQOK5[
MXC^&>M:C:"U72Q<^0B.C&258YU0R!LX7YE.!M/ Z\\>@>(=:A\.^'[[5YT:2
M.UB+[%."YZ!<]LD@?C0!>N+F"TMWN+F:.&&,;GDD8*JCU)/ JO+#IVOZ.8Y4
M@OM.O(@<'#I*A&0?<="#6%J,OB 6VI6^H6MG+I\FERR?:8,J8Y<$&(JS$L"#
MD, .G2L+P?KNJZ?I_@73;B"S.GZIIRQ1%"WFQM';AP6)X((!X X]30!U^F>%
M])TB59;2";>G$9GN99O+XQ\F]CMXXXQ6Q7$#QCJMXD%_I6G->6+WK6[P+:R^
M9Y2R&-I1+]S@KNVXZ<9S574/&/B*&U\5W%O9Z8%\/RDLLC2,9HQ$LA QC#88
M\]/8]: /0:KVE]::A&\EG<Q7")(T3M$X8*ZG#*<=P>U<S;>)=6'BC2["\MK,
M6FKV<MQ:^4S>9$T80E7)X.0XY &#Z]:S(?',EGX:;4;NUM;&,:S/8W$\4320
MVZJSCS7 P3EE )XY?)H ]!HK@-=UK6Y+'PO-::CIX6_UE;=Y;=#)'-'^\:-@
M0_0B-25SU.,\'-PZ[XGO/%6JZ)I]OI*_8$M9#/<-)\R2;]WRCO\ +D#.!C!)
MSD '9T5Q>E>*]3U#1 )(K2+75U,Z=-;!&*1LK98_>R1Y0,@/&1Q7:4 %%<OJ
MVNZO;^,;'0K&"RV7EG-.LT[,2C(4'*C&1\_3//J*P5\<Z^GAT:U/9::(;34O
M[/OHT9RTA$_DEX_[HR0<-G//3N >C45Q'BGQAJ7ATZA<&"T%O9O!Y4#Y>6ZC
M<J'<%6_=@%B!N4@E?<5/?:_X@;Q9J6A:;;Z:OV>PCO(IKAG;.YG7# 8_N=CQ
MG.3TH ["@D 9)P*XG1_&MWJMUX3Q;01P:[837+K@EH7C5"0#G!!+^@Z5FZ]K
M^IZO\+O%\^ZWMY[*2]LF9$;#I'E,CYOE8_4X]Z .[L=8TS4YIH;&_MKF2''F
M)%*&* ]"0.Q['O5VN,DN+_2SI\@BTJ.::Q*MJ+6YRQ7!C@6,/O8G<S<$@;3Q
MS1I'C2?7;'PXEK!#!?:O9O=OYF72!$VAN 06)9@ ,CC)[8(!V=%<!KNJ^*8K
M;PXD_P!ETZYN=;6TG5%,JRH-[(XPX*J=@)4G/.,]<VY_%>IV\/C-6CM'F\/Q
M++&PC8+,#!YI!&[(],Y]_:@#M*KQ7UI/>7%G%<Q/<VX4S0JX+1A@2NX=LX.*
MY"Z\4>()M5TC3M+L]-\W4M*>]22Y=]J.NS@A>=OSXXR:?'XCU*/4?%L+Z?IX
MN=)L[>=&1F_?%HW8AFQG V\#'>@#M**X?2?%VLW%_P"%?M]K8K:>(+0R(("^
M^&00B7DG@J1GC&1QR:@F\<ZH^EP:I9VEHT,VLG2A:RAQ(G[TQ!V8$\Y&XKMZ
M'KQR =_12+NVC=C=CG'3-+0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !6-XIT'_A)-!DTY;HVLAEB
MFCFV;]CQR*ZY7(R,KTR*V:* .;A\-WT7B:XUQ]5ADFFT]+(H;0@#:S,&X?U<
M\>F.>]8\?P[NK/1= AT[7FM=4T1'AM[T6H99(FQN22,M\P.!W&",UWE% %+2
M[.XLK,)=WKWMTS;Y9V0(&;I\JCA0   /S).363#X7<>)=9U.XO(I[;5;>.VE
MM?LY&$0.!\V_G.\YX_*K>N:_'H=QI44MK-*-1O$LTD0KMC9@2"V3GHIZ _A6
MQ0!R%CX)D@TS3-'N]3%WI6F3I-;1F#;*1&<Q([[B&"G'11G:/?,LOA"XDN?%
M,PU.,#7H5B*_92?("Q^6"/G^;Y3[<_E7544 <DO@R: Z!=VFI)%J>D6WV,3M
M;DQW$)4 JZ;P?X000W!_*KL'A.T_LK6;2\<7$FLM(][*$VABR!,*,G "@ <G
MIG.:Z"HTN(9)Y($D5I8@"Z@\KGIG\J .7M_ =G#+X=G>ZEDGTA7$DAZW9;#$
MOS_ST59!UP15^^T":[\7:;KJ7J1BR@F@$!@+;Q)MR=VX8^X.WK6[5+5]172-
M'O-2>"6=+6%IFCBV[F"C)QN('0>M '*OX"N7\-7.CG6(L3ZF=1,OV,\-YPFV
MX\SIN&,^GYUSNIS+=^,-5DDU^PT^[69(8[34]'\]W6-1AHCN4E2VY@!NY.<]
MAZ=I=\NJ:19:@B%$NH$G5&.2H90V#^=6Z ,RR6\U'PXD>I?N+JX@*2M""A4D
M$;E!R5/?!R1T[5S>F>!+^PN/#DLFOK+_ &'#);1*EDJ"2)E5<'YC\WR#)[]@
M#S72?V]8BWOKQY5CL+$L)KISA-R_? ]=I!!/KQR0<4&\5,-)?5O[#U0V"Q&8
M.%CWLF,[O+W[L$=L9]J *UCX*CC\-:QH6HW@N[;4YYYG:.'RF3SF+,!\S=">
M#[=ZAA\':Q/H5YI.L^*KB^BEM7M89([9870,NW>Y!.]@..PY.1GD7I?&FG6_
MB?3M!N(;J*XU&$RVLS*OE/P3MR&R&X/!'-6/%?BK3O!VA2:MJ8F:%75!' H9
MW8]E!('3)Z] : ,>U\%:E%J=MJ,OB#-Q%I;Z:?)LQ&NTD%67YB5(*@GDY[;:
MOV/A:2#Q#_;UU=6\FH_8C9F6WM?)\P%E.^0;FW$;1CIC)]1BYJ'B.VTU;&.:
MWN&OKYBMM8QA6FD(&6_BV@ <EBV!ZTW^WY$U"UL;G2KRWGNMXA9RC1L54L06
M5C@X'0CZ9P: +VF07=GI4$.I7XO;J-,377E"(2'UVC@5YYX5TMO$NC>*--.I
M0?V;=:Y>>?'''F4QM+D@/NP P'7:>"<=L>B:=J,&IV[2P;@8Y&BEC<8:)UZJ
MP]1^1!!&00:ENKA+2SGN75F2&-I&"#)( SQ[T 8\'AV6#QG+KRWD?E26*60M
M1!C:J,S [MW7+'MTQ66G@,Q:5J&A1ZB!H%[.TK6I@S)&KMN>-)-V I.>JD@,
M>>A%A_&QCU>STJ3PWK*7MW"\\,3&VR47&[)\[ (R.#4]GXOCN]<T_2VTR]MI
M;R">8&XV#9Y3A&4A6/.3],=": .,UN2"Y\9ZD'URPTN6(16T-KJFD"?S$50P
M:(DKE2S'@9Y7Z =3!HVJZO?^'==O[N""YTY9PT*VK 3"3Y=V"^4RJJ=IR020
M<UUM% '#:O\ #^ZU-?$$$>O&&TUB6.X9&M0[QR($ ^<MRGR#Y<#'KUSKP^'+
MV'Q1<ZX=3B>6>PCLMC6O38S,&R''=SQ@<8^M=%10!Q-MX#N+;P]X<TE=7C*Z
M)=I=)(;0YEV[@%(W\??//TK<\6:"_B?PW=:.EV+47&T-*8O,P P;@9'H*VJ*
M .?;P_=MXOC\0'4(=Z6#67D_9C@Y8.6SO]5''I^=8MEX O=/M]%%MKJ"?2KF
MYF1FL\I()RQ8%=_WAN.&SP.QYKNJ* .&A^'UU!96EJNNATM=9.JH9+0$DEV;
M8<,.[G)^F .\VI>!)=3/BCS-6\M==2%?W=O@P&( +R6.X$#D8&>>E=G6=JNK
MQ:6;.(H9+F]F\BVB!QO?:S')[ *K$GV[G H YF[T34M$N=4\43:G->W)TK[.
M]O9V04LR;RIC&6(^_P!#GGOCBL+PB);6YL4T?7]&U=1LAG@AT@PS"(D;RT@?
MY2.6^8?,1CJ:]&TB_FU*P$]QI]Q83!V1X)\;@5)&00<%3C(/<5>H X_0/!FH
M>'Y%LX?$4TF@PRF2WL&MU#QC.X(9<Y* ]L XXSC@PW'@*YN/#6O:,VKQ :O?
M/>-*+0YCW,K%0/,Y^Z.?K7;44 <S>>$VU+Q&VIWMY%)!+I<FFS6RVY7>CD%B
M&WG'(]#Q^=1^'/"^KZ(L-M=^)9=0L;1=MI"]LJ,HQM7S'!S)@'C@>IZ"M+4M
M?CTWQ!HVDO:S.VJ/(D<ZE=B%(V<@\YSA?3'O6Q0!Q \!7(\-)H_]L1834_[1
M\W[&?O>=YVW'F=-W&?3\ZT'\.7MGJ^O:M9:P;=M3@3*"T$IBF2/8KCGYAC!V
M8Y(Z]JZ>L>77XXO%MOX?:UF$D]I)=+.2NPA&52.N<_,.H% $^B+J2Z%:+JLJ
MR:@(\2R>6%W'L2H. <8R <9SBN9/@*Y/AJ31_P"V(L/J?]H^;]C/#>=YVW'F
M=-W&?3\Z[>B@#F!X6N[36-4O]*U..U7554W<4EL9 )0NWS(_G&TD8R#N&0#]
M66'@M-)UG2KO3KM(K73=.;3XK=X"Q*L5)8MN'.4';N:W]3NI[+3Y;BVL9;Z9
M,;;>)E5GR0#@L0. <]>U6Z .%_X5W*/#UK8QZT8=0L=0DU"ROHK;'E.[,S*R
M%B&4[V&,CC%7M5\):AK7A:YTJ^UP27=S)$\MU]EPJA'5@J1AOE&5[DGD^V.L
MK'U[7X]!.F^;:S3"^OHK)6C*@1M(V 6R<X^@- %?_A'[K_A,#XA_M"'>=/\
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MFWFLUNHYHVMGC$BRAAM*$9SGIC%9NA:-_8EA)I**CZ<C,;8'JD;$DQL.X&2
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M,KP;."Y.=V>H//4=*DA\*:);Z?;6-O8+#;VTOGPB*1D9),$;]P.[."1G/0T
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M/RHYR/F"YSCWYY&>E06?AK1]/G66ULEC*2-+'&'8QQ.V=S(A.U"<GE0.I]:
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M;;I"Z,4#%=R@CDC((&#P*Z"[\-Z1?7LMY<68,\T8BF979!,@Z+( 0''7A@:
M.!M9M2\4:MX42_U#4;(:IH$L]U%:7#0@N/*PP ^Z?F)X^G3(K7\):=#:_$/Q
MAMENG:*2T"F2YD;=F $E@3AC]1QVQ762:)ITNJV^IO;YO+=#'%*'8;%/50 <
M8.!D8YQ2IHFFQZS+JZ6<0U"5 CS@?,P P,]L@'&>N.* .7\417%U\0/#FG+J
M5_;6E[:WOGQVUPT8?8(]O3H?F/(Y]"*YJTUC5M+F'AZ?4;N>P_X28::M_+*3
M+Y!B\P1&3KG<0N[.<9%==X@T*ZU7QSX>OOLDCV-A%<K+,DXC96E"!2N&#<;#
MG'8]ZW)/#^DS:2VERV,3V3-O:-@3E\[MY/7=NYW9SGG.: .-NVUBS\2>(M T
MO472"72HKJUDNIF<6MP[M&$#DE@&VY'/!SBN>\2WPU#P1XHL[ZSU/3=3M$M'
MFL;B\>6-<RX$D3[OF1N>/5>F:]2'A[2_L5S:/:^9%=8$YED9WEQTW.Q+'';)
MXIK^&](EL[NUGLQ/%>(([CSW:5I%'0%F).!DX&>"210!5OM0U/2)X+/3?#M]
MJ=ML!-R+V/Y22<@^:^\D=>_6N+U2*ZN'^(^[5]53^RT2>R$5[(GDO]E$G&TC
MC<3\IX]J]-M+2"QM8[:VC$<,8PJCM_GUK.;PSI#G42UH3_:0Q>?O7_?C&,-S
MSQQ]..E '(VD]U9^*?!UT=2O9/[8L)WODFN&:)RL2.K!,[4P2?N@<&J6DZC=
MG7O!T]OJ-[<V>IR7:R7,\[#[8HC=U;R<E44$#;C! XP*[U?#>DK/I\PM3YFG
MH4M&,KGR5(P0.>A'!]@!TJI;^!O#%JUNT&C6R&WE,T. ?W;'.=O/ Y/'3GI0
M!QNFV,U[H/BW4+K5M4F>PN]3MX8GNV,?EA2H5E/#8[9Z5/\ #[4SJ%K:6]Z;
MJWOM-TJV-K8+.RQSP&)2)L XDR<KR/EZ=>3VL'AK2;:RO;.&U*6]\[/<H)7_
M 'K-]XGGJ>_KWIL?A;1HI[":.RVRZ?'Y5HXE?,*?W0<].V/3B@#CO#9U+7]*
M\.^)4UY86D=3>J)I'6<O\KP^66VH0QP"!E<?6LZPMS8?#?QY<V=W>P7%O>ZF
M8I$NY,KY;,5(RW7@9/4]S7?67@[P[IVM2ZQ9Z3;0W\K%FE0'[QZL!T!/.2!D
MY-2-X5T-DU%#IT0746+784D><3][.#W[^O>@#DUBN-2\;Z-8S:EJ*6ESX>>:
M:&&[>,.X>(9RI!!^8\@@^^"<TM-U/5Y/ 'A^0W=U<*-9:UO'$A-Q+;I-*@ (
M^9C\J9Q\Q4-[UWD?AS2HKR"\CMV6X@@^S12"9]R1?W!\W3@?D/2N=\1>#HSI
MMA8Z7HMG>Z9#=/<7%A-<-&68@X:-SG:0S$GIG/7KD N^$['48=5URYN9KXZ?
M)<@:=%=RN2L>U2QVMR!OW8SSCVQ6=X@M)]2^(]AI9U34K6SN=)N'ECM;IHOF
M62,*PQT(W=1].A(.CX3\-KHT\]S%8?V7%+&$-FMZ]P"0<[SNX4]OE]>3T VY
M=%T^;6(=6D@)OH4,<<WF,"JGJH&<8/<=Z .!0ZGXBMM=:WUW^SKS2=1>%9WG
MD)MXXB-I>,$*ZN@))8'.X^@Q9FOY=:M_&\UQ>W-O<:.TD-K%!</#Y*K KK(0
MI&2S%CEL\+CUSU%UX.\.WVN)K5SI-O)J*[3YY!R2OW2PZ,1@8)!Q@>E4_$WA
M#2]3AU#48])BGUF6T>".3.TL2I"[LD*<$CDY(QQ0!@^&;R\G\2^'(IKZ[DBN
M_"BSS(]PY5Y=T0WXSPV&/(YYK,M]2U"3X;>'[W^U+UISX@2%I?M#%I(S>LFU
MCG+#: ,'M78:7X3L;GP]H$6MZ:C7VF6D< +/G:0BJPRIPRG;T/![BKP\(: N
MGQV":;&EK'/]I6-&90)<[M_!Y(/(/:@#F+:TN;[QWXI$FIZJ8M->SN;:VBNV
M5"QC9BI'=6/!7IS],0^&O[1US3/#?B6/7UB,VTWJB:1UN"XP\7ED[48,>,#Y
M<>F:[BTT33[+4KK4;> I=W043RF1B9-O"YR<' X'I5.R\&^'=-UB75K/2;>"
M^E+,TJ CD]2!G"D]R #S0!YS<OJ$7@G6=836M5^W:=X@DAMG-XY"QB[6/:RY
MPXVG&&!]JU]6OK[PKXC\1II]W>7*IX<;44BNIWF N%=UW*&)V@@#*K@<=*[!
MO".A-I\^GM8YM)YOM$L1E?:\F=VX_-R<\_4 U:70M.75/[3^SEKWR?LYE>1F
M)C_N')P1GG'KSUH YC2=/NI[[2M5@\0$Z?>VK1R0K<RR_:B4W*ZEFPC+@G*@
M<<<8%<QH5QJ$7AOP#K;ZOJ4UY>ZBMK<^==.R21.)<@IG:3E0=Q&??I7H6E>#
M/#NARW$NEZ5#:27"E7:(L" >2%Y^4>RXZ#TIR>$M#CL[*S2QVVUC+YUK&)7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PWQ)UKQ-I
MMA#9^'?#TNJ_;8Y4GDC/, P .,'D[CU]*[FJ&J:A-81V_P!GL)[V6>;RA'$R
MKM^5F+$L0  %_44 >!Z)=_$#0O ]SX5MO ^JBUE218[A9BLT6_))!"^I]*I:
MJOQ)U33-&L3X=\26Z:7'MCD@NRLDCX(+LVS.<' ]!GU->TV?CB:^.I>1X>OV
M&FW)MKK$L1*, "2!N^8 ,#Q6KH?B#^VK[6+4V;VS:;="V;>X;?\ (K[N.G##
MO0!R7P@;Q!#HU]9:_I.H6DD4JR+<W\YEEN2V<Y) ^Z%4?E7%:YJ7C>3QD/$.
ME_#Z]M=4@#6_VJ.0LEU%G $B%>1P"""#TYX%>^44 ?/^G:OX[MO$\WB6_P#A
MU>W^L21"%)7D*I!'_=C0+QG)R22>3SR:Q?LGC?\ L_5M,'@;5/[/U>[^UWT7
MF?,[;]^$;9\JG !ZG ZBOIJL70/$']N3ZO$;-[9M.O6LV#N&+D(C;N.GW^G/
M2@#PK5=?\9ZMXN\.7$/P]O+:3P_O,=J@<JRL% &[;@  #UHCG^(%GXLU#6]+
M\%ZQ81ZF0U]:0R@I,P[@E"4)R>1SR<$5]"/<78U:*V6Q+6;0L[W?FJ C@@!-
MG4Y!)STXJW0!\X2S?$"/QC<^(]*\%ZQI<UZH6]AMY0R3X[_-&=IXZCGKC&35
MN74_'A\<)XJM_ .J6]W]E%I+&LVY)4!!&=R$CD#.#SCMS7T)51[Y7@OC9*+J
MXM,H8%<*3($#!,G@$AEY[9H \(\(:MX^\(#4U@^']_<C4+IKN3S9,;7;KC"]
M/:GZ)J7BO0M!U'1K;X57)LM0EFDG1IFY$F05X7H%PH]A7O-K)+-9PRW$!MYG
MC5I(2P;RV(Y7(X.#QD5-0!X/\-9O'FA:I8:/=^'-770Q.5C%Q(-MJK$Y)(0%
ML9/!..>F<8]XHHH **S-7UE-,EL;98Q+>7\Q@MHF;:K,$9R6;!P JGG![<<U
M)I=_<7FF"YU"P?3IE+B2&616V[21D,."IQD'CCM0!?HK!N/%$,>NZ#I\-LTT
M.L1R20W0<!5"1[^G4Y&/3K6GJ5Q=VNGS3V-B;ZY0#9;B58]_(S\S<#C)_"@"
MW115;4+^WTO3;K4+N3R[:VB::5\9VJHR3^0H LT5ST/B6Z+Z<;C1+J&#4'5(
M91(CB/*EAY@!^7(';<,\9K;BNH)YYX(I5>6 A95'\!(! /X$'\: )J**AM;J
M"]MDN+:5987SM=>C<XXH FHHHH **** "BH;NZ@L;26ZN95B@B4L[MT %34
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M-RE<$_*1R": -^BL&'Q,ITE-5NK.2VL3,T3RLZML ;:)#C^ GOV!!(QDC>H
M**J:?<7=S;N]Y8FSD$KHL9E63<@8A7R/[PP<=LU;H **A@NH+F2=(95=H)/*
ME _A;:&P?P8'\:FH **** "BBB@ HK%\1:__ ,(_%82&S>X6[OH;/*N%$9D<
M*&.>3UZ#]*VJ "BBH9+J"*YAMGE59I@QC3NP7J?PR/S% $U%%8OBOQ!_PB_A
MRZU@V;W2V^W=&CA3@D#.3VY]Z -JBL6X\0?9_%]EH#6;YNK66X6XWC;\A4%<
M=?XQZ5M4 %%%% !1110 4444 %%%% !1110 445#-=06\UO#+*J27#F.)3U=
M@I8@?\!5C^% $U%5(+B[DU&[@EL3%;1!/(N/-5A/D$M\HY7:>.>N:MT %%9T
M6IR1P7$VIVPL$2Z\B(O*K^:I8*C\=-Q(&T\U-)<7:ZK#;I8E[1XF>2Z\U0(W
M!&%V]3D$G(Z8]Z +=%%% !14-Q=06OE>?*J>;((HP?XF/0#\C^534 %%%% !
M16+XGU__ (1K21J#6;W*>?%"P5PNWS'5 3GW8=!6U0 4444 %%%% !114$EY
M#'=+:[P;EXGE2$'YF52H)'XNH_&@">BL?POKP\2Z&FIBU:VW2RQ>4SAB#'(R
M'D<<[<UL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!&00>] '#_#
M[_D+^-O^P])_Z+CKE=:M =/^)>I)<74-U8WGGVS0W#QA)%MXB&PI&3QWS^IK
MU.PT33-*FGFL+*&WDN&+S-&N#(W]YO4^YJ%_#.B/'>1OIENR7K;KI2G$Y]7'
M\7XT <==33>)/%&JZ'=:E%9LFG6\MHKAPV'5B\T>V1?F#8&><8'3)SUVG/<V
MOA*%UO/[6NH;3*W.S;]J95X;&3][ [\YS2:CX2\/:NEJFHZ/9W0M1B#SH@VP
M>@SV]NE;"JJ*%4!5 P !@ 4 >4I>73_#WPSXIL+N>76IKJV\]O-8_:6DD"2Q
M,N<;02V!CY=O&,5%-H\%[9?$+4'O[VTN+'4IIK>6WNGB$3K;Q,&PI ;H!\V>
M.F,UZ5;^'](M;PW<&GP1S&0RY5< .>"X'0,<G) R<FDD\.Z/+?O>OIUN;B0J
MTC[/]85^Z6'1B.,$Y(Q0!R&FW>I2>-O#TMV\XN;CPT\]S;&1@GG!H<_)G .2
M1P*I>&!/KVE>'?$G_"21P7GGK]L1(W+SNV0]NX,F!R>/E^7 ( %=3IVDZG=>
M*(M>U>&UMIK>SDLXXK>8RAP\BMOR57'"+QSU/I5^V\+:#9ZU+K-MI%G%J4N=
M]RD0#DGJ<^I[GO0!R/A22W\1>'M(U^[U:YMM52_/VKRY2"TF]E-LR'.$Y&%P
M.@/J:HZ1906WAKXB26\D\$\=_?B-XKAU9=L2,""#G.<'/6N]A\,:%;:W)K4.
MDV<>IR9W72Q .2>ISZGN>II[>'=&>6^E;3+7S+]=MVWE@&88QACW''/K0!PU
MW-)I&B^"?%LMS/\ 9((+>#4@TS;#'+&JB5AG!*.5.<=":LZS>S:;8Z))/<FS
M@UO52;N2<N5B1HW:*(_,-H)$8."!G.>":[<:3IXTH:7]CA^P!/+%N5R@7^[C
MTIVH:=9:M8RV6H6L-U:RC#Q3(&5OP- &-X7TN32+K5;=M8%[$\JS1VRHP6SW
M#E 6=C@XW;<\9Z8(K)M\>(_&/BS2]3EFC6Q6WCM%25HS%&\98RK@CYBV?F[;
M0/6NLTK2-.T.Q6RTNR@L[922(H4"C)ZGW/O4=]H6EZE<K<WEC#+.J&+S"/F*
M'JA(ZK_LGB@#S&P,^OQ?#.^UKS)+VYDN$ED$C)YBK#+L?@C!8 -D=<UZ#XU@
MCF\":]%(I*#3YSC<1TC)'ZBKUUH>EWL]K/<6,,DMI_Q[N5YAXQ\G]WCTJ])&
MDT3Q2HKQNI5E89# ]01Z4 >6II]M+>?#6U5Y5CEM)S)Y<S!N;521NSD9]B*J
M7\US;_"WQA#%>WB#3-8F@M7%R^^.,21X3=G)&'(P2>*](M_"VA6C6;6^DVL1
MLL_9BD87RL]=N.F>_K0WA?0GL[FT;2[9K:ZE\ZXB*965_P"\P[GIR?04 <CX
MUN+W3M1U#4I[=]0T..V1+@VEP8[G32,L957@,"&!.#GCG(%=KJ\FGMX>OI=1
M57TTVKM<!AP8MIW9_P" YIDWA[2)YS-+81/(R*CDY_>*OW5<?Q =@<U>N+>&
M[MI;:XB26"5#')&XRKJ1@@CN"* /-5L]:^'6HZ1!:ZB=8\+7M[%9QVMW\T]F
M7.$,;_Q*/0] ./6DL!I^CGXCWTMW/8B*Z<?:(6+/&&MXR652<%LG(S7>6OAS
M1K*YBN+?3H(Y(<^3@?+%D8.Q>B<<?*!3I/#^CRW5Y=2:9://>Q^3<R-$I,R8
MQM8]QC _ >E '#Z6LB>-+K2I0T-E<>'EF>U^U-(6;S"H=CT#D'!QG/J:Q_#M
MVEEX3^'^G?:H[6TU.!S</,S,CRJ@\M#AUP&^;C(!*C@UZ98^%]"TVX@N++2+
M.":WC,44D<(#(IZ@'K3&\(^'7TB323HMC_9\C^8UN(%"%_[V/7WH X;5].NM
M(TJPM%\17-UCQ-;(ODN\?V>.1U)@.7;>!G(W$XR*E&C0R>)?&.DM=:C]@@LK
M>ZBA^W2_)*ZR[F#;MW\ .,XSSBNW'AC0QIUKIXTJU%G:.)((1& L;@Y# ?WL
M\YZU*= THW-S<FQA\^Z01W$F/FE4=%8]Q[4 >>:3K%UK/_"(Z9J5_&B7V@+<
M@W(8BZG^4-G:ZY8+SC)^\3C(!$DFGW-K?^"=,E\17NHJ;V[MY;B*:2+S46&0
MA#ACDKC;NSGCJ#7;7?A'P]?:5!I=UH]G+8VYS# \0*Q?[O\ =_"K#:!I#&R/
M]G6X^P#%IM0#R.,?)C[O''% 'E>M0+_PK[QI822SRVVG:[&EJ)9G<Q(6@;;D
MG) +MC/3->KW;-INA73V$1EDMX)&AC+%BS $A<GD\\5%_P (WHOV>]MSIEL8
M;X[KI"@(F/JP[GISUXJ_;6T%G;1VUM"D,$:[4C1<*H] * /,%NK@>"O!_B73
MKR>75KJZM%N6\TG[5YIVS1LN<8!+$<?+MXQBMGP[I]LGQ3\72JK[XX[)E_>L
M>627.1GG\>G:NIM?#^D65V;FVT^"*7>T@*K@*[?>8#H"<G)')S4D&C:;:ZC/
MJ,%G%'>3X\Z=1AI,<#<>^.V>E %;Q3H<?B3PMJ6CR8'VJ!D5C_"_56_!@#^%
M>4S:KJ&K>&])\?3),ESX:EAAGB((+XREX0/?<OT\LU[;54Z;9-83V)M8C:S^
M9YL.T;7\PDOD=\EB3]: .(U_4KS2/AM<ZU$TD$^H7,<]Q,.'@AED5<^Q6+:N
M>Q&>U6KFW?3/B'H]CILD_P#9^IV-S]L@69RJ>7LV2J<Y5B7VE@1G([BNSF@A
MN+=[>>))89%*/&Z@JRG@@@\$52LM"TO3HWCM+..)701'&<[!T4'J%&3@#@4
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MO#$T7@J/6-*N=1FU6)+?4#&][*RW)C4%XRN< .H(P!C./2NL'A'PZ%E T6Q
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M*=\+K:6#P);22*56ZGN+J)3VCDE9D_-2#^- '0G7M-%XMI]H)E:0PKB-RK2
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M)%YA@#+NSC.W.<?K0!9HKB[#Q^UUHUKJUSH[V5C>QP_9)9KJ/$LLA(V$=5
MW;CV!^AEM_'UIMU5;NV*36$D,:BVE$T=R93B,1/A<DL=I! P>O'- '7T5S<7
MB2]_X24Z#<Z5''=&P>^C=+K?&RJZIM)V @Y;T(^N>*UIXYCN])\,ZDM@ZP:[
M.L" RC="S*[#(QR,(>_I0!U@()(!!QP?:EKAE\4V.D6'C#5K?098Y=-NB;Q%
MD7=<,(D.\G.!\I'KTJ^?&,L/E)?:8MA+=OBR^U7B*LR! S.Q&2@&0,8)R1^
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MHLB_*,8((DZYXQT-=;10!P]KX3U:XT70=$U=[-K71[B&7[3#(Q>X6'_5@H5
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M+56O!!+(S1O"^P-&^8^#A3S@C)J_X/\ #+>&8M1ACVP6=Q<^=;6,<K2):KM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQP0?ND\'OVI--\3>)]7N],TY9]/M+F9+^.XF-JTBF6UF2/<HWCY6W'CMSR:
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M/+<=> 0/4D5RGBO5=2G\-^,=(FE7?IZP[;E8\>=#*,[6&<!AR"1P1C@9H ]
ML[^SU"-Y+*[@N41RC-#('"L.H..A]JL5!:VJVZNQ6(SRD--*D80R-@#)QWP
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M[]\2%&20!ZFEH \[T'2+VZLKW3HKM7M+JQ:U>XFT::UEA 7:@!E?+@!FPH
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M&B@ HHHH **** "BBB@ HHHH **8DT4KR)'*CM&=KA6!*G&<'T.*?0 4444
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MT4";YI4C3(&YV &3P!S0 ^BF3316\32S2I%&OWG=@H'U)H$T33-")$,J*&9
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MK3/YC-&04.\'(VD C&,'ZFHF\(:,VLC51#.MR502;+F0)-L&$,B!L2$>K T
M85KXKULW5M)<#3S:/KDVDO''$X<A2X60,7(!RHRN#G)Y%:.DZQK6NV-GJ=BV
MFI8WBS;4E5_,B()$9X;#_=.X?+CL>.;R^$M'5440SX2^.H+_ *3)Q.227^][
MGCISTJ.W\,6&BRWE_I%HYNG\R6*VDNY! )6!)*J25C+'JP7N?4T 5?#?B.]U
MU;%'6WCN8HI/[5B"',,RML"+\W&65R"<Y"]LT>(?$UQHNLV]M*([6RF2/R[V
M:!I(C*7(,;LI'EG&W:6&"6]L'2T'3'LQ>7MS;6\%_J,PGN4@;<JD*J!=V!NP
M%&3@<DU)?Z#8:G/)+=+*XEC2*6/S6$<BJQ90RYQU8_7H<CB@#DAXBUJQEURX
M>YMKB*'Q#;6"1/ PV1R?9U."'XP)">AYR>^!>N/%UY;ZCJ&GM';^<NL0:;:/
ML8*/,A24LXW<D MT(S@=,UKW7A+1[S^T?-@E']H2)-/LN)%'F)MVNH!PK#8G
M(P?E%0OX)T.6"\BDMYW^URQSRR-=2%_-C "2*V[*L-H^8<^M '*P:AJ?AZZ\
M7:@GV.2.WUF![XK PQ;FW@WNH#<,H.XYSG!KNM*O9M0-Y.6B:T$[1VS(I!95
M^5B3DY^<,!@#@ ]ZRKG0)--ANUT2S2XEU1]M[)?7DC #R]F_:P;>0 HV\9]:
MW=.L+?2]-M=/M4V6]M$L,:^BJ,#^5 ')1>,;Z73M+UI(K=M.OM3^P>2$;S8U
M,K1(^[=@G<H)7;T/7CG1\)ZIK6LPS7E^U@MJD]S;+'!$ZN6BG>,,26(P0O3'
M7G/87H/#.E6UR9HH'4?:&NA#YC>6LS9RX3. 3DGZG/7FK.E:19Z+:O;6*.D3
MRO,5>5G^=V+,<L2>6)/XT <QJ/C&]M]-UO5[6*W>RT>^^RS6[(QDE5=GF,&W
M84_.<#!SM_VN,+4[G4KY+MKJX@G:V\76D-J#$5\L!H<#.3QSZ9SDYYKNY/#.
ME2WMQ=- P-S(DMQ&)&$<KIC:S)G!(P/K@9S@5%/X1T:XN9IW@F#S7<=ZX6YD
M5?.3&UPH; /RKT'.!G- &+;^+=3$TFF3QV\NH#5Y-.26&+:C*MN)]VQI.N#M
MQO\ ?VIKZYXM^WZ7I;0:7:WMV+L,TJ-(H\K:4?:LG 96&5R2/4]]F[\&:)>P
M7<4UO*?M5T+UW6XD#K.%"B1&#91@ !\N.!5B'PSID%S87*1SF>Q#B&1[F1F^
M?&\L2WSDX'+9Z4 1^)=7NM%TZ"ZAMI)H_."W+Q0-,T,>UB7$:D,P!"@@<@$G
MG%8%IKNIZCXDT]K75+&:SET26Z'E0,8Y'$B#</G!_ ].1U-=A>Z?#?B RM,C
M02>;&\4A0JVTKVZC#'@Y%4H/#&DVUS9W$%LT<EG$\,165P"CL&8,,X?+#/S9
MYYH YRV\<W2V&AZA>0P?9[W09]5N%B1MRM$L3$*2W0B0\'G@<U6:?4+GQAH.
MI3FQ,MSH5Y*BI"V%),#;6.[YP,CT[^O'167@G0K![9H;>9A:PR00I+<R.J1/
MC='M+$;<*!MZ"DM/!.BV+V[0I=_Z-#);P!KV9A%$^-R*"W ^48],#T% &'IG
MBC5M0T73[?1=/M%OO[#MM0\E8P(<RA@L:@R+M4%",_-C(XXYO_\ "57D?B*U
MTV^BBT\7#1>1YL3.EQN0%T293M#AL@*1R!D9SQ<D\#:"\>G(D%S"=/A^S6[P
M7<L;B'_GFS*P++P."35YO#VG-="<QR$"6.<1>8WEB1%"HP3.!@*.G' /7F@"
MAXAU36+76])TS2FL5:_6<&2ZB=]C(FX'"L,@],56L_$&MZC=QRV=E!)81ZA)
M976[:I549HVD#&3.=RYV[.0>OKOW6D6=YJ=EJ,R2&YLMWD,LK*%W##94'!R/
M4&J47A32(-;FU:&&:.XF?S9(UN)!"\F,>88L["WOC/?KS0!BVWBO4[U/#=]!
M]C6RUNY>%(VB8O$GE2NC%M^"?W8R,#KCMDKHOBS4M33PLTD=HG]L6L\DVV-O
MD= "-OS=.>A_.EN?!D-AK.B7&C6TJV]MJ+W<\373&.-6BE0B-&;"Y:0'"@=#
M["M.S\&:+87-K/;Q7"O:&0VX-U*5A$GW@HW8"^W3]* .=TWQ'K=SIWAJ#38=
M(M)-3CNMP-N_EQ-&21M57'![C/OGM6E8>)-9OWM[^&RA;23<3PW#':K1K&S(
M'!\PDG<G*[0?FZ\<ZMGX3T>P;3C;PS)_9OF?9<W,AV;_ +^<M\V??-%IX3TB
MQUB?4[:&6.::1IGC%P_DF0]9/*SL#'UQF@#EH=0NM<U_P)K<HMEAO?M$T4:1
MG?&K6[,JE]QSQUX'-:/B:*\;Q[X<.FO:Q7C65\HFN(BZ@?N>JJ5)^F1U_ Z5
MEX*T33[FTFMH;A/L<KRVL7VJ7RX"X(8*F[ !R>,8YK1U#1K/4KJUNIA*ES:[
MQ#+%*R,H?&X<'D' Z^@H Y+3O&^H8TRZUF*SM;"X^UVMQ)&C'9=0,PX8M]QE
MCD(XSD8R<UMZO>ZM:_#Z_P!09XK?58M/DN,K&2L;A"V,%CR.G7KS[4V]T)KI
M[+1DTRS708&BN#*TI,GF(^\*$*]R%)8MSEN.<UO7=K#?6<]I<QB2">-HI$/\
M2L,$?D: //)'U2'Q):W=K-9G4!X9>5YIH&97Q(A *AP2>V=WJ<=JTD\6ZQJ]
MLBZ)8PO>C2K;4#%+@JS3!B$R74J/D(W8;KTXYW(O">DPNCK'<ETM#9!FNY6/
MDDY*Y+>O?K[U!+X'T*7[ 1!<1-8VXM87ANY8V,(Z1NRL"Z^S9_6@#/\ B4?M
M'PIUR26)59K$N4)#;3P>O0X]:35M._XI_P 03W6BV%HR:5-'%);MOWJR,6!.
MU>ZKQC\>:Z35M&L=;TB;2KZ$O93+LDB1VCROIE2#BI+K3;>]TN73;@2/;2Q&
M)QYK!F4C!&X'/3OF@#S;Q!96NF?"#3-<T^&.UUBRL[26TN(4"R-(=@V''W@V
M2"IX.:VO'IN]4M_[/L'NHKRSB74(S;PR2 W"MF&-BH(VDJQ.?]DUT%OX4T>W
M^Q#R)95L=OV9+BXDE2(J,*55F(R!T.,BK]IIMM93W<T/F^9=R>;,7E9LMM"\
M9)V\ # P.* (=!UB#7] L=6M^([J%9-IZH3U4^X.0?I7#&_EL=3\1W5\MG>2
M+K]K:V@EMSB&5XK=4?)8X"AV.!R3GD9KN=&T.PT"UDMM.CDCADE:8H\SR ,Q
MRQ&XG&22<#CFJTGA31Y8M2BEMGD34I!+=*\[G<X"@,.?E(V+@KC&T4 <]J_B
MW6=*O+_3_+LI;FVGL#'*8W5)(KF;RL$;B592&YR01CBMCQ!<ZQIO@#5[MKJV
M&J6UE/,)X82$RJLP(4L2#@#J3SZ]*LS^%=*NK>2&YCGE,DL4TDC7#B1VB(,>
M6!!PI ('3//<UIWEG!?V$]E=1^;;W$312H2?F1A@C/N#0!Y]<R:I:^)A>6DU
ME]O3PT9GEF@8J^V3(!4.#[9W>^.U:?\ PE>LZK"5T*PADNTTZVO3%+@J[3!B
M$R74J,+C=AN3TXYVD\)Z2C;Q'<L_V,V)9KN5B82<E22WKWZ^]03>"-"E>Q?R
M+B-[.W%K&T5W*C-".D;D,"Z^S9_4T 6=;UN32]*M;A(0;BZGAMXT)!"O(P')
MR <<]QDX&1G-8EYXEU_2+5I=5L%A@2Z97NX8#/L@V961XD<L!NRI()QC/?CI
MM5T>PUK2Y=-O[=9;20 &/)7&#D$$8(((!!'3%5+?PQ86L,*0R7H>(L1,UY(\
MC%@ =S,Q+< #!SC QC H YV/Q!JC:Y>SKJ.G2V<7A^&_C4Y2!G8RY;S-W"DH
M#N(/R_B3E^(];O-5T36;&[A@=[&YTR6"3R&AW>9.G56)(P5//!P>GKV$W@O0
M)HQ$UB1%]A_LXQI,ZH8!G"$ X.-S8)Y&>M)_PA6B%+H20W,INXXHYGDO)69Q
M&VY#DMG<#R&Z\4 <GXKU/4KCP_XKT764LY9;*WM[F&XMHV1621R "K,V&!C;
MG/((Z5NWNM7]IX@\116FG6]S/:6%K/#Y47[Z0.\H*L=WS[=A*J,9R1WK7N/#
M&EW>GW=E<Q2S1WFW[2[3/YDNW& 7!S@8Z @=?4TLWAK39[NYNW2X^T7,<44L
MBW,BDK&Q9,8;@@DG(YY- ''3ZLVOZQX4O;*ZM)9UU2YA21K9XS%BTDRLD;'<
M&!SE<C/'3-7-.\5:[J4VCVB?V=%/>&_AFE,#LJR6TOEAE7>.&Z[2>/6NC'A;
M2A>07ABE-U#<-=++YSAC*R>66;!P?D^7GC%,M/".CV5Q;SV\,Z26SSO$3<R'
M:TS;I#@MSN///X8H Y[2O&6KRIH%YJ$=E]EU)+A)8H(W#QO"CL6#%B"#Y;?+
MC(R.35B'Q)XBGTG^UUL;06$VEO>12-C]W(%#JG$A+J5SR I&,XYP-JU\):/9
MKIRPP3*-.>22U!N)&V%P0V<M\V0QZYZU#8^"=#TZWNK>V@G2WN(WB,)NI2D2
M/]Y8U+8C!_V<4 <IK'BWQ#'X>U$F:RBFE\.-JMO)!"P:%@ &4Y8[OO @X&/0
MUZ-:B86L7GNDDNT;F1"H/X$G^=9$G@_1)8_+EMI'3[ VF[6N)"#;GJGWO8<]
M>.M:]I;1V=K';1&0I&NT&21G8_5F))/UH FHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI\RD$9.<9R.E10>)3;:OJ%C'86<%Y<ZX+!)$4X<_9DE,LG0LP4;<<9PHSWH
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MPVZ*W^M=SA0#Z<Y)[ $]JRI=<U0>+_[ AM[-V&GB]\YW903OV%< ''/.?TH
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M'5$499F. !ZDU$E[:2M L=U"[3QF6$+("9$&,LOJ/F'(]1ZT 3T444 %%%%
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M:A"+>Z87$@\R,9 7 ; QN;ICJ:8WA/1G&&MY3_H1L/\ CYE_U!_@^]^O7WH
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M;L[WD*P7 EF>19$4$ %6)'0D=.YH Y7QL=4?P'X@^W3V%Q:2::)8&A4JX?\
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MS21?NATC;:PWK_LMD=?4T ;D+F2&.0@ LH) ;(&1Z]ZX]_$]^=<O-*F=;"Y
MG-JDUL66>-5)5XI =K$<%D."/PR>AL-(CL-5U&^C=P;TQEHS(S*"@(R 3A21
M@$  ?**2/0--CNA<^2[N)))5$DSNJ/)G>54DA<[FZ#N?4T <MX8U[5+VP\.:
M4;N+[;=:&FHRW4D)8GB-0,;N3EB6.>W09R&67BOQ!K4FAP6?]GV<U_;7AF,T
M#RA);>5(R5PZY5BQP.HXY/2NCA\(Z+;6]C#!;RQ"Q#+;.ES*'C4@ J'W;MN
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MK;F&/:\,AA!#';G(\PD$$>^:W+6>2#XGZA9QY^SW&E074B]A*)'3=]2H _X
M/2@#J:KW]];:9I]Q?WDGE6UO&TLK[2=J@9)P.3^%02W]U'*R)I%Y*H. Z/"
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M8*KE58+N(VDX93@$]165X=O[^;5=>TV\E-PFGW2)!<LH5G5XEDVM@ 97=C(
MX([U5TVPBU27QA93,RQ3:H%<J!G'V:WSC(./KV[<T =(;RV6V-R;B(0!2_F%
MAMVCJ<^E12ZG:0:G;Z=([K<W"LT2^4VU@O)^;&W(],YK NO =A<^%[70C=70
MAM<-#(969@RC"$DG< .,A2H/L#BK&IQK#XK\,1KNVJ+D#<Q8_P"K'4GD_C0!
MT=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJQP>1;W,UOOV+GA3@AMO7@$=:GTJP.GV9CD=99Y'::>54VAY&.20,G [ 9.
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MII_Y=3"OE=<_=QCKS6C10!GQ:%I, M!%IEI&+-2EMLA4>2IZA>/ESWQUI(M
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M O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>T+3O;SM;W 0RL%GC )$PP-N"?FV@C[W/IU1/;6[O&[P1LT?W&* E?IZ5+0
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M,<C(RW7'J1W(% 'L-%>+:BVJ0^%1:WT5_P#VQ;:)#)'-+%)*Y(D8C9M'R2*
MN]B<_=&.,UU,-U:WGB:_M=7@O_[0^WQ7.F21PR+NM]B;0KXPJY#[U..ISUH
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M DA21D^0ALY*GI_*N6GTQ;7_ $>%K@:(WB2 V:B5\"$QCS<'/^JW[O;KC@T
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MVZA')<A)%F79=V;"WVEMP^62$@<] &;C)XKT&@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***PO%'C'0_!UE%=:W>BW25M
MD2A2[N1UPH!/'<]/SH W:*HZ/K&GZ_I4&IZ7<I<V<XS'(N>>Q!!Y!!XP:O4
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M<_7CMTJW-?6ENF^:Z@B3;OW/(%&W(&>>V2/SH GHJ&6\M8'B2:YAC:4XC#N
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MQ5!("3@X/'7@\&@"Q15'3-3CU**?:OESVTS07$1.3&XP<9[@@A@>X8=.E7J
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M$3)!&4CB,C 9VD!&< ^P.#D5072KOPWXZT^[M%NKNQOK3[%>;(!M@\OF%SL
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2Q/!8#;C/0N/6G>.O#K>'O!.A:]H]_-JDOANX4RRRR;S<P"3E7QP0IP/89H
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M(<'WP1Q[B@#T;3KQ[S2K>]FB6W,T0E*;]VP$9Y.!VK/\+>*=.\7Z.=3TQRT
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MXDE+J>ZL/-((]"#2V6JB:]^'&D:[,?["O-&;<9F_=R7#(RC<3P2/EQGH6!H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIGRS=AU,.< [5 8$8 [CI7L$?B[0I?#L.OQWZMID[!(9MC9D8MM"JN-Q)8$
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M\'?&&D+(NF>/!9+*VZ06UGY8<^IVL,FJD'P*\16U^;Z#QE#%=%_,,J6.#O\
M[WWNOOUKW6B@#Q>3X0>,YM0CU"7Q^9+V)=L=RUIF1!Z!MV0*@N_@GXHO[U+V
M\\:PW-VF-L\U@'D7'3#$Y&*]OHH \4;X/>-)KZ2_G^(#M>2V_P!FDD:!F+19
MSL)+<KD]*?IOP@\::/:_9=-^(+V=ON+^5!;%%!/4X#8KVBB@#PT? WQ(!= >
M,;<"[_X^0-/'[[G/S\_-SSS1<? [Q+=Z;%IUQXSADL83NBMVL1Y<9]57.!^%
M>Y44 >(WGP6\6:CIL>G7GCI9[*/'EV\EGNC3'3:N[ Q[4V?X)>*+JTMK2X\:
MPS6UK_J(9+ ,D7^Z"<+^%>X44 >(+\$_%"374R^-8EENU*7#BQ :93U#G.6!
M]ZDL_@YXPTZ.:.S\?&W2?B58K4J'&, '#<C'&/2O:Z* /";;X#Z_9F!K;Q=:
MQ- YDA9-. ,;'&64YX/ Y'H*MVOP;\76-[->VGCM;>[G_P!;/%9;'D[_ #,&
MR?QKVNB@#Q"Y^"?BF]U2+4[KQPDU_#CR[F2RW2+CIABV>.WI4D'P;\86VJ3:
MG;^/C%?SKMFN([4K)(./O,&R>@Z^E>UT4 >+7GP?\9:A<6]Q>^/OM,ULVZ"2
M:TWM$?526XZ#IZ5D:G\"_&#V"VEIXIL9X#<?:7AEB:!/,QP_RALMR>37T!10
M!X;:?!CQGIEI<_V;XVBMYKE<S)%;F-9&QC#,#G';I^%4-%^ _BRP$$Q\4V5E
M<6S$P-;0M*4SSD,0I!Y-?0-% 'BB_!OQ<FJ-JB>.U74&&&NQ98E(Z8+[L_K2
M:A\&?%VK.CZAX\^U.BE%::T+D*>J\MT/ITKVRB@#QV7X5^/)[1[27XCSO;.A
MC:)H&*E",%2-V,8XQ45]\(O&FJ6GV34/B"UW;9!\F>U+ID=."V.*]GHH \0_
MX4GXI$D\G_";1;[B(0S-]A&9(P  C<\K@#@\<"HA\"O$2K:*GC&!!9R>;;!+
M +Y+Y#;DP?E.0#QZ5[I10!XS??"7QOJEH]IJ'Q#>[MGQNAGMBZ-@Y&06Q54?
M!+Q0)9)!XUAWRPBWD;[ ,O$!C8>>5P!QTXKW"B@#PM?@5XA5;=5\7VH6V8O
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MA=IB4D&,JY!8EQTR!STQ7H7_  HOP!_T")O_  ,E_P#BJ/\ A1?@#_H$3?\
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MOK&DS^$_B3?)JUBIUZ]4V%HUR@E=5D)WE,Y7(;OCI7HTGP$\"7$J3107L<>
M=D=V2K>^3D\^QJPOP/\ AZY8)I<C%3M;%[*<'T/S4 <YK.J>'=9^!,.AV'B'
M1H-2&F6R&%[V*-B\>QFC.2.I5ASQD^]9,6M:+X@\9Z1?V_B'3K"UL?#9LII;
MFZ6']^Z.NP!B"VTL#D9''6N[_P"%%^ /^@1-_P"!DO\ \51_PHOP!_T")O\
MP,E_^*H \<E\1:>?A=X<\,^=!_:&E:WYMQB>/84W2MN5MV&'S]1QQSC(SU'B
M+Q3HMO\ $_7M2BU*SN[75/#DEI;R6]U$P\TA?E8[L+]T]?PS7<O\#_AY& 7T
MN102%&Z]E&2>@^]39O@G\.K=0TVG-&I.T%[Z0 GTY:@#S)]8LXO@_P"$&M-6
MTU]2T'4?MD^G/>1K(X61V& 3SU'3L3Z5L?$+Q3X7\4> &N="-A:3OJ4-Y/ \
MT$5Q,0&#,4#9)&0.>3SVYKMT^!_P\D!,>ER, 2I*WLIP1U'WJ=_PHOP!_P!
MB;_P,E_^*H W[7XB>#[FVCF/B728=XR$EOH@P';(W<?2O(-!\2:/IGACXD:3
M<ZG9">^FO)+5ENHV282(53:0W))/;IWQ7H'_  HOP!_T")O_  ,E_P#BJ/\
MA1?@#_H$3?\ @9+_ /%4 >7Z9K^D17'PMWZG9K_90G%\3.O[C<P W<^Q_#FN
MI\&^)O#$/Q5\;:A>ZQID=M>M$+6>:X0)(%SNP2<==OUQ73_\*+\ ?] B;_P,
ME_\ BJ/^%%^ /^@1-_X&2_\ Q5 'F^K:OI-BWQ(LAK6GW<OB!X9-.DAND=)
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MC[Q/IVK:MXLM+273=DUA"(KNSNH!]M==I)D<ODXP0$7TY!XQZ1_PHOP!_P!
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M- "T4@(/0YI: "BBB@ HHI"0.I H 6B@D 9/ HZC(H **0$'H0:7O0 4444
M%%-,B"18RZAV!(7/) ZG'XC\Z'D2-"\CJBCJ6.!0 ZBBB@ HHHH **** "BF
MO(D2[I'5%R!EC@9)P/UIU !1110 44UY$C7<[JJY RQP.:=0 4444 %%%% !
M12!E8 J00>A!I: "BBB@ HIID02!"ZAV!(7/) Z_SIU !114<,\-PA>&5)5!
MVDHP8 ^G% $E%%% !1110 444U9$<L%=6*G:P!S@]<'\Q0 ZBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *H:IHUAK4=O%J-NEQ##-YPBD4,C,%91N!X(^8GZ@5?H.<''6@#S#P;X7T3
M4;[QC#/IEK^YUMXX'6)0T "1D;#CY<'G XJ*TUJ?PG=^.[^ST>.XLK34UGN0
M)Q#M3R(BQ0;3N;J<':/?-=;X4T#4-$U#7I[QK5H]3OVO4$+L3'E57:<J,\+U
M_2LN\\':M=:9XQLQ+9*=?D+1-YC_ +H&-8^?EYX7/'KB@#4?5;1O']I:-I4;
M7#Z7+<1:AD%Q&'0&,+C."6!Z]J?X9\4MXFCMKNVM[<V$\#2^;%=>8\+@KB*1
M=HVOACW.-I'O4*Z!JG_"6:?K!>T6.VTM[%T61BVYF1MP^7& 4''O4&C^$;BU
M\3V^O7$5C:7@M7AO6L&;;?.=N'=2H QACW/S=>.0#3UGQ+'I>LV&DJMM]JO8
MI)(3=7'DHY0J-BMM.6.[IZ U!>>*FMGL[/[+#'J<]F+N2"YN#&L(X&TL%8D[
MLCI_"3QP"_Q-H4NO#[+/8Z=J&FO$RR6]XS(RR9^5T8*Q!QD=CTY&.<4^#M?T
MI]$O]$U:VFU*QT]=.NO[15S'=1@@@Y7YE8-G'7KS[@&AI?C1M:ATZ*STR2+4
MKN"6=[6[<Q"!(V",6;:2<L1MP.1SQ5'4?%.OE_"PBTE+&34+Z2"YM[J8JP*)
M(< A#\IV9#8R1CCGB;4O#/B$ZGI>OZ;J5DVM6\,EO=)<QLMO/$[!BHVDLNT@
M8Z].:L:MX=UC4$T.[%]:/J6G7QNI#)&PB8,CH54 D@ -QSSCGK0!%;^)=-T[
M4/&-W=Z9'8MI?E/>7$;!VN1Y093T'(7"@5;/BFYL]6TJRU735MEU4,MM)'<>
M9ME"[O+<%1M)&<$$C((^M";P3/J<WB^+4I81::^D2J822\12,("01CJ W7VY
MZU9A\/:K?S:$^N26;G1F,J-;LQ^TR["BNP*C8 &)P"W)'/'(!GK\0KW[!_:4
MF@".PBU0Z;<R&\!=&\[R@ZKM^8;B,Y(]LUU/B*Y2S\-ZG<RV:WL45K(\ELS
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MD6U_)?W-B _G9\N23;MFP4X8$D[1G'K3KV*YUGXGW^DZAI]G=Z:-&3]S+.2
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M0.N2"H VXX^N>W(KG-!9/%WC?Q--JD:W%II%RMC96LHW1QD+EY"IX+$G@GD
M8%==H-E<:;X?T^PNC&9K6WC@9HB2K;5"Y&0#SC.*Q&\-ZCI'BF^US0)+5TU(
M(;ZQNV9%:11@2(ZAMIQP1M(/6@":_P##.FV=IK=S!;QI%=V/ER6P7]WE Y#!
M>@/SG.!V!ZU7^%\$4/PUT!HXT1I+-'<J,%F(Y)]36O<6NJW>EWJRM;+<SPM%
M'"KMY4>01DMMRQY]!TQCJ3A:'HWBO0_"5EH5O)I >U@$"W9>0D <;MFWK[9Q
M0!3N[&TE^.-IYEK"^[099&#(#EO.49/O@D9]ZQK.YN?A_K5_JHRWA*\U&6&[
MA1>-.DW;5E4#I&> P[<'VKL'\/:C_P +"MO$*/;&TATYK#RWE;S&RX??G;CL
M!C]:O:7I,ZV6I6FJPVDL%W<2R&-&+JR2$Y5@5';CWH @\-6UG'JGB*:UA@42
M7Z$/$H^93;0-U';))_$FLB%8O$?Q,U^PU*%+BRTJQMXX8)!N3=-N9WP?XL*J
MY[ >YK6\&^%%\(:?>Z?%=//;27;36_F$EHX]B*J$GKMVX'L!2W.AWEMXFN-=
MTEK?SKRT6VN8KAF524),<@(!R1N8$<9&.1CD X'P_K=YKY\$Z)J$C7%NTU_]
MJ,G/VD6Q*1;O[W56.>I4&C6];O-&M_&V@Z?*T$,-_8PVK(<?9UN@OF!?[H!W
MD8Z%N*ZZW\"II5AX=_LV97OM$>1E>;Y5N/-!$P;&=NXMN!P<$#K2S^!4U'2-
M>COIU74-9G6X>:(9$#1A1"%SC<$V+Z9YZ9P "!Q%X>^)NB:=IL*6]EJ>GW"3
M01+M3=#M9'P/XL,RY[C'H*D\+1+!\0O&R(7V^99GYG+8S"2>ON36G:Z'=7'B
M:'7M5-N+BVM#:V\-NS,J[B"[DD Y.U0!C@ \G/":/HM_8^+-?U6<VQ@U,P%%
MC=BR>6FSG*@'/7V]Z )O%>OR^&M(&IK9K<VZ31I<%IO+\I&8+O\ NG(!()]J
MJ?\ "7^7XDUK2+BV@A.FV0O5E^TEO-C.>=H3Y<8YZ]1C.:W-3T^WU;2KO3KI
M=UO=0M#(/]EA@_SKC[?X?2JGAR:YU$RWU@2-0GQS>(5&4/J-T<0Y_A4^M %_
M^U=_C'1;6]T&"+4KC3IIH[@S!C!@IOB!VYY++D^W2N,UO5-2UWX<W]]JUI:M
M+;:['' 89"Q4I>+'M4,HQP,9SSDY KOKW1+VX\<:7K<;6XM;.UFMV1F;>WF%
M#D<8XV#OSFN>G\#ZTWAS4=%CNK!H9]6^WPNV]6"FX$Y#<'G(V\?7VH Z+2/$
M5U>>(]0T34-.6SN;:".YC,=QYJR1.64$_*-K J01R/0FI]9UFZTZZA@M[%)$
M>&262ZN)O)@BV[0%9]K89BW QT!/:JUKHM_'X[NM>E-L+>?3XK3RU=BZE'9M
MWW0,'>1^%,UC1-5N_%6FZK97-HUM;P20O;W:LPC=B")D ZN "O..">1F@"G;
M_$"UN]+\/7:10V[ZW&[PB\N/+C5E RF\*<L2>!CG!^E6;CQ;+;WFG:;+9V]O
MJ=[:M<+;W5WY:E@0/+1MIW-D^@XYK*TSP7J5IX1TSP]J,.CZM96\4L4\$P9%
M?)!C=6VL0P^;L/O<=,TK^!KI_#%KX?O8[#5[&*T\K_3'=7BEW,0Z.%8X (7L
M<*.1SD V_P#A(KFXU'^R[&PCDU&.S2[N8YYS&L._(5"P5B6)5NW &>X%5+#Q
MS;ZK9Z9]BM&_M"^FF@^R3/L\EX<^;O8 \+@#@'.Y?7B#3_"6IZ#K%KJ>GWD5
M]*=-BL+Y;QVC,[1?=F# ,0W)!!!SGKFJDW@&_LK73+W1;^W37+&\N+QGN$;R
M)S<$F5& Y Z 'DC:/K0!8UWQ X\,27&M^&-PBU.*U>WFE!1CYJJDR,5^9<LI
M' /!JQXD\:R^'%O[B;2_]"LGB4RS3^4UQOQN\E=I#[0PSR.01VHUWP]KFN>%
M_L-Q=61OY+N&X<KO6&,1R(X1."3G9U/<D^@K+\0>"=>U@>)(DOM/\K5DB\F2
M=7:2#:%_= C@)N4MD=R>,G- &H^OZG'\1KK2Y4M5TNVTQ;MG,S!@&=@6(V\D
M;,8STYSS@-LO')O-0TE%T[=9:H"8YX92[P?+N7S4V@*".X8X/'O4LWAK4+CQ
M8VJRW%HUM=:6NGWL>Q@W#LV4YZ'>1STQGGI4/AC0?%&D6]OH^H:I87&CV:^7
M!+'$XN98U&$1\G:,#&2,DX]R: ,#QCK#^(O"^EZG;Z="VFOK-K]GN7E_>[1<
M*OF!-O ;! ^;.""1U ]&U+3K;5M-N=/O(Q);W$9C=2.Q&,CWK@$\">(K?PM!
MX8AOM-?3[*]BGM+B4/YIC282!'4#&1C&0><=!UKTA<[1N(+8Y(&!F@#PN\C,
M_P )(M-^Q1S>(/#NHO;JH4#<UN3(Q/JK0K_P(D5Z3;/IOBO6-'OXK>&6UMK%
M;Q&9 <-,,1C\%63(]2IJ>S\(06GCK5/$8DRM];1QF#L)!P[XZ<JL8_ ^M+X+
M\*)X/T2;3XI?.W7,LJ%B?E0MB-,^R!1]<T <)H2:%;'QP;_P_-?"+6;C8+6P
M,KJFQ#M1E'RG.3P1C.:GLHO$&J?!S0;B"2+7;F"X6XNK7[0'^UP*[?N6?HS
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M=8TE-9.I_:H;[][%"BJ$MU/\ (4,2.02W?/ H WJ*** "BBB@ HHHH ****
M$90RE6 ((P0>]06EA9V"LMG:06ZN<L(8P@8^IP*L44 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB2,,S!5"Y8Y)QZGN:=110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!Q-F9[SXMZO%->WOV>RL+:2&V6Y=8@[F0,2@.&Z#J#
M570O'>I:KXUGT:32I7@MHBK7%IM:&5O,VF4,Y4[ !@@;CDL.< FWI/\ R5_Q
M)_V#;+_T*6NP^S0?:$N/*3S8T,:/CE5)!('ME5_*@#B-/\=WUYX[DT#^RY)X
MH(Y=US:%6BE(= &#.5QL!(8 MACCFIK8SVGQCFLX[V]:SGT5KIK>6Y>2-9?/
M"[E5B0O'&!@#M78-:6[7$5P84\Z%66-\<J&QN ]C@?D*Y _\EN7_ +%P_P#I
M2* -CQG=7>G^#-8O["Z>VNK2SEN(Y%56^9$+ $,",<5Y"_Q$\6:7\+="\:/K
M"WD]U>O;W%E/;Q+&ZAI "I158'">IZUZM\09HH?AYXA\V14,FGSQH&.-S&-@
M%'J3Z5Q'P9\/:%J/P_TBZO;*"ZU&TDE.)R7,#&5B"$)PI(P<X'K0!W4WCGP_
M97$=IJ6H)8WC6HNF@N%92L>W<3DC!Q@CCN".M/C\:^'IM+L-1AU)9;?4'*6G
MEQ.[SL"00L8&\X(.>.*\]U]+6X_:6T#SQ&\46FE3OP5$F)BH/;/(('N*L>)]
M.&B_&;P;JKQQ6GA^&VFME95"0P2E9>#V7=N7'KCVH ]"C\4:')H4NMKJ=N--
MAR)9V;:(R#@JP/(;/&",Y[56MO&WAZ[U"'3XK]A>3()(X)+>2-V4C(8!E!P?
M7I7B+:,EW\/O'^I:G=366D7NL_:-/E"%ED82, P'&4;<HS[9[5W/ADZ5KGQ'
MM?$#^)-%>\MM+6RBL=/N_,,F,EG)(4X&3P >@.>* .K?XE>#XHFDDUVW0+<?
M9F5E<,)?[NW&>._&!WJ[JOC+0-%>=;_4!']F*+<,L3R+ 6^Z)&52$SQC<1UK
MS;X/66G7NL^-FN;>WN&DU4R1B5 VY [E6 /;)SD>U<YXYO[>[N/B)I^GZ;<6
M$P$#3B."25KYED!,C,05C11DC&W=D'/:@#V_5?%N@Z(;+^TM3AMTO<?9I&SL
MDSCHP&.X[]ZH+\1_"+17L@UJ+_0CB=#&X=>">$V[F& 3D C KRGQ9<0S^&/A
M*=V5BDMC*&!&U5$08D'L"#STXJ[#/;K\8?B+.\D8C?1V1)"1AB(HPP![G(.1
M[4 >S:5JMCK>F0:EIMRES9SKNCE3HPSC\.01BO+_ (I^*/%GA+4QJ6CZ@7TN
MV%L]W:O!&PQ(\HX;;N"_NPO7.6%:GP*;'PML8B<21S3!D/5<N3R.W!S^-:FK
MVVE>)->\0>'+FZA+7FDP0E P+*P><Y ]5RK8[<4 ,\9>+)XO )U7P[<*MS=6
M;WEO,4#;(DC\QF*GC^ZGL7%5OAOXJN;_ .&L'B7Q-JRLTC2>9+*D<:(%D*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B)\*_&.'Q'>ZS:ZMHZ
MW%TBPNQVD&-"2@QY>,C)_.KO]F_'3_H-Z)_WPG_QNO8:X[XI75SI_P .M6O[
M*ZN+6ZMT5XI8)61E.]1V//!/6@#C_P"S?CI_T&]$_P"^$_\ C=9__"*?&?\
MX2#^W/[7T8W_ -E^R;_EP(MV_&/+QUYSUKT2QDT6?6K&#3=;NY;Q5:X:(7\L
MZ/&H"L&5G(ZNI'N*;/\ $72K>TOKQK'5#:V%V;2\F%N L##;EFR0=OS#H">^
M,8R <;_9OQT_Z#>B?]\)_P#&Z/[-^.G_ $&]$_[X3_XW7HEIXKLKG6I]*EM[
MRSFCMC=H]U&$26$':74YR "1D, >>E11>,M/?4;&SDM[R#^T8WDL99$7;<!5
MW$* Q8';R P!/UXH X#^S?CI_P!!O1/^^$_^-TATSXYD8.M:(1[HG_QNNUL_
MB)I%WI\NI&UU*#3H89I9+R:V(B7RWV,A()^8GD#'/U!%7HO%EHVN)H]Q:7MK
M>-;?:P)D7:(NA<LK$  \'/<CUH \NU?PM\9]=TU]/U#5M%EM)"IDB 50X!S@
MXCY''([UCQ?"KXCVVI6>H6B^&;6ZLY/-ADMH4B(.".=L8R.>AKV:/QEI[:A8
M6LD%W"NI(SV,\B+LN-J[L+ABP)7D!@,_7BJ=K\1-*NX["=+/4DM;V[-DMS);
MA8TFWE K<YY9< @$<C.#0!QG]F_'3_H-Z)_WPG_QNC^S?CI_T&]$_P"^$_\
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M= A!(W!F'. QVC)XZ<C(!N45S1\<:9)>VMI96][?2W=C]OM_L\.5ECRHX+$
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M/.TE61CM()'!PPSTK"\">)5C\*>#K/4&NIKS5K9O+N'.\,Z(SMN8G.< \XH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7*_$?2M0UWP)J6DZ9:FXN[I%1!O5 ,.I))8CL#7544
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M;KSS8RR+((W>+>/,5&/"L5R >WUK=HH \MN?!FMZ@/%T,%A%IJ:I%9S6<CW
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MW<G(/'J>)?"][J3+);:;);ZO:V2+8:KIDZ0B.7YLQNI8$Q [3C!X+=^OH5%
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MAX<TR_\ "FB>'?#\-H+RWBA,=W>"8((2%R"%/+!F) QT%=-10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2PW$8SC!QUQ6.;>XD^'?B3PK?VTKZ_)=7/DH4.;EY)2\4R'H5&5RW\.WG&*
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M2 W )*D;@<-@X/;I52#X@Z9<:CIENL9,.J$K:3+*C9;&Y0Z@[DW#IGZ'!XH
MZZBN5L/&T5_J4^EII=VFI07?V:6T=D#HNW=YQYQY>",-W) QDT_1/$-_J?B[
M7],FL3%;:=)%$CAU/WDWY/?)##CMB@#IZ*R-1UY++5K?2X8?/OIX9)TB\Q4W
M(A .">K?,,#V.2*R8?%.H7/C>QTE-,DCM)M*^W.7=0X+.@Y';;E@1U)/3B@#
MK:Q= T#^PGU-A=M<?VA>/>N&0+L=@ 0,=OE'7GWJE9>,X;O4=*MI-/NK>/5O
M.%F\N Q,0).].JY )'7WQ4-[X\M;2TGOX["YN;"&_P#[.:6)D#&;=LX#$#;O
M.W<2.>V.: .MHKE]:\;6>C_:U,!EELH%GNH?/C1T!&[:H+?,^!G XZ<\BMNV
MU:RNM%BUB.8"QDMQ<B5N (RN[)].* +M%<S'XRMP^D27-C<6UEJ[K'97+E2&
M=AN174'*%ATZ^AP>*P;&%O%?C#Q)::O83B.QN;=;:59PK6N(ED^4J<@LS$DC
MJ#@]* /1**YCQ)XAO])\0>'M/L[$SQZC<2)*V]0<+$[;1GOD Y]!COQRVC^)
M!X53Q?=36%]=6-OKSF>=9 P@C,<(S\[9;!.<#.!^% 'J%%<]K?BZTT>XN+98
MUN+FV@%Q+%YZ1D(<X W$;F.UL >G)&1G3TG4[37]%M=2LR7M+R(2)N&#@CH1
MV/8T 7J*\Q\,:XOAWPQXQUJZCO+V.PUN]C"B7>Z0HP"J-[<*/0?D:ZNT\6&Y
MUUM)DTF\MYWLVO+4RLF+A%(4@88[3EEX;'!YQTH Z.BN(\/^.GN_"EAJFJVR
MP7%_<216\?FH%<AI#C<2,!53DG&<< D@&S;?$+2YM-O;AHI5N+2]2Q>W1E<O
M*Y CV,#M*MN'.1CG.,4 ==6+IV@'3_$>K:Q]L:1M2$0DB* *GE@JNT]>A.<_
MI5$^,UCOM8LIM(O?M&DVXN+CRGB9&1@6786=2<A6[#[I]LQ67C=[VQM+M?#^
MI)#??9Q9NP0K*95)YP255<')(],9R,@'6T5PVM>/)HO!^JZEIU@WVRPOAI\Z
M2.N(I"Z+N!Z,/WBD?7G'-:NJ>,(-,:2!K8->PVXN9K=KB-"BDL  2<,QVM@#
MTY(R,@'245S5KXPLM9AL5TB&6\EOK/[8(]PB,<6=N7)Z$ME0!GD'L,U0^%DC
M2^"%=UE4F^O/EF;<Z_Z0_!.3R.G4T =I61XGT)?$WAZZT>2Y>WBNE"R2(H+!
M<YXSQV%<+=MIJ_$CQ/;ZKJ5U:VD>GV\L*Q7LL91VW[C&JL/FX' '6K7ACQ=K
M6F>%O#-KXATO4;O6=3$R1X5%=M@=D#AF!#%%7DC'.21S0!Z)$KI$BR.'<#!8
M#&3]*?7.1^*9+@R06NCW4M];VT=Q=VA=%:#>"5CSG!<X/'3U(R*+;QEI^IVN
ME2:4KWDNJ1O+;Q9"%43AV<G[H4D*>IR<#- '1T5YEX4\1#0].UJXN[.[*3>*
M'L]C2!WA9S&BY);D GL3Q772^+K&UU+6K2]22V72+9+N>=L%&C?=@K@YS\AX
MQZ=: -^BN>_X26Y6ZDM9-"O8YC9M=P%BNQP#@HSCA'Y''/'0FE\%:U>>(?"6
MGZK>V_DRW,*R\$$-D9XQT';GGB@"WK>C2ZPEO''JU]81HY,JVC*IF4C!4D@D
M?48/Z8TH88[>".&%%2*-0B(HP% & !3Z* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7#^+?\ DI/@
M'_KO>_\ I.:[BL'6?"T6LZUIFJMJ5]:W&FF1K<0>5M!==K$AT;/'% '-?$51
M:>*?!&HV0VZHVKI:Y7[SVS@^:#ZJ!@^V:FCU[Q+K-M_:FAV[O''J$D!MI/)$
M+P1RM&Y+%O,#X4L#TZ#!ZGHK;PQ9Q:TFLW<]SJ&HQH8X9[IE/DJ>H15"JN>Y
M R?6L^+P'96VLW5[:ZEJ<%I=S&XN=-CF MI9#]XD8W $]0" >_'% %5O$&HZ
M;XDU_2K^Y,A%HEUI(6-5,BL=A3..6$A5?HR\4MSJNMW&IWNA6,T[7NGV4,DE
MQ#'#^\FDWXW+(0 GR=%YYZC'/0:CX?L-4UC2]4N8R;G37=H"#P=PP0?49"D>
MZ@UG:UX-M]6UN'6;?4]1TO44B\AYK&15\Z+.=KAE8'!)P<9&: ,6XFU&?Q=\
M/Y=7MX[?43%>_:(HFW(K^2,X//%03>,-6E\!7'C>SF3R()I'&GM&NQ[=)3&0
M6QN$A"ELYP#Q@]:ZF7PK:2:IHU^EU=QOI*R"!%965]XPY<LI9B1WSUYZU43P
M-I\<-W9)<W2Z3=W!N9=.RGE%BP9@#MW!"1DJ#CKT!(H R6U+Q5K7B'Q'INE:
MK9V:64-M-:L]GO),B,VQLMWP,G\@*JZ;XPUS7V\&/;RVUFFM6ER]PI@WE)(E
M&2I+=,DX'TSGI5JPTZ[N_B+XLD6?4[""X@M8TF2VVI+M1@Q5W0C*DCD'OW[;
MJ^#]/AO]#N;6:XMDT6%X;6WB*>7M90K;LJ6/"CG- ''3^)_%%KX3UG5GU*V>
M30M3>U=?L@'VQ%D49;GY3M?^''(]\5NZGK6N:CJ6O6&@K*ESI7EQQ;5A*22M
M&)!YF]@0A#*/EP>"<GH+,W@&RGT/5])DU+43;ZK=M=W# Q;@[$$A3Y> ,J.Q
MZ4^_\#P7>N?VQ;:QJNGWDL2Q7;6<JH+I5Z%P5(W <97! Z4 9_\ :GB>^\7Q
M:+]KM=.$NBI>R!(!*T,Q<*P!+8;!SSTQV/6L2+6M7\0VOP]O9=0>VEO+N=+A
M8$78[I%*-V"#_=Z=.?88[>/PO;0>(%UB"[NXI4L18)"I0QK$#D8RI.<\Y)JA
M!X L;;2-(T^'4M13^R;EKBUN \?F MN#*?DP00[=L^] &EXO_P"1)U[O_P 2
MZX_]%M7$Z3X?U/Q)HGP\F,4-I9:1#;7C7'F[I9<1* BJ!P#_ !9/YUZ%JVF)
MJ^CW6F23S0Q7,30N\17?M8$'!8$=#UQ2:+I4>AZ-::7#/-/#:1+#$TVW=L4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6:Z81K#'*R-$\?ED E1G=G.3G(' DEUN]L_%HL=9>_LTN=0V6%[ P>TG0\+
MP'W),YZC)(ZXXH [])$DW;'5MIVM@YP?0TZO)-+U2Z\.?#[4KZ"[N&GFUV:S
M$T[^8(0UV4,G/4@'//4XKH-6N]3T3Q7;Z7;:A=/9ZEIMS*#(1(]M-"%.]68'
MAMP!!R,XQB@#NZ*\OT/4]92/X?ZC<:S=W)UF/RKN"0+Y; V[2!@ ,A@RCG/.
M3VXJW87OB/Q%I\>N:??VUJ8M0E$JS73>6((Y61HGC\O .T9W9SDYR!P #T6B
MO/\ ^W+VS\8)9:TU]:"XU%DL;N)M]G<QG(6!L?<D^HR2O7'%='XKNWM-+@\O
M4#9M-=PQ?)'ODF!<9BC]&89 ;MR>,9 !NT5Y/J>O:Y;>%?&GE7]U:S:7?PK:
MF1DDDCC=8B49L'(^<\YS_M5J:EK>H^%/$FN![ZYU&VBT!]46&XV_+*CE<+M
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MI.U<YP,^N*:(D3>T2(KOR2%ZGU/K0!X>VD:-=_#WQ#%:V]K_ &[%K5S'8>4
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MVT:+2[6VMH78R!((PB%FY+8''->6^%)M&UBVT*SU/5+Y?$VF7OF2V"K&DRW
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MV2/M"7OVC+-CKRI))Z;">U>R+&BNSJBAF^\P')^M)Y4?F^;L7S",;L<X],T
M>::M<S:=XEO+JSGL]5L)=6MA>Z7,,75M/^[5)(2/O# 1MI'0'!ZU7M!I/V+Q
M_IEW?)ITSZLQ:5%7?#&ZP!'(/_+/=USP1FO4_*C,@D\M=XX#8Y'XT[:IS\HY
MZ\=: ..\%WU]-J>MVVJPV#W=MY!?4K XANU*MM)'\+@#D9Z%>V*S? A-M\$H
M7N&$<?V2Y="YP!&7D*?AM(KM[[3EN]/DL8W^SPR@K+Y2X)0_>"D?=)]?RYY%
MF&WAM[:.WAB2.&- B1J,*J@8  ],4 >3:1-89^$<OFV_GBT>,ON7=C[(1MS_
M +W&/6L_5[;16\-?$^41V1FBO',# +E&\F(@KZ'>#TZD>U>U[%_NCCVHV)_=
M7\J /'_%.I7#>.'NM-FANXX_#\,M[;I*!)<6XF=I$1@>&VG/N!CC-:VN>(](
M6Z\):M;WXMO"[QS1_:;:-#';S%4\K>"K!./,7H,9/2O2MB?W5_*AHHW0HR*4
M/52.#0!Y-.VDZ$/#MQ9W<\_A.76II[JYGV^2)'C/EL-H"B(2DD<;0PSZ5O>#
M+K3IOB#XU_L^:W=)9+24&%@0_P"Y^9ACKSU([UW9C1HS&R*4(QM(XQ]*%14^
MZH7Z#'M0!PFKO;VOQ=L))3!'+<:)-%;-*!^\F\Z,J!ZG'/'.*YB)_P"T/A;I
M-K;L%\6VVH1#RV(%PEV)QYK,.O*EV)Z;3GI7L9 )!(&1T/I31%&)3($42$8+
M8Y(^M '.?$)KQ? NJ/8QRR2JJ,Z0C+M$'4R #N2F[BN,OK[PE=Z5K?B*QOK[
M6P='-O=Q6[+$GE;AM5_+12K\GKR%#<8KUFF)%'&I5$50220!C)H \;O[^>XU
MOQ(NAZA;W-]=>&$-J=/7"NRO)Q'@G<0O&<YR<<=*ZW0M6\':P]GJFD-$;JVT
MYH6\MBHM(< E)1D '<  #SU(XR:[A45<;5 P,# Z#TH6*--VU%7<<M@8R?4T
M >*Z -+M/#/PPO(3:Q7C7JQR3 J)"##*&!/7&=HP?8>E>C^-XHYM'MHSJJZ7
M.;R)K:YD0-&)E)90X) *DC'U(KH]B?W5_*E9%=2KJ&!Z@C- 'D%_?^?I6EW6
MLV5A:26?BR)+RY@;-M+\AW2J6Z*20#G^('/-5_'NJZ;/8>-[>U>*UND@MF=)
M,M-<[45D>-2?DC4'J ><D[>_LPC14"*BA!T4#@4&-&))122,$D=1Z4 >:>(]
M=TJQ\;/<W.I:>]MJ&A>3''>SB*, R-AE8C#*_P#%CG"J><BLRV?3/"8\(1SZ
MS$N@C3Y8!JEFD;0-=Y3+,2K*,JK ,>>HSR:[N^\/ZN^NW&HZ?J]JL5RD:26U
M]8_:%38#C80Z$9R20<\DUJZ;I%OI]BUMM23S',LI\L*KN>IVC@#IQ[=SS0!A
M>%I_#^@:18:?8ZA,UK?7,HL#<$?OB<NWEX  3[V. /3@BNMI"BDJ2H.WE>.G
MTI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K,USQ#I'ANR%YK.H06<#-M5I6^\?0#
MJ3]*TZ\U^+OPUO?B!::<^FWL,%U8EP([@D1NK[<\@$@C:.W.: /0=/U&SU:P
MAOM/N8KFUF&Z.6)MRL/K5FN4^'/A&7P3X.MM&N+I;F=7>61T!"AF.<+GG _6
MNKH *YG5_$-P/%ECX7TORUOI[=KRXGE7<+>!3MR%R,LS<#G ZG/0]-7#ZQI]
MQI'Q-L?%BPRS:?-IS:;>&)"[0?/YB2%1R5)X)'3J>* +E]KM[X9\0:19:G<+
M=Z=JTQM8K@QA)(9\956QPRM@@8 (([YXT7\8^&T<*VN6&3/]FXG4CS./ESZ_
M,OYXKG_$5L?&>O\ ARVL%=['3-034KJ[V$1@Q@[(U)^\Q)YQT Y[9YG5+:27
MP-\18H[*X:XN]6D>W06S[YEVQ;2HQEAE6P1Z&@#U.^UG3M,8K>7<<)$9E8,?
MNH."[8^ZH_O'CWIHUW26LH[R/4;:6WE?9')#()!(W]U=N=QX/ ]*X'Q'J=MI
MOC+4I@]PL>IZ/%#([V$T\:_-(%9?+4G@%LJV,Y&#UI;3R-.O_!6HV$\]_P"'
M;*QFTYKGRV)ADPJJ\BXRN=A4Y'RYYQF@#KM6URQE\,37]GXAL]/B8A$OWVR(
MCAN5VD@%N",=<U9OO$^A:9/-!>ZM:0S0QB22-I1N13T)'7FO.?$.EW1\*^/;
MNWMKAK75;V%[*W2%BTA41B20(!G#,K'..0N>A%=*'B;XMR7S0R&W&@K&)S"V
MS=YS,5W8QG:0<=: .I.L:<+&WO1>1/;W.W[.Z-N\[(R F.6)&3@>E&G:SIFK
M^9_9VH6UT8L"1890S1GGA@.5/!X/H:\HTR7^QO!_@*^GAO8KK3[BX1HFLY7"
MJR2!@Z*I<'!&T@''TKMO $^ER6NJFPOFN+BXOY+VZC:WD@,32G@!) &VX7KC
MDAC[  W]1US2](_Y"%[#;X7<Q<_=7.-S?W5SQDX%.CUG39M3.F1WL+WHC$I@
M5LOL/1L>GOTK@]6DM]/\::[;>(=/U:?3=7BB%I+9+.\;@1['A81'@YR1D?Q'
MD5;US2KW11X:UK0--87%G$NFR66\N1!* JJS9)(CD"$GTW&@#KFU[2UMUG^V
MQ&-Y6@3;DEY%SN10.2PP<@=,'TK"\4>))8M"TO4]"OX'@N-2MK=Y%42!T>4(
MP!['J/4>U5]? T.Y\+VJVL[Q(\J/J<5JT\MNWEXR%4'#2$D%B".O'.1R,,=Q
M'X"CLVLM0$T/B@2LDEL^[8+SS"W3D!>21Q0!ZFVO:4BWQ:_@ L,?:\M_J,C(
M+^@QSSVYI+G7]*M((9IKZ$1S1&>,@[MT8 )< ?P@$9;H,BN#U>9[+6_'T,EI
M>.^JZ;$UEY5L[K,%MW1OF P,'KDCJ*9#<RH-"LWTV^MF?PZL0NX[%VF>3Y0;
M8Y4^6/EW$D#/&",<@'9:AXPTC3M1T>S>Y1SJFYH9$.4\L(7WY'!!P /7/M5C
M3K^*?5-7VZU;WD4#H#;QJH^Q_+RK,#R206YQBO/-%,]KI?PSNYK"_$=C'+;W
M ^R2%HW-N4 *XR 6XSC'OBI=8TW4M5/Q,M-,AF6YO$MOLY9&03A85#JK$8.<
M%>#WH ]#MO$&D7DKQ0:A;LZ1><07QF/^^,]5_P!H<>]06WB[P]>7-K;VVLV4
MLMWN^SJDP/F8)!QZ]#]<<5S=S*GB+Q%X2U/3X9X!I_G37ADA:,V\;1;3$V0/
MF+;?E_V2>U<UI\#P_#[P?";*Y2>#Q"DTT?V9P\:B>0EV&,@;6')[&@#V"21(
MHVDD=4C0%F9C@*!U)-4;37-+OYI(;:]BDECC$K(#AMAZ. >2I_O#BL?XB:?J
M&J> M4M-+C,MVR(RQ \RJKJS(/\ >4,,=\UGRE?$7C;POK&F),D-C!<M>/)$
MT9570*L39 ^;=SM[;3TXR +H^OWOBG5;QM,U>*W2PU,P-:M"'6>W0*'8G[P8
MEC@@X&!D'DUU=]JMCINP7=RD3."57JQ ZD <X&1D]JYGP Q#^)5>*:,R:W<S
M1^;$R;XSMPPR!D''45!-J,FA?$Z^GU*UO)+34;&WBL;B"V>949&??$=@)4DN
M&YX..O% '36OB+1KV2T2UU.VF:\#FVV2 ^<$R&*'^+&#G%.37M)DLI[U=0MS
M;6\IAFDWC"2 @;#Z-D@8ZY(KROPW(;'1_A_JTL%Q]BMKG48YGBA:4Q&1I F0
M@)P2,9JY#=3VNA>()GT6ZD$GBCS\SV4C>3$6CQ.J ?/MVDX'0CGTH [+Q)XC
M"^"==U/0[Z'[5I]O*Y)3<8W1=VUE."#C'4=^E3P:GYNH:-')K=O%-+9M+-8%
M%,D^54[\YRH7GH,'/M7!7"SMIWQ,B6WU.9KVV5K:2>T=6GS;!!@!0,EN,  C
M'05O$F3QGX'E6&<QQ:;<I*_DMB-F6(*&./E)*MP?2@#>TKQIHNJVM]=1W210
M6ERUNSRG;D@A<X/JQP!U/'K2ZKXRT;3/#FH:T;E9H++<LB)G>) .(RN,JQR.
MHXSGI7#)<SZ9HFKV\NCW,TB>*))W>2RDD6WB>XWK<* /GP,$;<XX)XX-:_M+
MR[T3XEVL%IJ<\MVL4UNT]JR-.OD1C(^4 G(/R@9XZ"@#T9]7MKK6-(2VURVB
M$ZRL;':K/= +U!)RH4@G('/2K4&OZ3=6]Y/!J$$D5DQ6Y=6R(2.2&]".X[5R
MVI72ZAXV\$7L$%UY"K=EG>V==@:(*N[(^7)&!G&:2]T>^MO'ES:VMNS:/XAA
M66\<?=ADA(#Y_P"ND95?J": .HN_$>CV*(]UJ,$*.JN&=L!58X4L?X03T)QF
MM)G1(S(S*J 9+$X 'KFO,KXVMIXG\2:5XDTS5[FUU:59;1[19WBN$,21F(B,
MX5@4/WL<'.0*[74HVLO!5U'#I?VHPZ>RII^\OYF(\>5GJV>F>IH GM?$.CWK
M2+!J,#&.(3MEMO[H])!GJG^T./>H;7Q9X?O;NVM;76;*:>Z!:!$E!,@&<X]>
MA/T&:X?P_=,?'&C:@T6H-;/H,D!=K!X8H7$D;>6HVC:J@'[Q/IDFL_2K>2W\
M ^ 8397,<]MK4<D\?V9PT2@R[F88RHPR\GUH [3QYXI30O"^K2V6HP0:G:VY
MD0.F_:V,J#V!;MGKV!KI[.1I;*"1SEWC5F/J2*\EU*:XM?"GC[0-0LKU]4NK
MB[N+8I:R2+<Q.!Y;*R@C@ +C/&T5Z8HN+KPKMM/,AN9+/;%YB%&1]F!D$ C!
M]: $?Q+HL=VEJ^I6ZS22^3&I;AY,XV*>A8'J!R*4^)-%6QDO6U.V%K%-]GDE
M+_*DF<;&/8Y(&#W->91ZK'/X8\"Z2]A>VM]IVKV,%W%/;.@21%92=Y&ULG)X
M)X.33-8:>#PGXVT7[!?R7\NM-=1QQVDC!XGEB97# 8.0#P#G(Z4 >IZAK^E:
M5(8[Z_A@94$CAS]Q"<!F_NJ3D9.!Q4=[XFT/3KB2WO-6M(9HXO.>-I1N5,@
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M;Z&UMX)=$N8FGM[^-4 5%<\[P"5+ G[H)XYH ]$GUK3;:[%K-=QI,9%BVG.
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M"7_/:[_\!S1_PN/PE_SVN_\ P'-',NX>QJ=COZ*X#_A<?A+_ )[7?_@.:/\
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MPN/PE_SVN_\ P'-',NX>QJ=COZ*X#_A<?A+_ )[7?_@.:/\ A<?A+_GM=_\
M@.:.9=P]C4['?T5P'_"X_"7_ #VN_P#P'-'_  N/PE_SVN__  '-',NX>QJ=
MCOZ*X#_A<?A+_GM=_P#@.:/^%Q^$O^>UW_X#FCF7</8U.QTWB#0%U[^SMUW+
M;_8;Q+Q/+53N=,[0<]N3T_.MFN _X7'X2_Y[7?\ X#FC_A<?A+_GM=_^ YHY
MEW#V-3L=_17 ?\+C\)?\]KO_ ,!S1_PN/PE_SVN__ <T<R[A[&IV._HK@/\
MA<?A+_GM=_\ @.:/^%Q^$O\ GM=_^ YHYEW#V-3L=_17 ?\ "X_"7_/:[_\
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M'_"X_"7_ #VN_P#P'-',NX>QJ=COZ*X#_A<?A+_GM=_^ YH_X7'X2_Y[7?\
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M-RY)(!)'.%R?:IX/%.BW'A8>)4OD_LDQ&;[000 H.#QUSD$8ZYXHY$'UB?\
M5SS7_A5"_P#0OC_P=G_XQ1_PJA?^A?'_ (.S_P#&*]&T[Q597^JKI;P7=E?/
M!]HBANXMAECS@LO)''&0<$9Y%;E'(@^L3_JYX[_PJA?^A?'_ (.S_P#&*/\
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M (.S_P#&*]BHHY$'UB?]7/'?^%4+_P!"^/\ P=G_ .,4?\*H7_H7Q_X.S_\
M&*]BHHY$'UB?]7/'?^%4+_T+X_\ !V?_ (Q1_P *H7_H7Q_X.S_\8KV*BCD0
M?6)_U<\=_P"%4+_T+X_\'9_^,4?\*H7_ *%\?^#L_P#QBO8J*.1!]8G_ %<\
M=_X50O\ T+X_\'9_^,4?\*H7_H7Q_P"#L_\ QBO8J*.1!]8G_5SQW_A5"_\
M0OC_ ,'9_P#C%'_"J%_Z%\?^#L__ !BO8J*.1!]8G_5SQW_A5"_]"^/_  =G
M_P",4?\ "J%_Z%\?^#L__&*]BHHY$'UB?]7/'?\ A5"_]"^/_!V?_C%'_"J%
M_P"A?'_@[/\ \8KV*BCD0?6)_P!7/'?^%4+_ -"^/_!V?_C%'_"J%_Z%\?\
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M_P#!V?\ XQ1_PJA?^A?'_@[/_P 8KV*BCD0?6)_U<\=_X50O_0OC_P '9_\
MC%'_  JA?^A?'_@[/_QBO8J*.1!]8G_5SQW_ (50O_0OC_P=G_XQ1_PJA?\
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MM?,;://B:7:K2*IQRI&0,<@],UWVBZ/>:7<WTESK=YJ27#*T:W07,.!\P7:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>modificationno15effectiv004.jpg
<TEXT>
begin 644 modificationno15effectiv004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,5Q*LT4W[F(HJAPJ@X!(*9.T9]ZU;7Q6]Z=-N;;2;F;2]0F,4-W$=Q4<XD=
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M&)G6.-$!'EHVPECSG) Y)[5V5% '-ZQHVHWWC'P[JMNMM]ET[[1YX>5@Y\Q
MOR@*0<8SR11X.T74M L[VQO#:M!]LGGMY(78LZR2,_S @!2-V, GZUTE% 'G
M_BGPCX@UNY\1Q1OITUKJ-DL-E)<R/OLR$(954*1ACR6!!]0< 5I6FB:U%XQM
M=:GCL#%'H_V%T2=\^9O#Y&4^[QC/7OCM74&ZMUNEM6N(A<.I=82XWE1U('7'
M(YJ:@#S/2_!/B+1+?P[>VQT^74=*-U%-;M.XBN(9I"_#[,JRG'\)!Q73>$]&
MU72KS7I]26T U&_-W&MO*SE<HB[3E1_<Z]_05TU% '+7/AZ^E\;W6IJ;9M-O
MM,2QN SL)4*LYRH P<A\<D8QGGI53PQH_BS3+*WT'4Y]-ETJS00QWD+/Y\\2
MC"*R$;5., G)X'')R.THH XKPEHOBK0+2VT*XGTZ32;$[8+Q&;[1+$#E49"N
MU3T!;)X' SR,^Y\&Z]/X0U[20-.%QJ.L-?QM]H?:J&=9<$^7G/RXZ=Z]%HH
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ML=OS?*05 &=V!ZXYIKX!U=8+2W&NVQ2SU@ZI#(]F6DD)9R1(V_YB Y (QT%
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M\]A";9K!-)CNHHG9E)+NPRQ //R#MP/6F7?@F_NM.\6VG]HVRCQ Y;=Y#?N
M8UCQ][YN%![<U>A\-:A;^)H=:AU"W#?V:EC/$T!._8S,K*=WRY+'((/'3UH
MS=&\7^)-7\-C78_#]JUO)"YBACNR9#*)=F#E0 F,DG.?EZ<XIZ>/X[<>(1=+
M!<C2%MW2:S?Y+CSLA%&<X.\;<Y(YS[41>!KZ/X;_ /"*_P!JQ"9'W)<K 0K#
MS?,VNF[E3RI&>0:CN_A_=:M-KQU/58FCUBT@AD6VMC&8I(2Q1D)<\ D'!R21
MU XH T]0U7Q)8P:J'T^TVP:>UU;WBN3$)1G,3*?F) &01@'VK-T?Q3?IX?\
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M<<9!S\HKCO$NG:CX?\%^'M,O]8M[F:#7+%+:YDC*D()1MW@M\VT8R<C('XT
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MH  ,# Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+-+/%;PH.KR2.$0>W)&3V&: -&BL[2;Z^O%N5O\ 3&L98)C&/WHD25< AT;
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M?>Y.!NZ\YZUQ2^ )KJZN/[4\,^'[JZFFDD;5EN'C=MS$AC&J9W#(X#]OO5Z
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MKCC/6@#BQ-)KNE^.;F\N[BVU#2[RXCM729D-K''&&B90#P&Y8G^+)!R!BF6
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M7[I8=&([$YQVJ_+%'-$\4J+)&ZE71AD,#P01W% 'F>@W,UKXNT2-+B6&UO-
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M7&:7<:%K*:I'X@NA#K]GK4A 60)=+ME_<+%_$4*;5 '!R>Y)HU72M/U7Q/\
M$);^W2<0Z9:NBN<A&\J4A@.FX8X/4=NM 'J)('4XI&.%)XS[G KR.TU.WO[G
M0K'Q'?6D=I>>&[66V?4(P\4LI!\[EB!OQY?OCZFK>EM96_BG0-!U"_;4=&71
MY6L)[[!6ZF$N">>'(C VG^Z21UH [7PKKTWB#3[NXN+6.VDM[Z>T*)(7'[MR
MN<D#.<>@J_K-[+INBWM]#"D\EM \PC=]@;:"<9P<=/2O(8/L$/@21[=X!!8^
M, 0ZL"(8OM@&<]@5[]Q6]/=V3^+/'JVT\!#Z)$Q$;##,%GW'CJ>F: .^T+46
MU;P[INIR(L37=I%<,@.0I= V,^V:T*\GCU"""S\!6>JW-M;Z1<Z& CW<8>!K
M@)%M#9(4'9OQGU-=OX+L;33= ^RZ?J+ZA9I/)Y,IP44$YV(1U13D#KC&.U '
M0Y&<9YHR!WZUY=I=QH6LIJD?B"Z$.OV>M2$8D"72[9?W"Q?Q%"FU0!P<GN2:
M?MM=8@\?IKH1=0LKF4PR2</;6XB4P/&>JC(9LC^+- 'IV<4F0!G/%>6:?8-J
M_BWPHGB*#SKNX\-2->PRYQ(X:'AUZ'J<@C&?I531+6]NO"6C0:7/8SW-E>Z@
M(--U'+17,*3,FT'G#*I&T\X!/:@#U6YU&UM+NSM)IE6>\=HX$SRY5"Y_ !3S
M]/6K61ZUY&'T74;SX>WT^EP65JTE]$\-X$81;8Y!L+'@J&!V_@:MZ%I>BQOX
MTUB\BE+Z7JUU+%+%(QD@7[,FXH,]2"?R'H* /4 0<X/2JNGR7TEN[:C!!#*)
M7"K#(7!0,=I)(')&,BO,?#,]A!XV\.+:S64-O=Z%(IBBE#._S1;/-<8#R').
M<#DMUZU0D@@;X73+D@1>*"B%7(*C[<%X(/\ =H ]CN+F"TMI;FXE2*"%2\DC
MG 50,DDTEM<Q7=I#=1']U,BR(3QP1D?SKRK7M+L;&_\ B!IUI:Q):R>'%NV@
M"Y4S 3#S,?WOE7GKD ]:T9K/[3H?AC_A'#H]Q/#:-*=+N%'DW8V1[SD<+(NX
M8)!^^<\9H ]*HR"<9Z5Q=OJ<\WPBDO\ P_936MPNFR_9;9CN>-U#  ?WL$<'
MOQZUB^7:BW\ :KX=V"[N[B*.=XOO7%NT3--YO=B"H)+9(;W- '4W?B'49M4U
M*QT33X;N73&@6X2:;RR_F#<0AQ@$*0>>N<<=:O:GXETO2-5T[3;R[BCNK]G$
M:,X&%5&8L<]!\N/J17->$].TZ+XB>-'AL[5)(;BU",D2@INMU+8P.,G.?6CQ
MB+2/XB^!Y;H0K%OO0[RX"_Z@XR30!>TCQ-<'Q3XIL-8O+**TTR6V2WDQY0Q+
M'OPQ9CD\@=>W2NHN;NVL[<W%U<0P0CK)*X51^)XKS1=-T[4O%GQ+:[M8+D)!
M;;/,4.%S:=1GH>.M9FB:NL$G@-=6U-K*RG\/A;:Y?84-S\@()<$!M@P#UY([
MG(![##-%<0I-#(DD3C*NC AAZ@CK4-WJ%E8!#>7=O;ASA/.D";CZ#)YK"\$Z
M9I>DZ;>P:/?S7MH][)+O=D:-7;!98]@"[ <\#H=PKGK?4-)F\;^--(\33V\3
M310I"+J0('LS%@A"2.-Q<G'<^U 'H-S>6ME 9[NYA@A''F2N%7\S0;RU6U%T
MUS"+8C=YQ<;,>N>E>>Z9+;6_Q+T6P D&D#P_MTCSR3N<. Y!;DOY84^NWZFN
M5\16"P^#OB#"L2'2;?5X&L..(I&>(S"/^Z S$<=]P]: /:DO[.26>)+N!I+?
MF91("8_]X9X_&L[1_%.CZWILNH6E] ;6.21&D,B@85RN[KPI*D@]Q7,R:=8Z
M=\8-*BL[2"W2XT:Y698T"B0"2,C=Z]3UKB9XM/D_9\U9&2V-S#<SL1A=Z$7A
M /J.#^M 'M;:G8)%-(]];+' ^R5C*H$;>C'/!]C4L%S!=6ZW%O/'-"PRLD;A
ME(]B.*X?7K/P_H>N>';>ST^VM[^\O'E@D)\N'>D)!DEQ]]@K?*.I)ZCDUQ0U
M06G@SQ2RW,=Q:1^*]]\+;HUH7A,A503\AR0>O!- 'LG]M:5]CN+P:E:-;6P)
MGE692L8']X@\4S1-:L_$&D6VI6,BO#/&L@&02H(R P['!Z5S5_'X8U"35-2T
MV6"ZOYM&>-VMI0\?DCE-R@[0<GY21G@XZ&G^ =2TFR^'/ALR7EG 9+2VA.Z1
M5W2L@ 7W8D'CKQ0!V=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME1M I6//7:,8'X592Y@DF>%)XVEC^^BN"R_4=J?)(D,;22NJ(HRS,< #W-
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M'5<YQN.,X&3^E8'C#Q#/H7@R^US3%MKIK= Z[W)1AD#JO7KZB@#HJ*AENK>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\H^-_@?Q#XQT[2VT("X%H\AEM#*$WEMN&&X@$C
M!')[\=Z]7HH XSX6^&]4\*^ [/2]7<&[5W<QJ^X1!CD)GIQUXXR379T44 %>
M>ZV1X>^+VG^(]0;R])O-*;3#<OPD$PE\Q=YZ*&' )[UZ%3719$*.H96&"K#(
M(H S;C5HIX9;?2[B*XO6A=HQ$P<(=IVEL= 3@>_YUYG 8[_X=>%GT\A?$T&H
M0*0>)Q<>9BY\S^+!7S"V>HY->MP6T%K'Y=O#'"F<[8T"C/T%*MO D[3K#&)F
M&&D"C<1[F@#QW5]/T6:U^*KO;V;R0+OA)"GRW^RJ=R_W6+CJ.216WI^L6?\
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M/RJ/[0"F655DB\LR @9.,D CC'0$5AVC:<G@OPC).UM]CM/%,L1>0KLBBWW
M"DG@+]WVZ5[2T$3OO:)"WJ5&:!;PA"@ACVD@D;1C(H P/&T45S\.M>5(UD0Z
M9.T:[<_\LR1@5QTSZ-J%Y\-H8WLYK21I@Z(5*.?LC9!QP>< ^_!KU2HOL\ "
MCR8\*,+\HX^E 'D4%]I&F:;K5K*D(M$\8+';IYOEP6[%8W5I,<",,&..A/''
M44-2GLYO"?Q!A^T6UR8]5M[H>4@"A3Y&Z15R<*?FYSSSR:]L-K;E&0P1%6^\
MNP8/UIWE1D.#&GS_ '_E'S<8Y]>* *T,UE)I7G6;QFS,;%'MR-NWGE<<?E7G
MGA2XETS4;&QN7T_4[(Z1*VGZS:_)(+=3'E9UZ9^[AL]0>Y->G!0%V@#;C&.U
M1):6T7F>7;Q)YG+[4 W?7UH \;\/PZ;9^'?A??P+;1WLEVL4DXP)&4PRAE+=
M2,[1CMP*5-9TF2X\+WMI<6UK&GB.;? [[KF/>)PQF<G(+'HF.F!EL5[)]F@X
M_<1\=/D'%*+>$$D11@EMY.T<MZ_7WH \\M[F#^U_B=^^C^58RWS#C_1%'\^*
MZ;P(R2?#OPX5967^R[93@Y'$2@BMW[/#\W[F/YOO?*.:<J(B[4557T P* /$
M[Y--_P"%7>*D7[,(X?$\GE;2 (_]+3&W'3Y<].U:7B6'^S/$OB>V\,1QV]U+
MX864168"L[B5P6 7J^PG!Z]*]7^S6^,>1%CKC8*58(5<.L2!AT(49H Y#PY?
M^#M7U&SU309(7NH]/\EA;O@009#;95!PI!& #SUQP#7%:=/:Q_#+P%?221+!
M;:[&TL[$;8E,DPR6[#)'YBO8X[>")76.&-!(27"J!N)ZD^M!MH&A:%H(S$WW
MD*#!^HH \:UW5H1>>/9M-F66V>XTV2Z^SG)>UVJ)F7'5=N02.Q-;-U?:;-\2
M#/X<N;%[J?PQ<1V[6SH0\@D0QKQQG';TKTY8HTW;8U7=][ QGC'/X4V&VM[<
M 0P11@# V(!@9SCB@#S'P=)X:UJ7PU=VVKW3ZW8Q,CV2"-)(R4Q*)@$#;=PZ
ML>6QR2:V_'^H)IFI>'+B_N)+;1?M4BW5PJ*RQ2%,1,X92-N=PR1P2#7:)!#'
M*\J11K))]]U4 M]3WITD:2QM'(BNC##*PR"/<4 >9'3=+32H6\->(PCSZT;F
MSGNU22TFN#$Y:)0H4;"-WW>C#CD50OKNUN?#_A>ZU'3+/3A:^*&BNL,&M\_O
MM[JQ_P"6;.<\]^.U>LM:V[P"!X(FA P(R@*@?2G>3%Y2Q>4GEKC";1@8Z<4
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M8I20N&.<XW$ D @'@D$&N8A\):II5EX0MHK0W+6.J2WUZT,B!(O,$I(7<02
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M\I=WRX4KNR 21GYCTO76B:U+;?$)%TJ7=K*;;+]]%^\/V=8O[_'S#/../RH
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MUA^#K2[T_P &:-87ULUO=6MG%!+&S*V&10IP5)!'%;E !1110 4444 %%%%
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M#HV>&/(((QWXH ["BN1TSQ'K5WJ^EH^FF73[^%GDECM98OL;;=RAF?B0'D9
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M8^\#:3S@@X[$5M-X<O#XHL]<_M.(R6U@]EY;6I^?<RL6R'&.4'&.F?K71T4
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MV^T^(Q/J1DC83BT"1!%.2GE!OXLD$[L\CI@5T5% &'X>\-PZ!-J<\9B$FH7
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MY4'UI: ,73(]87Q#JS7=[]HTQO+-I&UN(S"V#N4-U<=#N/K@=#5/5O"MS?\
MB1]6MM6-LDU@;">$P"3Y"Q;<A)^1N><@@X''%=%-<0VX0S2*@=Q&N3U8G  ]
MZDH XW3?!%WI[^%F;6$F&@0/ H-ICSE9 G9_EP%'KSGZ"O+\/)9;*Y7^V/+O
MCK#:Q:7,=MCR)CU4J6.]<9&,CK7=4UW6-&=V"HHRS$X 'K0!SNC^'+^Q\37V
MN7NJQ7,UY;102116OE(/++8(R['^(\$GZ]J-4\,W5[XGBUFUU4VO^A-8S0M
M),H6W;D)(V-GN0P.!QQ6M)?R>?IXMK.2YMKK)>X1E"PKMW*S G)!X' /6KU
M&/X5T.3PWX:L='DO/M?V2,1++Y0CRHX'&3V]S_2MBBB@ HJ.&XAN%9H9%D57
M:-BISAE."/J""*DH ***C6XA>YDMUD4S1JKN@/*AL@$_7:?RH DHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9EET^]YFN7E#8$7S#<3R<\XZX%6/B/:QW)\+&1IA_P 3ZV3]W,Z<'=G[I'/
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M%L8!(#?K0!LQ^+O#LILA'K5BQOB!;8F7]Z22 !^((^H(ZU:O]<TO3'*7U_!
MP4,V]\;%)P&;^Z,\9.!7EDL)7X::M#%:3"=O$9G2-;=MY3[:KAP,9QL&<^@K
MHK.8:;KWC"VUJ":2'4V6XM)!$SK=0F$)Y2X!RP((V]?FSCF@#K[WQ!H^G3+#
M>:I:02M&90DDRAB@_BQGI[U2U#7K"ZT*VOK#Q%96D-Q/&L-VVV19/G :-02,
ML<%?4'Z5Q>BZ7>:5J_P[M-4C=[FQTRZ2X<H66%V6/8I;H#@%1S_#5"='/@+5
MH%MKC>?%)GCC$#[C%]K5]X&,[=H)STH ]'3Q3ILGBN7P\LP^V10+*^>!EB0%
M'J< D^E6H->TJYO5LX=0MWN'W;$#CY]OWMO]['?&<=ZX[5H;Q_'FMQVB7"3:
MEX>2"QN4B8QB4--U<#"XW*>2.HJA%%)K7A;P5IEK:SVVJZ7>6C7,3Q,C6HA7
M$I8XP%(! _O;AC- '=+XIT![Y+%-9L6NGF-NL2SJ6,@&2N,]0"./>KM[J5GI
MPC-W<)$96*QJ>6<@9(4#D\ GCL*Y/P?%$WBKQA(]N0TFI)+%(\)&]1"B[E)'
M(!W#(]3ZU/XKO3:^)?#X:TF6-_/']HPVK3O =JXC4 ,%+^I!X7'?( '^)?$4
MT-GX>OM%OK>2TO\ 5;:VDD11()(G?!VMG Z$?X5-9:KJ$GQ%U32)IHVLH=/@
MN846/!5G=U.3U/W!7 V"S1> ?#%I):7J36GB8/,DENX9$%U(Y8\?="L"6''/
M6NRL23\6]6DV2>4^DV\:R%#L9EDD)4-C!(# X]Z .IO=0M-/17NYTB#G:@/5
MCC. .IXR>*A&M:8VG0Z@M_;O:3X$,J.&60GH%Q]X\'@<\5RWB2_E\/\ C_2]
M:O;:ZFT=["6S:6"%I?LTK.K!F503A@H&0.PJE=1C3=<\*:O:Z5+9^'X6NTDB
M6 J8&F V3.@&5#'=G(^7?SC)  .VCUK3)M/-_%?0/:AMAD5\C?G;M_WL\8ZY
MXK-U3QIHNEVEM</=I(MQ>I9*%/21F ;=Z;0<G/ICJ:X^XTB.XO/$E_)-?66F
MZCJ=K)8W-JAW0S1Q#=<!<'Y"X )(P0">G-17DFLS>';:?4X1=FP\2VLC7]G:
ML/M<"%,S^6N3Q]T[>/EXH ]%GU[2K9D$U]"FY48$MP W"Y/;<>F>O:K5Y>VN
MG6DEW>W,5M;QC+RS.$51[D\5YUXD:[AUC4-4T&>X%ZX@6XT:\MBT6HKM7:4R
M,HX!P2#QM^8#K77^- 6\#:]&J,[R:?/&B*I8LS1L  !R220* +%OXFT.[2Y>
MWU6TE6VV"8I*#Y9?[H/N>P]>*P_%WBEH/ ]]K'A[4+=Y;:5(V;:)-I,BJRD'
M[K#=W'X5BZM'):>#_!^IVUA=36E@\#W\%FC),$\AH]V%PV49LX^M5?$4&EW/
M@#Q%?:%IVHDZC+;%I)DG,ETZR+DK&_S8"CK@9P?3- 'HE]KVDZ9,8KW4(('4
M*SAWQL#'"EC_  @G@$XS55O%.F+XK'AWSA]M^S^>V3@#+ *ON3R?;'O7 ^.+
MB2^3QE8V]A=Q23:;&87M;-G.H#RR=S/M("IG;@8.<\G(%;EG.Z_$FQO&MKQ8
M+S0$@BD-L^/,$Q8AN/E(!!^;% '6?V[I7]HII_\ :%O]K=F1(M_+,OWE'JP[
M@<BN>^('BS^PO#=])INI6T6I0-&NUTWX+,OR^@;:<@'G':N:\*QV-Q:Z5H&N
M:3K#Z_I5VLA1S.(0Z,?](#Y\O:02?<DC!S6;?SW$7PS\0^'+^QO7UU+Z25E6
MUD?[2&N1(LJL 01M('7MCTH ]@U'4+;2M.N+^\D\NVMT,DCX)P![#K6?IOBC
M3-1T"RU?[1'%%=(A5"V6#LH;9@=6 /0>E3:TCWOAC44MXW9Y[.58T*E6)*'
MP>0?8UY]I-Q<6S> M5FMKL:79Z8UA=&2W=?LTYCC&]E(SMRI3=C ]>: /3+&
M_M-2M5N;&YBN(&) >-@PR#@CZ@\$=JQKKQ59'7[GP];W*)J4=KY^YURJDG"C
M'&X\$]>,53\'V$T.M^*-217CT[4+Y);5&4KNQ$JR2 'LS \]\9Z$53O)38?%
M&\N)X+CR+G0XXHY4@=T+++(6!8# (# \^M %KP3XQM=:T'18[_4[5M;O+03O
M &578XR<*/;G'IS6_<:[I5I>I9W&H6\4[N(U1WQ\Y&0N>@8]AU->8Z/"UOX5
M^&D7V6:.:UO0;A?(8-"/*E5BXQ\HW,,D^M30Q64D^L>&?$FE:Q<WDVI37%LD
M9G\B[1I?,C8.AV)MX!)QC;0!ZK++'!$\LTBQQHI9W<X"@=23V%4[36],OVG6
MVOH)&MP&F7=@HI&0Q!Z @'!Z&L;XAVU_=>"[L:;;O<SQ20SFV3[TZ)*KN@]<
MJIX[].]<]XDEB\:>$M;N?#6E7!U"6R2)YY[5H'E59 QMQO +97>#CC) R<\
M'<VNNZ5>RR16VH6\CQQ^:RAP#Y?]_GJO^UT]ZK0>+?#MS<6L$&M6,LMV66W5
M)U/FD$@[?7E6'O@XKGKB2/Q#XP\*ZOIBRI%817,EZ[Q-&8XWC"B)\@?-NP=O
M;:3Z5RUI"8OAYH$?V29)X_$ZW$B?9V#J@O&8N1C('ED'/I0!Z):>,M%NM3U6
MR%Y%%_9A"SR2N$7.,GD]@".?>IH?%OAZY60P:S92>6D;MLF!($GW./\ :XP.
M^1ZUR]M(;3Q!X^BGM[D?:A'-"_D.4D3[,JY#8P?F!&,YSVJA;NFF?##P>_\
M9):2-[.*XE-HSO9%5.Z4H!DE6R.1@%\\]" >A6^LZ;=64U[#?0-;0,RS2%P!
M$5^\&S]TCN#69JOC71-+T+4M5:\29+!<RQ(?G#$952O4;NQ(QCGI7GCQ:DNG
M^)9+6QU.[-OXBMM3>&6V9'NK=5A)P-H!)VD[0,_+T'2MSQ1-9^*/ OBB]T+2
M;EY[FP"/</:/%).5R0@5E#-M&>>G.!GG !Z%:W4-[;)<6\BR1/\ =93D'M5.
M'Q!I-Q>"TAU"!YVW[$#_ ']G#[3T;;WQG'>K%A>1WVGQ74"2^6ZY021M&Q'^
MZP!'XBO*-+NI)]2\$W?]FW]JEM>W*3V,=A(L5D7BD4)G;EB21ELD=_E% 'I7
M_"4Z#]C2\_M>S^S/-Y"2^:-K2=-@/][VZU:GUC3;:2=)[Z")K>(33"1POEH3
M@,<] 2",^U>>:KX6U2\U#Q)X:LT>#3[QEUBVNATCN"#^[!['SD63CMN'>K=Y
M=WTWPYGU[4=$,U]?M;236<D32?9T5T )1?F8+AI=H[DT =C_ ,))HHM+JZ?4
M[6.&T(6X:60)Y1(R P;!&1R,]:2'Q+HEQ%=2PZK:2):NL<Y64'RW;[JGW.<
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M_-> &*0.2ZC+* ,DD#DX[<UYGJB2#P#XNTJ2QO&N6U^281?97.^-KI'!7C#
MID\9X%=?XANXK7Q-H/EV4D4,T4Y&I6UHTSQL0G[M0%(4N /F8'A,#U !T_\
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MZ;I$MI,+B]U*YU&Z"%%EG6- BD@D*J*HYP.3D\=:U** "BBB@ HHHH ****
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MJ>CZ3?Z;>:M-=O;K*0?*<$C9E1M96VXY'&>1Q7HI( ))P!W-(K*XRK CU!H
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MC=G@#UK$TBZO]+\7^/+E-)CGO5^P;;>U?"REE8;R2..N6X.,'K6WJ_A2_O\
M2]!DM;V"WUC19%D@E*%HI,)L96'!VLOIR*S+_P #Z[J,FOW$FK6,,VJBT/EQ
MV[E 8#G8Q+9*,,J1W!_"@"Q-X^FAL/%,B6=I=S:#"DY:"Z/ESHR%N#M."-K
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M,9SM.<]JW_#7A?Q!H"PZ2=:MIM M7S;CR&%UL!RL3/NV[1TSC) QQVRS\/\
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M&ZYS@A\9!SP#6CJ7AO7=7T_3A?:C9O>V^I07\GEQ,D($39$:+DGGNQ)//3&
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MDV_RJI"Y ZD%CP!SC'%+INAW=GXPUK69)H&M]1C@C$2@[D\H, 2>ASN/T]Z
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MH CFMX;E-D\,<J9SM=0P_6GJH50J@!0, #M2T4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !40MK<7!N!!%YQ&/,V#=CZ]:EHH **** "BBB@ HHHH
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M]<TUK2&<*I5U3[,-H^21BQ&[.3VZU>M-6TV_NKBUL[^UN+BV.V>**97:(^C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!4$@')!]!71ZOXYDLCJ#Z?IC7Z:=.()HXR_FRM\I?RU"$';N[D9((XX)I?\
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MR 4M1\01>(_"WC739[>V=M-M)%9X91-%*&@+JP) P0>".Q'6NE\+$CP9HI4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+M7RUW$8ZYY':C0O$"ZW<ZM +26V;3;PVC"1@2YV*V[C( PP[UR4-U+>Z_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\KUO3_$>HO<^=H=Y+/:Z_#=0F&6-87M4E4@JN\;I"HR2PSG/(&!7JE% 'GT
M^G:I)?\ C^3^S+G;J=E%%:?=/FN(&0@<\?,1R<>M5]-L=:T+7- U=M)N[JU.
M@Q:7<P0[3+:RHV[<06 *GD9![ UZ310!R?@"SO['2-0BU"PFLY)-3NIT65D.
MY'E9@?E)['O7+ZWI_B/46N/.T.\EGM=?ANH3#+&L+6J2J057>-SE1DEAG.>0
M,"O1M/UC3]4FO(;*Y69[.7R9PH(V/@''(YX(Z5>H PO%^D7/B+P7JFE6["&Y
MN[5DCW'@-C(!/IG@UD++K?B[P[>Z;>Z%-HMS-82VTUQ<,A'F.FW$6QB2N>23
MCH  >H[2B@#SQ-+U36]%\)Z9=Z;/976CWEO<7<CXV#R%(^1@?FWG&,= 3G'0
MYUSHNLR^!=?L%TFZ-W=:^UY#%\N6B-TLH;.[ ^53P3FO5** .(EM-2MO&VO7
MJZ7<S6FI:7 D4T93"O'YN58$@Y^=<<=^W-4[:UU_3?A7H%E;:9-]NM/LT5Y
M AF6-2/,,63MW<<'/N.:]#HH \EN?#?B"5O$LMAI%Q%(=0L=3L4NKA6%P85C
MS&S;F.XE3UXSCFNJO9-4\4^$M<B70I]-EN=.EMXH[PH)99&1@!\K$!03C)/.
M>@ Y["B@#)\,M<'PWIZ75E-9S1VZ1M%,5+ JH!SM)'4'O6!XN\*W>J^*M"U*
MQ(6,B2QU/_II:-\^T^VY-O\ VTKM:* .*T?PM>:=\1=8OL@:-,5OH(_2[D7R
MY&^NU#_W\J1+74-#^(.KZH;.XO-.U:V@ > !F@EA##85SG#!L@] <YQ78T4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)J$TXC#,2[;550>,95B>O8#&<T)X'@7P]K.BG5+U[?5I9I9W(CWJ93E]ORX
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M_M.WB4QXAEWES@E"2"2>&)QFKS^#H#<Z[+%J5[%'K*;9X5*%5;RQ&77*YSM
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M"4D\5:2]\1>(K34=1TK4+:SGL=3FA'G73"*..&3:R21B,@[D&[).1N!! XH
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M45Q-"L$[PW4B>=&N=H?!YQD\]>3S3W\-:4]_IMZL#1RZ9&T5F(I&1(E( ("
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MYF633;+ AM7E)'[W*D*#C/OZ5W]9-IX?@M/$=]K:75RUQ>QQQ2QL4\O:F=N
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M)>2AB@/7 4!0??&?>@#D?"C1WTNEM?>%=6M-4TN-A+/>B1HX#LVMY+%B'W<
M!1T^@SCVFGWT?PZ\+V;Z7?BYMM=CN)H?LDFZ.,7+N6(QTVD&O6Z* /,-?TC5
M=3U?QNFGVEP)+NQL?LKO&\:3O"SLZ!R .00O7O[5<MGMM7L-0U&'POK-I?+I
MLUN\FH1R&7+#B*,,27!/.0,<#UX]#HH \TT^SNXC\,@VGWJG3[=DN\VKCR";
M4QX;CCY^/UZ<UN?#V*ZL=(O=.O+&ZMYH-0NG+2Q[4</,[J4/\0((.1Q77T4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#R$%(U7&6VX)X'!8#KG%:T@=?^%7AK"Z'V.$BXS:/^X/V4I\_P OR_/@<]Z
M.NOO$>EWGA2\U*Q\0VUE H:,:@P5A!(..5;J1_=-/?Q5I\'B>U\//(SW<UJ;
M@OL.W[R*HZ8RVXGVQSU%<'J,%S+X/^)5O'8WK27E]*]M&+63,P:*-04&WYLL
MIY'I71,TD/Q(T2_-I=M:SZ+):K(ENY"R&6-MK\?)P"?FQTH [&\O;;3[5[F[
MG2&!,;G<X&2< ?4D@ =R:BL-4LM468V<ZR&!_+E3!5HVP#M93@J<$'D=ZQ?'
M5Q+;>'XY(].^V@7D!?$!F,"B0$S",<L4QD =_:LOP4)4\8^*VDAU'R[F2VFA
MN+NW:/S5$*J3DJ!G(/RX!&.@H Z;4O$FBZ1,8-0U2UMIA&93')( VP$#..O4
M@>Y-8/BOQ0?^$&&O>&]3@DC-Q;HLT:K(KJ\R1L.>A^8^XQ5?Q%<6UI\5?#$U
MR#L%A>@/Y9;8<Q<G X[C/O[USNHZ/<VW@7Q(T%C=>7J?B".\M+6.W<N(A-"6
M;8!E0?+=L$#C'K0!Z3>^(=)TZ=H;N^BB=-GF9SB+><+O/1,GIN(S3;[Q+HFF
M7;VEYJ=M#<I%YS0LXWA,@9QUZD8]:\X\<O=:C;>,[&#2KZ.62"%H!:V3-]O4
M(IWO)M_AY4*"#\O?.!TAD\[XIZ?J!M+L6XT.5/.>U<!7:5&"DD<,5#'!YH [
M"QO[34[&&]L;B.XM9EWQRQME6'M7)ZKXAGOO%\WAG3]4.G31V G6X6!9"9FD
M*JI#*1M&TDXQG/48J7X91RV_@>WMY[>>WECN;K,<T31L T\C+PP'!4@_C4.)
M7^+-_(D5S'&^AQ6Z7)MW\OS1-(Q ;&TD!E/6@#>MM?T]9+>QN-1MWO7/DEE!
M6.691\RH3QNR#\N21^%-;Q;X?74%L#K%F;MIQ;"(2 MYI&0G'?\ Q%>>PZ??
M7_PNL/";6=S!XAM;J&,EHFQ&R3AC.'Q@J4!;<#R3CKQ74>&(O^*[\92R6DR+
M/<VSQ2R6[*L@6%5)5B,'#9'% '5WM]:Z=;^?=S)#'N" MW8G 4#J220 !R:9
MI^IV6J0R2V5PLRQR&*0#(:-QU5@>5(R.#SS6%XYN9+73=/E33VNE&HP^9*EN
M9VM%R3YRH 267@#@XW9P<8.?X"6:'6/%22V]^@FU$7$<MW R>8AAC ;) &20
M>!T[@=* +/BW5M5T_P 0^&['3[M(8M4N7@FWPA]H6,N"O3GC'.:;X=\57<NO
M^)=$UI[4G1#$YOHAY<;QR)N&X$G:PQSS@^U4_'D)N?%7@\?9KN6&"]DDN'@A
MD81*8BH)9!\O)'>K'B[P\++P==+X>TS=,MW!>S00$K+=;)5=QNSN+$+USGB@
M#=/BO0EM[R>35+>&.RQ]I\X^68L\C<&P1GMQSVK&\2>/]+T_P[J%YI=];W5U
M;RQV^U<L$=V503CT#9]\8KG=8&F:UX3\2:EI&BZS]MN-*>T:6[BN#*['E8E1
M\EL$G) P/4Y.-7QJGF_"^*&SLKEY9&LML,-JY?"31,V5 R,*IZCM0!MV>I#2
MS/+J.O?;K6X_>V:M; 31HHP^X(!N4''S;1C/)-7+CQ3H-I%:RSZQ9)'=H9+=
MO.!$JA2Q9?48!YKGS/-I?Q*N=3O(IWTO4--BBMKA8698GC=BT; #*[MV1GKC
M'6N:T_1[K3+GPF)[&Z\@:[>WJ1"W=A:P2++Y0; .SEE.#C!/M0!W@\<>%VMV
MG77+)XUB68E)-Q"-G!P.>QXZ\&K,/BK0;F^M;*#5K62XNDWP(D@/F#;NX/3.
MWG'7'-8$*+!\5-5N7M)UM1HT$*RBV<H6621F4$#!."O KEM*MKBW\!?#JW;3
M[U)[/5(GN8_LD@:$!90S,-O RPY/K0!Z8_B'28[X63WT0G,PMP.=OFD9$>[[
MN_'.W.?:JMUXS\-V33K<:U9(8)!%+^]!V,>QQTZC/IGFO/M9FNKEI1_9.H6[
MVGB>&=[6VL',;1+,O^D%@O[QF'/RD]>G&:MW\,LT7Q0*Z?=E[ZW5;8?9'S.?
MLH3"\?-A\CC/- 'HM_J]AIB*UW<JFY2ZJ 68J.K8 )VC(R>@S39=<TR&R@O#
M>1O!.F^%HLR>8N,[E"Y)&.<BN#M]0G\/^)++4=1T[4)]+O\ 1+>T66&TDE:"
M:,L6C=%!8;MWIU&.U+J6-!U_1]1ET34;?07TY[18=-63=9/YF]=Z1'(#+@'&
M<$4 >B65[:ZC9Q7EE<1W%M,NZ.6)@RL/4$5QD'BO4K+XG3:!J+1OI5T#'8S[
M-K+.L:2-&Q'!RKG'^[BNA\+65G8:#%#I^G2Z?:,[R1V\S,7 9B<L&)*DDDX/
M(SS@Y%<IXBTB;Q!;>)8[!)X]4M+R&_TV5H64&:**/&UB #DAD./6@"YXV\5Z
MCI&N:!I>E^4OVR_@@O)G3<8DE+!0HZ;CL<^VWWKIM0UW2]'&-0ODAVJ&=GZ(
MI. SD#"@D'DX'6O/M>MK^33O"M]=V%R=2NO$%KJ5]%! \OV:,*P"D@' 1=BG
MWR>]3ZD\-EXOU^UU[2]8N].UE8FM)+)9WCD7RA&\+K&>#D$\]F.2* .ZO_$&
ME:8?],O8X_W7GMC+;8^F]L9VK_M' ]Z6]U[2]/3S+F\14$7GLZ@L%C_OL0#M
M7@\GC@UP&NQS1/J&CPZ+>6:GP\L%L;2W:=K@A7'D--@@*F1P2"=V<]C2GANS
MHMC?:7)J-AK$&A6\3VUS8N]OJ*J&'D.A7(<'<."#A\\@T >GG6-/%Y<6?VE?
MM-M&)I8L'<J'HV.N.#S[54E\6>'X;>TN)-8LUBO$9[=C*/WJJ"25]0 #S7-/
M<W.G_$;[=?:?=K]OT.&%!;P-*HG61V:,LHP"-PY8@8[USV@P3IH?PRCGTZ^5
MK*=S<*]G)^Y_=2*&;Y>!N*X/XT >CR>*M"CT^&_;4H3:2Q"=95RRB,_QG ^5
M?<X%+=>*=!LYV@GU:T658!<%!(&;RSC#8'8Y&/7M7&ZL8M*\:ZM'K6F:M<:5
MJMO"EK+IZS.GRJ4>%UB/&<Y&1CYC5C3+./3OB)IHCTRXM+*V\.FW0&-Y$A/F
MJPC\S!!8*#QDT =/%XO\/3S64,.L6DCWP'V8+(#YF>@!]3@X!YXJQ?\ B#2=
M,F\J]OHH&RJL7SM0L<+N;HN>V2,UYA:6T\/PU\/V_P#9UZEQ#XB2>2(6<@=$
M%XS[RNW(&P@Y]*OS);Q:UXBT3Q%HNLWT6IW9N+1K7SV@NHV1 $.PA592N"6P
M  .<4 =Q?>+O#VFRW45WJ]I%):A3.ADRT>[.,@?0GZ#-17/B_2K?7=,TH3>9
M+J$+3QR("4V#&#D#!SN&/;GTSS<<!@\9^*7>QN%B;1K>"-Q!(ZNRB7<BMM^;
M&Y?K6=X?CNK&;X=7$]A?A8-'FLY@+60F*8K#A7&/E^ZW)P..M '?^)KJYL/#
M&J7UG*([BUM99XR5# LB%@"#VXKCK[Q7KFB_#[2?%LMU;7GVB*UDGL6@V-)Y
MVW*Q,#PPW9&0<@&NK\8%CX,UJ-(Y9))+&:...*-G9F9&   !)R:\SO=&M)OA
MIHL.CZ%?Q>+;>UMA;2P6$L,D-P%4.7D*A0/O9W'!H ]5U'7]*TIV2^O8X62/
MS7!!/EIG&]\#Y5SD9.!P:=>ZWING+NNKI47RS,2 6"QC^-L X7W/%>?>*6U"
M=_$.FSZ==+=S:"J)/8V;/]ODV2;E:0*0JJQX7@G=U/ IFH17,EA87^ESZCIN
ML0:)$HCGLGD@OE&[]Q(A7[V0<=&Q)T- 'HFH:[IFEQ"2\NTB0IYA."=J=W.!
MPON>*QKS6;M?'GA^RMKR-]+U"SN9F5%4AB@C*L']/G[5S5U<2Z=XGFG\1Z1J
MILM6TVV1#IWG2)#(JL'@<1'/5R02,<GWJ['8K8^,_!D-II=S:V5KI]W'Y>QY
M%MP_E[$=^0#A3W[=>E &_:>(M,M;/4K^\\2VES:1WS1"3Y$6W.%Q#D??(SUZ
M_-CM6AI^OZ3JMW<VMAJ$%Q/;8\U(VR5!Z'W'!Y'%>8ZG;W$W@?QY;KI]\\MU
MKIE@B%I(6F0M#\RC;\P^1N1Z5N:W9W6I>-]3CT^*>,W7A:2T@N/)=8Q,78JN
M_& 0#G&: .RM?$&E7M\+*WOHGN&0R(G(\Q!P60GAQ[KD5D?$36M0\.>";_6-
M,E1+FUV%5D0.K;I%4@CKT8]#6)X2DT[5[K1FFT#6(-9TN-DD-Z9UCM"4VOM9
MCL8-@  9XYXQ5[XM1377PVU6SM;:XN;F<1+'#;PM(S8E0GA0>P)H ?+K^K:/
MX_T;P_=3P:A;:K!,X=(?+EMVC .YL$@HV<#@<]S70W_B#2=,F\J]OHH&RJL7
MSM0MPNYNBY[9(S7'Q6A\(>,O[7L[&XNM%UM5CF:.W>6:RE4<'H7\I@.1T4\\
M9K.E%M'K/B'1O$6BZS?1:I=?:+1K83F&ZC9$ 1MI"JR[<'=C  YQ0!Z+#K.G
MW&I7&G0W2/>VRAIH #N0'H2/?MZUGRZS9W>J:,MKKT,(N'D*VFP%KP!&R!GE
M0I&<CTQ6)XCTS4]/\0:-JVB6Y\ZX@.DW:H2PC1ANCE)/41N#R>2&I^OV@M/%
M?@:&UM9VM;*:96:.%W6)/L[(NY@"!DD#F@#I)/$&DQ:A'8R7T27$DGDH#D!I
M,9V!NF[_ &<Y]JA?Q7H4=G<WCZG MM:S>1<2G(6*3^ZQQP>1P?4>M<#H4%N\
M:^&]?T/6+C5K74'FC8M/]FE/FLZSAP=B@;LG/.<C!)Q6EK7AF\O/%&KZ/%$Z
MZ-XCMEGNIU'$$L6%;';+CROR8]J .[74+5KR.T$O^D21><L94@E.F>GJ1^=4
M=?UG^R8K.&%5>]O[E;6U1NFXY)8X[*H9CZXQQFLSP*FK3Z2+_783%J6Q;-@W
M4K#E2W_ GWM[@K5;QA#(GC#P3J)!^RP7\T,GH&EA94)_X%Q]2* #7=3UFR\:
M>&]$L]158=3BN3-)+;J[*8D4@C&!SNYK*3Q=XAN]#\3V\+6BZSHEXMM'<)'^
MXN=Q 7*DDJ>>0#P?RJUXLM_MGQ,\(%[:\DM;>.]$\T,4NV(NB!,NHXR0>]:V
MNZ=8:)X3GM=-L#%&\\;^5:P,[.WF*68A023QDD^E $OAGQ7!K/@N+7KO%NT4
M3?;4(QY,D>1(".V"#^&*YSP_XI\0:OX7\6:I>/':7>F7-Q%;VZQ B,1QAP'S
MRQYP<$=*<GA[4+?QU>V]M$?^$9U<IJERV" DT9&Y /\ IH?+8YZA6%4]%\Z+
MPY\0TDL[Y'NM0O9;=&M) TR/$JJ4&WYLD'I0!8O/%FNZ1\.-+\82W5K=F:"V
MFGL6@V&3S=N5B8'(8;N,ALXK8\1:MJUKXU\-:38WB06^JK<^;O@#LABC##;T
MZYYSFN'N=&LY?A=H\&F:#?Q^++>TMQ;206$L,D-R H8M(5"@?>R6.#70>)K*
M:_\ &?@>'4K:XN%@@NUOYK>&3RT=X5 .]1\N6!QS0!L^%?$.HZOK'B30[YH7
METB=(DOK5-JR!TW ;26 =>AZC/:M;0=9;49-0L;D(NH:;/Y%P$& V5#(X'8,
MK X['(YQFN?\$I<^%KBX\(WMG,8H',EAJ$=L?+N8F/ D91@2KT).,\&IO#,$
MC_$;QK?*#]F9K.V#=FD2'+?D'44 =-J.KV&E(&O;A8@5+XP6.T=6P 3@9&3T
M&:P=2UVY_P"$O\)PZ??12:7J@N#((U5A*%B+HP?TSCI63XBG;1_'QO\ 4K+5
M;C2+W3X[=)]/$S>3*CN2KK$<X8.,'!Y&*C_L^'3O$'@.'3])N[.PM3>'RO+D
MD%NKQD)O;G:23T)X)QVH [.;Q!I-O?QV4U]$D\D@A4-G:9",A-W3=C^'.?:B
M[\0:387(M[J^BBDWK&=V=J,WW59NBDY& 2,YXKSO2H+=OM'AGQ!H>L76HQZC
M+/"P:?[-<!IFD2;>IV*!N&<\Y'0GBKNFW/V&[U_PWKF@W=]-=ZI+=VF;1I8+
MJ-V#1EI,%5V8 .[&-HQGI0!U,'C'29M>U72VG$3::B-/++E4!8,2,D8P HYS
MCGVJ:U\7>'KT2FVUBSD$,*W$A$@PL;?=8^Q_J/6N>@,MCXY\8^?:7?EWMK;/
M!*EN[HX2)U;Y@,9!P,=>>E8<.G:@GPF\(R6NG7/G:5<V=Q?6?D,LSI&V74(0
M"2"=V.^.* /0U\2:,;>[G;488H[, W/G'RS"",@L&P5SVR.>U-L?$VB:E?BQ
MLM3MY[HQ><(D?DIQR/7J,^F>:XKQ%:R:MJ^MZWI\-P]H?#4]BQ6!P;B9R2B*
MN,L1ST'&['K3[2*1=9^'!6SNE2VL)HYS]E<"$M"BA7./ERRD<XZ4 =9I>K6C
M6^JWCZ_;7UK#=NID4*J6H 7]T6'#$9ZGGYL59C\1:1+;7<XOXDCLR!<^82C0
MDC(W*V",@C&1SVKS6:#4TT[7+RTTV]F^R^+5U-[80,KW-NHCR8P0-_(R,=UK
M=UO5+6_\-ZIJ^E^&9;@3/;":2XT]Q)+MD'S^40'D\H?,.V>G0T ;^K:_'-X9
MURYT>]1;W3[:1V#QG=$X0NNY&P1D>HY%8[:_JP7P%(+M=FK;5O5\I<R$VS29
MSV^8=L5B1^>;SQ^XMM6G6_TJ$VTT]FZM.1%(IP HP<L!MP#[=ZMNLWV7X:_Z
M)>?Z*Z&X'V:3]SBV9#OX^7YB!S0!VUOXBTB[LKR\@OHI+:S9EN9%SB(KRP;T
M([CMWJ\MQ$UL+E6)B*;PP!Y7&<XZUPFH:1>6WCJ73K2,-I'B)!<WHS_JGA*B
M0X])5*(??FO0* ,R#Q%I%SI0U2"^CEL2_EB=,E2V[;@$#GYN/KQUJO:ZK:C5
M-;DDUZVFM[01F6WPBBQPIW;W[YP3STQ7/Z-HU]8>+]1T?R&_L$7(U>"3^'>^
M<P_A*#(/3CUK,U,W,.I_$6>+1)=1$UO:B&"6V<QW.V,JX' W[<\@')QB@#O[
M#6=/U.::&TN0\T(5I(BI5U5ONL58 X.#@]#BK]>>^'7ED^)=Q>>7J<UO=:-"
MJ75S9M"K,LDA(P5 3 (P" ?KUKT*@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKAKSQ+XBO5U*?P[IXNC87K6JVSHN+C80),R%
MQL/+8X/09SG@ [FBN&NM=\23ZYXFT^SFTZW73+6"Y@>6V9V.]9&*, X'\ &X
M=/0YXBT[Q9KD\_A"]N?L/V#Q F&MHXFWP,8#*&#EOF^Z1C:,9ZG&2 =]6<^O
MZ5&NHL]_"BZ:0MXS' A)4,,D^Q!KE'\6ZK:ZUI4-PUHZWFJR6$UO#&SK"N'*
M'S@=OF80%E_VN@Q3I]8OM1TSQ]8W@MRNG))#$T,97<K6P?YLDY/S8_"@#M;6
MZAO;2&[MI!)!/&LD;CHRL,@_D:EK%\'?\B1H'_8-M_\ T6M8EU>:BGQ76 WZ
M+I\6BM<F$PDX'G*&Y#?>.T<]AVZD@':T5Y]+XUU2'P=8>,RMNVF3S1F:S$9W
MQP22;%8/GEQE21C!Y''6O03TXZT <WKUGINGZQ;>+-4U9[./3H9(0&VB+:Y7
M=GC<2=HQ@]JZ-2&4,#D$9%>0ZC<:G=_#'X@R:A?)<^7=WD"_N=I&PJHQ\Q&,
M #&/Q-=-+XIU/0-<N+;5FM9[%=%FU1!;Q,CQ>45#(26._(;[V%Y'04 =S17(
MZ7JOB>XU?3&FT]9=+O(&:XD"+']E?:&3:?,)=3RO3/0].*M^/]2N](\ ZY?V
M!9;J&T<QNO5#C&X?3.?PH T)?$6C0W$D$FIVRO$VV7]X,1GT8]%/L<5?M[B&
MZMX[BWE26&50Z2(<JRGH0>XK'\(6%K9>"](M;9%,!LXV)Z^864%F/J6))/KF
MJ3W@TS7-+\':/Y=L/L4ER9'3>(H49455&1SEN_0+WS0!U-%>;W'CC7(HFM!%
M8_VC::]!I5R6C8)-'*5*R+\WR$JW(.['-2ZAX@\01:=XYL);VU%[H]BMW;WE
MO;E/E>)VV["[<@QD Y/4'% 'H=%>>)JWB2T_X1'2+.ZTYCJEA*QFFMGS&8XD
M93@/\WWN>G3\*7Q)XKU[P[8:A<32:>\UA%;N(88F?S]V!*SX.8E)+!,^G?I0
M!Z%17*W.L:OJ>IZ]I^A/:Q3Z2D:J+A"PGF=/,"D@C:F"HSR<D^G-*VNM;F^*
M2VMQ=PQPKHD=PUJ(RRHS2[7 ;(R<H/F(Z#I0!UMCJ5GJ0N/L=PLWV:=[>;;_
M  2+]Y3[C-6J\XE\9:_%HUW<HNG-<0>)!I1'DNJO&9$0$?,2&^;.>?I6M9>(
M=7M=6\2Z?J*V]])IEI'>VYM(6B,@=9#Y>TLW.8\ YYS0!V-%<'IWBC6KS4?"
MB1S6,UOK=F]W/M@8FW"JC$*0_0[]N3G##WP.LUVZGL?#VIW=JNZX@M)98AC.
M75"1^H% #+KQ#H]C/)#<ZC;QR18\T%Q^ZSTWG^'\<5?:X@2V-RTT8MPGF&4L
M-H7&=V>F,<YKE/AC#$/AOH\H/F27<'VBXD;EI97)9RQ[G)(Y]*\]FEO8_A?X
M_P!-MIPEAINK7%M;AD+8A++F)3D8 +'UX.* /6HO%&BSFX6.^4RV[*LD11A(
M"PRN$(W'< <8!SCBETCQ-HNOR2QZ5J,-T\*J\BQYR@)(&<]#E6&.HQ7*>*;7
M4D\7>#3]LL_/DO90T@LR,LL$Q!(WY( 8@#/!).><5/<^+)M U3Q:MU!;-9:1
M80WL:V\1C>1I/,+!CD@DE1SCO0!W5%<Q+J&O:0LNI:B;*YTF+3Y+FX,*E'BD
M0;MJY)W*1GKSD>^*JZ=J_BJ[U#2Y/L$;Z=?0,T\AC51:/MW(1^\)D4G@\ ]^
M.E '8TA( ))  ZDUR'@;5O$7B'3K;5]1FTY;.59XV@@A</YB3,@8,6(QA3QC
MT.>>%\?WLD=OHFEJ2(]6U:"TGQWAY=U_X$$VGV8T =)+JEA!I_V^:\ABM.HG
MD<*A!.!@GU[>O:HK;7=*N[A+>"_@:=_NPEL.>"<[3SC //M7(:C(U]\;M)TR
MZYLK'2)+^WC/W3<&3R]V.Y5>GIDUV5]8P3RV]\T DNK+?);GODH5(SZ$'I[#
MTH CO-=TJPG:"ZOX(Y54.Z%LE%/\3 ?='N>*L?;[3[+%="YB-O,5$<RL"C;N
MGS#CGM]1ZUQOP@<W?P\M-4F?S;[49I[B[E/WGD\UEY^@4#'8"J_@F)9/$/CS
MP\\8DT>&]4Q1'[B^=&6E0>@SSCW- 'H=%<K\.=4N=6\$64MY(TMS \MK)(W)
M<Q2,@8^I(4$^^:/%&M:GIMS(EK-:PQ+8R3QDQF:6653]WRU.1&!U;W'([@'5
M45P:^*]<OY_!JV0L($U_3WN9?-B=S"XB1^,,-P^?IQTZTRT\:ZB-'6"Z6U?5
MWUU]$CE6,K$S*Q_>E,Y'R G;GD\9&: .S@U:PN=3N--@NXI+RV57FA4Y,8;.
M,^F<&KE<-H4=W%\6/$"W<\<[?V9:;'2/8=N^7J,GG.>G;%.^+>I7>E_#;4YK
M.5H9)#' TRG!C1W56.>W!(_&@#HCXFT-6<'5;0!&*LYE&Q6'52W3/MG-6KK5
M+"RMHKBYNX8HI2!&SN!O)&0%]3CL*;#I5A%HR:2EM%_9ZP>0(-H*F/&,8],5
MQ&@)YOQ@UNUG+-'HVF6MOIZN<[4=<NP]R0 3[8H [BSU:PU"*62TNXIEA.)=
MK<QG&<,.H./6J47B[PW-($CU[368R>4 +I/O_P!WKU]JYKQ+))I_Q;\'36>5
MDU&*[M;Q5_Y:Q(@=<_[K$D'WKB#>/-X1U_PZUDJ1:SXDO;-=0N2/L]N[29!;
M&6W<?+P!G'(H ]UJ&YNH+.W:>XE6.-2 6;U)P /4DD #N33-.M#8:9:69F>8
MV\*1&5_O/M4#<?<XS7(_$87A'AL6US'$C:Y:J0\1;+;B03\PX!'3OZB@#JM,
MU>PUF"2;3[E9DBD:&0 $-&Z]593@J1Z$5=KD(-3U/4M5UW3M(DLH)]+\I9)'
MMR1<W+1AB2 PVKC:.I/OQSC6?C;7?$3^'1HXL+0:Q87,Q^TPM(8)82JD<,-R
M[B1V]>>E 'I%%1P"86\0N&1I@@\PH"%+8YP#T&:X>]\6ZM8:Q9QRM:.D^M#3
MWMXHV<1Q-D(QE!P). Q4]CC'>@#O"0 2>@K&'B[PXT[0#7M-\U9/*9#=("'_
M +I&>OM6S7D5O9WNK6'Q'T:QTLW<M]JLT*R22(L43-$@#-D[OE^]PIY H ]+
MO/$&CZ?>+9WFJ6EO<N-RPRS*KL/4 G)%36NK:=>VLEU:7]M<01DAY(95=5(Z
M@D'@UYY<V=[HGCCP!8J/M]U:Z3<P.[2;/,*I&"V3GTJQX7N';XM^(CJ,!TS4
M+BRA:*Q4AUGA0D>>7'#-D[<=0/6@#O=/U.PU:T%WIUY;W=N25$L$@=21U&13
M)-7TV+4ETV2_MUOFC\T6QD'F%,XW;>N,]Z\R\%7,7@O5XK6ZD$.CZ[8_VC"[
M'Y8[F-/WR_\  D ?\#5KP[!,/C,]]=HR7>H>'C=2(W6,&X 1/JJ*@/N">] '
M;CQ=X;\QX_[>TT.C^6X-T@VO_=//!]JV0<C(Z5XG<:HUGI7CS3VL \&IZ_-9
M&\G8"WMFDC10TF,L #@YVXSCD5ZUX?TMM$\.Z;I;W#7#6=M' 9FZN54#/Z4
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M\K@'&>1C&0<5#:^"[73]3T2YL;EX(-(MI+:&WV!@ZOMWEFZEB5!SZYZUT]%
M!7$GX=@0I;IKU^EO#JG]IVT8CC/E2%RY&2I+#+-C/3/>NVHH 3!"X!YQU-8/
MA[PT=!OM6N1?-<?VG=&[E5HPNR0@#Y<=L <'/UK?HH YW5?"\NH^)[#78]3>
MWGL8I(H8UA5EQ)C=NSU/ ]*6Q\*1VNO76OSWTUYJ\UN+9)YE4)#$#NV(B@<9
MY.23[UT-% '+R^!["^T+2M+U.1KM-,N(YX)"H5CL[-C@@@D'ID59/AI_^$U/
MB87[";[%]A$'E#9Y>_?ZYW9[_I6_10!S&F^"[:TAUVWO+C[?:ZU.]Q<PRQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5SWB[QKHG@C3XKS69W03/LBBB3<\A'7 ]NY/'3UK
MH:XCXD?#BU^(>GVD4EZ]E=6;LT,PCWC#8W KD9SM7OVH Z/P]XATWQ1HT.JZ
M3<>=:RY )&"I'52#T(K4KG/ _@^T\#^&8M&M)GGP[2RS.,&1SU..PX Q[5T=
M !7%>,KF^A\4^%+2TU&ZM(=0NI8;E86'SJL98=0<'([5VM<7XQL]1N/%/A2\
ML],N;N#3[J6:X:(H-JM&5&-S#)R>U $.N:IJO@S7=%EEU&74-$U.\2PECN43
MS+>1\['5U RN0<AL^QK>O_%NE:8Y-R\RVR3K;2W8B)ABE) "LW;D@$] 3@D&
ML76M(U/QCKFC)<V+Z?HNF7:W\AG=#+<RH#L554G"@DDDD$],=ZRK+1[ZPU'5
M-&OO!UOJL5U?37-IJ<B1/#LD<R?OMQW90D] <X&/6@#M;3Q%8WNHZG81"87.
MF!3<H\97:&!*X)X.0"<CBHY/$]BMG%<1PW<QDM_M7DQ0$R+%V9E[9[ \G!P#
M@XQ_$7AV^N?%MCJ&G!1;WT#:?JV3C]P#O5A[\.F?^F@]*J:_I]]IWC=M87PY
M_;VF7EE';21QB,RVTD;.5($A VD2'.#VH GN]<&H>,/!=UI>I2R:7J4=TY2-
ML1RA8LJ2,9R"3P>A[9%;-[XNTFP$\D\DOV6VF$%S=K&3%#(<##-[$@$C('<B
ML.;2;V+Q+X-FM]%2VM+$79N([0((K;S4PJX!&3GJ5&,Y/>LZ/0]8M?"?B;PF
M^GRW$E_-=&RNP5,3I.2=SG.5*%CD8R<<9H Z34?'FBZ;>7UI)]NFN;%$DGCM
M[*60JC9(?A>5 4Y;ITYR:W-.U&TU;3K?4+"=9[6X0212+T93_GI7!Z(S:)\0
M-?LTM;J]$.E:?$&B4$L564 ')XW<\G@8Y(KIO ^A3>&O!FFZ3<%?.A1C($.5
M5F8N5![@%L?A0 ZW\8:3=7EK!&\I2\GDMK:X,9\J:6/=O4-ZC:W)P#M.":IS
M?$+0($NI&>\\JSNOLMU+]CDVP/\ +RY(^5<L!D^_:N533_$MU<^'KR^T&[-]
M8ZP\MT5FB$(C*RJIB7?C;AER2 Q_VC3M1T/6;CP=X[L8])N3<ZIJ4DUFF4'F
MHRQ@'.[ ^X>N.U '>:GK-K;2R6 -S)=>09G2TCWO%'R-Y].0<#DG!P#@UE_#
MF_N=1^'>CWU[<2W-Q+"7DED)9G.YN:H01:OHWCW4]2&D7=[I^LVUN$:$IOMI
M(E9=CAF& =V<@XS5_P"'5C?:5X!TNQU*SDM;JWC97B=E8_>)!&TGL?K0 ?\
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M^<-YJB,LIC4OM V#_9)],U/IOC2'4-4TRSDTR^M5U2U-Q9SS!-LNU59EP&+
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M'<WTT\<>.FU78@8['&1VK<KG(/&%M/;6O^@WD=]=74EI'92H%D,D>2YR3C8
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MZ $]^F#5OP]KUEXFT*UUC3RYMKE25#C#*02"I'J""/PH TZ*YFU\9VUQ?:9
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M\)D@<N0,D@@#V/2N7UWQ>-9TGPI=Z1;W%QIVKZA&DF"BF10LA,)!8<[DY[$
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M@& /][(X[57U?PKJ&N>)-6DN(TALM0T#^RS,D@8I)N=BVWC*_/\ 7CI7<T4
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ML0H/.,UZ//!%<P203Q)+#(I5XY%#*P/4$'J*S-+\+Z%HLWG:;I-I:RX(#QQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/[QP05<$$$'TK=UOQCXFL_#'PYN;#51;SZPT,-W_ *+$R/NV<[=O'4\*1^%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'BMI\5_!]E\2]=U*?4I%M)[.W@CD%M(<O&S[AC;G^(<UTO\ PO+X?_\
M08E_\ YO_B:Z1O 7@]W+-X6T9F8Y)-C'DG\JQ_$_AKPAX=\.7VL+X,T2Y6SB
M,KQ?98T)4=<'8>: *?\ PO+X?_\ 08E_\ YO_B:Y@_%OP:?BD-:_M.3^SQHI
MM/-^S2?ZWS@^W&W/09SC%=;;>%M&F@LKEOA[X=^S7)CW&%4=XU?'S%3",XSS
MSZUN?\(!X._Z%71?_ &/_"@#B]=^,'@76-'N-/B\22VGGKL>5=/E=@IZXRN,
M_7-/O_BY\-]9T6;2]6U4W<%Q&8YA]AF4-[@;3@]QSP:['_A /!W_ $*NB_\
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M$\VQ8AXP" N/+X #$>OOGFO8_P#A /!W_0JZ+_X Q_X4G_" >#O^A5T7_P
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M/ZJPR#^1JS0 4454MI;Y[V\2YMHHK9&46TJR[FE4J"Q9<#;@Y'4YH MT444
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M;P6]UI5C/!;G,,<MNC+&?]D$8'X58GL+.Z>![BT@F:W;?"TD88QMZKGH?<4
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M5?S%C^S)M#?W@,8S[URMSX-O;C5[Z6\TWPSJL%S.9([F_M29H4( 5,8(8*
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M'C_PO<QM)%JT;1K"\Q?RW"[5?8>2N,[B!MZG(P.15S2--TJSMDO[72XK:=X
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MMM8("5<$G.0 >Q- %S7KO7-&\%^)+W^UEDN;-9+BRG6*/)C6-2%=<$$[@^2
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MA#)$&#1D*"0#NW D8Z]Z .E?7=,33[:_%VDEM=%1;O"#(9BPR @7)8X!/ Z
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MG@$!@"< \[AC!P16SI%G=Q6UR7U>[N8;A_,MC/ $EMU('RG*\\Y(W+D9QS7
MW>A:A8^$746-V[WOB9=3CMHH6=H(/M"O\P4';\J[L>K8ZUZBTRK!YQ$FW;NP
M(V+?]\XSGVQ0!YWX4U76-?\ !<%_/XJDM]5N)IH(5,,&PNLCJ@*^7NY"C.#Z
MFNSU3Q'I>C>8;ZX9%B4/,R0O((5/1G*@A!P>6QT/I7)?#/P];P^$[0:EHQMM
M4MKJ:7?/:[)5S*[*0Q&3\I'0]#BH=0@GT[QAKT.I^']5U73=8,<EO)8[G3B)
M8WBE4, H^7.6XP3DT =I?ZWI]LHB:[D$DL)F0VL33.L?_/3"JW'/4C%8/@GQ
M*USX T;4=7NY+B\NU?YDB+R2D.W1$&3@#L.*HZ=%>^%_&]U)/I%T^G:AI]I#
M;-8Q-,EJT(8&$XY5?FR&.!ZFN;T>QUC1M!\(ZC<Z#JLUO9075I>V=N&6XB\R
M176144@L/D (]#TH ]&;QKX=2RM+QM4C$%W*886*-DR#.5(QE6&#P0#Q3/\
MA./#ILA>+?.T'D&Y9EMY28X@Q7>X"Y095N6Q]T^AKE]2L%%OX<ET_P /WEI#
M_P ) E_-#Y#/(J;'#2R@9PQ8@XSG&,\Y ?XQCU.]O_$=@FCWK1W&C&.SFLH1
M_I,A63*RR\$!21A,@'<W!R!0!MZKJ=W'X\\+6]K?,=/OX;II85"E'V(I1@<9
M_B/?'2CXD:MJ&@^ ]3U;2[HV]W:(KHVQ7!RZ@@A@>Q-9$$-Y)KGP_G;3;Z-+
M2RGCN2]NW[EFB15#$9 R5/T[XK0^*=K=:A\.=7L+&UN+J[N45(HH(F<L=ZGL
M.. >M $4^LZKHWQ!T+0O[0;5+;4X)GG26)!+:[%!$F8U4;6/R\CKT/:NAU/Q
M+I.CM)]NNC$L1432")V2'=T\QE!"9R/O$=17*IITOA/Q0FMZ+ID\NC:P%CU"
MT@MB)+:11\LRIC.TCAE ]#S5*2"6T\0:]8:KX;U;5K+5K@7-I+;!C"ZM&BF*
M8%@$P5ZL.GTH [J_\0Z7ICR)<W)#10_:)!'&\GEQ?WVV@[5X/)]#Z&H[?Q/H
MUW<6$$%Z)'OU=K4B-MLH49;#8QP.>M</K1DTKQ3J4=I8:CLN](@M;DV5@UY&
M"/,"[0K H54GKG.1P,<S.L%L? NI:39:E<Z3I7GV<BBV=KB+]SY0WQXW##+@
M\<?2@#3\9>)BW@75M2T#4I(KBQN$@D=8L%7\Q%="'7CANWYUOZGXGTC2)9H[
MVZ*-!$LT^R)Y!"A) 9RH(4'!Y..A]*\ZOK#59_ GC2U_L;4$N;W6FGMX?)+-
M(A>(Y&W/9&YZ<=35_P 8IJ>IR>*+*+1K\QW.D!;*2TM]OVIMCY$K\'*DX$9(
MZG@YQ0!UMQXLM(/%MKH'E7#R3VC7/G) [( &15Y (P=Q)/08&3S1I&M:<-*U
M"_.N->VL5Y*KS3)M\D[L>4,*,X)"CJ23CFL&TCOH?&/AO4GTJ^^SOHCV;D19
M,,F^-OWG/RC"D\_3KQ6*=(UB7PW?RVNGW7G6GBIM6%K)$8VNH!-O 7=C)(Y
M]1ZT >@IXGTAUO2UV8FLD$ES'-$\;QH>C%6 .#@\@8XJ'3_&.@ZI>VEI9WXD
MFO(?/M_W3JLJX!.UB "0",KG([@5SNJ64VK^([K7[6UO$MHM!FLR)+9XY)Y)
M&#*@1@&.W!YQC+#WQ3T^SO(H_AFK:?>J=.@*7F;9_P!P?LIC^;CCY^/UZ<T
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M8*"[ 98G 'U)I]>7^*=6F\1:/X8U>.PMQI\VNV;6TKR$S*GG *^-N & Z Y
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MSC!SO/';'>L63P3J[Z)JMFE_:)+=ZS_:B@JS1.I=6,,@X)4[<$CKZ5WM% '
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MW!2< X..,5T]<NW_ "5.+_L"O_Z/6NHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSHLVEZMJWVJ"XC,<P^PS*&]P-IP>XYX-=O\ \(3X4_Z%C1?_   B_P#B:/\
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MACCP<L!@[CG QQUK*TSQ!=:CJWB+3A8Q)-I4B1Q_OR1,7C#KD[1MZ@=\<]:
M.@HK/AU+RTTV#41%;ZC>)_Q[))OPX3<X!P,@>N/3UK0H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRP8SF%=Y(X!W8SD=J .3\0+]K^'_ (PU4LX:XM;EX&5RI6.*-ECP1V)4N/\
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MDO/MDEC;-=;=GGM$I?;Z;L9Q[5#_ &!HWV3[)_9-A]FW;_)^S)LW>NW&,^]
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M8\UF'))R0<_=%;T,5Y:>*/&C2Z;>F+4((9;>5(=Z,%M]A7(_BW#&!D\YZ<T
M=#IVL6%OX=TJX?4Y+Y+J)!!<&(F6Z)7.X(JY)(!8@#@9I)/&&@0Z2^IRZBD=
MI'-]GD9T8-'+D#8RD;E;)'! ZBN*TK3]4TRS^'^IR6%XT&F6+V5_;+"QE@9X
MT4.$QE@&3!P#P<C-0^(=#O[C3/&&H6UC=NFKWU@UK:K V]EA:/?(4QE<[6ZX
M)VCU% 'H>F>(]*UB]NK.QNO,N+8*TL;1LAVMG:PW ;E.#AAD>]:E<3+)/;?$
MF^UA=.OYK1- 5%:*V;,DBRO(8UR!EMI&!ZG'6NHT?5(]:TFWU"*&>!9@<Q7"
M;9(V!(*L.Q!!% '*>.O%:V>D Z3J,T5TFH06S/% 6C8F55>,N5*Y +< @@C'
MM72ZCXBTO2WF2ZN&!@C$LWEPO((4.<,Y4'8.#R<=">U>8?9]8M_AFOA:XT34
MY=6L=0A9WCMF:.=!=K(95D^Z<CDC.0<Y&,FNHL1=Z)XF\4'4-.O+FUU5H[FU
MDA@:4/\ N@C0MM!V$;1C. 0>O6@#I[OQ%I=G&))+DNA@^T[H(GF B[.=@.%/
M.">N#Z&EU#Q!INF1&2YFDVB+SV\J!Y2D?]]@@)5>#R<=#Z&O-8_"NHZ-X?TN
MVAFU2S\0Z?I"I'=6L+7$%P2SL;:10"I"G&"<?>SFM&Y74M,\3/>:SH&HW]IJ
MFGVT;C2MSBVG0,'C958?(=QP3Q^M 'H]M<P7EK%=6TJ303('CD0Y5U(R"#Z8
MJCJWB#2M#:V74KQ;=KE_+A!4G>V"<# /8&L[3]2M]&N='\/#1;JR2X@8PF*,
M-;P$!F\IG!^_M5CQQQUJIXVAGGU'PLT-I<7"VVKI<3&&%G$<8CD7<<#U9: -
M6/Q9HTUG;W4%S+-'<1--&L5M(\A0'!8H%+ 9XR0.:E7Q+H[KIKI?(\>IMMLY
M$5F25L$X# 8!P#P2.AK!>.\T7XDWNJ7%M=7&FZC80PQS6\+S&"2)F.PJ@) 8
M.2#C&>*YU= U+1-#T"[>PNI4M_$,VHRVMO&9)+>"7S0H"KDG&]20,XR?2@#L
M-;\;:7I.A:SJ*&:Y?2ODG@2%PRR%<JIR. <@[NF#FM"?Q%IUM:I/,UPN^-I/
M+%I*T@1>"QC"[@!ZD8KSW4M,U;5-&^)$46CWL<FHF.2T66, S 01C"\\GY3Q
M^'7BK^I7%Y;>+8=<GT'6KO2M0TZ.VV6JN)[:2-W(WQJP.U@_4]".<4 >@V5[
M;:E90WME.D]M.@>.6,Y5E/0BLZV\4Z-=WL%I!>;I+AI$@;RG"3-'G>$<C:Q&
M#T)Z'TJ7P_9PZ?H5K;6VG+IT*@E+12/W0+$@'&1GGG!(SGDUYO8QZO<7WA*]
MN- U*">SU&?[7;Q6XCM[8-'*H$:@@%<L#YG.<\MSB@#N&\>>&59@=44A;G[(
M["*0K'+D##MMPHR0,G )[\&K&OZ[::?9WD'VR6&[2V:;=! 96A7G#L K!1D'
MEAC@^AK@+_3]0F\">-;2/3+]KF\UIY[:+[*^Z5#)&0PXZ85OR^E;"O?Z5XK\
M4FXTS4+FVUJ**6QN(+=I!\L.PQ/Q^[.>1NP.3R* .D\$WUSJ?@;0[^]E,UU<
M644DLA !9BH)/%7+?7]-NKN.VAFD9Y2ZQMY+A'*9W;7(VG&#T-9O@""YM? &
MAVMW:S6UQ!9QQ213+M9650#Q7+:7I.IPZG!#HS:E;:9>K<?;+"_@;9I\C(V)
M()& P"YQM!.0Q/'8 [5/$VD7%[!817Q6>ZWK;OY;!)2OWO+<KL8CV)Z5S7@S
MQI;OI%K;ZWJC2ZC<7]S:I(\1PS"9U1"RKL5BJC .,]J3P7>7BZ1I&AZEX8NX
M+_2(EADN9H 8$"+MWQ/_ !%@,87GYCGCKAQ:?J"^ =.M3IE^+F+Q&+MXOLK[
MEB^V&3?C'380?TZT >B:GXETG1S)]NNC&L6WSG$3ND.[H9&4$)G_ &B*35]<
ML;.&: WDD=P;<S!K>$S-&G9R K #(/+#!P?0UQ5Q;RV/B77['5O#>JZM8ZO.
M+BUEM-S1.#&B-%*-P5,%.K<8/M5NQCOO#?C+6EN=)NYK+4[6V%G)90M-'$8H
MRAA8C[@R<@M@<G)% &AX'\4)?^&/#L>J7C2:OJ%D;@;HB/.V\N00-O&1P/45
M%XN\2E_!TVJ:!J4D;V^H0VLI6+!R9TCD1@ZY&-QZ8.:YO0;34M)L?AY>W6C:
MD$T^SNK2ZC2W+R1/(J;24'(4E",]N^*2>PU63P'K]JVCZ@ES/XD-S'%Y!9FC
M^UI(6&W/ 52<]#VS0!Z/JGB+2]&$AOKAT$2"24I"\@B0YPSE0=@X/)QT/H:T
MHY(YHDEB=7C=0RNIR&!Z$'TKSG4(YK#QCK7]I>']6U72]96)[=[(.RJ1$(WB
ME3<H4';G+<?,<UVATUV\*G2[=$L7-E]GC6,Y6 [-H /HO]* &1>*-'FN[>V2
M\^:Y9DMW:-UCF89R$D(VL>#P"<X-<V=8O?$GBG6M&L=2OM+;3_LXMI4LF92Y
M4NYDWKC!&% )&>HSFLN#3-0U7P3X8\.2:;=6FIZ7=6@G=X6$<2VY&Z19,;6W
M!>-I)^?V.-_P]'/'\0/%D\EI=1P736OD320.J2;(BK8)&.#Q[]J -+6/%-MH
M^O:1I,L%S)+J!D(>.W=U540D_=!R<X&!T!).*Y_3?&4&DZOXGAU_5I#!::BD
M4#/#GR8VBC/S>6N%7<Q&YL#WK0\4PW<?C#PIJ<-C<W5O:R7*3?9TW%#)%M4D
M=AD8R>!WKFM3L+Z?1/B3#'IMZTNHRG[(OV9_WW[A$&WC^\I_G0!Z#J>OZ;I"
MN;R9QY<?G2>5"\ICCY^=@@.U>#R>.#Z&KD-U;W%FEW#,DEM)&)$E0Y5E(R"#
MW&*\XN%N=,\33W5_H6L:EI>JV-NB-9*Y:&1%*M'+&"" <YR>.3[X[[2;:/3]
M%M8([-;..*(!;:/YA$/[HQUQTX_"@#*3Q]X8D2VD754\JYE,,<QB<1^8&*[6
M<KM4Y4X#$9[5>T[Q+I&JO>I:W?SV6#<++&T1C4@D,0X'RD D-T..M>=QZ??C
MX;V%D=+O_M4>OBY>'[*^X1_;#+NQCIL.?TZUHZ_H^HZSX@\7P65O<1_;]#BM
MK>>2)DC>53(2NXC'1E'X^U ':6?B/2K[4#80W++=>3YZQS0O$7CSC>N\#<ON
M,US>K>*A-XJ\)P:5J$_V6^NI%E3[.1%<1B)V#*[+\P!"\JV.1[5F?99?%FBW
MD<'AG4M,UL:=/;_:=1+ 0NZ%2D3,QW G'(&,#)YP*9'<W^HR>!0/#^JP2Z9<
M[+U'M2JPXMWCX8\,N2,$$C'H>* .OTG6M.^QZM>G7&O+:"^=)'E0*+=L+^Y7
M"C=@D8ZDEL9)J=?%6BF&_E>]$0T_;]J2>-XWBW#*Y5@&^;MQSVK@9=,UDZ/K
MES9:;=//;>*1JT=K)$T9NX%*'"[@ 2=I(]U'M6YK&IWFI^&-3U'3/"EP)G$*
MM'?62^?, XW$1'EO+7)4-U;ITY -VYUVVU#2M833;R6&^L829 T)22%BA9"4
MD7H<<<8/-/\ !U[<:CX)T.]NY3+<W%A!++(0,LS("3Q[FN1TZ"\BU[Q?<'3=
M7,%_IEOY$US$2TK*DH(QU!RP^4 8] *ZKP/#-;>!="M;B&6"XM[&&&6*5"C*
MZH 00?<4 6)_$^CVUXEM->;7>X%J'\M_+\X](_,QM#>V<YXZT7WB?1].DF6Z
MN]BP.J3R")VCA9L8#N 53J/O$=1ZBN1\+R:AID$GA;4_#EW<W$%_+-!>O"&M
M9$>9I%F,AX##<3C[V0,>T4=EJ%CHOC3P_=Z;=W,^I7-W-921PL\=PLZ_*"X&
MU"IX.XC  (XH [G^W=.^WW5B)V-U:PB>6(1.2(R2 PX^8$@],]*IMXS\/)!I
MTYU*/R]24M:'8W[T $G''H#UZ].M<M8V%_X:\5VRS65[?1OX>MK!;BWB+JTT
M3/N#-T7(8'+8%9V@6&HP:7\-H[C2K^)]/>7[4&MV/D@PN@+8'&68=>: .LU'
MQ_I%KX?_ +6M#/=Q_:ULBB6\@:.4N%(=2N5QNS@@$\ 9)%:U[XBTS3X/.N9)
ME41>>RK;2L\<?]YU"ED'!Y8#H?0UYYJ&FZE+I'BLQ:9?.S^([>_BC%NP:6%6
M@W,@(^;[C<=>*TM3:ZL?&5UJ%[H&L7^E:M9PHGV(,SP.F\%)$5AA6#YR>AR/
M6@#IK[QOX<T_ROM&J1_O;8W<?EHTF^(8^9=H.>H/';FF3^//#5NMVSZED6@4
MW C@D<Q!AN#,%4X7')/09&<9K$MM.>S\<^&C!H\UI96VEW$)2*)FCMV=HRB%
M@",X5LX.,_A4,]K='4_B*_V"\*WUK$EJPMG(G(MRA"\<_,<?KTYH ZRU\5:)
M>ZK'IMO?+)<RQF2(!&V2J,9V/C:V,C(!)%+)XFTB*^ALY+LK)/,;>)S$XB>4
M9S&),;"V01C.<@CJ*Y"VM;M;SX;DV%X!86SI=DVSX@)MO+ ;CCYN/UZ<U4\-
MV,L,5OX<UKPQJ5S?65V7CO9"S6;@2%EG#%L!@#G;C.?J< '<KXIT9KZ.S%Y^
M\DN&M4;RG\MIE!W1B3&TL,'C/8CJ*E.OZ:+Q;7SI#(TQ@#+ Y0R $E-X&W(P
M>,]B.M>;W,>KW;Z5-+H&I1W%EXC\^:WMK<);QQ;I,.F"!(6W*Q<YY+9*@XK5
M2PU"T\6)>:&NHP)<:HW]HZ;=P,UJR;CNN(W(PC$ -P>2<8H ZQ_%NB1Z9<:B
M]X5M+:X-K/(89/W4H(!5AMR.2!DC'-1WOC/P_I^HRZ?<Z@JW<31J\0C=BOF'
M:N< \$\9Z#OC->?ZQ9ZI'X8\9Z)'HNI3W=UJ[7D#10$QR1/+$P*OT)X(('([
MC&376Z5'.?B=K%Z]E=1V\^G6T<<TD#!2RM(67=C&1N7O_*@#:E\3:1!?0VDM
MV4>:<VT;F)_*:7G]V),;-V01C.<@CK5K5=7L=$L3>ZC,8;9656DV,P4D@#.
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MMOAFDNG7JMIT3K>9MG_<'[.T8W<<?,0/UZ57OK*8>'O%GG6&HK++XBCN[+9
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MR 21WKA7M+\W/CITTO6)(]4T:)+:6XB+-,XCF4C'8DNORX&,] *TH;>Z76_
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MI*=JVT2J<L=H)Y8 #'?K@5C^-M<CU_X=>*+2\LD@U'29XXIXMWF*K;T9)$;
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M523\SJ!P,\GC%0)X_P :?ITFH6(TJXN[N6T8W[-'"CH"00Y49#\;20,\^F"
M=M2%U#A"P#$$@9Y('7^8JMIT]S<V$4UW;K;SMG?&DF]1@D<-@9!ZYP.M<)8>
M)YE^&VM^.@@DNIEN9;96Y"1QNR1)]/EW'W9C0!Z"]Q#'(L;S1K(_W59@"?H*
M<70=64?C7)>&-$L$\%VEW>6::G=WEJES>32QK))<.ZAFR6ZCG '0  "N/\1M
MHNJ_"S1I],ADETW^U[=;9KF/YBAN,$#.3CDKSU H ]>R",@C'K2!U8X# GV-
M"QQI&(U15C P% P,>F*\/CTJTN] \=6UCHLL^M'7[I-/EM+4AX7^381, !&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKRV[/(93&<A0I V@_5L>]*GAG4M,U?6[C2+FV%KK)$LD=P&S;S;=ID7'WP0
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MIG.V- HS]!0!PVF^#->MSX4%SJ>GE/#VZ-!' ^9H_),0)RW#;3VX!]>@?=>
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ML&?88V9LMTR#O((XJBGAJ]\/1:]JNC?8--O+Y(=EM%&\MNLB$[GV@*2[AL8
M'('7-=S10!!9O<26-N]W&L=RT:F5%.0KX^8#VSFIZ** "BBB@ HHHH ****
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MG@_A0!R7A]9-7^*.IWVM[+36-+MOLMM8Q<HUL[;A.'/+Y.1T&WH1FNC\=?\
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MO9(Y7BSG8[@Y89YYJ[-X7TN6_P!-O5BEAFTZ(PP>3,R#RSC*, ?F7*J<'TH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRV#Z6;Z,"':Z-YP3:6SR,>U '5452UC5K/0M(NM4U"416EK&9)'Z\>@'<D\
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M/K'QIJFMQ?#S4)?M4,=MY?D2X C+88';WW&M;_A:OQ#_ .B8W_\ W[F_^(H
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M^TUX>(4 MI#DD#J<35A:AXT\5:M9PVFH?!U[JV@_U4,UK(R)QCA2F!QQ3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG?'
ME]>Z7X'U?4=/NGMKNTMGFCD55;D#."&!&*Z*N:^(-O<7O@+6K*TMY;BZN;5X
M8HHD+%F(X^GU- %?3KB2YBTAD\5RS7<XCD>V86["0;0T@PL88<9YR,'%6+KQ
M[X=LQ>M+=S;;&7R;HI:2L(#@'+X7Y5P1\QX]ZJ6$L$%EI*P>';O^THECB#M:
M&,1$J%=F?CY0"20,YQQVK#O=.U"72?B1"FG79DU-G^QKY+?OLVZQC'_ @>OU
MH [2S\4:1?ZQ_9=O<.;HQ&:/="ZI,@(!:-R K@9'*D]::OBO1WO[:T^TN'NM
MPMG:%Q'.5&2$<C:QQSP>>V:YJZL;R[\2>$GCM;N.*#3+JWGF\E@('D2(+GWR
MC?3'O53P?9S1VNE:/JO@Z>/4=)V(;^55:V C&!+&V[)9@. !D$\\4 =39>./
M#^H7)@MKUV8><&=K>1$0Q??#,5 4CT)%2P^+M&GO;.T6>83WL8EME:VD'G(?
MXE)7&.1],CU%<WH5F8/ OBFWU2PN(XIKK4)FBE_<F6&1G9<,>!E3U/3O6;H,
MQEO-!&LV.NVUS8V9L+2>?3O*B1Y5527=6;+':J@_*,GIR, '<CQ5HYO[:T^T
MNKW3,EO(T+B.9EY(1R-K' /0\XXS5-/'WAQV0+>RE6NOL9D^RRA(YMVW:[;<
M(2W W8S7,>$+&>&UTK1-6\'SKJ.DE%_M"15:VQ&,"6-MV2Q4< #()YP,U4N=
M,U*3P#KMDFEWINKCQ"UW#%Y#9:(W:2AO^^%)]>U '<6GBF"[\8ZAX?6VN5>S
MAB<RF!]K,^\]<8 P@P3C)) SBM.]U2UL)(8IC(TTV[RXHHVD=@O+'"@G R.?
M<>HKG;""\M?B9J]VUA<-9ZC8VHBN0H"*8_,W!LG(/S+QC/-.\9Z7#J=QIH==
M4MIHA*\&IZ:&:2U?Y1@JH.Y7&<@@CY?QH HZEXG\GQGX<GBO[DZ1?V-U*;=8
M"2[)Y>TA OF%OF/R_H*WX?%FBW&D6NJ179:VNIOL\($3^8\N2-FS&[<"K9&.
M,$]*Y73;?7G\1>#[S6;.5KBVL;R.\GB@PBM(R>62%X#,$R0. :I64.M:?HRH
MFCWAC?Q'<SSE+<&>*WD>1DDC#="<@$CD GH>0 ;7C/Q+Y_PXUK5=!U&:WN+-
MC&SK'M>.17"LC*ZY!Y]CT(-7GOKU/BK;Z?\ ;)38R:-+/]F(7:)!-&NX8&<X
M)ZD]:XVYT?5SX \;Z8FBZBMQ>ZD\UHDA$C2J_EX^;<<D;3DDX]S76M%<2_%*
MRU%;2Y^Q?V-);F8PL%61I4<*<C@X4T =+?ZC:Z9 LUW)L5W$: *69W/1549)
M)]!7)^'?$33^*/&!O+^<Z?8-;F-;J/R_LX,99QC:#U[G.>.34WC6UU%-3\.:
MW96<U]#I=X[W-K!S(R/&T>]5_B*[LXZ\US>HZ3K6MS>-Y++2KJ!KT6$]D;H"
M-9S"%8H><C.W'/3/.* .Y7Q;HQFNX9+B2":TB6:6*X@DC?RV. RJP!8$\<9Y
MXZ\5#JNOZ:VA:L\M[>Z<EK"1/.MLZR6^Y20Z@J<X'.0"*YP06>N:9>7,_@2_
MMRUL+:Y6X4+<.K2*2D1#$D+@OGCD+COBM+IFNKX-\7Z7YNH:I9RV1ATN2[@(
MNG9D8-&V0&8 E<,P'4^E '<MK-C9PV$3W$L\US%N@58R\LJJH);:H]QDX R0
M.X%9Z^/?#;6EK=C4&^SW4_V>&0V\H#2<_+DKP>#U]".U<YK$UQI^K>%K^TTW
M49;VWTZ6.9;>W$Q5"(QM>(LK#YAD,#_#C!SQ2CMXGT;PY9Z7I^K%[#7TN[Y+
MJT9)4W"1WD*]-I,@QC/'K@T >@Z/K^G:Z+G[#+(7M9?*GBFA>&2-L C*. 1D
M$$''-1ZIXETO1YI8;N:3S(;<W4JQ0O(8X02-[;0<#@_D?0UE>';>YB\=>+;F
M6UGBM[N2V:"5XRJR!(0C8/L1^/:LSQ=#JU[J^K62:3=RVL^D&.UFLPJ^;*=^
M5EDR& &00N<'+<$X% '27?B[1+*ZM;:6[=IKN W%ND4$DAF0 '*;5.X\C@<\
M]*DMO%&CW6A+K,5WFR9_+#&-@^_=LV;"-V_=QMQG-<AI-KJ"ZSX&GFTN]A2Q
MT>:WN2\6?*=EB"@XSUV-].,XK,&DZW%H4-Y!I=U))I_BF;4WLRFUY[=GDP4!
MP"V'# >WK0!TV@:U<:A\1?$%D;JZ>TM[2V>.WN(O+\EV,F[ *@D$!3DY^M=#
MJ6NV&E,4N9)#(L33-'#"\K+&.K$*"0/?OVKG-"^V7/Q%U?5&TJ^M[&ZT^VCC
MFN(Q'ED:0D$$Y!^8=OZ5'J+ZGX?^(%UJHT>]U33-3LH;<FS57>"6-G(!4D?(
MP<\^O6@#I/\ A)-*:VLYX;DW*WL1FMEMXVE:5  2P503@9')[D#J:K2^,] A
MTNTU)]046EU.+:*3RWQYI;;M;CY"#P=V,8.:PVM-1TKQOINO2::XTZ72FL)8
M+1/,-F_F>8ORKR01\I*@\@=JQKGP]J-OIC3K8W+-?>+(M6^SI&6:& 2(2S =
M"0F['7YL=<T =U8>*='U!-0>*Z:+^SN;L7,+P&)2-P8AP#M(!(/3BN?G\2O/
M\1=$MK6ZOEL9K"YGEMI+5D#;=FQU!4,W5N,GH.!WQO$V@ZOK-[XXBT^TF5[Z
MSL1:/(A1)VA9F=,GU!"\X!S6J+J_UKQUX8U1=!U.VMX+2[CN3<1!/)=_*P#D
M\CY3R.O;/. #HHO%VB36&FWT=VS6VI3BWM9/(DP\A) 4_+\IR#]['2G7WBK1
MM-E=+JZ9%CF2"681.T44C8VJ[@;5)R.IXR,XR*\[LK#6H/"_AK1CH&HM<:3K
MJ2W#;%"&,2R-N0D_,,,#GI[YQG;T9M7T:]UC0;OP[<WRW6I37EG>!4:V9)7W
MCS6)^4H>HP3P,=J .CTWQ3!J7BG5=$2VN4;3Q$ID>!PK,P9CSC & N"<9YQD
M5F>-[_4[+5?#,&GZG/9QZAJ(M9Q''&V4*,V1O1L'*BI='MKVR^(OB226PG^R
MZ@MK)#<@#R\)&58$YSG/;'?/2JGCZPFU'5?"RIITUY;VVIK<76V NB1;&7)X
MYY(XY- '.:[XIU^TLO'>EQZK)*VBV\4]MJ,<<:R*7&3$^%VY'J #7H6G>)]*
MU+49=-@N'-W%")RLD+H'CSC>C, '7/&5)%8_CC14_P"%<:UIFB:6JRW4)6.W
MM( N]V(YP /S-17$5Z_Q#L]2MK"X>%=#FMP\D3*GG-)&ZHQ(XR%/TH W+#Q7
MH^IW=M;6MR[/=QO+:LT+JDZ*0&*,1AL9'3L<].:EMO$>FW<\<44LA$JN\<K0
MNL;JGWB'(VD?CSU&17 :-:ZS+KO@S4+G0]3BDMH[B&^#*D<4#NB@".,-A8P0
M<$#D8Y8TV'PWJLL,NGZ(=0LM.U*QNH[O3[]"8K"5XV"M Y&<%V^ZI(P2>* .
M^M?$^E7FI0Z?'/(MQ<1&:W$L+QB=!C)1F #8R#QV.>G-3ZQ:ZC?6Z6^GWYL-
MS?O;E$5Y%7'1 P*Y)QR0<#/&>G)^$U>]N--^W>#KC3]3T]"LUW<JIC1MFT^0
MVXEMW'0 8SD],]'XFU>]TG3U;3]+O+^XE?8!;1!_*'=R"0#CL,C)].2 #-\&
M7FL&\U[2=6O/[0&F7:Q07QC5&E5HU?:P7C<NX D>M:FJ>)])T>6>*\GD#V\'
MVF<10O)Y,62-[[0<#@_D?0U5\*7AFMY;=-#U/3HHCO:74519+B1B2S85CDYY
M)..O ].=\86^KW]_XAL$TB\EM[C2#'92V851-(5D!$SY!^4D;4S@Y;@DT =3
M>>+=%L;V&SENG:YG@-S#'#!)(98QCE-JG<>1P,FI(/%&CW.B0:Q#=[[.=_+B
M(C;>[[BNP)C=NR"-N,\&N4TNWOAXG\*W<VF7L,5KHDEM.SQ$^7(?*PIQGKL;
MZ<9P>*QK32];L=+T;44TJ\E_LO7KN[N+$1XD>&9I0LB _>($F<=>30!U/A76
M;G4_&WBRV>ZN9;6U^R^3#<1>682R.6 &T'&0.3G(QR:;XIOM4A\<^%=+L]6N
M+.TU,W2W"Q1Q,?W<6]2"Z-CGK2^&5O)/'7B;4)=,O+:SO8K0P2W"!-VQ&##&
M<@\CM]<5!XNT]]0\>^$)GTR6[L+-KHW;?9S)&@>+:F1CGYO3.* .=U'Q;KR^
M'?&4']IL9-"OK>&#4HD13,CNNY'XV[E!P2N.HZ5Z#;^+=$N)K^(7;1-80_:+
MCSX7B BY_> L!N3Y3\PR.*R/'FCC_A7M[I>BZ8-TCQ>7;6<( XE1F. ,#@$U
MG>(8M6?Q;JNH:7I+W>_PX;> 7$!\J6;S&?RV#8S\IZ'@],YH ZNS\3Z3>SRP
MI</%)%;"[9;B)XCY)SB0;@,KP>>W?%26WB#3KIG"R2Q!(/M+-/"\2^5_?RP
MQ_+OBN%M+2_;Q1)J+Z#JUQ:W'AY[=Q>[09)0^XH5#80$< *![#'-1)X8UB;2
MM:T/2KK4&T:YTETMH]50B2TG) $*NPW-&1D'J!@8)H [VS\2:9?:F--CEE2[
M:'STBG@>(R1YQN7<!N&>N.E&OVUS<61\O6WTB"-6>6YB6/<,=.9 5"]<\9Z<
MCG.!X7<:G?6UU<^#[G2[^UC99KB[5<(Q&"L+;B6!/.< 8'K6_K&H06\D-E=Z
M3>7MO<AMSQ6OGQIC'#@9(SGCC'% %;P3>ZEJ/@_3KO5IHI[N5&)FC  E7<=C
MX' )7:2.Q-6-4\3:5HWG_;)W MXQ+<&.%Y!"ASAGV@[1P>O8$]!5+P3H+>'M
M%GM?*-O#->SW$%KD'[/&[96/C@8'.!P"2.>M8I?5- \9Z^LV@7NJZ=K1BEMY
M;54=598A&T<NX@*/E!!/&": - :I<M\3H;9+^272YM#>[6%=I3<)4 <8&3E3
MZGKQ3]/\5:'I^A0WL^MW-U:W-]);Q7-S$P/F&0KL.%&T*?E!(' ZU MM>1_$
MVSO9;*1;:/0VMI)88F,2RF5'V XZ84_RZ\5S,6F:FO@W3K5M+O1<1>)A>O'Y
M#96'[4TN_P"FT@^O:@#M9?%>C7^D:T8[^ZM!81E;J3[-)'-;!E)$@1DSTY!P
M1Q5R'6+&UTK3&:[GNC=0J;<^67FN!L!W;5&>F"3@ 9[5R.I65[)J_CR2/3[M
MH]0TB*WM6$#8FD6.52HX]77KQ^5,,6KZ)<>$M=CTB]O;>VTDZ=>VL*9G@8B,
M[PA(S\T>#CMSS0!UD/B_1+FTL[FVNVG%ZSI;QQ1.TCLF=XV8W K@YR!C\16+
MXG\1&Z\/Z'JVA:E(MO<ZM:0LT:@>8C3!'1@PW#N".#U!IFI3:HU]H<B>'[F#
M3YGN&G6T1/M,)8#8&8'Y-YW%BIXX!/4GGK72M6A^'ND:;)H]\ES:>(%N'C*;
MSY2W;2E\@G(VD<GKVS0!ZI=W<%C9S7=U*L5O"ADD=NBJ!DFN=U_QO8Z+H.J:
M@+>\DFL(5D:!K:1"=^X(3D#Y25.3VQZ\5J^((H[KPY?PRV#W\4L#*]HO#2J1
M@J.F#CZ5YWJ'A_7Y?"7BG1[*74-2TV2QC^P?VA&4N1(&):$%@&=0 "">[8!/
M- 'H4?B+3I-0M]/+SI=W$+S112VTB%D0@,?F4=,CCKR*9%XIT>?3?M\5TS0&
MX:U4>2X=I@Q4H$(W%L@\8[$]!7/ZK)??\);X9\0)HVH26RVUU;RQ)&#+$TGE
ME"RYX!V'G/'&<5S5EIFOZ=_9>KMHEXZ:=K]_<3VB[3))%.759$7/S;=W3J<\
M4 ;NF^(C/J/CK[;JM]#I]B(A'(T!62T#0DN579G@\@D'H#R*ZB'6;&UTG3F-
MS<W9GMEDA*PM)-.H4$N549[C)P!E@.X%<<UOJ-U-\0IQH]_''J=G&MF9(@#*
MWV<I@+G.<D=1QWQBHI[/4=,?POJ\FA7NI6<6D#3[RT@7]_;R?(0X0D;AE2#C
MV- ':0>*]'N[2VN;2Y>ZCN4>2,00N[E4(#DJ!D8) ((SGCK6G:W<-[8PWD#%
MH)HUEC;:1E2,@X//0UY_J&@03Q6,EKI>I^';E$FFM+K38][P,S E)D3<&WX#
M$'(XQG/)[3P\=1_X1O3CK$<<>HBW3[2D0&U7QR !Q^ X]* ,BS\4Z)IVAW>I
MSZU<W-D+^2%I[B%LQ2%\>5@("%4G:"1^-:NE^(],UB^NK*TFD-S:A6DCE@>(
M[6SM9=X&Y3@\C(XKSVXTO4Y/ &NV2Z7>FZN/$#7447DG+Q&Z64-]-H)_3K74
MVT%PWQ4NM0%I<+9R:/%;K.T3*ID65W*\C^ZP_EUH W-1UVPTNXCMKB21KB2-
MY4AAB:5RB8W-M4$X&1^8%-7Q%I<FGV5[#<^?#?*&M?)1G:88S\J@9X')XX[X
MK%\0MJ)\66$:Z9=3::]G*IN+(*)?-++B-Y,@I'@9X(R0,GC%<AH5EK_A[2?!
MFJ/H-_.NFVD]A?6<:J9T#E")$7/(RF#T.* /1;?Q3H]UIL5_!=F2&:8P1JL;
M>8THSE-F-VX8.1C@ GI1!XIT:YT^6]CN_P!U%<FT=3&PD6<''E[,;M^2.,=Z
MY?6UU=+K0/$UEH$YALKJ=KC38@OV@Q2IM\S:#@N#DX!SAL=<T[7;;5-2M]'U
MRRT6:!;'5EO)+!E59YHBA1G*@XWC<2%SG ]>  =#+XQT."RU&ZGNGA33L?;$
MD@D$D((R"4V[L$<@XP?6E@\7Z+<02S17,A6.9(!FWD!D=QE1&"N7R.<KD8YZ
M5QOBK1;W67\4ZQ965ULN]"&FV\)A99+B7<[%MA ( W*N6 []NNGX@M]21O"&
MN6>GW-U#I<K&ZLD3$H5X3'N"'&2N3QUYXH -#\4JNO>,Y]2U&<:9ITEOL%U%
ML, :/++MV@_>/'!)XZ\5T(\5Z0(=2DDGEB_LU%DNTDMY%>)&!(8KMR00#R,]
M#Z5Q-T-=-SXWU"P\/W3F]^Q/:K<PH?,5457*HQY8#) (Z@ \\4AL-1^W^,94
MTC5C#J>BQQV\EQ\[R2!95VD;B0277Y<#'<** .TT[QAHFJ:A;V5I=2--<P?:
M+??!(B3( "=CLH5B-PR 21^=21^*]'EO[6S6Z;?=NZ6SF)Q',R_>".1M8\'H
M><'&:Y'^S;^:Y\!H+.\B%II\\%U+Y+#[.[P+&,_\"!Z>F>G-6O!,^JV^DZ5X
M=U+PU<0WFE*L+WDBH;?:@VB2-\Y+,O& .,G/% '2/XITB*^M[62Y=3<3FVAE
M,+B*249^028VEN",9Z@CJ*LZSK5AX?T\W^I2O#:JRHTBQ/)M+' SM!(&2!GI
MS7 >%]-N+2*T\.ZOX2GN+VPN=T>I2!6M657++,&+9#X[ 9SZ<X]!UK2H-<T2
M]TJZ&8;N%H6]MPQD>XZ_A0!''KVGRZW+HZR2_;XH1</$8)!B,G ;<5P>01P>
MHK.77=,U#7-$\C5;R-[F&:2WM?(9([I,#+-N3^'J.1][N#7'Q^'_ !9,FA:U
M,&CUHJ=*OE5S\EJR[3+[L'7S1_O@=JZ/5K&5/'OA*2ULIC96,%U%))'&2D0=
M$5 3_P !(]N^* ,7Q)XWFO\ P=XBNM*DO=.FTN^6W65H"F]0\2MDLN!G>W (
M; !XKM--\2:7JVHW.GVLTANK=%D>.6!XR48D!UW ;E)!^89%>>ZMI>KCPOXS
MTE='O9)[S6#=V[1H&25&DB88(/HK9],8ZD"NJBAN)/BJ=0%I<BR;15MQ.T+*
MOF>:7VG(X.T_TZ\4 ;^H:Q9:9+;0W$CF>Y++!#'&SO)M&6PJ@G '4]/SKF/$
M_B(W7A[1-6T+4I%M[C5K6%FC4#S$:8(Z,&&X=P1P>H-7/%+ZBNNZ((-.N;BP
M8S"YFLU4S1L0-BAB045N<L"#P.0*X^UTK5H?AYI6FR:/?)<VGB!;AXRF\^4+
MMI2^03D;2.3U[9H ["RO;T_$_5-.DO)9+)-,@N(X6"[8V:213C '91US57QU
MJM_I>H^&EM=5DL;>^U$6MSA8B-A1FSEU.#E14]G!<_\ "TM1OC:W"VDNE00)
M.T1",ZR2,1GZ,*J^/;.>^U;PJ(K">[AM=46XN2D)=4CV,N3Z\D<#)H U]/ND
MMY;Z^?Q&U_IL"[)?-$6(9  QPT:+G*L..>:LV_B?2;BYN[8W#6\]I"+B:.ZB
M:$K$<_O/G RO!Y'3'-9?B[P])=>#=2M-!M84NY98KM81^[69XW1MI]-PC"US
M6JZ5/XN\+:O_ &9X5N-(U.2Q\CS;]5220AU?R5.XDH=I!)P.1[X -B?Q')=_
M$7PY:65W>+975K=2RV\MNT:/M5=C@LH)ZMW].!WW_P#A*M'%];6C7+JUU(T5
MO(T+B*5USE5DQM)X/&><'&:Y>2YU'7O&/A744T'5+2*"WO([IIX@GD.ZQ@=3
MR 0>1U[9YQ2\(Z?/;6NF:#J_A"=M0TJ1 -1D56M2(S\LR-NSO*] !G)YP,X
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MOA>VM[*=[>74]0@T\W$9PT22-\S ]C@$9[9K9O?"6BWGAV31/L$$5H8C&@1
M#&<8# ]=W?/6@#7%S;M=-:B>(W"KO,0<;POKCKCWHM[F"[A$UM/'-$20'C<,
MN0<$9'H01^%<?#&(_C'J#0QIYCZ!"Q_A#-Y\@Y('L.>:HV'C.X@\+Z#=V.@6
M4*ZEJLE@;:*?8L3>9(-PPF#DH23QR<X- 'H$LL<$+S32+'$BEG=S@*!R22>@
MI8Y$FB26)U>-P&5E.0P/0@]Q7&-XIO7TGQ;!J.DV4MWHL9:6!9RT-Q$T7F 9
M*9^[D$%<?G5NQ\137@T[3-*M+:*Z?2HK]U<D10HW"( .N2&'; 7Z"@#JJBGN
M;>V\OSYXHO,<1IYCA=S$X"C/4GTKF9/$>LI8V$EQI,6F2S6SRW#7LX,<,JD!
M805/S,V20?0=">*P==U:+Q-X5\$:Y]F$+7.LV$JHQW&,L_(!_P YH ]'DECB
M3?(ZHOJQP*;%/#-GRI4DQUV,#BLOQ8B2>#M;5U#*;"?((R/]6U>::+H\U_IO
MPZN/#^F2VUW:1V\NH7X@\E#;^6/,C+$#S-YQC&?7B@#V.BN*T[Q9XAU*35)(
M= MGM]-N[FUF6.[)ED:-,J(P4 .YL#G&,^U/LO&^W5[NQU-;4+;:6=2EEM9"
MXA"MB2-O5E]1U]!0!V517%S!9P-/<SQP0K@&25PJC)P.3[D"N?LM9UZ\?3IE
MTB$V6H6S3"03<VC;0R"3^]NSCY>A'<<URUKXGU)OA(NO:QI]AJGF3@O%*QVD
M-<E0=I4CY25P/0=>* /3J*YJ]\0:A+=ZQ:Z'8PW<^DHAECED*F:1DWB).P.T
MK\QXRP&.IIE_XHN4O/[.L[(B_6R2[FCECDD$>\L%C/E*W)*-D]!COF@#J*;Y
MB"01EUWD%@N>2!WQ^(K.T'59=7T"TU*ZT^XTZ:6/=+:W*E7B8$@@@@'MP<#(
MP:\^F\5WMI\&=6\;P_\ (2OMTD;$9\I6F\J(#V12#CIG)[F@#TQ[^SCNEM7N
MX%N&Z1&0!S^'6IPRE X8%2,YSQBN;AT?2-"\&O'+8+>VR6_F71*+(]P=N7=B
MQ^9CR>3GTKC3J%KK>I> _#=FMPOAZYM)+EH[C :YBB0>4C8)RO0D'K@9% 'I
M\%_9W08V]W!,%.T^7(&P?3CO3DO+:1@J7,+,>@5P2:HWGA[3KNYL;G[-%'<6
M,HD@DC0 KP05X[$$C'T/:O+Y=/L;O4_B39G1'O[R6=%M5AMMQ60P#:0^,)AC
MG)(]: /8A(C.R*ZEEQN4'D9Z9IU>>7SZGX3\*>%=3U&8R:G:2VUGJ$F[=YL<
MA".K'^+#%6!]5]SGL?$&L1>'O#VH:Q-$\L=G TS1IU; Z4 :5%<G%XDU8^)[
M30WL;)VNK WRW"SL!& 0I7;M.[EEYRN1GIC!JVGCJYNO#OAC5SI\2C6;Y;.2
M+S2?*W%QN!Q\WW.G'6@#L4N8);B6".>-YH<>;&K@LF1D;AU&>V:&N;=+E+9I
MXEGD!9(BX#,!U('4UQ\OBVUTC4_%]Q>:7!!_926Q:: @R7>]3Y88[1SG"@'.
M,]:I7AO8_BKX;GU*"SB)TZ]8O Q)X\K*L2.0O8]\G@=P#T*JK:E8+!<3M>VP
MAMV*SR&5=L1&"0QS@'D=?45RMEXTOKZ?1[BWT:XFTS5& #QV\V^W1AE)')38
M5/&<'Y<]6KGH;^/0?"7Q!O%TNTOH+?6YV>TG(6-U\N'/&T@^N,?C0!ZJ#D9'
M2BN6U#Q%JL/BV'P_I^FVDAFT][N.::X95!5U7# *<#YNV<\=.M4]/\>/J.D:
M0XLO*U'4#<*T05YEB\A]DC?(NYANVXX'WNHQ0!VM%<-_PGTUO86C:O8?V/+-
M?R637%ZCI;C:I99 6"G:_ &<=^>.>NTRXN;K3XIKN***9LY6)]Z8R0"K=P1@
M_C0!8DECA7=+(B+G&6.!48OK1B +J D\ "05%J&E6.JBW6^MH[A()?.1)5#+
MOVLN2#[,:X'P3H&DZA<^,X;C3K9E37Y5C/E+F/"1D;3CC!Y&* /18;JWN'E6
M&>*5HFV2!'#%&QG!QT.".*EKRFWUF^\+-X[U*PTVUFL[+5?.N%>4QDIY,6X(
M I^;J><#ZYXZO5O%ES%=7]KI%D;NXL8$F=3%*WF,X++&"BG:2 .3_>'!YP =
M715/2[Y]1TFUOGM)[5YXED:WG4K)$2,E6![CI7,6'C2ZDU_2--O[.WMY-2CF
M9H%FW2V;1KN"R]B2OTP?7K0!V=1SW$-K;R7%Q-'##&I9Y)&"JH]23P!7-:=X
MDU758-*U.QTI)])U"4J")<2PQ<[9F!X(.!E1R-PZ]*YU?$NKCPCXRU+5;'3]
M2AL+VYB^RNY",D84;<%2",#/N2>F: /2@0RAE(((R".]1SW,%JBO<3QPJSA%
M,CA06)P ,]R> *YZY\17-AXBT+3I+2!+#5(V$=P'(*2JFX1[<8Y&<'/\)XJE
MK?B&:/2[*[N-)LKNUFUF&TB\QR=JF8(LP!4@G/(Y'&#F@#LZBM[F"\MTN+:>
M.>%^5DB<,K?0C@URFFZKK=SX_P#$E@PM7M+*"V\F(NRXWK(<DX/).,G'  ZX
MJIH?C"%_"OAYK/2X;.?5!*8;2"-GC@1"=QVHN3_#T R6[4 =W17#MX\GM-*C
MGU?3VTISJ1L&N;N.1+<+M++-\P4[&P%&<8)Y/%=7I-U<7FG1SW20I(S/CR)-
MZ,H8A64]PR@-^- %VHK>YM[N,R6T\4R!BI:-PP!'!&1W%<SI_BMM6UZYTRW%
MF6MKM[:ZM)'*W$<:@XEVG[RL=N,<8;.>U<IX;UV^\-:!+/%I]L^E?\)%<6LS
M>:5D42710%%"XPI8=2,\].I /5JA-W;BY-L;B(3A#)Y6\;M@.-V.N,D<UR?B
M;QG=^'?MUQ+90+:VDD*HDLN);M7*AWC Z!=V.1R0>E,>"%OC-S$A\WP\PDRH
M^?\ TA1SZ\4 =A;W$%W LUM-'-$V=KQL&4X.#@CW!H6Y@>YDMDGC:>-0SQ!P
M60'."1U .#CZ5R?PJ 7X:Z.   !* !_UU>B3Q!);>(/%:1:/9_:=,L8+@3"7
M:UTI$A"NVS(QM.!SUH [&BN*TKQEJ5U?>&EOM-MH+37K4RPO'.6>-UB$I# J
M!@C.,$].:N:?XDU358-,U.PTM+C2;Z<QY67$L47S 3-G@@X'RCD!AUY% '20
MW-O</*D,\4C1-LD5'!*-C.#CH<5+7F$&L/X5M_B'JUI:0RBSU-9# 3L##R(L
MX(!P><]*ZR\\4?V=XJ;3+N*-+-=*EU)KG<<H(V56!7'HV<Y[=* -Z:YM[=XD
MFGBC:5MD8=P"[>@SU/M4M>9Z[?7NKW/@/5IK*VAMKO58I8<,3-&K0R%58XP<
MCDXZ$8^;K6O=^-[P+)=Z9H]Q?V<-Z;1XX;>9I7"R>6\B$(4^5@?ESR!G(Z4
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M8+.W>XN9HX(4&7DE<*JCW)X%2UY]J7C&X;P/XDNM1T2QNI](NFM;JU>4M!*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5TU<\E]>Q^/SIC73264FFM="-D7Y'$BKP0 <8/?-=#0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>8?&_PWXB\2^%K6#0%DG6*<O<VL;X:5<?*?]K![>^>U>GT4 >?
M?!O0==\.^!%LM?#QSM</)# [[C#$0N%/IR&..V:]!HHH *Y?Q7_R&_"'_88/
M_I+<5U%9FLZ)#K/V%GN;FVELKC[3!+;E0ROL9.=RD$8=N,4 7WMX9'1WB1FC
M?S$)'*M@C(]\$CZ&AH(7>-VC0O&Q="1RK$$$CWP2/QIX&  23[GO2T <P_\
MR5.+_L"O_P"CUKIZRX=#BC\12ZV]U<RW+P&W5'*[(XRP;"@*#U'4DFM2@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_"X_"7_ #VN_P#P'-',NX>QJ=COZ*X#_A<?A+_GM=_^ YH_X7'X2_Y[7?\
MX#FCF7</8U.QW]%<!_PN/PE_SVN__ <T?\+C\)?\]KO_ ,!S1S+N'L:G8[^B
MN _X7'X2_P">UW_X#FC_ (7'X2_Y[7?_ (#FCF7</8U.QW]%<!_PN/PE_P ]
MKO\ \!S1_P +C\)?\]KO_P !S1S+N'L:G8[^BN _X7'X2_Y[7?\ X#FC_A<?
MA+_GM=_^ YHYEW#V-3L=_17 ?\+C\)?\]KO_ ,!S1_PN/PE_SVN__ <T<R[A
M[&IV._HK@/\ A<?A+_GM=_\ @.:/^%Q^$O\ GM=_^ YHYEW#V-3L=_17 ?\
M"X_"7_/:[_\  <T?\+C\)?\ /:[_ / <T<R[A[&IV._HK@/^%Q^$O^>UW_X#
MFC_A<?A+_GM=_P#@.:.9=P]C4['?T5P'_"X_"7_/:[_\!S1_PN/PE_SVN_\
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M/^%Q^$O^>UW_ . YHYEW#V-3L=_17 ?\+C\)?\]KO_P'-'_"X_"7_/:[_P#
M<T<R[A[&IV._HK@/^%Q^$O\ GM=_^ YH_P"%Q^$O^>UW_P" YHYEW#V-3L=_
M17):#\1O#_B/54TW3Y+AKAU9@'B*C &3S76TT[DRBXNS04444R0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\U\4?#U=;\1W>HG1Q<><5_>_P!J&'=A0/N>4V.GJ:]*HI-7+A-P=T>._P#"
MJ%_Z%\?^#L__ !BC_A5"_P#0OC_P=G_XQ7L5%+D1I]8G_5SQW_A5"_\ 0OC_
M ,'9_P#C%'_"J%_Z%\?^#L__ !BO8JH:QK-EH5B+N^D94:18HT1"[R2,<*BJ
M.2Q/:CD0?6)_U<\L_P"%4+_T+X_\'9_^,4?\*H7_ *%\?^#L_P#QBO1M-\3V
M^H:U)I#V-_97J0?:1'=1!0T>X+D,I(/)'&<UN4<B#ZQ/^KGCO_"J%_Z%\?\
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MV'BJ'P]%HU[=W<UL;J-HGB5&0'!Y=Q@@T<B#ZQ/^KG!?\*H7_H7Q_P"#L_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>modificationno15effectiv005.jpg
<TEXT>
begin 644 modificationno15effectiv005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,K.58H=H V@\ANO!-GPY)<0_$?Q5IQO+N6SAM[.6&*>X>41LXDW;=Q.,X'%
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MK<0.3&NP#+<8'((_ ^E=3:?"_P")^GZQ:ZK8S^';.]M@XBDMK>&+&X;3D+"
MW![@XKH/[(^/'_0QZ5_W[A_^,T 3:[-'+\?/!5S&X>W33V5I5.54LDNT$] 3
MD8^H]:X+QA<KJ?AGQ3!IVCW6FI%K*R/9QVTC!SR&FED8$ DX 12H'H>H[?\
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M10 44$@=:* "BBB@ HHHH ***,CUH **** "BBB@ HHHH **** "BC(SBB@
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M*?)SZ\X]/>IIM&\4:3XKU*_T%]-GL-5:.2>*]=T:WE5 F]=H.X%57(..1U%
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M!)(JO:>+H=4@TK^R[9I[G4K+[='#*_EB.+Y>78 XY8   Y.>P)JMKVAZS?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBJVHWT6F:;<WT^3'!&TC!1DG Z
M=R>@'K0 EOJ-G=7MW9P7"/<6;*MQ&#S&67<N?J#FJESXDTJTUVVT6>XD74+D
M%H8?(D/F #)(8+C [\\=Z\[T^5O#/CK2-3FBNHEU]#9ZHTT#QH+LDR1$%ASR
M6C'H *Z3XDV4\6D6GB6PC+ZAX?G%ZBKUDAZ3)]"F3_P&@#I[S5[*PO;2SN'D
M6>\8I JPNX<@9(RH(&!D\]AFL*Y^)7A"TNYK6;6%$L,AB<+!*P#@X(R%(//'
M%6='O(/$6LMK-M();"WMUAM7'1FD"R2-_P!\^6OL0XINOQ1W%WHF@0HJPS7
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M%0L0,AG8C) SFNB\-W$^I_%3Q%?1VDUK;0V-M:3I(5):<%G&=I(R$8#KQD4
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M3SK"L84R?9=Q;!4C/S,/0 \8ZT >F45B^)[RXL=,B>VO8;-GN8HWDD4LY0N
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M4;P&4]TS@Y R>. 1Z5JPQH=\"22+:3D]_E- %>V\1:?>0:1/;F>2+54WVKK
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFK9:';1W-]'_ &*-MK*D^'VE-A4G'0KQQ@^A%=)10!DZ_P"'[7Q%9P07,MQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#2F@:=X&2,R&53M5B &X&>,BNHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPQ?:P_W&QG&<<9K$\(_$8>*==UVW33KU+:RE\F$?9V)RH8N7/16)& I]!WH
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M++MW8'U5@?8JU4]<\3:Y<?&3P_91:K=0Z+J392VB?8K1*[H&R.?F*%LYZ,*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?9>1+<N""?E(#.0!UZ'. 37.?\(-\:/^AXL?^_\ )_\ &J/^$&^-'_0\6/\
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M]#Q8_P#?^3_XU1_P@WQH_P"AXL?^_P#)_P#&J ,Z/1-3UGP]\.M!M;*[AO\
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MH_X0;XT?]#Q8_P#?^3_XU0!!HO@N^\3_ +/L?ATV\UIJ]K.\\<-U$T1WB1R
M=P'56(STR:[3P-XKCL_"6G:5K=GJ%CJMA EK+;O92L7V#:&3:I#@@ \5R7_"
M#?&C_H>+'_O_ "?_ !JC_A!OC1_T/%C_ -_Y/_C5 ':_$:^:3X1Z[<W-M):M
M+:L@AE(+#<VU,XZ$Y!QVSBMGP1I]QI7@70K&Z4K<06,2R*>JMM&1^'3\*\GO
MOAK\7=2CCCO?&&FSQQRK,J/-(0'4Y4X\KG!YKUSPA8ZUIOA>SM/$-]'?:K'O
M\^XC8LKY=BN"0#PI4=.U &W1110 4444 %%%% !1110 4444 %%%% !1110
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M%C+&MQY1>)?/E.#(K<!09.2>,#/M5?08IY+]=.FD\.:C:WULUI-+IMU+)/%
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M8('  &/E)WGUZ>_$5WX&UV?[4BZI8,K:U'JL4LL#M*P60.L;G=T4#:,=@.E
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MNQ_=PI&>F>.M &A167)JTD/B6WTF2V79<V\L\4ZR9_U9C#!EQQ_K!CD]*U*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KS/XU>,->\(>&K.;0AY3W,YCEN_+#^4,9
M ((R>>3Z&O3*CG@AN86AN(DEB<89)%#*P]P: .$^#WBC6?%O@?[?K8#7,=R\
M*3A GG( IW8''4D<?W:[^F111P1+%%&L<:#"H@P /0"GT %<OXK_ .0WX0_[
M#!_]);BNHK!\2:5?ZA/HMUI_V9I=.OOM31W$C(KKY4D9 8*V#^\ST[4 2ZCX
M7TO5=4MM1O+=9[FV?=$9OG51M*E0IX .<G'4@'L,)?\ A72=2U>VU2ZMEFN[
M=\HTHW@+M*[0#P!SNX[@'M6R,X&0 >^*6@#GK_\ Y'_0O^P???\ H=M70UBR
MZ=?S^,;34G6V2QM+2>%,2,9)&D,1R5V@*!Y9[G.>U;5 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8?\ DE^ ?5I=SHJ*YW[9<_\ /9_SIO\ :,OF^5]I/F8W;-W./7'I3_UJP_\
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MV7/_ #V?\Z'Q306].7X!]6EW.BHKG?MES_SV?\Z:NH3,2%N22.H#4?ZU8?\
MY]R_ /JTNYTE%<[]LN?^>S_G1]LN?^>S_G2_UJP_\C_ ?U:7<Z*BN=^V7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWGY^?ZBC423U-Y/B5+%;Z%J%]HOV;2]7<1).+D.\3GIN7:/E]\YP#QVK2O\
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MG_WY7_"M2BAX:BW=P7W(.9]S+_X1O1/^@39_]^5_PH_X1O1/^@39_P#?E?\
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MHD^ZB# 'X5+15PHTX.\(I>B!MO<****T$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$X!/I0W8!:
M*R_[:CW;?+Y]-U+_ &PO_/$_]]5Y/]NY?_S\_!_Y&OL9]C3HK,.LH!DQ$#_>
MI!K4;#(B)'J&H_MW+_\ GY^#_P @]C/L:E%9G]L+_P \3_WU1_;"_P#/$_\
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MH_MA?^>)_P"^J/[=R_\ Y^?@_P#(/8S[&G169_;"_P#/$_\ ?5']L+_SQ/\
MWU1_;N7_ //S\'_D'L9]C3HK,_MA?^>)_P"^J/[87_GB?^^J/[=R_P#Y^?@_
M\@]C/L:=%9G]L+_SQ/\ WU1_;"_\\3_WU1_;N7_\_/P?^0>QGV-.BLS^V%_Y
MXG_OJC^V%_YXG_OJC^W<O_Y^?@_\@]C/L:=%9G]L+_SQ/_?5']L+_P \3_WU
M1_;N7_\ /S\'_D'L9]C3HK,_MA?^>)_[ZH_MA?\ GB?^^J/[=R__ )^?@_\
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M+_\ GY^#_P @]C/L:=%9G]L+_P \3_WU1_;"_P#/$_\ ?5']NY?_ ,_/P?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7Z&MVOM^'J]2MA'*K)R?,]]>B..NDI604445[IB%%%% !1110 4444 %%%%
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MOY4>6G]Q?RH_U3G_ ,_?P_X(?6?(YBBNG\M/[B_E1Y:?W%_*C_5.?_/W\/\
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M(!]QD9K,T/PS?Z3!=+-(MQ+<W4ER[I&(U!;' &X\#'K0L'BW3ES4Y7=OLO\
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M>)M-_L_6+S3KJUWB3RVO OS#H<JP/>DT%?!_AC3C8:-=Z=:6ID,AC6\#?,<
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M]0.G;/'2O6;K7["73)A:ZSIL-XT+"(O<HRI(1QGGD XKP_\ LGX+?\^VK?\
M?<G^-']D_!;_ )]M6_[[D_QHYEW#V-3L:VE>&]5C\0>%=:U+6_#L]YITT[7T
MO]HYDF#]&+$<D X"C@8'KQZ'XVO++7/!NJ:3I^J:6US>0-"IEO$55R.I//\
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M&"Z1IIU.<#&!M//+$]!C'.:XG^R?@M_S[:M_WW)_C1_9/P6_Y]M6_P"^Y/\
M&CF7</8U.QV>NV+7_P 7]$\5V^I:,;#3K<P.CZ@@D?/F<@8Q_P M!U/:MWQK
M_9VK>!=2T+1]1TI9;M2J^9>(B(6?<2>O?/ %>7_V3\%O^?;5O^^Y/\:/[)^"
MW_/MJW_?<G^-',NX>QJ=CI)= N-7^'FD>"[W6]"L;.W\L7ES%?B5Y%0Y"HN
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M#[GE-CIZFO2J*35RX3<'='CO_"J%_P"A?'_@[/\ \8H_X50O_0OC_P '9_\
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M'(@^L3_JYX[_ ,*H7_H7Q_X.S_\ &*/^%4+_ -"^/_!V?_C%>Q44<B#ZQ/\
MJYX[_P *H7_H7Q_X.S_\8H_X50O_ $+X_P#!V?\ XQ7L5%'(@^L3_JYX[_PJ
MA?\ H7Q_X.S_ /&*/^%4+_T+X_\ !V?_ (Q7L5%'(@^L3_JYX[_PJA?^A?'_
M (.S_P#&*/\ A5"_]"^/_!V?_C%>Q44<B#ZQ/^KGCO\ PJA?^A?'_@[/_P 8
MH_X50O\ T+X_\'9_^,5[%11R(/K$_P"KGCO_  JA?^A?'_@[/_QBC_A5"_\
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M_P"#L_\ QBC_ (50O_0OC_P=G_XQ7L5%'(@^L3_JYX[_ ,*H7_H7Q_X.S_\
M&*/^%4+_ -"^/_!V?_C%>Q44<B#ZQ/\ JYX[_P *H7_H7Q_X.S_\8H_X50O_
M $+X_P#!V?\ XQ7L5%'(@^L3_JYX[_PJA?\ H7Q_X.S_ /&*/^%4+_T+X_\
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MM &"><8&*S]9\&KK.AV>F2ZO?C[/<I=&X8J\DDBMN&<C &>P '0# XKIE!"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?&,9[UN5!96=MIUE!96<*PVT"".*-!PJ@8 %3T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>modificationno15effectiv006.jpg
<TEXT>
begin 644 modificationno15effectiv006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN0@G# ?=Z'N?H*E\<:[/;ZQX<\-6<KPS:U=%9IHSAD@C :0*>S,"!GMSCG%
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MMQ\5_#W_  D?A3Q'!9:B;[2+0VES;NJ!)$,97*/NSD%B>1SGMBN<O?&>B/\
M#6_T&WBO6U/4M2^WW,DD:K%'S]U2&).,#D@=37THGB7P=(9 KV_[J40R$V;
M1N<?*QV84\C@^M:.FW&@ZM->Q64%O(]E-Y%P#;;=CX!QR!G@CD<4 >:VW[1?
MA);6)9=/UA9 @#!88R <=CY@S^5<;-\7]#B^+2^++2UOWLYK 6<\<L2K(GS
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M\@?6H-'^*4.@>&_%6DZ:]Y!-J-W+=6-XL:[U+[1AAN^3Y5(R"W)SVY^E[?\
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MWO+>S@:">-98RUN%)5AD9! (X/0U7TN?0=9%W]@@MY?LEPUM-FVV;9  2OS
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M@X5551[+7N-QH.CW@C%SI5C,(W#IYENC;6'0C(X/O4W]FV'_ #Y6W_?I?\*
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M& >?;K0!I45FQZ_IDVN2:*ER3J,:>8\'EL"J?WB<8Q[]*;+XBTN#[?YL[J+
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M#3/,C&G7.DR7?E"/YA(KQ@9;//#'L*S_  GXHN=5UE-/U*[EM-5C@=KS2;J
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M54J ,*&'!/))]>M+I_A2"R?3VGO[R^&FJ5LA<E#Y.5VYRJ@LP7*Y.>">Y)H
MXV;Q1XG@\/ZIK;ZC;,NEZXUDUNMJ )XA.L6"225X;(QSD<D]O0M<GN;30=0N
M;1T2XAMWDC:1-R@JI/(R,]/6L*3P#92Z'J&DOJ>H_9[^]-],V8MWF%Q(<'R\
M ;E!QCM717UB+_2Y["2>5%GB,3RIMWX(P2,@C/X4 <AIWB>_U1/".FBX$-YJ
MNEC4+NY5%R $3(0$%069^X( !XY!&'H>KWFB-K-H':XO+_Q7)9B940-C[.KE
M@&(7=M3'IDYQVKJY? ED;+1(K?4+^VN]%C\JSO8VC\T1[0I1@4VLI '5>U0R
M?#G2Y]/U"TGOM2D:\O1J'VCS562&X  $D951M. /;VH RM;UKQAH?AG7+N4Q
MQBVGMS8SW*1M+)&[JK*ZQG:"I)PV.1VJ^-1UR#Q5JVA7.IK*K:2+^WGBMU1K
M=M[(5 .01P"-V3]:NW'@>WOO#UQI-[J^J7)N6C::[DD0S,$8,J_<VA01G '<
M^IJ^/#4!\2-KDEY=R7#V7V%HVV"-H\EN@4'.23G- '$Z9J^L:5\+/"M_#J'F
MRW<]E',9X@S;)756 /'/)Y.36M]GNF^,\F+^4(-$1]FQ"-OGM\G3IQUZ^]7E
M\ V2>&[+0AJFIFTLIXYH&+QEU\M@R+]S&T$#MD]R:TE\.1+XJ/B#[?>&Z-J+
M0Q'R_+\L-NZ;,YR2<YH Y>U\8:I#HM\UR8Y[S_A(7TBW,42H%7>%!"EL9QG&
M3UQS5N?4/&.G6>M.;&>[AC6*2Q+"$W3*6 F79&=K%5R5X&3P<U=;P#I<NB:I
MI5S<WMQ!J-VUZ[NZJ\4S,&WQLJC:00".M3VWA$0Z9+;2ZYJ]S<NT;"^FE1ID
M$;AU"_+MQD<Y4YSSGC  >#]=@UZTO+BVU5KZ))]@66$13V_RC*2+M7#;MW;H
M1]:S);_Q%>^.]5TBUU6VM+.SM[6Z4_8_,8AF?<ARW<)U[<8%='I>B0:9>7UZ
M)))KR^9&N)G"@ML7:HPH P!^/-16WAZ&V\3WFO+>733W<*020L4\O:A)7 "Y
MXW-W[T <UI&N^)M;M]#UNPMW:QOI%:Z@F\@11V[9PR,&WEUXR#P>>%X%9=SX
M@\8MH'B76;;4[$?V%J%PGV8V?RW$46"5+;LK\N<8YSW].FTGP'8Z)>M)::CJ
M8TX2F>/2VF!MHG)W95<;L \A<XSSBL7PSX??58O%-KJ#ZE;V-[K-Q(UK)!Y2
MSPL5P063=M8 @X/3TSR 6(-7\1:YXMN+"QU.WL;,:?:7\8:T$C 2,VY#EN<A
M<9XQV%)IVO>)=<MM,UK2[=VM+BZ(G@E\E81;;F4E6W>9Y@ !YX)R,"NEMO#D
M%KXFN-=CNKGSI[=+9H#L\H(A)4 !<C!8]^]9NG^ ['2]3EN+34=32QDG-R=+
M\\?9A(3NR!C<!NYVYQGMVH HZ?XHN9?&"Z/J5W+IU[]KG"V5Q !%=VX#^6T$
MF/F;_5L06_O# J+3M>\2ZY:Z9K6E6[M:7%T1/!+Y(A%MN925;=YGF  'G@G(
MP*WU\*6[7-K)<WUW=16EX][;PS;,1R-NZ$*&VC>< GTZX%4]/\!V.EZG+<6F
MHZG'8R3FY_LL3C[,)"=V0,;@-W.W.,]NU ',W?BCQ/;Z!X@UG^TK7&CZPUL(
M%M !/$'C4J222.&/3G/?L-JR:_/Q3\0 ZC(T,&G6KQP2!1&-QEXSC(&1G/7\
M !5N;P#8SZ+J^E/J6H_9]5NS>7#!HMP<D$A3LX&57\JNS^$K.YUFXU*6[O"]
MU9BSNHE=52=!NP6PN01O;H0.>E '/:3XCU>;Q!H=A-?BYCU2PN))9HX5$231
M[#F!B 73YSRV0>"">:Q]-UC6])^#KZW#JAFN_MCY:XB5N&O&1L8QR=V><@=@
M*ZS3_ 5II]UHMQ_:VJSOH\;PVWFRICRF"C8P5!D#:O/4XY)'%(WP^L&\-W6@
M#4M26PGG\\()(R8OWGF[4)3[N\YYR>V<4 .U+6;S1O'5A!>W:KHFH6THCW(H
M\NXC ;#-C[I0,1[J:JOKFJK<Z1I1:Z-UJ,$]ZSQ)")8HE9-D8#X3=B1=Q(/W
M3QSQOZWX>L?$.GV]GJ0>5()X[A6R 2R'/.!C!&0?9C5?Q)X4M/$ALIGNKNQO
MK%R]M>6<@26/<,,.005( R".U $OAB77)-*=?$$4:7D<[HK(5_>Q _([!20K
M$'D ]17)6MWJUKK/C^YCU>(R6<D:P?;RJP1Y@5QN(&0JECTZ]^3FNYTO34TN
MR%NL\]PY.Z2>X?=)*W]YCP.P'       K#U/P%INJS:VTUW?I'K"Q_:88I55
M Z!0LB_+D, J]21QTH S+3Q%K9U;Q!IMIYM_);Z5'>V'VN$0O)*WF+M( 7Y2
MR#&0#U[8-4)_$<>O>"/&"KJ4\KP:1*);&]MQ#<VLGER;MZA1E2-N#ST/-=$/
M ]N;VZO9=8U:6ZNK#[#-*TJ LHW8< ( &&XXP .^">:ENO!MK?IJ)O+^\EN;
M^R_L^6Y C5Q!\V5&$QD[CDX^F* ,[P1J\NNV,4EK=F*UT^".T>S9 )&E5 2S
M9&54@C&.HYR.E,\(>*+C5]66QU"\FMM4BMF:]TF[MQ&R2;EP\1 ^>+[XSENJ
MUIVG@JSL=5@U&VU"_CGCLTLI0IC"W,:_=,@V<L!P",'%6+#PO!9WMA=SWMW?
M3Z? UO;/<[-R*VW<254;CA0,G^9S0 SQ!>WEOJ.FVUO>K;PSB7S%A027,C #
M:(U*L-O)+,1@<<C-<K;>+O$-]X9\'7T<]K#<:IJ#65UNM]P./-^8#=Q_JLD#
MUZBNOU7PU!JFM6.K"]O;.[LT>(-;.H\R-\%D8,IXRHY&"/6LRU^'UA9V&E6<
M.I:F(=,O6O;8-)&V'.[@Y3E1O;WYY)H QW\8:MH\.O6-W<17E[::I;6%G<O$
M$!^T*A4NJ\?+O/3&<=NM6[6VN;;XR(MQ?/=@^'W*M(BJR_Z0F1\H (_#/UK1
MO/ 6EZ@NMK>7-[,NL21RS NBF*2, (T9505("KUSTJ?3_"2V>O0:U/K.I7M[
M%:&SW3F,!HRP;!"(.<@<]?7- %?QCX@N- GL9I?MD&CNLGVN^M(!,UNXV["Z
MD-A""^2 >0O2J]MKM^WB'PM9KJ4%W:ZGILTTTL*+L>2-8\.A[ ER<<]JZ&_T
MI[R]@NXM0NK62*-XBL01DD5BI.X,IY&T8(QW]:R6\#:?'!HB:?=WFGOHZ/';
MRV[(6*. '5MZL#G /3@],4 <?J.J:GK.FZ(TUQ$;NW\8O:12M%P%C\Y5+*",
MG YQC/M6_IWB74-#US6]*\2W8O8;*WAO(;RWM&WF.1BFUHXP<D,O4#IR:NQ_
M#_3H=/\ LL5_J"E-3;5(93(K/#.2QXW*01\Q&&SGZUMZ;HT.G7-U=F66XO;K
M;YUQ+C<P4850%  49. !W)Y))H XWQ-K8UQ/#%QH^HWEO;2ZY';2JULT1<[&
M<$K(@)P5!';ZXX7Q=XFUC0X=9NK>^CD.G?9VBMX8@X*';O-P2OR$Y.T*P.,'
M!KK->T"W\006B37%S;26=TEW!-;LH=)%! ^\"",,1@CO6+J/P[T[41K$;ZEJ
MD5MJVQKF".9=OF*JJ) 2I;=A1G)(..10!6U'Q1<V7B]M+O[N72UDNH%T^22
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M[^L:'PW;P>)VUZ.ZN5F-HMG]G&P1")6+* -N>"3WK9H **** "BBB@ HHHH
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ME(OD; K%795X#G) )Y(!]#67HEC::=K?PWNK2,17%_IDD=S("=TZBV1E#'N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3 )(QGE>>:YWP_XSO-8TSPS;0P6=OJ.K037,F(V,4$49P<+N!))*@<CN>V"
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M^IJU>^&;2^\5:=K[NZW%G"\.Q?NRAB"N[UVD$CW.>U;=% &(V@2-XT3Q%]L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGMYBN0DL;!E)'<9&#[&H(M%U"_\ $>GZYJT=I%/I]M+#!#;3-(I>7;O8L57
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M>&)7<$!RH7..^0,CG#9-!U[_ (2?4=9A?3TDGTA;*'+N=LJL[!B-OW<OCKG
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M#)Y( P 3V%<K!X%U&+PA<>#'FM7T1YCY=SYC>>MN9/,,93;@MU4-NZ$''&"
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M6*>?N\Y67<K+\O0XP.IR"*H67A_Q3HVKZC;Z9?:<=$O[N2[WSA_M%JTAW2!
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M6YOLPM;NS@MU1)&+J8RYR05 P=_KVH JVWCB.YO/#,0M8A!K]NTT$WVG[A5
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M, #J* -^L^RUNQU#5-0TVWD<W6GE!<HT3)MW@E<$@9R 3D9%<1I7C+5+W1M
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M.],JF>+Y=N 2NT@KP05P>XSS6KIND6^F/=2H\DUS=R"2XN)2"\K!0HS@
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M2VW!!R01C!& >!5VT\.VMGXAO=9AGNA/>JGGQ>9^[=D78'VXZ[>.N/;-:]%
M&9?:-]MO1=IJ%Y:OY)A982A5U)SR'5AD=C]?6J$/@K2;6\TRXM#<V_\ 9]G]
MACCBEPLD.00KYY/*@]1GG.17144 <C8_#O2[#^R1%?ZHRZ3*SV:O<\1JRE3'
MP!E<$C^][XKF;/3]3DN+LB3QCIFJ37,TQMX#&]H'9R1AW5E*XQW^@'2O5**
M.6OO!%MJ.J0ZP^H:C8:F8%ANI=-N/)6Y [.,'WP1@CUKHEL[=;$60A4VPC\K
MRB,C9C&.>HQ4]% '.Z=X.L-.CL;<7-Y<6>GR>996L[JR0-@A<$*&;:"0-Q./
MP&+6F>'H-*U;4M1BN[J2749%DG64H5W*H48PH(PH Z]JV** ,G6O#UKKDMA-
M--<P3V$YF@EMY-C E2K#.#P58@]_0BLR;P'I]QI.LZ;)>WYM]8G-Q=#>F2Q"
M@X.S@$*H_#ZUU-% ',ZMX)L]5U2WU0:CJ=EJ,4/D/=64XB>>/.=LGRX(SD\
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MP.!^?J36K10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/%=L$1DC!$5RG#D\8P8V+\]3&?6J^KC1;;QA=^']<NK73=+;2H8]-6Y2,0E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU'(V')QV-==K<^G:?XQT^UAM$L?M%A.4OH+<N9"SJ6AC4 KO; 8D@G XZYH
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MZCU"=#E&5MIBC8_WMVYMIY&.V: .UMM>T>\NX[2UU6RGN9(A,D,=PK.T9Y#
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M+=E9H]]NQ? 4#HK'@=!FNNN[NUNOBGX<NH&!233;L;RI7.6CV9SZ@,1Z@<4
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M^CAM(,POAI0BC:3CCDXR>,\4_P >WT-AINF33VJRI_:<&)W5F2T.21,P4@D
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MSPY()O#.E.'W9M(LG.>=HS^.:TZ "BBB@ HHHH **** "BBB@ HHHH ****
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M*YR(RW ;W!QCF@#J:*PCXFCDU*ZM+6SEN1:745I<M&ZYC=]I#%2<[0'&3['
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MSAG/);ZGN>]7: . M/#6LP67@.%K:+=H0 NR)A@X@,7R>O)SSCBI?#>D^*M
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M"^=^!9%(],MZUC7'A#6;SPCXQTLQP17&K7\EW:EI<J5;9A6('!^3W'->BT4
M<C%IVLR>.K37KFQA2%-*DM)(X[@,1(TBN,9 R,+C/')].:M>!=(OM"\*PZ;J
M,<:7$4T[GRWW*0\KN,'Z-C\*Z2H;F[MK.-9+JXB@1G6-6E<*"S'"J">Y/ %
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M@C'8@YQ756]S!=V\=Q;31S02#<DD;!E8>H(X-.CABB+F.-4+MN?:,;CZGWH
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M5)B!;)M.T(=OSG(&2<=3T'39HHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ$'GN=>_\0:W_P )C/X>TZPL69=/%['/<3L!RY3# +GJ.@^N1TJOJO@634]
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M$.TKR<\MTXS3K7Q3>OXGTO3[VQ6SM=3T]KJ S9$JRJ%+PL.@90V<^Q]*;?\
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MVTD8^4$9Z9) Z5>?QA!I%QXRNK[3K>!=',)=[<Y>ZW1@IN) YY51GIZU'8^
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MJVX)^]+$<X+?)], ?4VK+Q-K-QJ]A;G1VDM;Z!Y!,L$T:VL@7<J2.RX8-T#
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MY$PC+1?+T^8'YO<>YT[WQ)XBE\2ZMHFCZ7I\DUE;0W$<ES<LJN'+\$!>&^3
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ME0F[RWW=25)S@8W'[W2NLH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ@GJ-W0FN(_X3MK+P]XAOUFODO["WAWZ;JL(62UD9BOF94#?&=RG()^Z>F:
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M^4A=E'7H/ZUF>!=:O=>\+Q7.HJGVR*::VF=%PLC1R,F\#MG;GZYKA=0BN/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW%8L\L18J=H0*?+,ARWS G Q@$G'/Z6L]MX%\&F6ROU_LWQ"S72FUD+QJ6N
M#M R1\Z\@$<T >I7FOZ1I[HEWJ-O"7VXWN !NX7)[9/3/6JWB+7+;2=-N_\
M3[>WO%MVEC\T;MN!PS#(PN>,G S7"W#6*ZWXBT;Q/IFLSQZK<B>T%NLYCNXV
MC11'^[.%92N#NQCCG%317#Z)K/B[3]5M+I3J%M&U@ZPR3I+$L&SR@P!Y5LY!
MZ[B>] ':^$M0N-6\':+J-VP>YNK&&:5@  69 2<#IR:L_P!NZ4-133SJ%N+M
MV*)$7&68=5'JP[CK69X!#K\/O#\4D4L4L6GPQNDT;(RLJ $88 ]17%>%X["X
MMM-\/Z[I>L2>(-,O1+L<W AWJY(N%<'R]N"6Y/))&#GD WKGQ1/JVO:SINEZ
MW::>^EB$QM*BR).2"\F\'G:% 'RD$')R>E.\.>);G7[:'7UUJTM]/26<7EE*
MBXCB#ND;!^"K?*"<D@Y. *?X>G2/Q_XRED#I%(UH8Y'0A9 D.&VDC#8/!Q7*
MV,-__P *MT&2"UN7.FZT+R^M/*82M MS(_"$9/57 QSMH ].BU[29X+F9-1M
MA':_\?!>0+Y/&1OSC;QSS6/J7Q"\,Z?I\MTFJVMRR"+$4,@9CYI&PG'0'.<^
ME8U_$-1\6ZEKU@6;3AX?DM9I50[9I6<LB@8^8J-W3IN [XK-NK(CX%:6L%C)
M]H@@T_SXT@/FKY<L;2 KC=QAB>/4T >DSZI96VER:G+<(+..,RM*.1M'<8Z_
MA5'2?$^F:KX=MM;6XCBMIXT8[W'R,P!"'_:^8#'K5B^8ZAX>NS;I(3/;2"-7
M0JQRIQP>1GT-><V4EU'X8^'FH"TO#8Z.T<6HPM;NK1M]G,6_:1DA&)R0#USV
M- 'IMCJ5EJ<3RV5S%.B.8WV-DHPZJPZ@^QJIJ'B70])EEBU#5[*VEBC\V1)9
ME#*F0 2,Y )( ]<UB>'[1YO'OB'6[7<--NH+:)7P0L\J!MSKZ@*57/?D=JIZ
ME<6-I\9+.6^,:I_8,@621<A3YZ]^W&1^..] '6C6],;38=12_MWLY\>5,CAE
MD]EQU/!X'H:A/B;0A:6UV=8L1!=-L@D,Z@2,."!SR1W].]>76MA<^&/[,U6Z
ML=17P^=1U%_)M%D62SBF=3"Y1/F"X1N.P?IGBM/5;+2DTS0I=+TV\CL[CQ-%
M?OYZ2NT@(.^9E?+(N?4#U[T =!JWCG36NM"M=.U:V\C5990U[$ZMY<:(Y)7.
M1DNH7D$=:U;/6(M)M([37];LI;]6VO,H$0(9CY>X9PK$8] 3TK(\2^7!XY\&
M&.(K##/=/*T<9V1AH& +$#"Y8]^IK%59+?1O'6@ZM:S27U_=74UHHB+?:XY4
M BV'&"1@*1_#M&<"@#N=1\3Z%I$TD.H:O96TL4?FNDLRJRID $C/ R0/QJ*?
MQAX;ME=IM=T]%CD$3DW"X5^."<\=1],BN3TK3I+;Q[H5KJD9N9;?PS]DGG>,
MNAFWQY!;&,D!C[CZU2OH0]C\4@+:0O=J5MP(6S-_HJH-G'S?."..] 'H=MKV
MDWFJ3:9;:C:S7T*[I($E!=1G!./8\'TJOX@\3:=X<%C]NE"M>W*6\2YQRQY)
M/8 9/Z=ZY2,*/%?@!XH7$<6G7,<K+$0L9:.(*K''RDE6P#W%:GQ!61;;P_=+
M#-)%:ZW;33F*)I"B#<"V%!.,D=N] $:^,$T_QCK5OJ^JV<&DP6EK/;,X" &0
MR9^;/S<(#_2NFNM9TVRM8[FXO84AE7?&^[(=<9R,=1CG([5Q1,<GCGQ5=26\
M@CET6".-Y(6&X_O2R D<GYER![5S^D73:'#X6O=9MM572VT"*Q:6U2;=:W"'
M++(L?S ,,#IU44 >M+J-DVG#45NX6LC'YHN%<%"F,[MW3'O55/$6BR?8MFJ6
MC?;L_9,2@^?C^Y_>_"H?"VGV&G>&[:TTZPFLK$;VBMYV8N%9B<D.21G.=IY&
M<<=*\YGT37+'1[NUM;>4+X1OFO-,(&?M49(D$8/4[8FDC('4E?2@#U,ZMIZK
M=LU[ JV;;;DF0 1' .&]#@@\^HJ!?$.C-:W-R=3M4AM3BX:20)Y/&1OSC;D>
MO6N2\2V&I1>&='U!;:662'5X-3U.WC4NYCW$LH Y;9E,#TC'I5#Q+;G4]3\2
M:SIP>2QD\,363LD;8N)V+%%48^9@,CCIN H VM?\8Q&725T#5;.?=J]K:7J)
MB1A'*3@=?E) /;\L5U=OJ-E=7,]M;W44L]NVV:-&R8SP<-Z'D?G7G/B&U\SP
M-X.AL5DMI_MEANEAM\O $7!=EQQL)_B&!WK<\):V;'0+VRU6SEAO]'W_ &EH
MH79;L*-QFC.,N6ZD<G<2#0!VE%0VEREY9P740<1S1K(HD4JP!&1D'D'GH:FH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2-*%+%0I&3P"<], G..:PO%'C!+70["?3S= WVI161D%I)NC'GB.7@KPW#
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M'I%UI4[S0ZK>V\"7-O"\@$3R .5(!^;;D =<]!D5OZ)92V=M+OU"[O(9I3+
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MD-N7) ) SCI73T4 >5^-++7=6M_%=BNBWLC.86L3:[5BF0!"6<Y!=\@C:<X
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MHW/^(K(^RZ_=S:!<W6@:@MW9:X\MS'%L2WCC(E ,:A@"/F4ER,Y)R>U>L44
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MSN?L]RS0ZT_E-&T1<L'8'Y_, .,8Z@<@<T >@W]_;:98RWMY*(K>(99B"?8
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MAP[$X4@X'4Y)XXYI]GXUL-1L-(N+.&9Y=5\W[/!(51LQY#@DG&01C@G/TR0
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M[;K%Q8I*&#E7:YE"ERS9(XZC)H ]%HKGY/&&G6]QKL5VD]L-%2-[B215*N)
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M5K75+>\ERX7Y(WW$#/4GM_,5TA( ))P!U)JIINJV&L6[W&G74=S"DK1,\9R
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MK8Y4EL$'MU)&*])JO?6%GJ=G)9W]K#=6T@P\4R!U;Z@T <;H#:G:>)K>36M
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MF6#/S%!@$^PY% '#^(_#OB36QK5L]E:W%K>:6(+$3W.!9R[&#_( 06+$$/V
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MZ)8[B*:%&;@8+(1@*QQZ$# P : *DGB+55U/QE9J]MC2+6&XM&,)ZO&[D/\
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M37-WIW]GSLT485ERWS !1@C><#UZYJ6+P<(1X: U&0C0$V6^8A^\'E^5\_\
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M+&70K/QWINFW=ZFEPV%M=QK]JD/V>=V8,JL3G#* Q4DCD5U&H65OI'C+P]I
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M7R;IGC<&-R 0I&,G@@\>M(GB_1)7OHX;MII;*'SY8XX7+&/^\@Q\XR,97(H
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MZ38FVM&W6\)@79$WJHQ@'W%30Z1IMO=W%U#86T=Q<C$\JQ*&E'HQQD_C4/\
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MNEV%OY]S+,B"/SG'V64M''DC<ZA<HO!Y8 <'TH E70-'6&]A72K(17S%KI!
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M;CP_IMMI]MI%[;O%/)N9)(F8\LJA2&XSU(.>]:VI>'=&UBW@@U32[2]CM_\
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MKV\4HFV@*N2=OF*#C/>O5:* /(M7L]3O/#GQ"B31=1$FHW4;VJ&W),H\N(<
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MQTRR_G7K-% '(^'89X_'WBZ>2UN8X+EK4PRR0LJ2;(MK;21@X/%0WQN=-^*
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MVB0QQ?%?Q48XU3?8V+MM&-S9FY/OQ5"S\$:W:>&_#VEM<:?*^DZK]N+@N@=
MSD+T/)\SZ#'?K70V&BWUKXXU;6I#;FUO;:"!%5VWKY>_DC;CG?Z\8H M7VM2
M1:S'H]A;1W-^UNUTRRRF)$C#;02P5CDMP !V/3'-&#Q7-<+I-L-)EM]6U&.2
M7[%=/Y?D+&<.SL >,E0,#G<.G.(=>\/ZR?%-IXC\/7-FMVEL;*YM[T-Y4L6[
M<""N2&#9[<YI+WPUJK:MHVO07=O-JUBLL5PDNZ.*>.3DJ" Q3:0-O!Z<YZT
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M:M>:?#?7<2I$EJKF&,JV[)+?,<D#/'  QWR =9;M.UNK7,<<<W\21R%U'T)
M)_(5RUGXUFFUG2=.NM*^R2ZK',\$4D_[Z+8-P$L94;-R@G@GTKI8%O'T\+=/
M$EVR$,T )56/IGDX]^OH.E<+I/@OQ#9W/AJ>YN]+9](EG,\BK(7NA(A4R,3_
M !GJ0>_<]* +4OQ#DM] _M2?2XHC%JITR[B>\Q]G;>$WD[.1R&X'W2#]-N^U
M^[M7U$6VE/>"T>&)/)D)9Y9-N01M^55#*Q;G@YQVK-O? =OJ&MZY<7,V[3M4
MM@K6H'W;@H8VF'H=FT#\:9<^$]6/@&VT>'48I-35XIKJ:;=Y=VP<-(CD<[&Q
MM^F!0!'=?$'[+I7B6Y.G1SSZ"5,J6]V'CD5DW ARHP1R",<$=ZO_ /"4WT<M
MM;7.C""\O[CRM/A:Z4^<@CWM(Y .P*,@C!YQC.:PK_P/KM[;^*XOM&EHNNVT
M,2H@=1 439Z'( ]N?]GI6SK_ (=U34)- U:PFM(=8TAV98Y68P2JZ;)$+ 9&
M1C!QQCI0!0\#K(OC+QN);2*UD^V6Y:*%]RY,"_,#@9SUZ#K3_%<^H2>._"VG
MI:VL]G-]JD,4TY5966,#YAL(& QQUSGM6EX=T35=/\1:]JFH26>W5'AD6*WW
M$QE(U0@D@9Z>G/7CI3]7T74;WQAH6KV_V7[-IJW =))&#OYJA>,*0,;?QSVH
M RH/$-IX?\-WUQHFC!_#^CSRPR[+@AP$;]ZT:$$%5);@L/NG'&,V;OQE>G7O
M[*T?0_[1=]/34(9?M:Q+)&S[>X..Y]_U%5/!VIVFEZ_H-I<6ITG5Y9I%ED9A
M+:B;_6*%VD/U)4EAUYSBM"R\-W5AXTBU. 6ZZ;#I*:;''YC>8 C[@WW<>V,^
M_M0!3^*D<;>"C,T(DDAOK-H^ 6!^T1C@GH2"1^-31>-VM-7OM.\0Z6=*:WLG
MU"*43B9)8$.'.0!AAQE>?J:TO%^AS^(O#DVG6TT<,YEAFC:0$KF.19 #CG!V
MXSVS5"^\)2>([N[NM<\F(S:;)IT<-K(9!&LF"[[V5<L<+@8XQWSP /\ ^$OF
MMYM%;4-,%M9ZRPBM9EGWLDK+N1)%VC:6 (X+#(Q[UQ7B35-1U_X8^,9=6M;3
M%I?R00^7(7V&.5$  *CT)W9R<G@5UEMX7U6[L_#]CK4MF\.BSQSK- S%[EXU
M*QEE*@)UW'!;D5GWW@C6I_#?B;1(;FP\G5;Z2Z@D?>&022!R&P#TP0,=<YXQ
M@@'0Z?XCN;CQ7/H-]IGV246@O+=Q.)/,CW["&  VL#C@%ASUK ^*<5OY?A:6
M:W$O_$_M8W CWLZ$/E,=P?3O6XNBZBWCV+7Y/LJVXTPV31K*Q<,9 ^X?* 1Q
MC]?:H_&6@ZEKQT7[ ;1?[.U*&_;SY&7?Y>[Y!A3C.>O;TH 328M(_MV[ETS0
MGLKJTM%&?LWV83"5B=N,#.#$.>V367:_$6[N-*T/5F\/.MCJMQ]E4K=J94E)
M8+\I !4E<9+#&>F.3TL8U^6_CDFBT^"WC1BR13N[2OC"J24&U1DGH3G'OGEK
M7P5K-MX2\-Z/YE@TVDZBEY))YKA9%5V; ^3@G=CVQWSP :<7C?[.NNIK&GBS
MN-(:'>D4XE643?ZO:Q5<$G@@C@]\4P^.98I]4@DTM97L[!K^.2TN?,AE5>&0
MN47:XZXP<@YJMJ?@B^U>^\4M-=0V\6KQVOV>6)BTD$D!)1B"H!^;!QGMCO5U
M-,\6ZAH.H6FM76DFXFLY+:);02+&S.,&1RP)!'90,<GGD8 (H?'%W_95EJ%W
MH1MHM2>TBT_-TK>=)..C8&4"]<X.1VSQ4H\;BVN]?@U+3_LZZ(B//)'.)%DW
M@&,+D*<GISC!'XUD^)+>33? GA_0+NXTR*],MM;))<LP@9H5W9\P;6C)$?!'
M.2 /41VNE76NV6M>'KY=*C;4(/.?4-+NY+ATE4J$\SS!G/ *_-T0CB@#;M_&
M4TFJW&GOIJ.ZV;74,MI<^;$^TX,;,578_?N"._:JNE^/;G4#X=FFT3[-9:ZI
M$$QN@S))Y9<*RA?ND*<-G/J!5_2[/Q<]E+'KEWI4LB0-%$+0.HF8C&^0D?+_
M +JC')]JRK/P=J]KI7@VS,EBQT"4/*PE?]Z!&T?R_)QPV>?3'O0!I>"=:U;6
MX=5FU*&V00ZC<6R>3*6QY;;-N"HXXSG/.>@H\2^,)O#T>I7#:7OM-/@29YIY
M_)$^[<2D/RD.P"Y(R.2!WJQX6T._T*75HIYK:2TN;^>\@,8;>/-;<0V>!C)'
M&<^U8WB/P?K>L7OB+R;RP:UU6P%K URKF2T(0AE0#C:Q.2<YSV.!0!J7OBNZ
MC\1VNC6&D?:I+JP>\AE>X$:85E&&X) ^?K@GV/40:=XY34],TAX; KJ6IS30
M)9O-@1M"6$I9P#\J[>H&3N7CGA;?P_K$?BC2M7F>Q=;33'LI%1W4LS,C9'RG
M@; /?.>.E8MIX$US3X-'O+6YL/[5TJ]NYD1W<PSQ7+EG1CMRI&1@@'ITYH N
M^ 5=/$?C02VD5J_]IQEHHFW*#Y"<@X&<]>@ZUK:AXJ-OKMUH]G:P7%];VR7'
MD2W/E23*V[_5+M._&WGIR0*;X:T/5-,UK7M0U"6S*ZG/'.L=ON/EE8E0@DXS
M]WTYZ\=*I^+O"5UXH%S!+#8,A"FQO6=DN+&3'+*57GD @;AG&#UX - ^)Y?[
M8U[318(9=*M8KE6,_$RN'('W?E(V'UZUR3ZO-J7C/PIK^F:0LMWJ.@SS"!IE
M3@F%@'DQT&2,X/7I6]>^&M97Q)J-_IUS9-;ZGI\=I.;G=YD;1[\,H48;(?G)
M&.O/2JNE^$-:T?\ X1BYCFL+FXTC3GT^6)F>))%;9AE;:QR/+'!7G/:@"WIO
MCR._L(@VG26^KMJ#:8VGR2@[)U4NV7 Y0(-VX#IT&:M2^+)K"QNI-4TF6UN8
M[V.RMXUDW)=O(5$9C<@<$MSD<8/7%9-]X#OFLEO=/OX(O$":JVK"61"86D9=
MAB('.S9A<]>,]\5=U;PSK/B+P^$U*^M8-6BN8;NT-LC&""2)MR_>^9LG.3QU
M&!QR +J'C2;2+K4;'4-+"WMMI[ZC D-QN2XB3[X#%5PP],="#2Z;XRNKO5=&
MM;K1_LL.L6C7%I+]I#G<JJS*ZA?E&&X.3G'('2H=5\+ZEKLEW?W@LH;YM*FT
MZVBCF=XT,OWY&8H#V  QV///#H/#.JIJ'A"X9K/9HEM)!.!*V9"T:QY7Y>VW
M//KCWH RK7QWK%EH&JZOJ.EPW*0:R]@$MKGE<3"$ !D&1G!SWR>!70/XAUF'
MRX[G0$M96\YVDFO1]GCC0J%+2A#AGW<*1V;GBL*[\$:X^BZMI4%SI[0W6L?V
ME"[EU8 SK,5; (ZKMX]<]L'=U?1=8O/$NE:I:S6306\,D<MK=;F6.1BI$J8^
M\PP1SC@GD9H 98>-8-4T70KRTM&-UK61;VTDFT+M4LY9@#\JA3R <Y''-9FL
M>*_$$)TJ*/1X[*6?6QI\HGG.V10I<-&VSE&"XW$9'(P>HJ6O@/7=/\->'H[3
M4;%=:T&:1K9V1_(FC?(9'[C(/4#C'XUKZMX?U_5K'2KB>[L/[3LM3COO+ <0
M!51D\L'ENCD[B.3V Z %V?Q+=/<:I!I>FQWLNEJOVI3<[,R%-_EQ_*=Q"D==
MHR0/7&=)X_-RVA?V+I+Z@NM6LMQ:LTZQ8,:@E&R#CK@GZ]:GM_#VKZ1K^L7^
MF2V4T.K!))H[AFC\F=4V%UP&W*0 2I(Y'6JUEX)N-'O_  DNGR0/8Z';SPR&
M5V624RA06 "D#D$XSWQQ0!<L_%T]]J4VGQ:? +RTE@BO+5KP>=%O5"SJH7#(
MN_[V1G:WX[&NZU;Z!I;7LZL^9$ABB3[TDCL%11GU)'TZUSNN>$+K7-5BNIH[
M&*>VO(Y[/4XG9;F&)64M&0%PV<,.6QANG'.OXN\/'Q-H+V,=Q]FN8Y8[BVGV
M[A'+&P921W&1@^QH A7Q-<0:^VAW^G)%?26K75IY-QOCN IPR[BJE6!(XQC!
MSGM65I7Q N-0A\.WLVAFVT[7'\F*8W0=TE*LR@H%Y4A#SG/M6DNB:C>Z];:[
MJ,=FEW96DD%M!!,S(7D*[W9BH(^Z !@XR>36-9>"]8M/#GA#3#)8L^A7B7$K
M^:X$H577 ^3@GS,\^GO0!V&L:A-IFG-<6]C->S%TC2&+J2S!<DX.%&<DX. "
M:H>'O$JZY?ZM8M#%'/IDR12-!/YT;AD# JV!ZD$8X(I?%VD7^MZ']DTZXBBF
M$\4K)/GRYT5@6B?'.U@,'\JJ>'= U32_$FM:E=RV)@U$0,L5NC QM'&$QSQC
M _'T'2@!NK>*]1M/$TF@Z=H!O[D6/VU&-VL2NN\(1D@X[_I]16U#Q_%9B:XM
M[);NTM[O[+,(I\W&0^QV2(*=RJV<_,#@$XQUT3HM_P#\+"&O VWV/^SOL13>
MWF9\S?NQMQ[8S[^U9EAX<\3:-JE_;:;J5A_85[=2769D<W-L9#ND6/'RD9)(
M)Z9Z'H0"QK7C631))I+C2REE#>Q6?F2S>7)-O* O$A7#J"X'WAT;TY@TZ&*+
MXPZV8XU0R:1:NY48W-YLHR?4X _*J&L^"?$&HIKT*7NG.M]>PW5O<3JYE1(W
MC80G' 0%#@C/4\9.:W[+1-1A\<W>N3O:M!<6$-H51F#!D9FW8(Q@ESQGC'>@
M"'Q/K6K:?XD\-6&GPVSPW]S*DOFS,A;;"[!>%.!P#GGD 8YS55?$5O87GC2Z
MAT)4N]*6.6Y9)5#78$.]23CC"<#K6EXDT.^U+4]"U'3IK9)],NGE*7 ;:ZO&
MT9Z<Y&[(]?45FS>%M6EF\9N'LL:] L4'[QOW9$/E9;Y?^!<?3WH 6/QMJ+WV
MCV[>'\#6;5IK)A>*3O5%<K(-ORK@YW L<#IGBI+7QU&^DRSWMFMI?1:DVEM;
MFX#(9QSD2;1\NWYL[<X!X)X+8_#.JK?^$+AC9[=$@>*<"5LR%HA'E?E[8SSZ
MX]ZSI? VLRV.HM%>VEKJ)UPZS82J6D1'VA?+D! R"NX$C^][<@'1^'?$C:W>
M:E9RV?D36+H#)'(989E<95D<JN>A!&."*WZRM$CUL1/+KLUD;E\ 0V0;RD S
MSEN23GGIT'N3JT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9@UVR;Q(
M= 'G?;A:_:SF,A/+W!>&/!.3VS6G7 ZQ975_\6([>UU*;3V;0'S/ B,X'VA>
M!O! YQV/X=: .^HKSC2?$&LW>EVEG?ZF/MEOJ]SI\S6\($VH+$&P8Q]U.=I8
M\ !3R*99^(_$4OA1;KR;R^-GK%S:WBVPC^UM;1LZ@J!\K,#LSMY(!QZT =_?
M7Z6!M0\%S+]HG6 >1$7V$Y^9L?=48Y)X'%6Z\[E\27$VC>%;[2]=FNH+S6UM
M)WDA16>-FD/EN-H*LNU5.,=#ZU-/XBO;/Q?_ &?J\][IZ3WZII]PL:O9W,?
M\DL 2DA.[K@YZ''% '?4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $5S:V]Y T%U!%/"WWHY4#*?
MJ#26MG:V, @L[:&WA'(CA0(H_ 5-10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DW_AZUOM6AU59KFU
MOXH3;B>WDP6B)R4((*D9&>F1ZUK5@:OXOL-$\1:3HU]#<QR:H[1VUP%4Q%QC
MY2=V022H'')- "7/@S1YX=-C1+BV;3I'DMY;>=DD!?._+9R=V3N)Y.<YIEIX
M*TS3P?L,]_;/]K>\#+<LVV1P0W#9!!W'@@]<]A5[Q'XAL?"V@W6L:B9/LUN
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M)YO,;)0<A<9Q@$DXQWJA'X+\/0I"D6FI$L,_VF(1NZA).?F&#P1DX],G'4T
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M@'_KZN__ $G-8.L)>3-\1Y/[8U5/[*C6XLEBO'01.+82<8(R-W\)X]J]$OM
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK6;_ /'MH<,"I&>C3S N7/N$"@>FYO6@#J%DC=G5'5F0[6 .2IQG!]."*=7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*0L[.43KL4L3M7I\HP.* /+YY1KG@#PIXBN+N>6^NM:LY9B)VV!C< &/9G:
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M+R(.QYQC/..F3F@#SX:E<?;_  YJ5CJ%W<6]YKTMN]W+<,HN(R)LH(<E0BE
M 3@Y7.!G-5#=?\([:>-;^VGF@/\ PD,5O+,]Q(5BBD%N)'(+=0&;YNH['BO0
M!X(\,ABW]B6F?M'VGE,@2<_,!VZG@<&K;>&]%>ZOKE],MGEOT\NZ9D!\Y< 8
M8'CH!]<#TH X?Q%-JW@[1]>UBTUE9(Y;%'ALP7F\E]ZH9U9V;C#YQT)&?6KE
MQIUM9?$[PC):W%Q,DMC>_-+<-*&PL6&&XGDYY(ZX'I73Z5X3T#1+"XL=.TJV
MAMKD;9X]NX2#!&&SG(P3QTY-1V/@SP[IMQ:W%KI4"36@86[MEC$&QD+DG XX
M';MC- !XLACN-+MH)D5XI+^U1T89# S*"#7%>&S<Q&Y^&MSYC_8+G/FL"0^F
MGYT!/0DY$1'H3Z5Z/?Z9::FL2W<;2+%()$ D9<.#D-P1R",@]J>;&V\^2<1
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M%/"VH:W<(9$M(MPC!QO8D*JY[98@52M=/U$:,EYK'B">VOY(P\CQF-(8&/\
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MA(8;N1E!Z=:RH/$_B;57\*V]G<:=;R:UHSWCR/;,_E2JL9X&_E<OTXQUR>E
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MO%O\MQ;ONYR-W<#IZUV?B35QX<T07$$41FFN(K>%6&$$DL@4,V.P+%CZX]Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"-KXHMH&:P>W6ZFC8?O$B(RQ'J5&3COC@],[T4L<\*31.KQR*&1E.0P/((H
MYV3P@+WP[J.E:MJUYJ$FH0^1-=2!$95P<!550HQDGH<D\YK:LK)[;34M+BZF
MNW";7FD"JS_]\@ ?@*MT4 <7IWP\CT\Z&%US49$T5W^R*PB&(V4J4.$YX.,]
M?3%;4GA?39?$=QK<D9>>XLQ9R1G[C*"W)'=L,5SZ<=ZVJ* .7;P-I_\ P@:>
M$XKBYBM41 DZL#(&5PX;D8/S <>G%1'P/ONM4NI=;OI9]3L5LKEF2( @!@&
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MU=$48*D(H*#"G'W1Z#\A0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SK
M[68;*Y6U2"YNKHIYAAMH]S*F<;F)("@D'&3S@XS@UHUASI?:9K5S?6]A)?V]
MW'&'2%T66-TR/XV4%2".^00>#G@ TM/U"WU*V\^W9L!BCHZ%'1AU5E/(/_Z^
MAJU65HMI<Q-?WEY&L,U]<"8P*V[RP$1 "1P6P@)QQSCG&3JT %>976O6EMXS
MU32O%M]J.ER3S#^R+M+F2&V,.Q<!2I"[PVXG>#G('3 KTVN2U.WO]2L=2TO6
M?#0U:SEE?[-MFBP4/W=^]@4(SP5R<8/7B@"[::L-(FT#P_?FXN+Z[M2JW0PR
M2/%&"Y)SG)Z].<US7C#Q'%J?A9[RS-_:R:?KEO9S*&*L66>,.N$8AU(;ISGT
MH@\+:YH5GX(>*(:K/HD<L-TBS!"1)'MRI? (4@#UQ4#>%?$,WAS6[>2RMUN9
MO$"ZI!&+@$21B5'*@XX.$.,XZ\XH Z*'QY8--J=O<Z?J=G=Z?;&[>VN( 'E@
M_P">D>&(89XZ@CO38O']C++I:?V7JJKJMOYUBY@7$YV!R@ ;(;!ZL O!.<<U
M5U/1-0UC4=1UIK!X)?['ETZUM7DC,CM(=S,Q#%0 0H'S'^(^E5[;0M8B;P#N
MT]_^)+"4O/WL?RG[.8OE^;GGGZ>_% %G5O%^D7W@C6;Z^M=6@M[*5K6^MXL)
M<1.NTX!1\?Q*<AL8-:$GB.Z3Q_'X=339FMQ8&Z:<.G.9%4'EL[1\V>Y)Z8&3
MS&I^&-<N_"_CC3X]./GZQ?&:TW31X*%(URQW<?ZLG\170RZ=J@^(=GKD5DK6
M<NEFSFWS*K0-YH?)'.[C(XSSZ#F@#9U368=+FLH&AFGN;V4Q00P@98A2YR6(
M  52>363+X\TN'PY_;;V][Y"W?V.6(1 R12B3RR& ..&XX)]LU)XJM]:GNM)
M.G6YNM/6=O[0MDG$+2*5(3YCU4-R5SS[C(KDO^$5U]/ ^I:,NE0K-)K?VR!(
M;A-GE?:1-WQ@;1@#KGL* .WTGQ+;ZKJ][I9L[RSO+1$E,=TBKYD;DA77#'C*
MD8.".XJ6;7K>#Q'!HCP7'VFXMY+B)P%V,J%0PSG(/S#J*S+73M0'Q(O-7>S=
M+&;3(;59"Z$[UD=SD YQAP/J#3-?T_54\9Z+KFGV(O8H+>XM9XQ,L;)YA0J_
MS=0"A!QSSP#0 /X_TJ/2K74'MK\17&H'3@HA#,LP<H00I/&5/3)/84^R\>:5
M.-66]BO-+FTI!+<PWT05Q&?NNNTD,#C'!SGC%<7>Z=JVA^&M'AO[*,7)\7)<
M1QQS!O,5YW<<]!U[_CBM?Q-X+U+Q5)KM^BBPN;BPM[2SCF9228IO.W/M) !;
M"\$\ GVH LRZG<W'Q4T)&MM1LHI-.NG>&XD'EO@Q[2%5V4,,G/0\BMBP\:V&
MH76G0QVEXB:G'+)8RR(H6<1\G'S94D<C<!Q63]F\3:KXMT/6)M$2P%K974$_
MFW2/MDD\O! 7.Y<KQT/KCOFZ7H'B<ZSX6U/4-*B-[8M.FHW,EXKO*7CV[UP.
M$SR%'3.,#K0!NZ!XU.H:)<:EJ%A-: 7TEI"FY&,C"4QJ@PWWLCDG ZG.!FK4
M7CG2B-42Y6>TN-,:,3V\H5G/F?ZO9L9@VX\#!SG@XKEF\)>(?^$8GL8K2U^U
MV&M2:G9^=*&CO%,KOL88^4%7(Y[_ )U<U;0]?\0>'#+%HMCHVH6MU;W=M9^<
MK^:\3[R'=!@ ]!U]3UX +%C?W-Q\7Y(9(;^UC_L/S#;W$H9"WG*-RA790<<'
M&#Q^)D^),UQ;V>@O;7EW;--K5I;2&WN'CWQN^&4[2,Y%/T^UUR[^(,.NW>C_
M &&T.DFT=9+E'=9/-#]%R"./7\NE2^/=*U+6+71HM-LS<-:ZK;7LO[Q$ 2-L
MD#<1DGM_.@"Q>^,;73]4O=)BTS5+N[L;9+AT@B5MT9R,AF89^Z>IR>V356^\
M;$R^%GTJPGO+37&++(I12$$3.% 9A\W Z\  \YI1IVIKXXU?5O[.D-K<Z7%;
M1'S(]QD1I&((W<?? S[&L:P\-:]8:!X%"V"27>AR%;F SJN087CW!N00"P/K
MCM0!T>H>-],TT^;/%<&Q%T+22]788XY-VP@C=NP&^4D*0#3M4\::=I::I*T%
MU/!I107TL"J5A+ -C!8$X4@G . ?K7/Z/HGB#1K^\THZ#IUY8S7DMQ;:J\J9
MA21RY5T(W,RECC'!XY%4=1LK[4-<\3+8:#-J.DWLZ070L]1AB69HT4.'$@R&
MSE#M8 A1W!- '57_ (WM+"[MK/\ LO5;BZNK1[N&&" ,SJF,@?,/F^8'^N<"
MBY\<:?:^=))9WPMK:XAM;F?RU"P22!-JL"VXX\Q,D XS['%*&*\U7Q?X>\06
MNFRQZ<FG30OO>,-&TAC(& W(&P@D9'(QFL;Q-X?\4:S%KD$FG17CF^@GTZ=K
MI51($>-O+5#]U_E;+'&<]3@"@#HX/%S_ /"5Z_I]W926^GZ3;PRO=,Z;5#+(
MS.WS9VD*,  G@YQFK5KXNLKC7+?2)K>YM+FZ@:>V\\)MF5<;L;6." 02&P<5
M@:CX6U;4]7\50R011VFOZ9#!]I68'R)$212"N,MRX]!C/TJUH-EKU[:FSUGP
M_8:4Z0-#->6\J2&=BI7,84 H.=W)SVP<Y !G^*O$7]I)X8NM.CU!+.?7;6..
M[239#.GF8(*ALE3C@LN#CW&>F\:Q32^$=0^SW=Q:3B/,<]O*R,C9 !R",]>G
M2N-AT+Q6OACP[H,NCQ-)HFHVKFZ6[013PPMPRC[P.,9!'YUW/B>"[N_#US;6
M=JUQ<2@*J*ZKW!SEB/2@##\(^*96\%W,FM%FU316>TU!1RSRQ\ CU+C:1ZEN
M*R?!.M7EA8>,-5\37]S.^GZA(L@#LZ1*(T<I&F<8!8@8'I6O-X0GE\?+KL3F
M+3KJ%)+^S.,RW$)_<DXXXSGKUC7UK-L]&\4V6E^-/L%L+34-2OGN["1Y4(VD
M(N#@G:V%..PR.: .E7Q?8QRZG%?6]U8RZ;:"^G6=5/[DACN!1F!^XPQUR*BU
M+Q8]EHFJWZZ/>%["R^V!':+;*A#'AE<CC82>^,8!R*Y^UT+6H/$&J:E%X>ME
M@O-%6W$%Q=K(7F4R';*>=Q;< 221COVI+3P9?V^F^(].TR.YL-)U#2W@M].O
M+@2K#<LK@E"&;8F".,]<\<4 ='9^*"VEZ<T]C</J-U:B?[,C1!BH"Y?)?:%)
M8 9.>>G!Q33XC:1/;Z5+:VNH7)U,S)!'% "PDB!+QL">&^4CT[YQS6++HOB2
MVGT+6HM!M;Z6WT\:=>:9-<IN"C:1(CD;<@@\>A'?IIW.DZQ-KWA6_P#[*ACC
MLIKB6YBMI$"PB2,HJC.-Q&02<>N/2@#JH+J:]TA+N&VE@FFA\Q(+I=KHQ&0K
MCL0>M>;>%M6MM:CM--N]6U/3?&-K/$]]:WEU(GGE7#2!4)V,C*&P%' QVZ^G
MW0E-G.(/]<8V\O\ WL<?K7!^)- U/Q?I&GVM[H2VFM02PN-56:,I;%6#.T;
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MMKO3+>54\N.0JP*,V%9@5&<XSVH I^&/$ZZ1I?B6_P!1BU)X$\1/;!)7$DD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 445@31OJ_B"[LIKNY@MK2&)EAMYFB:0ON^=F4A
ML?+@ $#(;.>, &_16/H,\Y?4K*:X:Y6RNO)CG?&YE,:/AB."07(S[#/.:V*
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M]'XET"#5H;>2W29I%$4I!9=CLG../X:Y?2KR?6?%K:'J>I23QV>CV\Z/;R-
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M66I:5+JNHE(?$XLK.,3,\TZ>6DGD&1FW!>6)8G.!CGI0!ZC17ED>H:Y%X/\
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M1;"U-FY<7+2.1(/E^7RP!@\]<D<4 7**9YL?F^5O7S",[,\X]<4N],9W+^=
M#J*3<"<9&>O6J&KZM%I-O"S+YD]Q,MO;P@X,DC=!GL  23V )YH T**Y35/$
MFJV'BO2] M]/LKB2_MY9A-)<M$JF,#<,!&Z[N*SI/B'<OX:UB^MM%WZGI%V+
M.ZT]KC[SEE4>6X4[@=PQD#\* .\HK+T?7K+6?#=KKL,BK9SVXG+,?N#&6!/M
MR#]*YC2?']YJ_A'7_$$6D1PII4MPBV\TY#R")=QW?+\I([<X- '=T5Q-SXXO
M=,\+Z?XEU/28%TJY2!YFM[HO);K+MVDJ4 8 L <'/L:OZSXDU'3_ !;I.A6F
MGVL_]I132)-+<M'L\H*2" C==PQ0!T]%<WX>\42:]/K.GO9K9ZKI4PAGB,GF
MQDL,HRM@$J1[ CTK4T?5HM7M975#%/;S-;W$).3%*O49[CD$'N"#WH T**9)
M+'$H:1U0$X!8XYK#U'7;JR\8Z)HRV\+6VHQW#M,7.]3&H. ,8P=PYS0!OT4P
MRQB41%U$A&0N>2/I2M+&KJC.H=ONJ3R?I0 ZBJ5MJMG=ZC>6$$ZR7%GL\]5.
M=A8$@'WP,X]Q5I98WSM=6P 3@YX/0T /HIB2QR1^8DBLG]Y3D?G2K)&[%5=6
M8 $@')P>E #J*IV$E\WVK[>MJNVX<0^0Y;]UQM+Y P_J!Q5E)8Y(_,2163^\
MIR/SH ?161X@U>32O"VI:O9)#=-9VTEP%:3"ML4L1D ^G_ZJS9/%%Y'J/A*W
M^RP&'6U8RR;SNC(@,F%&.G'4G\* .IHI-ZD$[A@=\T9&,Y&/6@!:*3>N,[AC
MUS52VDOFO[U+E;46JE/LQB<F0KM^;>",#YLXQGB@"Y13(Y8YEW12*ZYQE3D9
MI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S-W;Z?J'BFXM=;
M2&:-+>-K.WN<&)A\V]PIX9@< ]2HV]-W/35!=V5I?Q"*\M8;B,'.R:,.,^N#
M0!D^&'0QZC':RF738KLI9N6+#9L3<%8]5#[P/3&!P!6[2(BQHJ(H55& H& !
M2T %>;:YHFD:WJ6IZ[H>N?V#XDTYVBN;B.4!7V#CST/#*1CG^>,5Z356?3+"
MZ='N+&VF9#N0R1*Q4YSD9''- 'FT6L/>ZG\./$&N10V%Q<070GDDQ&H9H1M&
M3T#8) /K6--/83>"O$:0RQ"W3Q>CMY;[0D9N(OFXQM&,G->SW%K;W<8CN8(I
MD5@P61 P!'0\]Z!;0".2,01[)"2Z[!AB>I([YH \IU[0M-T_5_$ZZ/:V\.E/
MX:F>_BA $(N.3$V!P'VACZXP>^:=#I&D?VQ\.B+2WS?V$R71P,W*BW1@LG]\
M9 X.17J,=A9Q6OV6.T@2WZ^4L8"?EC%,6TT[.5M[7,!QD(O[OO\ AUS^- 'D
M&J06<?PJ^(=G&D*VUGJ\ZV\2@!8?]40%'\/+-P/4UUERFF1_&FWFN4M \VB@
MPO(JY>43@ J3U;&.G.*[-=/T]HODM+8QOAN(UPWH>G/6IA;0!HF$$8:($1G8
M,H#U ]* .:\?7EC::)9C4$+13:C;1H&E\N(/ORIE.#^[^7D8YX'?-9?P]NK<
M^(?%]I%=VLN+])E6V 5"&ACRRKDX!/?/)KNIH(;F)HIXDEC;JCJ&!_ T)!%$
M[O'$B,^-S*H!; P,^N!0!P6O:9I6H?%S2K?4K:WFCN-'N T4H!68K)&0&'1L
M#)P<],]JYEK?^SOAU>VR2$:7'XIC73=S9 MQ=1X"D]5#!\>PKT#4_#K7GC*U
MUNZ^Q/86]E):O#.,[M[HV[D8X* 8]^M=#):6TL2126\+QI]U&0$+]!VH \?\
M>:AILL'C!H)8(+VVN;02&Y?=.SKY94PC(,: '.><G?TZG>ETW0]9^*&L"XM[
M.[MI="@E(8!D<F24;\="<8PW8=*] :PLW9V:T@8N@C8F,'<H_A/J/:AK"S:1
MG:T@+L,%C&,D4 <Y\,YWN/AIX>D>0R-]B12Q.3QQC],5D1VEJ/BQX@:TM;1K
MY-'@EARBY$Q>7YOJ<KD^XKO88H+=?*ACCB7KL10OZ"FBSM1/YZVT(F)SY@0;
MOSH \FAV7OPW\-7VGX'B>._@1GZ3FY\W;<+)WP5\PL#Q@9Z"MSPIHFC77C;Q
M9/)9V\D]EJT<EN<#,+&!,E1VR2<^N.>@KO4LK2.[>Z2UA6Y<8:81@.P]SU-+
M%:6T$C20V\4;M]YD0 GZD4 <SX\O+"UM='COU!$^IQ)$99=D*R ,P,I[J,$[
M>[!>G49_PSNH'?Q1:Q75O+Y>M2NJP?*@1DC.Y5R<*3N(YYYKN)[>&YB,5Q#'
M+&2"4D4,/R-*D,43.T<:(SG+E5 +'&,GUXH X+Q8!+\5O!4*7CVTA@O\/'LW
M#Y$[,".<'M3/%.D6WA#P?=7%F;EHKC4H;G5[IOWLLD1D7S&;C!&."H&-N1C&
M:[R2RM)9O.DM87E_OM&"?SJ9E#*58 @C!![T >,>+;+PU)X4\1ZGI.L)?B=+
M1IO(,7D1.)D"L-@&V0J2/7 Y[5T7Q T+0M*\&J+:PLX$EU:TE/R##,T\8=N?
M55Y]0.:[J&PTW[+Y$-I:?9U<GRTC78&Z'@<9J62SM98TCDMH71.$5HP0OT':
M@#A;2'3IO'?BC2=;MK5;1;.W^P13*HC^R[#YI0'@?/G<1_L^@KFM.L/M\?PT
MB\01K<33&]B;[3]Z6#RG\L/GD@KLX/7//6O79M/LKA8EFL[>18CF,/$K!/ID
M<4^6TMII%DEMXI)%^ZSH"1]#0!YK!X<\/CQQXHTUM.LS90Z/:;;=E!1<"49P
M>X&.>H_&LS1[>SM]$^%^JQI$NHW%Q'#+=9_>R(;>0%6;J1PHP>!@"O6FLK)I
M69[:W,DG#$QC+?7UH_LZQPH^QV^%.5'E+Q].* /(-1U72GN[&]M;BVMO+\6C
MSA/)NN@?,*2,S9'EQXX"D'Y=O/:DUC2])FT;XH7!MK9I+6<RV[D#,+_9XVW)
M_=;=W&"<5ZX$TQTFN EHR%PTLF%(W+T+'U'OTHCM-,GW^7;VDF[!?:BG.>03
M_.@#@9M5TIO&4]GXLGMDL;O18#827CA8F!W^?M8\;SE,]\ 5!>76D6'B+1]-
MU*^:ST"31Q'I\VH!&C=PY#!C*" QC\LC.#CCOBO2I-/LIHXHY;2W=(CNC5HP
M0A]0,<4ZYM+:]B$5U;Q3Q@[MDJ!AGUP: ,CP=96>G>%+&TT^\N;RRB#+!/<,
M&9TW'&"  5Q]T_W<5QOBFTED&NZ_I>V35?#^KI>QHIY>,6D EC/LR9_$"O3P
M   !@#M4,=G;0LS16\*,_#%4 +?6@#R[7W\^?P?K-T##<:IXB@G6.7AHX1'(
M(D([?*02.S.U+J\NBZEXD\5:+XJU9-.>0QFT,PC4M;&)=IA9U)W"0.?EYW'I
M7ITMI:71#RV\$I7@,Z!L>U$EI9W$D,LEO!*\)S$[(&*'_9/;\* /(_&-SIKV
M/BJT\T"_MM#@5Y-3;=-*1&[IY2<;6R<LP_B[<9JYXAN'EMKG6[273M:LTTF'
M^TM.N& D$0#GS8).<,26X(Y*\<XKU&6UM9)?,E@A:1D,>YT!)4]5SZ>U,DT^
MP>6)Y+.V:2/ B9HE)7'3;QQT[4 <#+=:;;?$'Q$;WR;9+[0[:18IP%,IW2@C
M:?O-RHQR>E8&FP:9J6A?"I+@6\ZON@D!(.X?9GRC>HS@%3ZX/6O89;2VGFCF
MEMXI)8P0CN@++GK@]LTTV%FPC!M("(QB,&,?(/0<<4 >8:C#X?MO$VL>&M<O
M(-(TTV$,>FK,L:QF#:0XC:0$!@^>AS]WKCBS8:-I,WQ&T^SN(_MT)\,#<;]0
MSSA9E"M*I&&;'J/U%>CW%G:W;1FYMH9C&VZ,R(&V'U&>AH>RM9)3*]M"TA&"
MYC!)&,=?I0!XQIUGI\'P]\*:I''"+V+Q#'!'=$YD2(7CIL#'D)LXV],=JT[]
M]%U;5O%&D>)]8.G7HO5:W4B-96AVH86@9E+$Y!X7G<3QD\^H?8-..8?LEJ=O
MS;/+7C/?&/;]*DDLK66>*>2VA>:+_5R-&"R?0]10!Y=/H^DWOB+X@)>VL,_E
MZ7:R8G521)Y,V7(Z!^GS#D9XZTFBMI\GB3P'>ZC]F:2X\-\33A29)AY&,$]7
MZX[UZ@UE8M)(6M;<N_WR8URWU]:<+2UC$>+>%1$24P@&PGJ1Z4 8OCUU3X>>
M(RS!1_9EP,D]S&U>;>)(K6W^&7A[4+35Y+O4;:.SDM-+EF$\5U+A1L,75L9)
M&.F*]FEAAN8]LT4<J=<.H8?K4<-C:6[[X;6"-O[R1@']* /*?'=]87*^,(9!
M;V^I0Z/%YHO'WL3L=U6W7(Q@G)<9Y XXS5GQ'*]Q;R:O93:;K%NFB1'4=,NF
M 9H,R'S89.<,3O!XP=H[@5Z?):6TLIEDMXGD*&,NR DJ>JY]/:HY=/L)&CDF
ML[9C"!L9XE.P#I@D<8H \TU2_P!(U/Q1J^G^*-073+6\TZ!K$7JQJ#"R'S K
M2 A7#DYQSP.N.-.T2*V\?^$K9+FXG5-"N522Z/[YUW0X+]/F(&>GK7<O!8ZB
MD4SQ6]TJ'=$[*KA3ZJ>Q^E/:UMWG$[6\33#I(4!8?C0!XSJ<%B/ GC5 L*K#
MXJ3R]N!Y9,ML#MQTX+=/>M^[MO['\;^)K;PY!';W,OA@7$<-NH7?<AY@KD#J
MWW>>M>A_V98;2OV*VP3DCREY/Y4]+*UCE$J6T*R 8#K& 0,8ZT >=>$/^$9U
M;4/#^JZ9K32:E#;/&]I (E?:4^<7"A=V%8<%OXB.N>='XPNB?#6_WR!,SVP!
M) _Y;QFNTAL[6WEEE@MH8I)3F1T0*7/J2.M.GM;>Y $\$4H7IYB!L?G0!Y];
M*GAWXF&3Q#.UY_:,6S1]4N& \K^_;8&$4G[P( +#(R:R+I]%UB_\2Z5XDUE]
M/U)-1WP(!&MPT0VF!H&92Q.   O<GCYN?5WM+:2%87MXFB7[J,@*CZ"D:QM'
MN(KA[6!IHAB.0Q@L@] >HH X+6X)/#'CB#5+&T#_ /"0VW]GR'RP<7:Y:)WQ
MV(WAO]T&I-2TRPT?QWX M+6../R4O(5. &91!W]><GZD^M=\R*Q4LH)4Y4D=
M#TR/S-1R6MO+*LLD$3R)]UV0$CZ&@#R;16T;6XX(]7UF2U\366K.[VL8B6Z,
MPE; 7*[V0J0.N-O' '$VN>' VL^(?!]M9Q+#XA5-2M)3%\EO(N%F)].5C(]Y
M/K7J7V.U^U_:_LT/VG;M\[8-^/3=UQ4Q12X<J-X! ;'(!QD?H/RH X_P/<GQ
M#;1^(KJR%O<K;I8JK1@%&3/G8]!YF5Q_TS%1^*1(/B+X%9L_9O.O ?3S#;G9
M^.-^*[-45!A%"C). ,<DY/ZU3U72X=5MHXY"4EAE6>"5?O12*>&'Z@CN"1WH
M XSQ,/.^+OA2!+Q[:4V-[AXMA8<)V8$=CV[5?O\ 0M-\,>&IEMV?=<ZG;7%S
M<7$FYYI&N(\LQ_H, >E=2+&WD99KBVMWN !ND\H9R.XSS4DUM!<J%GACE4'(
M$BAL?G0!YKI^G7FF^*-3\#I YT6]F&J12@?)';,29H?QD 7']V1C5729XC\/
M/B:PE3']I:MSN'=.*]6\J/9L\M=NW;C'&/3Z5 --L I465L%;J/*7!_2@#QW
M7XK.'X3^'K^WUB2YU"W@LY+;3)9A-%=2X0>68NK8R< =,>U=)XH$U]\1_!D'
MVQ].O);&^RT11GB8QIT# @\@]NU>@0V-G;OOAM8(W_O)& ?TI7LK26;SI+6%
MY>/G:,%OSH XGX<S6^G_ -HZ#?Q)!XD@G,E^[.6:^S]VX4L<E6';^$Y&!5CP
MH)/^%A>.V7/V4W%F%QT\S[.N_P#'&S-==-;1R/YPAA-RHQ'(Z9*^GOBH-*TN
M'2K:2.,EY)I6GGE;K+(QRS'] !V  [4 <+XCN]-/CV]TSQ-J$5C8W.F1BQ>Z
M6/R7^9Q, T@(#\I[D >@HAAMK'Q3\/+2WO+BY@CM+Y(9KIAYDB!$VD\#/'3C
MIBO0;FSM;Q56ZMH9U1MRB5 VT^HSWI#!:3W'F-%!)-$0-Q4%D/4<]1US0!Y1
MIS:-K2RVVM:S):>([/6))#;QB);HR"4F/RR5W,I0J..-O' %7+2[\/ZE-XCT
MWQ/,L>LQ:PSQ1F39<NBN&M_)_B(VA0 O<GUY]+:VLQ>I<M! +L@HDI0>81Z
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M90=HR=Q P"WTX'2O1:K*EE:2Q*J6\,C+Y<8 525'.T>P]*LT %%%% !1110
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M8$$27Y>19&4# +1;2"V.N'&?:HY?#NH6/BU?$&F30W#S62V=Y!=N8_,VDE)
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M(8_,A)*N,D@\@8Z]*J^-=,EN4T?5;=&DDTC4([MT099HL%),#N0K%L=]N.]
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M"EBV.@Z$\57TWPKK-I?^%+B>6PD&C:?)9RA&=?,+*BY7*GIY8Z]<]JHGP'K
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M-K7T$C[F_P!H0E, G_?(!['I5>?PW<67BN3Q%H[PF>ZMUM[VVN&*I.$^XX<
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MEH ]%(!!!&0>HKQ+^S[&6R^($5OI=S+JRZI*FG265JYDBD\M"FV11\@#')Y
MQGUKVSD+V+8^@S7,>%- U'1-1UZ>\:U:/4[]KQ/)=B8\JJ[3E1GA>OZ4 <AK
M%L8?%_P[_P"$@M%N[U["Z6_"6_G>;*L,?)4 [L,2<XXJ_P"$IX+CXB^(+*QC
M>STA;2,-I=TIC+2YYE2%N5C*D G !-;NO:#JU]XRT+7++[$8M*2X7RII75I?
M-55/(0XQM]\^U):^&+^3QM)XKU&6U^U1V7V*UM+<ML52VXEY",L2?]D #L:
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MP6"VO885&%A9PRN%'8$J&QZDGO6_KFM1:):V[M&9KBZN$M;:$-M\R5SP">P
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MM+.-GU5OFB\\Y@4*2Y)V\E2NTC ^8@9HT/Q4=>N%-G;0/:B>6"9EN<RV[(6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME;6V\Y;R8E3=]<#FK5%% !1110 4444 %%%% !1110 BJJ#"J%'7 &*6BB@
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M#6EQM\B57#"4MT"X^\3Z"H?^$FT,6]O<'5K-8KB0PQ,TRC>X."HSW!ZCMWH
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ML Z$Y*9R0OX @?A5K3_#_P!@\2:KK(O))'U%8EDB* *@C!"[3UZ$YSG\*VJ
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M%<Q'R[S3Y4"@9P>=P)SC<#QQCH =Y9ZA#?:<E] )3$ZE@&C*OQVVGD'CIUK
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MZ!6R<XZ?7 !W-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69
MJ^@V>MR63WAFS93K<P>7(4VR $!N.N 3P>.:TZ* "BBB@ HHHH **** "BBB
M@#%U+PKIFJ:D-1D^UV]Z(Q$T]G=RV[.@)(5MC#< 2>O3-:5E8V^GVX@MD*IG
M)+.79CZLS$EC[DDU8HH **** "BBB@ HHHH **** "BBB@##O?"6E7VJ2:F?
MMMM>2A5FDL[V6W\X*,#>$8!L#C/6M:UM(+*V2WMX]D2YP,DDDG)))Y))Y)/)
M-344 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:_L+75+">QOH$
MGM9T*21OT8&L[3?"VG:9*DD<E_.8_P#5+=WTTZQ_[JNQ /OU]ZVJ* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXR1BN[N-4LK::VADN$\ZY8+#&OS,_N .< <D] *\9T@K_P )Y\6LD8^Q-_Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /#%N/C#:>+=1UR
MW\(Z<\EW$EN5:5=FR,MM('G9S\QSS^%:7_"4?&[_ *$K1_\ OX/_ (_7L-<A
M\4+V[TSX>:MJ-A=36MW;(KQ2Q.5*G>H/L>">M '&_P#"4?&[_H2M'_[^#_X_
M4<WB/XVSP21'P7I*AU*DB09&1C_GO7=6,^DW&L64&F^))KFZ56G>!;[SU>,
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M-\?S9(PPZ[3D@ 'G&WX8@\3>'_/\.OHXFM5O)9;;5?/3R_)DD,GSKG?O&XC
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M>)W^WQ6LR13%=A";69E^7=][!!Q[9!Y"#PWX@A\/06 T-E>#Q0NH!8[B(KY
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M)/H,4 :'AR\UG4+3[7JD%C##/'%+;+;NS, RY8/D8SGIC/\ CRTU[JU[J7Q
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M@RF9@ZEAL^;'0=R*O:%JT6O:#8:M#&\<5Y LZ(^-RAAD X[URNG?\CG\0/\
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M.<D#)(.3L]S5+Q>]V/#?Q"T2>XN9[#3EMIK.229RZ>: S1LV<L >0&SPP]J
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M'#M7'[M?X<]3ZFKU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5-2TRRU
M>QDLM0MDN+:3&Y''<'((]"#R".15NB@"A;:-8V<4Z0QR!IP!+*TSM*X P,R$
MEN.W/&:72='L=#L$L=-@\BUC^Y$'9E7G/&2<<GM5ZB@#B=.\+-<^+O%%[JNG
MRK9ZB\/E'[3A942((RNJ-R"0>&!&"?4BNDOM!TW4)K::>VQ/:@K!-#(T3Q@C
M!4,A! .!QG'%:5% &7=>'-'O-+ATR>PB:S@=9(HQE=CJ<A@0<@Y)YSGD^M5+
MWP3X:U'4X=2NM'MY+N%%17P5!5>@8 X8# X(-;]% &8_A_3'O[J^,#BZNHA#
M/()G!=!T7@]!D]/4U3NO!7AV]TBTTJXTR-[.S.ZV0NX,/^XP.Y?H#6_10!SN
MJ6>I6=C:Z-X>TJS6PEB>&6:2;8+4$<,(]I\SJQQD9/4\YK;LK.#3K"WLK5!'
M;V\:Q1H/X548 _(5/10!EW?AW2KZYGN+BV9WN%5)U\YPDJKT#H#M8>Q!ZFN=
ML/"[W/C+Q/?:G82K9:CY"PD7.T2(D81E=4;D$] P(P3TSBNVHH Q]:\+:'XA
MM[>#5-.BGCMCF#JAB_W64@CH. >PIFH>#_#^J:9:Z==Z7 ]K:$&W1<H8C_LL
MI!'O@\]ZVZ* ,F;PSH\]G8VC62BWL9!+;1QNR"-QT8;2.1D\]>3ZU(F@Z='J
MT^J)"ZWTZ".683/EE'0=<8&3CT[5I44 8O\ PB6A?V%-HC:=&^FS,6>WD9F7
M<3N)&3D'/.1WYJ,>"_#HT7^R!ID?V+S5FV%FW>8.C[\[MPP.<YQQ6]10!ACP
M;X=6._C&DV^S4$$=T,']Z  !GGKP.1R2 >M3Q>&])@O+.[BM-L]G&T<#B5_D
M5OO#KSD\G/7O6K10!D)X8T:.\DNDL@KR3"X=!(WE-+U\PQYV;L@'=C.1GK3W
M\/:6]]>7IMW^TWD8BN)!,X,B#.%.#T&3CZGUK4HH R;+PSH^GSV4]K9+')8P
M-;VS;V/E1MC*C)Z<#Z=JU64.C*<X(P<$@_F.E+10!G:5H.FZ'%-%IUN8$GD,
MLBB5V#.>K<D\GN:J'P?H3:?-8&R)M9I_M,D1GDPTN[=O/S==V#]1FMRB@#!U
M/P7X=UG48=0U'2H;B[A0(LKELLH_A;!^<>S9K8NK2WOK*:SNH4EMID,<D3C*
MLI&""/3%344 8=CX/\/Z;=VUU::9%'<6T1ABE+,S!#CC))ST&,YQVI=(\'^'
M]!O9;S2]+AMIY<Y9,X7)R=H)PH/?:!6W10!A'P;X?.FW&G#38UL[F7S985=@
MK-NW=CTW$G'3/.*T[G3;.\BMX[F!9EMY4FB\PEBKIRK9/.1ZU:HH H:AHUAJ
MD]I->0&22TD\V ^8R^6^,;A@CG!(_$U WAG1VN-0N/L*++J"[;IE9E,@P >A
MXR  <8SCFM:B@# OO!7AW4M+LM-O-,CEM;' M5+N&A &,*P.X#  QG' ]*M-
MX;TG99K':F 6<;16_P!GE>$QHV-P!0@X.T9SZ5JT4 0VMI;V-G%:6L*0V\2A
M$C08"@=JSK3PQI%BD:6]LZK%$T,0,\C>4AQE4RQV X'W<=!6O10!B1^$M#BM
M;"VCLBL&GR>;:1B:3$+<\K\W'4_F?6H9/ WAF62:232(&::X%TV2V/-SG>!G
M"DGKC&>^:Z&B@#+3P[I<=S?W,=LRS7ZA+IEE<>8 , 'GC X&.@XJUINFVFD6
M$5C8Q>3:PKMCCW%@@]!DGCVJU10!B/X1T.6SO[22R+6^H2>;=QF:0B9^.6^;
MGH/R'I5E=!TU=3BU+R'-Y%#Y"2M,[$1GJO)Y!(!Y[C-:5% &'I/@[P_H5U-<
MZ7I<5K--N#-&6^4'DA1G" _[..E._P"$2T+^Q)]&-@IT^9S(\#2.1OW;MP).
M0=W.01SS6U10!CV7A;0]/N)KBWTZ)9IX1!*[9<R(,\-N)SU.2>3GFJUGX&\-
M6$MK+;Z6BM:.SVVZ1W$)/78&)"CV'%=#10!A6G@SP[8:Y)K-KI4$5_(Q=I5S
MC<>"P7.T,<GD#/)J3P]X>M?#T5\EI&L27=TUTT2,Q5&8 '!//.,GIR:V:* ,
MJ\\.:5?WS7L]L?M+Q^5))%*\9D3^Z^TC>O)X;(YHU'PUH^JK9+=V*,+(_P"C
M;"8_*&,$#:1\I  (Z''2M6B@#$'A#P^NE76F+I<"V=W,9YHAD!I-V[=G.0<\
MC'3M6A-I=C<:4^F36L;V+Q&)H&&5*$8P:MT4 8-MX,\/6DT<]OIJ1SQP&W64
M2/O$9[;LY/USD#@583PSHR>'VT'[!&VE%=GV60ET"]<#)..>1CIVK6HH S-$
M\/:3X<M&M=)LTMHF.6PQ8L>@RS$DX[<\4^31-/EU?^U6A?[<(3 )EE=2(SR5
M&#C&>?KSUK0HH Q5\):$FE1:8M@!:0S>?$@D?,4F2=Z-G<IR2<@CJ?6K#:!I
M;Z7=:;)9I):W>?M"2$N9B1@EF)+,< #).>!Z5I44 5[2RM["SCM+6/RX(QM5
M03Q^/7/OUK+/A#0FTN;3&L2;*>;SY83-)M>3=NW'YNN[GZ\UN44 9HT#3AJ3
MZB(I!>20"W:;SY-QC'1<[O4D_4YZU63PAH<=A96*616UL9A/;1":0")QT9?F
MX(R<>F3ZUMT4 9?_  CFD_:-1G:T#R:DGEWF]V83+C: P)Q@ D#T!JI=^"?#
ME_I%OI5SI44EG;-NA4LP:,^H<'<#^-;]% &+<^$M!N]+M=-ETV+[+:.'MU0L
MC1-_>5E(8'DY(.3GFK&E^']*T62YDTZS2"2Y8/,X)+2-C&222>U:5% &?<:'
MIMUJ\&JSV<;WT"&..8YR%SG'H1GD9Z'D5!9>&-'TZ9)+2R$?ENTD4?F,8XG;
M.61"=J$Y/*@=3ZFM>B@"G;:38V>HWVH6]NL=W?%#<R G,FQ=JY[<#CBKE%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !6;J>AVVJW=C=RR7$5Q9.SPR0R;2"PVG/J"*TJ* "BB
MB@#,M-#MK/6;S5EDN);NZC6)VEDW!44LRJH[ %V_.M.BB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN#USC!''>O&[BXM8O!_PC*2PHT>H[WPP&W]\N2?3WKJKR:R?]H+7DN9<V[:
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MR$G>, -T/X]JYCQWJNG2ZI\0M.T^"6RN3;Q-=;@\CWCJ1RHY6-%')/4\8(%
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ME'O\R_F/6LGPWXDN'U+Q5<:KX@TJZTRRG!A2V!#V<?S9$W P>.^>5;H*XOX
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M/'.BZEDZ_+KJ#R&YEF9GB(*CJV<.01UH ]^U#Q1H6DWZ6.HZK:VETZ&1(YI
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MMSZX'I7JNK^*8=+FN(DL;J[-M9&_F,(4*L0)'!8@%CM; 'IVXSBZK>I?>-/
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MN/[#UB2VTNZ:VOI4B0B#:%)?[_S+\W\.2 "2!QD>X6?XK:/-;W$CVUSHD\H
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MLX(['.",5MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEC1=I\O"\$=R,_,36A<^']9F;QWBS7_B>6ZQ6A$RXW"#RCN]!GGOQ[\5WM%
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M&Z\TME]Z.BLN. "F"??@&MQ=+U#6O$VAZSJ-D+#^R8I_W?FK(9)9553M*_P
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MF_*OO4$[.0&Y_G0!!<:QJ&E^.HM.FO&N-/719[QT,2!VDCD09) '9CP !3M
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M0R+ RLY:14^7> C 8X)(.."#M:EX-T[5?#UEI%S/>8L2C6MW'*$GA9!A65@
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MJ6@VES?X\3:O8$(J6UW#&USO+8+(H"$*!UW?AWR 7M!U]O$L^EW.GW<GV(6
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M1?[#A:190I&[S),D@]]N.>N#6%X6U$PZ=\-KF^F4Z0MG- TKM^[BNMH$>\]
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MZ*,:AM:26/"^6&! RO7:".F.,UTOQ+M8X?A;JMK;0A(8H8E2.)<!$61. !T
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MQT'B;P]+KEMIL%M=0VBV5]#>8: N&\MMP7 88!K<CC6*,(BJH'91@?E7!_\
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MPN/PE_SVN_\ P'-',NX>QJ=COZ*X#_A<?A+_ )[7?_@.:/\ A<?A+_GM=_\
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M:P$[MH[>8^.!V&6/;.UIGAM;/69=9O+V:_U)X!;+-*JH(X@=VU54 #)Y)ZG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %><Z^U\GQHT8Z=%;RS_V-/\MQ*T:X\Q>Z
MJQ_2O1JP[CPO:7/BRV\1M<W:WMO"8(U5U$?EGDJ5QSD\]<T <\=#'AS3/$FM
MZUKIL[[5YHGN+JRC/[E5PD<<0()8X.W.,DMP!531;F>T^*L-C;IJ]O87>D23
M/;ZC<M+OD610)%#.Q4X)!SCZ5VNOZ#9>)-(DTV_$GDNRN&B<HZ,I#*RGL00*
MS8?!UI9ZO!KD=U?W.JV]N\(EN+@-YRGG8V1@#('0#'7N: /.'EU/5_"WEB[U
MEO&+:NT4J6]S.D803D,/D(01",=1CD=<UTEW=7E]\0+S0%MM2NM-TK3X/+@M
M[\Q,[OG]X[EU9R H R3SDGGFN>L=(U&S\';;+4_%]EXA".T6F10R?9HYRQ(0
M%T*^7D_>+XQSFO0[KPA%JEQ9:M=75W8ZW':K!/=:?-Y9D'4J1@@KNR1D<4 2
M^"H-<M?#45MX@+->Q22(KO()'>+<=A9AP6VX!^E>;?$>XO+OP[XGU#4]'U&)
MP$M+ M$/*A@$R%G+9^](0">.@0>M>P:?80Z99):P&5D3)W2R-([$G)+,Q)))
M)-4_$GAZT\4Z)+I%_).EI,5,@@<*6 .0,X/&0#QZ4 6-*OY=1M&GFL+BR/F,
MJQ7  <J#PQ )QGTJ]3(8S%"D;2/(54 N^-S8[G  S3Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>modificationno15effectiv007.jpg
<TEXT>
begin 644 modificationno15effectiv007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'=@1[<L< #DG/N>IZ@'H-%<G:^.[.XTF"XE@%K>37DMB;6XF50DT1;?N?IM
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MGR<]<\X]/>E\,Z'XK\/K'H?GZ=)H=O*3;W>Y_M(AW;A&4QMS_#NST[9KMZ*
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M .!4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M [XX4M@XR>^*XR2XM+CXN6L,=PC)/H,OF"*7&X^;%M/!Z[2<'KBN8T71K/\
MX4E>ZX6N#J3:/>(;C[3)G:K.P'WL<%1V]?4T >NP-*]O&T\8CE* NBMN"MCD
M ]^>]25YI<64-]XF\!07#2M#<:5<":,3,%D"QQ8R ?\ :/USS6=#+-:> [VV
M@N@EI8^*'MA!)-M\VV6ZQ]G#,>X..2!C() S0!ZY17&^$],">)==U:';%87!
MB6TM4G#+'A?WC;$8JNYL>_!/&:[*@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L76
M=%N=0U;2=1M+V*WET]Y&VRP&59 Z;2.&7'UK:K UW4]1MM=T/3;![:,7\DPE
MDFB:3"HF[Y0&7D^IH WZ*Y^?Q=8V_BJ+P](DRWKQF;&PMF/@!AMSU)QSC&"3
MQC.GJNIV^C:;-J%WN%M -\KJ,[%[MCOCT&3Z T 37B74EI(EG-%#<$8226(R
M*/JH92?S%4_#ND?V!X;TW2!/YXLK=(/-V[=^T8SC)Q^=9@\2R:IX%EU_2ML,
M@M&ND%S Y7A"P'5<]N0<5O64[W.G6\[!0\L2N<= 2 : (=0T72]6,9U'3K2[
M,1S&9X5<I]"1Q3FTK3GL/L#6%JUET^SF%3'_ -\XQ7/>&O&4FL>)M9T"^LTM
M;NP8M"R.66YB#%"XR!C##!'N*-6\8R6?CW1_"UI:)*]\LC37+N0L.U"X4 #E
MB!G&1C*^M '3VMI;6-NMO:6\5O"OW8X4"*/H!Q4%[H^FZE(DE[I]K<R1C"/+
M$K,H]B1D58-U;BY%N9XO/(R(MXW8]<=:)+JWB)$D\2$$ [G P3T'XT ,L["S
MTZ#R+&T@MHLEMD,81<^N!4DUO#<&(S1)(8G$D990=K $9'H>3S[TIFB#,ID3
M<HRPW#('J:R/$?B&#0=&%]E)6DFB@A7=PSR.J Y] 6R?84 :=S96MZJK=6T4
MZJ<A94# 'UP:F95="C*&4C!!&0163IU[?1//'K4VG*&EQ9RV[E?/0@=48G#
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M>'[3Q!86-C<6%U(@$*SMYL49<*68X(+ ')3C&",G'(!V5%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D7QXT?Q7J^CZ:
MN@17=Q9H[_;+>TR78G;L)4<L!\WTS7KM% '%_"FQU[3OA_8VWB(S"]5G*I.V
MZ1(\_*K'UQV[# [8KM*** "N7U[_ )'CPG_OW?\ Z)KJ*R-6T,ZGJ.F7\=[+
M;3Z>[LA1%8.'7:001Z>E %TZ;9&[2[%M&MPCF02*,,6*[221UXP.?0>@J::"
M&X55FB20*P=0Z@X8=",]Q4E% &)K=I!8^"=5MK:,1PQV$X1!T4;&X'M[5?TG
M_D"V/_7O'_Z"*9K6G/J^D7.GI=O:BX1HWDC16;:P((&[([U:MH%MK2&W4EEB
M0(">X Q0!Y=K.;.%/&.EC[3<:)K%RMU% 0S2VLDA61<#J1PPSZ&I;R/[#\0O
M 3W\D<>H7<NH7-TI<95W@ "_10%0>H45Z<D,48(CB10>NU0,TCV\+ON>*-F]
M2H)H \;U;5]*>>.>WN+:T-OXNC:>.9]UP&$H1Y'8G]W&1P!C&W'/.*GU2PT2
MZF^*DDEO9R&*V26+<JGRW-IG<H_A;=W'.:]=-O"69C#'ER&8[1R1T)^E(;:
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M\9>%->U^SE?7;"1+2<K8VJ3!I)IVRGF;1SP&*J/]HGTKN1;P @B&,%05&%'
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MTW_WMHS^= #ZX#X@17^DZ[H/B?2(#-=J[Z9+&/XUG&(RWLLH4_C7?TC*&&&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'S*JKS_$V[@=< UYYXFMM!U6SN/$FE74VB>,8%<1+;Y2:ZD4D*ABQ^]5\#!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !67JFAPZI>V%X;FYM[BQ=WA> K_$NU@0RD$8K4HH ****
M*.KZ:NL:9/8/<SV\4ZE)&@*AF4@@KE@<9![<^]6+.UCLK*"TBSY4$:QIN.3A
M1@9_*IJ* "BBB@ HHHH **** *NHVT]YIUQ;VMY)93R(52XC56:,^H##!_&H
MM(TS^RK,Q/<RW=Q(YDGN90H>9R -Q"@ <   #@ "K]% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%,CFBFW>5(C[&*MM
M8'!'4'WI)[B&VB,L\T<48X+R,%'YF@"2BH;>[MKM6:VN(IE4X)C<-C\J6YNK
M>S@:>ZGB@A7[TDKA5'U)H EHJK#J5A<VXN(+VVEA.?WD<JLO'7D'%+!J-C=2
M>7;WEO,^,[8Y58_D#0!9HJO<7UI:%1<W4$);D"20+G\Z9_:FG[HU^WVNZ3[@
M\Y<MSCCGGF@"W14$U[:VTB1SW,,3O]U7D"EOH#UJ<G R: "BH+6]M+Z-I+2Y
MAN$5MI:&0. ?3([T17UI/<2V\-U!)/#_ *R-) 63Z@<B@">BF/-%&\:/(BO(
M2$4L 6(&2!Z\ FHKB_L[26**YNX(9)CMC220*7/H 3S0!8HHHH **9+-%;Q-
M+-(D<:]7=@ /Q-16]]:7986UU!,5ZB.0-C\J +%%%% !14,%W;71<6]Q#,4.
M'$;AMOUQTZ5-0 45#<75O:('N;B*%2<!I'"@G\:E5@RAE(*D9!'0T +114-Q
M=VUHH:YN(H5)P#(X4$_C0!-12 AE#*00>01WI: "BBB@ HHHH ***@CO+66:
M2&.YA>6/[Z*X++]1VH GHJ*WN8+R!9[:>.>%_NR1.&4_0CBI: "BBB@ HHHH
M **** "BHC=6XNA:F>(7!3S!%O&\KG&<=<9[U+0 445%<7-O:1B2YGBA0G :
M1PHSZ9- $M%(K!E#*05(R"#P12T %%%% !1110 45'-/#;1&6>6.*,=7D8*!
M^)I8I8YHUDBD62-AE60Y!^AH ?1110 4444 %%17%S;V<)FN9XH(EZO*X51^
M)I8)X;F%)H)4EB<95XV#*P]01UH DHJ&XN[:T0/<W$4*DX!D<*"?QJ8'(R.E
M !114-Q>6UH%-S<PPAN 97"Y_.@":BH+>]M;L,;:YAF"]3'(&Q^5+;W=M=J6
MMKB*95."8W# '\* )J*** "BBB@ HJN;^S%Z+(W< NR-P@,@WD>NW.<58H *
M*;)(D4;22.J(HRS,< #U)J#^TK'RHI?MMOY<KB.-_-7#N>B@YY/M0!9HHJ*>
MZM[54-Q/%"'<1H9'"[F/11GJ3Z4 2T444 %%0O=VT=PMN]Q"L[\K&S@,WT'6
MIJ "BH!>6K7)MA<PFX'6(.-P_#K4] !1110 444CNL:,[L%51DL3@ >M "T5
M%;W-O=QF2VGBF0'!:-PPSZ9%2T %%%% !139)(X8GEE=4C0%F=C@*!U)/84D
M4L<\*30R))$ZAD=#D,#T((ZB@!]%%% !1110 4444 %%17%Q!:0//<S1PPH,
MM)(P55'N3P*D!# $$$'D$4 +1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534[6*\TVXMY@YC>
M,A@KLA/'J"#5NL+Q5XBTSP[I/FZEJ<&GK.3#%-/$TB[B">B\G@'N* .,^ ))
M^&$1)R3=S?S%6OBSINNZO8Z?:Z;X<BURPCD:>[MY+GR@2!A ,.K'JQX]!UKF
M/"'B/P?X2\$7GAR#X@6SO*)3!>1V4B/"SC&[!)!P>>U3Q^/-.L]/T6*U^*5K
M)/9(R7C7>G/(MYDY!/1E(''#<]Z .E^$5YH5QX;N[?1]"DT.>WNBE]8R.[LD
MV!SN;DC '7&,'CUY[3[@^,/V@-4LM6436.A6Q:RM)!E!)E 9"IX)^8G/^[Z5
MV/@C6?#.K7.JRZ+JL&H7]Q*MS?211-&,[0BX!Z#" 8R>Y[UQFO:WX(@\=GQ+
MI7C"UTS780UM>1RVTDL5PH^4JZC!!& ,@_PCTH ]/;P]IQ\06^MQVZ1WT43P
MF1% ,B-CAO7!48].?6O,_@2BK/XRVJ!_Q-".!VRW%:]I\4_# E:>^\:6#OY9
M2.&"TE2)2<?,V<LQX]0,$\=ZY/PAK_AGP:VK-9?$+29CJ-P;A_.TJ;Y&YZ8D
M''- &W^T1M;X<VYX)74HOP^22M7X@^"H/&MCI.FAQ;W4=K++:3 8V2*(\ X_
MA.<'\^U<7XFU3PCXH\&0:!>?$6S\X7CWD]Y_9TA,KLSD +NPH ?'4_=%=5_P
MLGPI_:.F71\9Z9LM(7BE06,V9=VWD'=\OW1V- &=X'\97&MZEI'AGQ-#Y?B;
M1[]UD$HYE06\P\P'UY&3WR".O&_\;-2N=-^%VI-:NR/.T<#.IP0C,-WYC(_&
MLB_\6?#*\\:Z5XJ3Q';0ZA8B2-V6*3]_&R,H#?+U!;(/ID>F+?BCQY\-O%GA
MN]T2]\2P+#=)C>L;Y1@058?+V(!H YO4M9N_#?Q%U,:=E$/A S%%^[YD4;%&
MQZC&/H:S-)OI]-M/@_=6[,)KJXN89V!YD6650V[U^\3SWYK>TSQ'\/8]:N]7
MUCQ997MU/IRZ9MCMI(T$(&&X.22QZ\\=/>J6CZE\/=/NO#XNO&=M<V?AXSFP
MC^S2*Y,C9!D;!!VC@8 R>?:@#9UVVC@_:/\ "CIOS+8SN^YV;G9*.,GC\*L_
M%WP=I.J:#<72V;W/B.]FAM]/;>=^_(^11G 4*'8]NI/K61JGBCP=J'Q%TOQ:
MOCJPB.G0M#':FPE;<K!P<MN'/S^G:JGB;Q-H^N>)!JUA\6(-+2.+RH((M,=_
M+4XW?,3R20,G X ':@#V738FTGP_:0W]T'>TM46>YD; 8H@#.2?H3DU1_P"$
MU\*?]#/HO_@?%_\ %5S&D_$_P+IVBVEC<>+8;R6*%4EN)(I,S-CYG(P>IR<>
M]3_\+1^&_P#T&K#_ ,!W_P#B: .PNY8;O19Y89(YH);=F1T(974KD$$<$$5X
MW\)]6F\/_ K5]8M8HGFM+F>8)(#M?:J<'&#TKLKWXK>!I]/FM[;Q/9PN\91&
M:"1E7(Q]T 9_,5P6AW_@K1?ASJOA!?']E+'?%\7)T^4&/> #\N[G@<<CK0!U
M^A_$C6+WQ)X5L=0T^QCM?$%BUS&8'<O$RJ6Y)X(..F.,]3BK>G^.=<UZ9[W0
MM)@O-*AUDZ9,FXB81@#=/N)  !(^7!.._IQ%CJ7@JRUCPEJ!\?6+_P#"/6IM
ME3^SY1YX(*DD[OE.#[\C\*GT#7_"/A?Q!J4VD?$*VAT74+C[3+8O8N[HYZA'
M/ !Z<J> .XS0 _1-:G\-ZS\6]8M(HI);.ZAE$<@.UN9<C@^]=5IWQ#U"\\4>
M$-+DL[80Z]IGVV1E+;HF\MG*CG!&17&1:AX$SXS%SX[M)(_$W+!+*13;L-VT
M@DG</FZ<9QVJ+1]2\)6&O^&=7NOB'83MH5H;-(4TZ1%DCVLHYR2&PW7D<=!0
M!/X\\77_ (S^&'BR\M[>TCT:SOX[./=N,SE9(SYF<X .X?+CH3SQ@]G-XU.E
MW'AWPW:&VCN[C2ENWGN@S)&@3"@*I!)9@1U& .]>=79\%MH>O>'['XA6=MHV
MJW8O!$^GR/)"^Y25#9 *_*.V>!SUSJZKKG@Z?5- UO2O'UG9ZQI-L+0RO8R/
M%<1 $89.".K=^_T- 'K/A/79/$GABQU::RELIIT/F6\H(:-@2I'(!QD9'L17
MD'CWQ=?^-/A9XEU""WM(M&MM02TB#;C,^V1#YF<XP=P&W'<\\8/>67Q8\$06
MD<=QXLM[B8<O*877<2<\#;P/0<\=SUKS*Z'@MO#VM>'++XAV=OHNHW@O$C;3
MY'DA;<I*[L@%?E'8'@<]<@'I8\7W2Z_HWA'28[<7;Z4+V:XN59T10N%4*I!)
M)')SP/6LJ?XI:G<_#.#QEI.EP2)%,8M1MI"S-#@X+*01D<@X/9O8UDS^)/!"
M:]INOV'C2QCU2UT\Z?*TEI*8YDQPVT<J0>>IST]Z;I.N?#W1?!]IX8M?&-F]
MAO9K_P ZUE+7>[[PR"-@/ QSP,=S0!W5UXDUIO EYXETN&RNP(S=6<)1U,MN
M.<GYCABO('X'D\1:3X[.I>'+#7]UN;$:9+?Z@$1BT13C8OS>H<<]=A]:X_P9
MXX\'> _#9TF?QG%K%JLW^CI'8R(\2L>5.205!)/;OUX%1^$]?^&6A^'-:TA_
M$$)M=3N+@-&R292!BRJ@^7@;22/]XT =AX>\4^*->_LN\32;0:7JEE).DZDG
M[)("=B2?-\^1MZ!>2?2J_A3QYJOB/3KF*6VL[37+;51836A5F"*.6;.[/W5D
M(]=F.^:Y?P7XP\,^#-/&GR_$.WO])M2[6UNM@ZRX.3M9^<@$D@ #GOCBI-%\
M9?#FW\?:IXL374@-_:0KY,D3C;+SO) !&<!!GU+>M '2R^.=<U&_UE?#>DP7
M\.CW\=E/ S$2SGD2,K9 4*>!D'/)XK"MCY?QO\>,J1L1HT;%9 2K?NX^#@C@
MUF6FO^$=&\9:IK.A_$*VL[+5G$MY:/8O(=^22R,> 22W4$#/0\8E7Q%X+3QK
MK_B-?'5CG5K/[)Y!L)3Y0"JH;=GYON\\#.>U #M(\=/X9^$'AO5=%T2R@AO-
M1:S^Q&20JNYY/F#DD_P'KGK[5U&G?$2[@U?QA8:]:6R?\(_ MSYEF6(D0INV
M_-_%T&>,YZ"O.V/@IO >C^%A\0[()IFH?;EN/[.ERYRQ"E=W'+MSGTK7BUCP
M _B/Q3J5]XUM)[?Q#;"VFMTLY$,2A0H(?)R<>W6@#LO"WCV\UO5-)@N+.)H-
M5LC=));(Y%JXY\J1CP25[_+R",5N>)]>OM'N=-AM;51;W4CK<:A,NZ&S4+D%
MQN7.XX ^8=^IP#Y[X*\:>&O"VGP:9>?$*TO]/M 5M46QDC<+V#MSD#/  'U/
M2G^+/%_@SQ)J^A7]MX]AL?[*G:;RC:/*DI.,'!  88."<XS0!H6OQ1O[OX4:
MIXL6QM1>:;<FWDARWERX9!D<Y7AP><]*O2>,/%4'A+4/$MSI.G06*:;%>VB^
M:SN[$ LKCC''3'3(Z\XX&WG\$6W@'7/"B?$*U:'4[O[2)WL)"T0+*2" 0&/R
M#GCOQ72ZAXT\$7_P\;PL?&=FCM9+9FZ^R2$8 "[MGK@?WJ +%G\2/$4^K^%K
M233-,V>(K(S0!99,PL%W98XY&.< 9[9[UT?P\\7WGBW3M3.H6T$-WIU_)9R?
M9R=C[<?,,\CK^E>;V^I^"[?4_"-[_P )]8L?#EL;=4_L^4>>"-I).[Y>,>O/
MY5K>!_%?@?P>NKB3QK9WO]HWK7AVV<D7ELW4=6R.E &[=7ENOQYM+)M,M6O&
MT=GBO\OO1-S?(5W;3R#S@'!Q7/I\7]>'AN/7I=*TW[''K7]F3(KOO8;<[E[#
M\<YST&.5N?%?@J?XEP>,%\;V2^39&S6T-E*<K\QR7SURWIT_.N6,'@H^#W\/
M_P#"Q;+:^K?VIYW]F2YW;=NS&[IWSF@#Z$U*:>WTN[FMO+\^.%GC\P$KN R,
MXYQ7@][JNKZ[^S9K&JZM<0SFYN%D5@I#AOM:YSSC'8 #@5Z/+\6/ ,]J\$OB
M6V/F(4<K'(.HP<?+7G$=QX+3X9W7@G_A8=F;664-%.=.DW(HE\S!&?F)( SP
M,=J .X\+>--1@\3V7A;5+6S2W.B17T$T#L610 "KYX/ )X _&C0?B=<:W/H]
MU%8H^G:I=RVRQQ(S36RJ2$DD/W<,0<C QD<FN:L]=\$6_C2Q\0S>.;&9;;2U
MTUK86$JB10.6W9."2>F#QQ[TO@SQ)X4\&F33[?XAVTV@B=IH+5K)Q*F3G9YG
M3;GK\O/MDT >E>./%:>$-!2]$*S7%Q<1VMM&S;5,CG@L?0 $GZ5AZUXZUGPE
MH/B"_P!?TB(BQF2*PF@.Q+W?T^4EBNWOR?:L3QUXM^'/CCPT^DS^+(;9Q(LT
M%PD4A,4BYP<8&>"1U[UGZCXF\'^)/!=SH/B;Q]:WLTJH([F"R>(1LAR'VX.Y
MB>O(!'0#K0!V-KXUOXO%5SX9U**T^W_V6-0MIX481GCYD92Q/!!Y!Y'I7,Z7
M\6]<N]/\+ZI<Z7IZ6.LZB;!TCD<R*=VT.,\ >W.<=LU5M/$O@C_A([KQ#J'C
M.QFU-].&GP&.TE6.)<<L0<EB3[C X]ZY^V7P5;>'_#VE+\1+(C1=1-^DATV7
M]Z=P8*1NX&<\^] '9^*O%U_XALO'^D:=;VBZ?HM@\5S)/N,DSLCYV8.%V[3U
M!R0.F<BMH?B^\\+> /AW#;V\$T6JRQ6<GF9#(&;&X$'W/%8U_JG@QM3\43Z5
MX]LK2T\1VYCO(9+&20J^UAN1N,9W'((/4X[8;>7_ ((F\)>&])A\>V:WF@72
M7%O<O8R%'VG.&3/TZ'M0!VUI\2Y(IO'!U.TB%OX:90C09#3[M^ <DX)*J/QJ
MU8^)O%=Q:/=2Z79?8Y]&&HVUXA;9'*1GR7!;+8!SN&W..GIP=A?^ 8W\6C4_
M'5M>P^) IF5+*2)HF&[!4\C@MD CL.O?1\*^,/#&B:#_ &)J?Q#M=0L(H&MH
M%2Q>)Q&1@;F.[.!P,8]\T =1\']3U?6O =MJ>JW$4YN99I%8*0^XS2;MW.,>
M@ &!Q3M8\=7J^*]8T'2(+;S-'TQK^YDN59@[8#+$H!&,A@=QSUZ5SW@/QGX)
M\%^'(]%D\;6E[! SF!A:21%59F8[NN3ENO X'%4=8\1>!;KQ'JFMZ9XSLK6X
MU73FT^[66UED&" !(N,88  8/!]J (/%7B:Y\7W7PSU2P\J&UO[XL+>7<P6=
M6"L'P1N4'('0]?6O5+RVC\*>"KQ-!MK>V6QM99;>(J3&I +'(SD\Y/6O))KS
MX?1Q>$8-.\;VMO;^&Y3,BRV<DC3N6#,205QD@]!WKNM0^*7P^U'3;JQE\2P+
M'<PO"Q6.3(# @X^7WH \XU^_U75OV;$U'5;B*X>XNA(C@'?DW#[MW..O3 &!
MQ7HFB^.K^/QCJ?AW6K6TBBL=+744FMF9ML8"[E;/4_-U '3I7GTUQX-G^&4?
M@I_B)9>1%,'CN!ILF0H=GP1NY.6ZYQ@#CN=:WU_P*OCB[\17?C:QGBN],_LZ
M:T6RE7*87)#9/4KZ=#^- '3^&_B1=:Y=Z%(;&-K+6#.H6!69[+8?D\UNAW '
MH!@^M2?'  _"/620"0T!'M^^2N6\$^*O"_@^W&E_\+$MKO18)&>V@-BZRJ&)
M.UGYRN23P!D]P.*T/'?C7P/XS\*W.A)XRL[*.Y9#)*UI)*<*X88'R]UH I:%
MX;U75/%7@C7-*TY]-L;'2H5OKQ]J?:OD'R!0<L/<CO["L'0?%FJ>"=*\9ZQ9
M6=G/:0^(W2=)68.P9L83' QQR<]>E=_H7Q-\#Z1H-CILWBNSG>TMT@$J6\B!
M@JA0=N#CIZUYW<)X*N?#FO:.WQ$L@NKZD-0>4:;+F,Y)*@;N1G'/UH ]3\6^
M,M2T2686ME%#:QZ8]ZE[=J6BFE'(MQAE(8@$YY^G>L>]^+'V?P_X3U26"*PM
M];\SS[J:-IHK9E&,$*5)W-WSP 3@US>MZSX.UK7EU%OB+##&=)?39(%L78 .
M"&=-V=F>,\$X&,TEIK?@RU\&6'AJ7QMI5[:6\$T,L=SITI27>P*-@'*LA!P<
MGJ>E '<ZAX]EL[SPYI+&QCU#5XGGDN-QEMX8U4G<N""^XC Y'J?2M[P=X@G\
M2^'(-1NK)[*Y+-'+"P( 93C*Y&=IX(^M>/S7/@2VLO##Z+X^AM-5\/HR174M
MK)(LRMDLK+Q@'+8P> 2/<=_8?%?P7;VBI>>+K:YN#S)*()$4G_97!P/09/N2
M>: ,#QQX#T^;Q=X:_L&&2/7Y=0^V75X)&+B!3EY'.?[VT+T]!Q7J&LZK!H>B
M7VJW6XP6<#S.%ZD*,X'N:\-N]9TR[UR^U'_A<:0)>N/.A@TMU_=C@1AMV0 "
M<>Y)ZDUWVJ_$OX<ZSH]YI=WXB@-M=PM#(%20':PP<?+UH LZ%XD\1:VME/=:
M1;'1M3TLW:W$#'-LYSB)\GY_E(Y '.>.*\F\-7MM9_##P6;O2[:_CE\0&-!,
MSJ8G+\."I&<<\'(-=1X1\7>'?#&CG1Y?B/9WEA CI:*=/=64-G =N=P&> ,?
M7'%<[;Q^"[?PSHNBK\1;$II6I?V@DITV7,C9R%(W<#KS0!Z+K?CS7;/QMK'A
MW3[+3G%EI3:BDTY<<+CY2!UZX[=<]L' \2>,(/$'P]\&Z_J&B6ERM]JD:&WD
M=P(I0SKO4J1D?(WRG(Y]JJWVO>"[SQIJOB)?'=C&;_2WTWR#82G8K ?-NW#)
MR.F!_6LN2;P4_@?0/#0^(5D%T>]-XLYTZ4F4[F8*5W<??/.?3I0!Z%<^.=<O
M]1UV/PUI,%^FB7<5K- [$2W!)/F%#D!-N,<@YP>E1^-?B!JWAEM8DCTZ"&#3
MTA> W8)_M#>1O$9##;LSSPWOBN3MM?\ "6D^,]2US1/B%:V=MJQ#WUJ]B\F7
M&<NA/W3DL>0<9/7I5/Q#=^"]?U7Q#=-\2(XX-8MHH/):Q9S"$(( 8_P[AD@
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M=XLM=0N]:10+*.TDC*"->H<G!^53G@4 >JT444 %%%% !1110 4444 %%%%
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M3,#(/F8=0!WR>?7TH [G_A7/@O\ Z%;2?_ 5/\*/^%<^"_\ H5M)_P# 5/\
M"N+\+Z[KDNM:YX+UC5KI]:M]1C:WNL*K-:'YB0 ,?<4\XZR**[_QA=WEAX0U
M.ZT^^M+&ZBA)CNKP_NHSD<G@]LXX/..#0!4_X5SX+_Z%;2?_  %3_"C_ (5S
MX+_Z%;2?_ 5/\*Y'P9XFU6^^)M[HDUU=R:;+HT=[&MQ]Y9"4!9"?F"MO) ;!
M'' Z5Q<'C7Q8G@>T\1/XANI+B/Q(+#R62,1O#LR0V%R3QZ_KS0!ZY=> O ]G
M:2W,OA;2_+B0NVRR5C@=< #)JGH'ACX<^)]'BU72?#NE3V<I8)(;$)DJ2#PP
M!Z@UC:CK6J:[\2_$GAY=1N+*PTC2O-2. *#+*ZJVYL@Y #XQTJY\"_\ DDVE
M_P#72?\ ]&M0!O\ _"N?!?\ T*VD_P#@*G^%'_"N?!?_ $*VD_\ @*G^%<-=
M^,-:U(?$+48+^6T7PXWDV,,8&W<A;<S@CY]VW&#P!TYYI+OQ7KT=A\+KA-3E
M#ZQ-"E_\JXG#;,Y&./O'ICK0!W7_  KGP7_T*VD_^ J?X4C?#OP6JEO^$6TH
MX&<"T4G^5<=H7B77[A?B1&=9@1]*NFBL9[_ BMU!?[Q Y  '7/0=:/!WBK5K
MGXF0Z1+>7,^G76B)>8N!PTN0#)'D!E1N2 0.#T'% $V_X1_\(S<^(1HFFG3;
M:Y^RRR?V:0RR<?+M*Y_B%7]<TKX9>'C M]X?TOS9XI)XX8K$.[1HI=VP!P H
M)Y^@R:\QT[5;_1/@CX@U#3;IK>YC\1. P56!!\L$$,"#79ZW;23?'_P@[7EP
M#+ITDG!7Y<(^5''0XY^IQB@#L;'P-X$U&PM[VU\,Z4]O<1++$QLU7*L,@X(R
M.#WJ?_A7/@O_ *%;2?\ P%3_  KC(=>US2O'GB'PCJ6JW4LM[ DNA3L%!0,V
MWL/FVDY.<\1M7IE^9[/0KHV]S$EQ#;.8Y[MOD5@IPTA],\G\: ,;_A7/@O\
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ML8W,8&)/'N: .HT'0/AMXE6\.E^'M,E^QSFWG#V&PI(.JX916O\ \*Y\%_\
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MW,RHUS,L$*GJ[GL/P!/T!H \$U+X@:-JFM?VO-X)\217S6YM9I;>9HO/B/\
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MQC'7++ZB@#=HK(N]4N+7Q%IM@(X7MKU92'R0Z%%!^A!S[5KT %%%% !1110
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M?6K.K>&K3Q5>Z_92RM!=0S6\UK=1G]Y;3",%77_#N*ZN32--FECEET^T>2,
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M?6-F)[Y"FN?U"VM6^%_B@2Q1R1VWB:389 &\L"[1>">GRDCZ&O9EBC1I&6-
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MPX\?FS0,NR0R1D DCY6VAC@\XH [4:SIK:7%J:WUNUC*%,<ZN"KY.!@]R3P
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M1:NDESLFC+/L*AB%5>N.<''3)NW&H):?$ZTU66WO/L=[HIMX'6UD):03;MI
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MA4)\HJI., _*V ?2N:9'_P"%/KI$UC=_:K?5E$T#6CY(^W%SCCYALY)&1@T
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MI9R6DD>HFR$[R>22JH6QL\S&"0W\.?>@#4HHHH **** "BBB@ HHHH ****
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MS$DT>X8.U@",CZ&@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L;7=%N-5N=)N;6\CMI].NC<
MJ98#*KYC>,J0&4CB0G.>U;-%  ,X&>M%%% %+5K2YO\ 2[BTM;B*WDF1H_,E
MA,@ ((/RAEYY]:72+#^RM%L-.$GF_9+>.#S-N-VU0N<=LXJY10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !53
M5!<'3+G[+<?9YA&Q678'VG'7!X_.K=5=1=UT^X$4+32F-@L:,H+$CU8@?K0!
MQ/P;UK4O$'@"/4=5O)+N[DNIMTDAYP#P !P!["G?$#QG<Z/JVC^'-,>2._U-
MF>6XBMVG>W@7EF2, EF.#C@C@YJC\.]'\2>$/AC=::VFQ#6H#-+;123H8Y6/
M*C*MQSZX^O>FWOA_Q%=^*O!_C6XL86U*S@:WU.PMYE^4,K#<A9L'!<Y&[Z$T
M =GX4U/2-7T..\T749;^U9BIFFD=WWCJ&#\J?; Z\"N)3Q!J'C7XK:AX9M[Z
MXL=$T:(M<_99#'+<RY VEQ\RJ"3]T@_+[\;?PT\*W7A;1M1^V[4GU#4);PP*
MP80JV JDC@G YQQ^59+>%-4\+_$^\\6:+;#4=/U2(I>V:2HDT;Y!WIO(5N5S
M@D?>- '6Q:!<VNM1R0ZI?-I9MI(Y+2:Y=R)"R%75R=_0,.6[\8YKBO@?JVI:
MYHNKW>JZC=WLT-^T$;3S,P5 JG &<=2>>M=_:ZCJ%P[RR:7):VZ(=L4LL9GD
M?(Z!6* 8SU;)SVQSY[\+='\0^"-$U2TU'0+B66YO&N8OL]S;D8*@8),@P>/>
M@!_QOU;4M$T;1[K2M1N[*::_6"1H)F4,A5C@C..H'/6IOB;:>*+:2PN_"&I7
MD=S:6\MS-:><TBW*1M$,;23DX<\?Q=.N*S_B%X=\6>+_  AHEN-,5M2BOVO+
MA/M,6V)<OM0,6&XA649''%>@O+=R^*+"X_LV=;5+2:.29I8OD9VB(! ?)X1L
MD9[=: .:\,^+[/QW'H&JVEQ<03"5XKVSCN&55<1LV&4'!&1D'N.O<58^+?BB
M\\*>!)KO3I/*O;B9+6&7&3&6R2P]]JG'O5:T^'L6B_%5/$^DLD=A=Q2_;+8-
M@),1PZCT.3]"3V/&C\3?"LOC/P7/IMI)&M['(EQ;[VPI=>Q/;()'XT <K=>-
M;SPEXN\8:/Y\UU:V.D#4+-;F1I620*H*[F)8JS,#@GCG&*K:%XLU33]9\ -=
M7]Q<Q^([.0WJS2%AYO570'A,$XPN!CM6NW@2X\1^)?%6M:G$;!-5TP:=;12.
MCNF47<[;"1PRC SS@]*J:#X&U676/!CZI;K;0^&;22.1_-1A<2GA=FTD[< -
ME@#T&.N #F_^%B:N/!T?CG[9/N;Q)]F-OYA\K[)LSY>S[N>^[&[/>NG^+%KX
METO39/$VF>*+ZWG@N(H[;3;< 12!F"A2.KN2<\Y';'>LG_A5^I'P^G@XQ+_9
MJ>(/[0^W>:FPVNS&W;G=YG.,8QWS6_XKD\=7/BV*XTOPQ97NFV'S6GVJ]10T
MN,&7:&'(!(7/3)/4\ 'H]HT[64#72JMP8U,JKT#XY _&IJS8K>6_\.I9ZJX%
MQ<6@BNC ^W#LF'VD=.2<&L[PWX/TKPM//-87%](TZA6%U=M,  <\!CQ0!QOQ
M;U34M*\0^#H]/U&\M([^_P#(N4AG91(FZ,8P#Q]X\CUKJ=5\=Z=HGB1/#CV&
MIW.H&T^U1)!&LGF(,]&+=?E;[V.G7D5S_P 3_#FL^(M=\*W&E6!N(=+O?M-P
M_G1I\NY#A0S D_*:DU70=8N?B_:>)(=.9M.ATA[5F\Z(-YAWMC!;_: SZ^W-
M %?Q7XZTS6?AO8:_8ZIK&EV=S>HGGV<2F9&4G,;@N.#@]">W4<'6F\<W?_"U
M%\*0Z5<R00V1GF=3'ERS(%8988103GN2>G'/ -\/O%'_  I>S\,#3 =3BU/[
M0R_:8MOE\G.[=[XQ7;-H.L6_QE7Q1#9+-IUSI8M9"9T5H'W G<,\\#^'//IU
MH K^&O&FEZ7I'BC5M1UK5+JWM=5>-TOHU#0,2 (H\,01GC.0/IR:V9?&-IK%
MOXFTF".]L=5TNT:22.0JK -&61T9&((Z=ZXFS\+^--,\*^,8-/TZ!-0U35#=
M6PGEA<&)FYQDE0X'K^'-6M&\(^(-/\4>*]0DTM5M]5TI880+]9F\T1A2K,V"
M6)R2QXZ\F@#J?A+J=]K'PSTB_P!1NI;J[E\[?-*V6;$K@9/T %-NOB?I=M=Z
MY:KI6KSRZ)AKT0PQD(G)W@EP",#..OMP<2_"_1[_ ,.?#[3M(U6 6]Y;&4.O
MF*X.Z1F!!4GLPKSVU_M&?QK\5;'3-->^FO84MU"31IL9XW4%M[#Y>3G&3QT.
M> #TJ?X@Z)#)X="_:)HO$#!;*:) 4SQPV2"N-P[5'!\1-)N-/\0WB6U\%T"1
MHKV,HFX%<[MOS8(&T]ZXN[\ :WI>A_#U+*!-0G\/W1ENX8YD0G>P=MI<@$ @
MCKZ4NF^$?$<.B?$:"YTU%N->FFELUCN8V5MY?C)(QC<#R!Q^5 '7Z;\2]$U.
M,W"6^HP6"V!OVOI[8K $! *[LG+C/09Z$9SQ4,OCNQUBTU/3;>'4+&^_L=M2
MMS* A>$K\KJR,<'..#@^W6JL7A&^O_@FGA.X"V>H?81 0SJRB12".5)X)'Y&
ME\/IXHD\"2Z/J^@QVUY;Z:UFLHNXW-P0FU-H!P >IW$<]N> #(^'/Q'3_A&?
M"UCKW]I37^K/-%'?RH#')(LK *6)W$X*C.,=L\''2ZQ\3="T:34/-2[F@TVX
MCMKV>!4*V[OTR"P8CW4']#7!:?X&\36VC?#NUDTO]YH6H2SWN+F+ 1I@XV_-
MSQ_*G^-_!_C3Q/\ \)1 =.M)(IIX6TUDNTC4QJW/R?Q2$8RSD8P0.." >C:E
MXYTW3]8N-+2WNKRZM[07DR6P0E(CT.&8%CWPH.!CUHUGQUI6C7E];21W5PVG
M0)<7S6Z*PMHV. 6RP).,G"Y.!G'3/%>-_!6I>(9;6_L-,FLM?M(H!9ZC;7<:
MA3_&DN6!PO)#*#UQSW?=>$-6L?B1JNIR:':^(=)UFWB68//''Y,B*%RRN>5.
M#T!X/M@@'JL$\5S;QSPNLD4JAT=3PRD9!'X5C:SXKL=&UBPTEXI[C4+Y7>&"
M$H"50<G+LH^@!)/I678:KKMCXWA\/RZ781:#]@#6L]L_S*8P@8%<\*"VT# [
M<GFL[XF>%!XLABB&ES3S00N]I>VD\<<MO/D;0=[*"AP,]QC\0 +K7Q$N+7Q/
MX5TNPTB\E35XS=/D()&C\MF"*&8 ,#@G)&,8&<UIZC\1='TZXU2-H;R>+2?*
M_M&>%%9+8R' !RP+$=]H;%<S=^%O$Z>(O >M2K'J=SI5J\&H'[0J-O9-N[+?
M>&3R1D\9QS5'4_ NN0)X\T^QM5NH_$LT4]M<^<BI"2Y,@D!(88R<;0V10!VV
MK?$/1M'UK3]+EBO9YM0MS<6CVT0E690I("X.23C X[BHS\1M+^SV96QU'[9=
MV<EZM@\:1SK$A(8L'8#/!P 22!FN=_X0W5+'Q_X'NK>W^TZ9H6FFSGN?-0$M
MY3("%+9ZD'^6:T/&VD^)=7\464=A:6L^B?8I8YF-R(6\U@P&\X+%!\IVC@G.
M>U &I_PL?07T'1M6@-Q.NLS"WL;=$ EDDW;2N"0!@\$DX]Z2#XCZ*]OKEQ<Q
MW=G%HC&.]:X1?D?.-HVL<DGIC@^M>:2Z5>>%/AUX.L=7T2YDU;3]6>2'[!*D
MTZ#<\NY$&0^> 0<@ 9/:IUT[3O&WA7Q7H&DV.KZ=XBO)$U&?^V8A"TYWY&,<
M!>"!P,9[\T >KZ/XHL]7U*YTSR+FTO[:*.=[>Y"AC&XRK#:Q!'8\Y!K:=UCC
M:1V"HH)8GL!7G6GP^(+#PW<ZI9>#]+L/$L=JD/[^XC;[00R[CN4\( "<%ASC
MIC)Z[1-4O-6\)66HR0107]S:++Y+,=BN5R!ZXS^E &-8?$S0]0U#1[:*.[6'
M6#*MA=,J>7,T9PPX8LIS_>4=:K:A\5M&TZ?6X7TW5I9-%91>>5"A"*QP&!WX
MQT]^>G!QQ-CX-\9S:OX1U74M+M_M.G7T\EX5O8\;'92I5!\J( /NKDDY)&35
MK4?!GB*XN?B.T>FY775A6Q/VB(;MC<[OF^7@YY_G0!Z!?^.-*MCHL-O'=7]S
MK<?FV5M:JN]X]NXN2S*% !SR1^E<Y\)M:U#5[GQ8M[=W<\=KJKPVZ73$M%&"
M<+SSQ6:/">O:;JW@'7X-/-U+H^FKI]]9+/&KKB(IO4E@IY8GKV'OC9^&>@:Q
MH5]XHFUBS2V&I:D]W#LG60%6)]#GN.H'X4 =!K'BRPL==@\/+;7M[J5S TY@
MLMH:*(<%V8LN.^,'.>@KB?AIXW>W^&<^M>(]0N;IQJ3V\1<EY9"=H2-0>I)/
M\\UJ:EH.L:=\78O%FG60U&SNM/-E/&LZ1M"P((;YB,KPO3)Z\'C/&6WPU\3M
M\*/[)>U@AU>TUC^TX('G1DF&W&W<#@'D]?;GG@ ZGXB>,C+\/?$<NE3WFFZQ
MH\\$<R;PDD1=TP<JQ!5E8XY/YBIX-;)\?^&K675-7^TRZ+YWV!%0V]T2A)=F
M+ AL@CD=0.0,YH^)O#&HZ]\.M8M=/\*6NEZKJ1MP\*7$1=S&X8L[@X( &%Y)
MYZ"IH?#>M_\ "S/"NMMIS)8Z?I L[AS/%E9-KCH&R0"PY% '1Z/\0M,UW1[O
M4K*RU K:WBV4D#HBR^:S*H&TOZL!R1W]*?J/Q!T;3+F_CF6Y>#3I(8KZZC53
M%;/(<*&);)ZC.T'&>:RM)\$S:7\4-7UJ*95T:]2.Z\@,,&[^92<>P+-]7'I6
M%;>#-2T[QOXC%SX=LM<T;6K@744\\Z!;=R22'1N2,GL#]T?@ =3JOQ*TC2==
MU#19+'5)[^RMQ<F*VMQ*94X^YAO1L\XX!JUI_CS3]0\4?\(Z+'4+?4#:"\5;
MB-$#1D C'S9SSC&."#G&#6+IGA[4[7XTZEXADL@NE3Z:MI%,)8_O#RS]W=N
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MC2GO'N8K9D<R)*J*#\YRN'/'7WK$M_&NO76A>&;V.+3O.U35);"8&-PJ[6F
M9?F..(N0<]>U &3_ ,,[>#_^?[6__ B/_P"-U37X%^ &U9M*76M5:_6+SVMQ
M=1EU3(&XCR^!DBNI'C;4M-M];M=22TN-2LM2@L+9X$:*.9IU0QEE+,1C?SST
M6EACU*/XP;;FYMII#X>?RI$@* 'SUX9=QR,^XX./<@'+Z=\"/ >K6$5]8:OJ
M]Q:RYV2QW,95L$@X_=^H-6O^&=O!_P#S_:W_ .!$?_QNM6S\9ZY<>&/"6H0P
M:<LVL7QM)T*.$3_6D%<-Q_J^^<Y[5/+XTU;2='\6MJ$-K=WNA31HLEO&T<<B
MR(C*S*68C;OR>>BT 8?_  SMX/\ ^?[6_P#P(C_^-U2U#X'?#W21&=1U_4+,
M2-M0W%]#'N/H,IR:[ZRUG5V\=2:'+)9SV4=@EZ;B.%E;YF90GWB!RNX>HSZ9
MK.^*99=)T!HTWN-?LBJYQD[^F>U ''VGP4^'%_=?9K/Q'?7%QM+^5%?PLVT8
MR<!,XY'YUH?\,[>#_P#G^UO_ ,"(_P#XW7H%O-J-YJTJW6EQVOD0!K:=I/,!
M=BP8<8X "\=\^U<?9^-/$\WA[PYK;II1CU.^%C+;".12"[NBN'W' !4?+M/?
MGT ,_P#X9V\'_P#/]K?_ ($1_P#QNC_AG;P?_P _VM_^!$?_ ,;K?;QEJ>D2
M>);;55M+J?2S:?9Y+:)HED^T':BLI9L8;J<\BI+O7_%6GQ:U+)80O:VNFO>6
M]W+;F)?-3),3)YA)! R&!&.0<T <Y_PSMX/_ .?[6_\ P(C_ /C='_#.W@__
M )_M;_\  B/_ .-UT!\3>(;'0M-U*_&G%-6GLH8#%&X%KYP^=I,M\PSC&,<G
M!I)?&6J:;/XF%[':SP:1)!! \4;(9I)MFP,=Q VEP&Q['CI0!@?\,[>#_P#G
M^UO_ ,"(_P#XW1_PSMX/_P"?[6__  (C_P#C=='=Z_XJT^/699+"%[6VTU[R
MWNY;<Q*)4R3$R>8200,A@1CD'-&G>)->;6/#L%\=/-OKMA)-&L,+AK>1(T?)
M);YP=QXPN/4]2 <Y_P ,[>#_ /G^UK_P(C_^-T?\,[>#_P#G^UK_ ,"(_P#X
MW75_#>ZU.^\,/=:E>)<N]Y= ,(BC K<2 Y.XC' P !@<<U'J/BZ>U\72:&]Q
M:Z?*9(?L:WD+;;U&VF39)N"AQEE"]<@=<\ '&6?P+\ :C<74%GK6JW$MJXCG
M6.ZC;RV(S@_N^OM5S_AG;P?_ ,_VM_\ @1'_ /&ZLW.H:QI&L_$75-*:R7["
M\%S(MS&S^:$M48H,,NW(!^;GZ5N^(/%6IV5G+>6GV.&%=*^W0+(C3R328+%"
MBD%4 "Y?&/F'(QR <;+\"_ $&IV^FRZUJJWUPK-%;FZCWNJC)('E]!ZT:?\
M OP!JJ3OI^M:K<I!*8)&BNHV"N "5R(^HR*ZJZO?[3\9?#[4"@0W-G=S;<YV
M[H8VQ^M7/ /^O\6_]C#<?^@1T <K_P ,[>#_ /G^UO\ \"(__C='_#.W@_\
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MYR,5T% '+:EX/DUZ*SMM;U62YL;:5)C;0PK$LS)]W>>21GL"*IZI\/CJ*:[
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M<1)=Z8FFW2)"A\Q$#!64MG8<.<@=<]JV['6I[C5VTR[TN>TG6#SQ(SJ\3KN
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M0&T2YU:8W?GC4;QKQU\K;L<JJD#D\80?K6U110 4444 %%%% !1110 4444
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M-12\AU2!["[TZ^M[L"ZL;B7S1 QC3 C;."A ##&.IX%:0\)^'QY^W1[)?/\
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MN?)>1 2F>H'MP..G% 'E^F2W.H^%_ +2:GJ!^U:K<6\SI>2 RQ_Z1P3GG[H
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M@-'?$"V8*<2Y!88X_N@GZ GI7+^ +-'T?6H+NQEB$^K7KE+BV:/S(Y)"0?F
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M! X/I5FPM?L-A;V@E>40QB,.^-S # S@ ?I5BB@ JCK&E6^MZ3<:;=-*L,X
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M?LWFKY^SS/+S\VW.,X],UF>'/$VE^*].DO\ 29GEMXYG@9GC*'>N,\'ZC\Z
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M"6V2ZD\H7$GE1NP^4N>BD] 3VSU/'6K= !1110 4444 %%%% !1110 4444
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M\2)J31"*1T+JLBC&-RCAL8'7T'I2^)?B1IGBRS@M-6\"^)9(8)A.BQY3#@$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K(\4:VWAOPY>ZP+47*6D9EDC\S82HZX.#S6O7)_$TX^&7B+/\
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M+305MYF'0223EU4^^U2?Q'K0!M:#XA_MN\U>V-E+:OIMU]F82NI+G8KY^4D
M88=S6U7'>#?^1E\:_P#863_TGBKJ[:[MKV(RVMQ%/&&*%XG# ,#@C([@\$4
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MT^?RWDCBN-TL4;L%#;=H#=>@-;U[X@C3P]%K6F)%?VTOEF,B;8'5V"@@X/\
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MM70(V]%;&,C->4S6%SIG[-,EI>*R3KI)9E;@KN.X ^X! KU6'_41_P"Z/Y4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%% !14<]Q#:P//<31PPQC<\DC!54>I)X%9MIXHT&^*BTUFPF+D!0EPI+$D
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M4:EGD=@JJ!U))Z"@"2BJ]E?V>IVJW5A=P75N^0LL$@=&P<'!''6K% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC(P!XW*RX&5.!D9!X'- &C=?%NXTO0O%/VJV@EU31=0%C&R@K%-O9@CL,DC
M1B0#VXQGC8US7O&/AO0O$]]=PZ?+#I\<<VG7>PXG!QO5XP^1@\ Y'XUYW+XC
M^%5YX?US3K[6;V:YUJZ-Y<W:V3JRRY)78N#A5R< D]3SS5V+X@^";CP?=^'M
M:\9:GJ27%M]F69M/,9C4#@@!?F;IRQ.<?7(!UFF>/M9N_%_@S2Y8[+[-KFD"
M^N-L3!TD\IF(4[L;<@=0?K46@^+?&WB37->TZPCT5(]'U86SS3)(IDA#L"
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MBV; J+@XXQR2>@H 2^U;4++X'>'M2U&/3-72XO(R(;VU=L%FD)8MYGS-D'G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCW'9*JDGCRS^\XYVGVJ2Z^W:UXCUWPY;7\ML^GVL"VK&]ECD7>A/G?+S(=V
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M7"JZE<@$@_-Z5:T#6[?5=-L=]U;-J$EG%<3V\<@W)O4'.W.0,GO4^KSW$%O
M;:[LK9VN(U9KO.UE+ ,J\CYR.![T 7DW%%+@!\?,%.0#[&G55EU*P@NDM9KV
MVCN'("Q/*H=L\# )R<U9=U1&=V"JHR6)P * .=_L74)OB!%KLS6J65O826D:
M([-(Y=T;<<@ ?<QC)HF\!^&;B2Y>32HR+F83RQB1Q&T@(._8#M#9') R>_6M
M5-:TI[9KE-3LFMT;8THG4J&]"<XS[5/]LM?M+6WVF'ST3>T7F#<%]2.N.1S0
M!GW7AC1[R[>ZEL\321"&4QR/&)8QT5PI <#D88'@XI]WX=TN]G:::W8.T MF
M\N9XP\0)(1@I *_,>#ZFI1KFDD,1JEEA4$C'[0G"DX#'GIGC-/;5]-6WEN&U
M&T$$,ABED,R[4<=58YP#[&@#.U;P9X=URXMI]1TJ":6V3RXG&4*I_<^4C*_[
M)R*GN?#6DW<TDDUJ?WL*P2(DKHDD:YPC(I"LO)&",8)'>K@U*Q,4$HO;?R[C
M_4OYJXDXS\ISS^%9^I>*]$TO0)]:EU&VDLHLJ)(I58._9%(."Q/&* -D *
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M,2;A@)#U5?X&92I/3&[T->P5EZ_I$FM::+:&_ELI4ECFCFC4-\R,& 93PRY
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M1(IE0,,#RSU7(+ 8XYKTGPWI#:!X=L-)>X6X^QP) LHCV;E48!(R><#UK4H
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MA(6),UC/K[SK)=@8D1XI"Q4$#$9<CC !/3@BJNN"W_L+XFVUF(S&E[;S+%"
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M@E3U&>V?4<^A% $R.LB*Z,&5AD$'@BG4BJJ(J(H55&  . *6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ JAJNKVNCPP27)<M<3I;P1H,M)(W11V['J0.#5^N<\8#6#::?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!DZOX:TK6[B"YO(91=0 K
M%<6]Q)!*@/4!XV!QQTSBHKCPCHEWIJV%Q9M)$LHF$C3R&82 8#^;NW[L<9W9
MQQ6W10!G:9H=CI.YK83O(PVF6YN9)Y,>F^1F('MG%:-%% !1110 4444 5/[
M+L/[3_M+[%!]NV>7]I\L>9MYXW=<<G\ZMT44 %4[O2=.OKFWN;NQMYY[9@\$
MDL89HV'(*D]#5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJM>ZC8Z;$);^]
MM[6,G :>54!/U)H LT55FU*QM[,7DU[;1VIZ3/*H0_\  B<5/%+'/$LL4BR1
ML,JZ'((]C0 ^BBJMGJ5CJ)G%E>07/V>3RI?)D#;'P#M..AP1Q0!:HHHH **K
M7FH66G1"6^NX+:-CM#32! 3Z9/>HEUK2GMWN%U.S:%!N>03KM4<C).<#H?RH
M O457L[ZSU"'SK*Z@N8LXWPR!U_,5"^M:5'=M:/J=DMR@RT+3J'4>XSF@"]1
M4%I>VFH0>?974-S"21YD,@=<CJ,CBFVNHV-\TBVEY;W#1G;((I5<H?0X/% %
MFBH+N^M+"$37EU#;1$[=\T@09],FE>[MH[0W;W$2VP3?YQ<!-OKNZ8]Z )J*
MAMKNVO(!/:W$4\)R!)$X93CKR*99ZC8Z@'-E>6]R$.',,JOM/O@\4 6:*BDN
MK>*XAMY)XDGFW&*-G 9]O)VCJ<=\5+0 452O-9TO3I%COM2L[61AE5GG5"1[
M FELM6TW4F=;#4+2Z9 "X@F5RH/3.#Q0!<HHHH **** "BBB@ HHHH ***JV
M^I6-W>7-I;7D$UQ:[1<11R!FB+9P& Z$X/7TH M4455GU*QMKVVLI[R".[N2
M1! T@#R8!)VKU. #0!:HJK9ZE8Z@]PEG>07#6[^7,(I WEOC.TXZ'VJU0 44
M44 %%%% !102 "2< =2:HV.M:9J<\T%C?V]Q+" 9$BD#%0>A(]#V/0T 7J**
M* "BBB@ HHHH **CGGAMH7FGE2*)!EG=@ /J36=9>)=#U*>2"SU:SGFB1I)(
MTF!9%4X8L.HP>#F@#5HK,'B+16LK>]&JV9M;F7R8)1,NV5]VW:IS\QW#'%:=
M !1110 4455;4K%=233C>0"^=#(MOY@\PJ.K;>N.>M %JBBJJ:E8RZC)IT=Y
M ][$@DDMUD!=%/ )'4#ZT 6J*;)(D4;22.J(@+,S'  '<FJ*Z]I+V-M?+J5J
MUI<RB&"<2@I*Y;:%4]"201Q0!H4444 %%%1W%Q%:6TMS.XCAB0R2.>BJ!DG\
MJ )**IZ;JMEJ]@M]8S^;:ORLNTJ&&,Y&0,CWZ59\Z+R?.\Q/*V[]^X;=N,YS
MZ8H ?16=J6NZ;HYM_P"T+I8!<.(XF96*LQ( &0, DD8S5Z66.")Y99%CC0;F
M=S@*/4GM0 ^BH+*]M=1LX[NRN([BVE&4EB8,K#.,@CK4] !1110 4444 %%%
M% !1110 4444 %%!( ))P!WJK8ZC9:G"TUA=PW42N8V>%PZAAU&1W% %JBJ[
M7]HNHII[7,0O'B,RP%AO* @%L>F2!5B@ HHK(OO%6@:9.T-]K-C;2+G*RS*O
M3&1SW&1Q[T :]%%% !1154:E8G4_[-%Y ;X1F8VPD'F!,@;BO4#)'/O0!:HH
MHH **** "BBJ6H:SI>D^5_:6I6=GYIVQ_:9UCWGT&XC- %VBH9[NWM;8W-Q<
M10P* 3+(X51GIR>*6WN8+N!)[::.:%QE9(V#*WT(H EHJ*WNK>[B\VVGBFCW
M%=\;AAD'!&1W!!%0VVJ:?>SR06M];3S1\O'%,K,O..0#QSQ0!;HHHH ****
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M"P%M]F.!&'+@[M_7)],8[4 <3!]K\#7U[XJM1)-H-YJ-TFL6JC/V<K<.JW"
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M&"$Z>LP\E(%Q(9 H!)[%=N1]:GT.+5XK_5CJ-\;NT>XW6>^W$31KSE./O*.
M&/)Y/3% '.>.Y'B\:>!9(H&GD6]N,1J0"W[ANY('ZUK7.I7T5IKFK'1EM;RQ
MMCY'VAP?.0+OY*$C&<@#J,'UJ3Q!X:NM9UK1M2@U&*V;2I7EB1[8R!V9=IW?
M.O&">E.N]#U;48+R.\UB K/:26T:0V91$+\%R#(2S8X'( R?6@#"M_%?B22X
M\+A[?2S'X@M2T:CS 8)!")=Q.3N4C/R@ ]!N/6I+7QO>QZ?=Q:A!;G4X=9_L
MA&MXW,;L4$@?9DM]PD[<\D8R,Y%^+P?<1/X6;^TXS_8$9C0?9C^^!B\KGY^/
ME_7\JJ7'P^-W9ZM%+JSQSWFI#5+>X@AV/:SJJJ",L0PPH&#ZGUX *FK>,?$F
MD:#KU[+I<+_V>\)M;F2&2&.Y1R%(V,2P92<=<'@UJ7&NZ[I^IZ7I=_'IRW&J
MWDJ030AVCBB2+> P)!:0D$<$#O[4S4/!VJ:QX7O=*U3Q$;FZN_+5[K[&J*B(
MVX!8PV 2>I).?P&*/C^;_2-%M+S4AI\:L\[WDMAY]JTB@*J,ISM;YBRY88VG
MJ<8 '6GC?4?L-VU[:VPG76#H]NT".RR.I.Z3;R<;03M!)R",]ZCU;QCXDTC0
MM>O)=+@?[ T+6MS+#)!'<HY"L-C$L&4GUP>M-L] NO$OAZ;39]5B-O;2Q7.F
M:G86'V4Q3*6)*H20P''(X.]AU%:6H>#M3UCPO>Z5JGB(W-U=^6KW/V-45$1M
MP"QAL DCDDG]!@ :^OZ]%X@U/1;D:>DHTLZA:311NPCPQ0HX+#?S@Y&WZ5=^
M']S?WO@71KS4;E+B>XM(Y=X0J?F4'YLDY.<\C'TJ23PU-/XJ.MSWR$/IQT]X
M$@*Y4MN+!MQP<^QX_.K'A;0YO#GA^UTF6_-XEJ@BB<Q"/"*,*, G)QU.>?:@
M#'UKQ?+8>)9-%6>SLKAH4DLA?1L%O6).Y4DW!01@#!R<FL:>[U;3_&GCR\TA
M;+S;>SLIW^U!F#;8Y3M 4CDXZYX]#72>(?"DOB."_L;N^B;3;P+F&2UWO 0
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M,8AV>60BH #N.1A1VZT:GH$NH>)]'UE;Q(AIHF A,.[S/,4*V6W#& !CC\Z
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MR2)C-M(W]-QZ^GYUMV<6LIXIOI)[\S:4T*>7 UN(Q#( ,[6ZN#R3G@9 '0T
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M7R9&&>,]5'?%<=JFI:[#X;\;:JGB"^$VB:HXM% 0*55(FVN O*_,1CCJ3R:
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M*-N<J!MZ=*YSX9ZD=8TO2K"6XN;&33-+M@EF&V_:4:-2)\_Q+G*@#H0=W4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *S-:T#3]?@@BOXY#]GF6>&2*9HGCD&0&5E((X)'7O6G10!S3^ ?#KVU
M[;FUG$-[.ES.@NY0'D7;AOO<'*J3ZD G.*THM L(==;6E68W[P"V:1IW(,8)
M(7:3CJ2>G<UIT4 9NHZ%8:K>6-W=I*TUC+YMN4F= CX(SA2 >"1SGK5&7P5H
M<]AJEE)!.UMJDIFO$-U+^]<X!/WN. !@8Z"N@HH RH_#VGQZW%K 6<WT=O\
M95D:X<_NL@[2"<'D Y(SFJ(\"Z ND_V6MM.+(3BX6(7<N%<-O7;\W #<A1QG
MM71T4 <W?^ _#^IS:A+=6LS_ -HHJW2"ZD5)2H #%0V-P 'S8SQ5Z'PWIL&L
MQ:M''-]MBMOLJR-<2-^ZSG:06P>1DD\D]ZUJ* ./\;Z5>:M?^&A;6=S-#::D
M+FXD@E5#&@C=<@E@<Y8<#WK4NO".CWVEWNGW<,LT-\X>[9IW#S$  ;F!!P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBCI0 44U)$D&8W5ATRIS3J "BFO+''C>ZKGI
MN.,TZ@ HHZ4@((!!R#T(H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRGT^71_+:>-F60NL@S&5*G!+=,>O%9,DUW+\7-#:ZL&M&?2[IO\ 7^8&&Z+
M.. PYSC(YX)IFN>"-5URZ\6YEMK:/58K3[)*)"S));DL-Z[1P3CH3Q5ZWTSQ
M-?>+]$UO4;/3;9;.TGM[A(KMG)+E#N7Y!Q\G0G\: .EUG5[;0]+EU"[W&.,J
MH1!EG=B%55'J6( ^M<6+V2W^+ANM2MOL21>'9II&\[S$VB:,D]L$ '/'XFNB
M\:>'[CQ)X<>SLKA(+V*:*YMI) 2@DC<,H;'.#C'XUAW'AO7=?U]KW5K6QL[6
MXT6?2YTANFD=3(P)9?D /3I[]>U &A9>.K&_UJPTMX0HU.)WMI([A9#\J[BL
M@4YC;;R.HX(SFN7T6\L-/^&$1U+3YKZT.MRQ!4DQL;[:PC8DL#@-MZ9KJ?#%
MOXPM(+:PUK^S#!9)L%S;2,7NP%PN5*@)V).3R.!BL3_A#M?_ .$!_L/98?:_
M[5^V[OM#;-GVGS\9V9S_  ]/>@#JX?$0?Q7>:!+:-#-!:B[25Y!MFC+%<KWX
M(P<]..N:J2>,H(X+(&&**\N[<W4<%Q=+$!%D $L>YR,#'KG&#2>*/"\VNW^D
M7MM.MM-;N\-T?^>EK(N)8_J<+@]B,U#X@T?7H?$UGXA\.BSFE2V-G=65W(T:
MR1;MRE6 .U@<]NAH KP_$>WO+?1'L-'O[E]6\]8HP8U*21*Q9&RW7*]>F.<]
MJZ2:>6Z\,RSSVSVLTEHSO!(P+1DIRI(X)'3BL*\T77[SQ!X8U.;[#(=/DGDN
M@LK*!YD90+&-IW!<]3C..V<#I-4_Y!%[_P!<'_\ 030!P.A6>K6_P@\/#PG#
M%!J<MI!)G:BQ,QC^9I<\D>X^;.WMFK%S'XT?X=:<NEN!K9ME&"NU47RP")=Y
M+&3/0K_%C/&:UOAI=V]U\./#_P!GGBF\JQACD\MPVQP@RIQT(]*ZN@#S;QM:
MR7'P@,^J0V\EW$EL\3>20T69(_[Y+!L<$\5Z37$_%>[MK?X?WT4T\4<L[PK$
MCN TA$R$A1WX]*[:@#A?'6KP:EX.\46=IIS:C'9VLT5Q+E D4@C+<;C\S)E6
M..G8YXK1TO6_)L='TBSM_M6H-I<=RT9DV*D8"J"S8/).0  >AZ8K%E\*>([.
MU\6:18#3[C3=<:YN(IIYWCDMY)DPRE0A##/0Y&.?I5NR\-ZUI6MZ7K<,=I-.
MFEIIE]:K.0I"-N22-BHR<YR"!P?;D O6_CNPO+2R:",QW=U>26/V>ZD$7E3Q
M@ET=N1GCC&<Y&/:Q<^+(K2.TBN+=+:_NO-*V]U<+$%6-MK,S],9*XP#G<.V2
M,8>"Y%TRXM+W3K#4X-2O[B^U"WD<@(\F-OE,5SE0 ,_+GD\=*J0^$/$VB0Z)
M?Z5>6]YJ&GK<6\EM>S,5DM9) RQ^;@G<FU "1SC\* -?3_']CJMMI_V6'9>7
ML\UNL%Q*$"R1??&\9#=1MQG(.>.<=-I]U)>6$-Q+;26TCC+0R8W(?0XXKFM6
MT/4-=T^VMM=TO3=2@D\QKFV$A7R&^7RS"Y7)(PV3\I^;(]*U_"VF7FC>&K+3
M[^[:[N8$*M*SER1N)4;CRV 0N3UQF@#(O_&T\&JZOIMCX<U"^N=,2*641O&H
M='#'*DMSPO ZGTXJ(_$.WN5T<Z5I-[J!U>TEN;0(T:;O+ W(<M\I!.#GCT)Z
M55L9M0B^)WB_[!:PSL;2Q'[R;9M;;)MSP?EZYQS['L:5X*O]#U+PDMJ;>:ST
M>UN(;B1Y"CN\VTEE7:1C<I.">_M0!K2>+G-O?S6NDSW TQ%-]&)%#QN4#M&@
MY#NJD9&0.< D\5,OBRWO_LZ:)#_:,L]DM^H#^6HA;A<D@_,Q! &/X3G%9T&@
M:QHVJ>(O[-2UN;+69#<IYTI1K><H$?<-IW*< C'/;'>LZV\&ZUX2U#3+OPR;
M.]CBTR/3;NWO96AW[&++*K!6P<LV1CH: -^S\7)=ZCH]F=-N[=]5M);F(7"[
M&C\O;N1U/(/S#UJE)\0((],AO?[)O'\S5CI+)&R$K*)/+SU&02#C'XXIVJ:+
MKS:YX>UJW%E>75E'<0W,4DK0H1-M.4(5N%* 8(R1[UBIX.\1II,5J5TYY8_$
MAU?<)W4-'YQDQC8<,<],GZT ;TOC0P*MO<Z<MIJGE-.]G=WD4>U [*IWY();
M:< >AR1W?I_C6SURUTLZ3;R3W&HV[W*02MY7E1HVUC(><?,=HP#D]. 2*^M:
M3XBM?%D?B'P^ME<&:T6SO+*[E:,$*S,CJX4\@NP((Z5'=:%XBM_%&G>);1K*
M\NQ9/8WUM)(T*%&D\Q3&VT_=/'(Y ]: &_#!F;1=8W1/"1K=X/*D;<8\2?=)
MR<XZ?A1XTO;P>)?"^EI9BYLKNYE,T32*%GVPR$(P/8'#<\$@>E:/@S1]3T:U
MU1-26U#76IW%Y']GE9\+(Y;!RHY'^<4GB#2-3O\ Q/X<U"SCMFM],FEEF\V8
MHS;XFC 4!2.-V>2* ,W0]<@TN[N_#VE^'[]+33+H1W,DEPA2V21?-WC<Y^0!
MN%'0=AP#>'C:!;?2M0GLI8M)U65(;6[+ D%_]673JJOV.3U&0,TW3?#MZ-:\
M62:@D"V.M,GE^3,6=5$*Q$,"H )QG@GK6;:^$=7G\+Z1X7U/[*;/39X2;N.0
MYGAA8-& F/E8[5!YP.<$T 6;SX@FUM=;NET&^DAT6X,5X?,C!50JL7 W<\-G
M [#G'2M.S\5?:/$<&D3Z;<6HN[9[FSGD92)D0J&R <J?F4X/8]CQ6%=>$]<N
M-&\;62QV0?79G>V)N&P@:)8_G^3@_+GC/6M(Z'JS^*_#NIM%:K;Z?8S6TX$Y
M+;I-G*C;R!L[D=: .MKSFZUS4++X@:=K$LY_X1[4)I-%6/\ A213E)?JT@D3
M/H%/>NWUH:FVCW2:.(/[0>,K"T[E$1B,!B0#TZXQS7+^(/A_IVH>"I],TW2;
M"WU+R5%O/@*T<JX*N9 NXG(Y.,GGUH Z"^UY+#Q'I6CR6[LVI+,8I5884QKN
M(8=>A&,9K-7QQ:?V9=W4MK,DMOJG]DK"&!,LY95&#TVDL.3C@&JE_I/B6YN/
M"^L&WT^75-,,JW4'VEDCD$D>QF5]A(P0#@KTXK!U+1]1TOP]J6GZA_937>L^
M(!<60:X>,,2P?&[;F-@(V(89_/ (!TMQXW-K-KUO-H]QY^B6PNKDI*AC:,J6
M&PDAB2%;JH&5//3-Y?%$1U71+(VL@&L6KW,,FX?($56(8>N''3/>N<M;'4KY
M==T34M*M;.^UC3Y0]]%?FY+87RU#@HI4#?P ,<-WSF6PT#Q,^K^%+V\M]-A3
M2+6>VF2.Y=RVY(U#J=@Z[,[>WKSP ;&F>*Y-9L8[[3]/$]I<6TEQ;RK<#&5*
M@1R<?(QW=.<;3W&*?X'UJ]\0^$=/U6_@6*6ZB$ORL""#SP.P'3\*QM%\'W=I
MXB@U?[-;:7+);21ZI'93%H;R5@-KA, #!W'. ><<]:V/ VDZEH/A.QTC4UM?
M,LHQ"C6\C.'4=&.5&"?3G'KZ %'Q%OC^(O@TI/.JRR7:R1"5O+;$#$$IG&1Z
MXS78US6N:1J5]XN\.:E:QVYM=->=IO,E*NWF1E!M 4@XSGDBK<FHZFGB^'3U
MMK5],DM3(TJR'SHY >ZXQL(P!SDGZ&@#:HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "H;J[MK&UDNKRXBM[>,9>69PBJ/4D\"IJK7FGVFH"$7<*3)#()51QE=P!
M )'0XS^>#VH 33]2L-6M!=:=>V]Y;DD"6WE$BDCMD'%%IJ=A?O(EG>VUPT?W
MUAE5RO4<X/'0_D:\NU^W?0_"/Q \0Z,OV6UU!8DMEB&T' $<DR@=-Q=L$==H
M;N*WM;C72?&'@*"Q'EJXN+%ECXS#Y(;'T!12/I0!UL&NZ1=:E+IMOJME+?Q9
M\RVCN%:1,=<J#D5+/J=A:W4=K<7UM#<2X\N*2559LG P"<GGBN3UCPSI\VO>
M&K32K.&WN-,NA>23Q( T4 5@5+#D^8Q P>N&/8UC6?\ Q-/"_P 3+J]^:4WU
M[;[CU2.&$",#TQ]X>YS0!ZA4%[>VNG6DEW>W,5M;1#<\LKA54>Y-9WA*\N-1
M\&Z)>W9)N+BP@EE)ZEFC!)_,UQ5[=ZM=VGQ-BO+V&:VM+:2&.,0%2JFUW@ [
MCC[QSP<GGCI0!Z3!-'<V\<\+AXI%#HXZ,I&0:DK@M!UO6;*[\,:3<I8M::GI
M3/;^6KB2)XHXS\[$X8$-V48]^M5;/QSKR>$9/%&HV^F?8D,UN+>'S!(\XN/)
MC^8D@*>_!/&>^  >CT5RLVNZMIGBG3=$OVLY5U6&;[+<0P,OES1KN974N=RE
M<D$$=,>]9EEXVU.Z\,^$=6:&T#:Q?I:7$81L*&W_ #(=W'W.^>M '>U4CU2P
MEU*73H[R![V)!)) K@NBDX!([?C7&:QXWU2VTWQ'J-E;VNW1;Y+/[+,C&2<'
MR_F!##&?,^48.=OOQ'<C63\4[E;!["._/AR M).CO$&\^7HH()!/'48]^E '
MH55+[5=.TP)]OO[6T\PX3SYECW'T&3S5#PCKC^)/"6EZS)$L,EW LCQJ<A6Z
M''MD&L#XG@'3?#V1G_BH+'_T90!W"LKH'1@RL,@@Y!%59M3L+?4+;3YKR%+R
MYW&"!G&^0*"20O4@ 'FN=;Q'J0U?Q98@6G_$IM8;FV<Q-\V]9&(<;N?N 9&.
MM9$FHRZSK?PRU29$2:\@GN'5 =JL]IN(&><9- 'HE%<3;>*M6$'B"RO%LAK6
MGW206L21.$E67 A<@N3AB2#@_+M/7%=I&'$:B1E9\#<5& 3WP,G'YT 4O[<T
MG^UO[)_M.R_M'&?LGGKYN,9^YG/3GI5F>\MK5HEN+B*)IG$<0D<*78]%&>I]
MA7"^.$LM-U'P[//HL@TZ#58YYM1@V9BE8D+N&=VUG8;C^')-7/'T,1OO"$QC
M0RKK\"A]HW ;)>,^E ':445#=6T5Y:2VTX+13(4=0<94\$?E0!5T_7=(U:::
M'3=4LKR6$XE2WN%D*?4 \5GWNE^$;_70+ZRT6XU?C FBB:<\9'7GH,_2LUM!
MLY?B+IE]IEK#;+I5K-'=R0($#^8%$<1QUP 7QV^7^]7$_:YV_9\N=?9B-4>[
M?4/-_B$XN^#^  7Z<4 >L7>NZ/IU[#8WFJ6-M=38\J"6=$=^PVJ3DU:NKRVL
M;=KB[N(K>%?O22N%4?B:Y3QIH.FWWAC4[7^SH)]2U93%#O4%VG*X1MW4! -V
M>P4U5^)%BD/PKN8)R+B2V2W42R#+%A)&-WL30!W=%%(Q(1BJ[F X&<9H 6BN
M'TKQ?J<WB+1M-ODLF.HV\[RI;*Q^RRQ[24\W<4DQN(.,8(]\5-X2\7S>([T1
M-<6<<T<3_;=.:)HKFTE!7:I#-\R\L-P4 D#UQ0!V5%9VO7EYI^B7-U81027,
M8!47$@CC49 9F)(X49;J,XQ7(3>.-3BL/&#1+9W$NAVT=U!,8)(DF1HV?!4L
M3_ <$'!!% 'H%%<?IWB+61XITO3M2CL#;:I8274/V=7#PNFS*L22&!#]0!C'
M?K71ZQ<W=GHUY<V%O'<7<4+/%%)((U=@. 6/ 'O0!=JI-J=A;ZA;:?->0I>7
M6[R(&<;Y H))"]2  >:XY?'S6%WKBZB]O=VFG:9'J*7%K"\0D!+J5&YF# E1
MA@<<^U5]1?59/'7@*XU%[/;*UV_EP1LIB8VS$KN+'</?"].G/ !W-_J=AI<4
M<E_>0VR2.(T,KA=[DX"C/4GTIT>H6<NH3:?'<QM>0HLDD(;YD5L[21Z'!KS3
MQ/K-_P")? 5IK41M8]+N=5M3%"8V,OEBZ558ONQDD XV\ XSQST-[KVJ#6_%
M6GP"S@>PTR*ZMKCRB[$MYG#\@'&S@>_>@#JKO4+.P:W%W<QPFYF$$(=L>9(<
MD*/4G!JS7GEAKNKV'A'P+-<-9WAU.:T@DDDB8.@>'=N'S'+_ "GYO?I6A/XI
MU6[T[Q!J6CQV;0:-<2P>1.C%[DPJ#)A@P"<DJ.&Z9/7  .SHKAH/%FL:UKUI
M9:,MA%:WVBIJ<$UU&[LFYE #*K#/7H"/7/&"[3/%VJ:IX:T'4O*LK3[:94NY
M7RZQNA90L<>X,Y9E. "2!ZT =9>ZG8::8!>WD-NUQ*L,(D<*9'8X"J.YR>U6
MZ\PU+79O$G@CPQJ=S$D<[>(K:-U0$+NCNBF0#R,[<X/(SBO3CG!QC/;- "T
M8&!TKS*?QSXJ@\.7_B+[%I+V.EW\UO=P+YGFRQQR["R'.%('/(.>>G?9B\0>
M(;_Q9JNF62Z4EEI_V28RSK(6:&0,6'!^]A>#T&.ASP =I17 3>.=0B\'VWC(
M0VK:-),IDMMC><D#2>6'#[L%AD,5V]R,\9.D^O:YJ::O-X>M[*7^S;S[&+>X
M!#7#+M,F'W )]X@9#?=SWH ZVC&*Y"3Q+J:ZAXOM MIG1K:*XMF,;?-OC=RK
MC=S]S&1CK5 ^*_$=[/X;MM.ATM)=9TAKW?<+(5CD5(VQ@')7,F,=?>@#OJ*X
M6Y\5^()K>_DTBPAN[C3K@6SVRV\A%RZA?,VR;@(^6(&0WW<GKPZ?Q'XCN-9\
M26%C'IL']F6EO=0M<QNY;S%D8HX##GY ,@\>C9X .XHKA-/\8:S<3^$[RX@L
M5T[Q F!#&',L#F$R [R<,#M(QM&,]33X/%NMZDECJ.E:<+K3[B\,3P"W<.L&
M\KYHE+;21C<5V]\9XR0#N**\WO/&WB2VT?Q%JH@TKR-#U)K:2,I(6GB'EYP=
MP"MAR<\@],#&3KVMYJTOQ5U"R:]A-A#IL$R0& Y&]Y <'=][*CG'3 P.I .Q
MHKE_B->WVG?#[6KS3KD6]Q%;,PD*;B!T..1@\\'G'I0-:U%]>M_#D$]G]N6P
M^W3W+V[% I?8BK'OSDX.3N_AZ<\ '44A(52S$  9)/:L'PEX@FU^PO?M<"0W
MVGWLMC=+&24,B8^9<\[2&4\],XK.U"[U;_A:>EV$-["EBVF3SM"T!;)$D0.2
M&'.#P>@YX.: .FL-2L=5MS<:?=PW4 =H_,A<,NY3@C(]#5JO)M$UK5O#V@W5
M_;I9-IP\2W%O/$ZL9662[*;E8$!<%AP0<^U=)J7BK69FU8Z!8I=/IMS]G%N]
MN[&Y8*K.!(&"Q_>P,@],]Z .S5%0810H]ABJ-SKVD6=W]DNM5LH+CC,4LZJP
MSTX)[U=A<RP1R-&T;,H8HW5<CH?>O,-0N=2\$76N#6-(.L^$M4NI;F6[MEWR
MVPD^\LJ?Q(,8!'0#Z"@#T3^T]+FO(K/[;9O=2+YD<'FJ79<9R%SDC'.:EN=1
ML;.:*&ZO;>"68XB26559S[ GG\*X7Q-H-MXHM_#":3J+0R16TEQIE_&>5940
MHQ]5(ZCT-.TGQ.^OWNA6>I0+::]IVIM#?VG]UOLEQAU]48<@T =C<Z[I%E=_
M9+K5+*"XX_=2SJK<].">_:KT<B2QK)&RNC@,K*<@@]"*\PU&YU/P/>:X=6TC
M^VO"6J7,MS-=6R[Y;;>,,LJ?Q(,8R.@'T%>B:-):2Z)8/83">S:WC,$O]]-H
MVG\J +M4H-6LKG4[G3H96>YM<><HC;:A(# %L;<X8'&<\U=KFM$C\W5O&$>U
M&WZBB[9!E3FSM^H[B@#HU=69E5@2IPP!Z'&>?P-#NL:EG8*HZEC@5SGA3PW>
M^'Y-0^UZM/?+<3B5-^, >6BXYRW&W RQ^7'4Y-)XM\-WFO&TDL]0:R>VE24^
M6,-,%D5MC$Y&WY<\J><=L@@%V7^PM&UE)WMX;;4-1=8OM"VYS,W.U6<#&>#@
M$ULUROBY#&GAI#(\A76;<%WQEN'Y. !754 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !5:_TZRU2T:UU"S@N[=OO13QAU/X'BK-% %+3=(TW1H#!IFG
MVME$QR4MXEC!/J<#FKM%% !1110 48HHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K(\1Z3>ZUIGV*SU1M.W,#+(L(D+K_<P3C![^HXK7HH YNV\,7DUC?6.
MOZU)J]I=6YM_)-M' J*<AL!.IZ8/;''6GVGAF2.^L;V]O_M=QIUL]O9,T.W9
MN #.XS\SD*!D;1UP!FNAHH X^Q\)^(+2XWOXQGDBDG\ZX06$2M-R,J7ZC@;>
M.@P!C JU?>#TN6UB&"]:VL=9(-_ L>2QVA&*-GY"R@ \'ID8-=-10 R&&.W@
MC@A0)%&H1$4<* , "N6N_!DD]QXD:'57B@UZ+9-"8 WEMY0B+ Y!/RCIZ^O2
MNLHH Y=/"=PE_P"'KL:E'OT6VDMXU^S'$H=54D_/QPB]/?\ "*U\"6P\$77A
M74+MKJTG>1Q*D?ENA>0RY')Y#G(^@ZUUM% &#:>'ISJ=AJ.KWZ7USI\3Q6S)
M!Y0!< ,[#<V6(7'&!R>.>,*W^'<]O8:5IX\03?8]*U 7EG&+9 RJ"Y",Q)W'
MY\9P..QZCNZ* /)7D>Y\3:G=+KIT_4&O&\NRO="^TS*$^5"C  E2%W#:3C=U
MSDUV=AH6I/KB>([J[ABOY]+CLY;80$I&P)<D'?S\S-^&/K73T4 8_A70O^$9
M\-66C"Y^TI:)L24IL)7.>1D\\U3U'PM-JNNI=7NJR3:;%<P7<-@80/*EB!P0
MX.=I)#$$'D=0.*Z2B@#EM1\(3W6N:EJ%IJ[VD>IVBVMY"(%<ML#!65B?EX<@
M\'/L>:CM?!<EH?"VW52X\/Q-%'O@&9@8_*YP1C"]/?KFNMHH XJPBTOQ5XVM
M_$=C'<[-.MY+=Y987A664MA1M<#=L'F<]!Y@_#M:** .?;0+^^4V^LZLE]8B
MX6=8EM!$QVN'178,0R@A3PH)QR<9!D\0Z!+KLNE.EXMN-/O4O5!AW[W4, #\
MPXPQK<HH Q=0@U=_$FE36=^Z6*!Q>6I@4I(I4X;>>00V, >IS6G>Q7$]E-%:
MW MIW0JDVP/Y9]=IX./>IZ* .5T7POK6ESVPN/%4UU9Q,7>W^QQ1F4G/+./F
M/S')]>_6@^";<V\FF_:?^)))>_;6LO+YW[_,*;\_ZO>-VW&>V<<5U5% '*7_
M (9UZYUN?4K7Q6]IO7RXHA81R")/12V>IY)[X'H +6O>&IM=\)'0I=3<%UC$
MUT\09W*L&W8! !)7Z<\5T-% &'KUOK4L.G?V9J!@N([J-IPEN&2>/^)6W$[!
MC)R#GC Y-:]U;K=6DUNS.JRQLA9#A@",9![&I:* .*TSP'<V$_AZ637Y9?[$
MBDMX5%JB!XF55VGKSA1EN_8 \U?L?";QZOIFJ:C?)>7FG6[V\4Z6_E22A@ 3
M(VX[N!T&!DDUTU% &/XGT'_A)-#DT[[6]HYDCE29%#;71PZY4\,,J,BL.Y\!
MW-V?$#3:](S:Y9I:W.;9,+M5EW* 1CAC@9X[DUVE% '.)X8G&N:+J;Z@C-I=
MK):B,6^!('"Y).[@_(N/QJ]XDT2/Q)X=OM'DN)+=;J/9YL?)7D$'!ZCCD=QQ
M6K10!QLO@(ZA?WEUJ^KRWBWVF#3[J)8$C5E!8AEQDKC>3CGGOCBBU\%:BEYH
M,][XCDNO[%9_(Q:*C2(T9CPYR<G:>H ^F>:[*B@#@3\-YX]#?0;;7Y(M'6[2
MZMH#:JSP;91)LWD\KD''&1ZD<';'A8MKVK:E-?&1-2LDLY(A%M*JN[!#9Z_.
MV>/2NCHH XY/!%RNB^']-?6C(-%N8IXG:U'SB)"B(0&'&"<GDD^G2IV\&O#-
MK4=AJ1MK#6G:2[MS#O99'7:[Q-N&TL.N0W//M7544 <Y;^%18^(X-5LKF.&&
MWTP:;#:F$E5C#!@<[@200/P_.LJP^'\^FPZ$+7772;26N DGV92)$F.Y@5)(
M# ]&'X@UW%% '$Q?#^2#0;32DUIVCM-4&I1O);J3D2F4(<$?Q$Y/?MBNU)VI
MEV  &2>@I:* /,?"6CMXB\/:YITU_'_9EQK5V\T"Q?O&C,Y8 /NX5P!_"3@G
M!Z8['3_#SV/BC5=9-VDB:C'%&UOY. @C#!<-N]&.>/RK=HH X^U\!I;:/_PC
MYO\ S/#ZW G2S:']XJB3S!%YF[E-PZ;<XXS3CX+N;?7K^]TS7[FQL=2D$U[9
M)"K;Y, ,R.>8RP S@'VQQCKJ* .3U#P;-<ZOJMW9ZN]G#JMFMM=P"!7)V*RJ
MRL3\O#$$8.>Q!YHT_P &RV%_X>N1JIE&C6362*]N,RHP0$D@C!^1<<>N<UUE
M% '(R>"[N#7[Z_TGQ#=:?9ZC();VS2%'#O@ O&YYC) &2 ?7TQ97PM+%J^MW
M\5^B_P!J6T5MY9MR1$L88*0=W/#MG\*Z6B@#D8/!4L%GX7MEU-2N@$&(FVYE
MQ&8QN^;CY2>G?\J32O!-UHU]+%9^(+I-">=K@:9Y*'8S-N*K+]X(6YV_AGDY
MZ^B@#B[GP')=:%XATI]5 36[MKJ606W,1;:"%^;I\B]??\-5/#DJ>+!KZZBR
MO)9I:W,"PC;+L9F4@DDKRQR.?K6_10!F>(=%B\1>';_1YY7BCO(6B,B#)7/<
M5EMX4N5U6PUJ'5L:Q;VQM)IY+8-'<1$[MK(&7&&Y!#<<YS73T4 9FB:+#HEK
M/'&YDFN;B2ZN)2,&25SECCL.@ [ #KUJKJ/AU[SQ-I^N6]^]M-:P26[H(PXE
MC=E;'/0Y0<^F?K6[10!Q3> I6\.SZ.=67;-J7]HF7[+R'\X3;<;^FX?E^=3R
M>#+V'Q!>:CI7B*YTZ#4&5[ZUC@1UD< *7C+?ZMB ,GFNNHH ;&BQ1K&@PJ@*
M!G/ KG&\.ZJMI?V4&N(+2\EF<B:S$DD0E9F*HV\# W'&X-^7%=+10!@VWAH:
M?)HL=A<+#9:5 ;>.%XB[.I"CEMPYPH[>M.O?"NGWOBO3/$FTQZA8ATWJ/]:C
M(R[6^A;(/U]:W** .;;P]JJ6M_9V^N(+6\EFD(FLQ(\(D8L51MX&!N.-P;\N
M*MV&@OI(TFUTZ^>#2]/MC;FS,:MYW "L7/((P>G7-;-% !7.:&9(/$_B6&:V
MN4\^\CN(96A;RY$^S0H</C;D,K#&<\5T=% !1110!R_BT2W-]X?MK>UN9G35
M(;B1HX6*1QJ&!+/C:.HXSFNHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJT1<$#GD8(ZD9Q]*TD\27=K;:1ISHDFI75F;EG6.694C78-Q"@L22X]!UYZ
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M7-H5)"[U/7..N!C/&>M=70 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5@^*="N]<ATXV5[';365ZEV%FB,D4NT$;74$$]<CG@@5O5F>(
M=870-!NM4:!IQ  ?*5@I8E@H&3TZT >=^,="N_#W@CQ))<ZK;R_VGJUM>)^X
M\O9(98 V?F.0-F0/3.2>W6:CI#M+>^(=3N+<R0:9+;0+%D(BM\SN23R3M7Z
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MH_/J>@&2>!69X=\/7WA[3-!TNVO8?L%C:&*ZC,66FDP,,K9^4;MQQCO7244
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MY F;RAMG*>08L[<;<+TW9YSFMRWL(F^,MW*S7*M_8L$VW[3)@,9Y.,;L;?\
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M H.W;P.,=A0!Q'F:OXCAUYK/6!I]WI>HO D[W<@$"1$8+Q ;75E!)+9SN/H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M24KN6.1=HVD@'&"PR"/>MC6-0FTW3S/;V,U[,9$C2&(=V8+EC@X49R3@X -
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M&0QRJNW> $P-PQD>V?:LRP^'MY_PA#:->W%O#J-O>27UA?6K,3!,SLZG!4<
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MH=_H=UK"3S6TEG=ZA->PE WF#S6W$-G@8Y'&<^U;EM:V]E L%K;Q00K]V.)
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MG ]\];10!2TD:F-.C_M@VAOLMYAM PCQN.W&[G[N,^^:NT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ,E5WA=8W\MRI"OC.T]CCO6/_9NN_P#0PC_P"3_&MNB@".W26.WC
M2:7SI57#2;=NX^N!TJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>RBNH4WK#+N4X?Y6QN50,^J_6NH\(6.GZ=X<A@TF.X2P+N\ N,ABK,3D @$
MDD@8'!% $=Y?7S>.[#2H;KR;0V$MW*JQJ3(R21J%R0<##GIS3+?Q=!<>+YO#
MZV\OF0(QDD1#(F<KM&Y<@<$[@V"#CUR63?\ )4['_L"W'_H^&NA%I;K.DRPH
MLB!PK 8P&(+?F0"?I0!@67C"WO?%MUH*6\PDM4_>R+&9$+%L##+D 8SG=C!X
M[59TV[O#XKUC3I[DS6\$%M/"&104\PRAAD 9'R#&>:UEM+=9TG6%%E1&16 Q
MA6()'XD UB:?_P C]KO_ %XV7_H5Q0!N7-U;V<)FNIXH(@<%Y7"J/Q-06^K:
M;=O<I;:A:3-:G%P(YE8Q'T;!^7H>M<M\64B;X<:D\J!@DENP.,D?OX^1[XST
MK.EL-)D\?0ZEHRV:Z=#H\\6HRP!?)8%E\I&(^4MPQQU  ]J .LO]=LIM,O/[
M,US2H[I(/-66697CC!^Z[@,/E]\U?N-1L]/M8YM0OK6!&'^MDD$:,<9XR?QK
MR>"PTQ?V=9)EM+87C:086?RU\PR<_*3USGM6Y=Z]9Z)XWLK[67VZ->Z*EO:7
M>PO$LN\ET) ."R[/KM [4 =[<:G86EHMW<WUM#;. 5FDE54((R,,3CIS22:K
MIT-K%=2W]JEO+_JYFF4(_&>#G!XYKSF_O+#POK'A^X=+W2?#)T^:VMY4C+"W
MD,BL-X96*AU QD9&,''-++86&FV.B'PYK+Z--']KEL'U),P7",R&1'#8*AB0
MRXP< D"@#TV&:*YA2:"5)8I%#(Z,&5@>A!'45F:_K,&D:9<.;ZRMKL0N\"W3
MC#L!_=W GG X/>HO"%U+>^$=,N)K!;"1H!FV7.U,<#;GG:0,CV(KC;C5+>P\
M2^-['7F$4U] IL/-4E;BW$)&R/\ O$.7RHYRQ.* .NT+Q#%<>"]'UK5[JUM6
MN[.*:1W<1IO9 Q R?KWK4;5-/2*&5K^U6.<%H7,R@2 #)*G// )X[5Y/IFKQ
MZ+9>"K_5+B\L]'.@K:?:HXLK!<?(2'RIP&"XSCJOUJSJ&G^']-_X0<0PLND_
MVK.R->KU1HI6SA@-J%CD @#'- 'I]KJFGWUD;VTO[6XM!G,\4RN@QU^8''%1
MQZWI,MG->1ZI9/:PG$LRW"%(SZ,V<#\:\KU*REL9O%&KZ+!*V@G4]/N'CLD!
M$@CYN'C7&&P2A.!@E&]#4WB%O#NK>"_%VM:1<W-_)>6 CEN95*H\B@B-5&U<
MN,GH,C(% 'J5OJFGWEU-:VU];3W$&/-BBF5GCSTW '(_&N>\3^*_[,U#1K33
MK[3Y)KG5(;.ZMV8/*J,>2 &^4C@<@]:P9_(A\=Z5_8QMHYY/#MS'$8]H4N6C
M,8./<$C\:P8M8TV?P=X&LCE=4T[6+1;ZW>-C-#*-PE9QC(W-DY/7- 'JD5\4
MU;4OM&IV!M((XV$*D"2WSNW&0[NAQQP.AJ>WUC3+RZ^RVVHVD]QY8F\J*=6?
M8<$-@'.TY'/3FO/+]K(>(?B0K>2%DTF#@@8=Q'+GZD$K[Y(J+2Q8VVH_#!H!
M!&_V&592F <FW48;W+COW'K0!Z1+J^F0W)MI=1M(YP<&)YU# XSTSGIS5P$,
M 000>017BQOM"D27P]J>MV-O%;^(WO3->;TF(68L5*LNW).5W;L;3G':O:,?
MNL1;1\OR^@]* *W]JZ=]O%C]OM?MAX^S^<OF=,_=SGI4=UKFD6)F%WJEE;F$
MJ)?-N$386SMW9/&<'&>N#7E48EO_ (4P:!G9XOMKY/W+']^ER+C<9L==I4LV
M_IM)YK6N(=,?QA\06GCM23I=NH+JO)V3!\>_*Y^HH ]-!#*&4@@C(([U@3>*
MM/FU+5-&L+ZU.J64 D*.0PWD.=NT$$D!,D \ BCP))YO@#P\=^YAIMNK\Y(8
M1J"#[@@@U@+=P6'Q$\7)=.83=:=:O"64X=464,<], D ^Y'K0!M>#_%$.NZ!
MI$EW>68U:[LDN9+6.0!\$9)"9SMK:?5=.COTL)+^U6\?[MNTRB1N,\+G)XKR
M?1!96NB_"Z2,017"38F90 RYMW5MW<?-M!SWQ4^FS:9?>=X;\0S:D-<M]5DN
M4LTCP9G\YGCF1PF=N".2W !S@4 >N5RVA:O?3:=K6IWMP)8[6^NX8X3LB5(X
MI64?,>^%ZL<?3K74URW@E%DTO5E=0RG6K_@C(_X^'H =H_C.VU?PW=ZVEO-'
M!;M*2LT9B^1'9?O/A2V%SC. 3@D=:L>'M?7Q9H37=L+JS+R2*C- 490LC*/O
MK@G"\CG!)%;*6EO&) L* 22>:XQP7XY^N0#]>:6"WAME=88U0.[2,%Z%B<D_
MB>: ,SPI?W.J>%-+OKQU>YGMU>1E7:"Q')QVK8KD?"FK6>E^"/#"7<C(UXD5
MM!B-FW2%20#@'' /)XKKJ .3O?$&J:?\0]-T2Y%FNEZE!(]O/Y3>894P3$3N
MQ]WY@<<],5J2WVH/XKBT^V:V-DEMY]UOC8R*2VV, [L?-ASTXV>_&7\1-'N=
M4\+/<Z>/^)KI<JZA8D#GS(^=OON7<N/>K?AF2:XT277;FVD2YU/_ $LP=71-
MH$<?UV!<C^\S4 :L&K:;=7;6EOJ%K-<H"6ACF5G7!P<@'/!XI1JFGF_^P"_M
M3><_Z/YR^9P,GY<YZ5Y+HFIVMQK'@*>TS;P(+N 6<<+LMFS1<1,[ LSY'.3V
MS@=:U?!>HZ3?:/H^A:K:2OXFTNZ+RV[QN'CGW-NG+="I#%LDX.<<G% 'HO\
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MF8/(1_$0 H)_  ?@* ,;P?J-WJF@&>^E$LZ7=U 7"!=PCG>-3@<9PHK>KF/
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M25?G(,6#RVQ>I.>.OKQ78>'-=A\1Z.E_%!+;GS)(98)<;HY$8HRG!(/(/(H
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M%A T@RJ/*VW<1W &3CO@"MZLOQ#H%EXETB33K[S%C9ED22%MLD3J<JZGLP-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI ZER@8%@ 2,\C-<KK2:])J;B>XN(=#P,'28]UP?7S"<L!Z>4-WN*U/#UOH<
M-I(VA^04=_WTB,7D9Q_ST8Y8M_O<T :]%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!E7)\0?:7^RIIA@S\AE>0-CWP,5-IT=^&FDU"*R25]H
M#6VXE@,_>) Z9XJ_10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPN/PE_SVN_\ P'-'_"X_"7_/:[_\!S1S+N'L:G8[^BN _P"%Q^$O^>UW_P"
MYH_X7'X2_P">UW_X#FCF7</8U.QW]%<!_P +C\)?\]KO_P !S1_PN/PE_P ]
MKO\ \!S1S+N'L:G8[^BN _X7'X2_Y[7?_@.:/^%Q^$O^>UW_ . YHYEW#V-3
ML=_17 ?\+C\)?\]KO_P'-'_"X_"7_/:[_P# <T<R[A[&IV._HK@/^%Q^$O\
MGM=_^ YH_P"%Q^$O^>UW_P" YHYEW#V-3L=_17 ?\+C\)?\ /:[_ / <T?\
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MDN9XH49U0-(X4%F. ,GN20 *.1!]8G_5SR+_ (50O_0OC_P=G_XQ1_PJA?\
MH7Q_X.S_ /&*]BHHY$'UB?\ 5SQW_A5"_P#0OC_P=G_XQ1_PJA?^A?'_ (.S
M_P#&*]BJ*ZF:WM99DA>=D4L(D(#/CL,D#/U-'(@^L3_JYY%_PJA?^A?'_@[/
M_P 8H_X50O\ T+X_\'9_^,5Z;X:UZW\3^';+6K6*6*"[0NB2XW 9(YP2.U:M
M'(@^L3_JYX[_ ,*H7_H7Q_X.S_\ &*/^%4+_ -"^/_!V?_C%>Q44<B#ZQ/\
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MU^8@-QN (SWHY$'UB?\ 5SB_^%4+_P!"^/\ P=G_ .,4?\*H7_H7Q_X.S_\
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>modificationno15effectiv008.jpg
<TEXT>
begin 644 modificationno15effectiv008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNXG.<X].,5:3['K)\;Z[X=U#3+G6;W3@EM#8S++/%LC9=V1R&8D#CCY5YST
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M4GL8[617-RLQ(D;"97R^<<').<\5YKXA.@/X#\;ZMH^JS7RZA:IY]PS((7E
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M<# Y R?;)KH-3\8P:6+PRZ9?N;&S%[>*@C_<QG=W+X9L(QPI/ ^F0#HP !@
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MI:EI/C6*4-,ES=2(MR0^3Y8SL:-@"  .!T]:]9H :Z)(NUU5E]&&12A5 (
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M<CAHVQR%8<9'3BNDHH \YUS4V\<W$_@66SN=(FD"27K7>T&2!6!86Y4D29(
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MZ(C0QM@MM7: &.%R2.PX'2JZ^"--/@R#PO-/=36=NJ+!,[J)HBA!1E95 RI
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MY>UT;;NW83.?E7H1TJ?Q!H$'B&TMX9;BXMGMKF.Z@FMRN])$.0?F!!ZG@@T
M84>KZOK4OB*/3+U;>31I!;0AX587$PC#L9,]%)8* N#P3GL-SPMK@\2>%M-U
MD0^2;R!96CSG:3U ]1G-4V\(0)J-[>6>HWMF^H1+'>+$4(F*KM#_ #*=KXX)
M'7TSS6W96-OIVGP6%G&(;:WC6*)%_@4# '- 'G7A>?6H;_QV=)TZRO'_ +:E
M*K<7;19;RTXP$8$=.X_#K5KX;:EI^D_"E94DN)1IQG6YB>/:Z3!RS1*H)[L
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M -EPS1LJML8@@,!G!]:\JT35[OP]X:U>[-R+B>X\23V4 FC&Q99+G9YC8P<
M$G&>V.*]3BB>.W6)IY)'"X,KA=Q/J< #/X8KF8_ 6F_V#J.CW-U>W5M?7+W;
MM*R!XY6??O0JHP0W(ZT 12ZMJVE^,8M!ENEN8M0L9;BTN981NBEC(W*P7:&4
MA@1T/;)H\ 7^O:YH.GZYJNH6TD-Y9JPM8K;84?)^;?GG([8X_GJ6_AT)=F]N
M=0N;J_%L;6.YD6,-$A(+;0%"Y)"DD@]!T'%3>'-"A\-:#:Z/;7%Q/;VJ[(FN
M"I<+V!*J ?RH SCJ=[K'B35])L;O[$FEQP[Y%C5VDED4L!AL@(% ]R2>1CG!
MTCQ=K%[I?@6]FEBW:U,\=VBQ@+@1R."O<<H!U/%;^H^%+=M?E\06^HZC8SR0
MK'>1V9!6Z1<[=RE2<C) *X;'0US_ (2\,-JOPW\,6]T^H:5J.EL)8W$7ERQ2
M#<I!612""K$<C'- %Q?$6KFV\5(+RS1]-U&.V@GN1M5(V6)B3@?,P#MM&.3@
M51N]<O=0T#XA:9=/++#8:>QMY9X1%*R26S-AE '0@XX!P>16O+\/+&:VU*-M
M3U/??7<5\9O,3=%/'MVNOR]?D'!R/0#BICX%MG;6VDU;4W?6K9;>[9GCR0%*
M;@-F 2I(Z8'8"@"A:ZOJ%E=^ M.@EB%EJ%HRSH8\N2EMO7#9X&<<8[=:S=';
MQ,^@>,+G3=5:XU.WU6Z6W2>%&60Q[0%X ZJ HQTX]ZZD>$;?[3H%Q_:-\7T1
M&2W'[O$@9-AW_)S\O'&*B^Q6_@Q=3U2!-7OHKV[,[V5M$)MDDA 9E4 -C@$Y
M)QSC'- "Z+KY\17.F3Z;=,U@U@+FYW(N2SG"*>.#E9=P'3:/6K/B*^NK2;38
MX+N.VAGF9)F5=]PP",56%-K!CD#.0<*"?<,\(:'%HNF7#):?9)+^ZEO9(<Y\
MLNQ(7T&%QD#C.<5-K?AN+6=0TR_%]=V5YISN89;8IDAQM=2'5@00!VR,<4 <
ME;^,]6_X1&TU.\AN3%'J-Q::A<V=N'EBBC:15D\OYAU5-V <<X'I:O?%TUIH
M.D:I]NDN]'N'F-UJVG6XD\I03Y99,':,<,=IP5QQFM;3?!<6CH%T_5]2BVW4
MURH=T<?O"2R$%>5R<\_-G'/%36GA.'38[9=.O[JV:%IW?:$*S-,X=RZE<?>&
M1MQCITXH R[7Q!?/K_A:U34K>]M-5LKF66:%!M=HPFUD/;.\Y!STK*G\6^($
M\,SW<-Q;&YA\1G3-TD'WXOM C'0@ X/)Q],5T!\"6,-OHR:?>WEA+I)E\B:#
MRRS"7F0,&4K\QYX P>F*B/P]L?[+FT]=4U-89=2_M,D/&S++OW@ LA.-P!YR
M3CK0!#J%WX@TR1;.YUN"60VT\\;6MH!.[AAL!C.Y1&H."Q(R2.1WHV_BK7M3
M7P,UO/:6W]NVLCW(,!?:ZP[\K\W3/;]3TKH]0\)P:AKL>K_VA?6]Q]D-E.L#
M(%GBW%L-E20<D\KM//6JFG^ [33AX?\ *U347_L-76V#M&0P9=A#?)_=X&,>
MO7F@#(L?%^J)9?V?=SPRZ@WB%]%2[\K:"H7S/,* XW;00!TSBM'4M5UWP]&\
M5W-#>"\U&&TTZ5542A7'S>8ORIN&UMN, \9I\_P\TVYT[4+.:^U!S>:A_:2S
MAT62WN.,/&548Q@=<U/<>"+/4-!GTS5-0U"^EF9'-])*%G1T.49"H 7:<D8'
M<YSDT 3^'Y?$']I:C!JT+&Q4HUE<2F(3,"/G5UC)7@XP0!D&H;G5[J_\9S>'
M+2Y-F+:P6[EG5%9V9W*JH# C VDGCG(P1S6AH>AMH\3F?4[[4KEP%:XO'4MM
M'10%  ')[9/<GBH]0\-PW>NP:W;W4]EJ,4)MS+#M(EB)SL=6!! /(/!!_*@#
M@=>UK4?$'P^D-U*MO>6&NQ:?=>2@V3/'=1@. <D#H<9Z\5ZC'#(EKY;3EIBN
M#-L )/K@<5@WO@FPO- 31UN[RWA%T+R26(IYDTWF>9O8LI&2_/ 'ITXKHT4J
MBJSER!@LV,G\N* /'(GU"X^&NAW-S?M=7$OB6$JTRCAA?.,G&,Y/Y=L5TLWB
MW5- D\70ZE-#?G2H+:XMI!$(L^=N 5@#T#*.<YP>M:(^'MDFFQ:<FJZFEK#?
MB_@C#1'RG$AE"C*'*[R3SD]LXJY-X,T^[O\ 6KF\GN;E-8MDMKJWD*"/8@8+
MMPH8$;CSF@!FER^)4\1^5>0O)I$EON,MP(4DBG!Z*(V.4(SUY&.IK.^(D5P]
MQX5\F\>%6URW3:$4\[9"&Y],=.E:_A[PJ-!V^9K&IZGY2>7;B^E5O)3T&U1D
M\ 9.3CCCG,^N^'8M?DTYYKVZM_L%TEW$(-F&D4$#=N4Y&">!B@#,&IZM'X\N
MM#%S;F :.MW&QM^?-,A0EL-\WW<X&.M8&B^*?$<VF^#-8O;RVE@UJ<6L]JEO
MMVEDD8.&SG(*=,8P?QKL'\-1OXDEUT:A>+=267V+:/+V!-Q;(!3.[))ZX]JS
M[?P%9VVE:%IT>IZCY&BSBXMB3%N+ , &.SD89AQCK0!E7?BC5K/5[#-U#.EQ
MKG]GRPP1[H(XFW!?WF ?-&T%@"0#D$"K_AW_ )*3XT^EC_Z*:D'PYLEAB@35
M]52W@U'^T;:%9(]L$A8L0OR9()9OO$XSQBMK3_#T.G:_JFL1W=U)-J7EB6*0
MIL7RQM7;A0>A[DT 5+_5[BX\9V_AJTG-J?L+7\\ZJK/MWA%5=P(&3DDD'@ =
M\CAM+U36=#\*W$EE<VQNI?%LMK.\D)(<27.TD#/R]?>N^UCPM#JFL66L07UW
MI^I6B-$MQ:["7B8Y*,KJRL,\CC@\UFCX>V8TU['^UM3V-J?]J%MT1;SM^\=8
M^F[!Q0 V*^UW3?&&C:+?ZI%>QWUO=RR.EJ(L>6R;,#)[/@]<XK-A\8:JNA13
M3R1Y?Q#)I4UYY8 @A61E#D=,G:JY/&6'':NHUCPTFK:AINHIJ%W97MAYBQSV
M^PED< .K!E8<[1VXQQ7*:[X:&A:7;6-I+K\EC<:I)?7%S9J)Y;=CN8#8%)=2
MS#J&QC/7!H WO"VIZMJ&LZ];W=Q#<:?8W(@M9UAVM+E%8Y8':2I8J<*.1]15
M?6-1U^3QW!H&G7]K:6]QIDMSYKVWF/&RR(N?O -][IP.>]2^$(=1CEE+:EJ=
MYIAC C_M.S6WD5\_PJ$1MN.NY?3'>J>JVMW<?%C3IH#?6\4>DS1-<QVQ:+>T
MB$(S%2O(!/4=!]" 8\/C#Q-+ING0/+91Z@GB)M$O)?()27"LPD4;N. .._J*
MW[74=7E\1)X6GU13=6VG_;+F^AME1I2TA5 J-N4  '=USQC%6IO ]C+:Z?"E
M[>PFSOSJ7F(8RTUP2Q+N2ASG<W P.PZ"KNH>&X;S7+;6K>ZGLM2@A:W,T.T^
M;$3G8ZL"" >1T(- '*Z5XWU'4[NPT"7RH-5?4;RQN;F-/EVVP!9XU.>6W)C.
M0,MUQBLB;4=4\.6OQ&U*WO%DOK.^MW65XEPX\F( ,O3[IYQCD9XZ5V5WX#TV
M>ULA;W-W:7UE=27<-_"R^=YLA)D9LJ58-GD8QC   %-/@*QEM=?M[O4+^Z77
M OVHR,@(94"AEVJ,'Y0?3VH AUGQ/=:)XMO896\W3K?09M3:(* V^-P,!O0C
M/7O5K33XBNQI=]_:-J]E>VADND,8!A=E#1F' ^8 D@[R>Q]J(/!4 U9=2OM4
MO]0N/L+V$OV@Q[)HF.2&54 '0=,>^:=X=\&0^'3$D>K:G=VEL"+.UNI59+8$
M8PN%!. 2!N)P.E %+X827EQX(M;J]OI+J2:6=B9% (/GR9.0.<GG^50ZEJM[
MKR^+;2RNQ:0:3$;<#RU8S2F+>Q;/\.&"@#!X)STKH/#OAV#PU8O96MU=36QD
M=XHYV4B$,Q8JN .,L>N3[\"J%YX*MY]8U#4;34KZP;4HA%?0VY0I/A=H8AE)
M5L<94CC\Z .?\.:S>'0?"N@V G60^'H+R26!8BX&U$4 2$+C.<]3TZ9S1J\V
MLS6/@=O$%O%!J:^(8UE6)@5;$4^UN"<9&#C/!K7F^'ED;'1HK75=3L[S2(?L
M]K?02()?*P!L?Y=K+P.H[?6KUWX0MKN#28VU"_4Z;=B\23>C/--AAND+*<_>
M;@8'/&,# !0M=3U[4=5\8:7!=VZ7&GM"M@XAPH+Q;P'!)SR0"<_3%)H'B6XU
MS2=%NUG9)!;//J:>6N59/D:/&/E/F!L>R-WP:V]-\/PZ9KFJZK'=W,LNIM&T
MT<FS8I1=J[<*".!CDFG:3X>T_1KK5+BTC(?4K@W$P8Y&X@ @>@SN;'JS4 <U
MI.M>*=7BT+6+.V+6&H!9+J*7R1'#$ZY5HR'WDJ<9!^]SPO2L^S\4^(H?#&I>
M);^^LY;>PFN[?[(EKM\UDE,<;%]WR@'J.>._IOZ-X#M="N-MIJNIG34D,L&F
MR2J8(&)S\HV[B >0"2 ><9JS8>#=/L_#^H:)/-<WUC?R323)<E,YE)9\%%7'
M))'I0!CW^O\ B+PV-0U34+62YT:WT]YRTWDI(LZ]$41L<HWODCU-5;^/43XU
M\ W-]?K<&9KEWC6)55'-LQ^0CG;SCYB3P.:VM.\"VMKIT^GZAJFI:O:R0-;)
M%?RAA%$PP0-H&3CC<<D=L<YCL_ :6MQHTLFO:K<_V.S&S64Q?*K)LVL0@+#:
M<9//N* &_$V6[A\'/):7DELQN[:-R@!WJ\R(5.>V&[?3IFIAJ=]?^*KKPY;W
M[6YL+*.>:Z$2%Y))"P4 $;0H"Y/&3D<C'.OXAT.W\1Z+-IEU+-%'(R.)(2 Z
M,CAU(R"."HZBJ<WA6)M6M]7M]1O(-2CM_LTMRNQC<1YW8=2NW(.2" ,9QTXH
M 9X+UZY\0:$\U]%''?6MU-9W/E A&DB<J67/8XSCMTKHJI:3I5KHNGI96@;R
MU9G9G.6=V8LS,>Y+$D_6KM !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %5-1U*TTJW2>\F6)'E2%,G
MEG=@JJ/4DD5;KB/BC!:R>'M.ENXH6CBU>R+/*H(13,H;)/08X- &PFOSGQU/
MH$MO"EO'IRWJSB0EFS(4P1@ 8P>YK>9E52S, H[D\5YY+IFC:Q\4GM)K:UNM
M/_X1R,I#@&(KY[X^7H0!T].U<QH&K1+H_@B'7+^*#29]-GCCFNE5X3<+(H57
M+?*#Y8(!/N!UH ]KKEX?$VH:E+JS:-IUM=0Z9<O:NDET8Y99$ +!1M('7 R>
M?8<U/X*L;+3?#J6NFZA+?6*2R>1,Y!7:6SM0C@H#D#Z>E<GK6BV%_/J_BKPM
MKAT37+&26.](<&&9HB1B>,\<@9#>ASS0!M:YX]/AV#1+[4=.VZ7J(437*2DM
M:EE!RR;>5!."<_A6[J6JSVL^EI:6\%S%?S^2)&G*A1Y;R;AA3N&$/IU%8%O=
MGQ#9>$9M7LXXY=0MY&GM''!W0'<-I[<]#ZUAV%IJ?A/Q?H7A:59;G0WO9)]*
MNV.3 HMYMUNY]MV5/IGTX .KB\27^I7VK0Z/86MPFES_ &:4371CDDD"AB%
M4@#Y@ 2>2#T S6WI5X^HZ197SPF![F!)FB)R4+*#M_#.*X+6M!T[6=1U3Q!X
M<ULZ%XBL':*[E20>7)LZ"=#P5(P<^GKBNN\(:K>:YX0TK4[^W%O=W-NLDD8!
M !/< ] >H^M &SN4L5W#<.2,\T%E!P6&<XZ]Z\9M=4TIM1\):G8W-M!%+K-R
M&,TH:[966;<9GR, L  A!P O/%0:MIFG+X+^(5^L$7VJQUN1[6;^*W8" @H?
MX3GN,9Z=J /:IY'CA9HQ&9,?(LC[0S=@3@X_(UD>$-<D\2^%-.UF6!8)+N/>
M8E;(7DC&>_2N:-WI]Y\2-?T_Q$;8PI86YTY+HC8T+!O.9<\9W8!/7"CTJ[\)
MY8I?AAH8BD5]D)1MK9P0QX/O0!T]G)?-+>?;8[>.))L6YBD+%H]HY?(&&SG@
M9XQ5L,"2 02.O/2O%];M[5?!GQ%0*BK%KT;)@XV$BW&1Z=2/SKJK;2=-M/BM
M>Z=;VD"6M[H(EN8 ORSL)RN]Q_$V"1D\F@#O\TFY0P7<-QY SS7F_@^QVS?\
M(?=6H:+P[>/-YCQY$L;?-;'/<X<DD<YBYZUCR8U'X:>(+RZ7;XJL[^?]Z!^_
MBN1+^X5#U *E%4#@@X[T >K;[_\ M@1^5;_V=Y&[S/,/F^;NZ;<8V[>^<Y[5
M:#*6*A@2.HSTKS75#?6_CW4)K-%&LGPC)(JQ\[IQ)Q@=^0!^52>&I_#.IV&A
MZGHMQ')KL=A(HCAE'F,YC^?[0O4X<#EOXB/6@#T8,I8J&&X=1GD4I( ))P!W
MKR?P?_8>LQ^&M1&N!=>MCMGMHD1;EY2N)DF'WRN06)/H#76^/+NQM['2HK\%
MA<:G#'$'E\N$R?,P\TX.4^4G'<@#WH ZH,I7<&!7KG/% 8'."#C@X[5X=?36
M;> O&L'VNU<6WB"*2/[.=B1HSV^60;CM4EG[XY-;/B'0++2_$FJIHL"Q6ESX
M<NI=1BC8["X_U,C?[9._GJ=I]Z /6 RDX# G&<9[4;ESC(SZ9KR2PT2QMA\.
MM5T5 NIW2QI=R1N29[;[.3(7YY"D(!GH2 ,<5'IVDQP^#O%^L:/:*^N6.H:I
M'931DEX1N(VIZ?+R!ZT >OAE8D!@2.H!Z4;ER!N&3VS7FLMM82W?@6]\.)%F
M\8QW'DX_?6AA)D\S'WL,%Y/1CZFN7T_1+)_AAH.L::@'B.+4UCM)T<F0M]J9
M6CZ_=V%B5Z8!)[T >Y%E!P2 ?3-5+&6^:.X.HQVT3+.XC\F0L#$#\I;(&&QU
M'2N'TC0=(U'XF>+6NK2*9[6>QN(0Q/[N3RB=X'8Y[UAZ?<:9::6UG<!=DGC"
M[CMU>4);AE9ROF\'*@#(7NP7IU !ZIJ.J6>E6#7MY.L<"E1N)^\6("@>I)(
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M0^7CS"B8PP7G.67.UL=L@&4_P6^'4:EGT!54=2;V< ?^1*4?!3X>$9'AX?\
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M&K;/F8A<\A1R.>: ,'_A2GP\_P"A>'_@9/\ _%T@^"OP[.<>'U.#@XO)^/\
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M;>/(7$APQ#;C@  ]#TQ0!A?\*4^'G_0O#_P,G_\ BZ/^%*?#S_H7A_X&3_\
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M!5+,0 .I-<G;_8M#UM+73]'M8=<U6(RS0PW!6$1P_*'8[>/OJ.$R2?09'/\
MC36[?Q%\.]9$EJ8+[3;^"WN('(8Q2">/E6[J5;(/&0>@Y% 'IFX;@N1DC(%+
M7#W+6UE\83>2[(D7PY+)-)C'"SIR?H!5T>-?+AT:^N].:#2]8D2*VN/.W.C2
M#,7F)@;0WL6P2 <4 =717&WWCJ6PLO$LTNDCSM!=3-#]IP98F7<)%.WH1T'J
M".W.E=:[YMNXCL([VV;33>2^7/P58':HR "& ;!R.%/'3(!OJP90RD$$9!'>
MEKA[#Q;%9Z7X0M=,T!Q!K%KFUACF4+ %BWA"3UX'7\>3Q5F'QW'_ &%=WMWI
M[P7EKJ0TM[590X,Y957#X'RG>ISC@9XH Z^BN?TSQ)->^)]0T*?33#/8QQRR
M3),'C99 =N,@'^%@>.,5T% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XDL;_4],%C9+;-
M'-(BW0GE9-T.X%T&%/++E?H:V** .+\6>"1J%A9R>';/3+#5;.\BNH;@IY84
MH>0=BDL""01QUI/%7A6^\4P2PW=EIA8P+]DN1.ZS6,_.71@F6&=IQE<[<'KQ
MVM% &)XCC:'P/JT;RF5DTV96D;JQ$1Y/UKGO#^BWNM^'_!<E^MM%9Z9#!>)Y
M4C.\T@AVID%0% #DGD\@#WKM[FV@O+=[>Z@CGA<8>.5 RL/<'@T6UK;V=NEO
M:P100H,+'$@55'L!P* //;?P7XE3^R6GN=*EN-/U5KR2Z8R&2[5A(H9^.& <
M +DCC@@#%;_AWP_J&GV_B"&^:V"ZG?3W4;02,Y02 #!!4<C'ZUU%% &#X-TK
M4-#\+6&E:D]J\MG"L"M;EB&51@$[@.3CICCWK%3PCJMEI_B+1;.:T;2]8EFE
M2:5V$MKYPQ(-@4AP"25^8=<&NXJC<:SI]KJUGI<URJWMX',$."2X498\# P!
MWH P6\,WEOXH\/7=BMJ--TBQELPDDS"1E<( 0 I''ECOSGM6AXQT.;Q)X1U'
M2+:6.*>YC C>3.T,&##..<<5N44 <K%HVMMXUM]?N%T_:FF/9O'',^=[2*^1
ME.@V@9[]<#I6%:^!_$.G:!HAL;O3X]:T>YN)8M[.UO/',[,Z-\H8<,.0#ROO
MQZ/10!GZ0FJ+:%]8DMFNY&R8[7/E1#& JEN6]<G'7I65J_A8ZEXLTW6$G$<4
M4+07L6/^/A RR1K_ ,!=<^X)'>ND=UC1G<X51DD]A5/2M6L=;T]+_3K@3VKL
MRK(%(!*L5/4 ]010!S>C>!(K#PSK&A75RTMM?>=;PE>L%JQ;RXQ_N[V_.F6W
MA?5KNP\/Z=K,EFT.BW$4XG@=B]RT2E8\J5 3J&/+<C Z\=I10!R.D^'M6L--
M\302BR:35+R>Y@V3/A?,4+M8[.V,Y&>M9WA7P9K/A.XTUK%[ 6S6<=OJEMYS
M[)98U"K/'\G#$#Y@>O'?FN_HH P?&>AW/B+PM=:;9RQ1W+O%+&TV=FZ.59 #
MCG!VX_&L^VT+6]+\4:AK=I]@F.K01"\MY)7C$<T8*JR,%;<NTX(('3/M703:
MSI]OJ]KI4MRJWUTK/##@DN%&6.<8&/>KU &/X7T%/#7AVUTI)?-,6YI),8WN
M[%V('8;F.!Z5SH\'ZL=*U_06ELQI^KWL\[72R-YJ1S-ET\O;C=C(#;L<YQQ@
M]U10!Q=QX>\0Z3XGN-3\,SZ:;2^ABCNK6_WCRVC7:KH5!S\N 5..G7TZEHY(
M=):.:8S2K"0\I&-YQR<=OI5NF30Q7$+PS1I+$XPR.H96'H0>M 'FO@S1;WQ!
M\._!]O=K;1V%IY%X721F>7R_F1=NT!?FQDY/3'?C7T'P]XHT":32;>^TY_#_
M -H>6&9@_P!JBC9RYCQ]T\D@-G@'IVKI+6;2=.ODT.SCAMIO(-REM##L7RPP
M4MP-O4CCK6E0!S?AW1M2TG4O$-S<BT9-1O3=PB.5B5_=JFULJ,?<SD9ZUB0^
M!-0N? -]X=OKBV@N9+N2\M[FW=G"2&8S+D%5Z' /J/2NRU;5K'0]-FU'4KA;
M>TA&9)&!.!]!DFKBL'0,IR",@T <K+H>JZIJUAJ^I16,=UIUK/';PP3NR/+*
M%5F+% 5 "X P?O'TK-D\&ZP_PDA\)"2Q^VQPQP>;YK^60CAMWW,Y..F/QKO:
MR]6\1:5H:LVHW7E*B"20K&[^6A. S[0=JYR,G X/H: ,UM'U0^/(]?V6?V==
M+:R,?GMNWEP^?N8QE<?K[5SEGX(\2:5IFBSZ?=Z<FL:5-=821G:"XAN)-[(Q
M"AE(.W! /*^]>D*RN@=6#*PR"#D$4M '%ZMX<\0ZB-'UA;NP&O:;=-.D1WBV
M*.FQX@V"WW>=V#SG@#@7/#VBZO9>)]>U;439+'J?D%8K=V<QF./:025&1[X_
M 5U%0W5U!96SW-S*L4,8RSMT'^?2@#GM8T757\7Z;KVE&S<PVLMG/%=.RX1V
M1@ZE0<D%.AQG/45A6'@K7K.PT&VDFTZ0Z;J\VH.PD==ZN93M VGG][^GXUVF
MF:UI^L&Y6RG+O:R>5/&\;1O&V,X96 (X.1QS6A0!Y]J7@34]47Q-NN;6VEU"
M]M[ZQE1F?RI(50*'!4<'9V)Z^U2W?A/7/$&LO=ZU_9MO!<:-/I=Q':2O(P\Q
M@=ZEE7TZ'IZFN\HH Y;PW9>+[2*&VUN[TN:&T39'+;;Q)=8&%,FX83U.,Y/H
M.#/X*T6^\/\ AT:;?FV:1+B>56@=F!$DK2<Y48(W8_"NBHH YO5-$U*3QIIN
MO6#VA2"TFM)XYRP.UV1@RX!R<ICG'7\*P(?!>N1>$M+TDMIYGL]8&HL_GOM9
M1.9MH^3.?FQ^&?:O0Z* .1GT'6QXHUG5[4Z>%O+&&VA25V/,;,3O&S&UMY'!
MJ3PMX4_X1_5M4O(((+"TO5C(T^UE9XDD7=ND&54*6RHP !\N>_'544 <AJ>@
MZ_:^,'\0>'9[!A>6R6U[:WQ=5.PDI(K*"<C<1@\4^?PYJMOXHL/$5G<6]U>+
M9&QO8IR8DF0OO#(0&VE6S@$'@XSQFNLHH X.\\$7[Z-)%;26AO;O6TU>Z+R,
MJ K(K;%(4D_*BKD@=SCG%2ZIX1U/5-1\4R-):10:SI2V,1$C,T;*) &8;0,9
MD['M7;T4 <:GA_7I-9\+7]S_ &:!I,,T5PL<S_-YB*GRY3G&W/..N.V3G>)?
M!>OZTWB6&.YTYX=32,6L]R7,EN%"YB  P$+*6R#U)R#V]#HH XDZ!XHTWQ1>
MZMI%SI3Q:JD1O8;KS (9479OCV_>&T#(.,XZBK[:!J<7C6QUJ"YMYH5TW[!<
M^?D2'#A]Z@#!)P1@XQG//2NGHH Q?#%[J]]IDDFLQV8N5G=$DLBWE2H,89=W
M/<CWVY'!%91T37;?X@7OB*WATZ6WGL8[-8I+IT8;7+;CB,CG/3]:Z^B@#CO$
M.A>(/$'AF^L)#IT,\]U"\4:S.8XHXY$D.6V99F*MG@#D>G-L:/J@\>/K^RS^
MSMI8LA'Y[;]X<OG[F,9./U]JZ:B@#S:R\$>(](T;P_+IUWIRZSH_VB(I(SM;
MW,,S[F5B%#*00I& >16SJVA>(=6MM$DGET]KNTU2._G4.Z1JJ*5\N/Y23USN
M..<\<X'844 >=^)WN+WQV(]+FT@7=EI^R9+N[EM9")6)^5X^77"=,8!.>IX;
M!I.MWMOI&K:!%I.GW^C^;8BV65I+*YMV"9"N%##!4<X^\I!S7<WVCZ9J;(VH
M:=9W;1_<-Q LA7Z9!Q5Q$6-%1%"JHP% P * .1U30=?U1-!FGFL'N;+4UOYU
M#ND8"HR>7'\I)^]G)QDYX&<"M=^#]2OE\;12RVD4>OQ!+=E=F,9$(C&\;1Z9
MX)KN** *.D17L&DVT6H?9Q<I&%<6Y)08&."0"?R%<U?> 8=1UK79;F<'3=4M
M@#; ?<N2AC:8>^S:![EJ[.B@#B[_ ,):G=?#"X\.?:X)M4N[?9<74S$*TC<L
MW )([#CH!5W4-$U2\\4>&]55;-8M-2<3H9FW,9$"_+\G(&,\XS[5T]% '.^$
M=%O]$BU9+XVQ-YJ4]['Y$C-A9&W;3E1R/UK&+WZ?&#4S8P6TQ_L2WW+-,8\?
MO9<$$*W\J[NJJ:981W[7Z6-LMXPPUP(E$A'H6QF@#CM/\$W^E:AX8DMY;66+
M3&NY;MW=D:62XR6**%( !)QD],#WJPV@^)])\3:E=:#=Z8VFZK(L\\5Z'WV\
MH4(SIMX8$*#@D<CJ*[.B@#@I?MT'Q?"VB0W+KX=17^T2F,M^_;YLA3SGKQW_
M  I(O!6K:>^CO:7%E<K%<W-U?V]SN6*2:9MPD4 ')0Y"@]NX/-=H-,L!J!OQ
M8VPO2NW[1Y2^9CTW8SBK5 'G5KX)U^UT+1=.,VF2MINM-J)</(@="\C8^Z<,
M?,^@QU.:UM4T/Q%:>+)-=\.3Z>PO+=+>]M;\N%)0MLD1E!.0&(P>#_+KZ* *
MD=O=#2S!)=YNVC(-PJ8 <CJ%[ $\#)X Y-</I/@[Q%9WOAFZN)-),FE+.ERZ
M-(SW1D4*92Q RYV\@^N<GI7H=% 'GA\%ZX?",FD;M.\]M8_M'?Y[[=OVCSMO
MW,Y_A_7VJS-X6UZSU#Q&-,DT^33]>0R.MS(ZO;3F/8Q7"D.IP#@[<5W5% &3
MX=TR?3/"NFZ5?-%)+:VD=L[0YVMM4+D9YYQ7%1^"/$UOX5L_#,<^ERV>G7T,
M]K=R22"1XHY1($= N 1C&0QSCH.M>ET4 <3:>'_%6CZQJ,6EWVFG1]1N6NV:
M=7\^UD?F38!\K G)&2,$]^^E;Z+J5OXYU'7,6K6UQ8Q6T:&5@^Z-G;)^7&#O
MQU.,=ZZ2B@#BM,\%3_\ "L7\)ZI)!YK1RJLUN[,JL7+HXR 058@_A5G4/"5W
MJ'@9-);4!'JZM'=_;@N1]J5Q)OQ_=WCIV'TKK** ..N]*\6:WX4U;3]6ETF.
M[N[*2TB2U:3R@74J9&9ESGT4#UY.>.ETBWGM-'L[:Z$8GAA2-_*8LN0,<$@'
MMZ5<HH Y!?#FK6^J>*I8)+)[760'BWLZNC^2L1#8! 7Y<Y&3VQWJG;^#]62#
MP7!+]A9-"A:*YQ,_[T& P_+\GH<\_3WKNZ* .,\+:%XJT*&VT6YO].FT6R(6
MWN$5_M3Q+]R-E(VC P"P)X'3)R-+QOHM[XC\(WVD6#6Z3W05=\[LJJ P;/ )
M/2NAHH Y?5-!U*;Q)I7B2Q^S+?6L,EK<VTDK".6%R#@.%R"& (^7GIQUK+U;
MP1?WOA[7889+0:GK5]%=3%Y&$42QLFU 0N6^6,<X&2Q/M7>44 <EJ'AB\U3Q
M:^H7(MAIT^C2:9,BS-YG[Q@S$?)C'&.OO[54M/".JS:'HF@ZK+9R66DW$,@N
M8G;S+A(?]4"A7"'A=QW'H<=>.XHH YG4?":W_C&WU@RJ+1K4PWML1D7!1@T)
M/^Z2Y_*H?#_A.YT#PE>:4MREU<.)(H'E8@+",K"A."<*F,\=2:ZRB@#A-/\
M"6L6:>"49K!AH$31SD3/^]S"8@5^3\>?I[UEZYI5UI&@:S:ZA-I2/KVNI-:F
M:5_+!;8=K-M4H=L1(8<@D8YQ7I]17-K;WEN]O=013POPT<J!E;Z@\4 <?X4D
MO[;7KFWO;+2C+=1>;+=V%_)<O\F%42>8H(&"=O/9N.IKM:K66G6.F0>186=O
M:19SY<$2QKGUP!5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH-2O4BLQ)YD1<$73..6E)&20<MQCDUJT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/%)\46HNH[2-+9X8Y8YX;@3(Q;.4)P"KK@;@1W'6NCH **** "BBB@ HHHH
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M:?$N]\2Z78_VA9ZG D=U;:A"%,3J H=2-V>%_4CT-?2_]G67_/G;_P#?I?\
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M110 4444 %%%% !1110 445CCQ3HATVRU'^T8OLM]*L-M(01YKEMH &,]>*
M-BBJ5OJ^GW6J76FP7227EJJO/$O6,-G;GMS@U=H ***I7NKZ?IUS:6]W=)%-
M>2^5;H>LC]<#\J +M%%% !152_U*STR.%[V<1+-,EO&2"=TCG"KQZFK= !11
M10 4452U'5]/TDVPOKI(#=3+;PANLDC' 4 >YH NT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&U2:_D$VEF0HJQJ%D+KM;=^'3&.: .,M%U1+GXBS+J$/FPRA@QM@WS+:QLI
M+$#&!QSSS[5>T76]3M]!\):3&[7%YJ&EBY,R1KN2-(XAC#N 6)D')/0'BN@L
M_"D=M<:[)+>S3IK3%KB-E50IV"/Y2!Q\H'7/2LV7X?1OI&D6T6N:C#?Z/\MC
MJ"",21IM";"NW:RE5&01SCK0!%%XC\1P1:=IFJ:<(=5O+N>*-XO+/F01KN$H
M7S-H8@@;2W')YX!K7_B'QAI>D0O>6EI#.VM064;RJ#]HMY'50V$<A&Y(/7U
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M;W2IYIK2]"H7 E8M(C+C:RDGT]*=+\/89K/5(9-:U!I;^]BOS-B,&*:/9M8
M+@_<&0>/;O0!EWGC/6+;2O&C6\D3RZ)%%/;37-HR&17C+$.F5Y!!P>.W%=EH
M8U<P23:K=6LWG%9(%MX2GE*5&5)).[G//'T'085U\/X[M==$VMW[G6K>."[)
M6/G:I7<N%&#@X]/;/-=9:0-;6<,#RF5HT">80 6QQD@<4 >?ZCXE\3I;^,YK
M>ZTZ,>'WWQAK5F\Y!"LNT_/QU(SS]!WT(O$FK6GB32$U"6U?3]6L)[I8HH2K
M6QB5&QN+'>"'(Z#D=NE79O!<<T'B2)M2GVZ_D7&$7,8\L1_)Q_= '.?6I_\
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MR?8#(ZUHVGA\6OBB]UW[9(\MW!'!)"44(%0L5([YRS=^]3:CI=Q>7<=Q!?M
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MTRIY44ET$'EIQQA0,DX&6.2<"@#<HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M[7-;LO#VDS:E?NRPQX "+N9V)PJJ.[$D "M&N!^*T4J:7H.IE6>RTO6[6\O0
MHSMA4D%B.X&0: -V[U[5M/TQ]1NM /D*NYHX;H/-&/5UVA0!U.UFQVS4L_B+
MS-=FT32[87E];QK+<EY?+BMPWW0[88[FP2  >!DXXSIR7MH+$7;31M;.H*NI
MW!P>F,?>SD8 ZYKB?!T;Z9\1?&EC>?+<7D\5];%O^6T)7;E?4*?E/IF@#H]/
M\1"\U2\T:>V^RZQ:Q"8V[R926,\"1' Y7/!X!!ZCIG C^)!'AN;Q%<Z'.FE6
M]P\%Q)'.KR1[7V%MG&5!]#G':FRP/J/QNMKFT^:'3-):*\D7H'D?*1D^N/FQ
MZ8]:X6UMKD^ 5NKN6:Y\+IK%U_:]C" &\KSVPX8#<54X+*#R/I0![I%*D\*3
M1,&C=0RL.A!Y!I]16LEO-:0R6CQO;,@,31D%2N.",=L5Y--?VYO-!U:PN2$N
M/$LD+7=Q,/M$R9E5T(&-L2X "G/ 4\4 >O5'.\D=O(\48DD5250MMW'TSVKR
M#6;"*31OB3=M/=&;3KHS6;_:9/W+B"-PR\]<_P"%=%97,&O^--=T[6RKK:Z?
M:O9Q2' V.A:291_>W8&X<C:,8H ZKPMKG_"2^&-/UG[/]G^V1>9Y6_=LY/&<
M#/Y57\0>)XM(\.:QJMI$M\VEAA/")=GS*H8KNP>0&%9_PL(;X8>'\$$"U Z^
MYKBGL[&U^'GQ*$$4,<PO;] %P#L 0X^G(_.@#V"WE\^WBEQC>@;'ID9J2O,+
MR.;0/%,4NC><;FY\-W4[(TC/YTT?EF,D$G)RQ'T..E3^%8K'4;CPYKMGXAMC
M+) R2P6T9$EX2F6$V9&)92"<D9!^M ';:YKEEX>TM]0OF81JRHB1KN>5V.%1
M1W8G@"J-UKFK:?8?;KO0OW&5W)!="26,$@9==H&!G)VLV,=ZP/BFDD,'AK5G
M#-I^F:U;W-[@9$<?(\P^RDC\Z[>6\M4LQ</*C0.!M93N#[N@&.N<\ =<T 93
M^(C<ZW=:1I%JMY=6:J;MY)?*BA+#*H6"L2Q'. #@=2.*DTCQ#%J6HWNESPM:
M:I9;3-;,P8%&^ZZ,/O(?7@@C! KF? $;Z9XJ\::7>?+>2ZHVH1[NLEO(!L9?
M4 @@^AXIUK ]_P#'"\U&UYM+#15LKF1>AG:7>$]R%P3Z9'K0!WM%<CXHDLY_
M$VBZ=,?.G>&XF6VG<+;,@"AGD!!W%<_*!ZDY'6F_"^[>\^'NF/+<FXD3S4+E
M]QPLKJO))/0 #Z4 &H>,[_3GTP3>'V4:G>"TMMUTH8L0Q4L,?*"%SZ\UT.EW
MMW>I<"\L&LI89O+VF0.'&U6#*1V^;'U!KEOB$0-6\$\_\Q^+_P!%R4_QKJ/V
M?Q%X<L+JXMK?3;TW"R-=QEX7F"KY:.-RCD%\ G!('&0* .UK$\3Z_)X=L;6Z
M6S%RLUY#:L/-V;/,<(&Z'.,]*XB22'P\^B:9<:T+S0;G69DN)/NPPYB+1V^2
MQS&'/0GMM/ (J3Q58:;9>%IK73+Z::!]?LW*"4,ELS31DQQD#Y0.NWMNH ].
MHKS&YM(]-U?QYIMI)/#:_P!C1781;A\K*5F!<'.03M7//..:CT>U2QUCX=W$
M$DXFU+39$NV:9F\X"V5U!R>QZ8Z4 >CV$U[/',;ZS2U=9G2-5F\S?&#\KYP,
M$CG':K=>0Q:K)I7A.8RW,RZ>?%TUK>3M*Q,=MY[#YG)R%R$4G/0FMW6X_#^D
M:5K)M=2NUAO9[0-;64RK%$[.%54.,1B3'S^Q)[\@'8Z[J3Z-H%_J:6_V@V=N
M\YBW[-P52Q&<'' ]*ETN].I:197WE^6;F!)MF<[=R@XS^->:+*88?B=I^^VC
MBBL Z6ML^8HF:V?>%''<#. .>PKT'PQ_R*6C?]>,'_HM: .??Q[<1_V](=!F
MD@T.4I>-#<*S$!0Y9%(&X!3GJ#75Z;J-MJ^F6NHV4GF6MU$LL3XQE6&1QVKS
MK1='DU[6OB!I_P#:4UI;7&HB*?R$4NR&%00&8';D9&<5+/X7TM_B%9>'B+D:
M4GAUE%LEU(JX2:-5Z,,''IU(R: /2J*\M+)J_AWQU<ZA*\.JZ7=W*V\V\K):
M)&@: H>J@@!N/O9.<TZ2YO+S4H$UV,74ESX<B;[(LB(UM<MG<VUB-I8\!ATV
M'IW /4**\MN=#GM!\/=-U.]N9KB662*]=;R5A,?LSEN2W.2.OY8S2W%I93^(
M=8\)W-_:V-M:6,"Z<MYO=TB*'=+$[2#Y@V06Y/RKSB@#U&BO*]?COK:Q6]WQ
M^)--@T>)+U6?RKN)/G/VJ(GC<PR3T)V#!J;Q3>30W-YKQM8]6T+[/#]H5'\N
M\TT;=V^,'@@A@2.">G(% 'H&LZ@^DZ->:BL G%K"\S1[]I95!) .#S@5S</C
MY4MM!N]2TN6TLM<:*.UN%E60*\B[D60<%21W&1ZUL^+"#X+UP]O[.G/_ )#:
MO,]-B:TM_ %WXBG>Z\.FRM3:$@(EG>^6/+,F -RD'"DG@]>N: /9:*\]UVXB
MU+QY>Z#JEY9V]NVF126:7D997):02.AWJ XPG/) '&.<YUKI$%YXPT'2KW5[
MS5;1]"G#RM.Z"ZV2QA6(#<\=P?FQGG- 'J=%>/6-Y?:9I5CI4]S/)H?_  E4
MNGB>20L6M1G9&S]2OF#83W QT.*E\7PS::WC>PT^26+2ET-+WRX9&1;>Y+.,
M+@C:&5<E>AQG'- 'JEW>VUBL37,JQB6588\_Q.QP /\ /K5BO+_$OAK2+.+P
MI.(#))=ZY:F>2>5I-Y:)P?O$@9PN0,9P*ZKQSJ%SI7P^U2]TIF$D-L#&\/)1
M,@,R_1<D'VH Z:BO/]2;3-.TO4]<\)WIDOGT61H+:VD#Q2;?F69EP29 3C<3
MDYQS59UCME\":KH,C--?W$4-R5<DW4#PL\CR?WF7:&W'D'ZT >DT5YL(#I/B
MG6O"81S#KQ2[LGY/EH?EN%!_AV ;E'0%Q56Z2VUS5/%&DW^L6>E3V$Z+:M(A
M$MK (D*20MYBA1G<20/8\8% 'J=5+.:]EGO%NK-((XY=MNZS;_.3:#N(P-O)
M(QSTK@X=&MM8^)%]:ZA/>7$2Z197&TSR19E\R3Y]H8;3\H^7I[5DZJ'3PA\3
MPMQ<C[/>.T3?:'W+^XB.,YSC)/'2@#UVBO/8+1=+^(MA'8SR1&^T.>2=I)6<
M/(CQ[78$]1N/X<=*R_#5A/K2>$9TD836PDDU2[CO,?;1M.TY1MTFY]KC(X&<
MXZ$ ].OKVWTZQGO;N58K>!#)([=%4=:S)=?>+QI;>'S9C9<64EVMSYO]QD4K
MMQ_M]<]JQOBS!#/\,]9\Z-7$:(Z[A]TAUY_G5+4=+TZ\^)>C6 C4V7]CW8,4
M3E5/[V+(.T],YR* /0:*\<TG5I(-(\+:;>WL4>F2WVHVK27P,L3-'*P@C?YA
MD;=V 3C*CT%>@>#M/CTRPO;6'5AJ,*WCLFU<);A@#Y2?,WRKGCDXSCM0!T=%
M>9/H-AKWC+QQ::E=78MX8K22/_2Y%$#-$QWCYN,$9'8<\5E:!93>)-1\*0>(
M9;R1KSPW,US&;F1/-Q)$%8X(P2I!)&"3UH ]BHKRB18-=E\1V=]KMMI=]IM^
M5AE=&-S;0H%,31L9!\K >AR2<YS6IJ\LGA;QO%?)$9X=?M#:(C*=HO5Y08_A
M$@)S[IDT =Q<S7L=Y9QV]FDUO(["XE,VTPJ%)!"X^;)P,<8SFK=<%JFGII'B
MGP#9P32[4FN(G_>$"3%LYW,N<$D\Y]ZYZ2XFU'X7ZQX@>22+Q19WLY\U2?-A
MF28A(1_LE=B[.AW="30!Z]17G:RK'XQ\617K)"CZ+;3O$SX0.?-#,.W4#GV%
M9-D=4N?!_A:_LX;;6_(T56N]+N92LD@8+^]C8Y'F J1SZ]030!ZU16+H]\EU
MX*LK[2TF='L$DMDG^^WR94-[],UR?A"31-6T7PSKS:I(-8"'[3Y<H\RYF*$2
MI*N"653E@.-H48P!0!Z-6)X>U]]<FUB*2S%LVFW[69 EW[\(C;N@Q]_I[5Y[
MH]];C7_!%]97.+74)+S=//,#<7<?E.P:;&!PP&!SC Y'2GW.IS:3I/C.ZCE,
M,/\ PD\274P!/E0,MN)&."#C!(."#@G!'6@#UJBO*]=TVVL_#7BV[T_789(Y
M]):<6FF@Q0Q.JG;*-KMM+>G ;;WP:L>4VA>+=&GTP323WF@W4DT;RL_VB2,1
M%,@GKEB!CL<=* .Q\1:_)H4FDA;,3I?W\5DS>;M\HOG#8P<]#QQ6W7CN=/U#
MPEX UPRI-J-SK%FUS<E_GDE;=YBL>^&X _AP ,5+KU] TTVI6%PWF0^*(+=K
MJXE'G!A(B/#&!C;$!G@DYRQQSF@#UVBO/=,TBRU;XD^)S<R7,T=J^GW-NHNI
M-J/L9MP ;IGMTY/'-7OB'&7'AG$T\>[7;6-O*F9-RL6R#@\]!].U ':45Y6^
MA6#:MX]TTB?[%:VL%S! +A]D<KPN6<#/7**<^M3Z#J$NLZUX5T_6C]HL[GPS
M'=QK-REQ<G9O+ \,P7GGIN)H ]-J.XGBM;>6XGD6.&)"\CL<!5 R2?;%>17Y
MO1X$U>WDN[K[/8^)4M;";SVW>1]HB7;G/S!2SKSG[OM3_%.G6UE/X]TR%7-F
MWAU+TPR2-(//!F'F?,3\WRKSZ@&@#O[_ ,2_9-;\/6,5IYT&L-(JW'F;3'MB
M:0?+CG(7U'6M^O-=1LK*6_\ AY:0@) \TV\0.5ZVCD\@Y&<_K6EX&GM]+C\2
MVDMRL-E9ZY);VPFE^6-62(A 6/\ ><X'O0!UVHW4MEI\UQ#;/=2H/D@0@&1B
M< 9/ Y/4USB^+=2;Q)+H*Z #?16:WA'VU=I0L5 !V]<@_P"-=;7#6Y'_  O*
M^'_4O0_^CWH U=&\43:IX@ETJ?3&LWCT^"^R\H9OWA8;" ."I4CJ:Z2O.]1T
MJTUCXE:];WJN\(T*W.Q9&4$^9-@G!&<=OSK'TO6IKS3O MGJ][;K:7^D.QDO
MT,D<]POEA5?YERVW<1DG)/3." #URN<O_$EX-1U"QT;2EU&XTY87N8S<"%CY
MF2%3((+!1GDJ.0,^C_!UDNFZ&UG'JS:G%%/((YB.$7.?+4Y.0I)7J<8QVK"\
M.Z58'XD>,\6Z*R?9-K(2K+OA.[!'(SF@#LM,GO;C3XI=0LUL[IL[X%F$H3DX
M^8 9R,'IWJW7C=FKW/PV\"&2ZN@TFN1Q.ZW#AG5II<@D'GH.3R.U:_B;2&T'
MS!IEC%J>CVFGG[5IKW+"YMD9Y&,\+N3\Q^88R#^[ !H ]%6]MGOY;%95-S%&
MLKQCJJL6"D_4JWY58KSOPQ'IEQ\3-:OXHD4SZ=83PM( KG>LN3]2, U=\=VR
MW.O>$(GEG2.;4FBD6.9D#H8)"00#[#GK0!V]%>6S65C+X@UGPG<7]M86UI90
MC3EO-[ND10EI8G:088/D%N2-J]ABI(=)M]5\=V&FZAJ%WJ-K)X:5W9IY(Q<D
M2JN\J&XR,$XZG!H ].HKQ_1;V^@3PUHU_<33Z%)K=_9K/,Q/GQ1[Q;H[?Q L
M#QWV =*C\61W-A8>.["UGGBTNU^PS6RQRLHMY9&'F(N#]TC:VWH-W3F@#URX
MO;:TEMHIY522YD\J%3U=MI; _!2?PID,UZ^IW,,MFD=FB(8;@39,K'.X%,?+
MC YR<YK@?$?AK1=-\4^$@ML"EQJ=P\S7$K29+6SYY<G )4''3(J'50?[7^)"
MI<7 1=%@FC*W#C8WESG*G/ R!P.* /3Z*\RTFU33O$O@*>VDF$NI:7,MVS3,
MWG!88V7()QP<XQTJG;6-UKD$%J)_,U.+7Y'N=2BNPGFVRRMN0%6#XVXC" <%
M<]!F@#UFBD4!5"C. ,<G-+0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C*KJ590RD8((R"*
M6J&J:UINBQPOJ5[#:K/*L,9D;&YV. !0!'9>'-$TV?S['2+*VE!)#0P*I4GK
MC XS[58O=,L=2$8O;."X\LYC,J!BA]03T_"J6E>*M#UM;QM/U*&469_T@'*&
M(8SDA@., \].*=!XFT>>>:!;T)+##]H=)HVB/E=-XW ;E]QD4 7;;3K*SM#:
MVUG!#;MDF*.,*ISUR!US4=GHVEZ=;RV]EIMG;02Y\R."!45\]<@#!KG=1\<>
M'+W1;S['XGBLF6V$_P!L2/<8D8X# ,N&YXQR:WKW6K#3"L=U.QD\LRE8XFD?
M8.KE4!(7WQB@"Q8Z=9:9;BWT^SM[2 '(BMXEC7/T  JF?#.@F660Z+IQDEF$
M\C?94R\@Y#DXY89//7FIGUO34T^WOA>1R6UR5%N\69/.)&0$"Y+' )P,]#Z5
M@>"];N=8U/Q,DMX]S;VFH"&WWQ"-D7RD8J1@'(8L.1F@#<;P_HKI<HVCZ>5N
MCNN ;9,3'U?CYOQI+CP[HEV]J]SI%A*UH,6Y>W0^4/1>.!["C4O$.E:09!?7
M7E^4@DE(C9Q$A. SE0=B\'EL#@^AIUYKNFV&WSK@L6B\X+#&TI\O^^0@)"^_
M2@"S8V%GIEJEK86L%K;I]V*",(H_ 56ET#1IWNFETFPD:\Q]I+VZ'SL=-^1\
MV/>H;GQ1H5I!8SSZK;+#??\ 'M)ORLO&<@CM@=:6S\3Z-?Z?/?6U\KV]O+Y,
MI*,K))D (5(W;B67 QDY&,YH L)HVE1W4-RFF6:W$">7%*L"AXU]%.,@>PIE
MEH&CZ;>SWMCI=E:W5Q_KIH8%1Y.<\D#)YYK-U;Q!ITFE2.FMOI9CNXK=I6@(
M=9,HWE['7/S*P'3HV:TK[7=.TV1X[J=E:- \FV)W$:DD L5!"@X.,XZ&@"^Z
M+(C(ZAD8896&01Z&LZQ\.Z+I<PFL-)LK:09PT,"J5SUQ@<?A5&S\7Z?=ZYK&
MG$30C2POGS31.B E2S$L1@ +@Y)YYQQS6G9:O9:A/+!;O)YT2)(Z20O&P5L[
M3A@,@[6Y]J '7NE:?J1C-[907#1Y\MI(P2F>N#U'X5+:6=K86ZV]G;Q6\*YQ
M'$@51GKP*@O]8L=-=8[F5O-9#((XHFE?:.K;4!.T9'.,<U@^*_&$&F>$XM5T
MR<7 O)(8[>>)#*F'D5"V0",@,2 >I&.>E '07VDZ;J<D$E_I]K=/;MOA:>%7
M,;>JY'!Z=*DLK"STZ%H;&T@MHF<R,D,80%CR20.Y]:S=-^T:?9WM[>:I<W]F
MQ\Z!9;3;-"F.5(507YR1\H/;FN6U'QM)?^'?#FNZ;<RV-M=ZK;0W"RQ !H'<
MY!9E]!U4^O- ';7ND:9J4L4M]IUI=20G,3SP*Y0^JDCC\*=J&EV&JV1L]1LK
M>[M6QF&>,.O'3@\55L/$NCZE;WD]K?QM'9,5N2X,?E<9^8, 0,<YZ&I+#7=.
MU*[GM+:<_:H%5I()8GBD53T;:X!*GUZ4 .?1-*DTD:2^FVC:<%VBT,*^4!UQ
MMQCK33X?T4Z?#IYTBP-E =T5N;=#'&?4+C -8WB[Q(='O=&TZ)IXWU&[$4DT
M4#2%(PCL=ORD%B4 QR<$G'>HM+U!-*U"_CU7QA]N^R6OFR0RVZ1>1&78J[E1
MRV"%[9VYP#0!OOH.CRRSRR:38O).GES.UNA,B?W6..1[&@:#HZM:LNDV :T&
MVW(MDS"/1./E_"J5IXS\/7X<VFI).46)ML:.S$2 E-HQEB<'@9(P<XQ4&K>-
M=,TS3K6\43SK<7T=BJI;R95RX5MPVY!'/!Y)&!S0!JQZ'I,-G<6<6EV4=M<D
MF>%+= DI/7<H&#^-1Q>'=$ATA])CTBQ33GY>T%NOE-WR5Q@]!^56Y;R**Q-X
MPE\K8'P(F+8/^SC=GVQ7#>&_%$NH:;I7B74-;FMK6['ESV4MF?)\R1L1!)-H
M(QP,Y8-GL: .N7P[HB)*BZ/IX66)8)%%LF'C'1",<J/3I5ZWM;>SMDMK:"*"
M",;4BB0*JCT ' K%US6XETW7+:POC#JEC9-<8\OYH_E8JV&&""5([]ZP3KFK
M?8OA].+YO^)HT27J^6F)MULTA/3(^9>V* .PL]'TO3YY9[+3;.VFF.99(8%1
MG/\ M$#)_&G-I6G/J*ZBUA:F^5=HN3"OFA?3=C.*;JNL:?H=B;W4[J.VMPP7
M>_J3@#WK-/C7PZ);F+^TT,ML SQB-RQ!S@HN,N.#RN1Q0!H3Z)I5U>B]N-.M
M);H #SGA4M@'(YQV/(]*YC7O"E[J?B*>]FTCP]K5I+'&D2:FI22V"YR%(1PP
M))/8\X["ND3Q!I4NEVNI17B2VMW@6[Q@N92<G"J!DG@\ 9X/I4+^*]#BT>XU
M6748H[*V<QSNX*F)QU5E(W!O8C- $&D^$=)T^PMH9M.L)7MY&EAQ;@K;ECG$
M6[)4#V^M7]2T'1]9DADU/2[.]> YB:X@60H?;(XJF/%^A.]['%?>=+9P&XEC
MBB=F,?3<H ^<9XRN>:YO4_&<MWX?\+:Y87,MC;WVI6L=TDL0 ,4@W,"SKT Q
M\RG'7F@#L;K1-*O;G[1=:=:33[!'YDD*LQ4'(4DCD9.<=*)M$TJXNS=S:=:2
M7)V[I6A4LVW[N3CG';/2FZ3KNF:XMP=.NA,;>3RIEVLK(V,X*L 1P<CUI]_K
M%CIKK'<RMYK(9!'%$TK[!U;:@)VC(YQCF@"Q=6=M?6SV]Y;PW$#C#13('5A[
M@\&J_P#8VE?V8=,_LRS^P$8-KY"^4>_W,8[#M6#XI\80:=X=L;[39Q.NH7,$
M,%Q#&95"/(JLX(!&0I. >I['D5HV$CZ3IMY?:IK3W%AN,\4MU"(7@BP/E8@#
M/.>2 ><<T 3WGAO0]1MK>VO='L+B"W.88I;9&6/_ '01@?A6/J/A>:_\=6&J
MRVMA+IEK8R6OER.?,#,RL&5=F!@*1U[U?L/&?AW4]2ATZSU6"6[GB\Z*,9'F
M+C/RDC!(') Y'<58G\2:1;7T=I->!)))OLZ,4;RS+_SS\S&W?_LYS0!;?3+"
M73CITEE;-8E=GV9HE,>WTVXQBH?["TG[!)8G3+-K20[I(&@4HY]2",$\#KZ5
M1;QKX<%\;(:I$]R)C;^5&K.?,"[MO /./SZ=:P-$\0W.O>?K3:U+I]G8WUPD
M]O-:@0O;HS(,LR@A^ V0QP21B@#L+C1],NM/33[C3K26R3&VWDA5HUQTPI&!
MBK912FPJ"A&-N.,>E9T'B'2KB2YC6Z\N6VC$LT<\;1.B'HQ5P#MX/.,5F#XA
M>$VB,HUNWV")9MV&P59MJD<<Y/&!S0!KZ9H>DZ*LJZ7IEI9+*VZ06T*Q[SZG
M YHLM$TK3IFFLM.M+:1LY:*%5/)R>@[GD^M4#XU\.B6YB_M-#+; ,\8C<L0<
MX*#&7'!Y7(XJROB32'L+*]BO5F@OO^/7R5:1IN"3M506. "3QQCF@#1:WA:X
M2X:)#-&K(DA4;E5L9 /8':N?H*I7F@:/J-]!?7NEV5S=V^/)GF@5W3!R,$C(
MYYJL_BW0(]/L[Y]5MTM;V3RK>1C@.^2"/8@@@YQC!SBI;'Q+HVHVMY<VU_$8
M;)BMRT@,?DX&?F# $#'.>AH M)I>G1ZBVHI86JWSKM:Y$*B0CT+8SBH#X>T5
MH[F-M'T\I=-NN%-LF)CZN,?,?K26OB'2KR:YACNPDMK&)9HYT:)D0YPY#@';
MP?FZ<4MCK^F:C?26-O<'[4D8E,,D;QL8R<!U# ;ESQD9% $=YH%E)!))8VEE
M:ZBMNT-K>"U1FM\@@8XZ \XSBN3TOP!MDM!>^'O#5G+;/&XO]/#&=RA!R,HI
M4G')W-U/6NNU/Q%H^C7$%OJ.H0V\TZLT4;GYF"@DX'T'X].M<UXJ\7177PXU
M/7?"^K+OMB%$L: E6WJ&5E<<'![@'I0!VEQ;07EM);7,,<T$JE9(Y%#*X/4$
M'@BJ<>@:-#+#+%I-@DD$?E1.MN@,:?W5..!["G?VS8#4I].\XF\@A$[PB-BW
MEDX# 8^89!'&>14,7B329[&UO+>Z\^&[5G@,$3R-(J_>(503@<9..,CUH <W
MAS0WTV33FT;3_L,C;WM_LR>6S>I7&,^]7+.SM=/M([2RMXK:VB&V.*% BJ/8
M#@4MG=P7]G!>6L@DMYT$D;@<,I&0>?:L^#Q/HUS>Q6D-ZK2S-(L)V,$E,>=X
M1R-K$8.<$]#Z4 8UGX2:3QEKVK:K8Z=<6E^L"P DR.HC4J0P* 8/!QD]*Z1]
M*TZ2_COWL+5KV-=J7#0J9%'H&QD"LH>.?#+2(BZO Q>X^R@J&*B7.-I.,#)X
M!. 3TK0M];T^ZU6ZTN&X+7MHH:>'RV!0'H3QCGMZT )<Z!H]YJ<.I7.EV4U]
M!CRKF2!6D3'3#$9&*NRV\,[1-+$CF)]\990=C8(R/0X)'XU%8W]MJ5HMU:2&
M2!\A6*%<X.#P0#UKA?\ A*WU2]UJX_MR;1[71[U%!DLB8I(51&D\S<H(+;V
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M-*3$,9?" G:,CYNG-8OB/6KB.[\)W&EZ@#9:EJ*0R>6JLLT31.X()&?X1T-
M&S;^&M"M-.ETZWT;3XK*4[I+=;9!&Y]2N,'\:F31=*CN(+A-,LEGMUV0R"!0
MT2^BG&0/84NJ:OI^BVHN=2NX[:$NJ!I#U8G  _&J>F^+-!U>:\BL=4@E>S7?
M.,E=B_WN<97_ &AQ[T +_P (IX=^T27']A:;YTDGFN_V5,L_]XG'7WJ2;PUH
M-Q-<S3:+ITDET5,[O;(3+@@C<2.<$ \^E)9>)=(U"9HK>\'F" 70$D;1[H3_
M ,M%W ;E_P!H9%8>I_$WPS9:/=7UM?"]:&V>X6*"-V+A6V=<8 W8&3T!!Z4
M=-!I6G6M[+>V]A:Q7<W$L\<*J[_[S 9/XTM[IEAJ7E?;K&VNO)??'Y\2OL;U
M&1P?<5):W*7ELD\8<(XX$D;(?R8 C\JH'Q+I"W<=LUZH>28VZ.481M*.#&),
M;2V01MSG((H F.AZ0TMS*VE6)DNEVW#FW3,P]'./F'UILF@Z/+9P6;Z79&VM
MSNAB\A0L1]5&/E_"N8N]<O-<\6ZKX>T[4KK2Y+.VA:&=+,R!IF:3)?<N-@"
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M&P?PEJS '#6,Q&00?]6>QZ5K55U*Q74],N;&262)+B-HG>+&X*PP<9!'3VH
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M\VL27E]<2OS%!-<%H;<[=I,:=%)&<GW/3)H T+.TAL+*"SMUVPP1K'&OHJC
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M5U8(N 3C"*N3[G'.*MS^']:_X275M8M9;%#>6MO;HDA9@/*=F.[Y>0P=A[4
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M@X(Z&@#.N?%=W=Z!XHAAM4M=9T:-UGB:<E5S&721'"\@KR 0.1@XZU/X'TJ
M:#HVKS:?;0ZB=,A@$\,A9I(BJM\Q*KR6Y[X]>32OX6NFLO$T^^W&J:\GEO\
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M$8@.AY(;)/X8[U>MM"U_3KCQ+>6$VG+=ZG<QW%MYV]TCVHB$.  3E5)X/4T
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MF(^TX[\$5)?^&?$?B3PS=V&O:G8PW;*AMFT^)MB2(ZNLC;SDG<HX& !GKG@
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ML/%,NO-!964LUIY%S#8LWEW,FX-YK*0 ",$#J?F.30!UE%%% !1110 4444
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MX[\=))=VT3!9+B)&+A &< ECR!]?:EN+F"UC\RXGCACSC=(X49^IH EKEYO
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MVFJ:=<:?>P+-:W$9CEB;HRGJ*R-(\&Z9I%I+:^9>7T4D)M]M_<-.$A/6-0W
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MZ=[NVC;:]Q"K;Q'AG .X\A?K[5 )+W^VVB+V?V#[.&5<MY_F;CDXZ;,8]\T
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M"G<-Z@X/KS3GCCDQO16QTR,T $:HL:K&%$8 "A1P!VQ7"?:;?_A?/E^?'O\
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M?Q+'&P8A=@%\Q (_APN#CL,5[2T:/MW(K;3E<C.#ZBD,,1&#$A&2<;1U/4T
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M%8EAC6->B!0 /PI6BC>(Q-&K1D8*$9!'TH \\L_#EOKVH^.]* 0Z#?>2L.P
MQI<F,^:Z=L@["<?Q ]\U=\'32^(-/CO=<M$2738'TV99D&TS*=L[<\%3L3'_
M  (5VZ(D2*D:JB*,!5& !1L7:5VC:<Y&.N>M 'B^AZC#9>"/AW)=2(- 6\E6
M^<G]VC_O/)WGH%#D'G@$*:?J5_:QWGQ ET>2.6'[3IUQ<+9%7:2W 7SRHY#<
M;L\$<G->QF"%HFB,2&-OO(5&#]12I%'$"(T5 <9VC'08_D* /(]=ETN?P_XA
MU[PEJ]UJ=U-811W9M=@C6$2+G(15Q+Y9DQW !Z<5JIJ/AVZ^*'A:XT>YL&CE
MTNZB5K=EY&8BB<=,#=@=>M>CQ0Q0)LAB2-<YVHH S^%-BMH(<>5#''C.-J@=
M>M '&?$B.UD'A87PC^Q_V[%Y_FG";3%,/FSQ@D@<\'..]4=)\+Z7?>(?%^GV
MEK$OAN]MX(I(X0!#]IPX<Q@< A=F2.^.XKT1T25&215=&&"K#(-4M3M+V72)
M+;1[N+3[K $,S0"1(\$9^3(SD9'7O0!R'@D7NI306NK6^)_#*M8F0IA9I^@D
M7_MB%/\ VV/I4_Q*%I'!X;N;P0K!#KEL999@-J(=P.XG@#..O%=3I.G'3;+R
MGG-Q.[M+/.RA3)(QR3@=!V [  =JNLBNNUU##T(S0!Y-J$.BZCJ_Q(>=+.=8
MM,MVA\P*1'_H[\J#T/3GJ.*2/6K2"\\,2:]J9M=+N_#T207<@C:(W''FJS.K
M $KM].A%>KF"(DDQ)D]?E'-#V\$D7E20QO'G.QE!&?I0!C>#K&QTWPK96FF3
MW4]A&&%O+<D%F3<2"" /E_N\?=Q7*_#:ZM_#-E?^%M7N([34;.]FD03N$^TP
MNVY94)^\#G!QT(YQ7H]13VMO<A1<012A3E1(@;!_&@#@_'ZMJ5KH6NZ?')=V
MNBZO#=3^4NX20CAW3'WMN<\>A]*M>/\ 4[35? M[INESPW][JT/V>SA@D#F4
MN0-PQ_"!\Q;H *[?I44=K;PR/)%!%&[\NRH 6^I[T >9:Y91VOC7X?Z*VIM;
MSV^GW=N9XI KJ1#&H89]=IQD<UI> +NTT-M1\.ZKY-MK]O*9KF=W.[44/W;@
M%B2V0,$9^4@CCI7>M#$S;FC0MZE1FE,:,P8HI8="1R* *^G:C::MI\%_87"7
M%K.NZ.5.C"N,\=W,$/C+P*LL\:-_:4APS <>4PS^9 _&N[1$C14155%& JC
M I&BC<Y>-&/J5!H XKXA?9)=3\'6]V8C')K*[HY",,ODRCD=QD@?CCO7)7MQ
M%I<7C.*P 33+77;.:[ALU4[+<I$9B$P01D'(Q@X.>]>QM'&Y!=%8CID9I%BC
M4DJB@GK@=: .1\))X?N=<U'5M"U>746NXHQ=/&8_(#+]WA%4>9@G/<#&<<4[
MXI2QQ?#'Q!YCJFZT95W'&2>@'O7610Q01B.&-(T'\** /R%*Z)(,.JL/0C-
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MWMKN&;46G2$2Q@8:'=O5L$X^Z<=CZTD/BW39K*]N2)X_LEZ;!XG0;VGRH"*
M3N)+#%<K'HGB>Q'A;4+F&XU>;2KN[#QM-&+@V\BLD99BP1G V[N?SZU5?PQX
MF?3-4GBL(HM0A\1_VS9PO<*4N5 4;"P^[D!N2!VH T/''B1;SP/XIBM'O].U
M/2HD:1=_ER)NP5(9&(((ST/UKI=-\3V=_K4FCB"\@NTMQ<I]HAV":+.TNG?
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M(P=JD2$ -M&<D \@GF@#M7\8Z;%=6*21W*6M_<?9;6]*#R99><*#G<,X."0
M<<$\51F^(NCP6EW=M;:E]DLKPVEW/]F(6!@5!9LG.W+#H"?;&*QO".A:QHR6
MNA7OA?3W6QD CUO=$1)$K95MGWQ)CCTSSGL:]]X<UZX\$>,M-329?M6J:G+<
M6J&:+#1L4()._ ^Z>/I0!V=EXJL;S6I]*:"[M;B*W^U*;J+RUEAW;2Z\] <9
MS@\CBHD\8Z<;ZQMI(;N%=1C>2QF>,;+D*NXA<$L#MY 8 GM67JFB:AJWC8W1
MLIH;"?0I]/><O'F.21U8?*&R<!3T[_G57PA8:S90V5CJ7A*PMIM/0(^I1/$P
MN JX!C ^8,W&=V .?I0!IV7Q"TB^33)8[?4$MM1N#:PW,EN5C$NYE",<Y!)4
MXP".QP>*LZ3XEGU/Q;K6CG3IXHM.,2><Q0@EE+9.&S@C;CCZXZ5R=IX<UZ'P
M3X;TY](E^UV.MK>3H)HOEB$[R9!WX)PPX]<UTNDZ=J5AX]\0W<EEFPU(6\D=
MR)5PICBV,I7.[.<=L8[]B :NI:_;Z=?PV @N+J]FADG6"W5=WEI@,V6('5E&
M,Y.>E9[>.M'\C19XA=S1ZRI:T,5NS;L(6P?0X!&/Z<U%X@M];G\2V2Q6#7NB
M-;2)+&DZQ!9RPVM+D@M'MR,#=SU4\5S6A>'?$%EIW@*"YTAT;1I9?M6VXB;:
MIB= ?O<Y+9P,\>_% '76OC/2[K2KB^*7,#6]W]ADMIH\3"?( C"@G).Y<8..
M<YZUDZ%J-S=?%#7+>07\$,>G6SBUN9-RHY>3+* Q7! 7H>WJ*Q+SPQXB>34K
M^UTX_:(?$D>L6T$D\8%U$L2QE,ACM;AB,\=*Z'1K;5YOB!?:U<Z/-965SIL$
M"F::)G5T>0D$(S?WAT)_H #L:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^=/T[PQ:Z;XFU36X9'WWX3,/\,;  .P]W"QY_P!P5N5%%<0SO,D4BNT+^7(
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MY_8&F?;I[[[.WVJ>(0RRB5]SH.BDYZ#)_.J@\&^'1'8Q_P!DVY2Q#"V4@D1
M]5&3]T_W>GM0!P&FWVHZGX:^'4L^JWXFN[M[>Y>.X93,@CE^]ZGY!SU[YSS5
MR*\;3M/\5:7)J^HQ6]OK,%M:,)6EGQ(L+>2KNV1N+,N2WRAB<\5VL/A#0+:.
MUCM],BA2TE::!8RRB.0]6&#U[9]..E+-X2T*YAOHI].CECOG$ERKLS>:XQAC
MD]1@8/48H XAK[7+:V^(5I97(MKBRBAEM$DNC(MN7AW-M=\8SC..@)K0\O4H
M-:NM9T]-432[716D%K=2RJ'O!DJ-C'+';G<>F<=3FM37/!EF='U!=#TK35O;
MN..&83J0L\2L-R%@"02N1NP3D@]JI^&_!\=CJUOJ$.@0Z&82V]8-0>;S@5*[
M"N NW)#9/.5' ZT 5O#UM=ZE'X=U^+Q$/(NH=MS&LLC_ &PNF2,%L(ZL"?E
MQ@C@"N=@-\/ ND:P-9U7[>FO?91*;QV!B:\:,J5)*M\IZL">!V&*](TWP=X=
MT?4)[_3M)MK6ZG!#RQ+M//7;_=S[8IP\):$-/2P%@HM$F\]81(^U9,[MP&>N
M><^O- '#ZKJ5[X4O_&D6GW=Y)#;Z5;WD0N)WN##(S2*[J7)/10V.G'2M&?3K
MJ".YU*U\1'[%=:5*4MX+B5S*RKN6='9R5(X!(X.1GM78+H6F+J$]_P#90US<
M1>3-([,WF1_W6!.".3Q[FJ6G>"O#>D6]W!I^D6]M'=J4G$>1O4]5SG(7V'%
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MD7( )&<@$D8]<UYVT<O_  A7C'PUJ5O+)K-S=7;6\90DW9E.Z&1#T(!VC/\
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MA8L_ESKNDP1RI52V>G)K4U-XAXM\8.B_N9O#\4:LJ';(X\[Y0>C-AEX'/(H
M[6U\2Z'>W8M+75K*:X,(N!%',I;RR 0V,],$'\13QX@T=K6&Z&JV1MYI?)BE
M$Z[7DSMV YP6SQCUKS_35CAG^%H2(H;>TD2?$9'E%K;:0_'RDN,<]363+<&#
MP=+H[6MXU_:^)A--$EK(VV,WOF!L@8(*D$8SG\#0!ZO<ZYI5G=BUN=1MH9]R
MKL>0 @MPH/H3VSU[5E1:MJ!^)-QHLDL36"Z4EW&JQX8.92ARV3GA?;K7">-;
MIKRS\86L5C=VLXN+:00PV;L;Q5\H^<[[2, # "X(V<Y)Q75VTZS_ !=DG59!
M%)H,:*SQLHW><S;>1PVT@[3SB@"WXZUS5-!LM,FTQ[97NM1@LG^T0F0!9&V[
MAAEY%5K3Q==:?XTOO#FORV(CAT]=1COX@84$>_85D#,VTY[YP1V%5OBF!+I.
MBPA9'(UFTD=8@Q98U?+-\O( '?M6IJNBZ5IWAO7KVTMP;B\LI!)<,[323?(0
MJ[F)8CD #/?B@#4M_$NAW:3O;ZO8R+;HCS%9U(C5QE"W/&>WK5FSU2POXI9;
M2\AF2%BLI5Q^[(&2&_NG'/-><R6LEMX(\"ZC:V;-;Z?+9R:E'%"?,"+$5+,H
M&X[';<1U')[5)K=A'JNJ>+]6MWG&C7'AX6T\MJFXSS#S#E!P'*I@>GS8SP<
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M:C8(ME]GUZQAV3@^=E0^ 06B;#D@=#SUH ](LM1L]161K.YCG$3^7)L;)1L
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B_V ?\
MA,1XA^UG>+/[%Y'EC;LW[\YSG=G\,=N];5% &1KFAR:TULG]JWEI;)O%Q!;E
M0+E& !5B02!UY4@\GV(UE544*H"J!@ #  I:* "BBB@ HHHH **** "BBB@
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M #X4*1(. 0,K[TZ3PYK']K^+KE5LVBU>RBM[8M.P8,B.F7^3@'?GC/2NTHH
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MV@@,I/../>I=6\+ZEK,VM:F\5M!?7>C/I5M 9B50,6+.[!?4C@ \+[X';44
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MXY'U'(ZURMCX8URW\02:FMCI%K#-H_V%K>&X<[9 [,#NV#=DMR<9^O6N^HH
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M&Z0;/E?9GH2":ZFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*W%R9I+XJCJ0A &(R0?W@_(\U9^&.IQZKX%M+F/3?[._>S*]LOW$?S6+[/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%NK>683K;2[1LD6/'*_WBV3T&.>HH ZJBN8MO$^CV-IJE_=>(EN;2/4# 7=
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M4M0<F)220#UYYY )YS@FO/K7^T[#PM<E=%NY&;Q-+.^ZQ9Y88'F9Q/$C+\S
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M<E-Z@D89&7(RK#@X(-6[1=<G,8U#[%;*A#-]DD>0RX[?,HVCU'S<<9% '*>
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MJ%>1U&T'/Z4EKX7U*YMM!L]:N+6:#19DGCEAW;[EXT*1EE(PF-V2 6R0.@H
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MF%OM2Q[MPB+9V[1TS@G'''9R^$+FY\2Z;K-XME%>V,TC->VNY9;J(JRK%(,
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MSU[8[@ N)!#_ ,+EG80H#-X>4R?*/G_?D<^O'%.^%\:1>#/+C4(B:A>JJJ,
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M&XS@\9J>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"SM;K[9$OFC*R[S(#G&3\Y+8Z<U+>^#-*U&XU2:\-Q,=4MEM;I6DPK1KG;@
M#!!)((]:W);B"#_731Q_*6^=@.!U/T%'VJW^S?:?/B^S[=WF[QMQZYZ8H YY
M/ VEI=&[-QJ+W369LGFDO'=GB)/!SP3R<<<9SUYJ6'P=IT"Z(J378711BR'F
M#Y!MV8/'S?*=O/;WIGA_Q'-JVM^(;2;[)]FTV6)89H&)#H\0DR23COV]*W8+
MVUN8&G@N8985SNDCD#*,=>10!A6O@;1[+69M1MC>1B:?[2]FMRXMC-G/F>5G
M&[//ID XR!36\":,==GU:,WD+7,@EN;:&Z=+>X<?Q/&#ACZ]CW!KH8;F"X+"
M&>.0KC<$<'&1D9QZCFD6\MG\S9<0MY8R^'!V_7TH P/B#:7.H> =:L;.WDN+
MJYMFBBBC7)9CT^GU-6=+T.!!:WTDMW+=16WDP-<D;K=6QN"C Y^49+9)P.36
MI)J%E#$DLMW;I'(<([2 !CZ YYI;F\M;-5:ZN88 YPIED"Y/H,T 8(\#Z2OA
MM-!#W8M(I_M,+B8B2&7?YFY7Z@[B3WZTZ+P3I,4NHS"2^,VHQ1Q7,K7;EF"?
M=.<_>Z\]1VP.*WY9X80IEECCW9QN8#.!D_H"?PIT<B2QK)&ZNC@,K*<@@]P:
M *%CHUO97T]\9)KB]FC2%[B8@MY:$E5^4 8!9CTR<\YK+U/P-HVK7FIW%Q]K
M7^TX1#>1Q7+HDNU=JL5!QN X]..E=%--';P233.$BC4N[,<!0!DDU@>#?%4?
MBS2I[K[.]K/;W4EO-;R<-&5.5R/="I_$T 36_A6RM=5AU*&XO!=0V?V)&:7?
MB+.[!W Y.X Y//X<50>R?PGHMMHFB:-=ZI;SM*@$DJ%("V6)D+$'868YQD]?
M85TDE[:0MMENH4.\)AI /F/0?4^E+-=VUON\^XBBVKO.]PN%Z9Y[<CF@"KH6
MD6^@:#8Z3:@"&TA6)2!C.!R?J3D_C4.H>'[;4=9T_599KA+FPW_9_+<!5WC:
MV1CG(XYS[8K1^U6Y:-?/BW2#<@WC+CU'K2"[MFBDD%Q$8X\[V#C"_4]J ,NT
M\+Z?:G5AF>9-69GO(Y7RKDKM)& ,?* ./2J=CX$T>PN=,N$DOY)=-C:*W,UV
M[8C; V$9P5&T<>W.:G\3Z^^E^#=3US2FM;IK2W>9=S[HVVC)&5Z_G6Q;2O<6
M$,WRK))$K=. 2,]* ,+1? ^CZ!>>=8F\6%79X+1[IVM[=FSDQQDX7J?IDXQF
MFS> ]&FTS4=-+7BV>H3F>>);AMH8MO(7/W06Y./Y<5@_\)]K46B:]K,FE64U
MIHFH36=Q''.RR.L9 :1<J1T.=I].M=O;ZO8W%C;W8N8TBN(DF3S&"G:^-IP?
MJ!]: *=WX;M+K4X-46>YM]1AA-O]JA<*\D9.=K@@J1GGIP>F*C_X1'2UETEX
M1-!_93N]JL<G 9P0[-G)8L&;).>I/7FM=KRV2Z6V:XA6X896(N Y'J!UHN+N
MVM0IN+B*$.<+YCA<GT&: .?F\"Z3<6E_;RO=L+V\6_D<3;72X7&)$( VD;5Z
M<<=*>G@G2D;5662^WZK (+MFNG8R*%VYY)Y*\9ZCMBMZ:ZM[<9FGBC&"<NX'
M &2>?2FR7UI$T*R74"--_J@T@'F?[OK^% $=A91:3I<%E"TK06L0C3=\S;5&
M .!S@#'K7%^"?##/X?-OK$=]&!J,]T;&?B-B9V>-NF2,;3MSC(Y&:[B6]M8)
MDAFN88Y7&51Y &;Z ]:&O;5+D6S7,*SD B(R ,0?;K0!SM[\/]$OSJ0E-ZL6
MH3K<S0QW3K'YP*GS H. V57\JTK+P[:6&MW&K0RW)N;B%() \FY61,[!SZ9/
M/4Y.2:/%.JW&A^&-1U:VCBE>RMWN#')D!PJDD9'0\=>:P!XTU"QN/#?]JV%M
M]EUYDCBEMI6+0RLNY596'(/3(/'I0!T.D>'['0Y;Q[+SU%W.\[QO,S(KN=S;
M5/"Y))XIEYX;L[K6/[6BEN+2_,/D236SA3+'G(5@00<'.#C(SP:TKB\MK4H+
MBXAA,AVIYCA=Q]!GJ:6:Y@MP3-/'& I<[W PHZGGL,B@#'N_".EW-EIEDHFM
M[;3)DGM8X'VA9$SM8YR6ZGKG.><ULRP)/;/;S#S(Y$*.&_B!&#G%(;JW6V^T
MM/$+?;N\TN-N/7/3% NK=K;[2)XC;[=WFAQMQZYZ8H Y^+P/I<%CI5G'/?>5
MI<RSVFZX+E&52J_>SP%) '3GI3KGP1HU\FL1WB37,>KLCW2R2<%D ",N,;2
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M-S>M/I:N+=WGWGYQARQ.=V1QST[8JI/X!T2ZTR]L+@7,L=W>&_9S+AX[@_\
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MZT >-7>H6I\/_%2$7]O,703*8P$1]]L@W*,G@GH<G/J:]<TN6-]&LY4D5HS
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MGC'4&O./##7$-Y;:.[6&M6<FCRC3M4M5VR" ;/W<Z#(R?EP>Y!XSFO4 H P
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M0-Q]33D140(BA5 P !@ 4 +1110 4444 %%%% !1110 4444 %%%% !1110
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M<GH>* )?!_B^"P\$V5[J]S?3F[U6>TADDC>1\FX=4#'^' P,'TP/2MMO'NF
MZA%]BU4W5@ T]L+-O,$9!(D Z;2 >^>,8SQ7*V^@:^GA'3+)]%F%S!XD%^Z"
M:(_N1<M+NSO_ +IZ=<UO+I^J)XO\47_]ESFVO=/@@MW#Q_O'029&-V1]\=<=
MZ +\NNZ1?:SX9>.]OMU_')/9+!O6&=#$6/F<8.%Y /(..*A;XAZ(L<LNR_\
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MB9 &@D,BJX;G!.#Q@D$D<XKF=,\/>)]%T3PY>0Z-YEWHE[>"6P%P@,\,SO\
M-&V<9 *D X)YZ=^B\1VNN:YX>LKI=(:.XM]5M;U; 2Q^:8HY%9@6W;-YP3C=
MC&.<T ;*^*[$_P!KJT%TDNDQ)-=Q-&-RHRE@1S@\*3@'MZU!=^.-(M%TLE+V
M9]4MC<VD<%J[M(H0/@8'WL$<=>><#FL"^T_7(M:\520Z)-.FN:;$L,B31A89
M$C=&1\MG/S#!4$']:6QTC68KWP \NDSJNE64D%ZWFQ$1,T*QC^/YAE3TSQ0!
MK)XDTD:Y=732ZO'-%I,=U+:20R!$A+$AA'C_ %G4'&?NX/2K&F^-])U2]TRV
MA2\C_M.#S[.6:W*1R@*'*AC_ !!3GTX/)K*U?3-5E\9ZS?0Z9-+:SZ!]BBD6
M2,;YM[MC!8$<..2 .M5+'1=9A7X=+)I4X_L> QWQ\R+]T?LQB_O_ #?-Z9XH
M Z*^\:Z1I\=Q/+]I:TMKH6<US%"71)B0-F!\QY(7(!&3C.:V9[^WM=-DU"X<
MPVT4)GD:12I1 -Q)!&1@=NM>7M!/))K$!\.:M>:!<ZN]Z18S6[QRLC@DC<X?
M!=-Q4=^ <=?0]3GO;[PI=7&AA'O)[-GLQ,,*69<KD'ZCK^- $%EXLL+VZ-MY
M-W#/]C%]&DD63+ 3C>H4G/./EX;D<53T_P ?Z+J;Z7Y"WJP:H2EK<26S+$[@
M$[-Q_BPI_+'7BL/1M-UJ#QC9ZS+H5ZD3:,]K.UQ=122^=YBMS\Y&#@@8X]E%
M5-.\/Z[;>$/ UA)I$XN=*U%)KM!+$=B*L@)SOP?OCI[T 7_'_B;/A:YDTJ6_
M0PWT-O\ ;;8[8]_G(KH6!R1C<I.-N>,YXKT&O))-"\36WP[N_!XT.>ZGM[Q7
MM[R.:(17$7VI9<G<P8-C((([=:]91BR*S*4)&2IQD>W% #J*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBL'Q;X@/AO3(+UEVV[7"Q3W+1-*MLA!/F,JD$C("]>-V>U
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MCM!!8DLH R.I/;!Y3Q1-K<EOX6.I6=K'J$?B5(X_+<^7*@CFVOW*@C!V\D4
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MCL* ._M=2L;VYN;>UO()YK5@LZ1N&,3'H&QT/'2K5<=X: 'Q#\;_ /76R_\
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M6?'XX>;4-5L(?#>KR76EI&]U&K6Y(#J67'[WYB0#P*ZJ*030I(N=KJ&&?0T
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M<;7!N-ZA2S?/P< =.^?I5^+7UD\7S^'C:2I)%9K>>>S+M=2Y3  .>H/7%;%
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MZMJL.J7^D6MQ?0X"3.F3QR,^N.V<T <S;RMXGUOQ-I-]JMQ;3V4%NMK);RM
M8U>$.9U4$9.\GKG 4#US"=-AUKXE/;S7MW)"_AJW)F@F:!Y<S288E,$>N!@>
MU=;JOA/0-;OX+[4])M;JZ@&U)9$R<9S@^H]CD58;0].?4I-1-OB\DB\AYE=@
MQC_NY!Z=\>O- 'FUA?ZAJOA?X;7$^IWRS7MQY-R\5PRF9?)E/S8/)^4<]>X.
M>:CU>:[T_P &?$*SMM1U!$TR\4V<ANY#)$&CB8KO+;BN6;@D]:]%C\*:'#!9
M01:>B16+E[5%9@(&/=1GCJ>GJ:)O"FAW$5[%-IZ/'?,'NU9F(G8="XSST'7T
M% &%-.-=\<ZSX?OKNXMT@TZ&2S2&9HF._>))1@C)4A /3\35#5)!,RV$&L7F
MI3VVA-*Q,Y@3&2!<LZ<ER5.W (X)R,Y/5ZIX2T#6S:G4]+M[MK48A:8%F4>F
M>I'L>*EO/#6B7]Y!=W>EVLT\$7DQNT8X3^[CH1Z ]* .'AO)]0MOA7>74IEN
M)R))9&/+,;-R2?<FNK\??\D[\2_]@NY_]%M5J+PIH4$5A'#IL426!+6JH2OD
MD]2N#UQQFKVH:=::K926=]")K:48DB)(#CT..H]J ..T;PJ^LV7A+4]3OQ)!
MIEI'+:VT$)C'F&( ,[%B6P.F-O-<TLVH:;X&\3>)8-1U.XU'3;R_@MA)=/(B
M1B4H"4)(;8/F!.>GH!7K%G8VVGV4=G:Q^5;QKL1 QPJC@ 9/ %5[#0]-TRWN
M+>SM$CAN79YH^661F^\2#G)/?U[T <M=^;I'BSPHVD7=S/:ZGYL-U').TJRH
M(BZR_,3A@1]X==V#VK&LK77-9L-)'GZB-476)1J5U#<2)#):B20,%=2%*X"!
M0O((Z#YJ[ZR\/Z=I2YTVUCAD2,QPEBSB)3SM4$_*N0/E7 X%<%I_P]D9%BO/
M#>FVFH#F35[2_D4F0\F5(U5<-GG;P!TZ4 7+:SFNO&GBYVOM3D&E36UQ:6R7
MD@3=Y&\J1GE6)^Z>.:;X82[U>R\,^)8_$:*957[6@:1Q=LZ_-&5+[596R1@?
M+@]!7<VNC:?9:A=7]M;B.[N\?:)0Q)EQP-V3S@<#T%4[#PCX?TO5YM5L=(M;
M>^F)+S1I@Y/4CL,]\=: .*TO4-0LM1BL=9>>WO;BVN7LM8BN6EM+P;2^]D)^
M1E7# $8P" <<5I^#KV[A\0'1]9LKNSU>.QWG_2FGMKQ%909D)/#9(R" ?F&<
MXKIK?PQHUM'Y<5B@C$;Q+&S,RHC?>"@DA0>^,9J>PT73]-D\RUM]CB,1*S.S
ME4'1%+$[5]A@4 <E\1!*VL^"Q!(D<IUD;6="P!\I^H!&?S%1>!5_XJGQ!)K9
M)\6J5CG_ (8VMA_JF@7LA[Y).X')KL-1T+3=6N+:XOK432VK;X&9F'E-_>7!
MX/OUIUSHFFW>HV^HSVB->VRE(KCD.JGJ-PYQ[4 <!X<-_P"(M(T+Q(/$"VMQ
M]K7[:@:1O,+,5>V9"^U>2 /EXP#ZUDW5M>R>#?%FM1Z]JT=_H^JWALF^VN54
M1N-J%2<."/EPV?;W]*@\)>'[37)-;M]'M4U)R6:=$ 8L>I] 3SD]3DUB^%?"
M?V9]7EU>P DN=6FOHE\[<C*S[D+*#M+KCN#CC!H KZ;//XG\5>(=,U62YMC9
M6UH((8)WB*>9&6>0;2,MN^7/.-ON<\[I=UJGB)? 2ZGJ-]&U_#?Q71M[AXA<
M+&I"/A3P2/FR.>:]-OM!TS4KM+NZM%:Y6,Q>:K,C%#R4)4@E?]DY%$N@Z7-=
MV5T]FGG6*[;5E)7R1C!"@' !'!QU'% '(>%-)MK#XD^)HTENG-O;6"JTUU([
M/F.0$OD_,>._3MBM'QM+/;ZCX3D@N9XO-UN*"58Y659$,<C%64'!Y4=?2NA_
ML;3?[8_M?[%#_:'EB+[1M^?:,X&?Q/YFC4-'L-4DMGO;<3-:R"6 EB/+<=&&
M#P>O/O0!Q%[?WNF>*A)JL5S-IEUJ<:6FIV5RQ6!MRH+>:+(PNX$9&1D@GFMO
MQ]J\VDZ/8"*9K>.]U*VL[BX1MIAB=\.P;^$X&,]MV>M:Z^']*6\:Z%HOF--]
MH8;VV&7^^4SMW>^,U:O]/L]5L9K&_MHKFUF7;)%*NY6'N* /.]2L(K#QYX@6
MUEN4SX7\Q<7#ED82R8*MG*\@'@]<GN:EL-0NGNOA@[7]RSWMDYN09V(GQ:;L
MN,X8[N<GG-=?8>%-!TRZ%U::7;I<"'R!,06?R^?ER<G'/Y<=JCL_!?ANP>W>
MVT:U1K9S)"=F?+8^F>GL.V>,4 <=HK7_ (DTNSUY=?2QO+?4F%TNZ1B,2E3;
M-'OVX(V@#;GH>IR?3%='+!65BIPP!S@^AK'3PCX?CU]M=32+5=38[C<!/F+=
M-WIN]^M7[/2['3YKN:TMHX9+R7SKAE',CX W'\ * +=%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 445P7QF4#X5ZS.!B:$1
M-'(.&0F5 2#U'!(H [VBO"?$2S^&_A!X7\7Z'<266JP0VK3O&Q"W*N@W"1>C
MY.#D\]:[:[^)<EMJGAS3XM#DNI==L!=P>5.%(8H6V$,,=<#.>!D]J /0**XF
M;QSJ-O!IT-SX<EM=2N[6>ZDAN)R(8!'GY6F5&&2!D<#KSVSQWC_QU=>(?@<N
MO:1')91WLHAG_?8DBP^TJ"!\P)!&<CCZXH ]GHKR WNI^%OB#H'AW1=,MH(]
M5,VI7,'VY]DDGE."@.SY$!&[ 7D@=,5WOCR-)/ 'B N@)CT^>1"1]UA&Q!'H
M0>] '145X;\.H=$\0>!]"T2\LIFU6]BNI#J!@=639(VTB7 WD97@$\#!KH4U
MVSTSXF>-[J/3KA]1L-+2XF+7Q,,L:(K *FSY&P1ZC.?4F@#U&BO-])^*SZA>
M^%TN-!>UM/$/FK;S?:@[*Z'!!4+T)(YSGGI5CQ-\31X=_M>7^QI);729H(;A
MY93"TOF=X04(?'^\/RYH ] HKRJ^N1+^T)X<D@9EAN=%:5E!P'_UF"1W.,?E
M6Q\9E ^%>LS@8FA$31R#AD)E0$@]1P2* .]HKYZGO5O;#P+I_@R62/Q:L5O+
M>>2&C'E>4I9ILX#@D@\YR,^O/J'B+XAVVBZOJ&FV]M'<SZ;8&^NO-N1" O4(
MGRG<Y&3C@=.>: .UHK@6^)3W/B72M&TG1Q>-JNFKJ-K,]UY2["&.'&T[?NGI
MFH(OB[IS>"9=>FT^6*\BO?[.;3_,!8W/90^,8QSNQV/% 'HM%<E9>-O/UG7-
M#N;%(=7TJW%R8DN"\4T94,"K[01C(!RO&>]9/AWXD:IXHTVTU'3O"<WV*9)S
M+<RWBA(GC!*K]W<0V ,@<9[X- 'H=%<'\*?$FL>*_"QU75(H0)[B5HY$E)/W
MR-FS;\H48 Y.:E\4_$%O#UQJL46D/.NEVJ74TD\IA20,<;8VV,&8>A(].QP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KRCX[>*++3?"3>'KA9!/JR@I*!E4$<B,<]R>U>KUF
MZWJ6E:/8-?ZPR1VL?WIGB+JF2!R0#CDB@#YLN_B+H>O^$M!\+:NUY;:7IJQ"
MX:TB$DEUY:[0!N*A!W_B[5I:I\5?#5Q\1?#6OV5O=QZ?H]N\'D-$ Y#*R_*
M2. 1WYQVKW>+5="FNH+80E);ABD0EL9(PYP6P"R 9P"?PK5^Q6G_ #ZP_P#?
ML4 ?.WBWXOZ5KWB;2KNTN+Q=)MHW$UG=6@=3(00) JR ,1D8R1@C(ZURS^-=
M*;X0)X+WR_:%NS*)_*P@3>6]<D\X[8]Z^LOL5I_SZP_]^Q1]BM/^?6'_ +]B
M@#YRUKXL:%?>./#?B>S6Z2738)()X)H05PZLNY2&^;&X\';G'45TGBCX\>%M
M7\+ZGIEG;:D)[RUDMU::)55=ZE<G#$\9Z5[3]BM/^?6'_OV*/L5I_P ^L/\
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M06XRP9B<MEQ@\]!GZUC>+_B5I_B77M8F6\N3IMUI_P!FM(;FTW-:N0-Q4"3
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MWR%LG=BF<;@ IRN>,]*MZ;>:%K"2MISV5SY3;)515W1MZ,.JGV- 'S)8^/\
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M %%,ED6&)Y7W;4!)VJ6./8#DU5TG5K+7-+@U/3IO.M+A2T4FTKN&2,X(![4
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M?VR*37+:S82VZI(D<C(KQR+M!5P2QR .".M2>(=5O9Q\0=)FF$EI::()H%*
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MM;J6VFCLI'$D6-W"\CD<9Z9'/H16#>6MZ?''A*"#466=M)O/])DB5F49AZ*
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M?A:QT!+Z_$%A-'/:S[T\V)T;<I!V8//J#71F BT$"3RH0@42Y#/]<L""?J*
M/-OA:=8D^'WAZW6RLGTJ22=+AVF9I#&7EXV%,?>P/O'BM/4?$.MV^H^.((KJ
M +I6FPW=EF#(0LDK$-S\V=@_PKI/#'ARV\*Z)#I%E<7,UK"6\O[05++N8L1E
M5&>2>M5;KP=:7=YKER]]?*VLVRVMRJF/ C4,!MRF0<.W//7Z4 8NEZWKL>O>
M%H[Z_BNK?7+"262$6ZIY,B1HX*D<G.X@YX] .E0V7B;5U\0>'H)KV.[BU*YN
M8+GR(A]F4HCNGDN0&8C8 3\PZ]#70IX1M4N]#N?MUZS:-"T%NI,>&5E"G?\
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M8:MK$5Y;26L,LRJ\,"[0JK*PV[5 /H20#U-=5I6FP:/I-IIML"(+6)8DSU(
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M:ZM)&CN&1($D7JGF.L>X>X#$TSQ+K&F^'[73]#>:2RM9X]C2Q1.WEP( "JE
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M,2!GC% %>7Q#J.D:_K^F:E=-*WV5;K2-L:*9 QV;.G+B0JO/9EXJOKGB/4M
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MP1QQFM"QT".UU!-0N;RYO[V. V\<USLRB$@L $51DD+DXR<"@#!\4_;'\?\
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M/0 =?<>M9?AS7Y]:N-:AN;:*W;3M0:S41R%PX"(P;) Y._IBL#QE;Z;_ ,+
M\&SZC#:>63>(\EPJX.(LJ"3[Y(]ZY+7;"SF\,?$G4GB1KRRU5Y+:8GYH'6*$
MAD_NG/<<G&* /:20,9(&>!0VX(2@!;' )P"?K7ENKS:7JWBGQ)H_B35+2P5H
M(6LGNE0'R#$,O"[' 82;SD<Y ]./1])3R]&L4,\\^VWC'FW Q))\H^9A_>/4
M^] '-Z-XKUO7K'4+FRT*RW65W-9F.34F!=XS@X/DXP>V:Z"WN-1FOH2]K#%8
MO:B1BTA\U9B1\FW&-H'?/7M7 > ='&J6FM3KJ5W$(O$UQ+Y44@\MMDX?!&.^
M/6K^J6]NWQ3O4=5Q+X9D,@)Z_O@,_D/TH [_ ""<9&:-PW;<C/I7COA^QL[+
M3_A=J5O&L=]<D0S3@_/(AMG)1CU*Y P.@QQ3-1U'3&O;'4;2X@@9?%BI+)<2
M@W1_>%),GC9$!P%.?EVY(Z4 >D:5KUQ?^*]=T::UCB334MVCD20L91*'.2,#
M&-HXY^M0^(_$MYHFL:-I]MIL%TVJ3-!&\ET8@C*I;D"-N, U1\/NK?$_QCM8
M'_1]//!_V):J>/1O\7>!HUN&@=M1EPZ;=P_<MTW C].] &YX?\4KK&J:MI%U
M9M9:GI3H+B'S/,0JXW(Z/@9!'J 1Z5T&1@G(P.M>:>/?"VGZ/\._%]^))[J_
MOHEEN+NY8%W*X"#Y0   <  #K5C5=.T[1?&'AJTCM8X]&U.>XDNBQ+1SW?E*
M(O,SP20&(SU89ZT >B Y&1TI 0PR""/:O)-4BN+#2_'EK9W<=IHT%Y:&U#OL
MB#ML:>!6Z*K$A<= 7.<#-:NGZ;IFHZYX@UBV^PI9RZ<D2VL,\;L' ;?(1&Q5
M<@JO7G;]* /1@0>A% 8$9!!'K7C-K;6&B?##PMKB1B%;L64.K7F#)FWP?OC/
M*AR@(]..G%;3Z3I;:?K0T/Q+:_Z=<6C@(B-8I.'&U"J''[S #C/.0>_(!Z9N
M7;NR,>N:7.:\JC%Y?V,^G1V>FZ/KMKK*M):2?O+&^E^S9VC ! 9,/C&0R@]:
M[#P+=I=>'&5=,_LR2"[N(9K57#HDHD8OL8<%=Q./3IVH JQ^+-8N=?U[2;/0
MK6:31Q"SDZ@5,WF(74*/*QG (Y(&>];'ACQ%9^*_#EGK=BLBV]TI(60892"5
M8'Z$$5YU?6&KZGXR^(T6@ZB]O>HFGD0J5 N!Y)S&6QN3(R RD$$U<O=<TF+X
M6Z9/H<7V'1[>[@@O[<*6:TB$F)4D7J<-][/4$]0: /3PP(R""/6@$$D CCK7
MCWBG3M%C\$^,;S2-6BO8[BSCEDALM@MXG!PK )P'8=?4 $]JVKG1XM'^(>D7
M?AB,"6\T^[DOU60LLZA5,4CDGDF1L;CR>?2@#T?(SC(SZ4C.B EF"@<DDXQ7
MD,.+OX;>'M9L/^1H6_@1IL8GDN#*%GCD/4C&\E3P OH!6IX>\-Z-J>L^,);N
MQBN9+35Y# ),L(\V\8.!TYR<^N!Z"@#T/3]0MM5L(;ZSD$MM,NZ-QT9>Q'M5
M@D @$@$]*XSX4BQ'PXT7[&+<2&UC-QY(7._'.['?Z\UD*EGJ\OCV#Q"L8O+2
M9C"\O#06ODJ8GC/\/S!VR/XLT >ED@=30#D9'2O*-.L7U7Q+X+7Q% )KRX\/
MS&\BF_Y:,##PZ]#U.0>^:Z7X8X3PC);H?W-MJ%Y!"N<[(UG<*H]@,8]J .QR
M,@9&3VH) ZD"O))O*U/P/XSNM1 3Q%8WMT4EZ3PR*<VPC/W@"-@7'7)ZY-7Y
M-$M-<^(]K::_:QS2S^&EDNH"Q"M*)E!. >QZ?0>@H Z_Q?KUQX;T!]3M[6.X
MV311LKR%,!Y%3(P#G!8<<?6MT$'.#G%<;\4PH^'E\&.U!/:Y.<8'VB/G/:L'
M5-*;0/%FHR>#X3%))H%S-=10DE#.,>0Y'_/1COP>I - 'J ()(!&1UKF[;Q!
MJ6J7\ITNP@GL+;47L+DR2E)!LP'D7C! 8XV]3C.>U<QX4B\.:O?Z%JNGZS!)
M=&U>.6TMD0/,K)\PN1RQVL.K?Q'ONK$"Q:5X&\57NFVT403Q'/#=2VT85TM/
MM"^8H*\A0N>.PR: /9@0>A!^E (/0BN O;"V@\?6":/'"FG7NDW#:E%  L3(
MNWR7('&22P!ZD ]A7+Z?:V>C_"#0_$$,6R29+2+4[M0SM]E\T;PPSRHZ$?W<
MCI0![."&&001[55DU*V35$TP2H;Y[=[A8L_P*RJ2?098#\_2N9\)66C0ZWJ-
MYHVKPWB744;306006T;#(5L+P'8=?4#GM5.^M]-3XTV4UW#:*\FBN8WE5<M*
M)XPN">K <#O0!T'A+7IO$6BF^N+>.VE%U/ 8DD+@>7(R<$@9^[GH*W"0" 2
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M8W ?WC[XFU6PAMO&5U#I<<4>FW.@S27\,.%BW @1/@<!B-X![A3Z4 >C9!.
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M4+$H\P?[7'/XTEII6G6!4V=A:VQ5=@\F%4PN<XX'3))Q56[\0V-G<S0,)Y#
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M2>60EOND\!>!DXY8]AFO0ZJ?VII_V<3_ &ZV\DR>3YGG+MWYQMSG&[/&.N:
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M[C^U4CCB-K\N[(E#$YSC&!G.?UKHV@NS\3HM5%C<_81HK6YFV<"0RJX7&<]
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M[%=26;:-!:13X!\V2,R$CKG.&')XZUI^ ;*ZTWP'HUA?6\EO=6UJL4L;XRK
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M,,5 &#D<9YZ4>(O!L_B&TN-.NKFWELW\LV\LT1:XM&4*"Z/GECMSVP2<YZ4
M;^O:S;>'M!O=7O-Q@M(C*P7JV.@'N3@?C6/-XDU'3-9TFQU2SM@NK*Z6\D,C
M8BG5=WEN2.00#AP.H^[6OKVBVOB'0+W1[PM]GNX3$S*?F'H1[@X/X5DP>&]0
MN)](FUB]M[J32 S0-'$5\Z4H4$CY)Q@$\#N<YXQ0!'X/\1ZUXFM8-1N-,L[7
M3Y!,I*7+/()$E*  ;0"I"GG.<CI23:IJ_P#PM*'2D>W&G+I37)0ELDF5%+'M
MD8X^I]:O^#]!N/#7AZ/2KBZBN3'+*ZR1QE,AY&?!!)Z%B*2[\/W,GC2U\06U
M['&J6;6<\$D)<NA<."IW#:<C'(/!H R;7QM>WTFE7=GI$]UIFH7 BS%;S;X8
MVSMF9BNPKP,@'@'J:MVWB35-3@M]2TK3([K3);XVI7S=LOEJYC:?GC 92=O4
MCG(/%5_#WA+6O#[IIL6O1OX>@E,EO ;<BX1=VX1>9NQL!_V<D<<4:-X1U?0[
MN>SL]<C'A^2Y>Y2V-N?/BW-N:)9-V A)/.W."0,=: .<BUB_\+S>/=2T[3K6
M:ULM2$]PLDIC)3R(BP0!3\V,G)P/KGCJ+OQ+K$GBN70M,TZR=O[.6^BGN+AE
M4AG*X8!21TZ#/U'2JMWX(OKO3/%EF=1MU&OR%]WD-^X!C5,?>^;A1Z<UH6WA
MW4+?Q4-;-Y:L1I::?Y(A8<JQ??G=ZGICIWH RT\8#5-)\&ZH^C6SIJUXD7[Y
M]S6LNQSN3Y>?N,,Y!Y]ZT6\2:I>1WEWHNF1WMM9WQLWA,NV6;:P61E)^4;3G
M@_>VGIQ6?9^!+^TT'PQIG]IVS?V'>_:_,^SL/.P' 7&[Y>)#SST%6+7PCJ^E
MZQJ/]F:W'#HVI7+7<]N]N6FBD?\ UGE2;@%#'GD'';UH /%7C*\\-IJ-T]E;
MBULEC9%FEQ)>@XW^6!TV9ZD')].M):1QI\9-19$52^A6[,0,9/GR\GWX%5]>
M\":EJ\GB6.+68([76XXP1):EY82B@!5;<!LR,XQW/KFMBR\/W\'C&37KF^MY
M?,T^.R>)("G*NS[@=QQRQ&/3')H DU_7;G1-4T6/[/$UA?W8M)9V8AH78$IQ
MCD,1MZC!(ZUEV/C*[O%UZW^SVG]H:;?I9Q0K(Q67>0$8G' ))!ZXV-UQ6YXG
MT-?$?AV\TLRF"25089@,F*52&1Q]& -9]OX+M+7Q/8:Q#,X^S6?V9XS_ ,MG
M!.R1CW8!Y?J7]J $E\1ZA=SZS%H]K;7#:/M282N5\^78',:8'RX! W'/)QCC
M-9@\>7^J3Z+'H&F6TZZQI\MY ]U<%-C)MRK@*<8+8R,Y/H.:TU\,W^GZ[J]_
MH]]!%%JP5YXIXBWE3!=OF)@C.1C*GN.O:H+'P2=)U?P]-I]S&ECH]E)9K#)&
M2\H?;EBP( .4!Z=S0!A:/JKZ=XZ\66-M!:G6;R>T:*T\S"$BW0R,3C.U<\G&
M3D<9.*]'!G%MDB-[@+TR54MZ9Y('X&N'U+X?76H:KJ^J)J<-O?W-S!=6-S'
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MKVXA:TO=)_LN:V2,AMI9F+!L_P"V1C% $6G>*=3NM9TVWET>8V6H0L_GQP3
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M)S47ASP_XCTB*&TO_$$-]962;+4+;&.1P!M7SFW$, /0#) )- &-%XQUO5/
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MK*%!Y!!4C:,'F@#$L?'\\L1L+W3A;ZXFH-I\D$9>:,%8_-\U=J[BA3D#&<D
MX'-;OAO6K_5A?1:AILMI+:3^6DIB=([E",AT#@'V(YP1U-8U_P" 99[<WEIJ
MOV;Q -0.I+?"'*>84\O84S_J]F%QG/>NDT:UU.WMV?5[Z*[O)"-Q@B,42 =
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MW/DS^=?0K!<N;J7,B*" #\W8$\CGD^M7M-TZUTC3H-/L8S':VZ".*,NS[5'
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M$#^;8$FU,<SQB(D8X"L!TX^G%6M1TZTU;3KC3[^!9[2X0QRQL3AE/;CFK5%
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MS;R.))AI(>:0?QRL(6=OQ8D_C6[:?$C5M4GN+W3-,DNK&WUG^SFMH;.620P
M#=,9!\H()!VXZ=>N: /4*,UY>?B1JU[=ZK<:3IDEW:Z;JHL#:0V<LLDL8XDD
MWK\JD$Y QT'/7ANC:CK^H?&SQ-8MJ=O]GT^UB2*-[8LHC<*^  XPV6&6.<XZ
M#C !Z18:E8ZK;?:-/O(+N ,4\R"0.NX<$9'<5:KPS1?'5[H?P2NO$6DZ7I%G
M-#J31FVB@<0L&903C?G//KVQBNMTGQOK@\=ZEH&J06EQ'%I U.'['&RL#\N8
M^6.[[W7CIT&<  ]&IDLL<,3RRNL<: LSN<!0.I)["O)-/^)'B6_L/"5]&NFJ
M/$-]-;&#[,\AME1]H((D!;@98G\J[;XB:%>>)?!&H:3I]RD%Y.$,1=L*[*P;
M8?KMQ0!LV>N:3J$@CL]3M+AVZ+%,K$\$] ?0$_A5^O(_"WCJXU'QAIFA>-M!
M?2_$MMO^QW*KB.;*$,/8$<\$J2HZ<"JMY\5?$5MX0\3:J(=-:YT?5_L" P/L
MD3=MR1OR#WZT >S45Y]KOB_7K7X@>'?#FGC3UBU>T>5I)X79HF5&;(PXR..G
M'ID9R.1;XK>*HO UUXA>+2B=-U7[!<1B%_\ 2!QROS?)P1_>S[8P0#V^BN U
M[Q9KUO\ $S2/"VF_V>EOJ-D\_G7$+NT3*']' 8?*../K7'K\6/%*^!8?$LD.
ME[;;5O[.N85B?,XZEE.[Y."!CYLGGCI0![?17G_CGQAK?AZYU!;>&UMK6WTY
MKJVGF7S3=3*<F,(&# !>2<''4D#KG:Q\2-9M]#\#ZG865FS:_-%%/;RAN"VW
M[C \=3U![4 >CWNI6.G>1]MO(+;SY1#%YT@3S'/15SU)]*M5Y)XUU'7M-M?#
M9\2V&@7T\VOI%$$AD98T/W'4E@0X^;KD=*T-6^(>K-K?B2RT.P^TMH7D*+=;
M629[MW)+C*<1@ $#/4\].* /2Z*\QU'XD7EMXZ;09O)TI98;>2Q^W6[8NBX!
M=2^X;&&=HR,;E.>PKTZ@ HKC?&/B35]%OX8+6*"WLI+663[=,!(3,HRD2QA@
MQ)QGC/7V)KDYOBEKLG@3PEKUK::>MSJ]_P#8KB&57* [V7<I#97[N><]?;D
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M0SY))1S#E,Y/09YX(P,6X?&'B>S\=:EXHL_A]X@BEU"%(Y[=D=D+(H"G/DY
MX&1W]17T910!\J)<>(D^'UQX/_X07Q ;6:[%R9_)DW@Y!V_ZK'4"MJS\6>*[
M/QLWB<?#_7&N6T\6!B\J0+M 7YA^ZZY4']/>OHJ6\MX+JWM9)56>XW>5'W;:
M,D_0?U'K4] 'ROX:\>^.M'U*)8O"D=[<QLQG8Z4PN903E]SJ-V3ZX].*[/7_
M (F^*];T]+:/X<^(;)TGCG6> N74HP88S 1SC'(/%>M>(]??0%TUQ9_:%O;^
M&R8^9M\OS&"ANASCTK;H ^>Y/'GBS4->TS5M8^&^K74NE[S:)#!+$ [@ LV8
MV).!P!@=\=,<IJ+^([ZVUVR3P5XD@T_5[W[<\"Q,2DF<GYC#DKZ#CMUKZKN)
M'BMY)(X_,=5)5-VW<?3/:N2MO';7.B^%M3&F%8]>N4M\>?\ Z@LK,/X?FX0^
ME 'D%YXM\57GB_0_$;?#[6UN-)@,"1"*3;)N4JQ/[K(X8X]/>L%Y/$<GA'4/
M#K>!O$'V>^U#^T))!#)N#X&5'[K&.!7U=10!\XW?C#Q7=^-]*\4M\/=:6YT^
MU-LL(BEV."&!)_=9_B/Y#K7.EO$;>#9?#1\#^(/L\NH_V@9?)??OVXV_ZK&.
M,U]844 ?,FN:WXFUWQ!?ZM+X(\3P&_TTZ=/#$K%=I'.W= 2HR <#G/?FH9=7
M\3RZ3X6L3X%U\CP].L\#M"_[QE(*@@1#CCZ^]?4-% 'SKXQ\9^*/%_\ 96_X
M=:Y:_P!G7:W:;4D?>Z] ?W0XJG)XF\6P>-+OQ)I'@GQ'IKWZ*E_ D32+-@8#
M+NA^4^^#W]37TM10!\V>(_$WB7Q.S07_ ,.M;DL#<13I&\4CRP[%4$1RF+*A
MMOS9!ZGIUJ_X?^('C;1-;UB]G\%>)]0MM0E\V.UN6E(MCEB0A\KI@@8 'W17
MT)10!\W^(?%/B;7_ !59Z[_P@?B>T:WM9+0PQ;F#(^=V-T!VDAL$@9P!TQ6*
MESXDC\+Z)H0\#^(3#I%\;V%VA?);<6"G$0XR3[\]J^JJ* /FB#7=>_M+Q3<W
MGPXUZXA\11A+F$)(GEX! *GRCR >_?%9T&H^+E;PU]H\'^(YD\/2%K-1;LN5
MRI 8^2<XV@9],<#DGZHHH \,U[XG^*=;T>;3Q\-O$%H9&1A/"TF^,JZL"N8,
M9^6LN[\=>+M7OM*GUKX=:M=QZ7<"ZMTC@DB9I0,*SMY9SC.<*%&<>F*^AZ*
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M+SAE!7/4 \50T'P9%9ZM;ZE)X?T+1YK<L?\ B5LS&;<I7#'8@"\YQ@\@<C%
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MI\ME;',$#VR%(_\ =&,#\* .&N]+TJ+Q+X!C^U2:A;Q+?0B\NY [R*D9(RW
M(!!P>X /-5=4U._T?2?B1<6$]R9+>^A"OYC.\,;1Q>8RDDD85G(],>U>FW.D
M:;>QVT=UI]K.EJP>!9(581,. 5!'!'M20:1IMK+<RV^GVL4EU_Q\,D*J9?\
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M?OJ/A[3M1G"(]S:1SR!>%4L@8XSVYKS2YN]+B@^(6E:T;6"]6)DLH)\+NM!
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M[FH)=0M(M/DOS/&ULB%S(K @@>AKE/&]R]IKGA.:[P-$%^XO6;[BN8V$)?\
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M##$1@Q(1DG&T=3U-+Y:?+\B_)]WCI]*IZ9J1U+3A=M8WEF=SJ8+J,+(-I(Z
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MX&2,=QZBL[6/%=IH]Q=P-:7=R]E9_;;G[.J_NH<L,_,PR?D;@9/R_3(!N@
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MNPS;N@W!\@D?*R@\>E=%6;J?A_2=:N;.XU*PANI;)S);M*N?+8XR0/P'7TH
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MI'F*@#J2<$ ISWYZ5Z910!YF_A7Q#)X+URR>Q@%[-KK:C!$MP")4^TK+C=C
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M=MVL1V]#ANX/8D5K!]3M?BG:VL<>G1+=Z9)<W9BC8&9DDC0%CW(4X7/3)_
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M]YO%-SHENUI%=6\\*_9+HE)9X7"%I8R3@A0S#: >4.2,T =;17-?$#4;_2/
M>LW^F2)%=06S,KN"=O')&._I[TBZY?-JUIX?B^RG4VL3>S2L&,<<>X(N%R"Q
M8Y[C&TGT% '354;5-/1RCWULK@X*F900?SK-\+>(3X@L[SSK<6U[87<EE=Q*
MVY1(F.5.!E2""..]<FI2+XP^(3_8\NH;M+M2RQ+$2.7Z[V7KTXSTH ](!#*&
M4@@\@CO2;UWE-PW@9*YYQZ_I7 ?"J5&M_$$:'[,BZI(R:4P(?3U.,(0>%S@M
MA<KSP>M8LOB6VMO'^E^*$U>WEM-2G?29;59U8Q0Y_<2;0<C+JS$GH) * /5)
M[VTM6"W%U#$Q&0)) I(_&GQ3Q31^9%*DD?\ >5@1^=<+\3EC\_P<\D'G >((
M1L"ABPV29 !^E0>!HEU/QIKOB33(18Z-,@LVLSA'>YC;YY'C'W"!Q@\D')H
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M'S<'^Z<<9Y]?:H+GQS(+JULHOL5M>W6FQ7MK%>,56[=\YBC?@ K@>I.X<=Z
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MU]:11S31_P!U7SC^7/U'K0!S-WX&O;K2?%5@=5MU&OS&4O\ 93^XRBH1C?\
M-P@].:TXO#EXOBZRUV2_@9;?3FL6A6W(W[F5BP;?QRHXP?K71T4 <(? -^/
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MAW/BJWLK31I[JPOX#JMQ';1Q21J'AD?H)!NXZ'IGI0! WAR^?Q+I&L-?V_\
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MQ8[N0#T%=I10!R$GA+5=:\/WNF>)M=6[:>$11R6=OY C((82$;CE]RJ>P&,
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M9(#,E^ACNVFD9WF4KMPS$YQC( [9XJM;^#]&M;G3[B*&X\[3XVCMG:\F8HK
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M85,?,<8/'3&O9>#+2^\.7&E:W!<SV4LXFAM[N\:>6VP!C$N=P.03PQQG )H
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M>:1\"X-1T_4;N"X%PHR),C!O"A R#C(8YQ@U[!)&LD31DL%88^5BI'T(Y%8
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MO"V_<I#90A@"-N.@J._\!^'=2O;>\N+.7[3#&(?-CN94:1.NV0JP+C/][.:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ5?7;F2:6QAFE?;RS&,$G ]\\"L$>--.UKPI-J,6J3:*GVHPI<RVYW?+,4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8&3@X!D\5&\T[QIX<US[)=7>EVZ7%O<"UA:5X&D"[9-B@L1\I!(!QGWKM**
M/*%EU"WL_$MQ%H%Y*EQXBAN5,M@SLD!6(&>.,C+,I0D#&0>2.,55U+3-2O-)
M^(MM;:9JLC7R036KW$+!IP(D!QGJV0?E R.F!TKV&B@#SG5[V>V\86^NSZ1K
MEQH]_IR6X^QQS+-;RI([#?$A#!6#]QP0,@5'?Z)%;VVF#1X-4\-WEK:RM926
MT#W$:JS[C#,@# Y^5MN>#G!XY]*HH Q]+DU$^#[62\T^)-2^PJ9+),!!)L_U
M8[ 9X]JX#13>R:_X*OY-(U6)8+2Y@NH_L+0PVCLD>(T3 P@P0&YS@<D\#U>B
M@#R)+*]7X?VUM_9>H"Y7Q(+HQ?8I=XC^V&3?C;G&SG/X5?G>^TV3QWIMYIFH
M7$FK"2XL+B"U>5)D: ((RR@A2NW&&QUKTZB@#&\(K)'X.T6*:"6"6*QACDBE
M0JRLJ $$'W%>=RVFH+\)-1T0Z3J1OHM38^6MH[;P;[S<I@?,-G.1Q[YKUVD+
M!1EB /4T <<!(/BQ)?FSN_LO]A+$)_LLFS?YS.5SMZ[2#C\.M<I86-[#\//!
MUJVEZ@MQ::Y%-/%]BDW1(LSL6(V\#:P.?>O7:* /+([79>ZWX>UWPYJ^H?:]
M0EN;62,RFTGCD?>F]@VU"IP#D<;01DU<U"TU"U\437V@_P!H)-+J,*WNF7-L
MSVMTN4!G1R,(P4 [@>J8QG&?1Z* .5^(-AJ%_P"&D;386N)K2]M[Q[9.LZ1R
M!V0>IXSCOBJRQ-JOC^Q\0VL%W%9V>F30SO+;21M*SLI6,*P#'&UB<#@D#K79
MT4 <C\,XI[;P+96MU:W-K<123;XKB!HV&Z9V'# 9X(/XURGCJ+4M1M_&6GQ:
M+?B1XX3:_8[0E;T!5R[R@?,R\J$ST X/;UFD#*Q(!!*G!P>AH XF%Y)/BA/J
M;6%\EJV@QQ"5[23&\2NY3./O;2#C\.O%8NG:)>2?!;3!Y,MCK&C)]LMQ<QF(
MQS1,S8(;'RLN5/;#5ZC61J_AZ#6KNUEN;R^2& ,'M89RD-P#CB51]X<=/<@Y
M!H ;X9AG_LD7UY$8KW4'^USQDY,98#:A_P!U B_\!K'59(OBQ?7KVEW]E_L6
M*$3BV<H765V*A@,$X(X%=C2;E#!<C<1D#/)H \DTVQO8/A_X#M&TO4$N++5X
MI;B+[')NA13)N9AMX'S#GWJS:VFRYU;PWKOAS5[^2;49KBVE4RFSG224R(SL
M&V(5)&<C(VC&3Q7J=% 'E[V_V?6?$&B:[X>UC4H=1O&N+22W,C6TZ.%PDA#!
M4*D8);' %;%K'/IGQ UYYM/NS;WFFVHAEA@>2/\ =B4,NX#J-RX'4YZ5W%%
M'D]E97L?@3X>6LNF7XGL=2MY+J(V<A:%420%F&W@ LO/O4^KV)N!\2Q=6.H"
MUNXH&A9(60S%(%4[&88)#C'?/O7J-4-9T>VUW3'L+MIEC9D</#(4='5@RLK#
MH0P!_"@#C/#NIVM_XRM[[43J,6J-8?8(5GTF:TC?!\QSN?(+';D#/ !ZUM>.
M]/NKC1(=1TZ%IM2TFY2^MHT'S2;3AXQ_O(7&/4BM'3M ^Q3)-<ZIJ&I219,1
MO'0^62""0$503@D9()Y/J:UZ //=,\/ZQ9>,)(9D+Z;JHCU2];.5BNHSS&OL
M282/41FI-3L[NZ\=Z^8;.Y,<_AT6L4I@81O+OE.T.1MSAE[]Z[U6# %2"#W%
M+0!Y>5NKCPE\/8?[*U)9+"^L_M*/92;HA' R.Q&,@!B!D]>HR.:Z'PS%.GCC
MQA-):W,4-Q/;/#)) Z)(%@5&*DC!P1BNOHH XZ^6XL_BI::@UE=RVDNCO;":
M&%I%63SE;#$?=^7)YZXP,GBN3LK*]B\ >&+9M+U!;FW\1+<S1?8I=Z1BZ=RY
M&WIL8'/O7KM% 'EQM_(U;7]#UWP[K&I1:A>O<VCP&5K6>-\$)(0P5"I&#NQP
M!7?ZQF+PY>HL4CM]E=%2%&D8G:0   2:TJ* .'^'/ARPM/".@W$VC+9ZM:VX
M25WM/)FW[2K!B0"0<_0\57T6Z;3OB+XROKFPU-;6\^Q_9Y5TZ=UE\N(J^"J'
MH3BO0*"0 23@"@#@](LKX>+-;\<:G87-O&UHEG96:Q^9.T*G<69%S\S-C"]0
M.N*JZGX3N=<^'UZ\^H:E%>7B&^-N+=?W=S]]0!Y?F?*P51SG"CM7HP((!!R#
MWHH QO"NJW6L>&[*[O[*YLKXQ*+F"XA:)ED ^; 8#(SR".U>>:C_ &C=R6[O
MH>I0RV?B=+B2VM;)EA$0E/[X$#]ZS##%LG!)X7OZY10!YAJ%K=30_$\+IE\6
MU"!5M1]DD/GG[*(\+QS\^1Q]>G-6+":]T7Q?8:E>Z?J,NG7FB06B216DDC6T
MR,2R.B@LN[/4CJ*]&!#*"""#R".]+0!R'PTAN+;P@+>ZL[BTE2\NF\N>(H<-
M.[J0#VPPK$CMKRQTWQOH=_IUW<SZE<W,]F\<#/'<I,@"+O VJ5(VG<1@ 'IS
M7I5% 'GNE:=?>'_&.AB[M[NYCC\.1V#W4,+2)YR.I;<1TX!//7H,GBL2VLKV
M/P!H=N=+U$7,/B5;J2/[%+O6,7C2%R-N<;"#G\*]=HH \LAM=EYK7A[7?#FK
MZ@;O4)KFUDC,IM)XY'\Q-[!@J%3@'(XVC&371^'H94^(GBZ>2SN8XKC[)Y,T
MENZI)LC*MM8C!P?>NPHH X_XAPRW&FZ0D-I<7.S6+2:18(&EVQI(&9B%!X J
MCXF>XTOQO:ZQ/IVJWND7%A]E8Z;YIDMY1(7!9(R&*L&QWP5%=]10!YCJ,5OX
M?N?"EYINC7]G]G^V%+6&V>Y*0R8+;XU.X,24.1PIR#VJK)#;MX,A;2X]1NYK
M+7X-3OX7L9(IANG\QRL+#=MP3@#/ /).:[W5O#46IZE#J46HZAI][%$8?.LY
M5&Y"<[65U93SSTS5_3].CT^-@)9IY9"#)/.VYW(Z9/  ]@ /;F@#B+26XG\4
M>,;[^S-1CMKS3;86[R6CKYI5)00!C.?F7Y2,\]*I:*U]9V/@VSN-'U"&./1_
M(FN8;)C.DP$8,!8C,2G!);@$J/F&":]0HH \BT6TU&R\*> ))](U)3I=_(MU
M%]F8R(#'*H;:.=N6 ST[]*VK5+O2KCQGI^IZ=>7 U2=[JT>.W:59TDA5/*+*
M"%*E=N&(&#GIS7H=% 'FWA[1K[1O%7A6UO;>YF-EX>>SFN5@=HDE+1D+OQCH
MK#.>WO5SQ!H]Y%XUC73POV+Q'#]FU)=V"GE8/F#_ 'HRT>>Q*5W9=%=4+*&;
MHI/)K*TSP]!INI75^;R^NYYV<J;N<R"!6.XI&/X5R!Q[#T% %W4#)'I=T;>V
M6XD6%_+MSP)#M.%^AZ5YKH(O9?$W@Z^?2M5C2/3[BWN%>R:"&U<B+$:I@!$7
M:P!/4 ?,Q%>J4V1%DC:-QE6!!&<<&@#QW3+JPM[+3M/U%-8MM*TO5I+Z"1M*
ME8 "20ING7*%,L26 Z<9X).M<0FS\1>(=+UO0-9U*TU6Y%Q:R6?F/!,C1HAC
MDVL%0@IC+8&.^!74Z?X,M].@2S75M6FTV-0B6$TZM$J#@)G:'*XXP6(QP<BN
MEH X:UMWM/B3<W#:?<I:IH$%L)$MY'CWK)(Q16V_-@%?K]:YO2(=7T/PQX"U
M232-0FBTE)H+^S2W;SX_,7:)!&1EMN.W9CBO7:* ///$ZG4/#-M/8:#=6XFU
MNUNC$EFPE=5E1GED11E3P?O<X ]<56NT-EXG\06.M:#K.I6.KRK/:R60E:*1
M3$D;12!6"H1LZMQ@\D8KTRB@#S'7=-OK*\N+KP]%?6FJ0P00-8&W>>QU% @
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MI5U:B10T$Q<+U/##Y@01U!'2M70_$4VIZSJNDWFG&RO-/$3D"82K)'(&VL"
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MI"A^7Y3P-@&3USG Z4 9D'Q%N)=)TS5F\/3+8WMZ;%F%RAD20RM&N%QA@64
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M!<[L;0"/WGKV]Z *ND>,;K^Q?#$>H1V8U/6+(3Q-)=&..3"1D\[.')DX0 \
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M37.^#=%O]!TFXM+\VS/)>3W*- [,,22,^#E1R-V*Z*@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHKC_%6HZA!J,\%EJ4D9CTV2=+:TC1IA(#Q(Y<%1&,8 )&3GKC@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU)-.N_"^GW^B6FEW)G=+-HWMI]^)8G3[C*P'4=/?OG)KFO\ A<?A+_GM=_\
M@.:/^%Q^$O\ GM=_^ YHYEW#V-3L6O&7AXCP1XBCLX[J_P!5U*U\DR%0TDI
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MT\\#PRB:.2!]K*P!'<$$<G@C!KC?^%Q^$O\ GM=_^ YH_P"%Q^$O^>UW_P"
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M5&WC!)_.J'_" Z0NFZ39PRWL#Z03]AN8IMLT*D8*[L<J1P00<UD_\+C\)?\
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MY32P?M,;::[/!)'<,')<$/N;.6W9.23DGG-177@W3KQ];:6>[_XG4:QWH$@
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MN/PE_P ]KO\ \!S1_P +C\)?\]KO_P !S1S+N'L:G8[^BN _X7'X2_Y[7?\
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MX#_A<?A+_GM=_P#@.:/^%Q^$O^>UW_X#FCF7</8U.QW]%<!_PN/PE_SVN_\
MP'-'_"X_"7_/:[_\!S1S+N'L:G8[^BN _P"%Q^$O^>UW_P" YH_X7'X2_P">
MUW_X#FCF7</8U.QW]%<!_P +C\)?\]KO_P !S1_PN/PE_P ]KO\ \!S1S+N'
ML:G8[^BN _X7'X2_Y[7?_@.:/^%Q^$O^>UW_ . YHYEW#V-3L=_17 ?\+C\)
M?\]KO_P'-'_"X_"7_/:[_P# <T<R[A[&IV._HK@/^%Q^$O\ GM=_^ YH_P"%
MQ^$O^>UW_P" YHYEW#V-3L=_17 ?\+C\)?\ /:[_ / <T?\ "X_"7_/:[_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P 8KTWPUKUOXG\.V6M6L4L4%VA=$EQN R1S@D=JU:.1!]8G_5SQW_A5"_\
M0OC_ ,'9_P#C%'_"J%_Z%\?^#L__ !BO8J*.1!]8G_5SQW_A5"_]"^/_  =G
M_P",4?\ "J%_Z%\?^#L__&*]"OO%]E:7][8P6>H7UQ8JK7:VEN6$(9=PR20"
M2.<+D^U6(O%.BS>%QXE2^3^R3$9OM!!'R@XZ=<YXQC.>*.1!]8G_ %<\U_X5
M0O\ T+X_\'9_^,4?\*H7_H7Q_P"#L_\ QBO1M.\4V6H:K_9;P7=E?-!]HC@N
MXMC2QYQN7D@X/4=1W%;E'(@^L3_JYX[_ ,*H7_H7Q_X.S_\ &*/^%4+_ -"^
M/_!V?_C%=]?>-=.M+C4(8K34;W^S?^/U[6V++ =N[!)QN.T@X7)JY)XIT=/#
M4?B#[6&TV5%>*1%),FXX557&2Q) QC.:.1!]8G_5SS7_ (50O_0OC_P=G_XQ
M1_PJA?\ H7Q_X.S_ /&*])TOQ+9ZGJ=QIABN;348(UF>UNH]KF-C@.,$AESQ
MP>#P<5E3_$71;>R?46AU!M)CF,,FHK:MY*,&VGK\Q ;C< 1GO1R(/K$_ZN<7
M_P *H7_H7Q_X.S_\8H_X50O_ $+X_P#!V?\ XQ7I>J>(['2KBRMF6>YN[X.;
M:"VB+M(% +'/W0 ".20.:30O$MAK[WD-L)XKJQD$5U;7$>R2%B,C(Z8(Y!!(
M-'(@^L3_ *N>:_\ "J%_Z%\?^#L__&*/^%4+_P!"^/\ P=G_ .,5[%11R(/K
M$_ZN>._\*H7_ *%\?^#L_P#QBC_A5"_]"^/_  =G_P",5[%11R(/K$_ZN>._
M\*H7_H7Q_P"#L_\ QBC_ (50O_0OC_P=G_XQ7L5%'(@^L3_JYX[_ ,*H7_H7
MQ_X.S_\ &*/^%4+_ -"^/_!V?_C%>Q44<B#ZQ/\ JYX[_P *H7_H7Q_X.S_\
M8H_X50O_ $+X_P#!V?\ XQ7L5%'(@^L3_JYX[_PJA?\ H7Q_X.S_ /&*/^%4
M+_T+X_\ !V?_ (Q7L5%'(@^L3_JYX[_PJA?^A?'_ (.S_P#&*/\ A5"_]"^/
M_!V?_C%>Q44<B#ZQ/^KGCO\ PJA?^A?'_@[/_P 8H_X50O\ T+X_\'9_^,5[
M%11R(/K$_P"KGCO_  JA?^A?'_@[/_QBC_A5"_\ 0OC_ ,'9_P#C%>Q44<B#
MZQ/^KGCO_"J%_P"A?'_@[/\ \8H_X50O_0OC_P '9_\ C%>Q44<B#ZQ/^KGC
MO_"J%_Z%\?\ @[/_ ,8H_P"%4+_T+X_\'9_^,5[%11R(/K$_ZN>._P#"J%_Z
M%\?^#L__ !BC_A5"_P#0OC_P=G_XQ7L5%'(@^L3_ *N>._\ "J%_Z%\?^#L_
M_&*/^%4+_P!"^/\ P=G_ .,5[%11R(/K$_ZN>._\*H7_ *%\?^#L_P#QBC_A
M5"_]"^/_  =G_P",5[%11R(/K$_ZN>._\*H7_H7Q_P"#L_\ QBC_ (50O_0O
MC_P=G_XQ7L5%'(@^L3_JYX[_ ,*H7_H7Q_X.S_\ &*/^%4+_ -"^/_!V?_C%
M>Q44<B#ZQ/\ JYX[_P *H7_H7Q_X.S_\8H_X50O_ $+X_P#!V?\ XQ7L5%'(
M@^L3_JYX[_PJA?\ H7Q_X.S_ /&*/^%4+_T+X_\ !V?_ (Q7L5%'(@^L3_JY
MX[_PJA?^A?'_ (.S_P#&*/\ A5"_]"^/_!V?_C%>Q44<B#ZQ/^KGCO\ PJA?
M^A?'_@[/_P 8H_X50O\ T+X_\'9_^,5[%11R(/K$_P"KGCO_  JA?^A?'_@[
M/_QBC_A5"_\ 0OC_ ,'9_P#C%>Q44<B#ZQ/^KGCO_"J%_P"A?'_@[/\ \8H_
MX50O_0OC_P '9_\ C%>Q44<B#ZQ/^KGCO_"J%_Z%\?\ @[/_ ,8H_P"%4+_T
M+X_\'9_^,5[%11R(/K$_ZN>._P#"J%_Z%\?^#L__ !BC_A5"_P#0OC_P=G_X
MQ7L5%'(@^L3_ *N>._\ "J%_Z%\?^#L__&*/^%4+_P!"^/\ P=G_ .,5[%11
MR(/K$_ZN>._\*H7_ *%\?^#L_P#QBC_A5"_]"^/_  =G_P",5[%11R(/K$_Z
MN>._\*H7_H7Q_P"#L_\ QBC_ (50O_0OC_P=G_XQ7L5%'(@^L3_JYX[_ ,*H
M7_H7Q_X.S_\ &*/^%4+_ -"^/_!V?_C%>Q44<B#ZQ/\ JYX[_P *H7_H7Q_X
M.S_\8H_X50O_ $+X_P#!V?\ XQ7L5%'(@^L3_JYX[_PJA?\ H7Q_X.S_ /&*
M/^%4+_T+X_\ !V?_ (Q7L5%'(@^L3_JYX[_PJA?^A?'_ (.S_P#&*/\ A5"_
M]"^/_!V?_C%>Q44<B#ZQ/^KGCO\ PJA?^A?'_@[/_P 8H_X50O\ T+X_\'9_
M^,5[%11R(/K$_P"KGCO_  JA?^A?'_@[/_QBC_A5"_\ 0OC_ ,'9_P#C%>Q5
MS%YXP:V\6R>&X-$OKN\6T%Z&BDA5&BW;<@NXYW<8HY$'UB?]7.$_X50O_0OC
M_P '9_\ C%'_  JA?^A?'_@[/_QBO2?#OB:R\2V]T]K'/!/:3M;W5M<(%DAD
M'4$ D?B"0:V:.1!]8G_5SQW_ (50O_0OC_P=G_XQ1_PJA?\ H7Q_X.S_ /&*
M]BHHY$'UB?\ 5SQW_A5"_P#0OC_P=G_XQ1_PJA?^A?'_ (.S_P#&*]BK$U/Q
M+!8ZBNEVMI<ZEJ93S#:VH7,:= SLQ"H#VR<GL#1R(/K$_P"KGG'_  JA?^A?
M'_@[/_QBC_A5"_\ 0OC_ ,'9_P#C%>P(Q:-69"C$ E202#Z<4ZCD0?6)_P!7
M/.O"/@%= \017XT@6VQ&7S/[3,V,C'W?*7/YUZ+1132L93FYN["BBBF2%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<]XR\,OXHTB""WO6LKZSNH[VSN NX),F=NY>XY(KH:Q
M]?T'^W%L6CU"ZL+BQN1<P36^TG=M9<,&!!4AR"* .9T_QIJ%I/J^G>)=*@@U
MW2]->_62U;=#=P+U9"?F7Y@ 5-9.DZGXKO=*\.:S:1ZO<WEW-#-?K((A:M;R
M#+!%W?+M!!4CDXYSFNTLO"D$>JW>JZC=2ZE?7-K]C9YE552#))154 8).3G)
M-5=%\%R:(EO:0>(=5?2K5@UO8L8P% .0AD"AV0?W2>G!R.* ,73X-6UKQIXQ
MTEO$6I6UC92VQMQ R[T,D6\@,P.%!/3]>*Y?4=0U'Q+\-=!FU._G^V6_B&&S
MFE@VH)BL^P2$8Z@ 'TSSCIC>T.WN+_XH>.&L=9GLC(UJH"1(ZR!80K,NX'E6
MR,CCGD'BNDN? .E2^#(?#4$MS;002+-#<(X,JS*^_P PDC!8MDGCOVH R?$.
MHW^D:]X?\,VMUJES%>">XN9HV1KED0#"*QP "6Y(YP..M0/=>)+?PCXT-VVH
MVT-E!)<Z3=SL@GVB(OM)4G.UUQD\D&M_4/!IU*/3IYM;OQK&G2/);ZDJQ"0;
MQAE*!=A0@#C';K5B?PS)=^'-2TF[UJ^N)-0C:*:ZDV;@K#:0B!0BC&1P.^3D
MT <5/=>(K2#P-J$?B.Z:;67BMKJ.2-&B DA+;E7'WACJ2<GKQQ6YX=N-1L_'
M'B30;G4[F_LX+6WNK=KHJ7C+A@RY &1E0?:KUQX(6XL_#EL=6NE&A2)) P2/
M,A1=J[^/[N1QCK5RU\,+;>+=0\0?;YWDOH$@> JNQ53.W'&<C)[]Z /+M'&L
MZ/\  G3O$MAKEU#<:?!YT=H%3[.Z"4@HZXRQ(SSGKTQ75W7B.^UGQK<Z5''J
MB6%GI\,[)IQ59&EER068D'"@8 '4YSV%7K3X;P6_AJW\,RZS?W&AQ%2UK(L8
M,@#;MC.%!V%N<=>V<5IZIX1%WKRZYINJ7>E:CY MI9+=8W6:,'(#(ZD9!Z'K
M0!Q^JZEXMM? >C3WUQ<6.LKK$-HTC;?W\32[5:15..5QD CG/3-=[HNCWFEW
M%\]SK5YJ27#J\:W07,.!R!M &"><8&*H:SX-76=%LM-EU>_7[+=)=_:&*O))
M(K;@6)& ,]@ .@&!Q72J"% )R0.3ZT 8/BA/$0TV4>&8M/\ M4BMYC7+LK=
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M58DYQQ^M>CUA_P#"+VG_  E__"3?:;L7_P!G^R[=Z^7Y6=VW;C^]SG.<]^U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>modificationno15effectiv009.jpg
<TEXT>
begin 644 modificationno15effectiv009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL+Q/XQT+P=9Q7
M.N7PMDF8I$H1G9R.N H)X]>G(H W:*S]$UO3O$6DPZII5TMS9S [)%!'0X((
M/((/8UH4 %%%<9XJO]5M_&GA;3++5)[2UU1[E+@1Q1,?W<6]2I=&QR.>M '9
MT5P&B>.38W7B>U\1WL36FB7<<*:BL1'FB09"LJ@C>IP#@ <C@5TL'BW1;F)I
M(+MY,7#6P1()"[R*NXA5V[F&T@Y (QSF@#:HK#E\8:%!H[:M)?$623>1)((9
M"8I,XVNH7<AR0,,!U'K5N^U>RM6,$]Q+!(UN\X80L=J+@%L[2 1D<'GD<4 :
M-%8>FZSI]MX8TR[?59;Z&XC18;IXCYMT2."$5<DD G '0$]JQ?#'B1KG5_%K
MWNHRR6%C>11P&XB\MH@8E)3;M4YWD@ C)XZT =M16=IVNZ=JMU=6MK,_VFUV
M^=!+"\4B!AE25< X/8XP:YS7-1U.+XC:+I$.KS6MC>VEQ+(B1PDAH]N,%D)Y
MW'- ':45Q_AK7KZZ\8:YH,UTFHVE@D4D=\J*K*SYS$^WY2PQG@#CJ*B\3>+K
MO1?%6DPQQJ='$Z6^I3'_ )9O,"(>>V"H+>SKZT =K17,?$/4K_1? NJZIIMT
MUM=VD7F1L$5P3D<$,#Q65+K>KZ1XT\-Z4-1;5(=6BD:YAFBC$MN%4,) 8U4!
M2>/F'T- '>45Q#W>KW7Q0N]"36[JWL$TM+U$BA@)#M(R$9:,\8'U]ZFTSQ!J
M>G^.G\*:U+%=">U-WI]ZD?EM(H.&CD4<;AUR, CL* .QHKBO&GBZ[\.ZGIC6
M\:MIT$\;ZO(?^64,I,<9_P"^LL?]SWKM: "BN<_X2>&\\3ZCX<A2\AN+:V20
MW"V[$!GWXP2I7 "]3P2<#.*R/ ?C6UU'P[X?M]3U%I=8OH"VYH6"RN,DKO"[
M-V!G;G..U '=45D2>)]'BOH+.2[*R3S&WB<PN(GE&<H),;"V01C.<@CJ*T;J
MZM[&TENKJ9(8(E+R2.<!0.YH FHK)A\2Z3-/<0?:7BGMX?/DBG@DB<1_WPKJ
M"5SQD9YXJC9>/?#&H7UE9VNJH\UZNZVS$ZK+QG <J%W8_ASGVH Z2BN8N?B'
MX4M#()]711%<&VE;RI"L4G'#D+A1\P^8X'7G@UK7VNZ?ITGESRR-)Y1F,<$+
MS,(_[Q" D#W- &C16#=>,_#UI'8R2ZG&4OXVEM6C5I!*JJ6.W:#G@=.I/'6J
M>G^/=+U/6+NSMX[QK>WM(;H7'V.;#B0.W3;D#:HY.,DD#I0!U5%9$7B?1YH]
M+DCO-T>J_P#'DXB?;-\I;&<8!P"<''2J4OCWPS#YV_4_EAN?LLS""0K%)QPY
M"X4?,!N.!GC/!H Z2BL*?4[2+Q9]F.JW'VB*P>9M-CA+JR!E_>\*26&0H /.
M>E4-+^(&D7V@66KW/VFTAO)_)A$EK*=S%RJ#(7!)P.AQGB@#K**JC4;8ZF=.
M#O\ :A$)BGEM@(3@'=C'4'C.>*R[WQ3;67BVQ\/M;W+37,#SF1;=V50I50,@
M'NW)Z#'.,B@#>HK'F\4Z-!<"&6\V@S_9O-,3^4)<XV&3&P-GC&>O'6M"^OK;
M3;&:]O)1%;0(7D<@G:HZGB@"Q16#9>,] U".1[2^,JQK$QQ!)EO,!*!1M^<G
M!X7)&"#C%))XUT"+3Y[Z2]=(+><6T^ZWE#0R' "NFW<N<C&0,Y'K0!OT5GW>
MK65M*;>::2*0V[3Y$+':@X+9Q@$9'!Y]JHZ3K-A#X:TRX_M2?48[B,>3<F%F
MEN>,[@BKD\#/"]* -ZBL.'QAH-P+$Q7Q;[=,UO;XADYE7.Y&^7Y&&#D-@\&I
M(_%&D30:E.EQ(8],8K>$V\@,1 R1@KD\8/&>#F@#8HJ-KB)+8W,C^7"$\QFD
M&W:N,Y.>G'K659^*M&OI?*@NGW_9OM:B2"2/?#G&]=RC<.1R,]1ZB@#9HKGK
M'QQX<U*XL8;34?,-_D6S>3($D(!)4.5VAL G:3G':L;XA^*UT[PKJ3:5J,\%
M_;21QF6&W+HKEE!1G*E0<-Z@@XH [JBD=UC1G=@JJ,EB< #UK*L_$VD7]_'8
MP71-Q+"9XEDB>,2QCJR%@ XY'*D]0: -:BL>'Q3HT]U;VZ7GS719;=VB=8YB
M.H20C:QP">"<@<53;Q]X912[:GB-;DVKR>1)LCER!AVVX3DXRQ )[T =)16+
M;>+-$N[B\MXKP^;:1":57A=/W9R Z[E&]>/O+D55B\>^&9VL]FIC;>(7MY&A
MD6.3 R0'*[=V/X<[O:@#I**RM.\2Z1JEG=W=M=XBLV9+GSXVA:$@9.]7 *\'
M.2.E0_\ "7:(KW:2W;P26D'VF:.>WDB81=-X5E!9<\9&: -NBL*Q\8Z#J5Y!
M:6EZ9)KB W$ \B0"5  3L8KAB 1E021W%'A?Q/;^*+*>YMX+B%8KB6$":%TR
M$<KG) &?E.0.1T.#0!NT5FG7M.%]>67G/]JLXEFGB$+DJASAAQ\P.#TSTK/?
MQUX:CCM7.IJ1=VYN8 D4C-)'QRJA<D\CCK[4 =%1619^*=$O]#76;74(Y;!V
MV+(%;)?=M";<;MV2!MQG)'%,;Q;H<=K?W,MZ8DT\!KM98722$$9!*%0V".0<
M8.* -JBL;3_%6BZIJ0T^SO/,N6A\]%,3J)(^ 61F # $@'!..]7=0U2STJ**
M2\F\L32B&)50NTCGHJJH))X)X'0$T 7**PI/&7A^+3EOY=16.V-S]D+21NI6
M;=M*,I&5.?4#%$7C'0IK?4ITNY-FF@-=AK:56B4C(;:5R5(!.X C )S0!NT5
MFIKVG26NG7*3.T6I,%M&$+GS"5+#C&0-H)R<<#-6;Z_M=-M6N;N411 A<X))
M8G 4 <DDD  <DF@"S17%:)XC:Y\<^)X9]0F_LVQM+:54NHO)%N6\POG<JG&%
M!RV>.^*Z&S\1:7?7RV,,[K<O%YT<4T#Q&1/[R[U&X<C.,XR* -2BL?\ X2K1
MOML%I]L/F3R/%"WDOY<KKG<JOC:S#!X!SP1VIO\ PENB?V:NH?;#]D:Y^R>8
M89/EEW[-K#;E3NXYQS0!M45S][XU\/V$]_#<7S>;IX4W21V\LC1!@2"0JGC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVUNP6:XBB)&0'<+G\Z(;NVN&*PW$4C 9(1PQQ^% '+^%H=77PY-?>((&&J&
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MUZ]M+9-+&T:3^7&@90QQU*%?QSTYJ<&/6='U.\B\):I8WXTR>W:2]C8REG7
MBCY)8$\YX' ]>/1J* /.;.TO$O?AP387BBPLY([LFW<"!C;A &XX^88_7IS6
MQ\/X+NPTR_T^\L;FWDBU&ZDWR)A)%>9W4H<_,,$<UUU16UU;WD GM9XIX6)
MDB<,I(.#R/0@C\* .,OEO-.^(NH78TR]N;?4-)B@AEMXMRB1'D)5ST7AP<G
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M$:0UK82W,'VX?:9K> 336Z;& >-2#@DD*6 R 3CUKIBZJ5#, 6.%!/4XSQ^
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M++GKC)Z]^GT?7]2N_$,VF7FF2K;BV%Q%?);RQQ$[L&)O,4?,."".H],5ER>
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M0>W?$"W(4E)1P",['7'0$CB@#T"BO./"6K:GJ42:#?W=XFKVE^\ETTCXD-L
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M_"6)'(YPIQBJOB+7-=TJS\8:;;:I<*-+>RFL[HA6<).X#1.2,D#!P?O8/)H
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M+2?=X+&@#UVBHK6YAO;2&ZMY!)!/&LD;CHRD9!_(U+0 4444 %%%% !1110
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MW/)Y))R23UJA9>&=-L);62)9W^Q[OLJS3O((=PP=NXGL2/8$@8%;%% '+_\
M"O\ P]P/L]SY:W?VV*+[7*$AEW%MT:AL)\Q)^7%7)O"6D3W=Y.T4P%\0;N%;
MAQ%<$ #+IG!X !]1P<UN44 9;>']/;7/[9"2K?"V^RAUF< 19SM"@[>O/3-4
M5\$:&FDVNEK#<"SM;G[7#']KE^27=O#9W9^\2<9QDUT5% &))X3TF6ZU.Y>.
M<RZFB1W3"YD&]4^[C#?+C)P5P>:63PMIDR3B<7,LL_E!YVN'$N(GWQ@."" K
M<\=23G.:VJ* ,*[\(:/?Z=?65Y%--'?LKW3M.X>8J %!8$' P.!@?K4UUX;T
M^[OX+]OM$5[##Y N89W21H\YV,0?F&>>>AY&*UZ* ,9_"ND,^ELMN\?]EDM9
MB*9T$9(()P#\Q()R3G.3ZU/IFA6.D7%[/9I*LE]-Y]P7F=][X W88G'  X]!
M6E10!F7&@:=<Z[#K,D+_ &Z*'R ZRNH9,[@K*#A@#R,@X-5K'PCH^G-"+:"1
M8()C/!;-,S0PN<Y9$)P.IP.@SQBMRB@"IJFF6>LZ7<Z;?PB:TN8S'+&21N4^
MXY'X503PKI:7UA>A;IKFPC>*"1[N5B%?&[.6^8G R3GH*VJ* .9G\ >';G2Y
M-.EM)6A>Z:]#&XDWI.229%?=N4DD]#6C;^'=.MM$ETF))A;3!A*QG<R2;A@E
MI"=Q)'&<]/I6K10!1T?2+/0M+ATW3T=+2!=L2/(S[%] 6).*SH_!ND0WU[>Q
M&_CN+Y@UR\>H3IYA P"<..@XXK?HH RH_#>DP:)-H]M:_9K*8,)$@=HV?=]X
MEP=Q)[G.35A])M)-&;26$AM&A\@KYK;BF,8W9STXZU=HH P[3PCI%C9Z9:6Z
M7*6^F2^;:H;J1MAP1CEN5P3P>*W*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *XWXJW%Q9_#?5[VSNKFUN8$1HY;>9HV4[U'52.Q-=E7+?$32+_
M ,0>!]2TC3(!+=7:JB;G"*N'4DDGV!Z9H CL7T:?6[""QU+4S=JCW.Q[RX>-
MT4!6#*[;3S(,<=1FHKCXC6-M8ZA?/I.J&TTV\:TO91''B C;EB-^67YA]W)X
MR0.,ZOVG6)IK-4T7R"'59;B:>-O+CX+[0I)).,=NN>V*Y*^\+ZY=>#O&>EI8
M 7.L:A+<6N9DV['" ;CG@C8<CGJ/P .KMO%EM+KD^E75E>6$J6IO(Y+I45)8
M58*SC#$K@D9# 'GI5:#QSITVJ6%B;>YC.I1O)92$H1-M7<5P&)1BO(# ?@>*
MIZOH%_K7BU;E[5X;";1+C3I9/,0LCRLIS@'D *?QI/"EMXGLX+6PU;1=.A6P
MCV-?V\RNUV%7"[$P-A/!)8^OKP 3V'Q"T^]TV75&T[4K;3(89YI;R>)1&AB<
MJR<,26XR,#!Z9R"!:7QE:IJ\.FW5A>6LLMH;T/+Y>Q81]YF(8XQD9'N*P+;3
MKG0_A'J6F:Q:6RS$7*K%/+F*5II7,:EE.1DR*O8YZ>M5;?3=1GE6PUW0KR&2
M]L)-(AU!]0AN#"C(21M54)SMR6P3P,\4 =-!XXT^;5;&P:VN8WU")Y;)F,9$
M^U=Q7 8E6V\@,!^?%5K'XB6%]#I5RNF:G%9:E=&SCNI8T")-N90K#?NY*GD
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M1@;F0KGV&37'6GA_7[4^$M7^Q1_:](M&L+JR6X!,D3(BED8X7<&0'!.".X-
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MK<W,$9B+QHQ8#C?\Q^0GY2?SXKEI_"FMW7@GQ3IHM4CN[_59+^U5YEPZ&5)
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M;*+3;[4[B6"ZF4JZ1[$9DV\D!I,# )..1S0!VU1W%Q#:6\EQ<2+'#&I9W8X
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M&FW4]Y9B6ZM&M)@[HT3,&QM8@$'N"!D>QI]Q>V]K/;0S2JDEU(8H5/5V"LQ
M_P" J3^% ''6.@W?B'PUJ.D:EJEY<Z;,L7V2YEL5M)HV5MW";1\H*H1E1GGJ
M,5I0>#Y(]9FU>;6[V>]FL!8R,Z1A67<S;MH7C&[@#'3G.:Z>L32-?DU/7]<T
MJ2S$!TN2)-XEW>:)$W@XP,<$<<T 9<'@**TM?#\=KK%[!+HD;PV\RK&6>)P
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MK=!( R3@4 <B_@ACK5QJ=IK=_IPO]K:C:6K+Y4[@ %@64E"0,$J03['FKO\
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M=O&]S<6=U:S"XM;NV8"2&0 C(SP002"#U%;=-DD2&)Y975(T4LS,<!0.I)H
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MR2=R$+SR3G.>#VK8N?$0;7I-#TRV%YJ$,2S7&Z3RXK=6^[O;!.YL'  )P,G
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M)=,\OEQ6X;[JLV&.X@9 "GCDXXI/^$F2S;5/[9M3IT>FV\=Q+.T@>)U8ORA
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MG=2J;7 )V[6)XP"1[U7^)MK)?6.@V\=A<WJ)K5K//'%;/,!"K'>6 !&,=N]
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M:*]LYK6=2T,\;1R*"1E6&",CD<&N6L?&DT^N:1IM[I@M)-4CF>.)I\SP;!N
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M,%))+.%  YY/&*X?0+Z#3/#TJWFA6\\<OC!X/(\P;+61IP%9?EYVD\8 Z=J
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M-+%O6(R9&2,@%L?3G'X5Y7=ZKJ.O>!O#NL:I:6\ER/$<)A,+[FXNW7:-P&W
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M$$XP3MZ=O?/&MIOB+28]430[33+VTF)!$8L&2-5*E@Y8#: =I'7.1@@&NDH
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MSG#*Y!QT]379#7+(^(_[!W2_;_LIN]IB8+Y88+D,1@\L.F:TJ .:.G^(KK3
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MAWG).Y5XXP ?6NRHH Y1=%\1:OH&HZ?XBO[ /=64EFOV"-POSK@R-N/)] ,
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M$5WI^I,SZ;!%+#;V\2,L/=O/+CG=V53G&#@=:TV.[XQV;>OAZ8_^3$56=0\
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M>Q+NIG4$?.K[54$9Z'KSS43^!-&GT?4=+N?M%Q;7]TUY+ODPRS$Y+HR@%3D
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M]-U-[FZ:YTZ%H8267!5L;MPV\YVK^7&*DT;0;;1)+][::=S?7+74PE8$&1@
M2, 8X XZ<4 <OXTUK5+ :])8:FX>PTP7,-O:Q(QB<!V+SEQC:=H 4') 8@=Z
M=?7+W?CSP)=.%#S:??2$#H"8X36QJ?@G2=5O]1NYWO$.I6PMKR.&X9$F4 JI
M8#N Q'IZ@U(GA&QCN])N1<7ADTJ%X+?=+N^5P ^[().0H^F.,4 <UH/BZ[2Z
MEAUR:^MM6M-/FGN=,N(4"3LNT^9;NJ_,@ 88R?O#/0FFOXCUFU\)^'/%?VXW
M OYK87=EY:>7LG(&(\#<&0L,9)S@Y]NKL/"]G9364KSW-XUC"T%K]J96\I&
M# $ %B0H&6R<#W-0V'@W3-/2WMXGN6L+6?[1;64C@Q0/DD%>-V 22 20#T P
M, $/Q#U*_P!&\"ZGJ6F77V:[MT5T?8K_ ,0!&&!'>L:]O/$>B>,+;3YM::\M
M-6LKF2,FVC4VDT2ALK@<H0V,-D^YK5^)-G<ZC\/]6L;.VFN;FXC5(XH5+,QW
M ]NG /-:$/A^VF;[9+<WLUP]L;>*:? >&-L%@HVC!.!DD$G R>* .)L/$&OV
M_A'PWJ]WK;SSZ_)9V04VT:I;/(26E&!R2H(P<C<1QCBN@2]U6V\<3^&7U&:6
MWN],-Y;731Q^;;.KA&7[NU@=P(R.N16BO@[2?^$4B\-RB:6P@"B'?)^\BVG*
M%6&""I P>M7K#18+*\DO7FGN[V2)83<W!4OY:DD*-H  R2>!R>N<"@#E_"^N
M:KJ^GZ?IUU?R+K-K=S0ZHRQQCB$X/&W #;HL8 .&//%4?^$NU73]"\0R3W0G
MNHO$(TNTEDC4+$K^4H)"@ [=['GJ:[BTT2PL=7U#5;>$)=ZAY?VA_P"]L&U?
MTK+;P1I$NF:OIUR)[FVU6<W-RLKC_6G'SJ0 5/RKC'3 H Y76;JX\,?$"^U1
M[J?4/LGA6YN$2<(#E)4.,JHX) [<<_0;^DGQ,VLZ;=27:3Z3<V[?:5FDCSO*
M[D>'8H.#SD$GC!ZYJU;>"--BU!+ZYNM0O[A;1K(M=W!</"QR58  'H.O7OSS
M3O#_ (*TWPW(IL[C4)8HP5MX+J[:6.V!ZB-3P..,\G&1GDT 5?&5]JMIJ?AN
MWTW46M$O]0-K/B)'RIB=LC<#@@J,=O7/2J<EWK;:R_AB+4[B6YL].CN'O$$,
M<DSN[J&*E2N%V#@#DMS72:OH%MK-UI]Q//<1O83_ &B#RF  DP5R<@YX)&.G
M-5-=\'Z=K^H6VHR37MGJ%LAC2ZL;@PR&,G)0D=5SSB@#$T35M>U76D\/ZI>Q
MVE[8Z<D][+8;6\Z5G91M+*0  F2 /O-CH,'(\'W5W:>!- MX]2\IIM2O4F6*
M,-<7.)ISMB&"!\P!). %!Y%=?/X*TN2^LKZVDO+*[M(3;B>VG*O+$3DI(3G>
M"<G)YR2<YJO#\/=&MK2P@MY=0A:PN);BWF2[;S%:3.\9/\+9.10!A:9XNU2;
M2].L[FX9+N[UZXTLW3HF](XS(1D ;-Y"!>F,G/-'C>UUFS\,7<=SKLDL?]J6
M9MS&J+*(7FC4I)\N&&=V.!G'.>16\_P\T&32;O366[,-Q>&^5S<N7@FR6WQM
MG*G))SU.><U8D\&:;<:!/I%S/?7"SNDDEU-<LTY=&#(V\],%1@#CVY- &=?Z
MAJUWXBN_#UA=W"26=A%/YZM$LDCR,X#$,A4A=@X '+<U#IFKZYJ&O67AO4[N
M*UOH-*^V7TMCM;S9#(8P%+*0 -I)XZD#H#G4U7P1IFJW5G>M<ZC:W]I'Y*WE
MI=M',\9.2CM_$">>>_3%27?@S2[BZT^[@>[LKNQC,,5Q:S%7:,G)1R<[P3SS
MDYYSF@#,^&"21^%[M)93+(NJWH:0@ N?/?)P.!FFV5_K/B2TU*_T[5TL9++5
M)+98)(U:'RX7VN).-V6 8Y!&,K[D]#H/AZR\.6DUM8M<&.:=YV\Z9I#N=BQQ
MGIR?\<UGGP-I/]NW&J1R7L/VJ02W5I%<LMO<2#^)XQP3P,]CW!H S%U;5=?'
MBJ2PU%["32+E[6UC6-&5F2-7+2;E)(9F(P".!QSS6=;^(M<\1W_A06NHMID&
MM:3-=3I' CF-U\OE"P/]\XSD8[5U=SX3L)]1OKV*:ZM6U!!'>I;R!5N !@%L
M@D''&Y2IQWK$U?1Y6\?^&OL4-Y:V5A97$/GVL7R0EO+"+RI7&%(Z$#CIQ0!B
M3>)?$EIX*USSM2W:CHNLQV/VQ8$'VF)I(AEEQ@-MEYQZ"MW4M2UW6-9\0:7H
MMPUM/IBQ)"RM& 9'C\P,X=6)7D+@8Z-WQC7N_!VF7F@R:.[7"V\UP+F=T<"2
M:7>'W,V.NX \8Z =.*BU3P1INJ:PFK&YU&TOO*$,TUE=- ;A!T63;C/U&#^E
M '/:UXFUC298CK<\VFVLMG"$U&QC6:UAN3GS!*2I95)*X/3'H>:ZWQ5K9\/>
M$M3UF.,3-:6S2HG9F XS[9QGVJ*[\)V%W'<P&:ZCLKJ%8)[.-P(GC5=H7!!*
M_+P2I!(^@K7N+.WN[*6RGA22VEC,3Q,/E9",$8],4 <?=:GJVB:GX7D?47U"
MUU>86ES&\:#:[1EUDCVJ"!\I!!R,>_-,\!VL\>O^+WDU"YF":N4*R+'ASY$7
MS':@.>W! ]JWM-\*V6FM98GNKE-/4K9)<R!Q;@C;\O ).WY06)(&0#R:FTCP
M_;Z-=ZA<V]Q<N]_,;B<2LI!DP!N& ,<*!@<<4 9WB&\O5UFVLK74)(@]I-)]
MFM$5KAW!4*Y+@JL:Y.22,D@<]*YG3O$>OZQ!X!<:I]F.LV\WVSRX$.YDA+!E
MR.#GGTSC@CBNSU'PQ8:EK=OJTDEU#=Q0M;EK>=HQ+$3NV-CJ,\\8-4M/\":7
MIG]C"UGOE&D;_L@:;<%WC:P.0<C;QCMVYYH YQ=3\42>#]?DL]4FGO\ 0M5F
MB5_)BWW<$>UBC#9M#;6(!4#D"NIT75CK^J/?6%ZTFD):Q!5"KMDE<;\YQN&$
M9.,XRQXXJ%K7_A#X;F;3=.U/5I-2OC-/%$T9*R..7.XJ ORJ#V'I5_POH<7A
MWP];:=%%%$5W22+%]T2.2S8]LD@>P% ',^//M'_"9>!OLGE>?]NN-GFYV_ZA
MNN.:O>(TU(?#SQ8^JBW^T&QN@C6X.WR_).T<\^N<]\]JU]6\-VNL:KIVHSW%
MTD^G.TEMY3*%1F&"2"#G(XYJWJ^EPZUI-SIMQ)*EO<QM%+Y1 9D88(R0<9![
M<T <[%%93?!Z&/40ALSH:>=OZ!?)!S^'6LGPUJ6I6WP:T)9?/;5+RW2VM]HW
M2 -G:X'<K$"__ :Z+_A"=,ETZVTV\GO;W3[=46.TGG_=D+C:&"@;P,#ALCBM
M.?1H9]5LM0\^=&LU98H4*B,!A@Y7'7  SV[8R: .'\%O%X:\<ZGX:BM9[/3-
M1C&H:='.FW:Z@+,@]?X6_.NS\37<]CX;OKFVO;>QF2/Y+FX4LD9) S@ Y//
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M :1UR0'"# ( ;(Z8.1Z%10!YII.C:AIUW>:'?>#[;44>]EGM=6D6)HC')(9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^%Q^$O^>UW_ . YH_X7'X2_Y[7?_@.:.9=P]C4['?T5P'_"X_"7_/:[_P#
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MS1S+N'L:G8[^BN _X7'X2_Y[7?\ X#FC_A<?A+_GM=_^ YHYEW#V-3L=_17
M?\+C\)?\]KO_ ,!S1_PN/PE_SVN__ <T<R[A[&IV._HK@/\ A<?A+_GM=_\
M@.:/^%Q^$O\ GM=_^ YHYEW#V-3L=_17 ?\ "X_"7_/:[_\  <T?\+C\)?\
M/:[_ / <T<R[A[&IV._HK@/^%Q^$O^>UW_X#FC_A<?A+_GM=_P#@.:.9=P]C
M4['?T5P'_"X_"7_/:[_\!S1_PN/PE_SVN_\ P'-',NX>QJ=COZ*X#_A<?A+_
M )[7?_@.:/\ A<?A+_GM=_\ @.:.9=P]C4['?T5P'_"X_"7_ #VN_P#P'-'_
M  N/PE_SVN__  '-',NX>QJ=COZ*X#_A<?A+_GM=_P#@.:/^%Q^$O^>UW_X#
MFCF7</8U.QW]%<!_PN/PE_SVN_\ P'-'_"X_"7_/:[_\!S1S+N'L:G8[^BN
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M_H7Q_P"#L_\ QBC_ (50O_0OC_P=G_XQ7L517%U;VD8DN9XH49E0-(X4%F.
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M /&*/^%4+_T+X_\ !V?_ (Q7L5%'(@^L3_JYX[_PJA?^A?'_ (.S_P#&*/\
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M/_!V?_C%>Q44<B#ZQ/\ JYX[_P *H7_H7Q_X.S_\8H_X50O_ $+X_P#!V?\
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M*/\ A5"_]"^/_!V?_C%>Q44<B#ZQ/^KGCO\ PJA?^A?'_@[/_P 8H_X50O\
MT+X_\'9_^,5[%11R(/K$_P"KGCO_  JA?^A?'_@[/_QBC_A5"_\ 0OC_ ,'9
M_P#C%>Q44<B#ZQ/^KGCO_"J%_P"A?'_@[/\ \8H_X50O_0OC_P '9_\ C%>Q
M5S6I^+S8>*H?#T6C7MW=S6QNHVB>)49 <'EW&"#1R(/K$_ZN<%_PJA?^A?'_
M (.S_P#&*/\ A5"_]"^/_!V?_C%>C^'O%%GXB>^@BAN+6]L)1#=VERH$D3$9
M&=I(((Z$$@UMT<B#ZQ/^KGCO_"J%_P"A?'_@[/\ \8H_X50O_0OC_P '9_\
MC%>Q44<B#ZQ/^KGCO_"J%_Z%\?\ @[/_ ,8H_P"%4+_T+X_\'9_^,5[%7%W/
MQ ECO[VWM/">O7T5I.\#W-O%'Y;,OWL$N.!1R(/K$_ZN<C_PJA?^A?'_ (.S
M_P#&*/\ A5"_]"^/_!V?_C%>G>'-;C\2>'[/6(K6>VBNDWQQS@!]N2 3@D<@
M9'/0BM2CD0?6)_U<\Z\(^ 5T#Q!%?C2!;;$9?,_M,S8R,?=\I<_G7HM%%-*Q
ME.;F[L****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVJ@)$CK(%A"LR[@>5;C(XYY!XKI+GP#I4O@R'PU!+<V\$$BS17".#*LROO\
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MUMHK>"-8X8D"1HO15 P /PJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>modificationno15effectiv010.jpg
<TEXT>
begin 644 modificationno15effectiv010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&#MZC^7)6-SH6JZ+K?ASQ5K=S;7Z:E.;BPS&DD[&8O$T64WMD; -I)X '&*
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MF>;O&S9C.[/3&.<UP^C^(K[Q;>W4VD:_:6YLM3>$V16.59[6-@K.?XP6))#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:6,D$I(FX''3@BOF^BCZE'N'UJ78^BV\;>!FE:5KNR,C9#.8>3D8.3CTIO\
MPF7@/9L^T6&P'.WR!C/KTKYVHH^I1[A]:EV/HF3QEX#EFCFDN+!Y8\;': %E
MQTP<<=!5O_A8_A3_ *"\7Y&OFNBCZE'N'UJ78^C8O''@BWN9;F&\LXYY?]9*
MD6&?ZD#)ILGC;P--=I=RW=D]S'PDS0Y=?HV,BOG2BCZE'N'UJ78^C9/'/@F6
M<3R7MF\PQB1HLL,=.<4U/&O@:-)$2ZLE20;7580 P]#QS7SI11]2CW#ZU+L?
M1?\ PFW@8R))]KLMZ !&\GE<=,''&*<_CKP3),TSWMHTKIY;.T66*?W2<=/:
MOG*BCZE'N'UJ78^BY_&W@:ZMDMKB[LI8$QMBDAW*N.F 1@8J67Q]X-GA\F;4
M+:2+CY'CRO'3@BOF^BCZE'N'UJ78^DV^(GA)T*-JL+*1@@J2"/RJ&#QSX)M6
M+6][9PL1@F.+:3^0KYRHH^I1[A]:EV/HNV\;>!K.222UN[*"24YD:*':7/N0
M.:0>-/ JAP+FQ <8?$(^;G//'/-?.M%'U*/</K4NQ]&'QQX(-JUJ;RS-L_WH
M?*^0_48Q3[?Q]X-M(%@MM0MH85^['''M4?0 5\X44?4H]P^M2['TB?B!X.9)
M$.I6Y67/F*4X?(P<\<\<4_\ X6/X4_Z"\7Y&OFNBCZE'N'UJ78^E/^%C^%/^
M@O%^1H_X6/X4_P"@O%^1KYKHH^I1[A]:EV/I3_A8_A3_ *"\7Y&C_A8_A3_H
M+Q?D:^:Z*/J4>X?6I=CZ4_X6/X4_Z"\7Y&C_ (6/X4_Z"\7Y&OFNBCZE'N'U
MJ78^E/\ A8_A3_H+Q?D:/^%C^%/^@O%^1KYKHH^I1[A]:EV/I3_A8_A3_H+Q
M?D:=_P +$\+;"_\ :L>T'!.TXS^5?--6U_Y!,G_7=/\ T%J3P<5U!8F3Z'T3
M_P +'\*?]!>+\C1_PL?PI_T%XOR-?-=%/ZE'N'UJ78^E/^%C^%/^@O%^1H_X
M6/X4_P"@O%^1KYKHH^I1[A]:EV/I3_A8_A3_ *"\7Y&C_A8_A3_H+Q?D:^:Z
M*/J4>X?6I=CZ4_X6/X4_Z"\7Y&C_ (6/X4_Z"\7Y&OFNBCZE'N'UJ78^E/\
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M[DD<$?A67M5?4T]F[:'G]%;,7ANZET35=4$T(BTV9(I4R=S%FV_+QZ^M:_\
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M_P#7$_R-8XC^$S6A_$1[S1117D'I!1110 4444 %%%% !1110 4444 %%%%
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M>C8'H*GTT#^V[;C^"3^0J*F*<XN-BH8=1E>YT]%%%<ATA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4
M-;_Y EY_US-8-;VM_P#($O/^N9K!I@%%%% @HHHH JWO2W_Z[+5JJM[TM_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA1ON)(\.)-BN64$L0!W]<\FO3*S[S1X;N]%X)KB"X\KR2\$FW<F<X/XD^_-
MS+OC]F^'%TUM=^<8],<K<QN3O(C/S!LYZ\U@RW3K]L?PW=W-R_\ 94CW),KR
M%9LKL.#TDQYG''3ITKK[K3K*W\-SZ<+>5K(6S1&*'+.RX(('<L?YUHQ@"-0
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M!R:MT <+:V>FZE=^&XK>9Y;3['<%_*N'Y;]SE2P.>O;/:J9NKDV>CQWMTJV
M%U&TEW</&C.DNU [CG.P'&3S@]P*]&HH P["62T\'&6:X;4#%;R/YENY+2J-
MQ 5NI.,#/4GFN2AO[GR]6.DRC:VF"4+:W,EP$?=R0S?QA3V]!7I-% '":M%H
M,_A\RZ?=R3VT-Y:R3.+J1U0>:NXDD\';DGTZ\&IKOSI9=7?3)Y'6TM;*ZM L
MI8.%,C8!SSN48]\UU]O.+A9"(I8]DC)B1-N[!QD>H/8U-0!Q4%W/?S:?JRRS
M""_U;$2;B!Y"PR*O'N06_$52LTMK&TN8+69TNTUU%EC\YBPC-R-N03T*GKW]
MZ[>RU"*^>[6-74VLY@?<!RP .1[?,*KZMK=MHL?FW4-TT07<TD4)=5YQR1TI
M#.3MY+B?7I!/J5O;:@FI$+')<2"1H0_RHL?W2K)W]3GK6CX=N8E\07-JMPE_
M(ZR2F[BN'8J-XPDJ$X5AG QV4\"MN+6X9;FS@-M=1/=-(J":+81L7<<@\XK3
MIB"BBB@ JNW_ "$4_P"N3?S6K%5V_P"0BG_7)OYK0!8HHKE?%T4LEYI9D$1T
MX&7S_/MFN(M^!L+HI''WN3P#CVH ZJBN!N((H].TZQGBBO+=DG>*YN;"5U3+
M_+$D6=P.#\I)Z+QFB!(VM]!;Q#;S3V?]EA<20O(!<?+G<H!.[;T)]^] '9VV
MH1W5]>VB*P>T=4<G&"64,,?@:MUP&IZ1%/!XGO4LYC<11Q/9,RMO0K"A!7/.
M[(P3UXP:W]?LEU#4]"AFA:6W-Q(9EYVD>2^ V.V<<'@]* .@HK@K;1DM(H+B
M"UD6XAULQ1/AB8[?S2NU?1-IZ=.]1FW5MRFUG_X2;^TMPG\ILB/SLYWXQY?E
M<8SCMC- 'H-9U[K5I9Z=?WN6E2QR)E0<A@ V.>^&'YURO]E!$DU%;:3[>NO#
M9+AMRQ&X ('HA4G...<U#>:=:P6'C"WAL"E]*7>/9 <O$T<?W6 P1NSP#US0
M,]!K/M=4%YJ=W:16TWEVK>7)<$J$W[5;:!G=T8<XQ6;I^FQ:7XLGCLK<PVLM
MBC/MSM>0.PR3W;!Y/4UB3:2EM%K,T5@R1MJT8N/)B(=[;;$7 QR5SDD#WH$=
MEJ&H1Z;!'+*KL))XX %QU=PH/TR:-/U"/48II(E=1%/) =V.2C%2?ID5Q;VR
M--<-I%K)'I1O-/,:+$R(9!-F1D4@8&W9DXQD>QIWD*DL!U2VE?2O[1OVF1HF
M=-YD/ELR@'*XW8.,9(I#.]J.>7R+>2;RY)/+4MLC7<S8'0#N:\_:*_TZR34-
M/MKCRY)[FTM8BC;DAE&8B5/(42*,9Z!J%T^]6PU337BG:+1M/N8;=V4_OC*"
M4(]2$ '']ZF!Z$C;T5L%=PSAA@CZTZN!O](%U;>([F6UD>YALHFM&(;*2"'.
M4_VL@<CGM5345M[W7;XZC#'Y$=W;EKR6"20PJJ1EHP54HJL<@@L,;B2#Q0!Z
M&UU EY':-(!/(C2(G<JI )_ L/SJ+3=0CU.R%U$K*A>1,/C.4<J?U6L/5K.R
M'C72;VZLU=6@EC67R2^)=\9CR0#@_>P3[UEV&D+;6VE7\=K(E\=6E$DN#O\
M*,DH(/HN,''3O0([NBN T2RE;5;9[NX2'5([J1I\6$GG2C+?*TN[:4(((XP,
M#'-2^(K1KCQ!>+?21QP/;1K9RRV,EQL/S;C&48;'!P?4\>E '=5%=7"VEI-<
MN"5BC9R!U( SQ7&:AHRWDNO274,ES+#IL/V>5E8'S C_ #*.S9 ]Q4&J0Q3S
M7IU>TN;B>33HA8%8G8A]K;]I4?*V[&>G&.U '86$%M/+_;$:OYMY!']\_=0
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MNC;I<"V>\"+Y2RD@;3SNZD#.,9[T"-JBLU-;M9-<_LE4G,_EO)YAC(C^4J"
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M@:2:Y(4Q\0KYKL YSQD$8ZYIGB#2)=6UF*)5=4.G7"+.!Q'+YD3(<^N5S^%
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MD_D*@J?3O^0U;?[DG\A0!TU%%%(84444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&M_\@2\_ZYFL&M[6UW:+=KDC,9Y%4_\ A&T_Z"%Y^:?_ !- &;16E_PC:?\
M00O/S3_XFC_A&T_Z"%Y^:?\ Q-,1FT5I?\(VG_00O/S3_P")H_X1M/\ H(7G
MYI_\30!AWO2W_P"NRU:J;4=!2$6N+ZZ;?<(GS;.,]_N]:N?\(VG_ $$+S\T_
M^)H S:*TO^$;3_H(7GYI_P#$T?\ "-I_T$+S\T_^)H S:*TO^$;3_H(7GYI_
M\31_PC:?]!"\_-/_ (F@#-HK2_X1M/\ H(7GYI_\31_PC:?]!"\_-/\ XF@#
M-HK2_P"$;3_H(7GYI_\ $T?\(VG_ $$+S\T_^)H S:*TO^$;3_H(7GYI_P#$
MT?\ "-I_T$+S\T_^)H S:*TO^$;3_H(7GYI_\31_PC:?]!"\_-/_ (F@#-HK
M2_X1M/\ H(7GYI_\31_PC:?]!"\_-/\ XF@#-HK2_P"$;3_H(7GYI_\ $T?\
M(VG_ $$+S\T_^)H S:*TO^$;3_H(7GYI_P#$T?\ "-I_T$+S\T_^)H Q4_Y"
M$O\ UR3^;58JPF@(=5GB^W7>%@C;=\F3EGX^[[?K5K_A&T_Z"%Y^:?\ Q- '
M#:C+>P^-8'LK2.Z?^SG#(TOEG'F+R#@CKBJ$'A>_T\V,P5[EDM#!-';7CVY5
MC(7RI&-R_,1SZ"O2/^$:CSG[?>9Z9^3_ .)H_P"$;3_H(7GYI_\ $TAG'Z=H
MK66JV4T=ND-M!IWV81B0N4;>K8!/)''6J%MHVIZ=)87D4$5Q+;R7@>#S=N4F
MEWJRDC&1@9'N:[__ (1M/^@A>?FG_P 31_PC:?\ 00O/S3_XF@#S^#1=4L;J
MUU1((9[CS[J2:U$NT()BI&UB.2-@SP,Y-:V@6-W8:7-'=QPBXDN9YBB-E/GD
M9@,XZ<^E=5_PC:?]!"\_-/\ XFC_ (1M/^@A>?FG_P 33 \Z&@ZI)IE[91P_
M9K-Q"(+22Y\T(RR!FVMCA-H  ]N@K1U+3-4:_P!5N].=(Y)[6WBB;=@DH[EQ
MT."5; /J?:NT_P"$;3_H(7GYI_\ $T?\(VG_ $$+S\T_^)I >=Q^'M2>._9H
MMAN+NSF19;DRL%B=2VYCWP#Q6_H]C-9-J1FP!<7CS)@Y^4A0/Y&NE_X1M/\
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M.".*[W_A&T_Z"%Y^:?\ Q-'_  C:?]!"\_-/_B: .3CM+^SU+5KR""*7[5-
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M2%;:1D DX[C)Q60_@RSU'6M2O;N222TNXH8D2&ZD7S$12&63!&X'CJ3W]3D
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M_0/^$:\,6FFML\Y 7F*$E=[') )Y('09[ 4 ;M4;G_D+6/\ NR?R%7JHW/\
MR%K'_=D_D* +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[B=[G46M(;:XN6)_>^7NP<=CEV/XU#9^%]/L&(MI+V.##!+9;N011[LYVKG
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M/B#6I;'0];ENX'M=6NDA-DL !A63=M*OG)9<#=G@\\"JUMXYOH[O28KSR1%
M9(-9?;CRY=[QQD>@+Q-^#"NGL-!\/1ZE)=V,$#7%O,P8)*66"1AEL)DJC$-S
M@ \^]2W'A;1+J+48I].B=-2=7NP<_O67&TGGC&.U '+)KFH[8-0N(;=;U_#U
MW?*YA&^/YT9$SUP PR.Y&:E?Q%KFE1F:]N;6[\_1)]1C00^4L4D80[<YY4^8
M.O/'OBNG:TTC4KNYC,<4L\$+64R@D%(Y K%#]1M-0ZSX<MM4TN:VBQ;SFRDL
MH9\%O*C<+D8SR/E7WXZB@#.\+W^L7^J7)NKJ:?3TMHBKS6!MCYS%MZ@, 2%
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M5YX5T34)(WNK!)"D0@^\P#1CHK '# =@V<5>DTVRETO^S9;:-[(Q"$PN,J4
MP!S[4 <'XLN]8M](\1:+<ZDER#HLEXMPMN$90"5:,@'&".AZCGK72:I?7'AC
MP//>+Y=S<6T/RGRPBLQ( RH[#(S]*MP^%]&@L[RU2SW17D?E7'F2.[2)@C:6
M8EL8)P,\9K2GM8+JUDM;B))8)$*/&XRK*1@@B@#DK?6=9L[?4GU226&SBMU>
M*^N;(*RR%BI01HQW_P ..^3CFJ*^*M7MK76()&+W$$UG%;S7=MY17[0^S+J#
M@A3SVSTKJ8O"^CQ6=Q:?96D@N$"2)--))E1T W,=H';&,4D7A;18K:\MQ8J\
M=XJK<^:[2&4+G;N9B22,\'.>GH* ,#6;36$UKPU VJQ2737D_EW+6H&Q/L[Y
MRH."?O8/ Y&0<<[GAC4+N_T^Y6^D26XM+R:U:5$V"0(Q ;;V)&,^]3V?AW2K
M%H7@M</#(TJ.\CNP=EV$EF))^7CGM5VULK>R$HMHA&)I6FDP3\SL<D_C0!PD
M/B/Q!'X3LM5FN(II]3N8[:&*&V'[@%F!;[PWL0O0X&2/QL2:WXD@M889 ())
MM4BM8+F[MPI>)T))**V,A@1P1G Z<UU+:%ICZ.NDM9H;%<;8B3\N#D$'.00>
M0<Y%9FI>#K&\LK2RC4BWCO4NIEGD>4R!5(QN8DYY&#GC% &3)XAUFUN+G16N
MH);P:G!91WQAP%22+S<L@."P ('0'*TR\U[7K.ZN='2\MI;N*_M8$O'@P"DR
MD_,@.-R[>V,@CI73+X8T9=+DTX6*FVDD\YPSLS-)QARY.[=P.<YX%/M_#FDV
ML"0Q68"K<+<Y9V9C*.CLQ)+$>Y- &%;P:LGQ"2";66EB33$>1/("K)^\(/&>
M"3SG\*S]"U+5K^U\/:=I\]IIT=SI4EU(8[4$*5=% 1<@#[_\Z[2XTBQNM2M]
M1E@S=VX*QRJ[*0"<X.#AAGG!R*;9Z+IU@]LUK:K&UM ;>$@GY(R02O)]5'Y4
M </)XPU>ZT[3O+E-O<RZ=)<,;:R:X,DZOL5=HSL4D$\]>F>*[S3/M?\ 9=J;
M\YNS$IFX P^.1QQUKF=4\$1S7]O-90Z>UO#:FWCM[R)V$1+EBZD,#DYY!]!@
MCFNDTBQ?3-'L[&2YDNGMX5C:>3[TA QDT 7:*** "J-S_P A:Q_W9/Y"KU4;
MG_D+6/\ NR?R% %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** *.L?\@>Z_W*O51UC_ ) ]U_N5
M>H **** "BBB@#.U;I9?]?<?]:T:SM6Z67_7W'_6M&@""\L[>_MS;W42RQ%E
M?:W3*L&4_@0#^%0W&CZ==RW$MQ9Q2O<PBWFWKD21@DA2.A&2?SJ[10!SFH^#
M=/N=$GTVUC6%+B6!Y3*6EWK'(K[3N)XP",=.:NP>&=%M[&ZLDTZ$V]UCST?+
M^9CIDG)X[>G:M:B@#*@\-:/;V<]I'8IY-PRM,&)9I"I!7<Q.3C QS5B^TFQU
M*:VFN[=9);5]\+Y(*'O@CL<#(Z'%7:* "BBB@ HHHH **** "BBB@ HHHH *
M*** *,7_ "';G_KVB_\ 0I*O51B_Y#MS_P!>T7_H4E7J ./\4:_>^'-3D8.9
M(+ZR:.RB('%XK85?^!AQ_P!\&LJ[O?%$FHZGI]G<7,ESI=O L<B/ D<LAC#&
M24/R59LCY<  ''-=AJNE0:KJ&E&>=0+*X-VL! )D95*J?4!2^>.^*9]AT#Q-
M'%J$EA9WP1FC26>W#$;6*D?,,X# T <OXFU^^M;JZGL;G4!)82VT<Z P"V1G
M*$H0WSN2K=1TR,=#6SHS:A?^*=;EGU.?[)8W@@AM%1 A!@C8[CC<>7R.1CGK
MFM>YT+2+R\^V7.EV4US@+YTD"L^!TY(S4OF6%G?B >3%=7I:7:JX:8J%!8^I
M VCGMB@#E]4O+Z\UC7HEUJ73(M*M8Y85B6/#EE9C(^Y3E<C;@8'![]*OA_[7
MJ/C:#5+FZN8I9]!M+B2V&P("YDRGW<X!R>N<GKCBNKU/2=&O"MYJFGV=PULI
M82W$*N8U')P2.!WJ>W>PN)8[RW\AY9X%*2J!O>+JO/7;EL_C0!S>K7%W=>,I
MM+779=-MDTM;H"(1[B_F."V7!^4 #(]ATYSA6OB#Q'KPL88C=13'1X;S_1&A
MC,DKEAO(DZJ-HX'][GM75'0M%\1ZBNN3):ZC:S6J0Q)+"KI\KNV\9[_,1T[5
M:OK+0-4U"+3;^QL[JYAA\Z..:W#[(\[<@D8 SQB@#%M)-;U/Q-%:7>J2V:P:
M5:74\%H(R&G9Y PW,I^7Y<8'7CD=\71'O=/\/Z7:1:M=1IJ>LW5O)<.(R856
M2=OD^7 9R@&3GECC'%>C16EM#+YL5O$DGEK%O5 #L7.U<^@R<#MDU#+I.G3V
M#V,MA;/9NQ9H&B4H26+$[<8R22?J<T <1<:GK*3S:1;ZQ*PBUJ"S6^,:-)Y;
MP[W0\;2RD]<>F<\Y76+C6;4^)/L^O7:)HFG17$(,<1,LFQV)D.WD'9R!CK7;
M0:3IUK;0VT%A:Q00/YD4:1*%1_[P&.#R>?>I)+"SF^T^9:PO]I3RY]T8/FK@
MC:WJ,$C!]30!QSZK>:)>7RZCK-U-;-I'VYI?)C+0R;MI\L!<8Y& V>G)ZUG3
M:[K=C:^);<75Y'+:6UK-;F],,DL32.RMGR_E((4'!YY/M7::O<Z#ID8FU=K*
M!)8S;[YU7YTZE.>J^W2LS3KKP4\2VVF)I;Q7<B6Q2VA4J[8>15; QT5R,\=:
M ,C5M5U?P[)K5H-5ENMEI:3QW%S&F8#+,T3M\J@%0!NP1QCTJWKESJ.C0Z?I
M]IJMY>O>WRPO*S0B:)?+9]BL5"@L5&"PSR<=JZZ2QM)GE>6UAD>:/R9&:,$N
MG/RGU')X]S52/P]HL6G/IT>DV*64C;GMUMU",?4KC!/ H K^&CJHL9X]6WF1
M+AEA,CHTABP"-Y3Y=P)(X[ &N3TO6-4:UT/5'UR2ZDO-3:REL]L?E[-S@X &
MX,H4-G/X8KOK*PL]-MA;6-K!:P DB.&,(N3U.!WK+T/PIIFB)$Z6MO)?)O'V
MPP*LI#,6QNZ]\=>U '.>&-0GMD\,VBS;+:Y?4?,4XP[+*2O/M\QJ+^V=7N]!
MAU1+ZXDL(;F_:Z>Q:(3>4DS"-UWC:R*JG(')XZ]#TEQ_PC-W-+H=S96LJ6?[
MZ2*2TS!"Q^;)8KL5B&SC.<'/>KL_AW1+F**.?2+"6.)F>-7MT(0L<L0,<9/)
M]30!6UO5(H?#\-Q'<W:_:GAC@>U1/-D9R H&\;03GJ<8SVKE(=9UJ2QELQ?W
M$$T>OQV FE$4DJQ-&K%6*@H2"QY]AGH:] N[*UO[5[6\MHKBW< -%*@93CIP
M:@@T;2[6)8K?3K2*-9!*J1PJH#@ !L =0 !GVH Y!]5U726U R:C-<VNCZK"
MD[S*FY[:6)"VX@#[C2;LC'"UO^'+F[UC1)[Z>YD5+Z662U*@ Q0$[8R.,9*@
M/SGEJ->@TVYT6[M?M$5K_;#"T:XBB#F1W&SG'4X&W)Z8]JVK>"*UMHK>% D4
M2!$4=%4# 'Y4 >:Z"FI0^'_"UA:ZU=PIJ-U.LK[8V9$5)&VI\O&2N<G/)_"K
MVM:W>6>H&2POM3E6SO[6RG,GD"W)<QAE(P'9BKYR.A/' -=O'I]E$+<1VD""
MW):$+&!Y9(()7TR">GJ:@FT+2+B^-]/I=G)=G;F=X%+_ "XQR1GC _*@#"TJ
M:\U>^U&ZGUN>U$&H2V4=I&(@@5?E7.Y22Q^^#GN.,=</0#<Z=X6T)DOYYA<:
MSY3+,(V"+YLH(7"C&2,GOGIBN[.C:6VJ#4SIUH;\# N3"OF=,?>QGIQ1%HNE
M02R2Q:;:1R23"=V6%06D&<.3C[W)YZ\F@#BXM8U1M-M->_M:4SS:L+-M-VIY
M80SF(Q@;=V\+\V<]CVI8-1UE1#JCZO.ZG7WL/LIC01^2;AHP#\NXL."#GL!C
MKGLET324U,ZFFF6:WYZW(@42'M][&:D^QZ>NRW-O;#,IN5CV+]\-N+@>NXYS
MZF@#C/[>NSXFTZ6TN]0EL;K4Y;)_M'D"%@JR9"*/W@VLF-QZX.<Y%:?A61X?
M DLL9VNDMZRGT(GEK4L=.T"[N&U:RL;!YVE8FZ2!=YD4E6.[&<Y!&:O-8P#3
MY;."-((I%<8C4  MDDX'N2?J: .$TS7+ZVB\.W]UKTEY%J=A+-=J4C*P[(M^
M] JY&T_*02<D^M0Q^(-5@.J!+K4#$V@3:C;M?&!G#KC:ZB/@ [NA]/K79:)X
M9TO0K.&.WLK7[0MNEO+<K JO,%4#+$=<XS4UMX>T6S21+72+&%94:.01VZJ'
M1L;E.!R#@<>U ''ZEIE]))X1DNO$&H--<7Q=I%$2A&:VD/R#8<#@@ YX8]3@
MCHO%%[=6QTBSM[IK07]\MM+=*%+1KL=L+N! 9BH4$COZXK5O-+T_4;-;2]L;
M:YME(*PS1!T!'3 (QQ3-1&F7"PZ;J4=O,EV2D=O,@99"HW$8/' &?PH X#6#
M?7?G:9)J]W+%8:]8Q17*B/>=YC8JQVX+(3D''<9S7I<:&.)$+LY50"[8RWN<
M<9JK#I&FVUI%:06%K';1.)(XDB4*K@Y# 8P"#SGUI]S?VUI/:03R;)+N0Q0C
M!.Y@K.1QT^56//I0!9JB_P#R'8?^O9__ $)*O51?_D.P_P#7L_\ Z$E %ZN9
M\2W5TNN:#I\&IO817LDR2N@3<VU-P"E@0#GVKIJR-7\/6FMWMA->I'-#:^9F
MWEC#I)O7'.?3K0!QBZ_K<SV.DQW-S<A[^]M_M<!B26=(<;1N8;,_,<D#)\LX
M[UH&;Q%,^@:9=ZC+937,UTD\L0B:1XTR4R0"H?&,D#&<\>G5RZ'I,^G1Z=+I
MEF]E'CR[=H5,:8Z87&!4D&F6%JENEO96T*VV[R!'$JB+=UVX'&>^* .+DU;4
M%NY]/6^:W6X\0?83=A$WQQBV5\#C&YF&,D'[WTILVL:I;W%QHRZK*\0UB"Q7
M465/,C1XO,9<[=NX$!0<?QCO7:SZ5IUS;W%O/86TL-P^^:-XE*R-@#<P(Y/
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M*XM98[B^#%U19,X@ P@#(,'@XQGK6OX2G\G07US5M8G?S9948W4V(HE$S(H
MZ \ 9ZG/TKIUL+-+AKA;2!9F;<T@C 8G&,D]<X)_.J-UJ&GV^H6^BFU:62=3
M+Y44&Y$7</G;L!N/YT 6=8_Y E__ ->TG_H)KB[BW:Z\+> (%GE@+S6P,D)
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MD+R^0T<B,[$;R7)+-TQG+$\#'M5C3=+M-+MHX;:&-66-(VE" -)M& 6(')H
M\]M[[5X] O[^'5HWC;1)YV_XF9N)&E" K*B[1Y>,G(''(XXK='VW2[KPS$NH
M7EV]Y+-)/Y\N?,;[,S8QT"[@" .!741Z;8Q&8QV5LAF!$NV)1Y@/7=QS^-3F
M*,LC&-"8_N$C[O&./3CB@#SG2-5N'A\,W\&LW%YJFHR[;ZR:;<@!C=I (_\
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M_P#%4 ;5%8O_  DD?_0/O?R3_P"*H_X22/\ Z!][^2?_ !5 &U16+_PDD?\
MT#[W\D_^*H_X22/_ *!][^2?_%4 ;5%8O_"21_\ 0/O?R3_XJC_A)(_^@?>_
MDG_Q5 &U16+_ ,))'_T#[W\D_P#BJ/\ A)(_^@?>_DG_ ,50!M45B_\ "21_
M] ^]_)/_ (JC_A)(_P#H'WOY)_\ %4 ;5%8O_"21_P#0/O?R3_XJC_A)(_\
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M2Y:%VN5#/O?E=RG&.^/<UV__  D<0_YA]Y^2?_%4@\0P*,#3;L#.<!4_^*H
MY;4FN]%A\6V>G75Z(8+>TF0M,\LD(=G$S*S$L/E4M[$9JE]NT;3M7UR[TNZN
MK^PCTB$%HKZ1\$RL"%F))4#()()VY)KM_P#A(XO^@?>?DG_Q5(/$,*C TZ\
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M@?>_DG_Q5 &U16+_ ,))'_T#[W\D_P#BJ/\ A)(_^@?>_DG_ ,50!M45B_\
M"21_] ^]_)/_ (JC_A)(_P#H'WOY)_\ %4 ;5%8O_"21_P#0/O?R3_XJC_A)
M(_\ H'WOY)_\50!M51?_ )#L/_7L_P#Z$E4_^$DC_P"@?>_DG_Q55&U^,ZM'
M+]AN\"!UVX3/++S][VH Z6BL7_A)(_\ H'WOY)_\51_PDD?_ $#[W\D_^*H
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M HHHH **** "BBB@ HHHH **** *&M_\@2\_ZYFL&M[6_P#D"7G_ %S-8-,
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M3T=Y-=%PVY02T7FCYCZC;G\*??:)<37>H(+(-;3:M:3A,#:R*L8<X].#GZ4
M=$FLZ7((2FI6;"=BD16=3YC>B\\GZ5(^I6$=ZMD][;+=-]V RJ'/T7.:Y?4=
M!E>'Q.T%@OFW,L+6Y50"^U$Y'T8-^--UFUU:]U&6(6DX1;^WEB\F*/RVC5D)
M=W/S;AAA@8X ZB@9N+XDT^==16TGAFN+'=OB,R+G:H).2>%Y +'@'-79=3L;
M>6*"YO+:&>4 I%),H9L^@SS^%<U=V%W]E\6V26$I>]222WE4+MDS"B!0<YSN
M!XJ*]T^\6/7K-M)ENY=251;SKM*J/*5 K$G*[6!/X\<T".KFU.PMIEAGOK:*
M5F"!'E56+'D#!/7D?G5B21(8VDD=411EF8X 'J37'7N@W,EEXG#6HGN;BTCC
M@D(&Z5EA X/^\/SK9\1V=Q>:+&D,)N&CGAFD@R,S(CJS+SQR!WZT +J7B73K
M+0KC5(+JVNHXOE7RYUVN_9=W//\ 2IGUF&ST!M5OY;=8DC,C-;R^8C>@1B!N
M)[>_%<YJ.FW>J)K5W;Z;+;I<6\$,<,BJKRNCDER >,!@.>>/I71Z_927WAK4
MK*WC#2S6LD<:< %BI 'YT 5V\3Z>M_#&;JU%G+;-.+IIU"9#JNW/3^+U[5HW
M&I6-G#'-<WMO#%)]QY)556^A)YK$M;(WNO6%]-IKQ01Z?)'B=%RCEUXQDXR
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MT5P2L0CC9W<C.0$ +<8.>.,<U4C\1VXU&]$TT:V,<%M)"X4[G:4R#&.I/RC
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MQMG,<LQ0"-6P#C.<G(/8?7'%5_[>E7Q+=:9)92K;06Z3&Y^7:N=^2?FSM^7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AK?\ R!+S_KF:P:WM;_Y
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MM^W@EO'N9ML420%8?(82JT@.%(_B8G& !D=ZKP:#*ITYUM[6U:"^:ZF2*9Y
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M%5[K0+F>]NYUDA"S:C:W2@DY"Q! P/'4[3BK6M6%]<WFFW=@;?S+.5Y"D[,
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M:S;P7-P9KFV6TAMXY]X8E@&+#<>,;3C@@^M-;Q)I*VR7!N6,3[MI6%SD#J<
M9QR.>E8,OA:]33;JRC,<H;2K6S1BV-SQL^[Z#!%:NNVFJW-U"MIO>S,+JT<5
MQY)$A(VLS8R5QG@?D:!$S>)+ :U;::K,[7$'G1RHI92"5"\@=]V<]*6/7[2+
M3K>XO;B$/.SJ@MP\F_:2#M&-QP!SQQ6=IFDZCILV@2>0DHM]-%E< 2 >6?W9
MW#^\/E/3VJ&QT?5-);3KN.VCN9((KB"6#S0I >4.&4GCM@CWH&;<GB'28K:W
MN&O8S%<@F$J"QDQU  &21GIUJY9WEO?VD=U:RK+!(,JZ]^W\ZY[3=!O+:]TR
MYF6+*2W<\ZHV1&TQR%7UQTS6EH^G36FDW-K/A&DN;EU*G.%>5V4_DPH$53XI
MM+C6=-L;">*87$LBR':WW51CE#P",J!D9%7(_$6ES>:(KDLT<9E(\MP60=67
M(^8<CD9ZUB:?I6LHV@036EO#'I2M&TPEW>9^Z9%8+C@9P3GGFETK2-8.L65Y
MJ0<O#:RQ32O<^8'D;9RB@ *ORG^HXI#-2Q\4:;>:+;ZDSO$D^T"-HV+;RN[:
M !ECCT!Z5IVEY;W]LEQ:RK+$V<,/4'!'L0>,5R,>A:K_ &1H:26S";2@86CA
MN_+,R[ N]7&,<CH<<9KHM(T\6NEO#Y#VS2N[NK3F5MS'DECW/6F(2'Q%I,]R
M8(KQ6D^;;A6P^W[VTXPQ&#P":J^&];DUJTN;V22/R1(PCC2!U9%5F'+$_,2
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MTLUPUJ+=8@9%E4$E2,X[=<XYSG'-/N/$UK;-+OM;LQVX0W4H1=ML6 .'YSD
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *GT[_D-6W^Y)_(5!4^G?\
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M54\^_P X_*J.D:[J$NH6=C+:-+ =-@N'N-R[BS#ECSDC(QC&<Y[5);^&+L-
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M%% !1110 57;_D(I_P!<F_FM6*KM_P A%/\ KDW\UH L4444 %%%% !1110
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M>H **** "BBB@#.U;I9?]?<?]:T:SM6Z67_7W'_6M&@ HHHH **** "BBB@
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MRD2L<%V +8'J< G\*\TL5M=.\!>'Y[T2S3:FL/VBYOK^6.)"(V(,C ]/X0N
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MCK'_ "![K_<J]5'6/^0/=?[E7J "O,)IX#X2U+3S+'_;#^(&VQ9'F&4W89&
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M"E(2J >6IQD+Z#@<#T%<1-=V,VMP6%QXCN8M'33S-;7"Z@8S/)YK*^9007V
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MC3;>YU&SOI WG6@<18/'S@ Y'?@5;HHH **** "BBB@ HHHH **** "BBB@
MHHHH *HW/_(6L?\ =D_D*O51N?\ D+6/^[)_(4 7J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MHZQ_R![K_<J]5'6/^0/=?[E7J "BBB@ HHHH SM6Z67_ %]Q_P!:T:SM6Z67
M_7W'_6M&@!"H888 CT-&U=V[ SC&<=J6B@"AJ&CVFI:>;*13%"98YOW.%.Y'
M5QV]5&?:KJ1QHI5$55/8# IU% #%AB2/RTC14_NA0!^5*R(^-Z*VTY&1G!]:
M=10 4444 %%%% !1110 4444 %%%% !1110!1B_Y#MS_ ->T7_H4E7JHQ?\
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MAGGG.<B@#U>BJT%]#<7EU:H)/,MBHDW1D+\PR,$C#<>G2K- !@9SWHQBBB@
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M/[=U#_GSMO\ O\W_ ,35.B@"Y_;NH?\ /G;?]_F_^)H_MW4/^?.V_P"_S?\
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M<0M=C]W";>0NS;02%&W+=>H&#0!U']NZA_SYVW_?YO\ XFC^W=0_Y\[;_O\
M-_\ $U@?V]8B]CM6-PCRN(T=[>14+XSMWD8S[9]NM)_PD-@UQ-#&;B1HBZLT
M=M(R%E&64,%P6&#P.>* .@_MW4/^?.V_[_-_\31_;NH?\^=M_P!_F_\ B:Y6
MP\5V5WHEKJ4L=Q ;C:J0^2[,SD9P@VY<8SR!C@U._B;2H[*.[:=Q&\QMPODO
MO\T G84QN#<=,>GJ* .C_MW4/^?.V_[_ #?_ !-']NZA_P ^=M_W^;_XFL>?
M4[:UT]+V8R)$^W:IB;>2V J[,;MQ) QC-95YXD2VU734*SBVNH)V\O[,YE+H
MR  )C=W;M[T =;_;NH?\^=M_W^;_ .)H_MW4/^?.V_[_ #?_ !-8+:]8_8;>
M\B,\\-PI:/R+=Y"0.N0H)&/?%9FH^(G5C+I\D<EL^D7%]&Y7JR%-I^GS'B@#
ML?[=U#_GSMO^_P W_P 31_;NH?\ /G;?]_F_^)KF-8UJ72_"4FJ!-\XMPZ@1
MLPWD<9 Z#--3Q!:V-K"E[<7$]QY9ED*6,@94R?F= "4''?K@T =3_;NH?\^=
MM_W^;_XFC^W=0_Y\[;_O\W_Q-<^_B'34O(+19GEFGC2:-88GDS&Q(#Y4$!>.
MO;CUI\.NZ;</IZ17(+ZA&TEL-I!=5 )[<8!Z&@#=_MW4/^?.V_[_ #?_ !-'
M]NZA_P ^=M_W^;_XFN=D\2:=':)=!KB2!@S;XK:1P%4D%CA3@9!Y/7J*?)K^
MG1WT%D)7DN)T26-(HF?*,2 Y(! 7(Y)X'&>M &__ &[J'_/G;?\ ?YO_ (FC
M^W=0_P"?.V_[_-_\37(7/BFWDU'3K6P=G\^\,+NT+A'4*^[8Y&#AE X)K4N]
M0%KJ5O \T2QO!+*RE&+D)MR01P -W(/)R,=Z -O^W=0_Y\[;_O\ -_\ $T?V
M[J'_ #YVW_?YO_B:YNV\2Z;?AEM)VWF!IXFE@=4D4=64D#<!D9Q4%KXFBDU#
M3[!XI97NK-;CSX8)/+).T<#:<+\V<D\< T =7_;NH?\ /G;?]_F_^)H_MW4/
M^?.V_P"_S?\ Q-<U#K\":9!<W#/.9=YW6EK*XPK$$X )&..O7M3H-6-UKT$%
MO(DEE-8?:D<#[V7 !SZ8- '1_P!NZA_SYVW_ '^;_P")H_MW4/\ GSMO^_S?
M_$US.M^(K32H;F/>YNH[=I<+"[K'P=I<@84$COBEM/$5H[65I,[M?SV\4S1Q
M0NP <?>) ("Y!Y/3B@#I?[=U#_GSMO\ O\W_ ,31_;NH?\^=M_W^;_XFN?C\
M06$EPT ^TK((WD4/:R+YBK][9E?GZC@9/-8&E>,I'AL)+R*YE.H2N%$5C*!"
M K-@?*?,Z#I[GM0,[_\ MW4/^?.V_P"_S?\ Q-']NZA_SYVW_?YO_B:IT4"+
MG]NZA_SYVW_?YO\ XFC^W=0_Y\[;_O\ -_\ $U3HH N?V[J'_/G;?]_F_P#B
M:/[=U#_GSMO^_P W_P 35.B@"Y_;NH?\^=M_W^;_ .)JJVLWQU2.3[);[A"R
M@><<8W+_ +/M3:KM_P A%/\ KDW\UH U/[=U#_GSMO\ O\W_ ,31_;NH?\^=
MM_W^;_XFJ=% %S^W=0_Y\[;_ +_-_P#$T?V[J'_/G;?]_F_^)JG10!<_MW4/
M^?.V_P"_S?\ Q-']NZA_SYVW_?YO_B:IT4 7/[=U#_GSMO\ O\W_ ,31_;NH
M?\^=M_W^;_XFJ=% %S^W=0_Y\[;_ +_-_P#$T?V[J'_/G;?]_F_^)JG10!<_
MMW4/^?.V_P"_S?\ Q-']NZA_SYVW_?YO_B:IT4 7/[=U#_GSMO\ O\W_ ,31
M_;NH?\^=M_W^;_XFJ=% %S^W=0_Y\[;_ +_-_P#$T?V[J'_/G;?]_F_^)JG1
M0!<_MW4/^?.V_P"_S?\ Q-']NZA_SYVW_?YO_B:IT4 7/[=U#_GSMO\ O\W_
M ,31_;NH?\^=M_W^;_XFJ=% %S^W=0_Y\[;_ +_-_P#$T?V[J'_/G;?]_F_^
M)JG10!<_MW4/^?.V_P"_S?\ Q-']NZA_SYVW_?YO_B:IT4 7/[=U#_GSMO\
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M %V6K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %=/\
MD(2_]<D_FU6*KI_R$)?^N2?S:K% &9K.GS:@ED(2@,%Y%.VXX^53DX]Z9)IL
MSZ[=7H*>5+8K;J">=P9SS[?,*=J.NVVG7:VC0W4]PT1F$=O$7.T'!/M45EXE
ML=1GABMQ.!<1-);S20E4E QG;GKC/M[4 8L?A:]M?L;B*.Z(TZ"TFC%[+;A6
MC!Y!4?,IW'@CM[FMV^T5+WPPVCKMME,"QIL)81%<;<9Y(! ^N*J6_B>W6RL
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M^G6@N9]^UF5$14)=V8X"@=R: .<70-7@LK&V21)(HEF$D27<D WL^Y7W(,L
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MHV#R* *]SX?GGL-9MQ-&&O[M9T)SA0!&,'W^0_G56^\.ZG+'J5G;7-HMG>W
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MYKFWUB+[2%_M&>.4'9GR]JHN.O/W/UJ!_"X75KF[B739([F83/\ :K+S9$;
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MVD%CQG=P .N#0(=!X<N;.#1Q;7D7G:<'0M)"2LBOUX##!X&.:E7P\RV,5O\
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M+4W9I !@H#&J8'_?.:BL-$N;?58=0O-3>[EBMFME7R0@VDJ<\=_DY_D*VJ*
M"J[?\A%/^N3?S6K%5V_Y"*?]<F_FM %BBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J?3
MO^0U;?[DG\A4%3Z=_P AJV_W)/Y"@#IJ***0PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&M_\@2\_
MZYFL&M[6_P#D"7G_ %S-8-, HHHH$%%%% %6]Z6__79:M55O>EO_ -=EJU0
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MGWD%G'$8YK96V.['E<[C]T=?J.G2I/%NH2-::SII1?+CT^.<-WRTC*1]/E%
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M/!!V'CMD<F@#0/AY$G$UGJ%Y9N8DAE\DH?-"#"D[E.#CN,5L 8 &2<=S2T4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4^G?\ (:MO]R3^0J"I]._Y#5M_N2?R% '34444AA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ7!U<V+2S0J6\ORRV2JG;NZ=../PH Z)]#L7OFO LT<KL'D$5Q(B2,,8+*K
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MAK9[MXI(RD0B2)79,AMV_<, GC'48[T6&JZNR:5?7%ZDD-Y?26K6XA50%!D
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M'6.XD1'88P60,%)X'4<XJ/6KM[2TMHTNIH[B:41IY$*R22':20H/RC@$Y/
MK!MM:U:[@TRW^U"">:_N+2662%2VV,.1\H.T-\HZ<9]>E CI(M&LH=0^W!96
MGRQ7S)W=4+?>VJ20N?8"H]0T#3M3G::ZAD9WC\F39,Z"1.2%8*0&')Z^M8":
MOJTDUOIXOHUE_M26R>Z,*G>BQ%P=O0-V],CIVI3JVKF%+..]C^T+K!L#=&$'
M?'Y9?.WIN'3CC*T =1!I]K;3R3Q1;9)(TB8Y)RJ9VCGTW&J]CH=CITH>U6=
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M)8M4F5'M!$H$0=68;6'S97'.<YYZ4".OHHHH *KM_P A%/\ KDW\UJQ5=O\
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MQ6XF:$#*M&'#8Z!ANQD46NKZN19WTUS"UO/J4ED;<0X.P2.@;=G[P*CVQ^=
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M/Y"@#IJ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *&M_\ ($O/^N9K!K>UO_D"7G_7,U@TP"BB
MB@04444 5;WI;_\ 79:M55O>EO\ ]=EJU0!#=6D%[ 8+F,21%E;:?56# _@0
M#5>[L=/UNVC$ZK<1))O1DD(PPR,@J?<BJ_B74)-.T"YE@#&YD AMU49)D<[5
MP._)S^%<G9ZB?#NGZU86,4]LL4*7-F+F(JW.V-\ ]?FP?3+\T =E'H6F16;6
MD=G&L#2+*ZC/SNI!!8]6.0.OI2:QI$6KVAC9O*F"NL4ZC+1[E*L1SW4D?_JK
MF7U35[/2]1O4NKR>!IH(+1KJ*)'7>RJ[8VKT+<;L#\.:FN;SQ!9:;=EY)X?]
M(M4MIKM87D^>4*X(C^4CGCH>3Z9H&=0^GVLEM!;/"IA@9&C3LI0@K^1 J.?2
M;"Y:Z::U1S=(J39_C"YVY]QGKUKF[K5-3TPZG9&_:9HYK1(KJ:--T0F;:Q(4
M!3C!(R._.:MWU]<^')K6XO-4DNM.WR17#2I&&C)0,A)51W4CM]\?6@1-J7A>
M"XL8H+38 EPL[I=,\RR[00%8ELXYSU[=*6Q\,0)836U^(Y4DN!.D46Y$@(
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO!8$9)]QGBEOK9M0GUR:>6YWV^F0RPA)F0+(4D.X $<Y H ZO3-+MM*LXK:
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M&W55#-C:I"[N<ABO7)R,5<UR8V\'BFS6"Y:2\6-[58H68.ODHI((&  5.?\
MZ] SL;;4([J^O;1$</:.J.3T)90PQ^!J6XNH+4Q":0)YT@BCS_$QZ#]#7(:G
MNAO-:,MBL\$][;*6FB9XT7R5R[*/O $8QZFLU=/A?1('O;(2VMMK)('V1E5(
M& SMC.2J$D<4 >CT5P.JP6CSZR+RRGENWC0:2R0.2J^4-HC('R,'SGIVSQ6E
M9Z''J&O:@^K6_G2+:VZ!WSM#%&#E>V>V:!'645R'A875YJ)^VAB=&A.GAF_Y
M:2;OF?\ %%C/_ C77T %%%% !1110 57;_D(I_UR;^:U8JNW_(13_KDW\UH
ML50U/4H=-^S[X)9YIY/+ABA4%V;:6.,D <*3UJ_7.>(M/@O-=\/F:)G'VF12
M0Q&!Y+GL?4"@#H#%&[K(T:EUZ,5&16.GAFV610;N[:U6Y^U+:EE\L2;]^<[=
MQ^8YP6Q6!):SKI&OZC"UV;P7LL099&+)!YHWA%[?+N/ S5:_> 6VL'0)Y6T\
M:>"[12,RB??QM)_BVYSCVS0,] \J/>7\M=QQEL<G'2F7!MH;:26X\M8(@9'9
MP-JXY+'^=<=>Z) FIZO;(UWY$>FK<1K]HD(\XF0;^O+?*M:FJ12:E\/)Q*KR
MSR::7P,[F?R\CIWSVH$:TEY:"^M;!DW//&\T7R@KA"N3]?G%6_*C\SS-B^9C
M&['./K7&1V.F:EJ7A^.W+26/V.Y)\N5L,<Q9!.<]<\>HK.,MP;/1X[Z=5T]5
MND+WCN$+K+M0.P(YV XR?7OB@#T0J C8.S.22,<>]86A:EH\-O:Z7I\L\D:@
MI%,\+[)B,EB)-H5CU/!YYI(K2ZG\"S6<5Y]JN9+26.*<$C<2&"<GGC(&3UQF
MJUIJ]EJ'AY=)LG:/4'LVA%L8V5H7$9&&X^7!&,GB@"]'XCT22Y7:[8ED$:7)
MMG$4C] !+MVD]AS]*R8QH6DW\-I/J-^\6FR@1Q2PDP6[LORYD5!V?C<QZU5N
MM1M-0\%0Z%:!O[3>&*W%IY9#PN-H)88^4+@G)XXJ+5[2[DN/$TXED:QCNH7N
M;14'[^(11E\-C(./3KC'>D,[U8HU=G6- [?>8*,GZTH11MPH&WA>.E8?BB9O
M['@D1Y1:/<1?:GA)!$!;YCD<@=,X[9KG+@++#J$6DSS_ -DO=6*1212-@.90
M)?+;TQMSCC.?>F([QXXDBF8$0[@2\BX!''7/^-<_I4N@W,&FZ;:FXDBM</;-
M)#(J2E0?F#%0KGDMQWY[5:UO2F_X0_4--TU&#-;2)$FXDDD'C).>>GXU3G\0
MV]YX?N8-$=_[1%FYBMUB8/$P0X!&/E(/ SWH Z5XTD7;(BNO7##(JIJ&HV.E
M1QO<MM+L5B2.,N[L>2%5023WX%<QI;6[:Q:#PY<.ZFTD^V-*SR('^789 3]_
M.[C(.,U9OY;C3/$&EZEK#Q-;I!/ T\,3".%V*%2022,A2,T :DFN:3]@6XD+
M>6\OEK$UN_F&3KM$>W=N[]/>EC\0Z6;&\NO.:*.S&ZY22%T>/ODH1NY^G-95
M_JEH^M:1K0=GTR(7$#W'EMLC=@FUNGW>&7=TYZUEZ]*FK0^(M1L0TEF-*%L)
ME4[99-S-\O\ > !Z^] SK=/U33M0N)8[8,MQ'AY(Y8&BD&<@-AP"1U&:FTS3
M+?2K*&UMP2L2; [X+$>Y K!M"VD>)-0FU>Y>X;[")8KHQ[<0H3O3:HZ@D'U.
MX>E=1&ZRQK(ARK ,#C'!H$ BC61I BAVZL!R?QHV( !M7 .1QT-.HH 0J"02
M!D=#Z4TQ1M(LC1J77HQ'(_&GT4 4]2TRWU2TDMYP5$@ +I@-@$'&2/459:*-
MGWM&I;&,D<X]*?10 QHHV=7:-2Z_=8CD?2E6.-79U10[?>8#D_6G44 -1$C!
M"(JY.3@8R?6G444 %3Z=_P AJV_W)/Y"H*GT[_D-6W^Y)_(4 =-1112&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/S2VWB#[59BYNFTR*&&5DW%Y!$P.TGONQ^.*GDLI8]9OG?3Y7>[TN-(YEBW
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M-O\ 1[T%46<,"JQ@G(!PV<?+R,5K7MQ=>(!86<>EWML4NHKBX>XCVK&(V#D
MY^8D@ 8SUS0,=:ZY8Z?-<QQZ;=Q6GV]H9;LE63SV8 D_,6 +$#.,#CI70I=6
M[W#VZ3Q-.@RT8<%E'N.HKF],\/-/=7TM_)=B'^TWN([4D")\$%7/&3R,\G''
M2ETB":U\1S1VUK/]CD::65[FW"M$[,#A)/XU8DG'.,#GM0(ZBBBB@ HHHH *
MKM_R$4_ZY-_-:L57;_D(I_UR;^:T 6**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I]._
MY#5M_N2?R%05/IW_ "&K;_<D_D* .FHHHI#"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:W_R!+S_K
MF:P:WM;_ .0)>?\ 7,U@TP"BBB@04444 5;WI;_]=EJU56]Z6_\ UV6K5 !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %=/^0A+_UR3^;5
M8JNG_(0E_P"N2?S:K% $?GQ?:/L_FIYVS?Y>[YMN<9QZ9K%U#_A%IBE]J#Z:
MWF(&665UQ(@/'^\/SHU%+VU\20ZC;V$MY$UH]N1$Z@H^\,"=Q'RGGD9QZ5S^
MG176D:CHD4VER7-Q!I#H\43(7C.]>1N(!].#WH [*XU;3;*VBN+B^MH8)0/+
MD>50K\9X/?CTI+C6-,M84FN-0M8HI$WH[RJ R\<@YY'(_,5S&F:7J.AOIES+
MI\EV([.6%H;=D+0,TF\ ;B 1CY<@_P ([5/HNA7=I?Z3+<VR!8(+QB 0P@:6
M565!]%W#(XX- '4I/#+;K<1RH\++O$BL"I7KG/I6?!J>AQ1W=W!>V00NK7$J
MRKC<0 -QSU(  JOHMA<6GA064L6R8+,HCR.,LVT>G0BLJ;1+V'PYX<2""5)-
M/\M[B&V,8DSY14E=WRE@S9YZ\XYH Z5M6TY+ 7[7UL+,\"<RC8><=>G6G0ZG
M87"(\-[;R+(_EHR2@AGV[MH]3MYQZ5S/]EW%NMC?PV-]/Y6H/=3V]PT7FL6C
M*;P%(7@D''!ZGK5.R@NI4GNX-.</:Z^UQ):HR;PIA"G'(4M\^2,^O)H [.74
M+*&&::6[@2*!MDKM( $;C@GL>1Q[BHFUG2TLDO6U"U%J[;5F,J[2?0'/7@_E
M7*S:3JUQ!+=FTN('&L?;?(CDC,AC\D(",Y3<#S@^AP>AJ=]+DCL_M,-IK0O&
MNGN$EW6YE1R@3)7(3:P&,=>_'6@#<7Q'I3ZRNEK>0FY:)95 D7#!N@'.2<<X
M]"#4&J^($LM<T_28I+07%SEF\^;;M4%0 !U+,6X^AJO:0ZG#KUE>7ED7:;3D
M@G> KLBE#%FR"<XYXQGI5ZZLYY/%.FW:QY@AMKA'?(^5F,6T?CM;\J )QK>E
M,)B-2M"(%#2GSEP@/ )YXIT>KZ;-9_:X[^V:VW!#*)5VALXQG/7D<5S<>B7E
MMX9TU%L0\]K??:I[92H:4;W/4G!/*L,G^$4ESI%[J4E]=MI[11W=[9-]FE*;
MBD3C>[ $CD=LYPM '0)X@T:18F35;)A*_EQD3K\S>@YZ\C\Q3]7UBRT.R%U?
M2B.,R+&,D DL<<9(Z=3[ FL#5-"N9XO%1ALU,MZL0@(V@R%4 Z]L$=ZU_$MK
M<7FA2Q6T1FF62*41@@%@DBL0,\9PIH B/BC3HM4EMY[RTBM?L\,T5PTP DWL
MXP#T/W ?QK1N]5T^P:-;N^MX&D^X)90N[Z9K%DTZ>]U/5+U[$HMSI<<$0EV[
M@V92R'!./O+GM65_8NHPR*9X=0DBN--@MI%LS 2K*I#(WF=CNSD''7/:@#L-
M1U"#2].GOKDD0PKN.T9)] !W). /K6>-<N;6UGN]5TM[*UBA,WF"99#QCY2!
MR&.> ,CWI-7TB6\\*-IMJ=LR1Q&+SFSEHRK*&(]2H!-5=1_M'Q%HMWIYTJ>Q
MD:+(DN)(ROF*00HVL202.O% %A->NX;BT74=)DLX+N0112><KE7/W5<#[N>G
M&>:BMO%+S2V[2Z<\5I<7;VD4XE#?.K,O*\$ E#ZU'<G4=>DT^WDTF>QC@NH[
MFXDG>,C]V=P5-K$ME@.<#C\JH6'ARYL&L-12U=KR/4)S-$\FX&&21_G4$X5@
M"K9&#C([T@.T8D*2!DXX'K6#::YJ5SJ\NGMHRQM (WF?[4"%5RV"/EY^Z>*V
M+::68S>;;/!LE*)N8'S%&,,,= ?0\\50L[.>+Q1JMV\>()K>V2-\CYBIDW#\
M-P_.F S0O$=GK-I;_P"D6RWLD7F/;+*"RCZ=?3\ZO0:II]S=R6D%[;RW$>=\
M22 LN.N1[5S>FZ'=VVG^&(_LPBEM))#<%=N8]T4@SQURQ7I3/#FC75J^EP7T
M.I>;IX8!RT'V?)4J2"OSD-G.#SGKTH ZB]U*QTU%>^O(+97.%,T@4$^V:CGU
MG2[6:*&?4;6*24 QJ\R@L#T(Y[UG:G%=6WB.VU..PEOH!:R6Y2$INC8LISAB
M!@@8//85EW5AJ"1Z[:C1FF.JHODNKQ[(OW2IL?)! 4@G@'KQS0!TUQK&F6DX
M@N=0M89BP41R2JK9/08)]Q^=0Q>(-,FUFXTE;J,7<"J60NOS9!) YR2 N3QQ
MD5A7.@7;6/B6/[.)IKJRCA@D.,RLL..IZ?-ZU?BMKNW\17SM:2/#>6<*+.I7
M:C(),ALG/.X8P#UH T1KVD&"28:I9F*/:'<3+A=PRN3GOVISZSI<=BE\^H6J
MVDAPDQE78Q] <\G@_E6'#9:EIGA#1;6SM6CFA6);I8%C,J#8=Q3=\I;=U//!
M-4-/TW5-.NK749M/N;E8[F[9H=T1E E*E7P"%S\I!Q_>- '2?\))I)U:+31>
MPF>:(2QXD7# D8 YY)SD#N*LP:OIMS>/9P7]M+<IG=$DJEACKQGM62\%X->L
M[M=/ECBFL6MV\MD/V9RRL-W(X S]W/2L_3=-OS!X?T^33'M6TJ0/-=%D*/A&
M4[,')WELG('?/- '46NIV%[,\5K>6\\D8!=8Y Q4'IG%6JQ_#&GOIN@6]O-
M(9@79U&.I<G)Q[8K8H **** "J[?\A%/^N3?S6K%5V_Y"*?]<F_FM %BBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ J?3O^0U;?[DG\A4%3Z=_P AJV_W)/Y"@#IJ***0
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** *&M_\@2\_ZYFL&M[6_P#D"7G_ %S-8-, HHHH$%%%% %6
M]Z6__79:M55O>EO_ -=EJU0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!73_D(2_]<D_FU6*KI_R$)?\ KDG\VJQ0!3NM5L;*XCM[BX"3
M2#*I@DXSC)QT&>YXK*M/$6GOJ]W!>R6T5Y%=&TA.WYBA"D GMEC[9Q2:[8W\
MNHPW.EV\D=V$5!=K.H3;NR5D0_>7'(P">3TJ&XT.\DTS6(5B3S;K44N(OF'*
M!HCD_P#?!H V7UK3DOQ8M=(+@N$"D'&[&=N>F?;.:S(-?N9;VVA,40674Y[,
MD Y"(CL#UZY452U#3-;O=54R+))#%J,,\;"=5B6%64XV=2W!Z_@>U6+?1;V.
M_M961=D>K7%TQW#_ %;HX4_FPXH&;-_K&GZ8Z)>721.ZED0@EF QG ')ZBFS
MZ[IEO;6]Q)>1^5<#="4RQD&,Y &214<UC-)XIM+\(I@BLYHBQ/(9GC(X^BM6
M'IVDZIHSZ?=)9+=-%;2VTD"RJK)NEWJRD\$8X//I0(UIO%&F17UA;";S!?(T
MD4L8++@8QR/4_P N:S]2\1+ID>R#[#%/<Z@T&\([J !DNX !+8 &,]QSQ3;/
M1M2TYM'G%NDSPR7+3Q1R "/SFW?*3C(7I4JZ+>B>%BBX76GO#\P_U11@#]<D
M<4#-J/5+,VJ3M<QE3+]G+#(!EW;-N.N=W%5]1U^STS4K.QN"P>ZW%2%)"X'?
M'KTK%CL)&\>2VRLIL(MNIL@_AG93& ?KAG^M:VKVUVVJ:5?6MO\ :!;/()$#
MA3AUQD9XX- B+3O$]I<7EQ9W5Q#%<K>26T:#/(!PN3T!..G?M5\ZUIHO_L)N
MX_M&_9MYQNQG;GINQVSFL9]#O#IMS"(D\R365O%^8?ZL3J^?KM!JO;>'[F&_
MDAN;6YN(&U W:2I>;8QF3S 63.=P/8#!QUH&;VKZHVG"VA@M_M%Y=R>5!$7V
M@D L2S8.% !)X-5;C6=1L8(H[K3H6O[B<06T4-QN20D%B2Q4%0 "3P>G&:?K
MEC=RW.G:C8(DMQ8RLWDNVT2(RE6 /8\@CZ55OH-7U#[%J"V$<%S87/F1V\DX
M)E0HRL"0,*<-QUZ<T"'/X@O+&2YM]3L88[B.TDNX3!,7254^\N2H((R.QZT_
M2]=N[K4(+*^LH87N+3[7$T$YD&W*@ALJI!^8>H/-5+S3M3UJ:YN[BT6T\NPG
MMK:!I59F>0#+,1P!\H Y/4U)H_A]]$U.UFL[>..">S$5XJD?+*N"K#ZY8''L
M: -:^UK3M,D$=Y=)$Q7<<@G:N<9) X'7D\4R]\0:3I\[0W=]%%(JAF4YR%/1
MCCH/?I6/XGT_6M1:\MK99)+2:S,42QSK$JR'<&,F>6&"N ..#GUJ4Z+=G^V\
MQH3=Z=%;Q?,.75) 0?0984 7=:\16&D6\P>ZA%TL#2QQMD@\';G'0$C'.,U+
M-K$=GX=&K72G:(%E9(QR20,*/J2 *P9=(U:WCU"&"RCN1J%C%!O:8*(G6,H0
MV>2.<C'?/3K6M?Z/-?\ A$:6'6*Y$$85CRHD3:PS[944 (VL:C86=Q?:OI\$
M%K%"9<P7!D<$8PA!4<G/4$C-,_MK4[.:S;5--@@MKN585:&X,CQ.WW0X*@<G
MC()P34=[!J^OZ1=Z==:?'8&2$@2FX$@\P$%< #[N1R3@^U)/#K&MO8V]YIR6
M4,%Q'<3R>>'WE#N"H!S@L!R<<4 ;S7<"7:6K2J)W1I%0]2JD G\,C\ZJ_P!L
MV,EG#<6]U"XN$=K<DG:^T$GG'08YK/\ %6EWVH6]O+I>T7D3/'EFQB.1"C?E
ME6_X#5"P\-75G>W\81!8PP2QZ<H;IYV&?([8( 'L: -.#Q-9OJ%GI\K#[3<V
MRSAHP6CR=N #C.#G(/''I3?#_B>TU>VM4DN(5OY4+&%,XR.H&>X')&<U!9:;
MJ%A?:+-]F$J1:<+.?;( 8FRAW<]1\IZ4RPT.\M[#PW$T2*]C.[SX8?*#'(./
M7EA0!H1^(;**PM9[^ZMHY+A69!$S.'VG!V\ GJ.U:5O=0WEHEU:R+-%(NY&0
M\,*YW2-$O+2;0FGC0"SM[E)?F!VL[(5Q^ -:6@V=QINABWEC'G+),X0,,$-(
M[+S]"* (K+6+\ZXNF:C8PP/+;M<1-!.9  K %6RHP?F'(XHT_P 0_P!HZ_<Z
M?';8MXHR\=QO_P!:0VUL#'0-D9SS@U0TNRU:>6]EU*SDM[V\B:,WD<Z,+=<'
M:D8ZX&<Y[GD^S]+\/7VF^(8)OMIEL8;(6ZCRD7HW"X [=<T#+5[XDMM-U^6R
MOIHH8%M$G5B"6)+N#T[ *#G'&:NWFN:98"/[3>1KYB>8F,ME/[W&?E]^E59]
M-GDU^^N]BF*73DMT)(R6#2$CZ?,M9>GZ;JVBF"6.P2\:33+>U=/.53%)&&R,
MGJIW=LGCI0(Z5+^TDE\N.X1V\D3_ "G.8SG#9].#59O$&E*UJIO8]UTB20*,
MDNK?=('I6#::)JNB_9%MH([S_B6+9.WFA!&ZL3GGDK\QZ9/'2K>@:+=V%UI\
MMQ&@\C2(;1B&!(D4Y8?3I0!LVNJV-[<206UP))(\[L XX.#@]#@\'%7*YW1;
M&_M-6EVV\EIII1R;>2=95\TL#F/'*K][(..HP!714 %%%% !5=O^0BG_ %R;
M^:U8JNW_ "$4_P"N3?S6@"Q1110 4444 %%%% !1110 4444 %%%% !1110
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MNXVG,ZVCRAE!4  C@#YCDG[N!G&:M7UGJ,&O?VII\-O<>9:BV>*:4Q[<,6#
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M+<!"<!YG5@%XY P1DXJ&WT/4]..GW5NEM//;278>)Y2BE)I=X(;:<$87MW-
M%[0O$$6I6T332KYES<7*6^U" Z1NP!]OE ZU:E\0:=%"LGFR/NF>!4BA=W9T
M)# * 2<8/.,5BVVAZO91V%RJ6D]W;W=U+)%YK(C+,S'AMI((R.H]:+70]7L6
ML[Y4M)[N&XNWDA\UD1EF?=E6VG!&!U'K0,TH_$UK+K<.FQP73": 3+*+>3')
MP ?EX'/))P#P>:NWFK6EC<1V\IE::12X2&%Y"%! +':#@9(Y-4OL>IC7K/4C
M#;,&M3;W"K*1Y9W!LK\OS=QVJ+Q#IE]?RQOI\4<=TB%8KT7+1O"2><J%(=>
M=IZ_K0(2^\3)ILLPE1K@+?1VH6WAD+1[E0_-@')^;( Z\ <YJ[<^(M-LVVSR
M2J1&LLF()"(5;H9,#Y/^!8Z&LR[T*_8W\T/D/*^IP7L*,Y4,J+&"I.#@G8WK
MVJ&]\/7<^IWETUI'<QW\<8EA.H2PK&P3:RG:,.I'?&>O% SK0<C(Z44V-%CC
M5%&%4  >@IU @HHHH **** "BBB@ HHHH **** "J[?\A%/^N3?S6K%5V_Y"
M*?\ 7)OYK0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *GT[_D-6W^Y)_(5!4^G?\AJ
MV_W)/Y"@#IJ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *&M_\ ($O/^N9K!K>UO_D"7G_7,U@T
MP"BBB@04444 5;WI;_\ 79:M55O>EO\ ]=EJU0 4444 %%%% !1110 4444
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MX_6@#I**** "BBB@ JNW_(13_KDW\UJQ5=O^0BG_ %R;^:T 6**** "BBB@
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M[=<+874WGSV@"[7;()^;&X D9(SZ],U8BT1K;4IKFVU"XBMYYO/EME5"K/@
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M$$-W=V9M=.\V"U%YNWN5VDL-G3DY4_-P/:KMKKSW5PZK"JQ_V;%?+D\Y<O\
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M_/M=_P#@,_\ A0(EHJ+SC_S[7?\ X#/_ (4><?\ GVN__ 9_\* ):*B\X_\
M/M=_^ S_ .%'G'_GVN__  &?_"@"6BHO./\ S[7?_@,_^%'G'_GVN_\ P&?_
M  H EHJ+SC_S[7?_ (#/_A1YQ_Y]KO\ \!G_ ,* ):*B\X_\^UW_ . S_P"%
M'G'_ )]KO_P&?_"@"6BHO./_ #[7?_@,_P#A1YQ_Y]KO_P !G_PH EHJ+SC_
M ,^UW_X#/_A1YQ_Y]KO_ ,!G_P * ):*B\X_\^UW_P" S_X4><?^?:[_ / 9
M_P#"@"6BHO./_/M=_P#@,_\ A1YQ_P"?:[_\!G_PH EHJ+SC_P ^UW_X#/\
MX4><?^?:[_\  9_\* ):*B\X_P#/M=_^ S_X4><?^?:[_P# 9_\ "@"6BHO.
M/_/M=_\ @,_^%'G'_GVN_P#P&?\ PH EJNW_ "$4_P"N3?S6G^<?^?:[_P#
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M %D3+V'J* .JHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH HZQ_R![K_<J]5'6/^0/=?[E7J "B
MBB@ HHHH SM6Z67_ %]Q_P!:T:SM6Z67_7W'_6M&@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"C%_P AVY_Z]HO_ $*2KU48O^0[<_\
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MBBB@ JC<_P#(6L?]V3^0J]5&Y_Y"UC_NR?R% %ZBBB@ HHHH **** "BBB@
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MJ+_\AV'_ *]G_P#0DJ]5%_\ D.P_]>S_ /H24 7J*** "BBB@ HHHH ****
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MYAN8XGC+1^81M;D@$<<X]>E,L/#U[#J)M+^#5I8UU5[Z.6&2W%N<RF16;.)
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MO[/3_"$,D4:OIDCM<X8?*&AD7CU^9A0!L:GXGL-)URPTJY\P2WBNRLJ$A<8
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MBL'AGLM1CG?S1DGY N,?B2#GTK!BTKQ-;VK,(2@N-3GN;JWL[I5D,;CY LC
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MO#<33#RMOGR+;2-'!N *^8X7"<$=2,9YQ6*OA[7DTJU.Z&6>TU1;RWM9[QY
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2_=*I*CL#P>H4C\:KZIX>VZ"=/\ #\5OIX\Y)&BAS;I*H8%D+1C*[@,;@,T
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MCBMI)+N\?<?F+_NT5C]X@;@2><*"<9Y .BHHHH **** *,7_ "';G_KVB_\
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M2*[1 ?41-_WT*DL_%@^R/<W43RFYOY[?3X+6,M)+'&2N[&<?PLV3@8(K,M/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4=8_Y ]U_N5>JCK'_ "![K_<J]0 4444 %%%% &=JW2R_Z^X_
MZUHUG:MTLO\ K[C_ *UHT 8GBNZU*ST)YM,64RB6,2M#$))$B+#>R(>&8+G
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MQS[6B%WJ"QJ(V7(9VVG:?8 ]>U16WC-M2L],.FZ<+B]OQ.1"UP%CC6%MCL9
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M&W)#$9"DJ"1Z]^U %>_^(-E9:I<V^RV:"UN$MIF:\5)BQVY*18RRC<,G(Z'
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MK2#4I&L;7S5$#1+\RLV8U+=1L' QU'6@#:HHHH **** "BBB@ HHHH ****
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M,L;7L-O$=H!"&&1I%.".<EN0>"!4"^#T9;IKG49YYKFZMKF1]B* T#*R@ #
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MV=N(RUU=S2)J']HF25U+/+Y>PYPH&,'.!C\N* -^BBB@ HHHH *HO_R'8?\
MKV?_ -"2KU47_P"0[#_U[/\ ^A)0!>HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HW/_
M "%K'_=D_D*O51N?^0M8_P"[)_(4 7J*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZQ_R![K_<
MJ]5'6/\ D#W7^Y5Z@ HHHH **** ,[5NEE_U]Q_UK1K.U;I9?]?<?]:T: .;
M\>&8>$;A8+F:VDDN+:+S8'*.H:XC4X(Y'!-<[J&N:A?>#X=(6YDBU@>=#?31
M,5=%MAF1P1R-_P"[ /\ TU%=UJ>FP:M8FTN=_E&2.7Y#@Y1U=?U452_X1?3/
M[4U341&XN=2@$$[!OX<;?E'8D8S_ +HH YR^\6W>B>&["Y6:PF>/2X[J6&>1
MVGF^7+?=!VYQPS9R<],5H6NIZQ)XUU.+S+=M-AL8)UB.=R[O-Y'N2HSVP!BI
M[KP1IMU"\(N;Z&*6S2RG2&8*)HD!"[N,Y 8],9SSD5?;P_;?VN-22>YCE-N+
M:2-'&R5%W;=PQU&]L$8ZT <]::YJ6I6'AK4=2L[>)=1NXF@2">3*!H9&RV,!
MN@^4Y'//(S5S1_$4^O:K=Z'<6,*R62O'J?S93+$B,)ZAERQSTZ=:U8_#UE%8
M:19J9?*TID:V.[G*QE!NXYX8U!:^&+/2I(KRP64WL$4J;WDYN2YW'S3CGY^<
M]LG''% #/!,\D_A&Q$KEW@\RV+GJPBD:,$_4(*Z"LOP[I;:+X?LM/D</-%'F
M5QT:1B6<CV+$FM2@ HHHH **** "BBB@ HHHH **** *,7_(=N?^O:+_ -"D
MJ]5&+_D.W/\ U[1?^A25>H Y[5-4U?\ X2.+1]+2R4O9M<M-=!F"X<+C:I&<
MY'<8]^E9FG^*M8UJXTF"QM;*%KFSDN;AIRS",QRB-@N,9R<XS]?8Z&J^&7U7
MQ1#J+7,]O#%9/ 'MIVCD#EP>W!& >O?'UJ[I>BZ3:/:W.G!=EM;-9Q>7)N4)
MN!(]SN7D]<YH PW\5:J+.36U@L_['COOLAB.[SRHF\DR!L[?O9.W'3OFLZPU
M;5=%@U>_6*S?3(]=ECE1MWG,'F"%E/08+#@@YP>173?\(CIGVTSYN?):X^UF
MT\]O(,V=V_9Z[OFQTSSBH7\)Z*FI;Y)[@&>Y:]:T:Z/ERRAMV\IGG:<'CC@9
MH P8M?DT5M0AMT!N+W7IXD=H7E6,",.S%$^9N%Q@8Z]0!5Z+Q3K5RFG6T-E!
M'=W5[-:F6YAEBC94C+B54;#8('0]P1GO6G>Z+H0"1S77V:>ZO3=V\BW/ER>>
M5VDQG/.1QCD$&KL6A6R26,LDUU<36<CRQ23S%VW,I0Y]L$\#B@#G;+Q3KC&U
MGO+;3UMCJC:7,L1<NSAV3S%)X"[@/E.3CO6EH>O7FH:U>65\;:VDB,FRR,3K
M,$5]JON)VR*1@Y48&0*O#P[IX@6+;)L6^.H#Y_\ EL7+Y^F2>*A33-+TK5X;
MZZU"5KJ3=!:B\NL[=Y!98P>I)"^IX H S/%GBNYT!YY+>:RD6VA6:2U,4LDK
M+DYRR_+&,#@L"#BH]9\3ZU9SZ_)9V]BUGHL:32>;O\R93&'91@X4XS@G/;CO
M6KJOA'3=7GNY+A[M!>1+%<QPSLBRA00I8#N,_CWS4TFB:7J5OJX#&2/5%,-T
M8Y,YVKY9 (Z$8(/N* .7\8:QJNHZ'XLM[".S6QL+-HI_.W>9(6AWL5(X7:KC
MJ#DYZ=:V-0_XF>O:%I(YBMU_M&Y'LGRQ _5SN_[9U8U+P;I>J2W;3-=HEY$(
M[F*&X9$FPNU2P'4@8'O@9S5O2](:RU/4[Z:17DNG18\?\LX47"K^9=O^!4 8
M-KXJU66WTS5Y(+/^R=1NUMHXEW>?&KL51RV=IR<97 QGJ<5I^&-4U76H9KV[
MCLXK/S98H4BW&0E)&3<Q)P,[3Q^.><!UMX1TRUNXID-R88)C/!:O.QABD.<L
MJ?B<#H,\ 5IZ;IUOI5D+2U#"(.\F&.3EW+M^K&@#DY->NK"'4I+.UCB0:Q)!
M<7+QRSK"HC#>8R!L\G"\$*,YJW<^);N+4M,B,UA%8W,$4@O6C=X;B1FP41P<
M(<8(W9SN&.AK4D\.VQ6<075[:M/<-<R/;SE"68 'VQ@#Z=JA?PCIK6]K:![M
M+&W2-%M%N&\I@ARNX=^0,\\XYS0!3E\474>E7MV((=\&L)IZCG!0SI'N//7#
MD_6J3^-+Z35KA+6S,MM;W_V)H5LYWD<!@CR"4#RQ@DG:>R]1FM>X\&Z7<WLE
MP[7862Y2[:!;AA%YRE2'V],_*,]OQYJP/#EK'J4E[!<WMOYLPGE@AN"L4DG'
MS%?? SC /?- %/1M>O+[7KRQO3;6SQ-(([-HG68HKX60,3M=6&#\HXR!FH&N
M=8;X@7EH+JW_ +.33HI?)*-D9:09!SC=E>N.F..]:UMX?M;?51J+3W=Q.BNL
M(N)RZPAR"P4'UP.N>!BB[TJQ.LP:K+<207.P6WRS;%F&251A_%R21]: .3\%
MZMJMEHWA2TO([+[%?6&V$QEO,C*1!@7)X((!Z 8]35BU\5ZC>WD]A%<6$S2Z
M?+=6]S!!*L:%"HQECB0'?D,I'3IS711>&M-BM=,MA&[1:;$88%9\_*4V$-Z_
M+4&G^%--TJY@G66ZE:&W:SA%Q<%U2)MOR '_ '![^I- "^#9]0N_".EW.ISQ
M3SS6L4@=%()!13\V2<MG.2,#VKG]/\4^);^'0Y!;:4@UF-_*&9/W!5=VYN?F
M! ;Y1C!Q\W>NNT;2(-#TY+"UEN'@CXC$TA<HH  4$]@!P*KV?A_3K2/2XH ^
M-*#+;C?G;N7:=WKP: ,5?%-[+HL$KS:?:7QNKBUD5XI9@[Q.R$QQH=Q!VYZ\
M ]Z;8^.&:TT^^U&"*"SN]/GN"ZYR)83\Z\]BH+#C/RFM:3PEIS>4T4EU;RQ3
MSSI+#,5<&9MT@SZ$_E@8JCJW@RVNM&TC1K6-?L5I?)._FR,6$8W%@#U);=M.
M>S&@#2&IWD/A./4K[[)9W9MUDE$Q811,<<'N<9Q[GZUSO_":ZDNEZJRP6MS=
MV5U:0QMY4MNDHF=%Y5\LI&X\\CH?:NOU33+;6-.EL;M6,,F"=C%6!!#*01T(
M(!_"LU/"6G+'<K))=3O=2P33233%F=XF#(<]N0.!Q0!E7VIZKIVIS%K&"\U6
M+23+_HWF!6_?8P$W'.!S_>., \XIL_C*:.RTY(+FSNKF]FEC^T0VDS)$L:Y;
M="I+[N0-I(ZY)'2NCO-$MKV\>[:2XBN&@%OYL$I1E4.'X([Y'XCCI5+_ (1#
M31;*BR7:W"W#70O%G(F\UEVLV[W7 QC& .* )M#UF>^T*2^O[5[>2%I%<>4Z
M!PA.'57 8!@ 0#]*YBWU#5]5USP=J-]'9):WAFN(4@+;XPUNY"L3PQP1R,<]
MN]=O:6:VEH+;S9IQSE[B0NS9ZY)_ETK(L/!VEZ==V=Q"]XQL2WV2.6X9T@5E
M*E54]L'Z\#GB@"MIOBBZO;+PK,\$*MK&[S@N<)B%Y/EY]5 YK,.NZIJ.D6^H
M7UK9?8Y-5AMH(XVD#Y%T(][$,!VSMZ<<Y!Q6Y8^#=+T^]M+F%KLFS=VM8GN&
M:. .K*RJIXQAC^0]*M+X=T]=,@T\+)]GANA=H-_/F"7S>OIN[4 8,_BG68I+
MZ\%O8_V;9:FEC(IW^;(K.B[@<X!&\<<YP>E1Q>+]0O/$D=A:/II4ZC+:2VNU
MGN(XHPV920P !VX'&!N')/%=%)X=T^6TN[5ED\JZNUO)1OY,@96&/091>*YR
MQ\+ZW9ZFKQS" ?V@]U+<1ZA,4DB:1G*?9L; 2#@GZMDF@#N:*** "J+_ /(=
MA_Z]G_\ 0DJ]5%_^0[#_ ->S_P#H24 7J*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J-
MS_R%K'_=D_D*O51N?^0M8_[LG\A0!>HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CK'_('NO\
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MNQFMX# Q0 4444 %47_Y#L/_ %[/_P"A)5ZJ+_\ (=A_Z]G_ /0DH O4444
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MIQM)AA5"1UQP/8?E6/?:%H9\3?:M5AM[N?4FCBM8I[</L:)'8X)SC(R>W04
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M*** "J+_ /(=A_Z]G_\ 0DJ]5%_^0[#_ ->S_P#H24 7J*** "BBB@ HHHH
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M7O\ A(]-_P">DW_@/)_\30!JT5E?\)'IO_/2;_P'D_\ B:/^$CTW_GI-_P"
M\G_Q- &K165_PD>F_P#/2;_P'D_^)H_X2/3?^>DW_@/)_P#$T :M%97_  D>
MF_\ /2;_ ,!Y/_B:/^$CTW_GI-_X#R?_ !- &K165_PD>F_\])O_  'D_P#B
M:/\ A(]-_P">DW_@/)_\30!JT5E?\)'IO_/2;_P'D_\ B:/^$CTW_GI-_P"
M\G_Q- &K165_PD>F_P#/2;_P'D_^)H_X2/3?^>DW_@/)_P#$T :M%97_  D>
MF_\ /2;_ ,!Y/_B:/^$CTW_GI-_X#R?_ !- &K165_PD>F_\])O_  'D_P#B
M:/\ A(]-_P">DW_@/)_\30!JT5E?\)'IO_/2;_P'D_\ B:/^$CTW_GI-_P"
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M0 =CEL$]#T]*BFTA5AU'45M'^WIK2-#+@[E3S8P=O^R06SC@]Z!G=T5PDFE
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M:\D<8R[JHQG).* Z%R@=2P&2N><4 .HJM+?VL-]#923!;B9&>-#W"D \_P#
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M&&:*=+>^$6[K!O'[E6/8@;1^'M3K""".ZTR?3]-GL?LEI*+^22 P9^3A69@
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MMRX1?*557>.(]KAB<D=<\T =NUQ"CA'FC5B=H!8 D^GUJ"/4[.2_GLEG3[1
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MT);QW#,DB)\K[L8#$9/RFL?4O#USK%WK%V8IX99;2W:V5I2$=U#DHZ [6&<
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MPN/PE_SVN_\ P'-',NX>QJ=C=_L/4?\ GZM?^_3?_%4?V'J/_/U:_P#?IO\
MXJL+_A<?A+_GM=_^ YH_X7'X2_Y[7?\ X#FCF7</8U.QN_V'J/\ S]6O_?IO
M_BJ/[#U'_GZM?^_3?_%5A?\ "X_"7_/:[_\  <T?\+C\)?\ /:[_ / <T<R[
MA[&IV-W^P]1_Y^K7_OTW_P 51_8>H_\ /U:_]^F_^*K"_P"%Q^$O^>UW_P"
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M  N/PE_SVN__  '-',NX>QJ=C=_L/4?^?JU_[]-_\51_8>H_\_5K_P!^F_\
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M?^_3?_%4?V'J/_/U:_\ ?IO_ (JL+_A<?A+_ )[7?_@.:/\ A<?A+_GM=_\
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M_A<?A+_GM=_^ YHYEW#V-3L;O]AZC_S]6O\ WZ;_ .*H_L/4?^?JU_[]-_\
M%5A?\+C\)?\ /:[_ / <T?\ "X_"7_/:[_\  <T<R[A[&IV-W^P]1_Y^K7_O
MTW_Q5']AZC_S]6O_ 'Z;_P"*K"_X7'X2_P">UW_X#FC_ (7'X2_Y[7?_ (#F
MCF7</8U.QN_V'J/_ #]6O_?IO_BJ/[#U'_GZM?\ OTW_ ,56%_PN/PE_SVN_
M_ <T?\+C\)?\]KO_ ,!S1S+N'L:G8W?[#U'_ )^K7_OTW_Q5']AZC_S]6O\
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MS/%"C,J!I'"@LQP!D]R2 !1R(/K$_P"KGD7_  JA?^A?'_@[/_QBC_A5"_\
M0OC_ ,'9_P#C%>Q44<B#ZQ/^KGCO_"J%_P"A?'_@[/\ \8H_X50O_0OC_P '
M9_\ C%>Q5%<RO!;2RQPO,Z*6$2$!G([#) _,T<B#ZQ/^KGD7_"J%_P"A?'_@
M[/\ \8H_X50O_0OC_P '9_\ C%>F>&M?M_%'AVSUJTBEB@NT+HDN-P )'."1
MVK6HY$'UB?\ 5SQW_A5"_P#0OC_P=G_XQ1_PJA?^A?'_ (.S_P#&*]BHHY$'
MUB?]7/'?^%4+_P!"^/\ P=G_ .,4?\*H7_H7Q_X.S_\ &*]#O?%UE::A>6$%
MGJ%_<V*J]TMI;EO)##<N22 21SA<GVJ>#Q3HMQX6'B5+Y/[),1F^T$$ *#@\
M=<Y!&.N>*.1!]8G_ %<\U_X50O\ T+X_\'9_^,4?\*H7_H7Q_P"#L_\ QBO1
MM.\565_JJZ6\%W97SP?:(H;N+898\X++R1QQD'!&>16Y1R(/K$_ZN>._\*H7
M_H7Q_P"#L_\ QBC_ (50O_0OC_P=G_XQ7?WWC33[2ZU"WAM-1O6T['VQK6V+
M+#E=V"21N.T@X7)JTWBK1E\,Q^(A>!M,D17CE522^XX50N,EB3C&,YXHY$'U
MB?\ 5SS;_A5"_P#0OC_P=G_XQ1_PJA?^A?'_ (.S_P#&*])TSQ+9ZGJD^EF&
MYL]1AB6=K6ZC"N8R<!UP2",\<'@\'%9=Q\1=&MK.74#!J+Z5#,89=02U;R48
M-M/7YB W&0",]Z.1!]8G_5SBO^%4+_T+X_\ !V?_ (Q1_P *H7_H7Q_X.S_\
M8KTO5/$ECI<MC PGN;F_W&U@M8S(TH4 L0>@ !')('-)H?B6PU^6]M[=9X;N
MQD$=U:W$>R2(D97(Z$$<@@D&CD0?6)_U<\U_X50O_0OC_P '9_\ C%'_  JA
M?^A?'_@[/_QBO8J*.1!]8G_5SQW_ (50O_0OC_P=G_XQ1_PJA?\ H7Q_X.S_
M /&*]BHHY$'UB?\ 5SQW_A5"_P#0OC_P=G_XQ1_PJA?^A?'_ (.S_P#&*]BH
MHY$'UB?]7/'?^%4+_P!"^/\ P=G_ .,4?\*H7_H7Q_X.S_\ &*]BHHY$'UB?
M]7/'?^%4+_T+X_\ !V?_ (Q1_P *H7_H7Q_X.S_\8KV*BCD0?6)_U<\=_P"%
M4+_T+X_\'9_^,4?\*H7_ *%\?^#L_P#QBO8J*.1!]8G_ %<\=_X50O\ T+X_
M\'9_^,4?\*H7_H7Q_P"#L_\ QBO8J*.1!]8G_5SQW_A5"_\ 0OC_ ,'9_P#C
M%'_"J%_Z%\?^#L__ !BO8J*.1!]8G_5SQW_A5"_]"^/_  =G_P",4?\ "J%_
MZ%\?^#L__&*]BHHY$'UB?]7/'?\ A5"_]"^/_!V?_C%'_"J%_P"A?'_@[/\
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M0F&,H59)E*J#YBL"&^Z"#Q@YJ;1/#<&CWNH:@UQ-=ZCJ#(US=3;06"#"J H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>modificationno15effectiv011.jpg
<TEXT>
begin 644 modificationno15effectiv011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]UC44>SAV0<\NYL_\);X@_Z"]U_WW1_PEOB#_H+W7_?=8U%'LX=D'/+N;/\
MPEOB#_H+W7_?='_"6^(/^@O=?]]UC44>SAV0<\NYL_\ "6^(/^@O=?\ ?='_
M  EOB#_H+W7_ 'W6-11[.'9!SR[FS_PEOB#_ *"]U_WW1_PEOB#_ *"]U_WW
M6-11[.'9!SR[FS_PEOB#_H+W7_?='_"6^(/^@O=?]]UC44>SAV0<\NYL_P#"
M6^(/^@O=?]]T?\);X@_Z"]U_WW6-11[.'9!SR[FS_P );X@_Z"]U_P!]T?\
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MGJSV.BBBO,.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#F_'W_ "(FK_\ 7#^HKYEKZ:\??\B)J_\
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M&91(^]@">,MW/O4%=2VU.=A1110!;N?^/.R_ZYM_Z&:J5;N?^/.R_P"N;?\
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M3_IM_P!]G_&C_A6VB?\ 3;_OL_XT?7*?F'U:9X_17L'_  K;1/\ IM_WV?\
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M_P"%;:)_TV_[[/\ C1_PK;1/^FW_ 'V?\:/KE/S#ZM,\?HKV#_A6VB?]-O\
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M &!SCM6_J-I/>6WE07*PY/S;X1*KKCH0:H:=X;@TWB.XD8"R6S^8#HK,V?\
MQ\\=L4 -OO$9M]+MM1@M4DMIH!.&FN%A."-P4 YRV.W3WK&UK5IY9+R>TN9X
MX7TRTGB <KM+S-DX'0D8!K2D\)*T5FD5\R>18K8,S0JY9 .JY^ZWOS^E/E\*
MPRVYB^U. ;*"TR%'2)BP;\<TAFAK6K+H]DEPT8??*L0W.$12QZLQ^Z/?Z4EO
MJK2ZE#8RV_ERR6IN25D#*,,%P#WZYS5C4+:>ZMO*@N%@8GDM$)%88Y4@]O\
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M4;'6=7D:PEN(H+2">6(7 "PC#EMN>K''8#.WJ.*Z#5M-75--:T\TPG>DB2*
M=K(P93@]>5'%5CH>\:DTUTSRW]JEO(P0#&U6&X#WWGCVH H:CXRM;*:5(XXY
M5@A6>7?<+$VUAN 13]YL<XXZCFKNNZI+:Z)'<6++YUU)## [C(4R,%#$>P.<
M5$?#CQ7)GLK[R&DACBF#P+(&V# 89Z'''<=.*T=3TR'5=-DLIV=5;:0Z'#(R
MD%6![$$ T 8^IB_\/Z3/<Q:I<7<LACAC%TJ$)([J@?Y5' W9QTXHN%O]"O\
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M.GVUHK%A!$L08CKM &?TH GHHHH **** "JZ_P#(1D_ZY)_-JL577_D(R?\
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M\,0O;3J][<M=37$=RUUA PD3&T@!=N/E';F@"UJ^IS:3HXO#;+-/YD,9A23
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M9G^T2V\UM+YL4L04E3M*GA@0>&/:JUIX<MK-[1Q<7$CVUQ+<!I&!+O(&#;L
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MS&!.,@CK[XKM719$9'4,K#!!'!%8]KX8TVUXVS3((6@CCGF:18HVX*J"> 0
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M/VUQ/'.+F\AF6$0/)#.5:5!R Q[\D\]>3S0!4N/$$\&GZS<"&,M87:P(,G#
MB,Y/_?9_*JAO=3^U>*1<O!+9VJ'9&-RL!Y(8 $'CKSWSTK1O/"UA>SW$DDMT
MJ7#+)+"DQ".Z@ ,1ZX4>W JQ+H5K+=WLYDG7[;%Y4\:O\C?+MW8]<<4#,R+5
M]1N UOI<%J!:6D,LGVAF.]G4D(N.1P/O'/7I4(\3:C?@R:9;6HB&FQ7Y-PS9
M^??\G'^[U[>AK2N?#ED_[P7%U;#R%@E,,VP21J#@-] 3R,'GK5F+1K&-Y'A0
MHLMJEKM4_*(UW;0/^^S^E C+\27T]S\/KR_M"(FFL?-^8G*JR9(!'?!I+>6_
MM)QHFE6NFP/:VZS2G:RQ9=FVJJCD9VDDG\C6O-I%K/H1T=]_V0P"WX;YMF,=
M?7%1:CHUM=W)O6N;FTE$7ER2P2[-T8).&^F3SU&3S0!F6/B*_P!7N[".RMK>
M..>T6ZF,S$E/G*LHQU/'!I?%3.;_ $2$17<\<L\@>"UF\MI,1,1SN7H1GKVK
M7M-'LK&>*:VC,?E6RVR*#\HC!R/Q]Z-2TF'4VMGDFGAEMG+Q20/M8$J5/Z$T
M <DNL-;^$);:YOI+:XEOVL<W,N)+56;.&<GDK$<ALGMS2-JQN/A[>)#>/<RV
M5PMH9X)LM*HE4*0P/5D(YSU)KJ+3P[86=S#<1B5Y8FD??)(6+NX 9V)ZG"@#
MT'%+=:!97<EX\@D!N_*\X*V 3&<J?KT!]@*!G(RSSIHWB7[.]]:P0^3&EM<S
MLTT3Y!9@=Q(5@5QACT/2MTP'1/$FEP6EQ<&VOA*DL$T[RA2J;@ZEB2.F#SCD
M5HW_ (?LM1DNWF\U3=PK#+Y;XW!6+*?J,GFF1^';1#-))-=SW$L+0^?-,6=$
M;J%[+^ ["@#FM%\0PS^*DN1JL<T>J/+"MJ)PWD^7_JCMSQN57)]V%=Y5";1K
M.;3[6RV,D5JT;0[#@H8R"N#^&/IFK] @HHHH **** "BBB@ JNO_ "$9/^N2
M?S:K%5U_Y",G_7)/YM0!8K,U#18M0O8;S[5=6T\4;1![=PN58@D'(/=16G7-
MZE!%JOB^#3+X>991V37 @)PLLF\+EA_%M';_ &J +C^&[$Z?':1-/"8Y_M*S
MI)F7S><N6;.2<D'.>#3%\+V26SQK/=B4W/VL7'FYD67:%+ D=P.A!')XQ4+^
M?::E;Z#H[16D8MWN6DE1I=HW !5&X=R>_ X J32M?>ZL;=KFUF-P\LD+M;PL
M\89)"A.>P)&>>U &K9VS6D'EM<SW#9R9)B"Q_( #\!67'X6LH[J*87%V8X;@
MW,5N9?W<;DDD@8[ECU)QGC%9^@:79ZU:R:KJ$9FOWNYAO+L&@V2,JHN#\H 4
M=.N>>M,TS2;#7K74+[5$\VZ-W<1^8SD-;*CE5"'^'  /'<YH LZ1X6$$<3WT
M]PS1W<MRMN)<Q!C([(V,9S@@XSC/.,U<3PS9I<!A-=&V6?[2MF9!Y*R9W;L8
MS][YL9QGM7'>?/J$>D7-[ICZK)_8C2M'Y@0DAU^?GN1Z<\\5W'AP./#>F[[O
M[6QMT/GY)W\=>>?SYH&']A6?V<09EV"]^V_>Y\SS/,].F>WI5FZL(;NYLYY"
MV^TE,L>#QN*,G/X,:M44",N;0XWOY;R"\N[5Y]IG6!P%E(& 3D'!P ,C'05F
MZ]X6%[::@UE/<)+=%9&MQ+MB>08&XC&<X [X.!D5TU% &)J7A:SU.6[>6XNX
MTO$"W$4,NU9"!@$\9R!CO@X&0:GET.-K^6[@O+NU:<J9T@<!9"!@$Y!(. !D
M8Z5J44 9K:+%+J<5[-=74ODR&6*!W'EQN5*Y'&>A/!)'-2:5I46D6IMH)IWA
M#$QI*P/EC^ZO X^N:O44 9@T*S"A<RX%Z;[[W_+0DGTZ<]*;?:#!>WCW2W5W
M:RR1B*4VT@7S4&< Y!Z9/(P>>M:M% &;'H5C"S^4C1JUFMD$4\+&N[&/?YC3
MX-(MH)[&5#)NLK=K:+)_@.S.?4_(/UJ_10!1GTJ*;58-1$T\4\2&,B-AMD3.
M=K @]_3%10:#9V\&FPH9-FGL7ARW4E67GCGAC6G10!EZ?H<>F.@M[R\^S1Y$
M=JS@QH#V'&[ [ DXIVHZ+!J-Q#=>=<6UU""J3V[[6VGJIR"". <$5I44 9$W
MAZWF@ME-U>+<6Q9HKL39E&[[W)R"#Z$8X''%-'AJR-E=6\LEQ,]TZ///))F1
MRA!7G& !CH !UK9HH J)IT$>JRZBA=9I8EBD /RL%)()'J,D9]#5"Z\,V=U/
M<.T]TD%TP>YMDD BF( &6&,\@ '!&<<UM44 5;:PAM+F\N(]V^[D$DF3QD(J
M#'X**M444 %%%% !4^C?\C"W_7H?_0Q4%3Z-_P C"W_7H?\ T,4 =-1112&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!F>(/\ D#R?]=(O_1BUBUM>(/\ D#R?]=(O_1BUBTQ!1110
M 4444 5YO^/NV^K?RJQ5>;_C[MOJW\JL4 07-G!>& SIN,$HFCY(VN 0#Q]3
M1<V<%VT#3)N-O*)H^2-K@$9X]B:GHH S+[P_IVHW+SW$4F^1 DOES/&)5'0.
M%(##D]:E?2+)[^.]\IEFCB\D;)&563G"LH.& R<9!QFKU% &79>'M-T^=)8(
M9-T:E(EDF>18E/4(K$A1]/I3(?#.DP030+;NT$L9B,,DSNBH3DJJDX49 Z8Z
M"M>B@#)3PWIBVUU T4LJW4?E3--.\CLG/R[F)(')X!J9]%LI-06]D69Y4<2*
MK3N8U8# 8)G:#COBM"B@ HHHH **** "BBB@ HHHH **** *\'_'S=?[Z_\
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M&<=>GIVJ_10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M**C\R7_GRO?_  &?_"CS)?\ GRO?_ 9_\* )**C\R7_GRO?_  &?_"CS)?\
MGRO?_ 9_\* )**C\R7_GRO?_  &?_"CS)?\ GRO?_ 9_\* )**C\R7_GRO?_
M  &?_"CS)?\ GRO?_ 9_\* )**C\R7_GRO?_  &?_"CS)?\ GRO?_ 9_\* )
M**C\R7_GRO?_  &?_"CS)?\ GRO?_ 9_\* )**C\R7_GRO?_  &?_"CS)?\
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M(^'M+:[-T=#N/,,GFD?9I-I?KNVXVYSSG%7?LL1FN)CIEV9+A!',3:O\ZC.
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M\!G_ ,*/,E_Y\KW_ ,!G_P * )**C\R7_GRO?_ 9_P#"CS)?^?*]_P# 9_\
M"@"2BH_,E_Y\KW_P&?\ PH\R7_GRO?\ P&?_  H DJNO_(1D_P"N2?S:I/,E
M_P"?*]_\!G_PJ!7D_M"3_1+O/E+Q]G?/5NV* +=%1^9+_P ^5[_X#/\ X4>9
M+_SY7O\ X#/_ (4 245'YDO_ #Y7O_@,_P#A1YDO_/E>_P#@,_\ A0!)14?F
M2_\ /E>_^ S_ .%'F2_\^5[_ . S_P"% $E%1^9+_P ^5[_X#/\ X4>9+_SY
M7O\ X#/_ (4 245'YDO_ #Y7O_@,_P#A1YDO_/E>_P#@,_\ A0!)14?F2_\
M/E>_^ S_ .%'F2_\^5[_ . S_P"% $E%1^9+_P ^5[_X#/\ X4>9+_SY7O\
MX#/_ (4 245'YDO_ #Y7O_@,_P#A1YDO_/E>_P#@,_\ A0!)14?F2_\ /E>_
M^ S_ .%'F2_\^5[_ . S_P"% $E%1^9+_P ^5[_X#/\ X4>9+_SY7O\ X#/_
M (4 245'YDO_ #Y7O_@,_P#A1YDO_/E>_P#@,_\ A0!)14?F2_\ /E>_^ S_
M .%'F2_\^5[_ . S_P"% $E%1^9+_P ^5[_X#/\ X4>9+_SY7O\ X#/_ (4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!68?^1I7_KR/_H8K3K,/_(TK_P!>1_\ 0Q0!IT444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1U;
M_CR7_KX@_P#1J5>JCJW_ !Y+_P!?$'_HU*O4 %%%% !1110!1N_^0GI_^])_
MZ":O51N_^0GI_P#O2?\ H)J]0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!1L_P#D(:C_ -=4_P#1:U>JC9_\A#4?^NJ?^BUJ]0!B:AXC
M:SUDZ5;:1?W]PMNMP_V<Q!51F91DNZ\Y4]*=K'B:RT2\TVUNTF\R^D"*44$1
M#<J[G.>%W.BYYY85F7NAS:CX]FN6FO[6V&F11K-;2&,,XED)4GO@$''O6?JW
MA_6?$FIZ\R/;VML\"Z?;FZMW9RJC>9$(88R[=<'_ %8H W]5\3+IFJ'3X]+O
M[Z5;;[5(;81X2/<5S\SJ2<@\ &K\6L6$NAIK(N%6P:W^T^<PP!'MW9/X5P\F
MC:MXHO$N+K^T-+N9="6)WC9HP+CS&W*V.HSSCT-;5UIUUKWPP?3HK(:?=S6'
ME+:LNQ8W QL]ER,?2@!IUZ'=<^(6\/:I"8M.D:*XGV*LL2CS-I 8E"<<;E']
M*Z.+4K5X[4R3Q127**\<3R ,<C. .]<WJ&LW&M^&=3L8]#U6"[ET^=626WVJ
MC^60%#=')/ VYKG?%-GJ=U:75G'I#B5;*W^SR0Z?YLDS 9.9>B;2.!U],YQ0
M!Z:T\*B0M*@$7^L)8?)QGGTXI&NK=;E;=IXA.XW+$7&XCU ZUY_XFAOXD\96
M46E7US)JL*-:M!"61L0A&!;H""IX/)R,9K0GMI;;QRMQ8V4\[W,T8NQ<668X
MU6/'FQ3]%(  VY.3G@9S0!V"75O)</;I/$TZ#+QAP64>XZBLS5M>.FZA:V,.
MF7M_<W$4DRI;&,;40H"27=1U=>E<;X4T2>"]TI-0%_%J-E+*\K#3PJ.Q#ABT
M^,.K9SU)SC@8KI/%$.F27-N][I^KS3QQ.L$VFB8,NXC*[HB,$E5/S<<4 7=2
MUV?3K2.<:)J-R3"9I4A$>80!DAB7 +>RD]*O6FHP7VDPZE;;Y+>>$3Q[5^9E
M(R./7':N,O;O7X?"VDZ-?6VH/<W=OMU&]MX#,T2="HV@_O".,]!R>>*Z:TOX
M+.SM+:UTN_2V2S9XU%N1L6/ $9!Y#D=!WP: (;'Q.EUJ,^GW&EW]E=QVQNDB
MG5&,L6<978S<YP,'!Y%):>*/M-[<V$FCZA;7T5M]JCMI?*W3QYQ\I#E0<\88
MC&161X>OIKG4;[6]2TS4X]2DMR$@-FZK!"A+")6( 9R3D^IP!P*E\*W$NH:Q
M<ZIJ5A?V^I7,014FM72*VA4Y$88@ L2<D]STX H T].\2M>ZW_9,^C:A8W'V
M<W.;@PE=@8+_  2-@DGC/7!]*GUSQ%::"(/M,-S*9I$C'D1%@FYU0,S< #+#
MJ<GL#6=HEAJ%U%JNKRL]CJ&HSXB\V+<T$$9VQJ5/<C<Q'J]5_&+74?AJ&P:.
M]U&\:XMY#);6;,"$G1V)V A?E!X[XH V=;\16FA&W%Q#<RF>5(QY,18)O<(&
M9N !N8=\GL#6O7(>,[XW7A^UCM[#49I)KFVG"1V4C%52>-VW +\IP#P>>*WK
M;6K>ZU)+".*X69K471\R(IL4MM 8'E6)!X(['TH S]3\70:9?WEJVFZA<)8P
MI/=3P(C)$C;L$@L&/"L3@'I6RE_:.(-MS%_I"AX@7 +@\@@=ZY2Y\.W&K^+M
M=$]U?VFG7%I;1.( JK<C][N4L5)& <':0?F^E8WB^QNYI[^RM-&V>4EO]CDM
M]-,KS!<$GSNB;,8 Z\<9S0!WUOJ]A=:E=:?#<HUU:E1+'GD9&1]>/RJPEW;2
MI(\=Q$ZQDAV5P0N.N?2N%U+2)_[5\716.G/'?ZA9AK*Z2WPI;RBK#S0,*Q;U
M(/(-4X='\S1M:DLX+Y;AM$FM!:G2C:JQ*_*O3YV!R!C/4\\T >A3:E9V]O<S
MR7,7EVREIB&!V #/.*=97UMJ-E%=VDJRP2H'5E]",_@>>E<7+X92*_6"STI(
MX)] FAE B 1YMT90.>A;ER,\]:W_  @L4?A6QBBL9;-HX426*2W,+>8% 8X(
M&>>_>@"#1_&=IJ\NGI_9]_:+J,;26<EPJ;9@!N(!1FP<9.#CI6M;ZG#)8175
MSBS$A("3R("""1C()!Z9X-<+X4T"^T9?"5Y<17TX-HUM/!<;F^PR%,AU7^ '
M:4.?4=.<X[6-]LT[3FTUI91I=PDL4MIYYA62<X?867:<+QUW>V* /2O[?M!K
M<FG.\:HMK'<BX,@"MO=E"C_OC]:2*XT>P\0W%HDJQZCJ %U(A8_/M"1@\\ X
MVC'?K7*6.AZ9JU\ES%8+>Z9_PCT,-K--!PQW29&".'P1GOS[T:7IS6NI^%;W
M4=)GED.BK;R2?93(\=P/*(WG&4( ;YCC&#S0!WT5Q!,\B131R-&=KA&!*GT/
MI4E<)X5L;NW%WIVG)+;6D<$?D7]UIODSJVXYC<-CS<#^/'?N>:[6UCFBM8X[
MB?SYE&&EV!-Q]<#I0!-1110 55.G6QU4:F4)NQ!]G#EC@(6W$ =.2!D^P]*M
M44 %%%% !1110 513_D.S_\ 7M'_ .A/5ZJ*?\AV?_KVC_\ 0GH O4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %9A_Y&E?\ KR/_ *&*TZS#_P C2O\ UY'_ -#% &G1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% %'5O\ CR7_ *^(/_1J5>JCJW_'DO\ U\0?^C4J]0 4
M444 %%%% %&[_P"0GI_^])_Z":O51N_^0GI_^])_Z":O4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 4;/_D(:C_UU3_T6M7JHV?_ "$-
M1_ZZI_Z+6KU &)?Z_+%JK:7INFRZA=Q1+-.%D6-(E8D+N9OXC@X ';M4NC^(
M+35X >;6Z$SP/:SLHD61/O+@'G P<C/!!K+E%]H7BS4M073+J_LM1BAPUH%9
MXI(P5*LI(X(((([YS63-HNLP://KD-@3K']K_P!IQ60=2P0J(3&6!QDQY)YQ
MF@#N%O[-HUD6[@*/(8582##2 D%1S][((QUX-16NLZ7?7!M[34K.XG""3RXI
MU=MAZ-@'.#D<^]<3X=\+:GIFN6=C<1,^F6@.H"=F!#W3Q+&RX_WC*_\ P(5/
MH/AVZL+'P0HL!!+912"\*JH,9: @[L=<OC\: .PAU;3;B^ELH-0M9;N+_60)
M,K.GU4'(J'_A(=%\B6?^U[#R80AED^TIM0,,KDYXSV]:XWPMH%Y:OI%MJ2:Q
M]ITPR$,4MQ;;BK*6WJ [!MV<$DY(STS4]GH'V#X?Z!:OI][!?6HBE+6$<;20
MS!&RS*W##+,".?O?B #>F\6:=;:PMM<7=G%9/9K=)>27"JC[G*@ G@],YS6A
M+J<<-\L3M"MN;9[EIVG4;54KSMZ[<'.[H/QKFM*TG4+S6K:_UK381+_8WD.=
MB[5D,A)7&3@E<9 XY(S6-+I&HV?A6![JV=!:^$;FUF+$?))MCPI]\*?RH ]"
MM=4T^^GF@M+^UN)H3B6.*97:/_> /'XUG7'B>RL?$%SINH3VUG%%;0S+//.$
M#M(TB[><=/+SU[UB>'[2XNM;T:\BT:73+:PTQ[>5G" 2LYC*JNTG*C:S9]QW
MS3M9MKB#Q=J-^?#\VI07&E16L;Q*AP^^4LAW$8!#+D].F: .N^VVO[__ $F'
M_1QNF_>#]V,9RWIQSSVJEJ_B'3-#L8;R^NHXX)I8XHVWKAB[  C)Z#.2>P!-
M<'>:#J&GC0-%W!VUBPATW42K=!#AF8>N8S*F?=:[#Q?8S76@(MI:FX>WN[:?
MR8P-S)',C,%S@9VJ>* %_P"$MTV/69[.YO+."V6VMYX;J2X4+-YID "YX/$>
M>"<YK3O-6TW3GB2^U"UMFF.(EFF5"Y]LGFN9N-'DU#5]<OGTPA+K18;> 3(N
MX,?.+1]\'E,]NE8TF@ZG'-F]CU5K>[TBVM'%C'!(055@\;^8"1DMG(P.3GH*
M ._U74[;1M+N-0NV800+EMHRS'.  .Y)( 'J:J:=JU]<._\ :&C3:=$(S*)9
M9HW7 QD-M/RMSGTX/-4_$&BW-[X,73[$,US;B"2%;AQEVB=7"L1QD[,$],FJ
M.MSZGXE\.WMC!H-];/L1V6[:-1*5D5FB&&.=RAAG@>_- '16VMZ3>6TMS:ZG
M93P0G$DL4ZLJ'W(.!5:37=!MK+4=5CO;)TMA_I<L,B,05'"L0>O8 ]SBN2UO
M2K_7EUF[M-'N+2.72A9K#,J(\\GF;ON@GA1D9/\ >.*UM2T":35M86RLT2WN
M=#%K'M 5#(&DVK^ 84 ;47B71)=.BO\ ^UK)+:5=RN]P@'&,\YZ@LH/H2*L#
M6-,;4?[.74;0WV,_9A.OF=,_=SGI7+V6F2W^H^%KFXTB2**QL[B.5;A%_=R%
M8E!P">N'P:IWMGKM[X@MA)97*16VLK.HBBA6W\@$@2%_OLY!YY]>/4 Z^Z\0
MZ/9R7$4^J6:3V\9DEA,Z!T4#.2N<BHK7Q1HEUHD6L#4[2.RD"_O)9T4(Q .Q
MCG ;GD=:P=$LKJVLKC1;K1)FN?/NI#?LJ&)O,9RK[L[LD,%QC(Y[52T^UO[2
MW\+7D^A7CII=H]G<6P5"Z2E(P)5&[##Y&7/7YNF* .VDU;38;..\DU"U2VD!
M,<S3*$< $\-G!X!/T!JS%+'/"DT,BR12*&1T.0P/((/<5P=IX<NW&C-<Z:$M
M_P"W)[]K5]K"VC:.79D XSN*G S@M77V.I17>H7]E#"ZK8LD;28&QF*AMJ_0
M$9^HH 2/6+=1=->2VUK'#<&!7>Y0AL*&YY^4XR=IYP,U2OH/#&L6@UBZEL9K
M9$*?;5G 39GE2X(!&>Q.,UA3:!>7%XPFL?,A/B47A#@$&$0 ;\>FX4R\T6_A
MN;NYCTYY[:+Q"E_]FCVYFB^SJI902 2)#NP>I7UH Z&#6["+4-,T[3A:OI\]
MG--'/!(OEHL1C7"XXQ\_KQBM9+RUD\C9<PM]H7?#AP?,7 .5]1@@Y'K7,26-
MSJ6N6-W%I<MC UA?1.)0JE7D:+:6"D\MM8^O'/-9%E8:U>PZ!9G2[JQ;3]+G
MLY;B9DVB4Q*@*[221E<Y]Q[X .GD\56+ZU9Z=8SVMXTWG"5H;A286C4'! SC
M/OCI5E/$&GQ:9;7FH7ME9>="LNV2Z0J <=&SAADXR.#7(Z7IMY)?>' /#LUC
M_9MC+;7$KB,#<8P JE22RY!.>G/UQ;\.>'[B&[\.O?V VVGA];9S(H;RY<Q@
MK]<!OUH ZJ\UG2]/BAEO=2L[:.;F)YIU0/\ [I)Y_"K4$\-U D]O*DL,@W))
M&P96'J".HKR5+#584L]*6UE\R+0!;WL:1Q2/%&\CC_EI(B@X7@@MTY' KT#P
M]KMEJ2PVFG13M;16,$ZS2# PX.U#WW;5!/\ O#UH <GBBQ36[_3;VXM;1K>6
M.*$S3JIG+H&P <<C..,UJO>VD2W#274*"V&Z<M(!Y0QG+?W>.>>U<'KFF7C7
M_BV)/#TMXVKP1P6MRHCV@^2%^8D@JH8YS['OC+=9TW6+:T\3Z?#IES?R:I81
MQPSQ,NPLL)C;<200<C/3G- '7IXDTE_$$FAB]A^WI&LGEF1<MNW?*!G)8!<D
M8Z$'O6M7,0VMQ:>.OM36$LEO=:=# )T"E8W1I"V[G(X9<'FNGH **** "J*?
M\AV?_KVC_P#0GJ]5%/\ D.S_ /7M'_Z$] %ZBBLS7]9CT'27OG@EN&#K''!%
MC?*[, %&?K^0- &G15&WUBPGTJUU+[3%%:W4:R1O*X4$%=W?OC)_ TY-6TV2
MS2\34+1K5R0DRS*48C.0&S@]#^1H N455@U.PN;>*X@OK:6&5]D<D<JLKMZ
M@X)X/%+-J-C;13RSWMO%' P69Y)541D@$!B3P<$'GU% %FBL>[U^WB.D/:-%
M=P:C=_9EFBE!4#RY'W C(/W,?C5BZU6.UUJPTUHV,EXDKJXZ+Y87.?KNH T*
M*HQ:UI4\CQQ:G9R.D?G,J3J2J8SN(SPN._2K'VNVS$/M$7[X%HOG'S@#)*^O
M'/% $U%4K?6=+NX)9[?4K.:&$XEDCG5E0_[1!X_&HI-?TF.PO+T:C:R068/G
MM',K;".QP>#[&@#2HK)L]?M=2.GO8/#<6]XCMYBSIE" #MVYR3\W..G>K5OJ
MVFW=S+;6VH6LUQ#_ *V*.969/]X Y'XT 7**IVVK:;>SF"UU"TGF""0QQ3*S
M!3T; .<'(Y]ZHZOKTVGZK::;:Z9-?7-Q#).%CD1-JH4!Y8@9RXH VJ*R+3Q-
MI5SH=MJ\MU'9VMQPINW6(A@2"IR<9!!'![5<N=5TZSB66ZO[6"-D\P/+,J@K
MP-V2>G(Y]QZT 6Z*IW&K:;9VD=W<ZA:P6TF-DTLRJC9Z88G!HGU;3;6!)[C4
M+2&*1=Z223*JLO R"3R/F7GW'K0!<HK+T_Q%I6J:C>V%I>127-G)Y<D8=23P
MI) !R0-P!/KD52N_$UQ#J][86FB7=]]B2-YGADC!PX) 568%C@&@#H:*HZ;K
M%AJUI;7-I<(ZW,1EC4G#E00"=IYX) /H>*6?6-+M;:.YN-2LX;>0[4EDG558
M^@).": +M%(&5D#A@5(R&!X(JE;ZSI=W'/);:E9S);@F9HYU81@==Q!XZ'K0
M!>HJK:ZE8WLLT5I>VT\D)Q*D4JN4/^T >/QI+W5=.TTQB^O[6U,IQ&)YE3>?
M;)YH MT55FU*PMIXX)[VVBFD*A(WE568L2% !/.2#CUP:M4 %%%% !68?^1I
M7_KR/_H8K3K,/_(TK_UY'_T,4 :=%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=6_X\E_Z^(/_
M $:E7JHZM_QY+_U\0?\ HU*O4 %%%% !1110!1N_^0GI_P#O2?\ H)J]5&[_
M .0GI_\ O2?^@FKU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4.K6NK7=Q;1-(H#PS.X()S@<,KX/=1WI)?"MYI%_9O9Q7]W:)ID=BXLIXHY
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MI=2MEM;C_4R^8")._P N.OX5DZWXO@L[_1[*QN[!I-2)=)9I"4\O'!&WKN/
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M-QJ,KPQ+(.4A0&./CW^9_P#@=-F\+E_ +>'HWA2X;3EM&G"8!8(%W'OC(S0
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M[?7;U5R\!F<0(Q!QGH!D_P ZP](\/ZYH']EW%O:VMU+'IOV&:)[CRQ&P<NK
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M+'%J<EKL:-2I#!3AU(/U'/'-7+GPO=MIGBJUMXHD&HV*6]HOF$@%8/+P2><
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M ;G[1$\+1@C()5P#@CH<<]J .?\ #/AS4+"Z\.27MHJ_8-+G@D8NK>7*TD9
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MA7[/XAAU5](L-*2VA>.*"UD\QG9R,DG: % & H_O$\5V-%% %&[_ .0GI_\
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M;PPPEI'5?O''8#(Y/J/6@#,MO#5]%>6,K&';!K=U?OAO^6<B2A<<=<NO'UK
M\0V5WI&H6SM>061N-7N;N*YDG$*(IA"@-(58*3S\I4Y_"O0+75[&[T@:I%.!
M9[&D,C@KM"YW;@>01@Y!Z8-9MMXNTNZ+*R7<&;=KF+[1;-&)HE +,F1S@$''
M7D<4 0>$YHIO!^V"V\F.(S1@B8RK,0S9D5R 6#$DYP.M<]X;T?5M<\.^%1=Q
M6UM8V5AN2:*8M)+YEN8U&W:-N Y)Y/(&*ZS2O%6FZQ=QVUN+E&F@-Q T\#1K
M-&" 60D<XW#\P>G-2ZGXAL]+NEM&BNKBY\KSFAM8&E9(\XW''09! [G!QG%
M'/\ A[PO=6 LXKVP!ELK9H8[LZI-*I.W;E(FX4$=1VZ#-6[?P[>Q>&_"E@?*
M$VER6SW&&X^2,JVWCGDU>/B[2FNK*WMVN+J2]A6XA%O SYB8XWG X [YZ5NT
M </9^&]92QTS0YHK5;#3[Y+H7JS$O*B2&11LV\,3@$YQUZYIJ^'==C@MM*2&
MR-E;:P+\71G.]X_M'F[=FWAAN(SG!Q[\=U10!6LWO'$_VR&*/$S"+RW+;H_X
M6.0,$]Q^M6:** "LP_\ (TK_ ->1_P#0Q6G68?\ D:5_Z\C_ .AB@#3HHHH
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MSO!&Z5RQR1QQTZ_AI:%X=N=-UF[U&XELU-Q&$>&Q@:*.1P23*REC\YZ<?F:
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MS#-MWKSWVDCWX-3T %9A_P"1I7_KR/\ Z&*TZS#_ ,C2O_7D?_0Q0!IT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!1U;_CR7_KX@_]&I5ZJ.K?\>2_]?$'_HU*O4 %%%% !111
M0!1N_P#D)Z?_ +TG_H)J]5&[_P"0GI_^])_Z":O4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 4;/_D(:C_UU3_T6M7JHV?\ R$-1_P"N
MJ?\ HM:O4 <IXF\2W%M!K%GIUA<W$MG9&2>XB=5\@LK%< D%B -QQT&.IXJ"
M'Q.NG6UY<W<EW/\ 9=-LIGC)39ND+KD'@@DCYBQP!SZU<U7PM<WMYJ4MGJQL
MX=3@6&[C^SB0G"E0R,2-IVG!R#T['FI8?#<UH]U+:7ZI--9VUH#);AU A+\E
M<C(8.01D8]: '3>))X8K"(:6\FH7S/Y-M'.A4HHR7WYQMP1[Y(XK-D\22:?K
MFJ75_'<Q6\.F6DHL\AF65Y9EVC!VEF(49SCI3[;P5+816LMCJ4=O?V]Q-,KK
M:CR )<;XQ%N^5?E4C#=1GO5B[\(?VC]M>\U*22:ZM((#*L2J5>*1Y%D Z?>8
M<?[/4YH ;<>,AIT=ZNJ:7/:7-M;K<B+S$<21EMF0P.!AB,YQ@'/(J:[\4_8;
M*R>XL@MW>R%((1<Q[& &XOYF<!<#ZY(&*2/P]J)N;B_N=6BFU)[<6T4@LP(H
MX]VY@8]QW;N_S#MC%4D\")%96XBO(%O(+N2Z1OL@-N#(NUD$.[A,8. V<\YH
M GB\:1W<-HECI\US?W$LT7V594&PQ8\PE\[=O*X(Z[A^$_@R_N=2T:YN+KSA
M)_:%VH28@O&HF<!#@D?* !QZ4V7PS=DZ?=6^HV]OJ-F90)8[(")TDQN7RPW^
MRI!W9R.]:&@:.=#TY[5KI[IWN)9VE=0I9I'+G(''4]J ,/3O%<K6&D6]K97N
MIW=[:27"-(\:-M1E!+GA1]X=!Z5?T_Q?97S69:*6WBNK)[Q'EP /+8+(A_VE
MR#1HWA5-(GTN07;2_8+*6S ,>-X=T?=UXQLQCWJE>>!(KSP[8:3_ &A)&UI)
M(?/1/F>.3<)(\9X#*Y&?8&@!DGQ MUMUF33Y25M$O)XWFCC:.-P2H 8C<Y4$
M[1[<Y-6;[QD()[E++2KF^CM[..^DEC=%41.&(QN();"' [^U/O\ PH9=8EU&
MPN+6!IXDBFCN;(3K\F=I3YEVG!QW' XJT_AY7NM5G^TD?VA8QV941@! @D&X
M<\Y\SIQTH I6_B.^O/%W]GP6.[37L(KI+@.H8!RWS8)Z< 8QG(STJ+3/%,DV
ME:/%8VEWJ=[=V*W9$LD<;+'P-SMPN23@ #L>E7;7PY-9:I8WEO?@+#8QV,\;
MPY\U$R5(.X;3DGUJI:^#[G2X-+.EZL(+NRL18/)+;>8DT8(()7<,$')'/<]:
M ')XT6[^P1Z;I5U=7%[!-*L19(_*,3A'5R3@$,<<9Y'O6I9Z_9W?AH:\0\-J
M(&GD#CYHPH.X''<8/Y54TGPK#I%Y87$5U)(;6UG@;>HS*TLBR,Y(Z'<IXQ_%
M[5/9^'8+?PJ^@32M-!)%+$[@;25D+9]<?>H P3XGOY/$6FRW&G7=C:'3;J[\
MIY$83 >45SM)PP!/!Z;NIK<7Q) S:4/(D_XF-G)=IR/D5%1B#[_./RJC:^$[
MLWEM/J>L&\6WLY;)$6W$0*.%!8G)RWR#)Z>@'=NG^$+NVN+"2[UDW26%G)9P
M(+81X1@HRQR<MA!D\ ^@[@#8/%$NJ6>BWQL[W3[>^NXE@)>,F96C=OF')"\>
MQ/!]14L'C,37,6[2;J.RDOWT_P"U,Z8\U79!\N<[25QGU-6H_#2QZ3X?L/M1
M(T=X7#[/];Y<93IGC.<]Z8GA5%T^"T^UL1%JC:EN\OJ3,TNSK_M8S[=* (;?
MQ>UUJ=E;PZ7,;6\N9K>&Y,J#)BW;R5Z@?(V/7':I=3UO4K3QAI>E6^GB:UNK
M>6223S%!RK1C(R>BAN1WR,=*Y?PWH^JZ=K=O.NG2+=274IO6N+6/9'$S,Q*S
M [F)^7USW [=GJ6CS7FLZ;J=M>+;S68DC96B\P21R%"PZC!^08//T- '/Z1X
MIN[::ZCO;*ZFM&UJ:R6\,BE4+2E8U"YW%02JY[9[U>'CBS.I" 0$VIO?L(N/
M.3/F[MG^KSNV[_ESZ]L<U8/A5#8/:_:VPVJC4]WE]Q,)=G7VQG]*BLO"CZ=J
M3RVUU:_8WNFN?*ELE:569MS*LN[@;B2/E)&>M &KJ^HW&G0H\%B;G<3N)G2)
M4^I8]^V ?PK(3QDMVFE?V=I=S=3:E:R7,4>]$V!"H8.2<#E^HST]ZMZ_X=;6
M;RPNX[F&.2T\P!+BV$\;!P 3M)&&&W@]LG@YK"C\+:GINJ:!;:7?&-+'3[J)
MKN2W#HQ:2(A67(Z@$\$?=].* -&/QH+M=.2QTJZN+F^CG80ET3RFA=4=7).!
M@DC(ST]ZK1^(VU36-'GMVN+:"6RO_/MR1N26)XU((Y!*G< ??WJ ^%M1T_6-
M#CTN]>/[-:WAFO)8!(KRRR1N=RY'WCO( (QCKZZECX/CLFL7%[)(]O#=)([(
M,S/<.KNYQT^93Q[^U $-CXHDDL-*@L;&[U.[FTZ*]DW21HRQL, L3A2['/ P
M.#TJW>>)VL-5M;6ZTV2*"YG2W28S1EMS?=.P'.W/&?TQ5:#PE=:>-/?2]7%O
M<6VGQZ?*\EL)!*B?=8+N&U@2W<CGH:@;P,S:K]K.HQLG]H)?DM:*9F=2#L,F
M?N<<  8]P,4 5]+\575D;YKZRNYK%-9FM#>F12L6Z;8@"D[BH)49[9[X-/L_
M%+:?%<Q7!:ZNI]6NX+9))E0*B,3RS' 4# _$#%6/^$-N&DF@DUAGTR?4#J$M
MK]G 8MYOF! ^>%R%SP2<=1G%.N/!:NRSPWD8NX[VXNXVFMA+'B;[R,F1D=.0
M0<@4 ;.AZS!KNFB\A1H\2/%)&Q!*.C%6&02",C@CJ,5I54TRTDLK%()9(9)
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M* "BBB@ HHHH **** "BBB@ HHHH HZM_P >2_\ 7Q!_Z-2KU4=6_P"/)?\
MKX@_]&I5Z@ HHHH **** *-W_P A/3_]Z3_T$U>JC=_\A/3_ />D_P#035Z@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C9_\A#4?^NJ
M?^BUJ]5&S_Y"&H_]=4_]%K5Z@#!E\077_"2W&E0:<KPVL44]S=/<; B/NZ+M
M))^0\<#KR.,Y.D_$*VU2[M8UBM/+O(Y)+<0WJRS+M4OB6,#]WE0>[8/!P:Z2
M+288M7O]1+LS7L,4,D;8V@1[\8^N\_E6=8>';G2;+['!JMQ-90PM%;VLD<?R
MKC"J7QD@=!R/?- %/3O&<]P-*GU#2A966J0--;RBY$C K'YA#J%&,J&(()Z<
M@'BI;#Q7=7$VE27FDBUL=6.+.87&]\E"ZB1-H"[E4G@MZ&JOAOP?-;Z9HIUB
M\N;A[&R$:6<NS;"[1A7&5&6P-RC). 3UZU>T[PDMC-I_G:G=7=KIF?L5O*J
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M?Q7DIAOF$DEJRKM$@54W XS]U!QG'6@"M#XBDN/%5QHR6]NJVY7>TMSMF<%
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M *&* -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO%_WP*/LMO\ \^\7_? KG]*EO]2\073W%Y/#%;QV[BT0 +N>/+!LC)&>U/\
M$]Q=6CQ70N)ET^")WN4M9$65>1A\,/F4 -Q[]^E &[]EM_\ GWB_[X%1VZV%
MU%YMNMO+'N*[D (R#@C\""*Q+.YDU#6;^2;59;9;2[CAAME*JK(41AN!&3O+
M$?RYK(CU34[G^SK-))ML\M\S-%(D3.8YRJJ&(QP#G Y./K0!VWV6W_Y]XO\
MO@4&VM@0#!#D]/D%<M$VKW5YHUA=ZC+ \EM<M<-;LA+['0)\V, X/..^:I0M
M<:E/X8N+O4+A)=]S$TB%5W%-PSTZD+S0!U,][H]M;O/(]MY:2^2Q1 Q\S.-F
M "=WMUJ>V.G7:N;=;>0(VU]J@[6P#@^AP1Q[UR%Z)]1>U\R\GC\OQ!)"OE$#
M"[6QVZC''U-6'U&\DU233VO9+>";5G@:==H8*MNKA 2, EN_7K0,ZW[+;_\
M/O%_WP*/LMO_ ,^\7_? JHSFWT"=HKQKEHH9-L[%2Q(SU(&,C&/PKF[)-3N+
MK1H9-<O=FHZ>UQ.5" AE\O&P[?E'[SGZ4".O^RV__/O%_P!\"C[+;_\ /O%_
MWP*XF'5]6OX]&M3+,3-:RR2/#(D3S.CA.K#' Y('KZ"IY;W6Y+C2].GD?S7M
M))96MIXT,KJP4?,1C@') [GT% '7_9K;('D0Y/;8*C@6PNHR\"V\J!F0L@!
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MMO\ \^\7_? J!;:#[?(/(CQY2G&P>K5=JNO_ "$9/^N2?S:@!WV6W_Y]XO\
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M<JKRI$I )RSL%4?F15B@"'[+;_\ /O%_WP*/LMO_ ,^\7_? J:B@"'[+;_\
M/O%_WP*/LMO_ ,^\7_? J&+5+:?4I["+S6F@ \UA$VQ20#M+8QG!!Q[U<H A
M^RV__/O%_P!\"C[+;_\ /O%_WP*FHH A^RV__/O%_P!\"C[+;_\ /O%_WP*F
MHH A^RV__/O%_P!\"C[+;_\ /O%_WP*FHH A^RV__/O%_P!\"K6AQ1Q^('\N
M-5_T4_=&/XQ4=3Z-_P C"W_7H?\ T,4 =-1112&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F>(/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLLD[S2.L:K]G0J&9>0F[\,XSUH [N2WAE5EDAC=7QN#*"#CUIX4*H4 !0,
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M(I6(64S 2>6V>FW;G'&?QKNK2Z@OK2*ZMI!)!*NY''<5-0(Y_1;<6'B+5K*
MRBU6*WE1'D9P&;S Q!8GKM&:Z"BH;:[@NXVD@D#HKM&Q'9E)5A^!!% $U%%%
M !1110 5/HW_ ",+?]>A_P#0Q4%3Z-_R,+?]>A_]#% '34444AA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9GB#_D#R?\ 72+_ -&+6+6UX@_Y \G_ %TB_P#1BUBTQ!1110 4444
M5YO^/NV^K?RJQ5>;_C[MOJW\JL4 %%%% !1110 4444 %%%% !1110 4444
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MN-RMW Z9Y[U1M8D,&AG7[6XGLUTXHBO"\FV<,.H )#;1P3[XKT&B@#S=8?\
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M )&%O^O0_P#H8J"I]&_Y&%O^O0_^AB@#IJ***0PHHHH **** "BBB@ HHHH
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MD^V*I_\ "3Z/_9R7PNRT+RF!56)S(9!G*>6!OW#!XQGB@#/_ ++U;_GA:_\
M?\__ !-']EZM_P \+7_O^?\ XFK!\:>'Q:071OSY5PSK#^XDW2%" P5=N3C(
MZ#U]#5J;Q+I%OJ LI;P+/O6-OW;%$9L;59P-JL<C )!.1ZT 9O\ 9>K?\\+7
M_O\ G_XFC^R]6_YX6O\ W_/_ ,36E)XDTF+4O[/>[ N/,6(_NV*+(W1"^-H8
MY&%)SR*EM=;T^]OYK*WF:2:(LKD1/LRIPP#XVD@\$ Y% &1_9>K?\\+7_O\
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MLO5O^>%K_P!_S_\ $T?V7JW_ #PM?^_Y_P#B:Z>B@#F/[+U;_GA:_P#?\_\
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M_O\ G_XFC^R]6_YX6O\ W_/_ ,373T4 <Q_9>K?\\+7_ +_G_P")H_LO5O\
MGA:_]_S_ /$UT]% ',?V7JW_ #PM?^_Y_P#B:/[+U;_GA:_]_P __$UT]% '
M,?V7JW_/"U_[_G_XFC^R]6_YX6O_ '_/_P 373T4 <Q_9>K?\\+7_O\ G_XF
MGZ5;W5MXC9;E(E)M"1Y;EOXQ["NDK,/_ "-*_P#7D?\ T,4 :=%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 4=6_P"/)?\ KX@_]&I5ZJ.K?\>2_P#7Q!_Z-2KU !1110 4444
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MLBN6!3;G<"N-O!QD]!5_Q'XB3P]:V<[6EQ<?:;J*#;%&S%0[ 9X!YYX'<\4
M8$?A2YCU6\BN;&:\L[G43>K*NIR11J"X?YH@<$JPXP"#@=*T=,TO4[7Q3+<0
MVYL=-D,SW$7VKS8YY&(*NB8^0GDMT&3T/6H6\:V]CKFJ0ZA]H6T@@MYDV6CL
M84=26:3 ^4#CKC'/H:UM0\4Z7IL[Q3R3-Y4:RSO# \B0(W1G900HX)^@STH
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M;=623>S!L8Q@9'>N8A\#ZI=BZ74988C<:1-I[RB\EN7>1RA\SYP, [3\H_\
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M*M@#TZ],NM/%L&I:G;VFGVLEPDEM#=-*9$0K'+DJP4G+8 YQT]SQ0!T5%%%
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M:727-J8;=O*!4%2'!;)#!F'!&..N*MV.OOJ.N7NGP:;<>393&&:[9E"!]BL
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MVJH;@@IG/\C43^ G62RN"^G:E<0V26<QU2U,P;:Q8.O.5/S$8R<C'/&:U?\
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M"6 >3"4$BLJ*#RQP1LY^M9\W@>9HK1!=6=PD,]W(T%[:F6%O/E,@;9N'S)G
M)]3TS0!?_P"$RM9ET[[!I]_?2ZA:M=PQPH@(12H.XLP"D;AW]O2M&VUF._\
M#R:Q8P33))"94AP%<G^[R0 <\=?QK-T+PHVBS:2_VM918:?)98$>W?N=&W=>
M,;,8]ZT=$T@Z1X?ATPS"4QJZ^8%QG+$],^] '*>'/$%\NC:+>ZA+JDL]];S7
M30.D+"?;$K_)M/RKS\HX.>N*Z";QCI4-O;7!:5H)[!M0\Q5!"0C;RW.<DL
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M?_0Q0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW$P)1PY4''!!!'&#UI-6\:RZ5=BPFATU+Z*U6YN$GO\ RDY+ )&2F78[3U
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M %%%% %&[_Y">G_[TG_H)J]5&[_Y">G_ .])_P"@FKU !1110 4444 %%%%
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M\J/_ )YI_P!\BF(Z7^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\ &N:\J/\
MYYI_WR*/*C_YYI_WR* -BZU.P;4;%A>VQ56?)$JX'RGWJ[_:NG?\_P#:_P#?
MY?\ &N2FBC^U6WR+U;M[58\J/_GFG_?(H Z7^U=._P"?^U_[_+_C1_:NG?\
M/_:_]_E_QKFO*C_YYI_WR*/*C_YYI_WR* .E_M73O^?^U_[_ "_XT?VKIW_/
M_:_]_E_QKFO*C_YYI_WR*/*C_P">:?\ ?(H Z7^U=._Y_P"U_P"_R_XT?VKI
MW_/_ &O_ '^7_&N:\J/_ )YI_P!\BCRH_P#GFG_?(H Z7^U=._Y_[7_O\O\
MC1_:NG?\_P#:_P#?Y?\ &N:\J/\ YYI_WR*/*C_YYI_WR* .E_M73O\ G_M?
M^_R_XT?VKIW_ #_VO_?Y?\:YKRH_^>:?]\BCRH_^>:?]\B@#I?[5T[_G_M?^
M_P O^-']JZ=_S_VO_?Y?\:YKRH_^>:?]\BCRH_\ GFG_ 'R* .E_M73O^?\
MM?\ O\O^-']JZ=_S_P!K_P!_E_QKFO*C_P">:?\ ?(H\J/\ YYI_WR* .E_M
M73O^?^U_[_+_ (T?VKIW_/\ VO\ W^7_ !KFO*C_ .>:?]\BCRH_^>:?]\B@
M#I?[5T[_ )_[7_O\O^-']JZ=_P _]K_W^7_&N:\J/_GFG_?(H\J/_GFG_?(H
M V+34[!;Z_8WML TBE295Y^1>G-7?[5T[_G_ +7_ +_+_C7)P11_:;GY%X=>
MW^R*G\J/_GFG_?(H U;B/0;G58-3DO81=PH8U>.\*!ESG:P# ,,\X(-5;#2O
M"VF7<=S:SPAH=WD(]ZSQP;NOEHS%4STX XXKG[K7]$LKHVUS<Q1S XV&,YSC
M/ISQ5JTO+&^EECM]KM$$+?)CAUW+U'I2&=#J":#J<]K/<WL/G6KEX9(KPQLN
M>HRK#(.!D'@TPVWAPV[0&>U\IKL7I'VG_EL'$F[[W]X XZ>U9GE1_P#/-/\
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M4=[HWA34)Y9;B>)C,J"5%OV5)-@PI90X#$ #!(SP/2J_E1_\\T_[Y%'E1_\
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M_M73O^?^U_[_ "_XUS7E1_\ /-/^^11Y4?\ SS3_ +Y% '2_VKIW_/\ VO\
MW^7_ !H_M73O^?\ M?\ O\O^-<UY4?\ SS3_ +Y%'E1_\\T_[Y% '2_VKIW_
M #_VO_?Y?\:/[5T[_G_M?^_R_P"-<UY4?_/-/^^11Y4?_/-/^^10!TO]JZ=_
MS_VO_?Y?\:/[5T[_ )_[7_O\O^-<UY4?_/-/^^11Y4?_ #S3_OD4 =+_ &KI
MW_/_ &O_ '^7_&C^U=._Y_[7_O\ +_C7->5'_P \T_[Y%'E1_P#/-/\ OD4
M=+_:NG?\_P#:_P#?Y?\ &C^U=._Y_P"U_P"_R_XUS7E1_P#/-/\ OD4>5'_S
MS3_OD4 =+_:NG?\ /_:_]_E_QH_M73O^?^U_[_+_ (US7E1_\\T_[Y%'E1_\
M\T_[Y% '2_VKIW_/_:_]_E_QH_M73O\ G_M?^_R_XUS7E1_\\T_[Y%'E1_\
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MUS7E1_\ /-/^^11Y4?\ SS3_ +Y% '2_VKIW_/\ VO\ W^7_ !H_M73O^?\
MM?\ O\O^-<UY4?\ SS3_ +Y%'E1_\\T_[Y% '2_VKIW_ #_VO_?Y?\:HPW5O
M<^)P8)XI0+,@F-PV/G'I61Y4?_/-/^^15C1%5?$+[5 _T4]!_MB@#J****0P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,SQ!_R!Y/^ND7_ *,6L6MKQ!_R!Y/^ND7_ *,6L6F(****
M "BBB@"O-_Q]VWU;^56*KS?\?=M]6_E5B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"O!_Q\W7^^O_H(JQ5>#_CYNO\ ?7_T$58H PM:
M_P"1B\.?]?,W_HB2L+5X'%UXMU"*[NH)K.".6$0RE%WK%N!('WNF,'(]J[DJ
MI() )7H2.E(8T.[**=_#9'7ZT <'JE[J%QJ^IQ_;[>SDA2(VC3ZB]NJ H#OV
M!2)!NW Y/;'%=%XHN9K72(6\]K>)[F&.YGC;:8XRP#$-_#Z9[9S6P\$4C*SQ
M(S)]TLH)7Z4]E#*58 J1@@]Z ./NKBQ6[TVSCUB;^R)'G\V<7K?ZU54K'YN=
MP&"QQNZC'M56SEN;^;3+0ZC>-8R7MU''-',0T\*+E<N.2,Y&[J0.M=N;> P^
M288S%_<VC;^5-\VW%PMONC\Y$WK&/O!>F0/3M0!P<R1RKI)U"^N5AM=8NK7S
MWNW0A LH7<P(YX W=>W<UKPL5O?$>I7-W?/%8RL(H8ICM5?LZ,<+T)YXST/3
MO710-;WUFDJP_NI1O"2Q%3Z\J1D'ZTU[ZTMWNO-/DK JR2R.A5,'ON/!Z<^G
M% S@O[7NX$U/[%=,(C8Q3'9?M=F+,@#/N8?*P0DX&1P#6AK4&DOIMJUMJUQ/
M;Q:C;F63^T'<1!F )+[N.QY/&<C&:[2."&(8CB1!Z*H% MX%A,(AC$1ZH%&#
M^% '$ZC>0>=K7VC6+BV>T@C.G*EVR[U,0(<#/[TE\CG=G&*T=(2ZO_$-S+?7
M-TC6T%LXMDE*QK(R'=E1UY'0\5TI@A9D9HD+)]PE1E?IZ42NEO%+.RG"J6;8
MI9B /0<D^U CF/$EV+'6+>YENR]NB(&LXKPPRJQ? D" _O,]-I].,\UFW,4E
MNOB'5(;NZCGM]43RT24K'TA!RHX;(..<^V*[A5AN!%<&($X#(73#+GZ\BGF-
M"&!1<,<D8ZF@#AM1U8_\)#$UK/)'(FJ16LBR7[98$J& @QMVX/4X/>GZ=_R,
M%G_V%M0_]!-=? UO<RS2+"1)&_ELSQ%22,'@D<CT(XIEG=VUY)<B%,-:SM"Y
M*@?/@$D?@PH RM8BDO/$^EV1N[J&W>VN))$@F,>\JT6,D<\9[?R)K$@NM0NM
M:G9K^WM[F+4S$$FU%T/E!P @@V[3N3H<Y).<]J[O:I8-@;@, XY%03FT@DCF
MG\I)&81H[@9+'@*#[T <+'J&7:6/5[B355UIH$M#<$CRO/(*^7G!79DY(XQU
M&,5)]O=HA=#4Y_[=_M/R?L7V@[=GG;=GE9QM\OYMV,]\UUMO9V.BV\LK.JJ9
MI)3++C*F1RQ&<=,M@5(ES:/K,UJL0^UQ0I*S[!]UBP SUZH:0SDKBSDOO#/B
MFZGO+Z60&]BBC^T.$55+%5"@X/([]CCIQ70VD%K<>%O)M;F6>%X"!(MRSL3C
MH'SGK[^U; 55! 4 $Y.!UJ**2V29K2)HUDC4.8EP"JL3@X]R#^1IB.$TR>U3
M1/#-K_:<L6GSQ?Z5*MXPQ*(EVQ;]V4'4[01TKH_#,KW6FWB-<2W%JMU+%;3M
M(2SQ#&#OZG!W -GMUK4_T5IWL?L_5!*P,/R')(ZXP3D=.M654*H50  , #M0
M!YS:VUO_ ,(O!;0WDXG_ +92.4?:"[P_Z4P! 8G:<<].>O-6]1NKW3$U2RM[
MN8VT5];(9)[E@8HY%!;,IW,HSQGG&XUV=JUO=0"XBA*B0[CYD11B0<9((![=
MZG,:'=E%.[[W'7ZT#,3PSYXCO!)>6\\(E'E)%>-=&+Y1E2[ $\\@'IFN<TF^
M?4?$4*O?RK/%>7)E1]0*B907$:+"&XQ\I((Z YSFNXED@TZS>41%8HQDI#$6
M/X*HR:S+?PS;V[VZ_;+N2VMIC/#;.4V(^2<Y"AC@L>I- CG--OFF31+B/5+B
M;5KJXV7UJ;AB%7#>8#'G"!,<$ =!ZU+::AJLC2:?'+-)=Z)!<&8DDF=\$0!O
M[VY?FY[@5UEM<VDVHWL,406XMRBS/L SN4,.>_!J>66WMF5I'CC:9P@)P"['
MH/<T#.&TRYO&L9+J+5(&#:9+)*BZF]Q(S[00X0J/+(.00..0,<5=:VG33O#L
M8U+4"]_<H;F7[0VYP8)&(']T9 X&,=1SS740FV:ZN8HX-LBX\UO**A\C/WL8
M;WQFK&Q?E^4?+]WCI]*!'$![H^1IPO[Q8DUU[7>)F\PQ>2S["YY/)ZGGISD
MTQ5N;6WGNEU*_=K/68[6%9+AF7RFE0%6'\?#GELG@<UW7EIG.Q<YW=._K1Y:
M8(V+@G<>._K0!PL=UJ%UK=R6O[>WN8M2\I4FU%T/E!P @@V[6W)T.<DMG/:G
MHUTBC4O[0O&F&O-;!&G;RQ$;@H4V=",'J>1Q@X%=.+ZUEUQK-+5Y+B% TDXC
M&V+<"0"QYR<'I6AY:8QL7&=V,=^N?K0,YCPO!:V^L:[&MS*;D7K_ +F2Y9CL
M*1D-M)]_O8]LUU--$:"0R!%#D8+8Y(^M.H$%5U_Y",G_ %R3^;58JNO_ "$9
M/^N2?S:@"Q116??ZU8Z9<107#3&65&=4AMY)3M! )(13@<CKZT :%%5[*^MM
M1M5N;299H6R R^HZ@^A]JL4 %%%% !14#W<4=P87WJ1$92Y0[ H.#ENF?;.:
MB;4[99[&)6+_ &[)A=.5("[LY],4 7**AEN4BG@A99"TQ(4JA(&!GDC@=.]3
M4 %%4-2UFSTD*;IIOF4MB*!Y2%'4G:#@#U-.N=7L+72?[4FN5%EL5Q* 6!#8
MQ@#DYR* +M%59M0MX=)DU(EFMD@-QE1R4"[N ?:IXI%FB25<[74,,^AH ?11
M10 4444 %%5[^^@TVPGO;@D0PH7;:,G\!ZTVUOX[G:A5X+@IYAMY<"15R1D@
M$\9% %JBBB@ HHHH **** "BBB@ HHHH **** "I]&_Y&%O^O0_^ABH*GT;_
M )&%O^O0_P#H8H Z:BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#,\0?\@>3_KI%_Z,6L6MKQ!_
MR!Y/^ND7_HQ:Q:8@K/L=;T[4C=?8[D2K;$"1E!V\C/!Z$8[BM"N4T75M/?Q)
MKCQW"%'$3Q[0?F5(_FQQVH V+#7K'4;M[2$S).L?FB.>!XBR9QN7<!D9K3KD
M] U.TUOQ!)JC3JLQA,%K:X.Y(MV69O\ :8@<=@!WS764 5YO^/NV^K?RJQ5>
M;_C[MOJW\JL4 4]0U.VTR*-[AGS*_EQI'&SN[8)P%4$G@$_A4UI=1WELEQ$)
M CYP)(V1A@X(*L 1R*RO$JZ>;>V:^O);&2.7?;W48.8GP1UP1@@D8/!KE[B^
MO[]=,DU:2%;$K<*)IXG2*9@X$;LH(VDIDC/'7':@#T.BN%*PPG1XM;O7N=+%
MK+MF^=4>7>-N[OD)D#/7!/6F:KJ$=E:^)+<27*M<V$;6*LKEW'DE<C/.01SG
MD=30!WI.!FJMOJ%O<?9U!:.6>,RI%*I1]HQDE3R,;A^=8<%BEYXQEDN1*RV]
MC;/$N]@@?=+\V.A(P/SK#TJVM1/X2N]11MTFG-'YDA;F7,10'W^]UZT >A5G
M:AK=EIES%;S^>TTB-(J06[RG:I ).T' R1^=<]H@NI-=CT>5I?*T1I'+L3^\
M#\09/?",V?=15K6K2^N_%EJMA>/9S?V;<;9A&KC.^+ ((/U]>* .BM+N"^M(
MKJUE66"50R.O0BIJ\Y+#[%H<4J1VFFI;2I)'=;S&MRK $,01S]\@GCKWQ4\A
MLX+S18-9OY+BS_L^<F7,BHY$B;=W? !QENIQW(H&=_17GUFR^5I*^(6G73#;
M3&'SRX!;S?W>_ON\K&,^_>IK&QEU&70+?4/M36QBO6"2.ZEXQ(GE;^Y^7!Y]
M*!';17$,[S)%(KM"_ER '[K8!P?P(/XU+7+>';6QL_$FO1!/+O&N?,126R8C
M'%R,\$;LUU- !1110 4444 5X/\ CYNO]]?_ $$58JO!_P ?-U_OK_Z"*L4
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MA'8?9?,5F^T3K NW'!;."?;BI;>X^T([>5+%MD9,2KM)P<9'L>QH X*&^O\
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M48[\@^?'$T*G/&UBI/'U458HH **** "BBB@ HHHH **** *\'_'S=?[Z_\
MH(JQ5>#_ (^;K_?7_P!!%6* .#\0V;W'B"_6^DCBBD@C6SEDL9+@IP=QB*,-
MCAN>F3Q5JZACA\4V[F)=1N)3#%(L]H^^(;>9(Y,8"X.67UR,YXKI8=16;5KR
MP\LJ;6**0N3P=^[^6S]:L1W,$L1ECFC>-<Y=6! _&@9PEG!9Z;X>O;5-(C,W
M]H,ERLEL^Q8S,Y1V 'SJ%(X'8CH*KI;?\2?RYK65[*/7 XCM[62-?)\H$E8^
M6"9)X]SZXKT(W=L(!.;B(1,<"3>-I_&I20!DD8ZYH X2VMLSJVGVTL>EG68'
MMD\IE50(\.RJ1PN[/MG-17MLJV#RW$8>2+4+V2*UN;1YHIP9#@$ <-TVGW.
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M/F6"::":!-175GU"VGVGY59\M&QZX*%E/UKKJ "BBB@ HHHH **** "LY?\
MD8Y?^O1/_0VK1K.7_D8Y?^O1/_0VH T:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LEO
M^1NC_P"O%O\ T8M:U9+?\C='_P!>+?\ HQ: -:BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[6
M?^/.+_KZ@_\ 1BUHUG:S_P ><7_7U!_Z,6M&@ HHHH **** ,Z\_Y#.F_P#;
M7_T&M&LZ\_Y#.F_]M?\ T&M&@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#.L/^0EJO\ UW3_ -%)6C6=8?\ (2U7_KNG_HI*T: .-\1:
MS=V7B-H)=8ETK3ELXY!,+'S4:0O(&W.5(7 5.I'6I_&%YJVF:1/K&G:M%&D$
M:F&U^S*XN9"<!2V<_-D ;<?C5_7--UG4X[BSMM1L[>QN8C%('M6>5 00Q4[P
M.0>,CCWJA>^%]3;4M.FL=1LQ9Z= L=K:WEJ\H1P,>9E9%RV. 3TYQUH Z.=;
MF:Q98)$M[ED^5V3>$;Z9&<?6N8TS4-6:Z\1V$^K1RQZ>(C'J+6R_(S*6D4JI
M )4!3_P(9S6S=V>M3V]XD.J0022VZI ZVV?)EYW/RW(.1@'ICO5#1]$UK2-(
M>QBO],4J 8I$LI,E]V6:3=*2Y;G)R#DYS0!2\/\ B@FUUVZO-274-.T^11#=
MB())(=@+)M&,D,0!P,Y[U;\):IJU[+K$6M-$LUM=(JQH !$KQ))LS_$5WXSW
MQ38?!ZWESJ%WKTT=U/>F#*6@>W2/R22A!#EBV3G.>P]*=IW@;2K.ZU1[B+[=
M!>S)(L%VSSJ@5%7D2,P8Y4G=U ..@H K^,?$=]IRB#2#'YT'ESW<CKN"1,X1
M5_WF)./96]JTO&.J7&C>%KN_M94BFC:("1UW!0TBJ3COP35#6O &EZE:7*6G
MGV,LYBSY-S*D0";0!Y2L%X50!QQP:T]>T1]4\-OI5M/Y3?NO+DFW2X\MU8;L
MG+9V]<YYH KZ7JCG2I[N*^DU[$@11:P)&P/'') [@Y)%,?QI9Q:>+F2POQ-]
MM^P-:"-6E6;;N"\,5((QR#CD>^#4M%UK6-(:UO;VP\Q9XY56*!Q%*JG)CD!<
MDJ?8_G5/3O!4EC#&GVBU3;JXU+9;6_EQJ!$$V*N3CD9S0!9N_&L%FURDFCZH
MSV<"7%X$CC/V>-@3ECOP2,'(7)X.,U/J'BZSL9;@):7=W%:PK/=36ZJ5@1@2
M"=S GY1NPH)Q]12WGAQ[J3Q$PN57^UK1;9?D_P!60CKD\\_?_2LJY\"AM2DO
M(H=&NFGABCE&I6'GE&C7;N0Y'! &5]NM $_B;Q<+/3=7BTVVO+B>UL6E>ZMT
M5DMV9"8R<G)['@' Y-6]:U2]T[PE#J\#!FMUAGN05SOAR/-QZ':2?PJIJOA3
M4+B76$T[4+:VM=7MUBN%DMR[1D1^7E,,  5P,$'&,UTB649TQ;&<"6/R1"X(
MX8;<'\Z ,J;6)W\2M:VH,MG:6!NKD1*&:1W.(E7WPCG\JS-:\53'1=52&VN]
M-U*S$$A2X$9.R23:&!5F4@[6'7(Q3]+\&W-AX5U+2GU:1[V\3RQ?*F&1%01Q
MC&>RJ,\C))/>JD?@*40ZH/-TZU-]#;Q>796IC1#%(SDGYB6)SUH W[OQ-96=
MOK4\D<Y72"!<!5&6RBO\O//##KCFH;_Q;:6%S=(UI=RV]DRK>742KY=N6 /S
M98,<!@3M!P#6?K?A+4M1?6XK/4[>"TUA4,PDMR[HZH$^4[@,$*N<C(YQUX+O
MP4LFNWM_';Z-<)>R++)_:%@)I(F"A3L;(X(4'!Z'/K0!=\::EJFFZ- VC-$+
MZ>[C@C\U-RG<3Q^/ K(\3>-+F/P;:ZCH>Q;R[MGNU$J[A%'&A>3(]0=J?5JZ
M?6=*;54L5641_9KV*Z.5SN"'./QKGW\!CRO$:)??+J<$L%JC)\MHLFYG YYR
M[%OP H U]2\2#20LESIM\UH-GFWD:IY<>X@#(+!B 2,X4XJO?>,[.PO+Z%["
M_DBT^5([NYCC7RX=ZJP8DL"1AQG )&#D8QG-UWP-<:Q>W<ANK-H[A8MCW%L9
M)+;8!D1'=A0Q&3QGD]>VC?\ A:2]LO$EN+I4.L.K*2F?*Q$B<\\_<S^- %S4
MO$2Z5=!+C3;[[)YL<37JA/*5G(5>"VXC+ $A2!56X\800Z@+:/3;^>,W@L?M
M,8C$?G8R5^9PW'KC&1@9K.UCP1<:KJUU=-<V;)-<0SI)/;%YX!&4_=QMNPJD
MIG@?Q'KG-8EO9:A;>*;B[2QFFNFU9G6WGL9R@B+;?-$P81 B/)!VE@/EY- '
M81^+;26\CC%I=BTEN6M([XJODO*"1M'S;L;E*YVX)'6J:^/+-S R:5JK0W$S
MVUO*(5VRS*6R@^;/\+?,0%X//!J+2_!2:5J8DCM]%E@6Y>X2>6P!NEW,6V^9
MGJ">&] .*MVWA:2WL-&MC=*QT[49+TML^^&\[Y>O'^M'/M0!(GB^TDL8Y5L[
MPW<ET]FMCM3SO.4$LOWMN H+9W8QWIK^,;-+2WE^Q7S3S7C6/V5(U,J3*K-M
M/S;>B]02.0<XR11O_ XO%DD,EI-,-3DOXX[JW\V%@Z;"CJ3SQR#V(%78/##1
MII.%TZU-E?-=M%8VOE1MF)X\ 9Z_.#GOCI0!4O?&TJ6MC+9:/=RR2ZC]AN8'
M\L/"P&2OWP"QX(()&.I'%:/BG4[[3M!2[LXWC8RQB>3R?-:VB)^=]BGYBH],
M^O(%5+GPK=-%</;7D*W+:N-3A,D1* A578P!!Z \BMN^CU1[*/[!<VL5VI!<
MS0L\;C'(P&!'/(.3T[T 9FE:[ ?[-MI-334SJ'FFVO88U6-M@!V-@_>QD\ ?
M=/3%-3QC:W!M5LK"]NY+D3/&D8C!,<;[#)\S@$$D$ <D'.*PM9\+7UIX7NC:
MS&36[G5$O(I+2 JD,KE8R0N3A0F[<2>Y-:NM>$7OM&L])L6LH;:V@$,4LT#-
M-;D  21,&&& 'Y_E0!)%XLD36]<MK[3YK>PTQ!(UV2FT+L+$MAR><<8'UP:E
M7Q?;+%=M=Z??6;V]D]^(YU3=+"OWBNUB,C@8;!Y%17OA6:\N]9C>\0V&KVJP
M3J8SYJLJ% RMG'<'D=JK6O@Z2/2M2LV@T.WDNK&2T%Q8Z?Y+G<N-S'=T[[1W
M[T 3CQO$\_V>/0]8>X> 7,,0A0&6'NXR^%QQPQ#<CCFN@TZ_M]5TVUU"U8M;
MW,2RQDC!VL,C(K/@T1HM:MK_ ,\%8=.-D4V]264[L_\  >GO57P_I^IZ/_9N
MC[D?3K'3ECEG*8,LV0%V\\ !6)_WEH Z.BBB@ K.7_D8Y?\ KT3_ -#:M&LY
M?^1CE_Z]$_\ 0VH T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LEO\ D;H_^O%O_1BU
MK5DM_P C='_UXM_Z,6@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.UG_CSB_P"OJ#_T8M:-
M9VL_\><7_7U!_P"C%K1H **** "BBB@#.O/^0SIO_;7_ -!K1K.O/^0SIO\
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M/FI =-;3!%&P 6$XZ<9SQ55O!4,\%]'>:I>W+WEB+%G81KLC!)&T*H /)]:
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M HHHH **** "BBB@ K);_D;H_P#KQ;_T8M:U9+?\C='_ ->+?^C%H UJ***
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M!W%-=UC7<[!5]2<"N(E\6ZO+JUX+&T>6WM+X6AMUL)G,J@J'?S@=BD9) (/
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MPRW<8ZEVPG3  X'<UL7OBO5M&35K6]6UNKRV>T6WD@MW53]H8H-R!F8[2I.
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MP-,"Q7. '*J3A=Q&3@#/>C0--\,&XDO-$CB=H"T09'=DBR?F$8)VJ#C^' H
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M]G.0-ORC.2I# \\C%:\6J:C9:IIL-W,]KI<L5O';R+;B2.:1A@H[YRC9P%X
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M@"Q1110 44UW2,9=E4$@98XY)P!3J "BBB@ K);_ )&Z/_KQ;_T8M:U9+?\
M(W1_]>+?^C%H UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH SM9_X\XO\ KZ@_]&+6C6=K/_'G
M%_U]0?\ HQ:T: "N0\-:=9Z?XD\4VD$*I;!K?<K$G.8LL6)Y).3DGDUU]8]I
MX5T&QG>>VTJUCD=2CL$^\I&"#ZC'% '.Z7:MIGQ&C2YL+&R-QILD=JFG\HR(
MZEC)\JD$97;QCEN:[JLW3?#^D:/*\NGZ?!;R.NQG1>=O]W/8>W2M*@#.O/\
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M+=$FXL()27\S]Y K?-@#=SWP ,^U69-0LIHFBECWQL-K(R @CT(KE_M; _\
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MB:[2[ELH7N4^Y,T*EU^C=10SZ0]RUR]E"T[8#2F%2QP01D]>" ?PH_M; _\
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M',8+-CVR3^%=*^G6,BPJ]G;L(3NB#1*?+/JO''X5+B*VML! D,2<*J\!0.@
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M6,T >9:O!K!'BF,- \(TZS744:,M,R>6WF&,YP& W$9!YQ7I]FT+6-NUL^^
MQJ8VSG<N.#GZ49M/M<D.8/M,D89TXWL@XR1U([5+'&D4:QQHJ(@"JJC  '0
M4 .K.7_D8Y?^O1/_ $-JT:SE_P"1CE_Z]$_]#:@#1KSGQIJ,EOXOL[1]3N[&
MUDM))&-K$'9G#1@9RC<88]J]&KE-6TY7\4QZGYA#16SP!,<$,4;.?^ ?K7AY
M_.$,*I35U?\ ]M=NC_(VH)N6@RVP;6+$CRC8/WCC#-QU(P.3]!66H=_$FIE6
MD+1V4'EA6^Z29<X!XR<#KZ"M)89Q?23-<EH&156#8,(P)RV>ISD<>U4X8IH_
M$MY,T+^3-;0JDHQMW*TF1US_ !#M7P,&ESZ]/U1VOH4H1XE_L:<2&U_M3S3Y
M> ?*QGC.>=N,=.<_C1="X6UT.2Y9EN?M,:OM)7@J<@\\^]=!69J\4T\VG+#"
M[A+M9'88PB@'DY/OVJX5N:>J2W?;IMZ":-.BBBN0H**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#8T?_ %,G^]_2M&L[1_\
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M<8XX]+P,YQSZTBQHN[:BC<<G ZT 87@ZR%OX9L+AKBZN+B[MHIII+B=I"SE
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MMY85)*N70F,D=,^8B+G_ &S6%H4^K?;6T.[OKF2?0(+A[F<R-F8R*/(W'O\
M*S_BH]*])(!&" 1[U#<7-M:>6T\B1^=(L2%OXG/ 7ZT >>:*EHWB'PK>ZC>3
M+/<Z#&8WEO)%\Z8&+Y<;@&)SDKSGJ0:9X<MFTZQ\)WT%W>>9>7\MO,C7#&-H
MRLS;=F=HP44@@9Z\\UZ644[<J/E^[QT^E5-5U"WT?2+K4;A&,%I$TSB-06PH
M).!ZT <)I0GUB3PS:W=]?&&:#4'G6.Y=#+MF0*&92#QGU]NF170>&MVH^!#!
M?7,KJ1<VSSR/E]BR21@ECU(4#DUL:KJUAH>DR:I?.8K6(+N98RQ&Y@HP ">2
M127FN:;IVAG6)[A5T_8L@E52VX-C;@ 9.<C\Z /-[N"^U-+?3]-U;3]5&G:/
M=QK+I\1&T-#Y<8=@[#<QP0HQ]TFMW3]0L-9UWPG_ &3/%.+.SF:X$1!\A#&J
MA'Q]TEL?*>?E/I7:V<MO<6<-S:X\B=!*A"[<AAD'%2JBH254 L<G ZF@#@_$
M]S:MXCU&WUC4[BRACTU'T](KEXA+(6D#D!3^\<8C&T@\'IS7.ZCJT<'@_3X(
MY6M[RU\.V\\,KZG); L8SM\J-01*X*\Y_P!D=Z]8@N+6^5I('CF$4C1EASM=
M258?4$$5,8T.,HIV\#(Z4 >?:M>ZE#JG]CQW-QN\1QP-;2JY_<$8%QM/\/[L
M!AC')-6]-O([?QY+:M>KJ$ES+-Y;PWSLUJ%7F.6#.T 8P&]2.,G-=%JL6G65
MS'X@U"9T6P@=%SRJ[RN2% R6. HQZXQS4^F:C;:FLLT%O<0NK!76YMGA?ID<
M,!D>] '->(;FR/BT6NNZE+8Z6NGB6W(NVMEDFWL'^92,LJA,#/\ $3BLO0+6
M:_\ $7AB\U-[QKPZ1<2%GGD0L%EAV%E! Y4@D$8)Z@X%=U=:A;1:I9:;-&S3
M72R21':"H\O;G/H?F&*O8&<XY]: .-\275H/%=K:ZWJ,ECI1L7DB87;6RR3A
MP#EU(R0N"!GN3CBL;6+ZT:ZU[^T-9N[:XMK>(Z.JW;Q-(IB!#H@(\QC)D'(/
M0#%>DLBN &4, <C(SS5/3-0MM9M!>01MM6:6(>8HR&1V1L=>ZG\* ."OTOKR
M#Q-=WM[?P7FGZ5!<11P7+QI%/Y+,S;5(!^9>AR/:K,2V<?C>_NKBZDBOKG1[
M>:W4W;J)7Q-OVINPV!@XP0O4 $YKM+K4;>UU&RL9$<RWQ=8R "/D4L=WX5=*
M*6#%02.AQTH \YB>WT[P1X?EO+B\N)]66!YI[O598(PYA+_/("=J]@H')"Y]
M:IZ?JAGTW1(M6U.6'1WOKZ*6X%ZZJVQSY"-/E6*XW8)(W;1GTKU%D1DV,JE?
M0CBAHT92K(I4]01Q0!P5M#HR>/\ 3;A=0G>*?3!]DEEOY,3LL@  RV'XQQSG
MKSUKOZ0HI()4$KTXZ4M !6<O_(QR_P#7HG_H;5HUG+_R,<O_ %Z)_P"AM0!H
MTUHT8Y9%)]2*=12E%2T:N SR8O\ GFG_ 'R*/)B_YYI_WR*?14>RI_RK[AW8
MSR8O^>:?]\BCR8O^>:?]\BGT4>RI_P J^X+L9Y,7_/-/^^11Y,7_ #S3_OD4
M^BCV5/\ E7W!=C/)B_YYI_WR*/)B_P">:?\ ?(I]%'LJ?\J^X+L9Y,7_ #S3
M_OD4>3%_SS3_ +Y%/HH]E3_E7W!=C/)B_P">:?\ ?(H\F+_GFG_?(I]%'LJ?
M\J^X+L9Y,7_/-/\ OD4>3%_SS3_OD4^BCV5/^5?<%V,\F+_GFG_?(H\F+_GF
MG_?(I]%'LJ?\J^X+L9Y,7_/-/^^11Y,7_/-/^^13Z*/94_Y5]P78SR8O^>:?
M]\BCR8O^>:?]\BGT4>RI_P J^X+L9Y,7_/-/^^11Y,7_ #S3_OD4^BCV5/\
ME7W!=C/)B_YYI_WR*/)B_P">:?\ ?(I]%'LJ?\J^X+L9Y,7_ #S3_OD4>3%_
MSS3_ +Y%/HH]E3_E7W!=C/)B_P">:?\ ?(H\F+_GFG_?(I]%'LJ?\J^X+L14
M5!A5 ^@I:**M))60@K);_D;H_P#KQ;_T8M:U9+?\C='_ ->+?^C%I@:U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 9VL_\><7_ %]0?^C%K1K.UG_CSB_Z^H/_ $8M:- !1110
M 4444 9UY_R&=-_[:_\ H-:-9UY_R&=-_P"VO_H-:- !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% &=8?\A+5?^NZ?^BDK1K.L/^0EJO\
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MXUN8(;2QAN;:*2">YVM+<.ZP0X1B#(%^\#C !XR1Z"NC$\1F,(E0R@9*;AN
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K);_D;H_\
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MP,FMKP9:7MOX)-LT4EM<B6Z$*RQ&/8#-(4^7^$8(P/3%=.LT33/"LB&5 &=
MPW*#G!([9P?R-<VGC)#>E)-+NTL_[0.G"[W(5\X/L&5W;@"W&<=Z .5\.:+(
MEO:^8EW#J5M8313Q#27B\QV3#!Y_NRY;Y@03D\U<TKPC9I=>$O-T1 @TJ3[=
MO@X,N(2HER.6R7P&[Y]*ZJ^\3VECXEL=$DBE,MT,F88V1$AMBM[MY;X^E5M5
M\6'3=0OK9-)N[N.PMTN;J6%XQL1MW0,P+<(QXH Y1+6ZAT'1=/N]&S$D%R@E
MGTM[MXSYF$B"C&P,N#N;C"BA],U1_#>G))8W;3KX1N[9U,3%A*5APAX^\<'
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M_P"1CE_Z]$_]#:M&LY?^1CE_Z]$_]#:@#1HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MR6_Y&Z/_ *\6_P#1BUK5DM_R-T?_ %XM_P"C%H UJ*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MSM9_X\XO^OJ#_P!&+6C6=K/_ !YQ?]?4'_HQ:T: "BBB@ HHHH SKS_D,Z;_
M -M?_0:T:SKS_D,Z;_VU_P#0:T: "BBB@ HHHH **** "BBB@ HHHH ****
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ME:P7$F-L<DH#')P..V3P/6LF^\43VE[J$"VT;"UOK*U4DGYA.4!)]QO./I0
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M_P AG3?^VO\ Z#6C63)INHRW$,[:E#OAW;<6O'(P?XJE^S:K_P!!*#_P%_\
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MDT_5_#=]?6WBV.(1;M5CC6WW-CE8PIW<<<BM[[-JO_02@_\  7_[*C[-JO\
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M4 :-%9WV;5?^@E!_X"__ &5'V;5?^@E!_P" O_V5 &C16=]FU7_H)0?^ O\
M]E1]FU7_ *"4'_@+_P#94 :-%9WV;5?^@E!_X"__ &5'V;5?^@E!_P" O_V5
M &C16=]FU7_H)0?^ O\ ]E1]FU7_ *"4'_@+_P#94 :-%9WV;5?^@E!_X"__
M &5'V;5?^@E!_P" O_V5 &C16=]FU7_H)0?^ O\ ]E1]FU7_ *"4'_@+_P#9
M4 :-%9WV;5?^@E!_X"__ &5'V;5?^@E!_P" O_V5 &C16=]FU7_H)0?^ O\
M]E1]FU7_ *"4'_@+_P#94 :-%9WV;5?^@E!_X"__ &5'V;5?^@E!_P" O_V5
M &C16=]FU7_H)0?^ O\ ]E1]FU7_ *"4'_@+_P#94 :-%9WV;5?^@E!_X"__
M &5'V;5?^@E!_P" O_V5 &C16=]FU7_H)0?^ O\ ]E1]FU7_ *"4'_@+_P#9
M4 :-%9WV;5?^@E!_X"__ &5'V;5?^@E!_P" O_V5 &C16=]FU7_H)0?^ O\
M]E1]FU7_ *"4'_@+_P#94 :-%9WV;5?^@E!_X"__ &5'V;5?^@E!_P" O_V5
M &C62W_(W1_]>+?^C%J7[-JO_02@_P# 7_[*DMM.N$U3[=<W:3,(3"%6'9P6
M!SU/I0!I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !117'ZU\2_#N@:O/IE])<BY@QO"0EARH8<_0BDVEN5&+D[)'845P'_
M  N/PE_SVN__  '-'_"X_"7_ #VN_P#P'-+F7<KV-3L=_17 ?\+C\)?\]KO_
M ,!S1_PN/PE_SVN__ <T<R[A[&IV._HK@/\ A<?A+_GM=_\ @.:/^%Q^$O\
MGM=_^ YHYEW#V-3L=_17 ?\ "X_"7_/:[_\  <T?\+C\)?\ /:[_ / <T<R[
MA[&IV._HK@/^%Q^$O^>UW_X#FC_A<?A+_GM=_P#@.:.9=P]C4['?T5P'_"X_
M"7_/:[_\!S1_PN/PE_SVN_\ P'-',NX>QJ=COZ*X#_A<?A+_ )[7?_@.:/\
MA<?A+_GM=_\ @.:.9=P]C4['?T5P'_"X_"7_ #VN_P#P'-'_  N/PE_SVN__
M  '-',NX>QJ=COZ*X#_A<?A+_GM=_P#@.:/^%Q^$O^>UW_X#FCF7</8U.QW]
M%<!_PN/PE_SVN_\ P'-'_"X_"7_/:[_\!S1S+N'L:G8[^BN _P"%Q^$O^>UW
M_P" YH_X7'X2_P">UW_X#FCF7</8U.QW]%<!_P +C\)?\]KO_P !S1_PN/PE
M_P ]KO\ \!S1S+N'L:G8[^BN _X7'X2_Y[7?_@.:/^%Q^$O^>UW_ . YHYEW
M#V-3L=_17 ?\+C\)?\]KO_P'-'_"X_"7_/:[_P# <T<R[A[&IV._HK@/^%Q^
M$O\ GM=_^ YH_P"%Q^$O^>UW_P" YHYEW#V-3L=_17 ?\+C\)?\ /:[_ / <
MT?\ "X_"7_/:[_\  <T<R[A[&IV._HK@/^%Q^$O^>UW_ . YH_X7'X2_Y[7?
M_@.:.9=P]C4['?T5P'_"X_"7_/:[_P# <T?\+C\)?\]KO_P'-',NX>QJ=COZ
M*X#_ (7'X2_Y[7?_ (#FC_A<?A+_ )[7?_@.:.9=P]C4['?T5P'_  N/PE_S
MVN__  '-'_"X_"7_ #VN_P#P'-',NX>QJ=COZ*X#_A<?A+_GM=_^ YH_X7'X
M2_Y[7?\ X#FCF7</8U.QW]%<!_PN/PE_SVN__ <T?\+C\)?\]KO_ ,!S1S+N
M'L:G8[^BN _X7'X2_P">UW_X#FC_ (7'X2_Y[7?_ (#FCF7</8U.QW]%<!_P
MN/PE_P ]KO\ \!S1_P +C\)?\]KO_P !S1S+N'L:G8[^BN _X7'X2_Y[7?\
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MX#_A<?A+_GM=_P#@.:/^%Q^$O^>UW_X#FCF7</8U.QW]%<!_PN/PE_SVN_\
MP'-'_"X_"7_/:[_\!S1S+N'L:G8[^BN _P"%Q^$O^>UW_P" YH_X7'X2_P">
MUW_X#FCF7</8U.QW]%<!_P +C\)?\]KO_P !S1_PN/PE_P ]KO\ \!S1S+N'
ML:G8[^BN _X7'X2_Y[7?_@.:/^%Q^$O^>UW_ . YHYEW#V-3L=_17 ?\+C\)
M?\]KO_P'-'_"X_"7_/:[_P# <T<R[A[&IV._HK@/^%Q^$O\ GM=_^ YH_P"%
MQ^$O^>UW_P" YHYEW#V-3L=_17 ?\+C\)?\ /:[_ / <T?\ "X_"7_/:[_\
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M:^*/AZNM^([O43HXN/.*_O?[4,.["@?<\IL=/4UZ512:N7";@[H\=_X50O\
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M0@,^.PR0,_4T<B#ZQ/\ JYY%_P *H7_H7Q_X.S_\8H_X50O_ $+X_P#!V?\
MXQ7IOAK7K?Q/X=LM:M8I8H+M"Z)+C<!DCG!([5JT<B#ZQ/\ JYX[_P *H7_H
M7Q_X.S_\8H_X50O_ $+X_P#!V?\ XQ7L5%'(@^L3_JYX[_PJA?\ H7Q_X.S_
M /&*/^%4+_T+X_\ !V?_ (Q7H5]XOLK2_O;&"SU"^N+%5:[6TMRPA#+N&22
M21SA<GVJQ%XIT6;PN/$J7R?V28C-]H((^4''3KG/&,9SQ1R(/K$_ZN>:_P#"
MJ%_Z%\?^#L__ !BC_A5"_P#0OC_P=G_XQ7HVG>*;+4-5_LMX+NROF@^T1P7<
M6QI8\XW+R0<'J.H[BMRCD0?6)_U<\=_X50O_ $+X_P#!V?\ XQ1_PJA?^A?'
M_@[/_P 8KOK[QKIUI<:A#%::C>_V;_Q^O:VQ98#MW8).-QVD'"Y-7)/%.CIX
M:C\0?:PVFRHKQ2(I)DW'"JJXR6)(&,9S1R(/K$_ZN>:_\*H7_H7Q_P"#L_\
MQBC_ (50O_0OC_P=G_XQ7I.E^);/4]3N-,,5S::C!&LSVMU'M<QL<!Q@D,N>
M.#P>#BLJ?XBZ+;V3ZBT.H-I,<QADU%;5O)1@VT]?F(#<;@",]Z.1!]8G_5SB
M_P#A5"_]"^/_  =G_P",4?\ "J%_Z%\?^#L__&*]+U3Q'8Z5<65LRSW-W?!S
M;06T1=I H!8Y^Z  1R2!S2:%XEL-?>\AMA/%=6,@BNK:XCV20L1D9'3!'(()
M!HY$'UB?]7/-?^%4+_T+X_\ !V?_ (Q1_P *H7_H7Q_X.S_\8KV*BCD0?6)_
MU<\=_P"%4+_T+X_\'9_^,4?\*H7_ *%\?^#L_P#QBO8J*.1!]8G_ %<\=_X5
M0O\ T+X_\'9_^,4?\*H7_H7Q_P"#L_\ QBO8J*.1!]8G_5SQW_A5"_\ 0OC_
M ,'9_P#C%'_"J%_Z%\?^#L__ !BO8J*.1!]8G_5SQW_A5"_]"^/_  =G_P",
M4?\ "J%_Z%\?^#L__&*]BHHY$'UB?]7/'?\ A5"_]"^/_!V?_C%'_"J%_P"A
M?'_@[/\ \8KV*BCD0?6)_P!7/'?^%4+_ -"^/_!V?_C%'_"J%_Z%\?\ @[/_
M ,8KV*BCD0?6)_U<\=_X50O_ $+X_P#!V?\ XQ1_PJA?^A?'_@[/_P 8KV*B
MCD0?6)_U<\=_X50O_0OC_P '9_\ C%'_  JA?^A?'_@[/_QBO8J*.1!]8G_5
MSQW_ (50O_0OC_P=G_XQ1_PJA?\ H7Q_X.S_ /&*]BHHY$'UB?\ 5SQW_A5"
M_P#0OC_P=G_XQ1_PJA?^A?'_ (.S_P#&*]BHHY$'UB?]7/'?^%4+_P!"^/\
MP=G_ .,4?\*H7_H7Q_X.S_\ &*]BHHY$'UB?]7/'?^%4+_T+X_\ !V?_ (Q1
M_P *H7_H7Q_X.S_\8KV*BCD0?6)_U<\=_P"%4+_T+X_\'9_^,4?\*H7_ *%\
M?^#L_P#QBO8J*.1!]8G_ %<\=_X50O\ T+X_\'9_^,4?\*H7_H7Q_P"#L_\
MQBO8J*.1!]8G_5SQW_A5"_\ 0OC_ ,'9_P#C%'_"J%_Z%\?^#L__ !BO8J*.
M1!]8G_5SQW_A5"_]"^/_  =G_P",4?\ "J%_Z%\?^#L__&*]BHHY$'UB?]7/
M'?\ A5"_]"^/_!V?_C%'_"J%_P"A?'_@[/\ \8KV*BCD0?6)_P!7/'?^%4+_
M -"^/_!V?_C%'_"J%_Z%\?\ @[/_ ,8KV*BCD0?6)_U<\=_X50O_ $+X_P#!
MV?\ XQ1_PJA?^A?'_@[/_P 8KV*BCD0?6)_U<\=_X50O_0OC_P '9_\ C%'_
M  JA?^A?'_@[/_QBO8J*.1!]8G_5SQW_ (50O_0OC_P=G_XQ1_PJA?\ H7Q_
MX.S_ /&*]BHHY$'UB?\ 5SQW_A5"_P#0OC_P=G_XQ1_PJA?^A?'_ (.S_P#&
M*]BHHY$'UB?]7/'?^%4+_P!"^/\ P=G_ .,4?\*H7_H7Q_X.S_\ &*]BHHY$
M'UB?]7/'?^%4+_T+X_\ !V?_ (Q1_P *H7_H7Q_X.S_\8KV*BCD0?6)_U<\=
M_P"%4+_T+X_\'9_^,4?\*H7_ *%\?^#L_P#QBO8J*.1!]8G_ %<\=_X50O\
MT+X_\'9_^,4?\*H7_H7Q_P"#L_\ QBO8J*.1!]8G_5SQW_A5"_\ 0OC_ ,'9
M_P#C%'_"J%_Z%\?^#L__ !BO8J*.1!]8G_5SQW_A5"_]"^/_  =G_P",4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KGO&7AE_%&D006]ZUE?6=U'>V=P%W!)DSMW+W')%=#6/
MK^@_VXMBT>H75A<6-R+F":WVD[MK+A@P(*D.010!S.G^--0M)]7T[Q+I4$&N
MZ7IKWZR6K;H;N!>K(3\R_, "IK)TG4_%=[I7AS6;2/5[F\NYH9K]9!$+5K>0
M98(N[Y=H(*D<G'.<UVEEX4@CU6[U74;J74KZYM?L;/,JJJ09)**J@#!)R<Y)
MJKHO@N31$M[2#Q#JKZ5:L&M[%C& H!R$,@4.R#^Z3TX.1Q0!BZ?!JVM>-/&.
MDMXBU*VL;*6V-N(&7>ADBWD!F!PH)Z?KQ7+ZCJ&H^)?AKH,VIW\_VRW\0PV<
MTL&U!,5GV"0C'4  ^F><=,;VAV]Q?_%#QPUCK,]D9&M5 2)'60+"%9EW \JV
M1D<<\@\5TESX!TJ7P9#X:@EN;:""19H;A'!E697W^821@L6R3QW[4 9/B'4;
M_2->\/\ AFUNM4N8KP3W%S-&R-<LB 816.  2W)'.!QUJ![KQ);^$?&ANVU&
MVALH)+G2;N=D$^T1%]I*DYVNN,GD@UOZAX-.I1Z=/-K=^-8TZ1Y+?4E6(2#>
M,,I0+L*$ <8[=:L3^&9+OPYJ6DW>M7UQ)J$;1374FS<%8;2$0*$48R.!WR<F
M@#BI[KQ%:0>!M0C\1W33:R\5M=1R1HT0$D);<JX^\,=23D]>.*W/#MQJ-GXX
M\2:#<ZG<W]G!:V]U;M=%2\9<,&7( R,J#[5>N/!"W%GX<MCJUTHT*1)(&"1Y
MD*+M7?Q_=R.,=:N6OAA;;Q;J'B#[?.\E] D#P%5V*J9VXXSD9/?O0!Y=HXUG
M1_@3IWB6PURZAN-/@\Z.T"I]G=!*04=<98D9YSUZ8KJ[KQ'?:SXUN=*CCU1+
M"ST^&=DTXJLC2RY(+,2#A0, #J<Y["KUI\-X+?PU;^&9=9O[C0XBI:UD6,&0
M!MVQG"@["W..O;.*T]4\(B[UY=<TW5+O2M1\@6TLENL;K-&#D!D=2,@]#UH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>modificationno15effectiv012.jpg
<TEXT>
begin 644 modificationno15effectiv012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-YXHQ*RB: 84G&<M(.];O_"4ZI_T*&J?^!%K_P#':\N^%/\ R.&H_P#7@O\
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M3_X]1_;^L_\ 0G:I_P"!-I_\>KH:* .4E\4ZVDA5?!FH$#UO+8'_ -&&F?\
M"6:[_P!"7?\ _@;;?_%UMS_Z]_K4=7RHR<V9'_"6:[_T)=__ .!MM_\ %T?\
M)9KO_0EW_P#X&VW_ ,76O11RH7M&9'_"6:[_ -"7?_\ @;;?_%T?\)9KO_0E
MW_\ X&VW_P 76O11RH/:,RX_%.N/(JGP7J'/I>VQ_P#:E6O[?UG_ *$[5/\
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M/VMM;>AHDN6YR%%%%=)F%%%% '9_"G_D<-1_Z\%_]&&O8:\>^%/_ ".&H_\
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MP6P5 /8'\JT,4<%9^([G7+U7U+Q0VD:';AA:W8V6SZH02#)N<;0HX^5>IYP
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MHHH S)_]>_UJ"9G2"1XD\R15)5,XW'' S4\_^O?ZU7GF2WMY9Y,[(T+M@9.
M,UJCG>YYP$T76?\ 2=0^(^HP7G_+6W@U%+(0MW7RL!EQT^;)]371>$[Q'GN;
M*SUZ37;&%01=2%7:-\_<,B@*_'/J._45BV*WOB6"#7]9\&:'=6%R@EA7 ENT
MB(RK'<NUN,' (/U/%;^BZJDGB2\TBS2V&FPV4%S;^3'LV[VD5E(''!CZ8!!)
M!I#9TE%%%,DEM_\ CX3ZUI5FV_\ Q\)]:TJB6YK3V.9\8VWA%K:TO?%RZ?\
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M *]Y_J/QJA5^\_U'XU0K2.QC/<Q_$CVBZ=&+BRGO93,IMH+;B4RC+ JV1M(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4VG21P7MQ T?F@9292" 'QU'/!ZCMQD&SX?LYM.\-Z797  FM[2*&0 Y 94
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MG<W5O9PF:ZGB@B!P7E<*H_$U@7,GA*YG:X&I:?!<M]ZXMKQ89&^K*P+?0Y%
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M^CD^U1^(;3Q%=268T'5+:P4,PN6GM?/R,?*0-R]QCKW]JRCHGCO!QXRT_/\
MV!1_\=J30ZRV$8M81%%Y4>P;(]NW8,<#';'I4M5M.CGATRTBNGWW*0HLK9SN
M<*,G\\U9H KWG^H_&J%7[S_4?C5"M([&,]SFO&-I;W,&ES7$D*"RODN@MP"(
MGVAAAFP0O#9!/&0*TY[&#4/+U"TD2*\"_NKJ/#9']UL??0^F?<8."&>(/$%G
MX<TY;R[6:7S)5AA@MTWR32-T15[DX/Y5DV#Z7JTDA@L+[1M4*F3R9%-K(_\
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MS4M:U&]>U7;8;RB?9#_?&U1N?@<MGW!K5TC2;FQN)9]0U>;4KMUV(TD:1B-
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MUM:1IFI6UQ)=:MJB7UP5\N/RK?R4C3.3A=S$DG&23V& .Z&[&O1113));?\
MX^$^M:59MO\ \?"?6M*HEN:T]CC?&FESZQK6@V=U<7D.@NTQO/LLC1[Y<+Y2
MNR\A#\_<#.!W%,\0:/=Z3X.U>SLFN]2L9+*9%MIG,TT+%#M*,?F<9Q\I)(Z@
M\;:V?$&K:QIDEFFDZ"=5,[,KXNEA\K R,E@<YY_*LH^(O&@!(\!@GT_MB'_X
MFI-#?\/LS>&M*9R2QLX22>I.P5I56TZ::XTRTFN8_+GDA1Y$Q]UBH)'YU9H
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M-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBDQH]%H) &3P**;(JO$Z.,HP(8>HIDF'9>,-'U#3+O4[:65[&TE,<LYB8*
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M^5#V''<T:***R.@**** "JU[_J5_WJLU6O?]2O\ O4UN3+8HT445H8!1110
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M51@#\A0-V)JFM?\ CX3\?Y5#4UK_ ,?"?C_*A[!'<T:1V5$9V.%49)/84M!
M(((R#U!K(Z#E;'QF;S0-1UI]'N[:ULB9-DY"R20! _FA>W!R%)!X_"NFMYXK
MJVBN('#PRH'1A_$I&0?RKSD>'++7T%A<^(=:L+&[5#)HUPJ0NZA1^[$A3<Z@
M  X8\=37H\,,=O!'#"@2*-0B*O10!@ 4 /JM>_ZE?]ZK-5KW_4K_ +U-;DRV
M*-%%%:&!S^G>)9-5GU-;;2KA8[0*89)F""Z&YU)0=AE#@G&<CH.:U-*U.VUG
M2K74K)R]M<QB2,D8.#ZCUKCKO28-1N9X/[?U?18;HF%[1D1!(NYN(I&3.#N8
MX#$@'H!Q7::=I]MI6FVVGV<8BMK>,1QH#G"@8% V6:GM/]>/H:@J>T_UX^AI
M/8([FA11169T!6!#XE>Z\4W.C6^F3F.")R;V1@L3RKL)C7J3@.,MC P1S6_7
M#ZY9"76;F5=8U?P^ Q1KA(HVMY0RIN<.RMY9X"Y)7E<C)R: .GT76;?6[.2>
M!61H9Y+::-NL<L;%67C@\CKW&*T:R?#>AZ?X=T.'3]-9Y( 3(9I)-[S,QRSL
MW<DG.:UJ "BBB@#,G_U[_6HZDG_U[_6HZU1SO<Q-9\0_V5J%A916%Q=RW4BA
MVCP$@C+JF]R?=A@#DX/I5JWU>*;6KK274QW<$:3@9R'B8D!@?JI!';WZUF>)
MX([B6!3/J%E(%W"]M(1*J[65@KJ588R <XXP>0"<KX8T"ST^2ZU5-4FU>]OM
MHEOI75LJN<*H4!549/ H#H='1110(D@_UZ?6M.LR#_7I]:TZB1K3V G R:Y>
MP\:)J&D:CJJ:5>Q6EF/-7S@%>>#;N\U%ST(!(!P3745YI)H":O'_ &?=>(=7
MT>QO(TBDTN>&.-G0#B%9MOS#!Q@$MC@U)H>C6MS#>VD-U;R"2">-9(W'1E89
M!_(U+45M;0V=K#:V\8C@A18XT'15 P!^0J6@"O>?ZC\:H5?O/]1^-4*TCL8S
MW"L&Q\1R:CJE_9VVF3B.V#"*XF8(EPR-M<+U. >,GK6]7#:AIT=[?S*NOZMH
M22R2Q&/RT5),O\QCE93@L1NP&SSP!3)1U>D:K;:WI5OJ-H6\B=20&&"I!((/
MN""/PJ]5+2-*M-#TFVTRPC\NUMTV1J3D_4GN2<D_6KM B:U_X^%_'^5:-9UK
M_P ?"_C_ "K1J);FU/8P[CQ*D/BJUT*.PNIFE&9KI5 A@)1F523U8A#P.F15
MO2]8@U.6^MU4QW5C-Y%S$QSM8J&!![@JP(/OR 017/\ B2VDDU?SH+_4=':+
M:_VV*U2>!VVLOS @[2JL?F.%P1DG QI>$M L=#TZ9[2_EU&6^E-S<7\L@=KA
MR ,Y'&    .!4EF_7':C_P E.M?^P-+_ .CDKL:X[4?^2G6O_8&E_P#1R4UN
M3+8VJR?$&MG0[!)H[&XOKB63RX;:#&YVP6/)X  4DD^E:U9'B)$DLH59;T,9
M<)/9)OD@.QOGVX.1C*XP?O=*T,4.7781J.G6<T9C;486DMFW9#%5#,I]" <C
ML<'I6K7(>'?#EE_:D>L2Z[<ZS=VL1MX/.V*MJI ! C4#:Q  )/-=?0#"L6P_
MY*?+_P!@9?\ T<:VJQ;#_DI\O_8&7_T<:4MBH;G8T445F;!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %>>?&;_ )$F#_L(0?S->AUYY\9O^1)@_P"PA!_,U=/X
MUZBELSQ>BBBOI3S@JQ8BU:^@6^:1;4N!*T6-RKW(S5>M/P_=SV6MV\UM81W\
MPRJ6TD9<.2"/NCKUS4RV8UN=OJ6G_#^33]-#ZY<($B*J\2EW89_C&T[3Z# K
MEO%,V@&2R@\/[VBA@V33LFPRMGJ1@<_A7702>)-'TBQ0>#K&[$B,W_'F[R)S
MT?C@\\>U<YXX34#+IMQJ&G65@TUN66&VC*$#/\8(X:N2C\:5[[]4:SVV.3HH
MHKM,0HHHH [/X4_\CAJ/_7@O_HPUZ%HHL!K^MG9"NJF<>=P!(8MB^6?4KC\,
M[N]>>_"G_D<-1_Z\%_\ 1AKT3Q#X.T3Q1Y3:G:%IX1B*XB<QR(/0,I!Q['BO
M#Q/\61TQV#7;^"VU/1K>-U_M">["Q1@_,8\$R$C^Z%!/ID+WQ6[7/>'?!.A>
M&)I+C3K5OM4HVO<SR-)(1Z;F/ ]ABNAK ;.+\0VNKZ5=ZGJ6DZ+!J4E^L8>5
M[G:\2H  @1E(*YRW!ZL>.,U+)K7B^0QI+X0AAB>5%DE&I)+L0L S;=@S@9.*
MFUFPU/Q+J,^GV^L7.E:=:A5F>SPL\TC#=@.?N*%*].22?3FG;^'M0\(%;ZT\
M1ZIJ-DKJ+FUU.4390D LC8!5AG..AQCWI#.UIDQ"PR,4W@*3M SNXZ4^JFIS
M7MO82RZ?:)=W*C*P/-Y6_P!@V#S]>/<4R3SN;Q#XI71Y9(-2\*VEL+(SP&(2
M-A0#E4;>%+)\O;'S#BO2;.7S[*WF\Q9/,C5MZKM#9&<@=J\\E@\0:GX?CM)_
MA[IC2,HF#S74.U9R.93&8^#GDC\*]$MBQM8B_EER@W>7]W..WM213):Y>+Q7
MIE@UU::KXIT0WIFD\H"54\M"?D5@6ZCOTS6MKD5G)ISG4[Q;;3D^:X+2>6KK
MZ,V1A?4=^G3(.?;V'@Y=%-];6>B?V8J%C/'%%Y6T=3N Q3$BUX=BU6/386U/
M5(=2ED3<TT2*J[L_P;0 5QCKSQU.>-BL'PS;Z8UA#J6B0BTL;M2XMXUVQL,_
M*X3HI(YX SGG. :WJ 9@:6+ >*=:+)"NJ%X\D@"1H/+7:1W*[M_X@T[Q%?PV
MD^E1*Z_VA/>Q);H#\Q0L/-./[HCWD]NG?%.\0^$=%\4)$-4M/,DASY4\;F.2
M/Z,I!Q[=*K^'O N@>&;E[JPM7:\==K7-Q*TLFWT!8\#Z8H#0Z.N8U?6K#PSX
MA:_U<FWL[NWC@CO"A9$=&<E&('RYW@@G@X/H*Z>HKH0&UE^U*C0!29!(,KM'
M7(]* 1QVJ^-/#^NV<NB:1>QZGJ%ZABBBM@7"$_\ +1FZ*%^]DGMQS7;5F6J:
M)I=C->6<=A:6JKOEEA1(U  SEB,=O6KMK=V][ )[:598SQN4]_3V- ,FHK/U
M.^NK9%BL+/[7>2 [$9]B*!_$[8.!] 2>PZXY_P CXB&7S?MWAL#_ )X?9YBO
MTW;L_CC\* L=A6LOW1]*YG3+R\G4PZE:+:WB#++')YD;C^\C8!(]B 1^()Z9
M?NCZ5,BZ9D^)1J/]BR-IFH6^GSJRLUU<*&CBC!!<D$@'Y<]Q7+>$;/PKJ>M?
MVG%XG/B37+=2//DN@?*4]=D2X55/L#]:Z?Q1IS:EHQA%DM^J2I*]D[!1<*K
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M%%% !1110 4444 %%%% !1110 4444 %>>?&;_D28/\ L(0?S->AUYY\9O\
MD28/^PA!_,U=/XUZBELSQ>BBBOI3S@I\,TEO-'-"[)+&P9'4X*D<@BF44 >K
MVEQX@O=!T^\U+QC::2)4)B5\;Y5S]YLD9/TKB_&*.-1@:3Q#'K;-'_K4.1'R
M?EZG'K^-;-EJ?A.^\/:=9ZO::M<7-FC)YD"C"@G.T'/(^HKGO$D>C)<0'1;:
M^@@9#N^V#!9L]O:N.C&U3:V_16^_<VF[Q,2BBBNPQ"BBB@#L_A3_ ,CAJ/\
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MVC4R1KT5L<@?0TD5(YGQX;<6FDB\TB[U>U^W@RV=K#YK28BD(RI(!4-M//'
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M-,[M);@B/:?NA0>0 ..?2MF@ HHHH S)_P#7O]:KW$Z6UM+/)NV1(7;:I8X
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MV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\\^,W_(DP?]A"#^9KT.O//C-_R)
M,'_80@_F:NG\:]12V9XO1117TIYP4444 >O^'=8FM=$T*RTRYM8HKNUGA&<;
MENQD@MGMG'US]*YCXDF]:[TDZI+&=0^QXGBC(*H=QYX]?Z54TNX\#)IT U*U
MU5KT+^]:%EVDY[?-4/C.PTRTN+"XTA+G[+=VXF$D[;BYR1]>,8-<-."C6O;O
MT_4VE*\#F****[C$**** .S^%/\ R.&H_P#7@O\ Z,->@^,[*>^\./%;:<FH
MSK/!(EM)($5RLBGYL@@KQD@]L]*\^^%/_(X:C_UX+_Z,->D>*;8WF@S0F.YE
M@+(;B*V)$DD08;U7'/(Z@<D9 Y->'B?XLCHCLCG=-FU&[U*U_P"*/T:VACG7
MS;FUOHYGA]]JH#[=>A-=W7F^BOX9DUVSB\(:#<6UQ%(/M-TMG);QQQ#[RR%@
M-Y/0#!YY[5Z16"*9GZY!<76B7D%JTJS/&0/)?:Y'<*QZ,1D ]B17&7.M?:5T
MC1?#>F:R+VVGA4W%U;2QK;PJP\P2._WLJ",<YX/4"NRUTW2Z'>&S:5)_+X:%
M \BCN44]6 R0.YQ7G$\)M[O3O,UGQ=>/<7=O-9P2A@LT>]=V_P#=C85^8D$C
M@#UI,:/6*;)N$3E!E]IVC.,FG4V3?Y;^7C?@[=W3/;-,D\W:[U74;V-GOM4L
M[+3+;?>7_P#9ZI<7-R>D2*8^57!S@'.0,GK7H5C)+-I]M+<*$F>)6D4=F(&1
M^=>8MXCAT;0-4T]]9U6^\23,'MH'#&<7)C7Y50#"QA\\?=QGKGGU"S,[64#7
M2JMP8U,JKT#XY _'-)%,S]>L[ZXM8KC2Y88]0M7\V'SP?+DX(*/CD @]1T(!
MYQBN:7Q#X_NF%LG@ZSL6; ^VW&IK)"N?XMJC<?I6WXF@T^YN-&BU6&&2S-Y_
MRV4%?,V-L!SQR?S.!WK:N!;I9R"X$2VRH=_F8"!<<YSQC%,1#I=B=.TV&U:9
MII$!,DK#!D<DLS8[98DX]ZN5D>&+QK_P[:719F20,8G?.7BW$1L<]24VG/O6
MO0(PO&-E-?\ A>Z@M[!;^;=$Z6SOM61ED5@&)!R.,D=P".,YKG[&;4[J^MT_
MX0W18(X[B/S9[:_CE>###G:J Y_&NG\36[W>@7,"+<.K%/-2W;$CQ;P9%4CG
M)7<..>>.:XK2F\+MK-E;^$?#]S;WT<R>?<K926ZPQ C>)&<#=E<@+SR0>V:3
M*6QZ767?G48$U*X%W:);+:$P"2(_NY &)9SGE?N\8'0UJ5B^*]-TW4_#=]'J
MD<K6T<+R%H21(N 3E<=_;OTIB1AW5MXWM]/:2YU[1(X]H#@6#KC/&-Q<@=<9
M(P*[:O.9/"_ABPT2VUK4M"OK>$,C7$%SJ$LA@!8 %EWE6 ."1Z=CTKT:A S
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MPB&_M(KA%.Y?,7)1NQ4]5/N.:MTUW6.-G8X502?I61T'.2:'JFF7,E]H]_\
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M>I6YM[VUAN(2<[)4##/KSW]ZPW\/7VGW7VW1=19I%B,2VNH,TT>"0<!\[UY
MY)8#L*Z0G S7'6/BW5)_#VJZQ>:9!:1VL0O((7GRTEN4+#>PX5R >.0*DT.I
ML#<G3K8W@ NC$GG = ^!NZ>^:L56T^]BU+3;6_@W>3<PI-'N&#M8 C/X&K-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<6=IH,]Q>W$UND95HY8$WR+)N&S8N#N); Q@YS@\5YM\*?\ D<-1_P"O!?\
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M110(*Q;#_DI\O_8&7_T<:VJQ;#_DI\O_ &!E_P#1QI2V+AN=C11169L%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5YY\9O^1)@_P"PA!_,UZ'7GGQF_P"1)@_[
M"$'\S5T_C7J*6S/%Z***^E/."BBB@ HHHH **** "BBB@#L_A3_R.&H_]>"_
M^C#7>220Q-KM])HUK+':2DGRU4RS$1(Q8[L '!QC/;K7!_"G_D<-1_Z\%_\
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M HHHH FM?^/A?Q_E6C6=:_\ 'POX_P JT:B6YM3V"BBBI+"N.U'_ )*=:_\
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M?S-73^->HI;,\7HHHKZ4\X**U_#VB?V[?RPM<I;000/<33.,A$7KQ]2*Z!O
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MR,'_ (1V\_Z&C6O_ "7_ /C5'_".WG_0T:U_Y+__ !JMZBL"KF#_ ,([>?\
M0T:U_P"2_P#\:H_X1V\_Z&C6O_)?_P"-5O44!<P?^$=O/^AHUK_R7_\ C5'_
M  CMY_T-&M?^2_\ \:K>HH"Y@_\ ".WG_0T:U_Y+_P#QJC_A';S_ *&C6O\
MR7_^-5O44!<P?^$=O/\ H:-:_P#)?_XU1_PCMY_T-&M?^2__ ,:K>HH"Y@_\
M([>?]#1K7_DO_P#&J/\ A';S_H:-:_\ )?\ ^-5O44!<P?\ A';S_H:-:_\
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M_A';S_H:-:_\E_\ XU6]16AA<P?^$=O/^AHUK_R7_P#C5'_".WG_ $-&M?\
MDO\ _&JWJ* N8/\ PCMY_P!#1K7_ )+_ /QJI;?PY>&=1_PE6MCKR/L_I_UQ
MK9J:U_X^$_'^5)[#3U,__A&KW_H;==_\EO\ XS1_PC5[_P!#;KO_ )+?_&:Z
M&BLS<Y[_ (1J]_Z&W7?_ "6_^,T?\(U>_P#0VZ[_ .2W_P 9KH:* .>_X1J]
M_P"AMUW_ ,EO_C-07?AR]6$?\57K9R<?-]F_3]S7456O?]2O^]36Y,MCD_\
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M "6_^,T?\(U>_P#0VZ[_ .2W_P 9KH:* ..G\.WOGOGQ3K1Y_P"G?_XS4?\
MPCMY_P!#1K7_ )+_ /QJNBG_ ->_UJ.M4<[>I@_\([>?]#1K7_DO_P#&J/\
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MVY/H..V!7C3$,Y(& 3D#TKGPK3O9?GY]_P"M32H)111769'9_"G_ )'#4?\
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M $<:4MBX;G8T445F;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUK+]T?2ID:4Q:***@U"H;O\ X]V^HJ:H;O\ X]V^HIK<4MC.HHHK0YPHHHH
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M;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKM.6!SU'7-<=23]K:_;K8VBERGF5;?@^PM-3\6:=9WV/LTDAW*3C=@$A?Q(
M_&L2M/P]I4VMZ]::=!,(9)7XE_N8!8GZX!KIJ? ];&4=T>I)I;:G=:6-0\,0
M6MJ\5W#<HL6Q;905V/GU^7@^Y(KQM@ Y"G(!X/K7J%Y+I=S:-8W7Q'NI8<;7
M7R6(;V)'4?B:\NKGPJ>M_P!?/N:5 HHHKK,CL_A3_P CAJ/_ %X+_P"C#7L-
M>/?"G_D<-1_Z\%_]&&O8:\/$_P 61T1V04445@,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *UE^Z/I636LOW1]*F1I3%HHHJ#4*AN_\
MCW;ZBIJAN_\ CW;ZBFMQ2V,ZBBBM#G"BBB@ J:U_X^$_'^50U-:_\?"?C_*A
M[#CN:-%%%9'0%%%% !5:]_U*_P"]5FJU[_J5_P!ZFMR9;%&BBBM# **** "I
M[3_7CZ&H*GM/]>/H:3V''<T****S.@**** "BBB@ HHHH S)_P#7O]:CJ2?_
M %[_ %J.M4<[W"BBB@04444 20?Z]/K6G69!_KT^M:=1(UI[!1114F@4444
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M/]>/H:@J>T_UX^AI/8<=S0HHHK,Z HHHH **** "BBB@#,G_ ->_UJ.I)_\
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MAKQ[X4_\CAJ/_7@O_HPU[#7AXG^+(Z([(****P&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %:R_='TK)K67[H^E3(TIBT445!J%0W?\
MQ[M]14U0W?\ Q[M]136XI;&=1116ASA1110 5-:_\?"?C_*H:FM?^/A/Q_E0
M]AQW-&BBBLCH"BBB@ JM>_ZE?]ZK-5KW_4K_ +U-;DRV*-%%%:& 4444 %3V
MG^O'T-05/:?Z\?0TGL..YH4445F= 4444 %%%% !1110!F3_ .O?ZU'4D_\
MKW^M1UJCG>X4444""BBB@"2#_7I]:TZS(/\ 7I]:TZB1K3V"BBBI- HHHH K
MWG^H_&J%7[S_ %'XU0K2.QC/<****9 4444 36O_ !\+^/\ *M&LZU_X^%_'
M^5:-1+<VI[!1114EA7':C_R4ZU_[ TO_ *.2NQKCM1_Y*=:_]@:7_P!')36Y
M,MC:HHHK0P"BBB@ K%L/^2GR_P#8&7_T<:VJQ;#_ )*?+_V!E_\ 1QI2V+AN
M=C11169L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5YY\9O^1)@_["$'\S7H=>
M>?&;_D28/^PA!_,U=/XUZBELSQ>BBBOI3SCI_ ]A;WVJWAGLQ>M;V,L\-L?^
M6L@P ,=^IKM;O2+&TT*;07TN _9='-W<WNP;X[CJHW>Y!X]/:N"\(:?-?ZV7
MBU!]/2TA>YFNH\[HXUZD8^N*Z;4]&CNUU4:?KU]*9].BU+;<G)NE4OG<<#&!
MMP/?\N*MK4W[=S:'P['G57;?6-2M(HHK>^N(HX7,D:I(0$8@@L/0X)'XU2KN
MO .IVD]]9:%-H6F7+32L6N;B(,X&"Q'(]!Q735ERQO:YG%7=KG/?\);XB_Z#
MFH?^!#?XUC5ZSHNL6>L^(9-*_P"$(T^VX<+(]JI\H@$C>-HXR,?C7D[#:Q4X
MR#CBHI23;7+8<EUO<2BBBMR#L_A3_P CAJ/_ %X+_P"C#7L->/?"G_D<-1_Z
M\%_]&&O8:\/$_P 61T1V04445@,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *UE^Z/I636LOW1]*F1I3%HHHJ#4*AN_\ CW;ZBIJAN_\
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M&O'OA3_R.&H_]>"_^C#7L->'B?XLCHCL@HHHK 84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5K+]T?2LFM9?NCZ5,C2F+1114&H5#=_\
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MS@GKQ@GTKS"NBT6?0;1+"XGNM2@OEN&\][9MNV+:V"AZ[LX_#-=.(BY0LO\
M,S@[,[Q].\>AV"^+=-VY.-TPSCW_ '=>0UW;6WP^)D9GUXE.9"57Y?KQQ7"5
M.'5KZ?A8=3^M0HHHKI,SL_A3_P CAJ/_ %X+_P"C#7L->/?"G_D<-1_Z\%_]
M&&O8:\/$_P 61T1V04445@,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_)3Y?\ L#+_ .CC6U6+8?\ )3Y?^P,O_HXTI;%PW.QHHHK,V"BBB@ HHHH
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MAKQ[X4_\CAJ/_7@O_HPU[#7AXG^+(Z([(****P&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %:R_='TK)K67[H^E3(TIBT445!J%0W?\
MQ[M]14U0W?\ Q[M]136XI;&=1116ASA1110 5-:_\?"?C_*H:FM?^/A/Q_E0
M]AQW-&BBBLCH"BBB@ JM>_ZE?]ZK-5KW_4K_ +U-;DRV*-%%%:& 4444 %3V
MG^O'T-05/:?Z\?0TGL..YH4445F= 4444 %%%% !1110!F3_ .O?ZU'4D_\
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M!;R74@>1Y))B"Q#+NS\W!RXXH&=E4UK_ ,?"?C_*N5/@#PL1_P @>+_OM_\
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M$$!AK5T<'UYDJ2SJ:X[4?^2G6O\ V!I?_1R5U5C!):Z?;6\LQFDBB5&E;JY
M +'Z]:X[7[1+_P ?"SE)$=QH,\3$=<-*@/\ .FMR9;'0T5QL'A;P!/=&UBTG
M2&E &T!5._()X]>A_*K5Q\._"DL#I%HEG;R$?)-%$ R'L0?4&M#'0ZBBBB@0
M5BV'_)3Y?^P,O_HXUM5BV'_)3Y?^P,O_ *.-*6Q<-SL:***S-@HHHH ****
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MVS/][9Z#VKD22Q))R3R3245,:<8MN*W!R;W"BBBK$=G\*?\ D<-1_P"O!?\
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M_&C_ (0OPW_T"+;\C_C0&AO45@_\(7X;_P"@1;?D?\:/^$+\-_\ 0(MOR/\
MC0&AO45@_P#"%^&_^@1;?D?\:/\ A"_#?_0(MOR/^- :&]16#_PA?AO_ *!%
MM^1_QH_X0OPW_P! BV_(_P"- :&]6LOW1]*XO_A"_#?_ $"+;\C_ (UIKX&\
M,;1_Q);;IZ'_ !J9&E,FU9?$R:BLNC?V9);-$%>.]DD0JX)Y7:IZ@\Y]!53S
M?'?_ #Z>'/\ P*G_ /C=3?\ "#>&/^@+;?D?\:/^$&\,?] 6V_(_XU!H6-%C
M\0_:[N?7&L%1TC2"&R=V52"Y9B64<G<H_P" UIW?_'NWU%8G_"#>&/\ H"VW
MY'_&HKGP1X:2!BFD0*>F5R/PZTUN*6Q?HK!_X0OPW_T"+;\C_C1_PA?AO_H$
M6WY'_&M##0WJYE/^$UA4QB/0IE4D+))/,K,N>,@)C.,9JQ_PA?AO_H$6WY'_
M !H_X0OPW_T"+;\C_C0&A"9/&V.+7P__ .!$W_Q%;^AQ74%G8Q7TJS7B0JL\
MB]'<+\Q'L3FL;_A"_#?_ $"+;\C_ (U+;^"?#33J#H]L1]#Z?6D]AK<["L[6
M1JWV)6T86K7:RJVRZ=DC=/X@656(XZ<=:S_^$&\,?] 6V_(_XT?\(-X8_P"@
M+;?D?\:S-R#[3XZ_Z!'AW_P9S?\ QBI+5O&4^J67VZUT:UL4D9K@VUY)+(Z[
M& 4!HE'WBISGM3_^$&\,?] 6V_(_XT?\(-X8_P"@+;?D?\: .AJM>_ZE?]ZL
M?_A!O#'_ $!;;\C_ (U!=^"?#:0C9I,"@G!"D@,/0\\__6IK<F6QHUFZRFL-
M%;OHS6GG)-ND2Z9E1TVL,94$YR5/X53_ .$+\-_] BV_(_XT?\(7X;_Z!%M^
M1_QK0QT(?,\;?\^OA_\ \"9O_B*FL4\42:I!)J?]EPV4:OO2TED9G8@8SN4#
M YH_X0OPW_T"+;\C_C1_PA?AO_H$6WY'_&@-#>J>T_UX^AKFO^$+\-_] BV_
M(_XU/:^"?#33@'1[8\'L?\:3V''<ZZBN>_X0;PQ_T!;;\C_C1_P@WAC_ * M
MM^1_QK,W+VMQZP]O;OHCVHN(Y@SI=,RQR)M8%25!/4@CZ5E^;X[_ .?3PY_X
M%3__ !NIO^$&\,?] 6V_(_XT?\(-X8_Z MM^1_QH ;9)XNFU6U?4AI$%C$6:
M5;2:5WD^4A1\R@8R<_@*Z.N>_P"$&\,?] 6V_(_XT?\ "#>&/^@+;?D?\: .
MAHKGO^$&\,?] 6V_(_XT?\(-X8_Z MM^1_QH 9K\>JNBMH[VPN4F#%;EF".N
M"""5!/?/X5D>9XV_Y]?#_P#X$S?_ !%6I_!?ASSWSI,!YP-V3@>G)Z5'_P (
M7X;_ .@1;?D?\:T,':XVU3Q7-J=HU^-)ALHW9IA:RR,\@V, OS*!C<0?PKH*
MP?\ A"_#?_0(MOR/^-'_  A?AO\ Z!%M^1_QIBT-ZBL'_A"_#?\ T"+;\C_C
M1_PA?AO_ *!%M^1_QH#0Z*#_ %Z?6M.N.A\%>&VF0'1[;&?0_P"-:'_"#>&/
M^@+;?D?\:B1K3V-'64U1]/\ ^).]LMXLB,HN2PC90PW E03R,]JR/-\=_P#/
MIX<_\"I__C=3?\(-X8_Z MM^1_QH_P"$&\,?] 6V_(_XU)8EF/&$NI6AU!-&
MALD=FF^RS2O(XV,  &0#[Q4]>U=%7/?\(-X8_P"@+;?D?\:/^$&\,?\ 0%MO
MR/\ C0!LWG^H_&O+M5\*^*+[Q!'?I)I<D$$\KI')<SJ)D9CA94"[3A3M&/3G
M(XKLKKP3X;2'Y-)@7)P=I(R/0\\BJ/\ PA?AO_H$6WY'_&KCL93=F0^9XU P
M+7P__P"!$W_Q%:^DQ7\.F0IJ<L4E[\QE:(DIDL3@9YP 0/PK._X0OPW_ - B
MV_(_XT?\(7X;_P"@1;?D?\:HC0WJ*P?^$+\-_P#0(MOR/^-'_"%^&_\ H$6W
MY'_&@-#I+7_CX7\?Y5HUQ]MX)\--.H.CVQ'/8_XU?_X0;PQ_T!;;\C_C42W-
M8;%6&;Q[%!'')I_AZ=U4!I3J$RER.^! <9]*<]SX\,;!-*\.JQ!PQU*8X/T\
MBK'_  @WAC_H"VWY'_&C_A!O#'_0%MOR/^-26;5DEQ'86Z7<BR7*Q*)G7HSX
M&XC@=\]JXWQ!'<3>/?*M)1%<OH,ZQ2'HKF5-I_ XK8_X0;PQ_P! 6V_(_P"-
M<EJ7@WP\?B';6G]EQ+ =*DD**64%A*@SP?0FFMR9;&D)/&^!FV\/D]_](F_^
M(IDZ^-[B!X530H"XV^;'/,60=R 4Z^E2?\(#X7_Z!2?]_7_^*H_X0'PO_P!
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MVSO9+/P]IMIXC\+MJ-NJLUE*C$.JYY5@.1SZX^E8WC:?4+NYT^YNK!+"T>V
MLK9#G9&#W]_P':N.GS>TOZ]K?(VE;E.6HHHKL,0HHHH [/X4_P#(X:C_ ->"
M_P#HPU[#7CWPI_Y'#4?^O!?_ $8:]AKP\3_%D=$=D%%%%8#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "M9?NCZ5DUK+]T?2ID:4Q:***
M@U"H;O\ X]V^HJ:H;O\ X]V^HIK<4MC.HHHK0YPHHHH *FM?^/A/Q_E4-36O
M_'PGX_RH>PX[FC11161T!1110 56O?\ 4K_O59JM>_ZE?]ZFMR9;%&BBBM#
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MU*_[U-;DRV*-%%%:& 4444 %3VG^O'T-05/:?Z\?0TGL..YH4445F= 4444
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M#2>PX[FA11169T!1110 4444 %%%% &9/_KW^M1U)/\ Z]_K4=:HYWN%%%%
M@HHHH D@_P!>GUK3K,@_UZ?6M.HD:T]@HHHJ30**** *]Y_J/QJA5^\_U'XU
M0K2.QC/<****9 4444 36O\ Q\+^/\JT:SK7_CX7\?Y5HU$MS:GL%%%%26%<
M=J/_ "4ZU_[ TO\ Z.2NQKCM1_Y*=:_]@:7_ -')36Y,MC:HHHK0P"BBB@ K
M%L/^2GR_]@9?_1QK:K%L/^2GR_\ 8&7_ -'&E+8N&YV-%%%9FP4444 %%%%
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MBBB@ HHHH **** "M9?NCZ5DUK+]T?2ID:4Q:***@U"H;O\ X]V^HJ:H;O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KSSXS?\B3!_P!A"#^9KT.O//C-_P B3!_V$(/YFKI_&O44MF>+T445
M]*><%%%% !1110 4444 %%%% '9_"G_D<-1_Z\%_]&&O8:\>^%/_ ".&H_\
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M7':C_P E.M?^P-+_ .CDKL:X[4?^2G6O_8&E_P#1R4UN3+8VJ***T, HHHH
M*Q;#_DI\O_8&7_T<:VJQ;#_DI\O_ &!E_P#1QI2V+AN=C11169L%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/>BXLO&:6TKP:[I$LRH2D9TEU#-C@9^T<9/>F1:/KJ^-9-1?4[@Z2Z"/[/\
MNMV5RP)(3.S+,N,[NA)(.!U- #(3(8(S* )"HW@= <<T^BB@ HHHH Y[6[F_
MM\?V=9Q75Q),$VRRF-%&"2S,%8CIZ=2*R_M7BS_H$:-_X,Y?_C%;U[/%;&::
M>5(HDY9Y&"JH]R>E9^F:WIVL"3[!=PSF)F5U1PQ7#%<G!X!P<>HK4YV4X+_Q
M"NHVD-]I%BMM.[(\UK>O*8L(S E3$HP2N,YZD5N444""BBB@"2#_ %Z?6JES
M;>*)]1NFM=4TVTLPZBW26P:9V78N26$R_P 188QT JW!_KT^M1:SXGTO09[6
M+4+A86N9!&FX$9R#TXYY&,#GD5$C6GL5OL'B[_H8=)_\$[__ "16AHPU9;.1
M-9>WDN5F8+);QF-73/RG:68@X[9J_'(LL22+N"N PW*5.#Z@\CZ&G5)H%%%%
M %>\_P!1^-<D;[Q-++,;?1]-$"RND9N+^1'958@,5$) SC(Y/!%=;>?ZC\:Y
MV]\0Z3IU[':7>H6T4SY^5Y5!7C(R,Y&>WK5QV,9[E3[5XL_Z!&C?^#.7_P",
M5I:7<W5YIL4][:?9+EMPDAW%@I!(X) R.,@X'!JYU&:*HD****!$UK_Q\+^/
M\JT:SK7_ (^%_'^5:-1+<VI['*0/X\F@CE;_ (1Z$NH8QNDQ9,]C\W44Z0>/
M5C9E?PXS $A?+G&3Z?>K1_X2G1O[:_L@:A ;W!_<JX+@YQMVCG/.>G3GI6Q4
MED%C+-/I]M+<Q>5.\2M)'_<8@$C\#7*ZC_R4ZU_[ TO_ *.2NQKCM1_Y*=:_
M]@:7_P!')36Y,MC2OY;B#3KJ:TB$URD3M%&>CN 2!QZG%8>[QM_SQ\/_ /?V
M;_XFNDK(L_$VC7^IR:?:ZA;372''EQRJY/&2< ]!T/H:T,30L_M1M(OMHA%S
MM_>"$DIGVSSBIZ**!!6+8?\ )3Y?^P,O_HXUM5BV'_)3Y?\ L#+_ .CC2EL7
M#<[&BBBLS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSSXS?\B3!_V$(/YFO0
MZ\\^,W_(DP?]A"#^9JZ?QKU%+9GB]%%%?2GG!1110 4444 %%%% !1110!V?
MPI_Y'#4?^O!?_1AKV&O'OA3_ ,CAJ/\ UX+_ .C#7L->'B?XLCHCL@HHHK 8
M4444 %%%!Z<'% &;9:'96&I7.H0*XN;K)N'+9\TYRN[_ '1P/0'%:5<SHR^)
M/^$AO6U*6/\ LUCFVV0[6?;\IW98[<\$ =>O'2NFH&PHHHH$%%%% !1110 4
M444 %%%% !1110 5K+]T?2LFM9?NCZ5,C2F5=0TVTU6V%M?0K/;[P[1/RCD<
M@,.A&<'!XR!4MK;1V=I%;0[A%$H1 S%B .@R>36+XPAUZXT5H?#TT:7LV80)
M4R@##!8L""NT9((SS@8-:>D&\;2K=[]V:[=0TH9 FUCU4 $\#IU/U-0:EVH;
MO_CW;ZBIJAN_^/=OJ*:W%+8SJ:Z"2-D)8!@1E3@CZ'M3JANA(;27R9&CD"DJ
MRH&(/T/7Z5H<Y#IVE6.DQ-%86ZP1MC*)T)  SCUP!D]3CFKE<]X4CUZ.VG&O
MNGG^8SHL2@)M<E^N2<@DKC.!@=>IZ&@;"IK7_CX3\?Y5#4UK_P ?"?C_ "H>
MP1W-&LW5="L=9>W>\1F>V;S+=@V#%)D$.O\ M#'7TR.A.=*N6\4CQ/\ ;K!]
M"DA\B.3S;E9("Q"8*G:=X#'#%@I'5,YZ Y'0=3138U9(U5G+L  6( +'UXIU
M !5:]_U*_P"]5FJU[_J5_P!ZFMR9;&-J&F6>JP+!?0+/ &WF)^48X.-PZ'&<
M\]P#U J>&)8((X4+%8U"@NQ8X QR3R3[UA^+8M?ET^-/#TL0NFD *S)E,#YM
MQ8$%<;<<9R2!CN-?3_/_ +/@-R[O,R!G+H$()YQ@<#'3J>G4]:T,2S1110(*
MGM/]>/H:@J>T_P!>/H:3V''<T***1B50D#) SBLSH,1/%>F2>(WT,-.;Q8U?
M8+>3."Q!)^7A1@?,>#D<UN5PUKXL\,M<1ZI)IVKPZC(NZ1CI-VSH2H!3<(^5
M&!Q]W(SUYJ[<?$+1XK:62&VUB:54)2,:1=#>0.!DQX&: .LHID+F6".1D*,R
MABI[9'2GT %%%% &5=J7>9 [(6R-RXR/<9XK+T;0['0;>2WT]&C@D?S#&6R
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M@38?^ R?X4?V!HW_ $";#_P&3_"@!/[?T;_H+V'_ ($I_C1_;^C?]!>P_P#
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M *"MC_X$)_C1_;FD?]!6Q_\  A/\:/[#TG_H%V7_ (#I_A1_8>D_] NR_P#
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M&(EGK%A#:11W6N6%Q.JX>42(@<^NW)Q4_P#;FD?]!6Q_\"$_QJ'_ (1G0/\
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M+:,#]*6[_P"/=OJ*:W%+8SJ1CM4GK@9I:*T.<YVWUK7[BWBF7PSM$B!PKWR
MC(SR,=:+C6O$%O;RS-X9W"-"Y5+Y"3@9X&.M1"_\0CQB;0VL']E.@476&(#C
M+%=O8E3][.W(]>*Z>@8R&3SH(Y-I7>H;!ZC(JS:_\?"?C_*H:FM?^/A/Q_E0
M]@6YHUCZSK%[IUQ:V]CHUQJ<LZNY6&6./8J[1DEV Y+C@5L5E^(;V]T_19[G
M3[9;FY482$L5+D\ *0IYR1U&/4@<UD=!F?\ "0^(_P#H2+[_ ,#K7_XY5K2=
M>OKW5&L-0T&ZTQ_),T;2S12*X# $#8QP1D=?6I_#=YJ-_HD%QJL$5O=L,20H
M2?+8<,"2!DY!Z#'ID<G6H *K7O\ J5_WJLU6O?\ 4K_O4UN3+8HU0U6XU*".
MW&EVD%Q-)+L;SY6C1%VL=Q*JQZ@#IWJ_534GNH].GDLBHN$0L@,1DW$=MH9<
MYZ=16A@9GG^+/^@=HO\ X'R__&:DM+SQ -2@@U#3;%+:56S-:W+R%& R 0T:
M\'GG-1^$TUU-*VZ^\?VQ#Y92)"% '0AB27R".>.F,<'.]0,*GM/]>/H:@J>T
M_P!>/H:3V".YH4445F=!4U/4K?2;![VZ\WRD*J1%$TCDLP50%4$DDD#@5D_\
M)EI__0/U[_P2W?\ \;K<N /(8F SE?G6,8RQ'(QD@9R!C)%<_P"%?%;>)7O@
M-.N;=+:=X_,F* -@\8"L2>_S#Y3C@F@":'QAIDMW;VS6^JP/<2"*-KG2[B)"
MQZ#<R #IW-;],DBCE"B1%<*P8;AG!'0_6GT %%%% &9/_KW^M1U)/_KW^M1U
MJCG>XWS$_OK^='F)_?7\ZX>U\/\ PZCN(]*%AHDUS&JIETC9G;)7![E\CD=>
M:U9OA]X1F@DB_P"$=TU-ZE=R6R@C(Z@XX- :'2T5';PBWMHH5)*QH$!/4X&*
MDH$20?Z]/K6G69!_KT^M:=1(UI[&)>^*M/L;^:S:WU.:6$@2&UTV>=5) 8#<
MB$9P0<9[U#_PF6G_ /0/U[_P2W?_ ,;IGBCQ*/"ZVTBZ;//]JN$1GA\OGLV=
MSJ<A1G<?E ') KH87>2%'DB,3L 2C$$J?0D<?E4FA3TG6+36K:2>T\\+%*8I
M$G@>%U< $@JX!'!';O5^F)%'&SLB*K2-N<@8W' &3ZG  _ 4^@"O>?ZC\:H5
M?O/]1^-4*TCL8SW"BN9\1:/X9GO1J&O16\TAA6*-9FZ*K$DJ,^KC/T%-@\$>
M#;J$36^D6$T39P\?S*<'!Y!]:9)U%%9.C>'=.T"6Z.FP"WBN"K-$OW00",CZ
M_P!*UJ!$UK_Q\+^/\JM7MY!IUC<7MT_EV]O&TLK[2=JJ,DX')X':JMK_ ,?"
M_C_*KL\:3021R1B1'4JR'^(>E1+<VI['-_\ "P?#W_/74?\ P577_P ;I5^(
M/APR(AN+U-[JBM)IMRB[F( R3& .2.M.T+Q?%KFN:CI<=A=12V+JLOF!1Y>5
MS\WS')W!A\N1Q70SP17,+131K)&V,JPX.#FI+)*X[4?^2G6O_8&E_P#1R5V-
M<=J/_)3K7_L#2_\ HY*:W)EL;5%%%:& 45C^&;34+'1O)U.1I+G[3</N:3>=
MC2NR#/\ NE>.W2MB@ K%L/\ DI\O_8&7_P!'&MJL6P_Y*?+_ -@9?_1QI2V+
MAN=C11169L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YY\9O^1)@_["$'\S7H
M=>>?&;_D28/^PA!_,U=/XUZBELSQ>K>ERQP:O9S32R0Q1SHSR1??0!ADK[BJ
ME6=.>UCU.U>]0O:+,AF0=63(W#\LU])+9GGK<].\YM3(_L7XC.';A8;W]VQ/
MIGC]!7+^,].\56$5N/$%X;J N?)<2[UW8YXX(X]J[>'5=&G@2/P=J&B:=<$8
MVW5J4D)]F/7\C7#^-;+Q9;/"_B*X:>)F(B99 4SWPHQC\A7GT&_:):+U6OY(
MWG\/]6.1J2"XGM91+;S212#HT;%3^8J.BO1.<[B/XH:S'=F3:K0_9A#Y#MN7
M<!C?DC.?:N7UC5Y=:O%NIK>U@D"!"+:+RPV"3DCUYZ^PK/HK.-&$'>**<F]P
MHHHK0D[/X4_\CAJ/_7@O_HPU[#7CWPI_Y'#4?^O!?_1AKV&O#Q/\61T1V044
M45@,**** "FNB21M'(JLC AE89!![$4ZJFHHDUF]LS /."D8\QH\O@D#<O(Z
M9R.>* )XO);=)#L.XX9EQR1QS],8_"I*P?"_AQO#MI-!)>2WKO(7^T3.S.<\
ML#DD ;BQ&.QYR<D[4D\43Q)(X5IGV1@_Q-M+8'X*3^% $E%%% !1110 4444
M %%%% !1110 4444 %:R_='TK)K67[H^E3(TID%W96M]&B7<"31HVX)(,KG!
M'(Z'KWJ2W@CM;:*WA7;%$H1%R3@ 8 YK \7Z;JVK:<MKHFI&SO-ZDL0C(HSN
M#.I4L>4P-I')] :V-+CN(M,MUNVE:Y* RF5U9MYY(RH Z^@ ]J@U+=0W?_'N
MWU%2AE+%0P+#J,\BHKO_ (]V^HIK<4MC.HHI&.U23V&:T.<H?VYI@OC9F^MQ
M/\N%,JC<22NT<\G(/%:%<3;:EX)N-9A\3)KVFQ7\L0!+W<2MY94?NV&>QY]<
M\9QQ6S/XU\,6]O),WB#2V$:EBJ7D98X&< ;N30.QNU-:_P#'PGX_RJM#*LT,
M<JY"NH89ZX(S5FU_X^$_'^5#V!;FC45Q<PVL1DGD5%YQDXS@9P/4X!J6N?\
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M'?-%QV-ZI[3_ %X^AJ"I[3_7CZ&D]@CN:%%%%9G0'6H8$M@";=8AL B/E@#
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M<T*Q\16 L=1C\RU+AWCZ;L=!GJ.<'C'3TR*O6T'V:UA@WE_+0)N8 %L#&3@
M?D*Q_%4NMQ:6/["C2:\9PJQLI&><YWY 48!Z]>G4UJ:>\\MA!)<E3,Z!FVQ-
M&!GG&UB2".G)ID]"S1110(FM?^/A?Q_E6C6=:_\ 'POX_P JO2ND<3O*X2-5
M)9B< #N<]JB6YM3V(8+6RBF+6\$"RQ[E)10"N\AV''3)PQ]>#5FN6T'PO>:5
MX@OM1N-2N+B&Y8M' ]S*P@Q\J]3^\RN,EN5(XSGCII98X(S)+(L:#JS' %26
M/KCM1_Y*=:_]@:7_ -')78UQVH_\E.M?^P-+_P"CDIK<F6QM4445H8!1110
M5BV'_)3Y?^P,O_HXUM5BV'_)3Y?^P,O_ *.-*6Q<-SL:***S-@HHHH ****
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M]7Z** *]Y_J/QJA5^\_U'XU0K2.QC/<Q-3M?$+:D9](U#3XK=H51H;RV>7#
ML=R[77&0P!Z_=%5O(\;?]!+P_P#^"^;_ ./5TE%,FYDZ-::Q!+=3:Q?6UQ)*
M5$:6L31QQ@ ]F9N23US6M110(FM?^/A?Q_E5F_LH-2T^YL;D,T%S$T4@5BI*
ML,'!'(X/456M?^/A?Q_E6C42W-J>QR__  @FG?\ 02\0?^#JZ_\ BZ/^$"TI
MF0RWFM3*CJ_ES:M<.A*D$94O@C('!KJ**DL*X[4?^2G6O_8&E_\ 1R5V-<=J
M/_)3K7_L#2_^CDIK<F6QM4445H8!1110 5BV'_)3Y?\ L#+_ .CC6U6+8?\
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M/]J>(O\ H6X__!@G_P 31_:GB+_H6X__  8)_P#$UO45@48/]J>(O^A;C_\
M!@G_ ,31_:GB+_H6X_\ P8)_\36]10!@_P!J>(O^A;C_ /!@G_Q-']J>(O\
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M31_:GB+_ *%N/_P8)_\ $UO44 8UMJOB,3KCPS&3SQ_:"?\ Q-7_ .UO$O\
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M7_L#+_Z.-*6Q4-SL:***S-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI?\ T<E-;DRV-JBBBM# **** "L6P_Y*?+_V!E_]'&MJL6P_Y*?+_P!@9?\
MT<:4MBX;G8T445F;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>>?&;_D28/\
ML(0?S->AUYY\9O\ D28/^PA!_,U=/XUZBELSQ>BBE52[A5&68X KZ4\X[+0K
M71=(\*_\)!J^GMJ4DUR;>"#?M1<#))/KU]:A\46&DSZ'I_B'2+5[**YD>&6U
M9MP5E[J?3K6YH&G>+?#^AN#HL5_9SSX?3KB(LRD#[^.@!P!WK.\;KKMSI5A?
M:I:P:?:K(T,%A$A3R^,EB/?%<497JW3Z]_PL;->[L</1117:8A1110 4444
M=G\*?^1PU'_KP7_T8:]AKQ[X4_\ (X:C_P!>"_\ HPU[#7AXG^+(Z([(****
MP&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:R_='TK)K
M67[H^E3(TIBT445!J%0W?_'NWU%35#=_\>[?44UN*6QG4445H<X4444 %36O
M_'PGX_RJ&IK7_CX3\?Y4/8<=S1HHHK(Z HHHH *K7O\ J5_WJLU6O?\ 4K_O
M4UN3+8HT445H8!1110 5/:?Z\?0U!4]I_KQ]#2>PX[FA11169T!1110 4444
M %%%% &9/_KW^M1U)/\ Z]_K4=:HYWN%%%% @HHHH EM_P#CX3ZUI5FV_P#Q
M\)]:TJB6YK3V"BJVH:A::58RWM]<);VT0R\CG ';\\\ =ZY(?%+0/-PUIK:0
M9_X^6TJ<1X]<[<X_"I-#MJ*@L[RVU"SBN[.>.>WF4/')&V58'N#4] %>\_U'
MXU0J_>?ZC\:H5I'8QGN%%%%,@**165QE6##)&0>X.#2T 36O_'POX_RK1K.M
M?^/A?Q_E6C42W-J>P45@V?C3PUJ&L2:3::W9RWZ,4,*R<EAU /1B/09K1CU6
MSEUB?25D(O88EG:,J1^[8D!@>A&01^%267:X[4?^2G6O_8&E_P#1R5V-<=J/
M_)3K7_L#2_\ HY*:W)EL;5%%0->VZ)<N\JHEKGSF8X"84,<GZ$&M# GHKF](
M\<Z+K5TD-J;Q%E.()Y[22.*8_P"P[#!]AU-=)0 5BV'_ "4^7_L#+_Z.-;58
MMA_R4^7_ + R_P#HXTI;%PW.QHHHK,V"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\\^,W_(DP?]A"#^9KT.O//C-_R),'_80@_F:NG\:]12V9XO1117TIYQZ#
MH]QXLU3P_9"+7I(4GOA;P*7/FM\OS'=G.U1VJEXYTJ[M8[>Y?7YM8MUE>W+2
MDYAE7[RX)/\ D5H^ -2U$V!MK/P^=1ELY'EMI_-$:PLZX()/!X_&L/Q'?79T
M#2[&73GM8V:2YDG8Y^TRDX9A_GO]*XHIJM96_#_AS9VY#EJW?"MC;ZAJ,T5S
MI=YJ$:PEO+M&Q(G(^8>O7&/>L*I;>ZN+.42VT\L,@XWQN5/YBNN:;C9&2=F>
MM2^$/"_]LR0[);9_[-,GD30ML7Y?]86'\0[BO,-8TV+2[Q88=0M;Z-D#B6V;
M(&21@^AXZ>XKJD^*6KI=&3RU> VPA\AVW OC&\DC)/M7*ZQJSZS>+=26EI;.
M$"%;6+RU;DG<1Z\_I7-0A5B_?V-)N+6AGT445UF1V?PI_P"1PU'_ *\%_P#1
MAKV&O'OA3_R.&H_]>"_^C#7L->'B?XLCHCL@HHHK 84444 %5[^]BTW3[B^N
M _DV\;2R;%+':!DX Y/%6*0@,I5@"",$'O0!R8^(FD,H*V.N$'D$:3/S_P".
MUK:'XAMM?%RUM;W4*0,$/VJ!H6)(S]U@#CWK6 "@ # '  H"J&+ #<>IQR:!
MZ"T444""BBB@ HHHH **** "BBB@ HHHH *UE^Z/I636LOW1]*F1I3.5USQ#
MKB^)X?#_ (>TZSN+D6HO+F>^F:.*.,L551M!)8E6[<8J+7?%E]I7ANYNI+..
MTU6U,;-:S-YD<J&148HXQN'S=>"#C(&1GI)=,M9=3AU+84NXHS$)$;!9"<E6
M'0C///0],9-1:YH6G^(=-:PU&'S(20P(.&1AT93V/_ZNE0:FC4-W_P >[?45
M-4-W_P >[?44UN*6QG5C^)-<DT*PAEM[%[Z[N;A+:WMU<)O=LGECPH !.?:M
MBH+NS@OHA'<)N57613D@JP.001R"*T.<Y<^(/%-YK(TZQ\/V]LT$"37<E]<G
M9EBP"QL@.[[IYQ]0*Z33KT:A9+/Y?EON>.2/=NV.C%6&>^&4\U;P,YQS533=
M-MM)LA:6BL(O,>3YV+$L[EV))Y.2QH&6ZFM?^/A/Q_E4-36O_'PGX_RH>P1W
M-&LCQ)JFI:/I1O-,T=M5E5P'MTF\M@G.6'!W8XX SZ>E:]%9'0>:ZAXY\7C^
MQ9;7PM:K#>WJPJRZK'*)P4<[ 0OR_=SG_9QWKT#3I[NYT^&:^LQ9W3#,EN)1
M*$.>FX  UG7OA;3KW5;/4<S0RVUR+K9"^U)9 K*&=<$$X8\C!/&2<"MN@ JM
M>_ZE?]ZK-5KW_4K_ +U-;DRV*-8NN:U+I.H:) D2/'J%Y]FD9B1L'ELP(]\J
M!^-;51SV\-U \%Q#'-$XPT<BAE8>X-:&!R>E>(]=\137%[I%A8C18I6BADN9
M7$EV5.&9< A5R" 3GI746%[%J-A!>0Y\N9 X!ZCV/N.E,LM,L]-TU=/LH%M[
M1 RI'&2 H))./3DFETW3K;2=-M]/LX_+MK=!'&I)) 'N>30-EJI[3_7CZ&H*
MGM/]>/H:3V".YH4445F=!5U*\_L_3+J\V>88(FD";MN[ SC/;ZUQ6J^,?$6C
MWMMH,ECIEWXAU$YL5MY6$*)SN:8-\P"@=1][D#!%=Y+%'/$\4J*\;J5=&&0P
M/!!'I6!;>!?#5I#>11:5'B\ $[.[N[ <J S$LH!P1@C! Q0!;T6YU,O/8ZP]
MG+>PHDAELT9$97W ?*Q)!!1NYSP>.@UZSM&T+3M MG@TZ!HUD;?(TDK2N[8Q
MEG<ECP,<FM&@ HHHH S)_P#7O]:CJ2?_ %[_ %J.M4<[W.1NY_&&J33RZ+/I
M-A90RR11_:HWEDE*,58G! 49!QU..?:IO"OB/4=2@M8]9LX()[F 3VUQ:N6@
MN%(!(&>58 \J>W() .)-7\#:+K5R\UR+R,2G,\5O=R11S?[Z*0"??J:W([&V
MBBM8HH52.UQY"*,! %*@ ?[I(H"Z+%%%% B6W_X^$^M:59MO_P ?"?6M*HEN
M:T]C-UO3[F_LXS9310WMO*)X&FCWQ[P",,H()!!/0Y'!'2N;&H?$DR^0="\/
MKSC[3]OD*?7;LW?A71Z]:ZK=Z68M&U%;"\,B8G:%90%W#=\K<'Y<X]P*PO\
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M^O!?_1AKV&O#Q/\ %D=$=D%%%%8#"BBB@ HHHH **** "BBB@ HHHH ****
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M  @?A7_H!VG_ 'R?\:/^$#\*_P#0#M/^^3_C1S![,MUK+]T?2N>_X0/PK_T
M[3_OD_XT?\()X7_Z EK^1_QJ6[EQC8Z*BN>_X03PO_T!+7\C_C1_P@GA?_H"
M6OY'_&D4=#4-W_Q[M]16)_P@GA?_ * EK^1_QI1X&\,+G;HUL,C!P#R/SH0F
MKHLT54_X0/PK_P! .T_[Y/\ C1_P@?A7_H!VG_?)_P :OF,_9ENBJG_"!^%?
M^@':?]\G_&C_ (0/PK_T [3_ +Y/^-','LRW4UK_ ,?"?C_*L[_A _"O_0#M
M/^^3_C1_P@?A;_H!VG_?)_QI<PU"S.BHKGO^$$\+_P#0$M?R/^-'_"">%_\
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M=%5/^$#\*_\ 0#M/^^3_ (T?\('X5_Z =I_WR?\ &CF%[,MT54_X0/PK_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O//C-_P B3!_V$(/YFO0Z\\^,W_(DP?\
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MFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&O;J^?Q?\:1W4O@04445SF@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MYEKPT"PO$\-^&_#EAJWB)ER5DB4QVP/_ "UN'QQZXZG\17IM>/:3KWPHTB!T
M.L/!>R,6O&$UU&[RY.XMM."<DT =IX+\$VGA*.266X%UJ]V"T\^ BXR,K&@X
M1 <<#VSVQUM<)X4UWP9K'B<+X<U.>\NX[.4R!IYY%5"\?_/0X!SCI[UW= $<
M]O#=0/!<0QS0N,-'(H96'N#UI888K>%(8(DBB085$4*JCT '2GT4 8^L:;'-
M<)J,VK7-A!;0.)#%*(UP2"68D$<;?U-<+ISZYXRU>.3P_K.K67AJ!SYFI3LI
M>](_AA4KPO\ MG\!Q6]XXT"R\37VGZ?JNN26.GHCSO:I(BBY<,FW=O!#*O/&
M/XA4[P10V311>.9X(TCVKM^Q!4 '& (N@H ZQ5VH%R3@8R3DFEJOI_\ R#;7
MY]_[E/G_ +W YJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %<=J/_ "4ZU_[ TO\ Z.2NQKCM1_Y*=:_]
M@:7_ -')36Y,MCF=9OK(Z@WASPIHUA?:P/\ CXGDA4PV0/5I6QRW7Y>I/7WV
M?"O@_3/"@=E<7.K7>6N+R10'E/&0H'"J.,*..E<I::SX"LXY(I?#MQ)<"5_/
MD.DO*7DW'<=X4[N<X]JV?#>K>%K_ ,311Z-H\UG=BVE8RM8FW!3<F1R!NYV_
ME5F3.YHHHIDA6+8?\E/E_P"P,O\ Z.-;58MA_P E/E_[ R_^CC2EL7#<[&BB
MBLS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KSSXS?\B3!_V$(/YFO0Z\\^,W
M_(DP?]A"#^9JZ?QKU%+9GB]%%%?2GG!1110 4444 %%%% !1110!WOP;_P"1
MSU3_ +!Z?^C#7MU>(_!O_D<]4_[!Z?\ HPU[=7S^+_C2.ZE\""BBBN<T"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MORDV;NN,#&?>K%5M.1HM,M(W4JZPHK ]B%%6: "BBB@ HHHH **** "BBB@
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M^.X[73+B.Y^RV,OVZ2%@RH6=/*1B.-W$A [#/K73UGZ-H6E>'K$66D6$%G;
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MU^L'L('B_P /])\2>%O$=[>WWA74WBFM%B40R6Y.0^><R@?K7H__  DFH?\
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M?]"AKO\ WU:?_'Z/^$DU#_H4-=_[ZM/_ (_70T4 <]_PDFH?]"AKO_?5I_\
M'Z/^$DU#_H4-=_[ZM/\ X_70T4 <]_PDFH?]"AKO_?5I_P#'Z/\ A)-0_P"A
M0UW_ +ZM/_C]=#10!SW_  DFH?\ 0H:[_P!]6G_Q^C_A)+__ *%#7?\ OJU_
M^/UT-% '/?\ "2:A_P!"AKO_ 'U:?_'Z/^$DU#_H4-=_[ZM/_C]=#10!SW_"
M2:A_T*&N_P#?5I_\?H_X234/^A0UW_OJT_\ C]=#10!SW_"2:A_T*&N_]]6G
M_P ?H_X234/^A0UW_OJT_P#C]=#10!SW_"2:A_T*&N_]]6G_ ,?H_P"$DU#_
M *%#7?\ OJT_^/UT-% '/?\ "2:A_P!"AKO_ 'U:_P#Q^C_A)-0_Z%#7?^^K
M3_X_70T4 <]_PDFH?]"AKO\ WU:?_'Z/^$DU#_H4-=_[ZM/_ (_70T4 <]_P
MDFH?]"AKO_?5I_\ 'Z/^$DU#_H4-=_[ZM/\ X_70T4 <]_PDFH?]"AKO_?5I
M_P#'Z/\ A)-0_P"A0UW_ +ZM/_C]=#10!SW_  DFH?\ 0H:[_P!]6G_Q^C_A
M)-0_Z%#7?^^K3_X_70T4 <]_PDFH?]"AKO\ WU:?_'Z/^$DU#_H4-=_[ZM/_
M (_70T4 <]_PDFH?]"AKO_?5K_\ 'Z/^$DU#_H4-=_[ZM/\ X_70T4 <]_PD
MFH?]"AKO_?5I_P#'Z/\ A)-0_P"A0UW_ +ZM/_C]=#10!SW_  DFH?\ 0H:[
M_P!]6G_Q^C_A)-0_Z%#7?^^K3_X_70T4 <]_PDFH?]"AKO\ WU:__'Z/^$DU
M#_H4-=_[ZM/_ (_70T4 <]_PDFH?]"AKO_?5I_\ 'Z/^$DU#_H4-=_[ZM/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>modificationno16effectiv001.jpg
<TEXT>
begin 644 modificationno16effectiv001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M%_,_C#L5;/.,@'!.*UO&>@37^K:C=V^F^>[>&[VWCE6,%C,Q4*H/7)!;'U-
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MKGC\:KZOK=KH\<+3DL9;B& (A&5\V01JQ!/W<GK[&O--!T62V^SRW&D:O/\
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M>5) Z$<\@U-IFE2:8UI<:YX<N]1M6L)K>.%+7SS#(;B1F!3^'>K)\W3Y>2*
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MUR.*OHBQHJ( JJ, #L*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K)_X1C1/[8_M;^S+?[?O\SSMO._&-V.F['&[K6M10 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 QY8
MXSAY%4GU.*;]I@_Y[1_]]"N?\1>!]$\5744^K03R/"I1/+N'C&#[*1S6-_PI
MOP;_ ,^E[_X'S?\ Q5 '<_:8/^>T?_?0J*-;"*YFN(_(6:?;YL@(!?:,#)[X
M%<7_ ,*;\&_\^E[_ .!\W_Q5'_"F_!O_ #Z7O_@?-_\ %4 =S]I@_P">T?\
MWT*/M,'_ #VC_P"^A7#?\*;\&_\ /I>_^!\W_P 51_PIOP;_ ,^E[_X'S?\
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M_P#@?-_\51_PIOP;_P ^E[_X'S?_ !5 '<_:8/\ GM'_ -]"C[3!_P ]H_\
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M:^"?#\-F;[4/!NKVMF;26Z21=6DD90B;]L@#?(2!QR1GB@#V;[3!_P ]H_\
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M\.^'-.\+Z>]AI<4D5NTADVR3-(<D =6)/8<5KT %%%% !1110 4444 %%%%
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M9(X9"2P9 .6^9NGK5N'PCXK\*>*8;WP[9V&HVL6C0:;F[N#$28^K8 /7'ZT
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MR7"A-B"4EB/E'/R@9(!XZ5K>'-(;0="@TYIA,8WD;>%VYW2,_3_@6*U:* .
MT3P1KOAX6QTW5M/5TT]+*1I[1Y/NRRR!E =?^>F,'TK8D\'1_P#"%VV@07KI
M-:M'-#>/&&(G202!RO0@N.1Z$BNGHH X^Y\+:WK$,[ZQK<(N0\$MDMI;D0V\
MD3[UD*LQ+$G /(XX]ZK:CX-UG61<7FH:I8_VD1;I;>3;,L,:13I,=P+EF+%
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M_P!]'_"C_A.O"_\ T&K;_OH_X4 =%17._P#"=>%_^@U;?]]'_"C_ (3KPO\
M]!JV_P"^C_A0!T5%<[_PG7A?_H-6W_?1_P */^$Z\+_]!JV_[Z/^% '145SO
M_"=>%_\ H-6W_?1_PH_X3KPO_P!!JV_[Z/\ A0!T5%<[_P )UX7_ .@U;?\
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MG7A?_H-6W_?1_P * .BHKG?^$Z\+_P#0:MO^^C_A1_PG7A?_ *#5M_WT?\*
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MW_?1_P * .BHKG?^$Z\+_P#0:MO^^C_A1_PG7A?_ *#5M_WT?\* .BHKG?\
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MZ/\ A0!T5%<[_P )UX7_ .@U;?\ ?1_PH_X3KPO_ -!JV_[Z/^% '145SO\
MPG7A?_H-6W_?1_PH_P"$Z\+_ /0:MO\ OH_X4 =%17._\)UX7_Z#5M_WT?\
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M5%<[_P )UX7_ .@U;?\ ?1_PI#X]\*APAURT#'H"_)_2@#HZ*YW_ (3KPO\
M]!JV_P"^C_A1_P )UX7_ .@U;?\ ?1_PH Z*N8^'G_(A:3_US;_T-JD/CKPO
MU_MJUXY^\?\ "L+P5XLT'3/"&G65[JMM%<1(P="V<?,3V^M 'H%%<[_PG7A?
M_H-6W_?1_P */^$Z\+_]!JV_[Z/^% $FBM?1:YJEG>:C+>B.."1"\:($+;\A
M0H''RCKD^];U>?6'B:RM]=N+^Y\5:-)%<*B21QVLB-A-V,,9#@_-SP>E;_\
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MB'3=1T_6-+MH+25I7BVR%G9@P.#O"K][/W3S0!Z917._\)UX7_Z#5M_WT?\
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M% $?DI_<7\J/)3^XOY5)10 U$"+@  >@Z4ZBB@ HHHH **** "BBB@ HHHH
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M$<\B@#KZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQG#N&"E]LB8&T[03P6&1C/2J?A]DL;'4;D6NJ7=_L$]S<7%L8GNWPV$C5L8
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MY_Z*%=/7,:Y_R/7A3_M\_P#10H Z>BBB@ HHHH **** "BBB@ HHHH ****
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M*[\'?]"WIW_?@4?\*[\'?]"WIW_?@4 =%Y\/_/5/^^A1Y\/_ #U3_OH5SO\
MPKOP=_T+>G?]^!1_PKOP=_T+>G?]^!0!T7GP_P#/5/\ OH4>?#_SU3_OH5SO
M_"N_!W_0MZ=_WX%'_"N_!W_0MZ=_WX% '1>?#_SU3_OH4>?#_P ]4_[Z%<[_
M ,*[\'?]"WIW_?@4?\*[\'?]"WIW_?@4 =%Y\/\ SU3_ +Z%'GP_\]4_[Z%<
M[_PKOP=_T+>G?]^!1_PKOP=_T+>G?]^!0!T7GP_\]4_[Z%'GP_\ /5/^^A7.
M_P#"N_!W_0MZ=_WX%9FN^%/!&A:=]JD\+64\CRI!!!% NZ:5V"JHS@#)/4\
M9- ':^?#_P ]4_[Z%'GP_P#/5/\ OH5YK+I7A2SM+DZC\/XK:\CFB@@MQ%&X
MNGEX01O]T\@[LXVXR>U07%GX0L3-;7W@&WAU))+=$M L3><)I/+1E?.,;@0<
MXQ^- 'J/GP_\]4_[Z%'GP_\ /5/^^A7E]Q:^#;-I+6Z\ 1PZDLL$:V;1PDR"
M9BJ.KAMN-RL#D@C%=!IG@?PS>PN]WX)L[!U; 258G+#URA(H L:K-%_PL;P^
M?,3'V2Z_B'^Q4MQ9:ZTM_%%K6FRV5X[%5N;<LUNA4 JN' 8=\$#DGK7.:AX'
M\,1>.]$M$T*P6WFM[EI(_*&&*[,?EFMC_A$/A[]N^P_V7H?VO./(PGF9QG&W
M.>E !J7A"RGFLKFV_LNXFMK-+(KJELMPKQKRI!R"K EN1P<\CH07'A"TN='M
MK9SHJW%K=&ZB1-/06V2I4JT6[D;3USG(![8IU]X-^'^EPK-J&D:+:1,VT/<*
MD:D^F3CFF-X3^':V,=\VF:$+20X2<^7Y;'G@-G!Z'\J -'P]I$>D2SRNFB0-
M*JKLTZS$ &,_>;<2W7VQ6ZT\>T[98]V.,L,9KD$\)_#J2T>[33=":VC(5YE\
MLHI]"V<#J*DL_!G@#4 YLM(T6Y"8W>2J/M^N.E #$T/5I="N=%N=3TH6ETT_
MG21PL7"RNSL%R^ 1O(!.<8!P:T=7L]4OM2LY[34M,BALY_/C26%G8DQ/&02'
M Q\Y/3L*C_X5WX._Z%O3O^_ K/E\,?#:"=H)K#P_'*IVM&YC# ^A!- &M>6-
MZ;V#4['4+&/4%M_L\XEB+12KG<, ,"I!SCD\,0<\$5SH#O9M(^K0G5C?"_\
MM(B'EB4((POE[L[/+&W&[/4YS5:\\'_#[3RGVW2M$MMX)3S@B;L>F>M.N?!G
M@"RA2:ZT?18(GX1Y510W?@GK0!K60U<22RWVJ:>Q\HK%#! 50-_?8EBQ],#'
M?KQC*T3P[/X>DLUT_4K&.V\O%_#Y)Q<29YD7Y_D;J"><]\X&$B\%^ ;BT>[A
MT?1I+9 2TR*A1<=<L.!BF6GA'X>:A(T=EI>AW+J,E81&Y ]< T ==Y\/_/5/
M^^A6'KEIJ&H7%HUEJ&G0PV\JSA9HF=BXSW#CC!]*S8/"'P]N;IK6#2]#EN%S
MNBC",XQUR <\5<_X5WX._P"A;T[_ +\"@"WJE@VI6MC(M];0ZE92BXAF\O=&
M)-C(V4+9VE788W9&1SD54.@F>SG>XU2)=4ENTO1<P)M2*545%"H6)*[5P03S
MN;D9&#_A7?@[_H6]._[\"C_A7?@[_H6]._[\"@"[8#51>>=J>JV+1*A58+2'
M8&)(^9BS,>,< 8ZG.>,:OGP_\]4_[Z%<[_PKOP=_T+>G?]^!1_PKOP=_T+>G
M?]^!0!T7GP_\]4_[Z%'GP_\ /5/^^A7._P#"N_!W_0MZ=_WX%'_"N_!W_0MZ
M=_WX% '1>?#_ ,]4_P"^A1Y\/_/5/^^A7._\*[\'?]"WIW_?@4?\*[\'?]"W
MIW_?@4 =%Y\/_/5/^^A1Y\/_ #U3_OH5SO\ PKOP=_T+>G?]^!1_PKOP=_T+
M>G?]^!0!!YT7_"U=WF)@:+UW#_GL*ZGSX?\ GJG_ 'T*\X'@?PQ_PLK[&=!L
M?LW]D^;Y7DC;N\W&<?2M+6_!WAC2K,7%MX&M-0 ),BQ"&/RU R6)D91C\: .
MU\^'_GJG_?0H\^'_ )ZI_P!]"N+T#PEX-U_0;/55\(VEJEU'YBQ3P+O"D\$X
MR.1@CV(JH=%\ #Q@/#G_  B]G]H,6_S_ +.OE;\;O*SUW[/GQCI0!W_GP_\
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MM[7PG=66D7$7PY0MJXWV<9%N"Z>7YFXG?@?+V/- 'J?GP_\ /5/^^A1Y\/\
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MJGVO<0>!F,8S4G_"N_!W_0MZ=_WX%9^L^$? VAZ/=:G=^&K'R+9-Y"0 LQZ
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M_P *[\'?]"WIW_?@4?\ "N_!W_0MZ=_WX% '1>?#_P ]4_[Z%'GP_P#/5/\
MOH5SO_"N_!W_ $+>G?\ ?@4?\*[\'?\ 0MZ=_P!^!0!T7GP_\]4_[Z%'GP_\
M]4_[Z%<[_P *[\'?]"WIW_?@4?\ "N_!W_0MZ=_WX% '1>?#_P ]4_[Z%'GP
M_P#/5/\ OH5SO_"N_!W_ $+>G?\ ?@4A^'?@_MX;T[_OP* .F5U<95@PZ9!S
M2U1TK2;'1;,6>G6D5K;ABPCB7:N3UXJ]0 4444 %%%% !1110 4444 %%%%
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MF?,<M^ IOBGPCJVLZQ=3Z??6<%MJ.FC3;OSXF>2./<Q+18.,D.1SQP#7:T4
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MSC)YZC\ZP_\ FJ__ '!3_P"CA4OB2[DFU32]*M(8[J;S/MDT!G$9*1X*]?\
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M /:EZ444 %%%% !1110 4444 %%%% !1110 4444 0W%K;W:!+FWBF0'(61
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MEKGB2^L+V]CL],5;*>>!H3(Y-P8G925;@)G;QD&@#J%M+9+E[A+>)9W&&E"
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M%*3]W!ZC=V) !R,=1E;GQ596\MR!;WLT%HQ2YN88"T41'W@3U..^T''.>AH
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <K_ ,U7_P"X*?\
MT<*T=7\.Q:OJ%G?&^O+:>S#>5Y/EE06QEL.C#=@8R.<$CN:SO^:K_P#<%/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .5_P":K_\ <%/_ *.%=57*
M_P#-5_\ N"G_ -'"NJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **3.,YP/2C- "T4F:,T +129HS0
MM%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T
M +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC
M- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129
MHS0 M%)FC- "T4F:,T <M_S5?_N"G_T<*ZJN3W?\77Z?\P3U_P"FPKJ\T +1
M29HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "
MT4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
M M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,
MT +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC<* %HI 0:6@ HHHH ****
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M[VX^5QC!SGI7.7EGJ$?AG6O"ITB_FU2^OYY8;M8"87$DV])FEZ*5!7@G<-G
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M7/\ T-FO_P#?V#_XU72T4 <U_P (I<_]#9K_ /W]@_\ C5'_  BES_T-FO\
M_?V#_P"-5TM% '-?\(I<_P#0V:__ -_8/_C5'_"*7/\ T-FO_P#?V#_XU72T
M4 <U_P (I<_]#9K_ /W]@_\ C5'_  BES_T-FO\ _?V#_P"-5TM% '-?\(I<
M_P#0V:__ -_8/_C5'_"*7/\ T-FO_P#?V#_XU72T4 <U_P (I<_]#9K_ /W]
M@_\ C5'_  BES_T-FO\ _?V#_P"-5TM% '-?\(I<_P#0V:__ -_8/_C5'_"*
M7/\ T-FO_P#?V#_XU72T4 <U_P (I<_]#9K_ /W]@_\ C5'_  BES_T-FO\
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M":E=KEVR?]:W4]Z .JHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.T6]O;.^EB\(>&=1@.JW8-U?/B8CSFR,>4W3MS0![%'<02RRQ1S1O)%@2(K
ME,C(R.V1S5?4-9TO2=G]I:E9V?F?<^TSK'N^FXC-<OX5 'Q$\= # $]E_P"D
MXJAX?T_3]8^(OC"36;6WNM0MIH8;>.Y0/Y5L8P5V ] 6+$D=Z .YEU33X+:*
MYFO[6."7_5RO,H5_H2<&D75M->T>[74+1K:,X>83*44^A;.!U'YUX9/;Q)KL
M>G:7IMOJ>E0>*94M+&1U$#$VN9$!8$!0Y)QC -7_ !7X5O+3PYXFU6ZT?3]&
ML[U;"V73K*7>K%;E"9&VJJ@D-C@?_7 /:)K^SMK9+F>[@BMWQME>0*K9Z8).
M#FH)]<TFVF:&?5+**5#ADDN$5A]037S]XLGFU#P2GA:21BWA;[0UUSU\N58;
M?\TD)_"NPT_2KV_\7>+Y+;POX?U95U/:9=3?:Z'RD^4?NWX[]>YH ]9BO;2:
M58XKF&21HQ*JI("2AZ,!Z>_2H9]7TRU)%QJ-I$58H?,G5<, "1R>N"./>O*-
M?TO4Q\58[W1(XX-2TCP[!/%90G$4H$KJ\'0?*5) X'(7I5CPD=%\8:)XTU:2
MPM[J&2_EF@^U0*S1$V\>?O#@@C!QZ4 >HVFIZ??LRV=];7+*,L(9E<@>^#4=
M_KFD:5(D>HZI96;N,JMQ<)&6'L&(S7._#+2M.L_ 6A7=K86L%S<:?"9IHH55
MY#M!^9@,GGUKG?#5I!>0^+=0N-#MM;U\:Q-%+;7+1AQ$&"QJ"XPJ!.1Z\T >
MFO=6\5K]JDN(DM]H;S6<!,'OGIBFS7UG;PQ3374$44K*D;O(%5V;[H!/4GMZ
MUXC)K-AJ7AK0/">GZ+J3V+7\TM]I]NXNI!;P2DE,@@;&D( YX"T?VH\W@;2=
M$N(KF&ZT7Q-9VOE72[91 7W0EAV^0@?\!H ]D;Q#HJ,5;6-/5@<$&Y0$'\ZN
MP75O=!C;SQ3!3AC&X;!QGG'L0?QKSS5_#6@GXKZ! =$TWRIK"\DEC^R)MD8-
M'AF&.3R>3ZFJGAK_ (26V\0>+H?#MEHS6::L5(NYI(BI$48PH1"-N,4 >BRZ
MUI4,<<DNIV<:2@F-GG4!\'!P<\\TG]MZ2+;[3_:EE]GW^7YOVA-N[&=N<XSC
MG%>&>'+.YOH_ T,&D:9JDO\ 9E^3;Z@V(O\ CX&3G8W([<=ZZ?Q?I=U;Z)X9
MMCX;T*UN9?$,9%A;M_HTO[J0#>?+'7&#\IZ"@#U&TU/3]0+BROK:Y*<MY,JO
MM^N#Q5>R\0Z)J-X]G8ZQ875TF=T,%RCN,=<J#FO*[&UMX?%_B!]<M=/\,M::
M)+$\&EQ,?.MWP3<!E4;MF",!<@U+IUD?#]SX,74;'1[_ $PSQ0:7JNF[K>?<
MT9"-*A^\&7.<'W([4 >HQZ]H\MPMO'JUB\S-M$:W*%B?3&<YJY'/#,\B1RH[
M1MMD"L"4.,X/H:^=AI%]_P *M.K/I.@KIT%Y)-+?("-1V+=-G8Q7:&XP/FZ<
M5ZIX'D'_  EGC=&^4G4(I=K<$*T"$$C\* .KEUK2H(XY)M3LHTDSL9YU ;!P
M<$GG!XJ:UO[.^A::TNX+B)3@O%('4'ZBO!O#]K<7R^"([72M-U1S9ZFP@U!L
M1$?:?O9VMSZ<=Z=+&\?AKQ=/-#;:0]QJ-E::MIEDAC6S@5]K/GH1(K9W  $?
MC0![?9Z]H^H7+6UEJUA<W"Y)BAN4=ACKP#FK<US;VQC$\\41E<1Q[W"[V/11
MGJ?:O./%$.D:'JOAZ2+PG ME'?VRVFI65Q%"5D<[0NT#<R8/(Z$5H_$K_CY\
M%_\ 8RVO_H,E ':I=VTD#SI<1-"F=TBN"JXZY/;%07NLZ7IL$<]_J5G:PR_Z
MN2>=45^_!)YKP6QN+KPKX!U>_=Y)=$UY=0MIQU^RW8:5(W'^RX 4^X%=EX+L
MK'4_%;)K%K!<2V_A_3CIZ7"!@L3(WF,H/^W@$_04 >H6]S!>6Z7%M-'-!(-R
M21L&5AZ@C@U+7-^#X?#UI#JMIX=D)@AU"47$:[O+AF(!=$R  HXX7@$FNDH
M**** "BBB@ HHHH Y7_FJ_\ W!3_ .CA755RO_-5_P#N"G_T<*ZJ@!&Z?B/Y
MUS7@C_D%7_\ V%+O_P!&M72MT_$?SKFO!'_(*O\ _L*7?_HUJ .FHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-Z/%JVHV%K<VUW)+]BG\MG*>7MR<'ID_G0!N+X*\-QZ#<:''H]O'IMPP>:!
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MWTV&&+37,EHD8*B)B""1CJ2">N>M6]3TNRUFP>QU"!9[9V5FC8D E6#+T]"
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M=7\1+%=VE[).=,#O/(RSX3<%5C@#CIQ7JO@T0G1Y'@NM<N$:8_-K*.LP.!P
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MX/LKJ\N)[E]$FEOP[EMS?N,,WON+ 'KUH T/[=\5_P#0HC_P/3_"C^W?%?\
MT*(_\#T_PKJJ* .5_MWQ7_T*(_\  ]/\*/[=\5_]"B/_  /3_"NJHH Y7^W?
M%?\ T*(_\#T_PH_MWQ7_ -"B/_ ]/\*ZJB@#E?[=\5_]"B/_  /3_"C^W?%?
M_0HC_P #T_PKJJ* .5_MWQ7_ -"B/_ ]/\*/[=\5_P#0HC_P/3_"NJHH Y7^
MW?%?_0HC_P #T_PH_MWQ7_T*(_\  ]/\*ZJB@#E?[=\5_P#0HC_P/3_"C^W?
M%?\ T*(_\#T_PKJJ* .5_MWQ7_T*(_\  ]/\*/[=\5_]"B/_  /3_"NJHH Y
M7^W?%?\ T*(_\#T_PH_MWQ7_ -"B/_ ]/\*ZJB@#E?[=\5_]"B/_  /3_"C^
MW?%?_0HC_P #T_PKJJ* .5_MWQ7_ -"B/_ ]/\*/[=\5_P#0HC_P/3_"NJHH
M Y7^W?%?_0HC_P #T_PH_MWQ7_T*(_\  ]/\*ZJB@#E?[=\5_P#0HC_P/3_"
MC^W?%?\ T*(_\#T_PKJJ* .5_MWQ7_T*(_\  ]/\*/[=\5_]"B/_  /3_"NJ
MHH Y7^W?%?\ T*(_\#T_PH_MWQ7_ -"B/_ ]/\*ZJB@#E?[=\5_]"B/_  /3
M_"C^W?%?_0HC_P #T_PKJJ* .5_MWQ7_ -"B/_ ]/\*/[=\5_P#0HC_P/3_"
MNJHH Y7^W?%?_0HC_P #T_PH_MWQ7_T*(_\  ]/\*ZJB@#E?[=\5_P#0HC_P
M/3_"C^W?%?\ T*(_\#T_PKJJ* .5_MWQ7_T*(_\  ]/\*0Z[XJ/7PC^5^G^%
M=710!!:--):QO<1&&5E!:/=NV'TSWJ>BB@ HHHH **** "BBB@ HHHH ****
M "BBB@#A=-\#Z_HMJUGI?C.6WM/.DE2(Z=$^TNY<C)Y/+&DU[X8VFO6^L1RZ
ME/$^I7D5YYD:#,3)'Y9 YYRNX?C6AIOQ"T?5=5M[*"#4%CNI9(;6]DMBMO<N
M@)(1^_W6QTS@T67Q!TB^U6"SC@OTAN)WMK:_DMRMM/*N<JCYY/RMC@ XXH H
MZG\-X;NXO9[/5)+*2>[LKN$K"KB!K9-J  GD< \U9N/".M:GI.I:9K'BN2]M
MKVU>WVBPBB,9;'S@KUP,\>]2Z9\0=(U34[:SA@U".*[D>.TO9K8K;W++DD(^
M>>%.,@9QQ5K7?&%CH&IVVG2VFHW=W<1-,D5C:M,VQ2 20.G)% ":YX3AUBVT
MK9<O:WVE3)+:W:*"R[1AE([JPX(JA+X)OK2]O9O#WB:\TB"]F:>>V%O%/&)&
M^\R;QE,]2.F:5_B5H:Z>ER(=2>5KW[";-;-OM"3;2P4QGG[HS5O2_'&EZGJ,
M^GR07^G74-N;HQZC:M;YB!PS@MQ@$C- &.GPV?3UT9M$U^YL9],CN(Q/+ D[
M2^<X=RV<#.1V'>M"?P?J&I0Z<NL>(9+Z2PU.'4(G^R)%_JP1LPO8[LYJLGQ1
MT1H8[Q[+5X=)D<(FJ2V3+;')P&W=0I/&2,5:N_'EO!KE_I-MH>MZA/8,BSO9
MVZ.@+H'7DN.Q]* )$\#V$/Q"/C""1HKJ2U,$T*J-LA./GSV. ![X%:&CZ FD
M:IK-ZD[2-JERMPRE<>60BI@>OW<_C63-\0K&&^:Q&CZ[-=I#'--#!8-*T(D!
M*A]I.#P?R-277CRSM_L,,>DZQ<7]Y$\R6$=IB=(U;:6=6(VC/3)YS0!I'0(S
MXR7Q%Y[>8-/-CY.WC!D#[L^O&,4:KH$>JZSHNHO.T;:7.\RH%R)"T93!].N:
MRC\1-&.B6VI117TLEQ=-91V*0?Z1YZYW1E"< C!SSCWIC?$C1X=&U?4+NUU&
MT?26B6\LYX L\?F$!#C=@@YZ@]C0!9OO!%A?^(+W4G=E@U&R-GJ%H%^2Y'\+
MD]0RC(!]*R_^%>7MU:6^E:KXKOK_ $*!EQ8O!&C2JIRJ22@;F7@9Z9Q6KJOC
M>PTS6'TF"QU+4[^*,2S0Z=;>:85/W=YR ">PSFJ[?$OPRFGZ=?27<D<%]=FR
M4R1%3#,.JR \H1WS_+F@"O\ \(-JD&HZK-IOBR[T^UU*Z:YF@AM(BP8J%.UV
M!(X44^?X>V]O9:+'H&I7&DW>CQR16UPL:S;UDQO$BL,-DC=VYS71?VU9_P#"
M1C0LO]M^R?;,;?E\O?LZ^N>U4M"\8:/XCU/4]/TZ9WGTZ3RY@R;0WS,N5/\
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M1<O?726D2H 2'8$Y.3PH"G)HT#7;/Q)H=OJ]CY@M9]VSS5"MA6*DD9/IGZ4
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MY?3$TZ8-"JK)ARQ<@<#.>G2JGACP%8^%-(UC2[&XD-MJ,\DJJR_Z@,H7:/4
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M.J6%O(FJ:RVJ2,^4D-LD.P8Z87K]:TZ* "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>2WFK6VO>,]!N-/&JQ:[:7XBN=)GB8PVT'SK)*1MV [3D.#D[@/:L_3)5O/#
M_A;P3&ER-;TS55:\C,##R8XFD)D+$;=I!&#GG<*]JHH \<T&\2^T[P1X5AAN
M1J^BWZ2:A$T#*+=8DD4EF(QAB5Q@\YKH?$UCJ-[\5=%73M1?3I!I5R3<+ LO
M'F1_+AN.?Z5Z%10!Y-XE\'3:;-H(CUB^FU+4O$4<]SJ.Q ZL()%!50NT   =
M#574_#VIQ:_KVC:C>W>IZGJVC3PZ-J$[!5VX!D@95 56R =W<>E>QT4 >2ZG
MXSTG5?AM)X9L[>Y?7KFP%@NE?9G$L4I79\V1@*IYW9Q@5)X?\*7EWXP\41MK
MFKZ<;<V41-C(B+*1:H"3N1L\BO5J* /'=7O+;2_B?KWVSQ7?:&KV=FJ20PI(
M;C"OG.Z-NF1TQ]ZI]9U/P_=7>D7%_J>K0P_87%KXKM9&B=W$F'A=53;VSR,'
ML*]95T?.U@V.#@YQ3J /&$U(7GA6RE\2VNH7&FKK$RVVO0(]M<01A?W5RRHN
M?F)92< < D&LO7+Z[OOA]XW@M]0N]9T>(6?V/4;J#;+(QE7>F_:OF!>.<<9K
MWNB@#S6PUNQ\#^,/$\?B*1[2/4KE+RTNVB9HYD\M5*;E!PRD8P?7BN3FTA?$
M.N6%Y>:=*NDZYXBFEBAGC*L\/V;9O*]5W%21GGH:]VH!!Z&@#P>35==\(>*]
M7@O8Y;F\TW0#8Z9<XR;L/<*(&/JPW8;_ '#6KINB^(/ .J>%;V_336L8Q_9%
MRUCYAD99CN#R;N.)><C^^?6O8Z* /+_AWXOT'3=).C7FH+#J+:G=*(&C?)+S
MMMYQCG(J]XLU>QT'XG>'=0U.?R+0:?=H9=C, Q:/ ^4'T->A44 >'^+#)XD'
MB37M/BNHM.F.F6=O<- T;3.MP&:158 X7<!DC'%=%+I=YH'Q'T*YU[4[_6;"
M<M#87$Q5?L=TRD8944!@ZY /8_G7IU% 'B?Q>TVYN?%4-U#H>DW:6>ESW<DE
MP'+NJC9M.!@D%P4'J#G&*]#^'^@W&@>"K/2[ZSL()43#I:%BDG !9MP!W'O7
M4T4 >;'0S--\1](TVU6W6>RA@MHXD")DVQ   XQDUS&NS?\ "?:3IEAH4-U)
M<Z;HMVMVC0.GE2M"B+"2P'SE@1@9Z5[AG'6B@#SG1M:M?%OCG0[W2EN'M],T
MRX6[>2%D$<DAB B.X#YAL;('I7HU%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RO_
M #5?_N"G_P!'"NJKE?\ FJ__ '!3_P"CA754 (W3\1_.N:\$?\@J_P#^PI=_
M^C6KI6Z?B/YUS7@C_D%7_P#V%+O_ -&M0!TU%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M .>]=15>QL;;3+"WL;*%8;6WC$<4:]%4# %6* "BBB@ HHHH **** "BBB@
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M#G(X/4XP*YS4_B5<1:UJ"Z;#!/IT.E)/"[ Y>Y=X0N2#]P+<1D]^O- '0_\
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M[I/F\R,HY).W"\_[5 $O_"?Z=_T"O$'_ (*)_P#XFC_A/]._Z!7B#_P43_\
MQ-<SX9^(^IZI9:!!J-O;V^J7UU%O"J=DUK(DC"2/G@ADVGK@CW%7V\2:ZV@W
M'BR.YMETZ*[=!IS6YW-"DQB),F[(<X+#C'0>] &O_P )_IW_ $"O$'_@HG_^
M)H_X3_3O^@5X@_\ !1/_ /$UU6!1@4 <K_PG^G?] KQ!_P""B?\ ^)H_X3_3
MO^@5X@_\%$__ ,3758%&!0!RO_"?Z=_T"O$'_@HG_P#B:/\ A/\ 3O\ H%>(
M/_!1/_\ $UU6!1@4 <K_ ,)_IW_0*\0?^"B?_P")H_X3_3O^@5X@_P#!1/\
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MX3_3O^@5X@_\%$__ ,3758%&!0!RO_"?Z=_T"O$'_@HG_P#B:/\ A/\ 3O\
MH%>(/_!1/_\ $UU6!1@4 <K_ ,)_IW_0*\0?^"B?_P")H_X3_3O^@5X@_P#!
M1/\ _$UU6!1@4 <K_P )_IW_ $"O$'_@HG_^)I1X^T[OI>OCZZ1/_P#$UU.!
M1B@"GI6J1:O9?:H8;J%-Q7;=0-"_'^RP!Q5VD4;1BEH **** "BBB@ HHHH
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MM'>"389(F(.UO7!&1Z'/J:KS>!=,NH;M;RYU"ZGN81 US/<%I$0,'VIQA?F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <K_S5?_N"G_T<
M*ZJN5_YJO_W!3_Z.%=50 C=/Q'\ZYKP1_P @J_\ ^PI=_P#HUJZ5NGXC^=<U
MX(_Y!5__ -A2[_\ 1K4 =-1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-_\ %4?\(3I__/\ :Q_X,IO_ (J@#I-P]#^5&X>A_*N;_P"$)T__ )_M8_\
M!E-_\52_\(3I_P#S_:Q_X,IO_BJ .CW#T/Y4;AZ'\JYO_A"=/_Y_M8_\&4W_
M ,51_P (3I__ #_:Q_X,IO\ XJ@#I-P]#^5&X>A_*N;_ .$)T_\ Y_M8_P#!
ME-_\51_PA.G_ //]K'_@RF_^*H Z3</0_E1N'H?RKF_^$)T__G^UC_P93?\
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M_P#03;_P%F_^(H ZFBN6_P"%C>%?^@FW_@+-_P#$4?\ "QO"O_03;_P%F_\
MB* .IHKEO^%C>%?^@FW_ ("S?_$4?\+&\*_]!-O_  %F_P#B* .IHKEO^%C>
M%?\ H)M_X"S?_$4?\+&\*_\ 03;_ ,!9O_B* .IHKEO^%C>%?^@FW_@+-_\
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MIUQ6#J7AWQ%XAU.[GDM1I=OJ3VL$P,L<KQ00>9)N8 E27=U7:,C:#GK7H]%
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MHUVI+Y&\NZC^[ND*C''R'M77T44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A>*-6N='T^W^Q
M)$UY?7<5G!YN?+1W/WFQR0 "<#&>F1G-9>H:QXET6V%M>#3;B[O+V&TT^ZCB
M>.,EP2QDCW,1M"MT;YN.E=#K6C6^NZ<;.X>:+#I+'- ^V2*12&5E/8@BL9?
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M4 <H!CXK].NBG.?^NPKJZY7_ )JO_P!P4_\ HX5U5 "-T_$?SKFO!'_(*O\
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MM_X+HJ/[$\3?]#>W_@NBH Z6BN:_L3Q-_P!#>W_@NBH_L3Q-_P!#>W_@NBH
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M  714?V)XF_Z&]O_  714 =+17-?V)XF_P"AO;_P714?V)XF_P"AO;_P714
M=+17-?V)XF_Z&]O_  714?V)XF_Z&]O_  714 =+17-?V)XF_P"AO;_P714?
MV)XF_P"AO;_P714 =+17-?V)XF_Z&]O_  714?V)XF_Z&]O_  714 =+17-?
MV)XF_P"AO;_P714?V)XF_P"AO;_P714 =+17-?V)XF_Z&]O_  714?V)XF_Z
M&]O_  714 =+17-?V)XF_P"AO;_P714?V)XF_P"AO;_P714 =+17-?V)XF_Z
M&]O_  714?V)XF_Z&]O_  714 =+17-?V)XF_P"AO;_P714?V)XF_P"AO;_P
M714 =+17-?V)XF_Z&]O_  714?V)XF_Z&]O_  714 =+17-?V)XF_P"AO;_P
M714?V)XF_P"AO;_P714 =+17-?V)XF_Z&]O_  714?V)XF_Z&]O_  714 =+
M17-?V)XF_P"AO;_P714?V)XF_P"AO;_P714 =+17-?V)XF_Z&]O_  714?V)
MXF_Z&]O_  714 =+17-?V)XF_P"AO;_P714?V)XF_P"AO;_P714 =+17-?V)
MXF_Z&]O_  714?V)XF_Z&]O_  714 =+17-?V)XF_P"AO;_P714?V)XF_P"A
MO;_P714 =+17-?V)XF_Z&]O_  714?V)XE'7Q:Y'MI\5 '2T52TN"\MK3RKZ
M^-[,&/[XQ+'D>F!Q5V@ HHHH **** "BBB@ HHHH **** "BBB@!,C_]5+6;
MJNFW6H1*EMJMQ8$'+- B$N/0[E-9?_",:K_T.&K_ /?N#_XB@#IJ*YG_ (1C
M5?\ H<-7_P"_<'_Q%'_",:K_ -#AJ_\ W[@_^(H Z:BN9_X1C5?^APU?_OW!
M_P#$4?\ ",:K_P!#AJ__ '[@_P#B* .FHKF?^$8U7_H<-7_[]P?_ !%'_",:
MK_T.&K_]^X/_ (B@#IJ*YG_A&-5_Z'#5_P#OW!_\11_PC&J_]#AJ_P#W[@_^
M(H Z:BN9_P"$8U7_ *'#5_\ OW!_\11_PC&J_P#0X:O_ -^X/_B* .FHKF?^
M$8U7_H<-7_[]P?\ Q%'_  C&J_\ 0X:O_P!^X/\ XB@#IJ*YG_A&-5_Z'#5_
M^_<'_P 11_PC&J_]#AJ__?N#_P"(H Z:BN9_X1C5?^APU?\ []P?_$4?\(QJ
MO_0X:O\ ]^X/_B* .FHKF?\ A&-5_P"APU?_ +]P?_$4?\(QJO\ T.&K_P#?
MN#_XB@#IJ*YG_A&-5_Z'#5_^_<'_ ,11_P (QJO_ $.&K_\ ?N#_ .(H Z:B
MN9_X1C5?^APU?_OW!_\ $4?\(QJO_0X:O_W[@_\ B* .FHKF?^$8U7_H<-7_
M ._<'_Q%'_",:K_T.&K_ /?N#_XB@#IJ*YG_ (1C5?\ H<-7_P"_<'_Q%'_"
M,:K_ -#AJ_\ W[@_^(H Z:BN9_X1C5?^APU?_OW!_P#$4?\ ",:K_P!#AJ__
M '[@_P#B* .FHKF?^$8U7_H<-7_[]P?_ !%'_",:K_T.&K_]^X/_ (B@#IJ*
MYG_A&-5_Z'#5_P#OW!_\11_PC&J_]#AJ_P#W[@_^(H Z:BN9_P"$8U7_ *'#
M5_\ OW!_\11_PC&J_P#0X:O_ -^X/_B* .FKF;'PS):^*?$.IL;<VNI0VR0Q
M '*-$K@DC&.K C'I1_PC&J_]#AJ__?N#_P"(H_X1C5?^APU?_OW!_P#$4 1^
M#M$USPYI6D:/<2Z?)86EAY<K1[S*9]W!4G V;?49S5F70+F3Q_'X@$L7V9=*
M>Q,?._>95?/3&,#UJ+_A&-5_Z'#5_P#OW!_\11_PC&J_]#AJ_P#W[@_^(H X
M6'X,O::-I,=I]@BU*&RO;>]N SXF::%XT(XZ L,\#CUINK?"K7[^*RMEDT,B
M&UM((]0*/'=6;1(JN8V11Y@)!(WGC/:N\_X1C5?^APU?_OW!_P#$4?\ ",:K
M_P!#AJ__ '[@_P#B* ':OX=NM0\;^&M;CEB6WTI+I9D8G>_FHJKMXQP1SDBN
M:U7X>:E>^%]5TQ);"26[U]M419F<1M$7#;&(&<D#!Q^=='_PC&J_]#AJ_P#W
M[@_^(H_X1C5?^APU?_OW!_\ $4 <1J7PKU35-)M+-(=$TLVLEQ-&ME),R^8\
M:A&RRYR'5<^PKIO W@:?PQI6J6-]/%.M_P"67:$G);R$20G(')<,?H16C_PC
M&J_]#AJ__?N#_P"(H_X1C5?^APU?_OW!_P#$4 <YIO@?Q(D&@Z)J%[IC:)HE
MW'<PS0+)]HG\HDQJRGY5ZC)!/2J6F_"B]T[4/#M]%>VZR6<$D>H1J6VSMLD6
M-UXZ@2$'.. *[#_A&-5_Z'#5_P#OW!_\11_PC&J_]#AJ_P#W[@_^(H Y_3?"
M/BE? %SX1U/^PVM/[+DM+>:%Y6?S<81F#+C /.1SD#%;&J^$[R?X;1^%=,FM
M[1VMHK260 A5CX$I4 <DC=UZYYJQ_P (QJO_ $.&K_\ ?N#_ .(H_P"$8U7_
M *'#5_\ OW!_\10!QUY\)M1V:E96VLBZT_4%LVE^U_)('@D'3RU  \H;<]<@
M?6MG5_A=I%Q;Z79Z9:QVUG%J2WMZ#/+YDP$;)Q)DMN^8=QWK8_X1C5?^APU?
M_OW!_P#$4?\ ",:K_P!#AJ__ '[@_P#B* ,>[\#WNC:YI-]X.MM*MX;*WN(G
M@O))0&,K*2V0&)/R]2:Q=7^&FNZN=0N+AM'EFO-4M-0>W=Y?)(CA*.A(7=@L
M>/;TKLO^$8U7_H<-7_[]P?\ Q%'_  C&J_\ 0X:O_P!^X/\ XB@#D=0^'FLW
M6B6-BFD^%3!!)-OL)!*8L.%PZ2[?,1\@Y X(Q78^'_#UWI'@&VT"YO!<W<=H
MT#3DD@L0?7G S@>PIG_",:K_ -#AJ_\ W[@_^(H_X1C5?^APU?\ []P?_$4
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M#'C/:NF\4>'=4O=5T;7-$FM1J>E^:BQ7N[RIDD4*P)7D$8!!Q4G_  C&J_\
M0X:O_P!^X/\ XBC_ (1C5?\ H<-7_P"_<'_Q% '+)\+[K4=7L]1U^:SN6DO[
MB]OX(&D1/GA$:)&?O'!4$DD9KK/$/AV:[\&R:)HHLXBJ(D4=[%YT+*I!V.&!
M)! Z]1P:9_PC&J_]#AJ__?N#_P"(H_X1C5?^APU?_OW!_P#$4 <5I7POUO3
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M_P#$4 =-17,_\(QJO_0X:O\ ]^X/_B*/^$8U7_H<-7_[]P?_ !% '345S/\
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M:@MQ+)'J31(1=2H%411D !6 ZD_G7:5SA\-ZA!?WUQI_B"XM([R?[0\(MHG
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M;GD5W5<ZO@;P]'<W-S#9/!-<121.\-Q(FU78,P4!L)EE!^7'.?4UT(&  .U
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M8Y!! (4 CH<=* .1LOB)K+6MC&FC07;,]E9R7,MYY1DGGMTE#;1&0%!;GGZ
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MJFJV,<FE1PZ=J,ES%9W"W.^0F$D$NFP;0P5B,,?>NFU#3+/5+(V=Y#YD&Y6
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M90(QN4X.[MSBJ5O\3-6U+4].M8M,@M@;VW%PWFR$/#+%._R[X5)(\DG(!!P
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M2VPG;N*Y!;&2#UJG'\/_  O%!<0II2A)_+W_ +Z3(\LDIM.[*;=QQMQC..E
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M1R7\W< IW%B2V0 .3T&* .6^'^M:W>7>H6FNRW?F1VMK<Q1WL<2R@.'WL#$
MNPE> ?F&#GM67#\6KJ0N!H4<A>));8)<R!9-UQ%!C>8@K?ZT'*%QQC/>N\TC
MPYI&A"8:;8QP&8 2-DLS 9P"6).!DX'09K/M_ 'A>UD$D&DQHRA54^8YVA9$
MD51\W #QH0!QQ[F@#G[SQ[K#0W.GVNDVJZO"+WS3]K/E(L"H2RL8\L3YJX!
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MRR3,=[*2SXW\@YPV!E>AP.* .;7XAZE<MO@T*.*V:Z%BK3W1643-;^<N4V8
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MMII4\MF1FQLSG: 3@#/8 5-%HEFNCS:7<*UW:3-*TB7!W[A([.5^@W8'H *
M.6A\;ZU)XHC\-/H=F-1$C^<ZWS&%8U2-]RGR\DD28P0.1UP>+>O>*I]*UJ_$
M:/+;Z5IZ7,MN@ :XDFD9(UW$?*%V,21_>'I@[&G>%M$TJ>&>RL$BFBW[9-[,
MQWA0V222Q(11SG  Q3KSP_:WNL?;Y0K+):-9W4#H&2XB)RH;/]T[L>S-^ !C
M/KFMVVKZ2NHP6UNL]\VGS6]O.)D?="94E5BJLI!0J5('!)]#6%XNUS7[?7M?
MATZYU=4L-.BN($L8+9XUD82DF7S!NQ\B_=/0&NM@\(Z=::G97-LBPV]HSRK
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M8V8)G )0D?CZUEZA\.+2X6Q2#4-1_<WL5Q))->RO(J1I(J+&<_*07!]\<YH
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MU!&.M2W7Q2L[$F"\TR:UO3<"%8)[B)%P8EEW%RVT?*P&.N3BM.+X>:%#;7T
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MTUL^GQR*2OD2V_G_ #<\D;)5SQSC\>JU/P;IFJ7ES</-?6XNP!>16URT<=R
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MM]2N7@>-;>)]@6"23*EE)R2@Z^IK9T[PUI.DW$4]E:^5)$DL:?O&(599!(X
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M!H!YTB.P##8!@,1V'0UA7_C35)]8OK"S2XL1)+I]K UU;!7MVG>4/)M/WN$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW< Y8EQC/ QS6!IGQ&U*6\LK,:5)<PQFSM[JX\N7<SS1QLS[@GEJ!Y@."P)
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M"1-^UHX]I&X8/3MCCV'2@#.D\5W,OA70-4L[!'NM:-NL44DI"1&6,OEF )(
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M4W5KZTLM5N)? EE'&+NP-AYEI;F*!KJ65%A8D  E%\YB1T'7J*]=HH \9O-
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M,;3QKF?>VU5558L&)P-K 'YA^$MIKIEU"*RO-,N[":=6:#SS&RR;>2 4=L$
MYP<9&<9P:9J&B3:[X>N-,UB:VD>5@P>"#"*58,A*.S9PR@D$X/2J&C^%9-/O
MQ<R0:%!M1D#:=I8@D.1C.\L<?0?G0!<3Q,!J4%I<:7>6RSS&".61X2"P!(RJ
MR%@#M."1Z9Q3-2\5Q6&J3Z=#IUW>W%O"LTB0/$IPV<!5=U+'Y3T!].M8MGX%
MOK233#'<:-$=.E6198M,(FN,*5)D?S,Y.23CJ>?:M+6?#=]JUQ=B6;2;JTG(
M\F.^T_S6M?D .U@PSR"W.,$]: -"YU]8YH+>UT^[O+J6 7!ABV*8HSP"Y=E
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MO L.H^#=>NHU;<JS:46"GU&3P:+CQ'IMW8I97'@W7I+5,!86TH[%QTP,X&*
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M_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\
MPG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C
M1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %
MS?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_
M]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG
M"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT
M =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UX
ME_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\
M0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =51
M7*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\
M!<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)
M?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\
M)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^
M-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<
MW^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_
M $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"
M<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^-
M'545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7
MB7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T
M+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545
MRO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P
M7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7
M_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\
MPG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C
M1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %
MS?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_
M]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG
M"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT
M =517*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UX
ME_\ !<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C1_PG"_\
M0M>)?_!<W^- '545RO\ PG"_]"UXE_\ !<W^-'_"<+_T+7B7_P %S?XT =51
M7*_\)PO_ $+7B7_P7-_C1_PG"_\ 0M>)?_!<W^- '545RO\ PG"_]"UXE_\
M!<W^-'_"<+_T+7B7_P %S?XT =517*_\)PO_ $+7B7_P7-_C2'QLK8'_  C7
MB4'L?[-;C]: .KHJAI&I?VK9"Y%I>6H)QY=W%Y;C\*OT %%%% !1110 4444
M %%%% !1110 4444 -*D]_QIU%% !1110 4444 %%%% !1110 4444 9<WB'
M2+?78-$EOHAJ4T;2I;CE@BC)+8X48]<9[56\/^,-!\4R7,>C7XNFMMID'E.G
M!R 1N W [3R,CBL_5/#,LOQ!T77K&UMD6&&Z6\GP SLZ(L>>[8VD>PK"T+1_
M&6F>*KW6Y])TU3>K!;7,4-ZQ5MKMNF3<N4 0@"//OUH ZK7_ !IH/ABZAM]6
MN9X9)@ICV6<TH;)( W(A&20>,YIH\<>'?[.U"_-\Z6^G+&]V7MI5:(2*&3*E
M<\@C@#CO3/&>C7FM6^C)9(K-:ZO:W<NY@,1QOEB/4X[5Q?BSX;:EKMSXSO(F
MG$]^;;[!&EZT<<FV-%;S$!P>0<;A0!U]S\0_#EKY@:YGDE2]EL?)AM9))&EB
M +A54$D $$GIS5R3QCH:>&(/$?VS=I<Y18YEC8Y+-L VXR/FXZ<5YSJ/@'6V
M%\TF@VNIQ2Z]>7R(M\;:X2.14"/'*#A3E3N5@<\5M77A'Q'=_"&RT&ZD%SK"
M3122&28-A5G#X+G[Q"8&>Y% &^WQ'\+IJDFFM>70NXR=\9TZX^4 D;B?+QMR
M#\V<>]-@^)?A2XL+B^2^N!:00?:))GT^X1/+R%R"4 ;EAP,FF:AX>U"X\9ZM
MJ<:(;:YT$6,9+C)EWN<8],,.:X:S\">)!X'N]!?1[B.>2P2W\V;7#/"S*Z$[
M8CPF=IQCH..] 'IMEXOT'4=3L]-M+]9;N\LEOX(Q$_S0'HV2,#Z'!]JJ:OX_
M\.Z)J4UA>W4WG6ZJ]R8;625+=6Z&1E4A>.>>U<9X$^'FM^'?&$.I7_E-;VZ7
M5I$ZR D6_P"[\@8_"3Z5HZGH/BC3[_Q3;Z3IEKJ%IXB^87$MWY1M6:+RVWJ5
M)91U&WZ4 =/+XZ\-0W&IP/JL?F:9;I=706-VV1,H97&!\XPR_=SU%6F\4:.M
MEJMW]I=H=*D,=X4@=C$P4,> N6P&!R,C\J\KUOX2ZS+IFI_V;)%_:"16MM;2
MEPHN8%M8X94;T!*;AGNH]:Z_0['Q'HGB36HSH,-UINJ:E]H-T;U5,<91$.8\
M$G&TG&1F@#IK'Q/HVIZH--LKU;BZ^RI>;8XV*B)_NL6QM!.<@$YQSBF6WBS0
M[O7[_0H+]7U*PC\VY@$;?(O'.<8/WAG!.,UC> /"9\(Z5J:FSC2YN+V:10CY
M+1 D0KGL N !VS7)Z1\/O%NFZCIFNS7MI/>R75Q)?VBQA"JW _>?O=QW[2J8
M&!TX]P#L;3XG>$+Z.22'5'V1VSW9,EG-&&B099EW(-V!V&33[;XD>%+M)&CU
M)UV&(%9;2:-OWC;$(#("06(&1QZUR>G?"R6U^'SPW$MU<>(!I$]G#%/=[X;=
MI%(*QCHH/'-3:G\-9K?PPDNGF[U'7?\ 0PYO;W=A(I%<QJ3PJY!QQ0!W.K>)
M])T2]BM-0N#%+);S72XB9AY<2[G/ /0=NI[5F1?$?PO+IUSJ"WMP+6WC65Y)
M+">,%6(5=NY!N)+  #)YKF_$&@^*/%6I07T^BPV!BTS4+/R_MJRY:6(*AR .
MK9'MBL^S\'>(%\(7>D2^'1,[6L*&/4=;DN()BC+E44$>4< D$'C % 'HNB^*
MM)UZUNY[&68_8VVW$4MN\<D9QNP48!N1R..:R8OB?X1E^U8U&=!:H7G:6PGC
M$8 S@ED !(Q@=3D8SFJWPVT#6-"AU4:C#+:6D\R&RL9KW[6UNH7#?O/0GH.V
M*HZOX'U75+;QG%&T,3ZE?6UW9%W^5_*6,X?'(!*$?K0!U.A>,-&\174MI8S3
M+=11B5H+FV>"0QDX#A7 )7/&156X^(GA6U@U>:;50J:1.MO?'R),Q2,Q4#&W
M+<@\KD<52T;3M?U/QNOB/6M,@TI+;3WLHK=+H3O(6=6+D@  #;@#KS7G6O\
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M>-_#EVCM!J2OY=]_9S 0OD7'.$QMSV//3CK7$#P?XH7P[_PA L+0Z7]O\_\
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M86UY<FY0%G62PGC$8VELL60!1@$\D9Q45Q\3/"MM(%:^F9/*CFDECLY62%)
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M%L?&'A_4KK5K:UU*-Y=()%\"C*(<9R<D $#:V2,]*ATN/6].\.W5B+*$S6$
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MLK3*('GD:9F=F;)Y4-G/?@<8H ]/HHHH **** "BBB@ HHHH **** "BBB@
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M  DNA?\ 0;TW_P "D_QH U**R_\ A)="_P"@WIO_ (%)_C1_PDNA?]!O3?\
MP*3_ !H U**R_P#A)="_Z#>F_P#@4G^-'_"2Z%_T&]-_\"D_QH U**R_^$ET
M+_H-Z;_X%)_C1_PDNA?]!O3?_ I/\: -2BLO_A)="_Z#>F_^!2?XT?\ "2Z%
M_P!!O3?_  *3_&@#4HK+_P"$ET+_ *#>F_\ @4G^-'_"2Z%_T&]-_P# I/\
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M (270O\ H-Z;_P"!2?XT?\)+H7_0;TW_ ,"D_P : -2BLO\ X270O^@WIO\
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M#J>RAL;^*\@N474(U9VEN0)4:=HWX+[TW$$>NW@C  .I_P"$7T#_ * >F?\
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ML:"1F<Y_NY';DK39/B4J^(-)V6\;:!?:=%=RW8)WVS2.44MSC9D!3QP3GH*
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M"!GK4TOQ(2:UMI;31M4A2^FB2PN;BV5HKH,X'RXD!!*Y(W;3CYL$#% '3?\
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M4>JBVM_#UZS->);M:R)&)8U$1FD.X2X+%"I"\;<'.3@4 =M_PB^@?] /3/\
MP$3_  H_X1?0/^@'IG_@(G^%<]>?$&WFBMGTB%Y@6T]YI)%&Q4NI54)D-D2;
M7W=P!CUKK-06_>T8:;-;0W.1A[F%I$QW^564_K0!4_X1?0/^@'IG_@(G^%'_
M  B^@?\ 0#TS_P !$_PKDM.\;ZI#HWAG5=:?3Q;:S* PMK:4&%?(DDQ]]BQW
M*HSCIGCN(+WXCW+ZD\-A-8PVAU+[&EU<6LTF$%JLQ)0,K$[R5[<8^M ':?\
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M@TJR:Z>[CL)UC9U5B8.9/O8"G()P#R* .W_X1?0/^@'IG_@(G^%'_"+Z!_T
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M#.P\TEN 6"C'IDTNK>.-7TSP['J-K-INJ2F^6!ECLYH (_+=W #N26PO!Z4
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M=,=^M='0!E?\(OH'_0#TS_P$3_"C_A%] _Z >F?^ B?X5JT4 97_  B^@?\
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MDQ:O:^1)<W< WA]]M,8W^F1VK+C\(F! EOXBUV) /NBY5OQRR$UTE% '/?\
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MBDXZ'83WP0IH 9JNC^%[;1-9\,W%OK>J6[>5<W]U%&LCVK")%5MV!\VR,,0
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MJ@8 Z8'2ME5T6R\6V>GWVK3ZAK5U926WE3B,EX<F0EU1% Z$#@9 [\FL?1_
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MB@1SH"OFJ"I&YE.&SD$ 9&>:@'@.T$(?^U=3_M(737G]I!T$QD:,1G@)LQL
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M!R"P&1GD"H;GP+H]QKD&JQK+:R1/#(8;?:D4C1,Q1F7;R1O89]#72T4 <R?
M>ADZYB*5%UF2.:X5'VA)$Y#ICE6W?-GUYJM<> (+Y9VU#7-6O+AX5@CN)6B#
M0HLJ2X4+&%)+1IDL">*Z^B@#G9_"LEY9M;WOB#5KAA+'-!,WD(]NZ$D,NR,
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M_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\
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M_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\
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M_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\
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M_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\
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M_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\
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M_H7--_\ !F?_ (W1_:7C/_H7--_\&9_^-T =117+_P!I>,_^A<TW_P &9_\
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MRB!F6-I&!!Y& K4V7QG:P:'JVIRV[K_9D[P20[UW,RX!Q^=3:JEE>W^F:O\
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M&+*.W;;EVD*G<1]T)D'&3GKVGQ"_M2_\&Q'1UNP)YX3<"")FE\@G+#8K*Q[
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MM=?4<,$-M$(H(DBC!)"(H4 DY/ ]R34E !1110 4444 %%%% !1110 4444
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M+ >*Q!_H[749N?#TD0FB499DW.-V 0<#G!'% 'HN1ZBC(]17G%MXCO;DH/\
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M_9'BO_H:+/\ \%7_ -MH Z3(]11D>HKF_P"R/%?_ $-%G_X*O_MM']D>*_\
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M5?\ VV@#I,CU%&1ZBN;_ +(\5_\ 0T6?_@J_^VT?V1XK_P"AHL__  5?_;:
M.DR/449'J*YO^R/%?_0T6?\ X*O_ +;1_9'BO_H:+/\ \%7_ -MH Z3(]11D
M>HKF_P"R/%?_ $-%G_X*O_MM']D>*_\ H:+/_P %7_VV@#I,CU%&1ZBN;_LC
MQ7_T-%G_ ."K_P"VT?V1XK_Z&BS_ /!5_P#;: .DR/449'J*YO\ LCQ7_P!#
M19_^"K_[;1_9'BO_ *&BS_\ !5_]MH Z3(]11D>HKF_[(\5_]#19_P#@J_\
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M1V=P%2?;%MD!XW8SQVR*],HH X?3O PEGU9=2GO$L9M3^T0V<4X$,B*(]I8
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M1LP=UP=A4?45Z2S!5+,0 !DD]J4'(R.E 'GWB+P?K7B74]7OOMK:>4@C@TU
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&IW=[:VX>QT_[
M;+O \KSECX[G+<?A65_;7B7_ *%,_P#@PC_PKH\#.>]+0!S?]M>)?^A3/_@P
MC_PH_MKQ+_T*9_\ !A'_ (5TE% '-_VUXE_Z%,_^#"/_  H_MKQ+_P!"F?\
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M_A1_;7B7_H4S_P"#"/\ PKI** .;_MKQ+_T*9_\ !A'_ (4?VUXE_P"A3/\
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MR0(+J6-8GE ^8HI)5<^@+'\ZL44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 54N],L;ZXM9[NS@GFM7\RW>1 QB;U4GH:MT4 0V]G;6AF-O!'
M$9I#+*47&]SU8^IX'Y5-110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !15#4[N_M;</I^G_;9MX7RS,(ACN=Q!Z5D_P!L^*/^
MA33_ ,&2?_$T =+17-?VSXH_Z%-/_!DG_P 31_;/BC_H4T_\&2?_ !- '2T5
MS7]L^*/^A33_ ,&2?_$T?VSXH_Z%-/\ P9)_\30!TM%<U_;/BC_H4T_\&2?_
M !-']L^*/^A33_P9)_\ $T 7?%63X5U4 $G[))C_ +Y-6=$!&@Z>#U%M&/\
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M_P 31_;/BC_H4T_\&2?_ !- '2T5S7]L^*/^A33_ ,&2?_$T?VSXH_Z%-/\
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M_P 31_;/BC_H4T_\&2?_ !- '2T5S7]L^*/^A33_ ,&2?_$T?VSXH_Z%-/\
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M_P 31_;/BC_H4T_\&2?_ !- '2T5S7]L^*/^A33_ ,&2?_$T?VSXH_Z%-/\
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M!#_WYD_^)H [2BN*_P"%M^!?^AAA_P"_,G_Q-*/BUX%) 'B"')_Z8R?_ !-
M':45Q7_"V_ O_0PP_P#?F3_XFE'Q:\"DX_X2"'_OS)_\30!T^JVTUS8LD%]/
M9L/F,D 7<0 >/F! ^N,U%X>GENO#6E7$\C/-+9PN[D\LQ0$G\ZY+4?BKX1GM
M&BL?%-G;RDX+S6<THQW&!MY]\U!H7Q(\):1I<.GW?BNTN?LR+#&\5E-%A54*
M,@[LGCKQ]* /1J*XO_A;7@7_ *&"+_OS+_\ $T'XL^!@<?\ "019_P"N,O\
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MQ/\ OD4 <U_PL/PS_P!!!O\ P'D_^)H_X6'X9_Z"#?\ @/)_\372^4G]Q/\
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MQ/\ OD4 <U_PL/PS_P!!!O\ P'D_^)H_X6'X9_Z"#?\ @/)_\372^4G]Q/\
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MQ/\ OD4 <U_PL/PS_P!!!O\ P'D_^)H_X6'X9_Z"#?\ @/)_\372^4G]Q/\
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MC_G_ &_\!Y/_ (FC_A87AC_G_;_P'D_^)KI?*3^XG_?(H\I/[B?]\B@#FO\
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M^&?^@@W_ (#R?_$T?\+#\,_]!!O_  'D_P#B:Z7RD_N)_P!\BCRD_N)_WR*
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MP7B:/IZW(?S/.%L@?=G.[=C.<]ZEAT;2[>_>_@TVSBO9,[[A(%61L]<L!DT
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MJUR$@B@C\WRLMEAYSX'.,YQQ7HMMX<TJWT9-)>TBN;%)'=8KE%D4%F+8P1C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9R((TBRF["$[=Q"9(.]SP01@9W9.+=W%&/$VF2A%\PQ3@OCDCY.,T :]%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3U2#2X8GE2:5YI!%%%"FYY'()P!]%8GV!H NT52340VF2WK6EW'Y:LQ@>/\
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MO \TC*.K;4!.!D<].151O%VC+I[7WG7)@28P2%;*9FCD&,JRA,J>0.0.>.M
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MXKTJYNH+96NXY;C<8!/931>;M4L=I9!G@$\58TO7;'6'F2S^U$PG;)YUI+"
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MMF"\T3,@&0.NX$Y_"L?PS%%%X@9=-GTV[;[!*OVC3Q)'&K;H]HF0LXWGG!W
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MKUFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"R:CY0:*TN)0@W?W68$C\CCW[T :-%063W,EC;O>1)%=-$IFC1MRH^/F /<
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M:W>JZ9;RZ$NH:9:6+6JR/)&&1F:/##)R"!&>1SSQ79T %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-)\8:=;Z3 +>*ZTZ9I/+C8"5MT1C9SCEMOF\MSUIFE:IHL'C/4C:/Y<=Y!;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#[ S.S2.79V8EF9F/))))K&UBX,VOVEA<:A)8V$EL\RR12B,S2!@-N_MA3G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *5WH^F7\ZSWFG6EQ,@
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MCC0@+'<VGG1*HZ (&7';'/%16'AZTM]%;3;U(K^.21Y9A/"I1V9BQ^3H "<
M=@!]:LZ?JMO?:+9ZH3]GAN84F F8 J& (!.<9YJY'(DJ!XW5T/1E.0: *UKI
M>GV+!K2QM;=@GE@PPJA"9SMX'3/.*;'H^F0W[W\6G6B7K_>N%@42-]6QDU9N
M+B&TMI;FXD6*&)"\CL<!5 R2?PK'@\2I--#'+I>H6OVD'[*URB*L[!2VT88E
M6(!(#A3P?2@"]+HVESWZW\VFV<EXN-MP\"F08Z88C-.O-)TW4)8I;W3[2YDA
M.8WFA5RA]B1Q46E:S;ZI96\XQ#+,I(@D==XP2#P#ST/2DOM5>QU*QMFLI7AN
MY/*%PK+M1]K-@@G/1>H'>@"[;VMO9QF.V@B@C+%BL2!02>IP.].EBCGB:*6-
M9(W&&1QD$>A%5]2O&L-.GNH[=[B2-"R0(P#2$#[H)XR:M%@%W,0 !DD]J (S
M;P$RDPQDS#$AVCYQC&#Z\>M4[?P_HMI.D]MH^GPS(<K)';(K*?8@9%78KB&=
M0T4T<@/0HP.:2.Y@F=DBFC=T^\JL"5^M %>\T?3-0GCGO=.M+F:+_5R30*[)
M]"1Q2MI6G-<37#6%J9YT,<TAA7=(I&"K'&2, <'TI8=2M;B[N;5)1YMLZI("
M<<E0PQZ\$5--<P6P4SS1Q!C@%V"Y/XT ):VEM8P""TMX;>%<D1PH$49Z\#BF
M7NGV6HPB&^L[>ZB5MP2>,. ?7!'7DU-)+'#&9)9%1!U9C@#\:I:;JR:C<WT*
MPLGV241[BRLL@*A@RD$\$$=>: )SIUBU\E\UG;F[C7:DYB7S%'/ ;&0.3^=,
MATG3;>^DOH-/M(KN3[\Z0JLC?5@,FKE5++4K74$=K>4,$EDA(/7<C%6_4&@!
MD^C:7=7@O+C3;.:Z"[1/) K.!TQN(SBK4$$-M D$$211(,)'&H55'H .E(]Q
M!'*L3S1K(_W4+ $_05+0!#=6D%[ 8+F(21%E?:W3*L&!_ @'\*9%IUG#8&Q2
MVC^R$,#"R[E())((/4')J#5M6BTB"&66WN)_.F6%%@0,VYNG4CTHT_6+?4)I
MK?RI[:YA4,\%Q'L<*<X8=B#@\@GI0 ^ST;2].E:6QTVSM9&7:7@@5"1Z9 Z<
M"I38V;7JWIM8#=JNQ9S&/,"^@;KCVI\-Q!<;O)FCDVG#;&!Q]<5#::E:WLDZ
M0R@M!*87!/\ $ #QZ]10!+-9VMQ-#-/;0RRP,6A=T#-&2,$J3T./2IJBDN8(
M71)9XXW?A59P"WT]:D+!1EB /4T +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '/>%/"W_  BEK<6L6J7=W;22&2*&<)M@+,S,%P >2W<G
MI70USOA_QE8^(K"]OXK._M+*T9@;B\B")(%+!BA#'(!4YJKH'Q$\/>(]:NM+
MLK^W:>.79 %E#&Y7RPY90.PR1]5- '65SVL>%O[9\0Z5JDVJ7:0Z=*)H[) G
ME-( PW'C=G#$=:H'XE^&E\5_V"=2MA((SF7SA@3>9Y?DXZ[\\_2M+5?%=MH_
MB#3=(N;#4&.HN(X;N.(& .=QVLQ8$'"DXP>* -ZBBB@ HHHH **** "BBB@
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MR6/!.PB-BR@XX;G[OODUVE% 'FUKI^G6/A:*ZM=#NH;H:XLH*:7,)E3[6')
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M8^&]O9ZSI.JZY D5NLEK$I-S(P*X+!6SD'D_-V/6NRHH 0=!VI:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH XOX5NC^ K9592RW-V& /(_T
MB3K4WACX?:;X5UBYU2SN;F2YNXV6Z\TJ1*YD+[^!\I&2N!@8[9YK;TGP[H^A
M27+Z5IUO:/=,&G:%-ID(S@GUZG\S6G0!R+?#W37\;#Q8;FY_M(3!QRNSR_+V
M>7MQTS\V>N>]0^.Y$_MCP9'O7?\ VY&VW/./*EYQ7:5F77AW1[W6+?5[G3K>
M74;8!8;EDRZ $D '\3^= &G1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK2<W"R-*I9WZ?-E<8P2,# YK:HH QV\.6DMQJ<ES+<7$>HH$G@D8;  ,#;@
MC [YI;'0C9W23OJVJ70CSY<=Q<91<C'(4#?Q_?W>O7FM>B@#%L/#OV#4)KQ-
M6U&1IY/-FCD:,I(VT(,X0'HJC@CI6U5:^U"UTRV^T7DOE0[@I?:2 2<#.!Q]
M:LT 4M3TV/4[=(GFF@>-Q)%- VUXV&1D9!'0D8((P:JMX>MYM,-E=7=[='S1
M,MQ+-B5'&,,I4 +C'0#')XY-:]% &5::(UJ)B^K:G<32QF,2S3+^['JJA0F?
M<J34>F>'O[+CFCAU749(Y/,.V5HSM>1BS.,(.=Q)].>E;-% '.)X,L5L%LS=
MWS0BSDL3ND7+1/V)V]1V/\ZLR^' ]V;N'5M2M[AX4AE>*1#YH3."592H/)Y4
M \UM44 5["R@TVP@LK92L,*!$#,6.!ZD\D^]0ZII<.K6J0RR2Q-'(LL4T) >
M-QT89!'<CD'J:O44 8-KX6BM;F[N1JFIR7-W;B":6696+!2Q4@;<*1N;& !R
M>,\T^/PS!'#H\2WU\%TEMT'SK\WRE '^7GY6*]N#Z\UMT4 <W?\ @NQU""\M
M'O=1BT^\WF:RAGVQ,7Y8CC<,DDD @$DY')KH((C!;QQ&5Y2BA3))C<V.YP ,
M_A4E% %#4](@U00M))-!/;L7@N('VO&2"#CL00<$$$'TXJHOAJT:RN;>[N;V
M]:Y*%YIYSO!0Y0KMP$*GD%0.>:VJ* ,:U\.QV\\ES)J%_=7C0M#'<3R*6A1B
M"0@"A0<@<X).T9SBHX_"UO%8:39I?WXBTM@UN=ZY.%VJ&^7D!21]#6[10!SU
M]X0L[X7<)O=0@L[PN;BS@GV1R%_O'IN7/4A2 222.3F2\\,K>6EM:OJVI)%;
MB/:$>,;FC<.C'Y.H(7VX'%;M% &?+I*7&D_V?<W5S,,AO/9P)0P;<K94 9!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+T^SN)+BVL+6":3EY(H55F^I R: //-6N(;OP,^K7NOW$&H2LHFMS<@(DAD
M:W\KIQRN<;N,Y[UZ:"" 000>A%4Y-(TR:YDN9=.M'N)%V/*T"EF7I@G&2*MH
MBQHJ(H5% "JHP /04 5M2U.RT>PEOM0N4MK6( R2R'"KD@#/XD5*+N!K7[4)
M%\C9YGF9XVXSGZ8HNK6"]MGM[F&.:%QADD7<I[\BG>3'Y0BVCRP-NS'&/3'I
M0!7TS5;'6;!+[3KE+FV?.V2/D''!IEEK6G:E=7=M9W<4T]H_EW"(V3$WH?>K
M%M9V]E;K!:PQPPK]U(U"@'Z"D@L;:VFEFA@CCDE;=(R+@N?4^I^M %BBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@".XGBM;:6XG<)#$A=W/15 R3^59NE^)=(UJ;RM/N_.?9YG^J=05XYR0!W
M%2^(+>6[\-ZI;0(7FEM)8T0?Q,4( _.N 2RU=O!]SIIL?%-S=M8+#%%<2V\4
M:2C:%9'0AEVGG)SP#UH ]0HKR6U\,Z^;2)==TS4=5>.2[2[2&^51<SN8_*N%
MRRA4"AE X*'H#R:S+_P]XHLKW5+^ZBOE9!=7!NXYE9%@,#A(S(7WMCY1MV#D
M;L]Z /9[B[M[7ROM$R1>=((H][8WN>BCU/!J:O&M*\+ZG>1:5J/]C7L5I!)I
MT\EO+=*[S2H)/-G7]X1@AX^I!.T\<5I_%#0O$&L:D3I>G7,Z+IS+;S0,I*S[
MB>=\BA. OS!68].,4 >I45YOX>T77+7XD7.H3V-XMK+YYEFN)59<-M*;&5\L
M./NLGR=CZX@TS5]5US7)-/LK[[3#JUY_I_VD"/R/(91 %WYSYC*<;<=\\4 >
MQU#=7<%E;-<7,@CB7&YB.F3@?J17DM_X)U2"T2"UTN^GGFTF".TGCNPOV*^&
M3)+(6<').PEE#9VD8]9-0\->+GU/5;1#=/IME*]QISI/@S-/)$S+USB,"4#/
M]Z@#U66]MH;RWM))E6XN QBC/5PN-V/ID5/7C=UX2\2RW]Q]FL+J'5O*U-7U
M9KA?+F,K9@"?.2N$POW1MQ18>%]<B"R3Z/J<VD+>1//IGF11-,!#(I95$Q'#
MM&3EQNV@XXH ]576M->PM[Y;R,VMS(L4,N>'=FVJ!]3Q5^O-E\+ZA<?"[P]H
MD]C*LT5[:&Y@,@W1QK.&?+ ]ESR#FL+5O"'B( 0PV=Y-ID4]^EO:0LCF/?*#
M$X#R* NW(#9)7TYH ]FJ$7<!O39B0?:%C$I3'.TD@'\P:\EN?!?B"32;FZDB
MO)=0&HP^<&F$CSVBP1[E +JK?O06()&2I]<%EIX4\22?8[>XM]12R9[??&]P
MH*1?;'=U^5S@>61P"< XSQ0!['3)94@A>:5@L<:EF8] !R37+^$TET1#HMQ:
MW""6\O9+7)W)' LN4!.<@$.,#^5<1XI\.^)KWQA>7=MIET4-XA2:-T*-;^4%
M;YFDW#DGY%0#ODYH ]3T[6],U:.62PO8ITB5&=E/"AT#J3]58'Z&K5M<P7EK
M#=6TJ2P3()(Y$.5=2,@@^A%>??#[P[J%GHVL6FI6<EO]JM;.)1)QNVV44;CC
MT8,/PKED\'>*(K?2HEL-03R;"T@@6*2,_99HV/FG<91LR?F!4-N! XQB@#V^
MBO(CX$OY[2V:>SNVG>VU1[G-P?GE,G^C!OFYPI^7TP*9=>$-9ATV>&.RU%TD
MCTZ640S*YDF5)1,61W D^8IN&Y<G!SQ0![!17GFIZ5KTGPNTC3O[.D>^C: 7
M5NDI=EC4\\&0!SP/E+XYZG%<M:^#/$4VCZG'>6-\)(=.N_[.C:<+MF:9FBP$
M<J& (QS@9QF@#V6XO;:UFMH9YE22ZD,4*GJ[!2V!_P !5C^%3UYA;^'M77X@
M6-[=Z5=2R1ZK-<MJ9F4Q"V:W=(X]N_((8@?=XZY^:M;6]$U"?Q9->#3[N^WB
MW-A.EX(HK)D8^86&X-SP3M5MP^4XH [FH[B>*UMI;B=Q'#$A>1ST50,D_E7C
MMMX/UYH+&%=-U*TVQ6L&JNUX#]LE%S$SRJ5<G 02_,=IP^,>DFK>$=8%M>6W
M]CWE]I@.HQ6=G#<!?)>1D,,OS./E #CN1GIS0!Z=_P )'H_EN_\ :$.U%=SR
M<E4178@=2 KJ>/45IJP=0RG((R#7C-WX0\0M!/<_V==27,<%[!;;)@&C,EE
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MC-=W4!MIXQ 5 ED4!)<KG*'/('0Y YJQ0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/43J M&.FK
MUSD8$[$)CW(!-8N_QM_SPT3_ +^R?_$UO7UL]Y8S6T=U-:M(NWSH" Z>ZY!
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M\\-$_P"_LG_Q-=-10!S._P ;?\\-$_[^R?\ Q-&_QM_SPT3_ +^R?_$UTU%
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M99--&C75S//$/'@U1U11*?M6_P"T8C55SGRS%MXQM*Y/J: .\W^-O^>&B?\
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M-&_QJ>/(T3_O[)_\37344 4=*_M'[)G5$MDN2QR+=BR8[<D YJ]110 4444
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MW+W[B@#?HHJM=WJ69MPT4\GGS+"/)B+[2<\MC[J\<D\"@"S1110 =JYK5/\
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M*T** &[$X^5>,8X]*IZGH]AK%F;2^MUE@+!F3)&><D''8XY'0C(/!J]10
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M5/'&.E0^'_AYX>\-ZB-1M(;B:]52D<]W</,T:GJ%W' _ 9H ZJBBB@ HHHH
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MW*8QA<9SD]*TQ;:Y9ZM>-90Z=+:7=PLS233NDD?R(A&P(0WW"0=PZ]* *?\
MPE)T_6=8LKY+FY2T=9 UM:,PAA9 WSD9SSNZ<G!XK:O-7AM$MV2WN[KSP6C^
MRP-(,#!R2.!U&,D9[=*S&TW5_-\0L(K'%^ +;-P_9 GS_N^.!GC/I[U0O?#N
MK7$>FF2UT^\%O:"![6>\ECBC<?\ +12L9WD@ 88#&.#R: -:X\6:9:Z5;ZE)
M]J^SSRF!=ML[,) Q385 R&W KCUXJYINKP:F\\217$$\&WS(;B(HZAL[3[@X
M/(]#Z5SEGX>UNQ\/6>FI'ICO;:DUUE9I$0QF8R@ ;&(/S%<9.,9R:V[2ROX_
M%&HWTR6PLY[>&*,I*QDRA<\J5 &?,/<_='KP ;%<O%?>)M4TYM5TQM,CMY 9
M+2UG@=WFC_A)D$@"EA@_=.,C.:ZBN+U+PKJ5UI#:&B:=-8*K1VMS*[I-:(>
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M-FD%W=7"H))([6$OY:G."QZ#.#@9R<=*;)XBT]=.M+Z/[1<0W3F.(06[R.6
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MIF%L=KE58*-LQR2'7D<<\D4 >H>;'_ST3\Z/-C_YZ)^=>=WMAX:TS2Y[[4?
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M^ M/L-(N[GPWY:ZFX58VMMKP+D!GE!/RJI903S]X=10!Z+YL?_/1/SH\V/\
MYZ)^=8'_  @?A7_H!6?_ '[H_P"$#\*_] *S_P"_= &_YL?_ #T3\Z/-C_YZ
M)^=8'_"!^%?^@%9_]^Z/^$#\*_\ 0"L_^_= &_YL?_/1/SH\V/\ YZ)^=8'_
M  @?A7_H!6?_ '[H_P"$#\*_] *S_P"_= &_YL?_ #T3\Z/-C_YZ)^=8'_"!
M^%?^@%9_]^Z/^$#\*_\ 0"L_^_= &_YL?_/1/SH\V/\ YZ)^=8'_  @?A7_H
M!6?_ '[H_P"$#\*_] *S_P"_= &_YL?_ #T3\Z/-C_YZ)^=8'_"!^%?^@%9_
M]^Z/^$#\*_\ 0"L_^_= &_YL?_/1/SH\V/\ YZ)^=8'_  @?A7_H!6?_ '[H
M_P"$#\*_] *S_P"_= &_YL?_ #T3\Z/-C_YZ)^=8'_"!^%?^@%9_]^Z/^$#\
M*_\ 0"L_^_= &_YL?_/1/SH,T8_C7\ZP/^$#\*_] *S_ ._=<YXN\'^';3^P
MA;Z1:Q^=J\$4FU/O*=V10!Z%YT1_Y:)^='FQ_P#/1/SKAY]*\#Q>*+7P^="A
MDOKA&<E;<[$"KN^9NF2.@&3ZXK%M;SP!<V]W=GPOY=C! ]PESY2.LR*P7@*Q
M*EB1M#A2P/'>@#U+S8_^>B?G1YL?_/1/SKA=)\/:#?7[6=]X&_LZ3R1.CR*D
MB,,X*ED) <<?*?PSS1K6A^&-*U&PL+?P?'?W5ZLKHD/EIM$>W<2791_&* .Z
M\V/_ )Z)^='FQ_\ /1/SKS6Z_P"$'L_#DFK2^%#YL5R;22P$*F<3+RRX#;3A
M07R"05&:=<V?AJ+5K.QMO OVQ;Z-IK2XB> )-&H4EAN<$#YQU S0!Z1YL?\
MST3\Z/-C_P">B?G7GVEZ5X>U>X;[-X$/V-;F6V-VS0A 8Y&C9MN_=C*GMFC6
M],\+:5K$&DVOA&WO[V6W:Y\M&CC^12!@;R-S$GH/2@#T'S8_^>B?G1YL?_/1
M/SKS*9_!$;3PIX1=[Q7MHHK4P!9)9)XS(J8)^4A0=V[&,&H]2D\(:!:F;7?!
M$EB%NHK<D1+*F'5F\P,IP54(VX#D>G- 'J/FQ_\ /1/SH\V/_GHGYUYU?P>"
M;1KM(?"\5V\%Q:VZB%4Q,UQC9M)8#'S#DD4EUIN@V9LHIOA\ZW=[.T$%OOMR
M6VQLY;(DV@84]3F@#T;S8_\ GHGYT>;'_P ]$_.N+T3P]X1UE+I3X8BL[JSF
M\BYMKB-=\;;0PY4D$%6!!![UJ_\ "!^%?^@%9_\ ?N@#?\V/_GHGYT>;'_ST
M3\ZP/^$#\*_] *S_ ._='_"!^%?^@%9_]^Z -_S8_P#GHGYT&:,#_6)_WU6!
M_P ('X5_Z 5G_P!^Z!X$\+ Y&AV8^B4 = KJ_P!TY'J*=533=+LM(M/LNGVT
M=M;[BPCC&!D]35N@ HHHH **** "BBB@ HHHH **** "BBB@ KB(?!VIV?AO
M2;&W?2)[FQ696-[:F5")"3E3PRD X]#GGM7<"B@#R<?":ZCMKJR7^Q[B.:SM
M[:.^N86:XMS'$$+QXZ'(W#YN..M>C06MW+:7EEJ)@>W8>5"T;,7>,H 2^?XL
M[NG;%-UZVU*[T]8-,O5LF>51//@%TA_CV9! ?' )&!UKB[BP\)6]]K8U/2[*
M:PT^.*.2^N=TUS)<OEF0.V6+8,> #G+T :NF^'O$JV=IHVI:C8-HUM;M;.;:
M-A-=)L,:A]V0N <G;U('09%0#PEK]]:Z=IVK7VGO9:9EH)($<2S.(VCC+@\*
M &).,Y([54M/B$=-M-+L9M*U&_D406=Y=1%2([I@!Y7S$;W!^]CIW[UT-[XT
MT^QM->NIXIUM]&PDDI "SR%=WEQG/+9*KVY(% &)8_#IM/U;PIJ,-U&DVF6\
M<-^BYVW31V[1(X]QN(R>H/L*O3^#IY]#UG3GFMV&H:L+X;@2OE^;&Y5ACKA"
M/3FETR9O$/CB2_EMI8(M'M$ACCDZK/.H>0''&Y4"+U/WC5CQ5*!KOA:)I&C0
MW\DLC"4HH1+>5CNQU&=O7B@#(N_ARHO;ZUTUK:UT+57B>_@4%)04;)$;*.%8
M  @GCG&,FG3>!+VQOI;C1]14!+F*_MQJ$DD["X5&BDWL26*M&P'7((IS^.GU
MCPS<ZEHD4D,D.K0V,0ECS]H5GC^8 \@,DF0>PYJCKTMIK_VJZL[*6'5KF[?P
MW#.S]8]Q\V10,_=42GU^6@#<NM#U_5_#FKV>JZA:&YOL+!% I\FW48Z$C<Q.
M,DG\ *LZKI&K+KZZUH<MCY[VHM;B&\#;&4,61E*\@@L_L<]L57M(#=>.#%'$
M$TW0;)8(<$X\^4 D?\!C5?\ OY5&VUS1;&Q?Q=!IMRVI:XRQ1VL3>9+<F/*I
ML&< ;1N)X&.30!'!\-H)Y[?^V3;WT'V*YBG&PJ3//.)F=/[H!+ <Y&13(/A[
M=R:5<VU[>6HN88H(-.GMXMHB6"4RQLZ8 R6V[@.#MXQ6A:_$"*XT>UOY=+N;
M7SM1.GE+B1 %*@F60."5*($DY[[#4<OQ.T-?"E_K\2W#P6]TUI!&R[7NI1C
MC'4@YZ]< G'% $.I>$=<\0K>3:Q<Z<LSV7V."*W5S&%:1'=F+#))\M1C'&#U
MS5_5O FE7B:5;6FF:;!8VVH"\N;86ZA)@(I$QM P3EU//I4EIXFU*\\0Q:3'
MHJ!H;:&?4I'NL?9FD#811M^<C:<_=[5U% '$:[X(%SJEA/IVDZ!-9VMK);K9
MWT/[M"SJVY%52 >#^=1S?#FUUA+\:O:V$?VBSM[>!;-.+5HBY^3(X7YEXZ'!
M!&*[NB@#BK?0/%.FW'VVPN='^U7-I%!>)+&XC$D>0LD>WL0>4/H,&J%O\*=/
M,-Y:7S1W,$FGP6L,S(/-CD1I&9QQ@9,@..G&#Q7HE% %#1+:\L]$L[6_:W>Z
MAB$;M;)LC;' *K_#QCCH.U7Z** (YIXK:)I9Y4BC7J[L% _$U'!?6=UC[/=0
M39)'[N0-TZ]/J*Y;XB)<W&FZ9:PV]W+"]_')<-;VAN=B1@R#*#J"ZH,>]<MJ
M47B -:W.BV%TJQ0;9)ET\VSXEF DQ&!G<%@49&3B3([4 >M4BL&&5((Z<5YC
MIDWBS>L.JP:YL:-7M?LH0%2TKEA*S9^Z@C #9)#'OTHZ-8^)+31%F']NP)#]
MF22!5)<F0F2ZD52,L<R%0>VTD9(H ]=IJ2))NV.K;3M.#G!]*\K>W\8RQ7<J
MS:S"D6PV,).7;S;D@>8<'.R-02#T#<]*?9-XG@,LEQ::X9)0;N""R2.-2S22
M2L)&<$;MOEQ[2,^G)R #U%Y$B7=(ZHN0,L<#). /SHCD26-9(W5T895E.01Z
M@UXG-'XSU.&Y2:TU:2%3%+$MQ&W,B13-NY4=9?)' 4<9"XY/8>$(=0.M76FQ
M7I?1-$=88'C8$3DP1@1D^D9WY'JR_P!TT =Y)(D49DD=41>K,< 4ZO)KB;Q5
M+<ZJ]Y'>"Q\\-YET/*B2(3!RKJV5PL<97S%8+AN02<BOH%]KWB75K>.UU'64
MM@+>+49&90%E*R2RE,9"J=L:#&/OC'7- 'L--+H)%0LH=@2%SR0.O\Q^=>0P
M'X@RR6$6=1!"PM$SI@ &1F;SCP"0N$(;G R 2:V_!R:O<:PVKZO;ZO\ :+;2
M5247<6U6N)&W2B%>F!Y:#CV^I /0T=) 2C*P!()4YY!P1^=.KQZVO-=T?0TO
MECU:VD\R&::SNB$-S<R72O)%"I_V6D&>AW#T->A:)%>6L%P^H37MQ?1Q@S@J
M?)9SER(1W W;?^ @=: ->*_LYYV@ANX))5SNC20%ACKD"K%>3P^$]8T;PW8Z
MM)ON=2A0ND%A9K%/#)/Q(SN=[/L#OP%YQTR!38=0\906$JM::RSSPWD=J/(9
MC'(TD:1,Y)) 4!V&X\ACZ8H ]6:XA42%IHP(R%?+#Y2<'!].H_.FO=VR&0/<
M1+Y> ^7 V9Z9],UPTFGW\?@#Q!.;&ZEO[R[FN!!L)ED59 D?'J8XT/XUSVI:
M!X@BN-0,>F/+)<6,6I74BJ6$U\&F\N(>H1FB/LL2^M 'K O[,J&%W!M(R#Y@
MQC@_U'YBK%>+IH6OPZE+<)IEU(D<FU1Y.WS(UD48 (P-T=C&,XP/-7UJUI/_
M  F>HZKY-P^MVM@TD!DDD5E8J$F:7:2HP2PB3A5'/ [D ]>KF_B%_P DY\2?
M]@V?_P! -<$!XYM=,@_>:S+-):VCSB2-GW2D2,Z97#( !&I9<G/7J:ZWQ*MT
MOP:U07PE%W_8LGG+,X=U?RCD,P !(/&0!F@#6U+2)=6L]$,4B)]CNX;MMV?F
M55.0/?FL.]\"3:GK&ZZ;3%T\7<UT7M[7R[F3S(WC*,PX(P_+=3M&:[.S'^A0
M?]<U_E4^* ./TK2/%MC'8VLNI::;/3H&CC$4;!KPA-D?FYSL X)VYR1VZ5=U
M_2=6U2RT:6W:R34+&[CNY%D9_*9A&ZL 0,XR_'':NCQ1B@#@YO VH:MJ7VO5
M]0B"W%W'<745D7BPL*$0HC [N'8N6R#D# %2VO@>XL98X+>^#:?#K*:G D[O
M)(H*$2*6.2278L"?[QS7;XHQ0!P5[X*N9/%6JZN-+T"_%Y-%+$]^K&6+9$B8
M!"GNA/XUM>*]$O=9CM%MH],NH(RWGV.I0!X9LC@[MI*LIZ8'.3GM71XHQ0!Y
ME;_#&]$/ES:C A6Q$4+1AF$$RW1N(PH;K&ORJ 3D@=JEU#P'K>M75U=WUQIM
MK--'&C):M*R2L)XI"[;NA B(  _B/->D8HQ0!YYJ/PV>2Z\2-I]Y'%;:O8F"
M.VD!VP2LY9R,=%8\X]2:>_@S4!9^79:7X<TV9+JVNE-H'42&*0.%?Y!QP?SK
MT#%&* .?T;1]0BUN]UK5Y[9[NX@BMDBM581Q1H6;JW+$LYYX[5OTN*,4 )VK
MFM4_Y*%X=_Z]+W_VC72XKF]4'_%PO#O_ %YWQ_6#_&@"EKG@N76AXD1YH!'J
MB6ODAU+ -"=V''=2<=.V:P7^'.H&\CO39:%(IO'N'TY6DAMD!A6,;<(3NRNX
M\"O4,4E '->%=$U'P[8P:<19FS,EQ,ZQN_[@N^Y(XP1RH!;))!Z<>F3K7A+7
MKE/$.GZ=<Z<--UYR\S7 ?S;<M$L;[0.'R$R,D8)KO,48H \VU;X9SZCIFH+%
M>10:C+J<MU!.N<&&0KNB?CD$*#[$*:U+SP??74OB)A/;J-2U.RO(<EOE2'R=
MP;CJ?*;&,]17:XIBR1M*\2R*9$ +(#RH/3([=#0!Q.N>#[J_\67>K+IFCZC#
M/;0PJE]-)&T10R$D;48$'>/RILWAOQ(6\06]JVDP6VM%2\K22.\ ^SQPL%3:
M WW"02PZC(KN\48H YW7=!N+KPY:Z9IZV4R6[1A[;48A)%<1*,;&^4[>QW 9
M! K%TGP3?V=E9QN]I;K#K*ZBMI!([Q6\0C*>7&6 /)RW0#+'%=W1B@#@]5\
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MN-.T_P /V$MC>/<"&WWK'+NA>,[L*#GYA^5=W10!B>'M'NM.DU*]U"XBFO\
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M;97DHO'0R1Q3VTD)D4=UWJ-WX58O/&?AVP\00:#<:I"NJSNL:6J@L^Y@" <
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MM+R:$/<6;,T#[B-A9=K<=#D$CFFKIEHFKOJ@1OMCPB!G\QL% <@;<XZGKC-
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M&'N976*-^&1 6(53Z#%/E\$:#(+;9;3VYMK=+6-K6\F@;R4&%1BC@L!_M9H
MQ#XA\33^,-/TJRDTQXYD6ZO()+*0265N>SOYN#(3P!M'<D8'/3W]^TD\NE0Q
M7T4\T3*EVENQBC8J<'?TX_G5>+P=HT&J3:E#'=QW<\HFE=+^=1(PZ%E#[2.
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MM;>XU&\V(T<P?R"K;DC7E3N!+-@8(+G'05G7O@2&\*_9]8@DTU RWUU)*C2
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M;_V:@#JJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGS8) J,;I((-W/4JSNPST Z4 =C_ &EXE_Z%VV_\&(_^(H_M+Q+_ -"[;?\
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M/AG2K==,6&W*KILCRVPWL<.RLK,V3EB0[<G)R<]:UZ2B@!:*2B@!:YOXA?\
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M"A8_)ZCEG[#BNH?Q'JT7PYM]9FCACOY3&KR&%O+B1Y0GFLA(.%0[R,]NN.:
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M*QR">%X]:72/$_B6?Q ;=;ZVGEN[N0)+)%+Y5JA>52-@DP<1V989P09.O)R
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MPMCYLER,XKU"@#!_M+Q+_P!"[;?^#$?_ !%']I>)?^A=MO\ P8C_ .(K>HH
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M[N@?G-1_Q6W]W0/SFKI:* .)BT'Q##J[ZK'8>'%OG!S-F?/( ) Z D  D<G
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M5M:U&YAUW5+&XU7R3J*16>I)J3):6JO'$49X@3E 7R?E(^;KZ 'HG_%;?W=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8U,BJ5#XY .,C/IP/RI]% $<-O#;(4@ACB4G)5%"C/KQ4E%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>modificationno16effectiv002.jpg
<TEXT>
begin 644 modificationno16effectiv002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^_5 &Y_;^C?]!:P_\"4_QH_M_1O^@M8?^!*?XUA_\*P\$?\ 0L:=_P!^J/\
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M/_A6'@C_ *%C3O\ OU1_PK#P1_T+&G?]^J -S^W]&_Z"UA_X$I_C1_;^C?\
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MPK#P1_T+&G?]^J -S^W]&_Z"UA_X$I_C1_;^C?\ 06L/_ E/\:P_^%8>"/\
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M"QIW_?J@#<_M_1O^@M8?^!*?XT?V_HW_ $%K#_P)3_&L/_A6'@C_ *%C3O\
MOU2'X9>!EQGPSIHR<#,5 &[_ &_HW_06L/\ P)3_ !H_M_1O^@M8?^!*?XUA
M?\*Q\#_]"SIO_?JE_P"%8>"/^A8T[_OU0!N?V_HW_06L/_ E/\:/[?T;_H+6
M'_@2G^-8?_"L/!'_ $+&G?\ ?JC_ (5AX(_Z%C3O^_5 &Y_;^C?]!:P_\"4_
MQH_M_1O^@M8?^!*?XUA_\*P\$?\ 0L:=_P!^J/\ A6'@C_H6-._[]4 =!;ZM
MIMW,(;;4+6:4\A(YE8G\ :N5S^E>!_"^B7Z7VF:'9VET@(66*/# $8/Z5T%
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M7UIJCR0"TAT^#5'C+(C1&:;,JD=$<%-Q'0%@3\IKU+:H &!@=!BC R3@9/%
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M%% !1110 4444 <)X&_Y'3QY_P!A*+_T2M=K=R3Q6S-;0B:;("H6VCD@9)[
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M>5MI],A2*J?\+F^'_P#T,*_^ LW_ ,17=$@$ D#/ ]Z-RC=EA\O7GI0!PO\
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M_P#^AA7_ ,!9O_B*[=9X7A$RRQM$?XPP*_G3D=)%W(ZL/53F@#AO^%S?#_\
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MF4,!C;GH.N,5[(9HEE6(R()&&50L,D>PI!<0E]@FC+9Q@,,T <1_PN;X?_\
M0PK_ . LW_Q%'_"YOA__ -#"O_@+-_\ $5W"S1/(\:2(SI]]0P)7ZCM0DT4I
M(CD1R/[K T </_PN;X?_ /0PK_X"S?\ Q%'_  N;X?\ _0PK_P" LW_Q%=W1
M0!PG_"YOA_\ ]#"O_@+-_P#$4?\ "YOA_P#]#"O_ ("S?_$5W=% '"?\+F^'
M_P#T,*_^ LW_ ,11_P +F^'_ /T,*_\ @+-_\17=T4 <)_PN;X?_ /0PK_X"
MS?\ Q%'_  N;X?\ _0PK_P" LW_Q%=W10!PG_"YOA_\ ]#"O_@+-_P#$4?\
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M /T,*_\ @+-_\17=T4 <)_PN;X?_ /0PK_X"S?\ Q%'_  N;X?\ _0PK_P"
MLW_Q%=W10!PG_"YOA_\ ]#"O_@+-_P#$4?\ "YOA_P#]#"O_ ("S?_$5W=%
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M_P +F^'_ /T,*_\ @+-_\17=T4 <)_PN;X?_ /0PK_X"S?\ Q%'_  N;X?\
M_0PK_P" LW_Q%=W10!PG_"YOA_\ ]#"O_@+-_P#$4?\ "YOA_P#]#"O_ ("S
M?_$5W=% '"?\+F^'_P#T,*_^ LW_ ,11_P +F^'_ /T,*_\ @+-_\17=T4 <
M)_PN;X?_ /0PK_X"S?\ Q%'_  N;X?\ _0PK_P" LW_Q%=W10!PG_"YOA_\
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M]GI^=<]:>'Y[3X/O-);::)I=&C55ATTQS@E5)$C;R7]^%R:]4::)-FZ5!O\
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MM)IMC'?-?)9P+=LH1IQ& Y4= 3UQ0^F6#VS6S65N8&<R&,QC:6)R6QZY).:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.2 ,\<^U>A5GZ]_R+VI_]>DO_H!H X+0=6^*'B'0;+5[8^$8X+R(2HDB7(8
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M&15++@LO4#J,5)-XJTR&6*%DU S20^<(DTZX=PFXKEE"$KR#U H Y[9\5_\
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M-A!\K1Y4%\YZ?,OYU&_C33Q:VES%:W\\%U(88I(H,@N'9-O7KE#0!C[/BO\
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MPWA%X;.!YW6-+G<0HR0,D#/%>BV\Z7-O'.BR*KC($D;1L/JK $?0BN?^(?\
MR3CQ)_V#9_\ T T 8&GW7Q4U'3;6^B?P>L=S"DRJR7.0& (!YZ\U9V?%?_GK
MX-_[XN?\:Z7PM_R*.B_]>$'_ *+6M:@#A-GQ7_YZ^#?^^+G_ !HV?%?_ )Z^
M#?\ OBY_QKNZ* .$V?%?_GKX-_[XN?\ &C9\5_\ GKX-_P"^+G_&N[HH X39
M\5_^>O@W_OBY_P :-GQ7_P">O@W_ +XN?\:[NB@#A-GQ7_YZ^#?^^+G_ !HV
M?%?_ )Z^#?\ OBY_QKNZ* .$V?%?_GKX-_[XN?\ &C9\5_\ GKX-_P"^+G_&
MN[IKNL:,[L%102S$X 'K0!PVSXK_ //7P;_WQ<_XT;/BO_SU\&_]\7/^-= ?
M%VAKI-CJAOL65]<+;02&)_FD)("D8RO*G.0,8YJ:Y\2Z1:7MY9SWJI/96ZW-
MPI5L)&3@'.,$GT'/(XY% ',[/BO_ ,]?!O\ WQ<_XT;/BO\ \]?!O_?%S_C7
M0+XKTGR;J2:2XMC;1B65+FVDB<(3@,%902,\<9P>N*EUCQ+I.@([:G=^0J0F
MX8^6S8C#JA/ /\3J/Q^M '-;/BO_ ,]?!O\ WQ<_XT;/BO\ \]?!O_?%S_C7
M47/B#3K601F2:9S"MP%MK>28F,G 8;%.1FGZ/K5EKUDMY8&X:W=5=));:2(.
MK#(*[U&01W% '*;/BO\ \]?!O_?%S_C1L^*__/7P;_WQ<_XUW=% '";/BO\
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M9(E+#NX+*#ZXSWKT.B@#(T;3[BRU#79IE 2\OQ/#@YRGD0ISZ?,C5RGPB_Y
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MSX7L)]*\):-I]TH6XM;&&&4*<@,J 'GOR*UJ* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "LV[ED?6].M$=T39+<OM.-X3:@4^V90W_
M16E5&ZM)'U2QO8=NZ'S(I-QZQ. 3CWW)'^&: .?\2ZH=.U,O'K/V9K:V^U/:
MR2QJ)L-\J ,,_,%D&0>#BMK5KK_B1G4;6X(2%5N@R'B2-<,P]PRY'X@]JDM]
M,:WNK^<WDTC7;!@'5/W6%V@+\O3@<'/.?4U5&BRV_A^+2(+EI8MRQN\P4$0;
MOF0!0!]W*CTS[4 ;5%%% !6?KW_(O:G_ ->DO_H!K0K/U[_D7M3_ .O27_T
MT 8GPR_Y)EX=_P"O&/\ E75URGPR_P"29>'?^O&/^5=70 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;_D4=%_Z\(/_ $6M:U9/A;_D4=%_Z\(/_1:UK4 %%%% !1110 4444 %%%%
M!1110 4444 85O+<2^##=FZE%Q/:M="4'E"X+@#.>!D >PJKH3SZ@T,\6H:E
MBW=1<1W<842AHL\ J#U93GVK2MM,F'A[^RIIO+VQM;I+#@D1C*H>1C=LQGCK
MFK>GVDEE:+!)=2W.W 5Y%4$   #Y0!VH KV$LB:KJ-E([N$9)XBQSA) 1M_!
MD?\  @5I52LK22*\OKJ?9YD\@";3G;&HPH_/<W_ JNT %%%% !1110 4444
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MF_X1_1?^@/I__@,G^%8?C+0M(B\#Z_)'I5BCIIMPRLMN@((C;!!Q0!SWP_\
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MP3_T-&F?]_Q6S_PC^B_] ?3_ /P&3_"C_A']%_Z ^G_^ R?X4 8W_"R_!/\
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MW_"R_!/_ $-&F?\ ?\4?\++\$_\ 0T:9_P!_Q6S_ ,(_HO\ T!]/_P# 9/\
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M_0T:9_W_ !6S_P (_HO_ $!]/_\  9/\*/\ A']%_P"@/I__ (#)_A0!C?\
M"R_!/_0T:9_W_%'_  LOP3_T-&F?]_Q6S_PC^B_] ?3_ /P&3_"C_A']%_Z
M^G_^ R?X4 8W_"R_!/\ T-&F?]_Q1_PLOP3_ -#1IG_?\5L_\(_HO_0'T_\
M\!D_PH_X1_1?^@/I_P#X#)_A0!C?\++\$_\ 0T:9_P!_Q7'6WCGPLOQAO]2;
M7K 63Z+%"LYF&PN)6)7/KCFO2O\ A']%_P"@/I__ (#)_A7&QZ+I7_"YKB#^
MS+/R1X?B<1^0NW=]H<9QC&<=Z -G_A9?@G_H:-,_[_BC_A9?@G_H:-,_[_BM
MG_A']%_Z ^G_ /@,G^%'_"/Z+_T!]/\ _ 9/\* ,;_A9?@G_ *&C3/\ O^*/
M^%E^"?\ H:-,_P"_XK9_X1_1?^@/I_\ X#)_A1_PC^B_] ?3_P#P&3_"@#&_
MX67X)_Z&C3/^_P"*/^%E^"?^AHTS_O\ BMG_ (1_1?\ H#Z?_P" R?X4?\(_
MHO\ T!]/_P# 9/\ "@#&_P"%E^"?^AHTS_O^*XC3?&_A>+XQZWJ;Z[8K8S:9
M!%'.9AL9PW(!]:]0_P"$?T7_ * ^G_\ @,G^%<;>:+I0^+^E0#3+,0MHUPQC
M\A=I(ECP<8ZT ;/_  LOP3_T-&F?]_Q1_P ++\$_]#1IG_?\5L_\(_HO_0'T
M_P#\!D_PH_X1_1?^@/I__@,G^% &-_PLOP3_ -#1IG_?\5Q'PQ\;^%]+TK6X
M[_7;&W>;6[J:-9)@"T;$;6'L:]0_X1_1?^@/I_\ X#)_A7&_##1=*N/!:R3:
M99RO]MNQN>!6.!<2 #)'I0!L_P#"R_!/_0T:9_W_ !1_PLOP3_T-&F?]_P 5
ML_\ "/Z+_P! ?3__  &3_"C_ (1_1?\ H#Z?_P" R?X4 8W_  LOP3_T-&F?
M]_Q1_P ++\$_]#1IG_?\5L_\(_HO_0'T_P#\!D_PH_X1_1?^@/I__@,G^% &
M-_PLOP3_ -#1IG_?\4?\++\$_P#0T:9_W_%;/_"/Z+_T!]/_ / 9/\*/^$?T
M7_H#Z?\ ^ R?X4 8W_"R_!/_ $-&F?\ ?\4?\++\$_\ 0T:9_P!_Q6S_ ,(_
MHO\ T!]/_P# 9/\ "C_A']%_Z ^G_P#@,G^% &-_PLOP3_T-&F?]_P 4?\++
M\$_]#1IG_?\ %;/_  C^B_\ 0'T__P !D_PH_P"$?T7_ * ^G_\ @,G^% &-
M_P ++\$_]#1IG_?\4?\ "R_!/_0T:9_W_%;/_"/Z+_T!]/\ _ 9/\*/^$?T7
M_H#Z?_X#)_A0!C?\++\$_P#0T:9_W_%8'CCX@>$;_P !Z]:6GB+3IKB:PFCC
MC28%G8H0 !ZUW'_"/Z+_ - ?3_\ P&3_  KD/BEHNE6_PRUZ:#3+.*5;?*ND
M"J1\PZ$"@"3P[\1/!UMX8TF";Q)IL<L5G"CHTX!5@@!!_&M+_A9?@G_H:-,_
M[_BM"PT#1FTZU)TBP),*$DVR>@]JL_\ "/Z+_P! ?3__  &3_"@#&_X67X)_
MZ&C3/^_XH_X67X)_Z&C3/^_XK9_X1_1?^@/I_P#X#)_A1_PC^B_] ?3_ /P&
M3_"@#&_X67X)_P"AHTS_ +_BC_A9?@G_ *&C3/\ O^*V?^$?T7_H#Z?_ . R
M?X4?\(_HO_0'T_\ \!D_PH QO^%E^"?^AHTS_O\ BC_A9?@G_H:-,_[_ (K9
M_P"$?T7_ * ^G_\ @,G^%'_"/Z+_ - ?3_\ P&3_  H QO\ A9?@G_H:-,_[
M_BC_ (67X)_Z&C3/^_XK9_X1_1?^@/I__@,G^%'_  C^B_\ 0'T__P !D_PH
M QO^%E^"?^AHTS_O^*/^%E^"?^AHTS_O^*V?^$?T7_H#Z?\ ^ R?X4?\(_HO
M_0'T_P#\!D_PH QO^%E^"?\ H:-,_P"_XH_X67X)_P"AHTS_ +_BMG_A']%_
MZ ^G_P#@,G^%'_"/Z+_T!]/_ / 9/\* ,;_A9?@G_H:-,_[_ (H_X67X)_Z&
MC3/^_P"*V?\ A']%_P"@/I__ (#)_A1_PC^B_P#0'T__ ,!D_P * ,;_ (67
MX)_Z&C3/^_XH_P"%E^"?^AHTS_O^*V?^$?T7_H#Z?_X#)_A1_P (_HO_ $!]
M/_\  9/\* ,;_A9?@G_H:-,_[_BC_A9?@G_H:-,_[_BMG_A']%_Z ^G_ /@,
MG^%'_"/Z+_T!]/\ _ 9/\* ,;_A9?@G_ *&C3/\ O^*/^%E^"?\ H:-,_P"_
MXK9_X1_1?^@/I_\ X#)_A1_PC^B_] ?3_P#P&3_"@#-L_'_A+4+R&SM/$.GS
MW,SA(XDF!9V/0 5T=4(M$TF"598=+LHY$.5=+= 5/J"!5^@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\;?\B%XB_[!ES_ .BFK=K"
M\;?\B%XB_P"P9<_^BFH @\)6T=Y\-=#M9@3%-I$$;X/.#"H/\ZG>VU>]M8].
MO([<1!E$]TLF?-12#PF."V,$9P,G!-)X'_Y$'PY_V#+;_P!%+6]0!D:C%J,F
MKV$MM:PR06[LSN\^T_,I7@;3TSGK45YI5QJ/B-)[@.EG!;E('@NGC?>Q!?(7
M'&%4#GU]:W** ,*QM-2L=!OK1+:!Y(_-^Q)-.9%D!R560D9 R<=^*T]-^U#3
M+47L,$-UY2^;% <QHV.0I/8'I5JB@!#G!P,GL*Y5-!U&32M.4K!;WEM-$LP$
MA9985E5SS@<C!(X]1QN)KJZ* "BBB@ HHHH **** "BFM(B%0SJI8X4$XR?:
ME9U12SL%4<DDX H 6BD!!&000><TB.DB!T964]"IR* '449&<=Z* "BBB@ H
MHHH **** "BBD)"@DD #DDT +12*RNH92&4C((.0:1'20$HRL <'!S@^E #J
M*:'0N4#+O R5SR!3L@$ GKTH **:[I&A=V55'4L< 4[( SVH **:CK(@=&#*
M>A4Y!IU !112 @]"#B@!:*1F5%+,0J@9))P *6@ HHHH **** "BB@D 9)P*
M "BD!!&0<CVI: "BBB@ HHHH ***:)$9V0.I9>J@\B@!U%->1(D+R.J*.I8X
M%#R)&NYW55]6.!0 ZBD)"J68@ <DGM0K*ZAD8,IY!!R#0 M%-21) 2CJP!P=
MIS@^E.H *XJ/_DMUS_V+D7_I3)7:UQ4?_);KG_L7(O\ TIDH [6BBB@ HHHH
M **** "N*O?^2S:1_P!@2Y_]&QUVM<5>_P#)9M(_[ ES_P"C8Z .UHHHH *X
MKX5_\B.G_7]>?^E$E=K7%?"O_D1T_P"OZ\_]*)* .UHHHH **** "BBB@ HH
MHH **** "BBB@ KC?BQ_R2SQ!_U[?^S"NRKC?BQ_R2SQ!_U[?^S"@#J=/_Y!
MEK_UQ3^0JS5;3_\ D&6O_7%/Y"K- !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVUE++) MC%?:G=Q[(TE&X1(/XR?X$!.>.2>!DU+=VJRZCH]A=G[1"D<DC>:
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M1KH1C[1J(C7Y('E6-C$9"=B_,1A2,9[CFM.Y%[;010Z79VC(J;0LL[1! !@
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MG\A5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L/QH,^
M!/$(_P"H9<_^BFK<K%\7C/@G7AZZ=<?^BVH C\$?\B!X=_[!EM_Z*6I+?Q$L
MRK)+IE];VYF,!GE\HJKAS'@A7)QN&,XQWZ<U'X(_Y$'P[_V#+;_T4M4]%LOM
MWFI=2ZFL2WDUP+6:#RHB#.SH<[ QZAL;C[CM0!TKW-O%,D,D\22R?<1G 9OH
M.].:6-9%C:10[9VJ3R<=<"N/N=.E%SJ4-Z;IC<RNRF.P$PE0_=&\ [=HPOS$
M8QD<<U:UNU@E30X+VSO;L0R!YV\AI&V^2ZD.4!!RQ7*@X.>XH Z&2\A6S>YC
MDCD0 [2)  Q';/3KQ3[65Y[2&:2+RGD16:/<&V$C)&1P<>HJE(UA;:>K_P!G
MOY$Q!,4=FS'.."R!<C@ <CL*R;6.>[\#06$=K<K<06L$<T$L;1&0*%WQ@M@?
M, RYSCGK0!T<-S!<[_(GCEV':VQPVT^AQT-5+_5X;,JJ&.:7SHHY(EE = [A
M0V/JPJA"D=UJ%I)IME+9^0K+++);&$;=I C (&[YMK<9 V=>><>\@B&B:?:#
M1+I[^TN;:65DMS\A25&DD$F,/D!C\I+-GD=< ';U'/<0VL?F7$T<48.-TC!1
M^9IX.0#SSZUCWRK;ZR+R[M9+BV\@1Q&. S&%]QW?*H)^8%>0/X.<<9 -.XNH
M+2U>YGE5(47<SD\8JGI6J2:FID^RB*(J&5A.CGGH&"G@_G]:S#;>3X8U))+"
M403O(;:S$7F-&K#@;1G&6RV/X=V.,5I:&;?[ BP6DEL555=7MS$20/<#/UH
MTZQ7\1+')>>;IE\D%G(4GN#Y11 %#;L!RQ&U@>!^%;5<K!9?VCJ^L07$NJ16
MMQ<9,'D;(94$4:'YRF[DJ1PPR!Z&@#I9;JW@:-9IXHVD.$#N 6/H,]:<\L<;
M(KR*K.<*"<%OI7*WUC-'K&HR73SF&[9?*,=@+E3&$52A^4E?F#'!POS9SDG"
MZO9Q'PYIEA<VE]=%'@)S"SR!%=2VYH\X.T<\\\]: .G%U;F%IA/$8E)5G#C
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M1110 4444 %<5>_\EFTC_L"7/_HV.NUKBKW_ )+-I'_8$N?_ $;'0!VM%%%
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M9E099@!ZDTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5P6G?\EQUO_L#6_P#Z,:N]
MK@[/CXZ:GCC.@PD^Y\YJ .\HHHH **** "BBB@ K@K[_ )+II/\ V I__1JU
MWM<'J?'QMT$C@G2+D$^HWK0!WE%%% !7GGP/_P"22Z1_OS_^CGKT.N#^#BJG
MPVLT4 *MS=  = //>@#O**** "BBB@ HHHH **** "BBB@ HHHH *X;XQ?\
M))]?_P"N4?\ Z-2NYKC/BRH;X6>( P!'V<'G_?6@#J=,_P"059_]<$_]!%6J
MK:=_R#+3_KBG_H(JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1\O:O 96^7!#<8'//?-4;O1K2>>Y:YTRXNKI+&Q5[F2Q<O(5D)D^8 Y;:4R
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"6G_ "734O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/Y"K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445C:U!B[T^Z6:X5A=1Q[%F94().
M<J#@_CGI0!LT50U6*V:V\V]N7AM(<M(%<H'[ $CDCV[G%,T..>+3R)A,J-(S
M01SN6D2,GY0Q/.>O!Z @=J -*BBB@ HHHH *Q?%[B/P5KSMG:NG7!./^N;5M
M5A>-O^1"\1?]@RY_]%-0 G@?_D0?#G_8,MO_ $4M;U<UX4N/LGPST2Y"[O*T
M>"3;ZXA!Q4T6CWD]A;W']LWBW[>7))*'S&PR"RB/[H4C(&!GW)Z@&_16+!;M
M_P )7=YN;HQQV\4JQ&9B@9VE!^7..BKQVQ2>(%$^EI=6]W.F)(E5[><J&#2*
M#T.#P30!MT5SVLQ7EF='73KF<RBY92DDI83KY4CE&)]2H /;]*ETBX6ZUF]E
MAN)Y+=[>&5(Y')",S2!AM/W3\H!';% &Y117*X<6,6LK<3_:VU!4):1MOEM<
M"(IMSMP%/''4 ]: .JHK"ELQJ^IZC'///&MN$B@\J5D\LE=QD&",GY@.<_=]
MSFO?22:CX/M-3DFGBG-M%-B"5HU+,%)S@C(Z\'CF@#I:*ANK=;N PO)*BMC)
MBD*-_P!]#D?A6/8F23P+;L9IA)]@5O-$AWY"9SNZY]Z -ZBN/TV^FBOM&"G5
M4CN@1.UZ2T3?NR0 3DARV,= 1N[XKL* "BN-\2:I%8ZQ*Z:M]GEL[473VSW0
M43G=\J!2<<JD@/NRFM^;4Y9IH8=+BAN6DA$YDDE*(L9^Z> 22W./]T\],@&G
M17,:9J-W;_VA&]LQNY-2,$,$ER60'R4<X<@D)@.PX[XP#Q4]E+?'Q7+'>0B+
M-F&_=7#21/\ /C(! VL.<\=QR>P!T%%9.D22O?ZJ)X1%,)T+!;AI5/[M<8RH
MV\ 9 '7)[U7L;S6I=7U*)K:S:WBNE12;IMR(8T/ \OD\DXSU.,]Z -ZBLG69
M)8Y]//DAX!=1@LMPT;*Q.T?*%(8<\@D5-?WT\%U;V=G;I-<SJ[CS)-B(BX#,
M2 3U90 !SGMB@#0HK#N]<O+2PN7-A%)>6TD:O MQA75R &5BOOC! Y!YQ@FU
M9W]T;U[._MX(91$)E:&4NI&<$'*K@CCZY[4 :5%<[8>)Q=ZC:VS?872Y++&U
MI=-+@A2V<E%!&%/(/!QZYJW-$(O%5G(CS#SK>;>GFL4.TQX.W.T'D\X[T :]
M%%9VLK=O:1BU69E\T>>L#A)3'@YV$D '.W/(.,X.<4 :-%<Q;WQTZWU*>WFN
MKE83&39WS.CP YSAF!+ ]0>1D$9XXV?MLRZVMB\"")X&F242$L=I4$%<<??Z
MY/2@"]16':ZMJUW?75NNE0(MI.(I96NSM?*JWR?)DD!N<@#/ )Y(CU#7KZWL
M-0U"STZ.YM+$2;@T^R24QYW[1M(X((Y(S@^V0#H**P+_ ,1_8KF.R<V$-WY"
MS2_:+HHBAB0 IVY;E6[#'Z5H:1J::M8_:$55*NT;!'WKD'JK=P>H/OR <B@"
M_15'6+F6TTR22W(69W2)&89",[A Q'<#=G'M5>+1I;>YM9H=4O6V.6N%FE\P
M3C:PQ@\)\Q#?* .,8H UJ*YP>* -22W)L)(7N/LX,%TSN"6P,C8%SGJN>.>N
M*L1:IJUS?:A;P:;:A;.<1>9)=L!+E%<8PA(.'&<]#TSV -NBL&Y\1JEI9S0F
MTC:Y5CY5W.4=2N 0%56+8.0<<#WS4L.O?:=*M+F"W62>ZG:WCC$GR%U+ACOQ
M]T"-CG&2!TR<4 ;-%4+.XU-KN2&]LH(XU0,D\,Y<,23E2"H((_'K4&B/*\^J
MB>$13+> .%N&E4GR8R"N5&T8(X QG)[T :U%8-A>:U+JNIQ/;6;6\5XJ*3=-
MN1/*C/ \OG[Q.,]21GO5[^T98]5N;:XBAAMXX!/%,93\X'#Y&W VG&>3PP]:
M -"BJ>E75Q?:9!=75LMM)*N_RE<OM!Z9)4'.,9&..E7* "BLO2]]W#?SR32'
MSKF6-5#$>4J,8L+Z?<+9]6-0Z !!83S3W<TA-W-$&N)BP 69T0#)XX 'OQ0!
MM45DL\H\5PI)" C6DIBD6X8Y :+=NCV@9RPP<G@'UJ2XOKQ[V6UT^V@D:%5:
M5YY2B@MG"C"DDX&3TQD=>P!I45@77B*2Q@M$O8+:SOKGS2(Y[K$:JC $[]O.
M=RD#&>>V#49\3R-I-Y=6UM;W4]HZJZ0W.4D#8P4?;UYQ@@<CKC!(!T=%9MG?
M7;7WV._MH8I6B\Y#!,9%(! (.57!&1]<]JS;+Q-/=ZI!:&VM8VD=E>![EDN(
MU )W;&0;N@SM)QG()'- '245BW&M74&F:K="SA:33G<-'YY =%0/D'9UP>F.
MO>I=7U.\T^XL8[;3UNQ=RF$?O]A5MC."<@C;A#DYSZ ]* -6BL2_UR72[>W6
M^2SAN[AV5 UR1$ !DL7*Y].,'DCMR)=(UF/5S<P$P-)"%+/;3>9&P;.,-@$'
MY3D=N/6@#6HK.T*:2;24$S,\D,DMN78Y+^7(T>X^YVY_&M&@ KB() _QPO%
M.4\/1 _^!#G^M=O7"6G_ "734O\ L 0_^CFH [NBBB@ HHHH **** "N(U"0
M)\:=%4YR^C7*C_OY&?Z5V]<)JG_);/#_ /V";K_T): .[HHHH *XCX32"7P%
M%(H(#WMVPS[W$E=O7"?![_DG-K_U]77_ */>@#NZ*** "BBB@ HHHH ****
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MY6Q4! )'R!<AMV[G_P =K4UD(=1C-\E\]EY)\L6@E.)<\[O+YSC&T]/O=\4
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M@#=HK%M[9=+UVVMK>2<PW%M*TBRS-)ED:/#?,3SAVR>_'I6U0 4444 %%%%
M!1110 4444 %%%% !6;J6DOJ4L+?VE=VRQ,KJD(BQN!.#\R,>_KBM*B@#+O]
M%^WFR9]0NTDM,LK((SO; &YE9"NX8." ,9-7+2VDMHBDEW/=,6W>9-M!^GRJ
M!C\*L44 %%%% !1110 5A>-O^1"\1?\ 8,N?_135NUA>-O\ D0_$7_8,N?\
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M=0W=Q:7 01M)#M.] <@,&5@<$G!QD9//)JS:V[6T.QKB:=LDF24C<?R  ^@
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M_P 36/4#>7#,D)A\HA-A!())^7.<@'KCVJM::#]G%HDNIWUU#:8,4<YC/(&
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M .UHHHH *XKX5_\ (CI_U_7G_I1)7:UQ7PK_ .1'3_K^O/\ THDH [6BBB@
MHHHH **** "BBB@ HHHH **** "N-^+'_)+/$'_7M_[,*[*N-^+'_)+/$'_7
MM_[,* .IT_\ Y!EK_P!<4_D*LU6T_P#Y!EK_ -<4_D*LT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5A>-O\ D0O$7_8,N?\ T4U;M87C
M;_D0O$7_ &#+G_T4U ">!_\ D0?#G_8,MO\ T4M;U8/@?_D0?#G_ &#+;_T4
MM;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<5'_ ,ENN?\ L7(O_2F2
MNUKBH_\ DMUS_P!BY%_Z4R4 =K1110 4444 %%%% !7%7O\ R6;2/^P)<_\
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MO&W_ "(7B+_L&7/_ **:MVL+QM_R(7B+_L&7/_HIJ $\#_\ (@^'/^P9;?\
MHI:WJP? _P#R(/AS_L&6W_HI:WJ "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5A>-O^1"\1?]@RY_\ 135NUA>-O^1"\1?]@RY_
M]%-0 G@?_D0?#G_8,MO_ $4M;U8/@?\ Y$'PY_V#+;_T4M;U !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N*C_Y+=<_]BY%_Z4R5VM<5
M'_R6ZY_[%R+_ -*9* .UHHHH **** "BBB@ KBKW_DLVD?\ 8$N?_1L==K7%
M7O\ R6;2/^P)<_\ HV.@#M:*** "N*^%?_(CI_U_7G_I1)7:UQ7PK_Y$=/\
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M!\.?]@RV_P#12UO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q4?_);K
MG_L7(O\ TIDKM:XJ/_DMUS_V+D7_ *4R4 =K1110 4444 %%%% !7%7O_)9M
M(_[ ES_Z-CKM:XJ]_P"2S:1_V!+G_P!&QT =K1110 5Q7PK_ .1'3_K^O/\
MTHDKM:XKX5_\B.G_ %_7G_I1)0!VM%%% !1110 4444 %%%% !1110 4444
M%<;\6/\ DEGB#_KV_P#9A795QOQ8_P"26>(/^O;_ -F% '4Z?_R#+7_KBG\A
M5FJVG_\ (,M?^N*?R%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *PO&W_(A>(O^P9<_^BFK=K"\;?\ (A>(O^P9<_\ HIJ $\#_ /(@
M^'/^P9;?^BEK>K!\#_\ (@^'/^P9;?\ HI:WJ "BBB@ HHHH **** "BBB@
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MV5<;\6/^26>(/^O;_P!F% '4Z?\ \@RU_P"N*?R%6:K:?_R#+7_KBG\A5F@
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M25VM<5\*_P#D1T_Z_KS_ -*)* .UHHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %[?^S"NRKC?BQ_R2SQ!_P!>W_LPH ZG3_\ D&6O_7%/Y"K-5M/_ .09:_\
M7%/Y"K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %87C;
M_D0O$7_8,N?_ $4U;M87C;_D0O$7_8,N?_134 )X'_Y$'PY_V#+;_P!%+6]6
M#X'_ .1!\.?]@RV_]%+6]0 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KBH_^2W7/_8N1?^E,E=K7%1_\ENN?^Q<B_P#2F2@#M:*** "B
MBB@ HHHH *XJ]_Y+-I'_ &!+G_T;'7:UQ5[_ ,EFTC_L"7/_ *-CH [6BBB@
M KBOA7_R(Z?]?UY_Z425VM<5\*_^1'3_ *_KS_THDH [6BBB@ HHHH ****
M"BBB@ HHHH **** "N-^+'_)+/$'_7M_[,*[*N-^+'_)+/$'_7M_[,* .IT_
M_D&6O_7%/Y"K-5M/_P"09:_]<4_D*LT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5A>-O^1"\1?\ 8,N?_135NUA>-O\ D0O$7_8,N?\
MT4U ">!_^1!\.?\ 8,MO_12UO5@^!_\ D0?#G_8,MO\ T4M;U !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<5'_R6ZY_[%R+_ -*9*[6N*C_Y+=<_]BY%
M_P"E,E ':T444 %%%% !1110 5Q5[_R6;2/^P)<_^C8Z[6N*O?\ DLVD?]@2
MY_\ 1L= ':T444 %<5\*_P#D1T_Z_KS_ -*)*[6N*^%?_(CI_P!?UY_Z424
M=K1110 4444 %%%% !1110 4444 %%%% !7&_%C_ ))9X@_Z]O\ V85V5<;\
M6/\ DEGB#_KV_P#9A0!U.G_\@RU_ZXI_(59JMI__ "#+7_KBG\A5F@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+QM_R(7B+_L&7/_HI
MJW:PO&W_ "(7B+_L&7/_ **:@!/ _P#R(/AS_L&6W_HI:WJP? __ "(/AS_L
M&6W_ **6MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 5Q4?_);KG_L7(O_ $IDKM:XJ/\ Y+=<_P#8N1?^E,E ':T444 %%%%
M!1110 5Q5[_R6;2/^P)<_P#HV.NUKBKW_DLVD?\ 8$N?_1L= ':T444 %<5\
M*_\ D1T_Z_KS_P!*)*[6N*^%?_(CI_U_7G_I1)0!VM%%% !1110 4444 %%%
M% !1110 4444 %<;\6/^26>(/^O;_P!F%=E7&_%C_DEGB#_KV_\ 9A0!U.G_
M /(,M?\ KBG\A5FJVG_\@RU_ZXI_(59H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K"\;?\B%XB_[!ES_ .BFK=K"\;?\B%XB_P"P9<_^
MBFH 3P/_ ,B#X<_[!EM_Z*6MZL'P/_R(/AS_ +!EM_Z*6MZ@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N*C_ .2W7/\ V+D7_I3)7:UQ4?\ R6ZY_P"Q
M<B_]*9* .UHHHH **** "BBB@ KBKW_DLVD?]@2Y_P#1L==K7%7O_)9M(_[
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M35NUA>-O^1"\1?\ 8,N?_134 )X'_P"1!\.?]@RV_P#12UO5@^!_^1!\.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KBH_\ DMUS_P!BY%_Z4R5VM<5'_P ENN?^Q<B_]*9* .UHHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?^N*?R%6:K:?_P @RU_ZXI_(59H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K"\;?\B%XB_[!ES_Z*:MVL+QM_P B%XB_[!ES_P"BFH 3
MP/\ \B#X<_[!EM_Z*6MZL'P/_P B#X<_[!EM_P"BEK>H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KBH_^2W7/_8N1?\ I3)7:UQ4?_);KG_L7(O_ $ID
MH [6BBB@ HHHH **** "N*O?^2S:1_V!+G_T;'7:UQ5[_P EFTC_ + ES_Z-
MCH [6BBB@ KBOA7_ ,B.G_7]>?\ I1)7:UQ7PK_Y$=/^OZ\_]*)* .UHHHH
M**** "BBB@ HHHH **** "BBB@ KC?BQ_P DL\0?]>W_ +,*[*N-^+'_ "2S
MQ!_U[?\ LPH ZG3_ /D&6O\ UQ3^0JS5;3_^09:_]<4_D*LT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5A>-O^1"\1?]@RY_]%-6[6%X
MV_Y$+Q%_V#+G_P!%-0 G@?\ Y$'PY_V#+;_T4M;U8/@?_D0?#G_8,MO_ $4M
M;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<5'_R6ZY_[%R+_P!*9*[6
MN*C_ .2W7/\ V+D7_I3)0!VM%%% !1110 4444 %<5>_\EFTC_L"7/\ Z-CK
MM:XJ]_Y+-I'_ &!+G_T;'0!VM%%% !7%?"O_ )$=/^OZ\_\ 2B2NUKBOA7_R
M(Z?]?UY_Z424 =K1110 4444 %%%% !1110 4444 %%%% !7&_%C_DEGB#_K
MV_\ 9A795QOQ8_Y)9X@_Z]O_ &84 =3I_P#R#+7_ *XI_(59JMI__(,M?^N*
M?R%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!_\ D0?#G_8,MO\ T4M;U8/@?_D0?#G_ &#+;_T4M;U !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XJ/_ )+=<_\ 8N1?
M^E,E=K7%1_\ );KG_L7(O_2F2@#M:*** "BBB@ HHHH *XJ]_P"2S:1_V!+G
M_P!&QUVM<5>_\EFTC_L"7/\ Z-CH [6BBB@ KBOA7_R(Z?\ 7]>?^E$E=K7%
M?"O_ )$=/^OZ\_\ 2B2@#M:*** "BBB@ HHHH **** "BBB@ HHHH *XWXL?
M\DL\0?\ 7M_[,*[*N-^+'_)+/$'_ %[?^S"@#J=/_P"09:_]<4_D*LU6T_\
MY!EK_P!<4_D*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5A>-O^1"\1?]@RY_\ 135NUA>-O^1"\1?]@RY_]%-0 G@?_D0?#G_8,MO_
M $4M;U8/@?\ Y$'PY_V#+;_T4M;U !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPH ZG3_^09:_]<4_D*LU6T__ )!EK_UQ3^0JS0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6%XV_Y$+Q%_P!@RY_]%-6[6%XV_P"1"\1?
M]@RY_P#134 )X'_Y$'PY_P!@RV_]%+6]6#X'_P"1!\.?]@RV_P#12UO4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO&W_(A>(O^
MP9<_^BFK=K"\;?\ (A>(O^P9<_\ HIJ $\#_ /(@^'/^P9;?^BEK>K!\#_\
M(@^'/^P9;?\ HI:WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XJ/_DM
MUS_V+D7_ *4R5VM<5'_R6ZY_[%R+_P!*9* .UHHHH **** "BBB@ KBKW_DL
MVD?]@2Y_]&QUVM<5>_\ )9M(_P"P)<_^C8Z .UHHHH *XKX5_P#(CI_U_7G_
M *425VM<5\*_^1'3_K^O/_2B2@#M:*** "BBB@ HHHH **** "BBB@ HHHH
M*XWXL?\ )+/$'_7M_P"S"NRKC?BQ_P DL\0?]>W_ +,* .IT_P#Y!EK_ -<4
M_D*LU6T__D&6O_7%/Y"K- !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$'PY_P!@RV_]%+6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N*C_P"2W7/_ &+D7_I3)7:UQ4?_ "6ZY_[%R+_TIDH
M[6BBB@ HHHH **** "N*O?\ DLVD?]@2Y_\ 1L==K7%7O_)9M(_[ ES_ .C8
MZ .UHHHH *XKX5_\B.G_ %_7G_I1)7:UQ7PK_P"1'3_K^O/_ $HDH [6BBB@
M HHHH **** "BBB@ HHHH **** "N-^+'_)+/$'_ %[?^S"NRKC?BQ_R2SQ!
M_P!>W_LPH ZG3_\ D&6O_7%/Y"K-5M/_ .09:_\ 7%/Y"K- !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %87C;_D0O$7_8,N?_ $4U;M87
MC;_D0O$7_8,N?_134 )X'_Y$'PY_V#+;_P!%+6]6#X'_ .1!\.?]@RV_]%+6
M]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7%1_\ );KG_L7(O_2F2NUK
MBH_^2W7/_8N1?^E,E ':T444 %%%% !1110 5Q5[_P EFTC_ + ES_Z-CKM:
MXJ]_Y+-I'_8$N?\ T;'0!VM%%% !7%?"O_D1T_Z_KS_THDKM:XKX5_\ (CI_
MU_7G_I1)0!VM%%% !1110 4444 %%%% !1110 4444 %<;\6/^26>(/^O;_V
M85V5<;\6/^26>(/^O;_V84 =3I__ "#+7_KBG\A5FJVG_P#(,M?^N*?R%6:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO&W_(A>(O\
ML&7/_HIJW:PO&W_(A>(O^P9<_P#HIJ $\#_\B#X<_P"P9;?^BEK>K!\#_P#(
M@^'/^P9;?^BEK>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBH_^2W7/
M_8N1?^E,E=K7%1_\ENN?^Q<B_P#2F2@#M:*** "BBB@ HHHH *XJ]_Y+-I'_
M &!+G_T;'7:UQ5[_ ,EFTC_L"7/_ *-CH [6BBB@ KBOA7_R(Z?]?UY_Z425
MVM<5\*_^1'3_ *_KS_THDH [6BBB@ HHHH **** "BBB@ HHHH **** "N-^
M+'_)+/$'_7M_[,*[*N-^+'_)+/$'_7M_[,* .IT__D&6O_7%/Y"K-5M/_P"0
M9:_]<4_D*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MA>-O^1"\1?\ 8,N?_135NUA>-O\ D0O$7_8,N?\ T4U ">!_^1!\.?\ 8,MO
M_12UO5@^!_\ D0?#G_8,MO\ T4M;U !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L+QM_R(7B+_L&7/_HIJW:PO&W_ "(7B+_L&7/_
M **:@!/ _P#R(/AS_L&6W_HI:WJP? __ "(/AS_L&6W_ **6MZ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N*C_Y+=<_]BY%_P"E,E=K7%1_\ENN?^Q<
MB_\ 2F2@#M:*** "BBB@ HHHH *XJ]_Y+-I'_8$N?_1L==K7%7O_ "6;2/\
ML"7/_HV.@#M:*** "N*^%?\ R(Z?]?UY_P"E$E=K7%?"O_D1T_Z_KS_THDH
M[6BBB@ HHHH **** "BBB@ HHHH **** "N-^+'_ "2SQ!_U[?\ LPKLJXWX
ML?\ )+/$'_7M_P"S"@#J=/\ ^09:_P#7%/Y"K-5M/_Y!EK_UQ3^0JS0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK"\;?\B%XB_[!ES_ .BFK=K"\;?\B%XB_P"P9<_^BFH 3P/_ ,B#X<_[!EM_
MZ*6MZL'P/_R(/AS_ +!EM_Z*6MZ@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N*C_ .2W7/\ V+D7_I3)7:UQ4?\ R6ZY_P"Q<B_]*9* .UHHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5Q4?\ R6ZY_P"Q<B_]*9*[6N*C_P"2W7/_
M &+D7_I3)0!VM%%% !1110 4444 %<5>_P#)9M(_[ ES_P"C8Z[6N*O?^2S:
M1_V!+G_T;'0!VM%%% !7%?"O_D1T_P"OZ\_]*)*[6N*^%?\ R(Z?]?UY_P"E
M$E ':T444 %%%% !1110 4444 %%%% !1110 5QOQ8_Y)9X@_P"O;_V85V5<
M;\6/^26>(/\ KV_]F% '4Z?_ ,@RU_ZXI_(59JMI_P#R#+7_ *XI_(59H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\;?\ (A>(O^P9
M<_\ HIJW:PO&W_(A>(O^P9<_^BFH 3P/_P B#X<_[!EM_P"BEK>K!\#_ /(@
M^'/^P9;?^BEK>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBH_\ DMUS
M_P!BY%_Z4R5VM<5'_P ENN?^Q<B_]*9* .UHHHH **** "BBB@ KBKW_ )+-
MI'_8$N?_ $;'7:UQ5[_R6;2/^P)<_P#HV.@#M:*** "N*^%?_(CI_P!?UY_Z
M425VM<5\*_\ D1T_Z_KS_P!*)* .UHHHH **** "BBB@ HHHH **** "BBB@
M KC?BQ_R2SQ!_P!>W_LPKLJXWXL?\DL\0?\ 7M_[,* .IT__ )!EK_UQ3^0J
MS5;3_P#D&6O_ %Q3^0JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6%XV_Y$+Q%_V#+G_P!%-6[6%XV_Y$+Q%_V#+G_T4U ">!_^1!\.
M?]@RV_\ 12UO5@^!_P#D0?#G_8,MO_12UO4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Q4?_ "6ZY_[%R+_TIDKM:XJ/_DMUS_V+D7_I3)0!VM%%% !1
M110 4444 %<5>_\ )9M(_P"P)<_^C8Z[6N*O?^2S:1_V!+G_ -&QT =K1110
M 5Q7PK_Y$=/^OZ\_]*)*[6N*^%?_ "(Z?]?UY_Z424 =K1110 4444 %%%%
M!1110 4444 %%%% !7&_%C_DEGB#_KV_]F%=E7&_%C_DEGB#_KV_]F% '4Z?
M_P @RU_ZXI_(59JMI_\ R#+7_KBG\A5F@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L+QM_R(7B+_ +!ES_Z*:MVL+QM_R(7B+_L&7/\
MZ*:@!/ __(@^'/\ L&6W_HI:WJP? _\ R(/AS_L&6W_HI:WJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *XJ/_DMUS_V+D7_I3)7:UQ4?_);KG_L7(O\
MTIDH [6BBB@ HHHH **** "N*O?^2S:1_P!@2Y_]&QUVM<5>_P#)9M(_[ ES
M_P"C8Z .UHHHH *XKX5_\B.G_7]>?^E$E=K7%?"O_D1T_P"OZ\_]*)* .UHH
MHH **** "BBB@ HHHH **** "BBB@ KC?BQ_R2SQ!_U[?^S"NRKC?BQ_R2SQ
M!_U[?^S"@#J=/_Y!EK_UQ3^0JS5;3_\ D&6O_7%/Y"K- !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %87C;_D0O$7_ &#+G_T4U;M87C;_
M )$+Q%_V#+G_ -%-0 G@?_D0?#G_ &#+;_T4M;U8/@?_ )$'PY_V#+;_ -%+
M6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7%1_\ENN?^Q<B_P#2F2NU
MKBH_^2W7/_8N1?\ I3)0!VM%%% !1110 4444 %<5>_\EFTC_L"7/_HV.NUK
MBKW_ )+-I'_8$N?_ $;'0!VM%%% !7%?"O\ Y$=/^OZ\_P#2B2NUKBOA7_R(
MZ?\ 7]>?^E$E ':T444 %%%% !1110 4444 %%%% !1110 5QOQ8_P"26>(/
M^O;_ -F%=E7&_%C_ ))9X@_Z]O\ V84 =3I__(,M?^N*?R%6:K:?_P @RU_Z
MXI_(59H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\;?
M\B%XB_[!ES_Z*:MVL+QM_P B%XB_[!ES_P"BFH 3P/\ \B#X<_[!EM_Z*6MZ
ML'P/_P B#X<_[!EM_P"BEK>H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKBH_^2W7/_8N1?\ I3)7:UQ4?_);KG_L7(O_ $IDH [6BBB@ HHHH **** "
MN*O?^2S:1_V!+G_T;'7:UQ5[_P EFTC_ + ES_Z-CH [6BBB@ KBOA7_ ,B.
MG_7]>?\ I1)7:UQ7PK_Y$=/^OZ\_]*)* .UHHHH **** "BBB@ HHHH ****
M "BBB@ KC?BQ_P DL\0?]>W_ +,*[*N-^+'_ "2SQ!_U[?\ LPH ZG3_ /D&
M6O\ UQ3^0JS5;3_^09:_]<4_D*LT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5A>-O^1"\1?]@RY_]%-6[6%XV_Y$+Q%_V#+G_P!%-0 G
M@?\ Y$'PY_V#+;_T4M;U8/@?_D0?#G_8,MO_ $4M;U !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<5'_R6ZY_[%R+_P!*9*[6N*C_ .2W7/\ V+D7_I3)
M0!VM%%% !1110 4444 %<5>_\EFTC_L"7/\ Z-CKM:XJ]_Y+-I'_ &!+G_T;
M'0!VM%%% !7%?"O_ )$=/^OZ\_\ 2B2NUKBOA7_R(Z?]?UY_Z424 =K1110
M4444 %%%% !1110 4444 %%%% !7&_%C_DEGB#_KV_\ 9A795QOQ8_Y)9X@_
MZ]O_ &84 =3I_P#R#+7_ *XI_(59JMI__(,M?^N*?R%6: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *PO&W_(A>(O^P9<_P#HIJW:PO&W
M_(A>(O\ L&7/_HIJ $\#_P#(@^'/^P9;?^BEK>K!\#_\B#X<_P"P9;?^BEK>
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBH_P#DMUS_ -BY%_Z4R5VM
M<5'_ ,ENN?\ L7(O_2F2@#M:*** "BBB@ HHHH *XJ]_Y+-I'_8$N?\ T;'7
M:UQ5[_R6;2/^P)<_^C8Z .UHHHH *XKX5_\ (CI_U_7G_I1)7:UQ7PK_ .1'
M3_K^O/\ THDH [6BBB@ HHHH **** "BBB@ HHHH **** "N-^+'_)+/$'_7
MM_[,*[*N-^+'_)+/$'_7M_[,* .IT_\ Y!EK_P!<4_D*LU6T_P#Y!EK_ -<4
M_D*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A>-O\
MD0O$7_8,N?\ T4U;M87C;_D0O$7_ &#+G_T4U ">!_\ D0?#G_8,MO\ T4M;
MU8/@?_D0?#G_ &#+;_T4M;U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !7%1_\ENN?^Q<B_P#2F2NUKBH_^2W7/_8N1?\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %8GC)S%X'U^1<973;@C/\
MUS:MNL+QM_R(7B+_ +!ES_Z*:@!/ _\ R(/AS_L&6W_HI:WJP? __(@^'/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<%IW_)<=;_[ UO_ .C&KO:X
M+3O^2XZW_P!@:W_]&-0!WM%%% !1110 4444 %<%??\ )=-)_P"P%/\ ^C5K
MO:X*^_Y+II/_ & I_P#T:M '>T444 %>>? __DDND?[\_P#Z.>O0Z\\^!_\
MR272/]^?_P!'/0!Z'1110 4444 %%%% !1110 4444 %%%% !7#?&+_DD^O_
M /7*/_T:E=S7#?&+_DD^O_\ 7*/_ -&I0!U^F?\ (*L_^N"?^@BK55=,_P"0
M59_]<$_]!%6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*PO&W_(A>(O^P9<_^BFK=K"\;?\ (A>(O^P9<_\ HIJ $\#_ /(@^'/^P9;?
M^BEK>K!\#_\ (@^'/^P9;?\ HI:WJ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *X+3O\ DN.M_P#8&M__ $8U=[7!:=_R7'6_^P-;_P#HQJ .]HHHH **
M** "BBB@ K@K[_DNFD_]@*?_ -&K7>UP5]_R732?^P%/_P"C5H [VBBB@ KS
MSX'_ /))=(_WY_\ T<]>AUYY\#_^22Z1_OS_ /HYZ /0Z*** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7!:=_R7'6_^P-;_ /HQJ[VN
M"T[_ )+CK?\ V!K?_P!&-0!WM%%% !1110 4444 %<%??\ETTG_L!3_^C5KO
M:X*^_P"2Z:3_ -@*?_T:M '>T444 %>>? __ ))+I'^_/_Z.>O0Z\\^!_P#R
M272/]^?_ -'/0!Z'1110 4444 %%%% !1110 4444 %%%% !7#?&+_DD^O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M )!5G_UP3_T$5:JKIG_(*L_^N"?^@BK5 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %87C;_D0O$7_ &#+G_T4U;M87C;_ )$+Q%_V#+G_
M -%-0 G@?_D0?#G_ &#+;_T4M;U8/@?_ )$'PY_V#+;_ -%+6]0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'O2&W^'PO'M#IFB>>@)9/L"< 9YSMQC@\^U %G_A9'@K_H:-*_\  E?\:/\
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MLCP5_P!#1I7_ ($K_C5[_A#_  Q_T+FD?^ ,7_Q-'_"'^&/^A<TC_P  8O\
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MXY.$').>3T!Q5S_A#S)<E9]2G-@DTL\,4!>&9))#EB9E<$C);@ ?>Y)KJ**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY&:]$HH Y;0]-U&SU*Q6ZW$6]K=>8?-:4+YLR-&GF, 7*JC D\],]:ZFBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB$(XACCV;@8]Q.4W+'@Y_P"6C# Y407EN\7BK4KAK;4;I9_,$Z1V<B-%"(
M89@<,2R@;00<N> 10!TEIX6TFRGBGCBGDEB*F-[BZEF*[0P &]CP-QXZ9P>H
M%:5M:06AF\A-@FD,KC)P6.,D#MG&>.^3W-<WX5$B:9=V$CW<(EN)OLDOV>2+
M]WM4Y1) 3& 6( ;.2I(X.!6T_3KZ.W\*.TFH9@NY4FC=F(VF*?#29Y)SL&6/
M<=S0!VE%<9X*BNHYSYD-]&XL85OVNED4278+;RN_AN^67@C;SP,=G0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>modificationno16effectiv003.jpg
<TEXT>
begin 644 modificationno16effectiv003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"]8_$#5)-.T+Q#>06<>B:S?_ &..%4;SX%8LL<C/NVMDKR HP&')Q5_7]?\
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MN*X5Q)M9N@R"0/4CB@#K]+\7WVK>!K_5;>UM1JNGM/!<P/(PB66+.[! )P0
M0/?&>]:>D^(XY? ECXDU5XK='T]+RY9 =B90,V!R<>@Y-<?X5MGTOX:>)M0O
M_P#18]4NKZ^A6?Y&$<@PF0>A. 0/<5!=V=SXB_9RAL='/GW?]E6Z&.,Y8M'L
M+IC^]A2,=<T =EX7UK4?$5NFJ2):VEA,N^"T(+W!C/*.[!L*2,';@X'?TZ.O
M)=&M-*O_ (C>%M3\(V\$%I!ILPU46R"-4#*!''(!QOWD_*>1MSVKUJ@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')6G@_4M.DNHK'Q
M1>1V%S/).T+V\4DB,[%FVR,/4GJ#BNDT^Q@TS3K:PM5*P6T2Q1@G)"J,#)[U
M9HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO[>+3[RSOW5;-N!Y4D((!4MG)P>_<T >GZEJ=EH^GS7^HW"6UI" 9)7/"Y(
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M?$EU)(NFB%)]ZH2VU\;>.O\ $*@U'QGH>E>)M/\ #][=F+4-04-;H4.ULD@
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MJQN <%)!<*\;@]N<?@353PAK\GB36/&5_<1&&]70HH+R(C!2=%D5QCZ@G\:
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M"M(Y:-CU*ONW#\ZAC\=V%Q<:!:VMI=W%WK-NEVL$2J3;0, ?,E.<*HSCODC
MS74T 9^C:%I?AZQ^Q:3916MON+E4'+,>I8GEC[DYIT>CV$6J76II;*+RZC6*
M:7)RZ+G:,=.,FK3W$,<JQ/-&LC?=0L 3]!3G=(U+.RJHZEC@"@#(C\*Z'%I>
MG::FGQBSTZ=+BTBW-B*122K YSP2>OK575? 7A?6]2;4=1T>&:Z?'F/N91)C
MIO (#X_V@:Z$R((_,+J$QG<3QCZUA:5XE_M/Q=KNABV54TM+9UG$F?-\U6;I
MCC&/4YH FU?PIH6NP6T.HZ;#,EKQ!MRAB&,84J00, # X-1Q^#/#L6E2:7%I
M,$=C)<+=-!'E5\T;<-@'C[J\#CBJ6L^,VL/$/]A:9HM[J^HI;BYF2W>-%AC)
MP,L[ 9/I3=6\<#3+G1K./0M3NK_58'GCM(Q&KQ!0I8/N8 $;NQ/0T ;\.DV-
MOJUSJD5NJWMTB1S3 G+JF=H].,FL+PMX5DT;7_$NLW8MOM6K7F]!!G"PJ,(#
MD#YCDEO<]Z34O',&B^'H]3U;2M0M+B><6]OIQ"27$\AZ!0K$'/U_IFO;^-]5
MDDD@G\$:Y#="+SHXP8F61=P!P^\*&&X':3G% '32:38S:Q!JTEN&OK>)H8I2
M3\B,06 &<<X'.,TR[T/3;[5;74[FU5[VU22.&;)!57&&'!P<CUKF]"\?3Z]J
M$MK;^%=7C6WNS:74TCP;8)!C=NQ)DX!!X!I[?$C1HO";>(98KI(3=O9PVX0-
M-/*K%0J*#R25..>E &P?">AMX;C\.FP0Z3'MV6^]L+M;</FSN^\,]:N7.D6%
MYJECJ5Q;A[RP\S[-*6(,>\;6XS@Y [UR]C\0\ZY8Z5K?A[4M$EU E;26ZV-'
M*_\ <W*3M;V-6=+^(.DZIXWU#PHD=Q%?6></*H"3%<;@A!SD;@<8Z4 ;[Z18
M/K4>L-;@ZA' UNDV3D1D@E<9QU [5S]W\,?!E]J,E_<:!;M/*V^3#.J.WJ4!
M"D_A6KX=\16WB2TN[BUBEC6VO);1A*!DM&V"1@G@TDGB*"/QC!X;,,AN);%K
MT2\;0JN$QZYR: *.K_#SPIKNHMJ&HZ0DUTR*C2"61,JHP!A6 X%)=_#OPM?7
M?VJ?3#YYC2(NES*A*HNU0=K#. ,<UU%8]AXBMM0\2ZOH<<4JSZ6D#2NV-K>:
MI8;><\8YS0!G:I\./">M-;/?Z0DKV\*V\;^=(K>6HP%8A@6'^]FNBL[.VT^S
MAL[."."VA0)'%&N%51T %<]?>/-*TV?Q(EVD\::!%#)<OM!$GFKN4)SR>@YQ
MR:;8^+-5N[2>:7P;J\#+"LT$9DA)F!8# ._"L <X;' /I0 D7PT\'0W:W2Z%
M TBR&4"1W= Y.<[&8KU]JVKC0-)N[J[N;BPADFO+?[+<.RY\R+GY#[<FN9TW
MXA7.J:M<Z;!X1UD36<J176YX,0%QD$_O.>#GC-;WB?Q/I_A/2?[0U#S7#2+#
M#!"FZ2>1ONH@[DX- %;1_ GAK0;]+[3M+6.Z12D<LDKRF,'J%WL=OIQBMC4=
M.L]6L)K'4+:*YM9EVR12KE6%<I8_$+=KMCI.M^']2T274,K:276QHY7'\&Y2
M<-[&G-X^EFUC4M/TWPQJ^H_V=/\ 9YYH#"$WX!XW.#T- %S1/AYX4\.:@+_2
M]'BANE!"2O(\A0'KMWD[?PQ6U:Z1866I7VHV]NL=W?E#<R DF38NU<C.!@<<
M5=KF-#\=:7KWB?5=!M8YUN=/)S)(H"3!6VN4.>0K<'WH VM6TBPURP:QU*W%
MQ;,ZN8RQ'*L&4Y!!X(!HU'2+#5OLGVZW$WV2Y2Z@R2-DJ9VMP>V3UXKDI_B+
M=V^L6VDR^#=;6^N4>2&+S+?+JF-QSYF.,BDO_B+=Z7+9Q7O@S6X7O9Q;VX+V
MY\R0@D+Q)QP#UH U]>\ ^%_$UZMYJVDQSW2J%\Y7>-R!V)0@D?6K1\):"?#3
M>'1ID*:0P -JF54X8-R0<YR <YS45WXI73/"-SX@U73;NQ6W4LUK*4:4G.%
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MQMK=8RWUP!F@#E?AO_Q^^-?^QCN/_04KSFVD%CX6\*:Q=9&F6'BFX>[DQD1
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M<9X#J"?PKSCP)X8T?QU9ZOXD\36*:E?7=_-"HN,D01(=JH@_AQZCFO6ZX%?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 %%<W/X]\,VVLC2YM7M5GP^YC(/+1E8*49LX#98?*>>:Z2@ HHHH ****
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MM0@\MO\ 5YQG=C;U'3.: -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@X/!!!![$$ _A0!Y-X/UOQFGBNUCFE\07NDW%C(UU/JFF>0D,P1F4H1Q@D
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MU*V$,MJP5BP!'W@Q& .HQ[UTD'P[@CTF_L+CQ'XBO&O!&/M,]_F6'RVW+Y9
M&TYZ\'-<MXG^%5W'X;N].\/75W>7NLW</]J7^I70>7R4R>N!G!QQUH O_!32
MYT\+7?B._&=0U^Z>[D8]=F2%'TR6(]FKTRJ]A90:;I]M8VR;+>VB6*-?15&
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MD]F9Q]G,C')?;CKUQDG&30!P'CW2=9NOCCX96S\0O9274$WV206J/]DVQG>
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MQ"NO1ZAJM[J7D-!)/?7/FF0$CELC.0  ,8&* .SHHHH **** "BBB@ HHHH
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MG"W%UC&$9V/W07'?N/3B*RUW6K3P!\2+9=0U: Z;<P"U%U=%[BVW2893(I]
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M=74J0V\*&221SA44#))/IBN=T;Q_X?U[4HK"SGN%GGC:6V^T6LD*W"+U:,L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVLM/(TDV.FZ0MNXQTSZ^M&C> ]!T"ZBN-/BO(VA0HB/?SR1A2,8V,Y7I[<4
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M 4444 %%%% ')?$__DF/B+_KR>H_%/P^TSQFMA-?R2[H#"=C.S1E%;<P";@
MS#Y2W7%:OC+1KCQ#X.U;2+1XTN+NW:*-I20H)Z9(!X_"M+33=G3H/M\,,-T$
MQ)'#*9$!]F*J3^0H Y/Q#\,]*\0Z;865S<WDBV7EK&;F=Y@55PS9!899AE-W
M4 T>,-.BTCP#:V$$D\D4%_8*C3RF1\?:XNK'D^GTKMJYOQEI>J:U86FGZ?#:
MF)KN":XFGG9#&L4R2?*H0[B=I')&/>@#I**** "BBB@ HHHH **** "BBB@
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M>!="UR_EN]1BNYO.*F6W-[,()"H !:,-M/ ';G% %3X71RQ?##P\DX97-H"
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MVUH0%RFU?XLGCVK1W+NV[ANZXSS7F5_#I=O\1_AX=)2UCMVCU!%%KM$9Q%G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3=2L]7TV#4;"<36EPGF12@$!E]>>:J:MX=L=5T>\TT*;-+N(PR2VJJDFP_>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF**WP2P['E1CU- 'IE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0+C+OM/!(&,#WJ&31O$7AO3M3OSXNO-1ACTZ=C%=P1[EF"Y5T90, 8/RG(H
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M29[:%D5Q"H9OF<*, D=VK*TSQY;WNLII5[H^IZ5<S6[75L+V-!Y\:]<;6.&
MYVG!H ZVBN$TOXJZ/J>C7>M_V?JEKHUK 96OKB *CL" 8UPQ);+ >F0>:NZ9
MX\CO-:L=+U#1-4TB74(V>R:]5-LVT9*_*QVMCG!Q0!UU%<AI?CZ#6;\)I^B:
MK<:8UR;5=42)3 7!P3C=NV9XW;<4^3X@Z5'X1N_$C6]Y]CMKHVKH$7S"XE$6
M0-V,9.>O2@#K**Y+4?']I8^*W\-0:5JE]J*+'(ZVT*LJQMU<DL, <9SZC&:K
M:A\3-/L7O9ETK4[G2K"?[/>:E#&IAB<$!N"P9@I(R0#0!VU%<?K/CVUL]1N]
M,L--U+5)K6V6>[DL(U9;97!*YRP))'.%R<4?"R[N;[X9Z'<WEQ+<7$D+%Y9G
M+LQWL.2>30!V%%<?=>/UL-3MH+[P_J]K975XME#?31H$:1B0OR[MX4D<$BJ>
MD>-]3O?B3K7A^;1;P65J85BD6-/W60V7D._[K8!7 )QU H [RBN(\>^,=2\+
MZAH$%CIEQ=)?7RQ3-&BMO4ALQIEAB0X!&>, \UC7/BW4;'XI31QZ9K%ZLVA0
MS)ID)7,3EV+%@6V*0."<G)P!F@#U"BN03XBZ3/X8TS6K:VO;A]4E,%I8QQCS
MY)02&7!.!C:<DG  K0\.>*K?Q#/J%H;*[L-0T]U2ZM+I5#IN&5.5)!!'0@]J
M -^BL>'Q)9S^(=2T58YQ<:?!'<2N5&PJ^<;3G.?E/85A2?$W2$T30M46QU.5
M=;9TM((H5:0LN?E(#<$D8')'/.!S0!VM%<#?>.[34O"'B69DU?1KK2 $ND$<
M9N(2<%63YBIR/?\ I4)\<ZG;?$*Q\/1Z3?W=B^F),91''YDC%E'FYW@; "0>
M,YS@8H ]$HK$\4^*;+PCI4>H7\5S+#)<);A;9 [[G/'&1G\.?:LNR^(%K->7
MUEJ&D:EI=Y:V+:@(+I$W2P+U*E6(SGC!(_G0!U]%>::E\1+36_ NH:M;0Z_I
M6GH(#'J,<$8=RTBJ5C#-@X)VD].N":W]4\<Q6.N7&C6&C:GK%W9Q++>"R1"(
M PRH.YAEB.0!DT =917(ZGX]@L[V:SL=&U35)[6W2YO%M8U'V9&&Y0V]E^8C
MG:,FHKGXD:<5TA=)L+[5[C5+9KN""U5581+U+;V !SQCDY!H [.BJ4FIPV^B
MOJMTDMO!';FYE65</&H7<0P]0.HKDO\ A8-S>>$]1UJS\-:M&D=E]JM))4C*
MS*>C</P!PQ!P<9QF@#NJ*XGP]XVU#4/!%CJ]QX=U2:\F2)1%!$F)V9-QD3Y\
M+'UY8CM534_B/*/"/B.]LM&OH-6T<%)K6X1&,+%-RNV'P4QR<'/M0!Z#17%V
MOCX1^%M,U#4-(U%+^^9(+>R6-/,NI"@8L@#$!.IRQ& .:<GQ(TF+2]8N]2M;
MW3KC2&1;NRG13*#)_J]NTD-N[8/Y4 =E17FEGXGO]6^+>E6DMCJNE1#2YWDM
M+LA5D.Y=KX5BI[CU%=KKFLSZ0D MM'U#5)IF($=HJX4#J69F"J/3G)H UJ*\
ML\7^.5U+X>#6-/\ [0T^2UUB&UNH3\LT;)*-Z'83GCL#SFNGTWQY:W6K3:;J
M6F7^CW"VAOHQ?*@$D ."P*L<$=U/(H ZRBN&M?B=93G3[F71=6M=(U"=8+74
MYXT$3LW"D@,656(X)'I6@/'VDC0M>U6:.YACT2>2WNH9%42;TQC:,X(;(VG(
MSF@#J:*XZ_\ B%;VUQ/!9Z)JNHR6ENES?+;1I_HJNNX*VYAE]O.U<UTNE:I:
M:UI-KJ=C)YEK=1++$Q&"5([CL: +E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8V=OXR\&76O
M6.E>&EUFROKZ6]L[A;V.(1&3DHZM@X!].M+8^!-5TG2_ %@@2Y.CW;S7LBN
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M!YEHT/BX^ CX4O/"3VNS1Y+-;LZA"ZM((2J_*#D9./IFK%CX7U>'4?AK+):
M1Z-I\T%^?,0^4[6Z(!U^;Y@1\N:]%HH \N\*> ]6\-?%:\NT16\-K9S)8L'7
M]R9)5D,6W.<!MY'&,=\UN^+])UA?$^@^)]%LA?RZ<L\-Q9^:L;2Q2*.59N,@
MC.">:[2B@#R6_P#!/B/7;?7M?EM(+'6KN]L[NRL7F#A!;#"AW7C+9;IP..:W
MM/L=?\0>.K#Q!J^B_P!D6NEVLT4$,ERDTDTLF Q^0D!0%[\\UWE% 'FNG+XK
M/Q,EU^X\(SP6=U916+9OX&,6)"Q<@-R,'H.>*D\71>*+[QCH5[8>%9KBTT>Y
MDE\W[; GGAX]O +9')[UZ-10!YSKFG:XOQ#M?$</A4ZK;/H@LWMS<P*8IC+O
MP=[8.!QD9ZUJ?#CPW?\ AW2=2.H0PVLFH:C+>I90/O2U1\8C!'!QCMQ7944
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M\+RP6;;M<65V0R_\>RQ*3(2<<X8!>V<_A5#Q/X#U'Q%XGT'61/;6ZI%'#K$
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M&NG>3%D%9!+O^5<8"8X'/X5+X&\/7?AG09;&]DA>5[RXG!B)(VO(6'4#G!H
MP5L6O?'_ (WDAB:6_ATZUCM"LYB9"\<N0C\["2!\V..M87@/PWXVT[4]=?59
M[F>&0W"J!=& /.4C D_U?S[L!1)V*,<<UU.B7EM%\6O%EI)<1)<SVUBT43.
MT@5)-Q4=3C(SCIFNWH \C^'?ASQGIGC/4+G6KBXELC*1)F?:'?R8P'/R#SL
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M%:=9!D[<YP/3K6EK?A[Q+%XY'B+PY-II^T:>+&>.^+@1X<LLB[1\W7H<?KP
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MJ2!VR <?A0!MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK8..".#S7G?A>^\5W'Q4\66EU<V4FGVTEMYD1DE/E(T3%/)!X!/!?/?I7*^
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MP6>JO9E(S:_NXTEQR$/503G![9S7'> 3X4L->MK%=!O_  _XE:W8-!=[P+K
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MJVGV68W-LTLCCCY@0R@'J3P>M=S10!S=KIWBFU\-)9KJNEG4HF54G-D_E>4
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MVQ"LH8G8(P>$P<8S797ND'6?#$VD:O(DC75J8+F2!=@)9<,R@DXYY&<UJ44
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M<?A7CG@CP/KOB'X;Z?I>H:R(- GF>6>Q:T(G 6=CY8?/"DJ&R1GGTKVVB@#
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M,=LMFTK1D,<-OR0<],8- 'I]%>8:+X\\4P>/=+\,^)].TD?VI;-<02Z<[G8
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M?VB([)+@6K22PR1E93C"E64,#\P/3O0!T-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 <M\1=3O=*\ ZM/IUO//>O"884@C+L&?
MY=V!Z D_A7C.L>!O''A[P7X=U!7L[E-"F2YM[2UMW^T(TC!F#<?-\V,U]'T4
M >#:EX'_ .$]^*_B1KRVO[2VN-(AEM+@JR*LICB #<8;'.5]CZ5O>$VU"Z^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7>" HP3GKVK0\/ZYXKU?PO?6MM)83ZWI^JS:9->SJ4CVIUFV+U;!'RC S[4
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M0V4CQ2QG!5@O!!H Z*BN/7QK;:9I^CV<EOJ.J:K<:?'<O;V,/FR!-H!D;)
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MD<DB@#<HKDQ\1=#/A[^UPMX?]+^P?8A ?M/VG_GCL_O=^N/>DT_XA:5?2ZK
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MFSOY6=LJD G ZKSU_2FM\0=.33K*Y;3-86YOI'2UT]K,BYE"C+,$S]T @Y)
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MKT_0K*'3= L+.WLVLH8;=%6V:3>8>/NELG)'3.36A10 4444 %%%% !1110
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M9.1U!KV:"TMK;'D6\46%"#RT"X4=!QVY/%1PZ;86]RUS#96T<[?>E2)0Q^I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ+\I]\G.: /6M(U>PUW3(=2TRY2YLYL^7*@.&P2#U]P15VO"=)\5>(-1\/>
M?#ND7MOI-UK(N9;B\@LXP$2-WX2, (,X.< <X]36EXN\1^*O#%QX=\*OKT\U
MY=F:6YU.TTT2SM$I)15B&1G (./0'UR >R45P'PMUGQ'JMCJL/B!+N06MULM
M+N[LS;23Q'."4P!D8[>M<YJFL^-]9\<^,-%T?Q#!IMGI,45Q&6M4=_\ 5 [
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MVKV-BTH)C%S<+&6 ZXR>:\\^&&J^,O%=_=:OJ6NQ'2;*\GM/L:VJ!IB!D$L
M,;=RX]<'/O!\0+*UU'XU^![2]MH;FVDBG#PS1AT;@GD'@\B@#U'3=6TW6+<W
M&F7]K>P@X,EM,LB@^F0:N5X1JDEK\//C)?R^'H$AM&T&:\NK*'B+S$5V4;1]
MWE4/MN/K4?A?QAXYO=5\.7PN=9U*'4+A5OX)-'\NUBB<@;DE Y"CG/M]: /5
MI/B!X6AL;V]EU>..WLKLV5Q(T;@),/X.G/0\C(KI0<C(KYMEU.XTGPAXQN+8
M0%V\7LA$]NDRX)/\+@C/'7&:Z;4_B5K?AJ[\?:5JE\KWUGMET8F) 0DC *
M/FVAT/.>AS0![917AVM^+O%B^(['PS)JNI6T]KI4=Q?3Z;I:W,TUPP&<J!A4
M&X<@#]1AESXT^("^$_"$32'3];U'4GL)&N[0*9!D*CLK+Q][/&,X_"@#W2BO
M'[WQ9XD^'OC33;#Q/K:ZGI%WI\K>>UND/[]-Q[#.>$&,D?/75_"O5==UWP-;
MZMX@N!-<WDLDD6(U3;%G:HPH'H3GT(H [6BBB@ HHHH **** "BBB@ HHHH
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M(Y[ 5Y//X+\<6]YK@L=,UNVU2\U"2YMKC3]42&R"LP.YDSDG&>IST]*^B:*
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M!\-?#V@1ZAL2YOKC48F@N[J^F,LLL9&"I/& ?8>GH*JZ%\,[?P]=VIL_$GB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLDD>1?"(1^=R1DJ.A'0CCD'@5L4 %%%% !1110 4444 %%%% !1110 4444
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M."PL_.WJD:+@R8R0"Y.<=>.:N^&?#=GX5TC^S[.2:8-*\\L\[ R32.<LS$
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M*;3C^' &*Z:B@#+\.Z!9>%]!M='TX2?9K<$*96W,Q)+$D^I))K4HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>modificationno16effectiv004.jpg
<TEXT>
begin 644 modificationno16effectiv004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-H/@ZPDG4_9=5L(M['&0G!;]* .@UW77T_4])TBT2-M0U25UB,@)2-(UW.Y
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M'M1\)K$ED^GS_P!J_9\!=N%\E9,?\M-Q;@_-\I]*]*H **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .:A\.:M:3W*VOB*064\SS&.:T221"Y)(60]LGC<K8&!T%;UE9PV%C;V< (
MA@C6- 3DX P*GHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%/<VLD<3'IC>1M'XFMO47U%_ &HMJT5O%?G3Y_.2V<M&#L;[I(!Z8KRNVO\
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M(V?><$]!TQ@YSWJ[-XNT:&YT.#[47;6P38LB%ED 4-G/;AAUKP31]/,WP_\
MA];7L)-K=^)OECDZ-$S8_(_-5O3#=Z-\3_"O@N\+N=#U.Y-K*W\=M*BM'SZC
M#?3IVH ]G\9>+?\ A%;73O)LOMU]J-['9VUMYFS<S=23@X ^G<51U/XH^&M*
MU>YTZ22\GDM&"W<MM:/+%;'T=@./PS6/_P C7\<?[]AX6M/J#=3#^B_D5KGO
M$<6I?#BZUCQGX6UNPO='N[WS-0TR<@DRE]K!&'<,3QP1W!Q0!WNO?$OPYX<U
MJ72;^2[-W%$)I%@M7D"(>Y('2G:E\2?#&FZ/INJM>R7%IJ3%+5K:%I#(1U&
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M89,G'7 QS6_J_CO0="\,V?B#49Y8;&\V"',+;V+*6 V]1P#7*^)/^3@?!?\
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M)7(^GX=1R!0!VU%>0RZ0YN_'FG?VQK(LM%@2>PB&H2YBD>W\PL7SN;#+P&)
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M1MSDDCG@T >F45EPV4!\0R:DFI73R26JQ_8C/F%5W$B01]F/3/I6I0 4444
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MXT^"34[5=L-R1\Z#GC]3^=:E% '+^"?";^%;/4#=7:WNH:C>R7ES<!-FYF/
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MZ%P%O9R(P[0@;MB=67YA\QP#VR*OVGB_1;U],6"YD;^TWE2S)@<"4QC+')'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8C(+>/R SMR0%&><9R>< X-=5>^+=-M;73IH%N;Z34H_-LX+2+?),FT,6 .
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MMC)LC89WYSC 'X^@-,L?B%HNHZAI]M;I>^1J)*V=\]N5@F<#)16/.< ]L9!
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M\;:?J&I3Z>EEJ4-REH;R&.>V*&YB!QNC!.3S@8.#R.*Y+5_"NO:QX9\:7?\
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MQ/;2HFUD8>9&'4\$-['@9H ZFX\=Z0D&F26,=YJ;ZG"T]M%8P[W:-<;F()&
M,@8/.>,5)J/C*RT^[M;-+#4[R\GMOM9MK6V+210YQN=21CGC'7(/%<QK?AQ8
M?#VEVNE^$=3@NK6W<V$MA?QK+8RL2=C.T@RI)R>6'7CI3/$FDZ]<Z7IS_P!C
M7T_BJ#3D2+6--NHXE2X(^9) S+F/< 3\I!R< 4 ==K7BJ+13\VDZO=JL/GRO
M:VA98DYZDD#/!^49(]*K:CX]T73K?2)A]JNO[8B,M@EK 7:; 4X XP2''7WS
MC%<UXBT?Q3J.JR07MOJ-]:RZ;'%;_P!FZ@+6!+G!$C3 .K$$X(P&&.,$U9T;
MPSJ]K<?#IY[/:-(T^>&]/F*?)=H44#KSR".,T =58>*-/OH]2+">U?355[J.
MY38T:M&) 2,],$_B".U6;;6[.X\.QZZQD@L6MOM9:9<,L>W=D@9[<UY_\1-+
MNY?%VF6NG.JKXFA_LN_4'#>5&PD,@'<B,RK_ ,"%>BWT032+B&*Q6Z40,BVF
M0HE&W&S)X /3GB@#*TSQC8ZAIESJ<MIJ%A8P0"Y^T7MOY:/$03O4@G/ SC@\
MCCFFZ9XSL-2U.WT]K34;*:[C:6T-Y;&-;E5&24.3R 0<'!QVKB8/".MZCHGB
M31+.TO\ 2=#N=/6*QL]1N4E:.XR20A5F*Q< 8)[\5K^%]"MAK-A=3^#]6L+Z
MT1B;J\U(SQ1,5*L(P9F+9R1G:.* +\?Q,T6:RO+Z*TU1[&S#?:+H6O[N-E<(
MRDYY(R&X_A_*MO5->L[.[BTTRRK=7-K-<(\2!_+2,#+GMU88]36-X.\-S6W@
M*;0]9MO+-Q+=K+%N5LQR2N1R"1RK"LSPGX<UZ.PU.XUZ!1J,=@NDV>)%;S(8
MU/[S(/!=FR0>?E&: -2R\8VEGX<T%GEU#6;W4K<20+#;*)YU !9V0$*@&1GD
M#GO5Z?QE8PVUDRV6I2W=X':*P2V(N,(<.65L!0#QDD Y&"<UR6DZ%KOAD>$]
M6&D37SVFC?V9?6<$L?FQ$E&#+N8*W*D'#>G6I?$6B:AJNNZ1XDO/#U]/$+26
MUN-/M+\1SP9D#(^Y70-P.5#<9[XS0!T;^/=&&BQ:E&+N5I;O["EFD!^T?:.<
MQ%#C##!)R0,#.:W--OO[2L([K[+=6I?(,-U'LD0@D<C\.HX(P17#R^';!/"?
MV=?!.IF&>^-T]LE^K7<4F,+.',OWN ,!\C\ZM:#JFO:)I6@Z9K-O+>:GJ%[+
M&%EG4RP6PW,'D900Q5=@..I8<YZ@'<T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%4]5U.VT;2;O4[UREM:Q
M--(0,G:HR<#N:YFU\=3MJFC6-_X>O;'^V&/V25Y4==HC+_-M/RM@#Y??J<'
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MG[S'KQP,'/X5DZ_X[U$Z5X2U3P]8/-:ZQ>0JVYXU+*RL?)^8\,<?>Z#;UYH
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ME5^0')7<,;N.?;DRZ3XGUZ[^).N:+-I;'3K58-CB6,>2&#_.><L'VC ZC'-
M'72:?9S7\%_+;1O=VZLD,S+EHPV-P![9P,_2K-9VKWU]8PQG3])EU&=VQL65
M(U0>K,QX'T!/M7.-\1;:+PS<:I/IMQ%=V^H#3)+)I$R+@L %\S.W;\P.[IB@
M#M**I:7=7EY9^9?Z>UA<!BIA,JR#ZAEZ@_@?:N3O_B,UJNMS6_A^]NK;1+AH
MKZ=9$5550"67)RQP<X[ =>10!W-%<UJGBX6U];Z?I=@^I7L]M]KV"9(42$G
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M:PUFSMQ/;SL[7!5656"E1L&T'())R?2O7*9)#%-L\V)'V,'3<H.UAT(]#[T
M>>ZIX6\2BY\76>F1Z>]CXA3<+F>=E:W8Q"-UV!3NSC@Y&,\YZ5I6?A>_M==\
M/W\C0&'3M$>PF 8Y,A\OD<<CY#S79TR*6.>,212)(ASAD((..#S0!XYX/T?Q
M%XD^%^@:+)!81Z.[Q3R7@G;S3$DN_P OR]OW]R@;MV,=LUW,7AJ^36?&EV6A
M\O68H4MAN.05@\L[N..?3/%=5##%;Q+%#&D<:\*B* !] *?0!PUOX0U*+3_
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ML,-Q!<7)@:.2+<%=6VME2&.1UXKLJ9%+'-&LD4BR1L,JR'(/T- '!MX%U!/
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M<#SH[=LG'<'AA[,*Z'_A 8;;0?#>DV-T5BT?48KYI)5W-.5WELXZ%BY-)>>
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M/VMPX;SY;O4&2!"#\JJ2@+$CUQC'>LFV^(D^H^&M#NK#38GU76+N2SA@:?\
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MWC(7_>,&:9BF$"@#&-V0.U;NG^']2TSQMJVJP75J^FZJ8Y)X7C;S8W2/8-K
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M7_:4=U:6SVY8#<#&58G/W1@CCF@#TRBN0T8^,[[2X;ZYU+2%^VVOFK$MD_\
MHKL 5&?,_>#!P?N^HJG\(GU6?X>Z9<ZE?QW4<L(, \IA(@W-G>Y8[STYP,>]
M '=T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR%F2:+=N *G'()."#W/6NCHH Y)O 5FWAH:1]MN&9[]=1N+IPIDFF$@D)(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\J96&5?:3]#^(]Z /5Z*\4M?BOKI^&>OWEXEM#XDTL6\JCR_DD@F:/8^W/\
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MQ5J-ZEG;M'$1$2S$YVGL%&"?4YJQX/\ 'PU3X92^)=6 2XL$F%]'&N,/'DD
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M,$B&W&W( PYZ8J&+Q1<:OXY\1P_VIJMA;:3"%M8UL'\G/E,SO-E,GG&T$KD
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MI-O>7.GSZ?-("6M9R"\>"1SCCG&?QJ]10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMYI_Q;OG>]6ZE3PR9(GN0L8&)SPY4 ;<CKC@'OBETGQ'K-SXAL](FU#S5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>JZ7::UIDVGWR,
M]O,!N"N4(((((8$$$$ @CTJY10!CZ?X=@L98Y)+W4+UHCF/[9<M($.,9 Z$^
MYR?>MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>modificationno16effectiv005.jpg
<TEXT>
begin 644 modificationno16effectiv005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(@=B!LX(!/X+Z\U:B^(-WJGPDMM;TUH_[:N86BP5!6.:-6:5B/0*C,![J.]
M'I5%>.Z'XN\37_P3U+Q9<:R_]I1&1XMEO"$4(<;2-G.>I_#&.<W?#.L>)_$/
MAO2[NV\3M)K$]N+R6R-I!Y9B$NTKD*"I(S@Y[&@#U6BO(?B#XM\9>$O%,U[I
ML@OM LH[>>]M7B3<BRM(N P7(7]WUR<$C.16Y%XCO_$UT;SPOK#O;7.BS7-K
M;-%%A;D$(JL2N1ACR">HZXXH ]"HKR#6-:\7Z1\2?#?A5_$\DL>I0;[B<64
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(6QGCI2TA4-UH \L
M\1^+]'U7XAVNCOXDBTB+2%>?SY!'L>Y(V[<OE1M0MU[MQR*XCX?>*-)\$?$[
M6-)CU>&Z\/:A(!'>95$67J#V 7)9<CCA3TKN=9^ OA;6]9O-4GO=5BENY6F=
M(98P@8G)QE">OO5$?LY>$@01J6MY'_3:+_XW0!A?$;Q?H%S\5/"%_::I;7-I
MIDH:[F@<.J NIX(^]Q_=S^=>M3>/_"$%JUR_B;2C&J[L)=H[$>R@DD^P&:X+
M_AG'PC_T$M;_ ._T7_QNE/[.?A,J%.IZW@=/WT7_ ,;H Q/@9XIT/1[37++4
M]4M;*6:[^T1&YE6-73 '#$XS[=?UK5G\5>'/&?BK5GF\60:996UHUA;K*(MM
MQ&_,S@R CDA5P.<+GO4O_#./A'_H):W_ -_HO_C='_#./A'_ *"6M_\ ?Z+_
M .-T <C\,_$6D0:1XE\!ZKK$$6E78G6POYG5$VL"I)W$;<C:P!QSGO6M\-O'
MFB?#_1Y_#.O:C;.8KEY+:[L)5N8ID;'="2IR#]X#K6Q_PSCX1_Z"6M_]_HO_
M (W1_P ,X^$?^@EK?_?Z+_XW0!G_ !7\<:/XA^&<UK;WEK]LNKE##:QW*2R>
M6K [GV$A"1S@G]<@<QXZU'P;>?"31+?1XM,76V$'G+# BS+L3$F]@,CYO4_-
MU&:[?_AG'PC_ -!+6_\ O]%_\;H_X9Q\(_\ 02UO_O\ 1?\ QN@"9_B'X3N+
M_P ')+J4)A-M(EQO^[#NC\O;)Z?,"/IR>"#7)>&H?#_@_1_&WG^)+"XA(N+;
M2K>*[24LLB#YU52>6_=J3VV'/%=/_P ,Y>$O^@EK?_?Z+_XW1_PSCX1_Z"6M
M_P#?Z+_XW0!QOA[Q3HUK^S]JN@W%[''J;&6)+<G+.7.Y2,=N#SVQSU&;G@[Q
MQX1\(>#K2\M0I\2+8/:RVT<.T2OYA9&=^%X]<DX/M73?\,X^$O\ H):W_P!_
MHO\ XW1_PSCX1_Z"6M_]_HO_ (W0!IV7CKPE>>.-;MKW5]/:WN--MK=Y)7 @
ME9&G\Q0Q^4C$J^QYQG%<YX$MO#7@;XBZN+;Q3I,FAW5H9+1CJ$9$3%UW1GYN
MHP.>X ]#6A_PSCX1_P"@EK?_ '^B_P#C='_#./A'_H):W_W^B_\ C= &#XS\
M8:!+\;O#6KV^IV]Q8:?%Y=S/$^Y$)+]"/O#YAR,UZ_\ \)OX6(&WQ!IC;AE2
METC _B#7GW_#./A'_H):W_W^B_\ C=3I^S[X7C5%&IZP0GW=S0''.>\7K0!@
M>,_&&@W/QH\+7]OJ,4MKINZ*ZE3)5&)(QGOU'3-=CJOQ%\,P_$'0K'[/IET;
MB)\:L;B/-ID'Y.A(W8'<9W#K64W[//A9KDW!U36O-+[R?-A^]G/3R\4]_P!G
MSPP]TMRVJZUYJD$'S(0!CIQY6* -KQC\0M'LM$CDT^]TS42]U%#/:FXC/F1,
M?G7YCC[N>O'K7FT9\ Q_$_0-5\(:K!I:Q2M)J2SS>1"B8^ZN\C);)&U"5^@K
MK9/V>O"TD7EMJ6L!<YPKP#G\(JB_X9Q\(_\ 02UO_O\ 1?\ QN@##^*GB[0;
MWQ]X)N['5+:[@TJ\$]W);R!U1/,B;@CACA6X&>E=IX\^(F@1^%5@L-<MW.J2
M"T^TVSB3[/&=OFN<=&5&R!UR1Q6/_P ,X^$?^@EK?_?Z+_XW4S?L]^%VLX[0
MZKK9@CD:55\V'AF"@G/E9Z*OY4 <+XWO],\->*_#/B+0/$UMK%W9*L3Q0^4H
M6W7@+F, <J67!YQCTKM_BCXY\,ZU\*[ZWL=8M);N_CB,-LLH,@^='(90?EP
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M!?Q7O+FP\3Z0V@WEA*UNO]H1D6\ADBW1GYO0#![@?[-:1_9R\)'_ )B6M_\
M?Z+_ .-T?\,X^$A_S$M;_P"_T7_QN@#"^)/B_0+KXG^#KZTU2VNK73)P]W+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,<CFO._&<HG_ &9K28# >&U;'IF1372>"&NX-%2X\2O;_P!FQ:;ICV+JC!%
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MQ()-:-U%#.<)+';LZ;O[I(Z'C.*EN?&&G6LNDQ-#>R/JJ;[016[/N& 3G'3
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M?@&D_P#'J .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /A7.@#3[2Q3[>EO:W!NHU6]DYFW;M[<_,V><G-=910!ROB+X>:!XJU&VO\
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M9-2FMK!XWM[>6_E:-2A!3Y2V#C ZU7^)/C*\\"^'X]8M[*"\C,RPO')(4(+
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M'BO_ (2;%Y_:V?\ 7?:WZ=-N,XVXXQ53X?\ CE_&]CJEY)8"P2SNS;A#+O.
MH)+'IG)/2G^'O%]UXQO[J71+>%-#M9C";ZX!9KEQU$: C"C^\3WZ=: -&]\'
M:/>:PVL+'/::DZ>7)=6<[PO(OHVTX;H.H/04[3O".CZ197EOI\$EN]Z2US<K
M,QGE8\EFE)+$\GOQDUMDX!(!/L.]<3X9\>W'B'QQK'AZ;1WT_P#LV(.WFS*[
MLQ(Z[<J.".A- '3:1HEGHFC1:3:B5[.)=B)/(9<)TVY;/&.,5)I&DV6AZ9#I
MNGP^3:0[O+C!R%!8M@>V2:\_U'XJ306VOZO9V$,VCZ'>QV<^YR)IR6"LR=@
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M?J&KZ@[1V\<<PD1,(S;W*$X7@>YSQ76/!#*VZ2)'/3+*#2+;0(P9(8U8="%
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MDZ17,RV<DN=S6X;"'!Y ."0/0BNT>&*1D9XD8IRI*@[?IZ4^@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%K3!19'GP0K,Y;IESS_"!45O\/OBQ:>*)?$D%YI2ZK*GEO/YQ(*8 V["NW&
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MM#=R"Z=?-C; *D 8QA0,#TH ETKQ)XC6Y^&-_+XAU"=M8GDANH7D_=,B2K&
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M!R.G/N/6M_0-7EUK3Y+N6R:U"W$L* R!Q($8J7!'8D''MSWKQ/Q'I/B'P?\
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M?4 ')'!Y]J (-1\-:'J]RESJ6D65W.BA1)- K':#D DCD9YQ6HJA5"J  !@
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MD6[U*SMVB4/()9U0HI. 3D\#)QFG3ZII]K8K>W%]:PVC@%9Y)E6,YZ88G'-
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MM]0M);N+/F01S*SICKE0<B@"Y16#XK\3Q>&-/MY/L[75Y>7"6MG:JVTS2N<
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M83K\\L>P84HP&"/;@UD:A'H4GQ$\>FY73V9=&0CS-G#['W'G^+E<]^1ZU[
M%Z #OQ2;$))VKD]>* /%?"FIQ65[X!U#5+F)=&_L)[6&>1QY4-WD9#-T5BB[
M1GW%5M6M5MO"FL:@@0:'_P )7#<VC_\ +-8=Z^8Z_P"P6STXX->YM&C(49%*
M'JI'%*5!7:0"N,8H Y_Q'J-E_P (!JNH10M>V)T^5Q' Q0RQE#]TCD CN/K7
MDVAZOI2^++*>;489+)_"<MN%L8RJQ;6!,*$Y+.J@DDG.><#I7O5,$,:@ 1H
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M"VIR>(9]7TK7S9M<PQPS07%FMQ&%3.W9DJ5^\<\D'- 'FP-AX2TWP3,NMEM
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M?$5Y/%):1"06\+(%AD".K 1[MY'R]&!')%>[NB2+M=58>C#-*0&!! (/!!H
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M=V.G<@5!;?$72KRSB>WMKI[R34&TW[$?+619U!9E+%]F,#.0QSP!D\5B>(]
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MGC+<H6).'SE@1C&<8Y(-'A[Q/I%EX1T&/3(]1NQ>PN]I!<2H;AD4_,SL[!0
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M@%2!D_0<&@#M9_&5K'!9&&QNY[JZLQ??9%,:211$#!?>X4')Q@$DD'L":T=
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M9K'-MYQ2/55G3R_LYF\S)3._?C(QMQG'-;/C'P5>ZOXFT74]+E\E=CZ?JAR
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MNSM*C8H&4SG))/;&.>/0: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%G>7-F\*R_WT:/>3D'H<X]J /2)H8KB%X9HTDB=2KHZAE8'J"#U%. "J%4
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M,F[Y6.&(&W P!S0!Z317G-QXL\2WWB35=.TJ33(;6#2HM1@EGMW=\,"=K .
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M9*9;6ZC0-C<,.K*>JL.HR#[TFC>$['2Q?2W&V^O+^X-S=3S1+\SXP %Z*H'
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M?:1P)%9P P(J(YC!8!0 .>O:KU% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,RHI9B%4#)).
M !2U2U:RM=1TJYM;VVBN;=T.Z*5 RMCD9!]P* ':=JNGZO#)-IUY!=Q1R&)I
M('#J''49'&>14EY>VNGVKW5[<PVUO&,O+,X15'N3Q7E_[/7_ "3:3_L(2_\
MH*5J?&VRM;CX6ZM<3VT4D]L(V@D= 6C)E0$J>V1QQ0!WUK=07MI#=VLJRV\R
M"2.1#D.I&01[$50O_$>BZ7.\%]JEK!*B>8Z/( R+_>8=A[GBJ?@/_DGOAO\
M[!EM_P"BUKS?Q+#XL\#>+M<\8:"EOKFCWS*-2M#S)#Y:XP<<@ $\C. >1QF@
M#V2">&Y@CGMY4EAD4,DD;!E8'H01U%25X[8_$?3[;PUX0T[PM;BS_MF^>V47
M0WBS'F#>  1NYD 7MC&?2M'4?%_B_18=!T;58K*#6=6U=K..Z1-Z&V4K^]"A
MN&.\<'\10!ZC17DMU\2-9MM+\;V8^S-JGAQU:&Y,)V31LV/F7/# >AQR.*9I
M?Q$\164G@E]::PN[?Q.2N((&B>W8E0O.XAA\ZYX'>@#UVBO'M"^)_B#Q%J?V
MO2]/>\T_^U_L36L5E(?+M=O^O:;[H;)^Z>W;O7L- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,,%E8+UX'6I-0O/B1J/@&#PC)X/U0VJH$FN'5GEFPX<<E>,$?EQ7K]EX\O\
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M>&2'3;"VLXY&WND$80,?4@=ZATWP[HNC7$MQIFE6=G-,,2200JC/SGD@<\T
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M:/8M->+MN9# I:8>C''S#CO43^#O#4D<4;Z#IK)"GEQJ;9,(F2=HXX&2>.E
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MXZUI000VT$<%O$D4,:A4CC4*J@=  .@H DHHHH **** "BBB@ HHHH ****
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M[3Y7V";>8_.W[\;<XV]_PH ];U+Q9HFD3S0WMX4:!5><I"\BP!NAD95(3/\
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MA<Q/#;_8S]HN7\Q&>1XT!V\+U;D[?<4 =K=:I!%XT@MF\1)"(K&26;2S"#O
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M;XY$EC62-@R. RL#D$'H:=6%IGBNQU;7KK2;>"\5X(4G2XDAVPSHP!S&V?F
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M-IE)\LY!;KTQD8KK=7UQ_+UVW&F0WME96'FS$W&T2LRDF+&TX^09)ST9>.>
M#HXY$FC62)U=&&593D$>H-(DT4DDD:2(SQX#J&!*YY&1VKS"Q\2ZHEY\/[#0
M],L;32M3LI+A;5KEP1MASL+;#\HW@C@EB.<5>A\6Z7HNI>,KV71H[.ZM;JV@
MFD2?<;R1U CR2 %QN&>N.3S0!Z)5:^L;?4K5K6Z5G@?[Z*[*''H<$9![CH>A
MKAF^)XMH=;-UIT<C:;:I<I+9SM)!,K,%P7* J5)&>#QS[5T_A[6;G68YI)8K
M(P*$,%S8W7GQ3 @YP=JX((P1]/6@#:551%1%"JHP !@ 4M<-_P ))K*?%*^T
MJ9+--(L],6Z),[ A&?F0_(<L-I&W@ =^::/B#<QZ3I>OW&D)'H.HW"0I,+DF
M:)7)5)'39C!.,@,2-PZT =1KVA6?B/3#87IF6/>LJ202F-XW4Y5E([@@&JNF
M>&(["YCN+G5-3U.6$DPF^G#",D$$A551G!(R03@GU-2>*O$$?A?PY<ZO)$)5
MA*+M+;5!9U0%C@X4;LDX/ /%8.H^.KS2_#<VLS:997,"7<4"/:7Y>.9)"H#H
MWE\X9L$>QYH [>BN2O\ QI-9:]K>E#2UE;3=,&HJXN<>:N2-I&WY3P?6LFR^
M)&HR#P[>:AX<^RZ5KK1P07*W8D9)G7*AD"C"DY .<XY('2@#T.BO-'^)^KKI
M&J:NOA3=I^DWTEI>NM^"X",%9D79\V,Y.<?4\XW&\8W>HWFI0>'--AOQIL$<
MDS3W!A\QG3>L: (V3MQDG&"0/7 !U]8.J>$[+5]?L]6NKO4,VR@"TCN66WD*
MMN!=!PQ!_D,YQ7,O\3KF\;0!H.@'4#K=I-/;A[H1%7C'S(V5(&#D9SVJSX7\
M1>(]5\?:_I^HV5I;VME!:9A6Y+- 9$=_[F'8D@'E0-HQN[@'8W^G6NIP""\C
M,D(8,T>XA7]F /S+_LG(/I5JN4\3>+;[0_$>BZ-9Z,+^751-Y3?:A%M:-=Q!
MRIXY'/IG@G@Y=O\ $MOL]U:WVD&VUZ#4HM,%B)]R22R\HPDV_<*@L3MR .AX
MH [^BN)N_'LVC7.M66L:6L=[IVG'4HEM9C(ES"#@X)52I#<'(]ZI:OXVUD>!
MM;UC3H-*?[-:I-;W=O>M/$V[=N_@'SI@?*?[PSCI0!Z'16+HVJ'^Q+%]7GM+
M>[D@1RHN=VX$<-EE4Y/T_$US6I?$+4[2\\56]KX>CG'AU(YIY&OM@DB:,R9'
MR'YMHZ=.O/3(!W]%<7IWCJXO-?T.RN-&-M9ZY:O<V,QN TF$17(D0#"Y#<88
M^^.U2/XBW2Z_IEA=Z/';1ZE>2VL,4ER1=(JY"RO$4&%8J<<]".M '?$A5+,0
M .23VI$=)8UDC971AE64Y!'J#7F-YXNU/Q3HOB:QD\+(NG6GVZRN[IKM75'B
MB+*0A4%LMCZ9!YYQJ?#C6GO?"F@V6G0V]S;VFG6\=Y<&YVF&3RU/EA0IW-@@
MGD8R!UZ '>4UW2-&=V"HHRS,< #U->?Q?%&&YN].>ULX;FPO[S[)&T-P6G3)
M*K*\>S 0D?WL@$'KQ5&Q\4:Q?^%_'-UKFEV5[9V%U=6[VR73*"D:*&C&4^[C
M<=V<DG[H[ 'IZ.LB*Z,&1AE64Y!'J*9<0BYMI8&9T61"A:-BK $8R".A]ZX6
M#QA<V4WAC1-)\.Q,FI:4)[53>;$A"(IV'Y2=H! SR?:G6_Q($OA>VU*72S'?
M7&JC2!:B;*"?>5R9-OW."<[?;% '1>&_#-IX8LGM[:YO;MY&W27%].9I6QT!
M8]AV XY/J:T+?3K6UN[BZCC/VBX(\R1V+,0,X4$GA1DX4<#)]36'X?\ $]WJ
MWB+6M%NM-CMY=):-998[CS%?S%#)@%0?N]?3%4-<\::Q8>,'\.:7X;&I7'V#
M[=&PO5BW+OV$'<N!WQR<G'3G !VM%>>W_P 48+::26VLX;JRAO?L<JQW!-SP
MVUG6((05#9_B!(&:NZEXZN8HO$%WI>F07=CH.Y+N26Z,3/(J[G2,!&SM!')(
MR>/>@#M:9+-% F^:1(UR!N=@!D\ <URMEXSEO-?TC2_[-1?[2TK^T8Y?M!.T
MX7*$;/5NN?PK U3QG:ZYX#M-5U'PY%<V\FJK:O;/='$;K-L5PVT9Y&<8% 'I
ME%<0?&VKR^,M3T&T\-B>/39;?[1=?;54+#*"2^"HY YVCKAN>F:ME\3XKZ_T
MGR+**:QU2?R(FAN"\\6<['DCV853CGYCC(H ]!HKS63XI7\.CW6KR>&O]!LM
M4;3KHK>@N"'";HUVC=R>A*]N3R1LV_CF2WUC6=/US35L/[.L!J7F1W'G;H,G
M.?E&'&WH,CW]0#L:*X32_B'+J.MV.G+IL$G]H6\DUN]M=&3RV5=PCF^0!"1W
M!89!'/6J6F?$^^OM.\/:K-X>6WTW6+\:>)/MH:2.4NZJ0NSE?DY.0>O'0D ]
M(HKSBQ\:ZW;7WC>\U.SMY;+1#\L5O.VX!8]P !3G.<EB1CT(%=1X9U^XUY9I
M7BL&M1'&\-U8W9GCD+;MRG*+M9<#(_VATH WZY*S\ 6>GJ;>TUG6X=.+,?L"
MWG[H!B20#C> 23T:NMHH I6>DV5A/)-;0!)'54+%B=J+]U%S]U1V48')]:NT
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5S'CKP]J'B30X+33KF".6&\BN'BN<^3<HAR8I,9.T\
M9^E=/10!Y/J?PX\2WVG>*K);G1DCUR2VE!7S$$)CV' &#Q\F!ZYSQC%=!?>$
M-2U?QE<ZI?\ V--/O-";2+B**9S(-S%F=<H!U)&/3GVKN** /+8_ /BY[7PS
MI]SJ>D/:>'[Z*:"81R>9+$@(4,O0$# P#^/'/8>-?#+^*O#QLK>[^QWL,T=U
M:7&W=Y<R'*DCTZC\:Z*B@#@+WP=XD\4^&;^Q\4:Q9+=RJ@M1IT3"*%T8.)#N
M.68D 'H ,XZUH1Z#K6H:YINMZRNG"\TJVFCM8K65RDLLH"L[,R@J,+@* V,G
MDXKKZ* /+K3X?^(+7P?X5T7S-,:70]574&D\^0+*JN[!1^[X)\PC/;:.N>+E
M_P""-==?&-K9W.G&R\0;G0S%Q)&[($.< C P3WS[5Z+10!Q.H>$-3NM+\+W%
MO/:1:YH!7RRQ9H91L".I. P# #G!Q[U%?^#=3U&S\3W<ILDU?7+-;$(LKF&W
MB"E?O;<L<L3]T=AQUKNZ* //=0\&ZQJ7AVST:^L]#O[6+38[0I<.X,,R@KYT
M;B,D97;QQTZ]STUGX=$7@B+PW=73W &G_8I9SU<;-A;FMRB@#SC1O#,/B+X8
M'P1KC-#?:>HMI=A^:,HQ,4J^JE0I![\CJ#C?L8/&BVJV5[<Z0=J;#J,7F&5N
MV[RB-H;O]XC/8CBNF\M/,\S8N_&W=CG'IFG4 <O)H%[<^)YI[J*UFTF;3/[/
MDWW#&5QDDDKLQSDC[WO[5RLWPOO[7X5WGA+3[FWGO+V0&6\NI74*BNI0 !6)
M 1%7' !R:]2HH XK4_!^HW5YHFOV-Q:V?B'3(/(8,6DM[B(C!1CA6QU(('!/
M0UM6::]++'/J\MC9PPY9HK.1I!+QCYG=5PHZX Z@<X!!VZ:Z+(C(ZAD8$,K#
M((]#0!Y[I=EJ6K^(?$_BS1)((VNH(K+2Y;I&\N4)RTI Y*%LA2.N,]"*] MQ
M,+:(7#(TX0>84&%+8YQ[9J0    8 Z"B@#C-5\-:Q>?$G2/$D'V'[)I\$D!C
M>=Q)('!RW"$#&>F>?45/J.@:K<?$/3?$$ LC:6=G+;&.29ED<O@YX0@8('>N
MLHH \MM/ASXAM=#M#;ZE8VNMZ=J4]]9S)NDB99L[XW!4$ @XR,UW7AZVUR&S
M>3Q#>6MQ?RMDI9HRPQ*!P%W<GN23Z^U;%% 'GWB#P/J7B+5(YKJ/2D:"_2XM
M=3C++=PQ*P/EX"@-P",EL#/0D9IL'@WQ5I&LZI!HFN65OH.J73W<HEA9KFV=
M_OB(CY>>Q/3T]?0Z* .''A36M*U;Q!)HLU@]CKC>;(ETSJ]M,5VLZ[00X/7!
M*_6N=ETF?PW\1_"&DZ(+>9[+1)HE6[E,8E 89.Y58@DY;H>A'N/6JJ/I>GR7
MRWTEA:M=KC;<-"ID&/1L9H X.Y^'.I+:KJ6G:I!;>)5U2;5!,4+0%I%V-%CK
MLV #/7@GOQU_AZVUV&S>7Q#>6MQ?RL,I9HRPQ*.@7=R3U))]?:MBB@#B?^$6
MUK2M;U^XT26P>RULB62.Z9U:VFV[6==H.\'KM)7GO52Z\!WUJ/!UKI#VAL_#
MS^8S7,K*\YV[3P%(&<DYSWQBO0:* $(#*58 @C!!Y%>9K\)A%X1OM)AU)EN_
MMHN--N<G-DB2%XT4]1C>^3ZN?05Z;10!R&M^$;@ZEX?U;07MXKO14:"."Y+"
M.:!E"E"R@E2, @X/TK&U[X?ZKK&BZ^4EL8]6URZMIIR9'\F%(-NQ5.W+GY>3
MA?O>V*](HH XCQ=X/O/%6M^'[BYM]/DL+%9A=V\LKDR>:FQ@N$_A'(/!)].M
M7_ VBZYX=T8Z3J]W;W<%NY6RE1V:00_PH^5&2HP 1^7%=110!Y?XH^'GB#6K
M_P 4&"\TMK?688DAENE<S6X0#]VN!A4+#)(_(FM8>&?$9\86NNM/IJF+1VT\
ME'?.\G>' *D8# #!/(YXZ5W5% 'FG_"LY=4U2>\U.+3;!KC39K*[;3"W^F.X
M'[QE*J%*D$X^;)QD\5I6?A+6KN#P[8Z]-8/:Z#.D\<ULSF2Y>-"D992 $QG)
MP6R1VKN:* .;\>:#>^)_!M_HM@UNDUV%0R3NRJ@#!B> 23QC''7K6?!X>UZ/
MQTOB)TTTH-&&G&$7+Y+A_,W9\OINX^G/M7:44 >4Z?\ #?Q)H^@>'6TS4=.A
MUW0S<1H[[WM[F&5BQ5_E##!/;/3.?39UWPIXFUGP[96T^H6%QJ*:C%?SR/OC
MA3RR"(XU 8[>.I.<Y/? [VB@#S[6_!FOW.L^);C2[G38[;Q!IZ6]S]HWEXI$
MC9!MP,$$-U/3K@]#%!X&\0:1>:!JVDWVG-J=AI::5=Q7".(9X5.5((RP8$9]
M_:O1J* /*[/X9^(++2%EM]9LH=<M=6GU&TE2)C%B4;7C<'G!'IT]^M=#)HWB
MR\TB)=5FT34;B6?-W921,MHT(1@$7*LV=Q#;B.V,8%=G10!S/@;PN_A+1+BQ
M9XPLUY+<QP0LS1VZN1B-"W) QUP.2>*Y#7/ASXDU)_$20WNDNFI7T=Y!<W"R
M&=51D*PD@85%V\8S]!G(]5HH \]/A+Q?IGB*_OM UG2X+75RDM]'<6[N89@H
M5GA&><XSAC6D/#&K67CM-=L;JVFMI--CLKA;LN96*,6# CC+9P2>G7!Z5V%%
M '#>'O!%S!X)U?PYKAM9([^:X<-;.S;1*2W\2CE2>#[#I5G1_"=]I'PXET'[
M1%=ZI/;/'-<2NP5Y&79DG!.%4*!QT4=*["B@#SJV\$:]:0^"YH+G31>^'X);
M:3>7:.1'0)N& #D!<XX^M,N_A[JNJ7/BI[B\M;3^U;FWN[*:W=G>WEAP$+ J
M 0< G!XYZ]:](HH XNUTOQW-I5R-5U31Y+["1P10P,('3>ID,NX$DLH*X  &
M3ZY$G@WP>_AS5M:U#R+.QBU$Q%;"Q=FAB* @L"57EL] H QWKL** ./O_"E]
M<>/)M9BFM#IU[IHT^\AE#>9M#,24QQR#CD\=>:R[/P)K!\.:?X4U&YLIM&L;
MF.1;E&<3S11OO2-DQM4Y !8,>!T[UZ)10!F:_:ZA>:4T&FFT\YG3<EVNZ*2/
M<-Z,,'JN1T[UP;?"^Y;PYXDL[8V.G2:I<07-M:6[N]M;/$5/4J#\Q!SA1@8Q
MTKT^B@#S6^\.>((+WQ%XEU:YTS;<:#):O!:ASL*JQX+8R.>I]>@ZU!X.T'4O
M$/@WP5_:#62:9IGD7\302,TLSHA\M6! "8+<X+9QVKTRXMH+NW>"YACFA?AH
MY4#*WU!X--MK*UL[86UK;0P0#.(HHPJ\]>!Q0!Y)X6TG5?$6A>,M%MY+&/3;
MW7KV.>X9V,T0+KN"H%VME>A+#&>AKJ[;PGJWAWQ!J=[X=>Q>SU.*)9+>\=U,
M$D:; ZE5.X$=5..1U%=;9:98::'%C8VUJ),%_(B5-V.F<#FK5 'GVF^ +S0]
M9\)/82VSV&AVTT$IE=A),9?O, %('.3C/?''6M>Q\.ZGI_Q"U?7(9[1M.U6*
M 3QN&\U6B1E 7M@Y!)/IC'>NJHH \Y\>-=K\2O )L!;M=!K\HEPY1&_<KD$@
M$C(S@X//:EOOAS>:@MWJS7EO#XAEU2#4XF4,T$;0KL2,]"R[<Y.!R>G&*[J?
M2]/NKN.[N+"UFN8L>7-)"K.F#D88C(YJW0!Q<OAO7+O5+WQ!))I]MK3Z>MA:
MQHS2PHGF;W+EE!;<>,;1@#KSFLA?AI-+;^* D>GZ5_;-BMLMI8LS0+(-Q\TY
M5<$Y P!Z\DFO2Z* ./A\!Z9JUA9/XKTG3+[4K>!;?S(T8J$7H 6Y/4GH.M9M
MSX-UV6\\<R1G31%XBM4MX 9WS#LB,0+?)SE3NP.XQ[UZ%10!P%MX1UV/5O!-
MW(VG;- LY+6X"S.3+OC6,LOR=@H;![DCWK%LOASXJM%T@&^T:2;3=4:]-RRR
MF6[#;LM*>[ , !Z?Q#'/K-% '":3X3UNP\/^+;&4Z>TVM7=S<P%9GVQ^<NTJ
MQV9^7&<@<^W6L_PSX UOPKJFDWFGRZ='']B2TU>W$K[+HH-J2J-G#X]>O3N3
M7I=% 'G_ (<\(^+/#DT6CP:Y8MX8@F,D.86^UJF[=Y6?N[>Q;DX)QCC#?^$*
MUVWTOQEI=O<:<]IKLUS/ 9"ZO&TX"G<0",* > #GCD5Z%10!P-EX2UZWUOPI
M?R?V:4T73FLIE6=\R$J%W+^[X'R@X/J1VR>7UG1[WPWX5AT74KO2(9-3\0&[
MCEGDD\@*292KR84QD%0 R\DG'&21[-4<]O#=0M#<0QS1-]Y)%#*?J#0!P_@B
M]F76;RS,>B7 GC-S->Z5>27+;P54+,SY.2#\OS'A#Q6DWA_4S\3U\2 VGV :
M9_9Y0R-YO^L\S?C;CKQC/3G/:NEMK6WLXA%:P101CG9$@4?D*EH \_L?"/BS
M1-4N[/2-<L4\.7ET]RRRPL;FVWMN=8B/EY).">F>GKC^*O#&N>']%\<W%A>Z
M>=#U2"XO9HYHW,\<IC(<+@@$-CJ>GH>_K%0W5I;7UNT%W;Q7$+8S'*@=3CV/
M% ' 6>@:M=1^#?$>ASV'FVVD+;3)=[]K1NB$,NWJ00>.,^HJD/AWXAC\ P^'
MUN],EN$U3[=YS%T4 2>9C[IR2>.V/>O3;:V@L[=+>U@C@A3[L<2!57Z <"I:
M .1T?PYJ5MXT\1ZO?"S^QZQ%!'Y44K,Z>4A7G* $$,?I[UG>&?"OB_P\UOI!
MURQF\.6;[H#Y3"[9 <K$S?="] 3@DC(X[=_10!Y9-\/O$<W@W5]$\W2EFO\
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M[9-JVGV4$OF).=UXI#$(3LX.!@#GGO6CH7C&3Q!IGAR[LK:W9]51Y9X_-/\
MHZ(,.0<<D.53''+4 =1!=6]R91!/%*8G,<@C<-L8=5..A]J&NK=+F.V>>);B
M12R1%P&8#J0.I KR34O%.H6O@_Q'>:)I=AI5U%XB:QNVBD9C(Q:-6D!VCYF+
M=2. /6NIO=92S\?Z7!JVD6"W TVXN!J$<I=HE7&]0"HX]\_E0!V]%<!I7Q$N
M=2U/1E32_,L-5SM:%9#); C*&3*!<$=<'@^O6K7A#QO-XKGB>)-/\AA)YT$=
MP3<VC*<*LB$#KSSTR._6@#M:*XGQ[K.MZ7J7AFVTHVRQ7VI)!*9'8,_!8+D
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MRV<RKN$,D9!0X[CC&/0UGR^%]5U._?5M4EL#J$6GRV5K';AQ$ID^_(Q/.>
M,<<\G/'95C6_B2TN/%EUX<$%REY;6RW3.Z@1LC-M&TYR><]NU '*W?@/5[CX
M5V7A!;RR%Q;F)3<D-M*QN''R]<G !K1\,^$]1\->(]2FM;BU30K]A.=/7<3!
M.5&]HSC 4G/'TZ=*[*B@#BO%6FR67C+P_P"+D#&VL1+:W^WDK#(.)/HK8)]
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MM!([4 <EX+US4M8AM/#5_>W7]N:7?S?VK*)2&:*,_*?]URZ #N%<CI4%A?\
MBGQ-9/KVGZC:636VIR"7S]2D$<<,<A4Q/ (RH)4 YW9R<Y'0>DVFBZ?8ZM?Z
MI;VRI>W_ )?VF4=7V#"_D#6,_P .O"S^)?[?.F*+\R"9BLC"-I <ARF=I;/.
M<=>>M '#ZQKMWX:UCXK:O8*#=01Z<(B1G:6BV[L=\;L_A6_>F^T'Q;X7M;+5
M[^YM-82:WN1-,9?F6/>LR;LA3UX'RX/2NDC\':)'?ZM>M;22RZLGEWRS3O(D
MR@8 *DD# R!@<"C3O"VEZ$4N;2&[N)+6%H[99KEYC$G&4CWMA<X [= ,XH \
MIM=2\20_"NR\:KXEU*>_MKW8UM(RF&:,W)B*,H&23GKGCH,8%:6KWFMO_P +
M'E3Q%J<0T5HYK)8G50I\K?@\<KVQ^>36S\./ WV+PQ9QZ_I]Y#>6UU)-]FFN
MR\._S"R2!%<ID CJ.HSC/-='+X#T*8ZQOCNS_;&/MW^F2_O0.@^]QQQQVXH
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MX)%\R2!93SN !PV=V"?:L;7=1@UWPC;&*[UN&2W\2VT$UI?2L)K<DIE&.3N
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MU)HM*U#^S;_38]0MX\@WDN(HF/3S,'(%58_%NEQZY9Z!=7]J=6EM?/D6.0;
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MJCL+8;?,94(*G#+SD$<'/>N]\!/X?U+7=6UK0M6U'5'NHXEN[B>)8XMRYVJ
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M158851C+<\L.*6]\9W6F:+I0NM.1M?U.X:T@L(Y<)Y@8AB7(^XH&2V.XXYK
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MORQF8DX]%VX/IBNBNO[+C\3?$VRM[F.SMY-'@/\ H:@E2(G#$(O4C(SCU[4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %-9%<890WU&:=7$_%R6:W^&6L7-O<7%O/"L;))!,T; F10>5(R,$\'B
M@#L_*CR3Y:Y/7BCRH\*/+3"G*_*.#ZBN4N]1T]/'^G6\HU4ZBFG2RQ)&W^CR
M)QNRN?F?ICBJMC\4M)OH=,N4TW5H[+4;S[#'=2P*$28L5"M\V>2O4 @9Y(.0
M #M1#$!@1H!G/W12F-"22BY/?%<KJWQ TK1S<RSP73V%I<+:W5]'L,<,A(!!
M!8.0"0"54@'Z'&YKMS#:^']0N+@7!@2W<R?9O]8%P<E3D8('.: +IBC*%"BE
M#U7'!IQ12H4J"H[8XKSFS\9/I\O@G2=)TS4;NPU2T:9)[B6-IGC2+=M.YQ\P
M+*6)(&.!GMMZA\0=*TZ4O-!=-8)=BRDOTV&))<[2"-V_ ;Y20I&: .I,49))
MC4D]3BCR8N/W:<=/E'%<;??$S3+%M9!TO5Y1H\JQWK1P*1&I&=^2PROZ^V*T
M-.\;:?J6OP:2EK?0O=6YN;2>>$)'<QC&2O.X=1]X"@#/L_!6K6*36<7B;S--
MEEDD*3Z?').-[%F_>DX)R3@E376V=E!8Z?;V,"8M[>)8HU/.%4  ?D*RO$WB
MNR\*QV$E];W<J7MTEI&;>+?M=NF1G/KTR>.E99^(VG1V6NSW.F:G;RZ)Y;7E
MM)''YBHXRK##[2"/?/M0!V 50NT* /0"D6-$0(J*J 8"@8%87_"6V7]N6FD_
M9KLW%W9->PL%4JR#&1][.[D<8_&L.#XK:+/8Z;?_ -GZO'87]P;6.Y:V!59@
MS (0&+$G:<;01SCKD  U8O"]S%\07\3+?PB!M/%@+,6Q!"!MX._=US_LXQ^=
M=&L4:'*QHIR3D*!R>M<)KOBN'7/!_C*U@AU+3=2TBR=Y8Y6\J1"T;/&P:-CP
M=OK[$4OA/QU9M9^'=)O[;4K>:\L8A;WMW#MBNI%C4L%8G.>I^8#/;.1D [KR
M8O\ GFG/^R*5HT="C(K(1@J1D5RB?$+2FO-/C-O=K:ZE*T-E>80QSN,X  8N
M-V/E)49I?#WC^Q\2ZC]DLM+U=%626)[B6V ACDC."C,"0">HH ZHQHV,HIQT
MR.E)Y,7/[M.>ORBN3\2ZM/=>*-*\(V5S);/?1275Y<0G$D=NG&U#_"7;C=U
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MB[#U7'!_"GT4 -**4V%04QC;CC%&Q-FS:NS&-N.*=10 4SRH^/W:\=.*?10
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF_RN2J[M@SP,\^YZ3XA6<EUH5E-'9R77V34[2XDCBB,K^6LRER% )/&>!VH
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M7\U/L\[PL5WC:Q1AVSV->/:M';ZAI7B21-,O3K.I?8_]#BT>XC(BBDCW;2R
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M&4JP!!&"#WI:*      8 Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2-6T#1[C1]0MXH[."XD.GF.<R,(&8LJ-P.5SC/ICTKK:* .?_P"$*T3^Y?\
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M::39O9Q6[P[BZ.5+%FW#YB4!Z8Z\5H:WX?EU/5M*U.UU V=UI_FA3Y(D#I(
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M\,^N: ,34/B7%9:);:N-,;[)-907G[Z<1LXD/*1#!WLHY;D  CGFM1O&4/\
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M??UXKS_#F6Y@OS+X@N!=SW\>IP7,<"*;>X1 F['1EP/NGL><GF@">7Q5KO\
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M1RK&P1) S$,2,' P,=\59F\&Z1=V,]O=1S3R3S)</<O*?.\Q/N,'&-I7'&,
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M#/O+#!P.!CKG:TW6M1UN]O[B/68K&*PUM]/EM'C0JT0^0<D;A(S$$'..@P:
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MJ^&Y(+J"VO(UU*R%VZL[M@)/RK-DEMK=?XCQ0!Z!;W$-W;QW%O*DL,@W)(C
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M'.\#%H9,E7C)Z[74AE_ UI5GZEK=AI,MM#=S,)[EBL,,432R28ZX503@=SC
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M8[Y2MRL:E?,4G)7CHN?X1Q[5T-% &#?^'(8XH[S1[.Q76+.W\BQFNP[)&O\
M=.#DC!/TS5[1["73[';<R1RWDSM-<RQIL5Y&ZX&20 , 9). *?IVJ6NJ6,%Y
M 9%CG++&)HVC<D$@_*P!_A)^G-7: "J>IZ59:Q;+;7\/G0JZR!=[+\RG(/!'
M0\_7%7** ,S5O#VE:[]F_M*T%Q]E?S(-SL/+?^\,$<^_6JESX*\-WFH-?W&D
M6TER\BS,Y!^9UZ,1G!;CKC)K4DU*SBU.#37N$6\GB>:.$GED4@,?PW#_ "#1
MJ>HVVD:9<ZC>,ZVUM&9962-G(4<DX4$T 9<_@OPW<ZBVH3:/;/=-,)V<@X,@
MZ/C.-WOCGO3V\(Z"]G<VCZ=&T%S<"YF1F8[I0<[^3][WJU>:Y8V&@2:W<22"
MPC@%PSI$SD)C.=H!/3GIQ3H-8M+B]-I&9=XMDNMS1,$\MB0/F(QG@\9S0!6_
MX130MM^K:;"R:@ +I'RRR@?=R"<<8&/3 Q39/"6A36#V,M@LEO)(LL@>1RSL
MOW2S$Y;&!C)XP/2KS:G;#4X-/_>---"TZ,L;%-H(!R^, \CC-7* ,*Z\&>'K
MV2XDN=-29[F5)I6=W)9T&%;.>"!P".W'2DA\%^';=X7@TJ&(P7!N8O++*$E/
M5@ <#O[<GU-;U4-9UFRT'37U#4)'CMD*JSI&SX).!D*#@9(YZ4 8WBKPW<:_
MJN@3*MNUKI]TT\ZR3/&Y!1D&PJ#R-V[.1RH^HT?^$8T826,@L4#V#M);$,P\
MMVY9NO).3DG).3GK6O10!E/X:T:34VU%K"(W3NLCMR [K]UF7.&8=B1D4P^%
M- ;7_P"W3I-J=4X_TG9\V0, ^F<<9ZUL44 8"^"/#27?VM-(@2?S'E$BY!5W
M!#%<'Y<Y/3')SUJ5O".@2>'AH#Z7 ^E Y6V;)53G.1DY'/I6U10!B0>$- M?
ML7V;38X/L2,EMY3,GE!OO8P>ISR>I[TMKX2T.R-D;:P6/["[/:A9'Q$6^]M&
M>,]_7)K:HH YZ+P)X7MY+^2#1;6)[]62Y,8*^8K'++P> >X& >]6%\)Z&KEO
ML"DFT-B=SLP-OC'EX)^[[5LT4 4[;2K"TTL:9!:1+8A#'Y&W*E3G((/7.3G/
M7-4K?PKHEK9S6L%@J0S1"%UWL3Y8Z("3D)R?E&!R>*V%97&58,,D9!S2T 9\
M>EPZ?H;Z=I<"1QI$T<$3.VQ>, 9Y('T''I6#X3\$6FB^&+/3[^VA>[CM/LLL
MD4SLI4_>V9QLW8!( &3USUK63Q-ILNLII<;3O.\DD(=8',7F(NYDWXVY ]_4
M=1BMB@#(;POHK:5:Z8;"/[):,&MD#,#"1T*-G<I&3T/3BDNO"NAWFGP6,^FP
M/;P.9(EP04<Y)8,.<G)R<\Y.:V** ,$>"O#8L[>T&CVRV]O,T\2*I&UV^\?Q
M[CH:9/X%\+W.EVVFS:):/9VKEX8ROW&/)(/7GOZUI6.LV6HW^H65L[FXT^18
M[A7C9-K,NX8R!D$'.1Q5^@#-7P_I,>HVNH)I\"75K#]G@D5<>7&,X4 < #)Q
MZ9/K45WHB2:]#K%N0ESY!M)P21YL);=C(Y#*<D'W([Y&JSJI4,P!<X4$]3C.
M!^ /Y5!?ZA:Z79O=7DHCB4@9P26). H Y))(  Y)- &0G@GPZEJ;1=.'V4N9
M# 97,98G))7=@DGU%7[W0M-U"[2[N+<_:E3RQ/%(T3E,YVED()7/.#Q58>*]
M)>_N[%&O)+JS*BXBCL9W,>X97.$/4<CUI8?%6C7%[I]G%<R//J$ N;51;R8D
MB(!W9VX P1G)&,\T 3MX?TIC8$6:(-/;?:K&2@B/0D $#H2/Q/J:;>>'],O=
M6M]7GLUDU&U&+>8R,"GL,'@'OQS[U/#JMI/JMQIL;2FZMT6213"X4*Q(4[B-
MIS@]#V/I3X=2L[C4;K3XKA'N[54>>('F,/G;GZ[30!6T;2%TJ*Y=G\V[O)S<
MW4V,;W( X'90H50/0#J<FH]/T2/3;[4C (S9:A(UQ+"PSMF8 ,1V*L!DCL<]
M<\7;74+:\EN(H7/FVS^7-&P*LAZC(/8CD'H11<:C:VUY;6<DO^DW);RHE!+,
M%&6;CHHXR3QR!U(H IV?AG1K"XBGMK"-'ASY()++#D8/EJ20G''R@5C:%X-%
MKK.LZAJMO:RO=ZC]MMS',[ #:H4.A 4LI7<#S@L<8QDZ,GC'1(X9[C[3*UK!
M(8Y;I+>1H48'!S(%VX!X)S@<Y(P:W5970.C!E89!!R"* ,6[\'^'[Z2\DN=,
MA=KQUDN#DCS&7&"<'V!^H!Z@5+/X8T6YO_MLUA&]P0@=R3^\V?<WC.'QV+9Q
M6E+/'"KEVY1"Y4#+8'4@#DU'87L6I:?;WL D$,\8D02(4;!&1E3R#]: ,N?P
MAH-S]L$U@'%[,L]R#*_[UU^ZQY[<8],#T%3V.CK;ZQ>:K._F7<Z+ F,XBA0D
MJHSSDEBQ/<GV%:M55U"V;47T_>5NE3S0C C<G3<I[@$@''3(SU% %JL;Q3I,
M^N>'YK"V>-)FEAD4R$A?DE1R"0#U"XZ5LTV218HGD<[40%F/H!0 D1D,:F55
M63'S*K;@#[' S^5/K*/B321HO]L-=;;$Q&99'C=2Z!-^54C+?+D\ \"I[S6-
M.L+%[RXNXU@0-EE.XG;G< !DDC!R!TP: *6HZ5=WWB;1K]3 MMI[RNV7.]R\
M93 &,#!/K5W4-&T[59K2:^M(YY+23S8&<?<;U'^%)>:UI]A;I<7%QB!Y!$)4
M1G0,7" %E! ^8@<]ZNNZQC+L%&0,DXY)P!^9H S+'PUHVFWANK/3XH9=S,NW
M.U"WWBJYPI/? &:AGTJ[/C*VUF(P- MB]I(CN58;I%;<."#PO3BMNJFH:G::
M7%'+>2F-995A3",Q9VX"@*"<F@"W39"XC8QJK/CY0S8!/N<''Y52GUK3K6XA
M@GNTCEF^ZKY!7Y2WS?W> ?O8Z4MQK&G6EY':3W<:3R9PI/3 S\QZ+QTSC/:@
M"IX8TFXT;29+:Z:)I9+RYN3Y1)4"69Y ,D#. V.G:MFJ8U6S.K#2S(PO#$TR
MQM&PW(I4,02,'!=1P>]7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR'XY>./$7A&#28-#D-HET9&
MENA&KG*XP@W @=<^OZUZ]5>\L;/48#!>VL%S"3GRYXPZY^AXH X_X3>)-4\5
M> K;4M8(>Z\V2+S0@7S0IP&P.,]N/2NXID4,<$210QI'&@PJ(H 4>@ Z4^@
MKS];E=/^-]R=2=8TOM(CCTZ20X#;7)DC4G^+)!QZ8KT"JU]IUCJ<'D:A9V]W
M#G/EW$2R+GZ$$4 </\2YM/?PU<R0-&9DU"P6X=>@Q.A )Z9 .<=0",]174Z_
M?VJ:=?6!F7[5)8SRK&.3L5<$^PRP_.K4FB:3+9Q6<FF63VL1S' UNA1#[+C
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M,4F!B =$. #\Y';/4GO4&K:O-/X=\<65Q?*\,"V$L$)O3<^4&92^';D\X)[
MGBO6UT'1U*E=)L040QJ1;)PASE1QT.3Q[FF_\([H8C\L:-I^S:J;?LJ8VKG
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MXAO+6UUHA;*XG10C,1E0Q#$J3QC([UN-JT:ZZFDF"?SG@:X$F%V; 0#WSG+
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M66.4PG<),G*G=G'3 Z<4GA^6PEB^'^IWTPE5)[^V>X>0N=Y9S&A.<Y/8=^*
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MD02-]U2PR?H*!-$9 @E3><X7<,G'6@!]9NLZ-'K"68>>6![2Z2ZC>/;]]00
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M+"*5'*G#!6!Q]:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-9^:7.>H.1CCBG>*KR5+&+3;;SDN=2D%LLT<#R+"I^^[%?NX&0,D<D>];U%
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M*X+ILZGC&5QT!&*XSQ'I9FTKQM<V>FW$FFWTEDUA#'9N2\Z_ZUTCVY&1@%L
M'!KV2B@#B?B3#:2?"76Q%!&(%LR\2>5M"X(((4C@UQ/BK0;.6SUZZT'1ITL9
M])BA>*.SD5I;OSMP.S;DN$W9;MGDYKUS7-&M?$&C7.E7IE%K<KLE$;;25],U
M=AC\J&./>S[%"[W.6;'<^] 'FUSI.G:5XO59=&)\,W>CND*16;R(MPSY<% "
M5=TV\D G;CK6!:6&IZ7I26GBG3KJ[,OAH6MF1:O<^5-F0M&=H;:Q!CY.!\G7
MBO:Z* /%KF![71+E)-*OR^H>"XK2-5L9"6N(UD!5OE^5AE?O8X QVJY(%&HW
M%MK_ (=U74;._P!*LDT[R;5\QM&I+QEA@PMOPV3CIR>!7KM% '%>#;2/3O$_
MBNW?3GMYY=0^T1RBV*HT+11 8DQM/S!N <Y!XK,T\2VD'Q)M[F.1[A[N25 D
M9=GCDMU$8  )/0CCT->D57:R@-^M\$*W 3RRZDC<O4!AW ))&>F3CJ<@' ^#
MY;;2M$\,*MOK,NIFRALY+:1+CRXMPC\QFWC8FW83V]!UJYX8O6\.-XAL=3M+
MM)3J]S=6RQ6TDGVB*5MZE"H()R2",\8YQ7=44 </;PWQL_#7A@ V\]I9PSW<
MDMJ\L.Z)4"Q[@5!._P";AO\ EG[U'X':XT7Q#K_AJ>*=K=;HWEG<+:21P$2#
M=)&I.0-KDX&X_>]J[RB@#R#XAQ32ZWK(BTV]680V+PS0V<DYN0DNYL. 5B"#
MJ!AF)'/8U+[3[9AXAU&'1+D7?_"1V=Q;2#3I!((LPEV3Y<C[LF<>G/:O:J*
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M/$-YJ-K:-=1WE@+<JC*"LJD[<Y(^4ANO;%9=IX<U#0(;JWMK<WBWFF16I=&
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MXHMK."5$C 9!4E3C/K6K<W4%G#YMQ,D4>0-SG')X ^IK'\3 +:Z:%  &I6O
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M NZJ"0 6.,D]!3J "BBFQR)*@>-U=3T93D4 .HIID02",NH=@2%SR0.O%.H
M**1F51EB ,@<GO2-+&KA&=0QZ*3R: '44@8'H0:7('4T %%&0>AH!!Z&@ HI
MHD1G9 ZEEZ@'D4+(C,RJZEE^\ >1]: '44F021GD=:1I$0$LZJ!@$DXQ0 ZB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8Y(X0Y,H#.H.[9P-_<G)Q@OUOP?/:^'="T;1HKNYL-/N?-94O1#<*H5MFQR
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNZ;_ . ZT ;']I6/_/[;?]_5_P :/[2L?^?VV_[^K_C6/_P@7A/_ *%W3?\
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MM_W]7_&C^TK'_G]MO^_J_P"-8_\ P@7A/_H7=-_\!UH_X0+PG_T+NF_^ ZT
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MVG)$-Q%(0,D(X.!^%35PUAHNFZ+\3(8--L8+2*32W9EA0*&(D7D@5W &!WH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*Y
M34/^2GZ+_P!@VZ_]#BKJZX3Q-:ZC=?$/1H]-U!;&?^SKK]XUN)LC?'Q@D8H
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M4NL:YI$,-AX2U5[HVFFQ6YO3#8S2BZDC *Q*50C&Y06.?11U..G_ +%\8?\
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M\8?]#A!_X*D_^+H ZJBN5_L7QA_T.$'_ (*D_P#BZ/[%\8?]#A!_X*D_^+H
MZJBN5_L7QA_T.$'_ (*D_P#BZ/[%\8?]#A!_X*D_^+H ZJN7\!G_ (D%U_V%
M=0_]*Y:;_8OC#_H<(/\ P5)_\76%X2TOQ+-HTK6GBB&%!?7:,ITM>9!.X=OO
M]V#'\: /1Z*Y7^Q?&'_0X0?^"I/_ (NC^Q?&'_0X0?\ @J3_ .+H ZJBN5_L
M7QA_T.$'_@J3_P"+H_L7QA_T.$'_ (*D_P#BZ .JHKE?[%\8?]#A!_X*D_\
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ME(R-^UL$CDX]15*UU6/PUX$T_P ,ZD]S8W>HI/-<2"UDD-K#+*[8PJG]X0V
M#T.2>F#V7]B^,/\ H<(/_!4G_P 71_8OC#_H<(/_  5)_P#%T 8'B:YT/4O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH(!?C@ <>E '?T5R?_"8:A_T)^M?E%_\71_PF&H?]"?K7Y1?_%T =917)_\
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M"'B"6XGVB6>=TDD<+]T9+]!DX'3DGJ36A_PF&H?]"?K7Y1?_ != '645R?\
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MX3#4/^A/UK\HO_BZ .LI#T-<I_PF&H?]"?K7Y1?_ !=(?&%__P!"?K7Y1?\
MQ= #Y?\ DJ=M_P!@B3_T:M=57!:7JDVJ_$V.6?2KS3V72G 6YVY;]XO(VDUW
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M'7O_ "5O2_\ L$S_ /HQ:[$G S7%:G<0V_Q6TJ2:5(T_LJ<9=@/^6BT =H.E
M+50:II^/^/\ M?\ O\O^-']J:?\ \_\ :_\ ?Y?\: +=%5/[4T__ )_[7_O\
MO^-']J:?_P _]K_W^7_&@"W153^U-/\ ^?\ M?\ O\O^-']J:?\ \_\ :_\
M?Y?\: +=%5/[4T__ )_[7_O\O^-']J:?_P _]K_W^7_&@"W153^U-/\ ^?\
MM?\ O\O^-']J:?\ \_\ :_\ ?Y?\: +=%5/[4T__ )_[7_O\O^-']J:?_P _
M]K_W^7_&@"W153^U-/\ ^?\ M?\ O\O^-']J:?\ \_\ :_\ ?Y?\: +=%5/[
M4T__ )_[7_O\O^-']J:?_P _]K_W^7_&@"W153^U-/\ ^?\ M?\ O\O^-']J
M:?\ \_\ :_\ ?Y?\: +=%5/[4T__ )_[7_O\O^-']J:?_P _]K_W^7_&@"W1
M53^U-/\ ^?\ M?\ O\O^-']J:?\ \_\ :_\ ?Y?\: +=%5/[4T__ )_[7_O\
MO^-']J:?_P _]K_W^7_&@"W153^U-/\ ^?\ M?\ O\O^-']J:?\ \_\ :_\
M?Y?\: +=<I:ZUJ4B^*;D-YS:;=O;VML(R58"&)QG8I<G+D<9X[5T']J:?_S_
M -K_ -_E_P :YCPGJ=@FI^*PU[;*6UEF7,JC(^SP#(YZ<4 1Z+XHUF[T#5+N
M2Q$UQ:N1 -CGSCYCC;E$(.W 7Y=W*Y;&:ET#7-4U?PQ>W-PS0S6Z%HYTC'[W
MY2<\KL(SQ\I/3D@\5TB:CID:[4O+-5R3A95 R3DU3U+4=,BT2\1+RS11 X"K
M*H'W30 :/K(D\%:?K>IS)&'T^.[N9,85<QAF/L.M<_%XP=?&MV+R:XL]$BT4
M7Y2[A5-I\S&\$#=]WL3G/:FV<%AK_P (;'1)-3M[=KO188-_F#*,8E&2,]CU
M%8FH^'-2\2O>+K&I:%:I<:+_ &:7M;QI#O$@=9,%5X) RN?Q- '9MXVTB![J
M*]^T64]M;+=-%<Q;6:)CM#+U!^8A<=02,XJ>3Q590IB:"YCN#,85MF51([!
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M^-']J:?_ ,_]K_W^7_&@"W153^U-/_Y_[7_O\O\ C1_:FG_\_P#:_P#?Y?\
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MG_" >$?^A=T[_OP*/^$ \(_]"[IW_?@5T=% '.?\(!X1_P"A=T[_ +\"C_A
M/"/_ $+NG?\ ?@5T=% '.?\ " >$?^A=T[_OP*/^$ \(_P#0NZ=_WX%='10!
MSG_" >$?^A=T[_OP*/\ A /"/_0NZ=_WX%='10!SG_" >$?^A=T[_OP*/^$
M\(_]"[IW_?@5T=% '.?\(!X1_P"A=T[_ +\"C_A /"/_ $+NG?\ ?@5T=% '
M.?\ " >$?^A=T[_OP*/^$ \(_P#0NZ=_WX%='10!SG_" >$?^A=T[_OP*/\
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M0!D:;X6T+1KEKC3=)M+29EVL\,84D>F:U@,#'/XFEHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!, VL 2=WS!1A<<>M#E/6PXT,,W!5++1]7KII?>SZO;=+NCK_L=K_P ^T/\
MWP*/L=K_ ,^T/_? J:BND\4A^QVO_/M#_P!\"C[':_\ /M#_ -\"IJ* (?L=
MK_S[0_\ ? I/L=K_ ,^T/_? J>B@"'[':_\ /M#_ -\"C[':_P#/M#_WP*FH
MH A^QVO_ #[0_P#? ILEI;"-_P#1XONG^ 58ILG^J?\ W30!S'PXX^'NB@?\
M\/\ V8UU-<O\./\ DGNC?]<#_P"A&NHH **** "BBB@ HHHH **** "BBB@
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MHS7(?\('/_T.GBK_ ,"XO_C5'_"!S_\ 0Z>*O_ N+_XU0!U^:,UR'_"!S_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 <I?\ _)4=#_[!=Y_Z'#75URE__P E0T/_ +!=Y_Z,AKJZ "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\& _^(H_MKQC_P!"M;?^# ?_ !%=910!R?\ ;7C'_H5K;_P8#_XBC^VO&/\
MT*UM_P"# ?\ Q%=910!R?]M>,?\ H5K;_P & _\ B*/[:\8_]"M;?^# ?_$5
MUE% ')_VUXQ_Z%:V_P#!@/\ XBC^VO&/_0K6W_@P'_Q%=910!R?]M>,?^A6M
MO_!@/_B*:^L^,"C9\+VPP.O]H#C_ ,<KKJ;)_JG_ -TT <M\-<_\*ZT3<,'[
M/R,]/F-=77+_  X_Y)[HW_7 _P#H1KJ* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X^\_Y*YI/_8'N?\
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MK;_OTO\ A1_9MC_SY6W_ 'Z7_"K5% %7^S;'_GRMO^_2_P"%']FV/_/E;?\
M?I?\*M44 5?[-L?^?*V_[]+_ (4?V;8_\^5M_P!^E_PJU10!5_LVQ_Y\K;_O
MTO\ A1_9MC_SY6W_ 'Z7_"K5% %7^S;'_GRMO^_2_P"%']FV/_/E;?\ ?I?\
M*M44 5?[-L?^?*V_[]+_ (4?V;8_\^5M_P!^E_PJU10!5_LVQ_Y\K;_OTO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_@._^%%T'LJG\K.ZHKA?^%O>#_\ G]G_ / =_P#"C_A;W@__ )_9_P#P'?\
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M .?V?_P'?_"BZ#V53^5G=45PO_"WO!__ #^S_P#@._\ A1_PM[P?_P _L_\
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>modificationno16effectiv006.jpg
<TEXT>
begin 644 modificationno16effectiv006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K.UW4I](T6ZO[:Q:]D@C,GDK(L
M>0!DY9N@P/<^U:-8_BN\MK+PIJDMW<101FUE0-*X4%BAP,GN?2@#-^'GBN?Q
MIX1AUNXMH[9Y99%$49) "L0.3U.*E\8:IXATK2[N\T6TT]TM+=KB26^E8*P
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M1L[L7FEV>BW,5S<V;AU!=D;:C@X+;8V. >.,XR*\J\/P:U9#5-(T6_@UR!]
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MC(Q7!>$M0\0^.?B%X@,FL:OIL6E:E$T<",/*6%&D5H)$#XW-A><-]UJ *?\
MPSE<9!_X32?(Z'[&?_CM!_9QG;KXSF/ULC_\=KU'Q-X[TSPIJNF:=?V]])/J
M3%+;[/$'#L"!MQG.<LO;O]:I6WQ-T6XTK7+UK74(9=$;;?6<L2B:,9QN W;2
M.#T/;Z9 .#'[/UWY,<7_  F4FV,8!%FP/4G_ )Z^])_PSY=?]#E-_P" K_\
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M[A5402] 7*L05S_=)S[9S0!Q_P#PSC.%(_X32;!ZC[$?_CM-/[-KGKXPD_\
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M4 %%%% !12$A022 !R2:IZ9J^G:U;O<:9>0W<*2-$TD+;E##J,_C0!=HHHH
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M3G&YB#G_ &0.))?AG/-X7O\ 0WUQ?+O-2.HO*+/YE<N'*@;\8W ?AG\+^H^
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MOGI\_P KYY]^_/-7M*\*26GB=_$.H7Z7>H&S^Q!XK80@Q[@V6 )W-D#G@>U
M%7Q?K^JZ3J=E;6<UG:VTT$LC3S1F>221<;8XX58,W7)(!P!VKGK'QYXCU9/!
M!M8],B;Q##<>=YD3L(GB4G<,-R.^WKQC<,Y'3ZUX/?4_%5KK]KJTUC/':-93
M(L2R"2)FW';NX5L]\&L?2?AI<Z3)X:*^(#*F@-+Y"M9@;UD&&4D-Z=.^2?8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#/:KL.'42;CD]L =_6O8O^%<_#[_ *$+7/\ OJ;_ ..T?\*Y^'W_ $(>N?\
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MEM;0P)'%!)G=&@4 *<DG( QU-6I9HX0#(X4%@H)]3TH ?1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$$!H^$SMW'[V,^W-<U'XJN=4^#=OK?B;1;75+>ZN@6B%TR9W7!"DC9\NT[0
M"<@<GM0!Z]17!:_\2H]*N-42RLX+P:9(L4\;7)2:5B 6$2!#NVAAU(R<CMFK
M!\>/<^(+C2M-L[622W6W=HKF[,,\J2J&+1Q[#N"J>>1R"..,@':T45R/C3PW
MI5SI&NZS<VD=Q>+I4D<;3*&\K8LC ID?*<MU]AZ4 =:2%!)( '))I$=)(U>-
ME9&&593D$>HKRC1_"^BWGP:L=4DTZW%Y'H\LK2K$H:5C ZG><?-USSW -6_
M_BR\L=,\#Z)=:/Y=GJ>GB.WN_M +[HH@QW1@<*0.#NSZ@=* /3J*\]C^*,%Q
M>:>]M9PW&GWM[]D5H;@M<("2HE:+9@(2/[V0"#[5UWB+59]$T*YO[73I]1N(
M]HCM8 =TC,P4= < 9R3@X )H U**X&'XF0Q)XE%_:V_F:'Y +6-UY\<[2\*J
ML57!W?*<CBK&K^*/$^G:=KI?0+:*>PTXWT-S]I>2WDP"60ML!WJ%SM[\<CK0
M!V<DT<6SS)$3>P5=S ;B>P]33Z\T;6GF\.> +CQ!HUO?S7UW:"&X%T<Q3-'N
M68C8,M]XE>@/<UK6OCR9W\4P7FEQ6UWH.#Y(NBYN RDH5.P8#< <'DT =D9H
MUE6(R()&!*H6&2!U(%$LT<$9DFD2-!U9V  _$UQ-]J3?\)]I=K)X?M#KCZ7-
M+;W3WC;8R,;H^$SMR?O8S[5S*>*[G5/@LNN^)M$M-4MKBY^:$73)D&Y*KD;/
ME"MM  )R!R1TH ]?HK@]?^)$>DW.J165I;WG]ELJ3Q-<F.61B S+$@1MV%8=
M2,G([5,WCU[G79]+TVRMI)8([>4PW5V89Y4E4.3''L.[:IYYZ@CZ@';4V21(
MHVDD=411EF8X 'N:S_$.L)X?\.ZAJ\D+S)9P-,8TZM@=/;Z]J\_\;ZO)XB^%
M?B26XM=.DM8[6*:VN;.Z^TQNQ;GDHNUEP/\ OH4 >I @C(Y%%<3HWB^\&O6V
M@W^BM;+)I7VZVE2<2.ZKA2K(!\K<] 6^M1:-\0+G4/$6DZ/J&D16<FJ6\LZ1
M"Z+S6X09"S1E%VDKSU/>@#MS<0".20S1A(R0[;AA2.N3VJ2O";RTME^#_P 1
MHA;Q".#7[LQ($&(\21@;1VP..*]NA9UTZ-HT#N(@54G&3C@9[4 2Q31SIOBD
M21,D;D8$<=:?7EVA^-H-*\)>'9='\+)!;:MJ<MFMM'=_ZJ0R.,Y*\YVD]L5K
M1?$5X+37_P"U=*6VOM(N8;;R(+GS5G>7'EA7*KC)(SD<#F@#NR0!DG IL<B2
MQK)&ZNC#(93D$?6N2O+_ %+4+#Q%I6M:%'!%#8&2.XCD,T$X96RH+(OS*1TQ
MZ&L3P1XE?2_#_P /M$-DLB:O9.%G\[!B,4>\Y7;R#P.HH ]*IHEC,IB#KY@&
MXIGD#UQ7$Q_$13INHS2::%O+?6SHEO;K<9%Q/E0IW%1M!W$G@X"GKTKG;353
MH'Q3\6:KK5I;6BV^B17$HM)#()0&ZY*J2Q^[R.PYH ]:IK2QHZ(SJK.<(I."
MQQGCUKCM#\=OJGB6#1YK& "XMC/'<6=R9T0CK')E%VMCGC(-9?C[S+;XA^!;
MNSL%NKWS;Q$3<$+_ +G@%ST49)[]\ G@@'H]%>=2_$ZYLM/U0W^@B'4M*O8+
M6[M1=Y7;,0(Y$?9\P.<X(%:6L^,K^SU37]*LM.MVNM-TP:A%+-<-LD&2,, F
M01M)Z\\#(SD '9T5SO@34-1U7P3I-_J@B^TW%M'(720OY@*@[F^4;223P,@>
MIK$UGXB7.C:@ZW&C)'9+J4>GH9[DQSS[L9ECC*89 6Z[N<'I0!WM%<-_PG6J
M/XLU?1XO#JO;Z3-!]LN_MJ@1PR+O\S:5Y(7G:/0\],Q:9\2DU+5='A2PB:SU
M4L(I(+@R2P<93SDV +N'HQP>* .^HKFO&'BF?PLFDO%IAOA?ZA%8X681E&D/
M! (YZ'N/K62/B,;"+Q0-=TL6D^@" NEO<><LWG#,84E5Y)P.1WH [NBN1?Q5
MJUGK]EHNI:1:6]UJ5O+)821WC21-*B[FBD/E@KQSD TSX9Z[JWB3PA%JFK)
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M!(XJW0!R6N^'-3O=<T3Q'ISVD>JZ<CQ2V\SMY,T<@^9=X7(P>0=OU%2Z5X2
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M=M)+:8K.Y,N^(1;DS'Q@*&P>YQVR<K2OAWXHT\^'R]UHKR:3?2W#SXE,ET)
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MZB]V[B:3]ZK,QV@>7P?G//L/6O4J* /.+OP/KUS9^-K</IJ_\)"ZM"?.?]R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7(Y.1D<#!YKD+#2=6M_AYX&L'T?41=Z;X@2ZNXOLKDQQ++(Q;ISPZ].O/H:
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M,,.<;VV@X'!]^#QQ7E?C/3_$.M6OBVW?P]J@FGD@ELDM8U6%XU*$F0H?WLF
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR.M 'J=87B#Q,F@:AHMK)92S#5+Q;19590L;$$C(/)Z'H.W6O-/#GB"6_L_
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M;X2\1Q>+/#-KK4-L]LEPT@$4C LNQV3DCC^'-<G%IEL/C_=2_O@YT*.X.)W
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M2 3R;8V+;#PK 8Y!QP1Q26/C?1;G0-,U2>[C@%_&K)#DN^_8&90 ,G:#R0*
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M+2&UB \DD#$3,N0<9R6/KZ\4 =-#X:T>"]O[Q+%#/J"[;QG9G$XQC#@D@C'
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MDN+B5(H8E+O([!551U))Z"LRV\4:)=Q7DD6I0;;)!)<[R4,*D9#,&P0,=^E
M#;3PEX?L-"ET2VTBT33)<^9;^7E7)[MGDG@<GG@46_A31+6RN;2*Q BND$<V
M9'9G0=%+$[MHR>,XY/K4FF>)=&UAYDL=0BE>!%DE0Y5E0C(8AL'!]>E5#XIT
MS4[>\M](U2!KY+5KB,;2<IT$B@XWKGN.* ')X+\/Q#3PFG!1IQ)LP)7Q 2<G
M;\W%8/C/P.EQX*UO3?#E@JWVJLK2EIR%9@X8NQ8GGC&>O2I? OCJRUC0-#AU
M/5K5M=OK?S&A!"LYY/ ' .!G'I76ZAJ5GI5L+B]N%AC+A%+<EF/10!R2?04
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M!RWA:[TO0M+TZSLM&U2RM]4NY3;I,CNXR-Q>7))C#8) /MTYQVE%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5S7C#QWH7@>UMYM9GD5KABL442;W?'4X]!D<^]=+
M7GWQ.^&$7Q#BL9$U V-Y9[E5S'O5U;&01D=QP?K^ !UGAWQ%IOBK18=6TJ8R
MVLN0"R[65@<%2.Q%:M<WX$\(0^!_"T&C17+7)5VDDF9=N]V/.!S@=!UKI* "
MN+UK7[V^\>V?@W2[DV9^R&_OKM%5I%B#;0D>X$!B2,D@X'3FNTKA]<T._P!.
M^(=EXRTZU:]B-DUA?6T6!+LW;ED0$@-@X!&<X'&: &:YJE_X(UO0Y)-0N+_2
M=4O%L)HKG:SPRN#L=&"@XX((.?:K4GQ/\,Q0W$[37H@M;HVES*;&4+ ^0/WA
M*_*,L!SWS5/7=.O/'6KZ%&MC=66DZ9>KJ$\]W'Y;RR)G9&B'YNYR2 ,=,UR6
MI:-K%S\/?'FG1:-?F[U377NK2,P$&2)GB8-[<1MU]O6@#T_5?%6F:1=RVLQG
MEGAMC=S1V\1D,4(.-[8[<'CJ<'BHU\9Z-+86%Y;2W%PNH$BSCCMI/,GP,DJI
M .T#G=T]^:X;7I;A_'6HSV&E:K(MSH\5K=M96\<S?.6(W*SJ8W5>F<YSR.!F
M2VM6M=0\)ZWHNF:E+IFCV\VEW5E+&/M5OP '*9^8Y SMSP1B@#HM9\6Z-J'@
MG5;U-5O].BMW:VN)X('^T6D@(R"N"5/3D\<]:LS^.-%TR]_LB22_N;^&S6Y,
M<=G)(\D? W#"_-[D<#GTKCM=\.ZI=>&/'E]#IMUY_B"6(6ED$S(%157<P'W=
MQ#'GH,9Y.*T[&.]7XE)J[Z7J"68\-K:&0V[<3"3S"F.N<?AGB@#J(_&6B3:-
MINJ07+30:FXCLTCC)DF<Y^4+UR,'.>!CFI]#\3:9XA>[CL&G,EG*8;A);=X_
M+D'5"6 !(] 3U'K7D]A8ZCI/@GP'9S:/?C6M/OIY/+BC5IHU&]CB-F7>A#("
M01C/7. >\\!R6L,NK6WV'5;34;JY;4+D:C L9D,AQE K,-HVXQDGUZT :^L^
M+=+T-K@7/VF06L8ENFMX&E%NAZ,Y XX!..N!G&*6U\7:1>>((]$MYI'O);47
MD>(FV/"<8=7Q@CD#@UPFM:1?Z;XYUJXN?!TGB/3=8\IH9(I%!A98PC)(&. I
MQG/3Z]K_ (P\-ZW%9^&-7\-VMO#K>E[+1H81^Z6&10C #NB'!'H,F@#IY?&F
MDQ1VQ NWENKF6UMX$MV,DKQYW[1W5<'+=..M<WXQ\5C4/ MEKGA[4KF!&U*"
M%BJ^6Q_>A'1@1D8Y';\:?XDTS4-+N?"=EI^G7MWH]JLD5U+8JOVH'8%3#D@H
M&.=S*03W/KR::+KD/PO_ +&_X1_41=Q:YYXCV!MT8G+D@YY&T#D]<\9YH ]2
M?Q9I4=SK%LTDWG:/$LUXGDME$8$AAQ\PP">,U7G\=:+#!82QM<W)OK0WT,=O
M;L[^0 "7(Q\HY'7O7)ZW9ZO:>*?%LUKHE]?0Z_I$<=O+"H"QR)&ZE7R05/(/
M0GMUK,@TWQ$EOX>T^\\/ZB+./P^+-A:&-9?M((&V60,"L6%#8##)/(/0 '77
MGQ&L$U3PU;6-M=7=MK8>5+F.W=E\M49L* ,EL[<C' SFK%GKNE6WB#Q5=3ZY
M>&.P2 W=M=1LD-F-K8*9 )W8SQG/&,YKB-'TO7+'3_AQ=R>']18Z-]IANH%5
M!("\6U6P6&%SQDD=/IF37_#.LZ_J/Q$M[2QN(3J*V,EC+,FV.=K<#<F3TR1@
M9Z]>E 'H-KXQTNXU#[ Z7MM=FW-U'#<6KH\L8ZE!C+$?W1\WM5"R^)7AO4#I
MK6\]T8=1F^SV\[6DBQ&7) 0N1@,=IXZU0E2]\1^+/#FN/I-]80Z+%<RW*W$6
M'9Y(P@C0 DOW.1QP/6N0L=&UFW^'7@K3GT:_%YIOB!+NZB$!)CB661RWOPZ]
M/?TH ]BU+4;32-.GU"_G6"U@7?)(W0#^I[8'6LRS\6Z;=ZC)IQCO+>^6W^U+
M;W%LR/)%G&Y!CYN>,#GVJC\1M#O_ !#X*NK/2P'O%>*XBB8[1*8W#["3ZX_/
M%4##=^(O&VA:^=,O;"VTBUN3,+J+:[R2JJB-5!);&&.1QTQG- %#PE?WOC.^
MO-2.IZO9O9ZO*L<2QLD#VR,%$3*1M+'DG^($^V*['4_$EAI=W]D=;BXNA"9V
M@M86E=(QQN8#H">!GK@XS@USOPPM;ZQTO6(+^PNK2275KBYC6>,KNC<@J0>G
MKQUJI=1:QX>^)&MZBFC7FI:?K=I D<UJ4/V=XE*E7W$84YSG^= '16/CC0]0
M317@FFVZUO\ L1:%@)"F=P)Q\IX/6A_'.A1V%_=M/*%L;L6,T?DMO\\X 15Q
MEB=PZ<5YMX<L[Y? 7PWUNSL+F_CTR>8SP6JAI-CB1=P!(S@X_.IFLO%5O8:_
M+%X=NT%WXDCO7&R*646QQN:($G]X-HP<<9R#QD '7^(?%4.I>!O%,^D75W9Z
MAI4$GFAH_+EAD5-PX8=",<C\Z;%J\+2^"4O-8U&&^N+0S"WBB9H[T^1N;>VW
M!(P3C.<GIR*Y6'2-6ATKXB6L>@:L@U6$&S\XB5Y"T(4 MN)+9))Y(&#D]JU7
MM-1;5OAK,-*OMFFP2+>GR3^X+0",!O\ @0/3MSTH U]'^)6G7VCZMJM];75C
M:V5XULJR6[[FP54+QD%RQ/RCD<9]:DU;XCZ;I^@:UJ$-K>RW6DE4N+-H&5XV
M9<H6SP%(YW>GO@5Q_P!A\3Z;X9U[3;;0;IY3X@>[:7RHI-]NTH;="&)R^!D<
M<?6H)?#NLW-I\1+:VT/5(UU:UMY+,W<@=I"D>"K,7)+DYXR<=..E '<76O6E
M[?\ A5I=1U.PN+MV>.U2V=$NB$)*N67@#&0,YZ'WK1L_&NC7^E:IJ4#W!M]+
MD>*[W6[JZ.O++M(R2,]JY;4EU*_U7P%=KHFI1I8S.UTKQ F%3'Y8+;2>_..N
M.H%.N/">J1?%"9K1,>'-66*]U#C@3P'Y5'IO.PGU :@#J-4\9Z3I"3/<B[*6
M\22W316SN+96Y!DP/E..<=0.2,5L_;+8V/VT3QFU\OS?.W?+LQG=GTQS7EVK
M:/?Z;XVUM[KP8_B/3]8>.6":*11Y;"-4:.0,<!?EZ^GKV[^ZM[VV\&36UC:6
MIOXM/,<-LJ_N?,$>%0 _P9P,'M0!2T[QYHFIW$4$)O%:>U:\M_,M)!]HA7JR
M#&6[<=3GI5>Q^)7AO46TPV\]T8=2F\BVG:TD6)I<D!"Y& QVGBN)\/V6KVOB
MCPQJ]SH&M@0:;+;WK2HN$EPN=D:MA(Q@[0H&<< FH+#1M9MOAYX&T]]&OQ=Z
M9KR75W$("3'$LDC%O?AUZ=>?2@#I_B5XP2T\(Z['I%S?I>V(5)+JSB)2&0D?
M(SXP#@C..1D9Q7=:?,9-)M9Y7R6@1V9C_L@DFO(=3TOQ%8>%_&GA?^P=0OI-
M3O)KRSO;<*T<BR,IPY+ JPQTP<UZ5+IUUJ7@&32RK6EW<:8;;$A&8G:/;R5)
M'!]#0!67QYHKW>GP+]L,>HS^1:7/V9O)F;_9;N.#@]".1D4Z7QWH,&D:GJDL
MTZVNEW)M;QC;OF*08R",9(^8<C(YKSI;K4UMOASI&IZ%>Z=/IFIP6KR3%#'*
M4B904(8D@@9S@#W-+XBT77TT3Q[X?M= OKJ35M0^VVMS&%\ID8QDC).=P*D8
MQ^G- 'HNL>.=%T2YNH+E[ES9PI<7306[2+;QL<*7('&<$XZX&:+WQUHEEJIT
MPM>37OV47:0V]G+(9(R0 4POS=>W3!STKS_Q?I_B+6)O$]M)X?U(QW.G0_V>
M+41JK,$)<3LK9=@Q(5<L/0=ZV='BU!/B%I^JW&CZC!:Q>&A9.SP9Q*) ^WY<
M]5'YG'7B@#3U#XEZ;';^';C3;>ZO;?6IQ''-';N5103N&!R7^4@*!V)^KKSQ
M/I^E^(->O3?:O=/8:>DLVEK;L$C7).],@9)[G.  >?3BM'T/7-/\$^!_,T2_
M>XT?5Y9;NV2,>8$9I"& ) (PR\Y[^U;U]IFJ7_C+Q<\>EW:1:AH/V2WE=,(T
MP5LKGI_$.>G'6@#>TWQ]97'A_0KV[M[I;[5HU\FTBMW+N_EAWV CE #][I[U
M6OOB7IRVFAW.G6MY=Q:K>"V5UMV_=D$AP1UW_*P"CZ].O.00>(#HW@FVD\/:
MHEE96YMKY8!&ET'6)57:V\%(V.02"I('.!C-#3-#UW3/"7AV-_#M^9=(\1-=
M2PQ[&9HF,O*?-SC<O7'7ZT =U+K^G6OB[4II-3U0M::6LTVF_9G\N--V?-4;
M<LW;C/0^E:MMXKTN\TO2]1MVGDMM3E$5JRPL2Q.3R,9 PK')Z $US]E;WLGQ
M?N]0FTRZCL9M&CMO.DC^3S0Y<H3TZ'KTR.M4_ GA35=$U_4+&]7_ (D>DSRM
MHV?XA/AC_P!\#*C_ 'WH Z:3QKHT5];V\DDZQW%R;.&Z,+>0\PR-@?&,Y!'I
MD$9XK6U/4[31]/EOKZ7RK>/&3@DDDX  ')))  '))KRCPOH&HZ9+;>'=2\#I
M=W%I=[X]9DD#0&/S"PE/.=X!. .<XZ<UVOQ&TC4]7\,(=&C6:_LKR"]B@9MH
MF,;AMF?\]* )I/'VAV]KJLUR;R!M*"->0R6K^9&KC*M@ \$9YZ#OBLK5O&FA
MZQHJO!K&JZ=&+V"(7-O:2*9"Q!4 E<;&!Z]#[]\_7;G7?%7@CQ!_Q2=QITMU
M9_9XXI K7%Q)GC[O1%&>6Z[NW>;QG9W][\/=#M;32[R6YCN+.1[=(OFC$94M
MGTQC\>U &S8>.K:\\6Z[H\MK<6L&DQ1M)<30LJY(=F9FZ*FU5()QGFK4/C?1
MY;PVK_;()C;&[B2:TD4S1#JR#&6QZ8S[5QVK>'M7U'Q'X[M(=/N5A\0:?;K:
M7F (E:.%@5<DY&6(& ">?2I/#<-U,RRW7@%M*O;*UD2:[<B0NQ0KM@ ))W'D
MGH ".<@T :ES\0_#FN>&]1DM-3U*U@%F9C>P6<F8U)VEE.T@D'KZ=\8.-*;Q
MGH^BV=M;S7%[>R1Z<M[(Z0-(X@  \V3 XSR?SXKE['2M3A_9^DT-]+NUU3[#
M+:_9?+^<NQ;'MCD'-9VJV&OWR/9R:%J36TWAQ;:V^RHL1^T!"&6=\ABH/1<E
M3Z'- 'KEE>6^HV-O>VL@DMKB)98G QN1AD'\017/6/C_ $'4+VUMH);DK>/+
M':3FV<17#1YWA&QSC!^N.,U-X+2\@\!:-;SV<MK=VUA% T-P #O2,+S@G R/
MK[5YIIFF^(1?^$]2OO#NJBZT^]N#>I&L:PH&5PHAC5@H3D9; R3R2: .]3XF
M^&I$619;SR3=_8WF-E*$BEW;0KDK\A)/0\T>-?%-O8:+KEG9S7O]HVEBTSR6
M4)<VQ*DH7;!"YQGUQSQUK@Y-(UI_AWJNGC0]0^V2^(C>11>3R\)F63=Z#@'C
MKFM:]M=<TG4?&MNNAZAJ-OXA@,MG<VRJ=C&$IY<@8@KCC'^/% '<>";N>_\
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MH]1ME#302VSKL4C*DMC;SVYYP:L:KKMGI,UM;3>=)=71806]O&9)'VC+$ =
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M4 %%%% !1110 4444 %%%<5XF\:RZ1XD70X&TZWN'LOM,#ZA*8TN7+%1$A'
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M,V=RP@?W0.3SR:EN/&.N3^+'T+3-*L69M)74HIKBY8#:6VX8!>#G(P,^N>U
M'<U#;WEK=F46US#,87\N01N&V-UVG'0\CBN'TKXA3Z[I7AC[#901ZGKB2R;)
MI"8X$BR'8X&6Y  ''7KQ5?X5+-'?>,XKB.".9=<DW);C$8.Q?NY[4 >C45Y[
M)XFU>S^)>M07TEL-&TW2A=E$+;ECR26Z89_E]@!T[Y?IOQ!O;G4M-^T:6W]F
MWUO),\\,,W^A[4W@2,R!6!'&5[^HYH [^J@EM=5L9EMKM)(GW1-+;R!MIZ$
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M>EY+,"05W_< '?.'Z]-OO3-<\0S6.N:5H5A#%)J&HB5U:9B(XHXQEF..222
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A6YTKQGJ>L":W^PW=K#;);*K;HUB&%Y/7@G-=-#;06^?(ACBW==BA<_E4M
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MU"B@#SO6_A_J]]<^)XM/U:SM]/\ $"(9EDMV:2.14"_*=V-IQDY!/ICK3I_
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MSE!U..PH ?I45_!I5M%JES'<WRH!--%'L5V]0O:KE%% !1110 4444 %%%%
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M<)!M8'#=,'CJ<DGI@!DOPPDE2Y8:Z\=S)K*ZW%*EJ,13@8QM+$,N,<'GCJ:
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MDAC>2SU&U2SO1&I9HY%;]W(0.JX^4^G!Z9(I7WPZFOE\4(^M;4\0F,S@6O\
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M%($CEMRB/H$PV .V!5:Z^%QNM(U[3Y/$-TZZU<I<W#O A*LI4Y7&,$E1[8X
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M9&W'D=3D<GTZ4ZR^'[/I5]8>(?$&H:XES;-:J9]J>5&<$XQU?*J=QR?E'OD
M+[6?$?AFVU#5-8-E?:3;Z8;GS($,3BX!_P!6 6.5(/#=JJV'B'Q?_:"F327O
M+*6PDF+?93;^5.J[E0$NVY6^Z.,YQ4^E?#OR+">QUK7]0UJU:V>TABN,(L,3
M#!Z?>? QN/3MUI-(^']YIMI-:S^+=5O84MY(+%9=J_9=R% ^1R[*#@$GCTH
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M<,X]"<9Q6MH.O^*;S7=,6YT]I=+O;=GN)OLIA%K)MW+@ESO4_=Z YP?:IQX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW(O].\3EQXHMM>>X6)%(N)I!)F'RR.J[=JCG  [#FO88K*T@GDGAM88YI?\
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M;C&>Q[UZ#;V%G9N[VUI! TGWVBC"EOKCK3Y[:"Y55N((Y0C!U$B!L,.A&>]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M \<<<0XNI/#OBN+3H;^[FM?$<>J/;RQ/YL]LOEG)R.I.#@\_*>.* /77\>:
ML.HLL]RT^GP?:)[7['*L^P]&$;*&(Y'.,#/)%6_"GB&/Q1X=M-5CADA\^-7:
M-XV7:2,X!8#<.>HR*Y>+Q%HGC.VU2\\/Z9-/=-I<T$U\]JT3)QE8-S#YB6).
M!D#'7D99X$\8:19?#;0/,:Y)B6WTZ0):R'9.1C:>.Q')'3(]10!Z+1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCK&A:';ZEJUL^NWMMYC0C"L[<D\#@''..N*W1XNT ZH--_M.'[49S;!>=IE
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M&MTGU"Y2".201)D$EW/15 Y)/H* +M%8/_":^&OLEO<MK5FL5Q.;>(O)M+2
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M9-I!RI;.!7=44 >1/9^']3T>[O[?3?$>FQ7U];O_ &F_FO<B>-7*R[&W-L7
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MNS[3=LA8+G.U0BJH&>3@<X&<X% &K111D9QGF@ HHHH **** "BBB@ HHHH
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M88Y+'  !Z'I7 ?#[Q1:^'/A_;BZ6&&XN]6NH(89[A8HT8,S-ND/ 50#S@Y.
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M6],@6Z/V3[5#'*_EAUV[ADX...:Y,^'_ !QH_B2_O]!N-%>UU<QS7<-X)/\
M1IP@5FCVX+*<=#CMTZUVEU82W.@3:<]P9)9;5H&G<8+,5V[B![\T <CH/C>^
ME\*^&Y+VS6?6=:&+:)90JRX3>\C''R*!GC!/3KFM[0/$W]L:EJFE75F;+4],
M=!/#YGF*R.,HZ-@94C/8$8KD;+P3XCM='\)S_P#$M75_#;-'%$)W,5Q"R!'!
M?9E6(''RD#^74>']"N[?Q!K'B'45ABO-2$,8MX9#(L4<:D#+$#+$DD\8' YZ
MT &K>*9[;4KW3M)TLZE=V%H+NY3SO+VAL[$7Y6+.VUL# '3GFF#Q?)=WEAI^
MF:6\NHW-@NH2074GD?9XB0 '.UCO+$C '8YQ67K/AWQ38>-I_$7A2;3'&H6\
M<%[;:B7"@IG;(I3G@'&/KUSP]O#.O:9XJM/$EG-:ZE=OI_V+4(IW, D._>)(
MR%;&"2-I[=\T $7Q*M+BPT]H[00WUU>RV$EO>3B%+>:($NKR8([#&!SN'2H-
M8\7^(;?6_"ME#H\<']I3S+/&]R"Q,:O\@.W&TX5MW?@8J/\ X0B]ATN2VN--
MTG5X]1OKF_U*UN961%ED*[?)?82-H!&<#/)XJI;> M?TO3_"1M)[.YNM%NKB
M0Q7%P^Q8I0P5%?:2=@('09QVH [SQ!K T#0;O5#:3W9@0$6]NNYY"2  /Q(Y
M[#FN7E^([6L7B-+K1C]LT*WCN)XK>[61&5@3]\@8(P01CZ9K:\;:1JNN>$+S
M3M'O%M;Z4)M<N4# ,"REAR P!&1ZUP]QX"\2.?$@M;#0[6'6=,CM%@AN'5+=
ME## Q'\WWLYP/3'>@#J-,\=/=Z]IVG7NCRV,>I637EK.\ZMN50I8,H^[PV>O
MY=N0\::_-XCL/".K0:6(]+D\0VWV:[:X_>,H<C)CV\*VW(^8G@9 K=_X1#7+
MG6O#-Q=Q6(MK#2Y+"\\NY;<Q= I*#9T&W/)'7VK'/@3QDOAS1O#@.CRVFC:E
M%=6]XT\BO+$C,0K($(!YQD$_UH ]%\2Z]!X9\/W6KW"%XX-HV@XR68*,GL,L
M,GL,FLN7QA)9:9)=7VG()'N8;:R6VNA,EX\N FU]JX&20<CC:3Z5J^(;:^O-
M$EM[&WLKB9V0-!>_ZF2/<-ZM\IZKN&<'G%>>?\*NU#^R]4&G26VCRM?VVHZ7
M9I,\T-K-$#DDE1]\D\ <8'7I0!/\0]4NM5^'?B^QU/1Y+*?3HXF60.9(9MQ!
M#1OM7..01CBMW3?&XCU<:1J>ES:>B:7_ &C%<2RJV^%<!BRCE2.N.>/3I6=K
M.@>./$O@K5K#59-'2^O8T@AM[9Y%AB ;<TC,0Q9C@# & !UYJ6_\'ZOJWBB"
M[NX[..P?0I-*N0EPS2 R=64; "!TY(H ETOXG:?J&MZ78&.V$6IQN]O)!>I,
MT>U=V)D7_5DK[GD8KFO&FOS>(]/\):M!I:QZ7)XAMOLUVUQ^\90Y&3'MX5MN
M1\Q/ R!71>&]"\;06L.A:[>Z4^C6L)@$]JK_ &BYCVE55L_*O!!)'/'N36"?
M GC)?#FC^&PVCRVFCZE%=6]XT\BO+$C,P5D"$ \XR"?ZT =7<>/!;V_BJ1M-
M)?PZ5,RB;B52F_*G;P<=CW[UDZG<17GQ/\!:FJ>5]JL+R5LGD+Y2, ?IN-1Z
M[X,\23WOC"+2QIS6?B*W3,D\KAX)%CV$;0O(/KD8]#T-MO">NRZ]X0N9H]/:
MVTBREM;O;</E_,C"$H-G;:#R1G/:@!UK\5-,N]3TJ&)+>2TU2X^S6\D-XCS(
MQX1I(0,HK$<')(R,@=*TOB5>:=8^ ]1FU;2Y-2T_Y!/;QS>42-ZX.[((^;;T
MK*\)^'_&_A\6N@S7^E2:!9./*NE5_M3Q Y6,K]T>A//'3GFMCXB:#J/B?P3?
M:+I@M_M%T8QNN)"BJ%=6)X4Y^[C'O0!5O_&]S9^(-1T*Q\/3W4]C9+=AC<(B
M/&<CJ<XZ<=2?0#FH--^) U"3P]*=$NH-/UPF.WN9)4R) I)!0<[>"-W?TQ31
MX>\1-XQU;6FMM/$5[I*V21B[;<)!DY/[O[N6(_"LRQ\$^([71_!%F\>G,^@7
M)EN&%R^)%P5&W]WUPV><=* +]S\2;V/^W6M?"EY<QZ),4O&%S&NU H8L!SN.
M,G:.PZ\U-JGQ(2ULI=0T_2GNM/ATV/49+F:;R%9'R51,J=SX!XR/3K7/:/!K
M5]K/Q$T[3+:R>*\OV@:>>X9# 6B +;0IW#!Z9'(_&G:C\-M;07VGV1L+W3I-
M&33[&2]E8/9,L95BB!2,N>201CWQ@@'7S>,GGECM]%TQK^Z.G+J4D3S>5LC;
M[BY"MEVP<#&..2.,Y,_C36;CQ9X4LK723!9ZI;274D=Q)LF^5.48$?+MW ^Y
M';O1B\)>,]'O]-UG1'T?[:=-BT^_M+J20Q'R_N.K  DXZC []:U;_P ,^(F\
M1>%]9CN;*\NM/CN([PS,T2GSL<H &X7D!2>@'/4T 7M$\8R:]?A;/3XVL?M4
MUK),+H&6%H]W,D6WY0Q3CGN/6MO1[Z]O[>>2^TR33WCN'B2-Y%<R(IP'R.@/
MI7$VW@G4Y?%^EZ[/8Z9IUY;3.]Y>V,[;KU"I 5H]BC).TDDGIQGMTGA/5=8U
M2/4CJT5B!!=M';S6+,T<L> 1RW4C."1QG(Z@T 81U_5=5\:^)?#UW80C3+2Q
M7&)LDAPYWGCDG &WMZFL7X=^+Y=+\)>"]-N=(G%IJ(:UBO3*O^M!8@;.NTXQ
MGCZ8QGHKCP[KMMXYUK6+".PFL]3L8X2)IV1T=%8  !""#D<YXYX-8UEX(\26
MN@>"K QZ:TN@WGGW#"Z?$BC<!M_=]<,>OI0!HWWQ6TNSN@56VFLQ??8G9+Q/
MM"MNVEQ!C)0,,9SG'.,8RV?Q#IVD>)O&>H1:#.=1TVQAFNI?M _TB,*Q7 )P
MN I]SZ4S2/#7C7P_?7&DZ;?:4?#LUU)/'/*K_:;='8LR*H^4G)."?7/M3=5\
M(^(+S6?&EQ#%8>1KFG+96Y>Y8,A5&3<PV=/F)P,]* .F\*^(KSQ'9F\N-$N-
M-MWBBFMGEE5_/5USD <KCW]0?:N@K+\-V=UIOAG2["]6(7-K:QP2>2Y9"44+
MD$@'G&>E:E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445P/C;
M7M6L-7EMK#4S;QQ:5+=)!:0+-</,#P7#*52( ?>)7)XS0!WU%>61^*/$^K7G
M@:WM=2M[/^W=,DGN6^RA]KI&K%E!/N<#H.^>E4+OQIXML+&[T]]0M9-0T_7X
M-.:[-L MQ%+@J64<*0.N/7CU(![%17E.L>(_%GAO4O$.D7&KPWKQ:&^KV=V;
M-4:(HVTQE1P03T)S^-6(M>\46MIX<AO=9@EN/$LL/E21VBI]C3RM\@'4.Q^4
M L, D\=J /3J*\SU+Q1KVAW?BG1GU.TEGL[&*]L-0OE6,(KML*R;%"D@Y*X7
MG@&J+_$#5=$_X2YIY;F_@TRPM[FS-]:K!(7D)7YE55^7=@X(!Q0!ZE?7L&G6
M,][=.4MX$+R,$+$*.IP 2?PIFF:E:ZQI=MJ5C)YEK<QB6)RI7<IZ'!Y%<M>6
MOB"TM=3-YK,6H:3-H\I'F1HDHN,$G9L4 QE<]22,=:Y3P?JNNZ18_#J ZA#)
MINJV[0/:"W V!8BRL'^\6XY[>W>@#U'6-7LM!TFXU349&BM+==TCJA<@9 Z
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M$ :2,L!DD+R/KCFI=0UCQ'I*^"TN;U3-J=\D-]&\";@&5FV C@;<;<@9.,T
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M!DY9L=!DB@#OM6UNPT-+1[^5HUN[E+2';&S;I7SM' ..AY/%-LM?TW4-8O\
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MU:PUG[+8ZF;:--,FN5AM(%FN9)0< LK*52(#JQ(R>,T =[17EEEXI\3:Q?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KEM8\"V6KZ_+J_]H:A:2W%F;&YCMG4+/%DG!RI(Z]00:ZFF32>7$S
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MEY:QI+.BG/EAR0H/H3M/'ICUJ/1;G4[C2Q-K-I!9W>]PT<,WF(%#$ [O<8H
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MZU:$B,Q4.I8=0#R* .3U'X?:?JF@7NE7%]?9O[A;F\NU,8FG=2NW)V8 &U0
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M[=+>U@C@@C&$CB0*JCT ' JG-X?T6XDGDFTBPE>X(,S/;(3+@Y&XD<X(!YH
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MWEM)MN%(RQ)Q^(&><TO@Q]$U&7PUJEEK]N^O0Q.KV-O;!+B>1D_>"X.XLPW
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MN.6P5R2>A]S7L%4K71]+L;J6ZM--L[>YE_UDT4"H[_4@9-7: "BBB@ HHHH
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M>(VR4S^.?PKG_$$.M^.O!NLM9>&9M)G<02)'>JL<]X\4@;:P!X4 8&[J3V%
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MMWE,4(.#(VT':N<]?0UB>$K:^TWQQXMAN=-NTAO;Q;J&ZV#R63RU&-V>3GL
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MQ2#HR,,@\^H-06&L:?J=S>V]E=)-+8R^3<JH/[M\9P?_ *U %ZBBB@ HHHH
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M((SNYZ[ !QWY]JI7/PQ6?0=5T1==NDT_4+PW?E>2A,),@D(4XR?F ZYX[=Z
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M8"P:$0!59-V\G.<@[N?IQ2>+?"C^*O[,!U)K-=/O([Z+9"')E3.TDD].>F*
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M0RJ<AN.AR3VQ[4 ><^.=;U/Q5\)]5UV.[AATLWZQ16@@RSQ)<*@8N3]XL-W
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MP!VS_%5J'QYJ]EHVL17H@N]2M-;32+::* HLA<KM8INZC<3C<,X R.M:MO\
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MH \:UJPU*Z\*^/;.+1M4>;4=:BN+1?L,O[Z,/&2P^7IA&Z^WJ*V_$>DW^O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O';R[UJZL?BG'J&HPW,%I;/"J"W*%1Y!90IWD*!N.<@DGG(KV*N(O\
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MSX.TCRRH?^SX=I89 /EC&17-'X=W1M_$T+>(9)!KZ!9R]HGR'8%9A@CL#@<
M9YW=:ZS2K0Z-H-I9W%TDHL[=8VG*^6"J#&XC)QP.>: /,4^(/C!/!"^,9X='
M?3K:[:*ZM8XY!))&)C&65BV%(R.,'IG/:K_B/Q]K>BZC>.IT\0V^H06\=D(F
MF=X'V@R/(CXB)+':& Z=#6=\//#<OB+P)_9][J0_LEK^66XL/LV)&Q,752Y/
M"-A6QMR<GG%;E_\ "Z6ZBUBW@\1306>HZB-3$)M4?RY]RL<L3EE^7@<8]^A
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MLA,4A?>1N/+#/0=N^:S]+MK^\^*_C--.UE;0R0VD;.]L)?-VQE6*\J RGCN
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Q/\ PF6M3^)?$&BV6AV<\NC112LSW[(9A(FX!1Y1P>,<G%=M
M7E&GV!U?XP^.K--6O+)7M[,/]C:,,X\K!&65B,9ZK@\T =SX6\6Z?XI\,V>N
M09MHKE7/ESL RE"0P]\8//I6Q)=VT.SS;B)/,^YN<#=]/6O*=?\ !_ANP\<_
M#[0$L(!8>5?1-$YYE C# .>K98L<'N33["TT-->\;:/XABM(HH+>&*S2Y(PE
MBL.%\LMS@'.2/XO>@#T>_GU2+5=,CLX;1K&5W%X\LA61 %RGECN2>OM5TW,
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M+NDLJO=H&\S+7$G&-QZ+CICEJ /H.BBB@ HHHH **** "BBB@ HHHH ****
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M@:&:6(%T9E;MURO'/7\:\J)&DZC\0_#E_>WP"VG]J:=+]ID,B1E3PASD;7(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KR+5? _BN^N+V2:UT^]N5UJ.^MKZ
M:[(D:W5P5@5=A\L #G!QGL>M>NT4 >7S^%/$MS;^/$>QM5;Q B"VVW60C"/R
MSN.!QW'%6;3PWXFT/Q#8:[IUG973S:7#I]_9S71C\MH^DB.%.1ZC&?Z>CT4
M<C\-M U3PSX/BTO5EMUN$GED'D2%QM=RW.0,'D^M<?J_@CQ9?S:@TUG87MP-
M92^MK^:[/F&W5P5@52I\L #G!Q['K7HNA^);37[K5+>VAN8I--N?LTPG0+EL
M Y&">.>^*V'=8T9W8*JC)8G  ]: .=\9>';CQ7X,NM)6:.VO9522.0$E$E1@
MXYQDKE<9QT[5@SZ#XP\8>&=3TKQ0^FV"SVA@B2R+/OERK"5B>@!7A1_>.>U=
M_'(DL:R1L&1P&5@<@@]#3J .%CT37M8O/#LVM6=O;?V&6F8P7'F?:IO+V+MX
M&U>23GGH/>N>_P"$)\2_\(+!HWV*W^UQZW_:!/VD;?+\TR8SCKSCI7K=% 'G
MMQX;\01>(O&-S;6=K+::_9Q(C-<[7B=83'M*[2#R<YST'<\5%=>&?$P^'7AO
M2+9(3<Z=) M]:"Z,:7<,8(9/, Z-P<$?X'T>B@#R$_#OQ%+9:W'!#INFSMJL
M.K::8I2T:2H% C*A!\H^89P.<<8K?U+1O&/BKP5K=CK(TVTNKJU\FVM;9V9
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M@H X>W\-^,=#UO5;72%T>?2-2O)+M+JZ!\ZS,ARXVXP^#R!^9KI_'6@R>)?
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M;IKB6%&#95W9%)!93M)![\\5P-G+>W?[-&I:A;.SZA?)<W-U(OWG+3MYA/\
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MK]]=KLR@X8GKSW- '0T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+^VO#>IRM;VL=T ;BS8(3PW\2XX],=AWP+B]DM_AK?[[R2.YM_%36\9:8AT
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MN<QR%&'[AL$%2".E8>AP&TM_AAJ27-V;O4&:&ZD>Y=O-0Q'Y2"<8'; ]^O-
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M HHHH **** "BBB@ HHHH **** "LS5O#VC:[Y?]JZ9:WABSY;31ABN>N#U
M]JTZQM1\36.G7XL/+N[N\\OS7@L[=IFC0G 9MHPN2#C/7!QTH U+6UM[*UCM
MK6"."WB7;'%$H55'H .!4M4M*U:RUJQ6\L9?,B+%"&4JR,#@JRG!5@>"",U=
MH *@O+*UU&T>UO;>*XMWQOBE0,K8((R#P>0*GK@_"UQ>S?$SQC8SW]W-9Z=]
MD%K!)*66/S(BS?7GIG.* .GT_P -:)I5V;JQTNU@G(*B1(QE0>H7^Z/88%5Y
M_!7ABZO+F[N-!T^6XNF#3O) K&0@@\YZ\@'WQ66^JQZ/XK\276H7MPNFZ?I]
MO=;&D9E0N9MY"]\[%P/RK23Q9:);WLU]97U@MHD4C"XC4F02$A FQFW$D8QU
MR0.] %FZ\+Z#>W27-SI%E+.B",.T*Y*#HI]5'H>*DN/#^D7>IQ:E/I\$E["N
MR*=E^=!TP#V'-5M*\46>J:O=Z0;>ZL]1M8UE>VNE4,8VZ.I4D$9XX/!I_B7Q
M+8>%-';5-2$_V975&,49<@L0!GT&2.30!%_PA?AH636?]B6?V9I?/,/EC:9/
M[V/7WJT/#VD+JRZJ-/@_M!8_*%QM^<)C&W/ICM6+#\1-'DO+VSEM]2M;FVMC
M=B*XM&1IX0<%XQU(^N#^1QDZCX_T+7?!FI70/B"QL!;)*;VVMVC?:QQ^[?D9
M!4@GI[T =II.AZ5H5N]OI.GVUE$[EV2",(&;U.*H7?@GPQ?7-U<W6@V$L]WC
MSY&A&Z3!!Y/U ^N*HS>.-,T[4AHBVVJWE]%8K=A(K8NTL>0,@\ GU/3((SGB
MK%OXWTF^T?2M0L5N+K^U=WV.VB0>;)MSOX8@#;@Y)('OR,@%E?!_AU!=!-&L
MT%V@CN L8 E0=%8=P/2M.RL;73;.*SLH$@MHAMCB0851Z >E<9KGBS1-7\'Q
MWSWFM6%NU^ML[6:F.>*99 I1CR ,\'GD&KNH_$72=/U/4M-^Q:M=7>G*KW$=
MM9L^$()W#I\H Z^XQF@#0D\$^%YKJXN9= TZ2:XD$LSO K>8^<Y.>O//UKGM
M-\"+-XU\1ZKKFDZ?/9W[PM:Y?>R*B!"K+M P< XY'%1ZSX@74_$/@'4='U*X
M.GZE<2AECD94E41,<,O<@]CT(K=N?'.E6EQ#YL=T+*:\^PIJ C!@\[)7;G.<
M;@5W8VY!&: -+5O#>B:ZL"ZKI5I>"W.8A-$&V?3T' X]JJOX(\+2:>E@WA_3
MC:I+YRQ?9UQO_O=.M)!XMM+K43:V]G>RPB\:R:\1%,*S*#N4_-N&"",[<9[U
MNR2)%&TDC!$0%F9C@ #J30!B_P#"&^&_LEY:?V'8?9[R02W$?DC$C Y!/T/3
MTI;WP?X;U$VAO-"T^?[(H2WWVZGRU'11Q]T>G2J5OX\TJ>;3=T%[!::I)Y5C
M>S1!89VZJ!SN&['R[@,]JYM[NZ\7^/O$.A32ZY806$%NEM)9SF'R'8.YD;:W
MS9PH&0PP.@S0!V^J^&M$UR2WDU32K.\>W.8FFB#%/89[>W2K&EZ1IVB60L]+
ML;>SM@<^7!&$&?4XZGWJ#7@\7AC4'2>598;21TE1RK!E0D'(QW'TKSOPOJUK
MK7@W2#+XUN%\0WT:J(UO5=A*3WB';CGVH [Z/PCH$,MU+'I<"R7:[;AP#F8>
MC'/S?C2+X0\/(EFBZ1:A;)BUJ G$)SG*^GX50UGX@:1HEUJ,4\-[+'I@B-_/
M!$&2V\S[F[)!/&#\H. :;?\ Q#T?3]>ET9K;4Y[R)8W9;>S9P$=MH?C^$'&3
M[C&: -=?#.AI<WUPND67G7X*W;F%29P>H;CD'OZUDZIX*LX_!^I:+X9M-/TQ
M[P#=F#*2<C(?'/*Y7/49R*J2?%+08[:YNFMM4%K:WILKJ<VA"02 A?GST&6
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MN(U)W?,W&?;TKK[#QSI.H:/+J$27:-'>&P:TDAVS_: ?]7MSUYSUP!DDC!P
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M =916)HWB6'6I8DCL+ZW2:V%U!+<(H26,D8*E6//(.#@\BMN@ HHHH ****
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MZ,\G&,]Z +=>/ZOX?\0W>C_$*UBT*[,FL7,;V69(OW@ 4$GY^/NYY]:]@HH
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M(/QO&!@]NH]:R? &GWVG^+/%+S:1J-I:7KP302WD@<D", AF+L2V2>YQW(H
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MO#.MO/=K"S00R-C"LXX'49[#(SBO.M,T;6;;P;\/K*71KY;C2M4$UXGE9\I
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MMSK;,VFR+ ZW+/@-&$5 XZD\'/%>E>,8YKCP;K-K;P2SW%S93011Q+N+.R,
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MN"2(*R*C AI%4Y# ]B:S?!-M=3ZG9O>> TT>[LHF2>^E=6R=NW$.#GYCR3T
M!')(J[\7K"]U?X?7FEZ;8W%Y>7$D12*&,MPLBL<GH.!WH KC6=4L/BAI.AV.
MM2:S875M*]_%*L3-9[1\C[HU7&XX&#_6NBU3QIHVCR3_ &MYQ!;2I#<W20LT
M,#MC =QP/O+GTR,XS7)+HU]X.\81:]X:TNYET'5P%U+3(8MCV\@'$J(<8[Y
M]_48R_[$U"RUS6K&[\##7(-5O7O+.]D=1&@DP=DP;E0I]L^@H ](L_%&FW^O
M7^BP&<W]B@DFC:$J I^Z03P<]L5D7_B'3-1NO"\T>J:G9+>W.^VCC@=4NQM/
MRR$K@*0,CD9&"/6LKQKX7UF7Q/HVJ^'\1R7,+:3J3H,;+9QGS!Z%<-CWVU;\
M8Z?<#7?!BZ=IMQ+:Z=>^9*8(\K#%L*#\LC@=A0!M7'C71K6\BAEDG6&6Z^Q+
M=^2WD&?)&S?TSD$9Z9!&<@U"WCW0EM=8N"]ULT:01WP^ROF(\\XQDCC.1D8Y
MKA-!\/ZCIER?#VH>!X[^2*]>6#69'5H#&TA<2."<[ER>!R<#IUKH=7\&WMU\
M0IKBWP-"UJR$>LKD@NT1&T#!_C4[3_LAN^* .OMM<LKNYLH(3*S7EJ;N$^6<
M&/Y>2>Q^=>#ZUF>+-<N;&XTK1=-=8]4UB=H8967<(45=TDFT]2J] >,D9XK/
M^'?A[5-"LKJ+5Y/,>V?[#9/W-I&S&,GW.\_@J^E0>,K:2U^('@G7F_X](+B>
MRF8]$:>/;&?;+#&?4CUH @U.YU6#XF:/X=BU^^@T^;2Y)I"!$79T. Q9D/7J
M:Q+;Q-XGU;P5XC^S:OF^TW5EL+#4XXD"W"F5$!8;2I^]R5'>M;Q#H[:K\7='
MN[K1)+W2(+&2WGDEM?,B$C$E>".>W.,#-=!XMMA:^%TLM,TR1\7-NZ6]G!P%
M29';@8 X4T 4O"GC87WP\;6M5#+?:<KP:A$!\_VB/@J /XF., =V KF_#&O^
M)=1\"^-=4U74Y8]3TVYO(HDA6/9 8HPP4?+\P#$C)SD"M*/P;>1?$B[U2-G7
MPU>)%J=Q;[.7NX\A1MZ]<2'CE@/2L[0K'5(/"/Q LIM'U".XU2^OI[)&@/[U
M9DVI[ YZYQB@"E?^*]6T[X:Z/XCL_%4EWK<RVS'39%@=;EG(#1A%0..I/!SQ
M71^(M4U.+XD>']*76KG3["_M)YKA$$7RLBY&&=#CWKG[KPY<WGPLL- @\'7'
M]O1VL,2W3)%%Y$R@9D\S=GC!Z9)J[KOAR?4O&OA2#5],N-5L+/39;34;DV[,
MAD>,#=SR<GG(Z9]J -?P-J^JZ]+XHT^ZU&2\T^TNO(L-5C54>0$'< 5 5BAQ
MR!SFMKPGKT^I2:II.H,C:IH]P+>X=!M$RLNZ.7;_  [E/(]0>U87@:UUSPA?
MW/A._MKN\T>)]VEZDJ[@L1Y\J3'(*]CC\ABI?!5NUSX[\<:[&<V=U=P6D+?W
MF@BV.1ZC<<?4&@#I]5\0V>DRB"1+FXN/*:<PVL)E=8QU8@=!G@>IZ9P:Y36_
M$9OM:\"W^BZI*VF:G=NKK&<)*GEL?F&,Y!'0]".F:I^,-+U"R\=IKJ^&7\0Z
M;<V*6DD,+@2V\BNS @$\J0W\_P 4U#2;Z&Y\"BV\.M:0V-[)<7%M9(&CM(W#
M  D<%AN&<=\D=J .LN/&NC6MW'#-).L,EU]B6[\EO(\_.-F_IG((STR",Y!I
MM[XWT6PNVAFDG,272V<MRD+-#',V,(SCC/(SV&><5P&A>']1TRZ;P]J'@>+4
M)([UY;?6)'4P&-I"XD<$YW+D\#DX'3K6AI,?BCP[?:OX>'A@ZE!>:E+>6>HO
M(OD*)&W9E!YRIYP.3CCL: -ZV^(EH^M^([2YLKZWM=%1#)*;21B<AF9B%!PN
M I&<$C)Z=+%E\1O#M_927<$]SY2B'9NM7!F:7(18QCYV)!&!G!!]*YR\T[5K
M7Q!\0T&CWL\.M6<?V2XA560D6YCVGG.=Q Z>YP.:2XT+67\ >")K;3YVO= F
MM9KG3VPKR"--CA<G!89)'/- '5MXZT6*WU62X:ZMY-*027<$EL_FQH1D-M .
M5]QP.^*--\=:)JNJ6NGV[W2S7EN;FU:6U=$G0 $[&(PV >U<GXATC4-<NO$V
MO6^F7L27'AYM)MK>2+$L\K,S;MO4*,J,G'?L*=;6.HCQ+\/+@Z7>K#INFRP7
MCF$XA=HE0 _\"4].V#0!NZ%XCTFVTS5;_P#MC4+^(ZO);A+F%A(DQ*@6\:%0
MV 3@#'KZ5<_X3S0UTZ^O)9)X38W"VL\$D#"42MC:@7N3D8QQ7GB:%XD73;[4
M++1[DW=EXLEUF&SG'E_:K=P1\I/&[!/!Y'ITK=UV\\4:OX<:^MO"TEB)+ZV:
M6W*1R7C1*3YDB@_*'&$"YY&">., &MX@\50ZEX)\52:3=7=EJ.DVTGFJT?ER
MPR",NO4'@CN*S)=8U./6?AJ?[0NFBU"UD-W""")RMMO!/&2<G/7TK%ATC5H;
M#XB6T>@:LBZM;+]B\]A*[L8=F&8N26RV3R<8.3VK4:RU)M4^&DO]E7P73('6
M]/DG]P6@$0!_X$#T[<T ==8^-=&U'1KG5;5[E[6VN/LLO^CN'$N0NW81NSE@
M.G>MV2;RK=YC'(VU2VQ%RQ]@.YKA+7PY<6OQ2OOLTB?V+=QQ:I<V_=;I2R+]
M V-_NT?M7?T <[9>-='U'PZNNVC7,MB\XMU*V[;V<N$ "8S]X@=*IKKNE6GB
MKQ!/<:U?!;"SCDNK2>-E@MU&3O3*_,3CMG-8VA^$]4TSXB:E;[ /"_VC^U[<
M8_Y>74H4^@.YL=B$JCKEEX@_X2?QK=:5H\DSW>EPP6CW$ :*5TSO&&X/#'&1
M@D=Z .WT;Q=IFMZBVGP+=0W8MDNQ%<P-&6A8X#C/49XK>KRWPG8:E!\2(=4?
M1=9BM+C1%MGGOF5F$HEW$M\QVC P%&/90*]2H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***\N_M[QAKT=_J>A%HQ9ZG) L,LD"
MVQAB?:PDW#S Q +9R,9&..: /4:*\GU;6O$YNOB$(/$,EO%H$<=Q:*EM$3S"
M9-A)4Y7MZ].>H.AI6N:_'XM\))>ZK]IM]>TV6XGMA B1PNL:./+(&[^+G<3^
M'  !Z16#<>+]*M(]:DG^U+'HV/M;?9G( *[LK@?,,=2.!WK@;#Q9KQU[PZYU
M>2]M]1U2>VN&BA0610;]JPL561BH49;D9R,FK6I:MJ5]H7Q2L+Z\-Q#I]O)'
M; QJNQ6MRQ'R@9Y/?- 'I=C>0ZA86U[;DF&XB66,D8)5@"./H:EWJ'"%AO()
M"YY('4_J/SK)\)?\B9H7_8/M_P#T6M</=7-UI?Q8\17[ZE?306&A"\%ME"I
M9B8P-F0OR@\<YZDT >H45Y<WB#7[#PQX5\5/J[W0U*XMUO+%HHQ%LG[1X7<"
MA(QECG!S7J#J61E#%"1@,,9'OSQ0!R7BM?#^CWL'C#5[B\632_W*-!N=8_,P
M"&50<;LCD^H]JZ[J*\"OH[O_ (4[X[EN-3N[MEUF2'%P4.=EQ$ Q(4')  ZX
MXX KL+[Q-KGA;Q7K=O>:@=3MH/#KZLD+0I&(Y5<KM7:,[#_M$GW- 'IM%<#X
M>N/%TVLZ/=W$SRZ/>6Q-U]ID@_UA3>C0B,9QU&"3QSVS6I\2KB\M?AOK\U@S
M+<+:-ADZJO1B/3"Y.: +3>--$ G>.6ZG@MV99;FWLII85*_>_>*I4X[X/'>M
M?3]0M=5TZWU"RE\VUN8Q+%)@C<I&0<'FLGP/%:Q> ]!2S""#[!"5V=#E 2?K
MDG/O6(UW(WC>U\%Z5>2:;I]II)O"]LJ%W/F>6J NK *N#G SG [&@#NJ.E>/
MR^+O%']F6-NNJJEY:^+%T*XN/LZ$749.0[+CY3@@$+CO3->U+7/[(^).C7&O
MWDRZ/!;RV]R$BCE*RQ%F1BJ@;<CL ?>@#V)65T5T8,K#((.012UY9=3>(X-3
M\$Z%IOB2>WBU.PG,LLEM"[)LB5E(P@Y&['X#.3UH>+?$_B30[779[?7Y+J?2
M1:(HM+:/R5)V"0W&Y?O.6.%1B0,<#K0![%32ZAPA8;R"0N>2!C)_4?G7"3ZA
MK?B7Q#XHTK2=8;3)](C@2U541EDED3?ODW*QV]%P,=">>U&W2_G^-=J)-:N'
M0^'1<[(2C0Y,R*RH"IPC;0<_>Z?-CB@#NM*UJUUG[;]E$P^QW3VDOFQ%/G7&
M<9ZCGK6C7CUWXL\3Q^%-8NHM9/VJS\4MIJ2-;QD-"'1 I  '<G(YYZUNV>L>
M(=/\5^*]'^VR:PUIIB7ME'/$B-YI#?)\BC*D@>_O0!Z)17EWAO7]<U?6/"GV
M77);VVO;!KG5T$,3+;R*%(7(4%,L67!.?E^IKNO%4MW#X0UJ6P)6\2QF: KU
M#A#MQ[YH AF\8:-%-<QI+=7/V5BEP]I9S3I$PZJS(I&1W&<CO5[^V],.AMK2
MWL+Z:L)G-RC;D\L#)/'T-<]\*U@7X8: ;<+M:V#.5[N2=Y/ONSFO+-3^TI\-
M_B7':74T&GVVMR+#'$%\ME:1 Z9()"\@X4CGZD4 >M+\0-%,\MM(E_#=H\4:
MVTMHZR2M("4V#'.0K?3!SBK/A[QEI7B:[NK6P%VL]J/WZ7%J\7EMD@J=P^\"
M.17(>,["[3Q/X$A.NZ@PDOI )"D&X-Y;$. (L9P=O((QVSS3M7\8ZOX>UGQI
MON3>0:5IEO<6L4D:C$C[ADE0"1G!/Z8H ]-HK@[V]USPQIESX@EUQ=4TY=(>
M86]PB*[W0&\,A11\A7.1DXQFH=)F\937]A<R7<G]EWEF_GR7#VY*RE-Z/"$'
M3KPV>.><4 >A4R::*V@DGGD2*&-2[N[855')))Z"N$^%USXBUKPY8>(-9UW[
M7'=V[#[(+9$",)" ^Y<$G ((QCGVIWQ+N69_"^CM_P >NIZU!%= ]'C4[MA]
MB0/RH Z67Q-I,&BPZO-<M'9SD"$M$X>4DX4(F-S$]0 ,D<U'!XLTF?5+73&:
M[@O;O=Y$5S930F3:I9L%E X _P YKD=:=I?CWX;MKO!M(M+FFM%;IYY+!B/4
M[ *[S4K6.98;C8ANK9FDM2QQB0HR?J&(H IW/BK2K:^GLA)<W-S;@>?'9VDM
MQY6>0&,:D*<=CS3AXGT9M(AU5+Y'T^601_:%!VHQ./GX^3G@[L8/7%<G\%&$
MOPTM)W.Z\FN;A[MS]]I3*V2WOC;^E0>$($N/B+\1M.,8?29);<M%C,9D>(^;
M^)[T >E45Q'PEU&YU#X=V/VJ0R26KRVHD8Y++&Y5<_@ /PJ/QGJ^IV^O16-C
MJDT*C3IKC[+81H]R\@("NV]2BQ#GDD9/'- '=T5Y-8>)?$NKR_#U%UDVPURS
MN3>&.VC)+1QY#KD'!Y^F1T(XIMCXTUQ-).ES:BTM_)XJDT.._:% ZPJ02^T#
M:7QP.,<]#B@#T:S\1:??:_?Z+ \OVVQ1'G5XF4 -G&"1\W3J.*U'=8T9W8*J
MC)8G  ]:\X\*VLUE\9/%4,U]/>$V%JPDG"[P.>/E 'Z5-\;+BZM_A?J!MF94
M>2*.=EZB(N WX'@'V- &[)X\T".Q>_:>[.GH"3>K8SM!@=Q($VD>X.*T;_Q#
MI>FPVLES<G-W_P >T4<;22S<9^5%!8\<GCCO5J.TLI-)2SCBC:P: 1+&O*&,
MK@ >V*\]T$ _'/68IF5X[;1K==.R<XA.W<5^K9R: .WT_P 1Z9J5U/:02RI=
MP())+:>WDAE"'HP1U!([9 (SQ6:WQ"\-+'>2->7 BLI3#=2_8+C9 X."KMLP
MI^IK!\>%X?B/X EM.+M[N>)RGWFA*+O!]0!S[5P=SKFHZ1I/CZ*.QC;2K[Q#
M<VEY?EB[6:R *7,0'S#!Z[AR1QZ@'OL$\-U;QW%O*DL,JATD1LJRGD$$=157
M5=6L]%LOM=[(5C+K&BJI9I'8X5% Y))( %5_#&FVFD>%]+T^QN/M%I!;(D4^
M0?,7'#<>O7\:Y#XK0322>$"E_<0(_B*TB*1B,@$[R'^93\PQQGY?4&@#LM%U
MVTUV&Y>VCN8GMIS;S17,+1NC@ XP>O!!R..:TZX.VO=6\1>(O$>D6NMW5B-%
MCA@BD2.(M-,Z%C+)E",9P,*%'7U&.;M?%GB?Q*O@+[)JO]F/KD5Y'=A+=' :
M%2-Z[AD$D$@9P..O< ]@HJO8PW%OI]M#=W/VJYCB599]@3S7 P6VC@9/..U>
M5ZYXLUVRU*XN;75Y)XXM?BLO+MH4-I% 2JF-V90QEY).PG;QTH ]<KFY/'OA
MR&:]BDN[A6L"!=G[#/MM\C(WMLPHQSDFNDKR+38M7O/&7Q+L-)M+*9[F2")G
MN[AD6/="PSM"-N'7CB@#O[WQGH-@]@LMX[G4!FS-O;2SB<8S\A12&X.>*FT_
MQ1H^J7=S9VMRYO+5!)-:RP213*IZ'RW4,1]!W%>::IH%SX3N_A?HMI)%=W-I
M<7"AI6,:.Q3<>0"0.3C@]JT('O8/CM9S^(H(;>YN]+>VTT63F2)PI+OYC,%(
M8#./EQTYH [S0_$^C^(S=C2KP7#6<ODW"&-D:-_0JP!['\C2WGB;2+#7+71+
MB[QJ5VADAMDB=V91G)^4' X/)QT->4V,\/@7Q38^)Y'$.D:U=WUAJ3GA4E6Y
MF,4A_ %?8 U;L8)I?C)X:UJ[1DNM5L[NX\M^L46T"),=B$P3_M,U '>2>/O#
ML4E]&UU=9L#B[*V%P1;\9^<A,+QSS6]9WMMJ-E#>6<\<]M,H>.6-LJP/<&O$
MK_7M5\/:Q\2;JQTR.ZMFNX([J8N2ULC1$&3RP/G SS\P_+)'J7@32K#1? ^D
M6&F7GVVS2 /'<XQYN\ERV.P)8\=NE '0,ZH,NP49 R3CDG 'YU'=VEO?6DMK
M=0I-!*I5XW&0PK@_B;'=-J/@\0:G=VJ3:W#"Z0E-IR&8,0RG)!48SD>U-CU3
M6_$+^+39:U/8-HLK6MJB11,'=(PQDEW(<AFXP,# XH ] @A6WMXX49V6-0H+
MN68@#')/)/N:DK%\(:U+XB\(:5K$T2Q37=NLDB+T#=\>V:P_[1U+Q%XX\0:%
M:ZK/I<.D6]OM:WCC9I99E9MQWJWRJ !@8ZG)Z4 =M17E?AWQKJWB>3PWI%Q=
MFQN;J&[>[N;=4W3- _E@)N! SRQX[8&*TI-4UVPO_#7A74=:C>_OY[H7&H6R
M('\N)=Z)@KM#L&3/R],XZ@T >A45YQK.H>)O#EKH<-QKL=S--XDALI'2*,F2
MUD)*K(-O#X Y7'6J>O>)]?M)/B-%;ZJZ#1H+6:R/DQ$Q;XRS#[O(SCKD\4 >
MFW5LEY:2VTC2*DJ%&,;E&P>N&'(/N.:2RLK73;*&SLH(X+:%=L<48PJBL?PG
M;ZPFEBZU?6/[0>[2.9%^SK$(,H-RC'49Z9YK(\<:QJGAS6O#NI)J#Q:%+>"T
MU&'RXR%W@A'W%2R@-UY]* .VK.M]:M;G7+S2(Q-]JM(TDD+1$)A^F&Z'I7GF
MD>+=8N]0U709M5G-_<7L3Z/.\,*M)9.QS(JA<, J2')'/R],TGB;5M9EN/B)
MIW]L7,4&G:7%<VODJB-&2CL5W;<X. #WQT(H [^Z\2:;::WIFD22R&ZU-7:U
MVQ,4<*I8_/C;T'3.>1ZU8UC5;;1-)N=2NQ*;>W7>XBC+MC.. .3UKRR2TO/M
M_P *(8=1D\^2VN"L\L:,8U-JF0H  .!G&0>V=W>:3Q1XCMOAKXRNO[7=]1T/
M5)[2"\:"/<\:%,;EV[<_.>0.U 'K$,JSPQRIG:ZAAD8.",].U/KSB>_\0W_Q
M GT2#7Y;.S;0DOU\JWB9TD,FW@LIZXYSGJ<8ZC?^'.M7OB+X?Z1JNHR"2[GB
M;S7"A=Q5V7.!P,X[4 :>J>(M-T>XAMKJ65KF=6>."W@DGD95^\VU 3@<<]*8
M?%.B#P^FNC4(VTV3&R9 6W$G:%"@;BV>-N,YXQ7,ZS8:OHWQ-3Q9;Z?)J6FR
MZ4;&=(IHT>W(??O_ 'C*-IQSSQR:\\T9;V>Q\*ZA/"T6G:GXREO88R<A5;_5
MCTZA\?G0![CI6M6.LI.;*5RUO)Y4T4L31R1/@'#(P!'!!''(-:%<!H+2#XT^
M+D3/DM8V;2 =-^T@9]\9K6\=Z_<Z'IFG164@ANM3U*WTZ.<H&\GS&Y?!X)"@
MXSQG% &I;^(M/N?$=UH,;R_;[:%9Y%:)E783@$,1AOPS6E+$DT+Q2#*.I5AG
M&0>M>4$7>A_%#Q1*-7\V>/PV)H;K4=H2(ASC>44?*#STSS4GAW7/$%]XL30C
MK6H&&\T#[9%>7-M"K>>'"^;&FP$1G)PKC/Z&@#OO#GA;2/"E@UII%L88W;<Y
M>1G9C[LQ)_#I6Q7G7@_Q%J^O6MAI=[J$B:W87DZ:P%CC&5B. ,;< ,7CP0 2
M-V#Q4.B^)]27QI!I6OWFHV%])=W CMIK>/['>0X;RQ#(%SD#8>6['U H ]+H
MK-\1:J="\-ZGJPC\TV=K).$_O%5) _2N&?6M=TFP\&:Y+K$E]%K-S;V]Y:O%
M&(Q]H3(:,JH8;3V).1UH ZO6?&6D:'-<17)N96M422Z-M;M*+=')VL^T< X)
M]<#/2N@!R,BO-_!EM<#XJ>.3)JEW*(9;,,CK%B4& XW80$;>VW'OFO2* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N-G^&>@S>(
M9]7634(/M4GG75G#=,EM<OZR(/O9[C.#W'-=E6!>>,]"L+TVMQ=NI6X6U>40
M2-$DS8PC2!=H;D<$\9&: *<W@&PGE\02/J.HYUY EZ \>"H&T!?D^7Y<K]#Z
M\U)#X'L8;_1+S[??O)HUN;:U#M&08R-I#?)SE0!GV'?FK.I^,=$TB:ZCN[B;
M_1 K73PVTDJ6X;D>8R*0O'/)Z<]*;>^-_#]AJ"6$U\S74EO]ICB@@DE,D?'*
M;%.[KG R<9/04 8UM\*]%M(K"&'4-86'3[HW-I&+OY8,YW*OR\*=QY^]Z$5>
M;P#8.OB -J.I$:\,7OSQ\C&WY?D^7Y?E^GOS5;4OB7H]OI^B7M@+B^M]7NUM
MX98K:0JOS8?("YW !L+C<2.F*NR?$+PS%K!TF2_=;X2Q0F%K:4$-)PF<KP"<
M#/09&>M &WI.G1Z1I-IIL,LLL5K$L4;S$%MJC !( !P,#IVK-N?"6GW7B@>(
M&ENDN3;"UEB27$4T8)(#KCGDGO@]\U'8^./#^HZA;65M>2-)=O+';.UO(L4[
M1YWA)"NUL8/0]J>WC/0DU&&Q:[D#S7)LXY?(D\EYQG,8DV[2W!&,]01UH JZ
M=X"TS3?LD*7-]-864WGVEA/*&A@?G!7Y=QQDX#,0/P%=37,>%_&=MXHU+5[6
MWM;N$6%P8 9[:1-V%7<22,*<MPI.[ SBK^L>*-*T.YCMKV:8W$D3SK#!;R3.
M(T^\Y"*2%&1R: ,.[^&6CW=CJUB;[5([/5;HW5Q;QW V!RP<[05.,L%/KQ@$
M#(.@_@NQG\0'6;J[O+F=[ Z=+'*4\N6 \E64(.IYR,<^W%31^,] FN=)MX[\
MO)J\9EL=L$A$R@9.&VX! Z@D$=Z6W\8Z'=6-]>0W4K0V$_V:Y/V64-'+D#;M
M*Y)R1T'>@#/\-_#O1_"]Z+FSN=2F6(,+:WNKMI(K4'@^6IX!P2,G)P3SR:ZN
M2-)8WCD17C<%65AD,#U!%<_=>.?#]E?R6<]Y('BN$M99!;R-%'*^-J-(%V@\
MCJ>,\TQ_'_AF/73HKZB1J"W$=L83!)Q(_P!T9VXP>.>G(YYH BL? EGI68=-
MU75[+3RS,+"&Y A7)R0N5+J,D\*PZ\59OO!NFW5U87EI)<Z;>6$1@@N+)E5A
M$>J$,&5E[\@\\URWCCQPL<>CC0]1NT+ZU#:RR16S&"9=^'3S63:<8(^5NQZX
MKTJ@#E;OP#I=U8V%HMS>P+9WW]HB2-T+RW.2?-<LIW')/MSTP!A9? >F3W?B
M"XN+J]F_MZ%8;U&= I55*IMPH(*@D#GZYKJ:* .5M_ EE;W^BWO]IZI+/HZN
MEL9IE;(<!6#97D%0!CC&.,'FJNJ_#'1=6EU@RW>IPPZLRR75O!<!8S(N,.!C
MKP.N1[5VE% '&ZG\-=&U35(M2>\U6WO!$L,\UK>M&UT@[2D=?PQ^@K1D\&Z8
M=>T_6+>2ZM)[&U%G&EM+L1H0P9488Y ('&1Z'(KH:* .*;X9Z8^GW=DVJ:J8
M;O4/[2F^>+)N,YW?ZOCD XZ<4NO>$98TU[6=-DN[[6+_ $\V?V>69(XY%Q@#
M*JI4C).01SWKM** /,/#FEZFESIT>GOXSM!;/&)5U>:$VWE*1O3:,EB5! V]
M"0<X%>GT44 <U%X+M;+SH]*U+4M+M)G:22TLY$$6YOO;0RL8\]?D*TFI>!=&
MU#PE_P (P@GL]*.-\5LP!?#;OF9@23N )/4GJ:Z:B@#F]2\&V^J7>D75SJ>H
M^=I+;[9E:(?/T+,-G)QQZ>U*W@K39M:U74[F:ZN&U2W^RW5O*R^4\8& N H(
MQD\YSS71T4 <AH?PWT/0TFC$E_?0R0M;I#?W+2I#$PPR1KT4$<>N.])H7PWT
MGP[([V5[JK (R6T<]T94M PP?*1@5!P2,D$X)]37844 9'AKP]:^%="@T>QF
MN)+2 MY7GL&903DC( R,D]?6JWB_PZWB+284@D2*_LKJ*]LI''RK-&<@'O@\
M@_6N@HH Y_4] L?%VFV<NIV=Q9WD#^;#(DFR>UD'!VNN?3W!&*GT_P .QV<\
M=Q<ZC?ZE/$28GO9%;RR1@D*JJN<9&<9P2,\FMFB@#G3X0M8+VZNM*O[_ $DW
M<GFW,=FR>7*_=MKHP5CW*X)[T2:<?"_A^2U\-Z<9KRXD;:7?.Z9\DS3.W) Z
MD\DX '85T5% &/X5\/P^%_#-CHT+^8+>/#R$8,CDY9OQ8DU4U?P5IVL:_'K,
MES?6]T+4V<OV6?RQ-"6W;'XSC)[$&NCHH X[3?AQINES:'+!J>J,=%$@M!)*
MC !QM<'Y.A4 8&,=1@DFD/PTT632M0T^>XOYDO;XZD96D59(;D]98V51M/Z>
MW6NRHH YK1/!5CH>N7&LI?:E=W]Q"L$LMW<;]RKTR  ,UO7EG;:A9S6=Y!'/
M;3(4DBD7*LIZ@BIZ* .6L? UII]NME%J^LMIBKL6P>Z!B5/[@.W?M[8W=.*O
MZGX7T[4KFTO%\VSOK-2EO=VC!)(T/5.A!7_98$>U;5% &)8>&+6SU!]3FN;J
M^U,Q>2MY=,I>-/1 JA%YY.%Y[YJII/@?3M*&L(;B[O(-8D>6\@NBC)([_>.%
M08R.,=/:NFHH Q/#'AJW\*Z8--L[V]GLT_U,5U(K^2,DX4A0<<]"3TXIOB/P
MK:^)FT\W=Y>0BPN4NX%MV0 3+G:QRISC)XZ<]*W:* .=O/!UI<ZQ+JUO?ZA8
M7MQ"L%U):2*OVE5Z;P5(R.S+@CL::_@G2_[0T*ZMY+FU&AJR64,#*$4,-K9R
MI)RO!R??KS7244 %<1<_"[1;C[8HOM5AANKX:AY$5R!'%/N#%U7;W([Y]L5V
M]% #(XQ%"D89B$4*"S%B<>I/4U@Z+X1M=#UW4]7@OKV6YU-E:Z$QC*N5!"D
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M.>"*ZMY;>>-9(94*.C#(92,$'\*YS3/ VG:8UB@N[^YM-/?S+&TN90\=LV"
M5^4,< D#<6QGBNGHH P-)\*6VCZ_JFLPWU[+<ZF4-RLS(48H,)@!01@''!^N
M:WZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ%H^G7ELMHR!9YT CGW+G,9!YQT/O6C10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN+DQO:3>64/12'7GV_#K75^#M,OM"\%:7IE\D)O+.V6%A#(65BHP.2!_+\Z
M.;'Q6B_LN/5&\/:BNG_;S83R[HR8Y-^T84'+\]=O'8$FM>S\<1R7FN6E_I-Y
M8W&DVPO'C8I*TD)!(*["?F^4_+^M<A_PA/B?_A!FT?[%:?:O[;_M$'[5\OE^
M9YF,[>O:MF_\-^);CQ+XHU&P\JR;4M+2UM)_/^>.5 >3@< DXR,D=: -31O'
M)U/6H])N-(GM;N;31J4*><CEHR0-K=-K\C@\>]8.A^,](T+POI$NF:#J0M-4
MU:6S2,S+(R3&1LY+-W*DC' QR1W9X<\*>(=*\6:;K+Z-IUND>DM97*17A=WD
MWJQD9B@W,Q'?IW;M5.R\%^)[?P]X>L'L;8RZ9KYU20K=##1[G;:./O?/]./>
M@#6UCXD7MOX:\3SVVB20:MHA1)H)YD94$BY63*Y##OM%:D_C.[LH+.!M&GFO
M7T][^?=,B)'&F!DOT+,3P/SQ6%J7@K7-3D^(*>3;Q)K\<(LV:;.&B3;AP!QG
MKWQ3K_PWXLU/4]/FO+#3;BR&F&U:QEO6,5K/NXGQLQ(VW ''!Z$=2 7=0\2:
M+KD?@G49],O9$U&\26R<2A!!+M.-X#9;OQ@BF7?Q36UL-7OSX<U VFD7IM+U
MS+$#'RHW ;CNY;H,_7FLVS\(^)X= \$64EC:>9H=VLT^VZSN0 KQ\OWCN)QT
MX'-,O_!?B.\\)>--+6SMUGUS4C=VY-R-JH2A^;CJ-G;/6@#U"ZO(K/3Y[V0.
M8H8FE;8N6*@9.!W.!TKE]#\=#5M;LM+N=*FLIKZP_M"WW2JY\O(X<#E6P0<<
M_6MG4;;4KSPI=6MG*++5);-HXI-V1%*4P#D>A[BN$\-^$/$.G>*=!U6?2M.M
MQ;V#VEZZ7ADDE<E29F.S+,V#QS[M0!UOBOQ<OA:33$;2[N];4+D6L7D%/]80
M2!R0<G'T]2*R/[9L[[QIX9;5-!U"RU:2UN9(#+,-L( Q(I56.XXQ@D=QCVN^
M-=%U35[_ ,.3:=!%(FFZDEY-YDNS*J""!P<GYOTJ/7=&UFZ^(6A:S96T+6=A
M;W$4CO, Q:50 0N.0"!GGO0 _2?%(\6:<)(M-==+O;662.Y6Y5B,8&QPO*,0
M<XR<8-8_PLUB9O ?AVQMK=KR7[.SW,OF@" &1MN[/4GG '/'I4.D^"]4L?$<
M6MVVDV6DR_8YH]0M[.[)AOY64;"$V@( =QR1Z<'K5'P?X$\2^#'T6ZT^WM!+
MY36VM6_VG$=PH;,<J_+]\!B.1T&.] '?>+_$T?A#PW<:U-9SW4,!4.D)4$!F
M"@\D<9(Z9//2LD^/+G_A()]#7PSJ!U#[*+RVC,L0$T6[;N8[L1\]CS^-6/B/
MHFH^)/ ]]H^EQQ/<W1C ,LFQ5"NKDDX/]W'XU4&D:Y_PLD>(S80_9/[%^PE/
MM(W^;O\ ,],8S\N?QH FMO'\&H^']"U/3M,N9Y-9E:*"!B%\LKNWEVY  V'G
MOZ52'Q0MCI&GWRZ->R&ZU4Z2T<3QMY<P..NX;@<$@CCU(K"T_P %>*[#PCX6
MTMK:SNHM,N)S?Z>]V4BNT<LR$MM.0I;)4@YQT-16_@?Q3;V5G9_8-/\ +M?%
M UD&.ZP&B#$[0NWCJ,?3G% '5I\0XH[+Q$]]HU[;WFA&(3VBE96?S1F/:5.#
MG//I4]KX[MQ<Z];:K9O8S:);I=7.V59E,;*6X([C!&,5SNK^$_%=S?>-[G3&
MBLY-9-H;61;DJQ6$!75B!E=RYP1]*HW&D:CX7'BK7;S2M&T_2[S2$A\@3F2.
M-P&4(P"#?N9QD\=>IZT =;9>._M&K:183:-<QG5K3[9;2)-&RK%@$F3)7:0"
M"0N[KQFJMO\ %'2KC4=,A2-6M=3G-O:S1W,;OO\ X2\8.Y V."?49 K"\/VM
M[I=QHR:GHEM<*;==,@NHM9^T211N #LCV $< D@DA1UP*T?"6@>-= 6TT*X_
ML=](L7'EZ@@/VB6)3E4V$8#'[I/8=,GF@!\OQ5BBTRZU1_#VHBPLM0:PNY2\
M>8G#!>%#$OR1PN?J:V+3QQ =6U73]4T^XTM]/L_M[-.Z.&M\D;OE)P1@_+7'
MW'@GQ/-X'UW1Q9V@NK_6SJ,1-U\JQF59,$[>HVX_&MK4_".IZYXNUJYN8([?
M3M3T/^S/,$P9XWR6W;<<@%L=>U %JP^)5E>ZS:::+,M-?VTEQ9K!=12L^Q=Q
MC<!L1OMYY..O-5]-^*$6H6V@WIT*]@T[6;K['#<O)&=LI9@ 5!SCY3S_ #I_
MABR\<620VNL6^C_9["(HLMH3YMZ0A50<C"#H2>N0.,$UA6?@GQ):^#/!ND&S
MMVN-$U=;V<BY&UT5W;"G'4[^_I0!T_A#Q/JNO>(?$5K>Z>+:#3[H6\>V56V8
M4'!QR2<Y]!T]S+JWC6:Q\5/X<L_#]]?W_P!B^V1^7)&B.F[;U9OE&<]<<C !
MR*;X9T/5]&\6^))IH;9M-U*Z%W'.)CY@.Q5V;-OL><^G'IBZI/?V_P =8I-/
MLDO'_P"$<P\33"([?M!Y!((ZXX],_2@"CXG\26OBOPSX8U:TCN+:1/$EK;S0
M2$J\4@DPZ, <'H/_ *U=#KWQ%BT&?4WDTBYDL-+EAANKG>J9:3&!&I^_@,,\
MBL6\\":U#X=L+>TBMI[YO$ UN\'GE8U;?N*(2N3Q@9('0GOBJGBSP+XHUX^)
MHFM["\^W/$^GW=Q<D/;1JR,843:0N2IRP(SWS0!T^H^/Y+36-;TRW\/WMS/I
M,"W,K"6-%:,@G<"6XX' ZG/08-=-HNJPZYHECJMLKK#>0).BN/F 8 X/OS7$
M?\(_XED\0>*M1ET^T5-7TQ+6)$N]VV15*\DJ/E^8\XSQTK8\*67B+1=(\.:1
M/:60M;6S,-[()BSJZ !-@Q@@]\]/Y@'6T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP3O%&]YM\N2-22#\N-O0YZXSQ78WFJ7UCX2EU:;3T6^@LS<2V9G^57"[F3>
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M#XAM= TRW@FU":V>[<W$A1(XE8+G@$DEF  ]B?J 6],\,:#HL[3Z7HNGV4S
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MQ9PZCI-W'<GS0S1/M4J1Q@]\U1U#P+?:SXCUJZU&>T^P:II0TYQ#N$B$$D2
M$8ZD_+GTY-=[10!QGAC0?%^FB*/6M>M;ZWL8C':Q01&,S';M5IFYZ#L >3GD
MBN'UO0-3\*^&O"&E3W5BUVOBN.>"0%MGSF1L," < MCCM7M=5[K3[*]*F[M+
M>X*?=,L8?;],B@#@=>^'VJ^(K?6;VXOK6VU>_B@MXTBWM D,;[RC$X+!SG/
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M8 $SP1AG6-MP8_,Q4'!4#!XZ4 =W167XCUC^P= N]16!KB:-,00("6FE)PB
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ML[.1$6.UW#!Q@98@9 )[$]SFN@H **** "BBB@ HHHH **** "BBB@ HHHH
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MC3TL--%Y%-<!+IS.(_L\>#E\'[W..!0 FOZY9^&]#NM7OR_V:V4,PC7<S$D
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MEZKJL,T%U#)*)=1FE6>(.-ZL'8CE<],<\=#57QMX9O\ 71HNLZ3Y<6LZ//\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEJ-I9)(VU&N9EC#'T&XC)JEX5O\ 5M3\-V=UKFG_ &#4F!$]N.@(8C(Y. 0
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M1;R:24000%!"S0YP&+'<,''..F>^  >MU1U;6=-T*S%WJE[#:0%@@>5L98]
M/4UPEAXU\2:R-.U72M,>YTZZO3$]O]E(V6VXIY@FWX+#&XC;CG';)N_&3/\
MPJ_4]H!;S;; /KY\= '>45YW?>)_%&A>(IM*U-],G%WIMQ>V4L$#J(7B&2C@
MM\RXQSD'V%.M/&NL7,7@.0K9J/$$;?:AY3?(PB+@I\W SV.?K0!Z%17 _#*Z
MUB]_X2275-1CN_*UJXM\^1L;,8100=Q 7 &%QQZFD\<>*]9T*]O5M)K.""VT
MQ[N%6A-Q+<2J3E2BL&2, #+D8YZ\4 =_17F<GB[Q;JFLZ+I^C?V1"VJ:&NI
MW,4A$3G;D$AOF&3CH,9SSC!=>>-/$UW_ &G-H.G&Z;3KXV?V5;5F6X,9 E_>
M[AL.2V.#T&<YX /2J*PO%VJWNC^#=4U:P$*W5I:O<*MPA9?E&2" 1Z>M<O8>
M,-=MO$&@1:O)8/8ZQI<EZ5@@97MVCC5R-Q8[P03V'^(!Z+17F;^.->A\&Z=X
MU?[&VEW%PGG6 A/F1P/)L4K)NY<94G@ Y/3%7?"%SK5S\1?&,-]J45Q;VDMO
M$D?V<KA3&74*=V !N.<@D]<B@#L;S6=-T^]M+*[O88KJ\?9;PLWS2'V%+;:O
M87FI7NGVUU')=V.S[3$IYBWC*Y^HKD?'W_(S^!?^PN?_ $4U9>K>,=:TP_$"
M6WBTP7&B"V>&3[,W[U73=A_GR2 0 <XXZ<T >GU2U75K#0].DU#4[J.UM(R
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MG06N?*5!M7:=W7:2"3W.>.E6%\$2-K6B:C/J22C2[)K+R?LN%F1AM;=\W!(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\DX\-_\ 8-@_] % '2T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?\ Q4^',GQ!TNRC
MM;U+6\LG9HS*"4<, "#CD?='//ZUZ!10!QGPS\#OX!\+OIDUVMU<37#7$KHN
M%#%57"YYQA1S79T44 %<=XC./B1X*_[?O_1(KL:K7>GV5_L^V6=O<;,E/.B#
M[<]<9'% %FBD "@   #@ 4M %/5CC1[[/_/O)_Z":QOAY_R3CPW_ -@V#_T
M5OW5G:WL7E7=M#<1@YV2H'&?7!I\44<$210QI'&@"JB# 4#L .E #Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ]9Z7%?MMB,EOYK(Q,A55" *V3N8<5E^$_B;#XQ\(WVI:=:PQZK8HSSV$TY
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M>0-+$0=N!@D*QP .AXXKT"[U.QG^-NA-%>02+)HTP0K(#DLZLH_$ D>HKT4
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MIS@5?GETW2?&?P_N%LY=.TP6=W;V\<ZL74841J0<MN(P0#SSCK7K) /49HH
MX7XJ/=6_A_3KV%;IK2TU."XOOLJ!Y! N[+!2"#M;8W(/3VKFGNO#=UX-\=:W
MI.H7UXFH:>4FO;U!%'-,(W541=B98 @' YR.^:]?H  & ,"@#QGQ#J=A_P *
ML^'[?:K?>MWIK,N\9&Q1YF?3;W].]:NM7$4OQ@\O3;FW6]G\,SQ0,CCF9G#)
MR.^!D>PKU&B@#R3P-K_A[4+'PSIQTJ\D\4:'"T3P>1(C6IV%97=L!,-CH222
MP[\US&A:Q82:AX"N(YH[6W@O[M6L(T9OL9=7PKR-EGD8\XXSV7O7T%@9SCDT
MFT>@ZYH \;\*:SH_V.U\+>(=/N[CQ58:Q)=+ (9-TDQF9EN-X&W:%?DL<8'0
MC%:=UHE]IOQ"O=!LH,Z)XGQ?3L.! T3+]H&/20%%_P"!^U>HX&<]_6N?\.>&
M[G1IKBYU'6[O6+R7*)-<JJ^5'G.Q57@9.,GO@=,4 7(/$FDW/B6Y\/176=4M
MH1/+ 4880XP02,'[PZ'O7"^+)-%M?C+H$^L_8X[8Z9/F2Z"A ^X;2Q;CV&:]
M"33(1JSZD[R27!C\J/>1MB0X+*H '4J"2<G@<XXK(O/#$]UXYLO$8OXU2UMG
MM?LIMR=ZL022^_KD#''YT >1W5K8V>FV"3>3'HU[XX6YLH9#A&M "K.%/2//
MX8([$5?U>^TRRN_BM&EE'>V^VR/V."0H&&P*[?)SA6.6Q]#UKW&B@#P&^U2Q
MEU#QK)/J<%Y]L\-+]GE6#RHI&"N (P>H!P 22<\9SQ5_Q!9>&[7X8>#KB&WT
M^,W5WIQGD55#2A!^\+'J<9;.>F3FO;L = /2EH \9NQH0\:?$4D6&%T:(0_<
MP#Y3!@O;.2@/U J&PUFRAM?AW')+%:R#1V1-3<&7RVV(K0H@.TR'&/F!QTP:
M]LH(!ZCI0!\_>%];CT+PSX!U:]$SZ/ILU_#?LD3-]FF=F$;,H'8$].1N]P*Z
M/4;K3(XO#FMZ38SP>%8M>>YNI'C<*Y=/EN-K<K&'9AR !@$<8KUW:,8P,>E+
M0!XKXI>WFC^(6KZ=<0MH]YI<,/G1N#%<76#]P]&8+M!QW..N:V/ /B..QU=]
M!URYM9KJ\M8KJPOU(VW%N5P(CV!3# #OR>N2?4@ !@# HH ^>);K2)O!,\3S
M6;*/&A8*67_5&4$D?[)7N.,5K>(@9O$/Q$M-!\MYY=.LBL%J5W2JA_>JH'4[
M,C&#UQWKW&B@#R&PN?#WB@:OJNBW>KZEJ(T.>UF-Q (TA7&5B8+&H9]V<8ST
M/M69=ZMI,GPO^'K+<P;[74]/20MP4* >9U[+QDCIQFO<0 .@Q1TH \;76=%M
M-3\6^&O%UC=75WJ.JF[LH8X)'-[%A#"L;H.-NP#D@#UZT[Q!J#Z7XHU&\TG4
M;6\DGU&U%]X=O$!E>5?+59(&!W''R'I@;3Z8KV+ SG'-&!G..: /,-4B75?"
M'Q!\12H'6ZMKBUM"PSB"WC=01]9/,;\16-IL6BWX^'4N@-9B_L%2;49+<@-!
M"(?WOG$?=RV!\W4D^]>J>(M)?7/#FH:1'<+;?;8'MVE,>_:K#!P,CG!..?SJ
M30M-?2-"L=.DG2=[6!(?-6/9O"C:#C)P< =Z /"+>72(OAMI]V'M%NAXJ65Y
M<KOVB<G.>N-F#]#4WCO5;2YMO&\$3)93+?6SO;A6DENPK1@3%CD)&!T"@>YY
MQ7T#2%0<Y .: /+-+B\/:W\9->DFBL;N-M.MI(?,16!()9B >X^4YZUQ-XVB
M-\,/%3H;,S/XG8HR[=QC\]"NW'.W9N(QQC/O7T510!Y)=W>EV/Q%\2&R@@G@
M'A8%;6T<)YQ4LVQ2O?9CIR 0:Y_0M1CN?$?AAM/OX?,E\/SVMK'!$RQVTNU=
ML(8Y9F4D;B2?7"YKWNDV@8P!Q0!Y)X&US0=2L?#6D'3;H^*M%C:$Q/!(AM&*
ME)9'; 7#=<$DDD<9YK&C=+WX/+X8+!?&<%^,6K'%P+G[3N\T#KC:2V_IC/->
MZX&<XY-)@9SCGUH \8U;5K;3)/B7IGB!O*U'4())+'S(R1<0B B,(<<[2.G8
MDGUJS/;36OP_\$>,]+MGFU#1+6W2:%5P\]NR".6/GN#R/3FO7B >H!K O?#E
MU?\ B2+4)M;N_P"S8PC?V6JJ(FD0[@Q;&XC(!QZCKCB@#B?B%96FG^&?"T&I
MFU^T2:];SW)D(P2SEICS_""W/8#%8>OW^F6.L?%!4M(;V![2P!M()=@? VN?
MDYPI8%L?0]:]RHH \(EU33Y-;\8//JEM>1WGAD"&98?*BD(#@",'^$$  DDY
MXSGBIK!-!:^^$496Q*_8Y?M"X7_6&!0-_OYH(Y_B!KW  #H!TQ2T >&I=:<?
MAE\3(EFM=G]L7K0*&7&&"A"H]\'&.N#BKR>(]+T/Q)!=>(R[Z%JOAZWMK2Y6
M%Y8^,^9%\@)!;//T&:]DH(!ZB@#QW7I;73!97>B:C%H5Y::*(XM+U>/=%=VA
M=]D1W'<'.SD?>^8#UKNO#GBO3;LZ9HDH-GK+Z;%=MI[(_P"Z4J/EW$8..F,Y
MXKJ, ]JI'3(6U9=1D>22:.,QQ*Q&V('&[: .IP.3GVP": .&\=+81?$?P7>:
MPD"Z9$EZLDUTH\E'*)LW$_*"2.,]Q7&>*-/@L?AQX\NHTBATN_U2&32X\!0^
M&CWO&OHV&QCJ%)'%>\D C!&110!YG:ZMING_ !%\3R^(;JV2PU6RM6TZXN&'
ME36X1@Z*QX/S-G:.3G.*YC19I-"B\$:?JX;3KG['=F"^N4:1HHWD^6%(SQYA
M3;]X' XP:]R(!Z@&EP#U'2@#PG2+*2^^ FCZEIGS:QX;N'O8QM.0R3.SQGZH
M<X^E;_B&]5OAE<^(=3TSS#K5Y;W#Q2LP6VBW*(3)M()5556*YY9CZUZM@ 8
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MRQ!8YU50S8YW @'N #VSQ3'\>:7'=6:O!=+97EW]CM[_  AA>7) & V\ E2
MQ7!QUQ@UY%8?$S0'U?P!)_I031+":&])B^Z3 J97!^;E"?H1WXK.\+_$?0M
MEAT:33--GM;:YW1:V]L?-\K?NY39N,F. <C!P><<EPY3VN+X@:;+J-K;?8[Y
M;:ZOGL+>]9$\F29,@@?-NQD$ [<9%6;?QA;W>HBVMM.OIK?[9)9&\01^6LJ
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M:*?)925+98*<<':#SVH#D9V1\>V,*:W]KT[4+:?1H4GNH'6-F\ME+!E*N5/
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MC6M9L?#^CW.JZE,8;.W4-(X4L1D@# '))) _&BPN9GEG_#.OAS_H+ZK^<?\
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M./\ ^)KV*N7U3QHFG>*HO#L>B:G>WTMN;F,VYA",@."<O(O0]C18.9G&7'P
MT&YAMHI-7U/;;QF-,>6.-Q;GY>>6-1P_L]^'H9HY$U?5"T;AQDQXR,?[/M7H
M/AOQ98^)7OX((;FUO=/E\F[M+I LD3'.,[200<'!!/2MZBR#G9Y3=_ C0KN!
M8&U34$16W839U_%:I_\ #.OAS_H+ZK^<?_Q->Q4460.;9X[_ ,,Z^'/^@OJO
MYQ__ !-*/V=_#JA@-7U7##!YC]<_W?:O8:X^]\>_9_[7EM?#VJWEGI+M'=W,
M8B5<H,OL#.&? ]!18.9G&C]G7PX"#_:^J_G'_P#$TJ_L[^'4;<-7U7/UC_\
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M%88]QR=JC S[\5<K.T+1X/#^AVFDVTLTL-JFQ7F8,[<YR2 .>?2M&@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>modificationno16effectiv007.jpg
<TEXT>
begin 644 modificationno16effectiv007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$0)0@EFW/D^YQ63J&L6"?"K4=&U9XX_%$&L":\AD3]ZSFY!\P>HV$#=Z<>E
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MMHKB!Q)#*@=''1E(R#^524 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKZ]<#F@#U&FJB)G:JKDY.!C-<[J7C*VTR.<MINH3R6EL+J\BA$9:V0Y(WY<
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M1+$^=#\Y$7EG/S_+SSSV]^*2#2_&'AO6-/UO2] 741<Z3;V-[8R7D<4D$D7
M8-DJ5Y/3/X5ZI10!P&L:7XBO/$'@N]ETX7#:?/+-?/;21K'$)%*A5W,&;;D<
MXY SUXKF]=\*^*7T'QGX>L=#%Q'JVJ_VA;W?VJ-4*L\;%<$YW#:>H QGGH#[
M'10!YM-I7B72?%?B&^L]%.HVGB&UAW;;J-&M)DC*;6W$;EYSE<_2L"W\&^)-
M+TSPOJ)\,6.KSV.GMI]YI5U-$2!OW+(C-E0<]?;CG/'M%% &1X:M9[718Q<Z
M;9Z9*[%S96@&R'/1<@ ,?4@=2:X=/#OB"#2_&?A\:2777M0N9[>_$\?DQQS
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KC_$7_)2/!?TOO\ T4M=A5&_T:PU.XMKBZ@+SVV[R)5=D:/<,-@J
M0>0* +I .,@<=*" 1@@$>] &  .U+0!E>)_^13UG_KQG_P#1;5#X-_Y$?P__
M -@VW_\ 12UHW^GVVIVK6UVCO"P(9%D9 P(P0=I&1@]#4MM;0V=I#:V\8C@A
M18XT7HJ@8 'X"@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,BR\3Z5J&NWNBVD\DM]8D"Y002;8B1D O
MMV\CIS5J'5K&XU:ZTJ*X#7MK&DLT6#E%?.TYZ<[37 ^!T,GQ,^)**[(6FM0'
M7JO[M^1FL'P[<:E/XBTP2ZSJ8BNKU[9+[["%FO%M26V3MGY4.^0 @9(7GV /
M7+_5K'3);.*\N!$][.+>W!!.^0@D+QTX!ZU5\0>)M)\+VD=WK$\EO;NXC$@@
M>10QZ E0<9]Z\[\<W6HV?BV^:#4+Z:&TM%U,QM9+*MEC]R&@.1F3#N^#QP?P
M=\5(FA^"]JCWL]ZPDM2;FX7;)+E@=S#L?:@#UFL36?%NAZ#=P6=_? 7MQ_J;
M6&-YIG]Q&@+8X/..U;=>"_!.X?7/B-XMUG5,R:F,!2_)C5G8,H] -JCZ#% '
MK5MXUT&ZNVLTNIDO$B:9K6:UECF"*,EO+90V/3CGM4<7C[PO/X:N?$46K1MI
M-K)Y4UP(WPK_ "\8QDGYEZ#O6EJ&E6EQ>1:H\?\ I=K!+''(.NUP-P/MP*^?
M?!NJSZ+^SSK=_#;V5R(]6"R6][!YL4BL(5P5R.A(/X4 ?1UG=P7]E;WEK();
M>XC66)P.&1AD'\0:+N[@L+*>\N9!';P1M+*YZ*JC)/Y"O(]4\=^)+"\\ V&D
MC38DUVQ@+Q/;D1Q,P7[N#D*-W3VZT[0/'?B+4-*^(5GJ4ME-=^'ED\F9;;"2
M[?,RK)GH?+]?XCUH ]0T/7-.\1Z1!JNE7'VBRGSY<FTKG!*G@@$<@UH5XGI_
MQ,O+/X?^#8[2UL+74==O'ME\FWV06\:SE"RH#C/S+QTSDUTMSKOQ!TCPWXBF
MN-(MKR[L[K9I\V5430$\R,H;L,'MU]C0!Z+(XCC9VW$*"3M4L?P Y/X5E:!X
MHT;Q1;37&BWRW<4,GER,J,NUL9QA@*X/P9\0-2U?XF:AX:FNK:_T^.S6YAN8
MXPK!L1DKE3M89<C(ZX!!JA^SY_R!/$/_ &$S_P"@B@#T/7?&OA_PS=0VVLW[
M6DLW^J#V\A$G3(4A2">1T/>BU\:Z!>:K;:7%=RK>W.[R89K66(R;02V-Z@<
M5Y;^T&Q75/!;*A=A<S$*.I^:'CFO0_#\EWXAN+^ZUJP:RN],U5Q9Q2,K&%3;
MHH.5X8,)&;K_ !>U '745Y+I'Q \1C7_ !9X?UN6PCU/38=VGB*W8"X).%."
M_.[='@?[?M6IXK\3^)=!O;"RF>TMK1[!Y)]5$8*O=!3B-(V;."0.!DG<.F#0
M!V>N^(-+\-:?]OU>Z^S6N\(93&S $],[0<?C5VTNH+ZS@N[:0203QK+&X'WE
M89!_(UX1XB\6W_C3]G.]U34HX5NA>1PL85(5MLB8.,G!YK?B\9ZQH6I?#G0K
M4VK6&JZ?;+*)(B77Y%!PV[^E 'KU%>5^&/'WB;5I/'5O]CM;Z[T*0Q644*&,
MS,&D7YLL?[@.!CO5#0/B5KEQ\0_#^A75Q9W4&IV7F721Q@&UG"R%D5E)! *#
MKGJ0>10![%O7?LW#=C.W/.*R=#\3:/XD%X=)O!<BSG-O/A&7:X[<@9'N.*\Q
M\$7/B/4/C)XM2ZUF*0686%MUL2#'N;8L8WX3!.>=V?QS6?HOQ0O-*\ >*-:E
MT_3A>V^I?9X1;6_DI+(W\<@!Y/!)[G&* /=:*\OTSQOK5EXZT#PYJL\-Y'K>
MEI=K,L C:"4JY(P#@K\G?GGK7(M\3_'$OAKQ/JL5UI<<>AWD<'_'J2\P:39C
M[V!ZYY_"@#WZBLSPYJ<FM>&-)U25%26\LX;AT7HI= Q ]N:TZ "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2C 8>8V5;)(8],"N=CUK7D\.^(M'.B3&/6[F.XD?R7S&5<OA>.YQU]*^RZ*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2X 4 ,TH8;$4DD\Y/& <8KATU.^U?X4^![S4;E[F[;Q';H\LC99MMQ(HR>_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWT,98QLP8H<<%E!!Q^5>,:E9Z5_PJSQ!?Z?>:=?3OK2:E=?V>WF>0K3J0A.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"BP+EV^SL9 B[P)L#YOGV888&[I5[Q[>ZO;VUB+>2>.R;R3=.4$85_/C"?O
MVY6+$#:%((+9(ZUWA52P8J"5Z$CI0RJXPRAAG.",T <9JLFHS?"O4;Z_EO;?
M5(+"YFW#-JZ2*KD?+&Y&!@8^8Y&#WKI-"D>;P_ILLKL\CVL3,S')8E!DDU1\
M<?\ (@>(_P#L%W/_ **:KGA[_D6M*_Z\X?\ T 4 :5%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5QNL2)%\5_#AD=4!TV]&
M6..=T-=E4,UK;W)4SV\4I7[I= V/IF@":BBB@#GO'<B1^ /$.]U7=IER!DXR
M?*:K_A[_ )%K2O\ KSA_] %79[:"Y4+/!'* <@2(&Q^=2 !5"J  !@ =J %H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,W-4IK/PQ!XCM]!;4=5.H30M,(AKMWE5!4?-^^XSNX]<'TH \5L?A=\4=/\
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MZ\ [203VYJY!J%E<VSW$%Y;RP)G=+'*K*N.N2#@4 6:*I_VMIH./[0M<\?\
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M;EV[LC;C.<\8H 6BN(MO%>KZ[K&HQ>'VTE[;3K]+26*X9C).H"F1T96PN-V
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MDC#90@X_V<UZ2((EE,JQ()" I<*,D#H,^E-FM+:X8-/;PRL,8+H&(QTZ_4T
M>2Z>=(UWXDZ"VH6<"P-X123['=,'$9,@(5@>N%)/([9K \.ZMID7@[X?V]S+
M:I(+N^,5U>RYM;8HS_ZQ<C<V&78"1SSGU]X>SM9)3*]M"TA&"YC!)&,=?I2"
MQM%0(+6 *K;PHC& WK]?>@#P.'4+)/@U/:F[A\R#Q$NY<A2H^T[@=O;@$XKT
M1+JW;X^E%GC+'PT% #CD_:-V/KCGZ<UW)L;1E*M:P$%BY!C'+'J?K[TJVELL
MHE6WB$@X#A!D<8Z_2@#@OB!JT&B>+_"=_K/&@(]PL\C(7CCG* 1LX_[ZP>V3
M6!=7&AV:>%YM)C=?!HUR5KF64'R6D9,QN-W2(2,PR>,K]#7K\L,5Q$T4T:21
MMPR.H(/U!H,,30^28T,6-NPJ-N/3'I0!XAXQMK0V7Q'N++[.VC/;6K*5*F+[
M9_$4[;MNW./45I>7::=\0M-_L!+6*[G\+3&+RMH\Z7(*;C_$21G)Y->L_8K7
M[.MO]FA\A?NQ^6-H^@Z4+8VB2+(MK KK]UA& 1]#0!X/'JWAU_"OP\"W-FFK
M6FN6_P!O60A9XWRWFM)GYAEL$D]>*E\0WFGZ;H/Q2TJXN(8KVXOA/#;,?GD5
ME1MRKU(ZG(Z5[F+*U$IE%M")"P<OY8R6'&<^O)_.E>SMI93+);PO(5VEV0$D
M9SC/IF@#Q^;6_#D7BK5[7QA/%_9>IZ/:)IL[@LC0[")51ES@ESGCT'H*O1_V
M-9?%'PO++ EI;2Z#Y=L+U0LC.)$$8.[DR8Q[UZG+;03E#-#'(8SN3>H.T^HS
MT-.>&*21)'C1GCSL8J"5SUP>U '"_$^^L;6'P]'?)"!+JL9BFNI-MM"ZJQ#2
MC^(#LN1D]QBO-YK^S'PE^(]H+ZWEF.M22+LP@=6>+:RKGA6P2/H>N*^@I88I
MTV31)(F0=KJ",CIUJ-K.U<.&MH6WMO;,8.YNF3ZF@#@;V]M9/C+X8V7,3;](
MN-N'!SDJ1^8!_*F?%>WTZXNO!R7R0%7UV&-_,P"8RK;E)_NDXR.E>A"SM0ZN
M+:$.@ 5@@R,>E+-:V]P5,\$4I7H70-C\Z /'==30O#_C2^T36+PZ)HD^F)%I
MVVV1X=A+F9 61MI+,#QC.!GHM2:=?:3H/CC1+36+R0:&OA[R]+FU4 !W,O).
M0 '*!>" =N!QG%>O36T%R%$\,<H4[E#J&P?49[T3V\<ZJ7BBD=#NC,BYVMV/
MM0!X-9"VM_AOX7OVVPV=CXQ65Y"-JQ1><X)/]T#(K7.HZ1J.K_%MTN;2>WFT
M^WDB)92LFVV8;ESU 8K@CN1ZBO0/!WA:7P[X?FTF_GM[V.2XEF^6$J"'8L00
M2<X)KH?LEMY;1_9XMCXW+L&#C@9'M@?E0!XK#9Z+JU_\)(+V*TN(IM*FBF5\
M'S-MNFU6]<-G /?--U(>'X=;\3>&O$VJSZ3"[0I8Q);(X>T6-1$L3%&;*D'@
M'J3CG->U+86:LC+:0!D^Z1&,KSGCCBGR6T$TD<DD,;R1G*,R@E3['M0!Y&;[
M3;+Q;XHL_%4B1&71[:/3#J97=)"(F\Q03QO,A^8#J1WQ76_"F:&?X6Z#LD21
M5MMCX(.""<@UU\MM!.R--!'(R'*%T!*_3/2GI&D<8C1%5%& H& !Z8H \-TK
M1;.7P=X]U+1;2%M;L]5U!+26W'[R*,\8CQT!0O@#\*UO#DOA76;]-3T;Q%?/
M>1Z3+!(D-LD0M8=O60(B\JV-HR3GID9->LPVMO;;O(@BBW==B!<_E534-)BN
M]*O[*V=K%[R-T:XM@%=2PQN!]?>@#Q_P9'HFNS^!5N;S0]^C02@Q-=1/+<R.
M $Q'U# _.<\AO?FLO6+[3M/^'OC/1I;F&.^3Q.\BVS$!Q'Y\1#[>H7'\73MW
MKT[3_!%^J6UMJNI:;<V=LT;(MMI2P2ML(*Y?>V.0,[0.G45V#6=JTK2M;0F1
M\;G*#)QR,GVH \VU35+*+XO7UR)?/1?"#N$MY!ODQ,7PA'\17D?4&N3\*7>D
MMXL\#&.XTQ;.;3KB 6T1#&,L%Q%*Y_UDA+<C Y/3G)]V^S6_G^?Y$7G?\]-@
MW>G6FI96L9C,=M"IC)*;8P-I/7'IF@#P?1;NTM?A?X90&W-K::XG]O(@!,<7
MGRE/. _A!VGGV[5N>)X+*;6/&]UIQM9-'?PP3=-&5:(W@+^6?3>$ Z<\CU%>
MO);P1K(J0QJLA+. H 8GJ3ZTU;*U2W^SK;0K!U\L1@+^72@#RU/ 6EZM\)-/
MNM"L[>/6?L=I?0W" $R7$29&X]R<LI^OM77>"+F37;)_%5S:-;3ZG'&L<3CY
MHX4& /H7,C#V85;U_1-7U!+*'1->.B6\;-]I6&TCD,J''"EON$<\CU]JV[:W
MBM+6&V@0)#"@C11T50, ?E0!Y1\0[[3SXRO;.1K6VO!X>E"SWIWB168XC@C)
M \PD?>R>.-IK%T+Q'I%A-X/G\031MH+^&_LD4LB^9%'=@KYBG&<-L &?P]:]
MR>"&219'B1I$!"LR@D ]<&F-96KVRVS6T)@7&V(QC:,=,#I0!Y!?Q^&;#4/A
MU<00I!H,4]Y&DU^,!H_+;827YVDDE<]B,5J:-I>DZWX]^)FBR+ ;:\2R5DC
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ML[2R\&Z;:6<UU/91P[89+P?O'CR=I(P."N,# XQQ6S-;07**D\,<JJ0P#H&
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MB,( ^=N[<P)X!/R@X')KE9_$SZ!\3_$2W#:I>VL>FP7"6=N&FV<MO95SM48
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MMYT6Z6'S2_RG?MSANA(H [_5/&MCI,5S-+9W\L5E&DE\\,:L+0,,@/\ ,"2
M<D+N(&">"*@USQ99-9W=GI\=_?S_ &#[6[:=C,,3 ['W%EP3@D 98XSBN1N]
M UJQ\6ZG>OX$T[Q!:ZPT<ZM<RPA[.38JLCLP.5XS\O'IG-75T?Q#X:\5:S<6
MFC#4[+6K&WB+6DD<0M98HS'MV.PQ&<DC&<=,4 =!\-;RYO?AKHEW=SS7-P]M
MN>21R[N<GJ3R35/0/B%'?Z?X@U+5+*XT^TTR]DM\R*"1L"+L.TG,A<G@>H )
MJ_\ #G3M0T?P!I.FZI:&UN[:+RWC+JW<D'*DCO7%S^#_ !%=Z%XMTB/3S#-+
MKLFKV-Q),GE7'[Q'6/ .1D*<Y  ./? !Z!I_BJUO-<_L6XL[S3]0,'VF.&[5
M!YL><$J49@<'J,Y'I5S1-8BUW31?0VMW;(7=/+NX3&_RL03M]..*YR&PU'Q!
MXVT;7KO2[C2XM*M9T,=P\;-++*%! V,WRJ%/)QDD8'6NCT.]U#4--$^IZ6=,
MN3(ZFW,RRX4,0&W+QR.: -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&.5W8_2L/XAZ7I?A+P;>:Y8:39R26ICS%.96#[I%3J'&,;L]Z /2:\Y^.?\
MR2C4_P#KK!_Z-6K">"S%>67G6^CW$$C_ +Z..*:*18\'+*3,P.#MXQWJ+4O#
MGPQU98+>\N-/=9)C#'&FJ,@DD&,IA9!N897CMD>M 'H$/^IC_P!T?RJGK=O>
MW>A7]OIMPMO?2V[I;S-TCD((5NAZ'':L&R\/^"=0N+BVL4LKF:U;9/'#=%VB
M/HP#9'0]?2HH-)\!75S-;6\FG2SPJ7EC2\RR*#@DC=P >I[4 <)>>#/C$]L;
M8>*]/NXI01,LP#*0>-N&B.1C^=<M%\&/B/;!XXM3TZ.W=M[P+<L(&/H8]FT_
M3&*]CM-*\ 7[E;2;3;AEB,Y$5[NQ&#M+G#?=!!&>F:+32O &H70M;.73;BX(
MR(H[S<Y&,Y #9QCF@#R;6_A)\4/$4]K/JFLZ=/):+M@_TAD$7.?E"Q@ ].>O
M ]!4=A\(?B?I>K3ZI::W917\X833_:W9I >N[*<_C7KT&D> KB[EM('TZ6YA
M5FDB2\RRA>&)&[C!Z^E116'P\N+BVMX;K2Y)KHGR(TO@S2X)!VC=SR"./0T
M>1:=\%OB-I.JG4]/O](MKT[L2QR8*YZ[1Y>%_#%5U^!7Q!2*ZB74K 1WA!N5
M%Y)B;!W O\GS<\\]Z]=TF+P%K>OZCH]C#;2W%CM5\7#?.QSN"C=D[<#)'&3[
M5H:GH?@?1PAU/[#9!P2GVBZ,>X#KC+=LB@#R'2/@KX\M-=T6[N]2L9+?39XV
MC7[7(QCC5]Q" KQWXJ*3X+_$>XU2]U&XU?3Y+J]1TN)6NG)E##!4_)TZ<=!@
M>@KOKF#P_8_$3^SKR+38M!;1?[06=Y'3:WFJ@)D+X(.>.!U%=)-HW@6VTZ'4
M9C81V4Y BN&NR(Y">FUMV#GVH \KTOX7_%;1[EKJRUW3XY_)\A',Y?RX\@[%
MW1G:OL,"J-K\&?B196FHVMKJ>EP0ZB-MTL4Q7S!G.TD1Y Y/ XYKT#QE:Z#I
M_A2VUKP_!IUS#)>0PF0.\RNKR!#M97 !&3ZU8CT;3?\ A:DOAV33K5M/_L<7
MT>WS X?S0F"V\Y'!/0=?:@#A-(^''Q>\,:6]IHVNV<5NI,@MX[C.6]%WI@9^
MH%/L? _QF:]EU@ZO:6FH7,:Q3-)*AD*J3M!*HP[GH?Y5ZS?>&/!^F6_VB_M[
M:UAR%\R:X9%R>@R6ZU"NB>!FTH:J/L!T\]+H79\H\X^]NQUX^M $OBG1]<U7
MX>7NDZ?<0#5KB%8S).!L.6'F Y!ZKN'3OVKPY/@5X]CCMHTGT0"VD,L1W<[C
MCJ?+RW0<'(KVA=+\ /ILFHK+IIL8FV27'VS]VC>A;=@'VIIT_P"'H:[4W&EA
MK-=UR/MW^I'J_P WR_C0!Y!/\%OB1/J=[J+ZQ8_:[T.MQ*+R0-*K?>4X3H?3
MI5[_ (5%\0XO"47AZWU'2Q8L[O/ \FY68D8(S&2#@=1C%>JMH_@-+:UN6?3E
M@NR%MI3>868GH$.[YC]*S[_3O"-UX7U?4?#QTR\FLK>23?'.TZ*RJ6PP5QUQ
MZT >8:/\%_B#I&L6NH6][HT<T#+B0-N8 >A,?7&>>M=U\5?!/C/QA>Q0Z)JD
M$.E>6/-MI)VC#.#D$X4Y_P#K5J:)IWA1_!6BZSK<-E:/>VD,KO).T:%V0,0,
MM]>*9J<GPZTR]TFVE^Q,VIMF%UNSL$>UCYA;=C;E< YY)X[T <4G@7XS*UJ_
M_"3V3O;*5A>2<NZ @ _,8R3D <FL6+X+_$N'6UUE-:L_[35@XNC>R&3.,<DI
MSQQ@]N*]DGT7P+:ZA'87!T^*\D(5+=[LJ[$] %+9R>WK1K>A^#/#ND3ZIJ=I
M%!:P+EF:5^3V &>2>PH \8O/@?X]NKN_F>YT1FOI"\S;L$DMNX_=_+SSQBI;
MCX,?$FYDTZ235]-WZ<BK:;;EU\C!R-N$&#GG/4UVL\OAY_$/A$VUOIHT75[>
MYEN6:5BT)BA#X,F_:,;AD8XP?7CKXM#\#W&EG5(?L$FG@$FZ2[)B&#@_-NQU
MXH \?TSX3?%#1-1N[_3]<L8;J[S]HD^U.QFR<DL&0@\GJ?4UF']G_P ;F(Q^
M?HP4OOXE(.?KY>0/;I7NUAX:\&ZM;M/IT5K=PABAD@N"X##J"0W7VJM=Z9\/
M]/:=+R;3+=K?;YRRWNTQ[ON[@6XSVS0!Y%<_!OXFW>K0:I/KEI)?P*JQ7#7L
MF] HX .SCO\ F?6H[CX*?$.[N;^YGO-%DFO_ /CY=F&7.<D_ZO@DC)(QDU[+
M%HO@6;4(["(Z?)>21B5+=;PF1D(R&"[LD8YS3&TOP"NJ#3&DTX7Y<1_9C>?O
M-Q&0NW=G..U 'D]]\'_B-?>'M/T274-&:PM%/EPYQL8LQ)!$><D$9.>>]-/P
MA^)K>'?[ _M/2!I6X-]F#X7=G.[/EYS[YS7JUQ9_#JT+BYN])A*2>2XDO]NU
M^NTY?@^U7#X=\%B\DLS'9"ZCB\YX?M1WK'_>*[LA>1STH \?O/A%\3+_ ,.V
MFA7.JZ3)IMJVZ& OCRSZ@^7G/)[]S4N@?!WQYHLNK7,-_IMO=W5@;6*2WG9-
MI+IGH@Q\JMR.<_G7;^,'\&:%X4&J6"Z9-+<R+%9L;HM&Y+A&88?Y@F23@]NU
M+INE^&-+><>(=6\/S6\Y$NGS)<F)GBZ$L"^TX;@$'% '"Z#\*_BMX8@F@T77
MK"SAF8,Z)<L5)QC.#&<'W'H/2J</P3^(D%OJ*1ZM8JVH8%T1>2?OER2=QV<Y
M./UKV;4-#\#Z3#'-J(L;2*3)1Y[HH&P,G&6YXK*OS\/;#6]+TJ1;,W&H*9$/
MVHA5CVE@Y.[&&( 'KGB@#R8_ GX@M;VUN=3L##:LSV\?VR3;$Q()*C9P20#Q
M4.N_"#XF7>MS7TBQ7UQ<D&6YAO$3. !SNVG@ =J]P.D^ 19O>&731:QR^2\_
MVWY%D_NEMV W(XZTEQI?@"TNFM;F738;A656BDO=K M]T$%LY/;UH S?ACX7
M\6>&?"M_IVNWT<LC'-DJS&3R<J<@DCCG!QR*\^UGX7_%7Q!Y#:IJ^DW$L&/*
ME+!9(\'/RNL08<^]>AV.C>%[<ZO=:K>Z&UA#=>7"\5T5%NNT?)*Q?&^M6ST+
MP/J-W<6=E]AN;FV.)X8;LN\9SCY@&R.?6@#RS2_AO\7='N)+BS\0:>+B1=C3
M2S>;(5_N[GC) ]LXJBWP?^)CWSW9U32O,>X%TZ"7$33#I(8_+V%O?&:]:&G_
M  ]-T+7[1I?VAF*K%]N^8D'! &[D@\5?N_"GA/3[22[O+2WM[>(;I)9IV15'
MJ26P* /&KSX2?%+4->37;G7K)M40 )<B[=60 8PN$&!R>!ZGUJ*P^#OQ)TG3
M[ZQL]8TV*UOQMN8?M#,LHP>H,9YYZU[#9Z)X&U"UFNK/[!<6\&1-+%=EECP,
MG<0W''/-9]V/AQ::->:J9M/FM+,#S6ANBY#$95<!NI[#O0!Y0WP3^(CZ&FC'
M4M,_L])3,+=;A@I<C&XX3D_7.*VXO 'QCBTI=+'B/3WL5C\KR99?,4IC&T[H
MSD8XYKL_[+\-:HGA^YTN;1X(;R0--!-<L\DJ[<E(\/\ >!Z_2M>#1_ =U;W-
MQ;OITL-K_P ?$D=[N6+_ 'B&PO0]: /)--^$GQ1TB\2[L=;L(IXX?(CD^TLQ
MCCSG8N4.U?88%48O@7\08OM&W4=,(N&#S![EV$C Y!8%.2#DY/J?6O6;G0_#
M*:_;NEUHJ:6+)[B:!KAO.8#!$JG?C8!U-9C?\(AK_@ZXU/0+C2+&83&*.;4+
MAMB@2E067<"-ZJ2H//(H =\*_!/C#PIJ^I7'B+4;>[ANXE&Y9FED9U( +,R@
MD!<@<\9Z54^)7@SQWK_C*PU?P[>6T4%A%_HV^0*\<AR'(^4]1CJ>U=;J&B>!
MM(:--2-A9O(,J+B[,9;G&1ENF:;?Z3X"TJ5(M0?3[21U#*D]X4+ G (!;IGB
M@#R_5?AS\7/$=@EOK&L:7<Q8W"*X96,9QV(C.#[@_C52Q^$?Q2T^_AO;?7;(
M7, *Q227;R&,'KMW(<?A7M%SX1\*V=O)<75G!!!&-SR2SLJJ/4DM@51M=+\
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M110 4444 %%%% !1110 5Y[\;)HQ\+-5MS(HFF,(BCS\SD3(3M'4X S7H5%
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MC<J@=FZ@ 8!& 17KM% 'A_C);>ZL?B#J]C+#)I-]:6L4,B',=S=+U,9Z,0N
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M1&2,\A>OICDUF^'=%M/%_@GQWHT$D1DFUR[FM64CY3E6B<?[)*]1U&:]AHH
MX+P1?7.L^'9?$_B&!;6=[46C"? "I%GS'.>FZ0N?HJUP.BW=O:_#[X:7D[;8
M++5G2Y;:3Y1/FX# <CJ/S'K7O=% 'B^NF74?$_Q#MM$?=>W.C6XA2+AY"H/F
M*!UW8.".N33[2^\)>)+>]U)9O$%Q-;:1/:WH>+RS:0,IW1\(JLV>@&>A/:O9
M:* /-O %]?'Q1=Z:^I6>NV,&GQF#5[>/:ZJ'(6"7'R[A\Q]?7KQZ3110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !65KFO6^AI9B6&6>>]N%MK>&(J"\A!;&6( X4]3[=36K7,^-=
M,.L:?;64N@)K-DTQ-Q#YJQR1@*=KQLS+A@<#J.">: .8\8:]+)-X.U,0:G8M
M_;AMIK0N2S!=X*E$8J^2HP>>#[UNI\1M,71M9O[JQU"TDTB98+FTEC4R[WP$
M"[6*G<6&#G]*Y:'PIXGMK'PU;R6UU>1Z=KC7JB:ZC>2"U&52-F+#<X!SQD=L
MT^_\/^,1+XSFTNRDMY-3O+>:W874:/+$@"NH8,2C$#@^AZ@T =!J'B>/6]"\
M7:9]EO\ 3M1TJR+S(T@5E+Q,\95XW/\ =]?:N;2YN?[*^%$_VNYWW#0I-^_?
M$H,!/S#.&.>YYJ33_"^O6%[XS>'P[%;VNM:?%';Q17B,5D6-T(8G&22^XD^_
M+'K./#VOKI7P^M_[(D,FB21F]'GQ84+'Y9V_-SGK]/>@#KO'%Y96'@S4Y]12
M^:S$)$QL6"RJOJI)&/SJ@WC6TT_4K/0+;2M6O+M].6[MUC5&\R,8&-S..>>2
MV!QU)(!M_$#3;[6? VJZ7IML;B[NX?*C0.J@$GJ2Q Q6'9:5KD7CS2M9DT:8
M6MOH7V&7$\)82[@^ -_(^7&?4^E &O8^/M-U/1=*U"RMKN:;57DCM;+:JS%H
M\^9G+!0%VG)SZ=R!7,^./$BZY\-9]3L1J&GW%KJ45M)$[F)T=9E5U;:V&&#Z
MD<^M9FF^#_%VCZ#X;O[+386UC0[J\+64UP@6YAN&).UP2 P!'7'?KWWO%>F^
M+?$G@*:VN-+@&I7-Y#*EG!<(5MHT9&PTC8W$[6Y _B [9H Z1O&%FNLZSI7V
M2\-SI5LMU+A4Q(C D;#NY/!ZXJ"+QQ87ECHTUC9WEU<:Q$TUK:H$601J,LSD
ML%4#('7J0!FL/6-&\0Q^,=4U/3=(2ZM]7TA;1B]RD9MY5W?>'.1AA]W/(_&L
MK2O"OBGP\OA/5[?3(;R[T[3VTV\L!=*IV$Y#HY^7.>H^GX %CP!XD73] UVX
MU#[<TC^([BUMK6XF\R?<0NV+<S8R #DEL  G-=IX>\56?B*?4;6*&:WO-.E$
M5S!-M)7<,JP*DJ01G!![5YT? _BF72+^Y_LVP74(O$DNL6UI<3K+'<1N"IC;
MC XZ$_I7?>$(-26WN+G4M"T_1'E*A+.T99" ,Y9W4 $G/ [8Z\T <K)KEQH?
MQ7\1K%9:OJB'3[>5;2U)DV<MN8!V"J.G //8'FNCT_XA:-JEYH-O9K<RKKD4
MTEK*$4(#$"75\MD,,8Z$9[U4FTW6M*^(NI:[:Z6=0L[^QBMU$5PB-&Z$_>#D
M?*<]1D^QK#B\$:SX:C\&W>GVD>J7.D2WCW<*3+%N-R#DH7P,*?7D@=* +^O?
M$IH?#T][I&E7;RPZO_9,QF,:^5('4,<;CNSNP.V>N!U[I[U(-,>^NHY+:..(
MRRI)@M& ,G.TD$CV)KRI_!OBA_".NVSZ=!]MG\2'5H(4NE(E0RJQ )P!PO&<
M?05Z5?\ ]JW7AFZ^R)'::M+:N(59PZQ2E3MR<8.#CM^= &)I7Q!M-4O;2U_L
MK4;=[VQ;4+/S1&?/B'IM<X)!! ;'6JVD?%'2M7TQ]373-6M]/$)D2ZGMP(Y'
M\SRQ$I#$%RQ&![]>#7-:)X9\3Z?XDT+6I?#P,L.GRVM^[Z@DDTTAVYD+$\YP
M=HS@=#M%6=/\#:W)\%;;PU-#%:ZQ93>=$LS+)%(RSF50=I.5(..>_;% '9Z+
MXNM-8UN\T9K:>TU"UB6=HIFC8/&W 961F!P>#SUJ/5?&<&E^)(]!72M2N[^:
MV:YA6W1-L@! (!9@ >>IP..N<"JW@ZWUDS2W.J^&M+T';'Y8CM'21YFR"6+*
M!M48X7)///05%J&F:J?BG8:W#ILDNGV^FRVSRK+&"79@PPI8''&.W6@"Q9^/
MM,O_  _I^J6UM=O)J%PUK;V151,TJE@RG+;1C:Q)SC _"LW7?B-]A\.>(9[7
M2KE=6T< 3V<[1@Q!QE)20Q#)_NY/; ZUS^D^#/$FGZ1H%ZNG@:EHNJ7-Q]D>
MX3%Q!.3NVL"0& (QG ZUI:WX/U;Q!9>,-1^R?9;W5K&*TM+.65"P$?.7925!
M8G P2 !R>> #O=(NYK_2+:YN+>6WEDC!:.0KNSCK\A(YZ]>_:O,-/U&VLO /
MCE]8EU:XL+?7KN M;7!:>.,% H5V;.!QW[UZ9H37IT.U_M"R%I<K&%: 2B0K
M@8^\.,_3\Z\VF\+>(YO /C32?['D6[UC59KNU4W$6/+D92-QW\$;>1[C&><
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 8XSCDCZ4RTA:"V6-II)B"3O
MD.6.3G^N*FHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"+:3*K;FX)X['
MZU+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% "$X&:%8.N1TH(SCGI4=O;0VD(B@0)&"6VCIDDD_J2: ):**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ H!!Z$&BD  Z"@!:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HKC]+O]3O\ X@>);674YDL=+^S>3:K'$$/F1;FW,4+]>>&%
M8OA[XAZAJ_BI-/D@M$MI1&JSF5A Y^?=Y#E 9"V%P#C[K8S0!Z517FEK\1=0
MN/&(TOR;/[,72'[5YK?92?-89639DR$#:%^[N!YK=MK[4K?XHMH\FISW.GRZ
M2UZ(98XAY<GG!1M*H#@ XP2: .NHHHH **\IU?Q/XB@^-=AX0M]7:/3KV SE
MOL\1DC^21MH)7IE!U&<?G69IGQ)\1W.E^.[&XG@-_P"'5D:WOHH0!+L=EPZ'
M(YV]L<$_6@#VFBN#\ >/K/6?"^B?VUK%BNN7Z.WD%U1W_>,JX7W"_C73:EXH
MT'1I6BU'5[.UD0!G664 H#T+>@/8F@#6HK-O?$&D:=;6]Q>:E:PPW/,#M*,2
M#&[*^HQSD=J=+KVD0:2-5EU.T73V^[<F9?+;G'#9P>>.* -"BJ>FZKI^L6S7
M&G7D%U$KE&:)PVUAU4^A]C65XT\4Q>$?#=SJ;0M<3JC>1 O61@I;GT4 $D^@
M/?% '0T5RWPXUR^\2> -*U?4G1[NY60R,BA0<2,HP![ 5H7OB[PYIUU-:WNN
MZ=;W$"[I8I;E%=![J3GO0!LT5G6NOZ1>Z2VK6VIVDNGH"7N5F4QJ!URV<#'O
M3=+\1:-K4CQZ;J=K=2(H=DBD!8*>C8ZX/KTH TZ*R+?Q5H%W<-;V^LV,DR[B
M46=<X7.X]>0,')[8K#\*?$G1/%^NZGIVGW,.+5E6W+N ]SP2[(IY*C Y_&@#
MLZ*JZAJ5CI-FUWJ-Y!:6RD!I9Y B@GIDGBLZ/QCX9FNXK2+7],>>5/,C1;I"
M67&<CGT!/TH VZ*S-)\1:-KT<TFDZI:7J0D"4P2A]F>F<=.A_*H;;Q;X>O+^
M.QMM:L9;J7/E1I.I,F.NW^]^% &S16//XL\.VMQ=6\^N:=%/:*6N(WN4#1 $
M#+#.1R0/Q%<1J_CG4$^*_A?2M*U&"XT/5K?SFV(K!OOC*OUQ\H_6@#T^BLZU
MU_1[Z:ZAM=4LYI;0$W"1SJQBQUW 'C\:JP>,/#=S#<S0:W821VT1GF9)E.R,
M?Q_[ON.* -NBO/\ 2?B9I?BGP[KUUINJ6&G3VQECM7O90N%"J$FD4\A2[8_+
MOQ6GH'BBUL_"^DR>)/$VC37]RK#[3#<(L5PP8CY.@.. <#J#0!UM%9>F>)-$
MUJYGM],U:SO)K?\ UJ03*Y3G'.#ZU0G\?^$;9RLWB/34(8H2;A<;AU&>F1F@
M#HZ*@>\MHK(WKW$2VH3S#,6 0)C.[/3&.]9<7C'PS,UJL.OZ;(;N7R;<)<HW
MFOP-JX/)Y'YB@#;HK)/B?01JO]EG5[+[=YGE>1YR[M_79C^][=:=J/B31-(N
M1;:AJMI;3E/,\N64*P3.-Q'8>YXH U**QY_%?AZVLDO9]<TZ*TDD:))WN4",
MZ\,H;."1BIH_$.BRZI_9D>K63W^W=]F6=3)C&<[<YQCF@#2HKB?#?B20W/B.
M]U?Q3H5YI4%RIM3:S+_HL1+8$IXP3P.2>0>:WK?Q7X?O+NTM;;6[">XO%+V\
M<5PK&51G)7!Y^ZWY'TH V**R;7Q1H-[J/]GVNKV4UWE@(8YE+$K]X#U([@=*
MK2>.?"D44LK^)-*"0N(Y#]K0[6.< \]>#^1H WZ*QT\5^'I=3@TV/6[![V=5
M>*!;A2SAAD$#/.1R/:GZGXET/1IU@U+5K.TE9=X2:4*=N<;B.PSQD\4 :M%9
M-UXHT"QNUM+O6]/M[AD\Q8I;E%8IC.[!/3 )S52;QSX9B\/W6N+K-I-I]J=L
MLL,@?#=EP/XCQ@4 =#17)>&?B#HNO^$CK\U[:6<,9/VA'G7-L"Y5!)S\I( ^
MN>*ZBVN8+RUBN;:9)H)D#QR1L&5U(R"".HH EHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBHIQ(T$BQ.%D92$8] <4 <CX:_Y*5XX_P!ZQ_\ 1!KK
M([.WBN9;A(56:4*'8=PN=OY9-<)I_AKQUIWBK4]2BU7P^\&I>3Y\LEG,77RX
M]HVQB3'UR_/7CI71?8_%_P#T'-%_\$\O_P DT ;(L[=;MKL0J)VC6-G[E5)(
M'X%B?QKDV_Y+7'_V+K?^E*UI_8_%_P#T'-%_\$\O_P DUS]MX;\<OXT?7KO5
M/#T16R:RB,5G-)N0R!P60R+@\=0Q],'K0!T/BRS\2WNFPQ^%]4MM.O!,&DEN
M(A(K1X.0 0><X/X4_P *6GB*RTEXO$^I6VH7QF++-;Q"-1'@8& !SG=^=1_8
M_%__ $'-%_\ !/+_ /)-'V/Q?_T'-%_\$\O_ ,DT >4>*9;"Y_:6T5+B["0"
MT\J1XK@QE6V2@+O4@J<D#J.OO7<>,- T/PM\+/$T6EV5O91S6<A=@?FD<@@;
MF)RQR<#)[UJ-X>UYY#(][X;9R=Q8Z$Y)/KG[15B;3/%-Q$8I]7T&6,]5?1I&
M!_ W- 'SSNTVW\,_"F>(VT<PU"9[EU*AABX3ESUZ#OV%:?Q U:Q?Q+X\LM-\
MRUDEMX_M?G%I&NG1TXC7HB@9)8YX'& :]J_X1S7" #>>&L#H/[!?C_R8J4Z-
MXD:220ZGX>+RKLD8Z))EU]"?M'(]J /(985U?PGX"DT+Q!%8>(]/T^26U,DB
MB*7;M#Q[B<!_8C!&0:SO$VL:E<?#[X?Z[-9FTL+?4)9;E;:/,8=904<*<CD"
M0@=.2!Q7MCZ!K\D"0O?^&VB085#H3E5'H!]HJ9]+\42VYMY-6T%X2NTQMHLA
M4CTQ]IQB@#&^'5IH8OM?U71-7N]5749HYKB>1 L7F_,2$PHYPPW>F5]ZYWXG
MP>-$B\27<%CI<^AFP:%)II6\Z&$H#)M4'&2P//?:OI7=P:9XIMH5AM]7T&*)
M?NI'HLBJ/H!<TZ73O%<\312ZSH4D;C#(^C2$,/0C[30!S?P.>_;X6Z<+R.%(
ME>46IC)):+>>6]#NWCZ 5S.J/91_M.VLE^T"Q+IX(:? 4-L;')XS7I$&F>*;
M6%8;?5]!BB7[J1Z+(JCZ 7-><:C\,/B%=^,Y_$J>)-&^VLK0QNUM\HB.0%V%
M&'0XY+'W/6@#@9[+5'^&_CB?3$D.C-KJ,OE?<:)6DW%<=5!,//3CVKN8I$O?
MC7H=YIC^=IMIX;'VQ[=\A(_+DPI([Y*8'TKJ_#GA[XE:?,T>I>)]#ELA$4CA
M&F[E4Y'14\K'&>Y'MW&];Z+XCM(WCMM2\/0HYRRQZ)(H8^X%QS0!Y)\/?MNA
M^,?#6FVE];:WX<OQ<3V#G'GV8,9+A@#E#R RG*D\CFK'PW-Y]N\?:1HM[;V.
MOR:D6M6FBWA%61MQ(P<#''/<BO4X=%\1VTK2P:EX>BD<89TT212WU(N*='I/
MB:&>6:+5= 267'F.NBR!GQTR?M/- '#>+;/Q=IWPN\5'Q=KEA?K);QK:BWB$
M>UM_S _*,Y^7'TKSIX='_P"+2ILL_+=\W@^7#9G3/F?^/=?>O?Y]+\47,?ES
MZOH,J9SMDT61A^1N:K_\([KO'^F>&OEZ?\2%^/\ R8H \L\&76EVOBCXL^>-
M]ALG=H;9@&>(-+NV8]CU'3(KCM,UBVDU?X=W!N8X-.M+YT2%V)^RH)E)\R5L
M!F.=W&  5X%?1$6A^(H'9X=1\.QNP(+)H;@D'MQ<4@T+Q L<4:ZAX<"0MNB4
M:&^$;U4?:.#]* /,6TO2M>_:;U:VU)(+FV%D/W,A#+(PAC7:1W(R3CL5SVJ+
MQW:)I/QB\(:;X>>RL9;:P\JU$O,<3$RA=PSGDGOUSWKU1=$\1+<?:%U'PZ)\
MD^8-#?=D]3G[1FEDT7Q'-.)Y=2\//*,8D;0Y"PQTY^T4 >-0>+KS6?A)XJ\,
M21^5XGLV9[H18WW:></.?(ZL!N#>WMTW?ARF@>(9_#NHQ:O>76L66DFQDL$A
M41PQJC*?,POW=QX))))'OCT>+1/$4$QFAU'P['*<Y=-#D#'/7D7%+;:-XDLR
M_P!EU/P]!YAW/Y6B2+N/J<7'- 'C7@"_LH_@'XOL7E1;Q%N6=",%5:-%7)[9
M(( [X..AK%UR>TE^#'P_@>:%MM],)4+#@>8V<CZ$?G7OHT+Q"(Y8QJ'AP)*V
M^1?[#?#MZD?:.3[TP^'==*A3>>&BHY _L%\#_P F* /,-+33&^.WC6SANH+.
MSFT5X5D@("I^[AW%0.,C#' ]#7.^'-/L]9T'PUI#^(-$L;33M3DN_M,VH(D\
MREAM A)W*QQ_$?2O9M4\->+)-.G&EZKX<M[YQA)DT4QL,GYOF,K@9&1]T]>W
M4>3O^SUXG>#RCJNAX_O")@WYA,T ?0.LND>A7[NRJ@MI"6)P -IKQCX%>%]%
MU3P5)J-Q9VUSJ=OJ+2022#+0,JKLQZ#))QT)^E>B:1H?C*TT"TT^]UW1)VBA
M$3^9I4DFX#@9/G*&XQ_"*MV^D>)K0,+;5/#\(;J(]$D7/Y7- '@_@:/3-4T>
M[\.>)=7U&RU:WUH7D=G#"IFGGVA1@E22V=V>0!P?4UO1:K!I?C/XJ1>(+I+:
M\N[21;(7#;?-CVN%5,]?E,> *]9_L;Q)]K-V-3\/?:L;?._L23?CTW?:,UPE
M_P"!_BOJ<<J7GBS0Y?,B>!F-D@?8P(8!O*R,@GH: .$NX))OV7K!XT++#JA=
MR/X5WNN?S8#\:Z'1]:TW4_V@]%NK*\BFMSI0B$BM\I<1-D ]SV^O%==X'\!^
M+_"WAV71)]:T26RWEHXI=/>X !Y8$[X^_."#72KH/B!6C9;_ ,.!HP A&A/E
M0.@'^D<4 >,^&[NV_L?XR?OXOWAE:/YQ\X+3@$>HR1^8KHOAYX5TZX^"Z:QI
M]G%-XC2UOC;7*\RQRD.BJ".^ N >F<CK7H0\/:ZJLJWOAH!AA@-!?D9SS_I'
MM4\&E>*+6/R[?5M A0G.V/19%&?7 N: /%_ABNAZSIWABSO=7OHM9T747>WT
MV"%026D#,S';DIC[Q)X (],Y&=-F3XNSRFU><SYMG8J6(-P^2A_[YZ>U>^1Z
M-XDAN9+F+4_#R3R??E71) S?4_:,FHO^$<UP9_TSPUSU_P")"_/_ ),4 >&Q
M-IMM<_"&2!K6-O,#7#(5!SYR\N?KNZ^]:NJSVUO\8O%^G>*M5GTNRU6T\F.Y
M\L,&BPNU06!P, \CN/6O7?\ A'==X_TSPU\O3_B0OQ_Y,5+/HWB2Z>-[C4_#
MTSQ',;2:)(Q0^HS<<4 >0ZQ::5;?$_X<Z<TC36-O8QH!?@!]NYRF]3T/W< @
M=N*K^#/L\_A;XMP0F)P5EDB1,'*@38*@=NG3VKV670_$4\WG3:CX=DEX^=]#
M<G\S<40Z)XBMBQ@U'P[$6&UC'H;KD>AQ<4 >?>%=4\+?\,\H-=@>]TZU79?0
MP*=P<SDH,@CYLE3UX!&>O/JGAF339O"^ERZ/$T.FO:QFUC8$%8]HV@Y)YQ[F
MLQ-$\1QVAM$U+PZML<YA70Y ASU^7[1BNALHYX;.*.YDADF5<,T,1C0_12S8
M'MDT 3T444 %%%% !16?K$5_<Z5=PZ9<K;WCH1#,XRL;>IJQ9I-'96Z7,JR3
MB-1(XZ,P')_.@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%4=9U-=&T>[U)[>6>*UB::1(BN[:H).-Q Z#UH
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M0<X)$(R/8U2M/">IZ5J4^JZ1X6\)V>IR@_Z0+N9@,]?E$0QGOC% '("\?4/
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M[(MKCC < ]CFM/7K.TM/B?X&AM[+996$%VN(K<^5!N11&,@87)!Q0!UB>+=
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MB+R".0QMDD,X&%48RV2> !DUY#!X0E\40>+Y[!9H=8@UZ74=/6XC98KF,$$
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MQ@A2RL1AAE@,@GK3O$FJ2Z)X8U35((//FM+62=(SG#%5) ..W%>?^!EOM/\
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MM)8[>6 () .0.>\5VDFH0>.];L(+AK'4-.M[2 +;N#=3KG+*N,D $+NQZ^E
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MH **** "BBB@ HHHH *9-$)H73)&\8)4X/YT^B@#G1X4D  'B/7@!_T\I_\
M$4O_  BLG_0R:]_X$I_\17,^#FA\?ZAKNM:NGVFVM-1DL+&SER8H4C"Y?9T+
MMNY)R1C Q2PZUX=\+WWBVYT;SYIK.VBN+S3#%+$L.P,25+KM7<K @#@[<]Z
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M'^ST8#MD@<8  +W_  BLG_0R:]_X$I_\11_PBLG_ $,FO?\ @2G_ ,170T4
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MW_@2G_Q%=#10!SW_  BLG_0R:]_X$I_\11_PBLG_ $,FO?\ @2G_ ,170T4
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M^!*?_$4?\(K)_P!#)KW_ ($I_P#$5T-% '/?\(K)_P!#)KW_ ($I_P#$4?\
M"*R?]#)KW_@2G_Q%=#10!SW_  BLG_0R:]_X$I_\11_PBLG_ $,FO?\ @2G_
M ,170T4 <]_PBLG_ $,FO?\ @2G_ ,11_P (K)_T,FO?^!*?_$5T-% '/?\
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M/G.VXG')(!. ,#[HY&<UH^%(O#WABQN%/B#3[F^O)C<WER9XU\R0^B@_*H'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%,FE6""29\[44L<#)P!F@!]%>'^$?CS=^(_'-KI$^CP0V%Y*8H71R94)^Z6
MSP?? '7VKW"@ J&ZN8[.SGNI<^7#&TC8&3@#)_E4U9VO_P#(N:H/^G27_P!
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M_8,LO_0IJ .OHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .4TSX:^$='\0-KECHT
M45^6+*^]BJ$]2JD[5//8<=JZNBB@ K/UR&XN=%O;>VCWR2V\B*N<9)4@#FM"
MB@#"\&P75GX1TFPO;.6UN+.R@@D61D.66, X*L>,BMVBB@ KE=(LK\^/M:U:
M>QEMK2XLK:&)I60EV1I"W"L?[PZUU5% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !114<HD)3RRH^;YMPSE>] $E% SCFB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P! 74O_  80_P"%'_"J3_T!=2_\&$/^%>X44<B#ZQ/N>'_\*I/_ $!=2_\
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M2_\ !A#_ (4?\*I/_0%U+_P80_X5[A11R(/K$^YX?_PJD_\ 0%U+_P &$/\
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M!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>modificationno16effectiv008.jpg
<TEXT>
begin 644 modificationno16effectiv008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37#G;M8##9/N*=10
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FH'&[>0
M>>,#H*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%,=6)7:<8.30 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI%W
M<[B#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M->,/MR2-K;N#3J*  <4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !02 ,FBH+FV6Y\O=G]VX<<D<CI0!/12#ISUI: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHIK,%QDXR<#ZT .HHZT4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 444ASCC&?>@!:*@FNX("HEGCCW#Y=[@9_.I(I$FC$D;AT;HRG(- #Z*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *1D5L;E!P<C(Z&EHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,K5
MO#FBZ\8SJFFVUX8LB/SHPVW/7&>E7;&QMM-M([2S@C@MXQA(XEPJCV%6** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "HIKB*W"&5PN]@BY[L>@J6F/&LF-PZ'(H ?12 8&*6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 0L <5EVWB71;S4?[/MM2MI;S++Y*."V5^]Q[8-:A4-UJLFG6<<IE2U@6
M0DDNL8!R>IS^)H M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113)) A3*D[FV\#I0
M ^B@'-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16)KGBG3?#TT,=_
M]JS*I9?)MI)>!Z[0<5GV?C[0]0O8+2 W_G3,$0/93(,GU)7 % '5T4#I10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 -90QY&:3RER,  ^N.13Z
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#&25&T X\H=2,[CTQR :_A'Q?!XWUGPW8:[:B/Q'IEW+'>(Z[3*$AD(8CV<
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M>&M(;0+B5;C3K83M;$6Y$L@*LP0G=A%W'.<,1R.:Y#_A*;3_ (5:/"6T^?\
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MX9@H'\.'Y)&!DXQZ'I6!X-\?Z;X1U>]L[=%DT*:Z$\<\]BLEU$HQ\JC=M!(
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MD7]_<>+;.\T6""]\/Q&4I'=%TE #'&[;D?=ZX[T ;W]F^*0/^/CPY_X+I?\
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MUV_D<C/?/\.>+_$FK^*?'<>HV]G+9Z7$83;)=.BQA!+C9\AW%B.6.TCC XP
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M:WJ5QE3V)/8F@#IO[)\2_P#/7PU_X+9/_CM']D^)O^>OAK_P6R?_ !VNJHH
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M,R>&C@8'_$MD_P#CM']D^)1_RT\-?^"V3_X[7544 <L-+\3KTF\-CZ:=+_\
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MU@9&AMH8RB>6A1 -J==HQT'M7!^ ?^1[^('_ &$(?_19KHOL/BW_ *#VD_\
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M16=P)7MG\N90I!C;^Z<C@].*CU3Q!I.BLBZC?10,ZLZH<EBJ_>; R=H[GH*
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MF1(H7E=E499@J G '4XP,BK.FZC9ZOIUOJ%A.L]I<('BD7.&4_7F@"U1110
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MS,^\Y?>2/FW$D_4GMQ4MWX MI[;2!!JVH07FFW#W"WNY9)97<$.6WJ020?3
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M6!# A@P)W9ZTA\!Z3)X<O]'G>XF_M"X-W<W;,!,TY8,) 0  057  P ,8ZT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!,I;801E=A]!D9H [?P;X^UG4_B=#H;ZG+>Z9<Z<)]T\"*R2[ 6*,J+N7=D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGG%M:0F63RUQN? [9('N3@9J]9ZC:W^FVVH02?Z-<QI)$S@ID/C;P>03D<4
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M5-9T6/65M-UW=VLMI-Y\,MJX5@VQDYR"",.>",5CW'P^T>YTM+,S7J2+J/\
M:GVN.8+,;G^_G&.AQ@#% '%>-?%.O:0=?N=/UJXG.F2VD<:V\49AA!*!_M!9
M!N=BQ^5"<<<+6QXL\2:C9>)M7L)-6.E00:.;K3-@3-U/SG[ZG<00HV#USWXT
M+[X5Z%J"ZG')=ZLD&I%'N($O#L:1<8DP0<M\HY.?7&<5AZKHE]!XOOII+3Q:
M(7@@@M[K1[U3YZHIR9=[ AMS-[?B3D L1:]XDN+CP_H5P]V-1N=(_M&\:'R8
M9=Y*KY8WKM 4DY &>![YBOM7\9Z1H>D2:XMY+'"TZ:I/HRQ23J!CRG92",8)
M+;1Z'V.PW@&'Q!HEB-?N=174;221K6]2Y"W<,;'A&D088XP#U]B>IU(_!-C;
M)9"PO]2LI+2.2,2Q3AGE#L&<R%PVXDJ#D_AB@"[X7U&/4O"FG7T>H?VBDEN"
M;L)M,Q'!8K@8.0<C YKSR3Q9KDWPR_X6%;ZG*KK<&7^S2B& P"<Q>5]W=G;S
MNSG/MQ7INC:19Z!I%MI>GQF.UMEVQJ6)/7)))ZDDD_C6'%X TB!I88Y;P:;+
M<_:GTSS0;8R;@V=N-P&X [=VW/:@#!%I<2_'HL-3O$4>'UG" 1X"FYP8^4^[
MQ_O?[53_ !4CN&C\+>1J%U:K)K]I"Z0E0&R^0Q!4Y*E00#QGJ#Q71_\ "*VW
M_"7_ /"3?;;W[=]G^R[=R>7Y.[=LQMZ;N<YS[U-XC\.67B>PAM+R2XB\BXCN
MH9;=]CQR(<JP.#[]J /.[V#4T\?>-'L=9GM);71K:4W"Q1M)(Z(Y7.5V@$@Y
MPHSVQ5RR\7:WKB>&=.B,PN;W11J5S):M%&\C95<+Y@*@9)8@#/3H,YZ=? EB
MM[J5V-1U,S:C:"SG9IE;,8&!R5)R!GDY/)[U6N_AEH=YHNEZ<\U_&^EKLLKR
M&?R[B%?[H=0,C''(H U/"!UW_A'HXO$;POJD3LDCQ,IW#/REMO ;:1D"O.SJ
MOB^X\/>,M7A\4RQMX?U*ZC@A-I$5ECA"MM<[>A' QCDDG/&/5-(TFTT/3(["
MS$GE1Y):1R[NQ.2S,>22><UYYX3\)-J<GBN/5AJ]K9WVLSW!M&!BBNX'(*DY
M7=S@@@$'& : $T_4_$_B7QI):6WB%].L_P"S+/4?*6UCDVESEHP2 =I&1DY/
M3Z&"3Q5KEW\-KGQ]:ZG+%)#</*FG%$,/DI,8_+;Y=V2HSNSG)["N]M?"]G9^
M*+C7XI[G[5/ MN\>5\KRU^ZH4+QCZYJBO@#2$>YC26\73KFX^U3::)1]G>3(
M;.,;@"0"5#!3Z4 <WJ6K7_BM?&UO%J-SI]II-F(HX843,CM"79G+*21_" ,<
M GJ>*_A35=1M)?AQID-[(MAJ&BR&:#8A!:.)2I!V[@?F]<<"NLU;P!I.K:O=
M:G]HU"RN+R#R+P65R8EN4Q@;QCD@<9XILGP]TDZ?HMI!=:E;-HVX6EQ#<D2J
MK#:REB#P1@8&.G&* .3T[QCK,UE;:?<:D_GWGB:XTL7ICC#QPQY( &W;O. H
M)'<^U-\?6>NV/A6X@OO$DMP!J]N;<1;$D^SR2*%67"\X(;'8XYST'3GX7^''
MT&[T=UO'MKB[-[N:Y8O%,2?F0_PGG\>^:F/PZT5O#4^B237\JSR)+)>2W)>Y
M9T(*-O.>F.!C'7CF@#:U*].@>&;V_EDENS8VLD[-)M#R;%+<[0!DX[ 5YA??
MVC?_ /"M-<O]6GN9+_4(9Y("B+$C/$6 0!01M&5Y)SWYKUF&QBCTT6,C27,7
MEF-S<,9&D!&#N)ZYKD;;X6Z):O8B.]U@V]A<_:;.V-ZWEP-SPHZ@<^N??DY
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MXL&RLK6U6"[\+.TD2*")W\X$,P_B;'.3DF@#T72M>T[6=(35;.X0V;[BLK$
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M- HR>IP*EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;>_NQ<ZJD<4L,VW9,;APA<[@2O7C!Z=N*ZF_^)4=G-K\:>'M3F_L-E-XRM$
MJ%=V\$OSQS@<^H%<]:^#?$MM\//"NB'3HFO=)U9+R;%RNQHTD9^#ZG?C\#[5
M>N_#&OW'_"P0NG*/[?B1+/-PG&(O+._GCU[T =#J?CW3[)4%M%]JE-DM\T9G
MCA*Q,,K]\C+-@X ].<<9BA^(-GJ*Z>-&LIKZ>^L6OXX3(D3>6&V[?F/+;LC
M].O2N>_X1?Q5H]]8:MI6FZ;?22Z;;V-_8WT@&QX@0LB.,C')X_3TM^)O"6I:
M[916FHZ)87\B6F8+NUF^S/:719R=AZ^6!L]_EY!SP =]#=-/IL=W' Y:2$2K
M"2 V2,A>> >U>2:#?65Y97WBWQ#8W:WEGK<OV:>&X'F.WF"..V #<KR!@_+U
M/K7J>C6U[IWARQMKV8WM];VJ)-*&YFD50"<GU(ZFO.;7P%KUQX%U#2IT@M=3
M75VU6R<R[XBV\.%8CGU'3N#0!UZ>,3#K$^D:AI-Q;:@MF;R")9$<7$8.&"-D
M#<.X./6F^$/&G_"7Q)<0:+J%I920":*ZN%41R'<5*C!SD$?C],$TY-&U?5]?
MCU^_TY+26RT^:VM[5+E9&DDDQN8M@ * ,#N<G.,<W_A[I-_H/@;3-)U.%(KJ
MT0QL$<.K?,2""/8T 4I?$NHW'Q*F\+-ID@L%TWSVE290S!W"[^H*@888!SSG
MTKEOAQXT_LKP3X7M+ZPOY(;^\DLEU!BI3SFFD*KRVXCC[V,=L\&NIOM(UJU^
M)P\0V-E#=V4NDBRD#7 C:-EE+Y (.<@X'3GJ17,67@SQ+:^"?".D-I\37.CZ
MTM_/MN5VM&LCOA3ZGS,8_P!DT =+K'Q,TG1I+F22-I;*TNA:W-PDT>Y'R Q$
M9.YE4D D#UQG%=)X@N(;7PYJ4]Q!//;I;2&6.W8*[)M.[:21@XSW%<+;^&?%
MNB:SJ5EIEGHUUI6H7<EW'?70_>V9D.6!7'SX/(_4^G<^(K:XO/#6IVEI%YMQ
M<6LD,:;@N692HR3T'.: .3TSQI8Z98>%](TW1-4G74].\^Q7S$8E50-M9F;J
M 1DG ]STJOKGC#1M=^'\]]J.E:F+5+];.ZMXI522&9)5'+!AD;L?=SUJ'2/#
M/B"SU/P--/IJB/0]/EM+HK<(<LR*@*C/(^7/;K6?/X-\2R^!-;T==.C^UWNN
M'4(LW*;!&95DP3Z_+CIWH ZNT\5ZI<?$;5-!.DR?8[*UCD5DDC+.6+8<Y(P#
MC 'XG';.\.>*-+L?#=D=&TK47;4=3GMXK:>4,XD#,79G+$*HVD]3^-7X-)UN
MS^)-[KL5A%+87]A#'(6N LD+Q[CMVX(8G('4#WKE;/PAXNM-"TNR;3X)[:#4
M[FXO=/-Z$2ZCD)9-S '(4DY4C!XX- &MJWQ+N'\*6^IZ1I4GF2:J--F$DB?N
M7$@5L<X;/(!Z=S[ZTNIZ:?B+81WMA>VNIII4LRRR3KY*Q;EW A6()![D=N]<
MG%X%\31>#K[3!86*S1:^NIVL45SA98_,#%1\H"@ <9_(=^@U+P[K&L^-[74+
MNP2&QDT>;3[IHKD,4:7DE<@$@=,X'TH O)\0+;RM,OIM-NH='U.X%O:W[,NT
MEL[&9<Y56QP3ZC.,U2O?B?%:1ZU*/#VJ21:+.(KUP8AY:X'S#Y_FZ]!DXZXJ
MA:>$?$%UX5T;PEJ=M;QVVFW,+R:A%/D311-N4*F,ACA0<\#DY/2H;[PGXAN=
M(\>6B:>@?79Q):$W"8 VA?GYX^[GOUH ]+-Y;BP^W-(%MA%YQD;@!,9R?PKF
M]/\ &R7M_IL4FD7MO9ZG ]Q:7C[2A15W9?!^3*\C/Z&M-=,?4/!YTB]5H&GL
M3:S $,5RFPX(X-<GX:T;QLFDP>&=<738=)M+<VIO+:0M+<Q!"BJ%(^3C&2?3
MISF@#3'Q!M1!IVH2Z=<QZ+J-P+>WU!F7;EB0C,N=RHQ'!/J,@9JK??$V*S.N
M%?#VJ2IHD@6]8&(!%(SN&7YXYP,G'7%9MIX/\07'A#2_!VI6]NEK87,3/J,4
M^1+#&^]0J8R'. #G@<G)Z4R]\*^(+BS\?0IIZ9UYE^R$W"< ($^?GCIGO0!U
M5]XHAN;D:7IMA<:C<2V(O)$BE$7EPMPN6)!#-S@#G@GBN1^&WBI=+^'_ (.M
MKR"ZGDU:XGMTGW!MK^=(?FR<]!UYJY8^'O$V@^)+?6]/T^VO%N]-@LKVUGNO
M*:&2(8#JP# KCMC-9NG>"?$VF^!O"L L[275-"U-KHVZW6%FC9I"1N*X5OG]
MQQU[4 ==_P )[IZ1:TT]K<Q2:5=)9M%\I:>5\;%3!P<E@.<=>:SM?\?W^F:'
MXBDC\/W,6HZ3$DA69U\IED!(<./O $'('.>/4C$N/ ?B?4[?Q/)*MC97EYJ$
M&I6#+.9%66(+A6&WIP1GUYQ6QJ&E^,_%7@S6K+68-.L;BXLV@M[6WE+AY.N]
MG/0<  #.,G/L =AHEW<7VBVES=V[P3R1*65RI)..ORDCGK5?Q%K\?A^TMI6M
M9[J:[NH[2WAA R\C],D\*."23Z5AVNM^(-.U'PWI-WI%DB743)<+'>>9+%L7
MA@,#*\#)Z#(&>F;7CO3=;U/3[!-& E2.]CDO;0SF#[3 ,Y3>.@SC([C\B 4)
MOB=96VBWNH3Z5? V.H_V;<Q1E'*29 !!#?,OS#ID^U7K7QU:F_UBTU2PNM+?
M2[47DIN&1@T)S\PV,>?EZ=:X:X\#>)TT77--MM'L8X[S68M1@$-T B(I0[ -
MHX&TC/'TQ6WK?@W5?$7B3Q$\L'V6QU72$LHYC*I:.526!*@_=R<<>E %:_U>
M[U/XG> KIM.O+"WN4NW3S9P1(OD$@,BDA6&<_CUXX[[7-<@T.VMWDC>>>ZG6
MVMH(R TLK9P 20 , DD] #7#6NB^,[S7O!UWJ.DZ? NA>='/(E\6$P:(1[U7
M9D=,X/T..M=#X\\/ZIK5CIUWH<D"ZKI5ZEY;K<$B.7 (*-CID'K_ "ZT "^.
MK>*RO7OM,O;6[MKY+!;5P"UQ,^-@C;.&#9Z\8&2:)/',=I<:K9W^E74&H:?9
M?;_LRNCF>#NT;;@#@@@@X_&L?6/#_B_Q/HMM>WZZ?::K87]O?V5A'(6B#1%L
MAY,=6#'H,#:OJ:DU/P]K.MWVJZY-IZVUU)HDFE6MG]H5BS2,2SLPX '&!R<9
M]A0!/;?$N"XET9?[!U14UF RV#8C)F<*&*8W97@_>;"\9SCFB7XF6=OX6O\
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M"$X'[LXX)'YCD[UB_B>:VM+^ZU&TNM+OM,:6>/RA&T4S)N418ZK@D?,2>,T
M=5I6J66MZ9;ZEITXGM+A=\4@4KN'3H0#3-6T73M=L_LFJ6B75MN#>5)G:2.A
M([UY/X)UC7=%\-_#X"[MGTW4Y#9O:"#E1\Y#^9G.[(Z8QV]SZ%XXU?4M%T2&
M[T^"XD3[5&MW);0B66& YW.J'@D8'8X!)[4 =%&B0Q)&O"( JY.>.@Y-/KQ_
M6=<O=:TCPI=:;XH^UVUSXBBMFDBMU0N,ET$BX&&7:/EX!Z^E6/&GC37_  ^^
MMRVVHQ2-IIM1%;PVPE1E8J':X;'[LDL0J@@].#UH ]8HKS_Q-XHU.T\2:OIT
M=['ID-CHYO[:1T1OM4F3D'=_", $#!YZ]*KV_B[Q!>IX?TUX95U*_P!,.IW3
M65O&'C7*A4"S/MZMR<D\=!G( /2**PO"-SKUUX?B;Q):);:FCLCA2N'4'Y7P
MI(!(QD9ZUNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]JOA6._P!?
MM]>L[^XT_5(8#;&:%5998B<['5@0<'D=,&NAK+UCQ!8Z*]M#<&26[NV*6UK
MF^68CD[1Z <DG '<T 8>I?#VQU#PN=!2_N[>&2Y^UW$Z;#+/,7WEV)7&2W/
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M+%@000 "N,8 '2KOAKPBGAS4-4OO[5O;Z?4I%DG-P(P"RKC("J,']/:NCHH
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M=6$,SQ(9I(I<0%R,G8S'D>E>?7=[X+UC0/&6I:"J7 N])8WDX0K '2-A$N&
M ?G/ R,#."1G!CU:VL8_!$^KZE)9:$_AV."*Z6!)HDNL+O5MRL%)48SC/!'3
M- 'M;7ELJQ,UQ"%E_P!62XP_&>/7CFL_5/$VCZ1H5QK5U?P?88029$D#!B/X
M5P>6/0"O)KG2O#EO%\/;2UE>\TXZI,L,U^JJTL)#' &!^[+'@8P1CL:IZM!9
M?\(?\5+.TB@\JWOTEBBB4;8^$RR@=.AY'O0![%=ZA>RW&D/I<NG-9W$I%R9Y
M#O*;2?W6."V1WK O_%FKWWB/5=%\,_V5)<:9%"[K>.W^D/)N)12I&W"KU(/)
MZ#K6)K]UHDGB3X=7>GRV)B:\E1)8"N"/+(P".V_/XU-X7ATF3XN>/8S#9,JQ
MV9 *H0!Y+"3^?S?7F@#M=%O[XZ MYK\FFPW 9_-:TF+0* Q ^9N^, ^^:T[>
MY@NX5FMIHYHF^Z\;!E/T(KP;0=6M]*\!>!+Z](?0+35;L:@%7>L;%Y?)9U'8
M%@WY>U>J^"'\/26NI3>&4<Z?<7C7#38;RY)6 W^7G^$8'3C.0.AH Z"34+*)
MB)+RW0AQ&0TJC#GHO7K[5(EU;R7$END\33Q@%XU<%ESTR.HKPC5;30WTSXK3
M>59--#./(.%/EDH.4]"6!Y')(]JW[5+&S^(?A@Z2;6.YNO#TQW(1F:0A2I<]
M6)()R<YYH ]52_LY+MK1+N!KE!EH1("X'NO6HVU&VD#Q6UY:O<[7V(91U7KD
M#G .,^E>->#Y= U;_A'(-0UC4?\ A)-.N29=.^RHD@E.1,9&\O<4(+,Q+<CK
MSQ5_P+HGARX\/>*M1DLK&2XMM2U"-96"GRXST4=@N.@Z<T =Y;^*H=/L]%M_
M$%[IR:OJ)*A+.7,1(#$LI8YV@#J>YQ7222)%$TLCJD:C<S,< #U)KPG3I=*C
MT#X4WU^UHMI&T\4\\VW8O[ML*Q/'7L>]>B?%&\LK3X?W;7ENT]M+)#&5$AC4
M9D7!=@#A,@9XY''>@#JH-3L+FW>X@OK:6"/[\D<JLJ_4@X%/BOK2>9H8;J"2
M55#,B2 L >A(';D5X/<7>FRK\48I[_3+PSZ=;30/;HJ12,L3C,:Y/W6P,Y/.
M.<UM6<5CI_B[P(^CQVD=U<:%<9,94&9_*4KO/\66SU[YH [?QCXP;P_<:1!8
MR6$TUUJ<%G<0R29D1)&P6"@YS]?;K6]K>MZ?X>TBXU34[A(+6!2S,QY)[*/4
MGH!WKPL:OH3> O"$5Q<VL>NVGB"!]028A;B-_-8R.X/S8Z9)XZ>E>G_%J%+C
MX6:Z?+60I;AT.,XPPY'X9YH ZD:K8"PCOI+RWBMI -LDDJA<GMG.,U++>VL%
MJ+J:YACMR ?->0!,'IR>*\DUG6M(M?$FA75QJB6?AF72GBMKNW@CFMQ<[_WB
MG*,H)4 9QG@CUJNMUHWA-O!,SW-Y<>#XVO%CNKV+(65O]6Y 487!<(<="3TY
MH ] U_Q3<:;KGAFWLA:3V.K7+0R3%BQ "%@5(..W7FNA74+)[0W:WENULO68
M2J4'_ LXKQ[48_"TEQX*L])3&BR:Y,T8F8A)@R$DJ&Y,>]BOH<$<@\Y&O)ID
M?@CXGVD*VBQ0ZLCV\*[<1L?+&4'8_>''O0![W%>6T\TL4-Q#))$<2(C@E/J!
MTK-T:_O3HAN]=GTR.59'#R6DI,(4,0/F;OC&?>N&L[?1K'XSPV]I'916EQX8
M;S43;LE_? Y;^\2N>3U%<CH6K6VE>"_!5]>%7\/VFL7@OPB[UC8M)Y+,H[ M
MN_+VH ]U_M*Q%E]M-[;_ &3_ )[^:NSKC[V<=:P/&GBB70O U]X@T<V=X;=0
MREW+1L-P4\J>>3ZBN"U;4O"5O:::=%C1;"\U\W27]V[+9)<>62SD'&Y1V4%1
MNSR,&L/[=:?\*=^(EJ+Z"64:S,R[<)O5GCVL%[!L$@>Q]* /?#<1QV@N)W2*
M,*&9F; 7\37&^&O%>K^(HK+6XSI*Z!.TWGHS,L]LBEA&Q8MM;<5R1M7&>]=-
M.]I/X=:29H9+1K;<6<@H5VYSSQBO$]-NK>Q^%7@?4/,\G28KT_VK/;0I(T9!
MD$;2*000K$'D'L1SB@#W9;^S:S-XMW ;4 DS"0; !_M9Q21:A93VC74-Y;R6
MR9W3)*I08ZY(.*\:U"Z\,6?ANZN=/OKC5;+4==M2]S<D0V<<Y.XLVU%!0!07
M&.<@9!SBOITVEWEKXYTZX\16ELUQJ=K-%>PQJ(LDQE7V9(\LOM!R2,'J>M '
MK^HZH\N@7EUH-WIL]S&I\MYYLP!N/OLIXXK'_P"$JO+;Q]#H5^+"*R;1S?O<
M!R,.)%0C)( 7D_I7GNL7[WOPU\>6NJVFE?:K26,F\L.8+F0HFUEST<*%!P>]
M;%['H=[\4M"?618S6$GAHF+[65,3N) ?XN"<9./QH ]#UJ]ODTJ*XT673FD>
M6,![R0B)HRPS@KU..E9\/B*];XE7/AJ6&W%HFEK?1RKNWDF39@]L<'MZ<UY9
M?64.F_#<-*(X[ >*_,TDR'[EIYXVE,\A2 Q]P<]Z[7[192_'6\BEE@=&\-*K
MHS @CSR2"/\ =.<>AH W(_%0TC1K6?Q/=Z9'=W5Y]EB6QE+(Y,FQ<;CG(!!;
MTP:Z"._LY9/+CNX'?&=JR G'KC->#69T_P#X5-X2GE^S>1:^*%$SMMVQ1FXD
M)W'LN,'TQBNU\51OH'B31O&?ARTBNDOX1I<T<(&V028^SN,<8#A03_=(H ](
MAGAN(Q)!*DJ'C<C!A^8J(:C9&]-D+RW-T.L E7?TS]W.>E5K33FTGP\EA8;3
M+!;E8V88WR8^\?<MR?J:\>ADMM0^%.BPVCQ_\)?!J<7R9 NENA/^\+#[WW2Q
M)/&.30!Z#JOBJ^G\53^'- GTQ;VWLA<N][N=7<L56(!6!4\$D\XR.*ZF*Y,=
MI;-?M#;W$BJKIYGR^81RJDXSSG'K7 :8NF'X[:T@6U,W]F0.H 7<) YW$?[7
M(SWH^+\-@T'A.74$A\@>(+9)9), "(A]X+=E.!GZ4 =\FI6,MM)<QWML\$9(
M>595*J1UR<X%+_:%EY,TWVRW\J$XE?S5VH?1CGCJ.M>(>+-.TJ#_ (3V31H;
M--%_LF#<+<+Y(O-QQM XWA/3^][UN:A8Z3H%SX$NX+>V@\/7-QYFHRC!CDG,
M 6!Y#T/S9.3WY/- 'JT%W;75O]HM[B*:'G]Y&X9>.O(XIMK?V=[&TEI=P7"(
M<,T4@<*?<BO&/$2W$">/+S1$,V@F>PDG2U^9)""#<A,<'Y=N_'OGO5SQ#J7A
M_5= \0:KX)2>YN+BWMO[1ELXF"B%)%!3:PQO,9?(Q]U3GKR >MVM]9WRLUI=
M07"H<,8I X!]#BBVO[.]:1;6[@G,9PXBD#;3[XZ5XU=/IFIZ5XCU?P;K6H:I
MJDNCB*98+=(D2,.IP0D:_O=I<#J< ^U2VUQHVJQ:AJ_@_6+^^UQ-#F@C@AMD
MA6%=N5#A(U&\-PHR>>G H [G6_&#6'B_P_H]E)87$>H7$D%R/,W2Q;4+# !X
MZ=ZV+._O4O=6;4Y]-CL8)5%LT4IWJFWGS<\ YZ8[5Y):ZQX8GNOA>VG7-BL]
MNYBN%4JLD3&'!#CJ"7]>IYYJCXF&F?\ "-?%.%!:?N]1MWA0;?E;Y!E1V/WA
MQ[T >]17=M/-+##<0R2Q'$B(X)0^X'2F1:A937+V\5Y;R3IP\2RJ67ZC.17F
MD4.E:?\ %]8=.>"SAF\+.6>VP"6\T$/Q]YL<YY)KG?!_]BZR?!%K<:AH@;1W
MF9O,NHVENF?(0",_,&)(8AL$$=S0!['K_B#3O#6DRZEJ=PL,"< $C=(W95'<
MFK,VIV%M D\]];10N<)(\JJK'V).#7%_&:&.3X8ZE(\:L8I+=@Q7.T>?'D^W
M&:S[;4M'/Q/N?M\VGG1[C24&DR,4^SLH<^<$/W<DXSCJ .U 'IJLKHKHP96&
M00<@BN+\0>/K:W\.>(;W09[2\N]&XD61\H6 !8#:<G&X#Z\4?"R"XM_!*1R;
M_LHNKC["'_Y]O,/EXSSC'(]B.U>>:A+I5EX>^*=DS6<%^;N4Q0_*LGE%8\8'
M7;G\,T >U:;J4-_;Q8FA-R84DEB1P2FX \CJ.O>IH[^SFNGM8KN![B/[\2R
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M7P]:^%[S4Y)+.PEO9KK6+B"!91%<2(2C,"K JK$J"0< +CD"L;Q&FA6WP?\
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M!"T/V6'RF.63RQM)]Q6(OA[4I?%#ZC?:Z]SI<;B6TTS[,B+#(%V[BX^9\9)
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M_-C::G:S704MY22 L0#@D>H!X)%2ZAK6EZ2]NFHZA:VKW#[(5FE"&1O0 ]:
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M%<6!(7;;L^ "6  P>?E[ <[G@NYT?6]?TJYBT_7QJ^FV[PS?;@ZQV8*89,D
M-DX  ^O&*]3HH X#X@:@+'Q)X6\R)[>,RW'_ !-8[=YWM3Y>-J* 1N?. 65@
M,'CT\\L9(!X1\,Z?=0S^9:>+_-N$N(&!$8DD+,V1C R,^F1GK7T%10!X;XCM
M[V_U#XF0Z5"\[22Z=,(8EYN(XE'G!/[V,8('T[UT5AKMAKWQ@TG4M.BNVMFT
M66!I&LY$"/Y@;:Q*X&,'VSQFO4** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6 ^YD9Z9/'X[%GXP\27_ (JU72K?0;.2WTJYBCN95NSN*.F[* J,M[<>G/4
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MDEC<J&DD='_<\L0H8#..^:UK[X=+<>'8=*MM4,,G]H_VI<W3VX=I[C?OS@,
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M3V].0#G_ !/XL\2R> ?&L,EY:07VC72VSW-K;LOG1.%' 9SL;Y^N3[<\UO\
MB;QAJ?AO4;/3K[4;"Q2>S9X]2FL)#;RW&X@1'$G[O"X)))SGMTJQ=_#@W]AX
MJM+K5@4\02+*YCMMI@=<;<9<Y'RC(X^HJY?^$=7U&SFM;GQ&)X;JS%K<QSV*
MLC<N=Z*& 1L.!W^Z,Y- %_Q%XF3PUX(N?$-S&LQ@MUDV1M\KNV H!YX+,.>>
M*RY->U[1O$^AZ9JLMC<P:RDD:26]NT9MYT7?@@N=R$9'8\5L77A33KWP7_PB
MLXD;3Q:): D_.%50%;/]X8!^HJE8>$KI;[3+O5]7&I2Z5&Z61^S"+#,NTO)\
MQWMMXXVCD\9Y !S_ ,.+>]O;[Q<=3FLKN%=?F5T-H03(@CVL"7( &!A<$@C.
MZIM?MKR3XQ^'0FKWT,,EC<N(D\LHA7;G 9#][/).3Z$5O>%?"]QX;N-7DDU)
M+M=3O'OG46_E[)'QG!W'Y< <=?>CQ!X4FUG7](UBTUB?3;C3UEC)BA23S(Y-
MNX?-D _+UP: . ADUVU_X63J&CZI%8?8;^6YYMA*TK)"&VG=PJX'7!//;'.S
M%XPUG7M3T[3K)+Z(OHD&HW#:<MN9/,EZ#_2#M"#V!))'(QSHP^ ]3CL/%%LV
MO6S'Q SM*_\ 9Y'DEUV-M'F\C;TSWYYZ56F^&5UY.BW-CXEGT_6M+LUL%O[>
MV&V:!?NJ\;,02/7.,]NF #H_!DOB*7P[&/%-NL.II(R,5*?O$!^5R$)4$CJ!
MZ5SRZEXA\63>*1H6KG3I=*NS8V<7E1LDDB*"S2ED8X).!MQ@#O78:)I3:1IX
M@EO9[VX=C)/=3D;Y7.,G X P  !P !7+WOP\N!XGO-8T/Q+?:,NHLK7]O!$C
MK*0,;E+?<8^N#R: (QJVKZUXY7PP^H-8"RTN.[O9+)5W2SN0-JEU;"#KP,G-
M<O=>-/%=CH>J6R:E#)?Z1KL>GFYEMU)N8I& 3=C 4@$Y('/&,=:[BZ\#I#K%
MEJ^A:@^FW]K9BQ)>+SXYH <A74D$D'G=NSZYK-U'X:&YT)]/M=9,5Q<Z@-2O
M;R:V$KSS @C #*%48QCGC\20!MI=^)(_']WX5U'7OM,-UHS7T5Q!:I#);OYH
MCPGW@1SGYLGI^/):7JOB#1/@;I.LZ=K4INI;E0R7$4;CY[AE(#;<\Y)).X^F
M*]$7PMJ)\>P^*)=7MR4L?L+6R614,A8.2&,AP=XR.#@<<]:P?^%67B^$?^$:
M7Q3.;!+@2P![-"80LAD !!!)W'DG/08 H EU"7Q3HMUIEGJ7BB.6&[NYV:2T
MLD%TR!!Y<44>UP0&W%F(.!C)%9-AX\UH^%XXI[@_VE<^)3H<-U-"@>)-_P!]
MU7Y"X7(XXSCK76ZWX/O-6U?2-9M]=>QU/3XI(3-%;*Z2!P-WR.2%Z>]9+?"F
MVFT75-+N=:O98KN_.HV\@1%DM9R<[PP'S'MVZG % !XDT_Q39^'_ !;Y_B":
M73ETUI[&91&ETDB(Q=6*QA=I(Z@9P>".M=#X&@D@\#Z()+N:Y+6,#@RA 4!C
M7Y1M4<#WR?4FJ5AX+NO[,O[?7/$-YJ]U=VDED+B2-8A#$XPP5%XR>"2<D[13
M]+\)ZKINC:1I_P#PE-Y)_9\\;,XMXT$T*+M$) '"X R<D]?; !U=%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 44'@5QVH_$[PQI6HW%A=W4R7%NVR11 Y /UQ1<<8N3LD=C17"_\+>\'_\
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M@_\ Y_9__ =_\*/^%O>#_P#G]G_\!W_PHN@]E4_E9W5%<+_PM[P?_P _L_\
MX#O_ (4?\+>\'_\ /[/_ . [_P"%%T'LJG\K.ZHKA?\ A;W@_P#Y_9__  '?
M_"C_ (6]X/\ ^?V?_P !W_PHN@]E4_E9W5%<+_PM[P?_ ,_L_P#X#O\ X4?\
M+>\'_P#/[/\ ^ [_ .%%T'LJG\K.ZHKA?^%O>#_^?V?_ ,!W_P */^%O>#_^
M?V?_ ,!W_P *+H/95/Y6=U17"_\ "WO!_P#S^S_^ [_X4?\ "WO!_P#S^S_^
M [_X470>RJ?RL[JBN%_X6]X/_P"?V?\ \!W_ ,*/^%O>#_\ G]G_ / =_P#"
MBZ#V53^5G=45PO\ PM[P?_S^S_\ @._^%'_"WO!__/[/_P" [_X470>RJ?RL
M[JBN%_X6]X/_ .?V?_P'?_"C_A;W@_\ Y_9__ =_\*+H/95/Y6=U17"_\+>\
M'_\ /[/_ . [_P"%'_"WO!__ #^S_P#@._\ A1=![*I_*SNJ*X7_ (6]X/\
M^?V?_P !W_PH_P"%O>#_ /G]G_\  =_\*+H/95/Y6=U17"_\+>\'_P#/[/\
M^ [_ .%'_"WO!_\ S^S_ /@._P#A1=![*I_*SNJ*X7_A;W@__G]G_P# =_\
M"C_A;W@__G]G_P# =_\ "BZ#V53^5G=45PO_  M[P?\ \_L__@._^%'_  M[
MP?\ \_L__@._^%%T'LJG\K.ZHKA?^%O>#_\ G]G_ / =_P#"C_A;W@__ )_9
M_P#P'?\ PHN@]E4_E9W5%<+_ ,+>\'_\_L__ (#O_A1_PM[P?_S^S_\ @._^
M%%T'LJG\K.ZHKA?^%O>#_P#G]G_\!W_PH_X6]X/_ .?V?_P'?_"BZ#V53^5G
M=45PO_"WO!__ #^S_P#@._\ A1_PM[P?_P _L_\ X#O_ (470>RJ?RL[JBN%
M_P"%O>#_ /G]G_\  =_\*/\ A;W@_P#Y_9__  '?_"BZ#V53^5G=45PO_"WO
M!_\ S^S_ /@._P#A1_PM[P?_ ,_L_P#X#O\ X470>RJ?RL[JBN%_X6]X/_Y_
M9_\ P'?_  H_X6]X/_Y_9_\ P'?_  HN@]E4_E9W5%<+_P +>\'_ //[/_X#
MO_A1_P +>\'_ //[/_X#O_A1=![*I_*SNJ*X7_A;W@__ )_9_P#P'?\ PH_X
M6]X/_P"?V?\ \!W_ ,*+H/95/Y6=U17"_P#"WO!__/[/_P" [_X4?\+>\'_\
M_L__ (#O_A1=![*I_*SNJ*X7_A;W@_\ Y_9__ =_\*/^%O>#_P#G]G_\!W_P
MHN@]E4_E9W5%<+_PM[P?_P _L_\ X#O_ (4?\+>\'_\ /[/_ . [_P"%%T'L
MJG\K.ZHKA?\ A;W@_P#Y_9__  '?_"C_ (6]X/\ ^?V?_P !W_PHN@]E4_E9
MW5%<+_PM[P?_ ,_L_P#X#O\ X4?\+>\'_P#/[/\ ^ [_ .%%T'LJG\K.ZHKA
M?^%O>#_^?V?_ ,!W_P */^%O>#_^?V?_ ,!W_P *+H/95/Y6=U17"_\ "WO!
M_P#S^S_^ [_X4?\ "WO!_P#S^S_^ [_X470>RJ?RL[JBN%_X6]X/_P"?V?\
M\!W_ ,*/^%O>#_\ G]G_ / =_P#"BZ#V53^5G=45PO\ PM[P?_S^S_\ @._^
M%'_"WO!__/[/_P" [_X470>RJ?RL[JBN%_X6]X/_ .?V?_P'?_"C_A;W@_\
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M:"2>:18XHU+N[G 50,DD]A1R(/K$^YXE_P *I/\ T!=2_P#!A#_A1_PJD_\
M0%U+_P &$/\ A7I&G^/]%U"^L+8"\MQJ6XV$US;M''=8Y^1CZCD9QD=*DO\
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M\*/^%4G_ * NI?\ @PA_PKW"BCD0?6)]SP__ (52?^@+J7_@PA_PH_X52?\
MH"ZE_P"#"'_"O<**.1!]8GW/#_\ A5)_Z NI?^#"'_"C_A5)_P"@+J7_ (,(
M?\*]PHHY$'UB?<\/_P"%4G_H"ZE_X,(?\*/^%4G_ * NI?\ @PA_PKW"BCD0
M?6)]SP__ (52?^@+J7_@PA_PH_X52?\ H"ZE_P"#"'_"O<**.1!]8GW/#_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^P I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>modificationno16effectiv009.jpg
<TEXT>
begin 644 modificationno16effectiv009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDLMQ'#+I]VTGESL&.;>,D!L[E!]B..F* /7ZKW]_:Z983WU[,L-M A>21N@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'8+6\M8M$L5@O<?:8Q N)0.@/L.WIVJ=O$6CJ=14ZA &TT WHW<VX.2"X[#
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MA43 [SDKP>G4$#U[4 6(_".@1-8,FF1*=/S]CP6_<9/.WGBJR?#_ ,)(^]=
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M =116;I.OZ3KIN/[+U""[^SL%E\E]VPD9 -:5 !1110 4444 %%%% !1110
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MF,)O#/N"X;/WN"2>:]VI P)(!!(Z\]* .;\>6]E=^%I+>_-\D$DT(\ZQ4M+
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M/%[5/"FK7>D^%KJV:TCUK061Q&\C&&8;-DB;MN1D#@[>/2@"9_'PM(M>AO\
M2;A-3T>-)7L[=O.\]'^XT;8!()X.0,5&GQ%M[6;7H-9LA:2Z-;1W$P@N!.KA
M^ H.%P^<#!'4]:S]<\&^(-9M/$6IP7$&G:UJ5O!:P1Q7#%8XHVW,&D"@Y?+#
M@<#'O69-\-M6U6?6XKBVTK3++5-,AMUCLY&86TL3%EP-B[ANVDGCN.>M &[X
MAUB^O]"\1:1JN@R6F-%ENXYTE\V(_*PV%MJXD! .!GUS5/P/XNDMM.\%:#=:
M1/#%J.EJMK=M(I#M%"K-E!R!CH3U]*LII7C[4M U&SUR?1S*UA+9P1VKNJSN
MZA?-D8J<8&2 HY+'IQ4-GX1\0077@&1XM/V^';>2"ZQ<M\^Z(193Y/0;N<=<
M>] &S\2KS3K'P'J$VK:7)J6G_NUGMTE\LD%UP=V01\VWIS45_P",[JS\377A
MVQ\/SW=S;6"WJ,;E(T=-VWJ<XZ$>I/;'-6/B)H.H^)_!-]HNEBW^T71C&ZXD
M**H5U<GA3G[N,>]4!H7B ^/KGQ UK8B";1A8",73;O,#%\_<QMR<?K[4 =#X
M8U^'Q1X9L-;MXGBCNX]XC<Y*G)!&>_(-<C-\4+M+/6+Z+PI>2V>C7DEM?2"Y
MC!0)MW,H_B(R20.@ YYXWOA[H5_X9\$:?HNI"#[3:!D+02%U8%BP/('KT]JX
M;P_8ZUK-G\0M&L(;+[+?ZY>V\ES-.P>#<JJQ\L*=WRGCYASG.* .G;XB3W'B
M%M)TGP[=ZA_H\%V)DF1 8)3C?@^F0<=3SP,4^[^(7V?2KG7HM)>?0+6Y-O+=
MK./,PK[&D6/;\R!L_P 0/!.*- \*:AHOCF?4%6W.E?V7!I\1\XF7]UT8C;CD
M>]94/@77+7PMJ7@R)K)M%NYY##>F9A+!"[[F0Q[<,PRP!W <Y/I0!T=EXR6Y
M\5ZEH4UHENUI:+>QW#SY2>%NCKQP!W/8^M95]K5CJ6J^")M3T"87-]*\UG(;
MC MF\LMR!@L2N.",#/M4OBSP&VN:KH-W87 M5M-UI>C/,UDR_-'[YQC_ ($3
MVJUXHT'5=3\4>&-0L(K0VVE7#RS>;,48AEV84!3T!SU% ''?%#Q _B#X=:U+
M8Z:DNF6MXEO]N:XVMO2559D3;RN<KG<.I.,5U5SJ-A%\3I8_[$FDUBWT-IX[
MH3@"2'S0/+"YQG<3R<'CTKE[_P"'WBN/PEK7@_3FTN72KNZ^T6EU/,Z2Q*95
MD*,H0@X(/.?\!TL^@^(6^(!\0+;Z>T']B'3BGVE@QD+^9N'R<+GCUQS[4 5]
M+^)KZA'X=NY- GM]/UR;[/#<-<*Q63YL#8!G!V]>/ITS-JOQ)33[36M0ATM[
MG3=&O5L;J43A)#(2H.Q",$ NHR6'?TK%LO WB2U\,^#-,:/3FFT'4!<SL+IM
MLB M@+\G4A^_I[UDCS-4U+Q!?P)X?O--FU-I'AN=5DM58PD >9$%(SE,Y/WN
M"1C% 'L$MZ;?2I+Z>WE0QPF9X5 =QA<E1M)!/;@\UR^A>.GU37[+2+S2C93W
MNG_;X0+@2,J9'RR+M!1L$''/UK7N&OO$'@F1[)GTV_O[ F$N3NMY'3C) SP3
MUQFN,\->#/$.F>(] U.XLM(MTL["2TNA!.[/(Q*DRD[!N=B#D'IUW'I0!VNO
M>($T:;3[.*#[5J.HS&&UM]^P-A2S,S8.%51DG!/3CFO/?#6O1>&M7\?ZCJEM
M':,NHVR?9TG#*9'0!0'8*,,2#DXP"2>E=;XS\.:GJ>I:%KNB26W]IZ--(Z0W
M3%8YHY%VNI(!(. ,'%<S+X \2ZFWB2ZNKC3K&\O[NUO[%H)'E$,\(&-V5&5X
MQG\<=J +&I_%&7^Q_$::;:6<NI:7:BX5X+T3V[1L,;PX49*GJI SQS6O_P )
M?J5IIVDQ2:1YUY/8-=S2R7/EPHB*O+2;2-S$C Q^-07&B>,_$?A+6=/\03Z1
M!<75F]O;Q66\QES_ !R,W/4   < GKVHS>%?%EUJ6AW-U#I%Q;6M@;62REN'
M:*"7(Q.HV?.VT8Q@8Z ]Z )KOQ3H_B&S\$:G<Z+/,FHWZ/:.TVW[+. V"<'Y
ML8;M@U4TW5;'POXV^)6I77R6MN;!V /5FB/ R<9+-WXR:AT_P1XGM?#O@S3W
MBTPR:%??:9B+I_G0;N!\G4[C[<"K>H^ M7UC4?&IGDM;6'6_LKV<T<K.\4EN
M!L++M P2 >"<=.: +]I\4-+-]J-K?_9HOL5@=0,UE>+=1-&#AEW*!AP2!M[Y
MZUCWEY?:A\6/ =Y>:2EB)[>\>,BX\QV4PY"N-H"D9[$CYNM:<GASQAXJ\-ZE
MI'BR[TJWCGM3!%_9RNV^3*D2N6Z %?NCKN/M5>U\.>,[KQ'X2U'58]'1=#6>
M*9H;B1C.KQJFX H,'C.,T =7XG\2Q>&X+$O'&\E]=+:P^=-Y488JS9=\':,*
M>QR<"JA\672_V;9MI*KK%_).L=H;G]V$B)W2&3;]TC:1A<G<..I%GQ7IMWJM
MG!;1:;IVI6AD)NK2^;:'3:<;6VMA@V#T]>17#6WPY\2:'::5?Z'=V2ZGIMU=
M-!9W,LDD M9B,0[\!CM !!P.2: #Q?K,NIQ^#-5GT:[M+V'Q&MNUJPRY*AP0
MI. 5)4$$X%=%#\1;>*QUV75M/?3[G1[B.WE@:='#M)CR\/P!G(SG@=2:IZMX
M;\7:LOA^XNY--FO+/5DU&X197CBC55VB*/Y23QDY..2>W2K?^ =;U.Z\62&>
MTM'U*ZMKS3YTE9S%+  %WJ5'!QV)QGO0!H6WQ2TH/K*7XMX_[+M5NVELKI;J
M*6,G&%8 ?-N(7:0.2*RKBXU*Y^,7ABXO-(BLII--NF0"Z\PO\HPK_*-I'?&1
MSP35^^\,>+?&'A/5-)\576EVK3P".!-/5V4R!E<2.6YZH!@=B?;!::#XRO?&
M'AW6M8CTB(:9!-!/]GN'8S;U4;P"@QR,X_6@"Q;_ !)BN/#&DZZ-+D6*_P!2
M&G&(S#=$YD*!NF",@^E4(;ZRT'XI^,=2NF\JUM])M[B9@,GC>3QW-9Q\!>*X
M]'MM#A_LG['8ZV-2@G>=PTJ>8TFTJ$^4C.._]:U]3\#ZGK?B/Q/)=_98=.UC
M34LTDCF9I(W3)#%=H&,GIGM0!?T3XAVFK>);?1'BMA+=6QN()+2]2Y48ZI)M
M'R.!SW'7!I?''B+6-%U/P[::;:121ZA?I#*[2[6/!;8!@XSCEOPQSQ)X6MO'
M,<T47B6ZTDVMJFU7L@YDNCC 9]V H[X Y/H.LGC;0=3UB30KO21:O<:9J*79
MBN9&C5U"LI&X*Q!Y':@#B[+Q!/X4\3_$2^M]%EO(K>:VN+A4F5%C7R<L<GJ<
MDG '8].,]=K'CMK!/,L])>Y@72_[4DGGF\B-8S]U VT@R'GY>/KS6+/X.\27
M$?CH/%IH;Q#&B0%;E\(1'Y9+?)TQSQGT]Z@O?!/BBZN(5DCTNYM_[#&GJEQ<
M.5LY@I5I8UV?,2,<_*>V<#D T/\ A-]4U#Q;X5M]/L%&F:K8-??/,!(XV*<$
M8.-N[/7D^F.>I\4>(K?POHC:C/$\Q,B0Q1(<%Y'8*HSV&3R?2N/TWP?XEL+G
MP7>*NFF;1[!["ZC:=\!2J*'4[/F/RDXXZ@9[UI_%.:/_ (1&.Q>2T1[^]@MX
M_M;%$)W;C\X^X<*2&[8XYQ0!)_PGR6>I:Y9:OIKVO]C6RW-S/%,)8RC+E=N0
MK$G!&-O6JEI\3;>?4Y=/-G!-<?87O818W\=P&"_>C8C 1P.>XZX)K%ATJ?6U
MUCP]?VNG)<:W:$R:A9:F]Y(AC ">8'4$*">,'KGUS6]IMCX_GTVYM==FT9Q'
M;/#%]E+AKIRNT-(Q&%'.< <GT P0!FE?$A]0F\.--H,]K9:]E;>X:X5BKA2V
M"H&<<<']*9+\5M+CO;8(MM-97%]]A5X[U#.K;BOF&#&0FX=<YQ@XYJA9^"O$
M=OIO@:V>+3R^@3%[@BY;$BX*C;\G7!SSBK7A_P -^-?#D_\ 8=I?:4WAM;AI
M(;AU<W443.6,8'W2>2-QSC.?04 7+#X@7>H:QJ%G%X8O3;:==26]W<K*C>7M
M3>"%'+$XQ@9QD<\XHTWX@7-_JEEIKZ'Y%WJ%@]]9Q-=@M@=%E&T&,D$'^*DT
M7PSK]E#XR5I;6UFUB>6XLIX)F=H79-HW948P0#D9K'\.>"O$>FZ]X:U&XL](
MA%A:RVUXT-P[/,S!<S$E!N=L$X/3U/0 %CPW\1;AO MCK.N1VT=QJ%Y+#:[[
ME8XV/F2<,Q'R*BKC)R3CN3@V8?BI82V%W(;>$7-MJ$5@=MVK6[-)DH_G 8V8
M!YQD$8Q619?#_P 4V/A+2[*VNM,@U30KZ2YT^;>[I.KM(660;1MR' XSTZ\\
M=%+IOB[4]&"ZW::#?233J)]-.X6_D!7SAV5CYA8J<XP-H'J: .DT:_NM0M9)
M+RR6TE24IM2;S4=>"'5L#((/I7,:_P#$0Z#/?R2Z/(VGV%S#:RW#S>6\C28Y
MB0K\X7<,\CO5WP%X8N/"ND7EG,4CAFO9)[:UCF:5+6)@,1AF )Y!/3O^-<AX
MD\ >*-7;Q+&%TRZ^WW44]G>7,[>;%$KHP@ V$(ORGD'GT.> #TO6M7M- T6\
MU6^<K:VL1DD*C)('8#U/0?6L,>+-3@N+J&_\-W$)BTXW\<D4XDC8 X,;,0H6
M09SCGC.":O>)=!;Q3X.OM%NW2"6\M]C-&2RQR<$$9P2 P'ID>E8.GZ;X]N=+
MN;;7KC2&\NSDMX5M&<?:79=HDE8CY0!DX Y)[8H RM3\<)KWPZU'5-6\'WC:
M%)9QRX:Z1?/#-@C((9<$#GJ00<5JP^(]67XE6GAZWT^-=+31_M2@3_,RET4,
M<CJN& 7/.<D^E:X\'Z[+\&%\(A;'^TOLRVI?SV\K 8'=G9GH.F/QJ\OA[7HO
M'6E^(8H[ QC2!IUW&\[9C(D#EDPOS=,#./6@"CX?\3Z1IVEZC+IVBRVMU>>(
M9K/[(UQN,]V<;V+<A5P"3C( 7@$G%:TOC*]M=,U.:Z\.7BWME=QVJ01$NEPS
M[=K))M'R_-R<<5RZ_#[Q(VCW;1S:?:ZO#X@DUK3W$K21G?UCD^4$#'< Y]JT
MM8T'QSKOAF47EYIT=^]Q YL+:1TMWA1B7C9R"V7W<\8PH'K0 FL^)8_$O@WQ
MWIMQ9)#=:19RK*(Y_.C9C"SJRL .01R"!@BNH\'L5\!Z"P4L1IEN0HZG]TO'
M-<=!X+\10Q>-8TL]'@CUZS2&WB@G94@80^5C_5_=&2<X&<=!GCN?#%E=Z9X6
MTK3[Y8EN;2UC@D\IRRDHH7() ZXST[T <7_PM>9=&?7)/"]XFCV]TUM=W7VA
M"82'V9"#EATSCU[XK1\0?$4Z$^H7#:--)IFGS00S732B,R-)@_ND(^< ,,\B
MN/\ "FC:OXG\ :KH$<5G'IMYJMPLMX9V\R-!-E@(]N"W'!W8Y]N='Q)\//$N
ML+XCMTETRXCOWB:QN;J:3S+>-&0^2J[2%'R\L#SW!SP :[>(-7U3QEXH\/76
MGP?V99V28(F^;#JYWGCDG &WMCO6-\.O%\NE^$_!>F7.D3BTU%6MHKTRK_K1
MN.-G7:<8SQ],8)WAX>\1V_B_5]7AATV2'5=/BAE5KEU,<J*P 7Y#E26')QT/
M':LJQ\$>([30O!5BT>G-)H-V9IV%T^)%^8#;^[ZX;OZ>] '7>.]1O=)\#ZS?
M:>@:XAM)6#>9L,?R'YQP<D=<?K7)>&OL&BKX=EM-"@7Q)JNGB,".YVI+"J([
M33,%ZYQSM9B3C/7'9^,=-O=:\(:II6GK";B]MW@4S2%%7<",D@$\9Z8KFO\
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MXZE/I&G-=K\QNGMD,@QWW$9_6N*OM?\ %&EZMXC\/VDC:M>0Z;'J&G2O$@E
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M/FVT4<GG33*SAOG5OD  X&"<GFL31_'&N:I)X&EDDCB&I7%U::A$L:E'>$,
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M@,VH"X^RK%&K)N0P;&,AP>,/DD>AZ ':ZSK^G: EJ^HS/$MU<);1$1,X,C'
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M SUI&=$(#.H+< $]: .*O/A=HMUIMK!'=ZC:WEK<RW46HVTPCN!)*<R'(7:
M?0 #CBK$WP]L);72H1J>IJVG7@OEF,J223S_ -^1G4ECCC' QQC@5UQ95ZD#
MC/)K.UFYU."P271[6"[G,J!DFE\M1&3\S ]R!VH HZCX9@N_%-AXEDOKU)].
MB=(X(@AC*L/F!&PL<X'0]N*XGX?^$)-0\+2VFM2:O!:_VC+/+I=S (HI?WN]
M#\R!RIPI(#8R.>XKT>WUBQNM8O-*@G62[LXXY)U4YV!RVT'W^0G'H1ZU=#HS
M%0ZEAU /(H YT^#K9/$.JZS;ZCJ%M/J<2)<11.GEEE38KX*GD*>Y([XZ51MO
MAQIMIHFD:=!J&H)+H\K26%Z'C\Z'=G<OW-K*<X((.178[UW;=PSZ9I'=4&78
M*/4G% '*:E\/M/U70=1TNZO[\MJ<R37UV#&)IRF-H)V;54;5P% Z>YS<@\)1
M1>+8_$CZG?2WJ60L2C^5L>/.[D! <[OFR"/RXIGBOQ)<>'9M"$-I%/%J6IPV
M#NTI4Q^9GY@,<\ ]QVZTNF^)+F\\<:QX?FM(HX[""&:.9)2QD#YZC QTZ<_6
M@"QKWAFUUZXL+QKBXL]0T^1I+6[MBH>,L,,,,"I4C@@@U3N?!-G=:#JFER7U
M[OU5BU]>9C\Z?*A<'Y-H&T  !1@#CO73,ZHNYV"CU)Q0655W,P"]<D\4 4](
MTX:1I%KIR7$UPEM$L223;=Q51@9V@#H/2N5O/ACIMYIVM:<=5U6*RU>Z:ZG@
MCDCVJ[,';;E#@%E4\Y/&!C)SVN]=F_<-N,[L\51U+6]/TJ*VDNKE%%S<1VL(
M!!+R.P4 #OR<GT )H RCX,M9?$8UNYO[VYF.GG3I(I?*\N6$G)# (#DGDX(_
M+BJGASX=:=X:OHY[;4]7N+> L;2RNKLO!;$@@E$P.<$@9SC)^M=<TB(P5G4,
M>@)ZTXD 9)P!0!@>*O".G^+;.WBNY;JVGM9?.MKNTD\N:%_56JDWP]TJ30H]
M.FN]1FN$NEO5U*6XWW0G4 +)O(QD !<8Q@=*ZK>F"=RX'4YZ5SOC;Q+/X6\.
M'5K6UANU6:*-E>4K@.X7(P#GD].* $/@V"6"]:?4]0EU"\\D2:ANC695B<.B
MIM0*H!R?N\Y.<U6NOA[IVHV.M0:C?7UW/K$<45S=.8T<+&<H%"(%&#ST.:ZQ
MI$5@K.H)Z GK5(:Q8MKO]C+.K7PMS<M&ISL3<%!/IDGCZ&@";3[,V%A%:M=7
M%TT8P9KA@7<YSDX 'Y "N-N_A9IEU_:4:ZMJL%O?7PU%K>*1-D<^X,74%#G.
MWH<CVZ5W(=2Q4,"PZC/(KG/&'BB;PU%ICP6T%Q]KU"&SD#RE6C$C8W  '/?N
M/QH SKWX8Z5>:W-J2:EK%K]K55OK>VNS'%>[1C]X ,G(X.",Y/J:DU7X;:5J
M6O2:M#?ZKILMPBQW<6GW1ACNE48 < 9Z<<$<5U.H7]KI>GSWU[.D%M A>21S
M@*!3K:[BNK&&\0[89HUD4OQ@$9&?SH P;GP9:'6!JNF7UYI-T;9;60V?E[98
ME^Z"KJPRO0$8(%1WW@+2[G2=)L+2>[TXZ3+YMI<6KCS$8@AB2P8-NR2<CDFN
MH!# $$$'H16-?^([:%]6M;(Q7.H:=:"ZE@,FU0#NVJS '!.P\8]/6@# G^%N
MESZ/JNF'5=6$&J7:W=R?-1F9P0>"R''*J?7CTXK4/@RVD\2S:Y/J-]-<36']
MGRQOY81XNIX" @Y).0>_IQ5SPKK;>(O"^F:M)$D,MY;K,8E;(7/I6OO7?LW#
M=UVYYH XO_A6EE_PCVFZ+_;6K_9M.N4N;=B\1963[@YCQA?ISGG-6)O -K-<
M>(YGU?4MWB"%8+P#RL!578-O[OCY"5[]<]>:ZZFJZN,HP8>H.: /+-=T&YTO
M6-'M5'B@Z=I^F_9;>_TM8Y9&.X?)(FW"X54^8+SW/%=GX/@U2'3[C^T+F_GA
M:7-J=1$8N!'M&=^P ?>S@'G'7T'0*Z.2%=6P<'!SBC>F0-RY/09ZT <Q/X)M
MY[A)+G4]2N;2*_.I1V+F+RUFWEQ@[ ^T,>F[%4]!@;Q)XJ3Q5?>'KK2IK.U:
MS@%Z%$LA9LLV 3A0!@'OO;MBNFL]9L=0O[^SM9UEEL&5+C:<A&89VY]0.OIF
MKOF)@G>N!U.>E ',ZMX(M]9DOTNM5U$V%_+'+<V(,?E,4"  $H74'8N<,*=+
MX&TR?6]8U&6:[>/6(5BO;(N/)DVIY8.,;L[??&>>N,=*'4KN# KUSGBJ&K:W
MI^B:3-J=]<)';1#ELCYCV4>I)X H YO1_AO9:-!-#'K>MW"&%H+9;JZ$JVB,
M,'RE*[0<<9(/''K2P?#BQM[+0+2/5]4\K0Y3+:9:+.?1CY?(P2/H:[.FB1&8
MJKJ2.H!Z4 8NA^&(-"U/5;Z&]NYY-3F\^9)]FT/C'R[5!'&!U/2H=8\(6VK>
M(+76EO[^RO(8&MG:TD"^="6W%&R"0,]UP??ICH<CU%!( )) QUH Y#2_A_!H
M>G:=9Z5KFK6JV"3)&P:)]RRLK,&#1D$97(XXR:K77PLT273]+M[.\U/3KG3%
M=8+ZSN/+GP[%G#'&""23T&,G&!Q7;B1&3>'4KZ@\4;T"EMRX7J<]* .4O?A[
MIEU::6D-YJ-K>Z8[R6^HQ3YN"S_?+LP(;=WR/TXJ[X9\)6GA>34I;>]OKF34
M+@W,[74@;+GJ1@#&:B\,>)I]>U77[*>UAA_LN[%NC12F02 J&SD@>M2:_P"(
M)]/U?2M%L(H)-0U+SFC-PY6.-8UW,3@$G.0 /<^E "7OA""?7I]:L=2OM,O;
MF%8;IK0IB=5^[N#JP##H&&#BH#X$TU+_ ,/W-K<7=HFA*ZV<$)39AQA]VY2S
M%AU.??KS6SH]U?3Z9;MJ]K#9:BP/FV\<PD4$$@%3W! !]LXJ^75>K ?4T 0W
MMM]ML9[4320^:A3S(\;ER,9&X$9^H-<E:?#>RLH?#\,6KZIY>A.SV@8Q'[W4
M,?+Y&"1]*T/''B2Y\)^&VU:WM(KK9-%&Z22E,!W"Y& <G)''%=&&5LX(.#@X
M/2@#C9OAMIMQIFO6$^HZC)%K5PMU.2T89)0P8,F$&/NKP<CBC5?AO8ZI>VNH
M#6=;L]3AA\B2^M+H1RW"9SB0A<'DGH!CZ 8[$.C,5#J67J >17(^)?'4.E^$
MM;UK2(X=0.DSBWF5I2J[_DS@@'./,'''(//% %A? ]E#KNFZK;7]]!)IULUK
M!$K(R;&^\6+*69B>22>M9Z_"_25T---_M#4MT-Z;^VNPZ+-;S$Y)0J@&">Q!
MKM8I1+&K C)4$@'ID5SOC'Q3/X5M]/FCT^.\%[>Q62AK@Q;7DS@GY&XXYH H
M1_#/2&&M_P!H7FHZB=:CBCO#=2K\QC ",-JC##&0>U2:;\.=+L]-O+&_O]4U
MB*Z@-L3J5T93%$<?*G "\A3D<Y4>@K7MK_7!J5O;WVCVL=O*&S/;7K3>60,@
M,#$N >><UK[U) W#)Z#/6@#C=.^'%I8:KI&H2:YK-Y+I"NEHMQ,A"HP"E3A
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MQ4C!Y]:Q_#7B:?7-:\06$UK#"-*N4A1XI3() R[LDD#\JZ-Y$C&7=5!_O'%
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MPR('"%U#'^'/-.H Y*Y^'VGW.C6-@=1U,36=ZM^E^9P]P\P!&YF<$'@XQC&
M/2N@OM)M-3T:;2;Z,W%I/#Y,BR,267&.3USWSZU;1TD!*.K8.#@YH#H2 &4D
MC(&: .,TSX:V&FV-S:'6M<NTEMVMH#<WF_[)&W!\H8PIX'.#TJW)X#L;PZC)
MJ>H7U_<7]@=.>>8QJR0$DX78BC.3G)!Z"NJ) !). .](KJZ[D8,/4'- ')'P
M!;NNA;];U9VT5_,MV9XB6.-OS?)TV\8&/SYJM-\,M/N-#UG2)=8U5K;5[S[;
M='="&,F0QP?+X!*J?^ CWSVS.J_>8#OR:0NH8*6 8]!GDT <S<>![.\UR;5;
MS4+^>6?33I<T;&,(\!ZYVH""22<@CGVXJIIOPWT_3;W1KI-6U>672$:&V\V9
M"/*( \L@(/EP.V">Y/&.Q,B!PA=0QZ GDUSUOXDN9/B%=>&9+2)(8M/6]2=9
M2S/E]F",#'0]S0!ECX7:*?#,F@27>HR68N/M-J3,JO9ON9@8B%&.7;KGK5NT
M\"0V=@D2:]K<EZLZSG49KD2SDJK*JY=2NP!V^7'<^M;M]K%CIUY86ES.JW%]
M*8;>//S.0I8G'H .3]/6FV]QJ;:Y?07%I!'IL<<;6UPLN7D8@[PR_P .#T]:
M (=!\/6^@K>M%/-<7%]<&YN9YMNZ1R ,X4!0, < 51F\$:;/X@U3599[MEU6
M!8+VSWCR)@J% 2,;LA6/?'?K71[U)(##(&>O:E#*5W @KUSGB@#F=*\%6NFO
MIPEU*_OX-,S]@@NF0K;_ "[0054%B%) +$X!_&NGI%977<K!AZ@YI: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O--6TC3-3^.4-M?VT4T,WAYVDB?[
MLI$X W+T;@=#Z ]A7I=49M%TJXNVNYM,LY+EUVM,\"ER,;<%B,XQQ]* /#-&
ML[2+P#X!U=.=1'B2*V^TLY9TA\Z5?*!)X3:!\HX_.NF,6FZS/\18_$L=N;^U
ME?R&GQO@M1$#$T9/*\Y;([FO1_\ A&]"\E8?[%T[RE8NJ?94VACC) QUX'Y5
M/=:-I=[<PW-WIMG//#CRI98%9DQ_=)&1^% 'DNE:8NJ^,_!L?B.W6>ZN?#;F
M[CN.?-8%<;U/WCCG![CU%9,*PK\(-(W$;;3Q*(H2S?ZM/M)X'MBO<)M&TNYO
M/MD^FV<MUC;YSP*SXQC&XC/2H/\ A&= \D0_V)IOE!MX3[)'MW=,XQUH \QN
M8K?3/'GQ%FTVVM(]973H9=.PBB0RM!(7:/N6/4XZ]Z6*VTXZ3\.-3\.+"NIS
MW<$<\D&/,FA,9-SYF.6QMR2>A]S7JZZ;8I>+>+96ZW2Q^4LPB4.$_NAL9Q[4
MRVT;2[*ZENK73;."XF_ULL4"J[_[Q R?QH \Y^&?AO1Y-8\1ZJ;4&]L/$5]%
M;.'8"%" N H.,$,>WIZ"K7CN73;GQQI&G78MC.EA<3*=28&S120I;81\\G!P
M-RX&3FN^LM+T_33(;"PM;7S,;_(A5-V.F<#GJ:+K3-/OIX)[NQMKB:W.Z&26
M)7:,^JDC(_"@#Q73;I9OA9\,BUPLCQ^([5&R^2N'EP#Z8&./3%=SHS+_ ,+H
M\4+D9_LZSX_[Z_Q%=2?#>A-!' =%TXPQ$M'&;5-J$]2!C@G%3Q:3IL%\]]#I
M]I'=OG?.D*B1L]<L!DT <%XLU/2K7XGZ?:^*FMET*729/LQO /(^T^9\Y.>
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M;V:]M]/M8;J;_6SQPJKO_O,!D_C43Z!HTET]T^D6#7$C!WE-LA=F'0DXR2*
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M_<7$45PT&-\UN8B;CS<?>P1R6Z-[FN<N[?2;/X;?$R&"&R@O$UFYC1$55D6
M2P[5 '.P$C Z5[I::/IEA=2W-GIUG;W$W^LEA@5&?ZD#)IDV@Z/</,\^DV$K
M3L'E+VR,9&'0MD<D>IH X+2-/LM(^,UK%IZ")+KPX99R'),[B90'8D_,V,\G
MFI_C%M_L3P\&E,0/B"TS(" 5^]R"?2NXCT328;F.YBTRR2XB4+'*MN@9 !@
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M=W5>RL+/3;86UA:06L .1%!&$4'Z#BK% !1110 4444 %%%% !1110 4444
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MR+^Y$[K920QQRJD1PSG>X7!R,8)SFI[3QUIVI:=I%SIMK=WDVJQ/-;VL819
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M>ARPPP(QZ#J3CFH1\5-)_LUM0;2]72W@N_L=Z[0*!9R[PF'^;GDC[F[&><4
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MV6KV,MEJ-K#=6LHP\4R!E/X&J&C^%-"T"4RZ9IL-O*5V^8,LP'H"Q) ]AZ4
M<;X*T3Q)ITUAIVI^%=#M$T]0C:Q"R,]PJC V(%W*QXRQ([\<UK^.='UR;4M!
M\0^'H(;N_P!'EES9RRB,3QRJ%8!CP&X&,_\ UCVE% 'G>KZ/XMUNUTC79[.V
MAU/3=26[BTI;@,/)V;&C,N "YY8'H,XJ#7O#6L:XOB?6%TJ:&[U#2!I5I9/-
M%YG5F9W(8H!EA@!B< ]SBO2Z* /.;;1=<_X2KP5?2:1-';Z9IKVMXQFB.QV1
M5X ?) *YR.Q'TK"'A/Q5%\/8/#O]A[Y[35A<I(EW%B6,3M(3@L,<$ 9YSV%>
MQT4 <)XJTW7]1\5::\6FF_T(V;QS6C7*Q*D[$8:49^= .-H##(S@\5RFA^%?
M&GAO3/#&J66CPSZCI=M/876G27:*9HG?>&5^54Y_D*]FHH \\U[2O%>IP>&]
M5ET^":_LM5^URV$-PH$,11E"B1L!B,@D^I..!70>-K;7KWP5?0>'R(]7=$V!
M9 /XAO56. #MW 'C\*Z.B@#QNY\ :UJUSXCA31ETJVU;3($B>2\65DFC<L!(
M1EF8D+D\\'J3Q76:<WC;7=,O+37=*L]*7[#+;G9<K,;J5EP'&!^[0?,<9)Y'
MI7<44 >3R:!XHD\">#]+;0&%WH^HVLTR+=PG,<(Y.2P&3G@ GISBMKQ)X,OM
M2\=Z=JM@XBL+RW-IK2$C]Y"C!T&.Y8@H2.QKOJ* .,U[3-4N?B5X7U2VTZ26
MPT^.Y2XG$L8V^:H484L&.-O/'0\9Z5S+^%_$T?P]\5^'!H_F2WEY/):2K=1X
ME623<#@D;0 .<\].#7K-% 'E=_X=\167B&+6[3PMI^MQ7MA!;W5C>S1+);2Q
M@@,KG<NW!YQG-2^)O"=_JMK#%+X<5KZ"Q!LM0TBX2W:TN"SDI\S*3&/DYP>Y
MQD\>GT4 9^F)?6?A^SCOV-WJ$-JBSM&1F64*-Q&<#DYZXZ]J\ML?"WB>V\&^
M%--?0I3<Z7KXU"<"Y@QY0>1N#OY/[S&/]D].,^Q44 <9X9TK5+/X@^+]2N]/
MDALM3:V-M*TD;;O*CV-D*Q(R>1QTZX/%8OC3P_XEUG7-9A731J.EW6EF&QW7
M2QQV\^ULLZ$_.V2-IP<<<CDUZ;10!Y/8:+XT\-7NE:SINAP7SR:/!IU]I\EZ
MD;1/%PKA^5Q[#-7]1TKQKI?B:P\56%C::O>2V!LM0LEN! %_>&13&[#&%W;<
MGD@9QD\>DT4 >?W6C>)HO$6A>*GMHKZ\@AGM[ZQMY54K'(VY!&S[58IPI)(W
M8S61KW@W7+S1=:N;?36?4-7U:WO/LOGQCR(HBN S%@-Q"D_*2,D#/&:]7HH
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ME3+"=P#*&) )XZ'C->I44 >8VOAS7_$.AZGINI^&-'\.M-8R6WVBU9'>>1@
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M^E>C44 >4Z;X9\2Z?#\/;E=(\R?0X;FVNX&N8UQYD857# D%>.V3[5ZM110
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MS*3M4X(^7YFSW.>HK9MO"D]KXGUO6TU5UEU6!(2BP >3L!",I).2,GJ,'VH
MVM)344TJV75I()-0$8$[VX(C+]]H/.*N53TJSGT_2K:TN;V6^GAC"/<R@!I3
MZD"KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\."Z^Q3"S\7K%*SJN(X&D<D$'[J''0\<>U;.JSZ!J?B#Q/I7B#7+/3(G$/\
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MJ&N($E$331K(>B%@"?PKP+6K[3;B\GO[62V@E3Q?'YANG#7I9756(/!CA &
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MR\?7VJ@WCR[AU/6]%NM(C@UC3K!M0C47)>">(8Y#[ P.3C!7_&L[XOG]QX/
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M()=X:/.$))Z,?2M%)$DW;'5MIP=IS@^E?/[V]@_P[B!$2I#XR,:%3M\M3-R
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M:=-8K8RV%K)9KC;;O"IC&.F%QBN)OKD2?%OPQ<1RS)!<Z5<RLCNP7&%(RI.
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M.S"RO+7S;:;*[1N4$$%1G!'3-<[\1O$IOO!OBFUTRRN[B/3T,-Q>0SB-8I<
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M864"'>P4-@_>.3@#\^*M7'BEUU%-+M=)N;G4_LWVJ:V$L:^0A.T!FW8W$@X
M)Z'I0!IC1-)46X&EV0%NQ>#%NG[ICU*\<'Z4U= T9#&5TFP4Q',9%L@V'.>.
M..>:B\.>(;/Q/HL6IV(D6-RR/%*NUXG4X9&'8@BLZS\8#4=3>"RTR>:UCOI+
M"2Z$J?NY4!SN3.X#*X!]P>AH W;33+"P9VL[&VMFD^^88E0M]<#FJ5UH8;Q!
M!K=G(L-X(Q;W&Y<K/!G.T^C*<E3[D'@\87_"R=/'AF;73IUZ+>#4#I\L?R;U
MDWA,_>P1DCOFEO\ X@&VUO5M(M/#FJWUWIB)+,(?+"E&!.X$OZ 8'WCGIP:
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M: .SK-;P_HK7?VMM'T\W.<^<;9-^?7=C-<K,S+\<+$)++Y<NA2NR&1BN?-4
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MC]*M06EM:QF.WMXH4;JL:!0?P%<-XN\<:OHWA:^O8-#EAN8IXH [S1LBK)M
MD7!^;EL8]1SQ6GJ_CJWTII86L)7N[:U%U<V[7$2-$ISA<EL,QVL0%)Z<D9&0
M#H[/3;'3U=;*RM[8/RPAB5-WUP.:CM-'TRPF,UGIUI;2D;2\,"H2/3(%<C<_
M%"R$NG1:=HNJ:BVHV)OK46Z(3(HQE<;L@CG.?3 R2*[B&0RPQR%&C+J&V..5
MR.A]Z 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[N<QFVE1=F[@'*D<X'/T[]C?:Q#8:IIUA)!=227[.L;Q1%D3:NX[V_A]JT:
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MP3T-:U '&:GI>KM\3M.URWT_SK"UT^6V=A,@9F8AA@$]. .<=:Y2V\&^)8/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+D9[#T'L*UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\MPY0R0MN 8=0?0\C\ZY6;Q#K>L>+/$.BZ'-:VO]BV\))N(#(9YI%+ ?>&U
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MG"JJ_-WR?0UZ9-J,=[X;N-0LK>6Z1K>1XH7C:-IL X7# $9QQQWS0!#9^+-
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M*)=EQ\O4L03Z8&.E '965QH/AE6TO^V+2WC7,L-I/<HI@CQDA02#L')&<X'
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M  )G>0!QT&#D]* ._HKS./XEZOJTFA1Z#H5O.^L6$MU$+BZ*;'C.&5OEZ9!
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MS?PCKM Y/4]J-/\ #>J67CS6?$33V;PZA!'"L W!D\L':2>^>_'_ -?K:"<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P ))]JRKS0]=ENO"=Q#X8M[1+34FN[BUL9(0EM&4V8))7>_.20,=NW-*_\
M#GB.YT;X@VJ:'/YFLW >RS/!\XVA3GY_E^[GGL: .\U/Q7::>YC@M+O4)4M?
MMDD=H$S'"<X8[V4<X. ,DX/'%9O_  L?1I9]+AL[;4+U]4MFN;3[/;Y$@7JO
M)&&'?L.Y%<QJGAS7+/Q#;:W!X0LM?@NM.@MKFQO)85DM9(\@,K-N7:0><9K3
M&BZU#XU\*WW]AQI:V-I<QW/V)HEAA:7E512P)"XP3M&>OM0 [5/B:O\ PC^F
M:EI&EWDOVS5$TZ19E16@?S KHREOO$;@,'&>I%=_"YEA21HWB+*"4?&Y<]C@
MD9^AKR"/PIXE'A'RO[%E%W;^*!JR6[3PYEA\S=@$.0&QV)'XUZ];O+);1/-%
MY,K*"\>[=L..1D=<4 >4W/B2&'Q_K.D^,-4U/1_-<#1YX[EX+;RMO4$$*SY.
M3OR.WM77V_B6+0[GPYX;U3[5/J-_;*B7F%,<TB(-Y+%NO?ISD8S5#6;?4-5L
MM4TG7?"4NKVLEQ)]BDBE@QL/W2Q9U*$$G!&3C\JP]8\*W%A\)=(TJ?4(1XDT
M?R9[&0/D^>'PB+GD@[@@[=/2@#M;KQ?9VD3,UI=LYO\ ^SH(U" W$W/"$L!C
MAN6(Z$=>*QM>\?76GQ:/]FT&_62^U5;"19O*#1D-\RX#D$LH.TYQCG/3,VN>
M&U/A+3=&GT5M=@$VZ]$<JQ2ABKLTR%F4!S(<]>C&N9;PKXJA\-:,K6]W?OIG
MB1;ZWMKFZC-PMFH8*K.6VEAG/WCP?;% '9:MXYL-'CO)9;*^F@L GVZ6!49;
M4L <-EP20&!(0-@$5#=_$/3+?4;NP@L=3O9[:T2\(M;<,)(F_B4E@,8]<>V3
M7+7'AS7M-\5ZI<)X*TC7[75Y5N4FNIHPUG(4565BRDL@(R-H_4XK131M<MO&
MNLWO]C226DVB1V44L+PHLDJ9X5"^54YXSC&* -BQ^(VC:C=Z1'!;Z@+?5LBT
MO'M]L3N%R4R3G(P1G&,]ZZUF5%+,0% R2>PKR?3_  WXBM]%^'UK+H<XET6Y
M+WH$\)"+M901\_.=V>/0UZI<P+<VLUNQ(65&0D>A&* .$T;4KOQ/X5U?Q7)=
MW,,%Q%<+IUO%*T:PQ1E@KG!&79ER2>@P!QG.+X4U/3]8\$Z0;GQ;?+X@OHUC
M 3479Q,2<$Q[L8'4C'0&M/P3!>VGPINO#S6KSZKIOVFPD@C*J2Q9BA&X@8*N
MK9SR#3O"Q\0:!\/]-T:?P=?7&H6<(4#[3;"(NK$J=WFY Z'[M #-?O;[PS\5
MM#N;G4+QM U<-:^2T[>7#=?PG&>C< #IU/:NA6*35?'5V4O+Q+'3[58988YV
M5))Y,MR >JIM/'_/0>E1>./"\_BOP'<:8[(=36-9H)4^4"X09!7/0$Y'L&JW
MX3TZ^T?PK$=2#7&KS!KJ]V;=SSOR5'(7CA1SC"B@#B_AQXAU6W\47V@ZY?37
M<5Z);O2YIW+-LCE:-X\GJ1M!^F3WI8_$.IZQ\:;&U6\GBT$VTX@ABE*K.T1*
MM(V.HW[@.Q" ]Z;=^"M=U?PMHSVT4NCZ_IFIRRQ3.\;%89I7+X*LP/R.#CU4
MCO6A)X=U"R^)WAZ[T_1I_P"Q-,TY[$S"6+C(X(!?<0.,G&?K0!A6WB 7FNZ_
MH?B;6]3T3Q"]S*--?[2\%OY/2+RQD(WON!)SUST[3Q%J<_A1],UF:XD>SFFA
MLK^%W+*N_P"595]"&QG'# GN!6+XBTS5/$OAB^T;6O",E]>L\XL;Q9H/+CRS
M>4Y8N&0@;<@ Y [YQ3/&>D74G@CPOX/\X7.J3SVD+N#G*P@-+*<\[1MZ_P"T
M/6@#TRO/X?&.AZ#9>*=;8ZY/#:Z@([N.8;_*DPHQ&I/RIR.N.:] KQW5O#/B
M6\\,>/+"+0;CSM9U);BSS/  R93);]YQ]S]1[T >@Z7XQLM4\1S:&+._M;Q+
M87<?VJ$(LT.[;O7DGKV(!]JM>)]:?P[X:U#5X[*2\-I"TOE1L!D 9)))' ZG
MOCH#7.PZ?J\OQ8M=<?2+B'3_ .P_L3RO+$=DID\S! <G '&0#S[<UT7BK3Y]
M6\(ZSIUJ ;BZL9H8@3@%F0@#/;DT >?7/B>^?Q+\.M3N%U*+[?9W37%G$25N
M'$"%2L:L5^\YP3C'?&*["Q\>:7J&B_VA%!>+)]M;3Q921JLYN%ZQXW;<X!.<
MX !)(P:Y>QTGQ(^M_#^YN/#T\$6B6LUO=M]I@;;OA2,' ?GE22!G@COD#)D\
M%^))M+OKE=#A>[@\2SZO!8WTD3QW<$H(V'#, P![\#WH ],T'Q-9Z_+J%O##
M<6UYI\PANK:X"AXR1D'Y25((Y!!--\1>*K#PPVG"^BNW%_<K:Q&"$OAVZ XY
M['ID\=*J>#;:\CMKFYN_#6G^'O.*A;.U9'?C.6=D !SG@=L=>>*?C_3=4U*?
MPRVF:;+>"QUB&]N"DD:;8T# _?89/S< >AZ4 1R?$[3(K?5'?2=9$^E-_IUM
M]F7? FW<)&.[;M(Y^]GKQ6EJ'C;3[.6SAMK:\U":ZLFOTCM53(@ 'SG>RCN
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M& #S1NT;.!P-Q4C=CWS6S:6EO8VL=K:01P01C"1QKA5'TJ:B@ HHHH ****
M"BBB@ K*N/#.BW>OP:[<:;!)JENGEQ7+#+(.>G;/)YZC-:M% !1110 4444
M%%%% %<65L+\WPA47+1^4T@X++G(!]<'.,],G'4U8HHH **** "BBB@ JLEA
M:QZA+?K OVN5!&TQY;:.B@GH,\X'?FK-% !1110 4444 %%%% !1110 4444
M %%%% %+5='T[7+!['5+.&[MG()CE7(R.A'H?<<U5T?POHN@R-)IUBL4K+M,
MC.TCX] S$D#IQ[5KT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445@7FOWS:Q/IFC:4M]+:H
MK7,LUSY$<9895 =K%F(YQC !'/- &_169H>LKK-I*[6TMK<V\S6]S;2D%HI
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M11DH-YDEP P/OG-=#XYDT*P^+.BWVL644]C_ &5<23XM#.&QT9E53G SR>E
M'KC.J+N9@%]2>*6O-_A=IHNM&UN[$2?\(UJUTTFFV$C+(L<)R&!4$A03_!VQ
MT%;'@G597U'Q#X<FD>7^Q+M8X97.6,$B[D4D]2O*Y[@#/.: .PJ-YXHY(XWE
M17D)"*S %B!DX'?BN3\1^-_[*U:XTNQAMIKNVM1<RBXD= =V=B+M5LL=IZX
MXZYXY[4-2BU[Q;\--;%B]I-=/=;HYDQ(F(3E"<9P#G^?>@#U&BO//^%G>;<V
MDUG8)=:=<7WV3]T[F=5W%/.*[-NW<.F[."#[#1B\8:I?[;W2=$6]TK^TOL#.
MDQ\[:&V/,%VXV!L\9S@9XH [*BO,[7QCXCM;SQU>7=G97$&BX*0)=.@55CWX
M&4.2022>.<#&.1?M?'FK/IVGSWGA^*VEU>2WCTN,W@82^8A=F?"Y0*!GH<Y
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M\_+Q@$= <<]: ._HKD?#/C*76O$NI:'<P68GLH(YS-97/G1G=D%#E1AE(_\
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M'%G]T5Y)!)R2>N ,<"NFT#Q&-8O=4TVYMA::GIDJQW,"R>8N'7<CJV!E6'J
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M6W6[TFQN%MAB 2VZ.(AQ]W(^7H.GI35\/:*CW3IH^GJUVI6Y86R S ]0_'S
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M D#]!6V/#.@B9YAHFF^:\?E._P!DCRR8QM)QR, #'I5NQT^RTRV%MI]G;VD
M)(BMXEC4$]3@ "@#C?%6E?V#KTWCFTUB"PE6S^R745S;&=)USE JAU/F9P
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M(B9(E!C#1<A?0$YZ5Z56?9Z%I&G74ES8Z58VMQ)]^6"W1';ZD#)K0H ****
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MVY&)!4\[<KP0.1Z\4 >E45YQIGBW6WUW1H)+VRNK"\T?^U+ITMCNBQC*J5?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5^;^X<6ZAD<LK$+ST)1>N>A]:[^B@#+UC14UWPU=Z->S-MNK<P22QC:<D8W
M<XYYQ7/Z/X"GTS7M-U>?Q#=7<]E8FPVM!&BO%D$+P.,8'/)/K7:44 <]XA\,
M-KVIZ/>B_:V.EW'VF-5B#;VQC!)/3!/2HM3\)2:CXL@UX:F\+PVDEHL*Q C8
M_4[LYSG!'TKIJ1F5%+,0% R23P!0!QX\#32WL5]>ZU+=7MM92V5M.UNBLJR
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MA<1&,LR=2N>J\\&@#0HHHH ***SM8UJTT2""2Z\QFN)EMX(HDW/+(V2%4>N
M3S@<4 :-%<B/B-HSVOF16^IRSJDLDEHMFWG1)&P5V93V!('7GMG!KIK&\AU'
M3[:^MF9H+B)98RRE2589&0>1P: +%%%,CECF4M'(K@,5)4YP0<$?4$8H ?11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.!P>_86GP^TJSNKZ\6]U66\O;46LUS->-([)^/&?PX[8I+7X>Z79G0_*N]0
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MTV=Q.=N1D@' XXH Q-7U&\\3S^.K(:C<V5MHUKY$4-OM'F,T3.SOD$D'[H'
MP#W/'2_#Q@OPU\.MR0--A/'^X*9J7P_TC5-2FU"2?4(+JYMQ;7;VMR8OM2 8
M'F!< G'T_+BMK1-&M/#^C6VE6 E%K;)LC$LA=@/J?Y=!VH \RD\4:Y-\+_\
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MVT;2RR$$[549)XYZ4 6**HZ-K%AK^DV^J:9/Y]G< M%)M*[@"0>" 1R#5Z@
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M[+=W%LT,201%;: 'OLR68^I+=L#'.>%3Q!>I\.)?!W]G79A>]%UY_P!F.X#
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MRC8+ @Y^@H ]!BA\6S0I)_:VC)O4-M?290PSV(^T=:?]E\6_]!C1/_!5+_\
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MOIBZ=\7_  HPU&\O?-TVZR]S.9,D!<LN>F<]!QP,"@#TZBBB@ HHHH ****
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M_<M\Y&X%CG:HQDGOQ6O;7E[-XGNH/MFF2:<MLCQPQ.3<JY/+,,XV$=* *_\
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M@X/(X-><>-+^TA^,?@ 274*&+[:) T@&S=$ N?3)Z>M>F]!@4THA.2BD^I%
M'G'C5M-N/BSX#M;YK9U5;XM%*01DQKLR#ZLO&>I%<1!?QV?AN\N+6>1=(L/&
M4\MW]@5)##;G/EN$(9=@;!'!' QR*]_*J3D@9]<4!5 ("@ ]>* .(^'W]A7-
MUK6JZ#J&H:C%?2QO/=W$8CC>4 @[%"(,@8W$#G([YK@?B)J5G+?>/[%6BLKL
M6EL'20&2:]"KN!C!.$10>< GN2*]U5510JJ%4= !@"FM%&Y):-22-I)'4>GT
MH \='B/0;'Q/J\7BR0MI.MZ3:Q:?<>6\B21!"LD:E02"78GCV/I6@DVG:?\
M$_PK+/:G3[>?0#!;0W(RX?>FR,]RX&/>O4RB-MW*IVG(R.AI2H)!(!(Z'TH
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M6JVTGG-9G$RIM.64]B!SGVK#M_&FFZ8NB:-;V6L7LUUIJ7%I^[5WE147AF+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5'-;P7*JL\,<JJP=0ZA@&'0C/<>M2
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9EUKUE::S!I+><][-"
MTZQQ1,W[L,%+$C@#+#\Z -.BLF[\2Z38W\=G/>1+(WF;VW#9#L4.?,;.$^4@
MC/6I-3U[3])5/M,X,CM&%BC^:0AY%C5MHYV[F )H TJ*R[_Q!I^GZ1)JKRM-
M81H\CSVR^:JJN=Q.W/ P?RK0MYX[JVBN(CF.5 Z'&,@C(H DHHILDB11M)(P
M5%!9F8X  ZDT .HK/TG7-/US18M7TV?[192J621$;+ $@_+C.<@C&,U6\/\
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MES-+@87GH-HZ   >E1W7@33+N/2M]YJBW&F;Q!=I>,)BK\.K/U(.!QQC'&*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)#N1B K<L2-H.2>YXZ5-8>+/$[>./'VFVCI>RZ=9O)8Q&WC#LXQM!*J"^,X
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M+=^.R=5;2'T1HET^T6&+]\IEV[SO4ELK@\$#YA7 ?;/&7G>&9/\ A$]6SX>
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M6FZW8>%[R]_LNU,32QAREPKHV!D*0NTNWKGVH C#RW_[5(BU3YEMD(LT;[H
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MKBW21[9\YA)&2IR >.G04 :-%%% !1110 4444 %%%% !1110 4444 %%%%
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M5/\ V1XA_P"AH/\ X 1_XUYW(7T#Q3\4M6TXW!O+&SM9X0;B1EWM Y+,I;#
M'D!@0N.,5N^%K:\&N:/JL/B&VDL+RU:-[9;Z6Y-VVW<) 'X5A@Y(QZ4 =/\
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MO$?@JYAO-1NK74Q?>9<7-VY;4-L996,!9EC4'&W!SCJ!0!Z?_9'B'_H:#_X
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M<W<FW=YJIN'S9#;1]X<]>>:XG31+IO[/6DZA97M];W+74>YH[N0#!NBI &[
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M0<.H/3.:ZV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *S=;T#3/$=C]BU:W-S:D@M"9756(.1D*1G! /-:
M5<G\0/%<OA+1[*XB\F,WE]%9FYN%+16RODF1@""0 #QD?6@"]'X-T..XMY_L
MTTDELX>'S;N:0(PZ$!G(R.WI4#> ?#+:=<Z>VG%K2YG^TSPFYE*R2_WV^;D]
M#GO@>@IMOJNH:;+->:MJ5A<Z"+/[3'?00E""",@X9@P(((QUY]*=H?CK0M;T
MFPOEO[: WTGE0PRS*'+D_*F/[Q&#CKS0!?B\-:3#K#:LMLYOFA%NTSSR.6C
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M$&F7VZ9D-Y:X2%CN("+R<D=/4XK:T[5+#5[3[5IUW#=0;BA>)@P##J#Z$>E
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M07LBO+:R,LDDZ[<M&G.<@]3CM5V3QOX6A($GB'31F8P?\?*X\P8RO7MD?G0
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MX9%GW--NQ]W9N;?G!SCJ:?J3VKS?%O"J9+BWB6 [.92(=I"_WL/QQWQ7M-%
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M@\=^G>LNQ\2Z+XB&JZQ8:1=6[?V8\5W?74+0E2/N0@'[Q^9B2.F .<BO0J*
M/#X+F*/P%\,$<E9+;5H&G4J<Q*H<,6'\(!89)]:34VM9-(^*RHBM-<SIY.$Y
MF&T ;>/F^8'IWKW&B@#R6XG^U^-O"RV<X69_#\\*S#.(Y71=@)['(/'M2^!M
M9L[FQ\.:%<^&[[_A(M%!B<30,BVWRE7E\S[IW#MW)'UKUFB@#P#2=12>X\&W
M'D7-FMMK,_G:9%9R&.R+>9@%BI9W;J?FQSPHKT#P'/')XT\<;6SYE_')&<<.
MHC"D@]QD$<5W]% 'G7C[;%KUO>V.MSZ/K5M8OY,KV_FVURC-S"XP>24&._/
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M >>:9/;M\;M0>!D,,NB0HCI]UF#EL ]"=I!QZ5Z'110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8^OZ]_
M8:V*)937ES?7*VT$49 &X@DEF/"@ &MBN0\=:3K>J'2#I<<=W:071>^L);CR
M5N8]N &;!R >2I!!]#0!RWCGQ+#XG^%&KWT$,]I/8:DEI(GF_=D2>-6P5.&4
MAOUKH%\8W\?Q"U?2[RR\C2=.L%N'F\Q3A26)E;OC"XVC)[GVYB;P+XF/@7Q+
MH,6GV"2:AK!O;?R[G"*AD1\8VC &S ^O08K>U/PGJ^I>+=7N#! NFZWHZV,\
MC3XDMFPP.% (?[P[@4 6K'XE6-YJ]CIPLG,FHP2360BN(I&DV+N*. W[MBO(
MR<=LUFQ_%U)/"\GB-?"^K?V4D!E%QF,*2)/+V\MGJ1^OIFK7A73_ !MIZVUG
MJUGHPMM/B*"XM3F6\PI51R $[$GVZ<UDIX)\0K\"CX--K;_VG@Q B<>7M\[S
M-V<>G&,=: .IM_',9UZ\TJ_TF]L9(-/;4HVD*OYL"MM)PI)#9_A/-5;'X@O>
MW4%F-"N(KN\TTZE9Q/.G[Q.,*_\ <;D'G/?OQ5'5O#_B:^\82ZQ8Q1V3/X>D
MTZ.4S@M%<,V\-@?P@X&>O?%9_AWP?XAL_$FAZG<Z386WDZ?)9WLBWADDED;;
MF9CMRS-@\9/N: -'PY\1)+CP9I.J:M;JE[J<LBVR--'&D@#.2=Q/RJJC&3R<
M#J371^%/%EIXKM;Q[>-HIK*Y:VGC+JX##NK+PRD'(-<#8^!O%UAX5\.I;P:6
M-6\.S2B&.68R17<4F[?N^4;#@C'7H>E>B>&HM96QDFUR&QMKF5LK;67*1*!W
M8_>8G))Z= /4@%?6/%1T[6UT:SL&O=0-HUYY7G+%N0-MPN[[S$@\=NYK&A\9
M:O/\07TA=&E-E'I2W@1)8_,<NP 8[B,8P5QGOD^QX\\+W/B::2%M#M+V(6H%
MG>?:?)GM;C+9(;&2OW#UZ@\'M#9>&_$FD>+K'5=MOJ:_V##IUW,]P4<RHQ9G
M *G=N]R.O- !8?%.._\ #[ZXOAO5ET_R=\4NU2)9/-$0C&#UR0<GC@^E-USX
MC7=IH?BG[+I#)JVAI&94>=&C42J2KAA][&.5QG/'N*5EX2\5V'P<M?#EJT<&
MK6TOSB*Y*K/%YI=E$@&5RK8_ ^M56\!:]/%XTABTO3=.@URQMTMXH;C*Q21J
M1MX09R3DMQ^/6@#J)?'*V-K8V]Q:K_:DMF+J2":[BB 3H#N)P2Q!P!Z'.,4M
ME\1-/U:V\/MI5M+<7&N+*]O#(PCV"('S-YYQ@C'&<GVYK#NO#WC&VU73O$.G
M:?I,MX=/6PO=.N9RR[48E'63:.>3D8_/K4/B)=7.O^&+-!IL^O6D-S>R)!<_
M9#&KD(%C9D8%.2""N6V \<T :;_%2VCT2+5Y-#U"*T-__9\TDCQ;89<[23AC
M\H(QD@=O6NPM]3-QK5YIZV[;+5(V:?<"I9LG9CKD  GV8>M>?PS:!_PAFK^%
M?$4-CHD91]V[45N/.=P7+JY"EI <,5QD97L175^ ](N]'\(6,6I2O-J4T:S7
M<C_>+E0 #_NJ%7_@- &;\6-6O](\!W<E@D@>9XX6GCE"&(-(JGWR02..F<TS
M37L?#^NW&GZ'H,JZI>6ZW=W8K<JL,"*2BMU*AF]%'.,G&*M_$K0]4\2>$)=)
MTF".2XFFB?=+*$5 CJ_OG.,5!<:-K5CXY'BG3K**X2]L5M+RRDN CQLK95U;
M!!'8CCUH CF^)]BFC:5J,.E:A/\ ;[[^SC @0207 )!C8%NN0<8X]Q76:/?S
MZGI4%Y<Z?/I\T@.^VGQOC()'...<9^AKSZX\#:S;V.BBVA@GNH_$1UR^ FVH
MNYF)C0D9. P ) S@GC->GT <9HZ"Y^)WBGS]T@M8K$P!F)$99)-VT=!G S]*
MPK:3Q,/'Q60W1<F/<,1>:++SY,%AGR\9SDCY]F.^:Z#0/^2F^,O^N.G_ /H$
ME=A0!YKXSD\1)XJM/L1F,?G'^SU(C&9OLTN_R_4;<_ZWC?MQQFM'QZCQ>%=/
MO3YL=\EY8H920L@#3H&!V\<Y(('')KN:X_XE_P#(JP?]A.Q_]*(Z .PKD?B'
MXDU'PSH,%SIMH)I)[J*W:0NH\H,X&<'J3T'8=3TYN:5K6IW?BW5]*NK.U6SM
M51[>X@F+DY_AD'\+=\>GX&H/B#H5_P"(?#'V73%B>[BNH+E$E?8K['#$9P<<
M"@#E9=7N]*^+.K7$6E7MU.^@Q3-9I,IV$2'=EF;:. !QU["NC7XAZ9/I.C7E
ML@,NK0M/##<3)#L1<;B[,<#!('&22?3)%&/1O$3^.-2UV?3;98KK1Q9*D=V&
M(E!+=2H^7G&?;.*P;+P1XLT71O#-YIUOITNK:3;2V5S9W,F8KB)V# JP'!!
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M!VD1_=D5P.O7(_GVW;WP_P")CXD\+:UFSOKFR2ZCO0TIA5?.QC9\I)5>@[D
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MP1D=><5S^L> -7U4ZGKT,MK;:]<7UK>VUM(?,A3[.A14<XY+!F)P,#( Z9H
MEUKQ?9^)?!WC33T1H+[2[!Y'\JX#HP,;,C)(AY&1R/;FM71?$?V71?#6CVEJ
M]]JEQI$5R8A($"1*B N['IEB , Y.?2JLVF^+=7\&Z[;:EI^EVMY?6;VMO:6
M;_*"RL"[N1[C@= .Y/%>R\,:]H^J>']>M;2">ZMM&72;^R-P%RJD%7C;&#\P
MZ''!H NS_$RS@\/KJQTR[VQ7_P#9U]$S*&LYMP7Y^<;<D<CU%: \:6Z^(M9T
M:XM'MYM,M/MIDDD7;+%_>7'('KD<51M? WVGPIXDT_4S&+C7[B>ZE5"66!G
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MA@,<J"H_PK TCPCXFL-4\+ZOJ6GZ<D^DR7+:C>R7^Z2Y$D97S78KG '09/\
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M%F23Y&W'Y\;EQQQG.<6GT[7[ZZTKQ7X9TO30\=F^E7&E7<H:,1QRL%:*0#!
M(.#QD8H TQ\5;*XL]!GT_1M1O#K0F%ND>P$21@[HSENN1UZ8.<UVVGW+WVF6
MUU+:RVLD\2NT$O#Q$C)4X[CI7$W7A_Q'<>(O!^I3P64C:9)<RWGD/L1?.4J%
MC!&6VCN<9_' [^@#Q[PKXM?PIIOB22;1]1N]+M?$%VMQ>(ZL+>/>JCAFWO@=
M< X%=9K?Q*TO23>-#&MY'8Q)+<E;F.-L,H8!%8@N=I#8&.H&<\#)C\(>($TC
MQ/X<-O:_9-;U&XN5U 3Y\J*8C(,>,EP <#.,]Z#X5\4^&O$5Y)X;MM)O]+U
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MM^_.53^ZG'ZUP&G>,O&$^@^#=9>_L'_MN[^Q26S6F%7<7Q)N#9R-O08!Z>]
M'K]%>8GQQK.BV7BV"_EAU"ZTF\MK:UF6$1[S.%QN4''REL]1G'4=:FO-:\:Z
M99>(KB6%ULK72GO+6[OHH-ZSH"6C*1.05(Y!/3OGN >D45YC+XC\6Z9X(LM<
MO[VSF&IO8A9([;:+".7'F.V3ANJX)P 3TQQ1-XVUG1SXRGEN(-1T_1C!'9RF
M$!II9@O#.I"_(6 ( '7J* /3JS=6\/:-KRQKJVEV=\(SE/M$*OM^F1Q7'/JO
MC:Q.K/)#(+"+2Y+B*[OH8 T=PF25"12'<I7IGD'N>]'2?%'B=[[P.][J%K+!
MXCM9#+"EJ%\EUA#A@V>23U' ]* .[_X1G0#%9PC1M/\ +L7WVR"W3$#'NHQP
M>AX]JUJ\_P#A6VHS6&N37^I/>-_:]S$2\8!)5@N[(]@..@QQ4NL^(-3T?Q[_
M &;>:E';:1?Z;--93F!28IX\%@Q_B 7+8_"@#NZP)?&OAZ#3=2U"7456UTVY
M:TNY#$_[N5<97&,GJ.1D5R_@[QAJWB*TTFRN9Q!K<=W<)JL)A V1Q=1MZC)>
M$ _[3=<5C:]K6H:S\)?'_P#:3PO+8ZE<62-#%Y8*1M& <9//)ZDT >FMX@TM
M-9M=(-V/M]U$9H8=K?,@&2<XP./4UIUYY?\ _)4_!'_8-N__ $!*U_'>MZCH
M-OHD^GR(HN=6M[.=70,#'(2#CT/ P?>@#>_L?3QJ;ZD+2-;V0*'F7AG"C"Y]
M<9.,^M7J\WUGQ;KEE>^/8+:Y@ T6R@NK0R0!B"Z,S X(STP/3WJ!?%7B71+S
MPQ?ZQ?6EYI>MQ'S8(;;RVMF\KS 5;)+]#G./8>@!WVJZ[INB-9KJ-T(#>3K;
M6X*LV^1C@+P#C\>*??:/I^IO&U]:1W!C9602<@%3D''3(/->3:YJ.J^(O#/@
MWQ%=7P6WO?$%I(M@D2[8D,C!/G^\6 ')S@DG@5I>*?&VNZ/?:G/!>PLEGJ-O
M;QVD, EC\EBH8S28^1R6.%R",=#UH ]3543(0*N3N( QR>].KRL:QJ.B>//'
MNIW5^]U;:586\RVQC4!DV2NL8(^[ACUY)SS6UH&I^,+C7=,:ZM)I=(N[9FNI
M9T@C$$FW<ICV.S,IZ8;)'!S0!W1('4XK.L-=TW5-0O["SNA+=:>RI=1A6'EE
M@2!DC!R >F:Y#XC-J0USP?%::D]M#/JJQO&(PP9@K,&.>N,=.G?TKG+NYUO3
MO%/Q0U'2;ZWMGL8+2Y=I(/,,I2UW;0,@*#@\\]J /8Z*\[E\7ZQJ]Y8:=ID-
MQ'/)HT.I3/:11.0\O"KB5@-H().,DY'([];X6N=9N_#5E-X@LTM-5*D7,*,&
M4,&(R""1R #C/&<4 ,O/%V@:?<SV]UJ<,;VV///)6'/(WL!A?Q(J[=ZOIUAI
MZW]W>0P6K[=LLC8#;ON@>I/8#DUY=>+K_P /+K7+^"QB\1>$-2NY[J[CB(\^
MV9CB3/4,HP0?ISMYJQ:WT&L?%OPLD3M+H\7A_P"V:<).\C';O(_O!./:@#T.
MP\0:5J5VUI:WBM=*GF&!U:.3;TW!6 )&>_2HD\5:')<WMLFHQ-/8J7NHP#NA
M4=V&.*Y+XL/)9KX4U*S)34(M=@AB=?O%) P=/<, ,CVJEXDO8/!'Q<M=>N2(
M],UO3Y+>[8]!+"-RD^Y4!1^- '?6OB31[[1Y-7M;^*;3H@2]RF2@ ZG/H.Y[
M5>M+N"_M(KNUE66WF4/'(O1E/0CVKQ;P?<7ECH.I?#R^58=1N+R-(XD.-EM<
MIYLNW_<02C/8D5ZGXLOKK1?"%_=Z:]G!<01 0M=.$B3D#)/L#P.YP.] &Y17
MD[_$74]''BLSR/?0Z;:VLUG)=6OV=V>9MGS* #LW$'H#C\ZW]9U;Q#X-L=7U
M:_O+?4]-M]/\V'=&(Y?M.[&W"C'EG(.>2* .YHKBY=0\0>'8;G6-3O[;4-'B
MTI[IP(UCD%PHW;4VCE"N>N2,=:S6\2:_I=EX1UJ[O8;NUURXM[>YM%@5!"9U
MRAC8<X4\'<3D>E 'HU9U]KNFZ=J=AIUW=".[OV*6T>UCYA R>0,#@=\5Y_IG
MBKQ1L\2ZU?ZA92:3X?O[R"6VCM=LEPL<8*@-D[?F*^O4Y/ JK?-JUYK_ ,-M
M5U'4EG^VSM.;=(51(F>$L A'S$ ''S$YZT >EV&MZ?J=]?V5G<>;<:?((KE-
MC#RV(R!DC!X],UH5Y5JWC+Q%9:!X[NH;FS%SHMXD<#?9>"A5<C&[K\W4D].E
M;.GZ[K]M\04T6_NK>]M[K1VU"..* 1&*0.%V Y.00>IH [RLZPUW3=3U&_T^
MSNA+=:>RK=1A6'EE@2O)&#D ],UYSI/C+Q'J8\*S0W]L;G6+F>*]L6M@PM%0
ML> "KC;MP=Q/)_"IHO[77QE\3I-!D1=3C2PD@#H'5V%N3M(]^GUQ0!ZC39(X
MYHGBE17C=2K(PR&!Z@CN*XOPAXKG\61:)/:W7R?8#/J2>6N1+NV*G^S\RRGZ
M(/6NVH JZ=IEAI%FMGIMG!:6RDE8H(PB@GJ<"K5%% !1110 4444 %%%% &/
MJ/A/P[J]Z+S4=#TZ[N0,>;/;(['TR2.:UD1(HUCC5410 JJ,  =@*=10 444
M4 %%%% !1110!GV>A:78:E=:C:644-Y=?Z^91\TO^\>]))H6ES:Q'J\EE$VH
MQKM2Y(^=5] ?3VK1HH **** "BBB@ HHHH **** "FR(LL;1N,JP*D>H-.HH
M H:5HNFZ';-;:7916D#,7,<0P"QZG%7Z** "BBB@ HHHH **** "L:^\(^'-
M3O\ [=?:#IMS=]YIK9&8_4D<_C6S10 BJ%4*H 4#  Z"EHHH **** "BBB@
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MXBU&*QOI9Y9X-D3;?-8LZQL4RH^8^OK5FY\%:3+::5%;++93Z0@2PNH&'FP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:QHWF7*A9I9B)G=0,*I9XR=HZ 9P*=X=\ ?$[1-<LKO^T='6WA?:43#>5$S
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M<<1_,V1U;)H ZCP4UQX\^&6H7$&NZG#K\I:-V2^F46LR#"!1O.%88+>I8^@
MA^'?B#4=;\/)=7SZH;WPU#<I>(]S)BZGR2@8;OGP V0>A*]N*YO2/AM\6?#$
M]U=Z-J>F0SW _?"-U/FG.<D/'C.<\^Y]:U=,\'_&?3A<O:Z_HUN;J9KF==B$
MO*P&2?W)&3@>U %KX:_VSXOTS3/$LWBJ[5UNKF#5+9YWV3!L;%10P$9 (QM
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MCLK?=###;/W?R9'&5P:A;X,_$1]&CTAKS2#I\4QN$M_/?:LA&"WW.N/YGU-
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MNK?46>.:&0HZG;",Y'XUT L?$$'PJG\82^+M8ENIM$1UM_/*I&^5(=2".=H
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M5V7@VX@O/CQXUNK:ZAE@-M;HI20$.=B=,=<;3G'2@#M_^$%\+_\ 0%M?R/\
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M(_XT?\(+X7_Z MK^1_QKH:* .>_X07PO_P! 6U_(_P"-'_""^%_^@+:_D?\
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M\/X8K?5_&<4,:11KK1"HBA0/W,?0"@#N**YGQQKE[X?T6"\M(I#&;I([J:.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3ZCJ$U[ ;;[3<JI,41ZJBCC)P,L<DX%7(/!<L6O:'JKZJSR:3:&T1/( $J$
M$MSUP!T_*NLHH \_;X8 ^"KKPHNO70TZ:<2H&@C)A42F7:IP"26QDG/ P *V
M7\*7$OC2R\2RZKNGMK4VGDBW 1T)RQ^]D$GGVXX-=/6!:>-O#-_K;:-:ZW9R
MZBK%?(63DL.H!Z$CG@>E &--\-;6]MM>@O\ 49Y5U>Y6\+Q((WMYEQM9#D],
M#K5BR\%7]MITJ3^*]4NM09H_+O9=N8E1P^U4Z8;&&SG-=1?7MMIMC/>WDRPV
MT"&261NBJ.I-1)JMF^GO?>8R6RJ6+R1,G &XD @$\<\"@#.T#PRFBZCJNI27
M1N;_ %-XVN)!$(U^1=JX4=.I)))SFF6GAAK7QK?>)/M[.UW;I;O;^4 H53E2
M#G.>36S:WMM>645Y;S*]O+&LB/TRK $'GID$=:CL]5LM0MY9[2;S4BDDB?:I
MR&C8JXQC)P01QU[4 <E8?#:/3-6DDL]?U2+1I+@W+:0KCRMY;<1GJ$S_  CK
MW-<_X;T:YUS6O'-JNJ7-E97VH.)8UMQF:%D"EHW8<9Y&>>V,=:]+T_5['5'N
M4LY][VSB.9&1D:-B 0"& (X(/XU>H YBR\&Q:?XNAURUN_*B@TY=,CLUB&Q8
M5.Y1G.<@]_3CWK-'PVCAUN[N;/7]4M-+OIVN+O2XG BD=N6P>JJW<#KZUW-%
M ')7W@F35+B-;_6)KBPBU :A';M"NZ-PY<*LG4+D].N.,@<53@^&T=IK-S/9
MZ_JEOI-U.;BXTF-P(G<G+ 'JJD]0.O3-=19:[INHZK?Z9:70DO-/V"ZBV,/+
MWYV\D8.<'IFG7FM6%A?065Q,PNIT9XH4C9V95(!.%!X&1S[T <Q<?#Y[A/%"
M-K#A?$.WSP+<?NL#;\G/]WCG/K5A/!!CU?1=3CUBXBN-.LOL#^7$F+B$$'!S
MG:?E&2.?3%=%<:I96M[;6<]PJ7%R76),'YBJ[FYZ#"\\TNH:G9Z5;?:+V=8H
MMZ)N()Y=PB\#GEF _&@#AK#X6'3[;2+6+Q)>_9M(O&N;./R(OW8;=E2<98Y8
M\G/TK2_X0(QP^)K>WUJXCM=>>626 PHPB>50LC XR3@8'.!GH:Z74=6LM*M&
MN[V5H[= S/*(V=4 Y)8J#@#U-6H98YX8YHF#1R*&5AW!&0: .5U#P':ZM\/[
M;PG?7<DD=M'%'%=*@5U\O&T@=,X&"?<U9\2>#+#Q#H=IIJS3Z>U@Z26-Q:-M
M>W9!A=OMCC%7+GQ5HEI>36DE\K3P8\Y(D:3RO]_:#M_'%1Q^,?#\\FFI#JD,
MIU-WCLS$"ZS,N=V"!CC!Z^E #O#F@RZ);2_:]6N]5O9B/-NKH@$@9VJJCA0,
MGCU)KG-9^&:ZM=>(6CUV[M;7750W-LD2,-Z !6#$;L<9P"/KCBN]HH X6\^'
M#RZNFK6'B74].OI($M[V6W"#[4J< D8PK < XX _/1/@F&#Q#I6K:=J%Q9&P
ML1I_DJJN)8 P8*2P)'(Y(Y/J.M=36?K.MZ=X?T\W^J7'V>V#K&7V,WS,< 84
M$]30!D^'?"":)::S:W%X;^#5KJ6ZG22(* THPX&#]T\<4[P]X/MO#'@__A']
M.N& VN#<2(&8LV?F([X& /8"NDHR,XSSZ4 <+#\-Q;Z%X?TZ'6[F*;0YVEM;
MI84+;6!!4J<@_>/./3BK,W@"WO=5\076H7TES;ZW;);7%OY87:J#"%6'\0SG
M..O:NQHH XG2_ %U8V-Q;W/BS5[UC;M;VDDS &U4C&X8^\X'&X^_J:U-*\+&
MR\1SZ_>W[7FHRVJV>\0K$/+#;N0O5LXY]N *Z*B@#G=8\+?;]?M-?L+^33]5
MMX6M_-6,2)+"QSL=3U /(P1@UFZK\/+?4O!]YX>74)8DO[DW5]=>6K23REPY
M/8+RJ]!T %=I6=:Z[IM[K-YI%O=![^R57N(MC#8&SCDC!Z=C0!<MTECMHTGE
M$LJKAG5-H8^N,G%<O!X)ETC4;NX\.ZS/I=O>2F:>S\E)H?,/5D#<H3WP<>U;
M=_X@TG2[ZULK^_AMKB[8);I*=OFL3C"GH3DC\ZN75U!8VDUW=3)#;PH9))'.
M%10,DD^E '+>(_ B>(?#4VB2:K<(ES,)[JX9 \LK@J1Z*H&T# &, =*N3>'=
M3O+NS>^\0236]M,LYMDMDC65UY7<1S@-AL#'(%;&FZG9:Q9)>Z?<+<6TGW)4
M!VM[@]Q[U;H X_3O!-SIDWB"6+6=SZVYDFW6HQ&Q&,I\WH<<Y[?CKQ>';>7P
MFGA[5"NH6HMQ;.7CV[T P"0#P>!R._/%;-% &;X?T:'P]H%EI%O(\D-I$(D=
M\;B!ZX[UB:QX%CU*]U26WU.XL8-8C2+4H8D4^>%&W*D_<8J=I/.1[\UH77C'
M0;+5(].GOBMQ)<+:@B&1HQ,P!$9D"[ Q!'!.>:W: .;U#PC%)=Z??:1=MI=[
M86S6<4D<2R*8#CY&5NH!4$<\$=Z6#PA;6'@N3PUI]P\,4L4D4EQ(HDD<R9WN
M>@W'<3Z#TKHZ 00"#D'O0!S+^%KO_A"(?#4&N3VQB@2V6]AB42>4H"X] 2!@
MD?I46@^$M2TB^MIKOQ1?7]M;1E(;,PQ0Q+D8!(C S@= >!75UGZGK>G:,]DM
M_<>2;ZY2TMQL9M\K9VKP#C.#R>* ,OQ-X4;7]2T?4K?4YM/OM*DD>&6.-9 0
MZ[6!5N.G?M6=I7@.[T2.0:?XEO$+7LUX!)!&RDR9RK#C=USGCD#&.<]K10!Q
MUAX%DT>"./2]:EM\O<27"-;H\4[3,K-E. H&W  Z ]^:BM/AO::3%HSZ-J,]
ME?:7#);I<&-9!-&[%V5TX!&XDC&,5VU95[XDTC3[[[#<7B_:PF\P1(TKJO8E
M5!('N: ,#4/AOI^H:+]E-]=0ZA]N.I#4HL+*+D_Q\#&,8&WT ],TR]^'C:AX
M1O\ 1+S7KRYN-09#=W\R*TCJARJJO 4 CWZGUKJ=*UG3=;MY)],O(KJ*.0Q.
MT1R%< $J?<9'%7J .%U'X<OJ%_JMU_;]S!_:U@MG?)' A$NU"JL"V2O7D#KZ
MU9M_ 9MM1T*^CUN[%QI=G]B9O*C_ -(AR#M((PO0#(YQWSS78T @YP>G6@#A
MM'^&R:)J2_9=?U0:*D_VB+2"X\I'W;@,]=@;G;^>><U-0^%,5UI^K:3;:_?6
MFBZE.+F2P2*-E23>K':Q&X*2O0=_R/HE4M6U:QT/39M1U*X$%I"-TDA4M@?0
M F@"U#&T4$<;2O*R*%,CXW.1W. !D^P%<P_@#17/B8F,Y\0#%ST^3Y,?+Z'=
MEOK]!7303QW-O%<0MNBE0.C8QD$9!J2@#D=6\!P:AX&LO"EO?26EI;+"/-6,
M,[>600>> 2P!-+>>"I;C7[S6(-:GMIKZR6TNHT@1DDV@@-\V2/O'@'TYKK:*
M .'MOAX;6S\-6R:Q(4T"0R6Y,"YDR",-SZ$CC%=9JVE66N:5<Z9J,"SVERFR
M2-NX_H0>0>Q%7** .5T_PGJ=C:+IQ\57\NF(OEI&T48G"= OG 9Z<9P&]P>:
M9?\ @J2Z\4Z=KMKJIM)-.MVMK:%;<,@1A@@Y.3^G2NMHH Y6?PE>WD>JF]UZ
M6XFO[0V8=K=0MO$=VX(H(Y.1R<_='I45MX+N[30=%TF'6L1:3*DD,AM06?8,
M*K?-C&"1QCM77T4 8/B3PGIWB<:>]ZF+C3[J.ZMYT'S(RL"1_NMC!'T/856U
MGP?_ &CJESJ-CJ<^FSWMK]CO#%&K>;&"<$9^ZXR0&YX/3I73T4 <S<^"K(6>
MB1Z7,VGW&B K8SJH?:I7:RL#]X,.O0Y .:A7P#II\+W>C2SW$DEW<F]FOOE$
MIN2P;S1Q@$$# QC Q7644 8&B^&O[-U:]UB\OGO]4NT2)YVC$:I&GW451T&2
M2>3DTGAWPY<:'J&K74NH)<C4KDW4B"W\O8^U5X.X\84<'\ZZ"B@#,UG3;O45
MM&LM3EL)K:;S0Z('$GRLNUE/5?FS]0*YJ7X;6S:+]D@U*:WO1JW]LK=QQ)A;
MGU$?3;CC;7<44 <,?AI;W%MXCAOM9O[G^WEC%RQ6-2K(  PPO7(Z=,'&.]:U
MEX5(U"VU#5]0?4KNT@>"U8Q+$L2N '; ZLP !/H. ,G/1T4 >>P?"YK32M&L
M[;Q)>I)HURTUC*T$3>6ISE2N,-G/4YJ[IW@*[T@W36/B:]22?4GU$EX(V!=T
M*LK  ;@<@]L8&,5VM% '"/\ #2(6]G'#JCQ/!K!UIV%NN)+@]!M! 5,<8'YU
MJ^&/" \+7VI-9ZA(VG7DS3I8&,".W=CD[#U ]NGTKIJ* .-UAQ:_%'0[N;<E
MN--NHS*5.T,7BP">@)P?RKLJ** "L#QM-''X+UJ)F_>3V,\<2 $EV,;   =2
M:WZ* ,OPVC1^%M(1U*NME"&5A@@[!P:U*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K$\1>+M#\)Q02ZW??94N&*Q'RG?<1U^Z#CK6W1@'K0!4TS4[/6=,M]1L)O
M.M+A=\4FTKN'T(!'XUY9\35C\4RZK:1R7JOH< >R-O;RNKWO#G+(I&50*O)X
M,C>E>N2*S1.J/Y;%2%8#.T^N*R= T)M!TF6Q6_FNGDEEF-Q,B[R\C%B3@ 'D
MGM[4 4-$O;+X@_#RWGN%#P:G9F.X0?PL05<#Z,#CZ"N#\+:O=_\ "(W7P]NY
MB-;M+W^QP0<,;9LGS1[")9,?[J^M=[X-\&Q^#+.YL[;4[JZM9IFF$4ZH!&[?
M>V[0, ^G2IT\(:8GCB3Q8J'^T)+06I'&W&?O?[V %^@H A\7ZB-"\,"VL=T-
MQ<E+&S$,;.8RPQN"J"3L0,^ /X:XSX:36?ASQIKO@^T:X&G2JNHZ<+F.2-L$
M!9%^< GG'Y'WKO[K0GNO$UCK+:A,%LXW2.UV+Y?S@!FSC.< #.>.?4U0UKP8
MNL>*]+\0KJMU:76G*R0K"B%6#?>#9!)!'&.W:@#?O;"UU".-+N%9HXY%E5'Y
M7<O0D=#@\\]P#VKF=%TN"\\=ZCXIM$2.TDLH[&-T  NF5RS2^X'RJ#WVGM@F
MSJ?A&?4]/U:S;Q%JL4>HSB0['0F%,8,294X4]_\ ZYRW0O"$^D:C%=W'B35M
M12&(QQ6]PR+$F<<[449( P,],F@"CX74+\2_'04 #?8<#_KA7!@//\'/B%<7
M8S=OJ]TTK'J'5TV\^V!CTKU32O#/]E^)-6UH:C<32ZGY?GQ.B!!Y:[5VX&1Q
M[\UGW_P^L;^YOE-[=1:9J-RMU?:<FSRYY5QSG&X!MJ[@#SCMS0!T&DRRSZ%8
MS3$F62VC9R>I8J":\1\+Z#JWC3X(Z+X=M+".*W:Z=WU*:9<1JL[DE$&6+=1S
MCZ\U[O/$\EL\<,ODN1A7"@[?P/%8G@[PI#X,T&/1K6\GN;6)F:,SA=R[B21D
M 9Y- 'G5U>:WI>N_$[4](O;>V-B;>X;S(/-,I6#.WD@ $ \\GZ=]W7_%NL*E
MK+:WL5HDFAG4%BMX1/,\Y (#(0=L0'\1QSQFM:;X?0SGQ-OU>]QXA55NALC^
M0 ;1L^7CY>.<^O6H9/AM UY%<Q:YJ,+?V8-+N1&L7^D0C.,Y4[3S@E<'CM0!
MB7OCS5(]%\.ZE?SS:7INH:6)Y]2M;+STCN6VX5P0=J8)/J>F>*N3^*M>U6\G
MTW0VDFGL],M[AKFR2"1)II5)4GS'4>7\O\(R<]1CG4M/ $EEI,.G6_B/41;K
M8K8.C1PLKQC=C@I@$!B,_GFH+OX7Z>9=.GTG5M5T>YL[1++SK*8!IH5Z!\C!
M/O\ _6P =/HDNHWOAZTDUFU6TU&2$"YAC<$(_0X()_GQ7.:[X>T_4K_P]HVF
MVL,7]D7L-[(\:C_1HTR53/JYP,>@)/09ZNST^/3]+CL+6215CCV+([;WS_>)
M/WF)Y)/4UQUK\-[BWWH?&6OO!+,9IX]\2^<2<MN8(&YZ=>G'2@#5^(__ "3;
MQ'_V#YO_ $$TW7M D\0>%["&%T26W"7"90%BRQG 1B?W9)(&[GC/KFIO']O-
M=_#[7[>VADFFDL952.-2S,2IP !R36KH]PEQI5LR"0;8U0B2-D(( SPP!H Y
MC2?!<\/@R_TFZFM?/U%5>0R6BR>62B@J^"!+M*D!N. .N*=X,\)WFB7MS>WD
MJEF\V!$D59)=GG,RMYH[,I#%<?>)/'2NSI'8(C.V<*,G S^E '(>$O\ D</&
M_P#V$8?_ $FCJ#QEKNJ:?K$5I97R6T)L)K@+!")[B652 HV8.V,<DL<#MD5/
MX/21O$GB^[,$\<%S?Q-"\L3)Y@$$:DC<!D9!'X5/K/@F'5?$RZY%JE[93M9&
MPN$MPA$T);=M.Y3MY/48/H10!RMCXP\3:Q<>!XH;RSMAKUA/)<'[+N*/&@.X
M9;OG@<8[YZ4FG>/-:FTVWTR>X@;5KCQ!-HZW@A 41QG+2;,XW8X Z9(/;G<T
MKX;Q:5<^'YH]<OI#H<<D=LKI'M*R## X7., =Z9_PJZP;2[FT?5+[SI-3.JP
M7:;%EM[@G)9"%Q@^A!H J^"X+FV^*?CF*[O&NY!'8$3,BH2/+? (4 <=.!6K
MJ/\ R5O0O^P3>?\ H<-6= \'#1-?U#6Y=9O[^]OXHX[@SB-5;8,*<(@P1ST]
M>_6JNL;[?XG:)>O!<&U73;J)I8X7=5=GB(!*@X)P?RH SO$O@*\U?Q%+=6\\
M*0WQQ.WD+MC"Q;5\Q"?WVX_*>F%X]ZO>,/"5WJ\EC>63QB>T$<82)%B<KYJ%
MCYASA54%@F/O 'G&#VE% '%ZYI)T/X/ZUIIDAD,&E72[X8!"K91SG:"<'GGU
M.3WK5%S/9?#_ .U6R[KB#2_,B7&<LL60/S%1^/')\#:Y;)%-+/<V$\4,<432
M,[F,@#"@]2:U=&C:/0M/CD0JRVT:LK#!!VC((H Y7X11QCX9:3<*V^:Z$D]Q
M*3EI)6D;<S'N>WX5D^,=*&E:]X(L]'$4);5[F5/-7<B-(KNQP,< L2!D=AD5
MT-EX'_L6>9= UR_TNPFD,KV,:121(QZF/S$8IGT''M4E[X'MKN]T:YCU"[A;
M2YVN4QM<S2M]YI"P))()'&/;&!@ Y>+QSK=AINL6=V\=[J,&NQZ1:SQPJFX2
M;2&*%@NX MCD G&31K7B+QOH?ASQ->S0F&"TBCFL+J]BA,C9(#HR1.5X)R&Q
M^!K<F^&NFWEIKEM>WUY/'J]R+MR-B-!,,8:,@<$8'7-,?X;QW/AV^TF_\0ZO
M?/>HL4MU<R*[K&#G8@(PH)Y)QD^O2@"DNK>+&\;6^@'5K()J&EF^$HL^;4A@
MI"#=\^<]6^N.U9Y\<:])\*M/UXRVOVXZ@MI.3!D2+]H,>0,X4X&>_MBNM3P:
M4\1V6N?VQ=M=6EB;% 4CVLAY)/R]<@'\*S3\,[;_ (0^/PT-9OA:)=_:Q)MC
MW[M^_&=N,;N>E %+6_%]_IOC673;_4)-'MS<6ZZ?)+:!K:\0[3(&E(.U_O+U
M &!UK,M;_7K"_P#B7J":P)9M,0/$)K<,N%@,B@ $8 Y'XY.377:GX'&L+=6]
M]K5[+I]U/'<36A2/;N380%;;N4$H"0#W.,9IEWX!@N;[Q#/'JU];Q:[%Y=U;
MH(RF?+\LL,J3G;GOC)SZ8 .7O=<\>:=X @\6OJ5G<Q/#:W4MK#: ,D#+F7!)
MY;E6ST'S<8Q7<Z)JS:WJ=[=VEVLVD(D20808>0J'9@W<;60?7=^&;?S?\(CX
M:TS0(]'U7Q!')";)/(A1@%"[5$IR JD<;L=CFM?PIH$/A?PMI^C0!0+:(*Y7
MHSGEC^+$F@#"\8ZYJFGZQ;V=G?):PM933[8(1/<2RK@*/+P<1CDEC@=LBL*R
M\8^)M6;P$L-W9V_]OVMR;D_9MVUXX]VX?-^./4=QQ75ZQX*BU7Q/'KL6J7MC
M<?8S8SK;A")H"V[:=RG;SW&#Z8K/TSX;1:7+X=>/6[Z3^P1(+972/!$@VL#A
M>F./7OF@##L_'FM+I,EA<3P2ZL_B9]!AN_)VJ%!!,I0'&0,X'3./>KWA:WNK
M7XO^*8[N]:\?[!:%97C5&V_-P0H ]>U7&^&&GRZ9J-G/J5Z[W>IG5H[A=B26
MUT3RZ$#]#FM+0_!G]D>(KK79];U#4+ZZMT@F,ZQ*K!>AVH@P1[?K0!A?%'P]
M_P )1-I.F(Q2Z:.ZDM9 <%)D160Y[<C'T)K"U'Q.WQ ^&QM%8I-'IL]UK"KP
M8VA5@L9]-\JAL?W48=Z]*O\ 0GOM?T[5?[0FB^P[]D"HA1MXPV21GIZ&J'_"
M#Z;#IVOVE@\EF=<E>2[E159OG7:P7(P!R3[%C0!R>B:Q?:?X!\!V]I>1VD-U
M;!9W2/S;A@L>56*+!W$MU.#@<U6MO'/B>Z\+^&+R.XM$N;W73I=P9+;[R[W
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M+Q+.TL191V&_,) (PY'4L ,9]* -BBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKE]4U&_/CS2=%@NVM[6XL;BXD,:(69D:, 98
M' ^8T =117GGBCQU>Z/XBDMH4A-M8MF7#%ED#0E@LK;"8]K8;Y=WR\G%7O&/
MBJ]TI+"VL?*$MXBR>;"?->,!TR0A7!0@E<D@Y9<#- ':T5R;Z[=:I\/KC7[2
MX6UGCM[B=!;D2KF/?A6WH#_",C (.1FMOP_>3:AX;TN]N"#-<6D4LA P"S("
M>/J: -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW4YOB)K'A>\T6]\):S-]NO3>W5R]N_F2-A H V * $' 'Y5JP^)?B; ?#O\
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M5EUFS-NP6)QM&Y ,'9SA5Y]>:HZ-:^/M(UOP_JB>$];EGT>,P('MSM:([OD
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ML430F922,LI)X& <C'&:A\/_ !"\4:CXP\-:;<W5@]IJ>F#4KDQVAS$/WA*
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M*'B/Q%=:;?VVF-<:?=ZFUI-;06,K?98?E"R-/]TD$Y(]/2N&L]0\=C5=)O\
M5? >JZE)I0;[.\ENZR-N!&'?82RC/ _,FH/"\_COPEJ$YT_PAXA71I)_M/\
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M TA("A4))&._'% &?;6,MW=RVMK\0;Z:YA_UL48L6=/J!#D?C5O_ (1W5O\
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M.KL6X^AP#69:?$;5M37P@;#1K3/B&&=AYUTP\IXE)/1?N\ YZGD8'6@#I_\
MA'=6_P"ARUG_ +\6?_QBC_A'=6_Z'+6?^_%G_P#&*Y@_$C48?#5SJ%QI=L;J
MQUPZ/=1QS-L)W*N]"1G'S#@BN@C\27T_C'5_#T-K;>99V<=S#,\C /O)&U@!
MQC'49H B%G(VHG3E^(5\;X#)M@+'S,8S]WR<]*N?\([JW_0Y:S_WXL__ (Q7
MG'@RZO%^&NB^(9M%L=0O_MTKV]W(Y!MS+-()9I6Q\J 9S@GMTQ71Z?\ $[[5
MI]]_H]K/>1:M'I5HUO,3#<O)C8^XC(7&2>OW>.M '2?\([JW_0Y:S_WXL_\
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MQ5%>2P^'-$M;N.WC#2RWDYB$C$9V1@ Y.,9)P.0.QJ@/B&EWX9\/7]A99O\
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ME\;OS1 Z^66V%N-Q[H ![\DUNR>&M5G\::)KTEQ9B.PLWMI8E#9<N!N(/;!
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M2'2Q;-"\6[<XE5F^;/'8=!Z]:=XR\5#PM::?LBB>XU&]CLH3.^R*-FS\SMV
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M]I08W9SGZ^] 'AU[<:'?:CXHT7Q1K-]8WDVI&6V@@M4:2>'Y3;F%S&S9P
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M6W$T<R*25."1AAD__6YRX>#]1'BK0M8;5UN!IL$L4OG1$R7!EY=L@@+ST &
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !10>!7':C\3O#&E:C<6%W=3)<6[;)%$#D
M_7%%QQBY.R1V-%<+_P +>\'_ //[/_X#M_A1_P +>\'_ //[/_X#O_A2YD7[
M&I_*SNJ*X7_A;W@__G]G_P# =_\ "C_A;W@__G]G_P# =_\ "BZ#V53^5G=4
M5PO_  M[P?\ \_L__@._^%'_  M[P?\ \_L__@._^%%T'LJG\K.ZHKA?^%O>
M#_\ G]G_ / =_P#"C_A;W@__ )_9_P#P'?\ PHN@]E4_E9W1 (P>10  , 8%
M<+_PM[P?_P _L_\ X#O_ (4?\+>\'_\ /[/_ . [_P"%%T'LJG\K.ZHKA?\
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M@_\ Y_9__ =_\*/^%O>#_P#G]G_\!W_PHN@]E4_E9W5%<+_PM[P?_P _L_\
MX#O_ (4?\+>\'_\ /[/_ . [_P"%%T'LJG\K.ZIKQI(,.BL/0C-</_PM[P?_
M ,_L_P#X#O\ X4?\+>\'_P#/[/\ ^ [_ .%%T'LJG\K.X**4V%05Z8QQ2JBH
MNU%"CT Q7#?\+>\'_P#/[/\ ^ [_ .%'_"WO!_\ S^S_ /@._P#A1=![*I_*
MSNJ*X7_A;W@__G]G_P# =_\ "C_A;W@__G]G_P# =_\ "BZ#V53^5G<@ 9P
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M1!]8GW/#_P#A5)_Z NI?^#"'_"C_ (52?^@+J7_@PA_PKW"BCD0?6)]SP_\
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M7_@PA_PH_P"%4G_H"ZE_X,(?\*]PHHY$'UB?<\/_ .%4G_H"ZE_X,(?\*/\
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M62V#7#(6W%/.+'CM]W.*[>VMXK2UBMH$"0PH(T4?PJ!@#\J ):*** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>modificationno16effectiv010.jpg
<TEXT>
begin 644 modificationno16effectiv010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ"]MC>6<MNMQ-;F1=OFP$!U^
MA(.#0!/17E'P"N[J]\(:O->7,US,=7DW2S2%V;]W'U)KJ?&G@9/&TMC'=:K>
MV5I:AV*6;A'D=MN"201@ 'MWH ZZBO-?@_H$6F6&LZA;W=W<VEW?/%9R74N]
MF@B)4-V'S-O/ Z8K$\6ZO=>*?C7IG@62XF@T:%?-NXHG*&Y;RS+AB.2N HQ]
M?; ![+17*R>!-,AUG2=0TN);!;.5VFMH25AG1HV3YD'RE@6!SC.,UP7PL@C;
MXK>.E*Y2RNF2V0G*PJ9'!"CHO  X[4 >ST5YO\<E"?#*\ND^6XAEB\J5>&3,
MB@X/49%86M>$$\0^ _!%A83&QOKJW4BY0D%F^RM)AR.2"X!/?DT >RT5X-X?
M\4MXA;2_"'BZW*^(M+U.*)C+]ZXB&<Y/?HN>S#!YYKT;XK:W=^'OAMJU_82-
M%=!$BCD7@IO=5)'H0"<'UQ0!V=%>$1ZS)X-\5^$_L,?E0ZAX;\V^B4<32K$[
MB1AW?*\L><$UB0ZU=Z;\._"7C"*9VUNXUQUN[IF.^X0L^4<]UPH&.@[4 ?25
M%?/^HZI-KUY\4[^[=FGT4)#IKY(-IL=QF,_PDE 21R:Z#7@OB7X,V^OZE8:C
MJ>HRZ8#&MJYVP2A3^]V@COR3ACCCI0![!17$?"&^CO\ X8:.R7DUV\2-%)),
M,,&#'*]3P,@ ^@'3I771:A97$HBAO+>20_P)*I/Y T 6:*\?_:(_T?P9I]Y
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M'&03R!DB@#T:BO,W\7>(IOC@/#4=O --M[0R&,3;=ZL5S*QVG)&2 G'UK?\
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MHXC%G*\=2< #IDM@9P: /2J*\[T?XM:??3PIJ-B]A'<:=)J5NXF$NZ)-Q8,
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MJ.:^DUT[Q0@(4^'%4@@@6DN#G_@=-.E>)#_!X9_\ I/_ (N@#BM:^+_AG5O
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M5?0?]E^)?[GAG_P"D_\ BZ/[+\2G^#PU_P" 4G_Q= 'S=<^+=,E^"UCX787
MO[;4'GBD1 8V )/S$D$?ZT] >GO4WB+XBV'C ROK5@BWGF1FSU&U0Q36:@*6
M& 3Y@R&P"P()SD=!]&KIWB=1A?\ A&P/06<O_P 736TOQ*YRR^&B?7[')_\
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MH#7T5\/9[:?X>: UHTC0I8Q1JTB[2=JA2<?4&H#I'B-F#&/PSN' /V*3(_\
M'_85T=A%-#8Q1W/D><%^?R%*IG_9!Z"@"S1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7(_%'_ ))CX@_Z]3_,5UU8'C?1[K7_
M  7JNE66S[3=0%(_,;"YR.IH FU_P_!XBT@VDTCQN(W\IPQ*HY0J&9 0'QG(
M!XR*9;>%K"WT*;22UPUO.XDFVSNF6^7(7#9125^ZI Y([UJVDDTENIG@,#]"
MA8-^HJ>@# \->%K?PZDKI,\MQ,6\QURD; NS+B,':" P7(Y(45G>!?\ C_\
M&'_8?E_]$PUUTC,D3,B%V )"@XW'TYKG?"6DWVF2:]/?1)$=0U1[N)%?<0AC
MC49([Y4T =)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN9[I$?GI\I.:Y;X7>,M3\7Z9JAU:*V6ZL+UK;?;*55P .<$GW[US?QD\+_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHSW*S2[=RE=N%&.HSGMTK:D\(^'Y=*;2Y-*MFL7D\UX2N1(_]YO[QX')ST%
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M4#H13M0T\0:%\18X[W4%CT6X#Z=&+V7%NQ16+#YLGGU) YQC)SZI'X&\,0K
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ME@KZ%"IV.5;!D;H000?<5Q&D375YX+^'#RZC?B2XUF:":1;MPTBF2;(8YY/
M&>H[$5[$?#FCG5)]3^PQB^GC,4MP"0[H1C:3GI5./P1X9BAMH8]&MECM93-
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M&NX[O3M#LK>XB!5)4B&Y0>N#V_PXJ]J^A:5K]M';ZM807D,<@E1)DW!6'?\
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M%]SQ0!L44T.K1APPV$9S[5DV7BO0M1OHK.UU*&2>96:%>0)@O4H2,.!_LDT
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MLRJW"%\F,MG ('T/TQS4]MXKT&\U5-+MM6M)KV2/S$B20$NN,\'H>#G [<T
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MUO3+H>'_ !!#JNG0M%-+J4DHCM<IAE7>V&)., #ISQBO4*** "BBB@ HHHH
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MX9B>A(X'2K%G=^#?#/BS6WLMUE=0Z?Y]]:1VLB1I&F6$@^4(,@XXZ\=ZM?\
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MN9+GR01$"A4!.Q;YFSCCKQH^'M!UG3?&_B76+Q+'[)J[0-&L,[M)'Y2;!D%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S7B/4
M_"T.H66GZ]:I<W5QN^RPR:<]R7V@%MF$;. 03BNEKSWQE_R5?X=_]=+_ /\
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MYW9Z=L<]: ()/!FG-K.C:E%-=0-H\316<,3+Y:JPVL""I)R  <GMQ@\U7B\
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M!Z]?>DT+1X?#^C6VE6T\\MO;((XC,5+*@& N0!G'OS5Q+F&2XE@256EA"F1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3O"9Y?," %D(;"KDXSWYZ"NAMO#.CVFO7.N06834;D 2S;V.[  SMSM!P,9
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M%+*LN_=C)*YP5 P>O&3V-M>(VB07MZBV:-;K+*DS8$65!(8GTZ<UXAI%TO\
MPI[P]<6Y2:QL=>$VKQQ#<1;BX=LL!_",HWT]J /;K76M*OK66ZM-3LKBWA_U
MLL,ZNB?4@X'XT^SU33]09ULK^UN615=A#,KE5894G!X!'(]:\QUJ2PU'Q5XD
MUC3Y[6?1F\,/%=W$;JT+W.\F,$]"X7\1D>HKH?A3IVD0> M&O]/M;9+B>RB2
MYFB4;G9<Y#'J2&+=: .KO-8TS3YXH+W4;.VFE_U<<TZHS\XX!.3S3;[6])TR
M9(;_ %2RM)9!E$GN$C9AG' )YYKR37+S2T\5^*M"\7ZGJMFFIRQM:QV]JLBW
M<&Q0J(?*=MP8'@$#)..<UG^,+VU7_A+M, :PNHM%M49;K,US>JL98!?X5"?Q
MD Y(SD8H ]MO]7TS2EC;4=1M+-9/N&XG6,-]-Q&:Y[4/%5QI_P 0+'2IIK%-
M'N-.ENVG?*LA0@9+EMNWGTKA8/$VBZ5XADD\4.S:+J^@VUM97/E/)&RJ&66(
M%03EB<\>@]JN?\2.3XD^#[66WBM[2#1)5AM+U@6B (\L.&.0VT9P>?Q% 'JU
MK=6][;)<VD\5Q!(,I+$X=6'L1P:J-X@T5+Y[%M7L%NT#%X#<H)%VC<<KG(P!
MD^U<=\&[BVE\$RQ6TL3)#J%RH2-@0BF0E>!T&""*Y_1M0%CXLTRUTS4K+6]*
MO=4N7^Q2H!>:=(_F%V."24Y?)8=&'J#0!Z%H_C7P_K>GW5_:ZI:BUMI&2262
M95  .W<<GA2>A/6M6TU33[^T:[L[ZVN+9<AIH9E=!CKE@<<5X99:SI6G^!(+
M&>*!KJ'Q/MG:8LL=D?.=DDF"XW*,?=)&:D:>UNO"GQ0M9-5<O)<+<>?' 074
MJA#;1T1CQG^Z2<G!- 'MEGK>E:A)Y=EJ=E<O_=AN%<],] ?3FEMM8TR\O);.
MUU&SGNHL^9!%.K.F#@Y4'(YKR;3=0L?$^OZKK.F:EI*ZV= :QL+.UGWR&8!F
M\P$JN,9 &,G&<XI_@6[\/:YJ/AGRM0UF;7-(A:)[)[9(EL\Q[9!(5B7*Y&!E
MB22.^: /6KC4;&TGBAN;RWAEF.(DDE56<]/E!//X5&FL:9(MPR:C:,+;_7D3
MJ?*_WN?EZ'K7*_%+2YKGPLFL6*!M2T*X34K?CKY9RZ_0KGCV%<BL.M#Q;'-]
MC:.R\=0C[1 0 ;18\$[L?Q-;Y!_VR?2@#T6?6S::Y--<:KH\>A1:?Y[@R_Z0
MK[A\YYQY>TCGU(K!O?B$MS'X7OM#GLYK#5-22SN!(-TD:L&(/#?*<+T(/6LJ
M_:P/QDU>SA-OYLOA<Q^2FW+2"5CMQ_>VX..N,=JY.WU'0KSP)\-K*2XM'$6K
M0)=Q.0 ,*X8-GKU4'ZC/6@#W:QU&QU.%IK"]M[N)6*,\$JR*&'4$@]:BO];T
MK2Y(X]0U.RM'D&46XN%C+#V!(S7$> 9K%/'_ (\M+.2W51=P.L4)  _=88@#
M_:R#[US?Q"U*U;7_ !C8YCLKL:&J;Y%,LEZNUV"Q+T15/WC@GOQC- 'LDYE-
MK(;9HQ*4)C9P67.."0",C\:Y7P'XSC\2^&-)NM1N["+5[V-Y#:1R!6(#LN50
MDMC"_P ZTO!]S%>>"-&F@D$J&QB7<.Y" ']0:\;T'3],O_A=X<T[3([4>+(]
M21BL8 N8&6=B[/CYE4)U)XQCVH ]S.LZ6()9SJ5F(H7V22>>NU&]"<\'VIFJ
MZQ8Z99>;<:G8V;2*?(DNY55&;''4C(^AKQGQ'?V6EZ?\4M(N)?+OKN=9X(-I
MW2(R*=P'< YR>@K=L]<T_3?'[3>()8X]/OM#MX=,GF0F-P/];&#_ 'B3T[@#
MVH Z[P3XL;6_ &G>(=:FL[1[C?YC!O+B!$C(,;C[#O706^K:;=V[W%MJ%I-
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MM:IJ%AX2NTNM*A_M&W2>]AG)623=$&Q ,]0<DYSP*W(-:TJYN5MH-3LY9V+
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MG#(P[$4 :@ '05S7AOPM/H6K:U?3WT-U_:=U]JV+;&,Q-@+@$NV1@#TKI:*
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MVCT%+10 @ '08I&16^\H/;D4ZB@!, ]A2@ =!110 @55SM4#)R<#J: JJ20
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?O%!#*<],=QW'@5IK*YU+2KS1VL;YG^WW$IO4N3<-(2"S,JKM/R\#:!@<=*
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MH;^UDL'@^WF>0.'.SY/*4,0,@CCC)(K'L/"WBBQC\ W2Z;:/<:';SVMS UX
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MB1X609#E@$!+#YOD8]ATYY%<=I&C0:=H'BK3?&!M;"SUO4[JYB,UU&-T<H&
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MXFO(+I[KRWA:3!9&4@[N1P<_4^@!Z+:W$UOX6M[B&W:ZG2S1UB#A3(VP<9/
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MNP9".><'C&>]4O!OB;6O%,T]A/>0VE]I'F6^I!%2033$D(\8[( "3GJ>.Q-
M'H=9UIH.F6.JW6IVUHL=[=X^T3!B3)CIG)YQV].U<C\))-2N?"T]WJ&I/>-+
M>W ^= "&$K G(ZY].@Z"H/$7B^^TKQ?/IU]J#Z-:DP#3YY+0/;7>0#(KRD':
MV<KU '!YH ]&[XHKRFQO]>LO$/Q#O!J\,[Z>(A"EX%CB&8BR MGY54L?KW.3
MFKWA[Q?J\OB34=-EEDU.*'1EU"%GM/(>23)4J@P,H2."1^8Y(!W&J:'I6MB
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M23^)[<5VE% '(2^ ;=VT5DU6^#Z5<-="20K(]Q*WWFD9ASD$C P!VZ"J5_\
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MW@E=K!@05(8=1BNBHH Y*\^'VEZIHVIV6I37%S<:G*DUQ>Y5)=Z !"N!A0H
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MV_CJ0!TQTJOX>^'-KX=O8VAUK5KC3K=S):Z;/<9@A;GMC+8SP#TZ\GFNTHH
MP/$_AA?$RZ:KWTUJ-/O8[Z/RD4[I$^[G<#P,GCO6=/\ #VPOK_Q'<:A=SW,6
MOQ1QW4!55"^6,1E2!D$?CS7844 <9IO@!]/T^ZMW\4:W<SR0&V@N9Y@SVT1Q
MD(,8W':!N(SQQBK">!K>#Q#IFLVFHW-K-86BV9CACC5)XA_"XV\_AC';%=71
M0!S_ (7\*1^%8[N"WU"[N+6:=YHX)MFV#<Q8A< $Y)[D]!536O!"ZZ^HPW>L
M7ITW4)8Y9[';&5!0( $8KN4'8"<'N<8KJZ* .)U?X:V.L76OR2:G?Q6^MI&+
MFVCV; Z* K@E=W& <9QG\,13>#;K2+F[\10:KJFJ:HFE-:>1F*,W&-Q4 A1M
MY(QCN 3GG/=T4 >.>$]/U"P-C'HU]XC6\4Q+<6]_HR0P[01O#RF,$X&>C%CQ
MC-=99_#2RT_69KFUU?58M,EG-R^DK/BW,A.3QC.W/.W.#].*[>B@#+\0Z!8^
M)]#N-)U!7-O.!\T;;71@0593V((!JE8^&'@U!=2O=5N-0U"&W:VMYYHT7R58
M@L0J@ L2%R3Z=N<]#10!S_A/PNOA2PN+.*_GNXIIWN,S*H*NYRV-H'&>:Y2:
MPO[SXTZA-9W=]IZ'28X1=):;XW8.2R9=2N0""#G\^17I=% '')\/+&WNO#\U
MG?75NNB/))"H"L9GD_UC2$C)+9.<8ZU<O/" ?Q#<ZWIFJ76F7=Y$L-WY*HZS
M!>%;#*<.!P#Z=JZ6B@#C[SX=Z:UMHPTJ[NM)NM'4I:75L59@K?>5PP(<-U.1
MU/N:@7X:61\/:WI$^K:C.FKW?VV69S&'CFW*V]=JCG*KGMQP!7;T4 <9#\.[
M5]1O[[5-6O\ 4I=0L?L-VL_EJLJ<\X51M(SQMQTSR<FET'X>6^C1O%<:UJVI
MP+ UM;17DP*VT;#:0H  SCC)Z#@8YKLJ* ,3PKX=_P"$6T.'2EU&ZO8H1MB:
MX" QH. HV@<#WR:VZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O/M3GM]5^+BZ%K6TZ>FD>?:V\KX2:4R
M8=L=&8*,#TY(KT&LW5O#VCZ\(1JVEVE[Y+;H_M$0?8>^,_04 >*:#J(T_P $
M^$].:\MK71[G5KV*YFNE:2$E6<Q))AERI//+ <#.1FMO4/#$LO@+74T?Q!'J
MES87?V^U6S5EB@P SVZG>V5*Y.W/!(KTL>%/#XTF32AHM@+"5M[VXMUV,W]X
MC'7WZU=T_3;'2;&.RT^TAM;6,86*% JC\!0!YGJ/B2;5? 6N>.='CDA)LHK>
MU(4[D4$>=(!Z@NRY_P"F61P:M^%[2PC\1"_TSQ/IMS#=::RMIVG0LJN%((F?
M,KD,,XR0"<^M>A6NG65CIZ6%K:PQ6:*46!$ 0*>HQZ<FJ-AX5T#2[>Z@L-'L
MK:*ZR)TAA51(/0XZCVZ4 >2^%+HOX9^&&D71(T>^:[^T@MA)9$WF*-O4%B3@
M]2!Z4GBZ.XTS0/B3IUG-<1Z78O9S6829@(99-IE12#]WD';T&[I7K8\+: -(
M_LD:/9#3P_F"V\E=@;^\!V/N*Q/&GA!]2^'U_P"'/#UI96S714 ,?+1?G#%C
MA223M_7K0!S.HZ.FC>.M(32+F],&K:7>-J:F[D?>$0%)2<Y4EV R,>@KG])L
ME_X1[X:WXO+U;O4+K[+<SK=R!I(B'RG7@<8XP>_7FO7=,\,:/9V,D:Z-8V[W
M,02Y2) 0P_N9P,KUXX'M0O@_PVL5K$NAV CM'+VZB!<1,3DE?0Y]* /+;G4+
MGPYHOCRUTZXE@LK35K:(99Y/LT$FSS".=P&">A!YX(/-3:K86EMH/BJ[T[Q1
M97,4^C-,+'25>*.-TQMER)7VDYQCC=SUP:]4@\.Z+:R7DD.EVB/>@BZ(A'[\
M'KO_ +W4]:@M_"'ARTTR?3;?1+&*RN&W30)"H60_[0[_ (T >>Z=IT%IXU\&
MPH\[)J^AS"_$D[L+C$:$;LGW/3%:'P@_LG2? $,[RVUK)+=31.TDH7)$[JB\
MGKV [UVT?AC0XKFTN8]*M5GLUV6T@C&Z%?13V'L*8GA'P[&DR)HFGJL\ZW$H
M%NOSR*<ACQR02<?4^M &S1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !574-3L-)MOM.I7UM9P;@OF7$JQKGTR2!FK5
M>2?&[P#K_C*'2[C0PMP;3S%DM6E"9W;<,NX@=B#D^E 'J]O<0W=NEQ;31S0R
M#<DD;!E8>H(X-25Q?PL\+ZCX1\"VVEZJZ&Z$CRLB-N$88YVY[^O'&2?K7:4
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M6\M7A0%>&PH)4>N=PX]ZZZS&C6GQFL8K3[#%;S>&F#K&5"R?O0><=?E&>>U
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M>AR/7-;7@>Y\,:YK^BW^F:MJEWJ=G9M ]K]FCB2VC*\K+LB4$!@ !D\\CC-
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M#,)@0O'\04=.H H ]3HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMH\S?9D,3-(?F;:H!/(!^F0..TF\6V7D6;V-M=ZC)>6@O8H;54W^20"'.]E
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M%&,GUI]% #$BCBW>7&J;CEMHQD^IH$,2[]L2#S.7PH^;Z^M/HH 8L,2A@L2
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M8]2%&321P0Q?ZN)$XQ\J@<=:DHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3KS3Y)F>(E^%D0,3L8=\=<#WI?\ A+M+\.0^-=;MO#]TMQ97D:WZFY!,S;0
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MP]-K\-G -$+2EK:=I/M,NS8" 578O);G)S@>] $ND^/!JV@WVH)ICQ7%G?\
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MG SU&2>.!0!W]%>?67Q,6YT#3[B:SBM]2O+R:S$+2LT2-$3O?<%R1@# QG)
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M9 R#L'(_*M:[\-Z_J'BGPQK5W/IC-I27"W"1AU$OG *0H.<;0!U/)STKM**
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MJ>H3>-_-NK2./Q%%$L14LQA:--J[N!D'J<=/>EU3P?XAUO13I>JMH-[;O9+
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M 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F7Q;^)M[X
M33H--L8)[J\WOYER&,:JN 1@$$DY]>/QKTVL;Q%X4T/Q9:1VNN:='>11MNCW
M$JR'OAE((S['F@#,^'/B^3QOX/@UB>U6VG,CQ2HA)7<O=<\X.17653TK2K#1
M--AT_3+6.UM(1A(HQ@#N?J<]ZN4 %><74O\ ;WQQCTB^!DL-)TO[;#;MRC3L
MX7S".Y"M@9Z'D5Z/7+^(/"+:EKEGX@TJ_P#[-UNTC,*SF+S8YHB<F.1,C(R<
M@@@B@"UJ^GZ5I][_ ,)9/&L4NF6DWF2(@R\6W<0?7&W(_'UKGAXTUJSL/#>M
M:A;6)TK6YH83%"KB6U\X9B)8L0_8-A5Z\5OKH5_J4$D?B'4(KJ.2&2$V]G"T
M$)5UVL6!=BQP2!S@9Z9YK(T_P+>166CZ5J6K17NDZ/.D]J@M=DSF//EB1]Q!
M"Y'11G ]\@&%?_$3Q/:Z+XEU5=/TGR-!U$VLJ%Y"TR H/E/&#\V<GCVXYW]3
M\0:AK&IZWH>BK8K_ &;8I+<O>1M('>569(P%88&T9+'/4<50NOAOJ%WX>\3Z
M2^M6P77KTWCR"R;]R25)4#S.?N+S]:N3^!]4BUZ;6-*UV*SGO[6.VU*-[/S(
MYBB[5=!O!5@..210!SW@7Q%>:1X8^'6EQ0PR6NK)-%*S [XR@9@0<XY^G:MA
M?B!>K%J4$MM;&]CU]=$LR-RH[, 0[C). "Q(!YQCC.:(/AS?67AOPW8VFN1+
MJ&@SF6"YDM,HZL"&5DWYZ-US43_"V6YTO6+6ZU^1KF]U(:I;W4=N$>VN!C##
MYL$<=..OXT 0>/-:\9Z5X'\2RR"SM6M&B6"_@0C[1%)A6VJ7)C=2V,DGV]:U
MM2U2^L_&?A#3;^PTJZGO5NRMV(V#PLD1;]WG)4$;03DYYXZ5'>> ]6UKPCJV
ME:[XFDOKZ_C2-;D6JQQPJC;UQ&IP23U.<GCTJU=^$]8O=>\-ZO/K=J]QHPF+
M?Z"0)C*NUNDGR@+@#J>Y)H YM?B-XD70O[;EL-*%I!K!TZ>-6D+N/,";D/08
MSWSGT'?9USQKJ=MJ?BBVTZ"T1?#UA'>2_:D9C<[E9RJD,-H"KC//)Z<53?X:
M:@_A.XT(ZY:_OM4_M$S"R;@[]^W'F=,CKGI^=<[XE>WO?'NIOJ.O6.G2Q+#;
M16^J:29EF4+N+1_,,H68\98Y'TH ]6T&_O-4\-V.HW,$,5S=6ZS^4C$JNX;E
M!)&>A&>.N:\[_P"%C^*D\*7'BA]*TIM,L;QX+N)))/.=%DV%DSP,9'7.>>!7
MH/AR\OKCP[!<ZLL<5P-^YEC:)616(5]C'*;E ;!Z9KS'P'HD_BOP9J.EMJUI
M_8L^JSM<P1PEIROF[MH??@*V <[2<$X[$ '1:KX_U)Y=5;P]I[7HTV98/L_]
MGW$K73X5G"R1C9'@, -V3D'( QE[^+?%5YXSGT/2]*TX)%:V]XQNY'5U1VPR
MG'\>,\8P,'DU-<^ ]5M_$EYJ/A_Q1-I-EJ+*][:+;)+EPH4M&6^X2 .<'^0K
M1T[PG<Z?XXN?$ U%'MYK*.S^RF$[@J'*L9"QR>N>.<T <3;W\EGK/Q&U'Q$F
MGWNGVC0"Y@-N3YH6',:KN8@<D=<\G/%=0?%.N:9J/AY-5@L)+76_W2?9U=&M
MIBF]58ECO4\C("^N.U$'@&66X\4C5=0ANK3Q"!YL45L8VB(7:"K%VSQ@\CJ/
MPJ:P\':ANT8:SJT%]'HOS6>RU,;.X38KRG><D G@8R>?:@#G[3QWXPN]"UK6
MUTO1Q8Z6;R-\S2!V:'D$#T.".QSZ5;@\:>*)-4\.VC:?I6/$%@UQ;8DD'V=U
MC5R7/\0PWW1@]L]ZNV'@.^L_!OB#0&UB"0ZM-/()OLA A$WWQMW_ #=3CG\Z
M=;^"-2AU3PI>MK%LW_"/VCVH06;#SPR!"2?,^7A5]><_0 %6T\<:U=>#[V^%
MA8_VC9ZJ^FSN9"EM&%<*TS;B"$ .<9S69<?$[58/"WB/48;;3[N71KV&!94$
MD<<\<A4!@I)(/S#^+!ZYJZWPSU Z-<6G]NP>>VN?VW$_V,^6),Y,;IYGS)G!
MZCIWJ/4OACJNHV7B*T;Q' $UN:&>9C8'<CQ[#E?WF,93@<\'DD\T 79O'6HZ
M'KVLV.OVMGY-EH_]K1FS9BVT.5\LENK9'4 #VJ]!K_B"R1=1UBTLWT8Z8]]-
M/:@JULR@-Y9W,=^5SA@%Y'05%?>!9]7\37>IZGJ$$MM>:.=)N+>.V*$J26+J
MQ<X.XG'!X_.HM#\!ZI:6O]G:[XGGU;2HK=[:WM?LZPX1D*?.P)+D*2!GZ]<8
M &Z)XRUO4=9TA'TJ273M2B9Y)(]/N(OL1V[DW22#;(#TRN.?:M/QKXDU'PX-
M$-A:6UQ_:&IPV+B9V7&_.",#V//;T-4_"W@S6]!FM[>\\67&H:39#%G:&W2-
M@,$*))!RX4'@<#@>F*T/%_AF[\2_V1]FU"&S_L[4([_]Y;F7>T>=J\,N!R<_
MTH YF?QMXK@_X2RU^Q:.;GP[&MS+-ND\N6-HC($5<YW8!YSCVK0N?'<]PVEV
MNGP^5=WFEIJ<A:RGNUC5\!4VPC/)W?,< 8Z'/#I_ NHSWGC"?^V+8#Q';I 5
M^QM^X"H8P0?,^8[2?3G!]JKW'P\U6*+1+O2/$O\ 9^LZ98KISW2V@>.X@7H&
MC9CR.O4\_A@ </&>O2:/H-Q<:9!HLM[YPO)-11B('3A56/<KL7/('7'K6?#\
M4+B;PGX:U:Z6STQ=5DGCGO)XGE@MVC9E (!4C>1QD\8/6MBX\#:D=9T35K?Q
M"S7UA%-'-+=VPE\WS3EF50RA#V&,@# YQS7T3P)K6@Z#9Z1!KME<6EN+A'M[
MO3R\4Z2N'&X"0993NYZ?-C'<@%F+Q;JB>(?"FF3II\T6M0W+23VQ)4-$NX-&
M=Q!5@1UK'O/B-K=OX;O]0BT^QFGL]?;2"FYE$BAE4,!DX)R>IP/>KT7PWGTW
M3?#,>CZPD%[H+SM'+-:^9'()\^8-@8$#GCYN,=^M5I/AAJ#:#?:8OB*,FZU@
MZMYTEEEE?<&QPX!Y SP._% %R?Q=KUG?0Z)?06<.L-#)=2/:VEQ>1+"'V1X2
M,;LL<Y)( QWSBJR>.O$LC>%8'T*"SN]8>XAGAO/,C:-XU)# $9VG ;GG''O6
MMXF\':CJNKV.NZ+KK:1K-M ;9YA;B6.:(G)5D8]CDCK_ %IEQX*U&;5?#E^V
MO>=+I$LLTKW%MN:Y>08?[K (N#@ #CCK0!SUS\1/$]IX;UW5)-.TECH%^UI=
MX>3%P RC]V/X#AQRQ/TK;U[QI?1:KJ.FZ+;^9<Z?;),X:PN+D2R."R1@Q<)P
M/O,?XA@<&J=S\-M0NO#WB?29-<M@NO7OVQY%L6_<DE20!YG/W%_6K>H^!]:;
M7DUO1/$YTN_GMX[?4-MFLL5QLZ.$8G:PR0.3_/(!!'XR\2W_ (CTW1[;2;.R
MEOM(^WE;XR;X'#!2K*,< DC'!/!R.E8=SXU\1ZYH'@V_M9+.Q?4-8%G=1*C,
M&='?&#D'8?+R1U.<9QG/71>#KZW\766N1:ND@M=.:Q"7$!=Y-QW%V<.!DL,X
M  QQ6/;_  SO[7PQI.F1:[ +K2]5.HP7!LB5))8E63S.>7/.1T_&@#HO'%]J
MNE> M5O].G@BO[:T:7S&C+*-JY;:,]?3.<=\UPUX^L'7OA=.?LESJ4D%WL9M
MR+@VJ\N2220"2?7VS7I6M:.=;\+WVC3W)#7=H]NTX09!9<;MOUYQ7,V_@?5U
MU#PK>7.NVTSZ LB*HL2OFJ\8C(_UG'RCKSSD].  5K3QSKD_AK4;B2RT]=0L
M-:;2KB8R%;:)%9=TYW,#M ;IG-86O>/-=OOAYXMN;*>TAN=*NA:_:X8G42Q/
MM&Y%8DHWS]<GV[&M>7X9:B]O<;=>MQ.^O_V[$39'RUD[HR^9\R],<@\>_$L_
MPTO+O2O%5A=:ZCKKTBS;UM-ICE&PY^]RN4X''!Y)- ';VSWD.DB2\$<]TD99
MA;J55R,D  DG.,#KUKAO#_C*?Q;I5X7N]*EC.FS/<V<4;QW%I+P!&X9CN'+#
M=M ROO7:P6>H#0C:76H++?-$R&ZBB\L!CG!"Y.,9'?M7+KX%OYM7_M>^U2QD
MU)+"2Q2>&P,9EW@#?+^\.XC!P!CJ?I0!S7@7Q)K.C^'_  '936ED=+U13:J0
M[&=6"LP<_P .#CI^O8:US\0=6LO$%E:W,&GI'=:T--^Q#<T\43$A)F<,5&<9
M"E0<=^]6+;X>:A;:=X3M%UNV(\/3&56-D?WPP1@_O.."?6J:?"_5(;2UM(?$
M<(@LM9_M6VWV.YBVYB1(V_YS\V.,>_L 0[$_X2_XJC:,'3;0XQW^SR5U?PY_
MY)MX<_[!\/\ Z"*I'P7J/]L>*M075[;_ (GULEOL-FQ\D(A13GS/F.UCGISC
MITK=\+:--X>\,:?H\UTERUG"L(F6+R]RKP.,GG'O0!P-QXXU#1_#GBK5[31=
M)BN=/UO[),L>Y1-DQKO8@ L^7ZG' K6F\=ZCH>NZY8Z_;69BL-*_M2)K,MDK
MN*^6=W5LCJ ![56O/AIJ5YHOB#36UVU5=9U)=0=Q8M^Z8,K;1^\Y'R+^OKQI
MW_@275_$U_J>I7\$EK?:3_9<UM';E3M)W;U8N<'<>.#QCZT 7](OO$UQJ-HN
MHV5C)IEW9>>TUL"I@DXQ&P9CO!!^\ .AX%<'X)\17GA[X=>#%MH8)8=2UF2P
ME$@.4#SR_,I![;3P1WKKO#7A#7]%\J._\62:E;V41CT^%[58U0[2H:0@[I,
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MC<>1#^XDF" *79BD?S-@+T'<CD#)&/X:\#:QX?G@LW\67-UH%HVZUL#;HK@
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MU"T-CIEI+&;:Y9&9TMG*EG'S-C;T)P<\YXJU;:WJOB&^\/Z-+=*&N/#<%_\
M-?RVC3S.,,P:,$L5 SMZ<DX.!@ ]:HKR.]/B6QTC2Y;RZE\26UA:3Q:BNE:@
M]O.&$A59AM*F0J$9,'N&-+#K%UXKU6'1M/U%_LZZ';SVCS7\MI-,SA@TQ\L$
MNPVKP3@'/7/ !ZW16-X86\/A:SBU#48K^\2,Q2WD!XD925+ ^O'7UKR$/K(^
M&6J>*HO$NL?VEI>HRBW5[IFB*K.%V.G\>0>^>PZ<4 >[T5XCX[UC4?L_BS5-
M.U+46N--^R -'<O;PZ>V5W1JH;$S,2<[E  .,\8KHOL%YK7Q7UG3Y->U>VL[
M:UM+I(;:Z*#>6)/']T@$$=\^PH ],HKQ6/6=0?5- U6QU34;JVOO$K6SWDER
MZ13Q$N/*2WW%0BA<;B%.1P.<TS5IM4&B?$*_77]7671]1S9!;M@(^$."!U7G
M&T\>V: /;:*\PCO=1T3Q[ $U&_OENO#\M]-!/,61YE(P53HGIA0!5;PS_;.M
MVGASQ%_;T,<%U\M^HU*:3[29!@QB+ 6-U8G&S&W'7O0!ZG#<P7!E$,JR>4YC
M?:<[6&,@^_(J6O"M%NW\-^!)9;.YFA^V^)7T^:6:]E5(H3*V6W9.PG:%+@;O
MFSG/-:GBF'7M \(>+9CK[1KY,%S9V]MJ$LTMKE@C'S7 ;8W) SU!Q0![#17E
M^L:1KNC1Z?-9WFK>(;=_-NKZQ.IM#<-E$ :(H5)13N.P'&7&.V.Q\'WUKK'@
MO3;JRN;N:WEM]J37)/G<94[B2?F!!R<GD4 ;]0W=Q]ELYK@123>4A?RX\;FQ
MV&2!GZD5XKIE[K&G?#?5?%Y\0:K<WEM-<6D<,]P7A1#.$WE2"2R@D@_AC Q7
M7Z18ZG9ZQ+<MK$#Z7>:8Y2R&HRWAD=<'SD:0<## '''(H ZSPUKT'B?P[9:U
M;1210W:%T23&X#)'...U7[BZM[41FXF2(22+$F]L;G8X"CU)KQ[PS<>9X'^'
MVEIJ%ZLERD['3[)S$]T%W<M*&4QHIY.,D] #6;;QSZYX<\#W>JW=Y/=1>)7L
MO--W)N$>Z3C<""3\@&[[V!UH ]YHKR>[EUKQ-JOBBRLM533[G2KA8;9WU.:)
MK>-45A(T:@K(&);)<G(XXQ79>)H_[0^&VI?:)C(SZ8\C2V[M&'81[L@@@X)'
M3N.#0!T-M<PWEM%<VTJRP2J'CD0Y#*>01[5+7D.B3/;:9\-M 2YO8;'5[1KB
MZD%W(&=DMU*Q*^[**2<[5('&!U-=3X.GO;;Q?XLT&2YN+G3["6WDM)+F1I'3
MS8RS1[V)) (&,G(!H [6BO/+J9_$OCOQ-X?N=6N].:RL8/[/^S7+PD%U8O-A
M6&_:VP8/ Q[FF6-Z^O\ C>'0;K5;J>QM=#BN8YK:=[?[9(S;6FS&P)'' SC)
M)]* /1JBEN8()8(Y951YW,<2D\NP4M@?@I/X5Y'9WWBF]\/01QM<:L-*U:\M
MIK=;UK:YO[>([%<.I!8J6&>>2!GFJT0T[Q#XF^'5W;W.KF*<ZC$WVB[F2>/R
MU8A"0^0RDE2P.6 &<CB@#VJBN9^(-^--\$:C/_:<NFNRK&ES#'YDBEF P@R/
MF.< Y&,YSQ7G=[?:Q9)\0+-;O4K%+/2X+JVB;4'GD@<JQ)\PDD$X&0"1[T >
MU5A^(/$T/AVXTB*>TN)1J=]'8QR1[=L;OTW9(..#T!Z5P$5_J&@>)O#MPFI:
ME>B^T&>ZN;>XN6D262.)74JIX4YXX _4YS+A#J?AOX<^([C4+NZOKW7K1YR]
MT[1%F+D@1YV+M*[1@# S[T >W45S_C6/5)O"US%HTZ17[O&(@\WD^9\ZEHPX
MY4LN5!'//;K7G7_"6B*"'36.KZ0T^O06NIQ7MV\CVB-'D*DQ8D(Y0'<",9;&
M,@T >E>*_$L'A+09-7N;2XN((W1'$&W*[F"@G<1QDCID\UMUY)\1+ :7\//%
M5DFMSWH:XM+B."=VE:S1YD 7>Q)8$JQ&>GZF34]3U/PCXN\2QVFHWU\D7AHZ
MDL5Y,95$ZR,NX#HHP,E5P/TH ]7K#U[Q-#H%[I%M/:7$HU2\6SCECV[8W;)&
M[)ST!Z ]*XBPEUC3HK+Q-#K$$]C)ILSO:G49KHWTBQ-(I57 ","IR%P,9'%8
M\\7V[2/AIX@FU"\N[V]U>W>X:2Z=XR[JS-B/.U=I!4;0,#(H ]KP#VK$F\2P
M0>,;7PV]I<">YMGN4G^7RRJD CKG//I7F^IZIJ=KX6^)9&JWRRZ=??Z&_P!J
M?= I5" ISD#D\=*U]2NI8?B7X>NPIFE3P]<R!3U=AM./QH ],K/UO4I=(TF:
M]ATZZU&2,J!;6BAI'RP' /IG/T%><>%9=;UBV\-^)UUVVCCGD'VY3J$LJW)D
MX,0A(V1LK'@+TQWZUT/Q8NKNP^']Y>V-Y<VEQ#-!MD@D*'#2HI!([88T =MV
MHKS'5(KS4/B+XDTYM9U6&SCT:.Y2&WNVC"29;E<<KT'3KWS61HNH:L+7X<ZQ
M-K>HSW6JS>1=K).?*DCV-@&,?+G@?-C<3U- 'LM%>*FWU.^T#Q_J'_"3ZU#<
M:)J-T;(+>,%01HK@$?Q XQ@\#L.3EFO:[J>J:5JM]%J&H-?V6@6MS-%;W#VD
M6GRO&9"QVM^\=NR[2 !@D4 >VU%)<P13PPR2JLLQ(C0GEL#)P/85YO:ZC-XF
M\4)H6HZG=V@_L""YM_L]PT#2RR [Y<H1N*\8'0<\52.F07'Q*\&^;J]WJ,@T
MRXCDO8[F2+SGB*KN 5L $@Y X;OF@#UJBO+/#6HW]CXMTRQ\0#4/MEX\[VNH
MPWSSV6H(0S@;-VV,A<$8';WKT'0],&DV#6PU&\O\S/)YUW-YCC<<[<XZ#H!V
MH ?J&K6^GVU[)AIY;2W^T26\17S-GS8(!('.UL9/8TW0-8A\0:!8ZO!&\<5Y
M"LR))C<H(Z'%>;V^F01_$#XCRK)=;HK&"10;J0J2\$F=R[L,.> 00O;%9WA<
M7FDP?#&>#5;]EU&-X;BW:<^24$)*@1_=&/7&?4F@#VJLZUU.6XUJ_P!/;3KN
M&.U6,I=R*!%/N!)"'OMZ&O,=#O-=\2Z=9>)(M9M[&:/4B;L/J$I4()"GV=K?
M&Q21M [YP<Y-/UO4-2AN_BG%'JU^BV%E:S6FVX8>0S1.YV?W03Z>@H ]<HKF
M?!&ESV.APWEQJ^HZC+?P0SO]KFWK&WEC.P8^4'.<<UTU !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9E4*HXV@D\9;(P.IZ_7>N;F"SMI+FZGC@@C7<\LK!54>I)X H YD_#7PB?\
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M*JF-0[*K,#RH;;D9QD&M"/Q%HLNFOJ,>K6364;^6]P)UV*V<;2<X!R1QUYH
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M5P'"\[,]3SCL"< ]Q6-XDT ^(+*WB34;JPGMKA+F&:WVG#KG&Y6!##GH?04
M>6O<P>)X_&NH:1J-H^OZGIJQP6-J9"X2-<,0SHA9FSC '''6K&FZAX:UY9=4
M@;6);ZRTN:WN/MT8CBLT*']VQV*K'=@!03Z]J]&TS0+N"\CO=6UF?5+F%66
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M'+<\G@8K"T;P=XKMM9\)ZI>:79->Z;+<"_NGOO,ENO,0IYC,5S@9X7)]/EH
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M(^&?&>M7?BK0=/O+R&[BU.SGEG,5MLBCE3!Q#)TD49P2,CWKE]4_Y([\1?\
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M%7@$GGS;-[;R>BYPHQ@]3GM639>-]?\ $.I>$H]/FL[*#7-/GFE#VYD:&2,
M$CYAN&>@X]\]* /4**\6U/Q'XBUGP=IDDNJ)!<1>)TTRX>"  3A9AM8C/ &
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M%O\ #X2?\)+NUJZ;_A((DBN2T290*NP%>.NW(.?K72:7ILFE:!:Z9'=-(UM
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MH] !0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEH;M+VV:V!P9A*I0'_>SBGPWMK<RRQ07,,LD)Q(B2!BA]"!T_&OGG6+C3I/
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M7JL,T=S!'/"ZR12*'1U.0RD9!% #Z*** "BBB@ HHHH **** "BBB@ HHHH
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M1R&1(8U<C!8* ?SJ6B@".*"& N8HDCWMN;8H&X^I]335M+=)3*MO$LA;<6"
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M!T50, ?E4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<3VK!;B)&^:(G/##J.A_*G:AK>F:5<6MO?7T,$]VQ6WB=OFE(QD*.IZCIZT
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M(DT22QL&1U#*P[@]#3Z "BCI1WH **K:AJ%II5C)>WTZ06\>-SM[G  [DDD
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MTJ1H,PD?.6/3GL#]*]7KFM+\(_V9XOU/Q%_:4TT^I*B3Q-&H3"#"[<<C'XT
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MODE<]68^O0>@  '2N./PK@6!+:'7]2BM8=4&IVT*K$1!+N+<$IENIQN) ]*
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M=K\<-;-EIKW\K:)"!$LJ1C[_ '+'I],GVKOO#^D+H&@66DI<R7$=G$(8Y)0
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M78)?6@BM_*9V96/EX!.1D #O]:E/PQC;2Y[ ZY>&.;5?[69O*CR)L[N./NY
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M%W)=V^FZ"9[O3[6*>^MYKH1M%)(F\0J0K!W '/0<CGG@ ZQ4BB9BJHC2-DD
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M!5"<9!V_>)&.>W)T8?%W]JZ9XIM-1T.2.XTA"EW:+<*XEC>/=\K\=5SGT]Z
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M3=Z@\$LZ6T32M'#C>P49.,D#I[U%H>K1:]H5AJT$;QPWD"3HDF-RAAG!QWH
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MJOH&8DX';GCM63!X'T&V-WY$%Y%]KD,MP$U"X F<]6;]YR3[T >1Z3>7%O\
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MLZ??&[N7>Y=F:UVAT!?.#EG1"O3 ->F:CI5CJT4,5_;).D,R7$8?^&1#E6_
MT1Z58Q:O/JJ6Z+?3PI!),.K(I)4?FQ_3T% 'BWBM[J^\!_$6.\U"]N!I^KHM
MOON&^5<QC;@$ K\QXZ9YZUTVJ:,LGQ6T'3H[Z_AB&BW&Z5;EC,P\P''F,2PY
M/4'.!@8KK?\ A!?#OV75;9K%WAU8[KU9+F5_.;.<\L<'W&#Q2V_@C0+2^M;V
M"UG2YM8FAAD%Y-E4;)8??YR222>2>>M &;\++^\U#P/"]_=S7<T5S<0>=.VY
MV5)6"[CW. .:[.LO0O#VF>&[-[/2H'@MWD,I1IGD^8]3\['&:U* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,I"@;CY>W=M&1\V,'(YY%*/&FAR6=E=6MS+>)>Q/-;K:6\DSLBD!FVJI( )
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M 5Z!%XDTW3-&TL3W]Q?23V:S1O';/)+/&%!,I1%)4<@G( R<5PNE6]^OP_\
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MM)&QN_\ ":VP,# Z5Y3HVGZC9^+M/N-"MM:LK6XO)9-4TR^A8VL(8,3+$[#
M)/93GYN0!D4 =)\4M9U+P[X!O]9TF\:VN[4Q[3Y:.K;I%4Y# ]F/3%4)M;UG
M1OB3H>A)JS:Q:ZA#*UU#+#&);3:,K)F-5PI/'S#L:F^,-K=ZE\-]1TVPL[J[
MO+IHA%%;PM(3ME1CG P. >M8<.C7G@CQ;:^(?#NEW4N@ZPJQZGIT%LPDMI .
M)5CP& ZY&/7U& #NM4\8:)HTTJ7US)&L+(L\JV\CQ0%\;1(ZJ53.1U(X()X(
MJIJ/Q#\,:7>7EG<W\GVFS56FBCM9795()W?*IRN!DD<#CGD5PDNG7-KK^NV&
MI>#=5UNUU>\:\L[B&1T@*NJ_),"RB/:1CYAGVX%7]/U"/1OBOXHCFTZZN5;3
MK*/996KS $(?EP 2 ><$\<<D4 =7??$;PIIT-G-<:J/+O(&N+=DAD<2(!DD$
M*>1Z=?:I[OQQX?LK<7,UW*;?RXY7FCMI'2)),%#(P4A,@@_-@X()KSWPYX:U
M/P]K'P\M;K3KF3[!!??:Y(H&>.V:<ED4L!CC.TD'CZ5-?Z9=:;XLU^SU+PAJ
MFNV6KW(N+6>TF81<HJF.4;@J@%>I[?A0!Z%>>+M(L[M[9Y9Y7C\OS6M[:25(
MO,^YN=5*KG(/)Z$'H:35/&&B:--+'?7,D:PLB3S+;R/% 7QM$CJI5,Y'4C&0
M3P17GWB#2=2M]2NKGP[9:MI^O1_9H!%#"\NGZBBH@^?<-JA067)(X7N3PRYT
MNZL/$?B#2]4\':GKEOJMZ]U:7%O.PMV#@?)-\P5 I'4@GVZ9 .ZOOB#X:TZ[
MO[6>]E-Q8*KW,<5K+(8U()W?*IRN!DL.!QD\BJ][\0M-M]?T+3;>&[N8M5A:
MX2YAM99$,>S<"NU26.2N<#Y0><5S3V=Y#XD\=O\ V9>^5=:1#;6S1V<I25TB
M9&5#MYY8 >O7M573+35-/F^&MZ^BZE*NGZ?/:74<=N0\,AC11N#8P,@_,>..
MM '>+XY\/OJ4=BMY)YDEV;))/L\GE/..L8DV[2W![]JS[#Q[8ZO>>(+,17]D
MFF9C-P]E+D$+EF^[@8R,*>3UQ7GTEKKMPVCW-UX=U=+NR\3"YN(+6UV6T<6Y
M_FC48WDY!,ASW^89P>ITV._TW7/'L-QI&HE+YS<6\\=N7C=3"% !');/& #0
M!N:'XKT>TTSP_8W&N7&H7.IQ_P"B74MI(IN^>3PN 1W!Q@<FMJ;Q%IEO]N\V
M=U^Q2)%-^X?[[@%47Y?G8[EP%R?F'K7FQ\.ZI=?!?0I+6RN8/$.@!+JWAEA9
M9/,C/S)@C)#+G@=>*TO$V@:U-X'TN\CL6O-4@U*/5K^RBE*-,2&WQJPYRH8*
M/9!UH [?2/$.FZY)=Q64S^?9N([B":)XI(B1D;E8 X(Y!Z&N:B\9M+:>(/$[
MR,NA:.9;>"! ,W3QXW2%CVW?(H'N3G(Q8\#Q0337^J0>&+W11<K&K-J#'[3.
MR[A\P+,0H! &>3D\8 KF?"'AF34_A/KO@NYD$-[;W5S:.S?PN6\Q'/JIW*<]
MQ0!TVA6WB/7?#MOJUWX@N+&\OHA<1VUM!"T,"L,HIW(6;@C/S#/.,5G-XCU]
MM3\.>#VG2#7+JR^UZG>^6K&%%X.Q<;=S,"!D$ <X-6O"_B"_TW0K+1M6\/:L
MFIV4*VQ\BU,D,VP;0RRCY " /O$8S5?5]&UBW\::)XU2Q69X;1[/4;.V;?(L
M;$LK)G&\J3R.IQP#0!/X@U?4O ][I-Y=:G/J>DWMVEE<+<QQ+) SYVR(8T7(
MX.00>V*SH=5UJ[\8>,]-E\4RZ?9:-';/;RM!;[5\R(L2Y9.0"/4<=ZL^*+6X
M\?SZ/IEG97MOIMM?)>WEW>6SV_$><1HK@,S,3UQ@ =>U<Q>>"8O&7CGQJE_I
MUY;1WJ6QTS49;21-DL4>&(8@8&< @XW#IVH ZWPMK?B+Q/\ #:PUPA;;5U#2
MB(QXCN@I8 $'D!QSD=#@C(X/3^'-=M?$WAZQUFSR(+N,.%;JAZ,I]P01^%<_
MX.\0ZI'X:FA\5V-S9ZCI4;BXG>%A#.D?_+1'QM.1VSZG&*R_A<U[H7@CPOIE
MQI=XYU$7$[31IF.U4LTB>8<Y&X,,>] 'I%%%% !1110 4444 %%%% !1110
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MW^B6AU71[FVCF2*X;RI8YR CH2N2?8X^O:@#U&BO/;OQUK^CZM?:9J^C6*7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP#^F.^>/1#J^F"1(SJ-H'DD,2+YZY9QU4#/)Y''O3KK4["RFCAN[ZVMY9?\
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M]W.: +5%5)-5TZ)MLE_:HWF>3AIE!W_W>OWO;K4D5[:3W,MM%=0R3PX\V))
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M-M'<W*64EHN!ND @8NR>WJ17H?V.UV[?LT.,YQL%/$4:OO$:A]NW<!SCT^E
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MS=<9VC!Z<"K.FSZ1J3R:+XBU?58?$=MK+W L(+:/S)9A*3&Z/Y9;;M*C);
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'4M;TK1Q&
M=3U.SLA)G8;F=8]V.N-Q&:O5Q4M[8Z!XTU>]UV)HUNTA%E>-"TB")5 :+< =
MIW[FQQG<.N. #L8)XKF!)X)4EBD&Y)(V#*P]01U%25S/@J#R['4IX;62TT^Z
MOWGLH)$*%8BJ G8>4#.'<#CAN@S734 %<!:>+=1UWQ?KVAV6I:?IMSIL@BM[
M6Z@,CW/RY,A^=3M]EY Y)Y%=_7E7BVS\*>*6O_[;CGTK6K&X>*SOX87263;R
MA1@/WGICD@@XQD4 =[INMQ_9])L]6N+:WUN[M5E:TW;69PF7VJ>2 <_2N?\
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MV.KV27FG74-U;.2%EB8,I(."/J#7&?$&^^QZ_P"%=]NT<37$V=32!YGM#Y>
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MFVJ0IP?FQD#KBM1?%F@2:?%?1ZO:26LLC11R)(&#NO55QU(QV[<UXQ<RQ_\
M"KI]%N+6Y-W;^("\]NUL_*&X+''&&^7DXSQUZUWFL+%X?^)&B:R]NL>@/8SP
M>;!#^[@N'8.7;:.-X &[VH ZT^*M 6PMKYM9L1:W,GE02F90)'SC:/4Y[=J2
MT\3Z'JEO>R:?K-C*MF/W\BRJ5AX."W/ X//3BO)-<T]H] U.Y,#BPU+Q5#=V
ML+1-\T0*^9)LQD*2"<XY'/<5U-E=VT7Q3\77!=5MY-+@Q+CY7*@[@#T) (H
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MVSP7DGE6TBR K,_/RJ>YX/Y5HUYKX$T34M-UJYT&[&_2O#MQ(VGS%LF03+E
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MNKNVL;:2YN[B*WMXQEY9G"*H]23P*I6?B/0]0N%M[+6=/N9W^[%#=([-P3P
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MI?"NL7.D'1+CQ*S:6T?DL5M MT\73:9=VWD<$A ?QKK** .-UKP']ON/#O\
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M   9/U)-9L_A&ZM_$6HZQHFKC3Y-3C1;R*2V$RLR#"R)\R[7P<<Y![BNJHH
MX._^&4"0:*WAS5[C1+[2(#;0W,<:R[XFY8.IP&R<GZD\>BZG\.9+J/3+NQ\1
MWUGKU@9#_:AC61IO,^^'0X!'H.@'%=W10!QFH>!)KO2=,CCUZX&K6-Z+\:C-
M$LADEP5.Y,@;<'  Q@ 5G77PPGN]'\1:?)XBD?\ MV>.>XD>T4E"NT_* 1R2
MH]@.,=Z]$HH BM8Y8K6&.>42RJ@5Y%7:&(')QDX^F:PKGP=I]UXXM/%4F?M5
MO:M;^7CY6)/RN?< N/\ @7M7144 <IHO@:V\.^%]4T72[@1B^FFD\R2+<(Q)
MP%V@C(5< <]L^U9T7PZN8-/\+PP:^T5UX?\ ,6"Y6T4[XW7805+$ X[\CVKO
M** .!N/AU=7.E>)[!];C":_.)Y6%ES$>,A?WG/"CK6A+X0U"3Q%HVLC6(!-I
MEF]JJ&R)63< "Q_><= <"NNHH \\B^&=U#X6TC0UUV+R],U(:C'*;(Y=@Y<*
M1YG3<S?ACIC)[Z=;AK=EMY8HY^,/)&74>ORA@?UJ6B@#$T?PU;Z9J-YJL\KW
MFK7@"SW<H ^0=(T7HB#T[]22>:Q+/X=Q6PL+!]1:70].O3?6E@80&23+,JM)
MGYD5F) P#TR3BNVHH Q_%/ART\5^'[G2+QY(TEVLDL1P\;J058>X(%<VGP]O
M[K5SJ.L^)I;Z5M,ETR0)9I#OC?J>"<'O]1VZ5WE% 'G=OX%N?#QT;5Y_$-S=
M)X=M)8DABL$W20;1\@ ).["XSR3VP>3;\)V5AK?BO4?&]K875JMW;QVL0NHC
M&\A7[\FT],@1J#_L'UKN:* ..NO!-UJ6H6<FIZPMU:V6I'4;9#: 31MO+K'Y
MNX_(,@8VY( &:[&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR6)Z<8'..E4O &C^)O!2Z+)_9>H36M[";?5;1R&-JZ,?+E0DXVD-RH]SUXH
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M_(K^IP0#T..":X'PN+JSO?#\GB+2->A>QM5TRRN'MHDBA,FU 7*R,Q)PJ@X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XSQ_\2=*^
M'\%I]M@GN;FZ)\J"' .T8RQ)X Y'UH [.BL/PCXJL/&?AZ'6=.65(9"4:.48
M9&'4'''Y>M;E !117FOC^YBM/B#X,CNM3N++3KMKL7FV^DMXW"1J4W%6 &"?
MUH ]*HKRGPWXLN=';Q3=O)J&J>'(;R"'1Y&)D>9Y#M9$D<Y90Q4;B2,=S70W
M'Q&M;/3?$%Q<Z3>K/H3HMW;HT;'#KN5@V[!&.O<>E ':T5YQ?_$756N]%CL?
M#5[!!?WZP"2\VQF9"F\>6">X[G&,8Z]- Z[HNG^-M>NKR&^M;JPTN.6ZEEE#
M0F')(V*&/.0>P)_F =O17-Z?XKEN]5&GSZ'?VLTED;Z#?L82("!L)#85^1P3
MWZUS.A^-M%T+PEHLVGZ5K,MIJE_-;0([K+*LOF/D-E\\E3C&1ZD4 =E9^&K"
MQ\17NNPFX^W7JJDY:8E6"_=&WH,=JV*XA?B98Q6FM'4-*U"RO])\OSK"14:1
MQ(0(RA5BI!) SGBF:C\0Y;73/$WDZ+,-4T&%)9K>29-FUT+!MP/( !R.M '=
M45QEGXW:/1M(%[9M_:M[:"X\AYX8P4"KF0L6V@$L !UYZ8!QM^&/$EEXKT&#
M5K 2+%(65HY  R.IPRG&1P1VH V**\\?Q9I&@7WC75UTS5FN+"2W%^C2HP.4
M.QHP7P%P03WYZ<5MZ7XTBU#Q*FB3:5>V4T]G]MMI)]FV:+(!.%8E3ST;!]<4
M =117.>*?%\/A:;38IM.O;MM0G^SP_9@I_>$$A<%@<G'ICU(K.N?B+;VUF9&
MTJZ2ZAM?M=U9S21Q2P*<X4AF&YB%8@#L!G&1D [2BN67QU87DNDP:3;S7USJ
MEHU[!$"L>V(8Y8L>#DXQSSGMS5&S^)NGWNFZ+J"Z5J4=MJ]^-/@>01<2$D9(
M#D[<JP]>.G2@#MZ*X3Q-XB@U;P[XZTJ.*ZM[K1K)C))OVY9H6D0J5;/0#.<>
ME,TSQ>-*\-^'[%+"ZO[O^P8]0EV,JA8D10268C))/2@#OJ*X>Z^)EE##H$EK
MH^IWAURW>>S6%$+$JNXH1NR&Z>W.<\5TEQK7V7PN^N2V%VH2T^U/:%569!MW
M%2"0 P&<C/:@#4HKAH/B9;SRZ.#H.JK'K-N9;!]L9\YPH8IC=E>OWFPO?..:
MMV?Q T^?0KW4;BUN+2:SOSILMI*R;S<9 "!@VTYW#G.!R3P* .NHKCK;XCZ2
MRZRMVCVT^E",RQB1)!().(]C*=IR2%Y(P>N*I7WQ,2"UUR*WTMWU33+'[<(/
MM$;))%W?>K$?*>HZ^F: .^HKSN?7H=0TCP3<:_INHI<WEY;-!)#,BH9RF0SA
M7^X<L=N.W.*FO/BC;VEMK%U_PC^JO;Z/=?9[YQY0\KI\P^?YNO1<^IQQ0!WU
M%<WJ7C"WM-6.EV=G-?7B6!U&1(V5 L(.!RQ&6)Z#\\50L_B):ZI;Z2VGZ7>/
M/JL<LUK!/)%$7CCVY;.\CJP '7@D@ 4 =G15.SOI+S1H+\6DJ236ZS"V8@.I
M*YV'G&>W7%<3X=^(MQ=^&Y]6U?2Y86?4&L[2&%T;S9#)L2)>02P(Y8X'4]*
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M\@!4@9/+<Y]..M9FN>'O$EAXWN]<T/3=+U:UU.&*.Y@OGV-"\8*AU;!^7!Y
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MI6XDC" CW&"2/3')/ ]!\26UQ>>&=4M+2'S;BXM9(8TW!<LRE1DGH.<UJ44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MABM[F[35#BUGM@KQM\I;D[A@;06STQ5G7-<T_P .:-<ZMJ<XAM+=<NV,DY.
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MBB@ HHILC%(W<(SE02%7&6]AGB@!U%8/A+Q=I?C72'U/2?.^SI,T)\Y-IW
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MBL"[\8:;8^,K#PM.EP-0OHFE@8(#&R@,3DYR/N'M6_0 4444 %%%% !1110
M4444 %%%% !1110 456LM0M-2A::RN(YXED:(O&<C<IPPS[$$59H **P_$WB
MO3?"EM:R7_FO)=SK;VT$*AGED;H!D@?B2!4GAGQ)9^*]'&IV,5S%%YKQ%+A
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M, [A[<X_ UPW_"/?&'MXMT;'O"?_ (BGQ>'_ (OK*AD\5Z,R!@6 A.2/^^*
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MRR(L,;/CG;N/'<XR>*DE\,> [?3UU";3M&CLF *W#[!&0>A#=.>U<[XZU5-
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MAWAU&UE8\,D@)AC]PK%VS_>2NW\<ZE/IWA.Z6S.+^\*V5ICKYLK!%(^F2W_
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M(QKEVR*$*@(6&W (]!7H= !1110 4444 %%%% !1110 4444 %%%% !1110
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M<:RT=X9XM3OY;\HT>TQN^,@'/(X':NAKF-9\;6FCR:BJV%]?)I<:27SVJH1
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MEMY"D@$A3@Y'8UEV6IQZ5\3?&,U[?3)I]KI]M<,)9F=(^'+%02<?04 >A4A
M(P0*Y6#Q]IIU*2POK6[T^9;)KY//V,'B7[V/+9L,.ZG!IFF?$'3]0N[>":PO
MK$7.GG4K>2X5"LD QD_(S$'!!P0* .NI" 1@@&N:T_QK:WEH+ZXL+NQTYK%K
M]+RX:,QM$,9^X[$'# X('YT:;XVLK_7H-&FL[NRNKFW-S;"?RR)4'4#8S88=
M<'!H ?XG\,3^(;[1;B+4([4:7>"[56MS)YC $8)WK@8)KH@ !@ 8]*6B@ Q2
M8&<X&?6EHH **** "BBB@!,#TKG_  ]X;NM(N)[K4=<N]8NI 4CEN$5?)CSG
M:H4=SC)[[1TQ70T4 %)@9S@9]:6B@!" <9'3I2T44 &**** .23PGJ]IJ5]/
MIWBJX@M;VY:YE@FM(YF5FP"%<\@8  !!P *C/@B[L;];O0?$-S8$VZV\D<UN
MEPC!69MP!QM8EV)P<$GI78T4 9ND:0NEP3[[A[JYNI?.N9Y%53(^U5^ZH  "
MJH 'IW.36E110 A /49I2 1@C-%% !C%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<OX]M-=O
M?#J1>'P[3BZB:>*.81/+ &^=%<D;2>.<CO74'@5QVH_$[PQI6HW%A=W4R7%N
MVR11 Y /UQ1<<8N3LD<YIOAK7=/;QRD?AU(+?6;5%M(X+J-L/Y)0@Y(YRQ+$
M]\XW9S4S>'_$2^&/ OEZ/NOM!GB%S;-<QKN58C&65@2,<Y]?:M3_ (6]X/\
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M+20Z[(R&18B^[!CP6:0 D Y '')QS1U+PCXMMO"7B;PC9Z1%?6U_=O<VE_\
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M_@._^%%T'LJG\K.ZHKA?^%O>#_\ G]G_ / =_P#"C_A;W@__ )_9_P#P'?\
MPHN@]E4_E9W5%<+_ ,+>\'_\_L__ (#O_A1_PM[P?_S^S_\ @._^%%T'LJG\
MK.ZHKA?^%O>#_P#G]G_\!W_PH_X6]X/_ .?V?_P'?_"BZ#V53LSNJ*Y;0_B#
MX?\ $6I+8:;<2R7!4OAHF48'7DUU .10G<AQ:W%HHHIB"BBB@ HHHH ****
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M\*/^%4G_ * NI?\ @PA_PKW"BCD0?6)]SP__ (52?^@+J7_@PA_PH_X52?\
MH"ZE_P"#"'_"O<**.1!]8GW/#_\ A5)_Z NI?^#"'_"C_A5)_P"@+J7_ (,(
M?\*]PHHY$'UB?<\/_P"%4G_H"ZE_X,(?\*/^%4G_ * NI?\ @PA_PKW"BCD0
M?6)]SP__ (52?^@+J7_@PA_PH_X52?\ H"ZE_P"#"'_"O<**.1!]8GW/#_\
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M&)3*JY.U@< Y;#'U(I^@^$M:TW6XM0U/Q=>:I'% \,=JUND,8W8YPG!(QW%
M&+\55U>/PM=V\5A;)X:7:U_);2_Z28MP+[$*A!SWW'OQ7?Z;);2Z7:26?_'J
M\*-#_N%1MZ^V*XU_ &KW&B3:#>>+[JYTB=CYJR6P:X9"VXIYQ8\=ONYQ7;VU
MO%:6L5M @2&%!&BC^%0, ?E0!+1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>modificationno16effectiv011.jpg
<TEXT>
begin 644 modificationno16effectiv011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@GVX'8 [7.**\A\7Z]-XC@\&:I!I?EZ9-XBMOLUVT_[QEWD9,>. V,CDG@9
MS7IFOZW:>'-#NM6O=Y@MU!*H,LY) 51[DD ?6@#2SSBBO+OMETGQJLKO5=/C
MTX+H4TCLMSYH*AU)R=HP5QSU'N:UM.^)VGZCK6DV(B@,.K;OLTD-XDLB$#<!
M-&.8]PZ<G!X.* .Z) !)(P.M+7C-G<:;I?P^^()U'2Y-0TR+Q%=)):QS>6=F
M8P/FR" #CIS7?V_BA8?&-OX6?3S )+'[5;7#3961%P"H&,[AW'H,T =/17'3
M^/K6WL-/EEBMH)]1DE%JMS>+%&\49P93(1PI^4@ $G<O'7&:/BO;OHMCJ%OH
MUS<-<:K_ &2\4,R,$G[;6Z.".01P?44 >AY&0,\FBN".LV][XQ\*G6O#=Q8Z
MO)#>/;R270(M@HQ("%.&RH4Y(XSQ1:_%/3+K5-*@C2"2TU2X-O;RPWB/*K?P
MF2$#**V.#DD9&0* .]HKE-!\92>(+J)K33HVT^2>:!IEN@TL+)NQYD6WY-VT
MXY/49ZU:\4^*/^$7&FRRV33VUY>1VCS"0*(&<X5FX^[UY_QH Z&C(SC//I7)
MCQL@UCQ%IDUD(KC1;=;D@S@^>C*6!7 R.@!SW(^M5Q=Z?=_$RVM+S198=7.B
MM)]I-QE1$74-&%!P?F)^8@=..* .SR,9S2UX,88_^%(*VWF'7SY9S]W_ $O'
M\J]JUO58="T*^U:X1WALX'G=8QEF"C.!0!?HKA-5\;:O!X0UC5[72;1OLMFE
MU;SQWOG0R*V[)R%'*[02O?<.>]2Q^,=2MM,T:*31VN+ZZL6NII'N!'"B(JDL
MTFW +$C"X[\XH [:BN 'Q02XLO#<]AH-[=/KT<IMXUD12'C!RAR?4=>!@Y]J
M?H'BW7M6\?7.EWFD+96L-A#.T+3AGC,F3EL#D\;<#IU[T =Y17/:_P"*/[ U
MG1;*:R:2#5;C[*MR) %BDZ@,,=QT]2#TJC;>.?M)\0P?V=MO=&GC@:W^T F9
MG^YM..-V0!GOP<4 =?D9QGGTHS7 7>LV]GXP\17%IH+'7;+2$E::6ZPDT6XD
M+@9  ()SC)Q7,7VL7^J:5\-]=O[-I+Z;4$($+ F8-&QX' 7)['ICK0![,3@9
M-'6N#N/&,&K>$_%B:KH,ZG2ED@O[);A3OC,>XE7!'52>G-%KXQ%A)H&@Z3X=
MN)1>:4ES9K]I4*J*JX0LQSP" 6//L: .\HK#\)>)(_%>@IJ26LEJ_FR0RP2,
M&*.C%2,C@].M8^@013_$GQA+-&DDD$EF(6=<F/, SM)Z9]J .THKR_2X/$R^
M.F\]+HOB W#>;%Y@M?-GV!SMV,,YR$PVW;R3FI/%T/B0^+H6L5N&S(W]G?O(
MP0WV=A*8SM*IQT\W.6Z8'- 'IE%</X^@1-.T&[,06[&KV$9F('F;3,N5+#MR
M<@<5TOB'61H&A76I_9)[PPA=MO N7D9F"@#\2,GL,F@#3I,C.,C/I7(6GC:X
MO)O$5@NEQC4]%CCD>-+L/'('4L,/M&",'((KS73+F]TWP]X(\16^BP-JNH7\
M=M-J)NL27 FD+,KC'.X*1EL[>WL >]45PVO_ !*L]#EOX_)M9I-.1#>0M?)'
M+N8!BL2$9D(4@GH.< DY 2Z^(LW]NKI6E>'+W4I)+"+4(FCE1-T+L!NP>F/0
M\GT[T =U17(_$GQ#J?AGPA-?Z7!&\QDCB,COCR@[!=P&#N.2/Y]L&KJ?CW4;
M#Q%_8,/A6[O-0^P"^$<-S'@IOVGD^G/N3@8YS0!W&021GD45P-KXCT/2-9\=
M:I)I<]G<:<+=M0E,N\W.(R8]JY*K\N!QC.>:T+#QI<W/B2PT6XT5HI;ZQ%_'
M)%<K(J1YP=V0IW D<#/6@#KJ*X'_ (68)+'3-3MM&EN--U/4#I]I(EPHD>3<
MR@E&  4E&Q\W89QFEUSXIZ9HTMZVRWGMK"Y%M<XO$6X#9 8I#U<*3@\CH<9
MS0!WM%<7_P )W=3>+KW0++PW>7+6<MN)[A9D"K%+_P M,>PP<=2,],5VE !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;>>(@/#*ARKKD$9'N"""15*U\&:9'8:O;7AEOY-8.;^>XP'F^7:!\H 4*.@
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MK-\][#]G>ZNYQ))'$>J)D87/&3C)P/05U6EV/]EZ5:6 GDG%M$L0EEQN8*,
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M'7WH \O\3:7X;T;Q5::)96ME9;-+N;E3?MNM$$C@-Y<;'YI21QA@ O8]*P=
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M(@$9QD'D*3Q]W@BO9[NQM-0A\F]M8+F+(;9-&'7([X-,ETO3YYXII;"UDEB
M$;O"I9 .1@XXQ0!XYXBO/#NK?""UN["SBL6@U*W2\C/RRV\PE DWO][=R3N/
M)!S6Q'HFDV'Q*O(-"M[=-*FT%VU*&$@PE]_[LL.FX@-[D GUKIO&/@P:WH8L
M-(@TZR=[J*>61HMH;RVW $*.<GU]:Z*VTG3[:Q:UCTZSAAE&98(H5$;$]<C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+ZW.HB/S3:B0&0)Q\Q7J!R*N5Y;/<W^D_&!+[7;FTFCM_#<\Q>UMVBVJL@+
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ME7-U:RI#Y@FE="%CVY) !8@'/N: /4:IW&K:=::A;:?<7UO%>76?(@>0!Y,
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M9YC-M'R9W[=W&[&#VSQG4UGQ+#HNKZ3I\MG<R'4K@6\<Z!?+1B&.&).<X4]
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M@U71KC2[_,T%S T$QZ%@PP3QT-7:KWE_:Z?$DMW,L222I"A;^)W8*JCW)(H
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MNQTBV-OI]K';Q,Q=@@^\QZL3U)Z<F@#D/&TD=WXK\.:2#-//(+B86)D,5O*
M@&^5QSA<D@ ')/;K7 Z;/=WW@?P"9=3OO,D\0-:2/'=R M%YDORDYYX4 $\@
M#@BO9-7\-Z-KTEM)JVFVUXULQ:$S)NV$XS^!P,CIQ5-/ WAB-8UCT6U01SFX
M3:I&V0_QC!Z^_:@# \ H;'Q?XUTB&6<V-G=6YMXI9FD\O?%N;!8D\GWJ]\1K
MJ*+2--M))[I7O=3M[>.&V.TW)+9\IFR-B'')].QZ5T%CH6F:;?W5]9V:0W5V
M<W$JDYE/8MSS3M8T33-?L?L6K64-W;AQ((Y5R PZ$>AY/YT >,'6[_1],\06
M,ER;:T/B:WLYS#<NRV=NX4RA'."HXVYXQN[5J:KL\*^.O%5WH, 66+PK]HB5
M27 <2-A@#G@8!Q[>]>C0^#?#5NEY'%H=BJ7B".X00C;(H  !'3' _(&ETKP?
MX<T2?S]-T:SMIO*\GS$C&[9G)&>O?_.* /-X[+35\0_"[4[29IY[L3--.T[2
M&9C;Y9F))R=Q/TZ5E^*8!=>#?B;%/)/.++4XVMQ+.[F/B/IDGCD\=*]5M? 7
MA*RNTNK;P]IT<\<GFHX@'RMZCT]O2K*>$M CCU"-=+M]FHC%X""1/_O9ZGWH
M Y/5HQIOQ$\ V]E-<""2*_#PFY=D<K""N021D%CSU_(5RS7-S>_![_A,8KBX
M7Q3'>>89%E;=YOVC9Y)7.-NTA=F,=*]4C\(>'XIK&6+2;:.2P&+0HN/)R<G;
MCIDDY]>].7PKH*:HVI+I5J+MI/.,@3K)_?QTW?[6,^] 'FNJZ<M]XB^)BW%W
M?E++3X+FWC%[*%CE,$C[@ W8C@=!GI4,U\^MV.B0RW%Q>WR>$A>313SF*",L
MJ@W#,/F:3(( Q[Y%>GR>%-#EN+Z>33HFEOUV7;Y.9E]&YY'MZ<5"_@CPQ(UF
MTFB6<ALD\NWWQ[O+3.=HSV!/ [=J /.[:[FO=$^$]Q=3O-.]VN^21MS,?*;J
M3U->PR()(V1BP# @[6*G\".1]16'%X)\-00V<46C6J)9/YEN%7'EM_>'OP.>
MO%;DA98V9%WL 2%SC)],T >!1V4Z?"23Q3;ZGJ;:]8ZBXM'-Y(__ "\[!'L)
MPP(;G().>N.*ZC3]*:^^(7C2X>ZU&632)K2ZL[5;R39YAA+[2,\@GC'3!(%;
M'@'P%%HFF*VLZ79G4XKJ6=)D?S =SEE;D ;@#C.,\=:ZZST'2]/U*ZU&TLHX
MKRZ_U\RYW28Z;O7';TH \H$LK_#+P]XML+NX?Q#)>P&282L3<.\NQXF7."O)
M&WMM&,5>CO-,UZ7Q2^O:[)IFJZ9J[^0ZW&R2"WC*F/8F<$, V< [BQ]J]"M_
M"N@VFHG4+?2K6.Y,AEWJF,.>K@= QYY SS1=^%- O]9BU>[T>SFU&(@I</$"
MX(Z'/<CMGIVH \]U.[,%[\5H3=R1I#I\%Q;HTK#RG-NYW)S\I+X/'?%5$T[_
M (2#Q'X-L+S4=12WO?#/F7 AO'3S&"I@]>#GGCKCG(S7I>H^$?#VKZ@;_4-'
MM+F[:(PF62/+%"",'\":6#PGH%K>6MW;Z5;0SVB;+=HUV^4O<*!P <G/KF@#
MRV5Y-<;Q&EQXGL](O]+U)HX9IWD-Q;PQ$>65'F ,K*#GY3N+'.35C5+(7VN_
M$U9[R_9++3[>YMT6[E41R_9W?< &XPPSMZ>U>E7?A+P_?ZU%K%UH]G-J,1!2
MX>(%LCH3ZD=B>E))X2T&:>^GDTN!I;]=MVY!S,,YPW/(XH \[T<SVWB3X:7P
MOKR6YUK3YVOVEN783D6RNH*D[1ACQ@"J?AVXF\0VFE:[/XGL;#58M3S=1CS#
M<.3(5-LR&3&T@J  O'!]37J$?A+0(I;"5-+@5]/&+0@']P,YPO/%+'X2\/Q:
MZVN1Z/9KJ;$DW(B ?)ZGZGUZT >/:M;/'X.^(.IK?ZE]KTK6W%DYOI3Y.&BZ
M?-SP<<YKK].TZT_X7E?7)1ED?18+C=YC#<YD*YZ\\ #'3CI76MX+\./:W5LV
MDP-!=R"6XC.2LS_WF&>3]:LGPUHK:C::@^FV[WEG&(K>=TW/&@Z $^F3^9H
MJ^.+2*]\"Z[#,A=/L$S!02,E4)'3W KSW0VC6/X<:#*9%TO4--:XF3SFVSSK
M"A5#ST );;T)QQQ7K\D:31/%*BO&ZE65AD,#U!%8J^#?#::4FEIHMFMDDOG)
M$L8&V3^^#U#=LYSB@#$\#?:;3Q'XNTA9II=+L;V+['YCE_+,D0=XP3V4D8';
M-4OBQI]O=KX3EFC9F7Q!:1;@[#",3NZ'C.!SUKNK#3K/2[46UC;1V\();;&,
M98]2?4GN3S3-5T?3M<LC9ZI9PW=MN#^7*N1N'0_6@#RG5-)MKSQ;\0@TURL=
MKH]L\(AN'3YEA<JQ(.6QCN2.>0>*9;:U<ZK-X3TO5=2M8[:Y\.1W*O?LX2XN
M#@-DJZY<*,C)_B)ZUZ6O@_P]&]RR:3;(;J(0S[%V^9&. AQ_#@ 8Z8XIMUX+
M\-7NE6^EW.BV<ME;$F"%X\B+/7;W'X4 0^!H)+3PG:VLNM#66@:2(7H!PX5R
M,9).=OW<Y/2LCQCX8T_Q3X@MX[74KG2O$UC;?:+2]@//EEBI!&?F7(Y''WNO
M)%=K:VL%E:Q6MK#'!;Q*$CBC4*J*.@ '051U+P[H^KSK/?Z?!/.J;$F9<2(N
M2<*PY'4]#S0!YS'KFKWW@7Q9IGB".V;4])G2">ZMAB.YSL(;&/O8QG\.!TK.
M\8Z;>_#.#6KK28'F\)ZS!+%=6B?\N-PZ%5D4=D)(!_+^[7J;>%M#?2?[*.F6
M_P!@+[V@"X5F[E@/O'W.:OR6-K-8/8S0K+:O&8GBD^8,I&"#GKQ0!Q'B;PUI
MGBFZTBU34+G3/$5I9_:;"]MVPRK\JL",_,,D9'OUY-/\#>(M4#:]I7BN6R%[
MHLT23:C&0D<ZNN59LX ;  /3J!BNHU#PYH^JM$]]IT$\D*;(I&7YXU]%;JOX
M&F_\(OH9T:;2#I=J=/F;=+ 4^61L@[F]3D Y//% &M7'>&/^1^\<?]?-I_Z3
M)78 !0 !@#@ 5S6D:5J&G>,O$-])#&]GJ<L#QR++\R!(50Y7'J* &67@73;+
M73J2/*0@C,*>8^]'!D+,TF[=)NWC(;(^4>@PNK>!M-U?6%OYGE ?<;A-[;I#
MM 3:^[,>TKD;<<D^M=110!QWC\8C\+@9X\06?4Y[M78US/BO2M0UFYT6*UAC
M\FSU.WO997EQ\J$Y &.3S734 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M @#.<Y/<"@#!\->#/$'AKPZVC6OB&R6,R22"X73F,JEV).,RE>">,@_2I'\
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M=3D,#T(/I0!YMJ7PRU273]>T;3-?@M]$UB9KEK>:T,DD$C,"P1PX^4D="/\
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M!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:)(8(E"1QHN%51P !V%8TG@W0I9=3D>TD+:HH6]/VF7]^!T#?-TQQ],CH<4
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M3SS5,> ?"ZZ FAKI,::8LGF_9TD=0S_WF(;+'@<DGH* -+0]&70[%[5+Z^O
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M)OEC,T;*P&W)&U6Y]JU=3,-KXL\06VO:)XBU'3];>.:S?3FF\N9#$JF)U5E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*\0Z%#XBTP6,\\T*K
M/%.KQ8W!HW#KU!&,J*U:* (X(WBA5))FF<=9& !/X  5)110 V16>)E20QL0
M0' !*GUYXK+T'08M"74/+N9KA[Z\>\E>7:#O95! "@ #Y16M10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!C3>'DD\4KK\5Y<0W'V1;1HU"%&C#E^X)!R>H-;-%% !6/XE\/
MIXFT:?2I[R>WMKA"DHA"989!ZL#CI6Q10 @& !Z4M%% !1110 4444 %%%%
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M::WU%D\Q+:[MY('D7N4W@;OPSTH W**S=>U[3?#6D2ZIJMP(+2(J&?!)RQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M62Y:XU%Q)<^;)N5F' (';CCBI];T'3?$6G&QU2V6>'<'7DJR,.C*PY5AZ@T
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MB=PH&TLRC9@'(!ZX]\@&7?ZKXLM/ .I:JNO7ZL-;%OISS118>U\X(C'Y QW
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MAE6)$$B1,^TX<AEYQDCIUS6=K5UXST31;6&YUP0W,GB""W@,;I.XMI6X64E
M21@],9'6NPN?ASX:N_#<>AS6<C6\<OGI+YS><)?^>GF9R6[?0 =A7.^,?!4=
MGX6TG1]"T^^N475X+NZ>.4M,54_.[2$@[L8 P>PQC% &7XBDUO2KSQ9X<F\0
M:C>VA\-RZM!/(46:&1"5*;D4#:Q&< #CCUSZ!X$@:#P)H0:>6;=80.#(1E08
MU^48 X':I+;PGID<%^)OM-W+J,'V>YGNI2\CQ8(V9_A W'@8Y)/6K>A:):^'
MM*BTZS>X>"( *;B9I6    !8\    #@4 <_X&4O/XQ4,5)U^<;AC(_=1<\TS
MP_X"_L/7FOEO&\J)LPA=NZ8-&!)YHVX!W_,-FWT/'%6?"%K>:=J?B2*[LYXA
M=ZO+=02%04>,I& <@^JGBNLH XB^\ ?;/%/]J"^=$<O+)* OFK)OC,:J-NPH
M%5P=P)^;J>")O&O_ "'?!G_89_\ :$M=C7)^*+6\U#Q#X96ULYY([+4A<3R[
M0$5/)D7.2>>6 XH E\>:C-IWAK=;ZF-/FFN88%E6,O(^YQE(P <NPR!Q^74>
M6^*=2U:]\&^/[&\O-2BBTRZLS;Q3RJ9523;NCD9,AE^;.,GMS7L?B+PY8>)]
M-2RU 2A(YDGBDAD*/'(I^5E8=".:QC\-?#SQZO'(+Z5=6C2.[$MV[[RN,/R?
MO94'<<G\Z .DC7[!IA\VZ:00QEFGN",X&3EB !@?TKRSPWXAUMO%/@Z.35+V
M\M=7CO#<SRJJP7)1-ZM"A 9%!P,D+D>M>I0:9;P:4--)EGM_+,;?:)6D9P<Y
MW,Q).<FN:L?AGH&GSZ7-#+J3/I;L;3??2$1JPP4 SPN.PZ]\T 2>.=;NM-.A
M:=:3M;2:OJ<=F]P@&Z.,Y+;<Y 8X ''<FN9TFTGTWQ]\0$AU&[:5-/M9(IY&
M5Y$^1R!E@0<'U%=]X@\.Z;XGTPZ?JD!DA#K(C(Y1XW7HRL.01ZUEV/@'2+"?
M4+B*XU-[J_@%O<7$U[)([J!CG)QG'?'';% '%)XA\0MX.\+:Q<_VK>Z=)I[R
M:E)I;*+E)#C9(1U*@!^!QW/0"M32]=F\3ZO8Z%:Z[<);KH$=XEY#\DMU*QV;
MSD9PN,[>.2<]*Z"U\ Z78VMK;V=WJ=NEK";>(Q7; ^46W%3ZC/KR.V*CU/X:
M>&-3L]-MVLY;?^S8_)M9;6=HY$C_ +NX')!]_4^IH RK;4M3N_%.C>$KS66=
MHM*DNKR\L\(;J9)1%M!Q\N"&) QR/PK#G\2:_:Z)>0OJDS3Z5XFBT\7>%!GM
MV9?E<8P2 V"1BN^N?!6BS1::L$4UE+IBE;2>TE*21J?O#/\ $#WW9R>>M%WX
M*T2]\.3Z%-!(;6>7SY'\UO-:7=N\POUW9&<_ATXH Y+6];UB#6?']M;:K<0Q
MZ=I$=Y:;0C>5)L=CC<IX.T?TQ4.EZAK</B#P/'/K][<Q^(-+F>ZC<1A4=8$=
M6CPO!R>ISFNG7X<Z&O\ :+&346FU*V%K=S/>R,\L8&,,2>21QD\@' Q5F+P3
MID-YHETLUX9=%B,-ENFR$0C:01CG*X7GL!0!YMX=U74-"\"Q-;WUS+/J?B.3
M3S)/,O[L&1R6#E3AF"XR<\G.*V=7UCQ7X2TO5C>7L0CN[FUATXO.+B:T$C;9
M&8E5!48)7(//!S74M\.O#DFG:GI\UM/-9ZA,9Y()+ARD;EMQ,8SA#DYR.?PX
MI;3X=^'+70+W1GM9;JVO0!</=3-)(^W[OSDY&T\C&,'F@# T_3FT[X[;#?7=
MV'\.%@;E][+_ *0 0#@<<9^I-7O&UUJZ>,O"6FZ=K%Q80:E)<17 B1&X6(MD
M;E/S>F<@'!P<<ZFD> ](T;68M7BGU*>^BM_LRRW5])*?+SG:03@CVZ< XSS6
M1XZT:]U?QAX1>"VOC:V<TSW-S:-L,.Y-JD'.?O#D<\=>#0!R.MZ]XGT/2/&>
MF1Z_=33:)>6)M+V1$\QX[@C,;G;SM!ZC!_#BNGUO^W/#-YX8@/B2]O1?:ZL4
MWFQQKNB92=G"YP"O&".OTK=O/ .BW^AW.DW!NWAO)Q<7<AG/FW$@Q@L_7C:N
M , 8%7-8\*V.N-ICWL]V7TV59[=DEVGS%Z.>.3^G)H Y73+_ %7Q/9ZAK4&O
MMILFGZQ)$T+X\B.WA;#(Z^K+EBQ/!(Q@51GU3Q9XC.O76AW4=I-IFIR6L/FW
M82&-(F ;S(]A)W#<<D]QC&*ZBX^&_AFX\1OKC6DJW,L@EFB2=EAF<<AG0'!.
M>?0]\TV_^&OAG4O$+ZU/:2BXF(:XCCG9(K@CH9$!PW\CWS0!UB$LBL<9(SP<
MBG5GVNC6MGK-_JL1F^T7RQK*&E)0! 0NU>B\'G'6M"@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQYBE& 4,5ZYR 1[8I%\8B9["UMM-EEO[X2R0P>:H'DQM@RENRG(V\9.X<=<
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M$7E0' #.Q/!);  SR#Z9KS[0M0L8O@\7UO3[^XM)-9=&CBN-KQ,;CY=S;@2
MV!QF@#VNBN*U'X@M9ZKKFG0>'M0N9M'A2XG*R1*IC*EMP);T' ZGT&#5S_A-
M[2X_L"+3[:2XNM<MS<VT3L(]D80.2YYQU P,\_G0!U-%8'A/Q1'XLTV6]BT^
MZLTBF:!A<%#EU)# ;6/ (QR!3+_Q2\6J7^G:7I<VI7.GPK-=!)50)O!*(,_>
M<@$XZ=.>: .BHKB/^%EV5PWA[^S=+OKU==CE>U:/RUPT8)9&RW# C!)X'J<5
MM>%?$T?B>QNYELYK.>RO)+*Y@E*L4E3&1E3@CD<T ;M%<0_B/4KWXCWWAB73
MF73H].\TNDRAG#MC><$$#@@ '/.?IS7PV\9G3/!/A"RO=-O7@U"9[1+]F7:9
MC(Y P3N(XZXQ]: /7**X?5?B?I.E33.\8ELK>\%G/.EQ'O5\[6819W%5;@GV
M. 1S74:\[)X=U-T8JRVDI# X(.PT :%%<+I,.I)\*]%GT,2?VK<65G*TB[&+
ML50LTA<\J<G<1\V,XYJ'P%)JS^&;HG[5]D%JO]GF/RR"</NV;_FW[NTGR_=Q
MQF@#T"BO-_!+^(3XEO%OC,T?GG[>4V8$_P!GAVAP>GRX_P!7QNW=L5JZ8BVO
MQ6U:U@REO_9-O+Y08[=YEE!;'3) 'Y4 =G117GGQ;L;R'0+?Q'ITER)M(N([
MBX@BF=%N+<,-Z, 1D=_IF@#T.BN/U.:T\5W7AN"SGE-M./[3>2&5D)MU484E
M2/O.Z<'J%;TJ+4?B)!IMW.'TJZ-A;ZC'IDEUN5?WK8Y5#RRC<,G\LT =K17)
MZKXX2P_M*6TTJ[U&VTN5(;V6W()1SM)5%ZN5# GIC/UP[5_&JZ>^I_8M*NM2
MCTK9]N: C*%@#M53R[!2&(X !ZYX !U5%<3=:OIL?Q%8_P!E:A)JD&AO<QR+
M*H22#S%RJH7 W;CU;'3Z5'I?Q+AU(Z!*VB7UM8ZVYAMKJ1XR/,P3M*@[L<'G
M'Z<T =U17#W/Q/TFVNX/D$EC+??81<)<1E@^XKN\K.[9N!&[\<8P3W% !17F
MOQ$\1MJ'@[Q7::;83W,6G1F"YNTG$8CEVAB%&<MM# MT'UK<T_Q&T-KI.CV%
MD]_J/]EQ74J>:L:QQD!068]V.<#'8YQ0!UU%<9;_ !&L+ZRTJ2SM93=ZC<2V
MRVUPZPF*6(9='8Y (X  SG(JQ<^-HK2*QBGLQ!J=TDDAM+BY2(1+&VUBSDXZ
MX QG.?0$@ ZNBN(L?B58:M9Z.^G6CR76J-.D=O-*D>QH<;U+<@G)&,9R#FNL
MTR\DU#3+>[EMI+625 SP2$%HSW4D<<4 6Z*P]6\0+:ZO;Z):6<E[J-Q ]QY2
M2",1Q*0I=F/3)( QDY^F:X3X?>)H-$\#O+>JRW%UK5S!!;S3@$-N)*L[' "@
M'))[<9) (!ZO17DWC;Q9:>*?A9XK\A9+>[TN18I528,-VY<,KH<,I!/^%=+<
MWUB/B#IENVFW<FK)I<LMO-YX6)TRNY=N[KGN0* .THKD=+\>0:OX9BUFWT^<
M-+>BQ%F[J)1)O"$'L,?>//W03576OB=I6BR7<CQB:SLKE;:ZE2XC#H^0&*QD
M[F"D@$^QQG% '<45QK>/RWBJ]T&W\/ZC/)92P+<3H8]B1R])3\WW0,''7&>!
M@U%;_$W2KC4]+@6+-KJDY@M;A)T=BW\)>,'<H;'!/MD"@#MZ*\C^(GB5]<\)
M1W6G6%P=.35H8([\3A0Q64*S! <E"05!/?MWKUR@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FNQ6
M-F5"[ $A1C)]N:=10!Q/P]T+5O#X\0+J=JD?]H:K/J$)CF#@+)C"GW&/I7-7
M7@KQ-<>!O$>CK8VZW>I:VVH0YN1M6-I5DPQQU&S'XUZW10!YQ<:#XNTKQ7J.
MHZ'9:1=V6L-'--%?N0UI,$"L<@?,O'0?IWA\6^"=5\0%T_LZS?484B73]<BN
M/L\T+!5W%E49*[MQ &>N,#K7IM(K*ZAE8,I&00<@T >;_P#".>,-"\2ZF^BP
MZ/?Z=JLPN'DOLJ]M*5"NV /F4[0<#].I[N[MKQM"GM;6Z"WQMFCBN"H&)-N
M^!QUYQ5ZB@#R70_"'BBPUWPQJL^CV(GT^&>*_E^W;YKIG50968KR3@X!)QTR
M!21>"O$D?@72M&-C!]JM-;&H.1<C:8Q*TF <=?FQ^%>MT4 ><7_ACQ"NJ^.&
MM+*UFM?$-HB1.]UL>-Q 8L%=I!Y.<YZ#N:2W\->((=0\ 7!L(2N@6<EO=@7
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M%@ED-]9(DD\;1,H4-G!!( /3MFG:MX>T;7E1=6TJSOA']PW$*N5^A(XH P_
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M 'M3/BC_ ,D_O/\ KYL__2J*M_1M$MM%AN%A>6::YF,]S<3$&2:0@#<<  <
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M#[@4).1COQCC%9+?#?3WT+6='?5=4:VUBZ:[NR6AW&1B"V#Y? )"\8[<8YR
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MO[)MS;6MM$4$0C(P005+'.!SG.:)? ^G7.NZKJEW<W=S_:EK]DN;60IY)B[
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M\84E<\G!]>:EC\#6::GHM^VI:A+)I%NUM;H_E;6C8;6#@1\Y  XQT^M '/\
MA_6O&.KMX?UJ))FTV^Q)>Q3M;"%(W'R^45/F94D##9)] >*3PUXIU*?Q9;Z3
MKM_?V.J-)/OTZYM8UM[A!N*M;R!,M@!>K<\^E;&B?#31] U,7-G>ZJUI'(98
M--ENRUK"YYW+'ZCMDG'7K5O3O!%K8W>F3S:GJ-\NEAA91731E82R[2<J@9OE
MX&XD#\J $\;Z_<Z)9Z5;V3B*ZU74H-/CG*!O)WD[GP>"0 < \9(KAKK4KKP=
MXW\;ZK-=3:G+:Z-;RQ&X5%/+$*K;%48#=\#BO2O$GAO3_%6DG3M1$H02++%+
M"^R2&1?NNC=B*Q[3X=:9#>W]U?7^I:G)?V@L[K[;,&$D?/95&#SV^O7F@"'0
MIO%J^)+?[;]HET6>U/F/>&U#K..08_)/*D9X.<>M<7X=UC4M$^$/A:XTVZ$!
MFUK[-,#&K;T>Z<$<].*[SP[\/['PVS-;:KK%R5C,5J+RZ\U;-2/^62D;0>G)
M!Z8Z9S67X9::GAFST!-6U9;*SN_MD1#Q;Q)NW#GR^@8D_CZ8H HW7BK4?#OC
M?6]-UB^DFLY=/%YI"B.-69@=K1 A?F?<1M![=<TMUK'B/^V;;PQ'<7DM_!I2
M7=U=6:6P>25V*\"7"A 5/09.1R,<]3JWA?3-;U+1]0OHVDN=)F,UNW'+$8^;
MCID*W&.5'TJCXG\"Z=XGO[747O-1T[4;9#''>:=<>3+Y9.2A.#D=?SH Y.ZU
M;QTU_P"#-(N-2MM-U'5([R.^\N".95>%<AQU&2,' . ?;BI)-9\9:F=7L='F
MN9=0T=HK198X[5(;B81JSO*LAW ,20 F  .I/3J#X$T\:CH5[%>ZA$^B^8;9
M5D5@YD_UC2%E+,7[G/?(P:KZO\.-*U7Q#)K27^K:?<W"JMVNGW9A2Z"C $@'
M)XXX(H R)-9U?Q/?>)-,CU!M+&DZ=#YBVR1R>9/-$SG+.K91< #;C/)STK8^
M%G_)+_#W_7H/YFGZA\/M+O-5.HVEWJ&ES26RVLZV$PC6>)1A5<%3T' (P<=Z
MV/#F@VWAG0;71[.6>6WMEVHT[AFQ]0 /TH XG4O$.NZ=XF\3:%-JKK.]E'=Z
M"1!%EF)*&/E<,?,*KSVYXZU?\'>)+WQ99Z;)%?O'/!8L-3C,296YR4 (QQ\R
M2-@8X"^M=-?>'=-U'7M,UFYAWWFFB06[=AO !SZ]./3-,TSPW8:,=6;3M]O)
MJ=R]U-(NTE9&4 E<@CMG!!&2: /*I=8UOQ#X-\ ZE=ZS<)<7GB!;>?R4C57Q
M+)M8KMP2OEK@=.Y!/-7KS^V+7QE\1[K2]6-G-9:=9SF7R$D>1D@<@?,-H!P<
M\>F,5U</PTTN#PS8Z%'J.IB&PO1?6L_F1^;#("3P=F,99CR#UJQ_P@-G]IUR
M?^UM4+ZU;+:W67B/R*NU<$QYR%)&3DG))YYH U_#&HS:OX3T?4KG;Y]W90SR
M;1@;F0$X]LFO.M5\8:]9ZNLT&K&XB/B./3VAMX$:UCMV(78TC(&,W<[6(7H<
M5Z5H>DQ:#HEGI4$\\T%I$(8GG*E]@X )4 <# Z=JY2;X5Z3(LT::IJ\,#Z@-
M2B@CF0)!/NW;E&S_ -"SB@#J]=_Y%[4_^O27_P! -<UH>BIX@^$?A_39)5CC
METRS+,T*2\!$)P'!&>.#C@\]JZ;58';P_?6\0>1S:R(@R69CL('U-9G@7?%X
M(T2SF@N(+BUL((9HYX'C*NL8!'S 9P0>1F@"CX3\)76D:;>_;)H1<WT(21/*
M63RR-P&9"-T@P0<.3CD#@XJKX7\"3:%KCW;W$1AMV*0#R8R9$:) 6&%'DG>&
M^5,*5P".,UW5% ''6_\ R6/4/^P#;_\ H^6CXB:MJOA[1[/6]/NFCM+2\B_M
M&,1*Y>V9@'(R"01D=.Q-.L(YKCXI:AJ*VMRMG_9$-N)I8'C5I%FD)4;@,\,#
MQZUTNIZ=;ZOI=WIUVF^VNH6AD7U5A@_CS0!YV?&M]!XJUW2VU)I8+JW5M F\
MN,+)+N\MT4@?/B1E'/8'KUK<AU75K?XIV^@37_GV)T0W14PHI:42JFXD#OR<
M# YZ5ICP;HJMH!6VV_V%D60!^Z"FPY]>Q^H!HG\*0S>+E\2C4;Z.\6U-HL:&
M/RQ&3G&"A).[YLD]?;B@#RC_ )H:/^P__P"WE>[5Q/\ PK+3?^$7/A[^U=5^
MQ&[^UYWQ;]^[?U\OINY_^MQ7:(I6-5+ER  6;&3[G'% #J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5#D\[6X(SV8<5R>IZ?H\7PV\?WL-M9K=6OB61;2557="OG0X$9_A&-W3M]*
M/H*>\MK9XTGN(8FD.$61PI8^V>M3'@5XKX@O-&NO%WBK2O%FM-IT=VD/V-FM
MD<2VWEC'E.58@A]QP.Y..:]<T=/+T*P3=<-MMHQNN1B4_*/O_P"UZ^^: ,'0
MO%EW?^!D\47ED&CDA\X6MH,N &(/+$ \#/;O4GA3Q</$?VB/[.=\+2,9(AB/
M9YC",?,=V\H QXP,]0>*H?#BRM=0^$^BVM[;Q7%O)!\\4J!E;#DC(/!Y KH=
M)\-Z;H[2R01>9<2M*7N)@&D*O(TA3=C[H9C@4 86A^/4UG7VT\6,R+(5$2$
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M3DAI%?<2?]W&*Z"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXV7I^9C@<'"JI5'JO>2T_NMIO73R/33-$LHB,B"0]%+#)_"D>>&)PLDJ(S=
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MV=-PCJXMOY2:O]R+5%%%:'(%%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+;BW#F_)ARRD@?)SDY%=%:^+=#O=/U"_M[W?;:<S)=OY+CR6498$%<Y Z^E
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M()_L\S"-RL;\?>(7 '(^8\>_% '4T5S*^-;&3QTWA=(KCSH[;SGE,+[<E@%
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MD5[>W^U21R6TJ/Y/_/159067W4$58@\3:1<Z;9:C#=F2TOI!%;2+$Y$C$D
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M;R3"-&)"LY12%!P<9QTK:H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ:6X, 98O-D@B+'RVF.?E 7&>I'2NB\=[W\":Y!%#/--/8S0Q1P1-(S.R$
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MI\H$1$ 0$_+P-_&3Z9Z<U2N-,UB>Q\1W%II.IR&W\5+JHMQ'+;O=VX&T^6V
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MFUU:ZGF@9E</&)6R=QY!P.  .>N1TJ^_A;6V\0^%M4WZ?C1K22WEC\QQYI=
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MC=GBD\LIO0J><@\Y[^O2NK\+:5<:%X6TS2;J>*>6SMD@,D2%58*,#@D]A_\
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M,!N=OS$.57'')]JI&T;P;XD\1>*=1U*RM]"OS!)/OC=I(W5!& ".,$D'H?3
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M/ENK*.36[Y;Z!E9V$3*R':W R/D'(]>E>A6(O!91"_>!KK'[PP*53/L"2?\
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M?Q-7)+W4]*T_P-KEMJ]Y=OJ]W;6U]%-(7CF6=-Q95Z)M(R-H''6@#U"BO-=
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MK.0!GKU/6@#VYT61"CJ&4\$$9!I:XG0[F_T[XDZKX=:\N+O33I\5_!]I<R/
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MU;,D4<T;1RHKQL,,K#((]Q7G5M<SOXF\/>%?MU]'82Z0U^\@G(DF?*JJ;QR
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M37-NC0LWVB$[/*9" <A0O_ <5[+H\\+^&K&9R%A^R(6,HV@ *,YST'UK2HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445F^(%NSH-Z;*]:SN%A9TG1%<K@9X# C
MM0!I45YW\%=5U#6OAZE[J=Y/=W3W<VZ69RS8STY[>U4/%VK7MQ\9O#OAFYN[
MFUT2XM))7$,[0>?+MDP"ZD'@JN!GJ?>@#U.BO-_@QXAU'7/#%_!J=U)=RZ=?
M/;)<2MN=T !&X]SR>:Y[Q#JALOCW::9?:]?6>AS61GGB;5)8(@^U\'(<;>0.
M 0* /::*\G^'/B"_F\4^+2^IW-[X2LR7M;RYE,JI@DD+*W+ #/<\ >O/1:-\
M3=*UG4-,MX[.]@BU83'3KB8(%N?*.&  8E>AQN S0!VU%>;)\9])DTR\U--$
MUG[!8W(MKRX,<6V D@ \/EN3VS^HSMZA\0M-M]333M.M;G5;HV!U%UM2@$<&
M 0Q+L.3D8'7D4 ==17!ZE\6O#VG>&M)\0^5>W&G:E(8D>%%S$XZJZE@01@],
M]/IGG_%OQ>O;/07FTKP]J5K*U\+'S[^)8PC%=P*J3DDC.,C [^A /7**\YO-
M?CD^+>@6-PVOV-[)822+IN^(VT@(D.9-LA&X;#Z\A>158_'+P^+#[<=*UA;1
M+T64TS0Q[8G(R,D.<\!NF3QVR,@'I]%</X@^)^EZ'K.HZ5'8WE]<:9:?;+TP
M; L*?+W9AD_.IP/6NB\-:]%XF\/6FL06T]O#=+OC2<KNVYP#\I(Y^N: -:BO
M#=(U:WB^+7BS3-?\37]MI%I'FV2?69H51B5^Z?,!)P3QS6Q\,O%^H6O@36M;
M\4WMU+I5G<$VEW<J2\L708/5\G !]3C/H >M45QFF_$O2+R6>*^@N=+>+3EU
M0"ZVG?;$9WC83R.,J>>>]5;;XJZ;-<Z'%+I6I0)KLFS3Y7$9$@W!2S /E1R#
MR.AH [VBN(OOB?I5AJ_B#3)=/U$W&AV_VFYVK'AX_EY0[^>'!P<?GQ6+XC\9
MZ;JB>!K]+K7K"#4[Y)+=;78HE^8+Y<PW_=Y'3(P30!ZC17G^J_%O2]*U[5=$
M.CZS<7^FIODCMX%D#K\IW AN!A@<G'Y\4Z[^+.BVIO'^Q7\EKIWD#4+@(H%J
MTIPJLI;<6!X8*#C% '?45Q.J_%#1]*U^YT1K#5+F\@MOM0%M"KK)'MW94[N.
M,GG'3Z9I6WQD\/70T5TL]5%OJTWV>*=[<!(Y=P7:QW<D9'*Y'/7J  >AT5Q&
ML_$_1]'O]4M_LMY=0Z1Y7]HW, 79;F1MJCE@6.>H4'%1ZM\5=)TO7;G1QINI
MW=S#9_;5:WC1DDBV[]P)<8^7)Y Z>I (!W=%>5^+_BQ);?#2Q\2^'K"5EU*1
MK=)I]H^ROEARN3N;*MCMQR>@.WJ?Q-L]+U%M-FTB^_M&.S^V36GF0>8J9/ _
M>8=L MA2>/?B@#N:*K7]_;Z;IESJ-TY2VMH6GE;&=J*,DX^@KC],^*&EZCK>
MCZ:;"]@&LPF>QGD\LK(HSPP5B5/RGK0!W-%>;W_QGT:P;6D;1]8=M&G6&\*Q
M1[4RY3.[?C&X8]3GIP<;.I>/=,2_T?2+2VN[^]UJV^T00VY6-EA*EM[,S+MX
M!QSG([4 =?17E?P,U;4-6T#6I-0OKRZ:/4G2,W<S2,B[5PN6)(^E5_BQ?ZAI
M_C7P3!8ZGJ%K#J=[Y%W'!=R1K(@DB&,!N.';D8/- 'KE%>1ZKKVI^!?B[HND
M)J-W>Z)K85#;7<IF:"1FV J[9;&=IP2>I]JZ)_BIHBWK*L%V^G)J*Z8^H@+Y
M(N""<8W;BHQRV,?AS0!W5%>&VWB*\MM;^*$5_JNLM862A8A;W!>2V#,P+1!V
M &..A'3BNIT'XC:98Q^%-"D@UJYDU6VC^RWUV(_WN>"7;?G<".1R>1US0!Z3
M17):E\0=.TK3WNKJRO4=M0.G6L&$+W4H;;\F&QMSD98CH:IW'Q1TFT\/:MJT
M]C? Z1=_8[ZU41F2)RVT'[VUE)QR#0!W-%>=#XR:(%$DNEZQ!!*L/V:::V"+
M.TOW0I+8['D\84D9XS/+XYMM?TGQ?I<,%]IVJZ/:2F56D"LIV,59'C8]QZB@
M#OJ*\8\!?$QM'\">'G\20:M<1WUS);_VM-(LJES(V 27WX XSCL<9Q4WA_Q8
M^C?$3X@3:SJMVVD:8JND4LSR+%ENB*2<$D@ #U H ]AHK@D^*^C1V]W)?V5]
M8O!IR:FD4H1FF@<@*5VL0&R0,$CK]:W?#'BN'Q.)V@LYH$CCBE61I(Y$E5]V
M"K(Q!P5((X(- '045Y!\9M1O-(USPD]KJU]8PW=V8KL0WLD2-&&CZ@, .&;G
M@TNGZW=-\;+/3?"^KW6J>'FLRVH@W;W<4+XDQAV+;3D1\ ]S0!Z]17"W7Q4T
M2VOKE/(NY+"UODT^XU!0OE1S-GC&[<0,8) _.B^^)]G:^(-8T.#0]6N[[2H3
M/.(EBV^6 &+ E_1@<8R>F,T =U17%_\ "S=#GTK1+RP2XO9M:D,5G:1A5D+
MX?=N("A3U.?IFF-\4-'3PUJ^LM:7N='N?LU_: (987W[/[VTC/<'U]* .WHK
MR_4/C''_ &%>ZAI/AS5IA#9)>1S740BA*LP7EMV3@G&!G.#CCFK.F_$Y;;P_
MX:&KV-R=5U:W#QAI((UFPBDN"7VJ&+853@Y["@#T>BJ>DZ@NK:3::@D,T"W,
M2RB*9<.F1G##L:N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  SSHW_0Q:S_ -]I_P#$T =[X&\'6G@?PW'I5M*9Y&<S7$Y7;YLAQDX[#
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M>#_$]A8Q7-QI^EIIU[8O=+&051EW!^01\V?P'KQW?_"!^$?^A8T?_P  H_\
M"C_A _"/_0L:/_X!1_X4 <W\(_"VM>$]+U>WUJ"WB>ZO3<Q^5,'R" "#@<=!
MW[]JI_$WPYKWB#Q9X4OM)TI[BWT:Z^T3.9XDW@O&V%#,#GY#U ZBNP_X0/PC
M_P!"QH__ (!1_P"%9FG:'X U74]2TZT\/:4]UIK(ETC::$V%@2OWE&<@9R,B
M@#&N?!FK^+?B5IGB?6H8M.T[254VMH)A)-(X)8,Q7Y5&XCH3]WWS6%X6^&^L
M>'M>U*QN- T35-+N+L7%MJ-XRLUN,_W""S-C'' R.O->D_\ "!^$?^A8T?\
M\ H_\*/^$#\(_P#0L:/_ . 4?^% 'FESX&\427GQ"D73$*:^H6T/VF/L_P#%
MSQP<_A5W5_ASJ^K?"WPUI\2I:>(M%DC,3^:IV_-AB&!QTVOZ_*!7??\ "!^$
M?^A8T?\ \ H_\*S$T/P!)XDD\/KX>TK^TH[?[4T1TT >7N"[@Q7!Y..">_I0
M!B?$KX>WVN^&-%AT)HIKW2)A(L=RX N 0-Q8G@L2 3GKDU7\0^$-8U?X:ZKI
MUEX9TG2M0U&6$FULI4  1PQ>23"ACP0  <9ZG)QVW_"!^$?^A8T?_P  H_\
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MQN =[94D8Z =R.O2ND_X0/PC_P!"QH__ (!1_P"%'_"!^$?^A8T?_P  H_\
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M<D^3;1-(P'4X'0>I/0#U-7*R/$&@1^(;6"VFOKNVBBG2<K;%/WC(P90VY6R
MP!QW[T >2Z;,WACQ_P"'M>N([^.77@]IK+7%I-%&MQ(V^,*9% .#A!C^%/<U
MU/C?Q1JFA:[/%<WU]I&E/:I]BU""T2:W$Y+!A.61BH^X!C'&374^+/"5IXQT
MB/3;^[O(($E6;=:LBN67H<LIQ^&*J:AX(34X[N&YUW5FM[Z)8KR',.V<!=N3
M^[^4D=2NW^5 &KX@NY[?PMJ5]83HDT5I)/#+M#C*J6!QT/2O/+3Q'XML=/\
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MM;P^4(E1AAA@H3R ._';%7O$6@VGB?P_>:-?&1;:Z0*[1$!A@@@@D$9! [4
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M_F375Y,99I6P!EF/L  !@ "DU+PYINK:QI6JW<.^ZTMW>V/8%EP<^O8CW H
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M@L6))))))ZDDDD^IK ?P#IYFU-4O]0CL-5G:XOK!73RIG;&[DKO4-@ A6&:
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MVB=GC-RREEW$L0"JKQDD_C0!R^KI?/\ &O18EU6ZCMCILTP@ 0HI#*" "O\
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M-YJ+(J97.UBH.?O>XZ5K:C\---O]0M]035M:LK^.%8)KJSN_*DND'02$#!_
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MG6K*WO)(GBNDQM\M]K'!(SUXY'/H >BZ)XHM-;U#4=.6WN+34-/9!<6UP%W
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M-)Y;#(=2KE2/^!<=ZP/%WQ!FN?!D\^D:9K-MYUS!;I=21+#E)&0[D)8$[E)
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MB""*TZYK2CK.G0Z/:#P_90P7#2M>"TF5([ <LBA<#S"<X)&.<GI72T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5EWWAW3-2U
M:QU2[@D>]L23;2">1?+SUP P'(X/'(X/%:E% !1110 4444 %%%% !1110 5
M!>V5KJ-G+9WMO%<6TJ[9(I5#*P]P:GHH P=*\%^'M$N5N-/TR..5/N,SM)Y?
M&/EW$[>..,<5O444 %%%% !1110 4444 %9:^'=,3Q"VO+!)_:;1>29O/DYC
M_N[=VW&><8Z\]:U** "BBB@ HHHH **** "BBB@#+U/P[IFL7ME=WT$DD]D_
MF6[+/(GEMZ@*P&:U*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M] -I'X'TKI]?\/7OA[XN*=&M$-CXNMI+2? P(' !DD''4*-^.Y+5W[>']="
M+X@@.T':/[+CP/UKRRWL?CG#?+=R6MK<2HTK1F>:!@GF;<[1NX VX'H"?6@#
MW6TM+>PLX;2TA2&WA0)'&@PJJ.  *\<\37EK%^TYX8DDN(E1-/,;L7&%8K<
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M8^A/WB?Q/K7JQ\/ZZT:QMXB@,:?=4Z7'@?09I%\.ZXK;E\0VX.,9&EQ]/SH
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M)>/:V5D5CE<Y)SC/'Z ':VGCC2M2TO3KW3([F]?4 Y@M8E59<(</N#LH7:<
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M@C:?0_6@"YH]S?+\4-?L)]1N;FT2QMIXHI2NV(LTF0H4#C@<G)]2:P/%NJW
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MG)/F<8V?J/?&Y>Z%J^J^/EO)-+N;;3[CP[)IDMP98B897;=T#DG'3('7VYH
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M^=E!Y(  )/M6+I^G:HGQ8U/5I=,FCTVXTZ*WCN6DC(+HQ)^4,6QSZ=JK>/=
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M1(K:*1V*NOF 2$L. RD$+C=GJ._?^)M>7PMX4O=:NT$YM(0Q1/E$CD@ #.<
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M>5*89 X1\9VDCOS7 :5X_P!9F\3:#IU^FF_\32:YBGMK=&9[,Q@LBF8.R.Q
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M,20#]: .ANKJWLK=[B[GB@@3&Z25PJKDXY)X'-9W_"5>'?\ H/Z7_P"!D?\
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MT KO20JDDX Y)KF-%\82:Y<V+VVB7O\ 95_&\EOJ&5*84G[Z@Y3=CCUR.G.
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M\&IZ;:PZ=<7,%X7\RZCQLMPJY!?//S=!0 FG:'::?X:MM!&Z:T@M%M/WAY=
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M'!O]6U&-[Y[VWNC!<-%]H2-7",0#U('WNO.00<&K-@=>GT+7M,TR]FNY-/\
M$[PP6UU?NDEQ;HH<P+,3NSC)Z] <\5Z5/X7T:XNM.N'L@LFFC;9^5(\:P#&/
ME52 ...G(XZ55_X07PZ$E46,G[VY^UN?M4NXSX(\S.[(;#'D<_D* //-1UMI
MOAW+<Z?)K&FW-KKT5O<6UQ=.9('+IOC+[LNF&XSQ@].*O^(KV_T?Q9<:CJL5
M[<Z&^HVWD:A87S?Z$5* PRP!@"K,#DX/W^YP!V\_@KP]=:7_ &9-I^^T\XW#
M(9I,O+_?=MV7;@<L3TIS>#=!>\:Z>Q9Y'E69P\\C))(N-K,A;:S#:.2">* /
M/=.TB5-9^)<>E7TME?F:*.VFEO) JO)$,9RW4L<!CDC/&*Z'P#J+2:UJ^FWN
MG:AI>J0PP-/9W%VUS%CYP)(G+'ANA'^R.IS70WG@SP[?W]Y?76EQ2W-ZBI<.
M6;]X%P!QG&< #(YQQ5O2]!TW1I)I+*W999@HDEDE>5V"YV@LY)P,G S@9H Y
M:24^(/B9JVA7\UU%:6.G0R6T,%P\/F%R=\F4()(^51G@<^M<-JLMWJOPRT27
M5KJ[N)K7Q$EFEP9W0SQ+.5#-M(#-A<;NH(R#G->O:IX:TC6;N&[O;4FZA4I'
M<12O%(%/5=R$$K[9Q45_X1T+4M.M-/N=/4V=F0T$$<CQI&1T("D#(['MSZT
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M1MUNXGD3RF_O*%8 'WZU!<>#="NKZ]O9K.1KF]A,%S)]IE!DC_N'#?=XZ=*
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MV,"X\-P7N9KV2V-Q,_#MNCY9@%SCW)QZ>@)X(\/1->M'8,AO81;W&VXE DC
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MRE6E_OGYNO?Z\UJ6FB:=8:E=:C;6P2\NTC2XF+,S2!!A<Y/8=^I[T :%%%%
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MI=<>5)Y:* Q/W3E6 S62)(8OAY//F5'L_%WVN +"[)CS=R&15!;RR,\@'G&
M: /:;#Q!H^J7,EK8ZG:3W,63) DH\Q,'!RG4=1U'>F:CXGT+2)W@U'6+&UF2
M/S6CFG565,@9()Z9('OFN1^'^H:5J/B7Q#J,6H1/J>J-%,]FD4J"*.- @(,J
M(7R3R0!U%0>*+S3=/^,GAZYU,QI NF7&))$W*C;A@DXX[C/OCO0!W$?B'1YM
M(35H]3M7T]R MPL@*,<XP#ZYXQUS4/\ PE?A_P"PQWIUFQ%M+-Y"2&=0&DSC
M9_O>W6O(&T^]T1(_$"6>HIX=_P"$BN[L0V*%98X'B\M)@F,A<[CTZ$>M3>(H
MM$G\$S76FV6H&TU'6K:XD>^5B]UAAYCA",[0."<<\_B >DR^)+/4]2T7^QO$
MVE^1-/()(-RR/=*H.5CYR,$9)_R=*;Q/H=OJ L9M5M$N?,$7EM(!AST0GH&/
MIUYKCO%HL++QOX%^RQPQ0K>SS2>3& H$D9 <X&!N8]3UKFMLLGPOUSP=J%O+
M)XF:\F"0M$VZXD>?>DRG&"O(.[/ '- 'I7BWQ-9Z#I%[_P 3.TM=02U>:%)A
MO/ X)4$'!/&>F:F\(:I<:OX*T?5+YU-Q<V<<TS ;06*@DX[5YU<7DGA[6?&]
MCX@CN9)M5L(Q83I;/*EPJP%"@*@X(8G@^I-=S\.2?^%<^'T:.6-X[*.-EEC9
M""% /! /X]Z +_\ PEOAW[ ;[^W-.^R"7R3/]H78)/[N[.,^U.UC6;.VLK^%
M=8L;&\CM3*)+AUQ#GA9&!(^7=CZ]*\ZO?!^I7>M^*_!\,1AT/5=NK1W0Z0RM
MD%!QU,J*WLJGU!JY!<:E?_"+7]7U^ P:I>:;+:^6P^;]W&T:C'JTA=@/]L"@
M#7N/$&KVGB#P+9#4+6[M=6BE^U2Q0X$S)!O#J<\*200 /QJ[X.UO4M5U;Q/:
M:A+%(-.U'[/"8XM@";%/3)]?6N-ANX3??"5@QQ!:NLWRG]T3;",!O[OS@KSW
M!K?^'T\<GB?QMM)_>:IYL9((#IL"[AZC((XH Z[5->TG10IU+4+>UW*7 D?!
MVCJV/09&3TYHO=?TG3HH);O4;>))UWPDN#YBXR2H'48(Y''-<!K6JQ>&OB)K
M<GB'3KVZT?6K""WMY8;9ID&T.'A(7D;BY.*6PNO^$>\>6E]J=E)IFCW.AQ6M
MD'4LEJ4?/DN1D*Q7!Y],9.* .ZE\3Z##;V=Q+K-@D-[_ ,>SM<*!-_NG/--M
MO%.@WNFSZC;:Q92V5NVR:9)@51N, GU.1CUR*\C?31I^D^&DNH/*M9O&#WUO
M!+&1Y-F6?:64CY5Y!YZ;A5RZ73;O7_'UO=W%U:P7%_8-!=6:$M&Z*/WJC'(5
MP-Q'2@#O]:\2V4_A>^N]*\1Z=8212" 7EU@QQ2\,5(.,G:>GN*TKSQ)H^F3K
M:W^IVT5SA-REL$;CA21VR>F:\EUZ]U6\^%GC&UU&6+46^U0)::C!;&,ZA_JR
M3L'!*JN"5X^4^F:O>*KQX-7U35?#>HR/>S+;)<:/<6IDAU-=B%3$0,@A7P<'
M(*\XH ] T[QIH^J>*M0\/VUS&UU9*F_+8WN=^Y5!Z[0H)(_O>U:^H:G8Z5 L
MU_=16\;,$4R-C<Q[ =S["N*T*;[%\8?%<5S',CZA!9/;D1.RN$B<.=P&!@\<
MD<\=:E\733:7X_\ "^M72R'188[F":54++;R.HVNV.@.-N>@Y]: -?6O&FDZ
M=X/OO$%M?6MQ#!')Y6) 1),H.(_KD8QUJOX/N]8U-8]3GURRU'3;BU1O+BA"
MO!<<%E!7@K@]#ST_'B-5M]GAGXE:E"K)IVKNHL$V$>?((@'=%ZG<^>>^TGI7
MIGA:=+CPGI,D;AO]#B!QV8( 0?0@\8H D/B+1AJBZ8=3M1>LYC6'S!N+@9*C
M_:QVZTQ_%&A1ZF--?5K1;PRB'R3*,^81D)_O8[=:\F\,K:3+IWAK7[#Q!-X@
MT[4?/$/S" R"4L+@/C 7#%B2>><9R*S]4U 3OEK>XL6M?%\=Q<:?#:R,JKYG
M,\DA!+,W8*0,=%/6@#VR]\1Z-IUZEG>:G:P7#,JB-Y ""W"@^F>V>M<O9^-U
MT_QCXKL/$6K6-M8:?):+:-(!%_K8V<@DD[CT_+/%<U;ZK;:=?>)?#GB/0-0U
M"?4]4>^L46U9DNT;:8EW?PE=J@YP%QST-1:B;:76?BU+)&C2SZ9#%;L4SO86
M[(RH<<XDVCCOB@#V..1)8UDC=71P&5E.00>A!K.B\1Z--J@TR/4[5[TEE6$2
M#<Q7[P'J1W'45G>$R]S\.-'2WD*3_P!EQ1!B,%)!&%.?<,/TKB? VK6DEAX?
M\.W_ (;OSXCT9RI$L#*D'4/-YG3!4D^Y(^M 'HD/BC0KC4QIL.K6CWA=HQ")
M1EG7[RCU([@<BL7PWXBO;G7/%UOJUU;BUTFY18Y @B5(S'O)8DGIZDUY?IVI
M++-X/N6M[FS6UUJ8SZ9#9R&.S+&3@N5+.[=>O?A16CJBWEY)\0#ID5Q<.NJ6
M5V88 0]Q#'M\P(>^"IZ9Z>] 'J\?BOP_):W5R-8LA#:8^T.TP419Z;L],]O7
MM3K#Q/H6J:@;"PU>RN;L1^888IE9MO'.!]17F%W<:%K'AGQ7K.EVVLR3SZ/)
M:RW6HAEW.1\D2J?O-G/(Z<#/-.RIUWX?)IK1Q3)H=Q"'48$4K0JJ!O0[P1@]
MP: .F\7^.4L-3T&ST;5;-YKG68;*[A"^8Q1FPX!S@$=#U//:NGN?%&A6>H_V
M?<ZM:17>]8S$\H!#-]U3Z$]@>M>-QZI#_P (;X(T22QOH]6TC7;4WUN;*0M'
MM9RSY"D'.<\$D\^],\6WIN8O%$'V>XL98==AD:SAM7?ST5XQ]HDD(. 0.%4J
M/8YH ]DF\6^'H+]K"76K!;M9D@:$SKN$C9VH1GJ<'BKE_J^G:4;<:A?6]J;B
M010B:0*9'/ 5<]3S7 ^'4TS5/B[XIN9;:.<26UD]L\T'=%RV-PX96V9'4$>H
MJU\6&A-AX<CF42*-=M99$V;OW2D[V(_N@'GZT =$?''A46<EY_PD.F_9XY?)
M:3[0N _7'7TYK0O-:TS3[:&XNKZ"**?'DL7'[WC/RX^]QSQVKRV^>R/B;XIS
M;$+3:3%%!)Y?^L(@9&53CD[B@('?%.T2[?2=0\"ZQ?\ F#1E\/?8&E*,5M;G
MY"V_CY<A-N3Z4 >DGQ1H*Z?;W[:Q8BTN7\N&4SJ%D?.-HYY.>U5G\;^&5TS4
M-136K2:VT\9N6@D$A3/3@<\]O6O*M=L!'X8UFX,!6PU+Q1%<VD+1D;X@R^9(
M%(X4X8YQR.>A%;6H!;SQMX\BLP)#=>'1%#Y8XED".-JD=2,CI0!K7/Q :XOO
M!E[97MI%I.K>8;U'VL82L/F;6?.%VY&>!TKM]*UC3=<L_M>EWT%Y;[BAD@<,
M PZCCO7D=M>V5]'\*8F1W6R41W"RP.HC=;=5!.X=-^ &Z9!YX-;/A#7;'06\
M;WMPDY@_MYY%$$#.7638@90!R"V>10!Z'JQU$:9+_9(@-\2HC,X)1<L 20""
M0!DXR.E<=!KGBF;XA7?A?[?I06WT]+P7']GR98E]NW;YWZYKOJ\UL;F$_'[4
MI!(/*?1DMUD_A,HD!* ]"V,\=>* )['QEJ&E^,+W3_%FHZ;:VMOID-PS*OE(
MLK.5(!+$G.,@9KLYM=TJWT^"_EU"W6TN ##+O!67(R-N/O< GCL*\_O7LC\6
M?$4UPJ%5\/B%9'3(W;F+*#ZX(R*Y32KN71M"\$ZM?)JHTFWTZ>RN'L5;S+28
MNI!=<9 (7'^>0#W.QO[34[**]L;F*YMI1F.6)PRL/8BN U?QK)J'B;5M%TGQ
M'INE-IUM&Z3W 5TEF)8LC$]%55&<<@GVQ70^!+/3[3PZ3I=G>VME/</-$+TG
MS)-V"7*GE03G /;GO7()?VJ?$3Q\TDJB&;3841S]V1DC8,JG^(@G! H [FS\
M7:!=6LDB:YITQ@B22=HIAA0W"G&> 3T^HJW;:_I%YI\]_!J5J]I;EEFF\T!8
MB.H8G[I'O7CMO9?8?A9X,U:STZX9-/N$;4UL8MMR% D!/3)VL^[!]<^]3:M'
M9W'A^;Q!X?L-9FLFUBQN]1EN4<O=QQ,=^V,C)"_)DXP?^ T >JV_BK0+LSB#
M5[1VMXS+,HD&8T&/F8=0.1R:G37](D-B$U.T8WXS:8E'[\=?D_O?A7GUAJ%K
MXB^*FK7.G>:\%QX958VDA>(R9E89 < X[9QVKG-#U-)[+X:6:6M]Y^F73Q7J
M_9)/W+!&7!^7\>,X'7% 'L4GB+1HM3739-3M5O&?REA,@!+XR%_WL<XZU4N/
M&WA>T9UG\0:;&4E\EP;E?E?^Z>>HSSZ5Y;HZVDC#POXBL/$$^N6^IR7$<*;A
M!,QE9UG#@8"X;))/KUZ4NIFU?3/BMM1&EN9%$&$YEP@ V_WOFST[T >O:GKV
MDZ,BOJ.H6]L'4NOF/C*CJWT&1D].:$U[2)-1BT^/4[1[R:(310+*I=XR,A@.
MZX[]*\OBUJ'P_P"(6N]=L+N\T76=$M;:">"W:95**P>%@.06+$X_R-3Q-IMS
MI^C>&O%>B:0UM?:.4A73F;#/:R$1^23_ 'AE3WP<]: /1;2^M;Y9&M;B.98I
M&B<QMG:XZJ?<>E4K_P 3:)I=R;>^U6UMYEVEEDD V;N%W?W<]LXJ;1K Z9I-
MO:NP>8 O-(/XY6)9V_%BQ_&O-%G73[/X@:'KL,KWVHW=Q/9J86?[7%)&%B6/
M ^8C:%P.E '3>+_&,.E:YHNA0ZK;6,VH22&>Y?:Q@C6,L#@\ LVT GWK4BB\
M4P>&8H6N]/NM9\Y5:Y\@B(QF3ER@8<B/G (YKA)4ETCQ+\+++4)<W.GVD\=X
MV<B)FMU0;F[98$ GKBO6Z . T[7/%6H>-M>\.B_TE/[,A@D2<Z?(?,,BYP1Y
MW&/K72-XDL-+M;2+7]0LK/4&AC:>,R *CMP>IX4MD D\XKD/#5S$_P ;/%SK
M(#'<6UJL+_PR,B88*>A([XK#U>2TM/%7B?1_%-KK\L&KW"RVGV%&>.ZC,:J(
M_E_B4KC_  [@'JFI^(='T4J-2U&VM2R[P)7 ^7.-Q]!GOTKF;KQBVE_$>YT_
M4]3LH-#71EODD<!-KF79RY/S9 .,8Z]*YI[Z#PMXJUNR\2:-J$VEZU8VD-IY
M4+7(VI%L> E>=V2Q]\YXS5FT>R7XL137=DEI%#X52'RI!N6W<2%C%NZ;@AY]
MLT =[+XIT""&TEEUJP2.[0R6[-<*!*H&2R\\@ 'FJ.H^)]-O?"=[J.C^(],M
MU4&-+^5U>**3T;GK[>XKRGP\T'_"-?"^"Y3$EIJ$QN$D0YAY?!8$?*,E<9]1
M5K4IHF\-_%.*/EKF]W6ZJO,N5494?Q<@\B@#UJYU_3-'L;9]6U6UC=X0YD+;
M0X &YP.R\]>@R*=?^)M#TM(6O=5M(5FC,T9:0?/&,9<?[/(YZ5YM_;=OH/B>
MXN];L+R\T36]'M;>VG@MFF5=JL'A8 9!8L3BJNO72QZHU@FDW&B;_#)@M?*@
M>::9,MMMNC*@'!;C=_M #- '<:[XBO;7Q5X0@T^ZMY-,U:659-J!BZB(NK*^
M<8/'0?C5[QSK-]X>\&ZEK&GF#[19Q>:%GC+JW(XX8&O.=.O86MOA./W@^RJR
M3;HF7RSY&S)R.F[C/3.:[?XJ.H^&NMPYS+-;F.)!RSL2. .I- &<WC/6=&U;
MPO%K#:?<V.O1G]Y!$T#VSA V3N=@R_-UXQ74V?BWP[J$_DV>MV$\GE/-MCG4
M_(IPS=>@(//M6-X3T'05TG2?$!C,M[%8(OVBYN9)C!\@WA=[$1]P0,=Z\^TS
M19-1^".N1Z38JVL_:K@L!%B9XS.&90<9(:-0..N * /8-.\1:-JURUO8:E;7
M$RH)#&C@L4/ 8#NON.*AG\6^';6=H;G6["%U=HB99U5=XZKN/&X=QG-<F]S;
M>*O'OA'5=$#M'817+7K^4R>4CQA5B?('S;C]WJ,$UPVC:CHXM=+T?4=1-E8:
M3KTFH)+<VEP)FVR2$))^[\M>6Y;>>.P.: /91XM\.M?K8+K=@UVTP@6%9U+&
M0_PXSU]JFM_$6C7>I?V=;ZG:R7GS8A60%FVG#8]<'KCI7GVBV5OJGC/XB?9X
MH'OI3"UC<.@.&$!4,C'^Z_4CH:SO!<NEZA)X>L;O3/$)U[1%"O#<!EAM2$VN
M^[IM(' ZG('O0!ZA:^)M$O;PVEMJ=M+.%=]JOG*J<,0>A )Y-.TWQ%I&KW#0
M:?J$%S*L8E*QMGY"<!AZ@^M>3:),U@8+"TNKG6?##Z9=N]K-:E+O3$\O=Y>_
M SNSM /IQP,UO^ I;^V\4+I46I'6]%@TTFWO9;4Q36GSJ! YP-Q(&>>?E[4
M>FT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5DB;^)7! X/!'7T!I6^)31#3WN/#&KPQ:C=QVUJ[>7^]WIN5@-V>??IWQTH
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MBC4M"DM7@ELK47@FDD7RYHCT9>^.Q/8T =+15"PU":^T.'41921RS0"9+9V
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MJ7'V>SA*AY-C-C<P4<*">I%7Z ,?7+;5]0\)7MO8S1V>KS6C+&Z.2L<I7LV
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M#*M]1WJ:UMH;*UCMK:,1PQ*%1%Z*!T H X+P=HWC/2?L6D:G#HJZ=IZB-;^
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M-_X@U>]DO0D<UW<2*\@B1MP1<C"C/).,GUH AMM:\26OC>?0;F_LY4FT,ZA
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MSXQUC4O%/@#QM>6]^+6PT^XEL4MEA5O.6,KO9V/.22<8Q@ =:]4TC_D"V/\
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M[*/3+N.[A6!4_P!9']S.X'@9/% '+P?\E!^(W_8,M/\ T3)6Y\,/^28^'?\
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MO[J*^T=D:SU"$(LR;0!@\;2" ,C'.*VM/TFXL]3NKV;5KV[^T1QIY$I41QE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJHVY#@=1G<,\9&>U<3;:C:-#X(N8K%M(\CQ!<65Q;M(&$;GS"T88<%-YX_\
MK4 >ST5X)XAN(I?!_P 2FM[HA+?6(3"89B @+1J<8.,<MQTS73OX<TQOB[>Z
M.RS'3[G01>7%L;F3;/,)BN]_F^8X/?OS0!ZI17A.EL^H^"OA=)=7=R[RZDT#
MN+AP60&0;<@^B@>M-U'1[*'1/B3%&9EBTB<2:?$+A]MLYC#%D&>#GO\ EWH
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ML,$FBPN8[? 3=YG8#@< 'CZ]Z /3**** "BBB@ HHHH **** "BBB@ HHHH
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MU1-I4#)ST] *E\0Z=J%KK5Y>>'(-7L]:$EM"]H+5YM/U%%2,;BQ7:NT$KN+
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MNG6?]CZJ+N/Q(+IXO[/FW"(3E]Y&WIM(_EUKW%6#*&&<$9Y&#^5+10 4444
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M;Y.<AB<#N />JD?@7Q%#=>&YA<Z7(NF:5_9TD4_F/'&XP//B7 RY4 8./3-
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M4;*L5/!Z<@UJ5X5X=OM9T3P5H&IV>K21P2^(C9O9")/+>*2X<-N)!;=GH00
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB)MR*I   !)/3GOFNGHH R='T&ST6>\GCEGGO+YU>XN+APTDI50JYP   !T
M%5I_"5G<>+8/$KW=X+^"(P1@,FP1DDE-NWD')YZ^];3P!YXI=[ QDG Z'(QS
M4M ',KX$T6/5]4U"-9T755*W]HK_ +BXRI!+)CKR3D8.?J:SK/X?Z/X5TW4)
MM.&HW,GV62*WBFG:?R0PQMB7MGCW]Z[>B@#SOX>^#A#X5T%M8_M+[1IX#K8W
M;_NX)AD;E7&3U.,D@9XQ6Y+X!T>2>^(DO([._F\^\L$FQ;SR<$L5QD9P,@$
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M](/+Y0)QZ=S]233-9\'Z;K?AZVT*9[B#3[?RPD=NX4XCQL&<'I@=/2M^B@#
M'A.V'B5_$ O[[^T&L_L1?>FWR^OW=N,[OFSZ^W%3^&O#=GX5T@:782W#VJNS
MH)W#%2QR<' XR2?QK8HH YM/!.G"\AFENK^>&&]:_BM99MT4<Y9FW 8SP6)
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M@_\ Y_9__ =_\*/^%O>#_P#G]G_\!W_PHN@]E4_E9W5%<+_PM[P?_P _L_\
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M'_\ /[/_ . [_P"%'_"WO!__ #^S_P#@._\ A1=![*I_*SNJ*X7_ (6]X/\
M^?V?_P !W_PH_P"%O>#_ /G]G_\  =_\*+H/95/Y6=U17"_\+>\'_P#/[/\
M^ [_ .%'_"WO!_\ S^S_ /@._P#A1=![*I_*SNJ*X7_A;W@__G]G_P# =_\
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M_P#S^S_^ [_X4?\ "WO!_P#S^S_^ [_X470>RJ?RL[JBN%_X6]X/_P"?V?\
M\!W_ ,*/^%O>#_\ G]G_ / =_P#"BZ#V53^5G=45PO\ PM[P?_S^S_\ @._^
M%'_"WO!__/[/_P" [_X470>RJ?RL[JBN%_X6]X/_ .?V?_P'?_"C_A;W@_\
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MHY$'UB?<\0_X52?^@+J7_@PA_P */^%4G_H"ZE_X,(?\*]PHHY$'UB?<\/\
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M7_@PA_PH_P"%4G_H"ZE_X,(?\*]PHHY$'UB?<\/_ .%4G_H"ZE_X,(?\*/\
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>modificationno16effectiv012.jpg
<TEXT>
begin 644 modificationno16effectiv012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^9S^-2']G^\,_GGQWJ'G>5Y/F>0=WEXQLSYF=N.W2O4=&\3:9J<\6G17HDU
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9.=P_.GZ);7^BZYH.IW5E>/8R^'H=/D$=N[O:SH0Q#(!N ;.,XZJ,]J]'HH
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MQW<1DAGB)#8.T@@@C((]: (K?QC>7VE:7=PZ+);-=B;[2]ZYBBL_+X^=]O\
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M#@U,VH^*-:_MJ/1;M%O-,NQ:Q&21%C)14+&5-A)#Y;H1@$8P020#T%55%"J
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M7#:1K=]XPU/4[2.[GTM;2RM)$$(4OYL\9D+'<#D#A0.G#9SQC$M_$WB'7H_
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MH"2,",- &QTX ). ,5K:CJL\_CBS\-QSR6T4FGRWLLL>-[D.B*H)!Q]YB>_
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M;)>1A&4W<I$(4D$EBO(RN2/P[5<EU"SMY#'/=V\;CJKR '\B: ,F7P?ID_\
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M3&"@(ZJ0!P>*W7D2*-I)'5$499F. !ZDU'%=6\\KQ17$4DD>-Z(X)7/3([4
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MMH7#XW[XU<9)/7YL<4 /NO!6E7NE7FGW!N9$OKE;JZE\S$DTBE2I) X V)@
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M-E+$DUA!'FU08\J,C"?A@5>6&) H6- %Z *.*4(H<N% 8@ MCDXH YWQ5/\
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M^Z"<GMS7H'@AU;P#X=96!']F6W(/_3-:VQ#$"2(T&0 ?E'('2G!0!@  >@%
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MRTD_#GX?3F*V\Y]?6)I.-S1F28,I/4J1@$=,5[QY4?\ <7TZ4GE1XQY:X^E
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M@ P!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K+UW7[#P[:0W.H-*L<TZ6Z&.,O\
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ML<T81EE;?M?<P8,#D="#[#FO4;,.+* 2(8W$:AD)!*G'3CB@":BBB@ HHHH
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M]CC!3[V>1V%&C>*[V_\ $5_HDQL;HQ:='>Q7$$;I&VYF4J<LVX C[RG';J*
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M!!]",UH @@$$$'H17CM_KUIX=\8?$>XOM*DOK24V$,GRJ8DW0$#S<G(0D\D
M_P L]3HGG> ?AWH6FW-T+^[>1+:*6-6D0M(S,-H'S,JKG&.H4=,\ '=45Y_K
M'C37]'\-^(;]]+1GT[RGM;B:WD@BN4<@$;&.X,I//.#QTJW+XMU30_$Z6'B&
M"R6QN[.>[MI[3>3'Y(#2(^[[WRG(88^E ':T5Q+>+M3M=,T#7+N"U_LO5I88
MWAC5O-MA-_JV+;L/R5## Z\9Q4-KXB\4ZM?:[#9QZ3;6^EWDML\L@D=RHB#*
MP7(!.XC(.!@^W(!W*PQ+*\JQH)'P&<#EL=,FGUROPWNK^^\ :1>:A<K<37$
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M9^ZRDC<,<CMQU!K4H YJPT9I[K3-:U/4(;HV-LRVIBA\I$WJ SL=S9;:,9&
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M76[6&W98X>8C$25(.[D')R,<CBK%IX3U&'Q*^NSZW'-<R::MC(BV81"59F#
M;L@?-TR?KCBNKJCJ6H2Z>MJ8K"YO//N4@86X!\H,>9&R1\H[T <O8^ )+'3O
M"]FFJJRZ!,TJ,;;F;(9<'Y^.&/Z5M:%X>?1=3UJ\-X)QJET+DH(MOEG:%QG)
MR,**W*1B0I(!) Z#O0!SC^%YCXEU;65U! U_9)9B(P9$87<0V=W/+'T[51M?
M CVMCX5M5U-67P^^]&-OS-\A3!^?CACZ\UN>&]?@\3:+'JEM#-#$\DL82;&X
M%'9#G!(ZJ>]:U '!'X=78M1:)K^+>+6!JUN&LPS*_F%RKMN^?D\'C\>URX\#
MRW$'BN-M5'_%0J%D;[-S"!&(^/FY^4>W/Y5TNJZ@FDZ1>:C+%)+':PM,Z18W
M%5&3C) Z#UI=*U"/5M'LM1B1DCN[>.=5;JH=0P!]^: .6E\"7+7DLT.MF)+G
M2ETRY0VH;*J" R$M\GWCD<Y]CS7.ZMIS:--H.BWFNK;QZ;IPBBNKO2?.MIFX
M08&?ED"ISELX?CJ:]6HH X)/#EYXET&W5M26SN]-N1)I6IV5B;<*-F#^Y8G*
M<LN,@,,=NM_4/!U]JOA^.POM?DN+S[7%=27;VR@$QL&55C4@*N1[GD\UUU8E
M]XGL[*]T2W$<LZ:Q)Y=O/%M,8^0OD\YP0., T 5F\+2MXBU;5Q?H#J-BEF8O
M(X3;NPV=W/WCQ]*R3\/)X='T&+3M>EL=5T6$V\%_';AA)$<91XR<,#@=^HS7
M=44 <M>>$;F]&B-/K,DUQIMZ+Z2:6 $SOM*XPI 1<,0 !V'7G-34/  U&T\5
MVTVIE4\0,CDK!S RJJC'S?,/E'IWK8U/Q1!IFOV.BFQO)[R^CDD@$(CVL$ +
M<LXQC(ZTLWB&2.PU"==$U)[FRVDV85#)*&Z%,,5(Z]^QH ACM=?B\0Z>S:OY
M]BENRWD'V-41G^8AU?)(.=H"\\ DG.,N\0^'9]8U+1]1M-0%G=:7,\B;X?-C
M<.A1@5W#G!X.>.:WE.Y02"N1G!ZBEH X3_A7<XTZ>S_MO<DFM_VP&:U&0WF;
M]APPSSCD8^@J]?\ @6#5=0\0S7]WYEMK5K%;20I%M,0CSM96W'G+9Z=A6MX@
M\00>';:TGN+>:5;F[BM%\K;\K2,%!.2.,GMFKFI7RZ;9-<M!-/AT010*"[,S
M!0!D@=6'4B@#F[/P?J8UK1-3U3Q#]NFTF.:),68C,JR*JY<[C\WR\D8SQP.<
MZ/B7P[-KDNE7%MJ'V.YTV[%S&7A\V-SM*D,F1GAC@YR*@A\8I<:O?:5%HNJ/
M>V,:2SQ#R?E5P2N#YF#G!Z5T%K<+=VD-RBNJ31K(H<88 C/([&@#%\,^&Y?#
MTVKLVH&[34;Y[W:T(0QLX4,,@\CY1C@?C576?"4^O2>5?ZC#)8K>1W<*FT_?
M0%&5MJ2[^ 2O7;G#$>F.IK(/B&!?%Z>'#;SBX>R:]$Q"^64#A,#G.<GTH P=
M5\!37\WB18-9-M::_&!<1?9@[(XC"95BWW2 ,C&?0BM"U\*S6OB>TUI=15FM
M]+_LT1-!]X;@V\D-URHXQT_.NEJO?W3V6G7-U';373PQ-(L$(!>0@9VKGN>E
M '(6_P /GM_#6B:,NJJ5TK4AJ"2FVYD(D:0*1OX&7//IBK-QX*DN&\6EM34#
MQ%$L3C[/_J (O*X^;YOE^G/Y5U-K,UQ:0SM#) TD:N8I,;D)&=IQW'2I: .7
M3PC(NJ>';UM04_V-:26H00$>:'55)SN^4_(/7O658_#J\L;?08!XA+Q:+=O/
M;9LQN9&# JYW<M\Y^;IZJ:Z;6O$$&AW.E0SV\TG]I7BV<;Q[=J.P)&[)SC"G
MH#5O5M2BT?2;O4IXY9(;6)II!$ 6VJ"20"1G@4 8-C91>!-*UW4KV[DNK>XO
MI-0D$%JQ:,R$ J%!8L!@?K2^#M'LK675]:LH9XH]8NOM*),C(57:!G8P!7<V
M]\'GYA4EGXWTVY.D^?!>62:NJM827*+LF++N"[E9@K$<@-@FNEH QO$GA^/Q
M#8P1&=[:YM;A+NUN$7<8I4/!P>HP2".X)IMOH,J:I<ZQ<7<<NJRVRVJ2K 5C
MBC!+8";B3ECDY;L.F*VZ* ,3PCX?/A;PS9:)]K%TEHI1)?+V$@DGD9/K52^\
M*2W?B34-834$C-WI?]F^4;?=L&YF#YW#)RQXQ7344 <A;>")+:/PG&-35AX>
M4JF;?_7@Q^7S\_'RGWY_*M*3PM9R>-8?$^]UN8[0VS1C[KG/RN?< N/HWM6[
M10!SG_",W%IK^I:KI6I+:G4U3[5%);^:-Z+M61#N&UL8!SD' XJ";P3 J>&H
M=/N1:VVA2^;%&T6\R_(5.3N&,AB<XZUH>(O$UKX:CLGNK6ZF%Y=):1?9U4_O
M7SM!W,,9QUZ4:?XGLK[7)]$DAN+/4X8A.;:Y4 O&3C>I4E6&>#@\&@#(TOP/
M=Z/J<ZV?B&Y309;AKDZ5Y"':S'<RB7[P0MSM ]L\G*P>";VQUV\N-/\ $=U;
M:1>SM<W.FB%&S(QR^R0\H&/4 =S@CMV%% '+ZAX2EU>_M9-2OH9X+2_%[;?Z
M+B>(AMP02[ONYP#\N2.*VM/M;ZVFO6O-1-VDTYDMT,*I]GCP,1Y'WN03D\\U
M>HH S(]+F'B.;59;I)$-N+>&'RL&$;MS$-NY+';GC^!:S4\+30>/+CQ/;Z@D
M?VFT6UFM?L^1)M.5<MN^\.G3IQ[UT!N8!=K:F5?M#(9!'GG:" 3CTR15;5=0
METVU2:*PN;UFF2,QVP!90QP6.2.!U- '*K\/I%\,P:-_:RXBU3^TA+]EZMYI
MEVXW]-QZYZ?G76ZG;75YI=Q;6EV+2XEC*+<"/>8R1C<!D<CMS5NB@##UKPW%
MK/@VX\.N\4<4UM]G#B+*H , A<]1@$<]0*H?\(A>22>&9+G6%FET-B0YML&X
MS'Y>6^?@X)Y]?RK4;Q! OBV/PZ;>87$EDUX)?E\LHKJA'7.<MZ5KT </>_#Z
M6]TG7]/.K*BZSJ"7SN+7)B*E"%'S\C]VO/U_#6D\+M/XLN-;GO%9;C3!ISVZ
MPX^7<6W!MQYRQ[=*Z*B@#A]-\ 75F/#:SZZ9H] =OLR+:!-Z%"@#'<<L >HX
MZ<5#%\.;N&RTZR3Q"3;Z;JIU*VWV8+\ER5=MWS',APW'N#V[ZB@#"T?P\^E^
M(=<U9KP3?VK)$YB\K;Y9C0(.=QSP!VZU%JGAF;4?&&C:^NH)%_9:3(D!@W>8
M)5"MEMP]!CC\ZZ*B@##\6>'F\3Z(=-6[%KF:*;S/*\SF-PX&,CNHI-6\.O?Z
MQINLVEXMKJ=BKQB0Q;XY8W W(R[@<9 (YX([UNT4 <#XHTB/2/#MT&N)O-U;
M48Y=0O%M/.C4<??BY_=;8U3'N,GDFH]%M;W4K._TJUU73KS3KVVE26ZMM):V
M$3L H.=^V0D$\#!&!D]CZ%10!R-[X&^V^$=(T<:K-;WND"(V>HP1A61XUV E
M22""N01G!S5VWT36X=/C$GB1KC41,))+F6T41N@!'E^4I&%YSUSGOTQT-% '
M)Z=X.GT>"X33]0M8C=W<MS=0M99MY-ZJI41[QM "@_>/)/8XK5\->'[?PSHJ
M:;;,&19))3M7:H9W+D*O\*@G '8>O6M>B@#F+'P>L&O>(M1O+J*\@UU8DGM6
MM\*JHA0#.XY!!YR*ST^'A7PK_P (]_;=S]GMK@7&ESA,3615LH-V?G"Y(Y X
M./3';T4 >:>/-+U'3_A1KJ:KK4NK7TT<:"4P+","1<!8UXSU)/)/T  ZF/PX
M-2OX=2UB[AU QVDEM L4/EQA)<>8Q^9MQ8*!G(&,\<UT5% ')V/@IK?3M,TJ
M[U(W>EZ7.DUK$8=LG[LYB61]Q#!>.BKG:,]\W-%\--I5QKLDEX)UU:Z:Y91%
ML,9*A, [CGA1^M=!10!B>$M!F\,^'+31Y;[[8MJGEQ2>2(\(.@(R<GWS^ I;
MWPS9WOBK3_$$C.MS9P20A5^[(&*E=WKM() ]3GM6U10!B:!X:M?#5O?PZ>Q"
MW5U)<@.,B,N<[0,_=!R<<=36%;_#Z2W\*Z'H:ZLI72=02^28VO,A5V<*1OXY
M8\UW%% &%:^'GM_&5]X@-XK"ZM8[8V_DXVA"2#NW?[1[>E&I>'I-0\5Z-KBW
MBQ_V8DZ"#R=WF>: #EMPQC:,<5NT4 <2GP]"V,T9U0B[&L/K%K<)!CR96))4
MKN.Y>2,9'!K3N/"B:@FKR:C="6\U.P.GO-#%Y:Q0X;A%)8YR[$DDYX]*Z.B@
M#-T#3;C2-#M-/N;Q;M[:)8A*L7E@JH"CY<GL/4\Y^E84/@8QVNK:9)J/FZ1J
M=[)=SP&#$O[QMSQ^8&QM)&/NYP2,]ZZ^B@#D+OP9?)XAN=3T3Q'<Z3#>[3>V
ML=O'*LC*H4,F[_5MM &<'H.*Z2\LC<Z1/812>7YD#0J[ OM!&,GD9_.K=% '
M(3>!1-X)TO0!JDT-SI7E-9ZA#&%>.2,;5;:20>"01GG)HO?!5YJ_AN2PU?Q#
M<76HF:.>&_2!(O(DC.Y"L8XX.<Y))R>>F.OHH \ZL+:YC^+IM]3OUOIF\.^5
M)*L0B4DSYVA03@XYQDGOTJUI_P /+FSA\/V\FOM+;Z%<F6U06JJ63:RA7.XY
M(#8W #Z9YKNZ* .,OO <E];^*X6U15'B$KO(MO\ 4A4"<?/SP!^/Y5:U[PA-
MK%II,EOJ\NGZOI?-M?P1 CE0KAHR<%6 '&>PKJ:* .2O_!ESJ&F67G:[<-K5
MG="\AU(PK\LF-I'E# V%>-N??.<DV]"\-7.E:_JVLW>IB[N-32!942W$2*8E
M*@J-Q..3P3^-=%10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<3\7(5E^&&MLQD!CA
M##;(R@G<!R >1['(KMJHZOH]AKNG2:?J4'GVDN/,B+LH;!R,X(SR* .8,ID\
M=6_AAY[N/3UTAKU<74H>:0RA#^\W;L*!TS_'["N9O=5UM?"PMCJEW'-9^*H]
M,BO _P \T'FJ!O/\1 8J<]=O/>O2;O0--OC:-<0NTMGG[/,LSK+'D8(#@AL$
M=1GFF77AK2+W3H-/GLE-K!*)HXU=EQ(#D-D$$G/.3WYZT 3:=I:Z=IIL?ME[
M=(6<^;<SEY<,2<;^#@9P.X '->.6UFD?P@T]XY9U>3Q"B[FF9]N+Y@" Q(!]
M\<]\U[D!@8K _P"$)\.^1) -."PO<BZ*+-( )0Q8, &XPQ)P.,G.* .-U+6M
M0\+ZCXXBMKVZGAM+"VNX!<RM,;=G+J[*6R<<!L=!CI72:'::A'KT-\NK0R:7
M=V?%J+R2Z\UP01,C./E&#@XX.1WK;&@:6-0N[\VH>XO(A#<,[LPEC&0%*DX(
MY/;N?6JV@^$/#_AAYGT;2X;1YOOLA))&<X!).!GL.* ,3QBUV_C/P?8P:C>6
MEO>374=PEO*4\Q5@9AG_ ![=1R 1S,NN:IX=N]6T.34IIM/AUJTMHKV\N&WQ
M131&1HVEP2 "%7=U ?J.".M\5^'[K6O%'A>Y2V>2RL)IY+ETF\MEW1E5*D,&
MR&P>/2MN3PWH\VD7&E36$4UE<L6GCER_FL>2S,226X').>!Z4 <'XK77-!\%
M^+9AK3)B*&>SBANI));3)VM^\;YBK$$@=N<5?\26]YH$/A\V^LZG*U[XBM1.
M9;@G*.,-& .B$KG;TY/;BNA@\#^&[709M#@TJ./3IR#-"KM^\(QC<V=QZ#J>
MU7K[0=.U.&SAO(&E2SE2:#,K@HZ_=;(.21ZF@#CTO+O7]-\97+:A=6=YI5[<
M06AAF9%A6*-61B@.'#'+'<#D''04FAZW=^*O$%E8ZH\]F/[!M[\V\$SPF264
MD,V5(;"X  SP6.><8ZVX\-:1=7L]Y+9CSKA0EQMD95G X D4$*_''S \<=*7
M5/#>D:S=6MU?68>XM<^3,DC1N@/4;E()4]P>* .=^$J&/X>VJ%F<K=78W-U/
M^D2<FL74)-4M_$/B;PH-2OQ=:I"EYH<WVIPT9/RNH;/"HPW$#^'/M7H>DZ-I
M^A6(LM,M4MK8,SB-,XR3DGGW-3/8VLM_#?/ C74*/''*1\R*Q4L!]=J_E0!Y
MU::W+XH^'^JZBS3Q_9-#FM+B)I&_X^@C>:&!/)7:N">?G-1Z%)=:5J/P[6"^
MO)(M3TF1+F"28M&WEVZ.FU/NJ0>,@ D=<UZ"VB::VG7EA]E5;6\:1[B-"5\P
MR$ER2#GG)S4,?AG2(IM,E2U8/I:&.R/G/^Y4C:0.>F !SV&* .+\.7>K^(M-
MT/Q'#J\%N7N5^VJ;N1U<,2K6_E$;48$@ CD8'7))Q;F^U2'PCKVM#6=2-WIO
MB5H+8&Y;8(Q<I'L9>C+M8C#9]L<Y]&MO!7ANRUZ37+;2+>+49&+-,H/WCU8+
MG 8Y/(&>3ZTK>#M!?3KK3VL2;2ZN/M4\1FDP\NX-O/S9SD _44 /\81B7P9K
M:EG7%C,P*.4.0A(Y!![5Y\+)!HWPKBCFN$\Z2-V;SF9AFS.0I8G:/88QVQ7J
M\D$4UN]O*@DB="C*_.Y2,$'/7BL>W\'Z%:Q:?'#9%4TY]]H//D/E-C;D$MSQ
MQSVXZ4 <(/$5_HFGZ_9F_E>VM_$45DES=W#%K>"0(Q!D.6 R2 QR1N]A79^'
M[+4K'6-06[U&.6TG2.6"S^T/.T!Y#-O?G:W&!T!!QWJZ/#&B^5J436"21ZFV
MZ\21F=9CC&2"2,X Z>@]*=H/AK1O#%H]MHUA':1.VYPI+%CVRQ))QVYXH Y/
MQ2MR_P 6_!PM98HI?LM]AI8C(OW4[!E_G4_CR75])^%&L7#ZFXU*%6<75KF$
MX,ORX&21\I ZGIUKJ+G0--O-8MM6GMV>^M0RP3>:X,8888  XY[\<U+JNDV.
MMZ;+I^HP>?:2X$D18J& .<'!'% ''WT-UJ7Q4FTB35=1AL)-!$YAM[EH@)/.
M*[@5Y!P!T]/0D''\/:S>:]X<\&QW>J7D]]<6]P\MI [1-=!#L$DDRL"BKP3U
M+$]#BO0E\/Z8NJ'4A!)]M-O]E,WGR;O*Z[?O>O/UYZU23P1X<BAT^*/351-/
M+?9=LK@QAOO+G=DJ>ZG(/I0!YZ=0O=3^$OABYU"X>XNO[>@C:5VW,P2\9!D]
MSA1SWKV*L!/!7AZ/38].33@MI'<?:DB65P%EW%@P^;C!)('0$\5O@8&* .$T
M#_DL?C#_ *\['_T%ZKW5QJOB34O$ME9:C'8W>F7*QP.;R2,P+Y:.)&C4;74D
MM][@CCM786WA_3+36KC6(+=EU"Y4)--YKDN!T!!...W'%5-3\%^'-9UB'5M1
MTBWN+Z$ +*P/('0, <,!_M T 8$=Q<>)]>\0Z--JT]E<V5I;?99+25HPIDCW
M-,%!&\;B!AL@!<<9.:T]JFJ_%+3(WOYWCD\-2%I[:0PM,/.3D,O*@]?E(_*N
MIUKP9X=\17T%[JVDP75S -J2/D';G.TX(W#V.1R:N-H6FMJZZM]G(OE@^S+*
MLC+B+.=H . ,\].M 'F5CJ^KWO@_P)))JUZL]QK365Q,DF&FC4S ;O4XC7K5
M_P"V7]GI'Q)L8=2O=NE*TEE+).TDL)-L),!V)8C=TR:[*+P=H,-M96T=B5AL
M9S<VR">3$4I))8?-UR3^9]:E?POH\@U0/:$C5 !>_OG_ 'PQMY^;TXX[<4 <
MGI6I2ZWJMAH-]J%U!GP[;W<313M')-(^5>3<""Q7"\9ZL2<\8GNC+<7NCZ.N
MO7>HW4-A,TL5NYMOM!5EC\^21&RH#;AM&[).<'&:W=3\$>&]8L[*UU#2HKB*
MQ4+;;G;=&N,;0P.[' X)Q5BX\*:'<W%E/)IT0DL8O)MS&2@2/^YA2 5X^Z<C
MVH \Y@U*\U?P5\,[Z_G:>ZEUJ'S)6ZL0LPR?? %>@^-?^1#\0_\ 8,N?_134
MV#P7X?MK*QLX=/V6]A/]HMD$TG[N3^\/FZ\G\ZUM0L+;5+":RO(S);3H4D0.
M5W*1@@D$'!% '!^'O"UQK_AKP1=:CJ$?V'3+>UO(+:"W*L\JQ#87<L>%ST &
M?TK.T^[U2VT'Q;XD_M34KJYT>_U&.UM7G+0E$&%#K_%MZCIC'USZ9I^GVNE6
M$-C91F*VA0)''O9MB@8 !))P!4.G:'IVDQW4=E;^6EW*T\ZL[.)';[S'<3R>
M_K0!R,\UWID_@W4-/U"[O!J<\=M=I+.TB3H\+.90I.%*E-WR@#!(Z8K.8^(M
M1BGCAGU$:LOB!HQ)"\@M_L8?D;A\FT1Y'][>,?>KNM.\.:3I+1&RM?+$(985
M:1W6$'J(U8D(#Z+BN'MO!-RTLXNO#T<=]++)(VH6FL301,S,6WB-""#S]W'X
M]Z +D-K>:G\2M>LGUG58[33X;&XA@@N2H+?.2#ZJVW!'?/L,0>'+C6/$&FZ!
MXCBU:"W\R93>J;N2190V0\'E$;48,0!CD;>^2:[6PT&RL+Z3455WU">)(KBY
M:1LS!1@9&<>O0=S52T\%>&['7I-<M=(MHM1D8LTR@_>/5@N< G)R0,\GUH Y
M?3]4OK#Q5;66NB^AFN;B=K+48KII;*\0J[*C)NQ&0N"!C^#KS4GA+4+RU\16
MVD:_%J5KJ_V.3#O=-<6FH8*%I8R3A6'7;@8#X]*ZJW\+:/;31RQVKDQ%VB5Y
MY'2,N"&**S%5)!(R .I]34NG^'M,TR:.:U@<211F*(RS/+Y2'&53>QVC@<#'
M0>@H Y3XJASIWAL1,JR'Q%9;69=P!W'!(R,CVR*J>$IFNOB7K!\2@)XHM8/)
MM4C&V![(MD/$#R26^]DD@\<<BNWU;0=-UP6XU*W,XMIEGA'F.NR1>C#:1R,\
M&DO?#^EZA?V=_<VN^\LLBWN [+(@/4;@02#Z&@#B=(N]9\16,&MV^J06LT&H
MNMR&NY&78LK(8&AQM!*[0#][.#G)K/EAU*_TWQ[>#Q#JL$^D7T[V12Z*I%LA
M1P".C+GC:<C&>,DFN[3P7X<C\1-KZ:1;C5&.XS@'EO[VW.W=[XS[UBZ!X/']
MK>)+G6+%_+O]2-Q$AN"8Y8MJ@!T5MK<J3A@>M %?1-5O/%6NMI^JR7-F$T6T
MNE@MYGA9Y)@QD?*D'Y2 H'0'-8L6K:Y?:;X1@N-3NXY9-;N-.GN(GV&ZBC\U
M0QQW.P<^HS7I-]H6G:C>0WEQ PNH4*1SPRO$X4]5W(02O X/%,G\.:1<KIZR
M62A=.<26BQLR"%@, @*0.G'XT <9HVB0Z=\7YK<7>H7)AT&%O-N;MW=SYSKE
MN<'@#C&.^,\UK_$B[N['PY:SV=W/;2?VE:(6A<J65I55E..Q!K?ET'3)]<CU
MF2U4ZA'%Y*S;F'R9W $9P<$Y&1P:?JNC6&MVR6VHP&:%)%E5=[+AU.5/RD=#
MS0!Q.K:E?:1XJ:;5X[XZ3<7T"VFI6-TQBM^47R9H0< %@P+8/W_88W?'^M7&
M@^$I[RVD\EWFA@-QC_4+)(J-)SZ!B1[XK0;PQI#W37#VSLSS+<.C3R&-I5QA
MRF[:6& <D=AZ"M"]LK74;*:RO8(Y[:9"DD4BY5@>Q% '!_V;#9_&*WBBFNF2
M3P[/_K;J21@?.CY#,2P_ ^]8^E:SJ<O@SX<7DFI7;7-YJ:0W+F=LSH1+D/S\
MWW5Z^E=_IG@[0='O(;NRL ES!$88I7E>1DC/\(+,>/;M44'@;PU;-"8M*C @
MN/M4*EW*Q2<\H"<*/F)P,#/.* .5M+S6/$EM>ZE:ZM!875AJDL<I>[DVPQQR
ME?*>$#:=R <GG+9![#TH$$D C(ZUA2^"O#<WB$:])H]LVIA@WGX/+#HQ7.TL
M.Q(S6C9Z18:?>WUY:VZQW%\ZR7+@D^8P7:#R>.!VH NT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5Y3\=/%%IIOA1O#TT%RTVK)\DL2!EC".C'(R,D
M]*]6JCJVL6&A:>]_J=P+>TCQOE9257)P,X!QR0* /FF]^(>CZ_X1T+PMJT&J
MVVEZ<D(G-I;J\EUY:[0,LX" ]?XNU7]=^*'A^_\ '/A?6K'3M3AL=$0IY#P(
M&92,87#D# Z<\^U?046OZ?+<P6X>X26=BL0EM98PY +8!90,X!/X5IT ?-7B
MOXL67B'Q3;7$8U(:(EH\36=Q9*VR5@1YH42@,P!&"QXQQ6$/'5@?@W_P@[V]
M]]H\\L+@0#8$\WS/[V2<\=J^LJ* /F'5?B;I=[K?@[6+:UU".XT2(PSQR6RL
MC J%W*0X)[\''UKL/$/QZ\.:GX=U'3[32]9$UU;20*TL"*J[U*Y.')XSTKVZ
MB@#YU^'WQ;\.>$_"=CH^H:9JL\UB\C13PP(<[V8G@N,<-CO6;%\4-*A\>>*?
M$*V.HF+6++[-#$85#1D(JJ6^;H=N3CIGO7TY10!\A67B^PM-)\(61M[UO[ U
M%KUV\D#S@9%<*/FXZ$=ZL^*?'</B:7Q*+J2^FBOS'_9YFLP7M41]WEC$F$!X
MR0"3@$U]9Y&2,C(YQ2T ?,#_ !.TR7QGX2UV2SU#9HME]FGC6!<R,496*_/T
M&[C/7':MKXA_&/0?%W@Z[T*QT_5HGNBF99X$ 0*ZMT#G.=N.U?0M9@U_3FO=
M3M!,_G:8B/=CR7^0.I9<''S< _=SB@#YFUKQOH=_IOAN]TZWU33O$VB110+=
MI;HT<R(H'S?.#VZ8/!(.<U;N_BA:1^/XO%^F6=TMS<VBVVHVMS:AHSC'S1D/
MG^%>#CIUYKZ''BS1FLM)O!=-Y&KND=D_E/\ O6894=/ER 3SCI6U0!\R>)OB
MOI>H^-?"FMV=I?L-(63SEN($C,I8#[H5B .OT]ZR+KQ3X9U30O$2WT.L)J^L
M:B-05HK5&BA*EMB<R L,.P)P.O3CGZGN-+T^[N$N+FPM9IT "R20JS+CD8)&
M13[Z]@TZQGO;IREO ADD<*6VJ!DG !/2@#YXLOBSH,GCFZ\7ZEIFJ"]-@+*V
MM8(U:-.[,SE@>3Q]W@'O1\,_BOH/@GPJ^CWUEJT[FX>4206Z8(8#@@N/2OH>
MPO8-2T^VO[5]]O<Q+-$Q!&Y& (.#R.#5B@#YN^&GQ6T7P/HMWI-Y:ZI<P&Z>
M:!X;5 Q#8^]F3 / X&?K5#Q5\3;3Q'XDU*X/]HMI-QIDEI;6]Q9JQMI'7!D5
M1*!N//S9R V,<5]0'@51TG6++6]+AU*PE9[6;(C=T9"<,5/# $<@]J /EJZ\
M=6%SX)\)Z)]FO1/HMT+B1_(&UPI)"CYL\YY.!]#5E?'&@7=[XW.H6NJK;>)%
M7R_)@1G@9"2I(+@'D@GGMCOFOJJL^;7-/@UFSTF2<B]O(WD@C",0ZJ,L=V,<
M9'?O0!\PP?$6";4O!=S?6]T%\-IY.(;<$S( J@\N,'"].Q'4YX] \1?'GPYJ
M?AS4=/M-+UD37=M) K2P(%7>I7)PY/&>E>W44 ?.WP^^+GAWPIX3L-'U#3-5
MGFL7D:*>&!#G>S$\%QC[V.]9#?$O2AXS\7:XEEJ)BUNP-I%&85W1D(J!F^;_
M &<X'K7T3=>)M)L]6&E37$GV\Q^<+=+>1W*9QN 53D9XS5G3M9T[5C,MC>13
MO VV:-3\\1]&4\J?J* /E2P\9Z?:6?@BW:VOF'ANZEG=A"/WX>4/@?-Q@#'>
MD\2^-H_$<?B-;J2]F-]<I)8R3V@+P1*V1$#YF$7&,[0<D<U]=44 ?,TOQ2TJ
M;XC>'O$SV6H^3IEA]DEB$"AG)5P67Y^@+\ ]<=JU/B'\8]!\7^#KO0K'3]6B
M>Y*;I9X$ 0*ZMT#G.=N.U>V0^*=(N-2M[&.Y8RW._P"SOY3B.8H<,%DQM)&.
MQ^E:\DBQ1M(V[:HR=JEC^0Y- 'RKK7C?1+_3O#=]IUOJFG>)M$BB@%VENC1S
M(B@?-\X/;I@\$@YJU=_%"TC\?Q>+],M+I;JZM%MM1M;FU#1G  W1D/G^%>#C
MIUYKZ$@\9:#=6*7T%Y))9N<+<K;2^4>=OW]N.O'6M"WU>RNM7O-+BD8W=FD;
MS(8V 4."5PQ&#T/0F@#YQUWXKZ9=_$'PSXAM;2_D72K>2.9)X4B:5F##Y0K$
M <_A[]\B;Q3X:O?#VLI=1:NFLZCJW]K(Z6B-#"X+;4YD!88=QG Z]..?JB;2
M]/N;I;J>PM9;A,;99(59QCI@D9JW0!\VVOQ6T%_%^K^*K_3-46_NK 6-M;0Q
M*T<:X&2SE@220.B\#UJ?X;?%O0/!GA!-$OK'5YY$F=Q)!;I@ACGNXP:]\T_6
MK#5+J^MK29GEL91#<*8V78Y ;'(&>"#D<5#?>)-*T[4HM.NKAUO)4,D<*P2.
MSJ.I&U3D#OZ4 >5? #7K9K/4_#D"W#)!*UW%++"$+(Q5>?F//3@?G7M55=/U
M*QU:T%UI]W#<P$E=\3A@".H/H1Z5:H **** "BBB@ HHHH **P7\:>'XFNQ)
M?E19/LNF,$@6!O1VVX7\36W#-%<01SP2)+%(H9'1@58'D$$=10 ^BBB@ HHH
MH **16#*&4@@C(([UD:MXHTG1#-]MN'7R$62?RX7D\E&) 9]H.T$@\GT/H:
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M+\ZR\0#2+R^6,!4@W+^_*]%.UE!SP"<XQQ1<^)->M]*\;W<%]%/;:.C&PNC
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M9K+U+P7IVJZ)J.F7,]T1J,BR7=RK()92NW;SMP  J@  <#W-="BE(U5G9R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLT,]M$X:(2J?F,9'523^!R.U #!XKU2X\4:SH=CHUM-+ID,4I>2^*>:) 2H
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MH'N_F1;LCZYKF-$L]!L_@U%K-_#,UQ<>99//#/L<H]X<(S'(5,@9)' +>IR
M>RW-Y;6=G+>7$\<5M"A>25FPJJ.I)JC+J%]<+I-QI=M#-9W3!KAYI-C1Q%<@
MJ.YSCBO*;I;8CXGV).GLG]D0S106B@1*XAER5&>6&%RPQT!P*V;A-/1/AJUB
MMLH-XF[R-H!)MF)SCOTS^% 'J)8 @$C)Z#UH+*O4@<9Y->3RB+4_!7C>?4D
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M!VLP0L <'"^G<58\/ZFVL^'-+U-T6.2]LX;EHU.0I= V![<UYY'!IUOKWQ/
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M7FHVDANY+C3HDFN8X;21RB-DAN!R,*22./QJ2T\8Z+?:C86<$\K-J,1ELY3
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MT5M52:00K<&U:-X6$HG#;/*V8W;]W&,4 :=MIMC9Q216ME;01R??2*)5#?4
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MX+:SO)QIVH17<LD*C"RA80R$C&<\]/TH [6JL>F:?$+@1V-L@N>9PL2CS?\
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M<$C:>_-,\2Z5J5YJL^JZ)I^JZ9KX$2PRHZFWO$P/DN%W%<+E@>_'!/2O2**
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MN7*@DDC)YZDT <%I^BWMGJE]HNH>#;?4H9KZ:YM]6D\MHMDDADS*&^;<I;&
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M //SI%Y=ZCXUN-4\-W5QI^JR6/EVXD0/(BHBN1AN&3[W7JN <UO>";+5]/\
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M;%3ROH1[@X/X5EV_AR^N+G1Y]9O8+J32-S0M%$4,TA0IYCY)Q\I/ [G.>,4
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M9<_<!]LD<<"DTGP;K&B:A-;6/B )X>DN6N19&VS+'N;<T:R9X0DGMG!..>:
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M#M/A_>6GA?PUH_\ :<#-HNHK?>;Y! F 9SMQN^7[YYR>G2@#O:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***YWQB^KQZ9;R:1;O=,ERK7-K%<>3+/"%;*QOD88':W49"D9YH
M Z*HYYXK:WEN)W"11(7=VZ*H&23^%>:OXB-QI?A:XTN_U-!+XB%G=17A99D4
M^86@D!)SMPHR<G '/6EU*>XO8OB?8W%W<O;65NK6Z><P\O=:ER 0<X+$\=*
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M'O4?AVSUBQU+4X]0NXI+.3RY+2W^TO<20<$."[J"5)&1G..16-K/_):/"_\
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MN26LMTS%8)XCYF(XXB2,+L WX!)&1D'-;_A?_DI7CO\ ZZV/_I.* .UHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *I:CI5KJJP"Z$N8)/-B>&9XF1L$9!0@]&(QTYJ[7
M-^//$%WX5\'WVMV<<,LEH$;RI@<."ZKU!&/O9[T 6)_".B7.D_V9+9L;<7'V
MH$3.)!-G=YGF!M^_/\6<TU/!N@QQZFB63 :H@2]/GR9G 7;\QW9Z9R>IR<YR
M:SYO$VI:3XOT71-3@M9X=827R+BU#(T;QKN8,A+9!!&"#^%=+/J5C:W,5O<7
MMO#/*0(XI)55GSTP"<F@#.N?"FC7>E66ESVTC6=DT;V\?VF0;"GW#D-DXP,9
M-69="T^;6;75Y(7:^M8VBAE\Y_E5OO#&<'.!U'85)=ZQI=@9!>:E9VYC +B:
M=4V@],Y/&>U33WUI:VPN;BZ@A@.,2R2!5YZ<GB@#%TOP-X;T76)-5T[2XX+N
M1F;*NQ12W4JA.U2>F0!4C^#M ELM3LY=/$MOJDIFO(Y97<2/Q\W).T\#D8Z#
MTK3_ +2L?LD=W]MMOLTA 2;S5V,2<##9P<FLJ;QIH$.KV.F#5+22XO-Y0),I
M"A<@DG./O#:!U)SZ&@".'P)X<M_#]QH<>GG^S[D@SQF>0M)C& S[MQ P.,XK
M170--76(=6$,AOH;?[*DIG<XBR"5P3@\@'D9XJ]//#;0//<2I%"@W/)(P55'
MJ2>E5DUC3)+%[Y-1M&M(R0\ZSJ8U(ZY;.!0!%HN@:;X>LS9Z7 T%ON+",RNX
M7))PNXG:,D\# Y-4-1\#^'M5O;N[NK%_-O8O*NO*N)(EG7&!O5& 8@="1D?A
M6S;ZA974\\%O=V\TT!"S1QR!FC/HP!R/QKF]?\6BQU[0M.T^[L)S>:A]DNXM
MV^2,;&;/#?*<KCD4 6=4\">&M8BL4O=,5_L"".V9)71T0<;=RL"5]B2*N7/A
MC1[J;3)9+,*^F K:>5(T8C4@ KA2 5(4#:<CCI4?B[5[K0/">I:O:)#)+9P-
M,(Y0=KA>2.",5#I]YKUS;Z5>,VGRP7:I)/$D31O&C+G*DN0V"5!X'!H B'P_
M\-*B(MA(L<=W]MB1;J4+%-DG<@W83))R%P#Z5?/A?2&N-5N#;/YNJQB*]83R
M#S5"E0/O<8!(XQUI-.U&6./4)-5U'2S''>O'"UO)@1IQL20L?]9SR/<5?MM0
MLKPS"UO+><P-LF$4JMY;>C8/!]C0 :?86VE:=;V%G&8[6WC$42%RVU0, 9))
MX%98\&Z!Y&HP&P#0:C*9KB)Y79"Y.XLH)PAW '*XY /:M&TU2PU(2#3]0M+E
MD'S>3*LFTGIG!K(\"Z[>>)/"L.I:@D*7+S3QLL (0;)608R2>BB@#5L=)L].
MD>2!9&F=51I9IGED*KG W.2<#)XSW)[U#K/AW2]?^S'4+=GDM7\R":*5XI(F
MZ$JZ$,,]\'FL&/Q!KU[XRUW0;,::O]FP0S1/-&_[TR D*<-\N".N#]*T?!OB
MF/Q7X6AUE[?[(2SI-&S[E1D8JQ#<97C.: '#P3X=_LF_TMM,22ROY3-<Q22.
M_F2''S9))#<#D8/%):>"M L-)_LVULWAM_-68E+B02%U^ZWF;M_';GBM6+5=
M.GM9;J&_M9+>(D22I,I1".N2#@46VJ:?>7,EM:W]K//&H9XHIE9E!Z$@'(!H
M S;GP;H%[I=WIUW8"YM[R037!FD=WD<  ,7)W9   P> ,"F#P3X?'A\Z&+ _
MV>T@E>/SY-SN""&9]VYCD#J>P]*UEU/3VOC8K?6QO!G_ $<2KYG'7Y<YJ*XU
MO2;1W2YU2RA="0ZR3JI4@;CD$^@)^@H ;J&A:=JDUC->0O))82B:V;SG78X&
M-W!&3C/7/4U6D\*:-)>W=TUJX>](-TBSR+'.0,9>,-M;C@Y'(ZYJ3P[XCT[Q
M/I:ZAIDZ2PLS+@,"P 8J"1VSC(SV-6CJ^FC[1G4+0?9N)_WR_NO][GY?QH S
M-;\%>'?$5];WNJ::LUS;KLCE61XVV_W3M(W+['(Y/K6['&D42Q1HJ1HH5548
M  Z #TJ)+ZTD$.RZA;SQNAQ(#Y@QG*^O'I7(:MXDUG1_"MOJ#7&DW=S)J<=J
M[VRLT7EO-LP/FX< \]1D&@#5TCP-X;T+59-2TS2X[>YD+'*NQ5"W4HA.U,_[
M(%68/"VC6]P\L5H5#W'VDP^:YB\W.=XCSL#9YR!UYZ\U4CUR]/Q'F\/LL'V-
M=+6]5@A$F\RE,$YP1QGH.M-U[Q!<Z3XK\-Z>IMELM1>X%R\@(9!'"T@(;. ,
M@9R* +K^%M'DEU:5[:0OJR".^/VB3]\H7:!][CY21QCBE3PQI,5QI=PEM)YN
ME1&*R/GR'RD( (P6P<@ <YZ5=@U*PNK$WMO>VTUH 29XY5:/ Z_,#BGVE[:W
M\/G6=S#<19*[X9 ZY'49% '&>#_!_P!GM=0.M6,R23:M/>)"]T7B96DWQL45
MRA(XZCJ!Z"NJMM#T^TUF\U:"%UO;Q46XD\UR'"_=^4G:,9.,#N:EN=5TZSN$
MM[J_M8)G&5CEF568>P)R:4ZE8J;@->VP-L 9\RK^ZSTW<_+^- &/8>!?#6F:
MW)K%EI4<-[(YD+*[;0QX+*F=JDY/( /-/?P7H$FF7FG/9R&TO;G[7<1FYE^>
M7<&W9W9!R >.XJIJ?BF2P\8:+8^?9#2+ZSN+E[ACC;Y84@A\[=I#YSC\:Z :
MG8-;0W*WML;>=@L4HE7;(2< *<X))X&* ,C5/ WAO6=6AU34-,2:]B0)YOF.
MN]1T#@$!Q_O9JZWAW3&U2YU,P.+RY@%M+()Y!NC'10 V!U/0#K3_ .W]&%J]
MS_:]A]GCD\IY?M*;%?\ NDYP#[=:CU2XO8K[2UM+O3X899\7"W1.^5-IXBP>
M6SS]* *T/@[1;:VM+>UAN;>.TB:"$07DR%8V.2N0^2,@=>F.*F/A;1B^E,MG
ML_LD8L1'*Z"'C:< $ \<<YK.E^(GAB&UU>Y?5;;RM+<QRD2J2[!5)"#.6Y8+
MQWR*V8];TUM+BU%[^UCM)0")6F4)GTW9QG@_E0!(^E6,FL0ZL]NAOX86@2;N
M$8@D?FH_7U-9>L^"/#GB#4XM2U/3$FNXEV"4.Z%E_NMM(#CV;(K8FO[.VM%N
MI[N"*V;&)GD"H<].2<<U@^#/$-QXBBUF2=K9TL]4ELX)+<$*\:JA5NIR3N/(
M.* +][HEI]N76K>R$NJVEL\-J#.\:8(SLP#M ) YP?TJ#P]:7LL\^M:OIMO8
M:I=11PO##*)=D:;B 7P,G<['CM@=JDM_%6D7?B:Z\/PWD+WUM&KR()!U;=\@
M]6 4DCL"*T(]3T^:]>SBOK:2Z0$M LJEU ZY7.: %U'3[75=.N-/OH1-:W$9
MCEC)(#*1@CCFLZV\*:/:WEE=Q03?:;*)H8)7NI794;[P.6.<\<G/0>@J;Q!X
M@T[PSHT^IZG.D4$0X!(!=NRKZDUBOXO6/QS'I[7FGC1&TB2^^U[P,.LRQX+[
MMNWD_C0!=E\#^')M#GT:;35DL)IC</%)*['S"<EPQ;<IR3R".IK1T;1-.\/V
M LM,MA!!N+$;F=F8]V9B2QX')/858:_LTLEO7NX%M6 83F0!"#T.[.,&GV]S
M!=VZ7%M-'-"XRDD;!E8>Q'!H J0:)I]MK5UJ\,++?72+'-)YKD.J_=&TG:,9
M/0=S6=8^!_#>FZ[+K5GI<<-]*YD9U=MH<]6"9VACSR!GD^M-_P"$@N=3\2WN
MB:,( =.5#>W<ZEU1W&5C501N; R3N&,CJ3PRX\17>@1ZS=>(D@33M/MXYX[N
MW5AYVXN&7:2<,"J@#)SN'// !?M?#.E6=S#/%#,S0.TD*RW$DB1,P(+*K,0I
MP2.!QDXZFJ1\!^&VD9CI[8:[%Z(_M$NQ)@<[T7=A#GD[0,]Z>EYXDETD:FEK
M9!VC\Y=-8-YF,9V&7. ^/]C&>,]ZQM3\>/)HGAG5M!^SRVVMW\-D/M"-F(ON
M!)PPY4J01^M '3#P[I8U.]U'[,3=7T(@N6:5V$D8! 4J3MQR>@[FJEMX-T:R
MM;6WM4O(([5&CA,=_.K*AV@KNWY(^5< \# QBJNF^)KW_A.;KPKJ=O 9TL1?
MP75MD*\9?80RG)5@?<Y%=)<W-O9V[W%U/%!"G+22N%5?J3P* &V=E;:?90V=
MI"D-M"@2.-1PH%8$'@#PU;"U$-C(JVDYN+9?M4NV%SG(0;L*IW'*CY3Z5M+J
MNG/8_;EU"U:TSCSQ,ICSG'WLXZU);7]G>2SQ6MW!/) VR9(I QC;T8 \'ZT
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M"1QH,!0.U3T4 <];^!_#EKXADUV#3$34)',C.';:7/5]F=N[WQFK/_"+:/\
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M'.,U;EUYKSX:K#;:<^GWNCW4"ZGI5I&OF11QRJ9#&A!#*0-PX((R.>:]5HH
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MKS6\T.3PWX%\!Z5JLHANSXBAN;A$EVF$.TC'D'("[@"PZ'O7MU% 'FWAQO\
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M6FS^?:3;O+DV,N<,5/# 'J#5ZB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_:#\%S, &DTB1R!TR4F-/O\ XFZ[IU_H4=Y8V=O/>ZH;*[TX_.\"%L(WF*Q
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M0DJ"2I[CTH LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Y=\:+KQ/-HB:%H.A3:C;:C&PNIHHF=H@"I &. 3
M[^E>HUB^*]?/A?PY=:R;)[N*U4/+'&P#;<@$C/!QG)]@: /'/#?C/XE>'M L
MM)'P]N;A+.(0Q2-!*K;!C&>.O'M7/6=_\4;#QAJOB:V\)7D=[J<8CF463E%
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M"1QUYK'O]?\ B9J]A:Z9JW@F^OM/MYDF*26SB68H<J)' P1GKA03Z]<_1U%
M'R[KC?$+6/$.K:O%X,U2S?5K$V5Y'' S!UP ""R\<*OY'IFFW"^/[KPQH.B2
M>"=2":)-YUO,D#AF89V[@5(P"?QQVKZDHH ^:_[5^(;R^(;V;P%=R:GKD'V:
M>Y%O(!%%LV!47MQSR3DUCP6WQ#@L_"]LO@Z_*>';A[BU)M7S(6D#D/[9&.,5
M]644 ?+4)^(T-MXKA'@R^/\ PDCE[EOLLG[HEF)V>V&(YSVJ>&[^)46@)HC^
M"[NXTX6*V+6\]F[H0I<B0#^&0;NHX^4<' Q]/44 ?,VH7OQ U#1Y-$D\!7C:
M.T$4"VLMO)(81&H4-&Y&5? Z\CVZY7[;X^/C.7Q"_P /[MTEL/[.:S,$NPP[
M0,9ZYXZU],44 ?+UB?'EK#HEG/X#O[G3=$N'N;*W>"0'>6W+O8#Y@I)QP/?-
M07L?Q$O;SQ-<-X-OE/B!%2X46LG[L*01M_ 8YS7U110!\S?VE\2SH,.BR>"K
MJ;3TTY-/>WGLW=&5-VV0#^&0 CD'' ..F/>/ GV@>!M'CNM.DTZ:*W$1M),[
MHPGRJ#GG. #^-=#10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7$M[=LG/V>'9CYO3<>!ZT_7M&N_&]OKT26MI+9RPMIUI+-<LA1D;+R "-O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!L=OMTWQ!$-2BGV92WDX67/N66,CTW9[5L>'[R[UOP5>ZEKMMY-TMG)931S
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MU73?[!-A>Q0RR+<2NKVV\J=A()#MM8XX7D=#FM[Q9Y7_  B&LF;9L%E,<OC
M.PXZUYSJ1LE^$'@>8>0,7.E'?P,,"FXY]>N: /5X[RUE+B.YA<Q\N%<';]?2
MDDO[.&W6XENX$A<X61I %)]CTKS_ %B&\\._$=GTR%O)\5VPMV>-?]3=1_\
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M,9?+VG:'V \GDD=>2*ZOP]K]KXDTO[=:QSQ!97ADBG4!XY$8JRG!(R".Q(H
MTVCC=U=D4LN0"1R,]::((E"A8D&T87"CCZ5PE_XHO]0F\<:6;*YM(]*LAY4\
M<JJRL8G<.65MPS\N,9QCG&<58\'^+(6TSPKI%W;WRW-_I<<D%U,HV7#)$ID
M.[=GG.2 #U!- ':/#%(RL\:,5R 64'&>M/ P,#I7.#QKI?VNPC99EMM0G^SV
MMV=ABEDYPHPVX;MIP2H!QUY&8_B)<3V?P^UN[M;B:WN8+5Y(I89"C*PZ'(-
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M25)!"C(!!QU KEO"EEK?A^;Q&TVB32G4=7FO;<I<1!=CA0 YW9!^7L#7=44
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MN"^8B,J !CG#&)!R?XB3Q7=T4 >9'PQK)O\ Q5-!HBV\.KZ,MM$IND=_-VR
MASGELN,G)^I/%:%[X>UL>&_"%Q96T;ZIH)B:2RDE"B8"(Q2*'Z X)()XKO:*
M .0\-:;J\?C3Q%K-_8+:6^I16@A0SJ[@QJP((7C^+U[=ZDU?2]3_ .%@Z-K=
MI:+<VL5G/:S?O50QEV1@V#U'RGIS75T4 >7/X3UUO ]WIG]GXNY=>-^J^='C
MROM EZ[NN!C'K^=7GT/Q!I?BG5'M- TO5].U2<7*3W4JQO9R%55@^5)=?ER
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.X;0 ,#VZYYKI?$OBC4=$BFE@M;2*UM]/-VLEPW%Q(,GR(U!R" N2V#C(XH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *R/$/A?1?%5DMGK>GQ7D*-O0.2I4^H8$$?@:UZ*
M *>EZ58:)IT.GZ;:QVMI",1Q1C '^)]^]7*** "N;USPU<ZMXGT#6(KZ*$:1
M)*XA: OYOF)L(SN&,#V-=)10!C>)_#T7B;1C8O.]M,DJ3V]P@R894;<C8[X(
MZ=QFJQ\.W-U?OJ>H75O)?K9/9P&*$K'&'(+M@L222J]Q@#'<FNBK/@U9);O4
M89;6ZMH[$KNN+B/9%*"NXLC9^8#H3V- %3PUH']A>$K+0;F>.\2V@^SE_*V"
M1.G*Y/;WK!7X9:>OA;3=$-W,XL;Q;A9V^^R E3&>?NF(^7],&NCN/$%K;^([
M#1'CF-Q>PR312!1LVIC=DYSGYAV[UK4 <QJOAB]O/%0UFTU..%'T]K"6&6W,
MFU2Q;?&=PVL<X.00<#CBL[1O =[I<OA1Y=6@E&@6\T 5;4KYRR*J]=YP1M'K
MGGI75ZAJMMIMG>W$I,GV.#[1-%%@N$P3G&?]EOR-.TK4(M7TBRU*!76&\@2X
MC5P P5U# ''?!H YF\\&WZZMK5SI.K16UKK<6V\MY[8R[9-FSS(R&7:2,9!!
M'&?:M[P]I3:%X<TW27G%P;*VCMQ*$V;PBA0<9..!ZUIUGZWK%MH&CW.J7BR&
MUMD,DIC7<54=3CO^% '(R_#V]D\.:AH:ZS MK<:E]NB8VA+(/.$Q5CO^;D 9
M&.,\'/&EJ'@I=6U[5KZ_NU>UU+2UTV2WCB*LB@L=X?<><L>W85IP>(XIVL_^
M)??QQWA AE>(;#E2PR03MR!QG'.!5:R\96>H/?BTL=1E%A</:W)2#=LD7[R@
M Y;J.@- #?#FAZ_ICJNL^)3JD,*[(%%JL)/;=(P)+MCCL.YR<8F\4>'IO$*Z
M4(KQ+;[!J,-^=T1?S#&20OWAC.>O-:&D:SI^NV(O=,NDN("Q0D @JPZJRG!5
MAW! -1QZ]ITWB.?04G!U&"W6YDB]$8D#\>!Q[CUH YVY\#W-S;^+H6U.(#Q%
M@9%L?]'_ '8C_O\ S< 'MS5P^%;EM?\ #NIM?Q8T>UEMS$(#^^WJJEL[OE^X
M.,'O7444 <))X O'\(Z]X<&L0K;:E<2RQ2?926B$DF]@WS_,><#&W\:GU'P7
MJ-YJ6I7,.L0QQ:EI8T^=)+4N8\!ANB.\;0=V2"#T_+M** ..M/!M[!=^$IY=
M3@<^'[>2 JML1YX:,1Y^^=N H/?)]*TO%?AMO$5K9M;7IL=0L+E;JTN0F\(X
M!&&7(W*02",BMV21(HVDD941 69F.  .I-95SXBL[;7]+T=DF:;4HY)()%4&
M/$8!;)SGH1V[T 8(\%ZG-/XDNKO5[9KC7+!+-Q%9E4BVJRA@"Y)X<\$_CVJ6
M[\'7LFB^&;6VU2%+G0GB96EMB\4^R,Q_,F\$'!R#G@UV%% '"MX"OG\/^*=)
M.L0XUVZDN#+]D.8O,5588W\\+QTQGO6C>^%KRYU+PWJ$6HPQ7&CI+$V;<LLJ
MR(J' W#:?E!')_&NIHH P?&'A^7Q1X<FTF.[2U\V2)S*T1DQL=7QC(ZE0.M1
M_P#".W0\9W'B$7L.9=-6Q$'D'C#E]^[=SRQXQ^-=%10!PL/@"Y@\(^'=!758
MC_8U[%=^<;8_OO+8L%V[_ESGKD_2K5QX,N9Y_%\AU*(#Q% L./LY_P!'VQ&+
M/WOFX.>W-=A64NOVK>*G\/>5.+M;,7F\J/+,9?9P<YSG/;M0!B?\(??V]]X?
MOK+5(([K2[$V$IDM2Z31D+R '!5LH#U(YJG'\/;J#PWIVFQ:Q&;FPU?^U(9Y
M+7*LV]V*,H89^^>01^%=Y4<,T5PA>&19$#,A*G(RI*D?@01^% '(R>$-9MO$
M5SJ6C^)6LK?4"CW]LUHL@:15"F2,D_(2%'4$?7I4GB'P;-XBCELKR[MGT\R1
M20,]N6N;7:%SY<F[J2I.<9&X]:ZZB@#,\1:0-?\ #>I:0TQA%[;/!YH7=LW
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M%;X2_92/-PSL%QOX^^><GITJS>> EU*X\4F\OSY&NB A88RCV[1* C!LG)R
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MRC+  D?4U=G\,:1=:E-J%Q;/+<S69L9&>9R'@/5"N<8Y/.,T <1HM_J+^)]
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MG?:),^5G.W&['7G.,YK/B\!^'H(--A@M)H5TQG-H8[N96C#G+KN#9*GN"<4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD ;A6!0HI!(;Y@,J0#AAQQUH U**S;/7M-OK]K&"X/VH1^<(I(VC9X\XWKN
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M;Z-/;2&2V>-YG=E*H$8!CMVD].K >N.XHH X7POX<34_@[9>'M2M)+5Y=/\
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M1V36^]F;"YSD%<8.X]Z ,G3-/U:T^#.JPZZ[R3BSNI+=99?-DBBVL8PSY.6
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M\PL%"C<.,8SDUR/AM[O3;;1KS[/X;OHT(%N+75)3(AE(W^5"5**W)^52 !D
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MP!8X4$]3C.!^ -+7"^*8[F3XF^#HH]0NH(I4O6*1E=H9(UP<%3SAB.<\=,5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEUKQ-IN@7>E6U_*4EU.Z%K;@ <N1U/MG SZL* -"_LTU"PGLY'D2.>-HW,9
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MXUBYMYIX8-H9(=N[YF"@\D<9(H A?PM:SRAKJZN[B'[2MV;5W!B\X'<& QD
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MS74Q$C!P 0!D<'UH X#Q?H5YX8\(>+/$4>K2G7-1EMWDN;93 $572-450Q(
M4D9SDYK8E273O&&E>')=2U*:SU!+J\:6:Y;>\B[ (E=<$* 6;:#^@Q76:MI%
MCKFG2:?J4'GVDA!>(LRAL'(S@CN ?PIM_HNGZG%;QWD!D^S.)()!(RR1L!C*
MN"&!QQG/- '!R6VO:EHGC+0K'4KX7.EW0_LR\6X<2',:2B%GSEL;MN22<,.X
MK<\)ZTOC*.VUFWDGBLTLQ$T2RL!]H;!D##/)0!0">[-Z5T]G96]A"8K:(1H6
M+MR268]68GDD^IYIMGIMGI]HUK9P+! SO(4CROS.Q9CQT)))H \N\,Z_?WNB
M^!M+OM1NBNJSWS7-T9F$LODN^R/>#D9R.A'"8'%1Q:@_AJZ\9?9YV6-M>L[>
M2XN)V/E1R)&&+2') P=N[J,Y[5Z _@KP[)HL.COIB&P@E\Z&/S'S$^2=R-G<
MIR3T(ZFI(/"&@6]M?VZ:7 8M0 %V),OYV!@;BQ))]_7GK0!5\/V.I6&L7XN=
M1CFL[B-)8;3[1).T)Y#,'?G:W''3(..]8GC99W^)7@%;:6.*8R7VUY(RZC]P
M,Y (SQ[UU>@^&M'\,VCVNC6$5I"[;F"9)8^Y))/Y\4:CX<TO5K^UOKR"1[JU
MW?9Y4GD1HMPPVTJPQD<''6@#B[);G3?C:/[7DBO;S4=**6EQ;H8EMXD?<R-&
M2QY/.[=[8%0^,M'O?&%CKD]KIT\LL*B'2KA'0>6\+[F898$%I%VGCD(I'6N\
MM/#VEV-S/=06H%W.GER7+.SS,OIYC$MC\:L6&F6FF:>EC9QM%;("$3S&.T>Q
M)R* . \6:Y'XE^ =]K"8!NM/5G4?PON =?P8$?A4%N9I/B)H-OXJ9#%%:B70
M9+=#'#)+L D$@))\P#&.<8[9KL8_!/AV'1)]&CT_;IL[;Y;832;&.<G(W>H%
M7;WP]I6HZ?;V%Y:":WMG62$.[%HV7[K*V=P(]<T <O\ \U\/_8K_ /MU46L9
MNOC7X;6P.9;.PNGU$K_#"X C5O\ @>2!^-=/-X6TB?5/[3>&<7_E"#[0EW,K
M^7G.W(8<9YQZU;LM&T[3H9H[.U2#SSNF>/(>0^K/]XGW)S0!Y_XQTB_\5V6L
MWEEI\TMQ!M72+A'0>6\#[F8 MG+2 KTY"J17<>&-<B\2>&-.UB' 6[@61E'\
M+=&7\&!'X5;L--M-,T]+"SC:*VC7:B"1CM'H"3D5!HN@:9X=LVM-)M?LUNS%
M_+5V90QZD DXS[4 <5!9Q?\ "RO&DA>XW)IMLZC[1)MR5ESE<X(] >!VQ6/X
M7>YTS2OAE/;W]YMOD-M<0-,?*=/)9A\GW005&#C/J37I=QX<TFZU234Y;0&]
MDA^SO*KLI9.>#@@?Q'!ZC-11^%=%BATV%+/;'IC;K-1*^(3C''/H2/IQ0!QV
MCW.L>(K*UUVWU:&UF@U%UN5:ZD9=@E*&!H?N XV@'[V<'.3STGC[6+G1/"<U
MW:R&%VG@@>X _P!0DDBHS\^@)Q[XJRG@SPY%XB;7TTBV75&.XW !^]_>QG&[
MWQFM>[M+>_LYK2[@CGMYD*212+E74]010!Q]R+G2/'NG:9:7EY)8:I87)GBE
MN'E,+Q;-LB,Y)7._:><=#UKC]+N-9A\!^#_%,>N:G<:E/>003P37+/%<QR2E
M"FP\;L'(;KP>>F/5+71K+2XG>SMW>41>6IDF:1]HZ(&=B0OMD"N=\ >#DT+P
MKI%OJ=J1J-DIR&G:2-')/SHNXJI(/4 'D^IH YF6'4;_ $KQY?#Q#JUO/I&H
M7#V1CNF"1>7"CA2O1E/3:<CK@9)K:T#4[KQ9KMY9:M)=6AM]+LID@MYW@)>9
M&:1\J03AL*!T&/>K/A_P?MU3Q)<:O9/Y=_J37,2_:#LEBVJ '16PW*DX8'K7
M37NA:=J%[%>SP,+N)#&L\,KQ/L)R5+(02N><'C- 'F5IJ>M:S:^!X+O5;V&2
MZOKVSNI;>0QFX2)955CCN0H.?7D=JT]*T6*V^)FM6QO-1F:#1;4":2\D\QSF
M0;F((R>,],9YQFNXE\/:3-+I\C6:AM..;0(S((>,< $#IQ]*<^A:9)K::RUH
MIU!8A$)@Q&5!) (S@XR<9'&: /-M*U?4I?"WPTNY-2NVN+R]6*Y8SM^_0I(2
M'&?FY5>M5=5O-3B\+>.=636=36YTC66%EBZ8+&H\KY2H.&7YB-K9'MDDUZ);
M>!_#=H;<PZ5$OV:?[1 "S,(GY^Z"<*.3\HXYZ5+)X1T.6RU"SDL=UMJ$OGW<
M9F?$S\?,?F]A^0]* ,>]GN)/BI8:>;JX%E<:+/)) DS*A821@, #P<$\]>:X
M[0-,OQ\$[34=%NKY+^RGFNQ%'=RA;A8[B0M$1NQAE!Z=3BO4_P"PM..K6^J&
M!C>V\1@BF,KDJAZKUP<^_I63+I%WX=CBA\(Z18>7<SLUU]HN'41 Y.Y1@\;B
M3M&!SQU) !/X9U*+Q$)/$%K-,UA<QQQVJ%SM*@99MN<!MS%3_P!<ZPM9LH9?
MC)X>D9IPS:;=,=L[J/E:/' .,<\CH>^:[+2]/@TG2[73[90L-O&(U 4#.!UP
M/7K45]H6FZEJ%G?W=JLMU9[O(D+$%0V,C@X(.!P<CB@#SF36-2N_A?+XR@O;
MM-:AN'E$ F?R@5G*?9VBSM(VX7IG/.<UWOBN::#P;K-Q#+)!/%832(\;89&5
M"001[BI$\-:1'>2W2685YIA<2(';RWE&/WACSL+9 .[&<@'K5Z]LX-0LIK.Z
M3S+>=#'(FXC<I&",CGD4 >:"ZO-&\->%[N76;V4Z\]I%=RWEVPCC_<.P",!F
M/>P4$CKZY)-7-5T+Q&OAOQ!;VFN3&]A9+S3X(+N5Y(@!EHF<D,ZOM; /3/L*
M[*?PWH]UH"Z%<6$<VF*@C6WE)<!1T ).1CMSQVI^BZ#I?AVP%CI%E':6^[<5
M3)+'U)/)/ Y)[4 8_AS5HO%UFNN6DTZ6;VBQ1HLK#$C#=)D="5RJYZ@AJXOP
MWX@U*_T3P5I]W?NS:G9W4KRSW<D37$J.H5/,7YLX9C@$9P/3!]2M=,LK'3_L
M%I L%K\V(XB5 W$EL8Y&22?QK*N/ _AJZT&'0[C289-.@;=#"S,?*/JK9RO4
M]#WH Y+78-?T3P4-1.LS7MSH6H?:9DMYWS+:!@6AD.1O*H<[CS\ON:CAUZZ3
MQ=?0)=W4FF>)8%.C2-.["-U(20H,_*,-YHQ_"OX5Z)::/IUCI(TJULXHK (8
M_(5?EVG.0?7.3GUS2C2K &Q(M8A]@XM<#_4_(4^7_@)(H @UNXCTSPU?SM?&
MRCM[5S]K<&4PX4X<@\L1UQU-<#I5UJ5OXM6P:[U%+6?PT]SBYNVDD>574"4@
MEO+8@GA3Z=#7I5Y9V^H64UG=PI-;3H8Y8W&0RD8(-8T'@GP[;202Q:<%E@@:
MWCD\Z0L(VZJ26R1P,9Z8XQ0!PF@WNI16/PXU)]6U">?4V,-V)KEF253"[<IG
M;D%00V,^I-4O$D\GB/X2:]KEU>77VL:@T9MUG81PJER$6(Q@[?N@$DC.3G/2
MO3H_">B16^G01V6V+37WV:B5\0MZCGW(^AJO=^!?#-]<7DUQI,3M>,'N%WL$
ME8$$,4!VELCKC/7UH M>*]3N=&\(ZOJ=G&)+FUM)9HE(R-RJ2"1Z#K6)$PT^
MQB\0Z?K5U?1RZ5(\=G+,TJW<@7S!(N3\AX((4 ?,.F!78>5'Y/E;%,>W;L(X
MQTQBL;1/!WA[PW<SW.CZ3;VDTXP[Q@YQG.!D_*,]A@4 <B;^]B\.^#O$EEJ%
MW<7=_<6D=Y&T[-'<+.,2#RR=JE2<C:!C:1TS6-K5WJ?_  C'Q U!=:U-)])U
M-OL1CNF41 )$<8!^9>3\IR/;/->G6/AK2-.E5[2S$81VDCCWL8XF;.61"=J$
MY/W0.I]344GA+0Y;74;:2QW0ZE)YEXAE?$S>I^;V'Y"@#G[1KJT^*$6G?VC>
MS6U[H;W,R33LP\U944.HZ(<,>% 'M7(Z;=:K)X,\$:N==U7[=>ZR+.:0W3%6
MB>24$%#E2?E&"02/I@5ZK_PC^F?VC#J'D/\ ;(8#;1S><^Y8SU7K]#]0#59/
M!^@Q:=9Z>ECMM+*X^TVT0F?$4N2=P^;KDD_B: .(NM=O_#9\?107MS+!ITMD
MUNUS,TS6XG5?,8,V3A<E@.0,=*U9K?5+*'5KZ/6E%E/H\LL-O%>R7#>:@R)D
M=^0,$ @<9P:ZR/P_I<=YJ%V+16FU%0EX79F$R@;0&4D@@#CITJEIG@CPWHUE
M>6FG:5#;0WBE)PC-EU.?EW9R!R> <<T <7HMQ?P7WPYF?5=0G;6-/D6]6:Y9
MEDQ;"13MS@,#_$!D]R:U_A99Q6VEZT8VF.-:O8P'F=QA92!PQ(S[]3W-=+'X
M7T>(Z84M"#I8*V7[U_W (P0.?3CGMQ4VG:%INDW%W/8VJPR7<K33$,3N=CEB
M 3@9/)QC- ',/=7/_"Q_$%BUY<BT&B13K%Y[!4<O("R\_*<*.1CI7,Z5>ZIJ
MEI\,HYM9U%!J4%R+QH[@AI]L!8%CUS[]1U&" 1Z1?^&M'U34H]1O+)9;N.(P
MB3<R[HR<[6 (#+GG!R*YS5O!B'7/",6F:?Y6CZ2UP91#.8VC#Q[5VD,&SNY)
M!_.@#GEUS5=!O=0\/R:C=W-@GB"SL8[Z>4M+%#-'YC(9#SD'"[B<C?USBM?4
MYK_1_$.O:9:7EXUA)H$E^ADN'D>VG1BHVNQ+ ,.<9ZJ<=Z[!O#VDOI,VER6,
M<EG.Q::.3+&1B<EF8\EL@'<3G@<TJ:#IJVES;&!W2ZC\J=I)G>21,$;2[$MC
MD\9[GU- ' :)=7]OJ'PXG;5+^=M7L'%ZL]PSI)BV$BG:> P/\0&3W)KK/&=T
M(;/3;<7US;276H11+%:C]Y==6,0;<NP$*<MD8 /K5Z/POHT1TLI9[3I8*V7[
MU_W (VD#GTXY[<5/J^AZ=KUO%!J5L)DAE$T1#LC(XSAE92"#R>A[T >5ZEJV
MM0>!/&BC4KNWGTW68X;9TNFD>*-FARGF'YF'SMU]:Z5;6Y'Q"U;PZNKZF+.\
MT1+O<UTY>&;S63?&<_)P =HP..F.*WW\$>')(+V!M+C\J]D66X0.X$C+C!P#
MQ]U3QU(![5)J>DFUDN=;T>PBN->%L((C<7#JKH#G83D\=3TZ_G0!S?@G5+W5
MH[+2+V:X_M'06DCU1C,^9)5RD>XY^97!,G/]T5K>.-5FTZWT:UBF:W34]4AL
MIKA&VM'&P9C@]BVW;GMNXYQ6IH5A<6T=S>7\5O'J-]()KE8#N52%"*H8@%L*
MHY(ZYJSJND:?KFG2:?J=I'=6LF-T<@XXY!]B/44 >7ZQ=S^$_$GCN_TQYI+B
MWT2VEA\^1IBAW2#.6)) ^]@G]*Z:^DN=&\1>%Y=,O+NZMM3=[>YAFN&E$B^4
M9%E7<3M(*_PX!#8]*W;'PGH6G3336^G1^;/"+>:25FE:2/GY6+DDCGO4^G>'
M],TDQFSMRGE(8X@\KR")3C*H&)V#@<+@<#T% '*>%+EO$.A:'XF?7+F"Z>=O
MMD'FLT4C,63R/+)VKM)7! SQGG)-<]J6K:E#\//&URFIWJW%CX@>&VE%R^^)
M!+$ @.<[<,>.G->@VO@OPW9:_)KEMI%M%J4C%FG4'[QX+ 9P"<G) R<GUI+O
MP3X<OYKV6ZTN*0WK*]PI9MLC+C#%<XW<#G&2.#UH YC4HKO4?'?B;3WU;4H;
M6+1X9X8[>Z:(12$R#<I4@C[H]CWS6=HNHZF(OASJLNJWTT^K P7J23$QRJ86
M8'9]T,"H^8#)[DUZ'_PCFE?;KJ\%J1<74(MYG$KC?&!@+UX YZ>IJ*/PIHL4
M6FQQV95-,.;-1*^(3C''/IQ].* ..TZZUCQ%:MJ]MJT%G<V>J2I.&NI"JHDK
M+Y+P?<Y0* >N2"#DUDZQ/J?]E?$.^76]42;2+P26.RZ95BQ&CXVCAEY(VG(]
ML\UZ'_PAGAS_ (2+_A(/[(MO[4)W&XP<EO[V,XW>^,T^3PGHDT&I0266Z+4G
MWWB&5\3-ZGGV _"@#EH;>.Z^,L%S(\ZL_AQ;@A;B15W>>.P;&W_9Z'N*7PKJ
M-]:>([32O$$=[%J<L$C1727;SV>H@;270$XC8#G;@8!/;%=:_AO29-0M+][,
M-=6D7DPREVR$R#M//S $ C.<'FDT[PUI.E2PRVELRM!&8H-\SR"%#C*H&8A
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M5G0 =<H",=^G>JSM%KGQ T#5]%F66"WL[E;Z:/[I1@OEQL?[V_+;3R,'.,T
M0:EX_CN_#>G:QX?N+>2*XU6&SD$B[F\MIO+SC(VD@9&1T/2NPLM6TW41.;&_
MM;D6[;)O)F5_+;T;!X/UKQRU:*3X/^'M.EC8S6VM0K<PO&?DQ=,6!!'9>3Z
M\]:V-=@O9_$/CV'2XGDFETVR,<<7'G!"^]%[$[3MQ_M"@#TB'6]*N([B2'4[
M.1+< S,LZD1@]"QSP/<T^QU?3=4+BPO[6Z,:HSB"57VAQN4G!X!'(]17GD=Y
MH/B#3M9UK3WU:>[31Y[69[V-XQ&""1$05 9MV>F<<\\C/4?#^RM+;P-H<D-M
M%%.^FVZ3LL85V94&0QZY#%N#T)- &Q/KFDVUR;:?5+**<.D9B>=0P9\[%QG.
M3@X'?!I_]K:=_: L/M]M]L.<0>:N\X&3\N<].:X[3;.SN?B[XE-S;12_Z'9&
M(R(&&Y2Q.,\9!V'U'%8'AN2RO#I_A_7H]:/B'3=0$YMA&PC,@<G[0) NW80Q
M)RW.2.<C(!Z;/K>DVLY@N-3LXI0VTI).JD'&<<GKCG'I3AK&F,\Z#4;0M;QB
M691,N8T/(9N> ?4UY+=76C;M<T"_UF"SAD\0-?O-<I(DT8617(4;-OWDPK;O
MND'':M^^O(+#XBZU--N\K4="B%FT:%UG*F3(4@$$X8'Z'/2@#>\0>))[2[\,
M-I<]K/9:KJ"V\DBC?N0H[91@<?P^AZUMOK>E1Z@+!]2LUO"P00&90^XC(&W.
M<XYQZ5Y?99C\'_"U)$D1X;Z$R*Z%2@$4BDD$<#) STY%5-<OH;B&?RX)+%[;
MQ7#+/9I"[,<3*#/(Y!QN !&W QQS0!Z?IGBK2=7UO4=*L[J*2>P*I( XR6()
M( [@<9(XY]JNVNLZ7?7#V]IJ-I/,B[VCBF5F"YQG /3/>O-KN.^NKSXFZ;IH
MF34[V.*2T78RF1?LR@X..,X*_6M26:W\0:CX)N=%3:UC*TER N#:0>25:.0?
MPDML7:>N,]J .L?Q5X=CSOU[3%P&8[KM!@ [2>O8\?6KXO[-C;@74!-R,P8D
M'[T8S\OKQSQ7!> =#TS4_#6LPWEC!(9]2OXV9HQO\N20]#U *XZ=<"K?P^M]
M6^SFVUA6WZ'OTN"5O^6X# ^;^*"( ]<[_6@#L[R^M-/M_/O;F&WAR%WS.%7)
MX R>YJ*+5=.GT\ZA%?VKV0SFX653&,'!^;..M<WXZOH+*?P^;FU'EG4,K?.K
MLEFXC;:Y52,DY*C/ )R<XKA$\M?!?B=9I[I'@\5?:4DEM7PW[V-E,BJHPI(.
M<#CK@]" >OVVKZ;>S-#:W]K-*N=T<<JLPQUR <BF0ZWI5R)S!J5G((%W3;)U
M/EKZMSP/>O-9)[?7[;QI>Z%J=K<ZSJ=E&(["V=MVR)2IY95)9MQ7IQ\HJU8W
M^@^((;O5K-=7>_M]+GMYOMD31+;*1GRFRH5FW 8 ST)X[@'?6VO:/>W<=K:Z
MK93W$L0F2*.=6=HR,A@ <D8/6I#K&F#4!8'4+47C$@0><N\D#)&W.<XY^E>7
M:/'';VGPH*1"-HED6;"8*$VQ4[O3+\'/>KWA74[![>S\,ZWIEU-XCT[49)Q&
MUO)M+F5V%P) -NW:Y.2>>F#D9 /0H-:TJYM[BX@U*SE@MB5GD2=66(CJ&(.%
MQ[U=1UD171@RL,A@<@BO/KG2;VP^(5UIUI"3HWB.(75T1TADB*B7CTD0HI]S
MGM7:#5K0ZXVC[G^VBW%R5\MMOE[MN=V-N<]LYH P_&WB#4O#\>BMIXM#]OU2
M"P?[1$S[1(2-PPR\C'2M2%]7@U%1>76GS60A9I#% T3QMD;2<R,"I&_MV%<K
M\5O*DL_#44G*C7[224#/RQ@MN8XZ*!U/:MG3[GP[9ZTW]ES+-/>1!9S'*9$C
MCBWG<Q)(7E\>^1Z&@#3B\2:%-/!!%K.GO+<*S0HMRA,@7.2HSR!@]/0U8LM6
MTW4[:2YL+^UNH(V*O+!,KJI'4$@X&*\=TRU@_P"%;_#Z*6W3>FOHTZ-'RJ[Y
MMQ8=A@KDGU%:>K07LU]\28],@DFF:2PF2&(<SHB(957U)564]>3B@#TN+7=(
MG@N)HM4LGBMP#,ZSJ5C!Z%CGC\:(==TBYBGE@U2RDCMPIF=)U(C##*ECGC(Y
M&>M><SW6A:_H7B/6M,.JW%XVA3VDLMY$\83()6+!4!GW$_=SCUY&9=4M=/LO
MA;X>O8E2UDBDTV9Y%@+*[QLI"S;06VYSDX)![$\4 >B6VKZ9>.Z6VH6LSQY+
MK',I*XZY&>,4V'6])N8KB6'4[.2.W ,SK.I$8/(+'/ ^M>8SS6NLV'C2^T/4
M+>]U;4HX)O[/M&;>(80JL!N52Q8;@?E[J.:N"[T'Q!I6N:WI[:K<70T6>TGD
MO8GC5 02(B"H#/NSTSCUY&0#T"VU_1[VX^SVNJV,\_DB?RX[A6;RR 0^ <[<
M$'/N*KZ!XHTKQ*MTVF74<RV\S1'##)V\%L=<9R >^*X'2XHH+_X4&.-8VCT^
M9)BJXV$VR@AO0E_7O[UO_#658[/6[%PZ7,6LWCO&R$;0TI*G.,<CD>U '6-J
MVFK=S6C:A:BY@C\V6$S+OC3^\PSD#W-$.K:;<V\%Q!?VLL%PVR&1)E99&]%(
M.">#T]*Y'Q;9:CIWC'1?$6C6QGFN%?2KN,#@HX+1NW^RCC)/H:@\#:1?Z)J]
M[X<F61]+T>1IK&=_^6BSC*@>Z?O@?]X4 6/$/B35=(\#^)-8M=2TN]N+*X?[
M.84+K$F5Q&^&_P!8 W)]QQ6E>:Y?V_C_ $;1E,/V&]LIYW^0[]Z;,<YQCYO2
MO/K]=WPR^)$42$O-K5RT2*O+AFCP5'<'!P1UP:Z[4)8Y?BMX7DC8,@TVZRPZ
M?-Y>WGWVG'TH [&[U&RL/*^V7D%OYK;(_.D";V]!GJ:JP^(M$N=.EU&#6+"2
MRA)62X2Y0QH1V+9P*Y;XH&V2'PJ]XJ&W7Q#;>9O7<-NR3.1Z>M<UXKL$G@\?
M:GI2*=-N]*AAW0C*7-T"V2F.&(4J"1W..H- 'J2:WI4D$\Z:G9M%;R>5,XG4
MK&_'RL<\'D<'UIIU_1ET]M0;5K%;)7\MK@W""-6Z;2V< ^U<=J\$.F7'@W5K
M:VC71H9]U\T,?"LT!CBE?'92<9/3(]*?;Z!#XBUWQH",Z+JUM;P+(HRDLH1@
MTB=C@%!N'=?:@#N#?6@>%#=0AYU+1+Y@S( ,DKZC'I67I.J;='GO=3UC3+B)
M+B0?:K=@L2KOPJDDD;AP#SUK#^'DFJWVE1W&NP-%=:;&VF O_P M&C;$DH/<
M-M3\4/K7&:7/+I^CZ'J$T,KZ39>([V6^"1EO+#-((I"HYV@L&S]#0!WWAWQ1
M)J_BGQ/:-=6<NG:;]G^SRP],.C,^YLD$@C';I70V6J:?J7F?8;ZVN?*($GDR
MA]A/(S@\9KR>^\_4+WXAW6AVT]PLS:;.@AB9?M*( TJH2,,2H([YSWS76>$+
MK0]<UR77-+;59[DV@MYY[R)XU0!MPC(*@,P);D9QZ\B@"YXLU_5-'UKP]96!
MLPFJ79MG:XA9S'A2V1AUSTZ46GB2_M_'8\+:I';3/-9&\M[JU1D&T-M970LV
M#Z'.#6-\2#;OXB\&).[+%'J323,KE?+3RR-Q8<J,D<Y%06=M':_%2TO/#;3W
M&G7%I(-9N)F:6) H_=;)GR=V[.55L8YQWH W?'7C3_A#XM/E6V\Y)+A/MC8X
M@MMRHTA]\NH'KD^E:OBO5;G1?"6J:M9>2TUG:O<*LJEE?:I.."#SCKFN>_LI
MO&FFZW=-?0QV6IJ]FJ/!O9(8RRJ<[A@EBT@XXW#TK"L]:EU/X#ZM:7I/]IV=
MA/82H0=TC*I5&7NVX;<$=3F@#;;QAK&FGPG<:A'8W-KK\D4!6VB>*2"21-P/
M+L&4=#TQUJ]J>O:Q%\0;'P[9O8QV]S8R71EFMW=U*,!CB11SFN.L[63PQ-X8
M\6JMQJ.DR6$-I>1REYY-.<HH\V('+(,_*ZC'T]-K4]1LT^,6BWK7,0M!H\RF
M<M\@+.I4%N@) - &VOB:\TWQ=9^'M;@@SJ$;O87ML"J2L@R\;(22K <CD@^Q
MXJ/QQXT_X1 ::XM_.CEN4^V.>EO;%@C2'WW.H'KSZ5FZG')XK\?Z!=6<<BZ1
MH1FN;B^D0I'+(R[52,G&['))''OFI#I#>-=)UNY>^ACL]4#VJH\&YDAC+*AS
MN&"3ND''&\>E '> Y&1TJDVLZ6MQ<P-J5H)K5-]Q&9UW0KURXS\H]S7.?#/6
M9M6\%645[D:A8@VER&ZDH=H?GJ&4 Y[\U5\46.HZ?XRT_5](MO.;5('TJ[&W
M*H<%XIF'<+A\^QQZ4 =?#JFGW$-O-#?6TD5R<0.DJE93@G"D'YNAZ>E<]-XM
MMM!T>[O]8U?3[M&OV@MOLAP "0$C;D_,,_,>@K,\!Z7?Z/?7N@7*2'3M#E=;
M":0Y\V.;#ISZH-ZD_P"U7*7(/_" >(G5&*Q>+3<-M4G$7VI&W_[N.<]* .Z/
MB]+?QO=V5Y?V$6BQ:5%>QW#,$&7D9.7+8(^7C&.M=9#/%<P1SP2I+#(H9)$8
M,K ]"".HK@DDM;OXLWUX0K0MX=C$<LB8'^MD)'(X.T@X]#6C\*P5^&6A1N"L
MD=OL=6&"I#'@CM0!7?Q9<:SK^L:5HFJ:9;SZ:T(B^T$.ER67?)G!R !Q\O0@
MY]*V=&UR!=*T]-5U[2;F^N6=8Y;:142<AR,1@L2<< XSR#6+X7GB_P"%@>.I
M&=1$\UJ59N P6 !B">H!!!KEM(T6YO?@;I<^G1E-7T:>6_LT*D,'2:1MA'7Y
MD)&.^10!ZV;ZT62>,W4(>!0\RF09C4YP6]!P>3Z4RRU*QU)9&L;R"Y$;;',,
M@?:W7!QT-<1X@&I7/@,:U#971GN+NWU&ZLX<>=]G5E/E@?W@BJ2.Y#>M:'@Z
M?1=6U.]UO2'U*X>XACBGNKN-XU8J3M0!E7)&3D@<9QF@#:U'6?*UFST2TV-J
M%S&TYW#*PPJ0&<@=>2% [D^QK%U;Q/>S>*3X?T'4M!BO844S0ZBSF1RPW (J
ML,X7!/7K[&H8HI8?C=/+,I\NYT "W<]/DG^=1[_.I_&F^+[C1O$UAJ&B6^^3
M7[9@+0+ ZRP7 P4D5B.%!P2P.,9YH Z*]U@Z7K%A:WNS[/J#F""91C;,%+!&
MY_B 8@^HQW%4_'FLWOA[P3JFKZ>81=6L6]/.0LO4#H"/6LKXE0R7.F^'K6+F
M[DURT\HCJ"I+,WX*K&K?Q.MI[SX:Z];VT$D\SVWRQQJ69L,#P!UXH V[77](
MNY+B"'5;*6>U7-S&DZEH?7< ?E_&I%UK2G2T=-2LV6\.+9A.I$Y]$Y^;\*XX
M65GJWC?PUJF@I UM965REW/;@!-CJHCB..^[)V]L'.,BN0T2Y4^$_AUIPBN#
M>:?K")=Q"!\P,%F!#<<'G\N: /81K&F-?_8%U"U-YDKY F7?D#)&W.<@<XK/
ML-8C@@U*YU36]*DMXKUXXY(G"+"N!MCD)./,&>>G4<5Q^GW-QI_BRTBTK4$U
M33+O4YS-IMQ'BXTZ1O,+RJPY\O);[PQAQ@G-8&K*C^ /'T*IN,OB3?&@7)=?
M,@.X#N/E;D>AH ]@L]6T[49KB&RO[6YEMFVSI#*KF(^C '@]>M%MJ^FWLTL-
MK?VL\D0W2)'*K%!ZD \#KS7G7B.TN+GQIK]MHRA9KCPD8;?R<*&D\Q]J@CC.
MTC'H"*=I=YX=\21M?[-=:ZLM.G@NHI8GB-K&R8>/[H5FR!@ GD9XQ0!Z!:ZW
MI5[YGV74K.?RT\Q_+F5MJ_WC@\#WJ2RU33]2,@L;ZWN3'C>(90^W.<9QTS@X
MKS6RDED@U;2=4U)=9T(:2535[.+9<P(S!?)<+PS@?,.,_*<CFM[P5?:G)K6I
M65Y>6NL00V\)AUFWC"&49?$4F/E+KR?E[-SUH ZN_P!3LM.C!O+ZVM2X/EF=
MPH) ]R,X[US_ (.\6#4_ ]AK>MW=G;R7,DJ%\B-"1*ZJ%R?11QDUGW6IKH?Q
M2N)]9$B6-YIT4.GW'ELT:NKL9(^ <,V5/OM'M7*>%[V'3_"_@B&YLGMF%U?!
M+Z:&3%HQ:3 "< LZOA2V0.>">* /5QKVCE+1QJMCLO#BV;[0F)STPG/S?A4\
MNH64+3B6\@0VZ"28-(!Y:GH6]!P>3Z5Y1H^CSZM\,]5ALO-75M,UBYO;%Y(B
MC+,DS.HQ@ ;AD$<?>Z"NFN%BU3P!/JFL27.FOJCP7)DAYDM/G3R3]%PC-VY:
M@#L;/4;+44=[*[@N51MK&*0-M/7!QT-6:Y#P-?:G=/JT&I2VE\;>9%CU6TCV
M)>@H.2!QN7@';QV[5U] !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445S.MW&FIXV\,075K=/?2&Y-G-')MB3$67#KN^8D 8R#0!TU%<6_Q&M4M
M+F];2-06RM-2.G74[>6!"^\1[L;LL-S#[N>/RKIM8U$Z1H]WJ(M9;H6T32M#
M#C>RJ,G;D@$X[4 7J*YJ/QG:27OAV 6\GEZ]"TMK/O78,('VMSG.#QC-87B_
M4Y'U?PC=10W&!K,D/E129\X+'(.F0.67@GZY H ]"HKCKGQ18ZKX3\3-J&FW
MT2Z8LUOJ%HKKYNT1[B496QRC9!R#UJW:>(;>+3-/M=+L;BYE_LV.[6W$@+1P
M[0%W,3RQP0.N2I^M '345YUK&LFZ\9^ ]3L[>^9+RWO9!:-E'/[I2H96(4$;
MCR?SKKO#GB"'Q'ITMS';RVTL%Q):W$$V-T4L;;67()!^H]: ->BN/@\7W"^+
M_$=E?6HM]+TBVAF>X+J=JLLC,[#K@A0 !GI[XJ_'XKB6^TR"\L;BTBU48LYI
M"I5FV[@C8/RL5R0.<X(SGB@#H:*QO$_B.#PMH_\ :5S;3SQ"6.(B  D%V"@X
M)'&2.F3[52;QC'&%AN-/EL[]O,86MY/%$=B-C=NW$8;/&,]^P)H Z:BN0M/B
M'IU\?#TEO:W!MM;=XH9VVA8I4SNC?GAOE(&,@D5-XIU>Q_X1/Q#)J-E=3:=:
M(T4WV>4*THV@MM.X8QG!YZ@CG% '4T5R]]XNT[1K4PQIYK6MFEQ)";A%=8R#
MM WD;G(4\?F1D9?:^-+*]U72+.VMYGBU>S:\L[DE0CA0"4ZY# $<8_E0!TM%
M<[H_BV'6M.:ZM[.5)4OWL'MY'7>LBMALX)' RW7[HS6AK>L1Z)8+<O;SW+R3
M1P10P+EG=V"J.> ,GDG@"@#,L_"]]8;[>W\27XL&D=Q T43.N]BS 2%<XR3R
M<GWKH;>"*UMHK>! D,2!$0=%4# 'Y5REU\0+.RT37;^XT^Z$NB3"&[MT*,<D
M*593D J0P]^O%7K7Q9!+K]QI%Y97%A+'9_;DDN"FV2$-M9N"=N#C@X.#0!T-
M%>;>(=;FU75/ ]W!:74%E=:JCQ2M* )8S$Y&Y >,\,,]AS@\5V/BCQ#!X5\/
MW&L7-M//# 5#)  6^9@H/)'&2/?VH V**Y>+QK&-9N=*O=)O[*Z2U:\MTE\L
M_:8EX8J0V P_NL0>:@T[X@6U]H\>K2:5J%O93QPM:R2!/])>5MBQH V=V[ Y
MP.<YQS0!OZUIT^JZ5+:6VI7.G3.5*W-MC>F"#QD$<XQ^-3Z?9)I]E';)))+M
MR6DD(+2,22S'&!DDD\ #G@"L23Q;Y%[?Z?/I=RNI6MI]M2V1U;[3#G!,9S@D
M'@@XY(]<U/I?BBWUC2=%U"S@=X]5YC7<-T:[2Q+?3&#CN0* -VLK7=%.M6UN
MD=_<V,]M.MQ#-!M)#@$?,K AAACP1Z>E8.F:_HFFKXHOX[:\@:#4_)N5E?>T
MTY5 HC&X@;BR@#CD]JSX]3EA^+L\VHQ2V,$/AQYY%DFWQ@"9<N,' P!@\=N_
M6@#KM/TF>"=+G4-2EU"X12L;/&D:Q@XSA5 Y.!R2?;&3G5KF+'QQIUYKMEI1
M7RY;^)Y;5A*DF[8 65@I)5L'.#V!YR,5K:EJ\>GW-G:+$T]Y>,RP0J0,A1EF
M)/10,<^XXYH T:*YZ#Q=;2V-M*]E=P7=S=O916<J!9&E7=NP<XVX4MNSC ]>
M*@N/&]K96>N/=V-S'=Z+$)[JU4H6:,J6#H<@,I /H<@C% %[1-!DTF6>:ZU:
M]U.:1B(WNRN8D)SL7:![9)ZX'H*VJY./QN'U6UT[^Q+\37UH;NRYCQ.!C</O
M?(1N!^;'Y\4S_A8-B/#EIK!L+W;/?C3G@ 4O#-YGED-SR 1_#G/% '7T5R#^
M.V2;6;4Z!J'VW2HUGF@WQ<PLI8.&W[>BGY<YR*NR>,M--GILUNZNVHVOVN!)
M95A_=84Y8L>#\P&.3G/8$@ Z*BN.@^(VG7D&B26=C>W']K2RP1*@3,<D88LC
M?-U^7&1QWSBJ>M_$&:'P-K>KV&FRQW^FW)LIX)W7]S)E1NR"0P^=2,=?:@#O
M:RM=T5]8BM3#J-S87%K-Y\,T&UOFVE<,K AAACQ5*Z\5-;W4]G'I<TU[;6HN
MY[9)8_,"$L!M&?G/R'IQTYR<5MWMT+*QGNFC>188VD*)C<P S@9(&?QH I:?
MI,]O<+=7^HRW]TJ&-'>-(U1206PJ@==J\DGIQCG.I7&:?\1+>\.B33:/J%I8
M:SM2TO)MFPRLN50@-N&<$ D8)'''-3Z=XT76[F\MK?0M4,%O/<6D\W[L!)(@
M,K]_OR 1QTYYX .LHKC/#/B'28?"?AV+2+6ZV:BCBPM9I-TFU<EB[$G  ')R
M>H [5)>_$&QT[0=6U*YL+M9M)G6WO+0;3)&S%0K=<%#N4@CL>G!H Z^BJ&E:
MC-J-O-)-IMU8M',T:QW&W<ZC!#C!(P<_SKF-%\<2S6?B"_U>S-M;:?J4EG'L
M=7)*E$5!ZLS-]/FQGB@#MJ*Q;;Q$C:^NB7MI+9WLL!N+?>RLDR @-M8'[RY&
M1[Y&:YWXJSR6F@Z7/#<7,#?VM:QNUO(Z,T;/AE^4Y(([4 =%XA\/_P!O/I3&
MZ\C^SKZ.^3$>[>Z @ \CCYC^E;5<SIPTN77!_9[:FMQ;0EY(YC.J2*V0!B4@
M$Y&<CICMFLZ#XE6L^GZ9J/\ 8^HI8W]Z;%9B$)27>R*"H;)R5ZC(&>O6@#MZ
M*YF#QK9;M<2_MI]/ET?RS<),48E9!F,J5)!W8QC/6HH_'FGF[U"S>%S=6=B=
M0\N"6.7S(0<'#!L!@>H)'48)H ZNBN0M?'\$^CPZG+I-_;V]T+461D"?Z4\Y
MPJ+\W!!ZDXXYZ8JS'XUM$O-:M;VTN+5]&1'NY"R-'AQE-ISEMPS_  CD8- '
M345RT/CJPDO[RQ>)C=6]F;Y8X98Y?-B!PP!#8# XRI/<8)J+3/'UOJ-QH2'2
M[VW@UN%I+.>39M9E3>4(#9!VYP2,'''K0!UU%<3HVJWWC/2_$EG>VMQ:1Q7L
M]DC6MR$=?+VKM#CD,3DYZ<XK4746T"#1M#D,E]J4T#!#), 9!&%W$NV-Q^8=
MLGJ<8)H Z*BJ]C=&]L(;EK>6W:10QAF WH?0X)&1[&L?1_$_]MQ6]S::?*UG
M=1/)!<"1"IV_PN <JQSTYZ'.",4 =!17)VWCVRNM%\/ZJEE<BWUJ[%G$#MW1
MN2P!89Z?(>F>U<WIGB6;PYJ7C:Z;3-2U&TMM4WSO"ZM]GB\E"3AV!;')PN<#
MTXH ]0HKEW\:P2ZNNF:=IMW?S2Z:NI0-$R*DL3-A<%F&/QQ^-5K'XAV5_;Z%
M>)IU]'8:S*+>&YD" ),0V$*[MW56&<8R* .QHKC)-?T72?$WBB\DMKR.ZL;:
MU-W(\H*2JV\1A 6PON3MZ\^M:=UXI73;"YN]2L9+986A1&,J%)3*VQ=KYP!D
MC).,?3J =!17&^+M8M/^$'UB?7=)OA:6[HDT5O, T@RC*R.&'RY8 G@\'BMF
MZUX1:C/IMA9RWUY;0+/-&CJH16)"C+'[S;6P/;DCC(!LT5R1^(&G20:#-9V=
M[=+K,CQ0"-5!1T4ED<%AA@5(].#SBM/PYXBB\0P7I%K/:7%C=/:7,$Q4E)%
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M/PS=I-)YLJV;AY,8W'8<G';-:51S0QW$#PS('BD4JRGH0>HH \V\)Z1?>(?
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M=MO:QW"WL/EX10X#0*6QWY.2?7FI?B%'_8]_H7C".,LNF7/DWJJN2UM-\A;
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MT 17%A9WDD4ES:03O"VZ-I8PQ0^H)Z&H8M&TN"]:]ATVSCNV)8SI H<D]3N
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MX[8% '84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5S'C5M22UTQK"P>[B%_&;HPQ+)-#%@_/&
M&_BS@9'(!./4=/10!XY<Z%K!T'Q18Q:+J(>ZUZWO(!(?,+Q!H23NW$D@(V>3
MTQG-=I9V5U_PM34=1:UF%E-I4$"3,A"LZR.Q7\F%=4+JW-T;43Q&X"[S$'&\
M+TSCKCWJ'5--MM8TRXTZ\#FWN$*2!'*-@^A!!% '(^"] N]&UG5;%W1M(TZY
M?^S%!R4$P61D([;,X'LYJW\2+&[U+PB;2RM9;F=KNV?RXUR=J3(S'\E-=%IF
MF6FCZ?%8V492"(8 9RS$]R6)))/J:D-_9 D&[@!'8R#_ !H XKQ9;7UGXMLM
M<30;C6M.DLS:306Q FA;?O5PI(R#D@\\8JIK-H-*3PK<6.@3VUS:7$]Q'9V"
M)*T*,A#AH]Z[L[UW%3@,>IR,^C1R)*@>-U=#T93D&LO5_#MAK-Q;W,YN8;JW
M#+%<6MP\,BJV-RY4C(.!P<CB@#@+_3CJGP]\1:9I5AJ7]KSW2:E<0WMOY#S.
MTRN2@)VXQ&5 !/W>>3D[NG+?W7Q-FUQ])O;;3WT1(%DF4!MXF9MI4$G.#TY_
M6NLT_2[;3$80><[OC?+/,TLCXZ99B3@9.!T&3BIX[JWFFEABGBDEA($J*X+)
MGID=OQH \L\/66NZ5X;\(V-QHEX(89+M;TP1K]I@9F8QA6)^56#'+*0>@R.:
MKVNAZS;>$-+B;1KX2:?XI%])%@,[0^<YW+\V6X8<]_>O6Y+JWBGA@DGB2:8D
M11LX#.0,G:.^ ">*(;JWN7E2">*5H7\N4(X8HV,[6QT/(X- '&:;#J&B^(O$
MCW>G75Q:ZNT=W:M&F\[_ "@C0O@D*1M&"?EP>M96A^&-3T/5_ 5M/!).NEZ=
M=0W=PBY2-Y FT9[C(89]ATS7I$]U;VJHUQ/%"KN$4R.%#,3@ 9[D]JEH X;Q
M%X?NY?'>GW=@R+;ZI;O9:M&3]Z%#O#8]?O1Y[>8*[68R+;R&%5:4*=BL< G'
M -9FE>&=+T;4+Z_LX9!<WLC22O),[X+')"AB0H)YP,=!Z#&O0!Y+I-AK4FL^
M"M1N]#U&*:SDN4OD")'# 7B90(XU;:$!/WL<C&2345NL:QS65UI&O_V1%K4F
MI(+>S$ZDK*6&)5;)0L-^-N><9/6O7ZYRU\$Z/99CMVOTM,DBR%]-Y SR1Y>[
M&W_9Z>U '*3V5S;>(]72Y\*R^(-,UJ5;JTNH77:NZ-5,<P8C:HV@@\\'H>@O
MQZ7>V_B[Q)/_ &?*MM+HL%M"T49V/(@?*I]-P S7?@ # X%0I=6\DGEI<1-)
M_=5P3^5 'EVDV?B#PO;>$M671+R_CM]'_LR_LH0//@;*L'56(#<K@\],5T'B
MG2[K5_A[-<+9II>HV3?VC91#;F"2,EU#%>-Q&0<<?,>O4]O61J/AG2]6U>RU
M.\ADDN;,$18F=4Z@_,H.&Y&>10!-H=K/:Z5']K"B]F)GN=IR!(_+ 'N!]T>R
MBN#\9V6M:G<^*[$:1=O!/I833Y+-55;AMC;O.?(9B&.%0\8)X.:]-HH \_T.
MSOX_'6G:C/IUW!:IX:2T=Y(_NRB4-M.,\[1G].O%8.@:/KFA:5X)U&72+N8:
M5]M@O;.-09HQ,V5D52?FQ@9P<X/UKUZB@#C?!5I?0ZUXJN[O3KBSAOM06>W\
M[:"Z^4B] 3W!JE<7RV/QIN':WN9E;P_&/W$1D(/GOC('//KT]<5W4%S;W0<V
M\\4PC<QN8W#;6'53CH1W%45T*T3Q))KP:7[:]L+5B6^7RPQ8#'U).>M 'GVG
M>%M2TF?P=OL92L&J7E[<QQC<MHDP?8I(XXW*#C/.>W-=':PWVA>.M?NY[.YN
MK'5D@EMY8$W['C38T3 ?=S@,"<+R<D5V-1RSPP &:5(P>A=@,_G0!YK<>#-5
MT[X6:1!:1!]?T28:A;1HV<OYC.T0/<%69?? K4\9:)J$_P *-1TN"![K5+J(
M,Z1#.^9G#OCT&<XST  KMXIHIEW12)(/56!I] '#1#4M%^(&I:DVDWM[I^L6
MELL4ENH+021!@4=6(V@[\YZ>M<MI6A:YHOA?PC>W'AVYOAI\%U;7NG*ZB95E
MD5UD09P2-@!&0>:]BHH QO#-M';Z4SQ:,-(6XE:;[*=N_)Q\TFTD;SC)Y/;O
M7$7^DZJ+/XCV"Z5=N^J;I+.1%!27= J  YZ[@>W&.:]0HH \]FTF_NO$GA61
M;6YCAAT:XM9YO+(\B1TC"@^^5/Y5#X-L+E?[-TS5?!C6]_I056U*1E> [%VA
MXCG<68=L#&3D]CZ14#WEK&</<PJ>1AI .G!H P?B!H%SXG\"ZII%F5%U,BM#
MN. 71U<#/;)7'XTS4+ZXU_0)-,CTN_@N[V(PS":'8MON&&9G/RMCG[I;/%="
MEY:R;MES"VT9.UP<#UI/MUH5+"Z@VC@GS!B@#&UPQW=U-IFKZ))?Z+-;H3(L
M'G*)-S J4&7SC:00./45Q,'P]U-_!T]C9226YL-974M"@O7+&)$QM1SR0"=^
M!U&1GG(KU.*>&<$Q2I(!_<8&G*Z/NVL&VG!P<X/I0!POC2:]\2^ -1TB'1-0
M35;R$1K;/#E5?(/,O^KP,==U=II\!MM-M8&4*T4*(0.@P *L5 ]]:1N4>Z@5
MAP09 "* /-[KX?ZA>?\ "2:*'$.CR2MJ.ELK8*74@SVZ*CJQQ_TT'I5W7],U
MG4?@[J%O/9/+KNI6XDFMXER?-8CY?3Y5 7_@-=_%-%.NZ*1)%SC*,",T^@#B
M4MKVV^)\.J?V?=26,^AI:^<B<1R+*6(8$@C@YZ<]!S7-6FAZM'X \-63Z9=+
M=VOB);N:+R_FCB%R\A<_\!8=,GG%>MT4 <_XV.I?\(C>_P!DV2WMV=F(&C63
M<N]=Q"MP6"Y(![@=>E<+?:3JDUWXS>#2-6=-5T!(+=[C#,\NV48/S':<L..,
M9Z 5ZU10!P$&G7W_  E'@:X^Q7 AL=,GANG,9 B=DC"J?Q1JO>.['4)&T?5;
M'36U1-/N':XL$?:\L;H5+)G@LO!QWYKL:* .,M(HSX?NA#X3>Q359A%);31A
MG*L K2S!21@#/RYR<#D9XQ=-MO$7A_PSXA\,6VE-J(M(G_LFYN(@4ND(_P!7
M(#@%EZ9/#  5Z;10!Y%<^'-5UG5[WR;+5(8]2\,26(N;W:-LY?.&4'"#'&U0
M!UP*Z_POJNL:JMO#JGAB?3;JU@\NXN;C849L $0E2202 <X P._%=9))'#$\
MLKJD:*69V. H'4D]A4(O[,_9L7<'^E<P?O!^]XS\O][CGCM0!S'PRM;W3? F
MGZ7J%A<6ES9*T4@E  8[V.5P3D8QS[UEZ=_;>B:SK6B3>')M1M]0U&2]M+Y2
MAMU60AL2Y.5V$=@2<<#I7?175O/++%%/%))"0LJ(X)0GH".WXU+0!Q-E;W^@
M^)_$QN;&XO+3572YM9H8]^6$81HG_NXVC!/RX/45S=EI\_A'7OASIUZDMQ-:
MZ;>QS?9T,A4D1DX Y(!.. 3[5ZU69=:%:7FNV.L2F7[79)(D&&PH5\;P1WS@
M?EQ0!R=OX,.K:#XLAO8VM%UR]>YMT;AH,*HCD('1MR;\=>0#SFMWP4FH2>&K
M:_UC8=3O8TFN"GW<[0JX_P" @''J35S6_#>F>(6M#J44L@M9#)&J3.@)(P0P
M4C<#Z'^IK2FFAM+=YIY(X8(EW.[L%5%'<D\ 4 <?);R6GQFAO901!?Z(UM"W
M;S8Y=Y7Z[6S^!]*QM1TC4YH/B8J:=<L=4C5+(>7_ *X_9Q'Q_P "'?ZUZ)<V
MUKJ%NGF@.@(DCD5L%3V96'3@]1V/O4EO<P7<"S6T\<\3$@21N&4D'!Y'H01^
M% '#:7::AHGBBTU6>SNIK&[T:"TD,<1=[::(D[2@^;:VX\@'D<^M9C^&=3L;
M3P^%LIG/_"42:K-#&-PM87,N <<<!UR!GDG&:]1ILDD<,322NJ1J,LS'  ]2
M: ."L_#VH7WB3Q@#=:GI,5Y=VTUO>6N$:14A", 6!&,CT^E+JOA^_L]1\'QI
M/J.KK9:D\]Q=7.'=$:-E!8J , L.V:[N*6.>%)H9$DBD4,CHV593R"".HI]
M'G.KV5YI_C+59;GPM<:]INKK$8GMG0F%UC$;1R*S !3M!STY-6+>TU'PUXV%
MXNBS7&F7NEV]HJV #"SDB+?N\$C"$-PW3CG%=]4"WUHTSPK=0&5.702#<OU'
M:@#R[0K#7]*\,>%+&?1+Q(DN[LWC0)&UQ"'=S'L.<HK;\,PP0.XSFJ]AHWB/
M2M*MKZTT6ZDGTCQ!=736<CKNN8)=ZED)8[F"OD9Z\\FO7)IXK>(RSRI%&.KN
MP4#\30L\3PB9)4:(C(<,"N/7- ' ^)H]3U_PB+RW\/7-HZZG:W7V-U3[1(L<
MBEW8*2,X' SG"_@(-3M[VT\6WUW=>$KS6=.UB&$H(63?;.J;&CD4L!M(P<YP
M,GK7H<=W;3-MBN(G;T5P34U ' 6EGJ/A?QL]TFB33Z9?:;;VT:V #"SDBW?N
M\$C"$/PW3CG%4-/L[W1_@)>Z?J-E+;7AM+J!8'P69Y7<1@ $\DNHQUR:].JO
M<6-O=3P33IYC0-OC#$[5;^]CH2.Q/3M0!DVNB3KX!AT%IO+N1I:V9E!^Z_E;
M-P^AYKF(-*U+6/#'A;1;G3Y[2^TF[M9+J1EPB"W_ (D?HV_  QDC=SC%>BDX
M&345O<V]Y")K:>.>(D@/$X9202",CT((_"@#E-"M;N#XD>*KR6TG2TO([,6\
M[(0LAC1@X_ L.O7M1XOM+X^)O"6J6MA/=P6-W,9U@ +*'A9%."1QD]>U=7/<
MP6L?F7$T<*9QND8*/S-.CECE4-'(KJ1D%3D$4 >9:CH^IW&G?$J--.N2^J$"
MR7R_]=^X5./^!#O]:6ZLM1TO7HK^X\-7>MZ=?Z;;P.EN0);::,,"K*S*-K;N
MN>"/S])%W;&Y^S"XB\\#/E;QNQ].M34 4=(MDL-&MH%LHK)(XQBU@Y6+OM&.
MN.G'6N.\">'E0:^^K:1Y<T^OW%];//"-QC+JT; ]N1G'45W]% '"ZQ!>1_%;
M2=533[R:PMM-F@EFBB+ .[ @>IX':I;K2M0\2^--)U:[LI++2=%$DL*S$&6Y
MF==H.U2=JJ.><$GM7:U%+<V\$D4<T\4;S-LB5W +MC.%!ZG )P/2@#EK?0H_
M$-KJEWJBZA;-J)>"6V+%,0+N1%QCG*DM]7-)\.!JEKX3@TK5[2YAN-.9K:.2
M9,>="IQ&X_X#@8Z\5U]% '"ZWI<U[\5=#O9--DN-.@L9X9I6AW1H[$%<Y^G4
M=,U:\6:'<I::'<Z+:!TTG4TO'LH@%\R,A@^P<#<-Y8#VKL** /._$&C7NKW?
MB?6;2UN!'<^''TRWA:(K)/,3(<[3@@#<HR<=3V&:=K&FW\WA/P/;Q6%PTME?
MV$US&(SF%(EPY(]O;KVS7<C4;%KXV(O+<W@7=]G$J^9CUVYSBK#,J*69@J@9
M))P * /.[K2]0;5/B/(MC<%-2L(HK,B,_OG6!T('_ F Y^O2NM\,6\T'@[2+
M699(+B*PAAD5EPR.J!3U]"/I6I!<0W4"3V\T<T+C*21L&5AZ@CK4E 'G.K^#
M-9BO?#,=GK^J7$%K?EW=H;;,"^5(/,R(AN))P=V<[B>O-0>+M"O=5U7Q''JN
MG7=];36<)T*2U7<;>90=P!'^K<OM.XX!  )XQ7IM'09- '+6]S<6>A:9I'B#
M3+S5+IK%!=31VXFB>4* RL<]2<\D8]ZL>!]$F\.^$;/3)U"/&TKB(-N\I7D9
MU3/?:&"_A6Y;W-O=PB:VGCFB)*AXW#+D'!&1Z$$?A4M 'DGBFPUW5;#Q';/H
ME\;A=4AEM1:HJ0RP+)$0YP09)"%.=V<8&,8K;:POW\3>-;LZ==+#?:5!#;DQ
MY\QU20,HQGD%P/2O0** /+M%L=9\.W?A/5)=)O+JWBT%=*NX85!EM905;=M)
MY!*[21Z UT7P^L;ZQL-:%_8S6C7&LW=S$LI7+1N^5/!-=?10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5R/Q#U35-*T:QDTN6*)I]1MK>5G!)V/(H(&#QGH3Z9^HZZL'Q=X
M?E\1Z/':6]REM/#=0W43R(77=&X8 @$'!QCK0!S$K:E!\6[YK*"T>]/AR%F,
MC%(MPGDYX!)[?XU?T[Q[_:VC:)/;VK17FJ6;W93RI)UA5"JG(C&XY9@!TXS[
M Z,7AR]7QA-X@DO8':73$L&B$)4;E<OOSN/&6(V^F.:PK;X>:II>AZ!'I.O)
M;:OHT4ENER;;=%<0NP)1XRWJ%.0>H]^ #JO#.KW6MZ,MU?:;/I]RLCQ20S(R
MY*G&Y=P!*D8()'?VKBM'6*+XK^/,:*]_D:>V(EB^4^2V?OLO7V].:]!TNVN[
M2Q2.^O?MEV26EF\L1JQ_V5&=H'0#)]R3DUS]CX9U73O%FO:[!J%F?[7\C,,E
MLQ\H1(5&"'&<Y]* *]QX@M/#&@:(XMX-)@U23<S70(AM'D4RE6Q@ EB1U Z\
M\8-;5=;\0'Q/X.MHI+**&_ENC*D;,ZR[(G*G<.J$$,!CKCTK;ETC6IH-MQ?V
M%WYKR?:;>>U/D2(0 J*NXE<;<Y.<DGCGC&M/A]/ID/AH6&I1)+HUQ<R@20%H
MRLX8,JKNRH7=A<D].: 'ZQXWOM&U#%S86\=N=2BL8X'E_?RQN57[0H' 7<V
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M&/R@P!W9YSN/85OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU=WDUW:D/!(%$8(<X8 #.['!Y_+ J'2I''QP\0)?'$ATNW_L_=WAR?,V_P#
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M""H&$.X97VXK4NKW4-(NO"=];W]Q=PZM.EI>12-N#[XF<2J.B;2A.%P,$\4
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M#D\9P<>N#4MWJ%EI\(FO;RWMHB<!YI513^)- &==^%M+OKFYFN5N'2YD22>
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MP6PM$6*\E7]R,X0_-SC)P3R.Q%;-M:P6=G%:6T2PV\*"..-!@(H& !]!4/\
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M.2-5=20"N'1N&&&/I@X(.10!P,!TO7;;Q]J&F:EIU[J&JZ<52SLI?,>-4@9
M3D Y8D9XQPO6HM)U:RU#Q%\,S:3><(=.N8I6121&_D1 JQQ@,",$=N/45Z'I
M^D7$%TMYJ-_]MND0QQLL"Q*BD@G &3DX'4GIQCG.M0!XL9G@\.^()K>-IK"#
MQD;B_B@7<6M R%CM'5<@$XZ@'WJYJMXNN^,/$LWAF9;F:Z\*[8)K?I))YDG
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MB]XEAF<))>65D]NI_P"6JJ)=Q'L.YJ+QI;V5S\0_ T=W%#(IENPZR $%3"<
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M3DL5&<Y)(P>G2L;1-6.F?#KP3=O+=IIVFS2QZF]K$'>U<AU1G4JWW23GC(W
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M(#\JQKD@E0>>216Q9/IE_P#$ZYN'^S31-X9A^=P""?,?=U[[2/P([&O3<44
M<%X :!_@SIQNVD\N/3I$F*??51NW =P0!T^E0^";N\C\1+I4E]8:W90Z=NM=
M5ME"R1QAE AF .,GJ.A^5N.M>AT4 >>>,-630?'5A>ZM=7EEH\U@UO'>00K(
MD4Q?+*^4;&Y0O..=OY5KK0]+NO"6C:#H,\]KJ*2/>://=G;+ %8L9"",[""0
M$QR&' P<>F44 >33^)!?_#_3[^WAN(9-,U2-M;@M0LLB;2WF2 $$.-Y60'!S
MC/;ANIR:?/H5]XE\/S:GJUI)J%E=:D[1%5GBB<;PB;%R0H7=@8.!GH<>MT4
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MPQ?:*;G[,EV@1I0F\J,@\#(]*MWME=76C2V<-^]I=/%L6[AC&4;'W@IR/PH
MXOP/I^H6=_/X>O(G-CX<N7^Q3L<^:DBYA&>Y1'D4_5?2M3XAO=0Z'87$,;R6
MEOJEK-?HBEB;99 7.!U (4GV!K?TC3GTRQ$4UW+>W+G?/=2JJM*^ ,D* !P
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MS$)RSEB-K8(&.J\FK":-K$FN^![V33C''I=G/%>?OD/EL\:(N.?FY4YQZ]Z
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M'"6ZX7=G#$[ANP,!&)Y)XK.L-?T>PE\3W;7&HXM+Q5NEN6+@2%%"I"N>ARH
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MNWEC20JZ30MM>)U(974]B" :QSX'%_H%WIFO:S?:K+<JJ_:I D;0A2&4H%&
M0P!R<DD#/ Q76T4 8EOH,W]H0:E?WPO+^UMW@MI#"$6,/C<Q4'ECM7)R!@<
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MMCH#6LADN[:6X6?<-H"%01CKGYA0!?T^R^P64=N9YKAUY>:8@O(QZL< #\
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MOI$%NPMU?( /(SV.1UP!2:>E_P"*?%.BVVJW^HVWVOPHEW<Q6UR\/[XR(-P
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MXFT"[T>[FGBM[I=DC0%0^,YP"01V]*T8D,4*1EV<JH&YL9/N<<4^B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XS5?BCX:T;5+C3KN2Y%Q;
MML<+"2,_6DVEN5&,I:)'9T5P'_"Y/"7_ #VN_P#P'/\ C1_PN3PE_P ]KO\
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M#_A<GA+_ )[7?_@.?\:/^%R>$O\ GM=_^ Y_QHYEW#V-3L=_17 ?\+D\)?\
M/:[_ / <_P"-'_"Y/"7_ #VN_P#P'/\ C1S+N'L:G8[^BN _X7)X2_Y[7?\
MX#G_ !H_X7)X2_Y[7?\ X#G_ !HYEW#V-3L=_17 ?\+D\)?\]KO_ ,!S_C1_
MPN3PE_SVN_\ P'/^-',NX>QJ=COZ*X#_ (7)X2_Y[7?_ (#G_&C_ (7)X2_Y
M[7?_ (#G_&CF7</8U.QW]%<!_P +D\)?\]KO_P !S_C1_P +D\)?\]KO_P !
MS_C1S+N'L:G8[^BN _X7)X2_Y[7?_@.?\:/^%R>$O^>UW_X#G_&CF7</8U.Q
MW]%<!_PN3PE_SVN__ <_XT?\+D\)?\]KO_P'/^-',NX>QJ=COZ*X#_A<GA+_
M )[7?_@.?\:/^%R>$O\ GM=_^ Y_QHYEW#V-3L=_17 ?\+D\)?\ /:[_ / <
M_P"-'_"Y/"7_ #VN_P#P'/\ C1S+N'L:G8[^BN _X7)X2_Y[7?\ X#G_ !H_
MX7)X2_Y[7?\ X#G_ !HYEW#V-3L=_17 ?\+D\)?\]KO_ ,!S_C1_PN3PE_SV
MN_\ P'/^-',NX>QJ=COZ*X#_ (7)X2_Y[7?_ (#G_&C_ (7)X2_Y[7?_ (#G
M_&CF7</8U.QW]%<!_P +D\)?\]KO_P !S_C1_P +D\)?\]KO_P !S_C1S+N'
ML:G8[^BN _X7)X2_Y[7?_@.?\:/^%R>$O^>UW_X#G_&CF7</8U.QW]%<!_PN
M3PE_SVN__ <_XT?\+D\)?\]KO_P'/^-',NX>QJ=COZ*X#_A<GA+_ )[7?_@.
M?\:/^%R>$O\ GM=_^ Y_QHYEW#V-3L=_17 ?\+D\)?\ /:[_ / <_P"-'_"Y
M/"7_ #VN_P#P'/\ C1S+N'L:G8[^BN _X7)X2_Y[7?\ X#G_ !H_X7)X2_Y[
M7?\ X#G_ !HYEW#V-3L=_17 ?\+D\)?\]KO_ ,!S_C1_PN3PE_SVN_\ P'/^
M-',NX>QJ=COZ*X#_ (7)X2_Y[7?_ (#G_&C_ (7)X2_Y[7?_ (#G_&CF7</8
MU.QW]%<!_P +D\)?\]KO_P !S_C1_P +D\)?\]KO_P !S_C1S+N'L:G8[^BN
M _X7)X2_Y[7?_@.?\:/^%R>$O^>UW_X#G_&CF7</8U.QW]%<!_PN3PE_SVN_
M_ <_XT?\+D\)?\]KO_P'/^-',NX>QJ=COZ*X#_A<GA+_ )[7?_@.?\:/^%R>
M$O\ GM=_^ Y_QHYEW#V-3L=_17 ?\+D\)?\ /:[_ / <_P"-'_"Y/"7_ #VN
M_P#P'/\ C1S+N'L:G8[^BN _X7)X2_Y[7?\ X#G_ !H_X7)X2_Y[7?\ X#G_
M !HYEW#V-3L=_17 ?\+D\)?\]KO_ ,!S_C1_PN3PE_SVN_\ P'/^-',NX>QJ
M=COZ*X#_ (7)X2_Y[7?_ (#G_&C_ (7)X2_Y[7?_ (#G_&CF7</8U.QW]%<!
M_P +D\)?\]KO_P !S_C1_P +D\)?\]KO_P !S_C1S+N'L:G8[^BN _X7)X2_
MY[7?_@.?\:/^%R>$O^>UW_X#G_&CF7</8U.QW]%<!_PN3PE_SVN__ <_XT?\
M+D\)?\]KO_P'/^-',NX>QJ=COZ*X#_A<GA+_ )[7?_@.?\:/^%R>$O\ GM=_
M^ Y_QHYEW#V-3L=_17 ?\+D\)?\ /:[_ / <_P"-'_"Y/"7_ #VN_P#P'/\
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M (.S_P#&*]BHHY$'UB?]7/'?^%3I_P!"^/\ P=G_ .,4?\*G3_H7Q_X.S_\
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M.1!]8G_5SQW_ (5.G_0OC_P=G_XQ1_PJ=/\ H7Q_X.S_ /&*]BHHY$'UB?\
M5SQW_A4Z?]"^/_!V?_C%'_"IT_Z%\?\ @[/_ ,8KV*BCD0?6)_U<\=_X5.G_
M $+X_P#!V?\ XQ1_PJ=/^A?'_@[/_P 8KV*BCD0?6)_U<\=_X5.G_0OC_P '
M9_\ C%'_  J=/^A?'_@[/_QBO8J*.1!]8G_5SQW_ (5.G_0OC_P=G_XQ1_PJ
M=/\ H7Q_X.S_ /&*]BHHY$'UB?\ 5SQW_A4Z?]"^/_!V?_C%'_"IT_Z%\?\
M@[/_ ,8KV*BCD0?6)_U<\=_X5.G_ $+X_P#!V?\ XQ1_PJ=/^A?'_@[/_P 8
MKV*BCD0?6)_U<\=_X5.G_0OC_P '9_\ C%'_  J=/^A?'_@[/_QBO8J*.1!]
M8G_5SQW_ (5.G_0OC_P=G_XQ1_PJ=/\ H7Q_X.S_ /&*]BHHY$'UB?\ 5SQW
M_A4Z?]"^/_!V?_C%'_"IT_Z%\?\ @[/_ ,8KV*BCD0?6)_U<\=_X5.G_ $+X
M_P#!V?\ XQ1_PJ=/^A?'_@[/_P 8KV*BCD0?6)_U<\=_X5.G_0OC_P '9_\
MC%'_  J=/^A?'_@[/_QBO8J*.1!]8G_5SQW_ (5.G_0OC_P=G_XQ1_PJ=/\
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M/_!V?_C%'_"IT_Z%\?\ @[/_ ,8KV*BCD0?6)_U<\=_X5.G_ $+X_P#!V?\
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M84444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]%45:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>modificationno16effectiv013.jpg
<TEXT>
begin 644 modificationno16effectiv013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]H\F4M:N#OPV<6G3G_:Q^-7]/LM-_P"$C^)JFWMBBB(X*KA=UJ"_TRPR?<4
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M^%C^%/\ H+Q?D:/^%C^%/^@O%^1KYKHH^I1[A]9EV/I3_A8_A3_H+Q?D:/\
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M,Q#%#C#*>.?\:F511=FAQ@VKGFM%=-HGA&+6HK91KVG6]Y=$K#:.6+D@D8;
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M:!I[6DMRVJEG^UHX_=J,_+MX],5E441IJ.S"4VRW8]+K_K@W\Q52K=CTNO\
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M\)FM'^(CW2BBBO)/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH S/$7_(NW_P#UQ:OEW^S[W_GSN/\
MOTW^%?4FO?\ (!OO^N1K"P/05O1K.E>RW,JM+GL?/']GWO\ SYW'_?IO\*/[
M/O?^?.X_[]-_A7T/@>@HP/05O]=?8R^K+N?/']GWO_/G<?\ ?IO\*/[/O?\
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MH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %>ZZP?]=1_6K%5[KK!_UU']:L4 %%%% !1110 4444 %%%% !1110 4444
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M4.MV\UY:P?9KJ.2X\S9YT)C(V $Y!YQ\W\ZT^!D\#UIB%HHHH *JM_R%(O\
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M4!?9((V0;=Q( #$D #@9/0"M:BB@ JJW_(4B_P"N+_S6K556_P"0I%_UQ?\
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M]3E(Z#RQAE(]W6$_B: .QDECB7=)(J#DY8XZ4W[5;^2)O/B\IAD/O&TCKU_
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M6EZ?;7LAF,SV:,TD<:DX*\;2<8!SZ_7I4_\ PD.E[+=C=8\\$H-C9P#@DC'
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M]_UR-8=;FO?\@&^_ZY&L.F 4444""BBB@"O==8/^NH_K5BJ]UU@_ZZC^M6*
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MP58 C@@]*DN-/LKQU>YM+>=D^ZTL88K],B@06%S'>:=;74*NL4T2R(KC# $
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M,(+^SLA#'8O-#=VT"NT8216!=,J,JK;001T))Q535-.ELO#]S*E@EK<S7=F
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M.3^E '44444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?FG_ ,31_P (VG_00O/S3_XF@#-HK2_X1M/^@A>?FG_Q-'_"-I_T$+S\T_\
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M#-_9"PF*37++;-%-':WC6Y1S(7R""-R_,1SZ"O1_^$9BW;OM]WNQC/[O./\
MOFE_X1M/^@A>?FG_ ,32&<?INC-9:I93QVZPVT&G&W$?F%RC%U;&3R> >:HV
M^CZEIMU;7T5NER\<UZ&A$H4[)IMZLI/&>!D>_M7??\(VG_00O/S3_P")H_X1
MM/\ H(7GYI_\30!P%OH^J65Q::DMO%-<?:+F6:V67 038(VL1@D;1GUR:UM
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M*6QTS5)/[$M+JTAMX=*(9IDE#>:5C:-0HQD [LG/TYKN_P#A&T_Z"%Y^:?\
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MM)^PR3O&RR1RK*%!PZ,&4E2,$949%-T;1/[)FOIWNY;J>]E665W55Y"!, *
M ,*/_KT 9,?C%W37IOL<'DZ2DY:/[5^_)BS]Z/;\BM@E3D\?6M"7Q"L=[';?
M9B=^FR7^[?T"E!MZ=]_7VZ57F\)I?:C-=ZE?270>VFM$41)&5BEQN#,HRV ,
M#T],\TEEX3:"X%Q=ZM<WDJV#V"ET10(V*G. /O?+R>^: *=OXNU6Z?3DCT!%
M?5+8W-GOO1C"A2WFX7Y>'!&W=GVYQ+#XON;V/2$L-)$EUJ4$\NR6Y")"T3*K
M!FVDD98C(!Z#CG(T[;P]!:RZ-(LTA.E6K6L8./G5E09/O\@_.HM-\+V^FSZ=
M+'<2N;&*XC0,!\PF=7.?H5XH H:7XPN;^?2FFTC[-9ZC));QRM<!G69%8L"H
M&-O[MP&SGCH,T6GC":YUQ](^S::]VT$LL*6^I"4JR$#9* G[LG=U&[H:O0>%
M;:"UTNW%Q*5T^ZEN4/&7+B0$'V_>GIZ"JVB^#DT>XT^3^T9IX].@DM[:)HT4
M*C;>I499OE'/?TZY ,_1?$.I7FA^%[W54V2WUPJ!K><;9089&W.NP8'R_=!Z
MX.>,5<LO%UU<C3KV72TBTC4IA#:W N-TOS9\MGCV@ -CC#$C(S[3V'A);.ST
MRSDU"6>#3+GSK53&H(4(Z!&(Z\.>?84VS\(?97L89-3GFTW3Y?-M+-D4!",A
M S 98+G@<=!G.* (K'Q?<W<UA)+I(@T^]NY+..<W(9_,3?@[ OW3Y;#.<Y[8
MYK3U?6+FTU"STS3K..ZOKI))0LLQBCCC3:&9F"L>K*  #G/M44/A>W@L=-M1
M<2E;"]>]0D#+,QD.#[?O#^0J?5=&>^O;6_M+U[*]ME>-95C#AD?&Y64]1E5/
ML10!R>K:Q?Z]<Z%:1V&Q7OY[>\M_M[Q9EBCDRN]%R5X#@]\#@=M[Q/JNKZ;J
M&AQ:9;6\R7=X891+-LW?NI&"_<; ^7.?;&.<B6S\*V]F^G2_:9I9K2YFNGE?
M&9Y9596+8&!]\X Z8 JWK>CMJRV;17;VMQ9W N(950. VUD((/4%7:@#ESXB
MU/2=6\37#6/VK3[6^A$KO=8,2M##D1IM.<$EB"5'/&235C5?B'::9JUU;8LF
MALYDAG$E\J7#%MI)CB(^<#<,\C.#C.*UKGPO;W5IK-N]S+C59DEE8 90JB)Q
M_P!^P?Q-#>'IX=4N;O3]4>UBNY1-/#Y"2 N %)4M]W(49Z^M %W6]1DTO3S<
MQBTR& +7ET+>)!ZE\'\L=ZP[3QH^IV-A_9UC!/?WDT\*Q_:OW"^22'?S0IRO
M3!"\[ATK7US1!K'V*1;EK>XLKC[1#($5QNVLIRK<'AC[@X-9T?@X6T%NUIJ<
M\=];W,]RET\:,29B3(K+@ @Y[8P0* &#6M?/C&QTYM/MH[>6Q:::,W62A$B*
M6!"<X#' XSGG&*9HOBJ+R[6&Z69(9H;J9;JXF#DF&4JZG"CHN&'L".V3I'0)
M_P"T].U$:I,;NVB:"9WB0_:(V96((  4Y48(Z"J-[X%L;[0;729+FX5+>XDF
M$J$!F$A?>A_V6$C*?:@#*U7Q7J*Z7J-_9VTD%VNA)?I#-."D0+28.W9RX R0
M3@X XQFM*Z\12:7=P7&K1/ 4TNYNY8H+CS(\1M'ZHI+$-QTQR.<YK1U+PS:Z
MG-J#S22*M[IW]GNB8&U,L<CW^<_E4,OA2._2,:K>27C"QGL9"$$>])2A)P.A
M 04 9-I\0XYH;\O;6D\UM8M?+'IU\MUE5(!5B%&U@2/4<G!.*Z;1-1DU734N
MY%M/G)VM:7/GQL/4/M7Z=.U5;71]4MX)8GUZ60^6$BD^S1AE((^9N/F/&#T'
M)[])M"T1-%ANAYYFFN[@W$S[ BER ORJ. ,*/J<D]: -6BBB@ HHHH *SI/^
M1BM_^O67_P!"2M&LZ3_D8K?_ *]9?_0DH T:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK3?#EAI=ZU[";F6[:+R6GN+AY6* Y"Y8G@8_GZFK$NCV,US>SRP"1[VW6VN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'R<G@<=O?UI8_"&E+!=Q2?:IS=VILYGGN7=FBY^7)/'4]*PM6UK6M 76+/\
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MDD#^?/&(Y629T#@=,A2!D=FZCL:GTW2K/28'BLXB@D?S)&=V=W; &69B23@
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MG).XB,KHTABX*[RGR[N2./0&N5TW5-3>WTG5&UJ:XEN=7>QDL\)Y?E^9(N,
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M1110 4444 %%%% !1110 5G77_(<T[_<F_DM:-9UU_R'-._W)OY+0!HT444
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M_A(4_P"?"[_\A_\ Q='_  D*?\^%W_Y#_P#BZ -FBL;_ (2%/^?"[_\ (?\
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M4%H%;Y =IR&(.0<CZ5V9UZ%F5CIUT67H3Y>1_P"/4O\ PD$?_0/N_P#R'_\
M%T <5J>KB3Q?$]H5M[B'68;657OY6G="55CY/W5B(;CMT/4U9LQ_Q/-/_P"Q
MHO?_ $GEKJ_[?BW%O[.NMQZG]WG_ -"I?^$@C_Z!]W_Y#_\ BZ ,?Q'-8_\
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M ')OY+5?_A(4_P"?"[_\A_\ Q=11:BM_KMD!;S1;(Y?]9MYSM]": -ZBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,[7O\ D WW_7(UAUN:]_R ;[_KD:PZ8!1110(**** *]UU
M@_ZZC^M6*KW76#_KJ/ZU8H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6:U>6.\BBC,R12!BJJH4$[<CGKP*U-%AF?Q)JVH'3I+."XA@5#(%#2,IDR2
M>#R.O/2@1T-56_Y"D7_7%_YK5JJK?\A2+_KB_P#-: +5%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !4NG?\AZU_ZYR?TJ*I=._P"0]:_]<Y/Z4 =11112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!G:]_R ;[_KD:PZW->_Y -]_UR-8=, HHHH$%%%% %>ZZP?\ 74?UJQ5>
MZZP?]=1_6K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZR_LFPOX;^&.00RF>(^67?<5F!;#*2 3MSC'% '4/J%G$EP[W,:K;,%F)/\
MJR0" ?P8'\:R+[Q3!I=UJ*WH"PVSP(A7[S&3Z^G7Z UG:KINKNNNVEO8>>-1
MDCF2<2JJ+A$5E()SGY..,<]14^K:/?SMKDD,&\SM:O"N\ R>6P9AR>#QCG%
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M1HS;P7+11R(<AE"J<GW^8_E5'1_%,%[:7M_=7=I':13M%&J@[E =E7<2>2V
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M(85S6E:)>VU]I5Q/"BB,WLLJJP(A,SAE0>N!D9'I5[2]+N8O"\VG3?N9I#<
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M:?AJVO[07$,T5S#IZ!%M(;IT>2/ (894G*_=QDD]?:@#?HHHH *JM_R%(O\
MKB_\UJU55O\ D*1?]<7_ )K0!:HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ET[_ )#U
MK_USD_I452Z=_P AZU_ZYR?TH ZBBBBD,**** "BBB@ HHHH **** "BBB@
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MV(/)QC'% S3E\1Z=:I%]IN,,\22NT<3NB*W1F8#"@\\MBK']KV7]IG3Q([7
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MBI&SLQQDX502>/:K=<]XATJYN]0L+ZW2>46ZRQO%!<F!R'VG(8$=-G0GO[4
M:<>LZ=,MNR7<96XC:2)CP&5?O<^W<=>OI5:;Q/H\"(SW?WX5N %B=F\LYP^
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M[$?H10!DOXRMY='74+<>6J7L<$WGQL J&;RRV<#L"?;O6O'K^F26$]Z+G;!
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MN6ZD\B&W(BDB4R[I"RJN5.&8D =@/6G2^'Y)-,O[3[0H-U?"Z#;?N@.C8_\
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MWEO]AL;O[1&!&?,=<L0K'.!C=VZ^U)IOA1=-U!76STJ6))FE2Y>W_P!( ))
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M2HH S?\ A']*_P"?*/\ 7_&C_A']*_Y\H_U_QK2HH P8]#TTZQ<1&T38L$;
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MV8$QQHL8V 9PS$R#YCV!XJ_'K^N74UCI<=S;1W3:C<V,]WY.0RQ(7#JN<!B
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M \@BC8$XZ#<QZ5<\(7][.MU9:M<7C:K;K&US#<QQJ$+ \QM&,-&2K8SDC'-
M%]/#6F#3[FQD2XGM[D 2"YNY9B<=,,[$K@\C!'/-2Z9H.FZ1///9P,L]PJK-
M+)*\CR;<[=S,221N//\ @*TJ* "LZ3_D8K?_ *]9?_0DK1K.D_Y&*W_Z]9?_
M $)* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<NH3VMO->:H6E@PCOY4^U(PV..&)]3M^M '8W.AZ7=P303V,+QSS>?(".LF
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M#FG?[DW\EK1K.NO^0YIW^Y-_): -&BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[7O^0%>_P#7
M(UHUG:]_R KW_KD:T: "BBB@ HHHH HZE]ZS_P"OE?Y&KU4=2^]9_P#7RO\
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MM#*T9RAD0,5/MGI7G6O6*B;QMJR/<)>V3P26SQRNH1E@C.0H.#GH<YXXJ+Q
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MK1K.D_Y&*W_Z]9?_ $)* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.NO^0YIW^Y-
M_):T:SKK_D.:=_N3?R6@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.U_/\ 8-[C&?*/6LW^
MV]2_Y][3_OMO\*TM>_Y -]_UR-8=,"U_;>I?\^]I_P!]M_A1_;>I?\^]I_WV
MW^%5:*!%K^V]2_Y][3_OMO\ "C^V]2_Y][3_ +[;_"JM% "WFL:@YM]T%L-L
MRL,.W7GVJS_;>I?\^]I_WVW^%9MUU@_ZZC^M6* +7]MZE_S[VG_?;?X4?VWJ
M7_/O:?\ ?;?X55HH M?VWJ7_ #[VG_?;?X4?VWJ7_/O:?]]M_A56B@"U_;>I
M?\^]I_WVW^%']MZE_P ^]I_WVW^%5:* +7]MZE_S[VG_ 'VW^%']MZE_S[VG
M_?;?X55HH M?VWJ7_/O:?]]M_A1_;>I?\^]I_P!]M_A56B@"U_;>I?\ /O:?
M]]M_A1_;>I?\^]I_WVW^%5:* +7]MZE_S[VG_?;?X4?VWJ7_ #[VG_?;?X55
MHH M?VWJ7_/O:?\ ?;?X4?VWJ7_/O:?]]M_A56B@"U_;>I?\^]I_WVW^%']M
MZE_S[VG_ 'VW^%5:* %36-0&IS2""VWF&-2-[8P"^.WN:L_VWJ7_ #[VG_?;
M?X5FI_R$)?\ KDG\VJQ0!:_MO4O^?>T_[[;_  H_MO4O^?>T_P"^V_PKF-<O
M]6T^:W-J+)H9YXX%$H?<"W&3@XQ4$_B&;2]8%IJ0WJ+(3L+2!WP=[ GC)"A0
M.M '7?VWJ7_/O:?]]M_A1_;>I?\ /O:?]]M_A6!=>(M.M%C<O+*KPB?,$+R!
M8CT=MH.!UZ^A]*L:CJEOIVC3ZFY\R"*+S1L.=_' 'UX_.@#7_MO4O^?>T_[[
M;_"C^V]2_P"?>T_[[;_"N?AN]2M8GN]7^PPVBQ&23RV;=#@9P2>&[\C'TI(O
M$FG217#N9X/L\!N76>W>-C$.K $9(^E '0_VWJ7_ #[VG_?;?X4?VWJ7_/O:
M?]]M_A7.'Q/8-;W4D(GD:WA\\)Y#@R)T#+Q\RY[C/K4</BJP?3;&[F2YB>\
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M* IWC/&1VR>U '>_VWJ7_/O:?]]M_A1_;>I?\^]I_P!]M_A56B@"U_;>I?\
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MBC>5TD7#A5R3QGT%9H\56K2")+'46E>/SHHQ;G,L?=AD\ ?[6#R/44",Z_\
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M 4444 %%%% !1110 4444 %%%% %=/\ D(2_]<D_FU6*KI_R$)?^N2?S:K%
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ML+R*-X%F8R7QL57 SO )W=?N[1NSZ4 6KNTN]1\/75G<>1%=7%O)$3&Q9%+
M@') /<=J9'I4B:O:WAD39#8M:E>Y)9#GZ?*:RK+Q+>2W>CV\=G/=PWEO)(\Y
M$:,2K*,XWX &>1CN,9YHTGQ',K-%>6UT\;ZE/:I=G;L!\UPBXSNQ@ 9QB@!J
M>$[E=)%I]HBW#1GTW=@XWMCYOI5S4_#LFHM,//5%DTN2QSC)#,1\WTXJ;7=8
MN]+NM,BMK![H75P8GVL@. C-@;F'/RYYXP#WQ6>GB.>RU36!=6MU+:07<:F9
M=FVW5HX^#SD_,Q)QG&:!EFVT?4IM1DN]1FM5WV)M!';ACMR<[LGK_3WZU2?P
MQ>SV6D_:8M/N)].B:W$;L_ERQE4&XG&5;* ]"*T;GQ/;VUW+&;:9[:&98)KE
M2FU';'&"VX@;AD@<9]C3O$^I2Z98VLD5TEJ);J.*29U#!%.<GGCM0!0OO#=S
M<:5;6=O:Z9;21ARLL3.K6SLV=\9 R?4@XR>M:VKZ=<7MK:FVE075I.D\9E!V
MN0""&QT!#'ITK+>_O)Y=)MK'64F6[>;?=+"AR$7( '3K4L&OW%G%K<6I".2;
M2U63S(E*B9&4LORY.&R",>M ALV@7U];ZA)=2VZ7=X\'RQ%BB)$X8#) ))^;
MG ZBM/7+"XU'2VM[:41R%T8AF95D4,"4)7D @$<>M5?#=_?W$5U9ZL8SJ-I(
M!(8UVAE90RD#\2/^ FG7WB$6D]VD6GW5U'9*&NI8MF(\C=C!(+$*0<#L10!G
MVOA6>""9-UK%YNHP7HCA#;$6/9E1GDGY#S[]NE.U[2633O$-XSY:98[BWV*2
MR21*-O'<[E'2M.+78[G5?L-K:SS[8XY9)EVA$1P2IR3D]#P!2WVL&UOA96UC
M<7MSY7G.D15=B9(!)8@9)!P/8T 2:'8OI^C6T$IS/M,DS?WI&.YS_P!]$UEQ
MZ!>6ECIIMI8'O+&:60"3(CD60MD9 R#AAS@]*!XGEN-6TJ&RT^:>SO;>24R?
M(K*59 >"PQMW'<,9Z8SS46D>(Y@YAO;:Y:.349[5+L[=@82N$7&=V, #.,9X
MH F3P_=R,+FYGA^U2:BE[,(P=BJB! BYY/ ')QWJU<Z-+/=:S*)4 O[-+= <
M_*5$@R?;YQ^5,@\36\][%$+:9;>>9H(;HLA1W&>,!MP!VG!(YQ[BK.EZP-5E
MG\FSN$@ADDB,\FT*SHQ4@#.3TZXQ0!GWGAZ[G1?L]Z()%TMK)9%SD.2AW#';
MY3[\U23PC<FUU=/]#MVO[:*$)#O*HREB22>3G=U__6>PHH **** "JK?\A2+
M_KB_\UJU55O^0I%_UQ?^:T 6J*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I=._Y#UK_U
MSD_I452Z=_R'K7_KG)_2@#J****0PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[7O^0#??]<C6'6YK
MW_(!OO\ KD:PZ8!1110(**** *]UU@_ZZC^M6*KW76#_ *ZC^M6* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *Z?\A"7_KDG\VJQ5=/^
M0A+_ -<D_FU6* ,B]TR]_M7^T=-N8(IG@%O*L\1=2H8LI&""""S?7-1Z=X>7
M3KC3I$N2XM+::%MR\R-(Z.6]N5/'O[5->ZM+!J\&FVUDUQ-+$9BWF!%1 P!)
M/XC'^36?;>,;>YU*&!8H_L\\[6\4@N%+EAGDQ]0I*G!^G S0!KWVG&\O]-N1
M+L^QS-*5VYWYC9,>WWL_A5"T\/&VMM%A^TAO[-E:0G9CS,HZXZ\??SWZ5#:>
M*9+N_MHET[%O=><8IC.,D1G#$KCCGWJY::_'=QZ,X@9?[4B,J9;_ %>$#8/K
MUH K)X=GMK&P6UNXQ=V4\LL<DD9*,)"VY2 <]&ZYZC\*(_#LK8GN;M'NWOTO
M9G2/"G:H4(HSP, <Y/>J-CX@N;#PAIU[/&MQNMO,DEGNEC9B.PSDLWY?6KD>
MO7DWB*.WCM5.G/9)<^8T@#*"?O$>W3% RY<:*9[K59O/ ^WVB6P&W[FWS.>O
M/W^GM52\\,O=0JBWS1%=-:Q#JG.24.[K_L]/?K3K/Q))</82S:<\%EJ#;;6<
MR@L25++N7'R[@#CD]LXIL'B=Y;:.]?3GBL9+D6PF:4$@ERFXKCA=V!G/?\P1
M43P<WV75(_-LX&O[6.#;:6OEHA4L=V-W).[]*WM4TXZE%;H)?+\FYBN,[<YV
M,&Q^.*6PU%=0DO!'&1';3F .3]]E W$>P)(^H-9T/B4?VJ;&ZMDB8Q22KY=P
MLK )C(=1]TX/'7H: '7OAXWD6M)]I"?VELP=F?+VJ%]>>GM5=_"^W5KBZBBT
MN2.XF$S&ZL_,E0X (5LCCC(ST)/6F6WB_?OENK V]JMC]O$HG5SY7;@#[WMG
M\:(?&,31WIFMHQ);63WJK#<K*&1>H)'W6Z<>_4T#')X7\C5IKF*+3)(IKG[0
MS7%GOF0DY8*^1WR03TSWI]WX=N;B/7;9;R);75 S<Q$O'(45.N[!7"YQC/-*
MWBD6WVDW]A+;+':?;(P'5S(F<8P.C9*\9(YZU8;6;NU6!M1TPVRRW$<&Y9Q(
M%WY )X'\6 ?]X8)H$,O?#YO(==C^TA/[4B$8.S/EXCV9Z\^O:N;N[2[@\27U
M['9237?VI&MH9+*21) $10WF@A%Z'&>5]Z[/3M174OM31QE8X+AX%<G[Y7AB
M/;=D?A69XI^VV]C]ML]4NK8B2&+RXUB*'=*JD_,A.<-ZXX'% R]KNEMK&E/:
MQS_9YPZ2PS[=WENK!@<?A6?8>%(M/UNWO8[@F""V6)8-O_+4*$\S.>NP8Q4%
MQ/JFF^([6TMVN=4+6,KE9I4C!(D3#':H' .!@9Y^IJ27QA!]GL'MH8VDN[?[
M1LN+A8 B\#!8]6R<8'H: 'VOAVYL?[(:VO(B]C')"_F1$B1'92<8;@C:/6I5
M\/%;.*#[2/W>I-?;MG7,K/MZ^^,U977K1O#8US#_ &;R/.V@9;I]WTSGBH)=
M;O;6V5KK23'<2RI%;0K<*WFLP)P3QMP 2>/IF@18UC3I[\6<MK/'%<6EP)T,
MJ%E;Y64@@$'HQJK<^'GN;36(3=*&U&5)=PCXCPB+C&>?N9_&F2>)FMXKA;G3
MI%O()X86MXY%;=YK (RL< @G/7'0U6U+Q+?PZ5?M#8"*_LYXHY(VE#+M<J0P
M..<@XQV/TH D;POY>K7%U#%I<L=Q.)V-U9^9*AXR%;(XXR,]"3UK7U+3CJ'V
M/$NS[/<I<?=SNVYX_6JG]LW7]JPZ:-,)N&A6>4^<-L2%BIYQR>.G?VJ)/$JI
MJ_V"[@CAW)(ZE+A9&4(,G>H^[QSWH LZKIMW=WMC>65S##-:%\":(R*P9<=
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M ,UJU55O^0I%_P!<7_FM %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*YO_ #(DC#"1!Y4NT,22&R.3@#!]:WM0O[XZO!I>G?9XY6A:XDFN$9U500H
M4$9))]>,=Z &7?AFWO+FZD:\NXXKJ2.6:"-E"LZ;0#DKN_A7C..*FET&TFMK
M^!I)ME[<+<2D,,A@$&!QT^0?K6'_ &OK%_>Z-Y$MM;LUQ<V]Q&59E9XPX)ZC
M*_+D>E1P7^I:9+J]W$MJUDNKB.1'#&1MYC0D'.%QN!Y!SSTH&;%]X6M[YKQ3
M>WD-O>,))[>%E"LX &[)4D?=&1G!QTK1U33H]4LC;22218=)$DCQN1T8,I&0
M1U ZBN='BJ]EU5T@@$ELE[]D,2VDS.0'V-)YH^0 ')QZ#KFM;2K^_P!0U"^W
MBVCL[6X>W50K&1R,'=G. .<8P?PH$+-X=M[E;G[1<7$DES%!'*^5!/E,64\#
M )+'/;TQ4UQHUM<RZA([R@WULMK+@CA!OP1QU^<^O:L^XUJ^BU/5ODMUT_3(
MA+*2K&20&,M@<@#&.O/T[U1M/%-_Y5Q-<6PGC2QDN@8K6:$(R@'RRTG#9SPP
MQT/% S6;P^$N&FLM1N[(R(B3"(1D2;1@$[E.#CC(Q4MSHJW>HQ74][<O##*L
MR6QV;%=1@'.W=[XSC-<]!XKU%K'5+SS-.NH;.U257MXW"F1B<H26/*@<]^1T
MZ5<\5ZA(;'7M-V+Y::.\X;OD[UQ]/EH$;&H:2+VZANX;RXL[J)&C$L&TED."
M5(8$$9 /3BF6V@6=I]@\MI<V32.A9@2[.#N9CCDG<3VYK)U3Q'-IMVB136TL
M:20QR0+;R,ZARHR9 =J'YL@$<C'K48U?4]/N_$ES<R0W%M9R+Y4*J5.3&A4
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M+_S6@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5+IW_(>M?^N<G]*BJ73O^0]:_P#7
M.3^E '44444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC3[-$CR2$*20 WRC@$Y/'%85MK6JW=EI</VKR)Y]2GLY99(D+[4$A' ^4/\
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MS330:2%'F2PQ+)B3<!B0'D)CNO?J:H033V%[XHN[C5IEAAG4 >2K[28HRI
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M36EY(T*R,PLHC"#%,H0'_6#D/G)(/8<#O0!T5,EECA3?+(D:9 W.<#).!^I
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M<A@>A!IU<=X9N-0LX?#MM/=)/;7NGY6,1!?**(A7!ZG@X.>_ITKL: "BBB@
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MQCIP>] SM4M;:"9[A(DC<QK&S@8^1<D#Z#)_.LBWLO#&K;8[46-U]E0Q[89
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MU3491&S7JQQ@ <A%7'/N23^ %4K.[O8?$\MMJ,]P%N&D^QJHC,#HH!QD#>'
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MRC[O3AN1B@#9CTVSA^R>7 J_9(S'!R?D4@# _ "K5 .1D44 %%%% !4NG?\
M(>M?^N<G]*BJ73O^0]:_]<Y/Z4 =11112&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G:]_P @&^_Z
MY&L.MS7O^0#??]<C6'3 *K-J%DMZ+)KNW%TPR(#(-Y'^[G-6:X63RY/#E\Q"
MF_\ [;(!_B\P7(V8[_<V_A[4".O_ +5T[[7]D^WVOVG=M\GSEWY]-N<YJW7)
M3BX\.WRW,<UE=6U_J04Q&$K,K2,%.U]Q!V]<;1P#76T 5[KK!_UU']:L57NN
ML'_74?UJQ0!#<0V\BI)<)&RPMYJLX&$(!^;GIC)YK&OH=(\5V<\%I>VDLZKL
M\Z(K*44L"5(!Y5MN",\BF^,VV^'\R _9?M,'VK'_ #Q\Q=^?;'7VS2^(=0@M
M[%#:W4,,TCPQ//&5WQ0O(JLP]!SUZ \T +IGAJ*UDO'NELY$NHUB>WMK40PX
M&>2F6RQSU/8"M"#1=,MH&AALH5C=U=EVYRRG*DY]"!CTKE]2O+O31K%I8ZG/
M*D,%M(LLC^8T$CR%2NX]<J <'^M:5S:SKKVEZ6FI7RV[6UQ+*?-^>0JT>,MU
M&-QZ?3I0,W)M/L[@7 FMHG%PH6;<H/F = ?7&:S[WPW97&D_V;;Q0V]L\\<L
MRB//F!6#$?4[0,^E8.D76LWU_%>^:RC[;)'.CW:[ @9EV"+'## .<Y./0TR7
M4;ZPL];CGNYWOOL-Q=03QSAX60$[2H_@(RHQT//)H [JBN&NM3NM-6>6PU26
M_P#,TF2Z=G8.$<%0K@#@ AG^4<?+[5/=7$NESR0V.K7%XDNE7%PYEE$A1E"[
M) >V<GCH<<=*!'95"]W!'=PVKR 3S*S1I@_,%QN_+</SKE([N_TZ:.1;RXNV
MN-'ENS',01YJ;,;0 , [R,#VK.:=[.\TZ^MM2FU&Z.D7-R$ED#_/M0@@#H&(
MQCIQQWH ]"HKBM+EU9+:2[-T[VTFG22%I+Q9BTF 5=  -HY;(''2HVO]2TRU
MMKN.]N+J:ZT:>Z9)B&7S45&4J ./O$8[\=Z .YHKCM0GETW05ELM6GNYKEK=
M9&DN%.Q7< NIQ\F<XST'IQ6KX=348FO([UR80ZF!7N!,Z CD%L#C/(SZT ;E
M%%% !1110!73_D(2_P#7)/YM5BJZ?\A"7_KDG\VJQ0!6N-/LKN6.6YM+>:2/
M.QY(PQ7/H2.*5["SDE@E>T@:2W_U+M&"8_\ =/;\*Y[6Y[<^*K2SO]2EM+-[
M*1]BW)A5W#+C+ @\ D]1TJCIC76J2^'X+N\O/*DLKB5MLS1F8+)&(V8J0<[2
M#^/N: .K_LK3O+N(_L%KLN&W3KY*XE/JPQR?K3X-.L;6)(K>SMXHXWWHD<2J
M%;&,@ <'!/-<9'=EH(;P:E.=<;4A$UK]I. OG;6C\K. HCR<XSQG-6;"ZOVU
M^/P])<SLUE=2W,LI<[I+? ,2EN^6D _[9F@#IDAT[4[ LL%O/:W)WL&C!60^
MI!')X'7THTI[":Q6?3HHXX)"<;(]F2/EZ?\  <?A7'V5Y]KBTF/5M3N+>V:T
MGF$OVIHC)(L@'+@@G:IR!G\#BJ%C/<OI^C6?G*+1K6:16EOWL_,D\TC.Y%))
M YV\=2>W ,] FLM-A-S=RVMLI==T\K1+EE7GYCCG&._I4-GJ&CZO),+6:VN)
M&C E  +,G.,@\E>3[<FJ9^T?\()-]JN8KF?[ X>>)]RR'8>0<#/UKGM(U%;;
M5]/N)]1MK^--*?>8%"FT10C'?@G.< <X^[QWH$=;IJZ-;7-U8Z9'9PS0E3<0
MVZ*I4D<;@/:HX=4T*\N9+**XLY)I9"6BP/WCKP>#]XC:/R]JY32I;O3]1TC5
M;O3I[;[>[Q74SNA#&9M\? 8D8.%&0.#2:=%<!-&FO9HVTM=4N/+6./:\<QEE
M"%V).Y221P%Y9>M(9U;:KH$UY-9R7-FT\K>1*CX^<C(V'/4\GBG2V^A:5;+9
MR6]A:V]Y((A"8U597/08Q@FN7N+S3V\,>(M/FEBENIKR[2&U5@9'D+G9A>N<
MX.?;--UBUO\ 6;B>R2SFNVL+%;<2QR(H2[8*^[YF&<;4Z>II@=D-+TR"PDM%
ML;2.S;YI(A$HC/N1C';]*C+:5%):VHAM\7:@0A(P5=8QN7H,8 Y'Z52BNQK_
M (*:Y(D5Y[5MZQL599 "&7(YX8$5S]G9VEW;>$H(;RX:)T<R-'=,6!\@$J&S
ME1[ C'M0(ZS5M'BU2W*!A#+OCD\P1JVXH<J&!^\N>U5K+PS:1+=?;E@O6NG5
MY%>W18QM&!A.1W//)KF)+R^,5A8M.6M5N[V$R7%\]N7\N3$:M*H+$[=W'?;U
MXYZ;2WOH?";.UQ%>7<<<IC>*7S@V"VP;L#<0, G')!H&:\=K;Q&,QP1(8TV1
ME4 V+QP/0<#CVISQ1R,C/&K-&VY"PSM.",CT."1^-<;I5Q$+S0GL-4N+N>[C
M=KY'N6E&WRR2Q4DA"'VC@#KBJWAR]$W_  C4\&JW%W>7*,M]&]R7&P1DDLN<
M+A@@S@$YY)S0([IK>%FD9H8RTBA)"5'SKSP?4<G\S5>YTG3;WROM6GVL_E#$
M?FPJVP>@R.*XK1K\O;Z)<V^J7%WJ<UP\=Q ]RS H%<D%,X &%.[&>G)S4^E7
M8==!N8-4GGU2[E O8&N"PQL8R QYPFP@ 8 Q@#O0!VTKPQ0DS,B1<*2Y 7GC
M'/Y57@TG3K5)4M]/M8EF&)!'"JAQ[X'-<3=6@NO UQJ-W>7LDK7669KJ0*J+
M<[0, XP%&<_CV&-.YU.#3;_4(_[29;;^RD:U,ER7WONE!*DDEF^X.YZ4 =)!
MI>GVML]M;V-M% YRT21*JL?< 8-+)+8K=2I*81-Y&Z0L!_J@3U/IDG]:Y2%)
M]4GMH9[^]6/^Q(9R(KADW2$M\Y(.<_S[YJO/=76JZ0BSSS-]H\-FX=8Y&7=)
M\ISP?P]P2.E SL[6QL;:.+[):V\2(#Y?E1JH ;!.,>N ?>FM8Z;;2RWS6MI%
M)_K)+@QJIX'WBWTSS7(R:A_8&GZ7J5E=37=G+:M;M$;AIE\\H'CQDG!)!7_@
M0K5URPEC^'=[:W,\TT\6GN7E\QMSN$)))!R03VZ8XH$;<.FV$%S)=065M'/-
M_K)4B4,^?4@9-1G1=*:T^R'3+,VV_?Y)@79N]<8QGWKFV>Q:^T^RFU29-+-F
M\L;B_=?-EW#(,N[)V@Y"Y[^U:.E75Q+X+EG>>21UCG\F=C\SQJSB-\^I4*<]
M^M &XEK;QB()!$HA&(@$ V#&,+Z<>E,N[&TU"(17EK#<Q@[@DT8< ^N#7%W)
MN;?2=  N99$OU$EW+<ZA)"'?RP57S!DH"<\+C.T#ZS&_N]#TJPU:[OQ<VEO/
M+%<>1<&=?*<G9EB!N96"KDC/)H ZQ?L<5Y';JD27 A.Q53!$8(! /89QQ22:
M5ITOD^986K^0,1;H5/EC_9XX_"N1N;K6;"VC/G3/?-HUW=-&6+ 2EXV&!WV[
MB![#%-LH-0N+._6QU.+]Y8EXEAU22ZD,P(*O\R@J#T('!R.* .T:SM64JUM"
M04$9!0<H.B_0>E3UYNWB/4;X27=O/*D&MQK:V"@G]S(-BLP]#EY3G_IG7HR+
ML14R3M &6.2?J: '4444 %%%% !55O\ D*1?]<7_ )K5JJK?\A2+_KB_\UH
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M_P"0]:_]<Y/Z5%4NG?\ (>M?^N<G]* .HHHHI#"BBB@ HHHH **** "BBB@
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M+R>2.N,]L5R>@FU2/1%TZ60ZP)Y/M,3.V1#M<G<IX"?<P<8SC'>@#T411@*
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M9O=8:"UU:U>_9+T:O$L4?F$.(R\1X'7:5W>W6@9U5MI5K:7\UY"FV26-8\
M*J@LV !TR6)/J:NDX&3TK@FFO[G7KMC?6UM<PZ@J1B?49(R(@5PH@V[6#+GG
M/);KQ5N)U;Q'>64UT]V;SS_+DMKY\PJN,QO&#A,= PYSZ9H$=?%+'/$DL4BR
M1N RNAR&!Z$'N*?7.^!UME\(Z>+><RGR(_-!G,FQ]@RO).W']T8 ]*Z*@ J7
M3O\ D/6O_7.3^E15+IW_ "'K7_KG)_2@#J****0PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[7O\
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M7_FM %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J73O^0]:_P#7.3^E15+IW_(>M?\
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M,;1E01G*[@3G!]#CM4CZ6T6G">WM=;%X;J2XCF)@,J2% N2N0NTCC&/7IG-
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MPU8RZ=H<5O/"(I?,E9EX_BD8@\>Q%:] !1110 55;_D*1?\ 7%_YK5JJK?\
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M-O).LB^:7SNCQRJX+9!QR1@"NBH **** "JK?\A2+_KB_P#-:M55;_D*1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4NG?\ (>M?^N<G]*BJ73O^0]:_]<Y/Z4 =1111
M2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!G:]_P @&^_ZY&L.MS7O^0#??]<C6'3 ****!!1110!7
MNNL'_74?UJQ5>ZZP?]=1_6K% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %=/^0A+_P!<D_FU6*KI_P A"7_KDG\VJQ0!0EUBS@O+JUF=
MHY+:W%S(6''E\\@]\;3FJ(\26\9N9I'=HA';-'"(2),S9"KUY)/;C'>F>(_#
MLFM3VLD,ZPXS#=9!_>V[$%D'O\H_,TZ]T2:6ZU.98;.YCO(X(_L]QD*0F[.2
M <?>&#@]* )Y-7*W-F/+FC\Z&9S;/!^]8IMZ'.!U]\Y&#5/3O%B76C6-Y-8W
M2SW9"QP(F3(=I8[<D9  /)Q3M-T&[M)M+EN+I93:+<*1N9L"0J552>2% QD\
MU53P_J*^'+?29K?3;E;8[8W>613@#"N"%RK#/0?F*!FCK5[,T&GVEF\D-S?S
MHJG&&CC'SR'!Z$*"/J14ZZW"=3CL9+:ZA:9G6&26/"2%020#G/0$\@9 XJCI
M&GW@UCS;YY)OL%I':0S2#'G.0&ED'UP@_ U4LO"][%K5G?7$EL[6UQ+(T^YV
MEF5U< '/"XW#@9'';I0(VH=<L[B'3Y4+[;]S'#E>X5F.?3A#67>^)]][8064
M=RL<M^+=KAH?W4@&X.JM]1UXS@XIEAX?U2WETF*:>T-IIL\CIL#;Y0RNH)SP
MI&_ISGU[40>']4B6QLVGM/L5C>FX1QN,DB[F(4C& 1NZY.<=J!CQXH>*>PA^
MS2W@N9[B)I(8=N/+9Q@ DY(V\\].?:M:SU>&^O9[>"&X*PNT;3E,1EU.&4'.
M<CZ8XK)30+^U2PDMI+:2:UO+F<K(65665G/4 G(#CMVJ>VT:[C\2MJ.VUMH3
MO\P6[OFYSC:74@*" .O)/M0(2_UV6P\2M:&&YN(?L0F$-O$&8-O8%L\<8 [_
M $JS%XETR:"YG69O*@M4O&8KC=$P)##U^Z1]:BO]/U4:X=3TU[,[K46YCN"P
MYW,V[(!Z9'&.>>E8M[X<\BX\.:=#*S#RS;W;;>)84*R'/IEU ^CF@#K9KSRK
M);D6]Q+N (BC3+\]L=OQ-4/^$EL19+<O'<J3<_93"8B9%E_ND#/Z9ZBI->T^
MYU*P2&VD4,LJN\;NR+*HZHS+R ?QZ5EV/A>>U@CCWVZ;=4%]LB#;578!M&>^
M>_\ +I0!HV_B.RN)((RD\,LMPUKLE3!255W;6[#*\CUJ[:7\%]'-)"6*12O$
M6(P"RG#8]1G(_"N=UW2IK72-;O$<-</=QWMIL4DK(BQJHQ[E"/HU;VEZ>--T
M:WL0VYHX]K/_ 'F/+-^))/XT 48?%%G<6$5Y%;WC1SLJVX\K#3D@G"#/8 Y)
MP.,]*D_X22S-G',L5RTKSFV%L(_WOF $E<9QP 3G.,=ZSYO"TDGA[1;(FWFN
M-,"?)+D12X0H02!D=<@X[=*S=9TU[*RTV(V]M8+]L>:22V,K1QGRR Q==K[C
MTSP/6@9TFG^(;/43:B-)XVN3*(Q*FTGRR V>?4X_ U!)K1N+[1C9N1;W-U/#
M*&49;RTDR/;YDK+TNSOKBUTV[L+>VA-A)/"B3>8J31OC]X-P+9)&><YYYYS5
MRS\.7EO;:6DEW$9K2XN9I)$4C/F^9@J/;S!Q[4A%U?$,32R0FRO8YU@:>..2
M+!E12 =O/4$C@X/-5[#Q5'<Z)87LUG<K<7@41VR1Y:1BH8E>?N@9Y.*J:-X7
MN[+4K>[N6MM\=I);R/&SN\S,4/F,6[_*>.V>I[.M-#U:SL-("M9-=:6I@C!=
MPDT10+DG;E6X!X!''O3 O/XHL$M8IC'=&26X-J(!%^\$H4ML([<#KTY'..:E
M7Q#9&UN)F69&@G2WDB9/G$C;=HQWSO6J=OH%T+FUO+B:'[0-0>]G6/.WF$Q!
M5SR<#;R<9YJ"YTLS^/H9$)%MY"W5PFWAI4W)&<^N&)_X * -^]O#9QJRVMS<
MLQP$@0$_CD@#\ZSI/%%B+2UGABNK@W,;RI%#%EPJ8#D@D8P2!]>F:=KVE7.I
M/9F$PR11,QEMYG9$DR, DKU*^AX.>U<E?Z/)IG]E6-Q.D<<%M< W 698VWR
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M@ 4AA&#A68'N>OXBL#2O"MY:7UO=7+VIDBM98))$9W>=FV_O&+=/N].V>I[
M&MI_B2RU&>".*.YC%Q"9H))HBBRJ,9VD^F1_,9%44\3?;M:TB"TCN8[6Z:4^
M9+#A)T$;$%3Z9 /8D8[5-;^'I8X-#BDF0KI]HUO+MS\Y,:IE?R-0:=H6JP3:
M*MU/:&WTI6C4Q[MTR^64#'(PIQCCGOS0!T]%%% !1110 55;_D*1?]<7_FM6
MJJM_R%(O^N+_ ,UH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*CWR_P#/E>_^ S_X4;Y?^?*]_P# 9_\ "@1)14>^7_GRO?\ P&?_  HWR_\
M/E>_^ S_ .% $=UU@_ZZC^M6*J73RY@S9W@_>CK;N,]?:I]\O_/E>_\ @,_^
M% $E%1[Y?^?*]_\  9_\*-\O_/E>_P#@,_\ A0!)14>^7_GRO?\ P&?_  HW
MR_\ /E>_^ S_ .% $E%1[Y?^?*]_\!G_ ,*-\O\ SY7O_@,_^% $E%1[Y?\
MGRO?_ 9_\*-\O_/E>_\ @,_^% $E%1[Y?^?*]_\  9_\*-\O_/E>_P#@,_\
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M7 C\II+>%E+IG.TY4]^A'(R>:@NO#D-U-.QAUF.*YV_:8(XW"3X 7YOESR
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MW4OV75(WN7B>1HXI%.8\8 (' XY]:T-\O_/E>_\ @,_^% B2BH]\O_/E>_\
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M^ S_ .%&^7_GRO?_  &?_"@"2BH]\O\ SY7O_@,_^%&^7_GRO?\ P&?_  H
MDHJ/?+_SY7O_ (#/_A1OE_Y\KW_P&?\ PH DHJ/?+_SY7O\ X#/_ (4;Y?\
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M;027$5P\2--"&$;D<INZX],XJ6B@ K.D_P"1BM_^O67_ -"2M&LZ3_D8K?\
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M-%9K*=@=%73YI(G0FWE^0[FRPR.#RN>E5/#/A^[MFTRWOK?64N=.MFA2:26
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M)2PN2DJ@PN"A+<_>7Y3TR?:FV7AW4(-*\.6[QH)+'4Y+F<!QPC";!'J?WBT
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MBBB@ K.NO^0YIW^Y-_):T:SKK_D.:=_N3?R6@#1HHHH **** "BBB@ HHHH
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M2ADB*L >^TE,=.AIEQ9:SJ\NE3WEK:6ALM06X,:7!E)01.IYV#G<XX]!U[4
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MBBB@ HHHH **** "LZZ_Y#FG?[DW\EK1K.NO^0YIW^Y-_): -&BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,[7O^0%>_\ 7(UHUG:]_P @*]_ZY&M&@ HHHH **** *.I?>L_^
MOE?Y&KU4=2^]9_\ 7RO\C5Z@#'\3ZG=:3HC75F(3<&>"%/.4L@\R5(\D @G
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MS+*",DA8RPP>W(K8K(UO2)]0EL;RRN4M[ZQE:2)I8RZ,&4JRL 0<$'J#P0*
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M[32>6CJ#_P LV "@-]0,=Q76:A#>S6VVPNX[6X# AY(?-4CN"N0<?0@USO\
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M*[O4E=FN8H8F4@8 C# '\=U9%]X-^V-?Q)JMQ!8WUPMU-;)&I_>#;T8C(4E
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M6.2ZAMXOE52$,,C2(<$8/S-R#P0*C7PA&T=W]IU">::ZN[>[ED**OS0E"H
MP =@'K[T 26GB5U361JUI'9R:4@EF\J;S4,90N"&*J<X!!&.U2>$K6XM_#T$
MMX"+V\9KNX!/W7D.[;_P$$+_ ,!JIK?AF2^GN#!)F+4KBV^W*YP!#%DD+Z[L
M!3[$UT] !1110 4444 48O\ D.W/_7M%_P"A25>JC%_R';G_ *]HO_0I*O4
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M;B.$1,LI50H;YT8@[0 2,=!4EWX;L[V/6DDDG U>$0W&UA\JA"GR\<'![YH
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M0RVRVI9[N[80*74YV\<=.@'S''2LQO$<FNZ?I\O[M)+?7X;5VMW8I(  V1D
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MAS3O]R;^2T :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0AY85=(V)/RAP P_' H \]TF:[;5='U0S1+#'X9CN?LL=N H7Y"47TR0,>F
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M02%8$LN1Z9[UU%UH&EWBW0GM0QNI$FE8.RL750JL"#E2 H&1CI1#H&G0V\<
MBED2.<7*F>>25A(.C;F8D_3.* ,_PQ=ZGJ;7UY>7<9MTN[FVAMTB PL<S*&+
M=2<+CTZ=ZQY]6OK6]U.'3Q:6\LNOQ6GF&#((>WC)9@"-S9/7/8"NRM+*WL(G
MBM8A&CRO*P!)R[L68\^I)-0-HNG-,\IM5,CW*W;')YF50H;KV4 >G% ''S:U
MXBLH]4EEU&WFCTC4(;=E^S!3<I)Y3'<<_*0LN!M'4<U)J>O:Y GB+48;VW2V
MT:[5$MC "9EV1NP9L\9WD#'?UZ5U=QI&F/!>^?;H8[J19[G+'YV0* QY[!%_
M*L33O"FEWU]>:U/LNTO[F.\MVCE<(R"./9O4$*^"I89!QF@"GJ_B6\M==C%E
M=2SVRZA!9S1"RQ#'O958&4G)<;L\<= 16AI=QK.MRWEY'J45M;1W=Q:I;"V#
MX$;-&&+$YW;ANQTQ@8[U?E\+:--J#WLEGF9YDN#^]<)YJD%7V9V[OE'.,GH:
MD3P[I<>JMJ26[+<L_F';,X0OC&[R\[-V.^,T 9?@#[:_A*TFO;YKII Q4LF"
MH#$8)SS6?:Z[K+6.E:[)>0O::A>QP&P$ 'EI(^Q</G)9>"<\=>!75:9H]CHZ
M2QV,311R.7*>:S*I)).T$D*,DG P.:JV_A;1K74%O8;0K*LC2HIE<QH[9RRQ
MD[%8Y/( /)]: .>M=>UMFLM0FNX&M)M8ETXVJP8.P2R1JV[.=P*CVQVSS6WK
ME[?G6=+TBPN%M6O%FEDN#&'*K&%^50>,DN.3G@&KZZ+IRP1PK:J(XKDW:+D\
M2EBY;K_>8GTYHU/1['5TB6\B=FA;?%)'*\3H<8.'0AAD=>>: ,,SZ]?:O=Z7
M;ZK;VSZ?:Q/)-]E#>?*^[!*D_*@"]!R23R,50B\4:I<#0M2N6:PTJ\M8)'E2
MW\U#,[89'.<HI!4*W3+<GM6W+X8\/:CB/R=QMD^ROY%U(AV_>\N0HP+#YLX;
M/WL]ZM7'AO2;FX@FEMB?)"*D0E=8L(<IF,':V#TR#B@#)\(+J)U#7VN]2:YB
MCU&2-8VC VG;&<@YX&#C'3O75UA:CX5L+U;_ ,L/ ^H[5NRLC[9%RN[Y,[0Q
M50NX#-;H&!@=* "BBB@ K.D_Y&*W_P"O67_T)*T:SI/^1BM_^O67_P!"2@#1
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *SKK_D.:=_N3?R6M&LZZ_Y#FG?[DW\EH T:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH SM>_Y 5[_ -<C6C6=KW_("O?^N1K1H **** "BBB@
M"CJ7WK/_ *^5_D:O51U+[UG_ -?*_P C5Z@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"C%_R';G_ *]HO_0I*O51B_Y#MS_U[1?^A25>
MH Y/Q/>W^FZM:WLEQ=1:+$BB8VAC+1R%P TBL"6C(X^7D<\>C]$EO-4O[S4)
M]7GB%OJ,UJMD@01;$)4!@5W%C][.>X[5MW6BZ7?7L5[=:?;3W4.!'+)$&9<'
M(P3Z'D>AI#H>E'5?[4.G6IO_ /GX\H;^F,Y]<<9]* ."\+S:AI&E^%IDU"XN
M(+X31/9LJ;%"QR2+LP,@Y3&23G<?:KWA:_\ $MZ=.U29+N:SN[9I;@32P&/<
M5W)Y2I\PY^7!SP>>17:QZ=91);)':0(MJ28 L8 B)!!*^G!(X]35:U\/Z/97
M[7UKIEI#=,23+'$ V3UY]^_K0!P^G2W5YJG@;4[K69+J74#+</;,$"QL;:0G
M8  0%W;2"3V[]=+1?$%[=6_@E9KT//J,,CW:X4&0K"23C'&&QTQS73VN@:/9
M7)N;72[.&?>9/,2%0P8@@G./1F_,^M4+"/PQ!J#26=I90W9O'@WK;A7,X4LP
M!QUVEN>G)H XK2+[5I;#1-(L#?+&-.>Y/V*2%'=O-*\F7@A?0?WAFNW;4;K3
M_!!O]<D:VNX;/=<O;A7*N%Y*CE2<\@=/PJY<^'M'O+6&VN-+M)((,F)&B&(\
M]=OIGVI2^D1:;;6O^B_8+G%M!$J@Q."#A !QC /'2@#AI->UK3[+Q3%Y][')
M9V$%U;_;6ADEC9S(#DQ_+@[0<'ISV(J]JNJZMX=?7H!J<MXT6EQWD4MQ&F89
M"[HQ 4 ;> V#TP:ZJ#P_HUK;2V\&E6<<,J".1%A4!U&2 W'(Y/7UJW)96LLL
MDLEM$\DD7DNS("6CY^4^HY/'O0!R6E6LEE\1W@DU:;4"-(W?O]A=,RCNH'!Q
MD9'KVZ0ZS?:A)JWB9$UZ6QCTNRCN8(HUC^\48EFW DKE1QQU^E=7I^AZ5I3;
MM/TZUM6V[=T,2J2/3([<#\JQKW0=#_X2<W>K0V]U/J3QQVL<UN&V-&C,<-SU
M )YQ]T=: .>FUCQ3K%W?-IL-Y'<6<5N8H8Y($AWO$LA\T2?,02Q7CH%XYS6R
M1J.J:[XBA?5KJVMK(1K##;B,8+P!FR64YY.1^/7MO7_A_1]4N$N+_3+2YF1=
MH>6(,<9SCGJ,]JNK:VZ232+!&KSX,K!1F3 P-WKQQ0!Y]X<%Z=(\(Z,NL7<$
M%WI9NVE C\P[4B"PH=N HWENA; ZU/!J6KWS:3IHU:5%DU.[M)+R-$WSQ1*Y
M!Z;0WRX) Z@UU]UH>E7MC!97.G6LMK!@0Q-$-L>!@;1VXXXJ:'3;&WCM4ALX
M(TM,_9U6, 19&#M]."1QZT </J]_K5NGBB[@UJX1='FA6VA\J,JV88F;S/ER
MP)8\ C&3[8LW.IW6B7VM6-[J]_<1);V<D,B1Q><)9I'C*IE0H!*KC=P,GFNP
MDTZRE2Y22T@=;H@SAHP1*0  6]> !SZ"FW.EV%Z)Q=65O,+B-8IO,C#>8BDD
M*<]0"21Z9H X-=:UN/3=6M1=W,%Q;ZM96T4ESY4LL:2M%N#%?E;[[>^#BK%S
MJ>JZ?>:AI U:=T-_9P)>3*ADA28?-C"A<Y&!D<%J["#1-*MH#!!IMI'$720H
ML*@%E(*MTZ@@$'VJ2XTNPNDN4N+*WE6Z 6</&#YH'3=ZX[4 <GK,VJ6-_IFB
M6=]J5Z+C[1*\L<D"3_($Q'N8!<?.3TW8 [9KH= FOUT>TCUIE346+KM9TW.%
M8[2=O&[: 3CC.:<WAK1&T];!M)LS:(_F+%Y*[0_]X>_OUI(_#]A!?6-Q#$L,
M=A'(EM;QJ%1"^-S8'? Q^)]: ,'QGJMQ;R3V^GW.I+=VUBUXRVI@6.-<D*[F
M09/*GY1V!XZ5!-?:MJM\T::M/91+H4-\5MHTR9F,G.64\?*./;ZYZR^T72]3
MGBFOM/M;F6($(\T2L5!ZCGM4R6%G&Q9+6%6,0@R$'^K&<)_NC)X]Z .%_M/4
M->M\3:O)IJPZ#;W[&)4"RR2ARS-N!^0; ,#'WC[5KZ9?Q:9\*],O)IY8$CTF
MW_>0J&=28U VA@03DC&>/6MJ?0-'N3:F?2[23[(H2#?"I\I1C 7C@<#CVJR;
M&T-A]@-M";/R_*\@H-FS&-NWIC'&* //9=?UK3]-\41M<W4$EA%:RP-?-#))
M%YC$-N*?*1A0<'D9/M5C6M5U/08M9A@UJ6Z,>FQ7B7$ZQGR7,I4GY0!M8#..
MV#BNDO\ PGIL^AW>F6-M;6"W*HKO% .0K;@"!C/?OW-)?>$M,FT*^TNPMK;3
MUO,>8\, YP01D#&>F/QH Y[5]4U/0H=<AM]8FO6CT?[='-,L9,4FYAD;5 VM
MC('^R<5HS1:A_;NGZ$^NWJ)+:RW<MP!&))G5D78IVX51N+8 STYQ6[;^']&M
M+:YMK?2[.*"YXGC6%0L@]&&.1[5+J.D:=J\21:C90721G<@E0-M/3(]* .*M
M=6U74+K0].DUIX$GFOX)+F-(P]TL+A49<@@$@') ]<8XPZUU+5M1;1].&K3(
MDE]?6LMW&B>9/'"6VD'& ?E ) ]?PZ+4/">FZA=Z89;>W^Q6$4L2V9@!0A]N
M,=EV[../RK4ATVQMTMDALX(UM01 $C \H$8.WTR/2@#CI-4GCN=6L?M%\9WU
MA;:V6R6%)9,6L;D%G 4?Q,6//&!Z5E":_P!;LO#3W6IWD$\6NW%IO0PEL*LX
M5B0I4N NW(X.3QT(]!NM%TN^BECNM.M9DEE$T@>('=( %#'WP ,^@Q39=!TB
M?3_L$FF6C68?S!!Y*[ WJ!C@^] ''OJ'B:_UO47T\7C"QOUMTC$L"P>6H0MY
MBM\Y+ L<C'5<=*]!K-N/#VC7=ZEY<:7:27*;=LK0J6&W[O/MV]*TJ "BBB@
MK.D_Y&*W_P"O67_T)*T:SI/^1BM_^O67_P!"2@#1HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *SKK_D.:=_N3?R6M&LZZ_Y#FG?[DW\EH T:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S
MM>_Y 5[_ -<C6C6;K[!= O2>GE&H_P#A([#^[<_^ [_X4 :U%9/_  D=A_=N
M?_ =_P#"C_A([#^[<_\ @._^% &M163_ ,)'8?W;G_P'?_"C_A([#^[<_P#@
M._\ A0!8U+[UG_U\K_(U>KGK[7K*0VNT7'RSJQS XXP?:K?_  D=A_=N?_ =
M_P#"@#6HK)_X2.P_NW/_ (#O_A1_PD=A_=N?_ =_\* -:BLG_A([#^[<_P#@
M._\ A1_PD=A_=N?_  '?_"@#6HK)_P"$CL/[MS_X#O\ X4?\)'8?W;G_ ,!W
M_P * -:BLG_A([#^[<_^ [_X4?\ "1V']VY_\!W_ ,* -:BLG_A([#^[<_\
M@._^%'_"1V']VY_\!W_PH UJ*R?^$CL/[MS_ . [_P"%'_"1V']VY_\  =_\
M* -:BLG_ (2.P_NW/_@._P#A1_PD=A_=N?\ P'?_  H UJ*R?^$CL/[MS_X#
MO_A1_P )'8?W;G_P'?\ PH UJ*R?^$CL/[MS_P" [_X4?\)'8?W;G_P'?_"@
M"Q%_R';G_KVB_P#0I*O5ST>OV0U>XEQ<;6@C4?N'SD,YZ8]Q5O\ X2.P_NW/
M_@._^% &;J44M_X[LK%[R[BM%T^2X:&"=HP[K(@4DJ0>-QX[]^*YSP_<ZO?Z
MO;7DE_;Q3_;Y4NHI=6<DH&=?*%L4VJ0 I!!SQG)S79_\)!IV_?Y=QO QN^S/
MG'ITJ+^UM&^U_:_LC_:<8\[[&V_'UQF@#DD6]FLK'4#K&IK/<:[/9/MN3M$!
MFE38%Z# 48;&X=B,##+N]U"TCDTJ.ZE>RCUU[4RW.H20L(OLXE5&GPS@;VP#
MU. N>:[3^W=,  $,^ VX#[*W!]>G6FR:UI,L<D<EO*\<ARZM:,0WU&.>@H Y
M837D5GI%AJ>K*EA<:G+&\]KJ+R%(Q&SQPM<85L[AC/4@ 9YJOH5U]E-HEC?S
MSVTOB>:,RF4N9X_LSD M_&,JISWP#SUKKO[4T7[+]E^QM]F_YX_8VV?EMQ4@
MUS2UQB"8;3N&+5N#C&>G7'% '&Z#JC:GXDT]+>XN([+4[*X:2,ZO)/-CY=K,
MG2!QS]T^H[4OAN5;+P9X6%E?SEYK^".Y7[2S[>'RF"3M''W>!77Q:QI$+,T5
MM)&S,6)2T8$D]3TZT)K&CQ%C':R(6?S&VVC#+?WCQU]Z .1LK]WM]+U!=8N7
MUZXU18;BR-TQ4+YI62/R<[5"("<XS\N<\U):O>+'9:J=3OWG?Q#-:%'N&,7D
M^?(FS9]TC &"02.QP,5U*ZOHRW372VKBX88:46;;R/<XS4G]NZ9@#R9\!MX'
MV5OO9SGIUS0!F>,KI8+_ ,/P3ZG-86=S>/'<213>5N7RG(4MV!8 9X/H16'9
MW9;4M(Q<37=G:ZY=QVLSR&5GB6UD.-QR6PQ=023TKH=0N](U.\L+BX%T?L<C
MNL9MF*ONC9"&!'3#&KB:WI421I'!,B1?ZM5M& 3MQQQ0!QN@ZU+/KMNUK<2+
M:WNE3W!C?57NWR#&49U(Q$WS,,*2.O3%6M%ENK7_ (1B[DU>\9M4TF26[>ZG
M+H&$<;API.U<9/3&1USUKIXM8T>'/E6LD>XDG;:,,D]3T[X%/&NZ8-F(9QL&
MU?\ 17^4>@XXH P/">L0:=;WUMJE]OFM%@-Q>F_:Y@F,A*JREC\A8CE, #(Q
MZUW%846K:-!$8H;1XXRVXHEFP!/K@#K4_P#PD=A_=N?_  '?_"@#6HK)_P"$
MCL/[MS_X#O\ X4?\)'8?W;G_ ,!W_P * -:BLG_A([#^[<_^ [_X4?\ "1V'
M]VY_\!W_ ,* -:BLG_A([#^[<_\ @._^%'_"1V']VY_\!W_PH UJ*R?^$CL/
M[MS_ . [_P"%'_"1V']VY_\  =_\* -:BLG_ (2.P_NW/_@._P#A1_PD=A_=
MN?\ P'?_  H UJ*R?^$CL/[MS_X#O_A1_P )'8?W;G_P'?\ PH UJ*R?^$CL
M/[MS_P" [_X4?\)'8?W;G_P'?_"@#6HK)_X2.P_NW/\ X#O_ (4?\)'8?W;G
M_P !W_PH UJ*R?\ A([#^[<_^ [_ .%'_"1V']VY_P# =_\ "@#6HK)_X2.P
M_NW/_@._^%'_  D=A_=N?_ =_P#"@#6HK)_X2.P_NW/_ (#O_A1_PD=A_=N?
M_ =_\* -:LZ3_D8K?_KUE_\ 0DJ+_A([#^[<_P#@._\ A5%]>LCK<,P%QM6W
M=3^X?.2R]L>QH Z2BLG_ (2.P_NW/_@._P#A1_PD=A_=N?\ P'?_  H UJ*R
M?^$CL/[MS_X#O_A1_P )'8?W;G_P'?\ PH UJ*R?^$CL/[MS_P" [_X4?\)'
M8?W;G_P'?_"@#6HK)_X2.P_NW/\ X#O_ (4?\)'8?W;G_P !W_PH UJ*R?\
MA([#^[<_^ [_ .%'_"1V']VY_P# =_\ "@#6HK)_X2.P_NW/_@._^%'_  D=
MA_=N?_ =_P#"@#6HK)_X2.P_NW/_ (#O_A1_PD=A_=N?_ =_\* -:BLG_A([
M#^[<_P#@._\ A1_PD=A_=N?_  '?_"@#6HK)_P"$CL/[MS_X#O\ X4?\)'8?
MW;G_ ,!W_P * -:BLG_A([#^[<_^ [_X4?\ "1V']VY_\!W_ ,* -:BLG_A(
M[#^[<_\ @._^%'_"1V']VY_\!W_PH UJ*R?^$CL/[MS_ . [_P"%'_"1V']V
MY_\  =_\* -:BLG_ (2.P_NW/_@._P#A1_PD=A_=N?\ P'?_  H UJ*R?^$C
ML/[MS_X#O_A1_P )'8?W;G_P'?\ PH UJ*R?^$CL/[MS_P" [_X4?\)'8?W;
MG_P'?_"@#6HK)_X2.P_NW/\ X#O_ (4?\)'8?W;G_P !W_PH UJSKK_D.:=_
MN3?R6HO^$CL/[MS_ . [_P"%0IJ5OJ&NV0@$HV1RYWQLO7;ZB@#<HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#+\1_\B]>_P#7/^HK&K9\1_\ (O7O_7/^HK&IB"BBB@ HHHH
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MA;3H$M9+BQ><H=IW^658;'!P?7[OI0!Z.2!U/6H6NH$O([1I )Y$:14QU52
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MXR3TI] !1110 5+IW_(>M?\ KG)_2HJET[_D/6O_ %SD_I0!U%%%%(84444
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MWDI6[PT\&R5HW7&%)#*003OQCODUEV]K:P>+;:Z72GBAFL(TA86A_=NK-PQ
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MKE,-C##:1T)Q[5FII$MQ?VBW5BTD UJZF<21Y784?:Q]LXP?I3$=>;JW%O\
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M6@5+!UNLP\;]L9&_U.=QY[YK/ABCL9_#,>I:?-*D-O>CROLYE,8$D84[ "2
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MVDTO3KBXDU.265HU*HP=,*^[>P (P!@>E;&EZE#JU@EW LB*69&2089&5BK
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MA&J170%NJ%W40!&95<%20^#R/X>.<5M^';06UK=2?Z=NN+@RN;Q$1B=JC(5
M !QZ YR: (H?$PDN$#Z?<);/>-9I<;D(,BL5Y7.0"5/.*GNO$-M:>(+;2'CD
M,DX&91C8C$,54^[;&Q]*Y>/1;L7*^1IMZFH)JLEPMR\O[A8C,23M+8Y0D<+G
MFIKW0-<O[+4[])H8;J:Y^U06[P9D!B.(EW[\#(4=OXS2&;>H>)A87%^ITZXF
MM[!5>YFC9/E4KNR%)!.!4L^O2+J,MI::;/>>5!'.[1NB_*Y;& Q&3\IK#O\
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M[A[&IV-[^P;_ /Y_K?\ \!S_ /%4?V#?_P#/];_^ Y_^*K!_X7)X2_Y[7?\
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MG8WO[!O_ /G^M_\ P'/_ ,51_8-__P _UO\ ^ Y_^*K!_P"%R>$O^>UW_P"
MY_QH_P"%R>$O^>UW_P" Y_QHYEW#V-3L;0\.7JSO*+^#<RA3^X..,_[7O4G]
M@W__ #_6_P#X#G_XJL'_ (7)X2_Y[7?_ (#G_&C_ (7)X2_Y[7?_ (#G_&CF
M7</8U.QO?V#?_P#/];_^ Y_^*H_L&_\ ^?ZW_P# <_\ Q58/_"Y/"7_/:[_\
M!S_C1_PN3PE_SVN__ <_XT<R[A[&IV-[^P;_ /Y_K?\ \!S_ /%4?V#?_P#/
M];_^ Y_^*K!_X7)X2_Y[7?\ X#G_ !H_X7)X2_Y[7?\ X#G_ !HYEW#V-3L;
MW]@W_P#S_6__ (#G_P"*H_L&_P#^?ZW_ / <_P#Q58/_  N3PE_SVN__  '/
M^-'_  N3PE_SVN__  '/^-',NX>QJ=C>_L&__P"?ZW_\!S_\51_8-_\ \_UO
M_P" Y_\ BJP?^%R>$O\ GM=_^ Y_QH_X7)X2_P">UW_X#G_&CF7</8U.QO?V
M#?\ _/\ 6_\ X#G_ .*H_L&__P"?ZW_\!S_\56#_ ,+D\)?\]KO_ ,!S_C1_
MPN3PE_SVN_\ P'/^-',NX>QJ=C>_L&__ .?ZW_\  <__ !5']@W_ /S_ %O_
M . Y_P#BJP?^%R>$O^>UW_X#G_&C_A<GA+_GM=_^ Y_QHYEW#V-3L;W]@W__
M #_6_P#X#G_XJC^P;_\ Y_K?_P !S_\ %5@_\+D\)?\ /:[_ / <_P"-'_"Y
M/"7_ #VN_P#P'/\ C1S+N'L:G8WO[!O_ /G^M_\ P'/_ ,51_8-__P _UO\
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M_P#%4?V#?_\ /];_ /@.?_BJP?\ A<GA+_GM=_\ @.?\:/\ A<GA+_GM=_\
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MC4[&]_8-_P#\_P!;_P#@.?\ XJC^P;__ )_K?_P'/_Q58/\ PN3PE_SVN_\
MP'/^-'_"Y/"7_/:[_P# <_XT<R[A[&IV-[^P;_\ Y_K?_P !S_\ %4?V#?\
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MCBF0KM1E0N0P)ST';-'(@^L3_JYYM_PJ=/\ H7Q_X.S_ /&*/^%3I_T+X_\
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M ,'9_P#C%>Q44<B#ZQ/^KGCO_"IT_P"A?'_@[/\ \8H_X5.G_0OC_P '9_\
MC%>Q44<B#ZQ/^KGCO_"IT_Z%\?\ @[/_ ,8H_P"%3I_T+X_\'9_^,5[%11R(
M/K$_ZN>._P#"IT_Z%\?^#L__ !BC_A4Z?]"^/_!V?_C%>Q44<B#ZQ/\ JYX[
M_P *G3_H7Q_X.S_\8H_X5.G_ $+X_P#!V?\ XQ7L5%'(@^L3_JYX[_PJ=/\
MH7Q_X.S_ /&*/^%3I_T+X_\ !V?_ (Q7L5%'(@^L3_JYX[_PJ=/^A?'_ (.S
M_P#&*/\ A4Z?]"^/_!V?_C%>Q44<B#ZQ/^KGCO\ PJ=/^A?'_@[/_P 8H_X5
M.G_0OC_P=G_XQ7L5%'(@^L3_ *N>._\ "IT_Z%\?^#L__&*/^%3I_P!"^/\
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M/^KGCO\ PJ=/^A?'_@[/_P 8H_X5.G_0OC_P=G_XQ7L5%'(@^L3_ *N>._\
M"IT_Z%\?^#L__&*/^%3I_P!"^/\ P=G_ .,5[%11R(/K$_ZN>._\*G3_ *%\
M?^#L_P#QBC_A4Z?]"^/_  =G_P",5[%11R(/K$_ZN>._\*G3_H7Q_P"#L_\
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MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6:/S,9V')'KCC-=7#%'!#'#$@2.-0J*.B@# % #Z*** "BBB@ HHHH ****
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M4K,+57*MU 8E@#^!%=9110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>modificationno16effectiv014.jpg
<TEXT>
begin 644 modificationno16effectiv014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH P/&]Q-:>#-4N+>5XIHXMR.AP5.17SY_PF?B3_ *#=[_W]->_>/_\
MD1-8_P"N']17S+7?@XQ<7=')B)--69N?\)GXD_Z#=[_W]-'_  F?B3_H-WO_
M ']-8=%=?LX=D<_/+N;G_"9^)/\ H-WO_?TT?\)GXD_Z#=[_ -_36'11[.'9
M!SR[G36_B[Q"]E>.VLWI9%4J?-/&6 JK_P )GXD_Z#=[_P!_35"T_P"0??\
M^XG_ *&*I5,:<+O0;G*RU-S_ (3/Q)_T&[W_ +^FC_A,_$G_ $&[W_OZ:PZ*
MKV<.R%SR[FY_PF?B3_H-WO\ W]-'_"9^)/\ H-WO_?TUAT4>SAV0<\NYN?\
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M/Q)_T&[W_OZ:/^$S\2?]!N]_[^FL.BCV<.R#GEW-S_A,_$G_ $&[W_OZ:/\
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M?^_IH_X3/Q)_T&[W_OZ:PZ*/9P[(.>7<W/\ A,_$G_0;O?\ OZ:/^$S\2?\
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M7D2^:VHF\\UGR-I3;@]R?>FE5>XGR=#4\->$M&\0+;6R:AJ(OIU;+I99@A8
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MO3YB#);2M$Q7H2#C(JI4UY,MQ>SS('"22,RB1][ $\9;N?>H:ZEMJ8,****
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M-#URWU+3K*.^LK1KNWN[: 1,-O56QU!X_6N;\%^(X/#&NM?W%O)/&T#PE(V
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MIRC:***U("BBB@ HHHH **** "BBB@ KUWX)_P"LO_H?_9*\BKUWX)_ZR_\
MH?\ V2N?%?PV;8?XSV&BBBO*.\**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_'_P#R(FL?]</ZBOF6
MOJ7Q7;)>>&[JVD)\N8I&V/0NH/\ .O.O^%;:)_TV_P"^S_C77AZT:::9SUJ3
MFU8\?HKV#_A6VB?]-O\ OL_XT?\ "MM$_P"FW_?9_P :Z/KE/S,?J\SQ^BO8
M/^%;:)_TV_[[/^-'_"MM$_Z;?]]G_&CZY3\P^KS/++3_ )!]_P#[B?\ H8JE
M7KS> =(@=;=/-V7'RO\ ,>@^8?J*=_PK;1/^FW_?9_QI+%P3>XWAY:'C]%>P
M?\*VT3_IM_WV?\:/^%;:)_TV_P"^S_C3^N4_,7U>9X_17L'_  K;1/\ IM_W
MV?\ &C_A6VB?]-O^^S_C1]<I^8?5YGC]%>P?\*VT3_IM_P!]G_&C_A6VB?\
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MTV_[[/\ C1_PK;1/^FW_ 'V?\:/KE/S#ZO,\?HKV#_A6VB?]-O\ OL_XT?\
M"MM$_P"FW_?9_P :/KE/S#ZO,\?HKV#_ (5MHG_3;_OL_P"-'_"MM$_Z;?\
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MQ^BO8/\ A6VB?]-O^^S_ (T?\*VT3_IM_P!]G_&CZY3\P^KS/'ZMO_R"8?\
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M:/\ A6VB?]-O^^S_ (T?7*?F'U>9X_17L'_"MM$_Z;?]]G_&C_A6VB?]-O\
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MQH_X5MHG_3;_ +[/^-'URGYA]7F>/UZ[\$_]9?\ T/\ [)3_ /A6VB?]-O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]M<RVL22JUI*SQL&;:<G;D;>IX/'-:!\,03&[>^O;J[ENH%@D=RJX522I4*
M 03GZU:CTR]6WEC?6[QY&V[)#'$"F#GH$P<]#G\,4 45UAI9M&E8QR_:#-\U
ME<%XF"H3GH-W3IV-4],\6W5^^[[+9F$V+7O[JY+L@[(PVX#?CZ^E7O\ A&(8
M+53#+)+<QM/,&D(59))5*G<% P.>V*S-"T74K<I:2175O:-;-%=^>\+>8VT
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MBC;@JH/0$ #UP,9H YWPJTT>KV(GBGM&DLW!>65W&H/E3Y@W?=( +8.&P_3
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M026=+AH%E(C\U2"&Q_P$<=/;/-23^'[2XFU%VEN FHQ&.XB5_D;*A-PXR#M
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M\U:[T]+&&"*&YLDO9&FRQ4%L%  1S[^W>F>)VD.L:/ (;ZXBD$Y>"SN/*9B
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MPY9"SN+=WGE>YE2:>>1\R2,A!7)QC V@8  Q6O10!4CTZ"+5)]03>LT\:QR
M'Y6VDX./7DC/I5"Y\,VES/.6N;M+:YD$EQ:(X$4K<<GC(S@9 (![UM44 5K>
MQAMKR[NH]WF73*TF3QE5"C'X"K-%% !1110 5+HO_(R2?]>?_LXJ*I=%_P"1
MDD_Z\_\ V<4 =11112&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!F>(/\ D#R?]=(O_1BUBUM>(/\
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M_P#/E>_^ S_X4>9+_P ^5[_X#/\ X4 2577_ )",G_7)/YM4GF2_\^5[_P"
MS_X5 KR?VA)_HEWGREX^SOGJW;% %NBH_,E_Y\KW_P !G_PH\R7_ )\KW_P&
M?_"@"2BH_,E_Y\KW_P !G_PH\R7_ )\KW_P&?_"@"2BH_,E_Y\KW_P !G_PH
M\R7_ )\KW_P&?_"@"2BH_,E_Y\KW_P !G_PH\R7_ )\KW_P&?_"@"2BH_,E_
MY\KW_P !G_PH\R7_ )\KW_P&?_"@"2BH_,E_Y\KW_P !G_PH\R7_ )\KW_P&
M?_"@"2BH_,E_Y\KW_P !G_PH\R7_ )\KW_P&?_"@"2BH_,E_Y\KW_P !G_PH
M\R7_ )\KW_P&?_"@"2BH_,E_Y\KW_P !G_PH\R7_ )\KW_P&?_"@"2BH_,E_
MY\KW_P !G_PH\R7_ )\KW_P&?_"@"2BH_,E_Y\KW_P !G_PH\R7_ )\KW_P&
M?_"@"2BH_,E_Y\KW_P !G_PH\R7_ )\KW_P&?_"@"2BH_,E_Y\KW_P !G_PH
M\R7_ )\KW_P&?_"@"2BH_,E_Y\KW_P !G_PH\R7_ )\KW_P&?_"@"2BH_,E_
MY\KW_P !G_PH\R7_ )\KW_P&?_"@"2BH_,E_Y\KW_P !G_PH\R7_ )\KW_P&
M?_"@"2I=%_Y&23_KS_\ 9Q5;S)?^?*]_\!G_ ,*L:&6;Q))NBEC/V3I+&4/W
MQV- '4T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 4=6_X\E_Z^(/\ T:E7JHZM_P >2_\ 7Q!_
MZ-2KU !1110 4444 9U]_P A72_^NDG_ *+-:-9U]_R%=+_ZZ2?^BS6C0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!GV7_(6U/\ WX__
M $ 5H5GV7_(6U/\ WX__ $ 5H4 9NK:]INA_9?[1N/)^U3+!%\I.7/3.!P/<
M\#-)?:[;:??/:2I*9$LI;TE0,;(RH(Z]?F&*Y;Q%8:EXDU_4K6VL+>>TMK V
M8>XN&A"RRX9F3"-N*A8_3!S5.*ZO=66"[NK:5+H^&[R&X4H1B97C5A^)4D>U
M 'H5G=)>V-O=Q!A'/&LBANH##(S^=35QVM13M\*EAC$JS?8H%Q'D.#\F<8Y!
MK(\3Z5:6.L6=FZ:=:Z*+-O*%Y;R21>>7^<_*RX<C:02<_>QSF@#TBBO,IUTJ
M'6]%M_$=T]]:+HF/.EC?RY7W@!G7GDC.-W?WQ3+-+=4T8>+XY&TX:6?LZWB,
MRB7S#PXQ_K/+\O&>?O8YS0!ZA4%M>6]WYWV>59/)D,4F/X7'4?K7 :+I4NHW
MWAR#5[>XD@CTZ[D$5QNZ">/R1(#U81D<'G(SU%5X],TBWL/%%@TJ:7=F^+&1
MH68"$NC+N ZQMT/(X)YH ].HKG?"MT6\*>9'IJ6XB:58X;;<(Y0K'#1[@"%;
MJ!VSZ5Q>@NTNIRSV=M!;Q7&B7#2PVD,J[)08\+([??D&6&< \GU% 'JU4I]3
MAM]6L]-=7,UVDKHP V@1[<YY_P!H8KA+32Y],31)])@E2_NM!N/.<EB9)@D1
MCWD]2&+8STY'2F>&K?2/^$F\/3Z1;S*XT^87KE' \TB/AR>/,R&SW]>U 'I1
M(523VJII.I0ZQI%GJ=NKK#=PK,BR !@&&1G&>:Y+Q,FGR>+-FO0R261T[_00
MJN?W^]M^S;SYF/+QCGKCO6'I46FPV6B1^*X6_L]-"MUM4G1C&LPW>:, ?ZS'
MEX[XSCO0!ZK17F-M'"AT@>,4E:R_LO\ T<72LV)O,.=V.?-\OR\9Y^]CG-+K
M-^+6S\6:>HO/M-S/;R6<0CD+-$881N!QP 5;)/0CGDT >FT5YUXCTI;R?QI=
MR0323VUE&]DP9OW<@B8AD XW9 Y'/;O46L:9=::VK1:)#<1M<:-')*8][-))
MYI#MURTFPMSG<>/:@#TJH;JZ@L;.:[N9!%! C22.W15 R2?PKS 6D:>'/$#Z
M5?VCQR6T*_9M,MY85C</]_ECAR#@XP?E&:O:]H,,">+=-LK%S:RZ&DZ1*&8/
M<#SAN'J_RIGN<#- 'HRL&4,IR",@U";RW%\MD95^TM&91'W* @$_F17G&M2Z
M3<:=I]E86-DUHUE*]O//!+*IDR 8XT7'[S/.<Y';O5C3;6S'B'PMJ&K09N+C
M18U6>922UR#$0"?[^,]?>@#T"TN5O+99TCEC5L_+-&488..5/(Z5-7E]FMJL
M>C?\)-&QT@17FT7"L8OM'V@XWCIG9G;GWQS5C3-+.H7/AVVOH+B73L:BT44Y
M?!@\Q/)$@/4;,8#>WI0!Z117.>#DEB\'Q0R"0&*2YC0/G(19I @YYP%  ]L5
MQJZ5]B\!^&9?*CCBN/*?59;N)Y0W[EMOG $,5#D#!.!\N>!0!ZK17F0@MK?1
M])CO;N&]\/-JDK7'DPNMO$AC8QH0228Q)[[<D#H*CTVY@M;.&]@:X32[3Q,Y
M9G#GRX3 47(/(7++C/0$4 >EW%RMNT(:.5_.D$8\N,MM)!.6QT''4\=*FKSN
MVFGNW%Q&ER(I/%"NN^-D)B\H8.#R%-56TJ6+P7>7T4+"[GU25;N65'=A:B\;
M<N 0WE[0"54C@L>] 'IU4K?4X;G5KW3D5Q-:)$\C$#:0^[&.?]DUY\MND/A?
M46M;ZWN=+DO;9KF#38)(XXH=ZB8*"Q."O+!>V?6MKP;!I\7B7Q"^DP/%I[QV
MIA.QEC;B3/EY_ASZ<9S0!T^GZG#J,M]'"KJ;.Y-M)O &6"JV1STPPJ[7E&HQ
M60N_$JB&<>('U-6TUMCYSMBPT9Z=0=V.PYXQ6M<)=#QM_P (P/-^R7%XNL%\
MG A499/^_P JG'H] 'H-%%% !1110 513_D.S_\ 7M'_ .A/5ZJ*?\AV?_KV
MC_\ 0GH O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %9/_,W?]N'_M2M:LG_ )F[_MP_
M]J4 :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 4=6_P"/)?\ KX@_]&I5ZJ.K?\>2_P#7Q!_Z
M-2KU !1110 4444 9U]_R%=+_P"NDG_HLUHUG7W_ "%=+_ZZ2?\ HLUHT %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9]E_R%M3_WX_\
MT 5H5GV7_(6U/_?C_P#0!6A0!C7?B.*VU:738M/O[NXBB263[/&I"*Y8+DEA
M_<:I=2\06&E:GI^GW3.)[]RD6U<@8(&6/8$LH'N16.='N;OQWJES]JO[.#['
M:JKP85)2&FR"64YQD=.F[WK+UC1]>\0WNO36T-M"A"6EH]UO5U\H^8)$&,8,
MAZ]]@H Z35/%-KI=_/:/:7T[6]NMS.]O"'6*-BP!/.?X&Z ]*TO[1LQI?]IF
MX067D^?YQ/R^7C=N^F.:X&]TO5O$UQJ-[$-0TZ:XT.VQ"5,:2R[IBT+DC/<
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MB\G4Y],>&5CN;,<JMM\Q@/XAC[W/-=O:I/';1I<S+-,!\\BIL#'_ '<G'YT
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MG!. >30!=HJC>ZSI>FPQ37VI6EK%-_JWFG5 _P!"3S3KG5M-LTC>YU"UA60
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MNC;\["0>>.XXJGI&D:MI#^$I)-/>?[)I;6%TL4J9A=C"=QRPRH\ML[<GT!H
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M#_N'C#( 22K$@G.#DC@\D '10>)].%E82WMW:P37B;DCCE,B]<$AL#@$@9(
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M2UW2-<D_X2:RL],^T+JSQ31W'GHB)MCC1E()W;OW>1Q@YY(Q6K+H%W<W'BX
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MV[=I*-D#)PX.1QP?:NCH SK[_D*Z7_UTD_\ 19K1K.OO^0KI?_723_T6:T:
M,SQ#J;Z1H5U>0HLEPJA+>-NCRL0J+^+,!67I_BKR?#$M_K2[;FRNOL5XMM&6
MQ+Y@0%5Y.#N1L<G#=ZNZ_H3:])IT,L[QV5O<?:)EBD:.1V52$ 92",,=W!_A
M%8TW@>2.34H[*]<6E]+:3LMS+),ZRPRJS'<Q)(9%4<GC [4 :9\86$5CJ-S<
MV][;-I[(+B"6(>8 ^-C *3D'/8YX/&:!XOL5CO3<6M[:R6AAWQ3Q .5E;:C
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MSN+QYL>2LBA7!3&21@[<=>,XJ?4O#-]=:?XL@B\HMJ9C^S;G_NPHGS<<<J:
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M;45GE.X#:@CD4GGKRPZ5B#P]J TU8Q;*)?\ A(S?_?7_ %/V@MNSG^YVZ]J
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MN=ZXP#^% '04444 %%%% &?9?\A;4_\ ?C_] %:%9]E_R%M3_P!^/_T 5H4
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MD5Q"T3;6SM8 ]C@_D<XJG-XE@L;K4([F0S-#=QVL,%O QD+O$KA>N&."3D8
M'TJU;:7-#XHU'5&=##<VMO"BC.X&-I"2?;YQ^1K(U#PU<SS:Q)]CL;Z.^O(I
MTBGG>$H$A5-P=5)5PRY!'8]10!T8OX!IIOYBT$"Q&5S,I0QJ!D[@>1@5RK>,
MFNM:6&U6>UMQI5S>$7EHRY*F/8X'!*X9N <^N.*U5T&ZN/ \FA:A?&:YFLWM
MI+DY;EE(SD\G&>IY..:S)- U_4KK[3J+:="5TFXL%2"1WR\FSYR2HX^3ICCU
M.> #6M?$EK<75O9(L]Q.\,4LLD-NWEQ^8,KN/\.<'CG'>H9_%-M-%?)8QW3F
M%)@ET+=C 9(P<C?TX((],C&<UG/X9U+^T=)E@2SMWLUMTEOHKB199(T WQ-&
M%VNIY )/&<XS5BPT;6[+3KG10+!M/;[1Y5R97\TB0LRJ4VX!!;!.XY Z9- #
M[?Q?;PZ98_:8[JZO'L(KNY%I;F3RE9<[FQTR0V .>#Q5\>)M/DO;:UMO/NFN
M(8YP]O"71(Y"0CL1T!P?R).!6-::%KVB,6TP:?<&>QM[>87$SH(I(D*[UPAW
M*0>GR].O-12>$+V!=&M[ 6T9T^&"$:F)W2?8A&]#&%VNK '@M@;CQ0!MKXJT
MYM2%F%N=K3FU6Y\AO),PSE _3.01Z9&,YK+UCQE%'<6MMIZW&YM4ALGN#;DP
ML?-59$#XQD#</J#CI5?3_!LFGZME]/L;JW%Z]U'=R7<JR)N<N!Y6TJ64G .1
MG -._P"$9UM8;?38Y+#^SK?5AJ F9W,KIY_G%"NW ()(SDYP.!G( .UJBG_(
M=G_Z]H__ $)ZO513_D.S_P#7M'_Z$] %ZN=U&RU2U\3?VQIMK!=B:S%I)%+/
MY6PJ[,K [3D'<01UX'6NBKF->UV\LO$-GIEO?Z9812VDMPT]_&7!*NBA1B1/
M[Q/?I0!4O-'UY!KUI:6UG-#K7S&=YROV=FB6)\KMRP&W(P1UQQUI]UX5O&T[
MQ/:0/&1J-BEM;%V/582GS<<<D>M7F\1Q:>^HOJ%Y%)%96UO-(8(&&/,W#<#N
M.02O '0#J<U/;>)K6Z^VHEK?K/:*CM;O;D2,KY",J]P<'TQ@YQ0!SWC72KB/
M2M>U(E/(_L!K7&?FW@LQX],&IKS0]<UL7\U[!9VTQT>?3H%BF+K(\N"7)VC:
MOR+@<GDU:U/Q1YNC3RV236UW;W]I;3PW,0#H))8P01R""C\$>OM6KK&IS:?>
M:-#$D;+?7WV:0N#D+Y4CY'/7*#]: .7O?!UR=1OGDL/[1MK^.(.@U2:U5"L:
MQLK*O#*0H.<9Y(Q6K<Z-J0U;7/(@A>TU2S6-93-AHG6-E *XY!R.<^M6H?&&
MFSWL=LD=YM>Z>S$[0$1"92P*;CW)4X(X[9SQ4MOXITNZL].N8Y7V:A(\<(9"
M""@8ON'\.W8V<]* ,6WT77=&,_V&UL[LWEC;P.99R@AECCV$GY3N0\'CG@^M
M6M+\+W&F7$:+*DD$.B1:<K$X9G0MR1Z8(J_IWBBQU&Y2%(;N'SHFGMWGA*+<
M1C&60_B#@X.#G%06/C/3=1\DV]O?E;BW:XMF:V91.% +*F>K#(X[]LT 12>'
M+N;X=6N@F2);V"S@C#$DQF2+:<'C.TE<=.AJO<Z/K&M7.H7MY;6]E(VE36%O
M"L_F;FDP2S-M& "J@#GN:?I/BY]6TK1;UH'L3>W*PLDL)8291VPC9&/N_>(/
M3&.:NVWB[3KJ[@B2*[6"XF:""\>'$,L@SPK>^TX) !QP30!+?Z))J'@R;0VE
M$<LUB;8R#D*VS;GW&:P(?#FJK97SVMF-/U5K,P0WCZM-<\EE)"AP=BG;][J.
M.*VH?%^FSWL5LL=V%DNGLQ.T!$7G*6!3=ZG:<$<=LYXJ/Q/K=UI=[I5K;7=A
M9K>22+)<7R%D0*A8<!TY)XZT 82>#]4==5G"1PRSFRFMXIKZ2Y)D@D:0J[N,
M@'@<9 S6[<V>KZO+I%Q=6EO:&SU$7#1K<&0F,0R)UV@;MSCCT[]JATOQ=YNA
M6]Y?6[27,]S);0)9(6%UL+8DC!/W"JELDX []*M/XPTQ;2TGV7;/=3/;QVZP
M$R^:F=R%>Q&#[=\XYH L:'IL^G3ZN\Q0B[OVN(]IS\I1%Y]\J:PIO"=[)X-M
M]-W1FZMK]KP(D[QK(//=]N]?F4E6ZCH:UAXNT]K&*>.&[DGEN'MELUAS/YJY
MW*5S@8 R23C&.>136\8Z8MC#<&.[WRW1LA;B ^:LX4ML*]C@=>G(.<<T <WK
M&ES:?X8FEBTU;2\GU.Q*^??R71D83QA2[-R!VP,\5=NO#^M:C>7.LR06L%\L
MMH]O:>>75E@+DAGV\%O,;'!QA36KIOB=M2\1WFDMI=Y"L"1.))(L %@Q^;T^
M[QZFI]9\2VVDS/:^3=SW"VYN'%O"9/)CR0';VR#P,G@\<4 8U[X>U;68]6N[
MF&WM;F\%I#%;B;>%CAE+DLV!R=S< =AZUKZC87X\5:9JMI#%/%'!+:SH\FPH
MKO&V\<'.-AXXZBH?#OB-+[1; WDC-?-I4%_<$)@$.#DC''56XJ6;Q;81P6DD
M%O>W9NK47BQVT.]DA(!#L.W7IU.#@'% %#2O#5]97FD2RM"5M)[^23:Q/$TA
M9,<>AYKE]8L;C1[W3+:XO[:Q?.HS?:)+O[,FV6<.%$A5LL5/W<=LYX%>C2:S
MI\6B?VR]POV#R1.)@"<H1D$#J<Y''7FL]?%>GM#>M=VUY:/:6IO'ANH-K-$,
MY91D@XQC'4'&0,T 4K>XBN?A;*\%H;2%=-ECCAW%@JHC*,,0"00H() R"#63
M'X>U;Q-H]G'?1VUE#%H\EK#)#*9#*\J( Q&!M4!>1SR?;-=7IOB*RU6]>SBB
MNHI!")T^T0F,2QDXW+GJ,^N#R..:BU'Q38Z9=3VY@O+@VL8DNFMH"ZVZGD%C
M] 3@9..<4 8MKX:NI++4EDTL6UY-I\MHD\NK370)<= 'SM7(!SUXZ5HWOAZY
MNUT"/>BI91R1SD'D;H&C^7CGD^U73XDL6U>+3($N+F>2&.?,,>Y%B<D!RW0#
M*_7VZUL4 <99Z'K5Q'H5AJ$%K;VVC\FXAF+M.RQ-$NU=HVC#$G)[8YZTS2M!
MUV&3PQ;7,%E'::(61I4F+/.!"\:L%V@+U!()[^W/;44 5K!KUK4'4(X$N-[_
M "P,67;N.WD@<[<9]\U9HHH *R?^9N_[</\ VI6M63_S-W_;A_[4H UJ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH HZM_QY+_U\0?^C4J]5'5O^/)?^OB#_P!&I5Z@ HHHH **
M** ,Z^_Y"NE_]=)/_19K1K.OO^0KI?\ UTD_]%FM&@ HHHH **** "BBB@ H
MHHH **** &/#%))'))$C/$2T;,H)0D$$@]C@D?C3Z** "BBB@ HHHH ****
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MUVGS969F=1GCYF.!GC KG++X=A(KF.YFLHQ<::^GN;&T\HL201*Q+$LW&>:
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MDQ9S^0\C ;6?:K';SSC< ?<&N9\->+)Y8+*#4K2\/VJ\N+:*^<)Y;NLDA5<
M[ONK@'&,C%;GA?3IM,\.VD%T=UXZF:Z8CEIG)=S_ -],:I6_A9H-.TFU^U@F
MPU%[TMY?WPS2G;UX_P!9U]J +*^(MNMP:;=:;=VIN3(MO-(8RLA0$GA6+#(!
M(R!T[5)X?UY?$-G]L@LKB&U<!H)92A$JDD9 5B0>.0<'D>^,'2_ TUAK5GJ#
MW5D\EI-/()UM")YQ(K >;(6Y(W#VX[=M+0/#MQI>K7NHW$MFKW2*C0V,#11L
MP))D92Q^<YQ]!U- !?\ B^&QEO6&G7L]C8.$O+R/9LA. 3P6#-M!!. <?@:L
MIXA^T:M+9VFG7=S#!,L$]W&4\N-R V,%@QP&7) .,_6LV^\+:C.NK6-KJ,$6
MEZM(9+A6@+3)N4+($;=CY@.I'&3UJY::+J.F:I<M87EJFG75P+F6*6!FD4[5
M5E5@P&#M')!QD]>* (AXQB;3KO5!I=\=+@AEF2['EE95C!SA=^X9P<$@ ^W%
M:%QK]K;7;V[QS%UL6OB0!CRU(!'7KS_]>LB#PMJ":#=>'GU&W_LA[>:WB*P'
MSPK@A=S%L?*#V'.!TIT/AG4YKJ:ZU+4[:2233'T]4@MRBID@[^6))XZ?Y(!(
MOC)&L+"Z&C:C_P 3&41V41$8>7*%PQ&[Y1A3UQZT77C.WM)Y1)I]V;>V>.*[
MN%:,K;NP4[2-V6V[ER5! SWP:M#P^P3PZOVD?\2A@3\G^M_</%Z\?>SWZ5F7
M'@P?V[=WT%OHLZ7DRSN;^P\Z6)L*IV-D<';D ]"30!%XJ\6SV^G:FFFV=Z?L
MLJ6[W\80QQR$J2,$[B,, 2!@$_6NDU?5H](M8Y&AEN)9I5A@@A WRN<X R0!
MP"220  :Y_4O".HW4>J65KJD$&GZA<BZ<-;EY5;Y=R@[@-I*@YQD9(]ZV]=T
MF;5(;1[6X2"[L[E;F!Y$WH6 92&&0<%68<'C.: *#>,;:"VN&NM/O8;JWN8K
M:2TVH\FZ4@(1M8J0<]0?6M#1]:75FO(7M)[.ZLY1'-!/M++E0RD%20001T/K
M62?"EU=-+=7U]$U]/>VMRYBA(C5(&#+&H)SSSR3U;I6Q8Z4;/6-5OS,'%\T3
M!-N-FQ O7OG&: *T_B+[+K%O8W6FW<,5S.;>&Z9HRC/@D?*&+ ':<$BI=8UU
M-(N+*V%G=7=S>LR016X7DJ,G)8@ 8[GTK!C\#2#7H]0>XLF\K46OEF-IFY<-
MN_=M(6^ZN[  '0#TYN>)K34[CQ!X>ETQECDADG9I9(3)&H,>,-@C /3.>OKT
MH =_PF<#06@CTV^DO+FXEM1:*$WI+'G<K$MM P,YSC%+-XRMX+QXVL+K[-#.
MEM<70,>R*5MHVD;MQ +*"0" 3[&DT_PK+:W>GWD]XDES#=7%W<%8]JR/*I7"
MC/R@ @=\XJL?!@BURYO8;?1IXKFY^TLU[8>9-$QQN"N"..,C/0GO0!I#Q78M
M;B017'F'4?[-\G:-XEW8]<8V_/G/W>?:JEIXIS:V\4-O=ZG?3SW2I&B1QL$A
ME9&8Y8*%!VJ#G)R.,YP]?"2KXV;7OM9^SD>;]CV<"XV>7YN<_P!SC&/?-00>
M%+[39+6ZTV_M_MD#W8;SX28Y(YYO-VX# @J=O.>>>.> #0T_Q39ZA-8P)#<1
MS7?GJ8Y% ,+PD!T?GKD]L@U _C"V,%DUK975Q->SSP0P*8T8F%F5SEF"_P )
MQSDY''7%6/PG?V9L+NTU* ZC!-<2SRSVY,<IG(+X4,",$+@9Z#!]:CE\'7A\
M+1:+]IT^Z'F3R2RW=H6.Z21G#H%8;67<?_K4 3-XC:P\2ZFMYYQLE6P1%"C]
MPTS2*6;VR$!ZXK=L=4AU"\O[>!)/]"F$$DA VL^T,0O/. P!]ZP+[PPL.DZZ
MT]Q/=K<Z7%;X5"TI:%'PXYRS$L"/<5H^$-.N-,\,VD=\2U_/NN;MB,$S2$NV
M?H3C\* -RBBB@ HHHH *HI_R'9_^O:/_ -">KU44_P"0[/\ ]>T?_H3T 7JQ
MKK0UO/%%MJ<ZP2V\5E+;^7(NX[F=&!&1CHA_.MFN8U;6KW3_ !E96=O:W5[%
M-I\TGV: (,NLD8#%F(  !8<GOCKB@!FK^%KB_DUPPS0QKJ%M:P1 Y^0Q,Y.<
M#IAAC'I2Z[X<U#4+[4KJRNTA:YM+:!!O9"?+E=W4LO(5E;;D<C)J8>,+:>UL
MI+"PO+V:ZA:?[/'L1XE4[6W[V !#?+C)R0<=*S+GQ%/JOB;0(;!-0&F7-J]Z
MTD!B3?AHP-^YLA5W'< ,\C&<< #;;P5=QV>HQYLK<WE]9W2Q0L[)&(71F7<P
MRQ(0\X')Z"NCU?2Y=1O-'FC=%%C>_:7#9^9?*D3 ]\N/RJE9>+X+R>RSIU[!
M9Z@Y2SO)0GES'!8<!BR[@"1N S38/&5O<:8^HIIU\+8R"&W+! ;B0OLV(-V?
MO=S@<$YP* (H_"]RFFVUL9X=T6LOJ)/."AF>3;TZX8#ZU#:^"FC\0:G<S7*M
MITZ3?98%!W0O.%\X^G)7(_WC6YI&LIJWVF,VTUK<VL@CFMYBI920&!RI(((/
M4&N5O/%^J3^&M?N1IUS826%SY4<O[ML@.@VX#L2^">V/0T 7/#GA2;2981/I
MVEJUO 84O(9I&D?@#.QEPF1UPQJUIGAFYLH/"L;SQ,='MFAFVY^<F()E>/4=
MZE7Q?;1QZ@;ZQO;&6RCCE:&94+R+(2L>W:Q&2P*X)!S5S2==74[JZLY;*XLK
MRV5'>"<H24?.U@49@1E6'7@B@#%T[PSJ<&EZ)87,EH$TF]$J21NQ,L0211D%
M1M;YQQDC@\TVQ\,:M%:Z3I%Q+9?V5I=PDT<T;,9IEC),:E2H"]LD,<XZ#-:-
MQXOM;>^>(V=T]I%<K:2WR[/*25B  1NW$ L 2%P"?8U);>*[&ZU4:7'#<"_$
M\D,EN5&Z(( 3(W/"$%<'ON'O@ IQ^&+E-.MK8SP[HM9?42><%#,\FWIUPP%:
M.K:(-5U?2;F589+>S:4RQ2KNWAT*C QCJ>]4M.\9VVHRV!&G7\%K?NT5O=3*
M@1Y &)7 8L.%;!Q@XZU%9>+5-II4*6]]J-Y?12R)Y<4<9(C8*Q;+;5^\._ZD
M"@#/F\#W?V"TMP]K=IIUY,]G!<,ZHUNXXC9E!*E<\$ C"@8]&7FEW^FW?AF/
M3K#3[6Z6]N)6A1W>'F%\Y?:&R1QNQU[&NBE\1?9]7@L;G3+V%+B5H+>X8QE)
M756;  <L 0C8) '':L>R\77E[HSWEU8W.G[-36T#A(W#@W/E;,>82#T#'H.2
MN>* '1>&=7M9(-5BDLGU47D]S-"SNL+"50A17P2,!$YV\D'@9J6V\+WWVFUO
MKJ>W^U'5FU&Y6/.P#R&A5$)&3@;>2!GGZ59E\86T<\K?8+UM/AN?LDE^JIY2
MR;MAXW;RH8[2P7&?I1/XQM8+RXB^P7S06MVEI<W01?*B=MNWJV2/G7. <9YH
M L0:;?6OBV\U"/[,]C>PQ++N=A)&T8?&T8(8'<.I&,'K5?4=(U8:[=7^E26>
MV]LTM9OM);,10N5=0H^;_6-E25Z#FM+5]8BTB*#,$US<7,HAM[>  O(^"<#)
M   4DDD  5S/B#Q7<R:*8[&QU&WO1J,%E<QJ8A+#O=.A+;265L*P)'/.,< "
MV_A76M.@LTLI[!G&C1:9.TQ?"%,X= !\WWCP=O;FHI?!%Q'_ &7,MO87\MMI
MD.GS17,LD2YCSAT95)ZLW!'IR*V->UJ\\/>&[2Z@L;F[F,EO"RRLA=0[JIWG
M< 6YQD$C<1VR:H77BB^L?$UVCZ9J$]NFEP736L8BW0'?+O+$MC.%48#'...]
M &M?Z";SP@-&A\FS=88Q&(@3'&Z%64 =2N5'X5F7GA[6-;74IM2-A;W$VES:
M?;I;R/(@\S!9V8J#U5< #@9Y-6[SQE:0#?;65Y?1):I>3R0! (8G!*DAF!)(
M!.T9.!],ZFH:S::=H_\ :;EY8&">6(AEI"Y 15!QR2P ^M %:'1YH_$-IJ)D
M0QPZ<UH5YR6+HV?I\IK/O]%UJ/4-7?2GL&@U95\PW+.K0.$$990H.\;0#@E>
M1UYJU+XFD@C@CET74%OYY3'%9YB+OA=Q?<'V;0#R2W7BHV\8VBV,,YL;XSR7
MIL&M%13+'.%+;3\VW&!G()&"#TS@ FTCP^=)U>2>.4-;#3K6RC4_?_=&3D]N
M0X_(UNUQ]]XUGCMK62ST:[>9M2%A<V[F/?$V < [P"2""""1ZXK5B\1B?6)M
M,BTR^>:W1'N6PFV'<FY03N^8]L+GD>F#0!MT5SR^+K:%[U-2LKO3FM;4WC"?
M8VZ('!(V,W.>QYY%5-7\6ZC8:/\ ;$\.W\<GVBWC"3F+!220+GB3KSC'8E<\
M9- '645';RO-;QRO!) [J"8I"I9#Z':2,_0FI* "LG_F;O\ MP_]J5K5D_\
M,W?]N'_M2@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU!%:E5-,M9;*Q2&>6&60$DM# (DY/9<G'YFK= !1110 4444 %44_P"0[/\
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MMKZ9HHB$"PLFV-03GHG4]R?I74T4 9?B+2I=9T:2S@F2&;S(IHW==RAHY%<
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M!L 8JFP$$@D?*%! Z[1[UJ6%M?QZIJ$US.?LC"..U@R#M"K\SGW8MC'HH]:
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MN=GGQ1Q1NK%5"AAO4[3M 'IP.* -X'(!'0T444 %%%% !5%/^0[/_P!>T?\
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M4?;;7_GYA_[^"@">BH/MMK_S\P_]_!1]MM?^?F'_ +^"@">BH/MMK_S\P_\
M?P4?;;7_ )^8?^_@H GHJ#[;:_\ /S#_ -_!1]MM?^?F'_OX* )Z*@^VVO\
MS\P_]_!1]MM?^?F'_OX* )Z*@^VVO_/S#_W\%'VVU_Y^8?\ OX* )Z*@^VVO
M_/S#_P!_!1]MM?\ GYA_[^"@">LG_F;O^W#_ -J5?^VVO_/S#_W\%9L<L<WB
MTM'(K@6.,J<_\M* -FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1#_SR3_OD403PW4"3V\J2Q.,J\;!E8>Q%24 1^1#_P \D_[Y%'D0_P#/)/\
MOD5)10!'Y$/_ #R3_OD4>1#_ ,\D_P"^137NX([@6[RJLIC:7!_N@@$YZ=Q3
M'U"V2>TA\T%KO/DE>0V%W$Y''2@"7R(?^>2?]\BCR(?^>2?]\BDDN88IX8'<
M"28D1KC[V!D_I4M $?D0_P#/)/\ OD4>1#_SR3_OD55U#6-/TO9]MNDA+ D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD]Z@N=-L;R:*:ZL[>:6(YC>2(,R?0D<5QKS7UGH6O3PW\/EK8&2)8M3>[=)
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MO<1^>^Z.,71PS#/ V$G/?KVS4VKM%+J4T(U&RMK(6D?]GSW%VZ#G=EXV!PS
MXSDD\+V-(9W$R66F6%U/]FBCA2-I)5CC W  D\=^*>;FV%E]OD9(X?*\QI'P
M-J8SR>PKA]=>V?\ MA-7NY#<K81_80DC+YF8SN9%'7+9SUX SQ6[K=K]J^'=
MU%L9V_LXE54G)81Y'3KSVIB-V*SM(HV6&WA1)/O!$ #?7'6I)(8I2ADB1RAW
M*64':?4>E<5)-HC7E@MS>H-#-H[0.UT1$\V[Y@6W<L!T!/KCI6SH8N[GP<$9
MY?.>.98'E)WE-S"(DGG.W;UH L1:QHUY<PV\9$I5RL,GV=C$''&%DV[<C'8U
M&VMZ#'?NY:,3*_E/="W;8&SC:9=NT'/&,^U4_#6K6">']-TM)TAU!+=8&M2/
MWD<BK@[EZ@9!.3Q6,E_9CX<G0FQ_:QM&M?L.,RF8Y7.WKC=\V[ICG- SI[K6
MM$TR]FBG=(9D*O,X@;:I/0LX7 [\DU?OY;2WLI+V[5&AMD,Q<J&V@#)(]\5Q
M6JV.HR2^(%BN&,:6ML+F!4!:X0(=ZJQ^Z2,_G6[XF2VO/ -^T(+0&Q:2':2.
M-F5_IQ0!L6,JW-K%/]DDMC@A8Y54,H_ D#/'>I7MH)4"201NBMN"L@(!]?K7
M(7D>E6>K):ZQ<-;Z:EBK6HEN&5&D+-YASG)<#9@9R >*33+>XU&]T.'4WN74
M:;+*R.[+O(DC"%\8R=ISSWH$=A+;031>5+!')&3G8R C/KBG+%&@4+&JA!A<
M#&T>@K#\1P?:K_0[5GE6&6\82B-RN]1#(=IQV) KG+U9/[<O(9-0LK&XAN(U
MLC<7$BR"(*FW8N<,"=P/7))!H [^6&*XC,<T:2(>JNH(_(U% ]O=12-&F4+L
MC[HRN2IVG@CGIUKDIC>IXED\/B2?R;J\2_67<?E@ +.F>P\Q ,>CU0O)[@F%
M+F>)+ ZC?"1[N5TBW"3]VK,#P,;L \9 ]J!G?RVT$R,LL,<BN06#J"#CIFG[
M%"; HV8QMQQCTKA);B\T?2=-OH+X7RR1W%FKPR-(A9R6AY/7!4)N]ZN>&OMC
M:N-,N9II!HL;Q/(Y/[YG;]V3ZD1C_P >H$=6MG:K;FW6VA$!ZQA!M/X=*<D$
M,<:1I$BHG*JJ@!?H.U<CKT^F+XJEAUB\>&T_LU61#,R(7WOSP0"V.G?TZ4W2
MK:XO]3T==5:X9X](25XVD909=P^9@.K?7O0!UD+6U];,ZQAHI&96$D97<0=I
MR"/:I4BCB&(XU0 !?E&.!T%<)#/$[6"ZW<M'I9FO\M+*41I1.0BNV1QMW8!X
MX]J?91/J$FCVTTMR^GR7-YY0,C RP#F/<<Y(],]0!0!V;?8[!!(PA@4N%W8"
MY9B !]2<#WXIR6EM&DB);Q*LGWU5  WU]:P?&EM;OX?C:<$1075N[-O("IYJ
M!B2#T"YY[=:R;Z;1C>7RZA>LD"6L9TPK<,-R%3EHB#\[[NXR>E '<1QI%&L<
M:*B*,*JC  ^E.JGI#73:+8M>@B[-O&9@>N_:-WZYJY0 577_ )",G_7)/YM5
MBJZ_\A&3_KDG\VH L5SNIV::CXLM;6Y\UK4V$SM&LC*K,'C S@C/!-=%2$@=
M2!GB@#A-(22UC\.W^;J:YN(YDN"TC,TJK&Q52"<=5&/_ *YJMH]WYVH/+:>5
M'#/I,\CQP322%9 4P'9O^6@W$>O//:O120.IQ2,P49)H XFQM7M6T=[=KAIK
M[29C<%Y6<R.%C*DY/!!9L?7%,T_5HKTZ!%%?29BTR873IN/EN$C'S?[0(/'7
M\ZZVPU."^T:#5!F*WEA$W[P@;%(SSVXJO#XBTZ?2;O4XY'-I:%_-8QL#\HR<
M C)XH&<=;7")H[VJR))9075LM[?VD[M'/$<[B23\IR!OP3P>36K-;:9?7>B6
MVGS/)ICW$^\13,8WQ'G&<\KGL..OO72V.H+?ARMM=0A<?Z^$IG/IGK5O(! R
M,^E C@]5F\@WZSSW$5JNMP1L8W8%8O(CR 1SCKG'O5:\AL)[*ZFA<OHL&JVK
M12B5O+1<H)2K9^Z#WZ YKO+RR@OS )2V;>99U"G'S+TS[4W3=1BU/38;V-62
M.4$J'QD<D?TI#.7,UG;^+;1[:XAOEF\J.*%)V\VV39PZC.&C(Y)/KU-6_%4U
MI'J^BIJ%P\-B[3";$C(A^48WD?PY]>/6NH) &3P*K3V4$]]:WDA82VV\1\X'
MS#!S3$<=9P_;ET>V+SOILNH70B&]AYD 5R@)ZE<CC/48IVH.8;N_BGEFCTM=
M4@2Y(=@$A^S+P3V7?MS]3FNMTW48M3TV"]C5DCF&55\9ZD?TJX2!U- ' 2+'
M<0W$.FW$QTB34[2.)X96QR0)0C9^[TZ<9S6[XKTZ'_A"-1M883LBMV:-%)XP
M,_C70D@#D@54T[48M2LA=1JR(9)(\/C.4<H?U4T <I<2Z"=0MUN[N/\ L/[&
M6M'-PWE/+O;S/FSRP&W SD<XK6TY[K_A!"]PTWG"UE*M+D/M^;83GG.W;[UT
M-17$27%O);R$[94*'!YP1@T >?6,L-Q!:_V/<3SW;Z5,;_\ >,S;MB[-^3PV
M[./;..*T]/U6+4=3TM+6Y:9$TB;SBI)7?F+@GIN'/'49]ZWKF\31(-.L+>VE
MN9)3Y$,:LH.$0DDDD#HM:F1G&1GTH&>=^&FLO*\/)ILTK7GV9AJ"%V+*@BZ.
MIZ#?LV^W3BFQ27T6@6JVK3JR^'H21'G(^9=Q'^UMS[UZ/D9QGFDR,XR,^E '
M&7MYH%OI(&F&">UFN8XY7:ZD%O$2K'<[ GCC!'<E<UEB*";0]/FU%O\ 1;;6
M70R>8ZI'"=V.2<A<[<$^HKO++48KZ2[1%93;3F!MV/F( .1[?,*MY&<9Y]*
M.'U&8K=:@'FE72_M]JL[J[ + 8!W'12VW)]":BE:-['4TTFXE.EM>V20202L
M0&,JB41MGI@KT.,D^]=Q:W<%[:175M()()5#HXX!![\U+N' R.>E &#H< LM
M<UFRAWK:H89(T9RP#,IW8)/? K?I,C.,C/I45M=P7EOY\$@>+<R[NG*DJ>OH
M010(FHHHH **** "I=%_Y&23_KS_ /9Q452Z+_R,DG_7G_[.* .HHHHI#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH S/$'_('D_P"ND7_HQ:Q:VO$'_('D_P"ND7_HQ:Q:8@HHHH *
M*** *MQ_Q^6G^\W_ *":M55N/^/RT_WF_P#035J@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"K;_ /'[=_[R_P#H(JU56W_X_;O_ 'E_
M]!%6J "BN1U!8H?&L-Q'''>3R/%$T,ENWF6Z\_O(Y.@7!RPZ'!YSQ5.RG?R]
M&T[RKC[5:ZK*UP/*;"+F;!+8Q@[E(YYH Z_3]0BU"*5XE91'/) 0V.2C%2?I
MD5:P,8P,>E>>0VUK]HE6*TF76SK320R-$V?*\\EB&Q@1[-^0#@GW-3R:.DML
M]RUM+]J;763S06#B%IR& (Y"%2<XXYS0,[B:=8!'^[D<.X0>6A;&>YQT'O4@
MQR!BN*-BUG<W-K:6S16D>MVKQ1QH0JJ4C+$#TSGVZU#:16Z76L6B,7AN+>X>
M74(K:1+B LWW'X^<C<=N.0%Z=Z!';2SK 8@(Y&\V39F--P4X)RV.@XZ^XJ7C
M/;-<+IX=K6PAM[.%(8-6C GM(6CCG7RCE]IZ>AZC(ZU#800_\2Q8[9QXC6^#
M7DOE,'V[SYA9\<H5X'..5Q0!Z#QFC SGO7#1Z9L6._6VD%Z-?D EVG>(FG8$
M ]D*D\=.]=E:W<=V)C&LB^5*T3;T*Y*]2,]1[T 3T444 &!Z=:3 XX''2EHH
M **** $P,8P,4M%% !1CG-%% !1110 $ ]11110 48!.<<BBB@ H(!&",BBB
M@ HHHH K"Q@&I-?X/GM"L).>-H)8<?4FK-%%  0",$9HHHH *3 XX''2EHH
M**** "JZ_P#(1D_ZY)_-JL577_D(R?\ 7)/YM0!8KC/&0^TW36C6-NQ-D[13
MS6;W#,^2-D>TC8W .[/<>E=G10!Q?]E+JEYG4;1KA?[#A_UJDCS<OGCIN&?J
M,U7$<,ITY]>M)[E7T:$0 PL["?DR8P/ED^YSP>.O6N\HH Q?# -IX-TL7"/&
M8K--ZLIW+A>1CKGVK)TRXL+VP\06UVES]GN+B5W'V>0%HF"KD?+GUZ<UV%%
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M^S+%"\CRE?O *JELCN,9&#Z&@"I_9&K?W;+_ +^O_P#$T?V1JW]VR_[^O_\
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M!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/&X8J2%^52!P>3DC@8JEJ'A_5];.IWMQ!!:3W,=K!#;B;?A(IO,9F8#&3N(
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M?_H3T 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "LG_ )F[_MP_]J5K5D_\S=_VX?\
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M;*,K&'N25+':"_  4DEL# R,\4 7?#NDW&A6DNFM,DMA"^+$Y.](C_ WKM/
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M"/QH H6/BR=]&TR6YTB[EU.[MC<26=J@W(H(!8[V7 .1@$YYQS@U8E\7V/\
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M5EV85AU(.T@X]?:H;GPMJ.JC4+K4+FV2]NOLL:+ K&.**&7S,9/+$DMS@=J
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M!!8Z8;9&CG#1QL07V[A]YSG<,8H ](HKE=7\<6NDWUW";?S8+$H+N43HICW
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M1MD\[3(+"Y>:$L08E8*Z $=0[<'V^E56\ >4;1UM]'OY([""SE&HVGF &)2
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MV8W+NW8*O@Y![,>">:E@GU3Q#K&L);:I+IUIIUP+6-88HV:60(KLS[U/R_.
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M*3F%9HY-Z,VT$,K;1\W!R1CKTYJWKGA6'7+JYEGN"B3V!L]@0':=X</DGG!
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MO,Z3-M610S[\DDX;.,XQ[UL:EXML=.EN(_+DF,,<+ QE<.\S%8T!) R<9R>
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MY%#@*5YP>>O3BNOHH Y.;P:\=Y]HLKJT)>"*&;^T+(7+,8UVAP=RD,1USD'
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M"*/5H&:S1;LL_F"(R*K_ "  ,%/(SCC(YXU-,\3)JUYIL-K;Y2ZL/MLK%L&
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M<D<,C+':HQ&.50RNH[!F5/Q0GO73T %%%% !1110 5D_\S=_VX?^U*UJR?\
MF;O^W#_VI0!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVJL]Q/J$9CEDB#&(>3+G_>/7D_K0!UFG>#8-/N;&3^T+N:"P:4VMNX0(@D#
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M*,IC*NF0VT\D%>N>@!T6H>%1>7=]+!JEY9Q:@JK>PPA")<+MR"RDJ2H"D@]
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MQX1$&9VEWY4L>@PO;G..>N0#K*HI_P AV?\ Z]H__0GJ]5%/^0[/_P!>T?\
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M^&M U4F2:SBN!Y7V9\2-M95R K '#%3G&<D'TJAJIU0_$'1HK;4A#:O9W#O
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M% !1110 4444 9^M2)%IP>1E5%GA)9C@ >:M._MO2O\ H)6G_?Y?\:B\0?\
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M-A)*RL\_]J2><=H(4>9OW8 8\9QR:633?",EO9P?:8(TLPXA,5\R, _+@LK
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M^Z/RH Z#^V]*_P"@E:?]_E_QH_MO2O\ H)6G_?Y?\:Y_:O\ ='Y4;5_NC\J
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5M_P#C]N_]Y?\
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MPQC#D",6Y7;]W!!SD\'/-=YM&X-@;@, XYJO,+*&XBFF6%9Y&$<;LHW,V"<
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M=V<^F* +E%127$<4\,+;]\Q(7"$C@9.2!@?C4M !15'4-7M-,*BY\XE@6Q%
M\N .I.T' ^M+<ZM86FE_VG/<HMEL5Q*,L"#C!&.3G(Z4 7:*K7%_!;Z9+J#$
MM;QPF<E1R5"[N!]*FBD6:%)5SM=0PSZ&@!]%%% !1110 456U"^ATRPFO)]Q
MCB&2$&23G  ]R2!1;7L=PPC96AN/+$C6\A&]%)(!."1U!Z'M0!9HHHH ****
M "BBB@ HHHH **** "BBB@ J71?^1DD_Z\__ &<5%4NB_P#(R2?]>?\ [.*
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M*BJ71?\ D9)/^O/_ -G% '44444AA1110 4444 %%%% !1110 4444 %%%%
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M:R1KY.S)*Q\D)R>/<^M>@->VJP+.US"(7.%D,@VM]#TJ9F5$+LP50,DDX %
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MFS<3U;DX)YKMJ*!'/>&[G3[;1],M;2U>+SEVL([<J%D5 6W\#![9/4UT-%%
M!1110 4444 %%%% !1110 4444 %2Z+_ ,C))_UY_P#LXJ*I=%_Y&23_ *\_
M_9Q0!U%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO29'U(R7!DGDM258LS$-YI&"""!P2>V.*[C^Q=4_YZV?_CU']BZI_P ];/\
M\>H \V%K$OA?2#%8W4%]9Q%?*;3'D2281JK*Z[><] _3@\UW5H9#90&6$0R&
M-=\2G(0XY4?3I5_^Q=4_YZV?_CU']BZI_P ];/\ \>IB*U%6?[%U3_GK9_\
MCU']BZI_SUL__'J *U%6?[%U3_GK9_\ CU']BZI_SUL__'J *U%6?[%U3_GK
M9_\ CU']BZI_SUL__'J *U%6?[%U3_GK9_\ CU']BZI_SUL__'J *U5U_P"0
MC)_UR3^;5H_V+JG_ #UL_P#QZJJ:5J)U6:(26N]848GYL8);'\C0 M%6?[%U
M3_GK9_\ CU']BZI_SUL__'J *U%6?[%U3_GK9_\ CU']BZI_SUL__'J *U%6
M?[%U3_GK9_\ CU']BZI_SUL__'J *U%6?[%U3_GK9_\ CU']BZI_SUL__'J
M*U%6?[%U3_GK9_\ CU']BZI_SUL__'J *U%6?[%U3_GK9_\ CU']BZI_SUL_
M_'J *U%6?[%U3_GK9_\ CU']BZI_SUL__'J *U%6?[%U3_GK9_\ CU']BZI_
MSUL__'J *U%6?[%U3_GK9_\ CU']BZI_SUL__'J *U%6?[%U3_GK9_\ CU']
MBZI_SUL__'J *U%6?[%U3_GK9_\ CU']BZI_SUL__'J *U%6?[%U3_GK9_\
MCU']BZI_SUL__'J *U%6?[%U3_GK9_\ CU']BZI_SUL__'J *U%6?[%U3_GK
M9_\ CU']BZI_SUL__'J *U%6?[%U3_GK9_\ CU']BZI_SUL__'J *U%6?[%U
M3_GK9_\ CU']BZI_SUL__'J *U2Z+_R,DG_7G_[.*D_L75/^>MG_ ./4:7:W
M%IXF=+AHF8V>1Y><8W^] '24444AA1110 4444 %%%% !1110 4444 %%%%
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MHYI+(R([LSALO]U<87J1UJYXJNM7TRQGU:RU&$1PJODV1M@WVAR0 A;.<L2
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M[/5HA)86IU$VQ\NRM?+BB,3;CQGG/KQ0!NR^)K*&SO[IHYREE>+9R *,EV*
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MB3$DR[OD W9YV-\Q 7CDBH=$\%KHNH1-'9Z(\$,CO'<FQ_TO!R0"^>HSC=W
MZ5;MO"SV^G:-:F[5CIU^]X6V??#>;\O7C_6]?:@!R^,+=[.-DT^\:]DNGM!8
M_()!(@);)+;, #.=V.1W.*7_ (3"T-G9RI97KSW5S):+:JBF19D#%E;YMH^X
M><XZ'..:S[_P,+MFG+65Q,NH37B17EMYL++(H4HRYZC (8=QTJ_;>&FB_L9M
MFGVG]GW4EPT-C;^7&VZ)X\ 9Z_."3WQTH IW?C681:7)8Z/=S-<Z@]E<PMY8
M>)T5R4Y<#=E<@Y*X!YSBM#Q7JEWI>CPW-N6@5IXTN)_)\TVT1SN?:.N.!W S
MGG%5+CPK=B+S+2\@%S'J[:G'YL9*'<K+L.#GHQYK=OTU-K6/^SYK5+A6!?SX
MV9'&.0,$$<X.>>E &?IVM0JNEVTNH)J+:AYI@O8$58WVC=M.&/S;<].#M/2J
M\/C.UO)K2*QL+VZ:Y5Y5"",8B63R_,^9AD$\@#)QSBL+6?"MYI_@VXBLI2^L
M3:FMY"UK"52*61@AVKD[4"%LDGN36KJ_@][W3M/TRS:RAM;.*..&=X6-Q;E<
M?-&X88) ']<]* 'V_B^5=0U]+_3+BWLM+? N/D.1Y:M@@.268M\N!T(!P>*L
M#Q?;PVNI2WUA>64MA:_:Y()?+9GBY^92C$'[I&,@@_6J^H>%)[^?7H7NH18:
MNJLP,1,D<JHJ#OAE^0'!'J*A3P?(^AZOIYM=#L7OK1K82Z=9&,_,",MSR.?N
M_K0!9D\9JDTMN-"U9KE8?M*0^7&#)#SEP2^!C'W6(;D<5T%C>0ZCI]M>V[%H
M+B)9HR>ZL 1^AK.DT5I-<;4// !T\V>S;W+;MV?Z5#H-EJ&EK8Z2S(^GZ?IL
M-N92F#+, !E>> %7GW8>AH WJ*** "LZ+_D8KK_KUB_]"DK1K.B_Y&*Z_P"O
M6+_T*2@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *R?^9N_P"W#_VI6M63_P S=_VX
M?^U* -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,[6?\ CSB_Z^H/_1BUHUG:S_QYQ?\ 7U!_
MZ,6M&@ HHHH **** ,R__P"0WI/^]+_Z!6G69?\ _(;TG_>E_P#0*TZ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,S3_ /D,:O\ ]=8_
M_1:UIUF:?_R&-7_ZZQ_^BUK3H YM=;U-O&]WH_V &QBLXIA,)%R-S2#=CJ0=
M@&.HP3WK,\'^*;J71]!@U:TG0WECOCO995?SF1 6+ <C(R03UQSBM^71I_\
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MT6EL;5FO+03QNA;>,)N7;@DXP> <<UIZ]87#>!-4L(E$]RVG31*L,>P.YC(
M51TR>U %9/%S(THO=*GM ;&2_MP\BL98TQN! ^ZPW+QSUZ\40:_/=W6AR2VU
MS91W\KB*+>C>8GDLX+\97IT!SG&?2HK;PK>7$+/JNJ_:)/[.>QM\6XC,2R ;
MV;YCN;Y5Y&T<=.:U#H2F70W^T'_B5$[1M_UF8FCYYX^]F@#,TSQH+]]-DETJ
MXM;/41((+B21#ED4N05!R!A6P?;H.*9/XGNKGPO?ZLNGW=E8?87N[>[22,R,
MH&1\ASM)'(SD>N.E6[7PG%;V.A6K71D32F<\ICS0T;H0>>/OY_"J\?A2^_X1
MVYT";6A)IS63V4 %J!)&I&U2S;OG*CC@+GO0 _4/%TMI<ZC#;:/<W:Z="D]S
M(LB* C+N^7/+-@'CVZ]*IOXJ33]3UNZDE>XML62VD.\*"TJG&"W"@\$D]A3)
M_#NK7WB#Q D&H-8V-Y#! Y:V$GFKY9#%#D;6&2,\CGI5Z]\%6UU]K\NX,1D-
MLT ,8<0M "%R#]X$'!!QQ0!#_P )W;KIMS/):J+F"ZCM6C6Y1H]TF"K>:. O
M/)/(((Q6_+JB6>A2ZI?Q&W2&!IID#!]H4$G!'!Z<5G)H>HII<ML+S2UFD<%M
MFF8A9,8*M'YF3ZYW5):>&+6#P>WAR65Y;9X)(7<#:<.23M'\(&[@=@ .U %9
M/$]Z)%M[G1)K:XN+9Y[1&G1O,VX)1B/N, P..1UYXIG@26[F\&6E]>?:3<W,
M*SL\]P9O,+(IW+D_(I/\(QCTJ>S\/W_V^"[U;54O7MH'AMQ';>5MWX#.WS-N
M8@ <8'7CFM+1],72= L=*$IE6UMDMQ(5P6VJ%SCMTH Y?P7J]UJFDVU_-JVI
MW]VUD)Y;1[-(8BY4'"/Y2@\\#Y\?SJXOC>*.#6&NK,)+IEJ+MT@N%F#H=W 8
M=&RAR#[46GA/4(?#3>'Y]:233_L1LT,=IY<BC;M#;MY!(^G-0KX%+VNJ1SWT
M ?4-/%B?LMFL,<:C=A@H8Y/S=S^72@"]-XEO(9;"V;0YS>7XE:&'ST^54"G+
MMT7AN<9QCO5=_&\']GZ?+%:C[5>>;_H\]PD0C\IMDFYSQPV ,9SGTS6U<:2M
MQK6G:B9BILHY8PFW[_F!><]L;?UK$?P5Y<-FUK=P?:K62Y97NK031LD\GF,I
M3<.AVX((Z>] $L?C$7UKIS:7ITEY=7J2R>1YRIY:Q,%DRW(X<A1CKGTYJ?P3
M>W&H^%8+JZ:4S//<9$QRZ@3R *?H !^%,E\.7OFZ=>6FI6]M?VD4L#NMG^ZD
MCD(8CRPPVX*J0<GOG.:T- T@:%H\6GBY>YV/(_FNH#,7D9^0./XJ -.BBB@
MHHHH *SHO^1BNO\ KUB_]"DK1K.B_P"1BNO^O6+_ -"DH T:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "LG_ )F[_MP_]J5K5D_\S=_VX?\ M2@#6HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#.UG_CSB_P"OJ#_T8M:-9VL_\><7_7U!_P"C%K1H **** "BBB@#,O\
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M(&T!]X89!Y#>O'M6/K7A*Z.FW<EO<W6H7MU-:O.7:.-RD+Y_=C 0-@]&X]:
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M[:_'*[@IQZJ* .;L'\42Z#JD4]U>7=W;:I$;M+=PLHB:&)Y(XCQC#.<<@X!
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MAL[[31Y!A+>9'LC0@L3P<@]@,'UZTW3?%5U#I_AQ=EM96-W9QR&XNS+(C.6
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MHZ=)>S;<Y0I&CX7_ +[/Y5H1^'K426LMQ/=7<MOYNV2XEW%O,&&SP!C X
MJG8^$-*TVZLW-S=SM;PO;6T=S/O58F R@7N !]<#DG H P5U/5KG7/"^IZI'
M9I:SPW%S&MONWQ@P[MK9X8X(Y&.<\5;\-^,K[6=1L4EMXS;7T+2@16TRFVXW
M*'=AM?(XRN.>F0<UJV/@[3[&ZLYQ/>SFR1HK9)Y]R11LNTH!CD8[G)X'-6=*
M\/1:.\:VU_?FUB4I#:22AHHU[ <;B!VR3B@#/N;K6?\ A8=O9P7%N+ V#3/$
MZL2<2(">#][GCM6-X4U75=/L-&CGCLVTV]OKBU3:6,RMNE<,3TQE",8XX.>U
M=A=Z-!=ZM::F)KB"YMU,>8G $B$ABC @Y&5'H?>H(M TV"'3[-&?_0;AKN!3
M)\VX[\D^H_>-^E ',CQ1=V&E630QV]K:R7=['+=W?FRQ1&.=E56;.5W\G<3M
M7&,=!7>@AE!!!!YR*YRZ\-Z9]E32SJ5U;0W#3[K=+@+]H$C%W4@C)Y8_=P0#
MUKHHXTAB2*-0J(H50.P'2@!U%%-$B%V0.I=0"R@\C/3/Y4 .HHHH *SHO^1B
MNO\ KUB_]"DK1K.B_P"1BNO^O6+_ -"DH T:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"LG_ )F[_MP_]J5K5D_\S=_VX?\ M2@#6HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.UG_CSB
M_P"OJ#_T8M:-9VL_\><7_7U!_P"C%K1H **** "BBB@#,O\ _D-Z3_O2_P#H
M%:=9E_\ \AO2?]Z7_P! K3H **Y/QV'>WT6);=[D2ZHBM;K+Y?FCRY#@G(]
M?PI+BY.AZ1:06J+I%Q<2.1:_9WOI&QUVK&WI@D] * .MHKB+/Q-K.KVGAU+7
M[);7&I)<>?+) [",Q$#*IN!YYX)XS[<DOB/78S=WNZP^Q6FKI8&$0OYDJ-(B
M%MV["D;\]#G% ';TUW6-=SL%7@9)P*X;_A+M7N-:E%G:RRVL.H_8FMUTZ9MR
M!PCR>>#L!!RV,8P,=35;Q)J&K:KI>H3QS6B:9;:M!:&W,3&5MEQ&"^_=@'?V
MV].^: /1**YOQA*^G0:?KB.P33KI6N #PT#_ +N3([X#!O\ @-9ZZFXFU[7/
MMR6\9N8].LVDB>9<1G:VV-2"S-(T@ '7:* .R9U3&Y@N3@9.,GTIU>=G6KK6
M;"U%X,RV?B.WMPYMW@+C"N"8V)*GY\?AGO6Q!XFO9=*TVZ:.#?<ZQ)8. IP(
MUFE0$<_>P@]LYXH ZRBN%TKQ;JVI:I;21VLLEC<73PF)=.F411@LHD\\G8QR
MHR,8YP.G/=4 %%%% !1110 4444 9FG_ /(8U?\ ZZQ_^BUK3K,T_P#Y#&K_
M /76/_T6M:= '*:GJ>NRZ]JEAID]C;Q6-E%<AYX6D9W8R?+PP 7Y.3UK*370
M^KS:UY\=D;G0+"56EB:4(9)9<*$4@L?FP .IQ6Q>^#X-4\2W^H7SR?9[BTAM
MU6"XDB8A3(75]I&5.Y>.>G:M&\\,Z3?^9YUJ07AB@S'(R%%C8O'MP1M*L201
MS0!S,?BW6/[+OU40O>6VJ6ME')<VCP;EF,?+1DY4CS#SGG@XKH-!O]0EU/5M
M-U&6">2R>/9-#$8PRNF[!4LW(.1U]*EA\+Z5#%)'Y,K^;<174CRSN[/+&5*,
M6)SP57VXJ_#86UO>W5Y%'MGNMGG-N)W;1A>.@X]* .4NO%-W!XFMK>"ZCNK2
M6_\ L4D:6$BI$<'/[\G:7!'( ]1P15W0=:O[K7+RQU22.WN%,C161MF0^6KX
M61)"2) 01G X)'2K@\)Z0M_]L\J;>+G[6L?VB3RUF/5PF=H)R<\=SZFI[+P_
M8V.HM?QFYDN-C1HT]R\HC1B"50,3M!('3T'I0!CZIJFN/K>K66FSV-O%8645
MT&GA9V=F\SY3\P 7]WUZBLO5O&]W#IL.IV4R-BUM[F:R%A)+M$@#$/,#M3@\
M9'N<@UJ3>%[+7M?U#5)[@RV=Q;16J_9;IT+;&D$J/M(!4E@,<\@]*O7_ (2T
M.]EE>YAD5)HUCEA2X>..0(,+E%(!(' /L/04 57OM;O]>UFRM+JTM;:P5 I>
MW:1W+Q;N?G7 !YXZ^V.7^"KB_;P-IEYJ=X+N22SCF#B,A]IC!PQ+'>W7+<9]
M*UXH=.M=0FF1XENM08;@9.92BXX!/91VI-(T>TT2R%G9><+=3\B2S-((QT"K
MN)PH[ 4 <S9:_KC6NA:I<S636FM2+&MM' =UOYB,\9W;OGQ@!A@=3C&*F^'M
MK<1:/>3W$MM))+?W0WQ6_EL2+B4$L=QW GH.,#CGK6I9>%-)T^\AN((Y_P#1
MRQMXI+AWB@+9!V(3A>"1P. 2!BM"QM+/38S9VH6,,\DWE[R22[EV/)SRS'\Z
M /.IWUN7PM>O=:C!=2+XACB@#PLH5EO5 R=[?)TPHZ#C)K7O/%&K:1%JEI=/
M!=7D%S:P03PVK8/G=S&&)8K\V #SP..M=#_PB^E^;<.8YBMQ<)=/%Y[^6)5<
M.'"YP#N4$XZ_B:ENO#^FWOVTSVY9KSRS,PD8',?W&4@_*1U!&#F@"EX7U/4[
M_P"VQ:C#+M@D7R+B2S>V\Y2,GY&).0<C(X/%8MUXC\0JEU>P-I_V>#5QIRP/
M$^YPT@C#%]W&"X. .<'UXZW3M,BTR-UCGNYBYR6N;EY3^&XG ^E1-H.FM;R0
M&W/ER78O6&]N9@X<-U_O*#CI0!S<GB+6;66YTF26SEU'^TH;*&Z\DK&%DB\S
M<R;CD@!AC/)V^]+>>(]9TN#5K21[2YOK*>R6*?RBB.EQ*J890QP1\W0^AQ70
M7?AW3+W[69H&WW4D<LDB2LK!T ",I!RI  Z8ID7AC2XK.:V:*683SQW$TDTS
MO))(C*R%G)R<%%P.G&* .5U_5=?32]<L3J%O'=6$UHZW4,#)OCE8?+C?P00>
M<G(XQSFK%['K:^-)!:W]FEU'HJM+,]JQ5R)7P%3?QD]?F/\ AT]YX?TV_6_%
MQ 6^WHB7!$C L$SMQ@\$9SD8I]OHMG;S>>!+)/\ 9Q;-++,SLT>2V"2>3DGG
MK0!QIUC4+R\M-;L8(C?2^&OM:P$$JQ+HY0<YYY _"NFTC7&UK5[O[(8VTR""
M$K)CYGED7>1G.,!&C/U:IX-+TG1VLY8U2!H+=;"W,DI^YD;4&3R20/>LK2O"
M+67A.#1VE2%I+@7%VT!.#\^\HAX..%0'^Z* -+Q%J3:=90^5>);332B./_17
MN7<X)VI&A!)XSGH #FN>L_%&LZA8Z,D'V6.ZO-1N;*62>W=0%B$AW>7N!5CY
M8^4GKQ73:SIVG:BMI'?R&*19PULZ3F&02;6X5@0<E=W'<9J'3M#T6.&TDL45
MX[6XEGA=9V<"5MRR'.3D_,X.<\^] &$OB/6VL[.W5K(WSZS+IDD[1-L*JDC;
MP@;(/R#C/KTSQ-9>(]2^U65C<FWEE_MB73IY4C*AT6!Y58#)VGA0>3WK;DT;
M2;5/M,L:Q);W3Z@9'E(5)2K!G))QC#-UX%,N/#>E7MO(OER+YMT+WS89V5A-
MM"[U8'(^7CCC!/K0!D3>);EK:\4W<-K.FJ26< 2S>Y>157=A8U.2W<GH #Q5
M&PU>XUN[\(WETH6<7M]"^(S'DQI*F=IY7.W.#TZ5T \'Z*EM'!#!-#Y=PURD
MD5S(LBR,-K-O#;N1P>><^M30>'-.L8;9;*W"/9O+-;;Y'8+))NW$Y.3G<>OK
M0!H7DZVMC<7#RQQ)%&SM))]U !G)]A7#Q^,=2B@UW,B7/V327U&VFDT^2U!8
M!N-KG+)P#GCO75Z?HD-KX<CT:Y=KN(PF*=I2?WN[._/L<GCM5*#PQH2->6>9
M)YIK/[+<+->222?9VW +RQ('# $8Z'WH R;GQ/J^BF]?4C:7(72'U&-((FCV
M,I V$ECN!W#GCH>*?IT>K1?$.W&JW=K<N='E96MX3'C][%D8+'(ST-=)/HFG
M74C//;"0M:M9L&8D&%L94C..<#GK5?3O#>F:1=B^A$[7"P&#SKBY>5A%D';E
MB>!M'Z^IH Y[4+:ZD^(.I2R2VDMO#HR.L4EL2P4M*,!M_!W+DD#D8&.,TVTU
MK6[JVL[736L+1%T&WOR9(&DPS!AL W#Y?E'))(]\\=>^F6<MY->M'F:>W%L[
MAC\T8+$#&<=7;GKS45MH6G6A4PVY4K9I8CYV/[E,[5Z^YYZT <CK'C6[BT.'
M5+&XC$HTR/4)+);"2?&Y2V'D4XC4@8!//!/2MK2'\SQQKSXQNL[(X_[_ %23
M^"="N(A"UO,L/V1+-XX[F1%DB0$*K@-\V 3@GGFM>#3K6VO9[R*/;//'''(V
MXG*IG:,=.-Q_.@"U1110 5G1?\C%=?\ 7K%_Z%)6C6=%_P C%=?]>L7_ *%)
M0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %9/_ #-W_;A_[4K6K)_YF[_MP_\ :E &
MM1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &=K/_'G%_P!?4'_HQ:T:SM9_X\XO^OJ#_P!&+6C0
M 444T.C,RJREE^\ >1]: '45!!>6MTSK;W,,QC.'$<@;:??'2IZ ,R__ .0W
MI/\ O2_^@5IUF7__ "&])_WI?_0*TZ *&JZ1::S!#%=^:!#*)HFAF:)D< @$
M,I!Z,?SJG+X7T^6*W5YK\O;NSQSF^E,J[@ R[]V[:0!QFLGXAZ:NKV.CZ>TC
M1^?J2HLBG!1O*E*L/<'!_"N7\4ZO+XI\(R6L@V2:?9/<ZFBG[MPA,:QG_@:R
M/_P!?6@#T6S\/:98?8?LUN4%B)1;_.QV"0Y?J><GUI7T#3I+:>W: F.>Z6\D
M&]N90RL&Z^J+QTXKFO$/B2]L-4D>PNKB:&UN[>"XA6S7R$WL@96D)W;L."-O
M RH(INI:YK<+:[?0WL*6NDZA%"MMY /FHR0E@S9R/]8<8QSUSTH Z/\ X1NR
M74GOHI;R!I)1-)%#=.D4CC'S,@.#G SZ]\U#<^$-'N[N6XEBG(EF6X>$7#B(
MRKC#[ <;OE%8FH^)+VW\0P"SNKBXM/[2BL9D^QJ($W$*1YA.XN"0<CCMBHM-
MUO7=5\2Q1PW$XM1?W$<\0L<0I!&S*C+,1ABQ4 X)ZGIMH [:\M(-0LI[.ZC$
MEO/&T4B'^)6&"/R-9Q\,:5_8-OHR0/'9VY5H?+E97C93N#!\YW9YSGN:YOP_
MX@\0:M?6%Y]FNWL+N1Q+&]M&D4$>&VLKAMQ((4'(YR>!BH[76?$EQ9Z)>?VG
M;*-4O9+,Q?9 1$H$I#@YR6_=?3GIQR =1!X8TJWC*+#*V;M;UFDF=V:90 &)
M)R>%''2H4\'Z,E^MWY4Y>.Y-W%&;AS'%*22S*F<#)))X[GUKFY?$VM+';Z8L
MLLMTVHW-L]U;6R-(T<0R"$)"[CN&3TP#QZ7(M6\23+HEC,XLKJ\N+F*66:W7
M>T:*61P@8A6( [D ]B.* -^V\.65G?&ZMI;R)3(TOV=+J00[VR2=F<<DDXZ9
M.<5KUYU<7NLZDF@ ZJ8+B+6[BQEECA&)3&LZARO3D)RO3)SV%>B $* 3DXY/
MK0 M%%% !1110 4444 9FG_\AC5_^NL?_HM:TZS-/_Y#&K_]=8__ $6M:= '
M,3ZAJ;^+-0MX[ORK#3K.&Z:%(E+S,QDRNX]!A.W.<<]<YOA76O$>I7.GW5S%
M=265[;F68R6\210DJ&3RV5BS#M\V2>#QTKII;O1-/U=VGO+*WU"YC1&62=5>
M15+;>">F6;\S3;'PYI6FW)N+.V,+X;:JROY:9Z[4)VK^ % '):9XCUN+3/#N
ML7M]'>1ZI$_FVD<"H$*PO(&4CG/[O!R<?-P!5_3M3UF&3PY=W>I1WD6M';);
M+ J"$M"TH,9') VX.XG.<\5>\,>#=.\/6%B/(CDOK>W$33 MM)(&XJI.%W8Y
M( )[TOA[3_##W,E[HL"LT!:)7_>%(\GYA$&^4 D8^3CB@#F)KC7M4\&Z-JL^
MMM'+>7UG\D,"*J S*O'&3V)!.#TZ<5OS:AJNG^*;:VU&[FCT^3RH;>9;9&CN
M)"IW"1A\R,6^[C"_6MN30M,ET9=(>T7[ H4+""1MVG(P0<@@@$$'-1IX;TE+
MV&[^REIH=NPO*[ %5VAMI."P QN(S[T 9_AJ4Q:SXGM<X@AU)6CST!DAC=@/
M^!,3]6IOC[3;"]\&:Q/=65M/-;V%PT,DL2LT1V$Y4D9!R!T]*NVGARV6VNH]
M05+M[F^-ZY*X&\,#'C_=54'OMK4N[6"^LYK2YC$D$Z-'(AZ,I&"/RH XK4M'
MBM-3\*V^BI;:6\LLS-)!;+_SP.3MX!;'&3GZ'I4+^)M9:UL=/5[B6\>]O+:6
MZM+>-I'6!BH(1R%!.5SUZ' ].Y>QMI)[:9X5,EJ286_N97:<?@<53N/#NE75
ML8);0;//:Y!1V1EE8DLX92""<GH>] #/#USJEQH:R:I;O'>JTBX=51I%#$(Q
M"DA21@D ]<UA>"],TV^\+Z=K-W:0W&J2DW,UTZ RB?<=PW=1@_+C.,#%=996
M5OI]JEM;(RQ+D@,Y<Y)R22Q)/XFLNTT3P[=71U*RAMYF\XREH9BT?F@\MM!V
M;\]\9S0!@Z=K>LM9>'];N-02:#6+A(WL1"H6)9%8KL8?,67 SDG.&Z4W3]:U
MR6/1K^XU"-X=0OYK)K=;=5" >;M?=U+ QCV(/3O70:;H?AY+Y[[3X8'FAE=<
MQS%UAD/WPJY*HW/. #S[U>31]/CAMH4M4$=K,9X5Y^20[LL/?YV_.@#A]-O-
M:T[P>]Q%JOG7$^LFTC,\*D1[KQHV/')SG.,\=!BK/BG7-2T2UNQ9:I>75WIM
MG]HF5+*(H?O$&5C@ $+C"8(QGFNIC\.:3').Z68'GW"W,B[V*^:K;PP7. =W
M/ &3UINH^&=&U:Y>XOK%)I)(O)D)9@'3G 8 X;&3C/3M0!G6]WJFK^(=1BM]
M1%E;Z=)"@A$"OYVZ-9&+$\@?-M&TCH>M8-K?:OI6G:_<KJ9GD;6/L<7GQ+LB
M:22-/,..< -]WI78W7AW2KR^2]GM TZA1N#LH8*<KN4'#8/3(.*)/#FD32WT
MDEDK&^7;<J6;9)TY*YQGY1R!G@<T <QJ^MZUX?&KV?V];Z:"QCO()YH54HQD
M*%6"@ @XR. >O6NGDBU:TT"Z6&Y6^U189&@>5%C5I,':"!@!<X'TZGO38/#.
MCV]I<VR68:.ZV^>99&D:3;T!9B6('89XK1N;:&\MI+:=-\4JE77.,@_2@#SZ
M^O[O4= M('OI_P"TX=:M(Y!>6JH]NY92 57"L.<@@X(/4UH'6[^T74],N]3F
M>ZM[^.VMIX+1&FF#Q"0*$QL##+?,1C KH[?P]I5K (8[0%1.MR6=V=FE7&UB
MS$DD8&,GM1>:!I5\9A<VJL\\JS.P=E8NBA58$$$$*,9&.* ./M]4O=4AT(W^
M\SVWB)[?=)&J.P6*7&Y5. V#@XXXK8\*W,=GX">ZEF6".%[R1I67<$ FE)8C
MOCKBM&2P\.Z':P&9;.QMX[GSXFED$:B8J1N!)Y8@M^M7+.TTQ])^S6B02Z?,
M'^5"'C<.26]0023^= '!W6M:C<Z9XET^ZDO);9M!FNHGO+9(7R5=3@)_"1C[
MPR,5L0ZGJ-GK]A#>S36VES1P16A2!7BF<IRKM]Y&STZ \=36U;>%=$M8IXXK
M!<3P&VE+NSL\1_@)))Q[=NU2_P#"/:5_:*7YM0;A"&4EV*A@NT-LSMW <9QF
M@#E[77-9;3]+U^2_1K>_OTMSI_DJ%2-Y#&,-]XNO!.3CAN!6OXMO=4L(K6>S
M:>*Q4NU[/;0K-+$H7*D(W5<YS@$],4Z/3?"]IK,MP%@BO()E=@\K!(Y9<@%5
M)VAV)/(&23[UI:GHFGZQY?VZ R>6& Q(R9!QD':1D' R#D<4 <Y>>)KM-/\
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MVFAEEO94D8E,@PQ+PQ&/F/X'@5ZS:W=K?Q&>VD65$D>/<!T96*L/P((_"I\
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M<]<]\UWU(5!() R.A]*6@ K.B_Y&*Z_Z]8O_ $*2M&LZ+_D8KK_KUB_]"DH
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MBB@#,O\ _D-Z3_O2_P#H%:=9E_\ \AO2?]Z7_P! K3H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH S-/_ .0QJ_\ UUC_ /1:UIUF:?\
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MYF[MZYXKTR"\CETZ*]D*PQO$LI+L %!&>30NHV369O%O+<VHZSB5=@_X%G%
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M[>%6N(49(Y".55L;@/KM'Y5-110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5D_\S=_VX?\ M2M:LG_F;O\ MP_]J4 :U%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 9VL_\><7_7U!_P"C%K1K.UG_ (\XO^OJ#_T8M:- !1110 4444 9
ME_\ \AO2?]Z7_P! K3K,O_\ D-Z3_O2_^@5IT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 9FG_\ (8U?_KK'_P"BUK3K,T__ )#&K_\
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M4.%/H<4 <7X>\/RO=>'!J>F%HK;2[E7$\65CD:6/:"#T)7=^&:SH])U&VL]
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M *%)0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %9/_ #-W_;A_[4K6K)_YF[_MP_\
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M?WL]XFG6XC2311;*4*J&990PCYXY7<.1CFM#PS9,-4NM0F&M^>\$<+-J,<"
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MM+N(KBXL+1[CRG5EZ*Q4D'!*G:>16BNLV*VEQ//<Q1_98EENLGB(%=V3^'-
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M9Z:+D:O81Q1S>>B+$ZQ%&5LG/H1@$'/)'6MW2?%%K+H NKZ;;/:Z=#>7A*8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K)_YF[_MP_\ :E:U9/\ S-W_ &X?^U* -:BBB@ HHHH
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MT?9-3_Z"B_\ @,/\: -"BL_[)J?_ $%%_P# 8?XT?9-3_P"@HO\ X##_ !H
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M/S-TXZU,_AB^'@1=%CEMS>1S"=&8L(V*W'F@$XR,@8SCCWK<^R:G_P!!1?\
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M=/<6$@EAQ;Z1-8-R>7?RL$<=/W9]^16K]DU/_H*+_P" P_QH^R:G_P!!1?\
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M"B_^ P_QH^R:G_T%%_\  8?XT :%%9_V34_^@HO_ (##_&C[)J?_ $%%_P#
M8?XT :%9T7_(Q77_ %ZQ?^A24OV34_\ H*+_ . P_P :A73+];M[D:F/,=%0
M_P"CC& 21W]S0!K45G_9-3_Z"B_^ P_QH^R:G_T%%_\  8?XT :%%9_V34_^
M@HO_ (##_&C[)J?_ $%%_P# 8?XT :%%9_V34_\ H*+_ . P_P :/LFI_P#0
M47_P&'^- &A16?\ 9-3_ .@HO_@,/\:/LFI_]!1?_ 8?XT :%%9_V34_^@HO
M_@,/\:/LFI_]!1?_  &'^- &A16?]DU/_H*+_P" P_QH^R:G_P!!1?\ P&'^
M- &A16?]DU/_ *"B_P#@,/\ &C[)J?\ T%%_\!A_C0!H45G_ &34_P#H*+_X
M##_&C[)J?_047_P&'^- &A16?]DU/_H*+_X##_&C[)J?_047_P !A_C0!H45
MG_9-3_Z"B_\ @,/\:/LFI_\ 047_ ,!A_C0!H45G_9-3_P"@HO\ X##_ !H^
MR:G_ -!1?_ 8?XT :%%9_P!DU/\ Z"B_^ P_QH^R:G_T%%_\!A_C0!H45G_9
M-3_Z"B_^ P_QH^R:G_T%%_\  8?XT :%%9_V34_^@HO_ (##_&C[)J?_ $%%
M_P# 8?XT :%%9_V34_\ H*+_ . P_P :/LFI_P#047_P&'^- &A16?\ 9-3_
M .@HO_@,/\:/LFI_]!1?_ 8?XT :%9/_ #-W_;A_[4J;[)J?_047_P !A_C2
M6VG31:D;VXN_.D,/D@",* ,Y]: -&BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***XS5?BCX:T;5+C3KN2Y%Q;ML<+"2,_6
MDVEN5&,I:)'9T5P'_"Y/"7_/:[_\!S_C1_PN3PE_SVN__ <_XTN9=RO8U.QW
M]%<!_P +D\)?\]KO_P !S_C1_P +D\)?\]KO_P !S_C1S+N'L:G8[^BN _X7
M)X2_Y[7?_@.?\:/^%R>$O^>UW_X#G_&CF7</8U.QW]%<!_PN3PE_SVN__ <_
MXT?\+D\)?\]KO_P'/^-',NX>QJ=COZ*X#_A<GA+_ )[7?_@.?\:/^%R>$O\
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M#_A<GA+_ )[7?_@.?\:/^%R>$O\ GM=_^ Y_QHYEW#V-3L=_17 ?\+D\)?\
M/:[_ / <_P"-'_"Y/"7_ #VN_P#P'/\ C1S+N'L:G8[^BN _X7)X2_Y[7?\
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M%=J,J%R&!.>@[9HY$'UB?]7/-O\ A4Z?]"^/_!V?_C%'_"IT_P"A?'_@[/\
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MC>I5F5AG@X/!HY$'UB?]7/./^%3I_P!"^/\ P=G_ .,4?\*G3_H7Q_X.S_\
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MX8D"1QJ%11T4 8 H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>modificationno16effectiv015.jpg
<TEXT>
begin 644 modificationno16effectiv015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0?!54# 2(  A$! Q$!_\0
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MHH **** "BBJ][<_9+&YN=F_R8FDVYQNP,XS0!8HKPH?M%RLH(\(\'_J)?\
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MO_M5'_#14O\ T*/_ )4O_M5']DX[_GU+[@YX]SW2BO"_^&BI?^A1_P#*E_\
M:J/^&BI?^A1_\J7_ -JH_LG'?\^I?<'/'N>Z45X7_P -%2_]"C_Y4O\ [51_
MPT5+_P!"C_Y4O_M5']DX[_GU+[@YX]SW2BO"_P#AHJ7_ *%'_P J7_VJC_AH
MJ7_H4?\ RI?_ &JC^R<=_P ^I?<'/'N>Z45X7_PT5+_T*/\ Y4O_ +51_P -
M%2_]"C_Y4O\ [51_9.._Y]2^X.>/<]THKPO_ (:*E_Z%'_RI?_:J/^&BI?\
MH4?_ "I?_:J/[)QW_/J7W!SQ[GNE%>%_\-%2_P#0H_\ E2_^U4?\-%2_]"C_
M .5+_P"U4?V3CO\ GU+[@YX]SW2BO"_^&BI?^A1_\J7_ -JH_P"&BI?^A1_\
MJ7_VJC^R<=_SZE]P<\>Y[I17A?\ PT5+_P!"C_Y4O_M5'_#14O\ T*/_ )4O
M_M5']DX[_GU+[@YX]SW2BO"_^&BI?^A1_P#*E_\ :J/^&BI?^A1_\J7_ -JH
M_LG'?\^I?<'/'N>Z45X7_P -%2_]"C_Y4O\ [51_PT5+_P!"C_Y4O_M5']DX
M[_GU+[@YX]SW2BO"_P#AHJ7_ *%'_P J7_VJC_AHJ7_H4?\ RI?_ &JC^R<=
M_P ^I?<'/'N>Z45X7_PT5+_T*/\ Y4O_ +51_P -%2_]"C_Y4O\ [51_9.._
MY]2^X.>/<]THKPO_ (:*E_Z%'_RI?_:J/^&BI?\ H4?_ "I?_:J/[)QW_/J7
MW!SQ[GNE%>%_\-%2_P#0H_\ E2_^U4?\-%2_]"C_ .5+_P"U4?V3CO\ GU+[
M@YX]SW2BO"_^&BI?^A1_\J7_ -JH_P"&BI?^A1_\J7_VJC^R<=_SZE]P<\>Y
M[I17A?\ PT5+_P!"C_Y4O_M5'_#14O\ T*/_ )4O_M5']DX[_GU+[@YX]SW2
MBO"_^&BI?^A1_P#*E_\ :J/^&BI?^A1_\J7_ -JH_LG'?\^I?<'/'N>Z45X7
M_P -%2_]"C_Y4O\ [51_PT5+_P!"C_Y4O_M5']DX[_GU+[@YX]SW2BO"_P#A
MHJ7_ *%'_P J7_VJC_AHJ7_H4?\ RI?_ &JC^R<=_P ^I?<'/'N>Z45X7_PT
M5+_T*/\ Y4O_ +51_P -%2_]"C_Y4O\ [51_9.._Y]2^X.>/<]THKPO_ (:*
ME_Z%'_RI?_:J/^&BI?\ H4?_ "I?_:J/[)QW_/J7W!SQ[GNE%>%_\-%2_P#0
MH_\ E2_^U4?\-%2_]"C_ .5+_P"U4?V3CO\ GU+[@YX]SW2BO"_^&BI?^A1_
M\J7_ -JH_P"&BI?^A1_\J7_VJC^R<=_SZE]P<\>Y[I17A?\ PT5+_P!"C_Y4
MO_M5'_#14O\ T*/_ )4O_M5']DX[_GU+[@YX]SW2BO"_^&BI?^A1_P#*E_\
M:J/^&BI?^A1_\J7_ -JH_LG'?\^I?<'/'N>Z45X7_P -%2_]"C_Y4O\ [51_
MPT5+_P!"C_Y4O_M5']DX[_GU+[@YX]SW2BO"_P#AHJ7_ *%'_P J7_VJC_AH
MJ7_H4?\ RI?_ &JC^R<=_P ^I?<'/'N>Z45X7_PT5+_T*/\ Y4O_ +51_P -
M%2_]"C_Y4O\ [51_9.._Y]2^X.>/<]THKPO_ (:*E_Z%'_RI?_:J/^&BI?\
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M,HL ?A1^%%%'* OX4GX444<H!^%'X444<H!^%+^%7KS1-5TZZ@MKW3KJWGN
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M[77)O.=+63:4//&3CVY]J2V\?>'M1\.66B^*-!N+N'3F(LY;>;:PCZ!6Y'8
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MH **** "BBB@ JCK/_("U#_KVD_]!-7JHZS_ ,@+4/\ KVD_]!--;B/BJ/\
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M7]0FTB[NI[15,=U%,BQP9'\2E@6_ &DL_AGXPOX;2:VT:1X;N$3PR>;&%9"
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M** "BBB@ HHHH **** "BBB@ HHHH **** "J.L_\@+4/^O:3_T$U>JCK/\
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M>:9*$N;8.61T..AZ9^8'.!T(]*HVGP:\2W=G%+]HTR&YEA$R64MP1/M/JNW
M_.N6GF>%2=2K^[E>SO:]UZ7NK/?;4;A+9:GGE%>I>&/AA!JWP]U+5;BXMH]3
M,ACM_.N-D=OL<!O,P.&.& SD8(]:QM$^%/B'6]*@U!9;"T2YYMH[N8H\X]5
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MM ^!FFZKX<TS49-8O8WN[6*=D6-2%+*&Q^M:'_#/NE?]!R__ ._25Z3X)&/
M7AW_ +!EM_Z*6MVNU9EC$K*K+[V3R1['C7_#/NE?]!R__P"_24?\,^Z5_P!!
MR_\ ^_25[+13_M/&?\_9?>PY(]CQK_AGW2O^@Y?_ /?I*/\ AGW2O^@Y?_\
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M?^@U>_\ ?I:]9QP*7%:K,<7_ ,_9?>S&R/)?^%#:;_T&KW_OTM'_  H;3?\
MH-7O_?I:]:HI_P!HXO\ Y^R^]BLCR7_A0VF_]!J]_P"_2T?\*&TW_H-7O_?I
M:]:HH_M'%_\ /V7WL+(\E_X4-IO_ $&KW_OTM'_"AM-_Z#5[_P!^EKUJBC^T
M<7_S]E]["R/)?^%#:;_T&KW_ +]+1_PH;3?^@U>_]^EKUJBC^T<7_P _9?>P
MLCR7_A0VF_\ 0:O?^_2TC_ G354G^VKW !/^J6O6Z9*!Y3\?PT?VCB_^?LOO
M8[(\5\.?!NQUK0K:_DU:[5YE+%4C7 P2/Z5I_P#"AM-_Z#5[_P!^EKM? ('_
M  A6G\#[K?\ H35TM"S'%_\ /V7WL&D>2_\ "AM-_P"@U>_]^EH_X4-IO_0:
MO?\ OTM>M44?VCB_^?LOO8K(\E_X4-IO_0:O?^_2T?\ "AM-_P"@U>_]^EKU
MJBC^T<7_ ,_9?>PLCR7_ (4-IO\ T&KW_OTM'_"AM-_Z#5[_ -^EKUJBC^T<
M7_S]E]["R/)?^%#:;_T&KW_OTM96L_!VRTR;38X]4NY#=W:V[9C4;00QR/?Y
M?UKV^N9\7#_2_#G_ &%4_P#06H>8XO\ Y^R^]C21Q?\ PH?3?^@U>_\ ?I:/
M^%#:;_T&KW_OTM>M8HH68XO_ )^R^]A9'DO_  H;3?\ H-7O_?I:/^%#:;_T
M&KW_ +]+7K5%']HXO_G[+[V*R/)?^%#:;_T&KW_OTM'_  H;3?\ H-7O_?I:
M]:HH_M'%_P#/V7WL+(\E_P"%#:;_ -!J]_[]+1_PH;3?^@U>_P#?I:]:HH_M
M'%_\_9?>PLCR7_A0VF_]!J]_[]+1_P *&TW_ *#5[_WZ6O6J*/[1Q?\ S]E]
M["R/)?\ A0VF_P#0:O?^_2T?\*&TW_H-7O\ WZ6O6J*/[1Q?_/V7WL+(\E_X
M4-IO_0:O?^_2T?\ "AM-_P"@U>_]^EKUJBC^T<7_ ,_9?>PLCR7_ (4-IO\
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MA9'DO_"AM-_Z#5[_ -^EH_X4-IO_ $&KW_OTM>M44?VCB_\ G[+[V%D>2_\
M"AM-_P"@U>_]^EH_X4-IO_0:O?\ OTM>M44?VCB_^?LOO861Y+_PH;3?^@U>
M_P#?I:/^%#:;_P!!J]_[]+7K5%']HXO_ )^R^]A9'DO_  H;3?\ H-7O_?I:
M/^%#:;_T&KW_ +]+7K5%']HXO_G[+[V%D>2_\*&TW_H-7O\ WZ6C_A0VF_\
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MR3-<6SZ:@DNX9K=Q)$A&0VT DK@'D9'%']HXO_G[+[V'*<)_PH;3?^@U>_\
M?I:/^%#:;_T&KW_OTM=QIOC71=5U&SL;>2X$M[!Y]LTMNZ),H )"L1AB ><5
M6TW7=+M9=?O)-9O+B*&\6.2*XB8?9Y" !%&NW<<DC  .2:/[1Q?_ #]E][#E
M.0_X4-IO_0:O?^_2T?\ "AM-_P"@U>_]^EKT31_$-CK5Q>VUN)HKJR95N+>>
M(H\>X94D'L1R,5A7^L7VK^/_ /A%K"Z:SMK.U%U?7$07S7+$!(U)!"CD$G&>
MPQ1_:.+_ .?LOO8<IS'_  H;3?\ H-7O_?I:/^%#:;_T&KW_ +]+7=6NDZEI
MVOQ3C5[JYTG[-()8;ID;9+N0JP; )&-_7./QHMO&6CW-W:0JUPD=ZQ2TN9(&
M6&X89.$<C'.#C.,]LT?VCB_^?LOO8<J.%_X4-IO_ $&KW_OTM'_"AM-_Z#5[
M_P!^EKK+OXD^&[-[I7DO&6TG\BZ=+.0K >.7.WY1DXR>N#C.*TK3Q5IM[XAD
MT2#SFNTMQ= [/D>(XPZMT8'(Z4?VCB_^?LOO8<IP/_"AM-_Z#5[_ -^EH_X4
M-IO_ $&KW_OTM>G:9J4.K:>E[;I*L,F=OF+@D XS]..#WKGM&\=6FH_V[/=V
M\]C9Z7</$TT\9  15W;O]K<QPO7&.]']HXO_ )^R^]ARG)?\*&TW_H-7O_?I
M:/\ A0VF_P#0:O?^_2UZ#I_B6PU#4SINRYMKWRO/2&Z@:-GCSC<N>HSVZCN*
MV:/[1Q?_ #]E]["R/)?^%#:;_P!!J]_[]+1_PH;3?^@U>_\ ?I:]:HH_M'%_
M\_9?>Q61Y+_PH;3?^@U>_P#?I:/^%#:;_P!!J]_[]+7K5%']HXO_ )^R^]A9
M'DO_  H;3?\ H-7O_?I:/^%#:;_T&KW_ +]+7K5%']HXO_G[+[V%D>2_\*&T
MW_H-7O\ WZ6C_A0VF_\ 0:O?^_2UZU11_:.+_P"?LOO861Y+_P *&TW_ *#5
M[_WZ6C_A0VF_]!J]_P"_2UZU11_:.+_Y^R^]A9'DO_"AM-_Z#5[_ -^EH_X4
M-IO_ $&KW_OTM>M44?VCB_\ G[+[V%D>2_\ "AM-_P"@U>_]^EH_X4-IO_0:
MO?\ OTM>M44?VCB_^?LOO861Y+_PH;3?^@U>_P#?I:/^%#:;_P!!J]_[]+7K
M5%']HXO_ )^R^]A9'DO_  H;3?\ H-7O_?I:;)\"=.6-F_MJ\X!/,2XKURF2
MC]R_^Z:3S'%_\_9?>QI(R/A<NWX;Z&@SA8"!_P!]M785R/PPY^'&B$]3"W_H
M9KKJ\WJ=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %4M8_Y E__ ->\G_H)J[5+6/\ D"7_ /U[R?\ H)H
MS_!/_(A>'?\ L&6W_HI:W:PO!/\ R(7AW_L&6W_HI:W: "BBB@ HHHH ****
M "BBB@ HHHH .U<EXF_Y'#PO_O77_HM:ZWM7)>)O^1P\+_[UU_Z+6FMQ2V-?
MT^E%'I]**T1SA1115 %%%% !1110 4444 %-E_U3_P"[3J;+_JG_ -VDP.=\
M _\ (E:?_NM_Z&U=)7-^ ?\ D2M/_P!UO_0VKI*$-A1113$%%%% !1110 5S
M/B[_ (_/#G_85C_]!:NFKF?%W_'YX<_["L?_ *"U)@=-1110@"BBBF 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-:U_R
M._A?_M[_ /15=+7-:U_R._A?_M[_ /15)@=+1110@"BBBF 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4HZTE*.M '.Z?_P CWK7_ %XV?\YJZ&N>T_\ Y'O6O^O&S_G-70U*
M *Y+Q9!<S>(O"\T%I<316EZTUP\<981H8V4$^O)' YKK:*H:$9@JECG &>!D
M_E7F_A>TEL'\41:MX=OIH=1U:XN8O]'5P\+X SSD=#Q7I-%%@3//]836-7O/
M"=Z^C7$(MM3>>6( %H80&12_/WB,' SUK(T#0[[3)ET.^\$6]Y/#=LT.LR"-
MHF0N6$C9^;< >@YR!TZUZO12L.YYKI:^(] NM6T'_A''U".ZU"6ZM-09U\A1
M(VX&3)SE3S@<G''8U!JNE:RESX_LHM'NYUUB)6M)X]NQCY.S!R<@[N.GO7J-
M%%@N<!K>DZI-X4\)W5I8RO<Z/<6UQ/8\!V5$VN!S@L,G'//:H-:TF_UG4/$.
MM6]A=1I-H#Z7;PR)MDGE8LV=N> ,@9..I["O1J*+"N><6FF:DNL?#R9M.N5C
MTRQE@O"4_P!2[0J@!YY^93TSZUEWWA_7YO\ A(;NRTZ;[1#KT&K6D4ORB[2,
M %0>W3.#CM7K=%%A\QS_ (=U'4=6GN+R[T&32(BJJ%N"IFE89R3MZ*!@#/)R
M>E8VHZ5J.A?$-_%-C8RZA97UJMK>00%?-B92-LB@D;A@ $9SWKN:*+"N<]=R
M7WB/2KZQALI]/AN+66$S78"ON92J[5!)P,Y)..@P#G(Y2#2]6U;PIX8\/3Z5
M<V=WIEU;-<S2*/*1(/XE8'YBP QCUYX%>F446"YY-823W%M\1-)MM,NKN>]U
M"XAB:-1Y>YXPOS,3A<9!)/;IDUHZ[X6OM/L/"3Z5=I'K%BD>E/*!_K(7CVN<
M=]N"X],$UVFDZ!9:+<7TUH9M]],9Y_,D+!I#U;!Z=NGI44'A71;;Q'/K\5D!
MJ<XP\Y=CVQPI. <<9 _G18=S4M;:*SM(;6W0)#"BQQJ/X5 P!^0KRJ^\-Z]=
M:3XRT>#39EFN=5;4[69F40SKNC81YSG)VGM@8Y(KUJBAJXD['&?9[OQ%XS\/
MZP-/NK&#3(+@S?:D",SRJJB,#/.,$D].E=G113 ****!!1110 4444 %%%%
M!1110 4444 %%%% !1110 4R7_4O_NFGTR7_ %+_ .Z:F0UN9/PO_P"2;Z'_
M -<&_P#0S77UR'PO_P"2;Z'_ -<&_P#0S77UD= 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M8_P"0)?\
M_7O)_P"@FKM4M8_Y E__ ->\G_H)H S_  3_ ,B%X=_[!EM_Z*6MVL+P3_R(
M7AW_ +!EM_Z*6MV@ HHHH **** "BBB@ HHHH **** #M7)>)O\ D</"_P#O
M77_HM:ZWM7)>)O\ D</"_P#O77_HM::W%+8U_3Z44>GTHK1'.%%%%4 4444
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M% !7-:S_ ,CQX7'?_2__ $572U!+9P37=O=21(\UON\IVZIN&#CZCK28$]%
M&!BBA %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]%K36XI;&OZ?2BCT^E%:(YPHHHJ@"N-^(,:%/#;E%+C7[(!L<CYZ[*L;Q!H
MU]+%6O)+<6=W'>)Y: DR(<KG/;VH8UN;-%(N0H!.3CD^M+0(**** "L?Q;_R
M)FN_]@^X_P#1;5L5F^(K66]\,ZK:0*&FN+2:*,$XY9& _6A@B?2O^0/8_P#7
MO'_Z"*MUD^%[]=2\,Z=<K"T>Z$ HQR1M^7M[@UK4(#B=*T6PU\>*K'4H!/;'
M7"Y0DC)$,)'2MV/PMI$>K6VJ+;?Z9;1+#%(7/" $8QW^]SZD ]A4VFZ)#I>H
M:E=PW-PPU"83R0R%2B/M"DK@ C(5>I/2M"5#)"\:R-&64@.F-RY[C((S2L-L
MYSP!_P B;;?]=[G_ -'R5TU9^B:1!H.D0Z=;RS2QQ%R'F(+L68L22 !U8]JT
M*:!A1110(***S]3U:/3);&-XVD-W<K;KM(X)!/\ 0T :%%%% !1110 5S7@&
M17\'6<>'5X2\<BNA4JV\G'/U%=+10!C>+9D@\(:PS[L-9RH JEB692H&!SR2
M*NZ0I71K%6!!%O&"#V^45<HH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***HW6JPVFJV&GNC&6]\SRR.@V+N.: +U%'>B@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .;\+?\A/Q3_P!A<_\ I/#725S?A;_D)^*?^PN?
M_2>&NDI)C84444Q!113719$9'4,C#!5AD$4 >$VFG7]YX0\07MG<37=E:Z_<
MR7^DJ^U;J %2P#+A@<<]<''3UZ?Q-KVDW%MX.OK>\%MX8D>17ECA5TA?RP(E
M=&! Q\XY'!'MFO2H+*TM2QM[6&$L,$QQA<_E31IUBL+PBSMQ%)]]!$NUOJ,<
MU-BN8\=UBP\/0>'--?3]0DO--D\40.]S)M2--_,@B*A0J<<XX!SZ4SQ7I6GZ
M==>,HM&@@CTC^Q(WGCAQY*77F87 ' ;8,\>OO7I/BGPP^N6>E6MFUM;16-_%
M>;'CRK>63A !T!R:W(]/LXK86Z6=ND.=WEK& N?7&,46'S'EVN6>E>'M-\+7
M4?\ H6C7<ZR:C=1QB4-)Y.(G<,&!^8DDD=>>O-!TS1Y-$:+0/$:,+C65N();
MN)#9R7'ENQBPH4;2!DX'WL8YKU5K:W>W-NT$;0$8,90%<?3I4;Z=8R6R6SV=
MNUNARL31*54^PQ@=33L+F/'9-;7['H[:E;Q:/IMOK%U;Z@]JBS6WV@(-CJ&4
MC869NH.",]J=K=CH,/@>5M*U&2^LY-=@D^T,%2-'9UWB(J% 'KMX!SZ&O8OL
M5H+3[(+:'[-C'D^6-GK]WI2&PLVA2$VD!BC^XAC&U?H,<4K!S'EMYIUA:>)/
M'VG65I;Q0-H*2BWB0!2X1_FVCC/3FJ=G?^'Y['P39QMIXF33V9IKIU^R12>2
M@?S$XWRXQP2N,\FO7TLK6.4RI;0K(1C>L8!_.H_[,T_9$GV&VVPMNB'DKA#Z
MKQP?I3L',>(Z3-IS>!_ ,MY):NEMK317#RE2(U+RD*V?NC&#@^U=I#:Z;J'Q
M8U6S,<$EI>>'XPR*!B13(1G\L?I7>?V=9>08/L=OY);>8_*7:6ZYQC&?>GBS
MMEN/M MX1.?^6@0;OSZT6!R/+? =M>R7Z^$=0@W0>%[R24RE!B4'_CW_ !PS
MM_P%:S-*?1=3(@UO6KFV\1VVK/*UI%!&)VF$IV!&V;F4J5'7 'H!7M*QHKLZ
MHH9L;B!R<>M1_8[4W0NOLT/V@#'F[!OQ]>M%@YB:BBBF2%%%% !1110 4444
M <G\3?\ DFNO?]>Q_F*Z&6:UM-/6\O&CCBMX]YD?^#C!/Y''XTW5=)LM;T^2
MPU")IK67AXQ(R!AZ':02/:JVI^&M*UG2XM-U&WDN+.,@K&UQ)R1TR0V6Q[DT
MAF)!-%I$FN^+;]3!-=6P>*T<XD$$(.W*]=S%^1VW*.M0ZGILNE?!W5;:X.;L
MZ9<37+?WIG5GD/\ WTQK1LOA]X6TXRFTTI8S*$#DS2-N"NK@<L>-RJ<=\<UN
M:CIUKJUA-8WL;26TRE)$$C)N4\$$J0<>U%AW.4USPU<>*/AYIEG9W"07D*6U
MS;M(#L+HH(#8YP>:P[;4+Z]^*%WK&HPVEO:^']*>.\DM9FE0.WS%=Q5>0,G&
M./7->BQZ9;1:;'I\?G);QJ$4+<2!@!T&_=N_6H3H&E?V/)I*V4:6,GWX4RH?
MG)R1R<GKGKWHL%S)T 1:)X4AU/55"7EQNNISMR_F3-N\M1U)R50 ==HKC_'&
MD7$/PX\573@)J.I317UQ:JP+0PJZ*H./14R3TSN["O0==\,:1XEBABU>U-S'
M"Q:-/.= #ZX4C)^OOZU%I'@[P_H4-Y#IVFQQ1WBA+A6=I/,4 C!W$\?,>/>B
MP)]3GM6/G_%CP>UL=R+8W<DFT](RJA2?;.*NZ-_R5+Q1_P!>=E_*2MO2O#>E
M:+*TMC;,DIC6'S))GE98UZ(I<DJH_NC J2WT/3[76+C588I%O;A0LLAG<AP.
M@*DXXR<<<9HL%S&\88O7TCP[&!_Q,[L-.H_Y]XOWDGYD*O\ P.NJJJVG6C:H
MFIM"#>1PF!)"3\J$@D =.2!SUXJU3$%,E_U+_P"Z:?3)?]2_^Z:F0+<R?A?_
M ,DWT/\ ZX-_Z&:Z^N0^%_\ R3?0_P#K@W_H9KKZR.@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6L?\@2
M_P#^O>3_ -!-7:I:Q_R!+_\ Z]Y/_030!G^"?^1"\._]@RV_]%+6[6%X)_Y$
M+P[_ -@RV_\ 12UNT %%%% !1110 4444 %%%% !1110 =JY+Q-_R.'A?_>N
MO_1:UUO:N2\3?\CAX7_WKK_T6M-;BEL:_I]**/3Z45HCG"BBBJ **** "BBB
M@ HHHH *;(<1/C^[3J;+_JG_ -VDP.=\!<^"M/S_ '6_]":NDKF_ /\ R)6G
M_P"ZW_H;5TE"&PHHHIB"BBB@ HHHH *YGQ<3]K\.\GG5(P>?]EJZ:N9\7?\
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M !1110 4444 %%%% !3)?]2_^Z:?3)?]2_\ NFID-;F3\+_^2;Z'_P!<&_\
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MTM%%%" ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ [5R7B;_ )'#PO\ [UU_Z+6NM[5R7B;_ )'#PO\
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M1[UK_KQL_P"<U=#4H KF/$6J:GI_B;PW;V]Q"ME?730SQ^3ESB-F^\3@#@<
M9]ZZ>N0\7),_B3PI)%:W4T=M?-+,\-N\BQJ8G4$E0<<D4V-'7.I9&4,4)& R
MXR/<9XKSOP[JFK:K_P )&U]XHFM4TO4Y[6,B"W_U2 $,V4Y/)Z8KT1F"J6.<
M 9X&3^5>5^&]/TQ9O%2^(/#UW(+W5[B:!Y='EE+PMC!!$9QW]*&-&]K.HZWI
M=WX.MY-2WO=W@@O3'&H6<;"<],KTZ#%;LOBS18=1BLI+MEDEG^S)(87\II?^
M>?F8V;N",9SD8ZURVMSWVKWWA"]&D:A#'#JCR.AMG+10@,BM( /E)X./0UC:
M#ITEJR>'M7\(ZI>7\%ZSQ7S,YLW!D+B8MNPI .< $\>II7"QZ%=^+=$L;X6=
MQ>%)/.6 N(G:-)6Z(T@&U6.1P2#6;!X_TI]3UJWN!<6MOI6T2SS6T@7."6R=
MN ,8QG!/49%<WID^IZ-/J_AV^\*WNIRSZG+=V=T;</:OO;>K2.>%*GD]^..:
MAU:UU&&Y^(EB-)U&5M4B5K26&W9XY/W.W&X=]W&.OX9-%PLCM[3QKX>OK2ZN
M;?4D>&U9$E(1L[G'R #&6)Z #//'6I8?%>BS6M]<&\,*V !NDN(GA>$$9!9'
M 8 CH<<URNMZ??GPCX/O;.PN7_LJYM+BZLDB(EV(FUL)U+*3T_*H=<L;K5M3
M\2ZU965Z+67P\^G1H]K(DEQ.Q8C"$!B "!DCO[&G=A9'6Z=XQT#5;^"QLM06
M6XGA\^%?+91(F,G:2 "1GD Y'>J^FZU90R:[>7'B);RU@N0I5H@BVAP/W8(^
M^22/?)QUKF+.TO%UKX;R'3KU8['3Y8;IC:N! [0J@#<<?,I'Z].:R[[3-:?_
M (2.\LM,O))+;Q#!JD4#PNGVN*,#(0D<\C./;Z4KA9'IVE:_IVM/<QV4SF:U
M8+/#+"\4D1(R-R. 1D<CCFL+4-=O]1\<+X6TJ?[(MO;?:K^["*SJ"<(B!@5R
M<@DD'BKGAO4SK-Y=WZ>'KK2HY%19);ZW$,\[C.,@$DJHZ$^O'2L6_L;WPY\2
MI?$T=C<WVF:C:+;7/V6,R2P2*1M;8.64@=@2/YL#>M;+6['Q!$9=8FOM):VD
M\P7$42NDH9-IW(JY&-_;MW[2VGBS1;V^@M(+MC)<;OL[/!(D<^WD^6[*%?C^
MZ3534KFZ\2Z%J5CIEK=6XGLYHA<7<+VY#LI"A5<!CR>3C ]STY:*VO=;\.^#
M=)33+ZTO]*N[62Z,]J\:0K I#D.1M;=@ ;2<[OK1<+'2W7Q&\*V<LT<^J!6@
MG-O-B"0B-QC.XA< <@9/'7T-:5MXFTF[UV718+EWU"*+SVC\EP/+.,,&V[2#
MD<@UYQ87*RV'Q&TJ.PO+FZO-1NHH1#:O(C,R!5!<#:N#@_,1@'-:FM^&]4TB
MT\)WNDS1KK%I!%I$[=I(W0*6]3L8;Q^-*["R._T[4K75;);RS9W@8D*S1,A.
M#@\, >HZUAZ+XXT[5WUEF6>TM],G>-YKF!XUVHJEBS, %.6/RD[L#.*Z"RM(
M;"QM[.W7;#!&L4:^BJ,#^5>37^CZU<:+XWT>WTR]^U3:NVI0L8\17$6Z-@@<
M\$D*>!GIS38))GI>G>(]+U2]>RMYI5NEC\WR9[>2%S'G&\!U!*Y[CBM6N)*R
M^(_'/AW5[2SO;:WT^WN#=-=6SP$F1558_F W$').,@8Z\BNVIH3"BBB@0444
M4 %%%% !1110 4444 %%%% !1110 4444 %,E_U+_P"Z:?3)?]2_^Z:F0UN9
M/PO_ .2;Z'_UP;_T,UU]<A\+_P#DF^A_]<&_]#-=?61T!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52UC_D
M"7__ %[R?^@FKM4M8_Y E_\ ]>\G_H)H S_!/_(A>'?^P9;?^BEK=K"\$_\
M(A>'?^P9;?\ HI:W: "BBB@ HHHH **** "BBB@ HHHH .U<EXF_Y'#PO_O7
M7_HM:ZWM7)>)O^1P\+_[UU_Z+6FMQ2V-?T^E%'I]**T1SA1115 %%%% !111
M0 4444 %-E_U3_[M.ILO^J?_ ':3 YWP#_R)6G_[K?\ H;5TE<WX!_Y$K3_]
MUO\ T-JZ2A#84444Q!1110 4444 %<SXN_X_/#G_ &%8_P#T%JZ:N9\7?\?G
MAS_L*Q_^@M28'34444( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5S6M?\COX7_[>_\ T572US6M?\COX7_[>_\
MT528'2T444( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"_15*\UC3-/GB@O=1M+::;_5QS3*C/\ 0$\U1B\6:--XFFT".^@-]#&&=/,
M^8D_(/5@ 20.E 6-NBL72-2E73]^L:EI3S/<O%&]K)B,_-A4^8_?[$>M:%KJ
M=A?023V=];7$,1*R212JZH1U!(/&* +5%9UIK^C7\WDV>K6-Q*3@)%<(S'\
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M2< *<X)SQQ3$7:*@M+RUO[9+FSN(KB!\[987#JV#@X(XZ@U/0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !3)?]2_^Z:?3)?\ 4O\ [IJ9#6YD
M_"__ ))OH?\ UP;_ -#-=?7(?"__ ))OH?\ UP;_ -#-=?61T!1110 4444
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MTE<WX!_Y$K3_ /=;_P!#:NDH0V%%%%,04444 %%%% !7,^+O^/SPY_V%8_\
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M! ^IKVR@C/6BP[GD.IWVE:7_ ,([JEA%?Z?X4CN;K-S!&QVO(%VR[7!(0DR
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M$+P[_P!@RV_]%+6[0 4444 %%%% !1110 4444 %%%% !VKDO$W_ ".'A?\
MWKK_ -%K76]JY+Q-_P CAX7_ -ZZ_P#1:TUN*6QK^GTHH]/I16B.<****H H
MHHH **** "BBB@ ILO\ JG_W:=39?]4_^[28'.^ ?^1*T_\ W6_]#:NDKF_
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M .1[UK_KQL_YS5T-<]I__(]ZU_UXV?\ .:NAJ4 44450!1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%'.'LS,\M_[IH\M_[IK3HHYP]F9GEO\ W31Y;_W36G11SA[,S/+?^Z:/+?\
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M'PXT0$$?N6_]#:NOKF?A\,> ]&QT$&,?B:Z:I- HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:Q_P @2_\
M^O>3_P!!-7:I:Q_R!+__ *]Y/_030!G^"?\ D0O#O_8,MO\ T4M;M87@G_D0
MO#O_ &#+;_T4M;M !1110 4444 %%%% !1110 4444 ':N7U[_D=?"_UNO\
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M16T"R63"*) J@M"23@>I)/XUWU<-X3FBG^)/CMX9$D3?8C<C C(@(/3WKN:
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M4?\ JT^@H!H=1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1G!![#D\T4=>HH P+%"/'.LN4(#65H,XX
M)!EZ5OUSWANZGN=6\3+-*\@AU(11!CG8GD1':/09)./<UT-)#"BBBF(****
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MA:%I[B_NXK=(U.-JLX4N3C@#</J2![BQKNMKHPLAY8D>ZN!'C.-J!2\C_P#
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***, \$9%
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M/_(A>'?^P9;?^BEK=H **** "BBB@ HHHH **** "BBB@ [5R/B;_D</"_\
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M2F3?ZB3_ '3_ "H YSX>C'@+1_\ KC_4UTU<U\/O^1"T?_KC_4UTM !1110
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M"#SQ7JBV%FEF;-;2!;4C!@$8"8]-N,5"-%TH6<EF-,LA:RG,D/D+L<^ZXP:
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MT68<Z+E%4_MA_NT?;#_=HLPYT7**I_;#_=H^V'^[19ASHN453^V'^[1]L/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 4444 %%%% !1110 4444 %%%127$,<\4#RA9IL^6A_BP,G]*3
MEHHZ\T4(#COA?_R(EM_U\W7_ */DKL:S-(\/:3H)N3I=C':FY;?-LS\YYY.3
M[FM.FAO<X[XA?ZKPU_V,%G_Z$:[&LS4/#VDZKJ-GJ%]8QSW=FP>WE;.8R#D$
M<^HK3H ****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFNOK(Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'.')(JT5:^PG_GI1]A/_ #THYPY)%6BK7V$_\]*/L)_YZ4<X<DBK15K["?\
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M^>E'.')(JTR7_4O_ +IJY]A/_/2F363""3$G\)_E0Y7#E:>I@?"__DF^A_\
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M_P!;K_T6M=1VKE]>_P"1U\+_ %NO_1:T =..E+2#I2T %%%% !1110 4444
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MWQ_VI*GF);[6RR[=V0<8Z#/6M>@ HHHH **** "BBB@ HHHH **** "BBB@
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MGZ&LCP3_ ,B%X=_[!EM_Z*6MV@"!;&T2U^RI:PK;_P#/(1@)Z].E1?V3IO\
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M -<?ZFNEKFOA]_R(6C_]<?ZFNEH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J6L?\ ($O_ /KWD_\ 035V
MJ6L?\@2__P"O>3_T$T 9_@G_ )$+P[_V#+;_ -%+6[6%X)_Y$+P[_P!@RV_]
M%+6[0 4444 %%%% !1110 4444 %%%% !VKE]>_Y'7PO];K_ -%K74=JY?7O
M^1U\+_6Z_P#1:T =..E+2#I2T %%%% !7*ZGX2N)?%I\2:5J,5I>R6)L9TN+
M8SQNF[<" '4A@?<@CM7544 8OA+PW;^$?#%EH=K*\T5JK?O'X+LS%F..W+'C
MM6U110 4444 %,E_U;_[M/IDO^K?_=H YOX>?\B+IG^Z_P#Z&U7;[PMIVH>(
M[/7I6NDO[2/RD:&X:-63=NVL ?F&>QX-4OAY_P B+IG^Z_\ Z&U=/0 4R6,3
M0O$Q8!U*DHQ4C/H1R#[T^B@#'\.^&M/\+V4]KIWGE+BX:YE>XF:5WD8 $EFY
M/W16Q110 4444 %<IXS_ ./SPU_V%XO_ $%JZNN4\9_\?GAK_L+Q?^@M0!U=
M%%% !1110 5RWB;P_JVH^)?#VLZ3<64;Z6TXD2Z5B'6554XV]P ?TKJ:* "B
MBB@#EO"_A_5M-U[Q!JVKW%E+-JDD+*MHK*J+&A09W=\8_6NIHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I"P'4XI:YK6[F>/QIX:MHYI$@
MN/M/FQJV%?;'E<CO@\B@#I:*.U% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C9QQ2
MT'I0!F6NJFX\0W^E^5@6L$,V_/WO,+C'X;/UK3KFM,_Y*!KO_7A9?^A3UTM
M!1110 4444 %-=!)&R-]U@0?I3J* .6C\ :0FFP:6\VH3Z5#MVV$UTSQ':05
M!SR5! .TG''3'%,UGX=>']<UQM7N$NX+N1!'.;6Y>$7"CH'"GGCCZ5UE% ')
MZU\.O#^MZE!J$D=S:744(@\RQN&@+Q#HC;>H'^>U=&EA!#IJZ?;!K:W2(11B
M$[3&H& %/; JS10!FV&AVNFZ"FC6SS+:I&8D)?+JI_VCS^)K%A^'6@0>%_\
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M)?\ _7O)_P"@F@#/\$_\B%X=_P"P9;?^BEK=K"\$_P#(A>'?^P9;?^BEK=H
M**** "BBB@ HHHH **** "BBB@ [5R^O?\CKX7^MU_Z+6NH[5R^N@_\ ":^%
MR!D#[43[#8M '3CI2TT.N/O>]+O7^]0 M%)O7^]1O7^]0 M%)O7^]1O7^]0
MM%)O7^]1O7^]0 M%)O7^]1O7^]0 M,E_U;_[M.WK_>J.5E\M_F_AH YWX>?\
MB+IG^Z__ *&U=/7+_#[Y? VF!N#M?_T-JZ?>O]Z@!:*3>O\ >HWK_>H 6BDW
MK_>HWK_>H 6BDWK_ 'J-Z_WJ %KE/&?_ !^>&O\ L+Q?^@M75;U_O5ROC(YN
M_#6.?^)O'_Z"U '5T4F]?[U&]?[U "T4F]?[U&]?[U "T4F]?[U&]?[U "T4
MF]?[U&]?[U "T4F]?[U&]?[U "T4F]?[U&]?[U "T4F]?[U&]?[U "T4F]?[
MU&]?[U "T4F]?[U&]?[U "T4F]?[U&]?[U "T4F]?[U&]?[U "T4F]?[U&]?
M[U "T4F]?[U&]?[U "URNO?\C]X2^MW_ .BJZG>O]ZL74M*-YXBT?4EG518>
M=\A7._>FWKVQ0!MCI130RX&3S2[U_O4 +12;U_O4;U_O4 +12;U_O4;U_O4
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M36XI;&N"0N,]Z7)]:3T^E%:(YQ<GUHR?6DHJ@%R?6C)]:2B@!<GUHR?6DHH
M7)]:,GUI** %R?6F2D^4_/\ #3JBN98[>UGFFD6.*.-F=V. H .23Z4F!A>
MW)\$Z=G/W6_]#:M>?5M/M;V&SN-0M8;J?_5023*KR<X^52<GGTJCX4L)-,\-
M65K,0TB(3OC8%2"2?QX-8=Q!#/\ &:U,L22&/0G="R@[6\]>1Z'D\TD,[);B
M)YI(4F1I8\%T# LN>F1VSBF_:X-TR_:(\P#,HWC]V,9^;TXYYKC= \!RZ/XG
MFU66_EF@?>(X#=3,(0,K'C<QW?(S9W9P3\N*/#G@.31?$,^HSWTES#('"0-<
M3.(N2J#YF(<>6<'=G!Z<4QG76.IV.J0&?3[ZWNX0VPR6\JR*&ZXR">>1^=6L
MGUKBOAW%' /%,4,:1QIX@N0J(H 4;8^ !7:4(3%R?6C)]:2BF(7)]:YGQ<Y6
M\\.8S_R%8_\ T%JZ6N9\7?\ 'YX<_P"PK'_Z"U)C.GR?6C)]:2BA"%R?6C)]
M:2BF N3ZT9/K244 +D^M&3ZTE% "Y/K1D^M)10 N3ZT9/K244 +D^M&3ZTE%
M "Y/K1D^M)10 N3ZT9/K244 +D^M&3ZTE% "Y/K1D^M)10 N3ZT9/K244 +D
M^M&3ZTE% "Y/K29HHH 7)]:,GUI** %R?6C)]:2B@!<GUHR?6DHH 7)]:,GU
MI** %R?6C)]:2B@!<GUHR?6DHH 7)]:,GUI** %R?6C)]:2B@!<GUHR?6DHH
M 7)]:,GUI** %R?6C)]:2B@!<GUHR?6DHH 7)]:,GUI** %R?6C)]:2B@!<G
MUHR?6DHH 7)]:,GUI** %R?6C)]:2B@!<GUI,GH,Y-%!_#\: .?L&/\ PG>M
MC)P+*TQ^<U=#D^M4(=,2#6[S4Q*2US#%$4(X7RR_/X[_ -*O5*0Q<GUHR?6D
MHJA"Y/K1D^M)10 N3ZT9/K244 +D^M&3ZU&)8R[()$WKC*[AD9Z4^@!<GUHR
M?6DHH 7)]:,GUII8 @$@$G SWIDT\-N@>>6.)2P4,[!02> .>] $N3ZT9/K2
M44 +D^M&3ZTE% "Y/K1D^M)10 N3ZT9/K244 +D^M&3ZTE% "Y/K1D^M)10
MN3ZT9/K244 +D^M&3ZTE1M/$LJQ-*@D;E4+#)^@H ER?6C)]:CDECB"F214#
M,%&XXR3T'UIV1N*Y&0,XH =D^M&3ZU$T\22+&\J*[_=4L 6^@ISR)$H:1U0%
M@H+'&23@#ZDD"@8_)]:,GUI@D1G9%=2Z_>4'D4C2QHZHSJ'?.U2>6^E B3)]
M:,GUICR)'C>ZKDX&XXR:5F5%+,P50,DDX % #LGUHR?6FJZN@=&#*1D$'((I
M: %R?6HYB?)DY/W3_*GTR7_4O_NFID-;F7\,3GX<:*2<_N6_]#:NMKD/A?\
M\DWT/_K@W_H9KKZR.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "J6L?\@2__P"O>3_T$U=JEK'_ "!+_P#Z
M]Y/_ $$T 9_@G_D0O#O_ &#+;_T4M;M87@G_ )$+P[_V#+;_ -%+6[0 4444
M %%%% !1110 4444 %%%% !VKDO$W_(X>%_]ZZ_]%K76]JY+Q-_R.'A?_>NO
M_1:TUN*6QK^GTHH]/I16B.<****H K@)KF77_B-KFA7M_>6=M86,4EHMM<O
M69AEI<J06VD@8.1QTKOZY3QAH3:_";:WT2RFO'0Q1ZE>1QLMLIZE1RQ/H, 9
MZFDQH/AQKMWXB\#V-_?N)+K+Q22 8\PHY7=^( KJZS/#VAVOAO0+/2+('R+:
M/:&/5CU+'W))/XUITT#W"BBB@05C^+?^1,UW_L'W'_HMJV*Q_%O_ ")FN_\
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M25PUC8VME\9;XVMO'"9]%2:4HH7S',[ L<=2<#FNYI@PHHHH$%%%% !1110
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MBBBX!1111< HHHHN 44447 ****+@%%%%%P"BBBBX!1111< HHHHN 44447
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MM'_ZX_U-=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %4M8_Y E_\ ]>\G_H)J[5+6/^0)?_\ 7O)_Z":
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M_!/_ "(7AW_L&6W_ **6MVL+P3_R(7AW_L&6W_HI:W: "BBB@ HHHH ****
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MHHM&M!!&D$9B5_*C7@%ADX]!DUSGQ(_Y >F_]ABR_P#1HKI=)YT>Q_Z]T_\
M017-_$E9?^$<M)8K>>?R-2M9G2"(R/M60$D*.3P*70:W+&N^!-)\0:U!JMVH
M^T0*H3$,9&0P)+94[L@;<-D '@ \TFL^ M(UO78-7N8U%Q J","&,KPW.[*G
M=E?EYS@=,'FNDMKA+NTAN8UD5)4#J)$*, 1GE3R#[&I:=D%V<==#'Q?TP#I_
M8L__ *-CKL:XDS-=_&" QVMV(K32Y89)WMW6,NSQL K$8;CTKMJ$#"BBBF(*
M**3<H(RP&3@<T-@+1110@"BBB@ KB;35]=G\3^*_+NX)+32MB6]E)&$5F:)7
MRTH!('7L>M=M7'>%/^1V\;?]?EO_ .B%I,:*GAKQ?KVK:1JMY<:9;1-;*9X5
MGN&0LC'?&#A.%\LCYN22.0.:/#GB#Q%XFT'4RZQZ5<Q$O#,R^8ZJQ,B QE0,
M>44&<\\\ \5WE0W?_'G/_P!<V_E18+F-X)U2ZUKP7I.I7SA[JX@#R,%"@G)[
M"M^N4^&?_)-M!_Z]1_,UU=-; ]PHHHH$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !7-:U_R._A?_M[_ /15=+7-:U_R._A?_M[_ /15)@=+1110@.>A
M\::5)J6IVDHGMHM,;9<WEP@2W5LJ-OF$XS\PXI]GXT\.WMF]TFK6B1QOY<GF
M3*I0EF5<\\;BIQZBL7PM:I?7GCBT=G19M5="R8W+F&,9&01FM2V\$:19>'[W
M1+7SX;*[X95<93@ [21D9P2>O+$C%&I6A7NOB+H5OX=77(C<7EGA3-]DC$C6
M^Y=P\P _)U'7UKJP=R@CH>:X#QOHEGH'PEU^RL%9+?871"00@+@[1_LCL#G%
M=]'_ *M/H*$)V'4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4HZTE*.M '.Z?\ \CWK7_7C9_SFKH:Y
M[3_^1[UK_KQL_P"<U=#4H HHHJ@"BBB@ ILDB11M)(P5$!9F)P !U-.J"]\G
M[!<?:5W0>4WF+ZK@Y'Y4 <[;^.;>YM;6^BTG4SIMW<);P7NR/8Y=PBL5W[U4
MD]2H_45U->23VVI_#>P@U#3+M=8\&/)$[6=R<R6P=P5:-NXW$$#].IJY=MJO
MBC5?$L%OK$>G7.FW8CMV-W)&;>-55@YC4A6#'=DMGT[4KE6/3Z*\NGFU7Q7K
M>MZ9%K$5M/906_V:1;J6 KNB#F940@,"S?Q9P !QDY]$TAY)-%L9)KJ.ZE:W
MC+W$8PLIVC+@=@>OXT)B:L5-5\3:;H^LZ3I5W(5N=4D:.  # (&<GTR< >YI
MOB+Q%'X=73VEM)IUO;R*S#1E0(V<X!;)SCKT!Z=J\\\76&H^(]'U7Q#:Z:TD
ML,J7&EW:RKF.& D@A>OS$R-QU!7TK2\8ZI'XC\%>$]2MI&B6]U:Q<,F"8V).
M<9R,@Y'X4KCL>ET5Y!XDU35O FH^(K72]0OKNW.D1WJ&[E,[6\S3B(LI;MM)
M;![CTKHKN!]%\7>';6QOK^XL=8CG@NHYKN27=MCWB56+$HWNN.M.X6.]HKR/
M0KO45OK_ , WEY?R:C%J:R"\:YD\PV7^LW;LY'"A.#C,@]ZLS/JWB:Y\126^
MMQ:;<Z7J#112-=R*;:./&"8@=C*P#$E@<Y/H "X<IZG13(F+PHQ(8E020, T
M^F2%%%% !1110 4444 %%%% !6!J?BI=/U3[!#HNKZBXVB26R@5XXF/(5F+#
M!P0?H16_7GWB70G\/7#>*-!O[Q+Q[V+[39M.TD-WYDBQE=A/##/&.F,?1,:.
MOU768M+GTZ!HGEFO[H6T2(1D<%F8^RJI)J+3?$5KJFMZGI4,-RDVG",RM-%L
M#;]V-N>2/EZX[UF1?\3?XD32];?0[01+Z?:)L,Q_"-5'_ ZAT+_DIOB__KA8
M?^@247"P:A\1=.TR^=+C3=5_L^.?[/+J@MO]&1\[3ELYP&X) QFM_5]9@T>*
MU>52YN;A($ ('7)9C[*JLQ]EK'\316^O02^%X=BPOL:_E& L$60VW_?;' [
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M-7OM'MYK]2I\ULC<1TW '#=!U!Z5T%% 7"BBB@04444 %%%% !1110 4444
M%8ECX1T'3=1>_M-/6.X>1I2?,=E#MU8*3M4G)Y '6MNB@"K9Z?:6#7+6L(C:
MYF,\QR27<@ DY]@!^%0V^B:?::I<:G#"RWER )I?-<[P.@()QQGCT[5H44 <
MM=?#?PA>W4MS<Z)#-/*Q>21W<EB>I)W5MVVCV%G!<PVUN(H[GF4(Q!;Y @YS
MD855 QTQ5ZBBP[LY6W^&W@^UNHKF'0K=9HG$B-N8X8'(/)]:U+[PSHVI7WVR
M\L(Y9B%#DDA9 IRN]0</@]-P.*UJ*+!=G/ZOX(\.:_??;=5TN.ZN-H3?([<
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M2/&DB,Z?>4,"5^H[4^CF8<D2I]B;^_1]B;^_5NBCF8<D2I]B;^_4<MFWEO\
M-_#5^F2_ZM_]VCF8<D3D/A_:,_@C36W<%6_]#:NG^Q-_?K#^'G_(BZ9_NO\
M^AM3_%'B:\T/4-&L+#2EU"ZU29XD5[GR0FQ-Y.=ISP#1S,.2)L_8F_OT?8F_
MOUSDGQ!T^/QBGALV6HFY*G)%I*2#O50P&W!C.2=^<#;[T#X@Z>?&7_"-BRU'
M[5CD_9)<@^9LW8VX\OOYF<8HYF'(CH_L3?WZ/L3?WZQM \37FJ^)-;T6^TI;
M*73/*976Y\T3))N*G[HV\+TYZUTE',PY(E3[$W]^C[$W]^K=%',PY(E3[$W]
M^N7\7VI6\\-9;KJT8_\ '6KLZY7QG_Q]^&O^PO%_Z"U',PY(F_\ 8F_OT?8F
M_OU;HHYF')$J?8F_OT?8F_OU;HHYF')$J?8F_OT?8F_OU;KF;SQ3>0^.X_#E
MMI'VB(6(OKBZ^T;3&A=DP(]I+'*CH1UHYF')$V_L3?WZ/L3?WZYC2/B/IVLW
M^IVMOI^J%K %F LI2W$88JRE1M?.Y0N225XZTS2_B$OB"TU1M#TFYNKJQ=U6
M.8/!&^TJ"#(R81\,3LP3Q1S,.1'5?8F_OT?8F_OU2\*Z[_PDWA?3]:^S?9OM
MD7F>3OW[.2,9P,]/2MBCF8<D2I]B;^_1]B;^_5NBCF8<D2I]B;^_1]B;^_5N
MBCF8<D2I]B;^_1]B;^_5NBCF8<D2I]B;^_1]B;^_5NBCF8<D2I]B;^_1]B;^
M_5NBCF8<D2I]B;^_1]B;^_5NBCF8<D2I]B;^_1]B;^_5NBCF8<D2I]B;^_1]
MB;^_5NBCF8<D2I]B;^_7+ZW:E?'7A52WWC=X_P"_5=G7*Z]_R/OA/ZW?_HJC
MF8<D3?\ L3?WZ/L3?WZMT4<S#DB5/L3?WZ/L3?WZY^7Q1J7_  G5WH=MIL4U
ME9627=Q,)3YQW!]JHF,,<KCDCK530OB-!KDNKI!HVJM_9[-PEO\ ,0JK\I!(
MQ)N+@+R/D/-',PY$=7]B;^_1]B;^_7&Z;\0[CQ!H.JWVB:0[S6+2%3=EHH71
M6Z;L$[RF&VXQR.:ZGPUJS:]X8TS5WA$+7MLDYC5LA2P!QGO1S,.2)9^Q-_?H
M^Q-_?JW11S,.2)4^Q-_?H^Q-_?JW11S,.2)4^Q-_?H^Q-_?JW11S,.2)4^Q-
M_?H^Q-_?JW11S,.2)4^Q-_?H^Q-_?JW11S,.2)4^Q-_?H^Q-_?JW11S,.2)4
M^Q-_?H^Q-_?JW11S,.2)4^Q-_?H^Q-_?JW11S,.2)4^Q-_?H^Q-_?JW11S,.
M2)4^Q-_?H^Q-_?JW11S,.2)4^Q-_?H^Q-_?JW11S,.2)4^Q-_?H^Q-_?JW11
MS,.2)4^Q-_?H^Q-_?JW11S,.2)4^Q-_?H^Q-_?JW11S,.2)4^Q-_?H%F0>6J
MW11S,.2)R.G6A/C[7%W=+&S_ /0IJZ/[$W]^L73/^2@:[_UX67_H4]=+1S!R
M1*GV)O[]'V)O[]6Z*.9AR1*GV)O[]'V)O[]6Z*.9AR1*GV)O[]'V)O[]6Z*.
M9AR1*GV)O[]'V)O[]9R>,O#KW2VZZQ:F1IA;I\_RO(3C8K=&;/& 2:W*.9AR
M1*GV)O[]'V)O[]6Z*.9AR1*GV)O[]'V)O[].N-1L[2ZM;6XN8XY[MF2WC9L&
M0A2Q ^@!-0:KKNFZ(;0:C=" W<ZV\ *DEY&. HP#W-',PY(DOV)O[]'V)O[]
M6Z*.9AR1*GV)O[]'V)O[]6Z*.9AR1*GV)O[]'V)O[]6Z*.9AR1*GV)O[]'V)
MO[]6Z*.9AR1*GV)O[]'V)O[]6Z*.9AR1*GV)O[]'V)O[]6Z*.9AR1*GV)O[]
M'V)O[]6Z*.9AR1*GV)O[]'V)O[]&I:I8:/9/>:E>06ELGWI9I B_3)[^U)>:
MM8:=I;:G>W<5O9*@=IY6VJ >G)]<BCF8<D1?L3?WZ/L3?WZKZ)XBTCQ):-=:
M-J$%["C;&:)L[3Z$=1^-+/XATBU2^DN=0@@CL'$=S)*VQ8V*APN3P3M8' ]:
M.9AR1)_L3?WZ/L3?WZGAN(KBVCN8G#0R()%?L5(R#^596C>+= \0W$MOI&K6
MU[+$NZ187W%1G&:.9AR1+WV)O[]'V)O[]4-2\7:!HZW3:CJD%J+618IC*2,.
MR[@H]3M.<#/%6['7-+U+2/[6L[^WFT_:7-PL@V #J2>V,<YZ4<S#DB2?8F_O
MT?8F_OU7TKQ#I.M"4Z=?1S&(!G7E2JGHV" =IP<'H>U5M)\9>&]=U"6PTK6K
M.[NH@2T44F3@=2/4>XS1S,.2)H_8F_OT?8F_OTTZQIHU==)^W0'4"AD^S!P9
M HQR1U Y'6KM',PY(E3[$W]^F363>3)\_P#"?Y5>IDW^HD_W3_*CF;&H(Y?X
M:QF+X>:*A/(A/'_ F_\ K5UE<S\/A_Q0>C_]<?ZFNFI%!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52UC_D
M"7__ %[R?^@FKM4M8_Y E_\ ]>\G_H)H S_!/_(A>'?^P9;?^BEK=K"\$_\
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M<HMHLP_N\DX"X.0*.4.9'K@Z4M<%_8/B?G_BM[_KT%G#_A1_8/B?_H=]0_\
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M?%>E>(+>30S+XLNYR^IQ)&TEM$/+8AOF&!V]^*.4.9'K]%<%_8/B?_H=[_\
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M_87B?_H=]0_\ X?\*/["\3_]#OJ'_@'#_A1RL.='>T5P7]A>)_\ H=]0_P#
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M0SD0@EP(XA%T;/ .>I/X5#!X)U8Z%IOA*:*(:38:C]H-YYH)E@5V=4"]0Y)
M)Z#&>:T-3/C&;Q&UU'X>LKJRMC_H4<NH!,-R#(RA3EO3^Z,]SFBP=3MH=YMX
MS, )"HW@=,XYKF/$/_([>$/^NEU_Z)-='8&[.G6QOQ$+PQ+YXBSL#X^;;GMG
M-<YXA_Y'?PA_UTNO_1)H$=8>II*4]324T(****=A6"BFR"0Q.(F59"#M9EW
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MCN)F8C=O@DB$8[EBRC!]NI_4"0Q]QKVEVMSY$]Y&CB18F)!V*YQA&;&T,<C
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MO;LL4<<98LXEQM;<-I !))^E>PT44DK W<****8@IDO^J?\ W:?3)?\ 5/\
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M=JO_ $-^I_\ ?J+_ .)H_P"$.U7_ *&_4_\ OU%_\31SA[.1LT5C?\(=JO\
MT.&I_P#?J+_XFC_A#M5_Z'#4_P#OU%_\31SA[.1LT5C?\(=JO_0WZG_WZB_^
M)H_X0[5?^AOU/_OU%_\ $T<X>SD;-%8W_"':K_T-^I_]^HO_ (FC_A#M5_Z'
M#4_^_47_ ,31SA[.1LURGB'_ )'?PA_UTNO_ $2:TAX.U0'/_"7ZF?;RHO\
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MK7_"':K_ -#?J?\ WZB_^)H4ANF^ALT5C?\ "':K_P!#AJ?_ 'ZB_P#B:/\
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MVJ_]#AJ?_?J+_P")I<P^21D6VE:OHVKZ\]O9I>6VK,+B,B91Y$VP(RONP2G
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M+K2_X0[5?^APU/\ []1?_$U4N?A_=W5[:7DOBK4GGM"QA8Q1_*6&#CY?2DY
MJ;ZG25#=0O<6LL,<[V[NI42Q@%D]QD$9^HK,_P"$.U3_ *'#4_\ OU%_\31_
MPAVJ_P#0WZG_ -^HO_B:%('3?0FBT6*/PV-$\YVA%M]FWLJ[BFW;R,8SCVI/
M#VBCP_HMOI:7EQ=0VRA(GN-N\*.BY4#('2HO^$.U7_H<-3_[]1?_ !-'_"':
MK_T-^I_]^HO_ (FGS!R2)-)\/6&BWVJ7=FA674KC[1-_O8 P/;.YOJQJQ>Z<
ME]<V,LCL%M)C.L8Z.VQE&?IN)^H'I5/_ (0[5?\ H;]3_P"_47_Q-'_"':K_
M -#?J?\ WZB_^)HY@Y)%S4;%]1@-N;N6"!QMD$/RNP[@-_"#[<^A%5[SP]87
M6DVVG1Q_9HK1XY+4P  P.ARI7MQ[]02#UJ/_ (0[5?\ H<-3_P"_47_Q-'_"
M':K_ -#AJ?\ WZB_^)HY@Y)$MEHPL9;Z[2<R:A>E3-<2(#]T850HQA0,X'J2
M3G-2:=H]OIT]S=!GGO+H@SW,I!=\?='  "CL  .O<DU6_P"$.U7_ *&_4_\
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M]#AJ?_?J+_XFCG#V<C9HK&_X0[5?^APU/_OU%_\ $T?\(=JO_0WZG_WZB_\
MB:.</9R-FBL;_A#M5_Z&_4_^_47_ ,31_P (=JO_ $-^I_\ ?J+_ .)HYP]G
M(V:*QO\ A#M5_P"AOU/_ +]1?_$T?\(=JO\ T.&I_P#?J+_XFCG#V<C9HK&_
MX0[5?^AOU/\ []1?_$T?\(=JO_0X:G_WZB_^)HYP]G(V:*QO^$.U7_H<-3_[
M]1?_ !-'_"':K_T-^I_]^HO_ (FCG#V<C9HK&_X0[5?^AOU/_OU%_P#$T?\
M"':K_P!#?J?_ 'ZB_P#B:.</9R-FBL;_ (0[5?\ H<-3_P"_47_Q-'_"':K_
M -#AJ?\ WZB_^)HYP]G(V:*QO^$.U7_H;]3_ ._47_Q-'_"':K_T-^I_]^HO
M_B:.</9R-FBL;_A#M5_Z&_4_^_47_P 31_PAVJ_]#AJ?_?J+_P")HYP]G(V:
M*QO^$.U7_H<-3_[]1?\ Q-'_  AVJ_\ 0WZG_P!^HO\ XFCG#V<C9HK&_P"$
M.U7_ *'#4_\ OU%_\31_PAVJ_P#0WZG_ -^HO_B:.</9R-FBL;_A#M5_Z&_4
M_P#OU%_\31_PAVJ_]#AJ?_?J+_XFCG#V<C9HK&_X0[5?^APU/_OU%_\ $T?\
M(=JO_0X:G_WZB_\ B:.</9R-FF2_ZE_]TUD_\(=JO_0X:G_WZB_^)I#X-U0@
M@^+]3(/;RHO_ (FAR&J;ZB_"_P#Y)OH?_7%O_0S77UE>'=%B\/:%::5!+)+%
M;(4#R<$\D\XX[UJUF:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>modificationno7effective001.jpg
<TEXT>
begin 644 modificationno7effective001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M2_.N\B7RHC/.)6PHXP#D\?+D],8&A!>7ESJ.FVB^+&GL[I+V1;FU6, HOEE
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MZY&?3CJ?"VK_ &ZWN8[EV2X2Z:$(\ZRJQ"(Q\IP!YB8.<D9!)!Z4 =%1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5!;6D5G 8+<&.+)*J.B9YP/09[=OIQ4]% $-M:PV
M< AA7:N2QYR2Q.22>Y)))/O4U%% !1110 4444 %%%% !1110 4444 0FUB-
MX+H+MFV;&8?Q+U /K@DD>F3ZG+IX5N('A<L$<;6VG!(/49[5)10 R**."%(H
MD6.-%"HBC 4#@ #L*?110 4444 %58;%(;R:Z,DLDDG \QLB->/E4=@2,_\
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MT G_ / ZX_\ CE'_  I?P!_T G_\#KC_ ..4 =[0 !T%<%_PI?P!_P! )_\
MP.N/_CE'_"E_ '_0"?\ \#KC_P".4 =[17!?\*7\ ?\ 0"?_ ,#KC_XY1_PI
M?P!_T G_ / ZX_\ CE '>T5P7_"E_ '_ $ G_P# ZX_^.4?\*7\ ?] )_P#P
M.N/_ (Y0!WM%<%_PI?P!_P! )_\ P.N/_CE'_"E_ '_0"?\ \#KC_P".4 =[
M17!?\*7\ ?\ 0"?_ ,#KC_XY1_PI?P!_T G_ / ZX_\ CE '>T5P7_"E_ '_
M $ G_P# ZX_^.4?\*7\ ?] )_P#P.N/_ (Y0!WM%<%_PI?P!_P! )_\ P.N/
M_CE'_"E_ '_0"?\ \#KC_P".4 =[17!?\*7\ ?\ 0"?_ ,#KC_XY1_PI?P!_
MT G_ / ZX_\ CE '>T5P7_"E_ '_ $ G_P# ZX_^.4?\*7\ ?] )_P#P.N/_
M (Y0!WM%<%_PI?P!_P! )_\ P.N/_CE'_"E_ '_0"?\ \#KC_P".4 =[17!?
M\*7\ ?\ 0"?_ ,#KC_XY1_PI?P!_T G_ / ZX_\ CE '>T5P7_"E_ '_ $ G
M_P# ZX_^.4?\*7\ ?] )_P#P.N/_ (Y0!WM%<%_PI?P!_P! )_\ P.N/_CE'
M_"E_ '_0"?\ \#KC_P".4 =[17!?\*7\ ?\ 0"?_ ,#KC_XY1_PI?P!_T G_
M / ZX_\ CE '>T5P7_"E_ '_ $ G_P# ZX_^.4?\*7\ ?] )_P#P.N/_ (Y0
M!WM%<%_PI?P!_P! )_\ P.N/_CE'_"E_ '_0"?\ \#KC_P".4 =[17!?\*7\
M ?\ 0"?_ ,#KC_XY1_PI?P!_T G_ / ZX_\ CE '>T5P7_"E_ '_ $ G_P#
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MI?P!_P! )_\ P.N/_CE '>T5P7_"E_ '_0"?_P #KC_XY1_PI?P!_P! )_\
MP.N/_CE '>T5P7_"E_ '_0"?_P #KC_XY1_PI?P!_P! )_\ P.N/_CE '>T5
MP7_"E_ '_0"?_P #KC_XY1_PI?P!_P! )_\ P.N/_CE '>T5P7_"E_ '_0"?
M_P #KC_XY1_PI?P!_P! )_\ P.N/_CE '>T5P7_"E_ '_0"?_P #KC_XY1_P
MI?P!_P! )_\ P.N/_CE '>T5P7_"E_ '_0"?_P #KC_XY1_PI?P!_P! )_\
MP.N/_CE '>T5P7_"E_ '_0"?_P #KC_XY7*V/PZ\$V_@&WUJZ\/O>7+!5*B_
MGCWLTNP='P.H[4 >ST5XS-X(\"6:W\%WX,F34;58&2VBU6:03F9V2-5;>,'<
MISD<#GI5M_A]\/9XM,&E>&)+VXU&W-S"AU*XC5(@%RSMO..748 )R>G!P >M
MT5XU=^ _!=K)8V[>"GCO+DS!H[C6)HE7R]N2'WD,#N!!_D>*W[#X/^!;JQBG
MF\.B*1P24CU.XD4<]F#C- 'HU%>7:M\+_ =A<6EG:^%Y+N^N]YBA_M*X10J
M;G9BYPHRHX!.6'%9%QX*\!P"*W/@]UU$WOV*6WEU>9%1O):8-YF\@J57@XZG
M& 0: /:**\XT_P"$'@:[L8Y[CPX(9&SE(]4N)5'/&&#C-8$O@?P-#-<22>#9
M/[/@OQ8O<+JTY;>75 0A<9&6'0Y]C0![-17CT/@OX8N=::;P]/##I:M(9#?7
M!\^-2RLR 2<X>-UQ[#U%2?\ "MO"-O#+-J'@6XMH5MI+A&759Y,;%W;),/\
M(Q'3&X<'GID ]=HKQB'P/X&_LBYU6[\(I':P6AN<0:W-*Y& 0"N\8X/4G Q6
MIHGPO\#ZH)?.\*^2%572:'5IYX95;/W7#CD8Y&.XZYH ]3HK@O\ A2_@#_H!
M/_X'7'_QRC_A2_@#_H!/_P"!UQ_\<H [VBN"_P"%+^ /^@$__@=<?_'*/^%+
M^ /^@$__ ('7'_QR@#O:*X+_ (4OX _Z 3_^!UQ_\<H_X4OX _Z 3_\ @=<?
M_'* .]HK@O\ A2_@#_H!/_X'7'_QRC_A2_@#_H!/_P"!UQ_\<H [VBN"_P"%
M+^ /^@$__@=<?_'*/^%+^ /^@$__ ('7'_QR@#O:*RO#_AO2?"VG-I^C6IMK
M5I#*4,KR?,0 3ER3V'>M6@ HHHH **** "BBB@ HHHH **** "BBB@""]NX-
M/L;B]N7"06\;2R.?X549)_(5P_@[XC3>)M"UFZNM,%C?:?$+A;9G)WPO'YD3
MY_VAFMCQ[H>I>)?##Z+ITT<*WDT<=W*[$%+?=E]O!RQ Q@^IKF%^&NI:-KZW
MND:O<7UO=:;-I]XNI3+N5-G[K9L0# ;UZ#I0!GI\:)V^',GB$Z1$-26\%L++
MS3@J8_-WYQG&S)_"M"X^)&L2:S;Z?8V>BQ&32[>_>34;XP#,@^ZIVG.*P$^#
MNLJZDW%IL_L!K5HO,.TWOD- &^[]W8W7K[5I7'P_UR+7K6_71/#VL1)I%M8M
M%J3DA)(Q\S*-A_.@#5U7XF2^'-2\-6VLVMGY&J([7-U:3F2*WPP56#8&5^9<
MGC&:35_B1?V4.J?9-,MI9[76XM)A$DI57WJ"&) XY-22>![K6=2T:35M.TRV
ML(=-NK*ZLK-R43S"-GE_*.,#.>,'I7-VOPN\3Z?X8N;!+NSO+Q==@O[>2>5E
M$D42@+O.TD,0!Z_6@#I7\?ZOI4NL:?K^C6UMJ=GI4NIVWV>Y,D-RB Y7)4%2
M"/3I^N'=_&B>W^'UGKJ:1$^IS7DEM)9&4[4"*79LXS]W8?\ @5:=YX-\2^(K
MK6-6ULZ;;WLNC3:98VMK([HID!R[NR@YS@<#I7.W7P=UF634"EQ:>5+I"06\
M)D.U+LQQ1R/]WH5B//7GI0!T=[\0]9/BG4-'L+70XTLX;>4R:E?F OYL8;"_
M*<XY_2K&H_$I]!\3^'M(U>UMEAU.U66:[MYB\<+LVU<''*$X&XXZUE7W@36U
M\8ZGJR:!X<UFWO(+:.-=3<[HC'&%; \ML9/\A6K<^ Y]>UBVEUBSL(-/;07T
MV>UM7)$3F167R_E'"A1@\8('% "S^-O$$^E>(+_2]*T^5-%U"ZMIQ<7#(6CA
M16#+A3ECD\>PK;\%:UKGB#1HM4U:PL;2"ZABGM!;3M(S*XR=X*C!'R],]ZY[
MPEX&UO1/A_XFT/4+N"ZO]2ENFBG#DA_,B5%9R1D$D9/7\:[#PKID^C>$M'TN
MZ*&XL[.*"0H<KN5 #@^F10!RC>-_$NJS:K=>&= L[O2M+G>W>2YNC'+=.GWQ
M$ I QT!/7]*J3_%"[O[S18O#]GIS1:GIQOO,U*Z, 3:Y1DR <D$?H:?#X;\:
M>&3K&F^'/[)N--U&YEN8)KN5TDM&D^\"H4AP#R/UJ+3?A/;6>L:#'>P66I:3
MINDO:R+<H&+SM)O+A"",<MWR,T =S9:C>+X9_M+4H(#<I"\SQ6,AE1@,D!&(
M&[( _$UQW@_XA:QXFO;&0Z;I<NG7BLS&QO\ S9[' R//0@8STXKNFL!!HSZ?
MI933]L!BMFBB7; <84A>G!P<=.*\ST[P#XAN/%&B:CJ>GZ#83:=*9+K4M.)6
M6_\ E(PR!5 W9^;/X>E %Y?B'XCOM'N_$^D^';6?PU;-(0TEV5N9XHR0\B+M
MV@<'@G/%;^C^-8];\6QZ5:P V4VC1:I%<%OF(=\!2O;CWKEH/"'C;1_#%WX,
MTI](DT:;S8H+^>1Q-!!(264H!AF&YL'.*LIX/\2>&O%-I?\ AN#3;RT@T2'2
M\7MPT3?(Q.[Y5/7C\S0!M:MX\CT3Q/JVGWEN!9:=I U)IE.78[RNP#IVX]S4
M6B>)?%]W>Z;+J7A>"+2]27<LEK=&26U!&5,H( Y]NGZ5G7O@75O$FLZK>:U]
MDM4U+0AI[BVD:3RYA(6!&0,J.#^E7=$L?B +S2;34KC2K33=/7;<2VC&22^
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M2L V$4VTZ@GCIN91^- '>T5SW_"=>&/^@Q;_ )-_A1_PG7AC_H,6_P"3?X4
M=#17/?\ "=>&/^@Q;_DW^%'_  G7AC_H,6_Y-_A0!T-%<]_PG7AC_H,6_P"3
M?X4?\)UX8_Z#%O\ DW^% '0T5SW_  G7AC_H,6_Y-_A1_P )UX8_Z#%O^3?X
M4 =#17/?\)UX8_Z#%O\ DW^%'_"=>&/^@Q;_ )-_A0!T-%<]_P )UX8_Z#%O
M^3?X4?\ "=>&/^@Q;_DW^% '0T5SW_"=>&/^@Q;_ )-_A1_PG7AC_H,6_P"3
M?X4 =#17/?\ "=>&/^@Q;_DW^%'_  G7AC_H,6_Y-_A0!T-%<]_PG7AC_H,6
M_P"3?X4?\)UX8_Z#%O\ DW^% '0T5SW_  G7AC_H,6_Y-_A1_P )UX8_Z#%O
M^3?X4 =#17/?\)UX8_Z#%O\ DW^%'_"=>&/^@Q;_ )-_A0!T-%<]_P )UX8_
MZ#%O^3?X4?\ "=>&/^@Q;_DW^% '0T5SW_"=>&/^@Q;_ )-_A1_PG7AC_H,6
M_P"3?X4 =#17/?\ "=>&/^@Q;_DW^%-/CSPL&"G6K8$]!SS^E '1T5SW_"=>
M&/\ H,6_Y-_A1_PG7AC_ *#%O^3?X4 =#7/>!O\ D2]-_P!QO_0C1_PG7AC_
M *#%O^3?X5A^$/&'A^R\*6%M<ZG%%,B$,C!@1\Q]J .]HKGO^$Z\,?\ 08M_
MR;_"C_A.O#'_ $&+?\F_PH M::]XFMZA:W-ZURB0PRIF-5"%C("!@9Q\HZDG
MWK7KA;3Q3ID.M37T_BC2Y(YHTC>)+*1#M0N1AC(>?GYX[5L_\)UX8_Z#%O\
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M"J %"-@!0.@/KF >"X)(A#=ZKJ-W!%;R6]O',T?[E7382&"!F.TX!8M^)YH
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M(Y(8,03V(SG%-LH9H/$LD"7]W/!#:!I4G<,"[O\ )C@8($;Y_P!X4 ;M%%%
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MR]S-\NTE&R-I*@*20>@Q@]>5O+/P7;WDEE#X,TN6Z6]-DBM;01JS"%)2=S#
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MQ,YD//X>@& ,51M?"/@:^C\RTT'0+A/[T-M$X_,#V-6/^$$\(_\ 0L:/_P"
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M4 >D[AZBC</45@?\()X1_P"A8T?_ , H_P#"C_A!/"/_ $+&C_\ @%'_ (4
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M1_\ P"C_ ,* -_</44;AZBL#_A!/"/\ T+&C_P#@%'_A1_P@GA'_ *%C1_\
MP"C_ ,* -_</44;AZBL#_A!/"/\ T+&C_P#@%'_A1_P@GA'_ *%C1_\ P"C_
M ,* -_</44;AZBL#_A!/"/\ T+&C_P#@%'_A1_P@GA'_ *%C1_\ P"C_ ,*
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MH:*S-,\1:3K,KQ:?>I.Z+N8*I&!^(K3H **** "BBB@ HHHH **** "BBB@
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M=L\;EM<1W5K%<0MNBE0.A]01D4 2T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!SW_-1?\ N$_^U:U)--236(=2,\XDBB:)8PPV;6()XQGDA>_\(K+_ .:B
M_P#<)_\ :M:]^+YHXTL&A1V?#RRJ6$:X)R%!&3G ZCKGG&" 4)?#=M-]K\RZ
MO";FX2Y)$NTI(F-I7 &.%48.<XY[YLVFE+;327$EW<W-RZ>7YTQ7*KUPH50H
MYYZ9/&<X%4X=8N(M&U>ZG$=R^G-* \*E%GV(&X&3@@DH>3RI^@6RU&ZAUJ'2
M[^[M+F6XM6N8V@C*;0K*"""S9!WC!]CUH MZ7I2Z5&\<=W<S(S%MLS*=I)+$
MC '4DU%#H-O'97=G)/<3PW3,[B5AE68DDJ0!@Y.<]B!BJ[:S<R>(X+2W2(V'
MF-!+(P)9I0A<A3G&%P >#DDCC:<U[G6[B+7+JV>_M;2W@DC4"6S=\AE4Y,@<
M*N22!D=N] &PFG :A#=R3O*8+?R8PX&02068D=2=J]N,'UINH:5'J$]O<>?<
M6]Q;[O*E@< KNQG(((;IT((_&K]9FNWUSIVGI<6JP%C<11-YY(4!W5,\>A8'
M\* (W\/P26,MN]U=%YIDGEN-X\QW4J5/3  VKP !Q]:E;0[.34#?.':Y:U-H
M[[L;T)!.0.,\=:K6E[JURS;!I\T3))LGA9BBR(X4JW_CW3^[5C1+^XOM"M]1
MOE@B,T2SXB)(52H/)/<<T 1VGA^&U:V5KR]G@M<&W@FD#+&0, YP&; Z;B?7
MJ :UZP!K.HI8IJ\UK NFN!(T>X^=%$?^6C=N <E>PSR2,%D?B"87DMG<FVBN
M9+F2WM% <@E1NRY[ AD_%@.XH Z*BN5'B+43:Z7._P#9UO'>63W;O,[!4V[3
MC_OEQ^1JY=:EK%MIGG-;6@G^V10#+-L='=4#COU?I[&@#>HK&@UBX234H+NW
MCDGL85G/V1B^\,&PN",AOD/'/4'//#=-U#5+N6UE*:?<65PI9IK28MY)QD#G
M[^>F1CZ4 ;=%%85SJ6JIJM]!"FGB"UACFW3R,F0V\8)P0N-AYP>M &[16*-9
MN+V+3TT^W59[RV%T3<9Q!'@?> Y+98 #(Z-SQR'5[F.QU'[0EO!>6"^9(6+&
M)H\;@X[X(##'8J1R.2 ;5%9.BZC>:AITGVNVCMM1A.R:$,616*AEYZD89?QR
M.U4[#6]2?3]-U"^MK46EZ(>8';=$9<!,@CYAN8#((QG.,9P =%1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 5=22]DT^9-.ECBNV $<D@R%YY/?G&<<$9QD'I5/1K.]L$\B6*TC@
M +$QR/)))(3RS,P&2><GDFM*>9;>!YG#E4&2(XV=OP502?P%5+'6;#4;"2]M
M9RUO$6#LR,A4@9.58 C@@].] %)M'FO-6%U=6]C!&DBN3 -TMQM.4WL5& "
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MM0TQ;>U@MIF^T0R.ES(40JDBN1PK9SMQT[_A5DZK9#53IAE(O/*,PC*,-R#
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MZ[/#A3[G!_(UT5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/?\U%_
M[A/_ +5H\371>2PTF!X!/=3J[+,Q52B'=C(!^\P5<=P31_S47_N$_P#M6NAH
M YC19HMVHZ3J#6Q:TN/M86)R412WF#DXY5P>.PV^M2^&[C3[Z"9XY8I9;>]N
M95(/*!Y7P?H5-=%10!R-KXETZSAUB6*YAFF-T[PPA\&7Y$ Q]2,53OKBYU*3
M5]5LI+%HK62-86EE967R6W>F &<L,YY7%=U10!Q]W<6VM:Y;2V-RBW9LEN+)
MGX^<,3@]\%=RL.N":N:#<6IT/^T[Z(VOEWETX^T#:T1:9P0?SQ7244 <CIFI
MV6G^!+75(C$]S#I\-OR?^6@08C/I\QY],U'I+2Z'JVFPW4UF8[VU6W#0R,S2
MNN65SD#[VZ3)[EEKLJ* ,NPUZVU+6M4TRWBG+Z:R)/,R@1EV4-M4YR2 1GCC
M(K4JO:6-K8B86T*Q^?,T\N.KNQY8_P">P%6* ,*^N(]-U]KR[D2&"6T$,5Q*
M/W<3AF+!C_#NRG<9V?2L:\UB:ZT>]M6GL6>^NQ:07$2-'',A1#(^[+= 60,,
M\J!7;44 <WHMS)9Z_?Z9=FU228+=11V[$A3@*Z\@8Z*WON-=)110!RVMW=G?
M7=JMM?2O>V]U'C3N0)"'&2Z$;L#E@W08!Y[V;C4+;1]=U"6^8HEQ;Q- <9,Q
M7>#&H_B;D':.3NX[UT%% &%:R0Z-X8TVSU.Y^QN+2.!I<X5&" 'Y\;5.>F>M
M4M/MKR7PUJ%MIDYD,EPP@O+ARCSQL5+N7 )SRZJP&/E4@8KJJ* .8\)SDWFM
MPF&S@2&XC54MIS(J@0HN.47@;,?4$=N9M%U;3[G7-5C@NXI'FG1HPK?? B0$
MCUZ'\JZ&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Y[_FHO\ W"?_ &K70USW_-1?^X3_ .U:Z&@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .>_P":B_\ <)_]JUT-<]_S47_N$_\ M6NA
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH RO$ 0:>)9=:N-)CC<;IX/+RV> OSHPY)& !DG%9EIHMQ?V
ML=U:>-M:F@D&5D3[(0>W_/#UJSXNL[F\TRV6WCG<1WD4LIML><B*<[H\\9!
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M6PC$,8<$I"$:!\GY?F!.3\OSGGK3I-)OVT'QE"-.$,EY:!+>"(Y4M]C5-B'
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M_0X:[_WS:_\ QBC_ (1K4/\ H<-=_P"^;7_XQ70T4 <]_P (UJ'_ $.&N_\
M?-K_ /&*/^$:U#_H<-=_[YM?_C%=#10!SW_"-:A_T.&N_P#?-K_\8H_X1K4/
M^APUW_OFU_\ C%=#10!SW_"-:A_T.&N_]\VO_P 8H_X1K4/^APUW_OFU_P#C
M%=#10!4TZREL;7R9M0NKY]Q;SKD)OQZ?(JC'X5;HHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!,#<#@9'&:6BB@ HHHH **** "BBB@
MI"JL02H)4Y!(Z&EHH **** "BBB@ HHHH **** "BBB@!" P((!!X(-+110
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M<?CU)H ]'BN[:=U2*XBD9HQ*H1P24/1A['UJ&XU73K4$W&H6L(#E#YDRKA@
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M_P"U:Z&@ KGO"'_'EJ?_ &%KS_T<U=#7/>$/^/+4_P#L+7G_ *.:@#H:***
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M\R.UFF9<1@#.YXPI^K5KVOBBXT2ZUYXY]8FM;/1WO8[;6XRDKRH3S'E0Q3&
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MKRO9V?BCQ/\ VAJ_B'36EU+S(DL;>5HY$\F(;\K$P)R".O:O5J* /.;O0_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5@;4KZX! R#D<^U9FDZCK5]I5CXBDOK86ETHF>Q,.-D3 E55\Y,@^7.>"<C
MH N?\)A:_P#0)U[_ ,%4W_Q-'_"86O\ T"=>_P#!5-_\36;;ZOK46E:/K]S>
M02V^HRVRR620@")9V54V/G)*EUR3D$ X JAI?C/5+JSL;6]\F'4;F[01R*GR
MS6SNR[E!_B4C:P^A_B% '0_\)A:_] G7O_!5-_\ $T?\)A:_] G7O_!5-_\
M$UA76J>(-/T_Q9=OJZS'1]R0J;1!O/V>.4,<>AD/'M4^F^*IX;[5'NKR:XTW
M3K)KBZDN;$VLL+C!50K8+!EWG..JCDYP #6_X3"U_P"@3KW_ (*IO_B:/^$P
MM?\ H$Z]_P""J;_XFN?TKQO>WV@R1"YT^;6!>6]J98&$D,8GVD-\IYVY=<9&
M6C[9K8U%/$%AI>I,-<A=K: W,,GV9?,.%;*.OW=N0N&&#U';- %C_A,+7_H$
MZ]_X*IO_ (FC_A,+7_H$Z]_X*IO_ (FLJZU_5=(T2WN9+E+V<V4E])NB$:XV
MHJ(<=!ODSGKA33?$&KZ[X6LWDFU"&^:>SNF0FV$?DS1PO*I !Y3Y",')SCF@
M#7_X3"U_Z!.O?^"J;_XFC_A,+7_H$Z]_X*IO_B:YB7Q;J\%KK#VMW+=?8M(F
MNY3>:>;9H)0N8L*V"ZMA^V/EZ]JN^(=;USPS!-')?Q7AFL9KB"7[,%>)XVC!
MRH.&!$GH"".^> #:_P"$PM?^@3KW_@JF_P#B:/\ A,+7_H$Z]_X*IO\ XFL2
M]UW5++1)KE;[4&<W=K &GT@QLJR2A6*)C+G!Z 'G'K6KX2UB\U:XU-9)WN;.
MV=(XIYK4V\OFX/F(T9Y&WY""0,[N^,T 3?\ "86O_0)U[_P53?\ Q-'_  F%
MK_T"=>_\%4W_ ,37/Z7XTU.:WM+>_6&.^GOT$3*ORSVK3%"0.S*?E/U4_P 5
M6H]<UG_A'[3Q2UW";2XDB8Z?Y  6&20* 'SGS &!]"01@=: -;_A,+7_ *!.
MO?\ @JF_^)H_X3"U_P"@3KW_ (*IO_B:Z&B@#GO^$PM?^@3KW_@JF_\ B:/^
M$PM?^@3KW_@JF_\ B:Z&B@#GO^$PM?\ H$Z]_P""J;_XFC_A,+7_ *!.O?\
M@JF_^)KH:* .>_X3"U_Z!.O?^"J;_P")H_X3"U_Z!.O?^"J;_P")KH:* .>_
MX3"U_P"@3KW_ (*IO_B:/^$PM?\ H$Z]_P""J;_XFNAHH Y[_A,+7_H$Z]_X
M*IO_ (FC_A,+7_H$Z]_X*IO_ (FNAHH Y[_A,+7_ *!.O?\ @JF_^)H_X3"U
M_P"@3KW_ (*IO_B:Z&B@#GO^$PM?^@3KW_@JF_\ B:/^$PM?^@3KW_@JF_\
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M@#G20/B)DG &D\G_ +:UAV^HQ&\@1M7G_L'[:?)U W;;I9NT!;=_J\Y ;HV
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MGRUCXYX^5%''I3=1\.Z;JMXEU=0,TJHL9*NRAT#K(%8 _, R@X/J1T)SJ44
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M)).<Y(Y/!XZ>@IB>%-*2Z68)/Y:3?:$MC<.8%ESNW"/.W.[G&, \@9YK;HH
MB@@6WB\M7D8;F;,CESR2>IYQSP.PP!P*EHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y[_ )J+
M_P!PG_VK70USW_-1?^X3_P"U:Z&@ KGO"'_'EJ?_ &%KS_T<U=#7/>$/^/+4
M_P#L+7G_ *.:@#H:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX3?0O^>UY_X+KC_XBC_A-]"_Y[7G_@NN/_B* .AHKGO^$WT+_GM>?^"ZX_\
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M3!!KLZ* .>T"V8ZMJ-^%"V_E06$&U=H=8=Y+ =AND91_N<<$5T-%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 9/B#4[C3;2W6S6,W5W<QVL)E!*(6/+, 02  3C(R<#(SFLZ
M]U#7]*CCMIY-/N;B\NH[:SN%B9%4L&9S)'N.=H0D88;L@<=3MZGIEMJUD;6Y
M#[=RNKQL5>-U(964CH00#6:/"5@\-P+F>\NKF=HV:[EEQ,IC),>TJ %VDD@
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M2:VA\B."))L!V(9F8X!.!RH'T/;!(!-IFI37TUY%/9FU>WD5=K2!R05# G'
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MZ*F5OL]J=VT8''E<<59_L#6O^AQU/_P%M?\ XU0!T-%<]_8&M?\ 0XZG_P"
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MNDCL+%VM1)]W<H4LWJ=@8"M77I-2T%K. ^)]=O;V]=DMK2TL[-I)-HRQ^:,
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M7_0XZG_X"VO_ ,:H_L#6O^AQU/\ \!;7_P"-4 =#17/?V!K7_0XZG_X"VO\
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M>?\ 0VZ]^=O_ /&:/^$8O/\ H;=>_.W_ /C- '0T5SW_  C%Y_T-NO?G;_\
MQFC_ (1B\_Z&W7OSM_\ XS0!T-%<]_PC%Y_T-NO?G;__ !FC_A&+S_H;=>_.
MW_\ C- '0T5SW_",7G_0VZ]^=O\ _&:/^$8O/^AMU[\[?_XS0!T-%<]_PC%Y
M_P!#;KWYV_\ \9H_X1B\_P"AMU[\[?\ ^,T =#17/?\ ",7G_0VZ]^=O_P#&
M:/\ A&+S_H;=>_.W_P#C- '0T5SW_",7G_0VZ]^=O_\ &:/^$8O/^AMU[\[?
M_P",T =#17/?\(Q>?]#;KWYV_P#\9H_X1B\_Z&W7OSM__C- '0T5SW_",7G_
M $-NO?G;_P#QFC_A&+S_ *&W7OSM_P#XS0!T-%<]_P (Q>?]#;KWYV__ ,9H
M_P"$8O/^AMU[\[?_ .,T =#17/?\(Q>?]#;KWYV__P 9H_X1B\_Z&W7OSM__
M (S0!T-%<]_PC%Y_T-NO?G;_ /QFC_A&+S_H;=>_.W_^,T =#17/?\(Q>?\
M0VZ]^=O_ /&:/^$8O/\ H;=>_.W_ /C- '0T5SW_  C%Y_T-NO?G;_\ QFC_
M (1B\_Z&W7OSM_\ XS0!T-%<]_PC%Y_T-NO?G;__ !FC_A&+S_H;=>_.W_\
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M@B^%]YIB7:Z7J<&W^U;:_LDN49A"D(.V(X.2!G YZ 5UG_",7G_0VZ]^=O\
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MC%Y_T-NO?G;_ /QF@#H:*Y[_ (1B\_Z&W7OSM_\ XS1_PC%Y_P!#;KWYV_\
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M*F>:QLTA=EV9!)VKG.U03A5SS@8%4-3\&Z1J%K>QK;K#)=JZN_+!=[!G(4G
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MOG:1!'<7\%M/9HMV64B9B )&V#;MQDX#9Z"NFT_1=/TN.6.TM]@E #EG9V8
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M9)&<"ETOQ/<7U[9"6QBBL]0,PM9%G+2?N\_?7: ,@$\$XZ&MN[TZTO[$V5U
MLEL=O[LY_A(*D8Z$$ @^U0VNA:997SWMM9QQW#[LN,\;CEL#HNX\G&,GDT <
MK<:[XA/BF2RMEM6C75C;1(\I4&/[%YI#$(3PQ#<9.3C@#-)'\0YIV@,&C32
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M J.)%&!UPXW#WSZF@#G(_'5Z+:VFGTF!?MUN);-4NB<L9HH0)#L&T;ID.1G
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MK'*R1QHTKK\S["&!]OF&[ [\U8;POH;23NVF6Y:<,'RO'S,&; _A)8!B1C)
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M?-QFXWL((^G_ "T5&;/;C@YJJGCF_L_M=N+&6_FMI;N:0K'(Q,:W4T:(NQ&
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M8MXS'<L6G4KD2$C!W#OD "L__A%=#^S>1_9L.P/Y@/.[=MV_>SG[O'7IQTH
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M:ZD*QQ2$%U4;OE!('3D8'I0!5B\5SFYGM(=/FO+R-YF>(.B"../8" Q^\<N
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M>:I']FNHK:R\J&V^RH[P1,HF9UW %W.3GH1CG%7X;[6[SQ1JT!N-;^SVM]'
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M,,+Y?11DEQ]##!XNU.'4+.Y:[-YI-O;2?VCOM?)D7;.T1E*XR"A7YATQN('
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M07,HD 8Y9?,#;B">Q..!Z4V;PGHDS0M]C,1AA6WC^SS20@1J257",. 2?SH
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MM(L'NS=M;*9S,LY?)SO5"@;\%)%.M=,LK&XN[BUMHXI;R02W#(,>8^ N3[X
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MPJ2VX8;/'<=?7O3[/1-+T_;]DT^W@*%BI2, @L #S[A5'T ]* ,L^(Y[C0M
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M;:?;17<F[=,D0#'<<MS[D9/J>: +]%%% !1110 4444 %%%% !1110 4444
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M5) YKT.UD62W3#AF"@-SD@X!Y]^1^=<M)X1U.6W@MY-4TMX+?_4QMHL96/\
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M7B?_ *&>W_\ !8/_ (N@#H:*Y[^RO$__ $,]O_X+!_\ %T?V5XG_ .AGM_\
MP6#_ .+H Z&BN>_LKQ/_ -#/;_\ @L'_ ,71_97B?_H9[?\ \%@_^+H Z&BN
M>_LKQ/\ ]#/;_P#@L'_Q=']E>)_^AGM__!8/_BZ .AHKGO[*\3_]#/;_ /@L
M'_Q=']E>)_\ H9[?_P %@_\ BZ .AHKGO[*\3_\ 0SV__@L'_P 71_97B?\
MZ&>W_P#!8/\ XN@#H:*J:=!>V]KLO[U+R;<3YB0^4,>F,FK= !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO)#,MA#)=103O=J;83)O22159MI7(SP&(Y&"H/;%4QXID  'AK70!V^S)_\
M%U#=:]%?0^3=^$M8N(LYV2V<;C/T+T (UXVG1Z],MG:P:C'%'+--"Q>-L@A7
M88!!4*21Z;>>>-"&TFM-0LW_ +>FE27<&@N/+/GG:3E<*"".N!QCM6?::Y!8
M0>19^$=7MX<D^7#9QHN3U. ]16NI6%C(\EGX)U*W=QM9H;")"P]"0U #;!+N
MQTY+]=0G;=JKQ?9R%\K8]V4(QC.1NSG.<CTXHEN]8OM0U(0_;HS:S&*-8)(
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M5)_T+>O?^ Z?_%T =#17/?\ "52?]"WKW_@.G_Q='_"52?\ 0MZ]_P" Z?\
MQ= '0T5SW_"52?\ 0MZ]_P" Z?\ Q='_  E4G_0MZ]_X#I_\70!T-%<]_P )
M5)_T+>O?^ Z?_%T?\)5)_P!"WKW_ (#I_P#%T =#17/?\)5)_P!"WKW_ (#I
M_P#%T?\ "52?]"WKW_@.G_Q= '0T5SW_  E4G_0MZ]_X#I_\71_PE4G_ $+>
MO?\ @.G_ ,70!T-%<]_PE4G_ $+>O?\ @.G_ ,71_P )5)_T+>O?^ Z?_%T
M=#17/?\ "52?]"WKW_@.G_Q='_"52?\ 0MZ]_P" Z?\ Q= '0T5SW_"52?\
M0MZ]_P" Z?\ Q='_  E4G_0MZ]_X#I_\70!T-%<]_P )5)_T+>O?^ Z?_%T?
M\)5)_P!"WKW_ (#I_P#%T =#17/?\)5)_P!"WKW_ (#I_P#%T?\ "52?]"WK
MW_@.G_Q= '0T5SW_  E4G_0MZ]_X#I_\71_PE4G_ $+>O?\ @.G_ ,70!T-%
M<]_PE4G_ $+>O?\ @.G_ ,71_P )5)_T+>O?^ Z?_%T =#17/?\ "52?]"WK
MW_@.G_Q='_"52?\ 0MZ]_P" Z?\ Q= '0T5SW_"52?\ 0MZ]_P" Z?\ Q='_
M  E4G_0MZ]_X#I_\70!T-%<]_P )5)_T+>O?^ Z?_%T?\)5)_P!"WKW_ (#I
M_P#%T =#17/?\)5)_P!"WKW_ (#I_P#%T?\ "52?]"WKW_@.G_Q= '0T5SW_
M  E4G_0MZ]_X#I_\71_PE4G_ $+>O?\ @.G_ ,70!T-%<]_PE4G_ $+>O?\
M@.G_ ,71_P )5)_T+>O?^ Z?_%T =#17/?\ "52?]"WKW_@.G_Q='_"52?\
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MT?\ "52?]"WKW_@.G_Q= '0T5SW_  E4G_0MZ]_X#I_\71_PE4G_ $+>O?\
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M-%5-.OFU"U\]K.ZM#N*^7=(%?ZX!/%6Z "BBB@ HHHH **** "BBB@ HHHH
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M RO@?*").",\U5O_  +J_B2_N-2UFWL(S=W=D)+&.9I$%M"S%MS[1N9MYXP
M!CF@#OK35;.]O+^U@EW2V,BQW *D!69 XY/7Y6!XK'T_QYX?U.^BM;:YGS.7
M%M-);2)#<%<EA'(RA7Q@]#SCC-9O@WP9?Z#:>(+'4;T7,-[,%MY@V9/(6)8T
MW<?>"J![XS6?8^$O$DMIX=T745TV+3M!E65+N"9FDNO+1DC&PJ G#9;D].*
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M00$DVD[EVKDE?FYZ5C/\,;[4Y()M3GMXYIKB^O9VMF;_ $6>;RO*,1(!.PQ
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MS2F9G8NPW= Q.><\#  % 'HM%%% !1110 4444 %%%% !1110 4444 %%%%
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MS3/_  +C_P :/^$GT#_H.:9_X%Q_XT :M%97_"3Z!_T'-,_\"X_\:/\ A)]
M_P"@YIG_ (%Q_P"- &K165_PD^@?]!S3/_ N/_&C_A)] _Z#FF?^!<?^- &K
M165_PD^@?]!S3/\ P+C_ ,:/^$GT#_H.:9_X%Q_XT :M%97_  D^@?\ 0<TS
M_P "X_\ &C_A)] _Z#FF?^!<?^- &K165_PD^@?]!S3/_ N/_&C_ (2?0/\
MH.:9_P"!<?\ C0!JT5E?\)/H'_0<TS_P+C_QH_X2?0/^@YIG_@7'_C0!JT5E
M?\)/H'_0<TS_ ,"X_P#&C_A)] _Z#FF?^!<?^- &K165_P )/H'_ $'-,_\
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M?]!S3/\ P+C_ ,:/^$GT#_H.:9_X%Q_XT :M%97_  D^@?\ 0<TS_P "X_\
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M &K165_PD^@?]!S3/_ N/_&C_A)] _Z#FF?^!<?^- &K165_PD^@?]!S3/\
MP+C_ ,:/^$GT#_H.:9_X%Q_XT :M%97_  D^@?\ 0<TS_P "X_\ &C_A)] _
MZ#FF?^!<?^- &K165_PD^@?]!S3/_ N/_&C_ (2?0/\ H.:9_P"!<?\ C0!J
MT5E?\)/H'_0<TS_P+C_QH_X2?0/^@YIG_@7'_C0!JT5E?\)/H'_0<TS_ ,"X
M_P#&C_A)] _Z#FF?^!<?^- &K165_P )/H'_ $'-,_\  N/_ !H_X2?0/^@Y
MIG_@7'_C0!JT5E?\)/H'_0<TS_P+C_QH_P"$GT#_ *#FF?\ @7'_ (T :M%9
M7_"3Z!_T'-,_\"X_\:/^$GT#_H.:9_X%Q_XT :M%97_"3Z!_T'-,_P# N/\
MQH_X2?0/^@YIG_@7'_C0!JT5E?\ "3Z!_P!!S3/_  +C_P :/^$GT#_H.:9_
MX%Q_XT :M%97_"3Z!_T'-,_\"X_\:/\ A)] _P"@YIG_ (%Q_P"- &K165_P
MD^@?]!S3/_ N/_&C_A)] _Z#FF?^!<?^- &K165_PD^@?]!S3/\ P+C_ ,:/
M^$GT#_H.:9_X%Q_XT :M%97_  D^@?\ 0<TS_P "X_\ &C_A)] _Z#FF?^!<
M?^- &K165_PD^@?]!S3/_ N/_&C_ (2?0/\ H.:9_P"!<?\ C0!JT5E?\)/H
M'_0<TS_P+C_QH_X2?0/^@YIG_@7'_C0!JT5E?\)/H'_0<TS_ ,"X_P#&C_A)
M] _Z#FF?^!<?^- &K165_P )/H'_ $'-,_\  N/_ !H_X2?0/^@YIG_@7'_C
M0!JT5E?\)/H'_0<TS_P+C_QH_P"$GT#_ *#FF?\ @7'_ (T :M%06E[:7\/G
M6=U#<Q9V[X9 ZY],BIZ "BBB@ HHHH **** "BBB@ HHHH **** (YH(;F/R
MYXDE3.=KJ&'Y&JW]D:9_T#K3_ORO^%7:Y'7K.W?7KB;5M(GU.S>R2.T2.W,V
MR4-)Y@& ?+9@8\.<#Y>HQ0!T/]D:9_T#K3_OPO\ A1_9&F?] ZT_[\K_ (5Q
MK:3KC173+NCMVUNRF^R-"9'*+);%F\S=R!M8DX/W36=I>D7$>CW\$%@(M4>"
M904T=[>9LN21]I/RDE<@'CD@YXH ]#_LC3/^@?:?]^5_PH_LC3/^@=:?]^%_
MPKB[S3!=RVR^%]+GT<_:8B]TUDT:*?+F!/DG;DKN'SXP2RC+8Q6G]BNG\"-9
MPZ?-!=1R*+JW5B6G"RJ9MKDY?S%#X8G)W<X.< '0_P!D:9_T#[3_ +\K_A1_
M9&F?] ZT_P"_*_X5PU[H(U.\V:-876F:6TMMGRK=K<K,K.?-6,@8VC9EB,-P
M.0*I7&G:G=:E]HUG2US]MG\POICWL3$06Z!U1>0K%&(/;D'F@#L/%.E:<GA#
M6G2PM586$Y!$*@@^6WM5W3M)TTZ9:$Z?:$F%.?)7^Z/:J>L+&GPYU%8HQ&BZ
M5* BVY@ Q$>D9Y0>W:MG3?\ D%VG_7%/_010 S^R-,_Z!UI_WX7_  H_LC3/
M^@=:?]^%_P *Y_Q)XO&AZ]8V8:U%N%66^,K8=(WD$:%.?[Q9CU^5#ZUU,HD:
M%Q$ZI(5(1F7< >Q(R,CVR* *W]D:9_T#K3_OPO\ A1_9&F?] ZT_[\+_ (5R
M,GB#Q%8Z=X@OKJZTZ=-*G\A8XK"13(=L3;O]:W_/0C ';KVJ34O'$B7TL6GP
M2>7';Q2'[9930-N:=(S@.%R-K'IWQ]* .J_LC3/^@=:?]^%_PH_LC3/^@=:?
M]^%_PKFCXCU2+Q+]CNY+6TB:\\B*WN+251-&> Z7&2C.>NS&?X>O-:=_?ZG<
M>(#H^ERVMLT-JMU-/<0M+D.S*BJH9?[C$G/IQSD &E_9&F?] ZT_[\+_ (4?
MV1IG_0.M/^_"_P"%8$?BJYL=<DTW6K=A(EA!.?[/M)[D>8[S*W**<+B-2 0#
MR>3BLJ3X@S0:3X<NYOL2-=V45_J(8E=D3E%/E@G.<NS<Y^6-AU(H [3^R-,_
MZ!UI_P!^%_PH_LC3/^@=:?\ ?A?\*Y+4O&UYIM_XF@FMX%BLHG_LZ<@XDF2V
M6=HY.>IW9&,9"MW',]WXCU)TU*\@OM+L+.QF%NOVR%V\^78K'+!QL7+;1PQX
MS[4 =-_9&F?] ZT_[\+_ (4?V1IG_0.M/^_"_P"%<B?%>H7>NW=K;WUM!;Q&
M 1;-(N+P.'B1\^;&P4#+<9 XP:Z#6=1O8]2T_2M-:".YO!+(9YT+K'''MW84
M$;F)=0.1W/.,$ O?V1IG_0.M/^_"_P"%']D:9_T#K3_OPO\ A7'ZAXMU73[N
M/3+B:SBNDO\ [--=+92S(T9MVF5EB5]P;*[2-QQC/?A;#Q-KFJC3XK2>P1;N
MZFCBOGL9-D\21A@ZQ&0,OS%EY8YVY'!% '7_ -D:9_T#K3_OPO\ A1_9&F?]
M ZT_[\+_ (5QMWXOU:"Y@T]Y+6"ZCNY[6YGCT^:Y5]D:2*R1HVX961<Y)P<\
MFG:AXMOK">RBFU2T@ADLI;J6ZET>X_AD"C]UO#1@ \ECV[9H [#^R-,_Z!UI
M_P!^%_PH_LC3/^@=:?\ ?A?\*Q'U_4HO 7]MSVT<5\(PWELC*I^? ;:3N7*X
M;!.1G!Z55/B/5(O$WV.[DMK2)KSR(K>XM)5$T9X#I<9V%SU"8S_#UYH Z7^R
M-,_Z!UI_WX7_  H_LC3/^@=:?]^%_P *R-;UO4K/4;FSTZTCN94TU[J*,@EF
MD#A0.HR,$G'4XQFLN'Q-J\NF:@UK+;7]S;M!PFGS130J[$.7MF;>VT D8(W<
MCMR =7_9&F?] ZT_[\+_ (4?V1IG_0.M/^_"_P"%<UI?BB[N;O3K=KFRNUN-
M0DMI)(X)(751;O* T3G,;[EQ@YR.>,\5]5\7:E;ZG)9PO;P*NJM9B7[#+=,$
M%JDV=D; D[F(R. .U '6_P!D:9_T#K3_ +\+_A1_9&F?] ZT_P"_"_X5SB:K
MKMY?Z986>H6*M<VES<R3SZ5,F?+DB0*(FE5E_P!8>23G QUI\_B>\C\":CK!
MCMX[^Q,\,@(9HO,BD,98#(.T[<XSGG&: .@_LC3/^@=:?]^%_P */[(TS_H'
M6G_?A?\ "N0B\7:HL[(LUGJ%O]HLXA>0V<D" RSB-TPSMN8*=P(/'<=,V?$G
MBJ_TK5+JT@-O''']AVRR6[S%?.DF5R55@6P(UP!ZGK0!TW]D:9_T#K3_ +\+
M_A1_9&F?] ZT_P"_"_X5R-OXJUJZTJ_N+-(KV*"YCB2]@T^91M/$I\@L7<H1
MCY3SGI\I%7-'\3W=[?Z?:M<6-TD\UQ&\L,3Q-A$5@&C<YC?YB"ISQ@\9P #H
MO[(TS_H'6G_?A?\ "C^R-,_Z!UI_WX7_  KEM4\87MKIEW]G%D-0.IR65HL[
M%8R$&\ESG^ZK<Y')6G/XY_XFVDRQ11OH5[8I<2W'.^!I&VH6[;<_*?0D'H#0
M!T_]D:9_T#K3_OPO^%']D:9_T#K3_OPO^%<F==\175IHMU;7>F0IJ-VUJR26
M3R%"!*=P(E7/$8&,=SS6MXIO-:TK0A?6-W8B6$*)A-:,XD9F5<KB0;1R3@[N
MW- &M_9&F?\ 0.M/^_"_X4?V1IG_ $#K3_OPO^%8BWGB"ZU6;2;>]TY)K*".
M6XNGLG*R-(S[56/S?E "<DL<YXQ5_P .ZS-K-@)9[1H98R\4K*08S(DCQN$.
M<\&//('#+UYP 7/[(TS_ *!UI_WX7_"C^R-,_P"@=:?]^%_PK U'7]4-I=W>
MFP*;2&\^R>:+=IV14)$LOEJ07 <; HY^4MR.*+;Q:\-C;F:,:M-.D\\4FEJ
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MI_#>EW;:DUU;B<ZB-LQE )"[ FU?08R?J2:N6=H+" H;F>90%^:=P2H50O7
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MEV8M;?=Y?F22?,<G+NSM^K&K=%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1574'OTM"=-
MAMIKG(PES*T:8[\JK']*R/M'C+_H%Z#_ .#&;_XQ0!T-%<]]H\9?] O0?_!C
M-_\ &*/M'C+_ *!>@_\ @QF_^,4 =#17/?:/&7_0+T'_ ,&,W_QBC[1XR_Z!
M>@_^#&;_ .,4 =#17/?:/&7_ $"]!_\ !C-_\8H^T>,O^@7H/_@QF_\ C% %
MKQ7_ ,B=KG_8/G_]%M5[3?\ D%VG_7%/_017)>)KCQ:?"FL";3=$6(V,V]DU
M"4L%V') ,(R<>XJY87'C#^SK79IFAE?)3!.HS XP/^F% '545SWVCQE_T"]!
M_P#!C-_\8H^T>,O^@7H/_@QF_P#C% '0T5SWVCQE_P! O0?_  8S?_&*/M'C
M+_H%Z#_X,9O_ (Q0!T-%<]]H\9?] O0?_!C-_P#&*/M'C+_H%Z#_ .#&;_XQ
M0!T-%<]]H\9?] O0?_!C-_\ &*/M'C+_ *!>@_\ @QF_^,4 =#17/?:/&7_0
M+T'_ ,&,W_QBC[1XR_Z!>@_^#&;_ .,4 =#17/?:/&7_ $"]!_\ !C-_\8H^
MT>,O^@7H/_@QF_\ C% '0T5SWVCQE_T"]!_\&,W_ ,8H^T>,O^@7H/\ X,9O
M_C% '0T5SWVCQE_T"]!_\&,W_P 8H^T>,O\ H%Z#_P"#&;_XQ0!T-%<]]H\9
M?] O0?\ P8S?_&*/M'C+_H%Z#_X,9O\ XQ0!T-%<]]H\9?\ 0+T'_P &,W_Q
MBC[1XR_Z!>@_^#&;_P",4 =#17/?:/&7_0+T'_P8S?\ QBC[1XR_Z!>@_P#@
MQF_^,4 =#17/?:/&7_0+T'_P8S?_ !BC[1XR_P"@7H/_ (,9O_C% '0T5SWV
MCQE_T"]!_P#!C-_\8H^T>,O^@7H/_@QF_P#C% '0T5SWVCQE_P! O0?_  8S
M?_&*/M'C+_H%Z#_X,9O_ (Q0!T-%<]]H\9?] O0?_!C-_P#&*/M'C+_H%Z#_
M .#&;_XQ0!T-%<]]H\9?] O0?_!C-_\ &*/M'C+_ *!>@_\ @QF_^,4 =#17
M/?:/&7_0+T'_ ,&,W_QBC[1XR_Z!>@_^#&;_ .,4 =#17/?:/&7_ $"]!_\
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M '0T5SWVCQE_T"]!_P#!C-_\8H^T>,O^@7H/_@QF_P#C% '0T5SWVCQE_P!
MO0?_  8S?_&*/M'C+_H%Z#_X,9O_ (Q0!T-%<]]H\9?] O0?_!C-_P#&*/M'
MC+_H%Z#_ .#&;_XQ0!T-%<]]H\9?] O0?_!C-_\ &*/M'C+_ *!>@_\ @QF_
M^,4 =#17/?:/&7_0+T'_ ,&,W_QBC[1XR_Z!>@_^#&;_ .,4 =#17/?:/&7_
M $"]!_\ !C-_\8H^T>,O^@7H/_@QF_\ C% '0T5SWVCQE_T"]!_\&,W_ ,8H
M^T>,O^@7H/\ X,9O_C% '0T5SWVCQE_T"]!_\&,W_P 8H^T>,O\ H%Z#_P"#
M&;_XQ0!T-%<]]H\9?] O0?\ P8S?_&*/M'C+_H%Z#_X,9O\ XQ0!T-%<]]H\
M9?\ 0+T'_P &,W_QBC[1XR_Z!>@_^#&;_P",4 =#17/?:/&7_0+T'_P8S?\
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M&,W_ ,8H^T>,O^@7H/\ X,9O_C% '0T5SWVCQE_T"]!_\&,W_P 8H^T>,O\
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M=5)[FLIO#TBL^DVVK:?,^9[B>QOK/SXRDT[R*^P.I!!9ESG#8Z"@#4UWQ/\
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ML(*W:F2-TW8\Z/&8U8K@'+'D9 S5=O&.HPV.I7=QHD,<=C<+:MB^SNE+(!_
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M, '3V>KV-_;37%O/F. E9=ZLC1D -\RL 1P0>1T(-4[3Q1I=R]O;M=1I=S!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***9-&9H)(Q(\9=2H=" RY[C/>@!]%<EI5U?7^JQZ7)?2J^D'_2IE9?
M]-)X7 QTXRW3#?*,\FNMH **** ,CQ7_ ,B=KG_8/G_]%M5[3?\ D%VG_7%/
M_015'Q7_ ,B=KG_8/G_]%M5[3?\ D%VG_7%/_010!9IKE@C%5W,!P,XR:=10
M!Y+*GB&!3+/#J$)OHX8'CC=T=Y9)U:0*6E;+)&D@5AL'/'&,7&CO?[9:S>QU
M>6P*W%U#8QW3"1 RQ1Q!SOR S)._)^7<,XP<>F,B.5+*K%3N4D9P>F1^9H"(
M)#(%7>0%+8Y(&<#/XG\Z . &AZXM@T]_+?W-S%+:V\GD7#!G@2.,3.@##EG\
MS)^]MZ<U0>+47U.2P:QU62V2"XN(+**Z(:/S65(!(P?(&8IF&20NX=,5ZA30
MB"1I JAV !;') S@9_$_G0!P::-KR0K<S-=W.H&]B7/VEE010QH2<9P!))#R
M<9Q)Z9K(31-<O8IXKRUOFM)Q9"9274R$S[IB0TK$E57;D;<A^!@"O5:* /.+
MC3==DANEN+;4I7GAG:P6&Y*""=YI-ID(88"Q^3@\XP^.3@Z=EI&K'6;._N7N
MS*VIS/,3,P1;=(FB0!,[0'94?IW_ "[2B@#A/$6EZAJNLW-M+:7TD4ES:+;R
MQ3;8([8,IFW#< 6/[Q2""2"O8<8EWI?B34(M0::RO46ZL)TN(E9\^9))& H)
ME(?8A<@A5&!@=2*]6HH \[DMM6M?$L%T+6[M]/L[EMY#.0MK' VT!C+M8,0N
M5V<$\G(!/1>*UU.\T&#^S1-'YDT37"JA,@AZL-JLI/. 0&!QG%=%10!YFVAZ
M\%BG$-X;N"PNC:L&VF)I95P@S(V&6,':"QQNQGY>.HTRY@T:QNYWLM2MK/YY
MA]IE,I"H$'0L64N<X7DG!)P3BNDIKHD@ =%8 A@&&>0<@_G0!E^&+*?3O"^E
MVETNVXBMD61 <[&QROX=/PKEK*QU2'5K:&VT^_@B6ZEDGMKGRIK2(,'S)#(?
MG#$MP >-Q!4"N_HH X?P'#J-AIVEV-]_;P>&QCA>*ZB@%O&RH 0K(H;C! R3
M[UO>%[.XLM,N8KF(QN^HWLJ@]T>YD=3^*L#^-;5% '"6/A757\"7NGOJ5VMQ
M=6MQ"EG-Y0BC9V;'*IOQSW8\,:37X-1\26UO';:)=V36=O<L_GA%R7MY(A"F
M&.[+.#D?+\@YSBN\HH XW2M$U2P\1:7/?W-WJ5LMDT43RB)392X7<"$5=P8
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M[&\1?]#7)_X 14 =#4=Q$TUO)$DTD#.I42QXW)[C((S]0:PO[&\1?]#7)_X
M14?V-XB_Z&N3_P  (J )XO#D4$>E+#?7<;:<3MD7R]TP;[PD.SD'J<8R<'J
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M&N3_ , (J .AHKGO[&\1?]#7)_X 14?V-XB_Z&N3_P  (J .AHKGO[&\1?\
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M7)_X 14?V-XB_P"AKD_\ (J .AHKGO[&\1?]#7)_X 14?V-XB_Z&N3_P BH
MZ&BN>_L;Q%_T-<G_ ( 14?V-XB_Z&N3_ , (J .AHKGO[&\1?]#7)_X 14?V
M-XB_Z&N3_P  (J .AHKGO[&\1?\ 0UR?^ $5']C>(O\ H:Y/_ "*@#H:*J:=
M;7=K:^7>WYO9=Q/FF)8^/3"\5;H **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_KBG_H(JCXK_P"1.US_ +!\_P#Z+:KVF_\ (+M/^N*?^@B@"S1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVE_^#=__ (Q0!T-%<]_:'BW_ *%[2_\ P;O_ /&*/[0\6_\ 0O:7_P"#=_\
MXQ0!T-%<]_:'BW_H7M+_ /!N_P#\8H_M#Q;_ -"]I?\ X-W_ /C% '0T5SW]
MH>+?^A>TO_P;O_\ &*/[0\6_]"]I?_@W?_XQ0!T-%<]_:'BW_H7M+_\ !N__
M ,8H_M#Q;_T+VE_^#=__ (Q0!T-%<]_:'BW_ *%[2_\ P;O_ /&*/[0\6_\
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MVE_^#=__ (Q0!T-%<]_:'BW_ *%[2_\ P;O_ /&*/[0\6_\ 0O:7_P"#=_\
MXQ0!T-%<]_:'BW_H7M+_ /!N_P#\8H_M#Q;_ -"]I?\ X-W_ /C% '0T5SW]
MH>+?^A>TO_P;O_\ &*/[0\6_]"]I?_@W?_XQ0!T-%<]_:'BW_H7M+_\ !N__
M ,8H_M#Q;_T+VE_^#=__ (Q0!T-%<]_:'BW_ *%[2_\ P;O_ /&*/[0\6_\
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MVE_^#=__ (Q0!T-%<]_:'BW_ *%[2_\ P;O_ /&*/[0\6_\ 0O:7_P"#=_\
MXQ0!T-%<]_:'BW_H7M+_ /!N_P#\8H_M#Q;_ -"]I?\ X-W_ /C% '0T5SW]
MH>+?^A>TO_P;O_\ &*/[0\6_]"]I?_@W?_XQ0!T-%<]_:'BW_H7M+_\ !N__
M ,8H_M#Q;_T+VE_^#=__ (Q0!T-%<]_:'BW_ *%[2_\ P;O_ /&*/[0\6_\
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M._DS%E;R1&"VWD[,;0,+D-UP0#T^BH+,J;*#8LJ)Y:[5FSO QT;/.?7/-3T
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M+;P?9);RTU!I7E*N@2WBC9-FW[V8\]<8/K56+P!>CP^\#K:_;A;Z?&K@@EA
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M$"3N"^5<O)* 2.A5@/?O0!W_ -KMO*CE^T1>7(=J-O&&/H#WI6NK='*-/&'
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MX=_Y_+C_ , I_P#XB@#I**YO_A//#O\ S]W'_@%/_P#$4?\ ">>'?^?NX_\
M *?_ .(H Z2BN;_X3SP[_P _EQ_X!3__ !%'_">>'?\ G[N/_ *?_P"(H Z2
MBN;_ .$\\._\_=Q_X!3_ /Q%'_">>'?^?RX_\ I__B* .DHKF_\ A//#O_/W
M<?\ @%/_ /$4?\)YX=_Y^[C_ , I_P#XB@#I**YO_A//#O\ S^7'_@%/_P#$
M4?\ ">>'?^?NX_\  *?_ .(H Z2BN;_X3SP[_P _=Q_X!3__ !%'_">>'?\
MG[N/_ *?_P"(H Z2F/-%'(D;RHKOG8I8 MCT'>ECD66))$)*NH89!'!]C7+Z
MEH5W-XCGO$L;*[CN!;!)KAL-:^6Y8[1C)Z[A@CYNO'- '2BY@8R!9HR8SM?#
MCY3Z'TIBWL+RPI&WF"5&=9$Y3"D \_\  OT->:W_ (4U&TT.V1],LB;2W@LI
M5C<M_:#FY@.^3"Y PC$YR?WC>Y-Z\\%:K??;Y(A;6(NXKH);I)E8O,%L N0N
M,-Y#EL @;^A[@'>_;;7R5F^TP^4[;5?S!M)] ?6FW6H6ME-:Q7$RQR7<ODP
M_P ;[6;'Y*?\FO/+CP/J<L$LJ6R":21RJ-<0G;F-5RR^3Y1!VX(VYP 0<Y%=
M/KNAWNI66B*@MVN;*</*X^4+F&2,LF0?NLX8#_9ZYH Z*.:*8N(I4?8VUMK
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M9-S_ '0.CA1QG Y["H;?P1?VD4!6"SE2&*TWVN["3F*6=V!XQTE1AD=5[=:
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M.02,L<JQ*579\VYF  SGD  G( !-_P )OH/_ #VO/_!?<?\ Q%'_  F^@_\
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M9&7*Q$AFP0.,ANF>GKQ4MKXATV\E2&.61)F+CRYH'C8; K-D, 0,.IR>NX4
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M^>UY_P""^X_^(J.^\<:1!I/VZSG%WN)6)$5AO(F6$\[3QO8 >O;-6&\8:*L
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M1V4T@;C/!5"#QZ&@#-M/#%Y;PVUG)KD\FG6B&."!8PC%=A11*X/[P*#P,#)
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M   <[CGIZ5H:#XFL?$8NFL8KQ8K>0QF6>W:-)"&96V,>&P5(..E6+/7=.O\
M4;NPMKE7GM619!V)9 XVG^+Y3GB@"K;>&;:T\6W&OP2R(]Q;F*2W'W"Y*DR#
MT8A%!]< ]:+#P['8V^F0?:&DCL&E= 5QN=PP!_ .X_&K,^O:;;ZO!I<MRJW4
MT<DBC/ "% P)Z _.O'O4&N>)K+P_/917L-X5NY5A26&W9XT9F"J'8<+DL,9H
M Q;?X>6EO!#$M],1%:6UN!L&-T1CS)C^\RPQK[!?>KMQX2DF@O-/CU22+1[V
M222>T$(+_O"6D19,_*K$MD8)^8X(XQTU% '+/X0FE^V6LFJM_95W=&YEM4MU
M#-E@Q3?D_*<8. #CO5JV\+06^L+J!G:0K+<R^6R#&9BA/Y;/UK?HH P=2\+P
MZC>WEW]IDAEFCMEB:-1F%X)'='&>#R_(/&!CO5>?PI-J<B-K>JR7T?G1R/;+
M%Y<#! Q4;-QP=[!B<DDHHX KIJ* .;/@ZT32M;TRUF:WL]4Y\I5R(&*!6*_7
M ./7/K5C5_#-OK%Y)<33RQEK80KY> 8V619$D!/=652,C'%;E% '+W?A*?5H
M[@ZMJIN)WM)+2%HX!&L*N06;;DY8[5YSCC@#)S=@\,VUMXNF\00RR(\ULT,E
MN/N%B4)D]F(C0'UP*VZ* .97PY/-'=AIFMKB+5'OK.Y4!^67&2O<8=T(.#CI
MC@U)%X6WZC%J5_?-=7HG261_+"(517"1JN3M4-(7ZDD]^F.BHH \_M_"NKWU
MY):W$EQ8:="MXT!#QEEFG8X=&4Y( >3E@I^8#!Y-:NF>"(-/U)+XSQ;Q<K<&
M."V6&,E8GC4  G@>8S<DG)ZUU=% ''2>!7_L^>V@U9XVN$BBG=H<^8BO([*0
M&! =I6)P>G%277@:"^OX[JZEM)"88H)U:P1@RQLQ CW9\L$,01SQTP>:ZVB@
M#GM,\+MI^I6\[Z@TUO:FX-O 8@NTS.&)9L_,1\P!XX;UY,<_AJ7^T+N\:\EG
MMIKM-0:S6-0SRQJ@C4.2,*#&AP?XAU R*Z6B@#GO"6A/H]G<37((O+R9Y60L
M&\B,NS)"".,*&/3C)8]ZC@\*/%-%%)J32:9#>O?1VOD@,96D,@W/GYE#MN P
M#D#).*Z6B@#GK/PU<V4D<$>KS+ID5PUQ';(FU\EB^QI <E QZ8!(X)(R#H:+
MI$.BZ3:V*-YK01A6F90&D;JS'W))/XUHT4 <IJ?@A-6O[R>YOV$=U#+"WEPA
M)2DB%=CN#AT7)*@KP<<FFV_@E;7RKFVN;6#4(K@3I+#8)''Q&\84H#DC$CGE
MNIXXXKK:* .9;PB9=02YN=2FN%_T<R"1!OD,(?;EA@#+/NP!P1^4$7@@>38P
MW6I//'81PP6RB$(%ACDCD*MS\S,88P3P,#@#)KK:* ,67P\DFCZS8?:G5M4:
M9I)@OS+YB[>/HH 'TJCJW@NVU.Z:Z,L7FK+%)"DUN)8E6.-XPA0D;A^]<]1@
MD>G/444 <5>?#JUNK9+7[5&+;R%B9&M$."'9V>,#"H7+D-A<D <C&:LW'@M[
MA9H3JTBVQ>[E@C6$;HI+@/N8MGYBOF/MX'#<YKK** .6N_!\!TV2&-FE N)K
MH0Y$8E9H7B1"W.T*K* <'[H-9^F>&-6O(KU]3F,1>"WM((KF"*0&*/<6$B(Q
M4JY;! ;)VY^7@#N:* ,?0M)NM&@%FUWY]I''B,$'<'+NS8R3A &557)P%ZU1
M/@Z,I?\ ^G2"6[M[N$2!!F/[1(79A]/D4>R"NFHH Y:;P<SVVH6$6J20:;>>
M86MTB&09$","V>5QG P,$]3@"DNO!:WMU/Y^HR?8I;F2Y^SI$%.YX3#RV>=H
M.5X&,#.>,=510!RT7@^4W,5U=ZJ9YH_LX7;;A%"PB38 ,G^*0,>>JCH.E74?
M"+6VF60L?.N9K"WMK>W5"@9?*D5R_P Q"L243*DC.WJ#79T4 <[H6CZA%H%[
M'?7,D.HZA---),@4M$6^5/5<J@0=QD=^M5+/P7+I\B7%GJ4<%TDLCHL=KBWC
M5U56"1;OESM#9!ZYXP<5UM% '(1_#ZQ2(PM>7#Q$G.<;SFW:'.?7]Y(_3J_M
M5B3PI<W<$27NL22-"DBQ>7"(UC+0M$&5<GD!V/7DGL!BNGHH X]? B-?VMS/
M>QRBWFMYE!M1N4Q*JA$8L=D>5#;1SDGD]*=!X'\BUM5_M(M<VD4$<$QA& 8I
M'?<RYYW;@&Y'W<C';KJ* .77P<,WLSZC*UY=VUQ"\_E@;7FV[G49XP(XU ]$
M&2>M2_\ "*>3!:M9W@AO+:Z:Y29X=ZDF-H@I7(X6,A1S_".O.>CHH YD^$G,
MLBOJLTMK<2P7%TDD8,DTD2HH)<8PI\M"5 YYP0":BE\$1OIMI:)?N&M;-+5'
M:(,&/F1R.S#(SO,:@C(XSS75T4 <W=^$EN;98A=@DWTMY*LT(DCEW[@%9,C.
MT%0,_P!T'!J'2/!K:(8%L=4DCA$4,=P!"H:7RV9A@]%#%SN !]MM=510!B6V
M@26WA@Z.M\=_S?Z1Y(.[+ECN4Y#9R0WKD],\9 \"RQVHBMM8:V)M[FW/EVXV
M1),4)$*ECY8!C7 RW?IQCLJ* ./NO"US8Q7,UE-)=Q?:$NX[!41"TL:(D0WL
MP 1?+1L=<KU_A,6G?#RTLY;.222WD$:6YF$EJDCM)$BJ-LC<JIV@D8SG)!&3
M7:T4 <M%X1N(M)ATW^V':VM6M_LT9@&U5AD$B[^<NQV@$Y'3IUSH:SX?76)9
MI&NGA9[">Q0JH/EB7;N<>_R+BMFB@#F=0\'QWEQ)-'=*N^:-_)EA\R(QI$8Q
M&R9&X LSC/0D<'%4[?P"MI!##!J.$CCMUPUN.6AN&GS@$ !F8Y ]!Z8KLJ*
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M44 %<]K&K6%MK^F)-=1HT+R&0'^#,9QGZY%=#10!@:EJ-I8^*=/>YG6)197
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.QFO)8E#2['5%3.<#+$98XSCZ9(R,@&E16-)XB1;:S865P+J[#LEK*5C=0I
M8L2<  E>A/WAC-6M,U2/4TFQ&T4T#^7+$S*2IP"""I((((((_0@@ %^BL[1M
M5.L6;W!T^^L=DSQ>5>Q>6YVG&X#)^4]C6C0 45R]]<WWV?5]7CO98QITC>5;
MKCRW2-07##&26.X9SP,8[YD\0ZA]EU.WAN+J^@MFMY)%^P0F61G4CE@JLP4
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MS@EELYQ<3OY<5J"A=GY.,AMO12V<]!2V.I-<W$MK<6LEK=1J',;L&#*<@,K
MX(R"#T(].1D OT45R\ES?&VGUD7LH$5\81;#'E^4DWE,",9+'#-G/!('3@@'
M445RWB'4_LFJ/%<7E_;P)9^=%]@A,K;PS!B^%;  V8W84Y;.<<;,=^;;P_'J
M&H% R6PFG,1W+G;EMN.O.<>M &A163:VFHMH@22Z:"_G;S99.'\K<V61<\?*
MOR@XQP"0><LT:24WU_#'=37=C%L6.:8@D2Y82(&P-P&$]<$L,\8 !LT5QEEK
MC1WVF>9J4L][=3F*^L2 1;$JV. ,IM8*H)^\#GGJ-[6)9)I;33('9)+I]TC(
M<%(4P7.??*IZC?GM0!JT5D:Q&R![NXU6>SM(HP%6W W&0D\\@EC]T*H')SP<
MC$$TVHS6.B6MQ(UK=WA NVBP&7$3,P7J 2P [\9P<X- &]16+8F^FMM3L%O6
M\^UN?(CNG0,^PHDF2.A8!R 2.P)SS1I+RKJUY;17D]W9Q(H:28AMDV3N4, ,
M\8)'8X'J  ;5%<8NN-;7UN\FI2R7LFH?9I]/P"(HVD**=N,J!E"'/WL]]PQV
M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]QIUQ>:8D%Q=J;M)!,EPD6U5=6W+\N3Q_"1G)&>><TMEI]S;F[N)KJ.:^N<
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MC&R2*V^T#S,$D2*&WXQMX4=#U[#1CT'38[E9U@?*OYBQF9S$K]=PCSL!SDY
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M(.X&29V<'.00Y.X$'H<Y':HAH.G"RN;0Q2-'=#;.SSR-)(/0N6W$8XQGH2*
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MRXB^T6LL(8IYB%-PZC(QFJNGZ-8:7),]G"T;3D-*3*S;V_O').6]6ZGN:OT
M<?!X8TX:Y<6T4$,3VUO92I*L0!#++(6(]"P0 FIM5UV^MY;FZLC+-:6TFQ@M
MJ/+R" ZERX)(.1E1@'@YP:VX=&LX-2DU",7'VF3AF:YD92.<#:6VX&XX&,#/
M&*KW7AG2;PR_:+>1TE8N\7VB01[CSN"!MH;/.0,YYZ\T ,UJYU**ZACL@X@V
M,TSPQ++(IR-OREA\I^;H">.W?/U.[:Y\(VE]<*EY/'>VS8@A*DNMR@(5'.5;
MJ,$\'(-;-QH=C=3),ZW"S)&(A+%=2QN4&2 65@3R2>:D.DV)M+>U\DB"WD66
M-%=@-ZG<"<'YOFYYSD\GF@"MX?NKR_L6O;N>!Q,Q,<,494P#)&QR3DL.AX&"
M#Q6M52WTRUM;VYNX4=9KDAICYK%6( &=I. < #(':K= &'IME:V7BK5%M;>*
M$/9VSN(T"[F+SY)QU/O6M)=VT5S#;27$27$V?*B9P&DQR=HZG'?%4X=!L8+\
MWT?VK[0<99KR9@0,D @M@@;C@8P,FHCH,,GBP:_-)YDL=F+6WC*\1 L6=@?5
MOD'L%]Z ->L?6E%Q=Z98S,1:W,["50<>;M1F$9]CC)'<+@\$BMBH+RSM[^W,
M%S&'C)!QD@@@Y!!'((/((Y% '+ZQ(WAM=2;1?(MXXM-DO6@9?W,;QD;?E!&T
M.-X./[F<9SG32XU*QOM/6[O+>ZCOI#$5CAV;&\MG!4Y.5^0C!R>0<\8*ZAH2
M_P!@ZC9:;&AN+V)HFDNIW8G(*Y9SN8X!X'\JL:9H]I8[9UT^VMKG:5(A8NL8
M)^ZA(&%X'  % &?HD.J'4-2:74HI(DO2&C^SX)'EIP#NXZ^E6]5\Y=9T9\P/
M UR4V/#N=&\F4[U;/!P,=.A/K5B71+":\>Z9)A([!W5+B14=@  60,%8X '(
M[#TI+W0['4+E+BX^TF1#E-EW+&%.",@*P ."1GW- #+^XNY-3@TZSF2W+PO-
M),R;SA2HPHSC.6Y)SCCCG(S;K5-6CTZYCAEM/MUKJ$%H97B)CD60Q<[0V00)
M1WZKVSQLW&DV=U#!%*LI\@8BD6=UD7C!_> AN>_//>HGT'3I+!+(PR"!)1-A
M)W5BX.0S,#N8YYR2>0#U% #-.GO$U2[T^[G2X,4,4Z2B/8<.9 5(!QP8\Y]_
M;)U:K)86\>HRWZJ_VB5%C=C(Q!5<X&W.!C)Z#N?4U9H YKQ%9^0D-S#9VBVZ
MW45Q=W &)QM=3N48Y/ !R<[<X!X%69+2VO\ Q3>Q7D,<Z1Z?"$250P =Y0^
M?78F?H*M'0M.-U]H,,A/F>;Y9F?RM^<[O+SLSGG..O/6I+_2++4V1KJ-RRJ4
M#1RO&2IQE25(RIP,@\<4 8-CB]L/":79\Z)X?,S)\WF.L7R$YZG!9OJ,]JT-
M)M+:6+5]/:&.2P2]9$B*@I@HCLN.F-[/Q^%:5UIUI>6R6\L6(XR#'Y;&,QD#
M *LI!7C(X(X)%)'IMK%I_P!AB1XX.<^7*RL23DG>#NR3DDYR<G- %+PS%'#H
MOE1(L<:75RJH@P% GDP .PK7#*6*A@67J >15+3M(M-*#BT$ZJY)(DN))!DD
MDD!F."223CKFDM-$TZQU6_U2VM5CO;_9]IE!.9-@PO&<# ]* +]%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 45A:EKMW9W4T=OIR3QQ201,[7&S+2L%7 VG@%ADU9MM;A_LS[9J'EV1$TD!
M1I-P+*[+A3@;L[21Q0!J456@O[2YLS>0W,3VR@EI0PVKCKD]L8.<]*BL]9TW
M4)C#:7L,LP7?Y:M\VWINQU*Y(YZ4 7J*Q['7H)(+==0FMK6\GGF@CA\W/F-'
M(4.W.">@/3O6Q0 45FZQJ%WIR0206L4T331QRL\Q0H'D5,@!3N/S9QD=.M:5
M !112$A022 !R2: %HK#37YC!%?OIY32Y2NR<R_O K'"NT>.$.0<Y) .2!SB
MS+XCT:"62*34[57B<I(OF#,9&,[O[N,CD^M &G167J7B#3M*GL8[JYB3[8Y5
M&+@  (S;OI\N/Q%6CJ5D+#[=]JB^R8SYVX;>N.OUXH M454TVZ>[TFTNIFMR
M\L"2.T#[HLD DJW=?0^E,L]9TW493%9WL$SA=VU'!RO]X>H]QQ0!>HK-A\0:
M/<7"P0ZE:R2,Q0*D@/S D;?KP>.O%:5 !156^>]6-19);EB?F>=R%0>N .3[
M9'UK.CUYVT%[\VZ/.LYME2.3*22>;Y2X;'W2Q'...>N* -NBLRRU"X^U75GJ
M,<,<UO&DV^%B4:-MPSSR""C CGL>^!6L-9O9I;![NTBBMM14FWV.2Z':7"N,
M8R4#'CH1CGK0!N45FKJ%V-?6PFM8D@D@DEBE68LS;&C!RNT ?ZSU/2M*@ HJ
ME>ZOIVG2+'>WL$#LNY5D< L,XX'?DXI8M5L)K)[R.\A:VC)#R;AA".H/H?8T
M 7**HVVLZ9>7 M[:_MIIB@<)'(&)4@'/'L0?H1ZTVPU)+^]O(XI[66* JJ^5
M)N<$@YWCMR.* -"BL^\UW2=/F:*[U"W@= "_F2 ! >FX]%S[XHU'4X[-[2)9
M[59KB9%59Y-N]2P!V^K<\#N<4 :%%5;W4['351KZ[@MA(2J&5PNX@9P,]3@4
MD&IV-Q9R7<5W$;>//F2%@ F!D[L],#GF@"W16=;:]I-Y<);P:A;O/)G9$'&\
M@#).WKC'>M&@ HK/EU)%UFWT^.>UWLK-+&TF)0,97:O?OFI;W4[+3MGVNYCB
M,F=BL>6QUP.IQD9]* +=%0VMU;WMLEQ:SQSP/G;)$P96P<<$>XJOK-[-IVBW
MM]!$DLEO"TH1V*A@HR1D XX!H O452LM7T_49&CM+R&9U7<51L\=,CU&>,CB
MFIK>F/>_8UOH#<;B@0..6'51ZL,'CKQ0!?HJC<ZSIMG,\-S?V\,J*'9'D (!
M( ./J0/Q%$VLZ;!:PW,E["(9_P#5,&SYG^[CK^% %ZBLB^UV"VAL;R*:UDT^
MXEV27!FPJ+M8[@>AY4@Y(JU!K&G7-M/<17L+16X)F;=CRQC.6STXYY[4 7:*
MI'5].$=I(;ZWV7;!;=O,&)2>@7UJ[0 451O=8TW3I1'>7L,+E=^UVP0O]X^@
M]SQ4DFHV4-Q;6\EW"LUUDP(7&9<#)VCO0!:HK)O?$FEVFCWNIK>0306>]9/+
MD!^=1DIG^][5<LM2LM15VL[J*<)@,8V!Q]: +5%4+76M,O;C[/;7T$LI!(5'
M!W =2OKCOCI3/^$@T?[4;7^TK4SB3RF02 E7S@*?0D\#/4T :5%4;_5[#3B$
MN;R"&5E+*LKXX]3Z+GOTJO9Z[;MHMOJ%_)#;>:Q3&_(+ D87NV<$],T :U%5
M8]3L9K%KY+R VJ EYMXVKCKD]L=\]*HVNOP7VN1V5K)!-"]O)*71SO1E9!AE
MQP") 0?:@#8HHKG]6\406&JIIL,UC]I\LR2?:;CRP@&W X4G)W9^@H Z"BJ4
MVJ6=EY27]W;6TSH7V/* .!EL$XR  >>.!2#6---@;X7T'V4-M\W>,;LXQ]<\
M8ZT 7J*SFU[24L3?/J-LEJ'\MI7D"JK_ -TYZ'V-+::[I5_.(+2_MYIB"=B.
M">.HQV(].M &A116;<ZA=V^L6=L;6(VES(8A-YQW[A&S_<VXQ\F,[OPH TJ*
MS=0OKJ.\MK&QBB:YG1Y2TS$(B)M!/'))+J ..Y[8,VEWQU"P6=XO*D#O%)'N
MW!71BC 'C(W*<' R* +E%9,>KXM]4U"8 :?9EPA499Q&#YC?]]!E _V<]Z2R
MU&_^WPVFI6L$+W$+31>3(6VE2H9&R!S\PP1UP>!CD UZ*S;74+N76KFQN+6*
M)(XEEB=)BY<%F7D;1M^[ZGK4VJ7W]G:=-<A/,D "Q1YQYDC$*B_BQ _&@"Y1
M6?<2:G'%;0V\4$L[+^^GD)6-" ,X49)))X'IG)XY9::C=7FEO/#:Q-=QRO"T
M1F(C+(Y4D/M)QP3TSVQF@#3HJEI-Z^HZ3;7DD2Q/*@9D5MP4^@.!G\A5V@ H
MK-CU"[_M[[!-:Q1PO"\L4JS%F;:R#E=H ^_ZFF7M_?'46L=-MX))8H%GE:=R
MJX8L$48!Y.QN>V!P<T :M%5K"]CU#3;:^0%(YXEE ?@J",X/N*JV%]=WVDM?
M1PQLTQ9[6-F* QY^0L<'&1\W3C.,<4 :=%96G:C<RZA=6%XMN9;>-)3);N2N
M&+#!!Y!&W\0:KV&MW=P^GS7%K%'9ZEG[,5<F1/D+KO&,<HI/'0\<]: -VBJ&
MJWLMI!#';!3=W,JPPAAD GEF/LJAFQWQCO27L^J"X\NQMK<QI&':6XD*JQR?
MD& 2.F23TR, \X -"BL=]:>;2M,N;.W!GU+8($E;"IN0R$L1GHJMTZG [YI]
MMJ=W+9WP:S5[^SD,311O\LC;592&/0$.N<].>N.0#5HK+LKZ\_M)K"_BMQ*8
M?/1[=R1C."&!&0<XP>_/3%0IJ>HQ75G]MLX(H+R4Q1HLI,L9VLPW<8/"G('3
MU(YH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#'\1"[DM((;2PFNF^TP2L8WC4*(Y4<YWL.2%.,?CBDU@:A,EHT$-
MY]G.3<0VLD:39P-HW,P&!SG:V<XP<9K9HH Y6PL=1CTC7+>?2WD-S*6BAN+I
M7\Y&C52K.#D'"D'/KP3UJUI-O?+JPE>WOHK1('3%_+%*X8LI 1E9FQ@'.YNR
M^]=!10!R.EZ;J.E7G]I"PFG>]GG$\#R1E[9&E=T*'=C!R-R@G)YZ@YZZBB@#
M'\1?:Y+*."TT^>Z8S12$QO&H4)(K'.]AR0#C'Z4S7];N=)\*W6J16#F\5 L%
MI(02TK,$C4[21RS+T/>MNB@"&T^TFR@-YY8NO+7SA%G9OQSMSSC-.GA6XMY(
M7SLD4HV/0C%244 <T\&JW6C#0IK J6C%O->^8GE-'C#,HSOW%<X!7 )ZD#)9
M:R7]OX@U^2UTZ&Z62YC7<)0C!A!'PV1]WGMDCGBNHJK!IFGVUW+=V]C;17,N
M?,FCB57?)R<L!D\T 9!TRZT_3-$6*$W3Z?-ODCA*J2#%(F$W$# +C )' ]:T
MQ?7?V(SG2;KS-^!;B2+S,>I._;_X\:O44 <U965]=^#3H\]E)9SI9K!F=T9)
M&VX(^1F.WC!SC@U9 O=2U'3I)=,DL4LY&E=Y9(VW$QLFU-C'CYLDG'W1QSQN
M44 <JMG?CP])$-)F6X.J_:3%OBW,GVKSMV=^/N\=<Y'IS75444 4=3>181&-
M,;4() 5EC5DSCM\KD*1USSZ<'MDQ:1=IX=EMX;=+<K=)<VMD7&V)4D1UBR.!
MDH>F0N[ R *Z2B@#&M+>YO;^^O+NUDM(YK=+9(9&5GP"Y9CM) SO  S_  ^]
M5K"UU*5](M[NS,"Z8-TDY=2L[B-HAL )."'9OF (P!SSCHJ* ,*YDOO^$FMK
MA-(NGMX8)H#*LD(!+M$0P!?./D.>,].*W:** .>U\7 UO0Y;:VBN)(I)G\N1
MMIQY>#M/9N>_7D9&<U8M([V&>_U2:Q82SB-4LX9%+$+GYF)(7<=W//15Y-7[
MG3-/O)XI[JQMIYHO]7)+$K,G.>"1D<U:H P_"EO+8>'[/3I=+DL6M+>.,@F,
MJ[X^8KL8]\G)QG/UIMC-?G7[FXET:\AAN(XHP[R0G:5+Y) D)Q\PZ9K>HH Y
MY8[RRBOK!M&>_CN9I9!*)(Q'(LA)VR;F## .W@-\H&/02ZZ;Z2TM[:VTJ>X8
M36\S-#)&$79*CLOSLI)PIQQCD5N44 8FI+=7CZ-*-,F81W?G31LT68@$=03\
MV#RP/!/3UJO/IM[=OK*"V\OS+JWN(&E9=DWEB,[3M)(!,>"2.AZ'I71T$ C!
M&10!S5O+=7/C>UEN+**V*:=.N/,#R<R0_>QP%X.WGG#=,5TM5K/3K'3D9+&S
MM[57.6$$2H"?? JS0!@ZI+?G6+*2#1[N>*UD=FD22$!PR$<!G!ZGN!1K$-S-
M?6\R:;>2!(6"S6=RD<L;,1E2&8*R_*/7D"MZB@#/T6&Z@TJ)+Q0L^YV(PH."
MY(W;0%W8(W$<;LXIOB"">Z\.ZE;6T+33S6TD21J5&2RE1RQ [UI44 8ICN3K
MNE3)I\L=NEG+'(VZ,"$N8R%(#=O+(^7(Y'X8=GH5];V-II5Q%JDZ6[1KYJW,
M*P-L8$/_ 'QT!QM)SW/6NVHH Y[44N#XGLKU=$GNX[2WFC256AX>0QG*[G!'
M"L">.O<&DUG3;QM8AU*V^V2)]G,#1VDD:2)\V[(W\$'OR#\J]>W144 <?/I=
M\MC:?9]+FFD_M(7LD=W<1D@*.IQ\H8D9 7(SR2,FMBSBN;O67U&>R>RC6W\@
M1RLA>7+;LML+#"XXYS\S<#OL4R6*.>)XI8UDC=2KHXR&!Z@CN* .<T6TE;5)
M+=RK6&CNT5H0<[F90>?^N:-Y8]<G/-=-56RTVQTY'2QLK>U5SEA!$J!CZG J
MU0!RUYIM_;:U?W4(U*:&\9''V*:%2A5%0JPDQQ\N003]X\#J2YTF[ETO2]&A
MLYX(%PSWB3(9+3'38<CYNV0" ,C!%=310!S<%C?3^#]0TA[%;6;R);>%BR[9
MLJ0'.TL5R3DYR<YZU=G-WK6FWUB]C=:<)[9XA-*\9(9@1D!';IG/.*UZ* .4
MLM-O6N;%+JUU,?9I%?=)<P&!" 1E=OSD8) &U<@\XIT]E?2:1XDC32Y1->3,
MT*[XLRY14#9W8&-N><'&/I74T4 89^VV&I7ES'IDMXMX$8&.2,-$54+L;<P^
M7N",\LW'KBVNAZG;Z;I#FVG@EL%G@DMK*6,$AV4AHRWRD#;C!VG!/I@]M10!
MR\>DW36%S*MM<^>UW#<F*]GC9IO+*]=F5!PHQR>0N<5-$M_<^+;347T:2VMU
MLYK9I))(C("S1L-P5C\OR$#!)R3P!R>BHH *PKF2^C\2K<1Z1=36Z6[0^8DD
M(!)93D!G!QP>U;M% &#X@AGN+W2BFD2WT5K=?:7*M%@$1R*,!W'S!F4_US4^
MHQ74KZ=J$5F\KVS%WM&9 XW(5RISMWC..N,%N:UZ* .5O;/4+LW5\-+D5IIK
M("U,D>_;#-YC.QW;<D'  )^ZOT$T6GWD6H0R?9&V)JTL[,'3F-XG4-U[%@".
MOM7244 %8>KR7QU33FM])NKB*UG,KR1R1 ,#$Z8 9P<Y<=0.];E% &3J"74.
MIV>I6]I)<B.&6"2"-D#X<HP8;B%."F",_P 7M4$<6H:?X<=(X_\ B8W,TC*$
M&\0O-*6R?4)OR3WV^];M% &;<:1$_AN;1K=C'$]HULC'DJ"I7)]3WJM:+J%]
MJUK=7E@UFMK Z,&D1_,D<KRNTGY0%/)P3N' Q6W10!A))??\)/).=(NA;O"D
M F\R''#L=V-^=N".V?:K,\,E[K]NKQL+6R3S@Q'$DS95<>NU=Q/NZ^E:E% &
M-KSZFWD6]C:W$EO+N^T36TD:R(HQA5WLN"V3\PR1CCD@B>TDDM=(7RM'FA\K
MY([-'CW[0<#G=MZ<_>_6M*B@#%T&&X.A+I]_83VQ2/RVWR(=X.<[2C$C].M/
MLO#.E:==I=6T,RS)G:6N97'(QT9B.]:]% &%-)?'Q-!.ND736\<,D!E$D.#N
M>,A@-^<84]L^U27:WUEK,M]:V+WJ7%LD)2.1$*,C.03N(^4^8<D9(V]#FMFB
M@#GY-.N8?#NG:$,NTJ);W,R [5C"YD.>VX J.^6![5M7#RP6K-;6XF= -L08
M)D9Y )XSCIG ]QUJ:B@#"TFQ9-4NKN/3#I=M-&!)"2F9I,_ZPA"5! XSG)SS
M]T57TZRU$#1;&XM#%'I7W[DNI6?;$T2[ "6&=VX[@,8QSUKI:* ,N"&2ZU^X
MO)HV6*U3[/;!AC<6PTCCU!^51_NMZU3UH:A=7RVATRYN-*"!I!;R1 SMS\C;
MW4A!QD#.[.#@ AN@HH Q[Z*\FMM,O8K,B>UF$SV@==V#&Z,H;.W(WYZX.W&>
M<U%"-4MK'5;^*PW7MU.)8;1Y%RH")&-QSMS\I8@'OC/>MVB@#$T-+F%Y?/TZ
MZ2>5=\]W<O$6E<=% 1VPH!.!P![DDU5TPZG+J*7FI:-<K=/E S2PF*UC/4+A
MRQ)P,MC)]@ !TM% &==W6IQ:S86]MIJSV$PD^U79G"FW(&5PF,MN/''2M&BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\-7JSZA")DF7RYH8<$QY7 8$\-DG../IG% '3T56LX;J&-A=78N6)R&$03
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MQOL<J0KXSM/8X[URFG:KJS^'-.UVXO[:83B'S+:*'"$.RKA6SG?D_3/&!UH
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M1DU6XL+U+A0(%FC:XCC5P2Q!_P!6Q!' ZX(YZ]D\-0:B(I9)]2$T2WETK1F
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M8.,DYQ@ DXP: 'II%BAO3Y&\7IS<+(Q=9.,<@DCIQ] !VIMIHUE93B>))6D
M*JTT\DNP'J%WL=H^F*6WU:UFL9[MRUNEMN%PLPVM"5&2&_#!R,@@@C(--L-7
MBOIV@-O<VTVP2K'<)M+H3C<.3^(.",C(&10!H5GW>B:?>SM-/"^]P%D\N5T$
MH'0.%(#CMALTZQU6WU"XN((5G5X I830-'D-G! 8 D?*>:O4 4;K2+*\$/F1
M,C0KMC>"1H61>,J&0@XX'&<<#TI'T73WM[:W^S[8K9]\2QNR!6]>",GKU]35
M^JNGWT>HVGVB))$&]XRLBX961BK CZ@T +#86T%Y<7<:,)KC;YK%V(;' X)P
M/PJ"ST2PL)5DMXY%*#;&K3NZ1CT16)"#''R@<<5?) !)Z"F03QW-O%<0N'BE
M0.C#NI&0: *5MH5A9W;74"3K*S;V)N9&#'&W)!;!X '/H/2F7GAW2]0DF:ZM
MC*L_^NB,KB.0XQED!VL< #)&>!Z"M2B@"C/H]E<6\$,D<F(!B*19G61.QPX(
M;GOSS2QZ3816$MDMLIMYL^:K$L9"1@EB>6.,<DYXJ[10!3LM,M;!G:$3,[@!
MGFG>5L#MER2![5<HHH H'1[(ZE_:!27[4/X_/?&/3;G&/;&*6\T>ROIQ/*DJ
MS;=AD@G>%F7L&*$%AR>#GJ:O44 9TVAZ?-'!'Y+Q"!2D9@E>(A3C*Y0@D' R
M#QQ21:!ID&G2:?!;&&TD8LT44C(N2<G&#P"<D@<')]:TJ* *MCIUMIT9CMA(
MJ''#S.^,>FXG'X5:HJK<WT=K=V=O(DA:[=HXV5<J&"EL$]LA3^5 %4^'=+,S
MR?9W >0RO$)Y!$[D[BS1[MI.>>15@Z7:&\N+O8XGN(A%(XE<94= !G QDX(Q
MU/J:N5&;B);E+8N!,Z-(J>JJ0"?S9?SH I?V'IW]G06 @98+?F#;*X>+J/E<
M'<O!(X/3CI4B:18)IT]A]G#6UP&$RNQ8R[AAMS$Y8D<9)S5VB@"I'IEE#+-+
M%;I')/$D,CQ_*6100HR.F-QQ]:ACT/3XK>S@2%Q%9/OMU\Y_D/3UY&"1@\8X
MJ<WT:ZHNGLD@E>%ID8K\K*I4-SZ@LOYU:H *I7NDV=_(LLZ2"55VB2&9XGV_
MW2R$$CV/%)>ZK%93I;^3<3SNI?RX(]Q"@XR>PY/U/;H:NHV]%;!&1G!&"* *
M3Z/8/'9Q_9]B6;!K=8V9 A QP%([9'/J?6I8+"WMKJYN8D99;E@TI+L=Q P.
M"<#CCBK-% #)3((G,2JTFT[ YP">V3@X'X5A>'_#<&G65I]KL+$7MLBH)8<L
M&(4+OY PQYYQGWKH** ,J[\-Z3?-,;FU,B3$F2(ROY3$_P 6S.W=[XSGG.:;
MJNDI=6UND>GVET\(V*;N1@53'(W ,3G R#U[U9?5;=-5CTXK.)Y,[6,#",X&
M[ <C:3CT)I;_ %..QDAA$$]Q<3!BD$"@L57&YN2  ,CJ>I ZF@"O9Z%;0Z(F
MFW*1RH':5MB[ KLY?*8.5P3Q@Y&!S5FRTRUT]I&@60R28#R2RO*[ =!N<DX&
M3QGO4MG=PWUI%=6[%HI5W*2"#]"#R".A!Z5%'J4,DM\#\D-F0LDS$!=VW<P_
M $9/N1V- %RJ,FC6$M\+QX"9MRN?G8(S+]UF3.TL,#!(R,#T%1V&LP7\XA$%
MS;N\?G1">/;YL>0-R\^XR#@C(R!FI+75;>[U"XLHUG66!0S^9 T8()(^4L!N
M&5/(XH KR:##-XJAUV9S)+;VIMK>,KQ$6;+N#ZD!1[ 'UK6JO?7D6GV,]W-G
MRX4+D*,DX[ =R>@'K4%UJ8M!;QFUGFNIU++;0@,V!C<<DA0!D#)(ZCUH MW$
M"7,#PR;MC<'8Y0_F""*JVVCV%IISZ?%!FT=2C12.SKM(QM^8G QVZ4)JUM)I
MHOT$[19*E4@=Y P;:5**"<@@@\<8J:QO(M0L+>\@W>5/&LB;A@X(R,CM0!3A
M\.Z9!=QW:PRM=1@JD\EQ)(X4]5W,Q.WVZ=\4R+PQH\+ QVC*N_S&3SG*2/G.
MYUW8=L\Y8$\#TK7K+?7K5+TP&.<Q+,MNUR$'E+*<80G.<Y(&<8R<9SQ0!)>Z
M)8ZC.LURDS.N"NVXD0 CH0%8#//6GSZ39W-O##*DA$'^JD69UD3C'#@[AD=>
M>:9?:M'93K +>YN9=GFNENFXQIG&X\CWP!DG!P#@U<@GBN;>.>%UDBE4.CKT
M92,@B@".SL;>PB:.V0J&;>S,Y=G;IEF8DDX Y)[5++&DT3Q2+N1U*L/4'K5.
M'58I]/EOEBF:%79$V(7:0*VW*@=02./;GI3K'4DO99H&MY[:XA"L\,X&X*V=
MK94D$':W0]C0!#::!IUC+#)!%*#!_J@UQ(RIP5X4L1T)'2F6N@PP>);_ %UW
M,MU<PQVZ97'DQ)D[1]6)8_AZ4ZSUZUO;F.)(YTCGW&VG=,1W&WKL.<].1D#(
M!(R.:M:A?)I]KYS(SL76..->KNS!5 _$]>PR: +55-0TVUU2W\B[1WBSG:LC
M)GZ[2,U%>ZM':7/V=+6ZNI@@ED2W0,8T)(#')'4@X R3@X!I9M8MH[.UN(1)
M="[P;=(%RTN5W<9P ,<Y) H D33+1;&2R:(RV\F=Z3.TF<^[$FFV6DV=A(\D
M"2&5P%:2:9Y7VCHNYR2![9Q3[&^BOX6DC5T9',<D4B[7C8=01^(/H001D&K5
M &=::'86-R;BW2996)9BUS(P8XQD@L03@ <^@K1J."XBN49X7#JKM&2/[RL5
M8?@014E %*\TFSOY5EF202JNWS(9GB8KZ$H02/8\4Z33+*33UL#;H+50H6-/
ME";2"I7'(((!!'((JW5>]O([&W,TJ3.N<;886D8GZ*"?QZ4 ):Z?:V5LUO#%
MB-B2^]BY<GJ6+9+$^I)J.PTBQTQG:UA*LRA26D9R%'106)PHR<*.!GI4D>H6
MSZ6NHF0):M")][\;4V[LGTXJ"PU>*^G,!M[FVE\L2HEPFTO&3C<.3[9!P1D9
M R* &PZ%807QO8TF%P<9<W,AR!G (+8(&X\=.36E56ZODMKBT@V,\MS(455[
M  LS'V 'YD#O56^UZUL)Y(Y(IY%@027,L:92W0YP7.?8G R0.2 .: )KW2+.
M_E66=)!(%V%HIGC++UVMM(W#V.1R?6H5\.Z7'9QV<=L8[:.;SHXHY754?.>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@W% S'Y<@\J<9R11X3ATN<&1+J6XO8IYVC#S,3%%YK!54= NTCZ\$YXKKJ*
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M^1"@).5VX/4YS6SK5KHZ^);*^U,11P26DR&>60HA;=$5&<XR0&P.^#Z5U-%
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M:>YE6*)< LQ[G@#ZYHM$ECLH$N#&9EC42>6,+NQS@=AFJ.N1WLEM +,3LGG
MW"6\BI*\>UN%9B #NVYY!QG!S0!:MM2L[RVDN()U>.,D2'D%"!DA@>0<$'!]
M14$&O:3<SQ00:A;R2R_<57!)Z_D>#Q['TK-T&VOK"YU66;3[I8YBLL"R7:S2
M-A -I);ALCU(_P!JIO#4,]G;S6\VDR69>>>X:0M$0Y>1F&=K$[L$=1VZ]* +
MHUS3#>_9!>Q>=O\ +QGC?_<STW?[.<UH5Q4&@7EO8QZ5-;ZE<)&0HE6\18'
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MQL%Y4L0"047J1QGG/5MM92)HUY]NL3<27<KRR6B,I.&. N20N0H&><9!P>E
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MO;K1FOXK997G?=:P[M@\LD!&8GID?.>,@'&"1S5ETVXB\/:=H0S)YB);W4R
MA1&%S(?;=@J.XW@]JT]4DO;?39#IELLUR,+&A(  ) )Y(!P,G&1G&,CK0!#I
M][=OJ%QI]ZL!FAB28209VE7+  @\@@H>YS^E0)J=_#JUK:7J6?\ I18+%!(6
MDAPI;+9^\O&,X&"RCG-.T2*:W29'T^XA=L227%U+&SW$AX).PG' 'H , # J
ML+:YO=:L[PZ/]AGA8FXNC)&3*FPCRU*G<RY*GY@OW0<9Q0!T-%9UQ<ZHFN6=
MO!I\<FFR1N;B[,X5HF'W0$Q\V?7M_/1H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "J]YI]EJ$:QWMI!<HIRJS1AP#Z
M@$58HH 1$6-%1%"JHP% P /2EHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@#OZ9++'!$TLTBQQH,L[G 4>I)KS8QZ[::/!Y]QK[W<FD1S6QC$CDWY!WK(
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M: .MI"0 23@#J37FD<GB*6RMD@DUM;J2WB&J-+&X\NY,\(/E;AC&TSYV97:
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MY20#TY'61%=&#(PRK Y!'K2UQVKO?6WAC0;>*"^!81I.8#*IC B/#^4K28W
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MK+FUO39?A?J^G+JEFVH(MV7MC.ID4"=_O+G(&,?A0!U^SQE_S\:#_P!^)O\
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MU-10!0?1=.E^W^9;!_[03R[HLS$R)@C;UX7!/ P.2>YJ^  , 8 HHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!E)X!)/6NN\ O_;$>J>+'1E_MFXS;!Q@K:Q?)$,=LX9_^!T =E1110 4444
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MO!J,MJ;:"5)6DAW;[AD(9<J1A!N"DX+9QC@4QK36X]9O+V%=/*31QQ*KR."
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1/M=M_S\1?\ ?8H^UVW_ #\1?]]BN6T?PKX)UK1[34[?PEHZ1742RJKZ?%N
M(Z' Q^7%7O\ A ?!W_0JZ)_X 1?_ !- &W]KMO\ GXB_[[%'VNV_Y^(O^^Q6
M)_P@/@[_ *%71/\ P B_^)H_X0'P=_T*NB?^ $7_ ,30!M_:[;_GXB_[[%'V
MNV_Y^(O^^Q6)_P (#X._Z%71/_ "+_XFC_A ?!W_ $*NB?\ @!%_\30!M_:[
M;_GXB_[[%'VNV_Y^(O\ OL5B?\(#X._Z%71/_ "+_P")H_X0'P=_T*NB?^ $
M7_Q- &W]KMO^?B+_ +[%'VNV_P"?B+_OL5B?\(#X._Z%71/_   B_P#B:/\
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M@; QD"10/D)'3KZ$@\5/KGAGPEI$5IY/@G1KJ:[N1;QQBSA3YBK-DDKTPIH
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M $7_ ,30!M_:[;_GXB_[[%'VNV_Y^(O^^Q6)_P (#X._Z%71/_ "+_XFC_A
M?!W_ $*NB?\ @!%_\30!M_:[;_GXB_[[%'VNV_Y^(O\ OL5B?\(#X._Z%71/
M_ "+_P")H_X0'P=_T*NB?^ $7_Q- &W]KMO^?B+_ +[%'VNV_P"?B+_OL5B?
M\(#X._Z%71/_   B_P#B:/\ A ?!W_0JZ)_X 1?_ !- &W]KMO\ GXB_[[%'
MVNV_Y^(O^^Q6)_P@/@[_ *%71/\ P B_^)H_X0'P=_T*NB?^ $7_ ,30!M_:
M[;_GXB_[[%'VNV_Y^(O^^Q6)_P (#X._Z%71/_ "+_XFC_A ?!W_ $*NB?\
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MW_0JZ)_X 1?_ !- &W]KMO\ GXB_[[%'VNV_Y^(O^^Q6)_P@/@[_ *%71/\
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MO*K?PLS29XQ@BNQHH JZ;;S6>FV]M<3K/+%&$:58]F_'&=N>#5JBB@ HHHH
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M+VFBC$<B^X=<,/P- $ \:>'V?9'J'FMC.(89),#_ ("II_\ PE^B_P#/>?\
M\ YO_B*HZLNH^%[..^L+B6\L+=@;JVN7\Q_*_B9'/S%AUP2<XQ74CD9H PYO
M&7A^W+"XU..#: Q\Y63CUY J]8:WI.J9_L_4[.[QU\B=7Q^1J\0#U -9E_X:
MT34SNO=)LYG[.T*[Q]&QD4 :E%8$NB:CIUH1H.INK)DI;WY:>)O]G<3O7_OH
M@>AJ31O$*W]RVFWUN;#5XD\R2S=PV5SC>C#AESWZCN!0!MT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5S_CK_ ))]XD_[!=S_ .BFKH*Y
M_P =?\D^\2?]@NY_]%-0!OK]P?2EI%^X/I4,5Y;3W4]K%<1O/;[?.C5@6CW#
M*[AVR.: )Z*S(?$>B7.K/I,&KV,FHQYW6J3J9!CJ-N<\=_2KDE[;17D=H\Z+
M<21M*D9/)12 S?0%E_,4 3T5F:;XCT36;B:WTS5[&]FAYDCMYU=E'3) /3WI
M]SKFE64=W)=ZC;0)9LJW#RRA%B+ $!B> 2"#CW% &A15'3M9TO5[)KW3M0M;
MNU4D--#*KJI'4$@\5'I?B#1M<,HTK5;*^,)Q(+:=9-OUP: -*BLF+Q/H,^K-
MI4.M:?)J"DJ;9;A#)D=1MSG(]*+[Q/H.F:@EA?:UI]M>/C;!-<(KG/3@G//:
M@#6HHHH **** "N>OO\ DH.B?]@Z^_\ 0[:NAKGK[_DH.B?]@Z^_]#MJ .AH
MHHH *\M^-^FV,GAF'48X91KL<@BLIK9BLNW!:49'\/EB0G/ KU*N#U2)_$'C
M;45.6L=$TUX@,\?:IT.?KB(C_ON@"?3OA[X;ETRU:.359[1H4,*/JMQL"$<
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MBB@ IKEPO[M58^C-C^AIU% $.ZY_YY1?]_3_ /$TUQ/(C(\$#(PP5:0D$?\
M?-6** (=UR/^6,/_ ']/_P 31NN?^>47_?T__$U-10!EZKIAU>U$,\2HR.)(
MIHIBKQ..C*=O!_0@D'()JA%-XHTQ'%U;6^K1+]Q[=Q%.W^\K80_4$?2NCHH
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M(22&CVY9EW$ @XZ5UUMX(\.1Z9I]E=:-I]\;*UCM8YKJU21]B# Y8'W/U)H
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M_4W_ ,51M\9?\]M!_P"_4W_Q5=#10!SVWQE_SVT'_OU-_P#%4;?&7_/;0?\
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M]NQHH Y[;XR_Y[:#_P!^IO\ XJC9XQ_Y[Z%_WYF_^*KH:* .>V>,?^>^A?\
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MGC'_ )[Z%_WYF_\ BJ-GC'_GOH7_ 'YF_P#BJZ&B@#GMGC'_ )[Z%_WYF_\
MBJ-GC'_GOH7_ 'YF_P#BJZ&B@#DFT?Q"VI+J30>&C?(,+<?99=X&,==V>G'T
MJYL\8]IM"_[]3?\ Q5=#10!SVWQE_P ]M!_[]3?_ !5&WQE_SVT'_OU-_P#%
M5T-% '-26WBV9HVD;0&,3;TS#-\K8(S][T)J3;XR_P">V@_]^IO_ (JNAHH
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M%6Z<"-H/N895\L9XR1T.*T?#L4][JEU-<[I%_M2]C$K:]<*X5;B15 MQ\F
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M:#_WZF_^*KH:* *>FC4A;'^U&M&N-QP;56"[>,?>).>M7*** "BBB@ HHHH
M**** "BBB@ HHHH **** (YX(KJWDM[B))895*21NH974C!!!Z@BB6WAN(A%
M-#')&&5@CJ" 5(*G'J" 1Z$"I** *1T?33J?]I'3[7[=_P _/E+YG3'WL9Z<
M?3BGIIMC'MV6=NNV9IQB(#$C AGZ?>(9LGJ<GUJU10!F)X;T..TFM(](L5MY
MRIEB6W4*Y4Y7(QS@]/3M2?\ "-Z'M@7^Q[#;;DF$?9TQ&2=QQQQSS]>:U**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M95MF[YWSM.3LXQS@ [Z/2--AN_M<6GVB7/\ SV6%0_\ WUC-63%&TJRE%,B
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>modificationno8effective001.jpg
<TEXT>
begin 644 modificationno8effective001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M)E7@P[-M8\;F P#RWXC-N/B=8HMFD45I%=30//+%J-_':K%MD:,H&(.YMZ.
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MX2V/G!CV?-QZ>F*34-'FE\317\2EH+JRDL+O! *+G?&XSUP=ZX_VQV!K?HH
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M"E6Z\*QSV*CZ&YXE\&:!XO%L-<L3="VW&'$\D>W=C/W&&?NCK6!_PI?P!_T
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M6'_P@:36B6E[K%Y=6]M:2VEFCH@,*R1F,L2!\[!#M!/J>"3FJ/\ PI?P!_T
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MMG4/#]M?Z%#I8EFA6W\IK>9""\3Q$%&R<@D%1UZ\YZUS'_"E_ '_ $ G_P#
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M .]HK@O^%+^ /^@$_P#X'7'_ ,<H_P"%+^ /^@$__@=<?_'* .]HK@O^%+^
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M'_QRC_A2_@#_ * 3_P#@=<?_ !R@#O:*X+_A2_@#_H!/_P"!UQ_\<H_X4OX
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MA1HOL5OITMJX+'?O9P1@8Z8'K7*:E\)8]<NO%=U?1VBWM_=+<:9=J-SPE5&
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M '0T5SW_  G7AC_H,6_Y-_A1_P )UX8_Z#%O^3?X4 =#17/?\)UX8_Z#%O\
MDW^%'_"=>&/^@Q;_ )-_A0!T-%<]_P )UX8_Z#%O^3?X4?\ "=>&/^@Q;_DW
M^% '0T5SW_"=>&/^@Q;_ )-_A1_PG7AC_H,6_P"3?X4 =#17/?\ "=>&/^@Q
M;_DW^%'_  G7AC_H,6_Y-_A0!T-%<]_PG7AC_H,6_P"3?X4?\)UX8_Z#%O\
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M_A1_PG7AC_H,6_Y-_A0!T-%<]_PG7AC_ *#%O^3?X4?\)UX8_P"@Q;_DW^%
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M '0T5SW_  G7AC_H,6_Y-_A1_P )UX8_Z#%O^3?X4 =#17/?\)UX8_Z#%O\
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MJB3@$8VJ-N!QW&0?K5>7PCITVJ+J#O/YPO?MN PVEMB+M/'W<Q1OC^\@.>U
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MCE9 &5AN("@]B%''>@"C!XCU&Y%I:6MSIUU>WDSJDRP21Q0HBAF+*6W,?F4
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M,?V?8,#!W[LG//3&,5RJ^"=DD>HB^F_MA=0-\TIFD\DY8AE\K=M'[D^7G&>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;L6:T@+$Y),8R3^5+/96MU&([BVAF08PLD88#'3@U/10 @ 4    < "EHHH
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M/LEBN69!(CA2C'9P?O=,_=-3Z+J%QJ&B6^HWD,-OY\2S!8Y2X5"H/)('/)H
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MO[ZPMXK2]$6&@N&=HC)C9N!09!+!<@\$CC&2 #H:*** "BBB@ HHHH ****
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MVD+HV <% NX'# ].,T 4(]&N](2^BT&*SMXKF%Y$C;(2"YQ@$ #E"<9'&-O
M.>$M-,N6UF"].F6>G-&6-Q);R;FN<J1M.%&5R0V6YRHXY-;&GZA:ZK8Q7ME+
MYMO+G8^TC.#@\'D<@]:LT %<S>^&H]8UZ]FU/3K.2UDMXHH+@/F:-D9VR,I\
MO+]C_#WS6I)K4,-T(I+:[2(RB'[2T6(_,)P!Z\D@!L;<GK1?ZW;Z?.T+0W$S
MI'YTWD1[O*CR1N;\C@#).#@<4 5!:ZQ#);7YCMI[N.)K>>-9"JS)D%74[?E;
M@G;T^8C/ -4]0TC5;^WN&DBMR]]+$EQ&MRR>7;H<[ X7)9B6R>,!R!T!.]<W
MZ6]O%+'#-=>:0(UMUW;LC.<\ #'<D#\Q3K&^BU"W,L0=2K%'CD7:R,.H(_R#
MP1D&@#)M=*N],UV:>RC\RSGMPLK7-])(YD7.S 8-@<D'GTXXJ#3],U=M)TO2
M[V&S@@LQ 9)(KAI&D,6TJ "B@ LH).3QQCG(V-.U>TU5;IK1G9;:8PNQ4@%@
M <KZC!&#WI=.U6VU3S_LZSKY#A'$T+1')4-T8 XP1VH NT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &3XDU(Z7H<\J2I%<28A@=^BR/PI/L,[C[ UCZ8O\ 9>M+I-V+1+>^LE2.
M*&1FYC&T$Y Y9"!G_IG7744 <U;3Z7=>*KVR$L,@6VM52,-_'%),V![J=I_*
ME.M:;:^+;[S[V&/%I!&=S8^8/*2/J,C\Q7244 <7)J#^*+VS@ABM"$L3/-;7
M$C ;IEV\8&3M0L#_ -=!41U"SU;2-!M]2NHY66\DMKF0/PS+!,F\'MN)5@?]
MH=Z[FB@#E])66YU?4X=5B+26T-JCRLNU96C>1UD';D;&('0Y':GZ)>:9=RZA
M-Y\,GV>]DN5;=]P%-N_Z8+"NEHH X&*^GCAM_$KO9BVEOC*S!V\TQ./+V$8Q
ME4",1ZQUU,OB"TC\1V>AI'/+=7-N]UOC4%(XU(&YSGC).!@'FM6JZ6-JFH2W
MZPJ+N6)87E[E%+%5]AEF/XT 6*R-<_=2Z9>.C-;VMWYDQ52VQ3%(@; YP&9<
M^@YZ"M>B@#E9/$RPW%_>+<V%[96]JTBR6J'<&W?+$7W$$GTX^E5-+>?1=0TA
MKR>Q9+Z$V[R02,3,Y)D$AR.FYGZ=Y17:T4 %8/B*ZTZ:UFTZZU6?3Y2N08B4
M>0$'A./G^BY/XUO44 <V9S8OH.HZC%'9Q+9O!..D=O(XC8 ]E4>6RY]2!WJQ
MI-U%;:9>:C,'CMIKN25#Y;$["P4-@#(!QNSZ')K<HH YK1BCZSJ4^G7AU"&6
M%#]ID?>J."V(U<<%>2<#E23G[W%'1_MEGXJLK&\2R\];.X:>2*Y9V>1WC8L0
M8UQD@D#/ Z=*[.B@#G;K5]/3QA91M>0ADM;B)@6^Z[/#A3[G!_(UT5%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '/?\U%_[A/_ +5H\371>2PTF!X!
M/=3J[+,Q52B'=C(!^\P5<=P31_S47_N$_P#M6NAH YC19HMVHZ3J#6Q:TN/M
M86)R412WF#DXY5P>.PV^M2^&[C3[Z"9XY8I9;>]N95(/*!Y7P?H5-=%10!R-
MKXETZSAUB6*YAFF-T[PPA\&7Y$ Q]2,53OKBYU*35]5LI+%HK62-86EE967R
M6W>F &<L,YY7%=U10!Q]W<6VM:Y;2V-RBW9LEN+)GX^<,3@]\%=RL.N":N:#
M<6IT/^T[Z(VOEWETX^T#:T1:9P0?SQ7244 <CIFIV6G^!+75(C$]S#I\-OR?
M^6@08C/I\QY],U'I+2Z'JVFPW4UF8[VU6W#0R,S2NN65SD#[VZ3)[EEKLJ*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y[_FHO\ W"?_ &K7
M0USW_-1?^X3_ .U:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYUM[:]2SF^(&K)</M 1OLO!;[H)\C )[ XS2^7!_:G]F_P#"?ZM]LW^7Y?\
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MH Y[_A&M0_Z'#7?^^;7_ .,4?\(UJ'_0X:[_ -\VO_QBNAHH Y[_ (1K4/\
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MW'D1>8\+Q[]T;+G(!W@@],YSC S6L?"6K1W%M=QP"UU"SM'FL\L"D3-<2/\
M9F(_A\MPAQD#@CH* -V33C%I_P#:$GCS54L\@>>S6@3EMH^;R<=>/K3I]+>U
M,PN/'6K1>3$)I?,:T79'DC<<P\#@\^QJ@NCW=[\+[+3;O3G$\D]NT]I( 2$^
MU(SANQ 7.?:LV7P_KL6K7,4EK)>V>GK9&V<N"UW#'.\FPY/,B@@<_>*J<_-P
M ;NG6(U=)'T_Q[JUR(R _E&T8J3TR/)XJ]_PC6H?]#AKO_?-K_\ &*KVTL]W
MXI.M)IM[!:I9BT;S8MDD[O*I!V'G:@W<G^^<9Q74T <]_P (UJ'_ $.&N_\
M?-K_ /&*/^$:U#_H<-=_[YM?_C%=#10!SW_"-:A_T.&N_P#?-K_\8H_X1K4/
M^APUW_OFU_\ C%=#10!SW_"-:A_T.&N_]\VO_P 8H_X1K4/^APUW_OFU_P#C
M%=#10!SW_"-:A_T.&N_]\VO_ ,8H_P"$:U#_ *'#7?\ OFU_^,5T-% '/?\
M"-:A_P!#AKO_ 'S:_P#QBC_A&M0_Z'#7?^^;7_XQ70T4 <]_PC6H?]#AKO\
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MY]Q;SKD)OQZ?(JC'X5;HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!,#<#@9'&:6BB@ HHHH **** "BBB@ I"JL02H)4Y!(Z&EHH **
M** "BBB@ HHHH **** "BBB@!" P((!!X(-+110 4444 %%%% !1110 4444
M <CJ]DVI>*[^Q1]C7.@R0AO[I9R,_K67=:#J/BG3M!O84M;=]+MTDCBG&2]T
MC*&ADXXC!0@XR=VT_P  SI:II46J_$"..6XO80FE$@VEU) 3^][E",CZU?\
M^$.L_P#H)Z]_X-[C_P"+H +"*2Z\;:C?[-L4%E!9D]FEW/(P![A0Z<^I/I1X
M0_X\M3_["UY_Z.:C_A#K/_H)Z]_X-[C_ .+J+P/;K:Z3?VZ/*ZQZI=J&ED+N
M<3-U8\D^YH Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC@"JSZKIT;LCW]JK*<%3,H(/IUK@+"YGUVVT#PK=MYES87+'5<_Q):, F?\
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MM?@\5>+H]$L=*DMEU&('[5<O$5/V6'@!8V&,8[T =S)J%E"B/+=VZ*^=K-(
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M%% !1110 4444 %%%% !1110 4444 %%%% '/?\ -1?^X3_[5KH:Y[_FHO\
MW"?_ &K70T %<KX=TZQU+3M1COK.WND36+QU6>)7"MYS<@$<&NJKGO"'_'EJ
M?_86O/\ T<U &E/HFDW-ZM[/I=E+=KC$\ENC.,=/F(SQ5M;>!/-VPQCSFW28
M4#>< 9/J< #GTJ2B@#/M]!T:SBFCMM)L((YEV2K%;(HD7T8 <CZU<>"&62.2
M2)'>/.QF4$KD8.#VR.*DHH HW.BZ5>V\-O=:993P0#;#'+ K+&,8PH(P. .E
M0OX;T*2*&)]$TUHX01$IM4(CR<G:,<<\\5J44 5-0TZ#4M,FL)=R12IMS'@%
M/0CMD$ CZ4V;2-,N+^._GTZTEO(\;+AX%:1,=,,1D5=HH S?^$=T3[;]M_L?
M3_M?F>;Y_P!E3?OSG=NQG.><T6WAW1+.Z6ZM='T^"X4DK-%:HK@G@X(&>YK2
MHH B-M 3,3!&3,-LI*#YQC&&]>..:KWFC:7J,<4=]IMG=)",1+/ KA!Q]T$<
M=!T]*NT4 4H]&TN&W^SQ:;9I!MV>4L"A=N[=C&,8R2<>IS5J.&*(N8XT0NV]
M]J@;F]3ZG@4^B@"%K2V:&6%K>(Q39,J%!M?/7<.^?>HX+"&&_N;W+//<!5+,
M?NHN<*/09+'ZL?;%JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R+0)]/T^"YCU#6_$
MUC<+J-VYM;>UF,0!N'92,0L"""#U[U9U)=0TGQ-KOBFPT^XN9;?4$C6)(SF>
M&6SA7CU E6(GTVFO5** /&=0T&?2-/U:T<7FR*_TAY;JWB9G8J4:65< Y(.Y
MN >:VKVYL+OPGXFM-.U?Q!J=S+I%R$AOK:4#_5G[NZ)1NR0,9R?2O3** /-+
MO0KW2KGPYJ%]?:KK&D1R1>?:S$$VLO'ES815W*K<$'..&[5+;7[>&;+5M%OY
M]0TRZ?4)[JVO[>P:Y%Q')*9!MPC*6PVTJ>>..U>C44 >0W+ZC(WA*]\0W&L6
M3*-1#W-K:%9E1G3RMZ1HVTL@!(P.]:]V+/5=,TJVL[G5=6A76X&G;4;>0,$*
ML"/F1<ICV[UZ,""2 1D=12T >;:/IFJ:/\1M+TB6":;2["RN_L-X02!#(T.V
M%C_>380/5=OO71>%8)8M:\6M)$Z++JP>,LI =?L\(R/49!'X5T](2%&20![T
M <5K&E:CJ'Q*MY+/4;S3472'#7%O#&X8^<OR$R*P]_7BJ&K^$#9ZAX<M[2^U
M-IKC5YKJ\U%2IFWFUD7<3LV*,!5QMQCCK7HI.!DT @C(.10!Y5?>&=2>7Q1H
MMU)=ZAJ5_IQ_LW4[D_+)"#DV[8 1&#=< ;@P/:M/Q)KT7BOPI<:!IVGZ@-5O
MT$#6TUG)']D)(W/(Q4* O)R#S@8SFO020HR2!]:6@#S_ $GQ!:>'M9\507T&
MHM/-JIFA2"PFE,J^1"H*E5*\E2.O:L[2K2Z\)OX7U/5K2XCMUMK^.Y$,32_9
M&GF29%8("<  KD# (%>HT4 >6WMI>:ZVOZ_I]C=2VHOM.N+>)X6C>[2V8-)M
M5@#SD@9')6NMM?%UOJ^JV5GI-A=709F:ZFFMY(%M$"GJ749<G "CGDDXQ72T
M4 <QH\$J>/\ Q/,\3K%)#9!'*D*V%DS@]\9%4_%%]%I7CGPYJ%TEQ]ECM;V-
MY(;:2;:S>3M!"*2,X/Y5V=% 'DOBB.XUVR\3Z[;6=_#8RV]A:0$V[I+-Y=P7
M>18R-V 'P"1S@]JZ;PU>Z3+JODV^N:_?R2QLHAU"WE6+'4G+1*,\>O<UVE%
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M'J3QJ1Y;1W!A\Y>3\F5R0>@8G/R\@'0?\)A:_P#0)U[_ ,%4W_Q-'_"86O\
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M?^@3KW_@JF_^)KH:* .>_P"$PM?^@3KW_@JF_P#B:/\ A,+7_H$Z]_X*IO\
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M;ZI!+"3'J;;KH;R-Y\M8^.>/E11QZ4W4?#NFZK>)=74#-*J+&2KLH= ZR!6
M/S ,H.#ZD="<ZE% &7J'A[3-4GDFNX"\DD(@9ED93M5]ZG@C#*W(8<@DX--M
MO#FGVT-ZA\^=[V/RKB:XG>21TP0%W$Y &YL 8ZD]36M10!GC1;#9+&\ DCEM
M4LW20[E:)=V%P?\ ?.?6J(\'Z28IXYA=7*RVSVO^DW<DICB<894+,=N1W'/
MYK>HH RM2\.:9JV?M<#,6M9;-BDC*6AD #(<'D< CT/(JL?!^DR0W,<XN[AK
MB'R'EN+N61Q'D':K,Q*C(!XQG ]!6]10!C1^&;%5"R37]PHEBF47-Y)*%>-P
MZD;F..0/K5Z'3;6WU.YU"*,I<72(LQ#'#[<[21TS@XSUP .PJW10!COX7TAX
MM.C:T!&G3_:+4ESF-\DDYSDCD\'CIZ"F)X4TI+I9@D_EI-]H2V-PY@67.[<(
M\[<[N<8P#R!GFMNB@"*"!;>+RU>1AN9LR.7/))ZGG'/ [# ' J6BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#GO^:B_P#<)_\ :M=#7/?\U%_[A/\ [5KH: "N>\(?\>6I_P#8
M6O/_ $<U=#7/>$/^/+4_^PM>?^CFH Z&BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#GO^:B_]PG_VK70USW_-1?\ N$_^U:Z&@ KGO"'_ !Y:G_V%
MKS_T<U=#7G%K8^'[:QU;5-9O;VV#:O=1CRM2N(@S><P 5$< GZ#U- 'H]%<5
M/I7A:WU0:=)=:T)RR1EAJ=\8T=_N*SB3:K'L">X]1FOIUMX3U2Y@@@F\0JUQ
MN\AYK^_C2;;DD*S. 3@$XST!/:@#O:*Y#5?#_A[1K1;F[EUPHTB1*L6J7LC,
M['"@*LA)R35>#3O"MQ8WMW]JUN%+%2]TEQJ5]%)$ N[)1I <8Y!Q@]J .WHK
MS^YB\)VUE9WA?Q));7@0Q20WNH."7;:JG#\,20-IYS2M;^&!<-;K%XJDF1$D
M=([G46*!L[=V'X/!X- '?T5P#0^$H[N6"2;Q"BQ3BWDG:^U#R4D.!@R;]HY(
M&2<<UK7GA;0;"W\Z>?5PI944#6+LEF8X50/-Y)) H ZFBN%@LO"EQJ"6B3Z\
M#)*\$4S:C?+%)(F[<BN9-I(VMWYVG&<5'96WA:_@6YA_X246K1&<7,EYJ"1&
M,+NW;B^,8Z>M '?45Q.EZ3X>U9U%O'XF173S%DGO;^)"..C,X'>H-0M?"FFP
M74\TOB%XK28PSO#?W\@1@JL<[7/&'7GUR.U '>T5P#6WAE)4A\KQ49WC,ODK
M=:@75<[<LN_(!(.,]<5;L](\,7NHS:?%<ZTMW#;QW$L4FJWJ,B/G;G,G!XY'
M4<9H [2BN-TW1O"VK:.-6M+[538'?B=]8O$7",58\R#C*GG\:JFU\('3;>_B
MO-;N+>X,GDFWU*^E+A"0S *Y.T8Z].1ZC(!WE%<E9^'?#E_(\=M=ZM(5CCER
M-8O,%'!*,/WO(.#^1JY_PA6D?\]=7_\ !S=__': .AHKGO\ A"M(_P">NK_^
M#F[_ /CM'_"%:1_SUU?_ ,'-W_\ ': .AHKGO^$*TC_GKJ__ (.;O_X[1_PA
M6D?\]=7_ /!S=_\ QV@#H:*Y[_A"M(_YZZO_ .#F[_\ CM'_  A6D?\ /75_
M_!S=_P#QV@#H:*Y[_A"M(_YZZO\ ^#F[_P#CM'_"%:1_SUU?_P '-W_\=H Z
M&BN>_P"$*TC_ )ZZO_X.;O\ ^.T?\(5I'_/75_\ P<W?_P =H Z&BN>_X0K2
M/^>NK_\ @YN__CM'_"%:1_SUU?\ \'-W_P#': .AHKGO^$*TC_GKJ_\ X.;O
M_P".T?\ "%:1_P ]=7_\'-W_ /': .AHKGO^$*TC_GKJ_P#X.;O_ ..T?\(5
MI'_/75__  <W?_QV@#H:*Y[_ (0K2/\ GKJ__@YN_P#X[1_PA6D?\]=7_P#!
MS=__ !V@#H:*Y[_A"M(_YZZO_P"#F[_^.T?\(5I'_/75_P#P<W?_ ,=H Z&B
MN>_X0K2/^>NK_P#@YN__ ([1_P (5I'_ #UU?_P<W?\ \=H Z&BN>_X0K2/^
M>NK_ /@YN_\ X[1_PA6D?\]=7_\ !S=__': .AHKGO\ A"M(_P">NK_^#F[_
M /CM'_"%:1_SUU?_ ,'-W_\ ': .AHKGO^$*TC_GKJ__ (.;O_X[1_PA6D?\
M]=7_ /!S=_\ QV@#H:*Y[_A"M(_YZZO_ .#F[_\ CM'_  A6D?\ /75__!S=
M_P#QV@#H:*Y[_A"M(_YZZO\ ^#F[_P#CM'_"%:1_SUU?_P '-W_\=H Z&BN>
M_P"$*TC_ )ZZO_X.;O\ ^.T?\(5I'_/75_\ P<W?_P =H Z&BN>_X0K2/^>N
MK_\ @YN__CM'_"%:1_SUU?\ \'-W_P#': .AHKGO^$*TC_GKJ_\ X.;O_P".
MT?\ "%:1_P ]=7_\'-W_ /': .AHJIIVFV^E6OV>V:X,>XMF>XDF;)_VG8G'
MMFK= !1110 4444 %%%% !1110 4444 %%%% !15'4]6L]'@2:]:54=MH\N!
MY3G&>B D5F?\)OH7_/:\_P#!=<?_ !% '0T5SW_";Z%_SVO/_!=<?_$4?\)O
MH7_/:\_\%UQ_\10!T-%<]_PF^A?\]KS_ ,%UQ_\ $4?\)OH7_/:\_P#!=<?_
M !% '0T5SW_";Z%_SVO/_!=<?_$4?\)OH7_/:\_\%UQ_\10!T-%<]_PF^A?\
M]KS_ ,%UQ_\ $4?\)OH7_/:\_P#!=<?_ !% '0T5SW_";Z%_SVO/_!=<?_$4
M?\)OH7_/:\_\%UQ_\10!T-%<]_PF^A?\]KS_ ,%UQ_\ $4?\)OH7_/:\_P#!
M=<?_ !% '0T5SW_";Z%_SVO/_!=<?_$4?\)OH7_/:\_\%UQ_\10!T-%<]_PF
M^A?\]KS_ ,%UQ_\ $4?\)OH7_/:\_P#!=<?_ !% '0T5SW_";Z%_SVO/_!=<
M?_$4?\)OH7_/:\_\%UQ_\10!T-%<]_PF^A?\]KS_ ,%UQ_\ $4?\)OH7_/:\
M_P#!=<?_ !% '0T5SW_";Z%_SVO/_!=<?_$4?\)OH7_/:\_\%UQ_\10!T-%<
M]_PF^A?\]KS_ ,%UQ_\ $4?\)OH7_/:\_P#!=<?_ !% '0T5SW_";Z%_SVO/
M_!=<?_$4?\)OH7_/:\_\%UQ_\10!T-%<]_PF^A?\]KS_ ,%UQ_\ $4?\)OH7
M_/:\_P#!=<?_ !% '0T5SW_";Z%_SVO/_!=<?_$4?\)OH7_/:\_\%UQ_\10!
MT-%<]_PF^A?\]KS_ ,%UQ_\ $4?\)OH7_/:\_P#!=<?_ !% '0T5S:^//#KR
M/&MU=,\>-ZBPN"5STR-G%/\ ^$WT+_GM>?\ @NN/_B* .AHKGO\ A-]"_P">
MUY_X+KC_ .(H_P"$WT+_ )[7G_@NN/\ XB@#H:*Y[_A-]"_Y[7G_ (+KC_XB
MC_A-]"_Y[7G_ (+KC_XB@#H:*Y[_ (3?0O\ GM>?^"ZX_P#B*/\ A-]"_P">
MUY_X+KC_ .(H Z&BN>_X3?0O^>UY_P""ZX_^(H_X3?0O^>UY_P""ZX_^(H Z
M&BN>_P"$WT+_ )[7G_@NN/\ XBC_ (3?0O\ GM>?^"ZX_P#B* .AHKGO^$WT
M+_GM>?\ @NN/_B*/^$WT+_GM>?\ @NN/_B* .AHKGO\ A-]"_P">UY_X+KC_
M .(H_P"$WT+_ )[7G_@NN/\ XB@#H:*Y[_A-]"_Y[7G_ (+KC_XBC_A-]"_Y
M[7G_ (+KC_XB@#H:*Y[_ (3?0O\ GM>?^"ZX_P#B*/\ A-]"_P">UY_X+KC_
M .(H Z&BN>_X3?0O^>UY_P""ZX_^(H_X3?0O^>UY_P""ZX_^(H Z&BN>_P"$
MWT+_ )[7G_@NN/\ XBC_ (3?0O\ GM>?^"ZX_P#B* #_ )J+_P!PG_VK70UR
M6FZI:ZMX\-Q9M(T8TLH3)"\9R)1V< ]^M=;0 5Q%KILFJ^$]>M($1KA]3O!&
M6XP?//?MQ7;USWA#_CRU/_L+7G_HYJ *5]H>I2ZK>P10HUG?:E::@UR9 /*\
MGR=R;>I)\A<8X^<YQCG)\/>%M6T^^TB1[.2%K%Y3/++J+31R(RN-L<1)5"25
M.1MP 1SDBO1** ,#Q#:ZAJ&CV+V]FK7<-W;W+VYE ^XX9E#=/7FL:^\/ZUK=
MW=3SI'IZ:@]K!,D<JR-';P&23)R-I9W<*1R-O?M7<44 <7'X:U6WLIM.$PN;
M==8M[^"60JK;/.2652%  PP<C _B [4W4M#OCXKU#4%T^]N8+B.$1M:ZL]K@
MH"#N567/4=<UVU% '#7.C:Y=6&N:,-/BCM]5NG<W;W Q'$X4,0H!)8 ''09Q
MS6YK$;R>(M R/W*RS,.,@2^4VW/_  $R5NT4 <!_8WB14NI+*RCL+F6TN/M,
M<=WNMKFY9#M>-#GR\N=Q/RGL0Q.0G_".7Z>%;_2[+2[Z"22P^QQBXU=YD*G"
MD*I<JAVYP0!CI7H%% &!X<L)+-IM]A?6@VJJBYU-[H$<] SL%Q5'_A'[^3PZ
MME*L?G76K?;+OY^!']I\W;[_ "*J5UM% '%:GHVH3^*[_4'TV\N(9(88('M-
M5:UPB!F.X*RY^9VZYJM=>$]6FUR[NU\M8;]YHKK][\YM]L 10?5A"P/IYI/6
MN^HH Q-$TF32_!]EILL,4MQ#:J)$.-CRXRWM@OFL>[T35X_!EMX>MX/-W:>(
M'N(KHPM'<8&78CJA))(&<],$&NSHH Y[0+9CJVHWX4+;^5!80;5VAUAWDL!V
M&Z1E'^YQP170T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!D^(-3N--M+=;-8S=7=S':PF4$
MHA8\LP!!( !.,C)P,C.:SKW4-?TJ..VGDT^YN+RZCMK.X6)D52P9G,D>XYVA
M"1AANR!QU.WJ>F6VK61M;D/MW*ZO&Q5XW4AE92.A! -9H\)6#PW N9[RZN9V
MC9KN67$RF,DQ[2H 7:22  .ISG)H Q]3U_7=*NSI,D]C+=RO:F"[%LP4)+,(
MG#1[^HR""&&<]!CF/5_$^M:,]SI]Q+9O=QR6;)=0V4CJ8IY'0_N0Y8L#&W1N
M<CWK9E\'V4\,WGWE]+=RR0N;QY1YH\IM\87Y=J@-DX YR<T/X/L9+>57NKYK
MF6:*9[QILS;HSE,$C  R> ,<GU- %OP_>7-[8R2W-U]H82%0W]G2V9 P.-DA
M)/7KT_*M:J>G6#6$;H]]=W98YW7+*Q7V& .*N4 %48]5MY=5;3A'<+,$9]SP
MLB,%*@[20-WWEY&1SUJ]7/7.JV2^+[-#*<I;3PM\C8#L\.!G&.<'\J -.]U%
MK20)'87ET=N]C BX4?5B 3QT&3[=*=)JMG'I::D9LVLB*Z.JDEPV-H  R2<@
M  9)-4=>NM/:"2PO+^ZL6=-RR0%T8YR,(P&&;_9&3TXZ5FWUM=OX9T*1]]E]
MEDB>Y$$7S1Q^6R'"\[<;@>^W!/:@#;;5O)TRXOKFQN[=(1GRY A=QZ@*Q'?N
M0:GLKN2[5R]E<VNTC GV_-]-K&L.W>WN='U2.YEN[O2/,"12C>[LA5=VUE^9
ME#$_-R>O/%3:*\+:K<#3;BXN-.\E=SRS/*GFY/W&<D]/O ' X[YH MVFO6]W
M<0(L%S'#<DBVN'4".? )^7!R. 2-P&0,C-2W>K);77V2&VN+RZ""1HK<+E%.
M0"Q8A1G!P,Y.#@'!KEM#BVWNC*MU=37,3/\ :+"1?W=CF-L[1C*[6PBY)RK'
M''(DU-9K'5-;F:_NH;F8I-IL,*G;*XB5,?\ 30[DP5/ !!XSF@#I[[4ULI88
M%MKBYN)59UA@"[@JXW,2Q  &0.N3G@&K%I=0WMI%<V[;HI5#*<$''N#R#[&L
MC6WBMY[:[.H_8KWRGC55B\XRJ=I(5!RS @8Q^1S4_AFRFT_08()_-\PO+*1,
MP9QOD9P&(X+ , <<9SB@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#A=3U2XT6Z\7W]KL$T3V04O&T@&X*I.U2"W!/ I;_Q3J%AH FCO
MK.>_NKD6]I]KL);&,$*7;<LC9(VJ<$8&2!5V#3X-5\0^)[.YW>4TEFQVG!RJ
M!A^H%;UQI-I=ZG!?W$?FRP1/%&K\HH<J6./7Y ,^F?6@##A\0W7B"XL8="GM
M[>*?3UOWN)X3*0KG"H%#+SD-DD\8QCG(K:GXDUG2I8K>YBLOM MXGE,88J6:
MY2(D9((!5B<=CW..=/\ X1"PB*O97%Y8RH\K));2 %5E?>Z8((V[N0"..V*;
M+X*TF2T6W7[1$%A$0=)<O_K1-N).<L7&23UR: +.K:A>0:OINGVCPQF]6<&2
M2,OL94RIP",C)Y&>?:L.TU3Q4UAJ%\9K"]%A=R0M:PV;1O,D;8;:QE.&*Y(&
M.N!FM^VT&*&YM;B:\O+N>V9VB>X=21O4*1P!QQ5NRTVWL$N$@W8N)WG?<<_,
MYR<>U %#1-8FU6QN-79%33)/GLAL(D>(#_6-G^]U48^[@GDX&;8ZOKKZ-;>(
M;E[!M.FMC=RVB1,LD,1C+KM?<0[= 1M .21C'/1:;I\&E:5::=;!OL]K"D$>
MXY.U0%&3WX%95KX0T^UEM_WMW+:6I+6UE++NAA)!7Y5QD@ D ,2 #QB@"E#J
M^NVD>D7^HR6,EKJ,L<3V\$+*UN9!\F'+'?@X!^49SD8QBJVC^(-=;3_#VIZC
M-83VNKF-&B@MFB>!G0LI#%V##(P1@=<]L5L6?A2RLY[5OM%[-!9G-I;3S;H[
M<X*C:,9. 2!N)QVQ3-+\(6.EM98N;ZYCL!BTBN)MR0_*5R  ,G:2 3G&30!E
M>"O$>I>(+:PNKR\1OM%HL[P)HUQ JEE!PLSL48 GMU[5VM8>B^&H]"CM8;;4
M]1DM;:(116\TBL@4# '"@\#WK<H **** "BBB@ HHHH **** "BBB@ HHHH
MY[_FHO\ W"?_ &K70USW_-1?^X3_ .U:Z&@ KGO"'_'EJ?\ V%KS_P!'-70U
MSWA#_CRU/_L+7G_HYJ +-]J]W#=7$-CIZW0M(A+<$S;#SDA$&T[FP,X)4<KS
MSQ)=:LV+%-.ACN9;U3)%YDIC38 "6+;2>XP #U] 356Z:^T[4=0DMK"6[%Y&
MC0E"H"RA2I5\D87 4YY_B]LU[_1O*L=%M9[66_L;&+9)'"</Y@4*DF,@D ;P
M0#_$#@XX -K3+XZC9"=HO*D622*1-VX!T<HV#W&5.#@<=ATIEK?275]?(D8-
MM;%8E8=7EQEP.V "@^NX=JS[ 7&B>%F"6;AT9Q:6C'<RAG(B1B,^JY.3@=2<
M9K2L;,Z7I*6\>9Y8T+,> 9I#EF8]@68D_C0!6MM3O?[2AL[^QA@:XC>2(PW)
ME(V[<AAM7'WAR,CMGIF&37ITEDF6R5M-BN1;/<>=A]VX(6";<%58X)+ \,<<
M#,-M;?:/$<6HVVDS6$I5EO9I0B^<N/E0A6.Y@V#NZ  C/-0RVM\+:YT5;*5E
MFO6E6ZROEB)Y?-<GG(8;F4#') /0D@ W]0O8].L)[N4,RQ(6VKU8]E'J2< #
MU-5Y;G4HK2T5+**>^D4>:/,,<,9 RQ+88XSP!@D_F1'>QO?ZU:6A1OLUL!=S
M$CAWR1&OO@AG]BB^M-UVYU**.&#3K2>3SB1+<0["T"C'16(!8YP.PY)S@ @
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0URL'A'4;>]NKN+Q=J@FNBIE;[/:G=M&!QY7'%6?[ UK_H<=3_\  6U_^-4
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M (S0!T-%<]_PC%Y_T-NO?G;_ /QFC_A&+S_H;=>_.W_^,T =#17/?\(Q>?\
M0VZ]^=O_ /&:/^$8O/\ H;=>_.W_ /C- '0T5SW_  C%Y_T-NO?G;_\ QFC_
M (1B\_Z&W7OSM_\ XS0!T-%<]_PC%Y_T-NO?G;__ !FC_A&+S_H;=>_.W_\
MC- '0T5SW_",7G_0VZ]^=O\ _&:/^$8O/^AMU[\[?_XS0!T-%<]_PC%Y_P!#
M;KWYV_\ \9H_X1B\_P"AMU[\[?\ ^,T =#17/?\ ",7G_0VZ]^=O_P#&:/\
MA&+S_H;=>_.W_P#C- '0T5SW_",7G_0VZ]^=O_\ &:/^$8O/^AMU[\[?_P",
MT =#17/?\(Q>?]#;KWYV_P#\9H_X1B\_Z&W7OSM__C- '0UB6FA/;>)M:U4S
M(T>H06\2QA>4,8<$GZ[Q^50_\(Q>?]#;KWYV_P#\9H_X1B\_Z&W7OSM__C-
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MT-NO?G;_ /QF@#H:*Y[_ (1B\_Z&W7OSM_\ XS1_PC%Y_P!#;KWYV_\ \9H
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MWU ^-[&TCU[48K6YM;FY>%!#M5HWA"@$QDXQ(V><].:RK;QQJ&FZ2D^J6*W
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MN4'(5@#AAGG!R* .4UCQG?IH-U=PVB6T5Q!=?8+A9M\@>)6(+H5P,A21R<<
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M8SKVD+#:<_4#% '&1^,]3LY+F*XM%NI'OHK6U$?F,0#:),Q81QLW<G@'EL<
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ME$D:&(JH' ,0 C_[Y &/I4,_AC1;EE,VG0L0SL>H#;W+L&_O L2V#D9/2@#
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M LEL=O[LY_A(*D8Z$$ @^U0VNA:997SWMM9QQW#[LN,\;CEL#HNX\G&,GDT
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MZG<WYT <E?:[KZ^(I+2V%LT::Q':Q(TA4-&;-I"&.PD?-AN,GC' J.3XAW
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M-/A4P(D<>T8"JCAU&!UPPW#/?/J: .<C\=7HMK::?28%^W6XELU2Z)RQFBA
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M7D=[:-FEECF<D?>=,;&/N-JX^E '':=XSOY+2&46$<EK']C6>66Y/FGSW"#
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M"L<C$QK=31HB[$8 [8B,L5' YY)':2:)I<MR]S)80-.\Z7#2%!DRH-J/]0.
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M=,>TC-D5V^3CY<9R/UYH XE_%FK66B:C)>PH\1.J_9YXI\2CR))2HP4P!M7
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ML853RI(L!>J.07!]=Q ))ZFGWFD:?J%M#;W5JDD<)!B'(,9 Q\I'(X)''8T
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MW:9*CGTW'GK66?!.B,&5H9VC*31K&US(51)3EU4;L $^G]* (5\6S->MIO\
M9$O]J";9]G\]-NWRQ)OW].A QZGTYI;+Q)+%X&L-;OD0SS11F0/(D*AF('S,
MQP ,]L^P-:%WX;TV]NGNG2:.Y>02>=#.\;@A-G!4C V\$=_K0WAS33H]II:Q
MR1VUF4:WV3,'C*_=(;.<_P"- & ?B'$=.-Y#I4\R16]S<W&R5,(D$FQRI_BS
MU7ID>E2W7CV*RG:SNK P7XF,?E2W"*FT1K)N+].CJ,>I].:U(_"&C1VMQ;"W
MD,=Q#-!+OG=BR3-NDR2<Y)YSUJ6[\-:;=W3W;)/%=._F&>"=XW!V!."I'!4
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M9-()9K=;B1897&/F:,':3P,\<XYS0!E7/B*^3PWXGOXV42Z?.Z6VY/N@1QL
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M[GP<'+GZ#%;4GA+2GATZ*,75N-/@:WMVM[N2)EC;;D%E8%L[%ZYZ4A\)Z?\
M:Y;E)]2BEF*&4Q:A,@D*HJ L W)VJH)[XYH PSK.MP:?>ZX=0CDMK;4Y;9K)
MK=0#$MP8OE<<[L<C.<GC'-$_B'4!I\^NR:HMG:1WDT,=M]B:6/RXI&1C*R L
MI.QCG@+D<''.ZGA'2$O#<%+I\W)N_)>[E:$2EM^[R]VW.XY''!YI+KPAI%Y/
M.\L=R([E]]Q;QW4B0S,>I:,,%.>_'/?- &-I>LZI?Z]=1R7E^L,6HRP+'%IP
M:'8CX ,N...ISQ6*_CO6D\$7\Q:#^VHYG,+>7\I@"M)O*_[J2)G^\H]:[:+P
MO807SW<,VH1-).;AXX[Z58V<G))0-MP3U&,5&W@W0F1E-EPUF]D3YC9,+,6*
M]?4GGJ,F@#'MM8U2\\3:A;&\OT@M]0%NB0:<)(MFU#\TF./O')SP*IZ=XSU.
M2W@MK[RH[R?446WD5?EGMC<>6V!V9>A^JGO74'PO8#4)KV.;4(9)YO.D6&^E
M1&? &2@;;T4=J>_AC2)8;")[0,MA<_:K8ECF.3<6SG.>I/'3\J ,W16UE_$V
MI6MWK+7%M8F+$?V:-?,WH3R0,C!]*+IM97QG;V*:RZV<UK-=F,6T9*[)(U"
MXS@ASSUXKH(;"WM[VZNXT(FNMOFMN)W;1@<=N*&L;=]2CU H?M,<+P*^X\(Q
M5F&.G5%_*@#D;?6M:&@:9XGEO8GMKZ2V+:>(0!'%.ZJH5_O%UWJ3G(.",#(Q
M+XGUK4[/Q##8V<UXD1L7N"MI8BY9G#@#([#GVK8A\*:3!=1SI%/LBE,T5NUQ
M(8(Y,YW+&3M!R21Q@'D8-2ZEX>L=4O8[R9[R.X2(Q![:[D@)0G)!V,,\B@#C
MK7Q1J^J7:XO+J)38VLY&G:?]I3S)%)?YB"0,C@&O11D* 3D^M8 \&Z1'(&M?
MMMGB%(=MI>RPJ40$*"%89QD\GFM]5"(J@D@#&2<G\Z %HHHH **** "BBB@
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MRX_)*)*4\H_+OWD#&=WWCTQQ7:Q6=O#=3W,<06:XV^:XZMM&!^0J@WAG1WU
MWK62F8RB8KO;RS(.CF/.POGG=C.>] '%OX@ULZDZQWFIB2367L[</#;"R*++
MC8S%?,SL#8YR6QC-=)XO&H0QV5Q8ZS>6/F7EM;/'#'"RE9)55F^>-CG#<<XX
M'%:\NBZ=-8SV<EJC6\\IGD3)YD+;]V>H.[G(Z&K%U9V]ZD:7$0D6.1)5![.K
M!E/X$ T <?<Z]K&F7FO626VHZHMG:QM%<H+9?+8QL2SY9,G(!X4CCIVJA8ZK
MKVIZC*GVK7&C2"U.=.BLMBEX59BWFKNR22>.*[PZ=:&2[D,"[KM0DYR?G !
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M!N(8WCCD[JKE2P_$HOY50E\,Z/-?F]DLE,K2"5EWL(WD&,.T>=I88'S$9X%
M&)=:YJ,?AKQ%=I<;;BTOWA@;8OR+E,#&,'[W?UK&3Q!K;:D%2\U/S9=:EM(1
M+#;+9&-)V!0MM\S/EJV.<EAQFNTG\,Z/<ZD;^6S#3EUE;]XP1W7&UF0':S#
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MZJ1#<:@([@WB^1A)950"/.>  .G49JHD^L6W@*_U5_[8AN!HYF2XGODD5G*
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MFRILDL+=TW2-M:,$9<Y<_P# CR?6@#AI/%>MZ=J%W<W<D,]A:KJ<S01KAW6
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ML17*C:05X]B!CZ4 >?ZAX[U:?2-0FLK,6ZM#<FVG:)_W9B;&267:V0#T^Z<
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MYIHM/LV:TMY)KD-,P#&.=X65..,["03TZ8-=D-,L0<BS@!\Q9.(Q]Y0%4_4
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M7B?_ *&>W_\ !8/_ (N@#H:*Y[^RO$__ $,]O_X+!_\ %T?V5XG_ .AGM_\
MP6#_ .+H Z&BN>_LKQ/_ -#/;_\ @L'_ ,71_97B?_H9[?\ \%@_^+H Z&BN
M>_LKQ/\ ]#/;_P#@L'_Q=']E>)_^AGM__!8/_BZ .AHKGO[*\3_]#/;_ /@L
M'_Q=']E>)_\ H9[?_P %@_\ BZ .AHKGO[*\3_\ 0SV__@L'_P 71_97B?\
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M!O[!IC'*#,L@C^9>AS]?E-3#P;<ZIJ'B&S)LTMVN((A>7-H9+K"VL WQR;@
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M.GV-MIZ>8HQE8@\C+QGDR<D'KGTX[)K:%[N.Z:,&>-&C1^X5BI8?B57\JEH
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M.XKY=T@5_K@$\5;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,L^TML,6W>#@$]*2?QYH]L+02PZJ);L2-%!_9DYE(3;N)39N &X<D=ZY35_
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MIEE!'L/PK7T[PCXC-IX<T/4%TZ/3=!N$G6\@F8R7/EJRQCRRH"=?F^8]..M
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M1**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HJ&ZO+6Q@,]Y<PV\0.#),X1<_4U0_P"$GT#_ *#FF?\
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M _Z#FF?^!<?^-'_"3Z!_T'-,_P# N/\ QH U:*RO^$GT#_H.:9_X%Q_XT?\
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M?\)/H'_0<TS_ ,"X_P#&@#5HK*_X2?0/^@YIG_@7'_C1_P )/H'_ $'-,_\
M N/_ !H U:*RO^$GT#_H.:9_X%Q_XT?\)/H'_0<TS_P+C_QH U:*RO\ A)]
M_P"@YIG_ (%Q_P"-'_"3Z!_T'-,_\"X_\: -6BLK_A)] _Z#FF?^!<?^-'_"
M3Z!_T'-,_P# N/\ QH U:*RO^$GT#_H.:9_X%Q_XT?\ "3Z!_P!!S3/_  +C
M_P : -6BLK_A)] _Z#FF?^!<?^-'_"3Z!_T'-,_\"X_\: -6BLK_ (2?0/\
MH.:9_P"!<?\ C1_PD^@?]!S3/_ N/_&@#5HK*_X2?0/^@YIG_@7'_C1_PD^@
M?]!S3/\ P+C_ ,: -6BLK_A)] _Z#FF?^!<?^-'_  D^@?\ 0<TS_P "X_\
M&@#5HK*_X2?0/^@YIG_@7'_C1_PD^@?]!S3/_ N/_&@#5HK*_P"$GT#_ *#F
MF?\ @7'_ (T?\)/H'_0<TS_P+C_QH U:*RO^$GT#_H.:9_X%Q_XT?\)/H'_0
M<TS_ ,"X_P#&@#5HK*_X2?0/^@YIG_@7'_C1_P )/H'_ $'-,_\  N/_ !H
MU:*RO^$GT#_H.:9_X%Q_XT?\)/H'_0<TS_P+C_QH U:*RO\ A)] _P"@YIG_
M (%Q_P"-'_"3Z!_T'-,_\"X_\: -6BLK_A)] _Z#FF?^!<?^-'_"3Z!_T'-,
M_P# N/\ QH U:*RO^$GT#_H.:9_X%Q_XT?\ "3Z!_P!!S3/_  +C_P : -6B
MLK_A)] _Z#FF?^!<?^-'_"3Z!_T'-,_\"X_\: -6BLK_ (2?0/\ H.:9_P"!
M<?\ C1_PD^@?]!S3/_ N/_&@#5HK*_X2?0/^@YIG_@7'_C1_PD^@?]!S3/\
MP+C_ ,: -6BLK_A)] _Z#FF?^!<?^-'_  D^@?\ 0<TS_P "X_\ &@#5HK*_
MX2?0/^@YIG_@7'_C1_PD^@?]!S3/_ N/_&@#5HK*_P"$GT#_ *#FF?\ @7'_
M (T?\)/H'_0<TS_P+C_QH U:*@M+VTOX?.L[J&YBSMWPR!USZ9%3T %%%% !
M1110 4444 %%%% !1110 4444 1S00W,?ESQ)*F<[74,/R-5O[(TS_H'6G_?
ME?\ "KM<CKUG;OKUQ-JVD3ZG9O9)':)';F;9*&D\P# /ELP,>'.!\O48H Z'
M^R-,_P"@=:?]^%_PH_LC3/\ H'6G_?E?\*XUM)UQHKIEW1V[:W93?9&A,CE%
MDMBS>9NY VL2<'[IK.TO2+B/1[^""P$6J/!,H*:.]O,V7)(^TGY22N0#QR0<
M\4 >A_V1IG_0/M/^_*_X4?V1IG_0.M/^_"_X5Q=YI@NY;9?"^ESZ.?M,1>Z:
MR:-%/ES GR3MR5W#Y\8)91EL8K3^Q73^!&LX=/F@NHY%%U;JQ+3A95,VUR<O
MYBA\,3D[N<'. #H?[(TS_H'VG_?E?\*/[(TS_H'6G_?E?\*X:]T$:G>;-&L+
MK3-+:6VSY5NUN5F5G/FK&0,;1LRQ&&X'(%4KC3M3NM2^T:SI:Y^VS^87TQ[V
M)B(+= ZHO(5BC$'MR#S0!V'BG2M.3PAK3I86JL+"<@B%00?+;VJ[IVDZ:=,M
M"=/M"3"G/DK_ '1[53UA8T^'.HK%&(T72I0$6W, &(CTC/*#V[5LZ;_R"[3_
M *XI_P"@B@!G]D:9_P! ZT_[\+_A1_9&F?\ 0.M/^_"_X5S_ (D\7C0]>L;,
M-:BW"K+?&5L.D;R"-"G/]XLQZ_*A]:ZF42-"XB=4D*D(S+N /8D9&1[9% %;
M^R-,_P"@=:?]^%_PH_LC3/\ H'6G_?A?\*Y&3Q!XBL=.\07UU=:=.FE3^0L<
M5A(ID.V)MW^M;_GH1@#MU[5)J7CB1+Z6+3X)/+CMXI#]LLIH&W-.D9P'"Y&U
MCT[X^E '5?V1IG_0.M/^_"_X4?V1IG_0.M/^_"_X5S1\1ZI%XE^QW<EK:1->
M>1%;W%I*HFC/ =+C)1G/79C/\/7FM._O]3N/$!T?2Y;6V:&U6ZFGN(6ER'9E
M154,O]QB3GTXYR #2_LC3/\ H'6G_?A?\*/[(TS_ *!UI_WX7_"L"/Q5<V.N
M2:;K5NPD2P@G/]GVD]R/,=YE;E%.%Q&I (!Y/)Q65)\09H-)\.7<WV)&N[**
M_P!1#$KLB<HI\L$YSEV;G/RQL.I% ':?V1IG_0.M/^_"_P"%']D:9_T#K3_O
MPO\ A7):EXVO--O_ !-!-;P+%91/_9TY!Q),ELL[1R<]3NR,8R%;N.9[OQ'J
M3IJ5Y!?:786=C,+=?MD+MY\NQ6.6#C8N6VCACQGVH Z;^R-,_P"@=:?]^%_P
MH_LC3/\ H'6G_?A?\*Y$^*]0N]=N[6WOK:"WB, BV:1<7@</$CY\V-@H&6XR
M!Q@UT&LZC>QZEI^E::T$=S>"60SSH76../;NPH(W,2Z@<CN><8(!>_LC3/\
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MM-:FE:O=W_AFXO86M-0NXA*(A;;HUE9<[596YC8\ J2<&@#2_LC3/^@=:?\
M?A?\*/[(TS_H'6G_ 'X7_"N)?QEJEOI.HS/=64EU!;QR^3+IT]O+"QD53F%F
M)D3YN&4CD8YS6@VKZX^@:E?6VJ6;RV<9EQ/H=Q;@A58E</*"<X'(Z8Z'/ !T
MW]D:9_T#K3_OPO\ A1_9&F?] ZT_[\+_ (5CW&J:KIO@/4-9NIK2XO8;&2[B
M\NW:.,8CW!2I=B>1R<C/M6?%XCU3[''LN[:ZN;NYBM;<OI4]HD3,&8LP=R7
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M3S7B1G&<DAHG+8QP.U69?'#0ZUI%JYM%@FBMS?%FPZR3@B+8,] P&>O#J?J
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M,S /J]RRG"$\@O@CV-=;IO\ R"[3_KBG_H(JCXK_ .1.US_L'S_^BVJ]IO\
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ME5;"NJR+)@C'(+(,^HR.],F\+Z9-J:WZQM#*#$2L1"HQB8LA(QU!9OP-;-%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **JZ@]^EH3IL-M-<Y&$N96C3'?E58_I61]H\9?] O0?_!C-_P#&* .A
MHKGOM'C+_H%Z#_X,9O\ XQ1]H\9?] O0?_!C-_\ &* .AHKGOM'C+_H%Z#_X
M,9O_ (Q1]H\9?] O0?\ P8S?_&* .AHKGOM'C+_H%Z#_ .#&;_XQ1]H\9?\
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M^T>,O^@7H/\ X,9O_C%'VCQE_P! O0?_  8S?_&* .AHKGOM'C+_ *!>@_\
M@QF_^,4?:/&7_0+T'_P8S?\ QB@#H:*Y[[1XR_Z!>@_^#&;_ .,4?:/&7_0+
MT'_P8S?_ !B@#H:*Y[[1XR_Z!>@_^#&;_P",4?:/&7_0+T'_ ,&,W_QB@#H:
M*Y[[1XR_Z!>@_P#@QF_^,4?:/&7_ $"]!_\ !C-_\8H Z&BN>^T>,O\ H%Z#
M_P"#&;_XQ1]H\9?] O0?_!C-_P#&* .AHKGOM'C+_H%Z#_X,9O\ XQ1]H\9?
M] O0?_!C-_\ &* .AHKGOM'C+_H%Z#_X,9O_ (Q1]H\9?] O0?\ P8S?_&*
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M,O\ H%Z#_P"#&;_XQ1]H\9?] O0?_!C-_P#&* .AHKGOM'C+_H%Z#_X,9O\
MXQ1]H\9?] O0?_!C-_\ &* .AHKGOM'C+_H%Z#_X,9O_ (Q1]H\9?] O0?\
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M+T'_ ,&,W_QB@#H:*Y[[1XR_Z!>@_P#@QF_^,4?:/&7_ $"]!_\ !C-_\8H
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M4?:/&7_0+T'_ ,&,W_QB@#H:*Y[[1XR_Z!>@_P#@QF_^,4?:/&7_ $"]!_\
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M#8;:68EFYYST4 #J3GQZ7I.J6\.E/JT<Y.D?98%B(5PJL%DE7D_Q)']"O?-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !113)HS-!)&)'C+J5#H0&7/<9[T /HKDM*NKZ_U
M6/2Y+Z57T@_Z5,K+_II/"X&.G&6Z8;Y1GDUUM !1110!D>*_^1.US_L'S_\
MHMJO:;_R"[3_ *XI_P"@BJ/BO_D3M<_[!\__ *+:KVF_\@NT_P"N*?\ H(H
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M90)+$RAHB0,;.IR5VC/;D<FN;BTG4[#0-+C?2Y[F1O#O]FM#'M)BF*K\K9/
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M#7)_X 14 =#17/?V-XB_Z&N3_P  (J/[&\1?]#7)_P" $5 '0T5SW]C>(O\
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MKD_\ (J/[&\1?]#7)_X 14 =#17/?V-XB_Z&N3_P BH_L;Q%_P!#7)_X 14
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>*_\ D3M<_P"P?/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT]JK?V5K-OJ;-:W&K2*NIHD'GW4C)Y2VX9W8$X*NX*8/ )&T#- &W_:7BO\
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M_P &I_\ C5']I>*_^A;L/_!J?_C5=#10!SW]I>*_^A;L/_!J?_C5']I>*_\
MH6[#_P &I_\ C5=#10!SW]I>*_\ H6[#_P &I_\ C5']I>*_^A;L/_!J?_C5
M=#10!SW]I>*_^A;L/_!J?_C5']I>*_\ H6[#_P &I_\ C5=#10!SW]I>*_\
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MI>*_^A;L/_!J?_C5=#10!SW]I>*_^A;L/_!J?_C5']I>*_\ H6[#_P &I_\
MC5=#10!SW]I>*_\ H6[#_P &I_\ C5']I>*_^A;L/_!J?_C5=#10!SW]I>*_
M^A;L/_!J?_C5']I>*_\ H6[#_P &I_\ C5=#10!SW]I>*_\ H6[#_P &I_\
MC5']I>*_^A;L/_!J?_C5=#10!SW]I>*_^A;L/_!J?_C5']I>*_\ H6[#_P &
MI_\ C5=#10!SW]I>*_\ H6[#_P &I_\ C5']I>*_^A;L/_!J?_C5=#10!SW]
MI>*_^A;L/_!J?_C5']I>*_\ H6[#_P &I_\ C5=#10!SW]I>*_\ H6[#_P &
MI_\ C5']I>*_^A;L/_!J?_C5=#10!SW]I>*_^A;L/_!J?_C5']I>*_\ H6[#
M_P &I_\ C5=#10!SW]I>*_\ H6[#_P &I_\ C5']I>*_^A;L/_!J?_C5=#10
M!SW]I>*_^A;L/_!J?_C5']I>*_\ H6[#_P &I_\ C5=#10!SW]I>*_\ H6[#
M_P &I_\ C5']I>*_^A;L/_!J?_C5=#10!SW]I>*_^A;L/_!J?_C5']I>*_\
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M]I?_ (-W_P#C%']H>+?^A>TO_P &[_\ QB@#H:*Y[^T/%O\ T+VE_P#@W?\
M^,4?VAXM_P"A>TO_ ,&[_P#QB@#H:*Y[^T/%O_0O:7_X-W_^,4?VAXM_Z%[2
M_P#P;O\ _&* .AHKGO[0\6_]"]I?_@W?_P",4?VAXM_Z%[2__!N__P 8H Z&
MBN>_M#Q;_P!"]I?_ (-W_P#C%']H>+?^A>TO_P &[_\ QB@#H:*Y[^T/%O\
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M>TO_ ,&[_P#QB@#H:*Y[^T/%O_0O:7_X-W_^,4?VAXM_Z%[2_P#P;O\ _&*
M.AHKGO[0\6_]"]I?_@W?_P",4?VAXM_Z%[2__!N__P 8H Z&BN>_M#Q;_P!"
M]I?_ (-W_P#C%']H>+?^A>TO_P &[_\ QB@#H:*Y[^T/%O\ T+VE_P#@W?\
M^,4?VAXM_P"A>TO_ ,&[_P#QB@#H:*Y[^T/%O_0O:7_X-W_^,4?VAXM_Z%[2
M_P#P;O\ _&* .AHKGO[0\6_]"]I?_@W?_P",4?VAXM_Z%[2__!N__P 8H Z&
MBN>_M#Q;_P!"]I?_ (-W_P#C%']H>+?^A>TO_P &[_\ QB@#H:*Y[^T/%O\
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M>TO_ ,&[_P#QB@#H:*Y[^T/%O_0O:7_X-W_^,4?VAXM_Z%[2_P#P;O\ _&*
M.AHKGO[0\6_]"]I?_@W?_P",4?VAXM_Z%[2__!N__P 8H Z&BN>_M#Q;_P!"
M]I?_ (-W_P#C%']H>+?^A>TO_P &[_\ QB@#H:*Y[^T/%O\ T+VE_P#@W?\
M^,4?VAXM_P"A>TO_ ,&[_P#QB@#H:*Y[^T/%O_0O:7_X-W_^,4?VAXM_Z%[2
M_P#P;O\ _&* .AHKGO[0\6_]"]I?_@W?_P",4?VAXM_Z%[2__!N__P 8H Z&
MBN>_M#Q;_P!"]I?_ (-W_P#C%']H>+?^A>TO_P &[_\ QB@#H:*Y[^T/%O\
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M*/\ A//#O_/W<?\ @%/_ /$4 =)17-_\)YX=_P"?NX_\ I__ (BC_A//#O\
MS^7'_@%/_P#$4 =)17-_\)YX=_Y^[C_P"G_^(H_X3SP[_P _=Q_X!3__ !%
M'245S?\ PGGAW_G\N/\ P"G_ /B*/^$\\._\_=Q_X!3_ /Q% '245S?_  GG
MAW_G[N/_  "G_P#B*/\ A//#O_/W<?\ @%/_ /$4 =)3'FBCD2-Y45WSL4L
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M+.6\SR+B.1F^Z, JAP.N>M '>K<P.7"31L4&7 <':/?TIT4T4Z;X9$D7^\C
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M%'_";Z#_ ,]KS_P7W'_Q%,L=>UBZM;?4)-%B33KJ$S1LMUF6)=A=3(I4 9
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M(&%O<+*8O+;CD,RD!NY*\?-0!?\ ^$WT'_GM>?\ @ON/_B*/^$WT'_GM>?\
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MV\4-TTC-F0JY;,:XVJ"W&<@'I0!8_P"$WT'_ )[7G_@ON/\ XBC_ (3?0?\
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MFP3TJ)?%>CO \OG3C:4 C:UE61]^=FU"NY@=K8(!^Z?0T 0?\)OH/_/:\_\
M!?<?_$4?\)OH/_/:\_\ !?<?_$5%)XUL6O%MK5'<M!'()9HI8T#23")$;Y"0
MQ;<,$9!4^^+7_"8:&(YI6O&6**)IO,>"14=%8*61BN' +*,KGJ/44 1?\)OH
M/_/:\_\ !?<?_$4?\)OH/_/:\_\ !?<?_$5HVFM6-]:W5Q#)($M'*3B6)XFC
M(4/RK '[K*>G0BLK2_&VF7^DPW<_G6UP\,$KVQ@D+YE!V!!M!DR5<94$?*:
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M0!SW_";Z#_SVO/\ P7W'_P 11_PF^@_\]KS_ ,%]Q_\ $5T-% '/?\)OH/\
MSVO/_!?<?_$4?\)OH/\ SVO/_!?<?_$5T-% '/?\)OH/_/:\_P#!?<?_ !%'
M_";Z#_SVO/\ P7W'_P 170T4 <]_PF^@_P#/:\_\%]Q_\11_PF^@_P#/:\_\
M%]Q_\170T4 <]_PF^@_\]KS_ ,%]Q_\ $4?\)OH/_/:\_P#!?<?_ !%=#10!
MSW_";Z#_ ,]KS_P7W'_Q%'_";Z#_ ,]KS_P7W'_Q%=#10!SW_";Z#_SVO/\
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MV\,VUIXMN-?@ED1[BW,4EN/N%R5)D'HQ"*#ZX!ZT6'AV.QM],@^T-)'8-*Z
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M?!UHFE:WIEK,UO9ZISY2KD0,4"L5^N <>N?6K&K^&;?6+R2XFGEC+6PA7R\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEO 4 + '@94DEC@4 ;=%<O/J.HZ/JVEPW=VLUI]E5+UF0#YR0@E!'3+D CH
M<\8JM%KFI3Z/K6H/.(HTDC:W"HH:*W8*VX9ZR;&R ?XL#'J =C17/^';XW-[
M?PQ7%W-:PK%L^VQF.57;<6&&56VXV$$CJ6 /&!T% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQSVYE ? &Y<.N,@#(.1D9P,G.K10!E'2[P:G872WZ.EM T+B:#<\NXJ6;<&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW1C#_-$45^>.K'C!.".1D&37FM+9;'3FDM;>T*/(L]_*[1<$83&X;S\V0"W
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M0<^] &I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 'IZ50L]*6VNC=2W5S=W&PQK).R_(I() "@ 9(&>,G ]!5^B@ HHHH
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MDC4#Y%3;)N8' V]0&X/3(YW:* .:O;*^M/!\6CV]E+>S_8Q 7A>-45@H'\;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<UV^-IK=E%-KW]
MF6LUO,Q+&%071H\8,BGJ'/'L/>B#Q&T.G6QN%$]U<22K >(5EC1L>:=Q^5<;
M?7.1@8(J_>Z=>SZQ;7]M>PPK#"\7ER6Y?<'92QR'&/N+CCUZ]EU;1TU)[>=6
MB2YM]WEM+")4(;&Y64D9!P#P0<@<]00!-/UI=0@NO*@/VJV.'@$BMDD9!5@<
M$'L>.ASC%1Z1KLFL1P7$6EW<5K,F?.F*K@XS]W.2,\9 Y/3(YJ6RTZZL[6<+
M<6@N),;3%:".-,?[ ;)_%ORI-%TZ]TNRBM)[V&XAAB6.+9;F-A@8R3O.?TH
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M[826;S F$M(KJY R5)!X;'..F <$X-6K^R34+*2VD9T#8973[R,I#*PSQD$
M\^E5(--O'O8;K4;V.X-N#Y*0P&)0Q&"S99B6P2!T')X] #+2YU74/$=W"8[Z
MWMK:1(U\F6$+@@,68').<]/3MG-=16/::9J5MJES=-J%L\5Q('DB%H0<!0H
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MD&./E7&""-HY/.;>F6,EC%()9('=VSB"W$*#CL,D_F30 S1M5;5[-[A].O;
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M@&5@FMS(GF9^_P .O('3.<=1S0!6>YU'_A'[".662&[NYUA,K(!(L98G<1C
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M/,A@BA,8W?PER6;<1VQ@9YQP,:= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !113&FC25(FD19'SL0L 6QUP.^* 'T444 %%%% !14<D
M\4.SS943>P1-S ;F/0#U-24 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGY"HET33TT]K!;<BW:3S=HD;(?=NW!LY!W<Y!Z\T 95_K-]IR:R5*W+020+
MNP#9YK!>>1D+D'J,@=1UI^FWFKI?K'<07LUJT;,\EQ#$C1N.0%V-R#R,$9!Q
MS6C;:%IEF+@0V<8%RNVXWDOYPY^_G.X\GD\FG6FBV%E.)X8G,B@JC2RO)L![
M+N)VCV&* .;OWU"ZT32M3GOH'CN;VQD-L8P$0//&0(VZ[AD<G.>>!GCLZR9?
M#&CS,3)9AAO\Q4,C;$?.=R+G"-GG*@&M8# Q0 R66."-I)9%CC7JSG 'XT_(
MQGM5/5=*L=;TV;3M3MDN;.;'F1/T;!!'Z@&K!@B:V-N8U,)384QQMQC'TQ0
ML4L<T:R1.LD;#*LIR#]#0DL<C.J2(Q0[7"G.T^A]#5?2]+L=%TV'3M-MDMK2
M $1Q)T4$DG]233+#1].TNXO9[*TC@EO9?/N60<R/_>- %ZBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* /1*9++'!&TDLBQQKU9S@#\:\YGCUVST\*;C79+UM+BEL2HD<-?'<9!+@8
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MS%\TKN"9^;'3./3FO/;F/Q.+"^O))]1,YO;>&1%#A5M_)B,C1HF3_K"P)3)
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M4;22@CSYA (.1SDCH?&HNY'\D_VG]B>QN @T^-W9KCY0@?8"<8W8S\IYSVH
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M;[<,50F ';D<# /3TK52ZTOPYXYOHI%BL;632[1(%CA*H2)KDL %&/X@3]:
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M+(#G/.WIFNQ\,;G&KS*Q:WDU*7R">X551C^,BR'\: &;/&7_ #\:#_WXF_\
MBZ-GC+_GXT'_ +\3?_%UT-% '/;/&7_/QH/_ 'XF_P#BZ-GC+_GXT'_OQ-_\
M770T4 <]L\9?\_&@_P#?B;_XNC9XR_Y^-!_[\3?_ !==#10!SVSQE_S\:#_W
MXF_^+HV>,O\ GXT'_OQ-_P#%UT-% '/;/&7_ #\:#_WXF_\ BZ-GC+_GXT'_
M +\3?_%UT-% '/;/&7_/QH/_ 'XF_P#BZ-GC+_GXT'_OQ-_\770T4 <]L\9?
M\_&@_P#?B;_XNC9XR_Y^-!_[\3?_ !==#10!SVSQE_S\:#_WXF_^+HV>,O\
MGXT'_OQ-_P#%UT-% '/;/&7_ #\:#_WXF_\ BZ-GC+_GXT'_ +\3?_%UT-%
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M^1&C;<Y_UX)W8^[(:7P\?#SPZ4M\1)XK>7;>I&<W/FD$2B4=?)'/7Y<;<=J
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MO[7;?\_$7_?8H^UVW_/Q%_WV*Q/^$!\'?]"KHG_@!%_\31_P@/@[_H5=$_\
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MT*NB?^ $7_Q-'_" ^#O^A5T3_P  (O\ XF@#;^UVW_/Q%_WV*/M=M_S\1?\
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MFW/534NKZ)X0T[58-,MO ^BW5W+"TX0V]O%E0<87</F;/8?B1D4 =S]KMO\
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MZN.F5.:=5/3=)T[1K8VVEV%K90%BYBMHEC4L< G"@#/ _*KE !1110 4444
M%%%% !1110 4444 %%%% !7-IX?O[/3[2&SNK)I('N"WVJVWJPE<MQ@A@1G'
M!P1G/8CI** //9/AM(L$MK#<:<\4EG#:BXNK(R3P^6FS?&P8;3W'H<>E=O\
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M&\4A9F?<RO&P7&>",^U==10!SUSHFIZGX?UJQU'4HFGU*WD@3RHBL5N&0J,
MDEN3DDGGVJ6]TB_35QJFE75O'</;+;3QW,1=)%5F9"-K @@N_KD-^-;E% ''
MI\/]/GN('U9;?4E$-T)UGMQAY9Y$=G4$G9C:0 .0".>.5M_!DZZ9+:W.I!Y8
ME@CLKA8N8E@D,D189PQR0&QC<%[9KKZ* .1U/PIJ&OQ73:M?6IF>SDLX%MX&
M$<:R,I=F#,2Q.Q1CC !ZYJ]J'A#2KN*QMX;"Q@M8+P74L"VR[)L(ZX*@8S\P
M.3GI7044 <IK'@]+O4-.GL+;1U@L[>: 6MW9>9$/,9&W*H( (V'_ +Z-13^
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M4>T1.9_.4H"3A4( 53GA0*CO_!5_K$]U<W]YI\=S+9R6WF6EJR&0N -SY<\
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MR[.R!$,6,Y8 XPS9YP /E'N:WJYWQ7KT^E06]AID8GUK46,-E$>54X^:5_\
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MPTFUL[B<7$D$8C\W&"X' )]\8S[YJ[110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@5CG8HZ$JN%&>,C)ST)I-Q<R3W]L;LW<5NP2.Z=%!+X.Y#M #;3CD =<=5-
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M+KJFM:1&=,N;T^7;*8UOC:L[2ND,1$:C)W%FD;!Y)V,.O(=-KNL"&.^U'-M
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M)]XD_P"P7<_^BFKH*Y_QU_R3[Q)_V"[G_P!%-0!OK]P?2EI%^X/I2T %%%%
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M%\V!PD.9DBX&[[OEPS/CU93GF@#NWDU(.0EI:,O8M<L#^7EFF^;JG_/G9_\
M@6W_ ,;KCH_$VN&6U@FD2&>2YBCA5K1O])C>=@7/.%Q$H;'KUX(%:6N36_\
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MG'F.P.2G<*1RI/'/4#.,'!":7;7EI;&"5;*.*- L$=LC*%QG.<GZ?KZUHT4
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M@YZD8X;HW/ Q5>Y\;7T4Q=;:W6SBN)XYYR'D"K'.T0W;,F,84G>5*YR.,9H
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MZ&B@#GMOC+_GMH/_ 'ZF_P#BJ-OC+_GMH/\ WZF_^*KH:* .>V^,O^>V@_\
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M ,570T4 <]L\8_\ /?0O^_,W_P 51L\8_P#/?0O^_,W_ ,570T4 <]L\8_\
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MN,UT7AMIH_!%]'K>L7"21W=Q#/>^:0R?O2#M8YVCL/0=,8H T]OC+_GMH/\
MWZF_^*HV^,O^>V@_]^IO_BJYBQGN)M8_L34+VYAM$OIPWE:A*P&((W2,3Y#M
MPSN0<8(QT SKPZE>W'@;P\TTTGG:@]K#-/G:Q1B"S9'0LHQD=VXH T-OC+_G
MMH/_ 'ZF_P#BJ-OC+_GMH/\ WZF_^*KC(Y=2%VERS74$<OB"> :D^JS-&BK=
M.!&T'W,,J^6,\9(Z'%:/AV*>]U2ZFN=TB_VI>QB5M>N%<*MQ(J@6X^3    S
MT - '1;?&7_/;0?^_4W_ ,51M\9?\]M!_P"_4W_Q596B7MY>:A8Z-/=3>;H?
MF'49"Y!EVY2#>>X="93[J*Z76EFN-"NOL=Z]LYB++/$ S 8S\N<C)'?G% &?
MM\9?\]M!_P"_4W_Q5&WQE_SVT'_OU-_\569;RW[3>"+AM2N##<1!)8,\2M]E
MD<NYZL<A<#IP3R<8S]2N#>6$<B:E>_VGJ?GRZ?!%>-#'&A8".=RI'RJ@C.#D
M$D@ DT ='M\9?\]M!_[]3?\ Q5&WQE_SVT'_ +]3?_%5AVEU=?VW:SOJ$\EZ
M^M2V4L'G-Y9@6%R/W6=HX5)-V,\]<&JUU<:O;6FIV9U&:ZD?Q!#:O/),8-D;
MP0MM#(,QKN./EY^;KDYH Z7;XR_Y[:#_ -^IO_BJ-OC+_GMH/_?J;_XJLK1-
M0GCGT1?-G;S+R\T^9'N6G4[/,<,KD L%,6T$\@,022,UVU '/;?&7_/;0?\
MOU-_\51M\9?\]M!_[]3?_%5T-% '/;?&7_/;0?\ OU-_\51M\9?\]M!_[]3?
M_%5T-% %/31J0MC_ &HUHUQN.#:JP7;QC[Q)SUJY110 4444 %%%% !1110
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M3K2WV,77RH57#$;2>!U( &?2KU% &:WAW17FMYFTBQ,ENJI"QMUS&JG*A>.
M#TQT[4W_ (1O0\7 _LBQQ<',W^CK^\.[=SQS\W/UYZUJ44 9+^%_#\D:1OHF
MG,B%BJFU3 +8W8X[[5SZX%37>A:3?HRW>F6<ZM)YK"2!6R^T+N.1UV@+GT&.
ME:%% "(BQHJ(H5%&%51@ >@I:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *1E#*58 J1@@C@BEKG_'3.G@7
M6FC)#BU?&&*\X]1TH U[/3;'3HWCLK*WMD<[F6")4#'U( YJ2*VMX"##!%&0
MBQC8@&$7.U>.PR<#MFN$DT[6M 9[NU2QTI;J6ULUMX)Y+I 7F"M*0ZH P5L
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M:<G9QCG !WT>D:;#=_:XM/M$N?\ GLL*A_\ OK&:LF*-I5E**9$!"N1R <9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:* &I&D:[4157.<*,"G444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>modificationno8effective002.jpg
<TEXT>
begin 644 modificationno8effective002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HR:WI
M44C1R:G9)(A*LK7"@J1U!&:;_;^C?]!:P_\  E/\:R+OX=^#[Z\FN[KP[82W
M$\C22R/'DNQ.23[DFHO^%8>"/^A8T[_OU0!N?V_HW_06L/\ P)3_ !H_M_1O
M^@M8?^!*?XUA_P#"L/!'_0L:=_WZH_X5AX(_Z%C3O^_5 &Y_;^C?]!:P_P#
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M_P# E/\ &C^W]&_Z"UA_X$I_C6'_ ,*P\$?]"QIW_?JC_A6'@C_H6-._[]4
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M._[]4?\ "L/!'_0L:=_WZH W/[?T;_H+6'_@2G^-']OZ-_T%K#_P)3_&L/\
MX5AX(_Z%C3O^_5'_  K#P1_T+&G?]^J -S^W]&_Z"UA_X$I_C1_;^C?]!:P_
M\"4_QK#_ .%8>"/^A8T[_OU1_P *P\$?]"QIW_?J@#<_M_1O^@M8?^!*?XT?
MV_HW_06L/_ E/\:P_P#A6'@C_H6-._[]4?\ "L/!'_0L:=_WZH W/[?T;_H+
M6'_@2G^-']OZ-_T%K#_P)3_&L/\ X5AX(_Z%C3O^_5'_  K#P1_T+&G?]^J
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MW_?J@#<_M_1O^@M8?^!*?XT?V_HW_06L/_ E/\:P_P#A6'@C_H6-._[]4?\
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M/^A8T[_OU2'X9>!AC/AG31G@9BH W?[?T;_H+6'_ ($I_C1_;^C?]!:P_P#
ME/\ &L(_#+P,.OAG31_VRI?^%8^"/^A8T[_OU0!N?V_HW_06L/\ P)3_ !H_
MM_1O^@M8?^!*?XUA_P#"L/!'_0L:=_WZH_X5AX(_Z%C3O^_5 &Y_;^C?]!:P
M_P# E/\ &C^W]&_Z"UA_X$I_C6'_ ,*P\$?]"QIW_?JC_A6'@C_H6-._[]4
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MLHH,\#2JI(&,$J=RGC^1KT7P_KNIWGQ1UC2KB[9[&#3+::.$J,*[ ;CG&>:
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M$<&(DCHI()^4UZGM4 # P.@Q1@9)P,GK0!QVB7.E6?B2]72+N!=$6UB\XQS
MV\=PSD*%.=H9@1D#_8[GF;Q(UDWB338-<E2/1FMIBHF?9"]P&3:'.<$[=Q4'
M@_,>H&.J6-$0(J*JC^$# H=$D0JZJRGJ&&0: /+!!+J=_I]I9I#?:9]NO/L
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M4UO444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@8L%!(+$L0,DD+Q@8QWS5.RT6]A;3[6:: V&FL6@*9\R0!2B*X/ VJW4$[B
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M9\OF^9YF,9SMS\N,YV]\U+:Z;/+)?7&I^49+R)8&BA)*)$N[ R0"22[G.!U
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M+">(A>I#CBGK)&Z;T=67^\#D4 <-_P +F^'_ /T,*_\ @+-_\11_PN;X?_\
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M5_\  6;_ .(KNZ* .$_X7-\/_P#H85_\!9O_ (BC_A<WP_\ ^AA7_P !9O\
MXBN[HH X3_A<WP__ .AA7_P%F_\ B*/^%S?#_P#Z&%?_  %F_P#B*[NB@#A/
M^%S?#_\ Z&%?_ 6;_P"(H_X7-\/_ /H85_\  6;_ .(KNZ* .$_X7-\/_P#H
M85_\!9O_ (BC_A<WP_\ ^AA7_P !9O\ XBN[HH X3_A<WP__ .AA7_P%F_\
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MH_X7-\/_ /H85_\  6;_ .(KNZ* .$_X7-\/_P#H85_\!9O_ (BC_A<WP_\
M^AA7_P !9O\ XBN[HH X3_A<WP__ .AA7_P%F_\ B*/^%S?#_P#Z&%?_  %F
M_P#B*[NB@#A/^%S?#_\ Z&%?_ 6;_P"(H_X7-\/_ /H85_\  6;_ .(KNZ*
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ME.\)&5;@+D8)[XKL?^%S?#__ *&%?_ 6;_XBN[HH X3_ (7-\/\ _H85_P#
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MBY_QKNZ* .$V?%?_ )Z^#?\ OBY_QHV?%?\ YZ^#?^^+G_&N[HH X39\5_\
MGKX-_P"^+G_&C9\5_P#GKX-_[XN?\:[NB@#A-GQ7_P">O@W_ +XN?\:-GQ7_
M .>O@W_OBY_QKNZ* .$V?%?_ )Z^#?\ OBY_QHV?%?\ YZ^#?^^+G_&N[HH
MX39\5_\ GKX-_P"^+G_&C9\5_P#GKX-_[XN?\:[NB@#A-GQ7_P">O@W_ +XN
M?\:-GQ7_ .>O@W_OBY_QKNZ* .$V?%?_ )Z^#?\ OBY_QHV?%?\ YZ^#?^^+
MG_&N[HH X39\5_\ GKX-_P"^+G_&C9\5_P#GKX-_[XN?\:[NB@#A-GQ7_P">
MO@W_ +XN?\:-GQ7_ .>O@W_OBY_QKNZ* .$V?%?_ )Z^#?\ OBY_QHV?%?\
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M .<YR/2O4ZX2T_Y+IJ7_ & (?_1S4 &SXK_\]?!O_?%S_C1L^*__ #U\&_\
M?%S_ (UTNH:_;V%[]B2VO+RY6,2R16D.\QH20&;H!D@X'4X. <5)8:]I^ISQ
M16<QE\VV6Z1@I *%BO?H<@Y!Y% '+;/BO_SU\&_]\7/^-&SXK_\ /7P;_P!\
M7/\ C6^WBS24MM,G:5PFI2^3;Y0YSG;EO0;BHSZL/6GOXHTJ.]U>S:9A<:5"
M)[F/;SL*;\K_ 'N/3H2/44 <[L^*_P#SU\&_]\7/^-&SXK_\]?!O_?%S_C6X
M?%EO_:L6G+IVIM-*ADC80#:R J"^<] 77\Z9<>,K&""WG6SU">&XE,,<D,&X
M&0.T>WKUW*?TH QMGQ7_ .>O@W_OBY_QK%M_$?Q-N?%][X;0>$Q=6ELER\AC
MN-A5C@ <YS^%=T?%6G1V]Y).+B"6T\OS+>6/$I\P#RPJC[VXG:,?Q CJ*X^T
MO[>R^.VL?:',9N--M88QM)RY8X''T/M0!H;/BO\ \]?!O_?%S_C1L^*__/7P
M;_WQ<_XUTE]XGT?3;DV]Y>"&07$5L=R-@22 E!G&.0#ST'>I)M?TZ"\-H\S?
M:!,(-BQ,Q+F)I0!@<_(I/Z=>* .7V?%?_GKX-_[XN?\ &L7PWXC^)OB>UO;B
MT'A.);2\ELW$L=P"7C(R1@GCFN\TSQ/I^KWLMI:QW_FPMLE\ZPFB5&VAL,S*
M #M93C/<5RWPB_Y WB'_ +&"\_FM $^SXK_\]?!O_?%S_C1L^*__ #U\&_\
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M7P;_ -\7/^-&SXK_ //7P;_WQ<_XUW=% '";/BO_ ,]?!O\ WQ<_XT;/BO\
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M/&]I]OJ;:[>:U<V'D&XB@M$MO.4NL:-(QD<CY<YD.%!/ Z\X'144 %9^O?\
M(O:G_P!>DO\ Z :T*S]>_P"1>U/_ *])?_0#0!B?#+_DF7AW_KQC_E75URGP
MR_Y)EX=_Z\8_Y5U= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.]020&#JP."3@XR,GGDU!?Z*;GP_-I$4\FRX'ESRS.6=D9OWG/J5+ = ,C'
MQ0!IV\RW-M%.@(61 X!]",U)2*H50J@  8 ':EH *\IOM0ETOXK^*[JWQ]H_
ML:UCA+#($CR!$)]@S"O5J\ODTU=7^+_BJP9S&9M$MPD@&2CALJWX$ _A0!VF
MJ17,(T:T@U&ZA#W'D22*59Y%$+GDLIYR@.?K4MF;E-0O-*N;N6X00)+'.VU9
M '+J5)4 <;<@X!Y]LE]YIMQJ4%@\MV]G=6S"8_9@KKO*%2/G4Y'S-C@5)::<
MUB+F<327=[,HW2W# %MN=J_*H"J"3T'<GDF@"'PU?3:AH44ERV^YADEMIGQC
M>\4C1LWXE"?QKD_A%_R!O$/_ &,%Y_-:[+1--.DZ1!9LXDE7<\T@& \KL7=O
MQ9F/XUQOPB_Y WB'_L8+S^:T >A4444 %%%% !1110 UW$:,['"J,FN46^OI
MOAVNL&\N(;JXA%[NB 9D#G<(P"#D!6"\#G'J:ZT@$8/(K M_#TJ^%DT*2[>&
M*']S%+!M+>2I_=@[@1D+M!^F>] "Z(T]U=/<QZA?RVL?F0O#>PK&Q?*%6 V*
M0,;ASUR*ET>[F.J:QITTC2&UG62)V.3Y<B[@#]&W@>P6I;?29H]1BO+C5+FZ
M:*-T1)$C51N*Y/RJ#GY13M+TZ2UNM1O+@H9[VXWG8<A8U 1%_P"^5R?=C0!I
M4444 %<U\0_^2<>)/^P;/_Z :Z6N:^(?_)./$G_8-G_] - %_P +?\BCHO\
MUX0?^BUK6K)\+?\ (HZ+_P!>$'_HM:UJ "BBB@ HHHH **** "BBB@ HHHH
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M6W0$$1M@@XH Y[X?^/O"6G?#_0K.\\0Z?!<PVB))%), RL!T(KI/^%E^"?\
MH:-,_P"_XJ/P7H6D2^!?#\DFE6+R/IMNS,UNA))C7))Q6[_PC^B_] ?3_P#P
M&3_"@#&_X67X)_Z&C3/^_P"*/^%E^"?^AHTS_O\ BMG_ (1_1?\ H#Z?_P"
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ME^"?^AHTS_O^*/\ A9?@G_H:-,_[_BMG_A']%_Z ^G_^ R?X4?\ "/Z+_P!
M?3__  &3_"@#&_X67X)_Z&C3/^_XH_X67X)_Z&C3/^_XK9_X1_1?^@/I_P#X
M#)_A1_PC^B_] ?3_ /P&3_"@#&_X67X)_P"AHTS_ +_BC_A9?@G_ *&C3/\
MO^*V?^$?T7_H#Z?_ . R?X4?\(_HO_0'T_\ \!D_PH QO^%E^"?^AHTS_O\
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M[_BMG_A']%_Z ^G_ /@,G^%'_"/Z+_T!]/\ _ 9/\* ,;_A9?@G_ *&C3/\
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MW_%'_"R_!/\ T-&F?]_Q6S_PC^B_] ?3_P#P&3_"C_A']%_Z ^G_ /@,G^%
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MG-+#/#<Q^9!*DJ=-R,&'YB@"2BBB@ HHHH **** "BBB@ HI-P#!<C)Z"EH
M**"0!DG H!! (.0>] !14274$EU+;)*K3Q*K2(#RH;.TGZ[3^52T %%%% !1
M110 4444 %%0F[MA>BS,\?VHQF40[AO* XW8ZXR0,U-0 4444 %%%% !1110
M 444@8,,J01TXH 6BH;:[MKV(RVL\<\88KNC8,,@X(R.X-34 %%%% !1110
M4444 %%%% !1110 5PEI_P ETU+_ + $/_HYJ[NN(@C"?'"\89R_AZ(G_P "
M'']* .WHHHH **** "BBB@ KA-4_Y+9X?_[!-U_Z$M=W7$:A&'^-&BL<Y31K
MEA_W\0?UH [>BBB@ KA/@]_R3FU_Z^KK_P!'O7=UQ'PFC$7@*&-<X2\NU&?:
MXDH [>BBB@ HHHH **** "BBB@ HHHH **** "N-^+'_ "2SQ!_U[?\ LPKL
MJXWXL?\ )+?$&?\ GV_]F% '4Z?_ ,@RU_ZXI_(59JMI_P#R#;7_ *XI_(59
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\;?\ (A>(
MO^P9<_\ HIJW:PO&W_(A>(O^P9<_^BFH K^%3.OPRT5K89N!H\!B'JWDC'ZU
M78:;!X>TAHM)6^M#+;NDH=0RS&1 KDDY+;R"3UZYJ_X'_P"1!\.?]@RV_P#1
M2UH?V)I7VS[9_9EG]JW;_.\A=^[^]G&<^] $TU_9VUW;VD]W!%<W.[R(7D >
M7:,MM!Y.!UQ5#Q(B'2'<JI=9(@&QR 94S_*K\UA9W%W;W<]I!+<VV[R)GC!>
M+<,-M)Y&1UQ3+W2]/U+9]OL+6ZV9V>?"K[<]<9''0?E0!;K*\2$C0I\EA$6C
M$Y4X(AWKYI_[XW5H6]M!:0+!;0QPPI]V.- JCOP!Q4M &8]CHXO=-F\JV2XB
MW"S*84X*$$+CJ-I)QTXS6-'>7W]A6VNG4Y6FE:,M9%4\K+,%,(&W=N!)7.<[
MASQQ706FD:;82M+9Z?:V\CC#/#"J$CKC(%"Z3IJWQOET^U%V3DSB%=^<8SNQ
MGI0!BW2ZE-J.LE-8N88K6-'@BCCCPK%"3DE26' X/J>>F$U..?4;CPU<K?W%
MH9922L C(!-O(V1O5N>H^GYUN'2M.+W+FPM=]T-L[>2N91Z-Q\P^M$FF6$UD
MEE+8VSVJ8V0-$I1<=,+C Q0!0UQKJS\*:A);:C,+JUMI)%N"L98LJEAN&W;Z
M=AQ3R)](L+J_U'4Y[@)"TDBK$BHF!G]V,9]@&8^YJR=&TMK$6+:;9FT!W" P
M+Y>?7;C&:DM]-L+2WDM[:RMH8),[XXHE56R,'( P>* ,#3+S4H/$MO87DESL
MN+26;R[F6%WRK1@'$:C'WR#U'2GJ;V_TRZU$:])82))*H&V/R8 CE<,&7/0<
MDGKG&!Q6M;Z%I%I(DEOI=E#(AW*T=NJE3C&00..*=)HVES7HO)=.M'N@0WG-
M"I?(Z'.,Y% &5=6-Q/XQ+1ZM>6P:RR$B6(@8< @;D)]_QKH4(*##;QC[WK5>
M]TRPU((+ZRM[D)G9YT2OMSUQD>U3Q11P1)%#&L<: *J(,!1Z #I0!D>*HS)H
MJ!88I7%Y:%$E.%)^T1]3@X],X-9<$UWIUQKUV]A;P7\5GYD-E;$LDZH&*ONP
MNXDG:1M!7 Z@@UTUY86>HPB&^M(+F(,&"3QAP".^".M.^RVYDAD\B+? "L3;
M!F,$8(4]N .E ',Z=<ZO]HL;@O>2V\[ 2O<R6WE.K#ADV'(.<8 SD9SD\BK;
MWUT=(U6]E\32FYL+FXB6-DB &R1@BNH4%BP Z8SD8P>3U$.BZ7;W?VN#3;.*
MYR3YJ0*&R>IR!GFJ>DZ$;-FDOS8W<RRR2PS)9^6\9=V=ADLQQEN,8_&@"+4S
MJ<NIZ7':W\EDMRCB>/RT?;A<Y4D</SC)R/\ 9-0:M/J-G<Z9I<,U[.)UF=YX
MS"LKE2NU,MA>C,>!G"?4UL7>BZ5?S":\TRSN90,!YH%=L>F2*FN+"SNK46MQ
M:02VXQB*2,,HQTX/'% &'%=:K'HVHQSSBWN$<1VLUV\6\;]H4/LRH.XX!QW&
M0><PPWVI:<VH"4WTUQ'8O<06EQY3B1EZE7C /)*C# =>.^-Z/2=-BLGLH]/M
M4M7.6@6%0C'U*XP>@I;+2[#3M_V&RMK;?C?Y,2INQTS@<T <]IUUK!EL+G?>
M303LOFO<26WDNK#@IL.X'I@#.1P<GD)=R:G%%XCOQJ]QC3I&>V@$<83"PI)M
M;Y<L"6(Z@X[YYK?BT72H+O[7#IMG'<Y+><D"A\GJ<XSS2G1],,=S&=-L]ETV
MZX7R%Q,>N7&/F/UH R]6LYKCQ3I;1ZE=6H-O. (5B(R"G]Y&Y/\ 3ZU8U2XE
MAMK6QMY[N:[F)57A,2NVT?,6++M Z9P,Y/ J_<Z;8WELEM<V5O-!'@I')$&5
M<# P"...*8^CZ9+91V;Z=:-:QG<D)A78IYY"XP.I_.@#"LKB\U'0-=M9KJ99
M;65X%E5HWD $2.02%VDY8CIG'7GFM/P_;26^EVC2:E<70DMXRBS",!?E'W=J
MJ3^.:O6FG6-@7-G96]N7"AS#$J;@!@ X'.!TJ.TT?3+"8S6>G6EO*PP7BA56
M(],@=* *MAY\7B+4K>2ZDGC^SP3()%0%"S3 @%5!(PHZY^M9FHW6H:?<:I:_
MVE<-/=HC:9E(OD9F"%1\G(5BI);/RL/0FMF+P_HMO<+<0Z181S*0RR);(&!]
M00,U<DMX)9HI9(8WEA),3LH)0D8)![9''% '-7T^J1ZM#I,<NH3K':+,9H#;
MI).Q9E.=^!A<+PH_C&>V93<ZL^AQPO<+!J#77DH7DC$DJC+;<@,@D* ]L<'[
MN>-R\T^RU&-8[VT@N44[E6:,. ?49Z4QM(TU[)+)M/M&M$.5@,*[%/J%Q@=3
M^= %#09K@S7UM=3W;2Q,C"*Z$1:-6'&&CX8$@]>1W[5?TW5;'5[=Y]/N4N(4
ME:%G3.-ZG##WP:?;:?:6-L\%C;Q6B-DD01A.2,9P!C-0Z+I%IH&C6FE62D6]
MM&$4L<LWJQ/<DY)/J30!?K#(N=3U;4(!J4]FMHR)'' $RP*!O,.Y3D9)4#I\
MAZ]MRJ=[I.FZBZO?:?:W+(,*9H5<@>G(Z4 836]S>:EH,?\ :Y>06%QYUW;*
MG[\AH 2."%R>>/I4JZC<C0UB>>ZEO9+V:SADA$8D<I(^"=PV#Y(SDX[' S@5
MMG3K$W4-T;.W-Q NR*4Q+OC7T4XR!["HAHNE"UDM1IEF+>1_,>(0*%9O[Q&,
M$^] &+IM[?O#KEG-<RK-:("CEXY)(RR$XR%P<8!&X9Y],5)IKZA;R:-)<ZG-
M=F_B/G+(B*H;9ORH501T(QD\'G)YK5CT328HWCCTNR1)(_+=5MT 9,YVGCD9
MYQ4BZ7IR&V*V%JIM01;D0J/)SUV<?+^% ')W>HWAT:WU%?$$EM=W%Y%;M;!(
MBL9:94:(*5)W*">3GD$GCBK5Q=ZM=ZSJ-K#_ &B$LV2./[*ULN08U;>PDY.2
M6'0+\OKFM.]T(WNIBX9[..+?&[%+3$[;&#!3+NZ;E'&WIQ[U>O=)TW475[[3
M[6Y9!A3-"KD#TY'2@#(N;G5+K3=*1)XXKV9?,N(8)45Y JX;RV(9>&*GZ?Q>
MMWP_/--:7"7$]S+-#<-&XN4C#Q\ A28_E;@@Y'KSR#5NYTK3KR&.&YL+::.(
M8C22)6"#V!''0=/2I;:UM[*W6"U@B@A7.V.) JC//04 2.I>-E#LA((#+C*^
MXSQ7/>%K.:"Q\V35;J9/M-RGE2B(*3YSC^% <Y]^M='5(:/IBWQO1IUH+LMN
M\\0KOSZ[L9S[T <X%O+2VU74HM1F40Z@Y2W")Y97> P;().>><C'&/>>^O-3
MNM>O+.!;]([9(R@LW@4MN&=Y\WDC.5  Q\ISGMM'1-)-O+;G2[+R97\R2/[.
MFUV_O$8P3[T^[TC3;Y8UN]/M;@1#$8EA5M@]!D<#B@!-(FNI]+@DO0@N<%9-
MA!!()&>"0"<9(!.#Q5VF10QP0I##&D<2#:J(H 4>@ Z4^@ HHHH **** "BB
MB@ HHHH *XJ/_DMUS_V+D7_I3)7:UQ4?_);KG_L7(O\ TIDH [6BBB@ HHHH
M **** "N*O?^2S:1_P!@2Y_]&QUVM<5>_P#)9M(_[ ES_P"C8Z .UHHHH *X
MKX5_\B.G_7]>?^E$E=K7%?"O_D1T_P"OZ\_]*)* .UHHHH **** "BBB@ HH
MHH **** "BBB@ KC?BQ_R2SQ!_U[?^S"NRKC?BQ_R2SQ!_U[?^S"@#J=/_Y!
MEK_UQ3^0JS5;3_\ D&6O_7%/Y"K- !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+"UKY=RNHF[6)I%^=1=>< "#@$CCGO[<UK07EY+#-+)I<T)0?NXGEC+R'O\
M=8J.W\7Y4 ,MM=TN\N(X+>^AEED&553G/&<>QP"<'G )IR:SI\E[]C6Y4S%B
M@&T@,PSE0V,$C!X!SP?2J7AF"YLM.6SGTLV>S<[.'0J[,Q)/RG.>>IK'_LW6
M7DT^6:RO9KNWN$ENI9+\"*3&<^5&&VXYXRJD#U- '37FLZ?I\WE7-RJ.%WL
M"VQ?[S8'RC@\G X-5;WQ-IMD^G;IU>._.8I$RR[-C.&! Y!V_K3,7VF:EJ$D
M6G/>QWDJS*\4B*4(C5"K!R./DR",]3QQR7=K=16^CS06$9:RDW/:VSJ JF)T
MVH6V@X+#KMX'X4 :+:A:K8?;3*/L^,[]I]<=,9ZU%97X;0;?4+R:WYMUFED@
M),7W<DJ3R5],\XI?ME[]B\\Z9+YI; MQ*FX+ZDYV_@":S-,BU&+PF-/FTV2.
MX@LU@5?-0B1MFW@@\?CB@#1LM;TW4I?*L[R.9BI==N<.HP"5/1@"1DC.,U%/
MXDT>VE>.:_B0H_EDG.W?G&P-C!;_ &0<^U58;2\1O#P^Q%%M8RL^'3]U^[V@
M=>>?2LG48;^QTBQTAX;-H8KZU5)S+EY%$Z,"(\??XR3G'5O:@#M%8,H8'((R
M*H7VH30W<5E96RW%VZ&0B27RTC0'&68!B,G@  YP?0UH5E7D5W:ZJ-2M+8W2
MR0B">%&57PI)1EW$#C<P()'4'/&" .M]8C-K=27L?V66T?9<)G>%) (*D#YE
M(8$' ]P""*J>'-=FUV$77^BB!XEE"1ER\>[D!B0 >,\CO4MM%>PQW^H2VA>Z
MNF79:QR+E$ "@%B0"?O,>W.!G&2_PZ+R#1;6SO+%[>2UMXXLF1&#E5P<;2?3
MOCK0!2LO$IU369+6R:U\B*;ROGW[WPH9F'RX&,D8/7':M-=1$FN_8(Y8"$@9
MY(SN$NX%<$<8*X;GW(JGHQU".\O!<Z7+!'<7#3"0RQL%&Q1@@-G.5IMS)J7_
M  D5O=1Z1,\$$$T&\31C=O>(A@"W3$9Z\\B@#2O=5LM/=4N9]LC#<$52[8[G
M"@G'OTIC:UIJV,5Z+V)[>8[8GC._S3SPH7)8\'IGH:JS)>6&LW-Y#8/>Q7,4
M:_NG17C*;N#O*@K\V>#D'/'-4K_2;N9].ODM6B>W29)+2QN C8D96RK':"<H
M,@X!W'GCD VX]4LIK%KV.X5K=,AG&3M(X((Z@CTZU'::UIE_.(+2]AFD*;P$
M;((P#UZ9P0<=>15+2[:>PM;VX73[OSIY _E372R2R84+DG.U3@=F/ 'TIWA:
MWGL-!L].GT[[&;2WCCX9"KL!AB-I]1GG'6@ TS6+J]\3:[IDMJD=OI_D>3,&
M),OF(6;([8/%6;O7M+L9WBN;Q(VCQYA()6/(R-S8PI((ZD=16@% )( !/4^M
M<IJ-AJ,L^H?9M/GBN9V/E7$-TOV=QM"AIHV;'0 '"-D <^@!UE9NK:A=V4ME
M':6D-PUU,8?WLYB"G8S@\(V>%/Z?AI5B>(K.:^?342R>ZABN3+,$E"$+Y;J.
M20>K \>AH LVFKADO!?I'9R61'GDRAHPI7<&#D#C'J 1CIC!+[?6M/NEF,5R
M"84\R165E8+_ 'MI ..#SC!K#G\-SQZ=>:39(%M&FCO+>3S-K;UD5VC9N6.2
MO#\D \_=&;.EV,HU5+R>SU"(Q1.@DO;U9,;BI(55+ @[1R2.@X] "];>(M(O
M)(DMK^*3S<"-ESL<XSM#="WMG/M4ESK>F6<[P7-Y'',@!,;9W'/3 _B/L,US
M>@VVI7W@_1]/-M9QVPBMY#<QRG[JE7&$V\/P.^ ><GI6K=QW@\417R:.\\<%
MN\*3"2,$%F4DC+9 XP: -"?6M.MX8)7NE*W"[X1&"[2+QR%4$D<CG'&:>VJV
M":>M^;N(VK8VRJV0Q)P ,=23Q@<YK)U?2[DZW_:4*7DT;VZP/%:7 B=2K,P(
MW$!@=YSR",#KGB,Z9/%HL<*:9+('NS/+$UZ?.4')WJX( ?=C@'')YYH V;;5
M]/NX)YH;I-EO_KM_R&+C/SAL%>.>>U)9:Q8:A*8K:X#R!=^PJ5)7^\ 0,K[C
MBL0Z-?W^D:E;/YUNDYC:W2ZE5I04()#NF?E) '5B!GGH!+I]A.VJ6]Q/9:BA
MMPQWW=\KJ"5Q\@4G=G_:V]CU% &A;>(M(O)UAM[Z*1V<QC;G&\9RA.,!N#\O
M7VJ.Y\2Z=::P^FSR[)$B$A;:2.3TX'XUGI9:B/#ZP_V<RSG5?M1C\U.$-UYV
M<YQG'&/7VYK1O5N[76EOH+*2\C>W\EEB=%92&R"=[ 8Y/0YXZ4 7;O4K2Q1&
MN)2OF?<549V;Z* 2:JZCKUCI^AOJQE66V"[D*'(?VX^E5-3BU*XFMG>UNWMS
M$=UO978B99<]6?<I*X]#ZY!XQ7L]*U ^#;[3)H%BNW>X,8:?S%;?(SK\_4_>
M R1G@G% &]9ZA:W\;O:R^8J'#':1C\Z@TO41J/VR1)8)(8Y]D9BW9"[%.'!'
M#9)Z=BM.MKR\G$K2:7-;JBY5998RSMZ *Q 'N2*HZ0VH)J>H-<Z7+!%=W F6
M0RQL% AC3! ;.<H>GJ* +(\0Z2;![[[;']E23RFEP<!^F.GKQ3[K7=,LG"7%
MVB,4$A&"=B'HS8'RKUY.!P:H2:3=-K)B4)_9,DZWK_-SYJ_P >A8))GU#9ZU
M5NM)N[?5[^YCBU"XBO)%E7['=K'L(14(968#'R Y!/7&.,D ZA65U#*P92,@
M@Y!%+5/2K06.DVEH(_*$,2H(_,,FT =-Q SCZ5<H RXM:B=M6FD 2RTYBCS9
MSN95W2<>@R!]0WI4::O>Q/;R7^FK;6MPZQHXGWO&S'"B1=H"Y)"_*S<D=N:H
MV&F/)8^(=$F+1^=<3R)+MSE)\L&'KAF=<?['O5F5=4U06UI=6 M5CGCFN)_-
M5D?RV#@1@'<<LH^\%P,]30!'_P )!?QPW5U<:9;K9VLS1S/'=EG 4X+!2@!]
M<9SZ9/!Z&N/3P[+=/>WDE@8-0CO#=6K33!XY#V#*"0.F,XR,Y'(KK87>2%'D
MC,3LH+(2"5/ID<4 /HHHH **** "BBB@ HHHH **** "N*C_ .2W7/\ V+D7
M_I3)7:UQ4?\ R6ZY_P"Q<B_]*9* .UHHHH **** "BBB@ KBKW_DLVD?]@2Y
M_P#1L==K7%7O_)9M(_[ ES_Z-CH [6BBB@ KBOA7_P B.G_7]>?^E$E=K7%?
M"O\ Y$=/^OZ\_P#2B2@#M:*** "BBB@ HHHH **** "BBB@ HHHH *XWXL?\
MDL\0?]>W_LPKLJXWXL?\DL\0?]>W_LPH ZG3_P#D&6O_ %Q3^0JS5;3_ /D&
M6O\ UQ3^0JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M6%XUY\!^(?\ L&7/_HIJW:Q/&0SX'U\>NFW'_HMJ &>!_P#D0?#G_8,MO_12
MUO5@^!_^1!\.?]@RV_\ 12TEE>:[=W]Y 18)#9W(B:4HV9@51\!=WR8#8R2<
MD=!0!OT5R<_B:^>>[:SA;RK:5XEA.FW,IG*$JW[U!M3)! X;ID^@T=3U._CB
MLI+2!X8IXR\DDEG)<-$<+M0Q(0V3EN>@VX[T ;=%<R^LZL]KH[6S:<\E]=26
MSL5?:NU9&# 9!R!'RAYR<9&,U8?6+S3_ +;!>I!<7,$<4D30 QK)YC%%4@EM
MGS+R<G@Y[$4 ;U%9$=UJ5G?VD&HO:31W;-'&]O$T9C<*7P06;<"%;GCD#CGB
MA:ZMK/V=+V[^P&W^W&R:**-P[#SS") Q; YP=N#Q_%0!TU%<[K6K:G97<JPK
M'# D0=))+.6=96YR"\9Q$!@<L#USVJ77GEET".?%I+#F.26-U9U?YE(VL&&.
M>0>>U &[16!XF619-(FMH87NUO@D32\!=R."<]<8YP.N,5;L[J]34FT[43;R
MNT/G1301E R@@,I4LV",KSGG/;% &I4 L;07AO!:P"Z(P9O+&\C&/O=:S- M
MH+.ZUNWM88X(4OEVQQJ%5<V\). .G))_&LF/Q7?3Q"^AMI9+9FRMJNF7)D:/
M.,B4#9NQSC&.V[O0!V%%%87BQ;Q]'5+2>*(27,$4OF1LVY7E12.&7 ()!]1D
M<=: -VBL)8GT'3HK>UM[ 7=U<"-!! 88MQ!.XKDGA5)Z\X XSFK%K=WT6I#3
M[]K>622%IH9H(VC!"E0P92S8QO7!SSD],<@&K16!I5[KE^[M*M@D,%S)"[!&
MS.%<J2HW?)@#ONR<]!S6_0 45@:B=7/BJSBL[VVB@>SG;RY8'<$AX1DX<9/S
M<>F3US3==ANO[0T&2V%K]N^TM&9Y$.U5,,A;@')&0#MW#H.>* .AHK,L+J]N
MH;ZWE: 7EK,8?-6,^6Q**ZMLW9 PXR-W8\TSPYQH^WRXHV6YN480@A2PG<%@
M"21D@G&3UH UJ*YG3]:U2;4;2&]$$!G9A);26DL31D(QVI*24E(('W<9&2.E
M=-0 45E75U?3:H^GZ>]O"T,*32S7$;2#YV8*H4,O]QB3GTX.>(3?:LL-G:21
M6D>I7$DH+?,T21H3A\9!)*[/ER.6//% &W39(TFB:*5%>-P596&0P/4$5S]Y
MK&IV.GZNKK:2W]A;K=(RJRQS(=V 5R2IS&PZG'!YZ5<M;K4H]46QOWM9&FMV
MGC:"-E";64%3ECN^^,'CH>!0!H6MG:V41BM+:&WC)W%(D"#/K@5-7/>'#K,D
M4DEY?6DT*W=RC*+=P_$K@ ,9" !@8&#P,>]2WM[K"Z\FGV:V9BF@,HFE1OW.
MTJ#D!OGR3P!MQW/J ;E%8>IZG=6@MK=;F%+QH]\JQV,UU[9"H057.>6/;'--
MAURYN](TZ6"*-+N^F:!?,5@B,H<LQ4X;&(VPO!R0"1R: -ZBLRW&M[KJ&Y>Q
M.$0V]S'$P#,2VX-&7)XPO1N<U5\*-JDN@:;/?W=O.LEG$PVPLKDE0<LQ<Y/X
M#F@#=HK.675CXADB:VMAHXM@R3B0^:9MW*E<8VX[Y_\ K:- !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<5'_ ,ENN?\
ML7(O_2F2NUKBH_\ DMUS_P!BY%_Z4R4 =K1110 4444 %%%% !7%7O\ R6;2
M/^P)<_\ HV.NUKBKW_DLVD?]@2Y_]&QT =K1110 5Q7PK_Y$=/\ K^O/_2B2
MNUKBOA7_ ,B.G_7]>?\ I1)0!VM%%% !1110 4444 %%%% !1110 4444 %<
M;\6/^26^(/\ KV_]F%=E7'_%09^%WB'_ *]3_,4 =/I__(,M?^N*?R%6:K:?
M_P @RU_ZXI_(59H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K'\6C/@S7!ZZ?<?\ HMJV*P_&C%? GB%E)!&FW)!';]VU #?!'_(@>'?^
MP9;?^BEJW9:%;6%V]Q#/>L\CEW$ER[JS;0N2"<= /RJIX'_Y$'PY_P!@RV_]
M%+6]0!F3Z';RW$LR3W=OYQS,EO.T:R'&,\=#@=5P33KK1;>YGBG6:Z@GBC\I
M9(9F!V<'!!R&Z#D@FM&B@#FM6T O%I5K:62W%M;737,IDNF23<4<;@W+;MTF
M[.0>*U8M%L(K:XM_):1+D;9C-*TK2#&,%F).!V&>.U:%% &=:Z-;VUP+@S7-
MQ*BE(VN)F?RU/4+GOQU//O42^';)=.6QWW1A6Y^U9-P^[S-^_.[.<;N<=,UK
M44 9<^@VTUU<3K<7D#7)!G6&X95DPH7I_"<*!E<'WI;[0K._M(K1VN(K>- B
MQ03-&NT8P,*>V!6G10!DW7AZRO;:W@NGNY5MY/-C+7+[@_9L@YR.WIVJ>UTF
M"U\]_-N)9YU"//+*2^T9P ?X0,GICDYZU?HH S+'0K;3[N2YAGO6>1M\@EN7
M=7;:%R03CHH'X4TZ!:^8QCGO(87<R-!%<,D98G). <C)Y(! //')K5HH *HZ
MGI4&K0QQ7#W"HCK(!#,T>64A@3@\X(!J]10!1?2K:73_ +%,T\L88,'>9C(&
M!R"'SD$'H<TEII,%H\LOFSS3RKL:::0L^T= .RCGMCUJ_10!FZ?HEMIDK/!/
M>-N9F*RW+NI9CDG!/7-:5%% %*^TR*^EBF,L\,\094E@DVL%;&X>A!VK^0IC
M:-;/)8NTET6LG+Q%KASEB""6R?FX)'/K6A10!GQZ-;P_;O+ENE:]D$LK"X;(
M8 #Y3GY> !QV%-L-#M=.25(9;ITEWEDEN'<9=BS'!/!)).?>M*B@#)L_#UI9
MO;;9KN6.U_X]XIIV=8OE*Y&>3P2/F)Q6M110!1O=*AO)UN!+/;W"KL\V"0H2
MO7:>Q'ID<9.,9-,?1+-[.*V_?CRG,L<PF8RJYSEMY.<\D<\$''3BM&B@#*?P
M_92Z?=6<K7#B[_X^)3,WF2#I@L.0,<8&!R>.:LC3(/[1@OBTQGAA,"YE8C:2
M"<C."3@<GGBKE% &:NBVZ79FCGNXT:7SC D[+&7)R3@>IY(S@Y.1R:;<:%;7
M&H_;FGO4GV[!Y=RZJ%XX !QC@5J44 4+S2(+RY^T>=<P2E!&[6\Q0N@)(!QZ
M$G!&",GGFH8O#NGP:8MA&)UACE,L1\]R\3DDY5LY'4]^A(Z$UJT4 4[+38[)
MY)!-<3RR !I)Y2YP.@ Z <]@*AL=%M]/>/R9[LQ0KMAA:=C'&N,8 [@#IG..
MU:5% &<NBV:>(9-;'G?;'MA;-F5MFP-N^YG&<]\5HT44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q4?_);KG_L7(O\
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M3_L#7/\ Z,CH [>BBB@ K@O@U_R3'3_^N]S_ .CY*[VN"^#7_),=/_Z[W/\
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MJ"Q/F8Y7"D@@9.0, YQ<T37DU6>YMB;5I8%5]]K/YL;*V0.< @@J<CW')SP
M;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<-;QE/CC?,2,/X?B(_[_L/Z5W-<5'_ ,ENN?\ L7(O_2F2@#M:
M*** "BBB@ HHHH *X;4HR_QJT-@1\FCW+'Z;T']:[FN*O?\ DLVD?]@2Y_\
M1L= ':T444 %<-\(XS%\/K>-B"5N[M3CVG>NYKBOA7_R(Z?]?UY_Z424 =K1
M110 4444 %%%% !1110 4444 %%%% !7&_%C_DEOB#_KV_\ 9A795QOQ8_Y)
M9X@_Z]O_ &84 =3I_P#R#;7_ *XI_(59JMI__(,M?^N*?R%6: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ/\ Y+=<_P#8N1?^E,E=K7%1_P#);KG_ +%R+_TIDH [6BBB@ HHHH ****
M"N*O?^2S:1_V!+G_ -&QUVM<5>_\EFTC_L"7/_HV.@#M:*** "N*^%?_ "(Z
M?]?UY_Z425VM<5\*_P#D1T_Z_KS_ -*)* .UHHHH **** "BBB@ HHHH ***
M* "BBB@ KC?BQ_R2SQ!_U[?^S"NRKC?BQ_R2SQ!_U[?^S"@#J=/_ .09:_\
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M>J6$<VH?:9KIV\ZT6-1'%&%)+*0 P .T98G.>@)&#P1G_A /#N.O]EVV,_\
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M'T."/SKEUW)X7GANF21XM5C%W*@Q%)FY1G8#LN&((.<88$G!)V8&1?%>I,I
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\;?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "L+QM_R(7B+_L&7/\ Z*:MVL+QKSX#\0_]
M@RY_]%-0 G@?_D0?#G_8,MO_ $4M2VJ:@/$UW<2V.RUE@CA67SE)^1I3G'7G
M>*B\#_\ (@^'/^P9;?\ HI:WJ .1ET&X@GO8A;7MW%=322HT.HM$GSDDJZ[A
M@ DC*ALC'&:T-7MK[^Q8=/L; 2X6,$FX&$V,IQEN6X'6MZB@#GM6T^\U1+"]
M-O-'-:NY:VCNS&S*PQE74@;N!C/&"1QUK-U.P^S^%/$<TMO+:M<V31AKR[-P
MS85\;@20!\W0,<Y[5V9.!DU'+##<Q;)HHY8SSM=0P/YT 8\4.I:A=V$]W#9Q
M16;M,&MYS)YK%&3 RHVKAR>I/ 'O5,6.J#P_';BP47']I_:6C\Y<!/M/G9SZ
MXXQZUTL<4<,:QQ(L:+P%48 _"GT 8GEZCIM[?FVL%O$O)1,C^<J;&V*I$F><
M?*,%03@XQQS%8Z7=V&H:+$(EEM[+3Y+62<,%PQ\O&%ZX_=_J*Z"B@#DY-$O[
MG3(#)"T<]KJ5Q=K%'=&,R)(TO1UZ'$OTR,< Y&CHFGM;WES=/9W4#2QI'NNK
MTSR,%+'!&6"@;CC#'.3TK;HH *XV;0=4NM'<)!';WPN)QM:4%98)92Y!(Z$9
M!'NN.C&NRHH Q;F/4;76;JYL[);E;FWBC5FF"+&R%\[^^,./N@G@\5C_ -BZ
MJ^C"R:TC5_[!:QW><"/-VXQ]..M=E10!RFJ:9JUP;O[/90.9[ZTNT\Z4!1Y?
MEEE. 3G,> 0#U![59NM-N]>>Y:Z@.GQO83V2Y=7D)EVY;Y3@ ;!CG)R>F.>B
MHH Y:STBX-W9_:+"\#6\@<R2:H[P@@$91<DMUZ,J\$U:BBOH_%-U?'2E,4T,
M5L)_.3<%1Y"3CKCYP<>U;]% &5KJWS1V/V'3;.^(O(S*+I]HBCYS(O!^8=JU
M:** "N)^'-Y']FUC362=+J#5;R5UD@=%VO.Y4AB-K9'/!-=M10!BV?A31=/U
MJ36+6S$>H2&4R3AVS)YA4MNYY&5& >F.,47WA/1=2UF+5[NS$M_"8C%.9&!C
M\MBR[>>!ECD#KWS6U10!Q/Q/O(U\-Q::$GDN[RZMS"D4#N"$GB9LLH(7 YY(
MS7;444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ7PK_P"1'3_K^O/_ $HDH [6BBB@ HHHH **** "BBB@ HHHH **** "N/\
MBH,_"[Q#_P!>I_F*["N2^* S\,?$7_7FU '2:?\ \@RU_P"N*?R%6:K:?_R#
M+7_KBG\A5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M/QHQ3P+X@93AAIMP0?\ MFU;E87C;_D0O$7_ &#+G_T4U ">"/\ D0?#O_8,
MMO\ T4M;U8/@?_D0?#G_ &#+;_T4M;U !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<7'_ ,EMN1_U+L7_ *4/7:5Q4?\ R6ZY_P"Q<B_]*9* .UHHHH *
M*** "BBB@ KB[W_DLVD_]@2Y_P#1L==I7%7O_)9M(_[ ES_Z-CH [6BBB@ K
MB_A7SX'3_K^O/_2B2NTKBOA7_P B.G_7]>?^E$E ':T444 %%%% !1110 44
M44 %%%% !1110 5QWQ68I\+O$!4X/V7'YL*[&N-^+'_)+/$'_7M_[,* .IT_
M_D&VO_7%/Y"K-5M/_P"09:_]<4_D*LT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5A>-O^1"\1?\ 8,N?_135NUA>-O\ D0O$7_8,N?\
MT4U ">!_^1!\.?\ 8,MO_12UO5@^!_\ D0?#G_8,MO\ T4M;U !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<5'_R6ZY_[%R+_ -*9*[6N*C_Y+=<_]BY%
M_P"E,E ':T444 %%%% !1110 5Q5[_R6;2/^P)<_^C8Z[6N*O?\ DLVD?]@2
MY_\ 1L= ':T444 %<5\*_P#D1T_Z_KS_ -*)*[6N*^%?_(CI_P!?UY_Z424
M=K1110 4444 %%%% !1110 4444 %%%% !7&_%C_ ))9X@_Z]O\ V85V5<;\
M6/\ DEGB#_KV_P#9A0!U.G_\@RU_ZXI_(59JMI__ "#+7_KBG\A5F@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+QM_R(7B+_L&7/_HI
MJW:PO&W_ "(7B+_L&7/_ **:@!/ _P#R(/AS_L&6W_HI:WJP? __ "(/AS_L
M&6W_ **6MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 5Q4?_);KG_L7(O_ $IDKM:XJ/\ Y+=<_P#8N1?^E,E ':T444 %%%%
M!1110 5Q5[_R6;2/^P)<_P#HV.NUKBKW_DLVD?\ 8$N?_1L= ':T444 %<5\
M*_\ D1T_Z_KS_P!*)*[6N*^%?_(CI_U_7G_I1)0!VM%%% !1110 4444 %%%
M% !1110 4444 %<;\6/^26>(/^O;_P!F%=E7&_%C_DEGB#_KV_\ 9A0!U.G_
M /(,M?\ KBG\A5FJVG_\@RU_ZXI_(59H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K"\;?\B%XB_[!ES_ .BFK=K"\;?\B%XB_P"P9<_^
MBFH 3P/_ ,B#X<_[!EM_Z*6MZL'P/_R(/AS_ +!EM_Z*6MZ@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N*C_ .2W7/\ V+D7_I3)7:UQ4?\ R6ZY_P"Q
M<B_]*9* .UHHHH **** "BBB@ KBKW_DLVD?]@2Y_P#1L==K7%7O_)9M(_[
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M35NUA>-O^1"\1?\ 8,N?_134 )X'_P"1!\.?]@RV_P#12UO5@^!_^1!\.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KBH_\ DMUS_P!BY%_Z4R5VM<5'_P ENN?^Q<B_]*9* .UHHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?^N*?R%6:K:?_P @RU_ZXI_(59H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K"\;?\B%XB_[!ES_Z*:MVL+QM_P B%XB_[!ES_P"BFH 3
MP/\ \B#X<_[!EM_Z*6MZL'P/_P B#X<_[!EM_P"BEK>H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KBH_^2W7/_8N1?\ I3)7:UQ4?_);KG_L7(O_ $ID
MH [6BBB@ HHHH **** "N*O?^2S:1_V!+G_T;'7:UQ5[_P EFTC_ + ES_Z-
MCH [6BBB@ KBOA7_ ,B.G_7]>?\ I1)7:UQ7PK_Y$=/^OZ\_]*)* .UHHHH
M**** "BBB@ HHHH **** "BBB@ KC?BQ_P DL\0?]>W_ +,*[*N-^+'_ "2S
MQ!_U[?\ LPH ZG3_ /D&6O\ UQ3^0JS5;3_^09:_]<4_D*LT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5A>-O^1"\1?]@RY_]%-6[6%X
MV_Y$+Q%_V#+G_P!%-0 G@?\ Y$'PY_V#+;_T4M;U8/@?_D0?#G_8,MO_ $4M
M;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<5'_R6ZY_[%R+_P!*9*[6
MN*C_ .2W7/\ V+D7_I3)0!VM%%% !1110 4444 %<5>_\EFTC_L"7/\ Z-CK
MM:XJ]_Y+-I'_ &!+G_T;'0!VM%%% !7%?"O_ )$=/^OZ\_\ 2B2NUKBOA7_R
M(Z?]?UY_Z424 =K1110 4444 %%%% !1110 4444 %%%% !7&_%C_DEGB#_K
MV_\ 9A795QOQ8_Y)9X@_Z]O_ &84 =3I_P#R#+7_ *XI_(59JMI__(,M?^N*
M?R%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!_\ D0?#G_8,MO\ T4M;U8/@?_D0?#G_ &#+;_T4M;U !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XJ/_ )+=<_\ 8N1?
M^E,E=K7%1_\ );KG_L7(O_2F2@#M:*** "BBB@ HHHH *XJ]_P"2S:1_V!+G
M_P!&QUVM<5>_\EFTC_L"7/\ Z-CH [6BBB@ KBOA7_R(Z?\ 7]>?^E$E=K7%
M?"O_ )$=/^OZ\_\ 2B2@#M:*** "BBB@ HHHH **** "BBB@ HHHH *XWXL?
M\DL\0?\ 7M_[,*[*N-^+'_)+/$'_ %[?^S"@#J=/_P"09:_]<4_D*LU6T_\
MY!EK_P!<4_D*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5A>-O^1"\1?]@RY_\ 135NUA>-O^1"\1?]@RY_]%-0 G@?_D0?#G_8,MO_
M $4M;U8/@?\ Y$'PY_V#+;_T4M;U !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPH ZG3_^09:_]<4_D*LU6T__ )!EK_UQ3^0JS0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6%XV_Y$+Q%_P!@RY_]%-6[6%XV_P"1"\1?
M]@RY_P#134 )X'_Y$'PY_P!@RV_]%+6]6#X'_P"1!\.?]@RV_P#12UO4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO&W_(A>(O^
MP9<_^BFK=K"\;?\ (A>(O^P9<_\ HIJ $\#_ /(@^'/^P9;?^BEK>K!\#_\
M(@^'/^P9;?\ HI:WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XJ/_DM
MUS_V+D7_ *4R5VM<5'_R6ZY_[%R+_P!*9* .UHHHH **** "BBB@ KBKW_DL
MVD?]@2Y_]&QUVM<5>_\ )9M(_P"P)<_^C8Z .UHHHH *XKX5_P#(CI_U_7G_
M *425VM<5\*_^1'3_K^O/_2B2@#M:*** "BBB@ HHHH **** "BBB@ HHHH
M*XWXL?\ )+/$'_7M_P"S"NRKC?BQ_P DL\0?]>W_ +,* .IT_P#Y!EK_ -<4
M_D*LU6T__D&6O_7%/Y"K- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %87C;_D0O$7_8,N?_135NUA>-O^1"\1?]@RY_\ 134 )X'_ .1!
M\.?]@RV_]%+6]6#X'_Y$'PY_V#+;_P!%+6]0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7%1_\ENN?^Q<B_\ 2F2NUKBH_P#DMUS_ -BY%_Z4R4 =K111
M0 4444 %%%% !7%7O_)9M(_[ ES_ .C8Z[6N*O?^2S:1_P!@2Y_]&QT =K11
M10 5Q7PK_P"1'3_K^O/_ $HDKM:XKX5_\B.G_7]>?^E$E ':T444 %%%% !1
M110 4444 %%%% !1110 5QOQ8_Y)9X@_Z]O_ &85V5<;\6/^26>(/^O;_P!F
M% '4Z?\ \@RU_P"N*?R%6:K:?_R#+7_KBG\A5F@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$'PY_P!@RV_]%+6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N*C_P"2W7/_ &+D7_I3)7:UQ4?_ "6ZY_[%R+_TIDH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7%1_\ );KG_L7(O_2F2NUK
MBH_^2W7/_8N1?^E,E ':T444 %%%% !1110 5Q5[_P EFTC_ + ES_Z-CKM:
MXJ]_Y+-I'_8$N?\ T;'0!VM%%% !7%?"O_D1T_Z_KS_THDKM:XKX5_\ (CI_
MU_7G_I1)0!VM%%% !1110 4444 %%%% !1110 4444 %<;\6/^26>(/^O;_V
M85V5<;\6/^26>(/^O;_V84 =3I__ "#+7_KBG\A5FJVG_P#(,M?^N*?R%6:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO&W_(A>(O\
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M9:_]<4_D*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MA>-O^1"\1?\ 8,N?_135NUA>-O\ D0O$7_8,N?\ T4U ">!_^1!\.?\ 8,MO
M_12UO5@^!_\ D0?#G_8,MO\ T4M;U !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L+QM_R(7B+_L&7/_HIJW:PO&W_ "(7B+_L&7/_
M **:@!/ _P#R(/AS_L&6W_HI:WJP? __ "(/AS_L&6W_ **6MZ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N*C_Y+=<_]BY%_P"E,E=K7%1_\ENN?^Q<
MB_\ 2F2@#M:*** "BBB@ HHHH *XJ]_Y+-I'_8$N?_1L==K7%7O_ "6;2/\
ML"7/_HV.@#M:*** "N*^%?\ R(Z?]?UY_P"E$E=K7%?"O_D1T_Z_KS_THDH
M[6BBB@ HHHH **** "BBB@ HHHH **** "N-^+'_ "2SQ!_U[?\ LPKLJXWX
ML?\ )+/$'_7M_P"S"@#J=/\ ^09:_P#7%/Y"K-5M/_Y!EK_UQ3^0JS0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%XV_Y$+Q%_V#+G_T
M4U;M87C;_D0O$7_8,N?_ $4U ">!_P#D0?#G_8,MO_12UO5@^!_^1!\.?]@R
MV_\ 12UO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q4?_);KG_L7(O_
M $IDKM:XJ/\ Y+=<_P#8N1?^E,E ':T444 %%%% !1110 5Q5[_R6;2/^P)<
M_P#HV.NUKBKW_DLVD?\ 8$N?_1L= ':T444 %<5\*_\ D1T_Z_KS_P!*)*[6
MN*^%?_(CI_U_7G_I1)0!VM%%% !1110 4444 %%%% !1110 4444 %<;\6/^
M26>(/^O;_P!F%=E7&_%C_DEGB#_KV_\ 9A0!U.G_ /(,M?\ KBG\A5FJVG_\
M@RU_ZXI_(59H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK"\;?\B%XB_[!ES_ .BFK=K"\;?\B%XB_P"P9<_^BFH 3P/_ ,B#X<_[!EM_
MZ*6MZL'P/_R(/AS_ +!EM_Z*6MZ@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N*C_ .2W7/\ V+D7_I3)7:UQ4?\ R6ZY_P"Q<B_]*9* .UHHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Q4?_ "6ZY_[%R+_TIDKM:XJ/_DMUS_V+D7_I3)0!VM%%% !1
M110 4444 %<5>_\ )9M(_P"P)<_^C8Z[6N*O?^2S:1_V!+G_ -&QT =K1110
M 5Q7PK_Y$=/^OZ\_]*)*[6N*^%?_ "(Z?]?UY_Z424 =K1110 4444 %%%%
M!1110 4444 %%%% !7&_%C_DEGB#_KV_]F%=E7&_%C_DEGB#_KV_]F% '4Z?
M_P @RU_ZXI_(59JMI_\ R#+7_KBG\A5F@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L+QM_R(7B+_ +!ES_Z*:MVL+QM_R(7B+_L&7/\
MZ*:@!/ __(@^'/\ L&6W_HI:WJP? _\ R(/AS_L&6W_HI:WJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *XJ/_DMUS_V+D7_I3)7:UQ4?_);KG_L7(O\
MTIDH [6BBB@ HHHH **** "N*O?^2S:1_P!@2Y_]&QUVM<5>_P#)9M(_[ ES
M_P"C8Z .UHHHH *XKX5_\B.G_7]>?^E$E=K7%?"O_D1T_P"OZ\_]*)* .UHH
MHH **** "BBB@ HHHH **** "BBB@ KC?BQ_R2SQ!_U[?^S"NRKC?BQ_R2SQ
M!_U[?^S"@#J=/_Y!EK_UQ3^0JS5;3_\ D&6O_7%/Y"K- !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5A>-O^1"\1?]@RY_]%-6[6%XV_Y$+Q%_V#+G_P!%-0 G
M@?\ Y$'PY_V#+;_T4M;U8/@?_D0?#G_8,MO_ $4M;U !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<5'_R6ZY_[%R+_P!*9*[6N*C_ .2W7/\ V+D7_I3)
M0!VM%%% !1110 4444 %<5>_\EFTC_L"7/\ Z-CKM:XJ]_Y+-I'_ &!+G_T;
M'0!VM%%% !7%?"O_ )$=/^OZ\_\ 2B2NUKBOA7_R(Z?]?UY_Z424 =K1110
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A>-O\
MD0O$7_8,N?\ T4U;M87C;_D0O$7_ &#+G_T4U ">!_\ D0?#G_8,MO\ T4M;
MU8/@?_D0?#G_ &#+;_T4M;U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_)+/$'_ %[?^S"@#J=/_P"09:_]<4_D*LU6T_\ Y!EK_P!<4_D*LT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A>-O^1"\1?]@RY_\
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MI_(59H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\;?\
MB%XB_P"P9<_^BFK=K"\;?\B%XB_[!ES_ .BFH 3P/_R(/AS_ +!EM_Z*6MZL
M'P/_ ,B#X<_[!EM_Z*6MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6ZY_[%R+_P!*9* .UHHHH **** "BBB@ KBKW_DLVD?]@2Y_]&QUVM<5>_\
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M $HDKM:XKX5_\B.G_7]>?^E$E ':T444 %%%% !1110 4444 %%%% !1110
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M#I]/_P"09:_]<4_D*LU6T_\ Y!EK_P!<4_D*LT %%%% !1110 4444 %%%%
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M^26>(/\ KV'_ *$M '5:?_R#+7_KBG\A5FJNF?\ (*L_^N"?^@BK5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %87C;_D0O$7_8,N?_13
M5NUA>-O^1"\1?]@RY_\ 134 )X'_ .1!\.?]@RV_]%+6]6#X'_Y$'PY_V#+;
M_P!%+6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$6G_);-3_[ 4'_H
MZ2NWKB+3_DMFI_\ 8"@_]'24 =O1110 4444 %%%% !7$:A_R6C1/^P-<_\
MHR.NWKB-0_Y+1HG_ &!KG_T9'0!V]%%% !7!?!K_ ))CI_\ UWN?_1\E=[7!
M?!K_ ))CI_\ UWN?_1\E '>T444 %%%% !1110 4444 %%%% !1110 5QGQ9
M_P"26>(/^O8?^A+79UQGQ9_Y)9X@_P"O8?\ H2T =3IG_(*L_P#K@G_H(JU5
M73/^059_]<$_]!%6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %87C;_D0O$7_8,N?_ $4U;M87C;_D0O$7
M_8,N?_134 )X'_Y$'PY_V#+;_P!%+6]6#X'_ .1!\.?]@RV_]%+6]0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7$6G_);-3_ .P%!_Z.DKMZXBT_Y+9J
M?_8"@_\ 1TE ';T444 %%%% !1110 5Q&H?\EHT3_L#7/_HR.NWKB-0_Y+1H
MG_8&N?\ T9'0!V]%%% !7!?!K_DF.G_]=[G_ -'R5WM<%\&O^28Z?_UWN?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N(M/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUQGQ9_Y)9X@_Z]A_Z$M '4Z9_P @JS_ZX)_Z"*M55TS_ )!5G_UP3_T$5:H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\;?\B%XB_[!
MES_Z*:MVL+QM_P B%XB_[!ES_P"BFH 3P/\ \B#X<_[!EM_Z*6MZL'P/_P B
M#X<_[!EM_P"BEK>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBVGQ[7V]1NV_>ZG'< ^E4+2+P3?O!]E\(6<T,BPL\R:9"5B\U0R!A][D,N2
M0,\D8- &I_PL?P7_ -#1I/\ X%+_ (T?\+'\%_\ 0T:3_P"!2_XU1L+7P'J0
MA^S>'=*+2WDECM;3H@4E17<AAC@%4)![@CUHO;'P=IVHFTNO!]D@\N2;S_[.
M@,>R-=S-QS@9 R1U('>@"]_PL?P7_P!#1I/_ (%+_C1_PL?P7_T-&D_^!2_X
MUGM;>"(M&&J7/A73K>%I1$B/I\!=V..@7/OGTVDGI5BWTKP7<:HU@GA?3 =S
MHDS:=%Y<CIC>JG&<C/<#H<9P< %C_A8_@O\ Z&C2?_ I?\:/^%C^"_\ H:-)
M_P# I?\ &JAT[P0NHR6C^&M+149H_M#:?$(C(J;V0'&<A<GIC@\Y!%6=.T'P
M9JFF#4(/#FDK;DN,RZ=&A&QBIR"N1RIZT ._X6/X+_Z&C2?_  *7_&LKQ/XY
M\):GX4UBPM?$VD-<7-E-#$INT +,A &<\<FE:/P*;&UNX?"UA,MU/+!$BZ;"
MCDQLRL<.%P,KWYY'K5R+2/!\NJ+8-X2L(F<NL<DFFQ!)&0 L!QGC/4C!P<$T
M 4?"_CGPEIGA/1K"Z\3:0MQ:V,,,JB[0@,J $9!YY%:W_"Q_!?\ T-&D_P#@
M4O\ C6?<P>!+.]NK>X\-::BVP??-_9T13<D8D91@9)",#TP>@.>*C>+P3'^[
M;PA9_:E=EDM1ID)ECVA&)('!XDC("DD[@ "<B@#4_P"%C^"_^AHTG_P*7_&C
M_A8_@O\ Z&C2?_ I?\:K1:1X3EUPZ4W@VRCFV-()'TZ#844@9R,D9)XR!GGT
M-:O_  AGA;_H6M'_ / &+_XF@"G_ ,+'\%_]#1I/_@4O^-'_  L?P7_T-&D_
M^!2_XU<_X0SPM_T+6C_^ ,7_ ,31_P (9X6_Z%K1_P#P!B_^)H I_P#"Q_!?
M_0T:3_X%+_C1_P +'\%_]#1I/_@4O^-7/^$,\+?]"UH__@#%_P#$T?\ "&>%
MO^A:T?\ \ 8O_B: *?\ PL?P7_T-&D_^!2_XT?\ "Q_!?_0T:3_X%+_C5S_A
M#/"W_0M:/_X Q?\ Q-'_  AGA;_H6M'_ / &+_XF@"G_ ,+'\%_]#1I/_@4O
M^-'_  L?P7_T-&D_^!2_XU<_X0SPM_T+6C_^ ,7_ ,31_P (9X6_Z%K1_P#P
M!B_^)H I_P#"Q_!?_0T:3_X%+_C1_P +'\%_]#1I/_@4O^-7/^$,\+?]"UH_
M_@#%_P#$T?\ "&>%O^A:T?\ \ 8O_B: *?\ PL?P7_T-&D_^!2_XT?\ "Q_!
M?_0T:3_X%+_C5S_A#/"W_0M:/_X Q?\ Q-'_  AGA;_H6M'_ / &+_XF@"G_
M ,+'\%_]#1I/_@4O^-'_  L?P7_T-&D_^!2_XU<_X0SPM_T+6C_^ ,7_ ,31
M_P (9X6_Z%K1_P#P!B_^)H I_P#"Q_!?_0T:3_X%+_C1_P +'\%_]#1I/_@4
MO^-7/^$,\+?]"UH__@#%_P#$T?\ "&>%O^A:T?\ \ 8O_B: *?\ PL?P7_T-
M&D_^!2_XT?\ "Q_!?_0T:3_X%+_C5S_A#/"W_0M:/_X Q?\ Q-'_  AGA;_H
M6M'_ / &+_XF@"G_ ,+'\%_]#1I/_@4O^-'_  L?P7_T-&D_^!2_XU<_X0SP
MM_T+6C_^ ,7_ ,31_P (9X6_Z%K1_P#P!B_^)H I_P#"Q_!?_0T:3_X%+_C1
M_P +'\%_]#1I/_@4O^-7/^$,\+?]"UH__@#%_P#$T?\ "&>%O^A:T?\ \ 8O
M_B: *?\ PL?P7_T-&D_^!2_XT?\ "Q_!?_0T:3_X%+_C5S_A#/"W_0M:/_X
MQ?\ Q-'_  AGA;_H6M'_ / &+_XF@"G_ ,+'\%_]#1I/_@4O^-'_  L?P7_T
M-&D_^!2_XU<_X0SPM_T+6C_^ ,7_ ,31_P (9X6_Z%K1_P#P!B_^)H I_P#"
MQ_!?_0T:3_X%+_C1_P +'\%_]#1I/_@4O^-7/^$,\+?]"UH__@#%_P#$T?\
M"&>%O^A:T?\ \ 8O_B: *?\ PL?P7_T-&D_^!2_XT?\ "Q_!?_0T:3_X%+_C
M5S_A#/"W_0M:/_X Q?\ Q-'_  AGA;_H6M'_ / &+_XF@"G_ ,+'\%_]#1I/
M_@4O^-'_  L?P7_T-&D_^!2_XU<_X0SPM_T+6C_^ ,7_ ,31_P (9X6_Z%K1
M_P#P!B_^)H I_P#"Q_!?_0T:3_X%+_C1_P +'\%_]#1I/_@4O^-7/^$,\+?]
M"UH__@#%_P#$T?\ "&>%O^A:T?\ \ 8O_B: *?\ PL?P7_T-&D_^!2_XT?\
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M+_C1_P +'\%_]#1I/_@4O^-7/^$,\+?]"UH__@#%_P#$T?\ "&>%O^A:T?\
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M]#1I/_@4O^-7/^$,\+?]"UH__@#%_P#$T?\ "&>%O^A:T?\ \ 8O_B: *?\
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M]#1I/_@4O^-7/^$,\+?]"UH__@#%_P#$T?\ "&>%O^A:T?\ \ 8O_B: *?\
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M71TGP^((+C[+*_V.+"2[@FP_+UW$#'O4MSH/@>SNX;6XT70HYYL!$:RBR<G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC?Y=OS$;<J<CL#C&2T^$=3M+J"]L&M_,.HSW5U [D+*#+*\3 XX<!PI]0?\
M9%:B>.-*DFGCC6=C$B.,!,R;]@0!=VX;C(H!8 'UI)_&^GVIE%Q:7L36Z2/<
MJRI_HX3;]X[L'.],;2<[A[X ,8>#M9T^!?LUW%>O-]GFNEE(B!FBN4F+*0O\
M69<D\_<KH-4TV]UVQT]9X_L<D5XLTJQ7!W*@##Y7 !SR*S[OQ]9_V/>W6G6L
MUU<VT$\C1(8V$?EJK99E<J5^=/NECR>.#C1U7Q'_ &1JH@FM)I+1;1KF:>(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270342224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EMERGENT BIOSOLUTIONS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">14-1902018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Professional Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-3200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,203,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant's definitive proxy statement for its 2024 annual meeting of stockholders which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the end of the registrant's fiscal year ended December&#160;31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K. With the exception of the portions of the registrant's definitive proxy statement for its 2024 annual meeting of stockholders that are expressly incorporated by reference into this Annual Report on Form 10-K, such proxy statement shall not be deemed filed as part of this Annual Report on Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188276273184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tysons, Virginia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268781552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 111.7<span></span>
</td>
<td class="nump">$ 642.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">191.0<span></span>
</td>
<td class="nump">159.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">328.9<span></span>
</td>
<td class="nump">350.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">47.9<span></span>
</td>
<td class="nump">57.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">679.5<span></span>
</td>
<td class="nump">1,210.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">382.8<span></span>
</td>
<td class="nump">817.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">566.6<span></span>
</td>
<td class="nump">728.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">194.3<span></span>
</td>
<td class="nump">191.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,823.2<span></span>
</td>
<td class="nump">3,166.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">112.2<span></span>
</td>
<td class="nump">103.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">74.1<span></span>
</td>
<td class="nump">87.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Debt, current portion</a></td>
<td class="nump">413.7<span></span>
</td>
<td class="nump">957.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">32.7<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">651.3<span></span>
</td>
<td class="nump">1,228.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, net of current portion</a></td>
<td class="nump">446.5<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">47.2<span></span>
</td>
<td class="nump">59.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">28.9<span></span>
</td>
<td class="nump">41.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,173.9<span></span>
</td>
<td class="nump">1,778.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200.0 shares authorized, 57.8 and 55.7 shares issued; 52.2 and 50.1 shares outstanding, respectively.</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 5.6 and 5.6 common shares, respectively</a></td>
<td class="num">(227.7)<span></span>
</td>
<td class="num">(227.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">904.4<span></span>
</td>
<td class="nump">873.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net</a></td>
<td class="num">(5.7)<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="num">(21.8)<span></span>
</td>
<td class="nump">738.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">649.3<span></span>
</td>
<td class="nump">1,387.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,823.2<span></span>
</td>
<td class="nump">$ 3,166.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270286160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">57,800,000<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">52,200,000<span></span>
</td>
<td class="nump">50,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188269226848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,049.3<span></span>
</td>
<td class="nump">$ 1,117.5<span></span>
</td>
<td class="nump">$ 1,773.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">705.4<span></span>
</td>
<td class="nump">693.1<span></span>
</td>
<td class="nump">748.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">218.2<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">306.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">111.4<span></span>
</td>
<td class="nump">188.3<span></span>
</td>
<td class="nump">235.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">368.4<span></span>
</td>
<td class="nump">339.5<span></span>
</td>
<td class="nump">348.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">65.6<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,775.7<span></span>
</td>
<td class="nump">1,287.5<span></span>
</td>
<td class="nump">1,432.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(726.4)<span></span>
</td>
<td class="num">(170.0)<span></span>
</td>
<td class="nump">341.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(87.9)<span></span>
</td>
<td class="num">(37.3)<span></span>
</td>
<td class="num">(34.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="nump">74.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="num">(11.7)<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(49.0)<span></span>
</td>
<td class="num">(38.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(731.2)<span></span>
</td>
<td class="num">(219.0)<span></span>
</td>
<td class="nump">303.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">29.3<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
<td class="nump">83.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (760.5)<span></span>
</td>
<td class="num">$ (211.6)<span></span>
</td>
<td class="nump">$ 219.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net income (loss) per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (14.85)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
<td class="nump">$ 4.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (14.85)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
<td class="nump">$ 4.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="nump">50.1<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="nump">50.1<span></span>
</td>
<td class="nump">54.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 944.5<span></span>
</td>
<td class="nump">$ 966.2<span></span>
</td>
<td class="nump">$ 1,023.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_CommercialProductMember', window );">Commercial Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="nump">497.3<span></span>
</td>
<td class="nump">386.6<span></span>
</td>
<td class="nump">438.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">210.3<span></span>
</td>
<td class="nump">160.3<span></span>
</td>
<td class="nump">187.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember', window );">MCM Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="nump">447.2<span></span>
</td>
<td class="nump">579.6<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">305.6<span></span>
</td>
<td class="nump">264.3<span></span>
</td>
<td class="nump">195.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_BioservicesMember', window );">Total Bioservices revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Bioservices revenues</a></td>
<td class="nump">78.5<span></span>
</td>
<td class="nump">109.9<span></span>
</td>
<td class="nump">615.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">189.5<span></span>
</td>
<td class="nump">268.5<span></span>
</td>
<td class="nump">365.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="nump">72.8<span></span>
</td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">310.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">305.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 26.3<span></span>
</td>
<td class="nump">$ 41.4<span></span>
</td>
<td class="nump">$ 134.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_CommercialProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_CommercialProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_BioservicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_BioservicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270224288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (760.5)<span></span>
</td>
<td class="num">$ (211.6)<span></span>
</td>
<td class="nump">$ 219.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gains (losses) on hedging activities</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassification adjustment for losses (gains) on hedging activities</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax', window );">Reclassification adjustment for gains on pension benefit obligation</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(8.8)<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss), net of tax</a></td>
<td class="num">$ (769.3)<span></span>
</td>
<td class="num">$ (192.4)<span></span>
</td>
<td class="nump">$ 228.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188267963744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (760.5)<span></span>
</td>
<td class="num">$ (211.6)<span></span>
</td>
<td class="nump">$ 219.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">45.1<span></span>
</td>
<td class="nump">42.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">125.1<span></span>
</td>
<td class="nump">143.3<span></span>
</td>
<td class="nump">123.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent obligations, net</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(28.6)<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of travel health business</a></td>
<td class="num">(74.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">218.2<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">306.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Write off of contract asset and liability</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(17.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(21.6)<span></span>
</td>
<td class="nump">118.1<span></span>
</td>
<td class="num">(16.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(57.1)<span></span>
</td>
<td class="num">(66.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="num">(19.9)<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(55.7)<span></span>
</td>
<td class="num">(66.7)<span></span>
</td>
<td class="num">(9.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual', window );">Long-term incentive plan accrual</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(10.4)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Income taxes receivable and payable, net</a></td>
<td class="num">(16.2)<span></span>
</td>
<td class="nump">28.7<span></span>
</td>
<td class="num">(31.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(206.3)<span></span>
</td>
<td class="num">(34.1)<span></span>
</td>
<td class="nump">320.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(51.6)<span></span>
</td>
<td class="num">(115.8)<span></span>
</td>
<td class="num">(224.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Royalty settlement payment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(21.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Milestone payment from prior asset acquisition</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Asset acquisitions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(243.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of travel health business, net</a></td>
<td class="nump">270.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">212.3<span></span>
</td>
<td class="num">(381.3)<span></span>
</td>
<td class="num">(224.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(82.1)<span></span>
</td>
<td class="num">(106.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Principal payments on convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facility</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">598.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal payments on revolving credit facility</a></td>
<td class="num">(398.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfMediumTermNotes', window );">Principal payments on term loan facility</a></td>
<td class="num">(164.6)<span></span>
</td>
<td class="num">(33.8)<span></span>
</td>
<td class="num">(25.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from stock-based compensation activity</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid for stock-based compensation activity</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(5.9)<span></span>
</td>
<td class="num">(13.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the-market sale of stock, net of commissions and expenses</a></td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities:</a></td>
<td class="num">(535.7)<span></span>
</td>
<td class="nump">481.2<span></span>
</td>
<td class="num">(141.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(530.9)<span></span>
</td>
<td class="nump">66.3<span></span>
</td>
<td class="num">(45.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">642.6<span></span>
</td>
<td class="nump">576.3<span></span>
</td>
<td class="nump">621.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">111.7<span></span>
</td>
<td class="nump">642.6<span></span>
</td>
<td class="nump">576.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">68.3<span></span>
</td>
<td class="nump">33.0<span></span>
</td>
<td class="nump">30.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">52.8<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment unpaid at period end</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NoncashPurchasesOfTreasuryStock', window );">Purchases of treasury stock unpaid at period end</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Long-Term Incentive Plan Accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NoncashPurchasesOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Purchases Of Treasury Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NoncashPurchasesOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270447440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>$0.001 Par Value Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,450.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 784.9<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">$ (25.3)<span></span>
</td>
<td class="nump">$ 730.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">219.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">44.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(112.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (112.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">1,611.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">829.4<span></span>
</td>
<td class="num">$ (152.2)<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
<td class="nump">950.3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(211.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">44.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">$ (75.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">55.7<span></span>
</td>
<td class="nump">55.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,387.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">873.5<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">738.7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (760.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(760.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(8.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">At-the-market sale of stock, net of commissions and expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">At-the-market sale of stock, net of commissions and expenses</a></td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 649.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 904.4<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="num">$ (5.7)<span></span>
</td>
<td class="num">$ (21.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270604496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188273772416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the business and organization</a></td>
<td class="text">Nature of the business and organization <div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats ("PHTs"). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following four PHT categories: chemical, biological, radiological, nuclear and explosives ("CBRNE"); emerging infectious diseases ("EID"); emerging health crises; and acute, emergency and community care. The Company has a product portfolio of 12 products (vaccines, therapeutics, and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures (&#8220;MCM") Products, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial product, Smallpox - MCM products and Emergent Bioservices (CDMO) ("Bioservices").</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Beginning in the fourth quarter of 2023, the Company manages our business with a focus on three operating segments: (1) a Commercial Products segment consisting of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray and other commercial products which were sold as part of our travel health business in the second quarter of 2023 (see Note 3, "Divestiture" for more information on the sale of the travel health business); (2) a MCM Products segment consisting of our Anthrax - MCM,  Smallpox - MCM and Other Products, described below and (3) a Services segment consisting of our Bioservices offerings (See Note 18, "Segment information</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" for more information on our reportable segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Products Segment:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">NARCAN</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA (including in over-the-counter form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Travel Health Business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;15, 2023, the Company completed the sale of its Commercial Products segment's travel health business, including rights to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed typhoid vaccine; Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#8217;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California. For additional information, refer to Note 3, "Divestiture".</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MCM Products Segment</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.14pt">Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the United States Food and Drug Administration (&#8220;FDA&#8221;) and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax vaccine adsorbed (AVA), adjuvanted), previously known as AV7909, which was recently approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bacillus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">anthracis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is procured by certain authorized government buyers for their use; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Smallpox - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Ebanga&#8482; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#8482;;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services Segment:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bioservices - CDMO</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations. These services, which we refer to as "molecule-to-market" offerings, employ diverse technology platforms (mammalian, microbial, viral and plasma) across a network of nine geographically distinct development and manufacturing sites operated by us for our internal products and pipeline candidates and third-party Bioservices. We service both clinical-stage and commercial-stage projects for a variety of third-party customers, including government agencies, innovative pharmaceutical companies, and non-government organizations. In August 2023, the Company initiated an organizational restructuring plan (the &#8220;August 2023 Plan&#8221;) which included actions to reduce investment in and de-emphasize focus on its Bioservices business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188409872464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation and consolidation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements are prepared in conformity with U.S. generally accepted accounting principles ("GAAP"). The accompanying consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Reclassifications of certain prior period amounts have been made to conform to the current period presentation.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared on the going concern basis of accounting, which assumes the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $219.2&#160;million outstanding on our senior revolving credit facility ("Revolving Credit Facility") and $198.2&#160;million on our senior term loan facility ("Term Loan Facility"</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that mature in May 2025. As of December 31, 2023, the Company had $111.7 million in cash and cash equivalents. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The evaluation considered the potential mitigating effects of management&#8217;s plans that have not been fully implemented. Management has evaluated the mitigating effects of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern. Management's plans include (A) amending the Senior Secured Credit Facilities, and (B)  improving operating performance, reducing working capital and the potential of the sale of assets to pay down the Senior Secured Credit Facilities before they become due. As neither plan is in the complete control of Management, neither is probable of occurring. In this regard, management may not be able to find a buyer for the assets it is willing to divest and may not be able to close on any asset sale for which management is able to reach an agreement with a buyer, and as a result the Company may be unable to meet its obligations as they become due. In addition, any asset sales that are completed could have potential negative impacts on the Company's future operating cash flows and profitability.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt Covenants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities mature in May 2025, which provide for (1) revolving credit commitments, (2) a term loan, and (3) the issuance of commercial letters of credit. As of December 31, 2023, we had $417.4&#160;million outstanding under the Senior Secured Credit Facilities. Under the Senior Secured Credit Facilities, the Company is subject to a monthly minimum consolidated EBITDA covenant through February 29, 2024, and is also required to raise at least $75.0&#160;million through the issuance of equity and/or unsecured indebtedness by April 30, 2024. Beginning with the quarter ended March 31, 2024, the Company is subject to a minimum consolidated debt service coverage ratio and a maximum consolidated leverage ratio covenant. As of December 31, 2023, the Company was not in compliance with the minimum consolidated EBITDA covenant under the Senior Secured Credit Facilities and did not expect to be able to raise the remaining of the $75.0&#160;million through the issuance of equity under the at-the-market equity offering program (the "ATM Program") that we entered into on May 18, 2023, by April&#160;30, 2024, as required by the requisite lenders. In addition, the Company is required to deliver audited annual financial statements without a &#8220;going concern&#8221; explanatory paragraph with respect to its financial statements for the year ended December 31, 2023, within 90-days of year end, while the financial statements included in this Annual Report contain an explanatory paragraph related to Going Concern. On February&#160;29, 2024, the requisite lenders agreed to enter into a &#8239;Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement (the &#8220;Forbearance Agreement and Amendment&#8221;), which includes a limited waiver of any defaults or events of default that result from (a) any violation of the financial covenants set forth in the Senior Secured Credit Facilities with respect to the fiscal quarter ending December 31, 2023 and the fiscal quarter ending March&#160;31, 2024 and (b) the going concern explanatory paragraph contained in the audited financial statements for the fiscal year ended December 31, 2023. This forbearance period will expire on the earlier to occur of (i) any other event of default and (ii) April&#160;30, 2024. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Senior Secured Credit Facilities. The Senior Secured Credit Facilities and the Company&#8217;s other debt facilities are described in more detail below in Note 10, &#8220;Debt&#8221;.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, acceleration of the repayment of the Senior Secured Credit Facilities would result in a cross-default of the Company&#8217;s obligations under the 3.875% Senior Unsecured Notes due in 2028. If the Company would be unable to obtain additional waivers or forbearance of such covenants or defaults, to successfully renegotiate the terms of the Senior Secured Credit Facilities, or to cure the potential covenant breach or default, and the lenders enforced one or more of their rights upon default and/or the default resulted in a cross-default under the 3.875% Senior Unsecured Notes due in 2028, the Company would be unable to meet its obligations under those agreements and could be forced into insolvency proceedings.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the facts and circumstances described above, there can be no assurance that the Forbearance Period will continue to remain in place, and that the Company would be able to comply with covenants in the future. As a result, the Company continues to evaluate a number of factors related to its ability to continue as a going concern, including its ability to comply with the terms and operating and financial covenants required by the Senior Secured Credit Facilities, its ability to satisfy the capital raise requirement, other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, and disruptions or volatility caused by factors such as regional conflicts, inflation, and supply chain disruptions. The Company has engaged legal and financial advisors to assist with a comprehensive review of alternatives to enhance its capital structure, which may include taking steps to cure any potential defaults or seeking forbearance, waivers, further cost reductions, asset sales or other alternatives to avoid an event of default.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make estimates, judgments and assumptions that affect reported amounts and disclosures in the consolidated financial statements and accompanying notes. Due to the inherent uncertainty involved in making those estimates, judgements and assumptions, actual results could differ from those estimates. Our most significant estimates relate to revenue recognitions and the assessment of the recoverability of goodwill, definite lived intangible assets and other long-lived assets. Other estimates include allowances for expected credit losses, inventory, depreciation and amortization, business combinations, contingent consideration, share-based compensation, income taxes, and other contingencies. Management continually re-evaluates its estimates, judgments and assumptions and basis its estimates on historical trends, projections, current experience and other assumptions that it believes are reasonable. These estimates are sometimes complex, sensitive to changes in assumptions and require fair value determinations using Level 3 fair value measurements.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Also, the Company maintains cash balances with financial institutions in excess of insured limits.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs for identical assets or liabilities such as quoted prices in active markets;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs other than quoted prices in active markets that are either directly or indirectly observable; and</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#8217;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant customers and accounts receivable</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billed accounts receivable are stated at invoice amounts and consist of amounts due from the USG, commercial and Bioservices customers, as well as amounts due under reimbursement contracts with other government entities and non-government organizations. The Company's branded and generic opioid overdose reversal product, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, is sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for expected credit losses, which represents the estimated aggregate amount of credit risk arising from the inability or unwillingness of specific customers to pay our fees or disputes that may affect our ability to fully collect our billed accounts receivable. We estimate the current-period provision for expected credit losses on a specific identification basis and we consider factors such as the age of the receivables balance, knowledge of the specific customers' circumstances and historical collection experience for similar customers. Amounts determined to be uncollectible are charged or written-off against the reserve. Accounts receivable, net of the allowance for expected credit losses, represents the amount we expect to collect. Our actual experience may vary from our estimates. At each reporting date, we adjust the allowance for expected credit losses to reflect our current estimate. Unbilled accounts receivable relates to various service contracts for which work has been performed and the Company has a right to bill but invoicing has not yet occurred. Contract assets include revenues recognized in advance of billings and the Company does not have a right to invoice the customer under the terms of the contract. The Company has receivables from contracts containing lease components. At each reporting period, the Company assesses whether it is probable that the Company will collect all future lease payments. The Company considers payment history and current credit status when assessing collectability. The Company does not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration Risk</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Customers</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has long-term contracts with the USG that expire at various times from 2024 through 2036. The Company has derived a significant portion of its revenue from sales of our Government - MCM products under contracts with the USG. The Company's current USG contracts do not necessarily increase the likelihood that it will secure future comparable contracts with the USG. The Company expects that a significant portion of the business will continue to be under government contracts that present a number of risks that are not typically present in the commercial contracting process. USG contracts for ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Anthrax Vaccines and other medical countermeasures products are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of its medical countermeasures products, including ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Anthrax Vaccines to customers in addition to the USG, which would harm their growth opportunities. The Company's commercial product sales, largely NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, are sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. Refer to Note 13, "Revenue recognition" for more information regarding significant customers. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company seeks to expand its customer base and to renew its agreements with its customers prior to expiration of a contract, a delay in securing a renewal or a failure to secure a renewal or securing a renewal on less favorable terms may have a material adverse effect on the Company&#8217;s financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable do not represent a significant concentration of credit risk. The USG accounted for approximately 38%, 43% and 51% of total revenues for 2023, 2022 and 2021, respectively. The Company&#8217;s accounts receivable as of December&#160;31, 2023 and 2022, consist primarily of amounts due from the USG or other large multi-national highly reputable customers for product sales, Bioservices or from government agencies under government grants.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financial Institutions</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are maintained with several financial institutions. The Company has deposits held with banks that exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and, therefore, bear minimal credit risk.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lender Counterparties</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is lender counterparty risk associated with the Company's revolving credit facility and derivatives instruments. There is risk that the Company&#8217;s revolving credit facility investors and derivative counterparties will not be available to fund as obligated. If funding under the revolving credit facility is unavailable, the Company may have to acquire a replacement credit facility from different counterparties at a higher cost or may be unable to find a suitable replacement. The Company seeks to manage risks from its revolving credit facility and derivative instruments by contracting with experienced large financial institutions and monitoring the credit quality of its lenders. As of December&#160;31, 2023, the Company does not anticipate nonperformance by any of its counterparties.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories, net</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value with cost being determined using a standard cost method, which approximates actual cost. Actual cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. The Company records inventory acquired in business combinations utilizing the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to short-dated, contaminated or expired inventory. Inventory reserves for write-downs are relieved when the inventory is disposed of through scrap or sale.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pre-launch inventory</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the Company's Commercial Products and MCM Products segments costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and the Company believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, the Company considers a number of specific facts and circumstances, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a Bioservices contract as Bioservices pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost less accumulated depreciation and impairments. subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes internal-use software when both (a) the software is internally developed, acquired, or modified solely to meet the entity&#8217;s internal needs and (b) during the software&#8217;s development or modification, no substantive plan either exists or is being developed to market the software externally. Capitalization of qualifying internal-use software costs begins when the preliminary project stage is completed, management with the relevant authority, implicitly or explicitly, authorizes and commits to the funding of the software project, and it is probable that the project will be completed and the software will be used to perform the function intended.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally depreciates or amortizes the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.388%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-39 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-39 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7 years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of the asset life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the property, plant and equipment acquired in a business combination utilizing either the cost approach or the sales comparison approach. The cost approach is determined by establishing replacement cost of the asset and </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach determines an asset is equal to the market price of an asset of comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and research and development ("R&amp;D") tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax effects of transactions reported in different periods for financial reporting and income tax return purposes are recognized under the asset and liability method of accounting for income taxes. This method gives consideration to the future tax consequences of the deferred income tax items and immediately recognizes changes in income tax laws in the year of enactment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. The Company considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if the Company determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, the Company will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to income taxes in the period in which the determination is made. Likewise, if the Company determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, the Company will establish a valuation allowance against deferred tax assets, with an offsetting increase to income taxes, in the period in which the determination is made.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under sections 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a "loss corporation", as defined therein, there are annual limitations on the amount of net operating losses and deductions that are available. The Company has recognized the portion of net operating losses and R&amp;D tax credits acquired that will not be limited and are more likely than not to be realized.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because tax laws are complex and subject to different interpretations, significant judgment is required. As a result, the Company makes certain estimates and assumptions, in (1)&#160;calculating the Company's income tax expense, deferred tax assets and deferred tax liabilities, (2)&#160;determining any valuation allowance recorded against deferred tax assets and (3)&#160;evaluating the amount of unrecognized tax benefits, as well as the interest and penalties related to such uncertain tax positions. The Company's estimates and assumptions may differ from tax benefits ultimately realized.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Impairment Analysis</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill and Indefinite-lived Intangible Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized but is reviewed for impairment. Goodwill is allocated to the Company's reporting units, which are components of our business for which discrete cash flow information is available one level below its operating segment. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and at interim if an event or other circumstance indicates that we may not recover the carrying value of the asset. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative goodwill impairment test is performed using a one-step process. The process is to compare the fair value of a reporting unit with its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not impaired. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the reporting unit is impaired and an impairment loss is recognized in an amount equal to that excess up to the total amount of goodwill included in the reporting unit. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company has material indefinite lived intangible assets associated with in-process research and development ("IPR&amp;D"), a qualitative assessment is performed. If the qualitative assessment indicates that it is not more likely than not that the fair value of the indefinite lived intangible asset exceeds its carrying amount, the Company compares the estimated fair value of the intangible with its carrying value. If the carrying value of the intangible asset exceeds its fair value, an impairment loss is recognized </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in an amount equal to that excess. Determining fair value requires the exercise of judgment about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows (see Note 7, "Intangible assets and goodwill"). </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Long-lived Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, they are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when the disposal of such assets is likely or there is an adverse change in the market involving the business employing the related assets. If an impairment analysis is required, the impairment test employed is based on whether the Company&#8217;s intent is to hold the asset for continued use or to hold the asset for sale. If the intent is to hold the asset for continued use, the impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. If the carrying value of the asset exceeds the undiscounted cash flows, the asset would not be deemed to be recoverable. Impairment would then be measured as the excess of the asset&#8217;s carrying value over its fair value. Fair value is typically determined by discounting the future cash flows associated with that asset. If the intent is to hold the asset for sale and certain other criteria are met, the impairment test involves comparing the asset&#8217;s carrying value to its fair value less costs to sell. To the extent the carrying value is greater than the asset&#8217;s fair value less costs to sell, an impairment loss is recognized in an amount equal to the difference. Significant judgments used for long-lived asset impairment assessments include identifying the appropriate asset groupings and primary assets within those groupings, determining whether events or circumstances indicate that the carrying amount of the asset may not be recoverable, determining the future cash flows for the assets involved and assumptions applied in determining fair value, which include, reasonable discount rates, growth rates, market risk premiums and other assumptions about the economic environment.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company's acquisitions accounted for as business combinations, the Company records contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones at fair value. The fair value model used to calculate these obligations is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales and achievement of the milestones. The inputs the Company uses for determining the fair value of the contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales and/or the achievement of development and regulatory milestones. Any future increase or decrease in the fair value of the contingent consideration associated with sales-based royalties and sales-based milestones along with development and regulatory milestones are based on an assessment of the likelihood that the underlying net sales or milestones will be achieved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The associated payments which will become due and payable for sales-based royalties and milestones result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of contingent consideration associated with sales-based royalties and sales-based milestones will result in a reduction in cost of product sales. The changes in fair value for potential future sales-based royalties associated with product candidates in development will result in a charge to cost of product sales in the period in which the increase is determined. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based royalties, sales-based milestones and development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date.</span></div><div style="margin-bottom:7pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for corporate offices, R&amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases with future minimum lease payments in excess of 12 months and total lease payments greater than $0.4&#160;million are included in right-of-use ("ROU") assets and liabilities. The Company has elected to record expense on a cash basis for leases with minimum lease payments of 12 months or less and/or total lease payments less $0.4&#160;million. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services by analyzing the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Multiple performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the products or services promised in a contract and identifies a performance obligation for each promise to transfer to the customer a product or service that is distinct, including evaluating whether the contract includes a customer option for additional goods or services which could represent a material right. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. Contracts sometimes include more than one product, a lease, or options for customers to purchase additional products or services in the future for free or at a discount, which gives rise to separate performance obligations. For contracts with multiple performance obligations, the Company allocates the contract price to each performance obligation on a relative standalone selling price basis using the Company&#8217;s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts&#8217; inception. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Transaction price and variable consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the performance obligations in the contract have been identified, the Company estimates the transaction price of the contract. The estimate includes amounts that are fixed as well as those that can vary based on expected outcomes of the activities or contractual terms. The Company's variable consideration includes net profit received from sales of the Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, certain products sold on a net basis, cost-plus-fee contract terms and consideration transferred under its development contracts as consideration received can vary based on developmental progression of the product candidate. When a contract's transaction price includes variable consideration, the Company evaluates the variable consideration to determine whether the estimate needs to be constrained; therefore, the Company includes the variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration estimates are updated at each reporting date. There were no significant constraints or material changes to the Company's variable consideration estimates as of or during the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product sales</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our product sales, we recognize revenue at a point in time when the Company&#8217;s performance obligations have been satisfied and control of the products transfer to the customer. To indicate the transfer of control the Company will have a present right to payment, legal title must have passed to the customer, and the customer must have the significant risks and rewards of ownership. This point in time depends on several factors, including delivery, transfer of legal title, transition of risk and rewards of the product to the customer and the Company's right to payment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contracts for the sale of the Company's Government - MCM products include certain acceptance criteria before title passes to the customer. The primary customer for the Company's Government - MCM products and the primary source of funding for the development of its MCM product candidate portfolio is the USG. The USG contracts for the sale of the Company's Government - MCM products are normally multi-year contracts with annual options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCM product revenue is recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. Provisions for variable consideration revenues from sales of MCM products are recorded at the net sales price. Calculating certain of these provisions involves estimates and judgments and the Company determines their expected value based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs&#8217; regulations and guidelines that would impact the amount of the actual rebates, the Company's expectations regarding future utilization rates for these programs and channel inventory data. These provisions reflect the Company's best estimate of the amount of consideration to which the Company is </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entitled based on the terms of the contract. The Company reassesses the Company's provisions for variable consideration at each reporting date.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over-the-counter ("OTC") customer contracts are fixed price contracts. For that majority of the Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC contract, the Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for these NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC arrangements are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration includes allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC may also be sold on consignment through third-party online retailers where revenues are recognized point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as selling general &amp; administrative expenses and cost of commercial product sales, respectively, in the Consolidated Statement of Operations. Revenues from NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC, including inventory levels within the distribution channel and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bioservices</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs it's Bioservices offerings for third parties. Under these contracts, activities can include drug substance and drug product manufacturing services for injectable and other sterile products, and development services such as pharmaceutical product process development, process design, technology transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging, stability studies, and suite-reservations. These contracts vary in duration, activities, and number of performance obligations. Performance obligations identified under these arrangements may include drug substance and/or drug product manufacturing, technology transfer activities, and suite-reservations. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug substance, drug product manufacturing, development services and technology transfer performance obligations are recognized as revenue over-time because the Company&#8217;s performance does not create an asset with an alternative use and the Company has an enforceable right to payment for performance completed as work is performed. In drug product arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (API), that is used in the manufacturing process; in drug substance arrangements, the customer provides certain seed material that is used in the manufacturing process. The transaction price generally contains both a fixed and variable component. The fixed component is stated in the agreement as a fixed price per unit with no contractual provision for a refund or price concession and the variable component generally results from pass-through costs that are billed at cost-plus over the life of the contract. The Company uses an input method to measure progress toward the satisfaction of the related performance obligations based on costs incurred as a percentage of total costs to complete which the Company believes best depicts the transfer of control of goods or services promised to its customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suite reservations are classified as leases when the customer directs the use of the identified suite and obtains substantially all the economic benefits from the manufacturing capacity. If a customer reserves more than one suite, the allocation of contract value is based on relative selling price which varies due to size, location, capacity, production capability for drug product or drug substance, and the time of planned use. The associated revenue is recognized on a straight-line basis over the period of performance. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling price basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Bioservices customer contracts generally include provisions entitling the Company to a termination penalty when the contract is terminated prior to the contract&#8217;s nominal end date. The termination penalties in the customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated duration of the contract. The Company accounts for a contract cancellation as a contract modification. The determination of the contract termination penalty is based on the terms stated in the related customer agreement. As of the modification date, the Company updates its estimate of the transaction price, subject to constraints, and recognizes the amount over the remaining performance period or measure of progress under the arrangement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts that contain lease components, the Company assesses the collectability of the lease payments. If the collectability of the lease payments is probable, the Company recognizes lease income over the term of the lease on a straight-line basis. If collectability is not deemed probable at any time during the term of the lease, the Company&#8217;s lease income is limited to the lesser of (i) the lease payments that have been collected from the lessee, or the straight-line recognition of the contract value. If the collectability assessment changes to probable after the Company has determined collectability is not deemed probable, any difference between the lease income that would have been recognized if collectability had always been assessed as probable and the lease income recognized to date is recognized as a current-period adjustment to lease income. Changes to the collectability of operating leases are recorded as adjustments to lease income in the Consolidated Statements of Operations in the period that they occur.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contracts and grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates contract and grant revenue primarily from cost-plus-fee contracts associated with development of certain product candidates. Revenues from reimbursable contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company uses this input method to measure progress as the customer has access to the development research under these projects and benefits incrementally as R&amp;D activities occur. When applicable, the Company considers fixed fees under cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract, the cost-to-cost measure of progress. The Company analyzes costs for contracts and reimbursable grants to ensure reporting of revenues gross versus net is appropriate. The USG contracts for the development of the Company's MCM product candidates are normally multi-year contracts. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses R&amp;D costs as incurred. The Company's R&amp;D expenses consist primarily of:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">personnel-related expenses;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of the Company's clinical trials and obtaining and evaluating data from the Company's clinical trials and non-clinical studies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of Bioservices for clinical trial material; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of materials intended for use and used in clinical trials and R&amp;D.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive income (loss)</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is comprised of net income (loss) and other changes in equity that are excluded from net income (loss). The Company includes translation gains and losses incurred when converting its subsidiaries' financial statements from their functional currency to the U.S. dollar in accumulated other comprehensive income (loss) as well as gains and losses on its pension benefit obligation and derivative instruments.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Translation and remeasurement of foreign currencies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income (loss) and are recorded in accumulated other comprehensive income (loss), a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are remeasured at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are remeasured at current rates of exchange as of the balance sheet date. Income and expense items are remeasured at the average foreign currency rates for the period. Remeasurement adjustments of these subsidiaries are included in "Other income (expense), net" in our Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) per common share</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury stock</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When stock is acquired for purposes other than formal or constructive retirement, the purchase price of the acquired stock is recorded in a separate treasury stock account, which is separately reported as a reduction of equity.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When stock is retired or purchased for formal or constructive retirement, the purchase price is initially recorded as a reduction to the par value of the shares repurchased, with any excess purchase price over par value recorded as a reduction to additional paid-in capital related to the series of shares repurchased and any remainder excess purchase price recorded as a reduction to retained earnings. If the purchase price exceeds the amounts allocated to par value and additional paid-in capital related to the series of shares repurchased and retained earnings, the remainder is allocated to additional paid-in capital related to other series of shares.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the cost of treasury stock that is either sold or reissued, the Company uses the last in, first out method. If the proceeds from the re-issuance of treasury stock are greater than the cost, the excess is recorded as additional paid-in capital. If the </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from re-issuance of treasury stock are less than the cost, the excess cost first reduces any additional paid-in capital arising from previous treasury stock transactions for that class of stock, and any additional excess is recorded as a reduction of retained earnings.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for share-based compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two share-based employee compensation plans, the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "Emergent Plan") and the Emergent BioSolutions, Inc. Inducement Plan (the "Inducement Plan") under which the Company may grant various types of equity awards including stock options, restricted stock units and performance stock units. For all of our share-based awards, the Company recognizes forfeitures and compensation costs when they occur. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2023, the Company's Board of Directors adopted and approved the Emergent BioSolutions, Inc. Inducement Plan, pursuant to which the Company may from time to time make equity grants to individuals not previously an employee or director of the Company or any of its subsidiaries (or following a bona fide period of interruption of employment) as a material inducement to their employment by the Company. The Inducement Plan was adopted by the board of directors without stockholder approval pursuant to New York Stock Exchange Listing Rule 303A.08. The board of directors reserved 5.0 million shares of the Company's common stock for issuance under the Inducement Plan. The terms and conditions of the Inducement Plan are substantially similar to the Company's stockholder-approved Emergent Plan as discussed below.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plan is determined by the compensation committee of the Company's board of directors, which administers the Emergent Plan. Each equity award granted under the Emergent Plan vests as specified in the relevant agreement with the award recipient and no option can be exercised after seven years from the date of grant. The Company records the estimated fair value of awards in expense on a straight-line basis over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), the Company estimates and recognizes expense based on the period from the grant date to the date the employee becomes retirement eligible.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of restricted stock units using the closing market price of the Company's common stock on the day prior to the date of grant. The Company's performance stock units settle in the Company's stock. The fair value is determined on the date of the grant using the number of shares expected to be earned and the ending market value of the stock on the day prior to the grant date. The number of shares expected to vest is adjusted each reporting period by assessing the probability that the performance criteria will be met and the associated targeted payout level that is forecasted will be achieved. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below is a discussion of the Company's methodology for developing each of the assumptions used:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Expected dividend yield &#8212; the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Expected volatility &#8212; a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. The Company analyzed its own historical volatility to estimate expected volatility over the same period as the expected average life of the options.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Risk-free interest rate &#8212; the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Expected average life of options &#8212; the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of option exercise behavior subsequent to vesting of options.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pension plans</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically maintained a defined benefit plan for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The Company's defined benefit plan was included in the sale of the travel health business on May 15, 2023. See Note 3, "Divestiture" for more information. The plan was valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increase, and pension adjustments. The Company reviewed its actuarial assumptions on an annual basis and made modifications to the assumptions based on current rates and trends. Actuarial gains and losses were deferred in accumulated other comprehensive income (loss), net of tax and were amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return were amortized to net periodic benefit cost over the estimated remaining life as a component of selling, general and administrative expenses in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative instruments and hedging activities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. From time to time, the Company enters into interest rate swaps to manage exposures that arise from the Company's payments of variable interest rate debt under its senior secured credit agreements. The objective and strategy with respect to these interest rate swaps is to protect the Company against adverse fluctuations in interest rates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, the Company terminated its designated interest rate swap transactions with a total notional value of $350.0&#160;million. Hedge accounting was also discontinued at that time. As of December 31, 2023, all accumulated other comprehensive income associated with the terminated interest rate swaps was amortized to earnings over the remaining term of the interest rate swaps prior to termination.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy. See Note 9, "Derivative instruments and hedging activities" for further details on the interest rate swaps. </span></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards board ("FASB") issued Accounting Standards Update ("ASU") 2023-07 ("ASU 2023-07"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which improves reportable segment disclosure requirements, on an annual and interim basis, primarily through enhanced disclosures about significant segment expenses. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker ("CODM"). The ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The amendments in the ASU are effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires a public business entity ("PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on it consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188273772416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestiture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestiture</a></td>
<td class="text">Divestiture <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, pursuant to the Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;), by and between the Company, through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc., and Bavarian Nordic (&#8220;Bavarian Nordic&#8221;), the Company completed the previously announced sale of the Company&#8217;s travel health business, including rights to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed typhoid vaccine; Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#8217;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, Bavarian Nordic paid a cash purchase price of $270.2&#160;million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing. Bavarian Nordic may also be required to pay </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payments of up to $80.0&#160;million related to the development of CHIKV VLP and receipt of marketing approval and authorization in the U.S. and Europe, and earn-out payments of up to $30.0&#160;million based on aggregate net sales of Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in calendar year 2026.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the divestiture, during the year ended December 31, 2023, the Company recognized a pre-tax gain of $74.2&#160;million, net of transaction costs of $4.0&#160;million recorded within "Gain on sale of business" on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the disposal of the travel health business does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on our operations and financial results. No adjustments were made to prior period results as a result of the disposal. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture, the Company entered into a Transition Services Agreement (&#8220;TSA&#8221;) with Bavarian Nordic to help support its ongoing operations. Under the TSA, the Company provides certain transition services to Bavarian Nordic, including information technology, finance and enterprise resource planning, research and development, human resources, employee benefits and other limited services. Income from performing services under the TSA was recorded within "Other, net" on the Consolidated Statements of Operations and was $3.2&#160;million for the year ended December 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188275986944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-lived asset impairment and restructuring charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Long-lived asset impairment and restructuring charges</a></td>
<td class="text">Long-lived asset impairment and restructuring charges<div style="margin-bottom:7pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Impairment of long-lived assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its long-lived assets that are held and used for recoverability whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, due to deterioration in performance and resulting downward revisions to our internal Bioservices forecast made during the second quarter, including future expected cash flows, the Company determined there were sufficient indicators of impairment on certain asset groups within the Bioservices reporting unit to require an impairment analysis. As a result, the Company performed recoverability tests on certain asset groups within the Bioservices reporting unit and concluded that the impacted asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset groups are written down only to the extent that their carrying value is higher than their respective fair value. The Company, with the assistance of a third-party valuation firm, applied valuation methods to estimate the fair values for each of the assets within the different asset classes. An orderly liquidation value was applied to estimate the fair value of the personal property assets and market and cost based approaches were applied to estimate the fair value of the real property assets. All of the valuation approaches applied represented Level 3 non-recurring fair value measurements. Based on this analysis, the Company allocated and recognized a non-cash impairment charge of $306.7&#160;million during the year ended December 31, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the total impairment charge by asset class for the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">107.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total impairment of long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">306.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">January 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company initiated an organizational restructuring plan (the &#8220;January 2023 Plan&#8221;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. As part of the January 2023 Plan, the Company reduced its workforce by approximately 125 employees. The Company incurred $9.3&#160;million in charges during the year ended December 31, 2023. These charges consist primarily of charges related to employee transition, severance payments and employee benefits. All activities related to the January 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">August 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company initiated the August 2023 Plan intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its Bioservices business for future growth. As part of the August 2023 Plan, the Company reduced its workforce by approximately 400 employees. The Company incurred $20.0&#160;million in charges in connection with the August 2023 Plan during the year ended December 31, 2023. These charges consist primarily of charges related to severance payments, transition services, and employee benefits. All activities related to the August 2023 Plan were substantially completed during the third quarter of 2023. Restructuring costs are recognized as an operating expense within the Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs associated with the Company&#8217;s segments as well as unallocated corporate and research and development ("R&amp;D") charges for the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.427%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Commercial Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total restructuring costs by segment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs, by function, for the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.150%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Employee transition</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Severance payments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of and changes in the Company's restructuring accrual for the January 2023 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of and changes in the Company's restructuring accrual for the August 2023 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188275932448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, net</a></td>
<td class="text">Inventories, net<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">142.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">113.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">92.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">328.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Inventories, net is stated at the lower of cost or net realizable value.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270292544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text">Property, plant and equipment, net <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consists of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023 </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Land and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">229.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">433.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">567.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">794.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,201.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(411.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(383.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">382.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">817.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> During the year ended December 31, 2023, the Company recorded a non-cash impairment charge of $306.7 million related to certain Bioservices long-lived assets. See Note 4, "Long-lived asset impairment and restructuring charges" for more details regarding the impairment charge.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, construction-in-progress primarily included costs incurred to advance the Company's MCM Product capabilities. For the year ended December&#160;31, 2022, construction-in-progress primarily included costs incurred related to construction to advance the Company's Bioservices capabilities. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense associated with property, plant and equipment was $59.5 million, $83.4 million and $62.2 million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. During the year ended December&#160;31, 2022, the Company recorded accelerated depreciation of $12.7&#160;million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement (the "Janssen Agreement") with Janssen Pharmaceuticals, Inc. ("Janssen"). For additional information related to the termination of the Janssen Agreement, refer to Note 13 "Revenue recognition".</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270278592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible assets and goodwill</a></td>
<td class="text">Intangible assets and goodwill <div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. Components of the Company&#8217;s intangible assets, excluding goodwill, consists of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:19.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Weighted Average Useful Life in Years</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">13.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">855.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">288.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">566.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">982.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">253.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">728.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%">Bioservices</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">13.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">889.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">322.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">566.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,016.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">287.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">728.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company sold $102.9 million of intangible assets, net as part of the sale of its travel health business to Bavarian Nordic. See Note 3, "Divestiture" for more information on the sale of the travel health business. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2023, the Company recorded a $6.3 million intangible asset addition related to the contingent consideration payment to Ridgeback for the award of a 10-year contract by the Biomedical Advanced Research and Development Authority for advanced development, manufacturing scale-up, and procurement of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment for Ebola. The related intangible asset was acquired through an asset acquisition that was completed in 2022. </span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company's intangible assets was recorded as follows: </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.5</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates our future amortization expense for our intangible assets as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">&#160;As of<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">260.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total remaining amortization</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">566.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the changes in the carrying amount of goodwill by reportable segment:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Commercial Products </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">MCM Products </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Services </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(218.2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(218.2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Amounts for the Company's Commercial Products segment include gross carrying values of $41.7 million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $41.7 million as of December&#160;31, 2023, 2022 and 2021.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts for the Company's MCM Products segment include gross carrying values of $218.2&#160;million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $218.2&#160;million as of December&#160;31, 2023.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts for the Company's Services segment include gross carrying values of $6.7&#160;million as of December&#160;31, 2023, 2022, and 2021, and accumulated impairment losses of $6.7&#160;million as of December&#160;31, 2023 and 2022.</span></div></td></tr></table></div>The Company performs its goodwill impairment evaluation annually, during the fourth quarter, or sooner if triggering events are identified. During the third quarter of 2023, the Company observed continued market volatility including significant declines in its market capitalization and revised its financial outlook during the third quarter of 2023, which was identified as a triggering event. As a result of the quantitative assessments performed in connection with the preparation of the financial statements as of and for the quarter ended September&#160;30, 2023, the Company recorded a $218.2&#160;million non-cash goodwill impairment charge for the MCM Products reporting unit, which is included in "Goodwill impairment" on the Consolidated Statement of Operations for the year ended December 31, 2023. The MCM Products reporting unit and segment had no remaining goodwill as of December 31, 2023. The goodwill impairment charge resulted from a reduction in the estimated fair value of the MCM reporting unit due to changes in the risk profile of the Company as well as revisions to the long-term operating plan that reflected lower expectations for growth and profitability than previous expectations. The Company used a quantitative assessment, utilizing an income-based (discounted cash flows) approach, Level 3 non-recurring fair value measurement, for its goodwill impairment testing.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270233488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">320.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">320.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-672"><span style="-sec-ix-hidden:f-673">Derivative instruments</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">320.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">179.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingent consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s products are classified in the Company's <span style="-sec-ix-hidden:f-706"><span style="-sec-ix-hidden:f-707">Consolidated Statement of Operations</span></span> as cost of product sales. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s product candidates are recorded in R&amp;D expense for regulatory and development milestones.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the beginning and ending balance of the contingent consideration liabilities measured at fair value during the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the current portion of the contingent consideration liability was $2.7&#160;million and $3.4&#160;million, respectively, and was included in "Other current liabilities" on the Consolidated Balance Sheets. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-current portion of the contingent consideration liability is included in "Other liabilities" on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:18.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.349%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Contingent Consideration Liability</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Fair Value as of December 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Range</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Royalty based</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$5.6 million</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">9.5%</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.0% - 75.0%</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2023 - 2028</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Non-Variable Rate Debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the fair value of the Company's 3.875% Senior Unsecured Notes was $184.3 million and $225.1 million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, "Debt").</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Non-recurring fair value measurements</span></div>Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. As of December&#160;31, 2023 and December&#160;31, 2022, other than those liabilities mentioned above and those assets outlined in Note 7 "Intangible assets and goodwill", there were no material assets or liabilities measured at fair value on a non-recurring basis.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188275876352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and hedging activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments and hedging activities</a></td>
<td class="text">Derivative instruments and hedging activities<div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risk management objective of using derivatives</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. From time to time, the Company enters into interest rate swap transactions to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements. The objective and strategy with respect to these interest rate swaps is to protect the Company against adverse fluctuations in interest rates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, the Company terminated its designated interest rate swap transactions with a total notional value of $350.0&#160;million. Hedge accounting was also discontinued at that time. As of December 31, 2023, there was no remaining accumulated other comprehensive income associated with the terminated interest rate swaps.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the Consolidated Balance Sheets: </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"></td><td style="width:40.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Fair Value of Asset Derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to their termination, the valuation of the interest rate swaps was determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflected the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps were determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) were based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporated credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gains or losses reclassified from "Accumulated other comprehensive income (loss), net" into "Interest expense" on the Consolidated Statement of Operations during the years ended December 31, 2023 and 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"></td><td style="width:43.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.731%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188275868176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below present the components of the Company's debt:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Senior secured credit agreement - Term loan due 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">198.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">362.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Senior secured credit agreement - Revolver loan due 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">219.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">598.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">868.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,413.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(413.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(957.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Non-current portion of debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">446.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">448.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023 and 2022, the Company reclassified the debt issuance costs associated with the revolver loan to a contra account to directly offset the loan balance in "Other current liabilities" on the Company's Consolidated Balance Sheets. As of December 31, 2023 and 2022, the Company had $5.3&#160;million and $1.3&#160;million of debt issuance costs associated with the revolver loan, respectively.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">3.875% Senior Unsecured Notes due 2028</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company completed its offering of $450.0&#160;million aggregate principal amount of 3.875% Senior unsecured Notes due 2028 (the "2028 Notes")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related indenture, plus accrued and unpaid interest. As of August 15, 2023, the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest as set forth in the related indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of 101% of the principal amount of such 2028 Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, the Company entered into the Fourth Amendment to Amended and Restated Credit Agreement, Waiver and First Amendment to Amended and Restated Collateral Agreement (the "Credit Agreement Amendment"). The Credit Agreement Amendment amended the existing Amended and Restated Credit Agreement to, among other things, (a) extend the maturity date of the Senior Secured Credit Facilities from October 13, 2023 to May 15, 2025, (b) reduce the available commitments under the Revolving Credit Facility from $600.0&#160;million to $300.0&#160;million, (c) remove the Company's ability to incur incremental loans and (d) amend certain mandatory prepayment triggers, affirmative covenants, negative covenants and events of default thereunder. In connection with the Credit Agreement Amendment, the Company used the approximately $270.2&#160;million of proceeds from the sale of its travel health business to Bavarian Nordic, which closed on May 15, 2023, together with approximately $217.2&#160;million of cash on hand, to repay approximately $144.4&#160;million in outstanding principal amount of loans under the Term Loan Facility and $342.8&#160;million outstanding principal amount of loans under the Revolving Credit Facility. The Credit Agreement Amendment also requires that the Company make quarterly principal payments on the Term Loan Facility of approximately $3.9&#160;million, which commenced on June 30, 2023 and will extend through March 31, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement Amendment also (i) amended the consolidated debt service coverage ratio financial covenant to require the minimum level to be 2.25 to 1.00 for the fiscal quarters ending March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and then 2.50 to 1.00 for each fiscal quarter ending thereafter, (ii) amended the consolidated leverage ratio to require the maximum level to be 4.50 to 1.00 for the fiscal quarter ending March 31, 2024 and each fiscal quarter ending thereafter, (iii) added minimum Consolidated EBITDA requirements and maximum capital expenditure requirements for each of the months ending April 30, 2023 through February 29, 2024 and a minimum liquidity requirement as of the end of each calendar month and (iv) requires the Company to increase its liquidity by April 30, 2024 by raising at least $75.0&#160;million of equity or unsecured indebtedness. See Note 2, "Summary of significant accounting policies" for additional information related to the Company's compliance with the debt covenants described above.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Credit Agreement Amendment replaced the interest rate benchmark such that borrowings under the Revolving Credit Facility and the outstanding principal amount of the Term Loan Facility shall bear interest at a rate per annum equal to (a) a rate based on SOFR, EURIBOR or CDOR plus a margin of 6.00% until March 31, 2024 and thereafter, a margin ranging from 2.75% to 4.00% depending on the Company&#8217;s consolidated leverage ratio, or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a SOFR rate for an interest period of one month plus 1.00%) plus a margin of 5.00% until March 31, 2024 and thereafter, a margin ranging from 1.75% to 3.00% depending on the Company&#8217;s consolidated leverage ratio. In addition, the commitment fee the Company is required to pay in respect of the annual daily unused commitments under the Revolving Credit Facility shall be 0.15% to 0.40% per annum, depending on the Company&#8217;s consolidated leverage ratio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Credit Agreement Amendment, the Company and the other guarantors also agreed to provide a lien over certain assets as additional collateral for the benefit of the lenders, including owned real property, equity interests of foreign subsidiaries and certain deposit accounts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 29, 2024, the Company entered into the Forbearance Agreement and Amendment to, among other things, (a) provide that the Administrative Agent and the Lenders forbear from exercising all rights and remedies under the Senior Secured Credit Facilities and the other related loan documents arising from the occurrence and continuation of certain specified events of default during the Forbearance Period and (b) provide consent by the required revolving credit lenders to make further loans to the Company or other extensions of credit to the credit parties during the Forbearance Period, notwithstanding the occurrence of the specified events of default, subject to certain conditions set forth in the Forbearance Agreement and Amendment, including a limit on Revolving Credit Facility indebtedness of $270&#160;million. The Forbearance Agreement and Amendment also amends, among other things, (x)(A) the </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest rate benchmark to provide that borrowings shall bear interest at a rate per annum equal to 5.00% with respect to Base Rate Loans, (B) the interest rate benchmark from 6.00% per annum to 6.50% per annum with respect to SOFR Loans, Daily Simple SONIA Loans and Eurocurrency Rate Loans, and (C) 0.40% with respect to Commitment Fees, (y) the mandatory prepayment threshold amount for unrestricted cash and cash equivalents from $125,000,000 to $100,000,000, and (z) the mandatory principal prepayment amount from 75% of all milestone payments received by the Company and its subsidiaries from certain project milestone payments to 100%. Under the Forbearance Agreement and Amendment, the Company and the other guarantors have also agreed to cause Emergent BioSolutions Canada Inc. to (i) become a guarantor under the Senior Secured Credit Facilities and (ii) grant a security lien in all collateral owned by Emergent BioSolutions Canada Inc. (subject to the exclusions and exceptions specified in the Collateral Agreement) to the Administrative Agent. In addition, in connection with the entry into the Forbearance Agreement and Amendment, the Company paid a forbearance fee of approximately $1.2&#160;million. Refer to Note 2, "Summary of significant accounting policies" for further discussion of the Forbearance Agreement and Amendment. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt Maturity</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future debt payments of long-term indebtedness are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">As of <br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">418.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">868.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188276090224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share-based compensation and stockholders' equity</a></td>
<td class="text">Share-based compensation and stockholders' equity<div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two share-based employee compensation plans, the Emergent Plan and the Inducement Plan, which include stock options and performance and restricted stock units.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, an aggregate of 29.1 million shares of common stock were authorized for issuance under the Emergent Plan, of which a total of approximately 5.9 million shares of common stock remain available for future awards to be made to plan participants. As of December 31, 2023, an aggregate of 5.0 million shares of common stock were authorized for issuance under the Inducement Plan and no shares had been issued under the Inducement Plan. The exercise price of each option must be not less than 100% of the fair market value of the shares underlying such option on the date of grant. Options granted under the Emergent Plan and the Inducement Plan have a contractual life of seven years. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">63%-69%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">54%-62%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">47%-48%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.00%-4.46%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.54%-4.31%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.43%-0.94%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected average life of options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.5 years</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option award activity under the Emergent Plan:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Aggregate </span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no cash received from option exercises for the year ended December&#160;31, 2023. Cash received from option exercises for the years ended December&#160;31, 2022 and 2021 was $0.5&#160;million and $10.4 million, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of options granted during the years ended December&#160;31, 2023, 2022 and 2021 was $5.35, $17.85 and $35.16 per share, respectively. The intrinsic value of stock options exercised is the amount by which the market value of our common stock on the exercise date exceeds the exercise price. There was no intrinsic value of options exercised during the year ended December&#160;31, 2023. The total intrinsic value of options exercised during the years ended December&#160;31, 2022 and 2021 was $0.3 million and $15.7 million, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2023, there was $4.4 million of unrecognized compensation cost related to stock options.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Performance stock units and restricted stock units</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of performance stock unit and restricted stock unit award activity under the Emergent Plan:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Aggregate<br/>&#160;Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">42.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">46.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">16.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Performance stock units granted and forfeited during the year ended December&#160;31, 2023 are included at the target payout percentage, or 100%, of shares granted.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock unit awards released during the years ended December&#160;31, 2023, 2022 and 2021 was $31.8 million, $30.9 million and $26.9 million, respectively. As of December&#160;31, 2023, there was $22.6 million of unrecognized compensation cost related to unvested restricted stock units. That cost is expected to be recognized straight-line over a weighted average period of 1.8 years.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units represent common stock potentially issuable in the future, subject to achievement of performance conditions. Our current outstanding performance stock units vest based on certain financial metrics over the applicable performance period. The vesting and payout range for our performance stock units is typically between 50% and up to 200% of the target number of shares granted at the end of a three-year performance period. The total fair value of performance unit awards released during the years ended December&#160;31, 2023, 2022 and 2021 was $2.4&#160;million, $2.5&#160;million and $3.8&#160;million, respectively. As of December&#160;31, 2023, there was $2.2 million of unrecognized compensation cost related to unvested performance stock units. That cost is expected to be recognized straight-line over a weighted average period of 1.8 years.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Share-based compensation expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of Commercial Product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of Bioservices</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders' equity</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Preferred stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 15.0 million shares of preferred stock, $0.001 par value per share ("Preferred Stock"). Any Preferred Stock issued may have dividend rights, voting rights, conversion privileges, redemption characteristics, and sinking fund requirements as approved by the Company's board of directors.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Common stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has one class of common stock, $0.001 par value per share common stock ("Common Stock"), authorized and outstanding. The Company is authorized to issue up to 200.0 million shares of Common Stock. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters, except as may be provided by law.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">At-the-Market Equity Offering Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, from time to time, sell up to $150.0&#160;million aggregate gross sales price of shares of our common stock through Evercore Group L.L.C. and RBC Capital Markets, LLC, as sales agents, under an ATM Program that we entered into on May 18, 2023. Between the entry into the ATM Program and December&#160;31, 2023, we sold 1.1 million shares of our common stock under the ATM Program for gross proceeds of $9.1&#160;million, representing an average share price of $8.22 per share. As of December&#160;31, 2023, $140.9&#160;million aggregate gross sales price of shares of our common stock remains available for issuance under the ATM Program. We intend to use proceeds obtained from the sale of shares under the ATM Program for general corporate purposes.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 Share Repurchase Program</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2021, the Company announced that its Board of Directors authorized a stock repurchase program of up to an aggregate of $250.0&#160;million of Common Stock (the "2021 Share Repurchase Program"), of which $187.9&#160;million was utilized to purchase approximately 4.4&#160;million. The 2021 Share Repurchase Program expired on November 11, 2022. During the year ended December&#160;31, 2022, the Company utilized $75.5&#160;million to purchase approximately 1.8&#160;million shares. The 2021 Share Repurchase Program did not obligate the Company to acquire any specific number of shares. Repurchased shares are available for use in connection with the Company's stock plans and for other corporate purposes.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accumulated other comprehensive income (loss), net of tax</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.598%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Defined Benefit Pension Plan</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">19.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present the tax effects related to each component of other comprehensive income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2023</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Tax Benefit (Expense)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Defined benefit pension plan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188275935888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per common share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net income (loss) per common share</a></td>
<td class="text">Net income (loss) per common share<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share adjusts basic loss per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units and performance stock units. Diluted net income (loss) per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plans that were excluded from diluted net income (loss) per common share because their effect would have been antidilutive. No adjustment for the potential dilutive effect of dilutive securities is reported for the years ended December&#160;31, 2023 and 2022 as the effect would have been anti-dilutive due to the Company's net loss.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net income (loss) per common share:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(760.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(211.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">219.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Weighted-average number of shares-basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Dilutive effect of employee incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Weighted-average number of shares-diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income (loss) per common share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(14.85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income (loss) per common share - diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(14.85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the share-based awards that are not considered in the diluted net income (loss) per common share calculation generally because the exercise price of the awards was greater than the average per share closing price during the year ending December&#160;31, 2023, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price. </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Anti-dilutive stock awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270254624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in three business segments (see Note 18, "Segment information"). The Company's revenues disaggregated by the major sources were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:19.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.833%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="51" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:20pt"><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">496.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">497.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">385.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">386.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">435.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">438.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">373.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">444.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">135.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">579.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">527.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%">Bioservices:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">243.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">305.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total Bioservices</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">243.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">372.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">615.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">394.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">654.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,049.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">482.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">634.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">903.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">870.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,773.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company's product sales from NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Other commercial products, Anthrax MCM, Smallpox MCM and Other products as a percentage of total product sales were as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">% of product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Products:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other Commercial products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Anthrax MCM</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Smallpox MCM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023 and 2021, aside from sales to the USG, there were no sales to an individual customer in excess of 10% of total revenues. For the year ended December 31, 2022, there were two customers in excess of 10% of total revenues. The USG accounted for 43% of total revenues and the second customer's revenue accounted for 10% and was primarily attributable to the MCM Products segment. For the years ended December&#160;31, 2023, 2022, and 2021, the Company&#8217;s revenues from customers within the United States comprised 58%, 79% and 92%, respectively, of total revenues. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, the Company, through its wholly owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Janssen Agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the Company provided to Janssen a notice (the &#8220;Notice&#8221;) of material breach of the Janssen Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Janssen Agreement and (ii) to confirm Janssen&#8217;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Janssen Agreement and instead, wind-down the Janssen Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#8220;Janssen Notice&#8221;) of the Janssen Agreement for asserted material breaches of the Janssen Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company&#8217;s breaches were not curable and that, therefore, termination of the Janssen Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Janssen Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process through arbitration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023 there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Agreement. As of December&#160;31, 2023, the Company has no billed or unbilled net accounts receivable related to the Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2022, because the arbitration process is expected to extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from "Inventories, net" and from "Prepaid expenses and other current assets" to "Other assets", resulting in $152.7 million in long-term assets related to the Janssen Agreement on the Consolidated Balance Sheet as of December 31, 2022. The long-term asset balance within "Other Assets" related to the Janssen Agreement as of December 31, 2023 was $158.8 million. These assets include termination penalties, certain inventory related items and raw materials inventory representing materials purchased for the Janssen Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of the inventory as of December 31, 2023, concluding that because the Janssen Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. As of December 31, 2023, all non-cancelable orders have been received by Janssen and are included in the long-term asset balance within "Other Assets". </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">BARDA Centers of Innovation and Advanced Development and Manufacturing Agreement ("CIADM")</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company announced the issuance of a task order under its existing CIADM agreement with BARDA for COVID-19 vaccine development and manufacturing (the "BARDA COVID-19 Development Public Private Partnership"). The BARDA COVID-19 Development Public Private Partnership is considered a lease and is accounted for under ASC 842. The initial task order had a contract value of up to $628.2&#160;million and included the reservation of manufacturing capacity and accelerated expansion of fill/finish capacity valued at $542.7&#160;million and $85.5&#160;million, respectively. Subsequently, the task order was expanded to include incremental capital activities which increased the value to $650.8&#160;million. On November 1, 2021, the Company and BARDA mutually agreed to the completion of the Company's CIADM contract and associated task orders, including the BARDA COVID-19 Development Public Private Partnership. The Company did not recognize lease revenues under this arrangement during the years ended December 31, 2023 and December 31, 2022. Revenue associated with the base arrangement was $71.3&#160;million during the year ended December 31, 2021 and is reflected as a component of contracts and grants revenue on the Consolidated Statements of Operations. Revenue associated with the BARDA COVID-19 Development Public-Private Partnership was $243.1&#160;million during the year ended December 31, 2021 and is recorded as Bioservices "Leases" on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bioservices Operating Leases</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain multi-year Bioservices arrangements with non-USG customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates 5.0 years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components. During the year ended December 31, 2023, the Company's non-USG lease revenues were $5.7&#160;million, which is included within Bioservices "Leases" on the Consolidated Statement of Operations. Excluding future amounts related to the Agreement as discussed above, the Company estimates future operating lease revenues to be $0.8&#160;million in 2024, $0.9&#160;million in 2025, $0.9&#160;million in 2026, $0.9&#160;million in 2027, $0.9&#160;million in 2028 and no lease revenue in 2029 and beyond</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction price allocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has future contract value on unsatisfied performance obligations of approximately $379.5 million associated with all arrangements entered into by the Company. The Company expects to recognize $372.3 million of unsatisfied performance obligations within the next 24 months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> associat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of December&#160;31, 2023 and December&#160;31, 2022, the Compan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y had $21.9&#160;million and $34.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within "Accounts receivable, net" on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liabilities:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">&#160;Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">29.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the current portion of contract liabilities was $27.2&#160;million and $26.4&#160;million, respectively, and was included in "Other current liabilities" on the Consolidated Balance Sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Expected Credit Losses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of "Accounts receivable, net" as presented on the Consolidated Balance Sheets:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Billed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">141.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">102.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">51.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">57.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Allowance for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">191.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">159.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company's provisions for expected credit losses for the year's ended years ended December&#160;31, 2023, 2022 and 2021 was $2.1 million, $0.3 million, and $(0.1) million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188275799680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, R&amp;D facilities and manufacturing facilities, which may include renewal or termination options. The Company determines if an arrangement is a lease at inception. Operating leases are included in ROU assets and liabilities. The Company's leases have remaining lease terms of less than one year to approximately 10 years. Most leases included one or more options to renew, with renewal terms that can extend the lease term up to five years.  For a discussion of lessor activities, refer to Note 13, "Revenue recognition".</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total operating lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of "Cost of Commercial Product sales", "Cost of MCM Product sales", "Cost of Bioservices", "R&amp;D" expense and "Selling, general and administrative" expense on the Company's Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline">Leases</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Classification</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1164"><span style="-sec-ix-hidden:f-1165">Other assets</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1168"><span style="-sec-ix-hidden:f-1169">Other current liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1172"><span style="-sec-ix-hidden:f-1173">Other liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity analysis below summarizes future undiscounted cash flows for our operating leases as of December&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">As of<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188275921856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company reassessed the valuation allowance and considered negative evidence, including its significant losses in the current year and the substantial doubt about the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued, positive evidence, scheduled reversal of deferred tax liabilities, available taxes in carryback periods, tax planning strategies and projected future taxable income. After assessing both the negative and positive evidence, the Company concluded that it should record an additional valuation allowance of $192.7&#160;million on its global net operating losses, credits and other deferred tax assets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global intangible low-tax income (&#8220;GILTI&#8221;) provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. The Company is subject to incremental U.S. tax on GILTI income. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not provided any deferred tax impacts of GILTI in its consolidated financial statements for the years ended December&#160;31, 2023, 2022 and 2021. BEAT provisions do not have material impact on the consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, the Company has evaluated its historical indefinite reinvestment assertion in connection with the Company&#8217;s going concern uncertainty. The Company recognized a deferred withholding tax liability for the undistributed earnings of the Company&#8217;s international subsidiaries available cash and net working capital in the amount of $5.5 million. All other international subsidiaries&#8217; outside basis differences are indefinitely reinvested.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of income taxes attributable to operations consist of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">36.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(37.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net deferred tax liability consists of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal losses carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State losses carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign losses carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRC 263A capitalized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRC 163(j) Interest Limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Withholding Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has approximately $279.3 million in U.S. federal net operating loss ("NOL") carryforwards, $36.0&#160;million of NOL&#8217;s which will expire in varying amounts in 2031 through 2035 and $243.3&#160;million which will carryforward indefinitely, although, limited to eighty percent of taxable income annually. The Company has U.S. federal tax credit carryforwards of $16.9 million which will expire in 2027 through 2042. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had post-apportionment NOLs totaling approximately $667.6 million that will begin to expire in 2028. The Company has state R&amp;D tax credit carryforwards of $5.0 million which will expire in 2027 through 2038. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deductibility of such US federal and state net operating losses and credits may be limited. Under Section 382/383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and corresponding provisions of state law, if a corporation undergoes an "ownership change," which generally occurs if the percentage of the corporation's stock owned by 5% stockholders increases by more than 50% over a three-year period, the corporation's ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. Certain of the net operating loss carryforwards and the credit carryforwards are subject to an annual limitation pursuant to Internal Revenue Code Section 382 and 383 as a result of historical acquisitions. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control, which may further limit our carryforwards. If we determine that an ownership change has occurred and our ability to </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use our historical NOL and credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately $55.7 million in net operating losses from foreign jurisdictions as of December&#160;31, 2023, which will carryforward indefinitely.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s valuation allowance increased by $192.7&#160;million due to the Company&#8217;s generation of significant losses in 2023. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes differ from the amount of taxes determined by applying the U.S. federal statutory rate to income before taxes as a result of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(805.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(442.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">73.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">224.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Earnings (losses) before taxes on income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(731.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(218.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">303.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Federal tax at statutory rates</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(153.6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(46.0)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(52.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">193.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill Impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Adjustment of prior year taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Compensation limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Unrecognized tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">GILTI, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Foreign withholding tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual tax rate for the years ended December&#160;31, 2023, 2022, and 2021 was (4)%, 3% and 28%, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual tax rate of (4)% in 2023 is lower than the statutory rate primarily due to the impact of a valuation allowance charge in the U.S., state and certain Foreign Jurisdictions, goodwill impairment, GILTI, and other permanent items. This is partially offset by tax credits and favorable rates in foreign jurisdictions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual tax rate of 3% in 2022 is lower than the statutory rate primarily due to the impact of a valuation allowance charge in the U.S., state and certain Foreign Jurisdictions, a charge due the Company&#8217;s indefinite reinvestment assertion, goodwill impairment, GILTI, and other permanent items. This is partially offset by tax credits, favorable rates in foreign jurisdictions, and the release of an indemnified unrecognized tax benefit.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual tax rate of 28% in 2021 is higher than the statutory rate primarily due to the impact of goodwill impairment, state taxes, GILTI and other non-deductible items. This is partially offset by stock option deduction benefits, tax credits, and favorable rates in foreign jurisdictions. The jurisdictional mix of profit has changed from the prior year largely due to lower U.S. Bioservices margins, the termination of the CIADM arrangement in the U.S. and an increase in sales of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which a portion of the profit is attributable to a foreign subsidiary.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized tax benefits recorded at December&#160;31, 2023 and 2022 of $6.6 million and $6.8 million, respectively, is classified primarily as a non-current liability on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the gross unrecognized tax benefits activity for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions for prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions for current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross unrecognized tax benefit of $6.6 million, includes the release of $0.7 million of liability that related to the 2019 R&amp;D and other reserves due to a lapse of the statute of limitations during the year.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes interest and potential penalties related to unrecognized tax benefits in income tax expense. As of December&#160;31, 2023 and 2022, the total amount of interest and penalties accrued was $1.6&#160;million, respectively, in each of the years. The Company recognized interest and penalty expense (benefit) in 2023, 2022 and 2021 of $0.2 million, $(2.1) million and $1.1 million, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate a significant change within the next twelve months for unrecognized tax benefits and when resolved, all of these liabilities would impact the effective tax rate. However, the Company maintains a full valuation allowance as of December&#160;31, 2023 and the recognition of any unrecognized tax benefits would be offset with a change in the valuation allowance and therefore there would be no income statement impact.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's federal and state income tax returns for the tax years 2020 and onwards remain open to examination. The Company's tax returns for Canada remain open to examination for the tax years 2015 through 2022. The Company's Irish tax returns remain open to examination for the tax years 2017 through 2022.</span></div>As of December&#160;31, 2023, the Company&#8217;s 2018 and 2020 Canadian Scientific Research and Experimental Development Claims are subject to proceedings with the Tax Court of Canada and the Company's 2021 Canadian Scientific Research and Experimental Development Claim is under audit. The Company's 2016 and 2017 Canadian income tax returns for the Adapt entities are under audit. The Company&#8217;s Irish group is under Level 1 Compliance Intervention review for 2021. In addition, the Company&#8217;s 2019 through 2022 Michigan state income tax returns are under audit.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270292544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined benefit and 401(k) savings plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined benefit and 401(k) savings plan</a></td>
<td class="text">Defined benefit and 401(k) savings plan<div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Define benefit pension plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically sponsored a defined benefit pension plan covering eligible employees in Switzerland (the "Swiss Plan"), which was sold as part of our travel health business to Bavarian Nordic, as described further in Note 3, "Divestiture". Under the Swiss Plan, the Company and certain of its employees with annual earnings in excess of government determined amounts were required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. The Swiss Plan's assets were comprised of an insurance contract that had a fair value consistent with its contract value based on the practicability exception using Level 3 inputs. The entire liability was listed as non-current because plan assets were greater than the expected benefit payments over the next year. The Company recognized pension expense related to the Swiss Plan of $0.6 million, $0.8 million and $2.0 million, reflected as a component of selling, general and administrative expenses, for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The funded status of the Swiss Plan for the years ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in Plan Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net benefits received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Fair value of plan assets, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in Benefit Obligation:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest Cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net benefits received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Projected benefit obligation, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Funded status, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accumulated benefit obligation, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic pension cost incurred during the years ended December&#160;31, 2023, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023 </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">The Swiss Plan was sold as part of our travel health business to Bavarian Nordic, as described further in Note 3, "Divestiture".</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used to calculate the projected benefit obligations were as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.788%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Expected rate of return</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Rate of future compensation increases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall expected long-term rate of return on assets assumption considers historical returns, as well as expected future returns based on the fact that investment returns are insured, and the legal minimum interest crediting rate as applicable.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents gains (losses) recognized in accumulated other comprehensive income (loss) before income tax related to the Company&#8217;s defined benefit pension plans:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.483%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net actuarial gain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Prior service cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total recognized in other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no future benefits expected to be paid as of December&#160;31, 2023.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">401(k) savings plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code (the "401(k) Plan"). The 401(k) Plan covers substantially all U.S. employees. Under the 401(k) Plan, employees may make elective salary deferrals. During the years ended December&#160;31, 2023, 2022 and 2021, the Company made matching contributions of approximately $8.3 million, $8.8 million and $8.9 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188276049840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Purchase commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Purchase Obligation, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock', window );">Purchase commitments</a></td>
<td class="text">Purchase commitments <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with vendors for raw materials and other goods or services. Purchase commitments are agreements to purchase raw materials and services that are enforceable, legally binding, and specify terms that (1) include fixed or minimum quantities to be purchased, (2) include fixed, minimum or variable price provisions and (3) are longer than one year. Purchase commitments exclude agreements that are cancellable without penalty.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has approximately $526.9 million of purchase commitments associated with raw materials and Bioservices that will be purchased in the next five years, of which the Company estimates that approximately $117.0 million will be purchased within the next year. For the years ended December&#160;31, 2023, 2022, and 2021, the Company purchased $107.8 million, $199.6 million and $110.7 million, respectively, of materials and services under these commitments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for arrangements in which the entity has agreed to expend funds to procure goods or service from one or more suppliers, or to commit resources to supply goods or services to one or more customers. May include identification of the goods or services to be purchased, the goods or services to be furnished, identity of the buyer or seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, effects on pricing (such as penalties) of failing to deliver minimum quantities required to be furnished, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188276049840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment information<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting process. The revised reporting structure reflects the internal reporting and review process used by our CODM for making decisions and assessing performance and is consistent with how we currently manage the business. We now manage our business with a focus on three reportable segments. Our Commercial Products segment, which includes NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products and other commercial products which were sold as part of our travel health business in the second quarter of 2023 (see Note 3, "Divestiture" for more information on the sale of the travel health business), our MCM Products segment, which includes the Anthrax - MCM products, Smallpox - MCM products and Other Products, and our Services segment consisting of our Bioservices offerings. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of these reportable segments based on revenue and segment adjusted gross margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. We define segment adjusted gross margin, as segment gross margin excluding the impact of restructuring costs and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. We define total segment adjusted gross margin, which is a non-GAAP financial measure, as total segment gross margin, excluding the impact of restructuring costs, inventory step-up provision and the fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment cost of sales or services, segment gross margin, segment gross margin % and total segment adjusted gross margin for each of our reportable segments for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,076.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,639.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,773.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost of sales or services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total cost of sales or services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total segment gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross margin %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment adjusted gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total segment adjusted gross margin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Services revenue, Services gross margin and Services segment adjusted gross margin for the year ended December&#160;31, 2021 includes the impact of $243.1 million of Bioservices leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Segment revenues less total cost of sales or services.</span></div></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the Company's total segment adjusted gross margin to the Consolidated Statement of Operations:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total segment adjusted gross margin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment inventory step-up provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(235.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(368.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(348.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(218.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(731.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each segment:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Depreciation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">59.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes revenues by country. Revenues have been attributed based on the location of the customer:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">607.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">886.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,623.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">224.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">217.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">83.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,049.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,773.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table included long-lived assets, net by country. Long-lived assets, net includes right-of-use assets and property, plant &amp; equipment, net, excluding software, net:</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Long-lived assets, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">352.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">696.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total long-lived assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">392.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">826.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268326048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text">Litigation<div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268269936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-style:italic;font-weight:400;line-height:100%">(in millions)&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Beginning Balance</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Charged to Costs and Expenses</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Deductions</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Ending Balance</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270273520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (760.5)<span></span>
</td>
<td class="num">$ (211.6)<span></span>
</td>
<td class="nump">$ 219.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270299808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263956064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements are prepared in conformity with U.S. generally accepted accounting principles ("GAAP"). The accompanying consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Reclassifications of certain prior period amounts have been made to conform to the current period presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make estimates, judgments and assumptions that affect reported amounts and disclosures in the consolidated financial statements and accompanying notes. Due to the inherent uncertainty involved in making those estimates, judgements and assumptions, actual results could differ from those estimates. Our most significant estimates relate to revenue recognitions and the assessment of the recoverability of goodwill, definite lived intangible assets and other long-lived assets. Other estimates include allowances for expected credit losses, inventory, depreciation and amortization, business combinations, contingent consideration, share-based compensation, income taxes, and other contingencies. Management continually re-evaluates its estimates, judgments and assumptions and basis its estimates on historical trends, projections, current experience and other assumptions that it believes are reasonable. These estimates are sometimes complex, sensitive to changes in assumptions and require fair value determinations using Level 3 fair value measurements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Also, the Company maintains cash balances with financial institutions in excess of insured limits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs for identical assets or liabilities such as quoted prices in active markets;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs other than quoted prices in active markets that are either directly or indirectly observable; and</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#8217;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MajorCustomersPolicyPolicyTextBlock', window );">Significant customers and accounting receivable</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billed accounts receivable are stated at invoice amounts and consist of amounts due from the USG, commercial and Bioservices customers, as well as amounts due under reimbursement contracts with other government entities and non-government organizations. The Company's branded and generic opioid overdose reversal product, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, is sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. </span></div>We maintain an allowance for expected credit losses, which represents the estimated aggregate amount of credit risk arising from the inability or unwillingness of specific customers to pay our fees or disputes that may affect our ability to fully collect our billed accounts receivable. We estimate the current-period provision for expected credit losses on a specific identification basis and we consider factors such as the age of the receivables balance, knowledge of the specific customers' circumstances and historical collection experience for similar customers. Amounts determined to be uncollectible are charged or written-off against the reserve. Accounts receivable, net of the allowance for expected credit losses, represents the amount we expect to collect. Our actual experience may vary from our estimates. At each reporting date, we adjust the allowance for expected credit losses to reflect our current estimate. Unbilled accounts receivable relates to various service contracts for which work has been performed and the Company has a right to bill but invoicing has not yet occurred. Contract assets include revenues recognized in advance of billings and the Company does not have a right to invoice the customer under the terms of the contract. The Company has receivables from contracts containing lease components. At each reporting period, the Company assesses whether it is probable that the Company will collect all future lease payments. The Company considers payment history and current credit status when assessing collectability. The Company does not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk</a></td>
<td class="text"><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Customers</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has long-term contracts with the USG that expire at various times from 2024 through 2036. The Company has derived a significant portion of its revenue from sales of our Government - MCM products under contracts with the USG. The Company's current USG contracts do not necessarily increase the likelihood that it will secure future comparable contracts with the USG. The Company expects that a significant portion of the business will continue to be under government contracts that present a number of risks that are not typically present in the commercial contracting process. USG contracts for ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Anthrax Vaccines and other medical countermeasures products are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of its medical countermeasures products, including ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Anthrax Vaccines to customers in addition to the USG, which would harm their growth opportunities. The Company's commercial product sales, largely NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, are sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. Refer to Note 13, "Revenue recognition" for more information regarding significant customers. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company seeks to expand its customer base and to renew its agreements with its customers prior to expiration of a contract, a delay in securing a renewal or a failure to secure a renewal or securing a renewal on less favorable terms may have a material adverse effect on the Company&#8217;s financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable do not represent a significant concentration of credit risk. The USG accounted for approximately 38%, 43% and 51% of total revenues for 2023, 2022 and 2021, respectively. The Company&#8217;s accounts receivable as of December&#160;31, 2023 and 2022, consist primarily of amounts due from the USG or other large multi-national highly reputable customers for product sales, Bioservices or from government agencies under government grants.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financial Institutions</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are maintained with several financial institutions. The Company has deposits held with banks that exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and, therefore, bear minimal credit risk.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lender Counterparties</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is lender counterparty risk associated with the Company's revolving credit facility and derivatives instruments. There is risk that the Company&#8217;s revolving credit facility investors and derivative counterparties will not be available to fund as obligated. If funding under the revolving credit facility is unavailable, the Company may have to acquire a replacement credit facility from different counterparties at a higher cost or may be unable to find a suitable replacement. The Company seeks to manage risks from its revolving credit facility and derivative instruments by contracting with experienced large financial institutions and monitoring the credit quality of its lenders. As of December&#160;31, 2023, the Company does not anticipate nonperformance by any of its counterparties.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories, net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value with cost being determined using a standard cost method, which approximates actual cost. Actual cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. The Company records inventory acquired in business combinations utilizing the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to short-dated, contaminated or expired inventory. Inventory reserves for write-downs are relieved when the inventory is disposed of through scrap or sale.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pre-launch inventory</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the Company's Commercial Products and MCM Products segments costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and the Company believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, the Company considers a number of specific facts and circumstances, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a Bioservices contract as Bioservices pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost less accumulated depreciation and impairments. subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes internal-use software when both (a) the software is internally developed, acquired, or modified solely to meet the entity&#8217;s internal needs and (b) during the software&#8217;s development or modification, no substantive plan either exists or is being developed to market the software externally. Capitalization of qualifying internal-use software costs begins when the preliminary project stage is completed, management with the relevant authority, implicitly or explicitly, authorizes and commits to the funding of the software project, and it is probable that the project will be completed and the software will be used to perform the function intended.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally depreciates or amortizes the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.388%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-39 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-39 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7 years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of the asset life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the property, plant and equipment acquired in a business combination utilizing either the cost approach or the sales comparison approach. The cost approach is determined by establishing replacement cost of the asset and </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach determines an asset is equal to the market price of an asset of comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and research and development ("R&amp;D") tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax effects of transactions reported in different periods for financial reporting and income tax return purposes are recognized under the asset and liability method of accounting for income taxes. This method gives consideration to the future tax consequences of the deferred income tax items and immediately recognizes changes in income tax laws in the year of enactment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. The Company considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if the Company determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, the Company will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to income taxes in the period in which the determination is made. Likewise, if the Company determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, the Company will establish a valuation allowance against deferred tax assets, with an offsetting increase to income taxes, in the period in which the determination is made.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under sections 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a "loss corporation", as defined therein, there are annual limitations on the amount of net operating losses and deductions that are available. The Company has recognized the portion of net operating losses and R&amp;D tax credits acquired that will not be limited and are more likely than not to be realized.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because tax laws are complex and subject to different interpretations, significant judgment is required. As a result, the Company makes certain estimates and assumptions, in (1)&#160;calculating the Company's income tax expense, deferred tax assets and deferred tax liabilities, (2)&#160;determining any valuation allowance recorded against deferred tax assets and (3)&#160;evaluating the amount of unrecognized tax benefits, as well as the interest and penalties related to such uncertain tax positions. The Company's estimates and assumptions may differ from tax benefits ultimately realized.</span></div>The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Asset Impairment Analysis</a></td>
<td class="text"><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill and Indefinite-lived Intangible Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized but is reviewed for impairment. Goodwill is allocated to the Company's reporting units, which are components of our business for which discrete cash flow information is available one level below its operating segment. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and at interim if an event or other circumstance indicates that we may not recover the carrying value of the asset. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative goodwill impairment test is performed using a one-step process. The process is to compare the fair value of a reporting unit with its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not impaired. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the reporting unit is impaired and an impairment loss is recognized in an amount equal to that excess up to the total amount of goodwill included in the reporting unit. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company has material indefinite lived intangible assets associated with in-process research and development ("IPR&amp;D"), a qualitative assessment is performed. If the qualitative assessment indicates that it is not more likely than not that the fair value of the indefinite lived intangible asset exceeds its carrying amount, the Company compares the estimated fair value of the intangible with its carrying value. If the carrying value of the intangible asset exceeds its fair value, an impairment loss is recognized </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in an amount equal to that excess. Determining fair value requires the exercise of judgment about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows (see Note 7, "Intangible assets and goodwill"). </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Long-lived Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, they are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when the disposal of such assets is likely or there is an adverse change in the market involving the business employing the related assets. If an impairment analysis is required, the impairment test employed is based on whether the Company&#8217;s intent is to hold the asset for continued use or to hold the asset for sale. If the intent is to hold the asset for continued use, the impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. If the carrying value of the asset exceeds the undiscounted cash flows, the asset would not be deemed to be recoverable. Impairment would then be measured as the excess of the asset&#8217;s carrying value over its fair value. Fair value is typically determined by discounting the future cash flows associated with that asset. If the intent is to hold the asset for sale and certain other criteria are met, the impairment test involves comparing the asset&#8217;s carrying value to its fair value less costs to sell. To the extent the carrying value is greater than the asset&#8217;s fair value less costs to sell, an impairment loss is recognized in an amount equal to the difference. Significant judgments used for long-lived asset impairment assessments include identifying the appropriate asset groupings and primary assets within those groupings, determining whether events or circumstances indicate that the carrying amount of the asset may not be recoverable, determining the future cash flows for the assets involved and assumptions applied in determining fair value, which include, reasonable discount rates, growth rates, market risk premiums and other assumptions about the economic environment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ContingentConsiderationObligationsPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company's acquisitions accounted for as business combinations, the Company records contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones at fair value. The fair value model used to calculate these obligations is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales and achievement of the milestones. The inputs the Company uses for determining the fair value of the contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales and/or the achievement of development and regulatory milestones. Any future increase or decrease in the fair value of the contingent consideration associated with sales-based royalties and sales-based milestones along with development and regulatory milestones are based on an assessment of the likelihood that the underlying net sales or milestones will be achieved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The associated payments which will become due and payable for sales-based royalties and milestones result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of contingent consideration associated with sales-based royalties and sales-based milestones will result in a reduction in cost of product sales. The changes in fair value for potential future sales-based royalties associated with product candidates in development will result in a charge to cost of product sales in the period in which the increase is determined. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based royalties, sales-based milestones and development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for corporate offices, R&amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases with future minimum lease payments in excess of 12 months and total lease payments greater than $0.4&#160;million are included in right-of-use ("ROU") assets and liabilities. The Company has elected to record expense on a cash basis for leases with minimum lease payments of 12 months or less and/or total lease payments less $0.4&#160;million. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services by analyzing the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Multiple performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the products or services promised in a contract and identifies a performance obligation for each promise to transfer to the customer a product or service that is distinct, including evaluating whether the contract includes a customer option for additional goods or services which could represent a material right. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. Contracts sometimes include more than one product, a lease, or options for customers to purchase additional products or services in the future for free or at a discount, which gives rise to separate performance obligations. For contracts with multiple performance obligations, the Company allocates the contract price to each performance obligation on a relative standalone selling price basis using the Company&#8217;s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts&#8217; inception. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Transaction price and variable consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the performance obligations in the contract have been identified, the Company estimates the transaction price of the contract. The estimate includes amounts that are fixed as well as those that can vary based on expected outcomes of the activities or contractual terms. The Company's variable consideration includes net profit received from sales of the Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, certain products sold on a net basis, cost-plus-fee contract terms and consideration transferred under its development contracts as consideration received can vary based on developmental progression of the product candidate. When a contract's transaction price includes variable consideration, the Company evaluates the variable consideration to determine whether the estimate needs to be constrained; therefore, the Company includes the variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration estimates are updated at each reporting date. There were no significant constraints or material changes to the Company's variable consideration estimates as of or during the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product sales</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our product sales, we recognize revenue at a point in time when the Company&#8217;s performance obligations have been satisfied and control of the products transfer to the customer. To indicate the transfer of control the Company will have a present right to payment, legal title must have passed to the customer, and the customer must have the significant risks and rewards of ownership. This point in time depends on several factors, including delivery, transfer of legal title, transition of risk and rewards of the product to the customer and the Company's right to payment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contracts for the sale of the Company's Government - MCM products include certain acceptance criteria before title passes to the customer. The primary customer for the Company's Government - MCM products and the primary source of funding for the development of its MCM product candidate portfolio is the USG. The USG contracts for the sale of the Company's Government - MCM products are normally multi-year contracts with annual options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCM product revenue is recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. Provisions for variable consideration revenues from sales of MCM products are recorded at the net sales price. Calculating certain of these provisions involves estimates and judgments and the Company determines their expected value based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs&#8217; regulations and guidelines that would impact the amount of the actual rebates, the Company's expectations regarding future utilization rates for these programs and channel inventory data. These provisions reflect the Company's best estimate of the amount of consideration to which the Company is </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entitled based on the terms of the contract. The Company reassesses the Company's provisions for variable consideration at each reporting date.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over-the-counter ("OTC") customer contracts are fixed price contracts. For that majority of the Company's NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC contract, the Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for these NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC arrangements are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration includes allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC may also be sold on consignment through third-party online retailers where revenues are recognized point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as selling general &amp; administrative expenses and cost of commercial product sales, respectively, in the Consolidated Statement of Operations. Revenues from NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OTC, including inventory levels within the distribution channel and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bioservices</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs it's Bioservices offerings for third parties. Under these contracts, activities can include drug substance and drug product manufacturing services for injectable and other sterile products, and development services such as pharmaceutical product process development, process design, technology transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging, stability studies, and suite-reservations. These contracts vary in duration, activities, and number of performance obligations. Performance obligations identified under these arrangements may include drug substance and/or drug product manufacturing, technology transfer activities, and suite-reservations. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug substance, drug product manufacturing, development services and technology transfer performance obligations are recognized as revenue over-time because the Company&#8217;s performance does not create an asset with an alternative use and the Company has an enforceable right to payment for performance completed as work is performed. In drug product arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (API), that is used in the manufacturing process; in drug substance arrangements, the customer provides certain seed material that is used in the manufacturing process. The transaction price generally contains both a fixed and variable component. The fixed component is stated in the agreement as a fixed price per unit with no contractual provision for a refund or price concession and the variable component generally results from pass-through costs that are billed at cost-plus over the life of the contract. The Company uses an input method to measure progress toward the satisfaction of the related performance obligations based on costs incurred as a percentage of total costs to complete which the Company believes best depicts the transfer of control of goods or services promised to its customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suite reservations are classified as leases when the customer directs the use of the identified suite and obtains substantially all the economic benefits from the manufacturing capacity. If a customer reserves more than one suite, the allocation of contract value is based on relative selling price which varies due to size, location, capacity, production capability for drug product or drug substance, and the time of planned use. The associated revenue is recognized on a straight-line basis over the period of performance. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling price basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Bioservices customer contracts generally include provisions entitling the Company to a termination penalty when the contract is terminated prior to the contract&#8217;s nominal end date. The termination penalties in the customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated duration of the contract. The Company accounts for a contract cancellation as a contract modification. The determination of the contract termination penalty is based on the terms stated in the related customer agreement. As of the modification date, the Company updates its estimate of the transaction price, subject to constraints, and recognizes the amount over the remaining performance period or measure of progress under the arrangement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts that contain lease components, the Company assesses the collectability of the lease payments. If the collectability of the lease payments is probable, the Company recognizes lease income over the term of the lease on a straight-line basis. If collectability is not deemed probable at any time during the term of the lease, the Company&#8217;s lease income is limited to the lesser of (i) the lease payments that have been collected from the lessee, or the straight-line recognition of the contract value. If the collectability assessment changes to probable after the Company has determined collectability is not deemed probable, any difference between the lease income that would have been recognized if collectability had always been assessed as probable and the lease income recognized to date is recognized as a current-period adjustment to lease income. Changes to the collectability of operating leases are recorded as adjustments to lease income in the Consolidated Statements of Operations in the period that they occur.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contracts and grants</span></div>The Company generates contract and grant revenue primarily from cost-plus-fee contracts associated with development of certain product candidates. Revenues from reimbursable contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company uses this input method to measure progress as the customer has access to the development research under these projects and benefits incrementally as R&amp;D activities occur. When applicable, the Company considers fixed fees under cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract, the cost-to-cost measure of progress. The Company analyzes costs for contracts and reimbursable grants to ensure reporting of revenues gross versus net is appropriate. The USG contracts for the development of the Company's MCM product candidates are normally multi-year contracts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses R&amp;D costs as incurred. The Company's R&amp;D expenses consist primarily of:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">personnel-related expenses;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of the Company's clinical trials and obtaining and evaluating data from the Company's clinical trials and non-clinical studies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of Bioservices for clinical trial material; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of materials intended for use and used in clinical trials and R&amp;D.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income (loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is comprised of net income (loss) and other changes in equity that are excluded from net income (loss). The Company includes translation gains and losses incurred when converting its subsidiaries' financial statements from their functional currency to the U.S. dollar in accumulated other comprehensive income (loss) as well as gains and losses on its pension benefit obligation and derivative instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation and remeasurement of foreign currencies</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income (loss) and are recorded in accumulated other comprehensive income (loss), a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are remeasured at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are remeasured at current rates of exchange as of the balance sheet date. Income and expense items are remeasured at the average foreign currency rates for the period. Remeasurement adjustments of these subsidiaries are included in "Other income (expense), net" in our Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net income (loss) per common share</a></td>
<td class="text">Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_TreasuryStockPolicyTextBlock', window );">Treasury stock</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When stock is acquired for purposes other than formal or constructive retirement, the purchase price of the acquired stock is recorded in a separate treasury stock account, which is separately reported as a reduction of equity.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When stock is retired or purchased for formal or constructive retirement, the purchase price is initially recorded as a reduction to the par value of the shares repurchased, with any excess purchase price over par value recorded as a reduction to additional paid-in capital related to the series of shares repurchased and any remainder excess purchase price recorded as a reduction to retained earnings. If the purchase price exceeds the amounts allocated to par value and additional paid-in capital related to the series of shares repurchased and retained earnings, the remainder is allocated to additional paid-in capital related to other series of shares.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the cost of treasury stock that is either sold or reissued, the Company uses the last in, first out method. If the proceeds from the re-issuance of treasury stock are greater than the cost, the excess is recorded as additional paid-in capital. If the </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from re-issuance of treasury stock are less than the cost, the excess cost first reduces any additional paid-in capital arising from previous treasury stock transactions for that class of stock, and any additional excess is recorded as a reduction of retained earnings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for share-based compensation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two share-based employee compensation plans, the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "Emergent Plan") and the Emergent BioSolutions, Inc. Inducement Plan (the "Inducement Plan") under which the Company may grant various types of equity awards including stock options, restricted stock units and performance stock units. For all of our share-based awards, the Company recognizes forfeitures and compensation costs when they occur. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2023, the Company's Board of Directors adopted and approved the Emergent BioSolutions, Inc. Inducement Plan, pursuant to which the Company may from time to time make equity grants to individuals not previously an employee or director of the Company or any of its subsidiaries (or following a bona fide period of interruption of employment) as a material inducement to their employment by the Company. The Inducement Plan was adopted by the board of directors without stockholder approval pursuant to New York Stock Exchange Listing Rule 303A.08. The board of directors reserved 5.0 million shares of the Company's common stock for issuance under the Inducement Plan. The terms and conditions of the Inducement Plan are substantially similar to the Company's stockholder-approved Emergent Plan as discussed below.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plan is determined by the compensation committee of the Company's board of directors, which administers the Emergent Plan. Each equity award granted under the Emergent Plan vests as specified in the relevant agreement with the award recipient and no option can be exercised after seven years from the date of grant. The Company records the estimated fair value of awards in expense on a straight-line basis over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), the Company estimates and recognizes expense based on the period from the grant date to the date the employee becomes retirement eligible.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of restricted stock units using the closing market price of the Company's common stock on the day prior to the date of grant. The Company's performance stock units settle in the Company's stock. The fair value is determined on the date of the grant using the number of shares expected to be earned and the ending market value of the stock on the day prior to the grant date. The number of shares expected to vest is adjusted each reporting period by assessing the probability that the performance criteria will be met and the associated targeted payout level that is forecasted will be achieved. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below is a discussion of the Company's methodology for developing each of the assumptions used:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Expected dividend yield &#8212; the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Expected volatility &#8212; a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. The Company analyzed its own historical volatility to estimate expected volatility over the same period as the expected average life of the options.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Risk-free interest rate &#8212; the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Expected average life of options &#8212; the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of option exercise behavior subsequent to vesting of options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy', window );">Pension plans</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically maintained a defined benefit plan for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The Company's defined benefit plan was included in the sale of the travel health business on May 15, 2023. See Note 3, "Divestiture" for more information. The plan was valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increase, and pension adjustments. The Company reviewed its actuarial assumptions on an annual basis and made modifications to the assumptions based on current rates and trends. Actuarial gains and losses were deferred in accumulated other comprehensive income (loss), net of tax and were amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return were amortized to net periodic benefit cost over the estimated remaining life as a component of selling, general and administrative expenses in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative instruments and hedging activities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. From time to time, the Company enters into interest rate swaps to manage exposures that arise from the Company's payments of variable interest rate debt under its senior secured credit agreements. The objective and strategy with respect to these interest rate swaps is to protect the Company against adverse fluctuations in interest rates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, the Company terminated its designated interest rate swap transactions with a total notional value of $350.0&#160;million. Hedge accounting was also discontinued at that time. As of December 31, 2023, all accumulated other comprehensive income associated with the terminated interest rate swaps was amortized to earnings over the remaining term of the interest rate swaps prior to termination.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy. See Note 9, "Derivative instruments and hedging activities" for further details on the interest rate swaps. </span></div>he valuation of the interest rate swaps was determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflected the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps were determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) were based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporated credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards board ("FASB") issued Accounting Standards Update ("ASU") 2023-07 ("ASU 2023-07"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which improves reportable segment disclosure requirements, on an annual and interim basis, primarily through enhanced disclosures about significant segment expenses. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker ("CODM"). The ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The amendments in the ASU are effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires a public business entity ("PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on it consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ContingentConsiderationObligationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contingent consideration obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ContingentConsiderationObligationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_TreasuryStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_TreasuryStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481097/715-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 80<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480576/715-80-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188275996704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property, Plant and Equipment Useful Lives</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally depreciates or amortizes the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.388%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-39 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-39 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7 years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of the asset life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consists of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023 </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Land and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">229.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">433.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">567.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">794.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,201.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(411.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(383.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">382.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">817.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> During the year ended December 31, 2023, the Company recorded a non-cash impairment charge of $306.7 million related to certain Bioservices long-lived assets. See Note 4, "Long-lived asset impairment and restructuring charges" for more details regarding the impairment charge.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188276181936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-lived asset impairment and restructuring charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock', window );">Schedule of Impairment of Long-Lived Assets Held and Used by Asset</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the total impairment charge by asset class for the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">107.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total impairment of long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">306.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs associated with the Company&#8217;s segments as well as unallocated corporate and research and development ("R&amp;D") charges for the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.427%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Commercial Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total restructuring costs by segment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs, by function, for the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.150%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Employee transition</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Severance payments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of and changes in the Company's restructuring accrual for the January 2023 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of and changes in the Company's restructuring accrual for the August 2023 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188267962672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">142.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">113.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">92.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">328.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188276079872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally depreciates or amortizes the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.388%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-39 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-39 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7 years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of the asset life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consists of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023 </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Land and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">229.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">433.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">567.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">794.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,201.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(411.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(383.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">382.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">817.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> During the year ended December 31, 2023, the Company recorded a non-cash impairment charge of $306.7 million related to certain Bioservices long-lived assets. See Note 4, "Long-lived asset impairment and restructuring charges" for more details regarding the impairment charge.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188272717728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. Components of the Company&#8217;s intangible assets, excluding goodwill, consists of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:19.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Weighted Average Useful Life in Years</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">13.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">855.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">288.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">566.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">982.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">253.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">728.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%">Bioservices</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">13.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">889.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">322.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">566.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,016.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">287.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">728.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company sold $102.9 million of intangible assets, net as part of the sale of its travel health business to Bavarian Nordic. See Note 3, "Divestiture" for more information on the sale of the travel health business. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2023, the Company recorded a $6.3 million intangible asset addition related to the contingent consideration payment to Ridgeback for the award of a 10-year contract by the Biomedical Advanced Research and Development Authority for advanced development, manufacturing scale-up, and procurement of Ebanga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment for Ebola. The related intangible asset was acquired through an asset acquisition that was completed in 2022. </span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Finite-lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company's intangible assets was recorded as follows: </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.5</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Summary of Future Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates our future amortization expense for our intangible assets as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">&#160;As of<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">260.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Total remaining amortization</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">566.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the changes in the carrying amount of goodwill by reportable segment:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Commercial Products </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">MCM Products </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Services </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(218.2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(218.2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Amounts for the Company's Commercial Products segment include gross carrying values of $41.7 million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $41.7 million as of December&#160;31, 2023, 2022 and 2021.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts for the Company's MCM Products segment include gross carrying values of $218.2&#160;million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $218.2&#160;million as of December&#160;31, 2023.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts for the Company's Services segment include gross carrying values of $6.7&#160;million as of December&#160;31, 2023, 2022, and 2021, and accumulated impairment losses of $6.7&#160;million as of December&#160;31, 2023 and 2022.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188273913280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">320.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">320.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-672"><span style="-sec-ix-hidden:f-673">Derivative instruments</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">320.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">179.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Reconciliation of Contingent Consideration Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the beginning and ending balance of the contingent consideration liabilities measured at fair value during the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:18.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.349%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Contingent Consideration Liability</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Fair Value as of December 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Range</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Royalty based</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$5.6 million</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">9.5%</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.0% - 75.0%</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2023 - 2028</span></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270527216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and hedging activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the Consolidated Balance Sheets: </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"></td><td style="width:40.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Fair Value of Asset Derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Derivative Instruments, Gain (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gains or losses reclassified from "Accumulated other comprehensive income (loss), net" into "Interest expense" on the Consolidated Statement of Operations during the years ended December 31, 2023 and 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"></td><td style="width:43.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.731%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188269452736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below present the components of the Company's debt:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Senior secured credit agreement - Term loan due 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">198.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">362.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Senior secured credit agreement - Revolver loan due 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">219.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">598.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">868.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,413.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(413.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(957.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Non-current portion of debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">446.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">448.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Future Debt Payments of Long-Term Indebtedness</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future debt payments of long-term indebtedness are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">As of <br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">418.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">868.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268037728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Valuation Assumptions, Stock Options Granted</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">63%-69%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">54%-62%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">47%-48%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.00%-4.46%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.54%-4.31%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.43%-0.94%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected average life of options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.5 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Award Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option award activity under the Emergent Plan:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Aggregate </span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of performance stock unit and restricted stock unit award activity under the Emergent Plan:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Aggregate<br/>&#160;Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">42.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">46.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock awards outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">16.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"> Performance stock units granted and forfeited during the year ended December&#160;31, 2023 are included at the target payout percentage, or 100%, of shares granted.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of Commercial Product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cost of Bioservices</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.598%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Defined Benefit Pension Plan</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">19.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present the tax effects related to each component of other comprehensive income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2023</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Tax Benefit (Expense)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Defined benefit pension plan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 45<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270538352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per common share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Income Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net income (loss) per common share:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(760.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(211.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">219.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Weighted-average number of shares-basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Dilutive effect of employee incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Weighted-average number of shares-diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income (loss) per common share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(14.85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net income (loss) per common share - diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(14.85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the share-based awards that are not considered in the diluted net income (loss) per common share calculation generally because the exercise price of the awards was greater than the average per share closing price during the year ending December&#160;31, 2023, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price. </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Anti-dilutive stock awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270245568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Disaggregation of Revenue</a></td>
<td class="text">The Company's revenues disaggregated by the major sources were as follows:<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:19.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.833%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="51" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:20pt"><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">496.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">497.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">385.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">386.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">435.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">438.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">373.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">444.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">135.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">579.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">527.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%">Bioservices:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">243.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">305.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total Bioservices</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">243.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">372.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">615.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">394.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">654.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,049.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">482.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">634.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">903.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">870.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,773.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company's product sales from NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Other commercial products, Anthrax MCM, Smallpox MCM and Other products as a percentage of total product sales were as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">% of product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Products:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other Commercial products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Anthrax MCM</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Smallpox MCM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Deferred Revenue Contract Liabilities</a></td>
<td class="text">The following table presents the roll forward of the contract liabilities:<div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">&#160;Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">29.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of "Accounts receivable, net" as presented on the Consolidated Balance Sheets:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Billed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">141.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">102.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">51.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">57.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Allowance for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">191.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">159.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accounts Receivable, Net [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ScheduleOfAccountsReceivableNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188275890672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Expense Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total operating lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Leases Supplemental Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline">Leases</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Classification</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1164"><span style="-sec-ix-hidden:f-1165">Other assets</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1168"><span style="-sec-ix-hidden:f-1169">Other current liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1172"><span style="-sec-ix-hidden:f-1173">Other liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity analysis below summarizes future undiscounted cash flows for our operating leases as of December&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">As of<br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188272812208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Significant Components of the Provisions for Income Taxes Attributable to Operations</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of income taxes attributable to operations consist of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">36.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(37.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net deferred tax liability consists of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal losses carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State losses carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign losses carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRC 263A capitalized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRC 163(j) Interest Limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Withholding Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Income Before the Provision for Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes differ from the amount of taxes determined by applying the U.S. federal statutory rate to income before taxes as a result of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(805.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(442.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">73.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">224.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Earnings (losses) before taxes on income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(731.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(218.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">303.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Federal tax at statutory rates</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(153.6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(46.0)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(52.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">193.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Goodwill Impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Adjustment of prior year taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Compensation limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Unrecognized tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">GILTI, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Foreign withholding tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the gross unrecognized tax benefits activity for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions for prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions for current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270252208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined benefit and 401(k) savings plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock', window );">Summary of Funded Status of the Swiss Plan</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The funded status of the Swiss Plan for the years ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in Plan Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net benefits received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Fair value of plan assets, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in Benefit Obligation:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest Cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net benefits received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Projected benefit obligation, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Funded status, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accumulated benefit obligation, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Pension Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic pension cost incurred during the years ended December&#160;31, 2023, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023 </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">The Swiss Plan was sold as part of our travel health business to Bavarian Nordic, as described further in Note 3, "Divestiture".</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used to calculate the projected benefit obligations were as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.788%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Expected rate of return</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Rate of future compensation increases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Loss Before Income Tax</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents gains (losses) recognized in accumulated other comprehensive income (loss) before income tax related to the Company&#8217;s defined benefit pension plans:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.483%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net actuarial gain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Prior service cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Total recognized in other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)(b)(c)<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (h)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188269289152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment cost of sales or services, segment gross margin, segment gross margin % and total segment adjusted gross margin for each of our reportable segments for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,076.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,639.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,773.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost of sales or services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total cost of sales or services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total segment gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross margin %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment adjusted gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total segment adjusted gross margin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Services revenue, Services gross margin and Services segment adjusted gross margin for the year ended December&#160;31, 2021 includes the impact of $243.1 million of Bioservices leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Segment revenues less total cost of sales or services.</span></div></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the Company's total segment adjusted gross margin to the Consolidated Statement of Operations:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total segment adjusted gross margin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment inventory step-up provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(235.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(368.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(348.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(218.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(731.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each segment:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Depreciation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Commercial Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">59.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes revenues by country. Revenues have been attributed based on the location of the customer:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">607.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">886.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,623.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">224.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">217.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">83.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,049.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,117.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">1,773.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Long-Lived Assets by Geographic Areas</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table included long-lived assets, net by country. Long-lived assets, net includes right-of-use assets and property, plant &amp; equipment, net, excluding software, net:</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Long-lived assets, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">352.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">696.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Total long-lived assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">392.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">826.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270242368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and organization (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>segment </div>
<div>category </div>
<div>product </div>
<div>Category</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfCategoriesOfPublicHealthThreats', window );">Number of categories of public health threats | category</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfRevenueGeneratingProducts', window );">Number of revenue generating products | product</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfProductAndServiceCategories', window );">Number of product and service categories | Category</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfCategoriesOfPublicHealthThreats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of categories of public health threats.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfCategoriesOfPublicHealthThreats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfProductAndServiceCategories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product And Service Categories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfProductAndServiceCategories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfRevenueGeneratingProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of revenue generating products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfRevenueGeneratingProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268524080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Going Concern (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 07, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 868.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,413.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">111.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member', window );">January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Restructuring and related cost, number of positions eliminated | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member', window );">August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Restructuring and related cost, number of positions eliminated | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Credit Agreement Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt instrument, periodic payment, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember', window );">Term Loan Facility | Credit Agreement Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantConsiderationThreshold', window );">Debt instrument, covenant, consideration threshold</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding credit facility</a></td>
<td class="nump">417.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">219.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Term Loan | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">198.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Senior Unsecured Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantConsiderationThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Consideration Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantConsiderationThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268081728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Concentration Risk (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Customer Concentration Risk | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">3800.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263794816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">31 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">39 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">39 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188269591552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Accounting for Share-based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 28, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfShareBasedEmployeeCompensationPlans', window );">Number of stock based employee compensation plans | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life of awards</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ebs_A2023EquityInducementPlanMember', window );">2023 Equity Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfShareBasedEmployeeCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of stock-based compensation plans the company maintains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfShareBasedEmployeeCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ebs_A2023EquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ebs_A2023EquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270606048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Derivative instruments and hedging activities (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 350,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263579120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestiture (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of business</a></td>
<td class="nump">$ 74.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DispositionOfBusinessTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">$ (49.0)<span></span>
</td>
<td class="num">$ (38.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal group, total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business | Development-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DispositionOfBusinessTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposition Of Business, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DispositionOfBusinessTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_DevelopmentBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_DevelopmentBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268532736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-lived asset impairment and restructuring charges - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Total impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member', window );">January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Restructuring and related cost, number of positions eliminated | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member', window );">August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Restructuring and related cost, number of positions eliminated | employee</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188267987232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-lived asset impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Total impairment of long-lived assets</a></td>
<td class="nump">$ 306.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Total impairment of long-lived assets</a></td>
<td class="nump">81.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Total impairment of long-lived assets</a></td>
<td class="nump">117.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Total impairment of long-lived assets</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Total impairment of long-lived assets</a></td>
<td class="nump">$ 107.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268108192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-lived asset impairment and restructuring charges - Schedule Restructuring and Related Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedResearchAndDevelopmentMember', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee Transition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Commercial Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | MCM Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188262464336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-lived asset impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">$ 29.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member', window );">January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member', window );">August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(14.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee Transition</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee Transition | January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee Transition | August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Payments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">27.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Payments | January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(7.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Payments | August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">18.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee Benefits | January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee Benefits | August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263687776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 128.7<span></span>
</td>
<td class="nump">$ 142.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">113.3<span></span>
</td>
<td class="nump">116.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">86.9<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">$ 328.9<span></span>
</td>
<td class="nump">$ 350.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268465168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net - Summary of Property, Plant and Equipment Useful Lives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 794.2<span></span>
</td>
<td class="nump">$ 1,201.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(411.4)<span></span>
</td>
<td class="num">(383.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">382.8<span></span>
</td>
<td class="nump">817.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Total impairment of long-lived assets</a></td>
<td class="nump">306.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">54.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">229.9<span></span>
</td>
<td class="nump">327.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">433.6<span></span>
</td>
<td class="nump">567.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="nump">65.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 36.7<span></span>
</td>
<td class="nump">$ 185.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268258080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="nump">$ 83.4<span></span>
</td>
<td class="nump">$ 62.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">$ 705.4<span></span>
</td>
<td class="nump">693.1<span></span>
</td>
<td class="nump">$ 748.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc. | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188264254672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life in Years</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 889.5<span></span>
</td>
<td class="nump">$ 1,016.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">322.9<span></span>
</td>
<td class="nump">287.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 566.6<span></span>
</td>
<td class="nump">728.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_BARDAMember', window );">BARDA | Ebanga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_RevenueFromContractWithCustomerTermOfContract', window );">Term of contract</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixMember', window );">Chimerix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent', window );">Intangible assets disposed of in sale</a></td>
<td class="nump">$ 102.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life in Years</a></td>
<td class="text">13 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 855.4<span></span>
</td>
<td class="nump">982.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">288.8<span></span>
</td>
<td class="nump">253.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 566.6<span></span>
</td>
<td class="nump">728.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life in Years</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 28.6<span></span>
</td>
<td class="nump">28.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">28.6<span></span>
</td>
<td class="nump">28.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_BioservicesMember', window );">Bioservices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life in Years</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_RevenueFromContractWithCustomerTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Term Of Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_RevenueFromContractWithCustomerTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_EbangaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_EbangaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ebs_ChimerixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_BioservicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_BioservicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188264304240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 65.6<span></span>
</td>
<td class="nump">$ 59.9<span></span>
</td>
<td class="nump">$ 58.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270363248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (218.2)<span></span>
</td>
<td class="num">$ (6.7)<span></span>
</td>
<td class="num">$ (41.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 218.2<span></span>
</td>
<td class="nump">$ 224.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=ebs_MCMProductsMember', window );">MCM Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">$ (218.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=ebs_MCMProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=ebs_MCMProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188267886992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets and goodwill - Future Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 65.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">63.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">60.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">51.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">260.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 566.6<span></span>
</td>
<td class="nump">$ 728.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188264239056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Summary Changes in Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 218.2<span></span>
</td>
<td class="nump">$ 224.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">(218.2)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="num">$ (41.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
<td class="nump">224.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember', window );">Commercial Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, accumulated Impairment loss</a></td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember', window );">MCM Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">218.2<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">(218.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">218.2<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, accumulated Impairment loss</a></td>
<td class="nump">218.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, accumulated Impairment loss</a></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268619824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Fair Value Measurements, Recurring and Nonrecurring (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets, Prepaid expenses and other current assets<span></span>
</td>
<td class="text">Other assets, Prepaid expenses and other current assets<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">320.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">179.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">320.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">320.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263698656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Cost of goods and services sold, Research and development<span></span>
</td>
<td class="text">Cost of goods and services sold, Research and development<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Business combination, contingent consideration, liability, current</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 184.3<span></span>
</td>
<td class="nump">$ 225.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188269427376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Reconciliation of the Contingent Consideration Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 38.4<span></span>
</td>
<td class="nump">$ 59.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(33.0)<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 38.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263919056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Level 3 Significant Unobservable Inputs (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 38.4<span></span>
</td>
<td class="nump">$ 59.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Discount rate | Discounted cash flow | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Probability of payment | Discounted cash flow | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Probability of payment | Discounted cash flow | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityOfPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityOfPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270469728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and hedging activities - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 350,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188364018352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and hedging activities - Fair Value by Balance Sheet Location (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swaps | Designated as Hedging Instrument | Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value of Asset Derivatives</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188273759168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and hedging activities - Cash Flow Hedging on AOCI (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expense | Interest Rate Swaps | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Interest rate swaps gain (loss)</a></td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268472400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components of Long-term Indebtedness (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 868.4<span></span>
</td>
<td class="nump">$ 1,413.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of debt issuance costs</a></td>
<td class="num">(413.7)<span></span>
</td>
<td class="num">(957.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(8.2)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt</a></td>
<td class="nump">446.5<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Term Loan | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">198.2<span></span>
</td>
<td class="nump">362.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 219.2<span></span>
</td>
<td class="nump">$ 598.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188260293568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 07, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 868,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,413,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance costs, current, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal group, total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Prior to August 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Upon the Occurrence of a Change in Control | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Federal Funds Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Until March 31, 2024 | SOFR, EURIBOR, Or CDOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt instrument, periodic payment, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantConsiderationThreshold', window );">Debt instrument, covenant, consideration threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Maximum | Fiscal Quarters Ending After March 31, 2024 | SOFR, EURIBOR, Or CDOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Maximum | Fiscal Quarters Ending After March 31, 2024 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Maximum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Minimum | Fiscal Quarters Ending After March 31, 2024 | SOFR, EURIBOR, Or CDOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Minimum | Fiscal Quarters Ending After March 31, 2024 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Credit Agreement Amendment | Minimum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantLeverageRatioMaximum', window );">Debt instrument, covenant, leverage ratio, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement Amendment | Fiscal Quarters Ending in 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Debt instrument, covenant, interest coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement Amendment | Fiscal Quarters Ending After 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Debt instrument, covenant, interest coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement Amendment | Revolving Credit Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentMandatoryPrepaymentThreshold', window );">Mandatory prepayment threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage', window );">Mandatory principal prepayment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement Amendment | Revolving Credit Facility | SOFR, SONIA, and Eurocurrency | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Forbearance Agreement And Amendment | Revolving Credit Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="nump">$ 270,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, unused capacity, commitment fee percentage</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentMandatoryPrepaymentThreshold', window );">Mandatory prepayment threshold</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage', window );">Mandatory principal prepayment percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Forbearance fee</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Forbearance Agreement And Amendment | Revolving Credit Facility | Base Rate | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Forbearance Agreement And Amendment | Revolving Credit Facility | SOFR, SONIA, and Eurocurrency | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Senior Unsecured Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Term Loan | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantConsiderationThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Consideration Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantConsiderationThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Consolidated Interest Coverage Ratio Required</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum allowed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentMandatoryPrepaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Mandatory Prepayment Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentMandatoryPrepaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Mandatory Principal Prepayment Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ebs_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ebs_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtTermsAxis=ebs_UntilMarch312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtTermsAxis=ebs_UntilMarch312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ebs_SOFREURIBOROrCDORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ebs_SOFREURIBOROrCDORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtTermsAxis=ebs_FiscalQuartersEndingAfterMarch312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtTermsAxis=ebs_FiscalQuartersEndingAfterMarch312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtTermsAxis=ebs_FiscalQuartersEndingIn2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtTermsAxis=ebs_FiscalQuartersEndingIn2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtTermsAxis=ebs_FiscalQuartersEndingAfter2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtTermsAxis=ebs_FiscalQuartersEndingAfter2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ebs_SOFRSONIAAndEurocurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ebs_SOFRSONIAAndEurocurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_ForbearanceAgreementAndAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_ForbearanceAgreementAndAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188269605936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Future Debt Payments of Long-term Indebtedness (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 418.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 868.4<span></span>
</td>
<td class="nump">$ 1,413.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188258240880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>vote </div>
<div>plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 11, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 28, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 11, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfShareBasedEmployeeCompensationPlans', window );">Number of stock based employee compensation plans | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.35<span></span>
</td>
<td class="nump">$ 17.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to stock options</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_CommonStockNumberOfVotesPerCommonShare', window );">Common stock, voting rights | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,500,000<span></span>
</td>
<td class="nump">$ 187,900,000<span></span>
</td>
<td class="nump">$ 112,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares of common stock repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ebs_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_SaleOfStockAggregateOfferingAmountMaximum', window );">Aggregate gross sales price</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.22<span></span>
</td>
<td class="nump">$ 8.22<span></span>
</td>
<td class="nump">$ 8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares', window );">Sale of stock, amount remaining available for sale of shares</a></td>
<td class="nump">$ 140,900,000<span></span>
</td>
<td class="nump">$ 140,900,000<span></span>
</td>
<td class="nump">$ 140,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ebs_A2023EquityInducementPlanMember', window );">2023 Equity Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2006 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized for issuance under the plan (in shares) | shares</a></td>
<td class="nump">29,100,000<span></span>
</td>
<td class="nump">29,100,000<span></span>
</td>
<td class="nump">29,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for future awards (in shares) | shares</a></td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum', window );">Exercise price of option as percentage of fair market value at grant date, minimum</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue', window );">Total fair value of awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,800,000<span></span>
</td>
<td class="nump">$ 30,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount</a></td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period expected to be recognized related to unvested equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue', window );">Total fair value of awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period expected to be recognized related to unvested equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_CommonStockNumberOfVotesPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number Of Votes Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_CommonStockNumberOfVotesPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum exercise price of option as percentage of the fair market value of the shares underlying such option on the date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfShareBasedEmployeeCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of stock-based compensation plans the company maintains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfShareBasedEmployeeCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_SaleOfStockAggregateOfferingAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Amount, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_SaleOfStockAggregateOfferingAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Remaining Available For Sale Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received On Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payout Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation awards vested. Includes options, share units, stock appreciation rights, and restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ebs_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ebs_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ebs_A2023EquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ebs_A2023EquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270451968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity - Stock Options Valuation Assumptions (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">1.54%<span></span>
</td>
<td class="nump">0.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.46%<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
<td class="nump">0.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected average life of options</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268639920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity - Stock Options, Restricted Stock Units, and Performance Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember', window );">Performance Shares And Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage', window );">Target payout percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember', window );">2006 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, beginning of period (in shares)</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted (in shares)</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock options forfeited (in shares)</a></td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, end of period (in shares)</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable, end of period (in shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 51.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options granted (in dollars per share)</a></td>
<td class="nump">9.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Stock options forfeited (in dollars per share)</a></td>
<td class="nump">42.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, end of period (in dollars per share)</a></td>
<td class="nump">34.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, end of period (in dollars per share)</a></td>
<td class="nump">$ 56.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Stock options outstanding</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options exercisable</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options outstanding</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock options exercisable</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember', window );">2006 Stock Incentive Plan | Performance Shares And Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted/performance stock units outstanding, beginning of period (in shares)</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted/performance stock units granted (in shares)</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted/performance stock units vested (in shares)</a></td>
<td class="num">(700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted/performance stock units forfeited (in shares)</a></td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted/performance stock units outstanding, end of period (in shares)</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted/performance stock units outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 42.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted/performance stock units granted (in dollars per share)</a></td>
<td class="nump">8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted/performance stock units vested (in dollars per share)</a></td>
<td class="nump">46.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted/performance stock units forfeited (in dollars per share)</a></td>
<td class="nump">26.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted/performance stock units outstanding, end of period (in dollars per share)</a></td>
<td class="nump">$ 16.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Restricted/performance stock units outstanding</a></td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263879872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 23.1<span></span>
</td>
<td class="nump">$ 45.1<span></span>
</td>
<td class="nump">$ 42.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales | Commercial Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales | MCM Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales | Bioservices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="nump">$ 30.6<span></span>
</td>
<td class="nump">$ 29.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_CommercialProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_CommercialProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_BioservicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_BioservicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188262463312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 1,387.7<span></span>
</td>
<td class="nump">$ 1,611.5<span></span>
</td>
<td class="nump">$ 1,450.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(12.4)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(8.8)<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">649.3<span></span>
</td>
<td class="nump">1,387.7<span></span>
</td>
<td class="nump">1,611.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
<td class="num">(25.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(8.8)<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(5.7)<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Defined Benefit Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (5.7)<span></span>
</td>
<td class="num">$ (6.6)<span></span>
</td>
<td class="num">$ (7.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263883248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="num">$ (11.0)<span></span>
</td>
<td class="nump">$ 23.9<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Benefit (Expense)</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(8.8)<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Defined Benefit Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Benefit (Expense)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Benefit (Expense)</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Benefit (Expense)</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188276951840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per common share (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustment for potential dilutive effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (760.5)<span></span>
</td>
<td class="num">$ (211.6)<span></span>
</td>
<td class="nump">$ 219.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares-basic (in shares)</a></td>
<td class="nump">51,200,000<span></span>
</td>
<td class="nump">50,100,000<span></span>
</td>
<td class="nump">53,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities-equity awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares-diluted (in shares)</a></td>
<td class="nump">51,200,000<span></span>
</td>
<td class="nump">50,100,000<span></span>
</td>
<td class="nump">54,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share - basic (in dollars per share)</a></td>
<td class="num">$ (14.85)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
<td class="nump">$ 4.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (14.85)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
<td class="nump">$ 4.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock awards (in shares)</a></td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188261852800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 191,300,000<span></span>
</td>
<td class="nump">$ 194,300,000<span></span>
</td>
<td class="nump">$ 191,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract with customer, asset, after allowance for credit loss, noncurrent</a></td>
<td class="nump">34,800,000<span></span>
</td>
<td class="nump">21,900,000<span></span>
</td>
<td class="nump">34,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customer, liability, current</a></td>
<td class="nump">26,400,000<span></span>
</td>
<td class="nump">27,200,000<span></span>
</td>
<td class="nump">26,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provisions for expected credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="nump">305,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">Lessor, operating lease, payment to be received, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">Lessor, operating lease, payment to be received, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">Lessor, operating lease, payment to be received, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">Lessor, operating lease, payment to be received, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">Lessor, operating lease, payment to be received, year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter', window );">Lessor, operating lease, payment to be received, after year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300,000<span></span>
</td>
<td class="nump">41,400,000<span></span>
</td>
<td class="nump">$ 134,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Geographic Concentration Risk | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember', window );">USG | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 243,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember', window );">USG | Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400,000<span></span>
</td>
<td class="nump">$ 37,200,000<span></span>
</td>
<td class="nump">$ 130,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember', window );">USG | Revenue from Contract with Customer | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3800.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_CustomerTwoMember', window );">Customer Two | Revenue from Contract with Customer | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase in other assets</a></td>
<td class="nump">$ 152,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_BARDAMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,800,000<span></span>
</td>
<td class="nump">$ 628,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_BARDAMember', window );">BARDA | Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_BARDAMember', window );">BARDA | Reservation Of Manufacturing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_BARDAMember', window );">BARDA | Accelerated Expansion Of Fill/Finish Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ebs_ReservationOfManufacturingCapacityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ebs_ReservationOfManufacturingCapacityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ebs_AcceleratedExpansionOfFillFinishCapacityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ebs_AcceleratedExpansionOfFillFinishCapacityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263443744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,049.3<span></span>
</td>
<td class="nump">$ 1,117.5<span></span>
</td>
<td class="nump">$ 1,773.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember', window );">USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">394.7<span></span>
</td>
<td class="nump">482.6<span></span>
</td>
<td class="nump">903.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember', window );">Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">654.6<span></span>
</td>
<td class="nump">634.9<span></span>
</td>
<td class="nump">870.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_CommercialProductMember', window );">Commercial Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">497.3<span></span>
</td>
<td class="nump">386.6<span></span>
</td>
<td class="nump">438.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_CommercialProductMember', window );">Commercial Product sales | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_CommercialProductMember', window );">Commercial Product sales | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">496.5<span></span>
</td>
<td class="nump">385.8<span></span>
</td>
<td class="nump">435.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember', window );">MCM Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">447.2<span></span>
</td>
<td class="nump">579.6<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember', window );">MCM Product sales | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">373.5<span></span>
</td>
<td class="nump">444.6<span></span>
</td>
<td class="nump">527.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember', window );">MCM Product sales | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">73.7<span></span>
</td>
<td class="nump">135.0<span></span>
</td>
<td class="nump">58.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_BioservicesMember', window );">Total Bioservices revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Bioservices revenues</a></td>
<td class="nump">78.5<span></span>
</td>
<td class="nump">109.9<span></span>
</td>
<td class="nump">615.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_BioservicesMember', window );">Total Bioservices revenues | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Bioservices revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">243.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_BioservicesMember', window );">Total Bioservices revenues | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Bioservices revenues</a></td>
<td class="nump">78.5<span></span>
</td>
<td class="nump">109.9<span></span>
</td>
<td class="nump">372.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">72.8<span></span>
</td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">310.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">72.8<span></span>
</td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">310.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">305.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember', window );">Leases | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">243.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember', window );">Leases | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">62.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">26.3<span></span>
</td>
<td class="nump">41.4<span></span>
</td>
<td class="nump">134.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">20.4<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
<td class="nump">130.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_CommercialProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_CommercialProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_BioservicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_BioservicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_BioservicesLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188264309360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Percentage of Product Sales (Details) - Sales Revenue, Product Line - Product Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_NARCANMember', window );">NARCAN&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_OtherCommercialProductsMember', window );">Other Commercial products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_AnthraxMCMMember', window );">Anthrax MCM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_SmallpoxMCMMember', window );">Smallpox MCM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_OtherProductsMember', window );">Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_NARCANMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_NARCANMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_OtherCommercialProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_OtherCommercialProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_AnthraxMCMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_AnthraxMCMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_SmallpoxMCMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_SmallpoxMCMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270283072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ChangeinContractWithCustomerLiabilityRollForward', window );"><strong>Change in Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 31.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">29.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</a></td>
<td class="nump">$ 20.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ChangeinContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ChangeinContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188272683920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts receivable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed</a></td>
<td class="nump">$ 141.8<span></span>
</td>
<td class="nump">$ 102.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled</a></td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">57.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for expected credit losses</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 191.0<span></span>
</td>
<td class="nump">$ 159.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188269424512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188272781744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="nump">$ 19.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 17.3<span></span>
</td>
<td class="nump">$ 20.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270420256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268693728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease liabilities</a></td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 17.3<span></span>
</td>
<td class="nump">$ 20.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188262469328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount', window );">Valuation allowance increase, including CTA component</a></td>
<td class="nump">$ 192.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DeferredTaxLiabilitiesForeignWithholdingTax', window );">Deferred tax liabilities, foreign withholding tax</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase</a></td>
<td class="nump">$ 192.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate reconciliation, percent</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_UnrecognizedTaxBenefitsNoncurrent', window );">Unrecognized tax benefits, noncurrent</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued income tax penalties and interest</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties expense (benefit)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">279.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">243.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">667.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 55.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DeferredTaxLiabilitiesForeignWithholdingTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Foreign Withholding Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DeferredTaxLiabilitiesForeignWithholdingTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_UnrecognizedTaxBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns, and classified as a non-current liability as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_UnrecognizedTaxBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Including Cumulative Translation Adjustment, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188267938528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Components of the Provisions for Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (9.4)<span></span>
</td>
<td class="num">$ (3.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International</a></td>
<td class="nump">36.7<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">36.6<span></span>
</td>
<td class="nump">26.3<span></span>
</td>
<td class="nump">40.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(37.7)<span></span>
</td>
<td class="nump">37.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(7.3)<span></span>
</td>
<td class="num">(33.7)<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) provision</a></td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="num">$ (7.4)<span></span>
</td>
<td class="nump">$ 83.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188271092400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Net Deferred Tax Asset (Liability) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal losses carryforward</a></td>
<td class="nump">$ 58.7<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State losses carryforward</a></td>
<td class="nump">38.9<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D carryforward</a></td>
<td class="nump">21.9<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign losses carryforward</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory reserves</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts', window );">IRC 263A capitalized costs</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">IRC 163(j) Interest Limitation</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DeferredTaxAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">269.5<span></span>
</td>
<td class="nump">130.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(257.8)<span></span>
</td>
<td class="num">(65.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(63.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(40.4)<span></span>
</td>
<td class="num">(46.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use asset</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DeferredTaxLiabilitiesForeignWithholdingTax', window );">Foreign Withholding Tax</a></td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(4.2)<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(58.9)<span></span>
</td>
<td class="num">(125.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (47.2)<span></span>
</td>
<td class="num">$ (59.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Capitalized Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DeferredTaxLiabilitiesForeignWithholdingTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Foreign Withholding Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DeferredTaxLiabilitiesForeignWithholdingTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188263762320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (805.1)<span></span>
</td>
<td class="num">$ (442.6)<span></span>
</td>
<td class="nump">$ 100.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">73.9<span></span>
</td>
<td class="nump">224.0<span></span>
</td>
<td class="nump">203.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Earnings (losses) before taxes on income</a></td>
<td class="num">(731.2)<span></span>
</td>
<td class="num">(218.6)<span></span>
</td>
<td class="nump">303.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rates</a></td>
<td class="num">(153.6)<span></span>
</td>
<td class="num">(46.0)<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(52.7)<span></span>
</td>
<td class="num">(13.5)<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Impact of foreign operations</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(7.2)<span></span>
</td>
<td class="num">(18.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">193.6<span></span>
</td>
<td class="nump">37.8<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill Impairments</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustment of prior year taxes</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount', window );">Compensation limitation</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Unrecognized tax benefit</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount', window );">GILTI, net</a></td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Foreign withholding tax</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference', window );">Permanent differences</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) provision</a></td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="num">$ (7.4)<span></span>
</td>
<td class="nump">$ 83.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Compensation Limitation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188271018672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits, beginning of period</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) for tax positions for prior years</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) for tax positions for prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for tax positions for current year</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits, end of period</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188262442512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined benefit and 401(k) savings plan - Swiss Plan Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of period</a></td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Net benefits received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
<td class="nump">$ 29.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of period</a></td>
<td class="nump">37.2<span></span>
</td>
<td class="nump">46.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest Cost</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Net benefits received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
<td class="nump">$ 46.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Accumulated benefit obligation, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188264212064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined benefit and 401(k) savings plan - Components of Net Periodic Pension Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188276052736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined benefit and 401(k) savings plan - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Matching contributions made by employer</a></td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 8.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188271064432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined benefit and 401(k) savings plan - Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of future compensation increases</a></td>
<td class="nump">1.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270469728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Defined benefit and 401(k) savings plan - Accumulated Other Comprehensive Loss Before Income Tax (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial gain</a></td>
<td class="nump">$ 9.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total recognized in other comprehensive income (loss)</a></td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270303568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Purchase commitments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Purchase Obligation, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total purchase commitment</a></td>
<td class="nump">$ 526.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase commitment period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase commitment, year one</a></td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Materials purchased under commitment, amount</a></td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="nump">$ 199.6<span></span>
</td>
<td class="nump">$ 110.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188276031328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188268893232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 1,049.3<span></span>
</td>
<td class="nump">$ 1,117.5<span></span>
</td>
<td class="nump">$ 1,773.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales or services:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">705.4<span></span>
</td>
<td class="nump">693.1<span></span>
</td>
<td class="nump">748.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">$ 317.6<span></span>
</td>
<td class="nump">$ 383.0<span></span>
</td>
<td class="nump">$ 891.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_GrossProfitPercentage', window );">Gross margin %</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Total segment adjusted gross margin</a></td>
<td class="nump">$ 335.7<span></span>
</td>
<td class="nump">$ 437.0<span></span>
</td>
<td class="nump">$ 894.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Segment restructuring costs</a></td>
<td class="num">(29.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="num">(306.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(111.4)<span></span>
</td>
<td class="num">(188.3)<span></span>
</td>
<td class="num">(235.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="num">(368.4)<span></span>
</td>
<td class="num">(339.5)<span></span>
</td>
<td class="num">(348.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">(218.2)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="num">(41.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="num">(65.6)<span></span>
</td>
<td class="num">(59.9)<span></span>
</td>
<td class="num">(58.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(87.9)<span></span>
</td>
<td class="num">(37.3)<span></span>
</td>
<td class="num">(34.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="nump">74.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="num">(11.7)<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(731.2)<span></span>
</td>
<td class="num">(219.0)<span></span>
</td>
<td class="nump">303.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,023.0<span></span>
</td>
<td class="nump">1,076.1<span></span>
</td>
<td class="nump">1,639.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Segment restructuring costs</a></td>
<td class="num">(14.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_InventoryStepUp', window );">Segment inventory step-up provision</a></td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(51.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_BARDAMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales or services:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">26.3<span></span>
</td>
<td class="nump">41.4<span></span>
</td>
<td class="nump">134.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | Contracts and grants revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">26.3<span></span>
</td>
<td class="nump">41.4<span></span>
</td>
<td class="nump">134.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember', window );">Commercial Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales or services:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">210.3<span></span>
</td>
<td class="nump">160.3<span></span>
</td>
<td class="nump">187.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">$ 287.0<span></span>
</td>
<td class="nump">$ 226.3<span></span>
</td>
<td class="nump">$ 250.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_GrossProfitPercentage', window );">Gross margin %</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Total segment adjusted gross margin</a></td>
<td class="nump">$ 287.0<span></span>
</td>
<td class="nump">$ 226.3<span></span>
</td>
<td class="nump">$ 250.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember', window );">Commercial Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">497.3<span></span>
</td>
<td class="nump">386.6<span></span>
</td>
<td class="nump">438.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Segment restructuring costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember', window );">MCM Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales or services:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">305.6<span></span>
</td>
<td class="nump">264.3<span></span>
</td>
<td class="nump">195.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">$ 141.6<span></span>
</td>
<td class="nump">$ 315.3<span></span>
</td>
<td class="nump">$ 390.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_GrossProfitPercentage', window );">Gross margin %</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Total segment adjusted gross margin</a></td>
<td class="nump">$ 151.3<span></span>
</td>
<td class="nump">$ 369.3<span></span>
</td>
<td class="nump">$ 393.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">(218.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember', window );">MCM Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">447.2<span></span>
</td>
<td class="nump">579.6<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Segment restructuring costs</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales or services:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">189.5<span></span>
</td>
<td class="nump">268.5<span></span>
</td>
<td class="nump">365.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="num">$ (111.0)<span></span>
</td>
<td class="num">$ (158.6)<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_GrossProfitPercentage', window );">Gross margin %</a></td>
<td class="num">(141.00%)<span></span>
</td>
<td class="num">(144.00%)<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Total segment adjusted gross margin</a></td>
<td class="num">$ (102.6)<span></span>
</td>
<td class="num">$ (158.6)<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">78.5<span></span>
</td>
<td class="nump">$ 109.9<span></span>
</td>
<td class="nump">$ 615.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciling items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Segment restructuring costs</a></td>
<td class="num">$ (8.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AdjustedGrossMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Gross Margin</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AdjustedGrossMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_GrossProfitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Profit Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_GrossProfitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_InventoryStepUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Step Up</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_InventoryStepUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188264310272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="nump">$ 83.4<span></span>
</td>
<td class="nump">$ 62.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember', window );">MCM Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">29.7<span></span>
</td>
<td class="nump">24.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember', window );">Commercial Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="nump">$ 43.2<span></span>
</td>
<td class="nump">$ 28.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188270452512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Revenue from External Customers by Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 1,049.3<span></span>
</td>
<td class="nump">$ 1,117.5<span></span>
</td>
<td class="nump">$ 1,773.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">607.2<span></span>
</td>
<td class="nump">886.1<span></span>
</td>
<td class="nump">1,623.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">224.2<span></span>
</td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">66.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ebs_OtherGeographicalAreaMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 217.9<span></span>
</td>
<td class="nump">$ 82.8<span></span>
</td>
<td class="nump">$ 83.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ebs_OtherGeographicalAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ebs_OtherGeographicalAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188269398944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Long-Lived Assets by Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets, net</a></td>
<td class="nump">$ 392.4<span></span>
</td>
<td class="nump">$ 826.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets, net</a></td>
<td class="nump">352.3<span></span>
</td>
<td class="nump">696.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">88.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets, net</a></td>
<td class="nump">37.2<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ebs_OtherGeographicalAreaMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets, net</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ebs_OtherGeographicalAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ebs_OtherGeographicalAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140188262453504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Details) - Prepaid expenses and other current assets allowance - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to Costs and Expenses</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>176
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&S>4V\>XT-+<I29/1S/!E6 T(1H2=$T8X3&@A953Z&Q.)'"=@J8Q8>?H(_J
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M@:W;T6D2A\.Y>@GAL!I3\5"+C5.7<:R\8>U3L'M]QQ(3J D]4.]W;<UKU]M
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M6^:+S0R;]J_T#?Z5>O6O7MDR7VQFW+1_I6_TK]1VG FV-L"IO0&.0FO( ,\
M&G>2YG/"VKQ&[@WP\0>FW0TOO?!>V3)?;&;0M%^-T/</F,CI=2^.FT^VS!>;
M&3=MAR.W'78D&_ DH/4,'@"BENT 0.V-P<@B2:0=:.1^J'#):]GD*WF<,#=-
M7L,/2[II+K[\7LVH+S8SA-J,1O0-P\;GX8NE5[;,%YL9M]YA#O<3 -^<9R+[
M_ 6.[;,<-HI:3U]G  H1:HV?>>_DV8XUF^X$GPA6_%#+XWFM\Z?G4X(?N[-Q
M@\_OT%5V/.NG:8Y'#^_S9E/6(JC86E&&LT3UJ3F>YCN^D7S?G6][Y%+R7?=R
MR_*"-2U ?;_F7+Z\:7_@?*;R]D]02P,$%     @ LH)H6,GN1 ?1 P  D0T
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M+#0 WF\X5Z\/>H+F%+;X'U!+ P04    " "R@FA8&"D?.((*  !8-0  &
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MO C&:GAU[LT(1!E3!RX!,TW_3A@"SH+ZGJ@IT"(+\2/+Z@1@?8/*I9/(V<D
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M]/<;(=3IC?F!\\-4R[\ 4$L#!!0    ( +*":%CBG92GU0<  +%%   8
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M:-D1U^JJHLG745@9HU5WU,%9AJ0Y%<U^I@\N:%0*19/S7-MPN-N'<V*_ITN
MM7D'=>&PQH:S%8L&-*8#2G-!:12*)FNC]N)PMQG7TD8O/9A*!O$,8V7EQWV\
M. UL0983J[6F:UAC;!/%Q='@QGC6CDHUQ9:VT;#MY-&L'3G<;<F]]$P#->1
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M5':H>]02(8:H&04HF [4<&81S$B(F*11A;,N69ZAM$$V(I,-WK(=R22 #;S
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M!U)&,YDJ5$S]ZR!W>LA1.6JQBK08O5K9#.M4CM.GA#YH%=1PZ!NDV@H5WZF
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M-D::&&+K<EVN]HIES#)T0.?RMG%&,X]2*[XD2R+>G.\J4PISU Q!NC<.V.'
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M#A_X!L<^@=*3/W #G$Q)QWOU_P!02P,$%     @ LH)H6(7K E%#!@  ,@X
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M/HA.TW? 5CQ]3;V7KE  J&D.U='@ -\?+GVAI)=@Z_A5,+,!\R\^H@D@4BR
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M"+[F*\*2%*J'0  V)F\)$]J+!?H<J(L]IMX#@,DT)*7($(.XM=]-X'U&CE7
M>1V3C#,(:]JE!R78M^*#D?H90KDO9%GF&GZMUPL5%C9EJB-0NH@9VM7+5!=*
M)@N27VND.M&)7:JS#+ 351B:)*=/0@IPN%0Y())K4"N-6J/O2T2EL>AI_8U6
M,,Q;RL+288(B[VH[B!V8?[ZJABA(2IHK4A+N+ Q7-2N^7QG&L2U%\";/FPUK
M!#M*&OF@+]5R9MG/J(VYF(!5Y@",K!P7BH[&0DF/LD")!A57;+@E6+5O$V\S
MUV2>VX0[::Q@B9T;_1M]92U,YT[VQOY AN]-AD?]8TP]>4Z6=XK62DG$F"8)
M@3E %3,0LID%(O$"Y]&,ADY1>Q=S*M@ K+;US59=,C")_DC3>_%WNLL3C;BJ
M=$YE$\[/ZDO2XI#3C!4[GP,\M;#H4QNW]L3)J'\H?JH<RD?E8JFGTE:RA:/1
M,>[>V2PL*7N'_0FP-;&G I@#;0X@; XOO1@-C_M3\>6QDSL[[)Z( /]%&E3_
M%?LD?G%SB? P62!C<RRZR9'TG\S&B<U@:WB@ZV CES9D;<X!)<EZ2V??_' R
M'@]/-\P@3;P^.GW''8U!YI*?5E0[0'7))9<2"*#7@'9N(,GFVN!678^Q"/[*
M]![%IR%2;39I&AV?4N&?VRBT*'1@Z* 3DC,=&84JN@P+[BQ4LYK\VK)]$Y5H
M=,H3##VE@%U)I!QEXP.G-FK.:'PH5%'F=J6H&GW9P)5R$2+V?D3XFY2@L:4>
MIUZ2'5ZUQX +U6.X"".<AA'PJ+GIZ@F8"E!MEL#XBQ,4T7W,#M2PJ)27<K5F
M>;MWAGD+P-6E2*[GZ([@G>@U(\2,.@7XE,,NA*3,%9WJN(H^ >,?C5/]1ZQE
MAG#CZQ8?SPQMV4+MU0"83IN@)+,Y-0'LOPOX:'+IEWB,ABYRF$1SV= 9U=/9
MNBBV ?R3;W<DL1"7$)VLUMV*2N3<.@[ EEE L)KC:? %.=HY\%2*TFI7+A_M
M)AOD*C/'-L/433!$HKIYS'H^>IYI0]E$W<=&5A"KF>Y< ,T];"OB$,@'4G4
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MG@9@>K/W Z>;SF K[<BN7;>B]Q&-7T#SA=9N._ ;#"]N^@M02P,$%     @
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M%]CZQ>G27QJGVM$)T _I8$$;. LD?"BAL\KZA16T_T4X^PM02P,$%     @
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MZX5/+9B.^,/3X0/)1?HNL%V>OJ[\(MV*LZ.I@NA\^N+9!-4<OUBDFV#;^)4
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M.@#J4W"#(OZ8PW07Z]L"J[GVQ\>4URR'<+=1+@V:$?<= 054_GOQM,-6_X^
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MK>EBOA"W\$7 &A7V&D=\<#XXUPZ;YO[J&@U^JBBF+?,0]\.'ZQX):P_RJ77
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MII[/P3ADGR5+05N\0Z,L.MU2JH,ME9(3[R>I"/>8G6+]B!;>JN_0,9X+5C&
MS!Q2VN3@]>!-O)>-M;)$SU9:^77#]9G ,-9 ]7X%MH%V^2-[)&;?5GALNEX\
M/@W<J=+J'V-").$9B\.(';I.C0:W7\SYC;OCT_6CEM9?A/NO_6_$A;\][Z;[
M?Y O7&]P U@!:UP:A>_QUJ[]O=YWK*K<77JE+-[,73/'7R'0- ''UPI+=]LA
M _W/U?)_4$L#!!0    ( +*":%C*TM->#!$  *LQ   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(R+GAM;)U;6W/;-A;^*QBMVR8SLBQ1DB4[EQG'Z7;321I/
MW,OL[.P#1$(2MA2A$J1E]]?O=PX WDPY;A],22!P<.XWP*\/)O_=;I4JQ/TN
MS>R;P;8H]I=G9S;>JIVT([-7&=ZL3;Z3!7[FFS.[SY5,>-$N/8O&X_.SG=39
MX.UK'KO)W[XV99'J3-WDPI:[G<P?WJG4'-X,)H,P\$5OM@4-G+U]O9<;=:N*
M7_8W.7Z=55 2O5.9U283N5J_&5Q-+M_-:#Y/^%6K@VU\%T3)RIC?Z<>'Y,U@
M3 BI5,4%09#XN%/7*DT)$-#XP\,<5%O2PN;W /V?3#MH64FKKDWZFTZ*[9O!
M<B 2M99E6GPQAW\I3\^<X,4FM?P4!S=WMAB(N+2%V?G%P&"G,_<I[ST?&@N6
MXR,+(K\@8KS=1HSE>UG(MZ]S<Q YS08T^L*D\FH@IS,2RFV1XZW&NN+M%W6G
MLE*!O['99)HX]?JL &!Z?19[(.\<D.@(D$DD/IFLV%KQ?9:HI W@#!A5:$4!
MK7?1DQ#?JW@DII.AB,;1] EXTXK,*<.;?H7,=6YVXAJXYE 'L+K8BFMFLLK%
M?ZY6EL?_V\<!!W_6#Y],Y]+N9:S>#& ;5N5W:O#VVW],SL>OGL!^5F$_>PKZ
M<X7T))!^%'L@BY^W"BS:[67V(&#\N2R4%3H3Q3972JQ*"\#6"JLV,,["BA<6
MPS^90HG)<B@&MVX<*YS+ ,C!RU$3ZG<6^_&^5B3:RLTF5QOLDHC5 W91T.__
M&3@.4^8QIAQ4KH2T8FU2N!![*?ZM9.XT34!/U&X%X05=H4=$CXGXY?8'H)6=
MTN?/II#ILT: (Y0AUOAZDYNDA)I8F0*-$S$>+?&<79R/YORY&$VKT>ER[C_/
M1^?XC$81S9FZT=ET.1J+3]>?.C"GBRE@X;$0L]D"2V:S&99/L&PLYHL+?)]'
M"X"8+T<3/.:C"_%.&Q*>!FLNQ:W_)K[]QS*:1*_$(L)L?H21R9B N6<8FT[&
MP-T]/RHXM1K '+C07_@]PY;T%\VF0.$\PF,*6)%G5P,;T!D6G8C%DIGD/^KQ
MR?@"P.I/!Q9\ \XS?)Y/YE@1+-0*F25BDTO2LVB,&<2!Z)R09W;1WP3#D^F8
M?X+0Z:Q"KM(RP+^8@2C G\]8/I/A>';!\ILM(QXYG\X<9L/)9,%87XRG/&.Y
M&//G9+B J,X%P@&KZ0/TT K5KXA#IXF$/VGCD%?4!K!OZ0&[I9^NOEQ?_01>
M31:S5V(H/F-%+N):'_T:.Q17<+:YO">-&HK;G4S3O>%?O)];&&:3Z4@!.XYA
ME8BSPJQ%P>QIX_!WS>P; M@"==EC1!ALTS>GE=,+/&81'@[GZ\?$"II'?T&'
MOFG:$< V> &$""@]HG,\6IR9+&EX%MZY#6^J76C1N?][EH ;HI56)SZV.%X6
MAM?#J[#<P5CF;F;J]S*#ATSTG4Y*4!N'( 0_J^YC\J_@ZF3\32VMH,RC%GI'
ML(M:^Q8'4^U@G[7%SPY[)$VQ*3-RS7#F<&,]DYD/A(Y%#,'7L%'MY3M0:$M:
M<Y!D!AJYH$X?A"R*7*_*0JY2%?C7%'2(-Z._8G[#?OMC55J\:H0AEEW-(DH,
M..*!"XB*V."VX# (:P3*%@/SY3=#L;API%Q$^(&@NE><9*8/PUZFJAP9'$=$
M>KV36;F&DRMSG6U$Y44EHJ'B",KIR8\RLU9EXF8K$4UC518ZEBE\P(<,*=+G
M3/Q8@GL1TSMN44D_<E-NMD*#?8<M[!H!_9 !>5NNH+(:6?A0? ^*-[3=IQ8^
MGSGR U4KWLFTT#N3JZ'X^/%Z")87T*H$BN3E%'"\ZD4=O,B<UVE,;9/C4=:*
M=?)'L\TL>/2MW.U?A5]#UIU4 M=3BR5*)'FY84H*F<6JP\YC8"K1Z^Q.V4)O
MF$9@<'OUY?;TVOQZ&HD[Z"MR'+C9!*'F^O.OT>GMD%.DW0KR WE4!R0@BTFZ
M2GZ5L2A4O,U,:C8/X@6-TD;1^)577_XU>?722PS\.&_8:95NP>G!(0 T&!LX
M)>$VP"35 OL3#P6H3IL@%'*<*]1F\;;+[UHT8"/,8F>(2>P#2=4W4*BUU&D)
M;X$D+*QZH5\2*AZM%JKT/5=_E-K"/@BHBJ4M;-B77Y&2_%&"8;IXH!<A^0'(
ME1)[I'=;9F1CQQ+FG!_!G"SMA78HP=6L=;X+LQIB+6@J9H!KU18=;&&%>E?N
M6KC1C( ?EEEZ)8[J-Z&B,UN@#!Y"V;/D-(%E'9N\Q33:8UVF:YVFI)^8:6M$
M/+<XGQZ)CR1*TJ[CB@)N*SB:Q#FN6E6 ^=[DY+ .N2[ BJ \1&'#_31U*:Q^
MK%-'%0@1#_Z*MNFHG;+'U_GDOO)..HO3,B%F($JK#1%3:V!+U0RE+U1-L"<S
MJ]2;+<<R<LFI9A? 7B<N\YRVVQB3=)S"GG)*=K(O!O$/GVX&H#+W5B#W@!)S
M]$GEP44UE"5EZG>BWU_'TY8 4VLS(]30K%$M*@^JV,JB-S15_/290T&$,7HN
MWLK"A_@U.^:B'5N.>&53I@F9GEJO7:2BA(]<)<40KVBM4HWJLWU)D<]#^\YZ
MV;>9XIC4E&EC_DJG9&1@C]NWA>PQ6W/:V$:&M@OON7"D@M1[83@T52"@D6LK
MJ5Q@SDKP+BFKA*("1"DQXG69%EW+6-$V#V*GL$][]Y5*-6*Y94AAEQ[@C@>0
M";(91H"$E^H=YQ&%&;+&JLRZ_<B:JM@?_#]%&[U;@36UR>7R4%F;;3A/8DJ&
M$C8F$TA90TP.)VI=\K-6E-Y@/;(E"+E!:JV,6^)'4R&1J,HDT3XT.EJ%[J4V
M:&-KT&Y9T_:R-@5)OIT2)+W6A+6#V15$JT;JFEO##SP1)MI"(]*(_Q2]\X39
M]4#!HX".$F?A.5@]*?7(P;ZB%7P#$L$'V!:5385X8$F3O1M('2F5#D$"3CCA
MC/].;PSR,0LI)&JM?-;<* F-=0V8Q'DK>NO-CUADTM(93&XX>0_)G<Q7NLB]
M1-_72Y^H#J:=HD0#!4JQ&;JZTPY)WQ/Z4R55(@\U2A2FH$(K7%>VXAAM";Y"
M]6W#!S6D<L6>IB=1+QZ)2T D*258.03MO\.Z0QUA??AC7>^@T-CPG=KH+"-V
M^%1^;<H<_AA1/^< N_:!=874I?1)0H.;%:>A^.J>4GNWC;HGD8H4&13K(#2;
M$ESB]Z,@G<)9-A7>=O'M":\4T0<?D)XBO<ZAET.B?>",F=_=Y&HO=<)(9=97
M8"Z*A>!'/KJP ]IEX"I=/S+TUN;9<C*91Z,%\A!D)88J4B;KE+R$7_%UA+T#
MOH:%F%0G/!DE T?D6SY8D+VB]Y&FLR%RZ[0*YL#'HW_E"?HJ-OU[3;G:!+7+
MT3)0R]M;%>CT;KL=G%1&M0_)($;,DSKCNH$$\U"A K^^\_E"RT4W9W+'E9U.
MKP]?FV,Y[V&KXVW+43MOYJ-#TO9VZDZFI>,/1LEDD$6D^D^V%'I7U6$U<D<8
M-O36G#A_ @??-)/'B ;7WG:19#J48J<^]/75'>U0!US:;#P:WX)9DV_B=9(=
M.W?VFT+D?)7-47(=>1P_"EBU#08:O7! >0NQ)SP:8L81E+<2.==*J:S.X%?-
M&)EP&/&JF 0*_Y*)P/%=?7E_):ZY3&<4/V29N7/,H"VNDCM:3G'A3J5F7U4T
M[0Y +=L7@^L/5^\_(5W^D#WN,V!I!M\6>ZW3EO(Y5W)(44C[NR/>QVS*X-6]
MMFP+#+;;\7#H$]=1>G]X?SJY"!4Y@D\;X79ZST7-P%,?EC9IO"E1.L1(QA$[
M$%1O$ <RL&BK]^&$XF\M)BV"YE$3D"I>*5)JJ;OP;SO-+\>$J]MKL9QY!ZCI
MW 5I5H-56YDTM;FRW')/6GIR'BU'4>6T79KA-<85NI10'NDSQ1*QGM)Q5K88
M^LDG/!Q-9!9B-Y6I9VM@9K?U"D8#BPIQ,I\UPP:!.EE2X]Z/M)MA(W%;KBQ*
M7+ Q?7"ZTR"6/#-O[AL?P1'CTY7$U!^5>TV??(CKLC7G&7D2^U""ZAC%+)J/
MFY[^,Q44=\Y.G9E.NCJ<>.'ORJ*4U"ICM6SD-B@S5;.^JC,WI\:5N)BSUAK*
MD@A 16JK0"K^KKIU"[2D2G Y6_/:5[4V0ZI,JICG$DD+PT_:F>+3;>Z>T!U.
M#AN$5M7NBM6_L1D'W\5D-*U4)GE6HCH)1H0R-W4)&%<,) SD7,[MQWV'157&
MVI.<<"_7G5UB>=WH?)JHK\KJM,\U,.7ND.MODQXJ%]LZ;1NX@[O!7R2Q"<*/
M QE_"'CMDYP=98BGC%US?D.DKD?.48[."9JG"\YZ304[=; /5'+XCDEUW+'U
M)55.ER?(U!*=<X< 8Y1K4 RAY';%:/EF+WE+LD]$66^*=/)@=C"7E<K46CNJ
M?482=QOMI:9^AC_93CI-'&=<#?D'1?*2\ 41.3U!MP4([U,Z:B>EQQPX&9?*
M<;CVZ#$''&1X-%#"\N<)6<>5=-A6:[JE#E5N[O6.#R+H-)?MMNT-4"(BW5/.
M1FQQND<Y)G8F42DS5[F\R.5PQ,KD5*94O%CEVI+[/#0+ ]H-6Z-3JS0U,>EX
MY>Q"X//=$U4<*+NIEX?TK4O.LVO5[LEI4+F.F^-:]F1>1Z5AB!"VCHX^8?KK
M9M2UHN_O@QM?(USDZEAYUZI+4,Q#\;EGLX*>M ,0'48XT7J(74VH*'7=\Y-&
M?*,\$:R:#6GTHC,Z[QT][QU=](XNO1#;B/B7%_QRI1[H[.]G^ <K8U\]DRH%
MA6&.U,KO^S@N3VST<Y_=)/!,ZJ9(W&0"+,LU][%=R*O4Q@17<C)=7-39RR/W
M3YZFY?M:)V!]#J22*O<-K",^!.@3NNQ0AT+*ZYZ!=.-,,E/W!1UE[_C2E7=9
MOJ%&;26]\T=@><_U'I>%?GT_%"\"Y2EH=AMXCM?'OIY)(G#I.4#5O2^RMXUZ
MM 0]=.K/9VI[7WCGVB15B7?DW+8E%"1YZ\*[GIH#;=_?2!\=:;8^RJMB4H:L
M+_3_W1TD(>^D3GT?>R1^(">?N4(1V14#)G6"QC=XYYIJ'73"/0DX9*3&U-UQ
MS+5E'$[DV]ZN5?'4V'-![DO(UIR $!U$F-Q7LH4_S7>I8'-ZG3L1RJAJ33_>
M/8HTJN_1^0Y*4_%#6+"]33MB+O5 <S(B"E3VD<V%'3>(Z-X/5L@&UQZ:Z\UZ
MN6YL&+X# TTJ4'/L4^FM@X[:Z@JRZ5<2HVPX:<FY5G'U>EV)T56-*E6AQN30
M>^.XS8JCO8'^;+KIWL0#5W\GT:3AA[G FLX:'K_GND$'ASIQ#&V"J\>2\+W%
MK[;P;$/:S9;Y;UN5'37V()Z"HH(7-N40M:GY8P-JIW*W(%>DM#Y P $,H99V
M6_=*'CEF'W5;4:;8(KH?1:I;3,1]9'V='R$[K[08>.C403,A+WT:C0Y;FGFQ
M][A\$XMS)+8:WT3T&3->DB\_R#P);J./ELM:<!\;% 9J((%'ZDC7Y29(I)Z8
M0]?A(KK!U[E ^F?=M'(2= XHR*EIJ(^0?0CJL*H:]YXN!^J2]J1K?D_95FU.
MH17.&N7";*^L786VZ#143J+ST:R_G3&L;B\UR?%-N+!K8X=GF!?\1;#-+VTO
M>44JP!,I;G\?CB&NH30:$C662JL^97&W[+D6".T+7T> $4^X KZ4Q7I6WW!Y
MP@XNC]T-[-GA$HDWG^6<B,ELPA=C)V/J(_T2#GGF=)=S3K)HTUT=O\2.[M31
M_2(:12_%B_%H\;)O/Z:(-KF8H%K"Y_P"D/ON8Y\U+M#S=2CZ-P'R#8#H[M)7
MH]5_(ERY"_CU=/=O#)]D#NVUR)776 K4Y@,7,L*/PNSY.O[*%+!U_DKW0U1.
M$_!^;4P1?M &U?]GO/T_4$L#!!0    ( +*":%B]SR Q#04  -H+   9
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;'U6;6_;-A#^*X26=1O@RI;MO#1-
M#"3.A@58UB!I5PS#/M#2R2(JB1I)Q4E__9XC)<=.''\P39&\YU[XW/'.5MI\
MLP61$X]56=OSJ'"N.1T.;5I0)6VL&ZJQDVM328=/LQS:QI#,O%!5#L>CT=&P
MDJJ.9F=^[=;,SG3K2E73K1&VK2IIGBZIU*OS*(GZA3NU+!PO#&=GC5S2/;DO
MS:W!UW"-DJF*:JMT+0SEY]%%<GHYY?/^P%^*5G9C+MB3A=;?^.,Z.X]&;!"5
ME#I&D/A[H#F5)0/!C/\ZS&BMD@4WYSWZ;]YW^+*0EN:Z_*HR5YQ')Y'(*)=M
MZ>[TZG?J_#EDO%27UH]B%<XF.)RVUNFJ$X8%E:K#OWSLXK A<#)Z0V#<"8R]
MW4&1M_)*.CD[,WHE#)\&&D^\JUX:QJF:+^7>&>PJR+G9'P27[-G0 8M7AFDG
M=QGDQF_()6-QHVM76/%KG5&V#3"$$6M+QKTEE^.]B%>4QF*2#,1X-)[LP9NL
M/9MXO,E>S\0_%POK#"[_WUU.!HCI;@A.B%/;R)3.(S#>DGF@:/;NA^1H]'&/
M@=.U@=-]Z'M"OU=NMU6=MY\+$G-=-;)^$LH*A\^2K"42R%^!5#;2J7J)17_<
M+^:Y2LD.Q-T[634?KT0N4U4JI[ OZPQDJULLN=:PX//F0*P*E1;8AZHZ+=N,
MD*4UK60I .O(@*[2IYYN^,_&6^9E%(Y C<JA24AC9+TD9+QCVV4P4DC'\.0A
M8O'II0O24*\^PT3<??HB)#QVP?I2R45G\);ZGVP/4,@'-IP+V!K66V\1&A\]
MA!'FZ9K$$TEXIH5L&J,?%8H"E4\B&?D-*+C1UO6X:Z-8$ &I-"SM(L$8/E8(
MHG+%.FY!+=0YD4(E/3J"#^$6>[-$V[!XCF+6JT5]0K@R95$P?+7L#.=EKGK=
M?:'>D3?_3^U()).!B.[H@>J6_4_ULE9L7!3BE").L+QV71A8/3WB+<#_BN"*
M9/J4*.KV5/S-<?&%0""-J5I 3Y_*/(QY2%Y>'G18=RHN$!FGOG=4R87A0OI>
MY^];OOUPE0=B&H\P'L9'W7A=(QB$<$,HH&U<M1C%)R*)$_PFXK-V3,D=NCWL
M"<:C^-B/'W::&$B&Z/%3 A?A^79THCF#80)R5612!7VW1F=MZH25N(EH\'SF
M9G[S]N:ETIS0G)"\W*5DM(X\4SJZQQL&"P=B"=H8Z.)5F2&7%)<Z?N:>)1 >
MMT7[.?BG2Y5)=N7>X:_J_>B<]ZEZWS9-Z;>@8"%+B1P4H4]0=6@&PKM<>B"P
MJN/]"N'9Y,86(;HR-2]QKPIU)X \T^1E^'=QX1/\,<_$2([B,?]]B*>OQ#<H
M,<!K:@S7EH;I!JT!IU_=9,^!F,2'GF<G^R [A,V59,+$8U+M9MVVEN08]#R
MY^#SR\)V*K[ZCH+Y]H"MY>XB)7[V-> 7P5$X!(%?27%9T"T\!#SAR$3\"-8G
M&#G-<8TH[.X)')+EDT7=77"CUC5IZCL_$BV.D&CK'@G@J;2%R/F"PQO2[GA<
MI.?4JWK058L+OXN%J<]"?_^'B/LQ3X[$&*Y@@J^P=8+)B"U&YYG#<3@R[F*\
M9=CK,".Z4_#.(J+75=,Z_TQTM6.". 20-Z]GUT,_W.BWD.]+WU5R48 -H?5:
MKZX;UXO0KST?#UWOC31+5?-CE$-T%!\?1H'T_8?3C>_>%MJA%_33 LTW&3Z
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MAZR,Q?N E].L5,<ZMX%"Z0_RH,2J3 %L)">&CG2N.:/H_ YIBTL=,G[!@45
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MQM$(*JV5GW$_ZIP[ ]G^N26Q.Q:=ZQ?;2+9#Q;95=;][]V%V^$; SW0["9E
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MXK)BU6,+ L;K( +@:*CH+T#6'+1L%?=-#**[SJJM67W/<]1C^;8#U,[P>I#
MA.=[4VW#X*.7-VA[_-O);Q1K:/;'C&4WL?2FK9:2LRL..)0/8\XQAZ85#N0F
M6E0%3W)-FD1T<A)'([@;EZ7F 493TQBCTV.:\Z*(%Q)&+!="Y RG!/FC_MS
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M[4<0F #[2XMJWKSP =V'O/,_ 5!+ P04    " "R@FA8$&JX:* #  "$"
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R55MN.VS80_96!&@0;0-#-
M>X]M8+UID#XLNDC0!D71!TH:2T0H4B$IR_[[#BE+:W>]V^1%$LF9,V<NG-&\
M5_J;J1$M;!LAS2*HK6UOX]@4-3;,1*I%22=KI1MF::FKV+0:6>F5&A%G27(9
M-XS+8#GW>X]Z.5>=%5SBHP;3-0W3NQ4*U2^"-!@W/O.JMFXC7LY;5N$7M'^T
MCYI6\812\@:EX4J"QO4BN$MO5^=.W@O\R;$W!]_@/,F5^N86OY6+('&$4&!A
M'0*CUP;O40@'1#2^[S&#R:13//P>T3]ZW\F7G!F\5^(K+VV]"*X#*''-.F$_
MJ_X3[OVY<'B%$L8_H1]D+V8!%)VQJMDK$X.&R^'-MOLX'"A<)R\H9'N%S/,>
M#'F6'YAER[E6/6@G36CNP[OJM8D<ERXI7ZRF4TYZ=OG8Z:(FKZ!03<,MA=N:
M>6P)V9W'Q1YE-:!D+Z"D&3PH:6L#O\H2RV. F"A-O+*1URI[%?$#%A',TA"R
M))N]@C>;_)QYO-G_^?E[+GC%7$6$\)&;@@GX"YF&!V8[S>T._K[+C=54+?^<
MBL-@Y?RT%7>#;DW+"EP$=$4,Z@T&R[>_I)?)^U=\.)]\.'\-_8=S]?,H\!6!
MWJB!2ZN 51IQ.. 2;(T@W0T0I-)ITE1KR#M#N,90N=H:-BA+I0U0DP#->BI0
MPN),&&"R!$4(&BJE2@,DX,+""S01G*3"-!X2(#KM*/8<>L0BDLQZ591$HD"6
M"PQ!8,6$V$'.9<EE%0XZ+19\O0/":?:*9^D[\K0078FPYELL'4^Z;;SI&OC>
M,6FYY>C)Y#CQ*4,XR_ZC&$YJA+!AQ)2(0*N))#W5AKMN-G _F[WSC(62%<6'
MB$A0$F%'Y?A";' [F#J,S^AXP61!S<W;<TFA#@S4NIFPNPCNC$L:72IL<K(U
M7JS0)_=>-2V3.R!SP%IBN>4NRA2W-Q?9971#+@GA6BA!M"=39HPJ.*F40SD\
MS].*J^-4]01Y%,NITG!K*92;(0XF=$;[FA?U$54TUG,<_3]FG:9743*Q?F[*
MD3PT-T2<NKS?\G:ICJB1G8H8/;.AD.@K/8[@DXDW:7(578\<0EK?W$27$R>G
M3C23Z.I)A!I&BWY(B9UW^X52[XB99WJ<A>A4AXD/)D.#NO+SS[A[+.TP)*;=
M:<3>#9/E27R8SP],5YQ*5^":5(GY10!ZF'G#PJK6SYE<69I:_K.FWP343H#.
MUTK9<>$,3#\>RW\!4$L#!!0    ( +*":%CE@.Q(+ H  *8;   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;*U9:V_CN!7]*X0W.W4 1[$D6Y8S28 \
MMM, G9D@F=U%4?0#+=$VN[+H$>DXV5_?<TE*EA,[R;3]HA<O+\\]O"])IVM5
M_:'G0ACVN"A*?=:9&[,\.3[6V5PLN [44I08F:IJP0UNJ]FQ7E:"YW;2HCB.
M^OWD>,%EV3D_M<]NJ_-3M3*%+,5MQ?1JL>#5TZ4HU/JL$W;J!W=R-C?TX/C\
M=,EGXEZ87Y>W%>Z.&RVY7(A22U6R2DS/.A?AR>6 Y*W ;U*L=>N:D243I?Z@
MFYO\K-,G0*(0F2$-'*<'<26*@A0!QG>OL],L21/;U[7VOUK;8<N$:W&EBM]E
M;N9GG;3#<C'EJ\+<J?7?A+=G2/HR56A[9&LG&XT[+%MIHQ9^,A L9.G._-'S
MT)J0]O=,B/R$R.)V"UF4U]SP\]-*K5E%TM!&%]94.QO@9$F;<F\JC$K,,^?W
M8@:*#;LIW0:#J=-C \4T?)QY)9=.2;1'21BQSZHT<\U^*7.1;RLX!J(&5E3#
MNHQ>U7@MLH#%88]%_2A^15_<F!E;??$;9MZ)I:J,+&?LGQ<3;2HXQ;]VV>NT
M#79KHT YT4N>B;,.(D&+ZD%TSC_\%";]CZ]@'318!Z]I?^^6O*ID-\1:L]QH
MQBK,S 6;JE5EYNS[BE=&5$Q-+?,]MA8(/5[(62ER!AG<$8-\4@B&S%!Q2Z9V
MBC4SBB*50@[GC-;*YKR<"8TU[7190GW)B]9D7N9>*]TM*Y4)K0/V;4Y+/T@M
MVL/8LU5F5I6HU]$6?J-V(^G4/E!B\#K9BG1-GBR0JZ_7GV%UA6#Z@\1SD4G*
M--I.Y%IC@L4C*DM6F0D[(C7+("6U(>O6$J3-L;_@*5M5%9X53U!9(J%98),5
MM%A[?A>LA* ?(PCUF-/"@08!SQ1M2"5$F^F:WX!])>AJL1!5)F'N;:7R%9'@
M);!A<YG-P4=6K'+0_N7B[NKB"X-SC@8?B0@G3I8HX*M@3*.L&74ZU@(L:U40
M&VP)OR"O(-P(FP=1L#G\ K@;*Z3S)"W 3_[<DUA7PZ0OR@@&K^I<(Q5K(VDC
M.VX75"6V_%)Y;9P<;6JO=Z][V+.@/E]]?IL-TG*!1%7Q1W9DI]0V]]C]@A?%
M4CT?L%1]M53=-K*6/BQZC[B2<*UZP=HUR'$\69=2Z5I*3:>BPICW;NSCDI=/
M3#SP8L6-Q]=V.&>XWND+MACES-;&!U&NG'O60'C^;Q0/C,\JA;U!P9W)LN$#
M5L$9RZ-/%Q>W;"I++$8.L!!<8T<"5B>*6G-#H'CT<>9*$TBA#0(CDQ72BF&Y
M@E"I3#W#!>91C:IFPD8#:B<V\"W$?$-N>P!(: $BVL8_F,RL@R+9^11!8YG2
M?@O)W(QK&&_$0D.LX+08$E8K0TVYK!CMAJ4>FTD[V>QK;C,6M1*4!TI08U3U
MA)0DED>K)7G,@TTA;>N,,F#K_[$KEHIM==M:?H"1WFOPK7FV)KR+C6U?;AP
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M^R0PI ^ARM0WM$#S:^[\/U!+ P04    " "R@FA8)#RWQ!L"  #&!   &0
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M>:#*>5D:1B[=C)I)0Q//+5/ZQ*"R#O1^+J79&):@^FAU?@-02P,$%     @
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MH8VKN&5A/A0@;8(Y7PFA]X$MT'YZDC]02P,$%     @ LH)H6&0ZHFM# @
MB@8  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULG95;;YLP%(#_BL6D
M/;7AELN6 5+2;EH>.D5IMST[< "KQF:V">V_KVT(RZ:$2GD!VYSS^3M&'**6
MBV=9 BCT4E$F8Z=4JEZZKDQ+J+"<\!J8?I)S46&EIZ)P92T 9S:IHF[@>7.W
MPH0Y2637MB*)>*,H8; 52#95A<7K&BAO8\=WC@L[4I3*++A)5.,"'D']K+="
MS]R!DI$*F"2<(0%Y[*S\Y7IAXFW +P*M/!DC4\F>\V<SV62QXQDAH) J0\#Z
M=H [H-2 M,:?GND,6YK$T_&1_LW6KFO98PEWG/XFF2ICYY.#,LAQ0]6.M]^A
MKV=F>"FGTEY1V\6&GQV4-E+QJD_6!A5AW1V_].=PDJ YYQ."/B&PWMU&UO(>
M*YQ$@K=(F&A-,P-;JLW6<H29E_*HA'Y*=)Y*-OIX,Q#H2>",L *MA,"L 'WL
M2D:NTCN8.#?M:>N.%ER@A>B!,U5*])5ED/V;[VJS02\XZJV#4> ]I!,4^C<H
M\()PA!<.Y8:6%U[@G2OS!NU?T89EY$"R!M-S57?0Z7FH^6Z6LL8IQ([^,"2(
M SC)QP_^W/LRHCP=E*=C]&374$"^MY_=^J?::)7Q6OU_R)WN.##'5,*(V&P0
MFXUR?G!V>X7<./0]N?D@-[_JU)Y Z*\(7W ;9[[GMAC<%E<?W+C?./>BGWO2
M'RH0A>V"$J6\8:IK%</JT&A777_Y&]YUZ0<L"L(DHI#K5&^RT*]3=)VOFRA>
MVVZSYTKW+CLL]<\"A G0SW/.U7%B-AA^/\D;4$L#!!0    ( +*":%CC8==^
MFST  .'8   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;.U]V6X<1[;@
MKR1X;[=)H$A1E&S+EFV DNR^ KP(DGT;@\$\9%5&L=+*RJS.113]]7/V.)%+
MD7+?1C_,/-AB567&<N+$V9=O;IOV?;<+H<\^[JNZ^_9DU_>'KQ\]ZC:[L,^[
MB^80:OAEV[3[O(>/[<VC[M"&O*"7]M6CJ\O++Q[M\[(^^>X;^NY-^]TWS=!7
M91W>M%DW[/=Y>_<B5,WMMR>/3_2+M^7-KL<O'GWWS2&_">]"_]OA30N?'MDH
M1;D/=5<V==:&[;<GUX^_?G'U.;Y 3_QW&6X[]W>&6UDWS7O\\+KX]N025Q2J
ML.EQB!S^^1!>AJK"D6 =_Y!!3VQ.?-'_K:/_0)N'S:SS+KQLJK^71;_[]N39
M25:$;3Y4_=OF]K^";(@6N&FJCOZ?W?*SGS\]R39#US=[>1E6L"]K_C?_*(!P
M+SR[7'CA2EZXHG7S1+3*5WF??_=-V]QF+3X-H^$?M%5Z&Q97UG@J[_H6?BWA
MO?Z[=WP:6;/-NO*F+K?E)J][ -:F&>J^K&^R0U.5FS)TV>D;^>OLFT<]3(T#
M/-K(-"]XFJN%:1Y?93\U=;_KLN_K(A3I (]@S;;P*UWXBZNC([X*FXOLR>-5
M=G5Y]>3(>$\,$$]HO"<+XUW''>L^L_]]O>[Z%A#G_\SMF,=[.C\>WJ:ONT.^
M"=^>P'7I0OLAG'SWU_]X_,7E\R.K?6JK?7IL].]>Y%W9X:'1V'6?,XK71;9I
MZ@[67] W<\L^/O O0YMMRSJO-V5>91T,'. .]EV6MP$G.\"_15;6. _2A+*_
M XSM=]EO%^\NLIM0AS:OJCM$H'#HX5&/26T)PQXJQ*63OUU?OSDYN\A^W05Z
M9G_(ZSM\*FX WIY="HQ2#47(>GEUP"\!%M_O0PLKZ D.)7QWNVMP+<UM#4-U
MP[HKBS)OX60OLNNJ2A"^K/O0GLLRXJ@X$F! W>5$1+ILEW\(V3J$.@M5"?>1
M5LG@B&"_R-Z&395W'8W.+\+Z-J'M@4XB')HV.P3X!^"SYYGBP/L<]]8HA/%/
MW.EF:%O<G+SG#_[B"$9];ACU^=&#_ZT+N,;0]270NM#-H<[Q$? D&4,8&V&T
MV>-KPS^&$E8/&ZV!\..7N,=]_C[$Z5?9[T-Q(Z@'AP# '/8'!F6_R^&,MUL@
M[##8H6D)S_;QQ(JRVU1--^ D &^"WKU81;-X1*R;'C'EU1#T",IZ%^@,AEK.
M$K"_K#\TU0?& M@#OMGOFFZRES"[F17RI0%6 FL%1M+!0H<*=P#;@YO8-OOQ
M:!<9WM%]T_4) MOO,%(%_^*:V_ AU+#\-FP:>)*A1RB--Z?K0M<1].&D\!M\
M[ /<WW59X;6&;V^:IK@MJVJ%C*Z$$4)6E;S7/J]ORG7%X\B^&ABES:JFOCGG
MQ_@W6#']$)>H-QA(17,+1P%? :IGX>,!SA3>VP"1*7L8"=>X0A##,IOV#M<!
M* 9'9_0.SKWMRS_HBU6V'CK R@[!N%_C[608P^DC!<*](B*416CEA6X'!.T<
M^3J2SCT(.YW\ FML]@#&_",N(6[/QMH0(?DI(C'_,A#]@T'#A[P:>+L GP=A
M-GY>$VE/7LE@K[L29($6SKH"@A3J L8YM,WO+-S@%H4\( R!Q %,W9HGMP>
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MYYN &_>JX38@Z:MLR(OLR(WZRF[45\=%\:;&F82DOBV[]W.7YIXQ["8Z7,F
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MWMYL<"_NPNQ#0:*F$!$38NQ\B7H/Z]])7FI@PR4:?_"..16;]8G"K)$JE47
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M5?">FMRK%E%D](.YX8IVN$GVR5KS%+J";2M3J4FTT_/9@'@A\3QX+49/[4/
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MO'1[3\X??RZ/O%/P/SG_4K[Z$5WB._0-)@/_B"I&F[(DIB<8^$M>=(PN^.U
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MX^-G'_?5U]TAWX1O3PYBGCE)2#2+*XVV(Q*"*Q64O/6<$BWP9D72%F--*,9
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MFA GUO]]8X[]P"4"R ?ECWO5\Q;'IB1PVK"=@(KDR(0M6' AC9<R*X39(9?
MNV3(\I12J?8R;?DY#1EAI:L;5E+S*24SZBVEJUV?VRP_-%4(#XC<,@AI#X+[
M_ZR?YF2ZM!]^BUI*+0H;4 T:(/V09*64RI+=3IC\2/L'X.&YDW)P<M652%9\
MH5OPIW=[ZW6SW3?#;7M5OIBW'QR?*(FLB"YNR7483D8!F/82;P=.U_[BW&A'
MU[!_+>B[!PT;C)@0*7(8<(+N2VKY+U!+ P04    " "R@FA8)^U"FY8$  !L
M#0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S=5UMOVS84_BN$&F0)
MD,B2?&UB&[#=%NW0 (:3;AB&/=#2L464(E62LNM_OT/2EIW,=I<^[&$O$B_G
M_GV'HOIKJ;[J',"0[P47>A#DQI1WC89.<RBH#F4) G<64A74X%0M&[I40#.G
M5/!&$D6=1D&9"(9]MS95P[ZL#&<"IHKHJBBHVHR!R_4@B(/=PHPM<V,7&L-^
M29?P".9+.54X:]16,E: T$P*HF Q"$;QW;ACY9W ;PS6^F!,;"9S*;_:R:=L
M$$0V(."0&FN!XFL%$^#<&L(POFUM!K5+JW@XWEG_X'+'7.94PT3RWUEF\D'0
M"T@&"UIQ,Y/KC[#-IVWMI9)K]R1K+]OI!B2MM)'%5ADC*)CP;_I]6X<#A5YT
M0B'9*B0N;N_(1?F.&CKL*[DFRDJC-3MPJ3IM#(X)"\JC4;C+4,\,/TNQO.58
MF(Q0K9$$K"@I4UAV0ZC(L.[:J"HUE6)B2=*<JB5H<O5$YQST=;]A, 9KJ9%N
M_8V]O^2$OS@A#U*87)/W(H/LN8$&!E]GD.PR&"=G+;Z#-"3-^(8D4=(\8Z]9
M5Z3I[#5/V)L]R]C68 :<&BS0R#*(&88%^',T1RFDU%_'2N =M(X[L&UVITN:
MPB# /M*@5A ,+]_$G>C^3/BM.OS6.>O#1VS;K.) Y()\VF.),P?U9P?UR$*M
MR4?@F<OPB\;%^<:O'\OHK,_C&3WE0(RE"9G;UB=N1Z!78S>DH?R0:YY9-@9/
MPY3CF^"AX\0W0!4!2QB"<$,Q!U5#?D?^L+N.3F1<,9XA;OJ&S+=#ZT7)%13.
MN<V6 [9Q+C'W9UL7I!>';?*A4H(A^N!DX5O%2A=A''=Q]U$NS)KB9A0VR40*
MSQ4\7VZ9N$5C2\Q2DSCJABWR]#))!(&_Z#?KMAEUPBXY@WV[QK[]K[$_3>.)
MU$8? _FL\=,@+R1'?*T7#_<1H%^<(C8 F[Y,F8MHS4SNI"<2BR4VEV]Z2=R]
MUT3#<@N;)FL\N>V[$A3]I4XQE:J4"H>[LPJ9D.9NDL$*:>>ANPIFE[0H[]\%
MU_41]FIJ86P%*(R8DZF2&69CL7.A)O?D8?*P7VZ''?*(!6(I.NK53#A6!23\
M-DD2M\((O>PRBF,DQ39NTD2+IXU<D.0MTO'GP;BQ<2PJX9A\\_K:O"]*+C>
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MM3,8.D*DR'[@$G3?5HO_ %!+ P04    " "R@FA8_%5'EU4&   L$@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6RU6&UOVS80_BL'-^@2P)$M.9*=
M-#'@O+0KT Q!DJX8AGV@)=HF*HDJ2=E)?_WN2$NQ8T5-B^V#+8HBG[M[[HW2
MZ4JJKWK!N8&'+,WU66=A3''2Z^EXP3.F/5GP')_,I,J8P5LU[^E"<9;835G:
M"_K]J)<QD7?&IW;N1HU/96E2D?,;!;K,,J8>SWDJ5V<=OU--W(KYPM!$;WQ:
ML#F_X^9S<:/PKE>C)"+CN18R!\5G9YV)?W(^I/5VP9^"K_3&&,B2J91?Z>9C
M<M;IDT(\Y;$A!(:7);_@:4I J,:W-6:G%DD;-\<5^GMK.]HR99I?R/2+2,SB
MK#/J0,)GK$S-K5S]SM?VA(07RU3;?UBYM=%1!^)2&YFM-Z,&F<C=E3VL>=C8
M,.J_L"%8;PBLWDZ0U?*2&38^57(%BE8C&@VLJ78W*B=R<LJ=4?A4X#XS_I@;
MEL_%-.7 M.9& \L3F$N9K$2:POX]PT?ZX+1G4!AMZ<5KX',''+P [ =P+7.S
MT'"5)SS9!NBAEK6J0:7J>="*>,EC#P9^%X)^,&C!&]2F#RS>X 6\#Y619/$&
M#Q/'PZ70<2IUJ3C\/9EJHS" _FGBP4DY:I9"276B"Q;SLPYFC>9JR3OCMV_\
MJ/^NQ8:CVH:C-O3Q'29I4J+2<@;O12X,/_R$4=Y@3Y/FK=C-FM\O.%S(K&#Y
MXV\:Q$[TQ!+S51O2IU R*6.*J/A;*10JM10,IJ5&.9I69E.1,\I-#5(Y +=6
M"SOK64DRYSF"(*!YDOWVS2CPA^\:-.@"?XC3,A'YO [C;J56#3.3*98C7',"
M&%8\FW)5A];.3 !?;'*C!9,E5UBKX+/FLS*%3V+&407XBS.EX8.2:-<%4^J1
MI$\R6>8&)G%<9F7*[/9,*B.^6Z/A#S3W^>+_ .*FHGW?/]@/#L ?>!'LP2@,
MO2.\!J.1-\)K&$5V_G@4>#[-AP-O@-=A0,\O;.5!"A1/G8L6HM#0]_H(@/OL
MGW5"\*YAYEQ(BA<1<[<G]$+[JYX_O[^7AJ4-T82ZAZ3[Z-A>!T'@'6_H[G?[
M?N0%UJJAM<YICY;#9:F(%'+V(WH'.%6A76=W-Z,*M$P3V//[)";#P"&.,6(:
M@BRG6-50,&6JF-+,Y:% Q;%:+'D*"\Y2LWB*>2/AG"V9$@Q])U4BL*+=<8YC
MPP%UZ5QB\FHC#%:=#@:I O0V19CKOE:=?$L8C9N%>4#>_R4:%(]1.5S'8"_"
MJ*BH>,X#L"2QJ>K"!#>@@02$Z690+":NR[P$L\:N*]AC1K.X[E8D<SYE\5=K
M)^UB*Z82,HJ!WS^TZA(0%5Z8/MHE&%@91]HP6B;)DN4QRKS%VL14O+!U_)(C
M%;*P0B:E64@ES*.5P*KUR=.2+K;2O)RA $>31F!^6!9=BX4%+$9'6"S4ZFJ*
MQC.XOT;".3-VFH"OIC)E'E!EK&C8(6K%-LJ@62A9SDG?W:*'#YE;CO6Q2+E#
MLU7(@Y:&$=8-(_S9AI$V-XSM2G/U@,= S9NZ2+O +13N4,AL&0M+U4I@S)H?
M=!7BXRDH];I\ZQ-;>-T!HZ&.V]*-?SXT*A&%6$3"8TSU<.2%+=Q&-;=1.[?N
M8&NI+2F%7TUA*^X/&S%0R<#R@,56E@IF3C9KLIGBE=;L4KS#ZL0V2Z2/ZBIR
MY=,XK$<11 .D#D=#B/K4 /K!"$+?&U(F8(+,#/HBP$?!NKQC)N%+ J79EFI5
M.6]QP+!VP/"U#J@.=TULMX,0L89.O3"E5Y;UZXKXCNS:TK9 XC@%J;NMNB]S
MW1=%UX?G*572 DVU:)K/J62<D->PLV+XIUN]&JXOKC<FL';?52UT?W"PYO"<
MI53$ &O$\WBG)E[U4VR(_L@VQ@C]@7?!$?JJ/O *#!NA; &K=E37?=QPL/YO
M$18T"GL^TR9PWRXYV+EO$3K8$M$V(CK=<4C7W>6IOC0Y8.T=="L='CG,[4&L
M]NZ2I26W";%W1"%>=41FYQK:J>6(F@AYQK43MG&*VR $WS'TKT.[+O^RK5M!
M]7HCG?_^'RM?A>W9H'_9KCHW7F]3]%IRNS]MTBN@*\S :RITO8TW>(S-N?U.
M06< --^]S->S]:>0B?L"\+3<?4>Y9FHN\)4JY3/<VO>&V)^5^S;A;HPL[/>
MJ31XQK=#/#KB$8T6A'3LQ-/H^H8$U!^(QO\"4$L#!!0    ( +*":%@^!/&N
MN 0  $$-   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;*576V_;-A3^
M*X1[V0JTLBS'CN/:!G)IL0+)$"1I]C#L@9*.+:X4Z9)47._7[QSJ8B6QE6)[
M,2GR\#O?(<_-LXTVWVP&X-B/7"H[[V7.K:?]ODTRR+D-]!H4[BRUR;G#3[/J
MV[4!GOI#N>Q'83CNYURHWF+FUZ[-8J8+)X6":\-LD>?<;,] ZLV\-^C5"S=B
ME3E:Z"]F:[Z"6W!?U]<&O_H-2BIR4%9HQ0PLY[W3P?1L3/)>X%[ QK;FC"R)
MM?Y&'U_2>2\D0B A<83 <7B <Y"2@)#&]PJSUZBD@^UYC?[9VXZVQ-S"N99_
MB-1E\]ZDQU)8\D*Z&[WY#2I[1H27:&G]+]M4LF&/)85U.J\.(X-<J'+D/ZI[
M^)D#474@\KQ+19[E!7=\,3-ZPPQ)(QI-O*G^-)(3BA[EUAG<%7C.+3YS8=@#
MEP6P'+@M#."-.\M^O>.Q!/MNUG>HA63[285X5B)&!Q '$;O2RF66?5(II(\!
M^DBOX1C5',^B3L0+2 (V'+QG41@-._"&C<U#CS?LLOG>VWPA;"(UF6W9GZ>Q
M=0;=Y*]]1I>01_LA*72F=LT3F/<P-BR8!^@MWKX:C,./'82/&L)'7>AMPE>M
M1WK/;B IC!%JQ;A*V>]:F7IAGPF=2O:;<)<!<^0)+*;X97Z'_$.H,B'XR(HQ
MVIE#T7.=K[G:_F(9MQ90C&A)P6,AA1-XQR[CCG$#&,^K0G(CM[7;I5XVX<B>
MYHXM=YY).T*E(N$.O!X)#T"1XC*A_$)+.!-@N$FR+=-+OT?+)5$'2:;$]P*)
M;( 5#EG]@\J<QCAV8#"\VDA3AHX'>0RF<;YG*Q&[TXY+=ND)#:HQJL;A"[NG
M_I*F%"^ %\'--\S"/$ET05?\FAV%P6@WO'TUB0;1QT>S810&D];X7.8.4RB:
MM]96(&:]>F@<'(?!\8&O"S#B@5,2Q<? 2"G*3/$2Y 3)[YN75_,S1H[", A;
M1@Z.3X*H)7&Y<[ INJ!RZ/](C24::T>*WN ?'W&"\2$-?F?BM>S;IYV:[_]#
MZ<@&HR8;C#JSP6U9/\F],?ZU2M#VTD1<:9E__LC\UB752<2'V2ZW[$L9G4P.
MIXREEI@M*"^5R4-@)L"0?TJ6HC.&E5"J3F& 48[3F$NN$JAEDD-OVDXM><NH
M5CI("Y\?"68+W%A2@4+/0KL*9R*!D\'T\$V>5>10SU,4>OG123!DYQG'HQ@G
M;2I1<,*PRW&RKK'1,)B\Z\(;D-=/@J-#>./'>,-A$';B1947[H4+,:@>TPO&
MG6C#RN<[?'K<^/3X/U0X]D6MBZJ*W#=9_*[)XOL\MEL/.6=3(YL\O#S0!&&)
M>U+67O3$+5YJ(HNTK%.[.+!BI<02*QB>+)2.*5C*T/ F=KC;98/<NB1N*3:>
M/\B>6V)?V^K\C;(;__PW>LLEXE)7F[+7])2YD)).4U]$50BH)-N,+:GXUXO,
M4!T^"49OV+71<4T/":WYUK\;YNLW[ ,['M&(,G]C#XY0%(!M,4_Y PV3?3[4
M;[6U.9B5;][I#9!#V>$VJ\W_@].R+=Z)EW\NKKC!-&.Q<5CB4:QJF-A,V;"7
M'TZO?9,<:X<MMY]F^!\'# G@_E)K5W^0@N9?T^)?4$L#!!0    ( +*":%CZ
M+LVODP,  &@(   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;)56;6_;
M-A#^*P>U*!(@L&PY:3/'-F [2UM@18.XZS ,^T!+)XDH16HD%2?[];VC;,4N
M5&,#!(EO]_8\=SQ-M\9^<R6BAZ=*:3>+2N_K21R[M,1*N(&I4=-.;FPE/$UM
M$;O:HLB"4*7B9#A\&U="ZF@^#6OW=CXUC5=2X[T%UU25L,]+5&8[BT;1?N%!
M%J7GA7@^K46!:_2_U_>69G&G)9,5:B>-!HOY+%J,)LLK/A\.?)6X=0=CX$@V
MQGSCR<=L%@W9(528>M8@Z/.(*U2*%9$;_^QT1IU)%CP<[[7?A=@IEHUPN#+J
M#YGY<A9=1Y!A+AKE'\SV ^[B"0ZF1KGPANWN[#""M''>5#MA\J"2NOV*IQT.
M_T4@V0DDP>_64/#R5G@QGUJS!<NG21L/0JA!FIR3FDE9>TN[DN3\_!:M?!2,
M#'S4SMN& /<.A,Z@Q*R0NFB!DUZB@[,O8J/0G4]C3[990YSN["Q;.\E/[(P2
M^&2T+QW\JC/,CA7$Y'3G>;+W?)F<U'B+Z0#&HPM(ALGXA+YQA\0XZ!O_?R0^
M[)!8O"!Q*UVJC&LLPE^+#1TGE/[N@Z4U>MEOE$MNXFJ1XBRBFG)H'S&:OWDU
M>CN\.1'291?2Y2GM\S65<-8H!)/#3\*3&M9>>.09'[N36NA4"@7WQDDNG NX
M$]+"5Z$:[ OPI O] 7XI$3QG$FSX5H"PP]YXVLC9VB-;8W]X966J6NCG-Z^N
MD]&[&T=%UX62=^[*@Z R=++0%%4&PH4\)L9HM*7BYR\I)1NI$L[)7*8BW _T
MM,:T,TIF07HI%*E'6'-]N<D!$NS;PCFZ-5^ I:S %*L-VI"7JV/]G*;\2@A_
MCQ2QAP<R NNMJ!U\)ML65HVU3$30[. UA)B3&QI=#Z[@1$I<=2EQ=3(E^M/@
M M[3_0UGOQG77]RGE3*?N5%$)5=)RVQ[R\M_L6555*9I,ZP@2PZ,!2H?1[L6
M]T00X+DU%42+-&VJ1@4*3  FI12P6'(S(,^EICG"&6LXOP"-/J(U;R#JH,4G
M:EL.HUY:CS+^<XTV,$1YT]@0 )U_1F$=(-]5QZP&&OE28"HG/Y+\)XFU-UR/
MU#'YELEW@?PB@!^B@1\C"-3_0N^SX6!TWI<!\<'M7Z$M0H]S!!D!WC:";K5K
MHXNV>[P<;WOP)V$+9D=A3J+#P3OBW;9]K9UX4X=>LC&>.E,8EO0K@)8/T'YN
MC-]/V$#W<S'_#E!+ P04    " "R@FA8VIF1N&H#  #P!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,"YX;6R-56V/VS8,_BN$^[(+<!>_)$Y\:1+@7E:L
M0-L=[JXKAF$?%)M)C,J2)\F7WGY]23EQ4\P-]D42)?+A0XJ4YCMMOM@MHH.O
ME51V$6R=JV=A:/,M5L(.=8V*3M;:5,*1:#:AK0V*PAM5,DRB:!)6HE3!<N[W
M[LQRKALG2X5W!FQ35<(\7Z/4NT40!X>-^W*S=;P1+N>UV. #ND_UG2$I[%"*
MLD)E2ZW X'H17,6SZY3UO<(?)>[LT1HXDI767UAX5RR"B FAQ-PQ@J#I"6]0
M2@8B&O_L,8/.)1L>KP_H;WWL%,M*6+S1\G-9N.TBR (H<"T:Z>[U[C?<Q^,)
MYEI:/\*NU4U).6^LT]7>F!A4I6IG\76?AR.#+/J)0;(W2#SOUI%G>2N<6,Z-
MWH%A;4+CA0_56Q.Y4O&E/#A#IR79N>4MKAR</8J51#N8AXX@^2#,]^;7K7GR
M$_,X@0]:N:V%7U6!Q8\ (7'I""4'0M?)2<1;S(<PBL\AB9+1";Q1%^#(XXU.
M!7A;VEQJVQB$OZY6UADJAK_[HFVQQOU8W" S6XL<%P%U@$7SA,'R]8MX$KTY
MP73<,1V?0E\^4,,5C430:V#6??Q.(O3S>]PB.+Y?6'$+@C]1#ASMY[JJM2+)
MLE/>N:$=H9Y_L53:*S<C(CE6*S3=E?"0P .J4E-O8TXY+2"GH70@-@:Q8O +
M>$13@=1"0=$@&Z7P$N++;)C0/)HDP^Q_@-SCDY9/Y/U'H"2^))B4P"(8#;-I
M^NJ ]4D=T#YJA_9@DL$XC4BY'7^G0 W$WCB"1^V$]-$2L6R2#<=,]'P<$S+<
M-,8PE5H;_XA0EJ16FPO'T;'-.2AZ.6G; Y36-D+EG%A+.3UCD.D SB[3Z7 T
M(':B8J!_B5^O/F5GP&,T(/[J(O^O]SW/\7@R3/V<T7RB^-*N^-+3Q=<^RNSB
M;>.X47SCW(GGZE >[SEP?ZWO%-/ 0J&U?55ZTE5_E>Z=^O#J(Z??LUT>.05!
MNL+"6DLJ:3N#/U$8N/(6=-U\@^.8;]*7R^L761(G;UB8' O38^%0(M0N]+FM
MR65WVE,A?1D/CU[A"LW&_S66KK91KGV0N]WN.[MJ7_'OZNU?^$&83:DL2%R3
M:32<4D9-^[^T@M.U?]-7VM$/X9=;^I+1L *=KS65_UY@!]TGO_P&4$L#!!0
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M:W7N;E=28.IG 3Q?:&V;'[Q!^U+W]']02P,$%     @ LH)H6*W@=Z?^ P
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MS0V]X%"[!31?*67[CG,PO D7_P!02P,$%     @ LH)H6.?7&N%M!0  U0T
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M:7 QM<,U_KN$(@%\7TIIVA=:H/N3F_X+4$L#!!0    ( +*":%C[C/A@W@,
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MU9SJHS8XN4@+5'OW7-#@;&CNU&ZV>Y&LFXOX<7OSG+EF:L]+3?HS$@W]*54
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M0,\_J:?PIZG /X4;ZHF+6A":/*3^$4/?'\ TLH5(:,P6.@-J+CN.P''@#SI
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M7D#S2T7-HGKA#9J/Q<E_4$L#!!0    ( +*":%A]H$ JO <  )04   9
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M>J,+%1FW0\AN)&M-6WY@4EU@LZS4W :N#=3[@C&YVV@'_3^!Y#]02P,$%
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M^V8E]7)(O1Q2XG6VX$T+QF/#6J&_Z(9E+"W2MT@Y0>Q&.%4YC6#LF4I7()_
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M22E'H:D4H# ;!J/VQ:3OUOL%WRFN]%8;').YE'>N<YT.@Y8+"!DFQB$0^WG
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M<MP6AVY>;^ZTF'NO-[=;S/UN\SOZ1.Q!F^^-6+B5>&Z.<X_@;M. )4 >))6
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MR9+\<0T4MWJJ ;Y?,B:?"^H#U<7=[!]02P,$%     @ LH)H6-'E?;PG!
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MN&Z@[N\8DT\%W4%[ZK/^#E!+ P04    " "R@FA8601YM/P#  !H%@  &0
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MX'U7-]?X(H&R 3B_E-*\=NREU[UQZ5]02P,$%     @ LH)H6(L[ZO?0!
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M'>O07TJ2+6=B<#(7J),<-5N #ZOI?#Q2\^30E*EO!9$#1^.VF:\-\40!)I4
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MPT)_ET"8 +V_YESM)N: _DL7_P-02P,$%     @ LH)H6*;XF_(. P  60T
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MMP+)=9IB\7P!E&^'5L?:G;@CBZ4R)YQXL,(+N ?UL+H5>N24768D!28)9TC
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M53L[7.I]%0A3H*_/.5>[@5FZRYU:_!=02P,$%     @ LH)H6#DU,A<*!0
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MUH&^SR6UO^K%)JBO=>-_ 5!+ P04    " "R@FA80<%T!SD#  !\"0  &0
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M:0 9SME2V&NUOL Z'T\P5<+X+ZQKWRB =&FL*NI@8E!P6?W9?:W#5D#[9$]
M7 ?$3P.Z>P(Z=4#')UHQ\VE-F&5)7ZLU:.=-:&[@M?'1E V7KHHSJVF54YQ-
M)JCYBCDI82J-U4NJD#7 9 8Y9@LN%Y72W'(T< QC9G(XI]K#1;U,M1A^&T_A
M<(*6<6&.R.MF-H'#@R,X "[AD@M!%3/]T!)AMVV8UN1&%;EX#[EV#)=*VMS
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M!ZCG"Z;VZ6J@CVGK<_S9=U!+ P04    " "R@FA8:E2HR]X0  "N^   &0
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MES:O'U!]_SK+RN^?G%;^URS_?3O&V;\!4$L#!!0    ( +*":%BY2$&>K0(
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M]V_F=58OU#J#TCPHS8?2 B@MA-(HBJ8JNK'.G->VSARH=0:EN5":!Z7Y4%H
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M7"C-@])\*"V TD(HC:)HZBG0>(,CH_'2,NV VGM0FEO3E+3#WD\ZH*8=E!9
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M8,I WE]1*IX;Z@'%J<ST!U!+ P04    " "R@FA88$D"1DT&  ".)@  &0
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M<$A89B#_OZ)4/%UD U1'T!;_ 5!+ P04    " "R@FA8OY4!^K\$   Z&
M&0   'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6R]66MOXC@4_2M6=K0[E880
M)T"A"T@MZ6@K3;6HG=G]L-H/;G(AV28V8QMH__TZ#_(T3*>*X$.;Q[G'/O?:
MEU-WNF?\600 $KW$$14S(Y!R<]7O"R^ F B3;8"J-RO&8R+5+5_WQ88#\=.@
M..K;EC7JQR2DQGR:/EOR^91M91126'(DMG%,^.L-1&P_,[!Q>/ 0K@.9/.C/
MIQNRAD>0WS9+KN[Z!8L?QD!%R"CBL)H9U_C*M=. %/%7"'M1N4:)E"?&GI.;
M.W]F6,F,( )/)A1$_=K! J(H85+S^)Z3&L6826#U^L#^.16OQ#P1 0L6_1WZ
M,I@98P/YL"+;2#ZP_1^0"QHF?!Z+1/H3[7.L92!O*R2+\V U@SBDV6_RDB>B
M$H!'1P+L/,!N!@R.!#AY@//6@$$>,$@SDTE)\^ 22>93SO:()VC%EERDR4RC
ME?R0)G5_E%R]#56<G#\&A$,OR9R//!:KY21(5A#J(S6Z]QRPR <N?D/P?1O*
M5]1#7\D+NEVM5.4$>H"(2!4K&;HE7H 6BH-1H!*Q%;KVO&V\S0!_R@!X^II#
MD*R;':"/7Y@0%^B.JI'5G0N2A)%ZT$/?'EWT\<,%^H!"BN[#*%)3$M.^5(J3
M>?>]7-U-ILX^H@[;Z)Y1&0AT2WWPZP1]E:HB7_8A7S?V2487/!,Y^!.R+=O1
M3&CQ]G!;$^Z^/1R?4.,4U7=2/N<(WX\*=*A,5J=_OJAP="<A%O_J:I&--="/
ME32P*[$A'LP,-8( O@-C_NLO>&3]KLMCEV1N1V2U' ^*' ].L<^77"WK%UV^
MLCALI8%)@][->UB5=5?-0P8:5C"V8T[J(%?#A.T"4YOVL)CV\.2TDTU^ Q16
MH40?;U^2Q@ 7.A49S65U@J;=$-'&] ;F94.$!F2;8[V*4:%B=%H%DR1"+%W:
M7FUIA_G2CI*E_0E12#O6D4J-VE,;FV.K^FG6K1V")\V\N&W0Q,23VD>O_[+0
M?WE2OZOJ1]7F/E1RF7]C+R-"=4)/LOWL%NZ2S.V(K);%<9'%\1G;Y+C+''=)
MYG9$5LOQI,CQY)UM<J)K'LWMU@:-S=&1G92);4<,3$>_V[!5NBFKFZZ9\U2'
MM\Q10Y0&U,.M)J)#5;GJ4BK&$)^C=>:CU&;GF,.FTC;JL@ER-2"G\BU2UVF7
M.NT?M$@>[HC,]K&0?*O^JI%ZKWF2Z&=W;J=L;E=L]226/A*?TTCB3IUDIVQN
M5VSU1)=F$K_73>:!#9/2VFAM%!XT&X^K08W-(U8$EXX2=V0IL<Y3.DTE&K_8
M=L8ZE&T.CD@I;24^BZ_$&F,Y:KEG#0I;+?NL08TJY:\++?TC/FT@/S,.X9JB
MQ99SH-XK^LH)%5%V1G#M_[<5\GB_[-1-=LKF=L563VMI*/$Y'27NU%)VRN9V
MQ59/=.DJ\7MM)6X;0-QV8&U0RZ:Y&E#-IM4/FDHO:7?D)6VM 6STAX4&954:
M87[\I ,=4U):2?LL5C(?95B;W*0I$VO.0IHJ-9@>;JCL5PY58^#K]'!:J/EO
MJ<S."XNGQ0'X=7KLVWA^@Z_<[!B[I,E.U>\)7X=4H A6BE*53$GCV4%U=B/9
M)CVZ?6)2LCB]#(#XP!. >K]B3!YND@&*?Q?,_P=02P,$%     @ LH)H6*O#
M;9WZ P  U0\  !D   !X;"]W;W)K<VAE971S+W-H965T.#,N>&ULK5=M<]HX
M$/XK&E_G)IDI^ 5C( >>(7$[=Q_2R323ZX?.?1"V %ULBTHRM/_^5K)C#!:&
M7LF'H)?=1WIV5^O=Z8[Q5[$F1*+O69J+F;66<G-GVR)>DPR+/MN0'':6C&=8
MPI2O;+'A!"=:*4MMSW$".\,TM\*I7GOBX905,J4Y>>)(%%F&^8][DK+=S'*M
MMX7/=+66:L$.IQN\(L]$OFR>.,SL&B6A&<D%93GB9#FSYNY=Y Z4@I;XFY*=
M:(R1HK)@[%5-_DIFEJ-N1%(22P6!X6=+'DB:*B2XQ[<*U*K/5(K-\1OZ1TT>
MR"RP( \L_4(3N9Y98PLE9(F+5'YFNS])16BH\&*6"OT?[2I9QT)Q(23+*F6X
M04;S\A=_KPS14'"#$PI>I> =*_@G% :5PN!2!;]2\+5E2BK:#A&6.)QRMD-<
M20.:&FAC:FV@3W/E]V?)89>"G@P_06C1/&8903<I$^(6;0A',,_ *6*-.:Q'
M1&*:PE8/O3Q'Z.;=+7J'[')7@#9ZR:D4[V$1QH\T3<&A8FI+N)XZQ(ZKJ]R7
M5_%.7,7UT"/+Y5J@#WE"DD, &WC5Y+PW<O=>)V)$XCX:N.^1YW@#PX4>+E?W
M#.K1Y>IN!YM![:J!QAN<P/N >4[SE4!/X*%G[9JO\X60'-[./R9SEW"^&4XE
ME#NQP3&969 Q!.%;8H6__^8&SA\F4UT3++H2V($9_=J,?A=Z.$_^A6<%J4LB
M2)MHPR0,*4Y10M-")2%$EDO(2H@M]TN"Q 6GDD*\W]#J88A;D]'+PP-]N$JZ
MV]"9VMNF)<]*1)T$_J=YAK5YAIU1]JG(",>2\3L3N^$U0^J:8-&5P YL%M0V
M"SI#JI5$3:8K(88-M_=&@=,?'D6'0<QSW7YP%")M,<^=-, .>(QJ'J-.WT<D
M9_"-.>G]T36]?TVPZ$I@!U8;UU8;=WK_BZXM2-+#6W@Y*X+R(EM BH;\4>:)
M'A0F-#Z7.,:MM#!TH7J#OZ,(,0@ZKD$P,@@.AH>"!X0G->%))^&HG15[Y%M!
MY0^$=Y@G9W/DY&R./"L1M26"#FJNLZ^'G%_TIOXHD.0<R>J<"QQJDC1[U"3I
MNUV\&W6@^W,YK%T(]M ^D!.6II@++:1WS38HSYPTLYGK]\?'2<\DY_=5T75(
MORWF]]T3S+T]<^_7F3>=?B%W[T+N!CD3][:8WW>"$^3W-:7;66N%<ZA]>OLR
M1[+X]<)'7 $W8W$0&,.[+>B-C='=%BQC^SBX[4:_ ]7*2O>- EQ6Y++L#NK5
MNC>=ZX[L:/U>]:RZC]K#E WO(^8KF@N4DB5 .OT1?&IYV4.6$\DVNJM:, D]
MFAZNH>\F7 G _I)!85E-U %U)Q_^!U!+ P04    " "R@FA8ZRFCA>H+   [
MBP  &0   'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6RUG6UOX[@5A?\*X1;%
M%LC$UIN=I$F Q"+9*>8E2';:#XO]H-BT+8PLI1*=S #[XTO)BFG:#&VE9Q>#
MC:V0#\7<(U[QB)(N7XKR>[400I(?RRROKGH+*9\N^OUJLA#+I#HMGD2N?C,K
MRF4BU==RWJ^>2I%,FTK+K.\/!L/^,DGSWO5EL^VNO+XL5C)+<W%7DFJU7";E
MSUN1%2]7/:_WNN$^G2]DO:%_??F4S,6#D-^>[DKUK;^A3-.ER*NTR$DI9E>]
M&^^"#Z.Z0E/BWZEXJ;8^D[HKCT7QO?[R<7K5&]1[)#(QD34B43^>Q5AD64U2
M^_'?%MK;M%E7W/[\2F=-YU5G'I-*C(OL/^E4+JYZ9STR%;-DE<G[XN6?HNU0
MLX.3(JN:_Y.7MNR@1R:K2A;+MK+:@V6:KW\F/]H_Q%8%WW^C@M]6\'<J!&^U
M$+05@F-;"-L*X;$5HK9"=&R%85MA>&R%45MAU 1K_==M0A,G,KF^+(L74M:E
M%:W^T,2WJ:TBDN:U%!]DJ7Z;JGKR^EX\BWPEE*HFQ3Q/&WE\(%^2LDQJC9!?
M8B&3-*O^?MF7JKFZ4G_2HF_7:/\-=$ ^%[E<5(3F4S&UU!^[ZWN^ ]!7_=QT
MUG_M[*WO),9B<DH"[X3X ]\GWQYB\LM?;1T;'X\)7C&D$G-UB$H++L;L%3T>
MXSDPS(WY.I%'8?CQ>S.P8XP0!AN]!@TW>(,[+O*)^BO7ZE1*O4^K[^2W3ZH,
M^2C%LOK=IM(U,+0#ZZ'^HGI*)N*JI\;R2I3/HG?]M[]XP\$_;,I PF(DC")A
M# GC()BAEW"CE]!%O_ZR6CZ*DA0S-<(]%:5,'C/Q>JA6Y _'47OK!'?5S1HV
M;&#UZ<'S=7#9?]X6 [(YBH0Q)(R#8(88HHT8HB/%H$[EZB$DGQ^I!2>WJQ:B
M@UI -D>1,(:$<1#,T,)PHX6A4PM?Y4))(:DJ(2M;Q->UO<%6E+QS+QC4_YG1
M&EN+AK:B\?%4ZMS]KF%#PC@(9H1MM G;R!FV3T+-.ZP!<];K>HB.]@[1:&2+
M)[)1BH0Q)(R#8$;$SS81/W-&O)VAG*@$7D^MZS%;#=[-)%R="I+B,4OGS=G@
M"4F6Q<H^?CN;Z"J.L_WQ>W0>V>2!;)8B80P)XR"8(8_SC3S.G?)0$P(U&YA(
M-6^6BW;&+,J3]<BN?LQD/<QG6?'2R$7IADQ*,4TER8JJ.B&YFE"LRO*-O'^^
M'^KPS)8#]@OZWKE-$L<2J;/;7<.-A'$0S BW-]"&Q>!= <_2Y#'-4OGSA#@"
MVL*-0 U#6T1M)4>^+:1',ZF[:UV#"J5Q%,T,ZY8/Y3G#>E<6SVEM<%;-,2I^
M/(F)%-/M@]6>]]W<KF-[2S,/9&O0]PM:3^/:<L8IWP<;D4$[PE$T,YR^#J=_
M7-:^WV3MNZVL_74K:]/74/^:+NMR:GKVH'Y5S9+)NL"#3$I)XD0*\MO-C[3Z
M_:)VE<(/ T_]LTK"N6^=)8&DQ5 :A=(8E,91-%.!VBCTX$ZA![4*H;082J-0
M&H/2.(IFZD8;AI[;,83,-]QM=%92N)]#@I%O=1B@+5,HC4%I'$4S=:*]1,]M
M)G;0R>9D1FXR7&5D.%4Q+6R7R&[=.]%92.XN^2%9-E?<K ,0U)2$TAB4QE$T
M4UC:F/3<SN3;%I>[8F<Q(&DQE$:A- :E<13-E(<V0+T1_+P&ZHU":3&41J$T
M!J5Q%,W4C;91/;>/ZAA6H.YH2S-.5NSFN;=OI(8VSXQ:"@:#R.;%,&A?.(IF
MADQ;FY[;V_PDJJHH3[:N5F9U$-7Y0O*SOE))9$$>F[4[(GT6TQ/R4R0E*7)A
MC3+2 QQ[^SZFS<6,H:U2*(U!:1Q%,U<V:5O4=]NB[].*?"EL6G&WU54K_KX_
M:K7&H:U2*(U!:1Q%,[6BO5;?[;6^4RN+4EA'%G=KG=6R;ZS:U8)LE4)I#$KC
M*)JI%FWE^FXK]WUJF16KTBH6J#?;T@Z+!>JZ0FD,2N,HFBD6[;KZ3G?NO6)1
MGZUB@1JR+>VP6*!6*Y3&H#2.HIEBT5:K[[9:.XME?37?+1FH\^KOK]O<4PO4
M<(72&)3&4313+=IP]=WNY.N%_XHD^93,RR2WK]QS8SHK $F+H30*I3$HC:-H
MIEBTB>H/T2Z9#W57H;082J-0&H/2.(IFZD:[J[Y[?>E=64Q7$TFJ)+.;9>[Z
MG56RO]#4'UJOZUE*AIYUD5%;TEQD'(16NPS:&XZBF;'3#J?O=CB_Y6E]D>U!
M)E+4Z_G?=CS=H,Y!1-)B*(U":0Q*XRB:*1?MKOKG\!0!]5"AM!A*HU :@](X
MBF;>@*B=UN"0T_K6L.*NV%4>+<T8QW>SPA%E*'2O&)3&430SE-H(#=Q&Z)<B
M__#M@5MC"34UH;082J-0&H/2.(IFZD-;GX&/3A$!U-^$TF(HC4)I#$KC*)JI
MFZV;U ^[H$)8C"V]5JS90*0HEU8586]:=^]MU#AJUD5?T/V@4!J#TCB*9BI&
M6Z&!VPI]?0['K"R6Q+S%9=S>XJ)F-%P4\S)Y6J038AF:_B#&#,BJ*Z@["J7%
M4!J%TAB4QE$T4VO:2 TB>%:#>JI06@RE42B-06D<13-UHSW5P+TPU=1-6>M&
MY;=Z4S*W7HMQ\SJKIKUYWM^>ZYQ&9[M3(FNQT?GNK,A:[-S?,<B@7> HFAE
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MVM (ZHU":3&41J$T!J5Q%,W4C?90([>'>G =D+M^9Y5 35,HC4:69:<CZQL
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MA.H)KM-=7O_T'IM8?^*M[_,BW3>#RQGLX^3P._K2$-$:0(*> ;090+L#>,\
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MK@/4]QO&Y,M WZ ]<IU_!U!+ P04    " "R@FA8$P8E0I\"   A!@  &0
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M-I7]'05!U)!0RK0$M??IO*QU7A[4^8/IDY>]3.WE[CKWW&A+[6Y0Z+M=N]K
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MGZ!3#J:S#E]=<(R$2*^!L9Y+W0H-?$L9A*VF0+>HJ&3")+KX^Q+<%H+( 2G
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MO0#RD*98O%V3A)\6 SAXO_% MSN5W1@MYWN\)8]$/>_OA;X:55YBFA(F*6=
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M:EDU<M5$B]*V-@NAL5&RPS4VOR!- /Z_%$+O)^8%33L=_P)02P,$%     @
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M)FAOO9XI$4O3A4@(%R(LGZ-ZM6YTKLW[OK<^A@:H[%=>:,KN:8K%DF82,;(
M2@@!8A)E1U).%,_-&SWG"EY\,TR@B2-"&\#W!>=J,]$.ZK8P^ =02P,$%
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MP%>*$@8W LE5DF#Q= Z4;X9.X#S?N"7SA3(WO'BPQ',8@[I;W@B]\G*6*4F
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M:X"*5-&XBXF12]?*'J7!QNB&&;YU0%D#_#Z7TFPG=H/J]13] U!+ P04
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MIDO&%1-U;<&2A(HGNU<MK\A4OVYOZ>OK$YJ2)5?W+3ARN_(WFK!E%K=7W<)
MU%=UY:_0/;T5;MY-="PF$KJBR:2NROFT*CJZH*/6!Q!VD9OJL",8QV!V!# L
M#N8 XQ@6%N=_ZL\ [8_!,&\#*S) .0.48U@V9%)]L#AV3JP/>T_C. RC"!O1
MR<3J8(*-6Q3!UZZ&>0,&%@<B/6^L\=G&,V1_'F!SNB]#L)[BF8CU%!]K0.SC
M!HPXML\V%@<8V"Q@N0/Q[7$@I^R<,(19Q;QA*QA'XAA#(!?M.1I%R.A$\+'/
M#[9*PC".[0A@=@=AB"&P&G$$<P >,"0,J^?@SO/(:YY37O<?]/@/4$L#!!0
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MCYL)LE!";"&,:8^;";)00IW\],7>\V$A;5,_KE@=XL]6J,H>D!)DH81\E<"
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MW<]*@-Y)]4X O9/JG0!Z)]4[ ?1.JG<"Z)U5[PS0.ZO>&:!W5KTS0.^L>F>
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MY_/?EQ\G^W[E.]?#UQC3S5]02P,$%     @ LH)H6-&<,ZAW @  G3T  !,
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M/XW]/H[[?QR_/..^:H?7_&3Y5_;-3U!+ 0(4 Q0    ( +*":%@'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ LH)H6 P6PM[N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ LH)H6)E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "R
M@FA8I1B__V0(   Q,@  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ LH)H6/S>NS\Y @  N 4  !@
M         ("!IQ   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( +*":%CN&&@V+08  +49   8              " @183  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "R@FA89+FR^0$#  #Y"@
M&               @(%Y&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ LH)H6%.H$-?,"   7SD  !@              ("!L!P  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( +*":%C)[D0'T0,
M )$-   8              " @;(E  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " "R@FA8&"D?.((*  !8-0  &               @(&Y
M*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ LH)H6.*=
ME*?5!P  L44  !@              ("!<30  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( +*":%CG]IM[50(  "P&   8
M  " @7P\  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "R
M@FA8$I<J%%,-  !0(0  &0              @($'/P  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( +*":%C4_K-KY2@  )N%   9
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M970Q-2YX;6Q02P$"% ,4    " "R@FA8&"2P7_8%  !1$   &0
M    @(&0C   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M +*":%AN*4JLA@8  -,1   9              " @;V2  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ LH)H6%&&&]T_!P  0A(  !D
M             ("!>ID  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " "R@FA8YL<'<! -  "8)0  &0              @('PH   >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +*":%A"V*2]/@T
M -TG   9              " @3>N  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ LH)H6 0"M5#X!   : T  !D              ("!
MK+L  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "R@FA8
MRM+37@P1  "K,0  &0              @(';P   >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( +*":%B]SR Q#04  -H+   9
M      " @1[2  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ LH)H6-D:?K^C$   O"\  !D              ("!8M<  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "R@FA8I1W(_[X'  #4$P
M&0              @($\Z   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( +*":%@0:KAHH ,  (0(   9              " @3'P  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ LH)H6.6 [$@L
M"@  IAL  !D              ("!"/0  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " "R@FA8)#RWQ!L"  #&!   &0
M@(%K_@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( +*"
M:%A[. RST (  , &   9              " @;T  0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ LH)H6/N)5#9@ @  A@8  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( +*":%BD-,17@@(  'P%   9
M  " @>)/ 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
MLH)H6*NKA(<Q!   9PD  !D              ("!FU(! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " "R@FA8_%5'EU4&   L$@  &0
M            @($#5P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( +*":%@^!/&NN 0  $$-   9              " @8]= 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ LH)H6/HNS:^3 P
M: @  !D              ("!?F(! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " "R@FA8VIF1N&H#  #P!P  &0              @(%(
M9@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( +*":%CE
MPL9)SP<  . 5   9              " @>EI 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ LH)H6*W@=Z?^ P  'PH  !D
M     ("![W$! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +*":%A]H$ JO <  )04   9              "
M@?F, 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ LH)H
M6$O59N"_ @  T08  !D              ("![)0! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " "R@FA8 3*W#]@&  "[/   &0
M        @('BEP$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( +*":%C<"O")I@(  !4(   9              " @?&> 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ LH)H6#P'2_1@ P  ZA(
M !D              ("!SJ$! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " "R@FA8"<XL6RD#   G"@  &0              @(%EI0$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( +*":%A*N&]"
M7 (  $X%   9              " @<6H 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ LH)H6'T$T[::!   Q!L  !D
M ("!6*L! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "R
M@FA8T>5]O"<$   !&@  &0              @($IL $ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( +*":%A9!'FT_ ,  &@6   9
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M970V,"YX;6Q02P$"% ,4    " "R@FA8A?!\>!H#  !+"P  &0
M    @(&PRP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M +*":%C3?Z#FHP4  ,@?   9              " @0'/ 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ LH)H6##3BT.A @  ]08  !D
M             ("!V]0! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " "R@FA8IOB;\@X#  !9#0  &0              @(&SUP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( +*":%A&+Z.%VP(
M +4)   9              " @?C: 0!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ LH)H6#DU,A<*!0  DB$  !D              ("!
M"MX! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " "R@FA8
MQJWK4"4&  #@+   &0              @(%+XP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( +*":%@[^9AB]P,  .(-   9
M      " @:?I 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ LH)H6$'!= <Y P  ? D  !D              ("!U>T! 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " "R@FA8;I(&RS<$  #_&P
M&0              @(%%\0$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( +*":%AE&_)90 (   L%   9              " @;/U 0!X
M;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ LH)H6-3-= 6
M @  =P8  !D              ("!*O@! 'AL+W=O<FMS:&5E=',O<VAE970W
M,BYX;6Q02P$"% ,4    " "R@FA8)7K^X:\"   B!P  &0
M@('A^@$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( +*"
M:%B0MV/S: 0  -,7   9              " @<?] 0!X;"]W;W)K<VAE971S
M+W-H965T-S0N>&UL4$L! A0#%     @ LH)H6&I4J,O>$   KO@  !D
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M=#<Y+GAM;%!+ 0(4 Q0    ( +*":%CH>+Y^3 0  *$9   9
M  " @3HN @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @
MLH)H6&!) D9-!@  CB8  !D              ("!O3(" 'AL+W=O<FMS:&5E
M=',O<VAE970X,2YX;6Q02P$"% ,4    " "R@FA8OY4!^K\$   Z&   &0
M            @(%!.0( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4
M Q0    ( +*":%BKPVV=^@,  -4/   9              " @3<^ @!X;"]W
M;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ LH)H6.LIHX7J"P
M.XL  !D              ("!:$(" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX
M;6Q02P$"% ,4    " "R@FA8OJ +QQ4(  ":2@  &0              @(&)
M3@( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( +*":%AR
MN.46Q0,  'X5   9              " @=56 @!X;"]W;W)K<VAE971S+W-H
M965T.#8N>&UL4$L! A0#%     @ LH)H6!,&)4*? @  (08  !D
M     ("!T5H" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +*":%B<%=X0] (   <+   9              "
M@<MI @!X;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ LH)H
M6,W(%YI2!@  @RD  !D              ("!]FP" 'AL+W=O<FMS:&5E=',O
M<VAE970Y,RYX;6Q02P$"% ,4    " "R@FA8Z:\!))L#  "^#0  &0
M        @(%_<P( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0
M   ( +*":%CI]QFK(@4   H6   9              " @5%W @!X;"]W;W)K
M<VAE971S+W-H965T.34N>&UL4$L! A0#%     @ LH)H6( =RJ)!!0  /10
M !D              ("!JGP" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q0
M2P$"% ,4    " "R@FA87@"A)IT#  "4#   &0              @($B@@(
M>&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( +*":%@OO!;(
M[ 0  "4;   9              " @?:% @!X;"]W;W)K<VAE971S+W-H965T
M.3@N>&UL4$L! A0#%     @ LH)H6#S(EMAO P  6@L  !D
M ("!&8L" 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    " "R
M@FA8P^/3C;P"  ".!P  &@              @(&_C@( >&PO=V]R:W-H965T
M<R]S:&5E=#$P,"YX;6Q02P$"% ,4    " "R@FA8DD!$+'\"  #/!0  &@
M            @(&SD0( >&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"
M% ,4    " "R@FA88G8FYXD"  "'!0  &@              @(%JE ( >&PO
M=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"% ,4    " "R@FA8R=)C?/D"
M   B"@  &@              @($KEP( >&PO=V]R:W-H965T<R]S:&5E=#$P
M,RYX;6Q02P$"% ,4    " "R@FA8,7ZF)28"  "I!   &@
M@(%<F@( >&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " "R
M@FA8F#(T""(+  #?4P  &@              @(&ZG ( >&PO=V]R:W-H965T
M<R]S:&5E=#$P-2YX;6Q02P$"% ,4    " "R@FA8!)61BLD#  !(%   &@
M            @($4J ( >&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"
M% ,4    " "R@FA8[C)<RHX#  "E$   &@              @($5K ( >&PO
M=V]R:W-H965T<R]S:&5E=#$P-RYX;6Q02P$"% ,4    " "R@FA87B;#$V,#
M   R$   &@              @(';KP( >&PO=V]R:W-H965T<R]S:&5E=#$P
M."YX;6Q02P$"% ,4    " "R@FA8(K41("<#  !)"0  &@
M@(%VLP( >&PO=V]R:W-H965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4    " "R
M@FA8[J6US%L#  "0%@  #0              @ '5M@( >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( +*":%B7BKL<P    !,"   +              "  5NZ
M @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +*":%C1L1;1?0<  (U'   /
M          "  42[ @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "R@FA8
M%&2G9A,#   $0   &@              @ 'NP@( >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "R@FA8T9PSJ'<"  "=/0  $P
M        @ $YQ@( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     =0!U #0@
(  #AR (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>408</ContextCount>
  <ElementCount>526</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>124</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Nature of the business and organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Natureofthebusinessandorganization</Role>
      <ShortName>Nature of the business and organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Divestiture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Divestiture</Role>
      <ShortName>Divestiture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Long-lived asset impairment and restructuring charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Longlivedassetimpairmentandrestructuringcharges</Role>
      <ShortName>Long-lived asset impairment and restructuring charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Inventories, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Inventoriesnet</Role>
      <ShortName>Inventories, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</Role>
      <ShortName>Property, plant and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Intangible assets and goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill</Role>
      <ShortName>Intangible assets and goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Fairvaluemeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Derivative Instruments and hedging activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivities</Role>
      <ShortName>Derivative Instruments and hedging activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Share-based compensation and stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity</Role>
      <ShortName>Share-based compensation and stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Net income (loss) per common share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Netincomelosspercommonshare</Role>
      <ShortName>Net income (loss) per common share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Revenuerecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Defined benefit and 401(k) savings plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplan</Role>
      <ShortName>Defined benefit and 401(k) savings plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Purchase commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Purchasecommitments</Role>
      <ShortName>Purchase commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Long-lived asset impairment and restructuring charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesTables</Role>
      <ShortName>Long-lived asset impairment and restructuring charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Longlivedassetimpairmentandrestructuringcharges</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Inventories, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetTables</Role>
      <ShortName>Inventories, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Inventoriesnet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Property, plant and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables</Role>
      <ShortName>Property, plant and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Intangible assets and goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables</Role>
      <ShortName>Intangible assets and goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Fairvaluemeasurements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Derivative Instruments and hedging activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesTables</Role>
      <ShortName>Derivative Instruments and hedging activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Debt</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Share-based compensation and stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables</Role>
      <ShortName>Share-based compensation and stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Net income (loss) per common share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetincomelosspercommonshareTables</Role>
      <ShortName>Net income (loss) per common share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Netincomelosspercommonshare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Revenue recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionTables</Role>
      <ShortName>Revenue recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Revenuerecognition</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Leases</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Incometaxes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Defined benefit and 401(k) savings plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanTables</Role>
      <ShortName>Defined benefit and 401(k) savings plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplan</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/SegmentInformation</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Nature of the business and organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails</Role>
      <ShortName>Nature of the business and organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Natureofthebusinessandorganization</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Summary of significant accounting policies - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails</Role>
      <ShortName>Summary of significant accounting policies - Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Summary of significant accounting policies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails</Role>
      <ShortName>Summary of significant accounting policies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Summary of significant accounting policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of significant accounting policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Summary of significant accounting policies - Accounting for Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails</Role>
      <ShortName>Summary of significant accounting policies - Accounting for Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Summary of significant accounting policies - Derivative instruments and hedging activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails</Role>
      <ShortName>Summary of significant accounting policies - Derivative instruments and hedging activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Divestiture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DivestitureDetails</Role>
      <ShortName>Divestiture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Divestiture</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Long-lived asset impairment and restructuring charges - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails</Role>
      <ShortName>Long-lived asset impairment and restructuring charges - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Long-lived asset impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails</Role>
      <ShortName>Long-lived asset impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Long-lived asset impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails</Role>
      <ShortName>Long-lived asset impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Long-lived asset impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails</Role>
      <ShortName>Long-lived asset impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Inventories, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetDetails</Role>
      <ShortName>Inventories, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/InventoriesnetTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Property, plant and equipment, net - Summary of Property, Plant and Equipment Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails</Role>
      <ShortName>Property, plant and equipment, net - Summary of Property, Plant and Equipment Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Property, plant and equipment, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails</Role>
      <ShortName>Property, plant and equipment, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Intangible assets and goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails</Role>
      <ShortName>Intangible assets and goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Intangible assets and goodwill - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible assets and goodwill - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Intangible assets and goodwill - Summary Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails</Role>
      <ShortName>Intangible assets and goodwill - Summary Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Fair value measurements - Fair Value Measurements, Recurring and Nonrecurring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails</Role>
      <ShortName>Fair value measurements - Fair Value Measurements, Recurring and Nonrecurring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Fair value measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails</Role>
      <ShortName>Fair value measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Fair value measurements - Reconciliation of the Contingent Consideration Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair value measurements - Reconciliation of the Contingent Consideration Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Fair value measurements - Level 3 Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails</Role>
      <ShortName>Fair value measurements - Level 3 Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Derivative Instruments and hedging activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails</Role>
      <ShortName>Derivative Instruments and hedging activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Derivative Instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails</Role>
      <ShortName>Derivative Instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Derivative Instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails</Role>
      <ShortName>Derivative Instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Debt - Components of Long-term Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails</Role>
      <ShortName>Debt - Components of Long-term Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Debt - Future Debt Payments of Long-term Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails</Role>
      <ShortName>Debt - Future Debt Payments of Long-term Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Share-based compensation and stockholders' equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails</Role>
      <ShortName>Share-based compensation and stockholders' equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Share-based compensation and stockholders' equity - Stock Options Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Share-based compensation and stockholders' equity - Stock Options Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Share-based compensation and stockholders' equity - Stock Options, Restricted Stock Units, and Performance Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails</Role>
      <ShortName>Share-based compensation and stockholders' equity - Stock Options, Restricted Stock Units, and Performance Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Share-based compensation and stockholders' equity - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails</Role>
      <ShortName>Share-based compensation and stockholders' equity - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Share-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Share-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Share-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>Share-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Net income (loss) per common share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails</Role>
      <ShortName>Net income (loss) per common share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/NetincomelosspercommonshareTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Revenue recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails</Role>
      <ShortName>Revenue recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Revenue recognition - Percentage of Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails</Role>
      <ShortName>Revenue recognition - Percentage of Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Revenue recognition - Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails</Role>
      <ShortName>Revenue recognition - Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Revenue recognition - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails</Role>
      <ShortName>Revenue recognition - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Income taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails</Role>
      <ShortName>Income taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Income taxes - Components of the Provisions for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails</Role>
      <ShortName>Income taxes - Components of the Provisions for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Income taxes - Net Deferred Tax Asset (Liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails</Role>
      <ShortName>Income taxes - Net Deferred Tax Asset (Liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Income taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails</Role>
      <ShortName>Income taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Income taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Defined benefit and 401(k) savings plan - Swiss Plan Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails</Role>
      <ShortName>Defined benefit and 401(k) savings plan - Swiss Plan Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Defined benefit and 401(k) savings plan - Components of Net Periodic Pension Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails</Role>
      <ShortName>Defined benefit and 401(k) savings plan - Components of Net Periodic Pension Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Defined benefit and 401(k) savings plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanNarrativeDetails</Role>
      <ShortName>Defined benefit and 401(k) savings plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - Defined benefit and 401(k) savings plan - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails</Role>
      <ShortName>Defined benefit and 401(k) savings plan - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Defined benefit and 401(k) savings plan - Accumulated Other Comprehensive Loss Before Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails</Role>
      <ShortName>Defined benefit and 401(k) savings plan - Accumulated Other Comprehensive Loss Before Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Purchase commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PurchasecommitmentsDetails</Role>
      <ShortName>Purchase commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Purchasecommitments</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9954545 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9954546 - Disclosure - Segment Information - Revenue from External Customers by Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails</Role>
      <ShortName>Segment Information - Revenue from External Customers by Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9954547 - Disclosure - Segment Information - Long-Lived Assets by Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails</Role>
      <ShortName>Segment Information - Long-Lived Assets by Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="ebs-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9954548 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccounts</ParentRole>
      <Position>109</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ebs-20231231.htm">ebs-20231231.htm</File>
    <File>ebs-20231231.xsd</File>
    <File>ebs-20231231_cal.xml</File>
    <File>ebs-20231231_def.xml</File>
    <File>ebs-20231231_lab.xml</File>
    <File>ebs-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ebs-20231231_g1.jpg</File>
    <File>ebs-20231231_g2.jpg</File>
    <File>ebs-20231231_g3.jpg</File>
    <File>ebs-20231231_g4.jpg</File>
    <File>ebs-20231231_g5.jpg</File>
    <File>ebs-20231231_g6.jpg</File>
    <File>ebs-20231231_g7.jpg</File>
    <File>ebs-20231231_g8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="1448">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>182
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ebs-20231231.htm": {
   "nsprefix": "ebs",
   "nsuri": "http://emergentbiosolutions.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ebs-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "ebs-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ebs-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ebs-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ebs-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ebs-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 484,
   "keyCustom": 42,
   "axisStandard": 43,
   "axisCustom": 1,
   "memberStandard": 68,
   "memberCustom": 50,
   "hidden": {
    "total": 14,
    "http://fasb.org/us-gaap/2023": 10,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 408,
   "entityCount": 1,
   "segmentCount": 124,
   "elementCount": 934,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1448,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://emergentbiosolutions.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://emergentbiosolutions.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
     "longName": "0000008 - Statement - Consolidated Statement of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statement of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquityParenthetical",
     "longName": "0000009 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statement of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://emergentbiosolutions.com/role/Natureofthebusinessandorganization",
     "longName": "0000010 - Disclosure - Nature of the business and organization",
     "shortName": "Nature of the business and organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies",
     "longName": "0000011 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://emergentbiosolutions.com/role/Divestiture",
     "longName": "0000012 - Disclosure - Divestiture",
     "shortName": "Divestiture",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://emergentbiosolutions.com/role/Longlivedassetimpairmentandrestructuringcharges",
     "longName": "0000013 - Disclosure - Long-lived asset impairment and restructuring charges",
     "shortName": "Long-lived asset impairment and restructuring charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://emergentbiosolutions.com/role/Inventoriesnet",
     "longName": "0000014 - Disclosure - Inventories, net",
     "shortName": "Inventories, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet",
     "longName": "0000015 - Disclosure - Property, plant and equipment, net",
     "shortName": "Property, plant and equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill",
     "longName": "0000016 - Disclosure - Intangible assets and goodwill",
     "shortName": "Intangible assets and goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://emergentbiosolutions.com/role/Fairvaluemeasurements",
     "longName": "0000017 - Disclosure - Fair value measurements",
     "shortName": "Fair value measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivities",
     "longName": "0000018 - Disclosure - Derivative Instruments and hedging activities",
     "shortName": "Derivative Instruments and hedging activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://emergentbiosolutions.com/role/Debt",
     "longName": "0000019 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity",
     "longName": "0000020 - Disclosure - Share-based compensation and stockholders' equity",
     "shortName": "Share-based compensation and stockholders' equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://emergentbiosolutions.com/role/Netincomelosspercommonshare",
     "longName": "0000021 - Disclosure - Net income (loss) per common share",
     "shortName": "Net income (loss) per common share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://emergentbiosolutions.com/role/Revenuerecognition",
     "longName": "0000022 - Disclosure - Revenue recognition",
     "shortName": "Revenue recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://emergentbiosolutions.com/role/Leases",
     "longName": "0000023 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://emergentbiosolutions.com/role/Incometaxes",
     "longName": "0000024 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplan",
     "longName": "0000025 - Disclosure - Defined benefit and 401(k) savings plan",
     "shortName": "Defined benefit and 401(k) savings plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://emergentbiosolutions.com/role/Purchasecommitments",
     "longName": "0000026 - Disclosure - Purchase commitments",
     "shortName": "Purchase commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://emergentbiosolutions.com/role/SegmentInformation",
     "longName": "0000027 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://emergentbiosolutions.com/role/Litigation",
     "longName": "0000028 - Disclosure - Litigation",
     "shortName": "Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccounts",
     "longName": "0000029 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-401",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-401",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesTables",
     "longName": "9954472 - Disclosure - Summary of significant accounting policies (Tables)",
     "shortName": "Summary of significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesTables",
     "longName": "9954473 - Disclosure - Long-lived asset impairment and restructuring charges (Tables)",
     "shortName": "Long-lived asset impairment and restructuring charges (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://emergentbiosolutions.com/role/InventoriesnetTables",
     "longName": "9954474 - Disclosure - Inventories, net (Tables)",
     "shortName": "Inventories, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables",
     "longName": "9954475 - Disclosure - Property, plant and equipment, net (Tables)",
     "shortName": "Property, plant and equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables",
     "longName": "9954476 - Disclosure - Intangible assets and goodwill (Tables)",
     "shortName": "Intangible assets and goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables",
     "longName": "9954477 - Disclosure - Fair value measurements (Tables)",
     "shortName": "Fair value measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesTables",
     "longName": "9954478 - Disclosure - Derivative Instruments and hedging activities (Tables)",
     "shortName": "Derivative Instruments and hedging activities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://emergentbiosolutions.com/role/DebtTables",
     "longName": "9954479 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables",
     "longName": "9954480 - Disclosure - Share-based compensation and stockholders' equity (Tables)",
     "shortName": "Share-based compensation and stockholders' equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://emergentbiosolutions.com/role/NetincomelosspercommonshareTables",
     "longName": "9954481 - Disclosure - Net income (loss) per common share (Tables)",
     "shortName": "Net income (loss) per common share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionTables",
     "longName": "9954482 - Disclosure - Revenue recognition (Tables)",
     "shortName": "Revenue recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://emergentbiosolutions.com/role/LeasesTables",
     "longName": "9954483 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://emergentbiosolutions.com/role/IncometaxesTables",
     "longName": "9954484 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanTables",
     "longName": "9954485 - Disclosure - Defined benefit and 401(k) savings plan (Tables)",
     "shortName": "Defined benefit and 401(k) savings plan (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://emergentbiosolutions.com/role/SegmentInformationTables",
     "longName": "9954486 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails",
     "longName": "9954487 - Disclosure - Nature of the business and organization (Details)",
     "shortName": "Nature of the business and organization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "unitRef": "category",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "unitRef": "category",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails",
     "longName": "9954488 - Disclosure - Summary of significant accounting policies - Going Concern (Details)",
     "shortName": "Summary of significant accounting policies - Going Concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails",
     "longName": "9954489 - Disclosure - Summary of significant accounting policies - Concentration Risk (Details)",
     "shortName": "Summary of significant accounting policies - Concentration Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails",
     "longName": "9954490 - Disclosure - Summary of significant accounting policies - Estimated Useful Lives (Details)",
     "shortName": "Summary of significant accounting policies - Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails",
     "longName": "9954491 - Disclosure - Summary of significant accounting policies - Accounting for Share-based Compensation (Details)",
     "shortName": "Summary of significant accounting policies - Accounting for Share-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ebs:NumberOfShareBasedEmployeeCompensationPlans",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails",
     "longName": "9954492 - Disclosure - Summary of significant accounting policies - Derivative instruments and hedging activities (Details)",
     "shortName": "Summary of significant accounting policies - Derivative instruments and hedging activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-83",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://emergentbiosolutions.com/role/DivestitureDetails",
     "longName": "9954493 - Disclosure - Divestiture (Details)",
     "shortName": "Divestiture (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ebs:DispositionOfBusinessTransactionCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
     "longName": "9954494 - Disclosure - Long-lived asset impairment and restructuring charges - Narrative (Details)",
     "shortName": "Long-lived asset impairment and restructuring charges - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
     "longName": "9954495 - Disclosure - Long-lived asset impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)",
     "shortName": "Long-lived asset impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
     "longName": "9954496 - Disclosure - Long-lived asset impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)",
     "shortName": "Long-lived asset impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-101",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails",
     "longName": "9954497 - Disclosure - Long-lived asset impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "shortName": "Long-lived asset impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-108",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://emergentbiosolutions.com/role/InventoriesnetDetails",
     "longName": "9954498 - Disclosure - Inventories, net (Details)",
     "shortName": "Inventories, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails",
     "longName": "9954499 - Disclosure - Property, plant and equipment, net - Summary of Property, Plant and Equipment Useful Lives (Details)",
     "shortName": "Property, plant and equipment, net - Summary of Property, Plant and Equipment Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
     "longName": "9954500 - Disclosure - Property, plant and equipment, net - Narrative (Details)",
     "shortName": "Property, plant and equipment, net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-137",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
     "longName": "9954501 - Disclosure - Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)",
     "shortName": "Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails",
     "longName": "9954502 - Disclosure - Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)",
     "shortName": "Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails",
     "longName": "9954503 - Disclosure - Intangible assets and goodwill - Narrative (Details)",
     "shortName": "Intangible assets and goodwill - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-162",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails",
     "longName": "9954504 - Disclosure - Intangible assets and goodwill - Future Amortization Expense (Details)",
     "shortName": "Intangible assets and goodwill - Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails",
     "longName": "9954505 - Disclosure - Intangible assets and goodwill - Summary Changes in Goodwill (Details)",
     "shortName": "Intangible assets and goodwill - Summary Changes in Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails",
     "longName": "9954506 - Disclosure - Fair value measurements - Fair Value Measurements, Recurring and Nonrecurring (Details)",
     "shortName": "Fair value measurements - Fair Value Measurements, Recurring and Nonrecurring (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
     "longName": "9954507 - Disclosure - Fair value measurements - Narrative (Details)",
     "shortName": "Fair value measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails",
     "longName": "9954508 - Disclosure - Fair value measurements - Reconciliation of the Contingent Consideration Liabilities Measured at Fair Value (Details)",
     "shortName": "Fair value measurements - Reconciliation of the Contingent Consideration Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails",
     "longName": "9954509 - Disclosure - Fair value measurements - Level 3 Significant Unobservable Inputs (Details)",
     "shortName": "Fair value measurements - Level 3 Significant Unobservable Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-185",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails",
     "longName": "9954510 - Disclosure - Derivative Instruments and hedging activities - Narrative (Details)",
     "shortName": "Derivative Instruments and hedging activities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-83",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
     "longName": "9954511 - Disclosure - Derivative Instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "shortName": "Derivative Instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-191",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-191",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
     "longName": "9954512 - Disclosure - Derivative Instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "shortName": "Derivative Instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
     "longName": "9954513 - Disclosure - Debt - Components of Long-term Indebtedness (Details)",
     "shortName": "Debt - Components of Long-term Indebtedness (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
     "longName": "9954514 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails",
     "longName": "9954515 - Disclosure - Debt - Future Debt Payments of Long-term Indebtedness (Details)",
     "shortName": "Debt - Future Debt Payments of Long-term Indebtedness (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
     "longName": "9954516 - Disclosure - Share-based compensation and stockholders' equity - Narrative (Details)",
     "shortName": "Share-based compensation and stockholders' equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ebs:NumberOfShareBasedEmployeeCompensationPlans",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails",
     "longName": "9954517 - Disclosure - Share-based compensation and stockholders' equity - Stock Options Valuation Assumptions (Details)",
     "shortName": "Share-based compensation and stockholders' equity - Stock Options Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-230",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-230",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails",
     "longName": "9954518 - Disclosure - Share-based compensation and stockholders' equity - Stock Options, Restricted Stock Units, and Performance Stock Units (Details)",
     "shortName": "Share-based compensation and stockholders' equity - Stock Options, Restricted Stock Units, and Performance Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-239",
      "name": "ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-239",
      "name": "ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails",
     "longName": "9954519 - Disclosure - Share-based compensation and stockholders' equity - Stock-based Compensation Expense (Details)",
     "shortName": "Share-based compensation and stockholders' equity - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
     "longName": "9954520 - Disclosure - Share-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)",
     "shortName": "Share-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails",
     "longName": "9954521 - Disclosure - Share-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)",
     "shortName": "Share-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails",
     "longName": "9954522 - Disclosure - Net income (loss) per common share (Details)",
     "shortName": "Net income (loss) per common share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
     "longName": "9954523 - Disclosure - Revenue recognition - Narrative (Details)",
     "shortName": "Revenue recognition - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
     "longName": "9954524 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)",
     "shortName": "Revenue recognition - Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-323",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
     "longName": "9954525 - Disclosure - Revenue recognition - Percentage of Product Sales (Details)",
     "shortName": "Revenue recognition - Percentage of Product Sales (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-329",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-329",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails",
     "longName": "9954526 - Disclosure - Revenue recognition - Contract Liabilities (Details)",
     "shortName": "Revenue recognition - Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails",
     "longName": "9954527 - Disclosure - Revenue recognition - Accounts Receivable (Details)",
     "shortName": "Revenue recognition - Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:BilledContractReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:BilledContractReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails",
     "longName": "9954528 - Disclosure - Leases - Components of Lease Expense (Details)",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "longName": "9954529 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://emergentbiosolutions.com/role/LeasesNarrativeDetails",
     "longName": "9954530 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "longName": "9954531 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails",
     "longName": "9954532 - Disclosure - Income taxes - Narrative (Details)",
     "shortName": "Income taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ebs:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ebs:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails",
     "longName": "9954533 - Disclosure - Income taxes - Components of the Provisions for Income Taxes (Details)",
     "shortName": "Income taxes - Components of the Provisions for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails",
     "longName": "9954534 - Disclosure - Income taxes - Net Deferred Tax Asset (Liability) (Details)",
     "shortName": "Income taxes - Net Deferred Tax Asset (Liability) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails",
     "longName": "9954535 - Disclosure - Income taxes - Reconciliation (Details)",
     "shortName": "Income taxes - Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails",
     "longName": "9954536 - Disclosure - Income taxes - Unrecognized Tax Benefits (Details)",
     "shortName": "Income taxes - Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails",
     "longName": "9954537 - Disclosure - Defined benefit and 401(k) savings plan - Swiss Plan Funded Status (Details)",
     "shortName": "Defined benefit and 401(k) savings plan - Swiss Plan Funded Status (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails",
     "longName": "9954538 - Disclosure - Defined benefit and 401(k) savings plan - Components of Net Periodic Pension Cost (Details)",
     "shortName": "Defined benefit and 401(k) savings plan - Components of Net Periodic Pension Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanNarrativeDetails",
     "longName": "9954539 - Disclosure - Defined benefit and 401(k) savings plan - Narrative (Details)",
     "shortName": "Defined benefit and 401(k) savings plan - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails",
     "longName": "9954540 - Disclosure - Defined benefit and 401(k) savings plan - Weighted Average Assumptions (Details)",
     "shortName": "Defined benefit and 401(k) savings plan - Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails",
     "longName": "9954541 - Disclosure - Defined benefit and 401(k) savings plan - Accumulated Other Comprehensive Loss Before Income Tax (Details)",
     "shortName": "Defined benefit and 401(k) savings plan - Accumulated Other Comprehensive Loss Before Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://emergentbiosolutions.com/role/PurchasecommitmentsDetails",
     "longName": "9954542 - Disclosure - Purchase commitments (Details)",
     "shortName": "Purchase commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails",
     "longName": "9954543 - Disclosure - Segment Information - Narrative (Details)",
     "shortName": "Segment Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R105": {
     "role": "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
     "longName": "9954544 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "shortName": "Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
     "longName": "9954545 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-381",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails",
     "longName": "9954546 - Disclosure - Segment Information - Revenue from External Customers by Geographic Areas (Details)",
     "shortName": "Segment Information - Revenue from External Customers by Geographic Areas (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-384",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails",
     "longName": "9954547 - Disclosure - Segment Information - Long-Lived Assets by Geographic Areas (Details)",
     "shortName": "Segment Information - Long-Lived Assets by Geographic Areas (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails",
     "longName": "9954548 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-402",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-407",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ebs_A2023EquityInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "A2023EquityInducementPlanMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Equity Inducement Plan",
        "label": "2023 Equity Inducement Plan [Member]",
        "documentation": "2023 Equity Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_AcceleratedExpansionOfFillFinishCapacityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "AcceleratedExpansionOfFillFinishCapacityMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Expansion Of Fill/Finish Capacity",
        "label": "Accelerated Expansion Of Fill/Finish Capacity [Member]",
        "documentation": "Accelerated Expansion Of Fill/Finish Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r945"
     ]
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable:",
        "label": "Accounts Receivable, after Allowance for Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Pension Plan",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r25",
      "r61",
      "r317",
      "r318",
      "r1053"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r290",
      "r766"
     ]
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r317",
      "r318",
      "r684",
      "r912",
      "r1053"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss), net",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r182",
      "r297",
      "r762",
      "r795",
      "r796"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "Total",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25",
      "r61",
      "r692",
      "r695",
      "r739",
      "r791",
      "r792",
      "r1053",
      "r1054",
      "r1055",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation Adjustments",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r61",
      "r317",
      "r318",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r1053"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r945",
      "r1157"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r804",
      "r1063",
      "r1064",
      "r1065",
      "r1133",
      "r1159"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ebs_AdjustedGrossMargin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "AdjustedGrossMargin",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total segment adjusted gross margin",
        "label": "Adjusted Gross Margin",
        "documentation": "Adjusted Gross Margin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r983",
      "r993",
      "r1019"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r986",
      "r996",
      "r1022"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r987",
      "r997",
      "r1014",
      "r1023",
      "r1027",
      "r1035"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r642"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance for expected credit losses",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r411",
      "r415",
      "r416",
      "r418",
      "r1152"
     ]
    },
    "ebs_AmendedCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "AmendedCreditAgreementMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Agreement Amendment",
        "label": "Amended Credit Agreement [Member]",
        "documentation": "Amended credit agreement dated October 15, 2018."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred financing costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r494",
      "r723",
      "r1058"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense",
        "negatedTerseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r94",
      "r98"
     ]
    },
    "ebs_AnthraxMCMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "AnthraxMCMMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anthrax MCM",
        "label": "Anthrax MCM [Member]",
        "documentation": "Anthrax MCM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive stock awards (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r294",
      "r333",
      "r379",
      "r394",
      "r400",
      "r412",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r466",
      "r468",
      "r470",
      "r471",
      "r682",
      "r686",
      "r712",
      "r757",
      "r838",
      "r945",
      "r960",
      "r1087",
      "r1088",
      "r1142"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Leases Supplemental Balance Sheets",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r301",
      "r333",
      "r412",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r466",
      "r468",
      "r470",
      "r471",
      "r682",
      "r686",
      "r712",
      "r945",
      "r1087",
      "r1088",
      "r1142"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ebs_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering",
        "label": "At-The-Market Offering [Member]",
        "documentation": "At-The-Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://emergentbiosolutions.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r979"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://emergentbiosolutions.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r979"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://emergentbiosolutions.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r979"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ebs_BARDAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "BARDAMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BARDA",
        "label": "BARDA [Member]",
        "documentation": "BARDA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r138"
     ]
    },
    "us-gaap_BankTimeDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BankTimeDepositsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time deposits",
        "label": "Bank Time Deposits [Member]",
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BaseRateMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BilledContractReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BilledContractReceivables",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Billed",
        "label": "Billed Contracts Receivable",
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ebs_BioservicesLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "BioservicesLeasesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Bioservices, Leases [Member]",
        "documentation": "Bioservices, Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_BioservicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "BioservicesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Bioservices revenues",
        "verboseLabel": "Bioservices",
        "label": "Bioservices [Member]",
        "documentation": "Bioservices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings, building improvements and leasehold improvements",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building improvements",
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of contingent obligations, net",
        "negatedTerseLabel": "Changes in fair value of contingent consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r1057"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r127",
      "r680"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, contingent consideration, liability, current",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r127"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, contingent consideration, liability, measurement input",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada",
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "country_CH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CH",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Switzerland",
        "label": "SWITZERLAND"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property, plant and equipment unpaid at period end",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r759",
      "r805",
      "r833",
      "r945",
      "r960",
      "r1050"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r288",
      "r907"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r194",
      "r329"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r194"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedging",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ebs_ChangeinContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ChangeinContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Contract With Customer, Liability [Roll Forward]",
        "label": "Change in Contract With Customer, Liability [Roll Forward]",
        "documentation": "Change in Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Funded Status of the Swiss Plan",
        "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]",
        "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ebs_ChimerixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ChimerixMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chimerix",
        "label": "Chimerix [Member]",
        "documentation": "Chimerix"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ebs_CommercialProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "CommercialProductMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Product sales",
        "label": "Commercial Product [Member]",
        "documentation": "Commercial Product"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_CommercialProductsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "CommercialProductsSegmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Products",
        "label": "Commercial Products Segment [Member]",
        "documentation": "Commercial Products Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$0.001 Par Value Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r949",
      "r950",
      "r952",
      "r953",
      "r954",
      "r957",
      "r1063",
      "r1064",
      "r1133",
      "r1155",
      "r1159"
     ]
    },
    "ebs_CommonStockNumberOfVotesPerCommonShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "CommonStockNumberOfVotesPerCommonShare",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting rights",
        "label": "Common Stock, Number Of Votes Per Common Share",
        "documentation": "Common Stock, Number Of Votes Per Common Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquityParenthetical",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r825"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r171",
      "r825",
      "r844",
      "r1159",
      "r1160"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 200.0 shares authorized, 57.8 and 55.7 shares issued; 52.2 and 50.1 shares outstanding, respectively.",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r761",
      "r945"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss), net of tax",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r312",
      "r314",
      "r321",
      "r753",
      "r770"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Software",
        "terseLabel": "Software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r1081",
      "r1082"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r146",
      "r147",
      "r408",
      "r890"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r146",
      "r147",
      "r408",
      "r797",
      "r890"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r146",
      "r147",
      "r408",
      "r890",
      "r1044"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r248"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r146",
      "r147",
      "r408"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r81",
      "r82",
      "r146",
      "r232",
      "r890"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r146",
      "r147",
      "r408",
      "r890"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r337",
      "r381",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r402",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r469",
      "r470",
      "r1048",
      "r1049",
      "r1087",
      "r1088"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r337",
      "r381",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r402",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r469",
      "r470",
      "r1048",
      "r1049",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation and consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r913"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction-in-progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_ContingentConsiderationObligationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ContingentConsiderationObligationsPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Contingent Consideration Obligations [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for contingent consideration obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type [Domain]",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Revenue Contract Liabilities",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, asset, after allowance for credit loss, noncurrent",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r516",
      "r535"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r515",
      "r535"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r515",
      "r535"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized in the period from amounts included in contract liability at the beginning of the period:",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "ebs_ContractsAndGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ContractsAndGrantsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contracts and grants",
        "label": "Contracts and Grants [Member]",
        "documentation": "Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate",
        "label": "Corporate, Non-Segment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r393",
      "r394",
      "r395",
      "r396",
      "r402",
      "r1068"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of goods and services sold",
        "verboseLabel": "Cost of goods and services sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r749"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSoldAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales or services:",
        "label": "Cost of Goods and Services Sold [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1061",
      "r1128"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1061"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r669",
      "r675",
      "r1061"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1061",
      "r1128"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r408"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ebs_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Two",
        "label": "Customer Two [Member]",
        "documentation": "Customer Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r331",
      "r472",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r488",
      "r495",
      "r496",
      "r498"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r166",
      "r167",
      "r234",
      "r236",
      "r337",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r724",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r1059"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentCovenantConsiderationThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DebtInstrumentCovenantConsiderationThreshold",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, covenant, consideration threshold",
        "label": "Debt Instrument, Covenant, Consideration Threshold",
        "documentation": "Debt Instrument, Covenant, Consideration Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, covenant, interest coverage ratio, minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "documentation": "Debt Instrument, Covenant, Minimum Consolidated Interest Coverage Ratio Required"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentCovenantLeverageRatioMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, covenant, leverage ratio, maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum allowed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forbearance fee",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, stated percentage",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r474"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r724",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r1059"
     ]
    },
    "ebs_DebtInstrumentMandatoryPrepaymentThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DebtInstrumentMandatoryPrepaymentThreshold",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mandatory prepayment threshold",
        "label": "Debt Instrument, Mandatory Prepayment Threshold",
        "documentation": "Debt Instrument, Mandatory Prepayment Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentMandatoryPrincipalPrepaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DebtInstrumentMandatoryPrincipalPrepaymentPercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mandatory principal prepayment percentage",
        "label": "Debt Instrument, Mandatory Principal Prepayment Percentage",
        "documentation": "Debt Instrument, Mandatory Principal Prepayment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r337",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r724",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r1059"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, periodic payment, principal",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior to August 15, 2023",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upon the Occurrence of a Change in Control",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, redemption price, percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r111",
      "r112",
      "r148",
      "r149",
      "r151",
      "r152",
      "r216",
      "r217",
      "r337",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r724",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r1059"
     ]
    },
    "ebs_DebtTermsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DebtTermsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, Terms [Axis]",
        "label": "Debt, Terms [Axis]",
        "documentation": "Debt, Terms"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtTermsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DebtTermsDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, Terms [Domain]",
        "label": "Debt, Terms [Domain]",
        "documentation": "Debt, Terms [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs, current, net",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized debt issuance costs",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r1061",
      "r1127"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r228",
      "r257",
      "r674",
      "r675",
      "r1061"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r235",
      "r663"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r758"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IRC 163(j) Interest Limitation",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ebs_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D",
        "label": "Deferred Tax Assets, Capitalized Research And Development",
        "documentation": "Deferred Tax Assets, Capitalized Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DeferredTaxAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Intangible Assets",
        "documentation": "Deferred Tax Assets, Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserves",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ebs_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "documentation": "Deferred Tax Assets, Operating Lease, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal losses carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign losses carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State losses carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D carryforward",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r1126"
     ]
    },
    "ebs_DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IRC 263A capitalized costs",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Capitalized Costs",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Capitalized Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r1125"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DeferredTaxLiabilitiesForeignWithholdingTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DeferredTaxLiabilitiesForeignWithholdingTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails",
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities, foreign withholding tax",
        "negatedTerseLabel": "Foreign Withholding Tax",
        "label": "Deferred Tax Liabilities, Foreign Withholding Tax",
        "documentation": "Deferred Tax Liabilities, Foreign Withholding Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNetDeferredTaxAssetLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1126"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total recognized in other comprehensive income (loss)",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r61",
      "r1094"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated benefit obligation, end of period",
        "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax",
        "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r575"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net actuarial gain",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r575"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanAccumulatedOtherComprehensiveLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prior service cost",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r575"
     ]
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual return on plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r935"
     ]
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial gain",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of loss",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r571",
      "r590",
      "r935",
      "r936"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of prior service credit",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r572",
      "r591",
      "r935",
      "r936"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected rate of return",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r594"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate of future compensation increases",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Projected benefit obligation, beginning of period",
        "periodEndLabel": "Projected benefit obligation, end of period",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net benefits received",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r597"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee contributions",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Benefit Obligation:",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Plan Assets:",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r561",
      "r593",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expected return on plan assets",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r570",
      "r589",
      "r935",
      "r936"
     ]
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value of plan assets, beginning of period",
        "periodEndLabel": "Fair value of plan assets, end of period",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r559",
      "r561",
      "r562",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency impact",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funded status, end of period",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r557",
      "r935"
     ]
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanInterestCost",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails",
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Cost",
        "verboseLabel": "Interest cost",
        "label": "Defined Benefit Plan, Interest Cost",
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r545",
      "r569",
      "r588",
      "r935",
      "r936"
     ]
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net periodic benefit cost",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r586",
      "r935",
      "r936"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net benefits received",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r1095"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency impact",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlements",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r573",
      "r592"
     ]
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanServiceCost",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanComponentsofNetPeriodicPensionCostDetails",
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service cost",
        "verboseLabel": "Service cost",
        "label": "Defined Benefit Plan, Service Cost",
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r568",
      "r587",
      "r935",
      "r936"
     ]
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanSwissPlanFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matching contributions made by employer",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r100"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r384"
     ]
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative asset."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative instruments",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r711",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r831",
      "r832",
      "r877",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r911",
      "r950",
      "r1156"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r817",
      "r830",
      "r831",
      "r832",
      "r834",
      "r835",
      "r836",
      "r837",
      "r839",
      "r840",
      "r841",
      "r842",
      "r853",
      "r854",
      "r855",
      "r856",
      "r859",
      "r860",
      "r861",
      "r862",
      "r877",
      "r878",
      "r880",
      "r882",
      "r948",
      "r950"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Asset Derivatives",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r136",
      "r180",
      "r302",
      "r911"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r137",
      "r139",
      "r140",
      "r815",
      "r817",
      "r830",
      "r831",
      "r832",
      "r834",
      "r835",
      "r836",
      "r837",
      "r839",
      "r840",
      "r841",
      "r842",
      "r853",
      "r854",
      "r855",
      "r856",
      "r859",
      "r860",
      "r861",
      "r862",
      "r877",
      "r878",
      "r880",
      "r882",
      "r911",
      "r948",
      "r950"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and hedging activities",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r690",
      "r697"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "documentation": "Disclosure of information about derivatives and hedging activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r134",
      "r139"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, notional amount",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1130",
      "r1131"
     ]
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives, Fair Value [Line Items]",
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative instruments and hedging activities",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r129",
      "r130",
      "r132",
      "r141",
      "r336"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impairment of Long-Lived Assets Held and Used by Asset",
        "label": "Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]",
        "documentation": "Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r211"
     ]
    },
    "ebs_DevelopmentBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DevelopmentBasedMilestonesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development-Based Milestones",
        "label": "Development-Based Milestones [Member]",
        "documentation": "Development-Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]",
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DivestitureDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DivestitureDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DivestitureDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r35"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal group, total consideration",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets disposed of in sale",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r156",
      "r162",
      "r206",
      "r209"
     ]
    },
    "ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments receivable",
        "label": "Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable",
        "documentation": "Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Divestiture"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestiture",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r205"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DivestitureDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938"
     ]
    },
    "ebs_DispositionOfBusinessTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "DispositionOfBusinessTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Disposition Of Business, Transaction Costs",
        "documentation": "Disposition Of Business, Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r979"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r979",
      "r1015"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income (loss) per common share - basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r359",
      "r361",
      "r366",
      "r367",
      "r368",
      "r372",
      "r700",
      "r701",
      "r754",
      "r771",
      "r915"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income (loss) per common share - diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r361",
      "r366",
      "r367",
      "r368",
      "r372",
      "r700",
      "r701",
      "r754",
      "r771",
      "r915"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Netincomelosspercommonshare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r369",
      "r370",
      "r371"
     ]
    },
    "ebs_EbangaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "EbangaMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ebanga",
        "label": "Ebanga [Member]",
        "documentation": "Ebanga"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation, percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ebs_EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation limitation",
        "label": "Effective Income Tax Rate Reconciliation, Compensation Limitation, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Compensation Limitation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GILTI, net",
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Amount",
        "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "ebs_EffectiveIncomeTaxRateReconciliationPermanentDifference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifference",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Difference",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_EffectiveIncomeTaxRateReconciliationTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Effective Income Tax Rate Reconciliation, Transaction Costs",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_EmergentBiosolutionsInc2006StockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "EmergentBiosolutionsInc2006StockIncentivePlanMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2006 Stock Incentive Plan",
        "label": "Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]",
        "documentation": "A share-based compensation plan adopted by the Company in 2006."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_EmployeeBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "EmployeeBenefitsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefits",
        "label": "Employee Benefits [Member]",
        "documentation": "Employee Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period expected to be recognized related to unvested equity awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Payments",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_EmployeeTransitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "EmployeeTransitionMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Transition",
        "label": "Employee Transition [Member]",
        "documentation": "Employee Transition"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r281",
      "r316",
      "r317",
      "r318",
      "r345",
      "r346",
      "r347",
      "r349",
      "r355",
      "r357",
      "r374",
      "r413",
      "r414",
      "r513",
      "r635",
      "r636",
      "r637",
      "r670",
      "r671",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r699",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r739",
      "r791",
      "r792",
      "r793",
      "r804",
      "r865"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r983",
      "r993",
      "r1019"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r980",
      "r990",
      "r1016"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ebs_ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of option as percentage of fair market value at grant date, minimum",
        "label": "Exercise Price Of Option As Percentage Of Fair Market Value At Grant Date, Minimum",
        "documentation": "Minimum exercise price of option as percentage of the fair market value of the shares underlying such option on the date of grant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r704",
      "r709"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r704",
      "r709"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r143",
      "r145",
      "r231"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r704",
      "r741",
      "r742",
      "r743",
      "r921",
      "r922",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r704",
      "r706",
      "r707",
      "r710"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Fairvaluemeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r561",
      "r566",
      "r704",
      "r741",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r561",
      "r566",
      "r704",
      "r742",
      "r921",
      "r922",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r704",
      "r743",
      "r921",
      "r922",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Contingent Consideration Liabilities Measured at Fair Value",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r145"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsReconciliationoftheContingentConsiderationLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of period",
        "periodEndLabel": "Balance, end of period",
        "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r741",
      "r742",
      "r743",
      "r921",
      "r922",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r710"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r135",
      "r142"
     ]
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalFundsEffectiveSwapRateMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Funds Rate",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r733",
      "r944"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r733",
      "r944"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Useful Life in Years",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r438"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-lived Intangible Assets Amortization Expense",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r437",
      "r438",
      "r439",
      "r750",
      "r751"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r751"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillFutureAmortizationExpenseDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r750"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible assets acquired",
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ebs_FiscalQuartersEndingAfter2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "FiscalQuartersEndingAfter2024Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Quarters Ending After 2024",
        "label": "Fiscal Quarters Ending After 2024 [Member]",
        "documentation": "Fiscal Quarters Ending After 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_FiscalQuartersEndingAfterMarch312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "FiscalQuartersEndingAfterMarch312024Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Quarters Ending After March 31, 2024",
        "label": "Fiscal Quarters Ending After March 31, 2024 [Member]",
        "documentation": "Fiscal Quarters Ending After March 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_FiscalQuartersEndingIn2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "FiscalQuartersEndingIn2024Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Quarters Ending in 2024",
        "label": "Fiscal Quarters Ending in 2024 [Member]",
        "documentation": "Fiscal Quarters Ending in 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_ForbearanceAgreementAndAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ForbearanceAgreementAndAmendmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forbearance Agreement And Amendment",
        "label": "Forbearance Agreement And Amendment [Member]",
        "documentation": "Forbearance Agreement And Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation and remeasurement of foreign currencies",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r987",
      "r997",
      "r1023"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r987",
      "r997",
      "r1023"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r987",
      "r997",
      "r1023"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r987",
      "r997",
      "r1023"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r987",
      "r997",
      "r1023"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and equipment",
        "verboseLabel": "Furniture and equipment",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnContractTermination",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Write off of contract asset and liability",
        "label": "Gain (Loss) on Contract Termination",
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/DivestitureDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of business",
        "negatedLabel": "Gain on sale of travel health business",
        "verboseLabel": "Gain (loss) on sale of business",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r1058"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r109",
      "r110"
     ]
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicConcentrationRiskMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Concentration Risk",
        "label": "Geographic Concentration Risk [Member]",
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r890"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, beginning balance",
        "periodEndLabel": "Goodwill, ending balance",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r422",
      "r752",
      "r919",
      "r945",
      "r1071",
      "r1078"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets and goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_GoodwillGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillGross",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, gross",
        "label": "Goodwill, Gross",
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r432",
      "r919"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, accumulated Impairment loss",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r432",
      "r919"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      },
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "negatedTerseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r423",
      "r429",
      "r434",
      "r919"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r919"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross margin",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r333",
      "r379",
      "r393",
      "r399",
      "r402",
      "r412",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r466",
      "r468",
      "r470",
      "r471",
      "r712",
      "r917",
      "r1087"
     ]
    },
    "ebs_GrossProfitPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "GrossProfitPercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross margin %",
        "label": "Gross Profit Percentage",
        "documentation": "Gross Profit Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r689"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r979"
     ]
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]",
        "label": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]",
        "documentation": "The name of the impaired assets to be held and used by the entity."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairedLongLivedAssetsHeldAndUsedByTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impaired Long-Lived Assets Held and Used by Type [Axis]",
        "label": "Impaired Long-Lived Assets Held and Used by Type [Axis]",
        "documentation": "This element represents the categories used to group impaired long-lived assets held and used by the type of asset."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairedLongLivedAssetsHeldAndUsedLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "label": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of long-lived assets",
        "terseLabel": "Total impairment of long-lived assets",
        "negatedTerseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r99",
      "r208"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Impairment Analysis",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings (losses) before taxes on income",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r318"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r676"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "terseLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r184",
      "r238",
      "r379",
      "r393",
      "r399",
      "r402",
      "r755",
      "r768",
      "r917"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r676"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DivestitureDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r35",
      "r45",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r210"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r446",
      "r849"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r849"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r125",
      "r226",
      "r227"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Incometaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r645",
      "r653",
      "r660",
      "r667",
      "r672",
      "r677",
      "r678",
      "r679",
      "r803"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IncometaxesComponentsoftheProvisionsforIncomeTaxesDetails",
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision (benefit)",
        "totalLabel": "Income tax (benefit) provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r258",
      "r356",
      "r357",
      "r387",
      "r651",
      "r673",
      "r772"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r647",
      "r648",
      "r660",
      "r661",
      "r666",
      "r668",
      "r799"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of foreign operations",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax at statutory rates",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill Impairments",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment of prior year taxes",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign withholding tax",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r70"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r1057"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes receivable and payable, net",
        "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "IncreaseDecreaseInLongTermIncentivePlanAccrual",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term incentive plan accrual",
        "label": "Increase (Decrease) in Long-Term Incentive Plan Accrual",
        "documentation": "Increase (Decrease) in Long-Term Incentive Plan Accrual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive securities-equity awards (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r368",
      "r603"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r987",
      "r997",
      "r1014",
      "r1023",
      "r1027",
      "r1035"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r1039"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r1039"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r1039"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r240",
      "r319",
      "r383",
      "r722",
      "r850",
      "r958",
      "r1158"
     ]
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense [Member]",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r327",
      "r328"
     ]
    },
    "us-gaap_InterestRateSwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateSwapMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDerivativeinstrumentsandhedgingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swaps",
        "label": "Interest Rate Swap [Member]",
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r955",
      "r956"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Inventoriesnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories, net",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r909"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://emergentbiosolutions.com/role/InventoriesnetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/InventoriesnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories, net",
        "totalLabel": "Total inventories, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r908",
      "r945"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, net",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r287",
      "r299",
      "r419",
      "r420",
      "r421",
      "r748",
      "r914"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials and supplies",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r1051"
     ]
    },
    "ebs_InventoryStepUp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "InventoryStepUp",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment inventory step-up provision",
        "label": "Inventory Step Up",
        "documentation": "Inventory Step Up"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r910"
     ]
    },
    "ebs_JansenPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "JansenPharmaceuticalsIncMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jansen Pharmaceuticals, Inc.",
        "label": "Jansen Pharmaceuticals, Inc. [Member]",
        "documentation": "Jansen Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandAndLandImprovementsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and improvements",
        "label": "Land and Land Improvements [Member]",
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r944"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails",
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease cost:",
        "terseLabel": "Operating leases:",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Lease Expense Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Litigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, remaining lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payments to be received",
        "label": "Lessor, Operating Lease, Payment to be Received",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, year five",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Five",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, year four",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, year one",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, after year five",
        "label": "Lessor, Operating Lease, Payment to be Received, after Year Five",
        "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, year three",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received, year two",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r333",
      "r412",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r466",
      "r468",
      "r470",
      "r471",
      "r683",
      "r686",
      "r687",
      "r712",
      "r824",
      "r916",
      "r960",
      "r1087",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r237",
      "r764",
      "r945",
      "r1060",
      "r1069",
      "r1135"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r286",
      "r333",
      "r412",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r466",
      "r468",
      "r470",
      "r471",
      "r683",
      "r686",
      "r687",
      "r712",
      "r945",
      "r1087",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding credit facility",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r236",
      "r1151"
     ]
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current borrowing capacity",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets by Geographic Areas",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "totalLabel": "Total debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r236",
      "r485",
      "r499",
      "r921",
      "r922",
      "r1151"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Current portion of long-term debt, net of debt issuance costs",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, fair value",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r337",
      "r1090"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r337",
      "r490"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r337",
      "r490"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r337",
      "r490"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r337",
      "r490"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtFutureDebtPaymentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r337",
      "r490"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, net of current portion",
        "verboseLabel": "Non-current portion of debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/PurchasecommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Materials purchased under commitment, amount",
        "label": "Long-Term Purchase Commitment, Amount",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r108"
     ]
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/PurchasecommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitment period",
        "label": "Long-Term Purchase Commitment, Period",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_MCMProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "MCMProductsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MCM Products",
        "label": "MCM Products [Member]",
        "documentation": "MCM Products"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_MCMProductsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "MCMProductsSegmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MCM Products",
        "label": "MCM Products Segment [Member]",
        "documentation": "MCM Products Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r928",
      "r1092",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_MajorCustomersPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MajorCustomersPolicyPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant customers and accounting receivable",
        "label": "Major Customers, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r81",
      "r198"
     ]
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contracts and grants revenue",
        "terseLabel": "Other",
        "label": "Segment Reconciling Items [Member]",
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r599",
      "r745",
      "r790",
      "r816",
      "r817",
      "r870",
      "r872",
      "r874",
      "r875",
      "r884",
      "r900",
      "r901",
      "r918",
      "r925",
      "r939",
      "r947",
      "r1089",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "ebs_MeasurementInputProbabilityOfPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "MeasurementInputProbabilityOfPaymentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of payment",
        "label": "Measurement Input, Probability Of Payment [Member]",
        "documentation": "Measurement Input, Probability Of Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_MedicalCountermeasuresMCMProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "MedicalCountermeasuresMCMProductMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MCM Product sales",
        "label": "Medical Countermeasures (MCM) Product [Member]",
        "documentation": "Medical Countermeasures (MCM) Product"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r599",
      "r745",
      "r790",
      "r816",
      "r817",
      "r870",
      "r872",
      "r874",
      "r875",
      "r884",
      "r900",
      "r901",
      "r918",
      "r925",
      "r939",
      "r947",
      "r1089",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market accounts",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ebs_NARCANMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "NARCANMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NARCAN\u00ae",
        "label": "NARCAN [Member]",
        "documentation": "NARCAN"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r928",
      "r1092",
      "r1153",
      "r1154"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://emergentbiosolutions.com/role/Natureofthebusinessandorganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nature of the business and organization",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r259"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      },
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r196",
      "r239",
      "r284",
      "r310",
      "r313",
      "r318",
      "r333",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r356",
      "r357",
      "r365",
      "r379",
      "r393",
      "r399",
      "r402",
      "r412",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r466",
      "r468",
      "r470",
      "r471",
      "r701",
      "r712",
      "r769",
      "r846",
      "r863",
      "r864",
      "r917",
      "r958",
      "r1087"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r987",
      "r997",
      "r1014",
      "r1023"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ebs_NonUnitedStatesGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "NonUnitedStatesGovernmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-USG",
        "label": "Non-United States Government [Member]",
        "documentation": "Non-United States Government"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-USG",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "ebs_NoncashPurchasesOfTreasuryStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "NoncashPurchasesOfTreasuryStock",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of treasury stock unpaid at period end",
        "label": "Noncash Purchases Of Treasury Stock",
        "documentation": "Noncash Purchases Of Treasury Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total long-lived assets, net",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "terseLabel": "Other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, current portion",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableOtherPayablesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Notes Payable, Other Payables [Member]",
        "documentation": "A written promise to pay a note to a third party."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_NumberOfCategoriesOfPublicHealthThreats": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "NumberOfCategoriesOfPublicHealthThreats",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of categories of public health threats",
        "label": "Number Of Categories Of Public Health Threats",
        "documentation": "Refers to the number of categories of public health threats."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ebs_NumberOfProductAndServiceCategories": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "NumberOfProductAndServiceCategories",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of product and service categories",
        "label": "Number Of Product And Service Categories",
        "documentation": "Number Of Product And Service Categories"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ebs_NumberOfRevenueGeneratingProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "NumberOfRevenueGeneratingProducts",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of revenue generating products",
        "label": "Number Of Revenue Generating Products",
        "documentation": "Refers to the number of revenue generating products."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_NumberOfShareBasedEmployeeCompensationPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "NumberOfShareBasedEmployeeCompensationPlans",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock based employee compensation plans",
        "label": "Number Of Share-Based Employee Compensation Plans",
        "documentation": "Represents the number of stock-based compensation plans the company maintains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income before reclassifications",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r61"
     ]
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r393",
      "r399",
      "r402",
      "r917"
     ]
    },
    "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Bioservices revenues",
        "terseLabel": "Revenue",
        "label": "Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax",
        "documentation": "Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r738"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesFutureMinimumLeasePaymentsDetails",
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r944"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r944"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ebs_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, not subject to expiration",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_OperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, subject to expiration",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r402"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ebs_OtherCommercialProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "OtherCommercialProductsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commercial products",
        "label": "Other Commercial Products [Member]",
        "documentation": "Other Commercial Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation adjustments, net",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r24",
      "r229"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pretax",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r24",
      "r229"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on hedging activities",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification adjustment for losses (gains) on hedging activities",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate swaps gain (loss)",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r306",
      "r308"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss), net of tax",
        "terseLabel": "Other comprehensive income, net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r24",
      "r229",
      "r311",
      "r314"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification adjustment for gains on pension benefit obligation",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax",
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r182",
      "r309",
      "r574"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax Benefit (Expense)",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r24",
      "r229"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r142"
     ]
    },
    "ebs_OtherGeographicalAreaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "OtherGeographicalAreaMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Geographical Area [Member]",
        "documentation": "Other Geographical Area"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r945"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ebs_OtherLongTermDebtFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "OtherLongTermDebtFacilityMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Long Term Debt Facility [Member]",
        "documentation": "Other Long Term Debt Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Other Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ebs_OtherProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "OtherProductsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Products",
        "label": "Other Products [Member]",
        "documentation": "Refers to product sales from other products."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r985",
      "r995",
      "r1021"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r988",
      "r998",
      "r1024"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r988",
      "r998",
      "r1024"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contingent consideration payments",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Milestone payment from prior asset acquisition",
        "label": "Payment for Contingent Consideration Liability, Investing Activities",
        "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of treasury stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r1056"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes paid for stock-based compensation activity",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Royalty settlement payment",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Asset acquisitions",
        "label": "Payments to Acquire Other Productive Assets",
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Defined benefit and 401(k) savings plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r558",
      "r560",
      "r566",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r595",
      "r596",
      "r598",
      "r935"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementPlansPensionsPolicy",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension plans",
        "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r28",
      "r115"
     ]
    },
    "us-gaap_PensionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionExpense",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension expense",
        "label": "Pension Cost (Reversal of Cost)",
        "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ebs_PerformanceSharesAndRestrictedStockUnitsRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "PerformanceSharesAndRestrictedStockUnitsRSUsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares And Restricted Stock Units (RSUs)",
        "label": "Performance Shares And Restricted Stock Units (RSUs) [Member]",
        "documentation": "Performance Shares And Restricted Stock Units (RSUs)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Units",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r501"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r825"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r501"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r825",
      "r844",
      "r1159",
      "r1160"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r760",
      "r945"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of travel health business, net",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from at-the-market sale of stock, net of commissions and expenses",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock-based compensation activity",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r33"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from revolving credit facility",
        "label": "Proceeds from Long-Term Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received from option exercises",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r33"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Concentration Risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Product sales, net",
        "verboseLabel": "Products",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "verboseLabel": "Products and Services [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r749",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r904",
      "r926",
      "r946",
      "r1046",
      "r1085",
      "r1086",
      "r1092",
      "r1153"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r749",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r904",
      "r926",
      "r946",
      "r1046",
      "r1085",
      "r1086",
      "r1092",
      "r1153"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r249",
      "r255",
      "r256"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r289",
      "r767"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant and Equipment Income Statement Disclosures [Abstract]",
        "label": "Property Plant and Equipment Income Statement Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r756",
      "r767",
      "r945"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Net [Abstract]",
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r249",
      "r255",
      "r765"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property, Plant and Equipment Useful Lives",
        "verboseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for expected credit losses",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r417"
     ]
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/PurchasecommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total purchase commitment",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/PurchasecommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitment, year one",
        "label": "Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationFiscalYearMaturityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, Fiscal Year Maturity [Abstract]",
        "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r558",
      "r599",
      "r629",
      "r630",
      "r631",
      "r744",
      "r745",
      "r790",
      "r816",
      "r817",
      "r870",
      "r872",
      "r874",
      "r875",
      "r884",
      "r900",
      "r901",
      "r918",
      "r925",
      "r939",
      "r947",
      "r950",
      "r1083",
      "r1089",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r558",
      "r599",
      "r629",
      "r630",
      "r631",
      "r744",
      "r745",
      "r790",
      "r816",
      "r817",
      "r870",
      "r872",
      "r874",
      "r875",
      "r884",
      "r900",
      "r901",
      "r918",
      "r925",
      "r939",
      "r947",
      "r950",
      "r1083",
      "r1089",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts reclassified from accumulated other comprehensive income (loss)",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r61"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r980",
      "r990",
      "r1016"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on convertible senior notes",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on revolving credit facility",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r1059"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r801"
     ]
    },
    "us-gaap_RepaymentsOfMediumTermNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfMediumTermNotes",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on term loan facility",
        "label": "Repayments of Medium-term Notes",
        "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ReportingUnitAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Axis]",
        "label": "Reporting Unit [Axis]",
        "documentation": "Information by reporting unit."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r919"
     ]
    },
    "us-gaap_ReportingUnitDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Domain]",
        "label": "Reporting Unit [Domain]",
        "documentation": "Level of reporting at which goodwill is tested for impairment."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r919"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "negatedTerseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r644",
      "r1150"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ebs_ReservationOfManufacturingCapacityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ReservationOfManufacturingCapacityMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reservation Of Manufacturing Capacity",
        "label": "Reservation Of Manufacturing Capacity [Member]",
        "documentation": "Reservation Of Manufacturing Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r981",
      "r991",
      "r1017"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r982",
      "r992",
      "r1018"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r989",
      "r999",
      "r1025"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueMeasurementsRecurringandNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Longlivedassetimpairmentandrestructuringcharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived asset impairment and restructuring charges",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r445",
      "r448",
      "r454"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, number of positions eliminated",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Accruals",
        "negatedNetLabel": "Segment restructuring costs",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r449",
      "r451",
      "r1084"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r451",
      "r452"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r451",
      "r452",
      "r453"
     ]
    },
    "ebs_RestructuringPlanAugust2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "RestructuringPlanAugust2023Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2023 Restructuring Plan",
        "label": "Restructuring Plan August 2023 [Member]",
        "documentation": "Restructuring Plan August 2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RestructuringPlanJanuary2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "RestructuringPlanJanuary2023Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2023 Restructuring Plan",
        "label": "Restructuring Plan January 2023 [Member]",
        "documentation": "Restructuring Plan January 2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r450"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings (accumulated deficit)",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r218",
      "r763",
      "r794",
      "r796",
      "r802",
      "r826",
      "r945"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r345",
      "r346",
      "r347",
      "r349",
      "r355",
      "r357",
      "r413",
      "r414",
      "r635",
      "r636",
      "r637",
      "r670",
      "r671",
      "r691",
      "r693",
      "r694",
      "r696",
      "r699",
      "r791",
      "r793",
      "r804",
      "r1159"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales",
        "verboseLabel": "Revenue",
        "netLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r392",
      "r397",
      "r398",
      "r404",
      "r406",
      "r408",
      "r533",
      "r534",
      "r749"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r1042"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r902"
     ]
    },
    "ebs_RevenueFromContractWithCustomerTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "RevenueFromContractWithCustomerTermOfContract",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of contract",
        "label": "Revenue From Contract With Customer, Term Of Contract",
        "documentation": "Revenue From Contract With Customer, Term Of Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Revenuerecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r537"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Geographic Areas",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenues",
        "terseLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r333",
      "r380",
      "r381",
      "r392",
      "r397",
      "r398",
      "r404",
      "r406",
      "r408",
      "r412",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r466",
      "r468",
      "r470",
      "r471",
      "r712",
      "r755",
      "r1087"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ebs_SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets allowance",
        "label": "SEC Schedule, 12-09, Allowance, Prepaid Expenses And Other Current Assets [Member]",
        "documentation": "A valuation allowance relating to prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SOFREURIBOROrCDORMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SOFREURIBOROrCDORMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR, EURIBOR, Or CDOR",
        "label": "SOFR, EURIBOR, Or CDOR [Member]",
        "documentation": "SOFR, EURIBOR, or CDOR"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SOFRSONIAAndEurocurrencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SOFRSONIAAndEurocurrencyMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR, SONIA, and Eurocurrency",
        "label": "SOFR, SONIA And Eurocurrency [Member]",
        "documentation": "SOFR, SONIA And Eurocurrency"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SaleOfStockAggregateOfferingAmountMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SaleOfStockAggregateOfferingAmountMaximum",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross sales price",
        "label": "Sale Of Stock, Aggregate Offering Amount, Maximum",
        "documentation": "Sale Of Stock, Aggregate Offering Amount, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SaleOfStockAmountRemainingAvailableForSaleOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SaleOfStockAmountRemainingAvailableForSaleOfShares",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, amount remaining available for sale of shares",
        "label": "Sale Of Stock, Amount Remaining Available For Sale Of Shares",
        "documentation": "Sale Of Stock, Amount Remaining Available For Sale Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction, gross",
        "label": "Sale Of Stock, Consideration Received On Transaction, Gross",
        "documentation": "Sale Of Stock, Consideration Received On Transaction, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SalesBasedMilestonesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestitureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Based Milestones",
        "label": "Sales-Based Milestones [Member]",
        "documentation": "Sales-Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueProductLineMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Revenue, Product Line",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ebs_ScheduleOfAccountsReceivableNetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ScheduleOfAccountsReceivableNetTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net",
        "label": "Schedule Of Accounts Receivable, Net [Table Text Block]",
        "documentation": "Schedule of Accounts Receivable, Net [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r1136",
      "r1137"
     ]
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive Loss Before Income Tax",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Assumptions",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Components of the Provisions for Income Taxes Attributable to Operations",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Future Debt Payments of Long-Term Indebtedness",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r111",
      "r112",
      "r148",
      "r149",
      "r151",
      "r152",
      "r216",
      "r217",
      "r921",
      "r923",
      "r1062"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Gain (Loss)",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r139",
      "r689"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsandhedgingactivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Income Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits Activity",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r919"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impaired Long-Lived Assets Held and Used [Table]",
        "label": "Schedule of Impaired Long-Lived Assets Held and Used [Table]",
        "documentation": "For a long-lived asset to be held and used by an entity, the table may include a description of the impaired long-lived asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r177",
      "r178",
      "r179"
     ]
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Definedbenefitand401ksavingsplanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Net Periodic Pension Cost",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentUsefulLivesDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r451",
      "r452",
      "r453"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r105",
      "r106"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r107"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r183"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r602",
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Award Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r117"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Award, Valuation Assumptions, Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Income Before the Provision for Income Taxes",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1124"
     ]
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r344"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r81",
      "r82",
      "r146",
      "r232"
     ]
    },
    "ebs_SecuredOvernightFinancingRateSOFRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r408",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r447",
      "r453",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r919",
      "r1046",
      "r1153"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r406",
      "r407",
      "r809",
      "r812",
      "r814",
      "r871",
      "r873",
      "r876",
      "r885",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r905",
      "r927",
      "r950",
      "r1092",
      "r1153"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r391",
      "r396",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciling items:",
        "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "negatedTerseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SeniorUnsecuredNotesDueAugust2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SeniorUnsecuredNotesDueAugust2028Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtComponentsofLongtermIndebtednessDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.875% Senior Unsecured Notes due 2028",
        "label": "Senior Unsecured Notes Due August 2028 [Member]",
        "documentation": "Senior Unsecured Notes Due August 2028"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ebs_ServicesSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ServicesSegmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "label": "Services Segment [Member]",
        "documentation": "Services Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Restricted/performance stock units forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted/performance stock units forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted/performance stock units granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted/performance stock units granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restricted/performance stock units outstanding, beginning of period (in shares)",
        "periodEndLabel": "Restricted/performance stock units outstanding, end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restricted/performance stock units outstanding, beginning of period (in dollars per share)",
        "periodEndLabel": "Restricted/performance stock units outstanding, end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payout percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payout Percentage",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payout Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted/performance stock units vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted/performance stock units vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r602",
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized for issuance under the plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for future awards (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Stock options exercisable, end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable, end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Stock options forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Stock options outstanding, beginning of period (in shares)",
        "periodEndLabel": "Stock options outstanding, end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Stock options outstanding, beginning of period (in dollars per share)",
        "periodEndLabel": "Stock options outstanding, end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Target payout percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of awards vested",
        "label": "Share based Compensation Arrangement Share based Payment Award, Awards Vested in Period, Fair Value",
        "documentation": "Fair value of share-based compensation awards vested. Includes options, share units, stock appreciation rights, and restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting for share-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r607",
      "r626",
      "r627",
      "r628",
      "r629",
      "r632",
      "r638",
      "r639",
      "r640",
      "r641"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted/performance stock units outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesAccountingforSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual life of awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected average life of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of significant accounting policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r330"
     ]
    },
    "us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Purchasecommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitments",
        "label": "Purchase and Supply Commitment, Excluding Long-Term Commitment [Text Block]",
        "documentation": "The entire disclosure for arrangements in which the entity has agreed to expend funds to procure goods or service from one or more suppliers, or to commit resources to supply goods or services to one or more customers. May include identification of the goods or services to be purchased, the goods or services to be furnished, identity of the buyer or seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, effects on pricing (such as penalties) of failing to deliver minimum quantities required to be furnished, cancellation rights, and termination provisions."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r212"
     ]
    },
    "ebs_SmallpoxMCMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "SmallpoxMCMMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPercentageofProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Smallpox MCM",
        "label": "Smallpox MCM [Member]",
        "documentation": "Smallpox MCM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillSummaryChangesinGoodwillDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r408",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r441",
      "r447",
      "r453",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r919",
      "r1046",
      "r1153"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r58",
      "r281",
      "r316",
      "r317",
      "r318",
      "r345",
      "r346",
      "r347",
      "r349",
      "r355",
      "r357",
      "r374",
      "r413",
      "r414",
      "r513",
      "r635",
      "r636",
      "r637",
      "r670",
      "r671",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r699",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r739",
      "r791",
      "r792",
      "r793",
      "r804",
      "r865"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r271",
      "r406",
      "r407",
      "r809",
      "r812",
      "r814",
      "r871",
      "r873",
      "r876",
      "r885",
      "r889",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r905",
      "r927",
      "r950",
      "r1092",
      "r1153"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r374",
      "r749",
      "r798",
      "r806",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r825",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r834",
      "r835",
      "r836",
      "r837",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r845",
      "r847",
      "r848",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r865",
      "r951"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r374",
      "r749",
      "r798",
      "r806",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r825",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r834",
      "r835",
      "r836",
      "r837",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r845",
      "r847",
      "r848",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r865",
      "r951"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r984",
      "r994",
      "r1020"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market sale of stock, net of commissions and expenses (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r170",
      "r171",
      "r218",
      "r800",
      "r865",
      "r886"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation activity (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r170",
      "r171",
      "r218"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityStockOptionsRestrictedStockUnitsandPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Stock options exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r170",
      "r171",
      "r218",
      "r613"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market sale of stock, net of commissions and expenses",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r170",
      "r171",
      "r218",
      "r804",
      "r865",
      "r886",
      "r959"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation activity",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r170",
      "r171",
      "r218"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchases of stock (in shares)",
        "terseLabel": "Shares of common stock repurchased (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r170",
      "r171",
      "r218",
      "r801",
      "r865",
      "r887"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchases of common stock",
        "terseLabel": "Stock repurchased during period, value",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r170",
      "r171",
      "r218",
      "r804",
      "r865",
      "r887",
      "r959"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r174",
      "r175",
      "r199",
      "r827",
      "r844",
      "r866",
      "r867",
      "r945",
      "r960",
      "r1060",
      "r1069",
      "r1135",
      "r1159"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation and stockholders' equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r332",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r698",
      "r868",
      "r869",
      "r888"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r740"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r740"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r740"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ebs_TermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "TermLoanFacilityMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "documentation": "Term loan dated December 2013."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_TravelHealthBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "TravelHealthBusinessMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DivestitureDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Travel Health Business",
        "label": "Travel Health Business [Member]",
        "documentation": "Travel Health Business"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/ConsolidatedStatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "negatedPeriodStartLabel": "Beginning balance (in shares)",
        "negatedPeriodEndLabel": "Ending balance (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock, at cost, 5.6 and 5.6 common shares, respectively",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r113",
      "r114"
     ]
    },
    "ebs_TreasuryStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "TreasuryStockPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock",
        "label": "Treasury Stock [Policy Text Block]",
        "documentation": "Treasury Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r451",
      "r452"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationLongLivedAssetsbyGeographicAreasDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationRevenuefromExternalCustomersbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_UnallocatedResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "UnallocatedResearchAndDevelopmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LonglivedassetimpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D",
        "label": "Unallocated Research And Development [Member]",
        "documentation": "Unallocated Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnbilledContractsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnbilledContractsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled",
        "label": "Unbilled Contracts Receivable",
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ebs_UnitedStatesGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "UnitedStatesGovernmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USG",
        "label": "United States Government [Member]",
        "documentation": "United States Government [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails",
      "http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits",
        "periodStartLabel": "Gross unrecognized tax benefits, beginning of period",
        "periodEndLabel": "Gross unrecognized tax benefits, end of period",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r655"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increases (decreases) for tax positions for prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income tax penalties and interest",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and penalties expense (benefit)",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases for tax positions for current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases (decreases) for tax positions for prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ebs_UnrecognizedTaxBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "UnrecognizedTaxBenefitsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, noncurrent",
        "label": "Unrecognized Tax Benefits, Noncurrent",
        "documentation": "The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns, and classified as a non-current liability as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails",
      "http://emergentbiosolutions.com/role/IncometaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations",
        "negatedTerseLabel": "Lapse of statute of limitations",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ebs_UntilMarch312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "UntilMarch312024Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Until March 31, 2024",
        "label": "Until March 31, 2024 [Member]",
        "documentation": "Until March 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r246",
      "r247",
      "r250",
      "r251"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance increase",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ebs_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance increase, including CTA component",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Including Cumulative Translation Adjustment, Amount",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Including Cumulative Translation Adjustment, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r343"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charged to Costs and Expenses",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r342",
      "r343"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r342",
      "r343"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted cash flow",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3SignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for potential dilutive effect of dilutive securities (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average number of shares-diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r368"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average number of shares-basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r368"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/ConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetincomelosspercommonshareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares outstanding",
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "b",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a),(b),(c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i-k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481097/715-30-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "80",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "b",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)(b)(c)",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a),(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "45",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815/tableOfContent"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "b.",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>183
<FILENAME>0001367644-24-000033-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001367644-24-000033-xbrl.zip
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M^^NVP2<R*]Y%:-IYS')&:"UZ=!_V!I]\V+A\?EI301HYY4 BKE1B&*SO4MC
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MBQH@+ D'3;#T+84*/=7O0N:9DA+,A]S#R6MC(TCS7!E>GUNUXG#O(5:O\4D
M?E.. 7%' ]<?#4A;3,I4_M8/OF)H?")KN%"]7W%\<;LOPN'_*A3HQ6L"L$.Q
M)C;^>OLD?Q9/R?]$_3A>+@[_==GB\%?.B>J<-OND;/@AFM"^:6BE:I+D1P&"
MAP@G\H,:CA8KU@M6,#3VI_/EYW<%G-7S<,4CV*O9CV"?E3HO1["?F?_FPP3>
MX;  \:I!?(/C:=3@C(C GW/! LSO!'.'/V F/.B./!H47T![;=".I6><Q$%J
M.0!./ @KQ!;ZF!1#<SS0(8[YJ'+TI4]-M@N,K!HCS2[W/)P[,X$1*S0C9U8D
M6LF;M<V?3#X**.H<C>$2H%R0$7=/TU\"X>\\KU'+4/_&%"N,2(L):Q,3L:/-
MV0:8G!RL1)RQNTR5T9JTM@TV(M_HH3N:-L$U!^TZ*7[)?)7_==N^/KGXWFR?
MKMOT6VIA.OO_EH1PQ&!FU'Q4C LJL7,=>_SL=W*H,&R&0_.XFF$PP %M8QHZ
MB</!NIP[R5C<*+0 ;#@U[!9;"=!@<&1JB?MLY/$1@[NH5_@H] #:./=M7J'9
M%PH0%?,(7N-AU+%]+^_S"*94@:5TH_6=)9Q90ABVN.G*,?''(0Z)ER?_E/NF
M)T91XXR%Y@!D,/UR-LDLT [W[6OX@'DP+X6SUPZ\!;KA9M5<0 ZLR;K9<:ZG
M_3RH(E1!<QXC3$??VM20^WD=Y8?V\Z78/7H>X1HNAZ)&P^WAL2B<L)Y2#>*(
M9GG@'$@_<,W[D;!Y-..W$X^_O(H2;3OQ-=M;G:O.U@XL$>>!QI9**/N",#D@
MV/- 1_"'B:BO&->4L<=IU.5>B>:,E@J:7 5-TM!/.4KTR@V$G$#:(A<TM5&@
MY#VEODE3AC F M\X>P)4@UTA'.:-C3N?T^).<5QU)^P.A8_)-\;VV=W5:6<G
MCG^*> ( 124_M&DUTM&U&;A(1O6#B([.))T%.*=\*() 3G$-1VI<+!#PB0"T
M]"G34;;/Y]A1/W+2&]O^R8_F#JX#-WC7H2/L<WZ/*2_1Y,0D /P$^/;5_J<@
M4HQ3?2=9 PYD4&0.30V)\Z*CIU( >D4R38D#,/]B86!AF\U!)!+N*IV*&JVM
MBBQ0+-C UV.UAT0CGE];CAIG?;("GZ>>X?-^2Z>? 1Y-D[A0/SJ!+;*EI+UX
MJI[0@H=ZKDW+N$GZTVUOM4Y;6SNE%+? E5C\@?F!'/2LUE!2A2<XIA=5?3!B
M/:H^\27?@7\;U?^L&#CL*@(.Z.-#',&!E22*<_WD2\*$'\=^P(=R//0#M]V1
M+&1Q+2H\07',;=N/8-BU7=>BK[GM<]G;)A@ TS,97> 8 VZ/Y*6N-39ZB"S@
M,+VTRI&(>]&;2"^)KW!-P*9/C++#1X&4N WDE+4CFC^=3+K&5[%'YL5HH;'0
M^+YH!B? P0Z1FP9&.**RT*FQTB#OU5!I'+M=JZILE8A31C/G+<F-Q_CTXM"N
MXM ZZJ2 -E8"RO7#(8DJVTYPYXZDIQS3^OD3Z(!P#"PD;S@@0-2! /%81GPE
MMXBI@>J -#@K:K;XR&8FCV+<5 TPK0@GJJ3D%<3&41:[CGH3 A//D8"C@!//
MN0>D,B0]!8X)TFB*Y*:(K790K<13S.74=@??*O<I*4^>WF2DNH4N)8,L='FR
M4N]_Q!-H 6X?N')=T1)A][00.D*7;&S4#TG/J,XX/1%8XP.$?/(4O5IQ,H#2
MO'"UE' !I])[ !7$!\[UZZ^H2D?#\80'XFT*>Z44.   ^VD  (*4WTUMLSA<
M*SE<K]'03$2]3$WU*E'3WT.@XQHQXWKM%7("VHC/&98Z62^3QF&]4B](8_VD
M\3N7Z3T\4#A3*"?1ANRW /,[P"R)E21!O2[/(>HDY@"^IR1:-T@."5JP*=Z?
MW!;Q[?W(/B25$K!&?>^B5E-X^^/ !2VV[#XZI*)T?6$),(53%J5RWP)3)PV/
MN/IW)K# V.^&7M^X<,Q**6V$Q\=T"(I@+[8+HQ*ZZUY/V>CX5]/' :D8VNYP
MT^,!VN&H/-VD0R,H.]K<'[EHMFY3D+[ZM=FY:=/'VM<=%(:46FR.HP<O)XG4
M,X'G)(]4<":U FNQ@0&2ACY M55X)+])_@(/"UE*[Z I[OPIX,I&5FK(-MZI
M7G1+#[B6R#M3"(U>30"($:#4$&"<Q<EZGUFMU,7*FLJ^7DTQJ6=9<Q:/,9Y)
M>JCXSM<[Z['212?A$0S%(;.X4@G0YXD6(I:L31QY.!\1%2-IUPZ^^G LX+CC
M,:I5IU1O,L2DXH!'&U1FHQGV0] T&M624DAQ_;.5YT0[F;T_C_\K%*B7I,^5
M$EV%BK"2$Y8VR1"+?T<7@<1=O4&$DQ)#!C,'@J/ B/4'<A, '4H$S\M.FA5,
M731"O=Q0\?7'&Q<8!:=UP#%+<JL8F4_2RS/XC.TEYN?MH'C PTL9,B/7'IMV
MU']&D*].]IOA(4XUFA<-),4ID_%S9+3$+E[*6PT>W5CTJ.Y&:'!2]()6X@O;
MB$'T_>*W8Z.V(]VJL1I,*Y16)OT=B[+'@3 '27(0J8+*H\2?1MBE3:2=D\ ?
M=Z-T1U]@BQ[,_%!P\4UWQ*6SIXX+B!Q74EYB 87%>P(3]F).^B7UW;]"!$@P
M3A:7N"9M6[E2T7*#J\H1#D8V\X<,W6I@HH-)QR3V@13"'CP"K6J<9!7")N6E
MDO<#_=P3Q,F2"$@ND^:,S6L'R.KQMY$T*+[*^^-EF:[T&\3 4D_V ]<#S;X4
M"Y!(G<9])"N*M/2T-1J_5[UR4D+)F%OL%XQ<#I%U-(&>!I$0PL@4(Z0R\EN3
M]0O8A"=;PH\X062 J/63&]Q&\\T- QDLE*E@CZ!1X0H2:[K+>]AMG)PDC1K)
MS;T*G,>8'$AG<8$+X#&CT#6S:0)K3+&4OX57QL0'WTA7)J;0RQ@>\ $GE9TV
M4=Y.(AJ#I)CSEEPSG93V8OJ.+O+UY:F >96L:P>;L< LP.D)<]]WR+*MU;X:
M\63 ;--],AP)F6N]@,4H3\M\3CA->%ITS2Q93_Z59^D6SZ0_^@J1*3FOS#.L
M%*A<!2H7ULI>&5 YT>P^-:WR'0,J%YQ/J;*TF>V[R6[@+D5DH]#S4=G!!4R0
M7^Q[F)_MXQL>[X=2%RT(;L6\8Y 2'3%!)9<FC2FG<RW2W ,IE-KO,%#V,/-"
MQOE)[XL?FI 0I5D]IZ"3F##C93+5F$)^(37%Y)0H2P)N:($.!T_#&K,4?:O\
MA="GSM%R&27,5^"R!F#$8+%C/$J@[:$O.W;.SX^I@MJ*-8Y)@AE-(U0S+))+
M$VM#&2^E9\D*?]W;FX@8"\EU(PTZ\9DE3KCI4'GJ-U0IT6Q2*C:B3(6;94 P
M]7T)@-IW T'ID5.V3NV(D/M*8L71Y,+]E!M<N=MCIUUQ6M]]6M-V$1ZW.(^E
M2X8C[0(.6NR\G67IT4.(=B?L/)5OD2(.R<%5<H0_8<^E[%Z)WM>H9#>ADLD,
M'$F8*G \09FO/+*QOS]%><E,4-I0="JGEPK?S0++9%X0O&_( %),\3JE4*5L
M<>54B-YDLA'K"LK5PG7$K,Z+PF'P!,<!G,PW%%-U2,I>+$[,>T],E-?E*S<"
M6=E3N8$JW4X1GY#7UO9F6> J=-N8/S9RCDG]BC=<8]O\]>&O6AOHV=;:S!WW
MO&Z;>ZE"L8R#G5G/%\XUJTLE1\>*_&OE/J,79N?&TP*6F*&;^83H3<$@*5S+
M#[N+QL[),L_9D1<0@T-A8JM*4(1D%&@<&7*4HBXC!:\.R-.+;VDS/B(*=4;!
M,<K"=P-,_2<CN,>PN&=VC8&/LTO+F"%!*GMDR:Y]U%?.87TQ,RJI(F!P5@R;
M@]5/@91ABK.1_AVY+TH%ZUH5ZYH:?<GF2QF?!](X108$3&L8^F9H,V]^Z*KH
MF_ <^/N3T-*^;\*BW0/6#KAX^!2&RQG&D3DOHVL B%0,T>/L2RN0/ +,\,53
M>0A/'40)3\:-\L:1 ]1F76Z7P.!WD?B5CX$&5*1/!#R$/ :UND'/@DL0'U%0
M.1V.GEP$W@2*5ZVNUD"VZP.V]D(ASNDIA0*V1BXV5^N*V!@E70 -H2_)# /F
M<)<ZU?\9-0!#7^PCY_?P>,QR?LM@X->'&!>ZP@L83BR5W[%\\9&*Q))Z,5!_
M0ZRN]%U3>L())2H#/-(L%)7X)97];8@ ;NVA.]!7OGG4N>'NZ(%Q)GTZ]PC/
M,WKWR"%>G-KWG]I4[E/6<^PW I[;J"]S;]88=HN:!G4I PJXT8S&A,O[,]?E
M&%T[P"Y2?4+JU=H^!0BQU0C5UDA^77:=J? ?I6V=MN)815)M/"O(43^J[,9A
MDR2.5K"-]Y,Y(B"5T9XN4E9Z7P]^DZ4/JI*!R[JBZ930VE0)>_TH539)Q99]
M; E*9.&X9=--UV3&U4<EE8R:Y*!BTJ),892)CO+WJ/H];F174,,*J '0?\D\
M *]*YZRK*ECXJ2:+\^JEB0#\3_Z<^A:LN4GG$:>+*^"I39!4J4!3%-G'UA8Q
MGT"229)-15Q>(Y]@T,J8$Z*14)/+W9VH')Q(4P#;0<B4 )]+@F%.*A>Y')V!
M=()R.4Y&WMZZ.+WXKZV=.>G3JDL%J,/#<"@#ME%&0[VQ5SF,>5>2%!"1JXK.
MI(]C*.N),?.A"R?&'$AV%UM:0PROXJYA,S<>+Y]%6OE-2BO?OO'.;F1EWI0K
M6U5+ ^4\9\DSBA!/>8^Z[VQOG;JG  %4W.S$:?=W5\BB2SC<0RQ? M4?VPNI
MJDE\?TN-+"REFOJ4C#:SDA8_^-"KT+21RZ@74B@[:H]ER;R2A!516P#6!W-#
M]:LDEN1.M-"0Q'8H,[&9DXZ )P]2]:A$((]N:$<)W9-I)H"WZ0<W/E'P<P&%
ML@A^S@U^9LG9YP5>2_#IS_"!Y/%.EM QMJ?4:W3\T+0EF9L;M?(2JAD#9AWL
MK*LB=F6G06M-(U/@18(.]8/E(WS8W"/N3/>*)R@=K7ONATD'=&N'L7*YOS<Q
MODL-*I_RABWKM0)EY<)1NK B<MQ^I Z[WF@ B* \K*A+(SXZW?"Y$X34I$K.
M,!C@B2&1E7=:S-8=9@L3FTI@T9;G.GV0[:I16)RM%E([A1Y_C%W: >*J,#;>
M;VQ$EIY 0T$=8+3\\5@GY9,T!YN9 PJDN0&7S2MMK&JDDDSJ. @:^A KT3PV
M$A8VN2N.Q7OJXGW%AB1"D$?CN,D(_'$J!3KT9<#(XWU8@6-LP[: &\L^],41
M>4?SCR08IV"[\[IDG++S2O.$UU1*C/3]OR+ +J9RXJ?<?.F'+E9QC&\&$@%!
M309@TWI@9*FW.2P>/1!X:[J'3S+(8'OKI-D^;6(+2<5!DKYU4Q;B;-]$JO]C
MP2C>0:7+4J0LB4[:F*22^,D9(P)*RGIT)WV])<I.Y_\*93F\;-DB>9,,.$YZ
MAH6C?%A I@=3)2&3F?QIRDQG]3_K$C;A.SBH[*7].>F*E<0W7=#5JAJST'3Y
M=,G%!#),N)T8B \*\ECR&W0L#YEWSRDLC8Q-D#=+LK&XK:JD-_)'JT;LTM'(
M'0],B[CJT[@9(.DVY!N^TKH:I<.]*E(EQK:-@!@E1[>?K/GR68\'Z$E$Y<3M
M<P?53+DXVR4FB#W$J/D7V@$3/D[9>O#"H1(+UE4C*R2_#/U2$CBAEK\Q R=;
MF5*-SNZ:LJNV[ 4^8N8]&C)$ _+0%+3YGG2[\]CN)'=U FHL4P&Q9'1YGT4#
M=O"R MSO8 437>W05IO=RS/Q#M6.0 N=UQBLOE]+F/7.\Z:;LC8FZ0F:[KZA
M' 04QP"^(&LA<46SFWVF'5;5])+^6M\[G+.(625:!?6\@WKF1S=5F5N4A59Z
M'LV,^R<RQ\44LV<(GD]FC:.C*0P_:]Q6H'4EK1$5&@\5&D';2[5)FFCNAU,F
MT8V0.H@'>PF.*-C(*7H5B57)S56AV]=4(^&)GH$HP$$6HS"V)+^?Z!ZGF,/$
M+;*ETH2B6M^5/L+FR!.V"K,^IJ.?;NBEI3HI)E$TS9\](6/KY ?82#("5U#;
MNZDMZA02-XX%\,X.3VB675<@_ST5M$E67>'0>D^4+\F9 Z,F/5MM\03Y#>JD
M>=9E3I^M)>ZZ5DJZO<PV5@PWAP^@9W7+_Q[?VSLE.1@K2C'/MH'7JSC5E#N\
MB-,/X Q3.)4U@Z#/N=,].^,"S@>!C0%5:\)Q%*"P8AL-:U6</D@_'-/M]$(Y
M%(U4Q7W4RQU0\OR=V=VD_IMANTO>=6TFAY._TM\SW8O0X:Y#DX>ZKD>^0=P'
MV0XX?A[VU;XMW[3:AL33@\R.FGYA:NY$*=$$J>2*/$3X6$R7\'F +:3,P60F
M%.4Z117/J>\)>&UA]3G.%T=AEFJ!FC24CZ^(>[O+'J"1/JN:'\D&']@ONR#Z
M51"]:CJ3"F1$&%3:IX0S(&7WL ZVB,<LCB[.R*-NPCZQ10OV^@1DTSQR/^WS
M*_"T(CS]SN-&J"I)@!K@/FON6@+3#VS+J,LK5J6+;DCNX0(7*Q(4L]NOT?"-
MF-$1LGSJF*:Z O=MMTOBPZ0IYLP+'"P=1/,[-N'FY1&#-4:)2ZKU/WL^%: [
MEHZ#&7V;X@1AX)M_/:CN)DV;9"LI%0%-Q4]+4PV#?4 ++X>CTK/ :LR*%8N8
MKU[G24UN \  BR'@7!<M[SKT#"^UK+A5LY_R$/5"['5 O<AG:C++=Q]7^$X'
M5V=V([?"HCO%JR&<%W"H!L.J(<G/>\"^U.F=5*QY/>*7[0$O&Y%3DYK7L2X3
M/6S5S0N;0Q*!"56!C4.8DJZ5R&N2=V\(H^B<YG8H1;;)Z6VNYD%W[@55\L$M
M\")%J3]<^N<?(G@I2?P#CNPK"-948]+ \78OB*]1:<WSMM=3XT-!F0 K&3F$
M \+)PZZNW#!5^0YH/EZ/&CKTB=W%CF<?*&>B)3_KAO"%SSS\WL=-E P31W ,
M^-/8CG[XK0W_^R>H.,!*<*1MGTFF=UNNR^:V!=;?A76L=:-\)QJK$!$ ]?J(
MLNY U<0B+9PDD6Y 79+W1B-(C+,0I 6';;1<A]HS41)>ZVQKA_)L5/5>?-4I
MC9@ :/FEB,BFE9P+WV/<-BYENZ[QU+ [G*@5^D1_["<?,[AB;>F[ZUJ^T9QH
M] 7&LTLEHE)K+[KG+$$I!SGKGK.(4I(1*$&?<G#:B@WGQH?51>/0"R;V=B:F
M"EZ(@]&X3)&JA>U\GQX$<^J>QI'WJTA)_AZ"=)%*?\30GA>^TIW*JA<3'0WJ
M=>F13C*+D^';\<N93#=.5\E+_1W#]M(7G:XVE9?X,QJ@-PZ.*OL ^_WJU^<U
MPP4EO8>2EBFMEN.34'A2H^0"\.\!/+JPX?Q&;:1--X3S0P<Y#'RL+(G!'W65
M1E_<%6BB\1$LJ4QOVPT(87BN"J2\!RGHQ@0UC:G,)?(:@8IX3Z/+9%F%2>7P
MU*,SW4^>W F8M2@K*E"CY+V>U/AL:DH0F124? \&0\+#'5?EQ"A?QI^A) 3,
MTF-42!E'+"B[5JX0KY5+PMD3GAPE)T=["U2@9#F 3,X9DE]&]0V1:X=M20DA
M0RD3A*7>,#$Z+LFZPG?'@UB9;&-6POW3$&;Y0LKP25*S_,D]\ 3(71:8 \E8
MO/1X/]B,H+@ U:?8-'Q-3:Q+[I?6%I:";H2_YO;L\N3LG\U-=-FL_?QN=TG1
MM-R>^R"\'32W@5HE.;H8&*=Z:&JF P?P54 7?/*%.LC$I4^0324?S"E=?SZ=
M"HZT/7*?9O0\?F"@!=K,>'.>P73#I?U4P@ S%=OB3W";CQZ^1]>SK4<4N"H^
MC.GN:5J23*8U "AZX@F$L%F9XP9WHNC&L^U1A0X8])3V\'S/])L7#%R\1^4[
MI"LJU,(EQ4A[_EF(+<G.G:% [Q]6*]4)!;J4TJ#E1;7*05+!1:=')DS&YX98
M<31>"S=<'*.W'R/4-!SW(2T356"5Z#<VM50/IT8I&7D>Y]HRD-HH="F?%<6S
MH$).HM?GH_M0OYD_.\WH)'G4VV=W5Z>='95&9J4&P3^C^3GT_MH4N,ES^TB9
M0<+I,2I'NTT%F='E5H\2. @3J!E)9"?*2T&(;R?$9*INA)!N*+596PR%)$]D
M.5AU;6.!GA6E&%R#K=CGQHGKWA\;AZ6C_7KI$-O;'94:U4:INE>CCP>U4F-W
MMP0,JU2KU4O4*I)Z'5=+NX<'I>I^K6(0RE$_] -9!X#+N'/H[9V DL=0_?S_
M[+T+4QO9DC7Z5RK\W3L#<05M\*/;[9B)D ';G&-C#F#WS-RX,5%2;4EU*%7I
MU .L_O4W5V;N1^F!P08+:,TWWS262E6[]LZ=.Q\K5P:M><=Q#8)D$8PJ+![8
M??KL^15];A^4/7CRZ<WA.U+I#]4B7"DLEC1.,0&I3M5D XZ#%STZT[_20Z+^
MB :!,S]NZF)+0!1%N5H,Q756>ZW&EJYVN)"+>91,PJVSNT.N,<;A]A$9'Q26
MA-UNCT4ANA#8&Y,-T2Y2O_:,"Z2)WII>*52+T@B2=-F#7\:5NG'M94PK/HB"
MJ(!=4W!:S25OUY-_RY//_:(<2E.9B$3^_Z1_!2T)>\W49G807)J+81[F=A^)
M^[)>J%M=J'F EA%O@11=RUX76L&B#.CA0D8X::*K4 ;F&_Q*5GM1#N.\F) )
M.!FQ,>;-^XU_&]:O46H:\L-M\GH[W2C<$LY]N1HJ^LW.GCM/6SUE=?<OH&AE
MP[$35I(C/O[@!>\^. L=8.W3G'-\H2C*.;I.0?QH0LYOWE"9ABFY%G^/4J=4
M"^F EQ!1(UJ$*TG'MSE_-0M+3MFC\*&^'+X[_!+M'?UMZ^G.RX?J1ZT6#"DL
MN6D<'0H-Y+NLZ*%Q.BEYDK\+DZ.CS<9[1((VKVQ=>HM#_77Q#EKE]A5)"SMM
M3HIL>E.0>^"(:.P.1V"2E"C+L 5-G(MS% X<[RN-?D(Z64+G+B@GU?,6%"9-
MI&8P.:QU6B_ .!*8",S0 .#^^_=BQS'7B^.+\E4@<4 HAN.= 73O3Z.EA" O
MGKV8"4K/M-FVMHQMTYP$#3%TL+,MS]U+3TH8 R8AYXYTF5S=QOZY'@D(P+M@
M5]YPV)6>L*#!\PW2C'>N[A;O@#T0%I9] .:M'_LSU/B=;ZX0IQ2\(]+,@X)$
MIW4&<G[*I4_49JE^O^9$/%\&G^.DB = D@%;;C$?V:0RO]L_7I.[-,GBZ>]I
MSF_!/WK=?L("C<\/E*\]1'#[J< $ZY+^?V*?K%]OTU>_S'^^^^OVLU]W%W[U
M='MGX>?+;O7BZ?;N;[_=RJUV7FT_?;[X*WNK7_@MY4UI,K%4__'DU1,WWW'_
M?%B2JDFVVGM)%R(S Y*520UH4II$D$C[52ERM/ [G,$SWTQ .)4/?]^=?(UV
M%J)49]9NG"9)9A9OC '_S_=LC%?;+[^UXUDZ]CY]_'APLG?8_1 =GWS:_[QW
MYCA-?JF3)?/Z[#;F]3;F3D1^57.G*K(U7^MIFINF0Y<#W*@V[W:R[GJOKG8B
MQ=@Y,4-DT8MR"FHJ9DJJ?FS+#EX,XH&;7CUE%D_BK0DJ;C1WBA430;7_="-A
MAXZ\_SSJGNQUCU85>J A/,B((D_=!CDIQ=>"+/OW>X>;T5%<D75U.BGCZ4SI
MP4UV_;T3RQM:ZW<YZZP/#JX=I"TF:4%O#U>$^<_)DZ&GIP/#"7GR8$"[D):B
M5<B'_ 4)$@-W+..@+EST:DH7CZ/$3.!,AC7C*UO;VU/WR]=]%0O;PBYTU).?
MU_&_L'=P+==,7UTG\T[C:3>J8Y<U2$Q?.9E_Y[(WT6O[S&XVL9B-F_BF]S>@
M^,U#9AU)7#IU_E19+=1BM8;"@\Y1!&O8D>XSC!Z[-%'10VS2]8+*PZXHR+P%
M$%9H@VX2DW(_'L7E.!90+8.W *1 91GP@'1ZY?RX 'B*GSI;91'>>#Z >O.4
MZ(+3-C'C(N?:VA\X;U'FP&4?'FH\BZEU[\;88)J2M:S>AJQ*D!R.[ 7ZZ!U_
MV(LV!K^<_Q)'GR9IG%M!['-@GOPQELA-%RX?(X_=+F!=K\NMK NJ?BJ82=%(
M-FWBDOAD.&4%"O*S^#(RJ+'O*YN?UKQVN(T%=[K:P@LF@E1(_XRU)@D=4FK.
M=\8]9%(E)D!?#!0+YN\DW2[RJL$"\T;U!4_HO9*.$6N&I%B5EY'US00.!E]"
M#_&@?;N*MRB1X"1)%C>HJI3RJW>&%(3HLL/#M1C=CA@)9X.MT5.BABQ.QY)/
MST?"(D;Z>(+);YC7O-^44IS&=0ZDRM$2A)O71[LO\((O7^]M1Z=,5L[K.)0#
MKM6"4[NON%;=-@%1C4PV$"&A3];+?'M:?/>Y$MOC_'SVTK'<AYVO?[M&YVMK
M,;"T]&$&9"89ZB[EY=OBY6LM[7HA;V\AW=IA(9_;=@61JO+<,KMC[4"\NO/K
MZXK) P2O0II=&5>3N(ZO@/Q_+W7V_<V&'N::XVQ*.C'_12)?2\[:%;I)(R3I
MCS"A8PQ'$TV^J_9I]410EMOJ:+_K"&[7)LXMNDGLS\";V*)EV^)2?UJOC2>?
MSO:>;"[T2S#]WW9,Q#[EXZC?1\6CTA$'B\O,Q\ \V+ZZQV@DC5US0D>FN=R.
MH#<]COU%)Z#Z9*C9VT)Y.T1P6B1#T08]?#,Z*G+X."[8L\]<?=WD(JW@'^UQ
ML[':&$=#TLU-1?\%" 8?=<GK&9J*_L7/< C\!7=H<C+PQN1>9=/HHM!JI$%\
M0=.T :P,I)PVPLXK_K;:]*J^1W;7(*VWRK0ZAQ&'+;+6Z+>FT0'KA:XA*YEA
MA0,N.&S$>XZC?$9$9EUL-.XH*S7)ZZO0AVO"JOF5^.V!$5;=&WJJ]>:_M<WO
M@G%RW-'9IHQZLM]=6Z=7'4MG([4 GDV [/JA#X!)Z*^2*('C:<5M0XIK'( Y
MO1$^=\%(J*)1.IFP"50+AV--=S"*4,<9S+D(8]LDT!>"D&0F 'I MQDV5:TV
M%0W6E2^DE<,6!B7T,?-I#R4"P+$$%RQ2?["'IND <7) -!CNS4&%-VWYLB(L
MHA[C",,F*9@('P<4$1(G4$ )%8SHNTSBN46 4O301$#O=2KZ;BJNBT;\]4&C
M$9__MOWKR\50P9M"")^_VG[Z[-7-(80OUQ@N#SU2A&!$9][^X7[W[. TFL]*
MK\&"5X$%O3I;PP:OGK S4C.FCCQZ\#9!;G<*&+IJWNX<.[+W[F1_Z^G3G6CC
M&%R_,XP%OSA:@U;EW??!,J\]I7>+TUGI=)^%N>!)D58%US7VIJVRUP(5-;/5
ML7,7,$D)S6]0*'(=47_L$GWPYG3K0_?T2[11?CG]LG7!$DOFL[;UY&#7A[BJ
MXFB *,"U9/FO++)=Z4V0<NY3DIU2YHSFIW4XE3>3P[^LRH6 ?NR>7"F@Y+WV
MFM(6URG1U5KMWI$,+YSMM5:=%=K3S_M7"NUID]# ;BZR:\E<*ID+IG2M9:\U
ML<=QOG6 CI[1N-NKUIKS-@Q6[I#:EL: 5S3-!XK"E"Z804>N?I$/TG(,D+H7
MZ+6"#2?Z]+![%&THS !\1^0;Q.-I%N5I7:;U6I-^4Y/F-;FOM5$BT;0&]+^%
MO;6$!JTD=]QO:B#KXARQ>.>2;?]@J.JOHF8_Y^G;K(DVZ+^:4B4UD#4F_S.V
MML':;/W>R3T,^H*E>=*@3U19Q(E2)4_*> M*F#D_4L6F1C%P@U4=K(/ U-^(
MUC7?I7=75TZWT@7XX^#+P<'6EP_'UU>^][,X;;4VA+=GYZV&/U!46.:=Z"#6
M/R"L7TQN_FQ,!JSKOQHX&";OF\F(WJ9.*T?7K@;'(I'^:U6[K2;[>><U7#8Z
MO;U2KB6F"+=Q\CDVQ)Y!!%<[1EM.Q.\+\[9:H"R/]X9ME&RW)#"I5:B#RK;]
M6!>,3N 2[9<8<.^7# <XLQV]?/H4V C.)/N< +;EKG[NT@)B:]5E/&ZJ?I/%
MI>\1'9#B!._H""!MM8MK^VM'6I$<ZC3Z>]&;YD6^99LFNI<-J=TK8*C]3^CW
MO29)Z$!,6=&@ 3GHZ\=,=5\]$M9N&^U>,9LT&@794)"#'4C3MM)HWV7T4K\
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MC9VD5&KI;>L X=1B^AUW?W"D555#(DLCZ:<5]\VM(GJEJ _>2;HH2N)I)<X
MRV95,?,:"?"^Z:L [X8V?EOT()W1";TE3;,WNH=EG$/&G1B^28M3QQ"G/SW,
M^]M\1]RC$[GF'$QHRHJ863U@&<H\KU7=[8AOS)34EM;M49A+WUOKOY:H.S"G
M?O\Q_HAUL?VZV'Y=;'_7Q?8GK!,E*K>&!UT[\;O: ^-!0V+7T*0?+,HPN<F:
MKQZ%M&]R*+T./,<BM_B_MW0<,FCHG8$[,.U$AY 4?')8QR!\MJBCTTF<YD :
M&::(_&'@X%W76CX/:BW_*.$2Y MK=E]\7T'ESM,7UZVH_"N+(63,2M#]Q)I>
M1Y9>!++T#DY1%PY"6IWO+*S1_?7[1.K%N@S\-DK_[ITF>AE(SPDG2D1X5B,[
M:Q'Y;A&Y WCK=>3GUV7:)]I=*$(O?XX(K8&>2^3K!E#/GTC]?&L(P(#=^G&$
M _\PFC!E,L^9SA#2K+?HH5=GNV<($CMT<:N1'W?N)%-G-N$'=EMN_"7TN+8K
MR8)G?3Y]AT92:7\4&>[=F3)$:D?Z]O1F^O8H)$)[]04,US /)O#< 44Q'*:G
M1T?_:F@%!JDT1'']2245WV19!.QL4CLB[!_AOEX1B?E>,9Z8.FT%*AZR</*R
MMYB/R4MSI,=%.<]_K D^DK4^IWUP4=7T260JK/'4=UV<::,C[1FS]-Q(3KO/
M4VF4'5@8[^=(F&>YE_GAN _);=BF _%SZ;@Z-IRJEO2DYJ/Z?M4<J^ZWGB10
M4*- $AO.7\Z_^U=I_O'S#XO%#26NP3?Y_4,-PE\W'.O=!,1^^J0_^<^?U(UW
MB5I:-9OH@\Z&N2:/<M"GE>^QVYNR/GNKS;I=E_3P@E92O4/7C+GQ*).]E^D8
M2-MJ'&?9I/CJNF%6==$_GZ29?X1M:<"'>Q6=FVDT,#$Z[TFVLPT_XM[;<C/!
ME6C#S$#C]\N49SQ Z;M>XA'#,,/?5_V121IM+#,&]]F67 /T@AHFVMAM+6L_
M+FO1()8>@L%!"QC'W_[[Z.C@T\IH.[Y_:L\^KK0C^/6VL+5Z)@ @Y[:OJ=N<
M+/KX(TDK[F#)35]I+U31SF_1U,0E-T!<MQ2X2:7@[H.N%+RN7;JBV:5IDT,#
MW7'(P*^!(-0>V3WZJHY&*:I]$)V"\#M1I[]9TM-\( VTMQ^NZKE'6AU-KA%2
M<-A TB"*F!-,,*N?@\\1!W"TUW2< &6/X1Q^_-+]^/GH8+T&W[$&F&!,X-'!
M?ZWG[^;SUV&PN^TL?.TV0O?8<5_JP"T.53T(5_Y7S-LUR-W6KOP/N/*L2JY!
MH_EX)ODVM,L]BY?<</>OU'M9-5OC/9>L6]FLZPG\AO$J*:Q6;W9NZ=C1*!8]
M.8A5=20HU7*D8^ZKXMSG[?6R_*A</W3%<!]B0K-R#0$N<OQQ63B1M0Z<<]QF
MHD97"GKG4:S5RH5]K2U^9 )+XR5[1JHKWYXW2#;88.CIT2E7FL:U84P$(M/1
MI*@A[G$6#1KD(.92PIP\!BW,--P0[H'IP#VG/RJ*2A 5.@Q@IZ0C\(7Q>>5%
MR?-J.WJW%QTSTJ,3O<D:$_V1(K4,8<F*8=JO?CDNRIH&11],]#H(T[O2# ;F
M*\\+-Q/W"D#SX-)9O;W]YP=@(\J:0[^@<Q EW54=#PU'@_NT&+9<U*;7MZ-/
M_/[5XCNZ5Q*Q7_16TB*=BTD- "1T/=UL)ZI+6I-KXS[NGW.^\TBRZCO;+UY@
MEJYNK/)X',1[EE"_1=S2$GVZ2F7.T+*B;NB;9@P=E=;%5]IA*6@D!/^&[YQN
M22NO^D=F4L<7J ^O@U\NRV>WZ\&M7J]+$]>VU7LU'4](E\2@;Y)!56.^,LZR
MJ()5%(PU-TU9R"/IW8MZ.H$*WY>"\/ (H2%[A9RE8Y0B/%RM]MBP0M\FS[T5
MS;;68W=O%T*7?#E\=_AEH;8 WT4\80CM-74$".:2I#05N54)6+S(O+I@8*W0
M4+2!+H(M8<1B:90$A<RNB[2$#34#B@$D%]S<ED"BI2_R"+E-MKCF5=2BAU9I
M0D,;(+U9"1Z E4PG.CU\UR7SBF[5JV-.EAY\5K\/YBYIMK/C3_^USB%]%Z]
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ML3 )F.K7\G0[C+$+;*2YN*[*0!8W.0H!>:'MRBUL!1"0_VO;F)U.=$QW&I+
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MF\R3202+%B(??7, ,?,=+QNC??W*:,/3JMWQE"ZC_6BB/<&.=!\O3/]3.4&
MA$NK5WN.^Z+ 8$R8^DX0C,]K/0.DZ"V(>KDV#$%4*.9 MY)^%G)7'&E/K,;Y
MO'VZ;7-VMN@L)(SA!J\ \G'EV,(&K]W%#6L9+IJ#B@J:B'\O@5QMAAX-S"6_
M;LSL[1V:7%(Z!3GCK;&YTC6NAHL0-"H83JI1-DW\NMZL0..3IM0B8M>:ED'S
MS*/(* @,P[$MVL>U^C);LP>FBK3V$;1DG$F<>.X7F(@6_)ICBG:=@KEO\<F[
MGI@*:9DM?=QV>36_O@F6-;BATP1T6 Y!^"I(?9!$T<DJY9*#1F+>^.;DW\@
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M=SIEUW88^.J S+1ML"O"G>AU=,=K"-VV,YMT*:R\/1I1L1Z1WK'HCP"]+=<
MD['=BERU9LJS;<O+<))*Z<Z"TRK@@&41\TTP'&?6[!+.5M^+,*1C1"'&12*1
MH?Y,#.F3#R)Y*VQNZ,(KZDP"!<[@US;<!"G9<J41R[9?+=:,1=$P*$5_([:[
M=H 5S(;-SXFF=L%YS9BQD1.^XS])T56)K(][&?GUXU!K]NQ2K+]L-4?6KCR<
M,PK=1W" @I##8_82I\,8X:2%*0[J/A>N")&C,Z<Q1J=#*1>5[JPA0M=8YMVG
M#QTBM+($2VCPA+5CCVG[_WO5)@Z7/MOVA/(A)UL,Q+M;#O1>RYCFG0SBE*"8
M)>S#D2\,C?'1*W8TEY^TD1_"[3#CG/D\?U$.X]P6O?%I2V<V^!DS5)2FF;#0
M<L[>#:3# 51M567CZQQJ;Q&&>,..RY>MB]S/"MC;O@.7>[)FC/6.5= ,@K_W
M=5'N I"E+2II8XNB*"4?Z2\7M\$NC-H>\@^:_MP:27%V :-PADU^F?$^".+/
M'!/*R*;CHA9:7"7/M8T$YSV,L- %]I%&4-7Y\'TFN D29]F90-%1LLS*AWU9
M=]R*.]6*571LNCM<@HY_I4XP9;;G(&=,I*GRPF8=[=D'[(>.*"]5%;K/]]7I
M'UAZ"SMM+2M;8G;<T/7C7'Q%'#%.QW]/)1DG 9GMU_'^MLJ0@J-V::V9W9MJ
MMK>",54K6-VQ.Y99JGE.F!JG78;6L4LYO8MBM)9-WLK77\<8>(#*6-!3<?0$
MT=JM'I.M\&K'_=$3:4'@)K C=.*6T5DL78XCDWC]B?VL=IFKH0W#/>%*:-8+
M3I>$B>7!D/[H(BY3IG89N!;F49^>@)8S/@7F>B^!ZZ,3KN6(Q(WTF)6FD<#K
M)<,HC6R4 "TX1Q0D:&\ZNY5<?:J8[*[/,I/1*YR%M'Q&KU<6N5163T;32AE\
M1(NV8GQS.P$9P2R>BG(PN?QA47(=:;0S$"J;A8$A'F,&[& (EM,B7Y]S10 ^
M:4#E$S,Q[I[4S%I?9J'2[KAU\(3U[I"RYY-V;)AC3V_1]?*&90]TSM465GU7
M_\O)B58AA\:>Y84<O [O\$$/D,Y2M*$C:F^#&L#(<G5:F(%5I%-:=,_Z$U6.
M;2=$.ARUNT(I\XEG+)I)G*N;Z&"4DNDPOG9!N.!59SOES]S(8=2\TTJ0N11J
M0%[3HMF;>R^Z=LNO6\NU\MPM2]\B'(F+4OY[>QW"&N_%-?]S.4(]I5T<6\%B
M"5/R\4W9/V1+#KT(XC1K2A%HH>QN!29%QGD*G1AXBR(I^HW';.K>LDDWZ6:J
MW.E;"%=,9P*[X>DJ$A_PN>KQZ4[4;YRC]Q\,%N0[/C4U*CBM#,"O?A1'Y)[T
MX6.* Y4;;I46]BJ3#'"_78X*6=F+\SB)PSX)=N/--'W=C@Z FX%V0R!?/I\R
M+0V Z2B8"M""<TD9/G,=LG,V&AY%AS*N@\\=>VD(*X5&#J3/L]S'SK^P]>M*
MX")]B)0<,;9!.KG4V7WA9.RWNEXIJ"YX)F9$44Z71800@&M!&Q*>CINZT=-T
MF'/,Y)>$N8)*DAW=.=*":H[%T]KV\[?P/\+S<XM*<#K48N2=[2A$5-Q40)NO
M*GY YCCZ**4["JPKVJ]PL]'Z.E0;BE]&OF)7B GWY00FB:/1C&4TE98>O]'T
M[1Q:4 @)VU0@>ARF5GRNG1>U@"^+< H3HP>?-Z/=ISN__O+K\Q<.$1#09HDT
M"'=T@6,G_2JU"0<1P*<S12#J:+*'QQ/%?735Y84?"?N0S<DJF@/",9AN#C$L
MK%#EN-U-,F[%@V&8FFRP)8_C<W6^=X$>&*WCHOV#6$T-9$**A&S./X0NE _)
MP*UA)%=81AH %MH\*3/9![MPK(+XUN&VU(S053U&'TEK4>[9Y$I7=CIA8=W?
ME3$@(U,$W7SCL@YVLU>'FFYX4YJO::T)!P'&N*Y2='T6HP-.)-SR)"G[I*!X
M!SZ3IS[U9&.ET?9'=#V-@G[9:9$GZ5F!Z'_E 5B*U6,HCT=HQNU:%QDD-D<#
M;]GV?E+,B^U>00^U%I&,'%+"XD=+"+/ZJ.!RDCPZ1 #, V7$N&I3BM =A&U$
M$&)<=7#5N11 ?>8>XRHU?.LZ.T"IYD(5EQB?BD*96]HV1PFKY64ZJ>/R!AX:
M1?/^CADMWI!^IU7HV&0K+S.I8BY3..T7=29681+] <8'%YKP)PD/.S Q9V_-
MYZ$MW$D  +==G[PXL6?*%4#WWRH\=JG\4SHIV$!_%#KDK1ZJ&FU6Q]77S:2^
M#W9 01VW3X01QRU2I5OG\U2+]@,)$8EIA\([04>8(!M)HW0RBXA#(> (VEP!
M 8K@#15 G HO3.I\3.3QC3FG^U["@@]B+]HB@T^KN.^9-G"^S"+_Y-2L)5[!
M;_?[-5>=TV9 U>7#K<P,ZM]W?_VV'&S=K/KL+1E2YRAS>D>6=]IG9=",E\G#
MSK7D@8^ ERNLD&W/VL[.]HL7F)-9SCDOH3.@]G)9@/[U>N7NQ<JUH#$M\INP
M+?9ZM>[':BTB2EROTWU8I\ E$E)2/CT#T!:#E7R'SAGT^WKA5K-PE[&X$9FI
M:SVP&MNK1C];+\V*EB:@>VV%3ZI9AM?E*[2&32V 3>T\:-C4>IO=]M$U:"J<
M0[Y5C0UAMN@/F7+99OB"!GF2R/?7.9"DZXNZ5J"K6EG@IP,PPOHH6]%*H/ZR
M$J9VK2Z4CD+5L"B'$ON051JDTI:7.2:;M9>\J@4+R>7+J&V)S-.YKI=I]6?7
M!/7L@AU)QX+Q+P.T/_ATUEIPM:OEX'HF_;-!0_<X3VX0M5\OQ>TM19K_L\G[
MSK"SNZ9R#=S[Z47*;3;Z);IH<2LP^K_US0BD[G&FY;WF*P*"K !I,0^?D9RH
M[2XD6<C92H*@_;5Q8$;@)< K!I>U57E%2BO\]_U/NM$&:9).U.UI>Y:HF]?I
MUEY1EHV0>WR(+V^<AEN]))R%<"JFX)&E#Q='ES]!-CTS[2)R]7B$B[+0U+3D
ML[A\(KT KESS8_U8"!:'93S61.Y<R>< \RQ?\50C5=>):OJ^0K=)H*'EH]F.
M)B<F,Q= \_#K#$S";'+",>+'P$-8E/ZS92GKI-IJE#($T2X:;ZV_I_WS7MP_
M9YP7HD_KA5G9PLQVH%FOQ>HWB9[AA[D6047'9.W;1D-\0/7Y_+8?:<?VG5>O
M7D8;3]X?'G>[3S:9+2 >"]A= 7;NQIZ1XLST1SD*JX4B]*!?Y,58Z33V;"Y'
M?X=[GQWLO7^RN9:4U4H*G;XSM#7!N>W!88+;2A,!$9^8'D[+8SFE'=CJ"QB$
M:)!VE?=PCGJ1VEVO\^HUPC%70Z4TLN-XRC;8:9-7(Q#=,4/Z7%F/A99_(O?&
M_J:R2[_V4%>WJEWR-HMAT2A'GOI=8L<N,EX?AU?ZJ2DCM.NS#N4"G/8B?/Q;
M+>I07XSDU_;&A7[:>/)V[YA..E\!P*R)*.DN)X5[5B[-#2[2I.&V'W!8^W)#
MT*1JT6"!1D):I4Z?,630E@E8).Q$]YX447'-%?Z^B#/E[<^GK@XE<)<*=-E)
MP;D8?$@K/AAHA0'(OU%4S;6?#'4O2ON'^RTC%.U5?120H",K2J%1VY5-+86_
M_*O#I?LY&%>8QY4K40<T3F8.T[+[Z+(HI5,;7VN?17>?Q/U4AN&KK(J>E._D
MKODBN'/ CSHT@K['BFJ!"ET2SY 28K&L(1)PEVD0TR& BI(KPC-74F\+Q.DW
MKNU9BTB +K@@,\=>"1QW+$190R',LJ\1]5 !RMV6:7)!$:"-#B9-+Q/6&MH;
M"O#FX885=Q7HS[F@X%S"!. #BWI%<6XWK12JBMO<[S=*["1L!FG)-9N#C''7
MF2-#9_<W!(@RB^E%JJ$(7S65^Z[J6BN*'NA(P'/)C5B$(5_!=O2=N^[S]M^W
M ;#N@4Z;CQ?98$J9S?!U_3981VY]J7!KG<\P3H!&\P5)NM1UN3+3(,J"?O:Z
M>8[E]Y]4(&6[A_J2->6B6K!'H2W?2A7F+,J9WK5:$N'0NEE=5Y%3%^%$M)/#
MGM\3ZEQY>61%5H$MBC@QZ;C7E!4;.8]BJ<]&85V:[_U.FX&#79-6LZ<%5(BS
M&_K;T3&&"0F&/CB/T+L2E +^8AO->QP6R*&OW>KX4M)V DW)-U3&[-FU;$;;
M,4_'K&!]KH[^A1+%LU+_X,BF-?=FUC9H$NJF'D0*TYG:UKF@/0=)'\4B?8E+
M].]IQWG#V7;U0%-I<W(I#9WH+8HQ=H3R.O<EG(6 1EJ##Y/K-,H9MK-E*YU-
MV[MA-KCM"S?F10.D[UOG-KXIX>P!A]AT3#["S9=R)229!6C<ENF72CL=3WWP
M?>Y!6U>,L'7NA@649+_"YGD4HG*?SLA[/$U=Q[@-GT#91(0:*>5BIUCJGTA^
M8FTL'-3*(TSHR%WF9)V;7J@PA\3E?4^*TA<*@/:#96&"DQRD)@T?:E6KQC;L
MB2:,_;;3-=/ZY^QAS%!3XL>'Y.E(=//$6,HO#6CM/MW=C39PD:,]=P28M//0
MHX;K-X7%%16$^&TS1*WUSDLND-QEI^&R! 8PUP>>=+E_;9N4PW.SD>>'27[_
M_E2\GR"4:[.SO,V=+Y>;85&GF.09)E_+RR4!0%9E]IB1#KJ3>-JB*9':]ZV*
MSKF^41HXZZ'@..&+USCCF^",=Q\TSGBQOEK17#*#E1/@2@&ZMO^ ;*J6$S[?
M7,8*^C%JS]_PGN(_]ZVP%])P$']@ Y8<!:\\999K$QUG?0]Y@"=>IL,AGK*1
M;IMMVUC-:C+65?V2NY6Q6=?4D[@OC+3P_,4]5T6D+17V6)#%,'%OS8WB?:C^
MU-HIJ5.&EA\$=[0A7B$9<3?A /\Q*X4CU1W:,PLF@:VLIENJD2#FA52!:WM$
M=Z^V;@Z5R8R]?/_=R/VXCC$M%VAR_3TPCOMYJ$=YP[P(W'B%I3D\-MDYF( M
M(Y&@8,WKA30@;2=K8'+1M5S5$9"4\<$BYKB166MSE.3V9$:D#)Z(=4*46F2&
M^9/#79[0YIUTIXIT6;A)JQS3GN/DR;O]XY,GFP$!Q\83YH.)]A#;(S._M:!/
M-ODXIIF898MXUHFN^)VP-;1("P;X+[^>97PYX[YA3 M_U:WFFL/0S6@ SQ>8
M)GLD4+2C\C2>OY<S479^HW?>X]BVH^2,F=,1_0-DTQ;Y#&_#TXX/5#*!IS+8
MRS+QD6_UB$1_N9>23P33_P:#H[MP?P$?\03;6Y)6ED]5JP'Y#4A=]DC]*3%?
M@L5% -<HTZ>%557D[\YT5HA!$%(%-P)'[*2&,@UU.]_2_ESM?')K.(QKJ4@=
M 9 0TUG_I\2^"9C/F3\5M\/9W!]AE=LV,L=^U=8]*^,$BSZV5.S:)F)JO3U2
M%F5NIK;M6J4T,4'_XWFSV;ZL[5*,^PH]1V'W(?=)C!%,MFQ&10XU,#NM3(1*
M>MI2ZPCW:9];>W*_$WI1VVW9Q7D]NHJ4/*UQI4]U*(&#S_]>1=B%G6B/@^!!
MX-5JA84>EL;^@^YGFH:<XQI-4IMN<9,5IFO:W7_%IF[!UN2E6E7$P4MP*(9'
M:/NEPG+0Z#UH^Z:2<H 8D*^29.W8FPYAIF%1,(/]HE+289W!^W\0?N(%/\P3
M.LE(97B%^R@.Q$]LE' O,4FWB$7CTCV.-@A?LDTYXUH&HGFA,2@/0)Q+R48V
M3B7QFA945A-!Z F6./I,3X -_D>7=G.-R*L6@W2@'VNA]J=9X>V0N<+X/!W'
M6<"8,R'W;L2-Q\'>2KY'AR3]0ALR2N% 1\L&O$(FY4%2+M4?H_A/4CC\XJ7O
M*)--@R]T7_?;Y"6D(M-"HPA,R=WDB<VZ\GF(G]KNZY*1PP"4HCK/50.R5@^,
M2R3!3%8H[3?4!Y,X3+4'FJ5[P7E!/_)YJ/N_%=]__M@]BO:ZQX=GW0^/8OO]
M830'CJ4PI":+J3&>,YP3DDKN4$F74RE\'K-E(367_5%J+CBA3O=PG4\*>TAJ
MQ&?$^A?].CGC#/4OC,)][O2)@);)+]*RD*2&9?9#!9KA6[)(>^)Y[<-RJ<S"
MO:G' =!VHK,V9SYX;%AK9$!/:&C9H0KD54T\;KVKAONYK6B32Y:4.WX'HVF-
M)93Y[>B3]F\3/E?'2F?GEUYT&&N1'?/5&[)5RFJ43L+;@&\(%A2X:>1$AL)3
MIGU9G7@2N]9PN3&)Y1UGID5>#J='A65P.+TBSWI_I71?F'K$,\!K>2?*RVQB
M0& A9@27P7TE1<MI_%=/GT:)'!@A^(!Y VW\4KL7>/)T9Z,S:E/"B!B VQND
M?4T !4 780WINTFG![Z)<2K1E!T5)1C:Z<8?X^D5CL\E>@ F,V^PTWE)[^#>
M]2;)\BO"3?=1P\H,,K&<R3+,XJ/0L]V:Y<3!5)26,C$&^0\8'5R7;GWQD9\&
M<.@*1E!E+9""/XSUG82HDPRI$6I$+XPOW>B1?\,UO-H&BZ/)E7129?VFOI]E
M;0=9+NP548&#%'314#Z7NARPWU-7F%$A&*VB3KY,,F@RE7QN"J&^#^RQ>,+;
M$DFUM.9KY%^JFR7]-2CZC<;V_),S,.##<VE-QZSSAZE1BFYWNS"]A&X,\^U+
M.8Y?VN87L@#:YB\6BT_X'\<#QG%G8@&&)Q4;5!:UQNR/L7C9-JMLRJ$ L^EE
M]SY].=S?VGD%DQ?-SI2(EUD?7>U-!2I].L6:K%9Z7GTOA/'8^9ENU<56@C[!
M#B+T'2KAI^]M[71-+WDF/;4_QKD]!Q_%+O_#B 1#?MU)K:<[DG'@])QJQ_DV
MDW"5 FC53[6Q*!JO]$>"X-<-XNV.ZARQ0$6;P5H0C\!D(-$,$!&NFTH01&*#
MS!EA'&[DW%S%S,ZU+$N[WZ1 UK#1T9/0<4%SEW7?YT_:U["--W:KRB5BTJA=
MANB-&[YSP[J#-T%&9R_OZC^,I:G^4R+R,&S8^+)=<?G]K449W$RTF74/V:P2
M[)%EHB[R+;KAUC^+'B,VAKEVY0SL+[$&[=2[T7L$0=U(06H;\N$71V"AN%<U
MOW(@9T93CC['G^!FYGU9B="IA8_'(5=2;,TD^L?.+M-6EHT8QH55,4OM25X6
M%_2RG2A)-C1Q.FF :N 6)=/*M>F62=)@8#0U$AD>QNQ,#V@1&!=1@+BUMHV+
M.01$-I0+O)0R)>K;M1V*T!Y=MY6[4=[RV4//6Z[HR-D#:7U>^1#K&[6&'L5Q
M@]A97=1LTUQRS!EJU"KTRG9:\T9ARQ8D_X4)XCM1K\B;RI(X<P-QMV_A?]*K
M<POYLLAL2S<@(/B)K+S<F2=,W!I?-72ZH)=-S_1CJ+1+&VH8%9?X1U)H[Q,8
M26,UEH:FKM6]'=,5N5%STS9FDC;KI=,P$[*%:,1;X?DS&:59415DT,ZI5FLM
M!XK)F:_:?F++M5[B"9JJ)1WF6ZI"^;@1'D=@B\_1(<<QR@C $46)B#6/EKT*
MINF'\B@@'*WQ+F6@)%@N\&Z^TB#9-N5CT_=/0JH7"A@FA-J$>B+?_Q#:/HP4
M4M%DL1^H(-'['[H3BS,V]>,Q"8/W-?Y]_0F]\63_X! Y4VEN-RPESJ-[1.Q[
MXXY/M9A<QX26XX@6O8BF2B,M*S.N;Z&:,CC<>SBRU=C33*^ $A([6C[<$[(S
M2#O0L3\L.3;<<3&OB:1+T;SKX# :-!#D5KR)?G%9CX!;PV7T;GEQ(6+OD1$+
M[-1+)^X=>R&=8?BX0D,*UR9=1J*SA%][6U&:NT?#K.BI]2QOA<1ZG4HK2D6=
MRNM(00FC2GAB@ZX<T&@3!EI82A(?..QI"T^!D\:IW UU'C <21=8<XU+1N:L
M(=L#GH.4=$Q+Y"XP?.F&-J$AKR6"(P:7EHC4G.4F3[D9-I"<@S%H].FQ)^KH
M1^]HY<@4W7AR</*N>B*=HGL9+6F'/-FQYE4NI(XT&&&H- L4(M+<C7B8<JB,
MFUSI]3K1R&03]IN_3C2:*69W*WRJ$56$:*-8F,38O.1C"8:EH$''>ODVNO=(
M0(SSFC1X<%(TR @/T70.B*/XW'9[7/Q,'$G6*,5*3$!]8MUR3A-"7U?3/"EI
M*CJN8D?<>$[:N%@%H@ :5C;<@T\"C3*'5E*+\IQ;R6Q'W5R24/[QTH2"<RTN
MI]6&!$$6U0T*IA,W/H7'\Z9,DZ&FJ'-V5B9!.;#VNQP@3J'NGO6(='6K?[?J
M8]!D4KR4ZH9TS67"@A_:"W20NK88>%O?MKRO$1=>&$[Q0$A4V-N"SJ4..AVZ
MESF/EZ&;!58]IHF>_LD!%SH;-6B%MB1V5H)<DXXT#./>_S/OX.C+X<FGHX\'
M1V?=#YWH]-/>8?=#U#W:C]Y]^G)P<M0]VCMX%(?=I^LE@'@#C(N:I2W1[+ZU
M=B!54H(8<=<'9J+!-NTCWL[59[NOPP <0I55P9%"/$@*8_A9I/1.WY'.HVW.
MQBKMF8ZK,!7=#E-9C#514 95S*I<G<TI0D>2R6A$AO<QK!IGHFN,Q.V$@H<+
M:H2LOF$-\]N"=BV &'6!W!QMPDDIC>VZXS.HSI/C6[/4B"ML1Z<IGB#((:?R
M,:FD/1I-C&'K2R25)L'Y[+ZFL_WVEL_X"V"(QQ9"U(FZ&N:HH[-2H@YEP%W@
M-,?>*#6#Z*T+V7+Y'UVZ\63O[2>&0G&.F(T+J'#'EGQ4" )&=_J>6YQW?B;W
MU,@QP:% 2D3RA@B8)@Q_Q-]P44*SN-6T6CI*D9,L<$H.Y)(J)%V80ON7AFW\
MOLUD]KTEBCX_-(FL;WEU:C?M/":+-7'I3*?/&^YSRMUS] >N?E+6BF\L,]J1
M<0$"I>]!8^-1\NRQVT-K<6[0S)I//A^1FWU1P_V[VI <-&4A]RSET X>:W."
MK>.B"M.XLA%NM$CS( U>=OH"C]0#2@7"?#7]AH]$[37)QYH3#I(=?N"!NZPM
MGA#:@Z]:1ML=P :3[6+!BGNTXRJ3/8YZ$*R$6S%V%[0HW*&_SN+J'+A%:<&U
MEW'V<.M$BP;W P3@@,P&PZ*U\>1L[^T^*<F@72.;'/3R9 IYGAI7I'SJ$&YO
M"OJ/D^<0^>:R.#Z9)55TO;2H'6V-NA/M6KI4@$ZI4:38:??T37!OZ\$/FQ01
M[URLO',#Z%AKQ*JK6;1=<88>++QC0L!L$#UH9[T<SL=J:.MH\\9@:K:2>S&R
M=)\8"4%+5T$^'TA7_!Y=7EYN&]W_- ,<F.2D#=WME\O)%GO^>?U+0T=@G%2_
M0,?]LO/TEX,WIX?_B[J5_Z6[_Z_<768E#$?8CL0.J^M5BO1XX^9)TM^M([!B
M=PBR[' 1F[;RK M50UU13_I*])BWJ"C:>;KU]\>QG4[=V>P4OB;<K-5M.]H'
M;-5SSJHX-%*/9?,3X&V*+V! ,X6+U"-8IKRZ[3VI'K0&LW=-J\XB'@IUHZRC
M-'5L"-P$,ZTE>!!&"NZ_<4S">BR=U*?1(6_:QR%?J>!-N>N*%;$!G5!HP,XM
MW:60S'?&%.AY:-)9221-G26:K>,*O9E&VZ037-I:@'@ZGZH$K2?HS$L?4!@;
M4X=6!6,6^[5EY[ATK\"65CARTAITE(QTV,]$DM-\TJAYYPDN8%?;8SHT8$2)
M-I-$6\JU!TV[Y;JTC\]GF8Z>O9PA\[Q36J/=!TEK]'3[U4LFJRHF=@.FU]Y[
M<S/^Z^[U9_S.]]Z__9]7OS[=O3]3_7S[N4RUA%R[&JA%\.S IVZEFFS?)\G7
M:W&':W' GKY.^IZO$%A/^AU.^K$BQ/^AII7,_K'$Y:-3ACFM%^ .%\"Y=1EJ
M[6U.9CWE/T'FNPA])-8]%<GO"@!*/ENOPAVNPHD-=V:(;3 YR]Z(=L(:AW03
M'-+S!XU#6KL)/^ FG*CHKWV%GZ.P]N*RA^2-1N+7DWVGDRVQ\NBXR%(M-#A)
MJ_, H+Z>_KN=?@%<GR&XY+F"UY-^AY/^#23>>N[O,OA@D?M!O=O:^[W[:<]-
M.9Q&G[6(_H"S*@ SK6?]3F<]P.J$1^SZ=/TY\W_Z+OIDH3?KF;[3Z!KSK(,7
MJA7G[* /6AIR1_J \WI![G!!_H@KLNJOT#,/JCA^!I/#1UA+M]Y8H=[O%/I,
M*6@L-?1!6P3.B$M7BUB(U7!!5MBR6:T!"'#E'EQVR:)Q:90 K%:6-R,F A<<
M $#O>7HNN;H'!0IIU1_1-)KMF>F?0R"A*M^@_T7F&' 5]3$RVHOCPJ+J;(6$
M(@5">%*:#\K8$>U:V!^7% @%EVTY08,;@Z<BL<5192UE!5+_H#U58P6<]M7I
M%4B!LM6AHH ^S-L(6ZFV:&A%%<WU2-HUD(09%*5A&A@U14Y_M8#[)2#>GYDU
M6UO,@&"'JK/E8=^ Y'G ; C.<Y \QT95_1YMI)L!NKA#_TXW'1Q0A)0^HL_P
M"D$)MC >T]B:DA'XMF1<I.<*Z=5[<^G&I90=Y#(!0F0G'&RZY4[[)*_1CO@Q
M_/<NZN%,/BI0^C>,\5;OW@.,;6Q "] 7P+8Q$8Y"R@),6LP&^U+V70BTU$CV
MRH%D@':MP,V05B-A$>(=C'(>)I^0*FR)6?YI+,'8H"AJ^I0+H)1H^K'T(/G#
M*(CG_V?O79O;.+)LT;^"T#WWM!119$NRVVZ/XTX$34D6IRV)(\KVG?OE1@&5
M(*L%5*&K"J30O_[DVH_,G54%D'3+ILC&F1/1,@'4(Q\[]V/MM02UKDTAD9&7
MN!NM)@[#"1U:]&?,>XV9;;49$\9.P&\&WDR0=D)#TO0H-)7PZE"/7>8K:C<"
MQ$C-VGF=0]XF3!X]4X$&E:40A6"O03)V1HT@D;;2[D%!YQ%7 BV&"-A4A&=M
MT9H">]=V*CD6KG+<U#^YM]'XA+I=:<G0<L0F[!/"??EP.L+D&C3V;1W_+WMI
MBX#B$GVYL9L ,'!OO&-W1N&7T+E=++=#L$LOQ#$OGC]!( F#2LNQH=XH+&&@
MV0?X]8!/9F9!1;>UVH<1N\ "/41H*2 9)J'7D"=A1D2_1?@)9"?YNT]>HC%%
M'X<[(.DF_CH+ET,QNC(7BDRB1E ]N55+V.SS)E]=)-)>\KY6V;E13>?82F/Z
M7BPRF5J_+O-R09M4X.!,BD8//;/(ZBLW)184WJM"51'GYU")*DR_!?,HP:+I
ML <Y[.N>+;.,N/QV=*!)XX@T9X"#2QACZ3#]XK?_T2]')S\=_?#3R\G)VU?O
MWK\Y^G#R[NV#V/KOI"4'YU)7SSY2%Q9(?D.? 6[T/_"^SNCSEY_$18L]3UTY
M^T@=G\MIO= E]O*'L["VF(VT]$?)RL]^W-Z$OV9,*H47A(;M)E\]?8I0/Q*\
MO$"W<S;Y,2^Q4]KINCG/?%36;!988,^?_O7;[Z1QU^^AU07VJ%#9^;=Y_/SK
MIT\FWWSU[."KYT^?9J'I6S>&7_5D*OQ7?^= FZ[X'X"3E[,;3,VN]H:[2PD\
M^D_JYF;-/S5"F7?2V<)S"*<.K(PQ-[5N;WW(D-%IO+>RV,C'K?W\O[/)L3 ]
M]#_]Z\'?N!L6/A@<BJ52='<7H"MNY/MSLE[>.GJ'O?(>+8#1ZZ9=<P?SY$QL
MYK.O'N=/\+5G?WE</%%K?L8$TC#@8?4'.>"OOF;UE$?V(V[\:6MB- )S)-@L
MIXO 9$N&FU <,+4.CK^/&%"K@]02VH/3QX?GE)G'9R(/;BKQS_?R^&$TCT3)
MS%LM+G9O[40'%C _-,1ABK"L9W9P^H:#F!;1LZ?_-QM![00<72+?&,N7+(>;
MSK@/Y,07X$GVC\Q\+4W@'2R8L(H[T/ =)D1M#P?'= P@TT'K#1)MD(2L/FI^
M$6]?(;S/U+VO9)_**;S(KV24UPM]<AY;X6_8=D;XX+'C*$8;S;P#)]2R""#"
MEJ6U7*.3G=C6J*.*3J:"&]>UPT*Z)I*F8F5<$^[$<>M.7;R@=&!>9BSX-3'\
M:(]675'#Q]8F,(PWO6T>.M&8Y 9#Q]F*++GS']LCML?5C>#J_K(=5X<W*HO_
MYU'Y[?3IM]]^,__FVZ??//_ZF^^>3Y]_\RS_YIOG\^=??SN???WM___LZ7??
M_>79LV^>?_?M7__RZ![A\N[.73[Y\/+-Y-G1X>3]R=G?)J^.CC^\>W_V($ZH
M#T10@#P/,;TC*0CM)3U!A)W$&)!@E*B)=.?FGK07),@'83=OF1&@;HS$&QNG
M>L:D5S-AO0\4 ^E3$6F]_V1=?:SJJ\ID8$'$3!HBY,^0Z%%!>>Q%D#^RE F9
MI@QQ8<-#-M++>P^X4LUZG)S]_.;-T?O_>2C+LF'JJMR0>)M.5]4+C^N##S):
M<%KG2:9]9(*WK859[CW2.71KC S"9V@RW#[4>T#Q#D Q*UL5;JF\@_Y__TRQ
M0\6D6LRX[^V(DR[HR?'_O'KY]L7/9[_+VWQS^)<;O<[ :^GJU7\<?$6_]@N9
M> QD36@5 M/P[-NO[W 6'OVG#N\/9?WAHLD_[<?P-XSAI?>EF76BF1P='[UY
M[N^W'\C?MA@ISJN)*";0*.G>EZ0P^RD_,_E., 1],FD]-&Y<G]G;\L]KRT]"
MV1BZ LA"J9]WP SW% O;*0Q3%E,@F.7U2I*Y[M.J;,*J$/>1LR,2JH]>[6&D
ME\:]I*B?NG>.'OJ&0HV@M)M*N2D#*PV1=R0KP@H%=H*FL)_[?ZE8$-'IKWMB
M >)NT5:=^3^47+G4[WJW(3#?!)::O<&]F_7QHFR;]8J+K%TV*?(E\=I!X A:
M)H05,[75GO+"G^L=:P.1MK<EKF NF60-!@'G9/5DECQ,=2C(#L4ELU\H=V=(
M(I;*JO]A@D23, H%*OX*3%07;@GGD2F@Z<],%EPV8(LG2<)6M3D-'5&4()PH
MYOEVXG[W[F >T3T,-%VNP>FKS(S[0_LA[[70QMC1%K)+PYRG6#W Y[$D Z&+
M_9,=L+9P(&QG O!ZW9$^==G&=.B-LY?[Z?V\TTM@@@VHWA?,6[TBA,0_ [*)
MZ""CB!/KDLUD42PV.)NC2:"*:[TL6[+%+"U9LL38<-$\9.LI&KRU2"T:+W9O
M+1_R=GKE]]&:E5RL3A_]VWT:ERE?L0D4AOR1LD%?YC" !A#%,.5U(;]6/+&Y
M2EGAV[?P5O9KXC.?H$%6>] =0&SLE[D(YBC7:EP<"4TK[/2B7)8=281H!P](
M*!DCP[TN5RX):3BB;CXZ LXO]VO@B[(+"MX7:=0903%A(_AH8#./XK5HG5,
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M(?@AB'L4]]+\EZ@I=@W9@@BRFLJ%6FK?0>6]].^0QWW[L]^K_G)G'5>A0A-
M$B$]Z$(#12F&1H*D)KUM(#X3:?=&AGFS#V4>Z&X[CA*^.(BG6DP@/$P4_QU?
M% VNW@KX=,Y2M4V2!:"<T^Q"OOD HI=[.<FG 7\"?''C5MBJC-@V$LZ4AU1Y
M;R29RAFF= "1F=\T@TDSKU?9S_U=S_V".-)(R92.SE53VCJ1_T_7@48FX01!
M#]K!17V5J6I?06K8#=B/.#LYRQL4"+G)&%UU5,'V)S=5%?T?02?F%'<7M2Z5
M[87.^/WJN)O5\5+=)@F%_91I<%PTZ_.6X>>KO#,X29OP!2:=#0G9 /XBNJ<G
MD"NGALH)G0;_5FY4XP2O03 8'T%2(WGI]AGAA[J/4+9A^^H=GGKA#AAN03J3
MX+^E+4(L!J"+@W!Z)5F+DMN!P0%584_M+>$=->S,)?K3K5K41 (A2L@ <BND
M1@7E!4B#F6V%8- 5F9;K\&-3LF/7.L%V:?Q*_01-4D5(X.3_)K W,-0M!*VT
M6G?*];HOI3WD;?=S-8<R-.T2G:2P%M#0YES!%#M5#Y@&SKP0</#*B'0(-UTC
M"H[3^QJ2U?V"N+/V#&(,]I-S^OH#**VULZ(0Q,$,C%ZSLEV&4D_2>:'$ON%K
M6>2X1JH^3X3$F9ZI<@N3V,\TM*%5I==#/9=65#1/V:0"K69YV:/@:"^8$:H$
M,;&AYQXI3N0L?2L+D<Z(CD1Q]POPCC)BFRF,"/'&(1B>E07%--[B2*5^W6:)
M90F:\QE10>=3D$35[/.Q3Y$& ;RLPG(RBX&7BDNO[FA=\1HC/MYS9GC%E_AU
M'%BN*/8FS/S"[3LB[JXC0HQ&/HLUR:AT08:*H+4],"^,D_2>49^JE!1#?F3"
M/I/0E_GXVE]@W5"0&:C5SXY>O?SP/R"TRR:GC"!Y[_*"5Q%I(S EY6PS.442
MT#NO]!$8\)@(\?3]RU,F0<SBXHU/[Y^F<P(<(YYJ*K&'NBKE# $QAD=\69?%
M< "RF"RF?"*E"+U#%H'I;=(Y%W#K#]GQC7[)WM=]R,;A7;]Y6!K8S18*\\4N
M2T_=P_]HE3,EID7R%F[J=SR195<"[I?T E/[[SV)+V*^)0.@T"($_D+M0JBF
MF"IH<LB72#<=*Z-4/@Q";B&%S30%@W_-;X4]QA%KYH1;0OS?9M[=_<.7P32?
M?3QO:O^2!S(/<_I_W^_7Q]CZL,4T9J*_=-[0=UI.P[8?>X?KAOEW/]7>!PSK
ML7<I_/G_BKD3_&G_P7DG]Z?:/VS\VYFK2N\A_%PQ+4XQ>5L#?W&7V#3BH0:C
MCBC"3'T\!K660$D] .*3,[]/UGX9.P><1T5)X.FHEW/E\H_DWHJ  2 ,3<5.
M4]?4"T(=6M^+:#W5'..H91\9.,$U167QNT'_@*Z>4[^ZW[K^97T8^)!=U5'$
MD HCS?Q0>1^>(8I$T4TYNHY8JQDGK]$QNS-[/_=![LY?DP*(@*?G:\BV32B9
MXL>2:!U4P4T 1[1ZZ#]T#41-&$8"^@57-,0##^6DIK[J+O8F^.Y,L$$"Q5FF
M+)4W!V0R>4J!V4QF],]4,VL=V4^Q(KO3I(WCLA@<HZFKW+SDA+WTIT6SLWT]
M[&?_=YM].SNLSJ13%#+O;;Z((* FOW0+;5P.B4Y_H1]R=#7[EWSK@YMRM@?2
MWPI(_^T] ](/]]^.7S] /VI,[]$J.AE?)O/;I*,CE5*LY'SM_9N[,W[!: D7
MI*GXB4N+-'V_.(C^,^1EA)M!6I>D59J.,Z-AL_=L[@[+%7!9_2U)Y>BI<XH<
M0!(W:5/S8XQP=')9XRQ:[.P&NV=V+!7-F#JDJ45E9[*L&Z,U6+AVUI2KL*P5
M&]RJ_U]B)TQK2,,9IDR3&C65$,02&M7[G13JIKN!'<QNI+B.&!]^^8J%/[[[
MY>7[MV]>OOTP.7[W]L/[H^,/)V]_)$&6>Z/$<LLF;Y1-0]NOMWU$J)"RE2 W
M$^E;(>"-+#>YEWTR=%4K_8.4$6[UKE]R^^XM)TV9_P/1S(>7;WYX^?\>[<?[
M]QEOE.0)( DRED8EZ"&?=E%"/E8X%7G[%/_Z_OFCQ!S^7><SV3]^S/\H%9)_
MU_$^G)S,558!ON>S;[]OOTRMG7_7&<KV>^!W'^&]5?^=K;J8D;TS]#L/,]-H
MJ8-##3DDGY9]CBKBY$IS.+W(TQ4/(YS_U=THSI*HC"DVI,-)4&7J0[9;G<C]
M<?EYM=N/I$>?Y)=[_(Y$5-40+W[.>1K*G0ABQ57*K&3Z_6?YFJC6"S\.F]B@
M:(INJERRG\C/.9':78*)H?#-@%:<])!4 PXK=&4K/6#C9O5YA8*;[,&'89-(
M)==PK25=$%H3%N,S8L!Q($3H.$7"*T<O-:%&+S0#K7(V8-'%%^XP:[=HZ*L.
M?FA4-]0DAY^H9:P\VU\*+9$WA!:G&;M\5X"6U:VHWL=:$/YFKE\N1>U/=A^X
MFH-0>E5/5 -8.'GT712/OP1#0]22O\4K4GSD'[5NHB06M14$>,];[<DDK?A5
MZ:__F++X3[\_>WM&_WKV_9.)*,CSDB7)!VZ1[=<]@$M=^/GEXZ8?F>5K0 E5
ML/[M6198!@Q'"3Y;@(U32"RN>\<LC!<!O&K6Y>,EQ?.P/[<^]Z[>"ZQ^)H%5
MP9[2>0T_5RO!?H!1& Z;WH?11^]?'#$(R^$ 9PF)C@$:J25<0)S'/QY738#D
MD;U->-[]3OB<,TF]'BM6CY\'V[0RO5A9_YS[5^.8V0./8Q*N5B75R%OR?.G$
MO$TZ7$(90)7H(-C+&?_K9DM/:7^T;W4PWIZIS] _W_<S\!EF0(89$7KAT,[<
MTGE!8 40CK3.5M[KE>5PP^[83\*_, E*&I/]05;]WN@MW#+A!]#5C57/@T:*
MJB*IUX_UW]+RCM':X>2HDNRA(D=VR["+]K;_>>O,/7E2D%5QGR4%2:AJTO>(
ML_PP#NT/8HW*5L/C"@[I(J@H!XGE-\=OC)!-4RY!4"C<6C(I\1RQ2P'JX! ?
ME -^1'52VH+LCU;EB@P'Q=O138X=]GAH"K3S15M+']CXPV.-T,-K&BX!R,M-
MV=W F2</8Z7<!P*J^G0)9*J[ /')54#:]SI_)T?!L",.SWNRM*.8 .AKFJ3N
M^ 8C.IX&W8F'DW<(,0#V7I1SAU8HW&B0#^X--2L:90+@YTG<AQN?]>B))WA?
MA]=.C,XI^UX4.68::I8(&_$MX(TOFGI]SJVI^57>$&:!%(6*$E:*69F\12J+
MM7;9A:7B?>_P!^*R2')PM 8L)X_*7:4* ,?>FGM;V;*?DG"8>B,;TDV< D/*
MSQO>%BP:&T@;^:DI_=>PR+6VSS?Q_I"?.FYG"^W3]%B(G>7G_-2MZ]U6"3G,
M4UJ8=Y"H99VMF!6,2D%0N?4N69"C9D>8S)-QE8LU.=+GBWJ*Z 52%DMB-B=D
M9<0YNH4S2EYMAVXJRDVNBW-F=\7]_#R4U<U)5[_LPR2U<-08%E;2 5:9V^8D
M=)N58*;.40A3 \]@57^#3/UCRJ2B><W_".R.0J,L B$U"W85 X= EC;,/O6L
ML3J]/_;+FDXM$-53ORG6II,/*)')G(-@=^'-$BATJ9-&!.2E\U^^C+?D3CI^
MC-[=L*%IZLMN+7F@9?[WNC$*&ET-NH'D5F1!%ALA$:#7\N:^FOS7V@_:5\^R
MR?.GS[\BQL,KZG* 6:!8^]G3 ]ITP;AX=XN34GI8Y\4EWB^9F\RH3Q([C)\=
M=[!>90.CY9_OY=1OE/S^Q20?WMQIJ_MC_]OUI7>DI@?_W'Q</)ETC<N[("'X
M<EHO<EYT8>[(1+5L8':M5:$NN*K[BX_6E%\6'5O/3R4<6K^"_M>SY\\F_AT7
MM)$H\]7?(P,,UG[:?].T2[.[-T-TFIDI6:]@2/[77_[ZE4X%Y6F\7>S/!NNT
M<\:@R(S-""N%C8>6HOKWZ$W^MT^_3NY(=1Q:9,85(%WXPO20YVOO\C:BLR8K
MA+FN5 >5*]U+EQ/1ELVN(OQC^EU8YHMRWDD92+R-"J\(YYI*Z5=..6!993%T
M(<.];QQ](L;+NNPQQ*"*51DJ6\PN<85TBW^.!:7T;0Z&.EJ3Y(N/"R+KK'8:
M,4=%B!3"<9.EF4P&L'  F40,GR$TO3>.PRUS#-=PK%W%I:UT.TQA8D1G=!6,
M>=AMY';!<B!J=59A7I5-2#1(=J$?#@ZOMF^.O55S[%_O67/L%[:5=OO@-\DK
M<#!G 'L1G\$J S??.@+9]H]0F<.B'::-V%@FS-I&=&+R\Y8M./H,VYB]*W=>
M=\(^DQB"88@=T!A@ IVM%WG,3*'!D/6I&&)".2@0*3 93;S)[EOP&-C4U\W&
M8JLU"F0OXT."KN3NQF;3<(%$J2$8O/A2)DWP$J&Z/S^OG* ]+9&(#@@'4+L'
MQ4?>G:8T*#DW\5^.)SIZ-=?(6I&3E'O/P"]@?#SJY$)+C-(+"W@4D;U:M;HC
MZ2M/XU$/5#=V9&R91D*P#(2<Z]%T)F>?33V G*5 B&W(B=5%B+7FSU:.N&>5
MY=N[!]8UU;G2 YJXIFQ6(4\$HJ=E4=BO,DTCF-,<_+WR'VOMD66('Z5SR:S=
MF_&\MH 3T'SAQ4?&TR:7+59R&A,,FHL<&=_#R?'(H&,WC=[*AP<M'1V4R1P?
M_SVEU)WWY-.A6;=MJ7;4@)N1IZY\E'U>*G^F:_UA5G R%A/IVDY3"?XB^>+[
M_2S>V2S"_RB[* X8,3FH'/&IU9%D&3L@_DF\3QXJ%Q_=9N*6JT6]<1P^<V$0
M,7[P6?RF#[QA--_M?L+O;L)!74M;46@4_<$(5L!E+FGH0/$M%(%^KRHOG#J0
MXCT&Q1TD;526I]I$]SI8!3R7.2_VTW]WT^]W^+*DFAU#+JP0 F.VO??*U'[L
MG,)VM[RWQ7:WB?&VM)&")_>C&9M8$"@6C9_YA5"/H$ ^>J7OL>)NX5OME\;G
M6QH"4T HTBG)#GEMH):119'HDR9Y4'(.>7>W7.[UJP7J+]O]0LY7KX(:IO4@
MO'M'V;85*94R5 '+240O\4W8&>WX&'NV=#5J538L?3V54 \H$#PNZX)9< !U
MI,2)U'_K1B^ ^-&'8QR#)? D_O$L''BA).^*6*=[$$&#(H6H?'E18RL+=)$A
M"'[.!5*71LZN%-V5 2H(:ZWR#S<20M?-KG:9D(Q]<_SF!OD4E28JJ[9S>2'/
MRWH7L0)=]]<^54(DX;&N>FEFDS8R:?\M>G,B)2.+R4_Z1Q>\8&%3I85--9+Z
MLL3BT;)#;>O8?1!1.?* 4B)D I\K2L]<Q1TK&Y73*Y64RS%8E&#1,HF_*"@E
M:7(C]HKJ4-HOU'+Z([H,_023=1%DT/Q$T#/G4&*<<7^$>@]&I[CWL)FAF%6"
MX\W-$B92R/P-$,ZQE,W#3J?D2U3K6EU0J[PL#&QI7GZB+87NN10>-)(PP^^#
M>54/LPU]  P*FFN/G<MZCF>P_F$)8:^PHEBZ7 ;;XT1ZS5@=G5>I^P3E.C8<
M^BS;MJK+&RP:/_7^UECSC?,FC2U].)URUA?51TB0)JE>62!(&U^#9KUQQ[R8
M1!Q<@/[=F^5V;;9)F]>O*R@<GAU.7B""#&'I:RXE_^]\N?I^\GKMGV9RIJ@;
M[7A\_3IV/"I"=>12+Z!UU,9&R1?UB_BSQG1))JO=K*Y?G73>1T=$CKPM[]7#
MFHH93.HG7!Q>E!_)S@B6=<O]?Z85EX]^G.G&M797N\8-[K8E[$=RB<:=>SN[
MD%9?H<&,^^?*\;H_G+SD[<.U[M8>6X:&WB;H4<:?S>JFB)B48-Q3;POI6H 7
M<:;Z=XG'*PXQ*FJ0+S!:!BCE/$M @NPPDF(+TR2*4LN%7YE0T@H(A[*:+^@9
M#B<]*F4+.X96NLJ >5NQ!'Q10V<>"Q-4UTU0-N#/! Z6U"[F6R8R>+!D$,0#
MFGM3+OFVP+2=N.&,=6?+].]I@VYYY%FU4W*ZN!>AK$:3T]FD]6.!L4^2X(PS
MSYL-PW05>IITRY.\E' *4)NHAA=^%CH_\Q$CFD!4@]?:YR40KR3H-%3_5C"2
MG7/ZXUA90>?(WRY0I)H))Q.6@$YM(I3 IUJ&@+()7(>EX$)X*2C^*!:;YA
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MF[PBUR"'QT-6[Y6;-FOPH#U_^OPY>RZ859E#/Q(O_9.!,BTXAL?YLF \%X_
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M%V9$ZO->\;7H$9K\*AS+>/>QRANC5R/4AR5[(O@)]KCV,Q]&7O"/?L,MJ-'
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MWI+\%QJK5"/.O#^BKXJHHP6]-8#B0).:$3K SY7_7,,%9ZP/L"^40E2\3\#
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M8=X)QC:,2)"V]2Z,O^AELH7F0@ A71_>J J0= 8#SIT3]%C3M?1&41\XE;:
M\Z*?,%4[RZV(Q I]]6$<X,>C.K)MOSRRB]='C^#3-^_;> 8+.SL76BQR,W2N
M2*ZV,Z>Q$3@W5^ >A_/&)1<(!Q)YX .\,N<J>+IRJ"$ 7>G=RQ:1V-5%';JX
MI3KCTG8T+KV_3TK6%-9Z-T(4=V)+!XOR+,MVVN25EK>;\WL4Z5Z' ]:R6$:
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M/MK/)(MQ4LUE]MX[O"3^=<02EL^?/G_.\G8"T#UY?V3PN0 X\W27%36,7>'
M.EJ?HPGEV3<9_=X?P!?E@MU1_W-JHN[0P6;C\[6/=_./F,_'%#/0 K'A"$=
MZ/'-)^=K[P$@O A]7#&*YP8P9OX)2U7ZB42<SS\$G_L-:L7H'R^)LL.L5G&>
MLLDY#E,T$!$X6%P4.K4M4+CP8<T,K'V5.Z^[DDF N_X!TCO(WU"74*-\P?DF
MT7\%>\8!?;N@%2BZL1A ^GY":-6#YD4AP-.\Z28_T /3/U_PM0@63PV^_A]X
MN\9-R:4*<EMZ@5F^F"6=U][!.S_'71Z7A^Y0LA!AYQ(/B80?G+GK5D&K0*A
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MBT<"3,7?U\6Y:27#Q<KV(S;"'BIV&ZC8=WNHV.<:2]<TU)5!8\-@\<AI3+W
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M2=S5RI'D2MHFIV^0Y!OA;!Z?/GIR."%_UO^;+\$6"SY=JV\ [\O_D82.T/Z
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MWWM<'KK#3+DBZOG\@"K52A;!/VSX?Q,4?M2XC< L7#* N(=P0NU/QV6L,KF
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ML4A8L'$V<EJ)4$R<F*I^4:2=PLYZ0PJ5,*0VZL0?)?<X@&ZGF:C]I?$]G$[
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MD01?R)MN68NG KM;LQ+L=SIKEJ)3FN+ ^*3.E4-WB-,E1+;[=4!AP<=46EG
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M&>!!8;M(.-))1G5>'E=6[C?K>$]R^FN,6%,\S?W@7?T%B,7!4NE+L*A&/ E
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M+]$GQ@0'I9D%KW U$<D^.#CH!8(Z_-X2FIY@;1/+&HK-"0+#TK_AMW>(,D<
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M=* 7%ML+YVR=YHS9)>#81: RL0=XPO$('A)"E_PY+(IJ-N?)(BBOG\"-(9N
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MLQ%9X7DX)X0;L"/@."SJUOGJP(,--U A6CH-.=[!#Z?AQ5@].!O&J5?;1Q[
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M!JY 7(RQ]I<AH/C(K J+<6NQG.J=/!8(SW;P"(IPG(_6,=RR\.6,,)44OHR
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MZ:(*'Z*KY*:AS'KRL!K%H8/ 6S,)_Q_F2_?%Q+ZO[0BF>[!?-D4?34?\!A-
MC'>#F@,C\9^FS*56'# !"EK")* $;/(.+3XHP#F!'UMH)]H607G*SY<L>,!,
M'5[)@CU><EF9?"\/,#&3^^?BC2BQ$PPXL_!*-/$[;<W4QO\%<O\BTE<@!T!"
M6YR?\&G>V%5D"SV+8F%+=\9L:<_2/+.SXL_^-;4K5PZWR&#3;0N.X(PO3"06
MMPP6#R(7QHO*^)UH^#=LH%@JOUN-I=/B0('PXN896=ZP-TR<GN(O ^M[[44M
MOL\>0: SBF-KGS&1I'7I\C*<R] C<9D83S0G(?L2:\Y%R355.$GQDY8X8#R[
M4W$A<Y8N-,:WT*%.R# >-:,2X6YGT!YJF9+C%T-S#;?D/KGNC#+89V#""67%
MK;B%7'B"65@L6\ S#-%/:Z5N6()9 )(KTO'H6;DN-G&TL"X]\@&$<8?2U<(-
ML.9PK-K:QQ="I&E&=R?4/#*^ZAL=XT<7'7Y2L[&5X</FPWNFF/ %4N-.D$V)
M:Q7/B?L@$4B"(XP>$3^/H_UN&-BN^^?&F&[2?8\7R#-IV6U(&0]2?OPKI):R
MO.\!B5N?%]C']L2&$#NO<#0CA&:Z]RKG[<>5^J9 <IM%50ARL_E!OV>K0)ST
M3EYU6'1GP-3>&OJH;42"(Y(R>1PDQ(U\)^*W9(R:A.:)X'E]WAA';JLEFXWP
M;7CS:?U%R9L*,WY!+/_.0OK*0C2Q%[,1>5/'W<S.67LPT73"QHQ@Y?$V%V*V
MG 0;AM^R>9Q5T'_"_HTFS_$D+_=(Y33+T4PYTQ8^0<+/(A6&(!]T$7[M_F@R
MKI+R"NA"'GI_:*@G;N;3U7^RDSPVM[EU"78E,AL9FXG-YUDN6>-'M_"%P?Q
M-;[\AFOJN72^BCQ+<],):FDA2@;*OE&V#T&0133F(F$$Q[;O3Y$9T"JEKEM1
M-Y8\4@9<A;S.S:>\4@95B;*]$J5;]TJ4$X7W?KG]>O7U^O;JL_;MUYN[J^^W
MW[[>:]]^O[G[_?;FCX;;AG>\A5>98&9U#<$_)"!L0+)4!.*E/I/MRN) NKP;
MJ!(].R=Z$CG:A&FC4B$[ID(2M678WRO1#4,R]BS)V:N7.'M;QPR9P$JTF2.Z
MK7=:07L*NY20:9<\9 GLPG@.<4MN,0DT(+A[$O<+]I-7('*Z" N+"*]&63S
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M454@Y,-O[?LV#(*F&9TU*13^"6?9AP,HA,$BIYZ'#]32/MU^_G[;2@1+0=8
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MJ46I,SD) NX..+@4I@<+Q[I.D2^IQ;')=X0S:-[N,QB^SQ*/*)^#9&;[2N:
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M@PW59LYX.4FV7$L3H(GB1,3&5(*N;XTX;&=.,Y&?@,%,+3!_H'W*EF U42"
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M.<<8EKX(N<J*:H<RZD1.F[8]@B<D+',@7)S7P'R!R&LD\A5(_]C!9#]6S*'
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M7[&(9@NM N111K98@**[V]/4%%LVN]5==^FB,T!F#S(HD;A(D:A6.J<E$9=
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M$8)$]E!:NM^@9W-*N^&$8K<T(I[<3STJ,$W%)Q\V;9=__)T"QI_X\#D5+ T
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MVM7#S>#^X[L(^\O?W8 T"-MK.K;)N;\"M 44-YM44#D@(1XY!@$8&=# 6C5
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M4G P8.J<3+@<6:+1F<AI<'E20YS2E+UWD?28ZT_N\D<,7U]W6DIWYJ0[N36
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M)V99]6#HN..;;8W617I;3<RV:E8:!=GFE6EX2-67%"0MGI)7%)#D>2Y6;YU
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M/P?4;#D%W!TU>/!7F&"[0DVNJ*EO.?;;'35MV&?!6"O*<?&%'M*$8BF:(ZH
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M'RZ+$X@N1H!S4)S* RDB:K9MKPEA$TY9FQ@_V?CZ+^;8<7#J89.F;KU6_Z
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M]5T.:P^T$/1G& 3\=+V.6)_NPIZG1$V93'Q])T2(L'!"K.='?I^$@MLI]4$
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MQ'"FC!*0^ W N]CS'*;,0OZ(7I,Y/^I94\&FA.O*D7'<.0&%.&..B_F2M2Y
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M .(%76PPTZ7P6#Q=DF^0'=R- *//D8P YQXU\:"F"._KC_0(6C]X*GFHQE"
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M89+P1@D[\,JE;:&&4KB/YC;B1%WQG0+SE(E6!4Z4/U *#C0\8/56N[Z\1-'
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MC=#='"E</7OB2 MIQ\4:KB+YX) Q$"SEA^$<T*/"L(6,R&>[%M$ T-62&38
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MOJG04T1JHD.%J5MZ <$^;3Q\L.(]D#Y7Z@M%/_/Y8F??!^23T94>CC*.!4"
M).1:.^P=Y'#$+\54J-+%9FTDUR$R1H#*<,!/77+"_DQXO[\7+$-1'(G]9Q4V
MR[BSD]25-!W-I?,%G$A^L,0-Z_RZL'I5200Z)HE =^VM5G,&=!1I0%M?<'N-
MZ]YEGC"@67E8W=V'97 9]/N-ZWZO@,@ I++JT'K['=J@<3WH% P-;C0!%@#+
MF!YL-I%5B?_;Q;%#S\>F9"1";N"4%[)2%.T55/7RX=VF2I\+\[2@"]^*1+JN
M4T4?QUH(?7<O?-E^BHM*A/0G!'#6UF]&S49--\E,P@=<KU?05"M_K[L+[7Q1
MT]E%6CXH*_O1*%0Y"VM:6MV%KIY,HS'YM3C3[M&G*2L RH=7&%LV=SQ^!%41
M<?!FXC"9MTZJ8<$/$5\1V2K2,6#22#ZM9?TF6]U@;#HR0&S,,"QL.9S_4\D7
MLZ!^@=/"6974(4%,0JL/G0[845 !()L6%)E3?00<P<8)<N8:\0DY>\1>H[^/
M:,UL5?F)*L1WR<I/M$0R8D#=!RG5&T7!A-K^J4":OHN6]^B@5GVA>\^4 @9D
M$36'7HNOR"91U.E2_G2JYPOX"J+?8TZ B/7$)4MR@=\+%U9QBR=$W,TL09#[
M^CC#3],\O2N&  >$>F:V$)!=7(S64"DM.,;(=+(PLCGJ:7@(40&YH_ORRFE@
M>!(..4GG '>F++LXTZ5#QT].+:K7I6V5NF%0+3_'(G$$' #>:$_-+<5^Q49L
M$D5%)V.G?&R7V!XLNPJ$>Q2$DEN?7_VOQ)9E[3 T11JZMAU.0?;+)XQU#-%6
MWR#?A[$CB2"]([WT:W"D-;BHHL'IZ$CC::*+^H7HHL%Q]BS\R!P,&./QG7B'
M/*1\5#E6>'@NJ&!CU3(P8,Q$!0^4PI&&&+ MW,X,S"[5!' Y>00G#\)+-,B&
MZ@=L"NW9X92^MG#B>3!5E2?Z[AU); M\#> UZA_R"A6E[U RJ +QX#'6_V:;
M(L.-9N[84[30/L ;7NF$P,S]B154 1,&7:AOPSNYK[7BUT68DKQ,<<\(2H-D
M6ADC)Y.+QML\BV1YAV(+D><EXDL*F4&L!#BB_E(G!>7\\$2B+$AZ*75=#I5-
M,XB'ODK%T]1KF*,>'BUNI+\JR6 ))*/(O,2._@*8M2!2@"T]"R8SH X:%,\*
M$($2E39*BE0/.WLI3EQP"@!U9%,G!MZ-]&$, *4)SFW-KM$(A 0C6BT] &PL
M_A<SGN@9 ">\%TD^88]>".@O* $)'GQ5'V[#QDY0]B6$1C^%6Q]%LKU) &>9
M$SN%W[%98XA,)46,8.Y'H<))E@=Z9.K'&K@EPZAT1<HL S0VX/D%L]FJZ9'8
M17&*)8X*=9"KB+AK;-FSD[!C+-,\0N ]EX-EZ!SCO& $%[# DN0%&5^FA/A)
M"QFP I  3DD"*9,034)[B4%90M"<]=WL2^A<>';B8PD4+\Q97,W^0<3QZ?O6
MK<[]?3%[U@,:0WT0.<Q49,@H=TD*[0=U/J3LM02 F!ID\H*9831>;I57")V[
MQ"/2<#RW[B&@'RJF000+*NEEMCP&+Z#:8P<"@-E-J;/%,G !ZXEWQ #SZ&#;
M<;#B_$AL9-US(%H"WCN5;,HBR_Q(#+A>TR")U)R&8\=W9H3KRYA\,C*RD9EY
MJU \3+(M(*4Q-,68ZZ2, W))> Q#+AJE[M9JA.TQI(E'4\LJDG-JD0 '*+=B
M$88$.XC010W+51>27TJ<\V)\F)&A*-($+(T8-D6)'.%;?,!-+G@/06XB<T=S
MO)H,831!+@J_7,(M:N(0B&F$!&P".4^PI"H2($%#C'YDO9B&R5UJGI0,RJ\N
M2UM398KPLBOW9R*4CSFZ0"TRWP)"802V,DD_]Z8S7R,#QDHC4,Q<CQN/I$?D
MR3[-3;.G&^17)YZC*.#S0S=@WOIBW;3N78/Z3>>I96]=<OZP:)88R)AS'UNW
MHP#AW5B?<0#,+Q(!618[-?E$;;.)G<&X;(J^G2YZTP#CU.>%[^00AVE'J+4A
M6(TR-1Z;I+;%(.*3JPT5IETL-%#T0'\&DG.(7B]EX[U=;G;RX5_@T3?^]+U\
M<.E-;U10%3HZGZK0E:N=N1&BPTK<9!-AV!*/VS!E" ^A!9\;<O33 (?1:<A,
M)NH[>%I"\D&U)@E-LKYT"0C05DQ2;4XSU=>J\ *9F8SFB(HZD@D$^48[XWM(
MTZC25TWDA3B!5^!RY!63"\!2#- 0.*?=[,FW7+N8?#AA.%9>LHSQH.<A?@I7
MYP74+I>\-'N8R#'@?9(B:;B.@4\4O!(&@84.S<SI!G8FYH8/;DAA9-W$H<3T
MG GD0!+ZL_NH[KW31$=G,XM(^R(ICIGB,LHY@=!=WB-?"!UX$E(42_1D["G=
M>>DB&E/7F"0";O!8,FFA;TC7H-0P;>RD@K2B)$HI'90.$,@[XXEGZM:>'<R9
MH(M2)29J%VAE0W'GOP D5Q3,X@=8.W30Q;SFV.L(PSKR3Z[^C?>H:5":*E33
MU&A6B*R("[[WJ'HQ8-0EW8Q7/DT<7,XT4OV(# &3[U8_,;V\#'2V"20NJA7P
M/?45E@0_?#L(L"NM#,5)'I=8D;^DYBNVCR?;LF[EPBGD#*8D9B@MQ2M)\CB&
M7G^1OO<LX2(/$8'P42H('"-WN+RJDVNJ):[*MRFGTT[B.1#)0<$X]"6:N,Q=
M!(V;Z%]-^:6_'$E3 $TZE6,I4URRQ%".FL?$?1Y+JISDP&7O:-V!5EZ0M#SQ
M5R0Q'SN*<@QD.J22MP[AOA0X+I<%CLOE^3@NIL;?2=" -H0$=Y%&,E)A+-5)
M?.5136%KW&/A1<-;+V $'&W5EE57$8NMGR4>DD\K'UQ#BM3)J[F6HF0!86PV
MX+, RB^C'0@0<UFP)R= ''5:O<O+J@2(_<O65;OX3U49$#=XU/:$9E+\CXGW
MZU.6K^TL9O6'\-BU'N^+D.X89_HV<3WLMG1 /CK#AN17XYGFO?+0&_4W/O7^
M1*/[2;BWJ;:S8EB3-\+!@I);?1Y>-:Y[G6P Y&+U4')-M/<RE$%;#.4J.Q2L
M$,X@K<Y8YL&I"\5!FB;-KN7_8C0\C-!U )!24?Y'AQE*]P7+_X<D]%WJA6JZ
MG+4&&&)W>1BQ@\**B@IP=9B1](4N#EZH GSC6W,M\5K.+MN'D;-!98F_W#SF
M4&DDP\;UJ%C@LY1VYR?QGX#980ZUM?OS>8YSGE%$R7"=@J'8<\B<0)"B7$?U
M7"5%><3QJ3^7F!J.N>&DA"@U4Y$H9IXR@4TRN*A3.F6I-@1,+0)L?2++QU2-
M&E7%/'(B!_QMX"_#G0BB"..PB#HGR);D/(,^U+JHU/I:DOW268C"?-;9910,
MV"*&=#4=-LOZFL2?@?*T"W&>!LR38_E*2A <P0VV,2")6$X"@KH1R %_P4@C
MJM^X*<:[\2,$+(6NN=$<7I6JT6")U)J+99UU0<!^"P(ZIUT0,"@L"!BNH.T$
MJ$1E&_!,VQ-#_BI*QJJR!W2?]-R ]HKO>* L3 VO$N.$]HTF!%62:1_".QE_
M@ P_LE]@?UL I3'0D_2W5+U-(Z2Z7 &,#W)T,N$E>RP@TAL/$]FC:F;R1<T<
MX+ W&L9,'4#B$74&MYT4Z]9,Y;Z;&DS9I$2UQ&XW%?B-?ZS.$ !XBZ-%+*?X
MH=C:29I&@T<!?*@&U4>5UO/' EKZ:/3BW*GP!![SW?Y9!D<:%,"1!F<$1S+7
M41=>,.%*D[!(DN$%^Q4&H?BY3S\ G+GQ<T1)I%@>=%I/'W&Z=1LE]UK6.R!S
MP>('^Z?9/-;LM$3.EZ('A8<S4 9^!&HC]-(AVMHX#MTQ%QL+/96%C_ WV1.N
MH&E&85\)S/ K[$;!L,AY=$,S]P@CTL2]R$ZKNK"C,\BT(L5PVE>-K_]I+Y:_
MOFN\IKE1L2*.3DQ;W.0!9[GIFC$]ERP,$OXD09#%KT),VIJH9!L[FX-ILW]R
MOPS<7D;$(J.F:G/#O6:<Q5+8T_ QM<S24TW!G1$/QL1##K3(F9KM]HS&OW*O
M$7D,E1M@D86)53V, ;4,+0MS*R#QK01-D[AA['GY@V$C!O+Z//QF)0FZ/;')
MMFIT1(QT;VQL72_K@0E\1SA!K1B:NY9KLN3#Q1TK"7W [,(=*J>:NKRY7.?Q
MJ"1+P2WF4\V5&4;,W[W#%'^Z88["FQ2; /:KIP5+(VY@"V[;N@ J.R*@4>./
M3"RD\3//?HA2>@#& 92)*J#/0I+23' &*3HK3*'*B2LR(+^)'4+OAVD^4GQD
M#O6?Y6H[Z,N>8''&6!C !ZH2*))!*6U$)Y4=!K7A'.MB.ZBZMN[SQH4AWB!<
MP HFS0)T=T.63/ ZH;.UINBDHKVL0!D+8+( 2,M21(M51LM<LF;@M?EW 9Z?
MXF4(4D7*,F#I<>Y<1[;69I)F&!X@WE"9"F:.A[4$[C0E!+7PPDT,J*5KI.4!
M_XY_8 YF-MGZ_(3#KVC16)-H[NEJ#X;#$F47KGV(93LIRM2BK557;>PQ0.3Q
M+DIH[OU-(TR#,8*I(^E@@Y0E4FUJB=#?./PR/<MQN>RIT[(^B?5Z<,%=WVB-
M84G7K3.O M2ZR@4H7MBUZZK6J$0]Y+H5KAF5G<(>S.  I\4K7K=F]87;T(2.
MCMJ$_HF'7^3P>=N[),:KWF5/;MQ'"4^5?(6WP91D!5;V0:AG-'>7? H1>;ZJ
M#HHD];EM-="1% JWY-MLHTGW2NKCC+PZKL\$.^29^SY<7$WKRW4L&LF?]U4E
MV:3#=7P&K;"B)RGDS9?N  J!5M[2-[#3:[B\D8[C40-JP]#B+!R#AZA$@[;P
M]HY;P-XZ$QL P<HGL4.)E/V)JV'4?V@/#['$2Z#SE)R;!GW?/Y,IEG023)Y6
M'$E0;+:26?J9'^ E42EB>6-*M "O.J^)/D5<'R>)K!1-N1FFUTJQ[6;AB4%2
M:'QNW'2:UJLNOTC:%C.:E#5R^J JMW:$&^_Q4QU^C+S,*H5)?%/4X=['U1K-
MK->C*@JHU%18@&PQ"\:&5)$GG?H<E,W1]);W X42'-IX3E(8@U)5HNCQ%JK%
M"=2KW>!)]U$7--T QX"X;N\2!U)/^QR^P^20[7V>?1(>V"<@M<=71A]E"9"P
MX<(Z0P,;^L/J/H># F#XH!(P_%3+YW\+@BE:;1#2CSX>3D! X&&C +V*%BWC
M65RBU)PS389T>$0%H?!HE UA*80LDY'YC)=L#$51+;EP=#57_X3355Y+L(=+
M231.O;7H.MZRU!QD!:\J?<(V/Q%7%O)C=6EA^I>2/T35J)O,;O)>![RE*9B^
M;J,C.T.H_)WN5 371G&:<4/:F3#L*8)G>+GB8X->,$@W0E=,O!)H#X3I##*M
M&\C<"Z&X,R68HNAN5HZ-]>>USQ1<DN<%)"<XI\^3.%"\8ATRX'Q$NPMV!+$T
M4_.2FD69JB:37;$'1Y5=<HPM7:>9DB(N0?N8OIFD"0=L??++X@UB2K-59444
MD<.PYB:=EV0[L_5ZBFN7%5YU)TZM6+9C1SZU=,R6/!4Q6B@)8QXYO0\Q'+\L
MTMK1$6LQ#QZP();F8[8LV^2>]DPSM=/SE)-3$SL+:_H]NYU*(0OV57<LDRQ8
M0O?%:>8L=3N3[P0>0'H0-Y)T2]R+?=T6:O[S]&8HA5KS>V)IC8KW4\U,%3.E
M?LLB2--FN2VIQU[Y7CW$35XI7\?P%G/5):PET[3-EP,Q\J1,4!M!E% >!D03
MK0>M-Y:24%,904@/ZDQ"K?^0E9OFK5DQO6@+894=,5GF5#%Q*=8K,DL?OZC<
M$AN00K-NJ)*2L[+OI@^C[6PEW8_6S'FU]J3Y8E"CLWU'B]ZI7I%7;?QF7LW*
M'I ?HZEI:U6G!O[L&?C3/6W@S[ 0^#,J!_[@C?)4@#]K#PI(<.M CJ&Y[-Y(
MOD7@(R*&1!7%LL=!$J=RQG!;P#=AQKL)QFWI(-$E=T0*523%B.[@/Z&H_BY%
M\R>;P<F+1V2]BAR'^M",FE;C8]Y40\][/MT:KS<^P$[UT@]!$W9LS^A:;\R*
MMU5"N0K.9F*^6\-,8]Y".%0-CFSN4JVNCRULF>#8Q([VB \I_H5B^#D F4]3
M35RQ3TPY8(:L;/1'2O)%T@$@*"VQ?=B^:LC#20YV]!A+!YU[B2$</E27?V>Q
M](+''/\.O@E/Z?01:W-,T+P2D9>0O3C0@\'AB#2]E^S(:[@5*8(1\I+$KF&5
M@5ZS&9$ D=T&T)Y%:>""KR%_IG0O*CVS>!XS-XQB;1]M$].(D6II!@N-&'OE
MFT0-5GQ'^3\Q,=_H-^I7-8VO4XLZ%C)N,Y&""U%ZR8CUTB\0.#HVT$VV/! D
M+:MZAV;YRPR;+ORFF]:R/NB#!K9"]<Q,8[KEM*0PYE<SW]? CC.KN&['03R(
M8H7S 1P)RO J%LL"Z9#&M9H@O+(%@0QN:CF(>8Q*#[ QE^>)^W/ "XVC+Q"'
M;.PB_]Z5;]C 52YS'LP8:\OZ5I#ABH@P9H9%&6E[GK(=ZGJC>Y1S^%49(-._
MH <(7R)9JB;E1)K]J$$BS+<*F#GUS:9EIJNDS3%HV0YAOLU7%DNO[-FML!HH
M3--<J@F)'1E,5NBMR;@N+R*@+FQACJBG6,8I,UVQICP+L(/',G06;K(PD<RI
M4:"_AT(ID>&.?^^& 34Z/4%L\RT.\ Y$\=9$O6V1WW+&T1O]N-33/BM"S:@T
M<W5U/C!G6"&?<!E%O68,(K\HVZHN*J:*3P<=)-?\1&]>&K*8/1.P\( [8H;!
M(^6#FZF/Q4) (QI?@3!*R6C-;\:I(^U[.MJR"*:.IWBS9%H>HY^12;(:I=PA
M.K (F";+(U[95M'Y3F]X;:4+.*C;SQ2D LY0\[E$!*989KG_,)7P$5Z$2C30
M^J3_B%ZCFCG-U?67":?<Y-8D$=.?YTQ?+B+T_+LG3/$GS%;U4MM&CH[N<&3(
MW85.5V4GY5.0CSGVF9[_5@-<,]\7AZ5,_"!V@#:,#D)UQ)IF&R>2+*?XWZXZ
M[!/TX]3=&71HQ:[^(H^;]'<V6J^6=2/6@(\P!4;#K>;_SL]R+UM-6)N2W0;G
M@GZ[^:8KG;!]PP&1@\UVJ&?_6C)+ZO4$^D+]8,F3QTM[1DDA8Y.6]B.WIZ6V
MUS1G-%93[MT@OD)U6.Q8%V^GL7":CM7F6EU*%5'-9JKEXRJDHY+(5%H1G%/Q
M+CM$0D4MOZME]G#RFB&@M0E%S1R*Q9/FVE=M28RQ(J>N(A_GN94,*C/T'$=[
M1,ZE5J+<6 ^P.V>C))NZ-URH87X';@_8M$1>@$K%3ZD?7=P!RUNN9[N?D)F^
M*F@IG4A=GC#^5#I6X(QE. XEFU2[:MUYKF7=KIVJJ\QT:MF*8GJYQ3;[%F9*
M9U1$34U@PFT8(KR!Z581Z7%!PLYVL;**#%\D+=XFD]EFP 2?C#/.!BXL>)/R
M(FHLC43J I<NUNE0 PH5P8$>@_IAD @ )U,G?^&YVV(51\]VE4,FDEV B4CQ
MX=!CRJYIPW8^631LGT^-:A9=;N#'<5TX0DI0>!"^F8O]/R2DG+M:J6,^U:Y,
M_[&T<Q9!LNPPA--.9LAM9EA!Z-;$65*)S^?LT*@K+IV!V-PV6? /36.BXY:=
M+C2KC.><CD*01.;[J?#:O[=;?4*2B87W)$V)B:$(D4TWF"&/]*O&U\]_-EZ7
M5(SF@?R.IVHX2>TUV3D>OG#KHU+7F>2<X3F73#8U1?Q)I"\!1;/%+^1F>2:'
MM-@,N14*+IJ%2L+78?UA^VP_3VXOHW6:\(>V%?]IE@.7O<'HK(*<Y3^<[!Y
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M3$=L$(0@:;:0>TS'$Q0S4?Q84-]0/K,HF_(G+ -POQ;^P* V$C:/P(73,D
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M&9? 1R@M-)UPT20]8*A>W5<S%2$%D51\D[S<P\4G%0*2IE+L=L3V9.7K)3@
MJC'<*%)7O%GBS<2='N>!DJ2QN683.OES[J!D86V994^AA -[,H&U9<RQS*Q%
ML@_H L#6&DXCX\JZ9R!4@KLR=NR+B;N4]OBFNA,"<7BJ4[1Y[:_%>T=#ZKR
M>)*I-+K]6":6+H?/QP =%,0KK&BABHPU3+26PEVDT,QBZ- .=BXP^,,<?13"
MWLA8$-@;(RC&+1H9Z?%H/EI^1C0-TAZ!I=6G.KQ&=GDDW@2H=*"T3ZJQ#;%Q
MB<5V[D$'6(9:ENQ21 _!BX6*F"M.,GBI;%"%I-%0PPLF,: @O"YOU.%?E+6S
M!V&]=0,)=SOHK7YL3WX &9T_O>!EF.'__/H<M0R<(P7N;'&K-)8 "KJ=$)GU
MR 2)0QY[X6'%\I^RW6AD7%R;)LAI8BM/TYJ&R1W:1TH\(>L$?"0E+%T;KD9
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M/G5#51N:1+G&=0Z?B>0]C4E'V78 4YR'A3MT^91$OJIQI0I?IXW"Q!;^B/!
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MJ+@68Z<G0H8T,M(F"(X"3FU-D0<5@#K:L/HA$*I7GS-THY:X)Y8XLMEBT\W
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MUC_([H3+@#ZF(UH+MTDR(=.5.H=NT%&07Z=I:C%!@/))3B7@NB'W)$RN"8%
MCTHNM>Y*35$V)\2.VD:'E]QO58?'50/'>STD9,VVR22_JIK>F)6,$1F%-(Z*
M5G!$B9ODT5N*T04P8\.-R[/UZFK]@HDUQ:BIF8'1>@;U69S;_"N6<%72H\.)
MO!R./X<'<EL\F9'$Z00J4 X-!P#B;'O@&8CI 1!5?'V14"NY1-*7"S<" OQ2
M=U.FM$AS9W#JH0/Z"0$KW0()FKOBQ>%D_F@$(Z\@&%GEHDCARAD484 W,&R\
MKFQLP<BRL)ALO*3255,<3KJLZ$LH[A>)7/+5_'*C"A14PV?D37FPC+*I;VQM
M-VT//-C%(S@J+O^B10!YM?Y'&-<;PO2?A9LDS-H?PF^DPA)U7_B@;J&%"T%0
MZ%>-#S??WC9>6U3H7/S5/[&CD_CNS;<_Q5?A%1?M$?U;_JOQNFD=.%%:23 :
MU]^<.PP[?%6POU??@Z4P#]W+]NLWUL<%HO;524A?0ULL?_E..!(>W;2?L^.[
M@B/3B",&,N)0(Q[J5 U5YJOX"$GE+-"U ^OJ+BA_T31B(S)BPT?0U'BF,.-C
M+&\Q3F/Y9AG^!L8V6:#J01OY6(X$.W0F8[%KU%X.@2O\<,K%0<\Y"B;(X+2"
MZXGC1L7-Q1:*FQIU2?W=_B&D_57C]O.[WQOLNH$XZN:\5%@S!R<^\WK59I("
M7;I;#\\)XD!W=Z%SAVZ;&,8"NS'91H_<?T%!CQO3>:?/8)R9(AQPXZ*]XL/8
MAMK#E)L&P\=,/'H9JED=;9WT9L:.,$M$ZXS8?W5UE3G"9FJ7Y<_@8BI>,W/A
M?LWYLW6/ZL,M&.J:0"CL$.Y24PW^6,(DXSC#($]<(S('B%7*<#W2[--IAPB[
M8OA"3>X2=TKUV1*B9R11BHC]SN."*RRW6G7#<@N3K RR,K%7S>.RKY(Z[[O]
M$RXW9%M'_2+;JK]Y/#8U;YQ43)K-Q*O&E[?OQ7EG6*MF00X8:!N%@B/4%#U6
M*+@0XNJYY&O3_1>O5+I/,1=/2?9 )I)I6N,P^.$@\H;\<%T\!*PN=P&Q/D*4
M2>4$Y-N09Q>8"Z5;;3QK_"A\8+R3PFO_F8C[RM1-\?X(?4!$SCQ0#(C$= -%
M-&H0RM+Q78H,/D7+<-4T.2.#)DQ3+WN_H<  8X+*2U.WZXANV/=T]B@3C(B%
MF3.E"P^:@%\0?4&F3E(Q8K^;Q_3DW!3^$T(Q,39;BZW!?^A6T7I<ZKY?.K)J
MQKM0LEPFBJQHV9_/'%>VQINEL^%6Y8[&[=%H.!N.VL-N?WC5'7>''7LX[,ZZ
M_=%LTA_];Z=]=37H=(;=JT'OLG'$I'4])I*MF/=T(^'SV-YOPOE:1A]E:.Z=
M$;+6J %M/ LNIX."[.@@GQTU0$-6?J,R^=NB9#4]M.!5W=--O7Y.XZS2Y?*@
M(U\D"1A8F6\ W+I1Q9O(V  AKV[[UQ7?PV]T?A7W) "287,N#8=A?6TJ+]Q%
M'H0 DK+! X114V7RJM3T(_AYODR]8ND_/%K]_3OAROZ;<&7P=S*:;VV,<\+%
M,02DS"L>?^9S/68S P59$ _+F\BP&/7_%$N9IK!MV1:JQ5BW%!:/NBZ+M?^[
M>Q\(03F(JS!L#3;"X.8@-G&P?'/1PU\CP[TXBEBL(29,P0=A"T;]9X0.@XL3
M(TYO M>S*;""S ,7(N&3B?CNK];?[9^3>1#:]=KNO+98SA;:>FTQ#:%;C@G7
M&O+VD[G[(_'O$O]1?57W=;-N__OC__N[]?=/7WXMU!HQYF0&Z2),%F/5LCC9
MWPKM;UK?A$?XEQ-ZXEF_DF/)SB$C&,PN<^(9$L$@OO!-K-T[5SB63>M6++-P
M2WS7/H^[U4ULUM\V<R8/'%# ^V&:)T=H6BT9GF) NABL/.17G_&WG#O ?U3.
ME0\;U]U1N]5=G2MO$L$]YK AG8#=)@$R*VN5S50,-AH2:T1=JL;"ZI.U?@C"
M'_!=Q7B&0%;=WEW!(B7YND+\Q/(]K=R>  \-INS'Z2L$E/-58"^K$9)%",G+
M$T9(;N=>/M-2BT<*%SOPG10"*UF")%>S*X-BNP+$:A5LRN_V3W>1+&[Q#^ 6
MIHS,5[S90H2RLKD9-:XOUR)SLCRWF9:GZMB39!608J=&6I %1W,DF90P;YJ(
M.W#H_L7B8;0_0<<W"8,E0_X!4W,!T8]==V%XW+L@;L6]];N@X0HRKH(A#G#4
M<6%J=W![A4=QJZ\JVZ\?,J=Z#N0;,3D!M_#AF;BA1,P*#8Q43:T.P33-QA$X
M<V*D+$ DFC=PL\,Y7, O('9YQQY_)>/66>VY_B:>^2F(HL\^!#,^S]ZR%U?9
M2%TUKD?]]8ZIK%,R'$G56;'2O$H\<FVS45'TA(R.9+?PPJH3O&PWKOL;'(5,
MU\OYN,9ON&>^BI>,U?H&VU<3G:BFF'%K S^HB'BF?-:NJ9E4&>!_)7"C)7(7
MS?UC2UX8A0A6Q0OB5@TQ;S?6SQ"_XX)$6P+=Q34EFKLSAA$#/X1X/O+X(/@+
MZ"?_":6HJN$5 NG211DZADZ6(6J)&U > 8>5A8B4!X0O@S[Y%Y+Q.6U8:(7.
MA$7H(S:1]!W2=H6M3IG/7 4%(:ZA8@55FM $WV3;7"-JRQ'/[]]N9)237I&]
MDXIGS1UO:47)$F2(( /^78!@/*V"UI^J"%(\,CTP;@L=J;A,K(>F.OJ*]V1>
MG8;JJJI>PB\C;+;)DL0-S!" B=4@0BZPI 5+*7V,?X < W"/NU@J)[QIS1.Q
M5>HGXFYO\+QA 65DM!3UW(6+5;8\;M5"C:C."11I5)":U:%B81#ZGC.#6._.
M7<VJ&#XJ9A5/K.;0CU8?>G\$OL*$T.3>4S"C\J'0@;30FD-/H4M7'?\;<;=7
M3:B-NJ-C3JCUMTJH 8\W],5!M^K&GWZEV^>-PIZN2J)=%I087A:4&'Z"HF4/
M,]58'88Y5#=<2,K.T!P$0)'".R?'?;E1MHW>7C"FE>&0499JY40@FQ_U,@H]
M]S*KO"F$];A/-=/-B9'9$PQL;JZ6ZM0\![8SU3N<O)D)U E)JD+@2W>@;@AX
M5F/T1XS&SQ,WG"0+(AJ-D+U[0GR>[%9-[# DJC-"20#-'E??6W<0UL"H+#A#
M8T>_^5R(/C<HOILFCL+UN2RTL+!F 0 K/7>IG08//A/YWB-<$4]W\ -=RM=Z
MP-FN#DC)!TG^WK1L1*8[P!4F!>5(:<\CY4>#2XE^993,9NX$"899'@+BTS#,
M6* )5 Q94$A">(DY!^U@(V,(D@AA_!Z$*64=J18*2^^D_YKQEFA=G6E6SDE;
M=AL8<U8S$XM2 L+ *',N'RG+4 RQE_48PFH5U!D996%3=XJ_91A5C.SS2MFH
MA.H\=.C&7#.P6 \A0)%\U .Q7]YC#F5&RYY;$, KS<63C?97;FA6&>E"E!3.
MJ6DP:$="NF+9Z\<&3%,XO<"R)*, 9B;$L<F(7K,TD$K2HA2U7KH AC)B&890
M[&.LY6_*I"<QBQ.V]$&(M%B.$$Z[1ZY7I[?2W+$HE$=4_G[Y5J$E$;4>@H@W
MS,ZH4^<*,A)V85BX,P?$T<7 )9_,YB\+G?R+Q&P\=1<WRKCT2^3SU25:_#<5
M%O60'SN$,G,T=B45:I @5$S51B%EVE[HGG<INFL(C<%;4"4-"T3>V+X#9=IS
M^3P#[_ 3'.6H&-%_B_/[0Q#^N<7] 6J?V\/6:,T-8L,88BOG<5;AY\ :K<^S
M-1,5'K>8Z/3M(WY4X&%7J*$Z;JL'YH> _40XS#).IP,#2W-2QY33LLO7)E>_
M30F'2U.@7'T@D]Q@?RZPA' 9.6_D?_P*L2//?GSC^CA5_-&O^=*P3!8!7TA_
MUDG@5IL2P7$H_G<JW\Q_;HD__9+_?'35Z@\&A7]JMSJ%GY<]JG/9ZO57/^H7
M'!H-3ZP K.]_-7H-M4CVY <<9_[T(GU+XCO5F[;5$7+WR]:_[RY_PA,*T +9
M+ TN;;&$S_!_MI'PJ]9PW0T<=_!_0"S?@UABOCXGFDHRX^D6:SH1?I$8/TLD
M9*K:D*BR,.QC@0*O6B^XUE99K>WM07ZU<@8!5^MMXGI3ZLLZYO^4-5NZ%A;0
MYPX@Z%-_2BVD%MI-UJRC5XP%PERTMG422_?OAUL <^*(*SVNF5>*6U[NQ0?)
MNQF#QO5EIS4H\3(.MC?PUTI[M(WE+G[O<:O#AR3T756N _=HC-1G-T+-OUMM
M_H5&X=1UX^I NC%L7'<ZH]V5X[GDGY7RI.3_6S"+'^S0V4K@"R9\C@)_U3Z0
MP(\:U^U6;T]G06WN-]AV2'5BNDBLL[C87@B_\$Y<)G->86WO#?'?3SPF+_Z7
M2";;ZI^&O9>W=C%0I_P^FOW6G@X1G,SHV+7K>S84LS*S6,W'Y<!(;PF0H03"
M+'AM+?: LQ?:,[^;[;8V9V2J#F6IKE8'AY]CV[:V<+]@O'&;GA\GB7/XO[:?
M0,$5!-&LS^&=[7-!@[!4*0 +]I(]BR3A1]\R9YU.X;A"?5Q.X5A!>CW26!IL
M#6!67*>6$E9+H?D@UXXA=4Q&0ZMG@^H'4<5-&80S_D!KRE30$G<#?,0 V.0D
M2[8V4\(!J?.P[#<NGCQS*?@N%.XAGF/.&S*1,FN6&WL6Y0V#)II?*+>;!8#H
MHS8D8? 3$W;>8WD7< GCR_E.J3[@[0T15 "+_@.[;GZ>?6'\=/0>X(#(<ZLL
M5%M9*'%%N>YT\S=GW3DB0U;A(R'*M%IB[JJWVKZFIG-+4*RJB3CA;5Y?E5Z*
M9!H.P#;T_(TS<I(,DW^&S)%1;+99FJD_&G54"J"I@:1-"]HLAYCX5@5/&#[*
M@CDI<:O)&+,%6CFIE* 1LS.ZY@ PICISPRC. FA:&8M&>'XBB=&IV@@U7VFA
M[%1L)-6+ :$%>%!X-*;7B+,FU>S8Z+C+WZ"6+=82.1]U;I_I=AZI,55F6!NA
M,>M:U!6UJ%<G7(NZ#GQYJD[)37(G7(87YI,8DRYS29#>R5@;-(FF<P%MVOP[
M\36_J,%%JMQ#\1N.^7@G;#\4-"P(CL?P_ MAMN>VF S"8X))HKK7FN V]1:B
MT\6408FOD9W!$[D:_2=R-81&BCT^M*M14H^]5U>CU[CNKB_G-7P-M[A,)B>R
M!_9)\NY'LZC.I;F=4Y*;S:8^">+_7IY/4@G<]6TR%_H/]9TK%#+*@[FNS@K,
M-0L\+WA N<%+6P&@*RR2FH+V']D+HJ1^!9EZ<$#0H2Q* Q<UGS\#R0LKM:Q7
MC:__:2^6O[YKO%8:N&<(V:G@Q2[;K7YWM XOMK>(^<;8LU&K-^H])_9LZ_G5
M.+8:Q\;IR,4"FC8+>_<E#(1?F$^/'$"OMD_D']\*5DZ9G&OJXZJ$.F=SAQG;
M_ES\Y81!D:\\ /82['5>XQ6>3@)^O_W]22Q#C7<P-&E-S7JQ)N4U9MBX'K2&
MIP%N.!,P&U]\GUU37@HP;@U*>E-- 7*[W6% QW6NG!)BI^BN/7Z45^EGUR9>
MX!V@/J>N9VL0UYOJ&0#NRIFSJAY)!\:IG/MA=2L#4<^N7R_DM!*_V(\:74&=
MPM[ 8$=R7AVWLG P]ME5Y85<@3KM-4C*S51E(#3NNG=N=R#:[]ZQJTRI:_><
M$<8:S%V#N?<$YM[4!'4:U]UR0.$)0[?7YW]/.=F+O9MFB3\AQ.7+S;UV!L5_
M>N;<ZW#-L.K<:YU[/>KS^7T>V'T$GM':=3US[V?]_,_)PVEW]^/C=*&0?.=K
M5G4-KX,5Q6FH+#RSCEL\E4)M5:&45RA !H_V%BD_DL#%<6O-^RQ.^=F5YL7$
MQ=?T5-Q4:?J-Z[,+B]?!OBU<VG2"L [V'6IMSLD([<<$#?83[-OC)AV(IV$?
M12?B'TYX[[Q]_/ZX%'^#RI-<X<F@/=RB\.18 X_<&PA[,02+I3!EW.<&&0AT
M(X=TK5#:K-J329@(8RLCDOD:[@VKO\XP7-GM[X]:6+C?5_U*CRK_O%</ZCD&
M=5DS0^\>U57WHN]5XI3UZF5C,5\VC\74BY<1O;>;7\GKM3-N9'O)N!QI%*=X
MVF]MC[HTQ3F'IWNPE,"YW1%?=$JD"O$#WV VKV,;M$?[KF,[9+KD +E9T_S6
M"E@K8%X!JQ22;J& E[4"U@I8*^ *!:Q2?[J% E[5"E@K8*V *Q2P2EEK=07L
MM$]) 5\$8N>&8OH[M8$P-B&;*=H009!-G3S-&FV84*FF07LI6!UT.GMID%)M
M@PYY2F5THZWEP,R8[50:_>)EK[.7*L]!IPND!#NC66K9>U&RMQ\80Z=7V[U:
M]BIR1.P'^=KIKZ+?/R+1.[-L2@E'!#147PLBWQ^&]:BUX=5>75"9#OX0A"G5
M*-*)0;$Y?OW4F-8M17UW<_MBI6B=,UE%BH:-ZU$M12]2BM:XA56DJ*1G:"U%
MYRY%ZQR\*D)T":;HZOF%Z,R"BY4A,;V#(=)?5K9BOZMS3KF,3I4*XRUR&?M+
M)NYU#Y\@F+&W5&.MVK5J;Z7:52(^2K5S*MR%UI%[:\)=JV^MOK7Z;J2^5:JN
MJY_,W4Y],M>J7:OVLZCV5ACVO IWS^-D/BONPD.4$&_;/[*N(#[-NMAZ4'4%
M<5U!?"*K5U<0UQ7$=07Q4:1+Z@KBNGQC@]O780L8N[U3*M^HZZ=J!7QR!3QL
M 6.W7RM@K8"U JY0P,,6,';WW@NZ5L!: <]* :O4/VZA@,-34L S _G5%<1/
M44G7W4\59[<$+GUTY4QU)=T1R=Y^JCB[T&[YLA:^6O@J"=]^6@)UKPZ ':AE
M[ZQE[ZH*;*5<]'KMQG6W?8@V\W4-<5U#_)1U>^N<T HE5[T2*INZ;N_\I6A_
MU9\]0 3V"DQK+4;G+T9K',,J8M0#Y[ V1B]/BM:Y>%6$"-J]]0NZCM95Q'45
M\1'YOW5!P^[YC.Y6I88;YS-Z^TLH/GNQ0UVK5*OV2:GV5F6(>14>-JX'3]]X
ML5;?6GU?MOKNI]2PAWG23JV^M?K6ZON4ZKL55CVOOI=P^IYEI7"V\3'\&Q;1
M]1,;YVB6O?)&]*%"=1E0J=N;T/'$-^\=79CZ'^DFQCS1MOZ)/1:32N+RGY04
M+:>*B8ZDC+G3::?+A,W_"U,"&7)'X_9H-)P-1^UAMS^\ZHZ[PXX]''9GW?YH
M-NF/_O>JTY _FH=R#DO[SKD8AX[]X\*>B3F_L;T'^S&"K3072ZR4N3,;+RJO
MV/7_&8<@'/E);/#CS')S*=@^ECL7I\'E'K18Z2IUZ/[HWPLQ"<+'=VXT\8(H
M"9WO3K85=^^*[(<0?6=Z$_-G\+!T@V[Y,->)FI;OQ'D=,E=RRT[B:L2W21B*
M__H.2IL?<[^=:Q^>46 ].WA=P?RZ)])R/+OL,)?(C6(@!XA-+H$S+-L?]EN7
MH^Y^ZKX'K<%PN*=B]'[%LO:5@SIL,7I5GP]EY\"%J<4>3L:K('N<!11<G5T]
MKAEVWZTL=T_US!4\L6-?VZ(LQKZ7HE[FZUP-]8DCH"XWLE=?[0=K88O-<,4M
M"WEZHF2Y],0YO4.91.>([^^;+<LNI3RK9O]L]_/-IEWE?KXF-JY\8"%AOTL!
MN_&GWUB\_G#BSS.^M1<A)?OB3M7I[J'+5*4->FJ@1O5"N5JW7H!NK0E<[ZQ;
M )7K=W=/21U<MTX<OK*99/PC"'^(._K%,@PF3K13F=R&H*VCFOXA#AU8TH_^
M%UK0M>H D+].;V\9VN<L^]BBRN/<96938UI-9@#AUQFVND<B,R_BLO+!]=UH
M[DRMNR"8/D6]QE'-_A!V4J[H;["@:V5^T+B^'!;TQMG.:S@"O[L6F>IFLIK(
M#!O75]W=K>1QH:'QO:-CMY;(D6BYN837@1+>+^EBNL^U.2,3LNFI(ZQ&D:T8
M-:Y[W<O=SY<][LXSN>^U4M9*^=3G>HE27@JE'+1W#\,^LU*6H*?2:*DL%F13
M4-,_DRAV9X_' K98@2+I%D QW$@,T([%M<J.$8SA!0].",B,20 (C1"_%3IB
MKG\AWN+>]A*GE5\_*X_=V! _U6]<'R]J:;@5:NE+&"R%,#Y"SXKXQI^^_U?B
M+J%^<!6*J5^ 8NH7H)CDPYO6$AZ/>3M'OH!V=2VPJ4A"\%UE?^WW+_&O)ZH5
M&ZP9@Y*B75!)!2M0 Y5JH%(-5#H.E,>Y )76254%,/9SXIJ4R[#7$0Q;W?X&
M0RB P<,V7/1:O6$!D8$=.?"$QO6KSNLU>E.CLHX.E;7QU>*XK\.?P&V!_W47
MT&_-*62NJN$D-9PD74JUINM Z67EMS"(BN+Z@W;CNK<''KL:G'5D8E5KTP;:
MM*:%0'5M$M?J07]OB=4:CK63++Q-7 ]&&S6M,?]GZK3%X]=SA#LX#[S5!W$-
MPS'59@WQ?W6UZ0K_L'NUMX31$21^:H$Q!*:WCF*TLL#T(,,X.AJ!>1F@K204
MFYR$3CKB6J.W5DG^.EK4RI+?;USW>[T"1L(:NW46 K.. +6RP R$2SH<M09'
M(C OPO/\%LSB!SMT:C=RE:BOX5NL+NK#QO6POS=._MJ+/#)Y68-*JRXO(R$O
M@]V/TMJ)W'S';P.?R)[$.G.IU%VX;:W4BW$*UA%:5Y9\ (,-]U:26SN11R8O
M:PC7JLL+-%JZ')R;$WD:\/\U>*<[V+,=^@VE(\MGG^VHO !G9!CV[4 -VXWK
MT55_;[63&V_*<:/Y:ZUZ45JUHW-F-A#PD\7%-(@O^'E%*@=L*LUN^R!M#_>O
M="_B3O-)W%_>6#>32;)(/,3?3YUE*+:00-<(]%D$8L!_X0<O[:I3J7?/FB/*
M6.1WQAJ+__8<^ ^A7S?&4I?J7I%F=1O7_4Z17IU4QZ@7<A^J)%1K+/0AA0H2
ME9>]UN7S"]4^[TR=WK';9*J97JXM%:DO3K6+=[B+4W$IYK /1J%;8!2.T(.K
MKTVU3AW5M:E$IX#2IC/:6S+G*6Y%<A"\A -B0B_4MTT+24K;B)O#7O.0P[RK
MT/WH='-OW:%$JK!@<Z]Z,(0BG+5Z4%Z.5%#T65B-],1EM:B[UCOLOX+ULH^.
M'5J./Q57V5P?SB9^XS98B#$^6L);!CD0-UQ+*-W%!/JPN^)/;@BZ:DWF=GCG
M0!GNOU?*8*RA.E O^#S[%/AWG\023V^BR(FC_W:\Z8<@_#,JZB S'$*Q0U'>
MRQ(+ZL&H<,?$=.+ FHB-LEW?>NL&0(OD3L1:>^)M%QZ\SK+Q?2WKF^-8?P2Q
M8_6;5N-3YN_F6H#S&9JM;GAU* 9DB1N&(V8M7NE%XGMW=CB5VY%;T%9!V=I&
MQ @G6O(M=K1,+LF\:^&<E"28Q5U R%,HQF:Y_L1+X!E BQ#!/Z&[!^ZY/;W'
M!K2&B/\MLGZ__=T2Y]%4/-6:V$M[['I"OQVQ^9L.K+O3P$RA-)Y2/F!39-,#
MWJG^_5C$80,&@!07!BQGT_)@L>U-HW0MZ]VJ/UO.SZ7C1PZH>0!?$L][<./Y
MZBNG]6!'>[6$YA@KAY)'C>O!54%.5QK#9K6AKJM-VVFLE\*]ZQ7$YI3AAG6N
M-MPUQ3\[#?>J<3TL8LM3PYT9AB-:8]+(?L $Q7^)3X756#H3\"N\Q]::8SMK
MA8K/[LG$\9PPKQ25S^W>&AFX%9KX>8:,@T!SS3;J6^!-JR[QJ VT\J40%GV>
MSSQ8*[%"MA7-A0([/OR#B4&2R)DEGN6Y,W12Y)&_1HGG[F1N/3CBO!86>(Q/
MF0IKC4\4QBV9V?*$9R9H^)YXSTP,JN!+RE3;XD# ^B/K%7RK\7^%C8P<W[J1
MGS=>DY&1?_@BO(&%/7$2]"BCIO71G[2L5_*'C==T0H%K#6N#+(*TS!E?!UX7
M.^'"]=7&PT>Y 8#PS80S*'Z"/D^G9S6^.O>.GS@H3G<^OJB1=5#J?G95^]EU
M]M'/KM.^NAIT.L/NU0@(/.O6=NM)HD9;D42!17L0VBV,VD<_MOT[5[CA="-9
M11,U*F@&-^H4-;N3S^1K!UJD.W[I=A11])Z"MZ]M1<=7]0NXEZ]0DGUL%3[Q
MC1L+'9VL51M2WBF<:CC3-XG0XY NU\8*TK;LI3\@4.C&#EX_L]M>TBIPU,VU
M"CR%MG_?4]<+-R>.1A? )5V4P-46)R9<7^Y=VQHGD7AH!-]<C/F4B8"2CJ[)
M^%VRX^*2 F\*?"S1Y8.(W_V?_W;9[8Q^+1A!4SCD<'F"\U3J17/O/&"*9^=I
M:<"NKEJ7PTY5%K#.5:O7'^R%<.NRU1N,]D0"UAM4HQ,KG9[XP7 _T^MTB&7M
M>4;U)$O5[N[I47M=JG9O]:.>B\OKH+_?C8OMM/G"NB9U6_J>NSL35[WJE5>]
M6Q9(?D:E.WY",US/?^ _A'MS(X8E[E'6GQ1+^ 2Q!->W_@<B.[NT^ZS)X]1:
M(U36NK7#\!$<O)N%F&XY\<#+6AL3=WJS"<ST92W/'^)VL4?!J96R5LI:*0^M
ME,?##5K&ZWQX+-47&4<Y""ADV.J-=H*R]'MKL"RONKN0ZZZO ZDNUT^&?RN)
M(_8NLY'$\O@A.9/@2Z828V)DDS?3)(1,GXXI0MM+@Q(H%P;>8>%K_LR:/[,\
MV[LFA;XB/%Y64CKJ-ZXO!X/=J]N>@I"V5HA:(?:E$(;':#J,12HR:%QW+R]W
M+Q^H5:16D5-2D6+D_V@(!'?#O3$BUA3FQR)7M3IMH$YKN)BW<<%&C>NKRVZK
M<PH*5>4">:YB7POW3N[4I7"G!KU6[TBXK6HK7UOY/2I"B=-TU;@>=4_A#O$B
M^()ODTB\W0D)D@T@N+F[W"YYO'[ZIQ<X[;</$SB];#>NC=Y'.\5-:Q;?S4Q9
M?TTOB"T<ULL.!$2.AL>WWO&][?CF7MQEMY:!\Y0!=&#,VK"9^].97OSEA$&1
M'/2@(^YEM]/]]0A%H3Y ]B!*:TIBMSE ^K7Q.,\=KW" #&H9.$\9J'B #(_M
M #EW#M7. 'HU:L:*?<!6SN/:VSW0M7>TOVOO"Z8@K6:_UO3UVL9KN6Q<'T]+
MAGK#][;A%9R6JUH$SE($JODL5^V]^2PU@_5QBM*:7GE;'!]7G=IVG.6&;WY\
M7'5K$3A+$:AX?.PO9GJ,7/5]I%W-WGY-8I6+JX):EB.@K\^QG-098<7'?HB+
M\54?"VD&ATX(K_M-38C^$@G1US09V,;% U+TRR**SR,D1:_UHM:+/>M%!4\8
MF,&[W=95K2FUIAS5S)]&4XI1HE>C/976/)%6U'Y9K55/WJAFO5]6C=CZZA(Z
M?+8[PY-IJUNK3:TV^U2;"F[;%8!V1J?1"[?6E%I3]JPIA6[;L-W>4W'/4VC%
MP7JA/6NWLV-_R,D->!_=YGKM;;O-+=SIU%O+U9[BQ=^@@])%:9>#[>W3!AWJ
MNKMTJ#L,&]F&+/056MUDVM0)FU6Q/5"GO^8V_<Z-Q"K:GG#RD^5'G\GGH=M#
MP"T5/B\=:D20-=NWT-:KJ%_TL-T1SG^[* ZE.@<%LR+V>^AY94?6T@YC278O
MQH9-;=PXLN+0OG<\:^[87CS79/QQ8+VU[^W0%7OYA] P=V+TLQ-+V'@G1$,(
M;IR$CM&ESFPB$_BIEV$CF<*797N/F41_&>O?.S;K_X*_5EO2@UC2[G/U^NQN
MT.MSE24U&GY6M*<;N;E>\860.HETBBQFMW$]+"!O4/8R:RQ5-ZQL_RNRVW?8
M91/ZADS9>@NC^HA-N<3WOKK3.P<<9=7 S7ZPPRE8/MM:@^8>RAD[X^@--\WZ
M$ :+6_$]&/4_W'@N"\&_.^'B\TS^96WF>M@&"L@<HOL"]W;"3['&CSCBMZYX
MPQ3$TKJA[I%3ZZL3B:].YMA7Z)T8FQ=0K[.;))X'H1L_XH1M^?VI_DHSV\T,
M=N@B65+'.FB )@X/?)98I/=CL1?V@1A-#ZBOWW]_5G6-0\>.<0UA%]Z/ \]N
M6="31XIP3LBAT:1JP!//A8]R!YN;;[<C_FC3UR="PSV'GH:] <I/['R;61,M
M4:F9TJHXD!'\>4_M-HN[*@W;_2VZ*I4?)\_8:.EFDQZC\9IN3+";VDY'W/8H
M>K-;]]<G;WO4:;>IV<QUI;Y'_5%KT*G6:J>T1<V@-1A6:YQ3_GG_JG_F@[K:
MI)E/QM?O](N<_5"(ZUH@Z":4_)W!.34>066 QB+6^UQS]B("]8W6>MWR;$6J
M?HP+E^HRM!L!?\E"[*$KQ,DO<;=>XD,O<:=(URL7W>R_6<*S9%J*/*92$=R@
MKF '<KT3ST.M*;$W%_KS+.NL%UW-!^)J/G@9Q+RUA&TB8=TU[>&KBQB0/U_M
M#ML\*1';C0?A"45H_9VWN@2MH0^O+D& <;PL@,CGS]@]1CUD"^E@50OI#PGD
M72I$02[/)0IBM)NV(/^TL&/Q\" )K1FNB647A4D@-@;?R0=$C!A(A1 (?P+6
M8'#2$9'1J#4<[*=I;U?\8,VC=NT?N@>O\]!>^*I.\W ]WT>'P>._CJ"JTD%[
M RW6_\\X_.7:#$E8N1OWV=Y5LHM5?-*)]>@?B.[ZN0&!FRW V9%];S;M)RIW
MRGL*?XCG?G]PO'OG=_&2>:$#=(6WM./O]G#B3. ;6XC!5M&+HR0"/'+M@*/Z
M^T,!)<*PT]Z/4M04@)5$?[A+X*X6_:JB/P\=ITCX.T+X>WL+JM1V?S/A']5V
M_PF%_T.0A$6R#W"R]M'0 +\4PW]9&_ZGE'WQW2+9[S6N!YW6J+;[3R<'W^=.
MZ-BSV"F/&=76?[\:< .KO4H-H!N . /V57Y])&< OG=T]/J Q&>AL[#%GOIW
MJ4#_EJ$(#K!GRL;JN-KN:U-;F-(:W,[@(%V)=]JOK8W/ZL0G_)MKWFS*G!I9
M-=Z0/J2W\M![E=7ZCW2NDJ?9UC^QQV)225S^DY7I34Z<'$EVL]/I9H#UQO^=
M*]#FTKYS+L;"._AQ@0["&]M[L!\CV!5SWF+2YB)OO#X\^6O,VA2-)[.MJG5D
MYZ+;L%21XTTL/^U5JNHJ7W_.@^VT_OC$-ZXX2]S)^IJ0%=F\WX)@^N!Z7GJ!
MMLKU?Y[)A^53]YWA.:7N*2D^=KS@P8J2A1B^>$!$159S83P=*%J@?]IA^,CG
M?$(E0G>\2%"N%#I+<?Q3BMVY@P*8%YF_[PEG]/+RS(L'ZD%M-JA^KWM0^ 5!
MSE"U5IP0^P4VK'2HJQWRSP7+O@T6XC28N.+V\B4,ILDDCE9Q)6P_H&&KV]\$
MHE):Z-@;KN%XV-]6;PO6/V]1^?WV]Q.7D6XM(P>6D6_<#.TTY:-WW/)Q9#@Z
M'?AZ&5BY;%U!\8*\M3W@&K#LV,IB"CMGBJ';-ZG>B6#H#M$[94VAB;R);]XE
M9=@9[;M+RM%4FU2KNJR5K5:VM+*MJ<G1RI97JLO&=;=SN7NN[=A4JE:<6G'6
M*\[5]HH#J.V]035JM3D6^:G59GT)Z/9:TVV+XZ;;/X%ZX;UVP.L4=L [*@&0
MFV:YBZ7MAI#JV04054X7?&18J0.<*H/V9OKQ4:WTIUR;BI4WH6YG;S>A:MMU
MR ,HHS^5N1UJP>L,UA"(["YXW5KP7HC@O:HF>6LZK9=)7E[">L5N]>M:L%ZB
M8*WCJ]E<KOK'+U=K7$Z)@1'#=\K%\"5^Z\2+='9.Q^08_^H;>WUC3Y_/:UK9
M;Y&.Z0[.-AU3!\%JE5JO4FLJ%E9%P89UTJ56G!>K.&OZD&QS%ITO-*!6J5JE
M=NQ?N>HD.IGT?YV/J?,QVQXXPT.'Q:_JL/@+$;R*8?%]A2][[3([?4P!S%JT
MGLZF;0CYV]JF]>H<\TL1O&HV;5\6K7L*%JU.R=0IF:U2,KD^5_6=O;ZSIT_P
MC5&4FY_9O3H,5JO4RU6IX8; RRHJU:]5JE:I%ZQ2&_K[552J!@[4*O5R56IC
MV,#F"C4\'84J[HL\6-$6>5,:BO5!@#5/J%^TP8L*[_7=?NZ5&UJKA3N=>AFR
MO11+X09<>Q=7^^?:&V*"<)WBE].S%)#1%3(\[770&W9[M&Z0ZB_"=GVQ;O3W
MM\@JXM!BWC_+]2=>,G4L83"B2/,&WMM> JT!9]:_'P21^%N8BUO[R>)B&B!A
M)/R\R"*.#D17L=UH+@\4&MAN-%>-ZWX1R?SZ#RPAC1Z,WL8-ES$O.F-DX(L0
MR9;M3Y$IIHG_94\FR2(1.N),C82VY8GQ'U)X* KM3&_TZU<E1-8O7K]](,':
M_T@[!Q*Z_8^T^Z0"V2I@QGJ"4RW#A7K^AUSW]2KJM(.?<N6'7(K][U"GVX9>
M_E86O-\[4%QLN]'T#\16L]UH!F5IQ?4?D-DXEC-NTTW;OSU>@T[?9(%6&-G]
M7_U>\-?J@VO_!U?O6 \N14EZJ$-K0QSQ=H:YZI5LT\CS=J.I>B7;E"EJN]&4
M<$GM_\AJ'OC,JH0.VN.9-:AZ+]M4UO<_TLZ&>[WYULH][9:>NCOTCSFEUA<K
M.J;TJ#$&&U-KZ82P;9'E"DM[EX?:6PX847J([8O'>=YCTYHF(=A7L,JS( GC
MN?6OQ YC)VQ:PEA'0> [H>7.K#AT[^X<_*YS[X QMT-'#$;\ISMSG6G+>J>?
M%,_=<"H?!)M,VFJ8?BL8BP6Y=Z:ZZ8LEMN6'$UOW 9QLGAL_\F$ 3XW$UHCW
M3&PQ#R&(L$[8[P/FRK^;V$OLS?*7G.+4"IU[-P(S &>/Z]L^A@&#)/:"X(<Y
M]9(!/\S=R=QZ$(*J)PIB:^>6HV7=P,>A$R4>=AR!IXKGB1_%>$Z+GPGS$RUP
MZ7BK8&0^+(#OD'H_N&+]X9?+T%G:U#A&/DR//Q)/=.A!I$(P57FTRCDX0G*G
MXGA=QJ9VM9L%6Q%"DQKXMEW5-&[)D%+1NI2B*M/F1/SE8F)'\T+9G\R%SCMJ
ME5+W96H( UL)LY6[[D;2%\%=:A04KS2LP.>5]#&?A&?.-[D]L#6?Q5;C-FKG
MY]&QY?;D$'8MZ_OJT>%>2U]I;D^MYTW3#80-\H-\#$OWVE.;D;;VF1FOV#)2
M*;%8LS!8H(K!NJ EI,5WA+U>X,K/Q$_)4Y1* RN96<"I^&L<9'L&A6[T0VA=
M,',]]6.I'V+D#P[-  T*[J9X!'S'"\2]0>C;P@IHI\5KEIX-#[5C\?69)U1;
M#,T+'D I?R[%/PUY$%[N@U!YV%1\N3C3R/*)G_M@!>[=((E2OZ,%DV-+(M3;
M$DO3M!*PI']A,R18L$FP<"[@7C"U7DW=: )N.=A@4)N9&&/TVK*78B3V9-ZT
M/@G+YED]5"QA(Y(0S9VQR O'CI+0H3?!=,I.GACVR+]KY8]E*WV\PR$-HN6.
MQNW1:#@;CMK#;G]XU1UWAQU[..S.NOW1;-(?_:^X6#0V:=ATN'9@93!:/+8O
M6YREKM35ZX-8L+_#TKX3>R,<5K&X4;ZO%P3B,JW2Q&?PM'2WKP^%.P7='[+.
MDKD%Q?X&OZ#@M=U&Q=9E:I+<3-6??G))[%TG^IT&.OWL?Y42)[[P1^ K 7QK
M1V[T'7R_@I49G&O',V$*(MP\UR?CC"[.6+@RF0NUC8N*%L73RTKF"#RVT+D3
M+G_H/4J9F.)WX:*-SDUL*CC\1:R%<+MBA\P=F@1P4]AN&E^>N\( AI/YH[2?
MVMV,G<G<=_\%-_@'AVV2>)FPH5,'C*>8OO&D"NW83J796O>RU>OOIUO7J"5N
MAO63-OB\-QB<_.R>YDFK5W8_S=\R >#.JIJTD^NV@S9[;;U,O7B;+UZ:_^T@
M(KC![PT861M"[!LV/CK&!<[W@GJY:T$WFUS'IQ>]&CG"Q1>]&H>SW2]K-6NK
M4UN=VNIL9W5>>*]&"@^]V4I MNI!5S]YVR<?[\C._,E[8I [%D-0C![Z/?"=
M1YGEM2>8M(BJ$JJ<=>%AT1S/J+RP,UQ3&W%K1_,;?PK_[_V_$O?>]B!67I!-
M*4IA#AO7?>$^[(D1:@_5N;4HG[,HKTG"[R3*HUJ4:U%^.E%>@S>L(,J; TXN
M]TWA5TMY+>4KI7P-T^Y!I'SOY+M'P$99:\DY:\F:FN!=W)IANW'=Z[9;E\>C
M"[4LG[,LKRGFW$F6.[4LU[+\A+*\IL;K$-[+<.\==6LIKZ5\E92/UM25'T3*
M]T=,NR<I/S-^ZF*Y@*>)O<8ZZ%P20)>+5YOUJ;#:5U.*-86K!U&*O5/+[O/B
M6DN%D(HU-7L'D8J]LZ/64K%GJ=A?@FUSJ=@[Q6<M%7N6BOWEJC:7BKVWO3P"
MON1:JDRIVE_:*"\]EXUK<1LHX*)X?MFI]U[L_3,D4X;[2Z;44G$8J3A@\F#4
MKBW"4>_]_H+M&UN$T?[Z .Y)*EX$CC/U5O&4R87[\V+N3J>._P9VI;O^*STH
M% R%%"#1A>M'<9@@J8':L/3_VZ*K\+EKW!J?7B\OX>^KJ-7^@C\'0"W46R^,
M[9ILT"Z;O[\83[WY!]G\RS5)DETV?W^AG'KS#[/Y:Y(!NVS^_B(VQP-6JX5'
M"\^:>$U>=/(B<@F,6$>$2Z^WU[0-:U)"N]B&HP:RUILO-G]-YF<#[1:.1:W=
MQ[O!A[OP7>XOCG)<$!B2@]ZQ!U0*R37VPPYP=A"XNC=GL?J3TF\62[_L[J>^
M\"E:W-9J4*M!I=A7)47HU8I0*\+Q3'NO<< 5BK"Y9[AW'&BM([6.'$^X="\Z
MLG=4[$%U9%<,7*UCM8Y5B"I7<L>&C>L!$+.?@A[5>E#K0:7P>R5-&.VIO+C6
MA%H3CBX744D3$ E^5=HUK-:$6A..6!.VC]IN?O_8.R[^<#IR9OC88L)CHPW6
M=JS'/&EC&WIBK:=! AV2=J.FK1^]!7;H;&=])(]^$80'MP&TW+O#CIB!'[E3
M;BBZ2XG"N7H*Y^H/K/$&WB81]$..;H/%V/51.K34W)I"(X^8QP)_X*K=N!ZT
MAD=2$5-+]%E+]-IT[%8RO;'O>W5T%6"UO)^WO*_+NAY8WO='R5;+>RWO>\B@
M[LEGZ1V9SW+H+&FM$\<UN3UF//>D$7T X^\K$UI;^5JB=\E='MBK.49>N5K>
MSUG>UV0H#RSOQ\B85\O[.<O[TT0>1\?DLZS)*DS=:.G9CS#0_\_>]_>HC2QK
M?Q4+W;V;2#,L-@9#<H4TF23GS=4F$R79/3I_71G<##YK;-8V,YGSZ=^J[K:Q
M<1O;V("!EL[)#N ?W=55U57554^1?*-?7E7OJH8.?"^RD"]]4L9&GCDLN]*4
MD29I<T&*O$"-)S(/RF57C4>-Q%T:7*T#M8600B:%K+$SK2(Q*^\(- ZK(46P
M#=PF1?#0QVQ-B:#1ZTD1E"(H1;#ZR5]58]/HJ1=B;-9-+)5B*L7T2(>1U854
M:R2&=WHAE4(FA>QHYZ/-F:.-=R.4(M@&;I,B>.@CV^9$L''X>RF";> V*8*'
M/D6N;FP.+L'8I&><OX4FO K^:]E/DVA"7]9+6)?9Y'_@RVCX2]-_M-UHE&-8
M)?[^6Q29-RJLFY@9U+&N#L@^S*#V(EZ@3WQCAS"%V6[NT'J_,!+ @GOLZ/\-
MD)SX>%6):C9*AIW33A#XW^L@M.<O["L;WN+N(L3^4K$AQ(YIYT].<38,KIA!
MX,UL,R26\FR'"V7*4RC@ECB' J[RB;(D)O*_I9BA,@>Y4)Y0,+K*CP4)2.J9
M/EGY\!V\%R;M38$V[+W>7 D71+GWED"-%R7TE-"'^<V)KR#OX#6F@R,B84!_
MA8L#XL#,'I5@ 6-8> Y, H;C6HKW[.*?]ER9KT,8ET*>L/..XLUF:U_Q?)PS
M>V8T_% TUKKSQT^V.R,K.D,<&'Q!S-E""=;3@/R]1C( 03P?UT*QX$UT&,IL
M8<+:P 1<.L_D$^%E*Q_4DP\\H5CP#:<%^;DB,QRIN02]$=*WA?82G^O%9' )
M: 504,&-\KRP81SX.-M=K9&F"QC<PGR"JSQ8&."K)Q1W!5[U%Y+G#E8E,:[$
MF,#LH$.8E>$IGSB4H'S8?+VI,6*\#6!NGK6>A8RJ,P=6P)[;<#FG!+_\UT#9
MW7[)Z V+.C09/8.* =62=$C?0_@/MFA"BCVL^.BW^C4!4\#L GH-'RPCZ9$I
MI,Q@A>G &:U\U&$6H]2W_S:7J[?O*4^X 7N]3Q[7\%S/?Z&L88%$.-Z*SA;4
M"PE"#SB[F]9MJ.+9D-=TF"EMQ]6)/D#UCBW.47W2L=M/Y.VS;86+: -.W,65
M8V]SBSF%%5B'^;?L5*LSF #QVZ)55;6_1<'$OPL_&L[*?"2W4Y^8?]V:<QC^
M&]-Y-E\"W&B3\X9))XE<FCY\\I/_F?J_343CV5K6Z*AVH-]J'<ZC:V+=A=&W
M_=B(XKO]MM6T;27%IE'"7/K,5>2#^XV %O9!#MZ9@1W\X6Z4S2=41?"SY\[@
M+CJX'_":=XXW^VMC48TZ"@$[:P4O#/TUJ< M+=N$4=7//<?QGE%-4^M*L4&<
MJ3!O2!#MC5,",W/Q4I1@XJ)%I4Q-QX0M)KJFE(;)V:VLM4_' 8]Y(2;LG_ *
MN.@]F9'EE/C,8NVK-XK6T_KT7XV.!/Y0W]2RBH#^;/:QEJ"&+*R#8ZX"\B;Z
MXVV4>V>[E)KTIK?I-Z"H;-FQ](7LYXT4=7M,DGCF'G\S_[D+/_V6_=XPNL.!
M^*=>5Q5^G_<H#6XH>%3EQ$)N/N^-:[%UO\#EY>JV@G_''9>]_+MA$1;-MBE[
MGXLZL2_^1FF7JBV! 3%>SSNN)4#@(W%6N"3W9%<&B?"U*R;2+\A3B3=[OL.C
M3?E/<)<R&WN0WMF#M!T09]W39XDB*>/.9##N]J\% 8R^UVB[ -U3AR?M[]3I
M:5L"5"E7O9RYH&D%_:7W%;0<.?N':;N_>T'PR9TY:S#T/KD?3!_-2T'C+$/M
M=29:=]QL&+-HD4_=5JGUPO>=A*%#TEVEJ\C<&7=N?]5BR4HLBTB45!"EO@#W
M^'7+RL<N ZIRA^FKUM!;UV3Z5IM]RQ5');U14"5Q+--7U3J3_JBK-[_]GMKT
M/>?=MS'3-^N17)WI:[38].VCZ=L4<%.;3-]S]COKFKZ"N9^+8%4S?8\K606F
MKP[[6%^0#5/>]-W!LR?8J-HB(Y5-7TU&?674MT;1Q=$LWV;2YV3,MY6&KXSY
M%A0@GM3N'78FO?I-B63(MU5V[[6$?(\K6 5FKR'V(&7 ]\A6;_\D]1&79A/+
MVI%]@*N.9C%?!-Y5W8*3]B9]W@68JRE.JHS2*;4;ELP)ZXYI;;1 8),'6ICC
M^:(\FX'R7Z=MVW//!I^N2G37RUO+HQ4W^"X1^XYQKS1RV!?6PXEJ*2K-KWE
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MG"(FQV363;@^7>6?[ #?7V&"VB;_9</@IH4Z@ T[VQ$]A?Z#2528B;WR,0\
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M3U,L;XTU<]O1IH*''.9=5P,A^KXJ8EBZ%64*^XSB0V9].&$O1#^52TK[S3)
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M!35%:+Q0T6Z4SG?:B9%:"LF&I3Q1B!H_P%@SFO*#?(%1-GRQB2TWV1SPQ5%
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M\R?.-K@QL+J@[*FHM:DZ2A*51>=9+&6ZH1?J&J3,](4GMO%MR(_W$ Y6S\4
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MLZSM@$5W]6V'JNMY2 VUX]AK[_%?M/E0;?)G*H$[S0>]GOD05)+"JB:$WIF
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MES5(E)49X8BMB,]FI+SJ;+B2OJKSNJO<P6)N?<W6TE*6YHNR,)^( OQJ6XC
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M>[\MB!1);JIB A^"F_H]<=MAR4WMXZ9&+=H&F"E9!#&W?Q+K]C_$]T1,IG;
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M.ML??FD(%[7=(O(>[GLR0U8@&83^>@F+EM_;J@0*VIEAG>T3*&D"^'%?(]+
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M0XA-87=LL;>M_/[)9>B.B= 72C.^*%0;!@\;X;F+,S\["EU.4(4V*!E8B3=
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M"#94\GPKV.*B>;[);)$"3H<7]I#5QVU#FMX.( TJ!9":MW^W\UCJ/EH.+;S
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M>'@)S#RS32>B;W"CW+GAPC=_*I_O/]\HWT$!."N/?J)KPVZ,KE9,^)^R@F<
MGYF/1/'F2DBSBM+K]4Q\@M?./<?QGH,WL7:@HE:1MX&5J:3&.H5I!B">8ZX"
M\B;ZXZUE!RO'?'ECNY0$]*:WZ3<(%HJ^D/W\]MFVP@4JWFZ/*5^>+L;?S'_N
MPD^_9;_7C>Y 584_];KB[_,>A47*PV&E1^5_KX_U"Q_4>.>C*N?]J6-='9#=
M::2(X5+V 0(3#.6'^%4L#;YO[F5I#+>TA"'4$O\"G:U\2*EL!;1U:F<_""U+
MW)^P!GJH;7<4V[>=S+CYY5:R-T0*268DLR;)? PRJ_4T!,_N+@VFT6Y/]A<T
MB5+&T)N]N+ .52I[L9PM#T@6L9/86%'']?"7).3A"-E0@<C.NI!QVXI"[C<^
MX5?NY>VGL7;$.Z_Z_H:PG$I+4\*[YH^XQ>O?#%<93CP5SQTTDM,W2HPA/Y2C
M]\O'<GCD\-KAJ-PU^HK9(Z,4@H>V'3%-A4DQ//HU#BNI<0SZ5DM$24>=R: 5
MK0-/95L>;-N7'$LYMM]KF&.Q;6$K4*XDQUXHQZK-<NRXUYGHK2C8;@7'-EDR
M;IR;9\".?NZS9T9[X7 **'.Q0JDU+)1J9](46/OYRV23_IQD6,:P_8895I,,
M*QGVD RKUV#8@@YM*49NO$7;^;/SH>)9K;:%,!VF7GBTH>C[Q=U_U29V(O=*
M&M4%*G_0L(VBX^&UU.K22#D8QPX;YMA!9]*7'"LY]G <:S3,L=AIKJF*@?/G
MV":[^IR=J9/,+)>-? KD<-2P'"(2ZTA&]>4YU,$XMN&S_O$(>Y1*CI4<>RB.
MU1L^ZQ^/F[!U+H9CKSJLPTY.O\KCTG*2V&P. PP"F\M+KT/ZR0?CV&8/^-6>
MVIE(-UDR[.$8MMD#?K6G28;=LG6R:!(;\(B+A'-0(B2'!(:#&=@686@-# @@
M].C]?WS_!P5X\ F#!G"]S>\P*YBH_61;:]-19KS)#'RGD)\S$@184*?V?ME
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MA,2T;D!@P6.R0#OD7;R R_ =\[4SMQT'90RN##8#X=3"JV$[^AV7$B4DGU&
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M2P508J/VZV80#_$8JHOZL#/I&V-!)#G.?=@.2*!?DO*44F4J(G<C-EUH)DO
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MC/G>6-S/".% ?XW0Q$7(XMN067B:&:4)JM4S_PHR2;]&@Q?8K96SY'3,DA/
M2BMQ?EREH6L%\-C-CMU ,SP?<8IE\_U7)9]!RS11"X#9X:]J,Q$,=H2#S1+Z
MM2+,1.QF)5/0$0D?;AO3GF$,YT.C-]3TX5B;:D/5' ZUN:8;\YEN_!]%*RR1
MW76B=$-5KUHG+((R#@3I@=B&+5,2K(^S)<'L"<I^];SL@:+W:.>=CYAH+\8
ME)'J5"MFH+WIE_,YP@#?*-_^VURNWKY7YN8LRG[.]E#:_!@!L2S-N%4NB()+
MGDT'X5=2K;A7'#0XU9@C@I$.%!O!PE-M&K!%1 3]3#%>R(J!0CUL3V&[9=FW
MAS^BIGHX^D36;^KUL#'P!U"8EPUB)'LI#HWF:SJL12L,KP#0KA2WEP3N?@;3
M(B#N1B(&O<XD:H>9@:U#4(,4.&/!2+6#08P/5#S#RT,8_^P%843T>,5P5L M
M2X_B/3-T HJB"(QT$Z$!,:9B:T*AR1!-C'<,W6"$4UQVU@%K)P7T<O.G+ZVP
M1* UY@B71F>[38.NHGS$3H 1 C8O.7 H'FP">0UWDSD"T7O8^ITH*I@EG6]9
M=+1.=X^,[<U\88+WL!IY^=G8K^AR\K/3"=B,5WB75X;WCNBH-(>[2D[UN210
MZT;7&.U.,#Y) G5_,+CL01DG@,!0!Q>7)8U W\J'3%,'F3 M$Z;/D\P93!))
MYD.0695YZ9OB^2VOB<)NRL3T]H[L6E)L*'/>+;$&^S]Q/U\:';_UYK?81VP+
M._<B\^DK@C6=5U)Q94BF@C#Z1]O%Y _FI.,K'N9_!(3!#288213+'>B=B5[_
M#+<]:4-2#"Y7#(J.9.K(P0";QPVE'$@Y. ,YR)SL-2<'PS;)P;44G% .^$0[
M*P4AXEPPET2$37WY52B'M(XB&G]@L6ZA!!B[>E'*(I2S9I4J%D097L':U-Q.
MYI)7SIM7*NRR97@%BSD%*3[G7[#4ZG1[NNP_O! S, 01OZH6S76D\NYG;E]X
M*F_3=DF<<B#2%L,>QF6:PCQH>VY]#3]6"J04R*:LO]T2J78FP\:@&*1$2HF4
M$EEH8^^62 TELBG$^7.M;)%]7D5]7O4S[O-:/M_^])0695&P!/2MGFXIP%^4
M:/SCWELNL0TU.&=?>9OFP$0PI)O--9_O/^?_^,[V8.!/F*R/7_-T_4Z<RXKI
M[IWOQ(&!/][PWJD._=:T8%WM(/2IG&SN\-RM=M IN.'O(?QG&<V#3Q[3^!N'
MQC[XRGU?KU8.G0M09,IAE .$459LEV5W(T]23<+ZX?$\=2P"RTT/+@V334\C
M@D0W/)L$+.D\+P-[6"T#^VR2D?5NK]]0,O*XG<#0C>8UCUO=14]X_T7A-/<.
MBM/<@-E_Z-FSL5G80)>JR#<P&^+C55'U79ULUGT)D5"%&=XY%9?<.V80V',8
M;IAHT\PMH -E^IZ) ,G<\F.1^4K N L;"@B3GDODE5XAE5)OQ>K&6_OG[<*V
MP&1_0RU1O<0U Z V;;:S1=;T?RZK!VLY\EY<#]:27-4<5M-676XZQ4L8*AMV
M)NJP:128LT9CDK)T);)4@*A4798,!#YK#*;XX/V,MP+%JL9B(PTB=%[C_6?>
M8'8_<S&1D'JSW2ZRCMUX5D0IM/Q&):X91]:AH!5C/5/Q&C:Q2]VJ*IE]V;:B
MV;W*Z'4F_>Z@)4F'1S#N)/>W:W(',]1*<3\V"6A-*G]#*;?M9N8=%L->!L(Y
MTJ!H\S>T$M?T(P.AM&%0*G>_;/7?F:N2_3;2+YX[VZ%-$/"Z?TE]R"3'U-U\
M"CAF0"%!V\(Q%U)-6>[D1USR47<[DF%'&78\Z!8D5",8O#<:*QV3P?NVL).4
MH@-MRT(I,C =H#ZTP:G"]OHYANT35-K.J#^GH5U8L%]L,6W#B-<"PSLUL%SC
M]U]%].:?] .F[,.PS$<Q!KSRBL)Y9SK$G4(OG94?6A)Z/;VG14MRQU8DBT&O
ME@"A-T98*:7E-H60*UAG!0NLDF96<(RA[/'.%;RP7:JDBL+N =BJ1@&2DX-M
M66>'AU+3%'?7F-Z_TZ?M5V+[]WR9OL$J?27^+!DRN]4VC#[")N#M@$DYT9K\
M(IGXH$P\. (3JXC>T0I<J%8P<8D:Y]I=LV+G_[.)?9G"E[PZPI&V1R>7T]=K
M8MN6)9^:8KJF\Q+8@3(ECO>L!.LEC!L>%BCS-5Q"0 :B?1%[ 9K!0IECM2;K
M;K46M+TR:46KN W@!;: ,8SN<+"[&TG91VEP0\&CKKPJ[E^T1==!:N+:6'1T
MAZ)$B_Z399)*IN3K0FN1BO595)JE'RC^?=KH?\GY7UCPO^2L&SQ!VVD$?#5?
M*$S#^S7Y D_\\4R<)_(9'K\0MC0=]=%@:_\)VUE'(<LKAL&EY#:U5RIP3_[Q
M[ F%0<>DX::0SEJ2M=)VEA]>"L)WRUE^X1,A/.]H@-W#:X.)R5SA*DQO2#U_
M#*;_"!Z_D.>'R/.UK1ZIZ*OP_$@J^J/P/$5U$_ \I@'5;W@E]7QI!OBQ(#ZA
M^(I2VQ^:\^^0S#O9?X3':[5Q(-JE\D^;D5Y6#&A">BHNWVB7GQJQ,2DZ(#I"
M:1G3G-&S@7JXZ'T$%_*-\FFY6J/LV+SCBMQ3#B(8?R3TU(>?,[CT;HF?1%(R
MID7FM4^[6[BGG*ZS388==E4Y%>XC)173.4/V'_C4Y2P1^X^O4RK48XS50U0U
MG0]\/]+!-J8]PQC.AT9OJ.G#L3;5AJHY'&IS33?F,]WX/U4#?[5<WH6 =?CY
M^4'T#P/:'W3Y<E7*W_GDSKPE^6'^Q(0JQPO6OBA19ZPQ[@.Z$>LNC+[$QZ7S
M=]CCE-#\B:HO)T-V)^(^>ZKH9>6 ^!E7_'L=A/;\I2T90SFSU0<&3);F$W&4
M>V6-&4 (>T^Q*BD^?K2;O"A+$BX\"[.#S!FU"#!K"/.([ 39N\H?F.\!#[$#
M?L<-:(HY\7T$CS=_<AC,U+-M$K4*F'F/+LS,HL_%@? T)KP1IA"0O]?$G>'E
M8>C;TS7+,0H]Q;+G\ [VVY2$SX0P_/XY;<Z'C06""+)?F9F^_X*#-ZDI0Q.>
MR$\[H!/*&QY\AN?9/@PR6)$9-@N@HYJ:@0VS?E]RBDO0AVN\;AW@VXAKTM8(
M>!?F+0>T_\", ^V;JY7S@G_ SW2BG-(VFQLMO\ /SXO_S][;-R>.)/O"7Z6"
M9_=,=P1F$.]T[W$$[7;W>$^W[6M[9IZ]_YP0J#":%A*K%[O93W\SLTI"@  )
MA!%0)_;,> "5JK)^^5I9F>9@!!\Y=#-C/'%<W9W.D01?'1_9Y2#(/%YA?^B6
M!(6.9?SUZ->X%R KJ6L#S,-U)JX)$Q0/&\& )^XJSA7A0X2E'3,!#>CBFC^X
M6$L?QP8^@5VN+(M$EK6!0B$Y+LY3X)O WIG>"(9_2:(V0CVBY8R70I+"_B*_
MN08U9G@U_1'[O?)885][O?NRW'K8GA<@-/*N#EHM@(\27^6-X#]P!V:3 B3:
M%ICU<E/$(\ 0N(VQR?2YS8<F3@?8VG%YM*$CH*[M^!6&:PXL'TP"GR\.E@05
M&,C@$TY[Q8*)[+<A6G.$S\VX/PY_(W"1=_#G8&:8CI&2"?I</([P]4T8,'.W
MCD*"K;<F8[,<;V*"NP*TA_^1+$N"",FL&-O:_)GZHC".^((?E'$3K !-)89P
M\( @5-D=2]<Y.'HHG<*"=BBE0O$)T.P#\H#?02"C708ZIN\$?GR6__7_=6I:
M^R-(':EW0&:$"IF$$7MV\.WPV8"[^"XP Y]'S+&%1&1#UQG3@ ;)*^0(^"\O
M41<(66=Z'BC[,A,]D.96ZPV 10(+2"%$)M:26,#S7#%$_44W+:&44!TB,4C=
MH+T:HK5,CTTLW:8;==1[AC^'6@9X^2\AIQ/17V$4VV5B)_%Y .F(UAMM%@VS
MO)8X%)!ZL(V$!""0"5)CY 26(>4^#,'0($9TP)*3D )D^%L.73"Q!TRDA'KA
MZ*$Z!=.0ZJ^"98?@A<_%OV]"$%X%XT"TN'IR@8<L,8R!+(K[&P8K8O>J/MC!
M^,)P*$<59Y/HD]2QM&MM9>X+<+%%(LHF)GBVG#Y0R0:3*99/3=Q09C!APY36
M@$.5G!*DX6E((E0!DA:F#6S^C$(6"/%Z@2N5TOL=,GBM^O'KS;>G&_I;^_A>
M:# /6R@! O\=F(C[&%Q!!@BY0\8/DI-T8$Q!N1R8Q<:-AAG9)&A,PT05 #(!
M^8QXD5,(BVS8$,LX1?FPU$'+8T0R*5J4W#86U_2@T> 19%XY7S=LJT23Q5G"
M&VC=$3/'GQ^!=./6S/H35C;9!^(A0<68XIOI/6!@$U=(4A=$F12X+L?%T,@+
M;3=4*[FLK>2:"Q0\JE9RY,$F.K;U[([M@;8 S,S0TD4%-9T7I"8PT4 X<R&+
MD: 8Q/NV)9H H:\I_"FT2(V5YA0V$B'F@C^T"OMTW7N*RR[#06,8^.V%+NG
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M,V2?^8"/^]P5MPWJ6IG5JK5ZF8%GS;!;M6Y/V4CWF#Z9N,Y/0(7/K2G[6Q9
MU5OU]9!:W<YUOA*8'8PO#,>_D&,E8@XO/+:["16\&9#0PJF:-ON]\EAA0PZ0
M 4?5!G/("6= K9_9N]+MW;?2^[D&T%XYIU7CB=CJ%3\&_;_XP']RKG].3)=N
M[&4G0KMT66^M[-08$@)V'Y9)Q=/:'SWV.C('(X;Y8'CH8[H<*?6BNU,DBSX&
MMO0]_*A6K6L #^#3YQ'^1Y/IMO$FM+EU_%S(TP&,-.HKJ[R'](D1) X$AJP[
M-&%YP EEIEO^"$E1!C-Z#)^!2>TPXK,I@Y4,@,N1TF!GHPR!A]&+ I+9@6Y9
MTPI[6F"T.6RB=3X 86OZ\UC$$?/E01#G5_2B.,5[M.O9"=P%#["5$%U@":2=
M80T$3SL&K$:MPB)%08+W# 2MP2:.!^N83!P728:)1,BE'J *NQD@*^XBB3>8
MWSE*XDZU=-EJM1-N;T0H\$>Z+T#0Y[";Q#AQ-'26N</S8=EAGY4\V6.#U9,G
M>W2H5\^R=,[$'?7.B7 '[K#!C0!H(+K%X>9Y 1#@]\=(#J*&$5N_K*UA*OBU
MP(''QOH4X!0*XPK['5;HLD<N0%#OU'ZM=^HDD>'%5-C>AA<\B,[D@#6#XY=:
MM],"V0Y# P?"]-@[_#GJREKU(_Z(_M0^OB^+ESM@$GL3QZ;<,N#/%].#UQ$0
MQ;PM_;7,S"'3\;? W+K$)$SNV:$EL)+S:G/7&YD3-AAA%F&Y)*'PS&TD ["[
M,Q@$KH<#X7RD?M&?>;B@V."_(+<X@Q\,AS58?\J:?Q>?8+H-QU%L()J.!(0O
MQP[@##C29LWJWYD#!C',%?#&^<64ZRZ^RW2,<L);9)<_9%_,2<9-F+C\0JP!
MA=<"<R+!'#RYB?^,+KG[OFOV Y^CM(,5#3W8;!H.9:+\H52@B]M\!0:\;MHA
M'1*,NN5)T%*2Q(<.I/"$I8$S 9H(?2U>)[9N OL0Z#;](!E&,<S1ZQ!WB"AL
MXAQ89!6,3-@0%QT/I@_^'0!H\ FOPOX4*\3L&]?D]H"S17"0+88K& 9^X/+%
MD6'Z'O]W@.H#'AH*T\T)W!@F:+0R.$MC@H^ FJ2K$_B>*5@!'T)IZ3I6.?:C
M8>#2'A))Q(_B-*RP&Q@261M(,P:N%](>2+FX$)+KA&N,1Q(X8+ 8J.;%'$I-
MG(YIBWH6<X)/2I9&$T0/@(:H^<'E%OSRA7]\-0U_%-[TCCTEY61U]HC>!Q<2
M@+CRD;42%GF2NT41L&"/+5 P]L^1&TYG E+DH@_RX,>%/H3I?]"M5WWJH0\<
M7S<L.D[DU/21B[_\1]]%KWIY/@O;&FI+K5O#F*'\BAL]/_JXF6%+I-([T!:@
M6$10Q]@=Q>),;2W('Q/5&.R!23)?RCA0'V M.8%E ,>X8QI0\OY,T@D!0 *=
M#X<H@%[02I22'G\1>PQEKM,'^NA"ZIR,/9%;X*+U=N8RGL@FE8&(QRT2C9^A
MZXSQ;93B_E?@FIYATJ,>ZH0UGD<:__;D,!&%.UZ6ZY-%!A%92YF@HJT'RG+U
MI<7R(%>D"V_L;7T*/'3MUE:6$0E!9(!Q BK53R"(,#)]&1GR8!O-(8@J," D
MT(034E_T.^:BH<MDF2?$XV $MK[%[X:_VRX?./"2_Q 1/L';AV#K/3B6]44
M\0D#)D\PV"<+3);86D$?<"#!!,;UW8!G5P-%P:4X4D<Y#&,:)@AL5[ S[H\(
MN<G8$7X?6E*$3A!K%D7F\*=S,2/T-P)0,U/FHN,!NRU-YCX?.F[XM@5SD0Q)
M!\&)P?*=F!YH2>'RF75%L7F@J:5///XA_..C87H32Y]^,&VB##WT<?X-S>6C
M<WJA^'IF?52JP@*1)_KRS?+K"GSUZ_+GC7:EU4S^JEK1$C]?-936K#1;K4Q#
MK?Z\T6V<]*0:]?5$SYR:H74;6I-O76>(,)[ _?+L:0ON[U9:J8[E%BH\"6-X
M,2U.:^ZT=.F+9#B-S'/=[<1U_POC"=<45@EM$P9FR=RIX*XHR%P323X?.TFL
M5IIKSQ*+3F94UEL5KLI "D5F)'--D?DMR*SM)B&R)A4>)M.E6^FD4AYH\^TG
MG_+ J3YI"9 ^UR?;Z@^4RI-VV9ER>9;<4G3KX*]%MTPX(AC%^ +NQY4(M@%%
M9(##L;U/Y#Q$.<#<^PQ_@+T_2/1&FZ7+3G6W.L+'D%^N^$WQVQR_U=H'8KA6
MZ;+1R*54HF*XHB#O3!DN$[]UUL==\V:S=ND2HTUY=6HN_/V68C.(/';'#="M
M4[F"O0\VV7 ZL067R.(MB4S2*5VVD\H0J(9Y)P"E90MGKUCJ@N-?2RJRI\!T
M"F#*7WVO 5,72T=45^=]'VEM@,-624D+BVO=M6'2'GLG3I/?SQ]'4GX#;N+I
MEP<H2*"G)Y,MZ9#=N=?=%974NQJJ<RV/,E2%=BT5T/85X4B-M!K(9ZUS\D&,
M\T7:?FR#U/BJER[KH/^7"U,H[_T 8/@2N^.F^PMI2]L6HL#-2+@??-+1O^P4
M*+B8V*/E S[" X<!!J9ED@<1?2P+*\H\Q)XOX?D8PG+V/, S4;PT2I=:L[Z3
M^LJ\E<4N.J&X\=RX,:-YN$]V;%)WDEW:,RAN5-Q8-&[,WX3>)P^VJ O;<AW.
M[0)N^V7$?97J+!1\'NDR,L7<RN(ZT3"Z.- 7^WPJE=Z+:&T2^7NV\<V!U<>B
MUHG,TRY=-I-N]*CR[T<.HEV-I$PHPK;E22)8H:AX*'H#Y9X).UC'IY%;MHN*
MBJ7):1E/@,BDEN657B<Z[#RW%)>WU,SRW'C.I/U,-S*Y[9N)EV[KU6KILE.$
M*O,J+:%8"GHK,.$YJVIL<8)@6E+4;P"F&FCNS@GU3"NVTKX*2U,E594X-W\Z
M]\34)8X(:V4LUM#PELML)#('U<I(.J@YC%VK'*,#9*CF#JI&Z;+>KG04IDX2
M4]LYV[MB"J]1)IB$ROW>&RB>HHJRRMO.7W%'5723PDWU:JMT6=VI)Y7R@ H)
MEBTU\@:T8)%[%7PY0;1LIVLWH*5S6CW$BZU%'ZG&,&P3Y@_0[B@G.&]=>NO8
M8=ETB\M,C<>1[O)/6,#R*D;[*\=+RH>N5[NERY;R6$X35%OJW-U1I563):U"
M54%1]:;![!SPI9U6D_MB:_*OCF-0A6@\ES9=;$=S=H[Q873YC.#?Z,)L(B_@
MC;GB7&A6GE!157@J,.&QR.[FH,)2(;&TG5.]-98:&+DNBEPZ"Y^[9V#]];%L
M-SAQ3<=EU+B)DKV5_YVWSKY'"F,EZ_5)E'6MB6)U9U90_E Q_:$=,\52HZB5
MK)Q5%G?Q /0&>CDU;-IXI%:4$-]9>,Q/+CPM=W[@>,I=WD+U8AOHZ[!]V5SB
MX\*9SXS6&"Y:Z+HU-']RX^(_W'426:.##3@Z-:WVL2!FJG)YWL1]?A-P=16X
M3AM<*_3V]N!:!E&MBLI[Y]M7RHG.D,@=.X"(-?M5WO/>5'B<XM\B@H==$!.8
M0D.F4.[T26)I5Y6=&4PU!),ZJSY-,.VHHC.#J5ZZK.U>]ESYVAEZ8,5ZR%(=
MP5U*F!RQY?J6%Z4QS]+!0MS/'#Y,#CO5&BA7<RB$I[R>8F%GUW!W*O T2Y?=
M/.JV*? <A3[. S)T.K+S12GE*6=(#+OY]G1#)<24<[SUT7(:,_2K:?GF&JL3
M6U*I>Z<GBI]-*6!Y *B#75&4$WRB -J@=/, 4)<JS.W<HDDYOAEJY\O:8*^F
M/QHY%DX<_=]S\WOWG^7UP">Z[XJ_[X:2[&$OHR1NJ%=SR;A0+DP1,;1E1G9V
M$&FYW*%2("HDB+;S@S> *'UN0KU6M-R$LW"8[SELD(WIV88LWC90:=F[Q*G3
MGN-$A/\<T3V1+>CZBW*#3A)+&^/6>8,)JX$5IG*3 M.^+T'O!T3-Y*CVL=YT
M%E"H%UU1BXVCX^1W\CSY/9NXSHOI):2";:*![%DBEI34MF2'#H_%H]VVC7EV
M)D_!Q<L^ A7SW7D2!4BK=%GKYG8-,Z>]*G:3+,6H9\VH>\Z&2,&S;2P#O]RB
M=MNN=8I;%;>>++?N)>R6@D<[I<M./;?X[ $YE2S[7ZES-OS;,%\NPS7=!F/8
ME,'E/^##< 5CW7TV[7"BW7FNP>H#YG J/C)M ]R;#QIL8][8T*J;H%&C:Y@C
MSGCHBS'=M@/9:AJ[2V.TE/GP"RR0X#&.12[89S[@XSYWQ2;6M3*K56MU^F>M
M#",8^)?&7G6/K=82=H!#K#7I:BO51++O*+*? MCFNZ@34(3*BUH,EMW298+B
M^'N999SNO%ZKY3S-1K5TN6R2_ITHG'6BG;U.5 /S>?DD#^CI<F\B1K:FE8C=
MB7U.DEV<84$AWZ@E0QY;<2#W,M-CEO/*D=N!J,CR\WWFL5 *[!,0E!D!./T.
M_<:,FG#I21T]V& $6TO]/O#7OU<>*V4:EQ.(!R!M=?@N/*3_9^":GF'2W+PR
M>PY+JIE1(9TRD^ET^+@#8[IL$AT7F#X?>Q7V-(*UP/\FNHM=7V#"SG#H<9_U
MI[11LFHY#3'47QP7A3JMT<.)AMW$_HI/YDRP6RSQ5T\6?P*QM2(B5@\?IQ?"
M\W@U1K>G=(K8_HCX,L!6 JH"X+AIOW!9B$CW/+0\''O?J"^GAKQX&R["Y1;7
M/0(($!J7,+;-H0F60+#B6HEBEP,HX4:R$I;\HB$X1K"Z[1DF$9E>O$\RP32&
M4IC(Q:PL6AJH>E00VYD0/>6C\)?$%;QB#LN91#C#_8Q_!+LY-G^*(F .C,Y&
M8+$.J!,)#.LZ8UI_K$"8A;P]HXZ0/B@BV"?3 9"]F .8@( X3A6>]H%/35L(
M&7@1R82;WN?O3'==?!%Q?TS8T)*(RV"1R'3PG0=[[>'3M[V'J]YMR%NYLD2K
MTDS!$Q\GCF?B6CZ 3- 1JQ_1U[JHT].+SA-,'P? ) JMW?BXEWFG9&4DX^O(
M'(Q 1$\<-[X=<N\!C[KONV8_("</]U>/@.0%?<\T3-T](2/6=WQ@@%42W&/X
MN8ONGNZO\/A"5Z^&I/Q;EA!#8_6Q8/RF(HA &5SP;AU[$+C8R&\^@P<D[87A
M^!=RN*0@1*.)U=N7[]@!\UL6*7]81J;I-]]T^JWDXO/A].>=K#(">6"!/2$T
M]$RD@VS322#+B3#+U/NF9?H@?FUIK-@4,0$Q:K!/ND7VT..(<W_1_L6Y#(1B
M(M$VQP@2:0T4"<ORXM4T_%$8E8H])?FF.GM$[\-L G_U(VLY;@!+Y&Y1&$Y#
MS3Q'P=@_1VXXG8G^S"_Z(/A_7.A#F/X'W7K5IQX&H.+KAD7'B9R:/G+QE__H
MNQC26I[/PK:&&-2Z-42Y_(H;/3_ZN!7%%F4<;-F[G;=R'@<CT.H6OQNFJOZ"
MLO@)AOMD@5T08PKP/#CPR@1&]MV 9P!&$44Q:9P^!X,"&)9[6#N<./+9=3QO
MC8Q&4?""')PU3!=%Z3[LI,^ 9F+N$1-3_!5H9^D3CW\(__AHF-[$TJ<?3)LH
M0 ]]G']#@@5!+Q1?ST!>J0J@RS0+^6;Y=06^^G7Y\T:[TFHF?U6M:(F?KQI*
M:U::K5:FH59_WN@V3GI2C?IZHF?.E]&Z#:W)UR=>:<WT R0<:DG%D>'X1IY.
M;'5\TUH0$NW$XQLL8,FNY[B: 4//G9_LA98IGH^=N531#5ASZE)T,J-\7)EH
MG!,I%)F1S#5%YK<@L[:;A)!9D:E/50^3&[#9T!+W\-?;4F7X"ZP1O"1"$2%X
MB6-DS1\]TUR*;*L_H52)%8& T-=9$0Q(]/([>;:8.WS&TIH,><5$BHGFCD6Z
M^7$1WK"OY78W2;%1073WB7%1RE5G8:)Z-3<F:E:)B?*ZD[7GG+R<;MNT"\X!
M-_(\T&/O8)O%G^]%V ^,V#!F[M$GLQ-+U5)A^^LC*S@FVH@'[@465EO[XCIC
M:C-R3SX#_/8^W(Y$]J*ZS,NY6*ID04$QM>--AU2H^LQW154-KT V52W( P)J
M#VI]4R[^WH14/9?B\<4J>W%DBCY9N8>G]ZC>55&,M]'N5X+F*5FGD4LS$E71
MH(BHVE*]YP&KINK 4 A8%5W+9T-5"U%5E/(KY^30/W+?MRC]5SGIN:OQ9'<J
M1O(_37\$OX<O>H$_<ES@$)ZI-ERS7;3:<&?L>!5(T[\!\E0[SN(@KSC&P!L
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M=UR,<EM3YDVPNK*+];29L0"H.!4 "F#J8SR/P_JH;#X']>),N:AM_P@J^#]
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M?W6H(MI'5EI8U2,O4J'L-X)ZWM6@QZ9A6/Q065I7T8$%"72A\3ZDH/8.A-D
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MSQF8=$1-K+?,$Y],9YXM7F'(.=Q&7 UKSBBN0_D;$F$FAT6NT!PI8*<''XS
M?04'T^-V;/VUTN4034FR%A<%;AD7_SHR!Z.Y7<5[7+C2$/-ON,&? W#;;V&
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MR+"SB#+8UGX >A\/>>%'MN-'\2G2%Q?AK&91.!#2XIAJTXSU&4+B7\BH5'@
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M+V[@RLM=J'Q'\$^*J).?;S];W*#=<BD'IKPP!AFI$79=_AQ8N@L&IK1KQ=[
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M*H_M-,&QX=1D$S@:I<NZUE2):Z<(CHV):YO T01P=*NY7;HO2*;:\88P5%>
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M1^?OSZYN^]$!LJI5=1[53&J-]?D-#P(.7UQG',+E3],?78%=X8RY>_T3<RR
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MD$DK$B_,V$1-F836L^T@\GIP5E_P4$ZK7OQ/\3V\JYF6R]NK*_:)^V>1:X0
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ME$,K<JT2T]Y7=]_OKV\?3\?/?EH0&LL@U_8+<EV ?#P#N;<9Y"B\WQBXK<S
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MV$-L 9O3(/^4QRX/HL^%3D:7G7&MI_']]\%UP_"K 7[WQ>_9LE6I[(4'41J
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M &H!M:U#+3/P7DV$:,A$B#;/A+A#(L1,B%G4;Q9\+>/(D\-C<B$VB[WE\9*
MO<!>8*_%<W[K6]BKYX5IM!L&WF--5%N6A!:I$%@),-IBC-KZ40:G[W$@++V<
M';P4:\31PZ-X"*_-EGDITB48, H8!8RN8W2$ACMDF\E8S.[B[5TCCFK T?TX
M"O&0@*/ T76.4NW>VB'AC'+'#7CE459C(*H#1/>#*,0= HBV%Z*%<8<&AKY+
M!IN,>T-C$(IR$A^^5-2A9IU'E<<C@O,H@&[KH%OF%$PEU^E>R8)0L\#;AY@I
M)R(O@I@I0%X@;Y'!*\7'\M"JTN[#TN#6.LZ!N'_1K<\J<(3X#=:XZ^L Q)*
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MKNBBEX@NR#&02:YE+\AV90LZG2^>J["!F]ZDR^WZG2.6M;1(&S,J?P))L>.
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M8+X=X^"!R.,GOIG)"),YDOK9=!R[HZ*-2+!I;K):<O2(I.]'N['6DJ/E_E+
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MO62<-]K:T[?/;]M\'B8%(^'/0)>M)"(XX:OB0T0%:V%PRF7I7]\RR9LN>$S
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MQMW"6GD/FY#6X714<"Q(Z@-)GF3IR\XB<KXBUC=_X36L8N1&!K26 !L*_EP
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M6^S(]Q&ZXL9Z.\0JZ6B!,MFF[R,R:@.]I0\D6U>+0,7>?1\;/;,3WW8]]9*
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M$ =!@*TCWZ*/0>/WU%7KP&B4V;=4B9>-MSGSQ3OP*65AD<,I_'V%%L/Q8;O
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M2Z[[NADTEEWSSAB7^%8=S;M9/DO+,JO5;IQTOMX+XT H[VC54YSO@W#@A:4
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M*A8TUHR1]K6MIA%0O,VV&!=%;'T::B>@0]H@.Z+BVE9DQV#7]>WCD"G@C<Q
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M__QR/O[I<YK.1MWD/WZF?R,__Y0FH8NCR8?_^/G/]R_ _/P___/?_NW?_S^
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MC5N@X2%Y913)MOEN<$(#;S@>'"+HRB;>!J3_<I,+-_U:-+..07B*)R'-0)G
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M+"%T<04XBN8*'F5>:R%<EK7+KOLA>]AL::B%!K= KZYDDIY%*;WGE@$+^(=
MFH+E7H(*P@EK;735W<"KSW\<>K^S1!L$@*ZO;SU6_*V;IT6+T8BL#/@#]R&=
M>1H-T]Q"2#RCF8.VCA<2D9HHC?%9,%X[:Z,_NL?!C$;::-"^ZIK/@Y;/V[3H
M.?VLF\W7,]/>=+.%"F:_CD?GHTGY\9GA/AJ12Q4#1[8C6#P!0P)-(TT$=SE?
MO7+X;D@?!Y\&T-+.?E4GK%E>5.].YDNCZ^UH]J_6A<L['SAX]7*_I5<J8=YX
MV"5K"5JS:-H:2-9H=' RFKH)21R(SS''0*VNW_]@%YKCFSS<^.35@*](K*34
M@4WEBK^T07 R2J#HSY5A#)F2VI&4[4B&*F>NI._-=M)'B_>^%#5O+.7IUZ=I
M$C[BF_NOQ94!5<:7-#ZP).*B8K;@0\[@=4[&)1E,JEW=L@_3J2Y8:ZA]'Y..
M$7^3(5DW\:W1K4+0??"UJHW8@^U$=1)5-;J7+A74<0K::!T--9&"HR%"J0@&
M0X(%KH*Q/!N:6>U S6GHLJ^RXJ1L.40+;6HNTN0BO4"I(-3%*.Q_CN8?GUW,
MYAU:ENL\,R48(DL@C58@&$''(BS&RV1.+-6<J-KCV7H!.T'.?E5];M9C5%9&
MDSDJ&Z_+MWX#2N/_<JD1I\*A04<Y^"@C1&N\<'@4B^J3,VZ!\[AME#L)O46Y
MYL9J+RN1^T ;RC(Y=9.6:BK<ZP@=)_\A3)$K$*-6*F:J0"V&$!IBP$4CP%*.
MWW72!E*]F'MH:AQN@#1GQB%B;\&(U9&V 7%UQDGE0E2$@=2E;(VF"(X) UDS
MIBD545>O#=D#Z1Z8&G=5WTU:5)1]1?MB-IV?_>[^3S==XUO.O$[,9N%+QVCA
M.0B>*)BLRL*Y)0Y?A9A[Q3[PXZ^P /]VR8#M3WX$UD,%D5:\&RYH2GW$ZWP-
MTXK1?4 =8BKLT?=.(,,:!S4TU+42;\5]_W9PEC*CJ<IXR,F,.XZF>,AQ4_8U
MC3L=<EWV<B_OE\YWG/J#J?P0J59.'/L3Y9?BXOIY]EOW.4TG5XK69.G]KU("
MQM$O%B4_Q2<J@)@8LH_&<-XG'?RV9PQW6%=40== ?D/X_Y?Y!?3,6.X"81FR
M+T,<J;" QU.&&*G(7-,R/:NU-7\%SSTPVAK==MU5Z#L)<<*;]U]G\]%YR2'X
M<Y;RQ?C5Z'.:M;Y\O^V9@]^_]Q9 I2OX-],.#=+YUU)V,'\RB27[^-.-!!(I
M+1<AH%LA\3B*'(\C2BQ0ZQ57EEAO:T=\]Z,ZNF]@^)CBQ1@WZYW/6AK;S&O!
M+8O G,YEZB0'1ZB$Q!SW1 1E;AY1Q[<3[(EMJ&O[RAS9Z#/80A7WY4)_YY*N
M!'90;B1(E)MT98I-)B6MVT4P:!1DBJ>XE;4[E_: =2JGMPT=NK9J:1 7V[WZ
MR]A/'XB-@NH]X)TFN%Y=M7VI<Z1>3D0A]#R2,&B%>I%*#2F/I2&8!YDBS2X3
MJ6[6ZCQ<ZNP)OM\'YARBC@:,>7HQ&D<T1]>-151BWDH-0999Z[[<+T<:@2C#
M@M()?=G:/MQU!,-[;=65U%63< ,/?HWFY?FG:?=Y8?JLFST;ZP//3@&A#I%%
M5:K+M !%([/&F20Y:Z3[332/EP='2K[!'O#B8HK"O9@F7/6+T9?RU1I9-IY:
M0BTPH\KNIQ.@Y<]PP33ZJ'CPOG92QVXTCX\3E23?)+/C_-/%/$W?=7G^EYNF
MEY.YFWP8H1G^9#9+ZW!D<,YY3A4P(4LXT@LPN<R*T$G)9+P5MG[.3P]@CX\I
M]?51^7;O+<)9#9X)1FMM A@;! AA UBF#!"NG9%9$JYZY9;NN='Y]L!'Z;?>
M7:05-X-O(%;TZ@.CXCWME4</?S-[1^'?5-\1DJM\!7L53C0L$\<%>*]-F>S#
MH)0, C'6)>L9][E7L=6I%7C+-6M=_1TBL,IZ^QTE=7YQ_NT", N>E ++#5DU
M9B>4@A2*99=<\J37B;LO)>;J0X>]4;VSV+L:,JN>U/3E"A#J;63,2\A.HIW/
MT.+'AS.@W"56.NO3W"O?<6\^TY<'K;P[RVS(B-KZNBZG,\\8)5I8X%8J$*94
MBTC*(*%UEUE,,52W@GO ND<V<)UKH]JJN(_7X4^^?2=WT\5 ;^]FI?[^_!.>
M>8L,@-:WXP= &/RR_*[BJ71WOGCBTYM/?#*=EEUO&3>^_)556YXGZ*W%RQ>
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MW,1H?8@>I20H[IFE]8SB968Y'GW"FV1)[;C7K8#N6R3@((W?9%$UR3>9P;3
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MSOOBCLO2K<(J0%6H3$32E@QQ-=L;<(M[ZGT/7_H46;F@C/; 8YET'&T&I[(
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M:B=HKXX[3U-*PW5G,IY>G(?AY_EU;0PUG[\VJY=8T_RUA^@" ^F244RQ0$Y
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M9F#.A3H#''A>-%B"+!P:5K#UC<\>J; A6F#?3-A&V#TPH,/2N'!SK9#!*2F
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M5KU9HNTUL+I\%J$S<%<;]:"U$'2BD;NDHM(^I-BIW,,3F/  S(LCPF[BWD?
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MKCNNKT::!>&+E]'G5&1K)V8SJI-!TX/V>C"&UR.\H#U129\-@7)U],6!*TE
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M'<,%)$+. 4/?8S2PC,9'/KNGU59EWEWOVMKA>A.C)8RO5HR'2VQG&!J47(*
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M__$9RQT9%\2&Q%OA'*QP]"? B--WOC<>C->C"[%.20!*5G"%J34[^N$_NH8
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M(VJ'D8L Y!XF(@6?5C"Z_(\IGK]V\T-^(4S<S8QH*J15XUS"<(S\3GKM(<B
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MN,%7:]$.91;/A3@/(T5L)>MIL6OWV_:#\B_"]UZ $<JTAT]1>/)D ( 0P 0
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MAOJX:LPT==VSB\BH@O.I$SJ,YK;'TLU;.O]F.1&[6'8WX^_78DD'^\D;O?&
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M ]6BLY4K&T8$JU45#]1RZA#^13[T% ^T# 9BU^!X@&Y'\K[?6L1@/R"&-/#
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M?>7RX0H" YTCO(IL LAE^L41E;^*$:^LQ^&!^ZK82L1\XG%P8^=G+V,WZNL
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MR$"?P"R4XR,\]O&0A(30S8NOM=1EB0U]?PHEY1TTGM.HR#:*(O^"C>Z@.?$
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MX_A)F'5*Q=TD7*9%HPUASJ0U"<G2>VV6$1%.DB0[A^B2@Y26^?0D1>G(%UC
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M2DM(;%'8(BN'DI>7EY115%) *6U%R:,V)^$30,8("HD)"8FAI"2D4/]G@S\
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M EM_Y/NA4%]2IS3QEKK7PVZZ&G?WETZ]/8:GCXU0M2[TA,8FU&6<?_=MA3!
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M<K6LN+V?8(AGDCVQL,(4!<%, >2/=A"(20HKSW=KENGC&,XS+#R5*F==F!!
MBO']'_/SVNKE6@K.'HF22%$3+59UZL2V),*+Y:=DE^?ZM)-%+EBW(NW-5]S^
M2/<AJKQ11+<M2W@S'SOH[WSK^]Z43$TLV[:!L1Z#P(ILU>SJQLCH*7_\A\+F
M7=7^NE3-PH8?G;/+A Z\U_'3@O_E.)^ +Y'4^_3NFS9;]6E:5D@4US"F-B33
M@B6IT@2!U)705:N-P22JUZI=NE62,G-LV\6%8^7W*XYF=JCX?>BOHK>];H1
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M"%P]0;=S%:,S*888NB,U&4]ZBL%"7*H"Y"AG KO*8W#Q( KR=]HX- "IIK.
MQZ T\P(S0\?E!>9"%W.''9R:]#&V%BR@-1^]BIBYZBE'G&..$B@)T[K_!UU
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M[RU/<%/Q_0UL.6P:N,3"U]5J6("_#PO(^4-,11 F9M:_1E[\'L'13L_G=\U
MTK"7[)<<V-32^+\-GX9T!!MLUO\PDP,&QK,N: +?;\ .C\6] P=>(FFGG=:?
MTB$5V/$_'EB2?;%KC6,>M37!"85;B$50QW@5HH2A428B&.6,WR<J,,6?^B'T
MHZBM@=%-V7T2UTQ#U:IO@6N)Q%-,UZ&Z!6:UK^RA-.+'#@N>$BL' 5*EAXBT
MFF')RA=\X)?FXVY+E;*"6U_?\_@T+*T.$^V<B!4W+S[$*!=OW#K6QU#P%'SI
M'M?M*3NY:W&BH+(BQ(.JM9YC&Z-];T,\.MTO/^GU^$30;AI/HOW4\[.JJM++
M?O=%I#-"<JS]JOT6;IK26^IH?S:T@BS! >88%*% E&9.H?TP\!2O7UEA <M_
MG\M=K4*R3R(885.0 E5N_CC^&V)HV.PB884=OY=DZ^)BKQIB#9O'*_CN%N?P
M+L!\QJ79V<LK;[(B8NMVI66*V3U3X^CR\\<X2>L;E%ZM1B\_K:$'QKD#C<CF
M,IK5K$P/^"!28@E7RADPL==\^:.^]U<!E+2FEMK;4S*=>0O(0906'=VT=F#Q
MX?G3IWCYU5:I,!_MXX.71?30BU3-8^F0I1\-"1O!_1?-NW#EY&!F'I&71CR?
ML>!9/N"T/EVTL5-#*YLVUE,7V/55_QE^A3]CG^>X2V3!TS67Y;99TZUS.:\P
M>=K0W?8E/S3R2@$Y!@Q#G:]+V2>;+3B;40&>'[W ]FV&$Q6((N5]8OJG_.CZ
M"&<]50M)8E>8>]>Y:]_'\H=]5NX!R*_F_7I#=1S,((_L7DC6L<K!KVCQXM.5
MRD5242M*$U\W4':94=O")[IWMF([']KT%:?[@&U&<&#RQ\%!2(C:4(?]SZU4
M"V3EOTX I92A+>'R.09M8(@%E-A]1@>/*E+D)E;05L34I!Q'I3V2*:XJ1ZHG
M-=DEU9Z;R%6H=CE,F]RQR!1YG9)?>\;76 ,3ODCXJ-3@I]N=)K:_I&1J)J:I
M9C_A2K[,-'9(G/P,-Q[Y(XL9.%V5$.1R?)U7[\7;@LQ6KFE@MRI;JY4A9B[R
M->D]NWQA$:/P8/Q &:[KTU1G3]58(.J0PI@_=#S<M/N!PT/1X.'2]P^;7<6>
M#=7RTX/$D@<D%S0NV?O%RW)JB6J:G..9-<A F3.$)\.10A27ZP/N;2_) D0)
MDN+EB6H13\XC44T\:,G_Y-N2+7D7Z47E=U_U"7.00DJVMDQ;$4E6@E10%BUP
MO\/-_\5R G;(MH:0V:8X<6\"L/Y-*COP$:-@N/-).8%]1GPHNFZ%3VDDNP\*
MM_Q?6?AO\?-O%);\"X6-)Z+B^/(%8IN?G5Y;L20VZO>=62[T-=QI;E8B?U#S
M+AC7-QX5IX53WX?FEQ0Z^\3IXZ>EUFQ=U5 \#.J@:HKQ</,K.^B3#L2?-X$<
MNC2Q'>6KXY)FG\A0&BIHJ&[>(;ZC7O/F=%1#W+?<MP\47UO-:>J<'K[VBU(_
MR4?$-2(/+N8W'B(?//O+J\V(<]%IO67@R7!K=="=&,Z<>@4:-]W1*5B7PI]S
M)2MNK?!HN?!UQ)D]R"P,9NK]KK/ CAQD*>59\'3]#SSCVQC,*7_9PNL<?F/T
M/?.V^A0YUQS/'UN6>:]&OY@AYKC-Z]<OM@K+B4A'Q/CX#"P@EC/>L8 &5;H:
MY?S/DBH?,\(1V)U71J^>HSRK9$CIN;M,\F.N5:5(0%*RGR1I@UL#@A:,:29>
M'ES&#;%;1)L^[SM5X')>BZ.\U&Y]?6 #WUU.-5>+(TFND-Y1Q4X1@\JC/^B%
M/\O/PDS[BVI!@=J,C1<DL5;EE]XZ"A3TIIJUX)KAB)7^_3U5%:U#I[4_A:LJ
MI>TE?. _+1%>I7AMZG&+SP^"'.UZILG$R;KL)<D A1"&QH0JTC@TH-73@6\B
M(>W7<Q9@L8$:/@CI=S2S@*UO8RQ ]U@!XB=HBK6@<(P_FTH X[*UG(XB-WID
M1RI11 F%%/I=L*V2TCK04<$">D(6;5K7'QU**/IV1X_J>'Q;!YFB_X?!\#RP
M -4<2^9#W!IR3GO,@]#E:+=5C5*'ER".JC2VGP404%"4XP:"<E(@* /J('J&
M^A_HWWZR4'*^$*-C>U[*=E[L0,:HQ19B< S2WVXDK'7!W6Y11G"4Y2:$UW%X
M%;;OWM?Y]>F8H[^"R-MC=XY!>48T7$?I.;31I!8Z_4/OYJ,NHMULU\""M4L#
MXH#.!!AF(]AGLA)A1>6=*%+4YDJFNUGYGC_=)"4MVCY^MBLM!W76+T^=9G[P
MBG+5P8S3F07;L8N&ASV<-5#5GHH75FISN<P>/#C55"PI@9O3N3;*,^V/M?UG
M2S<$M;5AQP+2$\/0%,D*&C8$N;7E\.?W+Y#5))XJ>A=LIHFG,^M0TV\H/E#C
M;_OV-F]BBYY>-_Z_#!9*+EO!0#T&TI]!+Y7&2%,H>A#A%H,3'KH.-[+- 7"^
M#-\6OD8AX9B-Z'QH!XQN25@-\+M1FQ9]>FYS-9J4LZ,?F5Q(/H:,RQ0(+-&.
M?S:+6N_1;IGH+I\Q&/]+@6JZ1^PF6\4*5<]["KN QB>(1-A>P']%1$$'#'8P
M[I',HO=B3*NMN(<]E"<O8&YSED\V$K/[YSB#O;Y9_"B* 7GU?4OM]FGPF27B
MJOS_AN'8NKHS8?E_/J)2_:]'5&X9N&/N3W+^ \A?6WD?2IDGR+/F/!I[9<7E
M1( =,3H*5&'GQP/120DLX-:ETH*MNSI,?4P<IL]BP\ME'!GYZ!7BO-Y!^^>T
MKPT\\,>@=!F#8>=$' .>[Y+NG\-.- L;-9F7K\A^<J)&X=^A[H'A8@B*YNC)
M:I)FN?N"[*B$_XCSB3=Q?SWY&;E[T17K2(6P&SU)*(/.)U\>#-ZZX]CVH=JF
MORZ*:8Q2YUS)(09#0<] XBVXH);<P@SZ75^QOOQ'SO=(XATBI-+KD5DCK]1W
M[$95;2I0Z3I=CEH-LH@GE.K<C_0!*L_P4%8$^"#*U6/O*=NH<2FT EM#'4+\
MB!UG?U9Z&*)W8K_V2;*J.MFF?^)[G9K7 [W@]<FJC8?U6T^OF&"<T%EA8U+X
M-N2^Q8)W7M6-B;F$^(<>EQPJQ!H[;[2NGR!8.$\?5#_(_JKCE9_C1=QS2G P
MV6O1E 4D*M)QC(,3+L.]_Y88%38]5Q;^[2$:H3XF"EY'T_KJW9"M)27OGW-&
M7R+ASW[J__LQ(Y(>]^>8<65*&2_'S)07=G:"+4+&)_TVERPK&\F.&+'#7W.U
MZHQJE3P=9S$G_JI [_<UYH[LULGZE8&X<?>VHT$#L>RX <_UQT\=WM=MK$>-
MU'P1QU2_%I.VR,DJ7U'L2]6)?+9DMIA1S(P36,V81P[:K"VS "$/[=#[MS9U
MSLK5WY%79NXIQ$-<"!9PU" 87'5$M8]6&@R6:V*G8G)9@%C<6=0V^:#U&AP*
MD4-C^YE/'9'M7+$DAH;:=86L,XLL@"JC9IA!T>?#-6#BK!&#-JWS_YGR=(EC
M@XV0/OTR<N7WGO,^G[C+C,!D\$L+@8*;U5#2G%(!(S'ZE#8MAF2JC'(70W\5
MW)1#YY>XNV1AKGMU0%IX?G#0 LY!ZO)T9)J7)UAH]OLQOZ]^&</K>&MF]&<8
M>:'$,0/*5@UL'J\U/SON/;8,=[^DP 2>ME6#I.XU/(WM]PJ&-)1Q1,*7;<3P
M$OH !=TH=(SCQ#HU^\ZO4X[703FTD'DWLL(L'VX5 7F]G4]';+-*JLA?8QZ#
M$@H;M<I;=G'UE6#>=!^AUG.;L'ZD+N27A1YO1;R5\^CE2Y?'DWW,YSF#02=\
M0-6AX.R%;DJ,]MV2BJB=IKUGB#L^'$96K811A&(C:YZKO?ZVO!%,I"Z^S_MF
M.%U;\*A\]2U-@ 7LRR*&0T$.6&;C(P+EAY?2RGU2!ER80,VE=UH3D7?UKZRV
M;]:\8D;9UVE>V=.1'D:MP!9(JEZRD\<>E!U/WF\=%B0=I^-V><2FGQ'L.ARU
M^3+U,[0+:X%N2,%V(SZA;D=:Z&%?7LQZ&5%GABOXU;Q[_DJ5UH4NQGX'F1)F
M$6%Z1 7.?%;P]&VF2Y.0%-@.A=:DN+74B<:]/A4]O'A#]LD3DBZX%Z:-GWDY
M9A"U_@@CVXJJ_AM9%Y&=@G$"P9.!PA9;QR#R6VH?V(^BMT37+8&I?;/TSJWW
M%2,N&T/YT)M53 BFA;#N4B?& C @4^C'\D#\@H>3_/ZT'M.3[2-G-65:0%LT
M56D- <(TBW0D3^FL@D<>="6<*QS8('QEQ),P_A ?*3ND5.NPXL67W;+"&/V?
M5HAK/+<\5G'E^,!>.$((IO>E1[0>*KGWL;AKWS'13+IK&+'J&&@X[=6%O]_G
MM.5JOF5Q-CU,NNN1U@"!: !NH0Z@EA9[68"& A]8#S=N'P-.D/@\ R9?GYG6
M>BL_^&7I("3;+2JP0F(!$JV-8V01+ NXVHE&X$?XMSG_MU%7U-UQ6>I!%C#<
MM7D43I%801;P2X'6!0_RNB-I1%@M- HPU]#_VN^T(PHP0B\BF%XP==+[TRUQ
MJI-*]4%;"?./+L;VU(DP:QBRAQ*FL'N]PN1-_'3[+2^ 0_8A]QE//S'R5FUD
MZE'.LIRMDR[^%^/6FV>MYY^TYESI>&YHLO*:J5+^!!QYCW%I5.[Z,-OG6)M4
M0IW'8-Q/A&E<>LWS/:*G/WCKL>RHPO; G].],V-0@P!(DQ_XG+<=Z;=!AT6A
MC;N<!10%CD&1"J\KM&8QL"'[4HB:1,?*@2[[G):1G \W24?&<AS)Q-)G,]'J
MVN"Q</1>\[XQXHU]'N]) OZEI^X<"YID#A=+Y#O!"0+CL5Z_M5G ,_"Y5#7*
M4!!5 >N$,,:_3W.17_G\.[79S/NCW4?'5<*RYV\BEM#OA]"?T6SUV1:MJ)>;
M.?>U#6TTRXUN!@(Q#NBT>5=.7L,OH@I&24DIY*=#8[.8NWZ%".H*DKFE-30.
MZVTW"QB[0C $)ZXRU%A &DJ'!7R^G^GR HDHAL$?%,<"GG<8NTVC)L7AI3\O
MAO9&R4Y%'Z='%&S*+])DR/V49^\IDDUBO#7=IT[+KRBN2ZUD!@VI)F49'3['
M."\S9V#A9+P9D2$7Y!(0=(:KW;RW+"6,]MI9$><FE"RG66^081M '8#UL1%]
MH'&R"_!RN?6\.(A^W7]"::^(O"-8@#$Y/V,@.!YA/I^][)E75TR_2-&?7GI8
M\A.1*==V@'G I,-M \_SP>V.O?G*B;HM%@!0E\B;__:H9J2?*-W[W\)<2YE:
MR7^1Z-X:!*L28=D'5F/Z!+C]@ 5TX]$I^[8-J"OH=!90O,9(6@LDC/P^$*O5
MV5 ["E;VP(HS[V/N/8<Y!M]Z% G)#"A$;5J::XQ^Z@HAK!LPX$F\O81E\OV0
M<2-Z(YNQN:CCFSCJ+@MP0 $R=:XRM98 FPH'H$_X]3S]GMQ+R)]%%,-59/$S
M%A"^(L ,.(&B'I+>-*"<5*WV*YG8:F64&/OPJ"T71=-DS%,PL&->MTZ#EYO5
M&$U1>AL<;FR(=4)Q;3(?C"B5A^9HN9TU;5NWMCBA]EG 3*W=T:#%39?42/+;
MT[9PKVYS8-%70;=21>@N"U!S^/$^>T4(!YLHVKL^-?;!ABNGXCT]#YPU\M'6
M[AIWFM_];68G%V.+&8]1'62(]LMN8@\4!S0F9H0VK_N/W<>Q86Y?&&RLG-?P
MZ\AB:!/+"QY4F&&.]:PZOWFT85L3$>&-2PH+1W8D&\1-/GZ6<DL7$:]?NI)1
MEWW9?3%'ZO1S <F% '2LFD25OGHSYEAU2(!H2_:3^<M?9&;/<F[B*PCVLD-)
MC:F'B?T9F5YVQN4#*CK/!/T5REQ/*=*#N+^,3SU_PB<2B^:T;"3;&QW1<[YQ
MWJ<7=9E(/U40;.KJD3Z9=0\_D(=Y&;<\5MQ,& +MG4^]'"'[*:X^0(UTQ</Q
M:>K'E,)FQ;+ NW"\F!?>PC[).25",51J7O!G2O!TCN'I?#\"OYG)$U]U/],Z
M)N(B,Z>L$0]]%Y-VKK1DVY7Z4BS-=C]X"S%C8VVI=K%OV((2.+ERM6WN='_)
MLV.H_+L/3%#;[06VIJ>QYB<SMGSK L]TZQ'5K?O/Q1_5JM4B?T'-E=I!.V7&
M8!G?L0 I4R(+1&VO!9CTYB_S\7WZ:U'";GQ\^S/^(^IW5XKZ(C-Q]*<66E_F
M1.ZKGVSNV'/QNO[Q7*=<U)FZGX^\=0.@G5*8'P@&V8 ^;[XHRSB)"QZI06:R
M@/'S1JC/.&#G0R\M7>.H])]2&W)-+" D/(@%X'CIW=07L'_\3CJ>Z# J-7!:
M''U&QF<A79L4^>["YUR^54R99GK!=3EK(Q"378YI24SKQ:C=M/2_,K:P?6BE
M]1TO"U!NG4&;8GX_=7%X:7)M^S1,Q??2%+OQKI"D!E"@!ID;?#)Z\5SC41;P
M_LE]Y*8C/8%<<Y1@AQ) DO]^;SSF:/--3X/0LV7.F<EJ6S)@-+5OS(OI(+Q:
M05W16]J2C]RV9)!S44_G_Y.'*X.=7MAEIS\=N[8]!W=L@<UH:=8GAA_<I5\:
M?CLFWVJZIY?F:?4)*&[R2&5EC\M5GW*[[2>1V9*#+RB)%&P_X0:D2)'WVIA
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MX;MYX%U%TDG\^=I<E00,9Z<$T5Z!14'D5JD\1-U:TG*3ZL__V5!+ P04
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M54Z.X)ZQ*.;:"WE3[M0[U1?&CO5T2^^,!P$;:;N\DXV[$AZ/U_+EMQ[,V_%
M0E^!!H*DJ1R@W_;*IX4%P^:3*H5%+UP=^(8-):HTW%6E7= M^J1QNH17.!K+
MOZW-7"><,L=9__2Y87Y\_7K%C==&5P\U6BA;@J7%ZG32[M:-+'" P%3BI6]F
M;O6,1?+&SKU>2] 9<4L89_!?4$L#!!0    ( +.":%BW_3") 0T  )D-   3
M    96)S+3(P,C,Q,C,Q7V<V+FIP9YV6>S34[_;'/XQ;AF9<QJTR,B2B1(K"
M).&+\',O]T)H0NCK%C,'Q9<&(:(PA)"8Y%*NXQ8)N=]OPT@N849F#,/,F<XZ
MY_S^^?UQSN_][+6>M9Z]GV?MU]KKV6NS)EA$ &IB:&P(<'!P #/L!;"F 7T
MQ,GYV]CB8ALW'S<W%Q<W/R\O#Y\ OX  F!\,%CPJ#!4\*G04#(:*085$1&$P
MF !$7$),5$)8%";Z^Q$.$/L.%_<1;NXCHH)@0='_6JP60(@/\ *\0!RR *<0
M!TB(@]4!P & @YOC'P+^*0Y.=HX\O'Q'^,'L@!HHP,D! G%R@7YGS?9&LOT
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M0;=G2_'%0J1BQ/L@053=%<:IST'_W"%>](\4RM;7*;>RUZ#5ICZS-J3Q2@@
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M$6ACL,QFL?"SH2B)6X\S<,MQ;=ZP&%FYOU98\=N?<"]Q9_C%0LF8)1QSN:3
MPXL.;Y^2(JLWH#GXV-X/A^0QEO-8SV*SQIE+KI9NPFR+CQ;*M9XJI3,QKCLK
MFVK,K8?LD],P"=\=4F/1W-;JY#]O9?9ZSU!D'TMK35B9W\7R!$<?G[%6]J2,
M SY@(FPOB,(H/D: \Z3(Q'W=X6\B4_DQ.9_:CJ)+ERIIHNJD&+G\FN]AQA=O
M=(^>)U;NGL,NFD2VI+<YAY3QQAW+1@Z-?.!0$!7W&QDQ7X=<C_E>1>-?J\Y2
M)[M/0I]]TG#,!,^Z/Y?0QKME2T"2[Z E4Z_.TO- "2CH:HB]2=A^@!;[ H0
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M$'%[,E&X[VL;8FF5Q@52'+A LR9;FPOD74<P].G[/9<@]/2H#BLT;8<+X+A
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MX@%]FB$8DFN,@D8.I.)G8%]C$=SA?P-02P,$%     @ LX)H6*FKFUZ_9 $
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M= ^5"&8)0OH>@>+S;&**TZ^,G[#";6K79Z16D =84GXS&WSR#OVEH68IX%S
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M^SAN^YX4S7.*G'$CZ1*=/]5=^.'H5A9 *=FJ;,'D]&T.Y/;8Q.FE=U63HFR
MY/=#.,W2>B))2Z].O33?@:6.D?MX5P_N'+/\\[7C5[L$[2T8VR1=NTU@ID0
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MD/HK4]_R.\^/I$#QR_U!#1Z7A \-;S?E::U?VKF^[[2@;S38YR%1?_W';5+
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M]<!W:LEL>C36X+S*^A>BUVM:G<A/VRG35(YBG_>>X^=<FS__ZF<22A=/PKW
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M%[XA#R)),<0O_*W$<SMW@9#P6:>K2N#:8+R%>GX8&Y33+AV%>F2\1QB:YJ.
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M.+DCX@VR%0;QO)2 !$'<8WZMYE^J&]* <9OKM&[7-ZL>V7ME_Z,>Z.,$VR3
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MF%L/RS'&S!C6?L]@[4;;G,)9%E)3[J\Q=Y!G$:@H,.-H%5\TCL$J778@C,E
M"BE:XL"[QAIDJSD' \W.KT#JD*U\VHH%':7+!\,'?1X4\C,909"\@$8T0_#\
MR#W#7C+RE9WPL:[#OD''"UC ]<>LH)4]R.HF11M/TD2U,476YC2'/[U'P7L:
M&R"QD%J[50NZ@9$L)L%0)UC=..WX]<9GZ.<2!$640]C]#>1L3:IC3D?"]9"*
MAN&CY]F@ FM!UH(-!OOGJTET12HSR2&5T &MT\#L6-TB<5"1@XO>JJ<8+<<
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MK6\RL+!9254S1W?=5XPG"TO8!,)3A:$2E;OGB&Y%I-R)2LU"S&DJ;*V?K@7
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MNBD 3Z9DWO)/Q3--[R*W2\G+I@5/4ON;VU#"ZO+6<TMG"/<U=9PZN'QN7]^
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MXAV#T>"H"^#-5!$P1)[V+ PQ/U4I_8LEG(M5#"VJ<Q[ZH[QI/V[KP1VO)G9
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M^(V/%"/>#-=\)XKQ@BN2'?']Q\.?+Q+BJ]!%\<2@:MSI](#9ELHO4\TN(JE
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MM1KAWQSS2"=.YA$L,C(;0FLF<E1H<\1GX[>YQ@(1&/'SL4.$KYW RL?H[3Z
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MTF-..A^,F27JYY ;!A6TVO&&;R^=E^<21]<N3U0Z^%-P;"GIR0*[R?(E8E:
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MAURC??QK00@R$#?L^2E%'+G 9O,U/;?7'!<8ZG 12B9#,H*^'_79S)&2V>3
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M0@3KB<V?O-RM[.-U/H)/6R<^%@EE0*DZ^ Z95/-9:-0%N[1HA9=/_Q/XDU6
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MFD<>A07B+DAK6?V&<;,X&"K@)<HZ0YFB$IX6H?LF,X$F42D^O3+](5%[4,#
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M7_3K?W= +C,U^)DMKQC%U4LC00)U^8=&5TQRGHD?_Y@\!/)^BO<'?/ZM6'<
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MY0Z&H07CJO45<0]\Y;7EQ@[H31N-PM&IXK4E9 >4<0NZ\A"ZI0=T[8"$ZZ%
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M;AQ&\88.G[W:"P9TTO/Q!FMP$10,0;4,[I<[85!*.Q3MA)^R_"A5V;,BMD9
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MZWTV3\<B-2373B24Y%;9IE^Z>UQ@X39FP'8'=!5,5J8=S4")L<]R1]%:[1U
M/F/2AUC[[43!.42C]Z6GC?,?7P@KW-'AEQ5PI)R0:+1,8 5LW^?*H4=YIGP
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MYT'O?7"&(PP,^(='FWGN@ 0-_#:,]LS+FQ6.&:!K[*?FFS$#JJCS34@"=^\
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M_=!67E47T-4*70L/.KZ%0^"#T4BECM.$[YK>C"SGHG?V4O\R4J=^=/1-V>Z
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MRZS<3M^:V4'QF9>T? WPPLG=]LI.LM<'I26JLX5U]))>_W>GSOQ/_$_\MX?
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M@TWTEK.M.DMX?W<OUWB<?2@V-Q_R!\XNFX2$O_ UDYNK/^3&ZQJ3-5]Q'-%
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MO1KN?*&9V8X<FJ;01;V2&1#/78OAW4Y[G%R5>5&JE(3=WWFU2E"D"+H\2-*
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M\H);J;PJG,2*ZZ#)=S/DCW'V!/5<UK(/Q(Z%IF%;?*)CG^?UL]+H%^G,I*9
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MUH6<O-*<'^)=7E&\_G^VN%2O]=LFZ;#Y2DN 4/>Z(9*F,<E\E9?)5 ?=%))
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MC;8,L2!O-%+\Z_5>IS,H9$U@UUQ.S 2FX<*BP_%+B^,!;>O['8X#=1PN*BQ
M<+6\,!&][$+# I2#)8?-&':D:?OUS.OB@6^P^N^FREF3R%ILKN7SJFZ+-5O1
M-(J"@'B0(>'+'0SCK3O"81R&*/1$%FDEEYH*GOU@1Z["\YTN%X!VVJB?!OJ
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M1H($11Z! <$$(A*F$*<XAH1$24@C/Z-"J_Q$3]S,+G!_%KI6TL%ZV)./MBJ
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MLM9S"C^":2:S\;F!9F'LG$H]U!BB*.^P? %!U;35W6YR.5&+;5W5>*,J0R\
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M.S/P<;'ZF_Y?PY!S8TD R';J/PYT,'M@4#-,!+==U/YH4=OS$MP,HP8V%W
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MQ4)$;X4L?;0FKF"Q$/NT=,7FH3$"=\VW-J.\*)(B1GG(&<*84U1D.4>QHJ+
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MLY2;35737%_P5<&].0]#P3**44S,X!1A)BO00B*I"JE8I&@>@L)FY\E,<1<
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M4)BEF(DHP0I;!5HO$1A9N3L)@HM]2AI0FT\PL=/@:R2%1D3W0E:DQLA\'&E
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MS0@RE0@IEW$J,:@<X1*AD>W GFQP\Z@=7LI_!'0E@CT3P9\U&\!HYT78[*R
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M"BF20,9SO?P(,RY+4@PQCM)4Q3HJXLRM^]<92BYVQ:OSEZ'K6B-Q&A,[BQQ
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M9"K)$^FX$W,A2V.OZW7O^'(!?K2D:R?5T/;<GO6'WW$3=Q)0W>Q-W06]_*%
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MD*(XBF8+]6""1,L]G4OXL5)K6JMUERNG],2:)R"Z3)G!,AX]<B\#WW+/9W1
M_;:"&H^_GL^X0_6 LWWVXA78,0?VW 7<( H!4JA]HXMXF78[*01L1[M,01[J
MWAOXFUI6C>V,#WW]M+'M"_SJMK%WFS_>@KK]WF%H[=!PX)2L_:;D0C$=#8.7
MA$X=@,_(XM7]]_6S)NO\>T:(;M??<Y=X#N90J_(',\>5G8#Q=U8N/B_7ZW<O
M_Z'D@U;%.S6OV^\_EL]5 9S*&(JD]@YBI!1$%"60FGJ%*"'4= +A3%JU@[N,
MC9'5LJ$*NF2=B@@O!-G.%1@?.C=5]T'-??S&14*'FL+AQ\2TPS@N NIH)L=E
M3[NTE<"WE>EVN7GYIK]PIL6OV>EZ-CS4VPV*%6F,=: BJ=D98@77<4O.M64B
MB=3F"B7$Z23:EO#H9]$U\2M0D:^V'78,7-IU8 !2RU.0$8!R/8.^!*,+&A38
M"1R\8\$ V3=J86 'QOF>!I;W^YF1MF%"]Y ORZ@4<91#C!(!49&;A%Y$(8EB
M%&>J$)Q9#3/HH3&R<=@WX3 T04/4T1R<@L9.\R\4V$W)765U5NL>:0)I\"D*
MDRIKCXBO];+O4O= _'[%S."?Z]7JW<O-0M;+BV4T?NK>D?6J(=D]WEY?F0-N
M3;_\4<HMF]L'YB=E'X[.+Q7;3;LL) ZWD Z)YQ6UGWS@9*%[GSC=^+WWN@L/
M5V\6S]O-VA2XS=.F5VVL5[(\E@@6W'183B,"&4TI3 1&4I(L56YSGWMHC:R2
M%2F0>AYFGH#&\7CR,H']#QQKNG5%J99_A,%U%B*&/C@\0>EMC@+/BWSV<*_G
M%C_]O5]51X,O509FTX.O:O0[DUA$+(T9Q$E"((JPUMZ\2&$>$91EI$CSC+IH
M[UE*HR^G-=TZG;K*H:[RIFT;G@\C%0N:XI0S6.0DT:X\3B!GE$"%"\5BF2J4
MXO;0\IM:E4OY?<-6FRE@.SR;?$W<&L-WZJ%<5'/(.9M7735'@!$SAC#A!40T
MT3#B5$"*]'+!BB*3/)%*8WH(X\>%Y2%P>!!;TM80ZAM&QL]N30FBAJ[N7:.!
M39)^3?6JZ0 ?;BT9%"W02G*>SJ3KR*"XKU>1X1O<&[ZTC61,PDF5Q-<.*B!*
M"8Z3#(HT-VGN.8<\T3\1B@O"$8L0XK;M7<X1&7GEV)&M]O0>*L+V'4C.(C,0
M?062UTU%#T6M:7H,M#@KLWV/E1"R^W54J4^$37O9E?:O%EL%%%LME*S[23^O
MEG)K %HOY]+4&*W5ZD<IU-K\1<>HN[[]FT<%S+S9M7D2,VD]E3Q79ES;?&L6
M 1W:;C=@L31-R9Y*DV2^65X!'6"JU>*I204Z^N+]6YBV+4/P]C1I.7OK9"U9
MAICO-F 9O';B:J(F ?I6N^\;5OD"7[>U:G"2)SEF.BQFVO>13+L]G$<P9B0E
MN2P49V+V[.HV!N?31?]><VNM@O7TEV7- ECN>= JLW-!M5K5!/R=J/!O,4&)
MXIEV_VDLE'Z+F8(D(1ED(I*"(I:3C#=OT=IK_07>H;.;V_,&E;9EO^2[LW.<
MW_1MN*WF 2JF=C51M]U76#/^"Y0Z#6'ZUL5*9_G[UR@W&H(W6,'0("&_5?K=
MMIS+.LF]_?'FR?AI]=E"XY2FF!9<" :YCO$ABGD&B9 "RCQ+\T))A11RV>&R
MHCIRS-(2-N<GS8^@[#!1>91ST__FT?BQW3^YF6$[B.U,:W#@W,QE2[/"9O=+
MEX,1-KZ=9 YDSNQH3FJBG&!X;7;<;G8_./ZZ7'Q3RZ]J>?WCH<IY%9LMF\]?
MOK%2.F1T#SQF9(N@J4.3 _U5_]<6,Q\Z!0T[P/#CG/D]A-' ;D=8>-ST/BPR
M3@?0EC)[G44//7NR8VE+(;LGU+:WO$WP7N\CW"SJ(X#!$N:9R*,"4X(ABX@.
M[14UPX91! L=+<8BRT@>)Y.T^O#C?V3#M&NQP!K=JS:Z@#0M%@IS"%TW/=(A
M8QM.5A<H&:0/TM3?A6F"S!'?\-N%H,UVM'[IM5BVW3E^G3C5\[7\(E&L*_?_
M4C&NYZL)'0'[LG'9E&73I7QOHC"5<59$!60$IQ")%$'&8Z%_+3B+%,-YXA0/
MGZ0R=J:6&1ILCE^ U%2O.@N)W_3D0X3LC/C%<KN9VOV<Y ^5R&,8P%Z1 D]$
M/J3Q)F.03XIY;O;QZ8O]%/.KVM3--TU5TRQ*!*6YY) @)2!B60XY5Q'$:9+D
M*"EPA.+9QE1DVBGDP=.=%'%'PSZX4F802M6%]K>Y)N?HGAT"P05*$<NU9<)8
M.]*Q0)#&^M<,Z=]5GD8)=FJ\XP^$1_P=$@BJ8IQB_67 <<H@(E$&*<LEE%$2
M2T:++.74;1R?-Q1>\_>"@F%GC;T%=-Q,4)NVZ_)OGWLE<S:^)R4(9'0/GSVI
ML3TIUFLC>_HB3Z]GWQ#G_7:UTA[8+,JP)'DA8<PQA8C&V.0<8IC&%"481UF:
M(1<+>TQB9#-;=S80-2W_(7<GH+'T=2X2V-'1V=.Z @VU@"[.64E"^3?'!*9U
M;LX*>.39G+_RTE8/;5K.O7[0A^43*Q>SE(A(*!Q!*C.IPPZ10HJS&(HXQ7&"
MD$JIT^+>1VSDM7Y/>C] \<^:LG??AA.(V:EF*!S<E-0+@@N:,)R7+7BKA1.D
MWJBAPGFAS[=-Z+G'/>WW3ID>#&*S-;WC3,WT_V&++5N]&/2:HU_!4X*%C+1O
M2A.(4F&2H:B"@N9Y*@B*6&$U5]:.W,B*W= #AB XX*:J^K?/D+4 ;N#$+#@<
M;OI]+#PX ,<]:=@"$OOTX;#0^"42#T 4)I'77M">E%Z+ATR6W&LO4#?-U^$N
MSP+7Y4J5#XO:#Q(O]RNV6&LK:O9LKQ>R^K5I.?-Z,!DN(H5I%L$X5MJO07D.
MF0XV(!91S%'*6.*67N3-R<BVL4.YRJ QW8%W38+-\5U1,]Y$*<(Y./%_!7:.
MTB3 NEG9AB70\@2Z3%4H=]D"S6"Y40?,78Q2J#I>;SZFK?*]%*ZC&N"+'^B>
M %5/?)+?E%K]OEINGS\M]KIEF?S4\XB1[5)#&1C2H*)]!3XMEYO%<F-Y&#0$
MP8"G%DYZ-^/1)SCX,ZAQL)31*X^I[[F3Y3!9"-?-7[*YW$,-E]_57(F-DDTC
M[Z_LR;J#S<F;QU:]Y=,S6[R EG([-@ 8V@ZZ=U)N"ZV[5&1'??.2UDW'^B3R
MTZZ33YQ.K_H$.M"HW@LO&;1\^USU?UX\U.-@]V:=*\0%3C#$!!'MN&<,,B)C
MJ!A.:,01IY*Y';+U$QS]U,U_Y/)9C"Q/!X+)[7A2T Q>WE'>C6 ><?;RD)A!
MQR^?)?8&$YB'!#\]A'GP+C_=OA;_W)8K)3^5BW*C/I<_E+Q9;/27H^3S9C;&
MYW9>^TP0DN<QU4J>(&8F+A>0LK2 &&6**I+**'7J)>U"?.0EN&4%U+S BAFP
MYZ:=]?NG80A4'#D>43@A;6<OQL+/S7H$A<[9F/A@$,BT.)&>U-#X@/+:['@]
MX^), QV;5S71IMQ.:W$](:V=&CCC<<(B#0C,J.00%5) 'HD8$B5R3%$>2X$=
M70U+TN,['3?7[VX^W]S??/P.KK]^ -_O;]__O_]Q^_G#Q[OO__-_D"3&_QM\
M_/_^N+G_+^]4A7YL+5V4$?!R=%;V'.R:1V]>1ADMZ2IL^,R'?K)OE0]A!49/
MEH3=_7ZVY$ZULZ!NB_=F?.)J8PR6R3J=T5Q[*#*BD/.$0B1B!(G($\@SR44:
MZW\2U;9,N[=W8WI(6JG!8<.T>W?GY=NJ7(CRF<UW<[# <F':XK2L@+5:E,N5
M::+C&MCTX6EG,BZ%Q_/<=0]% 3IDJZSO<";"0KA 5J&/TJ2&P$+DU[IO<XMO
MJE2AG1#Y3BWT#QMSHFG^J]V34T< ]9Y_.PACEG-"*$4QS(@9H(=,@G!:2(@3
ME!&,,TP3[)9,=0D[8V\SMJ=CY=.S-K2N&587 6UG*J:#S\V:-'R!AK$J2:$>
M8-$$-^;$X-019'/.:S@,GN<<!JQ@:5\7,3-Q8E@(X(Y3QX(\U;-4V[A3VLKJ
M[^^C*9G[4"=X5-5Q3;4:XTF:&]^G8-K2):F"7(D"8I['C"@N.,L\?)]!PM-X
M0'L.JO5>5-TZZQ;&CG7.@T RD>1YQB)(LSB!R/1JYWG$8$(D)YQ%/$&%4Y5Z
M$ 3]5X6Z!=EJSP"0=2;6<U,][%$..(RBW7H0%!LWDU_#TJ$-/C0):@TLH6NF
M;44-5>4\2&_:NF1;\8\JB:UO]$QH4V;NZ?S3=B'7'XM"F5&GZOM?[/E.FZHF
MWU(IE+,TU\94F>:]699JVYI5M3$$$<%SE+A-;ABF.;)1:#@ %0O D'7,0;-
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M8R?;!TG[O>Z1$?7;#;^N^SM!7M5VB6X-V+,!D<GEL\FOXR]@\ZA .Y:Y7%3
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M$ZJ[GRXWIC.(=J&DX<S4HJBB4&)C]J]V'ZWWG2-^*Q=UKQC7B:.^K\7.[$T
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M)"72Z3C0G861U^X=9; G[68$/%"ULPSC8N5F+C0O]8Y[RXW)O/W-,*2MQM_
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M&(9($893Q.)".C7L/'S\V&>#9KCH!5W<7F%AI\S^$CJ> =H+YSX'[J0,H>;
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M\^:OZ_4"]_8,^58(/9>:BVI=EN7&--&XJ0=MR'?;AAG376#&BBREIO5YJK"
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M75S$."WL@@ 5/&C"AY=7"J,8 -OEP(HA@_J&6JAR*447R7FOO[5W7.^,-DU
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MH@F7JIMKMO[?317++]7ZO^7ZVZ[6=1LKI?=+W4?FN62>(Y4S(1$@L;% )(>
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M7/-: &1YY6LS4M#>([N/._O99?_?K3](/39=--U/]+?F9?\^7<LY$S)6$F9
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MVE=228*0F2S-)"0H_124H./Z[DA,*46]G'Z1)A&?H%@)!6!F2C/GL>EVF"A
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M->6UI^MD_7IUAOS6RETMKS<ONQ__LY0K/="/ET_R6<^B*;E,$2Q2B@6 "8<
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MM>K"4[[!R7="Z&FLFSZ07U?WJ^JYU,S.LRS/$2HH(%0*H-6H #C1BH6)5(3
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MP]<L:L)Y(M[G8$#U51? [0SL%#"Z6=+#^JNS:,=4U.<JVK%EECD;=(>5:/6
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M2A@5)S<]OM  O4'.<!/MV(F:LKEW(R-G?Q\]'H)^E].AD72Z(O8#X\I]L>.
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MZE7BMS5=K2<#[)AF*-AF^B>]5#<)NMJ6M63"8)E+B6/,$J $AOIKE^6 "<1
M05B>%#%7#.(.R_=+,3&26XKA<)3:(0Z,H-T*&0 3M\7OHA<1;CF[(5.@E>H2
ME4D7H1NB'J\OMQ[W6SIV2U1WK+%^:=MFPQSE+(. B-2H,$2 8IX#27&19P5.
M<.R4$G&>S,@+1\\KVY'UZJ5] 20[+1TNNIN2^DCMK*;7A0JDI1>(3*JDUP4]
MUM$;3[M'L9@;>?IH=470>WQDO6IB,S09^_"3K1C7-<93 C?UN,F\4]S($;M>
M82+;,2:+"CEBNA\$<OPGSQ,:T_'Q#:VEZ ?LW*U6>B*:F_ W+_M'NO3\.U,/
M\@,M5TTGO[NZWK0]N6H3X<[74OR]6NAA3-47LYOZ7"[+Q\WCG.*,)<W*!+,,
MH(S'@"%( >9%KO(B33+NE'0R'>LC*^F6=O2\(SZ+'EO2CF<]T\VFY<G03SE'
MCN=(AD'0<'@4U;87(V(O4?^Y;;V21I999*1IVXM&/7EFT6[F]R(UIU*SZ/.-
MZ7<_?)I\)D(=54W'^+0'6Y-/R,DQV/0<>/:*6'7U!9MKWH:G>G^W.T>*I3G/
M.6!8I@!!KM<4O;( SC(%<TFD<.N[>)W<V![;EOBVT_-)1^?HEW+9?7HYQ\\'
M1SN3'@X=1V]P!TS7KKDEW8O/"-A_P4K&4 T6KA.;MH."E> G+1+LWO)3?F-]
M&E/2%A_)%4^AP E(828!XN96$";<')2C# F:,>QT*W@X_,C*;8@U"[R;WAY!
M8*>G_H*YZ>5.IA$J@Y^7(9#>'0T^J9Z=%^Q8KRX\Y9[G^%E2<Z]O%O"/RZ?-
M^GY5L:XNYU?5K>Q;_8IIDF00 804UHNIR@$E.0&L8"A50HE<6BVF;F1'7U1W
MA)OS_Y:T?6Z> WXWSDU&0\5-:7L\1 T3LZB/T5>UV\'<5.HA8-DG,8X#FE\"
MHS5X85(6W46_DJ[H,-ADJ8KN O;3%#W>]G1$-N5"E,N'[KM;4,J@8 (4$BF@
MC24&+)4*""D43(@B+':ZL3\<?FQ'I"/F>"5_!(&E(^(MF*,CTM$9PP\Y*T(H
M/^1P\&G]D+."G?@AYY\:&A/XUZH2?Y2+Q3[<+$=)*DB6@CB-$X"R% *2) A(
MIA2"!<-4H/FS7+'*/>COA)K+-[%/T_[@<//X2%>-Q[$E[ANZ=PJ5Y?EK&/$=
M#TQ[@7=;LA,%UEV4,GC<W"FE5PJ+NRCRY:BWRZ^$.Y_[NEG7:[HT9F.>"RBX
M0GJGKI4;H$(D@.(D!:F"*.5$R80YA2C<H/=*)W35GH.P1W1]*/W/Z#P!"G-(
MUR,^[BG=&2E'/*;K4WOU<[HSHML<U)U[S;,U1+5\,$6$[KLLK+?5XV.Y-O[W
M?1-P-\])3%4B,I D6"_OVDD&C* <4,8*D699*G*K6F6V!,<V!-M<0;ZCZQ5:
M>!,W.Z4/B8:;UN]+]^P@V1/7F^/KF+AW:+ 4-%1#AEODINV_8"G\2;L%V_<"
M=2K6/VP_ZPH?'EPR+L4V*O+\+>3;JE[/$TBQS)(<I"+! ,4X!2PN<D!H@5F*
MBYQ IY3L,9@<V<:T><F\1W1@:^,0\V)GCUX;;3<;=K8ELOEY]X>.Y]EA$(C)
ML=SW'KL8*V*8'[%G<D!HQ^JG'(+%U^VU'!#DFWV80]+RL^@FP*,EMEA4?YB&
M;29K])NLY>I9UN_T5I(W@1]SI#CB6&_L&,ZX\>H8(*F4(*:8BR1C*81JOI0/
M36UK>V-M2]_*))#6))QPX6 >MO3<[*\UBG8V-2@H?H<[[]]&VY.$6:0W\3&9
M13NVHCU?C67<<C:+=KR%LX*N8 2R;-9D)[56KF <6R#G]]VL2KU:]T@LQ?_=
MT$6I7IH$=&YJ<_32S]N::[# 7&9%9KIO90#15/M]+)/:RL0Y+V11%,PJ7-B9
M\M@>W74%,EJS9S':\M@KVN!6T<X=^.N6:%0X@YJB $A:FR1O5*[9)#UHSQ[I
MW_:VR)W>),;(&X:M-?(?P/?DNC*&[6W55+1M6U-_*^M_=A><!&L7!LH,)# V
M&U DM35B$"2(IQG%A4R)<#NXOD9N_" 80SPZH!X9\JY'U%<QLSVA#H6$ZP'U
M)1!&N#:V$S+8^?158A,?3]L(?GHZ;?66GZ:_K59/E1Y3?JF67=^=[@O+*8)8
MB@0H!"% C,> QBP&A<A0)G..D'0Z9;I(:63]WM%U4^?+P-AI<A!QW91X1[)I
M]@XZJB,H\$W9 NGN93J3JNU-<8\U]O8+/CTYGO4PU>KEM[5\^MO37*DB@9DP
M/?Y,7<XDS@$KB&E8A:'>!2C]"[-ONG$P]MB>?O>]++=4HUJ3!9LG4X3SN:RM
M#W//P7)=.0<*ZZ:..T*1H13][<E?*I>N%M[2^;:ML)72L2'%63FN=IPX?&/"
MEA)G63WL&7'^$;\U^PM=:S]_US[/')/IO3\D.4E!QF*FK8'"@#$B]8J=Q!#R
ME!?Z?:<(L5,BHP>&M21->-3ZAXS8IBZ7LFX/S/3H=%G^C\=-SQFP[!;P80"X
MF8J]Y'MJ>A<^1E#89;$"+=IG"$RZ6E\6\'B9OO*D[VTO6^^K27Y<ZL51UFN3
MJM)4T!?W<F5<>/H@YQE,BP3% B@.8X @88"9BUR$DEQB+&B<.\5^V9,>>77?
MDHY:1[1NJ)OXCXZ\ZSVM-:)V6CT.3F[:;GCH%:2=13O,VB3WEI/H_C9F'C>D
MKN('N_>T)CSQ;:8K(*=WE,XC>!>Z.FH\]?[Q:5&]2/E-+@RE3V6;X%'*>BY)
MHC?J10+R(C=515*N'0+! ">R@(K$61$KQ_)7UL1'MC!-9RVM'_[1'TY(VMF5
ML?!QW7*<[2&W927J>(EZS 2MJ.4,0;@Z6_:DIZZ^Y0S*F9I<[F,,['7U57TH
MEW3)2[JXK^JRN7=@VLA1OIZG$FOWA3% $$D H@4"IBXFH#0V1X.(Y-3)=[$A
M.GH\V;9WE/;!=TQ$6RZBW[=\^#;,NH:GG84)C9*;90D D'_7+0N)0_?BND;R
M=3IT68!PL6^7S;M^!N.OM%Q^JNKZZ_(W:G)HWG2[]GG,$-7_PR!.A0(H3Q.
M&5: (I4B1:!,"Z<[PDN$1C8,AFRDO]\U;1.WMJ<2;F;@(DI<) 6GB@.>(Z2W
M@3+6;IKVVE(4ZT]E2@K"MT%B$^!T& \V#"G][7K64/R0=+'^$1HWF1$N$2Z
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MPNU%SY#H+D'X*UN4#\W78]^1^;.Y2#:M$K8G>GF::^NGMZ>2F' ,DD) (9%
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MSM_;1,66'1.,OV<H:CAR\]\<X;5SZ<8#S<V$6^$UZO&0'Q*!G$%'XI/ZAW[
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MH/T6NYOU^Y][UNU3:W_.V??+R/T9OP5.";W33\:5/. )F9DL?7AZ@/M9QZ]
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MAIJLE,AY$?IU0RX\$;HJ0?WFY3/]1[5J:E0V!S0$X103' ,J6 Y01E. "92
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M_>)1^S=%9-?R<[]:RF*C>X,^*IF;21A+/45N.2]X.0=BMW^F:8P%Q#G@4"8
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M3[&CO2C#<^Q[4+_E2;95J]AF^F N@)YU>:ZF4;-^%=3,JQ_V[&OTJEJ H)3
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MXUV[K,*P<_Q4RF%3<!;0SA"Z95.;F*+LR2K.2N/6K7>PTG3M>><$..C'._O
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M,L(#9,9S,'@"WD83+?-.UK8>Q](VKH<[^*W4("IJ(GVSQ=EN:(E[#;F@GKC
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MC'B7/_EO$QJC\I2CC((#-+(QE3='BH3(\+NE:[4>H.SC,22.&Z4-A;8!U=0
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MC'2UBRLJLS#R*^LV=\M3P*'A<^<@^P<9%RYI2G5 ):1 )(V&H%U .8",&5T
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MP39\O9HO?O10;(]D)T)D:A,SA#I*2>D"3X+*D;C 0Z8HB.AK%SR<17"3'N7
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MZDWI-')2R?SZ']:MA-]#3"4CM/[H6YPP4UI[9<)#$.C5@L68O43O&A&496(
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M&P#0P2ZGNWS10!6+FA&F^\;U(/ 0=Y)DS91.H""()VO?>PK [!\,8(,HI@'
MW12$[_(1$G!M5""4]XTE&?*A01.>03.#,7"N/E'M$"U' <K]P0!51? M .AF
M@LR[Q?4<H7>YE(R]*5-FUIU+;T8*[;8TW>\_VNA\Y)Z1G"PKM[6<."4"L3$%
MG:BTS-0.'@=@X[C$*OVCX79D?8\(>0C+R<WM_ZJDF+NTF8IU6[)Y+\5CE5%.
M P;9@:&(E= 8!T5*J/6))\&HEOD'MT8G+7P<_/XHB?WA9=^ +5V_]EP_\KQW
M:>&XY+S<L!9Y24X=\3(%8BQDGXU,G@[SQG8O.<>!ZX]V"5!+_@U Z0?M!7:Y
MB[$T6,J)"(:BDPXD<<PE@BZK<IYS15GM&K/'47@<X/YHEP0#:JD)#"X!"2C7
M("^0T>G\R_I907GT!6O>)C[9;*,PQ&6*WJXN+1++XRZ5A?),&:]U[1+/(\@Z
M#FU_M"N"VOIH &+E">$"/I<'?J7-;@FI#J2DG35&.$>$MR@ML(9X(11AC$;M
M*$;ELG8X>RQMQX'MCW9/,(AF&D#<J_D"NHO9\RM<>X9\+/QL69JJKX?S]G^=
M'G!&07'T1M$%C64H$92N^=E[DG*&8(RQ:-UK7XF>2NQQF/RCW30\C>X: .EN
MV[M==ACUD07A2*(J%T<BD.#PKQ)IB<(S\-7'ZOZ I., ]T>[EJBIAY$3'Y\6
M?5W!][Z7Z[V<I;%46^ D!RF(M&7@$: UIQE2L-0Z%7:"T[TYCH?6. X@?Y1K
MA:H2;<#@].C^M32\WF[J\.[+II+\=7_#BXY N3[9&->)S0XXZ$"2,>AJ!D>)
M2TZ1J+PU6<A,Z[\4?SR9Q^'NCW;[,+2^&H#D@UT_UGRM?^.&/_0XM4V.0(PH
M3R,2.J(Z$^NH2,&A/8ZU0]''TGA<Z>T?[4IA4$TU@,3;03#W_,IHI?2\%* +
MDS#<=IP$']&O],D(+A.EOO:HV</4'(>N/\J-067I-X"CM_#[EHP6\QE^&=>C
M!_>'UI);BI;9D!1BX2^5T2,>"(?H4PA1,EL[J_M8&H_#W!_M(F%03?UC/*+[
MY,-TP"=TFX\?X0'=/L:&?S['A(R&QDB$BZ%T@M7$L2R)CQJ8=I0SDRIO]>&>
MSQTLMKK=,$))H,8QPCFS1":.\1$SBH3$DQ?)\_K# G],5;-/Z1Z#CJ,KWTY3
M1NO6JU2R3$LE2S^TO+NI=O&SA"NM%E>Q-.*:742,H"[.,&.GK5.WU\OYK%8;
MVK"U7-\*<NI7D&Y')-Z.UO8@T;WGQ'O&T/4WCCBJ)1%19BF4T!QJET$<3=SY
M<<+*=]/EN[Q58[5;6?47F":DX:\8N?_ZO?_65NFI889GB,0(7ZI=9""><D-"
M:5?)!+?H2%0/)LXB>>PQ#T.@[G[\\71:;2!(N6TE<4"\SS&\W^Z;(YW(,65T
M=3,0&?'LL.@-8T@FLM!6,%&]KNF1)([[WOEI0#JDUMH%92F(6'R%7[]_PL]Y
MEPN/6_?2.G@C;"K-U5GQF01!1T:0&&V45D=!<WX:8#Y$YKAOIT<%9S7MM>Z2
M7C]N0GG.\&0XU>/<^S&5)V7\B-!J(S,VS[WV#=W-*92N;H11@[%.>2UHD\C$
MF,"$P-A$Q-HO-A\@IY[ENEED7;ZP%N_6\(9@LV,4L2Z50\";3(*7FEBG6,P!
M@S)3F^UC:1M[E$8=K!RV2A4UT[HINDX&E/D3)4Z$ZV3 .8;IB ^MVV'^D4S4
M:CA_*)&RKH[[B"SM3#^X/3YY,%$9I8@.(2-0$;(VJ3*8P$NKD#8C:X_:.(/<
M)\C_*=RZ1C,@CEM9QA%[8AGUN+,T&(F[3>]6G/S#Y_^>"E\G) @?HZWV&S??
M/FKK$V=+-"$7\WGZO9M.SW#.?O29E3VU1[%0R0+^>;-$7V%R]V'@OIZ]@2DI
MC"4YI%A"!D,\:$-2],QGR[AEM6W>HPBLY]J]ZF;="OI\T.ZR.[Z$%]Q$+3E&
MVUX1F:DBUBA/.&- 4\Y:T-K7/">0.:X=' YEAUW 83380.;D <:>799._?_=
MZW7SB&2'5XZ&GDGD4.DR8QOP? E@(@;]&/_+P#*#VI=TY] [;J+OZ6#[9#IM
M +_76W3^T!9]=;4JLOTA[\IH%*U$+\E%Y)UZBWN7,:*,L4RPD#FK/@RD(OWC
MY@J?WBP_N<X;PON[?"WOK6:35L8 $DAV(1 9/3KYP242=<K:&LJ1H,&<AWOD
MC-N%<0PGX3R-M!\7E1:47TL+RLO;%I2G%T@\]&E58Z&CR:X4!=UTZMP7B&<?
M$T]*$L5*U:$*B03!9=]<W]D<J4RUWZD^1$^UAK$;]V*6WG0^=-/^<FC3J32]
MFWV >+78W"&]G<\6UW_]U2^[>PYT*AV0C""B-"V53F5BR^PYFZAR/%'A;>TY
MT?6Y&#="JH; @TUHQU%W ^?OC00>9KSG]*^S>2A7F(7AU[,O5RO\\7P6\5_U
M2-BN#I;4N&1)A,CPF"BMD3S&C)GITG9$"I]JST88@H]QXZOA03^6REN"_1D;
M_V;TS">(GV?=?UW!KBV01EATPX $A[J1+%""?E,@*"FAT&_R0M=^+?,DC(T;
MF#5]&M0%1>O7J[=OE5[/2J5+[XKZ6<((X@(EXF_J:D[VJA^[0E5/^RSV*GG?
M>VE Y/UE3<-MZ=*>,- 9;6WB@?ABF:5A"#6%7UF&?S<8RE%9NVW"&>362R7L
M)>+U[.9&L<]_>SS&_/3]?-D5K=_L_:W,86FWE[0GHK0SE99R$CA3&.Q2;H&6
MK$KM^YS*+(SKM3\5<@\G,)X>!PVX-C]@_\^^F[V9+P^) 1;]G.Y9W!* B4F
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MZ_?-#[><96]%!H&2=M(BK^@L.R4HX8E:SKW64@_8<.PQI([<BFD(J#Z%TAK
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M!N^]JGTFW:>B+;"<HMM=N)PGZ :@4IJ'+]_[[\78]D50FZ^7&W9\TA "8%!
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MF:23F9Q*=_HFW>^I^Y>+"YCH'5O*2':Z<S_]!67)JV1KX:.'SLPY51EO+8+
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MWP20'&.==Q=+:EVG.<(;P[5@Z  _%LJK:Z%<V_7!"!M"3E#2LNDP*8B8ZR!
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MW;=3.%8JF"FN5;8UNS!5A<X]N( >4K*E&.&B$7J'BVO'Y<8%32/!SH;E\LC
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MY9BHZ@CQ^$.0TY+KG2B2!Q%!F82TL4BHA:B@(L$_NNQ!VU)<]+(H-G!4=80
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M-KAH P@;Z3J5W$+T48,EK6=,T268UJWOCB"W707+5B*N7\ND48YS.M\.D:X
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M&QZDSD+M'(ZJ %/2@7+%@X^, 5G94EE74YQ;QZ=W)JX3"_+T -KI*>58:78
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M:%RP-1/[;G Z0 9= .KZ'?GMW]]PNEAWFQ,B!Q69!!YE 26+ARAR BX]*W0
MK62M?9B-A'0)H$,$O>7U_G"N=P"=)]-C2+[.*R2/BV,$Q4*=/2\"U(;;SKN0
M>3R%$;M75MM@#_GC7'O-Y-,5UC;DT9#_[J5AIG9)BG6NJP:?A &&UEF'"D,<
M+NGZ126M[27U?9+6]A%!!W#:DCV%R*VIN5B!5:L@6@LAYUH;RDW*"IW UF/W
M7ES2VEZ2WBUI;1^V=P">C=K\'\2;#[/%XB:*_@G/EP);?)U\6YZ]PHOC(EE
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MY]]P%FX"X?KU@B*2#U5KVR:2DV24+%CK_TN=YY%3@EC;3^=45)1!U !EA]J
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MQ21#DM$)O.$6 HO9%&Z*;]XCX73<G?VTB]Z7UP$@>FW+Z\-T^<\?%X@_S8A
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MF2W,NZ29VRD;\0(ZGB1@O)&0QVITWEJ\(\_V^YTV>\SK2XK+O\_)\Y_=NJ1
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MCRX$6D*L=5;W)9HZBUZ/0L"+\#I"'1W ZX74T-5.&YB5M9C 8>&@O!;@@U?
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M$OLH;=3CO#U[M9"SF&PUY1X3R3&O1^C*")@\XR%ATJQUO5G#!CJG#L_:X&\
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M[2,U(KT#'^HP/#W?FO0TJNQ@?[S7 O/>@/D]^$ZR*/J_!.9,[=GJ$;SB D1
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MX>OW6=X6]V'^X<]$O_KF2_UJ4HI(%JV#$FK*4TE/DB2>@PRUQ[?W%MOW'#B
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M^0*GGV9WUX4L,@4AB7Q&AED9$HU37((0K(2B1+2\M2%ZC(YQC^T'0<_1XNX
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MN-0Z<#,>,Y4_7U_)2S%Z5YP!R[TD0? "CH4$4@F18C%!-:]/>9:@<8N/!SY
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MSJ(I!Q5T.&S59(:VR+2=K5HE+=MQW7^(IW9[[[N)T49::B#@+/)(%>% .:4
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MU1,$&VDLVG=QP7;:N!0;R6FULA RLJ7++ZRQK:.'SG"((4!461#W1_349&
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MS;=+)W[RV[7CQ%F!&J26-9?AU[9U3Q.D7]NI>Q!+:BKB3+" >\:23Z'254\
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M/?KELKU K"K6=5A&%64%6C^/]\(O_K_NFN[!KN0QRD=\IA?(586^CI=AK55
M5S_&J@!ZOG*6ZI\]Q&:H_+G2]_^</^EMD[OPI\_Z _9U%,[P6I^'18HE7(]
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M(,Y[Y#>^15__1?K%Z+G_O__K_P-02P,$%     @ LX)H6$-W>(;8#@   "X
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M*Y0;>([22N_FIBERCUQQ4![0[Q$G]]#182/&:.1GTU@\"-3(6'YGB&6(0LV
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MU!CV<DCU*(I-"/=7JOZ).7A&7C HGSXIFM<.=Z[C^/:SCV^M5!!T_+Y=AV9
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M]U6^<*NY?-8WK*_=S>X_4$L#!!0    ( +.":%@NE_UL6@P   (D   <
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MH]<GO['9"2MD@9N85,:B<\)(G=<GJ,\)6PJY6!9P=?[JTIEQ>W,_&<^9D;_
M(GC?Z9"HO#C%FU>=57%-/KER+@G^&?1_F@\G8_8^F,[P+^M\?]DY>_7JXO(_
M%XS=#^_G#ZSW-A@/X/]S-I_8BV# >N,!FP:S>6\.%_UI,!C.6>_-- CHQ:]?
M^;Q82L/8=W_^H=L]N^YY[]!UY_I%B\6$$FZ82M@_RG3#.A<MUCWKGK<8SU2^
M8+#/] UN=3><S"8CLF_&AN-^&]Y@ Y'R-=>"L4CIE0+,296C5.%EWBFMU5IH
M+Y+Q/&:/P6@T8_>]Z9L)N^N-?VRQ<0\W[HU8;S:;](=TU4*]&(\SF4M3X-Y/
M@O$% KPIH;?]0F_1,+#-?LI38< \6*#7T@@F\UA&:#5LGZ8LXBM9 (Q_ 3<
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M /&:8?9Q7;T= ?H6XFC#Y3%S\!0=[A"!&&FH*@.-#3H)8Y8_J8JU/.K<AH<
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M.O@6Z:?-<%)G4?K #8):$/K@Z]5U_6EU3=KZ!=6U/;4RDX]NS>0$*&E L)#
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MW_KDQ[4?%[WV!_KY=G1S_>O_ U!+ P04    " "S@FA84C$"P- <  ":;@
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M6\CMF#DK58+<T]ZJY)[]M7! ?+5@*WDD2">(+!QH4B%=<%BCX?OG9UH7%SK
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MN/:#"DKIBC0XJ A449_(0U K#2H:\9!"R3&,?VI3LB[.*X(PM;]C8C$[<V7
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M[#",IV+(P2V%:#SZ%@%+4:,",9_F&ULTM&#1DO__)AB&4?L*!LDVQPJ&:?]
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M2P$"% ,4    " "S@FA8)@'1&JP&  "Y(   %P              @ $
M83,Q,2UP87!A8V5R=#$R,S$R,RYH=&U02P$"% ,4    " "S@FA8$>"01K(&
M  #R(   &@              @ 'A!@  83,Q,BUL:6YD:&%L8V5R=#$R,S$R
M,RYH=&U02P$"% ,4    " "S@FA87&*Y9+P#  #U#   %P
M@ '+#0  83,R,2UP87!A8V5R=#$R,S$R,RYH=&U02P$"% ,4    " "S@FA8
M#4.%N,8#  # #   &@              @ &\$0  83,R,BUL:6YD:&%L8V5R
M=#$R,S$R,RYH=&U02P$"% ,4    " "S@FA8TC)<*K4W! #@V#  $
M        @ &Z%0  96)S+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( +.":%C2
M5ABZ.1H  /0T 0 0              "  9U-! !E8G,M,C R,S$R,S$N>'-D
M4$L! A0#%     @ LX)H6"E*;*G-,@  V <" !0              ( !!&@$
M &5B<RTR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ LX)H6-R;YAD$JP
M/P0( !0              ( ! YL$ &5B<RTR,#(S,3(S,5]D968N>&UL4$L!
M A0#%     @ LX)H6$^C*F=BB@  B"<! !,              ( !.48% &5B
M<RTR,#(S,3(S,5]G,2YJ<&=02P$"% ,4    " "S@FA8H,R??.41   4$P
M$P              @ ',T 4 96)S+3(P,C,Q,C,Q7V<R+FIP9U!+ 0(4 Q0
M   ( +.":%C4&@2% 0D  *0)   3              "  >+B!0!E8G,M,C R
M,S$R,S%?9S,N:G!G4$L! A0#%     @ LX)H6("  %VJ0P  =T<  !,
M         ( !%.P% &5B<RTR,#(S,3(S,5]G-"YJ<&=02P$"% ,4    " "S
M@FA8P8"PP@02  "K$@  $P              @ 'O+P8 96)S+3(P,C,Q,C,Q
M7V<U+FIP9U!+ 0(4 Q0    ( +.":%BW_3") 0T  )D-   3
M  "  21"!@!E8G,M,C R,S$R,S%?9S8N:G!G4$L! A0#%     @ LX)H6&L8
MRRNY%P  <A@  !,              ( !5D\& &5B<RTR,#(S,3(S,5]G-RYJ
M<&=02P$"% ,4    " "S@FA8J:N;7K]D 0"JF@$ $P              @ %
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M;65N='1O86UE;F1E9&$N:'1M4$L! A0#%     @ LX)H6# (<O#6)0  C(D
M !P              ( !3;(* &UO9&EF:6-A=&EO;FYO,35E9F9E8W1I=BYH
M=&U02P$"% ,4    " "S@FA84C$"P- <  ":;@  '               @ %=
MV H ;6]D:69I8V%T:6]N;F\Q-F5F9F5C=&EV+FAT;5!+ 0(4 Q0    ( +."
M:%AVGMXFP0T  %U[   <              "  6?U"@!M;V1I9FEC871I;VYN
M;S=E9F9E8W1I=F4N:'1M4$L! A0#%     @ LX)H6%7(2?K##P  -X@  !P
M             ( !8@,+ &UO9&EF:6-A=&EO;FYO.&5F9F5C=&EV92YH=&U0
M2P$"% ,4    " "S@FA81]J-PB4$   1,@  '               @ %?$PL
M<W5B<VED:6%R:65S;V9T:&5C;VUP86YY+FAT;5!+!08     &@ : /@&  "^
%%PL    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>ebs-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ebs="http://emergentbiosolutions.com/20231231"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ebs-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:A2023EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-28</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:EbangaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">ebs:MCMProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-14</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingIn2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfter2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:UntilMarch312024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFREURIBOROrCDORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfterMarch312024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFREURIBOROrCDORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfterMarch312024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFREURIBOROrCDORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfterMarch312024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ebs:DebtTermsAxis">ebs:FiscalQuartersEndingAfterMarch312024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ForbearanceAgreementAndAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ForbearanceAgreementAndAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFRSONIAAndEurocurrencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-28</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ForbearanceAgreementAndAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ebs:SOFRSONIAAndEurocurrencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ForbearanceAgreementAndAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:A2023EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:A2023EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceSharesAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceSharesAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceSharesAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceSharesAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ebs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ebs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-11-11</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-11</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:NARCANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:NARCANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:NARCANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherCommercialProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherCommercialProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherCommercialProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AnthraxMCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AnthraxMCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AnthraxMCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:SmallpoxMCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:SmallpoxMCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:SmallpoxMCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:ReservationOfManufacturingCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:AcceleratedExpansionOfFillFinishCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:BioservicesLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ebs:OtherGeographicalAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ebs:SECSchedule1209AllowancePrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="category">
        <measure>ebs:category</measure>
    </unit>
    <unit id="product">
        <measure>ebs:product</measure>
    </unit>
    <unit id="category2">
        <measure>ebs:Category</measure>
    </unit>
    <unit id="segment">
        <measure>ebs:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>ebs:plan</measure>
    </unit>
    <unit id="employee">
        <measure>ebs:employee</measure>
    </unit>
    <unit id="vote">
        <measure>ebs:vote</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-32">0001367644</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="c-4" id="f-672">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="c-5" id="f-673">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-706">http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-27" id="f-707">http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1164">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1165">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1168">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1169">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1172">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1173">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-33137</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">EMERGENT BIOSOLUTIONS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">14-1902018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">300 Professional Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Gaithersburg,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">20879</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">631-3200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">EBS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-29" unitRef="usd">380700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">52203433</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of the registrant's definitive proxy statement for its 2024 annual meeting of stockholders which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the end of the registrant's fiscal year ended December&#160;31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K. With the exception of the portions of the registrant's definitive proxy statement for its 2024 annual meeting of stockholders that are expressly incorporated by reference into this Annual Report on Form 10-K, such proxy statement shall not be deemed filed as part of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName contextRef="c-1" id="f-36">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-37">Tysons, Virginia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-38" unitRef="usd">111700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-5" id="f-39" unitRef="usd">642600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-5" id="f-40" unitRef="usd">191000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-5" id="f-41" unitRef="usd">159200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-5" id="f-42" unitRef="usd">328900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-5" id="f-43" unitRef="usd">350700000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-5" id="f-44" unitRef="usd">47900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-5" id="f-45" unitRef="usd">57900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-5" id="f-46" unitRef="usd">679500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-5" id="f-47" unitRef="usd">1210400000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-48" unitRef="usd">382800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-5" id="f-49" unitRef="usd">817600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-5" id="f-50" unitRef="usd">566600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-5" id="f-51" unitRef="usd">728800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-5" id="f-52" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-5" id="f-53" unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-5" id="f-54" unitRef="usd">194300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-5" id="f-55" unitRef="usd">191300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-5" id="f-56" unitRef="usd">1823200000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-5" id="f-57" unitRef="usd">3166300000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-5" id="f-58" unitRef="usd">112200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-5" id="f-59" unitRef="usd">103500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-60" unitRef="usd">18600000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-61" unitRef="usd">34900000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-62" unitRef="usd">74100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-63" unitRef="usd">87300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-5" id="f-64" unitRef="usd">413700000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-5" decimals="-5" id="f-65" unitRef="usd">957300000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-66" unitRef="usd">32700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-67" unitRef="usd">45900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-68" unitRef="usd">651300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-69" unitRef="usd">1228900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-5" id="f-70" unitRef="usd">446500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-5" id="f-71" unitRef="usd">448500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-5" id="f-72" unitRef="usd">47200000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="-5" id="f-73" unitRef="usd">59700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-5" id="f-74" unitRef="usd">28900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-5" id="f-75" unitRef="usd">41500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-5" id="f-76" unitRef="usd">1173900000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-5" id="f-77" unitRef="usd">1778600000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-5" id="f-80" unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="-5" id="f-81" unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-82" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-83" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-84" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-85" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-5" id="f-86" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-5" id="f-87" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-88"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-89"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-5" id="f-90" unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-5" id="f-91" unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-5" id="f-92" unitRef="shares">57800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-5" id="f-93" unitRef="shares">55700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-5" id="f-94" unitRef="shares">52200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-5" id="f-95" unitRef="shares">50100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-5" id="f-96" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-5" id="f-97" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="-5" id="f-98" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="-5" id="f-99" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-5" id="f-100" unitRef="usd">227700000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-5" decimals="-5" id="f-101" unitRef="usd">227700000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-5" id="f-102" unitRef="usd">904400000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-5" id="f-103" unitRef="usd">873500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-5" id="f-104" unitRef="usd">-5700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-5" id="f-105" unitRef="usd">3100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-106" unitRef="usd">-21800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-5" id="f-107" unitRef="usd">738700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-108" unitRef="usd">649300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-5" id="f-109" unitRef="usd">1387700000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-5" id="f-110" unitRef="usd">1823200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-5" id="f-111" unitRef="usd">3166300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-5" id="f-112" unitRef="usd">497300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-5" id="f-113" unitRef="usd">386600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-5" id="f-114" unitRef="usd">438000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-5" id="f-115" unitRef="usd">447200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-5" id="f-116" unitRef="usd">579600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-5" id="f-117" unitRef="usd">585900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-5" id="f-118" unitRef="usd">944500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-5" id="f-119" unitRef="usd">966200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-5" id="f-120" unitRef="usd">1023900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-5" id="f-121" unitRef="usd">72800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-5" id="f-122" unitRef="usd">105000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-5" id="f-123" unitRef="usd">310300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-18" decimals="-5" id="f-124" unitRef="usd">5700000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-19" decimals="-5" id="f-125" unitRef="usd">4900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-20" decimals="-5" id="f-126" unitRef="usd">305200000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-21" decimals="-5" id="f-127" unitRef="usd">78500000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-22" decimals="-5" id="f-128" unitRef="usd">109900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-23" decimals="-5" id="f-129" unitRef="usd">615500000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-24" decimals="-5" id="f-130" unitRef="usd">26300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-5" id="f-131" unitRef="usd">41400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-5" id="f-132" unitRef="usd">134200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-133" unitRef="usd">1049300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-27" decimals="-5" id="f-134" unitRef="usd">1117500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-28" decimals="-5" id="f-135" unitRef="usd">1773600000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-6" decimals="-5" id="f-136" unitRef="usd">210300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-7" decimals="-5" id="f-137" unitRef="usd">160300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-8" decimals="-5" id="f-138" unitRef="usd">187200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-9" decimals="-5" id="f-139" unitRef="usd">305600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-10" decimals="-5" id="f-140" unitRef="usd">264300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-11" decimals="-5" id="f-141" unitRef="usd">195400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-21" decimals="-5" id="f-142" unitRef="usd">189500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-22" decimals="-5" id="f-143" unitRef="usd">268500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-23" decimals="-5" id="f-144" unitRef="usd">365500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-5" id="f-145" unitRef="usd">218200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-27" decimals="-5" id="f-146" unitRef="usd">6700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-28" decimals="-5" id="f-147" unitRef="usd">41700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-148" unitRef="usd">306700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-27" decimals="-5" id="f-149" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-28" decimals="-5" id="f-150" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-151" unitRef="usd">111400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-27" decimals="-5" id="f-152" unitRef="usd">188300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-28" decimals="-5" id="f-153" unitRef="usd">235200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-154" unitRef="usd">368400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-27" decimals="-5" id="f-155" unitRef="usd">339500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-28" decimals="-5" id="f-156" unitRef="usd">348700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-157" unitRef="usd">65600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-27" decimals="-5" id="f-158" unitRef="usd">59900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-28" decimals="-5" id="f-159" unitRef="usd">58500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-1" decimals="-5" id="f-160" unitRef="usd">1775700000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-27" decimals="-5" id="f-161" unitRef="usd">1287500000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-28" decimals="-5" id="f-162" unitRef="usd">1432200000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-5" id="f-163" unitRef="usd">-726400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-27" decimals="-5" id="f-164" unitRef="usd">-170000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-28" decimals="-5" id="f-165" unitRef="usd">341400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-166" unitRef="usd">87900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-27" decimals="-5" id="f-167" unitRef="usd">37300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-28" decimals="-5" id="f-168" unitRef="usd">34500000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-5" id="f-169" unitRef="usd">74200000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-27" decimals="-5" id="f-170" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-28" decimals="-5" id="f-171" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-172" unitRef="usd">8900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-27" decimals="-5" id="f-173" unitRef="usd">-11700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-28" decimals="-5" id="f-174" unitRef="usd">-3700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-175" unitRef="usd">-4800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-27" decimals="-5" id="f-176" unitRef="usd">-49000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-28" decimals="-5" id="f-177" unitRef="usd">-38200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-178" unitRef="usd">-731200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-27" decimals="-5" id="f-179" unitRef="usd">-219000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-28" decimals="-5" id="f-180" unitRef="usd">303200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-181" unitRef="usd">29300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-182" unitRef="usd">-7400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-183" unitRef="usd">83700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-184" unitRef="usd">-760500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-185" unitRef="usd">-211600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-5" id="f-186" unitRef="usd">219500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-187"
      unitRef="usdPerShare">-14.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-188"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-189"
      unitRef="usdPerShare">4.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-190"
      unitRef="usdPerShare">-14.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-191"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-192"
      unitRef="usdPerShare">4.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-193" unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="-5" id="f-194" unitRef="shares">50100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-28" decimals="-5" id="f-195" unitRef="shares">53500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-196" unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="-5" id="f-197" unitRef="shares">50100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-28" decimals="-5" id="f-198" unitRef="shares">54100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-199" unitRef="usd">-760500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-200" unitRef="usd">-211600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-5" id="f-201" unitRef="usd">219500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-202" unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-5" id="f-203" unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-5" id="f-204" unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-1" decimals="-5" id="f-205" unitRef="usd">2700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-27" decimals="-5" id="f-206" unitRef="usd">10800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-28" decimals="-5" id="f-207" unitRef="usd">12300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-1" decimals="-5" id="f-208" unitRef="usd">8900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-27" decimals="-5" id="f-209" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-28" decimals="-5" id="f-210" unitRef="usd">5800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax contextRef="c-1" decimals="-5" id="f-211" unitRef="usd">3500000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax contextRef="c-27" decimals="-5" id="f-212" unitRef="usd">-7500000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax contextRef="c-28" decimals="-5" id="f-213" unitRef="usd">-3700000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-214" unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-5" id="f-215" unitRef="usd">19200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-5" id="f-216" unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-217" unitRef="usd">-769300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-27" decimals="-5" id="f-218" unitRef="usd">-192400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-28" decimals="-5" id="f-219" unitRef="usd">228700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-220" unitRef="usd">-760500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-221" unitRef="usd">-211600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-5" id="f-222" unitRef="usd">219500000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-223" unitRef="usd">23100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-27" decimals="-5" id="f-224" unitRef="usd">45100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-28" decimals="-5" id="f-225" unitRef="usd">42400000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-226" unitRef="usd">125100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-27" decimals="-5" id="f-227" unitRef="usd">143300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-28" decimals="-5" id="f-228" unitRef="usd">123800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-5" id="f-229" unitRef="usd">200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-27" decimals="-5" id="f-230" unitRef="usd">2600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-28" decimals="-5" id="f-231" unitRef="usd">2900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-5" id="f-232" unitRef="usd">21300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-27" decimals="-5" id="f-233" unitRef="usd">4100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-28" decimals="-5" id="f-234" unitRef="usd">4100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-5" id="f-235" unitRef="usd">-8900000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-27" decimals="-5" id="f-236" unitRef="usd">-28600000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-28" decimals="-5" id="f-237" unitRef="usd">46000000.0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-5" id="f-238" unitRef="usd">74200000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-27" decimals="-5" id="f-239" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-28" decimals="-5" id="f-240" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-5" id="f-241" unitRef="usd">218200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-27" decimals="-5" id="f-242" unitRef="usd">6700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-28" decimals="-5" id="f-243" unitRef="usd">41700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-244" unitRef="usd">306700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-27" decimals="-5" id="f-245" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-28" decimals="-5" id="f-246" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GainLossOnContractTermination contextRef="c-1" decimals="-5" id="f-247" unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination contextRef="c-27" decimals="-5" id="f-248" unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination contextRef="c-28" decimals="-5" id="f-249" unitRef="usd">17200000</us-gaap:GainLossOnContractTermination>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-5" id="f-250" unitRef="usd">-13000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-27" decimals="-5" id="f-251" unitRef="usd">-6400000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-28" decimals="-5" id="f-252" unitRef="usd">-2000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-5" id="f-253" unitRef="usd">21600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-27" decimals="-5" id="f-254" unitRef="usd">-118100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-28" decimals="-5" id="f-255" unitRef="usd">16200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-5" id="f-256" unitRef="usd">-600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-27" decimals="-5" id="f-257" unitRef="usd">57100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-28" decimals="-5" id="f-258" unitRef="usd">66600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-5" id="f-259" unitRef="usd">-11700000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-27" decimals="-5" id="f-260" unitRef="usd">19900000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-28" decimals="-5" id="f-261" unitRef="usd">-7700000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-5" id="f-262" unitRef="usd">10600000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-27" decimals="-5" id="f-263" unitRef="usd">-14000000.0</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-28" decimals="-5" id="f-264" unitRef="usd">-1600000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-5" id="f-265" unitRef="usd">-55700000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-27" decimals="-5" id="f-266" unitRef="usd">-66700000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-28" decimals="-5" id="f-267" unitRef="usd">-9200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual contextRef="c-1" decimals="-5" id="f-268" unitRef="usd">4800000</ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual>
    <ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual contextRef="c-27" decimals="-5" id="f-269" unitRef="usd">0</ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual>
    <ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual contextRef="c-28" decimals="-5" id="f-270" unitRef="usd">0</ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-5" id="f-271" unitRef="usd">-10400000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-27" decimals="-5" id="f-272" unitRef="usd">-800000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-28" decimals="-5" id="f-273" unitRef="usd">4000000.0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable contextRef="c-1" decimals="-5" id="f-274" unitRef="usd">-16200000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable contextRef="c-27" decimals="-5" id="f-275" unitRef="usd">28700000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable contextRef="c-28" decimals="-5" id="f-276" unitRef="usd">-31300000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-5" id="f-277" unitRef="usd">5900000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-27" decimals="-5" id="f-278" unitRef="usd">9600000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-28" decimals="-5" id="f-279" unitRef="usd">-31800000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-280" unitRef="usd">-206300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-27" decimals="-5" id="f-281" unitRef="usd">-34100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-28" decimals="-5" id="f-282" unitRef="usd">320200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-283" unitRef="usd">51600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-27" decimals="-5" id="f-284" unitRef="usd">115800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-28" decimals="-5" id="f-285" unitRef="usd">224100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-5" id="f-286" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-27" decimals="-5" id="f-287" unitRef="usd">21800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-28" decimals="-5" id="f-288" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities contextRef="c-1" decimals="-5" id="f-289" unitRef="usd">6300000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities contextRef="c-27" decimals="-5" id="f-290" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities contextRef="c-28" decimals="-5" id="f-291" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="c-1" decimals="-5" id="f-292" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="c-27" decimals="-5" id="f-293" unitRef="usd">243700000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="c-28" decimals="-5" id="f-294" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-1" decimals="-5" id="f-295" unitRef="usd">270200000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-27" decimals="-5" id="f-296" unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-28" decimals="-5" id="f-297" unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-298" unitRef="usd">212300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-27" decimals="-5" id="f-299" unitRef="usd">-381300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-28" decimals="-5" id="f-300" unitRef="usd">-224100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-5" id="f-301" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-27" decimals="-5" id="f-302" unitRef="usd">82100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-28" decimals="-5" id="f-303" unitRef="usd">106000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-1" decimals="-5" id="f-304" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-27" decimals="-5" id="f-305" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-28" decimals="-5" id="f-306" unitRef="usd">10600000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-1" decimals="-5" id="f-307" unitRef="usd">20000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-27" decimals="-5" id="f-308" unitRef="usd">598000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-28" decimals="-5" id="f-309" unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-1" decimals="-5" id="f-310" unitRef="usd">398800000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-27" decimals="-5" id="f-311" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-28" decimals="-5" id="f-312" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfMediumTermNotes contextRef="c-1" decimals="-5" id="f-313" unitRef="usd">164600000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes contextRef="c-27" decimals="-5" id="f-314" unitRef="usd">33800000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes contextRef="c-28" decimals="-5" id="f-315" unitRef="usd">25300000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-5" id="f-316" unitRef="usd">1800000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-27" decimals="-5" id="f-317" unitRef="usd">5000000.0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-28" decimals="-5" id="f-318" unitRef="usd">15900000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-5" id="f-319" unitRef="usd">2500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-27" decimals="-5" id="f-320" unitRef="usd">5900000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-28" decimals="-5" id="f-321" unitRef="usd">13800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-5" id="f-322" unitRef="usd">8400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-27" decimals="-5" id="f-323" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-28" decimals="-5" id="f-324" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="-5" id="f-325" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-27" decimals="-5" id="f-326" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-28" decimals="-5" id="f-327" unitRef="usd">1200000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-328" unitRef="usd">-535700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-27" decimals="-5" id="f-329" unitRef="usd">481200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-28" decimals="-5" id="f-330" unitRef="usd">-141000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-5" id="f-331" unitRef="usd">-1200000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-5" id="f-332" unitRef="usd">500000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-5" id="f-333" unitRef="usd">-300000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-334" unitRef="usd">-530900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-27" decimals="-5" id="f-335" unitRef="usd">66300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-28" decimals="-5" id="f-336" unitRef="usd">-45200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-5" id="f-337" unitRef="usd">642600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-5" id="f-338" unitRef="usd">576300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-30" decimals="-5" id="f-339" unitRef="usd">621500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-5" id="f-340" unitRef="usd">111700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-5" id="f-341" unitRef="usd">642600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-5" id="f-342" unitRef="usd">576300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-5" id="f-343" unitRef="usd">68300000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-27" decimals="-5" id="f-344" unitRef="usd">33000000.0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-28" decimals="-5" id="f-345" unitRef="usd">30400000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-5" id="f-346" unitRef="usd">52800000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-27" decimals="-5" id="f-347" unitRef="usd">6200000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-28" decimals="-5" id="f-348" unitRef="usd">71600000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-5" id="f-349" unitRef="usd">5700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-27" decimals="-5" id="f-350" unitRef="usd">9400000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-28" decimals="-5" id="f-351" unitRef="usd">20000000.0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <ebs:NoncashPurchasesOfTreasuryStock contextRef="c-1" decimals="-5" id="f-352" unitRef="usd">0</ebs:NoncashPurchasesOfTreasuryStock>
    <ebs:NoncashPurchasesOfTreasuryStock contextRef="c-27" decimals="-5" id="f-353" unitRef="usd">0</ebs:NoncashPurchasesOfTreasuryStock>
    <ebs:NoncashPurchasesOfTreasuryStock contextRef="c-28" decimals="-5" id="f-354" unitRef="usd">6600000</ebs:NoncashPurchasesOfTreasuryStock>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-5" id="f-355" unitRef="usd">2500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-27" decimals="-5" id="f-356" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-28" decimals="-5" id="f-357" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-358"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-359"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-29"
      decimals="INF"
      id="f-360"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-31" decimals="-5" id="f-361" unitRef="shares">54300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-5" id="f-362" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-5" id="f-363" unitRef="usd">784900000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-33" decimals="-5" id="f-364" unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-5" id="f-365" unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-5" id="f-366" unitRef="usd">-25300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-5" id="f-367" unitRef="usd">730800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-5" id="f-368" unitRef="usd">1450900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-5" id="f-369" unitRef="usd">219500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-5" id="f-370" unitRef="usd">219500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-37" decimals="-5" id="f-371" unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-5" id="f-372" unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-38" decimals="-5" id="f-373" unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-39" decimals="-5" id="f-374" unitRef="usd">44500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-28" decimals="-5" id="f-375" unitRef="usd">44500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-40" decimals="-5" id="f-376" unitRef="shares">2600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-40" decimals="-5" id="f-377" unitRef="usd">112600000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-28" decimals="-5" id="f-378" unitRef="usd">112600000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesIssued contextRef="c-41" decimals="-5" id="f-379" unitRef="shares">55100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-5" id="f-380" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-5" id="f-381" unitRef="usd">829400000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-43" decimals="-5" id="f-382" unitRef="shares">3800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-5" id="f-383" unitRef="usd">-152200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-5" id="f-384" unitRef="usd">-16100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-5" id="f-385" unitRef="usd">950300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-5" id="f-386" unitRef="usd">1611500000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="-5" id="f-387" unitRef="usd">-211600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-388" unitRef="usd">-211600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-47" decimals="-5" id="f-389" unitRef="usd">19200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-5" id="f-390" unitRef="usd">19200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-48" decimals="-5" id="f-391" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-49" decimals="-5" id="f-392" unitRef="usd">44100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-27" decimals="-5" id="f-393" unitRef="usd">44100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-50" decimals="-5" id="f-394" unitRef="shares">1800000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-50" decimals="-5" id="f-395" unitRef="usd">75500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-27" decimals="-5" id="f-396" unitRef="usd">75500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesIssued contextRef="c-51" decimals="-5" id="f-397" unitRef="shares">55700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-5" id="f-398" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-5" id="f-399" unitRef="usd">873500000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-53" decimals="-5" id="f-400" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-5" id="f-401" unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-5" id="f-402" unitRef="usd">3100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-5" id="f-403" unitRef="usd">738700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-5" id="f-404" unitRef="usd">1387700000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-56" decimals="-5" id="f-405" unitRef="usd">-760500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-406" unitRef="usd">-760500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-57" decimals="-5" id="f-407" unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-408" unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-58" decimals="-5" id="f-409" unitRef="shares">1000000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-59" decimals="-5" id="f-410" unitRef="usd">22500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-5" id="f-411" unitRef="usd">22500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-58" decimals="-5" id="f-412" unitRef="shares">1100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-59" decimals="-5" id="f-413" unitRef="usd">8400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-5" id="f-414" unitRef="usd">8400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesIssued contextRef="c-60" decimals="-5" id="f-415" unitRef="shares">57800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-5" id="f-416" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-5" id="f-417" unitRef="usd">904400000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-62" decimals="-5" id="f-418" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-5" id="f-419" unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-5" id="f-420" unitRef="usd">-5700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-5" id="f-421" unitRef="usd">-21800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-422" unitRef="usd">649300000</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-423">Nature of the business and organization &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization and business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Emergent BioSolutions Inc. (&#x201c;Emergent,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats ("PHTs"). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is focused on the following four PHT categories: chemical, biological, radiological, nuclear and explosives ("CBRNE"); emerging infectious diseases ("EID"); emerging health crises; and acute, emergency and community care. The Company has a product portfolio of 12 products (vaccines, therapeutics, and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures (&#x201c;MCM") Products, NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercial product, Smallpox - MCM products and Emergent Bioservices (CDMO) ("Bioservices").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Beginning in the fourth quarter of 2023, the Company manages our business with a focus on three operating segments: (1) a Commercial Products segment consisting of NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nasal Spray and other commercial products which were sold as part of our travel health business in the second quarter of 2023 (see Note 3, "Divestiture" for more information on the sale of the travel health business); (2) a MCM Products segment consisting of our Anthrax - MCM,  Smallpox - MCM and Other Products, described below and (3) a Services segment consisting of our Bioservices offerings (See Note 18, "Segment information&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;" for more information on our reportable segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Company's products and services include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial Products Segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;NARCAN&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA (including in over-the-counter form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sale of Travel Health Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;15, 2023, the Company completed the sale of its Commercial Products segment's travel health business, including rights to Vivotif&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the licensed typhoid vaccine; Vaxchora&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#x2019;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California. For additional information, refer to Note 3, "Divestiture".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MCM Products Segment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Anthrax - MCM Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.14pt"&gt;Anthrasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the United States Food and Drug Administration (&#x201c;FDA&#x201d;) and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;BioThrax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;CYFENDUS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Anthrax vaccine adsorbed (AVA), adjuvanted), previously known as AV7909, which was recently approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bacillus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;anthracis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. CYFENDUS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is procured by certain authorized government buyers for their use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Smallpox - MCM Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;ACAM2000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;CNJ-016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;TEMBEXA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;BAT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;Ebanga&#x2122; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#x2122; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#x2122;;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt"&gt;Trobigard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. Trobigard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Services Segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Bioservices - CDMO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations. These services, which we refer to as "molecule-to-market" offerings, employ diverse technology platforms (mammalian, microbial, viral and plasma) across a network of nine geographically distinct development and manufacturing sites operated by us for our internal products and pipeline candidates and third-party Bioservices. We service both clinical-stage and commercial-stage projects for a variety of third-party customers, including government agencies, innovative pharmaceutical companies, and non-government organizations. In August 2023, the Company initiated an organizational restructuring plan (the &#x201c;August 2023 Plan&#x201d;) which included actions to reduce investment in and de-emphasize focus on its Bioservices business.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ebs:NumberOfCategoriesOfPublicHealthThreats
      contextRef="c-1"
      decimals="INF"
      id="f-424"
      unitRef="category">4</ebs:NumberOfCategoriesOfPublicHealthThreats>
    <ebs:NumberOfRevenueGeneratingProducts
      contextRef="c-1"
      decimals="INF"
      id="f-425"
      unitRef="product">12</ebs:NumberOfRevenueGeneratingProducts>
    <ebs:NumberOfProductAndServiceCategories
      contextRef="c-1"
      decimals="INF"
      id="f-426"
      unitRef="category2">4</ebs:NumberOfProductAndServiceCategories>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-427"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-428">Summary of significant accounting policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial statements are prepared in conformity with U.S. generally accepted accounting principles ("GAAP"). The accompanying consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Reclassifications of certain prior period amounts have been made to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared on the going concern basis of accounting, which assumes the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was $219.2&#160;million outstanding on our senior revolving credit facility ("Revolving Credit Facility") and $198.2&#160;million on our senior term loan facility ("Term Loan Facility"&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) that mature in May 2025. As of December 31, 2023, the Company had $111.7 million in cash and cash equivalents. The Company determined that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The evaluation considered the potential mitigating effects of management&#x2019;s plans that have not been fully implemented. Management has evaluated the mitigating effects of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern. Management's plans include (A) amending the Senior Secured Credit Facilities, and (B)  improving operating performance, reducing working capital and the potential of the sale of assets to pay down the Senior Secured Credit Facilities before they become due. As neither plan is in the complete control of Management, neither is probable of occurring. In this regard, management may not be able to find a buyer for the assets it is willing to divest and may not be able to close on any asset sale for which management is able to reach an agreement with a buyer, and as a result the Company may be unable to meet its obligations as they become due. In addition, any asset sales that are completed could have potential negative impacts on the Company's future operating cash flows and profitability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Debt Covenants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities mature in May 2025, which provide for (1) revolving credit commitments, (2) a term loan, and (3) the issuance of commercial letters of credit. As of December 31, 2023, we had $417.4&#160;million outstanding under the Senior Secured Credit Facilities. Under the Senior Secured Credit Facilities, the Company is subject to a monthly minimum consolidated EBITDA covenant through February 29, 2024, and is also required to raise at least $75.0&#160;million through the issuance of equity and/or unsecured indebtedness by April 30, 2024. Beginning with the quarter ended March 31, 2024, the Company is subject to a minimum consolidated debt service coverage ratio and a maximum consolidated leverage ratio covenant. As of December 31, 2023, the Company was not in compliance with the minimum consolidated EBITDA covenant under the Senior Secured Credit Facilities and did not expect to be able to raise the remaining of the $75.0&#160;million through the issuance of equity under the at-the-market equity offering program (the "ATM Program") that we entered into on May 18, 2023, by April&#160;30, 2024, as required by the requisite lenders. In addition, the Company is required to deliver audited annual financial statements without a &#x201c;going concern&#x201d; explanatory paragraph with respect to its financial statements for the year ended December 31, 2023, within 90-days of year end, while the financial statements included in this Annual Report contain an explanatory paragraph related to Going Concern. On February&#160;29, 2024, the requisite lenders agreed to enter into a &#x202f;Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement (the &#x201c;Forbearance Agreement and Amendment&#x201d;), which includes a limited waiver of any defaults or events of default that result from (a) any violation of the financial covenants set forth in the Senior Secured Credit Facilities with respect to the fiscal quarter ending December 31, 2023 and the fiscal quarter ending March&#160;31, 2024 and (b) the going concern explanatory paragraph contained in the audited financial statements for the fiscal year ended December 31, 2023. This forbearance period will expire on the earlier to occur of (i) any other event of default and (ii) April&#160;30, 2024. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Senior Secured Credit Facilities. The Senior Secured Credit Facilities and the Company&#x2019;s other debt facilities are described in more detail below in Note 10, &#x201c;Debt&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, acceleration of the repayment of the Senior Secured Credit Facilities would result in a cross-default of the Company&#x2019;s obligations under the 3.875% Senior Unsecured Notes due in 2028. If the Company would be unable to obtain additional waivers or forbearance of such covenants or defaults, to successfully renegotiate the terms of the Senior Secured Credit Facilities, or to cure the potential covenant breach or default, and the lenders enforced one or more of their rights upon default and/or the default resulted in a cross-default under the 3.875% Senior Unsecured Notes due in 2028, the Company would be unable to meet its obligations under those agreements and could be forced into insolvency proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the facts and circumstances described above, there can be no assurance that the Forbearance Period will continue to remain in place, and that the Company would be able to comply with covenants in the future. As a result, the Company continues to evaluate a number of factors related to its ability to continue as a going concern, including its ability to comply with the terms and operating and financial covenants required by the Senior Secured Credit Facilities, its ability to satisfy the capital raise requirement, other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, and disruptions or volatility caused by factors such as regional conflicts, inflation, and supply chain disruptions. The Company has engaged legal and financial advisors to assist with a comprehensive review of alternatives to enhance its capital structure, which may include taking steps to cure any potential defaults or seeking forbearance, waivers, further cost reductions, asset sales or other alternatives to avoid an event of default.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make estimates, judgments and assumptions that affect reported amounts and disclosures in the consolidated financial statements and accompanying notes. Due to the inherent uncertainty involved in making those estimates, judgements and assumptions, actual results could differ from those estimates. Our most significant estimates relate to revenue recognitions and the assessment of the recoverability of goodwill, definite lived intangible assets and other long-lived assets. Other estimates include allowances for expected credit losses, inventory, depreciation and amortization, business combinations, contingent consideration, share-based compensation, income taxes, and other contingencies. Management continually re-evaluates its estimates, judgments and assumptions and basis its estimates on historical trends, projections, current experience and other assumptions that it believes are reasonable. These estimates are sometimes complex, sensitive to changes in assumptions and require fair value determinations using Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Also, the Company maintains cash balances with financial institutions in excess of insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Observable inputs for identical assets or liabilities such as quoted prices in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inputs other than quoted prices in active markets that are either directly or indirectly observable; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#x2019;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant customers and accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Billed accounts receivable are stated at invoice amounts and consist of amounts due from the USG, commercial and Bioservices customers, as well as amounts due under reimbursement contracts with other government entities and non-government organizations. The Company's branded and generic opioid overdose reversal product, NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Nasal Spray, is sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain an allowance for expected credit losses, which represents the estimated aggregate amount of credit risk arising from the inability or unwillingness of specific customers to pay our fees or disputes that may affect our ability to fully collect our billed accounts receivable. We estimate the current-period provision for expected credit losses on a specific identification basis and we consider factors such as the age of the receivables balance, knowledge of the specific customers' circumstances and historical collection experience for similar customers. Amounts determined to be uncollectible are charged or written-off against the reserve. Accounts receivable, net of the allowance for expected credit losses, represents the amount we expect to collect. Our actual experience may vary from our estimates. At each reporting date, we adjust the allowance for expected credit losses to reflect our current estimate. Unbilled accounts receivable relates to various service contracts for which work has been performed and the Company has a right to bill but invoicing has not yet occurred. Contract assets include revenues recognized in advance of billings and the Company does not have a right to invoice the customer under the terms of the contract. The Company has receivables from contracts containing lease components. At each reporting period, the Company assesses whether it is probable that the Company will collect all future lease payments. The Company considers payment history and current credit status when assessing collectability. The Company does not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has long-term contracts with the USG that expire at various times from 2024 through 2036. The Company has derived a significant portion of its revenue from sales of our Government - MCM products under contracts with the USG. The Company's current USG contracts do not necessarily increase the likelihood that it will secure future comparable contracts with the USG. The Company expects that a significant portion of the business will continue to be under government contracts that present a number of risks that are not typically present in the commercial contracting process. USG contracts for ACAM2000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Anthrax Vaccines and other medical countermeasures products are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of its medical countermeasures products, including ACAM2000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Anthrax Vaccines to customers in addition to the USG, which would harm their growth opportunities. The Company's commercial product sales, largely NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Nasal Spray, are sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. Refer to Note 13, "Revenue recognition" for more information regarding significant customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company seeks to expand its customer base and to renew its agreements with its customers prior to expiration of a contract, a delay in securing a renewal or a failure to secure a renewal or securing a renewal on less favorable terms may have a material adverse effect on the Company&#x2019;s financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable do not represent a significant concentration of credit risk. The USG accounted for approximately 38%, 43% and 51% of total revenues for 2023, 2022 and 2021, respectively. The Company&#x2019;s accounts receivable as of December&#160;31, 2023 and 2022, consist primarily of amounts due from the USG or other large multi-national highly reputable customers for product sales, Bioservices or from government agencies under government grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Institutions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents are maintained with several financial institutions. The Company has deposits held with banks that exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and, therefore, bear minimal credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Lender Counterparties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is lender counterparty risk associated with the Company's revolving credit facility and derivatives instruments. There is risk that the Company&#x2019;s revolving credit facility investors and derivative counterparties will not be available to fund as obligated. If funding under the revolving credit facility is unavailable, the Company may have to acquire a replacement credit facility from different counterparties at a higher cost or may be unable to find a suitable replacement. The Company seeks to manage risks from its revolving credit facility and derivative instruments by contracting with experienced large financial institutions and monitoring the credit quality of its lenders. As of December&#160;31, 2023, the Company does not anticipate nonperformance by any of its counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value with cost being determined using a standard cost method, which approximates actual cost. Actual cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. The Company records inventory acquired in business combinations utilizing the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to short-dated, contaminated or expired inventory. Inventory reserves for write-downs are relieved when the inventory is disposed of through scrap or sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pre-launch inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within the Company's Commercial Products and MCM Products segments costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and the Company believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, the Company considers a number of specific facts and circumstances, including the product candidate&#x2019;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a Bioservices contract as Bioservices pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost less accumulated depreciation and impairments. subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes internal-use software when both (a) the software is internally developed, acquired, or modified solely to meet the entity&#x2019;s internal needs and (b) during the software&#x2019;s development or modification, no substantive plan either exists or is being developed to market the software externally. Capitalization of qualifying internal-use software costs begins when the preliminary project stage is completed, management with the relevant authority, implicitly or explicitly, authorizes and commits to the funding of the software project, and it is probable that the project will be completed and the software will be used to perform the function intended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally depreciates or amortizes the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.388%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not depreciated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31-39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7 years &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of the asset life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the property, plant and equipment acquired in a business combination utilizing either the cost approach or the sales comparison approach. The cost approach is determined by establishing replacement cost of the asset and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach determines an asset is equal to the market price of an asset of comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and research and development ("R&amp;amp;D") tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax effects of transactions reported in different periods for financial reporting and income tax return purposes are recognized under the asset and liability method of accounting for income taxes. This method gives consideration to the future tax consequences of the deferred income tax items and immediately recognizes changes in income tax laws in the year of enactment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. The Company considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if the Company determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, the Company will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to income taxes in the period in which the determination is made. Likewise, if the Company determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, the Company will establish a valuation allowance against deferred tax assets, with an offsetting increase to income taxes, in the period in which the determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under sections 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a "loss corporation", as defined therein, there are annual limitations on the amount of net operating losses and deductions that are available. The Company has recognized the portion of net operating losses and R&amp;amp;D tax credits acquired that will not be limited and are more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because tax laws are complex and subject to different interpretations, significant judgment is required. As a result, the Company makes certain estimates and assumptions, in (1)&#160;calculating the Company's income tax expense, deferred tax assets and deferred tax liabilities, (2)&#160;determining any valuation allowance recorded against deferred tax assets and (3)&#160;evaluating the amount of unrecognized tax benefits, as well as the interest and penalties related to such uncertain tax positions. The Company's estimates and assumptions may differ from tax benefits ultimately realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Impairment Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Goodwill and Indefinite-lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized but is reviewed for impairment. Goodwill is allocated to the Company's reporting units, which are components of our business for which discrete cash flow information is available one level below its operating segment. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and at interim if an event or other circumstance indicates that we may not recover the carrying value of the asset. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative goodwill impairment test is performed using a one-step process. The process is to compare the fair value of a reporting unit with its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not impaired. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the reporting unit is impaired and an impairment loss is recognized in an amount equal to that excess up to the total amount of goodwill included in the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company has material indefinite lived intangible assets associated with in-process research and development ("IPR&amp;amp;D"), a qualitative assessment is performed. If the qualitative assessment indicates that it is not more likely than not that the fair value of the indefinite lived intangible asset exceeds its carrying amount, the Company compares the estimated fair value of the intangible with its carrying value. If the carrying value of the intangible asset exceeds its fair value, an impairment loss is recognized &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in an amount equal to that excess. Determining fair value requires the exercise of judgment about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows (see Note 7, "Intangible assets and goodwill"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, they are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when the disposal of such assets is likely or there is an adverse change in the market involving the business employing the related assets. If an impairment analysis is required, the impairment test employed is based on whether the Company&#x2019;s intent is to hold the asset for continued use or to hold the asset for sale. If the intent is to hold the asset for continued use, the impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. If the carrying value of the asset exceeds the undiscounted cash flows, the asset would not be deemed to be recoverable. Impairment would then be measured as the excess of the asset&#x2019;s carrying value over its fair value. Fair value is typically determined by discounting the future cash flows associated with that asset. If the intent is to hold the asset for sale and certain other criteria are met, the impairment test involves comparing the asset&#x2019;s carrying value to its fair value less costs to sell. To the extent the carrying value is greater than the asset&#x2019;s fair value less costs to sell, an impairment loss is recognized in an amount equal to the difference. Significant judgments used for long-lived asset impairment assessments include identifying the appropriate asset groupings and primary assets within those groupings, determining whether events or circumstances indicate that the carrying amount of the asset may not be recoverable, determining the future cash flows for the assets involved and assumptions applied in determining fair value, which include, reasonable discount rates, growth rates, market risk premiums and other assumptions about the economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company's acquisitions accounted for as business combinations, the Company records contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones at fair value. The fair value model used to calculate these obligations is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales and achievement of the milestones. The inputs the Company uses for determining the fair value of the contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales and/or the achievement of development and regulatory milestones. Any future increase or decrease in the fair value of the contingent consideration associated with sales-based royalties and sales-based milestones along with development and regulatory milestones are based on an assessment of the likelihood that the underlying net sales or milestones will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The associated payments which will become due and payable for sales-based royalties and milestones result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of contingent consideration associated with sales-based royalties and sales-based milestones will result in a reduction in cost of product sales. The changes in fair value for potential future sales-based royalties associated with product candidates in development will result in a charge to cost of product sales in the period in which the increase is determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based royalties, sales-based milestones and development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for corporate offices, R&amp;amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases with future minimum lease payments in excess of 12 months and total lease payments greater than $0.4&#160;million are included in right-of-use ("ROU") assets and liabilities. The Company has elected to record expense on a cash basis for leases with minimum lease payments of 12 months or less and/or total lease payments less $0.4&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services by analyzing the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company assesses the products or services promised in a contract and identifies a performance obligation for each promise to transfer to the customer a product or service that is distinct, including evaluating whether the contract includes a customer option for additional goods or services which could represent a material right. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. Contracts sometimes include more than one product, a lease, or options for customers to purchase additional products or services in the future for free or at a discount, which gives rise to separate performance obligations. For contracts with multiple performance obligations, the Company allocates the contract price to each performance obligation on a relative standalone selling price basis using the Company&#x2019;s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts&#x2019; inception. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Transaction price and variable consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the performance obligations in the contract have been identified, the Company estimates the transaction price of the contract. The estimate includes amounts that are fixed as well as those that can vary based on expected outcomes of the activities or contractual terms. The Company's variable consideration includes net profit received from sales of the Company's NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Nasal Spray, certain products sold on a net basis, cost-plus-fee contract terms and consideration transferred under its development contracts as consideration received can vary based on developmental progression of the product candidate. When a contract's transaction price includes variable consideration, the Company evaluates the variable consideration to determine whether the estimate needs to be constrained; therefore, the Company includes the variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration estimates are updated at each reporting date. There were no significant constraints or material changes to the Company's variable consideration estimates as of or during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our product sales, we recognize revenue at a point in time when the Company&#x2019;s performance obligations have been satisfied and control of the products transfer to the customer. To indicate the transfer of control the Company will have a present right to payment, legal title must have passed to the customer, and the customer must have the significant risks and rewards of ownership. This point in time depends on several factors, including delivery, transfer of legal title, transition of risk and rewards of the product to the customer and the Company's right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's contracts for the sale of the Company's Government - MCM products include certain acceptance criteria before title passes to the customer. The primary customer for the Company's Government - MCM products and the primary source of funding for the development of its MCM product candidate portfolio is the USG. The USG contracts for the sale of the Company's Government - MCM products are normally multi-year contracts with annual options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM product revenue is recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. Provisions for variable consideration revenues from sales of MCM products are recorded at the net sales price. Calculating certain of these provisions involves estimates and judgments and the Company determines their expected value based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs&#x2019; regulations and guidelines that would impact the amount of the actual rebates, the Company's expectations regarding future utilization rates for these programs and channel inventory data. These provisions reflect the Company's best estimate of the amount of consideration to which the Company is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;entitled based on the terms of the contract. The Company reassesses the Company's provisions for variable consideration at each reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; over-the-counter ("OTC") customer contracts are fixed price contracts. For that majority of the Company's NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC contract, the Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for these NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC arrangements are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration includes allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC may also be sold on consignment through third-party online retailers where revenues are recognized point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as selling general &amp;amp; administrative expenses and cost of commercial product sales, respectively, in the Consolidated Statement of Operations. Revenues from NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC, including inventory levels within the distribution channel and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Bioservices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs it's Bioservices offerings for third parties. Under these contracts, activities can include drug substance and drug product manufacturing services for injectable and other sterile products, and development services such as pharmaceutical product process development, process design, technology transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging, stability studies, and suite-reservations. These contracts vary in duration, activities, and number of performance obligations. Performance obligations identified under these arrangements may include drug substance and/or drug product manufacturing, technology transfer activities, and suite-reservations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Drug substance, drug product manufacturing, development services and technology transfer performance obligations are recognized as revenue over-time because the Company&#x2019;s performance does not create an asset with an alternative use and the Company has an enforceable right to payment for performance completed as work is performed. In drug product arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (API), that is used in the manufacturing process; in drug substance arrangements, the customer provides certain seed material that is used in the manufacturing process. The transaction price generally contains both a fixed and variable component. The fixed component is stated in the agreement as a fixed price per unit with no contractual provision for a refund or price concession and the variable component generally results from pass-through costs that are billed at cost-plus over the life of the contract. The Company uses an input method to measure progress toward the satisfaction of the related performance obligations based on costs incurred as a percentage of total costs to complete which the Company believes best depicts the transfer of control of goods or services promised to its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Suite reservations are classified as leases when the customer directs the use of the identified suite and obtains substantially all the economic benefits from the manufacturing capacity. If a customer reserves more than one suite, the allocation of contract value is based on relative selling price which varies due to size, location, capacity, production capability for drug product or drug substance, and the time of planned use. The associated revenue is recognized on a straight-line basis over the period of performance. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling price basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Bioservices customer contracts generally include provisions entitling the Company to a termination penalty when the contract is terminated prior to the contract&#x2019;s nominal end date. The termination penalties in the customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated duration of the contract. The Company accounts for a contract cancellation as a contract modification. The determination of the contract termination penalty is based on the terms stated in the related customer agreement. As of the modification date, the Company updates its estimate of the transaction price, subject to constraints, and recognizes the amount over the remaining performance period or measure of progress under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts that contain lease components, the Company assesses the collectability of the lease payments. If the collectability of the lease payments is probable, the Company recognizes lease income over the term of the lease on a straight-line basis. If collectability is not deemed probable at any time during the term of the lease, the Company&#x2019;s lease income is limited to the lesser of (i) the lease payments that have been collected from the lessee, or the straight-line recognition of the contract value. If the collectability assessment changes to probable after the Company has determined collectability is not deemed probable, any difference between the lease income that would have been recognized if collectability had always been assessed as probable and the lease income recognized to date is recognized as a current-period adjustment to lease income. Changes to the collectability of operating leases are recorded as adjustments to lease income in the Consolidated Statements of Operations in the period that they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contracts and grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates contract and grant revenue primarily from cost-plus-fee contracts associated with development of certain product candidates. Revenues from reimbursable contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company uses this input method to measure progress as the customer has access to the development research under these projects and benefits incrementally as R&amp;amp;D activities occur. When applicable, the Company considers fixed fees under cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract, the cost-to-cost measure of progress. The Company analyzes costs for contracts and reimbursable grants to ensure reporting of revenues gross versus net is appropriate. The USG contracts for the development of the Company's MCM product candidates are normally multi-year contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses R&amp;amp;D costs as incurred. The Company's R&amp;amp;D expenses consist primarily of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;personnel-related expenses;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of the Company's clinical trials and obtaining and evaluating data from the Company's clinical trials and non-clinical studies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;costs of Bioservices for clinical trial material; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;costs of materials intended for use and used in clinical trials and R&amp;amp;D.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is comprised of net income (loss) and other changes in equity that are excluded from net income (loss). The Company includes translation gains and losses incurred when converting its subsidiaries' financial statements from their functional currency to the U.S. dollar in accumulated other comprehensive income (loss) as well as gains and losses on its pension benefit obligation and derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Translation and remeasurement of foreign currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income (loss) and are recorded in accumulated other comprehensive income (loss), a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are remeasured at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are remeasured at current rates of exchange as of the balance sheet date. Income and expense items are remeasured at the average foreign currency rates for the period. Remeasurement adjustments of these subsidiaries are included in "Other income (expense), net" in our Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net income (loss) per common share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Treasury stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When stock is acquired for purposes other than formal or constructive retirement, the purchase price of the acquired stock is recorded in a separate treasury stock account, which is separately reported as a reduction of equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When stock is retired or purchased for formal or constructive retirement, the purchase price is initially recorded as a reduction to the par value of the shares repurchased, with any excess purchase price over par value recorded as a reduction to additional paid-in capital related to the series of shares repurchased and any remainder excess purchase price recorded as a reduction to retained earnings. If the purchase price exceeds the amounts allocated to par value and additional paid-in capital related to the series of shares repurchased and retained earnings, the remainder is allocated to additional paid-in capital related to other series of shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the cost of treasury stock that is either sold or reissued, the Company uses the last in, first out method. If the proceeds from the re-issuance of treasury stock are greater than the cost, the excess is recorded as additional paid-in capital. If the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;proceeds from re-issuance of treasury stock are less than the cost, the excess cost first reduces any additional paid-in capital arising from previous treasury stock transactions for that class of stock, and any additional excess is recorded as a reduction of retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting for share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two share-based employee compensation plans, the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "Emergent Plan") and the Emergent BioSolutions, Inc. Inducement Plan (the "Inducement Plan") under which the Company may grant various types of equity awards including stock options, restricted stock units and performance stock units. For all of our share-based awards, the Company recognizes forfeitures and compensation costs when they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2023, the Company's Board of Directors adopted and approved the Emergent BioSolutions, Inc. Inducement Plan, pursuant to which the Company may from time to time make equity grants to individuals not previously an employee or director of the Company or any of its subsidiaries (or following a bona fide period of interruption of employment) as a material inducement to their employment by the Company. The Inducement Plan was adopted by the board of directors without stockholder approval pursuant to New York Stock Exchange Listing Rule 303A.08. The board of directors reserved 5.0 million shares of the Company's common stock for issuance under the Inducement Plan. The terms and conditions of the Inducement Plan are substantially similar to the Company's stockholder-approved Emergent Plan as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plan is determined by the compensation committee of the Company's board of directors, which administers the Emergent Plan. Each equity award granted under the Emergent Plan vests as specified in the relevant agreement with the award recipient and no option can be exercised after seven years from the date of grant. The Company records the estimated fair value of awards in expense on a straight-line basis over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), the Company estimates and recognizes expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of restricted stock units using the closing market price of the Company's common stock on the day prior to the date of grant. The Company's performance stock units settle in the Company's stock. The fair value is determined on the date of the grant using the number of shares expected to be earned and the ending market value of the stock on the day prior to the grant date. The number of shares expected to vest is adjusted each reporting period by assessing the probability that the performance criteria will be met and the associated targeted payout level that is forecasted will be achieved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below is a discussion of the Company's methodology for developing each of the assumptions used:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Expected dividend yield &#x2014; the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Expected volatility &#x2014; a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. The Company analyzed its own historical volatility to estimate expected volatility over the same period as the expected average life of the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Risk-free interest rate &#x2014; the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Expected average life of options &#x2014; the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of option exercise behavior subsequent to vesting of options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pension plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company historically maintained a defined benefit plan for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The Company's defined benefit plan was included in the sale of the travel health business on May 15, 2023. See Note 3, "Divestiture" for more information. The plan was valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increase, and pension adjustments. The Company reviewed its actuarial assumptions on an annual basis and made modifications to the assumptions based on current rates and trends. Actuarial gains and losses were deferred in accumulated other comprehensive income (loss), net of tax and were amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return were amortized to net periodic benefit cost over the estimated remaining life as a component of selling, general and administrative expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative instruments and hedging activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. From time to time, the Company enters into interest rate swaps to manage exposures that arise from the Company's payments of variable interest rate debt under its senior secured credit agreements. The objective and strategy with respect to these interest rate swaps is to protect the Company against adverse fluctuations in interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2023, the Company terminated its designated interest rate swap transactions with a total notional value of $350.0&#160;million. Hedge accounting was also discontinued at that time. As of December 31, 2023, all accumulated other comprehensive income associated with the terminated interest rate swaps was amortized to earnings over the remaining term of the interest rate swaps prior to termination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy. See Note 9, "Derivative instruments and hedging activities" for further details on the interest rate swaps. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards board ("FASB") issued Accounting Standards Update ("ASU") 2023-07 ("ASU 2023-07"), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which improves reportable segment disclosure requirements, on an annual and interim basis, primarily through enhanced disclosures about significant segment expenses. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker ("CODM"). The ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The amendments in the ASU are effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires a public business entity ("PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on it consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-429">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial statements are prepared in conformity with U.S. generally accepted accounting principles ("GAAP"). The accompanying consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Reclassifications of certain prior period amounts have been made to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:LongTermDebt contextRef="c-65" decimals="-5" id="f-430" unitRef="usd">219200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-66" decimals="-5" id="f-431" unitRef="usd">198200000</us-gaap:LongTermDebt>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-432" unitRef="usd">111700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LineOfCredit contextRef="c-67" decimals="-5" id="f-433" unitRef="usd">417400000</us-gaap:LineOfCredit>
    <ebs:DebtInstrumentCovenantConsiderationThreshold contextRef="c-68" decimals="-5" id="f-434" unitRef="usd">75000000</ebs:DebtInstrumentCovenantConsiderationThreshold>
    <ebs:DebtInstrumentCovenantConsiderationThreshold contextRef="c-69" decimals="-5" id="f-435" unitRef="usd">75000000</ebs:DebtInstrumentCovenantConsiderationThreshold>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-70"
      decimals="INF"
      id="f-436"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-70"
      decimals="INF"
      id="f-437"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-438">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make estimates, judgments and assumptions that affect reported amounts and disclosures in the consolidated financial statements and accompanying notes. Due to the inherent uncertainty involved in making those estimates, judgements and assumptions, actual results could differ from those estimates. Our most significant estimates relate to revenue recognitions and the assessment of the recoverability of goodwill, definite lived intangible assets and other long-lived assets. Other estimates include allowances for expected credit losses, inventory, depreciation and amortization, business combinations, contingent consideration, share-based compensation, income taxes, and other contingencies. Management continually re-evaluates its estimates, judgments and assumptions and basis its estimates on historical trends, projections, current experience and other assumptions that it believes are reasonable. These estimates are sometimes complex, sensitive to changes in assumptions and require fair value determinations using Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-439">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Also, the Company maintains cash balances with financial institutions in excess of insured limits.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-440">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Observable inputs for identical assets or liabilities such as quoted prices in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inputs other than quoted prices in active markets that are either directly or indirectly observable; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#x2019;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:MajorCustomersPolicyPolicyTextBlock contextRef="c-1" id="f-441">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Billed accounts receivable are stated at invoice amounts and consist of amounts due from the USG, commercial and Bioservices customers, as well as amounts due under reimbursement contracts with other government entities and non-government organizations. The Company's branded and generic opioid overdose reversal product, NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Nasal Spray, is sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. &lt;/span&gt;&lt;/div&gt;We maintain an allowance for expected credit losses, which represents the estimated aggregate amount of credit risk arising from the inability or unwillingness of specific customers to pay our fees or disputes that may affect our ability to fully collect our billed accounts receivable. We estimate the current-period provision for expected credit losses on a specific identification basis and we consider factors such as the age of the receivables balance, knowledge of the specific customers' circumstances and historical collection experience for similar customers. Amounts determined to be uncollectible are charged or written-off against the reserve. Accounts receivable, net of the allowance for expected credit losses, represents the amount we expect to collect. Our actual experience may vary from our estimates. At each reporting date, we adjust the allowance for expected credit losses to reflect our current estimate. Unbilled accounts receivable relates to various service contracts for which work has been performed and the Company has a right to bill but invoicing has not yet occurred. Contract assets include revenues recognized in advance of billings and the Company does not have a right to invoice the customer under the terms of the contract. The Company has receivables from contracts containing lease components. At each reporting period, the Company assesses whether it is probable that the Company will collect all future lease payments. The Company considers payment history and current credit status when assessing collectability. The Company does not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</us-gaap:MajorCustomersPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-442">&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has long-term contracts with the USG that expire at various times from 2024 through 2036. The Company has derived a significant portion of its revenue from sales of our Government - MCM products under contracts with the USG. The Company's current USG contracts do not necessarily increase the likelihood that it will secure future comparable contracts with the USG. The Company expects that a significant portion of the business will continue to be under government contracts that present a number of risks that are not typically present in the commercial contracting process. USG contracts for ACAM2000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Anthrax Vaccines and other medical countermeasures products are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of its medical countermeasures products, including ACAM2000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Anthrax Vaccines to customers in addition to the USG, which would harm their growth opportunities. The Company's commercial product sales, largely NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Nasal Spray, are sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. Refer to Note 13, "Revenue recognition" for more information regarding significant customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company seeks to expand its customer base and to renew its agreements with its customers prior to expiration of a contract, a delay in securing a renewal or a failure to secure a renewal or securing a renewal on less favorable terms may have a material adverse effect on the Company&#x2019;s financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable do not represent a significant concentration of credit risk. The USG accounted for approximately 38%, 43% and 51% of total revenues for 2023, 2022 and 2021, respectively. The Company&#x2019;s accounts receivable as of December&#160;31, 2023 and 2022, consist primarily of amounts due from the USG or other large multi-national highly reputable customers for product sales, Bioservices or from government agencies under government grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Institutions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents are maintained with several financial institutions. The Company has deposits held with banks that exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and, therefore, bear minimal credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Lender Counterparties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is lender counterparty risk associated with the Company's revolving credit facility and derivatives instruments. There is risk that the Company&#x2019;s revolving credit facility investors and derivative counterparties will not be available to fund as obligated. If funding under the revolving credit facility is unavailable, the Company may have to acquire a replacement credit facility from different counterparties at a higher cost or may be unable to find a suitable replacement. The Company seeks to manage risks from its revolving credit facility and derivative instruments by contracting with experienced large financial institutions and monitoring the credit quality of its lenders. As of December&#160;31, 2023, the Company does not anticipate nonperformance by any of its counterparties.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-71" decimals="2" id="f-443" unitRef="number">38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-72" decimals="2" id="f-444" unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="2" id="f-445" unitRef="number">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-446">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value with cost being determined using a standard cost method, which approximates actual cost. Actual cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. The Company records inventory acquired in business combinations utilizing the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to short-dated, contaminated or expired inventory. Inventory reserves for write-downs are relieved when the inventory is disposed of through scrap or sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pre-launch inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within the Company's Commercial Products and MCM Products segments costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and the Company believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, the Company considers a number of specific facts and circumstances, including the product candidate&#x2019;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a Bioservices contract as Bioservices pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-447">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost less accumulated depreciation and impairments. subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes internal-use software when both (a) the software is internally developed, acquired, or modified solely to meet the entity&#x2019;s internal needs and (b) during the software&#x2019;s development or modification, no substantive plan either exists or is being developed to market the software externally. Capitalization of qualifying internal-use software costs begins when the preliminary project stage is completed, management with the relevant authority, implicitly or explicitly, authorizes and commits to the funding of the software project, and it is probable that the project will be completed and the software will be used to perform the function intended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally depreciates or amortizes the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.388%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not depreciated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31-39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7 years &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of the asset life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the property, plant and equipment acquired in a business combination utilizing either the cost approach or the sales comparison approach. The cost approach is determined by establishing replacement cost of the asset and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach determines an asset is equal to the market price of an asset of comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-448">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally depreciates or amortizes the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.388%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not depreciated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31-39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7 years &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of the asset life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023 &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;54.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;229.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;327.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;433.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;567.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;794.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,201.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(411.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(383.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;382.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;817.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; During the year ended December 31, 2023, the Company recorded a non-cash impairment charge of $306.7 million related to certain Bioservices long-lived assets. See Note 4, "Long-lived asset impairment and restructuring charges" for more details regarding the impairment charge.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-74" id="f-449">P31Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-75" id="f-450">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-76" id="f-451">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-77" id="f-452">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-78" id="f-453">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-79" id="f-454">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-80" id="f-455">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-81" id="f-456">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-457">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and research and development ("R&amp;amp;D") tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax effects of transactions reported in different periods for financial reporting and income tax return purposes are recognized under the asset and liability method of accounting for income taxes. This method gives consideration to the future tax consequences of the deferred income tax items and immediately recognizes changes in income tax laws in the year of enactment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. The Company considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if the Company determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, the Company will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to income taxes in the period in which the determination is made. Likewise, if the Company determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, the Company will establish a valuation allowance against deferred tax assets, with an offsetting increase to income taxes, in the period in which the determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under sections 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a "loss corporation", as defined therein, there are annual limitations on the amount of net operating losses and deductions that are available. The Company has recognized the portion of net operating losses and R&amp;amp;D tax credits acquired that will not be limited and are more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because tax laws are complex and subject to different interpretations, significant judgment is required. As a result, the Company makes certain estimates and assumptions, in (1)&#160;calculating the Company's income tax expense, deferred tax assets and deferred tax liabilities, (2)&#160;determining any valuation allowance recorded against deferred tax assets and (3)&#160;evaluating the amount of unrecognized tax benefits, as well as the interest and penalties related to such uncertain tax positions. The Company's estimates and assumptions may differ from tax benefits ultimately realized.&lt;/span&gt;&lt;/div&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="c-1" id="f-458">&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Goodwill and Indefinite-lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized but is reviewed for impairment. Goodwill is allocated to the Company's reporting units, which are components of our business for which discrete cash flow information is available one level below its operating segment. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and at interim if an event or other circumstance indicates that we may not recover the carrying value of the asset. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative goodwill impairment test is performed using a one-step process. The process is to compare the fair value of a reporting unit with its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not impaired. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the reporting unit is impaired and an impairment loss is recognized in an amount equal to that excess up to the total amount of goodwill included in the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company has material indefinite lived intangible assets associated with in-process research and development ("IPR&amp;amp;D"), a qualitative assessment is performed. If the qualitative assessment indicates that it is not more likely than not that the fair value of the indefinite lived intangible asset exceeds its carrying amount, the Company compares the estimated fair value of the intangible with its carrying value. If the carrying value of the intangible asset exceeds its fair value, an impairment loss is recognized &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in an amount equal to that excess. Determining fair value requires the exercise of judgment about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows (see Note 7, "Intangible assets and goodwill"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, they are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when the disposal of such assets is likely or there is an adverse change in the market involving the business employing the related assets. If an impairment analysis is required, the impairment test employed is based on whether the Company&#x2019;s intent is to hold the asset for continued use or to hold the asset for sale. If the intent is to hold the asset for continued use, the impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. If the carrying value of the asset exceeds the undiscounted cash flows, the asset would not be deemed to be recoverable. Impairment would then be measured as the excess of the asset&#x2019;s carrying value over its fair value. Fair value is typically determined by discounting the future cash flows associated with that asset. If the intent is to hold the asset for sale and certain other criteria are met, the impairment test involves comparing the asset&#x2019;s carrying value to its fair value less costs to sell. To the extent the carrying value is greater than the asset&#x2019;s fair value less costs to sell, an impairment loss is recognized in an amount equal to the difference. Significant judgments used for long-lived asset impairment assessments include identifying the appropriate asset groupings and primary assets within those groupings, determining whether events or circumstances indicate that the carrying amount of the asset may not be recoverable, determining the future cash flows for the assets involved and assumptions applied in determining fair value, which include, reasonable discount rates, growth rates, market risk premiums and other assumptions about the economic environment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <ebs:ContingentConsiderationObligationsPolicyTextBlock contextRef="c-1" id="f-459">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company's acquisitions accounted for as business combinations, the Company records contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones at fair value. The fair value model used to calculate these obligations is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales and achievement of the milestones. The inputs the Company uses for determining the fair value of the contingent consideration associated with sales-based royalties, sales-based milestones and development and regulatory milestones are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales and/or the achievement of development and regulatory milestones. Any future increase or decrease in the fair value of the contingent consideration associated with sales-based royalties and sales-based milestones along with development and regulatory milestones are based on an assessment of the likelihood that the underlying net sales or milestones will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The associated payments which will become due and payable for sales-based royalties and milestones result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of contingent consideration associated with sales-based royalties and sales-based milestones will result in a reduction in cost of product sales. The changes in fair value for potential future sales-based royalties associated with product candidates in development will result in a charge to cost of product sales in the period in which the increase is determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based royalties, sales-based milestones and development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date.&lt;/span&gt;&lt;/div&gt;</ebs:ContingentConsiderationObligationsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-460">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for corporate offices, R&amp;amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases with future minimum lease payments in excess of 12 months and total lease payments greater than $0.4&#160;million are included in right-of-use ("ROU") assets and liabilities. The Company has elected to record expense on a cash basis for leases with minimum lease payments of 12 months or less and/or total lease payments less $0.4&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-461">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services by analyzing the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company assesses the products or services promised in a contract and identifies a performance obligation for each promise to transfer to the customer a product or service that is distinct, including evaluating whether the contract includes a customer option for additional goods or services which could represent a material right. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. Contracts sometimes include more than one product, a lease, or options for customers to purchase additional products or services in the future for free or at a discount, which gives rise to separate performance obligations. For contracts with multiple performance obligations, the Company allocates the contract price to each performance obligation on a relative standalone selling price basis using the Company&#x2019;s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts&#x2019; inception. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Transaction price and variable consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the performance obligations in the contract have been identified, the Company estimates the transaction price of the contract. The estimate includes amounts that are fixed as well as those that can vary based on expected outcomes of the activities or contractual terms. The Company's variable consideration includes net profit received from sales of the Company's NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Nasal Spray, certain products sold on a net basis, cost-plus-fee contract terms and consideration transferred under its development contracts as consideration received can vary based on developmental progression of the product candidate. When a contract's transaction price includes variable consideration, the Company evaluates the variable consideration to determine whether the estimate needs to be constrained; therefore, the Company includes the variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration estimates are updated at each reporting date. There were no significant constraints or material changes to the Company's variable consideration estimates as of or during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our product sales, we recognize revenue at a point in time when the Company&#x2019;s performance obligations have been satisfied and control of the products transfer to the customer. To indicate the transfer of control the Company will have a present right to payment, legal title must have passed to the customer, and the customer must have the significant risks and rewards of ownership. This point in time depends on several factors, including delivery, transfer of legal title, transition of risk and rewards of the product to the customer and the Company's right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's contracts for the sale of the Company's Government - MCM products include certain acceptance criteria before title passes to the customer. The primary customer for the Company's Government - MCM products and the primary source of funding for the development of its MCM product candidate portfolio is the USG. The USG contracts for the sale of the Company's Government - MCM products are normally multi-year contracts with annual options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM product revenue is recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. Provisions for variable consideration revenues from sales of MCM products are recorded at the net sales price. Calculating certain of these provisions involves estimates and judgments and the Company determines their expected value based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs&#x2019; regulations and guidelines that would impact the amount of the actual rebates, the Company's expectations regarding future utilization rates for these programs and channel inventory data. These provisions reflect the Company's best estimate of the amount of consideration to which the Company is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;entitled based on the terms of the contract. The Company reassesses the Company's provisions for variable consideration at each reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; over-the-counter ("OTC") customer contracts are fixed price contracts. For that majority of the Company's NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC contract, the Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for these NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC arrangements are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration includes allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC may also be sold on consignment through third-party online retailers where revenues are recognized point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as selling general &amp;amp; administrative expenses and cost of commercial product sales, respectively, in the Consolidated Statement of Operations. Revenues from NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; OTC, including inventory levels within the distribution channel and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Bioservices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs it's Bioservices offerings for third parties. Under these contracts, activities can include drug substance and drug product manufacturing services for injectable and other sterile products, and development services such as pharmaceutical product process development, process design, technology transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging, stability studies, and suite-reservations. These contracts vary in duration, activities, and number of performance obligations. Performance obligations identified under these arrangements may include drug substance and/or drug product manufacturing, technology transfer activities, and suite-reservations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Drug substance, drug product manufacturing, development services and technology transfer performance obligations are recognized as revenue over-time because the Company&#x2019;s performance does not create an asset with an alternative use and the Company has an enforceable right to payment for performance completed as work is performed. In drug product arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (API), that is used in the manufacturing process; in drug substance arrangements, the customer provides certain seed material that is used in the manufacturing process. The transaction price generally contains both a fixed and variable component. The fixed component is stated in the agreement as a fixed price per unit with no contractual provision for a refund or price concession and the variable component generally results from pass-through costs that are billed at cost-plus over the life of the contract. The Company uses an input method to measure progress toward the satisfaction of the related performance obligations based on costs incurred as a percentage of total costs to complete which the Company believes best depicts the transfer of control of goods or services promised to its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Suite reservations are classified as leases when the customer directs the use of the identified suite and obtains substantially all the economic benefits from the manufacturing capacity. If a customer reserves more than one suite, the allocation of contract value is based on relative selling price which varies due to size, location, capacity, production capability for drug product or drug substance, and the time of planned use. The associated revenue is recognized on a straight-line basis over the period of performance. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling price basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Bioservices customer contracts generally include provisions entitling the Company to a termination penalty when the contract is terminated prior to the contract&#x2019;s nominal end date. The termination penalties in the customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated duration of the contract. The Company accounts for a contract cancellation as a contract modification. The determination of the contract termination penalty is based on the terms stated in the related customer agreement. As of the modification date, the Company updates its estimate of the transaction price, subject to constraints, and recognizes the amount over the remaining performance period or measure of progress under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts that contain lease components, the Company assesses the collectability of the lease payments. If the collectability of the lease payments is probable, the Company recognizes lease income over the term of the lease on a straight-line basis. If collectability is not deemed probable at any time during the term of the lease, the Company&#x2019;s lease income is limited to the lesser of (i) the lease payments that have been collected from the lessee, or the straight-line recognition of the contract value. If the collectability assessment changes to probable after the Company has determined collectability is not deemed probable, any difference between the lease income that would have been recognized if collectability had always been assessed as probable and the lease income recognized to date is recognized as a current-period adjustment to lease income. Changes to the collectability of operating leases are recorded as adjustments to lease income in the Consolidated Statements of Operations in the period that they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contracts and grants&lt;/span&gt;&lt;/div&gt;The Company generates contract and grant revenue primarily from cost-plus-fee contracts associated with development of certain product candidates. Revenues from reimbursable contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company uses this input method to measure progress as the customer has access to the development research under these projects and benefits incrementally as R&amp;amp;D activities occur. When applicable, the Company considers fixed fees under cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract, the cost-to-cost measure of progress. The Company analyzes costs for contracts and reimbursable grants to ensure reporting of revenues gross versus net is appropriate. The USG contracts for the development of the Company's MCM product candidates are normally multi-year contracts.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-462">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses R&amp;amp;D costs as incurred. The Company's R&amp;amp;D expenses consist primarily of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;personnel-related expenses;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of the Company's clinical trials and obtaining and evaluating data from the Company's clinical trials and non-clinical studies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;costs of Bioservices for clinical trial material; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;costs of materials intended for use and used in clinical trials and R&amp;amp;D.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-463">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is comprised of net income (loss) and other changes in equity that are excluded from net income (loss). The Company includes translation gains and losses incurred when converting its subsidiaries' financial statements from their functional currency to the U.S. dollar in accumulated other comprehensive income (loss) as well as gains and losses on its pension benefit obligation and derivative instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-464">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income (loss) and are recorded in accumulated other comprehensive income (loss), a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are remeasured at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are remeasured at current rates of exchange as of the balance sheet date. Income and expense items are remeasured at the average foreign currency rates for the period. Remeasurement adjustments of these subsidiaries are included in "Other income (expense), net" in our Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-465">Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <ebs:TreasuryStockPolicyTextBlock contextRef="c-1" id="f-466">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When stock is acquired for purposes other than formal or constructive retirement, the purchase price of the acquired stock is recorded in a separate treasury stock account, which is separately reported as a reduction of equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When stock is retired or purchased for formal or constructive retirement, the purchase price is initially recorded as a reduction to the par value of the shares repurchased, with any excess purchase price over par value recorded as a reduction to additional paid-in capital related to the series of shares repurchased and any remainder excess purchase price recorded as a reduction to retained earnings. If the purchase price exceeds the amounts allocated to par value and additional paid-in capital related to the series of shares repurchased and retained earnings, the remainder is allocated to additional paid-in capital related to other series of shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the cost of treasury stock that is either sold or reissued, the Company uses the last in, first out method. If the proceeds from the re-issuance of treasury stock are greater than the cost, the excess is recorded as additional paid-in capital. If the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;proceeds from re-issuance of treasury stock are less than the cost, the excess cost first reduces any additional paid-in capital arising from previous treasury stock transactions for that class of stock, and any additional excess is recorded as a reduction of retained earnings.&lt;/span&gt;&lt;/div&gt;</ebs:TreasuryStockPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-467">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two share-based employee compensation plans, the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "Emergent Plan") and the Emergent BioSolutions, Inc. Inducement Plan (the "Inducement Plan") under which the Company may grant various types of equity awards including stock options, restricted stock units and performance stock units. For all of our share-based awards, the Company recognizes forfeitures and compensation costs when they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2023, the Company's Board of Directors adopted and approved the Emergent BioSolutions, Inc. Inducement Plan, pursuant to which the Company may from time to time make equity grants to individuals not previously an employee or director of the Company or any of its subsidiaries (or following a bona fide period of interruption of employment) as a material inducement to their employment by the Company. The Inducement Plan was adopted by the board of directors without stockholder approval pursuant to New York Stock Exchange Listing Rule 303A.08. The board of directors reserved 5.0 million shares of the Company's common stock for issuance under the Inducement Plan. The terms and conditions of the Inducement Plan are substantially similar to the Company's stockholder-approved Emergent Plan as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plan is determined by the compensation committee of the Company's board of directors, which administers the Emergent Plan. Each equity award granted under the Emergent Plan vests as specified in the relevant agreement with the award recipient and no option can be exercised after seven years from the date of grant. The Company records the estimated fair value of awards in expense on a straight-line basis over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), the Company estimates and recognizes expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of restricted stock units using the closing market price of the Company's common stock on the day prior to the date of grant. The Company's performance stock units settle in the Company's stock. The fair value is determined on the date of the grant using the number of shares expected to be earned and the ending market value of the stock on the day prior to the grant date. The number of shares expected to vest is adjusted each reporting period by assessing the probability that the performance criteria will be met and the associated targeted payout level that is forecasted will be achieved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below is a discussion of the Company's methodology for developing each of the assumptions used:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Expected dividend yield &#x2014; the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Expected volatility &#x2014; a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. The Company analyzed its own historical volatility to estimate expected volatility over the same period as the expected average life of the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Risk-free interest rate &#x2014; the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Expected average life of options &#x2014; the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of option exercise behavior subsequent to vesting of options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <ebs:NumberOfShareBasedEmployeeCompensationPlans contextRef="c-4" decimals="INF" id="f-468" unitRef="plan">2</ebs:NumberOfShareBasedEmployeeCompensationPlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-82"
      decimals="INF"
      id="f-469"
      unitRef="shares">5000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-1" id="f-470">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy contextRef="c-1" id="f-471">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company historically maintained a defined benefit plan for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The Company's defined benefit plan was included in the sale of the travel health business on May 15, 2023. See Note 3, "Divestiture" for more information. The plan was valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increase, and pension adjustments. The Company reviewed its actuarial assumptions on an annual basis and made modifications to the assumptions based on current rates and trends. Actuarial gains and losses were deferred in accumulated other comprehensive income (loss), net of tax and were amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return were amortized to net periodic benefit cost over the estimated remaining life as a component of selling, general and administrative expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-472">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. From time to time, the Company enters into interest rate swaps to manage exposures that arise from the Company's payments of variable interest rate debt under its senior secured credit agreements. The objective and strategy with respect to these interest rate swaps is to protect the Company against adverse fluctuations in interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2023, the Company terminated its designated interest rate swap transactions with a total notional value of $350.0&#160;million. Hedge accounting was also discontinued at that time. As of December 31, 2023, all accumulated other comprehensive income associated with the terminated interest rate swaps was amortized to earnings over the remaining term of the interest rate swaps prior to termination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy. See Note 9, "Derivative instruments and hedging activities" for further details on the interest rate swaps. &lt;/span&gt;&lt;/div&gt;he valuation of the interest rate swaps was determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflected the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps were determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) were based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporated credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-83" decimals="INF" id="f-473" unitRef="usd">350000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-474">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards board ("FASB") issued Accounting Standards Update ("ASU") 2023-07 ("ASU 2023-07"), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which improves reportable segment disclosure requirements, on an annual and interim basis, primarily through enhanced disclosures about significant segment expenses. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker ("CODM"). The ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The amendments in the ASU are effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires a public business entity ("PBE") to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on it consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-475">Divestiture &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2023, pursuant to the Purchase and Sale Agreement (the &#x201c;Purchase and Sale Agreement&#x201d;), by and between the Company, through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc., and Bavarian Nordic (&#x201c;Bavarian Nordic&#x201d;), the Company completed the previously announced sale of the Company&#x2019;s travel health business, including rights to Vivotif&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the licensed typhoid vaccine; Vaxchora&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#x2019;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, Bavarian Nordic paid a cash purchase price of $270.2&#160;million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing. Bavarian Nordic may also be required to pay &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;milestone payments of up to $80.0&#160;million related to the development of CHIKV VLP and receipt of marketing approval and authorization in the U.S. and Europe, and earn-out payments of up to $30.0&#160;million based on aggregate net sales of Vaxchora&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Vivotif&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in calendar year 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the divestiture, during the year ended December 31, 2023, the Company recognized a pre-tax gain of $74.2&#160;million, net of transaction costs of $4.0&#160;million recorded within "Gain on sale of business" on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the disposal of the travel health business does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on our operations and financial results. No adjustments were made to prior period results as a result of the disposal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the divestiture, the Company entered into a Transition Services Agreement (&#x201c;TSA&#x201d;) with Bavarian Nordic to help support its ongoing operations. Under the TSA, the Company provides certain transition services to Bavarian Nordic, including information technology, finance and enterprise resource planning, research and development, human resources, employee benefits and other limited services. Income from performing services under the TSA was recorded within "Other, net" on the Consolidated Statements of Operations and was $3.2&#160;million for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-84" decimals="-5" id="f-476" unitRef="usd">270200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable contextRef="c-85" decimals="-5" id="f-477" unitRef="usd">80000000</ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable>
    <ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable contextRef="c-86" decimals="-5" id="f-478" unitRef="usd">30000000</ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-5" id="f-479" unitRef="usd">74200000</us-gaap:GainLossOnSaleOfBusiness>
    <ebs:DispositionOfBusinessTransactionCosts contextRef="c-4" decimals="-5" id="f-480" unitRef="usd">4000000</ebs:DispositionOfBusinessTransactionCosts>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-87" decimals="-5" id="f-481" unitRef="usd">3200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-482">Long-lived asset impairment and restructuring charges&lt;div style="margin-bottom:7pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests its long-lived assets that are held and used for recoverability whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2023, due to deterioration in performance and resulting downward revisions to our internal Bioservices forecast made during the second quarter, including future expected cash flows, the Company determined there were sufficient indicators of impairment on certain asset groups within the Bioservices reporting unit to require an impairment analysis. As a result, the Company performed recoverability tests on certain asset groups within the Bioservices reporting unit and concluded that the impacted asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset groups are written down only to the extent that their carrying value is higher than their respective fair value. The Company, with the assistance of a third-party valuation firm, applied valuation methods to estimate the fair values for each of the assets within the different asset classes. An orderly liquidation value was applied to estimate the fair value of the personal property assets and market and cost based approaches were applied to estimate the fair value of the real property assets. All of the valuation approaches applied represented Level 3 non-recurring fair value measurements. Based on this analysis, the Company allocated and recognized a non-cash impairment charge of $306.7&#160;million during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the total impairment charge by asset class for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;107.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;306.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;January 2023 Organizational Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company initiated an organizational restructuring plan (the &#x201c;January 2023 Plan&#x201d;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#x2019;s ongoing commitment to profitable growth. As part of the January 2023 Plan, the Company reduced its workforce by approximately 125 employees. The Company incurred $9.3&#160;million in charges during the year ended December 31, 2023. These charges consist primarily of charges related to employee transition, severance payments and employee benefits. All activities related to the January 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;August 2023 Organizational Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company initiated the August 2023 Plan intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its Bioservices business for future growth. As part of the August 2023 Plan, the Company reduced its workforce by approximately 400 employees. The Company incurred $20.0&#160;million in charges in connection with the August 2023 Plan during the year ended December 31, 2023. These charges consist primarily of charges related to severance payments, transition services, and employee benefits. All activities related to the August 2023 Plan were substantially completed during the third quarter of 2023. Restructuring costs are recognized as an operating expense within the Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs associated with the Company&#x2019;s segments as well as unallocated corporate and research and development ("R&amp;amp;D") charges for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total restructuring costs by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs, by function, for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Employee transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Severance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of and changes in the Company's restructuring accrual for the January 2023 Plan during the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of and changes in the Company's restructuring accrual for the August 2023 Plan during the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-483" unitRef="usd">306700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock contextRef="c-1" id="f-484">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the total impairment charge by asset class for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;107.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;306.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-88" decimals="-5" id="f-485" unitRef="usd">81500000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-89" decimals="-5" id="f-486" unitRef="usd">117500000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-90" decimals="-5" id="f-487" unitRef="usd">300000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-91" decimals="-5" id="f-488" unitRef="usd">107400000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-489" unitRef="usd">306700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-92"
      decimals="0"
      id="f-490"
      unitRef="employee">125</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringCharges contextRef="c-93" decimals="-5" id="f-491" unitRef="usd">9300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-94"
      decimals="0"
      id="f-492"
      unitRef="employee">400</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringCharges contextRef="c-95" decimals="-5" id="f-493" unitRef="usd">20000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-494">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs associated with the Company&#x2019;s segments as well as unallocated corporate and research and development ("R&amp;amp;D") charges for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total restructuring costs by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs, by function, for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Employee transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Severance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-96" decimals="-5" id="f-495" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-97" decimals="-5" id="f-496" unitRef="usd">5600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-98" decimals="-5" id="f-497" unitRef="usd">8400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-99" decimals="-5" id="f-498" unitRef="usd">14000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-100" decimals="-5" id="f-499" unitRef="usd">11700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-101" decimals="-5" id="f-500" unitRef="usd">3600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-501" unitRef="usd">29300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-102" decimals="-5" id="f-502" unitRef="usd">600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-103" decimals="-5" id="f-503" unitRef="usd">27000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-104" decimals="-5" id="f-504" unitRef="usd">1700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-505" unitRef="usd">29300000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-506">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of and changes in the Company's restructuring accrual for the January 2023 Plan during the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of and changes in the Company's restructuring accrual for the August 2023 Plan during the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:18pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-105" decimals="-5" id="f-507" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-106" decimals="-5" id="f-508" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-107" decimals="-5" id="f-509" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-108" decimals="-5" id="f-510" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-109" decimals="-5" id="f-511" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-110" decimals="-5" id="f-512" unitRef="usd">8700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-111" decimals="-5" id="f-513" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-93" decimals="-5" id="f-514" unitRef="usd">9300000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-109" decimals="-5" id="f-515" unitRef="usd">300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-110" decimals="-5" id="f-516" unitRef="usd">7300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-111" decimals="-5" id="f-517" unitRef="usd">300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-93" decimals="-5" id="f-518" unitRef="usd">7900000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-112" decimals="-5" id="f-519" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-113" decimals="-5" id="f-520" unitRef="usd">1400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-114" decimals="-5" id="f-521" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-115" decimals="-5" id="f-522" unitRef="usd">1400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-116" decimals="-5" id="f-523" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-117" decimals="-5" id="f-524" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-118" decimals="-5" id="f-525" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-119" decimals="-5" id="f-526" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-120" decimals="-5" id="f-527" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-121" decimals="-5" id="f-528" unitRef="usd">18300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-122" decimals="-5" id="f-529" unitRef="usd">1400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-95" decimals="-5" id="f-530" unitRef="usd">20000000.0</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-120" decimals="-5" id="f-531" unitRef="usd">300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-121" decimals="-5" id="f-532" unitRef="usd">13000000.0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-122" decimals="-5" id="f-533" unitRef="usd">1300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-95" decimals="-5" id="f-534" unitRef="usd">14600000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-123" decimals="-5" id="f-535" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-124" decimals="-5" id="f-536" unitRef="usd">5300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-125" decimals="-5" id="f-537" unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-126" decimals="-5" id="f-538" unitRef="usd">5400000</us-gaap:RestructuringReserve>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-539">Inventories, net&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;142.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;113.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;92.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;328.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Inventories, net is stated at the lower of cost or net realizable value.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-540">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;142.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;113.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;92.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;328.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-4" decimals="-5" id="f-541" unitRef="usd">128700000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-5" decimals="-5" id="f-542" unitRef="usd">142300000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-5" id="f-543" unitRef="usd">113300000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-5" decimals="-5" id="f-544" unitRef="usd">116200000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-5" id="f-545" unitRef="usd">86900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-5" decimals="-5" id="f-546" unitRef="usd">92200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-5" id="f-547" unitRef="usd">328900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-5" id="f-548" unitRef="usd">350700000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-549">Property, plant and equipment, net &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023 &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;54.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;229.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;327.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;433.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;567.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;794.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,201.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(411.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(383.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;382.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;817.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; During the year ended December 31, 2023, the Company recorded a non-cash impairment charge of $306.7 million related to certain Bioservices long-lived assets. See Note 4, "Long-lived asset impairment and restructuring charges" for more details regarding the impairment charge.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, construction-in-progress primarily included costs incurred to advance the Company's MCM Product capabilities. For the year ended December&#160;31, 2022, construction-in-progress primarily included costs incurred related to construction to advance the Company's Bioservices capabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense associated with property, plant and equipment was $59.5 million, $83.4 million and $62.2 million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. During the year ended December&#160;31, 2022, the Company recorded accelerated depreciation of $12.7&#160;million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement (the "Janssen Agreement") with Janssen Pharmaceuticals, Inc. ("Janssen"). For additional information related to the termination of the Janssen Agreement, refer to Note 13 "Revenue recognition".&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-127" decimals="-5" id="f-550" unitRef="usd">30000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-128" decimals="-5" id="f-551" unitRef="usd">54900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-129" decimals="-5" id="f-552" unitRef="usd">229900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-130" decimals="-5" id="f-553" unitRef="usd">327900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-131" decimals="-5" id="f-554" unitRef="usd">433600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-132" decimals="-5" id="f-555" unitRef="usd">567500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-133" decimals="-5" id="f-556" unitRef="usd">64000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-134" decimals="-5" id="f-557" unitRef="usd">65600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-135" decimals="-5" id="f-558" unitRef="usd">36700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-136" decimals="-5" id="f-559" unitRef="usd">185500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-5" id="f-560" unitRef="usd">794200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-5" id="f-561" unitRef="usd">1201400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-5" id="f-562" unitRef="usd">411400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-5" id="f-563" unitRef="usd">383800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-564" unitRef="usd">382800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-5" id="f-565" unitRef="usd">817600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-566" unitRef="usd">306700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-567" unitRef="usd">59500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-27" decimals="-5" id="f-568" unitRef="usd">83400000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-28" decimals="-5" id="f-569" unitRef="usd">62200000</us-gaap:Depreciation>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-137" decimals="-5" id="f-570" unitRef="usd">12700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-571">Intangible assets and goodwill &lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. Components of the Company&#x2019;s intangible assets, excluding goodwill, consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.165%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.165%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.030%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;13.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;288.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;566.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;982.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;253.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%"&gt;Bioservices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;13.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;889.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;322.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;566.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,016.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;287.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the Company sold $102.9 million of intangible assets, net as part of the sale of its travel health business to Bavarian Nordic. See Note 3, "Divestiture" for more information on the sale of the travel health business. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the year ended December&#160;31, 2023, the Company recorded a $6.3 million intangible asset addition related to the contingent consideration payment to Ridgeback for the award of a 10-year contract by the Biomedical Advanced Research and Development Authority for advanced development, manufacturing scale-up, and procurement of Ebanga&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; treatment for Ebola. The related intangible asset was acquired through an asset acquisition that was completed in 2022. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense associated with the Company's intangible assets was recorded as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates our future amortization expense for our intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;&#160;As of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;260.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total remaining amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;566.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the changes in the carrying amount of goodwill by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Commercial Products &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;MCM Products &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(218.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(218.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; Amounts for the Company's Commercial Products segment include gross carrying values of $41.7 million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $41.7 million as of December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts for the Company's MCM Products segment include gross carrying values of $218.2&#160;million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $218.2&#160;million as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts for the Company's Services segment include gross carrying values of $6.7&#160;million as of December&#160;31, 2023, 2022, and 2021, and accumulated impairment losses of $6.7&#160;million as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company performs its goodwill impairment evaluation annually, during the fourth quarter, or sooner if triggering events are identified. During the third quarter of 2023, the Company observed continued market volatility including significant declines in its market capitalization and revised its financial outlook during the third quarter of 2023, which was identified as a triggering event. As a result of the quantitative assessments performed in connection with the preparation of the financial statements as of and for the quarter ended September&#160;30, 2023, the Company recorded a $218.2&#160;million non-cash goodwill impairment charge for the MCM Products reporting unit, which is included in "Goodwill impairment" on the Consolidated Statement of Operations for the year ended December 31, 2023. The MCM Products reporting unit and segment had no remaining goodwill as of December 31, 2023. The goodwill impairment charge resulted from a reduction in the estimated fair value of the MCM reporting unit due to changes in the risk profile of the Company as well as revisions to the long-term operating plan that reflected lower expectations for growth and profitability than previous expectations. The Company used a quantitative assessment, utilizing an income-based (discounted cash flows) approach, Level 3 non-recurring fair value measurement, for its goodwill impairment testing.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-572">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. Components of the Company&#x2019;s intangible assets, excluding goodwill, consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.165%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.165%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.030%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;13.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;288.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;566.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;982.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;253.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%"&gt;Bioservices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;13.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;889.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;322.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;566.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,016.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;287.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the Company sold $102.9 million of intangible assets, net as part of the sale of its travel health business to Bavarian Nordic. See Note 3, "Divestiture" for more information on the sale of the travel health business. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the year ended December&#160;31, 2023, the Company recorded a $6.3 million intangible asset addition related to the contingent consideration payment to Ridgeback for the award of a 10-year contract by the Biomedical Advanced Research and Development Authority for advanced development, manufacturing scale-up, and procurement of Ebanga&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; treatment for Ebola. The related intangible asset was acquired through an asset acquisition that was completed in 2022. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-138" id="f-573">P13Y7M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-138" decimals="-5" id="f-574" unitRef="usd">855400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-138" decimals="-5" id="f-575" unitRef="usd">288800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-138" decimals="-5" id="f-576" unitRef="usd">566600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-139" decimals="-5" id="f-577" unitRef="usd">982100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-139" decimals="-5" id="f-578" unitRef="usd">253300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-139" decimals="-5" id="f-579" unitRef="usd">728800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-140" id="f-580">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-140" decimals="-5" id="f-581" unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-140" decimals="-5" id="f-582" unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-140" decimals="-5" id="f-583" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-141" decimals="-5" id="f-584" unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-141" decimals="-5" id="f-585" unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-141" decimals="-5" id="f-586" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-142" id="f-587">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-142" decimals="-5" id="f-588" unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-142" decimals="-5" id="f-589" unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-142" decimals="-5" id="f-590" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-143" decimals="-5" id="f-591" unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-143" decimals="-5" id="f-592" unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-143" decimals="-5" id="f-593" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-4" id="f-594">P13Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-5" id="f-595" unitRef="usd">889500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-5" id="f-596" unitRef="usd">322900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-5" id="f-597" unitRef="usd">566600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-5" decimals="-5" id="f-598" unitRef="usd">1016200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-5" id="f-599" unitRef="usd">287400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-5" id="f-600" unitRef="usd">728800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent contextRef="c-144" decimals="-5" id="f-601" unitRef="usd">102900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-145" decimals="-5" id="f-602" unitRef="usd">6300000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <ebs:RevenueFromContractWithCustomerTermOfContract contextRef="c-146" id="f-603">P10Y</ebs:RevenueFromContractWithCustomerTermOfContract>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c-1" id="f-604">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense associated with the Company's intangible assets was recorded as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-605" unitRef="usd">65600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-27" decimals="-5" id="f-606" unitRef="usd">59900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-28" decimals="-5" id="f-607" unitRef="usd">58500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-608">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates our future amortization expense for our intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;&#160;As of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;260.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Total remaining amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;566.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-5" id="f-609" unitRef="usd">65100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-5" id="f-610" unitRef="usd">65100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-5" id="f-611" unitRef="usd">63900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-5" id="f-612" unitRef="usd">60600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-5" id="f-613" unitRef="usd">51700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-4" decimals="-5" id="f-614" unitRef="usd">260200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-5" id="f-615" unitRef="usd">566600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-616">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the changes in the carrying amount of goodwill by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Commercial Products &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;MCM Products &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(218.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(218.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; Amounts for the Company's Commercial Products segment include gross carrying values of $41.7 million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $41.7 million as of December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts for the Company's MCM Products segment include gross carrying values of $218.2&#160;million as of December&#160;31, 2023, 2022 and 2021, and accumulated impairment losses of $218.2&#160;million as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts for the Company's Services segment include gross carrying values of $6.7&#160;million as of December&#160;31, 2023, 2022, and 2021, and accumulated impairment losses of $6.7&#160;million as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-147" decimals="-5" id="f-617" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-148" decimals="-5" id="f-618" unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-149" decimals="-5" id="f-619" unitRef="usd">6700000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-29" decimals="-5" id="f-620" unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-150" decimals="-5" id="f-621" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-151" decimals="-5" id="f-622" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-152" decimals="-5" id="f-623" unitRef="usd">6700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-27" decimals="-5" id="f-624" unitRef="usd">6700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-153" decimals="-5" id="f-625" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-154" decimals="-5" id="f-626" unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-155" decimals="-5" id="f-627" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-5" id="f-628" unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-156" decimals="-5" id="f-629" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-157" decimals="-5" id="f-630" unitRef="usd">218200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-158" decimals="-5" id="f-631" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-5" id="f-632" unitRef="usd">218200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-159" decimals="-5" id="f-633" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-160" decimals="-5" id="f-634" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-161" decimals="-5" id="f-635" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-5" id="f-636" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillGross contextRef="c-153" decimals="-5" id="f-637" unitRef="usd">41700000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-147" decimals="-5" id="f-638" unitRef="usd">41700000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-159" decimals="-5" id="f-639" unitRef="usd">41700000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-153" decimals="-5" id="f-640" unitRef="usd">41700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-147" decimals="-5" id="f-641" unitRef="usd">41700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-159" decimals="-5" id="f-642" unitRef="usd">41700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillGross contextRef="c-154" decimals="-5" id="f-643" unitRef="usd">218200000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-160" decimals="-5" id="f-644" unitRef="usd">218200000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-148" decimals="-5" id="f-645" unitRef="usd">218200000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-160" decimals="-5" id="f-646" unitRef="usd">218200000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillGross contextRef="c-155" decimals="-5" id="f-647" unitRef="usd">6700000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-161" decimals="-5" id="f-648" unitRef="usd">6700000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-149" decimals="-5" id="f-649" unitRef="usd">6700000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-161" decimals="-5" id="f-650" unitRef="usd">6700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-155" decimals="-5" id="f-651" unitRef="usd">6700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-162" decimals="-5" id="f-652" unitRef="usd">218200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-4" decimals="-5" id="f-653" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-654">Fair value measurements &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-672"&gt;&lt;span style="-sec-ix-hidden:f-673"&gt;Derivative instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#x2019;s products are classified in the Company's &lt;span style="-sec-ix-hidden:f-706"&gt;&lt;span style="-sec-ix-hidden:f-707"&gt;Consolidated Statement of Operations&lt;/span&gt;&lt;/span&gt; as cost of product sales. Any changes in fair value for the contingent consideration liabilities related to the Company&#x2019;s product candidates are recorded in R&amp;amp;D expense for regulatory and development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a reconciliation of the beginning and ending balance of the contingent consideration liabilities measured at fair value during the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(23.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the current portion of the contingent consideration liability was $2.7&#160;million and $3.4&#160;million, respectively, and was included in "Other current liabilities" on the Consolidated Balance Sheets. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The non-current portion of the contingent consideration liability is included in "Other liabilities" on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Fair Value as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Royalty based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$5.6 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;9.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.0% - 75.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Projected year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2023 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Variable Rate Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the fair value of the Company's 3.875% Senior Unsecured Notes was $184.3 million and $225.1 million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company&#x2019;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, "Debt").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-recurring fair value measurements&lt;/span&gt;&lt;/div&gt;Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. As of December&#160;31, 2023 and December&#160;31, 2022, other than those liabilities mentioned above and those assets outlined in Note 7 "Intangible assets and goodwill", there were no material assets or liabilities measured at fair value on a non-recurring basis.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-655">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-672"&gt;&lt;span style="-sec-ix-hidden:f-673"&gt;Derivative instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-163" decimals="-5" id="f-656" unitRef="usd">40500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-164" decimals="-5" id="f-657" unitRef="usd">40500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-165" decimals="-5" id="f-658" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-166" decimals="-5" id="f-659" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-167" decimals="-5" id="f-660" unitRef="usd">320800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-168" decimals="-5" id="f-661" unitRef="usd">320800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-169" decimals="-5" id="f-662" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-170" decimals="-5" id="f-663" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-171" decimals="-5" id="f-664" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-172" decimals="-5" id="f-665" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-173" decimals="-5" id="f-666" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-174" decimals="-5" id="f-667" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-175" decimals="-5" id="f-668" unitRef="usd">170700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-176" decimals="-5" id="f-669" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-177" decimals="-5" id="f-670" unitRef="usd">170700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-178" decimals="-5" id="f-671" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeAssets contextRef="c-4" decimals="-5" id="f-674" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-179" decimals="-5" id="f-675" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-180" decimals="-5" id="f-676" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-181" decimals="-5" id="f-677" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-5" decimals="-5" id="f-678" unitRef="usd">8500000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-182" decimals="-5" id="f-679" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-183" decimals="-5" id="f-680" unitRef="usd">8500000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-184" decimals="-5" id="f-681" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-5" id="f-682" unitRef="usd">40500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-179" decimals="-5" id="f-683" unitRef="usd">40500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-180" decimals="-5" id="f-684" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-181" decimals="-5" id="f-685" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-5" decimals="-5" id="f-686" unitRef="usd">500000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-182" decimals="-5" id="f-687" unitRef="usd">320800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-183" decimals="-5" id="f-688" unitRef="usd">179200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-184" decimals="-5" id="f-689" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-4" decimals="-5" id="f-690" unitRef="usd">5600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-179" decimals="-5" id="f-691" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-180" decimals="-5" id="f-692" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-181" decimals="-5" id="f-693" unitRef="usd">5600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-5" decimals="-5" id="f-694" unitRef="usd">8000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-182" decimals="-5" id="f-695" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-183" decimals="-5" id="f-696" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-184" decimals="-5" id="f-697" unitRef="usd">8000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-4" decimals="-5" id="f-698" unitRef="usd">5600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-179" decimals="-5" id="f-699" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-180" decimals="-5" id="f-700" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-181" decimals="-5" id="f-701" unitRef="usd">5600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-5" decimals="-5" id="f-702" unitRef="usd">8000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-182" decimals="-5" id="f-703" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-183" decimals="-5" id="f-704" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-184" decimals="-5" id="f-705" unitRef="usd">8000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-708">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a reconciliation of the beginning and ending balance of the contingent consideration liabilities measured at fair value during the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(23.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-30" decimals="-5" id="f-709" unitRef="usd">59300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-28" decimals="-5" id="f-710" unitRef="usd">2900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-28" decimals="-5" id="f-711" unitRef="usd">23800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-29" decimals="-5" id="f-712" unitRef="usd">38400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-27" decimals="-5" id="f-713" unitRef="usd">2600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-27" decimals="-5" id="f-714" unitRef="usd">33000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-5" decimals="-5" id="f-715" unitRef="usd">8000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-5" id="f-716" unitRef="usd">200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-1" decimals="-5" id="f-717" unitRef="usd">2600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-4" decimals="-5" id="f-718" unitRef="usd">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-4" decimals="-5" id="f-719" unitRef="usd">2700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-5" decimals="-5" id="f-720" unitRef="usd">3400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-721">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Fair Value as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Royalty based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$5.6 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;9.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.0% - 75.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Projected year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2023 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-185" decimals="-5" id="f-722" unitRef="usd">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-186" decimals="3" id="f-723" unitRef="number">0.095</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-187" decimals="3" id="f-724" unitRef="number">0.000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-188" decimals="3" id="f-725" unitRef="number">0.750</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-189"
      decimals="INF"
      id="f-726"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-190"
      decimals="INF"
      id="f-727"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue contextRef="c-189" decimals="-5" id="f-728" unitRef="usd">184300000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-190" decimals="-5" id="f-729" unitRef="usd">225100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-730">Derivative instruments and hedging activities&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Risk management objective of using derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. From time to time, the Company enters into interest rate swap transactions to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements. The objective and strategy with respect to these interest rate swaps is to protect the Company against adverse fluctuations in interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2023, the Company terminated its designated interest rate swap transactions with a total notional value of $350.0&#160;million. Hedge accounting was also discontinued at that time. As of December 31, 2023, there was no remaining accumulated other comprehensive income associated with the terminated interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Fair Value of Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to their termination, the valuation of the interest rate swaps was determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflected the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps were determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) were based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporated credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount of gains or losses reclassified from "Accumulated other comprehensive income (loss), net" into "Interest expense" on the Consolidated Statement of Operations during the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.360%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-83" decimals="INF" id="f-731" unitRef="usd">350000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-732">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Fair Value of Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-191" decimals="-5" id="f-733" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-192" decimals="-5" id="f-734" unitRef="usd">8500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-735">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount of gains or losses reclassified from "Accumulated other comprehensive income (loss), net" into "Interest expense" on the Consolidated Statement of Operations during the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.360%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-193" decimals="-5" id="f-736" unitRef="usd">8900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-194" decimals="-5" id="f-737" unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-738">Debt &lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below present the components of the Company's debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Senior secured credit agreement - Term loan due 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;198.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;362.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Senior secured credit agreement - Revolver loan due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;598.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;868.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,413.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(413.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(957.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Non-current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;446.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2023 and 2022, the Company reclassified the debt issuance costs associated with the revolver loan to a contra account to directly offset the loan balance in "Other current liabilities" on the Company's Consolidated Balance Sheets. As of December 31, 2023 and 2022, the Company had $5.3&#160;million and $1.3&#160;million of debt issuance costs associated with the revolver loan, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, the Company completed its offering of $450.0&#160;million aggregate principal amount of 3.875% Senior unsecured Notes due 2028 (the "2028 Notes")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related indenture, plus accrued and unpaid interest. As of August 15, 2023, the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes plus a &#x201c;make-whole&#x201d; premium and accrued and unpaid interest as set forth in the related indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of 101% of the principal amount of such 2028 Notes plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Negative covenants in the indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2023, the Company entered into the Fourth Amendment to Amended and Restated Credit Agreement, Waiver and First Amendment to Amended and Restated Collateral Agreement (the "Credit Agreement Amendment"). The Credit Agreement Amendment amended the existing Amended and Restated Credit Agreement to, among other things, (a) extend the maturity date of the Senior Secured Credit Facilities from October 13, 2023 to May 15, 2025, (b) reduce the available commitments under the Revolving Credit Facility from $600.0&#160;million to $300.0&#160;million, (c) remove the Company's ability to incur incremental loans and (d) amend certain mandatory prepayment triggers, affirmative covenants, negative covenants and events of default thereunder. In connection with the Credit Agreement Amendment, the Company used the approximately $270.2&#160;million of proceeds from the sale of its travel health business to Bavarian Nordic, which closed on May 15, 2023, together with approximately $217.2&#160;million of cash on hand, to repay approximately $144.4&#160;million in outstanding principal amount of loans under the Term Loan Facility and $342.8&#160;million outstanding principal amount of loans under the Revolving Credit Facility. The Credit Agreement Amendment also requires that the Company make quarterly principal payments on the Term Loan Facility of approximately $3.9&#160;million, which commenced on June 30, 2023 and will extend through March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement Amendment also (i) amended the consolidated debt service coverage ratio financial covenant to require the minimum level to be 2.25 to 1.00 for the fiscal quarters ending March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and then 2.50 to 1.00 for each fiscal quarter ending thereafter, (ii) amended the consolidated leverage ratio to require the maximum level to be 4.50 to 1.00 for the fiscal quarter ending March 31, 2024 and each fiscal quarter ending thereafter, (iii) added minimum Consolidated EBITDA requirements and maximum capital expenditure requirements for each of the months ending April 30, 2023 through February 29, 2024 and a minimum liquidity requirement as of the end of each calendar month and (iv) requires the Company to increase its liquidity by April 30, 2024 by raising at least $75.0&#160;million of equity or unsecured indebtedness. See Note 2, "Summary of significant accounting policies" for additional information related to the Company's compliance with the debt covenants described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Credit Agreement Amendment replaced the interest rate benchmark such that borrowings under the Revolving Credit Facility and the outstanding principal amount of the Term Loan Facility shall bear interest at a rate per annum equal to (a) a rate based on SOFR, EURIBOR or CDOR plus a margin of 6.00% until March 31, 2024 and thereafter, a margin ranging from 2.75% to 4.00% depending on the Company&#x2019;s consolidated leverage ratio, or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a SOFR rate for an interest period of one month plus 1.00%) plus a margin of 5.00% until March 31, 2024 and thereafter, a margin ranging from 1.75% to 3.00% depending on the Company&#x2019;s consolidated leverage ratio. In addition, the commitment fee the Company is required to pay in respect of the annual daily unused commitments under the Revolving Credit Facility shall be 0.15% to 0.40% per annum, depending on the Company&#x2019;s consolidated leverage ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Credit Agreement Amendment, the Company and the other guarantors also agreed to provide a lien over certain assets as additional collateral for the benefit of the lenders, including owned real property, equity interests of foreign subsidiaries and certain deposit accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 29, 2024, the Company entered into the Forbearance Agreement and Amendment to, among other things, (a) provide that the Administrative Agent and the Lenders forbear from exercising all rights and remedies under the Senior Secured Credit Facilities and the other related loan documents arising from the occurrence and continuation of certain specified events of default during the Forbearance Period and (b) provide consent by the required revolving credit lenders to make further loans to the Company or other extensions of credit to the credit parties during the Forbearance Period, notwithstanding the occurrence of the specified events of default, subject to certain conditions set forth in the Forbearance Agreement and Amendment, including a limit on Revolving Credit Facility indebtedness of $270&#160;million. The Forbearance Agreement and Amendment also amends, among other things, (x)(A) the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interest rate benchmark to provide that borrowings shall bear interest at a rate per annum equal to 5.00% with respect to Base Rate Loans, (B) the interest rate benchmark from 6.00% per annum to 6.50% per annum with respect to SOFR Loans, Daily Simple SONIA Loans and Eurocurrency Rate Loans, and (C) 0.40% with respect to Commitment Fees, (y) the mandatory prepayment threshold amount for unrestricted cash and cash equivalents from $125,000,000 to $100,000,000, and (z) the mandatory principal prepayment amount from 75% of all milestone payments received by the Company and its subsidiaries from certain project milestone payments to 100%. Under the Forbearance Agreement and Amendment, the Company and the other guarantors have also agreed to cause Emergent BioSolutions Canada Inc. to (i) become a guarantor under the Senior Secured Credit Facilities and (ii) grant a security lien in all collateral owned by Emergent BioSolutions Canada Inc. (subject to the exclusions and exceptions specified in the Collateral Agreement) to the Administrative Agent. In addition, in connection with the entry into the Forbearance Agreement and Amendment, the Company paid a forbearance fee of approximately $1.2&#160;million. Refer to Note 2, "Summary of significant accounting policies" for further discussion of the Forbearance Agreement and Amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Debt Maturity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future debt payments of long-term indebtedness are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;418.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;868.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-739">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below present the components of the Company's debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Senior secured credit agreement - Term loan due 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;198.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;362.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Senior secured credit agreement - Revolver loan due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;598.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;868.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,413.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(413.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(957.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Non-current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;446.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt contextRef="c-66" decimals="-5" id="f-740" unitRef="usd">198200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-195" decimals="-5" id="f-741" unitRef="usd">362800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-65" decimals="-5" id="f-742" unitRef="usd">219200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-196" decimals="-5" id="f-743" unitRef="usd">598000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-70"
      decimals="INF"
      id="f-744"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-189" decimals="-5" id="f-745" unitRef="usd">450000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-190" decimals="-5" id="f-746" unitRef="usd">450000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-197" decimals="-5" id="f-747" unitRef="usd">1000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-198" decimals="-5" id="f-748" unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-5" id="f-749" unitRef="usd">868400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-5" decimals="-5" id="f-750" unitRef="usd">1413800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-5" id="f-751" unitRef="usd">413700000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-5" id="f-752" unitRef="usd">957300000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-4" decimals="-5" id="f-753" unitRef="usd">8200000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-5" decimals="-5" id="f-754" unitRef="usd">8000000.0</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-5" id="f-755" unitRef="usd">446500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-5" id="f-756" unitRef="usd">448500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-4" decimals="-5" id="f-757" unitRef="usd">5300000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-5" decimals="-5" id="f-758" unitRef="usd">1300000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-70"
      decimals="INF"
      id="f-759"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-70" decimals="-5" id="f-760" unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-70"
      decimals="INF"
      id="f-761"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-199"
      decimals="INF"
      id="f-762"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-200"
      decimals="INF"
      id="f-763"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c-201" decimals="-5" id="f-764" unitRef="usd">600000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c-202" decimals="-5" id="f-765" unitRef="usd">300000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-84" decimals="-5" id="f-766" unitRef="usd">270200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:Cash contextRef="c-203" decimals="-5" id="f-767" unitRef="usd">217200000</us-gaap:Cash>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-204" decimals="-5" id="f-768" unitRef="usd">144400000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-205" decimals="-5" id="f-769" unitRef="usd">342800000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-206" decimals="-5" id="f-770" unitRef="usd">3900000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <ebs:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="c-207"
      decimals="INF"
      id="f-771"
      unitRef="number">2.25</ebs:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <ebs:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="c-208"
      decimals="INF"
      id="f-772"
      unitRef="number">2.50</ebs:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <ebs:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="c-209"
      decimals="INF"
      id="f-773"
      unitRef="number">4.50</ebs:DebtInstrumentCovenantLeverageRatioMaximum>
    <ebs:DebtInstrumentCovenantConsiderationThreshold contextRef="c-68" decimals="-5" id="f-774" unitRef="usd">75000000</ebs:DebtInstrumentCovenantConsiderationThreshold>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-210" decimals="4" id="f-775" unitRef="number">0.0600</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-211" decimals="4" id="f-776" unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-212" decimals="4" id="f-777" unitRef="number">0.0400</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-213" decimals="4" id="f-778" unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-214" decimals="4" id="f-779" unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-215" decimals="4" id="f-780" unitRef="number">0.0500</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-216" decimals="4" id="f-781" unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-217" decimals="4" id="f-782" unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="c-218" decimals="4" id="f-783" unitRef="number">0.0015</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="c-219" decimals="4" id="f-784" unitRef="number">0.0040</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c-220" decimals="-5" id="f-785" unitRef="usd">270000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-221" decimals="4" id="f-786" unitRef="number">0.0500</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-222" decimals="4" id="f-787" unitRef="number">0.0600</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-223" decimals="4" id="f-788" unitRef="number">0.0650</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="c-224" decimals="4" id="f-789" unitRef="number">0.0040</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <ebs:DebtInstrumentMandatoryPrepaymentThreshold contextRef="c-225" decimals="INF" id="f-790" unitRef="usd">125000000</ebs:DebtInstrumentMandatoryPrepaymentThreshold>
    <ebs:DebtInstrumentMandatoryPrepaymentThreshold contextRef="c-220" decimals="INF" id="f-791" unitRef="usd">100000000</ebs:DebtInstrumentMandatoryPrepaymentThreshold>
    <ebs:DebtInstrumentMandatoryPrincipalPrepaymentPercentage
      contextRef="c-225"
      decimals="INF"
      id="f-792"
      unitRef="number">0.75</ebs:DebtInstrumentMandatoryPrincipalPrepaymentPercentage>
    <ebs:DebtInstrumentMandatoryPrincipalPrepaymentPercentage
      contextRef="c-220"
      decimals="INF"
      id="f-793"
      unitRef="number">1</ebs:DebtInstrumentMandatoryPrincipalPrepaymentPercentage>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-220" decimals="-5" id="f-794" unitRef="usd">1200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-795">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future debt payments of long-term indebtedness are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;418.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;868.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-4" decimals="-5" id="f-796" unitRef="usd">418400000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-4" decimals="-5" id="f-797" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-4" decimals="-5" id="f-798" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-4" decimals="-5" id="f-799" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-4" decimals="-5" id="f-800" unitRef="usd">450000000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-4" decimals="-5" id="f-801" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-5" id="f-802" unitRef="usd">868400000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-803">Share-based compensation and stockholders' equity&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two share-based employee compensation plans, the Emergent Plan and the Inducement Plan, which include stock options and performance and restricted stock units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, an aggregate of 29.1 million shares of common stock were authorized for issuance under the Emergent Plan, of which a total of approximately 5.9 million shares of common stock remain available for future awards to be made to plan participants. As of December 31, 2023, an aggregate of 5.0 million shares of common stock were authorized for issuance under the Inducement Plan and no shares had been issued under the Inducement Plan. The exercise price of each option must be not less than 100% of the fair market value of the shares underlying such option on the date of grant. Options granted under the Emergent Plan and the Inducement Plan have a contractual life of seven years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;63%-69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;54%-62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;47%-48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.00%-4.46%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.54%-4.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.43%-0.94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Expected average life of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option award activity under the Emergent Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Aggregate &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no cash received from option exercises for the year ended December&#160;31, 2023. Cash received from option exercises for the years ended December&#160;31, 2022 and 2021 was $0.5&#160;million and $10.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of options granted during the years ended December&#160;31, 2023, 2022 and 2021 was $5.35, $17.85 and $35.16 per share, respectively. The intrinsic value of stock options exercised is the amount by which the market value of our common stock on the exercise date exceeds the exercise price. There was no intrinsic value of options exercised during the year ended December&#160;31, 2023. The total intrinsic value of options exercised during the years ended December&#160;31, 2022 and 2021 was $0.3 million and $15.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of December&#160;31, 2023, there was $4.4 million of unrecognized compensation cost related to stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Performance stock units and restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of performance stock unit and restricted stock unit award activity under the Emergent Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;&#160;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;42.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;46.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards forfeited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;16.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt; Performance stock units granted and forfeited during the year ended December&#160;31, 2023 are included at the target payout percentage, or 100%, of shares granted.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of restricted stock unit awards released during the years ended December&#160;31, 2023, 2022 and 2021 was $31.8 million, $30.9 million and $26.9 million, respectively. As of December&#160;31, 2023, there was $22.6 million of unrecognized compensation cost related to unvested restricted stock units. That cost is expected to be recognized straight-line over a weighted average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock units represent common stock potentially issuable in the future, subject to achievement of performance conditions. Our current outstanding performance stock units vest based on certain financial metrics over the applicable performance period. The vesting and payout range for our performance stock units is typically between 50% and up to 200% of the target number of shares granted at the end of a three-year performance period. The total fair value of performance unit awards released during the years ended December&#160;31, 2023, 2022 and 2021 was $2.4&#160;million, $2.5&#160;million and $3.8&#160;million, respectively. As of December&#160;31, 2023, there was $2.2 million of unrecognized compensation cost related to unvested performance stock units. That cost is expected to be recognized straight-line over a weighted average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Cost of Commercial Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Cost of MCM Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Cost of Bioservices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stockholders' equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Preferred stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 15.0 million shares of preferred stock, $0.001 par value per share ("Preferred Stock"). Any Preferred Stock issued may have dividend rights, voting rights, conversion privileges, redemption characteristics, and sinking fund requirements as approved by the Company's board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has one class of common stock, $0.001 par value per share common stock ("Common Stock"), authorized and outstanding. The Company is authorized to issue up to 200.0 million shares of Common Stock. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters, except as may be provided by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;At-the-Market Equity Offering Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may, from time to time, sell up to $150.0&#160;million aggregate gross sales price of shares of our common stock through Evercore Group L.L.C. and RBC Capital Markets, LLC, as sales agents, under an ATM Program that we entered into on May 18, 2023. Between the entry into the ATM Program and December&#160;31, 2023, we sold 1.1 million shares of our common stock under the ATM Program for gross proceeds of $9.1&#160;million, representing an average share price of $8.22 per share. As of December&#160;31, 2023, $140.9&#160;million aggregate gross sales price of shares of our common stock remains available for issuance under the ATM Program. We intend to use proceeds obtained from the sale of shares under the ATM Program for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 11, 2021, the Company announced that its Board of Directors authorized a stock repurchase program of up to an aggregate of $250.0&#160;million of Common Stock (the "2021 Share Repurchase Program"), of which $187.9&#160;million was utilized to purchase approximately 4.4&#160;million. The 2021 Share Repurchase Program expired on November 11, 2022. During the year ended December&#160;31, 2022, the Company utilized $75.5&#160;million to purchase approximately 1.8&#160;million shares. The 2021 Share Repurchase Program did not obligate the Company to acquire any specific number of shares. Repurchased shares are available for use in connection with the Company's stock plans and for other corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accumulated other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present the tax effects related to each component of other comprehensive income (loss)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Defined benefit pension plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ebs:NumberOfShareBasedEmployeeCompensationPlans contextRef="c-4" decimals="INF" id="f-804" unitRef="plan">2</ebs:NumberOfShareBasedEmployeeCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-226"
      decimals="INF"
      id="f-805"
      unitRef="shares">29100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-226"
      decimals="-5"
      id="f-806"
      unitRef="shares">5900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-227"
      decimals="INF"
      id="f-807"
      unitRef="shares">5000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-228"
      decimals="-5"
      id="f-808"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <ebs:ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum
      contextRef="c-226"
      decimals="INF"
      id="f-809"
      unitRef="number">1</ebs:ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-229" id="f-810">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-811">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;63%-69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;54%-62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;47%-48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.00%-4.46%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.54%-4.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.43%-0.94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Expected average life of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-230"
      decimals="INF"
      id="f-812"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-231"
      decimals="INF"
      id="f-813"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-232"
      decimals="INF"
      id="f-814"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-230" decimals="2" id="f-815" unitRef="number">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-230" decimals="2" id="f-816" unitRef="number">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-231" decimals="2" id="f-817" unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-231" decimals="2" id="f-818" unitRef="number">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-232" decimals="2" id="f-819" unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-232" decimals="2" id="f-820" unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-230" decimals="4" id="f-821" unitRef="number">0.0400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-230" decimals="4" id="f-822" unitRef="number">0.0446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-231" decimals="4" id="f-823" unitRef="number">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-231" decimals="4" id="f-824" unitRef="number">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-232" decimals="4" id="f-825" unitRef="number">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-232" decimals="4" id="f-826" unitRef="number">0.0094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-230" id="f-827">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-231" id="f-828">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-232" id="f-829">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-830">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option award activity under the Emergent Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Aggregate &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock options exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-233"
      decimals="INF"
      id="f-831"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-233"
      decimals="2"
      id="f-832"
      unitRef="usdPerShare">51.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-234"
      decimals="INF"
      id="f-833"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-234"
      decimals="2"
      id="f-834"
      unitRef="usdPerShare">9.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-234"
      decimals="INF"
      id="f-835"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-234"
      decimals="2"
      id="f-836"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-234"
      decimals="INF"
      id="f-837"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-234"
      decimals="2"
      id="f-838"
      unitRef="usdPerShare">42.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-235"
      decimals="INF"
      id="f-839"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-235"
      decimals="2"
      id="f-840"
      unitRef="usdPerShare">34.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-234" id="f-841">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-235" decimals="-5" id="f-842" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-235"
      decimals="INF"
      id="f-843"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-235"
      decimals="2"
      id="f-844"
      unitRef="usdPerShare">56.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-234" id="f-845">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-235" decimals="-5" id="f-846" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="INF" id="f-847" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-27" decimals="-5" id="f-848" unitRef="usd">500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-28" decimals="-5" id="f-849" unitRef="usd">10400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-850"
      unitRef="usdPerShare">5.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-27"
      decimals="2"
      id="f-851"
      unitRef="usdPerShare">17.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-28"
      decimals="2"
      id="f-852"
      unitRef="usdPerShare">35.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="INF" id="f-853" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-27" decimals="-5" id="f-854" unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-28" decimals="-5" id="f-855" unitRef="usd">15700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-4" decimals="-5" id="f-856" unitRef="usd">4400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-857">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of performance stock unit and restricted stock unit award activity under the Emergent Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;&#160;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;42.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;46.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards forfeited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock awards outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;16.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt; Performance stock units granted and forfeited during the year ended December&#160;31, 2023 are included at the target payout percentage, or 100%, of shares granted.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-236"
      decimals="INF"
      id="f-858"
      unitRef="shares">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-236"
      decimals="2"
      id="f-859"
      unitRef="usdPerShare">42.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c-236" decimals="-5" id="f-860" unitRef="usd">25800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-237"
      decimals="INF"
      id="f-861"
      unitRef="shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-237"
      decimals="2"
      id="f-862"
      unitRef="usdPerShare">8.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-237"
      decimals="INF"
      id="f-863"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-237"
      decimals="2"
      id="f-864"
      unitRef="usdPerShare">46.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-237"
      decimals="INF"
      id="f-865"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-237"
      decimals="2"
      id="f-866"
      unitRef="usdPerShare">26.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-238"
      decimals="INF"
      id="f-867"
      unitRef="shares">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-238"
      decimals="2"
      id="f-868"
      unitRef="usdPerShare">16.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c-238" decimals="-5" id="f-869" unitRef="usd">6200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage contextRef="c-239" decimals="2" id="f-870" unitRef="number">1</ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage>
    <ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue contextRef="c-240" decimals="-5" id="f-871" unitRef="usd">31800000</ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue>
    <ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue contextRef="c-241" decimals="-5" id="f-872" unitRef="usd">30900000</ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue>
    <ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue contextRef="c-242" decimals="-5" id="f-873" unitRef="usd">26900000</ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-243" decimals="-5" id="f-874" unitRef="usd">22600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-240" id="f-875">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-244" id="f-876">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage contextRef="c-245" decimals="2" id="f-877" unitRef="number">0.50</ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage>
    <ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage contextRef="c-246" decimals="2" id="f-878" unitRef="number">2</ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayoutPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-244" id="f-879">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue contextRef="c-244" decimals="-5" id="f-880" unitRef="usd">2400000</ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue>
    <ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue contextRef="c-247" decimals="-5" id="f-881" unitRef="usd">2500000</ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue>
    <ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue contextRef="c-248" decimals="-5" id="f-882" unitRef="usd">3800000</ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-249" decimals="-5" id="f-883" unitRef="usd">2200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-240" id="f-884">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-244" id="f-885">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-886">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Cost of Commercial Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Cost of MCM Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Cost of Bioservices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-250" decimals="-5" id="f-887" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-251" decimals="-5" id="f-888" unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-252" decimals="-5" id="f-889" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-253" decimals="-5" id="f-890" unitRef="usd">3800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-254" decimals="-5" id="f-891" unitRef="usd">6500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-255" decimals="-5" id="f-892" unitRef="usd">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-256" decimals="-5" id="f-893" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-257" decimals="-5" id="f-894" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-258" decimals="-5" id="f-895" unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-259" decimals="-5" id="f-896" unitRef="usd">2000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-260" decimals="-5" id="f-897" unitRef="usd">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-261" decimals="-5" id="f-898" unitRef="usd">5000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-262" decimals="-5" id="f-899" unitRef="usd">16200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-263" decimals="-5" id="f-900" unitRef="usd">30600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-264" decimals="-5" id="f-901" unitRef="usd">29900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-902" unitRef="usd">23100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-27" decimals="-5" id="f-903" unitRef="usd">45100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-28" decimals="-5" id="f-904" unitRef="usd">42400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-905" unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-906"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-907"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-908" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <ebs:CommonStockNumberOfVotesPerCommonShare contextRef="c-1" decimals="INF" id="f-909" unitRef="vote">1</ebs:CommonStockNumberOfVotesPerCommonShare>
    <ebs:SaleOfStockAggregateOfferingAmountMaximum contextRef="c-265" decimals="-5" id="f-910" unitRef="usd">150000000</ebs:SaleOfStockAggregateOfferingAmountMaximum>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-266"
      decimals="-5"
      id="f-911"
      unitRef="shares">1100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <ebs:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-266" decimals="-5" id="f-912" unitRef="usd">9100000</ebs:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-265"
      decimals="2"
      id="f-913"
      unitRef="usdPerShare">8.22</us-gaap:SaleOfStockPricePerShare>
    <ebs:SaleOfStockAmountRemainingAvailableForSaleOfShares contextRef="c-265" decimals="-5" id="f-914" unitRef="usd">140900000</ebs:SaleOfStockAmountRemainingAvailableForSaleOfShares>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-267" decimals="-5" id="f-915" unitRef="usd">250000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-268" decimals="-5" id="f-916" unitRef="usd">187900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-268"
      decimals="-5"
      id="f-917"
      unitRef="shares">4400000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-50" decimals="-5" id="f-918" unitRef="usd">75500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-50" decimals="-5" id="f-919" unitRef="shares">1800000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-920">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity contextRef="c-269" decimals="-5" id="f-921" unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-270" decimals="-5" id="f-922" unitRef="usd">-4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-271" decimals="-5" id="f-923" unitRef="usd">-7600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-5" id="f-924" unitRef="usd">-16100000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-272" decimals="-5" id="f-925" unitRef="usd">8700000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-273" decimals="-5" id="f-926" unitRef="usd">10800000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-274" decimals="-5" id="f-927" unitRef="usd">1000000.0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-27" decimals="-5" id="f-928" unitRef="usd">20500000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-272" decimals="-5" id="f-929" unitRef="usd">1200000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-273" decimals="-5" id="f-930" unitRef="usd">100000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-274" decimals="-5" id="f-931" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-27" decimals="-5" id="f-932" unitRef="usd">1300000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-272" decimals="-5" id="f-933" unitRef="usd">7500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-273" decimals="-5" id="f-934" unitRef="usd">10700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-274" decimals="-5" id="f-935" unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-5" id="f-936" unitRef="usd">19200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-275" decimals="-5" id="f-937" unitRef="usd">3500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-276" decimals="-5" id="f-938" unitRef="usd">6200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-277" decimals="-5" id="f-939" unitRef="usd">-6600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-5" id="f-940" unitRef="usd">3100000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-278" decimals="-5" id="f-941" unitRef="usd">0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-279" decimals="-5" id="f-942" unitRef="usd">2700000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-280" decimals="-5" id="f-943" unitRef="usd">900000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-1" decimals="-5" id="f-944" unitRef="usd">3600000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-278" decimals="-5" id="f-945" unitRef="usd">3500000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-279" decimals="-5" id="f-946" unitRef="usd">8900000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-280" decimals="-5" id="f-947" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-1" decimals="-5" id="f-948" unitRef="usd">12400000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-278" decimals="-5" id="f-949" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-279" decimals="-5" id="f-950" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-280" decimals="-5" id="f-951" unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-952" unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-281" decimals="-5" id="f-953" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-282" decimals="-5" id="f-954" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-283" decimals="-5" id="f-955" unitRef="usd">-5700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-5" id="f-956" unitRef="usd">-5700000</us-gaap:StockholdersEquity>
    <us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-957">&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present the tax effects related to each component of other comprehensive income (loss)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Defined benefit pension plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-278" decimals="-5" id="f-958" unitRef="usd">-4100000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-278" decimals="-5" id="f-959" unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-278" decimals="-5" id="f-960" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-272" decimals="-5" id="f-961" unitRef="usd">8700000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-272" decimals="-5" id="f-962" unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-272" decimals="-5" id="f-963" unitRef="usd">7500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-284" decimals="-5" id="f-964" unitRef="usd">4300000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-284" decimals="-5" id="f-965" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-284" decimals="-5" id="f-966" unitRef="usd">3700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-279" decimals="-5" id="f-967" unitRef="usd">-8500000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-279" decimals="-5" id="f-968" unitRef="usd">-2300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-279" decimals="-5" id="f-969" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-273" decimals="-5" id="f-970" unitRef="usd">14600000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-273" decimals="-5" id="f-971" unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-273" decimals="-5" id="f-972" unitRef="usd">10700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-285" decimals="-5" id="f-973" unitRef="usd">8900000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-285" decimals="-5" id="f-974" unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-285" decimals="-5" id="f-975" unitRef="usd">6500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-280" decimals="-5" id="f-976" unitRef="usd">1600000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-280" decimals="-5" id="f-977" unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-280" decimals="-5" id="f-978" unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-274" decimals="-5" id="f-979" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-274" decimals="-5" id="f-980" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-274" decimals="-5" id="f-981" unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-286" decimals="-5" id="f-982" unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-286" decimals="-5" id="f-983" unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-286" decimals="-5" id="f-984" unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-985" unitRef="usd">-11000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-1" decimals="-5" id="f-986" unitRef="usd">-2200000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-987" unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-27" decimals="-5" id="f-988" unitRef="usd">23900000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-27" decimals="-5" id="f-989" unitRef="usd">4700000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-5" id="f-990" unitRef="usd">19200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-28" decimals="-5" id="f-991" unitRef="usd">12000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-28" decimals="-5" id="f-992" unitRef="usd">2800000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-5" id="f-993" unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-994">Net income (loss) per common share&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share adjusts basic loss per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units and performance stock units. Diluted net income (loss) per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plans that were excluded from diluted net income (loss) per common share because their effect would have been antidilutive. No adjustment for the potential dilutive effect of dilutive securities is reported for the years ended December&#160;31, 2023 and 2022 as the effect would have been anti-dilutive due to the Company's net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net income (loss) per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(760.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(211.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;219.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares-basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Dilutive effect of employee incentive plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares-diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net income (loss) per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(14.85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net income (loss) per common share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(14.85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the share-based awards that are not considered in the diluted net income (loss) per common share calculation generally because the exercise price of the awards was greater than the average per share closing price during the year ending December&#160;31, 2023, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-27" decimals="0" id="f-995" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="0" id="f-996" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-997">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net income (loss) per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(760.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(211.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;219.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares-basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Dilutive effect of employee incentive plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares-diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net income (loss) per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(14.85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net income (loss) per common share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(14.85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-998" unitRef="usd">-760500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-999" unitRef="usd">-211600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-5" id="f-1000" unitRef="usd">219500000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-1001" unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-27"
      decimals="-5"
      id="f-1002"
      unitRef="shares">50100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-28"
      decimals="-5"
      id="f-1003"
      unitRef="shares">53500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-5" id="f-1004" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-27"
      decimals="-5"
      id="f-1005"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-28"
      decimals="-5"
      id="f-1006"
      unitRef="shares">600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-1007" unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-27"
      decimals="-5"
      id="f-1008"
      unitRef="shares">50100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-28"
      decimals="-5"
      id="f-1009"
      unitRef="shares">54100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1010"
      unitRef="usdPerShare">-14.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-1011"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-1012"
      unitRef="usdPerShare">4.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1013"
      unitRef="usdPerShare">-14.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-1014"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-1015"
      unitRef="usdPerShare">4.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1016">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the share-based awards that are not considered in the diluted net income (loss) per common share calculation generally because the exercise price of the awards was greater than the average per share closing price during the year ending December&#160;31, 2023, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-1017" unitRef="shares">3600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-27"
      decimals="-5"
      id="f-1018"
      unitRef="shares">2800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-28"
      decimals="-5"
      id="f-1019"
      unitRef="shares">1000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-1020">Revenue recognition &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in three business segments (see Note 18, "Segment information"). The Company's revenues disaggregated by the major sources were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.093%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="51" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Commercial Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;496.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;497.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;385.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;386.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;435.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;438.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;MCM Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;373.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;444.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;135.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;579.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;527.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;585.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%"&gt;Bioservices:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;310.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;310.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;243.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;305.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total Bioservices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;243.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;372.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;615.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;394.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;654.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,049.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;482.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;634.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;903.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;870.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,773.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022 and 2021, the Company's product sales from NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Other commercial products, Anthrax MCM, Smallpox MCM and Other products as a percentage of total product sales were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;% of product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Commercial Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other Commercial products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;MCM Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Anthrax MCM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Smallpox MCM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2023 and 2021, aside from sales to the USG, there were no sales to an individual customer in excess of 10% of total revenues. For the year ended December 31, 2022, there were two customers in excess of 10% of total revenues. The USG accounted for 43% of total revenues and the second customer's revenue accounted for 10% and was primarily attributable to the MCM Products segment. For the years ended December&#160;31, 2023, 2022, and 2021, the Company&#x2019;s revenues from customers within the United States comprised 58%, 79% and 92%, respectively, of total revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2020, the Company, through its wholly owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Janssen Agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, for large-scale drug substance manufacturing of Johnson &amp;amp; Johnson&#x2019;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#x201c;Product&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2022, the Company provided to Janssen a notice (the &#x201c;Notice&#x201d;) of material breach of the Janssen Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Janssen Agreement and (ii) to confirm Janssen&#x2019;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Janssen Agreement and instead, wind-down the Janssen Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#x201c;Janssen Notice&#x201d;) of the Janssen Agreement for asserted material breaches of the Janssen Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company&#x2019;s breaches were not curable and that, therefore, termination of the Janssen Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Janssen Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process through arbitration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023 there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Agreement. As of December&#160;31, 2023, the Company has no billed or unbilled net accounts receivable related to the Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the fourth quarter of 2022, because the arbitration process is expected to extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from "Inventories, net" and from "Prepaid expenses and other current assets" to "Other assets", resulting in $152.7 million in long-term assets related to the Janssen Agreement on the Consolidated Balance Sheet as of December 31, 2022. The long-term asset balance within "Other Assets" related to the Janssen Agreement as of December 31, 2023 was $158.8 million. These assets include termination penalties, certain inventory related items and raw materials inventory representing materials purchased for the Janssen Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of the inventory as of December 31, 2023, concluding that because the Janssen Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. As of December 31, 2023, all non-cancelable orders have been received by Janssen and are included in the long-term asset balance within "Other Assets". &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;BARDA Centers of Innovation and Advanced Development and Manufacturing Agreement ("CIADM")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company announced the issuance of a task order under its existing CIADM agreement with BARDA for COVID-19 vaccine development and manufacturing (the "BARDA COVID-19 Development Public Private Partnership"). The BARDA COVID-19 Development Public Private Partnership is considered a lease and is accounted for under ASC 842. The initial task order had a contract value of up to $628.2&#160;million and included the reservation of manufacturing capacity and accelerated expansion of fill/finish capacity valued at $542.7&#160;million and $85.5&#160;million, respectively. Subsequently, the task order was expanded to include incremental capital activities which increased the value to $650.8&#160;million. On November 1, 2021, the Company and BARDA mutually agreed to the completion of the Company's CIADM contract and associated task orders, including the BARDA COVID-19 Development Public Private Partnership. The Company did not recognize lease revenues under this arrangement during the years ended December 31, 2023 and December 31, 2022. Revenue associated with the base arrangement was $71.3&#160;million during the year ended December 31, 2021 and is reflected as a component of contracts and grants revenue on the Consolidated Statements of Operations. Revenue associated with the BARDA COVID-19 Development Public-Private Partnership was $243.1&#160;million during the year ended December 31, 2021 and is recorded as Bioservices "Leases" on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bioservices Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain multi-year Bioservices arrangements with non-USG customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates 5.0 years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components. During the year ended December 31, 2023, the Company's non-USG lease revenues were $5.7&#160;million, which is included within Bioservices "Leases" on the Consolidated Statement of Operations. Excluding future amounts related to the Agreement as discussed above, the Company estimates future operating lease revenues to be $0.8&#160;million in 2024, $0.9&#160;million in 2025, $0.9&#160;million in 2026, $0.9&#160;million in 2027, $0.9&#160;million in 2028 and no lease revenue in 2029 and beyond&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction price allocated to remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company has future contract value on unsatisfied performance obligations of approximately $379.5 million associated with all arrangements entered into by the Company. The Company expects to recognize $372.3 million of unsatisfied performance obligations within the next 24 months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; associat&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ed with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#x2019;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of December&#160;31, 2023 and December&#160;31, 2022, the Compan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y had $21.9&#160;million and $34.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, of contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded within "Accounts receivable, net" on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;&#160;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Revenue recognized in the period from amounts included in contract liability at the beginning of the period:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the current portion of contract liabilities was $27.2&#160;million and $26.4&#160;million, respectively, and was included in "Other current liabilities" on the Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Expected Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of "Accounts receivable, net" as presented on the Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;141.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;102.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;191.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;159.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company's provisions for expected credit losses for the year's ended years ended December&#160;31, 2023, 2022 and 2021 was $2.1 million, $0.3 million, and $(0.1) million, respectively.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1021"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1022"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-1023">The Company's revenues disaggregated by the major sources were as follows:&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.093%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="51" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Commercial Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;496.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;497.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;385.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;386.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;435.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;438.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;MCM Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;373.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;444.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;135.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;579.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;527.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;585.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%"&gt;Bioservices:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:115%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;310.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;310.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;243.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;305.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total Bioservices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;243.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;372.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;615.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;394.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;654.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,049.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;482.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;634.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;903.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;870.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,773.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-287" decimals="-5" id="f-1024" unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-288" decimals="-5" id="f-1025" unitRef="usd">496500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-5" id="f-1026" unitRef="usd">497300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-289" decimals="-5" id="f-1027" unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-290" decimals="-5" id="f-1028" unitRef="usd">385800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-5" id="f-1029" unitRef="usd">386600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-291" decimals="-5" id="f-1030" unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-292" decimals="-5" id="f-1031" unitRef="usd">435800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-5" id="f-1032" unitRef="usd">438000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-293" decimals="-5" id="f-1033" unitRef="usd">373500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-294" decimals="-5" id="f-1034" unitRef="usd">73700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-5" id="f-1035" unitRef="usd">447200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-295" decimals="-5" id="f-1036" unitRef="usd">444600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-296" decimals="-5" id="f-1037" unitRef="usd">135000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-5" id="f-1038" unitRef="usd">579600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-297" decimals="-5" id="f-1039" unitRef="usd">527800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-298" decimals="-5" id="f-1040" unitRef="usd">58100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-5" id="f-1041" unitRef="usd">585900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-299" decimals="-5" id="f-1042" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-300" decimals="-5" id="f-1043" unitRef="usd">72800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-5" id="f-1044" unitRef="usd">72800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-301" decimals="-5" id="f-1045" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-302" decimals="-5" id="f-1046" unitRef="usd">105000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-5" id="f-1047" unitRef="usd">105000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-303" decimals="-5" id="f-1048" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-304" decimals="-5" id="f-1049" unitRef="usd">310300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-5" id="f-1050" unitRef="usd">310300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-305" decimals="-5" id="f-1051" unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-306" decimals="-5" id="f-1052" unitRef="usd">5700000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-18" decimals="-5" id="f-1053" unitRef="usd">5700000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-307" decimals="-5" id="f-1054" unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-308" decimals="-5" id="f-1055" unitRef="usd">4900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-19" decimals="-5" id="f-1056" unitRef="usd">4900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-309" decimals="-5" id="f-1057" unitRef="usd">243100000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-310" decimals="-5" id="f-1058" unitRef="usd">62100000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-20" decimals="-5" id="f-1059" unitRef="usd">305200000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-311" decimals="-5" id="f-1060" unitRef="usd">0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-312" decimals="-5" id="f-1061" unitRef="usd">78500000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-21" decimals="-5" id="f-1062" unitRef="usd">78500000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-313" decimals="-5" id="f-1063" unitRef="usd">0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-314" decimals="-5" id="f-1064" unitRef="usd">109900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-22" decimals="-5" id="f-1065" unitRef="usd">109900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-315" decimals="-5" id="f-1066" unitRef="usd">243100000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-316" decimals="-5" id="f-1067" unitRef="usd">372400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-23" decimals="-5" id="f-1068" unitRef="usd">615500000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-317" decimals="-5" id="f-1069" unitRef="usd">20400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-318" decimals="-5" id="f-1070" unitRef="usd">5900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-24" decimals="-5" id="f-1071" unitRef="usd">26300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-319" decimals="-5" id="f-1072" unitRef="usd">37200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-320" decimals="-5" id="f-1073" unitRef="usd">4200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-5" id="f-1074" unitRef="usd">41400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-321" decimals="-5" id="f-1075" unitRef="usd">130200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-322" decimals="-5" id="f-1076" unitRef="usd">4000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-5" id="f-1077" unitRef="usd">134200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues contextRef="c-323" decimals="-5" id="f-1078" unitRef="usd">394700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-324" decimals="-5" id="f-1079" unitRef="usd">654600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-1080" unitRef="usd">1049300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-325" decimals="-5" id="f-1081" unitRef="usd">482600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-326" decimals="-5" id="f-1082" unitRef="usd">634900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-27" decimals="-5" id="f-1083" unitRef="usd">1117500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-327" decimals="-5" id="f-1084" unitRef="usd">903300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-328" decimals="-5" id="f-1085" unitRef="usd">870300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-28" decimals="-5" id="f-1086" unitRef="usd">1773600000</us-gaap:Revenues>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-1087">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022 and 2021, the Company's product sales from NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Other commercial products, Anthrax MCM, Smallpox MCM and Other products as a percentage of total product sales were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;% of product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Commercial Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other Commercial products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;MCM Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Anthrax MCM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Smallpox MCM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-329"
      decimals="2"
      id="f-1088"
      unitRef="number">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-330"
      decimals="2"
      id="f-1089"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-331"
      decimals="2"
      id="f-1090"
      unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-332"
      decimals="2"
      id="f-1091"
      unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-333"
      decimals="2"
      id="f-1092"
      unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-334"
      decimals="2"
      id="f-1093"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-335"
      decimals="2"
      id="f-1094"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-336"
      decimals="2"
      id="f-1095"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-337"
      decimals="2"
      id="f-1096"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-338"
      decimals="2"
      id="f-1097"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-339"
      decimals="2"
      id="f-1098"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-340"
      decimals="2"
      id="f-1099"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-341"
      decimals="2"
      id="f-1100"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-342"
      decimals="2"
      id="f-1101"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-343"
      decimals="2"
      id="f-1102"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-72" decimals="2" id="f-1103" unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-344"
      decimals="2"
      id="f-1104"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-345"
      decimals="2"
      id="f-1105"
      unitRef="number">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-346"
      decimals="2"
      id="f-1106"
      unitRef="number">0.79</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-347"
      decimals="2"
      id="f-1107"
      unitRef="number">0.92</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-348" decimals="-5" id="f-1108" unitRef="usd">152700000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-349" decimals="-5" id="f-1109" unitRef="usd">158800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-350" decimals="-5" id="f-1110" unitRef="usd">628200000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-351" decimals="-5" id="f-1111" unitRef="usd">542700000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-352" decimals="-5" id="f-1112" unitRef="usd">85500000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-353" decimals="-5" id="f-1113" unitRef="usd">650800000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-354" decimals="INF" id="f-1114" unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-355" decimals="INF" id="f-1115" unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-356" decimals="-5" id="f-1116" unitRef="usd">71300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-357" decimals="-5" id="f-1117" unitRef="usd">243100000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-358" id="f-1118">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-1" decimals="-5" id="f-1119" unitRef="usd">5700000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths contextRef="c-359" decimals="-5" id="f-1120" unitRef="usd">800000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears contextRef="c-359" decimals="-5" id="f-1121" unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears contextRef="c-359" decimals="-5" id="f-1122" unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears contextRef="c-359" decimals="-5" id="f-1123" unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears contextRef="c-359" decimals="-5" id="f-1124" unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter contextRef="c-359" decimals="INF" id="f-1125" unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-4" decimals="-5" id="f-1126" unitRef="usd">379500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-360" decimals="-5" id="f-1127" unitRef="usd">372300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-360" id="f-1128">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-4" decimals="-5" id="f-1129" unitRef="usd">21900000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-5" decimals="-5" id="f-1130" unitRef="usd">34800000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-1131">The following table presents the roll forward of the contract liabilities:&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;&#160;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Revenue recognized in the period from amounts included in contract liability at the beginning of the period:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-5" decimals="-5" id="f-1132" unitRef="usd">31700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-5" id="f-1133" unitRef="usd">29900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-1134" unitRef="usd">20200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-5" id="f-1135" unitRef="usd">27200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-5" id="f-1136" unitRef="usd">26400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ebs:ScheduleOfAccountsReceivableNetTableTextBlock contextRef="c-1" id="f-1137">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of "Accounts receivable, net" as presented on the Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;141.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;102.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;191.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;159.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:ScheduleOfAccountsReceivableNetTableTextBlock>
    <us-gaap:BilledContractReceivables contextRef="c-4" decimals="-5" id="f-1138" unitRef="usd">141800000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables contextRef="c-5" decimals="-5" id="f-1139" unitRef="usd">102700000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable contextRef="c-4" decimals="-5" id="f-1140" unitRef="usd">51400000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable contextRef="c-5" decimals="-5" id="f-1141" unitRef="usd">57200000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-4" decimals="-5" id="f-1142" unitRef="usd">2200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-5" decimals="-5" id="f-1143" unitRef="usd">700000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-5" id="f-1144" unitRef="usd">191000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-5" id="f-1145" unitRef="usd">159200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-5" id="f-1146" unitRef="usd">2100000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-27" decimals="-5" id="f-1147" unitRef="usd">300000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-28" decimals="-5" id="f-1148" unitRef="usd">-100000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1149">Leases &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is the lessee for operating leases for offices, R&amp;amp;D facilities and manufacturing facilities, which may include renewal or termination options. The Company determines if an arrangement is a lease at inception. Operating leases are included in ROU assets and liabilities. The Company's leases have remaining lease terms of less than one year to approximately 10 years. Most leases included one or more options to renew, with renewal terms that can extend the lease term up to five years.  For a discussion of lessor activities, refer to Note 13, "Revenue recognition".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are reflected as components of "Cost of Commercial Product sales", "Cost of MCM Product sales", "Cost of Bioservices", "R&amp;amp;D" expense and "Selling, general and administrative" expense on the Company's Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1164"&gt;&lt;span style="-sec-ix-hidden:f-1165"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1168"&gt;&lt;span style="-sec-ix-hidden:f-1169"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1172"&gt;&lt;span style="-sec-ix-hidden:f-1173"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity analysis below summarizes future undiscounted cash flows for our operating leases as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-361" id="f-1150">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-362" id="f-1151">P10Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-4" id="f-1152">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1153">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-5" id="f-1154" unitRef="usd">4000000.0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-27" decimals="-5" id="f-1155" unitRef="usd">5600000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-28" decimals="-5" id="f-1156" unitRef="usd">5600000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-5" id="f-1157" unitRef="usd">800000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-27" decimals="-5" id="f-1158" unitRef="usd">1100000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-28" decimals="-5" id="f-1159" unitRef="usd">1300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-5" id="f-1160" unitRef="usd">4800000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-27" decimals="-5" id="f-1161" unitRef="usd">6700000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-28" decimals="-5" id="f-1162" unitRef="usd">6900000</us-gaap:LeaseCost>
    <ebs:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-1163">&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1164"&gt;&lt;span style="-sec-ix-hidden:f-1165"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1168"&gt;&lt;span style="-sec-ix-hidden:f-1169"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1172"&gt;&lt;span style="-sec-ix-hidden:f-1173"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-5" id="f-1166" unitRef="usd">16200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-5" id="f-1167" unitRef="usd">19400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-5" id="f-1170" unitRef="usd">3500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-5" id="f-1171" unitRef="usd">5800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-5" id="f-1174" unitRef="usd">13800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-5" id="f-1175" unitRef="usd">14800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-5" id="f-1176" unitRef="usd">17300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-5" id="f-1177" unitRef="usd">20600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1178">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1179">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1180" unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1181" unitRef="number">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1182">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity analysis below summarizes future undiscounted cash flows for our operating leases as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-5" id="f-1183" unitRef="usd">4300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-5" id="f-1184" unitRef="usd">3700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-5" id="f-1185" unitRef="usd">2900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-5" id="f-1186" unitRef="usd">2300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-5" id="f-1187" unitRef="usd">2000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-5" id="f-1188" unitRef="usd">5200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-5" id="f-1189" unitRef="usd">20400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-5" id="f-1190" unitRef="usd">3100000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-5" id="f-1191" unitRef="usd">17300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1192">Income taxes&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company reassessed the valuation allowance and considered negative evidence, including its significant losses in the current year and the substantial doubt about the Company&#x2019;s ability to continue as a going concern through one year from the date that these financial statements are issued, positive evidence, scheduled reversal of deferred tax liabilities, available taxes in carryback periods, tax planning strategies and projected future taxable income. After assessing both the negative and positive evidence, the Company concluded that it should record an additional valuation allowance of $192.7&#160;million on its global net operating losses, credits and other deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The global intangible low-tax income (&#x201c;GILTI&#x201d;) provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#x2019;s tangible assets. The Company is subject to incremental U.S. tax on GILTI income. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;not provided any deferred tax impacts of GILTI in its consolidated financial statements for the years ended December&#160;31, 2023, 2022 and 2021. BEAT provisions do not have material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, the Company has evaluated its historical indefinite reinvestment assertion in connection with the Company&#x2019;s going concern uncertainty. The Company recognized a deferred withholding tax liability for the undistributed earnings of the Company&#x2019;s international subsidiaries available cash and net working capital in the amount of $5.5 million. All other international subsidiaries&#x2019; outside basis differences are indefinitely reinvested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of income taxes attributable to operations consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;36.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(37.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(33.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net deferred tax liability consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal losses carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State losses carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign losses carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IRC 263A capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IRC 163(j) Interest Limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(257.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Withholding Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company has approximately $279.3 million in U.S. federal net operating loss ("NOL") carryforwards, $36.0&#160;million of NOL&#x2019;s which will expire in varying amounts in 2031 through 2035 and $243.3&#160;million which will carryforward indefinitely, although, limited to eighty percent of taxable income annually. The Company has U.S. federal tax credit carryforwards of $16.9 million which will expire in 2027 through 2042. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company had post-apportionment NOLs totaling approximately $667.6 million that will begin to expire in 2028. The Company has state R&amp;amp;D tax credit carryforwards of $5.0 million which will expire in 2027 through 2038. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deductibility of such US federal and state net operating losses and credits may be limited. Under Section 382/383 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and corresponding provisions of state law, if a corporation undergoes an "ownership change," which generally occurs if the percentage of the corporation's stock owned by 5% stockholders increases by more than 50% over a three-year period, the corporation's ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. Certain of the net operating loss carryforwards and the credit carryforwards are subject to an annual limitation pursuant to Internal Revenue Code Section 382 and 383 as a result of historical acquisitions. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control, which may further limit our carryforwards. If we determine that an ownership change has occurred and our ability to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;use our historical NOL and credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately $55.7 million in net operating losses from foreign jurisdictions as of December&#160;31, 2023, which will carryforward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s valuation allowance increased by $192.7&#160;million due to the Company&#x2019;s generation of significant losses in 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes differ from the amount of taxes determined by applying the U.S. federal statutory rate to income before taxes as a result of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(805.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(442.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;73.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;224.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Earnings (losses) before taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(731.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(218.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;303.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Federal tax at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(153.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(46.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(52.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(18.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;193.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Goodwill Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Adjustment of prior year taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Compensation limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;GILTI, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Foreign withholding tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective annual tax rate for the years ended December&#160;31, 2023, 2022, and 2021 was (4)%, 3% and 28%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective annual tax rate of (4)% in 2023 is lower than the statutory rate primarily due to the impact of a valuation allowance charge in the U.S., state and certain Foreign Jurisdictions, goodwill impairment, GILTI, and other permanent items. This is partially offset by tax credits and favorable rates in foreign jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective annual tax rate of 3% in 2022 is lower than the statutory rate primarily due to the impact of a valuation allowance charge in the U.S., state and certain Foreign Jurisdictions, a charge due the Company&#x2019;s indefinite reinvestment assertion, goodwill impairment, GILTI, and other permanent items. This is partially offset by tax credits, favorable rates in foreign jurisdictions, and the release of an indemnified unrecognized tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective annual tax rate of 28% in 2021 is higher than the statutory rate primarily due to the impact of goodwill impairment, state taxes, GILTI and other non-deductible items. This is partially offset by stock option deduction benefits, tax credits, and favorable rates in foreign jurisdictions. The jurisdictional mix of profit has changed from the prior year largely due to lower U.S. Bioservices margins, the termination of the CIADM arrangement in the U.S. and an increase in sales of NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in which a portion of the profit is attributable to a foreign subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total unrecognized tax benefits recorded at December&#160;31, 2023 and 2022 of $6.6 million and $6.8 million, respectively, is classified primarily as a non-current liability on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the gross unrecognized tax benefits activity for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) for tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for tax positions for current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total gross unrecognized tax benefit of $6.6 million, includes the release of $0.7 million of liability that related to the 2019 R&amp;amp;D and other reserves due to a lapse of the statute of limitations during the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company includes interest and potential penalties related to unrecognized tax benefits in income tax expense. As of December&#160;31, 2023 and 2022, the total amount of interest and penalties accrued was $1.6&#160;million, respectively, in each of the years. The Company recognized interest and penalty expense (benefit) in 2023, 2022 and 2021 of $0.2 million, $(2.1) million and $1.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not anticipate a significant change within the next twelve months for unrecognized tax benefits and when resolved, all of these liabilities would impact the effective tax rate. However, the Company maintains a full valuation allowance as of December&#160;31, 2023 and the recognition of any unrecognized tax benefits would be offset with a change in the valuation allowance and therefore there would be no income statement impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's federal and state income tax returns for the tax years 2020 and onwards remain open to examination. The Company's tax returns for Canada remain open to examination for the tax years 2015 through 2022. The Company's Irish tax returns remain open to examination for the tax years 2017 through 2022.&lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2023, the Company&#x2019;s 2018 and 2020 Canadian Scientific Research and Experimental Development Claims are subject to proceedings with the Tax Court of Canada and the Company's 2021 Canadian Scientific Research and Experimental Development Claim is under audit. The Company's 2016 and 2017 Canadian income tax returns for the Adapt entities are under audit. The Company&#x2019;s Irish group is under Level 1 Compliance Intervention review for 2021. In addition, the Company&#x2019;s 2019 through 2022 Michigan state income tax returns are under audit.</us-gaap:IncomeTaxDisclosureTextBlock>
    <ebs:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount contextRef="c-1" decimals="-5" id="f-1193" unitRef="usd">192700000</ebs:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount>
    <ebs:DeferredTaxLiabilitiesForeignWithholdingTax contextRef="c-4" decimals="-5" id="f-1194" unitRef="usd">5500000</ebs:DeferredTaxLiabilitiesForeignWithholdingTax>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1195">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of income taxes attributable to operations consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;36.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(37.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(33.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1196" unitRef="usd">-600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1197" unitRef="usd">-9400000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1198" unitRef="usd">-3100000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1199" unitRef="usd">500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1200" unitRef="usd">1900000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1201" unitRef="usd">14900000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1202" unitRef="usd">36700000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1203" unitRef="usd">33800000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1204" unitRef="usd">28900000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1205" unitRef="usd">36600000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1206" unitRef="usd">26300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1207" unitRef="usd">40700000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1208" unitRef="usd">-2000000.0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1209" unitRef="usd">-37700000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1210" unitRef="usd">37100000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1211" unitRef="usd">-1200000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1212" unitRef="usd">-3200000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1213" unitRef="usd">4200000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1214" unitRef="usd">-4100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1215" unitRef="usd">7200000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1216" unitRef="usd">1600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1217" unitRef="usd">-7300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1218" unitRef="usd">-33700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1219" unitRef="usd">43000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1220" unitRef="usd">29300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1221" unitRef="usd">-7400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1222" unitRef="usd">83700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1223">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net deferred tax liability consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal losses carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State losses carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign losses carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IRC 263A capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IRC 163(j) Interest Limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(257.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Withholding Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-4" decimals="-5" id="f-1224" unitRef="usd">58700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-5" decimals="-5" id="f-1225" unitRef="usd">14800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-4" decimals="-5" id="f-1226" unitRef="usd">38900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-5" decimals="-5" id="f-1227" unitRef="usd">13000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-5" id="f-1228" unitRef="usd">21900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-5" id="f-1229" unitRef="usd">18400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-5" id="f-1230" unitRef="usd">6800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-5" id="f-1231" unitRef="usd">10400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c-4" decimals="-5" id="f-1232" unitRef="usd">13900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c-5" decimals="-5" id="f-1233" unitRef="usd">9100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-4" decimals="-5" id="f-1234" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-5" decimals="-5" id="f-1235" unitRef="usd">2000000.0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-4" decimals="-5" id="f-1236" unitRef="usd">12600000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-5" decimals="-5" id="f-1237" unitRef="usd">10900000</us-gaap:DeferredTaxAssetsInventory>
    <ebs:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-4" decimals="-5" id="f-1238" unitRef="usd">4300000</ebs:DeferredTaxAssetsOperatingLeaseLiability>
    <ebs:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-5" decimals="-5" id="f-1239" unitRef="usd">4700000</ebs:DeferredTaxAssetsOperatingLeaseLiability>
    <ebs:DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts contextRef="c-4" decimals="-5" id="f-1240" unitRef="usd">2800000</ebs:DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts>
    <ebs:DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts contextRef="c-5" decimals="-5" id="f-1241" unitRef="usd">5200000</ebs:DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts>
    <ebs:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-4" decimals="-5" id="f-1242" unitRef="usd">35300000</ebs:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <ebs:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-5" decimals="-5" id="f-1243" unitRef="usd">27300000</ebs:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="c-4" decimals="-5" id="f-1244" unitRef="usd">26200000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="c-5" decimals="-5" id="f-1245" unitRef="usd">7900000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-4" decimals="-5" id="f-1246" unitRef="usd">26700000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-5" decimals="-5" id="f-1247" unitRef="usd">100000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <ebs:DeferredTaxAssetsIntangibleAssets contextRef="c-4" decimals="-5" id="f-1248" unitRef="usd">13800000</ebs:DeferredTaxAssetsIntangibleAssets>
    <ebs:DeferredTaxAssetsIntangibleAssets contextRef="c-5" decimals="-5" id="f-1249" unitRef="usd">0</ebs:DeferredTaxAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-4" decimals="-5" id="f-1250" unitRef="usd">2800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-5" decimals="-5" id="f-1251" unitRef="usd">500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-5" id="f-1252" unitRef="usd">4800000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-5" id="f-1253" unitRef="usd">6500000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-5" id="f-1254" unitRef="usd">269500000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-5" id="f-1255" unitRef="usd">130800000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-5" id="f-1256" unitRef="usd">257800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-5" id="f-1257" unitRef="usd">65100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-5" id="f-1258" unitRef="usd">11700000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-5" id="f-1259" unitRef="usd">65700000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-5" id="f-1260" unitRef="usd">2600000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-5" id="f-1261" unitRef="usd">63700000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-4" decimals="-5" id="f-1262" unitRef="usd">40400000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-5" decimals="-5" id="f-1263" unitRef="usd">46100000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-5" id="f-1264" unitRef="usd">4000000.0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-5" id="f-1265" unitRef="usd">4500000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <ebs:DeferredTaxLiabilitiesForeignWithholdingTax contextRef="c-4" decimals="-5" id="f-1266" unitRef="usd">5500000</ebs:DeferredTaxLiabilitiesForeignWithholdingTax>
    <ebs:DeferredTaxLiabilitiesForeignWithholdingTax contextRef="c-5" decimals="-5" id="f-1267" unitRef="usd">4700000</ebs:DeferredTaxLiabilitiesForeignWithholdingTax>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-4" decimals="-5" id="f-1268" unitRef="usd">4200000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-5" decimals="-5" id="f-1269" unitRef="usd">3900000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-4" decimals="-5" id="f-1270" unitRef="usd">2200000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-5" decimals="-5" id="f-1271" unitRef="usd">2500000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-5" id="f-1272" unitRef="usd">58900000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-5" id="f-1273" unitRef="usd">125400000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-4" decimals="-5" id="f-1274" unitRef="usd">47200000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-5" id="f-1275" unitRef="usd">59700000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards contextRef="c-363" decimals="-5" id="f-1276" unitRef="usd">279300000</us-gaap:OperatingLossCarryforwards>
    <ebs:OperatingLossCarryforwardsSubjectToExpiration contextRef="c-363" decimals="-5" id="f-1277" unitRef="usd">36000000</ebs:OperatingLossCarryforwardsSubjectToExpiration>
    <ebs:OperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-363" decimals="-5" id="f-1278" unitRef="usd">243300000</ebs:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-363" decimals="-5" id="f-1279" unitRef="usd">16900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-364" decimals="-5" id="f-1280" unitRef="usd">667600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-365" decimals="-5" id="f-1281" unitRef="usd">5000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-366" decimals="-5" id="f-1282" unitRef="usd">55700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-1283" unitRef="usd">192700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1284">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes differ from the amount of taxes determined by applying the U.S. federal statutory rate to income before taxes as a result of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(805.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(442.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;73.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;224.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Earnings (losses) before taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(731.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(218.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;303.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Federal tax at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(153.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(46.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(52.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(18.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;193.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Goodwill Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Adjustment of prior year taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Compensation limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;GILTI, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Foreign withholding tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-5" id="f-1285" unitRef="usd">-805100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-27" decimals="-5" id="f-1286" unitRef="usd">-442600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-28" decimals="-5" id="f-1287" unitRef="usd">100100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-5" id="f-1288" unitRef="usd">73900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-27" decimals="-5" id="f-1289" unitRef="usd">224000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-28" decimals="-5" id="f-1290" unitRef="usd">203300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-1" decimals="-5" id="f-1291" unitRef="usd">-731200000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-27" decimals="-5" id="f-1292" unitRef="usd">-218600000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-28" decimals="-5" id="f-1293" unitRef="usd">303400000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-5" id="f-1294" unitRef="usd">-153600000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-27" decimals="-5" id="f-1295" unitRef="usd">-46000000.0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-28" decimals="-5" id="f-1296" unitRef="usd">63500000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-5" id="f-1297" unitRef="usd">-52700000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-27" decimals="-5" id="f-1298" unitRef="usd">-13500000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-28" decimals="-5" id="f-1299" unitRef="usd">14100000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-5" id="f-1300" unitRef="usd">-8500000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-27" decimals="-5" id="f-1301" unitRef="usd">-7200000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-28" decimals="-5" id="f-1302" unitRef="usd">-18700000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-5" id="f-1303" unitRef="usd">193600000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-5" id="f-1304" unitRef="usd">37800000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-28" decimals="-5" id="f-1305" unitRef="usd">8200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-1" decimals="-5" id="f-1306" unitRef="usd">900000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-27" decimals="-5" id="f-1307" unitRef="usd">3500000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-28" decimals="-5" id="f-1308" unitRef="usd">4700000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-5" id="f-1309" unitRef="usd">6800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-27" decimals="-5" id="f-1310" unitRef="usd">4700000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-28" decimals="-5" id="f-1311" unitRef="usd">-3900000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-1" decimals="-5" id="f-1312" unitRef="usd">23300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-27" decimals="-5" id="f-1313" unitRef="usd">1800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-28" decimals="-5" id="f-1314" unitRef="usd">8300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c-1" decimals="-5" id="f-1315" unitRef="usd">1300000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c-27" decimals="-5" id="f-1316" unitRef="usd">-1800000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c-28" decimals="-5" id="f-1317" unitRef="usd">800000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <ebs:EffectiveIncomeTaxRateReconciliationTransactionCosts contextRef="c-1" decimals="-5" id="f-1318" unitRef="usd">0</ebs:EffectiveIncomeTaxRateReconciliationTransactionCosts>
    <ebs:EffectiveIncomeTaxRateReconciliationTransactionCosts contextRef="c-27" decimals="-5" id="f-1319" unitRef="usd">0</ebs:EffectiveIncomeTaxRateReconciliationTransactionCosts>
    <ebs:EffectiveIncomeTaxRateReconciliationTransactionCosts contextRef="c-28" decimals="-5" id="f-1320" unitRef="usd">100000</ebs:EffectiveIncomeTaxRateReconciliationTransactionCosts>
    <ebs:EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount contextRef="c-1" decimals="-5" id="f-1321" unitRef="usd">300000</ebs:EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount>
    <ebs:EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount contextRef="c-27" decimals="-5" id="f-1322" unitRef="usd">700000</ebs:EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount>
    <ebs:EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount contextRef="c-28" decimals="-5" id="f-1323" unitRef="usd">2900000</ebs:EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-1" decimals="-5" id="f-1324" unitRef="usd">-600000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-27" decimals="-5" id="f-1325" unitRef="usd">-9000000.0</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-28" decimals="-5" id="f-1326" unitRef="usd">1200000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount contextRef="c-1" decimals="-5" id="f-1327" unitRef="usd">17800000</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount contextRef="c-27" decimals="-5" id="f-1328" unitRef="usd">20700000</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount contextRef="c-28" decimals="-5" id="f-1329" unitRef="usd">13000000.0</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings contextRef="c-1" decimals="-5" id="f-1330" unitRef="usd">800000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings contextRef="c-27" decimals="-5" id="f-1331" unitRef="usd">4700000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings contextRef="c-28" decimals="-5" id="f-1332" unitRef="usd">0</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <ebs:EffectiveIncomeTaxRateReconciliationPermanentDifference contextRef="c-1" decimals="-5" id="f-1333" unitRef="usd">-1700000</ebs:EffectiveIncomeTaxRateReconciliationPermanentDifference>
    <ebs:EffectiveIncomeTaxRateReconciliationPermanentDifference contextRef="c-27" decimals="-5" id="f-1334" unitRef="usd">-3200000</ebs:EffectiveIncomeTaxRateReconciliationPermanentDifference>
    <ebs:EffectiveIncomeTaxRateReconciliationPermanentDifference contextRef="c-28" decimals="-5" id="f-1335" unitRef="usd">1200000</ebs:EffectiveIncomeTaxRateReconciliationPermanentDifference>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1336" unitRef="usd">29300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1337" unitRef="usd">-7400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-28" decimals="-5" id="f-1338" unitRef="usd">83700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="2" id="f-1339" unitRef="number">-0.04</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-27" decimals="2" id="f-1340" unitRef="number">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-28" decimals="2" id="f-1341" unitRef="number">0.28</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="2" id="f-1342" unitRef="number">-0.04</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-27" decimals="2" id="f-1343" unitRef="number">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-28" decimals="2" id="f-1344" unitRef="number">0.28</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <ebs:UnrecognizedTaxBenefitsNoncurrent contextRef="c-4" decimals="-5" id="f-1345" unitRef="usd">6600000</ebs:UnrecognizedTaxBenefitsNoncurrent>
    <ebs:UnrecognizedTaxBenefitsNoncurrent contextRef="c-5" decimals="-5" id="f-1346" unitRef="usd">6800000</ebs:UnrecognizedTaxBenefitsNoncurrent>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1347">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the gross unrecognized tax benefits activity for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) for tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for tax positions for current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-5" id="f-1348" unitRef="usd">6800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-29" decimals="-5" id="f-1349" unitRef="usd">12700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-30" decimals="-5" id="f-1350" unitRef="usd">12200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-5" id="f-1351" unitRef="usd">400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-27" decimals="-5" id="f-1352" unitRef="usd">1500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-28" decimals="-5" id="f-1353" unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-5" id="f-1354" unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-27" decimals="-5" id="f-1355" unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-28" decimals="-5" id="f-1356" unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-5" id="f-1357" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-27" decimals="-5" id="f-1358" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-28" decimals="-5" id="f-1359" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-5" id="f-1360" unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-27" decimals="-5" id="f-1361" unitRef="usd">5100000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-28" decimals="-5" id="f-1362" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-5" id="f-1363" unitRef="usd">6600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-5" id="f-1364" unitRef="usd">6800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-29" decimals="-5" id="f-1365" unitRef="usd">12700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-5" id="f-1366" unitRef="usd">6600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-5" id="f-1367" unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-5" decimals="-5" id="f-1368" unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-4" decimals="-5" id="f-1369" unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="-5" id="f-1370" unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-27" decimals="-5" id="f-1371" unitRef="usd">-2100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-28" decimals="-5" id="f-1372" unitRef="usd">1100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1373">Defined benefit and 401(k) savings plan&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Define benefit pension plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company historically sponsored a defined benefit pension plan covering eligible employees in Switzerland (the "Swiss Plan"), which was sold as part of our travel health business to Bavarian Nordic, as described further in Note 3, "Divestiture". Under the Swiss Plan, the Company and certain of its employees with annual earnings in excess of government determined amounts were required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#x2019;s contribution. The Swiss Plan's assets were comprised of an insurance contract that had a fair value consistent with its contract value based on the practicability exception using Level 3 inputs. The entire liability was listed as non-current because plan assets were greater than the expected benefit payments over the next year. The Company recognized pension expense related to the Swiss Plan of $0.6 million, $0.8 million and $2.0 million, reflected as a component of selling, general and administrative expenses, for the years ended December&#160;31, 2023, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The funded status of the Swiss Plan for the years ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in Plan Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net benefits received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Currency impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in Benefit Obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Interest Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net benefits received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Currency impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Funded status, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of net periodic pension cost incurred during the years ended December&#160;31, 2023, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023 &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Amortization of loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;The Swiss Plan was sold as part of our travel health business to Bavarian Nordic, as described further in Note 3, "Divestiture".&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used to calculate the projected benefit obligations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.318%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Expected rate of return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Rate of future compensation increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The overall expected long-term rate of return on assets assumption considers historical returns, as well as expected future returns based on the fact that investment returns are insured, and the legal minimum interest crediting rate as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents gains (losses) recognized in accumulated other comprehensive income (loss) before income tax related to the Company&#x2019;s defined benefit pension plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.317%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total recognized in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no future benefits expected to be paid as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;401(k) savings plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code (the "401(k) Plan"). The 401(k) Plan covers substantially all U.S. employees. Under the 401(k) Plan, employees may make elective salary deferrals. During the years ended December&#160;31, 2023, 2022 and 2021, the Company made matching contributions of approximately $8.3 million, $8.8 million and $8.9 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:PensionExpense contextRef="c-1" decimals="-5" id="f-1374" unitRef="usd">600000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense contextRef="c-27" decimals="-5" id="f-1375" unitRef="usd">800000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense contextRef="c-28" decimals="-5" id="f-1376" unitRef="usd">2000000</us-gaap:PensionExpense>
    <us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock contextRef="c-1" id="f-1377">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The funded status of the Swiss Plan for the years ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in Plan Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net benefits received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Currency impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Change in Benefit Obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Interest Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net benefits received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Currency impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Funded status, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-29" decimals="-5" id="f-1378" unitRef="usd">29300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-27" decimals="-5" id="f-1379" unitRef="usd">1500000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-27" decimals="-5" id="f-1380" unitRef="usd">900000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-27" decimals="-5" id="f-1381" unitRef="usd">3400000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-27" decimals="-5" id="f-1382" unitRef="usd">-400000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-27" decimals="-5" id="f-1383" unitRef="usd">5000000.0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-27" decimals="-5" id="f-1384" unitRef="usd">-400000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-5" decimals="-5" id="f-1385" unitRef="usd">29300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-29" decimals="-5" id="f-1386" unitRef="usd">46800000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-27" decimals="-5" id="f-1387" unitRef="usd">1900000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-27" decimals="-5" id="f-1388" unitRef="usd">100000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-27" decimals="-5" id="f-1389" unitRef="usd">900000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-27" decimals="-5" id="f-1390" unitRef="usd">10000000.0</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-27" decimals="-5" id="f-1391" unitRef="usd">3400000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation contextRef="c-27" decimals="-5" id="f-1392" unitRef="usd">5000000.0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-27" decimals="-5" id="f-1393" unitRef="usd">-900000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-5" decimals="-5" id="f-1394" unitRef="usd">37200000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-5" decimals="-5" id="f-1395" unitRef="usd">-7900000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax contextRef="c-5" decimals="-5" id="f-1396" unitRef="usd">34000000.0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock contextRef="c-1" id="f-1397">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of net periodic pension cost incurred during the years ended December&#160;31, 2023, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023 &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.24pt;font-weight:700;line-height:100%;position:relative;top:-3.36pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Amortization of loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:100%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;The Swiss Plan was sold as part of our travel health business to Bavarian Nordic, as described further in Note 3, "Divestiture".&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-1" decimals="-5" id="f-1398" unitRef="usd">700000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-27" decimals="-5" id="f-1399" unitRef="usd">1900000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-28" decimals="-5" id="f-1400" unitRef="usd">2400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-1" decimals="-5" id="f-1401" unitRef="usd">300000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-27" decimals="-5" id="f-1402" unitRef="usd">100000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-28" decimals="-5" id="f-1403" unitRef="usd">0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-1" decimals="-5" id="f-1404" unitRef="usd">400000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-27" decimals="-5" id="f-1405" unitRef="usd">800000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-28" decimals="-5" id="f-1406" unitRef="usd">800000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-1" decimals="-5" id="f-1407" unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-27" decimals="-5" id="f-1408" unitRef="usd">-100000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-28" decimals="-5" id="f-1409" unitRef="usd">-600000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-1" decimals="-5" id="f-1410" unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-27" decimals="-5" id="f-1411" unitRef="usd">-100000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-28" decimals="-5" id="f-1412" unitRef="usd">-200000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-1" decimals="-5" id="f-1413" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-27" decimals="-5" id="f-1414" unitRef="usd">400000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-28" decimals="-5" id="f-1415" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-1" decimals="-5" id="f-1416" unitRef="usd">600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-27" decimals="-5" id="f-1417" unitRef="usd">800000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-28" decimals="-5" id="f-1418" unitRef="usd">2000000.0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="c-1" id="f-1419">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used to calculate the projected benefit obligations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.318%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Expected rate of return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Rate of future compensation increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate contextRef="c-27" decimals="4" id="f-1420" unitRef="number">0.021</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets contextRef="c-27" decimals="3" id="f-1421" unitRef="number">0.035</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease contextRef="c-27" decimals="3" id="f-1422" unitRef="number">0.018</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1423">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents gains (losses) recognized in accumulated other comprehensive income (loss) before income tax related to the Company&#x2019;s defined benefit pension plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.317%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Net actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Total recognized in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-5" decimals="-5" id="f-1424" unitRef="usd">9000000.0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-5" decimals="-5" id="f-1425" unitRef="usd">300000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-5" decimals="-5" id="f-1426" unitRef="usd">-8700000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-1" decimals="-5" id="f-1427" unitRef="usd">8300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-27" decimals="-5" id="f-1428" unitRef="usd">8800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-28" decimals="-5" id="f-1429" unitRef="usd">8900000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock contextRef="c-1" id="f-1430">Purchase commitments &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into agreements in the normal course of business with vendors for raw materials and other goods or services. Purchase commitments are agreements to purchase raw materials and services that are enforceable, legally binding, and specify terms that (1) include fixed or minimum quantities to be purchased, (2) include fixed, minimum or variable price provisions and (3) are longer than one year. Purchase commitments exclude agreements that are cancellable without penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company has approximately $526.9 million of purchase commitments associated with raw materials and Bioservices that will be purchased in the next five years, of which the Company estimates that approximately $117.0 million will be purchased within the next year. For the years ended December&#160;31, 2023, 2022, and 2021, the Company purchased $107.8 million, $199.6 million and $110.7 million, respectively, of materials and services under these commitments.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock>
    <us-gaap:PurchaseObligation contextRef="c-4" decimals="-5" id="f-1431" unitRef="usd">526900000</us-gaap:PurchaseObligation>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="c-1" id="f-1432">P5Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-4" decimals="-5" id="f-1433" unitRef="usd">117000000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:LongTermPurchaseCommitmentAmount contextRef="c-1" decimals="-5" id="f-1434" unitRef="usd">107800000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount contextRef="c-27" decimals="-5" id="f-1435" unitRef="usd">199600000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount contextRef="c-28" decimals="-5" id="f-1436" unitRef="usd">110700000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1437">Segment information&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2023, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting process. The revised reporting structure reflects the internal reporting and review process used by our CODM for making decisions and assessing performance and is consistent with how we currently manage the business. We now manage our business with a focus on three reportable segments. Our Commercial Products segment, which includes NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products and other commercial products which were sold as part of our travel health business in the second quarter of 2023 (see Note 3, "Divestiture" for more information on the sale of the travel health business), our MCM Products segment, which includes the Anthrax - MCM products, Smallpox - MCM products and Other Products, and our Services segment consisting of our Bioservices offerings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the performance of these reportable segments based on revenue and segment adjusted gross margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. We define segment adjusted gross margin, as segment gross margin excluding the impact of restructuring costs and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. We define total segment adjusted gross margin, which is a non-GAAP financial measure, as total segment gross margin, excluding the impact of restructuring costs, inventory step-up provision and the fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment revenues, segment cost of sales or services, segment gross margin, segment gross margin % and total segment adjusted gross margin for each of our reportable segments for the years ended December&#160;31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;579.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,023.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,076.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,639.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,049.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,773.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost of sales or services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total cost of sales or services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;705.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;693.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(111.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total segment gross margin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;891.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross margin %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Segment adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(102.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total segment adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Services revenue, Services gross margin and Services segment adjusted gross margin for the year ended December&#160;31, 2021 includes the impact of $243.1 million of Bioservices leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Segment revenues less total cost of sales or services.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the Company's total segment adjusted gross margin to the Consolidated Statement of Operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total segment adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reconciling items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment inventory step-up provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(111.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(188.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(235.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(368.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(339.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(348.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(218.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(59.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(87.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain on sale of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(731.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(219.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation expense for each segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Depreciation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;59.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;83.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes revenues by country. Revenues have been attributed based on the location of the customer:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;607.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;886.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,623.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;224.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;217.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;82.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;83.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,049.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,773.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table included long-lived assets, net by country. Long-lived assets, net includes right-of-use assets and property, plant &amp;amp; equipment, net, excluding software, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Long-lived assets, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;352.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;696.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Total long-lived assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;392.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;826.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1438"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-1439">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment revenues, segment cost of sales or services, segment gross margin, segment gross margin % and total segment adjusted gross margin for each of our reportable segments for the years ended December&#160;31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;579.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,023.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,076.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,639.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,049.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,773.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost of sales or services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total cost of sales or services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;705.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;693.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(111.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total segment gross margin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;891.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross margin %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Segment adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(102.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total segment adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Services revenue, Services gross margin and Services segment adjusted gross margin for the year ended December&#160;31, 2021 includes the impact of $243.1 million of Bioservices leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Segment revenues less total cost of sales or services.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the Company's total segment adjusted gross margin to the Consolidated Statement of Operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total segment adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reconciling items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment inventory step-up provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(111.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(188.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(235.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(368.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(339.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(348.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(218.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(59.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(87.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain on sale of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(731.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(219.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-5" id="f-1440" unitRef="usd">497300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-367" decimals="-5" id="f-1441" unitRef="usd">386600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-368" decimals="-5" id="f-1442" unitRef="usd">438000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-5" id="f-1443" unitRef="usd">447200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-369" decimals="-5" id="f-1444" unitRef="usd">579600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-370" decimals="-5" id="f-1445" unitRef="usd">585900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-5" id="f-1446" unitRef="usd">78500000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-371" decimals="-5" id="f-1447" unitRef="usd">109900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-372" decimals="-5" id="f-1448" unitRef="usd">615500000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-5" id="f-1449" unitRef="usd">1023000000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-373" decimals="-5" id="f-1450" unitRef="usd">1076100000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-374" decimals="-5" id="f-1451" unitRef="usd">1639400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-375" decimals="-5" id="f-1452" unitRef="usd">26300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-376" decimals="-5" id="f-1453" unitRef="usd">41400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-377" decimals="-5" id="f-1454" unitRef="usd">134200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-1455" unitRef="usd">1049300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-27" decimals="-5" id="f-1456" unitRef="usd">1117500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-28" decimals="-5" id="f-1457" unitRef="usd">1773600000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-156" decimals="-5" id="f-1458" unitRef="usd">210300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-150" decimals="-5" id="f-1459" unitRef="usd">160300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-378" decimals="-5" id="f-1460" unitRef="usd">187200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-157" decimals="-5" id="f-1461" unitRef="usd">305600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-151" decimals="-5" id="f-1462" unitRef="usd">264300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-379" decimals="-5" id="f-1463" unitRef="usd">195400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-158" decimals="-5" id="f-1464" unitRef="usd">189500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-152" decimals="-5" id="f-1465" unitRef="usd">268500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-380" decimals="-5" id="f-1466" unitRef="usd">365500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-1467" unitRef="usd">705400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-27" decimals="-5" id="f-1468" unitRef="usd">693100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-28" decimals="-5" id="f-1469" unitRef="usd">748100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-156" decimals="-5" id="f-1470" unitRef="usd">287000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-150" decimals="-5" id="f-1471" unitRef="usd">226300000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-378" decimals="-5" id="f-1472" unitRef="usd">250800000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-157" decimals="-5" id="f-1473" unitRef="usd">141600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-151" decimals="-5" id="f-1474" unitRef="usd">315300000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-379" decimals="-5" id="f-1475" unitRef="usd">390500000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-158" decimals="-5" id="f-1476" unitRef="usd">-111000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-152" decimals="-5" id="f-1477" unitRef="usd">-158600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-380" decimals="-5" id="f-1478" unitRef="usd">250000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-5" id="f-1479" unitRef="usd">317600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-27" decimals="-5" id="f-1480" unitRef="usd">383000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-28" decimals="-5" id="f-1481" unitRef="usd">891300000</us-gaap:GrossProfit>
    <ebs:GrossProfitPercentage
      contextRef="c-156"
      decimals="2"
      id="f-1482"
      unitRef="number">0.58</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage
      contextRef="c-150"
      decimals="2"
      id="f-1483"
      unitRef="number">0.59</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage
      contextRef="c-378"
      decimals="2"
      id="f-1484"
      unitRef="number">0.57</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage
      contextRef="c-157"
      decimals="2"
      id="f-1485"
      unitRef="number">0.32</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage
      contextRef="c-151"
      decimals="2"
      id="f-1486"
      unitRef="number">0.54</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage
      contextRef="c-379"
      decimals="2"
      id="f-1487"
      unitRef="number">0.67</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage
      contextRef="c-158"
      decimals="2"
      id="f-1488"
      unitRef="number">-1.41</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage
      contextRef="c-152"
      decimals="2"
      id="f-1489"
      unitRef="number">-1.44</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage
      contextRef="c-380"
      decimals="2"
      id="f-1490"
      unitRef="number">0.41</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage contextRef="c-1" decimals="2" id="f-1491" unitRef="number">0.31</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage contextRef="c-27" decimals="2" id="f-1492" unitRef="number">0.36</ebs:GrossProfitPercentage>
    <ebs:GrossProfitPercentage contextRef="c-28" decimals="2" id="f-1493" unitRef="number">0.54</ebs:GrossProfitPercentage>
    <ebs:AdjustedGrossMargin contextRef="c-156" decimals="-5" id="f-1494" unitRef="usd">287000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-150" decimals="-5" id="f-1495" unitRef="usd">226300000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-378" decimals="-5" id="f-1496" unitRef="usd">250800000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-157" decimals="-5" id="f-1497" unitRef="usd">151300000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-151" decimals="-5" id="f-1498" unitRef="usd">369300000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-379" decimals="-5" id="f-1499" unitRef="usd">393400000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-158" decimals="-5" id="f-1500" unitRef="usd">-102600000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-152" decimals="-5" id="f-1501" unitRef="usd">-158600000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-380" decimals="-5" id="f-1502" unitRef="usd">250000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-1" decimals="-5" id="f-1503" unitRef="usd">335700000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-27" decimals="-5" id="f-1504" unitRef="usd">437000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-28" decimals="-5" id="f-1505" unitRef="usd">894200000</ebs:AdjustedGrossMargin>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c-357" decimals="-5" id="f-1506" unitRef="usd">243100000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:AdjustedGrossMargin contextRef="c-1" decimals="-5" id="f-1507" unitRef="usd">335700000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-27" decimals="-5" id="f-1508" unitRef="usd">437000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-28" decimals="-5" id="f-1509" unitRef="usd">894200000</ebs:AdjustedGrossMargin>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-24" decimals="-5" id="f-1510" unitRef="usd">26300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-5" id="f-1511" unitRef="usd">41400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-5" id="f-1512" unitRef="usd">134200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RestructuringCharges contextRef="c-99" decimals="-5" id="f-1513" unitRef="usd">14000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-373" decimals="-5" id="f-1514" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-374" decimals="-5" id="f-1515" unitRef="usd">0</us-gaap:RestructuringCharges>
    <ebs:InventoryStepUp contextRef="c-99" decimals="-5" id="f-1516" unitRef="usd">-3900000</ebs:InventoryStepUp>
    <ebs:InventoryStepUp contextRef="c-373" decimals="-5" id="f-1517" unitRef="usd">-51400000</ebs:InventoryStepUp>
    <ebs:InventoryStepUp contextRef="c-374" decimals="-5" id="f-1518" unitRef="usd">0</ebs:InventoryStepUp>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-5" id="f-1519" unitRef="usd">200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-27" decimals="-5" id="f-1520" unitRef="usd">2600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-28" decimals="-5" id="f-1521" unitRef="usd">2900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-1522" unitRef="usd">306700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-27" decimals="-5" id="f-1523" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-28" decimals="-5" id="f-1524" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-1525" unitRef="usd">111400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-27" decimals="-5" id="f-1526" unitRef="usd">188300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-28" decimals="-5" id="f-1527" unitRef="usd">235200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-1528" unitRef="usd">368400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-27" decimals="-5" id="f-1529" unitRef="usd">339500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-28" decimals="-5" id="f-1530" unitRef="usd">348700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-5" id="f-1531" unitRef="usd">218200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-27" decimals="-5" id="f-1532" unitRef="usd">6700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-28" decimals="-5" id="f-1533" unitRef="usd">41700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-1534" unitRef="usd">65600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-27" decimals="-5" id="f-1535" unitRef="usd">59900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-28" decimals="-5" id="f-1536" unitRef="usd">58500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-1537" unitRef="usd">87900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-27" decimals="-5" id="f-1538" unitRef="usd">37300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-28" decimals="-5" id="f-1539" unitRef="usd">34500000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-5" id="f-1540" unitRef="usd">74200000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-27" decimals="-5" id="f-1541" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-28" decimals="-5" id="f-1542" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-1543" unitRef="usd">8900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-27" decimals="-5" id="f-1544" unitRef="usd">-11700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-28" decimals="-5" id="f-1545" unitRef="usd">-3700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-1546" unitRef="usd">-731200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-27" decimals="-5" id="f-1547" unitRef="usd">-219000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-28" decimals="-5" id="f-1548" unitRef="usd">303200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1549">&lt;div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation expense for each segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Depreciation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Commercial Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;59.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;83.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Depreciation contextRef="c-96" decimals="-5" id="f-1550" unitRef="usd">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-367" decimals="-5" id="f-1551" unitRef="usd">3200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-368" decimals="-5" id="f-1552" unitRef="usd">3100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-97" decimals="-5" id="f-1553" unitRef="usd">22800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-369" decimals="-5" id="f-1554" unitRef="usd">29700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-370" decimals="-5" id="f-1555" unitRef="usd">24700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-98" decimals="-5" id="f-1556" unitRef="usd">22500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-371" decimals="-5" id="f-1557" unitRef="usd">43200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-372" decimals="-5" id="f-1558" unitRef="usd">28300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-381" decimals="-5" id="f-1559" unitRef="usd">13900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-382" decimals="-5" id="f-1560" unitRef="usd">7300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-383" decimals="-5" id="f-1561" unitRef="usd">6100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-1562" unitRef="usd">59500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-27" decimals="-5" id="f-1563" unitRef="usd">83400000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-28" decimals="-5" id="f-1564" unitRef="usd">62200000</us-gaap:Depreciation>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1565">&lt;div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes revenues by country. Revenues have been attributed based on the location of the customer:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;607.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;886.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,623.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;224.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;217.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;82.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;83.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,049.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;1,773.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c-384" decimals="-5" id="f-1566" unitRef="usd">607200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-385" decimals="-5" id="f-1567" unitRef="usd">886100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-386" decimals="-5" id="f-1568" unitRef="usd">1623400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-387" decimals="-5" id="f-1569" unitRef="usd">224200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-388" decimals="-5" id="f-1570" unitRef="usd">148600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-389" decimals="-5" id="f-1571" unitRef="usd">66700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-390" decimals="-5" id="f-1572" unitRef="usd">217900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-391" decimals="-5" id="f-1573" unitRef="usd">82800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-392" decimals="-5" id="f-1574" unitRef="usd">83500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-1575" unitRef="usd">1049300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-27" decimals="-5" id="f-1576" unitRef="usd">1117500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-28" decimals="-5" id="f-1577" unitRef="usd">1773600000</us-gaap:Revenues>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c-1" id="f-1578">&lt;div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table included long-lived assets, net by country. Long-lived assets, net includes right-of-use assets and property, plant &amp;amp; equipment, net, excluding software, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Long-lived assets, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;352.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;696.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%"&gt;Total long-lived assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;392.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"&gt;826.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c-393" decimals="-5" id="f-1579" unitRef="usd">352300000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-394" decimals="-5" id="f-1580" unitRef="usd">696100000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-395" decimals="-5" id="f-1581" unitRef="usd">0</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-396" decimals="-5" id="f-1582" unitRef="usd">88100000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-397" decimals="-5" id="f-1583" unitRef="usd">37200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-398" decimals="-5" id="f-1584" unitRef="usd">37500000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-399" decimals="-5" id="f-1585" unitRef="usd">2900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-400" decimals="-5" id="f-1586" unitRef="usd">5000000.0</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-4" decimals="-5" id="f-1587" unitRef="usd">392400000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-5" decimals="-5" id="f-1588" unitRef="usd">826700000</us-gaap:NoncurrentAssets>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-1589">Litigation&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Securities and shareholder litigation&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-401" id="f-1590">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-401" id="f-1591">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-401" id="f-1592">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-401" id="f-1593">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-1594">42</dei:AuditorFirmId>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c-1" id="f-1595">&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Charged to Costs and Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.6pt;font-weight:700;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-402" decimals="-5" id="f-1596" unitRef="usd">7100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-403" decimals="-5" id="f-1597" unitRef="usd">800000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-403" decimals="-5" id="f-1598" unitRef="usd">400000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-404" decimals="-5" id="f-1599" unitRef="usd">7500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-405" decimals="-5" id="f-1600" unitRef="usd">3700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-406" decimals="-5" id="f-1601" unitRef="usd">3900000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-406" decimals="-5" id="f-1602" unitRef="usd">500000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-402" decimals="-5" id="f-1603" unitRef="usd">7100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-407" decimals="-5" id="f-1604" unitRef="usd">3900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-408" decimals="-5" id="f-1605" unitRef="usd">200000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-408" decimals="-5" id="f-1606" unitRef="usd">400000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-405" decimals="-5" id="f-1607" unitRef="usd">3700000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
